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RESEARCH PODIUM PRESENTATIONS – SESSION I 
HEALTH CARE ExPENDITURE OR REIMBURSEMENT STUDIES – BIOLOGICS
BI1
ADHERENCE AND RESOURCE USE AMONG PATIENTS TREATED wITH 
BIOLOGICS. FINDINGS FROM THE BEETLE STUDy (BIOLOGICAL DRUGS: 
EvALUATION OF ECONOMICS, TREATMENTS, AND LABELING IN REAL-wORLD 
SETTING)
Degli Esposti L., Sangiorgi D., Buda S.
CliCon Srl, Ravenna, Italy
Objectives: Systemic administration of anti-TNF alpha leads to an anti-inflamma-
tory and joint protective effect in pathologies such as rheumatoid arthritis, psoriasis, 
Crohn’s disease. The aim of this study was to assess adherence to therapy and stay 
on treatment (no switches or interruptions) of patients treated with biologics accord-
ing to therapeutic indication and to calculate health care resources consumption 
(drugs, outpatient services, hospitalizations). MethOds: An observational retrospec-
tive cohort analysis based on 5 Local Health Units administrative databases was 
conducted. Patients who filled at least one prescription for anti-TNF alpha between 
January 1, 2009-December 31, 2011 were included. Patients were followed-up for one 
year. Patients were defined as adherent if they had > 80% of follow up period covered 
by drugs dispensation. Results: A total of 1219 patients were analyzed, 47% male, 
age 49.6±14.6. Patients affected by rheumatoid arthritis were 36%, psoriasis 31%, 
Crohn’s disease 10%, psoriatic arthritis 7%, ulcerative colitis 3%, ankylosing spon-
dylitis 3%, diagnosis not available 11%; 420 (34%) were treated with Adalimumab, 
615 (50%) Etanercept, 184 (15%) Infliximab. Among the 94% of patients who did not 
switch, patients treated with Infliximab seemed to have the highest rate of adherent 
patients across all indications: 51%, vs. 27% Etanercept and 23% Adalimumab; at the 
multivariable logistic regression model, Infliximab resulted a protective predictor 
of non adherence for all indications (OR ranged from 0.08 to 0.43). For patients who 
started a first-line biological drug, stay on treatment was 73% for Infliximab, 67% 
Etanercept, 64% Adalimumab. The mean annual expenditure for each patient in analy-
sis was € 11,120; in particular, non-pharmacological expenditure was € 988 for adherent 
and € 1,255 for non-adherent patients; at the multivariable generalized linear model, 
Infliximab was associated with the lowest cost for all indications. cOnclusiOns: 
Patients treated with Infliximab were associated to higher adherence and stay on 
treatment and lower costs, as compared to Adalimumab and Etanercept.
BI2
wHAT ARE THE KEy DRIvERS OF REIMBURSEMENT FOR BIOSIMILARS? AN 
ExAMINATION OF REIMBURSEMENT PROCESSES AND RECOMMENDATIONS 
ACROSS NINE COUNTRIES
de Silva S.U., Smith T.A., Bending M.W.
Mapi, London, UK
Objectives: Biosimilars are biotherapeutic products that are similar in terms of 
quality, safety and efficacy to an already licensed reference biotherapeutic product. 
The first biosimilar (Omnitrope) received EU regulatory approval in 2006; since then, 
14 biosimilars have received marketing authorisation. This study examined the dif-
ferences in the approaches to reimbursement of biosimilars in countries using HTA 
to inform decision-making. MethOds: Four biosimilar medicines were selected to 
provide sufficient documentation in seven European countries, South Korea and 
Australia. Regulatory approval and HTA reimbursement decision documents were 
identified and a qualitative analysis of the processes, recommendations by indica-
tion, evidence and key decision drivers was undertaken to explain differences in 
recommendations across countries. Results: Twenty-one different indications 
were appraised; 90% of appraisals were ‘recommended’, 9% ‘recommended with 
restrictions’, and 1% were ‘not recommended’. The Netherlands and Germany 
accepted ‘clinical comparability’ to the originator as sufficient evidence for auto-
matic reimbursement. Sweden and France were the only countries to appraise and 
to recommend for all indications. Scotland and Wales recommended all biosimilars 
but restricted indications in some cases. Agencies accepted the notion of clinical 
comparability and extrapolation across indications when appraising the evidence. A 
cost-minimisation analysis and budget impact analysis were key economic decision 
drivers. A full cost-effectiveness analysis was only requested by NICE. Other factors 
influential in recommending reimbursement were: lobbying, dual reimbursement 
processes, and other reimbursement mechanisms. cOnclusiOns: As the market 
for biosimilars continues to grow, it is imperative that specific HTA reimbursement 
processes are developed for assessing biosimilars. This includes further research 
on how different drug classes should be considered; especially pertinent due to the 
increase in biosimilars for monoclonal antibody-based drugs, which differ from the 
ABSTRACTS
product classes (erythropoietin, white blood cell stimulators, growth hormone and 
insulins) currently dominating the market.
BI3
DIFFERENCES IN APPROACH TO BIOSIMILARS: NICE vERSUS SMC 
RECOMMENDATIONS
Izmirlieva M., Ando G.
IHS, London, UK
Objectives: Several biosimilar products have been approved for marketing in the 
European Union, but their market penetration remains slow. Lack of clear reimburse-
ment guidance could be one of the reasons for this slow penetration. This study exam-
ines how many, if any, biosimilar products have been assessed in the UK by NICE and 
by the SMC and to what extent recommendations by the two HTA organisations are 
consistent. MethOds: Secondary research was conducted, including a review of all 
NICE and SMC final guidance and of guidance in progress by NICE to compare the HTA 
process outcome and issues raised by the two HTA agencies. Results: NICE has issued 
only one final guidance for a biosimilar product (Omnitrope) and has another guid-
ance in progress (for epoetin including biosimilars). The SMC has issued guidance for 
4 biosimilar versions of filgrastim (Ratiograstim, TevaGrastim, Zarzio and Nivestim), 
2 biosimilar versions of epoetin (Binocrit and Retacrit) and 1 version of somatropin 
(Omnitrope). All SMC guidance for biosimilars issued to date has been positive. The 
NICE guidance for Omnitrope is positive despite some reservations about the economic 
model. cOnclusiOns: Considering the limited overlap between NICE and SMC deci-
sions (only one drug - Omnitrope - was considered by both agencies), it is difficult to 
assess consistency in the SMC approach compared to NICE’s approach at this stage. 
Based on the biosimilars HTA guidance by NICE and the SMC to date, a cost-minimisa-
tion analysis may be acceptable for biosimilars even if such an approach - in the absence 
of a full cost-effectiveness model - might be rejected for an originator product. Both HTA 
agencies recommend that prescribing for biosimilars should be by brand name to avoid 
automatic substitution in the pharmacy.
BI4
IMPACT OF ExCLUSIvE HOSPITAL DISTRIBUTION OF BIOSIMILAR ON DRUG 
HEALTH CARE BUDGET
Rémuzat C.1, Vataire A.L.2, Cetinsoy L.2, Aballea S.1, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, PARIS, France, 3University Claude Bernard  
Lyon 1, Lyon, France
Objectives: There is an increased trend in shifting biologics distribution to exclu-
sive hospital pharmacy channel. Although it looks obvious that such process will 
generate savings through tenders at regional or national level such policy conse-
quences were not clearly quantified. We used a model developed for EU commission 
to assess the consequences of such policies on biosimilars for selected EU countries 
(model developed for the European Commission for the project”EU Pharmaceutical 
expenditure forecast” http://ec.europa.eu/health/healthcare/key_documents/index.
en.htm). MethOds: We built a model to assess policy scenarios impact on pharma-
ceuticals reference forecast for seven EU Member States (France, the UK, Germany, 
Poland, Portugal, Greece and Hungary). We tested the impact of shifting biosimilar 
distribution to hospital channel on pharmaceutical industry revenue, Health insurers 
budget and society cost. Results: For the period 2012-2016 the savings of biosimilars 
(based in million Euros) for Health insurance will be for: UK 2,023; GE 1,127; FR 1,634; PL 
200; GR 19; PO 272; HU 29. The extra savings by shifting of the biosimilars distribution 
to exclusive hospital pharmacy will be: for UK 353; GE 3,392; FR 1,684; PL 37; GR 206; PO 
65; HU 176. The difference is relatively small for UK, although significant. However, it is 
considerable for Germany and France (around 3 and 2 time original saving). Similar fig-
ures (revenue loss) are seen for pharmaceutical companies. cOnclusiOns: Although 
the impact of such policy varies from one country to one another based on initial pro-
portion of biosimilar distributed through hospital and level of discount over branded 
products, this policy appears to have a substantial impact on drug expenditures and 
might contribute to sustainability of health insurance in EU countries. Germany and 
France might benefit dramatically from such policy.
CANCER OUTCOMES RESEARCH STUDIES
CA1
RESPONSIvENESS OF THE EQ-5D IN ONCOLOGy: A META-ANALySIS
Smith A.B.1, Cocks K.1, Taylor M.2, Parry D.3
1University of York, York, UK, 2York Health Economics Consortium, York, UK, 3AstraZeneca UK, 
Macclesfield, UK
Objectives: The EQ-5D is often employed in clinical trials to derive quality-
adjusted life years for cost-utility analyses, and in comparisons of health-related 
quality of life across conditions. However, there are concerns that the EQ-5D is less 
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Objectives: To assess the economic burden of cancer by estimating years of poten-
tial productive life lost (YPPLL) and costs of lost productivity due to premature can-
cer-related mortality across Europe. MethOds: We derived the number of cancer 
deaths by sex for 23 of the most common cancer sites in 30 European countries from 
GLOBOCAN. YPPLL were calculated by multiplying the number of cancer-specific 
deaths for each productive age group (15-64) by standard life expectancy at the 
mid-point for each age group. Using the human capital approach, we multiplied 
standardised YPPLL for each individual by country- age- and gender-specific annual 
wages from age of death until retirement following adjustments for labour force 
participation and unemployment. Costs were expressed in 2008€ . Results: All 
cancer sites combined generated a total of € 150.9 billion in premature mortality 
costs in Europe in 2008. Western Europe accounted for almost half of the total, 
followed by Northern (21%), Southern (21%) and Central & Eastern Europe (9%). 
Findings contrasted with YPPLL where Central & Eastern Europe had the highest 
burden. Male costs exceeded female costs by 88% in Europe as a whole (male: € 98.4 
billion; female: € 52.5 billion) and across all European regions. Lung was the most 
expensive site (€ 34.7 billion; 23% of total costs), followed by breast cancer (€ 13.6 
billion, 9%), colorectal cancer (€ 12.1 billion, 8%), brain & CNS (€ 9.1 billion, 6%) and 
pancreatic cancer (€ 7.5 billion, 5%). According to premature mortality cost per death, 
testicular cancer was the most expensive site (€ 2.5 million per death), followed by 
brain & CNS cancer (€ 481,512) and Hodgkin lymphoma (€ 474,559). cOnclusiOns: 
Lost productivity costs due to cancer-related premature mortality are significant in 
Europe. Productivity costs provide an alternative perspective on the cancer burden 
on society and may inform cancer control policy decisions.
CONCEPTUAL PAPERS
CP1
INCREMENTAL COST PER QUALITy-ADjUSTED LIFE yEAR GAINED? THE NEED 
FOR ALTERNATIvE METHODS TO EvALUATE MEDICAL INTERvENTIONS FOR 
ULTRA-RARE DISORDERS
Schlander M.1, Garattini S.2, Kolominsky-Rabas P.3, Nord E.4, Persson U.5, Postma M.6, 
Richardson J.7, Simoens S.8, Sola Morales O.9, Tolley K.10, Toumi M.11
1University of Heidelberg, Wiesbaden, Germany, 2Mario Negri Institute for Pharmacological 
Research, Milano, Italy, 3University of Erlangen-Nuremberg, Erlangen, Germany, 4Norwegian 
Institute of Public Health, Oslo, Norway, 5The Swedish Institute for Health Economics, Lund, 
Sweden, 6Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, 
University of Groningen, Groningen, The Netherlands, 7Monash University, Melbourne, Australia, 
8KU Leuven, Leuven, Belgium, 9HITT, Barcelona, Spain, 10Tolley Health Economics, Buxton, UK, 
11University Claude Bernard Lyon 1, Lyon, France
Objectives: To critically appraise the problems posed by the systematic valua-
tion of interventions for ultra-rare disorders using conventional health economic 
analysis methods. MethOds: An international group of clinical and health eco-
nomic experts met in conjunction with the Annual European ISPOR Congress in 
Berlin/Germany, November 2012, to identify and deliberate underlying issues openly, 
adhering to the Chatham House rule. Results: The group reached a broad consen-
sus, including: The complexities of research and development new treatments for 
ultra-rare disorders (URDs) may require conditional approval and reimbursement 
policies, such as coverage with evidence development agreements, but should not 
be used as a justification for showing surrogate endpoint improvement only. As a 
prerequisite for value assessment, demonstration of a minimum significant clinical 
benefit should be expected within a reasonable timeframe. Regarding the economic 
evaluation of interventions for URDs, the currently prevailing logic of cost effective-
ness (using benchmarks for the maximum allowable incremental cost per quality-
adjusted year, QALY, gained) was considered inappropriate since it does not capture 
well-established social preferences regarding health care resource allocation. Such 
social preferences include, but are not limited to, a priority for care for the worse of 
(related to initial health state), for those with more urgent conditions (the so called 
“rule of rescue”), a relatively lower priority based upon capacity to benefit, and a 
dislike against “all or nothing” resource allocation decisions that might deprive 
certain groups of patients from any chance to access effective care. cOnclusiOns: 
Alternative paradigms to establish the “value for money” conferred by interventions 
for URDs should be developed with high priority. Such methods should capture and 
reflect prominent societal value judgments, beyond efficiency as conventionally 
defined by QALY maximization under a budget constraint.
CP2
THE MULTIMODEL ENSEMBLE APPROACH TO REDUCING STRUCTURAL 
UNCERTAINTy IN DECISION ANALyTICAL MODELLING
Parham P.E.1, Hughes D.A.2
1Bangor University, Gwynedd, UK, 2Bangor University, Bangor, UK
Decision analytical modelling represents an essential tool for undertaking health 
economic evaluation. Markov models provide a mathematical framework for such 
analyses, particularly in the context of assessing the cost-effectiveness of treat-
ments for chronic diseases where economic outcomes are typically extrapolated 
beyond the duration of clinical trials. However, structural uncertainty is a key chal-
lenge, to methodologists and decision makers alike, that has hitherto attracted 
insufficient attention. Best practice guidelines advocate the testing of structural 
assumptions through alternative modelling approaches or conducting scenario 
analyses. It should be recognised, however, that structural differences in model 
design represent a strength, rather than limitation, of the modelling process and 
in fields such as climate modelling, multi-model comparisons and ensemble pre-
dictions have been used extensively as the basis for more robust policy decisions. 
Methods for combining models represents an emerging field in climate modelling, 
but the simplest approach is to treat all models equally and the mean of all model 
predictions has been shown to improve on the ‘best’ model predictions in numerous 
studies. A weighted multi-model approach may also be developed, but this remains 
an area of ongoing debate. To date, health economists have not fully embraced the 
potential of the multi-model paradigm to reduce structural uncertainty. In this work, 
responsive to change particularly in oncology. Therefore the objective of this study 
was to determine the level of responsiveness of the EQ-5D in oncology. MethOds: 
A systematic review identified relevant articles reviewing responsiveness of the 
EQ-5D in adults (EMBASE, Medline). Effects sizes (ES) were calculated for the studies 
identified where not already reported. A meta-analysis was undertaken of the effect 
sizes: homogeneity of variance was assessed (fixed effects) and random effects 
models applied where there was significant heterogeneity. Responsiveness was also 
compared for improvement/deterioration in health status. Analyses were conducted 
in SPSS v18. Results: Data were available from 12 studies (3 breast, 2 prostate, as 
well as ovarian, lung and renal cancers) each with EQ-5D data at a minimum of 2 
time points leading to a total of 45 entries. The overall unweighted ES was -0.26 
(95%CI: -0.31 to -0.21), however there was significant heterogeneity in terms of effect 
sizes (Q(44) = 427.00, p< 0.001) which was accounted for using the random effects 
model (Q(44) = 39.58, p> 0.05). The overall weighted effect size (ES) was -0.17 (95%CI: 
-0.33 to -0.01). The weighted ES for improvement was 0.08 (95%CI: -0.02 to 0.18), and 
-0.52 (95%CI: -0.64 to -0.41) for deterioration. cOnclusiOns: There is considerable 
heterogeneity in the reported effect size of the EQ-5D. Responsiveness of the EQ-5D 
in oncology trials as measured by effect sizes is modest at best. The instrument 
appears to be more sensitive to deterioration in health status than to improvements. 
Further work will explore the ES of the EQ-5d in comparison with responsiveness 
of disease-specific measures and changes in health status.
CA2
THE BURDEN OF CAREGIvING IN CANCER: THE STATUS OF CLINICAL RESEARCH
Foster R.E., Bardos J.I., Wilson T.J., Hamerslag L., Kusel J.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: The responsibility of caring for cancer patients, often suffering from a 
magnitude of health problems, can result in a considerable burden for their caregiv-
ers, both physically and psychologically. The objective of this study was to assess 
the status and extent of clinical research into the burden of caregiving for cancer 
patients. MethOds: ClinicalTrials.gov was searched for all cancer trials that con-
sidered caregiver burden, using a matrix of search terms such as ‘carer’, ‘burden of 
care’ or ‘caregiver’. The impact of geographical location or cancer type on the pro-
portion of trials assessing caregiver burden, the outcome measures used and the 
proportion of trials including caregiver burden as an outcome over time were inves-
tigated. Results: From a total of 36,184 cancer-focused trials documented world-
wide, 1,596 (4%) assessed caregiver burden. Outcome measures included caregiver 
quality of life (QoL), satisfaction with care and mood states. The impact of caregiver 
burden in cancer trials within different world regions varied, with the highest pro-
portion of trials that considered caregiver burden located in Mexico (23%) and Asia 
(14-22%). Trials for five major cancer types (breast, lung, prostate, colorectal, liver) 
assessed caregiver burden at similar frequency (4-5%). Evaluation of completed tri-
als demonstrated that the proportion of cancer trials considering caregiver burden 
increased from < 1% between 1997-2001 to 7% after 2012. cOnclusiOns: Fewer 
than 5% of all cancer trials documented worldwide have evaluated the impact of 
caregiver burden, although geographical variation does exist. The equal assess-
ment of caregiver burden across cancer types may suggest that no single cancer 
type is considered to have a higher degree of caregiver burden. Interestingly, while 
the number of total cancer trials evaluating caregiver burden documented to date 
is relatively low, the incidence has increased over the last 15 years, suggesting that 
the growing importance of caregiver burden is being recognised.
CA3
EMA APPROvAL OF DRUGS ON THE BASIS OF PIvOTAL NON-COMPARATIvE 
PHASE II TRIAL DATA
Macaulay R.
HERON Health, London, UK
Objectives: The recent European Medicines Agency (EMA) approval of crizotinib has 
highlighted the potential for regulatory approval to be gained on the basis of pivotal non-
comparative Phase II data. This research aims to determine the circumstances under 
which the EMA will approve submissions on this basis. MethOds: All publicly available 
European Public Assessment Reports (EPARs) were screened up to June 2013. Submissions 
that were based on pivotal Phase II data were identified and the acceptance decision, 
disease, and level of benefit were extracted. Results: Eight drugs (bevacizumab, bort-
ezomib, crizotinib, dasatinib, everolimus, gefitinib, imatinib, ofatumumab) across ten 
indications been submitted to the EMA on the basis of pivotal non-comparative Phase II 
data. All submissions were for entry indications except imatinib, which was also submit-
ted for two further indications on this basis. All, except crizotinib, were for indications 
with no alternative therapies and all were for onology indications except everolimus 
which was for subependymal giant cell astrocytoma (SEGA). All, except crizotinib, were 
EMA designated orphan medical products for these indications. One submission was 
rejected (bevacizumab), one was restricted (ofatumumab), and eight were approved. 
Top-line supportive Phase III data was only available in two submissions (crizotinib and 
everolimus). Overall response rates (ORRs) were the primary endpoints in all submis-
sions except imantinib and dasatinib in leukaemia indications and everolimus in SEGA. 
Rejected drugs had ORRs of 47% (ofatumumab, rejected subpopulation) and 38% (beva-
cizumab). Approved drugs had ORRs of 60% (crizotinib), 58% (ofatumumab, approved 
subpopulation), 40% (imatinib), and 35% (bortezomib). Despite low ORRs, imatinib was 
used to treat a disease with no licensed therapies (gastrointestinal stromal tumours), 
and bortezomib offered a 10% complete remission rate. cOnclusiOns: Pivotal Phase II 
data can support EMA approval if it demonstrates substantial clinical benefits for small 
patient populations with severe diseases that lack therapeutic alternatives.
CA4
MEASURING THE COST OF LOST PRODUCTIvITy DUE TO PREMATURE CANCER-
RELATED MORTALITy: A EUROPEAN OvERvIEw
Hanly P.1, Soerjomataram I.2, Sharp L.3
1National College of Ireland, Dublin, Ireland, 2International Agency for Research on Cancer, Lyon, 
Ireland, 3National Cancer Registry Ireland, Cork, Ireland
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administrative censoring, and data generating models. Combining the findings 
from our review and our simulation study, we made practical recommendations on 
the use of adjustment methods in HTA. Results: Our review demonstrates that 
adjustment methods make important limiting assumptions. Our simulation stud-
ies show that the bias associated with alternative methods is highly associated 
with deviations from their assumptions. Our recommended analysis framework 
aims to help researchers find suitable adjustment methods on a case-by-case 
basis. The characteristics of clinical trials and the treatment switching mechanism 
observed within them, should be considered alongside the key assumptions of the 
adjustment methods. cOnclusiOns: The limitations associated with switching 
adjustment methods mean that different methods are appropriate in different 
scenarios. In some scenarios all methods may be prone to important bias. The data 
requirements of adjustment methods have important implications for people who 
design and analyse trials which allow treatment switching.
MO2
USE OF REAL-wORLD EvIDENCE (RwE) TO vALIDATE A TRIAL-BASED HEALTH 
ECONOMIC MODEL
Munakata J.1, Li H.2, Luo R.3, Guo Y.3, O’Sullivan A.4, Duran A.5, Nelson M.6
1IMS Health, San Francisco, CA, USA, 2IMS Health, Alexandria, CA, USA, 3IMS Health, Plymouth 
Meeting, PA, USA, 4IMS Health, Waltham, MA, USA, 5IMS Health, London, UK, 6IMS Health, 
Alexandria, VA, USA
Objectives: Decision makers often rely on health economic models populated 
with clinical trial data to inform initial assessments about treatment selection, 
coverage, and reimbursement. To date, there have been few (if any) published model 
re-analyses using real-world evidence (RWE). The purpose of this study is to 1) assess 
real-world health and economic outcomes associated with oral anticoagulant vs. 
low molecular weight heparin (LMWH) as prophylaxis for venous thromboembo-
lism (VTE) in patients undergoing total hip (THR) or knee (TKR) replacement, and 2) 
compare results of a health economic model populated with clinical trial data vs. 
RWE. MethOds: Patients who underwent THR or TKR between July 2011 and June 
2012 were identified in a US commercial insurance claims database. Patients were 
required to be continuously enrolled 3 months pre-/post-index and were excluded if 
treated with multiple anti-coagulants within 10 days post-index. A propensity score 
matching technique was employed to reduce selection bias. Patient characteristics, 
inpatient-related VTE events and health care costs were determined. A health eco-
nomic model previously parameterized with clinical trial data was repopulated and 
reanalyzed using inputs derived from the claims study. Results: A total of 14,880 
patients were identified (7,440 oral anticoagulant, 7,440 LMWH). In both groups, 
mean age was 59 and 53% were female. Compared with LMWH, oral anticoagulant 
use was associated with fewer symptomatic VTE events over 1-year. When repopu-
lated with clinical inputs from claims data, the model projected similar VTE event 
differences as trial-based model (-0.023 vs. -0.015). Costs (per patient/year) in oral 
anticoagulant and LMWH groups were consistent across the trial-based model ($385 
vs. $1,011), claims-based model ($437 vs. $1,290), and direct reported results from 
claims analysis ($506 vs. $1,125). cOnclusiOns: Use of RWE is a practical and 
objective way to validate a trial-based health economic model. Future work should 
consider study design issues and practical use of results.
MO3
MULTI-STATE STATISTICAL MODELLING TO QUANTIFy AN INDIvIDUAL-BASED 
MICRO SIMULATION MODEL FOR RADIOTHERAPy TREATMENT IN LUNG 
CANCER PATIENTS
Bongers M.L.1, De Ruysscher D.2, Oberije C.3, Lambin P.3, Uyl-de Groot C.A.4, Coupe V.M.H.1
1VU University Medical Center, Amsterdam, The Netherlands, 2University Hospitals Leuven/KU 
Leuven, Leuven, Belgium, 3MAASTRO Clinic, Maastricht, The Netherlands, 4Erasmus University 
Rotterdam, Rotterdam, The Netherlands
Objectives: We developed an individual-based micro-simulation model for radio-
therapy treatment in non small-cell lung cancer (NSCLC). The aim was to explore 
the suitability of multi-state statistical modelling in heath economics, as a tool to 
parameterize a simulation model that tracks clinical events over time, taking patient 
and tumour features into account. MethOds: The model contains the four clinical 
states ‘A: alive without local recurrence (LR) or metastasis (M)’, ‘LR’, ‘M’, and ‘Death’. 
Transition rates were estimated using multi-state statistical modelling, a technique 
that allows the simultaneous estimation of hazards for multiple transitions, taking 
covariates as well as the occurrence and timing of previous events into account. Each 
of the hazards from A to either LR, M and Death were adjusted for the presence of the 
other competing risks. Individual patients were simulated by repeatedly sampling 
a patient profile, consisting of patient and tumour characteristics. Subsequently, for 
each patient a pathway through the model was simulated. The internal validity of 
the model was verified by comparing intermediate simulation outcomes and overall 
survival under two different radiotherapy strategies to the original data used for 
estimation. Finally, the model was externally validated by comparing model outcomes 
to Dutch cancer registry data. Results: Model simulations for the two radiotherapy 
strategies demonstrated internal validity, with predicted probabilities for the occur-
rence of LRs, Ms, deaths, and the occurrence of toxicities within 3 years that fell within 
the 95% confidence intervals of the data. The same was observed for the prediction 
of overall survival. Comparison of the model predictions to the Dutch cancer registry 
data showed a moderate fit. cOnclusiOns: Multi-state statistical modelling is a 
useful technique for obtaining the transition rates that are required for the quantifi-
cation of a micro-simulation model. In future, our model will be used to evaluate the 
cost-effectiveness of individualized treatment strategies.
MO4
BAyESIAN CALIBRATION METHOD TO ESTIMATE TRANSITION PROBABILITIES 
FOR A MARKOv MODEL BASED ON A CONTINUOUS OUTCOME MEASURE: 
APPLICATION IN PARKINSON’S DISEASE
Neine M.1, Briquet B.1, Mokdad C.E.1, Vataire A.L.2, Aballea S.1
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, PARIS, France
we illustrate how this approach may be developed to a) simultaneously and system-
atically compare health economic outcomes predicted by multiple Markov models; 
b) address the question of whether (and how) to weight different models within an 
ensemble based on different performance metrics and model skill scores; c) identify, 
quantify, and partition total uncertainty across a multi-model ensemble into different 
sources (for example, to highlight where future research priorities may optimally lie to 
further improve the robustness of policy recommendations through model improve-
ment and data collection); and d) apply this approach to some real-world examples.
CP3
THE GROwING ROLE OF QUALITATIvE INTERvIEwS IN HEALTH OUTCOMES 
RESEARCH
Guillemot J.1, Gauthier A.1, Hass B.2, Basso F.3, Cognet M.1
1Amaris, London, UK, 2Boehringer Ingelheim GmbH, Ingelheim, Germany, 3Boehringer Ingelheim 
GmbH, Vienna, Austria
Objectives: Qualitative interviews, as tools for scientific evidence generation, are 
often excluded from consideration in health outcomes research. Lack of methodologi-
cal rigour and the non-reproducibility and non-generalizability of results are often 
used to justify quantitative methodologies. Here we present an illustrative exam-
ple of qualitative interviewing’s value within health outcomes research. In a study 
aiming to measure patient and physician preferences for hepatitis C treatments, a 
discrete choice experiment was designed and a systematic literature review was 
conducted. MethOds: To assess the comprehensibility and relevance of the ques-
tionnaire as well as to estimate the value and preciseness of assumptions, pre-tests 
consisting of a questionnaire pilot followed by a semi-direct interview were con-
ducted. The semi-direct interviewing followed rigorous methods, including defined 
themes assembled in a discussion guide and behavioural rules for the interviewer 
to promote axiological neutrality. Analytical methods using predefined codes for 
the interpretation enabled a systematic understanding of datasets. Results: The 
qualitative component mostly validated but sometimes challenged the theoretical 
assumptions of the discrete-choice experiment, which had been previously developed 
on the basis of the systematic literature review. Interviews shed light on occasional 
complexity and lack of comprehensibility of some questions. The qualitative analysis 
provided insights to patients’ and physicians’ experience of their treatment selection 
process. It included socio-psychological dispositions, like the aversion for work absen-
teeism or the importance of social representation encouraging patients to prefer treat-
ments which side effects would not affect their social capacities. cOnclusiOns: This 
method provided in-depth and structured feedback from a small group of patients and 
physicians. As health outcomes studies increasingly require to expand their level of 
detail and sensitivity by entering subjective fields of personal preferences, patients’ 
experiences and decision-making processes, there is a pressing need for conduct-
ing qualitative micro-level studies prior to supporting broader, field-based studies.
CP4
CONCEPTUAL AND PRACTICAL CONSIDERATIONS wHEN DEALING wITH 
MISSING UTILITy DATA IN LONGITUDINAL TRIALS, AND SUBSEQUENT USE IN 
COST-EFFECTIvENESS ANALySES
Weston A.R.1, Brnabic A.1, Standfield L.B.2
1Optum, Sydney, Australia, 2Griffith University, Queensland, Australia
Patient preference-based health-related quality of life measures (utilities) are a criti-
cal input in cost-effectiveness analyses of pharmaceuticals and other health care 
technologies. Over recent years it has become more common for utility data to be 
collected alongside key clinical data within the pivotal Phase III trials. However, utility 
data are often not available for all patients throughout the entire course of the trial. 
The authors discuss the concept that there are unique characteristics of utility data 
that need to be considered when dealing with missing values, including the large 
inter-patient variability typically present at baseline. Missing data arise because i) 
patients become more ill and are less able to complete patient-reported instruments, 
ii) patients die during the course of the trial, or iii) patients are censored at later stages 
of the trial due to rolling recruitment. Whilst this is often a problem in oncology trials, 
it is also a consideration in other interventional and observational research designed 
to inform pharmacoeconomic evaluations. Situations where individual patient data 
are accessible and where only summary statistics are available are discussed. The 
practical considerations of how such re-analysed data should then be included within 
an economic model are discussed, given the manner in which utilities are incorpo-
rated will vary depending on the nature of the health states used.
RESEARCH ON METHODS – MODELING STUDIES
MO1
A GUIDE TO ADjUSTING SURvIvAL TIME ESTIMATES TO ACCOUNT FOR 
TREATMENT SwITCHING IN RANDOMISED CONTROLLED TRIALS
Latimer N.R.1, Abrams K.R.2, Lambert P.C.2, Crowther M.J.2, Wailoo A.J.1, Morden J.P.3,  
Akehurst R.L.1, Campbell M.J.1
1University of Sheffield, Sheffield, UK, 2University of Leicester, Leicester, UK, 3The Institute of 
Cancer Research, Sutton, UK
Objectives: Treatment switching is a common issue in clinical trials of cancer 
treatments – often patients randomised to the control group are permitted to 
switch onto the experimental treatment at some point during follow-up. In such 
circumstances an intention to treat (ITT) analysis will result in biased estimates 
of the overall survival advantage – and therefore the cost-effectiveness – associ-
ated with the experimental treatment. Methods to adjust for switching have been 
used inconsistently and potentially inappropriately in health technology assess-
ments (HTA). We present an analytical framework to guide analysts on the use 
of methods to adjust for treatment switching in the context of economic evalua-
tions. MethOds: We conducted a review of methods used to adjust for treatment 
switching in HTA, and two rigorous simulation studies to assess the performance 
of adjustment methods in a range of realistic scenarios. We tested different simu-
lated trial sample sizes, crossover proportions, treatment effect sizes, levels of 
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Intra class correlation coefficients between the countries were high: from 0.89 
(England vs. US) through 0.99 (Canada vs. US). cOnclusiOns: This proof of con-
cept study indicates that computer-based choice tasks for the EQ-5D-5L in the 
general population are feasible and parameter of the choice tasks estimates are 
generally consistent and logical, and the estimated values are largely consistent 
between the 4 countries.
PP3
CAN THE USE OF SOCIAL MEDIA AND MOBILE APPS IMPROvE PATIENT 
KNOwLEDGE OF DISEASE AND HEALTH OUTCOMES? A SySTEMATIC REvIEw
Abogunrin S., Martin A.
Evidera, London, UK
Objectives: The use of interactive social media (SM) based on Web 2.0 technology, 
e.g. Twitter, Facebook, MySpace; and mobile apps, is increasing but its role in improving 
patient knowledge of their disease and its management is unclear. We conducted a 
systematic review to assess the evidence for health benefits from SM. MethOds: We 
searched MEDLINE and EMBASE for relevant articles published in the last five years that 
used words synonymous with SM; patient, carer, or parents’ preferences, opinions or 
views; pharmacological interventions; and disease. We included comparative studies 
or systematic reviews on the use of any SM by patients, that measured differences in 
knowledge about disease, uptake of pharmacological interventions, or clinical outcomes 
from better management of disease. Articles were excluded if they reported only the 
use of SM by health care professionals, or if they were case studies, narrative reviews 
or expressed expert opinions. Results: We identified 3,232 unique abstracts, 24 of 
which reported the use of interactive, internet-delivered programs (n= 13), Facebook 
(n= 4), and mobile apps (n= 3) , for improving health outcomes of patients with cancer, 
or inflammatory, mental health, musculoskeletal, neurologic, ophthalmologic, or sexual 
health-related disorders. Patients receiving SM-based interventions showed improved 
knowledge of their disease, and better clinical outcomes compared with controls. Two 
additional studies reported on the use of SM aimed at increasing knowledge, and self-
efficacy in parents of children with cystic fibrosis. Overall, the studies showed that 
SM-based interventions improved knowledge of disease and clinical outcomes com-
pared with control groups. cOnclusiOns: Surprisingly little research has been con-
ducted on the value of SM to aid and support patients. What evidence exists suggests 
that SM tools offer health benefits. fFrther work is needed to confirm these effects and to 
assess how best the tools might increase patients’ knowledge about disease, treatment 
adherence and clinical outcomes.
PP4
THE IMPORTANCE OF PATIENT REPORTED OUTCOMES IN REIMBURSEMENT OF 
ORPHAN PRODUCTS IN EUROPE
Lyons E.J.1, McGeagh J.1, Es-Skali I.J.2, Parmenter L.3, Nijhuis T.4, Boucher G.1
1Quintiles, Reading, UK, 2Quintiles Consulting, Hoofddorp, The Netherlands, 3Quintiles Outcome, 
Reading, UK, 4Quintiles, Hoofddorp, The Netherlands
Objectives: To determine the importance of patient reported outcomes (PROs) 
in the reimbursement of orphan drugs in Europe and identify any HTA authority 
preferences for particular PRO measures. MethOds: All 31 products assigned an 
orphan designation by the European Medicines Agency (EMA), between January 
2009 and May 2013, were evaluated against the following criteria: approval for 
marketing, submission for reimbursement/price negotiation to NICE, SMC, G-BA, 
and HAS, presence or absence of PROs, approval or rejection of reimbursement 
application. Where available, HTA guidance documents resulting from the appli-
cations were reviewed in detail to determine the impact of PRO measures on the 
reimbursement decision. Results: Of the 31 products assigned an orphan des-
ignation, 26 were granted marketing authorisation by the EMA. Eleven products 
were submitted to NICE for reimbursement in England of which 7 submissions 
contained PROs and 6 were approved. In Scotland, 11 products were submitted for 
reimbursement to the SMC and of the 7 submissions containing PRO data, 3 were 
recommended for reimbursement. One submission is still pending. In Germany, 7 
products were submitted to the G-BA of which 5 contained PROs and were allowed 
to enter into price negotiations. The French HTA authority, HAS, evaluated 20 sub-
missions of which 9 contained PROs and 19 were approved. cOnclusiOns: The 
results of our assessment of EMA approved orphan drugs indicates that a great 
deal of variation exists across Europe with respect to the evaluation of orphan 
drugs for reimbursement or price negotiation. In some countries, reimbursement is 
largely independent of evidence of reported patient benefit while in others, where 
evidence of economic value is critical for success, robust PRO data are essential.
RESEARCH PODIUM PRESENTATIONS – SESSION II
RESEARCH ON METHODS – CLINICAL STUDIES
CL1
A COMPARISON OF METHODOLOGIES FOR ESTIMATING SURvIvAL IN PATIENTS 
TREATED wITH SECOND-GENERATION TyROSINE-KINASE INHIBITORS (TKIS) 
FOR CHRONIC MyELOID LEUKAEMIA (CML)
Pennington B.1, Batty A.J.1, Clifton-Brown E.2
1BresMed, Sheffield, UK, 2Pfizer Ltd., Tadworth, UK
Objectives: NICE have previously recommended nilotinib, but not dasatinib, as 
a first-line (TA251) and second-line (TA241) treatment in chronic phase (CP) CML. 
Within these appraisals, different methods were used to estimate overall survival 
(OS). Bosutinib, a potent dual Src/Abl TKI, is undergoing a NICE appraisal in sec-
ond-line or later CML (ID495). The objective is to review the OS methods used and 
assess their impact on cost-effectiveness and recommendations in CML apprais-
als. MethOds: We identify the methodologies used for estimating OS in TA241 
and TA251 and investigate the impact of using these to estimate OS for the TKIs, 
including bosutinib, in relapsed/refractory CML. Finally, we consider the implica-
tions of the various methodologies on the cost-effectiveness results and recom-
mendations in previous and future NICE assessments of TKIs for CML. Results: The 
base-case in TA241 used a surrogate relationship between response (MCyR) and OS 
Objectives: Estimating transition probabilities for Markov models is challenging 
when the effectiveness of the studied intervention is measured using a continuous 
score, and only aggregate data by treatment are available. We developed a Bayesian 
calibration method to estimate transition probabilities and applied it in Parkinson’s 
disease (PD). MethOds: A previously published Markov model with health states 
corresponding to Hoehn and Yahr (H&Y) stages was adapted. Patient-level datasets 
were simulated to replicate results of clinical trials for different drugs, using the 
UPDRS scale to assess severity, and transition probabilities were estimated from 
simulated data to provide a reference case. Two calibrations methods were tested for 
obtaining transition probabilities without patient-level data. Firstly, the Solver tool 
of Excel was used, with the mean change in UPDRS score and associated variance as 
targets. Secondly, a Bayesian calibration was implemented in OpenBUGS to estimate 
the posterior distribution of transition probabilities, assuming the change in UPDRS 
score has a normal distribution, with observed mean and variance. All other model 
input parameters were taken from the original model. Results: With simulated 
patient-level data, the incremental cost (IC) was estimated at € -7,015 (95% credibility 
interval: € -23,953; € 5,977) and incremental QALYs (IQ) at 0.455 (0.112; 0.950). With 
calibration using the Solver tool, there was an infinity of solutions resulting in IC 
ranging from € -10,141 to € -8,206 and IQ ranging from 0.422 to 0.473. With calibra-
tion using OpenBugs, the IC was estimated at € -6,852 (€ -24,244; € 6,448) and the 
IQ at -0.448 (0.108; 0.959). cOnclusiOns: Incremental costs and QALYs obtained 
using the Bayesian calibration and analysis of patient-level data were similarly 
distributed. Mean results obtained using the Solver tool were comparable, but no 
statistical distribution around results could be provided. This example suggests that 
the Bayesian calibration is a valid method to derive transition probabilities from 
continuous outcome measures.
PATIENT PREFERENCE STUDIES
PP1
A METHODOLOGy FOR PREDICTING THE IMPACT OF COPAyMENTS ON THE 
UTILIzATION OF HEALTH TECHNOLOGIES
Sabatelli L.
GLOB MOD, Barcelona, Spain
Objectives: Copays (or copayments) for health-technologies, such as pharma-
ceutical products, are used by governments and insurers to prevent moral hazard, 
reduce unnecessary utilization of resources, and contribute to the cost of health 
care. Nevertheless they may also reduce access to necessary care, and the financial 
protection associated with health insurance. In addition, from the perspective of the 
manufacturer, the introduction of copays may determine unexpected and abrupt 
falls in demand. The methodology here presented uses data extracted from surveys 
on product utilization and patient income, prior and after the introduction of copays 
in various countries and regions, to predict the potential impact of copays on the 
demand for a pharmaceutical product in a given country or region. MethOds: This 
approach uses multi-level multivariate regressions and a micro-economic model 
of demand (which assumes maximization of utility and preference independence) 
to anticipate changes in utilization (and therefore in demand) as a function of the 
amount of copay charges. Data from a computer simulation were used to test the 
method. Results: A non-linear relationship between copay and drug-consump-
tion, determined by the combined effect of the amount charged and of the average 
population income was identified, predicting changes in aggregate demand and in 
income-specific demand. For instance: if we consider two countries both adopting 
a 1 Euro co-pay charge on a (not easily substitutable) product and whose average 
income differs by 20%, we expect the demand to be almost 3% lower in the country 
with the lower income than in the country with the higher income. cOnclusiOns: 
Under general market assumptions, it is possible to build models that estimate the 
potential impact of copay charges. These models can be used to help design health 
policies and market strategies.
PP2
MULTINATIONAL CONSISTENCy OF A DISCRETE CHOICE MODEL IN 
QUANTIFyING HEALTH STATES FOR THE ExTENDED 5-LEvEL EQ-5D
Krabbe P.F.M.1, Devlin N.J.2, Stolk E.A.3, Shah K.K.4, Oppe M.3, van Hout B.4, Quik E.H.1,  
Pickard A.S.5, Xie F.6
1University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 
2Office of Health Economics, London, UK, 3Erasmus University Rotterdam, Rotterdam, The 
Netherlands, 4University of Sheffield, Sheffield, UK, 5University of Illinois at Chicago, Chicago, IL, 
USA, 6McMaster University, Hamilton, ON, Canada
Objectives: To investigate the feasibility of choice experiments for EQ-5D-5L 
states using computer-based data collection, and to examine the consistency of 
the estimated parameters values derived after modeling the stated preference 
data across countries in a multinational study. MethOds: Similar choice experi-
ments were executed in Canada, England, The Netherlands, and United States 
(US). Interactive software was developed to standardize the format of the choice 
tasks across countries, except for England where face-to-face interviewers were 
used. The choice task required respondents to choose between two sub-optimal 
health states. A Bayesian design was used to generate 200 pairs of states that were 
randomly grouped into 20 blocks. Each respondent completed one block consisting 
of 10 pairs. A main-effect alternative-specific multinomial probit regression model 
was used to estimate regression coefficients and to derive values for each health 
state that capture the relative differences in levels between states. Results: In 
total there were 1775 respondents, at least 400 respondents from each country, 
who completed 17750 paired comparisons, resulting into 35500 assessed health 
states. The mean time to perform one choice task was between 29.2 (US) and 
45.2 (England) seconds. All regression coefficients were statistically significant, 
except level 2 for Usual Activities in The Netherlands (p= 0.51). Three regression 
coefficients with illogical ordering were observed (The Netherlands: level 3 Pain/
Discomfort, England: Level 3 Usual Activities & Pain/Discomfort). Predictions for 
the complete set of 3125 EQ-5D-5L states were similar for the four countries. 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A327
Evaluation (GRADE) approach using the example of male human papilloma virus 
(HPV) vaccination Europe. MethOds: A pan-European multidisciplinary expert 
group was established to develop an extended GRADE framework that includes 
explicit assessment of cost-effectiveness, medical needs, and patient aspects, ethi-
cal and social issues. Using an expert panel process, we assessed the feasibility of 
using this framework by applying it to male HPV vaccination in Europe. Studies were 
assessed using the specific framework tools; results and feasibility were discussed; 
and consensus was achieved through a modified Delphi method. Results: We 
identified three advisory committees (ACIP/USA; NACI/Canada; STIKO/Germany) 
using GRADE for vaccines assessment. Institutions handled data beyond vaccine 
efficacy and safety differently and did not formally grade economic evidence. We 
adopted the grading methodology of ACIP for the key factor ‘Benefits and Harms’ 
and developed modules for grading evidence type and quality of economic evalua-
tions (‘Economic Evaluation’) and for systematically assessing epidemiology, disease 
burden and unmet medical needs, as well as ethical, social and patient aspects 
(‘Values and Preferences’). The feasibility test demonstrated that all framework 
components were feasible in the case of HPV vaccination. Overall evidence type 
for cost-effectiveness was low with uncertainty in results. Cost-effectiveness was 
best, when all HPV-related diseases and outcomes were included and when assum-
ing low coverage in females and lower vaccine prices. cOnclusiOns: The GRADE 
approach is applicable in assessing vaccinations and was successfully applied to 
HPV vaccination in males. The assessment of benefits and harms can be extended 
by explicit assessment of the evidence on cost-effectiveness and other key fac-
tors including unmet medical needs, and ethical, social and patient aspects. This 
extended framework can better inform policy- and decison makers.
CARDIOvASCULAR DISEASE OUTCOMES RESEARCH STUDIES
Cv1
CHALLENGES IN MODELLING THE COST EFFECTIvENESS OF INTERvENTIONS IN 
CARDIOvASCULAR DISEASE
Burgers L.T., Redekop W.K., Severens J.L.
Erasmus University Rotterdam, Rotterdam, The Netherlands
Objectives: Modelling is essential in performing economic evaluations for various rea-
sons. For example, modelling is necessary if extrapolation of short-term or intermediate 
results to long-term outcomes is required and numerous strategies need to be evaluated 
without direct evidence. However, modelling inherently poses challenges that need to 
be dealt with since models always represent a simplification of reality. The aim of this 
study is to identify and analyse the challenges in modelling the cost-effectiveness of 
cardiovascular disease (CVD) interventions. MethOds: A questionnaire was sent to 
40 corresponding authors (systematically selected) of recent model-based economic 
evaluations of CVD interventions published in high-impact cardiovascular, health eco-
nomics and general medical journals. Respondents were asked to provide their own 
challenges and also rank the importance of challenges identified using a pilot version 
of the questionnaire distributed to 7 experienced researchers. Furthermore, we analysed 
the discussion sections of the papers to identify unmentioned challenges. Solutions, 
if available, were based on input from the respondents and the recommendations of 
the ISPOR-SMDM task force. Results: The systematic literature search identified 1720 
potentially relevant articles. The limit of 40 authors was reached after screening 294 
titles and abstracts. Beside the challenge of lack of data, preliminary results show that 
it was difficult to obtain a sufficiently valid, precise and accurate cost-effectiveness 
estimate due, for example, to interrelating clinical outcomes or extrapolating from sur-
rogate outcomes. Both challenges often exist in CEAs evaluating CVD prevention strate-
gies. cOnclusiOns: The preliminary results of this study showed examples of CVD 
modelling challenges encountered during studies published in high-impact journals. 
Modelling guidelines do not provide sufficient assistance in resolving all challenges 
but it is probably unrealistic to expect this. Some of the reported challenges are specific 
to the type of intervention and disease, but most challenges are present in all types of 
interventions and diseases.
Cv2
APPLICATION OF BEHAvIOURAL ECONOMICS TO THE UNDERSTANDING 
OF ADHERENCE: DOES AN INDIvIDUAL’S TIME PREFERENCE INFLUENCE 
ADHERENCE TO MEDICATIONS?
Fargher E.A., Morrison V., Plumpton C.O., Hughes D.A.
Bangor University, Bangor, UK
Objectives: There is general support that individual time preference affects health-
related behaviours. People with a high, positive time preference value their imme-
diate health higher than future health, even if presented with extreme scenarios 
of intertemporal choice. We hypothesised that adherence to medication requires 
trade-offs between immediate and delayed health benefits. Patients with lower 
time preference rates may be more adherent to medication as they place a higher 
value on the future benefits of adherence. MethOds: Hypertensive adult patients 
across Europe were invited to complete a web-based survey that had been translated 
and piloted. Patients’ time preference was assessed (4-items) to calculate individual 
discount rates (%) in both short term (3-years) and medium term (6-years). Medication 
adherence was measured using the Morisky questionnaire (primary analysis) and the 
Medication Adherence Report Scale (MARS, secondary analysis). Sample size calculation, 
based on 5% one-sided confidence, assuming 30% non-adherence with Morisky measure 
indicated n= 323 per country. Missing data were imputed using multiple imputation in 
STATA. The significance of the association with adherence was assessed using the Wald 
test statistic. Results: 969 patients completed the questionnaire across England, Wales 
and Hungary, 79% of possible responses were observed. Short and medium term time 
preference rates in England, Wales and Hungary were in the expected directions, but 
the relationship was not statistically significant. Based on Morisky adherence - Wales 
(short): adherent 8.7%, non-adherent 9.4% (p= 0.541); (medium): adherent 4.7%, non-
adherent 5.0% (p= 0.611). England (short): adherent 7.8%, non-adherent 9.5% (p= 0.163); 
(medium): adherent 3.7%, non-adherent 4.5% (p= 0.095). Hungary (short): adherent 
19.0%, non-adherent 18.2% (p= 0.504); (medium): adherent 8.9%, non-adherent 8.6% 
to derive OS estimates for nilotinib and dasatinib of 13.0 and 13.4 years respectively 
(second-line CP). Using the same approach for bosutinib gives an OS of 12.8 years 
(third-line CP). The base-case in TA251 used a cumulative approach, where OS is 
equal to the duration of treatments in the pathway. If this method is applied to the 
TKIs in second-line CML (TA241), OS is reduced to approximately 9.4 and 10.1 years 
for nilotinib and dasatinib respectively (second-line CP). Similarly, bosutinib OS 
(third-line CP) is also reduced using this method and a substantial increase in the 
ICER is seen. cOnclusiOns: There are methodological inconsistencies in NICE’s 
assessments of TKIs for CML. Applying the OS methodology from TA251 to TA241 
may have led to nilotinib not being recommended for routine use in the NHS. The 
impact of new methodologies on previous appraisal results and recommendations 
should be considered when assessing the validity of a new approach.
CL2
ADDRESSING HETEROGENEITy IN BASELINE RISK OF COPD ExACERBATIONS 
USING META-REGRESSION
Cope S.1, Buckley F.2, Baldwin M.3, Kraemer M.4, Jansen J.2
1Mapi, Toronto, ON, Canada, 2Mapi, Boston, MA, USA, 3Novartis Pharmaceuticals UK Limited, 
Horsham, West Sussex, UK, 4Novartis Pharma AG, Basel, Switzerland
Objectives: To evaluate differences across randomized controlled trials (RCTs) con-
cerning interventions for moderate to severe chronic obstructive pulmonary disease 
(COPD) in terms of baseline exacerbation rates and the association with treatment 
effects by means of a network meta-analysis (NMA). This NMA is performed based on 
RCTs evaluating the long-acting bronchodilators indacaterol 75/150/300µg OD, salme-
terol 50µg BID, formoterol 12µg BID, tiotropium bromide 18µg/5µg OD, and glycopyr-
ronium bromide 50µg OD. MethOds: The rate of moderate or severe exacerbations 
was extracted from RCTs identified with a systematic literature review. A Bayesian NMA 
was used to synthesize the treatment effects of the different trials. The association 
between treatment effects and baseline exacerbation rate with placebo was assessed 
with a meta-regression model assuming a constant treatment-by-baseline risk interac-
tion term. Results: Twenty-four RCTs were included that differed mainly in terms of 
smoking status, COPD severity, use of inhaled corticosteroids, exacerbation definition, 
and exacerbation history. Across the RCTs the rate of exacerbations per patient year for 
patients in the placebo arm ranged from 0.40 to 1.91. Baseline risk was negatively associ-
ated with the rate ratios reflecting treatment effects across the RCTs. The coefficient for 
baseline risk was -0.35 (95% credible intervals: -0.49, -0.18). cOnclusiOns: Based on a 
NMA of RCTs regarding the efficacy of long-acting bronchodilators in terms of the rate 
of exacerbations per patient year, baseline risk of exacerbations acts as a significant 
treatment effect modifier and should be accounted for in the model.
CL3
vALIDATION OF SURROGATE ENDPOINTS IN ADvANCED SOLID TUMOURS: 
SySTEMATIC REvIEw OF STATISTICAL METHODS, RESULTS, AND 
IMPLICATIONS FOR POLICy MAKERS
Ciani O.1, Davis S.2, Tappenden P.2, Garside R.3, Stein K.1, Cantrell A.2, Saad E.4, Buyse M.5, 
Taylor R.1
1University of Exeter, Exeter, UK, 2University of Sheffield, Sheffield, UK, 3University of Exeter, 
Truro, UK, 4Dendrix, Sao Paulo, Brazil, 5IDDI, Louvain-la-Neuve, Belgium
Objectives: Licensing and reimbursement of anticancer drugs should rely on evi-
dence from patient-relevant endpoints such as overall survival (OS). Nevertheless, 
evidence from surrogate endpoints may also be useful, as it may expedite the regula-
tory approval and coverage decisions of new therapies. It is therefore essential that 
candidate surrogate endpoints be properly validated. However, there is no consensus 
on statistical methods for such validation and on how the evidence thus derived 
should be applied by policy makers. MethOds: We review meta-analyses of thera-
peutic interventions against advanced solid tumours published until December 2012 
that quantified the statistical association between progression-free survival (PFS) 
or time-to-progression (TTP) and OS. We assessed the suitability of the two surro-
gates using three current surrogate validation frameworks: Bucher’s framework, the 
German Institute of Quality and Efficiency in Health Care’s (IQWiG) framework and 
the Biomarker-Surrogacy Evaluation Schema (BSES3). Results: Thirty-one meta-
analyses were included which employed a variety of statistical methods to assess 
surrogate validity. The strength of the association between PFS or TTP and OS was 
generally low. The level of evidence (observation-level vs. treatment-level) available 
supporting an association between PFS or TTP and OS varied considerably by cancer 
type, by evaluation tools and was not always consistent even within one specific 
cancer type. cOnclusiOns: Not in all solid tumours the treatment-level associa-
tion between PFS or TTP and OS has been investigated. According to the IQWiG’s 
framework, only PFS achieved acceptable evidence of surrogacy in metastatic colo-
rectal and ovarian cancer treated with cytotoxic agents, whereas in no indication 
did the two candidate endpoints achieve good evidence of surrogacy according to 
BSES3. Our study emphasises the challenges of surrogate-endpoint validation and 
the importance of building consensus on appropriate statistical techniques to exam-
ine surrogacy and on the development of evaluation frameworks for policy makers.
CL4
FRAMEwORK FOR EvIDENCE ASSESSMENT BASED ON GRADE AND 
APPLICATION TO HPv vACCINATION IN MALES IN THE EUROPEAN HEALTH 
CARE CONTExT
Siebert U.1, Sroczynski G.2, Baker P.3, Borget I.4, Castellsagué X.5, Chapman R.6,  
von Knebel-Doeberitz M.7, Mortensen G.L.8, La Torre G.9
1UMIT – University for Health Sciences, Medical Informatics and Technology / ONCOTYROL / Harvard 
University, Hall i. T./ Innsbruck / Boston, Austria, 2UMIT – University for Health Sciences, Medical 
Informatics and Technology, Hall i.T., Austria, 3Men’s Health Consultant, Brighton, UK, 4Institut 
Gustave Roussy, Villejuif, France, 5L’Hospitalet de Llobregat, Barcelona, Spain, 6Evidera, London, UK, 
7University of Heidelberg, German Cancer Research Center, Heidelberg, Germany, 8AnthroConsult, 
Aarhus C, Denmark, 9Sapienza University of Rome, Rome, Italy
Objectives: To develop and apply an extended framework for evidence assess-
ment based on the Grading of Recommendations Assessment, Development and 
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large polyps, natural history of adenoma transition to cancer and importantly, 
adherence. CTC was found to be cost-effective in three studies, assuming the most 
favourable scenario. cOnclusiOns: CTC has the potential to be a cost-effective 
CRC screening strategy when compared to COL. There is a strong need for a differ-
ential consideration of patient adherence and compliance to CTC and COL. Recent 
research shows that laxative-free CTC screening has the potential to become a viable 
alternative screening method for CRC as it can improve patient uptake of screening. 
This project is supported by the German Federal Ministry of Education and Research 
(BMBF) as part of the National Cluster of Excellence‚ Medical Technologies – Medical 
Valley EMN’ (Project grant No. 13EX1013B).
MD2
MARKET ACCESS OF IMPLANTABLE MEDICAL DEvICES: EvIDENTIARy 
REQUIREMENTS ACROSS GLOBAL MARKETS
Chawla A.S.1, Spinner D.S.1, Ransom J.F.2, Doyle J.2, Faulkner E.C.1
1Quintiles Consulting, Durham, NC, USA, 2Quintiles Global Consulting, Hawthorne, NY, USA
Objectives: With tightening health system budgets, medical devices (MDs) are 
being increasingly scrutinized for their impact on overall health care cost. The evi-
dence bar for implantable MDs is particular high since most implantable devices 
are not reimbursed separately by payers, but via direct bundled payments to the 
provider. To characterize that trend, the objectives of this study were to: 1) Identify 
specific evidence criteria that maximally impact the payer decision, 2) Note differ-
ences in HTAs across global markets, and finally 3) Outline differences in evidence 
requirements between drugs and devices. MethOds: A multimarket review of 
implantable MD HTAs and reimbursement decisions published from 2008-2013 was 
conducted. Identified by HTA Watch, HTAs included those from Australia, Belgium, 
Canada, France, Germany, Italy, the UK and the US. They spanned a variety of indi-
cations, including cardiovascular, orthopedic, neurological, trauma, among others. 
HTAs and reimbursement decisions were characterized for clinical and economic 
evidence requirements and apparent correlations and/or impacts on ultimate 
agency recommendation. Results: Evidence criteria evaluated by HTA agencies 
and payers primarily included: 1) Availability of supportive randomized controlled 
trials (RCTs), 2) Safety, 3) Efficacy/long-term outcomes, 4) Cost/cost-offsets/budget 
impact, and 5) Quality of-life improvement. In contrast to drug HTAs, clinician 
training and learning curve effects were often evaluated. Importantly, agencies 
recognized the challenge in demonstrating statistically- and clinically-significant 
evidence of improvement in outcomes. As such, many MDs were recommended 
on a restricted basis to specific patient subpopulations or on a coverage based 
on continued evidence development. While requirements considered most critical 
were largely uniform across global markets, regional nuances impacted the ability 
to obtain favorable reimbursement of implantable devices. cOnclusiOns: Similar 
to drugs, MDs face rising hurdles in terms of demonstrating value, both clinical and 
economic. Optimal global market access for implantable MDs hinges on monitoring 
evolving evidentiary requirements and on carefully planning to collect evidence 
early in the developmental cycle.
MD3
DECISON MAKING UNDER UNCERTAINTy: COvERAGE wITH EvIDENCE 
DEvELOPMENT IN THE CONTExT OF MEDICAL DEvICES
Sorenson C.1, Drummond M.2
1London School of Economics and European Health Technology Institute for Socio-Economic 
Research, London, UK, 2University of York, Heslington, UK
Objectives: Coverage with evidence development (CED) is increasingly being 
used to provide provisional coverage for promising, but unproven, interventions, 
while additional data are generated. This study aimed to explore the application of 
CED in the context of devices. MethOds: First, a literature review was conducted 
on international CED schemes and the CED approach more generally. In total, 50 
articles were gathered and reviewed. Second, semi-structured telephone inter-
views were conducted with different expert groups (payers/HTA bodies, industry, 
and academics/policy analysts) to better understand the use of CED in different 
jurisdictions; identify and explore device CED case studies; and, gather expert 
opinion on the challenges associated with the CED approach and potential strate-
gies to improve current policy and practice. A total of 25 experts were invited to 
participate, of which 20 (80%) agreed and were interviewed. Results: Canada, 
the UK, and US have the most experience with CED applied to devices; Germany 
and The Netherlands have both recently introduced new CED policies for devices 
and procedures. Devices that have undergone CED in these jurisdictions include 
ICDs, stents, TAVI, laparoscopic surgery, and spinal cord stimulators. While there 
are distinct differences in the national approaches to CED, common challenges 
were identified: 1) establishing a clear framework for initiating, overseeing, and 
stopping CED studies, 2) identifying and applying appropriate study methods, 3) 
funding CED studies, 4) incentivizing studies, and 5) applying new evidence to 
inform coverage decisions. cOnclusiOns: Devices are viable candidates for CED, 
given some of their unique characteristics and often uncertain evidence base at 
the time of coverage determination. However, improvements are needed, including 
enhanced clarity and predictability of CED selection criteria and processes, greater 
stakeholder collaboration, new models to fund studies and collect data, better 
incentives for physicians to engage in studies, and strengthened requirements 
for use of new evidence in coverage policies.
MD4
QUALITy CRITERIA FOR THE DEvELOPMENT OF IMPLANT REGISTRIES
Niederländer C.S., Wahlster P., Kriza C., Schaller S.U., Kolominsky-Rabas P.L.
Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of Erlangen-
Nuremberg, Erlangen, Germany
Objectives: During the last few years, there has been a steady increase in the 
number of implant registries, mainly in the field of arthroplasty. The benefit of a 
registry depends on its content and quality. However, there are no further data 
requirements, legal and financial issues or requirements for the organizational 
(p= 0.596). cOnclusiOns: Time preference rates were aligned with those in the pub-
lished literature but the association between time preference and adherence was non-
significant in both primary and secondary analyses at an individual country level.
Cv3
PATTERNS OF GENERIC AND PROPRIETARy PRESCRIBING OF STATINS OvER 
TIME IN ENGLAND
Leonard S.A., Wilson T.J., Hamerslag L.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: Given economic pressure on UK National Health Service resources, it has 
been recommended that general practitioners prescribe more low-cost, generic drugs 
as opposed to high-cost, proprietary drugs when a substitution can be made without 
compromising patient care. One of the Better Care Better Value (BCBV) indicators of good 
prescribing practice proposed by the NHS Institute for Innovation and Improvement is 
an increase in the prescription of low-cost drugs for lipid modification. The objective of 
this analysis was to evaluate patterns of generic and proprietary prescribing of statins 
from 2007–2012 inclusive. MethOds: Prescription Cost Analysis databases from data.
gov.uk were reviewed between 2007–2012. Data on the number of prescription items 
dispensed each year in the community in England for simvastatin and atorvastatin (as 
commonly-prescribed examples) were extracted, along with each drug’s preparation 
class: drugs prescribed and available generically, or drugs prescribed and dispensed by 
proprietary brand name. For both simvastatin and atorvastatin, the proportions of pre-
scription items in the different preparation classes were compared each year. Results: 
Proprietary simvastatin prescription items as a proportion of all simvastatin prescription 
items decreased each year, from 2.87% in 2007 (843,000 proprietary items) to 1.76% in 
2012 (752,000 items), representing a proportional decrease of 39% in the 6-year period 
assessed. Proprietary atorvastatin prescription items as a proportion of all atorvastatin 
prescription items were close to 100% between 2007–2011 (approximately 11 million 
proprietary items each year), but fell to 30.55% in 2012 (3.9 million items), coinciding 
with the expiry of atorvastatin’s patent in May 2012. cOnclusiOns: In England, pre-
scribing of high-cost proprietary items for these two examples of lipid-modifying drugs 
has decreased since 2007, suggesting that the BCBV prescribing indicator for statins is 
being met. Such reductions, particularly as seen with atorvastatin in 2012, are likely to 
have a significant budget impact.
Cv4
IMPACT OF SHORT PERIODS wITH IMPROvED OR wORSENED INR CONTROL ON 
LIFE ExPECTANCy AND QALyS IN PATIENTS wITH ATRIAL FIBRILLATION
Lesén E.1, Björholt I.1, Björstad Å1, Fahlén M.2, Odén A.3
1Nordic Health Economics, Gothenburg, Sweden, 2Department of Medicine, Kungälv Hospital, 
Kungälv, Sweden, 3Department of Mathematical Sciences, Chalmers University of Technology, 
Gothenburg, Sweden
Objectives: Warfarin-treated patients with poor international normalized ratio 
(INR) control, measured with time in therapeutic range (TTR) or the standard 
deviation of transformed INR (SDTINR), have an increased risk for clinical events. 
To what extent only a short period with an altered INR control may influence out-
comes remains unknown. This study assessed the impact of transient periods of 
improved or worsened INR control on life expectancy and quality-adjusted life years 
(QALYs) among warfarin-treated patients with atrial fibrillation (AF) using both 
metrics. MethOds: Warfarin-treated patients with AF, registered in the patient 
record system Journalia during years 1985-2000, were included. Information on all-
cause mortality was collected from the Cause of Death Register. Scenarios where 
patients were assumed to have a transiently altered INR control during 30 days 
were modeled statistically using hazard functions, and the impact on remaining life 
expectancy and QALYs was assessed. Results: When using SDTINR, a 70-year old 
man within the 2.5th worst INR control percentile was estimated to gain 10.8 days of 
life or 0.0168 QALYs from a 30-day improvement in INR control to that of an average 
70-year old man. Correspondingly, 15.5 days of life or 0.0196 QALYs would be lost if a 
70-year old man within the 2.5th best INR control percentile would have an average 
INR control during 30 days. The magnitudes were smaller when TTR was used to 
determine INR control. cOnclusiOns: Even short periods of altered INR control 
is expected to have impact on life expectancy and QALYs among patients with AF.
MEDICAL DEvICE & DIAGNOSTIC RESEARCH
MD1
COMPARING vIRTUAL COLONOGRAPHy wITH CONvENTIONAL COLONOSCOPy 
FOR COLORECTAL CANCER SCREENING: wHAT ARE THE DRIvERS OF COST-
EFFECTIvENESS?
Kriza C.1, Emmert M.2, Wahlster P.1, Niederländer C.1, Schaller S.U.1, Kolominsky-Rabas P.L.1
1Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of 
Erlangen-Nuremberg, Erlangen, Germany, 2School of Business and Economics, Institute of 
Management, University of Erlangen-Nuremberg, Nuremberg, Germany
Objectives: The majority of recent cost-effectiveness reviews concluded that 
computerized tomographic colonography (CTC) is not a cost-effective Colorectal 
Cancer (CRC) screening strategy yet. The objective of this review is to examine 
cost-effectiveness of CTC versus optical colonoscopy (COL) for CRC screening and 
identify the main drivers influencing cost-effectiveness due to the emergence of 
new research. MethOds: A systematic review was conducted for cost-effectiveness 
studies comparing CTC and COL as a screening tool and providing outcomes in 
life-years saved, published between January 2006 and November 2012. The fol-
lowing databases were searched: PubMed, Science Direct, Cochrane Library and 
the York Centre for Reviews and Dissemination databases. The search methodol-
ogy was in line with PRISMA guidelines, including the use of the PICOS review 
system. Results: Nine studies were included in the review. There was consid-
erable heterogeneity in modelling complexity and methodology. Different model 
assumptions and inputs had large effects on resulting cost-effectiveness. The most 
important assumptions that influenced the cost-effectiveness of CTC and COL were 
related to CTC threshold-based reporting of polyps, CTC cost, CTC sensitivity for 
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PR3
vARIABILITy IN HyBRID DRUG AvAILABILITy AND PRICING IN EUROPE
Flostrand S.J.A.1, Lor S.1, Hughes A.L.H.2
1IMS Consulting Group, La Défense Cedex, France, 2IMS Consulting Group, London, UK
Objectives: Medicinal products where active substance, strength, form, or 
administration route have been modified differ from generic drugs as bioequiva-
lence cannot be demonstrated. In Europe, these ‘hybrid’ products have a clear 
registration pathway (Directive 2001/83/EC) requiring investment in pre-clinical 
and clinical trials. However; beyond the regulatory pathway, pricing and market 
access remains a national matter and few countries have specific methods to 
evaluate hybrids; both innovative- and generic-like prices may result. This study 
evaluated hybrid price differences and consequences for availability of hybrids 
across Europe. MethOds: Using IMS MIDAS data and the HMA database of regis-
tered drugs, we screened 5,000 products to identify 40 hybrid products which were 
significantly differentiated from the reference product, launched between 2008-
2012 and analysed their prices and availability based on sales achieved, versus the 
reference product within and across 10 European markets. Results: Hybrid prices 
vary widely, but most frequently, generic rules are applied, limiting the interest of 
companies to make hybrids available across European markets. There is wide vari-
ation in availability of hybrids across markets, suggesting a decision not to launch 
in markets where prices are particularly unfavourable. Countries applying fixed 
generic pricing rules appear to have fewer hybrids. Yet where they are launched, 
hybrids are not classified as generics, so uptake is inhibited by non-substitution 
rules and prescribing quotas. cOnclusiOns: The lack of clear evaluation criteria 
and pricing variability within and across countries are barriers to the availability 
of hybrid products to patients in Europe. To the degree that such products bet-
ter meet patient needs versus generic medicines, these barriers reduce patient 
welfare and prescriber choice. In a context where patient-oriented outcomes are 
increasingly seen as important, hybrid drugs have a role to play given their ability 
to improve administration, compliance, convenience and in some cases improve 
safety and efficacy. Consequently, clear rules for hybrid evaluation, pricing and 
access are desirable as they would improve patient care and reduce uncertainty 
for hybrid manufacturers.
PR4
OvERvIEw OF COvERAGE wITH EvIDENCE DEvELOPMENT IN SwEDEN
Schroeder M.1, Kornfeld A.2, Ben Abdallah I.2, Rémuzat C.2, Toumi M.3
1Creativ-Ceutical, Copenhagen, Denmark, 2Creativ-Ceutical, Paris, France, 3University Claude 
Bernard Lyon 1, Lyon, France
Objectives: Coverage with evidence development (CED) in Sweden has become 
common over the last decade. It is considered as a tool to address uncertainty. The 
objective of this research is to assess from 2005 to 2012 CED in Sweden. MethOds: 
We downloaded available CED from pricing authority (TLV) database, and extracted 
detailed information in an ad hoc grid developed for that purpose. The following 
information was extracted: date of product approval, name, indication, date of CED 
installation, end of CED, type of evidence to be generated, limitation of initial file 
supporting the need of additional evidences. Results: A total of 28 cases were 
retrieved covering 9 main disease areas. Eleven were for orphan drugs and 10 for 
Central nervous system (CNS) disorders including depression anxiety, epilepsy, 
pain, ADHD, schizophrenia, restless syndrome and Parkinson disease. Other were 
classified as follow, 5 for cardiovascular disorders, 3 oncology, 2 diabetes, 2 res-
piratory disorders and 5 others. The main drivers to request CED were weak cost-
effectiveness model (14 cases) driven by uncertainty about utility, patients benefit, 
transition probabilities, model structure etc. The second reason was low relevance 
of clinical evidence for clinical practice (8 cases), followed by long term efficacy 
extrapolation (5 cases) and others mainly related to comparative effectiveness, 
daily dosage, safety, target population, etc. (11 cases). For each CED more than one 
driver could be identified. Requirements were mostly real world evidence genera-
tion. cOnclusiOns: CED in Sweden is likely to be driven more by uncertainty than 
drug prices due to low involvement of oncology, inflammation and other disease 
area where biologics are prescribed. Orphan drugs represent a leading target for CED 
as often little information is available at time of launch. Most CED are not finalised 
to assess the actual CED impact on long term coverage.
RESEARCH ON METHODS – PRO/QOL STUDIES
QL1
MAPPING THE CCQ ONTO EQ-5D SCORES (IM)POSSIBLE?
Boland M.R.S.1, van Boven J.F.2, Rutten-van Mölken M.P.M.H.1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2University of Groningen, 
Groningen, The Netherlands
Objectives: Studies assessing the effectiveness of new Chronic Obstructive 
Pulmonary Disease (COPD) treatments commonly use disease-specific health-
related quality-of-life (HR-QoL) instruments such as the Clinical COPD Questionnaire 
(CCQ). However, for the economic evaluations, utility data is necessary. This study 
aims to develop a model to predict mean utility values for a group of COPD patients 
using CCQ data. MethOds: We combined the data from two trials (RECODE and 
GO-AHEAD) including over 5000 observations with a broad range of disease sever-
ity. Data was randomly split into an estimation and validation sample. The overlap 
between the CCQ and EQ-5D was assessed using principal component and correla-
tion matrix analysis. Different types of models were created with increasing com-
plexity. We analysed the effect of using different observations of the same patients 
as unique observations and performed a sensitivity analysis using different EQ-5D 
value sets to estimate EQ-5D utilities. The external validity was tested with the 
dataset of the MARCH trial. Results: The principal component analyses showed 
a poor correlation of the dimension pain/discomfort with any of the CCQ items and 
the CCQ items cough and produce phlegm did not load onto any EQ-5D dimension. 
The model using ordinary least square with the individual CCQ items as dummy 
variables, controlled for sex, resulted in the best predicted performance. The mean 
procedure specified for implant registries in general. Therefore, the aim of this 
work is to identify quality criteria for the design and development of implant 
registries and to develop a minimal data set. MethOds: The systematic literature 
search was performed in different databases (Pubmed, Medline, the Cochrane 
Library, Scopus, Embase as well as the CRD York database) and different jour-
nals. Results: Ten articles were identified that describe a general implant registry 
design and structure as well as 45 articles about the creation of specific registries. 
Most recommendations for the organization of implant registries could be found 
in the field of arthroplasty. To generalize the results, it can be said, that all regis-
tries have to deliver a minimal data set including prostheses, patient and surgical 
procedure details. The geographical area, length and periodicity of data collection, 
number of patients enrolled, the composition of the team as well as information 
about security and confidentiality of data should be reported. cOnclusiOns: 
Well-structured registries are a cornerstone of the regulatory process of medical 
devices and a major tool for decison makers and managers. However, only a small 
number of papers that describe specific requirements for the construction of an 
implant registry could be identified. With the establishment of clear guidelines, the 
outcomes of the implant registries can be fundamentally improved. This project 
is supported by the German Federal Ministry of Education and Research (BMBF) as 
part of the National Cluster of Excellence‚ Medical Technologies – Medical Valley 
EMN’ (Project grant No. 13EX1013B).
PRICING STUDIES
PR1
PRICE DIFFERENCES TRIGGERED By THE AvAILABILITy OF BIOSIMILARS IN 
DEvELOPED COUNTRIES
Reinaud F.1, Ando G.2
1IHS, Paris, France, 2IHS, London, UK
Objectives: The goal of this study is to analyse price differences triggered by 
the availability of biosimilars in developed pharmaceutical markets. MethOds: 
1) Market availability of biosimilars in the following markets was studied: Australia, 
Canada, France, Germany, Italy, Spain, UK, Japan and the United States. Biosimilars 
were selected based on their availability in these markets, and 2) Ex-factory price 
differences at launch between biosimilars and their originator counterparts were 
analysed. Results: Price differences between biosimilars and their originator 
counterpart were on average 25%. One exception aside, biosimilars always trigger 
double digit price differences. Given the limited availability of biosimilars, it is too 
soon to say if results will be consistent over time. Nevertheless, the general trend 
shows that large price differences are observed in Canada and the US (at least 
35%) and lower trends in Australia (around 16%). In the top 5 European pharma-
ceutical markets, price differences range between 17% and 30%. In Japan, price 
differences are also high, 29% on average. It should also be highlighted that the 
market entry of biosimilars does not always trigger the price of their originator 
to drop; in rare occasions only are their prices brought into line. cOnclusiOns: 
Owing to the fact that biologic drugs are commonly expensive and with double 
digit price differences between biosimilars and their originator counterpart, the 
market entry of biosimilars should enable governments to generate significant 
savings. Nevertheless, a limited number of biosimilars are at the moment approved 
and in addition to the fact that no legislation is in place in the US, there is no sign 
of improvement in the other countries studied. As a consequence, savings will 
only be achieved if governments incentivise the development of biosimilars as 
well as their use.
PR2
PHARMACEUTICAL POLICIES, REGULATION AND EFFICIENCy
Maniadakis N.1, Kourlaba G.2, Shen J.3, Holtorf A.P.4, Kalo Z.5
1National School of Public Health, Athens, Greece, 2National and Kapodistrian University of 
Athens School of Medicine, Athens, Greece, 3Abbott, Basel, Switzerland, 4Health Outcomes 
Strategies LLC, Basel, Switzerland, 5Syreon Research Institute, Budapest, Hungary
Objectives: In the context of ever increasing demand and expenditure for health 
services it is important to identify policies which may maximise efficiency. Often, 
pharmaceuticals (approximately 20% of total health care expenditure) are a pri-
mary target for achieving efficiencies. This study aims to study the efficiency 
of pharmaceutical control policies. MethOds: Data on pharmaceutical policies 
and markets across 65 countries were collected from the published literature, 
with emphasis on the following domains: pricing, reimbursement, dispensing, 
expenditure and demand control. In each domain, policies were classified and 
through a multiple-country expert survey were graded for the degree of regu-
lation. Countries were clustered according to their policy mix. Principal com-
ponent analysis (PCA) served to group policies into three components: pricing 
policies, reimbursement policies and demand and cost control policies. Regression 
analysis with pharmaceutical expenditure as % of GDP as dependent variable 
was used to analyse the efficiency of policies. Independent variables were life 
expectancy, dependency ratios, mortality rates, GDP per capita and health system 
type. Results: Spearman correlation coefficients indicated that there was no 
statistically significant association between total pharmaceutical expenditure 
as % of GDP and regulation in the coverage, pricing, reimbursement, dispensing 
policy and system type. A statistically significant positive correlation between 
regulation and indirect price and cost controls (0.334, p= 0.028) and demand con-
trols (0.333, p= 0.019) implies that more regulation in these domains is associated 
with higher expenditure. Following the PCA, regulation in demand control policies 
was associated with higher expenditure (0.342, p= 0.025) and the same applies 
for the aggregate of the components (0.314, p= 0.040). In regression analysis the 
coefficients (p-value) were pricing:-0.003(0.950), demand control:0.062(p= 0.067), 
reimbursement: -0.057(0.439), mortality: 0.001(0.414), Life Expectancy: 0.062(0.474), 
elderly ratio: 0.689(0.774), GDP-per-capita: -1.788(0.017). cOnclusiOns: A variety 
of policies were developed recently to control pharmaceuticals. More regulation 
does not appear to increase efficiency or decrease expenditure.
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Outcomes Study Cognitive Functioning-Revised [MOS COG-R]; PHQ-9, Patient Global 
Impression of Severity [PGIS] and Change [PGIC]; SF-36 Health Survey [SF-36], Lam 
Employment Absence and Productivity Scale [LEAPS], Sheehan Disability Scale 
[SDS] and Work Productivity and Activity Impairment: Specific Health Problem 
[WPAI:SHP]. Results: The study population consisted of 855 subjects at baseline 
(418 US and 437 UK), with MDD patients representing 49% of the sample in each 
country; 169 and 153 MDD patients were invited for the follow-up in the US and 
UK, respectively. Internal consistency was high for the total scale and for the four 
proposed subscales (Attention, Retrospective memory, Prospective memory, and 
Planning), with Cronbach’s alpha ranging from 0.81 to 0.96. Convergent validity was 
supported by strong correlations with other measures of cognitive functioning (0.8 
Pearson’s coefficient) and moderate correlations with several construct measures 
known to be associated with cognitive functioning, including health-related quality 
of life, productivity at work, and other functional impairment (Pearson’s coefficients 
ranging from 0.3 to 0.6), and by substantial differences in scores in subgroups known 
to differ in cognitive functioning impairment. The PDQ-D was also responsive to 
changes in depression symptom severity. Confirmatory factor analyses supported 
the scoring of a global scale for perceived cognitive functioning. cOnclusiOns: The 
PDQ-D is a reliable, valid and responsive instrument for assessing MDD patients’ 
perception of deficits related to cognitive functioning.
RESEARCH POSTER PRESENTATIONS – SESSION I 
DISEASE-SPECIFIC STUDIES
INDIvIDUAL’S HEALTH – Clinical Outcomes Studies
PIH1
MOTHERS’ OwN MILK FOR THE FEEDING OF PRETERM INFANTS: A SySTEMATIC 
LITERATURE REvIEw
Garcia-Stewart S., Mitchell S.A.
Abacus International, Bicester, UK
Objectives: To conduct a systematic review to examine the incremental benefits 
of mothers’ own milk (MM), with or without fortification, compared with donor 
milk (DM) and/or preterm formula (PF) for the nutritional support of preterm 
infants both in the neonatal intensive care unit (NICU) and following hospital dis-
charge. MethOds: English-language studies published post-1990 were identified 
from electronic databases (Medline, EMBASE and Cochrane Library) and confer-
ence proceedings. Eligible studies enrolled infants with mean gestational age less 
than 35 weeks with no restriction on geographical location. Results: Thirty-three 
unique studies met eligibility criteria: United States (n= 12), Canada (n= 2), Australia 
(n= 2), Mexico (n= 1), Israel (n= 2), Europe (n= 13) or multinational (n= 1). There was 
a paucity of both RCT data (n= 7) and studies which reported exclusive use of MM 
feeding (n= 3). In addition, there was considerable heterogeneity between studies 
with regard to study design, duration of follow up and amounts of MM ingested, and 
a robust meta-analysis was therefore not feasible. However, a significant beneficial 
effect for MM over DM and/or PF for the incidence of sepsis, necrotizing enterocolitis 
(NEC) and longer-term neurodevelopment was reported in a number of individual 
studies. With regard to anthropomorphic outcomes of body weight, length and 
head circumference, there was no clear consensus on the effect of feeding regi-
men. Sixteen studies reported the relationship between the dose of MM received 
and outcomes; increased MM dosages in the feeding regimen were associated with 
significantly lower rates of sepsis, NEC, and hospital readmissions, reduced NICU 
costs, and improved neurodevelopment. cOnclusiOns: Exclusive or high-dose 
MM with or without fortification is associated with short- and long-term beneficial 
effects in preterm infants. These results confirm MM to be the optimal nutrition for 
preterm infants and stress the importance of developing comprehensive strategies 
to overcome the challenges of providing MM and improving breastfeeding rates in 
preterm infants in the NICU.
PIH2
UTERINE-SPARING SURGICAL TREATMENT MODALITIES IN wOMEN wITH 
UTERINE FIBROIDS: A SySTEMATIC REvIEw AND INDIRECT TREATMENT 
COMPARISON
Panagiotopoulou N.1, Nethra S.1, Karabis A.2, Ahmad G.1, Burls A.3
1Pennine Acute Hospitals NHS Trust, Manchester, UK, 2Mapi – HEOR & Strategic Market Access, 
Houten, The Netherlands, 3City University London, London, UK
Objectives: To evaluate the safety and effectiveness of conservative sur-
gical treatments for uterine fibroids in women who wish to preserve their 
uterus. MethOds: A systematic literature search of electronic databases 
(MEDLINE, EMBASE, CENTRAL) and grey literature up to October 2012 identified 5 
RCTs (436 patients): 2 comparing uterine artery embolization (UAE) with myomec-
tomy (MYO) and 3 comparing UAE with laparoscopic uterine artery occlusion 
(LUAO). Primary outcome measures included patients’ satisfaction, re-intervention 
and ovarian failure rate. Secondary outcomes were clinical failure, hysterectomy 
and complication rates, hospitalization and recovery times, pregnancy rate, preg-
nancy complications and live-birth rate. Standard and network meta-analysis 
were performed on relevant outcomes. Results: Of the three most popular 
uterine-sparing surgical treatments for fibroids, network meta-analysis showed 
that MYO and UAE resulted in higher rates of patient satisfaction and lower rates 
of clinical failure than LUAO in the first year after treatment [OR 2.56, 95%CrI 0.56- 
11.75, P(better)= 11% and 2.7, 95%CrI 1.1- 7.14, P(better)= 1%; 0.29, 95%CrI 0.06- 1.46, 
P(better)= 7% and 0.37, 95%CrI 0.13- 0.93, P(better)= 2% respectively]. Moreover, MYO 
resulted in lower re-intervention and hysterectomy rates than UAE and LUAO [0.08, 
95%CrI 0.02- 0.27, P(better)< 1%, 0.08, 95%CrI 0.01- 0.37 P(better)< 1%); 0.16, 95%CrI 
0.01-0.85 P(better)= 2%, 0.15 95%CrI 0- 8.74 P(better)= 16% respectively] even though 
the later techniques had an advantage over MYO due to shorter hospitalization 
and quicker recovery. There was no evidence of convincing difference between the 
three techniques in the number of women experiencing ovarian failure, minor or 
major complications. However, MYO may lead to better conception outcomes in 
absolute error was on average 0.15 but was considerably high (> 0.34) if the observed 
EQ-5D value was below 0.5. Sensitivity analysis revealed that different EQ-5D value 
sets resulted in different algorithms but similar predicting ability. cOnclusiOns: 
Our study showed that there are conceptual differences between the CCQ and EQ-5D 
and mapping should be considered as second-best option compared to directly 
collected EQ-5D data. Furthermore, the mapping performance seems to depend on 
the severity of the study population.
QL2
MEASURING PATIENT-RELEvANT TREATMENT BENEFIT IN DERMATOLOGy – 
DEvELOPMENT AND vALIDATION OF THE SHORT QUESTIONNAIRE “PATIENT 
BENEFIT INDEx 2.0”
Blome C.1, von Usslar K.1, Augustin M.2
1University Medical Center Hamburg, Hamburg, Germany, 2University Medical Center Hamburg-
Eppendorf, Hamburg, Germany
Objectives: Evidence on patient-relevant treatment benefit is the main criterion 
for reimbursement decisions in many European countries. Usually, an increase of 
quality of life (QoL) during treatment is used as benefit indicator. The Patient Benefit 
Index (PBI) method, in contrast, evaluates benefit retrospectively: Before treatment, 
patients rate importance of treatment goals; after treatment, they rate goal achieve-
ment. This prevents any bias due to response shift which has repeatedly been found 
in pre-post QoL assessment. Here, we developed a short PBI version (“PBI 2.0”) appli-
cable to different skin diseases. MethOds: Treatment goal items for the PBI 2.0 
were developed based on nine validated disease-specific PBI versions. Items were 
tested for content, completeness, and comprehensiveness in qualitative interviews 
with n= 16 patients with atopic dermatitis, leg ulcers, psoriasis, and vitiligo. Items 
were revised on basis of patient feedback. The PBI 2.0 was tested for convergent 
validity, completeness, and congruence with disease-specific PBI versions in a cross-
sectional study on n= 379 patients with the above-mentioned diagnoses. Results: 
The 74 disease-specific items could be condensed to 15 pilot items. Based on the 
qualitative interviews, we could reduce to 12 items. The majority of patients rated 
the PBI 2.0 to be comprehensible (93-98%, depending on diagnosis group), readable 
(94-100%), easy to answer throughout (78-90%), and complete (65-88%). Treatment 
goals mentioned as missing mostly concerned goals unrelated to benefit of medical 
treatment (e.g. information on the disease). The percentage of missing values ranged 
from 0.0% to 2.9%. PBI 2.0 preference-weighted global scores correlated significantly 
with QoL as measured with Dermatology Life Quality Index and EQ-5D (r= 0.19 to 
0.58). Convergent validity of the PBI 2.0 and the respective – about twice as long – 
disease-specific versions were equal, except for the vitiligo version. cOnclusiOns: 
The PBI 2.0 is a qualitatively and quantitatively validated short questionnaire on 
patient-relevant treatment benefit in dermatology.
QL3
THE MEASUREMENT OF HEALTH-RELATED QUALITy OF LIFE: GERMAN 
FINDINGS FROM THE MULTI-INSTRUMENT COMPARISON (MIC) STUDy
Schlander M.1, Khan M.A.2, Iezzi A.2, Maxwell A.2, Richardson J.2
1University of Heidelberg, Wiesbaden, Germany, 2Monash University, Melbourne, Australia
Objectives: Different multi-attribute utility (MAU) instruments are known to pro-
duce different values for “utility” and measure different constructs, despite the 
common label “utility”. To date, the Multi-Instrument Comparison (MIC) project has 
been the largest comparative study of health and well-being instruments under-
taken worldwide. Here we report the first results from the German branch of the 
study. MethOds: A total of 1269 German respondents (either healthy or suffering 
from defined chronic disorders, i.e., asthma, arthritis, cancer, depression, diabetes, 
hearing loss, heart disease) were recruited and participated in the study, completing 
various MAU instruments, including the EQ-5D, SF-6D, HUI3, 15D, QWB, AQoL(-4D 
and-8D). Cross-validation tests drew heavily on correlation. Preliminary findings, 
based upon Pearson correlation coefficients (indicating the extent to which changes 
in one variable correspond with changes in another), showed low correlations 
between measures of utility and measures of subjective well-being. While prefer-
ences might differ from subjective well-being, their correlation might be higher. 
Hence, a better measure should be intraclass correlation (ICC). Results: Intraclass 
correlations between MAU instruments ranged from to 0.8 (HUI3 vs. AQoL-8D) to 
0.4 (AQoL-4D vs. 15D). Linear regression results, reflecting the comparative perfor-
mance of the various MAU instruments with regard to changes in measured utilities 
(as applied in standard cost utility analysis), and detailed results including pair-
wise comparisons of instruments, especially as to sensitivity to changes in a given 
dimension, will be presented. cOnclusiOns: A major conclusion of the present 
study is that, despite some similarity in the mean scores, the instruments tested are 
dissimilar with regard to virtually all other criteria used to compare them. In effect, 
each instrument appears to measure a different construct of “health”. Implications 
for the presumably “generic” measurement of “utility” may be far reaching and will 
be discussed.
QL4
PSyCHOMETRIC vALIDATION OF PERCEIvED DEFICITS QUESTIONNAIRE – 
DEPRESSION (PDQ-D) IN PATIENTS wITH MAjOR DEPRESSIvE DISORDER (MDD)
Lam R.W.1, Saragoussi D.2, Danchenko N.3, Rive B.4, Lamy F.X.5, Brevig T.6
1University of British Columbia, Vancouver, BC, Canada, 2Lundbeck SAS, ISSY LES MOULINEAUX 
CEDEX, France, 3Lundbeck SAS, Issy-les-Moulineaux, France, 4Lundbeck S.A.S., Issy-Les 
Moulineaux, France, 5Lundbeck S.A.S., Issy-les-Moulineaux, France, 6H. Lundbeck A/S, Valby, 
Denmark
Objectives: The Perceived Deficits Questionnaire (PDQ) provides a self-report 
measure of cognitive dysfunction. The current work aims at assessing the psycho-
metric properties of the PDQ adapted for MDD (PDQ-D). MethOds: A non-inter-
ventional, online panel survey with baseline assessment and 6-week follow-up 
of US and UK residents (aged ≥ 18 years) with and without MDD [diagnosed with 
depression by a physician and current Patient Health Questionnaire-9 (PHQ-9) 
score ≥ 10]. In addition to PDQ-D, the following instruments were included: Medical 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A331
of 0.5 (95%CI: 0.3-0.8) for DRSP/estradiol vs. other occHRT. cOnclusiOns: Results 
indicate a good safety profile with respect to cardiovascular risk for DRSP/estra-
diol. Serious cardiovascular events occur less frequently in DRSP/estradiol users 
compared to users of other continuous-combined HRT. This specificAS approach 
proved to be a successful approach with high long term follow-up success and 
high validity of safety results.
INDIvIDUAL’S HEALTH – Cost Studies
PIH7
BUDGET IMPACT OF HPv16/18 GENOTyPING TESTS FOR THE MANAGEMENT OF 
NON-CONCORDANT COTESTING CERvICAL CANCER SCREENING RESULTS: A 
UNITED STATES PAyER PERSPECTIvE
Huang J.1, Hertz D.2, Conner A.2, Garfield S.2
1Roche Molecular Diagnostics, Pleasanton, CA, USA, 2GfK Bridgehead, Wayland, MA, USA
Objectives: To assess the impact of managing women with high-risk HPV positive 
and Pap negative results (hrHPV+/Pap-) attending cervical cancer (CxCa) screening 
with a Pap and HPV test (co-testing). The strategies tested reflect different options 
available if a hrHPV test versus a hrHPV including 16/18 genotyping (3-in-1 test) 
is used upon initial screen. MethOds: A budget-impact model was developed, 
from a US payer perspective. Data from the ATHENA (Addressing THE Need for 
Advanced HPV Diagnostics) trial and published literature were used to populate 
the model. The scenarios tested include repeat co-testing in 12 months, reflex 
genotyping HPV16/18, or routine co-testing with genotyping results already avail-
able from a 3-in-1 test for triage to colposcopy. The model examined the annual 
cost of testing and treatment for cervical intraepithelial neoplasia grade 2 or worse 
(≥ CIN2) and the cost of patients loss-to-follow-up. For a hypothetical population 
of women between ages 30 to 69, it assumes 48.5% were co-tested within the CxCa 
screening program every 3 years. Of those, 6.7% of women receive hrHPV+/Pap- 
results. Test performance was modeled as equivalent for both genotyping sce-
narios. Results: In the hrHPV+/Pap- population, the cost of ≥ CIN2 cases detected 
and treated for each testing strategy and the rate of progression to invasive CxCa 
per 10,000 hrHPV+/Pap- results was $10,530/9.2 (repeat co-testing at 12 months), 
$8,500/2.6 (reflex HPV16/18) and $7,278/2.6 (routine co-testing with 3-in-1 test). 
Using HPV16/18 genotyping to manage discordant co-testing results increased 
≥ CIN2 cases detected and prevented disease progression. Compared to other HPV 
tests that require reflex genotyping, screening with a 3-in-1 test reduced the cost 
of follow-up by 17% annually. cOnclusiOns: Genotyping for HPV 16/18 improved 
the detection of ≥ CIN2 cases over repeat co-testing in 12 months; moreover, com-
pared to other HPV testing strategies, the 3-in-1 test reduced costs and may be a 
prudent screening alternative.
PIH8
ECONOMIC IMPACT OF THE USE OF AN ABSORBABLE ADHESION BARRIER IN 
PREvENTING ADHESIONS FOLLOwING OPEN GyNECOLOGIC SURGERIES
Roy S.1, Carlton R.2, Clark R.S.2, Migliaccio-Walle K.2
1Johnson & Johnson Global Surgery Group, Somerville, NJ, USA, 2Xcenda, LLC, Palm Harbor, FL, 
USA
Objectives: Abdominal adhesions are common after gynecologic surgeries, 
often resulting in complications such as bowel obstruction and chronic pain, 
which may lead to increased length of stay and more frequent readmissions. 
GYNECARE INTERCEED® Absorbable Adhesion Barrier is associated with fewer 
adhesion-related outcomes compared to surgeries without an adhesion-barrier. 
This analysis assesses the budget impact of GYNECARE INTERCEED® for reduc-
ing the incidence of postoperative adhesions in open surgical gynecologic pro-
cedures. MethOds: A model was constructed to evaluate the budget impact to 
hospitals of adopting GYNECARE INTERCEED® for women undergoing open surgical 
gynecologic procedures. C-section surgery, hysterectomy, myomectomy, ovarian 
surgery, tubal surgery, and endometriosis surgery were modeled with and without 
the use of GYNECARE INTERCEED®. Incremental GYNECARE INTERCEED® material 
costs, medical costs arising from complications, and adhesion-related readmis-
sions were considered. GYNECARE INTERCEED® use was assumed in 50% of all 
procedures. Budget impact was reported over a 3-year period from a US hospital 
perspective (US$2013). Results: Assuming 100 gynecologic surgeries of each type 
and an average of one GYNECARE INTERCEED® sheet per surgery, a net savings 
of $439,975 with GYNECARE INTERCEED® over 3 years is estimated. GYNECARE 
INTERCEED® use resulted in 80 fewer patient cases developing adhesions. Although 
the use of GYNECARE INTERCEED® added $91,500 in material costs, this was com-
pletely offset by the reduction in complication costs ($230,766 savings) and fewer 
adhesion-related readmissions ($300,709 savings). By preventing adhesion-related 
complications, GYNECARE INTERCEED® prevented over 206 additional hospital days 
for patients. cOnclusiOns: This analysis represents the first economic assess-
ment of GYNECARE INTERCEED® use in open gynecologic surgeries that incorpo-
rates the cost of the adhesion barrier, complications, and readmissions. Adoption 
of GYNECARE INTERCEED® absorbable adhesion barrier for appropriate gynecologic 
surgeries would likely result in significant savings for hospitals which would largely 
be driven by clinical patient benefits in terms of fewer complications and adhesion-
related readmissions.
PIH9
BUDGET IMPACT OF DIENOGEST IN TREATING ENDOMETRIOSIS ASSOCIATED 
PELvIC PAIN IN BRAzIL: A PUBLIC PERSPECTIvE ANALySIS
Ferracini M., Nakada C.P.
Bayer Healthcare Brazil, São Paulo, Brazil
Objectives: Evaluate the budget impact to the public health care system in 
Brazil after introducing dienogest (2 mg) as a treatment option in detriment of 
GnRH analogues (GnRHa) for patients with endometriosis-associated pelvic pain 
(EAPP). MethOds: The analysis was conducted from the public perspective over 
a five-year time horizon. The budget impact model (BIM) specifically considered 
comparison to UAE (pregnancies: 3.44, 95%CI 1.18- 10.03; live-births: 3.02, 95%CI 
1.00- 9.09). cOnclusiOns: LUAO is less effective than UAE and MYO in the treat-
ment of symptomatic fibroids for women who want to preserve their uterus. The 
choice between UAE and MYO should be based on individuals’ short and long-
term expectations.
PIH3
META-ANALySIS OF BCG vACCINE EFFICACy FOR INFANTS IN IRELAND
Schmitz S.1, Usher C.2, Adams R.2, Kieran J.1, Barry M.2, Walsh C.1
1Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland
Objectives: BCG vaccination policy is greatly debated. An important issue for coun-
tries using the vaccine is to try and estimate any influence it has on the tuberculosis 
(TB) incidence in their population. The aim of this study is to estimate the effective-
ness of the BCG vaccine in infants in Ireland. MethOds: We searched PubMed and 
Embase for studies assessing a relative reduction in TB events after vaccination 
in infants. Studies meeting relevant inclusion and exclusion criteria were sought. 
Observational data from Ireland was combined with raw data from studies identified 
in the literature in a random-effects meta-analysis model to estimate the relative 
risk (RR) of vaccine efficacy against pulmonary TB, extra-pulmonary TB (EPTB), TB 
meningitis and TB deaths. Results: Two meta-analyses were found. The first meta-
analysis reviewed identified 5 randomised control trials and 11 case control studies 
against pulmonary TB (Trials 0.26 95% CI 0.17, 0.38; Cases 0.48 95% CI 0.37, 0.62) 
and TB deaths (Trials 0.35 95% CI 0.14, 0.88). The second meta-analysis identified a 
further 7 case-control studies and evaluated BCG efficacy against EPTB (0.23 95%CI 
0.13, 0.42] and TB meningitis (0.27 95%CI 0.21, 0.33). Estimates from observational 
data from Ireland for pulmonary TB were (0.14, 95%CI 0.09, 0.20), EPTB (0.11, 95%CI 
0.05, 0.21), TB meningitis (0.17, 95%CI 0.04, 0.75) and TB deaths (0.13, 95%CI 0.00, 6.37). 
Pooled RR estimates from Irish data and international estimates show a significant 
reduction in TB cases: Pulmonary TB: 0.26 (95% CI: 0.13, 0.54), EPTB: 0.16 (95%CI: 
0.08, 0.34), TB meningitis: 0.27 (95%CI: 0.21, 0.34) and TB deaths: 0.33 (95%CI: 0.14, 
0.81). cOnclusiOns: This meta-analysis of local observational data with interna-
tional trial data indicates that vaccination of infants with the BCG vaccine reduces 
the risk of pulmonary TB, EPTB, TB meningitis and TB deaths.
PIH4
CO-ADMINISTRATION OF ANTIPSyCHOTICS AND ANTI-DEMENTIA DRUGS IN 
AUSTRIA
Hinteregger M.1, Füzi J.2, Reichardt B.3
1Main Association of Austrian Social Security Institutions, Vienna, Austria, 2Sickness Fund 
Burgenland, Eisenstadt, Austria, 3Sickness Fund Burgenland, Eisenstadt, Burgenland, Austria
Objectives: The use of antipsychotics for people with dementia is regarded as 
problematic, causing cerebrovascular side effects and increasing mortality. In 
some countries, health-policy makers have already addressed a need for action 
to reduce the prescription of antipsychotics in dementia. The main goal of the 
analysis is to determine the extent of co-medication of antipsychotics for patients 
with medically-treated dementia in Austria, stratified by age and sex. MethOds: 
Provided in a pseudonymised manner, the data comprise all filled prescriptions of 
cholinesterase inhibitors and memantine in the years 2011 and 2012 at the expense 
of the 13 major Austrian health insurance funds, covering more than 97% of the 
Austrian population. Additionally, antipsychotic medication of the involved patient 
pseudonyms is included, as well as age, sex and – where occurred – date of death. 
For the analysis, the overlapping time frame is relevant, i.e. when both substance 
groups were consumed. Descriptive statistics are used to capture the extent and 
variability of a co-medication of these two substance groups. Results: Starting 
with 72,549 patients included in the data (66% female), 31,605 (43.6%) were concur-
rently being prescribed antipsychotics to their anti-dementia drugs. The median 
for the overlapping time frame is 294 days, for anti-dementia prescriptions it is 
eleven and for antipsychotics it is seven. Age is a factor for increasing antipsy-
chotic medication. Considering demography, there are no remarkable differences 
between men and women. cOnclusiOns: Our data demonstrate that the use of 
antipsychotics in dementia is notably common in Austria, with a high prevalence 
as well as a tendency to long-term use. The results reflect the prescription reality 
and can be used as a solid basis for discussions, possible actions and evaluations 
about antipsychotics in dementia in the Austrian health system.
PIH6
ASSESSING PRODUCT SAFETy vIA PATIENT BASED ACTIvE SURvEILLANCE (AS): 
A STUDy IN 30.000 wOMEN USING HORMONE REPLACEMENT THERAPy (HRT)
Heinemann K.1, Bardenheuer K.1, Potthoff P.2
1ZEG-Berlin, Berlin, Germany, 2Kantar Health GmbH, München, Germany
Objectives: The novel progestin drospirenone (DRSP) has antimineralocorticoid 
properties with potentially beneficial as well as unfavorable effects on cardiovas-
cular outcomes compared to other progestins. A patient based AS study was set 
up to compare incidence rates of serious adverse events – in particular cardiovas-
cular outcomes - in users of oral continuous combined preparations. MethOds: 
Prospective, controlled cohort study (2002-2011) with three arms: women using 
1) DRSP/estradiol; 2) other oral continuous-combined HRT (occHRT); and 3) all 
other oral HRTs. The study population included women aged 40 or older in seven 
European countries starting or switching to an oral HRT at time of inclusion in the 
study. Outcomes were collected from the patients and validated by the treating 
physicians. A multifaceted 4-level follow-up procedure was to ensure low loss to 
follow-up rates. The analysis is based on Cox regression models comparing the 
cohorts. Results: A total of 30,597 users of oral HRT preparations – reflecting 
more than 101,000 WY of observation – were recruited by 1,052 centers. Incidence 
rates of DRSP/estradiol and low-dose occHRT for venous thromboembolic events 
were 17.5 (95% CI: 11.2-26.0) and 18.2 (95% CI: 11.9-26.6) per 10,000 WY, respectively. 
The respective incidence rates for arterial thromboembolism were 10.9 (95% CI: 
6.1-18.0) and 29.8 (95% CI: 24.1-36.4 ) per 10,000 WY with a hazard ratio adjusted 
for age, BMI, hypertension, region, family history of fatal ATE, diabetes, user status 
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Objectives: Rotavirus (RV) is the most frequent cause of severe gastroenteritis fre-
quently requiring hospitalization. RV is responsible for > 1/2 of all hospital stays 
for acute gastroenteritis. The objective was to estimate the burden of community 
acquired rotavirus gastro-enteritis requiring hospitalization (CRVGE) in children ≤ 5 
years old in Czech Republic (CR) and Slovakia (SK). MethOds: Multi-center, retro-
spective patient chart review was conducted in both pediatric and infection disease 
settings in CR (n= 109) and SK (n= 115). Resource use analysis including length of hos-
pital stay and tests performed were evaluated. Patients requiring rehydration, compli-
cations and comorbidities were considered. Direct cost from payer’s perspective were 
retrieved from official DRG lists (CR) and fixed hospitalization cost rates per case (SK). 
Micro-costing was done in parallel based on the resource use data. Results: Mean 
length of hospital stay in CR and SK was 3.9 (SD 1.9) and 4.1 days (SD 1.7) respectively. 
Prevalent diagnostic tests used were latex agglutination 44.0% (CR) and immunochro-
matography 92% (SK). Rehydration was required in 84.4% (CR) and 97% (SK) of cases. 
Comorbidities were reported in 24.8% (CR) and 27% (SK); complications in 10.1% (CR) 
and 7.8% (SK). The national list-based reimbursement per hospitalized CRVGE is € 
370-645 (CR) and € 561 (SK). The calculated average total costs, including treatment 
prior to, and after admission, were € 462 (CR) and € 583 (SK). The major cost item was 
the hospital stay with € 391 (CR) and € 540 (SK). Costs for tests and drugs during hos-
pitalization were € 30 (CR) and € 25 (SK). The costs of pre and post-hospitalization care 
were € 20 (CR) and € 13 (SK). cOnclusiOns: Although the length of hospitalization 
in both countries is similar costs seem to be substantially lower in CR, possibly as a 
result of recently launched DRG system. Common complications and comorbidities 
account for 30% of average hospital costs.
PIH14
USE OF ANTENATAL CORTICOSTEROIDS LOwERS HOSPITALIzATION COSTS 
RELATED TO PREMATURITy
Meneguel J.1, Fonseca M.2, Fonseca E.3, Almeida F.1, Grinsburg R.1
1UNIFESP, São Paulo, Brazil, 2Federal University of São Paulo / Axia.Bio Consulting, São Paulo, 
Brazil, 3Federal University of São Paulo, São Paulo, Brazil
Objectives: According to WHO the use of antenatal corticosteroids (CEA) in pregnant 
women at risk of preterm birth < 34 weeks can prevent thousands of preterm neonates 
(PN) deaths. The impact of the use of CEA in hospital costs in developing countries is 
not known. Our objective was to compare morbidity and hospital costs of PN whose 
mothers received or not CEA. MethOds: Analysis of PN medical records with gesta-
tional age 26-32 weeks born from Jan/2006-Dez/2009 in a tertiary, public and university 
hospital. We excluded infants with malformations. Maternal characteristics, hospital 
neonatal morbidity, use and doses of CEA and all used resources (tests, medications 
and procedures) were collected. Costs were estimated in Brazilian Reais, from the 
hospital perspective. Results: Of 211 PN, 170 received at least one dose of CEA to 6 
hours before delivery (G1) and 41 did not (G2). The groups had similar characteristics 
but G1 had more male infants (p < 0.05) and cesarean sections (p < 0,00). Morbidity: 
G2 needed more advanced resuscitation (16.5% vs 34%, p = 0.01), experienced more 
intraventricular hemorrhage III / IV (7.6% vs. 22%, p < 0.00) and retinopathy of pre-
maturity (12.4% vs. 24.4%, p = 0.05). Resource use: G1 consumed less mechanical 
ventilation days (5.3 vs 10.6, p = 0.04) and oxygen days (10.7 vs 17, p = 0.02); the num-
ber of NICU and Intermediate Care Nursery days were respectively (19.6 vs 27.5, p = 
0.07) and (24 vs 29.5 days, p = 0.14); there was no difference concerning use of CPAP 
(p = 0.07) and surfactant (p = 0.06). The average cost of hospitalization per patient 
was BRL 18,409 in G1 and BRL 24,090 in G2 (p = 0.03). cOnclusiOns: The CEA is a 
simple measure, which helps to reduce PN morbidity and utilization of health care 
resources, reducing hospital costs.
PIH15
ExAMINING THE BURDEN OF ILLNESS OF THE UNITED STATES vETERAN 
PATIENTS DIAGNOSED wITH ALzHEIMER’S DISEASE
Wang L.1, Xie L.2, Du J.2, Li L.1, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
Objectives: To examine the burden of illness of patients diagnosed with 
Alzheimer’s disease (AD) in the U.S. veteran population. MethOds: A retrospective 
database analysis was performed using the Veterans Health Administration (VHA) 
Medical SAS datasets from October 1, 2008 through September 30, 2012. Patients 
diagnosed with AD were identified using International Classification of Disease 9th 
Revision Clinical Modification (ICD-9-CM) diagnosis code 331.0. The first diagnosis 
date was designated as the index date. A comparator group was created as well by 
identifying patients without an AD diagnosis but with the same age, region, gender, 
index year, and matching Charlson Comorbidity Index (CCI). The index date for 
the comparator group was randomly chosen to reduce the selection bias. A 1-year 
continuous health plan enrollment was required before and after the index date 
for both groups. One-to-one propensity score matching was used to compare the 
health care costs and utilizations during the follow-up period between the disease 
and comparator groups. Results: A total of 68,856 patients were included in the 
AD and comparison cohorts. After 1:1 matching, a total of 24,542 of patients were 
matched from each group, and the baseline characteristics were proportionate. The 
AD cohort had higher percentages of inpatient (18.46% vs. 2.06%, p< 0.01), emergency 
room (15.80% vs. 4.31%, p< 0.01), physician office (98.17% vs. 58.18%, p< 0.01), outpa-
tient (98.30% vs. 58.92, p< 0.01), and pharmacy visits (84.89% vs. 61.78%, p< 0.01). AD 
patients also incurred higher inpatient ($7,416 vs. $636, p< 0.01), emergency room 
($150 vs. $41, p< 0.01), physician office ($2,752 vs. $1,155, p< 0.01), outpatient visits 
($3,086 vs. $1,300) and pharmacy costs ($774 vs. $350, p< 0.01) compared to patients 
without AD. cOnclusiOns: In this study, AD was associated with higher health 
care resource utilization and a significantly higher economic burden.
PIH17
A COST OF A CHILDBIRTH wITH IN vITRO FERTILIzATION IN POLAND
Góra K., Hermanowski T., Wrona W.
Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
women with EAPP. A recently cost-minimization (CM) model developed for EAPP 
provided the estimates of average treatment cost in Brazil based on local guidelines. 
This CM model compared different treatment pathways for women with EAPP and 
used a 50% improvement in pelvic pain as a definition of a treatment response. A 
patient flow was developed based on epidemiological and demographical data. 
Based on market uptake assumptions, results from the CM model and the patient 
flow, the BIM estimated the incremental budget impact after adopting dienogest. 
The model assumed that during the first year, 6.76% of EAPP patients receive dien-
ogest in detriment of GnRHa. After five years, it was assumed that dienogest would 
capture 30% of the GnRHa market in EAPP. Results: Based on the patient flow 
developed, approximately 0.52% of the population were estimated to be diagnosed 
with EAPP and receiving treatment with GnRHa. In the year after introduction of 
dienogest, the overall budget used to treat EAPP was estimated to decrease by 
up to 2.98% with the budget saving estimated to increase to around 12.98% by 
Year 5. cOnclusiOns: This analysis portends that the budgetary impact of add-
ing dienogest to the public health care system in Brazil, in detriment of the GnRHa, 
result in a budgetary cost saving alternative.
PIH10
HOw MUCH DOES BENIGN PROSTATIC HyPERPLASIA COST? A BUDGET IMPACT 
ANALySIS ON ITALIAN PATIENTS TREATED wITH 5α -REDUCTASE INHIBITORS
Povero M.1, Pitrelli A.2, Pradelli L.1
1AdRes HE&OR, Turin, Italy, 2GlaxoSmithKline, Verona, Italy
Objectives: Second-line pharmacological therapy for benign prostatic hyperplasia 
(BPH) includes 5α -reductase inhibitors (5ARIs, dutasteride and finasteride). Aim of this 
study was the evaluation of the budget impact related to the variation in dutasteride 
and finasteride prescribing trends. MethOds: Target population is the number of 
Italian BPH-patients, age ≥ 40 years, treated with dutasteride or finasteride. The BPH-
patients management was modeled on a dynamic cohort for 4-years. Epidemiological 
input data were elaborated from a observational study on pharmaceutical prescrip-
tion data of Italian BPH-patients; hospitalization rates were taken from a cohort study 
investigating BPH-related surgical and not surgical hospitalizations. Costs were cal-
culated as average of Italian DRGs weighted for BPH-related procedure frequency. 
Current Italian prescription shares of dutasteride and finasteride were compared 
with a 20% shift of prescriptions from dutasteride to finasteride (Scenario A) and 
a 20% shift of prescription from finasteride to dutasteride (Scenario B). Results: 
According to current prescribing trends, 372,078 hospitalizations for BPH are expected 
in 4 years. Mean annual cost for BPH-patients management results in 355 million € . 
Hospitalization cost is the main driver (228 milion € /year) while pharmacological ther-
apy accounts for 35% of the total cost (126 million Euro/year). Scenario A: additional 
11.485 hospitalizations related with BPH occur in 4 years; these lead to an increase in 
NHS cost only slightly offset by the savings in drugs acquisition cost: -0,08% savings 
on NHS budget (-0,28 milion € /year) Scenario B: the cost of drugs increases of 5% (+6 
million € /year) and prevents 9,920 hospitalizations in 4 years; the net budget impact 
of scenario B is +0,08% increase in cost (+0,27 milion € /year). cOnclusiOns: The 
shift of prescription from dutasteride to finasteride leads to modest savings on NHS 
Budget while the shift from finasteride to dutasteride offsets the majority of increase 
in drug budget improving the outcome in patients.
PIH12
COSTS OF ALTERNATIvE METHODS OF CHILD DELIvERy IN SERBIA
Odalovic M.1, Lakic D.1, Tadic I.2, Tasic L.2, Petrova G.3
1University of Belgrade Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 2University of 
Belgrade – Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 3Medical University of Sofia, 
Sofia, Bulgaria
Objectives: Different types of labour need different resources. Therefore, 
different costs could be expected. Objectives of this study were to determine if sig-
nificant differences in costs of different type of labour and methods of delivery exist 
and to determine factors related to estimated costs. The costs of spontaneous labour 
with vaginal delivery (SVD), induced labour with vaginal delivery (IVD), and planned 
C-section (CS) without labour were estimated. MethOds: Retrospective, population-
based study was conducted for the period January – December, 2010. Health Insurance 
Fund of Republic of Serbia (HIFRS) database was used as a data source. Direct medical 
costs of mother/newborn pair were estimated. Costs were observed from the perspec-
tive of HIFRS and expressed in European Monetary Unit (EUR). Results: A total of 
99 women were selected for the study sample; average age was 30.55±5.42 years. The 
majority of women (46.5%) had SVD, 28.3% had IVD and 25.2% had CS. Women with 
CS were longer hospitalized compared to women with SVD and IVD (8.52±4.74 vs. 
4.59±2.89 and 5.04±3.01 days, respectively, p< 0.05). Newborns after CS were longer hos-
pitalized compared to newborns after SVD and IVD (5.76±2.20 vs. 4.0±2.07 (p< 0.05) and 
5.14±3.39 (p> 0.05)). Majority of women (88.0%) and children (80.0%) after CS were hos-
pitalized at semi-intensive and/or intensive care unites. The average costs of delivery, 
regardless of the method, were 417.02±284.14 EUR. The costs of C-section were higher 
compare to SVD (640.18±240.04 vs. 243.27±131.70 EUR, p< 0.05) and IVD (640.18±240.04 
vs. 497.10±327.91 EUR, p>0.05). cOnclusiOns: The highest costs of labour in Serbia 
were costs of planned CS. Longer maternal/newborns hospital stay and more 
frequent hospitalization at semi-intensive and/or intensive care unites after CS 
were leading factors of estimated high costs. Considering high costs of CS, it is neces-
sary to review such clinical practice for the purpose of optimizing the use of resources.
PIH13
COST BURDEN OF ROTAvIRUS GASTRO-ENTERITIS REQUIRING 
HOSPITALIzATIONS IN THE CzECH REPUBLIC AND IN SLOvAKIA
Vitova V.1, Mullerova J.2, Tichopad A.1, Dolezel J.3, Hlavinkova L.4, Pazdiora P.5,  
Stefkovicova M.6
1CEEOR s.r.o., Prague, Czech Republic, 2CEEOR Slovakia, Bratislava, Slovak Republic, 
3GlaxoSmithKline, Prague, Czech Republic, 4GlaxoSmithKline Slovakia, Bratislava, Slovak 
Republic, 5Charles University Hospital Pilsen, Plzen, Czech Republic, 6Regional Authority of Public 
Health, Trencin, Slovak Republic
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PIH20
CLINICAL AND COST-EFFECTIvENESS OF A PROCALCITONIN TEST AS A PROMPT 
INDICATOR OF PRODOMOL MENINGOCOCCAL DISEASE IN FEBRILE CHILDREN: 
COST-EFFECTIvENESS ANALySIS
Bell J.M.1, Shields M.1, Angus A.2, Dunlop K.3, Bourke T.1, Kee F.1, Lynn F.A.1
1Queen’s University Belfast, Belfast, UK, 2Belfast Health & Social Care Trust, Belfast, UK, 3South 
Eastern Health and Social Care Trust, Belfast, UK
Objectives: To establish if the procalcitonin (PCT) test’s diagnostic performance 
is more clinically and cost-effective than C reactive protein (CRP) and White 
Cell Count (WCC) tests for suspicion of prodomal stage Meningococcal disease 
(MD) in children presenting at emergency department (ED) with a fever without 
source. MethOds: A decision analytic model was designed to reflect realistic 
clinical pathways for a child presenting with non-specific fever to ED. Test accu-
racy was evaluated using data from independent studies carried out in developed 
countries identified through a systematic literature search. Studies were combined 
to determine the optimal cut-off value for the PCT, CRP and WCC tests, each as an 
indicator of MD. Summary Receiver Operator Curve (SROC) analysis was used to 
determine the inter-study and overall diagnostic performance of each test from 
the areas under the curve (AUC), with 95% confidence intervals (CIs). Components 
of each clinical pathway were costed in UK sterling using the National Schedule 
of Reference Costs 2010-2011. Hospital stays were costed using the appropriate 
Health Resource Group code. Results: Seven studies involving 881 children with 
non-specific fever provided data for inclusion. The PCT test was more accurate 
(sensitivity= 89%, 95%CI= 75-96; specificity= 71%, 95%CI= 37-91) for early MD com-
pared to CRP (sensitivity= 84%, 95%CI= 74-90; specificity= 60%, 95%CI= 44-74) and 
WCC (sensitivity= 50%, 95%CI= 39-60; specificity= 68%, 95%CI= 54-79). PCT had the 
best PLR (3.0, 95%CI= 1.8-7.8) to be viable as a rule-in test for MD and a borderline 
NLR as a rule-out test, making it a better option to either CRP (2.1, 95%CI= 1.4-3.1) 
or WCC (1.5, 95%CI= 1.0-2.3). Outcomes from the decision analytic model indicated 
that the PCT test was the most cost-effective (£2547 per patient treated), followed 
by the combined CRP and WCC test (£3069 per patient treated). cOnclusiOns: The 
improved sensitivity and specificity of the PCT test provides a more cost-effective 
test than the currently recommended CRP and WCC tests.
PIH21
COST-EFFECTIvENESS ANALySIS IN THE TREATMENT OF HEAvy MENSTRUAL 
BLEEDING IN SPAIN
Lete I.1, Calaf J.2, Crespo C.3, Canals I.4, Espinós B.4, Cristóbal I.5
1Hospital Santiago Apóstol of Vitoria, Vitoria-Gasteiz, Spain, 2Hospital de la Santa Creu i Sant 
Pau, Barcelona, Spain, 3Oblikue Consulting, Barcelona, Spain, 4Bayer Health Care, Barcelona, 
Spain, 5Hospital Sanitas La Zarzuela, Madrid, Spain
Objectives: To evaluate the cost-effectiveness of first-line treatment of heavy men-
strual Bleeding (HMB) from the perspective of the Spanish National Healthcare 
System. MethOds: A cost-effectiveness analysis was performed using a Markov 
model to simulate the evolution of a cohort of women in reproductive age, with 
HMB and who wish to preserve their fertility status, in a time horizon of 5 years. 
The treatment strategies were levonorgestrel intrauterine system (LNG-IUS), estra-
diol valerate/dienogest (E2V/DNG), combined oral contraceptives (COC) and oral 
progestins (PROG). Clinical data was modelled indirectly combining literature and 
expert opinion. Outcomes were symptom-free months (SFM), quality-adjusted life 
months (QALM) and costs expressed in € in 2012. A probabilistic sensitivity analy-
sis was conducted to examine the robustness of the results. Results: The mean 
treatment cost of HMB at 6 month was 205€ for LNG-IUS, 318€ for E2V/DNG, 412€ 
COC and 766€ PROG. In the analysis over 5 years, LNG-IUS produced savings of 
578€ compared to E2V/DNG, 991€ compared to COC and 1,821€ compared to PROG. 
Regarding the effectiveness, LNG-IUS provided 51.30 SFM, while E2V/DNG, COC and 
PROG provided 50.64, 49.09 and 47.77 SFM, respectively. Moreover, 77%, 65%, 56% and 
46% of the patients treated with LNG-IUS, E2V/DNG, COC and PROG, respectively, 
continued treatment without surgery during the 5 year period. Considering QALM 
as outcome, LNG-IUS and E2V/DNG were the options that yielded more gains in 
QALM (49.71 for LNG-IUS, 48.09 for E2V/DNG, 46.59 for COC and 44.66 for PROG). 
LNG-IUS was the most effective and less costly, therefore dominant option. In the 
oral treatments comparison, E2V/DNG was dominant, providing savings and gains in 
terms of SFM and QALM. The probabilistic sensitivity analysis on the key parameters 
confirmed the robustness of the base case. cOnclusiOns: LNG-IUS is a cost-saving 
option for the treatment of HMB in Spain. Among oral treatments, E2V/DNG is also 
a dominant strategy.
PIH22
SySTEMATIC LITERATURE REvIEw AND COST-EFFECTIvENESS ANALySIS OF 
FETAL FIBRONECTIN TEST FOR PREDICTING PRETERM IN BRAzIL
Decimoni T.C.1, Sansone D.1, Etto H.1, Santos A.M.1, Araújo G.2, Fonseca E.S.2, Fonseca M.2
1Axia.Bio Consulting, São Paulo, Brazil, 2Federal University of São Paulo / Axia.Bio Consulting, 
São Paulo, Brazil
Objectives: Brazil is among the countries with the highest incidence of preterm 
births. Incorporation of diagnostic tests to predict a preterm birth could improve 
the efficiency of the clinical practice reducing hospital expenses related to mater-
nal hospitalization. The aim of this study was to compare the cost-effectiveness 
of fibronectin testing (FN) vs cervical length (CL) measurement in women with 
symptomatic preterm labor. MethOds: Systematic review of the literature of the 
diagnostic tests and development of a decision analytic model using the accuracy of 
the diagnostic tests to predict preterm birth and project the results in terms of effec-
tiveness and cost. The analysis was performed for a hypothetical cohort of 10,000 
patients, for each test, with symptomatic preterm labor between 24 and 34 weeks of 
gestation. The primary perspective of the study was of the Brazilian Health system 
(SUS). Data sources were the medical literature, SUS official published prices for 
medicines and DATASUS (SUS database). Costs are in 2012 Brazilian Reais. Results: 
A total of 14 studies were included. There was a wide variation concerning the accu-
racy of the tests among the studies, particularly with respect to gestational age at 
Objectives: To predict the cost of a delivery following assisted reproductive 
technologies (ART) in Poland. Moreover, the cumulated in vitro fertilization (IVF) 
effectiveness ratio was calculated and the costs of drugs for each of the three 
stimulation protocols used in IVF (long with GnRH agonist, short with GnRH 
antagonist and short with GnRH agonist) were estimated. MethOds: In order to 
calculate the IVF effectiveness, a pooled analysis of the results from European IVF 
monitoring reports concerning Poland from 2008 to 2010 was performed. Costs of 
the clinical and biotechnological parts of IVF were based on the Ministry of Health 
calculation. Drugs’ costs were estimated considering both dosages based on the 
Summaries of Products Characteristics and the retail prices. Costs were calculated 
based on identified costs in both the patient and payer perspectives. Results: 
The overall birth rate per cycle was 21,70%. The probability of a delivery was 
1,5 higher during fresh cycle than in frozen embryo transfer. A total of 24,09% 
of embryo transfers resulted in delivery. The cost of drugs used during ovarian 
stimulation protocol was estimated on 6 055 PLN. The average cost per cycle was 13 
565 PLN. Drugs account for 45% of this value. The average cost per birth was 42 848 
PLN. cOnclusiOns: In vitro fertilization is an expensive procedure for a patient 
in Poland. It is due to a limited effectiveness, usually requiring several repeats of 
the whole cycle of IVF with no drugs reimbursement. The ovarian stimulation is 
the most expensive part of the procedure. Thus, reimbursement of medication 
should also be established.
PIH18
COST-EFFECTIvENESS OF MATERNAL TOxOPLASMA SCREENING IN AUSTRIA: A 
DECISION-ANALyTIC MODEL
Prusa A.R.1, Walter E.2, Pollak A.1, Hayde M.1, Kasper D.C.1
1Medical University of Vienna, Vienna, Austria, 2Institute for Pharmaeconomic Research, Vienna, 
Austria
Objectives: Toxoplasma infection during pregnancy presents a serious hazard 
to the fetus including lifelong disabilities of connatal infected children. This 
foodborne illness is a common burden worldwide. Prevention strategies of the 
health care providers are diverse. In Austria, the maternal toxoplasma screening 
has been implemented four decades ago. The aim of this study was to deter-
mine cost-effectiveness of the maternal toxoplasma screening. MethOds: We 
developed a two arm decision-analytic model. One arm of the model assessed 
the costs and consequences of no prevention, while the other one evaluated 
the screening. The study population included pregnant women and offspring 
screened and treated for toxoplasma infection. The average number of births 
was 76,547 and 50,000 pregnant women were susceptible to infection. The 
analysis focused on lifetime consequences of the connatal infection. This 
encompassed direct costs (screening, cost of illness, maternal and pediatric 
treatment), indirect costs (changed job situation of parents, human-capital of 
dead individuals, blindness and special schools), quality-adjusted-life-years 
(QALYs) and reduced expectation of life. Costs were presented per child and 
for the Austrian birth cohort. Costs from published sources were used (2012 
Euro) from the societal perspective. QALYs, life-years (LYs) and costs were pro-
jected over a life-time horizon and discounted at 3% p.a. Results: Maternal 
toxoplasma screening reduced transmission risk by 40% and one quarter of 
affected children showed symptoms. We found five-times higher lifetime costs 
per child without prevention compared to screening. Also direct costs were 
lower in the latter group; screening costs did not offset costs of sequelae. A split 
in direct and indirect costs components demonstrated that proportion of direct 
costs without prevention amounted to 20% and 95% with screening. Screening 
resulted in QALYs gained and LYs saved. cOnclusiOns: Funding the maternal 
toxoplasma screening saves money and is cost-effective for the society and the 
Austrian health care system.
PIH19
COST-EFFECTIvENESS OF UNIvERSAL PAEDIATRIC ROTAvIRUS vACCINATION 
wITH RIx4414 IN GREECE
Karabela P.1, Efklidou E.1, Lyberopoulou E.1, Panagopoulou C.1, Standaert B.2
1GlaxoSmithKline, Halandri, Greece, 2GlaxoSmithKline Vaccines, Wavre, Belgium
Objectives: Rotavirus gastroenteritis is a major health burden in young chil-
dren worldwide. This study investigates the cost-effectiveness of universal pae-
diatric rotavirus vaccination with RIX4414, a two-dose human rotavirus vaccine, 
in Greece. MethOds: A Markov cohort model with a cycle time of one month 
was constructed in Microsoft Excel. The birth cohort of 114,766 infants, based 
on 2010 official registry was entered into the model and followed over average 
life expectancy with acute rotavirus events measured up to five years of age. 
Probabilities, utility scores and costs for hospitalisations, hospital-acquired 
rotavirus infection, medical consultations, emergency visits and deaths due to 
rotavirus were taken from published sources and national databases. Costs and 
benefits were reported at 2012 euros, discounted at 3% and 1.5% respectively 
per year and compared between a vaccinated and unvaccinated cohort from 
a Social Sick-Fund perspective. Results: Vaccination with RIX4414 incurred 
an incremental cost of € 16,569 per QALY at a price of € 48/dose. The estimated 
number of rotavirus-related diarrhoea events per year up to the age of five is 
45,906. Total direct medical cost of rotavirus disease without vaccination is 
around € 8,980,000 per year in Greece. Vaccination (40% coverage) reduces the 
number of gastro-enteritis events by 27% to 33,492 and the number of rotavirus-
related medical visits from 17,214 per year to less than 11,000. Total cost of 
rotavirus disease, including the costs of vaccination, in the vaccinated cohort 
is estimated at € 10,087,614 per year, with a cost reduction on direct medical 
costs of € 3,343,781. This cost reduction reflects the high financial disease burden 
related to the medical visits including paediatricians, emergency and hospital 
visits. cOnclusiOns: Paediatric vaccination against rotavirus with RIX4414 
versus no vaccination in Greece improves health outcomes, reduces direct medi-
cal costs and is cost-effective from a social sick fund perspective.
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respectively. Cost-effectiveness ratio was $ 88.7 for oxyprogesteronicaproas and $ 
80.9 for dydrogesterone. cOnclusiOns: Cost-effectiveness analysis shown, that 
the use of dydrogesterone is more effective and less costly for threatened abortion 
treatment in Ukraine. The results of pharmacoeconomic analysis will optimize the 
government, insurance companies and patients cost.
PIH26
COST-EFFECTIvENESS OF INFANT PNEUMOCOCCAL vACCINATION IN THE 
NETHERLANDS
Vemer P.1, Postma M.J.2
1UMC Groningen, Groningen, The Netherlands, 2University of Groningen, Groningen, The 
Netherlands
Objectives: The Dutch National Immunization Program offers the 10-valent pneu-
mococcal conjugate vaccine (PCV10). Also licensed for use in the infant population 
is the 13-valent PCV (PCV13). To update cost-effectiveness (CE) estimates of PCV13 
over PCV10, using current epidemiological and economic data. MethOds: We mod-
eled vaccinating a birth cohort with either PCV10 or PCV13 (3+1 dose schedule), and 
calculated costs and effects linked to resulting disease. We modeled invasive pneu-
mococcal disease (IPD), non-invasive pneumonia and acute otitis media, and con-
sidered death and lifetime impairments after IPD. We calculated direct effects in 
the vaccinated cohort and indirect effects –herd immunity for the vaccine-type (VT) 
serotypes and replacement for the non-VT serotypes– in the rest of the population. 
Since no price is available, we use a price difference of € 11 per dose and vary this 
price difference in sensitivity analyses. Epidemiological and economic data are taken 
as current as possible. A set of scenarios explore different assumptions, including 
different sets of epidemiological data, assumptions on vaccine efficacy and indirect 
effects. Results: Taking only direct effects into account PCV13 cannot be consid-
ered cost-effective, unless the price difference is much lower than € 11 per dose. In 
three scenarios, PCV10 dominates PCV13; in the other scenarios the ICER is between 
€ 89000 and € 153000 per QALY gained. If indirect effects are also taken into account, 
the ICER of PCV13 compared to PCV10 is below € 20,000 per QALY for all scenarios. 
Scenarios do not have a large impact on the policy decision, unless we assume extra 
efficacy of PCV10 against non-typeable Haemophilus influenzae. cOnclusiOns: 
Replacing PCV10 with PCV13 is not likely to be cost-effective in preventing invasive 
pneumococcal disease in young children. Taking potential benefits in elderly into 
account, PCV13 is likely cost-effective. The CE of PCV13 was highly sensitive for indi-
rect effects our analysis.
PIH27
COST-MINIMIzATION ANALySIS OF DIENOGEST vERSUS GONADOTROPHIN-
RELEASING HORMONE ANALOGUES OR DyDROGESTERONE FOR 
ENDOMETRIOSIS TREATMENT IN RUSSIA
Avxentyeva M.
The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia
Objectives: To perform pharmacoeconomic evaluation of dienogest vs gonadotro-
phin-releasing hormone analogues (GnRHa) or dydrogesterone for endometriosis in 
Russia. MethOds: Literature search did not reveale clinically significant differences 
in efficacy between dienogest 2 mg and GnRHa in terms of pain reduction associ-
ated with endometriosis. There was no difference in efficacy with dydrogesterone 
60 mg once daily and placebo. Cost-minimization analysis was used to assess and 
compare drug costs of dienogest 2 mg daily, GnRHa - most often used in Russia 
including triptorelin, leuprorelin, buserelin (with obligatory application of add-back 
therapy for all three GnRHa) and dydrogesterone. Costs were calculated for a period 
of 6 months. Results: Costs of endometriosis treatment per patient per 6 months 
were 1102€ for triptorelin, 1118€ for leuprorelin, 340€ for buserelin, 369€ for dydro-
gesterone and 295€ for dienogest. Dydrogesterone is less effective and more costly 
alternative in comparison with buserelin and dienogest. Among alternatives with 
the same efficacy dienogest is the most efficient option leading to savings from 74€ 
to 823€ per patient in 6 months. cOnclusiOns: Using dienogest for treatment of 
endometriosis in Russia is as effective as using GnRHa but can lead to considerable 
cost savings because add-back therapy is not required.
PIH28
COST MINIMIzATION ANALySIS OF THE DIENOGEST USE IN PATIENTS wITH 
ENDOMETRIS UNDER BRAzILIAN PUBLIC AND PRIvATE PERSPECTIvE
Ferracini M., Nakada C.P.
Bayer healthcare Brazil, São Paulo, Brazil
Objectives: To provide the results from a cost-minimization (CM) model that com-
pares the use of dienogest with the use of GnRH antagonist (GnRHa) leuprorelin 
acetate, both for 6 months, in women with endometriosis-associated pelvic pain 
(EAPP) in Brazil. MethOds: A(CM) model was developed in the form of a decision 
tree to mimic treatment sequence in Brazil. The analysis was conducted under the 
private and public payer perspectives, only direct costs were included, procedures 
and drug costs were obtain from Brazilian official databases of public and private 
health care system fees. This CM model compared different treatment pathways for 
women with EAPP and used a 50% improvement in pelvic pain as a definition of a 
treatment responder to elicit treatment duration. Treatment response assessment 
was at 12 week period. Two basic treatment pathways were defined: a two treatment 
sequence (2TS) and tree treatment sequence (3TS). The 2TS consists of: GnRHa/dien-
ogest followed by surgery. The 3TS consists of: GnRHa/dienogest, dienogest/GnRH 
as second treatment and surgery as final option. Subsequent treatments were only 
for patients that did not respond to previous treatment. Discount was not applied 
as costs occurred within 1 year period. Results: The CM model shows that for 
both treatment pathways and perspectives dienogest is a cost-saving alternative. 
Under private payer perspective for 2TS and 3TS: BRL 1020.42 VS BRL 2328.94 and 
BRL 1461.22 VS BRL 2377.52 for dienogest and GnRHa respectively. Under public 
payer perspective for 2TS and 3TS: BRL 882.74 VS BRL 768.13 and BRL 942.18 VS BRL 
856.77 for dienogest and GnRHa respectively. Efficacy for 2TS and 3TS are: 91.58% 
testing/delivering and definition of the CL test threshold. The values obtained were 
LR+ 3,98/LR- 0,33 (FN) and LR+ 2,22/LR- 0,54 (CL). For the whole hypothetical cohort 
the total costs of the FN and CL were 2,3 billion and 890 million, respectively. The 
difference of avoided hospitalizations between the tests was 244 for FN. ICER was 
BRL 5,834,35. cOnclusiOns: Both diagnostic tests are important alternatives for 
the detection of premature birth in Brazil. Studies of prediction of preterm delivery 
using CL have important limitations beyond the fact that CL measure is an operator/
machine dependent procedure. In women with symptomatic preterm labor FN is a 
cost-effective test strategy for prediction of preterm births.
PIH23
COST-EFFECTIvENESS OF vACCINATION AGAINST HERPES zOSTER AND 
POSTHERPETIC NEURALGIA: A CRITICAL REvIEw
Kawai K.1, Préaud E.2, Baron-Papillon F.2, Acosta C.J.1
1Merck & Co., Inc, West Point, PA, USA, 2Sanofi Pasteur MSD, Lyon, France
Objectives: To systematically review cost-effectiveness studies of vaccination 
against herpes zoster (HZ) and post-herpetic neuralgia (PHN). MethOds: We 
searched MEDLINE and EMBASE databases for eligible studies until June 2013. We 
extracted information regarding model structure, model input parameters, and 
study results. We compared the results across studies by projecting the health and 
economic impacts of vaccinating 1 million adults over their lifetimes. Results: We 
identified 14 cost-effectiveness studies performed in North America and Europe. 
Results ranged from approximately US$10,000 to US$100,000 per quality-adjusted 
life years gained, though most studies in Europe concluded that zoster vaccination 
is likely to be cost-effective. All studies used similar model structure. Differences 
in results among studies are largely due to differing assumptions regarding dura-
tion of vaccine protection and a loss in quality of life associated with HZ and to 
a larger extent, PHN. In addition, studies found that vaccine efficacy against PHN, 
age at vaccination, and vaccine cost strongly influenced the results in sensitiv-
ity analysis. cOnclusiOns: Our review generally supports the economic value of 
this preventive intervention, particularly in Europe, which will become increasingly 
important as population ages. Future research addressing key model parameters 
and cost-effectiveness studies in other parts of the world are needed.
PIH24
AN ECONOMIC EvALUATION ALONGSIDE A CLINICAL TRIAL (EEACT) IN PELvIC 
FLOOR MEDICINE
Brennan V.K.1, Dixon S.2, Jones G.2, Radley S.3, Jacques R.2, Wood H.2, Ledger W.4
1RTI Health Solutions, Sheffield, UK, 2University of Sheffield, Sheffield, UK, 3Sheffield Teaching 
Hospitals Charitable Trust, Sheffield, UK, 4University of New South Wales, Sydney, Australia
Objectives: To determine the cost-effectiveness of using an online questionnaire 
(ePAQ-PF) in combination with a telephone consultation compared to standard 
care. MethOds: All women, aged ≥ 18 years and referred to urogynaecology ser-
vices in Sheffield were eligible. Women completed ePAQ-PF online and then received 
a telephone consultation (intervention), or face-to-face consultation (standard 
care). Costs for ePAQ-PF completion and consultation were derived in a microcost-
ing study. Resource use data were collected at 6-months follow-up. The SF-12 was 
administered at baseline and follow-up. SF-6D estimates were used to calculate 
quality-adjusted life-years (QALYs). Patient experience was measured by the Patient 
Experience Questionnaire and Client Satisfaction Questionnaire. Results: A total of 
195 women were randomised. Consultation costs for the intervention group (£31.75) 
were lower than for the control (£72.17). The intervention group incurred greater 
direct costs and personal expenditure during follow-up. However lower costs asso-
ciated with productivity loss for the intervention group resulted in lower indirect 
costs per-patient. Mean total costs per-patient were £38.04 greater in the intervention 
group (£1,139.86) than the control (£1101.82). SF-6D scores reduced slightly during 
follow-up for the intervention group, and increased slightly for the control, resulting 
in QALY loss for the intervention group, and QALY gains for the control. Statistically 
significant gains in patient experience were identified for the intervention group, 
although in strict cost-utility terms the intervention was dominated by the control. 
Incremental costs and QALYs resulted in a negative incremental cost-effectiveness 
ratio (ICER). cOnclusiOns: Although the intervention was not cost-effective com-
pared to the controls, there was a significant difference in an important aspect of the 
care process, which was not captured by the ICER. This highlights the importance of 
decision makers accounting for intervention effects that fall outside the conventional 
conceptualization of the QALY. Methods could be developed that allow non-health 
effects, such as process utility, to be incorporated into the QALY.
PIH25
PHARMACOECONOMIC ANALySIS OF PROGESTOGEN PREPARATIONS FOR 
THREATENED ABORTION TREATMENT IN UKRAINE
Tkachova O.1, Iakovlieva L.1, Mishchenko O.1, Matyashova N.2
1National University of Pharmacy, Kharkiv, Ukraine, 2National University of Pharmacy, Kharkiv, 
Ukraine
Objectives: Comparative evaluation the cost effectiveness of threatened abor-
tion treatment by two regimens: oxyprogesteronicaproas and dydrogesterone in 
Ukraine. MethOds: Pharmacoeconomic analysis was based on the results of com-
parative randomized trial (Belousov Yu. B., Karpov O.I., Ailamazian E.K., 2008). Two 
regimens for threatened abortion treatment: oxyprogesteronicaproas and dydroges-
terone were evaluated. Treatment with dydrogesterone (20 mg per day or 2 tablets 
per day) was carried out during 8 weeks before closure forming placenta (56 days). 
Oxyprogesteronicaproas (250 mg per day) was used from 14 to 20 weeks of gestation 
(42 days). For determining the cost of therapy only the cost of drugs and auxiliary 
materials (syringes, alcohol) for both schemes were taken into account. The prices 
of drugs were taken from the information system “Drugs” of Company “Morion” 
(February, 2013, Ukraine). The currency ratio of UAH to dollar (USA) on 01.02.13 was 
8,12:1. As an indicator of efficacy the number of saved pregnancy after treatment 
was used. Results: The effectiveness of oxyprogesteronicaproas therapy was 
88.6%, and dydrogesterone - 96.3%, the cost of treatment was $ 78.63 and $ 77.96 
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were asked to complete Accept and MMAS-4 questionnaires at Month 1, 3 and 
6 after having given their informed consent. The structure was explored through 
PCA, and confirmed with multi-trait analysis. Internal consistency reliability 
of dimensions was assessed through Cronbach’s alpha. Scale-scale correla-
tions were calculated. Results: After reduction, Accept was made of 25 items 
organised in 1 overall Acceptance score and 6 domain-specific scores (efficacy, 
tolerance, convenience, constraints, treatment duration, multiple medica-
tion). Cronbach’s alpha was 0,85 for overall Acceptance score, which met con-
vergent and divergent validity criteria (both 100%). The domain-specific scores 
showed satisfactory to good results (Cronbach’s alpha ranging from 0,67 - 0,87, 
convegrent validity ranging from 63% to 100%, and divergent validity ranging 
from 33% - 100%). Scale-scale correlations ranged from 0.02 to 0.58, confirming the 
multi-dimensional nature of the questionnaire. The good properties of Accept were 
stable over time. cOnclusiOns: Accept is a brief, comprehensive, generic ques-
tionnaire focused on Acceptance. Initial validation in a population of patients with 
a wide range of long-term treatment showed promising results and confirmed 
the position of Acceptance. Further, disease-specific, large prospective study are 
needed to assess the ability of Accept to predict persistence to treatment.
PIH32
DETERMINANTS OF NON-ADHERENCE TO MEDICATIONS AMONG CHRONIC 
PATIENTS IN MACCABI HEALTH CARE SERvICES
Simon Tuval T.1, Triki N.2, Chodick G.2, Greenberg D.1
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Maccabi Healthcare Services, Tel Aviv, 
Israel
Objectives: Implementation of co-payments may reduce the use of essential medi-
cations, worsen patients’ outcomes, and increase overall health care costs. The aim 
of this study was to examine to what extent non-adherence of chronic patients to 
medication stems from financial reasons and what determinants are associated with 
non-adherence. MethOds: A telephone survey was conducted among a representa-
tive sample of Maccabi Healthcare Services chronic patients aged ≥ 55 yrs (n= 522). 
Respondents were defined as non-adherent if they reported they had stopped tak-
ing prescribed medications in the previous year and/or not purchasing prescribed 
medications due to its cost. Additional information collected included: age, gender, 
income, receiving explanation from a physician regarding the therapy, and out-of-
pocket expenditure for prescribed medications. Results: Mean age of the study 
population was 69.9±9.0 yrs (53% were male). Sixteen percent of respondents were 
defined as non-adherent, in 60% of them it was due to medication’s cost. No sig-
nificant differences were found between adherent and non-adherent respondents 
with regard to: age, gender, family status, country of birth, supplementary insurance 
coverage, or education. In a multivariable logistic regression model, non-adherence 
was associated with: lack of physician explanation about prescribed medications 
(OR= 2.88, 95%CI: 1.46-5.68, P= 0.002); higher out-of-pocket expenditure on medications 
(OR= 1.93, 95%CI: 1.04-3.61, P= 0.04), and lower household income (OR= 0.81, 95%CI: 
0.69-0.96, P= 0.01). cOnclusiOns: Information provided by physicians is associated 
with adherence of chronic patients to prescribed medications. Low income and high 
out-of-pocket expenditure for prescribed medication are associated with non-adher-
ence. Since adherence is strongly affected even by a relatively low and flat co-payment 
as applied in Maccabi Healthcare Services, health policy makers may consider adop-
tion of value-based co-payments that are differentiated by treatment value rather 
than by its cost, and targeted mainly at chronic patients. This approach may lead to 
improved adherence and outcomes with the potential of reducing long-term costs.
PIH33
COST-EFFECTIvENESS OF MEDICATION ADHERENCE ENHANCING 
INTERvENTIONS: A SySTEMATIC REvIEw
Oberjé E.1, de Kinderen R.2, Evers S.M.2, de Bruin M.1, van Woerkum C.3
1University of Amsterdam, Amsterdam, The Netherlands, 2Maastricht University, Maastricht, The 
Netherlands, 3Wageningen University, Wageningen, The Netherlands
Objectives: In light of the presumed costs of non-adherence to medication and the 
pressure to reduce unnecessary health care expenditures in the current economic 
climate, a review that assesses evidence of cost-effectiveness of adherence enhancing 
interventions would be timely. The objective of this paper is to examine the cost-
effectiveness of adherence enhancing interventions and the quality of the studies 
reviewed. MethOds: MEDLINE, PsycInfo, EconLit and the Centre for Reviews and 
Dissemination databases were searched for randomised controlled trials that per-
formed full economic evaluations of adherence enhancing interventions. Information 
was collected on study characteristics, cost-effectiveness of treatment alternatives, 
quality of economic evaluations, and risk of bias. Results: Fourteen studies were 
included, of which the overall quality was found to be moderate. Five used a societal 
perspective, eight a provider perspective, and a single study used a patient perspec-
tive. Ten studies examined interventions that were both more costly and more effec-
tive than usual care, and four were less costly and more effective. Comprehensive 
evidence from the societal perspective yielded disappointing results for potential 
cost-effectiveness of adherence interventions. Studies from other perspectives pro-
vided weak to moderately promising evidence that adherence interventions can 
be cost-effective. cOnclusiOns: Few randomised controlled trials examined the 
cost-effectiveness of adherence interventions. There was limited evidence of poten-
tial cost-effectiveness of adherence programmes. Most interventions did not report 
whether their intervention was effective in the first place, and many suffered from 
methodological limitations. To demonstrate that adherence interventions offer soci-
etal benefits, we recommend that the most promising interventions are subjected to 
a rigorous cost-effectiveness evaluation.
PIH34
A SySTEMATIC REvIEw OF PATIENT PREFERENCES FOR SUBCUTANEOUS 
MEDICATIONS
Ridyard C., Dawoud D., Hughes D.A.
Bangor University, Bangor, UK
and 97.87% respectively. cOnclusiOns: This analysis portends dienogest as a cost-
saving alternative for the treatment of EAPP compared to GnRHa in Brazil from the 
public and private payer perspective.
PIH29
INvESTIGATING THE IMPACT OF MENTAL HEALTH STATUS ON HEALTH AND 
SOCIAL CARE COSTS OF OLDER PEOPLE AFTER ACUTE HOSPITAL ADMISSION
Berdunov V., Franklin M., Tanajewski L., Harwood R., Goldberg S., Gladman J., Elliott R.A.
University of Nottingham, Nottingham, UK
Objectives: In England, nearly two-thirds of older people in acute hospital care 
suffer from co-morbid physical and mental health conditions. This study inves-
tigated the health and social care costs for a group of older (70+) people iden-
tified with a mental health condition after hospital admission. MethOds: The 
Better Mental Health (BMH) study recruited 247 patients at hospital admission in 
Nottingham, England. Electronic administrative records were sought for six months 
post-admission from health (services: general practices, hospitals, ambulance trans-
port, intermediate and mental health care) and social care. The cohort was charac-
terised by one or more aspects of mental health: cognitive impairment, depression, 
delirium, and neuropsychiatric health. Differences in mean cost between groups 
were assessed using t-tests; association between mental health and service-level 
cost was investigated using GLM regression. Results: Health and social care costs 
were derived for all 247 participants, except primary care, derived for 122 (subset) 
participants due to GP recruitment. In the subset, mean (95% CI, median, range) total 
cost was £9842 (8573-11256, 7717, 715-48795). Mean cost (95% CI) for mental health 
care was significantly (p< 0.05) higher for patients: with depression than without 
(£194 (106-322) Vs. £55 (17-111)); bottom-50% on the neuropsychiatric health scale 
(£202 (124-298) Vs. £55 (16-118)). Patients with delirium, compared to without, had 
significantly lower costs for GP consultations (£316 (196-492) Vs. £552 (429-701)) 
and hospital outpatient visits (£333 (253-444) Vs. £497 (400-621)). The GLM did not 
identify a significant association between aspects of mental health and service-
level costs. cOnclusiOns: This study suggests a person’s mental health affects 
consumption of some, but not all, services evaluated. In general, these patients are 
costly, high resource-users, of health and social care services; however, this con-
sumption pattern cannot be attributed to one particular aspect of mental health. 
Future work should investigate the impact of physical and mental health comor-
bidities on resource-use.
INDIvIDUAL’S HEALTH – Patient-Reported Outcomes & Patient Preference Studies
PIH30
MEDICATION ADHERENCE AND ADvERSE HEALTH OUTCOMES IN COMMUNITy 
DwELLING OLDER PATIENTS
Cahir C.1, Fahey T.2, Teljeur C.3, Bennett K.4
1Trinity College Dublin, Dublin 8, Ireland, 2Royal College of Surgeons in Ireland, Dublin, Ireland, 
3Health Information and Quality Authority, Dublin, Ireland, 4Trinity Centre for Health Sciences, 
Dublin, Ireland
Objectives: To determine the association between medication adherence and 
adverse drug events (ADEs), health related quality of life (HRQOL) and hospitalisa-
tion in older community dwelling patients. MethOds: A retrospective cohort study 
of 855 patients aged ≥ 70 years from 15 general practices in Ireland in 2010. Medication 
adherence was measured by: (i) the Medication Possession Ratio (MPR) using national 
pharmacy claims dispensing data; and (ii) self-report using the Morisky Medication 
Adherence Scale. ADEs and hospitalisation were measured by patient medical record 
and self-report for the previous 6 months. ADEs were reviewed by two independent 
clinicians. HRQOL was measured using EQ-5D. Multilevel Poisson and linear regression 
were used to examine how the number of ADEs, utility and hospitalisation varied by 
adherence after adjusting for patient and practice level covariates; socioeconomic 
status, deprivation, co-morbidity, number of drugs, functional disabilities, social sup-
port and health insurance. Results: A total of 592 (69%) patients were adherent 
based on dispensed pharmacy claims data (MPR ≥ 80%) and 553 (63%) self-reported 
adherence to their medication. The median MPR for self-reported adherent patients 
was 0.88 (IQR: 0.78, 0.95) compared to 0.86 (IQR: 0.71, 0.93) for non-adherent patients 
(p< 0.01). Non-adherence (MPR< 80%) was not significantly associated with any ADEs 
but self-reported non-adherent patients had an increased risk of any ADEs (IRR 1.18; 
95% CI 1.05, 0, 1.33 p< 0.01). Non-adherent patients had a significantly lower mean 
HRQOL utility (MPR coefficient, -0.11, SE 0.03, p< 0.001; self-report coefficient, -0.06, 
SE 0.01, p< 0.001) and an almost two-fold increased risk in the expected rate of any 
hospitalisation (MPR IRR, 1.75; 95% CI, 1.42, 2.15, p< 0.001; self-report IRR, 1.53; 95% CI, 
1.16, 2.01, p< 0.01) compared to adherent patients. cOnclusiOns: Non-adherence 
was significantly associated with adverse health outcomes. Developing methods 
to assist older adults in accurate and safe management of their medications may 
increase their quality of life.
PIH31
vALIDATION OF ACCEPT, A NEw GENERIC MEASURE TO ASSESS HOw PATIENTS 
wITH CHRONIC DISEASES BALANCE BETwEEN THE ADvANTAGES AND 
DISADvANTAGES OF FOLLOwING THE RECOMMENDED TREATMENT REGIMEN 
IN REAL-LIFE
Arnould B.1, Gauchoux R.2, Meunier J.1, Gilet H.1, Regnault A.1
1Mapi, Lyon, France, 2Mapi, Real World Evidence, Lyon, France
Objectives: To reduce, score, and validate the Accept questionnaire. MethOds: 
Accept is a 32-items PRO questionnaire measuring the concept of Acceptance. 
It was developed based on grounded theory and qualitative research. Each 
treatment characteristic was assessed on a response scale opposing “easy to 
accept” to “not easy to accept”. We conducted an observational prospective 
study on 182 subjects engaged in long-term treatment regimen. Adult patients 
where consecutively recruited by a network of pharmacists when prescribed 
with a drug indicated in various chronic diseases (including asthma, diabetes, 
various cardio-vascular diseases, retroviral infections, osteoporosis). Patients 
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prescription medications. Given the financial burden of using multiple medications, 
and the lower incomes of these patients, cost-saving methods are more frequently 
utilized by these patients.
PIH37
PRELIMINARy ITALIAN ARCHIvE OF EQ-5D DATA ON INDIvIDUALS FROM THE 
GENERAL POPULATION AND wITH DIFFERENT DISEASE CONDITIONS
Cortesi P.A.1, Ciampichini R.1, Mantovani L.G.2, Scalone L.3
1Charta Foundation, Milan, Italy, 2Federico II University of Naples, Naples, Italy, 3University of 
Milano - Bicocca, Monza, Italy
Objectives: In the last 15 years our research activity collected several HRQoL data, 
through the EQ-5D-3L and other generic (SF-36) or condition-specific question-
naires. The objective was to assess and compare HRQoL among different popula-
tion subgroups. MethOds: We reviewed all the HRQoL studies conducted by our 
research group between 1998 and 2012. We identified several conditions to be com-
pared in terms of VAS score and utility index: these were assessed using the Italian 
social tariffs and then adjusted for age and sex. Results: The archive included 
QoL data from 7,754 subjects (51.5% male), grouped in 29 different subgroups: type 
1 and 2 diabetes mellitus, moderate to severe haemophilia, major depression, 
atopic dermatitis, severe and chronic hand eczema, psoriatic arthritis, schizophre-
nia/schizophrenic disorder, β -thalassemia major, gastroesophageal reflux, abdomi-
nal aortic aneurysm, systemic sclerosis, chronic hepatitis B, chronic hepatitis C, 
hepatitis from other causes, cirrhosis, hepatocellular carcinoma, liver transplant, 
general Italian population aged from 18 to 75 years. Overall, the subjects were aged 
from 14 to 96 years (mean(+SD)= 55.7(+17.1), median= 57.7). The adjusted EQ-5D-
VAS mean+SD ranged from a minimum of 33.9+14.1 in patients with a major 
depression episode, to a maximum of 82.5+12.9 in patients with atopic dermatitis 
8 weeks after flare. The mean+SD VAS was 73.2+11.4 in the general population. The 
adjusted mean+SD utility index ranged from 0.60+0.17 in psoriatic arthritis before 
starting treatment with biological agents, to 0.931+0.09 among chronic hepatitis 
B patients. cOnclusiOns: The many EQ-5D data collected in the last 15 years 
are merged now in a unique archive that can be used to assess and compare the 
burden of disease in terms of HRQoL in different subpopulations. This archive is to 
be considered preliminary and deemed to be integrated with additional data from 
ongoing or future projects, and perhaps with other analogous archives created in 
other contexts and Countires.
PIH38
LEvEL AND FACTORS IMPACTING THE PATIENT DISSATISFACTION IN THE 
PRIMARy CARE vISITS BASED ON THE CROSS-SECTION MEASUREMENT – A 
PROSPECTIvE FINNISH STUDy
Soini E.J.1, Koskela T.2, Kangaspunta V.3, Ryynänen O.P.4
1ESiOR Oy, Kuopio, Finland, 2Department of General Practice, University of Tampere, Tampere, 
Finland, 3School of Medicine, University of Tampere, Tampere, Finland, 4Department of Public 
Health and Clinical Nutrition, University of Eastern Finland, and General Practice Unit, Kuopio 
University Hospital, Kuopio, Finland
Objectives: A key dimension impacting clinical outcomes in health care evaluation 
is satisfaction (i.e. the level of meeting user’s expectations for the service), which 
impact adherence and persistence. Yet, evidence regarding patient dissatisfaction 
is scarce. Thus, we asked what the level of dissatisfaction is after a health centre 
(HC) visit, and which factors impact the dissatisfaction? MethOds: A prospective 
survey to primary care patients visiting 3 Finnish HCs (Linnainmaa, Omapihlaja, 
Pirkkala) in Pirkanmaa district during 31.1–11.2.2011 was done. No inclusion/exclu-
sion criteria were used. Comprehensive patient-, clinician- and HC-related data was 
collected. The patient’s satisfaction was measured immediately after the visit in the 
form of handling problem during a visit (Likert range 0–10). This was inversed to 
assess the drawback related to the visit (0= full benefit; problem was solved; 10= no 
benefit; full drawback). An explorative statistical analysis was done including mul-
tivariate data mining in order to find the model with the best Akaike information 
criteria. The model aimed to demonstrate the independent factors impacting the 
drawback and control heterogeneity. Results: A total of 90.1% of the full sample 
(n= 647) answered to the drawback question. 40.3% of the patients had problem 
solved during the visit (i.e. reported 0) and just 6.9% of the patients experienced 
drawback exceeding 5. The factors increasing the drawback in the stepwise OLS 
regression model with the +1 ln-transformation for the drawback were longer wait-
ing time, asthma/copd and male sex. The factors decreasing the drawback were 
patient’s higher subjective health status, patient’s higher subjective health status 
in comparison to others of same age/sex, some long-term conditions (rheumatoid 
disease, allergy, hip/knee joint erosion), clinician’s longer experience, clinician in 
specialising education and certain HC. cOnclusiOns: Some 60% of the patients 
experienced that their problem was not fully handled. Multiple factors impact the 
drawback which could be notified in the planning of HC services.
PIH40
MEASUREMENT OF SOCIETAL MEDICAL CARE PREFERENCES wITH THE SAME 
COST PER QALy: A DISCRETE CHOICE STUDy
Shiroiwa T.1, Saito S.2, Shimozuma K.3, Kodama S.4, Noto S.5, Fukuda T.1
1National Institute of Public Health, Saitama, Japan, 2Okayama University, Okayama, Japan, 
3Ritsumeikan University, Kusatsu, Japan, 4Kyoto University, Kyoto, Japan, 5Niigata University of 
Health and Welfare, Niigata, Japan
Objectives: The principal of QALY is sometimes referred to as “A QALY is a QALY 
is a QALY”, which means all QALYs have the same value, while QALYs may not 
fully reflect public preferences. If the use of QALYs in decision making proves 
beneficial but insufficient, what other factors should be taken into consideration 
simultaneously? MethOds: We conducted a face-to-face survey using a discrete 
choice method to measure societal medical care preferences. The profiles of 
assumed patients consisted of the following four factors: (a) age (young or elderly 
patient); (b) objective of care (treatment or prevention); (c) severity of health 
state (severe or mild); and (d) past experience of receiving care (yes or no). These 
Objectives: Of the many routes of drug administration, some are more accept-
able to patients than others; for example when a choice is presented, patients will 
usually prefer an oral over an injectable medication, all else being equal. Patient 
preference may be expressed in terms of health and non-health-related measures, 
which include: health technology-related attributes (including ergonomics, ease of 
use, convenience), behaviour (e.g. needle phobia and patients’ perceptions of treat-
ment), and adverse reactions attributable to the route of administration. Preferences 
may result in process-related (dis)utility, and be revealed as (non)adherence. 
This review aims to examine ambulatory patients’ preferences for subcutane-
ously administered, self-injectable medications, compared with other routes of 
administration for the same medicines. MethOds: Ten electronic databases 
were searched for publications published between 2002 and 2012 using terms 
pertaining to methods of administration, preferences and adherence. Eligibility 
for inclusion was determined through reference to specific criteria by two inde-
pendent reviewers. Results: Of the 1,146 papers screened, 70 met the inclusion 
criteria. Studies focused mainly on methods of administration for insulin and 
treatments of paediatric growth disorders and multiple sclerosis. Pen devices were 
significantly preferred to needle & syringes administration in 11 out of 12 studies 
– particularly with respect to ergonomics, convenience and portability; however, 
preferences between autoinjectors and pen devices were less pronounced. Oral 
administration was preferred to subcutaneous administration in 6 studies (but did 
not reach statistical significance), as was inhaler therapy (favoured significantly 
in 3 out of 4 studies). cOnclusiOns: The review identified a number of studies 
which revealed important differences in patient preference between methods and 
routes of drug delivery. Further evidence is required to support the notion that 
preference translates to better adherence.
PIH35
THE EFFECT OF MEDICAL DEvICES wITH DOSE-MEMORy AND REMINDER 
FUNCTIONS ON PATIENTS’ TREATMENT ADHERENCE, CONFIDENCE AND 
DISEASE SELF-MANAGEMENT
Hall R.1, Harald-Kongsø J.2, Humphrey L.1, Willgoss T.1
1Adelphi Values, Bollington, UK, 2Novo Nordisk, Søborg, UK
Objectives: Adherence to treatment is an important issue in the management of 
chronic diseases and an indicator of patients’ ability to self-manage their condition. 
Some medical devices have been designed to help support patients’ self-management 
and adherence by including dose-memory and reminder functions. This literature review 
explored the role and impact of these devices on patients’ adherence to treatment, 
confidence and disease self-management. MethOds: A search of Medline, Embase 
and PsycInfo was performed to identify articles published in English from 2003-2013, 
which studied the effect of devices with memory and/or reminder functions on treat-
ment adherence, confidence and self-management. The main attributes of the abstracts 
selected for inclusion and full-text review, were summarized. Results: The database 
searches yielded 940 abstracts. Of the 47 meeting the inclusion criteria, 32 were retained. 
The articles explored the impact of memory and/or reminder devices on treatment 
adherence, device usability and users’ (patients, health care professionals (HCPs) and 
caregivers) relationship and attitudes towards the devices. Devices with memory and/or 
reminder functions were found to improve self-reported and electronically-monitored 
treatment adherence in prophylactic medication use (e.g. contraceptives) and a range 
of chronic diseases including HIV, diabetes and asthma. Memory functions were con-
sidered valuable in disease management by patients and HCPs. Of particular value was 
that memory and/or reminder functions provided dose-history information, enhanced 
patients’ confidence with, and ability to manage their medication and condition, and 
helped reduce forgotten or incorrect medication dosing. cOnclusiOns: The incorpora-
tion of memory functions alone and in combination with reminder features in medical 
devices can improve patient’s adherence, confidence and self-management. This can 
lead to improvements in disease control and clinical outcomes, thereby offering clini-
cal and economic value. This review highlights the importance of conducting further 
qualitative and quantitative research in this area to fully understand the value of these 
types of devices to patients and HCPs.
PIH36
COMPARISON OF ELDERLy ADULTS By NUMBER OF Rx MEDICATIONS USED: 
RESULTS FROM THE NATIONAL HEALTH AND wELLNESS SURvEy ACROSS 5EU 
COUNTRIES
Annunziata K.1, Isherwood G.2, Sternbach N.1
1Kantar Health, New York, NY, USA, 2Kantar Health, Epsom, Surrey, UK
Objectives: Compliance with medications among elderly patients is particularly 
important, as the consequences may be quite serious. Results suggest that use of 
three or more medications may put a considerable burden on elderly patients and 
may affect their compliance. This analysis profiles elderly patients across 5EU by 
the number of medications currently used and their compliance related behaviors. 
Combination products were considered as one prescription medication. MethOds: 
Results were taken from the 2011 5EU National Health and Wellness Survey, a 
nationally representative, self-administered survey. Respondents were adults age 
18 and over from France, Germany, Italy, Spain and UK. This analysis focuses on 
adults age > = 65. Physical and mental quality of life was measured using the SF12v2 
scale. Activity impairment was measured using the Work Productivity and Activity 
Impairment scale. Results: Out of the total sample of age > = 65 (n= 10,612), ~37% 
of elderly adults across 5EU currently use four or more prescription (Rx) medica-
tions to treat their conditions, 44% use 1-3 Rx medications, and 18% use no Rx 
medications. Activity impairment is greater among those using 4+ medications 
(38.6 vs. 22.7 vs. 16.0). Emergency room visits and hospitalizations are also higher. 
This group appears to be more proactive in engaging in cost-saving behaviors to 
alleviate some of the treatment costs in the past 6 months (30% vs 24% vs 15%) (e.g., 
asking for generic alternatives (19% vs 16% vs 8%), ever changing prescription to 
another drug (61% vs 51% vs 45%) and switching to a generic version of a prescribed 
drug (35% vs 27% vs 18%). cOnclusiOns: Considerably higher health care costs 
and greater activity impairment can be seen among elderly patients using more 
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tive analysis aims to explore how PRO were used in the French affiliate of 
Roche. MethOds: A total of 89 local studies performed between 2003 and 2013 
were evaluated to determine how PROs were collected and evaluated. Results: 
Forty (45%) out of 89 studies were clinical trials, 44 (49%) were non-interventional 
studies (NIS) and 5 were expanded access program studies. A total of 33 (37%) 
studies used at least one PRO; 13 (39%) were clinical trials and 20 (61%) were NIS. 
There were no PRO in the field of transplantation, 21% of the studies in oncology 
used PRO, 47% in virology, 60% in anemia and 72% in rheumatology. More than 3600 
sites participated in the 33 studies using PRO: 17424 patients were included, 14237 
patients (82%) answered at least one PRO and 12314 (86%) of the questionnaires 
received were considered to be analyzable for statistical analysis (non analyzable 
PROs were usually due to missing data). The median number of questionnaires 
per study was 2, (range 1-6). While most studies in virology and anemia used 1 or 
2 questionnaires per study, rheumatology studies used at least 3 questionnaires 
per study. The median study duration was 12 months, (range 1-60). While 84% of 
PRO were collected at inclusion in the study, 73% of PROs were received after the 
6 month visit, 65% at the 12 month visit and less than 50% after 12 months. Seven 
studies (21%) used PRO as a primary endpoint, and the percentage of patients 
who answered the questionnaire answered was higher (mean 91%) than when 
PRO was a secondary endpoint (mean 79%). cOnclusiOns: Careful consideration 
should be given to number of questionnaires used per study as quality decreases 
as number of evaluations increases.
PIH44
CONFIRMATORy FACTOR ANALySIS AND EvALUATION OF CLINICALLy 
IMPORTANT DIFFERENCES IN MENOPAUSE-SPECIFIC QUALITy OF LIFE 
ASSOCIATED wITH BAzEDOxIFENE/CONjUGATED ESTROGENS IN A vULvAR/
vAGINAL ATROPHy POPULATION
Abraham L.1, Bushmakin A.G.2, Pinkerton J.V.3, Cappelleri J.C.2, Mirkin S.4
1Pfizer Ltd., Tadworth, Surrey, UK, 2Pfizer Inc, Groton, CT, USA, 3Department of Obstetrics and 
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USA, 4Pfizer Inc, Collegeville, PA, USA
Objectives: To confirm the factor structure of the Menopause-Specific Quality of 
Life (MENQOL) questionnaire for a vulvar/vaginal atrophy (VVA) population by apply-
ing confirmatory factor analysis (CFA), and to determine whether improvements in 
health-related quality of life (HRQL) observed in a VVA population with bazedox-
ifene/conjugated estrogens (BZA/CE) relative to placebo can be deemed clinically 
relevant. MethOds: In a randomized control trial, postmenopausal women with 
≥ 1 bothersome moderate-to-severe VVA symptom received BZA 20 mg/CE 0.45 
or 0.625 mg, BZA 20mg or placebo for 12 weeks. HRQL and treatment satisfaction 
were evaluated using the MENQOL questionnaire and the Menopause Symptoms-
Treatment Satisfaction Questionnaire (MS-TSQ), respectively. The structure of the 
MENQOL questionnaire was evaluated using a CFA. Clinically important differences 
(CID) for the MENQOL were determined using a regression model to estimate dif-
ferences in domain and total scores corresponding to one category difference in 
MS-TSQ items, which were used as anchors. Results: The postulated CFA model fit 
the MENQOL data (Bentler’s Comparative Fit Index > 0.9). Treatment with BZA 20 mg/
CE 0.45 and 0.625 mg compared with placebo was associated with statistically sig-
nificant improvements in MENQOL vasomotor and sexual functioning domains, and 
total score (p < 0.001). BZA 20 mg/CE 0.625 mg was also associated with significant 
improvements in physical functioning (p= 0.019). Change from baseline in MENQOL 
vasomotor functioning for BZA 20 mg/CE 0.625 mg over placebo was greater than the 
estimated CID, with BZA 20 mg/CE 0.45 mg approaching CID. Changes in total score 
for BZA 20 mg/CE 0.625 mg compared with placebo also approacöhed CID. Changes 
in MENQOL sexual functioning from baseline over placebo, while statistically signifi-
cant and quite large, were less than the CID estimate. cOnclusiOns: CFA modeling 
provides strong support for the existing factor structure of the MENQOL question-
naire. Improvements in HRQL seen with BZA/CE approached or exceeded CIDs for 
VMS functioning and total score.
PIH45
ExAMINATION OF PELvIC FLOOR MUSCLE FUNCTION AFTER PELvIC FLOOR 
MUSCLE TRAINING AND USING CUBE PESSARy
Hock M.1, Németh Z.2, Varga P.3, Ambrus E.3, Krómer A.3, Csengeri K.3, Kovács V.3, Kránicz J.1, 
Boncz I.1, Bódis J.1
1University of Pécs, Pécs, Hungary, 2Petz Aladár Hospital, Györ, Hungary, 3Zsigmondy Vilmos 
Harkány Spa Hospital, Harkány, Hungary
Objectives: Follow up of pelvic floor muscle function after pelvic floor muscle 
training and using cube pessary, paying special attention to the changes in 
the strength of pelvic floor muscle and in the ability to relax. MethOds: To 
determine the degree of the changes in the strength of pelvic floor muscle 
and in the ability to relax, 35 patients had been contacted before provided 
with cube pessaries and pelvic floor muscle training. Thirty out of 35 subjects 
supported our study. Five subjects were excluded due to vaginitis, so finally 30 
survey data were processed. Pelvic floor muscle function measurements were 
performed at the beginning when cube pessaries were given to the subjects 
and later after a 3-week period of usage. Patients were selected with the help of 
the non random sample method. Demographic data and gynecological history 
selection were based on our own general survey questionnaire, while FemiScan 
surface EMG was used to measure pelvic floor muscle strength and the ability to 
relax. Statistical analysis involved t-test or Mann-Whitney U-test, significance 
level was defined at p< 0.05. Results: Although pelvic floor muscle strength 
showed positive changes, statistically significant changes were not detected in 
the surveyed group. In the analysis of survey data of the ability to relax pelvic 
floor muscle statistically significant difference (p= 0,001) could be detected in 
the average results either at the beginning when cube pessaries were given to 
the subjects or after a 3-week period of usage. cOnclusiOns: Cube pessary 
usage and pelvic floor muscle training may have a positive effect on pelvic 
floor muscle function.
factors were orthogonally combined to construct 16 patient profiles. All assumed 
medical care had the same ICER (cost per QALY). Respondents were randomly 
assigned to two of the 16 profiles and asked which one of the patients should 
preferentially receive treatment from a societal point of view, given a limited 
medical resource. Respondents were stratified by age and sex. Results: A total 
of 1091 responses were collected from 50 sites across Japan. The most preferred 
factor was “younger patient (a)”, followed by “treatment (b)” and “severe health 
state (c)”, which had the same degree of preference. No statistical significance 
was found for “no past experience of care (d)”. Public preference for medical care 
for elderly patients increased with increasing age. University-graduated people 
tended to prioritize care for patients who are younger and in severer condi-
tions. cOnclusiOns: Our survey revealed that public medical care preferences 
are influenced by factors such as age, even with the same cost per QALY. Based 
on an economic evaluation, age is an important factor for decision-making that 
reflects societal preferences.
PIH41
POTENTIALLy INAPPROPRIATE PRESCRIBING (PIP) AND ITS ASSOCIATION wITH 
INSTRUMENTAL ACTIvITIES OF DAILy LIvING (IADL) IMPAIRMENT IN OLDER 
PEOPLE
Moriarty F.1, Cahir C.2, Fahey T.1, Bennett K.3
1Royal College of Surgeons in Ireland, Dublin, Ireland, 2Trinity College Dublin, Dublin 8, Ireland, 
3Trinity Centre for Health Sciences, Dublin, Ireland
Objectives: Older people are particularly vulnerable to adverse effects of pre-
scribed drugs. PIP can be defined as the use of medicines with an unfavourable 
risk benefit ratio. There has been little research on the relationship between PIP 
and humanistic outcomes, such as functional impairment. This study aims to 
measure the prevalence of PIP in an older Irish population and to investigate its 
association with IADL impairment. MethOds: A retrospective cohort study of 
2,051 community-dwelling participants in The Irish Longitudinal Study on Ageing 
(TILDA) aged ≥ 65 years with linked medication dispensing history from a national 
pharmacy claims database was carried out. Exposure to PIP in the 12 months prior 
to assessing functional impairment was determined using the Screening Tool for 
Older Persons’ Prescriptions (STOPP), the Beers’ criteria (2012) and Assessing Care 
of Vulnerable Elders (ACOVE) indicators relating to inappropriate medications. 
Logistic regression was used to determine the association between exposure to 
PIP and presence of any IADL impairment, adjusting for age, gender, socioeco-
nomic status, number of repeat drug classes co-morbidity and medication adher-
ence. Results: The overall prevalence of PIP was 66.89% (n= 1,372). Of these 514 
(25.06%) had one instance of PIP, while 858 (41.83%) had two or more. Prevalence 
was highest using the STOPP criteria (57.29%), compared to prevalences of 37.64% 
(Beers’ criteria) and 23.5% (ACOVE indicators. Participants with ≥ 2 PIP indicators 
were significantly more likely to have an IADL impairment (adjusted OR= 1.91; 
95%CI= 1.15-3.18) compared to no PIP. Similar associations were found for the 
individual measures of PIP. Age, number of repeat drug classes and co-morbidity 
were also significantly associated with IADL impairment. cOnclusiOns: PIP in 
the elderly is highly prevalent and exposure to PIP is independently associated 
with increased risk of having IADL impairment. This suggests the importance of 
considering appropriateness when prescribing medicines in order to minimise 
adverse outcomes.
PIH42
ADDING A REMINDER SHORT MESSAGE SERvICE (SMS) BEFORE AND TABLET 
COMPUTER DURING CLINIC IMPROvES ELECTRONIC PATIENT REPORTED 
OUTCOME MEASURES (EPROMS) COLLECTION
Roberts N., Williams D.
Royal Cornwall Hospital, Truro, UK
Objectives: Patient Reported Outcome Measures (PROMs) monitor both symp-
tom progression and treatment effectiveness, and play an increasing role in eve-
ryday clinical practice. Electronic PROMs (ePROMs) enable real-time reporting back 
to the patient and medical team, comparison with similar patient cohorts and 
long-term cost-effective outcome measurement. Concerns have, however, been 
expressed about electronic PROMs collection in the elderly. The primary objective 
of this three-phase pilot study was to measure uptake using a web-based ePROMs 
platform following the introduction of reminder short messaging service (SMS) 
before and Tablet Computer during clinic. MethOds: Eighty-seven consecutive new 
elective orthopaedic patients in a single surgeon’s practice were recruited. Group 
1 (n= 27) received only a reminder letter, Group 2 (n= 34) also received a reminder 
SMS message via mobile or home telephone and Group 3 (n= 26) also had access to 
a Tablet Computer in clinic. Results: Mean age in Group 1 was 55.1 (24-77) years, 
Group 2 was 60.5 (23-85) years and Group 3 was 54.2 (17-77) years (p> 0.05). Overall 
75% patients had Internet access and 33% of Group 1, 50% of Group 2 and 73% 
of Group 3 recorded an ePROMs score (p= 0.03). In Group 2 and 3 26% of patients 
did not remember receiving a SMS message that was delivered. cOnclusiOns: 
Collecting and using PROMs data in everyday clinical practice is challenging. This 
small pilot study shows that adding a reminder SMS before and access to a Tablet 
Computer during clinic improves ePROMs collection onto a clinical outcomes web-
based system. Further process improvements, such as additional staff training and 
telephone call reminders, might further improve uptake and a more comprehensive 
study is planned.
PIH43
EIGHTy-NINE LOCAL ROCHE SPONSORED FRENCH STUDIES PERFORMED IN THE 
PAST 10 yEARS wERE EvALUATED TO DETERMINE HOw PATIENT REPORTED 
OUTCOMES wERE USED
Pau D., Triglia A., Gavini F.
Roche, Boulogne-Billancourt, France
Objectives: Patient Reported Outcomes (PROs) are increasingly used in clini-
cal studies as well as requested by health authorities (EMA, FDA). This descrip-
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health, Mental health, Sexuality, and Couple Relationship, being the first dimen-
sion composed by 3 sub-dimensions: vasomotor symptoms, health, and Aging. 
Goodness-of-fit statistics were better than those of the extended version (chi-
square/df= 2.130, AGFI= 0.859, PCFI= 0.919, RMSEA= 0.044). Internal consistency was 
good (Cronbach’s alpha= 0.830) but slightly lower than that of the original scale. 
Correlations between extended and reduced subscales was high and significant in 
all cases (p< 0.001), ranging from r= 0.857 for Aging to r= 0.971 for Vasomotor symp-
toms. cOnclusiOns: The Cervantes scale may be reduced to an abridged version 
of 14-item (Cervantes-SF) which maintains the original dimensional structure and 
psychometric properties. This version extends 45% of the original length, being 
faster to apply and making it specially suitable for routine medical practice.
PIH49
vALUE ATTRIBUTES OF GENERIC vERSUS BRANDED DRUGS IN SãO PAULO, 
BRAzIL
Ferraz M.B., Nardi E.P.
Universidade Federal de São Paulo, Sao Paulo, Brazil
Objectives: To assess the patients’ and their accompanying family members or car-
ers’ value attributes and perceptions about GD when compared to the corresponding 
brand name drugs (BD). MethOds: A total of 25 patients and 25 accompanying 
persons were consecutively selected and interviewed while visiting 6 commercial 
pharmacies located in different regions of São Paulo city. Also 25 patients and 25 
accompanying persons were consecutively selected and interviewed while waiting 
for their regular outpatient visits at the university outpatient clinic. The question-
naire consisted of questions regarding socio-economic, demographic and educa-
tional items, quality of life (QoL), and the interviewee perception regarding the 
value attributes of GD when compared to BD. The study was approved by the local 
ethic committee. Results: Respondents were predominantly women (57%) and 
the mean age was 54 years. Additionally, 55% relied exclusively in public health 
care system and 55% were regularly employed. Mean QoL as assessed by SF-6D was 
0,74. Respondents overwhelmingly (99%) believed GD to be cheaper than BD. Some 
36% and 63% also reported GD to be less and equally effective, respectively, as 
compared to BD. GD were perceived as either safe or less safe than BD in 46% 
and 46%, respectively. Some 74% of the sample agreed with the statement that 
they would prefer to take a BD if there was no price difference to the GD, and 85% 
admitted they regularly compare the prices of BD and GD before deciding which 
drug to buy. cOnclusiOns: Multiple factors may contribute to the decision to buy 
a GD. Among these perceived effectiveness, safety and price appear to be the most 
important factors. Further studies are needed to better understand the decision-
making process regarding GD use and its consequences for the health care system 
and families.
PIH50
ARE ISRAELI ADULTS wILLING TO PAy HIGHER HEALTH TAxES FOR A wIDER 
COvERAGE OF LIFE-ExTENDING MEDICATIONS?
Greenberg D.1, Hammerman A.2, Shani A.3, Neumann P.J.4
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Clalit Health Services Headquarters,  
Tel-Aviv, Israel, 3Sheba Medical Center, Tel-Hashomer, Israel, 4Tufts Medical Center, Boston, MA, 
USA
Objectives: The Israeli National List of Health Services (NLHS) offers a generous 
coverage for drugs and other technologies. However, not all approved drugs are 
covered under the basic health insurance and are frequently subject to out-of-
pocket payments. We assessed the ex-ante willingness to pay (WTP) for a more 
generous public coverage for life-extending medications. MethOds: We con-
ducted a telephone survey among a representative sample of the adult population 
in Israel (n= 502). We asked participants to indicate whether they will be willing to 
pay an increased health tax assuring that all life-extending interventions will be 
covered and provided by their health insurance plans with no cost-sharing. We 
also collected information on respondent age, gender, income, education, self-
rated health and coverage of supplementary/private health insurance. Results: 
Mean age of the study population was 51.7±15.9 years. 63.5% indicated that they 
would be willing-to-pay an increased health tax for a generous public coverage 
of medications. Respondents willing-to-pay were younger (49.3±15.0 vs. 55.9±16.4 
years; p< 0.001), reported a higher self-rated health (p= 0.001), and WTP increased 
with respondent’s income (p= 0.005), and were also covered by a commercial 
health insurance (p= 0.002). Among all respondents (WTP set at zero for those 
unwilling to pay) the median extra monthly WTP was in the range of 0-$7. The 
independent predictors for WTP identified in the logistic regression analysis were: 
respondent age (OR= 0.974; 95% CI 0.960-0.989); and being Jewish (OR= 2.997; 95% CI 
1.745-5.147). cOnclusiOns: Additional sources of funding should be identified 
and allocated to allow a more generous coverage of life-extending medications. 
Respondents are willing-to-pay extra health taxes (up to 7.5% of the current aver-
age health tax) to assure that all life-extending interventions are included in the 
NLHS at no co-payment. While these potential extra funds are sufficient to cover 
a wide range of technologies it is unlikely that the health tax will be raised in 
Israel in the near future.
PIH51
wILLINGNESS TO PAy (wTP) FOR A BRAND NAME DRUG IN SâO PAULO, BRAzIL
Ferraz M.B., Nardi E.P.
Universidade Federal de São Paulo, Sao Paulo, Brazil
Objectives: To assess WTP of patients and accompanying family members or car-
ers for a brand name drug (BD) as compared to a GD for treating an acute and a 
chronic condition. MethOds: A total of 25 patients and 25 accompanying family 
members or carers were consecutively selected and interviewed while visiting 6 
commercial pharmacies located in different regions of São Paulo city. Also another 
25 patients and 25 accompanying family members or carers were consecutively 
selected and interviewed while waiting for their regular outpatient visits at the uni-
versity outpatient clinic. A questionnaire with 2 hypothetical scenarios describing 
PIH46
A PARENT-ADMINISTERED BUT CHILD-COMPLETED PATIENT-REPORTED 
OUTCOME (PRO) PROvIDES A MEASURE wITH CONTENT vALIDITy THAT IS 
vALID AND RELIABLE FOR USE IN CHILDREN AGED 6 TO 11 yEARS
Arbuckle R., Marshall C.
Adelphi Values, Bollington, UK
Objectives: Collecting data about symptoms and health-related quality of life 
impacts in children aged 6-11 is particularly challenging. Children themselves do not 
necessarily have the reading skills or the cognitive and recall capacity to self-report 
on their own, but equally parents are not always with their child or may not observe 
them closely enough and some symptoms are not observable. To overcome these 
challenges we developed a parent-administered child-report symptom measure in 
which the parents helped the child read and understand the PRO items. MethOds: 
Iterative rounds of qualitative concept elicitation and cognitive debriefing inter-
views with children (aged 6-11) and parents supported the development and refine-
ment of daily diary instructions, items and response scales. The resulting items 
were included in an observational study of 185 children (aged 6-11) who completed 
the diary at home for seven days in order to support the development of scoring 
and psychometric validation. Feedback on the draft scales was obtained from both 
children and parents following the at-home completion phase, with the parent 
survey and debriefing focusing on how much help they had provided to the children 
in regards to reading, understanding, recalling and responding during the seven 
days. Results: The diary questions were developed to be completed by the child, 
but instructions indicated that the parent could help the child read and understand 
them. Observation of parents helping the child and subsequent debriefing provided 
evidence that parental help aided the child in recalling accurately. However, the 
children did push back if they disagreed with their parent’s suggested response, 
suggesting they were not unduly influenced. Subsequent psychometric validation 
confirmed that this approach and the refined items provided valid, reliable and 
responsive scores. cOnclusiOns: This PRO development provides evidence that 
a parent-assisted child self-report symptom measure had strong content validity 
and was valid, reliable and responsive to changes over time.
PIH47
PATIENT SURvEy DATA RESULTS: PREFERENCES FOR REMINDERS IN PRO 
STUDIES
Ross E., Ross J., Holzbaur E.
Almac Clinical Technologies, Souderton, PA, USA
Objectives: To identify effective reminder strategies, survey data focused on 
patient preferences for reminders in Patient Reported Outcomes (PRO) studies was 
investigated. This presentation will share these results to provide recommenda-
tions for patient reminder strategies to optimize patient compliance and data 
quality. MethOds: A survey was completed in 2013, involving patients who par-
ticipated in at least one clinical study in the past two years that required patient 
diaries. The survey sought to establish patient preferences (modality/timing) for 
receiving diary reminders based on their experiences, including an evaluation on 
their personal technology behaviors. Results: Responses were provided by 405 
patients. The patients stated their reasons for non-compliance of their patient 
diaries: 51.4% reported “non-compliance due to forgetting”; 41.1% reported “being 
too busy”; 27.6% reported “a lack of diary access”; and 2.7% reported “other rea-
sons”. Patients also stated their modality preferences for reminders. The preferred 
choice was text messages (67.2%); followed by hand-held alerts (34.3%); phone calls 
(34.1%); calendar alerts (32.6%); and email (6.2%). Although the majority of patients 
indicated checking text messages and emails daily, significantly more patients 
checked text messages immediately when compared to email (52.9% vs. 15.1%) 
suggesting that text messages would be a more effective way to remind patients. 
The majority of patients wanted to be reminded of their diary assessments (97.3%), 
appointments (95.8%), and medication dosing (95.0%). cOnclusiOns: As the top 
reason for non-compliance was “forgetting”, this suggests that reminders can be 
helpful in improving compliance. Results show that patients prefer to be reminded, 
also suggesting that reminders can improve compliance. Technology behaviors 
suggest that text messages could be an effective way to remind patients. Patient 
preferences for reminders should be given careful consideration – since incor-
porating optimal reminder strategies can likely improve the patient experience, 
compliance and data quality.
PIH48
STRUCTURAL vALIDITy OF A 14-ITEM ABRIDGED vERSION OF THE MENOPAUSE 
CERvANTES HEALTH-RELATED-QUALITy-OF-LIFE SCALE
Coronado P.1, Sánchez-Borrego R.2, Palacios S.3, Ruiz M.A.4, Rejas J.5
1Hospital Universitario San Carlos, Madrid, Spain, 2Diatros, Barcelona, Spain, 3Instituto Palacios 
de Salud y Medicina de la Mujer, Madrid, Spain, 4Autonoma University, Madrid, Spain, 5Pfizer 
S.L.U., Alcobendas/Madrid, Spain
Objectives: The Cervantes scale is a specific health-related-quality-of-life (HRQoL) 
questionnaire developed in Spanish women through and beyond menopause. The 
original scale contains 31-items and it is time-consuming in the routine medical 
practice. The aim of this work was to reduce the 31-item scale and to produce an 
abridged version with the same dimensional structure and similar psychometric 
properties. MethOds: A representative sample of 563 women [mean age 60 years 
old (SD= 6.7, Min= 46, Max= 82)] extracted from the Ginerisk study was used. The 
Ginerisk was an epidemiological, cross-sectional study carried out in 4,157 Spanish 
post-menopausal women attending out-patient clinics of Gynecology throughout 
Spain in year 2011. Item analysis, internal consistency reliability, item-total and 
item-domain correlations and item correlation with the generic Spanish version 
of the MOS-SF12v2 questionnaire dimensions were initially studied. Dimensional 
Confirmatory Factor Analysis (CFA) and Full-model CFA were used to check struc-
ture stability. A 3-fold cross-validation method was used to obtain stable estimates, 
by means of multi-group analysis. Results: The scale was reduced to a 14-items 
version: The Cervantes-SF, containing four main dimensions: Menopause and 
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pregnancy outcomes. MethOds: To determine whether additional clinical tests, 
advice, planning, management or pregnancy follow-up were recommended for 
obese women during pregnancy,Clinical Practice Guidelines (CPGs) were collated 
from across the Endocrinology and Obstetrics National Societies websites of 
the 9 European countries participating in the FP7 DALI study (Austria, Belgium, 
Denmark, Ireland, Italy, The Netherlands, Poland, Spain, UK). This was comple-
mented by a Medline search and a survey among the investigators of the DALI 
study. Results: Fifteen CPG for 9 countries were retrieved. All but Spanish guide-
lines, which recommend O’Sullivan test, recommend OGTT 75g to detect GDM in 
obese women. Most of them include 24-28 weeks as the time for OGTT, but other 
schedules are also used, especially when risk factors other than obesity are pre-
sent. Other common recommendations for obese women in European CPGs were 
diet advice (included in the guidelines of 6 different countries), special birth plan-
ning (5 countries), exercise and other lifestyle recommendations (4 countries) and 
vitamin D supplementation, multidisciplinary follow-up (including endocrinolo-
gist or diabetologist) and additional ultrasound scan (3 countries). cOnclusiOns: 
Recommendations for obese women in the studied countries are heterogeneous 
and in many cases do not include actions beyond screening for GDM. Existing 
guidelines will be reviewed in the light of the findings from the interventions 
studied in the framework of the DALI study.
PIH55
LONG-TERM FISCAL IMPLICATIONS OF FUNDING ASSISTED REPRODUCTIvE 
THERAPIES: A GENERATIONAL ACCOUNTING MODEL FOR SPAIN
Villoro R.1, González-Domínguez A.1, Pérez-Camarero S.1, Hidalgo A.2, Polanco C.3
1Instituto Max Weber, Madrid, Spain, 2University of Castilla La Mancha, Toledo, Spain, 3Merck, 
S.L, Madrid, Spain
Objectives: Infertility affects 14% of couples in reproductive age in Spain. 
Progressive population ageing leads the assessment of policies that favor birth-
rates. The objective is estimating the lifetime economic benefits of publicly 
financing assisted reproductive therapies (ART) in Spain, by calculating the 
return on this investment. MethOds: Generational accounting model that 
simulates the flow of taxes paid by the individual minus those direct govern-
ment transfers received (e.g. health care, education, pensions) over the lifecycle 
of a child. The cost of ART was calculated as the average cost of conceiving a 
child through currently available ART in Spain. The difference between dis-
counted transfers and taxes minus the cost of ART equals the net present value 
(NPV) of a child conceived by ART. Year 2006 was set as the base case because 
of its macroeconomic stability. A 3.5% discount rate was applied. Sensitivity 
analysis tested robustness of results under different scenarios. Results: An 
ART-conceived child would contribute € 534,624 in net taxes to the government 
and would receive € 479,952 in governmental transfers over her lifecycle. After 
discounting the cost of ART (9,000€ ) the NPV is estimated at € 45,672. Each Euro 
invested in subsidizing ART reverts into fiscal benefits of € 5. Sensitivity analy-
sis shows that even in extreme macroeconomic scenarios, the long-run NPV 
of an ART-conceived child ranges between € 11,233 and € 62,470. The return on 
investment varies between € 1.25 y € 6.94 € for each Euro invested in ART. The 
break-even age at which the financial position begins to be favorable to the 
Spanish Treasury was set at 34-42 years. cOnclusiOns: Generational account-
ing models allow estimating long-term fiscal implications of public funding of 
ART. Each Euro invested in subsidizing ART reverts into fiscal benefits of € 5. 
Thus, investment in ART leads to substantial discounted future fiscal revenue 
for the Spanish Treasury, notwithstanding its beneficial psychological effect 
for infertile couples.
PIH56
wOULD A NEw THERAPy FOR CHILDREN BE REFUSED IN THE CONTExT OF THE 
GERMAN AMNOG?
Walzer S., Droeschel D.
MArS Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany
Objectives: The new German law AMNOG was introduced in 2011. According to 
it all newly launched therapy options would need to be evaluated by the Institute 
for Quality and Efficiency in health care (IQWIG) and the joint federal committee 
(Gemeinsamer Bundesausschuss, GBA) before a final price negotiation will happen. 
Given the specific characteristics of pediatric patients it is uncertain if a new drug 
for those patients would successfully pass the AMNOG process. MethOds: The 
AMNOG evaluation criteria were applied to the specifics of pediatric drugs. A special 
focus was given to the benefit assessment method, clinical trial designs and the 
AMNOG process. Results: Current HTA evaluation methods being applied to medi-
cal therapies, in general, need to be modified when applied to pediatric therapies. 
For example, traditional benefit evaluations that require randomized clinical trials 
are standard but cannot always be fulfilled in this patient population. In pediatric 
development programs one-arm studies are standard with surrogate endpoints in 
order to minimize the exposure of children to an experimental therapy. Additionally 
the naturally low sample size within pediatric indications linked to the different 
natural subgroups of children (babys, toddlers, etc.) make a formal additional ben-
efit proof even harder. Hence from a benefit assessment perspective the clinical 
study design, sample size and choice of endpoint are most crucial but could hardly 
be executed in pediatric trials. With respect to the AMNOG process only pediatric 
trials in orphan disease could pass successfully given the exception rules for the 
additional benefit. cOnclusiOns: If the German health care system is to secure 
the full benefits of potential new pediatric therapies, it will need to provide a similar 
process as it is granted for orphan drugs.
PIH57
HEALTH OUTCOMES OF FEMALE ANABOLIC-ANDROGENIC STEROID USERS
Noone J.1, Blanchette C.M.2
1University of North Carolina at Charlotte, Charlotte, NC, USA, 2University of North Carolina, 
Charlotte, NC, USA
an acute condition (acute tonsillitis in an 8 year old child) and a chronic condition 
(an adult with diabetes mellitus type 2) was developed. WTP for a BD as compared 
with a GD was assessed in both scenarios using the payment scale and the open-
ended formats. The study was approved by the local ethical committee. Results: 
Respondents were predominantly women (57%) and the mean age was 54 y.o. A 
family income of less than R$ 1.356,00 was reported by 16%. For the total study 
sample, the maximum WTP for a BD (over and above the mean retail price of a GD) 
for the acute and chronic case scenarios were on average R$ 27,54 and R$ 21,04 
when measured by the payment scale and R$ 36,54 and R$ 24,77 when measured 
by the open-ended question, respectively. These values are 36% to 65% above the 
mean retail prices of the corresponding GD. cOnclusiOns: Patients and accom-
panying persons were willing to pay considerably more for the BD when compared 
to GD. This may be driven by the perception of higher perceived effectiveness and 
safety of BD.
INDIvIDUAL’S HEALTH – Health Care Use & Policy Studies
PIH52
PROTECTIvE FACTORS FOR UNIvERSITy STUDENTS’ HEALTH
ViÂšnjiÄ‡ A.1, VeliÃ„ÂkoviÃ„Â V.1, SokoloviÄ‡ D.2, Ranđelović S S.3, MilovanoviÃ„Â Â M.4
1University in NiÂš, Medical Faculty, NiÂš, Serbia and Montenegro, 2University in Niš, Medical 
Faculty, NiÂš, Serbia and Montenegro, 3Viborg County Hospital, Viborg, Denmark, 4Clinical Centre 
in NiÂš, Serbia and Montenegro
Objectives: To assess which of the studied factors were positively associated with 
the students’ health and to investigate which of these factors stood out as the most 
important protective factors for their health. MethOds: Data were obtained from 
a cross-sectional study conducted during the academic 2011/2012th at the universi-
ties in Niš, Belgrade and Novi Sad, which surveyed a total of 2285 students of both 
sexes. This study examines variables such as physical, psychological and social 
health, protective factors and risk factors. Students were assessing their own health 
answering the questionnaire. Results: Only 11.8% of the surveyed students have 
assessed their health as excellent, 72.5% as very good or good, and 15.7% as poor or 
very poor. Better health status was positively correlated with the quality of sleep, 
the existence of free time, physical and social activities, religiosity and built health 
values in all three universities. Kruskal-Wallis H test showed that better students are 
more satisfied with their life (p < 0.001), that better assess their health (p < 0.01) and 
less drink alcoholic beverages. Female students had more physical pain, were more 
frequently depressed than men, they were more easily tired, they were much more 
nervous and had more problems than men with sleep. Men assessed their health as 
better than female students. However, the satisfaction scale (χ 2 homogeneity test; 
p < 0.001) were found females to be more satisfied with their lives than male stu-
dents. cOnclusiOns: General health is affected by various physical, psychological 
and social aspects of health. The results show that there are significant protective 
factors for better social, psychological and general health in students that may be 
affected. Therefore, health promotion decision makers should adopt contemporary 
strategies that will in the future put emphasis on the social and psychological 
components of students’ health.
PIH53
SOCIETAL BURDEN OF HySTERECTOMy IN REPRODUCTIvE-AGED wOMEN 
wITH UTERINE FIBROIDS
Vámossy I.1, Ágh T.2, Blasszauer C.3, Bagó M.3, Mészáros Á4, Kalo Z.5
1Gedeon Richter Plc., Budapest, Hungary, 2Syreon Research Institute, Budapest, Hungary, 
3MedicalScan, Budapest, Hungary, 4Semmelweis Univesity, Budapest, Hungary, 5Eötvös Loránd 
University, Budapest, Hungary
Objectives: Uterine fibroids (UF) affect approximately 20% to 40% of repro-
ductive-aged women. The mainstay of treatment of symptomatic UF is surgical. 
Myomectomy surgically removes UF while preserving the uterus. However, hyster-
ectomy that is considered to be the definitive treatment of UF, causes infertility.The 
aim of our study was to analyze the prevalence of hysterectomy in Hungary among 
reproductive-aged women with UF to assess the societal burden due to lost fertil-
ity. MethOds: Database were analyzed. Surgical procedures for the treatment of 
UF (ICD-10: D25), in 20-45 years old women between 2007 and 2012 were analyzed 
based on the Hungarian National Health Insurance Fund database. Economic bur-
den of lost fertility was assessed by the human capital approach. Present value of 
life for a newborn child was calculated by applying 2011 GDP per capita and 3.7% 
discount rate. Results: Among 11,095 women with surgical procedure related 
to UF the prevalence of hysterectomy was 61.5% (n= 6827). Most hysterectomised 
women (n= 4781) were 40-45 years old; unexpectedly a significant number of 20-40 
years old women with UF had hysterectomy (n= 2046). Present value of a newborn 
child was 262,314 EUR in 2011. cOnclusiOns: Our results indicate that immediate 
hysterectomy, even in women under 40 years, is still a frequently performed surgi-
cal procedure for the treatment of UF. The macroeconomic consequences of lost 
fertility due to hysterectomy in reproductive-aged women with UF are significant. 
Even only one additional child-birth due to avoided hysterectomy would result in 
significant societal and economic benefits. Further scientific evaluations are needed 
to define more accurately the long term macroeconomic impact of preserved fertil-
ity in women with UF.
PIH54
MANAGEMENT OF OBESE wOMEN DURING PREGNANCy ACROSS EUROPE 
ACCORDING TO CLINICAL PRACTICE GUIDELINES
Callejo D.1, Díaz-Cuervo H.1, Fernández-Ortiz L.1, Rebollo P.1, Simmons D.2, van Poppel M.3
1LASER Analytica, Oviedo, Spain, 2Addenbrooke’s Hospital, Cambridge, UK, 3VUmc, Amsterdam, 
The Netherlands
Objectives: To review, within the framework of the FP7 DALI (Vitamin D And 
Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention) study, 
guidelines for the management of obese women during pregnancy across Europe 
to assess the specificity of the recommendations in this group at risk of adverse 
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specific. Except for preschoolers, therapeutic management of patients with ADHD 
relied heavily on drug treatment.
PIH60
TRENDS IN HOSPITAL ADMISSIONS AMONG MEN AND wOMEN ABOvE THE AGE 
OF 60 LIvING IN STOCKHOLM AND UPPSALA COUNTIES IN SwEDEN
Karampampa K.1, Andersson T.1, Drefahl S.2, Ahlbom A.1, Modig K.1
1Karolinska Institutet, Stockholm, Sweden, 2Stockholm University, Stockholm, Sweden
Objectives: To measure the change in the risk of first, second, and third hospitali-
zation and the change in the proportion of hospitalization-free men and women 
above the age of 60 living in Stockholm and Uppsala counties in Sweden between 
1972 and 2010. MethOds: Individuals were followed in national registers for hos-
pitalizations and deaths from all causes between 1972 and 2010. Censoring occured 
at whichever of the following events appeared first; hospitalization (first, second, 
thrid), death, or December 31, 2010. Survival analysis was used to determine the 
proportion of hospitalization-free individuals. Discrete time logistic regression 
was used to obtain the the relative risk (RR) of first, second and third hospitaliza-
tion. Results: An increase in the proportion of hospitalization-free individuals over 
time was observed for both men and women; for example 87% more 82 year-old 
men, born in 1928, were free of hospitalizations since the age of 60 compared to 
those born in 1912. Between the years 1972 and 2010, the average annual decrease 
in the risk of first hospitalization after the age of 60 was 1% for both men (RR: 
0.991, 95%CI: 0.991-0.992) and women. The average annual risk for hospitalization 
decreased for the second and thrid event as well; however the reduction was not 
significant. cOnclusiOns: With the increase in the proportion of elderly in the 
population, the number of individuals with chronic diseases may increase, leading 
to higher demand for medical and social care. We have observed downward trends of 
the risk of first, second, and third hospitalization after the age of 60, which could be 
explained by a postponement of severe morbidity to higher ages. Focus on primary 
care and changes in inpatient care in Sweden may also partly exaplain the annual 
reduction in the risk of hospitalization.
PIH62
DO EMA AND FDA HAvE DIFFERENT OPINIONS/REQUIREMENTS IN TERMS OF 
PEDIATRIC STUDIES FOR SITAGLIPTIN (ALONE OR IN COMBINATION)?
Caron M.1, Emery M.P.1, Maier W.2
1Mapi Research Trust, Lyon, France, 2Mapi, London, UK
Objectives: Since the implementation of Pediatric Regulations/Legislations in the 
USA (Pediatric Research Equity Act - PREA) and in Europe (Pediatric Investigation 
Plans - PIPs), product development programs should include pediatric studies. The 
objective of this study is to review opinions (EMA) and requirements (FDA) given by 
both agencies in the case of sitagliptin (alone and combined) for the treatment of 
diabetes mellitus in children. MethOds: The EMA and FDA websites were explored 
to: 1) Identify the products marketed under the INN of sitagliptin (alone or in com-
bination), and 2) Identify the associated PIPs or PREA requirements. The search was 
performed on January 18, 2013. Results: Eight products were marketed in Europe 
[i.e., sitagliptin (Januvia, Ristaben, Tesavel, Xelvia) and sitagliptin + metformin 
(Janumet, Efficib, Ristfor, Velmetia)]. Four products were authorized in the USA [i.e., 
sitagliptin (Januvia); sitagliptin + metformin (Janumet, Janumet XR); sitagliptin + 
simvastatin (Juvisync)]. The FDA and the EMA provided the same opinion for sitag-
liptin alone, i.e., deferred pediatric study for patients aged 11 to 16. The FDA and the 
EMA disagreed on sitagliptin + metformin. The EMA granted a waiver for all subsets 
of the pediatric population on the grounds that the specific medicinal product does 
not represent a significant therapeutic benefit over existing treatments, while the 
FDA required a pediatric study under PREA for the treatment of type 2 diabetes in 
pediatric patients aged 11 to 16. As for sitagliptin + simvastatin, the FDA grants a 
waiver on the grounds that the product does not represent a meaningful therapeutic 
benefit over existing therapies for pediatric patients. cOnclusiOns: The FDA and 
the EMA have similar opinions except for the combination sitagliptin + metformin. 
One reason could be the higher prevalence of type 2 diabetes mellitus in children 
in the USA as compared to Europe.
INFECTION – Clinical Outcomes Studies
PIN1
THE GEOGRAPHIC CORRELATION BETwEEN LyME DISEASE INCIDENCE AND 
DEGENERATIvE NEUROLOGICAL DISEASE MORTALITy: AN ECOLOGICAL STUDy
Veley K.M., Malka E.S.
PPD, Morrisville, NC, USA
Objectives: The objective of the present study was to assess the geographic cor-
relation between the incidence of Lyme disease (LD) and mortality due to certain 
degenerative neurologic diseases (DND) in the US. MethOds: For this ecological 
study, public data sources at the CDC were queried to quantify LD cases and DND 
deaths for the 5-year period 2002-2006. Alzheimer’s disease, Parkinson’s disease, 
and motor neuron disease were preselected as DND of interest. The separate 
datasets, for LD and DND, were combined by matching county and state names. 
Counties with at least 1 case of LD and at least 10 deaths due to DND were included 
in analyses. All analyses were performed in SAS. Results: Of the 3141 counties of 
the US, 1372 reported at least 1 case of LD, 2742 reported at least 10 deaths due to 
DND, and 1339 met both conditions and were therefore included in analyses. The 
observed number of LD cases and DND deaths for a single county ranged from 1- 
6407 (mean: 78; median: 3) and 10-9207 (mean: 165; median: 55), respectively. The 
Spearman rank test indicated that there is a fair degree of correlation between LD 
incidence and DND mortality (r= 0.44, p< 0.0001). In sensitivity analyses, (1) exclud-
ing outliers, defined as observations ≥ 99th percentile (LD> 53; DND> 1255), and (2) 
evaluating each disease separately, the correlation remained similar in magni-
tude and statistically significant (coefficient: 0.32-0.41; p< 0.0001). cOnclusiOns: 
There is a fair degree of correlation between LD incidence and DND mortality: 
US counties with a higher number of LD cases tend to have a higher number of 
Objectives: Anabolic-Androgenic Steroids (AAS) have been used for muscle mass 
development for over fifty years. The health outcomes of supraphysiologic doses of 
AAS have been debated, but most existing information pertains to men. This pur-
pose of the study is to use the National Longitudinal Study of Adolescent Health 
(AddHealth) to elucidate health outcomes of AAS usage in women. MethOds: 
A cohort study of female AAS users were assessed in two time periods six years 
apart. Baseline descriptive statistics were used to describe age, income, race, drug 
use, education, and work performed for the sample. Follow up health outcomes 
include diabetes, heart disease, hyperlipidemia, anger, physician visit, use of medi-
cal care in the last year, Body Mass Index (BMI), blood pressure (BP), C-reactive 
protein, and HbA1C. Each dependent variable was tested in independent logis-
tic regressions and in sensitivity tests using a MANOVA. Results: The sample 
included 49 female respondents. Education was associated with a two-fold greater 
odds of AAS use comparing those who attended vocational school to those who 
attended college (OR= 2.22, p= .03). Anger was associated with 88% greater risk of 
AAS use (OR= 1.88, p= .04). HbA1c in the pre-diabetic range, while not statistically 
significant may be associated with AAS use (OR= 1.85, p= .05). No other health 
outcomes were identified. cOnclusiOns: This study contributes to the literature 
of female AAS use showing little in health care usage and long term health conse-
quences. Anger is associated with male users but little research exists pertaining 
to this phenomenon in women. Elevated HbA1c is not commonly associated with 
AAS use, but due to the small sample size more research should assess AAS use 
among females.
PIH58
USER AND TREATMENT CHARACTERISTICS OF ORAL CONTRACEPTIvES IN THE 
EUROPEAN UNION
Bezemer I.D.1, Verhamme K.M.2, Gini R.3, Mosseveld M.2, Rijnbeek P.R.2, Sturkenboom M.C.2, 
Penning-van Beest F.J.A.1, Herings R.M.C.1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2EMC Rotterdam, 
Rotterdam, The Netherlands, 3Agenzia regionale di sanità della Toscana, Firenze, Italy
Objectives: As a basis for future safety evaluations of oral contraceptive (OC) use in 
Europe, current user and treatment characteristics were assessed in four European 
health care databases. MethOds: A descriptive retrospective database study was 
performed over 2009-2010 in GP databases from The Netherlands (IPCI), UK (THIN) 
and Italy (HSD) and linked pharmacy dispensing and hospital admission data from 
The Netherlands (PHARMO). Study follow-up started at the first OC prescription 
in 2009-2010 (users), one year after database entry or at Jan 1, 2009. Health indica-
tors at start of follow-up included BMI and previous diagnosis of, or use of drugs 
for selected chronic conditions. Also, previous diagnoses of deep vein thrombosis, 
pulmonary embolism, cerebrovascular disease, myocardial infarction, breast cancer 
and cervical cancer were assessed. Treatment characteristics of OC included his-
tory of use, type of OC (chemical substance) used during 2009-2010 and switches or 
discontinuations. Results: Among 4.9 million women, 14% had OC prescribed in 
2009-2010. In The Netherlands and UK, 12-16% and in Italy 6% had a record of OC 
use. The prevalence of OC recorded prescription at January 1, 2010 was 81 per 1000 
women of all ages and 271 per 1000 women aged 15-24, a much lower figure than 
what is recorded by surveys, probably due to switches between use and non-use 
and to reimbursement and/or prescription policies that reduce recording in GP data-
bases. Among the non-users in 2009-2010, up to 22% had a history of OC recorded 
use. Little differences in health indicators were found between users and non-users 
in the databases where the information was available. cOnclusiOns: Trends in 
health among European women in general also apply to OC users. However, OC use 
is not registered very well in health care databases which limits the possibilities 
of pharmacovigilance. Distribution channels and reimbursement policies vary, as 
well as recording in the databases.
PIH59
MEDICATION TREATMENT AND HEALTH CARE UTILIzATION FOR ATTENTION-
DEFICIT/HyPERACTIvITy DISORDER (ADHD) IN GERMANy
Schlander M.1, Banaschewski T.2, Trott G.E.3, Schwarz O.4
1University of Heidelberg, Wiesbaden, Germany, 2University of Heidelberg, Mannheim, Germany, 
3University of Wuerzburg, Aschaffenburg, Germany, 4Institute for Innovation & Valuation in 
Health Care, Wiesbaden, Germany
Objectives: To explore health care utilization and treatment patterns for atten-
tion-deficit/hyperactivity disorder (ADHD) in Germany, with particular emphasis 
on psychostimulant prescriptions. MethOds: The complete claims database of 
the organization of physicians registered with statutory health insurance (SHI) 
in Nordbaden/Germany was available for analysis, covering the total regional 
population enrolled in SHI (2.24 million lives). The dataset for years 2003 to 2009 
was reorganized as to allow patient-centered evaluation. For calendar year 2009, 
21,287 patients with ADHD (male, 15,108; female, 6,179; including 5,931 patients 
or 27.9% [male, 4,582; female, 1,349] with coexisting conduct disorder [F90.1 or a 
combination of F90 and F91 codes according to ICD-10]) were available for anal-
ysis. Results: Preschool children (age 0-5 years) with ADHD were prescribed 
medication in very rare cases (1.6% in 2009) and after an average lead time of 
more than one year only. Most received some form of nonpharmacological therapy 
or were left untreated (42%). In contrast, 41% of children (age group 6-12 years, 
since 2003, continuously increasing from 32%) and 54% of adolescents (age group 
13-17 years, rate remaining stable since 2006) were prescribed either stimulant 
(methylphenidate, MPH, or amphetamine) or nonstimulant (atomoxetine) drugs. 
Males and patients with concomitant conduct disorder were more likely to receive 
medication treatment. Modified-release MPH formulations were more widely used 
than immediate-release MPH. Overall use of medication increased steadily, from 
32.2% of ADHD patients in 2003 to 39.9% in 2009, whereas its rate decreased over 
time in adult patients (declining from 38% in 2003 to 26% in 2009). – Upon indi-
vidual review of all prescriptions of ADHD medication for members of the control 
group, no evidence was found supporting potentially inappropriate use of stimu-
lant medication. cOnclusiOns: Treatment patterns were highly age and gender 
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above treatments and with the following endpoints: Sustained Virological Response 
(SVR), discontinuation of all medications (overall/due to Adverse Events (AE)), 
and incidence of anemia, rash (all grades) and pruritus-common adverse events 
of cHCV treatment. A Bayesian NMA was performed for all endpoints, assuming 
fixed study effects. Unpublished SMV studies meeting the inclusion criteria were 
obtained. Results: Three studies met the inclusion criteria: 2 phase III RCTs (SMV 
n= 183; TVR n= 189), and 1 SMV phase IIb RCT (n= 92). Baseline characteristics were 
generally comparable for all studies. SMV shows a higher odds ratio (OR) of achiev-
ing SVR versus TVR (OR 1.68 (0.66-4.26)). SMV shows a lower OR of discontinuation: 
overall 0.35 (0.12-1.00) and due to AEs 0.87 (0.23-3.34) versus TVR. SMV shows a lower 
OR of experiencing anemia 0.20 (0.07-0.56) and rash 0.42 (0.17-0.99) but a higher OR 
of experiencing pruritus 1.26 (0.46-3.47) versus TVR. The main limitation of this 
study is the small number of trials included in the analysis. cOnclusiOns: In this 
indirect comparison, SMV, in combination with PegIFN/RBV, showed a favourable 
risk-benefit profile compared to TVR with PegIFN/RBV in Japanese treatment-naïve 
Hepatitis C infected patients.
PIN5
PUBLIC HEALTH IMPACTS OF PROBIOTICS IN CONTROLLING UPPER 
RESPIRATORy TRACT INFECTIONS IN FRANCE
Gerlier L.1, Lenoir-Wijnkoop I.2, Berdeaux G.1
1IMS Health HEOR, Vilvoorde, Belgium, 2Utrecht University, Utrecht, The Netherlands
Objectives: Two meta-analyses (York Health Economics Consortium [YHEC]; 
Cochrane) reported the beneficial effects of probiotics (live microorganisms which 
when administered in adequate amount confer a health benefit on the host). They 
demonstrated efficacy at reducing the duration and number of upper respiratory 
tract infections (URTI) and antibiotics use. The purchase of probiotics by consumers 
is likely to have positive externalities to the national health system and society. The 
aim of this analysis was to estimate the public health consequences of probiotics 
consumption, in France. MethOds: A 1/1,000 virtual age and gender standardized 
population was generated using a Markov model (TreeAge 2009). URTI risk factors 
were age, active/passive smoking, living in the community. Influenza like illness (ILI) 
and flu daily incidence rates came from Sentinelles, a practitioner network aimed 
at identifying flu outbreak. Epidemiologic data were used to differentiate cold, ILI 
and flu. One-day cycles were used over the 2011-2012 flu season. Probiotics effects 
came from two meta-analyses. Outcomes included numbers of URTIs days and 
episodes, antibiotics courses and sick leave days avoided with probiotics. Results: 
According to YHEC data, probiotics reduced URTI episodes (average 7 days) by -0.77 
days [-1.5;-0.04]. Extrapolating these results to the French population, probiotics 
would save 2.85 million URTI-days, the number of antibiotic courses would drop 
from 1,004,000 to 674,000 (difference about -330,000) and the number of sick leave 
days avoided in adults would be 653,000. According to Cochrane data, probiotics 
would reduce the probability to have an URTI episode by 0.58 [0.36;0.92] and anti-
biotic prescription by 0.67 [0.45;0.98]. The probiotic impact would become larger in 
terms of URTI-days avoided (-7.1 million), antibiotic courses (-509,000) and workdays 
lost (-1.2 million). cOnclusiOns: The probiotics public health impact on URTI is 
significant at a national level even though this analysis was restricted to the 1% of 
patients visiting a practitioner.
PIN6
LONG-TERM OUTCOMES OF CHRONIC HEPATITIS C IN THE POPULATION OF 
NEwLy DIAGNOSED RUSSIAN PATIENTS
Ryazhenov V.V., Sboyeva S.G., Emchenko I.V.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To predict the future incidence of chronic hepatitis C in Russia and assess 
potential impact of the available antiviral therapies (pegylated interferon a-2a/a-2b 
or standard interferon a-2b combined with ribavirin) on long-term morbidity and 
mortality rates in the population of newly diagnosed Russian patients with chronic 
hepatitis C. MethOds: Based on the national epidemiologic data and published natu-
ral history studies, the prognostic Markov model was developed. Depending on the 
results of antiviral therapy, patients’ flows over 25-year time frame were simulated. 
End points of interests included: the incidence of compensated and decompensated 
cirrhosis, hepatocellular carcinoma and cumulative time that patients will spend in 
each state, the number of patients, who will require liver transplantation, and HCV-
related mortality rates. Results: During years 2013-2017 about 276,000 new cases 
of chronic hepatitis C will be diagnosed in Russia. After 25 years since being diag-
nosed 130, 189 and 227 of 1,000 patients received pegylated interferon a-2a, pegylated 
interferon a-2b and standard interferon a-2b, respectively, will develop compensated 
cirrhosis. The cumulative time that patients will spend in compensated cirrhosis state 
will be 848, 1,218 and 1,482 patient-years, respectively. During the established time 
frame, there will be expected 25, 36 and 43 cases of hepatocellular carcinoma and 35, 
51 and 62 HCV-related deaths. 28, 40 and 49 patients, respectively, will require liver 
transplantation. cOnclusiOns: The findings from the present study provide the 
opportunity to plan volumes of medical care that will be required to Russian patients 
with chronic hepatitis C during 25 years since disease was first diagnosed. The treat-
ment with pegylated interferon alfa-2a is considered the most preferable strategy 
due to considerably lower long-term morbidity and mortality rates as compared to 
pegylated interferon a-2b and standard interferon a-2b treatment.
PIN7
EPIDEMIOLOGy, TREATMENT OUTCOMES AND COSTS OF TREATING HEPATITIS 
C IN ROUTINE CARE – RESULTS FROM A LARGE MULTICENTER TRIAL
Stahmeyer J.T.1, Rossol S.2, Bert F.2, Abdelfattah A.M.2, Mauss S.3, Heyne R.4, John C.5, Pape 
S.6, Schober A.7, Teuber G.8, Bruch H.R.9, Zehnter E.10, Hueppe D.11, Pfeiffer-Vornkahl H.12, 
Alshuth U.13, Krauth C.1
1Hannover Medical School, Hannover, Germany, 2Krankenhaus Nordwest, Frankfurt a.M., 
Germany, 3Center for HIV and Hepatogastroenterology, Duesseldorf, Germany, 4Liver and study 
center Checkpoint, Berlin, Germany, 5Center of Gastroenterology, Berlin, Germany, 6Center of 
Gastroenterology, Paderborn, Germany, 7Center of Gastroenterology, Goettingen, Germany, 
deaths due to DND. This study is limited by its ecological nature and more rigor-
ous epidemiologic research is needed to elucidate the association between LD 
and DND.
PIN2
IMPACT OF HIGHLy ACTIvE ANTIRETROvIRAL THERAPy (HAART) REGIMEN ON 
ADHERENCE AND RISK OF HOSPITALIzATION IN vETERANS wITH HIv/AIDS
Rao G.A.1, Sutton S.S.1, Hardin J.2, Bennett C.2, Bramley T.3, D’Souza A.O.3
1WJB Dorn VA Medical Center, Columbia, SC, USA, 2University of South Carolina, Columbia, SC, 
USA, 3Xcenda, Palm Harbor, FL, USA
Objectives: High pill burden has been associated with poor adherence to HAART 
and adverse clinical outcomes. This study evaluated the impact of HAART as a 
single-tablet regimen (STR) and multiple-tablet regimen (MTR) on outcomes in 
HIV patients within the Veteran’s Affairs (VA) system. MethOds: A retrospective, 
cohort study assessed patient VA dispensation data for HIV medications during 
the study enrollment period (7/1/2006 to 9/30/2011). Patients were assigned to the 
following cohorts: STR if they received a HAART regimen of a single tablet/day or 
MTR if they received a regimen of ≥ 2 tablets/day and no single tablet/day regimen 
during the enrollment period. Patients were followed from the index date (start 
of HAART regimen) until the earliest of treatment discontinuation, end of study 
period, or last date of health care-related activity (eg, VA benefits file or death). 
Hospitalization and adherence (medication possession ratio [MPR] ≥ 95%) were 
evaluated. Multivariate cohort differences in outcomes were controlled for using 
Cox-proportional hazard and logistic models; covariates were measured during 
a 6-month baseline period. Results: In all, 15,602 patients (STR, n= 6,191; MTR, 
n= 9,411) met study criteria; average age of the study sample was 52 years. Both 
cohorts had similar CD4 counts (mean [SD]: 432.2 [282.8] vs 419.3 [280.9]; P= 0.287) 
but significantly fewer patients receiving STR vs MTR had an undetectable viral load 
at baseline (42% vs 46%, P< 0.001). During follow-up, significantly more STR patients 
were adherent compared to MTR patients (75% vs 55.7%, P< 0.001). STR patients were 
also significantly less likely to experience hospitalization compared to MTR patients 
(26.8% vs 31.3%, P< 0.001). After controlling for baseline covariates, STR patients 
had twice the odds of being adherent (OR: 1.98, P< 0.001) and 31% lower hazard of 
experiencing hospitalization during follow-up (HR: 0.69, P< 0.001). cOnclusiOns: 
Treatment with STR compared to MTR improves adherence rates and decreases 
hospitalizations in patients with HIV/AIDS.
PIN3
A DECISION ANALyTIC MARKOv MODEL TO EvALUATE THE HEALTH 
OUTCOMES OF SOFOSBUvIR FOR PREvIOUSLy UNTREATED PATIENTS AND 
THOSE wITHOUT TREATMENT OPTIONS wITH CHRONIC HEPATITIS C vIRUS 
GENOTyPE 2 INFECTION
Younossi Z.M.1, Gordon S.2, Saab S.3, Ahmed A.4, Cure S.5, Guerra I.5
1Inova Fairfax Hospital, Falls Church, VA, USA, 2Henry Ford Hospital, Detroit, MI, USA, 3David 
Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 4Stanford University, Stanford, CA, 
USA, 5OptumInsight, Uxbridge, UK
Objectives: Sofosbuvir (SOF) is a nucleotide polymerase inhibitor with excellent 
clinical efficacy in combination with ribavirin (RBV) for 12 weeks for patients who 
are chronically infected with hepatitis C virus (HCV) genotype 2. A decision-analytic 
Markov model evaluated the health outcomes of SOF+RBV compared with current 
treatment options for patients who are previously untreated, had no response to 
prior interferon treatment, or are unable to take interferon. MethOds: The analysis 
modeled 3 cohorts of chronic HCV genotype 2 patients with an average age of 50 
and 25% with cirrhosis at the start of treatment followed-up to 100 years of age from 
a US third-party payer perspective. SOF+RBV for 12 weeks was compared with 1) 
pegylated interferon (PegIFN)+RBV for 24 weeks in the treatment-naïve patients; 
2) PegIFN+RBV for 48 weeks in the treatment-experienced; and 3) no treatment in 
those unable to take interferon. Sustained virologic response (SVR) and adverse 
event rates were based on phase III clinical trials. Transition probability, utility, 
and cost estimates (in 2013 US dollars) were based on a literature review, public 
sources, and consensus by a panel of 4 hepatologists. Results: In the treatment-
naïve cohort, the SOF+RBV regimen resulted in an 83% decrease in the cases of 
liver disease complications including hepatocellular carcinoma, decompensated 
cirrhosis, liver transplant, and HCV-related death compared with PegIFN+RBV. The 
reduction of the listed liver disease sequelae was 59% in the treatment-experienced 
vs. PegIFN+RBV and 93% in the interferon-unable cohort vs. no treatment. The num-
ber needed to treat (NNT) with SOF+RBV rather than PegIFN+RBV to achieve one 
additional SVR was 6 in the treatment-naïve and 4 in the treatment-experienced 
cohorts. cOnclusiOns: SOF+RBV was projected to yield better health outcomes 
in genotype 2 patients compared to PegIFN+RBV, largely driven by superior efficacy, 
and the potential to cure those who are unable to take interferon-based therapies.
PIN4
THE RELATIvE EFFICACy AND SAFETy OF SIMEPREvIR AND TELAPREvIR 
IN TREATMENT-NAïvE HEPATITIS C INFECTED PATIENTS IN A jAPANESE 
POPULATION – A BAyESIAN NETwORK META-ANALySIS
Bryden P.A.1, Quigley J.1, Scott D.A.1, Kuwabara H.2, Cerri K.3
1Oxford Outcomes Ltd., Oxford, UK, 2Janssen Pharmaceutical KK, Tokyo, Japan, 3Janssen 
Pharmaceutical NV, Beerse, Belgium
Objectives: Simeprevir (SMV) is an oral, once-daily potent protease inhibitor for 
the treatment of chronic Hepatitis C genotype-1 infection (cHCV). In phase IIb/III 
RCTs conducted in Japan, SMV, in combination with peginterferon-α and ribavirin 
(PegIFN/RBV), demonstrated potent efficacy in cHCV genotype 1-infected patients 
relative to PegIFN/RBV and was generally safe and well-tolerated. Telaprevir (TVR) 
in combination with PegIFN/RBV is licensed for the treatment of cHCV in Japan. 
In the absence of head-to-head comparisons of TVR and SMV, we undertook a 
network meta-analysis (NMA) to examine the relative efficacy and safety of SMV 
and TVR in combination with PegIFN/RBV in a Japanese population. MethOds: A 
systematic review identified RCTs in Japanese treatment-naive patients with the 
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Increasing treatment rate to 16% showed a decrease of 816/571 DCC and 260/182 HCC 
cases, 74/52 LTs and 655/458 LrDs. The overall reduction in ESLD cases was estimated 
to be -6.1%/-4.2% and -8.8%/-6.1% in both scenarios respectively. cOnclusiOns: A 
1-year increase in treatment rate was predicted to reduce the burden of genotype-1 
CHC in 20 years in the UK. Different treatment rates across Europe imply unequal 
opportunities for patients to prevent CHC sequelae. Identifying CHC patients and 
offering antiviral therapy to maximise SVR could prevent substantial further severe 
liver disease and mortality.
PIN10
RECENT TRENDS IN INCIDENCE AND DEMOGRAPHICS OF PEDIATRIC 
MENINGOCOCCAL DISEASE IN THE UNITED STATES
Davis K.L., Candrilli S.D.
RTI Health Solutions, Research Triangle Park, NC, USA
Objectives: Approximately 1,000-1,200 people in the United States (US) develop 
meningococcal disease (MD) each year. MD is a life-threatening bacterial infection 
most common in infants (age < 1 year), adolescents, and persons living in close 
quarters. We estimated annual incidence and demographic characteristics of MD 
in the US pediatric population from 2000 to 2009. MethOds: Data for pediatric (age 
≤ 20 years) MD-related hospitalizations (discharges with ICD-9-CM 036.xx) from the 
2000, 2003, 2006, and 2009 HCUP Kids’ Inpatient Databases (KID) were retrospec-
tively analyzed. Annual MD incidence per 100,000 pediatrics (adjusted to 2010 US 
population) was estimated using KID sampling weights and year-specific popula-
tion denominators from US census data. Results: Pediatric MD incidence steadily 
decreased from 1.9/100,000 in 2000 to 0.7/100,000 in 2009, a 63% decline. Incidence 
was highest, by far, in infants, which also decreased during 2000-2009 (7.6/100,000 
to 3.8/100,000, a 50% decline). Among children aged 1-4 years, incidence fell from 
2.7/100,000 to 0.8/100,000 during this period, a 70% decline. In children aged 5-10 
years, we observed a 75% decline (1.2/100,000 to 0.3/100,000); similar incidence and 
trends were seen for age groups 11-18 and 19-20 years. Pediatric MD cases were 
predominantly male, with male representation increasing from 55% to 61% of cases 
during 2000-2009. The racial composition of pediatric MD shifted somewhat dur-
ing this period, with representation declining among whites (from 56% to 45% of 
cases) and increasing among blacks (from 8% to 11% of cases). Geographic distribu-
tion remained fairly constant, with highest representation from the South (~30% of 
cases) and West (~30% of cases). cOnclusiOns: Pediatric MD incidence declined 
during the 2000’s, possibly due to the introduction of the meningococcal conjugate 
vaccine in 2005. However, MD incidence remained substantially higher in infants 
compared with other age groups and there appeared to be a demographic shift in 
cases away from females and whites.
PIN11
THE GLOBAL BURDEN, INCIDENCE, AND PREvALENCE OF CHRONIC HEPATITIS C
Ainsworth C.M.1, Kiri S.2, Ling C.S.1, Heyes A.E.1, Hass B.3
1RTI Health Solutions, Manchester, UK, 2Boehringer Ingelheim Ltd., Bracknell, UK, 3Boehringer 
Ingelheim GmbH, Ingelheim, Germany
Objectives: To identify and understand hepatitis C virus (HCV) prevalence and 
mortality rates, disease course, and the availability of data on patient and viral 
characteristics that may affect treatment and outcomes. MethOds: A targeted 
review was undertaken in MEDLINE, using a predefined search strategy, to identify 
studies describing HCV burden. Additional searches were performed on the ISPOR 
conference and key epidemiological websites. Results: A total of 1,773 references 
were identified. Results indicated that global HCV prevalence increased from 2.3% 
to 2.8% between 1990 and 2005, with highest prevalence in East Asia (> 3.5%). HCV 
screening programmes and mandatory reporting are present in only a few countries, 
so prevalence is likely to be even greater. In 2010, there were estimated to be 499,000 
deaths globally related to HCV, making HCV-related complications the 25th most 
common cause of death and a significant global health problem. The prevalence 
of HCV genotypes varies geographically. Genotype 1 is most prevalent in North 
and South America, Europe, and the Asia-Pacific region (~45%-80%). Genotype 3 is 
most prevalent in South Asia (Pakistan, India, and Thailand) (~52%-80%); genotype 
4 is most prevalent in the Middle East (~60%-92%). There is a lack of data for the 
majority of African and some Middle Eastern countries. Genotype 1 is associated 
with increased insulin resistance, worse response to therapy, and higher risk of 
developing cirrhosis and hepatocellular carcinoma. Genotype 3 is associated with 
increased steatosis (up to 73% of patients vs. 51% in patients with other genotypes) 
and fibrosis. cOnclusiOns: In light of upcoming treatment alternatives, detailed 
epidemiological studies will help ascertain more accurately the prevalence of each 
HCV genotype, so that the true burden of HCV can be understood and treatments 
targeted appropriately.
PIN12
BURDEN OF vARICELLA IN EASTERN EUROPE: A SySTEMATIC REvIEw AND 
CRITICAL ANALySIS
Yang H.K.1, Song K.M.1, Manoff S.2, Liaw K.L.2, Kuter B.1
1Merck & Co, Inc., West Point, PA, USA, 2Merck & Co, Inc., Upper Gwynedd, PA, USA
Objectives: Varicella is a common and vaccine-preventable disease, but its impact 
on public health in Eastern Europe (EE) has received little attention. This study aimed 
to review the epidemiology and economic burden of varicella in EE. MethOds: A 
systematic literature review was conducted in PubMed and government websites 
to identify published data on epidemiology and economic burden of varicella in EE. 
Extracted study data included varicella incidence, complications, mortality, vac-
cination program availability and coverage rates, as well as health care resource 
utilization and medical costs associated with varicella. Critical analyses of study 
quality and data gaps were analyzed at the country level. Results: Published 
varicella data were identified from fourteen countries including Bosnia Herzegovina, 
Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, 
Romania, Russia, Serbia, Slovakia, and Slovenia. Only Latvia has a universal vari-
cella vaccination program, while the remaining countries either only recommend 
8IFS, Interdisziplinaeres Facharztzentrum Sachsenhausen, Frankfurt/M, Germany, 9Center of 
Gastroenterology, Bonn, Germany, 10Center of Gastroenterology, Dortmund, Germany, 11Center 
of Gastroenterology, Herne, Germany, 12Factum – company for statistics, scientific information 
and communication mbH, Offenbach/Main, Germany, 13Roche Pharma AG, Grenzach-Wyhlen, 
Germany
Objectives: Estimates assume that 400,000 to 500,000 people are chronically 
infected with Hepatitis C in Germany. About 27% of end-stage liver cirrhosis and 
25% of hepatocellular carcinoma are associated with HCV. The economic relevance 
of hepatitis C results from high costs for antiviral treatment as well as accom-
panying and secondary diseases. The aim of the study was to gain information 
on epidemiological characteristics, treatment outcomes and costs. MethOds: 
Underlying data were collected in a non-interventional trial between 2008 and 
2011. Inclusion criteria were a confirmed HCV diagnosis and need for antivi-
ral treatment. Besides sociodemographic and clinical parameters, HCV related 
resource utilization was gathered for a subgroup of patients. Data presented are 
mean values. Results: Data on 7,637 patients receiving antiviral treatment with 
peginterferon-α -2a and ribavirin were collected. This analysis relates on 3,708 
patients without HIV coinfection and/or drug substitution treatment. Mean age 
was 43.7 years, 60.3% were male. Most patients had a genotype-1 (61.3%) or geno-
type-3 infection (28.5%). The majority of patients was treatment-naïve (86.5%), 
7.3% were relapser and 5.6% non-responder. Main sources of infection were injec-
tion drug use (34.8%) and blood products (14.2%). Mean duration of infection was 
13.6 years. In average 48.9% of treatment-naïve GT-1(4-6) and 63.0% of GT-2/3 
patients achieved SVR. For prior relapse patients and non-responder SVR-rates 
were: GT-1(4-6): 35.4%; GT-2/3: 58.5 and GT-1(4-6): 23.3% GT-2/3: 37.9%, respectively. 
Costs for antiviral treatment amount for € 20,889 in GT-1(4-6) patients and € 13,610 
in GT-2/3 patients. Costs for the management of adverse events or HCV-related 
diseases sum up for € 11.70. Ambulatory care, diagnostics procedures and hospi-
tal care amount for a small proportion of total costs. cOnclusiOns: This study 
provides an overview on epidemiologic characteristics, treatment outcomes and 
treating costs in routine care. Treatment of HCV is costly and mainly affected by 
length of antiviral therapy.
PIN8
ESTIMATION OF THE NUMBER OF CASES OF NOSOCOMIAL SKIN AND SOFT 
TISSUE INFECTION IN ADULTS CAUSED By GRAM-POSITIvE BACTERIA IN 
PUBLIC HOSPITALS IN MExICO
Gryzbowski E.1, Peniche-Otero G.1, Herrera-Rojas J.1, Huicochea-Bartelt J.L.2,  
Muciño-Ortega E.2, Bolaños-Cornejo D.1
1Customized Premium Products S.A. de C.V., Mexico City, Mexico, 2Pfizer S.A. de C.V., Ciudad de 
México, Mexico
Objectives: To estimate the number of cases of nosocomial skin and soft tissue 
infection (SSTIs) in adults caused by Gram-positive bacteria (GPB) in public hospi-
tals in Mexico. MethOds: The total number of hospital discharges in patients ≥ 18 
years were extracted from databases of the National Health Information System. 
A rate of 5.97 cases of nosocomial infection (NI) per 100 discharges (issued by 
Instituto Mexicano del Seguro Social between 2011 and 2012) was applied. Through 
a systematic literature review and critical reading of studies developed under 
the Mexican setting (using the Critical Appraisal Skills Programme guidelines), 
we assessed the type of infection and determined the proportions of: microbio-
logical culture obtained and microbiological culture giving positive isolates. In 
the last stage, microorganisms were classified according to their Gram stain-
ing characteristics. Results: In the year 2011 there were 5,517,139 discharges 
from public hospital, inferring 329,373 cases of NI rate (16.9% under 18 years and 
83.1% in adults). We estimated that SSTIs represents 33.2% of NI (42,430 cases), of 
these, a microbiological culture was obtained only in 63.0% of the cases (26,731) 
and pathogen were isolated in 87.0% of microbiological cultures (23,256), among 
these, GPB was identified in 44.2%. According to our estimates a conservative 
number of cases of nosocomial SSTis in adults caused by GPB in 2011 was 10,279 
and the pathogens reported were Staphylococcus aureus (71.1%), Enterococcus spp 
(14.2%), and others (14.6%). cOnclusiOns: Although we found high heterogeneity 
in NI reports which may decrease the quality of the estimates presented in this 
research, in our opinion these results could help clinicians in the choice of initial 
antibiotics in order to reduce the probability of failure due emergence of resist-
ant organisms.
PIN9
EFFECT OF ANTIvIRAL TREATMENT RATES ON THE PREDICTED FUTURE 
BURDEN OF GENOTyPE-1 CHRONIC HEPATITIS C IN THE UNITED KINGDOM
Westerhout K.Y.1, Treur M.1, Cerri K.2
1Pharmerit International, Rotterdam, The Netherlands, 2Janssen Pharmaceutical NV, Beerse, 
Belgium
Objectives: Chronic hepatitis C (CHC) treatment aims to prevent end-stage liver 
disease (ESLD) through sustained viral response (SVR). Treatment rates differ sig-
nificantly across Europe (< 1-16%). New protease-inhibitor based therapy offers an 
opportunity for increased SVR rates versus pegylated-interferon/ribavirin (> 70% 
vs. 50%). The analysis estimates the impact of various treatment rates on future 
ESLD sequelae associated with genotype-1 CHC in the UK. MethOds: A Markov 
model was applied to estimate disease progression of a cohort of genotype-1 CHC 
patients over a 20-year time horizon. Endpoints included the following ESLD states: 
decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), liver transplan-
tation (LT) and liver-related death (LrD). Model structure, progression rates, CHC 
prevalence and disease severity at baseline were based on published economic 
evaluations. The number of ESLD cases averted by a 1-year increase in the current 
UK treatment rate (3%) to 12% and 16% was estimated for a 71.5% and 50.0% SVR 
rate. Results: Applying a 3% treatment rate and 71.5%/50.0% SVR rate predicted 
8590/8647 cumulative DCC and 3577/3595 HCC cases, 814/820 LTs and 7613/7659 
LrDs. The number of ESLD cases averted by applying a 12% treatment rate was 
estimated to be 565/395 DCC and 180/126 HCC cases, 51/36 LTs and 453/317 LrDs. 
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diseases, age at first pap smear, pap smear frequency, use of oral contraceptives 
and the number of pregnancies. Results: Overall, 600 respondents were eligible for 
the analysis, consisting of 465 patients (44.0±16.3 years) and 135 controls (44.0±13.2 
years). More than 5 sexual partners increased the risk of acquiring HPV infections 
up to 2.52-fold (95%CI: 1.34-4.74), while smoking or an early sexual debut (≤ 18 
years) raised it by about a factor of 1.62. Higher levels of education were associated 
with a protective effect. The overall rate of individuals at high risk with more than 
5 sexual partners and at least another additional factor corresponded to 26.3% (158 
out of 600). The proportion of subjects with an average risk (respondents with less 
than 5 partners and at least another additional factor) amounted to 53.2% (319 out 
of 600). cOnclusiOns: Analysis of risk factors can be used as part of the economic 
assessment of other effective HPV vaccination strategies, including an immuniza-
tion programme for pre-adolescents of both sexes in Italy.
PIN16
A STUDy OF A. BAUMANNII IN A TERTIARy CARE HOSPITAL wITH 
CONSIDERATION TO RISK FACTORS OF INFECTION AND RESISTANCE PATTERN
Sudhapalli V.1, Kanad D.1, Vilakkathala R.2, Mallayasamy S.R.2, Mukhopadhyay C.3,  
Varma M.4
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India, 
2Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India, 3Kasturba Medical 
College, Manipal University, Manipal, India, 4Kasturba Medical College, Manipal University, 
Manipal, India
Objectives: To ascertain the epidemiological factors associated with Acinetobacter 
infections and the resistance pattern of this organism. MethOds: A cross sectional, 
observational, retrospective study was carried out, over a period of 6 months in a 
tertiary care hospital (Oct 2012 to Mar 2013). The data collected was analysed to 
understand the pattern with respect to patient demographics, prescription patterns, 
comorbidities as risk factors to infection, and resistance patterns. Results: Based 
on this study it was observed that surgery was not a risk factor for Acinetobacter 
infections. Male patients had a greater risk of A. baumannii infections. Age distri-
bution of infections was mainly in 41-60 years and 61-80 years. The bacteria were 
found to be resistant to almost all categories of drugs except colistin, and tigecy-
cline. The mean length of stay of a patient of A.baumanni infection was found to 
be 23.51±27.97 days. Tigecycline and cefixime were the most prescribed antibiotics 
(97.9%) in the present study. Cefoperazone-sulbactam was found to have an antibi-
otic action against the bacterium. cOnclusiOns: This study concluded that male 
patients were at a greater risk of A.baumannii infections. However surgery could 
not be considered as a risk factor for the same. Length of stay of patients was on 
average 23.51±27.97 days. This study showed tigecycline and cefixime were the 
most prominently used antibiotic. The strain in this study was resistant to almost 
all cephalosporins except Cefoperazone-Sulbactam which had activity in 57.14% 
of the samples tested.
INFECTION – Cost Studies
PIN17
BUDGET IMPACT ANALISIS OF SwITCHING FROM DPT AND MONOvALENT 
vACCINES TO DTAP–IPv-HIB COMBINED vACCINE INTO RUSSIAN 
IMMUNIzATION SCHEDULE
Kulikov A.1, Akimova Y.I.2
1First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia, 2First 
Moscow medical academy named after I.M. Sechenov, Moscow, Russia
Objectives: The current Russian immunization program for children from 
0 to 20 months is carried mainly by DPT and monovalent vaccines. In addition, 
vaccination against Hib infection so far is only available for children at risk 
(approx. 20%). Introduction of DTaP-IPV-Hib combined vaccine could reduce the 
number of injections received by the child and increase coverage against Hib 
infection from 20% to 97%. The objective of this evaluation is to calculate the incre-
mental of switching from current monovaccines and DTP-based routine immu-
nization schedule using a pentavalent combined vaccine DTaP-IPV-Hib through 
a different schemes. MethOds: A budget impact analysis of the switching to 
the different schemes DTaP-IPV/Hib vaccine is performed on the suggested 
Markov model. The three alternatives (against current immunization program) 
are compared: a 3+1DTaP-IPV-Hib immunization (Scheme P), a mixed DTwP / 
DTaP-IPV-Hib immunization (Scheme mix) and a potential scenario - the cur-
rent scheme, but with expanded (97%) Hib coverage- Scheme 1.The cohort of 
infants born in 2011 year is followed over their lifetime. Direct and indirect medical 
costs are measured from the perspective of the public payer. For reference, 
accepted exchange rate is 1€ = 41 rub. Results: The budget impact analysis has 
shown that the switching from the current vaccination schedule for one of the 
alternative require additional funds in the amount of 705 101 317 rub. (17197593 
€ ) for Scheme mix, 708 100 310 rub.(17270739€ ) for Scheme 1 and 1818409 406 
rub.(44351449 € ) for Scheme P. cOnclusiOns: According to the budget impact 
analysis, the lowest additional cost of introduction one of alternative scheme 
would require Scheme mix. Thus, this scheme will be preferred for the Russian 
health care system.
PIN18
BUDGET IMPACT OF THE INTRODUCTION OF ELvITEGRAvIR/COBICISTAT/
EMTRICITABINE/TENOFOvIR, THE FIRST INTEGRASE INHIBITOR-BASED SINGLE 
TABLET ANTIRETROvIRAL REGIMEN FOR HIv TREATMENT, TO THIRD PARTy 
PAyERS IN THE UNITED STATES
Brogan A.1, Talbird S.E.1, Thompson J.R.1, Kim Y.A.2, Olson J.2, Peterson J.2, Piontkowsky D.2, 
Pietrandoni G.3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Gilead Sciences, Inc., Foster city, CA, 
USA, 3Walgreens Pharmacy, Deerfield, IL, USA
Objectives: Single tablet regimens like elvitegravir/cobicistat/emtricitabine/teno-
fovir (EVG/COBI/FTC/TDF) for the treatment of HIV infection are associated with 
varicella vaccination for high-risk individuals or have no recommendations. The 
annual incidence of varicella in EE ranged from 164 per 100,000 in Latvia to 481 per 
100,000 in Poland. Hospitalization rates associated with varicella ranged from 1 
per 1,000 cases in Estonia to 30 per 1,000 cases in Latvia. Frequent complications 
among hospitalized patients included respiratory, skin, hematologic, and neurologic 
complications. Mortality rates ranged from 0-20 per 100,000 cases in Poland, Serbia, 
and Slovenia. Varicella incidence peaked in winter in Poland and Slovenia. No data 
on direct and indirect costs of varicella in EE was available. Overall, Poland and 
Slovenia had the most data on burden of varicella while limited data existed for 
the remaining countries. cOnclusiOns: Epidemiologic and economic burden of 
varicella in EE have not been extensively studied. Given limited varicella vaccination 
policy in this region, gaps in evidence need to be addressed to inform policy makers 
about the public health impact on varicella.
PIN13
PREvELANCE OF HyDETED DISEASE IN SUGICALy OPERATED PATIENT IN SOME 
LIByAN GENERAL HOSPITAL
Hadida E.
NCDC, Tripoli Libya, Tripoli, Libya
Objectives: Determine the prevalence of HD in cases referred to surgical wards 
in four hospitals in east part of Libya during period from 2004 to 2009. MethOds: 
Data was collected from four hospitals; Tripoli medical centre, central Hospital, 
Alzawia hospital and Gharian general hospital. Hospital data of, patients diagnosed 
as HD were collected from surgical departments. Results: Out of 94,142 files were 
reviewed from four Hospitals there were 401(0.42%) confirmed cases of Hydatid 
disease. Among these medical records there were 233(58.1%) from Tripoli Medical 
Centre, 144(35.9%) from Centre Tripoli Hospital, 16(4%) from Al Zawiyah Hospital 
and 8(2%) from Gharyan Hospital. The gender distributions were 41.4% males and 
58.6% females. Young adult ages between 15-30 were most commonly infected (35%). 
Liver and lungs was most common site of infection (81.1% and 13.5% of cases, 
respectively) Spleen was (2.0%). Cysts were found in sites like Pancreas, Ovary and 
kidney were (3.4 %) cOnclusiOns: Hydatid disease is a Health problem affecting 
young Libyan population. The mean age of the patients was (2-40) years and more 
common in women) housewives) and students, the most common site of HD found 
in liver followed by lungs. Further studies are required to find the etiologic factors 
of HD in different areas in Libya.
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PREDICTOR FACTORS FOR THE PRESENCE OF POST HERPETIC NEURALGIA AT 3 
MONTHS IN HERPES zOSTER PATIENTS AGED 50 AND OvER IN ITALy: RESULTS 
FROM A GP-BASED OBSERvATIONAL PROSPECTIvE MULTICENTER STUDy
Bricout H.1, Perinetti E.2, Marchettini P.3, Ragni P.4, Zotti C.5, Gabutti G.6, Volpi A.7, Franco E.8
1Sanofi Pasteur MSD, Lyon, France, 2Sanofi Pasteur MSD, Roma, Italy, 3ISTITUTO SAN RAFFAELE 
DI MILANO E SCUOLA UNIVERSITARIA DELLA SVIZZERA ITALIANA, Milan, Italy, 4DIR. 
SANITARIA ASL REGGIO EMILIA, Reggio Emilia, Italy, 5UNIVERSITA’ DEGLI STUDI DI TORINO, 
Turin, Italy, 6Hygiene and Public Health, Chiavari (Genova), Italy, 7Università di Roma Tor Vergata, 
Roma, Italy, 8UNIVERSITA’ DEGLI STUDI DI ROMA TOR VERGATA, Roma, Italy
Objectives: To identify predictors for the presence of Post Herpetic Neuralgia (PHN) 
at 3 months in Herpes Zoster (HZ) patients aged 50 and over in Italy. MethOds: 
General Practitioners (GPs) from regions throughout Italy included immunocom-
petent patients over 50 years old with a new HZ diagnosis and followed them dur-
ing 6 months with visits (V) at 0, 1, 3 and 6 months. Occurrence and level of pain 
using a 0 to 10 visual analogic scale (VAS), clinical symptoms, patients’ quality of 
life (QoL) and their health care resources utilization were recorded. A multivariate 
regression model was run to assess the predictor factors for the presence of PHN 
at 3 months. Univariate analysis was first undertaken on each variable to identify 
possible associations with PHN (level of significance, 25%) to be considered in the 
multivariate regression model. Results: From March 2009 to July 2010, 108 GPs 
included 413 patients (148 Males and 265 Females) with HZ aged 67.9 y± 10.7 years. 
Most of them (89.6%) had pain at V0 (VAS score:5.8/10) and 91.5% received systemic 
antivirals, 70% within 72 hours after rash onset. During the follow-up, 52 patients 
consulted at least one specialist (dermatologist, neurologist, ophthalmologist…) and 
no cases were hospitalized. At 3 month, 20.6% presented PHN (VAS score: 3.7/10), 
and still 9.2% at 6 months (VAS score: 3.7/10). By logistic regression analysis a VAS 
score over 3, the presence of more than 50 vesicles and the gender male were the 
main predictive factors at the initial visit that were significantly associated with 
the presence of PHN at 3 months. cOnclusiOns: Even if most of patients with HZ 
received the standard of care, many experienced intense and long-lasting pain. This 
study identified specific factors at presentation that could help identify patients 
who will develop PHN.
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RISK FACTORS INFLUENCING THE vIRAL TRANSMISSION AND THE POTENTIAL 
DEvELOPMENT OF HPv-INDUCED PATHOLOGIES
Marcellusi A.1, Capone A.2, Haeussler K.3, Baio G.3, Mennini F.S.1, Favato G.4
1University of Rome “Tor Vergata”, Rome, Italy, 2Kingston University London, London, UK, 
3University College London, London, UK, 4Kingston University, Kingston, UK, Kingston, UK
Objectives: The current study has been designed to investigate risk factors influ-
encing the viral transmission and development of HPV infections within the Italian 
population. MethOds: A standardized and computer-guided questionnaire was 
administered to male and female patients with a HPV-induced pathology (e.g. atypi-
cal squamous cells of undetermined significance, cervical intraepithelial neoplasia, 
cervical cancer, anal-colorectal cancer, head-neck cancer and anogenital warts). Six 
clinical centres across Italy participated in this multicentre study. The patients’ risk 
profile was assessed and compared to that of a control group of healthy subjects 
attending the same clinics. The effects of risk factors were evaluated using a back-
wards stepwise multivariate logistic regression model with covariate adjustment. 
The following predictors were included: level of education, occupation, age at first 
intercourse, number of sexual partners, smoking, previous sexually transmitted 
A344  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
due to oral antibacterial switching in cSSTIs. Increased use of linezolid in the treat-
ment of MRSA-cSSTIs could result in substantial savings for the Greek hospital budget.
PIN21
COST REDUCTION ASSOCIATED wITH USE OF SUBGLOTTIC ASPIRATION TO 
REDUCE vENTILATOR-ASSOCIATED PNEUMONIA IN TURKEy
Kockaya G.1, Erslon M.G.2, Can H.3, Akin O.1, Ozcan S.1
1Covidien, Istanbul, Turkey, 2Covidien, Boulder, CO, USA, 3Covidien, Ankara, Turkey
Objectives: Ventilator-associated pneumonia(VAP) is a serious complication risk 
for patients who require invasive mechanical ventilation(IMV). VAP is associated 
with longer intensive care unit and hospital stays, which may increase health care 
expenditures. VAP may occur in 8% of IMV patients. Subglottic aspiration (SA) may 
decrease VAP by up to 45% in IMV patients. The goal of this analysis is to calculate 
the potential cost reduction associated with SA use for VAP reduction in IMV patients 
in Turkey. MethOds: A literature analysis was conducted in PubMed(2000-present) 
to determine the published cost of VAP in Turkey. Published costs were used for the 
conversion to Turkish Lira(TL). An annual inflation rate of 3% was applied to the cost 
data to project the estimated cost in 2013. The exchange rate for USD to TL was esti-
mated at 1.8. A weighted average of the number of patients in each study was used to 
calculate the cost of treatment. The cost of SA to the Social Security Institution (SGK) 
was calculated as 33.94 TL, which includes the cost of the SA tube(TaperGuard EVAC; 
25 TL) and the SA service reimbursement amount from the SGK of 8.94 TL. 8% and 
45% were taken as the VAP rate and reduction with SA rate in IMV patients, respec-
tively. The number of patients requiring IMV in a hospital was estimated at 1000 per 
year. Results: The average inpatient costs of IMV patients with and without VAP were 
calculated to be 13.556 TL and 3.971 TL, respectively. The total VAP cost, based on 80 VAP 
cases in 1,000 IMV cases without SA, was calculated as 1.085.297 TL. A hospital using 
SA for all IMV cases is estimated to have VAP costs equal to 488.384 TL and SA costs of 
33.940 TL for a total cost of 522.324 TL. Cost reduction from SA use was calculated as 
562.973 TL. cOnclusiOns: VAP increases health expenditures by 9.595 TL per patient. 
A hospital with 1,000 IMV patients per year that uses SA in all IMV patients may realize 
an estimated cost reduction of 562.973 TL associated with use of SA in IMV patients.
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BUDGET IMPACT OF AN INDIvIDUALIzED APPROACH IN THE TREATMENT OF 
HBEAG-NEGATIvE CHB PATIENTS ExPLOITING THE wEEK-12 PEGINTERFERON 
ALFA-2A STOPPING RULE IN ITALy
Iannazzo S.1, De Francesco M.1, Coco B.2, Brunetto M.2, Tomic R.3, Paolini D.3, Palmieri G.3, 
Bonino F.2
1IMS Health, Milan, Italy, 2University Hospital (AOUP), Pisa, Italy, 3Roche S.p.A., Monza, Italy
Objectives: Treatment options for chronic hepatitis B (CHB) are the direct inhibi-
tion of viral replication by continuous administration of nucleosides analogues 
(NUCs) or a finite 48-weeks course of peg-interferon (PEG). PEG can induce the 
off-therapy immune control of CHB leading to HBsAg loss/anti-HBs seroconver-
sion but at a low success rate. On the other hand life-long treatment with NUCs is 
expensive. Exploiting the early identification of PEG-non-responders by combined 
HBV-DNA and HBsAg quantification at week-12 (stopping-rule), a new sequential 
therapeutic strategy may benefit both patients and payers. We measured the impact 
on the Italian National Health Service budget using the PEG-week-12-stopping-
rule in the treatment of HBeAg-negative CHB. MethOds: A Markov model was 
developed over a 5 year horizon in the states: CHB, virologic response, relapse, 
HBsAg clearance, compensated and decompensated cirrhosis, hepatocarcinoma, 
liver transplant, post-liver transplant and death. The target population (treatment 
naïve CHB patients) was determined based on Italian national population forecasts 
and epidemiological data. The current mix of treatment with NUCs (entecavir, teno-
fovir, adefovir, lamivudine and telbivudine) and PEG (with no stopping rule) was 
compared with a mix based on a hypothetical uptake of PEG (with the stopping rule). 
The percentage of uptake from NUCs started at 25%, increasing over time. Results: 
The estimated impact on the Italian NHS budget, over 5 years of treatment, resulted 
in a saving of approximately € 74 million, 95% of which accounted for drug cost. The 
beneficial impact of the stopping-rule became clear from the second year, when a 
break-even point was reached. cOnclusiOns: The large estimated savings in drug 
costs following the uptake of PEG + stopping-rule in the treatment of CHB HBeAg 
negative patients, together with previously published cost-effectiveness results, 
demonstrate a potentially advantageous profile of such a strategy, that could allow 
for more efficient use of health care resources.
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ExAMINING THE RELATIONSHIP BETwEEN COUNTRy-LEvEL FACTORS 
AND vACCINE wASTAGE: A DATA DRIvEN MODEL OF SESSION SIzES IN 
BANGLADESH, MOzAMBIQUE, INDIA (UTTAR PRADESH), AND UGANDA
Yang W.1, Parisi M.2, Lahue B.J.2, Bishai D.M.1
1Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 2BD, Franklin 
Lakes, NJ, USA
Objectives: Vaccination is a cost-effective intervention; however limited infra-
structure in developing countries can pose significant challenges in efficient vac-
cine delivery. Countries prefer multidose presentations due to lower acquisition 
and cold chain costs, but open vial vaccine wastage is a major part of program 
cost. The aim of this study was to examine country-level factors that impact open 
vial wastage. MethOds: A demographics-based budget impact model with a 10 
year time horizon was developed in Excel v14 using Palisade’s @Risk v6.0 software. 
The model estimated daily vaccine utilization and wastage rates for Pentavalent, 
Pneumococcal, HPV and IPV using Lee’s (2010) model, calibrated to arrival distri-
butions based on field data session sizes from Bangladesh, Mozambique, India 
(Uttar Pradesh), and Uganda. The statistical distribution was determined using 
maximum likelihood, stratified by urban/rural for each clinic type. The model 
ran 1000 iterations, with each drawing independently from the statistical distri-
butions of session sizes by clinic type. Results: The negative binomial family 
offered the best fit to session size by Akaike Information Criterion. The leading 
improved medication adherence, better virologic suppression, lower hospitalization 
rates, and lower health care costs. The objective of this study was to estimate the 
budget impact to a US health care plan of the use of EVG/COBI/FTC/TDF in adults 
with HIV who are treatment-naïve or currently on treatment with no resistance to 
the components of EVG/COBI/FTC/TDF. MethOds: The model estimates total direct 
health care costs associated with HIV management before and after the introduction 
of EVG/COBI/FTC/TDF. HIV epidemiology, hospitalization rates, and adverse event 
incidence and their associated costs were calculated using results of published 
studies or publically available sources. Regimen utilization was obtained from recent 
chart audit analysis and EVG/COBI/FTC/TDF market share was projected to come 
from protease inhibitor (PI)-based regimens in relative proportion to each regimen’s 
market share. The budget impact was calculated annually and cumulatively over 
a 3-year period without discounting, following standard methodology for budget 
impact analyses. Results: For a hypothetical health care plan with 1 million mem-
bers, the model estimated 450 HIV-positive members currently on treatment and 
72 HIV-positive members initiating HIV therapy each year. Over a 3-year period, 
the introduction of EVG/COBI/FTC/TDF was expected to result in greater use of 
single tablet regimens and lower use of more expensive PI-based regimens, yielding 
lower pharmacy costs ($226,194, 0.5% lower), fewer hospitalizations (1.1% fewer), and 
lower hospitalization costs ($31,288, 1.1% lower) versus scenario without EVG/COBI/
FTC/TDF. Total cost savings over 3 years were estimated at $240,375 (0.4% lower), 
equivalent to a reduction in per-member-per-month (PMPM) costs from $1.61 to 
$1.60. PMPM results were insensitive to changes in parameters. cOnclusiOns: 
The introduction of EVG/COBI/FTC/TDF is expected to result in fewer hospitaliza-
tions with a negligible impact on pharmacy and total costs over a 3-year period for 
a US health care plan.
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BUDGET IMPACTS OF PROBIOTICS IN CONTROLLING UPPER RESPIRATORy 
TRACT INFECTIONS IN FRANCE
Berdeaux G.1, Lenoir-Wijnkoop I.2, Gerlier L.1
1IMS Health HEOR, Vilvoorde, Belgium, 2Utrecht University, Utrecht, The Netherlands
Objectives: Two meta-analyses associated with a public health model demon-
strated that probiotics (live microorganisms which when administered in adequate 
amount confer a health benefit on the host) have an important public health impact: 
they reduce upper respiratory tract infection (URTI) episodes with less antibiotics 
and sick leave prescriptions, in France. This analysis reports the budget impact for 
the National Health System (NHS) and the Nation. MethOds: The public health 
impact model (1/1,000 virtual age-gender standardized population generated with 
a Markov model: 1-day cycles, 2011-2012 winter period, URTI incidence from a 
General Practitioner [GP] network) was used. Economic perspectives were society, 
NHS and family. The analysis was limited to patients having visited a GP. Resource 
utilization came from the GP network. Unit costs were applied: Ameli.fr for drugs, 
Classification Commune des Actes Médicaux for GP visits, gross domestic product 
(GDP)/capita or allowances for sick leaves. Outcomes included direct medical and 
indirect costs. Results were reported according to each meta-analysis, Cochrane 
and York Health Economics Consortium (YHEC). Results: The economic impact 
of probiotics was about € 95 million saved from the Society perspective according 
to YHEC (Family: -€ 21.7 million; NHS: -€ 15.4 million) and € 229.1 million according 
to Cochrane (Family: -€ 130.4 million; NHS: -€ 34.6 million). Absenteeism was the 
main driver for the society perspective representing 98% (YHEC) or 78% (Cochrane) 
of the savings. For the NHS, the main driver was sick leave (94%, YHEC-based) or 
GP visit (67%, Cochrane-based): avoiding URTI episodes (Cochrane) generates more 
visit savings than reducing disease duration (YHEC). More savings were observed 
in children, active smokers and people with more human contacts compared to 
the general population. cOnclusiOns: Probiotics savings are substantial, whether 
they reduce URTI episodes frequency or duration. Noteworthy, 2011-12 winter URTI 
incidence rate was low and this analysis focused on the 1% URTI accessing the NHS.
PIN20
ANTIBACTERIAL TREATMENT OF METICILLIN-RESISTANT STAPHyLOCOCCUS 
AUREUS COMPLICATED SKIN AND SOFT TISSUE INFECTIONS: A BUDGET 
IMPACT ANALySIS IN THE GREEK HOSPITAL SETTING
Karampli E.1, Ollandezos M.1, Petrakis I.2, Tsoulas C.2, Patel D.A.3, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Pfizer Hellas, Athens, Greece, 3Pharmerit 
International, Bethesda, MD, USA
Objectives: Meticillin-resistant staphylococcus aureus (MRSA) is an important cause 
of antimicrobial-resistant health care-associated infections worldwide. Its prevalence 
remains high in the Greek hospital setting. Complicated skin and soft tissue infections 
(cSSTIs) due to MRSA are associated with prolonged hospitalization, additional costs 
of care and significant morbidity. The purpose of this study was to conduct a budget 
impact analysis relative to different management scenarios for MRSA-cSSTIs from 
a hospital perspective. MethOds: Equal efficacy for the pharmacotherapies under 
evaluation was assumed and resource use was elicited via an expert panel. The model 
was based on a decision tree for the management of hospitalized patients with MRSA-
cSSTIs, simulating costs and outcomes for the duration of hospitalization according 
to the therapeutic scenario, including empiric and first-line therapies. Inpatient costs 
consisted of hospitalization, diagnostic, medical and antibiotic costs. Economic results 
(Euros 2013) reflect the hospital setting. Results: Total per patient cost according to 
first-line agent was € 2,458, € 2,730, € 2,850, € 3,495 and € 3,098 and mean length of stay 
(LOS) was 9.2, 12.5, 10.3, 13.0 and 14.0 days for linezolid, vancomycin, daptomycin, tige-
cyline, teicoplanin respectively. An estimated 10,287 MRSA-cSSTI patients are treated 
annually in Greek hospitals. Thus, by increasing the use of linezolid by 11% over a 
three-year period, for the management of MRSA-cSSTIs, this could result in savings of 
€ 331,602 for the hospital budget (current:€ 29,081,597, projected:€ 28,749,994). By reduc-
ing the LOS for linezolid patients from 9.2 days (current LOS in Greece as per expert 
panel) to 7.6 days to match data from a large phase IV study in MRSA-cSSTIs (Itani 2010), 
potential savings amount to € 808,673. cOnclusiOns: The analysis corroborates litera-
ture findings with regards to the early switch/early discharge potential and outcomes 
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estimates. Results: Treatment with pegylated interferon alfa-2a was associated 
with lower total costs. The estimated budget savings varied from 20,907.97 RUB 
to 104,366.07 RUB per one patient. CERs for pegylated interferon alfa-2a were 
less than that for pegylated interferon alfa-2b in all patient subgroups. The low-
est CER was observed for patients with genotype 2 received pegylated interferon 
alfa-2a (240,789.70 RUB per one patient with SVR) and the highest CER – for cir-
rhotic patients with genotype 1 received pegylated interferon alfa-2b (1,879,694.72 
RUB per one patient with SVR). The analysis of the IRDU showed, that inefficient 
budget expenses associated with pegylated interferon alfa-2b treatment may reach 
58,770.84 RUB per one patient infected with HCV-genotypes 1/4. SAs demonstrated 
that results were robust to changes in the drug costs. cOnclusiOns: The present 
study has demonstrated that administration of pegylated interferon alfa-2a has 
the better pharmacoeconomic profile in the treatment of Russian patients with 
chronic hepatitis C.
PIN27
THE COST OF STOPPING (FUTILITy) RULES TELAPREvIR AND BOCEPREvIR IN 
THE TREATMENT OF GENOTyPE 1 HEPATITIS C PATIENTS IN BRAzIL
Morais A.D., Pereira M.L.
Janssen Cilag Farmaceutica, São Paulo, Brazil
Objectives: To estimate the cost of treatment discontinuation due to label stopping 
(futility) rules of telaprevir (TVR) and boceprevir (BOC) triple therapy in Brazilian 
public (SUS) and private health care system (SS). MethOds: Treatment costs con-
sidered drug acquisition costs from a public and private payer perspective in Brazil. 
Stopping rules (SR) were defined according to the label of each drug. For TVR the SR 
were defined at week4 (SR WK4) and at week 12 (SR WK12) as viral load (VL) > 1.000 
IU/ML. For BOC, SR were defined at week 12 (SR WK12) as VL > 100 UI/mL and at week 
24 (SR WK24) as detectable VL. Patients eligible for the SR were gathered for naïve 
and experienced patients from the respective phase 3 trials. As data for SR WK24 
was not published for BOC in naïve patients it was assumed to be the same as SR 
WK12 and a deterministic sensitivity analysis was carried out. Results: Under 
the SUS perspective, the average cost of naïve patients interrupting treatment with 
TVR was R$ 670 compared to an average cost of R$ 3.396 per interrupted treatment 
with BOC, and for treatment experienced patients, TVR had an average cost of R$ 
352 compared to an average cost of R$ 3.041 for BOC per patient meeting the SR. 
Under the SS perspective, TVR had an average cost of R$ 1.433 per interrupted naïve 
treatment and R$ 753 per interrupted treatment in experienced patients and BOC 
had an average treatment cost of R$ 8.305 per naïve patient interrupting treatment 
and R$ 4.753 per interrupted treatment in experienced patients. cOnclusiOns: 
BOC had higher costs associated with treatment futility when compared to TVR, 
especially in treatment experienced patients, in both the public and private health 
care systems in Brazil.
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COMPARATIvE EFFECTIvENESS OF TRIPLE THERAPy vERSUS DUAL THERAPy 
FOR CHRONIC HEPATITIS C vIRUS INFECTION IN KAzAKHSTAN
Almadiyeva A.1, Kostyuk A.1, Nurgozhin T.2
1National Center for Health Development, Astana, Kazakhstan, 2Nazarbayev University, The 
Center for Life Sciences, Astana, Kazakhstan
Objectives: Currently, 23 thousand people (registered) are suffering from Hepatitis 
C in Germany (more 60% genotype 1). TThe licensing of direct-acting antivirals 
heralds a new era in the treatment of hepatitis C virus (HCV) genotype 1. Clinical 
studies showed a significant increase in sustained virological response rates from 
38-46% to 63-79%. This study was to evaluate the cost-effectiveness of newly intro-
duced triple therapy with Telaprevir (TVR+PR) compared to dual therapy (PR) for the 
treatment of genotype 1 hepatitis C virus (HCV) infection in previously untreated 
patients. MethOds: A systematic literature review identified relevant studies. A 
Bayesian mixed treatment comparison model was fitted for each patient popu-
lation. Previously published economic Markov model comparing triple therapy 
(TVR + PR) and dual therapy (PR) has been adjusted for the Kazakhstan context of 
health care (payer perspective). Clinical outcomes and dose were taken from the 
phase ADVANCE-3 trial. Other parameters of the model - including utilities - were 
adapted from Kazakhstan or if not available from the international literature after 
an extensive search of the literature. Drug costs were taken from the list of drugs 
Kazakhstan. All costs were inflated to 2012 goda.Skidka of 3% and the horizon of 
life were considered. Results: Base-case analysis shows that the triple treatment 
(TVR + PR) than dual therapy (PR) leads to increased costs, and the best results. The 
results were robust when analyzing multiple sensitivity. The discount rate seemed to 
have a great impact. cOnclusiOns: Telaprevir triple therapy for previously treated 
patients with HCV-genotype 1, more efficient than the dual therapy, but it leads to 
increased costs (in particular, the cost of medications).
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PHARMACOECONOMIC EvALUATION OF THE FIxED-DOSE COMBINATION OF 
ABACAvIR/LAMIvUDINE IN THE ANTIRETROvIRAL THERAPy OF NAïvE HIv 
INFECTED PATIENTS IN RUSSIA
Pyadushkina E.1, Omelyanovsky V.2, Avxentyeva M.2, Rebrova O.3, Andreeva N.1
1Autonomous Non-profit Organization “National Centre for Health Technology Assessment”, 
Moscow, Russia, 2The Russian Presidential Academy of National Economy and Public 
Administration, Moscow, Russia, 3Pirogov Russian National Research Medical University, Moscow, 
Russia
Objectives: To estimate the costs of once-daily fixed dose combination (FDC) 
abacavir/lamivudine (ABC/3TC) compared with twice-daily combination of its 
individual components (ABC+3TC) and twice-daily FDC zidovudine/lamivudine 
(ZDV/3TC) in efavirenz (EFV)-based regimens for treatment-naïve adults with HIV 
infection in Russia. MethOds: An Excel based model was developed to estimate the 
costs over 48- and 96-week time horizon for three compared regimens. Probabilities 
of switching to alternative and 2d line therapy due to low adherence and side effects 
were estimated for each regimen based on literature search. Costs of antiretroviral 
determinant of wasted doses was the number of children arriving. Depending 
on whether the clinic setting was urban/ rural, or outreach/fixed center, median 
session sizes varied between 5-13 children. Vaccine wastage added significant 
cost due to variations in session size even when modeled using a low multidose 
vial strategy. For instance, open vial waste from pneumococcal delivered in 5-dose 
presentation contributed $20MM in waste to Ugandan 10-year program costs. 
Results for each country and the impact session size distributions will be pre-
sented. cOnclusiOns: Our analysis of field data confirmed significant session 
size variation within/across country immunization settings. Given challenges in 
mandating session sizes, pressures on vaccine budgets and high value of vaccine 
delivery, policy makers must consider new solutions to reduce the impact of waste 
on total program costs.
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BUDGET IMPACT ANALySIS OF CEFTAROLINE vERSUS LINEzOLID OR 
vANCOMyCIN ON THE TOP OF STANDARD THERAPy IN THE TREATMENT OF 
COMPLICATED SKIN AND SOFT TISSUES INFECTIONS IN RUSSIAN FEDERATION
Kulikov A., Komarov I.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To estimate the budget impact of the inclusion of ceftaroline com-
pared to linezolid or vancomycin on the top of complicated skin and soft tissues 
infections treatment scheme with antimicrobials according to Russian health care 
system. MethOds: The budget impact analysis was conducted. Direct expenses 
associated with complicated skin and soft tissues infections and resulting follow-up 
costs were calculated using general tariff agreement of Russian obligatory insurance 
system and official national statistics. For reference, accepted exchange rate was 1 
EUR = 40 RUB. Results: Ceftaroline inclusion into the standard complicated skin 
and soft tissues infections therapy provided cost saving benefits compared with 
inclusion of linezolid or vancomycin in the complicated skin and soft tissues infec-
tions standard therapy scheme. Total health care costs of complicated skin and soft 
tissues infections therapy were approximately 77 997 RUB (1 950 EUR) per patient 
in ceftaroline group (therapy duration – 9 days), 78 816 RUB (1 970 EUR) per patient 
in vancomycin group (therapy duration – 10 days) and 117 893 RUB (2 947 EUR) per 
patient in linezolid group (therapy duration – 12 days). Treatment of complicated 
skin and soft tissues infections using standard therapy with ceftaroline inclusion 
compared to one with vancomycin or linezolid leads to cost savings of 819 RUB (20 
EUR) or 39 896 RUB (997 EUR) per patient, respectively. cOnclusiOns: The results 
of budget impact analysis illustrate that including ceftaroline into the standard 
therapy of complicated skin and soft tissues infections in comparison with vanco-
mycin or linezolid has potential to reduce Russian health care system total costs 
for complicated skin and soft tissues infections treatment.
PIN25
ESTIMATING THE COST IMPACT OF SwITCHING FROM A vIAL TO A PRE-FILLED 
SyRINGE MODE OF ADMINISTRATION FOR THE DTAA-IPv-HIB ‘5-IN-1’ vACCINE 
IN INFANTS
Kumar G.1, Padhiar A.1, Carroll S.2, Woods B.1, Shread K.2
1Oxford Outcomes Ltd., Oxford, UK, 2Sanofi Pasteur MSD, Maidenhead, UK
Objectives: To estimate the cost impact to the NHS of switching from vial and 
syringe (V&S) to pre-filled syringe (PFS) administration of the ‘5-in-1’ vaccine for 
diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b. MethOds: 
A model was developed to estimate the cost impact of the switch in children less 
than 2 years old. Vaccines supplied were assumed to reach three destinations: 
administered (an estimate of 785,320 primary courses); opened and not adminis-
tered (assumed to account for 7% of V&S and 0% of PFS supplied); or not opened 
by the expiry date (assumed to account for 0% of supply). All vaccines accrued 
acquisition and storage costs. PFS has bulkier packaging, leading to higher stor-
age costs. Administered vaccines incurred costs for staff time, consumables (only 
required for V&S) and potential needlestick injuries (assumed not to occur with 
PFS). As prices paid for vaccines by the NHS are not disclosed, the cost of a single 
dose was assumed equal for PFS and V&S. Appointment times were obtained from 
a survey of 200 nurses, which estimated that PFS saved on average 4 minutes 47 
seconds relative to V&S across three doses. All unit costs were sourced from the 
literature. Results: The introduction of PFS was estimated to save £7.91 per 3-dose 
primary course and £6,214,562 per year for the NHS. Reductions in wastage and 
staff time contributed the greatest savings. Varying the wastage rate from 1-10% 
resulted in total cost savings of £3-8million; investigation into better estimates 
of vial wastage would strengthen the results. All other sensitivity analyses had 
a minimal impact on results. cOnclusiOns: The switch to PFS administration 
is estimated to have generated substantial cost-savings to the NHS. PFS has the 
potential to improve the efficiency of immunisation programmes by simplifying 
vaccine delivery and reducing the risk of handling errors.
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PHARMACOECONOMIC ANALySIS OF DIFFERENT ANTIvIRAL THERAPIES IN THE 
TREATMENT OF RUSSIAN PATIENTS wITH CHRONIC HEPATITIS C
Ryazhenov V.V., Sboyeva S.G., Emchenko I.V.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To assess the cost-effectiveness of pegylated interferons alfa-2a 
and alfa-2b combined with ribavirin in the treatment of Russian patients with 
chronic hepatitis C and identify potential budget impact considering the indica-
tor of rational drug use (IRDU). MethOds: The pharmacoeconomic model was 
developed based on the data from randomized controlled trial MIST (M. Rumi 
et al., 2010). The cost-effectiveness ratios (CERs) for different patient subgroups 
were expressed as costs of medicines per one patient with sustained virologic 
response. 24- and 48-week time frames were used for patients with genotypes 2/3 
and 1/4, respectively. To assess quantitatively the impact of pharmaceutical form 
and recommended dose regimens, the IRDU was used. One-way sensitivity analy-
ses (SAs) were performed to investigate the robustness of the cost-effectiveness 
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for both groups. One-to-one propensity score matching (PSM) was used to compare 
health care costs and utilizations during the follow-up period between the HCV 
and comparison groups, adjusting for baseline demographic and clinical charac-
teristics. Results: Eligible patients (N= 270,752) were identified for the HCV and 
comparison cohorts. After applying 1:1 PSM matching, a total of 107,953 patients 
were matched from each group and baseline characteristics were well-balanced. 
HCV patients were more likely to be hospitalized (15.90% vs. 3.19%, p< 0.01) and 
report more emergency room (20.36% vs. 8.17%, p< 0.01), physician office (99.18% 
vs. 61.06%, p< 0.01), outpatient (99.25% vs. 61.84%, p< 0.01) and pharmacy visits 
(91.11% vs. 63.13%, p< 0.01) which resulted in higher health care costs for inpatient 
($5,284 vs. $911, p< 0.01), emergency room ($237 vs.$76, p< 0.01), outpatient ($4,673 
vs. $1,760, p< 0.01), physician office ($4,247 vs. $1,560, p< 0.01), pharmacy ($889 vs. 
$460, p< 0.01) and total costs ($10,846 vs. $3,131, p< 0.01) for HCV patients relative 
to the comparison group. cOnclusiOns: Patients diagnosed with HCV were more 
likely to report higher health care utilization and were associated with a higher 
economic burden compared to the matched controls.
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vACCINE TIMELINESS: A COST ANALySIS OF THE IMPLICATIONS OF DELAyED 
vACCINATION
Curran D.1, Terlinden A.2, Poirrier J.E.1, Masseria C.3, Krishnarajah G.3
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2Navigha, Tervuren, Belgium, 3GlaxoSmithKline, 
Philadelphia, PA, USA
Objectives: : Pertussis (whooping cough) is a highly contagious bacterial disease. 
Infants in the first few months of life are particularly vulnerable with the highest 
reported rate of pertussis, risk of severe disease and deaths. Although, vaccina-
tion coverage rates have reached record-high levels in the United States (US), vac-
cine timeliness remains an issue. MethOds: Using data from the 2010 National 
Immunization Survey (NIS), we estimated the vaccination timeliness for DTaP vac-
cines in US infants. A previously published static model accounted for the reduction 
of incidence of pertussis by vaccination according to a strict adherence to the ACIP 
vaccination schedule. The annual numbers of pertussis cases prevented in infants 
and the associated costs avoided from a health care system perspective were esti-
mated. Results: From the NIS dataset, the mean age at DTaP vaccination was 
76.3, 147.4 and 223.9 days, which means that on average each vaccination was in 
average delayed by 16.3, 27.4 and 43.9 days (with delays accumulating over time), 
respectively. The model predicted 3052 pertussis cases annually in infants < 1 year 
of age in the US. Applying a strict adherence to the vaccination schedule, approxi-
mately 313 cases of pertussis, 112 hospitalisations and 1 death could be avoided 
each year. This translates into savings of 57 QALYs and $1.3 million of costs to the 
health care system. cOnclusiOns: Although previous publications have presented 
the number of cases avoided by timely vaccination, to our knowledge this is the 
first one to present the associated costs. Administering vaccines on time not only 
avoids cases but may also have a significant impact on quality of life and costs. 
These costs avoided may be redirected to developing tools and/or infrastructure to 
improve the vaccine timeliness of infants in future. Further research is needed to 
better understand the role of vaccination timeliness and completion.
PIN34
STUDy OF ANTIBIOTIC CONSUMPTION PATTERN IN HOSPITAL ACQUIRED 
PNEUMONIA
Kunhikatta V.1, Rau N.R.2, Naik A.N.1, Yamsani B.1, Thunga G.1, Nair S.1
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 2Kasturba 
Medical College, Manipal University, Manipal, India
Objectives: To analyse the antibiotic consumption pattern in hospital acquired 
pneumonia (HAP) patients in a tertiary care teaching hospital MethOds: A pro-
spective observational study, carried out in a tertiary care teaching hospital from 
January 2011 to December 2012. HAP patients who fulfill the inclusion criteria were 
identified and enrolled into the study after taking informed consent. Patients were 
followed from the day of diagnosis of HAP, till the day of discharge or death. Patient 
data like demography (age, sex), antimicrobial agents used (dose, duration of treat-
ment), length of hospital stay and clinical outcome were recorded in a predesigned 
data collection form. The cost of antimicrobial therapy was recorded from the day 
of admission till the day of discharge. Antibiotic consumption was calculated using 
defined daily dose (DDD) methodology. Results: Total 310 patients were included 
in the study. Among study population 229 (73.9%) patients were male and mean age 
was 55.9±18.4 (mean±SD). Out of 310 patients 218 were improved, 37 were worsened 
or discharged against medical advice and 55 were expired. Mean length of hospi-
talization was 9.45±6.75 (mean±SD) days. Total 27 antimicrobial agents were used 
for the treatment pneumonia among these patients. Among these antimicrobial 
agents, consumption (DDD/100 bed days) was highest for piperacillin-tazobactum 
(parenteral, 0.12) followed by ceftriaxone (parenteral, 0.10), azithromycin (oral, 0.10) 
and trimethoprim-sulphamethoxazole (oral, 0.08). The percentage of treatment suc-
cess was highest among patients treated with piperacillin-tazobactum+macrolide 
combination (10%) followed by cephalosopin+macrolide combination (8%). 
However the cost of treatment was high for piperacillin-tazobactum+macrolide 
regimen cOnclusiOns: This study provides estimate of quantities of differ-
ent antimicrobial agents used in the treatment of hospital acquired pneumonia. 
Piperacillin-tazobactum (parenteral) is highest consumed among 27 antimicrobial 
agents. Since percentage of treatment success is almost similar for piperacillin-
tazobactum+macrolide combination (10%) and cephalosopin+macrolide combina-
tion (8%), use of cephalosopin+macrolide combination should be encouraged in 
susceptible patients considering the lesser cost.
PIN35
COUNTING THE COST OF MENINGOCOCCAL DISEASE IN FRANCE
Faivre P.1, Bénard S.1, Wright C.2, Voisine J.3, Gaudelus J.4
1st[è]ve consultants, Oullins, France, 2Meningitis Research Foundation, Bristol, UK, 3Méningite 
France-Association Audrey, Ecouflant, France, 4Hôpital Jean Verdier, Bondy, France
drugs in the 1st and 2d line of therapy and routine follow-up costs were calculated 
based on prices of state procurements in the framework of national project of HIV 
prevention and the tariffs of the Russian health care system in 2012. One-way sen-
sitivity analysis was performed. Results: ABC/3TC+EFV is not associated with 
more costs vs ABC + 3TC + EFV regimen and even saves approximately 3390.60 rub 
(€ 80.30) per patient over 96 weeks of treatment. The sensitivity analysis showed that 
ABC/3TC FDC remains to be cost saving compared with ABC+3TC as long as the its 
package price is less than 6564.17 rub (€ 155.46) while keeping other model param-
eters unchanged. Still ABC/3TC+EFV is 28% more expensive than ZDV/3TC+EFV, 
though more effective and safe treatment option: the difference in costs vs 
ABC/3TC+EFV is 45267.05 rub. (€ 1,072.05) per patient over 96 weeks. cOnclusiOns: 
FDC ABC/3TC may be considered as a more efficient and convenient treatment 
option than its monocomponents combination for first-line antiretroviral therapy 
of HIV patients in Russia. FDC ABC/3TC is more expensive versus ZDV/3TC, but the 
difference in costs seems appropriate for more safe and convenient alternative.
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THE IMPACT OF CHLAMyDIA AND GONORRHOEA POINT OF CARE NUCLEIC 
ACID AMPLIFICATION TESTS ON CLINICAL PATHwAyS AND COSTS IN GENITO-
URINARy MEDICINE CLINICS IN THE UNITED KINGDOM
Adams E.J.1, Ehrlich A.1, Turner K.M.2, Shah K.1, Macleod J.2, Goldenberg S.3, Pearce V.4,  
Horner P.2
1Aquarius Population Health, London, UK, 2University of Bristol, Bristol, UK, 3Guy’s and St 
Thomas’ NHS Foundation Trust, London, UK, 4V. Pearce Consulting Ltd., Hove, UK
Objectives: To explore new patient pathways using a chlamydia/gonorrhoea point of 
care nucleic acid amplification test (POC NAAT), and estimate and compare the costs 
of the new pathways with the current pathways using standard laboratory-based 
NAAT testing in the UK. MethOds: Consensus building activities were conducted 
with four sexual health clinics in the UK. They were selected through purposeful 
sampling to reflect a wide range of service delivery. Current pathways in which a 
chlamydia/gonorrhoea test was used were mapped out, and then new pathways 
using a POC NAAT were constructed. The consensus pathways were then costed using 
a patient pathway model built in Excel, and the cost of the current and POC NAAT 
pathways compared. Results: Pathways using a POC NAAT for asymptomatic and 
symptomatic patients and chlamydia/gonorrhoea only tests were shorter and less 
expensive than most of the current pathways (average savings of £4-8 for sympto-
matic and asymptomatic screening pathways if the POC NAAT costs £18/test). Patients 
that are tested using the POC NAAT can be treated on the same day, thus saving costs 
compared to patients who are treated at a subsequent appointment. cOnclusiOns: 
A POC NAAT could be introduced to services and reduce current costs, and may mean 
more appropriate and quicker care for positive patients.
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COST ANALySIS OF vACCINATION FOR CHILDREN IN UKRAINE
Antonchak Z., Zalis’ka O., Horbachevska O.-H
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Objectives: In Ukraine immunization by age conducts against 10 infectious 
diseases: tuberculosis, hepatitis B (HBV), diphtheria, pertussis, tetanus, polio, 
Haemophilus influenzae, measles, rubella, mumps .The Law of Ukraine from 
21.10.2009 N 1658-VI approved the Program of immunization and protection against 
infectious diseases during 2009-2015.During the years 2011-2012 the media incor-
rectly submitted data on the results of vaccination and many parents refused vac-
cination and as a result there were about 12,000 cases of measles and rubella, it’s 
80 times more than in previous years. On State program of vaccination in 2010 
was allocated 237 mln UAH (1 USD= 7.99 UAH), in 2011 - 237 mln, in 2012 - 302 mln 
UAH. MethOds: We conducted a cost per 1,000 children aged 0 to 1 years. Direct 
costs were calculated for vaccine Pentaxim (Sanofi Pasteur) which combined vac-
cine against hepatitis B (ukrainian producer “Biolik”) and was compared the costs 
for vaccine Infanrix hexa (GSK). We included the vaccine costs, the loss during 
storage, and the costs of medical personnel for vaccination. We used the prices 
from the ukrainian electronic pricing database “MORION” on 01.06.2012. Analysis of 
evidence-based data has shown that Pentaxim is equal clinical efficacy of Infanrix 
hexa, but increases the rate of vaccination coverage against hepatitis B. Results: 
The costs for Pentaxim and HiB vaccine were 633 240 UAH and costs of medical 
personnel (pediatrics, nurses) were 36763 UAH. The costs using vaccine Infanrix 
hexa were 803880 UAH, the costs of medical personnel – 18 381 UAH, respec-
tively. cOnclusiOns: In 2012, 385 116 children vaccinated by Infanrix hexa and 
general costs were 118 307 590 UAH vs 363 000 children by Pentaxim were 95 830 
447 UAH. The results shown the need additional 22477143 UAH, which is justified 
to increase vaccination coverage against hepatitis B by 6%.
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ASSESSING THE ECONOMIC BURDEN AND HEALTH CARE UTILIzATIONS OF 
vETERAN PATIENTS DIAGNOSED wITH THE HEPATITIS C vIRUS IN THE UNITED 
STATES
Wang L.1, Xie L.2, Li L.1, Kariburyo M.F.2, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA
Objectives: To examine the economic burden and health care utilizations of the 
hepatitis C virus (HCV) in the U.S. veteran population. MethOds: A retrospec-
tive database analysis was performed using the Veterans Health Administration 
Medical SAS datasets 01OCT2008-30SEP2012). Patients diagnosed with HCV 
(International Classification of Disease 9th Revision Clinical Modification [ICD-
9-CM] codes 070.41, 070.44, 070.51, 070.54, v02.62) were identified, and the first 
diagnosis date served as the index date. A comparator group was created by iden-
tifying patients without HCV but with the same age, region, gender and index year, 
and matching them by baseline Charlson Comorbidity Index. The index date for 
the comparator group was randomly chosen to reduce selection bias. A 1-year 
continuous health plan enrollment period pre- and post-index date was required 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A347
Objectives: Among infectious diseases, tuberculosis is the second leading cause 
of mortality worldwide. Since 2000, Brazil is one of twenty two countries classified 
as “high burden countries” by World Health Organization. This study aims to report 
epidemiological and economic profile of tuberculosis related hospitalizations in 
Brazil. MethOds: Retrospective analysis of Brazilian public hospital admissions for 
tuberculosis was developed according to ICD-10 classification (A15-A19) as reported 
in Brazilian Hospital Information System (SIH/SUS) database, from January 2008 to 
December 2011. Epidemiological data were extracted from public reporting system. 
Costs represent federal reimbursement values for hospitalizations (medical pro-
cedures, exams, drugs and fees) estimated in 2013 Brazilian Real (BRL). Results: 
Reported tuberculosis cases and prevalence rates per 100,000 inhabitants for 2008, 
2009, 2010, and 2011 were: 85,329 (45.0); 88,800 (46.4); 86,654 (44.8); and 89,759 (46.0), 
respectively. Hospitalizations in the same period were 18,216, 15,338, 16,153, and 
19,048, leading to a hospitalization rates of 21.35%, 17.27%, 18.64%, and 21.22% with 
mean length of stay varying from 15 to 17 days. Mortality rates showed stabil-
ity, varying from 2.95% to 3.49% for overall tuberculosis related deaths, and 6.19% 
to 8.14% for in-hospital mortality. About 40% of all deaths were related to hos-
pitalized patients. From 2008 to 2011, hospitalizations costs were 19,546,160BRL, 
21,791,027BRL, 23,889,130BRL and 29,410,353BRL, respectively, with an increase in 
cost per patient over the years (1,073BRL in 2008 to 1,544BRL in 2011). Total cost for 
the period represents 3.5% of all hospitalizations costs related to infectious diseases 
(ICD-10 chapter I). Geographic distribution indicated southeast region accounting 
for 45% of cases, 38% of hospital admissions, and 47% of costs. cOnclusiOns: 
Tuberculosis is a major public health issue, with great impact on patients’ health and 
growing hospitalization related costs for the Brazilian health care system. Southern 
region concentrates most cases and costs, probably due to the presence of important 
treatment and diagnoses centers.
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USE OF ANTIBIOTICS AND PRESCRIPTION MEDICATION IN INFLUENzA DISEASE 
IN THE UNITED KINGDOM
Meier G.1, Pockett R.D.2, McEwan P.3, Watkins J.4, Humphreys I.2
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2Swansea University, Cardiff, UK, 3HEOR Ltd., 
Monmouth, UK, 4Public Health Wales and Cardiff University, Pontypool, UK
Objectives: Determine the use of antibiotics and prescription medication in pri-
mary care in the management of influenza, stratified by age, risk and complica-
tions. MethOds: A cross-sectional observational study was carried out using data 
derived from GPRD, (January 2001 - March 2009). Subjects included were: all those 
with general practitioner (GP) coded episodes of care for acute respiratory events 
related to infection (influenza and Influenza-like-illness). Analysis was stratified by 
age and ‘at-risk’ status recommended for influenza vaccination in the UK. Primary 
prescription information was collected for the following categories: antipyret-
ics/analgesics, antibiotics, amantadine, aminoglycosides, nasal decongestants, 
antisecretory drugs and mucosal protectants, and antihistamines. UK 2011 NHS 
reference costs were used. Results: A total of 53% of all patients had at least one 
medical prescription with 30% of patients receiving antibiotics. Proportionally more 
patients with complicated influenza had prescriptions (83%) compared to patients 
with uncomplicated influenza (50%), and most cases were unvaccinated. Across all 
age groups complicated influenza had a greater number of prescriptions compared 
to those with uncomplicated cases (3.0 vs. 2.5). 67% and 27% of complicated and 
uncomplicated influenza cases received antibiotics. Antipyretics and analgesics 
were prescribed to 7% of patients, with antisecretory drugs and mucosal protect-
ants prescribed to 6% of patients. Antibiotics, analgesics and antisecretory drugs 
(including mucosal protectants), were the three most commonly prescribed classes 
of drugs, and represent 41%, 31% and 12% of all prescriptions respectively. The 
annual cost is expected to be around £13,956,177 per annum with 40% of this cost 
attributable to antibiotics. cOnclusiOns: In-hospital and over-the-counter medi-
cation use is not collected in this database, therefore this is not a comprehensive 
assessment of the full extent of pharmaceutical management of influenza. The 
extensive use of antibiotics prescribed by GPs is of concern, especially in uncompli-
cated influenza episodes at a time of increasing resistance. Current clinical practice 
therefore needs urgent review.
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EvALUATING ECONOMIC BURDEN OF TICK-BORNE ENCEPHALITIS. EvIDENCE 
FROM RUSSIA
Avxentev N.1, Avxentyeva M.2, Platonov A.3, Kolyasnikova N.3, Gridneva K.3, Dolgin V.3, Titkov 
A.3, Derkach E.V.4
1New Economic School, Moscow, Russia, 2The Russian Presidential Academy of National Economy 
and Public Administration, Moscow, Russia, 3Central Research Institute of Epidemiology, 
Moscow, Russia, 4Autonomous Non-profit Organization “National Centre for Health Technology 
Assessment”, Moscow, Russia
About 3500 people have suffered tick-borne encephalitis (TBE) in 2011 in Russia, 
and approximately 16% of them had focal form with a high case-fatality and dis-
ability rate. However, no research has investigated its social costs. Objectives: to 
evaluate the socio-economic burden of TBE in Russia. MethOds: We proposed a 
probability-tree model accounting for 4 clinical outcomes of the disease: full recov-
ery, progression to chronic disease, disability, and death; probabilities were taken 
from Russian clinical and epidemiological studies. Each outcome was associated 
with particular costs that included direct current and deferred medical and social 
costs. Tariffs of the Russian health care system were used to calculate all medical 
costs; indirect costs were estimated using the average monetary daily productivity 
and mean disability allowance. All future costs were discounted to the basis year 
(2011). The model estimated the one-year average socio-economic burden of the 
disease which could be aggregated into the gross burden by incorporating data 
on annual TBE incidence in previous years. Additionally we evaluated disability 
adjusted life years (DALYs) attributable to TBE using standard WHO methodol-
ogy. Results: We found that economic TBE burden in Russia in 2011 was about 
$49.5 million, 78% of which was deferred costs, caused by death and disability. We 
Objectives: Invasive meningococcal disease (IMD) is life-threatening and can result 
in severe sequelae. In France, no data has been published on the costs of severe IMD 
cases. This study aimed to estimate lifelong management costs associated with severe 
cases of IMD in France. MethOds: Two scenarios were developed: a 6-year old child 
with purpura fulminans resulting in amputation of both legs below the knee and a 
3-year old with meningitis and severe neurological sequelae. Additional scenarios 
included other typical sequelae of IMD: chronic renal insufficiency (CRI), profound 
deafness, epilepsy. Scenarios were validated by national experts of IMD. Health, dis-
ability, educational and other resources were obtained from experts and families of 
patients with similar sequelae. Unit costs (2013) were obtained from the literature, 
the National Health Insurance (NHI) and companies’ websites. Time horizon was 
based on life expectancies of patients (77 and 55-years respectively). A 4% discount 
rate decreasing to 2% after 30-years was applied. Costs are presented from NHI, pub-
lic funded organisations and patient or his/her private health insurance perspec-
tives. Results: Purpura fulminanswith amputations is associated with a lifelong 
discounted cost of € 768,874. Adding CRI doubles the amount (€ 1,480,545). Meningitis 
with severe neurological sequelae results in a lifelong discounted cost of € 1,924,475. 
Adding profound deafness and epilepsy slightly increases the total cost (€ 2,267,251). 
The first year is the most expensive in both scenarios (€ 166,890 and € 160,647 respec-
tively). The main cost drivers are respectively for each scenario prostheses and child/
adult stay in institutions. Overall, NHI covers 1/2 of total cost, public funded organi-
sations 1/3 and patient/private health insurance for the remainder. cOnclusiOns: 
This study fills a gap in the body of knowledge on IMD sequalae care and costs in 
France. The potentially high economic burden of IMD, in addition to its physical, 
psychological and social burden, reinforces the need for prevention.
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HOw MUCH DENGUE COSTS TO BRAzIL? A RETROSPECTIvE ADMINISTRATIvE 
CLAIMS ANALySIS FROM THE PUBLIC PAyER PERSPECTIvE
Silva M.A, Fernandes R.A., Takemoto M., Haas L.C., Amaral L.M., Vasconcellos J.F., Menezes L.P.
ANOVA, Rio de Janeiro, Brazil
Objectives: In the 21st century, Brazil became the country with the most reported 
cases of dengue fever. This study aims to describe hospital costs for managing 
dengue in the Brazilian Public Healthcare System (BPHS). MethOds: BPHS Hospital 
Information Database (SIH/SUS) was used to collect data for the period of 2008-
2011. Individual claims coded as “Classic Dengue (CD) Treatment” or “Dengue 
Hemorrhagic Fever (DHF) Treatment” in the SIH/SUS (regardless ICD-10 codes) 
were identified in this system and compiled by geographic region, disease type and 
year. Results: A total of 304,548 individual dengue claims were obtained for the 
2008-2011 period. They represented an overall cost of 97,642,495BRL for all 4 years 
(ranging from 17,843,318BRL in 2009 to 31,235,501BRL in 2010). The 4-year national 
average cost per inpatient admission was 321BRL (295BRL [2008] - 333 BRL [2010]), 
with mean length of stay (LOS) of 3.3 days and in-hospital mortality rate of 0.46%. 
The northeast region represented 43.1% of overall expenditures, while the south 
accounted for only 1.6%. The hemorrhagic syndrome was responsible for 10%, 7% 
and 10% of overall cost, individual dengue claims and total hospitalization days, 
respectively. Mean cost per inpatient admission for DHF was 50.6% higher than CD’s 
(468BRL vs. 316 BRL), mean LOS was 55.2% higher (5.0 vs. 3.2 days) and in- hospital 
mortality rate was 997.8% higher than the one from CD (3.0% vs. 0.27%). Stratifying 
by region, 9.6%, 36.6%, 34.7%, 1.7% and 17.4% of DHF costs were respectively local-
ized on the North, Northeast, Southeast, South and Midwest. cOnclusiOns: The 
analysis of SIH/SUS administrative information provided insightful information 
about dengue costs. Although DHF represented only 7% of individual claims, its 
mean cost per inpatient admission and in-hospital mortality rate was considerably 
higher than CD’s, persisting as an object of concern for health authorities.
PIN37
BURDEN OF HERPES zOSTER AND POST-HERPETIC NEURALGIA IN SwEDEN
Nilsson J.1, Cassel T.2, Lindquist L.3
1OptumInsight, Stockholm, Sweden, 2Sanofi Pasteur MSD Sweden, Solna, Sweden, 3Karolinska 
Institute, Solna, Sweden
Objectives: Herpes zoster (HZ) and post-herpetic neuralgia (PHN), one of its more 
severe and frequent complication, are very painful and debilitating conditions. The 
societal economic burden of HZ in Sweden is not well described today. The objec-
tive of this study is to describe the burden of HZ and PHN in Sweden in the year 
2011. MethOds: Data for inpatient care, outpatient primary care, the prescriptions 
of drugs, sick leave and the number or diagnostic tests were collected from national 
databases. The incidence of the HZ was estimated based on the number of prescrip-
tions of antiviral drugs, on which a correcting factor has been applied. Results: 
Almost 30,000 patients were diagnosed with HZ, with two third occurring in patients 
older than 50 years. The societal cost to treat these patients, including the cost to treat 
those patients who later developed PHN, added up to nearly 227 MSEK (21M€ ) which 
corresponds to 7,600 SEK per patient (876€ ). The main contributors to the total cost for 
the treatment of HZ patients were primary care (43%); sick leave (28%); hospitalization 
(10%) and specialist care (7%). Medication was a relatively small contributor with 8.5 
MSEK (4%) to the overall costs for patients at all ages. cOnclusiOns: The current 
study demonstrates that the burden of HZ is significant in Sweden, especially in 
people aged 50 years and older. This economic burden is expected to increase in the 
coming years since the population older than 50 years represents a growing propor-
tion of the population. Thus, the society and the health care payers potentially have 
a lot to gain by introducing a vaccination program to patients aged 50 years and older, 
to reduce the burden and increase their quality-of-life.
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HOSPITAL ADMISSIONS RELATED TO TUBERCULOSIS IN BRAzIL: 
EPIDEMIOLOGICAL AND ECONOMIC PROFILE, FROM THE PUBLIC HEALTH CARE 
PERSPECTIvE
Amaral L.M., Fernandes R.A., Takemoto M., Vasconcellos J.F., Haas L.C., Silva M.A., Menezes L.P.
ANOVA, Rio de Janeiro, Brazil
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Results based on a large and representative patient sample demonstrate that the cost 
of seasonal influenza episodes is substantial, especially when complications occur. 
Costs in children may be higher of what is actually reported.
PIN44
THE COST OF CLOSTRIDIUM DIFFICILE INFECTION IN HUNGARy
Strbak B.1, Gulacsi L.1, Kertesz A.2, Kopcsone Nemeth I.3, Baji P.1, Pentek M.1, Brodszky V.1
1Corvinus University of Budapest, Budapest, Hungary, 2United Szent Istvan and Szent Laszlo 
Hospital, Budapest, Hungary, 3Hungarian Defence Forces Military Hospital, Budapest, Hungary
Objectives: Clostridium difficile is the leading cause of antibiotic associated infec-
tious nosocomial diarrhoea. C. difficile infection is a high-priority problem of public 
health in each country. The available literature of C. difficile infection’s disease bur-
den is limited. The authors aimed to identify the most important cost elements and 
quantify the cost of C. difficile infection in Hungary. MethOds: A retrospective chart 
review and experts interviews were done in a sample of 151 patients with C. difficile 
infection in 2011 in two Hungarian hospitals. In the chart review data on demographic, 
disease severity, therapy, the standard precautions and the infection related contact 
precautions were collected. Cost analysis was done from the service provider’s per-
spective. Results: In department of medicine the annual average cost of C. difficile 
infection was € 800 per patient, the annual total cost of a recurrent patient was € 1810, 
the annual additional cost of contact precautions was € 330 per patient, the annual 
average cost of an episode was € 570, the additional cost of contact precautions was 
€ 235 per episode. In intensive care unit the annual average cost of C. difficile infec-
tion was € 1810 per patient, the annual total cost of a recurrent patient was € 3680, 
the annual additional cost of contact precautions was € 470 per patient, the annual 
average cost of an episode was € 1070, the additional cost of contact precautions 
was € 330 per episode. The most notable cost elements in intensive care unit were 
the hygienic costs and nurse wages, in department of medicine were the hygenic 
costs. cOnclusiOns: The importance of C. difficile infection in public health and 
the associated disease burden are significant. The costs differed based on the length 
of isolation, and the type of the provider department. The available data in Hungary 
are limited, further studies in epidemiology and health economics are required.
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DyNAMIC MODELING TO ESTIMATE THE ECONOMIC IMPACT OF INCREASING 
INFLUENzA vACCINATION IN THE UNITED STATES
Inocencio T.J., Hughes K.E.
Avalere Health LLC, Washington, DC, USA
Objectives: This analysis was conducted to demonstrate potential downstream 
health care cost savings as a result of increasing vaccination rates for influenza 
in the United States. MethOds: An age-structured susceptible-exposed-infec-
tious-recovered (SEIR) compartmental model was constructed to model the course 
of influenza infection over the course of 1 year in the United States. A realistic 
age structure was incorporated using mixing rates between age groups from the 
European POLYMOD survey. The SEIR model was adapted to include another com-
partment for vaccination. A series of difference equations was used to model 
transitions to and from each compartment. Time-dependent vaccination rates 
were obtained using monthly estimates of vaccination rates obtained from the 
Centers for Disease Control and Prevention (CDC). Cost and health care utilization 
data were obtained from the existing literature, and included outpatient visits, 
hospitalization, and antiviral drug treatment. Costs were reported in 2013 U.S. 
dollars. Microsoft Excel 2011 was used to conduct the analysis. Results: Under 
a base case vaccination rate of 40 percent, an estimated 11 percent of individu-
als in the United States were projected to have symptoms of influenza infection. 
Health care costs attributable to influenza infection were estimated to be $13.6 
billion. Increasing vaccination rates to 50 percent decreased the percentage of 
symptomatic individuals to approximately 7 percent, resulting in downstream 
health care costs of $9.5 billion. Further increasing vaccination rates to 60 percent 
is projected to further reduce downstream health care costs to approximately $5.0 
billion. cOnclusiOns: This exploratory analysis demonstrates that significant 
health care cost savings can be realized by increasing vaccination rates for influ-
enza in the population.
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THE ASSOCIATION BETwEEN ADHERENCE TO ANTIRETROvIRAL THERAPy AND 
ECONOMIC OUTCOMES AMONG COMMERCIALLy INSURED AND MEDICAID HIv 
PATIENTS IN THE UNITED STATES
Korsnes J.S.1, Goodwin B.2, Candrilli S.D.1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmith Kline, Research Triangle 
Park, NC, USA
Objectives: Achieving optimal outcomes in the treatment of HIV requires high, 
sustained levels of medication adherence to antiretroviral therapy (ART). Across many 
conditions, suboptimal adherence has been shown to lead to poorer outcomes among 
patients. This study assessed the extent to which patients diagnosed with HIV are 
adherent with ART treatment guidelines and to illustrate associations between ART 
adherence and economic outcomes. MethOds: Commercially insured and Medicaid 
patients in the US from MarketScan claims databases with ≥ 2 claims containing an 
HIV/AIDS diagnosis code between June 1, 2006 and December 31, 2011 who received 
an ART prescription between June 1, 2007 and December 31, 2010 were selected for 
initial inclusion. For each patient, the first ART prescription received during that time 
defined the index date. Patients were ≥ 18 years old on their index date and had ≥ 12 
months of continuous health plan enrollment with drug benefits before and after 
their index date. Adherence was measured by patients’ proportion of days covered 
(PDC) with a complete ART regimen during the 12-month post-index date period; 
patients with PDC ≥ 80% were considered adherent. Multivariable models (i.e., general-
ized linear; Poisson) assessed the relationship between ART adherence and economic 
outcomes (i.e., costs; number of health care encounters), controlling for demographic 
and clinical characteristics. Results: A total of14,590 commercially insured patients 
met all inclusion criteria, and 59% were adherent; 5,744 Medicaid patients met all 
estimate total 4177 DALYs caused by TBE in 2011. cOnclusiOns: TBE burden is 
quite large in Russia, thus economic evaluation of preventive measures is essential 
in order to choose the most cost-effective options.
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HEALTH CARE COSTS ASSOCIATED wITH CHRONIC HEPATITIS C INFECTION  
IN EUROPE
Lingohr-Smith M., Lin G.
Novosys Health, Flemington, NJ, USA
Objectives: Chronic hepatitis C virus (HCV) infection is estimated to effect 
approximately 15 million persons in Europe. It is a prevalent cause of progres-
sive liver disease including cirrhosis and hepatocellular carcinoma (HCC) and 
nearly 90,000 deaths that occur annually in the European region are related to 
HCV infection. The objective of this study was to evaluate the direct health care 
costs of HCV infection in countries of the European Union. MethOds: ENTREZ 
PUBMED was searched systematically for studies published between 2008 and 2013 
that evaluated the health care costs of persons with HCV infection in countries 
of the European Union. Of the 110 studies identified only 3 contained overall 
health care costs. Cost data was extracted, inflation adjusted to 2013 costs and 
averaged. Results: Based on the included studies, the average annual health 
care cost for a person with chronic HCV infection is € 2,756 with mild disease, 
€ 6,258 with cirrhosis, and € 11,437 with HCC. An HCV-related liver transplanta-
tion is estimated to have an average cost of € 68,497. The reported annual health 
care costs of patients with chronic HCV infection vary widely, with annual costs 
ranging between € 340 and € 6,773 among those categorized as having chronic 
infection and/or mild disease and between € 34,834 and € 124,594 among those who 
have had a liver transplantation. cOnclusiOns: The majority of recent studies 
have investigated antiviral drug treatment costs; few have examined the overall 
health care costs associated with chronic HCV infection in Europe. Based upon the 
data available, chronic HCV infection is associated with a substantial health care 
burden even among those categorized as having mild disease. Further research is 
needed to better understand the costs of HCV infection to enable more relevant 
screening and treatment strategies, especially among those at high risk for devel-
oping severe liver disease.
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PERTUSSIS IN BRAzILIAN CHILDREN: MORTALITy, LENGTH OF STAy, AND 
COSTS IN HOSPITALIzED PATIENTS
Fernandes R.A., Haas L.C., Takemoto M., Silva M.A., Vasconcellos J.F., Amaral L.M., Menezes L.P.
ANOVA, Rio de Janeiro, Brazil
Objectives: Bordetella pertussisinfection is highly contagious and can progress 
to severe conditions, especially among young children and elderly. This study aims 
to describe hospitalization patterns and costs for pertussis in children in public 
hospitals in Brazil, from 2008 to 2011. MethOds: A retrospective analysis of Brazil 
public hospital admissions for pertussis was developed according to ICD-10 classi-
fication (A37: Pertussis) in children (aged ≤ 9 years), as reported in Brazilian Hospital 
Information System (SIH/DATASUS) database from January 2008 to December 2011. 
Costs represents federal reimbursement values for hospitalizations (includes medi-
cal procedures, exams, medications and taxes), presented in 2013 Brazilian Real 
(BRL). Results: A total of 3055 hospital admissions for pertussis during the four-
year period were identified. There was a downward trend in the first three years 
of the analysis, while the opposite occurred in the fourth year, with 2011 having 
the highest number of cases (907, 655, 394 and 1,099 for 2008, 2009, 2010, and 2011, 
respectively). Infants were the most affected, with those less than one year of age 
accounting for 91% (n = 2,779) of all pertussis admissions in the age group analyzed. 
In-hospital mortality rate was 13.9% for all cause in the period. Mean length of stay 
was 7.56 days. Total cost for the period was 3,754,877 BRL, which represents 94.9% 
of pertussis hospitalization costs for all ages (3,958,133 BRL). Mean cost per patient 
was 1,229 BRL. cOnclusiOns: The costs with pertussis hospitalizations in children 
can be substantial in Brazil, from the public health care perspective. Despite the 
existence of a National Immunization Program, the number of cases in children 
remains high. It is therefore important that decision makers reassess the prevention 
and treatment patterns of this disease.
PIN43
COST OF INFLUENzA IN GERMANy
Anastassopoulou A.1, Wahle K.2, Hain J.1, Schroeder C.3, Ehlken B.3
1GlaxoSmithKline GmbH & Co, Munich, Germany, 2University of Muenster, Muenster, Germany, 
3IMS Health, Munich, Germany
Objectives: To evaluate cost of children and adults diagnosed with seasonal 
influenza in Germany, filling a data gap of more than a decade. MethOds: This 
cost-of-illness study was conducted from payer and societal perspective based on 
a retrospective database analysis by using a longitudinal electronic medical records 
database (IMS® Disease Analyzer). Patients with influenza episodes (ICD-10 diagnosis 
J09-11) being observable 12 months before index date and 1 month afterwards were 
included. The selection window was May 2010 to April 2012 to cover two influenza sea-
sons. Published unit costs and tariffs for Germany in 2012 were used. Results: A total 
of 23,068 influenza episodes (19,446 patients) managed by primary care practitioners 
(PCP) and 7,295 episodes (5,988 patients) managed by pediatricians were eligible for 
analysis. Mean age of patients with at least one episode was 43 years (SD 20) in the PCP 
panel and 7 years (SD 4) in the pediatrician panel. Total average mean cost (SD) from 
societal perspective in adult patients was € 471 (576) and in children € 99 (140)/episode. 
In about 11% of the adult patients the total cost exceeds € 1,000/episode. This is primar-
ily due to the higher percentage of patients with complications (63%) compared to the 
entire PCP study cohort (38%). Workdays lost were the main cost driver (82%) in adult 
patients; more than 40% of patients missed between 2 and 6 days of work/episode. 
In children, the main cost driver was physician visits (66%). Complications increase 
the cost by three fold in children and two fold in adults (average mean cost (SD) for 
children: € 137 (144) vs. € 49 (33) and adults: € 622 (670) vs. € 377 (485)). cOnclusiOns: 
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transformed to common logarithms. Costs are stated in € (1€ = 25.5CZK). Results: 
A total 100 patients (about 10-15% of all HIV treated in the Czech Republic) were 
included. The mean age was 41.9 years (range 23-71), time since diagnosis 5.8 years 
(range 1-26), and period of assessment 30.5 months. Average total annual costs were 
highest for CD4+ <200 (22,905€ ; p<0.05) vs. CD4+ 200-499 (17,801€ ) and CD4+ >500 
(17,043€ ). HIV medication accounted for the majority of costs in all three subgroups 
(range 62% in CD4+ <200 to 88% in CD4+ >500). Patients with a disease duration of 
>10 years had highest annual costs of 22,841€ (p<0.05) compared to 15,783€ (dura-
tion 5-10 years) and 16,777€ (<5 years). HIV-medication accounted for the majority 
of costs here as well (from 70% to 88%; NS). In this analysis 17 % of costs in patients 
with disease duration of >10 years were due to hospitalization vs. 5 % in both other 
groups (NS). cOnclusiOns: Similarly to published literature, we found highest 
costs in patients with low CD4+ lymphocytes and longer disease duration.
PIN50
THE BURDEN OF CLOSTRIDIUM DIFFICILE IN SPAIN: A RETROSPECTIvE 
MATCHED-COHORT STUDy
Hart W.M.1, Asensio A.2, Isidoro B.2, Watt M.3, Nazir J.3
1EcoStat Consulting UK Ltd., London, UK, 2Hospital Universitario Puerta de Hierro, Madrid, Spain, 
3Astellas Pharma Europe Ltd., Chertsey, UK
Objectives: Clostridium difficileinfection (CDI) is the leading cause of infectious 
diarrhoea in hospitalised patients. The majority of published burden of CDI stud-
ies refer to US or northern European populations. Knowledge of the burden of CDI 
on health care resource utilisation in Spain is limited. The aim of the study was to 
provide recent data on the burden of CDI in terms of hospital resources and costs 
and in particular attributable length of stay. MethOds: A retrospective study was 
carried at a leading teaching hospital in Madrid. Data refer to sequential cases of 
CDI during the year 2011. Data were extracted from patient records using a prede-
fined structured protocol. Hospital onset CDI cases were matched at a ratio of two 
non-infected patients for each case to adjust for confounding variables. Results: 
A total of 44 CDI cases were identified of whom 25 were health care-associated 
and hospital-onset. The mean duration of diarrhoea (days) was 10.12+7.98. Using 
median regression, the attributable length of stay (LOS) due to CDI was 9.98+2.21 
days. The average number of isolation days was 9.21+8.27. The majority of patients 
were treated with oral metronidazole. The first episode cure rate was 83.7%, 30-day 
and overall mortality were 18.6 and 25.6% respectively, attributable mortality was 
4.65%. A total of 9.3% of patients experienced a recurrence occurring within 2-8 
weeks within hospital stay. The cost attributable to an individual case of CDI would 
be 4,331 euros, of which over 90% is associated with hospital LOS. cOnclusiOns: 
Our results highlight the significant burden of CDI in a large Spanish hospital. These 
costs will only continue to rise as the incidence of CDI continues to increase. A major 
breakthrough in cost reduction of CDI would be an intervention or procedure that 
shortens hospital length of stay and/or reduces episode recurrence.
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COST AND LENGTH OF STAy ASSOCIATED wITH vANCOMyCIN-INDUCED 
NEPHROTOxICITy
Stevens V.1, Yoo M.1, Brown J.2
1University of Utah, Salt lake City, UT, USA, 2SUNY Buffalo School of Pharmacy, Buffalo, NY, USA
Objectives: Decreased susceptibility to vancomycin has led to recommendations for 
increased serum concentration targets for some infections, which has been shown 
to increase the risk of nephrotoxicity (NT). The objective of this study was to deter-
mine if vancomycin-induced nephrotoxicity has a significant impact on cost from the 
hospital perspective or on length of stay. MethOds: A cost of illness study from the 
hospital perspective. We conducted a secondary analysis of a cohort of 398 randomly 
selected inpatients receiving vancomycin in a tertiary care hospital in Rochester, New 
York, USA. Total and variable costs were generated by hospital accountants using 
micro-costing methods. NT was defined as 0.5 or 50% or greater increase in serum 
creatinine from baseline. Generalized linear models with log link and gamma distribu-
tion and semi-log regression were used to model total and variable costs and length 
of stay, respectively. Cost estimates are reported in 2009 USD. Results: Forty-nine 
(12%) of patients had NT. The unadjusted median variable costs for patients with NT 
were higher than for patients without NT ($47,511 vs. $22,355, p< .0001). On multi-
variable analysis, variable costs were 18% greater for patients with NT compared to 
patients without, but this difference was not statistically significant. The median 
length of stay for patients with NT was two-fold greater than for patients without 
NT (22 vs. 11 days, unadjusted, p< .0001). After accounting for severity of illness 
and other factors, NT patients stayed on average 46% longer than non-nephrotoxic 
patients. cOnclusiOns: Patients with NT have significantly increased length of 
stay relative to patients without NT. Further research is needed to confirm whether 
increased length of stay has a meaningful impact on costs. As vancomycin suscep-
tibility continues to decrease, higher doses of vancomycin may lead to an increased 
incidence of NT and an increase in resource utilization among these patients.
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COST ASSOCIATED wITH ADvERSE EvENTS AND HEALTH CARE RESOURCES 
UTILIzATION IN HEPATITIS C vIRUS INFECTION IN QUEBEC, CANADA
Lachaine J.1, Vachon M.L.2, Lambert-Obry V.1, Beauchemin C.1
1University of Montreal, Montreal, QC, Canada, 2CHUQ, Laval University, Quebec, QC, Canada
Objectives: The purpose of this study was to estimate the health care resource uti-
lization, more specifically resource utilization for management of the most common 
adverse events (AE) associated with current treatment of hepatitis C virus (HCV) infec-
tion, in a real life setting. MethOds: A retrospective study of the Quebec provincial 
drug reimbursement program (RAMQ) was conducted using a random sample of 
patients who filed at least one script for an HCV medication (pegylated-interferon and 
ribavirin (Peg-Riba) +/-boceprevir or telaprevir) between January 2007 and December 
2012. Data on medical (excluding nurse visits) and pharmaceutical services were 
extracted from the RAMQ database. We report health care resources used during 
HCV treatment including outpatient physician’s visits and procedures, emergency 
inclusion criteria, and 42% were adherent. After adjusting for confounders, ART adher-
ence was associated with 29% and 31% reductions in non-pharmacy costs (p< 0.0001)), 
67% and 80% increases in total pharmacy costs (p< 0.0001), 43% and 49% reductions 
in hospitalizations (p< 0.0001), and 41% and 26% reductions in emergency depart-
ment visits (p< 0.0001), among commercially insured and Medicaid patients, respec-
tively. cOnclusiOns: This study suggests that ART adherence among commercially 
insured and Medicaid HIV patients in the US may be suboptimal, and that adherence 
is associated with improved economic outcomes among these patients.
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A SySTEMATIC REvIEw OF ECONOMIC EvIDENCE IN HEPATITIS C: AN 
OvERvIEw OF COST, UTILITy AND COST-EFFECTIvENESS DATA
Woods M.S.1, Kiri S.2, Ling C.1, McCrink L.1, Zimovetz E.1, Hass B.3
1RTI Health Solutions, Manchester, UK, 2Boehringer Ingelheim Ltd., Bracknell, UK, 3Boehringer 
Ingelheim GmbH, Ingelheim, Germany
Objectives: To perform a systematic literature review of economic evidence for 
genotype 1 hepatitis C virus (HCV) treatments. MethOds: Searches were per-
formed in MEDLINE, MEDLINE In-Process, EconLit, Embase, BIOSIS, and the Cochrane 
Library, to identify economic evaluations, cost/resource studies, and utility studies 
in patients with genotype 1 HCV. Searches were limited to articles published since 
2000. Additional searches were performed on the ISPOR conference and key Health 
Technology Assessment (HTA) websites. Results: The review identified 53 economic 
evaluations, 17 HTA documents, 57 cost/resource use studies, and 19 utility stud-
ies. The majority of economic evaluations were in interferon-containing regimens 
and were performed using lifetime horizon Markov models. Incremental cost-effec-
tiveness ratios ranged from $4,570.31 to $157,404.13, depending on patient severity, 
the treatment used and the duration of treatment. Boceprevir and telaprevir triple 
therapies were shown to be cost-effective compared with peginterferon and ribavirin 
alone. In the cost studies, total all-cause, annual costs for patients with HCV ranged 
from $3,236 to $85,081, depending on the patients’ disease status and whether they 
were currently receiving treatment. Indirect costs for HCV patients were reported less 
frequently, but they ranged from $1,424 to $10,316 per patient per year. Utilities for 
patients with HCV ranged from 0.24 for patients experiencing severe adverse events 
to 0.89 for patients in sustained virological response. Recent economic models tended 
to use utility data taken from previous models or HTA submissions. cOnclusiOns: 
Numerous recent cost-effectiveness studies are available for HCV; however, many 
of the economic evaluations are based on previous models. There is a particular 
scarcity of updated country-specific utility data. As more treatment options become 
available, and more robust models are developed, enhanced utility and cost studies 
may be needed.
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RECENT TRENDS IN HOSPITAL COSTS, LENGTH OF STAy, AND MORTALITy 
ASSOCIATED wITH PEDIATRIC MENINGOCOCCAL DISEASE IN THE UNITED 
STATES
Davis K.L., Candrilli S.D.
RTI Health Solutions, Research Triangle Park, NC, USA
Objectives: Meningococcal disease (MD) is a rare, life-threatening infection most 
common in infants (age < 1 year), adolescents, and persons living in close quar-
ters. In this study, we documented trends in hospital costs, length of stay (LOS), 
and mortality associated with pediatric MD cases in the United States (US) from 
2000 to 2009. MethOds: Data for pediatric (age ≤ 20 years) MD-related hospitaliza-
tions (discharges with ICD-9-CM 036.xx) from the 2000, 2003, 2006, and 2009 HCUP 
Kids’ Inpatient Databases (KID) were retrospectively analyzed. Charges were con-
verted to costs using a 0.5 cost-to-charge ratio. Weighted, nationally representa-
tive estimates of costs per admission (in 2012 US dollars), LOS, and case fatality 
rates were descriptively analyzed for each year. Results: By year, total (weighted) 
numbers of pediatric MD-related hospitalizations in the US were: 2000 (N= 1,680), 
2003 (N= 1,089), 2006 (N= 745), 2009 (N= 581). Mean [SD] LOS for these hospitaliza-
tions was 8.4 [12.9] days in 2000, which decreased modestly to 7.7 [9.6] and 7.9 
[8.3] days in 2003 and 2006, respectively, before a substantial increase to 9.3 [13.9] 
days in 2009. Mean [SD] cost per admission fluctuated accordingly, increasing from 
$25,739 [$60,929] in 2000 to $33,530 [$62,499] in 2009. Case fatality rates, however, 
remained relatively unchanged during the period, declining slightly from 4.7% in 
2000 to 4.3% in 2009, although a noticeable spike occurred in 2003 when 5.8% of 
cases died. cOnclusiOns: MD in the US pediatric population is associated with 
high costs resulting from hospital stays that typical exceed 1 week. Our estimated 
case fatality rate (~5%), while high, is lower than the 10-15% fatality rate estimated 
by the US Centers for Disease Control, which includes estimates from all age groups 
combined (pediatrics and adults). In light of these findings, recent efforts to raise 
awareness of MD as a serious public health concern should be continued.
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HEALTH CARE COSTS OF HIv IN THE CzECH REPUBLIC. A SINGLE CENTER 
ANALySIS
Skoupa J.1, Snopkova S.2, Dvorak P.3, Pospisil J.4
11st Medical Faculty, Charles University, Prague, Czech Republic, 2Faculty Hospital and Masaryk 
University, Brno, Czech Republic, 3EconHealth s.r.o., Prague, Czech Republic, 4Faculty Hospital, 
Brno, Czech Republic
Objectives: To assess direct medical costs of HIV patients, based on CD4+ lym-
phocyte count and duration since diagnosis in the Czech setting. MethOds: We 
analyzed retrospectively costs of HIV patients in a single center. The analyzed sam-
ple included patients with a disease history of 12 month and longer, who regularly 
visited the center. Resource use, derived from the hospital information system, 
included services delivered at the HIV center and other hospital wards. The ret-
rospective period covered up to 36 months; average annual costs were calculated. 
Resource use was analyzed separately for (a) groups of CD4+ count (<200; 200-499; 
≥ 500); (b) time since diagnosis (<5 years; 5-10 years; >10 years). For comparison, 
two-sided Student’s t-test was used; to achieve normal distribution, values were 
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Objectives: Most industrialized countries strive to guarantee long term sustainabil-
ity for HIV antiretroviral treatment . By assessing the most relevant current predictors 
of costs of antiretrovirals(HAART) might represent the first step to understand spend-
ing drivers and to plan cost reduction strategies. MethOds: A retrospective sample 
of HIV outpatients followed at 5 Italian Hospitals in 2012 was collected. Demographic 
features, current HIV viral load, current and Nadir CD4 T-celI counts, time from HIV 
diagnosis, AIDS-defining events, HAART line and HCV coinfection were taken into 
consideration. Individual ARV regimen-costs were based on local pharmacy data-
sets from December, 2011, and log-transformed in the final multivariate models. 
Univariate analyses were performed to identify potential predictors and stepwise 
multivariate regressions were used to identify independent predictors of higher indi-
vidual costs, using Stata 10.1 package. Results: We included 2044 patients, 69.0% 
males, mean age 47.2±10.0 years; 33.4% HCV-coinfected, mean time from HIV diag-
nosis 13.3±7.9 years, mean nadir CD4 T cell counts 239±169.3 cell/mm3; mean current 
CD4T-cell counts 590±302.6 cell/mm3, 30.8% AIDS classified. Patients on HAART were 
1,902 (93.0%),among treated patients, 19.0% presented an HIV-viremia> 50 c/mL. Mean 
annual individual HAART-costs were € 9,376±3,501 (782-29,852). At univariate analysis, 
a significant association was found between costs and age time from HIV diagno-
sis, previous AIDS diagnosis, HCV-coinfection current and Nadir CD4T-cell counts, 
HAART-line, HIV-viremia and site of care. In the final regression model, HAART costs 
showed independent and direct correlation with HAART lines (p< 0.001), detectable 
viremia (p< 0.001) and time from HIV diagnosis (p= 0.009); inverse correlation with 
Nadir CD4 T-cell counts (p= 0.01). Being treated at 2 of 5 centre was another predictor of 
higher costs.(P< 0.001). cOnclusiOns: Higher HAART-costs were strongly associated 
with previous treatment failures and detectable HIV-viremia; a more compromised 
immune status at clinical presentation and a longer duration of HIV infection showed 
independent contribution, focusing on timely diagnosis of HIV infection.
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ECONOMIC IMPLICATIONS OF ALTERNATIvE TREATMENTS AND CARE 
LOCATIONS FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS 
wITH SUSPECTED MRSA
LaPensee K.1, Fan W.1, Revankar N.2, Ward A.3, Kongnakorn T.3, Pelligra C.3
1The Medicines Company, Parsippany, NJ, USA, 2Evidera, London, UK, 3Evidera, Lexington, MA, 
USA
Objectives: Develop model simulating economic implications of alternative treat-
ment strategies for acute bacterial skin and skin structure infections (ABSSSIs) 
with suspected Methicillin-Resistant Staphylococcus aureus (MRSA) that consid-
ers antibiotic switches, course duration, route of administration and location of 
care (LOC). MethOds: Discrete event simulation (DES) tracks patient pathways 
through various LOC (ED, inpatient, outpatient) during ABSSSI treatment for sus-
pected MRSA. Model assumes 60% of patients hospitalized. Multiple pathways are 
allowed: patients responding can move to outpatient to finish treatment, switch 
treatment at discharge or receive 2nd line treatment if not responding. Patients 
accrue resource use, time in LOC and costs. Hospital days obtained from analysis 
of Premier Hospital Database. Three cohorts created; all assigned to receive van-
comycin (VAN) 1st line therapy. Upon discharge, one cohort continued on VAN, one 
switched to oral linezolid (LIN), one to daptomycin (DAP) to complete treatment. 
Costs are from the Medicare perspective in 2012 USD. Results: Hospital plus out-
patient days range from 11.1 (VAN) to 14.5 (LIN); costs ranged from $6,983 (LIN) 
to $8,122 (VAN) with suspected MRSA. By comparison, reatment duration ranged 
from 9.97 (VAN) to 13.02 (LIN) and total costs ranged from $6,889 (LIN) to $9,354 
(VAN) when MRSA is not always suspected. Despite longer LIN treatment, costs are 
lower because of avoided infusion costs. Outpatient costs account for 22% (LIN) to 
33% (VAN) of total costs. Sensitivity analysis examined impact on cost when treat-
ment duration varied per drug labeling. Total costs varied from $6,756 to $7,158 
when duration of LIN ranges from 8 days to 12 days. cOnclusiOns: Treatment 
choice and LOC have major impact on ABSSSI resource use and costs. Suspected 
MRSA increases treatment duration and cost. Economic implications for payers and 
providers should be evaluated using models that capture these elements in view 
of long-acting lipoglycopeptide IV antibiotics in development that avoid repeated 
infusions and may allow for less inpatient treatment.
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wHEN TREATMENT IS MITIGATED By ADvERSE EvENTS: THE ECONOMIC 
IMPACT OF TREATMENT-ASSOCIATED ADvERSE EvENTS IN CIRRHOTIC 
NON-RESPONDERS TREATED wITH BOCEPREvIR OR TELAPREvIR AND 
PEGINTERFERON ALPHA/RIBAvIRIN
Sullivan S.1, McDermott C.1, Dieterich D.2, Martel-Laferriere V.2, Saab S.3, Gordon S.4
1University of Washington, Seattle, WA, USA, 2Mount Sinai School of Medicine, New York, NY, 
USA, 3David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 4Henry Ford Hospital, 
Detroit, MI, USA
Objectives: Adverse events (AEs) and premature treatment discontinuation of pro-
tease inhibitor (PI) therapy in the treatment of chronic hepatitis C (CHC) may mitigate 
the benefits of improved sustained virologic response. We use data from a recent study 
to estimate the economic impact of PI therapy in the cirrhotic non-responder popula-
tion. MethOds: In the Compassionate Use of Protease Inhibitors in viral C cirrhosis 
(CUPIC) study, patients with compensated cirrhosis and genotype 1 CHC were treated 
with boceprevir (n= 205) or telaprevir (n= 292) in combination with peginterferon alpha 
and ribavirin. The investigators reported safety and tolerability in an interim 16-week 
analysis. Using CUPIC data and micro-costing technique, we estimate the costs of treat-
ment-related hematologic and rash AEs by severity (Grades 2-4) and the cost of drug 
wastage using PI discontinuation rates due to serious AEs (SAEs) (7.3% boceprevir; 14.7% 
telaprevir). We surveyed 3 hepatologists to ascertain treatment patterns related to AEs 
and combined these estimates with cost data to compute mean costs per treatment 
group from the US payer perspective during the first 16 weeks of therapy. Results: The 
AE-related costs were $1,980 and $2,161 for telaprevir and boceprevir treated patients, 
respectively, for the first 28 days of treatment. Medication-related costs of premature 
discontinuation due to SAEs were estimated at $8,463 for telaprevir and $1,575 for 
visits, hospitalization days and costs associated with adverse events, which included 
medical services and medications. Results: The study included 1,081 patients who 
used at least one HCV medication (mean age of 46.4 years [SD= 10.7], 64.8% men). 
Peg-Riba only, Peg-Riba+boceprevir and Peg-Riba+telaprevir was used by 1,029 (95.2%), 
50 (4.6%) and 18 (1.7%) patients respectively. Fifty-seven patients (5.3%) required a 
subsequent HCV treatment during the study period. The mean duration of treatments 
was 30.4 weeks (SD= 16.1). During HCV treatment, the average number of health care 
resources per patient was 13.2 physician’s visits and procedures, 1.0 hospitalization 
day and 0.9 emergency visit. While receiving HCV treatment, 191 (17.7%) of patients 
required erythropoietin, 353 (32.7%) received rash treatments and 541 (50.0%) were 
treated for depression. Estimated costs associated with management of these three 
AE were CDN$10,834, CDN$78 and CDN$268 per patient respectively. cOnclusiOns: 
HCV treatment is associated with significant health care resource utilization. A high 
proportion of patients experienced AE for which management was associated with 
substantial additional costs, especially the anemia treatment. Thus, the cost of AE 
should be considered in future treatment options.
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THE COSTS OF MANAGING GENITAL wARTS IN THE UK By DEvOLvED NATION: 
ENGLAND, SCOTLAND, wALES AND NORTHERN IRELAND
Chapman R.1, Coles V.A.H.2, Lanitis T.1, Carroll S.M.2
1Evidera, London, UK, 2Sanofi Pasteur MSD, Maidenhead, UK
Objectives: Genital warts (GW), 90% of which are caused by human papillomavirus 
(HPV) types 6 and 11, are a significant problem in the UK. The cost of managing GW 
in 2010 was previously estimated at £52.4 million. The objective of this study was 
to estimate the cost of GW management up to 2012, and to determine the cost by 
UK jurisdiction. MethOds: Population statistics were obtained from the Office of 
National Statistics for the UK, England and Wales; the General Register Office and 
2011 census data for Scotland; and the Northern Ireland (NI) Statistics and Research 
Agency. Numbers of GW cases in genito-urinary medicine (GUM) clinics were 
obtained from the Health Protection Agency for the UK and England; the Information 
Services Division for Scotland; the Communicable Disease Surveillance Centre for 
Wales; and the Public Health Agency for NI. The number of cases treated in primary 
care was estimated from The Health Improvement Network database. Population 
statistics and GW cases were extrapolated by jurisdiction to 2012. The number of 
visits and therapy required for GW management were estimated by GUM experts 
for standard and hard-to-treat patients. Costs were obtained from the most recent 
National Health Service (NHS) Payment by Results tariffs, Personal Social Services 
Research Unit and British National Formulary. Results: The model estimated 
220,779 GW cases in the UK, costing £58.42 million annually (£265 per patient). For 
England, 157,693 cases were estimated costing £41.72 million; for Scotland 7,461 
cases costing £1.90 million; for Wales 7,091 cases costing £1.87 million; and for NI 
3,619 cases costing £0.95 million. cOnclusiOns: The full NHS costs for the man-
agement of GW have never before been estimated separately for each jurisdiction. 
The results of the model reveal a significant economic burden which is important 
to quantify when understanding the value of quadrivalent HPV vaccination.
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IMPACT OF TREATMENT FAILURE ON THE TOTAL COST OF TRIPLE THERAPy 
INCLUDING BOCEPREvIR OR TELAPREvIR BASED ON THE FRENCH EARLy 
ACCESS PROGRAM (ANRS CO20-CUPIC) STUDy
Valladares A.1, Calleja J.L.2, Serra M.Á3, Chacón F.1, Nocea G.1
1Merck Sharp & Dohme, Madrid, Spain, 2University Hospital Puerta de Hierro, Madrid, Spain, 
3University Clinic Hospital, University of Valencia, Valencia, Spain
Objectives: The ANRS CO20-CUPIC study was designed to evaluate triple therapy 
(TT) efficacy and safety in HCV-cirrhosis treatment-experienced patients in the 
French Early Access Programme. A 60-week interim analysis has been reported 
confirming better clinical outcomes than double therapy in a real clinical setting. 
However, independently of the protease inhibitor (PI) used, boceprevir (BOC) or tel-
aprevir (TLV), treatment failure (TF) was reported in up to 60% of the patients. Little 
is known about these patients’ treatment cost: that of successfully treated patients 
can be generally calculated from the full course of PI treatment, but the cost of those 
who failed highly depends on TF timing. Our objective is to estimate the average PI 
cost/patient who failed treatment based on CUPIC study reported data. MethOds: 
Using reported data on ITT virological response and TF, BOC and TLV on-treatment 
rates over time were estimated. Based on this curve, the average PI treatment duration 
and average PI cost/patient who failed treatment were calculated. When not enough 
information about time to treatment discontinuation was available, the same con-
servative approach was applied for both drugs, considering the midpoint of the treat-
ment interval. Sensitivity analyses on the time to TF were performed to confirm the 
robustness of the results. Results: A total of 472 patients (72%) were included in the 
60-week interim analysis. Independently of the IP used, about 60% the patients who 
start treatment did not achieve viral cure and their estimated average PI treatment 
duration was 26 wks in BOC patients and 11 wks in TLV patients. The average PI cost/
patient who failed treatment with TLV (23.012€ ) was 26% higher than that of treatment 
with BOC (18.253€ ). The sensitivity analysis confirmed the robustness of the base case 
estimation. cOnclusiOns: In a scenario of comparable efficacy between both PIs, 
the resources wasted on TF acquire a great importance in selecting the least costly of 
the two alternatives. Based on CUPIC study reported data, the average PI cost/patient 
who failed treatment was significantly higher in TLV patients than in BOC patients.
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PREDICTORS OF COSTS OF ANTIRETROvIRALS FOR HIv INFECTION IN ITALy: A 
MULTICENTRIC RETROSPECTION IN 2012
Tontodonati M.1, Cenderello G.2, Celesia B.M.3, Trezzi M.4, Ursini T.1, Costantini A.5,  
Gaggero D.2, Gussio M.3, Manzoli L.6, Polilli E.7, Sozio F.7, Catalani C.4, Butini L.5, Parruti G.7
1Pescara University, Pescara, Italy, 2Galliera Hospital, Genoa, Italy, 3ARNAS Garibaldi, Catania, 
Italy, 4Ospedal Il Ceppo, Pistoia, Italy, 5Ancona Hospital, Ancona, Italy, 6Pescara Chieti University, 
Chieti, Italy, 7Pescara General Hospital, Pescara, Italy
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general hospital (PB 6M€ ). We chose 24 active ingredients (95 different antibiotics) 
that represent about 1/3 of total hospital antibiotics and 80% of the total anti-
biotics’ budget. We studied their consumption for the years 2011 and 2012 and 
calculated the costs based on the official drug pricelist and their price after the 
negotiation. Results: From 2011 to 2012 the discounts gained from each hospital 
were increased. Price negotiation does not apply in prototype drugs that their com-
panies are only obliged to offer a 5% rebate. Unfortunately, these medications are 
more expensive, represent 36% of the studied antibiotics’ cost and their consump-
tion was increased by 20%. But, the discounts for all the studied off-patent drugs 
and their generics were from 12.8% till 89.9%. Thus, the total cost saving for them 
was 33.2% at PAGNI, 26.0% at Evaggelismos and 43.1% at Tzaneio. The total benefit 
for the pharmaceutical expenditure was 3% for both PAGNI and Evaggelismos, and 
6% for Tzaneio. cOnclusiOns: Price negotiation is an effective mean of decreas-
ing the cost of off-patent and generic drugs but newer and expensive drugs get 
doctors’ preference, undermining the Pharmacy’s cost-saving effort.
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wHAT ARE THE CLINICAL AND ECONOMIC COSTS AND BENEFITS OF 
IMPLEMENTING POINT OF CARE TESTS FOR CHLAMyDIA TRACHOMATIS AND 
NEISSERIA GONORRHOEA IN GENITO-URINARy MEDICINE CLINICS IN THE 
UNITED KINGDOM?
Turner K.M.1, Round J.2, Horner P.1, Macleod J.1, Goldenberg S.3, Deol A.4, Adams E.J.4
1University of Bristol, Bristol, UK, 2University College London, London, UK, 3Guy’s and St Thomas’ 
NHS Foundation Trust, London, UK, 4Aquarius Population Health, London, UK
Objectives: To estimate the costs and benefits of patient pathways incorporating 
a point of care nucleic acid amplification test (POC NAAT) for chlamydia and gonor-
rhoea in genito-urinary medicine (GUM) clinics in the UK compared with standard 
off-site laboratory testing. MethOds: We simulated 1.2 million men and women 
GUM clinic attendees based on GUMCAD reports from the UK (2011). A Markov 
model with Monte Carlo simulation in Microsoft Excel was developed to compare 
existing standard pathways of testing and treatment for chlamydia and gonorrhoea 
with a POC NAAT. We conducted sensitivity analyses to evaluate the robustness of 
the model findings. The primary outcome was the incremental cost-effectiveness 
ratio (ICER = £/QALY). Secondary outcomes included the number of inappropriate 
treatments, complications and transmissions averted and change in time from test 
to treatment. Results: The total cost of using the POCT in our cohort was £103.3 
million compared with £113.9 million for standard care. The ICER was -£4,182/QALY, 
making the new pathways cost saving. Nearly 100,000 inappropriate treatments 
might be avoided by using a POC NAAT. Patients receive diagnosis and treatment on 
the same day as testing, which may also prevent 162 cases of pelvic inflammatory 
disease and 17,561 transmissions. cOnclusiOns: Replacing standard laboratory 
tests for chlamydia and gonorrhoea with a POCT could be cost saving and patients 
would benefit from more accurate diagnosis and less unnecessary treatment. 
Overtreatment currently accounts for about a tenth of the reported treatments for 
chlamydia and gonorrhoea and POC NAATs would effectively eliminate the need 
for presumptive treatment.
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COST-EFFECTIvENESS OF CHILDHOOD ROTAvIRUS vACCINATION IN GERMANy
Aidelsburger P.1, Grabein K.2, Boehm K.1, Helbig A.K.1, Dietl M.1, Wasem J.2, Koch J.3, Ultsch B.3, 
Weidemann F.3, Wichmann O.3
1CAREM GmbH, Sauerlach, Germany, 2University of Duisburg-Essen, Essen, Germany, 3Robert 
Koch Institute, Berlin, Germany
Objectives: Rotavirus (RV) causes highly contagious gastroenteritis especially in 
children under five years of age. Since 2006, two RV-vaccines are available in Europe 
(Rotarix® and RotaTeq®). We evaluated the cost-effectiveness of these vaccines for 
the German health care setting, inter alia to support an informed decision-making 
concerning a potential vaccination-recommendation. MethOds: A Markov Model 
was developed to evaluate the cost-effectiveness from the statutory health insur-
ance (SHI) (direct costs) and from the societal perspective (SHI plus indirect costs). 
Health outcomes considered were RV-cases prevented, RV-associated hospitalizations 
avoided, and quality-adjusted life-years (QALY) gained. RV-incidences were derived 
from the national mandatory disease reporting system. RV-vaccine efficacy was cal-
culated as pooled estimates based on data from randomized controlled trials. Costs 
(reference year 2010) were derived from official price catalogues. An annual discount 
rate of 3% for effects and costs was applied. The first five life-years were considered as 
model’s time horizon. Results: The base-case analysis (SHI-perspective) resulted in 
an incremental cost-effectiveness and cost-utility ratio (ICER) for Rotarix® of € 184 per 
RV-case prevented, € 2,457 per RV-associated hospitalization avoided, and € 116,973 
per QALY gained. For RotaTeq®, the results were slightly higher (€ 234, € 2,622, and € 
142,732, respectively). In sensitivity analyses parameter variation showed effects on 
the ICERs without changing the overall trend. A threshold analysis suggests that cost-
saving scenarios are possible with vaccine prices reduced by ~62-66%. When applying 
base-case scenario results to the 2012 birth-cohort with 80% vaccination coverage, an 
estimated 206,000-242,000 RV-cases and 18,000 RV-associated hospitalizations can be 
prevented in this birth-cohort over 5 years for an incremental cost of 44.5-48.2 million 
Euros. cOnclusiOns: Routine RV-vaccination is expected to prevent a consider-
able number of RV-cases and RV-associated hospitalizations in Germany. Though, the 
amount of QALYs gained is low. With current vaccine prices, RV-vaccination is not a 
cost-saving preventive measure.
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COST-EFFECTIvENESS ANALySIS OF 3 CANDINS AND FLUCONAzOLE IN 
THE TREATMENT OF CONFIRMED INvASIvE CANDIDIASIS IN ADULT NON-
NEUTROPAENIC PATIENTS IN SPAIN
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boceprevir. Total costs of AE and discontinuation were $10,443 and $3,736 for telaprevir 
and boceprevir treated groups, respectively. The results were not sensitive to variation 
in treatment practices and costs. cOnclusiOns: The costs of treatment of cirrhotic 
non-responders during the first 16 weeks were estimated to increase by 18% over triple 
therapy costs due to AEs. These data indicate that the total cost per cure may be sub-
stantially higher than the drug costs and underscore the importance of evaluating total 
cost of HCV treatment when selecting new agents.
PIN58
DIRECT MEDICAL COSTS AND HEALTH CARE RESOURCE UTILIzATION 
ASSOCIATED wITH SELECTED ANTIBIOTIC TREATMENT PATHwAyS IN ACUTE 
BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS IN THE UNITED STATES
Fan W1, LaPensee K.1, Mao J.2, Iorga S.2, Lodise T.P.3
1The Medicines Company, Parsippany, NJ, USA, 2OptumInsight, Eden Prairie, MN, USA, 3Albany 
College of Pharmacy and Health Sciences, Albany, NY, USA
Objectives: Current guidelines for the treatment of acute bacterial skin and skin 
structure infections (ABSSSI) recommend several treatment pathways based on the 
infection types and severity. The objective of this study is to establish the health 
care resource utilization (HRU) and costs associated with the most common patient 
treatment pathways in US. MethOds: The medical and pharmacy administrative 
claims of adult ABSSSI patients with continuous commercial or Medicare Advantage 
enrollment with Part D prescription drug coverage between 01 January 2009 and 
31 December 2011 were extracted from a large national health plan affiliated with 
OptumInsight. The four most common treatment pathways were identified based on 
the evidences of antibiotics over the entire ABSSSI treatment course. All four path-
ways start with vancomycin IV use during a hospital stay. At discharge, patients fol-
lowed one of four pathways: 1) continue IV vancomycin as an Outpatient Parenteral 
Antibiotic Therapy (OPAT); 2) switch to oral linezolid; 3) switch to daptomycin; or 4) 
switch to any oral antibiotic other than linezolid, clindamycin, or TMP-SMX. Health 
care resource utilization and costs were determined for each pathway. Results: A 
total of 1418 patients met all of inclusion/exclusion criteria. The majority of patients 
either continued Vancomycin IV (46.5%) or switched to oral linezolid (41.4%) at dis-
charge. Only about 12% of patients were switched to Daptomycin or other non-MRSA 
active oral antibiotics. The average ABSSSI-related total health care cost was $16,571 
for the entire ABSSSI treatment. Total costs were comprised of $12,519 (75.5%) for 
inpatient cost, $201 (1.2%) for emergency department (ED) visits, $879 (5.3%) for 
outpatient treatment/office visits, and $1,015(6.1%) for pharmacy claims cost. The 
costs overall and in various locations of care varied by pathway. cOnclusiOns: 
Inpatient treatment remains the largest component of total ABSSSI treatment cost. 
Utilization of linezolid and daptomycin increased the pharmacy or OPAT costs.
PIN59
COMPARISON OF THE HEALTH CARE COSTS AND UTILIzATIONS BETwEEN 
PATIENTS DIAGNOSED wITH THE HEPATITIS B vIRUS vERSUS THOSE wITHOUT
Xie L.1, Wang L.2, Kariburyo M.F.1, Li L.2, Wang Y.1, Baser O.3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
Objectives: To examine the economic burden and health care utilizations 
of patients diagnosed with the hepatitis B virus (HBV) in the U.S. veteran 
population. MethOds: A retrospective database analysis was performed using the 
Veterans Health Administration (VHA) Medical SAS datasets from October 1, 2008 to 
September 30, 2012. Patients diagnosed with HBV were identified using International 
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM 070.22, 070.23, 
070.32, 070.33, V02,61) diagnosis codes. The first diagnosis date was defined as the 
index date. A group of patients of the same age, region, gender and index year but 
without HBV infection were identified and matched by baseline Charlson Comorbidity 
Index (CCI) as the comparison group. A 1-year continuous health plan enrollment was 
required before and after the index date for both groups. Study outcomes, including 
health care costs and utilizations, were compared between the HBV and compara-
tor groups using 1:1 propensity score matching. Results: A total of 9,718 patients 
were identified for the HBV and comparison cohorts. After applying a 1:1 matching, 
a total of 3,093 patients were matched from each cohort, and the baseline character-
istics were proportionate. Patients diagnosed with HBV infection were more likely to 
report higher health care utilizations, including inpatient (28.74% vs. 3.3%, p< 0.01), 
emergency room (25.67% vs. 8.3%, p< 0.01), physician office (98.60% vs. 62.75%) and 
pharmacy visits (88.23% vs. 63.65%, p< 0.01). The risk-adjusted health care costs were 
also higher for patients infected with HBV due to increased inpatient ($10,481 vs. $804, 
p< 0.01), emergency room ($382 vs. $80, p< 0.01), physician office ($4,635 vs. $1,678, 
p< 0.01), and pharmacy visits ($1,166 vs. $398, p< 0.01) resulting in higher total costs 
($16,909 vs. $3,045, p< 0.01) relative to the comparator cohort. cOnclusiOns: During 
a period of 12 months, VHA patients diagnosed with HBV reported higher health care 
utilization and costs than their matched controls.
PIN60
A COMPARATIvE STUDy ON THE COST OF ANTIBIOTICS FOR THE yEARS 2011-
2012 IN THREE GENERAL HOSPITALS OF GREECE
Gkogkozotou V.K.1, Papandreou V.2, Papagiannakopoulou P.3, Asithianakis P.1
1UNIVERSITY HOSPITAL OF CRETE (PAGNI), CRETE, Greece, 2EVAGGELISMOS HOSPITAL, 
ATHENS, Greece, 3TZANEIO, PIRAEUS, Greece
Objectives: Since Greece came under the regime of IMF and signed the memo-
randum, several curtailments had to be made to various areas of the public sec-
tor. Drug treatment seems to be quite expensive. As part of the strict economic 
rules, Greek hospitals were obliged to reduce their health care costs. The phar-
macy of each hospital incurred considerable weight of this attempt. One of its 
implemented actions was the drugs’ price negotiation with the pharmaceuti-
cal companies. MethOds: In order to measure the effectiveness of this action, 
we performed a comparative study of the antibiotics used in 3 hospitals, PAGNI, 
Evaggelismos and Tzaneio. PAGNI and Evaggelismos are among the 5 biggest hos-
pitals of Greece (pharmaceutical budget around 40M€ ) while Tzaneio is a small 
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COST PER CURE OF TELAPREvIR AND BOCEPREvIR IN TREATMENT-NAïvE 
GENOTyPE 1 HEPATITIS C PATIENTS wITH F2 FIBROSIS IN BRAzIL
Morais A.D., Pereira M.L.
Janssen Cilag Farmaceutica, São Paulo, Brazil
Objectives: Compare the cost per cure of telaprevir of peginterferon and ribavirin 
(TVR+PR) compared to boceprevir plus peginterferon and ribavirin (BOC+PR) in 
the treatment of METAVIR scale F2 patients with previously untreated chronic 
hepatitis C genotype 1 in the Brazilian public (SUS) and private (SS) health care 
system. MethOds: Treatment costs considered drug acquisition costs of TVR+PR 
and BOC+PR from a public and private payer perspective in Brazil. The cost/cure 
was defined as the cost/sustained virological response (SVR) according to the 
phase 3 trials of TVR and BOC. The SVR rate for TVR+PR was defined as 79% and 
49% for PR in patients with F2 fibrosis. Based on the SPRINT-2 trial, the SVR-rate 
for F2 patients treated with BOC+PR was assumed 57%, average between F0/F1 
and F3/F4 patients, compared to 38% for PR. Treatment duration, based on the 
extended rapid virological response (eRVR), was taken from the respective trials 
of BOC (eRVR = 44%) and TVR (eRVR = 58%). Deterministic sensitivity analysis 
was carried out for the eRVR rate. Results: In the SUS, TVR+PR had an average 
treatment cost of R$ 40.093 per F2 fibrosis patient compared to R$ 36.185 with 
BOC+PR. Considering the SVR rate and the sensitivity analysis, TVR+PR had a 
cost/SVR of R$ 50.751 (R$ 49.797-R$ 51.705) compared to R$ 63.481 (R$ 61.771-R$ 
65.191) with BOC+PR. In the private health care system, TVR+PR had a treatment 
cost of R$ R$ 88.508 per F2 fibrosis patient compared to R$ 82.518 with BOC+PR. 
Considering the cost/SVR and sensitivity analysis, TVR+PR had a cost/SVR of R$ 
112.036 (R$ 108.253-R$ 115.819) compared to BOC+PR with a cost/SVR of R$ 144.768 
(R$ 140.631-R$ 148.905) per F2 patient in the SS. cOnclusiOns: Compared to 
BOC+PR, TVR+PR was a more cost-effective treatment of F2 fibrosis patients in 
both public and private health care systems.
PIN67
COST-EFFECTIvENESS OF PEGINTERFERON ALFA AND RIBAvIRIN FOR THE 
TREATMENT OF CHILDREN AND yOUNG PEOPLE wITH CHRONIC HEPATITIS C 
FROM THE PERSPECTIvE OF THE NHS IN ENGLAND AND wALES
Lion M.1, McCann E.1, Jiang Y.2
1MSD Ltd., Hoddesdon, UK, 2Amaris, London, UK
Objectives: To evaluate the cost-effectiveness of peginterferon (PEG INF) alfa and riba-
virin for the treatment of children and young people ages 3 to 17 years with Chronic 
Hepatitis C (CHC), from the perspective of the NHS in England and Wales. This analysis 
was submitted to NICE as part of a submission dossier for the multiple technology 
appraisal of PEG INF alfa and ribavirin for the respective population. MethOds: A 
Markov model was developed based on previous economic evaluations for treatment 
of adults with CHC with PEG INF alfa and ribavirin. The model evaluated the cost-effec-
tiveness of PEG INF alfa-2a or alfa-2b and ribavirin, and supportive care, for the treatment 
of people aged 5 to 17 years. An additional analysis was conducted on 3 and 4 year olds 
comparing supportive care to PEG INF alfa-2b and ribavirin in line with license. The 
cost-effectiveness was evaluated using the incremental cost-effectiveness ratio (ICER) 
from the perspective of the NHS over a lifetime horizon. The results were assessed 
overall and by age and genotype subgroups. Results: The results reported that both 
combinations of PEG INF alfa and ribavirin dominated supportive care for all patients. 
Driven by small variation in the comparative efficacy and costs, the comparison between 
PEG INF alfa-2a and alfa-2b, in combination with ribavirin, showed that PEG INF alfa-2b 
dominated PEG INF alfa-2a overall and in the following subgroups: 5 to 8 years, 14 to17 
years and genotypes 2/3. The ICER for the 9 to13 years subgroup was £4,697. PEG INF 
alfa-2a dominated PEG INF alfa-2b for the other genotype subgroup cOnclusiOns: The 
results of the economic evaluation demonstrated that treatment with either combina-
tion of PEG INF alfa and ribavirin is a cost-effective treatment option for children and 
young people aged 3 to 17 years with CHC.
PIN68
COST-EFFECTIvENESS OF 13-vALENT vERSUS 10-vALENT PNEUMOCOCCAL 
CONjUGATE vACCINE USE IN THE CzECH NATIONAL IMMUNIzATION PROGRAM
Tichopad A.1, Vitova V.1, Roberts C.S.2, Hájek P.3
1CEEOR s.r.o., Prague, Czech Republic, 2Pfizer, New York, NY, USA, 3Pfizer, Praha, Czech Republic
Objectives: Streptococcus pneumoniae is presumed to be the major etiology 
agent responsible for a significant amount of meningitis, bacteremia and sepsis 
(invasive pneumococcal disease; IPD) as well as Community Acquired Pneumonia 
(CAP) and Acute Otitis Media (AOM). The Czech Republic (CR), as well as many 
other European countries have only a limited local evidence on the underlying 
epidemiology. The objective was to estimate the expected outcomes, costs, cost-
effectiveness of the pediatric national immunization program (NIP) with 13-valent 
pneumococcal conjugated vaccine (PCV13) and 10-valent pneumococcal conju-
gated vaccine (PCV10) as a comparator among specific populations of children 
and adults in preventing and reducing the incidence of IPD, CAP and AOM in 
CR. MethOds: A Markov decision-analytic model was developed to examine 
impacts of infant vaccination with PCV13 versus PCV10. PCV13 direct effectiveness 
was extrapolated from PCV7 efficacy data from clinical trials, using assumptions 
regarding serotype prevalence and PCV13 protection against additional serotypes, 
while indirect (herd) effect was extrapolated from US surveillance data following 
universal PCV7 use. The local epidemiology and cost data were used to achieve 
maximum national specificity. Results: Model predicts incremental EUR 64.5 
million for the PCV13 NIP from the payer’s perspective in the 10-year horizon, as 
compared to PCV10. This would lead to an reduction in IPD, all cause inpatient and 
outpatient CAP and AOM by approximately 921, 22 900, 56 796 and 40 598 cases, 
respectively, thus savings EUR 35.4 million. This gives a total cost of EUR 29.0 mil-
lion in the 10 years. The incremental cost per LYG or QALY gained is estimated 
as EUR 929 or EUR 1 164, respectively, from the payer’s perspective as compared 
to PCV10. cOnclusiOns: Comparing the national GDP per capita with the WHO 
Objectives: To estimate the cost-effectiveness (CE) of the 3 echinocandins 
(Anidulafungin, Caspofungin and Micafungin) and generic Fluconazole in the treatment 
of adult non-neutropaenic patients with invasive candidiasis (IC) in a Spanish Intensive 
Care Unit (ICU) setting. MethOds: A 4 arm decision tree model was developed with the 
3 echinocandins and generic Fluconazole as first line treatment. In case of treatment 
failure, a 2nd line treatment was administered (Liposomal Amphotericin-B following 
the echinocandins and either one of the 3 echinocandins for Fluconazole arm). After 2nd 
line failure, treatment was discontinued. Total treatment length was 14 days. Efficacy 
and safety (adverse events/lack of efficacy) parameters where obtained from a mixed-
treatment-comparison and a meta-analysis respectively. Efficacy was considered as 
first line success (Anidulafungin 75.32%; Micafungin 71.65%; Caspofungin 70.62%; and 
Fluconazole 56.7%). Length of the first and the second line were elicited using experts’ 
opinion through Delphi methodology. Daily drug acquisition costs were considered 
only. The CE was expressed as an incremental cost-effectiveness ratio (ICER). Univariate 
sensitivity analyses were also applied and included, length of treatment in 1st or 2nd line 
and finally drug dosages calculated as per SmPC recommendations according to dif-
ferent patient characteristics. Results: Total costs of IC treatment for Anidulafungin, 
Micafungin, Caspofungin and Fluconazole were € 5,552; € 5,985; € 6,350; € 1,654 respec-
tively. Anidulafungin was dominant compared to Micafungin and Caspofungin. 
Anidulafungin and Micafungin were cost-effective (€ 20,934; 29.576€ respectively) 
compared to Fluconazole (CE threshold of € 30,000). Sensitivity analyses revealed that 
ICER was sensitive to increases in the length of the 1st and 2nd line treatments, although 
Anidulafungin was cost-effective in all scenarios. cOnclusiOns: Based on the model’s 
assumptions, Anidulafungin is cost-saving compared to Micafungin and Caspofungin 
and cost-effective vs. Fluconazole in the treatment of patients with confirmed invasive 
candidiasis from a Spanish Hospital ICU perspective.
PIN64
COST-EFFECTIvENESS OF LINEzOLID vERSUS vANCOMyCIN IN THE 
TREATMENT OF vENTILATOR ASSOCIATED PNEUMONIA IN jAMAICA
Garita M.1, Nicholson A.2, Cuesta G.3, Mould J.4
1Pfizer Central America and Caribbean, Escazu, San Jose, Costa Rica, 2University Hospital of the 
West Indies, Kingston, Jamaica, 3Pfizer Central America and the Caribbean, Escazú, San Jose, 
Costa Rica, 4Pfizer, New York, NY, USA
Objectives: The ventilator associated pneumonia (VAP) refers to the pneumonia 
that appears after 48-72 hours of endotracheal intubation and is the most common 
nosocomial infections in patients receiving mechanical ventilation. Late-onset VAP 
is responsible for prolonged ICU stay and higher mortality rates (24 to 50% and can 
even increase to 76%), which explains the importance of using more effective anti-
biotics depending on the severity of each case. The aim of this study is to assess 
the cost-effectiveness (CE) of linezolid against vancomycin in the treatment of VAP, 
from the public health care perspective. MethOds: A cohort of patients with VAP 
was simulated using a decision-tree model to compare costs and effectiveness of 
linezolid (600 mg/12 hours) and vancomycin (1 g/12 hours). Effectiveness measures 
were: microbiological success rates, mortality rates, and ICU and ward LOS. The model 
used a 12-week time horizon and only direct medical costs were considered (inpatient 
costs, medication expenses, adverse events costs). Effectiveness and epidemiologic 
data were retrieved from published literature. Local costs (2013 US$) were gathered 
from the official databases of Jamaican Health System. Monte Carlo probabilistic 
sensitivity analysis (PSA) was constructed. Results: Linezolid resulted as the most 
effective and less expensive option for VAP adult patients. Clinical success rate was 
higher with linezolid (64.4%) against vancomicyn (56.1%). Mean expected ICU LOS 
was 14 days for linezolid and 17 days for vancomycin, ward LOS was 14 and 24 days 
with linezolid and vancomycin, respectively. Mortality rate was found lower in the 
linezolid arm (10.13%) in comparison to vancomycin (15.74%). Overall costs per patient 
were $36721.65 with linezolid and $40776.82 with vancomycin. In the CE incremental 
analysis, linezolid appeared as the cost-saving option. PSA outcomes support the 
robustness of these findings. cOnclusiOns: Linezolid resulted as the cost-saving 
therapy for treating VAP adult patients in Jamaica.
PIN65
COST EFFECTIvENESS ANALySIS OF BOCEPREvIR (BOC) ADDED TO PEGIFN/
RIBAvIRIN (P/R) vERSUS PEGIFN/RIBAvIRIN (CURRENT STANDARD OF CARE) FOR 
THE TREATMENT OF PATIENTS wITH GENOTyPE 1 CHRONIC HEPATITIS C IN 
GREECE
Athanasakis K.1, Karampli E.1, Retsa M.P.2, Theodoropoulou T.2, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2MSD Hellas, Athens, Greece
Objectives: Boceprevir plus P/R has demonstrated a superior clinical profile, com-
pared to P/R alone, in the treatment of genotype 1 chronic hepatitis C (G1-CHC) 
patients. The objective of this study was to evaluate the cost-effectiveness of 
BOC/P/R therapy for treatment naïve and treatment experienced G1-CHC patients 
in Greece. MethOds: A Markov-model simulating the quality-adjusted life years 
and corresponding costs of G1-CHC treatment provided the basis of the analyses. 
The BOC/P/R regimens recommended in the label for treatment naïve and treat-
ment experienced patients were compared to P/R to calculate incremental costs and 
outcomes. The inputs for the model were derived from post-hoc subset analyses of 
SPRINT-2 and RESPOND-2 data. Resource use for patient monitoring and treatment 
of events was elicited via expert panel. Lifetime horizon with 3% discount rate was 
used and the perspective of analysis was third-party payers. Results: BOC-based 
therapy was projected to reduce liver complications (decompensated cirrhosis, hepa-
tocellular carcinoma, liver transplant and liver–related death) by 44% and 49-53% 
in treatment naïve and experienced patients, respectively, leading to correspond-
ing gains of 0.87 and 1.25 QALYs per patient. Taking into account medication costs, 
treatment and management of events, the ICER for BOC-based therapy versus P/R 
were estimated at 10,003€ /QALY and 10,852€ /QALY for treatment naïve and expe-
rienced patients, respectively. Extensive sensitivity analyses indicated that results 
were robust. cOnclusiOns: Based on the results of this analysis, the addition of 
Boceprevir to P/R for treatment of G1 CHC patients can be a cost-effective treatment 
option in the Greek health care setting.
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per equivalents will be recouped in less than two months. Over 5 years there were 
325 fewer infections in the copper arm at a cost per QALY of £262.84. cOnclusiOns: 
The investigation allowed the derivation of a spreadsheet-based model that uses 
the best current published information and shows the rapid ROI of a copper inter-
vention. It also calculates the impact on bed days and quality-adjusted life years 
(QALY). The model is simple, transparent to those with knowledge of spreadsheets, 
and allows adaptation to specific local settings.
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COST-EFFECTIvENESS OF A 13-vALENT CONjUGATE PNEUMOCOCCAL 
vACCINATION PROGRAM IN COPD PATIENTS AGED ≥ 50 yEARS IN SPAIN: 
PRELIMINARy RESULTS
Menendez R.1, Rodríguez-GonzálezMoro J.M.2, Gros B.3, Echave M.3, Oyagüez I.3, Lwoff N.4, 
Egea-García M.4, Guijarro P.4
1Respiratory Infections Health La Fe Research Institute, Valencia, Spain, 2Hospital Gregorio 
Marañón, Madrid, Spain, 3Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 
4Pfizer Spain, Alcobendas, Spain
Objectives: Patients with chronic obstructive pulmonary disease (COPD) are at risk 
of pneumococcal infection. A 13-valent pneumococcal-conjugate vaccine (PCV13) 
has recently been approved for adult protection against S. pneumoniae. This study 
estimated the clinical and economic consequences of vaccinating COPD patients 
aged ≥ 50 years with PCV13 compared to current vaccination recommendations using 
a 23-valent pneumococcal-polysaccharide vaccine, from the Spanish Healthcare 
System perspective. MethOds: A microsimulation model with a Markov process 
accounting for risks and costs for invasive pneumococcal disease (IPD) and all-cause 
nonbacteremic pneumonia (NBP) was developed. Prevalence, mortality rates, vaccina-
tion and serotype coverage, and vaccination and disease-related costs (€ 2013) were 
based on published data. Vaccines effectiveness was modified by a waning effect 
over time. Herd-immunity and revaccination were not considered. Outcomes and 
costs (both discounted at 3%/year) were simulated 100 times with, 1.6 million COPD 
patients per simulation. Outcomes were pneumococcal cases averted and incremen-
tal cost–effectiveness ratio (ICER) in terms of cost per life-year gained (LYG). Sensitivity 
analyses were performed modifying the time horizon, discount rate and vaccination 
coverage. Results: Over a 5-year period, the use of PCV13 vs current vaccination 
strategy in adult COPD subjects would prevent 529 IPD cases, 6,329 inpatient-NBP 
cases, and 697 outpatient-NBP cases. Additionally, 231 IPD and 148 inpatient-NBP 
related deaths would be averted. The ICER was € 24,557/LYG for PCV13 vs current 
vaccination strategy. In sensitivity analyses, ICER ranged from € 26,986/LYG (when 
changing discount rate from 3% to 5%) to € 7,661/LYG (when changing vaccination 
coverage from 80% to 66%). Using a lifetime horizon 1,271 IPD cases, 10,294 inpatient-
NBP cases, and 2,072 outpatient-NBP cases would be prevented, with an ICER of € 5,030/
LYG. cOnclusiOns: At a willingness-to-pay of € 30,000/LYG, PCV13 vaccination in 
COPD patients aged ≥ 50 years in Spain is a cost-effective strategy compared to cur-
rent vaccination recommendations under both 5-year and lifetime time horizons.
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LINEzOLID FOR THE TREATMENT OF PATIENTS wITH CONFIRMED MRSA 
NOSOCOMIAL PNEUMONIA IN NANjING, CHINA: A COST EFFECTIvE 
ALTERNATIvE TO vANCOMyCIN
Tan S.C.1, Li Q.2, Chen Y.3, Hájek P.4, Weinstein D.5, Patel D.A.6
1Double Helix Consulting, Asia-Pacific, Singapore, Singapore, 2Jiangsu Province Hospital, Nanjing, 
China, 3Pfizer Inc., Beijing, China, 4Pfizer, Praha, Czech Republic, 5Pfizer Inc., Paris, France, 
6Pharmerit International, Bethesda, MD, USA
Objectives: Vancomycin has been the treatment of choice for several years while lin-
ezolid is a relatively new alternative in China. Although clinical superiority of linezolid 
was demonstrated in a recent head-to-head clinical study, economic evaluation com-
paring the two treatments provides additional useful decision making information. 
This study aimed to compare the cost-effectiveness of linezolid versus vancomycin 
in treating confirmed MRSA NP from a payer’s perspective in Nanjing. MethOds: 
A cost-effectiveness model primarily driven by the head-to-head clinical data 
(Wunderink, CID: 2012), was adapted with local published data and expert opinion 
on resource use and unit costs. The model structure and assumptions were verified 
to reflect local clinical practice. Both linezolid and vancomycin arms were assumed 
to have same life expectancy in full health upon discharge. The base case analysis 
considered 10-day treatment duration for both treatments. Scenario analyses were 
conducted by varying treatment duration, per day total costs in ICU and general ward, 
drug acquisition costs, and including costs for managing key adverse events. All costs 
were reported in 2012 Chinese RMB. Results: A higher treatment success rate by 
2.7% was predicted for linezolid. Both treatment arms were estimated to have very 
similar average total costs in the region of RMB 78,800 with the key cost drivers being 
drug acquisition costs and ICU per day total cost. The ICER for linezolid was RMB 163 
for each additional successfully treated patient. Dominance of linezolid attributed to 
greater treatment success but lower total cost was observed in most of the scenario 
analyses. The highest ICER was RMB 31,663 in the scenario where the acquisition cost 
of vancomycin reduced by 20%. cOnclusiOns: Given the estimated low ICERs with 
dominance in most of the scenario analyses, linezolid can be considered a cost effec-
tive option compared to vancomycin in managing confirmed MRSA NP in Nanjing.
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A COST-EFFECTIvENESS ANALySIS OF LINEzOLID vERSUS vANCOMyCIN FOR 
vENTILATOR-ASSOCIATED PNEUMONIA PATIENTS IN COSTA RICA
Garita M.1, Solano A.2, Cuesta G.3, Mould J.4
1Pfizer Central America and Caribbean, Escazu, San Jose, Costa Rica, 2Hospital Dr. Rafael Ángel 
Calderón Guardia, San Jose, Costa Rica, 3Pfizer Central America and the Caribbean, Escazú, San 
Jose, Costa Rica, 4Pfizer, New York, NY, USA
Objectives: Ventilator-associated pneumonia (VAP) is the most common nosocomial 
infection in the intensive care unit (ICU). It’s associated with significant morbid-
ity, increasing the ICU and hospital length of stay (LOS), and raising overall costs. 
Literature suggests that costs could be reduced using the most efficient empiric 
recommendation on health care spending per QALY gained, PCV13 NIP in Czech 
Republic can be considered cost-effective.
PIN69
ECONOMIC EvALUATION OF FIDAxOMICIN FOR THE TREATMENT OF 
CLOSTRIDIUM DIFFICILE INFECTIONS (CDI) ALSO KNOwN AS C. DIFFICILE-
ASSOCIATED DIARRHOEA (CDAD) IN IRELAND
Van Engen A.1, Casamayor M.2, Loftus F.3, Crimin E.3, Lacey L.4
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Barcelona, Spain, 3Astellas Pharma Co Ltd., 
Dublin, Ireland, 4Lacey Solutions Ltd., Skerries, Ireland
Objectives: Fidaxomicin is the first in a new class of macrocylic antibiotics, indi-
cated in adults for the treatment of Clostridium difficile infections (CDI) also known 
as C. difficile-associated diarrhoea (CDAD). The study objective was to perform a 
cost-utility analysis of fidaxomicin for the treatment of CDI compared to oral met-
ronidazole (used to treat initial non-severe CDI and first non-severe recurrence) and 
oral vancomycin (used to treat severe CDI and any non-severe recurrence beyond 
the first one). MethOds: A Markov model was used to determine the cost-utility 
of fidaxomicin in the treatment of all adult CDI patients (base case), patients with 
severe CDI, and patients with initial CDI recurrences, respectively. The cycle length 
was 10 days. The patient enters the model in the CDI health state and is treated either 
with fidaxomicin, oral metronidazole or vancomycin for 10 days. The time horizon 
was one-year. Deterministic and probabilistic sensitivity analyses were performed. 
Health state utilities were derived from the literature. The perspective was that of 
the Irish Health Service Executive (HSE). Results: In the base case, fidaxomicin was 
dominant compared to current standard of care, resulting in cost savings of € 2,904 
and an incremental QALY gain of 0.031. The main drivers of cost-effectiveness were 
the reduction in rate of recurrence in patients treated with fidaxomicin and the cost 
of hospitalisation. Fidaxomicin was also found to be dominant for all patient sub-
groups. The ICERs were highly sensitive to recurrence rates. The probability of the 
cost-effectiveness of fidaxomicin in all CDI patients at a willingness to pay thresh-
old of € 45,000 per QALY gained was estimated to be approx. 82%. cOnclusiOns: 
Fidaxomicin was dominant compared to current standard of care with an approx. 82% 
probability of being cost-effective in all CDI patients at a willingness to pay threshold 
of € 45,000 per QALY gained.
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A UK CASE STUDy OF SOCIETAL AND HERD-EFFECT IMPACT OF UNIvERSAL 
MASS INFLUENzA vACCINATION IN THE UNITED KINGDOM
Meier G.1, Van Bellinghen L.A.2, Van Vlaenderen I.2
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2CHESS, Ternat, Belgium
Objectives: To demonstrate the impact of influenza vaccination in currently non-rec-
ommended populations in the UK. To understand critical elements of influenza infec-
tion (herd-effect and productivity losses) and management of disease. Management 
includes direct medical, non-medical and indirect resources. MethOds: A multi-
cohort, static, one-year Markov-model was constructed. Universal influenza mass 
vaccination of healthy individuals ≥ 6 months to ≤ 64 years was applied, using either 
trivalent (TIV) or quadrivalent (QIV) influenza vaccines. Current vaccination cover-
age rates for high risk persons were utilized as a proxy. Vaccine efficacy data were 
derived from Cochrane Databases (TIV) and meta-analyses (QIV). The impact of herd-
effect was evaluated by two different estimates from published literature, providing a 
range of results. A societal perspective was adopted and 2010 was the cost reference 
year. Results: Using the average influenza-B circulation and vaccine matching data 
of 2000 to 2010, between 71,000-82,000 additional cases will be prevented with QIV 
versus TIV in one influenza season. QIV is anticipated to prevent more medical vis-
its, complications, and hospitalisations (15,000-17,000); (8,000-9,300) and (889-1,044), 
respectively. QIV programme costs are higher due to acquisition costs compared to 
TIV, however influenza treatment and management costs are lower due to fewer 
cases/complications for direct medical, non-medical and indirect categories (absen-
teeism/presenteeism), (savings: £4,800,000-£5,700,000); (savings: £215,000-£253,000); 
(savings: £22,400,000-£26,400,000), respectively. In addition, future productivity losses 
caused by premature mortality are also minimized with maximal effect with QIV 
rather than TIV (savings: £5,100,000-£6,700,000). cOnclusiOns: Herd-effect is a well 
understood and appreciated benefit of vaccinating children and mass vaccination 
within a population. This model suggests that there are vast benefits in universal 
mass vaccination of healthy persons in the UK with QIV instead of TIV, due to greater 
health-related benefits and lower treatment-related costs. However, vaccine acquisi-
tion costs need to be considered.
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THE ECONOMIC ASSESSMENT OF AN ENvIRONMENTAL INTERvENTION: 
DISCRETE DEPLOyMENT OF COPPER FOR INFECTION CONTROL IN ICUS
Taylor M., Chaplin S.
York Health Economics Consortium, York, UK
Objectives: Health Economics evaluations are typically applied to medications or 
surgery costs, but this unique study has investigated the economic benefits of dis-
crete deployment of antimicrobial copper alloy touch surfaces in ICUs. Copper/cop-
per alloy surfaces have been shown to act as an adjunct to standard infection control 
practices in diverse clinical settings, continuously reducing contamination by over 
90%. A study by Salgado in 2013 investigated the use of copper surfaces in ICUs and 
reported a 58% reduction in hospital acquired infections. This study investigates the 
cost-effectiveness of this intervention. MethOds: Following an extensive literature 
review and use of expert opinion a number of factors have been considered in this 
evaluation. These are the component costs of the items used in the ICU, the cost of 
and extra day in bed due to an infection, baseline infection rates and risk reduction 
of copper items. The model is based on a single room configuration in an intensive 
care unit with 20 beds in the UK using 6 critical items - bed rails, overbed tray table, 
chair, call button, data device and IV pole. The model has been created to show the 
economic impact of an environmental intervention. Results: The model predicts 
the cost of replacing key, frequently-touched surfaces in a 20-bed UK ICU with cop-
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Objectives: To evaluate economic impact of linezolid (LZD) versus vancomycin 
(VAN) for treatment of confirmed methicillin-resistant Staphylococcus aureus(MRSA) 
nosocomial pneumonia (NP) in German health care system. MethOds: A 4 week 
decision model was developed capturing 1st and 2nd line therapy. Published lit-
erature (primarily Wunderink 2012, reported 54.8% clinical efficacy for LZD vs. 
44.9% for VAN in modified Intent-to-Treat population at End of Study for treat-
ment of MRSA NP) and expert opinion provided clinical and resource use data, 
such as efficacy, mortality, adverse events (AEs), treatment duration, and length 
of hospital/ICU stay. German cost data was obtained from published literature. 
Base-case analysis used 10-day treatment duration. In event of treatment failure/
severe AEs on 1st-line therapy, drug was switched after 7 days. Costs were reported 
in 2012 Euros. Results: LZD was associated with minimally lower costs (€ 16,119 
vs. € 16,144), and greater overall treatment success compared to VAN, resulting 
in LZD ‘dominating’ VAN. About 80% of treatment costs were related to hospital 
stay, primarily ICU (72%). Drug therapy, physician visits, laboratory tests and AEs/
treatment failure each account for ≤ 5% of total costs. Several scenarios were 
tested by varying treatment duration (7 or 14 days), and varying discontinuation/
switch of therapy (at 5 or 10 days). In cases of shorter treatment duration (7 day) or 
delayed switch of therapy (at 10 day), linezolid continues to ‘dominate’. However, 
with 14 day treatment duration or early switch (at 5 day) linezolid becomes more 
costly, but still has greater effectiveness resulting in a relatively low Incremental 
Cost Effectiveness Ratio (ICER) of € 8,207 and € 2,343 per successfully treated 
patient. cOnclusiOns: LZD is a cost-effective alternative to VAN for treatment 
of MRSA-confirmed NP, owing primarily to its higher clinical response rate. Future 
analyses should use other country costs/resource use data to test result generaliz-
ability and assess empiric treatment phase.
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COST-EFFECTIvENESS OF BOCEPREvIR ADD-ON TREATMENT OF HEPATITIS C 
vIRUS GENOTyPE 1 PATIENTS IN DENMARK
Ehlers L.1, Ferrante S.2, Kristensen M.H.2, Leutscher P.D.C.3, Chhatwal J.4
1Aalborg University, Aalborg, Denmark, 2Merck & Co. Inc., North Wales, PA, USA, 3Aarhus 
University Hospital, Aarhus, Denmark, 4University of Pittsburgh, Pittsburgh, PA, USA
Objectives: Despite available treatment options chronic hepatitis C virus (HCV) 
infection remains a significant disease burden in Denmark, in particular among 
genotype 1 difficult-to-treat patients The aim of this study was to evaluate the 
cost effectiveness of boceprevir (BOC), a protease inhibitor, in combination with 
pegylated interferon plus ribavirin (PEG+R), compared to PEG+R alone, among treat-
ment naïve and treatment experienced genotype 1 HCV patients. MethOds: A 
Markov model simulating antiviral therapy and disease progression was devel-
oped to estimate the lifetime health care costs and clinical outcomes of alternative 
treatment strategies. The model simulated the treatment regimens of dual therapy 
(PEG+R) and triple therapy (PEG+R+BOC), respectively, as recommended in the sum-
mary of product (SPC) and the Danish treatment guidelines. Data on clinical effi-
cacy was taken from phase III clinical trials (SPRINT-2 and RESPOND-2). Costs were 
measured in 2012 Danish Kroner (DKK) and clinical outcomes in quality adjusted 
life years (QALYs). The incremental cost-effectiveness ratio (ICER) was estimated 
for treatment naïve and experienced patients. Deterministic and probabilistic sen-
sitivity analyses (PSA) on clinical inputs, costs, health state utility values, and SVR 
rates were performed to assess the overall decision uncertainty. Results: The ICER 
for PEG+R+BOC therapy versus standard of care with PEG+R was DKK 241.774 for 
treatment naïve HCV patients and DKK 98.371 for treatment experienced patients. 
PSA for treatment naïve patients showed a probability of cost-effectiveness of 
PEG+R+BOC therapy compared to PEG+R of more than 65 % at a willingness-to-pay 
threshold of DKK 300.000 (approx. £30.000). cOnclusiOns: From a Danish health 
sector perspective, the model suggests PEG+R+BOC therapy is cost effective in HCV 
genotype 1 patients to prevent development of late manifestations in the liver, 
such as cirrhosis and hepatocellular carcinoma (HCC) irrespectively of treatment 
experience status.
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COST-EFFECTIvENESS COMPARISON OF GENOTyPE 1 HEPATITIS C vIRUS (HCv) 
TREATMENTS USING TELAPREvIR (TvR) IN PATIENTS wITH MILD FIBROSIS 
vERSUS PATIENTS wITH BRIDGING FIBROSIS AND CIRRHOSIS
D’Angelo E.R.1, Gonzalez E.2, Sola R.2
1Janssen-Cilag SA, MADRID, MADRID, Spain, 2Hospital del Mar, BARCELONA, Spain
Objectives: To estimate, from a Spanish Healthcare System perspective, the cost-
effectiveness of the usage of telaprevir (TVR) with peginterferon and ribavirin (PR) 
in patients with mild fibrosis (METAVIR F2) vs. patients with bridging fibrosis or 
cirrhosis (METAVIR scores F3 and F4, respectively). MethOds: A decision tree model 
was developed to assess cost-efficacy of TVR+PR according to the degree of fibrosis 
and previous response to treatment in patients with HCV Genotype 1. Treatment 
costs were estimated excluding futility rules but contemplating the potential to 
shorten treatment in treatment-naïve and relapsers that are either F2 or F3. The 
efficacy of triple therapy treatment by patient type is derived from the TVR phase 
III clinical trials. To estimate cost-effectiveness, the following values were calcu-
lated for each alternative: the cost per cured patient and the number of cured and 
not cured patients assuming a fixed budget. Results: TVR+PR in F2 patients has 
a lower cost per cured patient than F3+F4 both in naïve patients (20% less) and in 
experienced patients (in relapsers: 5% less; in partial responders: 47% less; and in 
null responders: 39% less). This difference is statistically significant for naïve and 
partial responding patients. For a 1 million EUR investment in each patient type, 
resources allocated to F2 patients offers maximum cured patients (94 in F2 vs. 71 
in F3+F4) and minimum non-cured patients (37 in F2 vs. 58 in F3+F4). This conclu-
sion stands when different sensitivity analyses are conducted. cOnclusiOns: The 
usage of TVR+PR in patients with mild fibrosis could be a more cost-effective alter-
native than in patients with bridging fibrosis or cirrhosis regardless of the patient’s 
previous response to treatment. A long-term cost-effectiveness analysis is required 
in order to validate this data.
therapy. The aim of this study was to assess the cost-effectiveness (CE) of Linezolid 
against generic Vancomycin as an empiric therapy for VAP patients, from the health 
care payer’s perspective. MethOds: A decision-tree model was used to compare 
costs and effectiveness of Linezolid (600 mg/12 hours) and Vancomycin (1g / 12 
hours) (comparator) for a cohort of patients with VAP. Effectiveness measures were: 
microbiological success rates, mortality rates, ICU and ward LOS and overall costs. 
Effectiveness and epidemiologic data were collected from published literature. Local 
costs (2012 US$) were obtained from Costa Rica’s Health System official databases. 
The model used a 12-week time horizon and only direct medical costs were consid-
ered (hospital LOS, medication costs, hematologic, gastrointestinal and skin adverse 
events and lab exams). Monte Carlo probabilistic sensitivity analysis (PSA) was 
constructed. Results: Results showed Linezolid as more effective and less expen-
sive option for VAP. Clinical success rate was higher with Linezolid (64.4%) against 
Vancomicyn, (56.1%). Mortality was lower with linezolid (10.13% vs 15.74%). Average 
ICU (and ward) LOS was 18 (9) days with Linezolid and 22 (10) days with Vancomycin. 
Overall medical costs per patient were $87782.52 with Linezolid and $92771.51 with 
Vancomycin. CE analyses showed Linezolid is the dominant strategy. cOnclusiOns: 
This is the first CE study for VAP developed in Costa Rica. Linezolid resulted as the 
cost-saving option for treating VAP patients in the Costa Rican clinical environment.
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COST-EFFECTIvENESS OF TELAPREvIR PLUS PEGINTERFERON/RIBAvIRIN 
(TvR+PR) vERSUS PEGINTERFERON/RIBAvIRIN (PR) IN TREATMENT-NAïvE 
GENOTyPE 1 CHRONIC HEPATITIS C PATIENTS wITH F2 FIBROSIS IN BRAzIL
Morais A.D., Pereira M.L.
Janssen Cilag Farmaceutica, São Paulo, Brazil
Objectives: To compare the cost-effectiveness of telaprevir associated with 
peginterferon and ribavirin (TVR+PR) compared to peginterferon and ribavirin (PR) 
alone in the treatment of patients with METAVIR scale F2) fibrosis and with previ-
ously untreated chronic hepatitis C genotype 1. MethOds: Markov model, Curtis 
et al 2012, was adapted to a Brazilian public payer perspective. The model estimated 
chronic hepatitis C disease progression based on transition probabilities for a cohort 
of patients with F2 fibrosis. Clinical outcomes and drug dosage were taken from 
the phase-3 trial (Marcellin et al), with the SVR-rate for TVR+PR as 79% and 49% for 
PR in patients with F2 fibrosis. Drug costs of TVR and PR were gathered from the 
ministry of health website, www.comprasnet.gov.br. Costs associated with each 
disease state were gathered from a study by Barros et al. A discount rate of 3.5 % and 
a lifetime horizon were assumed. Results: TVR+PR therapy resulted in higher costs 
(R$ BRL57,164 vs BRL27,971) and better outcomes (278 cirrhosis avoided per 1,000 
patients) compared to PR alone. Treatment with TVR+PR resulted in 19.94 life years 
gained compared to PR alone with 19.19. TVR+PR was estimated to give a quality 
adjusted life year (QALY) expectancy of 13.83, 1.16 higher than with PR (12.67 QALYs), 
resulted in an incremental cost-effectiveness ratio (ICER) of R$23,734 per QALY 
gained. Compared to PR alone, the treatment with TVR+PR avoided about 11 deaths 
and 17 liver transplants per 1,000 treated patients. Treatment with TVR+PR resulted 
in an incremental cost of R$1,595 per liver transplant avoided and R$2,613 per death 
avoided compared to PR alone. cOnclusiOns: Treating F2 fibrosis patients with 
TVR+PR was cost-effective compared with PR alone with an ICER below to the WHO 
recommended threshold. The benefits of TVR+PR treatment were clear with the low 
incremental cost per death or liver transplant avoided.
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COST-EFFECTIvENESS OF ANTI-RABIES PROPHyLAxIS AFTER ExPOSURE TO 
UNOBSERvABLE DOGS IN ERADICATION CONTExT: THE FRENCH CASE
N’Diaye D.S.1, Ribadeau-Dumas F.2, Yazdanpanah Y.3
1INSERM (French National Institute of Health and Medical Research), Paris, France, 2Pasteur 
Institute, Paris, France, 3Bichat Claude Bernard Hospital, Paris, France
Objectives: WHO recommends Post-Exposure Prophylaxis (PEP) in countries like 
France, where rabies cases observed are linked to bats or imported. This study aims 
to assess effectiveness and cost-effectiveness of anti-rabies PEP algorithms in this 
low rabies risk countries. MethOds: A model-based analysis simulated PEP admin-
istration incorporating risk of rabies according to exposure categories (CII: minor 
scratches; CIII: transdermal bite(s)), PEP strategy, and risk of death on car crash in 
trips to anti-rabies centers. Strategies compared were: A) No PEP for CII and CIII; B) 
vaccine for CIII only; C) vaccine for CII and CIII; D) vaccine+immunoglobulins for 
CIII only; E)vaccine for CII and vaccine+immunoglobulins for C III. We simulated the 
trajectory of 2,807 patients exposed to unobservable dogs in Metropolitan France, in 
2011. Model parameters were estimated from French and international literature. 
The probability that the dog to which the patient was exposed is rabid was 4x10-9 
and the average risk of death on car crash in trips to anti-rabies centers was 7x10-
7. Total vaccine, immunoglobulins and consultation costs for Zagreb regimens (4 
vaccine injections) were € 160, € 700 and € 70, respectively. Results: Strategy E led 
to the lowest number of rabies cases (4.36x10-8), the highest costs (€ 2,493,000), but 
also to 1.74x10-3 lethal car crashes. Strategy A had the highest number of rabies 
cases (5.71x10-6), but no risk of lethal crash and no costs; therefore it was the most 
effective and the least costly strategy. In the sensitivity analysis when the probability 
that the dog is rabid was> 1.4x10-6, strategy D becomes more effective than strategy 
A; and when> 1.4x10-4, strategy B becomes cost-effective (i.e. cost-effectiveness ratio 
vs. A> 3x French GPD= € 30,000). cOnclusiOns: In 2011, in France, anti-rabies PEP 
appears to be less effective and more expensive than No PEP. These model-based 
results could be used by decision makers to establish national guidelines.
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AN ECONOMIC MODEL TO COMPARE LINEzOLID AND vANCOMyCIN FOR THE 
TREATMENT OF CONFIRMED METHICILLIN-RESISTANT STAPHyLOCOCCUS 
AUREUS NOSOCOMIAL PNEUMONIA IN GERMANy
Patel D.A.1, Michel A.2, Stephens J.M.1, Weber B.3, Gao X.1, Charbonneau C.4
1Pharmerit International, Bethesda, MD, USA, 2Klinikum Hanau GmbH, Hanau, Germany, 3Pfizer, 
Berlin, Germany, 4Pfizer, Paris, France
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vancomycin and daptomycin. Second line intravenous daptomycin was assumed 
to be administered via an outpatient parenteral treatment service. cOnclusiOns: 
Findings suggest that use of first-line linezolid in the management of MRSA-cSSTIs 
could result in savings for the third-party payer in Greece accompanied by enhanced 
quality of life results.
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MATHEMATICAL MODELS OF HEPATITIS B vACCINATION AND SCREENING 
PROGRAMMES IN THE UNITED KINGDOM: A SySTEMATIC REvIEw
Keeping S.T.1, Allen F.2, Patel A.2, Carroll S.M.1, Kilcoyne A.1
1Sanofi Pasteur MSD, Maidenhead, UK, 2Abacus International, Bicester, UK
Objectives: The United Kingdom (UK) has a targeted hepatitis B (HBV) vaccination 
programme for at-risk patient groups; however such a programme can be challeng-
ing to implement. The World Health Organisation (WHO) recommends universal 
HBV vaccination and this approach has been adopted by most developed countries. 
A systematic review was conducted to identify UK-based mathematical models for 
HBV to determine whether current evidence supports the use of a universal vaccina-
tion programme versus a targeted approach. MethOds: Embase, Medline, Econlit 
and The Cochrane Library were searched for studies reporting HBV mathematical 
models (economic or epidemiological) in the UK population. Hand searching of 
Health Protection Agency and National Institute for Health and Clinical Excellence 
guidance documents was also performed. Economic models (cost-effectiveness, 
cost-utility, cost-benefit, cost-consequence) were included if they assessed HBV 
vaccination or screening programmes. Epidemiological studies were included if they 
modelled HBV immunity and infection rates. Data were independently extracted 
and summarised into evidence tables by two reviewers and quality appraisal of 
included studies was performed. Results: Electronic database searches identified 
a total of 649 citations resulting in 11 relevant publications. Hand searching yielded 
an additional two publications; a total of 13 included publications representing 
seven economic evaluations and six epidemiological modelling studies. Overall, 
there was considerable variation in model methodologies including methods of 
discounting used, static versus dynamic approaches and sources of model inputs. 
Only one epidemiological modelling study considered HBV transmission patterns 
across the UK. cOnclusiOns: Current HBV vaccination policy in the UK is depend-
ent on the demonstration of cost-effectiveness. However, this review highlights 
some of the limitations inherent in the models which have been used to support 
policy decisions. Alternative modelling approaches, as well as new data on key 
inputs, are desirable if the full value of a universal HBV vaccination programme in 
the UK is to be assessed.
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COST-EFFECTIvENESS OF ROUTINE INFANT vACCINATION STRATEGIES IN 
RUSSIA: AN ECONOMIC EvALUATION
Yagudina R.I.1, Akimova Y.I.2
1Moscow Medical Academy, Moscow, Russia, 2First Moscow medical academy named after I.M. 
Sechenov, Moscow, Russia
Objectives: Today vaccination for children from 0 to 20 months in the Russian 
Federation is carried mainly by DPT and monovalent vaccines. As a result, a child 
of this age receives 12 injections. Vaccination against Hib infection so far is only 
available for children at risk (approx. 20%). Introdution of DTaP-IPV-Hib combined 
vaccine could reduce the number of injections received by the child and increase 
the coverage against Hib infection from 20% to 97%. The objective of the present 
study is to assess the economic evaluation of DTaP-IPV-Hib vaccine introduction 
into immunization schedule and select the most cost-effective vaccination scheme 
against Hib infection. MethOds: A cost-effectiveness analysis of the DTaP-IPV-Hib 
vaccine is performed on suggested Markov model. The four vaccination schemes are 
intercompared : the current immunization program (Scheme0), a 3+1 immuniza-
tion DTaP-IPV-Hib vaccine (Scheme P), a mixed DTwP /DTaP-IPV-Hib immunization 
(Scheme mix) and a potential scenario - the current scheme, but with expanded 
(97%) Hib coverage - Scheme 1. The cohort of infants born in 2011 year is followed 
over their lifetime. Direct and indirect medical costs are measured from the perspec-
tive of the public payer. Outcomes are measured in life years gained (LYG).Exchange 
rate is 1€ = 41 rub. Results: According to the model, total costs of immunization 
Scheme are: 0 – 4216723519 rub. (102 846 915€ ), Scheme 1 –4924823829 rub.(120 117 
654€ ), Scheme P -6035132925rub.(147 198 364€ ), Scheme mix - 4 921 824 835 rub 
(120 044 508€ ). The values of cost/LYG are estimated at 4243 198 rub .(103493€ ) for 
Scheme 0, 1 224 270rub.(29860€ )for Scheme 1, 1500 283 rub. (36592€ ) for Scheme P, 
1223 525rub.(29842€ )– for Scheme mix. cOnclusiOns: The introduction of DTaP-
IPV-Hib combined vaccine would bring improvement into the Russian immunization 
program through a Scheme mix.
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DIFFERENT DISCOUNTING APPROACHES AND THEIR IMPACT IN ECONOMIC 
EvALUATION: A PRACTICAL ExAMPLE USING HEPATITIS B vACCINATION
Cure S.1, Bianic F.2, Nandini Kahol D.1, Davie A.1
1OptumInsight, Uxbridge, UK, 2OptumInsight, Nanterre, France
Objectives: To evaluate the impact of different discounting approaches on economic 
evaluation using an example of Hepatitis B model. Currently, constant discounting 
rates of 3.5% are applied for costs and outcomes in the UK. This study applied different 
approaches such as empirical, stepwise and time-shifted discounting in parallel to 
the constant discounting to identify their respective impact on the cost-effectiveness 
results with respect to the NICE threshold. MethOds: To compare costs and out-
comes of a vaccination policy, a Markov model was built for the UK population birth 
cohort. Patients entered after contracting Hepatitis B and were followed until 80 years 
old. The health states included chronic carrier phase, immune, compensated and 
decompensated cirrhosis, hepatocellular carcinoma and death. The different dis-
counting approaches were applied to the costs and health outcomes. The Incremental 
Cost-Effectiveness Ratios (ICERs) thus obtained were compared. Results: The ICER 
obtained was higher than the NICE threshold of £20,000 to £30,000 per QALY gained 
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COST-EFFECTIvENESS ANALySIS OF STRIBILD COMPARED TO SIMILAR 
ANTIRETROvIRAL THERAPIES IN A SPECIALTy RETAIL PHARMACy
Griggs S.K.1, Davelis M.2
1St. Louis College of Pharmacy, St. Louis, MO, USA, 2Schnucks Specialty Pharmacy, Bridgeton, MO, 
USA
Objectives: Approximately 1.1 million people in the U.S. are living with HIV, with 
50,000 new infections per year. The FDA approved Stribild™, a once-daily HIV medi-
cation, in September of 2012. The primary objective of this study was to assess 
the cost and disease-related outcomes of Stribild versus guideline-recommended 
treatment options for HIV patients in a specialty retail pharmacy. A secondary objec-
tive was to assess compliance via Medication Possession Ratios (MPRs). MethOds: 
HIV patients who were prescribed one of five antiretroviral regimens in the period 
from January 1, 2010 to June 21, 2013 and who obtained their medications through 
Schnucks Specialty Pharmacy were selected via a retrospective chart review. By 
measuring the direct cost of the medications to the pharmacy and the disease-
related outcomes, change in CD4 count and viral load suppression, the cost-effec-
tiveness of Stribild versus its comparators was assessed. Results: A total of 92 
patients were included in this study: 50 Stribild patients and 42 patients on alternate 
regimens: 15 Atripla®; 6 Isentress®; 10 Prezista®; and 11 Reyataz®. Incremental Cost-
Effectiveness Ratios (ICERs) were conducted between Stribild and the comparators 
for change in mean CD4 count and percent viral load suppression (< 20 copies/ml) 
achieved. In terms of CD4 count, Stribild was most cost-effective when compared 
to Prezista and least cost-effective when compared to Isentress. Analyses of viral 
load suppression indicated that Stribild is more cost-effective than Prezista and 
Reyataz but less cost-effective than Atripla or Isentress. Mean MPR was greater 
than 95% for Stribild and three of its comparators (not including Atripla); however, 
78 percent of Stribild patients achieved MPR ≥ 95% which demonstrates higher 
compliance than all comparators except the Isentress patients. cOnclusiOns: 
The once-daily regimen Stribild appears effective at treating the HIV virus while 
maintaining compliance for most of its patients; its high cost remains a concern 
for formulary decision makers.
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COST-EFFECTIvENESS OF ANTIMICROBIALS AS TREATMENT FOR PATIENTS 
wITH COMPLICATED SKIN AND SOFT TISSUES INFECTIONS: A COMPARISON 
BETwEEN CEFTAROLINE, LINEzOLID AND vANCOMyCIN IN THE RUSSIAN 
HEALTH CARE
Kulikov A., Komarov I.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To estimate the cost-effectiveness of antimicrobials (ceftaroline, 
linezolid and vancomycin) as treatment for patients with complicated skin and 
soft tissues infections. MethOds: A literature-based cost-effectiveness analysis 
was developed to estimate the costs of complicated skin and soft tissues infec-
tions patients initiating therapy with ceftaroline, linezolid or vancomycin. Direct 
expenses associated with complicated skin and soft tissues infections and resulting 
follow-up costs were calculated using general tariff agreement of Russian obligatory 
insurance system and official national statistics. For reference, accepted exchange 
rate was 1 EUR = 40 RUB. Results: Compared to ceftaroline, linezolid or vanco-
mycin results in increases in drug therapy costs: 77 997 RUB (1 950 EUR) per patient 
in ceftaroline group (therapy duration – 9 days), 78 816 RUB (1 970 EUR) per patient 
in vancomycin group (therapy duration – 10 days) and 117 893 RUB (2 947 EUR) per 
patient in linezolid group (therapy duration – 12 days). The values of cost/clinical 
cure rate are estimated at 96 055 RUB (2 401 EUR) in ceftaroline group, 98 030 RUB (2 
451 EUR) in vancomycin group, and 138 860 RUB (3 472 EUR) in linezolid group per 
patient. cOnclusiOns: The results of cost-effectiveness illustrate that ceftaroline 
is dominant in Russian patients with complicated skin and soft tissues infections 
who are initiating antimicrobials therapy compared with linezolid or vancomycin.
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ANTIBACTERIAL TREATMENT OF METICILLIN-RESISTANT STAPHyLOCOCCUS 
AUREUS COMPLICATED SKIN AND SOFT TISSUE INFECTIONS: A COST-
EFFECTIvENESS ANALySIS IN GREECE
Karampli E.1, Ollandezos M.1, Petrakis I.2, Tsoulas C.2, Patel D.A.3, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Pfizer Hellas, Athens, Greece, 3Pharmerit 
International, Bethesda, MD, USA
Objectives: Meticillin-resistant staphylococcus aureus (MRSA) is an important 
cause of antimicrobial-resistant health care-associated infections worldwide. Its 
prevalence remains high in the Greek hospital setting. Complicated skin and soft tis-
sue infections (cSSTIs) due to MRSA are associated with prolonged hospitalization, 
additional costs of care and significant morbidity. The purpose of this study was to 
conduct a cost-effectiveness analysis of different treatment scenarios in the man-
agement of MRSA-cSSTIs, under a third-party payer perspective. MethOds: The 
model was based on a decision tree simulating costs and outcomes for a maximum of 
28 days, consisting of empiric, first-line and second-line treatment, for patients with 
MRSA-cSSTIs. Inpatient and outpatient health care services were included in the 
analysis. Data on efficacy of the pharmacotherapies under evaluation were derived 
from a recent meta-analysis (Bassetti et al 2013) and resource use was elicited via 
an expert panel. Economic results, expressed in Euros (2013), reflect the Greek social 
insurance setting. Results: Three different first→second line treatment scenarios 
(daptomycin→linezolid, linezolid→daptomycin, vancomycin→linezolid) were evalu-
ated, as recommended by the expert panel. Total management costs per patient 
were € 4,199, € 3,809, and € 3,900; quality adjusted life years (QALY) gained were 0.058, 
0.059 and 0.057 respectively for the above scenarios. The scenario containing first-
line linezolid proved to be a dominant therapeutic option vs. the other scenarios 
(less costly, higher QALYs), whereas first-line daptomycin scenario did not appear 
to be cost-effective vs. the respective vancomycin scenario (incremental cost-utility 
ratio € 243,932) in the management of MRSA-cSSTIs. Second line oral linezolid was 
used as continuation treatment after failure/intolerance or switch from intravenous 
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propofol in critically ill patients, and subsequently determining the best strategy 
for administering propofol. MethOds: Costs of propofol-related infection and the 
different strategies of administration of propofol were computed according to the 
literature and microcosting method. The additional length of stay in ICU due to 
major infections related to propofol administration was estimated using the disabil-
ity model, assuming a cost of CHF 2’118/intensive care unit day (local cost). The cost 
of each strategy was estimated based on all costs and on the probability of major 
infections related to propofol administration. Results: According to the links 
found in the literature by genotyping bacteria (syringe-patient), we assumed that a 
patient has a mean 22.6% risk of developing an infection by a contaminated prepa-
ration of propofol. Thus, the ready-to-use syringe and syringes drawn from vials 
have an infection probability of 0.0014 [0.0009 – 0.0038] and 0.0118 [0.0056 – 0.0181] 
respectively. Probability of infection and the extended length of stay were the cost-
drivers of this analysis. Ready-to-use syringes of propofol saved money, decreasing 
the cost by at least CHF 251 per sedation. Ready-to-use syringes remained a cost 
saving strategy when the propofol related infection rate probability according to the 
literature was as high as 0.38%. cOnclusiOns: Ready-to-use syringes of propofol 
save money by preventing major infections related to its administration.
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COST EFFECTIvENESS OF PREPEx DEvICE AND DORSAL–SLIT TECHNIQUE FOR 
SCALING-UP ADULT SAFE MEDICAL MALE CIRCUMCISION IN HIv PREvENTION 
IN RURAL CENTRAL UGANDA
Kigenyi O., Kusiima J., Silas I.
Makerere University, Kampala, Uganda
Objectives: Averting 20% of new HIV infections, the country has to achieve 80% 
national circumcision coverage. Given the inadequacy of human resource at cir-
cumcision centers in Uganda, we conducted a study to assess the cost-effectiveness 
of PrePex device (none surgical) and Dorsal-slit technique (surgical) for scaling-up 
adult safe medical male circumcision. MethOds: In a four weeks cost effective-
ness course project during November 2012, we modeled the costs and effects of 
male circumcision of the 2 commonest strategies (Dorsal-slit technique as standard 
and PrePex device) used in Uganda. Effectiveness was defined as days of complete 
healing measured by costs from start of procedure to complete healing. This was 
the time until end of each procedure when all scores for drainage from incision, 
epithelialization, granulation of tissue, and edema were zero. We estimated costs 
and effects from previous studies in developing countries. Direct and indirect costs 
were included in a cost effectiveness analysis with limited government perspective. 
Costs for demand creation (training, patient counseling, and promotion campaigns) 
were excluded. One-way sensitivity analysis was done by varying costs and days of 
complete healing as main model parameters. Analyses were done using TreeAge 
Pro-2011 software. Results: PrePex (none surgical) utilized $52.13 over the days 
to complete healing (31 days) compared to dorsal-slit (surgical) utilizing $67.8 over 
the days to complete healing (23 days). PrePex was less costly ($52) and with lowest 
adverse-events (0.98) compared to dorsal-slit technique 0.96 adverse-events cost-
ing $65.9. PrePex device was mostly not sensitive to changes in costs and days to 
complete healing. cOnclusiOns: PrePex device was cost-saving and cost effective.
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COST-EFFECTIvENESS OF CASPOFUNGIN vERSUS vORICONAzOLE FOR EMPIRIC 
THERAPy IN TURKEy
Turner S.J.1, Senol E.2, Kara A.3, Al-Badriyeh D.4, Kong D.C.5, Dinleyici E.C.6
1Rutgers University, Piscataway, NJ, USA, 2Gazi University, Ankara, Turkey, 3Hacettepe University, 
Ankara, Turkey, 4College of Pharmacy, Qatar University, Doha, Qatar, 5Monash University, 
Parkville, Australia, 6Eskisehir Osmangazi University, Eskisehir, Turkey
Objectives: Two major clinical trials examined the efficacy of caspofungin (CAS) 
and voriconazole (VORI) for empiric therapy of febrile neutropaenia (FN). We inves-
tigated the cost-effectiveness of empiric CAS vs. VORI in FN from the Turkish per-
spective. MethOds: The downstream consequences of CAS or VORI were captured 
through decision tree analysis. Outcome measures included success, breakthrough 
fungal infection, persistent base-line fungal infection, persistent fever, premature 
discontinuation and death. Probability data were extracted from the major stud-
ies. An expert panel estimated health care resource consumption and alternative 
treatment after initial failure with either agent. Cost was based on 2012 data using 
Turkish Lira (TL). Deterministic and probabilistic sensitivity analyses were per-
formed. Results: Compared to VORI, CAS was dominant by TL2,533, TL29,256 and 
TL2,536 per patient treated, successfully treated and patient survival, respectively 
(approx. USD1,414, 16,328 and 1,415). CAS had a higher likelihood of success and 
lower mortality than VOR (34.17% vs. 26.02% and 7.37% vs. 7.95%, respectively). 
Increasing the list cost or length of stay (LOS) for CAS by > 35% or 1.3 days, respec-
tively, changes the study outcomes. A decrease of list cost or LOS for VOR by > 32% 
or 1.2 days resulted in it being favorable. Removing fever resolution as part of the 
composite outcome afforded a contracted difference (CAS preferred by TL298 and 
299 per patient treated and surviving with VORI preferred by TL488 per patient 
successfully treated). Monte Carlo simulation of 10,000 subjects, with variability 
imputed on the outcome probabilities taken from the literature, LOS and hospitali-
sation costs, resulted in a 78.8% chance of favoring CAS. cOnclusiOns: There is 
a high likelihood of CAS being cost-effective compared to VORI in the treatment of 
FN in Turkey. Sensitivity analyses highlighted a robust advantage towards CAS. The 
model is moderately sensitive to changes in LOS or cost of each agent.
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ECONOMIC ANALySIS OF PROTEASE INHIBITORS IN FIRST-LINE HAART IN 
ADULT PATIENTS wITH HIv
Avxentyeva M.1, Goryaynov S.2, Rebrova O.3
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia, 2Autonomous non-profit organization “National Centre for Health Technology 
Assessment”, Moscow, Russia, 3Pirogov Russian National Research Medical University, Moscow, 
Russia
using the constant discounting approach. The empirical , hyperbolic and propor-
tional discounting methods provided ICERs three times higher. The time-shifted and 
stepwise discounting led to favorable ICERs that were much below the NICE thresh-
old. cOnclusiOns: The use of different discounting approaches had a considerable 
effect on the cost-effectiveness results. For preventive programs and vaccines con-
stant discounting approach was unfavorable since the health benefits are revealed 
decades later. Constant discounting could not justify the theory of social and indi-
vidual time preference. The empirical discounting though discounted the outcomes 
at a much slower rate in the long term; the approach remained unfavorable owing to 
the heavy discounting in the short term. The time-shifted and stepwise discounting 
were feasible for the vaccines as they related to the moment of risk reduction and 
were persistent with the time-preference theory, respectively.
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COST-EFFECTIvENESS ANALySIS OF EMPIRIC LIPOSOMAL AMPHOTERICIN B 
vERSUS vORICONAzOLE IN TURKEy
Turner S.J.1, Senol E.2, Kara A.3, Al-Badriyeh D.4, Kong D.C.5, Dinleyici E.C.6
1Rutgers University, Piscataway, NJ, USA, 2Gazi University, Ankara, Turkey, 3Hacettepe University, 
Ankara, Turkey, 4College of Pharmacy, Qatar University, Doha, Qatar, 5Monash University, 
Parkville, Australia, 6Eskisehir Osmangazi University, Eskisehir, Turkey
Objectives: A pivotal clinical trial failed to demonstrate non-inferiority of voricona-
zole (VORI) vs. liposomal amphotericin B (LAMB) for empiric treatment of febrile neu-
tropaenia (FN). This study investigated the cost-effectiveness of the two options from 
the Turkish health care system’s perspective. MethOds: A decision-tree analysis 
was used to capture downstream consequences of each agent. Outcome measures 
included success, breakthrough fungal infection, persistent base-line fungal infection, 
persistent fever, premature discontinuation and death. Probability data were extracted 
from the published clinical trial. Resource consumption and alternative treatment 
after initial failure with either agent were estimated by an expert panel. Cost was 
based on 2012 data within Turkey. Deterministic and probabilistic sensitivity analyses 
were performed to determine the model’s robustness. Results: Compared to LAMB, 
VORI was the cost-effective alternative per patient treated and per patient survival 
(by TL2,523 (approx USD1,396) and TL2,520 (approx USD1,394), respectively). LAMB 
was preferred when considering the cost per successfully treated patient (TL5,362 
difference in favor of LAMB, approx USD2,966). LAMB had a higher likelihood of suc-
cess (30.57% vs. 26.02%) and lower probability of death than VORI (5.92% vs. 7.95%). 
Increasing the list cost or length of stay (LOS) of VORI by > 32.4% or 1.2 days, respec-
tively, changes the study outcomes. Decreasing list cost or LOS for LAMB by > 15.8% 
or 1.0 days, respectively, resulted in LAMB becoming favorable. Monte Carlo simula-
tion (MCS) of 10,000 subjects, with variability imputed upon the published outcome 
probabilities, LOS and hospitalization costs, resulted in a 69.4% chance of favoring 
VORI. cOnclusiOns: VORI appears to be cost-effective when compared to LAMB in 
the empiric treatment of FN from the Turkish perspective. One-way sensitivity analy-
ses did not change the conclusion with MCS indicating a 69.4% chance of favoring 
VORI. The outcome was highly sensitive to list cost and LOS.
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NON-HOMOGENEOUS COST-EFFECTIvENESS MODELING OF A NEw CHG-
DRESSING FOR PREvENTING CATHETER-RELATED BLOODSTREAM INFECTIONS 
FOR PATIENTS IN INTENSIvE CARE UNITS
Maunoury F.1, Motrunich A.1, Ruckly S.2, Timsit J.F.2
1Statésia, Le Mans, France, 2Grenoble University Hospital, Grenoble, France
Objectives: Catheter-related bloodstream infection (CRBSI) is a frequent (1-5/1000 
catheter-days) and life-threatening complication in intensive care unit (ICU), pre-
ventable by systematic use of a new antimicrobial transparent dressing containing 
a chlorhexidine gluconate (CHG) hydrogel (60% risk reduction in a recent RCT). Our 
purpose is to evaluate the advantages of routine use of the new CHG-dressing to 
secure central lines of patients in ICU from the medico-economic viewpoint compared 
to non-antimicrobial (reference). Both medical and economic criteria are embedded 
into an analytic decision model to support the choice of the best dressing strat-
egy. MethOds: A 30-day ICU-time non-homogeneous markovian model comprises 
eight states: five combining either occurrence or no-occurrence of: CRBSI, contact 
dermatitis, and the need of a new central line; one for changing alternative dressing 
in case of dermatitis and two absorbent states (death and discharge). The probabili-
ties of events derive a multicentre RCT on 1,879 patients. Monte Carlo simulations 
of 1,000 patients are used for probabilistic sensitivity analysis and 95% confidence 
intervals (CI) calculations. The final health outcome is the number of CRBSI averted. 
Costs of ICU stay are updated from estimations of a French study from 2010. This 
economic evaluation takes into account ICU perspective in France. Results: The 
CHG-dressing prevents 11.75 infections (95% CI: [-19.64; -3.85], number needed to 
treat= 85) for 1,000 patients as estimated via probabilistic cost-effectiveness sensitivity 
analysis. The mean adjusted cost per patient is € 2013 21,391 [95% CI: € 20,339; € 22,443] 
for the CHG-dressing group and € 2013 20,882 [95% CI: € 19,905; € 21,859] for the reference 
dressing. cOnclusiOns: The CHG-dressing, significantly more efficacious to prevent 
CRBSI when compared to the reference dressing, contributes to preserve patients’ 
health capital at the same cost for the ICU. According to the base case scenario the 
CHG-dressing is more cost-effective than the reference dressing.
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COSTS EvALUATIONS OF READy-TO-USE PROPOFOL SyRINGES vERSUS 
SyRINGES DRAwN FROM vIALS IN CRITICALLy ILL
Devaud J.C.1, Eggimann P.2, Voirol P.1, Jolliet P.2, Pinget C.2, Wasserfallen J.B.2, Pannatier A.1
1Lausanne University Hospital (CHUV)/School of Pharmaceutical Sciences, Lausanne, Switzerland, 
2Lausanne University Hospital (CHUV), Lausanne, Switzerland
Objectives: Primary nosocomial bloodstream infections (BSI) (5-15% of all infec-
tions) are associated with increased length of stay and additional hospital costs. 
Propofol infusions, commonly used for sedation in intensive care units (ICU), are 
formulated in lipid emulsion which promotes microbial growth. The present study 
aimed at identifying the probabilities and costs of contamination of syringes of 
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QUADRIvALENT vERSUS TRIvALENT INFLUENzA vACCINE: IS IT GOOD vALUE 
FOR MONEy?
Barbieri M.1, Patarnello F.2, Boccalini S.3, Silvestri R.2, Lapinet J.A.2, Tosatto R.2, Kheiraoui F.4, 
de Waure C.4, Bonanni P.3, Ricciardi W.G.4
1Centre for Health Economics, York, UK, 2GlaxoSmithKline Italy, Verona, Italy, 3University of 
florence, Florence, Italy, 4Catholic University of Sacred Heart, Rome, Italy
Objectives: To assess the cost-effectiveness of quadrivalent influenza vaccine 
(QIV) compared to trivalent vaccine (TIV) in the Italian population aged 65 years or 
more or at high-risk for influenza. MethOds: A static and multi-cohort Markov 
model was modified to simulate the disease process of influenza (type A and B) over 
a lifetime horizon using annual cycles. Several cohorts based on the Italian popu-
lation (nine different age-groups and two level of risks: high and low) entered the 
model and could be vaccinated with QIV or TIV. Vaccine coverage rate, epidemiologi-
cal and demographic estimates were taken from local statistics, surveillance data 
and Italian published studies, while circulation of type A versus B virus and type of 
lineage was taken from Euroflu estimates (from 2003-2004 to 2012-2013). Vaccine 
efficacy against influenza A and B were taken from 2 meta-analyses of clinical trials. 
Costs and resource use were based on local tariffs and published estimates (price 
year 2013). Quality of life scores were obtained from a Spanish study, using the EQ-5D 
questionnaire. The perspective of the National Health Service (NHS) was used and a 
3% discount rate was applied to costs and benefits, according to Italian guidelines. 
To deal with the issue of uncertainty both deterministic and probabilistic sensitivity 
analyses were conducted. Results: In the basecase, the incremental cost per QALY 
and per LY saved for QIV versus TIV were € 10,940 and € 9,452, respectively. The most 
sensitive parameters were vaccine efficacy and probability of circulation of virus 
A versus B, but the probabilistic analysis showed that at a threshold of € 50,000 per 
QALY, there was about 90% probability for QIV to be cost-effective. cOnclusiOns: 
This study suggests that the introduction of QIV at the same level of price of the 
most recent adjuvated vaccines is likely to be a cost-effective strategy from the 
perspective of the Italian NHS.
PIN95
vARICELLA vACCINE AS POST-ExPOSURE PROPHyLAxIS – A COST-
EFFECTIvENESS ANALySIS
Chui K.S., Wu H.L., You J.
The Chinese University of Hong Kong, Shatin, Hong Kong
Objectives: Chickenpox, or varicella, is a highly communicative infectious dis-
ease affecting mainly young children. Varicella is self-limiting in the majority 
of cases, yet serious complications, including secondary bacterial infections of 
skin and soft tissues, pneumonia and encephalitis, can occur and result in hos-
pitalization. Varicella vaccine is an effective post-exposure prophylaxis (PEP) of 
chickenpox. This study aimed to analyze cost-effectiveness of PEP using varicella 
vaccine for pediatric patients from the perspective of public health care provider in 
Hong Kong. MethOds: A decision tree was designed to compare cost and clinical 
outcomes of PEP with varicella vaccine versus no PEP in pediatric patients (aged 
1-18 years old) susceptible to chickenpox with household exposure. Two tiers of 
outcomes were simulated: 1) Total direct medical cost, and 2) the quality-adjusted 
life year (QALY) loss associated with chickenpox. Model inputs were retrieved from 
local epidemiology and medical literature. Sensitivity analysis was performed on 
all parameters to test the robustness of model results. Results: Base-case analy-
sis showed PEP with varicella vaccine to be less costly (expected cost USD320 vs. 
USD731) with lower QALY loss (0.00423 QALYs vs. 0.01122 QALYs), comparing to no 
PEP. Sensitivity analysis showed that PEP with varicella vaccine was less costly if 
PEP effectiveness was > 6.2% or chickenpox infection rate without PEP was > 8.6%. 
In 10,000 Monte Carlo simulations, PEP with vaccine was cost-effective in over 
99% of the time with mean cost saving of USD611per patient (95% CI USD602-620; 
P< 0.001) and lower mean QALY loss of 0.00809 QALYs (95% CI 0.00802-0.00816 
QALYs; P< 0.001). cOnclusiOns: Using varicella vaccine as PEP seems to be a 
cost-saving strategy to avert QALY loss in susceptible pediatric patients exposed 
to chickenpox in Hong Kong.
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LONG-TERM OUTCOMES OF SOFOSBUvIR (SOF) FOR THE TREATMENT OF 
CHRONIC HEPATITIS C INFECTED (CHC) PATIENTS
Cure S.1, Guerra I.1, Dusheiko G.2
1OptumInsight, Uxbridge, UK, 2Royal free hospital, London, UK
Objectives: Sofosbuvir is a uridine analogue polymerase inhibitor. Pan-genotypic 
efficacy and safety have been demonstrated in four phase III clinical trials of SOF 
administered with ribavirin (RBV) or with a combination of pegylated interferon alfa 
and RBV (PR). This analysis evaluated the long-term outcomes of SOF/RBV in treat-
ment-naïve (TN) genotype (GT) 1/4/5/6 and TN, treatment-experienced (TE), interferon 
ineligible (TNI) GT 2 and 3 patients MethOds: A Markov-model followed a cohort 
of 10,000 patients for a lifetime, with 50% initiating treatment at the compensated 
cirrhotic stage. In GT 1, 4/5/6 TN patients, SOF/PR for 12 weeks was compared to, 
telaprevir (TVR) or PR, respectively. SOF/RBV for 12 or 16 weeks for GT 2 and 3, respec-
tively, was compared to no treatment for TNI and TE, and PR for 24 or 48 weeks (PR24/
PR48) for TN and TE respectively. SVR 12 weeks have been reported as 90% for TN GT 
1 and 97% for GT 4/5/6 patients; 78% for patients with no treatment option (TNI and 
TE); 97% and 56% for GT 2 and 3 TN; for GT 2 and 3 TE, 86% and 30% with 12-week 
and, 94% and 62% with 16-week regimens, respectively. Results: SOF was shown 
to be highly effective in preventing advanced liver disease (ALD) and mortality due 
to HCV across all GTs. This was particularly favorable for patients with no current 
treatment option (TNI and TE) where up to 7,000 ALD cases can be avoided and more 
than 200 lives saved. The model demonstrated that in GT 1 and 4/5/6 TN patients, 
SOF/PR prevented around 5,000 and 900 more ALD cases than PR and TVR treatment 
arms, respectively. cOnclusiOns: SOF, including within interferon-free regimens, 
was shown to be highly effective in preventing progression to ALD and reducing HCV-
related mortality, particularly in patients with no current treatment option.
Objectives: To conduct pharmacoeconomic analysis of ritonavir-boosted ataza-
navir (ATV/r) vs ritonavir-boosted lopinavir (LPV/r) and ritonavir-boosted darunavir 
(DRV/r) in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in 
treatment-naïve adult patients with HIV-infection from Russian health care sys-
tem point of view. MethOds: Cost-effectiveness analysis (CEA) with calculation of 
incremental cost-effectiveness ratio (ICER) was used for comparison of ATV/r with 
LPV/r. Cost-minimization analysis (CMA) with calculation of cost minimization dif-
ference (CMD) was used for comparison of ATV/r with DRV/r. Direct comparison of 
clinical efficacy and safety of ATV/r vs LPV/r was based on the results of randomized 
controlled trial (RCT) CASTLE. Indirect comparison of clinical efficacy and safety 
of ATV/r with DRV/r was performed on the basis of results of RCTs CASTLE and 
ARTEMIS. Virological response after 96 weeks of treatment and protease inhibitors 
(PIs)-induced diarrhea were considered as clinical efficacy and safety outcomes, 
respectively. Direct medical costs were calculated for the hypothetical cohort of 100 
patients treated for 96 weeks. Results: ATV/r + NRTIs had statistically significant 
higher rate of virological response after 96 weeks of treatment than LPV/r + NRTIs 
(risk ratio (RR) = 1.090 [95% CI 1.002; 1.186], p< 0.05) with statistically significant 
lower risk of PI-induced diarrhea (RR = 0.202 [95% CI 0.107; 0.381], p< 0.0001). There 
were no statistically significant difference between combinations ATV/r + NRTIs 
and DRV/r + NRTIs in terms of rate of virological response and risk of PI-induced 
diarrhea (RR = 0.981 [95% CI 0.869; 1.107], p= 0.77 and 0.543 [95% CI 0.227; 1.296], 
p= 0.17, respectively). ICER for ATV/r vs LPV/r was 4063.58 EUR per one additional 
patient with virological response. CMD for ATV/r vs DRV/r was 5485.38 EUR per 
patient. cOnclusiOns: ATV/r is more preferable than LPV/r and DRV/r for admin-
istration in combination with NRTIs in treatment-naïve adult patients with HIV 
infection.
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TOO EARLy OR TOO LATE? IMPACT OF DIFFERENT HERPES zOSTER vACCINE’S 
wANING RATES ON AGE-SPECIFIC INCREMENTAL COST-EFFECTIvENESS RATIO
Ultsch B.1, Weidemann F.1, Reinhold T.2, Siedler A.1, Krause G.3, Wichmann O.1
1Robert Koch Institute, Berlin, Germany, 2Charite University Medical Center Berlin, Germany, 
Berlin, Germany, 3Helmholtz Centre for Infection Research, Brunswick, Germany
Objectives: Herpes Zoster (HZ) is a painful skin rash that occurs most frequently 
among the elderly. A vaccine has recently been licensed in Europe to prevent HZ 
in individuals aged ≥ 50 years. As of today, the actual annual waning-rate (WR) 
of vaccine-induced-immunity (VI) is unknown. To investigate the impact of dif-
ferent WRs on the incremental-cost-effectiveness-ratio (ICER) at different ages at 
vaccination, we performed a health economic analysis for the German statutory-
health-insurance setting. MethOds: Based on a Markov-model, we compared a 
HZ-vaccination-strategy to a scenario without vaccination in Germany targeting 
different cohorts to identify the most efficient age at vaccination (50, 60, or 70 
years). A societal-perspective (SP) was considered, country- and age-specific demo-
graphic, epidemiological, and cost-of-illness input-data were utilized. We assumed 
a vaccine-price of 140.48 Euro/dose and 10 year stable VI. Thereafter an exponential 
waning of VI based on several annual relative WR (0, 2.5, 5, 7.5, 10 and 50%) was 
assumed. All monetary amounts were in Euro 2010. The cycle-length was a quarter; 
we considered a lifelong time-horizon. The discount-rate was 3% for outcomes 
and costs. Results were presented as costs/quality-adjusted life-year (QALY) gained 
ICERs. Results: With annual WR < 5% ICERs increase with age at vaccination from 
50 (0% WR: 16,567€ /QALY gained) to 70 years (0% WR: 37,285€ /QALY gained). When 
WR is ≥ 5% the vaccination-age-specific ICERs become U-shaped with the minimum 
ICERs at 60 years (5% WR: 25,474€ /QALY gained). With high annual WR (50%) the 
ICERs at vaccination-age 70 (50,847€ /QALY) are lower than ICERs at 50 years (56,871€ /
QALY). cOnclusiOns: The annual WR has a high impact on vaccination-age-spe-
cific ICERs. To obtain lowest ICERs, HZ-vaccine should be given early in life (e.g. 50 
years) if WR is low. When annual WR is > 4%, the most efficient age at vaccination is 
60 years. Evidence on the actual WR after HZ-vaccination has yet to be established.
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COST-EFFECTIvENESS OF UNIvERSAL vACCINATION AGAINST vARICELLA IN 
THE NETHERLANDS
de Boer P.T., Postma M.J.
University of Groningen, Groningen, The Netherlands
Objectives: The Netherlands has no varicella vaccination in its National 
Immunization Program (NIP). Although varicella is regarded as a mild disease, imple-
mentation of varicella vaccination in the immunization schedule of several countries 
has shown to be cost-effective. Dutch children are infected with varicella zoster virus 
at younger age and make less use of the health care system as compared to other 
European countries. Therefore, a specific cost-effectiveness study of varicella vac-
cination for The Netherlands is needed. We aimed to estimate the incremental cost-
effectiveness ratio (ICER) of universal vaccination of children against varicella in the 
Dutch NIP as compared with no such vaccination. MethOds: A static cohort model 
was developed to assess the cost-effectiveness of varicella childhood vaccination 
in the first 30 years. Several vaccination strategies were explored by varying the age 
of the booster vaccination. Dutch sources of varicella incidence and health care use 
were combined with vaccine efficacy data from other countries. This study was per-
formed from the societal perspective as well as from the payer’s perspective. Results 
were expressed in euros (€ ) per quality-adjusted life year (QALY) gained. Results: 
Vaccinating a birth-cohort of 180,000 children could avert 105,091 varicella cases and 
save 301.1 QALYs and € 13.7 million of direct and indirect costs. The optimal vacci-
nating-strategy from cost-effectiveness point of view was vaccinating at 14 months 
and 4 years. This scenario resulted in an ICER of € 2844/QALY gained from the societal 
perspective and € 40,582/QALY gained from the health care payer’s perspective, when 
a vaccine price of € 45 was used. Results were sensitive to vaccine price, waning rate of 
the second vaccination and indirect costs. cOnclusiOns: Introduction of varicella 
vaccination in the Dutch NIP would be cost-effective from the societal perspective 
when a threshold of € 20.000/QALY gained was used, which corresponds to the mini-
mum threshold mentioned for the Dutch context.
A358  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
Guangzhou, ¥82,383(¥74,956-¥89,810) vs. ¥80,799(¥73,545-¥88,054) for Nanjing, and 
¥59,413(¥54,366-¥64,460) vs. ¥57,804(¥52,613-¥62,996) for Xi’an. The ICER of linezolid 
over vancomycin were ¥19,719(-¥143,553-¥320,980), ¥15,532(-¥185,411-¥349,693), 
¥15,904(-¥161,935-¥314,987), and ¥16,145(-¥100,738-¥234,412) per additional treat-
ment success for Beijing, Guangzhou, Nanjing, and Xi’an, respectively. Out of 10,000 
bootstrap simulations, majority cases had greater efficacies and higher costs for lin-
ezolid (in quadrant I of the E-EC plane: Beijing(64%), Guangzhou(59%), Nanjing(61%), 
Xi’an(66%)), more than one third had greater efficacies and lower costs for linezolid 
(linezolid dominated vancomycin: Beijing(33%), Guangzhou(38%), Nanjing(37%), 
Xi’an(32%)); only < 2% had greater efficacies and lower costs for vancomycin in 
all cities (vancomycin dominated linezolid). cOnclusiOns: In this clinical trial 
population, linezolid appears to be cost-effective from Chinese payers’ perspective 
when compared to vancomycin in treating patients with nosocomial pneumonia 
caused by MRSA.
PIN100
ECONOMIC EvALUATION OF FLUOROQUINOLONE-BASED REGIMENS FOR THE 
TREATMENT OF COMMUNITy-ACQUIRED PNEUMONIA IN A MULTI-FIELD 
HOSPITAL IN RUSSIA
Kozlov R.S., Dekhnich A.V., Ratchina S.A., Belkova Y.A.
Institute of Antimicrobial Chemotherapy, Smolensk State Medical Academy, Smolensk, Russia
Objectives: Respiratory fluoroquinolones are considered to be an important treat-
ment option in hospitalized adults with community-acquired pneumonia (CAP). 
We aimed to compare cost-effectiveness of sequential intravenous to oral therapy 
of CAP with moxifloxacin and levofloxacin ± beta-lactam in a multi-field Russian 
hospital. MethOds: Standard search of prospective randomized clinical trials (RCT) 
was performed for the period since 1st Jan 1995 till 31st Dec 2012. RCTs quality 
was assessed by Jadad scale. Three RCTs with direct comparison of moxifloxacin 
vs. levofloxacin±ceftriaxone in adults with CAP required initial intravenous anti-
microbial therapy [Torres A. 2008, File T.M. Jr. 2001, Anzueto A. 2006] were included 
in the analysis. As similar efficacy and safety was shown between comparators a 
cost-minimisation model was applied. Original drugs’ costs were extracted from 
hospital receipt notes of three multi-field hospitals and wholesale prices data-
base (www.pharmindex.ru). Cost of therapy was calculated to respective treatment 
regiments in selected trials: moxifloxacin 400 mg QD vs. levofloxacin 500 mg QD/
BID±ceftriaxone 2 g QD for 11 days. Uncertainty was explored in a series of one- and 
two-way sensitivity analysis. Results: The respective total drug therapy costs per 
patient were as follows: € 249 for moxifloxacin vs. € 161/€ 321 for levofloxacin QD/BID 
and € 419/€ 579 for levofloxacin QD/BID+ceftriaxone. In levofloxacin monotherapy 
regimens the results were sensitive for IV therapy duration and oral/IV levofloxacin 
cost. In both levofloxacin+ceftriaxone regimens the results were insensitive to all 
variables of interest. cOnclusiOns: Moxifloxacin is more cost effective strategy 
then levofloxacin+ceftriaxone for the treatment of hospitalized adults with CAP. The 
higher cost-effectiveness for moxifloxacin vs. levofloxacin monotherapy depends on 
IV therapy duration, levofloxacin regimen and oral/IV levofloxacin cost.
PIN101
ECONOMIC EvALUATION OF CEFTOBIPROLE COMPARED TO A COMBINATION 
OF LINEzOLID wITH CEFTAzIDIME IN THE MANAGEMENT OF HOSPITALISED 
PNEUNOMIA IN SCOTLAND
van der Scheer F.W.1, Kuessner D.2, de Silva S.3, Posthumus J.2, Bergman G.1
1Mapi, Houten, The Netherlands, 2Basilea Pharmaceutica International Ltd., Basel, Switzerland, 
3Mapi, London, UK
Objectives: Ceftobiprole is a new i.v. anti-infective, which has bactericidal activity 
against difficult to treat Gram-positive (including multidrug-resistant pneumococci 
and methicillin-resistant Staphylococcus aureus; MRSA) and Gram-negative (includ-
ing Pseudomonas aeruginosa) bacteria, which are important aetiological agents of 
nosocomial pneumonia (NP) and hospitalised community-acquired pneumonia (CAP). 
The objective of this analysis was to estimate the economic value of ceftobiprole (TID) 
compared to linezolid (BID)/ceftazidime (TID) in the treatment of hospitalised pneu-
monia patients in Scotland, when coverage of MRSA and Gram-negative pathogens, 
including P. aeruginosa,is required. MethOds: A cost-minimisation analysis, includ-
ing only direct medical (drug) costs, was considered appropriate since the ceftobiprole 
phase 3 trials in NP and CAP demonstrated that ceftobiprole is non-inferior to a 
combination therapy consisting of linezolid and ceftazidime (NP) or ceftriaxone with 
or without linezolid (CAP). The base case model included drug acquisition, treatment 
duration, and administration costs. In additional scenario analyses, the cost-minimi-
sation analysis included ICU and total hospitalisation costs as well. The resource use 
data were derived from the NP trial. Results: Treatment with ceftobiprole resulted in 
a cost-saving of £258 per treated patient compared to linezolid/ceftazidime therapy. 
While no change in the drug budget is estimated, cost-savings are expected due to 
less administration time. Scenario analyses evaluated the reduction in length of ICU 
stay and overall hospital stay that will potentially lead to further cost savings for NHS 
Scotland (-£2,182 and -£904 per treated patient, respectively). cOnclusiOns: This 
economic evaluation shows that ceftobiprole is at least a cost-neutral alternative 
to a combination of linezolid with ceftazidime and provides an effective and safe 
alternative for hospitalised pneumonia patients in Scotland.
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COST-MINIMIzATION ANALySIS OF MARAvIROC vERSUS DARUNAvIR 
RALTEGRAvIR AND ENFUvIRTIDE FOR CCR5-TROPIC TREATMENT-ExPERIENCED 
PATIENTS wITH HIv INFECTION IN RUSSIA
Pyadushkina E.1, Omelyanovsky V.2, Avxentyeva M.2, Rebrova O.3, Goryaynov S.1
1Autonomous Non-profit Organization “National Centre for Health Technology Assessment”, 
Moscow, Russia, 2The Russian Presidential Academy of National Economy and Public 
Administration, Moscow, Russia, 3Pirogov Russian National Research Medical University, Moscow, 
Russia
Objectives: New antiretroviral drugs have a major impact on future treatment 
options for treatment-experienced HIV-patients with antiretroviral resistance. The 
PIN97
ECONOMIC EvALUATIONS OF vARICELLA AND HERPES zOSTER vACCINATION 
PROGRAMMES: A SySTEMATIC REvIEw
Damm O.1, Ultsch B.2, Horn J.3, Mikolajczyk R.3, Wichmann O.2, Greiner W.1
1School of Public Health, Bielefeld University, Bielefeld, Germany, 2Robert Koch Institute, Berlin, 
Germany, 3Helmholtz Centre for Infection Research, Braunschweig, Germany
Objectives: This systematic review aimed to assess the cost-effectiveness of rou-
tine varicella and herpes zoster vaccination in high-income countries. MethOds: 
A PubMed search was performed for identifying English- and German-language 
publications on economic analysis of varicella and herpes zoster (HZ) vaccina-
tion programmes published before May 2013. A study was included if it was a full 
economic evaluation of a routine childhood or adolescent varicella vaccination 
programme and/or a HZ vaccination scheme targeting the elderly and if the study 
reported results for a high-income country as specified by the World Bank. To 
improve comparability between studies and across countries, all cost estimates 
were inflated to 2010 values applying country-specific consumer price indices and 
converted to Euros with the German level of purchasing power using purchasing 
power parities obtained from the Organisation for Economic Co-operation and 
Development. Results: After the study selection process, 37 model-based stud-
ies remained to be included in the review. Routine childhood or adolescent varicella 
vaccination was cost-effective or cost-saving from a payer perspective and always 
cost-saving from a societal perspective when ignoring a potential impact on HZ due 
to exogenous boosting. The inclusion of the impact on HZ led to net QALY losses or 
incremental cost-effectiveness ratios exceeding commonly accepted thresholds. 
Additional HZ vaccination could partially mitigate this effect. Results of the studies 
only focusing on the evaluation of HZ vaccination ranged from EUR 1,200 to 291,240 
per QALY in one study assessing multiple scenarios and from EUR 5,572 to 140,125 
per QALY across all other studies. cOnclusiOns: While cost-effectiveness of HZ 
vaccination was strongly dependent on the age of vaccination, cost-effectiveness 
of varicella vaccination was primarily dependent on the in- or exclusion of the 
potential impact on HZ. As a consequence, clarification on the role of exogenous 
boosting is crucial for decision-making regarding varicella vaccination.
PIN98
PREvENTION OF GRAM-POSITIvE INFECTIONS IN PERITONEAL DIALySIS 
PATIENTS – A COST-EFFECTIvENESS ANALySIS
You J.1, Wong C.1, Luk I.1, Ip M.2
1The Chinese University of Hong Kong, Shatin, Hong Kong, 2The Chinese University of Hong Kong, 
Shatin, N.T., Hong Kong
Objectives: Gram-positive bacteria cause clinically severe peritonitis and exit-
site infection (ESI) in patients on peritoneal dialysis (PD). Incident PD patients are 
most prone to developing ESI and peritonitis within the first year of dialysis. We 
investigated the potential costs, quality of life, and clinical outcomes of incident PD 
patients with or without regular application of mupirocin on exit-site from the per-
spective of health care provider in Hong Kong. MethOds: We designed a decision 
tree to simulate potential outcomes of incident PD patients with and without regular 
application of mupirocin over a period of one year. Outcome measures included total 
direct medical cost per patient, quality-adjusted life-years (QALYs) gained and gram-
positive bacterial infection-related mortality rate. Model inputs were derived from 
literature. Sensitivity analyses evaluated the impact of uncertainty in all model vari-
ables. Results: In base-case analysis, the mupirocin group showed higher expected 
QALYs (0.6496 vs. 0.6456), lower infection-related mortality rate (0.18% vs. 1.64%) 
and lower total cost per patient (USD258 vs. USD1,661) comparing with the control 
group. Rate of gram-positive bacterial peritonitis without mupirocin and the risk of 
gram-positive bacterial peritonitis with mupirocin were identified to be potential 
influential factors. In 10,000 Monte Carlo simulations, mupirocin group was signifi-
cantly (p< 0.001) less costly, gained higher QALYs with lower mortality rate 99.9% of 
the time. cOnclusiOns: Daily application of mupirocin at catheter exit-site during 
the first 12 months of PD seems to be cost-saving and effective in reducing mortality 
of PD-related gram-positive infections as well as improving health-related quality 
of life from the perspective of health care provider in Hong Kong.
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COST-EFFECTIvENESS ANALySIS (CEA) OF LINEzOLID vERSUS vANCOMyCIN 
IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA CAUSED By METHICILLIN-
RESISTANT STAPHyLOCOCCUS AUREUS (MRSA-NP) BASED ON A PHASE Iv 
CLINICAL TRIAL: RESULTS FROM FOUR MAjOR CITIES IN CHINA
Wan Y.1, Wang X.2, Wu B.3, Kang H.4, Li Q.5, Chen Y.6, Li J.Z.7, Liu S.1, Gao X.1
1Pharmerit International, Bethesda, MD, USA, 2First Affiliated Hospital of Medical College of Xi’an 
JiaoTong University, Xi’an, China, 3The 3rd Affiliated Hospital of Sun Yat-sen, Guangzhou, China, 
4Chinese PLA General Hospital, Beijing, China, 5Jiangsu Province Hospital, Nanjing, China, 6Pfizer 
Inc., Beijing, China, 7Pfizer, Inc., San Diego, CA, USA
Objectives: To assess the cost-effectiveness of linezolid versus vancomycin in 
the treatment of NP in four major cities (Beijing, Guangzhou, Nanjing, and Xi’an) 
in China. MethOds: We conducted cost-effectiveness analyses from Chinese pay-
ers’ perspective piggybacked to a phase IV, randomized, double-blind, multicenter 
study (Wunderink et al, CID 2012) in MRSA-NP patients (microbiologic confirmed 
intent-to-treat cohort). Efficacy was measured by treatment success (defined as 
Cure+Improvement) at the end of study (i.e., 7-30 days after the end of treatment). 
Direct medical costs from four cities in China (¥, 2012) were calculated from the 
health care resource use data collected from the trial, including study medica-
tion, hospitalization, mechanical ventilation, and continuous renal replacement 
therapy. Nonparametric bootstrapping method was used to calculate confi-
dence intervals (CI) for costs, efficacy, and incremental cost-effectiveness ratios 
(ICER). Results: Data from 391 patients (186 linezolid, 205 vancomycin) were ana-
lyzed. More linezolid patients achieved treatment success vs. vancomycin patients 
[mean (95% CI)]: 55% (48.3%-61.9%) vs. 45% (38%-52.3%). The total treatment costs 
of linezolid vs. vancomycin were: ¥79,551(¥72,421-¥86,680) vs. ¥77,587(¥70,656-
¥84,519) for Beijing, ¥90,995(¥82,598-¥99,393) vs. ¥89,448(¥81,295-¥97,601) for 
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SEK. cOnclusiOns: Given a willingness-to-pay threshold of 600,000 SEK/QALY, 
posaconazole is likely to be cost-effective for preventing IFIs in GVHD-patients 
compared to fluconazole.
PIN105
ECONOMIC EvALUATION OF UNIvERSAL ANTENATAL HIv SCREENING 
COMPARED wITH CURRENT “AT RISK” POLICy IN ISRAEL
Chowers M.1, Shavit O.2
1Meir Medical Center, Kfar Saba, Israel, 2Meuhedet Health Fund, Tel-Aviv, Israel
Israeli ministry of health guidelines for antenatal screening recommend HIV test-
ing only in women belonging to high risk groups. This policy resulted in the last 
10 years in an annual average of two infected children from unidentified Israeli 
women. Objectives: To evaluate an alternative strategy of universal screen-
ing using a cost utility analysis. MethOds: A budget impact analysis was first 
conducted to evaluate the cost of introducing universal screening using a payer 
perspective. Following, a cost-utility analysis (CUA) was carried out to evaluate 
long term effects of such strategy, compared with current policy. The model was 
comprised of two steps: a decision tree simulating the period from pregnancy 
to delivery and a successive Markov model simulating life expectancy of the 
newborn. Screening test sensitivity and specificity were regarded as 99.94% and 
99.5% respectively. Probabilities for having HIV for the low and high-risk popula-
tions were based on experts’ opinion. They were then adjusted to allow model 
calibration to reflect real-life finding as presented above. The cost of the screen-
ing test was US$ 5.5. Other costs included physician visits, viral load and blood 
tests, CD4 counts, and medications. QALY weights were 0.83 for HIV and 0.7 for 
AIDS. Results: Probabilities for having HIV for the low and high-risk populations 
were 0.0215% and 1% respectively. The incremental cost of the universal screening 
over current policy for an annual cohort of 166,000 Israeli pregnant women was 
US$1 million, reflecting a cost of $500,000 per a case of an HIV+ baby avoided. For 
this cohort, an incremental 18 QALYS were projected over a 90 year time hori-
zon with an incremental cost-effectiveness ratio of US$ -30,000. cOnclusiOns: 
Universal Antenatal HIV screening should be implemented in Israel. The current 
policy of screening identified high-risk women is both less effective and more 
costly.
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HEALTH ECONOMICS ASSESSMENT OF RILPIvIRINE vERSUS COMPARATORS AS 
FIRST-LINE ANTIRETROvIRAL THERAPIES IN HIv-1 PATIENTS wITH A vIRAL 
LOAD (vL) ≤ 100,000 COPIES/ML IN FRANCE
Cognet M.1, Druais S.1, Lahoulou R.2, Havet D.2, Guillon P.2
1Amaris, London, UK, 2Janssen, Issy-les-Moulineaux, France
Objectives: In France, rilpivirine is reimbursed for HIV-1-infected treatment-
naïve patients with VL≤ 100,000 copies/mL for whom the use of efavirenz is not 
appropriate. This analysis aims to compare costs and outcomes of rilpivirine vs. 
other third antiretroviral (ARVs) agent recommended in France (in addition to two 
NRTIS). MethOds: A cohort-based Markov model with four therapy lines and six 
health states based on CD4+ cell-count ranges was developed based on 1-year 
cycle and a 5-year time horizon. First-line efficacy data at 48 and 96 weeks was 
first assumed to be similar across treatments, and subsequently set to statisti-
cally significantly different (SSD) values from phase-III trial analyses of patients 
with VL≤ 100,000 copies/mL. Costs of first-line treatments were obtained from the 
French National Formulary. Costs associated with subsequent treatments and 
CD4+ health states were derived from a French cost-effectiveness analysis. Other 
clinical inputs, HIV-related mortality rates and utility were derived from inter-
national publications. Outcomes and costs were discounted at 4%. Robustness 
of results was assessed using sensitivity analyses (e.g. using efficacy values 
no SSD). Results: All phase-III trials (i.e. ECHO/THRIVE, STARTMRK, CASTLE, 
ARTEMIS, KLEAN, GEMINI, 2NN) demonstrated a non-inferior antiviral efficacy 
between arms. In patients with VL≤ 100,000 copies/mL, response rates were avail-
able for rilpivirine (1-year: 90,2%; 2-year: 84,0%), ritonavir-boosted (/r) darunavir 
(1-year: 79,5%; 2-year: 76,1%), lopinavir/r (1-year: 84,5%; 2-year: 75,2%), atazanavir/r 
(1-year: 82%; 2-year: 75%), fosamprenavir/r (1-year: 67%) and raltegravir (1-year: 
93%). CD4+ cell count changes per mm3 were available for atazanavir/r (1-year: 
+179; 2-year: +243), lopinavir/r (1-year: +194; 2-year: +267), rilpivirine (1-year: +185) 
and raltegravir (1-year: +180). Rilpivirine was the less expensive option in the cost-
minimisation analyses and dominated all treatments in the cost-effectiveness 
analyses when considering SSD efficacy values. cOnclusiOns: The analysis pro-
vided health economic results for HIV-1-infected treatment-naïve patients with 
VL≤ 100,000 copies/mL favoring rilpivirine over all other ARVs analysed.
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COST-EFFECTIvENESS OF TELAPREvIR COMBINATION THERAPy COMPARED 
TO PEGINTERFERON wITH RIBAvIRIN ALONE FOR NAIvE AND TREATMENT 
ExPERIENCED PATIENTS wITH GENOTyPE 1 CHRONIC HEPATITIS C IN POLAND
Kaczor M.P.1, Wójcik R.2, Pawlik D.2, Skrzekowska-Baran I.3, Tronczynski K.3
1Jagiellonian University Medical College, Kraków, Poland, 2Aestimo s.c., Kraków, Poland, 3Janssen-
Cilag Polska, Warszawa, Poland
Objectives: To assess the cost-effectiveness of telaprevir (TVR) added to peginter-
feron and ribavirin (PR) therapy in treatment naive (TN) and experienced (TE) 
genotype 1 chronic HCV patients in Poland. MethOds: Analysis was based on 
a previously validated Markov model, describing the progression of the disease 
over a lifetime, adapted to population characteristics specific to Poland and cost 
parameters obtained via questionnaire studies completed by clinical practition-
ers. The model comprises the following health states: mild CHC without/with 
SVR (remission), moderate CHC without/with SVR, cirrhosis without/with SVR, 
antiviral therapy, decompensated cirrhosis, HCC, liver transplantation, post-liver 
transplant, CHC related death. The following treatment strategies were considered: 
PEG++ RBV therapy for 48 weeks; TVR for 12 weeks with PEG+RBV (response-guided 
therapy in TN and 48 weeks in TE patients). A cost-utility analysis was conducted 
goal of this study was to perform economic evaluation of maraviroc compared with 
other new antiretroviral agents, such as raltegravir, darunavir and enfuvirtide for 
treatment-experience patients with HIV infection in Russia. MethOds: Indirect 
comparison was performed to assess the relative clinical efficacy and safety of 
compared drugs, all in combination with optimized background therapy (OBT). 
A mathematical model was created in Microsoft Excel software to estimate the 
direct medical costs of: compared drugs, an average OBT regimen and routine 
outpatient follow-up (including visits to specialists and diagnostic tests). Drug 
and medical services cost calculations were based on registered prices from the 
list of vital and essential drugs and financial standards of regional program of 
national guarantees for the provision of free medical care to Russian citizens in 
Moscow in 2012, respectively. The obtained results were tested in sensitivity analy-
sis. Results: According to indirect comparison results, there were no statistically 
significant differences between maraviroc, raltegravir, darunavir and enfuvirtide 
neither by the undetectable HIV RNA level nor CD4(+) cell-count changes. The rate 
of adverse events was comparable (except enfuvirtide that has more injection-site 
reactions). Maraviroc-containing regimen compared with raltegravir-, darunavir- 
and enfuvirtide-containing regimen is associated with reduced costs and saves 
an average 177 764.16 rub (€ 4 209.94), 59 929.92 rub (€ 1 419.30) and 462 295.92 rub 
(€ 10 948.42) per 48 weeks of therapy, and 340 714.64 rub (€ 8 069.05) and 114 865.68 
rub (€ 2 720.33) and 886 067.18 rub (€ 20 984.47) per 96 weeks of therapy per patient, 
respectively. Results were robust in one-way sensitivity analyses. cOnclusiOns: 
The analysis showed that maraviroc compared with darunavir, raltegravir and 
enfuvirtide is a cost-saving treatment option for CCR5 tropic treatment-experi-
enced patients in Russia.
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BOCEPREvIR USE IN FRANCE: A MARKOv MODEL OF DISEASE PROGRESSION 
AND COST-EFFECTIvENESS FOR CHRONIC HEPATITIS C (vIRUS G1)
Ferrante S1, Elbasha E.H.2, Poynard T.3, Boyaval G.4
1Merck, Whitehouse Station, NJ, USA, 2Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 
3Centre Hospitalier la Pitié Salpêtrière, Paris cedex 13, France, 4MSD France, COURBEVOIE, France
Objectives: The addition of boceprevir (BOC) to peginterferon–ribavirin (PR) 
resulted in significantly higher rates of sustained virologic response in naive or 
pretreated patients with the chronic hepatitis C virus (HCV) genotype 1 infection, as 
compared with PR alone. The objective is to project the long-term clinical benefits 
and estimate the cost-effectiveness of the treatment strategies recommended in 
the BOC label compared with PR alone. MethOds: A Markov model was created 
to estimate the expected costs and quality adjusted life-years (QALYs) associated 
with the BOC tritherapy and PR. The model simulates the treatment regimens and 
the natural history of the chronic HCV to project the lifetime cumulative incidence 
of advanced liver-related diseases (decompensated cirrhosis (DC), hepatocellular 
carcinoma (HCC)) and liver transplant. Series of 30 cohorts representing all com-
binations of pre-specified patient characteristics progress through the model. The 
baseline characteristics used to define the cohorts are: naive/pretreated, age, gender, 
baseline fibrosis score and race cohort for the treatment naive population only. 
Separate analyses were run for naive and pretreated patients. The distribution of 
baseline fibrosis score for each analysis was based on the subjects enrolled in the 
clinical trials; the average age and distribution of race cohort were based on French 
observational study (F. Roudot Thoraval, ADEQUATION, AFEF 2009). The comparator 
was PR (48 weeks). Results: The model predicted relative reductions in patients 
treated with BOC vs PR alone: 33% and 32% in DC/HCC in naive patients and also 
46% and 53% in DC/HCC in pretreated patients. The ICER of BOC-based therapy 
compared with PR were 15,681€ /QALY for naive patients and 10,563€ /QALY for pre-
treated patients. cOnclusiOns: Compared with PR, boceprevir-based treatment is 
projected to substantially reduce the burden of liver complications associated with 
the chronic hepatitis C virus genotype 1 and is highly cost-effective if a threshold 
of 50,000€ /QALY is assumed.
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COST-UTILITy ANALySIS OF POSACONAzOLE vERSUS FLUCONAzOLE FOR 
PREvENTION OF INvASIvE FUNGAL INFECTIONS IN PATIENTS wITH GRAFT-
vERSUS-HOST DISEASE IN SwEDEN
Lundberg J.G.1, Jensen A.V.1, Bjorkholm M.2, Hoglund M.3, Akerborg O.4
1MSD, Sollentuna, Sweden, 2Karolinska University Hospital Solna, Stockholm, Sweden, 
3University Hospital, Uppsala, Uppsala, Sweden, 4Optum Insight, Stockholm, Sweden
Objectives: In allogeneic transplant (allo-SCT) recipients with graft-versus-host 
disease (GVHD) the risk of contracting an invasive fungal infection (IFI) is high and 
antifungal prophylaxis to prevent IFIs is routinely given. Fluconazole, has been 
standard antifungal prophylaxis in GVHD-patients in Sweden. Recently many 
Swedish centers have switched from fluconazole, which lacks efficacy against 
Aspergillus, to posaconazole, for the prevention of IFIs in GVHD-patients receiving 
moderate to high doses of glucocorticoids. Although, the superior efficacy of posa-
conazole vs. fluconazole in preventing IFIs have been demonstrated in this clinical 
setting, the cost-effectiveness of posaconazole vs. fluconazole for GVHD-patients in 
Sweden has not been established. The aim of this analysis is to estimate the cost-
effectiveness of posacoanzole vs. fluconazole prophylaxis in allo-SCT recipients 
with severe GVHD receiving immunosuppressive therapy in Sweden. MethOds: 
A decision-analytic model was used to determine life-time outcomes of patients 
with GVHD at high risk of contracting IFIs. The model outcomes were quality 
adjusted life years (QALYs), costs associated with IFI-prophylaxis and treatment 
of IFIs and the incremental cost-utility ratio. The efficacy data were gathered from 
a clinical trial comparing posaconazole with fluconazole prophylaxis in patients 
with GVHD. The resource use for treatment of IFIs was gathered by expert opin-
ion. Utility, mortality and unit costs were gathered from the literature. To assess 
the uncertainty of the modeled outcomes a probabilistic sensitivity analysis (PSA) 
was developed. Results: The incremental cost-utility ratio of posaconazole vs. 
fluconazole for the prevention of IFI in GVHD-patients in Sweden was 541,628 SEK/
QALY. The PSA showed a 56.4% probability for a cost per QALY less than 600,000 
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observational studies also confirmed the indirect protection provided by rota-
virus vaccination in countries where rotavirus vaccination programmes have 
been introduced. France has not yet implemented such a programme. Previously 
reported models in France do not include herd protection, thus underestimat-
ing the effectiveness of vaccination. Our study uses a dynamic transmission 
model to account for herd protection and therefore better predict the effect of 
an oral rotavirus pentavalent vaccination programme in France. MethOds: 
We developed a dynamic model to account for susceptibility of rotavirus infec-
tion as a function of both age and the number of previous infections. It was 
parameterized with French data on rotavirus gastro-enteritis (RVGE) incidence 
and age-specific contact rates. We evaluated the direct and indirect effects of 
vaccination on disease incidence and clinical outcomes. A three-dose vaccine 
course was assumed to be administered to 75% of infant annually. Results: 
Our model predicts that vaccination can reduce the burden of RVGE by 66% in the 
four years following vaccine introduction, gradually increasing to 73% in the long 
term for children under 5 years of age. Our calculations show that herd immunity 
accounts for 11% to 20% of the overall RVGE reduction in children. Incidence in 
the unvaccinated adult population would also be reduced by more than 40% 
through herd protection. Vaccination is also predicted to reduce pressure on the 
health care system with the model estimating an annual reduction of 84% and 
82% in the number of hospitalization/nosocomial and outpatient visits for RVGE 
respectively. cOnclusiOns: The use of dynamic models is critical to account 
for the indirect effects of rotavirus vaccination via herd protection and thus for 
policymakers to understand the true effectiveness of a country-wide rotavirus 
vaccination programme.
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COSTS ASSOCIATED wITH COLD CHAIN USED TO STORE AND TRANSPORT 
THERMALLy UNSTABLE ANTIRETROvIRAL DRUGS
Omelyanovsky V.1, Fedyaeva V.K.2
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia, 2Fund for the Development of Social Policy and Health Care “Helios”, Moscow, Russia
Objectives: In Russia free access to high quality health care for patients with 
AIDS and HIV infections guaranteed by state. Some antiretroviral (ARV) pharma-
ceuticals need to be transported and stored in special cold chain conditions that 
significantly increase the burden on the state budget. Use of thermally stable 
formulation if available may be efficient due to fewer expenses for cold chain pro-
vision. To estimate the costs associated with the cold chain conditions in Russian 
health care. MethOds: We calculated the difference in costs associated with 
ARV drug lopinavir+ritonavir thermally stable and unstable form transporting 
and storage. Thermally unstable form requires cold chain conditions that drives 
the cost difference. Costs for additional equipment, electricity, staff salaries 
were estimated.We used prices and tariffs that were valid in 2011. Calculations 
were based on the assumption that all eligible registered HIV-infected patients 
in all regions of Russia receive lopinavir+ritonavir, the number of patients was 
extracted from state statistics for 2011with a forecast for 2012. Results: The 
difference in annual total costs of shipping toregional centers and storage till the 
moment patient gets the drug between thermally unstable and thermally stable 
form is 820,000 Euro. cOnclusiOns: Choice of thermally stable form of ARV drug 
lopinavir+ritonavir which do not require cold chain conditions of transportation 
and storage can reduce the economic costs associated with the treatment of HIV 
infection in Russian health care.
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RE-ESTABLISHING THE SOCIETAL vALUE OF PEDIATRIC COMBINATION 
vACCINES
Maman K.1, Zoellner Y.F.2, Greco D.3, Duru G.4, Sendyona S.1, Remy V.5
1Creativ-Ceutical, London, UK, 2Hamburg University of Applied Sciences, Hamburg, Germany, 
3Centre for Science, Society and Citizenship, Roma, Italy, 4Cyklad Group, Rillieux la Pape, France, 
5Sanofi Pasteur MSD, Lyon, France
Objectives: Over the past decades, the number of vaccinations recommended 
for infants has increased significantly, in an effort pursuing wider protection 
against severe infectious diseases. In their first year, infants would typically get 
more than 50 injections. The use of combination vaccines provides one solution 
to the problem of high injection burden but may be undervalued due to the 
underestimation of vaccine-preventable diseases’ seriousness and vaccination 
benefits. Our objective is to investigate the societal value of pediatric combina-
tion vaccines. MethOds: A literature search was performed using MEDLINE for 
relevant articles from 1990 to today, focusing on industrialized countries. A grey 
literature search on public health websites was used to complement the peer-
reviewed literature. Results: A total of 86 articles, of which 34 from the peer-
reviewed literature, met the inclusion criteria and were analyzed. Many articles 
presented qualitative argumentation but no quantitative evidence. Public health 
benefits included improved compliance, timeliness and vaccination coverage 
thanks to reduced injections and better acceptability by parents. Economic ben-
efits were linked to the improvement of daily practice efficiency through reduced 
administration burden (less visits, simplified record-keeping, handling, inventory 
management) and less administration-related errors such as the need for fewer 
syringes reducing risk of needle-stick injury. Combination vaccines could also 
enhance efficiency at health care system-level through reduced costs of trans-
port, cold chain, storage and wastage. cOnclusiOns: This review supports the 
broader value of pediatric combination vaccines which may plausibly generate 
time and money savings in the short and longer term, and enhance efficiency at 
both micro and macro levels in the health care system. Findings often stemmed 
from US settings, the portability to other industrialized countries being therefore 
plausible but subject to some uncertainty. While there is a paucity of quantitative 
data to support these arguments, they have significant economic implications 
and warrant further investigation in future economic evaluations of pediatric 
combination vaccines.
to calculate the incremental cost-utility ratio (ICUR) for triple therapy. A subgroup 
analysis was conducted to evaluate cost-effectiveness of TN patients with IL28B 
T/T; Scheuer ≥ 2 and in TE patients with Scheuer ≥ 2. Results: In the overall 
TN population, ICUR is 80917 PLN/QALY (»€ 19736/QALY). ICURs in IL28B T/T and 
Scheuer ≥ 2 subgroups were 42407 PLN/QALY (»€ 10343/QALY) and 86984 PLN/
QALY (»€ 21216/QALY), respectively. In the overall TE population, ICUR is 81793 
PLN/QALY (»€ 19950/QALY). For Scheuer ≥ 2 subgroup ICUR = 72448 PLN/QALY 
(»€ 17670/QALY). Calculated values are below the cost-effectiveness threshold of 
105801 PLN/QALY (»€ 25805/QALY) in Poland. Results for relapsers, partial respond-
ers and null responders are also presented. cOnclusiOns: Based on the cost-
utility analysis, telaprevir combination therapy is cost-effective compared to PR 
alone in Polish settings.
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COMPARATIvE COSTS ANALySIS OF CONvENTIONAL STRATEGy vERSUS STEP-
DOwN STRATEGy wITH LINEzOLID IN THE TREATMENT OF NOSOCOMIAL 
PNEUMONIA CAUSED By GRAM POSITIvE BACTERIA IN MExICO
Gryzbowski E.1, Peniche-Otero G.1, Herrera-Rojas J.1, Bolaños-Cornejo D.1,  
Huicochea-Bartelt J.L.2, Muciño-Ortega E.2
1Customized Premium Products S.A. de C.V., Mexico City, Mexico, 2Pfizer S.A. de C.V.,  
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Objectives: To estimate the cost difference between use and absence of use of 
Step-Down Strategy (SDS) with linezolid for treatment of nosocomial pneumonia 
(NP) caused by Gram Positive Bacteria (GPB) in Mexico, from public health care 
institution perspective. MethOds: To evaluate the potential cost savings between 
the two strategies, a microcosting was made along three phases: (1) characteriza-
tion of therapeutic protocol, (2) assessment of resources and (3) estimation of the 
unit costs of medical care. The temporal horizon of the analysis was set to 14 days. 
Costs were estimated for the year 2013, expressed in US$ and consider the follow-
ing medical services: days of hospitalization, consultation with specialists, route of 
administration, laboratory and imaging tests as well as outpatient control, based 
on unit costs by level of care reported by Instituto Mexicano del Seguro Social. The 
frequency of use of these resources were determined from Delphi method with 
a panel of 10 experienced infectologists. We calculated the differences between 
average total costs (ATC). The stastistical significance difference between strate-
gies was evaluated by Student’s t statistic. Results: The ATC of patients using 
SDS was $10,116, [95%CI $9,344.6 - $10,887.3] and the ATC of patients not using 
this strategy was $17,251.6 [$16,379.4 - $18,123.8]. The average potential savings 
due the use of SDS over conventional therapy (only intravenous) are $ 7,135.6, 
(p< 0.001). cOnclusiOns: The use of step down strategy could significantly 
reduce the costs of treatment of NP in terms of hospitalization, physician visits, 
laboratory and imaging tests, and drug administration, not as well the resources 
used in the outpatient control. In a challenging setting of cost containment poli-
cies, the use of step down strategy in suitable patients represents the opportunity 
to invest health care resources in a more efficient way.
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RESOURCE USE AND OUTCOMES OF PATIENTS TREATED wITH vANCOMyCIN 
OR LINEzOLID IN A TERTIARy HOSPITAL IN SHANGHAI
Yang Y.1, Ye W.1, Song Y.2, Liu W.1, Wang K.1, Li X.3, Papadimitropoulos M.4, Montgomery W.5
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Objectives: Vancomycin and linezolid are amongst the most commonly pre-
scribed antibiotics for hospital-acquired infections in China. The aim of this study 
is to estimate and compare the baseline characteristics, hospitalization costs, 
length of stay (LOS), length of therapy (LOT) and all-cause in-hospital mortality 
of patients treated with vancomycin or linezolid. MethOds: Data were extracted 
from the electronic medical records (EMR) of a tertiary hospital in Shanghai (bed 
size 1700). The analysis included patients admitted for any underlying cause 
who received either vancomycin or linezolid between January 2009 and July 2012. 
Continuous variables were compared with t test and chi-square for categorical 
variables. Results: Of the total 3234 patients identified, 93.6% were treated with 
vancomycin (female: 40.6%, mean age: 55.8 years) and 6.4% were treated with 
linezolid (female: 22.2%, mean age: 62.3 years). Cardiac Surgery was the most 
frequent admitting department for the both groups, while cardiovascular disease 
was the top admission reason for the vancomycin group and pulmonary infec-
tion for the linezolid group. The average daily dose was 1.6±1.1 g for vancomycin 
and 1.2±0.5 g for linezolid. The all-cause in-hospital mortality was lower in the 
vancomycin group compared to the linezolid group (4.2% vs. 21.7%, p< 0.001). The 
vancomycin group had shorter LOS and LOT compared to the linezolid group 
(23.6±24.4 vs. 37.1±40.8 days, p< 0.001; 7.0±8.8 vs. 8.7±10.6 days, p= 0.025). The van-
comycin group had lower total hospitalization costs, medication costs and antibi-
otics costs compared to the linezolid group (RMB 68788±64956 vs. 125425±117055, 
p< 0.001; 33258±39792 vs. 70372±69115, p< 0.001; 15206±18957 vs. 34681±33184, 
p< 0.001). cOnclusiOns: Vancomycin was more frequently prescribed than lin-
ezolid and was more likely to be used in females and younger patients. When 
compared to those patients treated with linezolid, vancomycin treatment was 
associated with a shorter LOS and LOT, decreased total hospitalization costs and 
decreased total medication and antibiotics costs.
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wHAT CLINICAL BENEFITS COULD BE ExPECTED FROM THE IMPLEMENTATION 
OF A ROTAvIRUS vACCINATION PROGRAMME IN FRANCE?
Yamin D.1, Remy V.2, Atkins K.E.1, Galvani A.P.1
1Yale University, New Haven, CT, USA, 2Sanofi Pasteur MSD, Lyon, France
Objectives: Rotavirus vaccines have shown great potential for reducing the 
disease burden of the major cause of severe childhood gastroenteritis. Real-life 
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Patient’s characteristics, drug utilization patterns and resource utilization were 
analyzed. Results: Data were available for a sample of 244 eligible patients. The 
average age of the study population was 24.3 years (SD= 12.5). While the maxi-
mum medication possession ratio (MPR) for alternate month administration is 
50%, patients on TIP had an average MPR of 52.8%, while patients on TIS and OTF 
had an average MPR of 41.4% and 39.7%, respectively. Treatment persistence at 3 
months was estimated at 85.5%, 69.0%, and 65.2% for patients on TIP, TIS, and OTF, 
respectively. Treatment persistence at 6 months was estimated at 78.4%, 62.8%, 
and 56.5%, respectively for patients on TIP, TIS, and OTF. Higher CF medication 
treatment costs with TIP were partially offset by lower costs associated with the 
use of antibiotics, other medications and additional health care resource utiliza-
tion. The median monthly cost per patient in terms of other medications was of 
$1,159 (including $79 for other antibiotics), $1,350 ($172), and $1,495 ($240) for 
patients on TIP, TIS, and OTF, respectively. The median monthly additional health 
care resource utilization cost per patient was estimated at $56, $188, and $220, 
respectively for TIP, TIS and OTF cohorts. cOnclusiOns: In a real life setting, TIP 
was associated with a high level of treatment adherence and limited utilization 
of additional health care resources.
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ADHERENCE TO ANTIRETROvIRAL THERAPy AMONG HIv-INFECTED PATIENTS 
ATTENDING TO A UNIvERSITy INFECTIOUS DISEASES CLINIC IN vENEzUELA
Bastardo Y.M.1, Castro J.S.1, Suarez J.A.1, Torres J.R.1, Comegna M.2, Damas J.1
1Universidad Central de Venezuela, Caracas, Venezuela, 2Central University of Venezuela, 
Caracas, Venezuela
Objectives: To determine adherence levels and factors influencing adherence 
to antiretroviral therapy among HIV-infected patients in Venezuela. MethOds: 
A sample of 46 HIV-infected HIV patients attending an infectious diseases clinic at 
the Central University of Venezuela were interviewed by the investigators for 20 to 
25 minutes. The interview was guided by a structured questionnaire that included 
questions on sociodemographic and clinical characteristics, medication use, and 
health behaviors. Adherence was assessed retrospectively based on a 4-day recall 
as used in Adult AIDS Clinical Trials Group (AACTG) follow up questionnaire. All 
data analyses were performed using SSPS for Windows Version 19.0. Results: Of 
46 participants, 30 (65.2%) were male and 16 (34.8%) were female. The mean age 
was 43.17 years ( Range 26-73, SD= 9,790). From 46 participants 69.7% reported 
adherence ≥ 95%. Forgetting to take the medications, alcohol use, and problems 
with the medications supply were main barriers for adherence in the present 
study. cOnclusiOns: A group of patients at this clinic reported unsatisfactory 
adherence. Forgetfulness was reported to be the major cause of non-adherence. 
Since adherence to antiretroviral therapy in critical to achieve optimal treatment 
outcomes, health care providers must identify possible barriers to adherence at the 
earliest and provide appropriate solutions.
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HEPATITIS C vIRUS INFECTION TREATMENT COMPLETION: AN ANALySIS OF 
THE QUEBEC PROvINCIAL REIMBURSEMENT PROGRAM DATABASE
Lachaine J.1, Vachon M.L.2, Lambert-Obry V.1, Beauchemin C.1
1University of Montreal, Montreal, QC, Canada, 2CHUQ, Laval University, Quebec, QC, Canada
Objectives: Hepatitis C virus (HCV) infection treatment completion is a key success 
factor for achieving optimal clinical outcomes. The objective of this study was to assess 
HCV treatment completion rates in a real life setting. MethOds: A retrospective study 
of the Quebec provincial drug reimbursement program (RAMQ) was conducted using 
a random sample of patients who filled at least one script at the pharmacy for an HCV 
medication (pegylated interferon and ribavirin (peg-Riba) +/- boceprevir or telaprevir) 
from January 2007 to December 2012. Treatment completion rates were calculated at 
week 12, 24 and 28 according to HCV medication type in order to assess the proportion of 
patients treated beyond the 12-week futility threshold and the minimal expected treat-
ment duration of 24 weeks (28 weeks for Peg-Riba + boceprevir). Results: A total of 1,081 
patients who used at least one HCV medication were included in the study. The average 
age was 46.4 years (SD= 10.7) and the proportion of men was higher (64.8%). During the 
study period, the number of patients who used Peg-Riba only, Peg-Riba + boceprevir and 
Peg-Riba + telaprevir was 1,029 (95.2%), 50 (4.6%) and 18 (1.7%) respectively. The propor-
tion of patients on Peg-Riba only who completed at least 12 and 24 weeks of treatment 
was 89.7% and 62.2% respectively. There were 96.0% and 58.0% of patients on Peg-Riba 
+ boceprevir who remained on treatment at week 12 and 28 respectively. The percent-
age of patients on Peg-Riba + telaprevir on treatment at week 12 and 24 was 50.0% and 
11.1%, respectively. cOnclusiOns: The proportion of HCV patients who were still on 
treatment decreased with time with high discontinuation rates especially after week 12. 
Treatment completion was not achieved by a significant proportion of patients, regard-
less of HCV medications.
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PATIENT SATISFACTION wITH HIv THERAPIES: FOCUS ON ADHERENCE TO 
TREATMENT
Murray M.1, Dang N.2, Swinburn P.3, Gallop K.3, Lloyd A.3
1GSK, Brentford, UK, 2ViiV Healthcare, Singapore, Singapore, 3Oxford Outcomes, An ICON plc 
Company, Oxford, UK
Objectives: Over the course of last decade the introduction of highly effective 
antiretroviral (ARV) therapies has transformed a once life-threatening disease into 
a chronic condition. However, maintaining patient adherence to therapy, in the long-
term, is challenging. Despite the enormous benefits offered by current ARVs, evi-
dence suggests that adherence to treatment regimens remains an issue. Numerous 
factors have been identified which compromise long-term adherence, including 
drug-drug interactions, therapy regimen, side-effects, and the overall demands of 
therapy. The aim of this study is to further understanding of the determinants 
of treatment satisfaction for HIV patients receiving ARV therapies. MethOds: A 
programme of research was developed in order to firstly establish the relation-
ship between patients’ views of their current therapies and the adherence to ARVs. 
INFECTION – Patient-Reported Outcomes & Patient Preference Studies
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ADHERENCE INTERvENTIONS TO IMPROvE ADHERENCE TO ANTIRETROvIRAL 
THERAPy IN LOw INCOME SETTINGS: AN INDIvIDUAL PATIENT DATA 
NETwORK META-ANALySIS
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Objectives: To determine the comparative effectiveness of different interven-
tions for improving antiretroviral medication adherence in low-income set-
tings. MethOds: We obtained individual patient data from all randomized trials 
that have evaluated an adherence intervention to promote antiretroviral adher-
ence within low-income countries. We created a treatment network of the differing 
interventions by pooling the individual patient data from comparable treatments 
and comparing them across the individual interventions using a Bayesian net-
work meta-analysis approach. Outcomes included self-reported adherence and 
viral suppression. Results: We obtained data on 11 randomized, involving 5432 
patients. Interventions included daily and weekly text messaging, calendars, peer 
supporters, alarms, counseling, and basic clinical care. For self-reported adher-
ence, we found compelling evidence for the role of weekly text messages (Odds 
ratio [OR] 1.57, 95% Confidence Intervals [CI] 1.22-2.02), counseling (OR 1.43, 95% CI, 
1.06-1.94), and peer supporters (OR 1.72, 95% CI, 1.28-2.29). We found no compel-
ling evidence for daily text messaging, alarms, calendars, or unsupported clinical 
care. Results were similar when using viral suppression as an outcome, although 
not all trials reported viral outcomes. Treatment supporters (OR 1.36, 95% CI, 1.02-
1.82) and weekly text messages (OR, 1.56, 95% CI, 1.01-2.39) were superior to basic 
clinical care. cOnclusiOns: Using individual patient data allowed us to increase 
precision to determine what interventions appear to work. Several common recom-
mendations for improving adherence are unsupported by the available evidence. 
These findings should influence guidance documents on improving antiretroviral 
adherence in poor settings.
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HEALTH CARE RESOURCE UTILIzATION AND ADHERENCE TO ANTIRETROvIRAL 
TREATMENT (ART) By HIv PATIENTS: AN ANALySIS wITH THE QUEBEC 
(CANADA) PUBLIC DRUG PLAN DATABASE
Lachaine J.1, Baril J.G.2, Lambert-Obry V.1, Beauchemin C.1
1University of Montreal, Montreal, QC, Canada, 2Centre de Recherche du CHUM, Montreal, QC, 
Canada
Objectives: Adherence to ART is a key success factor for achieving optimal 
clinical outcomes in HIV disease. The objective was to assess differences in 
compliance rates and health care resource utilization between patients receiv-
ing a once daily single tablet regimen (STR) vs. a multiple tablets per day regi-
men (MTR). MethOds: This retrospective study included patients covered by 
the Quebec provincial drug reimbursement program (RAMQ) who have received 
at least one script for an ART from January 1st, 2006 to June 30th, 2012. For each 
patient, the index date was defined as the date of the first script for an ART and 
compliance rates were estimated over a 1-year period. Patients were considered 
compliant if their medication possession ratio (effective treatment duration 
over expected treatment duration) was equal or greater to 90%. Medical costs 
(hospitalizations and ER, outpatient clinic, ICU and physician’s visits) were com-
pared between the STR group vs. the MTR group. Regression analyses were per-
formed to assess the relationship between compliance, hospitalization rates and 
medical costs with the ART regimen, adjusting for age, gender, comorbidities 
scores, mental disorders diagnosis and drug and alcohol abuses. Results: The 
study included 4,996 HIV patients (mean age: 42.4 years, 74.8% males). A higher 
proportion of patients were compliant (88.4% vs. 75.8%) in the STR group com-
pared to the MTR group (p< 0.001). Patients receiving a MTR were 2.0-fold more 
likely to be non-compliant than patients receiving a STR (p< 0.001). Moreover, 
hospitalization rates (25.8% vs. 15.9%, p< 0.001) and medical costs (CAD$2,785 
vs. CAD$1,909, p= 0.008) were higher for patients receiving a MTR than a 
STR. Linear regression analyses also showed a positive relationship between 
MTR (vs. STR) and hospitalization rates (β = 0.081,p= 0.001) and medical costs 
(β = 0.151, p< 0.001). cOnclusiOns: Patients receiving a STR are more 
compliant than patients on a MTR and have lower hospitalization rates and 
medical costs.
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TOBRAMyCIN POwDER FOR INHALATION FOR THE TREATMENT OF CySTIC 
FIBROSIS: ANALySIS OF THE RAMQ DATA
Lachaine J.1, Lapierre M.E.1, Beauchemin C.1, Balp M.M.2, Calado F.2, Debonnett L.2,  
Desforges J.3, Sagkriotis A.2
1University of Montreal, Montreal, QC, Canada, 2Novartis Pharma AG, Basel, Switzerland, 
3Novartis Pharmaceuticals Canada Inc, Dorval, QC, Canada
Objectives: To describe treatment patterns and measure real-world outcomes 
with tobramycin powder for inhalation (TIP), tobramycin inhalation solu-
tion (TIS), and other tobramycin formulations (OTF), using the provincial pub-
lic drug reimbursement program database of the Régie de l’assurance maladie du 
Québec(RAMQ). MethOds: Patients with a diagnosis of CF covered by the RAMQ 
drug reimbursement program who had used TIP, TIS, or OTF on at least one 
occasion during the period from January 1st 2011 to June 30th 2012 were selected. 
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Duracinsky M.6
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Objectives: Electronic Patient Reported Outcomes (PRO) provide quick and reli-
able assessment of patients’ health-related quality of life (HRQL). An electronic 
version of the PROQOL-HIV questionnaire was developed, and its face validity 
and reliability were assessed using standard psychometric methods. MethOds: 
A total of 70 French outpatients (63% males, mean age 47 years) were recruited. 
Hard copy and electronic questionnaires were completed in a randomized cross-
over design (2-7 day interval). Biomedical data were collected. Questionnaire ver-
sion and order effects were tested on full scale scores in a two-way ANOVA with 
patients as random effects. Test-retest reliability was evaluated using Pearson and 
intra-class correlation coefficients (with 95% confidence interval) for each dimen-
sion. Usability testing was carried out from patients’ survey reports, specifically: 
general satisfaction, ease of completion, quality and clarity of user interface (UI) 
and self motivation for electronic measuring to monitor HRQL in clinical follow-
up. Results: Questionnaire version and administration order effects (N= 58 
complete cases) were not significant at the 5% level, nor interacting together 
(p= 0.940). Reliability indices were acceptable, with Pearson correlations above 
0.7 and intra-class correlations ranging from 0.696 to 0.926, and scores were not 
statistically different between the two versions. On 77% of complete surveys, 57% 
of patients reported being satisfied and interested in electronic assessment of 
their HRQL in clinical follow up. Individual ratings of PROQOL-HIV user interface 
(85-100% of positive responses) confirmed UI clarity and usability. cOnclusiOns: 
The electronic PROQOL-HIV introduces minor modifications compared to the 
original paper-based version, following ISPOR ePRO Task Force guidelines, and 
it showed good reliability and face validity. Patients can complete the computer-
ized PROQOL-HIV questionnaire as intended and scores delivered from paper or 
electronic version share comparable accuracy and interpretation.
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ATTITUDE OF PARENTS TOwARDS OBLIGATORy AND RECOMMENDED 
CHILDHOOD vACCINATION
Lehocká L., Malovecká I., Minariková D., Foltan V.
Comenius University, Bratislava, Slovak Republic
Objectives: The immunization is currently one of the most discussed topics in 
the population and the number of its opponents is increasing. MethOds: Opinion, 
awareness and knowledge of parents (n-parents= 240, n-children= 463) about child-
hood immunization through self-reported technique of a questionnaire survey was 
conducted, with respect of gender, age, education and profession of parents in 
regard of their professional connection with health care in case of obligatory and 
recommended childhood vaccination. Results: In case of obligatory childhood 
vaccination all evaluated parameters influence and change opinion, awareness 
and knowledge of parents. Age (p< 0,01, Degree of freedom (df)= 10, Chi-squared 
distribution (χ ²)= 81,08, table value of Chi-squared distribution (tχ ²)= 23,21); gender 
(p< 0,01, df= 2, χ ²= 12,87, tχ ²= 9,21); education (p< 0,01, df= 10, χ ²= 79,11, tχ ²= 23,21); 
health care profession (p< 0,01, df= 2, χ ²= 13,75, tχ ²= 9,21. In case of recommended 
childhood vaccination all analyzed parameters influence and change parents’ 
opinion, awareness and knowledge, except for those working in health care. Age 
(p< 0,01, df= 5, χ ²= 13,29, tχ ²= 15,09); gender (p< 0,01, df= , χ ²= 79,82, tχ ²= 13,28); educa-
tion (p< 0,01, df= 4, χ ²= 49,10, tχ ²= 13,28); health care profession (0,01< p< 0,03, df= 1, 
χ ²= 4,85, tχ ²= 6,64). cOnclusiOns: Analysis confirms that age, gender, education 
and profession connected with health care influence and change parents’ opinion, 
awareness and knowledge about obligatory childhood vaccination. Regarding the 
recommended childhood vaccination, age, gender and education influence and 
change parents’ opinion, awareness and knowledge, although a profession con-
nected with health care neither influences, nor changes opinion, awareness and 
knowledge of the parents.
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MINIMAL IMPORTANT DIFFERENCE (MID) OF RESPONSE TO THE HEPATITIS-C 
vIRUS PATIENT REPORTED OUTCOMES (HCv-PRO) INSTRUMENT IN A TRIAL 
OF PEGyLATED INTERFERON/RIBAvIRIN (PEGIFN/RBv) AND DIRECT-ACTING-
ANTIvIRALS (DAA)
Baran R.W.1, Anderson R.T.2, Dietz B.3, Gooch K.1
1AbbVie, North Chicago, IL, USA, 2Penn State Medical College, Hershey, PA, USA, 3AbbVie GmbH 
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Objectives: Both chronic HCV infection and current treatments negatively impact 
patient reported outcomes. PegIFN/RBV-based therapies decrease general HRQoL 
scores 10%-30% (on SF-36). Psychometric analyses of validity, responsiveness, 
and MID for the HCV-specific HCV-PRO instrument were performed. MethOds: 
Responses to the HCV-PRO (presented ILC2012), the SF-36, and EuroQol-5D 
(EQ-5D)+VAS were analyzed in the M11-602 trial of pegIFN/RBV with placebo 
(n= 11) or DAA: ABT-450/ ritonavir (n= 24), ABT-072 (n= 23), or ABT-333 (n= 16). 
DAAs were administered for 12 weeks, pegIFN/RBV for 48 weeks. PRO instru-
ments were administered at baseline, week 8, end of DAA treatment (EODT), end 
of pegIFN/RBV treatment (EOT), and posttreatment week 24 (PT24). Convergent 
validity of HCV-PRO total score (range 0-100) was assessed through correlation 
(Pearson’s) to SF-36 MCS/PCS and EQ-5D VAS scores. Discriminant validity was 
assessed by dichotomizing HCV-PRO responses on EQ-5D Anxiety/Depression 
dimension severity (none vs. some) and treatment emergent depression/fatigue 
adverse events (MedDRA terms). Responsiveness was assessed through analyses 
of effect size (ES). MID was assessed by standard error of the mean (SEM) and 
The initial step involved undertaking a review of published literature detail-
ing HIV patients’ experiences of receiving ARV therapy. These findings formed 
the basis of a meeting of leading European HIV clinical experts, prominent HIV 
organisation representatives and patients themselves. Results: The literature 
revealed numerous factors such as convenience, tolerability, relationship with 
physician and disease characteristics which influences patients’ satisfaction 
with treatment. Discussion between the clinicians, representative from patient 
organisations emphasised the importance of patient preferences as they relate 
to adherence with HIV therapy. This additional insight emphasised the under-
recognised role played by individual differences and therapeutic knowledge 
in defining attitudes to treatments. cOnclusiOns: Treatment satisfaction is 
a complex issue. The work undertaken so far has highlighted that despite the 
advances in ARVs there are still concerns for PLWH. The next stage of research 
involves undertaking a series of in-depth qualitative interviews with patients 
across Europe and examining attributes of HIV treatment using the discrete 
choice experiment methodology.
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vACCINATION COvERAGEIN yOUNG CHILDREN: A DISCRETE CHOICE 
ExPERIMENT
Veldwijk J.1, Lambooij M.S.2, Bruijning-Verhagen P.C.J.3, Smit H.A.3, de Wit G.A.4
1National institute for public health and the environment, Bilthoven, The Netherlands, 2National 
Institute of Public Health and the Environment, Bilthoven, The Netherlands, 3University 
Medical Center Utrecht, Utrecht, The Netherlands, 4National Institute for Public Health and the 
Environment, Bilthoven, The Netherlands
Objectives: To determine parental preferences concerning rotavirus vaccination 
for their newborn baby, and to calculate the potential vaccination coverage for dif-
ferent vaccine scenarios. MethOds: A Discrete Choice Experiment (DCE) question-
naire was sent to the parents of 1,250 newborns aged 6 weeks in The Netherlands. 
The DCE included nine D-efficient designed choice tasks. Panel-mixed-logit models 
were used to estimate the relative importance of the five included rotavirus vaccine 
attributes; vaccine effectiveness, frequency of severe side effects, protection dura-
tion, location of vaccine administration, out-of-pocket costs. The potential uptake 
or vaccine coverage was calculated for different vaccine scenarios. Results: All 
attributes showed a significant estimate (P< .05). Parents were more likely to get 
their newborn vaccinated if the vaccine effectiveness increased, parents preferred 
a frequency of 1 in 1,000,000 children that suffer from severe side effects over a 
frequency of 1 in 10,000. Protection duration of 3 years was preferred over 1 year 
and parents preferred to get their child vaccinated at the GP’s office. Finally, increas-
ing out-of-pocket costs were associated with decreased willingness to vaccinate. 
With respect to the relative importance of these attributes, vaccine effectiveness 
was most decisive for parents, followed by out-of-pocket costs, protection duration 
and frequency of severe side effects. Vaccination coverage rates ranged between 
22.8% for the least preferred vaccine scenario and 87.5% for the most preferred 
scenario. cOnclusiOns: When deciding whether to vaccinate their newborn baby 
against the rotavirus, parents are mostly driven by the effectiveness of the vaccine, 
the out-of-pocket costs, protection duration and the frequency of severe side effects. 
Differences in vaccine scenarios resulted in a large range in expected vaccination 
coverage. Therefore, the context and content of the implementation strategy of the 
vaccination is expected to strongly affect the vaccination coverage. Specifically 
requesting an out-of-pocket payment of parents should be considered carefully if 
a high vaccine coverage is desired.
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PATIENTS wITH CHRONIC HEPATITIS C vIRUS TREATED wITH SIMEPREvIR 
ADDED TO PEGINTERFERON AND RIBAvIRIN ExPERIENCED LESS TIME wITH 
FATIGUE, DEPRESSIvE SyMPTOMS, AND FUNCTIONAL LIMITATIONS: RESULTS 
FROM PATIENTS IN THE QUEST-1, QUEST-2, AND PROMISE STUDIES
Scott J.1, Gilles L.2, Fu M.3, Brohan E.4, Amatya R.4, Jessner W.2, Beumont-Mauviel M.5
1Janssen Global Services, LLC, High Wycombe, UK, 2Janssen Research and Development, Beerse, 
Belgium, 3Janssen Research and Development, Spring House, PA, USA, 4Adelphi Values Ltd., 
Manchester, UK, 5Janssen Infectious Diseases, Beerse, Belgium
Objectives: To examine the value of adding simeprevir (SMV) to peginterferon 
and ribavirin (PR) for treatment of chronic hepatitis C virus infection using patient-
reported outcomes (PRO) and their concordance with virology endpoints and 
adverse events (AEs). MethOds: Patients rated severity of fatigue (FSS), depres-
sive symptoms (CES-D), and impairment in functioning (WPAI:HepC Productivity, 
Activity, Absenteeism) at baseline and throughout treatment/follow-up in three 
randomized, double-blind trials comparing addition of SMV or Placebo (PBO) dur-
ing initial 12 weeks of PR treatment. PR was administered for 48 weeks (PBO group) 
and either 24 or 48 weeks (SMV group) (response-guided therapy [RGT]). Analysis 
of pooled data from the trials using a piecewise-linear mixed model compared 
the area-under-the-curve from baseline to Wk60 (AUC60) between SMV/PR and 
PBO/PR for each PRO score. Subgroup analyses evaluated impact of Sustained 
Virologic Response 12 weeks post-treatment (SVR12), fibrosis level, and RGT on 
PRO scores. Results: Of 1178 patients studied, analyses included 768 SMV/PR- and 
393 PBO/PR-treated patients. 87.5% of the SMV/PR group met RGT and completed 
treatment in 24 weeks. Fatigue and anaemia AEs were comparable in both groups but 
FSS scores show clinically important increases in fatigue, lasting 6.9 weeks longer 
with PBO/PR (p < 0.001). No significant differences were observed for Absenteeism. 
Mean scores for all other PRO endpoints worsened from baseline to Wk4 in both 
groups and remained impaired to Wk24 (SMV/PR) and Wk48 (PBO/PR), resulting 
in significantly lower AUC60and fewer weeks with clinically important worsening 
scores with SMV/PR. PRO scores indicated better outcomes for patients who met RGT 
criteria or achieved SVR12; differences in PRO scores associated with fibrosis level 
were only observed in the PBO/PR group. cOnclusiOns: Greater efficacy of SMV/
PR enabled reduced treatment duration and less time with PR-related side effects 
without adding to the severity of side-effects during treatment.
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Objectives: Trials comparing addition of simeprevir (SMV) or placebo to peginter-
feron/ribavirin for treatment of chronic hepatitis C virus (HCV) infection found that 
all patient-reported outcome (PRO) measures except Absenteeism scores from the 
Work Productivity and Activity Impairment questionnaire for Hepatitis C (WPAI:HepC) 
showed similar patterns over time and significantly better outcomes for the SMV groups. 
Absenteeism scores using recommended scoring were available only if a patient was 
in the workforce at baseline and subsequent study visits. To appreciate movement into 
and/or out of the workforce in HCV trials, we propose two alternative scores for the 
WPAI:HepC: Missed Work and Work Impairment. MethOds: A total of 711 subjects com-
pleted the WPAI:HepC in the QUEST1 and QUEST2 SMV trials during study visits at base-
line and throughout treatment and follow-up. The WPAI:HepC assesses whether subjects 
were in the workforce during the past 7 days; and if so, number of hours missed from 
work due to HCV or its treatment/number of hours scheduled to work (Absenteeism); 
and how much productivity was impaired when working (Productivity Impairment). 
Revised scoring produced Missed Work scores (% hours not working in past week) and 
Work Impairment (Missed Work x Productivity Impairment) for all subjects at each study 
visit by setting scores for subjects not in the workforce to 100 (range 0 to 100% Missed 
Work or Work Impairment). Results: WPAI Missed Work score results showed modest 
differences between treatments but Work Impairment scores were significantly better 
for the SMV group with a pattern over time consistent with other PRO endpoints in the 
trials (p= 0.034). cOnclusiOns: Methods for evaluating impact of HCV treatment on 
work life in clinical trials need to provide data for all subjects in order to capture work 
force participation and productivity when working. Revised scoring of the WPAI:HepC 
enable more accurate comparison of treatment in clinical trials.
INFECTION – Health Care Use & Policy Studies
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ASSESSING THE FISCAL CONSEQUENCES OF IMMUNIzING THE FEMALE AND 
MALE POPULATION AGAINST HUMAN PAPILLOMAvIRUS (HPv) IN GERMANy
Kotsopoulos N.1, Connolly M.1, Remy V.2
1Unit of PharmacoEpidemiology & PharmacoEconomics, Groningen, The Netherlands, 2Sanofi 
Pasteur MSD, Lyon, France
Objectives: It is well recognized that HPV infection causes a substantial burden 
in females. The infection also causes a substantial burden in males as it is associ-
ated with HPV-related cancers. Traditional economic evaluations focus only on 
quantifying cost-effectiveness, however, it is increasingly recognized that immuni-
zations may generate broader benefits not captured in cost-effectiveness analysis. 
This research aimed at developing a government-perspective health investment 
model to estimate the fiscal impact of immunizing males and females with the 
quadrivalent HPV vaccine in Germany. MethOds: Methodologies from genera-
tional accounting, human capital and health economics were combined to esti-
mate the fiscal benefits of HPV immunization. Cohort models were developed 
simulating the medical costs and average lifetime fiscal transfers between the 
government and cohorts of 13-year-old immunized and non-immunized indi-
viduals. To estimate tax revenue attributed to immunization-related changes in 
morbidity and mortality, direct and indirect tax rates were linked to differences 
in age- and gender-specific earnings. Results: The lifetime discounted gross tax 
for the immunized male and female cohorts (n= 400,000 each) were € 208.7 billion 
and € 130.4 billion, respectively. Over the lifetime of the female and male birth-
cohorts, it was estimated that immunization with the quadrivalent HPV vaccine 
would result in the prevention of 986 female and 296 male HPV-related deaths. 
Compared to the non-immunized cohorts of 13-year old males and females, the 
immunized cohorts resulted in higher total net discounted tax by € 106.1 million 
and higher total gross discounted tax by € 80.4 million. cOnclusiOns: The com-
bined vaccination of males and females in Germany results in positive lifetime net 
and gross discounted tax revenues for the government. The vaccination of males 
and females with the quadrivalent HPV vaccine is likely to have positive effects 
on public finances and economic growth over subsequent generations.
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DyNAMIC NETwORK MODEL OF CLOSTRIDIUM DIFFICILE INFECTION TO 
EvALUATE TREATMENT INTERvENTIONS AND COSTS
Zowall H., Brewer C., Deutsch A.
Zowall Consulting Inc., Westmount, QC, Canada
Objectives: To date, efforts to model Clostridium difficile infection (CDI) have 
been limited. Most models do not address the contribution of asymptomatic carri-
ers as sources of new infections and are restricted to hospital acquired CDI. We aim 
to develop a simulation model to systematically examine the dynamic relationship 
between three major subpopulations of CDI transmission: hospitals, communities, 
and long-term facilities, to evaluate treatment effectiveness and costs. MethOds: 
We conducted a systematic investigation to determine the key epidemiological 
factors influencing CDI transmission according to the three major subpopula-
tions: hospitals, communities, and long-term care facilities. We have developed a 
stochastic agent-tracking meta-population network model of CDI transmission, 
and identified parameters that would capture transmission from symptomatic 
and asymptomatic carriers to uninfected individuals among the subpopula-
tions. Results: We identified eight infection states: susceptible, gastrointestinal 
exposure, colonized, diseased, deceased, clinically resolved colonized, relapse of 
CDI, and cleared. Key parameters include; health outcomes of target populations, 
time horizon, diagnostic characteristics, treatment effectiveness, transmission 
rates, susceptibility rates, recurrence rates, and costs. Initial treatments of CDI 
do not induce a lasting response in 15%-25% of patients. The estimated effective-
ness of antibiotic therapy for a first recurrence is 60% and declining with multiple 
recurrences. Major predictors of recurrences were advanced age and duration of 
initial hospitalizations. Recurrences of CDI were associated with major increases 
in hospital LOS and costs. cOnclusiOns: Our dynamic network model of CDI 
transmission will improve the capacity to project and to quantify the impact of a 
CDI outbreak in terms of clinical burden and costs.
Receiver Operating Characteristics (ROC) curves correlating HCV-PRO score to MID 
anchors on SF–36 MCS/PCS and EQ-5D VAS. Results: Demographics (N= 74): 22% 
female, 81% white, 51% > 50 years of age, 74% Genotype 1a, 69% IL28B non-CC 
status. Convergent validity: HCV-PRO total score correlations with SF-36 MCS/
PCS and EQ-5D VAS scores were 0.64-0.93 (all time points). Discriminant valid-
ity: HCV-PRO scores decreased 10-30 points more in subjects impaired by anxi-
ety/depression (EQ-5D) or experiencing depression/fatigue events. ES showed an 
increasing impact during treatment (-0.66, week 8; -0.76, EODT; –0.93, EOT). At 
PT24, ES returned to -0.10. SEM and ROC analyses suggested an HCV-PRO MID 
approximating -10 points. cOnclusiOns: The HCV-PRO is a valid, responsive, 
disease-specific instrument. In this study, an MID of approximately -10 points 
was identified. The HCV-PRO may enhance understanding of how HCV treatment 
impacts function/wellbeing.
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AN ASSESSMENT OF UNEMPLOyMENT AMONG PEOPLE LIvING wITH HIv/AIDS 
IN CANADA AND EUROPE
Cline S.K1, Wang S.1, Van Wyk J.2, Baran R.W.1, Gooch K.L.1
1AbbVie, North Chicago, IL, USA, 2AbbVie, Maidenhead, UK
Objectives: Neurocognitive impairment (NCI), depression, and duration of unem-
ployment have been reported as barriers to obtaining employment among people liv-
ing with HIV/AIDS (PLWHA) in the US. However, upon return to work, improvements in 
depression and health-related quality of life (HRQoL) have been observed. The objec-
tives of this study were to examine the burden of unemployment among PLWHA in 
Canada and Europe by 1.) estimating the number of PLWHA who are unemployed and 
their duration of unemployment, and (2) determining patient characteristics associ-
ated with being unemployed, including NCI, depression, and HRQoL. MethOds: Data 
was derived from CRANIum (sCReen for Anxiety, depression, and Neurocognitive 
Impairment in HIV+ patients), a multicenter, cross-sectional study of PLWHA in 14 
European countries and Canada between 2010 and 2011. Depression was assessed 
using the Hospital Anxiety and Depression Scale. NCI was assessed using the Brief 
Neurocognitive Screen, which consists of the Digit Symbol (DS) test and Trail Making 
tests A and B. HRQoL was assessed using the Medical Outcomes Study HIV Health 
Survey (MOS-HIV). Logistic regression was utilized in order to determine if these 
variables, in addition to demographic and clinical variables, were associated with 
unemployment. Results: A total of 2754 PLWHA (mean age = 43; 62% male) were 
included in these analyses; 960 (35%) were unemployed. Regarding the unemployed, 
110 (11%) had been unemployed for < 6 months, 99 (10%) for 6 to 12 months, and 737 
(77%) for > 12 months. Logistic regression analyses indicated that NCI, lower scores on 
the MOS-HIV physical health subscale, previous psychiatric diagnoses, lesser educa-
tion, Hepatitis B and/or C co-infection, older age and female gender were indepen-
dently associated with unemployment. Current depression was not associated with 
unemployment. cOnclusiOns: In tandem with previous reports, results from this 
multinational study suggest that NCI and HRQoL are salient issues with regards to 
employment among PLWHA internationally.
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vALIDATION AND PSyCHOMETRIC EvALUATION OF THE GERMAN-
TRANSLATED HEPATITIS C vIRUS PATIENT REPORTED OUTCOMES (HCv-PRO) 
HEALTH AND wELLBEING INSTRUMENT IN GERMAN HCv-INFECTED PATIENTS 
TREATED wITH DIRECT ACTING ANTIvIRALS (DAAS) wITH OR wITHOUT 
RIBAvIRIN (RBv)
Anderson R.T.1, Baran R.W.2, Xie W.3, Liu Y.2, Dietz B.4, Gooch K.L.2
1Penn State Medical College, Hershey, PA, USA, 2AbbVie, North Chicago, IL, USA, 3AbbVie, Inc., 
North Chicago, IL, USA, 4AbbVie GmbH & Co. KG, Ludwigshafen, Germany
Objectives: Chronic HCV infection and interferon-based treatments negatively 
impact PROs. The HCV-PRO is a validated disease-specific PRO instrument for patients 
with HCV. The purpose of this analysis was to ascertain the psychometric properties of 
the German-translated HCV-PRO. MethOds: Responses from German subjects to the 
HCV-PRO, SF-36v.2, and EQ-5D 5L+VAS were analyzed from the multinational AVIATOR 
trial of interferon-free oral DAA therapy in Genotype 1 patients. HCV-PRO was trans-
lated under Harmonization standards. Approved German-language validated ver-
sions of the SF-36 and EQ-5D were included for psychometric comparison. Internal 
consistency/reliability of HCV-PRO items and total score (range 0–100) were evaluated 
using Chronbach’s alpha. Convergent validity of HCV-PRO total score was assessed 
through Pearson’s correlation to SF-36 MCS/PCS and EQ-5D VAS scores (0.5–0.9 = 
moderate–strong). Discriminant validity was assessed by dichotomizing HCV-PRO 
total score on EQ-5D Anxiety/Depression and Pain/Discomfort dimensions by severity 
(none vs. some). Response range of HCV-PRO total score was examined. Analyses were 
performed at Baseline, week 8 (Wk8), End of Treatment (EOT), and 24 week follow-up 
(PTW24). Results: Demographics (N= 39): 46% female, 97% white, 46% ≥ 50 years 
of age, 36% Genotype 1a, 87% IL28B non-CC status. Clinical response was 92.3% of 
German patients achieving SVR24. Mean HCV-PRO, SF-36 MCS/PCS, and EQ-5D VAS 
scores were minimally changed during treatment (Wk8, EOT). Cronbach’s alpha for 
HCV-PRO items and total scores over time were 0.92–0.96. HCV-PRO total score exhib-
ited moderate-to-high correlation with SF-36 MCS/PCS and EQ-5D VAS total scores 
at each time period (r= 0.42–0.85), with highest correlation with SF-36 MCS. HCV-PRO 
mean scores were lower in subjects with anxiety/depression or pain/discomfort vs. 
none (p< 0.01). Mean HCV-PRO score at PTW24 was improved (p= 0.038) over baseline. 
Baseline HCV-PRO floor (0%) and ceiling (10%) scores were acceptable. cOnclusiOns: 
The German-translated HCV-PRO is a valid, responsive, disease-specific instrument 
for German-speaking HCV-infected people.
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REvISED SCORING OF THE wPAI:HEP C IMPROvES ASSESSMENT OF MISSED 
wORK AND wORK IMPAIRMENT IN HCv CLINICAL TRIALS
Gilles L.1, Peeters M.2, Beumont-Mauviel M.2, Scott J.3
1Janssen Research and Development, Beerse, Belgium, 2Janssen Infectious Diseases, Beerse, 
Belgium, 3Janssen Global Services, LLC, High Wycombe, UK
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at local level; inadequate data collection and follow-up process at later stages of 
life; poor awareness of immunisation schedule by health care practitioners (HCPs); 
lack of structural and operational policies to promote and deliver vaccination 
at later stages of life; infrequent interactions with the health care system dur-
ing adult-hood; limited and inconsistent information dissemination by HCPs and 
government; negative messages on vaccination through media; complacent public 
attitude towards the risk posed by vaccine preventable diseases. cOnclusiOns: 
Three main domains of barriers exist: low institutional facilitation to recommend 
lifespan immunisation as part of NIP; inadequate mechanisms at regional and local 
level to facilitate citizen access to immunisation / vaccination; low patient demand 
for immunisation at older stages of life. To overcome these barriers a broad-ranging 
approach based on awareness is required, which includes providing comprehensive 
pharmacoeconomic evidence to policy makers and payers, developing information 
tracking systems that enable follow up, and HCP education to facilitate informa-
tion dissemination.
PIN132
ECONOMICAL jUSTIFICATION OF THE INNOvATION METHOD OF LABORATORy 
DIAGNOSTIC OF THE STRUCTURAL AND FUNCTIONAL CHANGES OF SERUM 
ALBUMIN IN SEPTIC COMPLICATIONS (ATA-TEST)
Vorobiev P.1, Bezmelnitsyna L.1, Krasnova L.1, Muravsky V.2, Davidova T.3, Sytov A.3
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Albutran, 
Minsk, Russia, 3Russian Research Center of Oncology named after N.N. Blochin, Moscow, Russia
Objectives: The topicality of septic complications (SC) in early period after surgery 
reminds very high despite the antibiotic prophylaxis. The prediction of SC can be 
provided by ATA-test (DTE index) by the registration the structural and functional 
changes of serum albumin. MethOds: Prospective observational controlled study 
of typical practice for cancer patients. Inclusion criteria: cancer patients; age – 
over 18 years; major operations. Exclusion criteria: inflammation diseases during 
3 months before surgery; extended operations on pancreas, liver and bile ducts; 
renal and/or hepatic failure. ATA-test was made ones a day during 7 days in patients 
without SC, 14 days – with SC. Data about direct medical costs was collected via 
medical charts. Analysis was performed with methods of descriptive statistic, para-
metric and non-parametric criteria. Results: Data on 104 patients were obtained: 
11 had SC. Ratio (male:female) was 1:1,4. Average age – 61.2±12.5 years. Average 
level DTE in first 2 hours after surgery in patients with SC was 15.4±7.2%, without 
SC -31.8±14%, in case SC it didn’t increase till normal meanings (40-175%) during 
7 days. Direct medical cost of patient with SC – 8838$: 5352$ - cost for medicines, 
1949$- hospitalization during 36.5 days (7.5 days in ICU), 1537$-medical services; 
without SC – 2992$: 534$-medicines, 1309$-hospitalization during 30 days (3 days in 
ICU), 1149$-medical services. cOnclusiOns: SC can be predicted by ATA-test (DTE 
index) in first hours after surgery. It provides economy in 10 times for medicines 
and in 3 times in common direct medical costs.
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MODELLING STAFF RESOURCE USE IN AMBULATORy HIv CARE
Brennan A.1, Jackson A.2, Horgan M.1
1University College Cork, Cork, Ireland, 2Cork University Hospital, Cork, Ireland
Objectives: Information on staff resource requirements for outpatient HIV care 
is useful for effective planning of the service, especially given the increasing and 
increasingly complex patient population. The aim of this study was to estimate 
the staff resources used in the HIV outpatient clinic in Cork University Hospital 
(CUH). MethOds: Staff in the CUH HIV outpatient clinic completed time sheets 
for 6 consecutive clinics (March-April 2013). Patient identifiable data were not col-
lected, however basic patient characteristics (gender, route of transmission, age > 
50 years, Irish nationality, late diagnosis) and clinical information (type of visit and 
complexity) were included. Results: Over the study period 83% (127/153) of doctor 
visits were timed. 46% of patients were seen by a senior doctor. The average length 
of time spent with each patient by senior doctors was 14.5 minutes, while NCHDs 
spent an average of 24.1 minutes per patient. Patient gender, age, route of infection, 
nationality, late diagnosis and visit type had little impact on the average length of 
doctor visit, but visit length was affected by doctor type and complexity. In addition, 
clinical nurse specialists saw 62% of patients, and spent 14.3 minutes on average 
per patient. cOnclusiOns: Time spent with patients varies with the experience 
level of the doctor. Visit length was also affected by the individual complexity of the 
visit. The results of this study will be fed into a wider study estimating the factors 
influencing the cost of providing ambulatory HIV care in Ireland.
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UNITED STATES POLICy IMPLICATIONS OF GENERIC SUBSTITUTION OF 
BRANDED HUMAN IMMUNODEFICIENCy vIRUS MEDICATIONS
Hogue S.1, Brogan A.1, Goodwin B.2
1RTI-Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmith Kline, Research Triangle 
Park, NC, USA
Objectives: Increasingly, human immunodeficiency virus (HIV) infection is man-
aged as a chronic condition. Payers in the United States (US) typically manage 
chronic conditions as cost-effectively as possible. One element of cost containment 
is to institute policies driving utilization of less-expensive generic medications. 
As generic HIV drugs become available, concerns arise that “de-simplifying” HIV 
treatment by incentivizing use of generic components of fixed-dose combination 
(FDC) treatments will impact adherence, resulting in adverse treatment effects. 
This study evaluated US payers’ likelihood to incentivize patients/physicians from 
branded FDCs toward a combination of generic single-dose drugs. MethOds: We 
conducted targeted research of published literature and payer Web sites to identify 
information relevant to HIV coverage polices. This informed a discussion guide 
for one-on-one interviews with 10 payers from US commercial health insurance 
companies. Participants were recruited to ensure diversity from organizational 
sizes and geographical regions; interviews were double-blinded (i.e., payer and 
pharma). Results: Payers indicated HIV management is increasingly perceived as 
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CONSIDERING ECONOMIC ANALySES IN THE REvISION OF THE PREvENTIvE 
vACCINATION LAw: A NEw DIRECTION FOR HEALTH POLICy-MAKING IN 
jAPAN?
Akazawa M.1, Yongue J.2, Ikeda S.3, Satoh T.4
1Meiji Pharmaceutical University, Tokyo, Japan, 2Hosei University, Tokyo, Japan, 3International 
University of Health and Welfare, Otawara City, Tochigi, Japan, 4Aoyama Gakuin University, 
Tokyo, Japan
Objectives: Evidence of a significant vaccine policy shift can be witnessed not only 
in the number of new vaccines available in Japan but also in the way vaccine policy 
is being formulated. In 2010, policy makers decided for the first time ever to commis-
sion economic analyses as a reference in their consideration of subsidy allocation. 
This research offers a firsthand account of the recent changes in vaccine policies 
by examining the decision-making process from the perspective of researchers 
for economic evaluations. MethOds: In order to understand the vaccine policy-
making process, we analyzed all the documents that were distributed and dis-
cussed during the government committee meetings starting from February 2010 
when the revision of the Preventive Vaccination Law was initially proposed to May 
2012 when the final recommendations were made. We then created a time-series 
table to summarize the main issues of the discussions and final conclusions from 
official reports and other relevant information recorded in the minutes. Results: 
Economic evaluations were conducted for seven vaccines under consideration for 
the routine immunization program (Hib, PCV for children and adults, HPV, vari-
cella, mumps, hepatitis B). The findings suggested most of them were cost-effective 
options. However, for the Hib vaccine, the expected savings was less than the addi-
tional costs required (23.8 billion yen increased), and for the hepatitis B vaccine, 
the incremental cost-effectiveness ratio was far beyond the acceptable range (18.3 
million yen per QALY). Nevertheless, all the vaccines were equally recommended 
for inclusion in the routine immunization program. cOnclusiOns: The findings 
included reasons why policy makers decided to commission economic evidence 
in the first place, the importance of external influences, the choice of evaluation 
methods, the extent to which policy makers actually incorporated the economic 
evidence into new vaccine policies, and the implications of using cost-effectiveness 
analyses on the future of Japanese health policy-making.
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HEPATITIS A vACCINE POLICy PROCESS IN 6 COUNTRIES – FACTORS 
INFLUENCING POTENTIAL ADOPTION
Foley K.1, Ozawa S.2, Nanni A.3, Durden E.4, Maiese B.A.1, Nwankwo C.5, Brodovicz K.6,  
Acosta C.J.7, Privor-Dumm L.8
1Truven Health Analytics, Cambridge, MA, USA, 2Johns Hopkins University, Baltimore, MD, USA, 
3Aeras, Rovkville, MD, USA, 4Truven Health, Austin, TX, USA, 5Merck & Co., Whitehouse Station, 
NJ, USA, 6Merck & Co., North Wales, PA, USA, 7Hospital Privado de la Comunidad, Mar del Plata, 
Argentina, 8Johns Hopkins University, Baltimore, MD, USA
Objectives: Until recently, there has not been a global focus on getting hepatitis A 
vaccines on country policy agendas. Using a vaccine policy adoption framework, we 
sought to identify drivers and barriers of hepatitis A vaccine adoption in six coun-
tries. MethOds: We applied a four-part framework to identify the public vaccine 
adoption process and drivers and barriers for hepatitis A vaccine adoption: 1) evidence 
in support of hepatitis A vaccine adoption; 2) existence of supportive policies; 3) politi-
cal priority of hepatitis A within the country; and 4) whether or not the stakeholders 
were empowered and willing to act. Data were collected using a qualitative policy 
survey and a systematic literature review in Chile, India, Mexico, Russia, South Korea, 
and Taiwan between November 2011 and June 2012. Results: Because hepatitis A 
is more of a concern during periods of economic transition for most countries, and 
because it is often perceived as a non-serious illness, countries struggle to align all 
of the factors necessary for adoption. Even where solid data exist, political support 
is often waning due to apparent transition to low endemicity for hepatitis A and a 
reduced threat. Where data are lacking, other vaccines take priority. Where economic 
studies exist, narrow perspectives fail to capture the broader threat of the disease to 
regional or country economies. Hepatitis A vaccination policy is further complicated 
by the fact that as countries transition to lower endemicity, the major threat is in older 
age groups. This trend leads to a subtle shift in stakeholders from the pediatric vaccine 
community to those more focused on the adult health community. cOnclusiOns: 
Although the vaccine adoption process is the same for hepatitis A as for other pedi-
atric vaccines, this study suggests that drivers of hepatitis A vaccine adoption may 
come from sectors outside the traditional pediatric vaccine community.
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BARRIERS UNDERLyING LIMITED UTILISATION OF vACCINES THROUGHOUT 
LIFE (LIFESPAN IMMUNISATION)
Ghosh S.1, Tangari M.1, Baron-Papillon F.2, Sauty E.3, Rodriguez de Azero M.4, Adel A.li K4
1GfK Bridgehead, London, UK, 2Sanofi Pasteur MSD, Lyon, France, 3Merck Vaccines, Courbevoie 
Cedex, France, 4Vaccines Europe, European Federation of Pharmaceutical Industries and 
Associations, Brussels, Belgium
Objectives: Vaccination constitutes a standard element of public health preventa-
tive programmes worldwide; however, majority tend to concentrate on early stages 
of life, limiting opportunity for other population groups (adolescents, adults and 
elderly) to fully benefit. The goal of this study was to uncover barriers underpin-
ning limited and inconsistent utilisation of vaccination at all stages of life (lifespan 
immunisation). MethOds: Current access to vaccination was evaluated using pub-
lically available government websites in five market archetypes based on purchase 
and delivery mechanisms. A web-based survey and subsequent in-depth interviews 
were conducted with 22 country- and European-level vaccine stakeholders to iden-
tify perceived barriers. Results: Key barriers: constrained finance and compet-
ing health care priorities; policy decisions undertaken at disease level; national 
immunisation programme (NIP) recommendations based on age and risk; poor 
influence on policy by public health practitioners and lack of vaccination advocacy 
groups; constrained finances to implement effective immunisation programmes 
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for the FDA, EMA, Health Canada and Australia the Australian Therapeutic Goods 
Administration. The studies used to make regulatory decisions were then compared 
to the studies used in the reimbursement decisions of France, Scotland, Canada and 
Australia. Results: In all 15 cases reviewed the FDA, EMA and Health Canada used 
at least one of the same studies to come to their decision and in 13 of the cases 
Australia also used that same study. In 14 cases the FDA approved the drug before 
the other regulatory authorities; the longest time before another regulatory agency 
approved a drug was 15 months for rilpivirine. In six cases the FDA commissioned 
studies that other regulatory bodies and reimbursement agencies used later. All 
of the studies were interventional studies. Reimbursement agencies always used 
studies that were previously cited in regulatory documents. These agencies would 
also use studies intended for the regulatory approval of another drug as a source 
for information in a review. cOnclusiOns: Reimbursement agencies and other 
regulatory agencies are influenced by the FDA in the studies they consider, as illus-
trated by at least six cases in which other agencies used studies commissioned by 
the FDA after approval. This influence is easier to see in the last five years, but may 
be older than that due to improvements in published reports.
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ATTITUDES, BELIEFS AND BEHAvIOURS OF GENERAL PRACTITIONERS 
REGARDING vACCINATION: DEvELOPMENT OF A CHARACTERISATION TOOL – 
QUALITATIvE STEPS
Tugaut B.1, Arnould P.2, Benmedjahed K.1, Coindard G.3, Denis F.4, Duhot D.2, Gallais J.L.2, 
Martinez L.2, Raineri F.2, Seyler D.5, Arnould B.1
1Mapi, Lyon, France, 2French Society of General Medicine, Issy-les-Moulineaux, France, 3University 
of Paris-Sud, Le Kremlin-Bicêtre, France, 4University Hospital, Limoges, France, 5International 
vaccination center, Marseille, France
Objectives: General practitioners (GPs) play an essential role in France in the 
prescription and administration of vaccines. Understanding factors that influence 
GPs’ opinions regarding vaccination would help improve vaccination rate in the 
general population. The study objectives were to understand and describe GPs’ 
attitudes, beliefs and behaviours regarding vaccination, to develop a self-report 
tool enabling characterisation of GPs, to assess the prevalence and determinants of 
vaccination behaviours and to identify the modifiable barriers regarding vaccina-
tion. MethOds: Focus groups with French GPs (n= 36) were conducted following a 
semi-structured interview guide. Main themes of the guide were identified through 
a literature review. Qualitative analysis enabled development of a conceptual frame-
work based on the theory of planned behaviour (TPB). Items were then generated 
based on GPs’ quotations. Cognitive debriefing interviews with GPs (n= 10) were 
conducted to assess understanding, acceptability and content validity of the tool. 
Research methods and results were approved by a committee involving GPs, vac-
cination and tool development experts. Results: Focus groups revealed that GPs’ 
attitudes, beliefs and behaviours regarding vaccination varied depending on target 
disease and population. GPs were influenced by factors classified in 6 themes: vac-
cine characteristics, disease characteristics, practical aspects, expected benefits, 
personal background and relationship with patients. These qualitative findings 
supported item generation of the tool to capture 39 detailed concepts. The tool was 
developed to be generic for any disease that could be prevented by vaccination. 
Comprehension testing to confirm the relevance and understanding of the tool is 
underway. cOnclusiOns: The tool was developed following rigorous methodology 
based on documented qualitative research. The TPB seems appropriate for organis-
ing qualitative research findings. Characterisation of GPs based on their attitudes, 
beliefs and behaviours regarding vaccination is expected to predict their intention 
to vaccinate and thus enable development of efficient programs promoting vac-
cination. The next step is to perform psychometric validation.
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A CASE STUDy OF FDA PRACTICES AND ITS INFLUENCE ON REGULATORy AND 
REIMBURSEMENT DECISIONS FOR DARUNAvIR
Rubinstein J., Rubinstein E., Jaksa A., Jao R., Satyarthi H., Liden D.
Context Matters, Inc., New York, NY, USA
Objectives: It is assumed that agencies influence one another but little has 
been written on the extent of this influence. This analysis aims to explore how 
regulatory decisions affect reimbursement decisions within one HIV drug, daru-
navir. MethOds: Documents from the FDA, European Public Assessment Report 
(EPAR), Health Canada, and the Australian Register of Therapeutic Goods together 
with the reimbursement decisions from France, Scotland, Canada and Australia were 
analyzed. The clinical trials found in these documents were compared. Results: 
The FDA approved darunavir ethanolate on June 23, 2006 based on the POWER 1, 2 
and 3 clinical trials. After approval, the FDA also required further reports (to be com-
pleted by December 31, 2007) on two Phase III studies, ARTEMIS and TITAN. Health 
Canada approved darunavir on July 28, 2006 and used the POWER studies along 
with the ARTEMIS and TITAN studies in its decision. The EMA approved darunavir 
on December 2, 2007 but gave conditional authorization a year earlier. EPAR also 
used the TITAN and POWER studies to make its decision. The French reimbursement 
agency used the ARTEMIS and TITAN studies in two recommendations. Scotland 
and Canada cited the ARTEMIS study in their recommendations. Australia used the 
POWER and TITAN studies in two recommendations and the ARTEMIS study in its 
one negative recommendation, citing an inappropriate comparator for the popula-
tion under review. cOnclusiOns: Studies that required further review by the FDA 
after approval were key in determining regulatory decisions by Health Canada, 
EMA and Australia. The reimbursement decisions of France, Scotland, Canada and 
Australia also relied on these commissioned studies.
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CLINICAL GUIDELINES EvIDENCE AS A CRITERION FOR CHANGES IN THE 
LEGISLATION COMBATING TUBERCULOSIS
Stepanenko A, Lishchyshyna O., Melnyk Y.
The State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine
chronic (e.g., diabetes, hypercholesterolemia, schizophrenia) rather than life-threat-
ening and that treatments, while costly, lead to significant savings in medical ben-
efits and ultimately leave medication decisions to specialists. Payers are cautiously 
examining potential savings and were willing to institute modest management for 
generics (tier 1) while keeping branded FDCs on preferred tier 2 (branded preferred 
copay). Payers were unwilling to institute, high cost-sharing co-insurance, prior 
authorizations, or require failure for members to access branded HIV medications 
presently or in the near future. cOnclusiOns: Payers recognize the complexity 
of treating HIV, the role of adherence, the high cost of failure and the public health 
component of preventing resistance. We found payers to cautiously look at potential 
cost savings in medication management until all FDC components become generic. 
We found no widespread desire to drive generic adoption in HIV treatment, and little 
interest in the “de-simplification” of currently available FDCs.
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THE HEALTH AND ECONOMIC EFFECTS ON PUBLIC HEALTH DUE TO PATIENTS’ 
DEFAULT IN TUBERCULOSIS TREATMENT IN MALAySIA
Fun W.H1, Wu D.B.C.2, Cheong Y.M.3, Mohd Noordin N.4, Dony J.F.5, Lee K.K.C.3
1Monash University Sunway Campus, Bandar Sunway, Malaysia, 2Monash University Sunway 
Campus, Kuala Lumpur, Malaysia, 3Monash University Sunway Campus, Selangor, Malaysia, 
4Ministry of Health, Malaysia, Selangor, Malaysia, 5Ministry of Health, Malaysia, Putrajaya, 
Malaysia
Objectives: Inadequate or partial treatment of Tuberculosis (TB) is a known factor 
that would promote drug resistance, thus increasing the overall cost of TB manage-
ment. The study objectives are to identify the general characteristics of defaulting 
patients and to estimate the cost impact on health authorities as compared to non-
defaulters. MethOds: A retrospective case-control study was carried out in public 
treatment centres in Selangor, Malaysia. Defaulter is defined as TB patient who has 
interrupted treatment for two consecutive months or more and did not complete 
their treatment. All subjects were selected from 2011 TB District Registry database. 
Patients’ medical case notes and baseline characteristics were reviewed and analysed. 
The direct costs of TB management were estimated from public health cost refer-
ences. The study was performed from a government’s perspective. Results: A total 
of 176 defaulters and 204 non-defaulters were studied. Foreign-born patients showed 
a higher risk (OR= 5.929; p < 0.01) of defaulting treatment. Unemployed patients were 
also more likely to default treatment (OR= 1.521 p> 0.05). Defaulters were more likely 
to default treatment during intensive phase as compared to maintenance phase 
(68.1% vs. 31.9%; p< 0.05). No other significant findings were observed between the 
two groups including age, ethnicity, severity of x-ray changes, type of TB and overall 
medical risk factors. Mean cost of the non-defaulter group is higher than the defaulter 
group due to a complete treatment (RM 1,259.62 vs. RM 575.58; p< 0.05). No significant 
treatment cost difference was observed in foreign-born defaulters as compared to 
local Malaysians (mean: RM 576.43 vs. RM 573.78; p> 0.05). cOnclusiOns: Data from 
this study suggest TB treatment should be completed to avoid a potential huge waste 
of resources. More attentions are required for foreign-born defaulters due to over-
all consequence in public health and management cost. Additional costs would be 
required if susceptible TB strains of the defaulters turned into more virulent strains.
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THE DISEASE BURDEN OF INFLUENzA IN GERMANy
Ehlken B.1, Wahle K.2, Hain J.3, Pathak P.4, Anastassopoulou A.3
1IMS Health, Munich, Germany, 2University of Muenster, Muenster, Germany, 3GlaxoSmithKline 
GmbH & Co, Munich, Germany, 4IMS Health, Alexandria, VA, USA
Objectives: To describe the burden of influenza for children and adults diagnosed 
with seasonal influenza in Germany. MethOds: The study was based on a retro-
spective database analysis, using a longitudinal electronic medical records database 
(IMS® Disease Analyzer). Patients with influenza episodes (ICD-10 diagnosis J09-
11) being observable 12 months before index date and 1 month afterwards were 
included. The selection window was May 2010 to April 2012 to cover two influenza 
seasons. Results: A total of 23,068 influenza episodes (19,446 patients) managed 
by primary care practitioners (PCP) and 7,295 episodes (5,988 patients) managed by 
pediatricians were eligible. Mean age of patients was 43±20 years in the PCP panel 
and 7±4 years in the pediatrician panel. The presence of clinical risk factors was 
documented for 40% of episodes in adults and 31% of episodes in children. The most 
common risk factors were cardiovascular diseases in adults (28%) and chronic res-
piratory diseases in children (26%). The presence of risk factors correlated with the 
number of episodes/patient. Influenza episodes were frequently accompanied by 
complications (adults: 38%; children: 57%). Bronchitis (adults: 16%, children: 20%) 
and acute upper respiratory infections (adults: 15%, children: 21%) accounted for the 
most frequent complications. Mean number of physician visits was 1.2± 0.5 in adults 
and 1.5±0.8 in children. Nevertheless one in three children (34%) had more than one 
visit/episode due to complications. About 60% of episodes (adults: 60%; children: 64%) 
with at least one complication were reported in patients without risk factors. About 
50% of patients received drug prescriptions related either to influenza diagnosis or 
complications. cOnclusiOns: This study demonstrates that in Germany seasonal 
influenza is associated with a substantial disease burden and considerable resource 
utilization, which can be preventable by vaccination. The findings may suggest the 
modification of the current vaccination recommendation for at risk populations.
PIN137
HIv REGULATORy PRACTICES AND THEIR INFLUENCE OvER REIMBURSEMENT 
DECISIONS
Rubinstein J., Rubinstein E., Jaksa A., Liden D.
Context Matters, Inc., New York, NY, USA
Objectives: This analysis compares the studies that four regulatory agencies used 
to make their decisions and compares the relationship between the reasons for 
regulatory decisions and reasons for reimbursement decisions. MethOds: The 
scientific discussions and the studies used to make regulatory decisions for 15 
different HIV drugs approved over the last 12 years (2000-2012) were compared 
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p3= 0.002). Compared to the preoperatively measured, the fail of the three meas-
ured respiratory functional values on the 7th postoperative day was significantly 
smaller in Group1 than Group2 (VC, FEV1, PEF; Group1: 14.18±12.61%; 12.82±14.31%; 
-6.29±18.46%; Group2: 25.60±16.11%; 23.05±14.93%; 13.70±19.28%; p1= 0.043, p2 = 0.046, 
p3 = 0.004). There was no difference between groups in duration of mechanical ven-
tilation and average stay of intensive care unit. Incidence of atelectasis was 10% in 
Group1, while 0% in Group2. Pre- and postoperative respiratory functional values 
did not correlate significantly with extubation time (p> 0.05). cOnclusiOns: The 
applying of preoperative PT to cardiac surgical patients with COPD is effective since 
the examined respiratory functional values reduced less and increased better in the 
postoperative period at the preoperatively treated group.
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RESPIRATORy SyNCyTIAL vIRUS HOSPITALIzATIONS IN THE CANADIAN 
REGISTRy FOR SyNAGIS (CARESS)
Paes B.A.1, Mitchell I.2, Li A.3, Harimoto T.3, Lanctot K.L.3
1McMaster University, Hamilton, ON, Canada, 2University of Calgary, Calgary, Alberta, Canada, 
3Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Objectives: Paediatric advisory committee guidelines recommend palivizumab 
prophylaxis for infants at high risk for respiratory syncytial virus (RSV) infection. 
The objective of this study is to compare the hospitalization rates for respiratory 
illness (RIH) and RSV-positive hospitalizations (RSVH) among infants who received 
palivizumab for various indications. MethOds: The Canadian Registry for Synagis 
(CARESS) is a prospective registry of infants who have received ≥ 1 dose of palivizumab 
per RSV season across Canada. Demographic data were collected in 32 Canadian 
national sites during the 2005-2012 RSV seasons. Respiratory illness related hospi-
talization events were recorded monthly. Standard risk indications that qualified for 
RSV prophylaxis were categorized as prematurity (≤ 35 completed weeks gestational 
age), chronic lung disease or bronchopulmonary dysplasia (CLD), hemodynamically 
significant congenital heart disease (CHD), and other serious underlying medical 
disorders (MD). A Cox proportional hazards analysis was conducted to examine differ-
ences in hospitalization rates between the indications. Results: Of the 13,310 infants 
enrolled, 8751 were premature, 1048 had CLD, 1414 had CHD, and 2097 qualified with 
MDs. The overall RIH rate was 6.6% (n= 875) with premature infants having a signifi-
cantly lower rate than the other groups (4.4% vs. 12.2% [CLD], 10.3% [CHD], 10.3% [MD]; 
B= -0.770, df= 1, p< 0.0005). Details of hospitalizations did not differ between groups, 
except the number that were admitted to the Intensive Care Unit which was signifi-
cantly different between groups (χ 2= 11.420, df= 3, p= 0.010). The overall RSVH rate was 
1.55% but was also significantly lower for prematurity (prematurity, 1.36%; CLD, 1.64%; 
CHD, 2.05%; MD, 2.03%; p< 0.0005), with no significant differences between the groups 
in terms of time to RSV hospitalization (χ 2= 1.833, df= 3, p= 0.608). cOnclusiOns: 
RIH and RSVH rates were dissimilar across the groups with premature infants being 
significantly lower compared to the others. However there were no identified group 
differences regarding time to first RSVH.
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THE EFFICACy OF THE ExTRA FRONT LOADING SMOKING CESSATION 
COUNSELLING SESSIONS ON THE ABSTINENCE RATE COMPARED wITH USUAL 
CARE USED IN QUIT SMOKING CLINIC IN PENANG, MALAySIA
Blebil A.Q.1, Syed Sulaiman S.A.1, Hassali M.A.2, Dujaili J.A.1, Zin A.M.3
1Universiti Sains Malaysia, Minden, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia, 
3Penang General Hospital, Jalan Residensi, Malaysia
Objectives: To assess the impact of the front loading phone calls counselling on the 
abstinence prevalence at 3 and 6 months after quit date among smokers in Penang, 
Malaysia. MethOds: The study was carried out at Quit Smoking Clinic of two major 
hospitals in the state of Penang, Malaysia. All the eligible tobacco users who attended 
the clinics between February 1 and October 31, 2012 were invited. Participants were 
randomly assigned to receive either the usual care (a combination of nicotine gum 
for the first 2 weeks and cognitive behaviour therapy); (control group), or the previous 
combination plus extra counselling sessions through phone calls during the first month 
of quit attempt (intervention group). Results: Two hundred thirty-one subjects were 
recruited during the period under review. The mean age of starting smoking in the 
study population was 17.38 ± 3.9 years. The vast majority of our cohort (96.1%) was 
male. Participants smoked about 14 cigarettes per day on average (mean = 13.78 ± 7.0). 
At 3 months follow-up point, control group was less likely to quit smoking compared 
to intervention group but this did not reach statistical significance (OR = 0.669; 95% CI 
= 0.395-1.133, P = 0.86). However, at 6 months, the abstinence rate significantly differed 
between the standard care and combination of standard care and extra phone calls after 
verification with exhaled carbon monoxide (48.6% vs. 71.7%, respectively: < 0.001). The 
control group were significantly less likely to quit smoking (OR = 0.375; 95% CI = 0.217-
0.645, P< 0.001). cOnclusiOns: Smoking cessation intervention consisting of phone 
calls delivered counselling during the first month of quit attempt results in significantly 
higher abstinence rates compared with a standard care approach. Therefore, the front 
loading counselling is a promising treatment strategy that should be evaluated further.
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RESPIRATORy SyNCyTIAL vIRUS HOSPITALIzATION IN INFANTS wITH 
CONGENITAL AIRwAy ANOMALIES IN THE CANADIAN REGISTRy OF SyNAGIS® 
(CARESS) FOLLOwING PROPHyLAxIS (2005-2012)
Paes B.A.1, Li A.2, Mitchell I.3, Lanctot K.L.2
1McMaster University, Hamilton, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, 
Canada, 3University of Calgary, Calgary, Alberta, Canada
Objectives: Palivizumab is recommended for respiratory syncytial virus (RSV) 
prophylaxis. CARESS tracks palivizumab use and respiratory outcomes in high-risk 
infants, including those with congenital airway anomalies (CAA). Our objective was 
to compare hazards for hospitalization for respiratory illness (RIH) and RSV (RSVH) 
in CAA infants versus those prophylaxed for: 1) other medical disorders (MD) and 2) 
standard indications (SD). MethOds: Infants were prospectively recruited from 32 
Canadian sites who received ≥ 1 dose of palivizumab during the 2005-2012 RSV sea-
Objectives: Modern medicine provides continuous improvement of diagnosis, treat-
ment and prevention methods in accordance with the requirements of best medical 
practice. The system of medical care standardization with regard of the evidence-
based medicine is focused on developing medical and technological documents that 
assist a doctor to act effectively in specific clinical situations, avoiding inefficient and 
false interventions. In view of this, the Ministry of Health of Ukraine has approved 
the methodology for development of medical and technological documents on the 
basis of evidence. MethOds: Evidence of clinical effectiveness is the main crite-
rion in choosing the treatment methods combating tuberculosis. Results: Ukraine 
has recently introduced the methodology of developing unified clinical protocols 
of medical care based on adapted clinical guidelines, which in turn are the result 
of adaptation of the best international practice. In particular, within the project of 
combating TB the adapted clinical guidelines was developed based on the documents 
of NICE and WHO. In developing the protocol there identified found differences in 
the tuberculosis treatment in Ukraine compared to the best practice, which resulted 
in amendments to the corresponding regulations in health care. cOnclusiOns: 
Practical recommendations derived from the evidence-based medicine allowed the 
change of approaches to diagnosis and treatment of tuberculosis in Ukrainian regu-
lations. 3-time examination by sputum smear and culture microscopy is replaced 
by 2-time, the duration of the basic course of chemotherapy is reduced from 8 to 6 
months and its intensity is reduced from 5-component to 4-component treatment for 
the treatment of new and recurrent cases of tuberculosis with sensitive mycobacteria. 
In order to integrate these changes into clinical practice local protocols and critical 
pathways for management of tuberculosis are developing in all health care facilities 
taking into account peculiarities of the region and available resources of the hospitals.
RESPIRATORy-RELATED DISORDERS – Clinical Outcomes Studies
PRS1
CHARACTERISTICS OF PATIENTS wITH CHRONIC OBSTRUCTIvE PULMONARy 
DISEASE (COPD) RECEIvING INHALED CORTICOSTEROID/LONG-ACTING  
b2-SS2-AGONIST (ICS/LABA) FIxED COMBINATION PRODUCTS IN ENGLISH 
PRIMARy CARE
Blak B.T., Rigney U., Emmas C., Hamblin A.
AstraZeneca UK Ltd., Luton, UK
Objectives: ICS/LABA fixed combinations are used in patients with COPD with 
a history of repeated exacerbations i.e. worsening of disease including infections 
and who have significant symptoms despite regular bronchodilator therapy. This 
study describes the characteristics of COPD patients initiating ICS/LABA in English 
primary care. MethOds: Patients with first prescription (index date) of flutica-
sone/salmeterol (FP/SM) or budesonide/formoterol (BUD/FM) between 01.01.2005-
31.10.2011 and a prior COPD record were selected from CPRD primary care records 
linked to Hospital Episode Statistics. Baseline characteristics prior to first ICS/LABA 
prescription were described as proportions, means and rates (95%CI). Prior exac-
erbations were defined as: antibiotic or oral corticosteroid prescriptions or COPD 
hospitalisation; multiple events within 14 days were treated as one event. Results: 
26,875 patients age≥ 40 at index were included with 75.9% initiating FP/SM and 
24.1% BUD/FM; mean age 70.3(70.1-70.4) and 69.0(68.8-69.3) years, respectively. In 
both cohorts 54% were male, approximately 36% current smokers, and 56% past 
smokers. Pneumonia within 1-year prior to index was slightly higher in FP/SM 
patients (1.9%(1.9-1.9)) compared to 1.4%(1.4-1.4) in BUD/FM), as was prior mean 
annual COPD hospitalisation rate (0.17(95%CI:0.16-0.17); 0.11(95%CI:0.10-0.12)). 
Amongst FP/SM patients 12.7%(95%CI:12.6-12.9) had COPD hospitalisations 1-year 
prior with 9.2%(95%CI:8.9-9.4) amongst BUD/FM. 37.2%(95%CI:36.7-37.7) of FP/SM 
patients received tiotropium 1-year prior with 35.4%(95%CI:34.5-36.2) amongst BUD/
FM. The majority of patients had received short-acting ß2-agonist; FP/SM patients: 
89.8%(95%CI:88.6-91.1), BUD/FM patients: 84.8%(95%CI :82.7-86.8). Proportions 
receiving inhaled-corticosteroids within 1-year prior was 50.9%(95%CI:50.3-51.6) and 
48.0(95%CI:46.8-49.2) for FP/SM and BUD/FM, respectively, oral-steroids figures were 
42.2%(95%CI:41.7-42.8) and 39.8%(95%CI:38.8-40.8), respectively, and mean annual 
exacerbation rate was 2.15(95%CI :2.12-2.18) and 2.02(95%CI:1.96-2.07), respectively, 
with 75.3%(95%CI:74.2-76.3) and 73.9%(95%CI:72.1-75.7), respectively, having exac-
erbations. cOnclusiOns: Both groups had similar burden of COPD disease prior 
to starting fixed combination. The crude prevalences for some baseline character-
istics were slightly higher in FP/SM vs. BUD/FM highlighting the need for rigorous 
propensity score matching in any comparative outcomes research.
PRS2
THE EFFICIENCy OF PREOPERATIvE PHySIOTHERAPy IN PATIENTS wITH 
CHRONIC OBSTRUCTIvE PULMONARy DISEASE UNDERGOING OPEN HEART 
SURGERy
Sió E.1, Bajsz V.1, Mazur M.2, Molics B.3, Boncz I.3, Gombos G.1
1University of Pécs, Zalaegerszeg, Hungary, 2Zala County Hospital, Zalaegerszeg, Hungary, 
3University of Pécs, Pécs, Hungary
Objectives: Chronic Obstructive Pulmonary Disease (COPD) associated with heart 
disease is common; this fact leads to increase the number of postoperative compli-
cations. The aim of this study was to evaluate the benefits of preoperative physi-
otherapy (PT) among patients with COPD. MethOds: Thirty-seven patients with 
COPD were included in the study those who underwent open heart surgery. Group1 
(n= 17) participated in pre- and postoperative PT while Group2 (n= 20) received only 
postoperative PT. Inclusion criteria: open heart surgery and patients diagnosed 
with COPD or have FEV1< 80%. Spirometric measurements (vital capacity= VC, 
forced expiratory volume= FEV1, maximum expiratory pressure= PEF) performed 
preoperatively and on the 3rd and 7thpostoperative days. Operative data, duration of 
mechanical ventilation, average stay of intensive care unit, incidence of atelectasis 
were also assessed. IBM SPSS Statistics 20 software was used for statistical analysis; 
t-test and Pearson-correlation was applied (p< 0.05). Results: VC, FEV1, PEF showed 
significantly decrease in Group1 (21.29±13.40%; 19.71±17.96%; 4.18±20.09%) com-
pared to Group2 (34.70±17.54%; 32.85±11.95%; 24.65±21.65%), (p1= 0.013, p2= 0.011, 
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Objectives: Montelukast 4mg (MTL-4) is a recent add-on therapy for young asth-
matic children. French regulators have requested real-world evidence on effectiveness 
of MTL-4 in infants (6-24 months), compared to inhaled corticosteroid (ICS) therapy. 
National claims data (SNIIR-AM) are now available to public investigators. SNIIR-AM 
records exhaustive medical resource utilization of the French population, i.e. 65.4 
millions. Due to the limited population of infants exposed to MTL-4 from 2010 (i.e. 
78 000 children 6-24 months old), SNIIR-AM represents a good tool to investigate its 
effectiveness. We first tested the feasibility of such a study in a pilot phase conducted 
on a 1/97th representative sample of the full data set (EGB: Representative Sample of 
Beneficiaries), to validate identification and evaluation criteria, and to identify poten-
tial pitfalls in the methods or insufficient statistical power for groups comparison, 
in order to take them into account in the finalized version of the protocol. We pre-
sent hereafter the main conclusions of the pilot project. MethOds: We preselected 
infants receiving ≥ 2 consecutive dispensations of any respiratory drugs (R03 ATC 
classification) and presenting an initial exacerbation within 6 months following the 
first dispensing. Asthma exacerbation was identified by asthma-related hospitali-
zations, dispensing of oral corticosteroids, addition of short-acting beta agonist to 
existing respiratory therapy, switch to an ICS therapy with higher dosage, or switch 
to nebulized CS. Results: Our sample included 1,149 infants (mean age 13 months, 
64% boys). Among them, 51 and 768 were assigned to Montelukast and ICS groups, 
respectively. Infants with a exacerbation during the 6 months post inclusion were 
78.8% and 78.4% in each group, respectively (51% and 62% for oral costicosteroids 
only). cOnclusiOns: The results of this pilot study support the feasibility of our 
SNIIR-AM project, regarding inclusion criteria and identification of outcomes. These 
data allowed us to finalize the SNIIR-AM study protocol that is ongoing.
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CURRENT CHARACTERISTICS, TREATMENT AND HEALTH CARE CONSUMPTION 
OF PATIENTS wITH ASTHMA OR COPD IN THE NETHERLANDS
Overbeek J.A.1, Driessen M.T.2, Penning-van Beest F.J.A.1, Rutten-van Mölken M.3, Lammers 
J.W.J.4, Herings R.M.C.1
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Objectives: To investigate the characteristics, medication persistence and 
health care consumption of asthma and COPD patients in The Netherlands in 
2011. MethOds: Data were obtained from the PHARMO Database Network, includ-
ing outpatient drug dispensings, hospitalization records and information from gen-
eral practitioners (GP). From the GP-database, patients with a recorded ICPC-code for 
asthma or COPD (period 2001-2010) were selected and included if they were continu-
ously registered in 2010-2011 and had ≥ 1 respiratory dispensing in 2010. Persistence 
with any respiratory medication was determined among new patients and defined 
as the number of days of uninterrupted use. Results: The study included 6037 
asthma and 4489 COPD patients. In 2011, most asthma patients were most often 
categorized into GINA I (n= 1727), female (60%) and had a mean age of 45 (SD±18) 
years. COPD patients were classified as GOLD II (n = 1485), male (54%) and had a 
mean age of 67 (SD±11) years. On January 1, 2011, most common used respiratory 
treatment among asthma patients was fixed-dose combination of LABA+ICS (FDC) 
(25%), whereas COPD patients mostly either used FDC (14%), LAMA (14%) or both 
(15%). 30% Of asthma and 16% of COPD patients did not use respiratory medication. 
Among new asthma patients, after six and twelve months, 22% and 10% of patients 
were persistent with respiratory medication. These proportions were 42% and 30% 
for COPD. Most common selected co-morbidities among both groups were hyper-
tension, hypercholesterolemia, and depression. In 2011, asthma patients consulted 
their GP on average 5.3 times and COPD patients 7.7 times. On average, asthma 
patients were 0.4 days hospitalized and COPD patients 1.2 days. Cost calculations 
for health care consumption are available in November. cOnclusiOns: This study 
provides an overview of the characteristics and health care consumption of asthma 
and COPD patients in The Netherlands, and emphasizes the need for more research 
regarding persistence among these patients.
PRS10
ESTIMATION OF THE NUMBER OF CASES OF NOSOCOMIAL PNEUMONIA IN 
ADULTS CAUSED By GRAM-POSITIvE BACTERIA IN PUBLIC HOSPITALS IN 
MExICO
Gryzbowski E.1, Peniche-Otero G.1, Herrera-Rojas J.1, Bolaños-Cornejo D.1, Huicochea-
Bartelt J.L.2, Muciño-Ortega E.2
1Customized Premium Products S.A. de C.V., Mexico City, Mexico, 2Pfizer S.A. de C.V., Ciudad de 
México, Mexico
Objectives: To estimate the number of cases of nosocomial pneumonia 
(NP) in adults caused by Gram-positive bacteria (GPB) in public hospitals in 
Mexico. MethOds: To estimate the number of hospital discharges for each pub-
lic institution in ≥ 18 years, databases from the National Health Information 
System (SINAIS) were consulted. We apply the nosocomial infection (NI) rate (5.97 
cases per 100 discharges) issued by Instituto Mexicano del Seguro Social (IMSS) 
during the period 2011-2012. Through a systematic literature review and critical 
reading of studies developed in the Mexican setting (using the Critical Appraisal 
Skills Programme guidelines) we assessed the type of infection and determined 
the proportion of cases in which microbiological culture was obtained, as well as 
the proportion giving positive isolates; subsequently, etiologic agent was disaggre-
gated according to their Gram staining characteristics. Results: In the year 2011 
there were 5,517,139 discharges from public hospitals, applying a rate of 5.97 NI 
cases/100 discharges, resulted in 329,373 NI cases (16.9% under 18 years and 83.1% 
in adults). The NP represented 33.2% of NI (90,882 cases), of these, only in 63% of 
cases a microbiological culture was obtained (57,256) and pathogens were isolated 
in 87.0% of microbiological cultures (49,813), among these, GPB we identified in 
30.4% . According to our estimates the number of cases of adult NP caused by GPB is 
15,135 and the pathogens reported were Staphylococcus aureus (74.3%), Streptococcus 
pneumoniae (15.6%), Enterococcus spp. (6.3%) and others (3.8%). cOnclusiOns: In 
sons. Utilization and hospitalization outcomes were collected monthly throughout 
respective seasons. Results: A total of 13,310 infants were enrolled (309 CAA, 1816 
MD, 11185 SD). There were statistically significant group differences (p< 0.05) in: enrol-
ment and gestational age, birth and enrolment weight, proportions of: Caucasians, 
daycare attendance, smoking exposure, siblings, multiple birth, household crowding, 
and atopy. Compliance, calculated by inter-dose intervals, was similar across the 
groups - overall rate 73.2%. CAA infants had a RIH rate of 12.9%; MD (9.9%); SD (5.9%) 
with significantly increased hazard of hospitalization compared to MD (HR = 1.47, 
95%CI: 1.04-2.10, p = 0.030) and SD (HR = 1.92, 95%CI: 1.39-2.67, p < 0.0005). 40/309 CAA 
infants were hospitalized for RI, 32 were tested for RSV; 4 were positive (RSVH rate: 
1.61% versus 2.06% (MD), 1.47% (SD). By Cox proportional hazard analysis, CAA did not 
increase hazard of first RSVH compared to MD or SD infants (χ 2 = 0.79, df = 2, p = 0.67). 
After risk factor adjustment for daycare attendance, siblings, smoking exposure and 
crowding, the model was significant (χ 2= 66.1, df = 10, p < 0.0005); however, individual 
groups as risk factors remained insignificant (p = 0.73). cOnclusiOns: This is the 
largest report of CAA infants who have received palivizumab world-wide. Despite dif-
ferences in risk factors, the groups appear to have similar hazards in terms of RSVH.
PRS6
SySTEMATIC REvIEw OF COLISTIMETHATE SODIUM DRy POwDER AND 
TOBRAMyCIN DRy POwDER ANTIBIOTICS FOR PSEUDOMONAS AERUGINOSA 
LUNG INFECTION IN CySTIC FIBROSIS
Harnan S.E.1, Uttley L.1, Cantrell A.2, Taylor C.J.3, Walshaw M.4, Brownlee K.5, Tappenden P.2
1The University of Sheffield, Sheffield, UK, 2University of Sheffield, Sheffield, UK, 3Sheffield 
Children’s NHS Foundation Trust, Sheffield, UK, 4Liverpool Heart and Chest Hospital NHS 
Foundation Trust, Liverpool, UK, 5Leeds Children’s Hospital, Leeds General Infirmary, Leeds, UK
Objectives: To evaluate the clinical effectiveness of colistimethate sodium dry 
powder for inhalation (DPI) and tobramycin DPI for the treatment of Pseudomonas 
aeruginosa lung infection in cystic fibrosis. MethOds: Electronic bibliographic 
databases were searched in May 2012 (MEDLINE, MEDLINE in-Process, EMBASE, 
Cochrane Library databases, CINAHL, Web of Science and Conference Proceedings 
Citation Index, BIOSIS Previews). Randomised controlled trials were selected for 
inclusion in the review if they included at least one of the interventions of interest 
and reported at least one of the following outcomes: rate and extent of microbial 
response (e.g. sputum density of Pseudomonas aeruginosa); lung function (e.g. 
forced expiratory volume in one second % predicted (FEV1%); respiratory symp-
toms; frequency and severity of acute exacerbations; health-related quality of life; 
and adverse events of treatment (including rate of resistance to antibiotic treat-
ment). Results: Three poor to moderate trials were included in the review. Both 
dry powder formulations were reported to be non-inferior to nebulised tobramycin 
in terms of clinically relevant changes in FEV1%. However, follow up may not be 
long enough to detect slowing of the rate of decline in respiratory function and 
exacerbation rates were not always reported. It was not possible to draw any firm 
conclusions as to the relative efficacy of the treatments. cOnclusiOns: Whilst 
both dry powder drugs were reported to be non-inferior to nebulised tobramycin, 
some results should be interpreted with caution due to the means by which they 
were analysed, the length of follow up, and concerns about the ability of FEV1% to 
accurately represent changes in lung health. The clinical trials should have consid-
ered FEV1% alongside other clinically relevant outcomes, such as acute exacerba-
tions. This study illustrates the difficulty in assessing new technologies where the 
evidence base is poor.
PRS7
ASSESSING NON-INFERIORITy OF ACLIDINIUM BROMIDE 400 mG BID vERSUS 
TIOTROPIUM 18 mG AND 5 mG QD IN PATIENTS wITH CHRONIC OBSTRUCTIvE 
PULMONARy DISEASE (COPD) By MEANS OF A NETwORK META-ANALySIS
Karabis A.1, Lindner L.2, Prior M.3
1Mapi, Houten, The Netherlands, 2Almirall UK, Uxbridge, UK, 3Almirall S.A., Barcelona, Spain
Objectives: To assess non-inferiority (NI) of aclidinium bromide 400 µg BID 
(AB400), to tiotropium bromide 18 µg (TIO18) and 5 µg (TIO5) QD in patients with 
COPD. MethOds: A systematic literature search identified 21 RCTs: TIO18 (16 trials), 
TIO5 (3 trials) and AB400 (2 trials). All trials were analysed using a Bayesian network 
meta-analysis (NMA) and relative treatment effects between all regimens were 
obtained for change from baseline (CFB) in FEV1 trough, SGRQ total score, and TDI 
focal score, at 24 weeks. The posterior distributions of the relative treatment effects 
were used to estimate the probability of non-inferiority, based on the NI margins. 
Two approaches used for margin selection (a) NIMCID: 50% of the Minimum Clinically 
Important Difference (MCID) (b) NINMA: 50% of the difference between TIO18 and pla-
cebo (PLA), based on the NMA results. AB400 was considered non-inferior if it could 
maintain at least 50% of this difference with a probability > 99%. Results: For FEV1 
the MCID is 100mL, while the CFB for TIO18 vs. PLA is 104.1mL giving NIMCID= 50mL, 
NINMA= 52.05mL. AB400 is shown to be non-inferior to TIO5 and TIO18, for both mar-
gins. For SGRQ, a change of 4 points is the MCID and CFB for TIO18 vs. PLA is 2.65, 
thus NIMCID = 2 and NINMA= 1.325. AB400 was shown to be non-inferior to TIO5 and 
TIO18 for both margins. A difference of 1 unit is the MCID for TDI, while the CFB for 
TIO18 vs. PLA is 0.90 unit, giving NIMCID = 0.5, NINMA = 0.45. For these margins, the 
probability of aclidinium been non-inferior is 97% for the NIMCID, and 96% for the 
NINMA. cOnclusiOns: This analysis suggests that treatment with AB400 in COPD 
is non-inferior to TIO18 and TIO5 with respect to lung function, health status, and 
to breathlessness with a probability > 95%.
PRS8
EFFECTIvENESS OF MONTELUKAST ON ASTHMA CONTROL IN INFANTS: 
METHODOLOGy OF A CLAIMS DATA STUDy
Belhassen M.1, Tamberou C.1, Laigle V.2, Souchet T.2, Chanut-Vogel C.2, Lamezec L.2, De Blic 
J.3, Brouard J.4, Fauroux B.5, de Pouvourville G.6, Laforest L.1, Van Ganse E.1
1University of Lyon, Lyon, France, 2Laboratoires MSD France, Courbevoie, France, 3Necker 
University Hospital, Paris, France, 4University Hospital Caen, Caen, France, 5Trousseau University 
Hospital, Paris, France, 6ESSEC, Cergy-Pontoise, France
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(SDS) with linezolid. The aim of the study was to estimate the budget impact of 
SDS vs conventional strategy (CS, only intravenous) with linezolid in Mexico, from 
the perspective of Instituto Mexicano del Seguro Social (IMSS). MethOds: Budget 
impact analysis (BIA) considered direct medical costs of linezolid (intravenous 
and tablets), length of stay, physician visits, route of administration, laboratory 
and imaging tests, as well as outpatient control (unit costs extracted from IMSS 
sources). Costs are expressed in 2013 US$ (1US$:€ 0.719). The resource use profile 
was estimated by Delphi method in a panel of 10 experienced infectologists. A 
BIA considering two scenarios was performed: i) budget impact of use CS in 100% 
of cases of nosocomial pneumonia caused by GPB (15,135) and ii) budget impact 
of use of SDS only in candidates (7,718 cases), based on the National budget allo-
cated to health in 2013. Results: The per-patient average treatment cost (ATC) 
of SDS was $10,116 ($9,345-10,887) whereas the per-patient ATC of CS was $17,251 
($16,379-18,124). The scenario i) represents 2.79% of National budget allocated to 
health, whereas scenario ii) represents 2.19%. This means potential savings of 0.6% 
of National budget allocated to health ($55,078,697). With these resources, CS treat-
ment could be provided to 3,192 additional nosocomial pneumonia patients caused 
by GPB in Mexico. cOnclusiOns: In the Mexican setting, SDS with linezolid in 
suitable patients is an intervention that could promote significant savings regarding 
the use of only intravenous form of the drug, which represents an opportunity to 
allocate scarce resources in a more efficient way.
PRS14
POTENTIAL OF OMEGA-3 FATTy ACID IN PARENTERAL NUTRITION IN 
GERMANy: A BUDGET IMPACT ANALySIS
Pradelli L., Povero M.
AdRes HE&OR, Turin, Italy
Objectives: The costs to the German hospitals of intensive care (ICU) patients 
and of surgical patients not admitted to the ICU were estimated in a previous cost-
effectiveness analysis of omega-3 FA-supplemented compared to standard PN regi-
mens. The supplementation with Omega-3 FA results in shorter LOS and reduced 
infection rate, with cost savings for 3,277 € per ICU patient and 1,515 € per not-ICU 
patients. We aimed to estimate the economic consequences of increasing the rate 
of omega-3 fatty acids (FA) supplemented parenteral nutrition (PN) regimens in 
German hospitals MethOds: IMS-data recorded about 3 million lipid-containing 
PN days for Germany; the total number of patients in ICU or in ward receiving PN 
with lipids was estimated on average PN duration from the cost-effectiveness analy-
sis The costs related to the current use of omega-3 FA (about 29% of total lipid PN 
days) were compared with those expected with increasing percentages of omega-3 
FA-containing PN rates. Results: The yearly cost of the patient population (104,022 
ICU patients and 427,986 not-ICU patients) treated with current PN regimens mix 
amounts to about 6 billion Euro. The increase of omega-3 FA-containing PN propor-
tion up to 50% results in a saving of about 210 million Euro (2.7%); the exclusive 
use of omega-3 FA-containing PN regimes results in savings of 704 million Euro 
(11.6%). Encouraging omega-3 FA supplemented PN regimens is expected to save 
costs, because the use is associated with a reduction in hospital LOS (~ 850,000 days 
saved in the best scenario) and the number of nosocomial infections (~ 40,000 infec-
tions avoided in the best scenario). cOnclusiOns: The potential of PN including 
omega-3 FAs in contributing to an improved quality of care/patient recovery and 
significant cost savings is not fully exploited in German hospitals.
PRS15
REDUCTION OF COSTS ASSOCIATED wITH A NEw DRy-POwDER INHALER 
FORMULATION wITH BECLOMETHASONE DIPROPIONATE AND FORMOTEROL 
COMBINATION FOR THE TREATMENT OF ASTHMA
Sanz-Granda Á1, Hidalgo A.2
1Weber Economía y Salud, Majadahonda (Madrid), Spain, 2University of Castilla La Mancha, 
Toledo, Spain
Objectives: A new dry-powder inhaler combination for the treatment of asthma 
has appeared. The objective of the present study is to analyze the cost impact of the 
introduction of the new dry-powder inhaler (DPI) –beclomethasone dipropionate with 
formoterol combination (BEC/FOR) - in the treatment of the moderate to severe persis-
tent asthma MethOds: A mathematical model was designed to estimate the finan-
cial impact of the partial substitution of DPI budesonide with formoterol (BUD/FOR) 
and DPI fluticasone propionate with salmeterol (FLU/SAL). Only direct health care 
costs were considered because the perspective of Spanish National Health Service 
(NHS) was adopted. The time horizon was four years Results: The prevalence is 
4.6% and it increases 0.26% yearly. Current annual total cost of treatment with BUD/
FOR and FLU/SAL is estimated in around 512; 538; 565 and 591 million € for 2013-2017 
respectively. The new total cost is estimated in about 511; 537; 562 and 587 million € 
with the introduction of BEC/FOR. The major determinants of costs were the exac-
erbations of asthma (44.5% of total cost), and the antiasthmatic drugs (40.2%). The 
pharmacological cost of BEC/FOR represented the 37.02% of the total of this option 
while those of FLU/SAL and BUD/FOR were the 39.75% and 41.27%, respectively. Finally, 
the introduction of BEC/FOR (share of 2; 4; 9 and 14% for 2013-2017) was associated 
with a roughly saving of 0.7; 1.2; 2.8 and 4.5 million € in the same time cOnclusiOns: 
The utilization of beclomethasone dipropionate and formoterol in substitution of 
fluticasone and salmeterol, and budesonide and salmeterol, all of them as dry-powder 
inhaled, results in important savings of costs for the NHS
PRS16
THE INFLUENCE OF IMPROvED ADHERENCE AND PERSISTENCE IN CHRONIC 
OBSTRUCTIvE PULMONARy DISEASE (COPD) COSTS: SySTEMATIC REvIEw OF 
THE LITERATURE
Pérez M.1, Dominguez J.1, Armengol S.1, Paz S.2, Lizán L.2
1Almirall S.A., Barcelona, Spain, 2Outcomes 10, Castellon, Spain
Objectives: The lack of treatment adherence and persistence is associated with 
poor clinical outcomes and higher costs. The aim of this study is to estimate 
the variation on COPD costs that may take place as a consequence of improving 
spite of high heterogeneity found in NI reports (which may decrease the quality of 
the information recorded), the local data reported in this study can help clinicians in 
the choice of first line antibiotics in order diminish the probability of unsuccessful 
treatment and additionally to reduce the emergence of resistant organisms, which 
could cause negative economic impact in the health care institutions.
PRS11
FACTORS ASSOCIATED wITH COMPLIANCE wITH PALIvIzUMAB PROPHyLAxIS 
IN THE CANADIAN RSv EvALUATION STUDy FOR SyNAGIS (CARESS) REGISTRy 
(2005-2012)
Paes B.A.1, Li A.2, Yi H.2, Mitchell I.3, Lanctot K.L.2
1McMaster University, Hamilton, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, 
Canada, 3University of Calgary, Calgary, Alberta, Canada
Objectives: Palivizumab prophylaxis against respiratory syncytial virus (RSV) 
is provided monthly during the RSV season. CARESS is a prospective registry of 
infants who received ≥ 1 dose of palivizumab across 32 Canadian sites during 7 
seasons. The objective is to determine factors associated with palivizumab com-
pliance. MethOds: Neonatal and demographic data were collected at enrolment. 
Palivizumab utilization, compliance, and outcomes related to respiratory illness 
(RI) and RSV hospitalization were collected monthly. Compliance was defined 
as receipt of all expected injections at 25–35 day intervals during the RSV sea-
son. Results: A total of 13,310 infants were enrolled. Infants received 89.0% ± 
18.23% of their expected injections and 9745 (73.2%) were administered within 
appropriate inter-dose intervals.Compliant versus non-compliant infants had a 
rate of 9.2 RSV and 57.5 RI versus 11.7 RSV and 65.5 RI hospitalizations / 100-patient-
years respectively. Compliance differed between prophylaxis indications (χ 2= 24.6, 
p< 0.0005); with congenital heart disease the most non-compliant (CHD; n= 668, 
47.2%), followed by chronic lung disease (CLD; n= 470, 44.8%), prematurity (≤ 35 
weeks gestational age; n= 3643, 41.6%) and other medical disorders (n= 831, 39.6%). 
A greater proportion of non-compliant infants were Aboriginal (4.8% vs. 2.4%, 
χ 2= 57.8, p< 0.0005), attended daycare (4.0% vs. 3.3%, χ 2= 5.0, p= 0.03), had a mother 
who smoked (17.1% vs. 12.0%, χ 2= 69.0, p< 0.0005), and lived with ≥ 1 smoker (31.7% 
vs.26.1%, χ 2= 49.7, p< 0.0005). Significant factors independently associated with com-
pliance (OR, 95%CI) were: maternal education (1.38, 1.22–1.58), Aboriginal descent 
(0.57, 0.47–0.70), smoke exposure (0.70, 0.52–0.94), CLD (0.74, 0.56–0.99), maternal 
smoking (0.79, 0.68–1.01), daycare (0.82, 0.68–0.99), and indication for prophylaxis. 
Compliance by both expected number of injections and inter-dose intervals was 
associated with lower hazard rates of RI hospitalization (HR= 0.86, 95%CI= 0.74-0.99, 
p= 0.04). cOnclusiOns: Higher maternal education and lower RI hospitalization 
was associated with full compliance where as non-compliance was associated with 
other demographic factors and differed by palivizumab indication.
RESPIRATORy-RELATED DISORDERS – Cost Studies
PRS12
BUDGET IMPACT ANALySIS OF A NEw FIxED-DOSE COMBINATION INHALER 
FOR A CLINICAL COMMISSIONING GROUP wITHIN THE NATIONAL HEALTH 
SERvICE IN ENGLAND
Dunlop W.1, Heron L.2, Fox G.2, Greaney M.2
1Mundipharma International Limited, Cambridge, UK, 2Adelphi Values, Bollington, UK
Objectives: The economic burden of asthma on the UK National Health Service 
(NHS) is the largest amongst allergic diseases, costing approximately £800 million 
per year. Current Global Initiative for Asthma guidelines recommend adding a long 
acting β 2-agonist (LABA) to a low-dose inhaled corticosteroid (ICS) in patients who 
are on ICS monotherapy and have uncontrolled asthma. The fixed-dose combina-
tion of fluticasone propionate and salmeterol (FLUT/SAL), available in a pressurized 
metered dose inhaler (pMDI) device, is the most commonly prescribed ICS/LABA 
combination. A new fixed-dose combination of fluticasone propionate and formo-
terol fumarate (FLUT/FORM) in pMDI is now available. In a 12 week non-inferiority 
study, FLUT/FORM demonstrated comparable efficacy to FLUT/SAL. This study esti-
mates the budget impact of using FLUT/FORM as an alternative to FLUT/SAL for 
an average NHS clinical commissioning group (CCG) within England. MethOds: 
Current pMDI prescribing data were taken from a real-world UK patient database 
(Cegedim Strategic Data). Annual costs to the NHS for drug acquisition, administra-
tion, and monitoring were estimated for FLUT/FORM and FLUT/SAL. Annual cost 
data were used to estimate the potential budget impact for the use of FLUT/FORM 
versus FLUT/SAL, based on an estimated average population size for a CCG (260,000 
persons or 0.41% of the UK population). Results: Assuming similar levels of ICS 
use with both combination regimens, annual drug acquisition costs per person were 
lower with FLUT/FORM (£411.58) than with FLUT/SAL (£509.06). The difference in 
acquisition costs and otherwise comparable input costs between the treatments, 
results in potential annual savings of £61,952.14 for an average CCG, assuming 
uptake of FLUT/FORM over FLUT/SAL in 50% of existing patients. cOnclusiOns: 
The comparable efficacy and lower acquisition costs for FLUT/FORM compared 
to FLUT/SAL make it a cost-saving option, from a NHS England CCG perspective, 
for the treatment of asthma patients requiring combination maintenance therapy 
using a pMDI.
PRS13
BUDGET IMPACT ANALySIS OF STEP-DOwN STRATEGy vERSUS 
CONvENTIONAL THERAPy IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA 
CAUSED By GRAM POSITIvE BACTERIA IN MExICO
Peniche-Otero G.1, Herrera-Rojas J.1, Gryzbowski E.1, Baeza-Cruz G.1, Huicochea-Bartelt J.L.2, 
Muciño-Ortega E.2
1Customized Premium Products S.A. de C.V., Mexico City, Mexico, 2Pfizer S.A. de C.V., Ciudad de 
México, Mexico
Objectives: Previous reports of national literature estimated 15,135 cases of noso-
comial pneumonia caused by Gram-positive bacteria (GPB) in Mexico, of which 
approximately 51% (95%CI 43%-59%) are candidates to use the step-down strategy 
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COPD patients yields significant costs savings and has a beneficial effect on 
evaluated quality of life.
PRS19
DOUBLING OF HEALTH CARE COSTS AMONG ASTHMA PATIENTS wITH COPD 
DIAGNOSIS AND ITS ASSOCIATED CO-MORBIDITIES IN A CLAIMS DATABASE IN 
THE UNITED STATES
Andersson M.1, Gerhardsson de Verdier M.1, Kern D.M.2, Zhou S.2, Tunceli O.2, Hackett J.3, 
Ciaramella G.3, Butler S.3
1AstraZeneca, Mölndal, Sweden, 2HealthCore, Inc., Wilmington, DE, USA, 3AstraZeneca R&D, 
Waltham, MA, USA
Objectives: To estimate health care costs for asthma patients with and without 
a COPD diagnosis. MethOds: Asthma patients with and without diagnosed COPD 
were selected from the HealthCore Integrated Research Database covering admin-
istrative claims from approximately 27.6 million people in the USA. The index 
event was a patient’s first exacerbation defined as oral corticosteroid prescription 
fills or emergency department visits or inpatient visits with a primary diagnosis 
of asthma. Eligibility criteria were ≥ 1 asthma diagnosis, ≥ 1 exacerbation and 12 
months of continuous health plan enrolment on each side of the index date. Total 
all-cause and asthma-related direct health care costs for 12 months before and 
after the index date were calculated for all patients and those with and without a 
COPD diagnosis. Results: A total of 94,883 patients met all eligibility criteria, of 
these 15,127 (15.9%) had both asthma and COPD diagnoses. The mean patient age 
was 41.6 years and 62.4% were female. Co-morbid conditions were more common 
among asthma patients with a COPD diagnosis. Asthma-related direct costs repre-
sented 25-30% of all-cause direct health care costs for all patients. Among asthma 
patients, COPD and its associated co-morbidities roughly doubled all-cause and 
asthma related direct health care costs: mean annual pre-index all-cause health 
care costs were $20,012 (COPD diagnosis) versus $8,938 (no COPD diagnosis); mean 
annual pre-index asthma related costs were $5,623 (COPD diagnosis) versus $2,600 
(no COPD diagnosis). Mean annual post-index costs were almost unchanged: all-
cause costs of $21,692 (COPD diagnosis) versus $10,787 (no COPD diagnosis) and 
asthma-related costs of $5,242 (COPD diagnosis) versus $3,016 (no COPD diag-
nosis). cOnclusiOns: The economic burden of asthma among patients with a 
COPD diagnosis in a US claims database is twice as high as those without a COPD 
diagnosis. Further research could adjust for the effects of age on the prevalence 
of co-morbidities among the different groups.
PRS20
THE IMPACT OF SMOKING ON HOSPITAL COSTS IN TIMES OF CRISIS; AN 
ADDITIONAL BURDEN TO THE vULNERABLE GREEK HEALTH CARE SySTEM
Tsalapati K., Athanasakis K., Pavi E., Kyriopoulos J.
National School of Public Health, Athens, Greece
Objectives: Smoking has a tremendous impact on public health and has been a 
cause of major concern in Greece for more than twenty years. In times of economic 
recession when household income drops and health spending is decreasing, the 
demand for health services is transferred to the public sector. In light of the above, 
the aim of this study was to measure the number of smoking-related hospitaliza-
tions and the additional hospital costs for the treatment of smoking-attributable 
diseases. MethOds: A prevalence-based disease specific approach was used for the 
calculations. Greek-specific smoking-attributable fractions (SAFs) were calculated 
for all smoking-related diseases, coded according to the International Classification 
of Diseases ICD-10. Smoking attributable morbidity was obtained by applying the 
SAFs to all public hospital admissions for 2011. Total hospital costs associated with 
smoking were calculated by applying the smoking-attributable admissions to each 
DRG rate. Results: For Greece, lung cancer (C33-C34), bronchitis and emphysema 
(J40-J42, J43) presented the highest disease-specific SAF with a value of 88.4% and 
88.1% respectively. In 2011, smoking was responsible for 199,028 hospital admis-
sions (8.9 % of total). Smoking-attributable hospital costs, based on the current 
pricing DRG system, has reached 400,011,801€ representing 7.7% of public hospital 
budgets. Ischemic heart disease (I20-I25) was found to be the main cost driver (90.3 
million € ), followed by other circulatory diseases (I00-I09, I26-I51) (55.8 million€ ) and 
pneumonia, influenza (J10-J18) (52.6 million € ). cOnclusiOns: Despite evidence 
of a decreasing trend, smoking is still a considerable public health issue in Greece 
and has a great impact on public health care system. Vigorous efforts have been 
implemented to promote a smoke-free environment and to enforce existing anti-
smoking legislation however the Greek society still experiences a high proportion 
of smoking-attributable admissions and hospital treatment costs. The findings of 
this study further corroborate a call for stronger support of cost-effective tobacco 
control policies.
PRS21
IMPACT OF CHRONIC PAIN ON HEALTH CARE COSTS IN CHRONIC OBSTRUCTIvE 
PULMONARy DISEASE AS COMPARED TO OTHER CHRONIC DISEASES
Mapel D., Roberts M., Von Worley A.
Lovelace Clinic Foundation, Albuquerque, NM, USA
Objectives: Surveys have found high rates of pain medication use among COPD 
patients. However, few data exist on how chronic pain affects health care utilization. 
We examined how chronic pain affects direct medical costs in COPD and a matched 
cohort of patients with other chronic diseases. MethOds: We conducted a retro-
spective analysis using claims data from one managed care system. COPD patients 
were matched by age, sex, insurance type, and encounter type to persons with 
other chronic conditions but without COPD [Alzheimer’s, atrial fibrillation, cancer, 
kidney disease, acute myocardial infarction, diabetes, heart failure, ischemic heart 
disease, rheumatoid/osteoarthritis (RA/OA), and stroke]. Chronic pain was indicated 
by pain-associated diagnoses, procedures for pain interventions, or prescription 
fills for pain medications. Results: The study cohort (7,952 COPD patients, 15,904 
non-COPD) was 58% female; mean age, 69. A higher percentage of COPD patients 
were chronic users of any pain medication (41.2% vs 31.5%, P< 0.0001). The only 
patients’ treatment adherence and persistence. MethOds: A systematic review 
of the literature was performed in MedLine/PubMed, Cochrane Library, ISI WOK, 
MEDES, IBECS, CSIC, Google Scholar (2002-2012) to identify articles referred to 
direct COPD cost and treatment persistence and adherence. Based on the direct 
cost data extracted, the annual cost difference between an adherent and non-
adherent and a persistent and non-persistent patient in Spain was estimated. 
Costs were updated to € , 2012. Results: A total of 48 articles were included (9 
Spanish; 39 international). The mean annual direct cost of a COPD patient in Spain 
varies between € 301 and € 4.226, depending on the publication. Patients’ adherence 
and persistence on COPD treatment and their annual costs was analyzed in 3 arti-
cles (no Spanish publications identified). Multiple inhaled treatments and devices 
of complex use contribute to poor adherence and persistence and to higher medi-
cal resources use and more exacerbations. Treatment adherence and persistence 
implies a 9% and 3% decrease in mean annual direct cost of a COPD patient, respec-
tively, while non-adherence and non-persistence means an increase of 5% and 
13%. The difference between the mean annual direct cost associated to adherent 
and to non-adherent patient varies from € 43 to € 601 (depending on the selected 
publication) and rises up to € 89 to € 1.674 in severe COPD patients. A difference 
between annual direct cost in persistent and non-persistent patient was estimated 
in € 47 to € 666 that reached € 99 to € 1.855 in severe COPD patients. cOnclusiOns: 
Treatment adherence and persistence information is scarce. Therapeutic strategies 
improving patient adherence and persistence may optimize outcomes contribute 
to COPD costs contain.
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Objectives: The Casemix databases contain clinical costing information from hos-
pitals in Malaysia, Indonesia and the Philippines. The objective of this study was to 
determine burden of pneumonia in these three countries. MethOds: Pneumonia 
cases occurring in a single year were identified using ICD10 codes, J10-J18. Patients 
were further categorized into community-acquired pneumonia (CAP) or hospital-
acquired pneumonia (HAP); CAP if they had 1) a primary diagnosis of pneumonia, 
or 2) secondary diagnosis of pneumonia with primary diagnosis of a respiratory 
condition; HAP cases had pneumonia in any of the secondary diagnosis fields with 
non-respiratory primary diagnoses. Descriptive analysis was performed to ascertain 
patient age groups, mean age, mean length of stay (LOS) and case fatality rates 
(CFR). Results: A total of 15,851 pneumonia cases in year 2010 for Indonesia and 
Philippines and 2011, for Malaysia were included in the analysis. The mean age 
of patients was 47.5 years in Malaysia, 36.6 years in Indonesia and 23.5 years in 
Philippines. There was a preponderance of CAP cases among the very young and 
the very old while HAP cases were more likely to occur in older persons. The overall 
CFR of all pneumonia hospitalizations was 11.5% for Malaysia, 5.2% for Indonesia 
and 3.6% for Philippines. The cost of hospitalization was USD 1,177.50, USD 1,103.80 
and USD 254.30 in Malaysia, Indonesia and Philippines respectively. The mean LOS 
in days was 9.2, 8.0 and 6.6 in the three countries, respectively. cOnclusiOns: 
Our study is the first to utilize these databases to study and compare the burden of 
pneumonia across three countries in Asia. The CFR and LOS varied in each of the 
countries likely due to a variety of reasons including differences in socio-economic 
conditions, patterns of infection as well as health system differences. In conclu-
sion, pneumonia is significant burden in the South East Asian countries studied.
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COST AND COST-EFFECTIvENESS ANALySES FOR MODERATE AND SEvERE 
COPD PATIENTS TREATED UNIQUELy wITH TIOTROPIUM 18 MCG OD FOR 
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Objectives: To evaluate cost and cost-effectiveness of tiotropium monotherapy 
administered for 24 months (18 mcg die) in patients suffering from mild-to-
moderate and severe chronic obstructive pulmonary disease (COPD). MethOds: 
A recent published study showed that tiotropium monotherapy enables a sig-
nificant minimization of morbidity in two groups of patients corresponding to 
predicted FEV1 baseline values ≤ 50% (A) and > 50% (B). Clinical outcomes (days 
in hospital, visits in general ward, cycles of systemic steroids, cycles of antibiotics 
and maintenance therapy drugs) were evaluated from the Italian NHS perspective. 
In order to perform cost-effectiveness analysis, FEV1 value, available for each 
patient, was converted in SGRQ score using a published multivariate linear model; 
then utilities were obtained through the Ståhl equation. Results: Results from 
comparison between 24 months of standard therapy and subsequent 24 months 
of tiotropium monotherapy show that hospitalization cost, which represents the 
driving treatment cost, drops from 74.1% to 67.3% (A) and from 64.5% to 31.6% 
(B) of the total cost; differently maintenance therapy cost increases but it is 
more than offset by the savings accruing from the shortening of hospitalization. 
Furthermore, cost-effectiveness results reveal a mean saving of 216 € (A) and 
900 € (B) other than a mean gain of 0.07 QALY(A) and 0.03 QALY(B). Dominance 
of tiotropium calculated only with patients completing treatment course reveal 
that in almost 30% (A) and 37% (B) of subjects tiotropium strategy is dominant 
while only in 2% (A) and 7% (B) of cases are associated to costs increment and 
worsening on quality of life. cOnclusiOns: These results suggest that adop-
tion of tiotropium as unique treatment in selected mild-to-moderate and severe 
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11 other countries had been included. COPD patients were recorded from a ter-
ritary care hospital in 2012. One-year costs were identified by applying cost data 
to medical information obtained by medical records. The cost analysis was based 
on cost of illness methodology. Costs included those for medications, laboratory 
and diagnostic tests, outpatient visits and hospital stays. Results: There were 612 
patients recruited. Patients were categorized by GOLD classification: 14.29% GOLDI, 
15.28% GOLDII, 38.21% GOLDIII, 32.23% GOLD IV. The median of hospitalization day 
was 9 days. 36.1% of patients were rehospitalized in 90 days. The mortality rate was 
3.1% because of exacerbation. The mean total direct costs was € 4,135.60 per patient 
in a year. The total annual cost was correlated with disease severity. Hospitalization 
contributed the major portion of cost and also correlated with disease severity. 
The average outpatient cost was € 98.62, hospitalization cost including interven-
tion was € 1,548.56, laboratory and diagnostic tests cost were € 103,03, comorbid-
ity and complication cost were € 1.493,88, medication cost with side effects were 
€ 903,59. cOnclusiOns: There is a significant correlation between the cost of COPD 
and disease severity with hospitalization leading to disease exacerbation being a 
major contributor to cost. The keys to reducing health care costs lie beneath reducing 
the frequency of exacerbations and disease severity. As expected, the highest cost 
component was hospitalization, comorbidity and complication cost respectively.
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Objectives: Ireland currently administers a universal BCG vaccination programme 
to infants. In order to assess the cost effectiveness of this programme, it is vital to 
have accurate cost estimates of the burden of tuberculosis (TB) illness in infants. The 
aim of the current study was to cost the diagnosis and treatment of an episode of the 
following health states; pulmonary TB, extrapulmonary TB, TB meningitis and latent 
TB, from the health care payer’s perspective. The cost of contact tracing per primary 
case of TB was also estimated. MethOds: Decision trees were constructed to reflect 
typical episodes of care in the diagnosis and treatment of each health state. Resource 
use and unit cost data were applied to each node in the decision tree. The probabili-
ties of events occurring were derived from the literature and expert clinical opinion. 
Main costs included were inpatient medical/surgical costs, pediatrician outpatient 
appointments, medications, laboratory tests and x-rays. Each health state included a 
cost for a Directly Observed Therapy programme. Direct medical costs were calculated 
and the 2012 price year was used. Results: The direct medical costs of diagnosing 
and treating a case of pulmonary TB, extrapulmonary TB, TB meningitis and latent TB 
were estimated to be approximately € 8153, € 12224, € 15752 and € 894 respectively. The 
main drivers in the costs are the length of hospital stay and the number of pediatri-
cian visits. The cost of contact tracing per primary case of TB was estimated to be 
approximately € 4,248, which was based on a mean number of 9.4 contacts examined 
per primary TB case. cOnclusiOns: To our knowledge this is the first investigation 
of costs associated with paediatric TB within the context of the Irish health care 
setting and will allow for a more robust estimation of the cost effectiveness of BCG 
vaccination programmes, which will benefit the health care payer.
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PHARMACOECONOMIC ASSESSMENT OF DIFFERENT TACTICS OF COPD 
TREATMENT IN RUSSIA
Belevskiy A.S.
Russian Scientific Research Medical University named Pirogov, Moscow, Russia
Objectives: Comparative pharmacoeconomic assessment of COPD therapy of 
patients in GOLD 2-3 stages in Moscow health care system. MethOds: Retrospective 
analysis of 130 cases during 1 year routine practice of patients with COPD in Moscow 
outpatients departments. Basic therapy strategies were obtaned: 1) monotherapy with 
indacaterol (14 pts. Low # of pts is because of the product was launched less than 
year ago); 2) monotherapy by tiotropium (33 pts), 3) fixed combination LABA + ICS 
(38 pts); 4) tiotropium plus fixed combination of LABA and ICS (45 pts). Cost of illness 
via calculation of direct medical costs on diagnostic, hospitalization, treatment of 
main disease and complications based on Federal Standards of COPD treatment and 
regional tariffs on cervices was estimated. Data on prices on medical products were 
obtained from State Register of medical products and www.aptechka.ru. Results: 
The most expencive strategy is management of group 4 - 86.5 KRUR/pt/year (1 Euro 
- 40 RUR) where 67% are costs on base drugs and 31% are hospitalization expenses. 
Usage of fixed combinations LABA + ICS is comparable with monotherapy by tiotro-
pium, total costs are 47 and 49 KRUR/pt/year accordingly. But if the reason of main part 
of the costs in group 3 is hospitalization due to exacerbation - 69%, for group 2 - 61% 
are expenditures on tiotropium. The most preferable is treatment of group 1 - 32847 
RUR/pt/year, where 55% - part on indacaterol, 42% - hospital treatment, 3% - urgent 
care. cOnclusiOns: In spite of high price, indacaterol is the most economic prefer-
able product for basic COPD treatment of patients in GOLD 2-3 stages
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Objectives: To predict health care costs in asthma using the EQ-5D health-related 
quality-of-life (HRQoL) index score. MethOds: We extracted data from the 2000-
03 Medical Expenditure Panel Survey (MEPS) on adult respondents who had EQ-5D 
index scores. Asthma patients were identified using ICD-9 (= 493) and self-report on 
disease (n= 3,783). To account for non-random selection of positive spending, the 
chronic disease with a greater use of pain medications was RA/OA (44.8% vs 41.2%, 
P< 0.0001). COPD patients had more chronic use of short-acting opioids (24.2% vs. 
15.1%, P< 0.0001) and long-acting opioids (4.4% vs. 1.9%, P< 0.0001). Among COPD 
patients, those with chronic pain had higher mean annual direct cost [$24,261 vs. 
$10,390 (p< 0.0001)] which was largely attributable to increased hospitalizations 
(42.7% vs 25.4%, p< 0.0001). By comparison, the mean total medical cost for the 
matched cohort was $17,681 for those with chronic pain compared to $6,543 for 
individuals without chronic pain (P< 0.0001). Pain-related utilization was approxi-
mately 20% of COPD patients’ annual direct cost. cOnclusiOns: COPD patients 
have increased prevalence of and utilization for chronic pain as compared to all 
other chronic illnesses except RA/OA. Individuals with chronic disease and chronic 
pain have more than double the cost of those without chronic pain, and this differ-
ence is even higher among individuals with COPD.
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Objectives: To describe the direct costs to society of COPD per severity grades 
using the “Echantillon Generaliste de Beneficiaires”(EGB). EGB is a database 
which contains all health care resources used by a random 1/97 permanent sam-
ple of the French population covered by the national health care insurance sys-
tem. MethOds: Several algorithms were developed to identify patients with COPD 
and to distinguish patients between four severity grades (1-4) based on health care 
consumption. These algorithms were based on age, rate and history of hospitaliza-
tions, treatments and tests received by the individuals. Exacerbations as well as their 
severity were identified through both antibiotics/corticosteroids drugs prescribed 
and hospitalizations. Total health care costs were calculated and a case-control 
approach was then used to estimate the cost of COPD. Exacerbations costs were 
calculated through a linear regression analysis including age and gender. Results: 
Based on the 10,715 COPD patients identified in the EGB, its prevalence was esti-
mated to 4.2% of the population beyond 40 years. The mean annual overall direct 
health care cost in this population was estimated to be € 9,382. Annual average costs 
were € 7,628; 10,770, 14,979 and 20,747 for severity grade 1-4 (severity data-base 
defined) respectively. The yearly cost of COPD itself was 5,516€ : 45.5% related to 
hospital care and 20.0% to pharmaceuticals (6.0% to long-acting bronchodilators). 
The average exacerbation cost was € 1,664 (SD: € 86.6). The global economic burden of 
COPD in France was therefore estimated over € 7 billions (4% of the national health 
care expense). cOnclusiOns: Our study provides new solutions to estimate the 
burden of COPD in France using existing national databases. It confirms that COPD 
is associated with significant economic burden and the striking direct relationship 
between the cost of care and severity of the disease.
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Objectives: Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent 
chronic inflammatory disease. Some COPD patients show a co-diagnosis of asthma 
(COPD-A). This real-life observational study assessed the frequency of exacerbations, 
the use of health care resources and their associated costs in patients with COPD only 
and COPD-A. MethOds: Medical records from 6 Primary Care (PC) and one general 
hospital were reviewed and data from 2011 were collected from COPD and COPD-A 
patients aged 40 year or older who met specific inclusion/exclusion criteria. Main 
study variables were demography, co-morbidities, exacerbations and resources utili-
zation. Results: A total of 1210 COPD and 102 COPD-A, mean age (% male) 71.8 (85.5) 
and 71.2 (65.7) years, respectively, were included. Mean co-morbidity burden was simi-
lar in both groups with 7.9 and 7.8 diseases per patient. Most frequent co-morbidities 
(% in COPD; % in COPD-A) were dyslipidemia (63.0; 60.8) and arterial hypertension 
(59.5; 62.7) whereas the proportion of exacerbations (%) were 35.0 and 42.2, respec-
tively. Mean number of exacerbations per patient per year was 1.2 in COPD and 1.6 in 
COPD-A. The frequency of severe exacerbations (%) requiring hospitalizations was 
0.4 and 0.7, while those requiring oral corticosteroids was 24.4 and 33.0, respectively. 
Mean per patient, per year health care resources costs (Euro) were 2152.2 and 2207.5 
for PC-associated costs, and 1361.6 and 1754.3 for specialist care-associated costs, 
respectively. cOnclusiOns: Exacerbations are frequent complications in COPD and 
COPD-A patients. Both groups show high proportion of co-morbidities and use of 
health care resources which were higher in the COPD-A group. Health care-related 
costs are high and are mainly related to hospitalizations and drug therapy.
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Objectives: COPD has a major burden on Turkey’s health care system. It leads 
to high mortality, morbidity and frequent use of health care resources. This study 
determined the total direct health care costs for the management of COPD patients 
with differing degrees of disease severity. The study also aimed to find the key cost 
drivers in the management of COPD in Turkey. MethOds: The methodology was 
based on a study conducted by European Respiratory Society in which Turkey and 
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Objectives: According to the GOLD-2011 report pharmacotherapy in stable COPD 
is used to reduce the symptoms, frequency and severity of exacerbations, improve 
health status and exercise tolerance. MethOds: Our aim was to assess the list of 
medicines, which are available in Ukraine for COPD treatment. We compared the 
medications included in the State Formulary of Ukraine with the dosage forms and 
typical doses of COPD medications list provided by GOLD-2011. Also we calculated 
annual course costs for each drug in different dosage forms. The annual course was 
considered as amount of medicine for 365 days in appropriate for COPD basis dosing. 
Information about the medicine prices was obtained from the ukrainian electronic 
pricing database “MORION”. The EUR/UAH exchange rate was 1 EUR = 10.53 UAH 
(20.06.2013) Results: The State Formulary of Ukraine (SFU) contains 19 medicines 
for INN provided by GOLD-2011: 5 INN are in metered dose inhalers (MDI), 5 - in 
dry powder inhalers (DPI), 1 - in smart mist inhaler (SMI), 5 solutions for nebulizer 
and 3 - in tablets. Salbutamol, salmeterol, indacaterol, fluticasone, beclomethasone 
in DPI are not included in the list of SFU, formoterol in MDI and aminophylline, 
prednisone in tablets are not included in this list as well. The most expensive drug 
is tiotropium with annual costs 604.46 EUR for SMI and 533.81 EUR for DPI. The 
annual costs of salmeterol in MDI and formoterol in DPI are 318.55 and 277.30, 
respectively. The cheapest medicine is salbutamol in MDI with 22.13 EUR annually 
but annual costs of salbutamol solution for nebulizer amount 464.48 EUR per year 
per patient. cOnclusiOns: The State Formulary of Ukraine should be reached by 
medicines for COPD management recommended by GOLD. Annual COPD basis costs 
are depending not only from kind of medicine but from it dosage forms as well.
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Objectives: Inhaled corticosteroids in fixed combination with long-acting B2-
agonists could prevent and reduce chronic obstructive pulmonary disease (COPD) 
exacerbations. The aim of this analysis is to compare clinical consequences and direct 
health care costs related to treatment with budesonide/formoterol and fluticasone/
salmeterol for COPD considering the Italian National Health Service (INHS) perspec-
tive. MethOds: Effectiveness data by the PATHOS study, a population-based, retro-
spective, observational registry study conducted in Sweden, in terms of reduction in 
COPD hospitalizations and COPD-related emergency departments (ED) visits were 
considered in order to estimate the differences in resource consumption between 
patients treated with budesonide/formoterol versus fluticasone/salmeterol. Base case 
considers the dosages of the 2 drugs from the PATHOS study, the cost of drugs in 
charge to INHS, COPD hospitalizations costs from Italian real world data and Italian 
national tariffs for COPD-related ED visits. Results: The real world study PATHOS 
demonstrated a significant reduction in COPD hospitalizations and COPD-related ED 
visits with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -21%, 
respectively); average dosages reported were 568 mcg/day for budesonide/formoterol 
(as budesonide dosage) and 783 mcg/day for fluticasone/salmeterol (as fluticasone 
dosage). In the base case, the treatment for 1 year of 100 patients with budesonide/
formoterol lead to a saving of 43.892€ (21.859€ for drugs, 21.864€ for COPD hospitaliza-
tions and 169€ for COPD-related ED visits) corresponding to -25.2% compared with 
fluticasone/salmeterol treatment. In the most conservative sensitivity analysis which 
consider the DDD dosages for the 2 drugs and COPD hospitalizations and COPD-
related ED visits costs from national tariffs, the treatment for 1 year of 100 patients 
with budesonide/formoterol lead to a saving of 15.523€ (5.754€ for drugs, 9.600€ for 
COPD hospitalizations and 169€ for COPD-related ED visits) corresponding to -12.5% 
compared with fluticasone/salmeterol treatment. cOnclusiOns: Treatment with 
budesonide/formoterol compared to fluticasone/salmeterol could lead to a reduction 
in direct health care costs with relevant improvement in clinical outcomes.
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Objectives: To re-evaluate the economic consequences of parenteral glutamine 
supplementation (PGS) in light of the recent metaanalysis confirming that PGS at a 
dose > 0,20 g/kg body weight per day in intensive care unit (ICU) patients is associ-
ated with reduced mortality, infection rate (IR) and length of stay (LOS). MethOds: 
A simulation model was updated with the new meta-analysis data and clinical 
inputs for the control group from Italian ICU population reported in “Progetto 
Margherita”. Costs are evaluated from the perspective of the Italian hospital and 
derive from official sources. Sensitivity analyses are undertaken to test results’ 
reliability Results: PGS is predicted to reduce mortality rates (-29.0%), IR (-21.2%) 
and overall LOS (-1.07 days/patient), yielding a saving of € 1,047 per patient treated. 
Treatment costs are completely offset by the reduction in hospital stay costs and 
antibiotic costs. Probabilistic sensitivity analysis indicates PGS strategy as dominant 
in more than 90% of cases. cOnclusiOns: Also with contemporary comparative 
efficacy data is PGS in ICU patients expected to be effective in improving outcomes 
and containing costs in Italian hospitals providing intensive care.
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Objectives: To estimate the cost-effectiveness of a novel LAMA, glycopyrronium 
(Seebri® Breezhaler), compared with tiotropium (Spiriva®) in COPD patients from a 
Swedish societal perspective. MethOds: A probabilistic Markov model was utilized to 
Heckman two-step selection model was used. The EQ-5D index score was categorized 
into categories with 0.1 gradations. Marginal effects (ME) were estimated to quantify 
the marginal changes in costs corresponding to, for instance, 0.1 increments in the 
EQ-5D index score, or the presence of asthma or asthma treatment. All costs were 
adjusted to 2003 dollars. Results: The EQ-5D index score was a significant predic-
tor of health care costs in all models, as were asthma, asthma treatment and other 
covariates (p< 0.01). The Heckman model suggested a significant positive spending 
bias (p< 0.01). For the 3 groups considered--non-asthma, asthma and asthma with 
treatment--the mean EQ-5D index scores were 0.848, 0.755 and 0.706, respectively. 
The actual mean costs were $2,355, $4,284 and $5,577, respectively. The predicted 
mean costs using Heckman model were $2,673, $4,431 and $5,618, respectively. On 
average, a 0.1 unit improvement in EQ-5D score was associated with $502 cost reduc-
tion in asthma and $693 cost reduction if asthma patients had treatment (p< 0.01). 
However, after adjusting for positive spending bias, the cost reduction was $891 and 
$961 (p< 0.01) for these two groups respectively. Greater cost reductions were associ-
ated with improving EQ-5D scores at the lower end (< 0 to 0.3) and the mid-range (0.5 
to 0.7). cOnclusiOns: HRQoL is an important component of health care resource 
utilization. The findings suggest a significant relationship exists between health care 
costs and HRQoL data. The EQ-5D significantly predicts costs in asthma and asthma 
treatment, especially after adjusting non-random positive health care spending.
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DISEASE IN CLINICAL PRACTICE: A RETROSPECTIvE NESTED CASE-CONTROL 
ECONOMIC STUDy
Sicras-Mainar A.1, Rejas J.2, Navarro-Artieda R.3, Ibañez J.4
1Badalona Serveis Assistencials, Badalona, Spain, 2Pfizer S.L.U., Alcobendas/Madrid, Spain, 
3Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, 4Badalona Serveis 
Assistencials, Badalona, Barcelona, Spain
Objectives: Chronic-Obstructive-Pulmonary-Disease (COPD) is a prevalent health 
condition mainly associated with smoking habit, which is considered the reason 
for higher health care resources utilization and related costs in the National health 
System. The aim of this study was to analyze and compare health care resource utili-
zation and costs according to smoking status in patients with COPD in clinical practice 
in Spain. MethOds: A retrospective cohort nested case-control study was designed. 
Cases were current smokers, while two controls (former smokers) per case matched 
for age, sex, duration of COPD, and burden of comorbidity (number of diagnosis and 
Charlson index) were included using data from medical records. Non-institutionalized 
COPD, both genders, 40 years of age and older, seen consecutively over a period of 4 
years before the index date and fulfilling eligibility criteria were considered eligible for 
analysis. Analysis used regression and general linear models with covariates to com-
pare direct and indirect costs and resource utilization. Results: A total of 930 COPD 
medical records were analyzed: 310 corresponding to cases (current smokers) and 630 
to controls (former smokers). Mean age was 69.4 years (84.6% male). COPD was more 
severe in cases; Odds ratio (OR)= 1.7 (95% CI 1.1;2.1), and higher percentage of current 
smokers had exacerbations [OR= 2,7 (2.0;3.8)], with 4.2 vs. 1.7 exacerbations per year, 
respectively, on average (p< 0.001). Smokers used more physicians visits both at pri-
mary care and specialized level, and emergency room as well. Drugs-based therapies 
were more common in current smokers COPD subjects. As a consequence, smokers 
had higher average annual health care costs; € 3,784 (1,888) vs. € 2,302 (2,451) in former 
smokers (p< 0.001). cOnclusiOns: COPD smoker patients had more exacerbations 
and higher severity of disease. Also, used more health care resources, particularly 
physicians visits and drugs-based therapies resulting in higher health care costs to 
the national health System.
PRS29
COSTS AND EFFECTIvENESS OF NON-SMOKING CLINIC
Laine J.
Pfizer Oy, Helsinki, Finland
Objectives: In Finland a new Tobacco Act entered into force in October 2010 with 
the aim of limiting marketing and supply of tobacco products. The long-term objec-
tive of the Finnish government is to make Finland tobacco-free by 2040. Several 
work places and organizations have declared themselves non-smoking. The city 
of Mikkeli with a population of 55 000, has declared itself a non-smoking city and 
has established a non-smoking clinic in September 2011. Citizens contacting public 
health care and willing to quit smoking will be referred to the clinic. MethOds: 
Cross-sectional data was gathered 12 months after the establishment of the clinic. 
Costs related to investment and clinic’s resource utilization were estimated. A health 
care perspective was applied. Results: We studied 74 citizens, who had a least one 
visit during the first year since the establishment of the clinic. Of them 37% man-
aged to quit smoking. Investment costs related to planning and training of nurses 
were 168€ per quitter. Operational costs were 141-167€ per quitter. Total costs per 
quitter were 309-335€ . In the future investment costs per customer will decrease 
as investment costs were nonrecurring. cOnclusiOns: Our results were slightly 
better than what was achieved in an occupational health care non-smoking project 
in Finland (37% vs. 31%). In 2010 the average total costs of occupational health care 
were 340€ per employee in Finland. This is almost the same as the costs per quitter 
in this study. Cost of cigarettes is about 1800€ per average smoker in Finland. Health 
care costs related to lung cancer and stroke are about 18500€ per case during the 
first year. Pharmacological treatment costs about 200-400€ to quitter in average. 
Investing in smoking clinic is justified from economic and effectiveness point of 
views. The non-smoking clinic is still in operation.
PRS30
THE LIST OF MEDICINES FOR COPD TREATMENT IN STATE FORMULARy OF 
UKRAINE AND RELATED COSTS
Tolubaiev V., Zalis’ka O., Kacheray Y.
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
A372  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
(absorbent). Three additional sub-states: without exacerbation, mild and severe 
exacerbation were considered. The effectiveness of treatment options and utilities 
for each health state were taken from the literature. Only direct health care costs 
were considered. Disease management and exacerbation costs were obtained from 
the literature. Drug costs were calculated based on ex-factory prices with mandatory 
7.5% rebate. All costs were updated to € 2012. A 3% annual discount rate on costs and 
health outcomes was applied. Incremental ratios in terms of cost per life-year gained 
(LYG) and cost per quality-adjusted life-year gained (QALY) of the most effective 
therapy versus the comparator were calculated. One-way sensitivity analyses were 
performed modifying the following parameters: time horizon (10 years, lifetime), 
discount rate (0%, 5%), drug costs (±10%, ±20%) and utilities (±10%). Probabilistic 
sensitivity analysis (PSA) was also performed. Results: At 5 years, glycopyrronium 
bromide accounted a total cost of € 2,225.18 compared to € 2,374.81 accounted for 
tiotropium bromide. Glycopyrronium bromide yielded higher health benefits (4,321 
LYG and 3,388 QALY) than tiotropium bromide (4,315 LYG and 3,377 QALY). In all one-
way sensitivity analyses performed and in 100% of PSA simulations (1,000 iterations), 
glycopyrronium bromide compared to tiotropium bromide remained as a dominant 
strategy. cOnclusiOns: Glycopyrronium bromide therapy in COPD patients is asso-
ciated to less costs and higher health benefits than tiotropium in Spain.
PRS37
INHALED CORTICOSTEROIDS (ICS) IN TREATMENT OF MODERATE AND SEvERE 
ASTHMA IN RUSSIAN FEDERATION – COMPARATIvE PHARMACOECONOMIC 
STUDy
Krysanov I., Tyapkina M.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: We conducted this pharmacoeconomic study to compare mometa-
sone furoate (M/F), fluticasone propionate (F/P) and budesonide (BUD) in treatment 
of moderate and severe asthma. MethOds: Initially we conducted indirect com-
parison of efficacy and safety of studied therapies through the review of clinical 
data publications. We used cost minimization and cost effectiveness analysis for 
the pharmacoeconomic research. In the study we considered the direct costs of the 
three ICS and additional costs of β 2-adregenic agonist (salbutamol). We made calcula-
tions of costs for the most common treatment regimens in Russia: M/F 400 µg 1 dose 
once a day and F/P 125 µg 2 doses twice a day; M/F 400 µg 1 dose twice a day and F/P 
250 µg 2 doses twice a day; M/F 200 µg, 400 µg 1 dose twice a day and BUD 200 µg 2 
doses twice a day. Results: The review of clinical data demonstrated that M/F has 
similar efficacy to F/P and superior efficacy to BUD. The three ICS have similar safety 
profile. Use of M/F presents 10105 RUR (316 USD) in direct annual per patient costs 
for the treatment of moderate asthma and 20210 RUR (632 USD) for severe asthma. 
Cost minimization analysis showed, that the considered treatment regimens of M/F 
are cost effective compared to F/P 125 µg and 250 µg. M/F will save the health care 
system 28 to 50 USD per patient annually, though these results are price sensitive. 
Cost effectiveness analysis demonstrated that M/F has favorable CER compared to 
BUD: for 1% of FEV1 increase M/F 200 µg is 12 USD, M/F 400 µg is 24 USD and BUD is 
32 USD. These results are insignificantly price sensitive. cOnclusiOns: M/F is the 
most cost effective of the three ICS as demonstrated by the results of cost minimiza-
tion and cost effectiveness analyses.
PRS38
THE COST-EFFECTIvENESS OF DRy POwDER ANTIBIOTICS FOR THE TREATMENT 
OF PSEUDOMONAS AERUGINOSA IN PATIENTS wITH CySTIC FIBROSIS
Tappenden P.1, Harnan S.1, Uttley L.1, Mildred M.1, Taylor C.J.2, Brownlee K.3, Walshaw M.4
1University of Sheffield, Sheffield, UK, 2Sheffield Children’s NHS Foundation Trust, Sheffield, 
UK, 3Leeds Children’s Hospital, Leeds General Infirmary, Leeds, UK, 4Liverpool Heart and Chest 
Hospital NHS Foundation Trust, Liverpool, UK
Objectives: To evaluate the cost-effectiveness of colistimethate sodium dry 
powder for inhalation (DPI) and tobramycin DPI versus nebulised tobramycin for 
the treatment of Pseudomonas aeruginosalung infection in patients with cystic 
fibrosis. MethOds: We developed a state transition model based on transitions 
between strata of lung function measured in terms of Forced Expiratory Volume in 
1 Second (FEV1) % predicted. Health states representing post-lung transplantation 
and dead are also modelled. The model was informed by systematic reviews of evi-
dence concerning potential relationships between intermediate and final outcomes. 
The model assumes that treatment impacts on FEV1which manifests as changes 
in health-related quality of life. No survival benefit is assumed due to the absence 
of robust evidence. Model parameters were informed by two RCTs and best avail-
able evidence from the literature. Resource costs associated with drug acquisition, 
management of exacerbations and nebuliser maintenance were drawn from refer-
ence sources and expert opinion. Additional analyses of Patient Access Scheme 
(PAS) price discounts offered by the manufacturers of both DPI products were also 
undertaken. Results: Colistimethate sodium DPI is expected to produce fewer 
QALYs than nebulised tobramycin. Based on its list price, nebulised tobramycin is 
expected to dominate colistimethate sodium DPI. When the PAS is incorporated, 
the ICER for colistimethate sodium DPI versus nebulised tobramycin is expected 
to be approximately £288,600 saved per QALY lost. Based on its list price, the ICER 
for tobramycin DPI versus nebulised tobramycin is expected to be approximately 
£124,000 per QALY gained. When the proposed PAS is included, tobramycin DPI is 
expected to dominate nebulised tobramycin. cOnclusiOns: Under their list prices, 
neither DPI product is likely to represent good value for money given current UK 
cost-effectiveness thresholds. The price discounts significantly improve the eco-
nomic attractiveness of both products. The cost-effectiveness of the DPIs against 
other nebulised antibiotics remains unclear.
PRS39
EMPIRICAL THERAPy FOR RESPIRATORy TRACT INFECTIONS IN AN ERA OF 
INCREASING ANTIMICROBIAL RESISTANCE: A DECISION AND COST ANALySIS
Babela R.
St. Elisabeth University, BRATISLAVA, Slovak Republic
simulate the progressive course of COPD and its impact on quality adjusted life years 
(QALYs) in moderate to severe patients. Effectiveness was based on initial FEV1 increase 
included by using patient level improvement in one or more disease severity stages 
(according to GOLD guidelines) and annualized risk for exacerbation as observed in a 
1-year head-to-head randomized controlled trial (GLOW2). Initial FEV1 increase during 
the first year was followed by a constant decline in FEV1 in subsequent cycles. Based on 
list prices, annual drug costs were 3’825 Swedish krona (SEK)/447 EUR for glycopyrronium 
and 5’040 SEK/589EUR for tiotropium. Direct and indirect maintenance and exacerbation 
costs as well as utilities were extracted from published literature. Primary outcomes were 
QALYs and societal costs over 3 years, discounting future costs and benefits at 3%. Both 
one way and probabilistic sensitivity analysis have been performed. Results: Over 3 
years, glycopyrronium was found to be dominant (i.e. less costly and more effective) com-
pared with tiotropium. Treatment with glycopyrronium resulted in a minor QALY gain of 
0.005 compared with tiotropium. Total costs per patient were estimated at 73’752SEK / 
8’630 EUR for glycopyrronium and 79’357 SEK /9’286 EUR for tiotropium, resulting 
in an average cost saving of 5’605SEK /656 EUR per patient after 3 years. Univariate 
sensitivity analyses showed that base-case results were robust and probabilistic sen-
sitivity analyses resulted in 99% of generated samples with glycopyrronium to be 
dominant. cOnclusiOns: From a Swedish societal perspective, glycopyrronium was 
estimated to be cost-effective compared with tiotropium based on the progressive course 
of COPD and risk for exacerbation in moderate to severe patients as observed in the 
head-to-head study GLOW2.
PRS34
COST-EFFECTIvENESS ANALySIS OF CARBAPENEMS IN TREATMENT 
NOSOCOMIAN PNEUMONIA IN UKRAINE
Iakovlieva L.1, Bezditko N.1, Glumcher F.2, Dubrov F.2
1National University of Pharmacy, Kharkiv, Ukraine, 2O.O. Bogomolets National Medical 
University, Kyiv, Ukraine
Objectives: To conduct a cost-effectiveness analysis of carbapenems use (imipenem, 
meropenem, and doripenem) in treatment nosocomial pneumonia. MethOds: Cost-
effectiveness analysis based on decision-tree model was conducted from patient’s 
(out-of-pocket drugs costs) and state (drugs costs and hospitalization expenses) 
perspectives. The input data on therapy duration and drugs’ doses were retrieved 
from randomized controlled trials and clinical standards. The drugs doses were equal 
to: 2.0g /day from imipenem/cilastatin, 3.0g /day for meropenem, and 1.5g/day for 
doripenem. The model considered that in the case of drugs effectiveness the treat-
ment continued till successful outcome, and in a case of non-effective treatment, the 
second line therapy (vancomycin or colomycin depending on type of infection) was 
applied. The data on infections resistance and empirical effectiveness of antibiotics 
were retrieved from the largest microbiologic study conducted in Ukraine. Results: 
The lowest cost- effectiveness ratio correspond to the initial therapy with imipenem/
cilastatin (CER 910$/1158$ vs. 1280$/1648$ for meropenem and 1317$/1712$ for dorip-
enem from state and patient’s perspectives accordingly). cOnclusiOns: Thus, 
empiric therapy with meropenem increases the costs of medical treatment by 29 %, 
with doripenem – by over 35 %. Sensitivity analysis of the results of calculations versus 
changes of level of MRSA-resistant and carbapenem-resistant strains demonstrated 
reliability of the received results.
PRS35
COST-EFFECTIvENESS ANALySIS OF PALIvIzUMAB AS A PROPHyLAxIS 
FOR RESPIRATORy SyNCyTIAL vIRUS (RSv) INFECTION IN HIGH-RISK LATE 
PRETERM INFANTS IN THE NETHERLANDS
Langenfeld M.K., Visser S.
AbbVie BV, Hoofddorp, The Netherlands
Objectives: To determine the cost-effectiveness of palivizumab for the prevention 
of serious lower respiratory tract infection requiring hospitalization caused by RSV 
compared to no prophylaxis in high-risk infants born at 33-35 weeks of gestational 
age (wGA) according to the Dutch RISK model. MethOds: A decision tree model was 
developed using data from published literature, palivizumab clinical trials, the Dutch 
RISK score model, official price/tariff lists and Dutch national population statistic. 
The comparator was no prophylaxis. The primary perspective of the study was that 
of the society in The Netherlands. Time horizon was lifetime. The cost valuation is 
based on the direct health care costs, direct nonmedical costs and indirect costs. 
Costs were assessed in 2012 Euros. The costs and utilities are discounted by 4% and 
1.5%, respectively, from the second year onwards, and no discounting is applied in 
the first year. Results: The base case results show that the use of palivizumab 
leads to an additional cost of € 4,116, whereas the use of palivizumab leads to a 
gain of 0.201 life years and 0.265 QALYs. Although the use of palivizumab increases 
the costs compared with no prophylaxis, palivizumab-treated patients experienced 
more QALYs and a gain in life years. Subsequently, palivizumab results in an ICER of 
€ 15,520 per QALY gained compared to no prophylaxis. The ICER in cost per LYG is € 
20,440. cOnclusiOns: This analysis showed that palivizumab was cost-effective as 
a prophylaxis against RSV infection requiring hospitalisation in high-risk late prema-
ture infants compared to no prophylaxis. Extensive sensitivity analyses and explored 
scenarios underline the robustness of the demonstrated base case cost-effectiveness.
PRS36
COST-EFFECTIvENESS ANALySIS OF GLyCOPyRRONIUM BROMIDE IN THE 
TREATMENT OF CHRONIC OBSTRUCTIvE PULMONARy DISEASE IN SPAIN
Torres C.1, Betoret I.2, Sabater E.1, Figueras M.2, Casado M.A.1
1Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 2Novartis, Barcelona, Spain
Objectives: To assess the cost-effectiveness and cost-utility of glycopyrronium 
bromide versus tiotropium bromide in Chronic Obstructive Pulmonary Disease 
(COPD) patients, from the Spanish National Health System perspective. MethOds: 
A Markov model was developed to compare glycopyrronium bromide and tiotro-
pium therapies. Progression of a COPD patient cohort was simulated for a 5-year 
time horizon (3 months-cycle duration). The health states included were defined 
according to the severity of COPD: mild, moderate, severe, very severe and death 
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PRS42
ECONOMIC IMPACT OF A SMOKING CESSATION PROGRAM IN MExICO: 
ENROLLING EMPLOyEES AND EMPLOyERS
Huicochea-Bartelt J.L., Muciño-Ortega E., Hernandez-Reyes F.C.
Pfizer S.A. de C.V., Ciudad de México, Mexico
bAckgROund: Smoking costs at work affect both employers and employees. These 
costs are a result of a combined loss of productivity, time off work due to illness, 
smoking breaks and increasing insurance costs. Objectives: This study aims to 
evaluate the economical impact of a 12 week smoking cessation program with 
varenicline from an employer perspective in a medium size Mexican-Corporate set-
ting. MethOds: A decision tree was built in order to estimate the two endpoints of 
the program: resource used in terms of costs and productivity gains in labor hours, 
in a three year horizon. Smokers enrolling in the program were assumed to be the 
proportion of people who reported being very much indeed interested on quitting 
smoking in a 2005 UK survey (27%). A promotional cost of a 12 week combo-pack of 
varenicline was provided by the manufacturer. A literature review was performed 
in order to obtain smoking specific data of the country and response rates. Labor 
costs were retrieved from the Mexican National Institute of Statistics and Geography 
(INEGI). A base scenario of a medium sized company (250 employees) was assumed 
to show the potential benefits of the program. Results: Assuming a 250 employ-
ees company and a shared proportion of 50% of the costs of the program between 
employees and employers, companies would have to invest US$178 per employee 
only at the first year, and have potential savings of US$228 for each of them after 
3 years. At the same circumstances the net productivity gains per programme 
participant would be in an amount of 70.8 hours. cOnclusiOns: This research 
showed that if mexican employers invest in a smoking cessation program, signifi-
cant productivity gains and savings could be reached in a 3 year horizon.
RESPIRATORy-RELATED DISORDERS – Patient-Reported Outcomes & Patient 
Preference Studies
PRS43
THE RELATIONSHIP BETwEEN TREATMENT SATISFACTION AND ADHERENCE IN 
COPD PATIENTS IN 5 COUNTRIES
Vietri J.1, Isherwood G.2
1Kantar Health, Milan, Italy, 2Kantar Health, Epsom, Surrey, UK
Objectives: To assess the relationship between treatment satisfaction and adherence 
in chronic obstructive pulmonary disease (COPD) in European patients, and whether the 
strength of this relationship varies according to country. MethOds: Data were taken 
from the 5EU (France, Germany, Italy, Spain, and UK) 2011 National Health and Wellness 
Survey (NHWS), a cross-sectional survey representative of the total adult populations 
in each 5EU country. The current analysis included all respondents taking one or two 
treatments for COPD (including chronic bronchitis, COPD, and emphysema; n= 914). 
Satisfaction with medication was measured using a single item per treatment, and 
averaged for respondents taking two treatments. Adherence was measured using a sin-
gle 4-item Morisky Medication Adherence Scale (MMAS) for all COPD treatments used. 
Spearman correlations were used to assess the relationship when adherence was consid-
ered as an ordinal variable, and binary logistic regressions were used to assess the rela-
tionship between the two constructs when adherence was dichotomized. Regressions 
included age and gender as covariates. Results: Bivariate correlations demonstrated 
a modest relationship between satisfaction and adherence within COPD patients across 
the five countries rs = .133, p< 0.001). The strength of this relationship ranged from a low 
of rs = 0.05 in France (p = 0.60) to a high of rs= .37 in Spain (p< 0.001). A significant interac-
tion between country and satisfaction confirmed that the relationship varied by country. 
When the relationship was examined within each country, satisfaction was a signifi-
cant predictor of adherence only in Spain and the UK (both p< 0.05). cOnclusiOns: 
Mean level of adherence to COPD treatments differed across European countries. Higher 
satisfaction was generally associated with greater adherence, but the strength of this 
relationship varied. Ensuring treatments are satisfactory to the patient may promote 
greater adherence, but the strength of the impact is likely to vary across populations.
PRS44
FACTORS RELATED TO ADHERENCE AFTER A MULTIFACTORIAL INTERvENTION 
TO IMPROvE IT IN PATIENTS wITH CHRONIC OBSTRUCTIvE PULMONARy 
DISEASE (COPD). ICEPOC STUDy
Leiva-Fernandez F.1, Leiva-Fernandez J.2, Prados-Torres D.1, García-Ruiz A.J.3, Barnestein-
Fonseca P.1
1Distrito Sanitario Málaga (SAS), Málaga, Spain, 2Area Sanitaria Málaga Este-Axarquia, Málaga, 
Spain, 3Malaga University, Malaga, Spain
Objectives: To identify factors related to adherence after a multifactorial interven-
tion in patients with COPD. MethOds: Design: Randomized Controlled Trial (ISRCTN 
15106246) Patients: 146 subjects randomly allocated (random blocks of 4 patients) in 
two groups (intervention group-IG, control group-CG). Intervention components: 1)
Motivational aspects: beliefs-behaviour about COPD (group and individual interviews); 
2) Cognitive aspects: information about illness; and 3) Skills: inhaling techniques train-
ing. Follow-up: 1 year, 5 visits/group. Primary Outcome: adherence (pill/doses count); 
Secondary Outcomes: functional status (spirometry), quality of life (Saint George 
Respiratory Questionnaire-SGRQ); Independent variables: intervention, age, sex, edu-
cational level, comorbidity, COPD severity stage (SEPAR guidelines), prescribed medi-
cation. Statistical analysis: Four partial logistic regression models, fixed- and random 
effects estimation, were carried out, a final model was built considering them. Statistical 
packages SPSS 15.0 and Stata 11.1. Results: Predominance of males (91.8%), mean 
age 69.08 years (CI95%,67.58-70.44); low cultural level (78.1%), 32.2% current smokers 
(62.84 pack-years [CI95%,55.34-70.34]), Body Mass Index 30.78 kg/m2 (CI95%,28.78-
32.78), 81.2% mild-moderate severity stage, predominance of obstructive respiratory 
pattern; FEV1 (mean)= 67.58% (CI95%,64.58-71.08), 0.87 exacerbations/year [CI95%, 0.68-
1.06]. Pharmacological treatment: inhaled-beta2-adrenergic (80.1%); inhaled-anticho-
linergic (77.4%); inhaled-corticosteroids (70.5%); mucolitycs (11.6%); xanthine (8.2%); 
oxygen therapy (4.8%); oral-corticosteroids (0.7%). Adherence was 41% (41.2CG/40.8IG). 
Objectives: To analyze the costs of macrolides use compared to cephalosporines 
for treatment of Acute Bacterial Sinusitis (ABSs) in the era of increasing resist-
ance to Streptococcus pneumoniae. MethOds: We used a decision analysis model 
(TreeAge Pro 2013) to perform a cost-minimization and sensitivity analysis to 
determine what level of macrolide resistance in a community would trigger cepha-
losporine use. Costs and clinical outcomes of ABSs were extracted from a system-
atic review of the literature and official local databases. Clinical response was 
derived from prospective clinical trials, investigations and from clinical experts 
experience, were we had ≤ 1 source. Results: We have found that the mean cost 
of empirical treatment with macrolides for ABSs was 79 EUR when community 
S. pneumoniae resistance was at 0%; 77 EUR at 10%; 82 EUR at 20% and 88 EUR at 
30%. Cephalosporines were found to be cost-minimizing when the prevalence of 
macrolide resistance to S. pneumoniae exceeded 15%. Sensitivity analysis variables 
that had a significant impact on our cost-minimization threshold included propor-
tion of macrolide resistance to S. pneumoniae, cost of antibiotics and probabilities 
of clinical cure with antibiotics. cOnclusiOns: We believe we have performed 
the first cost-based model and sensitivity analysis to determine what level of 
macrolide resistance in the community could trigger a switch of empirical therapy 
for ABSs from macrolides to cephalosporines in Slovakia. Our investigation is 
to our knowledge also locally the first to employ decision analysis to explore 
the relationship between antimicrobial resistance and clinical decision making 
in ABSs. From a payer perspective, cephalosporines appears to be a reasonable 
alternative to macrolides for empirical treatment of ABSs, especially given the 
current prevalence of macrolides resistance among S. pneumoniae in community 
that reached 30% level, nationwide.
PRS40
ECONOMIC EvALUATION OF MANDIBULAR ADvANCEMENT DEvICE TO TREAT 
OBSTRUCTIvE SLEEP APNEA
Giannopoulou A.1, Burgers L.T.1, van Bruggen M.P.B.2, de Vries N.3, Redekop W.K.1,  
Rijnsburger A.1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Philips Research Europe, 
Eindhoven, The Netherlands, 3St. Lucas Andreas Hospital, Amsterdam, The Netherlands
Objectives: In the treatment of obstructive sleep apnea/hyoponea syndrome 
(OSAHS) moderate patients are primarily offered Continuous Positive Airway 
Pressure (CPAP). This study aims to assess the cost-effectiveness of mandibular 
advancement device (MAD), a commonly suggested alternative, as compared to 
CPAP for moderate OSAHS patients in The Netherlands. MethOds: The prognosis 
of a hypothetical cohort of 50-year-old patients with moderate OSAHS was simu-
lated with a Markov model to estimate the costs and quality-adjusted life-years 
(QALYs) for both CPAP and MAD. A distinctive factor incorporated in the model 
was switch of therapy. All input parameters, including the risks of experiencing 
myocardial infarction, stroke and motor vehicle crashes (MVC) were based on lit-
erature and clinical expert opinion. Costs and effects were estimated over a 5-year 
time horizon using a health care provider perspective and were discounted at a 
rate of 4% and 1.5%, respectively. Robustness of the results was investigated with 
several sensitivity and scenario analyses. Results: Compared with CPAP, MAD 
is less expensive (€ 4,511 vs. € 5,302) and only slightly less effective (3.44 vs. 3.49 
QALYs) resulting in an incremental cost-effectiveness ratio (ICER) of € 15,393 saved 
per QALY lost. The most influential parameter was the cost of MAD device and its 
titration. Quality-of-life values, compliance rates, costs and the probabilities of 
switching treatment, cardiovascular events and MVC were varied in the scenario 
analyses. Under the majority of the scenarios MAD remained less cost-effective 
compared to CPAP. cOnclusiOns: Over a 5-year time horizon, MAD therapy may 
be considered not cost-effective in the treatment of moderate OSAHS patients in 
The Netherlands. Further research on the impact of both treatments on long-term 
risks and improvement in the quality of life is required. Similarly, more long-term 
studies using a uniform compliance definition are needed to inform future cost-
effectiveness analyses.
PRS41
INTEGRATING THE LONG-TERM HEALTH BURDEN OF ORAL CORTICOSTEROIDS 
IN THE COST-EFFECTIvENESS OF OMALIzUMAB
Faria R., McKenna C.
University of York, York, UK
Objectives: Omalizumab offers an alternative to maintenance oral corticosteroids 
(OCS) in the treatment of severe persistent asthma. Despite widespread recognition 
of the adverse effects from OCS, there is little quantitative evidence on their health 
burden or costs. Failing to account for the adverse effects of OCS may underestimate 
the cost-effectiveness of innovative steroid-sparing medicines such as omalizumab. 
This study aims to explore the possibilities for integrating evidence on the burden of 
OCS in cost-effectiveness analysis using omalizumab as a case study. MethOds: A 
model was developed to evaluate the long-term cost-effectiveness of omalizumab in 
patients requiring maintenance OCS. Costs were from a health service perspective 
and outcomes were measured as quality-adjusted life years (QALYs). The burden from 
maintenance use of OCS was quantified with population-based approach, with a deci-
sion model and with threshold analysis. Results: The incremental cost-effectiveness 
ratio (ICER) was £37,987 per QALY gained, which is above conventional thresholds used 
in the UK. Threshold analysis showed that the annual health losses from maintenance 
use of oral corticosteroids would need to be 0.12 QALYs per year. This is double the 
quantifiable health losses with the population-based approach and with the decision 
model and 10% of the health gains achieved with omalizumab. cOnclusiOns: The 
burden from maintenance OCS can be integrated in cost-effectiveness analysis but 
the extent to which these estimates account for their full impact on health depends 
on the approach used and underlying assumptions. The challenges arise from sparse 
randomised evidence, time lag in the adverse effects and unclear relationship between 
risk and long-term steroid load. These are empirical questions which can be answered 
with further research. Such research would be valuable not only for decision making in 
severe asthma but also for other conditions treated with maintenance OCS.
A374  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
Objectives: Adherence and health-related quality of life (HRQoL) are two impor-
tant indicators in determining success of drug treatments. Although medication 
adherence and HRQoL have been studied intensively, less is known about the asso-
ciation of these factors. This research aims to undertake a systematic review of the 
published literature on the relationship of medication adherence and HRQoL in 
patients with chronic obstructive pulmonary disease (COPD). No comprehensive 
review has been published in this topic so far. MethOds: Peer-reviewed English-
language articles that examined the relationship between adherence/compliance/
persistence to medication and HRQoL in COPD were identified through database 
(Medline, EMBASE) searches. Reports until April 2013 were screened. Papers related 
to oxygen therapy were excluded. Results: Of the 243 papers reviewed, eight stud-
ies met the inclusion criteria and were analyzed in our systematic review. Evidence 
suggests that relationship between medication adherence and HRQoL is dual. Non-
adherence does not have a clear negative impact on HRQoL. Adherence to medica-
tion may affect HRQoL due to more factors, such as effectiveness/efficacy and side 
effects of the medication, daily life limitation and social stigmatization caused by 
the therapy. Effect of non-adherence on HRQoL can be derived from the resultant 
of these factors. Nevertheless, HRQoL may also influence patients’ drug use; poor 
or good HRQoL may trigger non-adherence. Relationship between adherence and 
HRQoL may differ depend on the duration of the previous therapy (as therapy in 
newly diagnosed COPD patients may improve HRQoL more than in patients treated 
previously for longer durations) and on the study design (cross-sectional versus 
longitudinal follow-up study) as well. cOnclusiOns: Association of medication 
adherence and HRQoL is multiple. Results from previous studies are limited. Further 
scientific evaluations are needed to better understand the dynamics between these 
factors. Such information would be critically important and needs to be considered 
when integrating adherence into health-economic evaluations.
PRS48
ESTIMATION OF GENERIC UTILITIES IN SPANISH CHRONIC OBSTRUCTIvE 
PULMONARy DISEASE PATIENTS
Miravitlles M.1, Huerta A.2, Villa G.2, Forne C.3, Cuesta M.3, Brosa M.3, Crespo C.3
1Hospital Universitari Vall d’ Hebrón, Barcelona, Spain, 2GlaxoSmithKline, Madrid, Spain, 
3Oblikue Consulting, Barcelona, Spain
Objectives: Chronic obstructive pulmonary disease (COPD) is a major public health 
problem and one of the leading causes of chronic morbidity and mortality worldwide. 
This study aims at determining generic utilities for Spanish COPD patients stratified by 
international guidelines GOLD 2006 (airflow limitation) and GOLD 2013 (airflow limita-
tion, exacerbation history and symptoms), and Spanish guidelines GesEPOC (clinical 
phenotypes). MethOds: Multicentre, observational, cross-sectional study, carried out 
in 15 Pulmonology Spanish public services, including patients aged 40+, diagnosed with 
COPD, who have not experienced an exacerbation in the previous 2 months and receiv-
ing pharmacological treatment for COPD. Utilities were derived from EQ-5D-3L scores. 
Medians, means and standard deviations (SD) were computed for groups of patients 
based on GOLD 2006, GOLD 2013 and GesEPOC classifications. Differences in median 
utilities between groups were assessed by means of Kruskal-Wallis tests. Post-hoc pair-
wise comparisons were based on Wilcoxon tests (Bonferroni-adjusted). Results: A 
total of 346 patients were included in the analysis. Statistically significant median dif-
ferences in utilities by groups of patients were found. GOLD 2006: moderate (n= 135, 
median= 0.87, mean= 0.81, SD= 0.22); severe (n= 145, median= 0.80, mean= 0.71, SD= 0.29); 
very severe (n= 66, median= 0.67, mean= 0.57, SD= 0.35); (p< 0.001). All pair-wise compari-
sons were statistically significant (p< 0.001). GOLD 2013: group A (n= 28, median= 0.98, 
mean= 0.94, SD= 0.06); group B (n= 66, median= 0.87, mean= 0.80, SD= 0.22); group C (n= 30, 
median= 0.98, mean= 0.87, SD= 0.24); group D (n= 222, median= 0.74, mean= 0.66, SD= 0.30); 
(p< 0.001). All pair-wise comparisons were statistically significant (p< 0.002), except-
ing groups A and C comparison. GesEPOC: (A) non-exacerbator (n= 215, median= 0.84, 
mean= 0.78, SD= 0.23); (B) overlap COPD-asthma (n= 21, median= 0.80, mean= 0.80, 
SD= 0.19); (C) exacerbator with emphysema (n= 46, median= 0.74, mean= 0.59, SD= 0.40); 
(D) exacerbator with chronic bronchitis (n= 64, median= 0.74, mean= 0.62, SD= 0.33); 
(p< 0.001). Pair-wise comparisons between phenotypes A and C (p< 0.002) and pheno-
types A and D (p< 0.001) were statistically significant. cOnclusiOns: Generic utilities 
are associated with airflow limitation, exacerbation history, symptoms and clinical 
phenotypes in a sample of Spanish COPD patients.
PRS49
PATIENT-REPORTED OUTCOME (PRO) CLAIMS IN PRODUCTS APPROvED FOR 
CHRONIC OBSTRUCTIvE PULMONARy DISEASES (COPD) IN EUROPE AND THE 
UNITED STATES
Caron M., Perrier L.L., Acquadro C.
Mapi Research Trust, Lyon, France
Objectives: 1) To identify COPD products approved with a Patient-Reported Outcome 
(PRO) labeling claim in Europe and the USA, and 2) to list the differences found in 
Europe vs. the USA in terms of products and labeling. MethOds: The search was 
performed on the FDA- and EMA-approved medicinal product labels and medical 
reviews/scientific discussions (from January 1995 - February 2013 inclusive). Results: 
A total of 25 COPD products were retrieved: 11 were approved by the EMA and 14 
by the FDA. Only three INN were approved by both agencies (aclidinium bromide, 
indacaterol, and roflumilast), representing 11 products (EMA, n= 8; FDA, n= 3). Out of 
the 25 products approved, 15 have a PRO claim (EMA, n= 8; FDA, n= 7). When focusing 
on the INN approved by both agencies, the review showed that the FDA and the EMA 
agreed on the granting of a PRO claim (i.e., “yes” for aclidinium bromide and inda-
caterol, and “no” for roflumilast). The FDA and the EMA reviewed the same clinical 
studies. However, the labeling text differs between the agencies. The FDA label of acli-
dinium bromide does not provide any mention of results measured by the St. George’s 
Respiratory Questionnaire (SGRQ) and the Transition Dyspnoea Index (TDI), while the 
EMA label does. As for indacaterol, the FDA label does not mention any TDI results, 
while the EMA label does. Reasons for these discrepancies are found in the FDA medi-
cal reviews. The TDI has been assessed as inadequate for use as a CT endpoint. As for 
the SGRQ, the results met the threshold of clinically meaningful improvement in only 
Both groups were similar at baseline. Drop out was 28.8%. Intention to treat analysis. 
Adherence increased significantly in IG (p= 0.046), NNT= 6.37 (CI95%,3.25-142.8). Factors 
related to adherence: intervention (OR= 1.88, CI95%,1.01-3.52), number of exacerbation 
(OR= 0.66,CI95%,0.48-0.91), number of visits to health centre (OR= 0.93,CI95%,0.87-1.00), 
severity (OR= 0.677,CI95%,0.43-1.04), number of devices (OR= 2.4,CI95%,1.09-5.30), SGRQ-
Activity scale (OR= 0.978,CI95%,0.95-1.00), SGRQ-Impact scale (OR= 1.03,CI95%,1.00-1.06), 
inhaled-beta2-adrenérgic (OR= 0.16, CI95%,0.059-0.43), xanthine (OR= 0.199, CI95%,0.05-
0.77). Rho coefficient= 6.07x10-6 (p= 0.498). cOnclusiOns: The more adherent patient 
was that who showed a lower number of visits to health centre, exacerbations, number 
of devices, level of severity, and impact on daily activities but with higher disease impact. 
The beta-2-adrenergic and xanthine treatment are associated with no adherence.
PRS45
HOw DO PATIENTS wITH CHRONIC OBSTRUCTIvE PULMONARy DISEASE 
(COPD) USE THEIR INHALERS? COMMON MISTAKES. TECEPOC STUDy
Leiva-Fernandez F.1, Leiva-Fernandez J.2, Porcel-Martin C.1, Prados-Torres D.1, García-Ruiz 
A.J.3, Barnestein-Fonseca P.1
1Distrito Sanitario Málaga (SAS), Málaga, Spain, 2Area Sanitaria Málaga Este-Axarquia, Málaga, 
Spain, 3Malaga University, Malaga, Spain
Objectives: To test the inhaler use in COPD patients. Frequent mistakes. MethOds: 
Design: Cross-sectional study at the beginning of a Multicenter patients’ prefer-
ence trial (ISRCTN15106246) Patients: 465 COPD patients from 9 health care centres, 
with inhaled treatment, written consent. Non-probabilistic consecutive sampling. 
Variables: inhaler devices, performance of correct inhalation technique, type of mis-
takes. Age, sex, Inhalatory pick flow, COPD severity stage, prescribed medication. 
Basal dyspnea index (BDI). Statistical analysis: Mean, frequency. 95% confidence inter-
val. Results: Predominance of males (91.4%), mean age 69.8 years (CI95%,69.00-70.59); 
FEV1(mean)= 55.91%(IC95:53.62-58.2), mixed respiratory pattern (65.9%). Severity stage: 
15.7% mild, 44.1% Moderate, 40.3% Severe. Pharmacological treatment: inhaled-beta2-
adrenergic (88.8%); inhaled-corticosteroids (76.7%); inhaled-anticholinergic (70.7%); 
mucolitycs (19.4%); xanthine (7.3%); oral-corticosteroids (1.3%). BDI: grade 2. Inhalation 
technique: 84.9% had received instruction about inhalation techniques (48.6% from neu-
mologist, 42.1% from general practitioner). The instruction was an explanation without 
device (59.6%). 67.3% of patients used Handihaler, 54.8% Accuhaler, 31.8% Turbuhaler, 
26.9% pressurised metered dose inhaler (pMDI). The 91.3% of patients performed an 
incorrect inhalation technique with handihaler, 89.5% with Turbuhaler, 85.6% with 
Accuhaler and 91.7% with pMDI. The most common mistakes in all devices were related 
to the action consist on: emptying or almost emptying the lungs before activating the 
spray (79.8%) and holding breath for at least 8-10 seconds or for as long as possible 
when inhalation is complete (69.5%). The most common mistakes per device were 
related to: repeating the inhalation with Handihaler (10%), Loading the dispenser cor-
rectly in Accuhaler (8.2%) or Turbuhaler (16.6%) and hand-breath coordination in pMDI 
(52.8%). cOnclusiOns: A high percentage of patients with COPD performed an incor-
rect inhalation technique although they had been received instruction about this. The 
most common mistakes are more related to the patient’s attitude than to the type of 
device.
PRS46
TECEPOC STUDy. HOw TO IMPROvE THE INHALATION TECHNIQUES IN PATIENT 
wITH COPD. THE INFLUENCE OF PREFERENCES
Leiva-Fernandez F.1, Leiva-Fernandez J.2, Porcel-Martin E.1, Vazquez-Alarcon R.1, Martos-
Crespo F.3, Barnestein-Fonseca P.1
1Distrito Sanitario Málaga (SAS), Málaga, Spain, 2Area Sanitaria Málaga Este-Axarquia, Málaga, 
Spain, 3Málaga University, Málaga, Spain
Objectives: to test the efficacy of two educational interventions to improve the 
inhalation techniques in patients with COPD and the influence of patient’ prefer-
ence. MethOds: Design: Multicenter patients’ preference trial or comprehensive 
cohort design ISRCTN15106246. Patients: 465 COPD patients (to detect a difference 
between groups of 25%, 80% statistical power, 95% confidence level, 40% expected 
losses), with inhaled treatment, written consent. Non-probabilistic consecutive sam-
pling. Allocation: Patients without strong preferences for a treatment are randomised: 
RCT group (block randomization), and those with strong preferences are given their 
choice: PPS group. Variables: Primary outcomes: Performance of correct inhalation tech-
nique. Secondary outcomes: Pick flow, dyspnea (Baseline dyspnea index), Functional 
status (forced spirometry). Interventions: Intervention-A: Written information. A leaf-
let with the correct inhalation technique for the main inhaler devices used in our 
area. Intervention-B: Intervention-A + individual training (by instructors). Follow-up: 3 
month, visits: baseline, 1 month, 3 month. Statiscal analysis: Mean, frequency, 95% 
confidence interval at baseline. Number Needed to Treat for a benefit (NNT) was cal-
culated. Intention to treat analysis. Results: Predominance of males (91.4%), mean 
age 69.8 years (CI95%, 69.00-70.59); FEV1(mean)= 55.91% (IC95%, 53.62-58.2), mixed 
respiratory pattern (65.9%). Severity stage: 15.7% mild, 44.1% Moderate, 40.3% Severe. 
Pharmacological treatment: inhaled-beta2-adrenergic (88.8%); inhaled-corticosteroids 
(76.7%); inhaled-anticholinergic (70.7%); mucolitycs (19.4%); xanthine (7.3%); oral-corti-
costeroids (1.3%). BDI: grade 2. Primary outcome: better inhalation technique (p= 0.002) 
in the PPS group, NNT= 7.4 (IC95%, 4.52-20).Among the RCT cohorts: there was no differ-
ence between control and intervention A and there were statistically significative dif-
ferences between intervention B versus control (p< 0.0001), NNT= 2.44 (IC95%, 1.87-3.5) 
and versus intervention A, NNT= 2.85 (IC95%, 2.08-4.56). In the PPS cohorts: there was a 
difference (p< 0.0001) between intervention B versus intervention A, NNT= 2.33 (IC95%, 
1.5-3.2). cOnclusiOns: The performance of a correct inhalation Technique improves 
with monitor training. The patients’ preferences enhance the efficacy of intervention.
PRS47
RELATIONSHIP BETwEEN MEDICATION ADHERENCE AND QUALITy OF LIFE IN 
COPD – SySTEMATIC REvIEw
Ágh T.1, Inotai A.1, Bártfai Z.2, Mészáros Á3
1Syreon Research Institute, Budapest, Hungary, 2Elizabeth Teaching Hospital and Rehabilitation 
Institute Sopron, Sopron, Hungary, 3Semmelweis Univesity, Budapest, Hungary
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Respiratory symptoms are common among adults living in Russian cities, which may 
indicate high COPD incidence. Awareness of COPD in Russia is lacking. A high propor-
tion of adults aged 40 and older in Russia report frequent respiratory symptoms, and 
these symptoms are associated with significantly worse health status.
PRS53
THE RELATIONSHIP BETwEEN COPD ASSESSMENT TEST (CAT) AND EQ-5D IN A 
REAL wORLD PATIENT POPULATION
Wood R.1, Small M.2
1Adelphi Real World, Bollington, UK, 2Adelphi, Macclesfield, Cheshire, UK
Objectives: COPD is a chronic lung disease that has a detrimental effect upon 
patient’s quality of life. The COPD Assessment Tool (CAT) has been developed 
to measure the impact of the disease. This research explores the relationship 
between the disease-specific CAT, and the general health related utility measure 
EQ-5D. MethOds: COPD is a chronic lung disease that has a detrimental effect 
upon patient’s quality of life. The COPD Assessment Tool (CAT) has been developed 
to measure the impact of the disease. This research explores the relationship 
between the disease-specific CAT, and the general health related utility meas-
ure EQ-5D. Results: A scatter plot relating CAT score to EQ-5D showed that the 
relationship is non-linear. Variance of the EQ-5D score increased with CAT score, 
suggesting the increasing influence of confounding factors for patients report-
ing a higher CAT score (CAT score range variance: 0-10: 0.013, 11-20: 0.026, 21-30: 
0.050 and 31-40: 0.126). A generalized linear model was used to account for the 
non-linear relationship, and control for confounding influences of age, gender, 
physician-perceived COPD severity and number of concomitant conditions, with 
no assumption of constant variance. The relationship between CAT and reversed 
EQ-5D was positive and significant (coefficient 0.070, p-value < 0.0001), illustrating 
higher CAT score was associated with lower EQ-5D. A one point increase in CAT 
score resulted in an approximate 7.2% relative decrease in EQ-5D score. Similarly, 
significant (p-value < 0.0001) negative relationships observed for older patients 
(coefficient 0.016), female gender (coefficient 0.147), greater severity (coefficient 
0.469), and a higher number of comorbidities (coefficient 0.070). cOnclusiOns: 
Increasing COPD impact as measured by the CAT was associated with lower EQ-5D 
scores. However, the increasing variance of EQ-5D for patients with higher CAT 
scores demonstrates the need for both COPD impact and overall health status 
assessment.
PRS54
THE RELATIONSHIP BETwEEN ASTHMA-SPECIFIC QUALITy OF LIFE AND 
MEASURES OF ASTHMA CONTROL AND GENERIC QUALITy OF LIFE
Stucky B.1, Sherbourne C.2, Edelen M.O.2, Eberhart N.2, Lara M.2
1RAND Corporation, Santa Monica, CA, USA, 2The RAND Corporation, Santa Monica, CA, USA
Objectives: Previous research has indicated a strong relationship between 
asthma symptoms and asthma-specific quality of life (QoL). However, past meas-
ures of asthma-specific QoL typically confound symptoms and functional impair-
ment with QoL, which in turn may cause a misleadingly high inter-correlation. 
The current research uses a newly developed measure of asthma-specific QoL 
(the RAND-Impact of Asthma on Quality of Life; RAND-IAQL) that controls for 
asthma symptoms and functional impairment while assessing the degree of 
asthma impact or burden. Using this new measure, we model the relationship 
between asthma specific quality of life, generic quality of life, asthma control, 
and comorbid conditions commonly associated with asthma. MethOds: Using 
a diverse sample of adults with asthma (N= 2032), we use structural equation 
models (SEM) to establish the relationships and suppression effects of asthma 
control, symptoms, comorbidities (e.g., COPD, Sinusitis), and multiple PROMIS QoL 
instruments (including anxiety and social QoL) on the prediction of asthma-
specific QoL. SEM models will be presented sequentially in order to evaluate the 
relative utility of increasingly complex models using likelihood ratio tests and 
changes in the amount of IAQL variance that is accounted for by each added 
predictor (latent) variable. Results: Close fitting SEM models suggest that 
“interference” caused by asthma, an indicator commonly used to measure asthma 
control, is most strongly related to asthma-specific QoL. Contrary to the research 
literature, symptoms of asthma (including shortness of breath, wheezing, and 
cough) and comorbid diseases are less strongly related to asthma specific QoL 
than are general assessments of interference and generic measures of anxiety 
and limitations in social functioning. cOnclusiOns: Asthma-specific QoL is best 
understood as the degree to which asthma impacts or burdens ones daily life. 
While asthma symptoms, control, and general QoL are highly inter-correlated, 
asthma control (primarily interference) is differentially predictive of asthma-
specific QoL.
PRS55
THE RAND NEGATIvE IMPACT OF ASTHMA ON QUALITy OF LIFE ITEM BANK 
AND SHORT-FORMS
Sherbourne C., Stucky B., Edelen M.O., Eberhart N., Lara M.
The RAND Corporation, Santa Monica, CA, USA
Objectives: In response to recommendations from the 2010 NHLBI Asthma 
Outcomes Workshop, we developed a new system for measuring the impact of 
asthma on quality of life (QoL) that avoids confounding QoL with asthma symp-
tomatology and functional impairment. This presentation summarizes the process 
of developing and validating an item bank and short-forms that measure patients’ 
perceptions of the impact or bother of asthma on their life. MethOds: Focus 
groups, supplemented by literature review and expert panel recommendations 
were used to identify key QoL dimensions and develop a pool of items which were 
refined based on cognitive interviews. Items were field-tested using a diverse 
national sample of adults with asthma (N= 2032). Modern measurement theory 
was used to develop an item bank and short forms. We validated our short-forms 
against the Marks AQLQ; ACT; and generic QoL measures. Discriminant validity 
was examined by evaluating scores from respondents who differed according 
one study. cOnclusiOns: Our review showed that PROs are often included in COPD 
product labels in Europe and in the USA. Although the FDA and the EMA agree on a 
general level, the FDA seems more restrictive in the label wording.
PRS50
STUDy OF QUALITy OF LIFE IN PATIENTS wITH CHRONIC OBSTRUCTIvE 
PULMONARy DISEASE (COPD) AND SyMPTOM ASSESSMENT DIFFERENCES 
BETwEEN PATIENTS AND FAMILy MEMBERS
Fernández-Lahera J., Gonzalez A., Prados C., F-Bujarrabal J., Martínez A.
Hospital Universitario La Paz, Madrid, Spain
Objectives: To assess the relationship between the questionary of quality of life 
“COPD assessment test” (CAT) and clinical, functional and comorbidity parameters 
and compare patient perceptions of symptoms with that of their family mem-
bers. MethOds: We analysed demographic (age, sex, BMI), lung function (FEV1%) 
and comorbidity variables (Charlson index) in patients with stable COPD. Patients 
and family members independently completed the CAT (family members reported 
their observations of the patient). Results: We included 70 patients (83% men, 
mean age 72±9.4 years, BMI 27.8±4.2 kg/m2, Charlson index (ChI) 2.41±1.7, mean 
FEV1% 57.1±15.1%. Air flow limitation (GOLD): 7 patients (9%) mild, 36 (53%) moder-
ate, 24 (34%) severe and 3 (4%) very severe. There was a significant negative cor-
relation between CAT and FEV1% (r= -0.265, p< 0.0028) but no correlation between 
CAT and ChI, age or BMI. A comparison of CAT scores between the patients and 
their family members showed that 61% of the patients underestimated and 33% 
overestimated their symptoms (CAT scores: 15.5±7.9 (patient) vs. 17.1±7.7 (family) 
(p< 0.038); correlation: (r= 0.72; p< 0.001). We observed correlations in the 8 CAT items. 
We found significant differences between the patients and their family members 
in items 1: coughing (p< 0.015), 3: chest tightness (p< 0.005) and 6: confidence leav-
ing home (p< 0,015) and in overall score (p< 0.038). cOnclusiOns: 1. We found 
a negative correlation between the CAT and FEV1but not between the CAT and 
Charlson index. 2. Patients underestimate their symptoms. Cough, chest tightness 
and confidence leaving home are the issues items that had the greatest discrepancy 
between patients and family members.
PRS51
COMPARISON OF TREATMENT SATISFACTION IN PATIENTS wITH ASTHMA 
TAKING LEUKOTRIENE MODIFIERS vERUS THOSE TAKING INHALED 
CORTICOSTEROIDS
Tomaszewski E.L.1, Mendelsohn A.B.2, Shah A.J.3
1Quintiles Outcome, Pittsburgh, PA, USA, 2Quintiles Outcome, Cambridge, MA, USA, 3Quintiles 
Outcome, Rockville, MD, USA
Objectives: To assess treatment satisfaction between patients with self-reported 
asthma for two classes of asthma treatments, leukotriene modifiers (LM group) 
and inhaled corticosteroids (IC group), using a novel patient community in the 
U.S. MethOds: Participants were identified via MediGuard, a digital patient plat-
form where patients enroll online to be part of a digital patient community. All 
information was obtained through participant self-report. Patients were invited 
to complete the Treatment Satisfaction Questionnaire for Medication (TSQM), a 
patient reported outcome (PRO) instrument, at random time points between 2009 
and 2011. Domain scores of the TSQM were compared between the IC and LM 
groups using regression analyses, adjusting for age, gender, self-reported severity 
and number of co-medications. Results: A total of 736 patients were included 
for the IC group, and 647 for LM group. Average ages were comparable (56.3 years 
(SD= 13.8) for IC; 54.9 (13.5) for LM). Both groups were predominantly female (76.3% 
IC; 83.2%, LM). Effectiveness domain scores were similar between IC and LM groups 
(p= 0.502). LM users reported significantly higher scores (i.e., increased satisfaction) 
for other domains: side effects (97.1 (SD= 0.8) vs. 93.5 (0.7), resp.); convenience (89.2 
(0.8) vs. 81.6 (0.7), resp.); global satisfaction (72.3 (1.1) vs. 67.3 (1.0). cOnclusiOns: 
Patients in the LM group reported higher satisfaction in the convenience and global 
satisfaction domains than the IC group. Patients in the LM group reported less 
interference with side effects than the IC group. Providing patients with informa-
tion on population-based satisfaction scores for these two medications could help 
inform patients’ treatment selection decisions.
PRS52
SyMPTOMS OF COPD IN URBAN RUSSIA AMONG ADULTS 40 yEARS AND OLDER
Vietri J.1, Ertl S.2, Isherwood G.3, Bevelskiy A.S.4
1Kantar Health, Milan, Italy, 2Kantar Health, Moscow, Russia, 3Kantar Health, Epsom, Surrey, UK, 
4Russian Scientific Research Medical University, Moscow, Russia
Objectives: Chronic obstructive pulmonary disease (COPD) is a major cause of dis-
ability worldwide, but awareness of COPD and information regarding the burden of 
this disease are lacking worldwide, including Russia. The aim of the current study 
was to assess the prevalence of COPD symptoms (cough with mucous, wheezing, and 
shortness of breath) among a representative sample of adults aged 40 and above in 
major cities in Russia. MethOds: Data was obtained from the 2011 Russia National 
Health and Wellness Survey, a cross-sectional survey of the adult population in the 
city adult population in Russia which includes information on awareness, experi-
ence, and diagnosis of medical conditions, health care-related attitudes, demographic 
characteristics, and health outcomes. The frequency of COPD symptoms was assessed 
using the Lung Function Questionnaire, and health status was assessed using the 
SF-12v2. Those experiencing a symptom at least ‘sometimes’ were compared to 
those who experienced the symptom ‘rarely’ or less using independent-samples 
t-tests. Results: A total of 5920 adults aged 40 and older completed the survey. After 
weighting, 45%, 27%, and 18% reported shortness of breath, coughing up mucous, and 
wheezing, respectively, and 54% reported at least one symptom. Only 23% of those 
surveyed were aware of COPD; awareness of COPD was greatest among those with the 
most symptoms but even among those with all three symptoms, only 31% were aware 
of the condition. Experience of each symptom was associated with worse mental 
and physical component summary scores on the SF-12v2, with decrements ranging 
from 2-6 points depending on the symptom and score considered. cOnclusiOns: 
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combinations include crizotinib/EML4-ALK test in lung cancer; clopidogrel/CYP2C19 
test in cardiovascular disease; natalizumab/ JC virus test in multiple sclerosis; 
maraviroc/HIV tropism test in HIV infection. To define key evidence required by 
health technology assessment (HTA) agencies and payers for reimbursement and 
access decision making, we evaluated global CDx/biomarker test HTAs. MethOds: 
HTA Watch conducted a search of global HTA agency websites for HTAs reviewing 
CDx/biomarker tests. HTAs were reviewed for key clinical, economic and other evi-
dence criteria scrutinized or raised as concerns by agencies, and potential impacts/
correlations of such evidence on agency reimbursement recommendations, distin-
guishing between true CDx and non-CDx biomarker tests. Results: CDx/biomarker 
tests reviewed by HTA agencies included those used to inform oncology, cardiovas-
cular or infectious disease, neurological disorder, and allergy/asthma treatments. 
Evidence scrutinized by HTA agencies included demonstration of clinical validity 
and utility versus competing tests or no test, cost-effectiveness and budget impact 
associated with implementing CDx testing, size of the responder population and, for 
solid tumor indications, the practicality of obtaining/availability of sufficient biopsy 
material for biomarker testing. cOnclusiOns: CDx/biomarker tests are necessary 
gatekeepers for informing use of PM drugs, especially in early lines of treatment 
when alternative treatments exist. Since optimal PM market access requires CDx/
biomarker test availability it is critical that the value of CDx/biomarkers is demon-
strated through evidence development that addresses key HTA agency and payer 
needs.
PRS59
DIRECT AND INDIRECT BURDEN ASSOCIATED wITH PARENTS wHOSE INFANT 
HAS BEEN HOSPITALIzED FOR A LOwER RESPIRATORy TRACT INFECTION (LRTI) 
IN GREECE
Tsolia M.1, Vo P2, Vlachopioti Z.3, Manthena S.2, Holton M.J.4, Gooch K.L.2, Kyriakakis A.5, 
Koilakou S.5, Kafetzis D.A.6
1Second Department of Paediatrics, University of Athens School of Medicine, P. and A. Kyriakou 
Children’s Hospital, Athens, Greece, 2AbbVie, North Chicago, IL, USA, 3AbbVie Pharmaceuticals 
S.A, Neo Iraklio, Athens, Greece, 4Lorimer Enterprises Inc., Red Deer, AB, Canada, 5AbbVie 
Pharmaceuticals S.A, Alimos, Greece, 6Iatriko Kentro Athinon, Private Hospital, Maroussi, Greece
Objectives: Severe respiratory infections result in infant hospitalizations for 
LRTI, of which the most common cause is due to respiratory syncytial virus (RSV). 
The economic impact of pediatric hospitalizations for respiratory infections is 
substantial; however the socioeconomic burden it has on parents and caregivers 
is less understood. MethOds: Data was attained from the Parent Burden Study: 
A prospective multinational study to determine the humanistic and economic 
burden of infant LRTI hospitalizations during the RSV season. Direct health care 
resource utilization including length of hospitalization stay (LOS) and intensive 
care use (ICU) were obtained from medical chart reviews. Indirect economic 
burden borne by parents were measured in parent surveys administered at the 
time infants were discharged. Lost work productivity was assessed via the Work 
Productivity and Activity Impairment questionnaire, specific to caregivers of chil-
dren hospitalized with respiratory illness. Results: A total of 47 infants (35 term, 
12 preterm), < 1 year of age were included in the Parent Burden Study in Greece. A 
total of 74% of infants had a confirmed diagnosis of RSV. The mean LOS was 7.50 
days (range: 0.66- 40.97, 6.33 days term, 10.91 days preterm). 8.5% (2.9% term and 
25% preterm) required ICU admission and 85.1% had supplemental oxygen and/
or mechanical ventilation support (80% term, 100% preterm). Among fathers, the 
average absenteeism (time away from work) was 19.2%, presenteeism (impaired 
productivity while at work) was 45.6%, and overall work impairment was 55.3%. 
For mothers, the average absenteeism was 47.0%, presenteeism was 35.0% and 
overall work impairment was 54.0%. On average, fathers reported 62.1% activity 
impairment and mothers reported 93.5% due to their child’s hospitalization. A total 
of 51.1% of families required family or arranged childcare to assist siblings during 
the hospitalization. cOnclusiOns: This study demonstrates, in addition to direct 
morbidity burden, infant LRTI hospitalizations have a substantial socioeconomic 
impact on parents and caretakers in Greece.
PRS60
PATTERNS IN ASTHMA MEDICATIONTREATMENT IN THE UNITED STATES
Li Y.1, Suh K.2, Chen W.3, Wei Z.3, Higuchi K.1
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Novartis Pharmaceuticals 
Corporation, East Hanover, NJ, USA, 3Novartis Pharma Co. Ltd., Shanghai, China
Objectives: Despite evidence of medication adherence benefits, many patients 
do not take their medications as prescribed. The objective of this study was to 
understand asthma medication treatment patterns among asthma patients in the 
US by initial asthma treatment medication. MethOds: A retrospective database 
analysis was conducted using Marketscan Commercial and Medicare Supplement 
Data. Patients were identified between January 1, 2005 through March 31, 2011 based 
on asthma related hospitalization, emergency room visit or at least 2 office visits 
at different dates within 1 year. Asthma drug utilization patterns were analyzed 
among patients aged 12 years or older who were initiated on an asthma medica-
tion (without asthma maintenance therapy in the past 12 months) and had at least 
24 months traceable insurance coverage information since their initiation of the 
medication. Results: Among the selected patients (n= 88,567) being followed up 
for 24 months, approximately 30% of patients switched treatments at least once 
regardless of their initial asthma treatment. The three most common medications 
were montelukast sodium (> 90% Singulair), fluticasone propionate and salmeterol 
(Advair) 250/50mcg and 100/50mcg. One prevalent prescription change was to step 
down the steroid component. Patients initiating asthma treatment on combination 
therapy (i.e. Singulair and inhaled corticosteroids) is low (between 0.3% - 1.8%) and 
switch patterns show that over 50% of patients switch to Singulair monotherapy. 
Regardless of their initial treatment and medication switches, on average, asthma 
patients initiate their treatment with 2-3 months days supply; have a gap of over 6 
months (~200days) and switch to another treatment. cOnclusiOns: Our results 
show the high frequency of asthma medication patterns changes. Despite the avail-
to indicators of asthma severity, control, health care utilization and comorbid-
ity. Results: A total of 661 QoL statements were identified from focus group 
transcripts and subsequently used to generate a pool of 112 items in 16 different 
content areas. Psychometric evaluation of field test data yielded a 65-item unidi-
mensional item bank, 4 and 12-item short forms (alpha = .86 and .93, respectively), 
and a simulated computer adaptive test suggesting that as few as 5-items are 
needed to obtain highly precise estimates of the impact of asthma on QoL (IAQL). 
Our measures correlated highly with Marks’ AQLQ and more strongly with the 
PROMIS global physical than mental scale. IAQL was greater in persons with indi-
cators of more severe asthma, less asthma control, and in persons with greater 
health care utilization. cOnclusiOns: The RAND-IAQL item bank is a new freely 
available system for measuring the impact of asthma on Qol that will complement 
other patient-reported outcomes.
PRS56
HEALTH RELATED QUALITy OF LIFE IN PATIENTS wITH CHRONIC 
OBSTRUCTIvE PULMONARy DISEASE IN NORTH INDIA
Negi H.1, Sarkar M.2, Raval A.3
1Post Graduate Institute of Medical Education & Research, Chandigarh, India, 2Indira Gandhi 
Medical College, Shimla, India, 3West Virginia University, Morgantown, WV, USA
Objectives: Chronic obstructive pulmonary disease (COPD) is a major health 
problem in India and constitutes an important cause of mortality and morbid-
ity. A cross sectional study was undertaken to assess health related quality of life 
(HRQL) and its determinants in COPD patients from India. MethOds: A total of 
126 patients (73.81% male, 26.19% female) recruited using convenient sampling in 
a cross-sectional study. Eligible patients assessed for socioeconomic status, anthro-
pometric measures, COPD severity, dyspnea, and health status using a validated 
Hindi (Regional Language) version of St. George Respiratory Questionnaire (SGRQ). 
Linear regression model was used to examine association between risk factors and 
HRQL with adjustment of age and sex. Results: Mean total score for SGRQ was 
52.66±12.89 showing marked impairment of HRQL. Impairment was associated with 
the severity of airway obstruction but within each GOLD stage the variation (SD) was 
wide [Stage I: 47.8±12.3 (n= 14); Stage II: 49.28±11.69 (n= 47); Stage III: 53.47±11.69 
(n= 44); Stage IV: 61.75±14.14 (n= 21)]. Regression analysis showed that body mass 
index, Forced expiratory volume in 1 minute (FEV1), dyspnea grade and depression 
were associated with poor HRQL. cOnclusiOns: HRQL of COPD patients was sig-
nificantly impaired across all severities. Marked impairment of HRQL was found 
even in patients with milder disease.
RESPIRATORy-RELATED DISORDERS – Health Care Use & Policy Studies
PRS57
THE FIRST ExPERIENCES wITH REASSESSMENTS AND APPRAISALS OF 
CONDITIONALLy APPROvED ExPENSIvE AND ORPHAN DRUGS IN THE 
NETHERLANDS (2006-2013)
van der Meijden C.M.J., Streuper C., Goettsch W.
Health Care Insurance Board (CVZ), Diemen, The Netherlands
Objectives: To provide an overview of the first experiences with reassessments 
and appraisals of expensive drugs after 4 years of coverage with evidence devel-
opment (CED) in The Netherlands. MethOds: Completed assessments, reas-
sessments and appraisals were summarized. Special attention was paid to the 
consistency of the conclusions at the initial assessment (T= 0) with those at the 
reassessment (T= 4), to the execution of the research proposals, and to the con-
sequences of the reassessments and appraisals. Results: From 2006 until 2012, 
46 T= 0 assessments have been performed: 36 were approved for CED and 10 were 
declined. By mid 2013, the 4 years’ period of CED had ended for 25 drugs. For four 
drugs, T= 4 assessments and appraisals have been completed: omalizumab and 
ranibizumab for treatment of patients with severe asthma and macula degen-
eration respectively; and the orphan drugs alglucosidase alfa and agalsidase for 
treatment of patients with Pompe’s disease and Fabry’s disease. Based on all the 
available evidence, conclusions regarding effectiveness were mostly consistent 
between T= 0 and T= 4 assessments. However, results from the requested outcomes 
research studies between T= 0 and T= 4 were of mixed quality and therefore of lim-
ited relevance for the T= 4 assessment. Nevertheless, most data from the outcomes 
research were useful to evaluate appropriate usage in daily practice and resource 
use. The resource use data was applied in health economic models. In contrast, 
the input for the clinical effectiveness component in the cost-effectiveness assess-
ment was generally derived from pivotal clinical studies already available at T= 0. 
The T= 4 appraisals led to a societal debate on the cost-effectiveness of these 
drugs. The appraisals resulted in pragmatic solutions like a pay-for-performance 
agreement and ongoing price negotiations. cOnclusiOns: Outcomes research as 
part of a CED in The Netherlands has yielded some information regarding the costs 
and appropriate use in daily practice of expensive drugs. The results from these 
CED experiments (or lack thereof) have been used in the subsequent negotiations 
on financial or risk-sharing arrangements.
PRS58
HEALTH TECHNOLOGy ASSESSMENT OF COMPANION DIAGNOSTIC 
BIOMARKERS AS GATEKEEPERS FOR PERSONALIzED MEDICINE MARKET ACCESS
Spinner D.S.1, Ransom J.F.2, Culp J.L.1, Chawla A.S.1, Doyle J.J.3, Faulkner E.C.4
1Quintiles Consulting, Durham, NC, USA, 2Quintiles Consulting, Hawthorne, NY, USA, 3Quintiles, 
Hawthorne, NY, USA, 4Institute for Pharmacogenomics and Individualized Therapy, Eshelman 
School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
Objectives: Personalized medicines (PM) are the subset of drug therapies whose 
efficacy and/or safety can be predicted or monitored based on the status of specific 
molecular biomarkers. In most cases, access to the applicable biomarker test (also 
called a companion diagnostic (CDx) if the biomarker/test is regulatory approved 
and included in the drug label) is critical for early patient access to the specific 
PM the biomarker status informs. Recent examples of PM and CDx/biomarker test 
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be averted. cOnclusiOns: Price elasticity estimates are greater than previous 
studies in Greece and consistent with literature internationally, while income 
elasticity estimates are far greater. With cigarettes regarded as a luxury good, a 
great opportunity is presented for decison makers to counter smoking. Increased 
taxation, along with focused antismoking campaigns, law reinforcement (to ensure 
compliance with smoking bans) and intensive control for smuggling could inflict 
a massive blow to the tobacco epidemic in Greece.
PRS64
PREvALENCE OF COMORBIDITIES AMONG CHRONIC COPD PATIENTS IN THE 
UNITED STATES
Mannino M.1, Higuchi K.2, Tian H.2, Yu T.C.2, Suh K.3, Zhou H.4, Li Y.5
1University of Kentucky, Lexington, KY, USA, 2Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA, 3Scott & White Health Plan, Temple, TX, USA, 4KMK Consulting Inc., Randolph, 
NJ, USA, 5Beijing Novartis Pharma Co. Ltd., Shanghai, China
Objectives: COPD is the third leading cause of death with increasing mortality 
while other chronic condition mortality rates are decreasing. This may be due to 
the fact that COPD is a complex chronic condition with a complicated diagnosis 
and treatment guideline in an aging patient population with increasing comor-
bid conditions. The objective of this study was to understand the prevalence of 
comorbid conditions among COPD patients in the US. MethOds: A retrospective 
database analysis was conducted using Marketscan Commercial and Medicare 
Supplement Data from year 1/1/2010 to 12/31/2011. Patients were included if they 
had continuous medical and pharmacy benefits coverage for at least 12 months 
after their first COPD diagnosis defined as primary or ancillary ICD-9 codes of 
491.xx, 492.xx, or 496.xx and were between the ages of 40 and 90 years old at the 
time of diagnosis. Univariate descriptive analyses were conducted to quantify 
comorbid disease prevalence. Results: Among the selected patients (n= 231,827), 
95.1% (n= 220,519) had medical claims (ICD-9 codes) for diagnoses beyond COPD 
within 12 months of their COPD diagnosis. The majority of patients were over 65 
years old (61.4%, n= 135,366). Over 60% (n= 130,325) of the patients had more than 
3 comorbid conditions. The most common were hypertension (64.9%, n= 143,189) 
(ICD-9 codes 401.xx-405.xx, 415, 416, 416.8, 459.1x and 459.3x), hyperlipidemia 
(46.5%,n= 102,498) (ICD-9 code 272.x), diabetes (27.8%, n= 61,225) (ICD-9 code 249.xx, 
250.xx, 253.5, 271.4, 357.2, 588.1, 790.29), coronary artery disease (27.4%, n= 60,364) 
(ICD-9 code 414.0x, 414.3, 414.4), and asthma (22.7%, n= 50,113) (ICD-9 code 493.
xx). cOnclusiOns: Our results show the significant prevalence of comorbid con-
ditions among COPD patients. Further research on comorbid conditions impacting 
COPD patient treatment adherence, COPD pathogenic pathways and worsening 
overall prognosis are necessary. More evidence is required to estimate the role of 
comorbidities in COPD.
SySTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
PSy1
ExAMINING THE BURDEN OF ILLNESS OF vETERAN PATIENTS DIAGNOSED 
wITH OBESITy IN THE UNITED STATES
Wang L.1, Xie L.2, Du J.2, Li L.1, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA
Objectives: To examine the burden of illness of diagnosed obesity in the U.S. veteran 
population. MethOds: A retrospective database analysis was performed using the 
Veterans Health Administration (VHA) Medical SAS datasets (01OCT2008-30SEPT2012). 
Patients diagnosed with obesity were identified (International Classification of 
Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis code 278.xx) with 
the first diagnosis date designated as the index date. A group of patients without 
obesity but with the same age, region, gender and index year were identified and 
matched by baseline Charlson Comorbidity Index as a comparator group. The index 
date for the comparator group was randomly chosen to reduce selection bias. Patients 
in both groups were required to be at least 18 years old, and have 1 year of continu-
ous medical and pharmacy benefits before and after the index date. Study outcomes, 
including health care costs and utilizations, were compared between the disease 
and comparator groups by using 1:1 propensity score matching. Results: A total 
of 1,525,218 patients were identified for the obesity and comparison cohorts. After 
applying 1:1 matching, a total of 634,257 of patients were included in each group, and 
the baseline demographic and clinical characteristics were balanced. The obesity 
cohort had higher percentages of health care utilizations for inpatient (6.21% vs. 
2.92%, p< 0.01), emergency room (11.96% vs. 7.28%, p< 0.01), physician office (99.84% vs. 
60.12%, p< 0.01), outpatient (99.86% vs. 60.85%, p< 0.01), and pharmacy visits (89.01% 
vs. 61.71%, p< 0.01) than the comparator group. Patients diagnosed with obesity 
also incurred higher expenditures in inpatient ($1,812 vs. $875, p< 0.01), emergency 
room ($117 vs. $69, p< 0.01), physician office ($2,936 vs. $1,436, p< 0.01), outpatient 
($3,288 vs. $1,621) and pharmacy visits ($641 vs. $423, p< 0.01) compared to non-obese 
patients. cOnclusiOns: Study results suggest that patients diagnosed with obesity 
incurred significantly higher costs and utilizations than non-obese patients.
PSy2
CLINICAL EFFECTIvENESS ANALySIS OF DEFERASIROx FOR THE TREATMENT OF 
IRON OvERLOAD DUE TO FREQUENT BLOOD TRANSFUSIONS
Walczak J.1, Lipińska M.1, Jarosz J.1, Moczyński W.1, Ślązak B.1, Laczewski T.2
1Arcana Institute, Cracow, Poland, 2Novartis Poland Sp. z o.o., Warsaw, Poland
Objectives: To compare clinical efficacy and safety of orphan drug deferasirox 
(DSX) versus deferoxamine (DFO) in the treatment of paediatric patients (age ≤ 18 
years) with iron overload from repeated blood transfusions. The underlying con-
ditions requiring transfusion included beta-thalassaemia, sickle cell disease and 
other congenital and acquired anaemias (myelodysplastic syndromes, Diamond-
Blackfan syndrome, aplastic anaemia and other very rare anaemias). MethOds: 
We searched CENTRAL, MEDLINE and EMBASE for relevant randomized controlled 
trials (RCTs) published up to April 2012. The review was conducted in accordance 
ability of prescription of asthma medications, there appears to be an unmet need 
and further research is necessary.
PRS61
ECONOMIC EvALUATION OF ENHANCED ASTHMA MANAGEMENT: A 
SySTEMATIC REvIEw
Yong Y.V., Shafie A.A.
Universiti Sains Malaysia, Penang, Malaysia
Objectives: To evaluate, compare, and assess the quality of the studies on the cost-
effectiveness of enhanced management (either as adjunct to usual care or alone) 
vs.usual care alone or none at all. MethOds: Scientific databases (ScienceDirect, 
Wiley Online Library, (EbscoHost – MEDLINE, CINAHL, PSYInfo), (OvidSP – EMBASE, 
MEDLINE), and Scopus) were searched for published journal articles in English lan-
guage from year 1990 to 2012, using the search terms “asthma AND (intervene OR 
manage) AND (pharmacoeconomics OR economic evaluation OR cost effectiveness OR 
cost benefit OR cost utility)”. Hand search was done for local publishings. Only studies 
with full economic evaluation on enhanced management (either as adjunct to usual 
care or alone) were included. Selected studies were data abstracted and assessed for 
their quality of economic evaluation using the Quality of Health Economic Studies 
(QHES) instrument, and quality of evidence. Results: A total of 14 studies were 
included. There were three distinct modes reviewed: environmental control, self-
management, education. Most of the enhanced managements were found to be cost-
effective with ICER ranged from dominant to $26700.00 per unit of outcome. Overall, 
the mean score of QHES was 76.69% (SD 9.26). For the quality of evidence, ‘clinical 
effect sizes, adverse events & complication’, baseline clinical data, resourse use, and 
costs components were ranked mainly 1 or 2 (best or nearly best) in all studies. For 
‘utilities’ component, one study ranked 5 because it used visual analogue scale to 
obtain patient preference values. cOnclusiOns: Despite the low qualities of the 
reviewed studies, it overall suggests that enhanced management (either as adjunct 
to usual care or alone) is mostly cost-effective than the usual care or none at all; 
environmental control is considered the most cost-effective, and there is also strong 
evidence for self-management, but provided the mode of it is made available, afford-
able, and accessible then this shall be worth to be adapted in one’s setting.
PRS62
ECONOMIC EvALUATION OF THE IMPACT OF NEw TREATMENT ALTERNATIvES 
ON MARKET DyNAMICS IN RESPIRATORy DISEASES; A CASE STUDy IN TURKISH 
HEALTH CARE SySTEM
Kececioglu S.1, Ulus P.2, Cukadar F.3, Ozkan M.3, Urganci B.3
1Boehringer Ingelheim Turkey, Istanbul, Turkey, 2Boehringer Ingelheim Turkey, ISTANBUL, 
TURKEY, Turkey, 3Boehringer Ingelheim Turkey, ISTANBUL, Turkey
Objectives: Economic evaluation of the change in market dynamics of a sample 
ProductA1 through its inclusion in Therapeutic Equivalence Band (TEB) (with products 
B2 and C3) between 2010 and 2012 in Turkish health care system. MethOds: IMS 
Dataview was analyzed for 2010-2012 unit sales values (market entry timeline for 
products A, B, C is 2006, 2009 and 2009, respectively) in the TEB. IMS Medical Index is 
used for estimating prescription data for the corresponding products. Assumptions on 
median patient adherence (receipt of prescribed treatment in pharmacy) are applied 
to prescription data in order to calculate unit sales (prediction). Deviation calcu-
lations and sensitivity analysis on market dynamics were performed in Microsoft 
Excel-2007. Results: Deviations between unit sales predictions and realizations 
for products A, B and C occurred as +11.48%, -5.41% and -20.85% in 2010, -10.16%, 
+8.14% and -53.87% in 2011 and -31.89%, +28.92% and -67.76% in 2012 respectively. 
Negative deviation values indicate that receipt of prescription cannot be transformed 
to receipt of the prescribed product in pharmacy, however positive deviation values 
correspond to receipt of a product in pharmacy which is different from the content of 
the prescription. cOnclusiOns: The TEB system allows receipt of a different product 
than prescription. This study shows alteration of market dynamics in pharmacy as a 
change from prescribed inhaler option (as negative deviation value), which is linked 
to receipt of another inhaler option (as a positive deviation value) within the same 
TEB. Real life data may be collected for further analysis of TEB system in dynamics 
of corresponding market. 1Originator treatment in TEB-Novartis-Budesonide(400m
cg)&Formoterol(12mcg), 2Second treatment in TEB-Bilim Pharma, 3Third treatment 
in TEB-Abdi Ibrahim Pharma.
PRS63
ESTIMATES OF PRICE AND INCOME ELASTICITy IN GREECE: GREEK DEBT CRISIS 
TRANSFORMING CIGARETTES INTO A LUxURy GOOD
Tarantilis F., Athanasakis K.
National School of Public Health, Athens, Greece
Objectives: Greece was long reported to show a smoking prevalence over 40% on 
adult population, as efforts to constrain smoking were rather ineffective. Following 
a sharp fall in cigarette consumption for 2012, our objective is to assess smokers’ 
sensitivity to cigarette price and consumer income changes as well as to project 
health benefits of an additional tax increase. MethOds: Analysis includes the 
conventional model of demand, the myopic addiction model and the rational 
addiction model. Cigarette consumption for the period 1994-2012 was the depend-
ent variable with Weighted Average Price as a proxy for cigarette price, GDP as a 
proxy for consumer income and dummy variables reflecting smoking restrictions 
and antismoking campaigns. Values were computed to natural logarithms and 
regression was performed. Then, 4 scenarios of tax increase were distinguished in 
order to calculate potential health benefits. Results: Addiction models are una-
ble to provide statistically significant information following a nearly 23.5% drop 
in consumption during 2012. Short-run price elasticity is estimated at -0.441 and 
short-run income elasticity is estimated at 1.040. Antismoking campaigns were 
found to have a statistically significant impact on consumption. Results indicate 
that, depending on the level of tax increase, annual per capita consumption could 
fall by up to 607.99 cigarettes; tax revenue could rise by at least € 39 million, while 
up to 595,866 smokers could quit and up to 2,696 smoking related deaths could 
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Objectives: CTEPH is a progressive and commonly fatal disease. A systematic 
literature review was conducted to synthesize evidence on mortality and survival 
in patients with inoperable CTEPH or residual/recurrent pulmonary hyperten-
sion (PH) after pulmonary endarterectomy (PEA). MethOds: Using specific search 
terms, we systematically searched for MEDLINE- and EMBASE-indexed studies on 
the epidemiology of CTEPH in various regions (including Western Europe, North 
America, New Zealand, or Australia) without temporal limits. Among these stud-
ies, we identified those that reported mortality and/or survival for patients with 
inoperable CTEPH or residual/recurrent PH post-PEA. These studies then under-
went analytical narrative synthesis. Results: In all, 71 articles met the criteria 
for acceptance into the review. Of these, 21 described mortality or survival in 
patients with inoperable CTEPH or residual/recurrent PH post-PEA. The propor-
tion of patients with inoperable disease was 27%–41% in seven registries and 
retrospective studies in Europe. The proportion of patients who underwent PEA 
was 59%–69% in two Canadian studies and 10%–65% (median 50%) in 11 European 
studies. Among studies with ≥ 18 months of follow-up, mortality was higher in 
patients with inoperable CTEPH (13.4%–58%, with seven of 10 studies reporting 
mortality rates of 13.3%–21.4%) than among those with residual/recurrent PH 
post-PEA (7.4% after a mean follow-up of 50 months). Overall survival was lower 
among patients with inoperable CTEPH than among those with residual/recurrent 
PH post-PEA. Survival rates for inoperable CTEPH were 73%–93% at one year (10 
studies), 41%–88% at three years (nine studies), and 53%–88% at five years (five 
studies). In contrast, patients with residual/recurrent PH post-PEA had five-year 
survival rates of 89.9%–100% (three studies). cOnclusiOns: Inoperable CTEPH 
carries a particularly poor prognosis, with survival rates lower even than those 
for patients who have residual/recurrent PH following PEA.
PSy6
ANALySES ADjUSTING FOR SELECTIvE CROSSOvER SHOw IMPROvED OvERALL 
SURvIvAL wITH DECITABINE COMPARED wITH TREATMENT CHOICE IN DACO-
016 PHASE III TRIAL
Tomeczkowski J.1, Güntert A.1, Thilakarathne P.2, Diels J.2, Xiu L.3, Tapprich C.1
1Janssen-Cilag GmbH, Neuss, Germany, 2Janssen Pharmaceutica, Beerse, Belgium, 3Janssen-Cilag 
Limited, Raritan, NJ, USA
Objectives: Among patients with acute myeloid leukemia (AML), the DACO-016 
randomized study showed reduction in mortality for DACOGEN®(decitabine, DAC) 
compared with treatment choice (TC): at primary analysis the Hazard Ratio (HR) 
was 0.85 (95% CI: 0.69- 1.04; stratified log-rank p= 0.108). With two interim analyses, 
2-sided alpha was adjusted to 0.0462. With one year additional follow-up the HR 
reached 0.82 (nominal p= 0.037). These data, together with significant outcomes in 
secondary endpoints and a positive benefit-risk resulted in approval of DACOGEN 
in the EU, however not in the US. With the primary analysis only showing a strong 
trend, the French Haute Autorité de Santé negated a mortality benefit. Though pre-
specified, the log-rank test could be considered not optimal to assess the observed 
survival difference because of the non-proportional hazard nature of the survival 
curves. We applied the Wilcoxon test as a sensitivity analysis. MethOds: Patients 
(age ≥ 65 years, ineligible for chemotherapy) were randomized to DAC (N= 242) or TC 
(N= 243). For testing the observed treatment effect, Wilcoxon-test is considered more 
powerful in the context of non-proportional hazard curves compared to the log-rank 
test, as the former assigns more weight to earlier events. Results: A total of 108 
(44.4%) patients in the TC arm and 91 (37.6%) patients in the DAC arm selectively 
crossed over to subsequent disease modifying therapies at progression, which might 
impact the survival beyond the median with resultant converging curves (and dis-
proportional hazards). The Wilcoxon-test stratified by baseline age, cytogenetic-risk 
and ECOG performance status showed a significant improvement in OS with DAC 
(7.7 [6.2; 9.2] months) versus TC (5.0 [4.3; 6.3] months) (p= 0.0456). cOnclusiOns: 
Wilcoxon-test indicated significant increase in survival for DAC vs TC in patients 
with AML compared to log-rank test at primary analysis.
SySTEMIC DISORDERS/CONDITIONS – Cost Studies
PSy7
BUDGET IMPACT ANALySIS OF DEFERASIROx IN THE TREATMENT OF NON 
TRANSFUSION DEPENDENT THALASSEMIA IN GREECE
Masoura P.1, Murphy D.R.1, Chatzikou M.2, Alexopoulos S.T.1, Magestro M.3
1Heron Evidence Development Ltd., London, UK, 2Novartis (Hellas) S.A.C.I., Athens, Greece, 
3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Objectives: Deferasirox is an oral iron chelator that has demonstrated efficacy in 
reducing excess liver iron concentration (LIC) in iron overloaded non-transfusion 
dependent thalassemia (NTDT) patients. This analysis estimated the budget impact 
of reimbursing deferasirox in Greece. MethOds: An open cohort budget impact 
model was developed from the Greek health care system perspective over 5 years. 
Comparators included deferoxamine, deferiprone, and combination therapy (defer-
oxamine plus deferiprone). NTDT prevalence, drug acquisition and administration 
costs were from Greece (2013 € ). No discounting was applied. Deferasirox clinical 
inputs were derived from the THALASSA trial. Rate of reduction in LIC (decrease 
of 26%) was applied each year for deferasirox. This was assumed the same for all 
comparators. Patients remained on treatment until the 3 mg Fe/gr dw discontinua-
tion threshold for LIC was reached. Treatment was reinitiated when LIC increased 
above 5 mg Fe/gr dw. Base case starting age was 10 years. Sensitivity analysis was 
performed on key model inputs. Results: A total of 280 patients with NTDT were 
estimated to be treated with iron chelation per year. With no deferasirox, total drug 
acquisition and administration costs were € 3,545,406 and € 11,889,133, respec-
tively. With the introduction of deferasirox, acquisition costs increased by 62% to € 
5,738,323 and administration costs decreased by 58% to € 4,993,474. Total expendi-
ture decreased by over 30% representing cost savings of € 4,702,742 over 5 years. 
Results were sensitive to acquisition costs, administration costs for deferoxamine, 
treatment efficacy and discontinuation threshold. cOnclusiOns: Reimbursement 
of deferasirox in NTDT resulted in cost savings to the Greek health care system. 
with the Cochrane Collaboration guidelines and the Polish Agency for Health 
Technology Assessment recommendations. Calculations were performed using 
the StatsDirect®2.6.8 statistical package. Results: : As a result of the systematic 
literature search 2 primary RCTs (subtype II A), satisfying the inclusion criteria 
were found: Cappellini 2006 (patients with beta-thalassaemia) and Vichinsky 2006 
(patients with sickle cell disease). The results of the performed analysis proved 
that once-daily oral deferasirox showed similar efficacy to parenteral deferoxamine 
therapy in terms of decreased in LIC (liver iron concentration) and SF (serum fer-
ritin). Treatment adherence was similar in both DSX and DFO groups. Safety analysis 
showed that deferasirox was safe and well-tolerated therapy. The most frequent 
adverse events in the deferasirox group were diarrhea, nausea, vomiting, abdominal 
pain and skin rash. In most cases, analysed adverse events were mild and transient. 
Discontinuation rates were similar in both DSX and DFO arms. cOnclusiOns: 
Deferasirox represents an important once-daily oral agent for the treatment of 
chronic iron overload due to blood transfusions. Once-daily oral deferasirox has 
acceptable tolerability and similar efficacy to parental deferoxamine in reducing 
iron burden in transfused paediatric patients. Moreover, deferasirox improves 
patients’ quality of life, may improve patient’s compliance with treatment and 
reduces morbidity and mortality from iron overload.
PSy3
META-ANALySIS OF EFFICACy OF ROMIPLOSTIM FOR TREATMENT OF IMMUNE 
IDIOPATHIC THROMBOCyTOPENIA
Aggarwal S., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
Objectives: Immune (idiopathic) thrombocytopenia (ITP) is an autoimmune con-
dition characterized by increased platelet destruction and suboptimal platelet 
production, resulting in low platelet counts (thrombocytopenia). Romiplostim has 
shown efficacy in increasing platelet counts. The objective of this study was to 
conduct meta-analysis and present total evidence for Romiplostim for treatment 
of ITP. MethOds: For this meta-analysis we included randomized controlled tri-
als (RCTs) evaluating Romiplostim for the treatment of ITP. We included RCTs 
that compared romiplostim versus placebo for management of ITP, had a treat-
ment duration of at least 24 weeks, were doubleblind (patients and investigators 
blinded) and reported data on platelet response. A systematic literature search 
for Etanercept trials was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar, and Cochrane. Data was collected for the study size, interventions, 
year, and the two outcomes overall and durable platelet response rate. For meta-
analysis, random effects and fixed effects models were used to obtain cumulative 
statistics. Results: Two RCTs with a total of 125 patients were identified. The 
pooled response rates for Romiplostim for overall platelet response rate were 
82% (95% CI 73%-90%); and for durable platelet response rate were 48% (95% CI 
26%-71%). The pooled response rates for placebo for overall platelet response rate 
were 7% (95% CI 0%-15%), and for durable platelet response rate were 2% (95% CI 
0%-4%). For overall platelet response rate the cumulative relative risk with placebo 
versus Romiplostim was 0.09 (95% CI 4%-14%). For durable platelet response rate, 
the cumulative relative risk with placebo versus Romiplostim was 0.03 (95% CI 
0%-6%). cOnclusiOns: Meta-analysis shows Romiplostim offers patients with 
Immune idiopathic thrombocytopenia an effective therapeutic option for increas-
ing platelet counts.
PSy4
BIS SENSOR vERSUS CONvENTIONAL ANESTHETIC MONITORING: SySTEMATIC 
REvIEw ON PATIENT-ORIENTED OUTCOMES
Nobre M.R.C., Costa F.M.
InCor - HCFMUSP, São Paulo, Brazil
Objectives: Adult patients who receive general anesthesia may not remain totally 
unconscious during surgery despite of anesthetics and analgesics care received. The 
retention of memory due to intraoperative awareness may cause serious clinical 
complications, requiring 1071 patients monitored to prevent the occurrence of one 
event. The proper conventional maintenance of general anesthesia is assessed with 
clinical signs or expired gases (ETAC/ETAG/ETCO2). Bi-Spectral Index Monitoring or 
BIS Sensor is a neurophysiological evaluation system that continually analyzes EEG 
to determine the level of intraoperative awareness. MethOds: We have made a lit-
erature search in PubMed to identify systematic reviews and randomized controlled 
trials that studied level of consciousness intraoperative or postoperative memory 
when used these alternatives of anesthetic monitoring. Results: We have found 
nine RCT and two systematic reviews published until April 2013 and conducted our 
own meta-analysis on seven trials. Two studies were excluded from the synthesis for 
not presenting the outcome of primary interest. Three RCT of moderate heterogene-
ity showed no difference in the occurrence of intraoperative awareness between the 
BIS group and the ETAC/ETAG/ETCO2 group. The quality of evidence was considered 
high in one study, moderate and low in the others (26,490 patients, I2 = 45.9%, RR = 
1.28, 95% CI = 0.54 to 3.03, p = 0.57). Four clinical monitoring control group studies 
with no heterogeneity showed that the sensor BIS was more effective, requiring 
between 71 and 167 patients monitored for an event of intraoperative awareness 
avoided. The quality of evidence of the studies was considered high (7,779 patients, 
I2 = 0.0%, RR = 0.42, 95% CI = 0.27 to 0.65, p = 0, 0.0001). cOnclusiOns: Clinical 
trials published until April 2013 showed favorable results in patient-oriented out-
comes of BIS group when compared to clinical monitoring group but not to ETAC/
ETAG/ETCO2 group.
PSy5
MORTALITy AND SURvIvAL IN INOPERABLE OR RESIDUAL/RECURRENT 
CHRONIC THROMBOEMBOLIC PULMONARy HyPERTENSION (CTEPH): A 
SySTEMATIC LITERATURE REvIEw
Byrnes M.J.1, Ashaye A.O1, Iheanacho I.2, Travers K.1, Sikirica M.3
1Evidera, Lexington, MA, USA, 2Evidera, London, UK, 3Global HEOR, Bayer HealthCare 
Pharmaceuticals, Berlin, Germany
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Objectives: The purpose of the budget impact analysis (BIA) was to estimate 
financial consequences of deferasirox (DSX) reimbursement within the health care 
treatment programme (HTP) on the budget of the National Health Fund (NHF) in 
Poland. MethOds: BIA was performed for a 2-year time horizon (July 2012 - June 
2014) from the Polish public payer perspective. The target population qualified to the 
HTP programme were children and adolescents (age ≤ 18 years) with iron overload 
due to frequent blood transfusions. The population was estimated on the basis of 
medical expert opinion. Two scenarios were compared: the “existing scenario” – 
without reimbursement of DSX (only standard of care with deferoxamine (DFO) 
was available) and the “new scenario” – DSX reimbursed as part of HTP. In the 
analysis, only direct medical costs were included: costs of drugs and their admin-
istration, costs of monitoring and costs of blood transfusions. It was assumed that 
the cost of deferoxamine was included in the cost of hospitalization procedures 
related to chelation therapy. Due to the lack of available data on adverse events 
(AE) incidence during therapy with deferasirox or deferoxamine, the costs of AE’s 
treatment were not considered. The calculations were performed in Microsoft Office 
Excel. Results: NHF annual expenditures related to the introduction of deferasirox 
reimbursement will increase by PLN 454 thousand in the first year and by PLN 
434 thousand in the second year of reimbursement compared with the “existing 
scenario.” cOnclusiOns: The positive reimbursement decision for DSX enables 
patients with iron overload access to safe and effective therapy. Deferasirox therapy 
will allow young patients to go back to normal functioning in their families and in 
society. The positive reimbursement decision will also contribute to improving the 
quality of life, self-esteem and emotional state of the patients.
PSy12
PHARMACOECONOMIC STUDy OF NUTRITION SUPPORT (NS) USAGE DURING 
INTENSIvE TREATMENT
Metelkin I., Yagudina R., Kulikov A.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To undertake a comparative analysis of 2 methodologies of inten-
sive treatment (IT) , precisely: IT without NS and IT taking into account NS han-
dling. MethOds: Pharmacoeconomic analysis “budget impact” was provided. Only 
direct costs were taken into account: expenses for drug therapy, hospitalization 
(intensive care unit and medical division) and late complications (pneumonia, sepsis, 
catheter and wound infection) treatment. Effectiveness data was taken from Russian 
clinical trial: Popov T.S., Shestopalov A.E., Tsvetkov D.S., Nechaev D.S., Kuz’min M.A. 
Nutrition Day in intensive care units of the Russian Federation. National association 
of parenteral and enteral nutrition – Moscow (Russia), 2011. Four types of NS were 
compared: IT without NS; IT + enteral nutrition (EN); IT + parenteral nutrition (PN) 
and IT + combined nutrition (CN). Results: When carrying out comparative phar-
macoeconomic study all calculations were made for 3 groups of patients depending 
on their health condition: lightly-severe, moderately severe and severe. According to 
the results of calculations transfer of patients from IT without NS to IT carrying out 
NS leads to reduction of total expenses, therefore economy of money for the state. 
Independent from patient health condition – the greatest economy of money arises 
when EN is used during IT. Further on degree of expressiveness of positive economic 
effect there is PN and the least NS economic type is CN. cOnclusiOns: The results 
received during the study were analyzed and the rating of NS types, which were taking 
part in the research, from the point of view of their clinical efficiency and economic 
effectiveness for the state budget, was made.
PSy13
A BUDGET IMPACT MODEL FOR NOvOSEvEN FOR THE MANAGEMENT OF 
BLEEDING EPISODES IN PATIENTS wITH HAEMOPHILIA A TREATED wITH 
INHIBITORS
Kaskens L.1, Martial L.1, Montoro Ronsano J.B.2, Ramirez de Arellano A.3, Darba J.4
1BCN HEALTH, Barcelona, Spain, 2Hospital Vall D’Hebron, Barcelona, Spain, 3Novo Nordisk 
Pharma, Madrid, Spain, 4Universitat de Barcelona, Barcelona, Spain
Objectives: To demonstrate the economic impact of using NovoSeven compared to 
Feiba for the initial treatment of mild to moderate bleeding episodes in patients with 
haemophilia A with inhibitors. MethOds: A budget impact model was developed 
based on a previous economic evaluation to calculate the annual budget impact 
and the treatment cost per episode according to the different treatment strategies. 
The model presents the costs of the strategies to treat a mild to moderate bleeding 
episode with up to three lines of treatment, in which the impact parameters are the 
weight of the patient, the dose, the efficacy and the costs of medication and admin-
istration. Three treatment strategies were used: strategy 1: NovoSeven - NovoSeven 
- NovoSeven, strategy 2: Feiba - NovoSeven - NovoSeven and strategy 3: Feiba - Feiba - 
NovoSeven. Costs per episode and annual costs were calculated based on local input 
data on costs and resources and the perspective used was of the Spanish National 
Health Service (NHS). Results: Total costs per patient for one bleeding episode 
were € 10,253, € 11,852 and € 12,042 for strategies 1, 2 and 3, respectively. Lower total 
costs per patient with NovoSeven are due to a reduced need for further treatment 
and associated hospitalisation. Only using NovoSeven saves € 23,985 compared to 
strategy 2 and € 26,842 compared to strategy 3 annually. cOnclusiOns: The use 
of NovoSeven in all three lines of treatment in patients with in haemophilia A 
compared to using Feiba in the first line of treatment and in the first and second 
line of treatment saves € 1,599 and € 1,789 respectively per bleeding episode. This is 
mainly due to reduced need for further treatment and associated hospitalisation 
with NovoSeven. Annual cost savings using only NovoSeven are the consequence 
of lower drug cost and higher treatment efficacy with NovoSeven.
PSy14
PHARMACOECONOMIC EvALUATION OF INTRAvENOUS FERRIC 
CARBOxyMALTOSE AND IRON SUCROSE IN CORRECTION OF PREOPERATIvE 
ANAEMIA IN PATIENTS UNDERGOING MAjOR ELECTIvE SURGERy
Gorokhova S.G., Ryazhenov V.V., Emchenko I.V.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Avoidance of administration costs for infused treatments could offset the higher 
acquisition cost for deferasirox. Additional data is required to confirm efficacy of 
other treatments in patients with NTDT.
PSy8
THE BUDGET IMPACT OF QUTENzA® FOR THE TREATMENT OF NEUROPATHIC 
PAIN IN SwEDEN
Chambers C.1, Nordling S.2, Smith D.3, Bentley A.3
1Astellas, Chertsey, UK, 2Astellas Pharma, Kastrup, Denmark, 3Abacus International, Bicester, UK
Objectives: Neuropathic pain (NP) is a common disorder which can be chronic, 
severe, and disabling and is associated with reductions in quality of life and consid-
erable costs. Current first-line treatments for NP include tricyclic antidepressants 
and anti-convulsants. QUTENZA® is a cutaneous patch that allows rapid dermal 
delivery of capsaicin directly to the source of pain. The objective of this analysis 
is to estimate the burden of NP, current treatment costs and the budget impact of 
introducing QUTENZA® for the treatment of peripheral NP in non-diabetic adults 
in Sweden. MethOds: We constructed a budget impact calculator to estimate the 
impact of introducing QUTENZA® for 100 people in Sweden. Drug costs for each 
management strategy are annual costs, based on estimated market shares, and 
range from SEK 231 to SEK 5,806 (with SEK 3,909 for QUTENZA®). We assumed a 50% 
uptake of QUTENZA® and a 50% reduction in the use of concomitant medication in 
the model, based on evidence from real-world data. Results: For a NP population 
of n= 100, the cost of current prescribing was estimated at SEK 1.00 million. The cost 
of alternative prescribing including QUTENZA® was estimated at SEK 1.01 million. 
The annual cost of treating a patient with QUTENZA® was estimated as SEK 11,941. 
The estimated cumulative budget impact by year (for 100 patients, with the market 
share rising from 10% in Year 1 to 100% in Year 5) ranged from SEK 9,664 in Year 1 to 
SEK 67,949 in Year 5. cOnclusiOns: The introduction of QUTENZA® results in a 
budget impact of SEK 67,949 for 100 patients over 5 years. This represents a minimal 
additional expenditure and could be considered good value for money given the 
added benefits for patients with NP in Sweden.
PSy9
PHARMACOECONOMIC ANALySIS OF ANTI-INHIBITOR COAGULANT COMPLEx 
(AICC) IN THE TREATMENT OF INHIBITOR HEMOPHILIA
Yagudina R., Kulikov A., Zinchuk I., Molchanova N.
First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia
Objectives: To identify the dominant scheme of inhibitor hemophilia bypassing 
agents therapy (comparing three regimens: Eptacog alfa monotherapy, combination 
therapy «Eptacog alfa + AICC» and «AICC + Eptacog alfa»). MethOds: Based on 
the crossover clinical research FENOC (Jan Astermark, Sharyne M., Donfield, 2007) 
the annual cost of treatment by bypassing agents in mild, moderate, severe and 
life-threatening bleeding is estimated. The analysis of the direct and indirect costs 
is conducted. Direct costs include the cost of bypassing agents therapy, the cost of 
emergency medical care, the cost of inpatient and outpatient treatment. Indirect 
costs include cost of patient’s disability, GDP losses caused by mortality and dis-
ability, and sick-pay. Value of bypassing agents on demand therapy in three dosing 
schemes is identified: monotherapy Eptacog alfa (there is no alternative treatment), 
«Eptacog alfa + AICC» (after the first episode of bleeding no response patients to 
treatment from Eptacog alfa to AICC transferred) and «AICC + Eptacog alfa» (after 
the first episode of bleeding no response patients to treatment from AICC to Eptacog 
alfa transferred). Results: Based on the clinical study FENOC, indicated that there 
is no significant difference in efficacy AICC and Eptacog alfa therapy in patients 
susceptible to this treatment. An analysis of the direct and indirect costs shows that 
the costs of the annual course of treatment of 142 patients in Russia are 66 mil EUR, 
60,7 mil EUR and 53,1 mil EUR for treatments Eptacog alfa monotherapy, «Eptacog 
alfa + AICC» and «AICC + Eptacog alfa» schemes respectively. cOnclusiOns: It is 
determined that the regimen «AICC + Eptacog alfa», will reduce reduces costs rela-
tive to the current treatment regimen for 12,9 mil EUR (19,54%) or provide addition-
ally treat of 34 patients of this disease.
PSy10
POTENTIAL FINANCIAL IMPACT OF SUGAMMADEx IN ANAESTHETIC 
DEPARTMENTS: A BUDGET IMPACT ANALySIS ON POTENTIALLy SHORT 
PROCEDURES REQUIRING NEUROMUSCOLAR BLOCKADE
Povero M., Pradelli L.
AdRes HE&OR, Turin, Italy
Objectives: To evaluate the economic impact on Italian NHS of using sugam-
madex within anaesthetic departments instead of neostigmine. MethOds: The 
number of procedures using neuromuscular blockings agents (NMBA) potentially 
eligible for sugammadex was elaborated by hospital discharge data available in 
Italy for the year 2010. Reduction in postoperative residual curarisation (PORC) 
rate and saved time allocated to extra procedures were taken from two recent 
meta-analyses. Costs considered in the analysis were drugs acquisition costs 
(sugammadex and neostigmine) and PORC management costs. Results: Overall 
annual costs of sugammadex and neostigmine usage result about 34.5 and 31.6 
Million Euro, respectively. Sugammadex prevents 99% of PORC episodes on 428,995 
procedures; this is associated with savings of more than 30 Million Euro. Also the 
saved time in surgery procedures due to sugammadex results in an annual savings 
of 154,867 (36.1%) hours that could be used for further procedures. cOnclusiOns: 
Sugammadex radically reduces PORC episodes during post-operative and it allows 
for shorter operating room occupation.
PSy11
THE BUDGET IMPACT ANALySIS OF DEFERASIROx FOR THE TREATMENT OF 
IRON OvERLOAD DUE TO FREQUENT BLOOD TRANSFUSIONS IN CHILDREN AND 
ADOLESCENTS (AGE ≤ 18 yEARS)
Walczak J.1, Obrzut G.1, Sołtys E.1, Laczewski T.2
1Arcana Institute, Cracow, Poland, 2Novartis Poland Sp. z o.o., Warsaw, Poland
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for sensitivity analyses showed cost-savings ranging from € 22,525 to € 996,384 of 
prophylaxis with aPCC vs. on-demand with rFVIIa. cOnclusiOns: Three times/
week aPCC prophylaxis could reduce 16% the total treatment cost of severe HA 
with inhibitor, saving up to € 98,000/patient/year.
PSy17
RELATIONSHIP BETwEEN BODy MASS INDEx AND HEALTH CARE COSTS By 
PLACE OF SERvICE IN EMPLOyED ADULTS
Abouzaid S.1, Kleinman N.L.2, Andersen L.2, Wang Z.1, Powers A.1
1Eisai Inc., Woodcliff Lake, NJ, USA, 2HCMS Group, Cheyenne, WY, USA
Objectives: While previous studies have shown that overweight and obesity are 
associated with higher costs, less is known about health care costs by place of 
service (POS) at various levels of BMI. This study measures the impact of BMI as a 
continuous variable on health care cost at different places of service. POS categories 
include: pharmacy, doctor’s office, inpatient hospital, outpatient hospital or clinic, 
emergency department, laboratory, and other. MethOds: Using 2003-2012 retro-
spective data from large employers throughout the United States, employees’ BMI 
values were calculated using health risk appraisal data. All study employees were 
> = 18, had > = 12 months of health plan coverage after their index BMI screening 
date, and had no medical claims indicating pregnancy. Employees with BMI< 18 (1st 
percentile) or BMI> 47 (99thpercentile) were excluded. Generalized additive models 
on 12-month post-index POS costs produced estimates of the nonlinear relation-
ship between BMI and cost after controlling for age, gender, marital status, race, 
salary, zip-code region and index year. Results: This study included 71,633 eligible 
employees; 32.0% were female. The average BMI, age and annual salary were 27.3, 
39.8 years and $81,382, respectively. Costs increased significantly with BMI in each 
POS (P< 0.001). Total adjusted annual per-employee health care cost estimates at BMI 
values of 25, 30, 35, and 45 were $3043, $3932, $4357, and $7248, respectively. Cost 
estimates by POS at these BMI values were: Pharmacy ($706, $903, $1106, $1372), 
Inpatient ($398, $678, $643, $2440), Outpatient ($799, $1057, $1113, $1516), Office 
($939, $1044, $1174, $1495), Emergency ($131, $159, $200, $186), Laboratory ($34, $38, 
$46, $43), and Other ($35, $53, $74, $196), respectively. cOnclusiOns: Employees 
with higher BMI levels incurred more cost at each of the 7 places of service. Because 
of the high prevalence of overweight and obesity, these costs represent a significant 
burden for US employers.
PSy18
COHORT ANALySIS ASSESSING HEALTH CARE COSTS ASSOCIATED wITH 
OBESITy AT vARIOUS PLACES OF SERvICE IN EMPLOyED ADULTS
Abouzaid S.1, Kleinman N.L.2, Andersen L.2, Wang Z.1, Powers A.1
1Eisai Inc., Woodcliff Lake, NJ, USA, 2HCMS Group, Cheyenne, WY, USA
Objectives: This study determines the distribution of health care costs by place 
of service (POS; pharmacy, doctor’s office, inpatient hospital, outpatient hospital 
or clinic, emergency department, laboratory, and other) among employees based 
upon body mass index (BMI). MethOds: Using 2003-2012 retrospective data from 
large employers throughout the US, employees’ BMIs from health risk appraisal data 
defined three main cohorts (BMI< 27 [normal weight], 27< = BMI< 30 [overweight] and 
BMI> = 30 [obese]). The 27< = BMI< 30 cohort was further divided into 3 comorbidity 
subcohorts: those without diabetes, hypertension or dyslipidemia (NonT2DHtnDys), 
those with hypertension or dyslipidemia without diabetes (HtnDys), and those with 
diabetes with or without hypertension or dyslipidemia (T2D). All eligible employees 
were aged> = 18, had > = 12 months post-index health plan coverage, and had no 
pregnancy claims. Annual post-index costs were compared between cohorts and 
between subcohorts using two-part regression modeling, controlling for age, gender, 
marital status, race, salary, region, and index year. Results: This study included 
39,696 (BMI< 27), 14,281 (27< = BMI< 30), and 18,801 (BMI> = 30) eligible employees, 
with total adjusted health care costs of $3,191, $3,695, and $4,844, respectively. 
Employees with higher BMI were significantly more likely to incur health care costs 
in every POS category. Obese employees (BMI> = 30) had particularly high inpatient 
costs compared to other cohorts, averaging twice the cost of the BMI< 27 cohort 
($919 vs. $431, P< 0.05). Total costs among subcohorts of 27< = BMI< 30 were $2,863 
(NonT2DHtnDys), $5,271 (HtnDys), and $7,594 (T2D). NonT2DHynDys employees had 
significantly lower health care cost than other subcohorts in every POS category. 
The T2D subcohort had significantly higher pharmacy, inpatient, doctor’s office, 
laboratory and other health care costs when compared to HtnDys. cOnclusiOns: 
Employees with higher BMI incurred higher average health care costs than other 
employees at all places of service. Comorbidities, particularly diabetes, exacerbate 
health care costs of overweight employees. This represents a significant economic 
burden for US employers given the high prevalence of overweight and obesity.
PSy19
HAEMOPHILIA A: ANNUAL COST COMPARISON BETwEEN FL-RFvIII AND BDD-
RFvIII IN FRANCE: wE SHOULD COMPARE THE COST PER PATIENT INSTEAD OF 
THE PRICE PER UNIT
Haarmann H.1, Epstein J.2, Grumel O.3
1Baxter Healthcare, Opfikon, Switzerland, 2Baxter BioScience, Westlake Village, CA, USA, 3Baxter 
France, Maurepas, France
Objectives: Hemophilia A is rare bleeding disorder where patients have defective 
or deficient levels of coagulation factor VIII (FVIII). Recombinant FVIIII (rFVIII) are 
manufactured to treat the patients, either as a full-length rFVIII (FL-rFVIII) mol-
ecule replicating natural human FVIII or with the B-domain deleted (BDD-rFVIII). It 
has been suggested that Deletion of B domain had been implemented to improve 
production profitability. However, this deletion has been shown to induce increase 
factor consumption by 32.8% in the US (Epstein 2011) and also may increase the 
risk of developing inhibitors for previously treated patients (PTP) Hazard Ratio= 10.8 
(Aledort 2011). Both differences can have an important impact on patient health 
and on the national health care budget. MethOds: A Excel-based decision tree 
model had been developed to compare the overall cost to treat severe haemophilia 
A patients from a health care system perspective with the most used FL-rFVIII and 
Objectives: To assess the cost-effectiveness of ferric carboxymaltose (FCM) and 
iron sucrose (IS) in the correction of iron-deficiency anaemia (IDA) before elec-
tive major surgery in non-cardiac surgical patients and predict potential budget 
expenses for the day care services and blood transfusions. MethOds: The pharma-
coeconomic model was developed based on the data from multicentre prospective 
study (E. Bisbe et al., 2011) on the efficacy of FCM and IS for correcting preopera-
tive anaemia in patients undergoing major elective non-cardiac surgery. The cost-
effectiveness of two intravenous iron formulations was measured as total costs of 
medicines and day care services per one patient attained iron replenishment or per 
one patient without IDA at the end of treatment. Budget impact analysis included 
expenses for the day care services and blood transfusion procedures during intraop-
erative and/or postoperative period. Sensitivity analysis was performed by including 
in the model of iron sucrose similars (ISSs). It was considered that treatment with 
ISSs requires dose increase up to 120-135% of dose of the original IS (E. Lee et al., 
2013; J. Rottermbourg et al., 2010). Results: The clinical efficacy of FCM was higher 
compared to that of IS, this was also reflected in better pharmacoeconomic profile 
of FCM. The CERs were 14,473.61 RUB and 15,222.83 RUB per one patient attained 
iron replenishment in the FCM and IS groups, respectively. Treatment with FCM was 
associated with 2.5-fold lower costs of day care services and 2.7-fold lower expenses 
for blood transfusion procedures. Additional expenses for the day care services were 
required for patients received ISSs due to increased frequency of injections; this was 
resulted in the highest CERs in the ISS group. cOnclusiOns: The present study 
has demonstrated that administration of FCM is economically effective strategy to 
replenish body iron stores and correct IDA in surgical patients.
PSy15
COST ANALySIS OF A FIBRIN SEALANT PATCH FOR MILD, MODERATE AND 
PROBLEMATIC SOFT TISSUE SURGICAL BLEEDING: A HOSPITAL PERSPECTIvE
Corral M.1, Ferko N.2, Hollmann S.2, Delatore P.3, Jamous N.4, Brown S.T.2, Rubinger D.2
1Ethicon Biosurgery, Somerville, NJ, USA, 2Cornerstone Research Group, Burlington, ON, Canada, 
3Ethicon, Inc, Somerville, NJ, USA, 4Ethicon Biosurgery, Norderstedt, Germany
Objectives: Although there are several hemostats available, drawbacks include 
limitations with efficacy on first attempt and sub-optimal ease-of-use. Literature 
suggests that more efficacious hemostats may avert hospital resources and offset 
upfront acquisition costs. A study was conducted to estimate the cost impact of a 
novel fibrin sealant patch (i.e., EVARREST™) versus standard of care (SoC) in mild-
moderate and problematic soft tissue surgical bleeding. MethOds: An economic 
model was developed to quantify 30-day cost impact of EVARREST from a U.S. hospi-
tal perspective. Key resources, collected from two trials, included quantity of initial 
treatment and re-treatment, operating time, hospitalization, transfusion risk, amount 
transfused, and ventilator utilization. SoC was composed of Surgicel (mild-moderate 
bleeding) or Surgicel (88%) and conventional methods (12%) (problematic bleeding). 
The primary analysis included resources clinically related to the significant hemo-
stasis benefit of EVARREST vs. control (i.e., initial and re-treatment, operating time 
and transfusion). A secondary analysis included all resources collected. Published 
data on U.S. costs were applied to resource use. Results: In problematic bleeding, 
the primary analysis predicted that EVARREST is cost-savings for the hospital vs. 
SoC (-$462 USD per patient) with robust one-way sensitivity results (range: -$199 
to -$6,212 USD). In mild-moderate bleeding, EVARREST acquisition cost is partially 
offset with a cost impact of $507 USD per patient (sensitivity range: $175 to $851 USD). 
Secondary analyses predicted further resource reduction with EVARREST leading 
to cost-savings (-$5,096 USD per patient) or reduction in cost impact ($233 USD per 
patient) for problematic and mild-moderate bleeding respectively. cOnclusiOns: 
This analysis suggests that the hospital cost impact of EVARREST depends on type 
of bleed. In problematic soft tissue bleeding, EVARREST may result in important cost 
savings for hospitals, in addition to meeting an important unmet need. Further study 
in additional populations may be required to confirm findings.
PSy16
COST ANALySIS OF ByPASSING AGENT PROPHyLAxIS TREATMENT vERSUS ON-
DEMAND THERAPy IN HEMOPHILIA A wITH INHIBITOR IN SPAIN
Villarrubia R.1, Oyagüez I.1, Alvarez M.T.2, Mingot E.3, Parra R.4, Casado M.A.1
1Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 2Hospital Universitario La 
Paz, Madrid, Spain, 3Hospital Regional Universitario Carlos Haya, Malaga, Spain, 4Hospital 
Universitari Vall d’Hebron, Barcelona, Spain
Objectives: To estimate the treatment cost of prophylaxis and acute break-
through bleeds with Activated Prothrombin Complex Concentrate (aPCC) versus 
on-demand therapy with recombinant Factor VIIa (rFVIIa) for severe hemophilia 
A (HA) with inhibitor patients, from the Spanish Healthcare System perspec-
tive. MethOds: A cost-analysis model was used to compare annual cost per 
patient of aPCC prophylaxis versus rFVIIa on-demand treatment. Cost estimation 
included prophylaxis pharmaceutical costs (aPCC), on-demand pharmaceutical 
treatment for bleedings, bleeding events management (excluding factor), surgeries 
and HA management. Prophylaxis regimen was 75.72IU/kg three times per week. 
Total dosage for each hemorrhagic event was 673.46µg/kg for rFVIIa and 233.13U/
kg for aPCC, annual number of bleedings was 25 for on-demand therapy and 8 
for prophylaxis, assuming 69% reduction due to prophylaxis. A baseline bleed-
ing management cost (€ 2,971) was estimated based on resource use provided 
by an expert panel for four bleeding sites (joints [62.5%], muscle and soft tissue 
[28.6%], mucous membranes [3.6%] and other sites [5.4%]). Drug (ex-factory price 
with mandatory 7.5% rebate) and unitary costs (€ , 2013) were obtained from local 
databases. Results: Estimated annual treatment cost of prophylaxis with aPCC 
(€ 523,473) was lower than on-demand treatment with rFVIIa (€ 622,183). Based 
on the total agent consumption (789,109IU [aPCC] and 1,050,067µg [rFVIIa]) the 
pharmaceutical cost accounted for € 496,350 for aPCC (14.6% on-demand bleed-
ings and 85.4% prophylaxis) compared to € 543,866 for rFVIIa (average bleeding 
cost of € 9,062 [aPCC] and € 21,556 [rFVIIa]). Yearly bleedings cost was € 23,770 for 
aPCC versus € 74,963 for rFVIIa. A baseline cost for HA management (€ 2,645) and 
an average cost of surgeries (€ 708/year) were estimated for both strategies. Results 
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on the prevalence of the disease has led to a cost study using a “top-down” method. 
Sensitivity analyses were conducted on the following cost parameters: medical and 
drugs costs in primary care, costs of public and private hospitalizations - chosen 
according to their weight in the pathway described by the Delphi Panel. Results: 
The social security paid a total of € 5,612,842 for 1377 AI patients in 2011. The annual 
cost per patient is therefore € 4,076, including 62% for primary care expenses, 29% 
for public hospital expenses and 9% for private hospital. The total population with 
AI is estimated between 26,000 and 30,000 patients, leading to a total cost ranging 
from € 106M and € 122M. A 1% reduction in hospital spending would generate a gain 
of € 430,000 to € 500,000 per year. cOnclusiOns: Despite AI concerns few patients, 
significant costs are borne by Social Security. An increased compliance and a better 
management of symptoms such as fatigue could help optimizing this cost.
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ECONOMIC BURDEN OF PATIENTS wITH PAINFUL DIABETIC NEUROPATHy IN 
EUROPE: A SySTEMATIC LITERATURE REvIEw
Alleman C.J.M.1, Westerhout K.Y.1, Hensen M.1, Stoker M.J.2, Chambers C.3, Long S.K.2,  
van Nooten F.E.2
1Pharmerit International, Rotterdam, The Netherlands, 2Astellas, Leiden, The Netherlands, 
3Astellas, Chertsey, UK
Objectives: Painful diabetic neuropathy (PDN) is a complication of diabetes mellitus. 
The aim of this research was to describe the epidemiology and economic burden result-
ing from PDN in Europe. MethOds: A systematic literature review was performed 
according to a pre-defined search strategy and review criteria in Embase and PubMed 
from 2003 to 2012. Conference proceedings and Health Technology Assessment (HTA) 
organizations’ websites were also searched from 2010 to 2012. Results: In total, 23 
original studies were identified that covered either epidemiology (n= 16) or economic 
burden (n= 7) for PDN patients in Europe. 13 - 26% of European diabetes patients are 
reported to develop PDN. Health care costs per PDN patient were between € 2,441 and 
€ 2,963 per annum in UK and Spanish studies, respectively. Inpatient care, medical visits 
and drug costs accounted for the majority of the total costs, although drug costs can 
vary widely depending on the choice of medication. Health care costs for PDN lead 
to a high total economic burden for European countries. Considering the identified 
prevalence data and cost estimates, the estimated total annual health care burden 
for the UK would be approximately € 1.7 billion, from a payer perspective. In addition, 
PDN is significantly associated with disruptions in employment status and productiv-
ity loss, primarily driven by impairment while working (presenteeism), resulting in 
average European per-patient productivity losses of € 10,484 per annum. Pain severity 
highly influences economic outcomes: higher severity has been linked to significant 
increases in resource use, productivity losses and health care costs. cOnclusiOns: 
The large number of PDN patients combined with the cost per patient results in a high 
economic burden of PDN for European countries. More severe pain results in increased 
resource use and costs for payers and society; therefore, more effective PDN treatments 
will lead to patient as well as economic benefits.
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COST OF OBESITy AND ECONOMIC vALUE OF OBESITy SURGERy FOR TURKEy 
(CEvOS-T)
Kockaya G.1, Tatar M.2, Ergin G.3, Atikeler K.2
1Covidien, Istanbul, Turkey, 2Hacettepe University, Ankara, Turkey, 3Polar Health Economics 
Consultancy, Ankara, Turkey
Objectives: Obesity and its comorbidities are among the primary challenges that 
health systems face globally. Obesity is rapidly becoming a problem in Turkey as well. 
Recent research has revealed that 30.3% of the population is obese(20.5% of males, 
41% of females) of which 2.9% of the obese population is classified under the morbid 
obese category. The 2003 Burden of Disease Study also concluded that 26.006 deaths for 
males and 31.136 deaths for females could be averted by decreasing the ratio of obese 
population. MethOds: The objective of this study is to find out the economic impact 
of obesity with its possible economic benefits of obesity surgery for Turkey. Results: 
Literature search and expert panel are the main methodologies used in the study. A 
comprehensive literature search was undertaken with key words in PubMEd to find 
out the extent of obesity and its comorbidities and treatment methods in Turkey. Cost 
of obesity for Turkey was calculated depending on the published literature. An expert 
panel questionnaire form was designed after the literature search aiming at finding the 
cost. The form was sent to the experts in advance and a panel discussion was under-
taken to reach a consensus. After the consensus building phase the economic ben-
efits of obesity surgery were estimated based on the price tariff declared by the Social 
Security Institution(SGK). cOnclusiOns: Cost of obesity for Turkey was estimated as 
US$ 787.184.000 for 2012. It was the 1.05% of gross domestic product of Turkey. SGK 
pays US$ 1707 weighted average for obesity surgery. It was estimated that return of 
investment on obesity surgery can be possible after the third year of surgery. The study 
indicated that obesity has a great impact to Turkish economy. On the other hand, obesity 
surgery can have a positive impact with its economic benefits to Turkish health system.
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A SySTEMATIC LITERATURE REvIEw ON THE EPIDEMIOLOGy AND ECONOMIC 
BURDEN OF ANAEMIA ASSOCIATED wITH CHRONIC KIDNEy DISEASE
Rizzo M.1, Iheanacho I.1, van Nooten F.E.2, Goldsmith D.3
1Evidera, London, UK, 2Astellas, Leiden, The Netherlands, 3Guy’s Hospital London, London, UK
Objectives: The epidemiological and economic burden associated with anaemia 
in patients with chronic kidney disease (CKD) in Europe has not been explored 
recently using systematic literature review (SLR) methods. Therefore, an SLR was 
conducted to assess these topics. MethOds: A systematic search was conducted 
of MEDLINE- and EMBASE-indexed literature on anaemia in CKD from 2007 to 2012 
for publications on epidemiology and economic burden. Data from included articles 
were abstracted into a pre-designed template and synthesised using qualitative 
methods. Results: The review identified 19 studies reporting on epidemiology and 
nine on economic burden. The prevalence of anaemia among patients with CKD var-
ied widely by setting, being generally lower in those from the general population and 
BDD-rFVIII in Europe. Clinical data are from the published literature. Pharmacy cost 
of rFVIII, immune tolerance induction (ITI) and bypassing agents for patients who 
developed inhibitors are considered from French health care perspective. Results: 
Both products are listed and reimbursed at similar unit price whereas the overall 
cost to treat a patient with BDD-rFVIII is higher considering the increased con-
sumption on prophylaxis and the risk of developing an inhibitor for PTPs. This may 
be translated into an increase cost of 36% over 1 year and 40% over 3 years when 
treating children and adult PTPs with prophylaxis. cOnclusiOns: The cost study 
confirms the cost advantage of rFVIII (FL-rFVIII) as well as the need to compare the 
rFVIII based on the overall cost and not on the price per unit.
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COST OF ILLNESS OF NEUROPATHIC PAIN IN SPAIN IN 2012 FROM A SOCIETAL 
PERSPECTIvE
Ruiz L.1, Liedgens H.2, Obradovic M.2
1Adelphi Real World, Bollington, UK, 2Grünenthal GmbH, Aachen, Germany
Objectives: To quantify the total societal costs of Neuropathic Pain (NP) in Spain 
following a bottom-up prevalence approach. MethOds: The sample was drawn 
from the 2012 Adelphi NP Disease Specific Programme, a cross-sectional survey of 
413 primary care physicians and specialists and their consulting patients across the 
EU5. Physicians completed patient record forms for 826 patients in Spain including 
patients’ socio-demographic information, treatment history and resource utiliza-
tion. Additionally, 577 patients voluntarily completed another questionnaire that 
included the Work Activity and Productivity Impairment Questionnaire (WPAI). 
Health-related costs were collected and adjusted to 2012 prices when needed. 
For professional caregivers’ costs and work losses, Spanish average salaries were 
used. Results: The 826 patients included accounted for a total of € 2,676,893.83, 
an average of € 3,240.79 per patient, with 72% (€ 2,350) of these being health related 
costs, including drugs (50%), consultations (11%), surgical (9%) and non-surgical (2%) 
procedures. Working losses related with patients’ sick leave (as reported by doctors) 
accounted for 17% (€ 555) of the costs and professional caregiving added up to 10% 
of the total costs. The results were extrapolated to national prevalence figures of 
2012 excluding patients assumed to be non-treated. The societal costs for 2012 were: 
health-related costs € 514,583,543, work losses € 119,417,964 and professional caregiv-
ers € 72,204,921. Additionally, 91% of the caregivers were non-professional. 191 (33%) 
of the 577 patients completed the WPAI with an Overall Work Impairment score of 
55%. Finally, 183 (33%) of the patients stated that NP prevented them from working 
at some point, with 26 patients stating this was “permanently”. cOnclusiOns: 
The economic impact associated with Neuropathic Pain (NP) implies substantial 
annual costs to the Spanish National Health Service of more than € 500 Mio. and a 
large burden on patients’ lives and their families. The results shown here suggest 
that an important part of the real cost is still hidden.
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ExPLORING THE BURDEN OF ILLNESS OF HEREDITARy ANGIOEDEMA IN THE 
UNITED KINGDOM
Helbert M.1, Drogon E.2, Mannan A.2, Holbrook T.3, Murray H.3, Piercy J.3
1Manchester Royal Infirmary, Manchester, UK, 2ViroPharma Europe, Maidenhead, UK, 3Adelphi 
Real World, Bollington, UK
Objectives: Hereditary angioedema (HAE) is a rare but potentially life-threaten-
ing condition with intermittent and unpredictable oedema affecting the larynx, 
abdomen and extremities. This study aims to define the burden of HAE in England 
and Scotland as published data are limited. MethOds: A comprehensive, cross-
sectional, retrospective study of the burden of HAE (type I and II) in England and 
Scotland. Three data collection methods: 1) secondary care data identified using 
Hospital Episode Statistics based on D.84.1 diagnostic code (defects in complement 
system, C1-esterase inhibitor deficiency); 2) primary care data accessed through 
The Health Improvement Network (THIN) database using C-376-000 HAE diagnostic 
code. Both database analyses identified patients diagnosed ≤ 10 years and include all 
episodes ≤ 2years. Costs were calculated using most up-to-date best-matched HRG 
tariffs. 3) Primary research in five secondary care centres in England and Scotland 
collecting information on > 100 patients (> 18 years) via medical records ≤ 2years, 
matched with patient self-completion questionnaires and centre interviews. 
Selected centres represent different approaches to HAE management to ensure a 
national representative sample. Results: Data collection from all three phases of 
the study is on-going. Early results from 1) indicate 1,174 HAE patients admitted 
to hospitals in England, for any reason, in the past two years. Mean length of stay, 
including day cases, was 2.8 days. The annual total cost of secondary care in England 
was £3,227,149, corresponding to per HAE patient cost of £2,749. cOnclusiOns: 
This is the first comprehensive UK HAE cost of illness study, providing a compre-
hensive understanding from both NHS and patient perspectives. Important insight 
into patient demographics, pathway of care, treatment patterns, and any regional 
or sub-population differences in the standard of care will be provided, helping to 
raise disease awareness in the UK.
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ADRENAL INSUFFICIENCy: BURDEN OF DISEASE IN FRANCE IN 2011
Bourguignon S.1, Reznik Y.2, Chenuc G.3
1Stratégique Santé, Evry Cedex, France, 2Caen Hospital, CAEN, France, 3Capionis, Paris, France
Objectives: Adrenal insufficiency (AI) is a rare disease caused by a deficiency in hor-
mone synthesis by adrenal glands, due to either the destruction of the glands (primary 
AI: PAI) or hypothalamic / pituitary causes (secondary AI: SAI). Patients are treated 
with hormone replacement therapy, mainly hydrocortisone. Our aim was to assess the 
cost of AI management in France MethOds: We used data from the French National 
Health Insurance (Social security) on patients who benefited from a long duration 
disease status N°31 for their AI in 2011 (primary and secondary combined) on the one 
hand, and the results of a Delphi Panel survey on the other hand. This survey, involv-
ing 15 endocrinologists from academic hospitals, was designed to better understand 
the patients’ pathway in the absence of guidelines. An epidemiological approach 
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Objectives: To estimate health and social care resource use in treating individu-
als with Fragile X Syndrome (FXS) in Canada and the United Kingdom (UK). FXS is 
the most common inherited form of intellectual disability (ID) worldwide; however 
its impact on resource use is not well documented. MethOds: Delphi panels 
were formed to generate consensus-based estimates of resource use. Panelists 
from multiple disciplines were recruited (7 panelists in Canada, 6 in UK) and a 
questionnaire developed to obtain estimates from each panelist by 2 age groups, 2 
severity levels and 24 service types for each of 9 items from the Aberrant Behavior 
Checklist (ABC) a proxy completed instrument to rate maladaptive behaviors of 
individuals with ID. A factor weight was estimated to differentiate costs by gender 
and a self-declared confidence score (1 – 5) was reported for each ABC item. Mean 
total service counts and coefficients of variation (CV) were calculated to assess 
variance between panelists and between rounds. Initial results were reviewed 
with panelists in a facilitated group discussion after which the questionnaire was 
repeated. Final data were based on the second round of estimation. Results: 
Comprehensive resource data were collected for both countries. There was lower 
variance and higher confidence in both countries in round 2 compared to 1. 
Rounds 1 and 2 means (CV) for Canada were [6,723 (0.69) 8,575 (0.52)] and for 
UK were [6,953 (0.96) 6,023 (0.76)]. The average level of self-declared confidence 
increased from 2.6 to 3.3 in Canada and from 2.6 to 2.8 in the UK. cOnclusiOns: 
The study generated comprehensive resource use data for treating individuals 
with FXS in Canada and the UK. Credible and validated estimates were generated 
through group discussion and refinement of initial estimates. The resulting data 
will be important in performing economic evaluations of treatments for patients 
with FXS.
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IMPACT OF BARIATRIC SURGERy ON OBESE PATIENTS MANAGEMENT AND 
RELATED COSTS: A FRENCH NATIONAL CLAIMS DATABASE ANALySIS OvER THE 
PERIOD 2005 -2011
Czernichow S.1, Emery C.2, Fagnani F.2, Gourmelen J.1, Szwarcensztein K.3, Lafuma A.2
1INSERM, Villejuif, France, 2Cemka Eval, Bourg La Reine, France, 3ETHICON SAS, Issy les 
Moulineaux, France
Objectives: To gain an understanding of the impact of bariatric surgery on the 
current medical management of obese patients. MethOds: The EGB database is 
a 1/97 representative sample (around 600,000 individuals) of the national claims 
database covering the whole French population including outpatients and inpa-
tient care. Adult patients treated for the first time over the period 01/01/2007 to 
31/12/2009 by bariatric surgery were identified through related procedures and 
obesity ICD-10 codes. A cohort of patients was constituted with a 2-year follow-up 
before and after the index procedure date (T). Reimbursed medical consumption 
over this 4-year period was recorded and presence of co-morbidities was identified 
through ICD-10 codes, reimbursement of specific drugs or procedures. Results: 
A total of 350 patients meeting the selection criteria were identified in the data-
base with a mean age of 38.9 (+/- 11.3) years, 83.4% female and 69.7% had a BMI 
in the range 40-50. The distribution of patients according to bariatric procedure 
was gastric banding (62.6%), gastric by-pass (19.7%), sleeve gastrectomy (16.6%) 
and bilio-pancreatic diversion (1.1%). The annual per capita reimbursed health 
expenses evolved from 2.633€ (+/-3.124€ ) in Year (T-2), to 3.557€ (+/-3.380€ ) in Year 
(T-1), to 4.240€ (+/-3.840€ ) in Year (T+1) (excluding procedure cost) to 3.755€ (+/-
5.037€ ) in Year (T+2). In 39% of patients those costs decreased between T-2 and 
T+2, (> 5%) and the only two variables significantly explaining this decrease were 
the reduction of consumption for anti-Diabetes and/or anti-Hypertension drugs. 
Most items of medical consumption increased over the period pre and post proce-
dure but started to decrease in Year T+2. cOnclusiOns: The visits for preparing 
bariatric surgery were probably an opportunity for those patients to benefit from 
a general check-up which has generated extra short term medical consumption. 
Additional research with longer follow up could better capture the benefits of 
bariatric surgery on medical consumption.
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COST-CONSEQUENCE ANALySIS OF A TREATMENT STRATEGy INCLUDING 
PONATINIB COMPARED TO A TREATMENT STRATEGy INCLUDING ONLy THE 
2ND GENERATION TyROSINE KINASE INHIBITORS (2G TKIS), DASATINIB OR 
NILOTINIB, IN RESISTANT PATIENTS wITH PHILADELPHIA CHROMOSOME-
POSITIvE (PH+) LEUKEMIA, IN ITALy
Chiroli S.1, Furneri G.2, Pane F.3
11ARIAD Pharmaceuticals (Europe) Sárl, Lausanne, Switzerland, 2Italian National Research 
Center on Aging, Ancona, Italy, 3Università Federico II, Napoli, Italy
Objectives: To assess treatment cost and duration (months) of major cytoge-
netic response (MCyR) using ponatinib in patients intolerant or resistant to 2G 
TKI, compared to treating with only 2G TKIs, in patients with Ph+ leukemia, in 
Italy. MethOds: A 3-year Markov model with 1-year cycles simulated patients 
with Ph+ leukemia to estimate outcomes in those eligible for ponatinib therapy, 
defined as 1) 2G TKI-resistant, 2) 2G TKI-intolerant if imatinib is not clinically 
appropriate, or 3) with T315I mutation. Eligible patients received treatment 
sequences including 2G TKIs and ponatinib in the ponatinib arm and 2G TKI 
only in the comparator arm. Patients without MCyR by 12 months were switched 
to the next therapy line until TKI options were exhausted, then to best sup-
portive care. MCyR rates for 2G TKI or ponatinib were estimated from clinical 
trial data and expert opinion. Patients were assumed to accrue MCyR months 
until estimated treatment failure. Monthly treatment costs reflect approved 
EU dosing and list prices; cost of ponatinib was assumed equivalent to the 
US. Results: We estimated 184, 280, and 360 ponatinib-eligible patients in 
years 1-3, respectively. Treating ponatinib-eligible Ph+ leukemia patients with 
2G TKIs yielded a 3-year cost of € 58.51 million and a total of 2,536 months in 
MCyR, at an average cost of € 23,068/MCyR month. Using ponatinib in eligible 
patients cost € 79.54 million and provided 5,649 months in MCyR, at an average 
cost of € 14,079/MCyR month. cOnclusiOns: The treatment strategy includ-
primary care (range: 1.0%–9.4%) than in general hospitals (range: 5.8%–43.3%), and 
highest in specialist nephrology settings (range: 16.0%–97.6%). Also, prevalence rates 
increased with the CKD stage (1–2: 14.1%–27.9%; 3: 25.5%–91.1%; 4: 36.0%–85.5%; 5: 
97.6%). The cost of managing anaemia per patient per year varied across studies 
from £2,616 (2006–2007 Great British Pounds; GBP) to £3,740 (2006 GBP) in the UK, to 
€ 5,617 in France (cost year not reported). One study reported that the overall cost of 
managing anaemia was highest in patients with CKD Stage 3 compared with other 
stages (3: £4,162,056 vs. 4–5: £243,288; 2006–2007 GBP). Another study reported higher 
costs per patient per annum for individuals with lower haemoglobin (Hb) levels (Hb 
> 12 g/dL: € 2,418; Hb < 10 g/dL: € 13,005; cost year not reported). Among patients with 
CKD, those with anaemia were more likely to be hospitalised (61% vs. 50% of those 
without anaemia). cOnclusiOns: Anaemia is a highly prevalent condition in CKD 
across treatment settings in Europe, and the limited evidence available suggests it 
is associated with a substantial economic burden.
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MODELLING THE PREDICTIvE vALUE OF PAIN INTENSITy ON COSTS AND 
RESOURCES UTILIzATION IN PATIENTS wITH PERIPHERAL NEUROPATHIC PAIN
Pérez C.1, Navarro A.2, Saldaña M.T.3, Wilson K.4, Rejas J.5
1Pain Clinic, Hospital de la Princesa, Madrid, Spain, 2Primary Care Health Centre Puerta del 
Ángel, Madrid, Spain, 3Primary Care Health Centre Raíces, Castrillón, Asturias, Spain, 4Pfizer Inc., 
Walton Oaks, UK, 5Pfizer S.L.U., Alcobendas/Madrid, Spain
Objectives: Peripheral neuropathic pain (PNP) implies a significant economic 
burden that results in major health care and indirect costs. The aim of the present 
analysis was modelling the association and predictive value of pain intensity on 
costs and resources utilization (health care and non-health resources) in patients 
with chronic PNP treated in routine clinical practice conditions in Spain. MethOds: 
Secondary economic analysis based on data from a multicenter, observational and 
prospective cost-of-illness study in patients with chronic PNP refractory to previous 
treatment. Data on resources utilization and pain intensity was collected at baseline 
and 12 weeks after starting a new treatment. Pain intensity was measured using the 
0-100 mm Visual Analogue Scale (VAS) of the Short Form McGill Pain Questionnaire. 
Univariate and multivariate linear regression models were fitted to identify inde-
pendent predictors of costs and health care and non-health care resources utiliza-
tion. Results: A total of 1703 patients were included in the current analysis. Pain 
intensity was an independent predictor of total costs ([Total costs(Euros)] = 35.6 x 
[VAS pain intensity] + 214.5; coefficient of determination [R2]= 0.19, p< 0.001), direct 
costs ([Direct costs(Euros)] = 10.8 x [VAS pain intensity] + 257.7; R2= 0.06, p< 0.001) 
and indirect costs ([Indirect costs(Euros)] = 24.8 x [VAS pain intensity] – 43.4; R2= 0.19, 
p< 0.001) related to chronic PNP in the univariate analysis. Pain intensity remain 
significantly associated with total costs, direct costs and indirect costs after adjust-
ment by other covariates in the multivariate analysis (p< 0.001). The impact of pain 
intensity on health care and non-health care resources utilization accounted for 
such findings. cOnclusiOns: Pain intensity predicts the health care and non-
health care resources utilization, and costs related to chronic PNP. Management of 
patients with drugs associated with a higher reduction of pain intensity will have 
a greater impact on the economic burden of that condition.
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RESOURCE UTILIzATION AND COSTS ASSOCIATED wITH RITUxIMAB 
TREATMENT IN PATIENTS wITH PEMPHIGUS AND PEMPHIGOID: A 
COMPARISON OF 6 MONTHS BEFORE AND 6 MONTHS AFTER TREATMENT
Heelan K., Shear N., Knowles S., Hassan S, Mittmann N
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Objectives: Pemphigus and pemphigoid are a rare group of potentially fatal dis-
eases, causing blistering on mucosal and epidermal surfaces. Long-term treatment 
with systemic corticosteroids and immunosuppressive agents such as intravenous 
immunoglobulin (IVIg) are usually required. Rituximab (RTX) is increasingly being 
used for autoimmune bullous dermatoses (AIBD) and has shown to be effective, 
however, in Canada, RTX is not approved for AIBD. Given the potential cost associ-
ated with the use of RTX, there is a need to quantify the issues around accessing 
it for AIBD patients. MethOds: Resources (e.g., treatment, lab costs, procedures, 
access to health care providers) associated with 89 AIBD patients were collected 
and quantified 6 months prior and 6 months post RTX initiation. Costs of adverse 
events secondary to standard treatment (e.g., steroid adverse effects such as dia-
betes, cataracts, osteoporosis etc) and costs of medications used to prevent steroid 
adverse effects (e.g., proton pump inhibitors, bisphosphonates) were not calculated. 
Unit costs (2013 $CAN) were applied to the resources. Overall cohort costs pre and 
post RTX, as well as cost per patient, were calculated. Cost drivers were identi-
fied. Results: The overall cohort cost for 6 months pre-RTX was $3.7million (M), 
and 6 months post was $2.6M (30.3% decrease). IVIg was shown to be the main 
cost driver. 6 months pre-RTX, 157 months of IVIG was used ($3.6M) compared to 
71 months ($1.6M) 6 months post. The cost associated with access to health care 
resources significantly reduced from $46,715 vs. $22,978, and fewer visits to the 
dermatologist were required (377 vs. 256 visits). A decrease was also observed in 
the cost of specialist consultations required ($5,807 vs. $3,234) and other treatment/
medication use ($64,548 vs. $48,045). The cost per patient decreased ($41,497 vs. 
$28,923). cOnclusiOns: RTX is effective in reducing the number of resources and 
costs associated with treatment of AIBD.
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HEALTH AND SOCIAL CARE RESOURCE USE By INDIvIDUALS wITH FRAGILE x 
SyNDROME: RESULTS OF TwO DELPHI PANELS
Barry S.J1, London P.2, Bostock T.1, Adlard N.3, Lakhdari K.4, Aubertin G.5, Burge P.6, Corbin J.F.7, 
Gagnon S.7, Hassiotis A.8
1Optum, Burlington, ON, Canada, 2Optum, Chicago, IL, USA, 3Novartis Pharmaceuticals UK, 
Surrey, UK, 4Novartis Pharmaceuticals Canada, Montreal, QC, Canada, 5University of British 
Columbia, Victoria, BC, Canada, 6Queen’s University, Kingston, ON, Canada, 7University de 
Sherbrooke, Sherbrooke, QC, Canada, 8University College London, London, UK
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outcomes. Regarding the acceptability threshold in Poland cysteamine therapy 
can be considered a cost-effective technology compared with CaST in patients 
who began treatment before the age of two.
PSy34
COST-EFFECTIvENESS OF SUGAMMADEx FOR ROUTINE REvERSAL OF 
NEUROMUSCULAR BLOCKADE, wITH ExTUBATION AT A TOF RATIO OF 0.9, IN 
ANAESTHETISED PATIENTS UNDERGOING ELECTIvE SURGERy IN ENGLAND 
AND wALES
Praet C.1, D’Oca K.1, O’Regan C.1, Insinga R.P.2, Maiese E.M.3
1MSD Ltd., Hoddesdon, UK, 2Merck & Co. Inc., Upper Gwynedd, PA, USA, 3Merck & Co, Inc., 
Whitehouse Station, NJ, USA
Objectives: To assess the cost-effectiveness of sugammadex compared with 
neostigmine + glycopyrrolate as a reversal agent for moderate and deep rocu-
ronium or vecuronium-induced neuromuscular blockade (NMB) in the elective 
setting in England and Wales, when extubation occurs at a train-of-four (TOF) ratio 
of 0.9. MethOds: A decision tree comparing the cost-effectiveness of sugamma-
dex versus neostigmine + glycopyrrolate when reversing moderate or deep NMB 
induced by commonly used neuromuscular blocking agents (NMBAs) (atracurium/
rocuronium/vecuronium) was developed. Extubation was modelled to occur at a 
TOF ratio of 0.9, as may happen when using objective NMB monitoring to deter-
mine when to safely extubate. Time to recovery was used to calculate the cost 
of patients recovering in theatre based on both the average cost per minute of 
theatre time, and operating room (OR) staff costs per minute. Effectiveness was 
measured by the number of prolonged paralysis cases prevented by each treat-
ment regimen. Results: Reversal of moderate NMB: when considering average 
cost per minute of theatre time, results show that sugammadex strategies are 
dominant compared with all assessed comparators. When considering OR staff 
cost per minute, results show that rocuronium with sugammadex is dominant 
over all assessed comparators, with the exception of atracurium with neostigmine 
+ glycopyrrolate (ICER< £100). Reversal of deep NMB: when considering either 
costing scenario, results show that sugammadex strategies are dominant over 
all assessed comparators, with the exception of atracurium with neostigmine + 
glycopyrrolate (ICER < £330). cOnclusiOns: In clinical settings where extubation 
occurs at a TOF ratio of 0.9, and time savings may be realized for all OR staff, under 
both moderate and deep NMB scenarios in the elective surgery setting, sugam-
madex is either dominant or shows reasonable levels of cost-effectiveness (with 
low ICERs < £330 when not dominant against neostigmine+ glycopyrrolate), whilst 
also filling an unmet need for deep NMB reversal.
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COST-EFFECTIvENESS ANALySIS OF A vACCINATION PROGRAMME FOR THE 
PREvENTION OF HERPES zOSTER AND POST-HERPETIC NEURALGIA IN ADULTS 
AGED 50 AND OvER IN GERMANy
Largeron N.1, Préaud E.1, Boehm K.2, Aidelsburger P.2, Anger D.3, Bianic F.3
1Sanofi Pasteur MSD, Lyon, France, 2CAREM GmbH, Sauerlach, Germany, 3OptumInsight, 
Nanterre, France
Objectives: A vaccine is licensed in Europe for the prevention of Herpes Zoster 
(HZ) and postherpetic neuralgia (PHN) in adults aged ≥ 50 years. The objective of 
this study was to assess the cost-effectiveness of a vaccination programme in 
Germany in this population. MethOds: An existing European Markov Model was 
adapted to the German health care setting and cost-effectiveness outcomes were 
assessed from the statutory health insurance (SHI) and from the societal perspec-
tive. The Markov Model compares a HZ vaccination policy for adults aged ≥ 50 
years with a no vaccination policy. Health states considered are healthy, HZ, PHN, 
healthy post-HZ and death. HZ and PHN states are further split by pain severity 
(mild, moderate or severe). Model outcomes include cost/HZ case avoided, cost/
PHN case avoided and cost/quality-adjusted life year (QALY) gained. Additionally 
we assessed the number needed to vaccinate (NNV) to avoid one case of HZ or PHN. 
Input data were obtained from German data sources, international and German 
study results as well as published literature. Discounting was done in accordance 
to guidelines from the German Institute for Quality and Efficiency in Health Care 
(IQWiG). Results: Preliminary results of the base-case analysis show incremen-
tal cost-effectiveness and cost-utility ratios (ICER) in amount of € 2,223 per HZ 
case avoided and € 22,923 per QALY gained from a payer perspective. In sensitiv-
ity analyses discount rates, vaccine prices and no hospitalization assumption 
showed a major impact on the results. cOnclusiOns: Our cost-effectiveness 
analysis shows that a HZ vaccination policy for adults aged ≥ 50 years in Germany 
could provide public health and economic effects in the German health care 
system.
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THE POTENTIAL OF A REDUCTION IN THE RISK OF OPIOID-RELATED 
FRACTURES TO DRIvE THE COST-EFFECTIvNESS OF AN ANALGESIC
Cawson M.1, Knight C.2, Hirst M.3, Dunlop W.3
1RTI Health Solutions, Manchester, UK, 2RTI Health Solutions, Sheffield, UK, 3Mundipharma 
International Limited, Cambridge, UK
Objectives: An increased risk for fractures has been observed in patients 
treated with opiates, possibly resulting from falls related to central nervous 
system effects, such as dizziness. Observational data suggest that the semisyn-
thetic opioid, buprenorphine, may be associated with a lower fracture risk than 
some other opiates such as tramadol. Our objective was to perform a preliminary 
analysis to explore whether a buprenorphine-class drug has the potential to be 
cost-effective due to a reduced risk for fracture. MethOds: Decision-analytic 
modeling was used to project fracture-related outcomes and costs over 1 year. 
Quality-adjusted life-years (QALYs) and costs (in 2012 pounds sterling) were esti-
mated from a health service perspective. Odds ratios for forearm, hip, and spine 
fractures, by drug, estimated from real-world hospital discharge data (Vestergaard 
et al., 2006), were applied to the risk for fracture in the general population. 
ing ponatinib provided more than double (2.2-fold) the MCyR months at 36% 
higher cost compared to the 2G TKI strategy. The average cost/MCyR month 
with ponatinib was lower than the average cost/MCyR month with 2G TKIs. 
While there are limitations with the methology and assumptions of the model, 
this analysis suggests treatment with ponatinib may provide good value for 
ponatinib-eligible Italian patients.
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EvALUATION OF THE COST-EFFECTIvENESS OF THE CAPSAICIN PATCH 
QUTENzATM FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN IN THE 
UNITED KINGDOM
Trueman D.1, Poole C.D.2, Chambers C.3, Odeyemi I.4, Currie C.2
1Abacus International, Bicester, UK, 2Cardiff University, Cardiff, Wales, UK, 3Astellas Pharma 
Europe Ltd., Staines, UK, 4Astellas Pharma Europe Ltd., Staines, UK
Objectives: To estimate the cost-effectiveness of using the capsaicin patch 
QUTENZATM prior to use of more costly neuropathic pain medications for individu-
als with peripheral neuropathic pain (PnP). MethOds: A decision tree and Markov 
model was developed using inputs from a prospective, observational study. This 
study provided estimates of clinical efficacy, health utility and resource use. The 
model considered two treatment strategies: 1. a capsaicin patch followed by pre-
gabalin and then a subsequent last-line therapy, and 2. no exposure to a capsaicin 
patch. A systematic review and meta-analysis were used to estimate the effective-
ness of pregabalin. Response was defined as a ≥ 50% reduction in pain at week-8. 
Patients who responded were assumed to experience pain relief and increase in 
health-related quality of life until the resolution of pain (or death). Non-responders 
were assumed to switch therapy, and individual’s that failed last-line therapy were 
assumed to experience baseline pain (unless resolution of pain or death). Costs 
were based on published sources. The primary outcome was the incremental cost-
effectiveness ratio (ICER). The perspective was the UK National Health Service and 
personal social services. Results: Key parameter estimates derived from the 
observational study were: the probability of response for capsaicin patch (29.5%), 
the mean number of patches per application (1.5), the mean time to retreatment 
(218 days), The baseline EQ-5D score was 0.370; response was associated with an 
increase in EQ-5D utility of 0.353 from baseline. The base-case ICER was £2,292 per 
quality-adjusted life-year (QALY). This varied by time horizon. Probabilistic sensi-
tivity analysis suggested that over a lifetime horizon, a treatment strategy placing 
capsaicin patches before pregabalin had a 99.9% probability of being cost effective 
at a willingness-to-pay threshold of £20,000. cOnclusiOns: The capsaicin patch 
used before pregabalin was a highly cost-effective treatment in the management 
of peripheral neuropathic pain.
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COST EFFECTIvENESS OF INDUCTION ANESTHETIC AGENTS
Nagappa A.N.1, Karthik R.1, Prabhu N.2, Umesh G.3
1Manipal University, MCOPS, Manipal, India, 2Manipal Univiersity, Manipal, India, 3Manipal 
University, Manipal, India
Objectives: To evaluate the cost effectivenss of Thiopentone and Propofol for over 
night induction anesthesia in a tertiary care hospital. MethOds: A prospective 
observational study in which the patients scheduled for general anaesthesia were 
adminsitred EQ5D 5L(Qol question aire) after six hour and 24 hours of administering 
Induction Aneasthesia. Kuppuswamy scale was applied to asses the socioeconomic 
status along with the demographic detials Results: The average of EQ5D5L scores 
for Propofal was 14.2 and for Thiopentone 16.0. The cost of the Propofol brand used 
in hospital were 250INR and 260INR. Thiopentone , only one brand was avialable 
costing 62 INR. The Propofol was the most commonly used induction anesthetic 
and it costs more than 4 times of Thipentone. The patients socioeconomic catego-
rirzation based on Kuppuswmy Scale revealed nearly 50% of patients belonged to 
lower middle class and 35% middle class and rest of the patients to Upper class. 
Incremental cost effectivness ratio for Thiopentone agianst Propofol was found 
to be -110; cOnclusiOns: The Propofol although expensive does not offer any 
advantage over the Thiopentone as for quality of life among patients who under 
went induction anethesia
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COST-EFFECTIvENESS ANALySIS OF CySTEAMINE IN THE TREATMENT OF 
PATIENTS wITH CySTINOSIS – A RARE DISEASE
Walczak J.1, Stelmachowski J.1, Obrzut G.1, Hubert A.2
1Arcana Institute, Cracow, Poland, 2Orphan Europe, Paris La Défense, France
Objectives: To perform a cost-effectiveness analysis (CEA) of cysteamine in the 
treatment of infantile cystinosis vs. control group consisting of patients who had 
been given only conservative and symptomatic treatment (CaST). MethOds: 
Markov model was developed in TreeAge Pro 2009. The model evaluated the costs 
and health outcomes of cysteamine treatment at a dose of 1.30 g/m2/day com-
pared with the use of CaST. The model distinguished two populations, depending 
on the time of initiation of the treatment (before the age of two – P1 and after 
the age of two – P2, which implies worse prognosis for the time of occurrence of 
end stage renal disease (ESRD)). The CEA was conducted from both a common 
payer perspective (a patient and a public payer) and a public payer perspective. 
The time horizon of the analysis covered the period from the age of one or four 
(depending on the start of cysteamine therapy) to fifty (currently, the oldest liv-
ing patients with cystinosis reach the fifth decade of life). The main measures 
of the outcomes in the CEA were life-years gained (LYG) and life-years gained to 
the onset of ESRD. Results: From the common payer perspective the cost per 
LYG was PLN 95,337 and PLN 192,272, respectively for the population P1 and P2. 
Cost of LYG to the onset of ESRD was PLN 33,317 and PLN 64,163, respectively for 
populations P1 and P2. The results obtained from the public payer perspective 
did not differ significantly from the results obtained from the common payer 
perspective. cOnclusiOns: Cysteamine treatment of patients with cystinosis vs. 
therapy involving only CaST is more expensive, however produces better health 
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cost of blood production accounted only for the resources expended for collection, 
processing, laboratory testing, storage, as well as the indirect donor’s productivity 
loss. Hence, the cost associated to donor recruitment, pre-transfusion preparation, 
transfusion administration, follow up management of adverse events, and other 
long-term relevant costs were not taken into consideration. Two separate question-
naires were used to collect data regarding: personnel time, annual blood quantities 
collected, percentage of wastage, consumables utilization, institutional overheads, 
information technology expenditure, medical equipment utilized, nuclear acid tests, 
other laboratory tests and indirect costs. Data gather by 53 hospitals across the 
country. An economic model was build using also economic data collected by the 
National School of Public Health and the Ministry of Health. All data referred to the 
year 2012. Results: The cost distribution was positively skewed (skewness:1.530). 
The unweighted mean cost of collecting a blood unit was estimated at € 146.43 
(standard deviation: +€ 28.18, min/max: € 110.25-€ 240.84). In addition, the indirect cost 
of donors’ loss of productivity was estimated at € 33,70 (+€ 49,23). Major cost compo-
nent appears to be the cost of personnel, which was estimated at € 46.86 (+€ 24.86, 
€ 16.49-€ 132.59), accounting for 32.0% of the total direct cost. The average of blood 
unit wastage was estimated at 4.90%. There were not differences between the cost 
of producing a unit of blood in Athens compared with the rest of the country (Man-
Whitney test, p-value: 0.341). cOnclusiOns: This study indicates that the cost of 
producing a cost of blood isn’t insignificant. These figures need to be complemented 
with those concerning the cost of transfusion to have a full picture of producing 
and using a cost of blood locally.
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BURDEN OF CySTIC FIBROSIS IN THE RUSSIAN FEDERATION
Holownia M.1, Krasnova L.2, Vorobiev P.2
1Russian Society for Pharmacoeconomis and Outcomes Research, Moscow, Russia, 2Russian 
Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
Objectives: The significance of cystic fibrosis associated with early disability, 
the need for long-term regular treatment and follow-up and is associated with 
high costs. Data reflecting the socio-economic burden of cystic fibrosis in Russia is 
low, which dictates the need for clinical and economic studies, for example – this 
study. MethOds: An assessment of the burden of cystic fibrosis with the use of 
tobramycin inhalation solution from different manufacturers and powder inhaled 
tobramycin (Tobi Podhaler) for the treatment of Pseudomonas infections in patients 
with cystic fibrosis. The study took into account only the direct medical costs of one 
patient based on standards of outpatient and inpatient care for patients with cystic 
fibrosis. Results: The burden of cystic fibrosis with the use of tobramycin powder 
for inhalation Tobi Podhaler with the time horizon of 10 years is reduced faster 
than in similar groups of patients: the point of profitability is on the eighth year of 
treatment when compared with tobramycin-Gobbi and a 9-year - with Bramitobom, 
when the use of Tobi Podhaler requires less cost to 46,372 USD and 50,138, respec-
tively. cOnclusiOns: Additional costs are difficult to calculate due to the fact that 
tobramycin solution for inhalation requires compliance with ‘‘cold chain’’ at all 
stages of the life cycle of the product: transportation, storage at the distributor and 
at the pharmacy, storage at home. Thus, obtained data in controlled efficacy studies 
of tobramycin solution in actual practice, may be significantly lower.
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QUALITy OF LIFE BENEFITS AND COST IMPACT OF PROLONGED RELEASE 
OxyCODONE/NALOxONE vERSUS PROLONGED RELEASE OxyCODONE 
IN PATIENTS wITH MODERATE TO SEvERE PAIN AND OPIOID-INDUCED 
CONSTIPATION DESPITE THE USE OF 2 LAxATIvES: A UK COST UTILITy 
ANALySIS
Dunlop W.1, Neufeld K.2
1Mundipharma International Limited, Cambridge, UK, 2Mundipharma Research GmbH & Co, 
Limburg, Germany
Objectives: To evaluate the cost-effectiveness of prolonged release oxycodone/
naloxone combination tablets [OXN; naloxone is added to counteract opioid-induced 
constipation (OIC)] in patients who are constipated despite the use of two laxatives, 
compared with prolonged release oxycodone (OXY) alone. MethOds: A model used 
data from one phase II randomised, controlled trial (RCT) in patients with moder-
ate/severe cancer pain and a pooled analysis of two phase III RCT’s in patients with 
moderate/severe non-cancer pain. A subgroup of patients with OIC who had failed on 
two or more laxatives at screening was applied in the analysis (n= 178). The drug cost 
for pain therapy was combined with laxative costs and other resources to calculate 
the cost difference between OXN and OXY. Quality-adjusted life-year (QALY) gains 
were calculated by mapping Bowel Function Index scores to EQ-5D utility values. 
Deterministic sensitivity analyses were performed. The analysis was conducted from 
the perspective of the UK National Health Service (NHS). Results: The incremental 
cost of OXN vs. OXY was £409.60 for the average treatment duration of 301 days. OXN 
gave an incremental QALY gain of 0.0524. The estimated incremental cost-effective-
ness ratio (ICER) was £7,821.80 for OXN vs. OXY. The ICER remained below £30,000 for 
all sensitivity analyses, with OXN dominating OXY in some scenarios when higher 
constipation unit costs were applied. cOnclusiOns: Patients treated with OXN 
experienced a quality of life gain, and OXN had an ICER considerably below thresholds 
normally regarded as cost-effective in the UK (£20,000 – 30,000/QALY). More research 
is required into the cost of treating OIC, with OXN dominating OXY (total cost saving 
to the NHS and quality of life benefit) in sensitivity on OIC unit costs. OXN is therefore 
estimated to be a cost-effective option for treating patients with moderate to severe 
pain and OIC, who are constipated despite the use of two laxatives.
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COST-EFFECTIvENESS OF PLERIxAFOR (PxF) FOR STEM CELL MOBILIzATION IN 
LyMPHOMA (NHL/HL) AND MULTIPLE MyELOMA (MM) PATIENTS IN POLAND
Kaczor M.P.1, Wójcik R.2, Pawlik D.2, Glasek M.3, Pieczonka A.3, Lis J.3
1Jagiellonian University Medical College, Kraków, Poland, 2Aestimo s.c., Kraków, Poland, 3Sanofi, 
Warsaw, Poland
Drug costs were based on the 10-μ g per hour buprenorphine patch and the equiv-
alent tramadol dose (2013 British National Formulary listings). Fracture costs 
were from a recent National Institute of Health and Care Excellence submission; 
utility weights were obtained from the literature. Results: For a population of 
100,000, the model predicted a reduction in the number of additional fractures 
(forearm, hip, or spine) associated with analgesic use from over 2,000 for patients 
treated with tramadol to under 20 for patients treated with buprenorphine. An 
estimated £5.5 million was saved and over 1,300 QALYs were gained. In sensitiv-
ity analysis, buprenorphine was dominant in most analyses and most sensitive 
to treatment duration. The cost-effectiveness estimate was below £20,000 per 
QALY in all scenarios. cOnclusiOns: Our preliminary analysis suggests that 
buprenorphine has the potential to be dominant and cost-effective, compared 
with tramadol.
PSy37
COST-EFFECTIvENESS OF ENzyME REPLACEMENT THERAPy (ERT) wITH 
ALGLUCOSIDASE ALFA IN CLASSIC-INFANTILE PATIENTS wITH POMPE DISEASE
Kanters T.A.1, Plug I.2, Rutten-van Mölken M.P.M.H.1, Redekop W.1, Van der Ploeg A.T.2, 
Hakkaart L.1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus University Medical 
Center, Rotterdam, The Netherlands
Objectives: Infantile Pompe disease is a rare metabolic disease. Enzyme replace-
ment therapy (ERT) has proven to have substantial effects on survival in infantile 
Pompe disease. However, costs of therapy are very high. This paper assesses the 
cost-effectiveness of ERT in infantile Pompe disease. MethOds: A patient simula-
tion model was used to compare costs and effects of ERT with costs and effects 
of supportive therapy (ST). The model was filled with data on survival, quality of 
life and costs. For both arms of the model, data on survival were obtained from 
international literature. In addition, survival as observed among 20 infantile Dutch 
patients, who all received ERT, was used. Quality of life was assumed to be the 
same in both groups and was measured using the EQ-5D. Costs included the costs 
of ERT, which depend on a child’s weight, and costs of health care use, informal 
care and infusions. A lifetime time horizon was used, with semi-annual time 
cycles. Results: On average, ST receiving patients were modelled not to survive 
the first half year of life; whereas the life expectancy in the ERT patients was 
modelled to be almost 14 years. Lifetime incremental QALYs were 6.7. Incremental 
costs were estimated to be € 7.0 million, consisting for 95% of treatment costs. 
The incremental costs per QALY were estimated to be € 1.0 million. The incremen-
tal cost per life year gained was estimated to be € 0.5 million. cOnclusiOns: In 
2012, the Dutch health care insurance board advised the Minister of Health to 
reimburse enzyme replacement therapy in Pompe disease, despite its unfavorable 
ICER. Other factors, such as the rarity of the disease, equity considerations, and 
the relatively modest budget impact have probably played a role in this decision. 
These and other factors could be incorporated in a formal multi-criteria decision 
analyses.
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COST-EFFECTIvENESS AND COST-UTILITy ANALySIS OF BELIMUMAB FOR 
THE TREATMENT OF PATIENTS wITH SySTEMIC LUPUS ERyTHEMATOSUS IN 
PORTUGAL
Gouveia M.1, Borges M.2, Augusto M.2, Costa J.2, Treur M.3, Lopes S.4
1Católica Lisbon School of Business and Economics, Lisbon, Portugal, 2Center for Evidence Based 
Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 3Pharmerit International, 
Rotterdam, The Netherlands, 4GlaxoSmithKline Portugal, Algés, Portugal
Objectives: To estimate the incremental cost-effectiveness (ICER) and cost-util-
ity ratio (ICUR) of belimumab compared to standard care (SC) for the treatment 
of patients with Systemic Lupus Erythematosus (SLE) in Portugal. MethOds: A 
lifetime microsimulation model represented the complex and multidimensional 
course of SLE, based on long term data from a US cohort of SLE patients. The 
analysis was undertaken using a societal perspective with 5% discount rates 
for costs (direct and indirect costs), and effects [Life Years Gained (LYG) and 
QALY (Quality Adjusted Life Years)]. The model was calibrated with the phase 
III BLISS trials data, and UK utility values. The ICER and ICUR were estimated 
by comparison of SC vsSC with belimumab, with a lifetime analytic horizon. 
Belimumab non-responders were discontinued after 6 months and belimumab 
treatment was maximized at 3 years. Results: The model demonstrated that 
adding belimumab to SC to treat SLE patients with high disease activity, positive 
anti-dsDNA antibodies, and low complement (C3, C4) levels, would result in a 
potential gain of 0.41 life-years, and 0.32 QALYs. Incremental costs were€ 8,400, 
resulting in an ICER of € 20,649/LYG and ICUR of € 25,917/QALY for the base case 
scenario. ICER and ICUR are insensitive to the follow-up treatment costs of SLE, 
and wastage of drug; moderately sensitive to duration of treatment, and waning 
time; and very sensitive to discount rates, and exclusion of indirect costs. The 
probabilistic sensitivity analysis reveals a cost-effectiveness probability of 59% 
for a € 30,000/QALY threshold, and a median ICUR of € 27,932/QALY (95% confi-
dence interval: € 14,215/QALY - € 52,279/QALY). cOnclusiOns: The analysis sug-
gests that adding belimumab to SC for SLE patients with high disease activity, 
positive anti-dsDNA, and low complement levels, is cost-effective, presenting 
an ICER and ICUR below the commonly used threshold. This study is funded by 
GlaxoSmithKline, protocol #HO-13-13626
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THE COST OF PRODUCING A UNIT OF BLOOD IN HOSPITALS: A NATIONwIDE 
ECONOMIC ANALySIS FOR THE CASE OF GREECE
Fragoulakis V.1, Stamoulis K.2, Grouzi E.3, Maniadakis N.1
1National School of Public Health, Athens, Greece, 2National Blood Centre (EKEA), Athens, Greece, 
3Transfusion Service of “Agios Savvas” Regional Cancer Hospital, Athens, Greece
Objectives: To estimate the cost of producing a unit of blood from a NHS and 
societal perspective in Greece. MethOds: In line with the official guidelines, the 
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COST-EFFECTIvENESS OF SAPROPTERIN vERSUS PHENyLALANINE FREE DIET 
IN PATIENTS wITH PHENyLKETONURIA IN EGyPT
ElSisi G.1, Elmahdawy M.1, Abaza S.2, Shalakani A.3
1Central Administration for Pharmaceutical Affairs, Cairo, Egypt, 2Roche, Cairo, Egypt, 3Ministry 
of Health, Cairo, Egypt
Objectives: Phenylketonuria (PKU) is an orphan disease with incidence rate 1:5000 
in Egypt. Cost-effectiveness of Sapropterin versus Phenylalanine (PHE) free diet in 
PKU patients from the insurer perspective was evaluated over a time horizon of 10 
years. MethOds: A cohort Markov chain model with six health states: healthy, mild 
PKU, controlled mild PKU, classical PKU, controlled classical PKU and death was 
identified based on the process of the disease. The length of a cycle was set at one 
year. The transition probabilities were derived from updated, previously published 
studies in Egyptian patients with PKU. Relative risk of Sapropterin and utilities were 
derived using international published sources. Direct Medical costs were obtained 
from the Ministry of Health mandatory Tarrif in Egypt. All costs and effects were 
discounted at 3.5% annually. All costs were reported in Egyptian pounds of the 
financial year 2013. Deterministic sensitivity analysis was conducted. Results: 
Total costs for Sapropterin and PHE free diet were 304.1687 EGP and 188.6498 EGP 
respectively. QALYs for Sapropterin and PHE free diet were 0.00566 and 0.00547 
respectively. The incremental cost-effectiveness ratio (ICER) for Sapropterin versus 
PHE free diet was 602,933 EGP/QALY. Sapropterin is not cost effective because it is 
more than 3 times GDP/capita in Egypt (57,566 EGP). The ICER was most sensitive to 
the utility of the states ‘classical PKU’ and ‘controlled classical PKU’. cOnclusiOns: 
World Health Organization recommends that interventions that cost more than 3 
times GDP/capita for one Disability Adjusted Life Year (DALY) avoided should not be 
reimbursed. Despite the difference between DALY and QALY, one can assume they 
are similar to be able to put a value on the outcome. Sapropterin doesn’t represent 
a good value for money compared to PHE free diet in the Egyptian PKU patients.
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A COST-UTILITy ANALySIS OF LIGHTERLIFE TOTAL AS A TREATMENT FOR 
OBESITy IN THE UNITED KINGDOM
Lewis L.1, Taylor M.2
1York Health Economics Consortium, University of York, York, UK, 2York Health Economics 
Consortium, York, UK
Objectives: LighterLife Total (LLT) is a weight loss programme for the obese (BMI 
≥ 30kg/m2) combining a very low calorie diet (VLCD) with weekly support groups 
for behaviour modification. This study evaluated the cost-effectiveness of LLT com-
pared with dietary and surgical interventions. This is the first study assessing the 
cost-effectiveness of a VLCD. MethOds: A cohort model was developed to assess 
the reduction in BMI in the first 12 months following intervention with LLT, gastric 
banding, gastric bypass, Weight Watchers, Counterweight, Slimming World and no 
treatment, and the subsequent yearly BMI increase. Published all cause-mortality was 
applied by age and BMI. Co-morbidity prevalence (diabetes, colorectal cancer, CHD) 
was applied by BMI. Costs were applied for each intervention and for co-morbidities, 
from a UK health care perspective. Utilities were calculated by BMI with an additional 
decrement for co-morbidities. A 10 year time horizon was used. Analyses were run for 
two subgroups: BMI 30-40 in and BMI > 40. Results: BMI 30-40: compared against no 
treatment, Counterweight, Weight Watchers and Slimming World, LLT was associated 
with higher costs, but also greater QALYs and was cost-effective against all, with incre-
mental cost-effectiveness ratios of £14,937, £16,004, £16,182, and £19,840, respectively. 
BMI > 40: compared against no treatment LLT incurred higher costs, but also greater 
QALYs and was cost-effective (ICER = £5,349). LLT was less effective than banding and 
bypass. The budget impact of uptake of LLT across the UK was assessed for both BMI 
30-40 and BMI > 40 groups. cOnclusiOns: BMI 30-40: LLT was more costly than 
dietary interventions, but lead to increased QALYs and was estimated to be cost-effec-
tive. BMI > 40: LLT resulted in a lower initial BMI reduction than gastric banding and 
bypass. LLT was estimated to be cost-effective against no treatment in both groups.
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FULL COST OF PLASMA FROM vOLUNTARy NON REMUNERATED DONORS IN 
ITALy
Zaniolo O.1, Povero M.1, Gandini G.2, Aprili G.2, Eandi M.3
1AdRes HE&OR, Turin, Italy, 2University of Verona, VERONA, Italy, 3University of Torino, Torino, 
Italy
Objectives: In Italy, within the legal mandate to pursue national self-sufficiency 
of secondary blood products, the Regions are starting to organize trade to off-
set need/availability unbalances. Therefore the determination of the full cost to 
the Regions of plasma collection and handling is needed. MethOds: Plasma 
is obtained from voluntary, non-remunerated donors either from full blood or 
from apheresis, and is collected either directly in facilities of the Regional Health 
Services, or indirectly through the net of donors’ associations before being deliv-
ered to the transformation industry for processing. Amount and costs of materi-
als and activities needed for collecting, producing, validating, and distributing 
plasma were obtained from the transfusional medicine department of the Verona 
province, Veneto Region. Attributable overhead expenses are assumed at 15% of 
direct cost. When plasma is collected as part of the whole blood or from multi-
component apheresis, common costs are attributed basing on the commercial 
value of single components, taken as proxy of the willingness-to-pay for them. 
In an alternative scenario, only product-specific costs are attributed to plasma 
recovered from whole blood donations, for which the driving need is the supply 
of red blood cells. Results: Total cost per liter of plasma sent for processing 
is estimated in 114 and 286 euros, respectively, for collection from whole blood 
and apheresis. Given the current mix of plasma origin, the weighed mean cost 
of plasma to the Regions before processing charges is estimated in 157 € . When 
plasma recovered from whole blood donations is considered by-product, its cost 
per liter sent to industry is estimated in 27 € , and the corresponding weighed 
mean cost in 92 € . cOnclusiOns: The Italian donor-based system, in addition to 
Objectives: To assess cost-effectiveness of PXF, used in combination with G-CSF 
versus standard mobilization options used alone, to enhance mobilization of haema-
topoietic stem cells to the peripheral blood for collection and subsequent autologous 
transplantation (auto-HCT). Target population, as defined by Polish opinion leaders, 
are patients with NHL/HL or MM whose cells mobilize poorly, i.e. predicted poor 
mobilizers (peripheral blood CD34+ cell count < 10/mL) and proven poor mobilizers 
(failure of previous mobilizations). MethOds: PXF is an add-on therapy to currently 
reimbursed standard mobilization (SM) options: G-CSF or chemotherapy plus G-CSF. 
Two scenarios were compared: with and without PXF. Analysis was performed using 
a Markov decision model, developed in TreeAge Pro 2013. A probabilistic (Monte Carlo 
simulation) model with time-dependent transition probabilities included initial 
cycle, during which the individual undergoes mobilization and auto-HCT if cell 
collection is successful, and four mutually exclusive health states: progression-free 
survival (remission and durable remission – lymphomas only), further treatment 
after progression, palliative treatment/observation and death. A one-year Markov 
cycle length was used with half-cycle correction. Baseline cohort characteristics, 
disease progression and utility estimates were obtained from systematic literature 
review and questionnaire study among Polish clinical practitioners. The analysis 
was conducted from the Polish public payer, patients, and societal perspective, over 
a lifetime horizon. Discount rates were 5% (costs) and 3.5% (outcomes). Results: 
The mean QALY gain were 7,378 (PXF) and 6,452 (SM). The mean costs were 188,404 
PLN (€ 45,019) (PXF) and 157,073 PLN (€ 37,532) (SM). Base-case incremental cost-util-
ity ratio (ICUR) in NHL/HL/MM population was 33,821 PLN/QALY (€ 8,082). Probability 
of PXF being cost-effective in Poland when compared to SM is 99,8% (current thresh-
old of 105,801 PLN/QALY (€ 25,281)). cOnclusiOns: Based on accepted cost/QALY 
threshold values in the Polish settings, PXF was proved to be cost-effective option 
for NHL/HL/MM patients with poor response to SM regimens.
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COST-UTILITy ANALySIS (CUA) OF BELIMUMAB (BEL) IN THE TREATMENT OF 
ADULT PATIENTS wITH ACTIvE, AUTOANTIBODy-POSITIvE SySTEMIC LUPUS 
ERyTHEMATOSUS (SLE)
Walczak J.1, Kopel J.1, Sołtys E.1, Dziurda D.2
1Arcana Institute, Cracow, Poland, 2GSK, Warszawa, Poland
Objectives: To estimate the cost-utility of BEL treatment of patients with SLE as an 
add-on therapy to intensive standard of care (SOC) vs. SOC in Poland. MethOds: 
The general population considered in the analysis were patients with SLE with sig-
nificant disease activity, who met criteria of SLE diagnosis and were ineffectively 
treated with SOC. CUA was performed from the public payer perspective. The lifetime 
horizon was assumed. The decision model was developed in MS Excel and adjusted to 
Polish conditions. The calculations were performed using Monte Carlo microsimula-
tion. The model included data from international clinical studies and Polish data on 
costs and resource utilization. Direct medical costs were included: costs of drugs, 
administration, diagnostic, monitoring and costs related to disease activity. Results were 
calculated for two patients populations: target population 1 (TP1) - patients with 
positive anti-dsDNA, low complement and ≥ 10 scores in SELENA-SLEDAI scale and 
target population 2 (TP2) - patients with positive anti-dsDNA, low complement, ≥ 6 
scores in SELENA-SLEDAI scale and necessity of corticosteroids use. Results: CUA 
results showed that BEL compared to SOC is more costly however, also more effective 
therapy. The ICUR was 113,986 PLN/QALY and 108,744 PLN/QALY, respectively for TP1 
and TP2. Obtained results are placed slightly above the Polish acceptability threshold. 
Additional health effects related to BEL treatment instead of SOC were noticed both 
in LYG and QALY (0.432 and 0.4 LYG; 0.322 and 0.294 QALY, respectively for TP1 and 
TP2). Moreover, the model suggests lower frequency of cardiovascular events, and also 
pulmonary and renal complications in BEL arm. cOnclusiOns: Since there is cur-
rently no effective treatment option of SLE in Poland, reimbursement of belimumab 
will give patients an access to a safe and effective therapy, which allows them to 
return to active life and career and also to improve their quality of life.
PSy44
COST-UTILITy ANALySIS OF DEFERASIROx FOR THE TREATMENT OF IRON 
OvERLOAD DUE TO FREQUENT BLOOD TRANSFUSIONS IN THE CHILDREN AND 
ADOLESCENTS
Walczak J.1, Sołtys E.1, Obrzut G.1, Laczewski T.2
1Arcana Institute, Cracow, Poland, 2Novartis Poland Sp. z o.o., Warsaw, Poland
Objectives: To estimate the cost-utility of deferasirox (DSX) treatment of iron over-
load due to frequent blood transfusions in children and adolescents in Polish condi-
tions. MethOds: Clinical effectiveness data were taken from previously performed 
systematic review of deferasirox for the treatment of pediatric patients (age ≤ 18 
years) with iron overload due to frequent blood transfusions. The way of administra-
tion of chelation therapy (parenteral vs. oral) significantly affects patients’ function-
ality and quality of life. Therefore it was decided to perform a cost-utility analysis. 
Analogous to other economic studies, it was assumed that patient survival was the 
same for both compared interventions: deferasirox and deferoxamine (DFO). In the 
analysis a simple decision model was developed. The calculations were performed 
using Monte Carlo microsimulation technique (100,000 trials). Only direct medical 
costs were included in the analysis: costs of drugs and their administration, costs 
of monitoring and costs of blood transfusions. The time horizon of the analysis was 
one-year period. Two perspectives were considered: a public payer (National Health 
Fund, NHF) and the patient and NHF perspective. The measure of effects was QALY 
(quality adjusted life years). Results: The results showed that DSX compared to 
current standard treatment of iron overload due to frequent blood transfusions 
(DFO) in the children and adolescents is more costly however also more effective 
therapy from both considered perspectives. The ICUR (incremental cost-utility ratio) 
of replacing DFO by DSX was 26,180 PN/QALY from NHF perspective. The results from 
both patient and NHF perspective was similar. cOnclusiOns: With reference to 
the acceptability threshold in Poland the oral chelation therapy in the population 
of children and adolescents with iron overload due to frequent blood transfusions 
with deferasirox is cost effective intervention when compared with deferoxamine.
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with rituximab iv preparation and administration, per treatment cycle, was about 89 
minutes versus 16 minutes estimated for sc. An average overall cost reduction of 93% 
was estimated with sc versus iv (3€ versus 45€ , respectively). DCU chair time capacity 
could be increased by 3 and 7 fold if one considers combination or maintenance 
therapy, respectively, with rituximab sc versus iv, due to SC much faster administra-
tion. Rituximab sc reduces the overall time patients spend in an infusion chair by 
95% (7 min with sc vs.143 min with iv). cOnclusiOns: Rituximab sc formulation 
potentially offers significant resource (material and HCP time) savings, improves 
hospital organization and provides clear benefits for patients regarding time saved 
and administration convenience. Ultimately, rituximab sc increases hospital effi-
ciency that’s critical in the current economic climate.
SySTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes &  
Patient Preference Studies
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THE ASSOCIATION BETwEEN SEvERITy OF ‘AvERAGE’ PAIN (NPRS) AND THE 
EQ-5D INDEx IN PATIENTS wITH NEUROPATHIC PAIN
Chambers C.1, Odeyemi I.2, Currie C.3, Poole C.D.3
1Astellas Pharma Europe Ltd., Staines, UK, 2Astellas Pharma Europe Ltd., Staines, UK, 3Cardiff 
University, Cardiff, Wales, UK
Objectives: Pain is an important driver of health-related utility. Our purpose was to 
characterise the association between pain severity and the EQ-5D index. MethOds: 
Paired values for the Numerical Pain Rating Scale (NPRS) average pain score (previ-
ous 24 hours) and the EQ-5D index were available from a prospective, non-inter-
ventional study of people with neuropathic pain treated with an 8% capsaicin patch 
(QutenzaTM). The NPRS records pain on an integer scale between 0 and 10 units, 
representing no pain and worst imaginable pain, respectively. The EQ-5D index 
is derived from impairment level (none/moderate/severe) across five domains 
(Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), and 
values health-related utility on a scale of 1 to 0, meaning perfect health and death, 
respectively. Generalized linear mixed models with a normal probability distribu-
tion, identity link function, and a first-order autoregressive covariance structure 
were tested to determine the relationship between EQ-5D index score (scale) and 
NPRS average 24 hour pain score (ordinal). Results: For the purposes of this pre-
liminary analysis, 170 patients with NP contributed 353 combined observations from 
baseline observation and follow-up assessments at week-8 and week-12. The GLMM 
model that best fitted the data (smallest Information criterion) had one random 
effect (subject + intercept) and one fixed effect (NPRS + intercept). The fixed-effects 
coefficients were: (Intercept) 0.728 + (NPRS1: β 0.000; 95%CI -0.0186, 0.186) + (NPRS2: 
-0.045;-0.205,0.116) + (NPRS3: -0.075;-0.227,0.078) + (NPRS4: -0.207;-0.364,-0.049) + 
(NPRS5: -0.181;-0.338,-0.024) + (NPRS6: -0.315;-0.471,-0.159) + (NPRS7: -0.323;-0.478,-
0.167) + (NPRS8: -0.458;-0.618,-0.299) + (NPRS9: -0.638;-0.825,-0.451) + (NPRS10: -0.740; 
-0.927,-0.553). Predicted utility was highly correlated (R2= 0.753) with observed util-
ity. Mean squared error for predicted utility was 0.033 (sd 0.052). cOnclusiOns: 
Neuropathic pain was highly correlated with utility with a difference of around 
0.8 utility units across the NPRS range. All domains of the EQ-5D differed across 
the NPRS.
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MEASURING PROS THAT MATTER TO BARIATRIC AND BODy CONTOURING 
SURGERy: THE BODy-Q
Pusic A.1, Cano S.2, Scott A.1, Tsangaris E.3, Klassen A3
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 2ScaleReport, Stotfold, United 
Kingdom, 3McMaster University, Hamilton, ON, Canada
Objectives: Health care payers are interested in funding bariatric surgery because 
it resolves a range of obesity-related health problems. However, following weight 
loss, many patients are left with unsightly excesses of skin and require body-con-
touring surgery. Our team has developed a new PRO instrument (i.e., the BODY-Q) 
to measure satisfaction and quality of life of bariatric and body-contouring surgery 
patients. Unlike existing PRO instruments, the BODY-Q is composed of scales that 
measure appearance-related concerns, which is an important reason why patients 
seek treatment. The BODY-Q also stands apart as it the only PRO instrument designed 
to measure change in patients concerns throughout the entire weight loss jour-
ney. MethOds: We followed international guidelines for the development of a PRO 
instrument. This abstract presents Phase I results, i.e., qualitative phase. Patient 
stories were used to develop a conceptual framework covering the key concerns of 
patients, and to develop a set of preliminary items. Items were grouped into clinically 
meaningful scales and instructions and four-point response options were developed. 
The scales were refined by obtaining feedback from a sample of surgical experts and 
patients. Results: From 59 patient interviews, we developed a conceptual frame-
work. Over 3,500 preliminary items were developed and used to inform the following 
17 independently functioning scales: 1) appearance scales measuring the body, abdo-
men, upper arms, buttocks, inner thighs, hip and outer thighs, skin and scars; 2) qual-
ity of life scales measuring body image, sexual, psychological and social wellbeing, 
physical function and symptoms; and 3) process of care scales measuring satisfaction 
with information, doctor and office staff. cOnclusiOns: Phase II involves a multi-
centered field-test in Canada and the USA. Rasch Measurement Theory analysis will 
be used to determine which items to retain in each scale based on their performance 
against a standard set of psychometric criteria.
PSy53
THE USE OF PREFERENCE BASED MEASURES IN HAEMOPHILIA: IS THE CURRENT 
EvIDENCE BASE USEFUL FOR EvIDENCE BASED DECISION MAKING?
Tolley K.1, Miners A.2, Brazier J.3, Pericleous L.M.4, Sharma T.4, Petersen J.4, Lonergan T.5
1Tolley Health Economics, Buxton, UK, 2London School of Hygiene and Tropical Medicine, London, 
UK, 3University of Sheffield, Sheffield, South Yorkshire, UK, 4Novo Nordisk A/S, Soborg, Denmark, 
5Tolley Health Economics, Derbyshire, UK
its ethical and social values, supplies plasma at a lower or comparable cost than 
commercially available.
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INDIRECT COSTS OF SySTEMIC LUPUS ERyTHEMATOSUS-RELATED 
ABSENTEEISM IN POLAND: AN ANALySIS BASED ON SOCIAL INSURANCE 
INSTITUTION DATA
Golicki D.1, Karczewicz E.2, Zalewska H.2, Dziurda D.3, Gryglewicz J.3, Gierczynski J.3
1Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, 
Poland, 2Department of Statistics and Actuarial Forecasts, Social Insurance Institution (ZUS), 
Warsaw, Poland, 3Institute of Health Care Organizations, Lazarski University, Warsaw, Poland
Objectives: To estimate indirect costs of systemic lupus erythematosus (SLE) in 
Poland, based on absenteeism in the workplace data derived from Department of 
Statistics of the Social Insurance Institution (ZUS). MethOds: Available insurance 
information consisted of data on: (1) sick leaves, (2) short-term inability to work - on 
the basis of decisions authorizing rehabilitation services (3) long-term inability to 
work – on the basis of medical certificates awarded because of incapacity for work. 
To calculate indirect costs we used three parallel alterations of the human capital 
approach (HCA) method - based on: the average monthly gross earnings, Gross 
Domestic Product (GDP) per capita or gross value added per 1 employee (adjusted 
by a factor of marginal productivity of labor). Results: In 2010, in patients with SLE 
in Poland, sick leaves, short-term and long-term inability to work were responsible 
for: 1897, 596 and 27 012 months of absenteeism, in 1600, 112 and 2481 persons, 
respectively. The total number of 2459 years of lost productivity corresponded to 
indirect costs of: 100,421,579 PLN, 97,215,041 PLN or 161,743,804 PLN, based on 
average earnings, GDP per capita or adjusted gross value added per employee, 
respectively. cOnclusiOns: Two of the three approaches, in addition - the most 
frequently mentioned in the literature, indicated the indirect costs of systemic lupus 
erythematosus in Poland at around 100 million PLN per year. Our estimates of indi-
rect costs may be undervalued because it did not include the cost of lost productivity 
due to premature mortality in the course of SLE, and the costs associated with a 
reduction in the efficiency of the work done despite of the disease (preseenteism).
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CHARACTERIzING DISEASE BURDEN IN AN ULTRA-RARE DISEASE IN 
THE UNITED STATES: TRANSTHyRETIN (TTR) AMyLOIDOSIS PATIENTS & 
CAREGIvERS
Stewart M.1, Loftus J.2, Lenderking W.R.3, Murphy B.R.3, Alvir J.4, Roberts L.5, Shaffer S.5, 
Cicchetti M.J.6, Gleeson S.5
1Pfizer, Inc, Groton, CT, USA, 2Pfizer Ltd., Tadworth, UK, 3Evidera, Lexington, MA, USA, 4Pfizer, 
Inc., New York, NY, USA, 5Evidera, Bethesda, MD, USA, 6Pfizer, Inc., Groton, CT, USA
Objectives: TTR amyloidosis, a progressive, degenerative ultra-rare genetic disease, 
can cause familial amyloid polyneuropathy (TTR-FAP) and cardiomyopathy (TTR-CM), 
requiring substantial caregiver support. This study evaluated the burden of illness 
on patients’ and caregivers’ work productivity, health care resource use (HCRU), and 
health-related quality of life (HRQoL). MethOds: An online survey including the 
Work Productivity & Activity Impairment (WPAI) questionnaire, EQ-5D, & HCRU ques-
tions recruited TTR-FAP and TTR-CM patients and caregivers through two U.S.-based 
patient advocacy groups. Results: Thirty-three TTR patients (26 males) and 18 car-
egivers (7 males) completed the survey. Most were aged over 60; mean disease dura-
tion was approximately 6 years (patients) or 5 years (caregivers with disease). Most 
patients and caregivers had a college degree. Generally caregivers (77.8%) were the 
primary caregiver for their patient; 61.1% also had amyloidosis. Unemployment was 
high in patients with TTR-FAP (42.9%), TTR-CM (60.0%), both TTR-FAP/CM (71.4%); only 
33.3% of caregivers reported working part/full-time. Employment was highest for TTR-
FAP patients (n= 10), yet 11.8% missed work, 32.2% were impaired at work and 38.5% 
reported overall work impairment due to TTR. Liver transplant, the primary treatment 
option, occurred in 42.4% patients and 18.2% caregivers with disease. A majority of 
patients reported outpatient visits to health care providers in the past 3 months for 
disease: 85.7% TTR-FAP, 100% TTR-CM, and 85.7% for TTR-FAP/CM. Hospitalization 
rates ranged from 14.3-30.0% across all patient groups, with 14.3-23.8% for emer-
gency visits. EQ-5D Index scores for patients were 0.80 (SD= 0.14) with transplant, 
and 0.68 (SD= 0.16) without transplant. Caregivers with disease and transplant had 
lower EQ-5D Index scores (M= 0.14, SD= 0.35) than those without transplant (M= 0.41, 
SD= 0.32). The pattern was similar for EQ-5D VAS results for patient and caregiver 
groups. cOnclusiOns: TTR amyloidosis is associated with substantial disruption 
in employment rates, work productivity, high levels of resource use, and poor HRQoL 
for patients and caregivers.
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RESOURCE CONSUMPTION EvALUATION ASSOCIATED wITH RITUxIMAB 
ADMINISTRATION IN PORTUGAL
Pereira C.1, Santos A.2
1Roche Farmacêutica Química, Lda., Amadora, Portugal, 2Prime Focus Health, Paço de Arcos, 
Portugal
Objectives: Determine the costs associated with rituximab intravenous (iv) prepa-
ration and administration in follicular non-Hodgkin lymphoma (NHL) and estimate 
the difference versus rituximab subcutaneous (sc) formulation, considering material 
resources (MR) consumption and health care professionals (HCP) time spent in each 
procedure. Patient’s and chair time savings in hospital Day Care Unit (DCU) were 
also estimated. MethOds: Rituximab iv data was collected, between November 
2012 and January 2013, through face to face interviews with pharmacists and DCU 
nurses responsible for the preparation and administration in each hospital. The HCP 
time cost was calculated by multiplying their income per hour by the average time 
spent on each procedure; MR costs were determined based in official databases or 
in “table values” provided by the manufacturers. Rituximab sc administration time 
was based in the respective pivotal clinical trial - SABRINA (BO22334). Results: 
Ten hospitals from mainland Portugal were included, with a weekly average of 7 
NHL patients treated with rituximab iv. The HCP average overall active time spent 
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A SySTEMATIC REvIEw ON THE EFFECT OF BEHAvIORAL vERSUS SURGICAL 
INTERvENTION ON OBESE PATIENTS’ PSyCHOLOGICAL wELL-BEING
Fortier K.J., Kiss N.
Oxford Outcomes, Morristown, NJ, USA
Objectives: Approximately 400 million people worldwide are considered obese as 
defined by the World Health Organization. In Europe, 15.5% of adults have a body 
mass index of ≥ 30 kg/m2. Diabetes, heart disease, and stroke, are among the most 
common obesity-related comorbidities. Furthermore, obesity has also been found 
to cause depression and emotional distress, negatively affecting the quality of life 
of obese patients. With obesity at the forefront of many social and health care dia-
logues, treatment guidelines currently suggest exercise (often linked with changes 
in diet) or weight loss surgery to effectively treat obesity. This review seeks to under-
stand which of these two types of interventions, exercise or surgical, have a greater 
impact on obese patients’ emotional and psychological well-being. MethOds: A 
systematic review of peer-reviewed literature was conducted to identify RCTs and 
observational studies that measure any type of emotional or psychological change 
in patients who underwent either of the interventions of interest for weight loss: 
exercise or weight loss surgery. Embase and Medline databases were searched for 
articles published from 2004 to 2013. Search terms were used to identify studies 
that assessed psychological well-being of obese patients who either exercised or 
underwent weight loss surgery. Results: The search identified 40 studies, of which 
11 measured relevant interventions and measures of psychological well-being. Of 
those, 9 investigated patients undergoing bariatric surgery, while only 2 explored 
exercise interventions. All of the studies indicated improvements in patients’ emo-
tional health, except for 1 bariatric surgery study, where patients were shown to 
have no change in symptoms after weight loss plateaued. cOnclusiOns: While 
both interventions, when they lead to weight loss, seem to result in improvements 
in patients’ psychological well-being, there is limited data to conclude whether one 
intervention is more effective in improving psychological well-being. Further study 
is needed, especially for exercise interventions.
PSy57
OBESITy TRENDS 2006-2012 IN THE UNITED STATES: RESULTS FROM THE 
NATIONAL HEALTH AND wELLNESS SURvEy
Pomerantz D.1, Wang Z.2, Annunziata K.3, Gupta S.1, Martinez-Triggs C.1
1Kantar Health, Princeton, NJ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA, 3Kantar Health, New 
York, NY, USA
Objectives: According to the Centers for Disease Control and Prevention, there 
were dramatic increases in the obesity rates in the US since 1980s which reached 
a plateau after 20031. The objectives of this study were to examine obesity trends 
across US adults from 2006-2012 by various gender/age groups and changes in 
activity impairment. MethOds: Results were from the US National Health and 
Wellness Survey, a nationally representative, online survey. Respondents were age 
≥ 18 years, and results were weighted/projected to reflect the gender, age, and race/
ethnic proportions, as determined by the Current Population Survey (US Census 
Bureau). This analysis focused on adults age ≥ 20 by BMI Class 1 (BMI> = 30 & < 35 
kg/m2), Class 2 (BMI> = 35 & < 40 kg/m2), and Class 3 (BMI> = 40 kg/m2). Activity 
impairment was assessed from the Work Productivity and Activity Impairment 
Questionnaire. Results: The proportions of adults age 20+ with Class 1, Class 2 
and Class 3 obesity levels have slowly declined from 2006 to 2012 (Class 1: 19.3% in 
2006 to 18.4% in 2012; Class 2: 9.2% in 2006 to 8.2% in 2012; Class 3: 7.3% in 2006 to 
6.7% in 2012). This is consistent across most age/gender subgroups, except in the 
group of men age 60+, which showed increases of Class 2 (7.5% to 8.2%) and Class 
3 obesity (3.7% to 4.6%); Activity impairment declined along with the decline of 
obesity prevalence (men and women), though women reported greater impairment 
than men in the corresponding BMI Class. cOnclusiOns: The data suggested a 
slight decline in obesity prevalence and improvement in activity function in the US 
population recently. However, obesity remains a pandemic with tremendous health 
and economic burden and calls for continuous effort in education, prevention and 
management. References 1 Centers for Disease Control and Prevention. Referenced 
June 11, 2013. http://www.cdc.gov/obesity/data/facts.html
PSy58
THE IMPACT OF INCREASING PAIN SEvERITy ON IMPAIRMENT OF REGULAR 
DAILy ACTIvITIES
Poole C.D.1, Chambers C.2, Odeyemi I.3, Currie C.1
1Cardiff University, Cardiff, Wales, UK, 2Astellas Pharma Europe Ltd., Staines, UK, 3Astellas 
Pharma Europe Ltd., Staines, UK
Objectives: To evaluate to what extent pain severity was associated with impair-
ment of regular daily activities other than paid work. MethOds: Study data 
originated from a prospective, non-interventional study of people with NP treated 
with the capsaicin patch QUTENZATM. Repeated observations from baseline- and 
12-week follow-up assessments for the Numerical Pain Rating Scale (NPRS) ‘aver-
age pain in the last 24 hours’ score, and the Activity Impairment (AI) score from 
the Work Productivity Activity Index (WPAI-NP) were analysed. The NPRS sub-
jectively records pain on a scale between 0 (no pain ) and 10 (worst imaginable 
pain). The WPAI-NP Activity Impairment Index measured the extent to which NP 
affected regular daily activities from 0% (no effect) to 100% (complete prevention). 
Generalized linear mixed models (GLMM; SPSS v20), with a normal probability 
distribution, identity link function, and a first-order autoregressive covariance 
structure were tested to determine the relationship between WPAI-NP-AI (scale) 
and NPRS (ordinal). Results: A total of 171 patients with NP contributed 253 com-
bined observations from baseline and week 12 follow-up assessment. Mean age 
at baseline was 59.4 years (sd 14.9) and 44% of subjects were male. The GLMM 
model that best fitted the data (smallest information criterion) had one random 
effect (subject+intercept) and two fixed effects (Sex+NPRS+intercept). The signifi-
cant (p< 0.05) fixed-effects coefficients were: (Intercept) 14.2+(Male: β -7.0; 95%CI 
-13.5,-0.5)+(NPRS3: 24.4;9.0,39.8)+(NPRS4:9.4;13.5,45.3)+(NPRS5:36.5;21.2,51.8)+(NP
Objectives: To identify and evaluate the published evidence base on the use of 
preference based measures for assessing haemophilia related outcomes, and to 
discuss their limitations and gaps for evidence based decision making. MethOds: A 
systematic review was carried out for 25 year time period 1988 to 2013 to investigate 
preference based evaluations of treatments and/or outcomes related to haemo-
philia. The search terms included:utility, QALY, standard gamble, time-trade-off, 
contingent valuation, conjoint analysis, and discrete choice. Results: The search 
identified 22 original peer reviewed articles, covering a range of countries and treat-
ments. There were 7 cost-utility analyses, and 7 studies reporting use of the EQ 5D 
to determine utility values for haemophilia health states. Two studies, both from 
Canada, were vignette type studies that directly assessed utilities for treatment 
related health states. The EQ 5D studies produced reasonably consistent utilities, 
whereas the vignette studies produced variable results. Six studies were conjoint 
analysis and/or willingness to pay studies and focused on the value of attributes of 
new treatments. As is typical of studies in rare diseases, there were limitations in 
all studies related mainly to small sample sizes, uncontrolled designs and poten-
tially confounding factors. The main evidence gaps were a lack of preference/util-
ity data for caregivers, or the direct impact of bleeding on utilities, and only one 
study used a generic measure other than the EQ 5D (the SF-6D) to generate utilities 
for haemophilia health states. cOnclusiOns: Given that haemophilia is a rare 
condition, there is a reasonably large evidence base of preference based studies 
for potential use in evidence based decision making. However, the limitations and 
gaps in the studies identified mean that there are still limitations in the evidence 
base to support a comprehensive assessment of the value of new interventions 
for haemophilia.
PSy54
PATIENTS AT THE CENTER OF REGULATORy DECISIONS: USING STATED-
PREFERENCE DATA TO HELP REGULATORS ANSwER DIFFICULT QUESTIONS
González J.M.1, Johnson F.R.1, Fairchild A.1, Irony T.2, Ho M.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2US Food and Drug Administration, Silver 
Spring, MD, USA
Objectives: In collaboration with FDA’s Center for Devices and Radiological 
Health (CDRH), we developed and administered a best-practice discrete-choice 
experiment (DCE) survey to elicit preferences for outcomes associated with using 
weight-loss devices to demonstrate how DCE data can help determine meaningful 
benefits for regulatory decisions involving serious side-effect risks. MethOds: An 
online DCE questionnaire was administered to adult residents of the United States 
who reported having or having had a body mass index (BMI) of at least 30 kg/m2. 
Respondents evaluated constructed hypothetical weight-loss devices with different 
features identified with the help of clinicians at CDRH. Weight-loss devices were 
defined in terms of device effectiveness, device-related risks of side effects, sur-
gery requirements for implantation, and diet restrictions. An efficient experimental 
design ensured that device profiles provided the necessary statistical information to 
identify the choice-model parameters. Random-parameter choice models produced 
preference weights indicating the strength of preference for device features. These 
weights were used to calculate the maximum acceptable risk of dying or minimum 
required weight loss associated with various device profiles. Results: A total of 
540 respondents completed the online survey. Results from the study show that 
respondents had well-defined, plausible preferences for different outcomes associ-
ated with weight-loss devices. Internal validity tests, including a scope test of sensi-
tivity to absolute risk levels, indicated the data are of high quality. Preference results 
were used to construct an Excel-based tool that calculates the necessary benefits to 
offset the device-related risks with confidence intervals for any device that can be 
described by features included in the study design. cOnclusiOns: Results confirm 
the feasibility of using DCE methods to evaluate patients’ tolerance for weight-loss 
device risks, as well as the feasibility of constructing a policy-relevant decision aid 
that makes this information accessible to regulators.
PSy55
HEALTH RELATED QUALITy OF LIFE By LINE OF THERAPy IN IMATINIB-
RESISTANT OR IMATINIB-INTOLERANT PATIENTS wITH CHRONIC MyELOID 
LEUKEMIA TREATED wITH BOSUTINIB MEASURED By EQ-5D
Whiteley J.1, Reisman A.1, Shapiro M.2
1Pfizer Inc, New York, NY, USA, 2Pfizer Inc, Cambridge, MA, USA
Objectives: Bosutinib a dual Src/Abl tyrosine kinase inhibitor (TKI) demonstrated 
efficacy in a phase 1/2 study of patients with relapsed/refractory Chronic Myeloid 
Leukemia (CML). Health utilities were reported in the imatinib IRIS study, but there 
is limited information from relapsed/refractory CML patients. The objective was to 
evaluate the effect of bosutinib on health utilities in patients with CML after failure 
with imatinib. MethOds: Evaluation of patient HRQoL was an exploratory objective 
in the clinical trial measured using the EQ-5D, which consists of 5-items: mobil-
ity, self-care, usual activities, pain/discomfort and anxiety/depression. Each item 
ranges from 1 (“no problems”) to 3 (“extreme problems”). The EQ-5D was completed 
at weeks 4, 8, 12 and every 12 weeks thereafter, as well as treatment completion 
and scored according to the UK tariff. Results: Of the N= 570 patients included 
in the trial, 288 were second line chronic phase (CP 2L) CML, 118 were third line 
CP patients (3L), 76 were accelerated phase (AP) and 64 blast phase (BP). For 2L 
patients, the mean utility score at baseline was 0.83 (SD 0.21), and was maintained 
throughout the course of the study demonstrating a significant improvement at 
week 36 (mean change from baseline 0.04, p= 0.01). For 3L patients, the mean utility 
at baseline was 0.80 (SD 0.22), and maintained throughout the study. There were no 
statistically significant differences from baseline through week 36 in health util-
ity in 3L patients. The mean utility at baseline for advanced patients was 0.78 (SD 
0.28) for AP and 0.66 (SD 0.30) for BP patients and was maintained throughout the 
study. cOnclusiOns: These data suggest that relapsed/refractory CML patients 
treated with bosutinib maintain their quality of life throughout the trial regardless 
of the line of treatment or phase of disease. These results highlight the value of 
capturing patient HRQoL in CML treatment.
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were used to compare outcomes across satisfaction groups. Results: Only 64 (4.08%) 
were satisfied with their treatment, and 1504 (95.92%) not satisfied. A positive relation-
ship was observed between satisfaction and HRQoL, with the most satisfied group 
recording a 31.62% higher EQ-5D score (mean 0.75 vs. 0.57, p< 0.01) relative to the next 
most-satisfied group. A negative relationship was observed between satisfaction and 
pain, with the most satisfied patient group scoring 30.89% lower pain scores (mean 
3.40 vs. 4.91, p< 0.01). cOnclusiOns: Most neuropathic pain patients are not satis-
fied with their current pain therapy. This analysis suggests a negative relationship 
between treatment satisfaction and reported pain severity as well as a clear positive 
relationship between treatment satisfaction and health related quality of life. The 
results highlight the need for a more targeted treatment of neuropathic pain patients.
PSy62
PROFILE OF BACK PAIN SUFFERERS ACROSS 5EU COUNTRIES
Annunziata K.1, Isherwood G.2, Sternbach N.1
1Kantar Health, New York, NY, USA, 2Kantar Health, Epsom, Surrey, UK
Objectives: According to the Pain in Europe Study, about one in five EU adults 
have chronic pain. Back pain / lower back pain is among the most commonly cited 
location of pain.1 Additionally, research has suggested that pain has a negative 
impact on sufferer mental health, employment, sleep and personal relationships.2 
This analysis profiles and compares adults experiencing back pain to adults with-
out pain across 5EU. MethOds: Results were taken from the 2011 5EU National 
Health and Wellness Survey, a nationally representative, self-administered survey. 
Respondents were adults age 18 and over from France, Germany, Italy, Spain and 
UK. This analysis focuses on adults diagnosed with back pain or experienced pain 
as a result of back problem in the past month- (“patients with back pain”). Quality 
of life was measured using the SF12v2 scale. Activity impairment was measured 
using the Work Productivity and Activity Impairment scale. Results: Out of the 
total sample of n= 57,512, ~10% (n= 5,984) have back pain. Relative to adults without 
pain, back pain sufferers are older on average (48.9 vs. 46.3), more likely to be women 
(57% vs. 48%), and obese (27% vs. 16%). Their overall mental and physical quality of 
life scores are significantly lower (43.2 vs. 47.9, p < 0.001 and 40.3 vs. 50.9, p < 0.001). 
In addition, back pain sufferers are exhibited more work impairment (absenteeism 
and presenteeism) and activity impairment, and utilized health care resources to a 
greater extent than non-sufferers (i.e., greater physician visits, hospitalization, and 
ER). All these results are notably higher among back pain patients treated with a pre-
scription. cOnclusiOns: Considering the prevalence of back pain among adults, 
the level of work impairment and quality of life limitations impacts a substantial 
portion of adults in the 5EU population. Improvements in treatment of back pain 
are needed to reduce this burden.
PSy63
EvALUATING wILLINGNESS-TO-PAy THRESHOLD FOR SUGAMMADEx 
REvERSAL OF ROCURONIUM-INDUCED NEUROMUSCULAR BLOCKADE: A 
CONTINGENT vALUATION SURvEy
Song H.J.1, Han E.2, Kang S.H.3, Lee E.K.4
1SungKyunKwan University, Suwon, South Korea, 2Gachon University, Incheon, South Korea, 
3MSD, Seoul, South Korea, 4Sungkyunkwan University, Suwon, South Korea
Objectives: Reversal of the residual effect of rocuronium or vecuronium by neostig-
mine may be slow and associated with side-effects. Sugammadex, a selective relaxant 
binding agent, encapsulates rocuronium to provide for a rapid reversal of residual 
neuromuscular blockade. Also, postoperative residual neuromuscular block can 
reduce delay of awakening, recovery, and dissatisfaction of patient. The aim of this 
study is to evaluate the willingness-to-pay (WTP) of sugammadex for effectiveness 
and safety using a contingent valuation method. MethOds: A total of 505 adult 
general population and 60 experts (anesthesiologist and surgeon) participated in 
a face-to-face survey. The respondents were surveyed separately each scenario of 
moderate and deep blocks for surgery. The scenario was designed to provide informa-
tion concerning reversal time on neuromuscular block, adverse reaction of PRNB, and 
quality of surgery or recovery. The out-of-pocket WTP for sugammadex was utilized 
open answer. Results: In general population, WTP values for sugammadex were 
81,768 Korean won (KRW) in moderate block and 128,622 KRW in deep block. The same 
sample answered 89,017 KRW and 141,536 KRW for WTP for their family members 
in moderate block and deep block, respectively. Experts were estimated the WTP of 
99,417 KRW in moderate block and 153,250 KRW in deep block. For patients, experts 
suggested that 82,517 KRW and 132,517 KRW were appropriate WTP. The WTP was sta-
tistically significantly higher in the general population who had been taken operation 
and older than their counterparts. cOnclusiOns: The WTP for sugammadex was 
ranged the 81,768 to 99,417 KRW in moderate block, and the 128,622 to 153,250 KRW 
in deep block. The WTP of general population for their family members was higher 
than the WTP for their own, and the expert’s WTP was higher than their patients.
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LIKELIHOOD OF USE AND PERCEPTION TOwARDS BIOSIMILARS IN 
RHEUMATOID ARTHRITIS ARENA: SURvEy OF RHEUMATOLOGISTS IN 
EUROPEAN UNION, BRAzIL, jAPAN AND CHINA
Narayanan S.1, Liu L.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Pfizer Inc. and Weill Medical College of Cornell 
University, New York, NY, USA
Objectives: To assess rheumatologist perception towards biosimilars and the 
likelihood of use of biosimilars to manage RA patients in the EU, Brazil, Japan and 
China. MethOds: A multi-country cross-sectional survey was conducted in top-5 
EU countries (UK/Germany/Spain/France/Italy), Brazil, Japan and China in April/
May 2013 using an online physician panel in the respective geographies; rheu-
matologists were randomly selected for survey participation to be geographically 
representative in select countries/regions. Surveys assessed the rheumatologist 
perceptions of biosimilars in terms of factors that would prevent them from using 
RS6:43.7;28.5,60.0)+(NPRS7: 46.3;31.1,61.5)+(NPRS8: 58.5;42.6,74.4)+(NPRS9:2.0;44.2,
79.8)+(NPRS10:72.2;54.7,89.7). The estimated marginal mean WPAI-NP-AI increased 
linearly from 10.1% at NPRS 0 to 84.8% at NPRS 10. Predicted WPAI-NP-AI was highly 
correlated with observed values (R-squared= 0.889); mean absolute error (predicted-
observed) was 9.6 (sd 6.9). cOnclusiOns: In people with chronic NP, increasing 
pain severity was associated with a linear increase in impairment of regular daily 
activities other than paid work. Interventions that reduce pain are likely to improve 
functioning.
PSy59
HEALTH-RELATED QUALITy OF LIFE IN BRAzILIAN OBESE PATIENTS 
SUBMITTED TO BARIATRIC SURGERy: A SySTEMATIC LITERATURE REvIEw
Vasconcellos J.F, Fernandes R.A., Takemoto M., Amaral L.M., Silva M.A., Haas L.C., Menezes L.P.
ANOVA, Rio de Janeiro, Brazil
Objectives: Bariatric surgery is the best long-term treatment for morbid obesity 
with clinical improves, like reductions in blood pressure, glucose and lipids levels. 
However postoperative complications and psychosocial issues may impact qual-
ity of life (QoL). This study aims to assess health-related quality of life (HRQoL) in 
Brazilian obese patients submitted to bariatric surgery. MethOds: A systematic 
review was conducted by April 2013 through Cochrane Collaboration, Medline, 
EMBASE, and Lilacs databases. Studies that described QoL in Brazilian obese 
patients were included in this review. Bariatric Analysis and Reporting Outcome 
System (BAROS), Moorehead-Ardelt quality of life questionnaire II (M-A-QoLQII), 
Abbreviated WHOQoL questionnaire and Short Form-6D (SF-6D) were used to evalu-
ate the behavior of patients who underwent bariatric surgery in relation to QoL 
domains. Results: Seven studies met eligibility criteria. In all studies, individuals 
presented body mass index (BMI) ≥ 40kg/m2 or ≥ 35 kg/m2 associated with comor-
bidities. Patients reported their self-esteem (SE), physical activity (PA), social rela-
tions (SR), disposition to work (DW) and sexual activity (SA), after bariatric surgery. 
According to the M-A-QoLQII, three studies showed HRQoL improvement in 28.9%, 
39.5%, 28.4%, 30% and 25.6% of patients for SE, PA, SR, DW and SA, respectively. 
And 68.9%, 50.6%, 53.1%, 52.2%, 45.6% of patients guaranteed greatly improved 
regarding those parameters, respectively. After weight loss, bariatric surgery was 
effective to improve QoL in PA domain. Besides, when compared to patients submit-
ted to medical treatment, patients who underwent surgical procedure presented 
an improvement of 93% in HRQoL, contrasting with 65.4% of the medical cohort 
(p< 0.001). Only one study measured QoL before and after bariatric surgery: SF-36 
domains and M-A-QoLQII showed that post-surgery results were invariably better 
than pre-surgery ones (p< 0.001 for all domains). cOnclusiOns: The present review 
demonstrated the potential QoL improvements in Brazilian patients after bariatric 
surgery, in addition to clinical benefits.
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STUDy OF QUALITy OF LIFE AND COSTS FOR CML PATIENTS IN BULGARIA
Kamusheva M.1, Vulchanova T.2, Georgieva S.S.3, Chervenkova N.4, Krusteva I.5,  
Camurjieva A.6, Stoimenova A.1, Petrova G.1
1Medical University, Faculty of Pharmacy, Sofia, Bulgaria, 2University chematology hospitals, 
Hospital pharmacy, Sofia, Bulgaria, 3Aleksandrovska Hospital, Sofia, Bulgaria, 4University 
hospitals Plovdiv, Hospital pharmacy, Plovdiv, Bulgaria, 5University hospitals Pleven, Hospital 
pharmacy, Pleven, Bulgaria, 6Military University Hospital, Hospital pharmacy, Sofia, Bulgaria
Objectives: To analyze the cost of therapy for patients with chronic myeloid 
leukemia (CML) and their quality of life. MethOds: It is retrospective as regard 
to cost and prospective as regard to quality of life analysis. Five university hospi-
tals in four major cities treating all 320 CML-patients are included for the period 
2011-2012. Information is collected from the patients’ records about the health 
care resources used as medicines for CML, additional therapy, hospitalizations 
and physicians visits. The assessment of health related quality of life is con-
ducted with validated for the country SF-36 questionnaire. Results: A total of 
164 (51.2%) men and 156 (48.75%) women, average age 53.96±15.41 were observed. 
The average CML pharmacotherapy monthly cost is 5976.4 BGN, the average total 
pharmacotherapy cost for additional diseases is 566.27 BGN and the average addi-
tional costs for physicians’ visits and hospitalization is equal to 1504.69 BGN. The 
most expensive CML therapy is with Dasatinib 7771.20 BGN and the cheapest is 
Imatinib therapy equal to 5245.15 BGN. The most common additional diseases are 
cardiovascular (68%), followed by endocrine (29%). There is significant correlation 
between overall assessment for quality of life and average total additional costs 
– the higher assessment for QoL, the lower costs for hospitalization and visits. 
With the significantly highest score is the scale Bodily pain, followed by Physical 
functioning, and the lowest are Vitality, energy or fatigue and Role limitation. In 
most of patients on Imatinib (77.9%) are recorded good hematological responses 
and 66.7% are with major molecular response. cOnclusiOns: CML is a disease 
consuming significant health care resources especially for major pharmacother-
apy with TKIs. Infrequent physicians’ visits and rarer hospitalizations generate 
higher assessment of quality of life.
PSy61
TREATMENT SATISFACTION AND ITS ASSOCIATION wITH HEALTH OUTCOMES 
IN PATIENTS wITH NEUROPATHIC PAIN
Holbrook T.1, Obradovic M.2, Liedgens H.2
1ADELPHI REAL WORLD, MACCLESFIELD, UK, 2Grünenthal GmbH, Aachen, Germany
Objectives: Neuropathic pain (NP) is a chronic progressive disease which is hard 
to control. This analysis investigates patients’ satisfaction with pain therapy and its 
relationship with pain severity and health related quality of life (HRQoL). MethOds: 
Data were drawn from the 2012 Adelphi NP Disease Specific Programme, a cross-
sectional study involving 413 primary care physicians and specialists across Europe. 
Physicians provided detailed records for 3956 NP patients, of which 1568 patients 
voluntarily completed EQ-5D and Brief Pain Inventory questionnaires. HRQoL was 
measured via the EQ-5D, satisfaction via a three-option question answered by the 
patient, and pain via the Brief Pain Inventory (BPI) interference score. Boxplot analyses 
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vARIATIONS IN TREATMENT PATTERNS AND DISEASE SEvERITy AMONG 
PATIENTS wITH PSORIASIS RECEIvING THEIR FIRST BIOLOGIC IN EUROPEAN 
UNION
Narayanan S.1, Franceschetti A.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess the treatment patterns and current disease severity of 
patients with PsO receiving their first biologic in 5EU, namely, UK, Germany (DE), 
France (FR), Italy (IT) and Spain (SP). MethOds: A multi-country multi-center 
medical chart-review study of PsO patients was conducted among dermatologists 
in hospitals/private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians were screened 
for practice-duration (3-30 yrs) and patient-volume (incl.> 2PsO biologic patients/
month) and recruited from a large panel to be geographically representative in 
each country. Physicians abstracted charts of next five consecutive biologic patients 
within each center/practice. Physicians abstracted patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease severity. Results from patients 
on first biologic treatment were analyzed. Results: In 4Q2012, 225 physicians 
abstracted 924 eligible PsO patient charts; 690 (75%) were on their first biologic 
(mean-age:46.9yrs, female:36%). Geographic distribution-UK:18%, DE:21%, FR:19%, 
IT:21%, SP:21%. Time-to-1st biologic from diagnosis (months)/time-on-current bio-
logic (months) varied- UK:140/17, DE:119/10, FR:138/15, IT:103/18, SP:127/17. Top-4 
first-line biologic treatments observed were etanercept, adalimumab, infliximab 
and ustekinumab. Treatment experience prior to first biologic varied dramati-
cally (not mutually exclusive): Immunomodulators-UK:92%,DE:51%,FR:68%,IT:73
%,SP:76%; phototherapy-UK:55%,DE:71%,FR:59%,IT:32%,SP:37%; topicals-UK:41%
,DE:69%,FR:46%,IT:43%,SP:39%; retinoids-UK:29%,DE:30%,FR:34%,IT:42%,SP:40%; 
fumerates-UK:13%,DE:69%,FR:0%,IT:1%,SP:0%; corticosteroids-UK:2%,DE:32%,
FR:10%,IT:14%,SP:10%; Average # of flares in the past yr were: UK-1.0,DE-1.3,FR-
1.1,IT-1.0,SP-1.6. Mean current PASI scores were: UK-8,DE-20,FR-12,IT-18,SP-11. 
Current disease severity per physician judgment was (remission/mild/moder-
ate/severe): UK-45%/25%/20%/10%, DE-26%/19%/21%/35%, FR-42%/34%/15%/9%, 
IT-39%/19%/31%/11%, SP-44%/29%/26%/2%. Mean number of treatments prior to 
first biologic varied by current disease severity (remission/mild/moderate/severe): 
UK-2.7/3.1/2.6/3.1, DE-3.0/3.7/2.7/4.1, FR-2.2/2.6/2.2/2.4, IT-2.2/2.2/2.3/2.1, SP:2.4/2.
2/2.3/2.3. cOnclusiOns: Among PsO patients receiving their first biologic, treat-
ment patterns and disease severity varied across 5EU, with patients in Germany 
disproportionately experiencing higher disease burden. Factors influencing the 
observed variations in care and optimal therapeutic approaches (including treat-
ment sequencing) aligned with clinical guidelines to decrease patient disease bur-
den warrants scrutiny.
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PHARMACOTHERAPy COSTS OF MULTIPLE MyELOMA IN THE CzECH REPUBLIC: 
A RETROSPECTIvE ANALySIS
Baloghova K.1, Fuksa L.2
1Masaryk University, Brno, Czech Republic, 2General Health Insurance Company of the Czech 
Republic, Praha, Czech Republic
Objectives: In the Czech Republic there are three modern molecules available for 
the treatment of multiple myeloma: bortezomib, thalidomide and lenalidomide. 
In order to better understand this evolving specific market, analysis of consump-
tion trends has been conducted with emphasis on the molecules’ mutual influ-
ence. MethOds: Time-consumption curves of bortezomib, lenalidomide and 
thalidomide since 2009, based on the economic data of the General Health Insurance 
Company of the Czech Republic, were analyzed. While there was reimbursement for 
thalidomide in the first line treatment and bortezomib in the second line in 2009, 
we focused on and evaluated the impact of the launch of lenalidomide in 2009 (as 
a second line treatment). We also investigated the extension of reimbursement of 
bortezomib for the use in the first line in 2010. Results: The introduction of lena-
lidomide (2009) led to a rapid decline in thalidomide consumption within the next 
year, in contrast to bortezomib, the consumption of which appeared unaffected. 
Furthermore, also the consumption of thalidomide decreased profoundly following 
the extension of reimbursement conditions of bortezomib (2010). The overall relative 
reduction in thalidomide consumption observed within the two years between 2009 
and 2011 was 70%. cOnclusiOns: The presented retrospective analysis shows that 
the impact of myeloma treatment on payers’ financial budgets has increased nearly 
3-times in the last four years. The extension of reimbursement of bortezomib had a 
clear impact on the consumption of thalidomide, which was its supposed compara-
tor in the first line therapy. However, it appears that even though the introduction 
of lenalidomide did also significantly affect the consumption of thalidomid, it had 
no apparent impact on the use of bortezomib.
PSy70
APPETITE SUPPRESSANTS: A DRUG UTILISATION STUDy
Truter I.
Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
Objectives: To determine the prescribing and cost of appetite suppressants in a 
defined private sector patient population, as well as the prescribing of other medi-
cines to the patient sample. MethOds: A retrospective drug utilisation study was 
conducted on a medical insurance claims database in South Africa for 2010 and 
2011. No clinical information was available in the database. Results: In 2010, 37 
patients (86.49% females) were prescribed 44 appetite suppressants at a total cost 
of R9813.39, of which 75.0% were for phentermine. The average age of patients 
was 40.95 (SD= 12.37) years. In 2011, 27 patients (77.78% females) received 42 pre-
scriptions for appetite suppressants at a total cost of R9967.73. The average age of 
patients was 40.04 years (SD= 10.41) (females: 37.95 (SD= 7.76) years; males 47.33 
(SD= 10.52) years). Most products (80.95%) were for phentermine, followed by d-norp-
seudoephedrine (14.29%) and diethylpropion (4.76). Prescribing patterns in 2010 
and 2011 were similar. Appetite suppressants are strictly regulated in South Africa. 
biosimilars among their biologic-eligible RA patients, and their likelihood of use of 
biosimilars. Descriptive statistics are reported. Results: A total of 173 rheuma-
tologists participated in the survey. Years of experience practicing rheumatology 
was: < = 1yr:0%, 2-5yrs:6%, 6-10yrs:17%, 11-20yrs:42%, > 20yrs:32%. Geographic dis-
tribution of rheumatologists was: 5EU-58%, Brazil-23%, Japan-11% and China-9%. 
Mean RA patient-volume/year was 291 (5EU-329, Brazil-259, Japan-232 and China-
189). Overall, 47% of rheumatologists reported that they would prescribe a biosimi-
lar to their eligible RA patients “definitely or highly likely” (5EU:58%, Brazil:21%, 
Japan:47%, China:47%); 51% of rheumatologists reported that they would try using 
biosimilars for 1-2 yrs among a small group of patients in their practice before 
starting to use it in a majority of biologic-eligible RA patients in their practice 
(5EU:60%, Brazil:33%, Japan:42%, China:47%). The top-5 factors that would prevent 
them from using biosimilars were diverse across the countries (Overall/5EU/Brazil/
Japan/China): Doubts in similarity to original molecule 60%/63%/67%/47%/33%), 
inadequate safety/efficacy profile/data (53%/51%/51%/58%/60%), lack of long-term 
data (46%/51%/41%/32%/40%), lack of national guidelines recommending the use 
of biosimilars (37%/39%/31%/32%/47%) and lack of data from local country/market 
(31%/23%/41%/42%/47%). cOnclusiOns: Across markets, over half of the rheu-
matologists expressed concerns/reservations towards prescribing biosimilars to 
their eligible RA patients. While payer organizations look to biosimilars to contain 
costs and make medicines more affordable to RA patients in need, potential bar-
riers to biosimilar adoption may exist.
PSy65
BARRIERS TO BIOLOGIC THERAPy USE FOR AUTOIMMUNE DISORDERS IN 
EMERGING MARKETS
Gross H.J.1, Vietri J.2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, Milan, Italy
Objectives: Biologic therapy is increasingly used to treat autoimmune dis-
orders in developed markets, but usage is still low in emerging markets. This 
analysis was conducted to identify factors associated with current use of bio-
logic medication among patients with autoimmune disorders in emerging mar-
kets. MethOds: Data were from the Brazil, China, and Russia National Health 
and Wellness Surveys, cross-sectional surveys representative of the total adult 
population (Brazil) or urban adult population (China and Russia) in each country, 
conducted in 2011 and 2012. Respondents self-reporting physician diagnosis of 
ankylosing spondylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid 
arthritis, or ulcerative colitis and using a prescription medication (Rx) for at least 
one of those conditions were included; patients with missing data for any covari-
ate were excluded. Binomial logistic regression included the following predictors: 
age, sex, country, income, Charlson Comorbidity Index (CCI), body mass index 
(BMI), monthly out of pocket (OOP) costs for Rxs, fear of needles, condition severity, 
length of diagnosis, and type of treating physician. Results: Of 1,507 respondents 
included in the analysis, 300 (19.9%) were using a biologic. Of those, 82.0% (n= 246) 
were in China. Relative to China, patients were less likely to use biologics in Brazil 
(OR 0.21; 95% CI: 0.13, 0.36) and Russia (OR: 0.29, 95% CI: 0.18, 0.46; ps< 0.001). Higher 
CCI was associated with use of biologics (OR: 1.18, 95% CI: 1.10, 1.26; p< 0.001), 
as were higher OOP costs (OR: 2.37, 95% CI: 1.04, 5.42; p< 0.05) compared to no 
OOP costs. Fear of needles was positively associated with biologic use (OR: 1.57, 
95% CI: 1.18, 2.09; p< 0.01). No other covariates were significant. cOnclusiOns: 
Country was by the strongest predictor of biologic use in patients with autoim-
mune conditions in emerging markets, but higher costs and more comorbidities 
were associated with biologic use across emerging markets.
PSy66
DISEASE STATUS, TREATMENTS AND OUTCOMES OF PATIENTS wITH 
ANKyLOSING SPONDyLITIS RECEIvING THEIR FIRST BIOLOGIC IN THE UNITED 
STATES AND EUROPEAN UNION
Narayanan S.1, Baskett A.2, Lu Y.2, Hutchings R.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To compare the disease status, treatments and outcomes of patients 
with AS receiving their first biologic in UK, Germany, France, Italy and Spain (5EU) 
with the US. MethOds: A multi-country multi-center medical chart-review study 
of AS patients was conducted between October-December 2012 among physicians 
(rheumatologists: 5EU: 97%, US: 99%) in hospitals and private practices to collect 
de-identified data on AS patients who were recently treated with a biologic as 
part of usual care. Physicians were screened for duration of practice and patient 
volume and recruited from a large panel to be geographically representative in 
each country. Eligible AS patient charts (> 2) were randomly selected from a sample 
of prospective patients visiting each center/practice during the screening period. 
Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient 
symptomatology/disease status/outcomes. Results: Seven hundred and ninety 
seven eligible AS patient charts (5EU:613, US: 184) were abstracted; 701 (5EU:549, 
US: 152) patients were on their first biologic (mean-age: 5EU:42.5yrs/US:42.4yrs; 
female: 5EU:16.2%/US:17.1%). Time-to-1st biologic from diagnosis (5EU:55.3months/
US:46.8months) and time-on-current biologic (5EU:31.7months/US:44.3months) 
differed between regions. Top-2 biologic treatments observed were – adalimumab 
(5EU:43%/US:35%) and etanercept (5EU:30%/US:41%). Among the top-3 reasons for 
biologic treatment initiation, ‘mechanism of action’ & ‘improve signs/symptoms’ 
were observed in both 5EU and US, whereas ‘positive personal experience’ (5EU) and 
‘prevention of structural damage’ (US) were also observed. Key lab measures docu-
mented were: ESR (5EU:17.4mm/h, US:20.9mm/h) and CRP (5EU:8.8mg/dl, US:2.7mg/
dl). Current disease severity per physician-judgment (mild:moderate:severe) was: 
5EU-63%:32%:6%, US-62%:34%:5%. Among patients with available data, current HAQ 
(5EU:1.3, US:0.8), BASDAI (5EU:2.9, US:3.4), VAS provider score (5EU:2.9, US:2.5), VAS 
patient score (5EU:3.0, US:2.7), Swollen Joint Count (5EU:1.3, US:0.5), and Tender Joint 
Count (5EU:2.0, US:0.9) differed across regions. cOnclusiOns: Among AS patients 
receiving their first biologic, disease severity differed between 5EU and US, with 
patients in 5EU with relatively higher burden and poorer outcomes.
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National Health System. The objective of this research is to analyze the differ-
ences in adoption of BS among the different Spanish Autonomous Communities 
(Regions). MethOds: Ecologic design. A retrospective analysis of the Spanish 
2011 Health System Survey was conducted to estimate the prevalence of adult 
PWI for BS in each Region. The results were therefore extrapolated to the total 
regional adult population reported by the National Institute of Statistics for 2011. 
The total number of bariatric surgeries by Regions during 2011were retrieved 
from the database of the National Health Ministry (ICD-9-CM: 44.31, 44.39, 44.38, 
44.95 and 44.69) Results: Variation in the annual provision of BS was large, rang-
ing from 0.81% of patients with indication for Murcia, to 0.11% in Navarra. For 
the rest of Regions, the percentage of PWI operated in 2011 was: Madrid= 0.62%; 
Castilla y León= 0.60%; Aragón= 0.35%; Cataluña= 0.33%; Pais Vasco= 0.32%; Com. 
Valenciana= 0.30%; Cantabria= 0.30%; Canarias= 0.30%; Extremadura= 0.23%; 
Galicia= 0.22%; Asturias= 0.19%; Andalucía= 0.18%; Castilla La Mancha= 0.15%; 
Baleares= 0.14% and La Rioja= 0.13%. cOnclusiOns: These results raise the 
hypothesis that living in a certain Region may strongly affect the probability of 
a PWI receiving BS. In such case, this variability should be tackled, particularly 
in a country where most patients are supposed to have access to this treatment 
without any copayment. Further research with more accurate estimations and 
multilevel analysis models would be desirable to confirm these results.
PSy74
PIvOTAL STUDIES OF ORPHAN MEDICINAL PRODUCTS – AN ANALySIS OF 
QUALITy OF CLINICAL EvIDENCE
Picavet E.1, Cassiman D.2, Hollak C.E.M.3, Maertens J.2, Simoens S.1
1KU Leuven, Leuven, Belgium, 2University Hospital Leuven, Leuven, Belgium, 3University of 
Amsterdam, Amsterdam, The Netherlands
Objectives: Recent debate on the long-term effectiveness of some orphan medic-
inal products (OMPs) led us to question whether the initial standards for clinical 
evidence for OMPs, set by EMA at the time of marketing authorization, are too low. 
Therefore, the aim of this study was to quantitatively evaluate the characteristics 
and quality of clinical evidence that is presented for OMPs to obtain marketing 
authorization in Europe. MethOds: We quantitatively assessed the characteris-
tics and quality of clinical evidence of the pivotal studies of 64 OMPs as described 
in the European Public Assessment Report and/or the Scientific Discussion docu-
ment prepared by the Committee for Human Medicinal Products of the EMA using 
a new and validated instrument. Results: The 64 OMPs were altogether author-
ized for 78 orphan indications, for which 117 studies were identified as ‘pivotal’ 
or ‘main’ studies. In approximately two thirds of the studies, the allocation was 
randomized (64.8%) and a control arm was used (68.5%). Half of the studies applied 
some type of blinding. Only a minority (26.9%) of the studies included a Quality-
of-Life (QoL) related endpoint, of which a third claim an improvement in QoL. 
Upon analyzing the quality of reporting, we found that some aspects (i.e. the 
endpoints, the sampling criteria, and the interventions) are well described, 
whereas other items (i.e. a description of the patients and of potential biases) 
are not reported for all studies. cOnclusiOns: In conclusion, the pivotal studies 
that are the basis for marketing authorization of OMPs are a cause for concern, 
as they exhibit methodological flaws. Additionally, there are shortcomings in the 
reporting of those studies that complicate the interpretation. A more demanding 
regulatory process for OMPs is needed to guide evidence-based clinical decision-
making.
PSy75
HOw TO DETERMINE SIzE OF PATIENT POPULATION wHEN THE RIGHT DATA 
ISN’T THERE?
Stuchiner A.
PAREXEL, New York, NY, USA
Objectives: As costs of health care continue to rise, payers need to quantify the 
potential patient population for a new treatment. In the case of a novel treatment 
for intractable pain that would be for end of life cancer patients, it was necessary 
to consider alternative methods for calculating the potential patient population 
size. This study determined different approaches for identifying patient subpopu-
lations in cancer for ‘end-of-life’ pain therapies MethOds: PAREXEL conducted a 
literature search on the number of cancer pain patients with intractable pain. Data 
was found on cancer patients with pain but not those at the end of their lives with 
intractable pain. Alternative measures were considered, and cancer mortality data 
was identified as a surrogate for end of life cancer patients. The WHO’s guidelines 
on cancer pain estimate that 10 to 25% of cancer pain patients have intractable 
pain. Based on such surrogate measures, we were able to determine an estimated 
number of cancer patients with intractable pain at the end of their lives. Results: 
Prior to this study, the target patient population was estimated to be 156,000 in 
the US and an equivalent number in Germany, UK, Spain and France. However, 
based on the surrogate measures, the results were much lower: 30,000 in the US 
and 31,000 in the 4 EU countries. These numbers were validated by interviewing 22 
pain clinicians in the US and EU and 23 payers in the US and EU. cOnclusiOns: 
By providing payers with accurate estimates of potential patient populations they 
will be better able to determine the cost implications of covering novel treatments. 
Given that the care provided to patients at the end of their lives is usually signifi-
cantly higher than at any other time, treatments for end of life care have economic 
implications for payers.
PSy76
COST-MINIMIzATION OF MABTHERA INTRAvENOUS vERSUS SUBCUTANEOUS 
ADMINISTRATION
Bax P., Postma M.J.
University of Groningen, Groningen, The Netherlands
Objectives: To identify and compare all costs related to preparing and administrat-
ing MabThera for the intravenous and subcutaneous formulations in Dutch hema-
tological patients. The a priori notion is that the costs of subcutaneous MabThera 
In 2011, a total of 630 products (all therapeutic classes) were prescribed. The most 
often other prescribed classes in 2011 were gastrointestinal tract products (14.60%), 
cardiovascular agents (11.11%) and antimicrobial products (9.52%). The most fre-
quently prescribed subclasses were HMG-CoA reductase inhibitors (statins), anal-
gesic combinations, non-selective COX-inhibitors and selective serotonin re-uptake 
inhibitors. The total amount claimed from the medical insurance scheme for all the 
products was R73013.71, however, only R37553.24 was paid out. Appetite suppres-
sants were excluded from patients’ medical insurance benefits. cOnclusiOns: A 
limited number of strictly regulated appetite suppressants were prescribed. Appetite 
suppressants that patients can buy over-the-counter were not included in this study. 
Pseudoephedrine has recently been rescheduled to be more strictly controlled due 
to its abuse potential. Further consumer studies on appetite suppressants which 
include clinical information will provide a useful insight into the role of these prod-
ucts in weight loss efforts.
PSy71
ANALySIS OF THE REIMBURSED PSORIASIS MARKET IN HUNGARy BETwEEN 
2007 AND 2011
Ecseki A., Nagy Z.B., Becsi R., Gerencsér Z., Rozsa P., Toth I.
MediConcept Ltd., Budapest, Hungary
Objectives: Psoriasis is a chronic skin disease of scaling and inflammation, typi-
cally characterized by erythematous papules and plaques with a silver scale. In 
Hungary, approximately 150.000 – 200.000 people are affected. We sought to evalu-
ate the available reimbursed psoriasis treatment options, the economic impact 
of the disease, and in general we attempted to see beyond the market trends and 
patients characteristics observed in the analysed dataset. MethOds: Data were 
derived from the nationwide dataset of the Hungarian National Health Insurance 
Fund Administration, the single health care financing agency of Hungary. Data 
were evaluated according to sex, age, geographical region, type of care and specialty 
of the prescribing physician. The analysis covers data of all reimbursed pharma-
ceuticals and other medical services between 1 January 2007 and 31 December 
2011. Results: The median age was between 51 and 55 years. A bimodal age of 
onset has been recognised in several large studies, but in this patient cohort peo-
ple between the ages of 30 and 69 were overrepresented. We found no significant 
deviation between counties, but there is a clear seasonality in the data. During 
each year of the analysed period the number of patients who redeemed at least 
one reimbursed drug fell short compared to the prevalence based estimates. At 
any given time close to 80% of the patients did not receive any reimbursed treat-
ment and the number of sold packages continuously decreased over the 5-year 
period. The introduction of biologic treatments also significantly affected the mar-
ket. cOnclusiOns: To our knowledge, no systematic empirical research exists 
addressing the question of how psoriasis market changed over the time in Hungary. 
The data suggest relatively poor adherence to treatment regimens frequently seen 
and documented in other studies as well.
PSy72
UTILIzATION PATTERNS FOR TREATMENT wITH STRONG OPIOIDS FOR 
CHRONIC BACK PAIN IN GERMANy
Theidel U.1, Mittendorf T.1, Mueller-Schwefe G.H.H.2, Ueberall M.A.3
1Herescon GmbH, Hannover, Germany, 2Deutsche Gesellschaft für Schmerzmedizin e.V., Oberursel, 
Germany, 3Institut für Neurowissenschaften, Algesiologie und Pädiatrie, Nuernberg, Germany
Objectives: Although opioids are a well-accepted and effective method for pain 
management, it is still a challenge for physicians to find adequate treatment 
schemes in non-malignant pain. Inadequate treatment might impact quality of 
life and induce social and psychological problems. Aim of this survey was to describe 
treatment patterns of chronic back pain (CBP) in Germany. MethOds: In a cross-
sectional, non-interventional survey n= 4,283 German physicians were asked to 
report experiences with strong opioids in CBP. Statistical analysis was performed to 
analyze relationships between strong opioids and potential side effects. Results: 
The majority of physicians (54.4%) at least partly accept strong opioid therapy in CBP 
noting treatment benefits in 69.6%. Most prescribed therapies are non-opioids like 
NSAIDs/COX-2 (55.1%) and physiotherapy (47.7%). 22.7% of all CBP receive strong opi-
oids (26.0% fentanyl, 19.9% oxycodone/naloxone, 17.8% oxycodone, 13.9% hydromor-
phone, 13.8% burprenorphine, 13.7% morphine, 7.3% tapentadol, 1.8% L-methadone). 
16.5% are treated in monotherapy, 23.6% with multimodal treatment. 67.5% show 
a reduction in pain intensity ≥ 50%. 25.8% need strong opioids for longer than 12 
months. 26.2% need an increased dosage. Furthermore, 20.2% of patients experience 
a decrease in efficacy, which leads to opioid rotation (15.1%). 23.4% have persistent 
side effects (25.3% never, 46.4% temporary) wherefore 16.1% switch and 15.2% with-
draw the treatment. Most side effects are observed near start of therapy, with con-
stipation being the most common and resistant side effect (49.1%). After treatment 
discontinuation, pain status is considerable worsened in 34.3%. Correlation analysis 
shows that morphine has the highest probability of side effects when compared 
to oxycodone and oxycodone/naloxone. cOnclusiOns: Although physicians see 
the medical need, CBP patients seem not to be overly treated with strong opioids. 
Obviously, morphine is not the treatment of first choice. Treatments chosen strongly 
depend on physician specialty. As anticipated, constipation is the most common 
and resistant side effect.
PSy73
vARIABILITy OF CLINICAL PRACTICE FOR BARIATRIC SURGERy IN SPAIN
Espallardo O., Busutil R.
Johnson & Johnson Medical, Madrid, Spain
Objectives: Geographical variations in medical practice are expected to be small 
when the evidence about a particular technology is abundant. This would be the 
case of bariatric surgery (BS), which has been demonstrated to be an effective 
intervention to promote weight-loss in patients with indications for this pro-
cedure (PWI). Moreover, BS has recently proven to be cost-effective and drive 
long-term savings, compared to a “do-nothing” intervention, for the Spanish 
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review of Medline and EMBASE databases was conducted for the period 2000 - 2013. 
The search sought to identify papers on the topic of assessment and reimburse-
ment policy for rare diseases. Health policy studies, commentaries, and review arti-
cles were included. Clinical or economic studies of specific drugs or diseases were 
excluded. Information was extracted on assessment and reimbursement challenges 
and author recommendations for addressing these issues. Results: The literature 
review identified 726 papers; 49 met the inclusion criteria. The most frequently 
identified issues included multiplicity of orphan indications (34/49), high per-patient 
cost (32/49), and the difficulty in undertaking robust clinical and economic evalu-
ations given limited evidence (32/49). Several authors commented on limitations 
of current health technology appraisal processes. The issue of equity and societal 
preference for funding rare diseases was highlighted in almost half of the papers 
(22/49). Lack of availability of alternative treatments was also considered an impor-
tant factor. Suggestions for improvements to the assessment and reimbursement 
process included: greater use of registries (22/49), adjustment to preference weights 
used in cost effectiveness analysis (19/49) and conditional reimbursement and risk-
sharing-schemes (12/49). Some authors advocated alternative pathways for assess-
ing rare disease treatments including a specific approach utilising multi-criteria 
decision analysis. cOnclusiOns: The debate on payer policy in rare diseases has 
grown in the last 5 years as concerns have increased about patient access to new 
medicines. While there is some consistency in the literature, there is as yet little 
consensus on how policy should be changed to address these issues.
PSy80
A SySTEMATIC REvIEw OF THE EFFECTIvENESS OF TAxES IN PREvENTING 
OBESITy TRENDS
Maniadakis N.1, Kourlaba G.2, Kapaki V.1, Damianidi L.3
1National School of Public Health, Athens, Greece, 2National and Kapodistrian University of 
Athens School of Medicine, Athens, Greece, 3Ludwig Maximilian University (LMU), Munich, 
Germany
Objectives: Obesity prevalence is increasing worldwide, a worrying trend as it 
relates to many diseases and imposes significant direct and indirect health care 
costs. The purpose of the present study was to assess the impact of taxation 
policies upon the consumption of Sugar Sweetened Beverages (SSBs) and High 
in Fat Sugar and Salt (HFSS) foods and ultimately caloric intake and weight out-
comes. MethOds: The review identified relevant papers from web-based searches 
in comprehensive databases such as: Pubmed, Web-of-Science, Cochrane Library, 
Ag Econ, Econlit and National Agricultural library. Searching was conducted 
with all potential combinations of various relevant for the purposes of the study 
financial, nutritional, and outcome terms. Thereafter, abstracts were reviewed and 
studies were selected based on predefined criteria. The search included studies 
published from 1990 up to February of 2013 in English language. The character-
istics and the results of the selected studies were extracted in a special form 
and consequently were reviewed and synthesized, based on the methodological 
design. Results: A total of fifty five studies were finally included in the review. 
Several different types of studies showed a reduction in purchases and consump-
tion of SSBs or HFSS foods when prices increase due or not due to taxation, but 
the subsequent effect upon total caloric intake was much smaller. A few studies 
which report weight outcomes, indicate that they are either insignificant or very 
small in magnitude to cause any public health improvements. cOnclusiOns: 
The effectiveness of taxation policies to curb obesity levels is doubtful and the 
desired objectives not easily attainable, mainly because of the complex nature 
of consumer behavior and the impact of substitution effects, for which there is 
limited evidence to date. There is need to investigate in more depth the potential 
underlying mechanisms and the links between price increase policies, obesity 
and public health outcomes.
PSy81
MANAGED ENTRy AGREEMENTS AND ORPHAN DRUGS: A EUROPEAN 
COMPARATIvE STUDy (2006-2012)
Morel T.1, Arickx F.2, Befrits G.3, Siviero P.D.4, van der Meijden C.M.J.5, Xoxi E.4, Simoens S.1
1KU Leuven, Leuven, Belgium, 2NIHDI, Brussels, Belgium, 3Dental and Pharmaceutical Benefits 
Agency, Stockholm, Sweden, 4Italian Medicines Agency (AIFA), Rome, Italy, 5Health Care Insurance 
Board (CVZ), Diemen, The Netherlands
Objectives: To identify, describe and classify managed entry agreements (MEAs) 
applied to orphan drugs by national payers and to analyse their practice in 
Europe. MethOds: To identify and describe MEAs, national HTA and reimburse-
ment decisions on orphan drugs across seven European countries were reviewed 
and their main characteristics extracted. To fill data gaps and validate the accuracy 
of the extraction, collaboration was sought from national payers. To classify MEAs, a 
bespoke taxonomy was implemented. Identified MEAs were analysed and compared 
by focusing on five key themes, namely by describing the MEAs in relation to: drug 
targets and therapeutic classes, geographical spread, type of MEA applied, declared 
rationale for setting-up of MEAs, and evolution over time. Results: Forty-two MEAs 
for 26 orphan drugs, implemented between 2006 and 2012 and representing a variety 
of MEA designs, were identified. Italy was the country with the highest number of 
schemes (n= 15), followed by The Netherlands (n= 10), England and Wales (n= 8), 
Sweden (n= 5) and Belgium (n= 4). No MEA was identified for France and Germany 
due to data unavailability. Antineoplastic agents were the primary targets of MEAs. 
55% of the identified MEAs were performance-based risk-sharing arrangements; 
the other 45% were financial-based. Nine of these 26 orphan drugs were subject 
to MEAs in two or three different countries, resulting in 24 MEAs. A total of 60% 
of identified MEAs focused on conditions whose prevalence is inferior to 1 per 
10,000. cOnclusiOns: This study confirmed that a variety of MEAs were increas-
ingly used by European payers to manage aspects of uncertainty associated with 
the introduction of orphan drugs in the health care system, and which may be of a 
clinical, utilisation, or budgetary nature. It remains unclear whether differences in 
the use of MEAs reflect differences in how ‘uncertainty’ and ‘value’ are perceived 
across health care systems.
injections are lower compared to intravenous infusion due to potential lower time 
investments, shorter pharmacy preparation time, less patient chair time and less 
spillage. MethOds: We use a prospective, observational, bottom up, micro-costing 
approach aiming at the inclusion of 50 patients with hematological disease. Primary 
cost outcomes comprise the labor costs for nurses and pharmacists/pharmacy 
technicians, materials, hourly daycare costs and drug spillage costs. Exact timings 
are measured using stopwatches, dosing and spillage is measured using registered 
MabThera volumes in the Hospital Pharmacies’ registrations and materials are exactly 
numbered and labeled. List prices are used for materials and MabThera costs, hourly 
nurse and pharmacy time is costed according to salaries, and day-care is costed 
using the Dutch guideline for costing research in health care. Anticipating positive 
outcomes of the currently ongoing non-inferiority study, efficacy of MabThera along 
both administration routes was implicitly assumed similar; additionally parity pricing 
is assumed. Results: Interim results based on 24 patients included so far indicate 
that extra costs of intravenous infusion over subcutaneous injections are on average 
€ 175 per administration. This difference is primarily constituted by € 100 lower daycare 
costs related to shorter chair time for subcutaneous as compared to intravenous 
administration. cOnclusiOns: Our interim cost-minimization analysis suggests 
that subcutaneous injection of MabThera involves lower administration costs than 
intravenous infusion. With similar efficacy assumed, cost savings can be achieved at 
no expense of health, by including subcutaneous MabThera injections in the Dutch 
reimbursement system. Notably, over a full course of administrations (8 cycli) cost 
savings may easily surpass € 1000 per patient per year.
PSy77
IS IT wORTH HAvING ORPHAN DRUG STATUS IN GERMANy POST-AMNOG?
Radicek S., Obradovic M., Rauland M.
GfK Bridgehead, Nuremberg, Germany
Objectives: To review the assessments of benefit for orphan drugs within 
the early benefit assessment process after implementation of AMNOG in 
Germany. MethOds: Secondary research was used in this study. Results: In 
contrast to other pharmaceuticals, by law, the benefit of orphan drugs (ODs) is 
proven by market authorization. No assessment vs. an appropriate comparator as 
defined by G-BA will be conducted, provided the revenue is less than 50 mio. EUR 
based on pharmacy retail prices including VAT over the past twelve months. IQWiG 
only assesses the accuracy of the number of patients and the therapy costs stated in 
the value dossier, while GB-A defines the extent of the benefit based on the Phase 
III data submitted with the abbreviated dossier. Seven ODs have been assessed by 
G-BA since implementation of AMNOG in 2011. Only one OD has received consider-
able benefit status in one patient subgroup, whilst two ODs have been classified 
as not quantifiable, and the other ODs assessed so far have been granted only a 
minor benefit. Prices have been negotiated for only 2 ODs so far: For Pirfenidon, 
with an unquantifiable benefit, a rebate of 11% was applied, while Tafamidis, with 
a minor benefit, received a rebate of 24.5%. cOnclusiOns: There is a clear benefit 
for ODs (with annual sales of less than 50 mio EUR) in terms of reduced administra-
tive burden and costs associated with the abbreviated value dossier submission. 
Furthermore, the OD status and the absence of a comparative added benefit assess-
ment warrant a benefit score, whereas 60% of the non-orphan pharmaceuticals 
failed to prove an additional benefit vs. the defined comparator. As only two orphan 
drugs have completed price negotiations, it is very difficult to estimate, whether 
OD status will have a positive impact on future pricing opportunities after AMNOG.
PSy78
COST-EFFECTIvENESS OF SCHOOL-BASED HEALTH PROMOTION IN CANADA: A 
LIFE-COURSE MODELING APPROACH
Tran B.1, Ohinmaa A.1, Kuhle S.2, Johnson J.A.1, Veugelers P.1
1University of Alberta, Edmonton, AB, Canada, 2Dalhousie University, Halifax, NS, Canada
Objectives: The Alberta Project Promoting active Living and healthy Eating (APPLE) 
Schools has been recognized as a “best practice in preventing childhood obesity. To 
inform decision making on the expansion and resource allocation for such school-
based program like the APPLE Schools, we evaluated its cost-effectiveness and 
return-on-investment following a life-course approach. MethOds: We developed 
a state transition model to represent the life-time progression of weight status of 
three groups of children who were obese, overweight or normal weight at 11 years. 
The model quantified impacts of the intervention in terms of prevented excess 
weight cases, improved quality-adjusted life years (QALY), and avoided health care 
costs. Both costs and QALYs were estimated to their present value using 3% dis-
count rate. Results: The incremental cost-effectiveness ratio (ICER) of the APPLE 
Schools program was CA$ 15,833 per 1 QALY gained, and CA$ 24,359 or 11,047 per 1 
obese or overweight case prevented in adult population. Every 1,000 children inter-
vened; the program costs CA$190,000, and the estimated saving in the health care 
costs is about CA$ 2.3 million, that is equivalent to a benefit-cost ratio of 13:1. The 
sensitivity analyses showed that the incremental cost-effectiveness of the APPLE 
Schools program was robust against variations of program costs and model param-
eters. cOnclusiOns: The APPLE Schools program is a cost-effective intervention 
for obesity prevention, and promises substantial return on investment. Expanding 
the coverage and allocating resources towards school-based programs is central to 
the fight against obesity epidemic in Canada.
PSy79
PAyER ASSESSMENT AND REIMBURSEMENT POLICy FOR RARE DISEASES: A 
REvIEw OF THE LITERATURE
Hutchings A.1, Palaska C.2, Schey C.2, Pericleous L.3, Petersen J.4
1Global Market Access Solutions, London, UK, 2Global Market Access Solutions, St Prex, 
Switzerland, 3Novo Nordisk A/S, Søborg, Denmark, 4Novo Nordisk A/S, Soborg, Denmark
Objectives: To review the published literature to identify: a) the most frequently 
cited challenges relating to payer assessment and reimbursement of rare disease 
treatments (including orphan drugs), and b) to review author recommendations to 
improve the assessment of these treatments. MethOds: A systematic literature 
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in the FACT-P total score of -9.68 (95% CI: [-16.10; -3.27]); pathological bone fractures 
and radiation or surgery to bone determined changes in FACT-P total score of -7.61 
(95% CI: [-16.79; 1.56]) and -6.68 (95% CI: [-10.25; -3.11]), respectively. The standardized 
effect size was moderate (any SRE: -0.32; spinal cord compression: -0.49; pathological 
bone fracture: -0.35; radiation or surgery to bone: -0.30). cOnclusiOns: Consistent 
with previous analyses in metastatic prostate cancer [Weinfurt K.P., et al. Annals of 
Oncology 2005;16: 579–584], our findings demonstrate that SREs lead to significant 
functional declines in patients’ daily lives. Therefore, any therapy reducing or delaying 
the occurrence of SREs should also reduce the effects of SREs on HRQOL.
PCN4
CAN ADMINISTRATIvE DATA PREDICT CHEMOTHERAPy ADvERSE EvENTS?
Pearce A.M., Haas M., Viney R.
University of Technology, Sydney, Ultimo, Australia
Objectives: The rates of adverse events (AEs) are an important component of 
chemotherapy cost effectiveness. However, AE rates in clinical practice are diffi-
cult to obtain. This study aimed to determine whether Australian administrative 
data could identify the incidence of selected chemotherapy AEs. MethOds: The 
Elements of Care study (EoC) was a prospective cohort of individuals in New South 
Wales undergoing chemotherapy for breast, colorectal or lung cancer. Primary 
data, including AEs experienced, was collected through questionnaires and medi-
cal record review. Linked administrative data of prescriptions and medical services 
for each participant were available from the Pharmaceutical Benefits Scheme (PBS) 
and Medicare Benefits Schedule (MBS). This data was used to identify if an indi-
vidual was treated for one of the selected AEs (diarrhoea, vomiting, anaemia and 
neutropenia) in the three days after a chemotherapy dose. These proxy-identified AE 
rates were compared with the self-reported AE rates using 2x2 contingency tables, 
with significance of any differences calculated using odds ratios and chi-square 
statistics. Results: There were 482 individuals in EoC. The proxy identified much 
lower rates of AEs than were self-reported, capturing 30% of self-reported cases 
of nausea and vomiting, 1.3% of self-reported diarrhoea, and less than 1% of self-
reported anaemia and neutropenia. Additional analyses did not identify a pattern 
in the grade of AEs or type of treatment received that the proxy was more likely 
to identify. cOnclusiOns: Overall there was poor concordance between the two 
measures of AE rates. This may be due to low treatment rates for AEs, poor capturing 
of AE treatments by the proxy, or over-reporting of adverse event by participants. 
Regardless, it would appear that administrative data such as the MBS and PBS are 
not suitable for estimating the incidence of AEs in clinical practice, and bottom up 
data collection techniques such as EoC are essential.
PCN5
EvALUATION OF THE BURDEN OF ILLNESS OF SKIN CANCER AMONG vETERAN 
PATIENTS UNITED STATES
Wang L.1, Dysinger A.H.2, Xie L.2, Du J.2, Huang A.1, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA
Objectives: To evaluate the burden of skin cancer among U.S. veteran 
patients. MethOds: Patients diagnosed with skin cancer were identified (International 
Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis code 
232.xx) using the Veterans Health Administration (VHA) Medical SAS datasets from 
October 1, 2009 to September 30, 2011. The first diagnosis date was defined as the index 
date. A comparison group of patients without skin cancer of the same age, region, gen-
der and index year were identified and matched on baseline Charlson Comorbidity 
Index with a randomly chosen index date to minimize selection bias. Patients in both 
groups were required to be at least 18 years old and have 1 year continuous health plan 
enrollment pre- and post-index date. Follow-up health care costs and utilizations were 
compared between the two groups after using 1:1 propensity score matching adjust-
ing baseline characteristics. Results: A total of 12,504 patients were identified for the 
skin cancer and comparison cohorts. After 1:1 propensity score matching, each group 
included 4,400 patients with well-balanced baseline demographic and clinical charac-
teristics. Patients diagnosed with skin cancer had higher percentages of inpatient (5.75% 
vs. 2.64%, p< 0.01), emergency room (11.89% vs. 6.50%, p< 0.01), physician office (99.95% 
vs. 66.70%, p< 0.01), outpatient (99.95% vs. 67.41%, p< 0.01), and pharmacy visits (91.89% 
vs. 71.30%, p< 0.01). Patients in the skin cancer cohort also incurred higher expenditures 
in inpatient ($1,494 vs. $555, p< 0.01), emergency room ($108 vs. $60, p< 0.01), physician 
office ($4,486 vs. $1,480, p< 0.01), outpatient ($4,780 vs. $1,639) and pharmacy visits ($707 
vs. $429, p< 0.01) than patients in the comparison group. cOnclusiOns: Study results 
suggest that cancer patients diagnosed with skin cancer incurred significantly higher 
costs and health care resources compared to patients without.
PCN6
EvALUATION OF THE BURDEN OF ILLNESS OF COLORECTAL CANCER AMONG 
vETERAN PATIENTS IN THE UNITED STATES
Wang L.1, Xie L.2, Li L.1, Wang Y.2, Kariburyo M.F.2, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA
Objectives: To examine the economic burden and health care utilizations of 
colorectal cancer patients in the U.S. veteran population. MethOds: A retrospec-
tive database analysis was performed using the Veterans Health Administration 
Medical SAS datasets (01OCT2008-30SEP2012). Patients (≥ 18 years of age) diagnosed 
with colorectal cancer (International Classification of Disease 9th Revision Clinical 
Modification ICD-9-CM codes 153.xx, 154.xx) were identified. The first diagnosis 
date was designated as the index date. A comparator group was created by cat-
egorizing patients without colorectal cancer but of the same age, region, gender 
and index year, and matching them by baseline Charlson Comorbidity Index. The 
index date for the comparison group was selected randomly to minimize selection 
bias. Continuous medical and pharmacy benefits for 1 year pre- and 1 year post-
index date were required. One-to-one propensity score matching (PSM) was used to 
compare the health care costs and utilizations during the follow-up period between 
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A LITERATURE REvIEw ON THE HUMANISTIC AND ECONOMIC BURDEN OF 
MINERALOCORTICOID ExCESS SyNDROME
Langham S.1, Ralston S.1, Webb I.J.2, Lin H.M.2
1PHMR Associates, London, UK, 2Millennium: The Takeda Oncology Company, Cambridge, MA, 
USA
Objectives: Notable side effects of abiraterone for advanced prostate cancer are 
oedema, hypertension, and hypokalemia, constituting a mineralocorticoid excess 
syndrome (MES). Although abiraterone is co-administered with prednisone to 
minimise MES symptoms, they remain a burden requiring concomitant therapies 
to manage each toxicity and/or treatment with costly mineralocorticoid receptor 
antagonists. A literature review was conducted to assess the impact of MES symp-
toms on health-related quality of life (HRQoL) and health care costs in patients 
across a number of disease areas. MethOds: Outside prostate cancer, MES is a 
broad syndrome which is best characterised as bilateral primary aldosteronism 
(PA). Electronic databases were searched for data on the economic and humanistic 
burden of MES (or its symptoms in combination) and/or PA. Results: Even though 
no studies were identified in a specific prostate cancer population, nine studies 
found humanistic burden and three of the economic burden related to MES (PA) in 
the literature. Patients with MES (PA) had significantly impaired HRQoL (measured 
by SF36 and SF12) compared with the general population, especially on physical 
domains, general health perceptions, and vitality. Patients also exhibited greater 
levels of anxiety, depression and somatization. Use of mineralocorticoid receptor 
antagonists was associated with reduced HRQoL. Despite sparse direct economic 
data on MES, hypertension and oedema were associated with increased health 
care resources and costs. Chronic oedema was additionally associated with hospi-
talisation and lost productivity. cOnclusiOns: MES symptoms can significantly 
impair HRQoL and may increase resource use. The impact of these symptoms in an 
advanced prostate cancer population is likely to be exacerbated, as many of these 
elderly patients already have serious co-morbidities. Further research is required 
to determine the incidence and severity of MES in patients receiving abiraterone in 
actual clinical practice and the impact these symptoms have on health care resource 
use and the well-being of patients with prostate cancer.
PCN2
BISPHOSPHONATES-ASSOCIATED OSTEONECROSIS OF jAw IN CANCER 
PATIENTS: A META-ANALySIS
Lin H.C.1, Lin S.J.1, Chan A.L2
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2Min-Sheng General Hospital, Taoyuan, 
Taiwan
Objectives: This meta-analysis aims to assess the incidence of osteonecrosis of 
the jaw(ONJ)associated with bisphosphonates in cancer patients. MethOds: The 
published literature was systematically searched and reviewed using MEDLINE and 
the Cochrane Central Register of Controlled Trials on 30 April 2013. Any randomized 
controlled trial assessing the role of bisphosphonates in cancer patients and clearly 
mentioned the event of ONJ were eligible for inclusion. Studies that included spe-
cific risk estimates were pooled using a random-effects model. The quality of these 
studies were assessed with RevMan statistical software (version 5.0). Results: 
Eight of 21 randomized controlled clinical trials were included. Thirteen studies 
were excluded due to no cases of osteonecrosis of jaw were reported. A total of 
13,399 patients were collected in eight studies, 6686 patients were assigned to bis-
phosphonates group and 6713 were assigned to control group. Twenty-eight cases 
(28/6686,0.42%) of ONJ were reported in bisphosphonates group. No patient was 
reported in control group. Risk ratio was used to estimate the risk of osteonecrosis 
of the jaw associated with bisphosphonate. Pooled results showed very lower risk 
of ONJ associated with bisphosphonates 5.61 (95% CI: 1.90, 16.52). No heterogeneity 
was found in our study. cOnclusiOns: Although the risk ratio of ONJ associated 
with the use of bisphosphonates is low in our study, we still need to suggest physi-
cians to make a particular concern on using bisphosphonates in cancer patients. We 
suggest that a large and well design of risk of ONJ as primary endpoint, prospective 
multi-center studies should be conducted in the future.
PCN3
SKELETAL-RELATED EvENTS HAvE A SIGNIFICANT IMPACT ON HEALTH-
RELATED QUALITy OF LIFE IN MEN wITH METASTATIC CASTRATION 
RESISTANT PROSTATE CANCER (MCRPC) FOLLOwING DOCETAxEL THERAPy 
FAILURE
Ivanescu C.1, Phung D.2, Holmstrom S.2
1Quintiles, Hoofddorp, The Netherlands, 2Astellas Pharma Global Development, Leiden, The 
Netherlands
Objectives: Patients with mCRPC are at risk of experiencing skeletal-related events 
(SREs), defined as pathologic fracture, spinal cord compression, and the need for radio-
therapy or surgery to bone. We examined the immediate impact of an SRE on patients’ 
HRQoL. MethOds: Data were obtained from the AFFIRM study, a phase 3 trial of 
enzalutamide vs. placebo in patients with mCRPC. Only patients experiencing any type 
of SRE were included in the analysis (n= 284). For patients with multiple SREs, only the 
first event was used. HRQoL was assessed at baseline and at fixed intervals throughout 
the study until treatment discontinuation using the FACT-P (Functional Assessment of 
Cancer Therapy–Prostate) instrument. We used linear mixed-effects models to model 
each patient’s longitudinal trajectory of FACT-P outcomes before the first SRE and to 
estimate how far the post-SRE value of HRQoL deviated from that trajectory. Results: 
SREs were associated with a deterioration of HRQoL with an adjusted mean change of 
-6.93 (95% CI: [-9.92; -3.95]) of the FACT-P total score for any SRE. The largest impact was 
observed in subjects with spinal cord compression, which induced a mean decrease 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A393
Objectives: Women of childbearing age with a diagnosis of breast cancer often 
want to conceive a child after treatment. Some reports found that pregnancy does 
not increase the risk of cancer recurrence after successful treatment. These reports 
and positive changes in the survival rates of breast cancer patients can impact the 
decisions of patients and physicians. The goal of this study was to estimate the 
number of women who survived breast cancer and subsequently became preg-
nant and to determine the time between the cancer diagnosis and pregnancy in 
the time periods between 2000-2002 and 2010-2012, respectively. MethOds: This 
retrospective study analysed longitudinal routine care data collected by gynaecolo-
gists in Germany (IMS® Disease Analyzer). Data from women aged 20-45 with a 
pregnancy within 10 years after the first breast cancer diagnosis from 102 gynae-
cological practices in Germany (Disease Analyzer database; 01/1992 to 12/2012) 
were analysed. Results: In the time period 2000-2002, 65 (projected to national 
level: 4615) women became pregnant after a breast cancer diagnosis; this number 
increased to 114 (projected to national level: 8094) between 2010-2012. The mean 
age did not significantly change between 2000-2002 and 2010-2012 (33.8 (SD: 6.0) 
and 34.2 years (SD: 6.1)). The time between the first breast cancer diagnosis and 
pregnancy identification was 896 days (SD: 690) in 2000-2012 and 552 days (SD: 
696) in 2010-2012 (p< 0.01). cOnclusiOns: This retrospective analysis showed 
that the number of pregnancies following breast cancer diagnosis has signifi-
cantly increased in the last 10 years. More over, the time to pregnancy has become 
significantly shorter. This is indicative of the positive and hopeful developments 
for young women affected by breast cancer. Further studies on this important 
research topic are necessary.
PCN10
EvALUATION OF vARIABLE RELEvANCE AND ACCESSIBILITy TO SUPPORT 
PERSONALIzED MEDICINE IN BREAST CANCER
Udomaksorn S.1, Stenehjem D.2, Welch B.1, Cheng Y.1, Anderson L.2, Colonna S.2,  
Neumayer L.2, Brixner D.1
1University of Utah, Salt Lake City, UT, USA, 2University of Utah/University of Utah Hospitals & 
Clinics, Salt Lake City, UT, USA
Objectives: About 1 in 8 U.S. women will develop invasive breast cancer during 
their lifetime. Response to treatment varies among women depending on several 
factors. This work identified and prioritized the essential variables to imple-
ment personalized cancer treatment, and determined the feasibility of obtaining 
these variables from available data sources toward a real time clinical decision 
aid. MethOds: A focus group of 10 breast cancer clinicians was conducted to deter-
mine possible variables for inclusion into the clinical dashboard. An electronic 3-cat-
egorical scale (must have, would like to have, unnecessary) survey was conducted 
among a broader group of breast cancer clinicians. Variables were classified by 
category and mention frequency (Mode). The accessibility of these variables from 
two separate cancer care databases was evaluated by data querying, text search and 
electronic chart review and categorized as available, difficult to access, or unavail-
able. Results: Ten clinicians identified 67 possible variables for inclusion into the 
dashboard. According to the broader electronic survey 25 clinicians determined 
39 “must have” variables with 9 patient specific variables (e.g. age at diagnosis, 
comorbidities, hormone replacement use, cancer history); 13 tumor specific vari-
ables (e.g. clinical stage at diagnosis, histologic grade, laterality) and 17 timeline 
related variables (e.g. date and type of surgery, chemo/endocrine/targeted therapies 
received by date, chemotherapy regimen and cycle information, overall survival). 
34 of identified “must have” variables were accessible from at least one of available 
databases. Of the relevant variables five may be difficult to access, including BRCA 
testing and status, performance status, date and site of recurrence, disease free 
survival and treatment delay. cOnclusiOns: Breast cancer clinicians identified 39 
essential variables, the majority of which can be obtained from currently available 
databases and then uploaded into a clinical dashboard to support personalized 
medicine at the point of care for patients with breast cancer.
PCN11
AN INDIRECT TREATMENT COMPARISON OF THE EFFICACy OF EvEROLIMUS 
(AFINITOR®) AND FULvESTRANT FOR THE TREATMENT OF HORMONE 
RECEPTOR POSITIvE (HR+) HER2 NEGATIvE (HER2–) ADvANCED OR METASTATIC 
BREAST CANCER
Chandiwana D.1, Vieira J.1, Granville J.2, McCool R.2, Fleetwood K.3
1Novartis Pharmaceuticals UK Limited, GB- Frimley/Camberley, UK, 2York Health Economics 
Consortium Ltd., York, UK, 3Quantics Consulting Ltd., Edinburgh, UK
Objectives: To indirectly compare the efficacy (progression free survival (PFS)/
time to progression (TTP) and overall survival (OS) of everolimus plus exemes-
tane (EVE+EXE) with fulvestrant in patients with hormone receptor positive, HER2 
negative advanced or metastatic breast cancer. MethOds: A systematic search of 
the Cochrane Library and other resources was undertaken to identify reviews and 
clinical trials reporting interventions for metastatic breast cancer that would allow 
an indirect comparison of fulvestrant and EVE+EXE. A Bayesian fixed effect model 
was used with exemestane adopted as the base treatment for the model because it 
provided the most information in the network. The basic parameters of the model 
are the log hazard ratios with respect to exemestane for PFS/TTP and OS from the 
included studies. In the absence of full networks for TTP/PFS, these outcomes were 
assumed to be the same measure in a disease with short survival times. Results: 
Six trials contributed to a network for PFS/TTP and five to a network for OS. Because 
the comparator treatment was used as the base treatment, a HR > 1 indicates that 
the comparator is less effective than everolimus. For PFS/TTP, EVE+EXE performed 
better than fulvestrant 250mg (HR 2.13 Credible interval (CI):1.72 to 2.63) and 500mg 
(HR 1.69 CI: 1.30 to 2.22). This difference was statistically significant. For OS, EVE+EXE 
performed better than fulvestrant 250mg (HR 1.36 Cl: 0.95 to 1.97) and 500mg (HR 
1.15 Cl: 0.76 to 1.75) but the difference was not statistically significant. A complete 
statistical assessment of heterogeneity for PFS/TTP and OS was not possible because 
of data limitations. cOnclusiOns: EVE+EXE confers better PFS/TTP benefit in HR+ 
HER2-ve metastatic breast cancer when indirectly compared with fulvestrant 250mg 
the colorectal cancer and comparison groups, adjusted for baseline demographic 
and clinical characteristics. Results: A total of 75,208 patients were identified 
for the colorectal cancer and comparison cohorts. After 1:1 PSM, 24,053 patients 
were matched from each group, and the baseline characteristics were proportion-
ate. Patients diagnosed with colorectal cancer had more health care utilization 
including inpatient (20.40% vs. 2.61%, p< 0.01), emergency room (ER) (15.32% vs. 
6.06%, p< 0.01), outpatient (99.60% vs. 64.31%, p< 0.01) and pharmacy visits (88.30% 
vs. 66.20%, p< 0.01). The higher health care utilization resulted in increased health 
care costs, including high inpatient ($9,867 vs. $795, p< 0.01), ER ($158 vs. $61, p< 0.01), 
outpatient ($5,020 vs. $1,585, p< 0.01), pharmacy ($1,345 vs. $523, p< 0.01) and total 
costs ($16,232 vs. $2,903, p< 0.01) for patients diagnosed with colorectal cancer 
compared to patients in the comparison group. cOnclusiOns: Veteran patients 
diagnosed with colorectal cancer incurred significantly higher health care utiliza-
tion and costs over a 1-year period compared to patients without colorectal cancer.
PCN7
EvOLUTION OF MOLECULAR DIAGNOSTIC TEST USAGE IN SOLID TUMOURS IN 
wESTERN EUROPE: AMBITION STUDy (ANALySIS OF MOLECULAR BIOMARKER 
TESTS IN ONCOLOGy)
Ricarte C.1, Bruce A.2, Anger C.2
1IMS Health, La Défense, France, 2IMS Health, London, UK
Objectives: The development of targeted therapies has changed the paradigm of 
cancer management necessitating the use of robust biomarkers to identify eligible 
patients. This study aims to evaluate trends in molecular diagnostic test (MDT) uptake 
across various solid tumors. MethOds: This study used IMS Oncology Analyzer™, a 
patient database collected through a quarterly physician panel survey. This database 
provides comprehensive insight into cancer care. Selected patients were at advanced/
metastatic stages and diagnosed with breast (BC), stomach (SC), non-small cell lung 
cancer (NSCLC) or colorectal cancer (CRC) and receiving chemotherapy. MDT uptake 
was analyzed from time 0 (year of the European Medicines Agency –EMA– approval 
of the associated targeted therapy) until 2012. The analysis was done on 5 EU coun-
tries (France, Germany, Italy, Spain and UK). Results: Trastuzumab was approved 
in HER2+ BC by the EMA in 2000 and had a line extension in 2004. In metastatic 
BC, the proportion of HER2-tested patients in 2004 was 60% (787/1,320) versus 94% 
(1,351/1,430) in 2012. Following further approval in 2010 for use in HER2+ advanced SC, 
HER2-testing grew from 17% (176/1,015) to 50% (501/993) between 2010 and 2012 in this 
population. In the year that Gefitinib gained EMA approval in EGFR+ NSCLC (2009), 8% 
of advanced NSCLC patients (280/3,465) were EGFR-tested. This proportion increased 
to 56% (2,092/3,708) in 2012. Panitumumab and Cetuximab obtained EMA approval for 
KRAS-wild type CRC in 2007 and 2008 respectively. In 2009, 42% (1,183/2,843) of meta-
static CRC patients were K-RAS-tested and 62% (1,782/2,873) in 2012. cOnclusiOns: 
The use of MDTs has become increasingly important in oncology as more targeted 
therapies are launched. While consistent growth in testing is established, differences 
exist in the delay to achieving routine testing of patients. Further observation of MDT 
usage is required, considering national health guidelines, to better understand move-
ment towards personalized cancer management.
PCN8
A LESSON LEARNT FROM AvASTIN®: - BEvACIzUMAB INDUCED 
HyPERTENSION AS A PREDICTIvE BIOMARKER OF PATIENT RESPONSE IN 
OvERCOMING REGULATORy AND HEALTH TECHNOLOGy ASSESSMENT (HTA) 
HURDLES
Fowler R.C., Street-Docherty L.M., Morrison S.
GfK Bridgehead, Melton Mowbray, UK
bAckgROund: The high cost of VEGF-targeted anti-angiogenic therapies within a 
financially strained health-system, makes reimbursement decisions a potentially lim-
iting factor for new compounds. Failure to demonstrate adequate clinical benefit and 
cost-effectiveness in HER-2 negative metastatic breast cancer resulted in significant 
regulatory and health technology assessment (HTA) challenges. There is increasing 
expectation for new drugs to have companion diagnostics that identify likely patient 
responders, with growing support for using biomarkers to inform treatment deci-
sions Objectives: The purpose of this study was to critically examine published lit-
erature on trials incorporating biomarkers related to VEGF inhibition across different 
cancer indications, to explore their value as predictive, prognostic, pharmacological 
or surrogate response biomarkers MethOds: A search with a strict set of inclusion 
criteria was used to review the current literature. Information was gathered for 13 
biomarkers that have been explored for anti-VEGF therapy and a database was com-
piled housing raw experimental data for comparison. Each biomarker was critically 
evaluated and ranked accordingly, to validate their potential as predictive, prognostic, 
pharmacodynamic and surrogate endpoint markers for bevacizumab-based therapies, 
with consideration for likely regulatory, clinical and payer acceptance. Results: A 
total of 222 published studies were incorporated into the analysis. Plasma VEGF-A, 
PlGF and soluble VEGFR-1/VEGFR-2 demonstrated value as pharmacodynamic bio-
markers with limited prognostic value. CECs and CA19-9 showed prognostic and 
predictive value under restricted indications. Blood pressure demonstrated superior-
ity in its ability to predict response to bevacizumab. cOnclusiOns: The evidence 
suggests the incorporation of biomarkers in clinical trial design must be tailored to 
the drug and the cancer indication to which the therapy is applied. The potential for 
blood pressure as a biomarker of response to bevacizumab has been highlighted. 
Bevacizumab-induced hypertension should therefore be considered as a key candi-
date for future biomarker-driven trials, increasing the likelihood of test-treatment 
acceptance by key regulatory and HTA stakeholders.
PCN9
PREGNANCy AFTER BREAST CANCER IN 2000-2002 AND 2010-2012: A 
RETROSPECTIvE DATABASE ANALySIS
Kalousidou N.1, Waehlert L.1, Rex J.2, Kostev K.2, Ziller V.3
1Fresenius University of applied sciences, Idstein, Germany, 2IMS Health, Frankfurt am Main, 
Germany, 3Philipps-University of Marburg, Marburg, Germany
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year or $49.0M/year nationally. cOnclusiOns: Differences in study design should 
be addressed when conducting an ITC. The evidence from this ITC shows that abira-
terone and enzalutamide have similar efficacy in OS in mCRPC post chemotherapy. 
However, abiraterone is cost saving compared to enzalutamide in this analysis.
PCN15
DIFFERENCES IN MEDICAL COST AND SURvIvAL BETwEEN TRIAL AND NON-
TRIAL PATIENTS wITH ACUTE MyELOID LEUKAEMIA – A UK POPULATION-
BASED PROPENSITy ANALySIS
Wang H.I.1, Aas E.2, Roman E.1, Howell D.1, Painter D.1, Smith A.1
1University of York, York, UK, 2University of Oslo, Oslo, Norway
Objectives: Information about acute myeloid leukaemia (AML), including the 
costs of treatment and survival-estimates, are usually derived from clinical trial 
data. However, it is not known whether this information is generalizable to non-
trial patients. This study was carried out to evaluate the differences in medical costs 
and survival between trial and non-trial patients with AML; and hence assess the 
external validity of trial data to the general patient population. MethOds: The 
Haematological Malignancy Research Network (HMRN, www.hmrn.org) is an estab-
lished population-based patient cohort that registers around 2000 newly diagnosed 
patients each year. All adults (≥ 18) newly diagnosed with AML between September 
2004 and August 2007 and treated with induction intent were included. Patients were 
followed until August 2012, and the comparative outcomes were medical costs and 
survival. Standard statistical analyses were used to measure unadjusted difference 
in outcomes, and propensity score analyses were applied to measure differences by 
adjusting for baseline imbalance in pre-treatment characteristics between trial and 
non-trial patients. Results: Overall, 173 patients treated with induction intent were 
included, of which 106 were trial and 67 non-trial. Trial participation was associated 
with younger age, fewer comorbidities, better prognosis, and being treated at teach-
ing hospitals. Before controlling for patients’ characteristics, trial patients had better 
survival and incurred higher costs (p< .0001 for both). After controlling for patients’ 
characteristics by carrying out propensity score analyses, these differences remained 
significant in both survival (median survival 28.7 vs. 8 months; p< .0001) and medical 
costs (mean costs £84,497 vs. £49,624; p< .0001). cOnclusiOns: For AML patients 
treated with induction intent, significant differences were observed in treatment costs 
and survival according to trial status, both before and after controlling for patients’ 
pre-treatment characteristics. Data generated solely from clinical trials may therefore 
not be generalizable to non-trial patients and should be treated with some caution 
when used to facilitate decision-making.
PCN16
THE EFFECT OF POSITIvE MARGINS ON OUTCOMES IN BREAST CANCER
Ling C.S.1, Weisgerber-Kriegl U.M.2, Njue A.1, Heyes A.E.1, Kaye J.A.3
1RTI Health Solutions, Manchester, UK, 2F. Hoffmann-La Roche Ltd., Basel, Switzerland, 3RTI 
Health Solutions, Waltham, MA, USA
Objectives: To review the data available on excision margins following breast-
conserving therapy (BCT), focusing on definitions of positive and clear margins, per-
centage of operations resulting in positive margins, the effect of positive margins on 
future treatment, and the relationship between positive margins and disease-free 
and overall survival. MethOds: Targeted searches of PubMed were conducted using 
a predefined search strategy. Data from robust systematic reviews and/or meta-anal-
yses were given priority. Results: Definitions of positive and negative margins are 
variable, but typically a clear margin of 2 mm is considered acceptable. Most studies 
indicate positive margins in 20%-40% of patients after wide local excision. Guidelines 
recommend that patients with positive margins after BCT undergo repeat surgery, 
and in surveys, most physicians said they would recommend re-excision when there 
is tumour within 1 mm of the margin. In the identified studies, 20%-30% of patients 
underwent re-excision and approximately 2% had multiple re-excisions (two or more); 
10%-15% of patients who initially had lumpectomy later had a mastectomy. There 
is a significant association between margin status and local recurrence (in a recent 
meta-analysis, the odds ratio was 2.42 for positive vs. negative margin status; 95% 
confidence interval, 1.94-3.02; P< 0.001). However, among patients with a clear margin, 
width is not clearly related to risk of local recurrence. Four studies that assessed the 
effect of margin status on overall or disease-specific survival were identified, three 
reported a significant association (e.g., cause-specific survival at 12 years significantly 
associated with margin status, P< 0.001). cOnclusiOns: Definition of adequate mar-
gins remains controversial. None-the-less, final margin status is a key prognostic 
factor following BCT. The data identified suggest that an intervention that reduces 
the rates of positive margins during BCT may have the potential to improve outcomes 
and reduce the burden on patients and health care providers.
PCN17
A MIxED TREATMENT COMPARISON (MTC) TO COMPARE PROGRESSION FREE 
SURvIvAL (PFS) ASSOCIATED wITH DIFFERENT CHEMOTHERAPy REGIMENS 
FOR PLATINUM-SENSITIvE OR PARTIALLy PLATINUM-SENSITIvE RECURRENT 
ADvANCED OvARIAN CANCER
Edwards S.J., Barton S., Thurgar E., Wakefield V., Karner C., Trevor N.
BMJ Group, London, UK
Objectives: This research was conducted during a review of the manufacturer’s 
submission (MS) to the NICE Single Technology Appraisal programme for beva-
cizumab, a vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab in 
combination with gemcitabine/carboplatin has recently been licensed for use in 
patients with platinum-sensitive or partially platinum-sensitive recurrent advanced 
ovarian cancer. This research compared this new triple therapy with treatments 
used in clinical practice in the UK: platinum monotherapy, gemcitabine/carboplatin, 
paclitaxel/carboplatin, pegylated liposomal doxorubicin hydrochloride (PLDH)/car-
boplatin. MethOds: Randomised controlled trials (RCTs) for inclusion were identi-
fied using the MS for bevacizumab. RCTs were assessed for comparability based on 
patient population, disease severity, platinum sensitivity, and treatments received. 
An MTC was conducted using a Bayesian Markov chain Monte Carlo simulation. 
or 500mg. The indirect analysis did not show a statistically significant difference in 
OS between everolimus compared with fulvestrant.
PCN12
SMALL MOLECULE TARGETED THERAPIES FOR THE SECOND LINE TREATMENT 
OF METASTATIC RENAL CELL CARCINOMA (MRCC): A SySTEMATIC REvIEw 
AND INDIRECT COMPARISON OF SAFETy AND EFFICACy
Dranitsaris G.1, Schmitz S.2, Broom R.J.3
1University of Ioannina, Ioannina, Greece, 2Trinity College, Dublin, Ireland, 3Auckland City 
Hospital, Auckland, New Zealand
Objectives: Patients with mRCC and a good performance status typically receive 
an anti-VEGFR TKI (sunitinib or pazopanib) as initial therapy. Upon disease progres-
sion or intolerance, there are four orally-administered agents approved in the 2nd 
- line setting (including cytokine-refractory). However, head to head comparative 
trial data are limited. In the absence of such data, mixed treatment comparison 
(MTC) models are a widely accepted statistical method for generating comparative 
effectiveness information. In this study, an indirect comparison on the safety and 
efficacy was undertaken between axitinib, sorafenib, pazopanib and everolimus 
for 2nd - line therapy in advanced RCC. MethOds: A systematic review of major 
databases was conducted from January 2005 to June 2013 for randomized controlled 
trials evaluating at least one of the four agents in 2nd- line mRCC. Bayesian MTC 
models were fitted to assess comparative effectiveness based on multiple endpoints: 
tumour response, progression free survival (PFS), grade III/IV toxicities such as diar-
rhea, fatigue, hand foot skin reaction, rash and stomatitis as well as treatment 
discontinuations. Results: A total of four randomized trials meeting the inclusion 
criteria were appropriate for the statistical pooling exercise. All four agents seem 
able to induce tumour shrinkage and provide patients with a clinically meaningful 
PFS benefit. Axitinib was superior to pazopanib (HR = 0.64; 95%Crl: 0.42 to 0.96) and 
sorafenib (HR = 0.70; 95%Crl: 0.57 to 0.87) in terms of PFS. However, patients receiv-
ing axitinib would be at an elevated risk for fatigue and to a lesser extent, stoma-
titis. cOnclusiOns: Keeping in the mind the caveats associated with cross-trial 
comparisons, axitinib appears to provide superior PFS benefits relative to pazopanib 
and sorafenib. However, this is at a cost of a higher frequency of some dose-limiting 
toxicities. Everolimus, an mTor inhibitor, is mechanistically distinct from the other 
agents evaluated and would be a useful option post anti-VEGFR TKI failure.
PCN13
TARGETED THERAPy IN TRIPLE-NEGATIvE METASTATIC BREAST CANCER 
(TNBC) - A SySTEMATIC REvIEw AND META-ANALySIS
Clark O.A.C.1, Engel T.1, Paladini L.1, Ferreira M.B.A.2
1Evidencias, Campinas, Brazil, 2Roche, São Paulo, Brazil
Objectives: To perform a systematic review and meta-analysis of all randomized 
controlled trials comparing the efficacy of targeted therapy to conventional CT in 
patients with metastatic Triple-Negative Breast Cancer (TNBC). MethOds: Several 
databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The 
primary endpoint was progression-free survival (PFS). We performed a meta-analysis 
(MA) of the published data. The results were expressed as Hazard Ratio (HR) or Risk 
Ratio (RR), with their corresponding 95% confidence intervals (CI 95%). Results: 
The final analysis included 12 trials comprising 2,054 patients with TNBC. It was 
evidenced studies with conventional CT plus targeted therapy including bevacizumab 
(Bev), sorafenib (Sor), cetuximab and iniparib. The PFS was higher in patients who 
received Bev plus CT compared to CT alone in previously untreated patients with 
TNBC (fixed effect: HR= 0.62; CI 95%= 0.51-0.75; p< 0.00001). The PFS was also higher 
in one study with Bev plus CT in previously treated patients (fixed effect: HR= 0.49; 
CI 95%= 0.33-0.74; p= 0.0006). Sor plus CT was available in first-line and second-line. 
The PFS was higher in the group with Sor versus CT alone (fixed effect: HR= 0.69; CI 
95%= 0.49-0.98; p= 0.04) and iniparib plus CT (fixed effect: HR= 0.75; CI 95%= 0.62-0.90; 
p= 0.002). cOnclusiOns: Bev, Sor and iniparib, when associated with the conven-
tional CT, demonstrated gains in the PFS of patients with TNBC.
PCN14
ABIRATERONE AND ENzALUTAMIDE FOR THE TREATMENT OF METASTATIC 
CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) POST CHEMOTHERAPy: 
AN INDIRECT COMPARISON AND BUDGET IMPACT ANALySIS
Li T.1, Thompson M.2, Todd M.1, Yu M.1, Kheoh T.1, Saadi R.1
1Janssen Global Services LLC, Raritan, NJ, USA, 2Cornerstone Research Group, Burlington, ON, 
Canada
Objectives: Abiraterone and enzalutamide are two new treatment options for 
patients with mCRPC after docetaxel-based chemotherapy. This study aims to 
understand the relative clinical and economic value of these therapies. MethOds: 
Two pivotal clinical trials were conducted to evaluate abiraterone and enzalutamide 
in post-docetaxel treatment of mCRPC: Study COU-AA-301 for abiraterone and the 
AFFIRM trial for enzalutamide. The PICO (population, intervention, comparison, and 
outcomes) construct was employed to assess the comparability of the trials, followed 
by an indirect treatment comparison (ITC) using the Bucher method and a mix treat-
ment comparison using Bayesian statistics. An economic evaluation was performed 
based on the ITC results. Results: Several key differences were identified between 
the COU-AA-301 and AFFIRM trials. First, the studies used different comparators. 
Abiraterone plus prednisone was compared with prednisone alone, while enzaluta-
mide was compared with placebo. Second, the endpoints rPFS, PSA progression, and 
PSA response were defined differently between trials, and thus were not included in 
the analysis. To address the difference in comparators, the ITC was performed using 
data from COU-AA-301 and subjects receiving corticosteroids concurrently in the 
AFFIRM trial. OS was significantly improved with both abiraterone and enzalutamide 
(3.9 and 3.2 months respectively). The ITC results were HR = 0.949 (95% CI: 0.712-1.26) 
for abiraterone versus enzalutamide using the Bucher method, and HR = 0.948 (95% CI: 
0.711-1.26) using the Bayesian method. Using the US price for abiraterone and enza-
lutamide (approved in the US only), and assuming 25% of patients received therapy 
following docetaxel, cost savings from using abiraterone would be > $10K/patient/
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months. MethOds: In PRIME, 1183 patients with previously untreated mCRC 
were randomised. Using data from an exploratory analysis conducted when 80% 
of patients had died, NNTs (Bender. Encyclopedia of Biostatistics, Second Edition; 
Volume 6, pp3752-61) were retrospectively calculated in patients with KRAS/NRAS 
WT (n= 505; exons 2-4 assessed) mCRC overall and in the ECOG performance score 
0/1 (n= 473) subgroup. ORR and PFS events were defined using RECIST. Results: 
In the overall KRAS/NRAS WT population, 59.3% vs 45.6% of patients receiving 
panitumumab+FOLFOX4 vs FOLFOX4 alone, respectively, achieved an OR; NNT(95% 
CI) in the ORR analysis was 7.3(4.5-19.9). In the ECOG 0/1 subgroup, 61.3% vs 46.4% 
of those receiving panitumumab+FOLFOX4 vs FOLFOX4 alone, respectively, had an 
OR; the NNT(95% CI) was 6.7(4.2-16.5). For the PFS overall population analysis, the 
HR(95% CI) was 0.74(0.62-0.90); HR(95% CI) for the ECOG 0/1 subgroup was 0.72(0.59-
0.88). NNTs(95% CI) in the overall population at 6 and 12 months were 12.8(8.3-34.1) 
and 9.2(5.7-25.9), respectively; corresponding values for the ECOG 0/1 subgroup were 
11.9(7.9-27.8) and 8.4(5.3-20.8). For the OS overall population analysis, the HR(95% 
CI) was 0.76(0.63-0.93); HR(95% CI) for the ECOG 0/1 subgroup was 0.74(0.60-0.90). 
NNTs(95% CI) in the overall population at 12 and 24 months were 16.8(10.4-57.1) and 
10.4(6.2-37.1), respectively; corresponding values for the ECOG 0/1 subgroup were 
16.0(10.3-44.1) and 9.4(5.9-27.2). cOnclusiOns: In these analyses NNTs for PFS, 
OS and particularly ORR were low, reflecting the high therapeutic benefit of adding 
panitumumab to FOLFOX4 in patients with KRAS/NRAS WT mCRC. Limitation by 
ECOG score 0/1 further lowered NNTs for PFS and OS.
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INDIRECT COMPARISON ANALySIS TO EvALUATE THE CLINICAL 
EFFECTIvENESS OF TRASTUzUMAB EMTANSINE (T-DM1) vERSUS OTHER 
TREATMENTS FOR HER2-POSITIvE METASTATIC BREAST CANCER (MBC)
Benito Garcia E.1, Hersberger V.1, Takyar S.2, Moser A.1
1F. Hoffmann-La Roche Ltd., Basel, Switzerland, 2Heron Health, Chandigarh, India
Objectives: T-DM1, an antibody-drug conjugate which combines the antitumor 
properties of trastuzumab (H) with the cytotoxic agent DM1, is approved for the 
treatment of patients with MBC previously treated with trastuzumab+taxane. We 
compared the clinical effectiveness of T-DM1 versus all available therapies used in 
the treatment of unresectable HER2-positive locally advanced breast cancer (LABC) 
or MBC. MethOds: This systematic review (SR) and indirect treatment comparison 
(ITC) included all published data between January 1, 1998 and December 20, 2012. 
Studies were chosen in accordance with conventional methods for performing and 
reporting SRs and ITCs (i.e., Cochrane Handbook for SRs, PRISMA, ISPOR guidelines, 
and major HTA agencies). Eligible trials were controlled trials of treatments for 
unresectable HER2-positive LABC or MBC that had progressed after treatment with 
combination of trastuzumab+taxane in the adjuvant or MBC setting. Progression 
had to have occurred after the most recent treatment for LABC or MBC or within 6 
months after treatment for early-stage disease. Results: Seven RCTs and two non-
randomized controlled trials (n-RCTs) met the inclusion criteria. Of the seven RCTs, 
five had a common comparator, being eligible for the ITC. The other two RCTs and 
two n-RCTs did not have a common comparator and were thus not included in the 
ITC. T-DM1 was the only treatment to demonstrate statistically significantly longer 
overall survival (OS) and progression-free survival (PFS) when directly compared to 
capecitabine+lapatinib, and when indirectly compared to capecitabine+trastuzumab 
(PFS HR [95% CI]: 0.53 [0.32, 0.86], p= 0.01; OS HR [95% CI]: 0.56 [0.35, 0.91]; p= 0.01) 
and capecitabine monotherapy (PFS HR [95% CI]: 0.36 [0.25, 0.51]; p< 0.0001); OS (HR 
[95% CI]: 0.53 (0.39, 0.72); p= 0.0009). cOnclusiOns: In this ITC, T-DM1 was associ-
ated with longer OS and PFS versus capecitabine+trastuzumab and capecitabine 
monotherapy in patients with HER2-positive LABC or MBC with disease progression 
after treatment with trastuzumab+taxane.
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SECOND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A 
SySTEMATIC LITERATURE REvIEw (SLR) AND FEASIBILITy ASSESSMENT OF 
CONDUCTING INDIRECT TREATMENT COMPARISON (ITC) ANALySIS
Xu Y.1, Martin A.L.1, Ross S.2, Knopf K.B.3, Strand L.1, Iqbal S.U.4, Joulain F.5,  
Jasso Mosqueda J.G.6, Fahrbach K.1
1Evidera, Lexington, MA, USA, 2SDRoss Consulting, Cohasset, MA, USA, 3Pacific Hematology 
Oncology Associates, San Francisco, CA, USA, 4Sanofi, Cambridge, MA, USA, 5Sanofi, Chilly-
Mazarin, France, 6Sanofi, CHILLY-MAZARIN Cedex, France
Objectives: To investigate the efficacy and safety of second-line chemotherapy in 
mCRC and to determine the feasibility of relative efficacy between treatments using 
indirect or mixed treatment comparisons. MethOds: An SLR on randomized trials 
published from 1992–2012 was performed. EMBASE, PubMed, CENTRAL databases 
were consulted. Manual searches (including ASCO and ESMO abstracts) were also 
conducted. Eligible studies evaluated second-line clinical efficacy and safety end-
points in mCRC. Results: Twenty-seven trials with patients enrolled ranging from 
n= 33–1,226 were identified. Patients were markedly diverse in terms of ECOG, EGFR, 
or KRAS status, and prior treatment exposures: oxaliplatin (k= 9), irinotecan +/- 5-FU 
(k= 5), bevacizumab (k= 7), and 5-FU (k= 22). On-study treatments and comparators 
were also diverse: FOLFIRI alone (t= 6) or with panitumumab (t= 2) or aflibercept 
(t= 1); FOLFOX4 alone (t= 6) or with bevacizumab (t= 1); bevacizumab alone (t= 1) or 
with chemotherapy (t= 2); irinotecan alone (t= 19) or with FOLFOX4 (t= 2) or cetuxi-
mab (t= 1); and miscellaneous other regimens (t= 19). Study methodologies varied 
in analysis populations (ITT [k= 24] vs. per protocol or not reported [k= 3]), primary 
efficacy outcomes (OS, PFS, and/or tumor response, as variably measured), follow-up 
durations, and timing of outcomes measurements. Preliminary network diagrams to 
assess feasibility of meta-analyses for ITC revealed only a single study for each treat-
ment comparison of interest. Assumptions of comparability of apparently diverse 
patients, past and current treatment regimens, and comparator arms would be 
necessary to pool treatment groups for meta-analysis of treatment effectiveness 
across studies and hence, is not feasible. Given the lack of SOC treatments used in 
many trials, introducing such assumptions will compromise the evidence-based 
criteria for quantitative clinical data syntheses for indirect or mixed treatment 
Fixed and random effects models were explored with results reported for the best 
fitting model. Hazard ratio (HR) was chosen as the summary statistic. Results: The 
network of 6 RCTs formed a linear series of “steps”, which facilitated comparison of 
all chemotherapy regimens of interest. The fixed effects model was the best-fitting 
model. There was reasonable agreement between the number of unconstrained 
data points, residual deviance and pair-wise results, suggesting a coherent network. 
Using bevacizumab/gemcitabine/carboplatin as the baseline, the results for PFS 
for the other chemotherapy regimens were: platinum monotherapy (HR 2.92, 95% 
Credible Interval [CrI]: 2.10 to 3.96), gemcitabine/carboplatin (HR 2.09, 95% CrI: 1.65 
to 2.60), paclitaxel/carboplatin (HR 2.16, 95% CrI: 1.50 to 3.01), PLDH/carboplatin (HR 
1.77, 95% CrI: 1.20 to 2.51); where a HR> 1 favours bevacizumab/gemcitabine/carbo-
platin and a HR< 1 favours the comparator. cOnclusiOns: This research suggests 
bevacizumab in combination with gemcitabine/carboplatin may offer significantly 
longer PFS compared with other chemotherapy options available in the UK.
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EFFICACy OF BRENTUxIMAB vEDOTIN AND OTHER TREATMENTS IN PATIENTS 
wITH RELAPSED OR REFRACTORy (RR) SySTEMIC ANAPLASTIC LARGE-CELL 
LyMPHOMA (SALCL): A SySTEMATIC REvIEw
Bonthapally V.1, Yang H.2, Macalalad A.R.2, Wu E.Q.2, Lutes R.3, Shonukan O.1, Chi A.3, Huebner 
D.3
1Millennium: The Takeda Oncology Company, Cambridge, MA, USA, 2Analysis Group, Inc., Boston, 
MA, USA, 3Takeda Cambridge US, Cambridge, MA, USA
Objectives: Brentuximab vedotin (ADCETRIS®), a CD30-targeted antibody-drug 
conjugate, has conditional approval in Europe for the treatment of adult patients 
with RR sALCL. This systematic review summarized the efficacy of other treatments 
for RR ALCL, for comparison with brentuximab vedotin. MethOds: A systematic 
literature review identified studies published between 1993 and February 2013 report-
ing efficacy of treatments in adult patients with RR ALCL, or more generally with RR 
peripheral T-cell lymphoma (PTCL) including ≥ 1 ALCL patient. Five databases were 
included: EMBASE, MEDLINE, and the WHO ICTRP; reviews published since 2011 were 
also searched manually for additional studies. English publications reporting com-
plete remission/response (CR) rate and/or 2-year overall survival (OS) in RR ALCL/
PTCL populations were included. Publications of principal treatment with bone mar-
row transplantation or radiotherapy were excluded. CR rates and 2-year OS, from 
the identified studies and from the brentuximab vedotin single-arm phase 2 trial 
in sALCL (SG035-0004), were summarized. Results: Of 1653 publications screened, 
12 studies were eligible for inclusion; all were phase 1 or 2 or unspecified prospec-
tive non-randomized studies. For these studies, the CR rates were 0–28% in RR PTCL 
patients (n= 4–130 PTCL; median age 36–69 years; n= 1–41 ALCL), and for the 6 studies 
that also reported CR outcomes in the subset of RR ALCL patients (n= 13–130 PTCL; 
median age 47–69 years; n= 2–41 ALCL), the CR rates were 0–33% in RR ALCL patients. 
For RR ALCL patients treated with brentuximab vedotin in SG035-0004 (n= 58 sALCL; 
median age 52 years) the CR rate was 59%. The 2-year OS ranged from 7–33% in the 
5 identified studies that reported OS, compared with 63% with brentuximab vedotin 
in SG035-0004. cOnclusiOns: The CR rate and 2-year OS for brentuximab vedotin 
in RR sALCL appear to exceed that of other therapies in RR ALCL/PTCL.
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A COMMUNITy-BASED, CASE-CONTROL STUDy EvALUATING MORTALITy 
REDUCTION FROM GASTRIC CANCER By ENDOSCOPIC SCREENING IN jAPAN
Hamashima C.1, Ogoshi K.2, Okamoto M.3, Shabana M.4, Kishimoto T.3, Fukao A.5
1National Cancer Center of Japan, Tokyo, Japan, 2Niigata Cancer Center Hospital, Niigata, Japan, 
3Tottori University, Yonago, Japan, 4San-in Rosai Hospital, Yonago, Japan, 5Yamagata University, 
Yamagata, Japan
Objectives: Although gastric cancer has decreased in the last three decades, it is 
still the second leading cause of cancer death worldwide. In Asian countries, the 
burden of gastric cancer has remained, and screening is still expected to prevent 
gastric cancer death. In order to evaluate reduction of mortality from gastric cancer 
by endoscopic screening, a community-based, case-control study was conducted in 
Japan. MethOds: Case subjects were defined as persons who had died of gastric 
cancer between 2003 and 2006 in four cities, Tottori Prefecture, and between 2006 
and 2010 in Niigata City, Japan. Up to six control subjects were matched by sex, birth 
year (±3 years), and residence of each corresponding case from population lists in the 
study areas. Controls were required to be disease-free at the time when the case was 
diagnosed gastric cancer. The odds ratios were calculated for those who had ever par-
ticipated in endoscopic screening or radiographic screening before the reference date 
when the case was diagnosed gastric cancer, compared with persons who had never 
participated in any screening. Conditional logistic-regression models for matched sets 
were used to estimate the odds ratios and 95% confidence intervals. Results: There 
were 288 males and 122 females for case subjects, with 2,292 matched control subjects. 
Compared with those who had never been screened before the date of diagnosis of 
gastric cancer in cases, the odds ratios within 48 months from the diagnosis date 
were 0.703 (95% confidence interval :0.497-0.996) for endoscopic screening and 0.860 
(95% confidence interval :0.631-1.171) for radiographic screening. cOnclusiOns: The 
result suggests a 30% reduction from gastric cancer mortality by endoscopic screening 
compared to no screening within 48 months before the diagnosis date of gastric cancer.
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BENEFIT OF ADDING PANITUMUMAB TO FOLFOx4 IN PATIENTS wITH KRAS/
NRAS wILD-TyPE (wT) METASTATIC COLORECTAL CANCER (MCRC): A NUMBER-
NEEDED-TO-TREAT (NNT) ANALySIS
Douillard J.Y.1, Sienna S.2, Davison C.3, Braun S.4, Sidhu R.5
1ICO René Gauducheau, St Herblain, France, 2Ospedale Niguarda Ca’ Granda, Milan, Italy, 
3Amgen Ltd., Cambridge, UK, 4Amgen (Europe) GmbH, Zug, Switzerland, 5Amgen Inc., Thousand 
Oaks, CA, USA
Objectives: To calculate NNTs for panitumumab+FOLFOX4 vs FOLFOX4 alone 
(PRIME study) to achieve one objective response (OR rate [ORR] analysis) or pre-
vent one disease progression (PFS analysis) or death (OS analysis) at 6/12 or 12/24 
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benign and malignant cases. Results: In 2008-2009 there were 477904 screening 
mammography examinations in Hungary. 5.15 % of participating women were re-
called. The attendance of re-called women was 92.25 %. Altogether 2092 women 
(9.7 %) were referred for breast surgery but only 1485 women (71.0 %) underwent 
surgery. Histological examination confirmed 281 benign (18.9 %) and 1204 malignant 
(81.1 %) cases. cOnclusiOns: The quality indicators of the Hungarian organized 
mammography screening program met the recommendations of international pro-
fessional guidelines. However, in addition to current indicators, new ones should be 
introduced in order to provide a more comprehensive monitoring of the program.
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THE ATTENDANCE OF THE FOURTH SCREENING ROUND (2008-2009) OF 
THE HUNGARIAN ORGANIzED, NATIONwIDE BREAST CANCER SCREENING 
PROGRAM
Boncz I.1, Dobrossy L.2, Péntek Z.3, Kovács A.2, Budai A.2, Vajda R.1, Sebestyén A.4
1University of Pécs, Pécs, Hungary, 2National Public Health and Medical Officers Service (ÁNTSZ), 
Budapest, Hungary, 3MaMMa Healthcare Ltd., Budapest, Hungary, 4National Health Insurance 
Fund Administration, Pécs, Hungary
Objectives: Organized, nationwide screening for breast cancer with mammog-
raphy started in Hungary in January 2002. Women in the age group 45-65 years 
are the target population and 2 years screening interval is applied. The aim of 
this study is to analyze the attendance rate of the 4th screening round (2008-
2009). MethOds: The data derive from the financial database of the National 
Health Insurance Fund Administration (NHIFA) covering the period of 2008-2009. 
We calculated two attendance indicators. The up-take of the program means 
the percentage of women aged 45-65 who, having been sent an invitation for 
screening, attend a screening unit and undergo mammography in response to 
that invitation. We defined coverage as the ratio of women in the age group 
45-65 years having either a screening mammography or a diagnostic mam-
mography. Results: In 2008-2009 there were 477904 screening mammography 
cases and 1204893 diagnostic mammography examinations in Hungary. We found 
49.4 % and 41.5 % up-take in 2008 and 2009 respectively; and 45.0 % combined 
rate for 2008/2009. The screening coverage was 31.2 % and the diagnostic cover-
age was 20.4 %, while the total coverage (screening and diagnostic) was 50.1 
%. cOnclusiOns: The attendance of the Hungarian organized breast cancer 
screening program – compared to the previous period before the implementa-
tion of the organized screening program – is promising, although to achieve the 
expected results in mortality decrease a further improvement of both the uptake 
and coverage is necessary.
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RACIAL DISPARITIES IN DIFFUSION, COMPARATIvE MORBIDITy, AND DISEASE 
CONTROL OF INTENSITy-MODULATED RADIATION THERAPy COMPARED TO 
CONFORMAL RADIATION THERAPy FOR LOCALIzED PROSTATE CANCER
Cobran E.K.1, Overman R.2, Carpenter W.R.3, Godley P.A.4, Chen R.5
1University of North Carolina at Chapel Hill, Gillings School of Global Public Health and School 
of Medicine, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA, 2University 
of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Pharmaceutical 
Outcomes and Policy, Chapel Hill, NC, USA, 3University of North Carolina at Chapel Hill, Gillings 
School of Global Public Health Department of Health Policy and Management, Chapel Hill, NC, 
USA, 4University of North Carolina at Chapel Hill, School of Medicine, Division of Hematology/
Oncology, Chapel Hill, NC, USA, 5University of North Carolina at Chapel Hill, School of Medicine, 
Department of Radiation Oncology and Urology, Chapel Hill, NC, USA
Objectives: Recent advances in prostate cancer radiation therapy (RT) technology 
have led to the development of costlier treatments such as intensity-modulated 
radiation therapy (IMRT) compared to the prior standard, conventional radiation 
therapy (CRT). This study examines the two treatment modalities to determine if 
racial disparities in morbidity and disease control may be explained by differential 
use of IMRT versus CRT. MethOds: A population-based study was conducted 
using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data 
from 2000 through 2009 for patients with non-metastatic prostate cancer. Adjusted 
Cox Proportional Hazards models were conducted, adjusting for demographic 
and clinical characteristics. Results are presented as (Adjusted Hazard Ratio [95% 
Confidence Interval]). In subjects without prior morbidity at RT, the rate of recur-
rence, hip fracture, erectile dysfunction, disorders related to gastrointestinal, 
and urinary (incontinence and non-incontinence) morbidity were compared by 
race with IMRT as the referent group. Results: Approximately 10,976 men [524 
African-American (AA) CRT; 423 AA IMRT; 4,746 Caucasian CRT; 5,283 Caucasian 
IMRT] met study eligibility. Diffusion of IMRT was slower among AA compared 
to Caucasians (p< 0.001). Caucasians receiving CRT were at a greater risk for hip 
fracture [1.29; (1.16, 1.43)], cancer recurrence [1.13; (1.04, 1.23)], or urinary incon-
tinence [1.09; (1.01, 1.19)] than those receiving IMRT. No estimates comparing 
AA CRT recipients to AA IMRT recipients reached statistical significance, though 
cancer recurrence, erectile dysfunction, and gastrointestinal morbidity rates were 
greater for CRT subjects cOnclusiOns: There were no statistically significant 
racial disparities in morbidity and disease control related to differential use of 
IMRT versus CRT. However, diffusion of IMRT was significantly slower among AA. 
Future research should include more years of follow-up data and a larger sample 
of AA in order to understand whether measured differences in treatment diffusion 
achieve clinical significance sufficient to explain a portion of the racial disparity 
in prostate cancer mortality.
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OFF-LABEL TRASTUzUMAB USAGE IN BREAST CANCER PATIENT IN TURKEy
Kockaya G.1, Tanyeri P.2, Buyukokuroglu M.E.2, Yenilmez F.B.3, Durmus D.4, Vural I.M.4,  
Akbulat A.4, Artiran G.4, Gursoz H.4, Kerman S.4
1Health Economics and Policy Association, Ankara, Turkey, 2Sakarya University, Sakarya, Turkey, 
3Hacettepe University, Ankara, Turkey, 4Turkish Medicine and Medical Device Agency, Ankara, 
Turkey
comparisons. cOnclusiOns: Current standards around second-line treatment of 
mCRC have evolved over time. The substantial clinical, methodological, and sta-
tistical heterogeneity in the available data prevents evidence-based quantitative 
comparisons of treatment outcomes at this time.
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COMPARISON BETwEEN EvEROLIMUS (AFINITOR®) AND CHEMOTHERAPy 
AGENTS (CAPECITABINE, DOCETAxEL AND DOxORUBICIN) FOR THE 
TREATMENT OF HORMONE RECEPTOR POSITIvE (HR+) HER2 NEGATIvE (HER2–) 
ADvANCED OR METASTATIC BREAST CANCER
Vieira J.1, Chandiwana D.1, Taylor M.2, Lewis L.3
1Novartis Pharmaceuticals UK Limited, GB- Frimley/Camberley, UK, 2York Health Economics 
Consortium, York, UK, 3York Health Economics Consortium, University of York, York, UK
Objectives: This study compares everolimus (EVE) versus the most commonly 
used chemotherapy agents in UK clinical practice (capecitabine [CAPE], docetaxel 
[DOC] and doxorubicin [DOX]) in patients with hormone receptor positive, HER2 
negative advanced or metastatic breast cancer with the purpose of determining 
the effect of everolimus versus chemotherapy through the derivation of hazard 
ratios (HR). MethOds: A systematic review of the literature was performed to find 
evidence that could link EVE with chemotherapy (CAPE, DOC and DOX) in terms 
of progression-free survival (PFS) and overall survival (OS). No head-to-head tri-
als comparing EVE versus chemotherapy were found, the only study that linked 
hormonal therapy with chemotherapy for treatment of metastatic breast cancer 
was Wilcken et al. (2003). Wilcken et al. identified three studies which compared 
OS for tamoxifen versus chemotherapy. None of the studies identified in the sys-
tematic review reported PFS. The link between EVE versus chemotherapy through 
Wilcken et al.(2003) was established via tamoxifen (using Bucher methods), so it 
was assumed that PFS for chemotherapy would be the same as PFS for everolimus 
versus tamoxifen (TAM) from the TAMRAD trial. Results: HR for everolimus versus 
tamoxifen for PFS from the TAMRAD trial is 0.54. For OS, Wilcken et al. derived a HR 
for chemotherapy versus tamoxifen of 0.94. To calculate the HR for OS for everoli-
mus vs tamoxifen the inverse was applied to the OS HR from the TAMRAD trial 
(0.45), hence (1/0.45)= 2.22. The HR for OS for everolimus versus chemotherapy is 
therefore (0.94x2.22)= 2.09. Because a class effect was assumed for the three chemo-
therapy agents, these HRs were applied to capecitabine, docetaxel and doxorubicin 
equally. cOnclusiOns: Compared with the most commonly used chemotherapy 
agents in UK clinical practice (CAPE, DOC and DOX), everolimus has a lower risk of 
death as demonstrated by the HRs derived.
PCN24
TREATMENTS FOR EGFR MUTATION POSITIvE NSCLC – A NETwORK META-
ANALySIS
Fonseca T.1, Lungershausen J.2, Wallenstein G.3, Stammberger U.3, Bertwistle D.1, Griebsch I.2
1IMS Health, London, UK, 2Boehringer Ingelheim Pharma GmbH, Ingelheim am Rhein, Germany, 
3Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany
Objectives: Lung cancer is the most common cause of cancer-related deaths 
world-wide. Afatinib is a novel, potent, irreversible ErbB family blocker. In EGFR 
mutation-positive locally advanced and metastatic non-small cell lung cancer, 
afatinib shows superior effectiveness as a 1st-line treatment compared to stand-
ard-of-care chemotherapy. To date, no head-to-head trial results exist to compare 
the efficacy of afatinib to reversible EGFR TKIs, gefitinib or erlotinib. The analy-
ses presented here attempt to fill this gap by means of a network meta-analysis 
(NMA). MethOds: A systematic literature review (2002-2012) identified the best 
available evidence. Results from afatinib’s pivotal trials (LUX-Lung 3, LUX-Lung 6) 
were added. A NMA following a Bayesian approach (in WinBUGS) was applied to 
estimate the relative treatment effects between afatinib, gefitinib and erlotinib. 
Outcomes of interest were progression free survival (PFS) and overall survival (OS). 
For PFS, results by investigator review were considered as not in all trials PFS was 
assessed independently. Versus erlotinib, afatinib’s results in the two most common 
EGFR mutations studied in erlotinib trials were considered. Sensitivity analyses were 
performed to confirm the robustness of results. Results: Twenty studies, includ-
ing LUX-Lung 3 and LUX-Lung 6, were included; 19 reported OS, 14 reported PFS. 
Results from random effects models are reported. All comparisons versus reversible 
TKIs favoured afatinib, although in most analyses the upper credible interval limit 
exceeded 1. The estimated probability of afatinib being best regarding PFS in all 
mutations was 80% compared to 17% for erlotinib and 3% for gefitinib, and was 43% 
regarding OS compared to 13% for gefitinib and 3% for erlotinib. cOnclusiOns: 
Afatinib consistently showed superior efficacy versus chemotherapy in the pivotal 
trials. In the absence of head-to-head trial results versus reversible TKIs, the NMA 
results suggest also potential superiority of afatinib for both PFS and OS when 
compared to erlotinib and gefitinib.
PCN25
QUALITy INDICATORS OF THE FOURTH SCREENING ROUND (2008-2009) OF 
THE HUNGARIAN ORGANIzED, NATIONwIDE BREAST CANCER SCREENING 
PROGRAMME
Boncz I.1, Dobrossy L.2, Péntek Z.3, Kovács A.2, Budai A.2, Vajda R.1, Sebestyén A.4
1University of Pécs, Pécs, Hungary, 2National Public Health and Medical Officers Service (ÁNTSZ), 
Budapest, Hungary, 3MaMMa Healthcare Ltd., Budapest, Hungary, 4National Health Insurance 
Fund Administration, Pécs, Hungary
Objectives: Organized, nationwide screening for breast cancer with mammogra-
phy started in Hungary in January 2002. Women in the age group 45-65 years are the 
target population and 2 years screening interval is applied. The aim of this study is 
to evaluate the quality indicators of the 4th screening round (2008-2009). MethOds: 
The data derive from the financial database of the National Health Insurance Fund 
Administration (NHIFA) covering the period of 2008-2009. We calculated the follow-
ing indicators: recall rate of women who underwent mammography examinations, 
attendance of re-called women, proportion of women referred to surgery, proportion 
of women who underwent surgery compared to referred women, proportion of 
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THERAPy SEQUENCES IN MULTIPLE MyELOMA – A CLINICAL MODEL STUDy IN 
REGARDS OF A GERMAN COST CONTExT
Wirth D.1, Loellgen N.2, Knop S.3
1Janssen, Neuss, Germany, 2Janssen-Cilag, Neuss, Germany, 3Universitätsklinikum Würzburg, 
Würzburg, Germany
Objectives: With a vast number of possible treatment options for Multiple 
Myeloma patients, it is unclear in which combination and sequencing compounds 
should be used to achieve prolonged overall survival. This question cannot be timely 
answered with an RCT, a health economic model (1) was used to approximate for 
OS and adopted for a German cost setting. MethOds: Using a combination of 
meta-analysis and -regression, the possible overall survival of different therapy 
sequences is approximated in a Markov model. Data source for this model is a 
systematic literature research covering 2008-2012, identifying a total of 68 studies 
and 11.115 patients in Multiple Myeloma. From each study treatment arm, response 
per therapy and therapy line was extracted. Subsequently, a regression analysis was 
used to specifically determine the “time to next treatment (TTNT)”. TTNT is used 
in our model study to reflect the positive correlation of response to therapy and 
disease progression, which has shown to be highly related (2-5). Using TTNT, the 
model can now demonstrate which sequence of therapies in 1st, 2nd and 3rd line 
will total to a possible OS of a patient. Results: We analyzed 13 sequences from 
over 200 theoretical combinations, based on their German approval. Early usage of 
new compounds results in a prolongation of overall survival of at least 6 months, 
compared to the standard therapy with melphalan/prednisone (6), with minimal 
possible OS between 3.98 and 5.06 years. Cost data from Germany were included 
to amount costs of therapy for a complete sequence. For the sequences presented, 
costs range between 69.000 and 135.000 € . The majority of those costs accrue from 
drugs, not from other resources. cOnclusiOns: An important topic of modeling 
approaches is to show both internal and external validity, which is both needed to 
validate the prognoses. The external validation is currently undertaken using data 
from cancer registries and non-interventional studies.
PCN32
THE ESTIMATED SURvIvAL OF PATIENTS wITH DOUBLE REFRACTORy CHRONIC 
LyMPHOCyTIC LEUKAEMIA; A REANALySIS OF NICE TA202 USING BAyESIAN 
METHODOLOGy TO MODEL OBSERvED DATA
Almond C.1, Stevens J.W.2, Ren K.2, Batty A.1
1BresMed, Sheffield, UK, 2University of Sheffield, Sheffield, UK
Objectives: Standard therapy for chronic lymphocytic leukaemia (CLL) is fludara-
bine, followed by alemtuzumab. Patients resistant to both treatments (double refrac-
tory (DR)-CLL) receive best supportive care (BSC). Ofatumumab is licensed for the 
treatment of DR-CLL, but was not recommended by the National Institute for Health 
and Care Excellence (NICE technology appraisal 202 (TA202)). There is little clinical 
data for BSC in DR-CLL. TA202 identified a single-arm study of ofatumumab and 
an observational study of BSC. Survival for BSC in TA202 was modelled by fitting a 
Weibull distribution to data for ofatumumab non-responders. The effects of ofatu-
mumab were estimated by assuming a proportional hazards model. The objective of 
this study was to investigate the potential sources of survival data for BSC, and the 
impact of the choice of survival distributions used in TA202 on the cost-effectiveness 
of ofatumumab. MethOds: Individual patient-level data was reconstructed from 
Kaplan-Meier curves using a published algorithm. Plausible survivor functions were 
fitted to the data using Markov chain Monte-Carlo simulation. Goodness-of-fit to 
the observed data was assessed using deviance information criterion and the clini-
cal plausibility of extrapolations using subjective opinion. The cost-effectiveness 
model from TA202 was reproduced including alternative survival data. Results: 
A Weibull distribution provided the best fit to the data and was most clinically 
plausible. If proportional hazards were assumed (as in TA202) the incremental cost-
effectiveness ratio (ICER, incremental cost per life year gained) was £52,400, simi-
lar to £49,252 reported in TA202. Relaxing the assumption of proportional hazards 
increased the ICER to £85,618. cOnclusiOns: The best fitting and most clinically 
plausible model was a Weibull distribution, giving results consistent with TA202; 
however both the use of a subgroup of a single arm trial and of data from multiple 
studies has a high level of uncertainty. Relaxing the assumption of proportional 
hazards increased the ICER.
PCN33
AFLIBERCEPT + FOLFIRI (AF) vERSUS. PLACEBO + FOLFIRI (PF) IN METASTATIC 
COLORECTAL CANCER (MCRC): MEAN OvERALL SURvIvAL (OS) IN A “BETTER 
RESPONDERS” PATIENT POPULATION OF THE vELOUR TRIAL
Joulain F.1, Naoshy S.2, Chau I.3, Iqbal S.U.2, Bridgewater J.4
1Sanofi, Chilly-Mazarin, France, 2Sanofi, Cambridge, MA, USA, 3Royal Marsden Hospital, Sutton, 
Surrey, UK, 4University College Hospital, London, UK
Objectives: The VELOUR trial demonstrated significant survival benefit for afliber-
cept plus FOLFIRI (5-fluorouracil-leuocovorin-irinotecan) versus FOLFIRI alone in 
mCRC patients previously treated with oxaliplatin. Multivariate analysis identified 
a subset of “better responder” patients who derive sustained benefit with AF, which 
includes patients who did not experience an early relapse directly from adjuvant 
setting (10% of patients included in VELOUR) and with either ECOG PS0 or (PS1 and 
≤ 1 metastatic site). Median OS was significantly improved in AF arm: 16.2 versus 
13.1 months for PF (adjusted HR = 0.73 [95% CI: 0.61–0.86]). Mean survival estimation 
can render a more meaningful estimate for long-term benefit of interventions and 
can be effectively applied to clinical and economic decision support. Our objective 
was to derive mean OS for the “better responders” subgroup in VELOUR. MethOds: 
As survival probability at the end of the follow-up period was 21% in AF vs 8% in PF, 
mean OS was estimated by extrapolating the KM curve using a survival function over 
a 15-year period. Five standard parametric distributions were tested: exponential, 
Weibull, lognormal, loglogistic and Gompertz. Goodness-of-fit of distributions was 
evaluated by Akaike’s Information Criteria (AIC), Bayesian Information Criteria (BIC) 
and graphical methods. Results: Of the 1226 patients enrolled in VELOUR, 404 
Objectives: Off-label use of medications is extremely common especially in 
oncology. The aim of this study is to help update the guidelines and determine 
pharmaceuticals and off-label indications in breast cancer. MethOds: This study 
involved patients (n= 1317) with metastatic breast cancer with tumors that were 
defined as human epidermal growth factor receptor 2, ErbB-2 positive who received 
trastuzumab or other medicine application off-label usage in Turkey. During this 
period using trastuzumab was licenced only for 9 weeks, not for 52 weeks in Turkey. 
A computer search was performed using the TITCK’s ( Turkish Drug and Medical 
Devices Institution) database. The patient base was searched for off-label medi-
cine applications between 1 June 2008 to 1 June 2010. Results: The average age 
were 49.02 ± 10.46. Overall, 85 % of applications were approved in generally 8 or 9 
weeks period. It was found that the Marmara Region had the highest application 
percentage (33.26 %) and then the Central Anatolia Region (27.9 %). Evaluated on 
the base of cities Istanbul, Ankara and Izmir had the most applications with 29.6 
%, 19.2 % and 15.7 % respectively. University hospitals were created the most of 
the applications (81.1%), other applicaitons were from education & research hos-
pitals (10.2 %) and private hospitals ( 5.9 %). Off-label drug usage in breast cancer 
medication, physicians were preferred trastuzumab, trastuzumab+vinoralbin and 
lapatinib. cOnclusiOns: Trastuzumab had the highest percentage in all off-label 
medicine applications for breast cancer usage. On the other hand, 85 % of all tras-
tuzumab off-label usage applications were approved. The reason of 15 % of trastu-
zumab applications is needed to be investigated further.
PCN29
ASSESSMENT OF PATIENT POPULATION wITH NSCLC By STAGE, ECOG-PS, EGFR 
MUTATION STATUS AND LINE OF THERAPy IN GERMANy
Schmidt U.1, Drechsler M.1, Assmann G.1, Kempel A.2
1Boehringer Ingelheim, Ingelheim, Germany, 2Pharmametrics GmbH, Freiburg, Germany
Objectives: To assess the patient population with advanced non-small cell lung 
cancer (NSCLC) with EGFR (epidermal growth factor receptor) positive mutation 
in Germany who are eligible for tyrosine-kinase inhibitor (TKI) therapy. An accu-
rate assessment of the relevant patient population provides the basis for budget 
impact analyses in health technology assessments. MethOds: A systematic litera-
ture review was conducted. In addition, data from various cancer registries, cohort 
studies and surveillance studies were analyzed and compared with the findings 
in the literature. Results: In a first step the proportion of patients with NSCLC 
was determined. Data was further differentiated by histologic subgroup (adeno-
carcinoma, large-cell carcinoma, squamous carcinoma and other carcinoma). The 
analysis revealed that the proportion of adenocarcinoma among the group of NSCLC 
has increased in Germany, especially among women from about 40% in 2000 to over 
58% in 2009, in men from 28% to almost 40%, respectively. The proportion of patients 
with locally advanced or metastatic NSCLC (stage IIIb/IV) ranged between 51%-70%. 
The proportion of patients harbouring an EGFR mutation ranged between 5%-17%, 
differing by histologic subgroup, with the highest EGFR mutation rates (9%-26%) 
in patients with adenocarcinoma. The distribution of patients by ECOG (Eastern 
Cooperative Oncology Group) Performance Status (PS) showed that at diagnosis 63%-
92% had an ECOG-PS 0-1. On average, first line therapy was received by over 80% of 
patients, while only 52%-65% underwent second line therapy and third line therapy 
was received by 15%-25% only. cOnclusiOns: By analyzing all available data it is 
possible to provide good estimates of the relevant patient population. Although 
significant advances have been made in reporting and data collection for relevant 
patient subgroups related to NSCLC, there still is a large lack of representative data 
on a national level in Germany.
PCN30
ESTIMATING PREvALENCE OF PROSTATE CANCER CLINICAL STATES USING A 
DyNAMIC PATIENT PROGRESSION MODEL
Dass R.N.1, Wheatley Price P.1, Goosey R.2, Spencer M.3, Prütz C.1, Ahlgren G.4, Berruti A.5, Ford 
D.6, Hamberg P.7, Klier J.8, Ribal M.J.9, Schrijvers D.10, Wolff J.M.11, Durand A.1
1Janssen-Cilag Limited, High Wycombe, UK, 2Kantar Health, Epsom, UK, 3Janssen, High Wycombe, 
UK, 4Skanes University Hospital, Malmö, Sweden, 5University of Brescia, Brescia, Italy, 6Queen 
Elizabeth Hospital Birmingham UK, Birmingham, UK, 7Sint Franciscus Gasthuis & Prostate 
Cancer Center Rotterdam, Rotterdam, The Netherlands, 8UPK (Urologische Partnerschaft Köln), 
Köln, Germany, 9Hospital Clinic, University of Barcelona, Barcelona, Spain, 10Ziekenhuisnetwerk 
Antwerpen-Middelheim, Antwerp, Belgium, 11AKH Viersen, Viersen, Germany
Objectives: Prostate cancer (PC) is the most common solid neoplasm in Europe. 
Accurate estimates of prevalence and patient flow through PC states are necessary 
to analyse disease burden and the health economic impact of novel therapies. This 
study presents a dynamic patient progression model (PM) estimating the popula-
tion size of 13 PC clinical states across 8 European countries (EU8; Belgium, France, 
Germany, Italy, The Netherlands, Spain, Sweden, and UK). MethOds: A dynamic 
PM was developed using a 27-year time horizon to estimate the prevalence and 
progression of PC from diagnosis through possible death, using a sequence of 13 
Markov clinical states (5 non-metastatic and 8 metastatic). Incidence data were 
taken from local country registries from 1993 to 2012, and a simple growth model 
was used to forecast incidence rates to 2020 and beyond. PM flow structure, prob-
abilities of prevalence, progression, and mortality per clinical state were determined 
using a Delphi panel of PC experts from the EU8 countries and based on published 
literature and local research. Results: A consensus of expert opinion was reached 
on the clinical states and flow rates of patients with PC in Europe. This resulted in 
a refined PM with new clinical states that represent the current treatment para-
digm for PC. The PM also estimated growth in prevalence and mortality of future 
PC patient populations across 13 different clinical states of PC from 2012 to 2020. 
Five-year prevalence rates from the PM were in agreement with those from the 
GLOBOCAN 2008 project. cOnclusiOns: The PM obtained by consensus of expert 
opinions provided patient prevalence and mortality estimates for 13 distinct PC 
clinical states. The PM and patient flow rates provide a representative simulation 
of the local environment, which can be used to assess PC disease burden, health 
economic impact, and cost of PC care in the EU.
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medium risk (OS mean time = 11.6 months, 61%) and other of low risk were obtained 
(OS mean time = 31.7 months, 38%). For NSCLC patients with immunotherapy a 
population of medium risk (OS mean time = 11.2 months, 55%); a population of 
low risk (OS mean time = 23.8 months, 33%); and another of very low risk or long-
term survival were obtained (OS mean time = 55.5 months, 12%). cOnclusiOns: 
Our analyses support the existence of several populations regarding OS among 
advanced stage lung cancer.
PCN37
SURvIvAL ANALySIS USED IN COMPANy SUBMISSIONS TO THE NATIONAL 
CENTRE FOR PHARMACOECONOMICS, IRELAND
McCullagh L., Barry M.
National Centre for Pharmacoeconomics, Dublin, Ireland
Objectives: Many company submissions received by Health Technology 
Assessment (HTA) Agencies evaluate the cost effectiveness of interventions which 
impact on survival. An accurate estimate of the survival benefit is required to cal-
culate a reliable estimate of cost effectiveness. Generally the relevant trial data 
is immature and must be extrapolated. Many extrapolation models are available. 
Model choice is critical; different models can lead to different cost effectiveness 
results. The objectives were to review the methods/justification of the survival anal-
ysis used in company submissions to the National Centre for Pharmacoeconomics 
(NCPE). A further aim was to develop NCPE Guidance for the future handling of 
survival analysis. MethOds: Relevant submissions to the NCPE (economic evalu-
ations which had dealt with advanced and/or metastatic cancer) were reviewed 
to determine the methods/justification of the survival analysis used. Results: 
Twelve submissions were evaluated. Appropriately, the mean overall survival (OS) 
had been estimated and used in eight cases (67%). Median OS estimates had been 
estimated/used in three (25%). It was unclear which measure had been used in the 
remaining submission. The submissions which had used mean OS estimates were 
further investigated. Parametric model-based extrapolation techniques had been 
used to calculate the mean estimates in all eight. The most popular parametric 
models were the Weibull (n= 3) and the loglogistic (n= 3). The methods used to fit the 
parametric models varied. Most commonly the model was fitted using individual 
patient-level data. Some justification for the choice of extrapolation technique was 
offered in five submissions; AIC +/or BIC were estimated in three and visual inspec-
tion was reported in two. cOnclusiOns: Survival analysis has not been conducted 
appropriately in all HTAs. Justification of the choice of model is not always offered. 
Moving forward, NCPE Guidance is required to ensure that survival analysis using 
patient-level data is conducted appropriately. These will be presented.
CANCER – Cost Studies
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BUDGET IMPACT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER 
(CRPC) TO GERMAN PAyERS
Jensen I.S.1, Wu C.1, Cyr P.L.1, White R.E.2
1PriceSpective LLC, Cambridge, MA, USA, 2Teva, Inc, Horsham, PA, USA
Objectives: The 2010 Urological Association Guidelines for Management of 
Castrate-Resistant Prostate Cancer (CRPC) recommend docetaxel plus prednisone 
for first-line chemotherapy for symptomatic metastatic CRPC patients who have 
progressed from hormone therapy. Since 2010, several CRPC agents with better toler-
ability and longer survival have launched. These improved therapies are causing a 
shift in practice. The aim of our analysis was to 1) quantify the 3-year mCRPC budget 
impact for the German health system based on the practice shift, and 2) estimate 
the cost per additional month of progression-free survival (PFS). MethOds: A con-
ceptual decision analytic model was developed for the German health system to 
estimate the impact on direct medical costs of a therapy shift in CRPC over three 
years. Guideline recommended regimens were represented in model with three 
lines of therapies: palliative, abiraterone, enzalutamide, docetaxel and cabazitaxel. 
Progression in therapy was measured as the duration of PFS. A targeted literature 
search identified US per-patient-per-month costs of docetaxel treated patients (hos-
pitalization= € 954, ambulatory= € 765, ER= € 32, MD= € 318) and were adapted to the 
German health system by applying a published purchase price parity factor. Drug 
costs were based on Ex-factory pricing. Adverse event rates were used as a proxy 
to derive relative resource utilization of other treatments. Utilization of CRPC regi-
mens was informed by interviews with EU opinion leaders. Results: The shift in 
practice pattern is expected to increase the German health system’s 3-year budget 
by € 23 million. The additional cost/month of PFS is estimated to decrease by € 99/
month from € 4,659 for current treatment mix to € 4,560 for future treatment mix 
by year 3. cOnclusiOns: From the German health system’s perspective, a change 
in practice pattern will result in an increase in total budget of € 23 million. The 
reduction in cost/month of PFS of € 99/month indicates the shift in practice will 
use more efficient therapies.
PCN39
ECONOMIC IMPACT OF DENOSUMAB FOR SKELETAL RELATED EvENT 
PREvENTION IN PATIENTS wITH PROSTATE CANCER AND BONE METASTASIS 
FROM A UNITED STATE MANAGED CARE ORGANIzATION PERSPECTIvE
Arellano J.1, Cristino J.2, Chen K.3
1Amgen Inc., Thousand Oaks, CA, USA, 2Amgen (Europe) GmbH, Zug, Switzerland, 3Amgen, Inc., 
Thousand Oaks, CA, USA
Objectives: To evaluate clinical and economic impact of increasing deno-
sumab use compared to zoledronic acid (ZA) in PrCa patients with BM to a 
MCO. MethOds: An economic model was developed to estimate clinical and eco-
nomic impact to a 1-million-member US MCO of introducing denosumab as bone 
targeting agent (BTA) for prevention of SREs in PrCa patients with BM. Total number 
of patients receiving BTA was estimated based on disease prevalence and treat-
ment eligibility in this population. The real-world SRE rates in ZA-treated patients 
were derived from a large commercial database and used together with the trial-
(66.0%) AF patients and 406 (66.1%) PF patients were classified in “better responders” 
subgroup. Lognormal and loglogistic distributions were the 2 distributions provid-
ing the best fit to the observed OS data, with very similar and good fit. Mean OS 
over 15-years using loglogistic distribution was 24.8 vs. 18.6 months for AF and PF, 
respectively. cOnclusiOns: Post-hoc analysis suggested that the “better respond-
ers” subgroup of patients within VELOUR derived enhanced survival benefit with 
the AF combination. The results highlight the therapeutic benefit of AF in clinically 
relevant patient subpopulations.
PCN34
FACTORS DRIvING INEQUALITy IN PROSTATE CANCER SURvIvAL: A 
POPULATION BASED STUDy
Burns R.1, Sharp L.2, Sullivan F.J.3, Deady S.2, Drummond F.J.2, O’Neill C.1
1NUI Galway, Galway, Ireland, 2National Cancer Registry Ireland, Cork, Ireland, 3Prostate Cancer 
Institutue, Galway, Ireland
Objectives: As cancer control strategies have become more successful, issues 
around survivorship have become increasingly important to researchers and policy 
makers. The aim of this study was to examine the role of a range of clinical and 
socio-demographic variables in explaining variations in survival after prostate 
cancer diagnosis, paying particular attention to the role of health care provider(s) 
(i.e. private vs. public) and socio-economic status. MethOds: Data were extracted 
from the National Cancer Registry Ireland, for patients diagnosed with prostate 
cancer from 1998-2009 (N= 26,183). A series of multivariate Cox and logistic regres-
sion models were used to examine the role of health care provider and socio-
economic status (area-based deprivation) on survival, controlling for age, stage, 
Gleason grade, marital status and region. Survival was based on all-cause mortal-
ity. Results: Individuals who were treated in a private care setting were more 
likely to have survived than those who had not, when other factors were controlled 
for. A socio-economic gradient was evident with respect to marital status, region 
of residence, clinical stage and Gleason grade. The effect of socio-economic status 
was modified by health care provider, such that risk of death was higher in those 
of lower socio-economic status for men treated by public, but not private, provid-
ers. cOnclusiOns: The role of health care provider (a proxy for voluntary private 
insurance) and socio-economic status in survival of men with prostate cancer may 
give rise to equity concerns regarding the operation of the Irish health care system 
and warrants further investigation.
PCN35
CONDITIONAL SURvIvAL (CS) PROBABILITIES FOR ADvANCED MELANOMA 
PATIENTS TREATED wITH IPILIMUMAB: MODEL BASED ANALySIS
Lee D.1, Kotapati S.2, Gueron B.3, Bapat U.4, Batty A.J.1
1BresMed, Sheffield, UK, 2Bristol-Myers Squibb Pharmaceuticals, Wallingford, CT, USA, 3Bristol-
Myers Squibb, Rueil Malmaison, France, 4Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK
Objectives: There are few treatments available for advanced melanoma and sur-
vival rates are low. While the incidence of the disease continues to rise, only two 
new treatments have come to the market recently: ipilimumab and vemurafenib. 
Ipilimumab is indicated in Europe for the treatment of advanced melanoma in 
adults who have received prior therapy. Ipilimumab has demonstrated a statistically 
significant improvement in overall survival in 2 Phase III RCTs. Prolonged survival 
(> 2 years in some patients) has been shown (MDX020 & 024). MethOds: Data from 
the MDX010-20 trial, which was conducted in previously treated patients with a 
maximum follow up duration of 55 months, was used to develop an economic model 
for health technology assessment in England & Wales. This model has been used 
to predict the conditional survival (CS) of patients treated with ipilimumab (based 
on both ipilimumab containing arms) compared to gp100 – the active control. The 
model used patient level Kaplan–Meier data for the first 18 months, parametric 
curves fitted to the patient level data from 18 months to 5 years, and published AJCC 
registry data beyond 5 years. Results: The curves were a good fit to the MDX010-20 
trial data (MAE 0.003) and consistent with published Phase II data (which provides 
a longer time horizon). Given an ipilimumab patient has survived 2 years, the mod-
elled probability of being alive at 5 years is 67% (49%,79%) (gp100: 15% [9%,21%]) and 
at 10 years is 54% (39%, 63%) (gp100: 2% [1%,3%]). cOnclusiOns: The model shows 
that a substantial proportion of patients treated with ipilimumab surviving to 2 
years are likely to have sustained survival benefits: more than 50% of ipilimumab 
patients surviving to 2 years are alive at 10 years, with 29% remaining alive at 20 
years. This level of sustained survival is not shown by gp100 patients.
PCN36
ESTIMATING AND MODELING LONG TERM SURvIvAL IN LUNG CANCER USING 
MIxTURE PARAMETRIC MODELS
Sánchez L.1, Luaces P.1, Viada C.1, Galan Y.2, Ballesteros J.3, Rodríguez P.C.1, Crombet T.1,  
Lage A.1
1Center of Molecular Immunology, Havana, Cuba, 2Cuban National Cancer Registry, Havana, 
Cuba, 3University of the Basque Country UPV/EHU, Leioa, Spain
Objectives: To ascertain the existence of several populations regarding overall sur-
vival (OS) in patients with advanced non-small-cell lung cancer (NSCLC). MethOds: 
Data of OS from the Cuban National Cancer Registry (CNCR) and from Cuban mul-
ticentre trials of immunotherapy were analysed with a lognormal mixed model 
assuming 1 to 6 underlying populations. The Bayesian Information Criterion (BIC) 
was used to select the best model fitted to the data in all cases. Results: The CNCR 
provided data for 31133 patients diagnosed with lung cancer since January 1998 
until December 2008. Of those, 7286 patients presented stages IIIb-IV of NSCLC at 
diagnosis and were selected for analysis. The immunotherapy Cuban trials provided 
data for more than 750 patients enrolled in 8 trials conducted since 1997 until 2010. 
The mixed model applied to CNCR data separated 4 populations: very high risk (OS 
mean time = 0.62 months, 23% of the sample); high risk (OS mean time = 3.1 months, 
34%); medium risk (OS mean time = 9.2 months, 35%); and low risk (OS mean time 
= 29.1 months, 8%). Results for clinical trials separated 2 populations for controls 
and 3 populations for the immunotherapy groups. For controls a population of 
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Objectives: Whilst the cost-effectiveness of everolimus + exemestane (EVE+EXE) 
versus placebo + exemestane (PBO+EXE) in patients with ER+ HER2- metastatic 
breast cancer has been demonstrated elsewhere, this is the first analysis to assess 
the implications for health spending at a population level. MethOds: The model 
uses a cumulative cohort approach, allowing incident patients to enter the model 
each year over a five-year period. The incident population was based on several 
factors: (i) the female population aged > 15 years; (ii) the proportion of those women 
with advanced invasive breast cancer; (iii) the proportion who are post-menopausal; 
(iv) the proportion who are hormone receptor positive; (v) the proportion who are 
HER2-; (vi) the proportion with asymptomatic visceral disease, and (vii) the propor-
tion for whom hormonal therapy is appropriate. Finally, the cohort was filtered 
to show those who had previously relapsed or progressed on NSAI. ‘Per patient’ 
treatment and adverse event costs were generated based on treatment-specific 
progression-free survival curves, and multiplied by the number of patients expected 
to receive each treatment according to market share data and likely uptake rates. 
An incremental analysis was performed, where two scenarios were compared: (i) a 
world without EVE+EXE, and (ii) a world with EVE+EXE. Results: It is expected that 
a total of 1,052 patients will be eligible to receive EVE+EXE over a five-year period. 
In a ‘world without EVE+EXE’, the total five year cost was estimated as £1,652,904. 
Assuming an annual uptake rate of 10%, in a ‘world with EVE+EXE’ the total cost 
over the same period was expected to be £2,271,606. Therefore, the incremental cost 
associated with the introduction of EVE+EXE in England and Wales is £618,702 over 
five years. cOnclusiOns: EVE+EXE was associated with modest increased health 
care costs but has, separately, been demonstrated to lead to incremental health 
benefits compared with other treatments.
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INCORPORATING STAKEHOLDER INPUT INTO BUDGET IMPACT MODELS TO 
COMPARE STEM CELL MOBILIzATION STRATEGIES
Jensen I.S.1, Halbert R.J.2, Grosvenor A.3, Schwartz E.L.4, Rossi D.G.5, Naoshy S.6, Iqbal S.U.6, Xiao 
Z.6, McSweeney P.A.7
1PriceSpective LLC, Cambridge, MA, USA, 2ICON, PriceSpective LLC, El Segundo, CA, USA, 
3PriceSpective, London, UK, 4PriceSpective LLC, San Diego, CA, USA, 5Medica Spedali Civili, 
Brescia, Italy, 6Sanofi, Cambridge, MA, USA, 7Colorado Blood Cancer Institute (CBCI) and The 
Rocky Mountain Blood and Marrow Transplant Program, Denver, CO, USA
Objectives: There is a dearth of published health economic evidence on stem cell 
(SC) mobilization that can be leveraged effectively for transplant center decision 
making. Our objective was to develop representative budget impact models (BIM) for 
key decision makers to estimate the total financial impact of adopting plerixafor for 
SC mobilization patients undergoing autologous peripheral stem cell transplanta-
tion (ASCT) for multiple myeloma and lymphoma. The BIMs were developed for EU5 
(France, Germany, Italy, Spain, UK) and United States (US). MethOds: Prior to BIM 
development, in-depth interviews were conducted in EU5 (n= 33) and US (n= 20), to 
determine the most influential decison maker(s) for choosing a mobilization regi-
men. The choice of inputs and outputs that are critical for the adoption of plerixafor 
at the hospital level, were determined. Additionally, the BIM was developed using 
inputs from published literature and market research. Results: Primary research 
revealed that the center director and treating physician are the most influential 
decision makers, while hospital administrators, transplant coordinators, pharmacy 
directors, and apheresis directors have a more limited role. There was consensus 
on inputs critical for assessment: clinical (drug/regimen utilization, apheresis days, 
and success/failure rates) and economic (mobilization costs; drug costs; apheresis 
cost and hospitalization costs). Model outputs include: first mobilization success 
and total mobilization budget impact. Interviews with clinical experts, and primary 
literature review determined that the relevant mobilization regimen comparators 
for the models are Granulocyte-Colony Stimulating Factor (G-CSF) alone, G-CSF and 
plerixafor, G-CSF and chemotherapy mobilization with cyclophosphamide and the 
triple regimen G-CSF, chemotherapy mobilization and plerixafor. cOnclusiOns: 
Conducting primary interviews with key stakeholders and using the latest clinical 
practice information for critical inputs/outputs is essential for developing a repre-
sentative model that is applicable to decison makers.
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BREAST CANCER SCREENING PROGRAM IN THE BASQUE COUNTRy: COSTS AND 
HEALTH BENEFITS ASSESSMENT THROUGH DISCRETE EvENT SIMULATION
Arrospide A.1, Mar J.1, Comas M.2, Rue M.3, Larrañaga N.4, Acaiturri T.5, Sarriugarte G.6
1Hospital Alto Deba, Mondragon, Spain, 2IMIM- Institut de Recerca Hospital del Mar, Barcelona, 
Spain, 3Biomedical Research Institute of Lleida (IRBLLEIDA), University of Lleida. Red de 
Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Lleida, Spain, 4Basque 
Government, Donostia, Spain, 5Hospital de Cruces, Barakaldo, Spain, 6Direccion Territorial de 
Sanidad de Bizkaia, Bilbao, Spain
Objectives: In the Basque Country (Spain), mammographies have been done in bien-
nial basis to women in their fifties and sixties since 1996. The main objective of this 
project was the evaluation of the impact of the Screening program in terms of costs 
and health in the Basque women population since 1996. MethOds: A discrete event 
simulation model was built to represent the natural history of breast cancer in women 
invited to the breast cancer screening program in the Basque Country. The disease 
progress was described in three main states (healthy, preclinical and clinical) in the 
model. We assumed all women would be diagnosed at the beginning of the clinical 
stage unless it had been diagnosed previously through the screening program. The data 
collected among the 15 years when the screening program was held allowed model’s 
validation. In order to compare the economic impact of these scenarios mammography 
and treatment costs – depending on the diseasestage at diagnosis – were included. The 
health impact assessment was based on quality adjusted life expectancy of cancer 
patients. Results: Since the screening program started working, 8,925 cancers were 
detected among 313,475 women who attended the screening which represents the 76% 
of the invited ones. 60% of the diagnosed cancers were detected through the screening 
program. All the mammographies carried out during the evaluated years costed 46 
million Euros. Each cancer detected in the screened scenario costs 29,581.06€ , in the 
based treatment effect for denosumab versus ZA to estimate the denosumab SRE 
rate. Total number of SREs, total SRE management medical cost, BTA drug cost, 
and total cost were calculated. The impact of denosumab per-member-per-month 
(PMPM) at increasing utilization rates was assessed by comparing to a scenario 
without denosumab, i.e., all patients received ZA and reported. Additionally, 
impact of annual increase in denosumab use was conducted. Results: A total 
of 63 PrCa patients with BM received BTA. In the scenario where all eligible patients 
receiving ZA, an annual total number of SREs was 120. An annual denosumab use 
of 20%, 35% or 45% resulted in 4.2%, 7.4%, and 9.5% reduction in total SREs and 
5.3%, 9.3%, and 11.9% reduction in medical costs of managing SREs, compared to 
all patients receiving ZA. The drug cost was partially offset by the reductions in 
the medical cost and the increase in total cost was minimal (1.2%-2.7%). The PMPM 
ranged $0.002-$0.005. Consecutive-year analysis showed $0.001 increase in PMPM 
with 10% denosumab utilization increase. cOnclusiOns: Due to superior efficacy 
of denosumab versus ZA in SRE prevention in PrCa patients with BM, increased 
denosumab use results in medical cost reduction in a US MCO. Overall, denosumab 
provides additional clinical value with limited budget impact.
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BUDGET IMPACT ANALySIS OF IPILIMUMAB FOR THE TREATMENT OF 
ADvANCED MELANOMA IN THE vENETO REGION, ITALy
Adami S1, Aiello A.2, Palozzo A.C.3, Magrì M.R.2, Visentin E.2, Chiarion V.4, Michelon A.2, Alberti 
C.5, Maran P.R.2, Saugo M.6, Scroccaro G.1
1Regione Veneto, Venezia, Italy, 2UVEF Regional Drug Coordination Centre, Verona, Italy, 
3Venetian Oncology Institute, Padova, Italy, 4Venetian Oncology Instituite, Padova, Italy, 5Azienda 
Ospedaliero Universitaria di Verona, Verona, Italy, 6Regione Veneto, Padova, Italy
Objectives: Ipilimumab is the first drug to be licensed in Italy for the treatment 
of advanced melanoma in adults who have received prior therapy. This study 
aims to estimate the budget impact of ipilimumab in patients who live in the 
Veneto Region. MethOds: Our analysis was performed from the perspective 
of the Italian health care system. Two scenarios were analyzed: one with the 
optimization of vials and the other without. Only drug acquisition costs (meas-
ured in euro) were considered into the analysis. All costs were referred to year 
2013. Results: Based on the incidence and mortality rates of the last three 
years, a total of 80 adult patients were assumed to be elegible for the treatment 
in the Veneto Region. The cost per mg of ipilimumab was € 53,70: one 10 ml vial 
contains 50 mg of ipilimumab and one 40 ml vial contains 200 mg of ipilimumab. 
The recommended induction regimen is 3 mg/kg administered intravenously 
every 3 weeks for a total of 4 doses. The costs per patient of one year’s therapy 
with ipilimumab ranged from € 45.108 with vial optimization (considering 4-5 
patients infused at the same time - average weight 70 kg) to € 53.700 without. 
The Veneto Region identified a single center for the preparation/administration 
of treatment to minimize drug waste and to reduce the yearly treatment cost 
per patient, with a saving of € 8.592 per patient/year. Applied to whole elegible 
patients (average weight 70-75 kg), it allows to obtain savings up to € 430.000-
690.000 per year. cOnclusiOns: High prices for new cancer drugs are a growing 
concern to payers, given the large number of cancer drugs in development and 
the limited health care resources. Vial optimization may be an useful strategy 
to decrease waste, maximizing the use of health care resources and ensuring 
that eligible patients are treated.
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ECONOMIC EvALUATION OF EPOETIN ALFA HExAL (BINOCRIT) COMPARED 
TO DARBEPOETIN ALFA (ARANESP) IN THE TREATMENT OF CHEMOTHERAPy 
INDUCED ANEMIA (CIA) IN GERMANy
Turner M.1, Walsh K.1, Whitehouse J.2
1Sandoz Biopharmaceuticals, Holzkirchen, Germany, 2GfK Bridgehead, Melton Mowbray, UK
Objectives: To compare the budget requirements of utilizing epoetin alfa Hexal vs. 
darbepoetin alfa in the German health care system MethOds: Anemia is a com-
mon side effect observed in patients receiving myelosuppressive chemotherapy. The 
purpose of this pharmacoeconomic analysis was to evaluate the cost-effectiveness 
of the short-acting biosimilar ESAs epoetin-alfa Hexal (EA) 30,000 or 40,000 IU weekly 
(QW) versus long-acting erythropoiesis-stimulating agent (ESA) darbepoetin alfa 
(DA) 150 mcg weekly (QW) and 500 mcg once every 3 weeks (Q3W) for the treatment 
of CIA. A budget impact model was constructed employing a payer perspective, per 
patient plus 5 year time horizon. The treatment period considered was based on 12 
weeks and was aligned with routine chemotherapy regimen administration. Model 
inputs included: medical treatment, outcomes, and health care service utilization 
from published clinical studies and summary of product characteristics recom-
mendation. Effectiveness of therapeutic alternatives was determined by comparing 
hemoglobin maintenance rates. Initial treatment with biosimilar epoetin α 30,000 
IU or 40,000 IU per week has been shown to produce a similar Hb response. Costs 
included only drug acquisition costs and reflect 2013 data. The analysis was per-
formed from the perspective of the German health care system. Results: The 
average expected pharmaceutical costs per patient were € 4,843 for DA Q3W, € 4,383 
for DA QW and € 2,944 for EA 30,000IU QW, € 3,946 for EA 40,000IU QW. Cost-savings 
associated utilizing with utilizing Epoetin Alfa Hexal 30-40,000 are 11-49% to DA 
QW and were 23-64% relative to DA 3QW. cOnclusiOns: In the treatment of CIA 
among cancer patients in Germany, epoetin alfa Hexal is projected to provide more 
efficient use of health care resources compared to alternative treatment strategies 
with darbepoetin alfa.
PCN42
A BUDGETARy IMPACT ANALySIS MODEL FOR EvEROLIMUS IN THE 
TREATMENT OF ER+ HER2- METASTATIC BREAST CANCER IN ENGLAND AND 
wALES
Taylor M.1, Lewis L.2, Vieira J.3, Chandiwana D.3
1York Health Economics Consortium, York, UK, 2York Health Economics Consortium, University of 
York, York, UK, 3Novartis Pharmaceuticals UK Limited, GB- Frimley/Camberley, UK
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prices fixed by negociation between the Comité Economique des Produits de Santé 
and the manufacturers. The average discount ranges from 11% to 73%. The aver-
age EMI varies between 1.42 and 2.69 € excluding value added tax (EVAT) per 1000 
international units and between 0.09 and 0.22 € EVAT per microgram according 
to the medicinal product. The average amount refunded to HF can be estimated 
at january 1, 2012 at 3.37 M€ , or 22.6% of the total budget. We assessed annual 
prices trends based on starting dates of contract, and we could figure out EMI 
trends. According to the product, the EMI quickly decline, remain broadly stable 
or increase. cOnclusiOns: Many of top-selling biologics are due to lose patent 
protection over the next years. The emergence of competition in pharmaceutical 
market contributes to better control expenditure in our health system. The great 
potential for cost savings concerning erythropoietic factors in our study could be 
investigated in other class of medicinal products.
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BUDGET IMPACT ANALySIS OF FENTANyL BUCCAL TABLET FOR THE 
TREATMENT OF CANCER BREAKTROUGH PAIN
Darba J.1, Kaskens L.2, Sánchez-de la R.osa R3
1Universitat de Barcelona, Barcelona, Spain, 2BCN HEALTH, Barcelona, Spain, 3TEVA Pharma, 
Madrid, Spain
Objectives: To assess the economic impact of Fentanyl Buccal Tablet for the 
management of breakthrough cancer pain (BTcP) in Spain MethOds: A 4-year 
budget impact model was developed for the period 2012-2015 for patients with 
BTcP from the perspective of the Spanish National Health System. BTcP products 
included in this model were rapid onset opioids containing fentanyl products 
(buccal, sublingual, or nasal transmucosal). Prevalence data on cancer, BTcP, opi-
oid use and number of BTcP episodes were obtained from literature. Input data 
on direct medical resources associated with opioid use and opioide-induced side 
effects (OISEs) were obtained by consulting experts in oncology from different 
Spanish hospitals. Resource utilisation included drugs, medical and emergency 
visits, other non-pharmacological treatments and the treatment of OISEs. Unit 
costs were obtained from literature and a 3% discount rate was applied to costs. 
Based on the unit costs for drugs and medical resources the annual BTcP treatment 
costs per patient associated with each product were determined, to estimate the 
overall budget impact based on the total treatment population and the percentage 
of drug utilisation associated with each product Results: Patients treated with 
oral opioids for BTcP was estimated at 23,291 in 2012 with an increase up to 23,413 
in 2015. The average annual budget savings with an increase of Fentanyl Buccal 
Tablet, Fentanyl Sublingual Tablet and Intranasal Fentanyl Spray and a decrease 
of Oral Transmucosal Fentanyl Citrate, was estimated at € 2.6 million over the 
next four years cOnclusiOns: The increase in the use of Fentanyl Buccal Tablet 
leads to overall savings in the budget impact for the Spanish NHS. Although the 
economic impact of BTcP treatment showed to increase over the next four years 
due to population growth the average annual cost per patient reduced with € 29 
by the increase in the use of Fentanyl Buccal Tablet.
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ECONOMIC IMPACT OF DENOSUMAB FOR SKELETAL RELATED EvENT 
PREvENTION IN PATIENTS wITH BREAST CANCER AND BONE METASTASIS 
FROM A UNITED STATE MANAGED CARE ORGANIzATION PERSPECTIvE
Chen K.1, Arellano J.2, Cristino J.3
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GmbH, Zug, Switzerland
Objectives: To evaluate clinical and economic impact of increasing deno-
sumab use compared to zoledronic acid (ZA) in BrCa patients with BM to a 
MCO. MethOds: An economic model was developed to estimate clinical and 
economic impact to a 1-million-member US MCO of introducing denosumab as 
bone-targeting agent (BTA) for prevention of SREs in BrCa patients with BM. Total 
number of patients receiving BTA was estimated based on disease prevalence and 
treatment eligibility in this population. The real-world SRE rates in ZA-treated 
patients were derived from a large commercial database and used together with 
the trial-based treatment effect for denosumab versus ZA to estimate the deno-
sumab SRE rate. Total number of SREs, total SRE management medical cost, BTA 
drug cost, and total cost were calculated. The impact of denosumab per-member-
per-month (PMPM) at increasing utilization rates was assessed by comparing to 
a scenario without denosumab, i.e., all patients received ZA. Additionally, impact 
of annual increase in denosumab use was conducted. Results: A total of 122 
BrCa patients with BM received BTA. In the scenario where all eligible patients 
receiving ZA, an annual total number of SREs was 155. An annual denosumab use 
of 20%, 35% or 45% resulted in 4.5%, 7.9%, and 10.2% reduction in total SREs and 
5.7%, 10.1%, and 12.9% reduction in medical costs of managing SREs, compared to 
all patients receiving ZA. The drug cost was partially offset by the reductions in 
the medical cost and the increase in total cost was minimal (2.4%-5.5%). The PMPM 
ranged $0.008-$0.017. Consecutive-year analysis showed $0.004 increase in PMPM 
with 10% denosumab utilization increase. cOnclusiOns: Due to superior efficacy 
of denosumab versus ZA in SRE prevention in BrCa patients with BM, increased 
denosumab use results in medical cost reduction in a US MCO. Overall, denosumab 
provides additional clinical value with limited budget impact.
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POTENTIAL LONG-TERM COST SAvINGS DUE TO SIGNIFICANT CLINICAL 
BENEFIT OF OBINUTUzUMAB (GA101) IN COMBINATION wITH CHLORAMBUCIL 
IN PREvIOUSLy UNTREATED CHRONIC LyMPHOCyTIC LEUKEMIA
Walzer S.1, Tournier C.2, Marino J.P.3, Mueller E.4, Duong M.3
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LA-SER International Inc., Loerrach, Germany
Objectives: Obinutuzumab is the first, glycoengineered type II antibody dem-
onstrating increased Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and 
background scenario the cost was 29,639.22€ . In terms of total costs the background 
scenario had a lower cost on average until the year 2009. cOnclusiOns: Early detec-
tion of breast cancer improves survival prognosis and decreases treatment costs for 
each detected cancer. In the future, the costs of the early detection program will be 
balanced by the savings in treatment costs.
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ESTIMATING THE BUDGET IMPLICATIONS OF RADIUM RA 223 DICHLORIDE IN 
CASTRATION-RESISTANT PROSTATE CANCER PATIENTS wITH NON-vISCERAL 
BONE METASTASES TREATED IN INFUSION CENTERS IN THE UNITED STATES
Hansen R.N.1, Seal B.2, Wen L.2, Valderrama A.3, Sullivan S.D.4
1University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, 
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Objectives: Metastatic prostate cancer (MPC) results from the spread of cancer to 
distant parts of the body and is associated with markedly decreased survival. First 
line therapy for prostate cancer involves androgen deprivation, however most MPC 
patients progress in spite of castration levels of testosterone. A recently approved 
infusion product, Radium Ra 223 dichloride (Radium-223), has been introduced in 
the U.S. market adding to concerns about the costs for end-stage treatments. We 
sought to estimate the budget impact of Radium-223 on infusion center expenses 
in the U.S. MethOds: We developed a financial model to estimate budget impact 
from a hospital-based infusion center perspective. Using data from the U.S. Census, 
SEER, and the Premier Perspective Database, we estimated the eligible population 
using a theoretical hospital’s catchment area. We modeled use, treatment costs 
and reimbursement for three radiopharmaceuticals (Radium-223, Samarium-153, 
and Strontium-89) and two common chemotherapies (docetaxel and cabazitazel) 
in terms of drug cost, infusions, and laboratory monitoring. Reimbursement for 
these treatments was estimated at both commercial and Medicare rates using the 
Average Sale Price and relevant Common Procedural Technology codes. We calcu-
lated total cost and reimbursement for one year with the current utilization from 
Premier and then estimated the incremental net budget impact associated with 
adoption of Radium-223 at 1, 3, and 5% of patients. Results: In a catchment area 
of 1 million lives, an estimated 45 MPC patients with non-visceral bone metastases 
would be treated with current agents and incur approximately $500,000 in treat-
ment costs for radiopharmaceuticals and chemotherapy. Adding Radium-223 to the 
treatment mix and assuming adoption rates of 1% to 5%, the annual net impact 
on the infusion center budget would range from $600 to $3,000. cOnclusiOns: 
Radium-223 presents a new treatment option for MPC patients with non-visceral 
bone metastases and a positive net impact for infusion centers.
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ESTIMATING THE BUDGET IMPACT OF ADDING AvASTIN (BEvACIzUMAB) TO 
FRONT LINE TREATMENT FOR ADvANCED OvARIAN CANCER IN BRAzILIAN 
SUPPLEMENTARy HEALTH CARE SySTEM
Tsuchiya C.T., Buschinelli C.T., Maximo M.F.M., Tobaruella F.S., Gonçalves T.M.
Roche Brazil, São Paulo, Brazil
Objectives: Ovarian cancer (OC) is one of the most lethal gynecologic cancers 
worldwide. According to Brazilian Institute of Cancer (INCA), 6,190 new OC cases 
were estimated in 2012. During the last 15 years, carboplatin plus paclitaxel (CP) 
has been established as front-line (FL) standard of care therapy for advanced ovar-
ian cancer, with no significant advances in treatment ever since. Bevacizumab 
(Bev) in combination with CP was approved in Brazil for FL treatment of advanced 
epithelial OC on May/2013. Therefore, this study aimed to estimate the economic 
impact of bevacizumab reimbursement for advanced OC in Brazilian Supplementary 
Healthcare System. MethOds: The potential number of eligible patients for CP + 
Bev in FL therapy for advanced OC was estimated following an epidemiologic 
approach. It was assumed that Supplementary Healthcare System attendance 
accounts for 40% of all patients. Additional drug costs and infusion fees were evalu-
ated. The ex-factory price (VAT 18%) and labeled dose were considered. Average 
therapy duration of CP + bevacizumab was 15 months based on GOG-0218 trial. Costs 
were reported in Brazilian Reais (BRL1.00≈USD0.44; Jun/2013). A total health assis-
tance budget of BRL 88.1 billion was forecasted for 2013, based on the last updated 
data from Brazilian National Regulatory Agency for Private Health Insurance and 
Plans (ANS). Results: A total of 1,287 eligible cases in CP + Bev FL therapy for 
advanced OC are expected in 2013 in the private setting. Adding bevacizumab to 
the treatment of all these potential patients would yield an increase of BRL 267 
million, corresponding only to an increment around 0.30% on health assistance 
expenses. cOnclusiOns: Treating all eligible FL advanced OC patients with CP + 
Bev will potentially result in a low impact in Supplementary Healthcare System 
budget, associated to unprecedented clinical benefits for this population with a 
high medical unmet need.
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THE FRENCH PUBLIC HEALTH CARE SySTEM: AN ORIGINAL wAy FOR COST 
SAvING
Karouby D.1, Bocquet F.2, Chevalier D.3, Paubel P.4
1CHRU STRASBOURG, Strasbourg, France, 2Agence Générale des Produits de Santé, Paris, France, 
3Groupe Hospitalier Paris Saint Joseph, Paris, France, 4Paris Descartes University, Paris, France
Objectives: The patent expiries of leading biologic products and development of 
biosimilars create opportunities for cost saving. The french public health policies 
has established a complementary means encouraging heathcare facilities (HF) to 
save money : the ‘‘écart médicament indemnisable’’ (EMI). We explored the evalu-
ation of EMI on the erythropoietic factors class. MethOds: We’ve carried out a 
comparative study in french HF, representing about 65% of national hospital beds, 
on the price of erythropoietic factors. The data have been collected on procurement 
procedures operative as at January 1, 2012. Results: A total of 25 care facilities or 
group of care facilities agreed to participate in the study. The overall sales turnover 
reached 15 millions euros (M€ ). All HF granted a discount from 5% to 69% on the 
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SAFETy PROFILE AND COSTS OF RELATED ADvERSE EvENTS OF TRASTUzUMAB 
EMTANSINE COMPARED TO OTHER REGIMENS IN THE CANADIAN HEALTH CARE 
SySTEM
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Objectives: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate com-
prised of the microtubule inhibitory cytotoxic agent DM1 and trastuzumab which, in 
addition to its antitumor properties, targets T-DM1 to HER2–overexpressing cells. The 
overall safety profile of T-DM1 was investigated in the phase III EMILIA trial (com-
paring T-DM1 [n= 496] to capecitabine plus lapatinib [CAP+LAP, n= 495]) in patients 
with HER2-positive locally advanced or metastatic breast cancer (MBC) previously 
treated with trastuzumab and a taxane, and the phase II TDM4450g trial (comparing 
T-DM1 [n= 67] to trastuzumab plus docetaxel [TRAZ+DOCE, n= 70]) in patients with 
previously untreated MBC. Both trials demonstrated clinically meaningful differ-
ences between T-DM1 and its comparators. The objectives were to estimate and 
compare the Canadian costs of managing the treatment-related adverse events 
(AEs) of T-DM1 as reported in the two trials, from the perspective of Canadian 
public payers. MethOds: An Excel based spreadsheet model was utilized for the 
analysis. Costing information was obtained from the literature, clinical experts, and 
Canadian standard costing sources. Costs were reported as 2012 CAD. The AEs that 
were considered were all treatment-related grade ≥ 3 AEs as well as grade 2 AEs that 
occurred in ≥ 5% of patients in both arms of either study. Results: The manage-
ment of treatment-related AEs as reported in the EMILIA trial resulted in higher per 
patient costs ranging from $3,060 - $10,499 for CAP+LAP versus $1,376 - $2,463 for 
T-DM1, yielding savings of $1,684-$8,036. In the TDM4450g trial, the management 
of treatment-related AEs resulted in higher per patient costs ranging from $5,124 
- $27,617 for TRAZ+DOCE versus $798 - $2,215 for T-DM1, yielding savings of $4,326-
$25,402. cOnclusiOns: This analysis demonstrated that utilizing T-DM1 for the 
management of HER2-positive metastatic breast cancer results in significant cost 
savings of related AEs management due to the improved safety profile compared 
to CAP+LAP and TRAZ+DOCE.
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A COST-ANALySIS OF STEREOTACTIC RADIOTHERAPy IN LUNG CANCER
Perrier L.1, Morelle M.2, Pommier P.2, Plommet N.1, Beckendorf V.3, Mahé M.A.4, Lartigau E.5, 
Boisselier P.6, Bondiau P.Y.7, Touboul E.8, Peignaux Casasnovas K.9, Gassa F.2, Dussart S.2, 
Claude L.2
1Cancer Centre Léon Bérard, Lyon, France, 2Leon Berard Cancer Centre, Lyon, France, 3Cancer 
Center Alexis Vautrin, Vandoeuvre-les Nancy, France, 4Institut de Cancerologie de l’Ouest - René 
Gauducheau, Saint - Herblain, France, 5Centre Oscar Lambret, Lille, France, 6Cancer Center Val 
d’Aurelle-Paul Lamarque, Montpellier, France, 7Centre Antoine Lacassagne, Nice, France, 8Hospital 
Tenon, Paris, France, 9Centre Georges-François Leclerc, Dijon, France
Objectives: Stereotactic radiation therapy is an innovative technique with high 
therapeutic potential due to excellent local control and increased survival rate. A 
cost analysis investigating stereotactic radiation therapy modalities either with lin-
ear accelerator (Cone Beam Computed Tomography (CBCT), Exac-trac) or Cyberknife 
was conducted. MethOds: The cost-analysis was performed prospectively based 
on a multicenter study. Patients included were treated for lung carcinoma (T1-T2, N0, 
M0). Cost calculations were strictly based on a micro costing approach according to 
the hospitals’ point of view. Only direct costs were taken into account. Productivity 
losses of personnel involved in the process, costs of administrative personnel, costs 
of logistics and general management were not taken into account. Time horizon 
included radiation therapy (preparation for radiation therapy and the fraction itself). 
All costs were given in 2011 euros. Uncertainty was captured by one-way and proba-
bilistic sensitivity analyses using a non-parametric bootstrap method. Results: 
113 patients were enrolled in 11 French centers from April 2009 to December 2011. 
98 economic questionnaires were exploitable. The costs of preparation for stereo-
tactic radiation therapy were 430€ (SD: 101€ ) with Cyberknife and 433€ (SD: 199€ ) 
with linear accelerator. When required, costs of implementation of fiducial markers 
with one/two days of inpatient care were 1,619€ . The costs of stereotactic radia-
tion therapy (all fractions included) were 1,811€ (SD: 760€ ) with Cyberknife and 
817€ (SD:403€ ) with linear accelerator. Costs per fraction were 550€ (SD: 224€ ) with 
Cyberknife and 201€ (SD: 97€ ) with linear accelerator. Depreciation periods of the 
accelerator played a major role in costs. cOnclusiOns: This is to our knowledge 
the first study highlighting costs incurred by different stereotactic radiation therapy 
modalities in lung cancers. Cost-effectiveness studies have to be conducted in order 
to shed further light on which modality to focus on.
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COST OF ADvERSE EvENTS DURING TREATMENT wITH EvEROLIMUS PLUS 
ExEMESTANE OR SINGLE-AGENT CHEMOTHERAPy IN PATIENTS wITH 
ADvANCED BREAST CANCER
Campone M.1, Yang H.2, Faust E.2, Kageleiry A.2, Signorovitch J.2, Zhang J.3, Gao H.3
1Institut de Cancérologie de l’OUEST, Saint Herblain-Nantes Cedex, France, 2Analysis Group, Inc., 
Boston, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Objectives: Everolimus plus exemestane (EVE+EXE) recently received approval for 
the treatment of patients with HR+/HER2- advanced breast cancer that recurs or 
progresses during/after non-steroidal aromatase inhibitors. This study was designed 
to evaluate the expected costs of managing adverse events during EVE+EXE therapy 
and single-agent chemotherapy in the western European region. MethOds: An 
economic model was developed to estimate per-patient cost of managing adverse 
events for patients receiving EVE+EXE or chemotherapies. Adverse event rates for 
EVE+EXE were collected from the phase III BOLERO-2 trial. Adverse event rates for 
capecitabine, docetaxel, and doxorubicin chemotherapies were collected from 
published clinical trial data. Grade 3/4 adverse events with at least 2% prevalence 
during any of these treatments were included in the study. The adverse event rate 
direct cell death compared with rituximab (Rtx) and is pending regulatory approval 
(in combination with chlorambucil (Clb)) for the treatment of patients with pre-
viously untreated chronic lymphocytic leukemia (CLL). Obinutuzumab+Clb has 
shown > 85% reduction in the risk of progression, relapse or death in comparison 
to treatment with Clb alone (HR 0.14), a broadly accepted treatment option for many 
patients with co-existing medical conditions. In a majority of markets the health 
economic consequences will be assessed in terms of affordability. MethOds: A 
health economic model was developed analyzing the cost impact of obinutuzumab 
on further lines of treatment due to the number of reduced refractory patients com-
pared to Clb and Rtx. Market share information for obinutuzumab, ofatumumab, 
Rtx, Clb and Bendamustine and the different relevant combinations were entered 
for Germany and Canada (Ontario province only). Results: Based on a 39% reduc-
tion in numbers of refractory patients treated with obinutuzumab+Clb compared 
to Rtx+Clb cost savings per year per patient (PYPP) for further line treatments in 
Canada (Ontario) range between Ca$950 and Ca$3,091, which leads to maximum 
cost savings for the whole eligible population (401 patients) up to $Ca1,239,491. 
In Germany the cost savings range PYPP between € 2,556 and € 8,318, which leads 
to maximum cost savings for the whole eligible population (1,302 patients) up to 
€ 10,830,036. The big difference in the cost savings PYPP between the two coun-
tries is mainly due to the different market share assumptions for ofatumumab. 
Key cost drivers were treatment duration and price/cost of further line treatments. 
Scenario analyses on cost, efficacy and market share data confirmed these find-
ings. cOnclusiOns: Obinutuzumab+Clb shows significant patient-relevant clini-
cal benefits and potential cost savings in further line treatments in patients with 
previously untreated CLL.
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PHARMACOECONOMIC ASPECTS OF CHRONIC PAIN MANAGEMENT IN RUSSIAN 
CANCER PATIENTS
Ryazhenov V.V.1, Gorokhova S.G.1, Emchenko I.V.1, Matveev N.V.2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2N.I. Pirogov Russian 
National Research Medical University, Moscow, Russia
Objectives: To assess the cost-effectiveness of the new transdermal therapeutic sys-
tem (TTS) of fentanyl and subcutaneous injections (SIs) of morphine hydrochloride in 
the treatment of chronic pain and predict potential budget impact of the implementa-
tion of fentanyl TTS in routine clinical practice. MethOds: The pharmacoeconomic 
model was developed based on the results of Russian observational study, included 
45 patients with terminal cancer: 25 patients received fentanyl TTS and 20 – SIs of 
morphine. At the first stage, the cost-effectiveness ratios (CERs) of therapies during 
the first month was measured as total costs of medicines and expenses for ambulance 
services for acute pain relief per one patient without side-effects. At the second stage, 
the CERs of therapies during subsequent three months was measured as costs of 
medicines per one unit of pain intensity (PI) reduction (visual pain scale). Results: 
During the first month of therapy the frequency of ambulance use was significantly 
lower in patients received fentanyl TTS (0.32 vs 1.05 per one patient per week in the 
morphine group), this was reflected in lower total costs (12 611, 42 RUB and 23,037.54 
RUB per one patient, respectively). Patients in the fentanyl TTS group were less likely 
to have side effects. The estimated CERs for fentanyl TTS and SIs of morphine were 
13,001.46 RUB and 27,756.07 RUB per one patient without vomiting and 23,354.47 
RUB and 82,276.93 RUB per one patient without constipation, respectively. Long-term 
treatment with fentanyl TTS was resulted in decreased PI as compared to SIs of mor-
phine. The three-month CERs were 4,897.05 RUB and 7,869.30 RUB per one unit of PI 
reduction, respectively. cOnclusiOns: The present study has demonstrated that 
administration of new transdermal therapeutic system of fentanyl has the better 
cost-effectiveness profile in the treatment of Russian cancer patients.
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BUDGET IMPACT OF LIPEGFILGRASTIM FOR THE MANAGEMENT OF 
CHEMOTHERAPy-INDUCED NEUTROPENIA
Montouchet C.1, Ruff L.1, Cerchiari A.2, Plich A.2
1Medaxial Group, London, UK, 2Teva Pharmaceuticals Europe B.V, Utrecht, The Netherlands
Objectives: Chemotherapy-induced neutropenia (CIN), a commonly-occurring 
adverse event in cancer patients undergoing chemotherapy, and particularly febrile 
neutropenia (FN), have potentially life-threatening and costly consequences. The 
standard of care for patients at risk of FN comprises prophylactic administra-
tion of recombinant granulocyte colony-stimulating factor (G-CSF) with pegfil-
grastim, a long-acting formulation of G-CSF, and the most widely used in Europe. 
Lipegfilgrastim is a novel, pegylated and glycosylated long-acting G-CSF designed 
for use in the same patient population as pegfilgrastim. We developed a model to 
estimate the economic impact over five years of managing G-CSF-eligible chem-
otherapy patients at risk of FN with lipegfilgrastim rather than pegfilgrastim in 
Scotland. MethOds: The eligible patient population was estimated based on cancer 
incidence in Scotland and current uptake of G-CSF by patients initiating chemo-
therapy to prevent neutropenia. Drug, monitoring and event costs were taken from 
the British National Formulary, Unit Costs of Health and Social Care and Scottish 
National Tariff. As lipegfilgrastim was shown to be non-inferior to pegfilgrastim (in 
a phase III study in breast cancer patients), the efficacy and safety of pegfilgrastim 
and lipegfilgrastim were assumed to be identical. Non-statistically significant trends 
towards fewer neutropenic events and dose modifications with lipegfilgrastim were 
explored in scenario analyses. Results: The model estimated that 315 patients 
currently receive pegfilgrastim annually. A progressive increase in lipegfilgrastim 
uptake was associated with cost savings ranging from £2,814 in year 1 to £16,883 in 
year 5, totalling £61,904 over five years. Savings were attributable to the low drug 
acquisition cost of lipegfilgrastim. Using event rates from the pivotal phase III breast 
cancer study, scenario analyses suggested that using lipegfilgrastim instead of peg-
filgrastim generated savings of £145,312, avoided 81 neutropenic events (including 
11 occurrences of FN) and 50 dose modifications, and caused 34 additional treat-
ment-emergent adverse events. cOnclusiOns: Lipegfilgrastim was cost-saving 
compared with pegfilgrastim.
A402  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
index date for the comparator group was randomly chosen to reduce selection bias. 
A 1-year continuous health plan enrollment was required before and after the index 
date for both groups. Study outcomes, including health care costs and utilizations, 
were compared between the disease and comparator groups using 1:1 propensity 
score matching (PSM). Results: Eligible patients (N= 384,596) were identified for 
the prostate cancer and comparison cohorts and after applying PSM, a total of 
112,693 patients were matched from each group and the baseline characteristics 
were well-balanced. Patients diagnosed with prostate cancer were more likely to be 
hospitalized (75.41% vs. 2.46%, p< 0.01), and report more emergency room (9.30% vs. 
5.45%, p< 0.01), outpatient (99.77% vs. 61.15%, p< 0.01) and pharmacy visits (85.65% 
vs. 63.77%, p< 0.01). Patients diagnosed with prostate cancer also incurred higher 
costs for inpatient ($2,216 vs. $695, p< 0.01), emergency room ($92 vs. $51, p< 0.01), 
outpatient ($3,364 vs. $1,462, p< 0.01), pharmacy ($582 vs. $413, p< 0.01) and total 
costs (6,162 vs. $2,571, p< 0.01) compared to the comparator group. cOnclusiOns: 
Patients diagnosed with prostate cancer were associated with a higher burden of 
illness compared to their matched controls during a period of 12 months.
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COST OF CARE wITH EvEROLIMUS vERSUS AxITINIB FOR SECOND-LINE 
METASTATIC RENAL CELL CARCINOMA PATIENTS IN CANADA
Perrin A.1, Chua A.1, Wang X.2, Hurry M.3
1LA-SER Analytica, New York, NY, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 
USA, 3Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada
Objectives: Everolimus and axitinib are approved to treat patients with metastatic 
renal cell carcinoma (mRCC) following failure on various first-line therapies. This 
analysis assessed the cost of care with everolimus versus axitinib for second-line 
mRCC patients from a Canadian payer perspective. MethOds: Costs considered 
in this analysis included those related to drug acquisition and adverse events (AEs). 
Drug acquisition costs were based on the Ontario wholesaler price. Adverse event 
costs were based on the Ontario Case Costing Initiative and literature. Drug costs, 
adjusted for dose intensity, and AE costs, based on daily incidence rates, accrued 
for the duration of treatment in each arm; the sums of these costs were compared 
across treatments. The mean dose intensities, treatment durations and rates of 
AEs in the treatment arms were the calculated from trial data. Scenario analyses 
are presented to estimate the range of costs within the treatment arms. Costs are 
presented in 2011 Canadian dollars. Results: In the base case analysis, the total 
cost of treatment with everolimus was estimated to be $24,931 while the total cost 
of treatment with axitinib was $39,010. The primary driver of the cost discrepancy 
was axitinib’s high dose intensity, resulting in high drug acquisition costs. Despite 
analysis limitations, the trend of the results remained consistent across scenario 
analyses. When treatment duration was estimated from median progression-free 
survival estimates in each study’s post-sunitinib populations, the total cost of treat-
ment with everolimus was $8,339 less than with axitinib. Sensitivity analyses that 
assumed equivalent treatment durations between each arm also demonstrated 
lower overall treatment costs for everolimus patients. cOnclusiOns: The analysis 
demonstrates that everolimus provides a less costly treatment option than axitinib 
for patients requiring second-line therapy. Significant uncertainty remains regard-
ing axitinib’s treatment duration and dosing, which could result in higher costs to 
the health care system compared to everolimus.
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RELATIvE CLINICAL AND ECONOMIC vALUE OF IPILIMUMAB IN MExICO
Juarez-Garcia A.1, Donato B.M.K.2, Appiani C.1, Davila A.1, Hernández-Rivera G.1
1Bristol-Myers Squibb Company, Mexico City, Mexico, 2Bristol-Myers Squibb Company, 
Wallingford, CT, USA
Objectives: Ipilumumab is a clinically proven treatment option for pre-treated 
metastatic melanoma (MM). Ipilumumab has clearly demonstrated survival ben-
efit, that is prolonged in a proportion of the responding patients. Karweit J and 
colleagues (2012) demonstrated that mean overall survival (OS) can be particularly 
useful for agents with a right-skewed survival curve where a subset of patients 
respond to treatment with long term survival. The research has demonstrated that 
several agents, including ipilimumab for MM, bevacizumab for non-small cell lung 
cancer, sorafenib for hepatocellular carcinoma, lenalidomide for multiple mye-
loma and trastuzumab for metastatic breast cancer (among others) have shown 
greater mean OS improvement than median OS improvement, reflecting the long 
term survival benefit for some patients. In this analysis we select oncologic agents 
that have demonstrated mean OS benefit in the above mentioned study and have 
received license in Mexico. We compare the relative economic value delivered by 
each asset, which broadly represent the therapeutic oncologic class. MethOds: 
The economic value of the analogues is estimated for the Mexican private per-
spective in terms of cost per month of mean OS versus comparators. The analy-
sis relies on the cost to treat to mean progression by the months of mean OS 
improvement. Results: Cost per month of OS for ipilimumab ($15,993 USD) when 
compared to bevacizumab, sorafenib, trastuzumab, sunitinib, lenalidomide and 
vemurafenib is below the average relative cost of the assets (range from $35,871 
to $9,845 USD). cOnclusiOns: This study demonstrates that ipilimumab is a 
competitive asset in terms of value for money. The analysis allows to evaluate 
within a clear and robust analytical framework, the reimbursement decisions 
across the oncologic therapeutic class in Mexico.
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COSTS OF PILOT PROGRAMS EMPLOyING ALLIED HEALTH PROFESSIONALS 
wITHIN THE CENTERS FOR POPULATION HEALTH AND HEALTH DISPARITIES
Walton S.1, Johnson T.J.2, Li C.C.2, Joyce B.3
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Objectives: To measure the costs of two pilot interventions within the National 
Institutes of Health-funded Centers for Population Health and Health Disparities 
(CPHHD) designed to improve health outcomes in medically underserved commu-
estimates do not count multiple episodes of the same event. Costs of managing 
each adverse event were obtained from the literature and averaged across west-
ern European countries (UK, Germany, France, Italy, Belgium, Spain, Sweden, and 
Switzerland), where available. The costs were inflated to 2012 Euros (€ ). Results: 
Expected per-patient costs of managing adverse events within the first year of treat-
ment among patients with advanced breast cancer receiving EVE+EXE were € 730. 
Among patients receiving capecitabine, docetaxel, or doxorubicin as single-agent 
chemotherapy, expected per-patient costs were € 1721, € 2390, and € 1230, respectively. 
The most costly adverse event for patients treated with EVE+EXE was anemia (€ 152 
per patient). The most costly adverse event for patients treated with capecitabine, 
docetaxel, or doxorubicin was lymphocytopenia (€ 861 per patient), neutropenia 
(€ 821 per patient), and leukopenia (€ 382 per patient), respectively. cOnclusiOns: 
Expected costs of managing adverse events in patients with HR+/HER2- advanced 
breast cancer receiving EVE+EXE are about one-half to one-third of the costs for 
those receiving chemotherapies. This economic consideration can have important 
implications for health care spending in the advanced breast cancer setting.
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ECONOMIC IMPACT MODEL OF LIPEGFILGASTRIM TO PREvENT NEUTROPENIA 
IN CANCER PATIENTS IN SPAIN
Sánchez-de la Rosa R., García-Bujalance L.
TEVA Pharma, Madrid, Spain
Objectives: To estimate the economic impact of managing chemotherapy patients 
at risk of neutropenia and eligible to receive Granulocyte-Colony Stimulating Factor 
(G-CSF) with lipegfilgatrim (LONQUEX, a new long-acting G-CSF) rather than peg-
filgastrim in Spain. MethOds: Both the BIA and CMA were conducted from the 
Spanish-payer’s perspective: they included direct drug cost, administration, neutro-
penic events and adverse event costs, but did not consider indirect costs. The drug 
acquisition cost of lipegfilgatrim used in the model was based on the anticipated 
price of lipegfilgatrim at the time of launch in Spain. All costs were expressed in 
EUROS-2013. A range of sensitivity, scenario and threshold analyses were performed. 
An additional analysis was performed within the BIA to explore the trend towards 
fewer dose modifications in the lipegfilgatrim arm of the XM22-03 trial. Results: 
The CMA shows that treating a patient with lipegfilgatrim instead of pegfilgrastim 
resulted in a cost saving of 650,06€ . At the population level, the BIA predicts that 
cost savings could range from 113.166€ in year 1 to 678.995€ in year 5, totaling to 
2.489.648€ over five years. Furthermore, the BIA shows a potential to avoid 50 dose 
modifications with the use of lipegfilgatrim instead of pegfilgrastim. The model is 
most sensitive to the cost of pegfilgrastim and lipegfilgatrim, but results are robust, 
with the model estimating cost savings over a wide range of inputs. When the trend 
towards decreased NE and increased AE with lipegfilgatrim vs pegfilgrastim reported 
in the XM22-03 trial is explored, cost savings was about 30% compared to the default 
scenario, reaching 3.208.619 € ., mainly due to decreased NE costs cOnclusiOns: 
Lipegfilgatrim is cost-saving compared with pegfilgrastim. These savings are con-
firmed across a wide range of input values.
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THE RELATIvE ECONOMIC vALUE OF IPILUMUMAB IN COLOMBIA
Garrido S.1, Juarez-Garcia A.2, Hernández-Rivera G.2, Donato B.M.K.3
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Objectives: There are relatively few treatment options for pre-treated metastatic 
melanoma (MM) patients. Clinicians have recently been provided access to a new 
option, ipilumumab that has demonstrated long-term survival benefits, in a subset 
of patients. Karweit J and colleagues (2012) present data to support the use of mean 
OS for agents with a right-skewed survival curve, where a subset of patients respond 
to treatment with long term survival -as is the case for ipilimumab. The research 
presents data for several oncology agents: ipilimumab for MM, bevacizumab for non-
small cell lung cancer, sorafenib for hepatocellular carcinoma, lenalidomide for mul-
tiple myeloma, trastuzumab for metastatic breast cancer and vemurafenib for MM. 
The data reveals a greater mean OS improvement than median OS improvement, 
since mean OS accurately captures the complete survival benefits. In this analysis 
we select agents from the Krweit J et al study and who have received regulatory 
authorization in Colombia, to compare their relative economic value. MethOds: 
The economic value of each asset is presented in terms of cost per month of mean 
OS within the Colombian health care payer perspective. The analysis uses the cost 
to treat to mean progression of each asset divided by the months of mean overall 
survival improvement using current list prices of assets. Results: Ipilimumab in 
comparison to bevacizumab, sorafenib, trastuzumab, sutinib, lenalidomide, and 
vemurafenib demonstrates a clinical and economic relative value. The cost per mean 
overall survival month gained for ipilumumab ($39,344,362 COP) is below the average 
of the comparator assets (range from $60,226,690 to $20,166,226). cOnclusiOns: 
The relative clinical and economic value of ipilumumab in the context of a variety 
of oncologic assets is clearly documented. This data provides health care decision 
makers critical data when determining coverage of oncologic treatments.
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ExAMINING THE BURDEN OF ILLNESS OF vETERAN PATIENTS wITH PROSTATE 
CANCER IN THE UNITED STATES
Wang L.1, Xie L.2, Kariburyo M.F.2, Li L.1, Wang Y.2, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA
Objectives: To examine the economic burden and health care utilizations of pros-
tate cancer patients in the U.S. veteran population. MethOds: Patients diagnosed 
with prostate cancer (ICD-9: 185.xx) were identified from the U.S. Veterans Health 
Administration (VHA) Medical SAS dataset from October 1, 2009 through September 
30, 2011. The first diagnosis date was defined as the index date. A comparator group 
was created by identifying patients without prostate cancer but with the same age, 
region, gender, index year, and matched baseline Charlson Comorbidity Index. The 
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REAL wORLD MANAGEMENT AND COSTS IN UNRESECTABLE METASTATIC 
MELANOMA (MM) PATIENTS: UPDATE OF A PILOT STUDy BASED ON AN 
INSTITUTIONAL PATIENT REGISTRy
Strens D.1, Specenier P.2, Peeters M.2
1Realidad, GRIMBERGEN, Belgium, 2University Hospital Antwerp, Edegem, Belgium
Objectives: To assess the management and associated lifetime costs in MM patients 
as from the diagnosis of unresectable metastatic disease until death. MethOds: A 
retrospective patient chart review was performed at the Antwerp University Hospital 
to obtain data on medical consumption related to the management of unresectable 
MM (uMM). A complete registry of all melanoma patients who visited the hospi-
tal between 2007 and May 2013 was compiled. Eligible for this retrospective chart 
review were patients with uMM with sufficient data available and who deceased 
before May 2013. Data on demographics, disease characteristics and management 
of uMM were collected. Direct costs were calculated by multiplying each item of 
resource use with its unit cost (2013, € ) using the Belgian public health care payer’s 
perspective (PHCP) and patient’s perspective. Average (bootstrap 95%CI) overall costs 
per patient were calculated. Results: Out of 338 registered melanoma patients, 
35 were eligible and included in this chart review. The median overall survival time 
(OS) in all patients was 6.2 months. 88.6% (n= 31) of patients were treated by sys-
temic treatment(s) of which 17% (n= 6) received up to 4 different treatment lines. 
Ten patients received “new drugs”: ipilimumab (1 to 4 cycles): 10; vemurafenib: 2. 
Fifty-six (41%) of the 137 hospitalizations were for treatment administration. The 
mean overall cost per patient was € 43,429 (bootstrap 95% CI: 33,372 - 54,351), of 
which € 42,367 (95%CI: 32,481 - 52,976) was reimbursed. The PHCP cost was driven 
by systemic treatments costs (46% of cost). Mean PHCP cost was € 87,468 (95 % CI: 
77,372-97,307) for patients treated with “new drugs” versus € 24,327 (95 % CI: 18,617 - 
30,634) for patients not treated with “new drugs”. Median OS was 9 and 4.9 months, 
respectively. cOnclusiOns: Management of uMM results in considerable costs for 
the PHCP, mainly driven by systemic treatment costs.
PCN66
MANAGEMENT COSTS OF THE FIRST FIvE yEARS AFTER DIAGNOSIS IN BREAST 
CANCER By STAGE IN FRANCE
Atsou K.1, Bardoulat I.1, Colin X.1, Lemasson H.1, Ricarte C.2, Maurel F.2, Ajjouri R.3, Lançon F.3
1IMS Health, La Défense Cedex, France, 2IMS Health, La Défense, France, 3Institut National du 
Cancer, Boulogne Billancourt cedex, France
Objectives: Few recent data are available on breast cancer treatment costs, espe-
cially by stage of the disease at diagnosis. This study was designed to estimate the 
management costs in breast cancer for the first 5-year period following diagno-
sis. Costs have been distinguished by stage of severity. MethOds: A patient-level 
analysis was performed from a French physician survey database, collecting data 
on patient demographics, cancer history from diagnosis and treatment patterns. 
Data were extracted for all breast cancer cases with at least 1 year of follow-up after 
diagnosis using data collected from 2011 to 2012. Cost analyses were conducted 
from a health care payers’ perspective adjusting for stage (stages I-IV) at diagnosis 
and year from diagnosis. Results: A total of 1,157 patients were included in the 
analysis. The stages at diagnosis distribution was respectively from stage I to IV 
29.7%, 39.2%, 15.0% and 16.1%. The mean (SD) age at inclusion was 62.5 (12.4) and 
the mean (SD) time from diagnosis was 5.0 years (5.1). The mean annual cost (SD) 
over the 5-year period after diagnosis was ranging from 4,293€ (9,526€ ) for stage I 
to 12,111€ (19,070€ ) for stage IV. The mean (SD) annual costs for the 1st year after 
diagnosis were estimated at 11,647€ (9,883€ ), 13,226€ (11,575€ ), 17,254€ (14,535€ ) 
and 24,003€ (24,888€ ), respectively for stage I to IV at diagnosis. The main cost con-
tributors in early stages were radiotherapy and surgery while cytotoxic treatments, 
hormonotherapy and supportive care droved it for the late stage. The mean annual 
costs for the following years after diagnosis (2nd to 5thyear) decreased, ranging from 
1,827€ (8,964€ ) for Stage I to 5,370€ (10,662€ ) for stage IV. cOnclusiOns: : The mean 
annual cost was strongly related to the clinical stage at diagnosis and the year from 
diagnosis. These estimates could be useful to populate models that explore impact 
of treating and preventing breast cancer.
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THE HUMANISTIC AND ECONOMIC BURDEN OF vENOUS THROMBOEMBOLISM 
IN CANCER PATIENTS: A SySTEMATIC REvIEw
Kourlaba G.1, Relakis J.2, Kontodimas S.3, Holm M.V.4, Maniadakis N.2
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Objectives: To systematically review the humanistic and economic burden of 
cancer-related venous thromboembolism (VTE). MethOds: A literature search 
was carried out on Pubmed, Cochrane Central Register of Controlled Trials, Econlit, 
Science Direct, JSTOR, Oxford Journals and Cambridge Journals. The search was 
limited to humanistic studies published from January 2000 to December 2012. 
Additional studies were also identified by searching reference lists of relevant 
published reviews and included studies. The identified studies were indepen-
dently reviewed by two reviewers against pre-determined inclusion and exclu-
sion criteria. A quality assessment of the selected studies was also conducted by 
using standard methods . The data of selected studies were extracted onto a data 
extraction form and consequently synthesized. Results: Fifty five studies were 
included in our review. It was found that cancer patients experience between 
2-fold and 20-fold higher risk of developing VTE in comparison to non-cancer 
patients. Cancer patients are more likely to experience a VTE event in the first 3 
or 6 months after cancer diagnosis and the onset of chemotherapy. Additionally, 
an increased risk of VTE in patients with distant metastases and certain types of 
cancer (i.e. pancreatic or lung) was identified. VTE strongly affects the prognosis 
of cancer patients as it has been found that it is a leading cause of death in this 
group of patients. The annual average total cost for cancer patients with VTE was 
found to be almost 50% higher compared to that of cancer patients without VTE 
nities through the utilization of allied health professionals. MethOds: Two local 
CPHHD programs with prospective randomized controlled trial designs (a virtual 
team care intervention aimed at reducing depressive symptoms in older adults 
with depression and cardio-metabolic syndrome, and a patient navigator program 
to increase mammography screening for breast cancer) provided the underlying 
data for this analysis. The programs collected detailed resource use data along 
with several clinical measures. Costs were measured from a payer perspective. 
The navigator program involved in-person or remote navigator consultations, and 
costs were based on a wage rate of $15 per hour. The depression program involved 
multiple services and all costs reflected institution-specific billing data. Results: 
There were 949 patients in the patient navigator intervention. On average, these 
patients received 8.28 minutes of navigator services per patient over the phone and 
1.23 minutes via in-person visits, translating to a per-patient cost of $2.38. For the 
six patients enrolled in the team care intervention for depression, resources used 
included social worker case management and individual psychotherapy, translating 
to program costs of $145 per patient over 12 months. Spillover health care service 
costs were similar between the intervention and control groups (intervention = 
$55 per patient, control = $64 per patient). cOnclusiOns: Costs are an important 
consideration for evaluating pilot, team-care based interventions to improve patient 
health. The two programs evaluated here offer insight into the potential impact of 
interventions that employ allied health professionals and demonstrate a relatively 
low cost per patient. Future work will examine these costs in comparison with 
measured effects of the program.
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ASSESSING THE BURDEN OF CAREGIvING FOR PATIENTS wITH LUNG CANCER 
IN EUROPE
Goren A.1, Gilloteau I.2, Penrod J.R.2, Jassem J.3
1Kantar Health, New York, NY, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Medical 
University of Gdansk, Gdansk, Poland
Objectives: To investigate the self-reported burden imposed by care of lung 
cancer (LC) patients in the European Union (EU). MethOds: The study included 
respondents to the 2010 and 2011 EU National Health and Wellness Survey from 
France, Germany, Italy, Spain, and the UK who reported being caregivers for a rela-
tive with LC versus respondents who did not report being caregivers for a relative 
with any condition (control). Outcome measures included Short Form (SF)-6D 
health state utilities and mental and physical health status (all derived from the 
SF-12v2), stress-related comorbidities, health care resource use during the past 
6 months, and work/activity impairment during the past week using the Work 
Productivity and Activity Impairment (WPAI) questionnaire. Productivity losses 
were converted into costs using the human capital method by applying median 
hourly wages per country (from Eurostat 2006 personal income inflated to 2010) 
to the total number of hours lost using results from WPAI. Multivariable analyses 
were used to test the potential impact of LC patient caregiving on health care 
resource use and work/activity impairment, as well as costs specifically associated 
with work impairment. Results: A total of 107 caregivers for patients with LC and 
103,868 non-caregivers were identified. Compared with non-caregivers and adjust-
ing for covariates, caregivers had higher mean levels of impaired presenteeism 
(27.1% vs. 14.8%), overall work impairment (32.4% vs. 18.0%), and activity impair-
ment (32.8% vs. 21.8%; all p< 0.005); higher odds of impact across all measures 
of the WPAI including absenteeism (all p< 0.01); and higher annual costs associ-
ated with impaired presenteeism (€ 5,672 vs. € 3,429) and overall work impairment 
(€ 6,905 vs. € 4,147; both p< 0.05). Health care resource utilization and mean level 
of absenteeism did not differ significantly. cOnclusiOns: LC patient caregiving 
in the EU is associated with significantly higher work/activity impairment and 
related costs relative to non-caregivers. Costs associated with LC caregiver burden 
deserve further attention.
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DIRECT MEDICAL COSTS (DMC) OF TREATING CHRONIC LyMPHOID LEUKEMIA 
(CLL) PATIENTS IN THE PUBLIC HEALTH CARE SySTEM IN BRAzIL: RESULTS 
FROM A RETROSPECTIvE ANALySIS OF AN ADMINISTRATIvE DATABASE
Asano E., Pereira M.L.
Janssen-Cilag Farmaceutica, Sao Paulo, Brazil
Objectives: To determine direct medical costs of treating patients with Chronic 
Lymphoid Leukemia (CLL) from the Brazilian Public Healthcare System perspec-
tive. MethOds: A retrospective longitudinal analysis of the Government admin-
istrative claims database (Datasus) was performed. Eligibility criteria were patients 
starting CLL (ICD-10 code C911) chemotherapy from Jan/2008 to Dec/2011, with 
complete information and no inconsistency in date of birth, gender. Outpatient 
and inpatient databases were combined through deterministic linkage. Outcome 
was direct medical costs (DMC), calculated as the sum of the medical claims for 
each patient included in the analysis, for a maximum period of 5 years or death or 
loss of follow-up, whichever comes first. DMC was categorized in chemotherapy, 
hospitalizations, and other outpatient costs. Results: From 5100 patients with CLL 
identified in the database, 613 met eligibility criteria. Median follow-up time was 25 
months. This population cohort had 54% males with average age at start of treat-
ment of 66.4 ± 11.7 years. Patients received an average of 12.0 ± 9.4 months of chemo-
therapy treatment, with 71% of them treated by one type of chemotherapy regimen. 
Total DMC in this population was R$ 7,021,631.48 (average cost of R$ 6,404.52 ± 
6,133.37 per patient-year), from which R$ 5,384,552.12 (77%) are related to chemo-
therapy, R$ 1,062,978.98 (15%) to hospitalizations and R$ 574,100.38 (8%) to other 
outpatient costs. Outpatient laboratory exams accounted for 6% (R$ 397,050.07) of 
total DMC. 30 (5%) patients underwent radiotherapy treatment, with total costs of 
R$ 53,944.96 (< 1% of DMC). A total of 862 hospitalizations were identified in 287 
(46.8%) patients, with an average cost of R$ 1,233.15 ± 3,879.86 per hospitaliza-
tion. cOnclusiOns: Patients with CLL represent a significant economic burden 
to the public health system. Chemotherapy and hospitalization costs accounts for 
more than 90% of the total costs.
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platinum-based agents 20.3%, UFUR 8.3%, taxanes 7.7%, etoposide 7.5%). Close to 
three quarters (74.8%) of treated patients received combination therapy with plat-
inum-based agents. Of 1,221 patients treated with platinum-based combination 
therapy, the therapy most commonly used includes gemcitabine (37.5%), taxanes 
(21.5%), and vinorelbine (18.2%), while 21.4% of patients received two or more other 
agents. We observed longer median survival in patients with a higher number of 
chemotherapy agents received. cOnclusiOns: Lung cancer patients in Taiwan 
incurred considerable health care costs after diagnosis. More than half of patients 
were treated with chemotherapy, in particular with multiple chemotherapy agents. 
Future research comparing cost-effectiveness among different treatment options 
is warranted.
PCN71
AUSTRALIAN STANDARD COSTS AND CONSEQUENCES OF FOUR 
CHEMOTHERAPy ADvERSE EvENTS
Pearce A.M., Haas M., Viney R.
University of Technology, Sydney, Ultimo, Australia
Objectives: This work aimed to develop rigorous models of the Australian costs of 
four common chemotherapy adverse event (diarrhoea, vomiting, anaemia and neu-
tropenia), which provide standard cost estimates and can be used in future models 
of chemotherapy cost effectiveness. MethOds: Decision analytic modelling was 
used to identify the costs and consequences of AEs. These are not only stand alone 
models, but also form decision tree sections to be incorporated into larger models 
of chemotherapy cost effectiveness. Model structures are based on best-practice 
clinical pathways, and incorporate efficacy of side effect treatment, quality of life 
and chemotherapy dose. Literature reviews identified clinical inputs. Costs of treat-
ment were obtained from standard Australian sources such as the Pharmaceutical 
Benefits Schedule. The perspective was the Australian health care system. One-way 
sensitivity analyses explored uncertainty in the models. Results: The base case 
average cost per patient of diarrhoea ranged from $19 (mild AE) to $4,821 (severe AE); 
those for anaemia ranged from $51 (mild AE) to $17,100 (moderate AE) depending on 
the type of chemotherapy and anaemia treatment. Vomiting prevention base case 
costs ranged from $0.84 (low risk chemotherapy) to $157.55 (high risk chemotherapy 
requiring breakthrough and refractory management). Neutropenia base case costs 
ranged from $2,235 (outpatient management) to $12,054 (intensive care required). 
Where possible, the impact on quality of life and chemotherapy total dose was also 
modelled. Estimates of AE costs vary widely in the literature, however our estimates 
appear consistent with studies of similar methodology. cOnclusiOns: The four 
models presented represent best-practice modelling techniques for chemotherapy 
AEs. Each has been designed to enable either the results or the model structure to 
be incorporated into larger models of chemotherapy cost effectiveness. This allows 
model builders to incorporate rigorous, Australian-specific estimates of the costs and 
consequences of chemotherapy AEs into models of chemotherapy cost effectiveness.
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HORMONAL RECEPTOR POSITIvE, HER2 NEGATIvE METASTATIC BREAST 
CANCER (MBC HR+HER2-): PRE AND POST-PROGRESSION COSTS UNDER THE 
PUBLIC HEALTH CARE SySTEM (SUS) AND SOCIETAL PERSPECTIvES IN BRAzIL
Haas L.C.1, Fernandes R.A.1, Bines J.2, Caldas A.3, Valentim J.3
1ANOVA, Rio de Janeiro, Brazil, 2Clementino Fraga Filho Hospital, Federal University of Rio de 
Janeiro, Rio de Janeiro, Brazil, 3Novartis Biociências SA, São Paulo, Brazil
Objectives: To estimate direct medical costs and productivity costs of hormonal 
receptor positive, HER2 negative metastatic breast cancer (MBC HR+ HER2-) under 
the public health care system (SUS) and societal perspectives in Brazil, being MBC 
cost data very scarce in Brazil so far. MethOds: A systematic literature review was 
performed in the following databases: Cochrane, MEDLINE via Pubmed, LILACS, 
EMBASE and CRD until FEB 2013. Gray literature was also included. National guide-
lines search and expert validation was carried out specifically for the direct medical 
cost estimations. Direct medical costs were stratified as pre and post-progression 
costs and terminal costs. Pre and post-progression costs considered outpatient, 
inpatient and monitoring costs. For post-progression, metastasis treatment costs 
were also estimated, including bone, lung, liver and brain metastasis. For the pro-
ductivity costs, the Human Capital method was chosen. Days of absenteeism were 
obtained from the literature and a Markov model was used to estimate the loss of 
productivity in 1 year (as the mean age of MBC in Brazil is 59 and official retirement 
at 60 years of age). Unit costs were obtained from Brazilian official lists and IBGE 
(income). All costs are expressed in 2012 Brazilian Real (BRL). Results: Pre, post-
progression and terminal costs of MBC HR+HER2-were estimated in BRL308, BRL731 
and BRL4.164 respectively, under SUS perspective. Post-progression metastasis treat-
ment costs presented an average of BRL12.047 under SUS perspective. The productiv-
ity costs were estimated in BRL26.056 under the societal perspective considering 
the available treatments at SUS for MBC HR+HER2- patients. cOnclusiOns: MBC 
HR+HER2- post-progression costs impose a significant economic burden under SUS 
perspective as well as productivity losses to the society. Novel therapies that post-
pone progression in those patients may reduce costs associated.
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ESTIMATING THE COST OF HPv-RELATED DISEASES IN TURKEy: A DELPHI 
APPROACH
Bakir M.1, Ayhan A.2, Arvas M.3, Kose M.F.4, Gungor M.5, Ortac F.6, Ozgul N.7, Yuce K.7, Ergun T.1, 
Gungor E.5, Altundag O.2, Saka G.8
1Marmara University School of Medicine, Istanbul, Turkey, 2Baskent University School of Medicine, 
Ankara, Turkey, 3Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey, 4Bahcesehir 
University School of Medicine, Istanbul, Turkey, 5Acibadem University School of Medicine, Istanbul, 
Turkey, 6Ankara University School of Medicine, Ankara, Turkey, 7Hacettepe University School of 
Medicine, Ankara, Turkey, 8Merck Sharp Dohme, Istanbul, Turkey
Objectives: Very limited data is available on the cost and burden of HPV-related 
diseases in Turkey. The aim of our analysis is to evaluate the corresponding cost 
through understanding the current clinical practices, use of resources and treat-
in the USA in 2002. Inpatient care costs accounted for more than 60% of total 
cost. cOnclusiOns: Although the economic impact of the VTE in cancer patients 
as well as the impact of VTE on patients’ quality of life is not well studied, the 
present review demonstrate that there is a substantial humanistic and economic 
burden associated with VTE in cancer patients.
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A MICRO-COSTING OF THE INPATIENT MANAGEMENT OF FEBRILE 
NEUTROPENIA IN THE IRISH HEALTH CARE SETTING
McCullagh L.1, O’Brien C.2, Fogarty E.1, Walsh C.3, Dempsey O.3, Barry M.1, Kennedy M.J.2
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2St James’s Hospital, Dublin, Ireland, 
3Trinity College Dublin, Dublin, Ireland
Objectives: Febrile neutropenia (FN) is a potentially life-threatening complica-
tion of chemotherapy which generally prompts immediate hospitalisation. The 
study objective was to evaluate the resource use and cost of hospitalisation for 
FN within the Irish Health care setting. Micro-costing techniques were used. The 
health payer perspective was adopted. MethOds: This was a single centre study. 
Adult cancer patients undergoing chemotherapy, who were subsequently admit-
ted for FN, were identified prospectively. Patient medical records were reviewed 
retrospectively. Results: Patient demographics and resource utilisation data (per-
taining to the management of FN) were obtained from a cohort of 32 patients (69% 
female, mean age = 58.8 years). Twenty-five percent of patients had more than one 
FN episode. In total, 42 FN episodes were captured; 60% of episodes had occurred 
within the first two cycles of chemotherapy. The bootstrap estimation was used to 
determine mean hospital length of stay (LOS) with standard deviation (± SD) and 
mean costs (± SD). The mean LOS was 7.3 (± 0.5) days. The mean cost per FN episode 
was € 8,915 (± 718). The major cost driver was hospital bed-stay (mean cost of € 6,851 
(± 549)). Other cost drivers included antibacterial treatment at € 760 (± 156), labora-
tory investigations at € 538 (± 47) and the requirement for blood bank products at 
€ 525 (± 189). cOnclusiOns: To our knowledge, this is the first investigation of the 
cost of chemotherapy induced FN within the context of the Irish Health care setting. 
Our results will be used in cost-effectiveness analyses of novel chemotherapeutic 
agents and interventions which prevent or treat FN.
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THE COST OF NSCLC IN FRANCE
Martin M.1, Mcguire A.2, Marty R.3, Lenz C.4
1OptumInsight, Uxbridge, Middlesex, UK, 2London School of Economics, London, UK, 3HEVA HEOR, 
Lyon, France, 4Pfizer, Berlin, Germany
Though lung cancer, and the most common subtype, non-small cell lung cancer 
(NSCLC), occur frequently, there are limited data quantifying the economic burden 
of these cancers in Europe.Objectives: To describe the burden of NSCLC in three 
European countries using patient-level data from commercially available health 
care data. MethOds: Patient-level data were obtained for France from the PMSI 
(French National discharge database; containing data from publicly-funded hos-
pitals) from 2008 to 2011 while excluding patients with a prior-hospitalization for 
lung cancer in the preceding 24-month period (2006-2007). As NSCLC does not have 
a separate ICD-10 code, expert opinion was used to eliminate patients diagnosed 
with non-NSCLC, based on particular procedures and tests. Hospital resource 
use was valued using French DRG tariffs. Chemotherapy regimens were valued 
using official rates. Results: A total of 61,144 patients were identified with lung 
cancer in 2008. 19,099 were excluded because of prior lung cancer diagnoses. Of 
this cohort of 42,043 patients, 25,054 were exclusively treated in the public setting; 
15,061 were identified as NSCLC and were considered in this analysis. Hospital-
related costs cumulated over the follow-up period were estimated at € 337,382m, 
with chemotherapy costs representing 9%. Mean cumulated hospital-related 
cost per-patient were estimated at € 22,401 over the follow-up period. Terminal 
care represented a mean per-patient cost of € 10,440. Adverse events triggering 
hospital-expenses represented a mean per-patient cost of € 5,694. Patients ≤ 55 
years incurred higher costs per-person over the follow-up period than patients > 55 
years; € 25,386 vs. € 21,368. These extra costs were mostly driven by chemotherapy 
costs(€ 13,287 vs. € 10,561). Patient with metastases incurred higher costs over the 
follow-up period than patients without these, € 23,118 vs. € 21,934. cOnclusiOns: 
This is one of the first analyses quantifying the economic burden of NSCLC. The 
burden for France is substantial. Subsequent analyses will allow for comparisons 
of this burden across other countries.
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CHEMOTHERAPy TREATMENT PATTERNS, HEALTH CARE COSTS, AND 
MORTALITy OF LUNG CANCER PATIENTS IN TAIwAN – A LONGITUDINAL 
STUDy BETwEEN 2000 AND 2008
Liang F.W.1, Chen S.Y2, Tsai C.F.1, Jen M.H.3, Li C.Y.1, Wasiak R.3, Boulanger L.2, Lu T.H.1
1National Cheng Kung University, Tainan City, Taiwan, 2Evidera, Lexington, MA, USA, 3Evidera, 
London, UK
Objectives: To examine chemotherapy treatment patterns, health care costs, 
and mortality of lung cancer patients in Taiwan. MethOds: This study analyzed 
medical and pharmacy claims from a random sample of one million taken from 
all beneficiaries covered under Taiwan’s national health insurance in 2000. Newly 
diagnosed lung cancer patients between 2000 and 2008 (first observed diagnosis as 
the index date) were identified based on medical claims with associated diagnoses. 
Patients were followed until death or the end of 2008. Per patient per month [PPPM] 
total health care costs (in USD) and median survival were reported. Chemotherapy 
treatment patterns during the follow-up were examined. Results: This study 
included 3,343 lung cancer patients (mean age: 67.1 years; 34.5% female; 35.4% 
secondary lung cancer). Median survival was 8.1 months. PPPM costs were $2,322 
USD (interquartile range $450-$2,902). Lifetime costs from diagnosis among those 
who died during the study period were $12,788 USD (interquartile range $2,674-
$17,546). Of the 1,633 patients who received chemotherapy during the follow-up, 
375 received only one chemotherapy agent (gemcitabine 35.7%, vinorelbine 20.5%, 
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INPATIENT HOSPITAL COSTS OF FEBRILE NEUTROPENIA (FN) AS A 
CONSEQUENCE OF CHEMOTHERAPy (CHT) FOR BREAST CANCER (BC) AND NON-
HODGKIN LyMPHOMA (NHL) IN SwITzERLAND
Mattli R., Pletscher M., Eichler K., Wieser S.
Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, 
Switzerland
Objectives: FN can be a serious complication of CHT, increasing mortality risk 
and health care costs. Incidence and inpatient hospital costs of FN in Switzerland 
are currently not reported; therefore this study aimed to: 1. Estimate the number 
of FN-related hospitalizations. 2. Assess inpatient hospital costs per FN event in 
Switzerland. MethOds: The main data source was MedStat, a comprehensive data-
base of all Swiss hospitalizations from 1997-2010. BC and NHL cases were identified 
from ICD-10-GM codes. Hospitalizations for FN were identified by a simultaneous code 
of BC or NHL and neutropenia. Incident cases of cancer were identified as patients 
treated in 2010 for the first time since 2002. Results were compared to data from the 
Foundation National Institute for Cancer Epidemiology and Registration (NICER). Cost 
data stems from the cantonal hospital of Winterthur. Results: Using MedStat data, 
645 male and 557 female NHL patients and 6’391 female BC patients were hospital-
ized in 2010 for the first time. Corresponding annual incidence data from NICER were 
780 male and 688 female NHL patients and 5’388 female BC patients. The proportion 
of hospitalizations due to FN was 8.2% (190/2’311) among male and 6.0% (123/2’063) 
among female NHL patients, and was 2.6% (255/9’650) among female BC patients. 
In-hospital mortality of FN cases was 9.5% for men and 5.7% for women with NHL, 
and 4.3% for BC. Median inpatient treatment costs for an FN event were CHF 8’399 
(mean: CHF 14’006) in NHL and CHF 4’208 (mean: CHF 10’020) in BC. Nursing time was 
the most important cost component and length of stay was the most important driver 
of total inpatient cost. cOnclusiOns: 3% to 8% of all hospitalizations in NHL and 
BC patients were due to FN. Our results suggest that FN leads to considerable risk of 
death and incurs high in-hospital care cost in Switzerland.
PCN78
COST ASSESSMENT OF METASTATIC AND NON-METASTATIC CASTRATION-
RESISTANT PROSTATE CANCER PATIENT-MANAGEMENT IN SPAIN
Morote J.1, Cozar J.M.2, Duran I.3, Gomez Veiga F.4, Leon L.5, Maroto P.6, Miñana B.7, Solsona E.8, 
Oyagüez I.9, Casado M.A.9, Roldán C.9, Gutierrez L.10, Hechmati G.11
1Vall d’Hebron Hospital. Universitat Autónoma de Barcelona, Barcelona, Spain, 2Hospital Virgen 
de las Nieves, Granada, Spain, 3Hospital Universitario Virgen del Rocío, Sevilla, Spain, 4CHUAC “A 
Coruña University Hospital, A Coruña, A Coruña, Spain, 5Hospital Clinico Universitario Santiago, 
Santiago de Compostela, Spain, 6Htal Sant Pau, Barcelona, Spain, 7Hospital Morales Meseguer, 
Murcia, Spain, 8I.V.O, Valencia, Spain, 9Pharmacoeconomics & Outcomes Research Iberia, Madrid, 
Spain, 10Amgen S.A., Barcelona, Spain, 11Amgen (Europe) GmbH, Zug, Switzerland
Objectives: To compare annual management costs of castration-resistant prostate 
cancer (CRPC) patients at high risk of developing bone metastases (BM) versus those 
that already had BM in Spain. MethOds: An expert panel of 5 urologists and 3 oncol-
ogists from Spanish health centres was asked to estimate the mean annual resource 
use in the management of non-metastatic CRPC patients and in the first, second and 
subsequent years after developing BM. Hospital resources were stratified into four 
major categories: 1) general resources [medical visits, diagnostic and monitoring pro-
cedures, hospital admission and surgeries], 2) hormone therapy, 3) chemotherapy and 
4) analgesic treatments. The last three categories included: drug costs, adverse event 
(AE) management-costs and pre-medication costs. Skeletal-related events (pathologi-
cal fracture, radiation or surgery to bone and spinal cord compression) often suffered 
by BM patients were excluded from the analysis as Spanish cost-related data had 
recently been published. Unit costs (€ , 2013) for each identified resource were obtained 
from a national cost-database. Results: Total management-related annual costs for 
non-metastatic CRPC patients were € 2,691.57; € 978.51 were hormone therapy drug 
costs, € 11.10 analgesics costs and € 243.55 AE management costs. No chemotherapy 
was administered in these patients. Annual management cost for BM patients was 
€ 6,000.37 the first year, € 14,468.35 the second year and € 14,313.87 in subsequent years. 
Hormone therapy drug costs accounted for € 946.67, € 948.13 and € 948.13 in the first, 
second and subsequent years, while chemotherapy costs accounted for € 1,892.21 
(32.2%); 9,485.41 (66.2%) and € 9,143.92 (64.4%), respectively. Analgesic costs increased 
from € 597.29 (first year) to € 915.16 and € 1,031.20 (second and subsequent years) and 
AE management costs increased from € 595.63 (first year) to € 758.58 (second year) 
and € 732.14 (subsequent years). cOnclusiOns: CRPC patients with BM had higher 
management costs than non-metastatic patients especially after the first year of 
treatment, which was mainly due to chemotherapy drug costs.
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ECONOMIC BURDEN OF TOxICITIES ASSOCIATED wITH ADvANCED MELANOMA 
TREATMENTS IN FRANCE, ITALy, THE NETHERLANDS, AND SPAIN
Bilir S.P.1, Zhao Z.2, Wehler E.A.3, Munakata J.1, Barber B.2
1IMS Health, San Francisco, CA, USA, 2Amgen Inc, Thousand Oaks, CA, USA, 3IMS Health, 
Alexandria, VA, USA
Objectives: Little is known about costs of managing adverse events (AEs) associ-
ated with currently-available therapies in advanced melanoma. This study identi-
fies and estimates the costs of these AEs in France (FR), Italy (IT), The Netherlands 
(NL), and Spain (ES). MethOds: A comprehensive literature search was conducted 
to identify common grade 3/4 AEs from product labels and published phase II/III 
advanced melanoma studies in PubMed, conference abstracts, and European treat-
ment guidelines. Resource utilizations for the management of each type of AE in typ-
ical inpatient/outpatient treatment setting were determined via in-depth interviews 
with 5 melanoma clinicians in each country. Outpatient and inpatient 2012 costs 
were then estimated for each type of AE by applying country-specific tariffs, except 
in Spain where costs were obtained from government database or best published 
sources. Results: Most frequent grade 3/4 AEs associated with chemotherapies 
included neutropenia, vomiting, and anemia. Vemurafenib was commonly associ-
ated with cutaneous squamous cell carcinoma (CSCC)/keratoacanthoma, rash, and 
ment algorithms based on expert opinion. MethOds: This study uses the Delphi 
method to reach experts’ consensus on the clinical practices currently being used 
in Turkey. Delphi method has been widely used in medical areas where empirical 
data is scarce. The survey developed for this study includes questions to under-
stand the clinical resource use in order to calculate the associated costs. Although 
the panelists’ answers are unlikely to change after the second iteration accord-
ing to the literature, a three-iteration panel was needed to reach a consensus in 
practice. The consensus is then used to calculate the cost of an episode of care for 
genital warts (GW), CIN 1, CIN 2/3, different cervical cancer stages from the payer’s 
perspective. Results: TDP-HPV included a total of 10 experts, including gyneco-
oncologists, dermatologists and a medical oncologist. The cost of a GW episode of 
care is approximately USD 263.58 to the government. CIN 1 cases are only treated if 
the disease persists for 2 years, which happens in about 5% of cases. The cost of a 
CIN 1, CIN 2/3 episode of care is calculated as USD 127, USD 262 to the government, 
respectively. The cervical cancer (CC) stages are divided into local CC, regional CC, 
and distant CC. The costs associated with these states are USD 1,340, USD 4,345, 
and USD 8,150. cOnclusiOns: Early diagnosis and treatment is crucial from the 
cost perspective too as a more severe disease costs more. GWs are sometimes left 
out when HPV-related diseases are considered. However, this study mentions that 
GW presents a serious burden to the society.
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COSTS OF HER 2 NEGATIvE, HORMONAL RECEPTOR POSITIvE, METASTATIC 
BREAST CANCER (MBC-HR+) TREATED wITH EvEROLIMUS (EvE) + ExEMESTANE 
(ExE) IN THE BRAzILIAN PRIvATE SySTEM (BPS): A REAL wORLD (Rw) AND 
PUBLISHED LITERATURE ANALySIS
Clark O.A.C.1, Paladini L.1, Engel T.1, Caldas A.2, Valentim J.2
1Evidencias, Campinas, Brazil, 2Novartis Biociências SA, São Paulo, Brazil
Objectives: EVE in association with aromatase inhibitor was recently approved 
by ANVISA (Brazilian Regulatory Agency) for MBC-HR+ patients. EVE redefines the 
role of endocrine therapy in MBC-HR+ reversing endocrine resistance. The aim of 
this study is to determine the costs associated to the introduction of EVE + EXE for 
the Brazilian private system population. MethOds: A previous study from real-
world (RW) data between 2011-12 (large private database of medical claims for 
chemotherapy (CT), Evidencias Database) and published data identified MBC-HR+ 
patients and evaluated costs of treatments and adverse events (AEs), by a micro-
costing approach. Patients were divided into three groups, according to metastasis: 
bone exclusive (B), Visceral exclusive (V) and Bone plus Visceral (BV). For this study 
the financial impact of the adoption of EVE+EXE was calculated in this population, 
based on the previous findings. Direct medical costs of EVE, hormones, CT, hospi-
talization, supportive care, radiation, monitoring and AEs were considered. A cohort 
of 100 patients with MBC-HR+ was simulated in a decision tree to obtain the costs 
for each group and the mean cost/ patient. Costs were estimated in 2013 Brazilian 
Real (R$). Results: RW data showed the following distribution of patients: B 38%, 
V 42% BV 20%. Lengths of treatment (months) were B 25.1-30, V 16.1; BV 14-19.6. 
Mean costs/patient/group, before EVE+EXE adoptions, were B R$135.744 (US$67,872), 
V R$129.079 (US$64,539) and BV R$117.172 (US$58,568). If EVE+EXE substituted 80% 
or 50% of the current treatments, the incremental percentage of costs would be B 
(5%; - 9%), V (5,7%; -16%) and BV (22%; 14%). Costs with AEs were at least 50% lower 
with the use of EVE+EXE. cOnclusiOns: EVE adoption in association with EXE 
may be cost saving for some groups of MBC-HR+ patients. For other groups, the 
incremental cost is not superior to 22%.
PCN75
ESTIMATED COSTS OF HER2-POSITIvE METASTATIC BREAST CANCER FOR 
PATIENTS INITIATING AN ORAL ANTICANCER TREATMENT: RESULTS FROM A 
FRENCH PROSPECTIvE OBSERvATIONAL STUDy
Woronoff-Lemsi M.C.1, Chaix-Couturier C.2, Durand-Zaleski I.3, Espié M.4, Lortholary A.5, 
Merrouche Y.6, Flinois A.7, Chabernaud H.8, Benjamin L.9
1Department of Pharmacy, Besançon Cedex, France, 2Conseil Chaix-Couturier, Meudon, France, 
3Hôpital Henri Mondor, Créteil, France, 4Hôpital Saint Louis, Paris, France, 5Catherine de Sienne, 
Nantes, France, 6Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France, 7Kantar 
Health, Paris, France, 8Kantar Health, Montrouge, France, 9GlaxoSmithKline, Marly le Roi, France
Objectives: To assess the cost of HER2-positive (HER2+) metastatic breast cancer 
(mBC) for patients initiating an oral anticancer treatment (OAT) from the perspective 
of the French National Health Insurance (NHI). MethOds:  A prospective observa-
tional multicenter study was conducted among 284 HER2+ mBC patients treated by 
68 oncologists initiating a treatment containing an OAT between March 2011 and 
February 2012. Costs data were available for 199 patients. Clinical characteristics, 
treatment patterns, quality-of-life, adherence and health care resources data were 
collected. Health care resource use data on hospitalization, medical consultation, 
drug and radiation-therapy were reported by oncologists at treatment initiation and 
after each 3-month period during a 9 months maximum period. Cost estimations 
were based on unit costs from national databases (French Diagnosis Related Group 
cost database and NHI database for drug unit cost). Results: A total of 109 patients 
(55%) received an OAT only and 90 (45%) received oral and intravenous (IV) drugs. 
Thirty patients (15%) were treated with radiation therapy and 43 patients (22%) 
with hormonal-therapy in addition to chemotherapy. The overall average cost of 
management per patient was 28,482€ ± 14,914 for all patients, 19,412€ ± 9,462 for 
patients with an OAT only and 39,467€ ± 12,770 for patients with oral and IV drugs. 
Drug costs were 27,669 € ± 14,976 and they represented 97% of the total hospital cost 
of management (hospitalizations, consultations and drugs). cOnclusiOns: This 
prospective observational study conducted among HER2+ mBC patients shows that 
the route of drug administration has an impact on treatment costs. Nevertheless, 
the study design does not allow concluding that OAT were associated with lower 
costs and cost savings. These finding however warrants further exploration within 
the context of micro-costing studies from the hospital and community perspective 
in order to better understand the health care resources used that are required to 
manage patients treated with OAT.
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Objectives: Prostate cancer (PCA) is the most common cancer in men worldwide. 
However, there is disagreement about the benefits of existing screening programs. 
This is mainly due to low specificity of currently utilized biomarkers. This can lead 
to both inappropriate medical treatment and increasing costs of care. For the future, 
many biotechnological developments are promising, but not all will be affordable 
for routine screening. The question is how much a complementary biomarker to 
prostate-specific antigen (PSA)-test may cost which would be applied to avoid false-
positive results. MethOds: Conduct of a hybrid discrete-event and system-dynamics 
simulation by applying AnyLogic. Based on clinical guidelines and expert knowl-
edge, a hypothetical PCA screening workflow was developed and supplemented by 
a proposed innovative biomarker. Demographic and patient behavior information, 
disease related data on incidence as well as sensitivity and specificity of PSA, digital-
rectal examination and prostate biopsy were further implemented in the model. 
Economic consequences were calculated by considering costs for examinations, 
biopsy diagnosis and complications. Results: In Germany, annual screening would 
be recommended for 18.8 million men aged ≥ 45 years. Assuming a biomarker speci-
ficity of 80%, approximately 70% of prostate biopsies could be avoided. This could 
lead to a reduction of biopsy caused complications. Regarding the latter, mean costs 
of 204.17€ were calculated. Due to prevented check-ups and biopsy-complications, 
cost neutrality for the supposed biomarker will be reached when applying a price 
of 48.50€ . cOnclusiOns: A complementary biomarker could lead to more precise 
diagnosis and additional value for patients and health insurance funds. Although the 
price may not be high, an implementation may nevertheless be feasible for companies 
due to the high number of examinations. Funded by the German Federal Ministry of 
Education and Research (BMBF) as part of the National Cluster of Excellence Medical 
Technology - Medical Valley EMN (Project grant No. 01EX1013B).
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RESOURCE USE AND COST OF DIAGNOSIS AND MANAGEMENT OF BREAST 
CANCER By STAGE IN AN IRISH TEACHING HOSPITAL
Tierney P.1, Tilson L.2, Barry M.2, Bennett K.3
1National University of Ireland, Galway, Ireland, 2National Centre for Pharmacoeconomics, Dublin, 
Ireland, 3Trinity Centre for Health Sciences, Dublin, Ireland
Objectives: To estimate the cost of diagnostic investigation and treatment 
for breast cancer in an Irish teaching hospital from a health payer perspec-
tive. MethOds: Retrospective population based resource utilisation data for n=611 
patients treated for primary breast cancer in a university teaching hospital in Ireland 
were available for the period 2009-2011. Health care resource use included diagnostic 
investigations and all treatments. Unit costs for diagnosis & surgical procedures, 
laboratory tests, and radiotherapy were derived from DRG costs, hospital finance 
departments, clinical opinion and literature review. Chemotherapy costs were esti-
mated from local hospital protocols, pharmacy departments and clinical opinion. 
Associated pharmaceutical cost, including oral hormonal therapy, were estimated 
from the HSE Primary Care Reimbursement Services claims database. Overall and 
mean costs by stage of breast cancer are presented with bootstrap 95% confidence 
intervals (CIs). Results: Total cost of diagnosis, treatment and follow-up was 
estimated at €15.2 million over the 3 year period, with an average cost of €24,863 
per patient (95% CI; €22,628, €27,197). Chemotherapy and other pharmaceuticals 
accounted for 47%, radiotherapy 19%, surgery 19%, diagnostics 5%, radiology 2% and 
follow-up 8% of total expenditure. The biological agent trastuzumab accounted for 
43% of total pharmaceutical expenditure. Costs varied by stage at diagnosis. The 
average cost per patient by stage at diagnosis was estimated as follows; Stage 1 (n 
= 186) €23,821 (95% CI; €20,113, €27,846); Stage 2 (n=248) €24,919 (95% CI; €21,358, 
€28,626); Stage 3 (n=121) €30,172 (95% CI; €25,434, €35,366); Stage 4 (n=56) €16,570 
(95% CI; €7,964, €25,836). cOnclusiOns: This study demonstrates the value of using 
existing data from national and local databases in estimating the cost of diagnosis 
and management of breast cancer from a health payer perspective and highlights 
the impact of trastuzumab on overall costs.
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ANALySIS OF PUBLIC AND PRIvATE HOSPITAL DATABASES (PMSI) 2010 / 
2011 TO ESTIMATE THE FREQUENCy AND ASSOCIATED COSTS FOR FEBRILE 
NEUTROPENIA IN FRANCE
Vainchtock A.1, Cohen S.2, Durand-Zaleski I.3
1HEVA, LYON, France, 2Amgen S.A.S., Neuilly-sur-Seine, France, 3Hôpital Henri Mondor, Créteil, 
France
Objectives: To estimate the frequency and costs of hospital stays for cancer 
patients receiving cytotoxic chemotherapies inducing febrile neutropenia (FN), in 
public and private hospitals in France. MethOds: The French Hospital National 
Database (PMSI) is a comprehensive claims database which includes information 
on diagnoses an procedures and allows record linkage. Hospital stays for patients 
admitted with hematologic or solid tumors in 2010/2011 were extracted and an ad 
hocalgorithm selected those for which the primary admission reason was FN, as well 
as those due to an infectious syndrome resulting from FN. Economic valuations were 
based on 2010 public national tariffs and National Scale Costs (ENCC). Results: 
A total of 14,685 hospital stays were analyzed (3,776 stays for the treatment of 
hematologic tumors and 10,909 for solid tumors) corresponding to 10,721 patients 
treated for FN (2,386 patients first treated for hematologic tumor and 8,343 first 
treated for solid tumor). The proportions of patients hospitalized for FN were 12.2% 
for hematologic tumors and 7.0% for solid tumors. The average length of stay was 
7 days for patients with hematologic tumors and 6.5 days for patients with solid 
tumors. In the sub analysis, non-Hodgkin’s lymphoma (11.7%) and lung cancer 
(11.8%) were, respectively, the most common hematologic and solid tumor types 
in patients hospitalized for FN. The mean costs of treatments associated with FN 
per patient were 7,820.67€ for hematologic tumors, 4,907.83€ for solid tumors and, 
in the sub-analysis, 6,816€ for non-Hodgkin’s lymphoma and 4,907€ for lung can-
cer. cOnclusiOns: The PMSI is a useful source to estimate the treatment costs 
associated with FN in France. In 2010/2011, febrile neutropenia induced a total of 
14,685 stays and a total cost of 59.6 million euros for the Statutory Health Insurance.
elevated liver enzymes, while dabrafenib was most often associated with CSCC 
and pyrexia. The most common AEs associated with trametinib were hyperten-
sion and rash. Common ipilimumab AEs were immune-related diarrhea/colitis, 
dyspnea, anemia, vomiting, and less frequently, hypophysitis. In the outpatient 
setting, the most costly AEs per incident included anemia (€ 1,431, € 1,309, € 1,276; 
ES, IT, FR) and CSCC (€ 1,058; NL). Other costly outpatient treatments include those 
for hypophysitis (€ 463, € 449, € 321; NL, ES, IT), febrile neutropenia (€ 593, € 430; IT, 
ES), and CSCC (€ 483, € 292; ES, IT). In the inpatient setting, the most costly AEs per 
hospitalization per country were hypophysitis (€ 10,189; ES), elevated liver enzymes 
(€ 6,868; FR), anemia (€ 2,826, € 2,628; NL, IT). Additional inpatient treatments with 
high costs were diarrhea (€ 4,083; ES), neutropenia (€ 2,322; IT) and vomiting (€ 2,036; 
NL). cOnclusiOns: Costs of managing AEs can be substantial, and effective new 
treatments with reduced AE profiles would be valuable.
PCN80
THE COST OF TREATING SQUAMOUS CELL CARCINOMA OF THE ANUS (SCCA) IN 
ENGLAND: RESULTS FROM AN EMPIRICALLy CALIBRATED MODEL
Keeping S.T., Carroll S.M.
Sanofi Pasteur MSD, Maidenhead, UK
Objectives: Squamous cell carcinoma of the anus (SCCA) generally requires a 
number of complex interventions as part of a multidisciplinary approach to treat-
ment. This research aimed to combine available data on disease progression 
and treatment in order to estimate the average cost of treating a case of SCCA in 
England. MethOds: Data on primary treatment, disease progression and follow-up 
were obtained from the Association of Coloproctology of Great Britain and Ireland’s 
anal cancer position statement, supplemented by expert opinion where necessary. 
First, decision trees were constructed to estimate the costs of diagnosis, staging 
and primary treatment. A Markov model was then developed to simulate disease 
progression and follow-up based on the mode of primary treatment (combined 
modality therapy versus radiotherapy alone). Values for unknown parameters were 
jointly selected from within plausible ranges and model outputs for each simula-
tion were then compared to empirical data on overall mortality and locoregional 
relapse. Goodness of fit was estimated using ordinary least squares. All costs applied 
to treatments and interventions were taken from the 2010/11 National Tariff, with 
the 2010/11 Reference Costs used for off tariff payments. A one-way sensitivity 
analysis was also performed. Results: The cost of treating a case of SCCA was 
estimated to be in the range of £16,448-£16,630 when future inflation was taken into 
account, and £16,278-£16,455 when it was not. In the one-way sensitivity analysis, 
the adjusted value ranged between £14,309-£23,264 (unadjusted £14,139-£23,077), 
with the results most sensitive to changes in the mode of admission for primary 
treatment and the costs of staging/diagnosis. cOnclusiOns: Despite limitations 
in the approach resulting from a lack of available data, these results indicate that 
the cost of treating SCCA is significant. Further observational work is required in 
order to verify these findings.
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ECONOMIC BURDEN OF TOxICITIES ASSOCIATED wITH ADvANCED MELANOMA 
TREATMENTS IN THE UNITED STATES
Bilir S.P.1, Zhao Z.2, Wehler E.3, Munakata J.1, Barber B.2
1IMS Health, San Francisco, CA, USA, 2Amgen Inc, Thousand Oaks, CA, USA, 3IMS Health, 
Alexandria, VA, USA
Objectives: Information on the costs of managing adverse events (AEs) associated 
with currently-available treatment regimens in advanced melanoma is limited. This 
study identifies treatment-related AEs associated with commonly-used regimens 
recommended in US guidelines, and estimates the costs of treating these AEs in 
the US. MethOds: Grade 3 and 4 AEs were identified by a comprehensive litera-
ture search of product labels and published English-language phase II/III advanced 
melanoma studies in PubMed, conference abstracts, and NCCN guidelines. In-depth 
interviews with 5 US melanoma clinicians were performed to obtain resource uti-
lization and treatment setting information for managing each type of AE. Costs 
(2012$) were then estimated for each type of AE in outpatient and inpatient settings, 
using Medicare reimbursement rates for the outpatient setting, and Healthcare 
Utilization Project estimates for the inpatient setting. Results: The most common 
grade 3 and 4 AEs associated with chemotherapy regimens included neutropenia, 
vomiting, and anemia. Cutaneous squamous cell carcinoma (CSCC)/keratoacan-
thoma, rash, and elevated liver enzymes were most common AEs associated with 
vemurafenib, while CSCC and pyrexia were most often associated with dabrafenib. 
The most common AEs associated with trametinib were hypertension and rash. 
Common ipilimumab AEs included immune-related diarrhea/colitis, dyspnea, ane-
mia, and vomiting, and less frequent hypophysitis. The highest cost per incident 
in the outpatient setting among these AEs was neutropenia ($2,039), followed by 
CSCC ($369), vomiting ($342), and dyspnea ($222). The highest costs per hospitaliza-
tion were for CSCC ($18,906), followed by hypophysitis ($15,721) and febrile/afebrile 
neutropenia ($11,125). Other costly AEs in the inpatient setting include hypertension 
($8,113), diarrhea ($6,881), dyspnea ($6,826), vomiting ($6,046), anemia ($6,014), and 
elevated liver enzymes ($5,942). All hospitalizations due to AEs were more than 
$4,000 per incident. cOnclusiOns: The costs of managing treatment-related AEs 
in advanced melanoma are considerable, and there is need for effective treatments 
with improved toxicity profiles.
PCN82
HEALTH ECONOMIC EvALUATION OF A COMPLEMENTARy BIOMARKER FOR 
HyPOTHETICAL PROSTATE CANCER SCREENING IN GERMANy
Meier F.1, Niederländer C.S.2, Djanatliev A.3, Gantner-Bär M.3, Höllthaler J.4, Voigt W.4, 
Schöffski O.1, Kolominsky-Rabas P.L.2, Emmert M.1
1Friedrich-Alexander-University Erlangen-Nuremberg, Nuremberg, Germany, 2Centre for Health 
Technology Assessment (HTA) and Public Health (IZPH), University of Erlangen-Nuremberg, 
Erlangen, Germany, 3University of Erlangen-Nuremberg, Erlangen, Germany, 4Siemens AG, 
Erlangen, Germany
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patients received medical services to the value of 927 million Euro or 14.2% of total 
reimbursed lump-sums (6.53 billion Euros) in Austria. 224 million Euros fall upon 
medical tumour therapy. With regard to monoclonal antibody therapies, 56 million 
Euros was refunded. cOnclusiOns: The current development in modern cancer 
therapies leads to efficient treatment pathways expressed in higher survival rates, 
reduced hospital days and an improved quality-of-life.
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COST-ANALySIS IN THE TREATMENT OF PATIENTS AFFECTED By MALIGNANT 
ASCITES IN ITALy
Teruzzi C.1, Mantuano M.1, Colombo G.L.2, Bruno G.M.3, Di M.atteo S3
1Temas. A Quintiles Company, Milan, Italy, 2University of Pavia, Pavia, Italy, 3S.A.V.E. Studi 
Analisi e Valutazioni economiche, Milan, Italy
Objectives: The objective of this project was to identify the treatment cost of 
malignant ascites from the Italian NHS perspective through a cost-analysis. Three 
reference centers in Italy contributed to this study during year 2012. MethOds: 
Three centers (Scientific Institute of Romagna for Cancer Studies and Treatment-
I.R.S.T; Medical Oncology Unit of San Gerardo Hospital; Department of Gynecology 
of University Hospital Agostino Gemelli) were chosen due to the fact that they treat 
a representative sample of patients with malignant ascites in Italy. Each center 
was asked to complete three case report forms: the first identifying the costs for 
the pre-procedure diagnostic tests, the second identifying the specific procedure 
costs (paracentesis) and the third identifying the specific costs due to treatment of 
complications. All these reports had to be completed for the last 5 patients diag-
nosed with malignant ascites in order to prevent selection bias. A total cost for each 
patient was calculated by DRG analysis (standard cost – tariff). The DRG analysis 
assessed: day hospital, admission number, hospitalization, number of hospitaliza-
tion days, principal diagnosis, main procedure/intervention, number of paracentesis 
procedures performed on the same patient with the same diagnosis, DRG type, 
DRG code, refund value for day hospital/ refund value for ordinary hospitaliza-
tion. Results: The analysis shows an average cost of € 1,464.42 per patient with 
malignant ascites using the DRG reimbursement rate (minimum value: € 1,405.63; 
maximum value: € 1,525.37). Analysis using DRG with complications resulted in a 
mean value of € 1,524.84 (minimum value: € 1,429.69; maximum value: € 1,625.55). 
The key cost driver of malignant ascites treatment was the paracentesis proce-
dure. cOnclusiOns: The economic impact of paracenteses is high, especially when 
procedures must be repeated. The reduction in the number of paracenteses could 
reduce the costs while improving the QoL of the patients.
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ECONOMIC EvALUATION OF AN ELECTRICAL IMPEDANCE SPECTROSCOPy (EIS) 
DEvICE USED AS AN ADjUNCT TO COLPOSCOPy
Bessey A., Whyte S., Minton J., Chilcott J.
University of Sheffield, Sheffield, UK
Objectives: Colposcopy is an essential part of the screening process for the preven-
tion of cervical cancer by diagnosing and treating precancerous lesions known as 
cervical intra-epithelial neoplasia (CIN). The objective of this study was to assess 
the cost and health impact of using an electrical impedance spectroscopy (EIS) 
device to aid in the diagnosis of precancerous lesions compared to standard colpos-
copy. A threshold for the EIS device that resulted in a similar sensitivity and higher 
specificity than standard colposcopy was used. MethOds: Two models to assess 
the cost and health impacts were developed; a short term model representing the 
initial colposcopy treatment pathway and a longer term Markov model that included 
colposcopy follow-up. Sensitivity and specificity of colposcopy were derived from 
the EpiCIN trial of the EIS device. Two referral thresholds were defined in the analy-
sis, the threshold for ‘See and Treat’ on colposcopic impression alone (CI) and a 
lower threshold for referral for biopsy to determine disease presence (DP) prior to 
treatment. Costs of colposcopy were estimated using data from Sheffield Teaching 
Hospitals. Different colposcopy clinic scenarios were modelled to represent the 
different ways colposcopy clinics manage patients. Health related quality of life 
(HRQoL) decrements were applied for colposcopy, biopsy and treatment. One-way 
sensitivity analyses were also conducted. Results: The analysis suggests that the 
use of the EIS device can result in fewer biopsies being taken, a reduction in over-
treatment with an associated small improvement in HRQoL, and a lower colposcopy 
cost per woman with CIN2+ treated for some colposcopy clinic scenarios. The results 
are sensitive to changes in colposcopy costs. cOnclusiOns: The use of the EIS 
device with a higher specificity and similar sensitivity to standard colposcopy has 
the potential to lead to a reduction in the colposcopy cost per woman with CIN2+ 
treated for some clinic scenarios.
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ESTIMATION OF THE EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF THE 
QUADRIvALENT HPv vACCINATION IN GIRLS AND BOyS IN SPAIN
Bosch X.1, Cortés Bordoy J.2, Gil de Miguel A.3, López Belmonte J.L.4, Bresse X.5, Serip S.6, 
Nieves D.6
1Catalan Institute of Oncology, Barcelona, Spain, 2Gynaecological Oncology Centre, Palma de 
Mallorca, Spain, 3Universidad Rey Juan Carlos, Alcorcon, Spain, 4Sanofi Pasteur MSD, Madrid, 
Spain, 5Sanofi Pasteur MSD, Lyon, France, 6Oblikue Consulting, Barcelona, Spain
Objectives: To estimate the epidemiological and economic benefits of a quad-
rivalent HPV vaccination in girls and boys compared with vaccination only in girls 
in Spain. MethOds: A population-based compartmental dynamic transmission 
model of HPV developed in the US was partially adapted to the Spanish setting 
updating epidemiological data of HPV related diseases, the vaccination coverage and 
direct costs of the diseases. The analysis was performed from the National Health 
System (NHS) perspective. The strategy of cervix cancer screening (CCS) and vac-
cination of only girls from 11 to 26 years (S1) was compared to CCS and vaccination 
of girls and boys from 11 to 26 years (S2) with the quadrivalent vaccine. Assuming 
the duration of protection against vaccine HPV types is lifetime, the results over a 
100-year time horizon, were estimated applying a discount of 3% on costs. In order 
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THE ANALySIS OF COSTS AND REIMBURSEMENTS FOR LUNG CANCER 
TREATMENT IN THE CzECH REPUBLIC
Rogalewicz V.1, Simrova J.2, Vojtisek R.3, Bartak M.4
1Czech Technical University in Prague, Kladno, Czech Republic, 2University Hospital Plzen, Plzen 
- Lochotin, Czech Republic, 3University Hospital Plzen, Plzen - Lochotin, Czech Republic, 4J.E. 
Purkyně University, Usti nad Laben, Czech Republic
Objectives: Lung cancer is the most frequently diagnosed oncologic disease world-
wide, annually diagnosed in nearly 1.4 million patients. In 2010, the incidence in 
men was 89.7 per hundred thousand people (in 1996, it was 102.3), while in women 
35.2 (against 22.9 in 1996). The severity of the disease is also reflected by the high 
mortality rate, which was 74.8 per hundred thousand people in men and 27.4 in 
women in 2010. MethOds: Identifying the costs spent by a clinic/hospital is dif-
ficult in the Czech Republic, as the majority of hospitals work with cost related 
data in the “confidential” mode. The costs were estimated and verified based on 
expert opinions of pulmonologists, oncologists, head physicians and staff mem-
bers of technical and economic departments of five pneumo-oncologic centres and 
university hospitals in this study. Results: Totally 32 procedures (process maps) 
were identified in lung cancer treatment (10 in diagnostic, 22 in therapeutic pro-
cesses). Each procedure consists of diagnostics, therapy and subsequent monitor-
ing of patients. Costs for respective steps were assessed, and total costs for each 
therapeutic scheme were calculated. cOnclusiOns: The calculations imply that 
treatment costs significantly differ depending on the selected diagnostic/ therapeu-
tic procedure. The setting of the reimbursement system generates different stimuli 
for providers who may reach both positive and negative balances. This fact may 
have an effect on economic results leading, in its consequence, to the preference 
of alternatives more suitable in terms of reimbursement regardless of the optimum 
procedures for a specific patient.
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TREATMENT PATTERNS AND COSTS ASSOCIATED wITH CHRONIC 
LyMPHOCyTIC LEUKEMIA CHEMOTHERAPy UNDER THE BRAzILIAN PRIvATE 
HEALTH CARE PERSPECTIvE: A RETROSPECTIvE ANALySIS OF THE ORIzON 
DATABASE
Ferreira C.N.1, Paloni E.D.M.P.1, Asano E.2, Santana C.F.S.D.1, Pereira M.L.2
1ORIZON - Companhia Brasileira de Gestão de Serviços, Sao Paulo, Brazil, 2Janssen-Cilag 
Farmaceutica, Sao Paulo, Brazil
Objectives: To identify the chemotherapeutic treatment patterns and associated 
costs in patients with chronic lymphocytic leukemia (CLL) in the Private Healthcare 
System. MethOds: A retrospective analysis of the Orizon database, containing 
inpatient and outpatient claims data of a pool of 102 HMOs (34% of the total Private 
Health System), from January 2009 to December 2012 was conducted. Eligibility cri-
teria were patients starting CLL (ICD-10 code C911) chemotherapy treatment from 
April 2009 to December 2012. This cohort of patients was followed until December 
2012, death or loss of follow-up. Chemotherapy regimens were identified based on 
the agents reported in the claims. Line of treatment was defined based on mean-
ingful interruption (> 6 months) and/or change in the chemotherapy regimen. 
Descriptive statistics (average, standard deviation and percentage) of treatment 
regimens, duration of treatment and costs were performed. Results: A total of 163 
patients representing 859 cycles of chemotherapy met eligibility criteria; 43.6% of 
the patients underwent more than one line of treatment, with total chemotherapy 
costs of R$84,979.63 per patient. The three most widely used chemotherapy regimen 
were: fludarabine, cyclofosfamide and rituximab (FCR), used in 81 (54.9%) patients 
with average treatment duration of 3.54 cycles and total costs of R$69,241.91 per 
patient; rituximab monotherapy, used in 44 (27.0%) patients, with average treatment 
duration of 4.05 cycles and total costs of R$59,543.12 per patient; and fludarabine 
and cyclofosfamide (FC), used in 19 (11.7%) patients, with average duration of 2.22 
cycles and total costs of R$7,075.95 per patient. Chemotherapy drugs accounted 
for 72.8% of the total costs, followed by other medicines (11%), disposable devices 
(5.5%) and hospital facility fees (5.0%). cOnclusiOns: FCR is the standard of care 
in CLL patients treated in the Brazilian Private Health System, and almost half of 
the patients undergo more than one treatment line, creating a significant financial 
burden to private payers.
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COST OF CANCER IN THE AUSTRIAN HOSPITAL SETTING
Walter E.1, Said M.1, Bauer M.1, Gastl G.2, Samonigg H.3
1Institute for Pharmaeconomic Research, Vienna, Austria, 2Medical University of Innsbruck, 
Innsbruck, Austria, 3Medical University of Graz, Graz, Austria
Objectives: In Austria, 38,000 people are yearly diagnosed with cancer, which 
is the world’s leading cause of death (Austria: 19,547), followed by heart disease 
and stroke. Advances in early detection, prevention and treatment have led to 
decreasing cancer death and more favorable outcomes. Moreover, significant 
increases in the cost of cancer care have come in parallel with these advances. 
The cost factor related to modern cancer treatment is increasingly a matter of 
debate. Hence, the aim of the analysis was to evaluate the cost of cancer expressed 
as reimbursed lump-sums of the DRG system, number of inpatients stays and 
Length-of-Stay (LOS) in the inpatient setting to bring more transparency in the 
discussion and bridge the information-gap. MethOds: We performed a retrospec-
tive claim-based analysis with Austrian DRG-System (LKF Leistungsorientierte 
Krankenanstaltenfinanzierung) data. The DRG-System is based on ICD-10 codes. 
Payment consists of one or several case-based lump-sums. Our analysis included 
all cancer hospital admissions. The cost-evaluation is based on the refunded 
lump-sums of the DRG-System for the year 2011. Results: In 2011, 353,883 
inpatient stays with a diagnosis of cancer were monitored. Hospital stays due to 
cancer accounts for 14% of the entire inpatient stays in Austria. The average LOS 
in cancer patients was 4.35 days and was associated with average costs per stay 
of 3,730 Euros. Compared with the total number of admissions these numbers 
are below average (LOS: 5.43; costs per stay: 3,949 Euros). Furthermore, cancer 
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and complications, and patient co-morbidities. To assist in medical decision 
making from clinical and cost perspectives, we have developed a simulation 
model that synthesizes the evidence on NMIBC using the Archimedes Model 
platform. MethOds: The NMIBC model consists of a patient generation compo-
nent in which virtual patients are constructed from SEER case listings; a natural 
history component that captures recurrence, progression, and bladder cancer 
mortality; a health care component that captures the effects of treatments, tests, 
and surveillance; and a cost component that tracks the costs relevant to bladder 
cancer care. Using this model, we performed a 5-year virtual clinical trial of 350 
NMIBC patients with demonstrated Bacillus Calmette-Guerin failure, randomized 
to either immediate cystectomy or conservative treatment with Mitomycin C 
(MMC) intravesical therapy. The model is integrated within the Archimedes Model 
platform, which captures the effects of both NMIBC and patient co-morbidities. 
This model, validated against 5 published studies, gives recurrence and progres-
sion rates within ±20% of published results. Results: The virtual clinical trial 
shows a 5-yr cystectomy rate of 51% in the MMC arm, with an average delay to 
cystectomy of 0.84 yr (median 0.44 yr). The immediate cystectomy arm saves 0.26 
life years (LY) and $5598 in total bladder cancer cost per patient compared to the 
MMC arm. cOnclusiOns: We have constructed a dynamic, quantitative model of 
NMIBC that can predict clinical and economic outcomes and help optimize treat-
ment and surveillance guidelines. The virtual clinical trial quantifies LY and cost 
outcomes for immediate cystectomy versus conservative therapy, and provides a 
valuable tool for trial design and health economic analyses.
PCN94
THE COST-EFFECTIvENESS OF BENDAMUSTINE-RITUxIMAB vERSUS 
FLUDARABINE-RITUxIMAB FOR PATIENTS wITH INDOLENT NON-HODGKIN’S 
LyMPHOMA (INHL) wHO HAvE PROGRESSED FOLLOwING TREATMENT wITH 
RITUxIMAB OR A RITUxIMAB-CONTAINING REGIMEN IN COLOMBIA
Bertwistle D.1, Munakata J.2, Wehler E3, Leyva V.4, Ariza J.G.5, Zambrano C.5, Gonzalez L.6
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Objectives: To determine the cost-effectiveness of bendamustine-rituximab 
(Ben-R) versus fludarabine-rituximab (Fdb-R) in patients with iNHL who have pro-
gressed following treatment with rituximab or a rituximab-containing regimen in 
Colombia. MethOds: An economic model was constructed from the Colombian 
health system perspective, with a 35-year (lifetime) horizon and a discount rate 
of 3%. The model included three health states, progression-free (PF), progressive 
disease (PD), and death, which were associated with utility weights of 0.81, 0.62 
and 0, respectively. Clinical inputs (response rates, Kaplan-Meier curves, haz-
ard ratios (HRs) and adverse event rates) were from the Stil NHL 2-2003 study. 
Resource use data were from interviews with three Colombian hematologists 
treating iNHL patients. Unit costs were from ISS and SISPRO report and were 
expressed as 2013 Colombian Pesos. Univariate and probabilistic sensitivity 
analyses were conducted to determine the key drivers of cost-effectiveness, and 
uncertainty around the results, respectively. Results: Total lifetime cost of Ben-R 
was $291,192,912 and total cost of Fdb-R was $260,463,392. Ben-R patients accrued 
more LYs (6.47 vs. 5.15), QALYs (4.66 vs. 3.56), and PFLYs (3.57 vs. 2.05) compared 
to Fdb-R patients. The ICERs were $23,286,360 (cost per LY), $27,956,124 (cost per 
QALY) and $20,259,063 (cost per PF LY). Univariate sensitivity analysis revealed that 
the ICER per LY was most sensitive to the PFS and OS HRs for Ben-R vs Fdb-R, the 
number of treatment cycles, and the cost of bendamustine. Probabilistic sensitiv-
ity analysis with 1,000 iterations estimated that Ben-R had a 52% chance of being 
cost-effective, compared to Fdb-R, at a willingness to pay (WTP) of $59M per LY, 
rising to a plateau of about 93% at a WTP of $175M and above. cOnclusiOns: At 
a willingness-to-pay of $59M (three times the GDP per capita of Colombia) Ben-R 
is a cost-effective alternative to Fdb-R.
PCN95
COST-EFFECTIvENESS OF THE OPTICAL IMAGING AGENT 
HExAMINOLEvULINATE FOR PATIENTS wITH NON-MUSCLE INvASIvE 
BLADDER CANCER
Marteau F.1, Kornowski A.1, Bennison C.2, Tempest M.J.2, Mariappan P.3, Witjes J.A.4
1Ipsen Pharma SAS, Boulogne-Billancourt, France, 2Pharmerit Ltd., York, UK, 3Western General 
Hospital, Edinburgh, UK, 4Radboud University Medical Centre, Nijmegen, The Netherlands
Objectives: Hexaminolevulinate (HAL) is an optical imaging agent used as an 
adjunct to white light cystoscopy (WLC) in the diagnosis and management of non-
muscle invasive bladder cancer (NMIBC). The objective of this study was to model 
the cost-effectiveness of HAL-assisted blue light cystoscopy (HAL-BLC) compared to 
WLC alone when used at initial transurethral resection of bladder tumours (TURB) 
from the perspective of the National Health Service (NHS) in England and Wales 
using available clinical data. MethOds: A two-part model was developed to esti-
mate the incremental cost-effectiveness of HAL-BLC at initial TURB for patients 
positively diagnosed in the outpatient setting with NMIBC over a lifetime hori-
zon. This consisted of a short-term decision tree, which estimated the outcome 
of the outpatient diagnostic procedure and inpatient TURB, and a Markov cohort 
model, used to extrapolate long term outcomes. Clinical effectiveness evidence on 
recurrence was taken from a recent meta-analysis of NMIBC with HAL-BLC, costs 
were derived from NHS reference costs, and utilities and disease evolution were 
from the literature. Results: Despite additional treatment and equipment costs, 
base case results suggest that HAL-BLC is a dominant strategy as an adjunct to 
WLC compared to WLC only, when used at initial TURB for patients diagnosed with 
NMIBC. HAL-BLC is expected to be associated with 0.060 incremental QALYs and 
cost-savings of £391 per patient resulting from fewer recurrences and fewer associ-
ated surgical procedures (33 avoided TURBs/149 positively-diagnosed patients), in 
turn due to improved completeness of lesion resection and better tumour staging. 
Probabilistic sensitivity analyses indicated that HAL-BLC was dominant in 91.9% of 
iterations. cOnclusiOns: HAL-BLC as an adjunct to WLC was shown to be a domi-
to assess the uncertainty on the parameters, univariate sensitivity analyses were 
performed. Results: At 100 years, compared to only screening for cervix cancer, 
S2 scenario reduced 73% of the genital warts cases, 92% of the cancer cases in 
women and 87% of the cancer cases in men; while S1 strategy only reduced 56%, 
87% and 63% the cases of the different diseases, respectively. S2 strategy was less 
costly compared with S1: during the first 10 years reduced more than € 25 million 
for the NHS and more than € 282 million over 100 years. The savings over 100 years 
varied between € 141 million and € 1,268 million when considering a 5% or 0% dis-
count, respectively. cOnclusiOns: Vaccinating boys and girls between 11 and 26 
years would significantly reduce the epidemiological and economic burden of HPV 
related diseases in Spain.
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COMPARATIvE COST-CONSEQUENCE ANALySIS OF THE BIvALENT AND 
QUADRIvALENT vACCINES AGAINST HPv IN SPAIN
López Belmonte J.L.1, Cortés Bordoy J.2, Gil de Miguel A.3, Bresse X.4, Serip S.5, Nieves D.5, 
Bosch X.6
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3Universidad Rey Juan Carlos, Alcorcon, Spain, 4Sanofi Pasteur MSD, Lyon, France, 5Oblikue 
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Objectives: To compare the impact of the quadrivalent (QV) (HPV 6/11/16/18) and 
bivalent (BV) (HPV 16/18) vaccines against HPV in Spain. MethOds: A population-
based compartmental dynamic transmission model of HPV developed in the US was 
partially adapted to Spain updating epidemiological data of HPV related diseases, 
the vaccination coverage and direct costs of the diseases. The reduction of the 
number of cases related to HPV and savings associated with the following strategies 
were compared: A) cervix cancer screening (CCS) of women between 25-65 years, 
every 3-5 years and a vaccination program of girls between 11-26 years with the QV 
vaccine; B) CCS+BV vaccine. The analysis was performed from the National Health 
System (NHS) perspective, costs were discounted by 3% and the time horizon was 
100 years. Univariate sensitivity analyses were performed to assess the uncertainty 
on the parameters. Results: At 100 years, considering the current indications of 
the vaccines, lifetime protection against HPV vaccine types and 20 years of cross-
protection, both strategies reduced 208 cases of vulvar and vaginal cancers and 
22,796 cases of CIN2+. The strategy CCS+QV vaccine reduced 18,689 additional cases 
of genital warts due to the protection against 6/11 HPV types, but 4 less cases of 
cervix cancer and 359 less cases of CIN2+ due to better cross-protection of the BV 
vaccine. Nevertheless, savings accumulated during 100 years due to the reduction 
of genital warts cases (€ 215.7 million) compensated the cost associated to cervix 
cancers and CIN2+ that the BV vaccine additionally reduced (€ 3 and € 27.1 mil-
lion, respectively). Therefore, during 100 years the QV vaccine saves € 185.4 million 
more than the BV vaccine. The sensitivity analyses confirmed the stability of the 
results. cOnclusiOns: The QV vaccine provides higher cost savings to the NHS 
compared to the BV vaccine due to the additional efficacy against HPV 6/11 types.
PCN92
ONE LINE DOES NOT MAKE A PICTURE: REAL-wORLD COST-EFFECTIvENESS OF 
MULTIPLE MyELOMA TREATMENTS USING A FULL DISEASE MODEL
Blommestein H.1, Verelst S.2, de Groot S.1, Huijgens P.3, Sonneveld P.4, Uyl-de G.root C1
1Erasmus University, Rotterdam, The Netherlands, 2Erasmus MC, Rotterdam, The Netherlands, 
3VU University Medical Center, Amsterdam, The Netherlands, 4Erasmus University Medical 
Center, Rotterdam, The Netherlands
Objectives: As with many types of cancer, treatment of multiple myeloma (MM) 
is characterised by sequential treatment lines consisting of innovative expensive 
drugs such as thalidomide, bortezomib and lenalidomide. While cost-effectiveness 
of single treatments has been studied, a full disease model evaluating treatments 
sequentially is currently lacking, consequently, high uncertainty exists on incremen-
tal cost-effectiveness ratios. Therefore, we aimed to take a look at the big picture 
and calculate real-world costs and effects for commonly used treatment pathways 
for MM. MethOds: We developed a patient-level simulation (PLS) for elderly (> 65) 
MM patients diagnosed since 2004. Real-world data (N= 621) including patient and 
disease characteristics, treatment information as well as resource use was collected 
from hospital registrations and medical files. Five treatment categories per line 
were observed resulting in 19 commonly used treatment pathways. Parametric 
survival models including patient characteristics such as age, performance sta-
tus, comorbidities and laboratory values were used to predict time to an event, 
i.e. the start of a new treatment or death. Logistic regression determined which of 
the two competing events occurred. The sensitivity of parameters was explored 
through sensitivity analyses. Results: In total, the costs and effects of 19 treat-
ment pathways were calculated. Depending on the treatment sequencing, total 
costs ranged from € 40,810 (Melphalan/Prednison-Thalidomide-Other) to € 132,613 
(Bortezomib-Lenalidomde-Other) while overall survival ranged from 28 to 50 months 
for Bortezomib-Lenalidomide-Thalidomide and Lenalidomide-Bortezomib-Other, 
respectively. Costs per quality-adjusted-life-year (QALY) were between € 21,881 
(Melphalan/Prednison-Thalidomide-Other) and € 57,743 (Bortezomib-Lenalidomide-
Other). Compared to real-world prescription, QALYs could be increased at a cost 
of € 33,785 per QALY (Lenalidomide-Thalidomide-Other). cOnclusiOns: The 
cost-effectiveness of 19 treatment pathways for MM patients was calculated and 
revealed that real-world treatment could be improved at a cost of € 33,785 per QALY. 
Our PLS model proved to be a reliable and robust approach to study entire treat-
ment pathways for MM.
PCN93
COMPARATIvE EFFECTIvENESS OF CONSERvATIvE THERAPy vERSUS 
CySTECTOMy FOR NON-MUSCLE INvASIvE BLADDER CANCER PATIENTS
Dinh T.
Archimedes Inc., San Francisco, CA, USA
Objectives: Non-muscle invasive bladder cancer (NMIBC) is a complex disease 
with wide variation in risks of recurrence and progression, treatment efficacy 
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found a survival advantage from SIRT compared to standard care in chemother-
apy-refractory patients. This study was used in combination with other sources to 
model the cost-effectiveness of SIRT vs best supportive care (BSC) in this indica-
tion. MethOds: A state-transition model was developed, with three health states, 
based on survival outcomes from a retrospective cohort study in chemotherapy-
refractory mCRC comparing yttrium-90 resin microspheres (SIR-Spheres; Sirtex, 
Sydney, Australia) vs. BSC. The model was developed from the perspective of the 
National Health Service in Italy. The model included costs for treatment acquisition, 
pre-treatment work-up and delivery of microspheres, and chemotherapy received in 
addition to, instead of, or after, SIRT. In addition costs of managing AEs and a cost of 
death were included. Costs were obtained from the University Hospital in Bologna, 
Agenzia Italiana del Farmaco, and the literature. Utility data was not available from 
the study, so was taken from a recent NICE economic evaluation in the same indica-
tion. Results: SIRT increased survival resulting in a life-year gain of 1.35 (2.12 vs 
0.98) life years and a quality-adjusted life year (QALY) gain of 0.83 (1.52 vs 0.70). The 
costs of SIRT, monitoring and further treatment were greater in the SIRT arm with 
partial cost-offset through a reduction in adverse events. Overall, SIRT lead to an 
increase in costs of € 24,626 (€ 39,973 vs € 15,347), resulting in a cost/QALY of € 29,850. 
Probabilistic sensitivity analysis showed a 97% chance of SIRT being cost-effective 
at a threshold of € 50,000/QALY. cOnclusiOns: The analysis demonstrates that 
SIRT using resin yttrium-90 microspheres has the potential of being a cost-effective 
option in the treatment of patients with chemotherapy-refractory liver metastases 
resulting from colorectal cancer.
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THE COST-EFFECTIvENESS OF BENDAMUSTINE vERSUS FLUDARABINE FOR 
THE FIRST-LINE TREATMENT OF CHRONIC LyMPHOCyTIC LEUKEMIA (CLL) IN 
MExICO
Bertwistle D.1, Munakata J.2, Wehler E.3, Leyva V.4, Valencia A.5, Hernandez A.5,  
de la Torre L.5, Gonzalez L.6
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Objectives: To determine the cost-effectiveness of bendamustine versus fludara-
bine for the first line treatment of CLL in Mexico. MethOds: An economic model 
was constructed from the Mexican public payer perspective, with a 25-year (life-
time) horizon and a discount rate of 5%. The model included three health states, 
progression-free (PF), progressive disease (PD), and death. Clinical inputs (Kaplan-
Meier curves, response rates, hazard ratios (HRs) and adverse event (AE) rates 
were from a phase 3 trial comparing bendamustine and chlorambucil, and from 
a network meta-analysis. Resource use data were from interviews with Mexican 
hematologists treating CLL. Resource use for PF patients was weighted based 
on treatment response. Unit costs were obtained from Mexican Social Security 
Institute (IMSS) and were expressed in 2013 Mexican Pesos. Univariate and proba-
bilistic sensitivity analyses were conducted to determine the key drivers of cost-
effectiveness, and the uncertainty around the results, respectively. Results: 
Total lifetime costs for bendamustine and fludarabine were $660,796 and $536,068, 
respectively. Bendamustine patients accrued more LYs (6.83 vs. 5.98), QALYs (5.13 
vs. 4.25), and PF LYs (2.97 vs. 1.13) compared to fludarabine patients. The ICERs 
were $146,848 (cost per LY), $142,853 (cost per QALY) and $67,647 (cost per PF LY). 
Univariate sensitivity analysis revealed the cost per LY ICER was most sensitive 
to number of bendamustine cycles, the PFS for bendamustine vs. chlorambucil 
and the cost of bendamustine. Probabilistic sensitivity analysis with 1,000 itera-
tions predicted bendamustine had a 48% chance of being cost-effective, compared 
to fludarabine, at a willingness to pay (WTP) of $125,000. cOnclusiOns: At a 
WTP of $125,000 (GDP per capita of Mexico) bendamustine is cost effective versus 
fludarabine.
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COST-EFFECTIvENESS OF INDUCTION TREATMENT wITH BORTEzOMIB 
ADDED TO THALIDOMIDE AND DExAMETHASONE IN NEwLy DIAGNOSED 
MULTIPLE MyELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL 
TRANSPLANTATION IN GERMANy
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Objectives: To estimate the cost-effectiveness of bortezomib, thalidomide, and 
dexamethasone (VTD) induction therapy, versus TD alone in newly diagnosed 
multiple myeloma (ndMM) patients eligible for autologous stem cell transplanta-
tion (ASCT) in Germany. MethOds: A life-time Markov model with monthly cycles 
is used to model disease progression and generate cost per quality-adjusted life 
years (QALY). It includes five health states; four of which are related to the lines 
of treatment, and death. Patients enter the first line state at randomisation and 
receive induction usually followed by ASCT. Patients can move to the next line 
upon progression or die within a line, until they enter the final (4+) line where 
they remain until death. Transition probabilities are derived from multi-state 
survival analysis of patient level data from the PETHEMA-trial for first line, the 
APEX-trial for second and third line, and an observational data set (eVOBS) for 
further lines. The model uses ASCT and time dependent utilities from the litera-
ture and trial estimated grade ≥ 3 adverse events (AEs) associated disutilities to 
calculate the QALYs. Cost estimates related to treatments, transplant and AEs 
are based on German specific sources. A payer’s perspective is chosen. Discount 
rates of 3% for both cost and utilities are applied. Results: Total life years of 
6.38 VTD and 5.06 for TD with first line duration of 50.47 versus 32.85 months 
respectively. Incremental costs of VTD versus TD are 22,179€ [95%CI:6,950€ ;33,528€ ] 
and incremental QALYs are 0.72 [95%CI:0.33;1.20], resulting in an ICER of € 30,655 
per QALY gained. The univariate analyses show that the model is most sensitive 
nant strategy over WLC alone when used at initial TURB for patients diagnosed with 
NMIBC in England and Wales, with improved patient outcomes and cost-savings 
expected to offset investment in HAL.
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UNCERTAINTy AND COST-EFFECTIvENESS ANALySIS OF THE SEQUENTIAL 
APPLICATION OF TyROSINE KINASE INHIBITORS FOR THE TREATMENT OF 
CHRONIC MyELOID LEUKEMIA
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Objectives: Currently, there are several tyrosine kinase inhibitors (TKI) approved 
for the treatment of chronic myeloid leukemia (CML). The aim of our study was 
to evaluate the long-term cost-effectiveness of different therapy regimens for 
CML focusing on the evaluation of the uncertainty using probabilistic sensitiv-
ity analysis (PSA). MethOds: We performed a cost-effectiveness analysis using 
a state-transition Markov model. The model evaluates seven treatment strate-
gies including different combinations of TKIs as well as chemotherapy or stem 
cell transplantation. For model parameters, we used published trial data, and 
Austrian clinical, epidemiological, and economic data from the Austrian CML 
registry, statistical and economic databases. We performed a cohort simulation 
over a lifelong time horizon, adopted a societal perspective with an annual 3% dis-
count rate. We conducted extensive uncertainty analyses and contrasted different 
methodological approaches to define parameter uncertainty distributions from 
our source data. We compared the base-line derived from the mean parameter 
values with the mean outcomes of all PSA scenarios. Results: In the base-case 
efficiency frontier, nilotinib without second-line TKI resulted in an ICUR (1) of 
118,600 € /QALY compared to the baseline strategy imatinib without second-line 
TKI. Imatinib followed by nilotinib after failure yielded an ICUR (2) of 123,900 € /
QALY compared to nilotinib without second-line TKI. Nilotinib followed by dasat-
inib after failure resulted in an ICUR (3) of 149,400 € /QALY compared to imatinib 
followed by nilotinib after failure. The remaining strategies were excluded due to 
absolute or extended dominance. The PSA resulted in ICURs of (1) 116,200 € /QALY 
(2) 130,300 € /QALY and (3) 130,300 € /QALY. cOnclusiOns: Based on our analysis, 
we recommend imatinib followed by nilotinib as the most cost-effective treatment 
strategy including a second-line TKI. Mean results from PSA show only small 
deviation from the base-case analysis. When new path to cure data are available, 
results will need to be updated.
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A SySTEMATIC REvIEw AND CRITICAL APPRAISAL OF ECONOMIC 
EvALUATIONS OF RADIOTHERAPy FOR CANCER
Barbieri M.1, Weatherly H.1, Sculpher M.J.1, Ara R.2, Basarir H.2
1Centre for Health Economics, York, UK, 2University of Sheffield, Sheffield, UK
Objectives: To review published cost-effectiveness studies which evaluate radio-
therapy in individuals with breast, cervical, colorectal, head and neck, or prostate 
cancer. To compare the economic methods used with the guidelines used in the 
appraisal programme for the National Institute of Health and Care Excellence (NICE) 
in the UK. MethOds: Systematic searches of seven databases (Medline, EMBASE, 
CDSR, NHSEED, HTA, DARE and EconLit) were conducted in July 2012. In addition, 
research registers, the NICE website and conference proceedings were searched. 
Studies that reported results of economic evaluations of radiotherapy interven-
tions in terms of incremental quality adjusted life-years or life-years for individuals 
diagnosed with cancers were included. The quality of these studies was assessed 
in terms of meeting, essential, preferred and UK NICE-specific requirements for 
economic evaluations. Results: Twenty-nine studies satisfied the inclusion criteria 
(breast= 14, colorectal= 2, prostate= 10, cervical= 0, head and neck= 3). The majority 
(13) of the studies were set in the US with just 2 conducted in the UK. Considering 
essential methodological criteria, only 3 (10%) studies used estimates for clinical 
effectiveness which were identified by systematic literature review. Just a quarter 
(8/29) used health related quality of life data from patients with the particular can-
cers. While the majority of studies used one-way sensitivity analyses, only a third 
(10/29) reported the results of a full probabilistic sensitivity analysis. Additional 
essential criteria such as the use of an appropriate horizon, a clear description of 
both the comparators and the patient group indication were generally satisfied. 
However, as only 2 of the studies were conducted in the UK, the majority of the UK 
NICE specific requirements were not met. cOnclusiOns: This review indicates 
there is little robust evidence of the cost-effectiveness of radiotherapy interventions 
in these cancers and very little evidence which could be used to support decision 
making in the UK.
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SELECTIvE INTERNAL RADIOTHERAPy (SIRT) USING RESIN yTTRIUM-90 
MICROSPHERES FOR CHEMOTHERAPy-REFRACTORy METASTATIC COLORECTAL 
CANCER: AN ITALIAN COST-EFFECTIvENESS ANALySIS
Cosimelli M.1, Golfieri R.2, Pennington B.3, Sennfält K.4
1Regina Elena National Cancer Institute, Rome, Italy, 2Sant’Orsola-Malpighi Hospital, Bologna, 
Italy, 3BresMed, Sheffield, UK, 4Sirtex Medical Limited, North Sydney, Australia
Objectives: SIRT using resin microspheres of yttrium-90 can be used to treat liver 
metastases resulting from colorectal cancer (CRC). A retrospective cohort study 
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treatment pathways in a hypothetical NSCLC population in the UK with a baseline 
EGFR mutation prevalence of 16.6%. Model inputs included parameters describing 
mutation testing accuracy, treatment response (EGFR inhibitor, standard chemo 
therapy or best supportive care) and adverse events arising from treatment. Inputs 
were based on published literature and costs in the NHS in England and Wales. The 
model examined cost-effectiveness over the patients’ lifetime. A one-way sensitivity 
analysis was conducted. Results: Using £32,500/QALY as a threshold, the cobas EGFR 
Mutation Test was cost-effective at an incremental cost per QALY gained of £18,394 
for the target population as a result of better test accuracy and lower detection limit 
relative to Sanger sequencing. The cobas EGFR Mutation test was able to correctly 
identify more patients with EGFR mutations (lower rate of false negatives) and more 
appropriately direct patient treatment than Sanger sequencing. cOnclusiOns: The 
cobas EGFR Mutation Test, by correctly identifying more patients for proper treatment, 
can be considered a cost-effective strategy for identification of EGFR mutations in 
locally advanced or metastatic NSCLC patients from a UK payer perspective.
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A CRITICAL APPRAISAL OF COST-EFFECTIvENESS ANALySES OF HUMAN 
PAPILLOMAvIRUS TESTING IN CERvICAL SCREENING: MAKING APPROPRIATE 
COMPARISONS AND USEFULLy INTERPRETING RESULTS
O’Mahony J.1, Naber S.2, de Kok I.M.C.M.2
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Objectives: To critically appraise published cost-effectiveness analyses (CEAs) of 
human papillomavirus (HPV) testing in cervical screening regarding the appropriate-
ness of comparisons between strategies and the usefulness of the interpretation of 
cost-effectiveness estimates. MethOds: The PubMed database was searched for rel-
evant CEAs of cervical screening using HPV testing. The identified CEAs were carefully 
appraised for their quality of analyses, reporting and interpretation of results. Specific 
examples of modelling shortcomings were selected as illustrations of what to avoid 
when estimating the cost-effectiveness of HPV-based screening. Results: The review 
identified 29 relevant CEAs. Regarding basic errors, 11 of the 29 calculated the incremen-
tal cost-effectiveness ratios (ICERs) either partly or completely incorrectly. Ten studies 
failed to fully report costs and effects; either simply reporting ICERs or depicting a 
cost-effectiveness plane. Regarding more fundamental errors, 23 failed to include suf-
ficient screening interval comparators against which to meaningfully estimate ICERs; 
effectively leading to average cost-effectiveness ratios being mistakenly identified as 
ICERs, which biases cost-effectiveness ratio estimates downwards. Finally, none of the 
studies gave specific consideration to the magnitude of the change in costs and effects 
of adding HPV testing to a given strategy, either with a simple graphical interpretation 
or with a formal interpretation using the net benefit framework. cOnclusiOns: Model 
specification is typically the most difficult part of a model-based CEA, whereas simulat-
ing relevant strategies is relatively straightforward once the model is built. Similarly, 
once results have been generated, their correct presentation and interpretation is rela-
tively straightforward. However, this analysis shows that these relatively easy aspects 
of CEA are being performed poorly in the HPV screening literature. Consequently, a few 
simple improvements to basic aspects of CEAs of HPV-based screening could greatly 
enhance the usefulness of such analyses to decision makers.
PCN105
COST-EFFECTIvENESS OF EML4-ALK FUSION TESTING AND FIRST-LINE 
CRIzOTINIB TREATMENT FOR PATIENTS wITH ADvANCED ALK POSITIvE 
NON-SMALL CELL LUNG CANCER IN A PUBLICLy FUNDED SySTEM (ONTARIO, 
CANADA)
Djalalov S.1, Beca J.1, Hoch J.S.2, Krahn M.D.3, Tsao M.S.4, Cutz J.C.5, Leighl N.4
1St. Michael’s Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 
3Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, 
Canada, 4Ontario Cancer Institute, Toronto, ON, Canada, 5McMaster University, Hamilton, ON, 
Canada
Objectives: ALK-targeted therapy with crizotinib offers significant improvement 
in clinical outcomes for the treatment of EML4–ALK fusion positive NSCLC. We 
estimated the cost-effectiveness of EML4-ALK testing in combination with first-
line crizotinib for ALK positive NSCLC in Ontario. MethOds: A cost-effective-
ness analysis was conducted, using a Markov model from the Canadian public 
health (Ontario) perspective and a lifetime horizon in Stage IV NSCLC patients 
with non-squamous histology. Transition probabilities and mortality rates were 
calculated from the Ontario Cancer Registry and Cancer Care Ontario New Drug 
Funding Program (CCO NDFP). Costs were obtained from the Ontario Case Costing 
Initiative, CCO NDFP, University Health Network and the literature. Population-based 
ALK testing included initial IHC testing followed by FISH confirmation for posi-
tive cases. Results: The strategy of genomic testing linked to targeted crizotinib 
treatment gained 0.11 QALYs compared to no testing or crizotinib treatment in the 
advanced non-squamous NSCLC population. The incremental cost was CAD $4,179 
per patient compared to the previous standard of care without ALK testing; the 
incremental cost-effectiveness ratio for the base case was $392,538 per QALY. The 
incremental cost and ICER for crizotinib therapy in known ALK positive advanced 
NSCLC patients was $96,554 and $254,617/QALY. The cost of testing was less rel-
evant to the ICER at a biomarker frequency of 7% and higher. The major drivers 
of cost-effectiveness are drug cost and low biomarker frequency in the popula-
tion. cOnclusiOns: EML4–ALK genomic testing in combination with crizotinib 
treatment for all Stage IV non-squamous NSCLC patients is not cost-effective in the 
setting of high drug costs and a low biomarker frequency in the general population. 
Modifying these key drivers will be important in improving the cost-effectiveness 
and accessibility to novel therapies with major clinical benefit in advanced NSCLC.
PCN106
OvERvIEw ON COST-EFFECTIvENESS RESULTS OF DECISION-ANALyTIC 
STUDIES FOR THE TREATMENT OF MULTIPLE MyELOMA
Rochau U.1, Jahn B.2, Qerimi V.3, Kluibenschaedl M.2, Kurzthaler C.2, Conrads-Frank A.2, 
Willenbacher W.4, Gastl G.4, Siebert U.5
to induction cost and percentage transplants. At a willingness-to-pay threshold 
of 35,000€ per QALY gained, VTD has a 57.1% probability to be cost-effective in 
this setting. cOnclusiOns: VTD induction is a cost-effective strategy for ndMM 
patients eligible for ASCT in Germany compared to TD.
PCN101
A COST-EFFECTIvENESS ANALySIS OF CISPLATIN PLUS PEMETRExED DOUBLET 
INDUCTION TREATMENT FOLLOwED By PEMETRExED MAINTENANCE 
COMPARED wITH BEvACIzUMAB PLUS CISPLATIN PLUS GEMCITABINE TRIPLET 
INDUCTION TREATMENT FOLLOwED By BEvACIzUMAB MAINTENANCE FOR 
NON-SQUAMOUS NSCLC IN SwEDEN
Bryden P.A.1, Kumar G.1, Winfree K.B.2, Boye M.E.2, Taipale K.3, Thompson R.4, Borgeke H.5
1Oxford Outcomes Ltd., Oxford, UK, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Eli Lilly 
and Company, Helsinki, Finland, 4Eli Lilly and Company, Windlesham, Surrey, UK, 5Eli Lilly and 
Company, Stockholm, Sweden
Objectives: This analysis compares the cost effectiveness (CE) of an induction 
and maintenance sequence of a cisplatin plus pemetrexed (cis+pem) doublet fol-
lowed by pemetrexed, with that of a bevacizumab (7.5mg or 15mg) plus cispl-
atin plus gemcitabine (bev+cis+gem) triplet followed by bevacizumab (7.5mg or 
15mg) for the treatment of non-squamous non-small cell lung cancer (NSCLC) 
in Sweden. MethOds: As no head-to-head trial data are available comparing 
these relevant regimens in the first-line induction and maintenance treatment 
settings, decision modelling and evidence synthesis were used to estimate 
CE. A series of network meta-analyses were performed to obtain hazard ratios 
for overall survival (OS) and progression-free survival (PFS) for each induction 
and maintenance comparator, and odds ratios for response for induction com-
parators. Bevacizumab doses were pooled in the meta-analyses. The CE model 
was structured using an area-under-the-curve approach. Costs and benefits 
were discounted at 3% per annum, consistent with Swedish practice. Results: 
Cis+pem induction followed by pemetrexed maintenance was associated with 
a higher median PFS, OS, total life-years gained and quality-adjusted life-
years (QALYs) than the bevacizumab triplets. Total costs were 416,478Kr for the 
bev(7.5mg)+cis+gem induction triplet plus bevacizumab 7.5mg maintenance 
sequence, 478,862Kr for the cis+pem doublet followed by pemetrexed maintenance 
sequence, and 541,677Kr for the bev(15mg)+cis+gem induction triplet followed 
by bevacizumab 15mg maintenance sequence. Total QALYs were 0.73 and 0.97 
for the bevacizumab triplets and pemetrexed induction and maintenance 
sequence. The incremental cost-effectiveness ratio (ICER) of cis+pem followed by 
pemetrexed compared with bev(7.5mg)+cis+gem followed by bevacizumab 7.5mg 
was 260,831Kr (30,477Euro). The higher bevacizumab dose of 15mg was dominated 
by the cis+pem followed by pemetrexed sequence. The results of the probabilis-
tic analysis support these results. cOnclusiOns: The results of the CE analysis 
suggest that cis+pem doublet induction followed by pemetrexed maintenance is 
a cost-effective treatment sequence compared with the bevacizumab options for 
NSCLC in Sweden.
PCN102
A COST-EFFECTIvENESS ANALySIS OF AxITINIB AND SORAFENIB FOR 2ND 
LINE TREATMENT OF ADvANCED RENAL CELL CARCINOMA AFTER FAILURE OF 
CyTOKINES IN THE UNITED STATES
Stillman I.O.1, Ambavane A.1, Cislo P.2
1Evidera, Lexington, MA, USA, 2Bayer Pharma AG, Montville, NJ, USA
Objectives: To assess the cost-effectiveness of axitinib compared to sorafenib from 
the perspective of a US third-party payer for second-line treatment of patients with 
advanced RCC who failed cytokines. MethOds: Phase III AXIS trial reported that 
axitinib increased median progression free survival (PFS) compared to sorafenib 
(12.0 vs. 6.6 months, p< 0.0001), while overall survival (OS) showed no difference 
(29.4 vs. 27.8 months, p= 0.144) in patients failing treatment with cytokines. A cohort 
partition model was constructed to estimate direct medical costs and health out-
comes, discounted at 3.0% per annum. Patients were apportioned into 3 health 
states (progression-free, progressed and dead) based on OS and PFS Kaplan-Meier 
curves from the AXIS trial. Active treatment was applied until progression, fol-
lowed by best supportive care (BSC) thereafter. The wholesale acquisition costs and 
adverse event (AE) costs were obtained from published sources. AE rates and utility 
values were informed by the AXIS trial. US administrative claims data (MarketScan®) 
was analyzed to estimate routine care costs. Probabilistic sensitivity analysis (PSA) 
was conducted. Results: The total per-patient lifetime costs were estimated to be 
$242,750 for axitinib and $168,880 for sorafenib and 84% of the cost difference was 
due to the higher total medication cost of axitinib. The quality-adjusted life-years 
(QALY) gained on axitinib vs. sorafenib was 1.3 vs. 1.2 and the incremental cost-
effectiveness ratio (ICER) was $683,209/QALY. 100% of the PSA iterations showed 
that axitinib was more expensive than sorafenib and the QALY difference between 
axitinib and sorafenib was no greater than 0.7. cOnclusiOns: For post-cytokine 
subgroup, axitinib resulted in an ICER > $650,000/QALY versus sorafenib due to 
high drug costs and lack of OS benefit, indicating that axitinib may not present 
good value for money as 2nd line treatment of advanced RCC when compared to 
sorafenib in the US.
PCN103
COST-EFFECTIvENESS OF COBAS® EGFR MUTATION TEST vERSUS SANGER 
SEQUENCING IN THE TREATMENT OF LOCALLy ADvANCED OR METASTATIC 
NSCLC: A PAyER PERSPECTIvE IN THE UNITED KINGDOM
Towse A.1, Gavaghan M.2, Strunz-McKendry T.3, Garfield S.2, Poulios N.4
1Office of Health Economics, London, UK, 2GfK Bridgehead, Wayland, MA, USA, 3Roche 
Diagnostics Limited, West Sussex, UK, 4Roche Molecular Diagnostics, Pleasanton, CA, USA
Objectives: We explored the cost-effectiveness of using the CE-IVD marked cobas® 
EGFR Mutation Test versus Sanger sequencing for identifying EGFR mutations in locally 
advanced or metastatic NSCLC patients from a UK payer perspective. MethOds: A 
decision-tree model was developed to compare testing methodologies and resulting 
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Physician Fee Schedule and represented in 2013 US dollars. Average wholesale prices 
for a 30-day supply of AA and ENZA were $7,674 and $8,940, respectively. One-way 
sensitivity analyses were performed against all probability, utility, and cost values 
incorporated into this cost-effectiveness model. Results: In this analysis, AA pro-
vides substantial saving with $13,322 per patient versus ENZA. The main drivers 
of the model are drug costs, health utility values, and efficacy (OS and rPFS). The 
robustness of the results was supported by sensitivity analyses. cOnclusiOns: 
Given similar OS benefits, AA is cost saving compared with ENZA for the treatment 
of patients with mCPRC post-docetaxel based on US data.
PCN109
COMPARATIvE STUDy OF THE COST-EFFECTIvENESS OF TRASTUzUMAB IN THE 
TREATMENT OF BREAST CANCER IN DIFFERENT COUNTRIES
Rabbani S.1, Ardam A.1, Salamzadeh J.2
1Shahid Beheshti University of Medical Sciences, tehran, Iran, 2Shahid Beheshti University of 
Medical Sciences, Tehran, Iran
Objectives: Pharmacoeconomic evaluations are more critical in developing 
countries in which economic effects of new and expensive therapies have sig-
nificant impact on patients, insurance companies and the health systems. Since 
cost-effectiveness studies are too costly and time consuming, in these countries 
new medications are often being used in daily practice before being well docu-
mented as cost-effective interventions. This would force health organizations 
to perform comparative studies as alternatives to cost-effectiveness analysis. 
Trastuzumab, an anti-cancer monoclonal antibody which was approved by FDA 
in 1998, is an expensive medicine introduced to the Iranian pharmaceutical market 
since 2003, with an annual usage cost of 308,352,730,640 Rials ($ US 25,000,000) in 
2010. MethOds: A systematic review on electronic medical databases including 
the Cochrane, CRD, EMBASE, HEED, MEDLINE, and PubMed, covering the years 2000 
to 2009, was performed using relevant key words to extract publications investi-
gating cost-effectiveness and efficacy of trastuzumab in breast cancer treatment. 
The Incremental Cost-Effectiveness Ratios (ICERs) were compared with a criterion 
introduced by WHO. Results: The reported ICERs were between $90,118/QALY 
to $217,264/QALY and $13,361/QALY to $65,250/QALY in metastatic and adjuvant 
breast cancer therapy, respectively. The metastatic ICERs were 8 to 20 folds of the 
GDP per Capita in Iran whereas the adjuvant phase ICERs were 1.2 to 6 folds of it. 
Sensitivity analysis showed the results are more sensitive to discount rate, drug 
regimen cost, duration of survival benefits, as well as the risk of relapse and metas-
tasis. cOnclusiOns: Trastuzumab therapy in metastatic breast cancer cannot be 
cost effective in Iran, however as adjuvant therapy it is still a challenging issue. 
Unlimited access to this medicine would not be rational and recommendations 
with an approach to optimize its usage, e.g. administration in younger patients 
with poor prognosis and higher risk of relapse or using clean rooms to reduce drug 
wasting, are strongly advised.
PCN110
THE COST-EFFECTIvENESS OF BENDAMUSTINE-RITUxIMAB vERSUS 
FLUDARABINE-RITUxIMAB FOR PATIENTS wITH INDOLENT NON-HODGKIN’S 
LyMPHOMA (INHL) wHO HAvE PROGRESSED FOLLOwING TREATMENT wITH 
RITUxIMAB OR A RITUxIMAB-CONTAINING REGIMEN IN MExICO
Bertwistle D.1, Munakata J.2, Wehler E.3, Leyva V.4, Valencia A.5, Hernandez A.5, de la Torre L.5, 
Gonzalez L.6
1IMS Health, London, UK, 2IMS Health, San Francisco, CA, USA, 3IMS Health, Alexandria, VA, 
USA, 4IMS Health, Mexico City, Mexico, 5Janssen, Mexico City, Mexico, 6Janssen, Raritan, NJ, USA
Objectives: To determine the cost-effectiveness of bendamustine-rituximab 
(Ben-R) versus fludarabine-rituximab (Fdb-R) in patients with iNHL who have pro-
gressed following treatment with rituximab or a rituximab-containing regimen in 
Mexico. MethOds: An economic model was constructed from the Mexican public 
payer perspective, with a 35-year (lifetime) horizon and a discount rate of 5%. The 
model included three health states, progression-free (PF), progressive disease (PD), 
and death, which were associated with utility weights of 0.81, 0.62 and 0, respec-
tively. Clinical inputs (response rates, Kaplan-Meier curves, hazard ratios (HRs) and 
adverse event rates) were from the Stil NHL 2-2003 study. Resource use data were 
from interviews with Mexican hematologists treating iNHL patients. Unit costs were 
obtained from Mexican Social Security Institute (IMSS) and were expressed as 2013 
Mexican Pesos. Univariate and probabilistic sensitivity analyses were conducted to 
determine the key drivers of cost-effectiveness, and uncertainty around the results, 
respectively. Results: Total cost of Ben-R was $1,726,828 and total cost of Fdb-R 
was $1,640,024. Ben-R patients accrued more LYs (5.82 vs. 4.73), QALYs (4.22 vs. 3.29), 
and PF LYs (3.37 vs. 1.96) compared to Fdb-R patients. The ICERs were $79,890 (cost 
per LY), $92,788 (cost per QALY) and $61,486 (cost per PF LY). Univariate sensitivity 
analysis revealed that the ICER per LY was most sensitive to the PF survival (PFS) and 
overall survival (OS) HRs for Ben-R vs Fdb-R and the use of bone marrow transplants 
in the PD state. Probabilistic sensitivity analysis with 1,000 iterations estimated that 
Ben-R will be cost effective over 90% of the time at a willingness-to-pay threshold 
of $125,085. cOnclusiOns: At a willingness-to-pay of $125,085 (GDP per capita of 
Mexico) Ben-R is cost effective versus Fdb-R.
PCN111
A COST-EFFECTIvENESS ANALySES OF USING SUNITINIB (SU) IN FIRST LINE OF 
METASTATIC RENAL CANCER IN ROMANIAN jURISDICTION
Berghea F.1, Skoupa J.2, Ciuleanu T.3, Miron L.4, Stanculeanu D.L.5, Jinga D.6, Dediu M.5, 
Mateescu D.N.7, Hájek P.8, Bradatan B.9, Xuan J.10
1Carol Davila University Of Medicine and Pharmacy, Bucharest, Romania, 2ISPOR Chapter Czech 
Republic, Prague 7, Czech Republic, 3Ion Chiricuta Clinic, Cluj, Romania, 4Oncology Institute, 
Iasi, Romania, 5“Alexandru Trestioreanu” Oncology Institute, Bucharest, Romania, 6University 
Hospital, Bucharest, Romania, 7Diagnosis & Treatment Oncology Center, Brasov, Romania, 8Pfizer, 
Praha, Czech Republic, 9Pfizer, Bucharest, Romania, 10Pfizer, Inc., New York, NY, USA
Objectives: In Romania the estimated incidence of metastatic renal cancer 
(mRCC) is about 1500 cases; less than 400 patients receive full reimbursement for 
1UMIT - University for Health Sciences, Medical Informatics and Technology/ ONCOTYROL - 
Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria, 2UMIT - University for 
Health Sciences, Medical Informatics and Technology, Hall in Tyrol, Austria, 3UMIT - University 
for Health Sciences, Medical Informatics and Technology/ Ss. Cyril and Methodius University in 
Skopje, Hall in Tyrol/ Skopje, Austria, 4Medical University Innsbruck, Innsbruck, Austria, 5UMIT 
– University for Health Sciences, Medical Informatics and Technology / ONCOTYROL / Harvard 
University, Hall i. T./ Innsbruck / Boston, Austria
Objectives: To provide an overview on published decision-analytic models 
evaluating treatment strategies for multiple myeloma (MM) focusing on the cost-
effectiveness results. MethOds: A systematic literature search was performed in 
the electronic databases Pubmed, NHS EED and the Tufts CEA Registry to identify 
studies evaluating MM treatment strategies using mathematical decision-analytic 
models. To meet the inclusion criteria, models were required to compare different 
treatment strategies, to be published as full text articles in English, and com-
prise relevant clinical health outcomes over a defined time horizon and popula-
tion. We used evidence tables to summarize methodological characteristics and 
economic results. For comparability, all economic results were transferred into 
2012 US Dollar. We used Purchasing Power Parity to convert the currency into US 
Dollar of the same year. For converting US Dollar from step one into US Dollars 
2012, we used Consumer Price Index rates for the relevant year. Results: We 
found eleven decision-analytic modeling studies. Economic evaluations were 
included in all studies. Eight studies reported cost-utility results. The modeling 
approaches applied included a decision tree model, Markov cohort model, discrete 
event simulations, partitioned survival analyses and area under the curve models. 
Time horizons ranged from seven years to lifetime. Half of the models chose the 
perspective of the health care system, while other perspectives were societal, 
third party payer and government payer. Among others, two studies reported cost-
effectiveness of autologous transplantation vs. standard-dose melphalan with an 
ICER of $31,263 /life-year gained (LYG) and $36,778/LYG. One study reported that 
bortezomib vs. lenalidomide plus dexamethasone is cost saving, while another 
comparable study reported an ICUR for lenalidomide plus dexamethasone vs. 
bortezomib of $22,301/QALY. cOnclusiOns: We identified several well-designed 
cost-effectiveness/cost-utility models using a broad variety of different modeling 
approaches. Results of most of the studies were not comparable due to different 
treatment strategies, target population and settings.
PCN107
ECONOMIC EvIDENCE OF SURGICAL PROCEDURES IN CANCER: A SySTEMATIC 
LITERATURE REvIEw
Ara R.1, Basarir H.1, Keetharuth A.1, Weatherly H.2, Barbieri M.2, Sculpher M.J.2
1University of Sheffield, Sheffield, UK, 2Centre for Health Economics, York, UK
Objectives: To examine the empirical and methodological cost-effectiveness evi-
dence of surgical interventions for breast, colorectal, and prostate cancer. MethOds: 
Systematic searches of seven databases including MEDLINE, EMBASE, CDSR,HTA, 
DARE, EconLit and NHSEED, research registers, the National Institute of Health and 
Care Excellence (NICE) website and conference proceedings was conducted in April 
2012. Studies were included if they evaluated the cost-effectiveness of a surgical 
procedure in either breast, colorectal or prostate cancer and reported cost per quality 
adjusted life-year or cost per life-year results. The quality of the studies included was 
assessed in terms of meeting essential, preferred, and UK specific requirements for 
economic evaluations. Results: The 17 (breast= 3,colorectal= 7,prostate= 7) studies 
which satisfied the inclusion criteria covered a broad range of settings with 9 set in 
European and 8 in non-European locations. Just a third (11/17) was published within 
the last 10 years. In terms of the essential quality criteria; the populations, inter-
ventions and comparators were generally well defined. However, very few studies 
were informed by the results of literature reviews or synthesised clinical evidence. 
Although the interventions had potential differential effects on recurrence and mor-
tality rates, some studies used relatively short time horizons. Although univariate 
sensitivity analyses were reported in all studies, less than a third characterised all 
uncertainty with a probabilistic sensitivity analysis. While a third of studies incorpo-
rated patients’ health-related quality of life data, only 4 of the 17 studies used social 
tariff values. cOnclusiOns: There is very little recent robust evidence describing 
the cost-effectiveness of surgical interventions in these indications. Many of the 
more recent publications did not satisfy the essential methods requirements, such 
as using synthesising clinical evidence informed by a systematic literature review. 
Given the ratio of potential benefit and harm associated with surgery in cancer, there 
is an urgent need to conduct additional robust economic evaluations in this area.
PCN108
ABIRATERONE ACETATE vERSUS ENzALUTAMIDE FOR METASTATIC 
CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPy: COST 
EFFECTIvENESS ANALySIS
He J., Li T., Saadi R.
Janssen Global Services LLC, Raritan, NJ, USA
Objectives: With approvals of abiraterone acetate (AA) and enzalutamide (ENZA) 
in the past 2 years, the treatment landscape has shifted dramatically for metastatic 
castration-resistant prostate cancer (mCRPC) patients who failed docetaxel-based 
chemotherapy. There is increasing interest in the relative cost-effectiveness of these 
therapies. The objective of this study was to assess the cost-effectiveness of AA 
versus ENZA among individuals with mCRPC post chemotherapy from a payer per-
spective. MethOds: A survival-based Markov cohort model consisting of 3 health 
states, progression-free, progressed, and dead, was developed to project over 10 
year period. Progression between states was determined by overall survival (OS) 
and radiographic progression free survival (rPFS). An indirect treatment comparison 
was conducted to determine the relative efficacy of AA and ENZA (data reported 
separately). Utilities were mapped from FACT-P to EQ-5D based on a review of the 
literature. Drug acquisition costs in the US were used since ENZA was approved only 
in the US at the time of analysis. Costs of scheduled and unscheduled follow-up 
visits were obtained from the Centers for Medicare Services Drug Payment Table and 
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is associated with decreased quality of life, and poorer health outcomes. Therefore, 
there may be considerable gains in the adequate treatment of depression in oncol-
ogy patients. We explored the cost-effectiveness of a collaborative care intervention 
specifically developed for the treatment of depression in cancer patients compared 
to usual practice. MethOds: A cost-effectiveness analysis comparing a collaborative 
care intervention for depression management, Depression Care for People with Cancer 
(DCPC), in addition to usual care with usual care alone, based on data from the second 
Symptom Management Research Trials in Oncology (SMaRT-2). SMaRT-2 was a large 
(n= 500), multicentre study, in depressed patients with a relatively good cancer progno-
sis, in a secondary care setting. Outcomes included costs expressed as UK sterling in 
2010-11 prices and health outcomes in quality-adjusted life-years (QALYs), estimated 
from a National Health Service and Personal Social Services perspective. Scenario 
analyses were performed to determine the impact on cost-effectiveness of alternative 
costing assumptions, and uncertainty was characterised through cost-effectiveness 
acceptability curves and probabilities of cost-effectiveness at key cost-effectiveness 
thresholds. Results: DCPC in addition to usual care was associated with greater costs, 
but also improved health outcomes. DCPC was found to be cost-effective at accepted 
cost-effectiveness thresholds. Results were robust across alternative scenarios, with 
probabilities of cost-effectiveness higher than 90% for cost-effectiveness thresholds 
ranging between £20,000-30,000 per QALY. cOnclusiOns: Compared to usual care, 
DCPC in addition to usual care is likely to be cost-effective at current UK cost-effec-
tiveness thresholds. This contributes to the growing evidence on the cost-effectiveness 
of collaborative care interventions for the treatment of comorbid depression. Future 
research will use a decision modelling approach to extrapolate trial-based results 
across a longer time horizon, and incorporate other relevant sources of evidence.
PCN115
PHARMACOECONOMIC EvALUATION OF ABIRATERONE ACETATE vERSUS 
CABAzITAxEL IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT 
PROSTATE CANCER IN KAzAKHSTAN
Kostyuk A., Almadiyeva A.
National Center for Health Development, Astana, Kazakhstan
Objectives: The purpose of this study was to explore the cost-effectiveness 
of abiraterone acetate (abiraterone) vs. cabazitaxel in metastatic castration-
resistant prostate cancer (mCRPC) patients who progressed after docetaxel in 
Kazakhstan. MethOds: Since no head-to-head trial data were not available for 
Abiraterone against cabazitaxel, indirect profitability model was developed using 
clinical data (progression-free survival (PFS), overall survival (OS), adverse events 
(AEs)) from the pivotal Phase 3 clinical trials COU-AA-301 (Abiraterone) and TROPIC 
(cabazitaxel). The basic assumption in the model was that the two comparator arms 
in the trials were “palliative” and are therefore equivalent. Using the resources, 
in particular for controlling the adverse events was calculated based on data 
Kazakhstan. For validation purposes, a secondary analysis was conducted using 
international resources use data. The analysis used a local expenditures 2011-2012, 
undiscounted. Hospitalization, day hospital visits, medications, and laboratory tWe 
developed a Markov microsimulation model with a lifetime horizon and a direct 
health-care cost perspective. The patient history was recorded and was used in 
calculations of transition probabilities, utilities, and costs. ests were taken from 
the public officially published rates. The cost of purchasing drugs came from recent 
price lists . Calculations were based on the average duration of treatment for each 
agent. Results: The total cost of treatment was lower for Abiraterone compared 
with cabazitaxel. Higher costs for the purchase of medicines for Abiraterone were 
offset by lower administrative expenses and lower AE management costs. Results 
were confirmed by secondary analysis. All sensitivity analyzes from the point of 
view of the model parameters and modeling assumptions are consistent with the 
expected findings, which confirmed both internal and external consistency of the 
model. cOnclusiOns: Abiraterone is a potentially cost-effective option compared 
with cabazitaxel in the health care system in Kazakhstan.
PCN116
REDUCING THE LENGTH OF ANTIBIOTIC PROPHyLAxIS IN CLINICAL 
CONDITIONS
Djozic M.1, Jovic R.1, Tomic Z.2, Sabo A.2
1University of Novi Sad, Faculty od Medicine, Clinical Center of Vojvodina, Novi Sad, Serbia and 
Montenegro, 2University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia and Montenegro
Objectives: The aim of this study was to evaluate duration and cost of prophylactic 
use of antibiotics, as well as occurrence of postoperative infection in the patients (pts) 
with laryngeal and pharyngolaryngeal carcinoma during 2005 and 2010. MethOds: 
Histories from 87 pts (2005) and 92 pts (2010) who were treated during the year 2005 
and 2010 from laryngeal and pharyngolaryngeal carcinoma at the ENT Clinic, Clinical 
Center of Vojvodina, Novi Sad, Serbia, have been used. All pts received triple drug 
therapy perioperatively. Since 2009, additional hygienic measures and education of 
staff (in terms of the proper use of antibiotics) have been taken to improve hospi-
tal treatment. From the patients’ histories, we followed: average length of hospital 
stay,average length of administrating antibiotics, occurrence of infection or other 
postoperative complication (fistula) and the price of used antibiotics. Results: 
During 2005, antibiotics were administrated as follows: aminoglycosides (amikacin) 
2x500mg during 10 days, cephalosporin (cefazolin amp. 2x1g, cefrtriakson 2x1g) 10 
days, metronidazole (solutio) 3x500mg 10 days.During 2010, same anibiotics were 
administerd for an average of 3 days. The average length of hospital stay was in 2005. 
was 13.5 days, x+/- SD= 13.5+/-4.2, and in 2010 was 11.18 days, x+/- SD= 11.18+/-5.9. The 
average length of administrating antibiotics was 9.4 days in 2005 (x+/- SD= 9.4+/-1.1) 
and in 2010 was 3.4 days (x+/- SD= 3.4+/-1.7). Occurrence of infection was in 4 pts (2005) 
and 6 pts (2010). The cost of used antibiotics in 2005.was 775748 dinars (9320 euros), 
and in 2010. was 366159 dinars (3698euro). cOnclusiOns: With reducing the length 
of administrating same antibiotics, after additional hygienic and educative measures 
have been taken, it is possible to significantly reduce the length of hospital stay (while 
the number of postoperative infections is not significantly increased) and cost of used 
antibiotics, which altogether leads to reduction of overall cost of hospital treatment.
their therapy. Our objective was to assess the cost-effectiveness of Sunitinib (SU) in 
the first-line treatment of mRCC patients in comparison with Bevacizumab (BEV) 
+ IFN- and Sorafenib (SO) -at the level of 2011 year- based on the latest clinical evi-
dence. MethOds: A Markov model (comprised of four states: 1st line treatment, 
2nd line, Best Supportive Care and Death) was validated in several countries and 
was adapted for the Romanian jurisdiction. The model was set to 6 weekly cycles 
for a period of 10 years, which corresponds with a lifetime length scenario. Costs 
for medication and application were derived from hospital databases, expert panels 
and structured interviews. Experts that managed more than 60% of all local mRCC 
were consulted. These experts identified several scenarios related to outpatient and 
inpatient treatment decisions predominantly based on social reasons; all these sce-
narios have been tested. A WHO methodology was used to set a threshold of price per 
QALY (3 x local GDP) Results: Cost per cycle in 1st line was lower than both 2nd line 
and BSC – consistent with other international findings. Neutropenia, proteinuria and 
heart failure have been identified as the most costly adverse events. The QALYs for 
SU was 1.86 compared to BEV 1.7 and SO 1.69. Incremental cost per QALY SU versus 
SO was 14.000 EURO and, respectively, -141.000 EURO versus BEV. cOnclusiOns: 
Sutent is cost effective versus SO and dominant to BEV in the treatment of mRCC in 
the study settings. The model was very sensible to price of medication and cost of BSC.
PCN112
THE POTENTIAL COST-EFFECTIvENESS OF OBINUTUzUMAB (GA101) IN 
COMBINATION wITH CHLORAMBUCIL IN CHRONIC LyMPHOCyTIC LEUKEMIA
Walzer S.1, Becker U.2, Samanta K.3, Wiesner C.2, Mueller E.4
1MArS Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany, 2F. Hoffmann-La 
Roche Ltd., Basel, Switzerland, 3Roche Products Limited, Welwyn Garden City, UK, 4Analytica LA-
SER International Inc., Loerrach, Germany
Objectives: Obinutuzumab is the first, glycoengineered type II antibody dem-
onstrating increased Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and 
direct cell death compared with rituximab, and is pending regulatory approval (in 
combination with chlorambucil (Clb)) for the treatment of patients with previously 
untreated chronic lymphocytic leukemia (CLL). Obinutuzumab+Clb has shown 
a > 85% reduction in the risk of progression, relapse or death in comparison to 
treatment with Clb alone (HR 0.14, 95% CI 0.09-0.21, p < .0001), a broadly accepted 
treatment option for many patients with co-existing medical conditions. The 
cost-effectiveness of this innovative therapy will need to be assessed in countries 
using incremental cost-effectiveness thresholds to make reimbursement deci-
sions. MethOds: A four-state Markov lifetime model from the UK NHS perspective 
was developed for patients with existing medical conditions utilizing the patient-
level information from the underlying clinical trial comparing obinutuzumab+Clb 
versus rituximab+Clb and versus Clb alone (CLL11 trial). Transition probabilities 
from PFS to progression were derived from this study’s data. Post-progression sur-
vival was estimated using published data and was part of the sensitivity analy-
ses. Cost data (e.g. administration and adverse events), utilities and the prices for 
rituximab and Clb were retrieved for the UK. As obinutuzumab is not yet approved 
a range of price assumptions of similar innovative oncology therapies has been 
applied. Results: Based on this early evaluation, obinutuzumab+Clb showed a cost 
per QALY in the base case analysis of £18,000 to £19,000 when compared to Clb and 
£29,000 to £32,000 when compared to rituximab+Clb. Probabilistic and deterministic 
sensitivity analyses confirmed these findings. cOnclusiOns: Obinutuzumab+Clb 
showed significant patient-relevant clinical benefits and might be a potential cost-
effective therapy in comparison to the current standard of care and could hence 
support access for a maximum number of patients with previously untreated CLL.
PCN113
COST-EFFECTIvENESS OF BREAST CANCER SURvEILLANCE By LIFETIME RISK IN 
wOMEN AGED LESS THAN 50 yEARS
Teljeur C., Harrington P., Murphy L., Ryan M.
Health Information and Quality Authority, Dublin, Ireland
Objectives: National programmes of breast cancer screening are common for women 
over the age of 50 at average risk. For women aged less than 50, surveillance may be 
offered to those at elevated risk either due to family history or because of identified 
genetic risk factors, such as a BRCA1 mutation. The lifetime risk for these women is not 
known with certainty. The purpose of this study was to examine the cost-effectiveness 
of different screening strategies as a function of lifetime risk. MethOds: A Markov 
model was developed to evaluate the cost-effectiveness of different MRI- and digital 
mammography-based surveillance strategies between the ages of 30 and 49. Costs 
and benefits were calculated to life expectancy. The perspective was that of the pub-
licly funded health care system in Ireland. Lifetime risk of developing breast cancer 
was varied between 4% and 94%. A cost-effectiveness threshold of € 45,000/QALY was 
applied. Results: The probability of cost-effectiveness increased with increasing 
lifetime risk. For women at moderate risk (i.e. lifetime risk of between 17% and 30%), 
cost-effectiveness was only achieved with annual surveillance from the age of 40 to 
49 when lifetime risk reached 28% to 30%. For women with high familial risk, cost-
effectiveness was achieved for surveillance from the age of 40 to 49. For women with 
a BRCA1 mutation, surveillance from the age of 40 to 49 was cost-effective for all levels 
of lifetime risk, while MRI from age 30 was only cost-effective for a lifetime risk of over 
65%. cOnclusiOns: Risk levels for breast cancer encompass wide ranges of lifetime 
risk. The cost-effectiveness of different surveillance strategies is sensitive to lifetime 
risk and suggests the need for individualised surveillance programmes.
PCN114
COLLABORATIvE CARE FOR DEPRESSION MANAGEMENT IN CANCER: A COST-
EFFECTIvENESS ANALySIS
Duarte A.1, Walker S.1, Richardson G.1, Walker J.2, Sharpe M.2, Sculpher M.J.3
1University of York, York, UK, 2University of Oxford, Oxford, UK, 3Centre for Health Economics, 
York, UK
Objectives: Collaborative care interventions for comorbid depression have dem-
onstrated their beneficial impact on health outcomes. Depression in cancer patients 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A413
times Colombian GDP per capita) bendamustine is a cost effective alternative to 
fludarabine.
PCN120
COST-EFFECTIvENESS OF CABAzITAxEL IN MHRPC IN TURKEy
Yesil A.1, Sahin T1, De Geer A.2, Kim K.3, Topcu T.1
1Sanofi Turkey, Istanbul, Turkey, 2OptumInsight Life Sciences, Stockholm, Turkey, 3OptumInsight, 
Stockholm, Sweden
Objectives: To determine the cost-effectiveness of cabazitaxel, based mainly on 
the TROPIC trial in 2nd line treatment of mHRPC relative to the standard of care 
at the time of launch of the drug. MethOds: A Markov model was developed to 
comprise set of different health states each associated with costs, effects and prob-
abilities of moving to other state. In simulation, a cohort of defined patients are run 
through the model during the time period of choice, it’s assumed that transitions 
between states only occurs at equidistant time-points and the interval is called a 
cycle. Because of the relatively short survival time of mHRPC patients, cycle length 
in the model was set at 3 weeks, corresponding to the length of one chemotherapy 
administration cycle. Transition rates between different states representing mHRPC 
disease progression were estimated based on progression of disease and survival 
rates from the TROPIC trial. Results: According to the approved labeling in Turkey, 
a subgroup of patients with ECOG PS 0-1 and measurable disease at baseline was 
identified on TROPIC results with a secondary analysis. The result of this analysis 
shows a similar OS outcomes with decreased death rates. Cabazitaxel was cost-
effective compared mitoxantrone with cost per LYG of TRY66,862 given the thresh-
old of TRY68,409 per LYG for the subgroup of the patients at ECOG PS 0-1 and with 
measurable disease at baseline. Although there has been no formal threshold for 
the cost-effectiveness ratio in Turkey, a threshold of TRY68,409 per LY gained was 
assumed based on WHO-CHOICE criteria (3xGDP percapita). cOnclusiOns: It is 
difficult for the results of the analysis to be interpreted because there is no official 
cost-effectiveness threshold in Turkey. However, from the WHO perspective; results 
showed that cabazitaxel is a cost-effective treatment with all ICER values compared 
to mitoxantrone, below TRY68,409.
PCN121
EvALUATING THE COST EFFECTIvENESS OF GENE ExPRESSION PROFILING AND 
IMMUNOHISTOCHEMISTRy TESTS
Rafia R.1, Ward S.E.1, Scope A.1, Wyld L.2
1University of Sheffield, Sheffield, UK, 2Royal Hallamshire Hospital, Sheffield, UK
Objectives: Gene expression profiling (GEP) and expanded immunohistochemis-
try (IHC) tests aim to improve decision-making relating to adjuvant chemotherapy 
for women with early breast cancer (EBC) at intermediate or high risk of recurrence 
following primary surgery. MethOds: A probabilistic model was developed to 
evaluate the cost effectiveness of treatment guided using the OncotypeDx and 
IHC4 tests compared with current clinical practice in England and Wales. Analysis 
was undertaken for women with oestrogen receptor positive (ER+), lymph node 
negative (LN–), and HER2– EBC from a NHS perspective. In the comparator arm, 
cancer registry data was used to inform the proportion of patients receiving chem-
otherapy under current practice. In the intervention arm (new test in addition to 
current practice) patients were classified into different risk categories based on the 
result of the new test. The likelihood of receiving chemotherapy was dependent on 
this classification. The natural history of breast cancer was then simulated using 
a state transition Markov model, taking into account the reduction in the risk of 
recurrence associated with chemotherapy. Results: The economic analysis sug-
gested that treatment guided using IHC4 has the most potential to be cost-effective 
at a threshold of £20,000 per QALY gained; however the evidence base to support 
IHC4 needs further research to confirm the analytical validity of the test and to 
clarifiy the cost of the test in clinical practice. OncotypeDX has a more robust 
evidence base, but further evidence on the impact on decision making in the UK 
and the predictive ability of the test in an ER+, LN-, HER- population receiving 
current treatment regimens is needed to confirm whether or not it constitutes 
a cost-effective option in the UK. cOnclusiOns: GEP and IHC tests have the 
potential to constitute a cost effective option in the UK, but further research is 
needed to confirm this finding.
PCN122
PHARMACOECONOMIC ANALySIS OF USING APREPITANT PLUS STANDARD 
ANTIEMETIC THERAPy FOR PREvENTION OF NAUSEA AND vOMITING 
ASSOCIATED wITH HIGHLy AND MODERATELy EMETOGENIC CANCER 
CHEMOTHERAPy IN RUSSIA
Krysanov I., Krysanova V.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To perform comparative pharmacoeconomic analysis of aprepitant 
plus standard antiemetic therapy – 5-hydroxytriptamine-3 antagonist and cor-
ticosteroid - for prevention chemotherapy-induced nausea and vomiting (CINV) 
versus standard antiemetic therapy. MethOds: Analysis of the published clinical 
trials was conducted to evaluate comparative efficacy and safety of three-drug 
combination. Cost-effectiveness analyses was performed. Direct medical costs of 
treatment with studied drugs were considering for each option: cost for 1-cycle and 
6-cycle cancer chemotherapy (CCT) with highly emetogenic drugs and for 1-cycle 
and 4-cycle CCT with moderately emetogenic drugs for 1 patient. The calculation of 
costs was based on drugs’ prices from the List of Vital and Essential Drugs in Moscow 
region. The incremental cost-effectiveness ratio (ICER) was estimated. One-way 
sensitivity analysis was made. Results: According to published trials the using 
aprepitant plus standard antiemetic therapy in patients receiving highly and mod-
erately emetogenic chemotherapy was associated with a significant improvement 
in control of CINV. The ICER was 593.7 USD per 1-cycle and 2906.6 USD per 6-cycle 
CCT with highly emetogenic drugs for 1 patient. The ICER was 852.7 USD per 1-cycle 
and 4570.1 USD per 4-cycle CCT with moderately emetogenic therapy. The one-way 
sensitivity analysis showed that the results are more sensitive to the variations of 
PCN117
SELECTIvE INTERNAL RADIOTHERAPy (SIRT) USING RESIN yTTRIUM-90 
MICROSPHERES FOR CHEMOTHERAPy-REFRACTORy METASTATIC COLORECTAL 
CANCER: A UK COST-EFFECTIvENESS ANALySIS
Bester L.1, Wasan H.2, Sangro B.3, Kennedy A.4, Pennington B.5, Sennfält K.6
1University of New South Wales, Darlinghurst, Australia, 2Hammersmith Hospital, London, UK, 
3Clinica Universitaria de Navarra, Navarra, Spain, 4Sarah Cannon Research Institute, Nashville, 
TN, USA, 5BresMed, Sheffield, UK, 6Sirtex Medical Limited, North Sydney, Australia
Objectives: Treatment options for chemotherapy-refractory liver metastases result-
ing from colorectal cancer are limited. The safety and efficacy of SIRT using resin 
yttrium-90 microspheres was studied in this population. The objective of this analysis 
was to assess the cost-effectiveness of SIRT compared to best supportive care (BSC) 
from the perspective of the UK NHS. MethOds: A state-transition model was con-
structed, based on survival curves from a retrospective cohort study of yttrium-90 
resin microspheres (SIR-Spheres; Sirtex, Sydney, Australia) vs. BSC in chemotherapy-
refractory mCRC. The model included costs for treatment acquisition, pre-treatment 
work-up and delivery of microspheres, and chemotherapy received in addition to, 
instead of, or after, SIRT. In addition, costs of managing AEs and a cost of death were 
included. Costs were microcosted using NHS reference costs and the British National 
Formulary 64. Utility data were taken from a recent NICE economic evaluation in 
metastatic colorectal cancer. Results: The results showed an increase in survival 
for patients receiving SIRT compared to BSC (2.09 vs. 0.97 years), with a correspond-
ing increase in quality adjusted life years (1.50 vs 0.69). The associated costs were 
£35,487 vs.£12,730 for SIRT and BSC, respectively. The additional costs were due to 
the SIRT treatment and the cost associated with extension to life. The cost per QALY 
was £28,216 (cost per life year £20,323). The results were robust to alternative assump-
tions tested in scenario analyses; survival functions, utilities or the time spent pre- 
and post-progression. However, one-way sensitivity analysis showed results were 
most sensitive to the parameters for the survival functions. Data shown here were 
also consistent with published clinical studies. cOnclusiOns: The analysis dem-
onstrates that SIRT using resin yttrium-90 microspheres has the potential of being a 
cost-effective option in the treatment of patients with chemotherapy-refractory liver 
metastases resulting from colorectal cancer.
PCN118
PHARMACOECONOMIC ANALySIS OF INTRAvENOUS TEMOzOLOMIDE FOR THE 
TREATMENT OF NEwLy DIAGNOSED GLIOBLASTOMA MULTIFORME IN RUSSIA
Krysanov I., Krysanova V.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To perform comparative pharmacoeconomic analysis of concomi-
tant, adjuvant and second-line intravenous temozolomide (ITMZ) for the treat-
ment of newly diagnosed glioblastoma multiforme versus initial radiotherapy and 
second-line therapy with ITMZ. MethOds: Analysis of the published clinical trials 
was conducted to evaluate comparative efficacy and safety of the studied therapy 
options. Direct medical costs included drug therapy and hospital treatment. All 
prices were for Moscow region, year 2013. Expected difference in direct medical costs 
was calculated in Excel based model. For the cost-effectiveness analysis, survival 
was expressed as 2.5 years restricted mean estimates from EORTC-NCIC study. 
The incremental cost-effectiveness ratio (ICER) was estimated. One-way sensitivity 
analysis was made. Results: According to published trials the treatment of newly 
diagnosed glioblastoma multiforme with ITMZ was associated with a significant 
improvement in overall survival. The difference in 2.5 years restricted mean survival 
between the treatment arms was 0.25 life-years and the ICER was 76,982.6 USD per 
life-year. The one-way sensitivity analysis showed that the results are more sensi-
tive to the variations of key model parameter, such as price of ITMZ. cOnclusiOns: 
The concomitant, adjuvant and second-line ITMZ was more effective and economi-
cally justified treatment option for patients with newly diagnosed glioblastoma 
multiforme.
PCN119
COST-EFFECTIvENESS OF BENDAMUSTINE vERSUS FLUDARABINE FOR FIRST-
LINE TREATMENT OF CHRONIC LyMPHOCyTIC LEUKEMIA (CLL) IN COLOMBIA
Bertwistle D.1, Munakata J.2, Wehler E3, Leyva V.4, Ariza J.G.5, Zambrano C.5, Gonzalez L.6
1IMS Health, London, UK, 2IMS Health, San Francisco, CA, USA, 3IMS Health, Alexandria, VA, USA, 
4IMS Health, Mexico City, Mexico, 5Janssen Cilag, Bogotá, Colombia, 6Janssen, Raritan, NJ, USA
Objectives: To determine the cost-effectiveness of bendamustine versus 
fludarabine for first line treatment of CLL in Colombia. MethOds: An eco-
nomic model was constructed from the Colombian health system perspective, 
with a 25-year (lifetime) horizon and a discount rate of 3%. The model included 
three health states, progression-free (PF), progressive disease (PD), and death. 
Clinical inputs (Kaplan-Meier curves, response rates, hazard ratios (HRs) and 
adverse event (AE) rates) were from a phase 3 trial comparing bendamustine and 
chlorambucil, and from a network meta-analysis. Resource use data were from 
interviews with three Colombian hematologists treating CLL. Resource use for 
PF patients was weighted based on treatment response. Unit costs were from ISS 
and SISPRO report and were expressed in 2013 Colombian Pesos. Univariate and 
probabilistic sensitivity analyses were conducted to determine the key drivers of 
cost-effectiveness, and the uncertainty around the results, respectively. Results: 
The total lifetime costs for bendamustine and fludarabine were $61,982,845 and 
$20,432,209, respectively. Bendamustine patients accrued more LYs (7.52 vs. 
6.50), QALYs (5.61 vs. 4.60), and PF LYs (3.09 vs. 1.14) compared to fludarabine 
patients. The ICERs were $40,530,919 (cost per LY), $41,117,127 (cost per QALY) and 
$21,264,817 (cost per PF LY). Univariate sensitivity analysis revealed the cost per 
LY ICER was most sensitive to progression-free survival and overall survival HRs 
for bendamustine vs. fludarabine, the number of treatment cycles, and the cost 
of bendamustine. Probabilistic sensitivity analysis with 1,000 iterations predicted 
bendamustine had a 71% chance of being cost-effective, compared to fludarabine, 
at a willingness to pay (WTP) of $59M per LY, rising to a plateau of about 80% 
from a WTP of $80M and greater. cOnclusiOns: At current WTP of $59M (three 
A414  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
years (QALY), costs and the incremental cost-effectiveness and cost-utility ratio 
(ICER and ICUR) of PET-CT versus CT based radiotherapy planning. Model outcomes 
were obtained from averaging the outcome for 50 000 simulated patients. To present 
uncertainty, a probabilistic sensitivity analysis was done. In scenario analyses, we 
explored the effect of varying the input parameters for costs and QALYs and the 
effect of changing the assumptions regarding the multi-state model. Results: The 
incremental costs of PET-CT based planning were € 534 (95% CI: € -4670 – € 6080) for 
0,43 incremental LYs (95% CI: 0,31 – 0,52) and 0,33 QALYs gained (95% CI: 0,26 – 0,45). 
The base-case scenario resulted in an ICER of € 1242 per LY gained and an ICUR 
of € 1618 per QALY gained. The probabilistic sensitivity analysis gave a 41% prob-
ability that PET-CT based planning improves health outcomes at reduced costs and 
a 59% probability that PET-CT based planning is more effective at slightly higher 
costs. cOnclusiOns: PET-based radiotherapy planning for non-small cell lung 
cancer is highly cost-effective compared to CT-based planning.
PCN126
COST-EFFECTIvENESS OF SySTEMATIC TESTING FOR LyNCH SyNDROME IN 
PATIENTS NEwLy DIAGNOSED wITH COLORECTAL CANCER IN THE UNITED 
KINGDOM
Huxley N.1, Snowsill T.1, Hoyle M.1, Jones-Hughes T.1, Coelho H.1, Cooper C.1, Frayling I.2, 
Hyde C.1
1University of Exeter Medical School, Exeter, UK, 2University Hospital of Wales, Cardiff, UK
Objectives: The cost-effectiveness of genetic testing for Lynch Syndrome for 
patients newly diagnosed with colorectal cancer in the UK has not previously been 
estimated. Therefore, the cost-effectiveness of nine testing strategies were simulta-
neously compared using a detailed and rigorous mathematical model. MethOds: 
In the base case analysis, probands were tested only if aged 50 or below. Testing 
strategies included use of family history, tumour-based tests and genetic testing. 
The clinical pathways of thousands of individual patients diagnosed with colorectal 
cancer (CRC) and their relatives were simulated. For each person, the total costs 
and quality-adjusted life years (QALYs) were calculated using methodology recom-
mended by the National Institute of Health and Care Excellence (NICE). Simulated 
clinical events included incidence of CRC and endometrial cancer (EC); surgery for 
CRC and EC, colonoscopies (including bleeding and perforation), mortality from 
CRC, EC, colonoscopy and background causes. A proportion of people diagnosed 
with Lynch Syndrome were assumed to receive prophylactic hysterectomy and 
to undergo biennial colonoscopies (assumed to reduce the incidence and stage 
of colorectal cancer). The costs of treating patients with CRC with surgery, chem-
otherapy, radiotherapy, stoma care and palliative care were captured. Similarly, 
the costs of treating patients with EC with chemotherapy and radiotherapy were 
included. Results: The life expectancies of probands and relatives with Lynch 
Syndrome are estimated to increase by up to 1.6 years, depending on the strategy 
for genetic testing. All testing strategies are predicted to offer good value for money 
versus no testing, with all incremental cost-effectiveness ratios below the UK basic 
cost-effectiveness threshold of £20,000 per QALY. Universal genetic testing is pre-
dicted to offer poor value for money versus targeted genetic testing. cOnclusiOns: 
Results suggest that targeted genetic testing for Lynch Syndrome for patients with 
newly diagnosed CRC in the UK is a good use of limited financial resources.
PCN127
COST-EFFECTIvENESS ANALySIS OF CAPSULE ENDOSCOPy IN SCREENING FOR 
COLORECTAL CANCER IN jAPAN
Sakamaki H.1, Tajiri H.2, Inoue S.3
1Meijo University, Nagoya, Japan, 2Jikei University School of Medicine, Tokyo, Japan, 3CRECON 
Research & Consulting INC., Tokyo, Japan
Objectives: The PillCam COLON2 is a colon capsule endoscopy (CCE) that 
makes a minimally-invasive colonoscopy possible and is expected to improve 
detailed examination rate which have been identified as a problem concerning a 
population-based colorectal cancer (CRC) screening system in Japan. The objective 
of this analysis was to evaluate the cost-effectiveness of CCE if newly introduced 
into the current population-based CRC screening system in Japan. MethOds: The 
subject of this analysis was a sequential screening system for which CCE has been 
incorporated (immunochemical fecal occult blood test (IFOBT) → detailed exami-
nation by CCE → detailed examination by colonoscopy) and the comparator was 
the conventional sequential screening system (IFOBT → detailed examination by 
colonoscopy). The target population includes asymptomatic adults aged 40 years 
old and a lifelong simulation was conducted using a Markov model which consists 
of 8 states, no polyp, adenomatous polyp (≤ 5mm, 6-9mm and ≥ 10mm), local-
ized CRC, regional CRC, distant CRC and death. The efficacy measures were life 
year and quality-adjusted life year (QALY). The analysis was conducted from the 
perspective of the payer and only direct medical costs were considered. Results: 
The incremental cost effectiveness ratio (ICER) observed when incorporating CCE 
into the conventional screening system was € 59,911 per QALY, € 25,060 per QALY 
and € 14,905 per QALY when assuming a 10%, a 20% and a 30% improvements in 
detailed examination rates (1 Euro= 128 JPY). Therefore, the introduction of CCE 
was determined to be cost-effective if the detailed examination rate increased by 
20% or more relative to current rate with CCE introduction. cOnclusiOns: Based 
on this analysis, the introduction of CCE into the conventional population-based 
screening system in Japan is shown to be cost-effective. The cost-effectiveness of 
CCE is primarily dependent on the degree of improvement in the current detailed 
examination rate.
PCN128
COST-EFFECTIvENESS OF FIRST-LINE TREATMENT OF ADvANCED METASTATIC 
NON SMALL CELL LUNG CANCER- A SySTEMATIC REvIEw OF ECONOMIC 
MODELS
Eijgelshoven I.1, Verduyn S.C.1, Bhatti T.2, Bexelius C.2, Jansen J.P.3
1Mapi, Houten, The Netherlands, 2F. Hoffmann-La Roche Ltd., Basel, Switzerland, 3Mapi / Tufts 
University School of Medicine, Boston, MA, USA
aprepitant price. cOnclusiOns: The using aprepitant plus standard antiemetic 
therapy was more effective and economically justified treatment option for preven-
tion of nausea and vomiting associated with highly and moderately emetogenic 
cancer chemotherapy.
PCN123
ECONOMIC EvALUATION OF FULvESTRANT 500 MG vERSUS GENERIC NON-
STEROIDAL AROMATASE INHIBITORS IN PATIENTS wITH ADvANCED BREAST 
CANCER IN NORwAy
Ekman M.1, Jacob J.1, Bjørheim J.2
1AstraZeneca Nordic-Baltic, Södertälje, Sweden, 2AstraZeneca Nordic-Baltic, Oslo, Norway
Objectives: In Norway, breast cancer represented 23% of all new cancer cases 
between 2004 and 2008, and was a leading cause of mortality representing 13% of all 
cancer deaths. The objective of this study was to perform an economic evaluation 
of fulvestrant 500 mg compared with anastrozole and letrozole used as second line 
endocrine therapies in the treatment of advanced breast cancer in post-menopausal 
women in Norway. MethOds: The economic analysis was conducted by using a 
simulation model estimating progression-free survival, overall survival and associ-
ated costs and utility gains over the expected lifetime of the patients. As there are 
no head-to-head trials comparing fulvestrant 500 mg with aromatase inhibitors, 
the clinical evidence for the comparative effectiveness was obtained from a net-
work meta-analysis. The economic evaluation was conducted from a health care 
perspective, with costs and resource use based on published sources and expert 
assessment. Results: The cost-effectiveness ratio of fulvestrant 500 mg versus 
anastrozole 1 mg was 36,000 EUR per quality-adjusted life year (QALY), with incre-
mental costs of 9,600 EUR and incremental QALYs of 0.27. The cost-effectiveness 
ratio of fulvestrant 500 mg versus letrozole 2.5 mg was 62,000 EUR per QALY, with 
incremental costs of 21,000 EUR and incremental QALYs of 0.34. In the sensitivity 
analysis the results were stable for variations of key parameters, such as the time 
horizon, the hazard ratios for overall survival, the choice of parametric distribution 
for progression-free survival and the discount rate. cOnclusiOns: Given an infor-
mal cost-effectiveness threshold of around 70,000 EUR/QALY in Norway, the results 
of the economic evaluations suggest that fulvestrant 500 mg is a cost-effective 
treatment compared with alternative treatments such as anastrozole and letrozole. 
These findings indicate that fulvestrant 500 mg is a valuable treatment option for 
patients with advanced breast cancer in Norway.
PCN124
COST-EFFECTIvENESS OF THE SySTEMATIC IDENTIFICATION AND TREATMENT 
OF COMORBID MAjOR DEPRESSION FOR PEOPLE wITH CHRONIC DISEASES: THE 
ExAMPLE OF CANCER
Walker S.1, Walker J.2, Richardson G.1, Palmer S.1, Wu Q.1, Gilbody S.1, Martin P.3,  
Holm Hansen C.3, Sawnhey A.3, Murray G.3, Sculpher M.J.4, Sharpe M.2
1University of York, York, UK, 2University of Oxford, Oxford, UK, 3University of Edinburgh, 
Edinburgh, UK, 4Centre for Health Economics, York, UK
Objectives: Comorbid major depression occurs in approximately ten percent of peo-
ple suffering from a chronic medical condition such as cancer. A ‘collaborative care’ 
approach can be used to systematically identify and treat comorbid major depression. 
However, we lack information on cost-effectiveness of overall approach as economic 
evaluations published to date have focused solely on the treatment stage. We there-
fore aimed to use the best available evidence to estimate the cost-effectiveness of the 
whole approach (both systematic identification and systematic treatment) compared 
with usual practice, for patients attending specialist cancer clinics. MethOds: A 
cost-effectiveness analysis using a decision analytic model structured to reflect both 
the identification and treatment processes. Evidence was taken from reviews of rel-
evant clinical trials and from observational studies, together with data from a large 
depression screening service. Sensitivity and scenario analyses were undertaken 
to determine the effects of variations in depression incidence rates, time horizons, 
patient characteristics and alternative estimates of treatment effect. Probabilistic 
sensitivity analysis was also undertaken. Results: Systematic depression manage-
ment generated more costs than usual practice, but also more quality adjusted life 
years (QALYs). The incremental cost-effectiveness ratio was £11,765 per QALY and the 
probabilities of systematic depression management being cost-effective at thresholds 
of £20,000 and £30,000 per QALY were 0.998 and 1 respectively. Findings were robust to 
tests of variation in key model parameters. cOnclusiOns: A combined approach to 
the systematic identification and treatment of comorbid major depression in cancer 
patients is likely to be cost-effective at widely accepted threshold values. Systematic 
depression management may be a better way of generating QALYs for cancer patients 
than some existing medical and surgical treatments. It could potentially be applied 
to other chronic medical conditions.
PCN125
PET-BASED RADIOTHERAPy TREATMENT PLANNING IS HIGHLy COST-
EFFECTIvE COMPARED TO CT-BASED PLANNING: A MODEL-BASED EvALUATION
Bongers M.L.1, Coupe V.M.H.1, De Ruysscher D.2, Lambin P.3, Oberije C.3, Uyl-de Groot C.A.4
1VU University Medical Center, Amsterdam, The Netherlands, 2University Hospitals Leuven/KU 
Leuven, Leuven, Belgium, 3MAASTRO Clinic, Maastricht, The Netherlands, 4Erasmus University 
Rotterdam, Rotterdam, The Netherlands
Objectives: PET-based radiotherapy planning for selective lymph node irradiation 
is an example of the current tendency to individualize treatment in cancer. We 
evaluated the cost-effectiveness of individualized radiotherapy planning, compar-
ing PET-CT-based to CT-based radiotherapy treatment planning in non-small cell 
lung cancer. MethOds: Our analysis uses a previously developed decision model. 
The model was based on data for 200 NSCLC patients with inoperable stage I-IIIB, 
provided by the Maastro Clinic. Transition rates in the model were estimated by 
multi-state statistical modelling and include the impact of patient and tumour 
features on disease progression. Resource use estimates, costs and utilities were 
obtained from the database of the Maastro Clinic, the literature and Dutch guide-
lines. Primary outcomes were the difference in life years (LY), quality adjusted life 
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COST-EFFECTIvENESS OF BENDAMUSTINE-RITUxIMAB IN FIRST-LINE 
INDOLENT NHL: A PATIENT-LEvEL SIMULATION
Dewilde S.1, Woods B.2, Castaigne J.G.3, Parker C.2, Dunlop W.3
1SHE, Brussels, Belgium, 2Oxford Outcomes, Oxford, UK, 3Mundipharma International Limited, 
Cambridge, UK
Objectives: To evaluate the cost-effectiveness of bendamustine-rituximab (B-R) 
compared with standard of care as first-line treatment for patients with advanced 
indolent non-Hodgkin’s lymphoma (NHL) in England and Wales. MethOds: A 
patient-level simulation was adapted from the model used by the University of 
Sheffield School of Health and Related Research (ScHARR) in a health technology 
appraisal of rituximab for first-line treatment of follicular lymphoma (the most 
common type of indolent NHL). This approach allowed modelling of the complex 
treatment pathways in indolent NHL; specifically, first-line maintenance and sec-
ond-line treatment choice could be modelled as a function of patient age, and prior 
treatment choice and outcome. Data from a Phase 3 randomised, open-label trial 
by the Study group indolent Lymphomas (StiL) in Germany were used to compare 
B-R with CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituxi-
mab). The relative efficacy of CHOP-R and CVP-R (cyclophosphamide, vincristine, 
prednisone, rituximab) was estimated as per the original ScHARR approach. The 
analysis was conducted from the perspective of the National Health Service, using 
a lifetime time horizon. One-way sensitivity and scenario analyses were conducted, 
including one using recently published randomised trial data comparing CVP-R with 
CHOP-R. Results: The base-case deterministic incremental cost-effectiveness ratio 
(ICER) was £5,249 per quality adjusted life year (QALY) for B-R vs. CHOP-R, and £8,092 
per QALY for B-R vs. CVP-R. The alternative scenario using direct data comparing 
CVP-R with CHOP-R more than halved the ICER for B-R vs. CVP-R to £3,468. Owing 
to its better toxicity profile, B-R reduced the cost of treating adverse events by over 
£1,000 per patient vs. CHOP-R. None of the one-way sensitivity or scenario analyses 
increased the ICER above £20,000. cOnclusiOns: The ICERs for B-R vs. CHOP-R and 
CVP-R were below the thresholds normally regarded as cost-effective in England 
and Wales (£20,000 – 30,000 per QALY).
PCN132
COST-UTILITy OF GRANULOCyTE-COLONy STIMULATING FACTORS (G-CSFS) 
FOR PRIMARy PROPHyLAxIS (PP) OF CHEMOTHERAPy INDUCED FEBRILE 
NEUTROPENIA (FN) IN BREAST CANCER PATIENTS IN THE NETHERLANDS
Somers L.1, Timmer-Bonte J.N.H.2, Gelderblom H.3
1OncoLogX bvba, Wuustwezel, Belgium, 2Alexander Monro Breast Cancer Hospital, Bilthoven, The 
Netherlands, 3Leiden University Medical Center, Leiden, The Netherlands
Objectives: To assess number needed to treat to avoid an episode of FN (NNT) 
and cost-utility in The Netherlands of PP with once-per-cycle pegfilgrastim vs. no 
prophylaxis and vs. PP with daily G-CSF filgrastim (11-days as per label or 6-days 
suboptimal use) for reducing FN incidence in women with primary breast can-
cer receiving high risk chemotherapy for FN (e.g. TAC, a frequently used reference 
regimen in The Netherlands). MethOds: A decision-analytic model was con-
structed from health care-payer perspective. Costs were from official list prices 
(April 2013) or literature and included drugs, drug administration and FN-related 
medical costs and hospitalisations. Effectiveness inputs in terms of relative risk 
reduction (RRR) for FN were based on a recent meta-analysis. Survival and utility 
inputs were modeled from available data for breast cancer patients in the US and 
the UK. Outcomes included NNT and incremental cost effectiveness ratio (ICER) as 
cost per quality-adjusted life-year gained (QALY). Univariate sensitivity analyses 
evaluated the robustness of the model. Results: NNT with pegfilgrastim PP was 
lowest at 4.4, with filgrastim 11-days at 5.6 and filgrastim 6-days at 13.4. In terms 
of cost-utility, pegfilgrastim PP was dominant vs. 11-days filgrastim PP and was 
considered cost-effective vs. no prophylaxis (€ 29,896/QALY) and vs. PP with 6-days 
filgrastim (€ 7,615/QALY). In a scenario analysis reducing the prices of daily G-CSFs 
by 40%, pegfilgrastim PP remained cost-effective. The sensitivity analyses revealed 
that most sensitive variables were FN effectiveness (relative risk reductions), incre-
mental survival assumptions and cost of G-CSFs, and overall the model was robust 
to sensitivity analyses. cOnclusiOns: In a Dutch setting, pegfilgrastim PP offers 
a cost-effective approach to PP of FN. In the cost-utility analysis pegfilgrastim PP 
was dominant vs. 11-days filgrastim PP and cost-effective vs. no prophylaxis and 
6-days filgrastim PP.
PCN133
COST-EFFECTIvENESS ANALySIS OF ABIRATERONE ACETATE AS SECOND LINE 
TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER 
AFTER DOCETAxEL TREATMENT IN jAPAN
Shibahara H.1, Shiroiwa T.2, Nakamura K.1, Shimozuma K.1
1Ritsumeikan University, Kusatsu, Japan, 2National Institute of Public Health, Saitama, Japan
Objectives: Abiraterone acetate improves overall survival of patients with meta-
static castration-resistant prostate cancer (CRCP). The NICE in the UK has recom-
mended abiraterone as a second line treatment for CRCP after docetaxel. Ministry 
of Health, Labour and Welfare (MHLW) has begun to discuss whether or how to use 
cost-effectiveness data for reimbursement or pricing. The purpose of this study is 
to evaluate cost-effectiveness of abiraterone plus prednisolone compared to pred-
nisolone alone in Japan. MethOds: Cost-effectiveness analysis was performed 
using a Markov model (TreeAge Pro 2013) based on data from the randomized control 
trial (COU-AA-301 study) and literature review conducted from the public health 
care payer’s perspective. The (1) abiraterone (1,000 mg once daily and orally) plus 
prednisolone (5 mg twice daily and orally) was compared with (2) prednisolone 
alone. The base case was assumed to be a 69 year-old man with metastatic CRPC. 
The model used a time horizon of 10 years. Outcomes were measured in quality-
adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) was 
calculated. MHLW has yet to approve abiraterone due to the delay in development, 
and drug cost was estimated based on prices in the UK and the US. Both cost and 
outcomes were discounted at a 2% annual rate based on Japanese guidelines for eco-
Objectives: To summarize the modeling methods used in published 
cost-effectiveness evaluations of first-line treatment for advanced NSCLC 
patients. MethOds: To identify relevant studies, a systematic literature search 
was performed in Medline®, EMBASE®, Medline-In-Process and the CRD data-
base from 2000 to 2013. In addition, Technology Appraisals (TA) were identified by 
searching the NICE, SMC and pCODR websites. Studies were included for review 
based on the following pre-defined criteria; 1) description of cost-effectiveness or 
cost-utility analysis; 2) inclusion of a comparison of drug interventions in first-line 
treatment of advanced NSCLC patients; and 3) results were expressed as cost per 
LY or QALY gained. Results: Out of 1009 unique citations, 21 publications and 
18 TA met the inclusion criteria. The identified cost-utility and cost-effectiveness 
analyses were all performed from a payer perspective for a variety of countries in 
Europe, Asia and North America. The economic value of targeted therapies for first-
line and maintenance treatment for advanced NSCLC patients were evaluated for 
different subpopulations according to histology type (non-squamous, squamous). 
The most commonly used modeling approach was the state-transition model 
with health states reflecting stable disease, progression, and death. Transitions 
between these health states were based on either fixed or time varying transition 
probabilities. Cost-effectiveness analyses that were based on a synthesis of clinical 
efficacy evidence primarily relied on the constant hazard ratio assumption. The 
impact of structural modeling assumptions on cost-effectiveness findings was 
frequently not reported. cOnclusiOns: Based on a review of published cost-
effectiveness evaluations, it was concluded that the rational for certain modeling 
choices are frequently not provided. In particular, choices pertaining to methods 
for clinical evidence synthesis and the impact on cost-effectiveness findings need 
to be justified in a more structured way.
PCN129
COST-MINIMIzATION ANALySIS (CMA) OF DIFFERENT STRATEGIES TO TREAT 
NEwLy DIAGNOSED LOCALLy CONFINED LOw-RISK PROSTATE CANCER 
(LCLRPC) IN GERMANy: RESULTS OF THE HAROw STUDy
Schädlich P.K.1, Baranek T.2, Häussler B.1, Weißbach L.3
1IGES Institut GmbH, Berlin, Germany, 2CSG - Clinische Studien Gesellschaft mbH, Berlin, 
Germany, 3Stiftung Männergesundheit - Foundation for Men’s Health, Berlin, Germany
Objectives: The optimal treatment choice for the about 64,000 men diagnosed 
with prostate cancer each year in Germany still remains unclear. The objectives 
therefore were to estimate and compare costs under day-to-day conditions of car-
ing for men in Germany with newly diagnosed LCLRPC using hormonal therapy 
(HT), active surveillance (AS), radiotherapy (RT), operation (OP), or watchful waiting 
(WW) – HAROW. MethOds: The long-term observational multi-centre HAROW 
study combined data collection from urologists (clinical data; utilized outpatient 
medical services, OMS) and from patients (employment status, QoL by EQ-5D, 
numerous health resource use items). Resource use was valued by year 2010 offi-
cial prices in € . Direct costs (DC) were given by hospital treatment, OMS and drugs, 
inpatient rehabilitation, patients’ co-payments. Indirect costs (IC: sick leave, pre-
mature retirement, premature mortality) were estimated by 2010 gross domestic 
product/capita/day. Costs and quality-adjusted life-years (QALYs) were discounted 
by 3% per annum. Strategies without significant differences in QALYs/patient-year 
(PY) were compared by cost-minimization analysis (CMA) using mean costs/PY, 
remaining strategies by cost-utility analysis. Results: From 07/2008 to 03/2013, 
3063 LCLRPC patients (T1a–T2c, N0, M0; 67.3±7.5 years) were included from 257 
urologists: AS n= 452, RT n= 378, HT n= 210, HT+RT n= 80, combination therapy (CT) 
n= 137, OP n= 1647, other therapy (OT) n= 18, WW n= 141. Observation period: aver-
age 1.9 years, maximum 4.6 years. From the societal perspective (DC+IC), HT+RT 
had the lowest cost/PY (€ 1033), followed by AS (€ 1265), RT (€ 1313), WW (€ 1316), 
HT (€ 1522), CT (€ 3209), OT (€ 5705), and OP had highest cost/PY (€ 6656). From the 
perspective of DC, WW showed he lowest cost/PY (€ 894), followed by RT (€ 905), 
HT+RT (€ 987), AS (€ 1014), HT (€ 1169), OT (€ 2176), CT (€ 2204), and OP had highest 
cost/PY (€ 5374). cOnclusiOns: The HAROW study provides meaningful results 
on costs of different LCLRPC treatment strategies under day-to-day conditions of 
care in Germany to support decision making.
PCN130
HEALTH TECHNOLOGy ASSESSMENT OF CONTRAST-ENHANCED ULTRASOUND 
(CEUS) TECHNIQUES
Dozsa C.1, Nagy J.2, Borcsek B.3
1University of Miskolc, Miskolc, Hungary, 2Medience Ltd., Tokol, Hungary, 3Med-Econ Ltd., Veroce, 
Hungary
The second generation of contrast-enhanced ultrasound (CEUS) techniques com-
bines the advantages of ultrasound techniques and the additional information 
provided by the contrast agent. Objectives: To prove that sulphur hexafluoride 
microbubbles contrast agent used for CEUS is as effective in detecting and ana-
lyzing abnormal-looking areas in the liver as currently used imaging techniques 
(contrast-enhanced CT and MRI: CECT and CEMRI), however the costs of CEUS are 
considerably lower. MethOds: Cost-minimization analysis was based on litera-
ture review (last 5 years MEDLINE research, evidence level 1++) and on Hungarian 
financing data. National medical protocols were also considered. Results: Average 
cost per patient of CEUS was 64,5 EUR, while costs of currently used techniques 
were 129 EUR. According to the literature 70% of currently used CT and MRI tech-
niques could be replaced by CEUS. Results made it evident that the equally effective 
contrast-enhanced ultrasound technique is more cost-effective than the currently 
used contrast-enhanced CT and MRI techniques. Health technology assessment 
suggested that the change for the new technology would save 64 509 million EUR 
for the National Health Insurance Fund at the end of the third year of application, 
counting with 5000 cases. cOnclusiOns: The widespread use of cost-effective 
CEUS technology is highly recommended as it is an evidently cost-saving technique 
from the insurer’s point of view. Further assessment is recommended to measure 
clinical parameters, burden of radiology and other quality of life parameters of 
patients, possibly by using a control group if this is ethically viable.
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OMS and drugs, inpatient rehabilitation, patients’ co-payments. Indirect costs (IC: 
sick leave, premature retirement, premature mortality) were estimated by 2010 
gross domestic product/capita/day. Costs and quality-adjusted life-years (QALYs) 
were discounted by 3% per annum. Strategies with significantly different QALYs/
patient-year (PY) were compared by CUA, remaining strategies by cost-minimization 
analysis. Results: From July 2008 to March 2013, 3063 LCLRPC patients (T1a–T2c, 
N0, M0; 67.3±7.5 years) were included from 257 urologists: AS n= 452, RT n= 378, HT 
n= 210, HT+RT n= 80, combination therapy (CT) n= 137, OP n= 1647, other therapy 
(OT) n= 18, WW n= 141. Observation period: average 1.9 years, maximum 4.6 years. 
From the societal perspective (DC+IC), AS and RT each dominated HT, i.e. there 
were savings/PY (€ 257 and € 208) and QALYs gained/PY (0.0811 and 0.0587) with AS 
and RT, respectively, versus HT. When comparing OP to HT, there were additional 
cost (DC+IC) of € 5134/PY and 0.0784 QALYs gained/PY for OP versus HT leading to 
€ 65,525 per QALY gained. cOnclusiOns: The HAROW study provides meaningful 
results on cost utility of AS, OP, RT, and HT as LCLRPC treatment strategies under 
day-to-day conditions of care in Germany to support decision making.
PCN137
A COST-UTILITy ANALySIS OF EvEROLIMUS PLUS ExEMESTANE FOR THE 
TREATMENT OF ER+ HER2- METASTATIC BREAST CANCER IN THE UNITED 
KINGDOM
Taylor M.1, Lewis L.2, Vieira J.3, Chandiwana D.3
1York Health Economics Consortium, York, UK, 2York Health Economics Consortium, University of 
York, York, UK, 3Novartis Pharmaceuticals UK Limited, GB- Frimley/Camberley, UK
Objectives: This study evaluated the cost-effectiveness of everolimus + exemes-
tane (EVE+EXE) versus placebo + exemestane (PBO+EXE) in patients with ER+ HER2- 
metastatic breast cancer in the UK. Whilst the effectiveness of treatment has been 
demonstrated previously, this is the first analysis to assess the cost of the intervention 
alongside those benefits. MethOds: A Markov model was developed to compare 
treatment with EVE+EXE versus PBO+EXE in patients with ER+ HER2- metastatic 
breast cancer over a lifetime time horizon (UK health care perspective). Follow-up data 
on progression-free survival and overall survival were taken from the BOLERO II trial. 
Weibull functions were used to extrapolate trial data beyond the follow-up period. 
Utilities from published sources were combined with trial data to calculate quality-
adjusted life years (QALYs) associated with each treatment. Drug costs (list prices) and 
background health state costs (i.e. non-intervention costs) were applied to calculate 
incremental costs offset. Results: Over a ten year time horizon, EVE+EXE led to a 
life expectancy of 3.27 years, compared to 2.41 for PBO+EXE. EVE+EXE resulted in 1.91 
QALYs, compared to 1.31 for PBO+EXE. Therefore, the incremental gains in life years 
and QALYs were 0.85 and 0.60 respectively. Drug costs were £22,074 and £628 for the 
two arms respectively, whilst non-drug costs were £22,332 and £21,108 respectively. 
Therefore, the EVE+EXE arm had an incremental cost of £22,670. The incremental cost 
per QALY was, therefore, £37,719 over a ten-year time horizon. Probabilistic sensitivity 
analysis demonstrated that, at a threshold of £30,000 per QALY gained, EVE+EXE had 
a 27.3% likelihood of being cost-effective. At a threshold of £55,000 per QALY gained, 
the likelihood of cost-effectiveness was 77.4%. cOnclusiOns: EVE+EXE was associ-
ated with increased health care costs, but was also estimated to lead to health gains 
in terms of both LYs and QALYs.
PCN138
COST-EFFECTIvENESS OF GEMCITABINE PLUS CISPLATIN vERSUS GEMCITABINE 
ALONE FOR TREATMENT OF ADvANCED BILIARy TRACT CANCER IN jAPAN
Arakawa I.1, Uemura S.1, Murasawa H.1, Inoue T.2
1Teikyo Heisei University, Tokyo, Japan, 2Tokyo Women’s Medical University, Tokyo, Japan
Objectives: Gemcitabine plus cisplatin is a common use for chemotherapy 
patients with advanced biliary tract cancer in Japan. This study aims to assess the 
cost-effectiveness of this combination therapy compared to monotherapy for bil-
iary tract cancer in Japan. MethOds: A Markov model of three states and monthly 
transmissions was constructed based on a phase II trial. Transition probabilities 
between states were derived from the trial conducted by Valle, J. et al (2010). and 
converted to appropriate parameters for input into the model. The associated cost 
components, obtained from literature published in Japan, were inpatient, outpa-
tient, and medication for biliary tract cancer as well as those for palliative care. 
We estimated cost-effectiveness per quality-adjusted life year (QALY) at a time 
horizon of thirty two months. An annual discount for cost and outcome was not 
considered. Results: The model demonstrate no statistical significance in the 
hazard ratio of 0.625, as compared to an actual ratio of 0.63 (95% confidence inter-
val: 0.51–0.77) retrieved from the clinical trial. The base case outcomes indicated 
that combination therapy would be more cost-effective than monotherapy when 
the incremental cost-effectiveness ratio (ICER) was approximately 720,000 YEN 
per QALY gained, retrospectively. A tornado diagram depicting the deterministic 
sensitivity analysis of the ICER revealed that the death rate resulting from the 
combination therapy influenced the base case, but robustness of the base case 
was identified. A probabilistic analysis resulting from 5,000 Monte Carlo simula-
tions demonstrated efficacy at willingness to pay (WTP) thresholds of 5,000,000 
YEN per QALY gained in approximately 95% of the population. cOnclusiOns: 
In Japan, combination therapy is a cost-effective treatment option for advanced 
biliary tract cancer.
PCN139
HEAD TO HEAD ECONOMIC EvALUATION OF TwO GENOMIC PROFILES OF 
RECURRENCE RISK FOR BREAST CANCER, MAMMAPRINT vERSUS ONCOTyPE 
Dx, IN SPAIN
Crespo C.1, Seguí M.Á2, Cortés J.3, Lluch A.4, Brosa M.5, Becerra V.6, Chiavenna S.M.6, Gracia A.6
1University of Barcelona, Barcelona, Spain, 2Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, 
Spain, 3Hospital Universitario Vall d’Hebron, Barcelona, Spain, 4Hospital Clinico Universitario, 
Valencia, Spain, 5Oblikue Consulting, Barcelona, Spain, 6Ferrer Internacional, Barcelona, Spain
Objectives: Cost effectiveness analysis of MammaPrint in the diagnosis of early 
breast cancer from the Spanish NHS perspective. MethOds: Markov model 
nomic evaluation. Sensitivity analyses were conducted to explore the uncertainties 
surrounding the assumptions. Results: Abiraterone plus prednisolone indicated 
higher QALYs than prednisolone alone, though it was more expensive. In the base-
case analysis, ICER for abiraterone plus prednisolone exceeded JPY 10 million (EUR 
80,000) per QALY gained. The one-way sensitivity analysis for discount rate (0 to 
4%) showed no affects on the results. cOnclusiOns: The present study concludes 
that the ICER may be more than JPY 10 million. Further deliberate discussion on 
cost-effectiveness of abiraterone in Japan is needed to consider the Japanese price 
and clinical outcomes.
PCN134
ECONOMIC EvALUATION OF HPv vACCINATION PROGRAM IN SOUTH KOREA
Kim J., Kim Y., Ahn J., Kim Y., Park J.
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
Objectives: To assess the cost-effectiveness of a national HPV vaccination pro-
gram that vaccinates 12 year-old girls with cervical cancer screening and the only 
current cervical cancer screening. MethOds: We analyzed the effect of HPV infec-
tion reduction by HPV vaccination on reduction of CIN and cervical cancer and 
finally conducted cost-utility analysis applying QALYs to which takes into account 
life span expansion and the quality of life. With the societal perspective, patient 
time costs, caregiver costs, and transportation costs were all considered as well as 
medical costs. Markov model was used with one year cycle and life time analysis 
period. Markov states in this model were classified well, HPV infection, CIN 1, CIN 
2/3, cervical cancer (initial cancer), follow-up cervical cancer, recurrent/persistent 
cancer, follow-up recurrent/persistent cancer and death. The HPV infection was 
limited to infections caused by HPV specific types 16 and 18. Results: When HPV 
vaccination program is introduced to 12-year old cohort, it was indicated that 
cervical cancer patients with HPV vaccination program would be 2,042 patients 
and cervical cancer patients with present screening program 3,709. It results that 
cervical cancer patients would be decreased to 1,667 by HPV vaccination. From 
this, it was estimated that all the cohorts would get an additional life expectancy 
of 1,648 LYG and quality adjusted life years of 1,849 QALYs. According to cost-utility 
analysis result, additional 1849 QALYs cost KRW 59.8 billion when HPV vaccination 
program implement, and the incremental cost-utility ratio was estimated to be 
KRW 32 million per a QALY. Considering the threshold of Korean cost-effective-
ness, the vaccination program is decided not to be cost-effective. cOnclusiOns: 
Though the HPV vaccination program for 12-year old girls was not cost-effective at 
the current condition of Korea, it is advisable to consider that cost-effectiveness 
varies sensitively.
PCN135
COST UTILITy ANALySIS OF EvEROLIMUS IN THE TREATMENT OF METASTATIC 
RENAL CELL CANCER IN THE NETHERLANDS
Mihajlović J., Minović I., Bruinsma A., Postma M.J.
University of Groningen, Groningen, The Netherlands
Objectives: Metastatic renal cell cancer (mRCC) is becoming an important part of 
Dutch health care expenditure due to expensive pharmaceutical options for disease 
control and lack of adequate prevention methods. New targeted therapeutics, such 
as sunitinib, sorafenib and everolimus, have recently emerged with relevant benefits 
on progression-free survival (PFS) for mRCC patients. This study aims to assess 
the cost-effectiveness of the most recent of these introductions, i.e. everolimus, 
in comparison to best supportive care in second line treatment of mRCC patients 
in The Netherlands. MethOds: A Markov model was designed in line with Dutch 
treatment protocols. Transitions between health states were modeled by time-
dependent probabilities extracted from published Kaplan-Meier curves for PFS and 
overall survival (OS). The cohorts were followed over 18 cycles, each cycle lasting 8 
weeks. Annual discount rates of 1.5% for health and 4% for costs were applied and 
a health-care perspective was taken. One-way and probabilistic sensitivity analyses 
(PSA) were performed to test the robustness and uncertainty around the base-case 
estimate. Results: The incremental cost-effectiveness ratio (ICER) for everolimus 
was esimated at € 92,258/QALY. Sensitivity analysis identified the hazard multi-
plier, an estimate of OS gain, as the main driver of everolimus’ cost-effectiveness. 
Through PSA a wide 95% confidence interval around the base-case ICER estimate 
was revealed (€ 49,677 - € 453,941/QALY). Additionally, at the threshold of three times 
GDP per capita (€ 95,700 in The Netherlands) everolimus had a 54% probability of 
being cost-effective. cOnclusiOns: The base-case ICER was just below the upper 
cost-effectiveness limit recommended by WHO, indicating that everolimus might 
be a cost-effective option in the Dutch setting. However, reasonable uncertainty of 
the main finding resulted from everolimus’ unpredictable gain in OS. Efforts should 
be undertaken to perform an integral assessment of the economic attractiveness 
of all current and new therapeutics in mRCC.
PCN136
COST-UTILITy ANALySIS (CUA) OF DIFFERENT STRATEGIES TO TREAT NEwLy 
DIAGNOSED LOCALLy CONFINED LOw-RISK PROSTATE CANCER (LCLRPC) IN 
GERMANy: RESULTS OF THE HAROw STUDy
Schädlich P.K.1, Baranek T.2, Häussler B.1, Weißbach L.3
1IGES Institut GmbH, Berlin, Germany, 2CSG - Clinische Studien Gesellschaft mbH, Berlin, 
Germany, 3Stiftung Männergesundheit - Foundation for Men’s Health, Berlin, Germany
Objectives: The optimal treatment choice for preserving quality of life (QoL) of 
the about 64,000 men diagnosed with prostate cancer each year in Germany still 
remains unclear. The objectives therefore were to estimate cost utility under day-
to-day conditions of caring for men in Germany with newly diagnosed LCLRPC 
using hormonal therapy (HT), active surveillance (AS), radiotherapy (RT), operation 
(OP), or watchful waiting (WW) – HAROW. MethOds: The long-term observational 
multi-centre HAROW study combined data collection from urologists (clinical data; 
utilized outpatient medical services, OMS) and from patients (employment status, 
QoL by EQ-5D, numerous health resource use items). Resource use was valued by 
year 2010 official prices in € . Direct costs (DC) were given by hospital treatment, 
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PCN142
AN OvERvIEw OF DOMESTIC CANCER DRUGS IN TURKEy: 2008-2012
Vural E.H., Safak Yilmaz E., Vural I.M., Dogan E, Akbulat A., Gursoz H., Kerman S.
Turkish Medicines and Medical Devices Agency, Ankara, Turkey
Objectives: Cancer is among the most common causes of death in Turkey. Cancer 
diagnosis and treatment management were substantially improved by the Ministry 
of Health. Generic market and price movements of different kinds of drug groups 
show different characteristics. In this study we aimed to demonstrate the impact 
of domestic manufacture of cancer drugs on import cancer drug sales in Turkey in 
terms of both boxes and cost sale trend analysis between 2008 and 2012. MethOds: 
This study was designed as an observational, retrospective study. Domestic oncol-
ogy drugs were chosen from the base oncology drug groups. The sales data of the 
domestic oncology drugs and both original and generic import drugs which have the 
same active ingredient with the domestic drugs was obtained from the Information 
Medical Statistics (IMS) database from September 2007 to July 2012. Sales data is 
evaluated with segmented regression analysis for interrupted time series. Results: 
Oncology drug sales report showed that the market share of domestic products 
increased approximately 38% at 2012 from 0,5% at 2008. Before the cut point, there 
was a statistically significant increase in the sales level of import oncology drugs, 
but after the cut point sales trend showed a statistically significant decrease. Import 
oncology drugs’ unit price per box decreased from 196.5TL between September 2007 
and October 2008 to 172.6TL between November 2008 and July 2012. But domestic 
oncology drugs’ unit price per box was 91.8TL between November 2008 and July 
2012. cOnclusiOns: In conclusion, domestic drug manufacturing has important 
contributions to a country’s economy including low drug prices, supplying for the 
domestic consumption, creation of employment opportunities and also as export 
potentials. Price cut in 2009 and 2011 in Turkey and “Reference Pricing System” 
should be taken into consideration for this price change evaluation in the case of 
domestic product manufacturing.
PCN143
SHORT-TERM DISABILITy (STD) ASSOCIATED wITH SKELETAL RELATED 
EvENTS (SRES) IN COMMERCIALLy INSURED PATIENTS wITH BONE 
METASTASES (BM) SECONDARy TO SOLID TUMORS
Qian Y.1, Song X.2, Zhang K.2, Balakumaran A.1, Arellano J1
1Amgen Inc., Thousand Oaks, CA, USA, 2Truven Health, Cambridge, MA, USA
Objectives: Patients with BM frequently experience SREs including pathological 
fracture, surgery or radiation to bone, or spinal cord compression .The study objec-
tive was to estimate STD (work hour loss) and associated costs in patients with SREs 
in a population with BM secondary to solid tumors. MethOds: Patients with diag-
nosis of solid tumors and BM were extracted from MarketScan® Health Productivity 
and Management Database and Commercial Database in 2002-2010. Eligible patients 
were 18-64 year-old full-time employees, had STD benefit eligibility, and had ≥ 6 
months continuous pre-index enrollment (pre-period) and ≥ 1 month follow-up. For 
SRE patients, index date was the first SRE claim. For patients without SREs, index 
date was assigned per the distribution of index dates from SRE patients. Monthly 
STD hours and costs associated with STD were estimated during the first (up to) 6 
months and the first (up to) 12 months. Generalized linear models estimated the 
marginal impact of having SRE on STD hours and associated costs, controlling for 
baseline STD hours and patients’ characteristics. Results: A total of 854 patients 
with SREs and 701 patients without SREs were included, with a mean age of 52.1 
and 51.6 years, respectively. 52.2% of SRE patients reported STD during the 6-month 
follow-up, compared with 19.1% of patients without SREs. For SRE patients, the 
mean STD hours were 21.2 per month in pre-period and 61.3 during follow-up. The 
hours for patients without SREs were 8.6 and 14.4, respectively. Multivariate analysis 
indicated that SREs were associated with significantly increased STD hours (39.4 
per month) and associated costs ($613 per month) during the 6-month follow-up 
period. Results from the 12-month follow-up period were similar. cOnclusiOns: 
SREs were associated with significantly increased STD hours and associated costs. 
Therapies that prevent or delay the development of SREs may reduce work loss and 
costs associated with it.
PCN144
ECONOMIC ACTIvITy OF CANCER SURvIvORS IN POLAND
Macioch T., Hermanowski T.R.
Medical University of Warsaw, Warsaw, Poland
Objectives: Although cancer is one of the leading causes of mortality worldwide, 
the number of cancer survivors is constantly growing due to improved treatment. 
Growing number of cancer survivors goes in line with trends to increase retirement 
age and this together leads to increase number of cancer survivors at economi-
cally active age. The aim of this study was to analyze economic activity of cancer 
survivors in Poland. MethOds: Data on disability (the number of medical certifi-
cates awarded because of incapacity for work) due to cancer and other diseases 
were retrieved from the Social Insurance Institution annual report for the year 
2009. Data included the number of medical certificates issued for the first time 
and the number of certificates reissued, their periods of validity, age of population 
and disability severity (complete or partial inability to work, inability of independ-
ent existence). Results: Cancer was the second (after cardiovascular diseases) 
cause of medical certificates issued for the first time because of incapacity to work 
and account for 22% of all certificates awarded for the first time. However, the 
number of certificates reissued was significantly lower – cancer accounted for 7% 
of all certificates reissued (cardiovascular diseases still accounted for the largest 
number of certificates reissued – 25%). The mean age of population with cancer 
was above the mean age of overall population with medical certificates awarded 
because of incapacity to work, however lower than those for cardiovascular or 
pulmonary diseases. Significant differences in disability severity structure exist. 
Significant higher percentage of cancer patients were judged as either incapable of 
independent existence (19.9%-24.9% compare to 4.4%-6.5% in overall population) or 
complete incapable to work (45.9%-71.1% compare to 23.4%-32.9% in overall popula-
assuming a 60-year-old women cohort with negative-lymph node, positive estro-
gen receptors and negative HER2 breast cancer. Costs and effects of the treatment 
by identifying recurrence risk using A!O, MammaPrint or OncotypeDX were com-
pared at 5 years, 10 years and lifetime horizons. Probability of low or high risk of 
recurrence by A!O was fixed 50/50 (ratios between 40/60 and 60/40 for sensitivity 
analysis). Risks predicted by OncotypeDX and MammaPrint were assumed to be the 
same. Cost of chemotherapy (2.825€ ), recurrence (6,357€ ) and other direct health 
care costs were derived from local data. Three health states (free of recurrence, 
recurrence, death) were defined in a given period of time. Results: A total of 31% 
patients required adjuvant chemotherapy with MammaPrint classification (36.6% 
with OncotypeDX, 56.3% with A!O). MammaPrint showed a life expectancy of 23.55 
years at lifetime Differences in chemotherapy costs, worse prognosis rates and a 
higher cost of the genomic profile (3,200€ vs. 2,675€ ) explained higher cumulative 
costs for OncotypeDX over both alternatives at any time. MammaPrint instead of 
OncotypeDX showed savings of at least 1,273€ after 5 years. MammaPrint resulted 
dominant (less costly and more effective) against OncotypeDx at any time hori-
zon and would be cost-effective from the 6th year versus A!O (43,912€ , 6,169€ and 
287€ per QALY gained at 5, 10 years and lifetime; 30,000€ /QALY gained thresh-
old assumed). Sensitivity analysis confirmed base case results with MammaPrint 
remaining cost-effective until a willingness-to-pay threshold below 275€ /QALY 
gained. Utility of recurrence, age at baseline and probability of A!O low risk were 
the key drivers at 10 years. cOnclusiOns: MammaPrint in predicting risk of recur-
rence in these patients and avoiding chemotherapy overtreatment is a dominant 
strategy over OncotypeDX and it is highly cost-effective against A!O.
PCN140
EARLy-STAGE ECONOMIC EvALUATION OF STRATIFIED MEDICINE IN MULTIPLE 
MyELOMA
Gaultney J.G.1, Redekop W.K.1, Sonneveld P.2, van der Holt B.3, Uyl-de G.root C1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus University Medical 
Center, Rotterdam, The Netherlands, 3Erasmus University Medical Center, Clinical Trial Center, 
Rotterdam, The Netherlands
Objectives: The clinical utility of biomarkers is often uncertain and difficult to 
demonstrate in an experimental setting. Modeling techniques can be used at the 
preclinical phase to evaluate their potential therapeutic and economic value. In 
multiple myeloma (MM), subgroup analyses of pivotal trials show that only patients 
presenting with adverse prognostic biomarkers demonstrate significantly improved 
survival with bortezomib-based versus some alternative therapies. A cost-utility 
analysis was conducted to evaluate the potential value of a risk-stratified treat-
ment (RST) approach versus uniform treatment (UT) in Dutch daily practice 
MM. MethOds: A Markov-type decision analytic model compared total health 
benefits and costs for two strategies: 1) UT where all patients received the standard 
of care consisting of bortezomib induction/maintenance and 2) RST where treat-
ment was stratified according to clinical and tumor biomarkers only, molecular 
biomarkers only, or any biomarker. In RST, high-risk patients received bortezomib 
while other patients received chemotherapy and thalidomide. Input data origi-
nated from clinical trials, literature reviews, observational studies and national 
tariffs. Various sensitivity and scenario analyses were performed. Results: RST 
dominated UT, with average health gains of 0.007-0.059 LYs (0.009-0.040 QALYs) and 
cost-savings of € 1,842-€ 4,924 depending on detection method. A scenario analysis 
for RST where all high-risk patients received an experimental treatment increased 
health by 0.40 LYs (0.30 QALYs) and costs by € 2,567 compared to UT. Influential 
parameters included the price of bortezomib and survival and quality-of-life-related 
parameters. cOnclusiOns: An economic evaluation of biomarkers in the pre-
clinical development phase provided evidence that RST in MM may improve health 
outcomes and lower costs. Modeling techniques made it feasible to assess the cir-
cumstances under which RST would be promising and hence guide the prioritization 
of designing experimental studies to evaluate clinical utility. These findings should 
encourage payers and users to support the clinical development and adoption of 
RST approaches in MM.
PCN141
COST-UTILITy OF ACTIvE SURvEILLANCE FOR THE TREATMENT OF LOCALIzED 
PROSTATE CANCER IN THE CONTExT OF THE GERMAN HEALTH CARE SySTEM
Koerber F.1, Waidelich R.2, Stollenwerk B.1, Rogowski W.1
1Helmholtz Center Munich, Neuherberg, Germany, 2University of Munich, Munich, Germany
Objectives: There is an on-going debate about whether to perform surgery on 
early, localized prostate cancer and put up with common long term side effects 
of prostatectomy like incontinence and erectile dysfunction. Alternatively such 
patients could be closely monitored and counselled (active surveillance). This study 
investigates the cost-utility of active surveillance compared to radical prostatec-
tomy. MethOds: A Markov model comparing prostatectomy and active surveil-
lance over a lifetime horizon was programmed in TreeAge. Comparative disease 
specific mortality was based on the Scandinavian Prostate Cancer Group trial and 
a review and meta-analysis of comparative effectiveness studies. Resource use 
was identified via national treatment guidelines and expert interviews covering 
in-patient, out-patient, medication, aids & remedies as well as out of pocket pay-
ments. Utility values were literature-based and used as factor weights to age specific 
German HRQoL values. Uncertainty is assessed deterministically and probabilisti-
cally. Results: Our results suggest that active surveillance is a cost saving treat-
ment strategy generating more QALYs at reduced overall costs. The probability of 
developing metastases under AS and the probability of recurrence as well as utility 
weights of patients under AS and after prostatectomy were major drivers of cost-
effectiveness. Monte Carlo simulation suggests that PE is likely to become at willing-
ness to pay thresholds > €400,000. cOnclusiOns: Active surveillance is likely to 
be a cost effective treatment option from the perspective of the German Statuary 
Health Insurance. An improved way of identifying cancers with a high probability 
of progression could favour active surveillance more clearly. It is not clear yet how 
the use of individual utilities for side effects would alter the results.
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This study presents a limitation regarding the subjectivity inherent to costs determi-
nation based on answers given by the HP. Moreover values may be underestimated 
due to lack of information regarding fixed costs.
PCN148
RESOURCE USE OF NON-SMALL CELL LUNG CANCER IN SLOvAKIA
Ondrusova M.1, Psenkova M.1, Berzinec P.2, Basso F.3
1Pharm-In Ltd., Bratislava, Slovak Republic, 2Specialized Hospital of St Zoerardus Zobor, Nitra, 
Slovak Republic, 3Boehringer Ingelheim GmbH, Vienna, Austria
Objectives: Data on economic burden of advanced or metastatic non-small cell lung 
cancer (NSCLC) are lacking in Slovakia. Therefore, the objective of this cost of illness 
study was to measure the resource utilisation and the costs associated with treating 
advanced or metastatic NSCLC in Slovakia and provide a basis for cost-effectiveness 
evaluations. MethOds: The project was run in two phases: in the first phase an 
Expert panel took part in the survey and developed the diagnostic and treatment 
algorithms to reflect the local medical practice and quantify the use of resources 
associated with anticancer drug treatment, management of adverse events and best 
supportive care. Then, in the second step, 2012 management costs were applied to the 
resources. All types of health care used in the NSCLC management were evaluated 
(outpatient and inpatient visits, diagnostics, prescription drugs and examinations). 
The analysis was performed from the Slovakian health insurance perspective reflect-
ing direct medical costs only. The structure of cost data follows the requirements 
of pharmaco-economic modelling in NSCLC. Results: Monthly costs of advanced 
or metastatic NSCLC management during the active treatment (before progression) 
count for € 1055.67, during the disease progression € 1101.21 and on the best supporting 
care € 1561.22. The most frequent regimens were cisplatin+gemcitabine (20.6%) and 
cisplatine+pemetrexed (19.1%) in the first line, erlotinib (49.1%) in the second line and 
gemcitabine (29.6%) in the third line. The most costly side effects were renal toxic-
ity (€ 1060.85), febrile neutropenia (€ 902.92), hemoptysis (€ 717.08), anaemia (€ 668.84), 
pain (€ 631.34), leukopenia/neutropenia (€ 629.58), dyspnoe (€ 628.35), thrombocytope-
nia (€ 578.60), nausea/vomiting (€ 562.72) and fatigue (€ 523.19). cOnclusiOns: Cost-
effectiveness must be demonstrated in order to get reimbursement in Slovakia and 
local resource use data are key drivers for health economic modelling and can guide 
resource allocation decisions in NSCLC. This study provides important information 
to support these decisions.
CANCER – Patient-Reported Outcomes & Patient Preference Studies
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ADHERENCE RATES FOR INTRAvENOUS CHEMOTHERAPy REGIMENS TO TREAT 
COLON CANCER
Seal B.1, Asche C.V.2, Shermock K.M.3, Anderson S.1, Cameron J.1
1Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 2University of Illinois College of 
Medicine, Peoria, IL, USA, 3The Johns Hopkins Medical Institutions, Baltimore, MD, USA
Objectives: It is widely thought that adherence rates to intravenous (IV) chemo-
therapy regimens for colon cancer are high. However, there are no known formal 
assessments of this issue. MethOds: A retrospective analysis was performed using 
the Optuminsight Oncology claims database. Patients aged 18 years and older, diag-
nosed with CRC between July 1, 2004 and December 31, 2010, who were insured by a 
commercial health plan were included in the study. Adherence to the following IV 
chemotherapy regimens was assessed using the National Comprehensive Cancer 
Network (NCCN) guidelines as the standard for expected cycle/regimen duration: 
FOLFOX, FOLFOX+bevacizumab, FOLFIRI, and FOLFIRI+bevacizumab. Adherence 
was assessed using the medication possession ratio (MPR), calculated as the num-
ber of days a patient was covered by their chemotherapy regimen, according to 
NCCN guidelines, divided by the number of days elapsed from the first to the last 
infusion of that regimen. Results: A total of 46,941 chemotherapy cycles in 6,880 
patients were analyzed. Overall, adherence rates to IV chemotherapy was fairly 
high, with mean MPR ranging between 0.84 and 0.88 for these regimens. However, 
a substantial proportion of patients for each regimen experienced low adherence. 
Twenty five percent of patients receiving FOLFOX, FOLFOX+bevacizumab, and 
FOLFIRI+bevacizumab regimens experienced MPR< 0.8. Additionally, approximately 
35% of patients receiving FOLFIRI experienced an MPR< 0.8. At least 10% of patients 
receiving FOLFOX regimens had an MPR less than 0.7; while at least 10% of patients 
receiving FOLFIRI regimens had an MPR of less than 0.6. cOnclusiOns: Although 
overall rates of adherence were fairly high, a substantial subpopulation experienced 
low adherence to each of these IV regimens per NCCN guideline recommendations. 
The reasons for the low adherence rates need to be explored as this could have an 
impact on efficacy. These results also highlight the drawback of relying solely on 
summary statistics at the population level.
PCN150
PERSISTENCE IN PATIENTS wITH BREAST CANCER TREATED wITH TAMOxIFEN 
OR AROMATASE INHIBITORS- ANALySIS BASED ON ONCOLOGy ANALyzER 
DATABASE
Schmidt N.1, Haas G.1, Mergenthaler U.1, Kostev K.1, Hadji P.2
1IMS Health, Frankfurt am Main, Germany, 2Department of Gynecology, Endocrinology and 
Oncology, Phillips-University of Marburg, Germany, Marburg, Germany
Objectives: Lack of non-compliance is often underestimated in breast cancer 
treatment. The aim of our study was to analyze the persistence with tamoxifen 
(TAM) and aromatase inhibitors (AI) in women with breast cancer (BC) and to 
identify reasons of treatment discontinuation and determinants of non-per-
sistency. MethOds: We used data of the Oncology Analyzer database, which 
includes individual information on patient history related to the treatment of 
patients across all cancer types. This enables a complete overview of cancer 
patient care from diagnosis onward, facilitating research in areas such as treat-
ment changesn, dosing and regimen compliance, market sizing and off-label use. 
We identified 7063 breast cancer patients with a start of TAM or AI therapy from 
1990 until 2011 and with a treatment duration of at least 365 days. Results: After 
tion). cOnclusiOns: Disability in cancer survivors is very common and is more 
severe than in other diseases.
PCN145
IMPACT OF NURSING AND PHARMACy CARE BETwEEN CAPECITABINE AND 
5-FLUORURACIL REGIMENS IN THE MANAGEMENT OF ADvANCED ESOPHAGO-
GASTRIC CANCER IN HONG KONG
Lee V.W.Y.1, Yao R.2, Yip E.2, Law K.3, Tang G.3, Zhou K.R.1
1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2Princess Margaret Hospital, 
Kowloon, Hong Kong, 3Queen Elizabeth Hospital, Kowloon, Hong Kong
Objectives: To compare the possible time savings from reduction of nursing and 
pharmacy time to manage advanced esophago-gastric cancer (AEGC) patients using 
capecitabine-based regimens versus traditional 5-FU based intravenous (IV) chemo-
therapy in the Hong Kong public hospital setting. MethOds: This was a time-and-
motion study conducted in 2 public hospitals of Hong Kong based on the simulation 
of previously data on both capecitabine-based regimen (XELOX and XP) and IV 
5-FU-based regimen (FOLFOX and FP). The preparation, dispensing and administration 
time for XELOX, XP, FOLFOX and FP were compared. The capital item utilization includ-
ing hospital bed, infusion pump etc and length of patient attendance were recorded. 
Each subject was based on 24-week cycle in the analysis. The projected cost saving 
in nursing and pharmacy time was estimated if all AEGC in Hong Kong were pre-
scribed capecitabine-based regimen. Results: The average nursing time for FOLFOX 
and FP was 83.7 and 83.4 minutes versus XELOX and XP was 33.7 and 39.8 minutes 
respectively. The average pharmacy dispensing time for FOLFOX and FP was 25.3 and 
71.4 minutes versus XELOX and XP was 18.7 and 19.9 minutes respectively. The total 
time saved for each patient for a 24-week cycle in FOLFOX versus XELOX was 734.8 
minutes in nursing and 154.0 minutes in pharmacy as well as in FP versus XP was 
182 minutes in nursing and 269.2 minutes in pharmacy. Nursing and pharmacy could 
potentially spare 3.3 full time equivalent (FTE) and 1.5 FTE if all AEGC patients were 
converted to capecitabine-based chemotherapy. cOnclusiOns: Capecitabine-based 
chemotherapy regimens saved in both nursing and pharmacy time as compared to 
traditional 5-FU based IV chemotherapy in the Hong Kong public hospital setting.
PCN146
wORKFORCE PARTICIPATION AND PRODUCTIvITy LOSSES AFTER HEAD AND 
NECK CANCER
Pearce A.M.1, Timmons A.1, Hanly P.2, O’Neill C.3, Sharp L.1
1National Cancer Registry Ireland, Cork, Ireland, 2National College of Ireland, Dublin, Ireland, 
3NUI Galway, Galway, Ireland
Objectives: There has been no estimate of the productivity losses associated with 
head and neck cancer (HNC) conducted using bottom-up data, or beyond prema-
ture mortality. The aim of this work is to investigate workforce participation, and 
estimate the productivity losses associated with temporary and permanent work 
absence, reduced work hours, and premature mortality in individuals with HNC in 
Ireland. MethOds: Survey data were collected from a cancer registry identified cohort 
of individuals in Ireland diagnosed with head and neck cancer between January 1994 
and December 2011. Data collected included employment status at time of diagnosis 
and workforce participation patterns following diagnosis. These data were combined 
with population-level survival estimates and national wage data to estimate the value 
of temporary and permanent work absence, reduced work hours and premature mor-
tality using a Human Capital Approach. Results: Of the survey respondents, 276 were 
in paid work at the time of diagnosis. 88% had time off following diagnosis, with 63% of 
these returning to work. The mean (median) time off work was 9 months (6 months), 
range of 0 to 65 months. Seventy percent of individuals returning to work reported 
reducing the hours they worked, by an average of 20 hours per week. Preliminary 
results show the average productivity losses per person associated with temporary 
and permanent work absence and reduced work hours are € 222,000. Productivity losses 
associated with premature mortality and the results of sensitivity analyses to test 
discount and wage growth rates will also be presented. cOnclusiOns: Head and 
neck cancer and its treatment can have a profound impact on workforce participation. 
This affects not only the individuals’ and their families, but also society in terms of 
productivity costs. These costs should be considered in economic evaluations of cancer 
treatments and health service delivery in this population.
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HOSPITAL RESOURCES CONSUMPTION ASSOCIATED wITH TRASTUzUMAB 
TREATMENT IN BREAST CANCER IN PORTUGAL
Andrade S.1, Santos A.2
1Roche Farmacêutica Quimica, Amadora, Portugal, 2Prime Focus Health, Paço de Arcos, Portugal
Objectives: Determine the costs associated with the preparation and adminis-
tration, considering the material resources (MR) consumption and time spent by 
the health care professionals (HP), of Her2 positive breast cancer treatment with 
trastuzumab intravenous (iv) and to estimate the difference compared with a subcu-
taneous (sc) formulation. MethOds: Data were collected in face to face interviews 
with the pharmacist and nurse responsible for the preparation and administration 
of trastuzumab in each hospital. The cost of the HP time was calculated by multi-
plying the value of each HP hour by the average time of each procedure; MR costs 
were determined based on the values presented in official sources or in price table 
provided by the manufacturer. Results: Five public and two private Hospitals from 
mainland Portugal, with an average of 12 patients with HER2 + breast cancer treated 
with trastuzumab iv, per week, participated in the study. The average time spent by 
the HP in trastuzumab preparation and administration was 79 minutes for iv and 18 
minutes for sc. Per treatment cycle, the estimated average overall cost of each treat-
ment was € 43.22 (HP - € 26.01; MR - € 17.21) for iv, and € 3.18 (HP - € 3.13; MR - € 0.05) for 
sc. Considering the total course of treatment (18 cycles), the treatment with tras-
tuzumab iv is estimated at € 777.96 versus € 57.19 on sc treatment. cOnclusiOns: 
Trastuzumab sc formulation would potentially allow savings of approximately € 720 
per patient, and provide an important benefit to the patients. Trastuzumab sc would 
also contribute to maximize the efficiency and effectiveness of health resources. 
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cycles of treatment in the same health state. MethOds: The GRID study included a 
double-blinded phase, plus an open-label regorafenib phase for those whose disease 
progressed. The EQ-5D index was evaluated using paired-samples comparison as 
the primary analysis, and repeated measures as a sensitivity analyses. Results: 
A total of 185 subjects were included; 63% males, with an overall average age of 58 
years; 55% received study treatment as 3rd-line, the rest as 4th-line or later. 67% 
were randomized to receive regorafenib as initial double-blind therapy. Average 
utility at baseline was 0.767 units. There were no differences in baseline charac-
teristics or EQ-5D for either treatment arm, or those whose disease progressed. 
The paired-samples analysis compared progression-free EQ-5D index versus any 
first, post-progression assessment. Of those with available data (N= 77) there was a 
difference of -0.120 units (p= 0.001). In the repeated analysis, the Δ -EQ-5D between 
progression-free disease and disease progression (in double-blind phase) was -0.041 
units (p= 0.051). The mean EQ-5D index following discontinuation of open-label 
treatment due to secondary progression was much lower, with a difference of -0.231 
units (p< 0.001). Whilst adjusting for disease status and treatment, the cycle number 
did not significantly influence the EQ-5D index (p= 0.341). cOnclusiOns: Heath-
related utility remained stable over successive treatment cycles after controlling 
for disease status and treatment type, suggesting that for subjects treated with 
regorafenib who remained progression-free, that active treatment did not lead to 
deterioration in utility. Due to the cross-over design, the repeated measures analysis 
did not contain a homogenous, group of people whose disease had progressed. Thus, 
the paired-sample analysis provides a better estimate of utility.
PCN154
ASSOCIATIONS BETwEEN OvERALL CARE ExPERIENCE RATINGS AND UTILITy 
AND PSyCHOLOGICAL wELL-BEING IN MEN RECENTLy DIAGNOSED wITH 
PROSTATE CANCER: FINDINGS FROM A POPULATION-BASED STUDy
Hennessy M., O’Leary E., Comber H., Drummond F.J., Sharp L.
National Cancer Registry Ireland, Cork, Ireland
Objectives: Patient experience is increasingly recognised as an important measure 
of quality of care. A few studies have suggested that patients who report higher 
levels of satisfaction with care also have higher quality-of-life and higher psycho-
logical wellbeing, and are more likely to cooperate with treatment. In Ireland, this 
area is under-researched. The PiCTure 2 study aimed to assess the care experiences 
of men recently diagnosed with prostate cancer – the most common cancer among 
men in Ireland - and investigate associations between experiences and health-
related quality-of-life (utility) and psychological wellbeing (depression, anxiety 
and distress). MethOds: Men diagnosed with invasive prostate cancer (ICD10 C61) 
5-20 months prior to study commencement were identified through the National 
Cancer Registry. The patient experience questionnaire was based on the Prostate 
Care Questionnaire (Baker et al. 2007), modified for Ireland. Utility and psychologi-
cal wellbeing were assessed using the EQ5D-5L and Depression Anxiety and Stress 
Scale (DASS-21). The questionnaire was administered by post to 2,180 men during 
January-April 2013. EQ5D-5L responses were converted to EQ5D-3L health states 
and valued with UK valuations. Results: A total of 1499 valid questionnaires were 
received (response rate= 70%). Men rated their overall care very highly; however, 
there were variations with those (i) further from diagnosis, (ii) in poorer health, 
(iii) younger, (iv) with third level education and (v) with private health insurance 
significantly more likely to report poorer care experiences. Almost half of men 
reported maximum utility scores; one-fifth had depression, one-fifth anxiety and 
one-eighth stress. Lower global experience scores were significantly associated with 
lower utility values and poorer psychological well-being (p< 0.001). cOnclusiOns: 
While men recently diagnosed with prostate cancer report quite high overall care 
experience ratings, variations were reported and associations with lower utility and 
psychological well-being were observed. These results provide further rationale for 
initiatives to improve quality of care.
PCN155
UTILITy MAPPING OF THE EORTC QLQ-C30 ONTO EQ-5D IN PATIENTS wITH 
SOFT TISSUE SARCOMA
Amdahl J.1, Manson S.C.2, Isbell R.2, Chit A.3, Delea T.E.4
1PAI, Brookline, MA, USA, 2GlaxoSmithKline, Uxbridge, UK, 3GlaxoSmithKline, Mississauga, ON, 
Canada, 4Policy Analysis Inc. (PAI), Brookline, MA, USA
Objectives: The European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is one of the most com-
monly used quality of life instruments in clinical trials of anti-cancer agents. Here 
we present an algorithm for mapping between the QLQ-C30 and EQ-5D prefer-
ences in an adult population with advanced soft tissue sarcoma (aSTS) who par-
ticipated in the PALETTE trail, building upon mapping work performed in other 
tumours. MethOds: Data from the PALETTE trial assessing pazopanib versus 
placebo for the treatment of aSTS (n= 369) was used, where EQ-5D was assessed at 
baseline and week 4, and the QLQ-C30 at baseline plus weeks 4, 8 and 12. Ordinary 
least squares (OLS) and generalised linear model regression using a generalised 
estimating equations (GLM/GEE) approach was employed with the EQ-5D disu-
tility value as the dependent value. A variety of model forms were tested with 
different link functions and error term distributions, as well as using two stage 
models and including factors other than QLC-C30 terms (i.e., age, sex, ECOG sta-
tus). Results: There was relatively little variability in the root mean square error 
(RMSE) and R-squared across 28 different models tested, with the RMSE ranging 
from 0.16 to 0.18 and the R-squared ranging from 0.54 to 0.63. Using GLM/GEE 
vs. OLS, adding non QLQ-C30 terms, two-stage models, and squared terms for 
QLQ-C30 scores all improved R2, albeit slightly. All the models overestimated the 
disutility for assessments with zero disutility and underestimated the disutil-
ity for assessments with large disutilities, as has commonly been reported for 
such algorithms. cOnclusiOns: The mapping algorithms tested had reasonable 
predictive validity. These algorithms were used in cost-effectiveness evaluations 
of pazopanib in aSTS patients and may be useful for future cost-effectiveness 
evaluations of other therapies for this indication.
one year of follow up, 11.2% of TAM, and 18.4% of AI treated patients discontinued 
their treatment. In these patients with , the reasons for stopping were: progres-
sive disease including local and distant progression (68.1%), side effects (15.5%), 
patient’s choice (8.6%) and other reasons (7.8%). The multivariate hazard ratios of 
the cox regression models showed that patients younger than 50 were most likely 
to discontinue initial therapy when compared with the reference group of women 
over 70 years of age (HR: 2.30, p= 0.01). In contrast, patients treated in gynae-
cologist or oncologist practice had significantly longer persistence than patients 
who obtained their prescriptions in general hospital or academic cancer facility 
(HR: 0.47, p= 0.02). Additionally, patients with therapy initiation in gynecological 
practices had significantly longer persistence than in oncological practice (HR: 
0.68, p= 0.04). Additionally, metastases were associated with strongly increased 
risk of treatment discontinuation (HR: 3.81, p< 0.01). cOnclusiOns: The propor-
tion of breast cancer patients with therapy discontinuation within first year after 
therapy start is high and needs to be significantly increased to improved outcome 
in clinical practice.
PCN151
HEALTH STATE UTILITy vALUES IN ADvANCED NON-SMALL CELL LUNG 
CANCER PATIENTS
Chevalier J.1, Le Lay K.2, de Pouvourville G.1
1ESSEC Business School, Cergy-Pontoise Cedex, France, 2Boehringer Ingelheim France, Paris Cedex 
13, France
Objectives: Lung cancer has an important impact on Health related Quality of Life 
(HRQoL). LUCEOR2 is a multi-country prospective study which aimed to measure 
HRQoL and EQ-5D utility values in Non Small Cell Lung Cancer patients (NSCLC). 
Previous results presented utility values calculated on the whole LUCEOR2 popula-
tion and on the French subgroup using the UK tariff for the EQ-5D. Our aim was 
to calculate utility values with the French tariff for the application in French cost-
effectiveness studies. MethOds: Data from the LUCEOR2 study that included all 
patients from participating countries which provided a meaningful sample size for 
data analysis. Patients were stratified in 7 health states defined by the response of 
treatment (progressive or stable) and the line of treatment (1st, 2nd, 3rd/4thand BSC).
EQ-5D health states were valued using the French tariff. Results: A total of 319 
patients were recruited in LUCEOR2, HRQoL were available for 258 of them (73 in 
France). Mean utilities for progression-free patients on 1st, 2nd and 3rd/4th lines were 
0.690 (n= 116; standard deviation [sd]: 0.258), 0.697(n= 46; sd: 0.221) and 0.609(n= 25; 
sd: 0.324) respectively. For patients with progressive disease, values were 0.608(n= 26; 
sd: 0.237), 0.550(n= 17; sd: 0.353) and 0.418(n= 21; sd: 0.399). Overall, patients with 
progressive disease had lower mean utility than patients with stable disease (0.530 
vs. 0.682 ; p= 0.001). Utilities calculated using the French EQ-5D tariff are lower than 
the utilities calculated using the UK tariff. cOnclusiOns: This study presents the 
French utility values for patients with NSCLC. It demonstrates the impact of the 
disease on the HRQol. Further investigations will be made on the potential differ-
ences in scores between countries.
PCN152
ESTIMATING HEALTH STATE UTILITIES FOR PATIENTS wITH RELAPSED/
REFRACTORy (R/R) HODGKIN LyMPHOMA (HL) AND SySTEMIC ANAPLASTIC 
LARGE-CELL LyMPHOMA (SALCL) IN MExICO AND BRAzIL
Shingler S.1, Swinburn P.1, Lloyd A.1, Bonthapally V.2
1Oxford Outcomes, An ICON plc Company, Oxford, UK, 2Millennium: The Takeda Oncology 
Company, Cambridge, MA, USA
Objectives: Benefits of treatment can be measured by utility values. Health utili-
ties typically range between 0 (dead) and 1 (full health) and reflect health-related 
quality of life (HRQL) in a given health state. Societal values for health states can 
be captured using the time trade-off (TTO) methodology. Currently, no values 
exist for health states depicting stages of R/R HL and sALCL for Latin American 
countries. The aim of this study was to collect utility values from members of 
the public in Mexico and Brazil for R/R HL and sALCL health states. MethOds: 
Health states were developed using recognized methods, including a litera-
ture review, patient and clinician interviews, and cognitive debriefing. States 
included stages of R/R HL and sALCL (complete response [CR], partial response 
[PR], stable disease, and progressive disease), and adverse events (AEs) including 
B-symptoms, acute/chronic graft-versus-host disease (GVHD), and grade I/II or 
grade III peripheral sensory neuropathy (PSN). Members of the public in Mexico 
(n= 100) and Brazil (n= 101) valued each health state using the TTO methodol-
ogy. Results: Participants showed a clear preference for the treatment response 
states; CR was valued as the state least likely to affect HRQL, with utility gains 
of 0.13–0.14 over stable disease. The experience of any AE was associated with a 
large decline in quality of life. The most burdensome AEs were acute GVHD and 
grade III PSN. Experiencing acute GVHD gave a disutility from stable disease of 
0.190 (for Brazil) and 0.125 (for Mexico). Only minor discrepancies existed between 
the mean utilities for the two countries, the largest being for PR (Mexico, 0.633; 
Brazil, 0.717). cOnclusiOns: Societal valuation of health states for R/R HL and 
sALCL revealed the notable perceived benefit of a treatment response and the 
significant disutility associated with AE experience. Utility values for Mexico and 
Brazil were broadly consistent.
PCN153
UTILITy vALUES FOR PATIENTS wITH ADvANCED GASTROINTESTINAL 
STROMAL TUMORS (GIST) TREATED wITH REGORAFENIB vERSUS PLACEBO IN 
THE PHASE III GRID TRIAL
Connolly M.1, Currie C.2, Chang J.3
1Unit of PharmacoEpidemiology & PharmacoEconomics, Groningen, The Netherlands, 2Cardiff 
University, Cardiff, Wales, UK, 3Bayer HealthCare, Montville, NJ, USA
Objectives: To estimate utility values by health states for regorafenib and placebo-
treated subjects from the phase-3 GIST – Regorafenib In Progressive Disease (GRID) 
trial, and test the assumption that utility values remained constant over successive 
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tiveness analyses were compared with methods specified by NICE as the reference 
case in its 2004 and 2008 Methods Guides. The review focused on guidance published 
before June 2013 for medicines treating metastatic breast cancer, metastatic colorectal 
cancer, metastatic hormone-refractory prostate cancer and metastatic non-small-
cell lung cancer. Nineteen technology appraisals published between March 2002 and 
August 2012 met the inclusion criteria. Results: Common themes or variations that 
exist between utility values selected by manufacturers and independent academic 
groups for each metastatic cancer and between the 4 metastatic cancers were ana-
lysed. The research also explored the methodological issues that were considered by 
the Appraisal Committee relating to the selection of utility values. cOnclusiOns: 
Therefore, this research provides insight to the methodological considerations regard-
ing incorporation of utility values that have informed health technology assessment 
decision-making in England for 4 metastatic cancers.
PCN159
PATIENTS’ AND CAREGIvERS’ PREFERENCES FOR BONE METASTASES (BM) 
TREATMENTS IN THE UNITED STATES
Qian Y.1, Mohamed A.F.2, Hauber A.B.2, Collins H.1, Hechmati G.3, Gatta F.3, Arellano J.1
1Amgen Inc., Thousand Oaks, CA, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 
3Amgen (Europe) GmbH, Zug, Switzerland
Objectives: Patients with BM from solid tumors often experience skeletal-related 
events [SREs]; commonly defined as pathologic fracture, radiation or surgery to 
bone, and spinal cord compression. Several bone-targeted agents are approved for 
the prevention of SREs. This study evaluated US patients’ and caregivers’ prefer-
ences in relation to available treatment options in the US. MethOds: Adults with 
or adult caregivers of patients with a self-reported physician diagnosis of BM from 
a solid tumor completed a web-enabled discrete-choice experiment survey com-
prising a series of 10 choices between pairs of hypothetical medication profiles. 
Each profile included 6 medication attributes within a pre-defined range (primarily 
based on prescribing information and real-world practice): months until first SRE 
(10, 18 and 28 months); months until worsening of pain (3, 6, 10 months); annual 
risk of osteonecrosis of the jaw (ONJ; 0%, 1%, 5%); annual risk of renal impairment 
(0%, 4%, 10%); mode of administration (subcutaneous injection, 15-minute infusion, 
120-minute infusion); and monthly out-of-pocket cost to patients ($25, $75, $150, 
$330). Choice questions were based on an experimental design with known statisti-
cal properties. The survey was pretested with 15 patients and 11 caregivers using 
open-ended interviews. A separate main-effects random parameters logit model 
was estimated. Results: In total, 187 patients and 197 caregivers completed the 
survey. Among the attribute levels included, out-of-pocket cost to patients, risk of 
renal impairment, and months until first SRE were most important to both patients 
and caregivers. For those attributes, better outcomes were preferred to worse out-
comes (p< 0.05) except that risk of renal impairment between 4% and 10% was not 
significant for patients; costs between $25 and $75 were not significant for either 
group. cOnclusiOns: When considering treatment choices for preventing skeletal 
complications associated with BM, patients and caregivers focused mainly on out-
of-pocket cost to patients, avoiding renal impairment, and delaying SREs.
PCN160
CLINICAL OUTCOME ASSESSMENTS IN FDA ONCOLOGy LABELS SINCE 2010
Meyers O.I.1, Foley K.2
1Truven Health Analytics, Cleveland, OH, USA, 2Truven Health Analytics, Cambridge, MA, USA
Objectives: In 2009, the FDA released Final Guidance on Patient-Reported 
Outcomes (PROs) and has stated that standards for PROs apply equally to Clinician 
and Observer Reported Outcomes (ClinROs, ObsROs; collectively, clinical out-
come assessments - COAs). The objective was to survey labels for oncologic drugs 
approved in the three years since the “PRO Guidance” was finalized and to charac-
terize any COAs in these labels. MethOds: CenterWatch maintains a list of FDA 
approved drugs following definitions established by the Tufts Center for the Study 
of Drug Development, including only drugs or NMEs newly approved by the FDA 
Center for Drug Evaluation and Research. From 2010 to the time of this review in 
2013, 45 oncologic drugs were approved by the FDA. The FDA approved product 
labels of each of these drugs was reviewed and each was tabulated according to its 
inclusion of COAs. Results: Few of the approved product labels reviewed included 
any reference to, much less data collected using PROs, ClinROs, or ObsROs. Several 
(e.g., carfilzomib) had clear statements to indicate that approval for the product was 
based on a predefined response rate rather than any “improvement in survival or 
symptoms.” The notable exceptions are fentanyl sublingual tablets and spray and 
abiraterone, with PRO data on pain. cOnclusiOns: There are several explanations 
for the low rate of COAs in oncology labels, especially that oncology trials tend to be 
unblinded. The FDA has stated that open label designs cannot support PRO claims. 
Yet there is still a heavy reliance on outcomes such as progression free and overall 
survival. Three labels were identified with PRO data on pain, two of which were spe-
cifically indicated for pain rather than tumor control. This review suggests there are 
opportunities for sponsors and the FDA to increase the degree to which the patient’s 
voice is heard during the regulatory decision making process.
PCN161
SySTEMATIC REvIEw OF PATIENT REPORTED OUTCOMES IN CHRONIC 
MyELOID LEUKEMIA
Aggarwal S., Segal J., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
Objectives: Patient reported outcomes (PRO) are becoming useful tools for collecting 
and generating evidence for new medical products to show improvements in health-
related quality of life (HRQoL). Chronic myeloid leukemia (CML) is now a chronic 
disease in which HRQoL is becoming important. The objective of this study was to 
review, analyze, and understand trends in the PRO instruments used in patients with 
CML. MethOds: A systematic literature search for CML randomized controlled tri-
als (RCTs) with PROs endpoints was undertaken for the databases Pubmed, Embase, 
Biosis, Google Scholar, and Cochrane. Data was collected for the study size, interven-
PCN156
COMPARATIvE RESPONSIvENESS OF DIRECT AND MAPPED SF-6D PREFERENCE-
BASED MEASURES IN COLORECTAL CANCER
Wong C.K.H.1, Mulhern B.2, Wan Y.F.1, Lam C.L.K.1
1The University of Hong Kong, Hong Kong Island, Hong Kong, 2University of Sheffield, Sheffield, 
UK
Objectives: This study examined the responsiveness of preference-based meas-
ures based on the anchor of self-reported change in general health condition of 
patients with colorectal cancer (CRC). MethOds: A baseline sample of 333 patients 
was recruited at the specialist outpatient clinic of academic teaching hospital in 
Hong Kong between September 2009 and July 2010, and was surveyed prospectively 
at 6-month follow-up. SF-6D preference-based indices were derived from the generic 
SF-6D measure (SF-6DDirect), from the Short Form-12 Health Survey (SF-6DSF-12) and 
also mapped from the condition-specific Functional Assessment of Cancer Therapy-
Colorectal (SF-6DFACT-C). The responsiveness of three measures was assessed using 
the internal responsiveness and external responsiveness. The 95% bias-corrected 
and accelerated bootstrapping confidence intervals were performed to compare the 
internal responsiveness statistics measured by standardized effect size, standard-
ized response mean, and responsiveness statistic. External responsiveness was 
evaluated by receiver operating characteristic (ROC) curve analysis that examined 
the ability to detect score changes with global health condition changes or dis-
criminate between the worsened and unchanged/improved groups. Results: 
Over half of patients reported no change in global health condition based on the 
self-reported anchor, whilst 15.1% and 32.9% of patients rated better and worse in 
current health condition compared to baseline respectively. In worsened group, 
internal responsiveness was satisfactory for the SF-6DDirect and SF-6DFACT-C prefer-
ence-based indices. The SF-6DSF-12 and SF-6DFACT-C indices were significantly more 
responsive to detect positive changes than the SF-6DDirect index in improved group. 
The SF-6DDirect and SF-6DFACT-C indices were more externally responsive based on 
ROC curve. The SF-6DFACT-C index was generally more responsive to changes in 
health status compared with other indices. cOnclusiOns: Direct SF-6D measure 
was more responsive than mapped preference-based measures in improved group 
but the direction was reversed in worsened group. Use of a preference-based index 
mapped from a condition-specific measure captures both negative and positive 
important changes in HRQOL score among CRC.
PCN157
QUALITy OF LIFE IN PATIENTS wITH METASTATIC COLORECTAL CANCER 
(MCRC): A UTILITIES STUDy IN THE UNITED KINGDOM AND THE NETHERLANDS
Stein D.1, Joulain F.2, Iqbal S.U.3, Naoshy S.3, Muszbek N.4, Payne K.A.1, Ferry D.R.5
1Evidera, Dorval, QC, Canada, 2Sanofi, Chilly-Mazarin, France, 3Sanofi, Cambridge, MA, USA, 
4Evidera, London, UK, 5The Dudley Group NHS Foundation Trust, Dudley, UK
Objectives: To elicit utility values from EQ-5D for patients with various stages of 
mCRC. MethOds: An observational cross-sectional study consisting of one-time 
EQ-5D completion at enrollment was conducted in five hospitals in The Netherlands 
and the United Kingdom (UK). Patients were categorized into stable or progressed 
cohorts based on investigator assessment. Patients with mCRC were eligible if on 
second or subsequent lines of treatment or best supportive care [BSC], received 
prior oxaliplatin, no prior irinotecan, and had Eastern Cooperative Oncology Group 
(ECOG) performance status scores of 0-2 at second line initiation similar to the 
VELOUR trial. Chart data on patient demographics, clinical history, prior/current 
treatments, serious adverse events (SAEs) were collected. Average utilities were 
estimated; uni- and multivariate analyses were conducted. Results: A total of 
75 patients were enrolled, 42 patients stable on second line or third line follow-
ing an AE on second line and 33 progressed patients. Mean age was 63 (standard 
deviation [SD]= 10); 52% male. Most patients in the stable (98%) and progressed 
(88%) cohorts had ECOG scores of 0-1 at enrollment. 7% and 15% of patients in 
stable and progressed cohorts respectively had ongoing SAEs at enrollment. Mean 
utility scores were 0.741 (SD= 0.230) and 0.731 (SD= 0.292) for stable and progressed 
patients respectively. Higher proportions of patients reported increased anxiety/
depression (36% vs. 12%) and fewer problems with daily activities post-progression 
(64% vs. 38%). 83% and 42% of patients in stable and progressed cohorts respectively, 
were on treatment at enrollment. cOnclusiOns: While the majority of the stable 
cohort had good performance status and few SAEs ongoing at enrollment, utility 
values were not much higher compared to the progressed cohort. Higher values in 
the progressed cohort may be attributed to exclusion of patients in palliative care 
centers, radiological versus symptomatic disease progression and patients remain-
ing on treatment, having few SAEs and good performance status at enrollment.
PCN158
UTILITy vALUES USED IN NATIONAL INSTITUTE FOR HEALTH AND CARE 
ExCELLENCE (NICE) TECHNOLOGy APPRAISALS OF MEDICINES FOR 4 
METASTATIC CANCERS
Burke M.J.1, Sidhu R.2, George E.2
1National Institute for Health and Care Excellence, Manchester, UK, 2National Institute for Health 
and Care Excellence, London, UK
Objectives: National Institute for Health and Care Excellence (NICE) considers 
the quality-adjusted life year (QALY) to be the most appropriate generic measure of 
health benefit that reflects both mortality and health-related quality of life effects. 
The QALY is the sum of a person’s length of life in each health state multiplied by a 
quality-adjustment weight (that is, utility value) associated with that health state. 
Cost-effectiveness results are often sensitive to the choice of utility value, but relevant 
and comparable utility values are not always available leading to debate about the 
most appropriate utility values to include. The objective of the research was to review 
the health-related utility values used in economic models across NICE technology 
appraisal guidance for 4 metastatic cancers. MethOds: A cross-sectional review of 
manufacturer submissions and reports produced by independent academic groups 
was carried out to identify the health-related utility values used. Information relating 
to the methods used to elicit utility values that were selected for use in cost-effec-
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total of 84 active ingredients had new indications or label changes. After removal of 
25 duplicate ingredients (or updated again during this timeframe), 59 labels and IFs 
were identified and reviewed. No product labels contained PRO information. However, 
in contrast 20 (34%) IFs contained PRO information. 10 of these IFs only stated that 
“QOL” or “PRO” was assessed without details on the questionnaires or results. The 
EORTC (European Organisation for Research and Treatment of Cancer) and FACT 
(Functional Assessment of Cancer Therapy) were explicitly stated as measures in 
four and three IFs, respectively. There were also three pain assessments; two Visual 
Analog Scale assessments and one utilizing the Brief Pain Inventory – Short Form 
(BPI-SF). cOnclusiOns: Although no oncology labels contained PRO information, 
the IFs contained PRO information. 1/3 of product information contained a mention 
of PROs which can be used in discussions with clinicians.
PCN165
CHANGES IN PATIENT-REPORTED OUTCOMES AMONG PEDIATRIC LEUKEMIA 
AND LyMPHOMA PATIENTS DURING THE FIRST 2-yEARS POST ALLOGENEIC 
STEM CELL TRANSPLANTATION (ALLOSCT)
Oberg J.A.1, Morris E.2, Cairo M.2, Kelly K.M.1
1Columbia University, New York, NY, USA, 2New York Medical College, Valhalla, NY, USA
Objectives: To explore changes in child-reported quality of life (QOL) of pediatric 
leukemia/lymphoma patients receiving alloSCT. MethOds: Hierarchical linear 
modeling was used to explore trends in select PedsQL 4.0 sub-scales and individual 
items of 43 children ≥ 5 years of age. QOL was assessed once pre-alloSCT and on 
days 100, 180, 365, and 730, post-alloSCT. Results: Median age: 13.54 years, Range: 
4.66-23.12 years; leukemia: 76.7%; lymphoma: 23.3%; reduced-toxicity conditioning 
(RTC)/myeloablative conditioning (MAC): 44%/56%; chronic graft-versus-host disease 
(cGVHD): 27.9%. Emotional and social functioning was stable pre-to-post-alloSCT 
and comparable to a normative pediatric sample (p> .05), whereas physical func-
tioning was 19 points lower pre-alloSCT (M= 67.42; p< .01; ES= 1.26SD) with improved 
scores approaching norms by Day +730. 51-65% of children at baseline reported dif-
ficulties with sports/exercise, strength, pain, and fatigue. Significant improvements 
from baseline (M= 51.41) were observed in sports/exercise at a rate of 1.06 points-
per-month (ppm)/12.90 points-per-year (ppy) (t= 2.57; p= .01) and strength (M= 47.47; 
t= 2.05; p= .04) at a rate of 0.84 ppm (10.21ppy). Recipients of RTC significantly 
improved at a rate of 14.04ppy (slope= 1.16; t= 2.41; p= .02) compared to children who 
received MAC (-4.01ppy; slope= -0.33). Similarly gains in strength were significantly 
better for the RTC group (12.94ppy; slope= 1.06; t= 2.25; p= .02) than the MAC group 
(-10.62ppy; slope= -0.83). Levels of pain (M= 64.82; slope= 0.05ppm; t= 0.15; p= .88) and 
fatigue (M= 58.01; slope= 0.39ppm; t= 1.14; p= .26) remained unchanged irrespective 
of conditioning regimen. Emotional functioning of children ages 8-12 significantly 
improved from baseline (M= 70.18; slope= 1.78ppm; t= 2.89; p= .01), whereas children 
≥ 13 significantly declined post-alloSCT (M= 72.61; slope= -1.34ppm; t= -2.64; p= .01). 
Presence of cGVHD did not significantly affect outcomes scores. cOnclusiOns: 
Improvements in exercise and strength were seen with RTC regimens whereas 
pain and fatigue remained unchanged independent of conditioning regimen. Older 
children may have more emotional difficulties post-alloSCT. These results highlight 
the importance of including QOL to monitor patients and further define outcomes 
for this population.
PCN166
QUALITy OF LIFE IN PATIENTS wITH OSTOMy IN POLAND: MULTICENTRE 
CROSS-SECTIONAL STUDy USING wHOQOL-BREF QUESTIONNAIRE
Golicki D.1, Styczen P.2, Szczepkowski M.3
1Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, 
Poland, 2Gabinet Lekarski, Konopiska, Poland, 3Faculty of Rehabilitation, Jozef Pilsudski University 
of Physical Education in Warsaw, Warsaw, Poland
Objectives: To assess quality of life of Polish patients with a stoma using validated 
generic questionnaire. MethOds: Adult patients with colostomy, ileostomy or uro-
stomy performed in Poland between July 2009 and December 2010 were included. 
Patients completed satisfaction survey at the discharge from the hospital, and The 
World Health Organization Quality of Life-BREF (WHOQOL-BREF) generic question-
naire at 3 months after surgery. Results: The study involved 1519 patients (71.5%, 
16.8%, 11.7% with colostomy, ileostomy and urostomy, respectively). The studied 
population was highly diversified in terms of: pain and discomfort, dependence on 
medical treatment and acceptance of physical appearance. 57% of patients with a 
stoma defined their quality of life as good or very good (mean 3.54 points; range: 
1 to 5; SD 0.73). The subjects were characterized by low quality of life assessment 
in the physical health and psychological domains (53.5 and 60.0 pts.) and by high 
evaluation in the environment and social relationships domains (69.6 and 70.2 pts.). 
Respondents highly assessed: the level of social support, home environment, physi-
cal environment, personal relationships. Low assessment was related to: sexual 
activity, ability to work, dependence on medical treatment, financial resources, 
satisfaction with health. cOnclusiOns: This is the first Polish study on the quality 
of life of patients with a stoma, based on validated generic questionnaire. The results 
should help improve standards of care for patients with a stoma.
PCN167
INFLUENCE OF ANxIETy AND DEPRESSION ON 1-yEAR HEALTH RELATED 
QUALITy OF LIFE IN COLORECTAL CANCER PATIENTS
Escobar A.1, Billbao A.1, Trancho Z.1, Quintana J.2, Sarasqueta C.3, Baré M.4
1Basurto University Hospital (Osakidetza).Red de Investigación en Servicios Sanitarios y 
Enfermedades Crónicas (REDISSEC)., Bilbao, Spain, 2Galdakao-Usansolo Hospital (Osakidetza).
Red de Investigación en Servicios Sanitarios y Enfermedades Crónicas (REDISSEC)., Galdakao-
Usansolo, Spain, 3Donostia Universitary Hospital. Red de Investigación en Servicios Sanitarios y 
Enfermedades Crónicas (REDISSEC), Donostia, Spain, 4Hospital Parc Tauli. Red de Investigación en 
Servicios Sanitarios y Enfermedades Crónicas (REDISSEC), Sabadell, Spain
Objectives: To assess the impact of anxiety and depression measured by Hospital 
Anxiety and Depression Scale (HADS) on 1-year HRQoL measured by EuroQol-3L (EQ-
5D) and EORTC-QLQ-C30 on patients with colorectal cancer.This aspect of continuity 
tions, year, PRO instrument, and results for PROs. Analysis was conducted to identify 
trends in commonly used PRO instruments and results were categorized as posi-
tive, neutral, or negative. Results: Eight RCTs with a total of 3,342 patients were 
identified. In these studies, there were eight different PROs instruments identified: 
FACT-Leu, SF-36, FSI, PSQI, MSAS-SF, FACT-BRM, EQ-5D, and MDASI-CML. The most 
commonly used instruments were FACT-Leu (used in 1,336 patients) and FACT-BRM 
(used in 1,199 patients). Five studies reported positive results with improvement in 
quality of life (QoL) symptoms versus comparator treatments. Two studies reported 
results highlighting significant deterioration in QoL versus patients with no cancer. 
One study reported QoL in various types of CML and showed significant deterioration 
in patients with chronic phase CML versus those with acute and blast phase CML. 
Studies also identified two QoL domains, depression and fatigue, which matter most 
for patients with CML. cOnclusiOns: Patients with CML have significant deterio-
ration in their QoL. PRO instruments such as FACT-Leu and FACT-BRM can aid in 
generating evidence to show which therapies improve patient QoL.
PCN162
PATIENT REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT 
PROSTATE CANCER
Aggarwal S., Segal J., Kumar S.
Novel Health Strategies, Bethesda, MD, USA
Objectives: Patient reported outcomes (PRO) are becoming useful tools for col-
lecting and generating evidence for new medical products to show improvements 
in health-related quality of life (HRQoL). Castration-Resistant Prostate Cancer 
(CRPC) is a chronic disease with high importance for patient HRQoL. The objective 
of this study was to review, analyze, and understand trends in the PRO instruments 
used in patients with CRPC. MethOds: A systematic literature search for CRPC 
randomized controlled trials (RCTs) with PROs endpoints was undertaken for the 
databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was col-
lected for the study size, interventions, year, PRO instrument, and results for PROs. 
Analysis was conducted to identify trends in commonly used PRO instruments 
and categorize results as positive, neutral or negative. Results: Ten RCTs with 
a total of 5,797 patients were identified. In these studies there were thirteen dif-
ferent PROs instruments were identified that were FACT-P, FACT-G, BPI-SF, EQC30, 
EQPR25, FLIC, SDS, SUF, PDA, IPDA, PROSQOLI, SF-36, and QOLM-P14. The most 
commonly used instrument were FACT-P (used in 4,297 patients) and EQC-30 (used 
in 1,091 patients). Six studies reported positive results with improvement in qual-
ity of life symptoms (QoL) versus comparator treatments. Fours studies reported 
results with deterioration in (QOL). Three studies reported improvement in pain 
scores. cOnclusiOns: Patients with CRPC have relatively longer survival and 
hence QoL is an important consideration for these patients. PRO instruments such 
as FACT-P and EQC-30 have been commonly used to generate evidence to show 
which therapies improve patient QoL.
PCN163
ARE “DIzzy” AND “LIGHTHEADED” THE SAME CONCEPT OR SEPARATE 
CONCEPTS? CHALLENGES IN CONCEPTUAL EQUIvALENCE OF THESE TERMS IN 
20 LANGUAGES
Eremenco S.1, Arnold B.J.2
1Evidera, Bethesda, MD, USA, 2FACITtrans, Elmhurst, IL, USA
Objectives: Feeling “dizzy” or “lightheaded” are common concepts in patient-reported 
outcome (PRO) instruments in a number of conditions. The Functional Assessment of 
Cancer Therapy – Anemia (FACT-An) subscale contains an item assessing “feeling dizzy 
(lightheaded)” as one concept while other instruments propose to assess the symptoms 
as two separate concepts or items. The purpose of this study was to translate and assess 
conceptual equivalence of this concept across 20 languages (21 countries). MethOds: 
The FACT-An was translated following the FACIT Translation methodology which is 
consistent with ISPOR guidelines for translation and cultural adaptation of PRO 
measures (Wild et al., 2005). The translation process for each language consisted of: 2 
forward translations by native translators, reconciliation of the forward translations, 
1 back-translation by an English-speaker fluent in the target language, 3 reviews by 
native translators or clinicians, final reconciliation by a native speaking linguist, and 
harmonization. Interviews were conducted among 456 native-speaking patients in 21 
countries. Data were analyzed to assess linguistic and cultural validity of the FACT-An in 
each language and confirm conceptual equivalence. Results: Mean age of the sample 
(N= 456) was 55 years, (range 19-88) and 58% were male. During the translation phase, 12 
of the 20 languages translated the concept of dizzy (lightheaded) using only one term, 
and the remaining 8 languages provided two terms. The rationale was that one word 
was used to describe this set of symptoms and it would be a complicated explanation 
to address the second term. The translations were well understood and considered rel-
evant. cOnclusiOns: The majority of languages in this study provided only one term 
for the concept of dizzy (lightheaded) indicating that it may be problematic to assess 
the concept as two separate symptoms in future questionnaires in other languages 
where this concept is not separated as it is in English.
PCN164
PRO CLAIMS IN jAPANESE ONCOLOGy PRODUCT LABELING
Crawford B.
Adelphi Values, Tokyo, Japan
Objectives: There is a growing use of patient-reported outcomes (PRO) in the US 
and Europe but little is known about Asia. Oncology in particular is an area of growing 
interest. This study sought to review PRO labeling within oncology products over the 
last five years in Japan. MethOds: Oncology labels were identified by reviewing the 
Pharmaceutical and Medical Devices Agency (PMDA) postings of label changes for 
the past 5 years (2007-2012). For identified products with label changes, labels and 
Interview Forms (IF) were acquired and reviewed. The IF is used as a supplement to 
the label in Japan to provide additional data that will not fit within the package insert. 
Only PROs used for potential promotion were evaluated. Symptoms such as pain listed 
in the adverse events or safety sections were not included in this review. Results: A 
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PCN170
AN ExPLORATORy ANALySIS OF THE ASSOCIATION BETwEEN EORTC-QLQ 
C30 DOMAINS AND PROGRESSION FREE/OvERALL SURvIvAL IN ADvANCED 
MELANOMA AFTER 12 wEEKS OF TREATMENT ON IPILIMUMAB COMPARED TO 
GP100 IN A PHASE III CLINICAL TRIAL
Lee D.1, Harvey B.1, Gaudin A.F.2, Gueron B.3, Bregman B.2, Lebbe C.4, Bonnetain F.5, Borget I.6
1BresMed, Sheffield, UK, 2Bristol-Myers-Squibb, Rueil Malmaison, France, 3Bristol-Myers Squibb, 
Rueil Malmaison, France, 4Hopital Saint Louis, Paris, France, 5CHU Besançon, Besançon, France, 
6Institut Gustave Roussy, Villejuif, France
Objectives: This study analyses the association between health-related quality 
of life (HRQL) domains and progression free (PFS) and overall survival (OS) for ipili-
mumab, ipilimumab + gp100, and gp100 alone during the 12 week treatment induc-
tion period compared to baseline. The aim of this study was to assess whether 
outcomes reported in the EORTC-QLQ-C30 summary domains impact the hazard 
of progressing and/or dying after 12 weeks of treatment. MethOds: Data from the 
MDX010-20 trial, including 676 previously treated patients with unresectable stage 
III or IV melanoma, was analysed. A domain correlation plot (excluding Global 
domain) was constructed to determine whether the EORTC-QLQ-C30 domains 
showed a high level of correlation for baseline scores. It was then used to derive 
two components summarising fourteen domain scores, Principal Components 
1, containing 10 domain scores (Pain, Appetite Loss, Nausea, Finance, Dyspnoea, 
Constipation, Diarrhoea, Role, Social and Physical) and 2 containing 4 domains 
scores (Fatigue, Sleep Disturbance, Emotional and Cognitive), based on the cor-
relation level between domains. These two Principal Components were entered as 
additional covariates in the Cox model for PFS/OS and hazard ratios were deter-
mined. Results: In the Cox regression model, Principal Component 1 showed a 
30% increase in hazard of progression when comparing the upper to the lower 
quartile of the Principal Component score , while a lower Principal Component 
1 score indicated a better HRQL at baseline. It was also showed a rate of death 
twice as high in the upper quartile than the lower quartile. Principal Component 
2 neither affected significantly PFS nor OS. cOnclusiOns: In advanced mela-
noma treated by ipilimumab compared to gp100, PFS and OS were associated with 
most of the HRQL domain scores. These findings suggest that poor baseline HRQL 
could be predictive of poor PFS/OS, while higher baseline HRQL could predict a 
better outcome.
PCN171
QUALITy OF LIFE (QOL) DURING TREATMENT OF NEwLy DIAGNOSED LOCALLy 
CONFINED LOw-RISK PROSTATE CANCER (LCLRPC) IN GERMANy: RESULTS OF 
THE HAROw STUDy
Schädlich P.K.1, Baranek T.2, Häussler B.1, Weißbach L.3
1IGES Institut GmbH, Berlin, Germany, 2CSG - Clinische Studien Gesellschaft mbH, Berlin, 
Germany, 3Stiftung Männergesundheit - Foundation for Men’s Health, Berlin, Germany
Objectives: The optimal treatment choice for preserving QoL of the about 64,000 
men diagnosed with prostate cancer each year in Germany still remains unclear. The 
objectives therefore were to generate long-term information under day-to-day condi-
tions on QoL of men in Germany cared for newly diagnosed LCLRPC using hormonal 
therapy (HT), active surveillance (AS), radiotherapy (RT), operation (OP), or watch-
ful waiting (WW) – HAROW. MethOds: The long-term observational multi-centre 
HAROW study was undertaken. The urologist provided all relevant clinical data of 
the patient. The patient provided inter alia data on QoL using the EQ-5D. Utilities 
derived from the EQ-5D based on the German value set were used to construct quality-
adjusted life-years (QALYs). QALYs were discounted by 3% annually and standardised 
to mean QALYs per patient-year (PY) for each initial treatment strategy. Differences 
between strategies were tested using the Kruskal-Wallis test (Bonferroni-corrected 
p= 0.0018 due to 28 tests). Results: Between July 2008 and March 2013, 3063 patients 
(mean age 67.3 ± 7.5 years) with LCLRPC (T1a–T2c, N0, M0) were included from 257 
urologists. Data on QoL were documented by patients as follows (% of patients/strat-
egy): AS n= 353 (78%), RT n= 291 (77%), HT n= 149 (71%), HT+RT n= 68 (85%), combination 
therapy (CT) n= 109 (80%), OP n= 1167 (71%), other therapy (OT) n= 9 (50%), WW n= 93 
(66%), over a mean time of between 1.6 (OT) and 2.5 years (CT). AS showed the highest 
undiscounted/discounted QALYs/PY (0.9297/0.9103) followed by OP (0.9289/0.9075), 
RT (0.9075/0.8878), CT (0.9071/0.8820), OT (0.8954/0.8818), HT+RT (0.8875/0.8699), WW 
(0.8646/0.8465), and HT (0.8485/0.8292). Compared to HT, QALYs/PY were significantly 
higher with AS (p< 0.0001), with OP (p< 0.0001), and with RT (p= 0.0002). Tests with 
undiscounted/discounted QALYs/PY adjusted for age, tumor stage and comorbidity 
showed no different results. cOnclusiOns: According to the HAROW study, active 
surveillance yielded the highest QALYs of the different LCLRPC treatment strategies 
in Germany evaluated.
PCN172
HR-QOL DATA IN THE AMNOG EARLy BENEFIT ASSESSMENT: INDUSTRy AND 
IQwIG/GBA PERSPECTIvE
Obradovic M., Radicek S., Rauland M.
GfK Bridgehead, Nuremberg, Germany
Objectives: To explore how often and which types of quality of life (QOL) data are 
included in the dossiers submitted for the AMNOG early benefit assessment and 
analyze how a drug’s effect in QOL is interpreted by the industry and the evaluating 
committee. MethOds: The published value dossiers up to June 15, 2013 and the cor-
responding benefit assessments were reviewed. Types of QOL data and the statements 
concerning QOL in the value dossier and the benefit assessments were collected and 
summarized. Results: A total of 46 cases were analyzed. In 6 cases no dossier was 
submitted. Of the rest, 13 dossiers (32.5%) did not include any QOL data, 13 (32.5%) 
included disease-specific QOL data only, 5 (12.5%) included generic QOL data only, 
and 9 (22.5%) both types. The QOL instruments used were considered as valid by the 
assessors. However, outcomes such as pain severity, fatigue, work productivity, and 
health care resource use were not regarded as QOL measures. Of 27 dossiers that have 
included QOL data companies have claimed an added benefit in QOL, either for the 
whole population or a specific subgroup, in 15 (56%) cases. However, the assessors rec-
of care could be nowadays a major issue MethOds: This prospective study carried 
out in 12 Hospitals. At baseline patients fulfilled EQ-5D questionnaire (utility and 
VAS scale), EORTC-QLQ-C30 (physical, role, emotional, cognitive and social function-
ing, and global health) and HADS. One year post-surgical management they com-
pleted the EQ-5D and EORTC-QLQ-C30. We used general linear models to establish 
the influence of baseline anxiety (HADS-A) and depression (HADS-D) on changes in 
HRQoL, adjusted by baseline score and gender. We have used the recommended cut-
off points of HADS ≤ 7 (normal); 8-10 (uncertain) and ≥ 11 (problem). Results: There 
were 778 patients. The mean age (SD) was 67.4 (10.4). Males represented the 62.7%. 
At baseline, in the HADS-A there were 282 (36.4%) of patients scoring higher than 7 
points (17.6% higher than 10 points). In the HADS-D 137 (17.6%) scored higher than 7 
and 9.3% were higher than 10 points. Both anxiety and depression at baseline influ-
ence the changes in EQ-5D, with less gains in patients with more level of anxiety 
or depression (p< 0.0001). Regarding the EORTC-QLQ-C30 domains, baseline anxiety 
level impacts significantly in all domains, except in physical functioning, with gains 
around 5 to 11 points lower in patients with anxiety problems comparing with those 
classified as normal (all p< 0.05). Baseline depression level impacts significantly on 
changes in role and social functioning, and global health, with gains around 10 to 
13 points lower in patients with depression problems (all p< 0.01). cOnclusiOns: 
This study supports the importance of providing psychological interventions for 
cancer patients before surgical management.
PCN168
A PROPOSED 6-ITEM REDUCTION FOR THE EUROPEAN ORGANIzATION FOR THE 
RESEARCH AND TREATMENT OF CANCER-QUALITy OF CORE QUESTIONNAIRE 
(EORTC QLQ-C30) - CUBAN GROUP OF TRIALISTS ON EPIDERMAL GROwTH 
FACTOR (CGT-EGF)
Viada C.1, Ballesteros J.2, Fors M.3, Luaces P.1, Sánchez L.1, Crombet T.1
1Center of Molecular Immunology, Havana, Cuba, 2University of the Basque Country UPV/EHU, 
Leioa, Spain, 3National Coordinating Centre of Clinical Trials, Havana, Cuba
Objectives: To develop an unidimensional and short version of the QLQ-C30 to be 
used as a patient-perceived quality of life in cancer trials. MethOds: We analysed 
data of 873 patients diagnosed with non-small-cell lung cancer who participated 
in 4 Cuban multicenter trials of immunotherapy against the epidermal growth 
factor. The analysis followed a 4-step approach. First, we conducted a Mokken 
nonparametric item response analysis to ascertain the QLQ-C30 dimensionality 
and separate several scales if appropriate. Second, we conducted a parametric 
Samejima’s graded response model (GRM) to assess the item characteristics and 
information. Third, we did a confirmatory factor analysis (CFA) to test the scales 
unidimensionality and to obtain standardised factor loadings to suggest a reduced 
version of the QLQ. Finally, we assessed the discriminative validity of the reduced 
version by using receiver-operator curve (ROC) analysis. Results: Mokken analy-
sis of the QLQ-C30 resulted in a unidimensional scale, with an overall scalability 
of 0.43 that defined a medium scale. The unconstrained GRM showed that most 
items presented appropriate difficulty and discrimination parameters. The CFA 
supported an underlying unidimensional latent structure for the whole QLQ-C30 
(CFI = 0.98; RMSEA = 0.05) with modification indexes pointing to important redun-
dancy of information. The selection of items with standardized factor loadings 
> 0.70 lead to a 6-item QLQ that showed good discriminative validity against 
independent criteria of quality of life (ROC area = 0.76; 95% CI = 0.72 to 0.80) as 
compared with the values for the whole scale (ROC area = 0.70; 95% CI = 0.66 to 
0.74). cOnclusiOns: The EORTC QLQ-C6 suggested in this study presents good 
psychometric properties and includes an unidimensional structure of patient-
perceived quality of life.
PCN169
EvALUATING THE BURDEN OF BONE METASTASES (BM) ON PATIENTS wITH 
CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND THEIR TREATING 
PHySICIANS: FINDINGS FROM A ROUTINE PRACTICE STUDy IN 13 MEDIUM-
SIzED EUROPEAN COUNTRIES
Hechmati G.1, Vrouchou P.1, Arellano J.2, Cristino J.1, Haynes I.3, Liede A.4, Rider A.5,  
Worsfold A.5, Pollard R.5, Crossland V.5
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen Ltd., 
Uxbridge, UK, 4Amgen Inc., San Francisco, CA, USA, 5Adelphi Real World, Macclesfield, UK
Objectives: To evaluate the burden of BM on patients with CRPC and their treat-
ing physicians. MethOds: A total of 167 physicians (100 oncologists and 67 urolo-
gists) completed a prospective 5-day workload form, interview and average of 8 
patient record forms (PRFs, October 2012–March 2013) for non-metastatic and 
metastatic CRPC patients. Data from 142 workload forms, 167 interviews and 1,274 
PRFs (including 475 CRPC patients at ‘high risk’ of BM, 505 CRPC patients with BM 
only, 102 CRPC patients with BM and VM and 192 CRPC patients with VM only) 
were included in these analyses. Results: Physician interviews showed 92%, 
63% and 60% of the physicians believed the greatest patient burden of BM was 
back pain, reduced ability to perform daily activities and fractures, respectively 
(from a predetermined list where ‘other’ was specified). PRF data confirmed that 
Eastern Cooperative Oncology Group (ECOG) performance status was significantly 
worse in patients with BM (with/without VM) when compared with patients at 
high-risk of developing BM (p< 0.0001). 92% of the patients at ‘high-risk’ (defined by 
treating physician) of developing BM (n= 475) had a PSA doubling time (PSADT) ≤ 6 
months. The biggest burden of BM on treating physicians was seeing patient dete-
rioration (70% [n= 117]; 67% of oncologists; 75% of urologists), inability to propose 
effective treatment (57% [n= 95]; 60% of oncologists; 52% of urologists), managing 
complex regimens (29% [n= 49]; 27% of oncologists; 33% of urologists) and trans-
ferring patients for respite/hospice care (23% [n= 38]; 26% of oncologists; 18% of 
urologists). cOnclusiOns: These data highlight the burden of BM on patients 
with CRPC and the perceived burden on physicians treating this population. BM 
are associated with a significant reduction in patients’ performance status and 
an increased burden on the patient. There is a need for treatments to prevent or 
delay the onset of BM and their associated burden.
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were included and assessed with respect to their evidence for special subgroups. 
Regulatory guidelines were compared against the IQWIG evaluation methods 
with respect to the handling of subgroups and its impact on the clinical benefit 
assessment. Furthermore GBA decisions and potential price impact with the GKV-
Spitzenverband are taken into account for the pricing impact of new evidence 
with special subgroups based on target profiles developed. Results: Overall, ten 
new compounds were approved by the EMA in the last 2.5 years for which no 
subgroup trials were presented. Regulatory guidelines and IQWIG methods differ 
significantly with respect to subgroup handling from a statistical and health policy 
perspective. Most important clinical trials with a special focus on subgroups of 
interest could even have a negative outcome on the market access of such a com-
pound with respect to subgroup-only reimbursement (in case of positive subgroup 
results) or exclusion of subgroups (in case of negative results) based on target 
profiles included in the analyses. cOnclusiOns: Incentives from a health policy 
and investment decision perspective are low for the pharmaceutical industry in 
terms of research focus towards subgroups of special interest. Further research 
with respect to incentives is needed.
PCN176
DOES PERSONALISED HEALTH CARE (PHC) IN ONCOLOGy REQUIRE NEw 
APPROACHES TO CLINICAL DEvELOPMENT, REGULATORy ASSESSMENT, AND 
ECONOMIC EvALUATION?
Teale C.W.1, Satherley A.W.1, Maertens P.2, Kreyenberg K.3, Konieczny A.3
1GfK Bridgehead, Melton Mowbray, UK, 2GfK Switzerland, Basel, Switzerland, 3Daiichi Sankyo 
Europe GmbH, Munich, Germany
Objectives: To identify the extent to which current approaches to clinical devel-
opment, regulatory assessment, and economic evaluation of personalised health 
care drugs in oncology are aligned with real world clinical practice at product 
launch. To identify and critically evaluate alternative approaches that should be 
factored into future clinical development and health technology assessment (HTA) 
planning. MethOds: Structured interviews were undertaken with physicians and 
payers (n= 50) to identify the key issues surrounding the phased development and 
early use of personalised health care drugs in oncology. Analogue analyses were 
undertaken, based on “treatment tracking”, to develop a comparison between 
theoretical RCT (randomised control trial) evidence based, licensure aligned, uti-
lisation and that observed in real world clinical practice Gap Analyses identified 
drivers of differences. The utility and limitations of retrospective and prospective 
observational registries in addressing these were explored. Results: Early results 
indicate that the level of unmet need, the magnitude of incremental clinical ben-
efit, the timing of biomarker testing in the treatment algorithm and, increasingly, 
the number and prioritisation of diagnostic tests for an increasing number of dif-
ferent biomarkers are drivers of real world utilisation. Differences exist between 
countries. The greatest differences between theoretical and real world utilisation 
are in markets where decisions are driven by considerations of relative clinical 
effectiveness rather than cost effectiveness. Comparative SWOT analyses were 
developed of current and alternative clinical development, regulatory and health 
technology assessment systems. These highlight areas where improvements in 
approach would be beneficial. cOnclusiOns: Additional evidence sources should 
be used to reinforce the regulatory and health technology assessment of PHC 
products in oncology with the aim of bringing closer alignment between the RCT 
approach to drug development and assessment – and the utilisation and outcomes 
(economic, clinical, and humanistic) seen in real-world clinical practice.
PCN177
THE UNITED STATES PHySICAN SURvEy TO POPULATE A DECISION-ANALyTIC 
MODEL FOR THE TREATMENT OF CHRONIC MyELOID LEUKEMIA
Rochau U.1, Kluibenschaedl M.2, Stenehjem D.3, Kuo K.L.4, Jahn B.2, Brixner D.5, Siebert U.6
1UMIT - University for Health Sciences, Medical Informatics and Technology/ ONCOTYROL - 
Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria, 2UMIT - University 
for Health Sciences, Medical Informatics and Technology, Hall in Tyrol, Austria, 3University of 
Utah/ University of Utah Hospitals & Clinics, Salt Lake City, UT, USA, 4University of Utah, Salt 
Lake City, UT, USA, 5UMIT - University for Health Sciences, Medical Informatics and Technology/ 
ONCOTYROL - Center for Personalized Cancer Medicine/ University of Utah, Hall in Tyrol/ 
Salt Lake City, UT, Austria, 6UMIT – University for Health Sciences, Medical Informatics and 
Technology / ONCOTYROL / Harvard University, Hall i. T./ Innsbruck / Boston, Austria
Objectives: The overall goal of our project is to adapt an Austrian decision-analytic 
model for the treatment of chronic myeloid leukemia (CML) to the U.S. context. We 
conducted an electronic survey to gain expert knowledge about the state-of-the-
art in CML treatment. MethOds: The expert survey was constructed as an online 
questionnaire and contained 14 questions. The questionnaire was developed in col-
laboration with ONCOTYROL project partners and distributed to CML experts at the 
Huntsman Cancer Institute in Utah. Data were generated using Qualtrics and dis-
cussed with experts in order to incorporate the findings into the model. Results: 
Four out of six experts (67%) stated that effectiveness of second-line TKI depends 
on the response to first-line TKI therapy. NCCN and ELN guidelines are the most fre-
quently used guidelines when treating CML patients. Furthermore, expert opinion, 
literature and personal characteristics influence decision making. Patients younger 
than 50, or between 50 and 54 years, most frequently receive stem cell transplanta-
tion after TKI failure. The recently approved TKIs bosutinib and ponatinib are used 
by 17% and 100% respectively. Experts stated that quality of life (QoL) on dasatinib 
is better (17%)/ about the same (50%)/ worse (33%) compared to imatinib. QoL on 
nilotinib is better (17%)/ about the same (83%) in comparison to imatinib. QoL on 
ponatinib is better (17%)/ about the same (67%)/ worse (17%) compared to imatinib. 
Although bosutinib is rarely (67%) used, experts answered that is better (17%) or 
about the same (17%) compared to imatinib. cOnclusiOns: The results provide 
valuable insights into the state-of-the-art of CML treatment in the U.S. context. Due 
to the small sample size and the limitation to the region of Utah, results should 
be interpreted carefully. However, the responses for ponatinib and bosutinib are 
particularly valuable for the model due to lack of QoL and long-term data.
ognized the added benefit claim in 2 cases only. In an additional 2 cases no clear scor-
ing was provided for the QOL outcome and in the remaining 11 cases no additional 
benefit was acknowledged. The main reasons were missing statistical significance 
of results or the submitted QOL data were regarded as not usable. cOnclusiOns: 
In a majority of value dossiers companies included QOL data and also most often 
claimed an added benefit in QOL. However, the assessors have accepted this added 
value in exceptional cases only. In order to get an added value recognized showing 
both statistical and clinical significance of results is required.
PCN173
FEASIBILITy OF A SURvEy ON THE wILLINGNESS-TO-PAy FOR COLORECTAL 
CANCER SCREENING USING SOCIAL NETwORKS
Hessel F.P., Fortes C.S., Jantzen J.H., Pion E., Andriejauskaite M., Da Costa P.ina de Sousa 
Piscarreta M, Jarvpold A.
SRH University Berlin, Berlin, Germany
Objectives: To investigate the feasibility of a online survey using social media 
(facebook) to estimate the willingness to pay (WTP) for a new diagnostic blood 
test to determine the risk of colorectal cancer. According to the approval docu-
ments of the manufacturer the new biomarker test shows a better performance, 
better handling and improved compliance of patients and physicians compared 
to standard fecal occult blood tests (FOBT). MethOds: A standardized question-
naire was accompanied by background information on colorectal cancer and 
alternative screening approaches. WTP was asked for in categories (e.g. < 100 or 
> 100 EUR) and maximum values. Other parameters such as age, sex, insurance 
status, income, family history of cancer and risk factors were determined in 
categories. The survey ran for 14 days in November 2012 and was started via 6 
facebook accounts with the possibility of further distribution. Results: Overall 
123 completed questionnaires were submitted anonymously. The average age 
was 24,2 years and in 94% the monthly income was below 1500 EUR due to their 
student status. 68% of the participants had cases of cancer in the family and 
36% knew about the colorectal cancer. The most important quality aspects of 
screening tests for were accuracy (69%), handling (14%), price (11%) and the time 
to result (6%). 24% stated that their WTP is lower than 100EUR and the mean WTP 
for S9 was 271EUR. Higher income, family history of colorectal cancer and private 
insurance status were positively correlated with a higher WTP. cOnclusiOns: 
WTP and patient preference studies via social networks such as facebook are fea-
sible, easy to perform and reveal plausible results. Advantages of online surveys 
in social networks are that the results are gained voluntarily and anonymously 
avoiding interviewer bias. Disadvantages obviously lie in a selection of young 
and healthy populations.
CANCER – Health Care Use & Policy Studies
PCN174
CANCER PATIENTS MAy HAvE A DIFFERENT POINT OF vIEw ON ONCOLOGy 
DRUG COvERAGE DECISIONS THAN NON-PATIENTS
Foley K.1, Hansen L.G.2
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Northwood, NH, USA
Objectives: Recently a major cancer center in the United States decided not to 
offer treatment using a newly launched oncology drug citing comparative effective-
ness and cost as reasons. This study looked at health care consumer opinions about 
the decision to restrict treatment options based on outcomes and price. MethOds: 
The nationally representative Truven Health PULSE Healthcare Survey gathered 
responses from 2,615 US households via landline telephone, cell phone or Internet. 
Respondents were asked their opinion regarding a decision by providers not to offer a 
new cancer treatment because it demonstrated the same benefit as an existing drug 
with the same side effects, but its cost was higher. Demographic data were gathered 
and respondents were asked if they are being/have been treated for cancer, and if a 
friend, family member or loved one is being/has been treated for cancer. Results: 
Overall, 40.5% of respondents agreed with the decision; 37.5% disagreed. Agreement 
with the decision varied with the respondents’ exposure to cancer. Those who had 
a family member, friend or loved one with cancer were least likely to agree (36%), 
while those who not only had a family member, friend or loved one with cancer, but 
also had cancer themselves were the most likely to agree (50.8%). Respondents who 
had cancer themselves with no family member, friend or loved one with cancer or 
had no experience with cancer were equally likely to agree with the decision (44%) 
(P< 0.0001). cOnclusiOns: Findings suggest that fear and experience may play roles 
in consumers’ opinions regarding restrictions on cancer medications. Individuals who 
have experienced cancer may place more value on outcomes, side effects, and/or out-
of-pocket costs than those with no personal experience or may have more realistic 
expectations for treatment. Additional research is warranted to better understand the 
drivers of consumer opinion regarding cancer treatment coverage decisions.
PCN175
ADDITIONAL INvESTMENTS, ADDED vALUE, REAL wORLD EvIDENCE AND 
ADDITIONAL CLINICAL BENEFIT IN THE CONTExT OF SUBGROUPS OF SPECIAL 
INTEREST
Walzer S.1, Holbein B.2
1MArS Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany, 2University of 
Bremen, Bremen, Germany
Objectives: Definition of target profiles for new compounds and lifecycle plan-
ning lead to clinical studies in the context of a clinical trial program. Currently 
subgroups of special interest such as elderly, pediatrics or females/males are nor-
mally not separately included in these research programmes, most of the time 
not even stratified for. The objective of this research is to analyze the inclusion of 
patient-relevant endpoints in special patient subgroups during the clinical trial 
programme which would thereafter increase the pricing opportunity of this new 
compound in the German market. MethOds: New oncology therapies which 
were authorized by the European Medicine Agency (EMA) after January 1, 2011 
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tool enables personalising therapy by analysing discordance in hormone receptor 
(HR) and Human Epidermal Growth Factor Receptor 2 (HER2) expression in CTCs 
compared to solid tumors in metastatic breast cancer patients. It is estimated that in 
total 4,41% of metastatic breast cancer patients could be treated in a more efficient 
way, leading to increase in progression free survival of 5,59 months. Increase in clini-
cal utility is expected to be the most important consequence of this implementation 
option. cOnclusiOns: CTCtrap as a monitoring tool is expected to be of most 
value. In this stage, a more appropropiate prescription of expensive therapies can 
be administered to patients who are sensitive for these therapies.
PCN181
THE IMPACT OF AMNOG ON ONCOLOGy DRUGS
Walker S.1, Honoré A.C.2, Ando G.1
1IHS, London, UK, 2IHS, Zurich, Switzerland
Objectives: The implementation of the 2011 German health care reform (AMNOG) 
introduced pricing mechanisms which oblige newly launched patented drugs to 
undergo an early evaluation of their additional benefit by IQWiG, with a final resolu-
tion given by the G-BA. Medicines which demonstrate an incremental therapeutic 
benefit versus an appropriate therapeutic comparator – with an innovation score 
ranging from 1 to 4 – enter the preferable pricing negotiation system; those failing 
to prove benefit – a score of 5 or 6 – are relegated to the reference pricing system. 
The study aims to discern how oncology drugs, which began the process of benefit 
assessment during 2012, fared under the new system, and whether survival data 
influenced the decisions. MethOds: We reviewed both IQWiG and G-BA documents 
relating to eight cancer drugs assessed during 2012 to determine whether each drug 
received a positive or negative early benefit assessment. Reasons for each specific 
decision were then investigated. Results: Of the five drugs qualifying for pricing 
negotiations, vemurafenib (Roche, Switzerland) was the only drug to demonstrate 
a statistically significant improvement in overall survival (OS) at the time of assess-
ment. It received the highest innovation score of the five qualifying drugs. For the 
three drugs not qualifying for pricing negotiations, the G-BA cited an incomplete 
dossier or issues with comparators as the reason for rejection. cOnclusiOns: 
Although OS is considered the favoured clinical endpoint, the study results show 
that this endpoint is not always necessary to enter pricing negotiations. However, 
when OS is not proven, the G-BA often gave a positive assessment to only a small 
portion of eligible patients. Additionally, two of the qualifying drugs were orphan 
drugs, which entails exemption from the need to prove an additional benefit if 
annual sales are below EUR50 million.
PCN182
DEvELOPING PERSONALIzED MEDICINE DRUGS - INCENTIvES FOR 
PHARMACEUTICAL COMPANIES
Noweski M.1, Hessel F.P.2, Walendzik A.1, Jahn R.1, Wasem J.1
1University of Duisburg-Essen, Essen, Germany, 2SRH University Berlin, Berlin, Germany
Objectives: Stratification of oncology drug therapy by genetic marker diagnostics 
can reveal additional patient benefit but also might influence the development 
process of drug manufacturers. The objective of this study is to identify and describe 
the most important incentives for pharmaceutical companies to develop person-
alized medicine drugs. MethOds: To describe the main factors influencing the 
decision-making process in the development of personalized medicine drugs. The 
main factors influencing the process and their priority ranking were determined by 
structured expert interviews with pharmaceutical companies, test manufacturers 
and other key stakeholders such as regulatory bodies, reimbursement decision mak-
ers and payers. Results: In contrast to small companies big international compa-
nies constantly look for suitable companion diagnostic tests to select subgroups of 
high responder. The most important key factor for market success is the extent of 
clinical efficacy in comparison with competitors respectively the current treatment 
standard. Stratification of patient populations according to treatment response or 
frequency of adverse events using biomarker is regarded to increase clinical efficacy 
of the target indication. The test performance is important due to unsolved safety 
issues although not regarded as crucial for the success of the drug. In contrast 
to other stakeholders pharmaceutical companies did not consider personalized 
medicine to relevantly decrease development costs or marketing efforts respectively 
to increase the price potential for new drugs. A low prevalence of the remaining 
patient population after testing is not seen as a factor which might lead to a stop 
of the development of a new drug by pharmaceutical companies. cOnclusiOns: 
Genetic stratification is seen as a breakthrough in cancer therapy by pharmaceutical 
companies and physicians. Due to the current need for improvement of approval 
and reimbursement processes for personalized medicine approaches in oncology 
especially in Europe future sales are more difficult to predict.
PCN183
ARE ICER THRESHOLD vALUES MALLEABLE? THE CASE OF LIFE-ExTENDING 
CANCER TREATMENTS AT THE END OF LIFE
Moïse P.1, Sweeney N.2, Lie X.2
1Quintiles Consulting Europe, Levallois-Perret, France, 2Quintiles, Hoofddorp, The Netherlands
Objectives: HTA bodies treat end of life (EOL) conditions differently than other 
conditions? And if so does this depend on whether they have a specific policy for 
EOL? MethOds: NICE’s website was searched for single technology appraisals of 
cancer drugs evaluated between January 2009 to May 2013 for which NICE’s supple-
mentary advice for EOL treatments was accepted. The websites of other agencies – 
SMC (Scotland), TLV (Sweden), PBAC (Australia), pCODR (Canada, except Quebec) and 
INESSS (Quebec) – were searched for HTAs of the drugs deemed to have met NICE’s 
EOL criteria. A literature search was performed to identify estimated willingness-
to-pay ICER threshold values (WTP-ICER) for each agency and to determine if the 
agency has a specific EOL policy. These were compared against the final ICERs of 
the retained HTAs. Results: Seventeen drugs were identified for which NICE’s 
EOL supplementary advice was accepted. Several of these were also evaluated by 
other agencies, but only those with final ICERs below the WTP-ICER were retained: 
PCN178
BURDEN OF HOSPITALIzATION IN PATIENTS wITH ADvANCED LUNG CANCER 
IN THE UNITED STATES
Taylor-Stokes G.1, Rider A.2, Roughley A.1, Iyer S.3
1Adelphi Real World, Bollington, UK, 2Adelphi Real World, Macclesfield, UK, 3Pfizer, New York, 
NY, USA
Objectives: To assess the burden of hospitalization in advanced lung cancer 
patients in the United States. MethOds: Oncologists (N= 101) actively involved in 
management of advanced lung cancer in United States were invited to participate 
in a lung cancer disease specific program. Each consenting physician was asked to 
complete patient record forms for 12 advanced (stage IIIB/IV) lung cancer patients 
seen in their practice and receiving 1st, 2nd or 3rd line of therapy for advanced lung 
cancer. The study period extended from Oct- Dec 2011. Data on hospitalization that 
included reasons of hospitalization and the length of stay (LOS) over the past year 
was provided by physicians from patient records. Results: Majority of the patients 
(N= 1200) were male (56%), Caucasian (71%) and Stage IV (78%), with an average age 
of 65 years. Hospitalization records were obtained for 93% (n= 1110) of the patients 
among which 22% (n= 248) of the patients ≥ 1 hospitalization events in the previ-
ous year with an average (SD) LOS of 4 (2.4) days and a median LOS of 3 days. The 
reasons reported for the 293 hospitalization events were disease symptoms (61%), 
surgery (19%) and therapy side effects (43%). The LOS for surgery related hospitaliza-
tion (n= 57) ranged from 1-12 days (mean (SD): 6 (2.9) days; median: 5 days). Among 
disease symptoms reported as reasons for hospitalization, the most frequent were 
pain (51%), dyspnea (47%) and cough (47%) respectively. Among side effects reported 
as reasons for hospitalization anemia (25%), febrile neutropenia (21%) and fatigue 
(20%) were most frequently reported. cOnclusiOns: Burden of hospitalization in 
advanced lung cancer patients is significant in the United States. Innovative thera-
pies with favorable side effect profile that also alleviate need for surgery and are 
effective in improving lung cancer symptoms could help significantly in decreasing 
hospitalization burden in advanced lung cancer patients.
PCN179
PERCEPTION OF COUNTRy-SPECIFIC HEALTH CARE REFORM AND 
CONSIDERATION OF REAL wORLD EvIDENCE IN ROUTINE PRACTICE: SURvEy 
OF ONCOLOGISTS IN EUROPEAN UNION, UNITED STATES, CHINA AND BRAzIL
Narayanan S.
Ipsos Healthcare, Gaithersburg, MD, USA
Objectives: To assess oncologist perception of their country-specific health care 
reforms and the consideration of ‘Real World Evidence’ (RWE) when prescribing 
medications in the EU, US, China and Brazil. MethOds: A multi-country cross-
sectional survey was conducted in top-5 EU countries (UK, Germany, Spain, France, 
Italy), US, Brazil and China in February 2013 using an online physician panel in the 
respective geographies; oncologists were randomly selected for survey participation 
to be geographically representative in each country. Surveys assessed the oncologist 
perceptions of health care reforms in their respective countries, and their considera-
tion of the following, when prescribing oncology medications: RWE on product effec-
tiveness/safety, patient quality-of-life (QoL) and product cost/patient affordability. 
Descriptive statistics are reported. Results: A total of 257 oncologists participated 
in the survey. Specialties included: medical oncology-69%, haemato-oncology-11%, 
radiation-oncology-9%, surgical-oncology-5%, gynecologic-oncology-3%, pediat-
ric-oncology-2%, other-2%. Geographic distribution of oncologists was: 5EU-36%, 
US-33%, China-17% and Brazil-14%. Overall, 40% of oncologists indicated that 
they were ‘not sure whether their country’s health care reform is heading in the 
right direction’ (5EU:39%, US:40%, China:44%, Brazil:36%); 38% indicated that they 
were ‘concerned of country’s health care reform’s implications for them and their 
practice’ (5EU:30%, US:50%, China:44%, Brazil:19%); 23% indicated that the health 
care reform ‘did not have enough focus on RWE needs and cost-effectiveness of 
medications’ ((5EU:16%, US:24%, China:37%, Brazil:19%). When prescribing oncology 
medications, consideration of following attributes ‘all the time’ differed across the 
countries (Overall/5EU/US/China/Brazil): RWE on product effectiveness and safety 
(37%/29%/38%/47%/42%), patient QoL (54%/48%/59%/42%/69%), product cost/patient 
affordability (23%/15%/20%/42%/28%). cOnclusiOns: Across markets, a significant 
proportion of oncologists raised concerns regarding their country-specific health 
care-reforms, and between one-third and half of the oncologists reported consid-
ering RWE data while prescribing medicines. As the health care reforms evolve in 
the studied countries, its actual implications warrant closer scrutiny to alleviate 
physician concerns and improve care delivery and outcomes.
PCN180
THE ExPECTED HEALTH ECONOMIC vALUE OF USING CIRCULATING TUMOR 
CELLS TO PERSONALIzE CANCER TREATMENT
Schreuder K.1, Hummel J.M.1, Terstappen L.W.2, Ijzerman M.J.1
1University of Twente, Enschede, The Netherlands, 2Universiteit Twente, Enschede, The 
Netherlands
Objectives: Research has shown that circulating tumor cells (CTCs) in the blood 
can give valuable information about the prognosis and treatment options in oncol-
ogy. A new approach, CTC therapeutic apheresis (CTCtrap) is being developed for use 
in breast and prostate cancer. At the moment it is not clear where in the diagnostic 
track CTCtrap could be of most value. The goal of this study is to estimate the health 
impact of using CTCtrap in 1) screening for breast cancer; 2) early staging of tumors; 
and 3) therapy response monitoring. MethOds: A systematic literature study and 
experts’ interviews were used to document the diagnostic track in breast cancer. 
Headroom analysis and early health economic modelling was used to estimate the 
health impact of implementing CTCtrap at the three different purposes. Results: 
Dependent on the assumption of sensitivity, the CTCtrap could decrease the total 
screening costs. Yet, it is expected that this application only has limited clinical util-
ity. In the early staging, the CTC trap can replace the currently used FDG-PET-CT. The 
CTCtrap could provide additional staging information and therapy can be selected 
more specifically, eliminating unnecessary costs. Finally, CTCtrap as a monitoring 
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initial analysis of the first 18 months of the SPA scheme indicated that the length of 
gefitinib therapy was at least that anticipated by NICE. This study aims to validate 
the length of therapy in a larger cohort with up to 3 years follow-up. MethOds: The 
SPA administrative database contained information on packs (30-days therapy/pack) 
dispensed to patients from September 2009 to December 2012. This retrospective 
study included patients registered on the database prior to the end of 2012, fulfill-
ing NICE eligibility criteria and receiving at least 3 packs for which the NHS was 
invoiced. Patients were considered censored if they had ≥ 1 pack recorded in the last 
3 months of the database. Median time to treatment cessation was estimated from 
a Kaplan-Meier curve of packs supplied to patients and the mean number of packs 
dispensed per patients from a parametric failure time model. Results: 883/1160 
registered patients met the study eligibility criteria (460/883 censored). These 883 
patients, for whom the NHS was invoiced the single fixed payment, received a median 
of 13 packs 95%CI[12,14], equivalent to 12.8 months to treatment cessation. A mean of 
19.4 95%CI[18.0, 21.0] packs were dispensed per patient. cOnclusiOns: The results 
of this observational study confirm the average length of gefitinib therapy and mean 
number of packs dispensed in the SPA scheme exceed that assumed by NICE.
PCN187
TREATMENT PATTERNS OF INDOLENT NON-HODGKIN LyMPHOMA PATIENTS 
UNDER THE BRAzILIAN PUBLIC HEALTH CARE PERSPECTIvE
Vitale V.1, Asano E.2, Rego M.A.2, Pereira M.L.2
1Janssen Cilag Farmaceutica, São Paulo, Brazil, 2Janssen-Cilag Farmaceutica, Sao Paulo, Brazil
Objectives: To identify the chemotherapeutic treatment patterns in patients with 
indolent non-hodgkin lymphoma (NHL) treated in the Brazilian Public Healthcare 
System. MethOds: A retrospective longitudinal analysis based on the Government 
administrative claims database (Datasus) was performed from January 2008 to 
December 2012. Eligibility criteria were patients with indolent NHL diagnosed until 
January 2012 and starting their first chemotherapy regimen from January 2008 to 
January 2012. This cohort of patients was followed until December 2012, death or loss 
of follow-up. Patients without interruption during treatment and without change in 
medication were considered in the same chemotherapy regimen. Descriptive statis-
tics (average, standard deviation and percentage) of treatment regimens, treatment 
free interval (TFI), age at the beginning of treatment, gender and length of treatment 
were performed. Results: A total of 817 patients with indolent NHL representing 
5,449 APACs (Authorization for High Complexity Procedures) met eligibility criteria. 
The population cohort comprised 50.7% men with an average age of 61.3±14.5years. 
72.2% of the patients had only one chemotherapy regimen, whereas 18.2% had two 
and 9.1% had three or more chemotherapy regimens. Time between diagnose and 
the beginning of treatment was 3.6±6.2 months. The most widely used first chemo-
therapy regimen was cyclophosphamide, vincristine and prednisolone (CVP)(22.2%) 
followed by cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) 
and rituximab(15.7%), cyclophosphamide, vincristine and prednisolone (COP) and 
rituximab(5.6%), chlorambucil and prednisone(4.8%). Average length of treatment 
was 5.0±3.7months. For second chemotherapy scheme, the most widely used regi-
men was CHOP and rituximab(14.1%), CVP(7.5%), interferon(9.3%), chlorambucil 
and prednisone(6.2%). The average length of treatment was 4.0±4.1months, with 
an average TFI of 3.3±4.2months. cOnclusiOns: The most used chemotherapy in 
first regimen was CVP. Rituximab in combinations was present in most patients in 
the first scheme. Rituximab in second scheme in combination with CHOP was the 
most used therapy. The length of treatment was longer in first scheme.
PCN188
CURRENT SITUATION OF ORAL ANTICANCER TREATMENTS USE IN FRANCE: 
THE ACTOR STUDy (ANALySIS OF CANCER TREATMENTS GIvEN ORALLy)
Benjamin L1, Maurel F.2, Bardoulat I.2, Ricarte C.2
1GlaxoSmithKline, Marly-le-Roi, France, 2IMS Health, La Défense, France
Objectives: Within the last decade market authorizations for oral anticancer treat-
ments (OATs) have increased. This analysis aimed at describing the current situ-
ation of OATs and their modalities of use. MethOds: An analysis was performed 
from Oncology Analyzer™ (IMS Health, France), a physician survey database covering 
more than 10,000 cancer patients per year treated in both public and private insti-
tutions from multiple French regions. The database includes patient demograph-
ics, diagnosis and treatment patterns. Data was extracted for all types of cancers 
and described as number of patients treated by oral and intravenous (IV) anticancer 
drugs. Data was collected from October 2011 to September 2012. Analyses were split 
into different active anticancer treatment categories and excluded supportive care 
agents. Results: A total of 7426 patients treated with oral and IV anticancer treat-
ments in France were included in the analysis. The male/female ratio was 47%/53% 
and 58% of patients were aged over 60 years old. Patients receiving OATs were mainly 
diagnosed with a solid tumor (74%) such as breast cancer (34%), non-small cell lung 
cancer (8%) and colorectal cancer (7%). OATs represented 45% (54/119) of all molecules 
available (oral and IV) of which 44% (24/54) were cytotoxic chemotherapies, 28% (15/54) 
were targeted therapies, 22% (12/54) were hormonal-therapies and 6% (3/54) were 
immunotherapies. 32% of patients (2,410/7,426) received a regimen containing at least 
one OATs among them 78% received OATs only versus 18% received a combination 
of oral and IV drug. Sixty-one percent of patients aged over 80 years received OATs, 
as compared to 26% of patients aged less than 60 years. cOnclusiOns: The ACTOR 
study is the first analysis focused on the understanding of the pattern of use of OATs. 
One third of cancer patients in France are treated with OATs especially among the 
elderly. Further research is needed to understand the OATs uptake.
PCN189
A DISEASE MODEL OF METASTATIC COLORECTAL CANCER INCLUDING 
MULTIPLE TREATMENT LINES
van Rooijen E.M.1, Uyl-de Groot C.A.1, Punt C.2, Koopman M.3, Coupe V.M.4
1Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands, 
2Academic Medical Center, Amsterdam, The Netherlands, 3University Medical Center Utrecht, 
Utrecht, The Netherlands, 4VU University Medical Center, Amsterdam, The Netherlands
11 SMC; 9 PBAC; 3 TLV; 4 pCODR; 3 INESS. The literature search revealed the follow-
ing WTP-ICERs: NICE (20,000 - 30,000 GBP); SMC (30,000 GBP); PBAC (45,000 – 75,000 
AUD); TLV (777,000 SEK); pCODR and INESS (50,000 – 70,000 CAD). Of the agencies 
with specific EOL policies, the number of drugs recommended as cost-effective 
despite final ICERs greater than the respective WTP-ICERs were 11 (65%) NICE; 5 
(45%) SMC; 0 PBAC and 1 (33%) INESSS. The corresponding figures for the agencies 
with no specific EOL policy were 0 TLV and 4 (100%) pCODR. cOnclusiOns: The 
evidence suggests some HTA bodies treat EOL conditions differently, however the 
example of pCODR suggests this need not depend on having a specific EOL policy. 
In fact, the results for PBAC and INESSS show that having a specific EOL policy is 
no guarantee EOL conditions are treated differently.
PCN184
TREATMENT PATTERNS OF CHRONIC LyMPHOCyTIC LEUKEMIA PATIENTS 
UNDER THE BRAzILIAN PUBLIC HEALTH CARE PERSPECTIvE
Vitale V.1, Asano E.2, Rego M.A.2, Pereira M.L.2
1Janssen Cilag Farmaceutica, São Paulo, Brazil, 2Janssen-Cilag Farmaceutica, Sao Paulo, Brazil
Objectives: To identify the chemotherapeutic treatment patterns in patients 
with chronic lymphocytic leukemia (CLL) treated in the Brazilian Public Healthcare 
System. MethOds: A retrospective longitudinal analysis based on Government 
administrative claims database (Datasus) was performed from January 2008 to 
December 2012. Eligibility criteria were patients with CLL (ICD code C911) diagnosed 
until January 2012 and starting their first chemotherapy regimen from January 2008 
to January 2012. This cohort of patients was followed until December 2012, death or 
loss of follow-up. Patients without interruption during treatment and without change 
in medication were considered in the same chemotherapy regimen. Descriptive sta-
tistics (average, standard deviation and percentage) of treatment regimens, treat-
ment free interval (TFI), age at treatment start, gender and length of treatment were 
performed. Results: A total of 1,538 patients with CLL representing 15,371 APACs 
(Authorization for High Complexity Procedures) met eligibility criteria. The popula-
tion cohort comprised 56.6% men with an average age of 67.4±12.1 years. 55.0% of 
the patients had only one chemotherapy regimen, whereas 44.9% had two and 19.4% 
had three or more chemotherapy regimens. Time between diagnosis and beginning 
of treatment was 4.3±7.6 months. The most widely used first chemotherapy regimen 
was chlorambucil (54.9%), followed by cyclophosphamide, vincristine and predni-
solone (CVP) (9.1%), fludarabine and cyclophosfamide (FC) (8.1%) and chlorambucil 
and prednisone (7.0%). Average length of treatment was 6.3±5.7 months. For second 
chemotherapy scheme, the most widely used regimen was chlorambucil (45.3%), fol-
lowed by FC (11.0%), CVP (7.8%), chlorambucil and prednisone (6.2%) and CHOP (3.5%). 
The average length of treatment was 4.9±3.6 months, with an average TFI of 3.5±5.0 
months. cOnclusiOns: Chlorambucil was the most used therapy as both first and 
second chemotherapy regimen. There was a decreasing of Chlorambucil and an 
increasing of FC in second scheme. The length of treatment was longer in first scheme.
PCN185
EvOLUTION OF ORAL ANTICANCER TREATMENTS USE IN FRANCE FROM 2004 – 
2012: RE-ACTOR STUDy (RETROSPECTIvE ANALySIS OF CANCER TREATMENTS 
GIvEN ORALLy)
Benjamin L.1, Maurel F.2, Bardoulat I.2, Ricarte C.2
1GlaxoSmithKline, Marly-le-Roi, France, 2IMS Health, La Défense, France
Objectives: Within the last decade market authorizations for oral anticancer 
treatments (OATs) have increased but no published data are available on their 
use over time. This analysis aimed at describing the evolution of OATs use in 
France. MethOds: A retrospective analysis was performed from Oncology Analyzer™ 
(IMS Health, France), a physician survey database covering more than 10,000 cancer 
patients per year treated in both public and private institutions from multiple French 
regions. The database includes patient demographics, diagnosis and treatment pat-
terns. Data were extracted for all cancers patients treated by oral and intravenous 
(IV) anticancer drugs from October 2004 to September 2012. Analyses included active 
anticancer treatments (chemotherapy, targeted therapy, hormonal-therapy, immu-
notherapy) excluding supportive care agents. Results: The proportion of cancer 
patients receiving OATs increased from 2,241/7,891 (28%) to 2,410/7,426 (32%). Data 
showed an increasing use of OATs over time especially among patients aged over 70 
years (i.e. 40% in 2004 vs. 46% for patients in 2012). The proportion of OATs among all 
anticancer drugs (oral and IV) remains stable over time (45.1% in 2005 (41/91) vs. 45.4% 
in 2012 (54/119). The number of molecules available in oral form was stable except for 
targeted therapies (4 in 2004 vs. 15 in 2012). Data related to some molecules available 
in both forms (oral and IV) such as melphalan, fludarabine, topotecan, confirmed 
the preferential use for the oral route of administration over time. cOnclusiOns: 
The Re-ACTOR study confirms the increasing uptake of OATs in oncology in France. 
The number of patients receiving OATs increases over time especially for targeted 
therapies. This trend draws the attention of the necessity to reinforce measures to 
accompany the development of OATs in terms of safety and health care delivery, 
especially for the elderly who require specific attention to provide them with patient 
support tools and programs.
PCN186
THREE yEARS OF THE GEFITINIB UK SINGLE PATIENT ACCESS (SPA) SCHEME: 
DURATION OF TREATMENT FOR PATIENTS wITH EGFR MUTATION POSITIvE 
NSCLC IN NHS CLINICAL PRACTICE
Vioix H.1, Franzen S.2, Selby D.1, Collomb D.1, Hauch O.3, Emmas C.1
1AstraZeneca UK Ltd., Luton, UK, 2AstraZeneca R&D, Mölndal, Sweden, 3AstraZeneca 
Pharmaceuticals LP, Wilmington, DE, USA
Objectives: The UK National Institute for Health and Clinical Excellence (NICE) 
recommended gefitinib as cost-effective for use first line in locally advanced or 
metastatic, EGFR mutation positive NSCLC, when supplied via the SPA scheme, 
based on the mean duration of treatment observed in the IPASS study (8.8 months). 
The single fixed payment under the scheme is triggered at the order of the third 
30-day pack and covers a patient for their total supply of gefitinib treatment. An 
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A FRAMEwORK FOR THE COST-EQUALITy ANALySIS OF HEALTH CARE 
PROGRAMMES
Asaria M.1, Griffin S.1, Cookson R.1, Tappenden P.2, Whyte S.2
1University of York, York, UK, 2University of Sheffield, Sheffield, UK
Objectives: To describe a methodological framework for the economic evalua-
tion of health care programmes that addresses effects on unfair health inequality 
as well as overall health. The framework is designed to highlight the social value 
judgements required to define unfair health inequality and how these impact on the 
estimated level of inequality, and is distinct from equity weighting or multi-criteria 
decision analysis. Application of the framework comprises characterisation and 
quantification of the distribution of health, and this is illustrated using an existing 
decision model evaluating a bowel cancer screening programme. MethOds: The 
decision model of bowel cancer screening is restructured using additional infor-
mation on the distributions of screening uptake, baseline health levels, quality-
adjusted life expectancy and health opportunity costs in order to estimate the 
health distribution resulting from alternative bowel cancer screening policies. 
Standard screening is compared to two re-design policies wherein reminders are 
used to increase uptake. Different sets of social value judgements are applied to 
explore the robustness of the results, using different approaches to measuring ine-
quality and to adjusting health distributions for fair sources of inequality. Results: 
A universal reminder to participate in bowel cancer screening results in the greatest 
improvement in total population health, but increases inequality compared to no 
reminder or targeted reminders. Targeting reminders by deprivation and ethnicity 
reduces health inequality. The choice between screening policies depends on the 
type and level of inequality aversion and on the value judgements about which 
sources of health inequality are unfair. cOnclusiOns: The framework imposes 
additional data requirements and requires that decision makers consider sup-
plementary value judgements compared to standard cost-effectiveness analysis. 
Differential uptake of screening results in significant, potentially avoidable, health 
inequalities. This framework can provide decision makers with useful information 
to help address such inequalities while appropriately addressing any trade off with 
improving overall health.
PCN194
DECISION MAKING IN HIRA FOR 5 yEARS OF POSITIvE LIST SySTEM
MiHai P.
Health Insurance Review & Assessment Service, Seoul, South Korea
Objectives: In Korea, the Positive List System was adopted in the end of 2006 
and the cost-effectiveness had been important in decision making process 
for reimbursement. We tried to check the appraisal results. MethOds: Total 
of 5-years decision-making from 2007 to 2011 were reviewed and classified in 
several categories according to relative effectiveness and submission type of 
cost-effectiveness. Results: Among 219 results which were made decision 
there were 149 recommendations(68%) for listing. Fifty submissions were cost-
effectiveness(utility) analysis report but 26 submissions of those were improved 
relative effectiveness compared to the comparator. Twenty-four drugs were sub-
mitted CEA or CUA even though they didn’t have evidence for improvement. If 
there was no evidence for the relative effectiveness or the new drug was inferior 
HIRA decided not to list. If new drug had evidence for non-inferiority it could be 
evaluated by cost-minimization analysis. Eleven drugs were decided to be listed 
among 12 submissions by CMA. There were 9 essential drugs to be appraised 
for 5 years. cOnclusiOns: The most important factor in decision-making for 
reimbursement was relative effectiveness and the method of economic evalua-
tion was determined by drug’s relative effectiveness. In deciding acceptability in 
cost-effectiveness results the other factors are considered whether the drug used 
in severe disease or it was orphan drug, etc.
PCN195
HEALTH CARE RESOURCE UTILIzATION AND ExPENDITURES OF INCIDENT 
BREAST CANCER PATIENTS IN THE NETHERLANDS: RETROSPECTIvE ANALySIS 
OF HEALTH INSURANCE DATA
Tariq L.1, Steins Bisschop C.N.2, Haj Mohammad G.1, Stricker M.S.2, de Wit G.A.2,  
van Rossum-Schornagel Q.C.3, Hövels A.M.4, Peeters P.H.2, May A.M.2
1GlaxoSmithKline, Zeist, The Netherlands, 2Julius Center for Health Sciences and Primary 
Care, UMC Utrecht, Utrecht, The Netherlands, 3University Medical Center Utrecht, Utrecht, The 
Netherlands, 4Utrecht University, Utrecht, The Netherlands
Objectives: Breast cancer generates a considerable economic burden. This study 
aims to quantify health care resource utilization and health care expenditures of 
breast cancer patients in The Netherlands. MethOds: A bottom-up cost-analysis 
was conducted using health insurance data retrieved from the AGIS Health Database 
in The Netherlands containing information on health care usage and –expendi-
tures. Additionally, we estimated cost of in-hospital breast cancer medication in 
a top-down manner, based on Dutch National Breast Cancer treatment guide-
lines. Incident breast cancer cases (2008-2010) were included based on Diagnosis-
Treatment-Combinations (DTC) codes containing the diagnosis of breast cancer. 
Health care resource utilization and expenditures were examined per phase of treat-
ment (the year of diagnosis, second year, third year and last year of life). Results: 
A total of 3494 newly diagnosed breast cancer patients were identified in the AGIS 
database, with an average age of 63 years at diagnosis. During the follow-up period, 
220 patients died. Health care expenditures of Dutch breast cancer patients insured 
at AGIS were on average € 17.120 per case in the year of diagnosis, € 9.014 in the 
second year, € 5.499 in the third year and € 14.900 in the last year of life. The major-
ity of the expenditures were related to health care utilized in the hospital setting. 
Additional costs of treatments with expensive drugs varied between € 15.462 and 
€ 38.877, depending on the type of treatment. cOnclusiOns: Health care usage and 
expenditures of Dutch breast cancer patients are substantial in the year of diagnosis, 
decrease in the second and third year after diagnosis, and then increase again in 
the last year of life. Treatment with expensive drugs adds a substantial cost burden.
Objectives: To develop a decision-analytic model describing the current course of 
disease, including the available treatments, in metastatic colorectal cancer to serve 
as a baseline for the analyses of new developments. MethOds: A disease model 
was constructed containing six disease states, namely ‘first-line treatment’, ‘pro-
gression of disease after first-line’,’ second-line treatment’, ‘progression of disease 
after second-line’, ‘third-line treatment’ and ‘death’. Time spent in each state was 
predicted using log-logistic, log-normal or Weibull survival models, utilizing simu-
lated characteristics. All survival models and simulated characteristics were based 
on patient-level data, provided by the CAIRO trial (n= 820). The model was validated 
by comparing various outcome parameters with the original data. Results: The 
overall survival of the simulated cohort resulted in a median survival of 498 days. 
The original patient level data had a median OS of 508 days (95% CI: 463- 545). For 
the subgroups age and treatment line data continued to match consistently with 
patient-level data. Patients treated with sequential therapy in the RCT had an OS of 
492 days (95% CI 416-557), the model predicted an OS of 489 days. Patients in the RCT 
with combination therapy had an OS of 525 days (95%CI 442-591days), the model 
predicted 509 days OS. Similar results were achieved in other subgroups and for 
various other outcome measures. cOnclusiOns: The model constructed during 
this study is a good basis on which to model the effectiveness and cost-effectiveness 
of numerous new treatment options, including expensive drugs. It will also allow 
- in future - for the evaluation of these treatment options while accounting for the 
heterogeneous nature of colorectal cancer As such this model offers a method to 
aid in determining the optimal sequence of treatments for patients with metastatic 
colorectal cancer, both in terms of costs and effects.
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Objectives: To describe the utilization of chemotherapy agents administered 
to women with a diagnosis of breast cancer, by stage of disease. MethOds: 
Chemotherapy utilization was extracted from two databases with population-
level coverage [New Drug Funding Program (NDFP) and Activity Level Reporting 
(ALR) data] for women diagnosed with breast cancer between January 1, 2005 and 
December 31, 2009 and resident in Ontario, Canada. NDFP included expensive 
antineoplastics. ALR included only intravenous antineoplastics for agents admin-
istered at cancer centres. Each entry in the database represented one exposure to 
an antineoplastic medication administered and funded by the province. Hormonal 
therapies were not included in this analysis. All duplicate entries (same patient, 
same drug, same date of administration, same dose) were excluded. Overall utiliza-
tion and utilization by stage of disease were determined. Chemotherapy regimen 
utilization was not analyzed, only individual drug use was. Results: There were 
39,656 breast cancer cases (34.4% Stage I; 31.8% Stage II; 12.0% Stage III; 3.9% 
Stage IV; 17.9% Unstaged) with a mean age of 61.6 ± 14.0 years. Among all cases 
(staged and unstaged), 17,383 (43.8%) received chemotherapy. The most common 
drugs administered across the entire cohort were cyclophosphamide (68.4%), doc-
etaxel (52.8%), epirubicin (47.3%), fluorouracil (36.2%), doxorubicin (31.6%) and 
traztuzumab (24.3%). The drug utilization for Stage I/II was cyclophosphamide 
(72.9%), docetaxel (52.0%), epirubicin (49.6%), fluorouracil (37.9%), doxorubicin 
(31.2%), paclitaxel (23.0%) and traztuzumab (22.8%). For Stage III/IV utilization 
was as follows: cyclosphosphamide (68.3%), docetaxel (62.4%), epirubicin (45.6%), 
doxorubicin (36.1%), traztuzumab (27.8%) and paclitaxel (26.0%). cOnclusiOns: 
This frequency distribution of chemotherapeutic agents provides population level 
data on the management of breast cancer, by stage. Future work will involve cost-
ing of these medications from a population perspective.
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RACIAL DISPARITy IN HEALTH CARE ACCESS AND OUTCOMES ASSOCIATED 
wITH PROSTATE CANCER IN THE UNITED STATES
Roy D.1, Blanchette C.M.2
1University of North Carolina, Charlotte, Charlotte, NC, USA, 2University of North Carolina, 
Charlotte, NC, USA
Objectives: Clinically significant prostate cancer is characterized by the growth 
of a tumor of more than 20 cc of cancerous cells within the prostate gland. 
Literature suggests significant disparities in prostate cancer prevalence and out-
comes between Whites and African-Americans resulting in greater health services 
utilization. This study assessed the count of health care visits between White and 
African American prostate cancer patients. MethOds: This cross-sectional study 
used data from the 2010 Medical Expenditure Panel Survey. Negative binomial 
regression models were used to estimate the count of health services including 
emergency department visits, outpatient services and inpatient services associ-
ated with race in patients with prostate cancer while controlling for age and count 
of comorbidities. Patients who were not White or African-American were excluded 
due to the small numbers. Results: The total sample consisted of 141 patients, of 
which 104 were White and 37 were African-Americans. Being White was associated 
with 43% less use of emergency services compared to being an African American 
while adjusting for age and comorbidities (IRR 0.57; 95% CI 0.33-0.97). Similarly, 
being White was associated with a 44% lower count of outpatient service use (IRR 
0.56; 95% CI 0.32-0.99). No difference was found with inpatient services, most 
likely due to a low number of events. cOnclusiOns: Being White was associated 
with less emergency and routine health care visits compared to being an African 
American, suggesting a disparity may exist among prostate cancer patients. More 
research should explore the sources of the disparity and whether this translates 
into other health care services like access to treatments.
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(95%CI: $U.S.334 to $U.S.856) per dose of IV and SC bortezomib. Over a full cycle of 
therapy (i.e. 4 doses), the total cost for drug delivery including wastage and drug 
acquisition would be substantial at $U.S.7,113 and $U.S.6,327 for IV and SC bort-
ezomib respectively. cOnclusiOns: SC bortezomib resulted in a significant savings 
in drug delivery resources. However, drug wastage remained an important factor, 
regardless of the route of administration.
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RETROSPECTIvE ANALySIS OF ONCOLOGy INDICATIONS UTILIzING DRUG 
ExPENDITURES FROM 2005 TO 2012 IN THE REPUBLIC OF SRPSKA
Guzvic V.1, Komjenovic D.1, Zah V.2
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Canada
Objectives: Analyses were conducted on Republic of Srpska (RS) Health Insurance 
Fund (HIF) national prescription database. Analyses explored health expenditure 
in pharmaceutical consumption of oncology medications for the fiscal year 2005 
through 2012, in order to determine impact of introduction of public tenders in 
2008. RS HIF provides coverage for a population of 1.2 million. MethOds: RS HIF 
national prescription database was explored. Key cost drivers and the differences 
were identified across all medications covered by the RS HIF. Results: In 2005, total 
expenditure for all Oncology medication was € 1.2 million. In 2012, total expenditure 
for all Oncology medications was € 8 million. This increase of 681% is a result of two 
critical factors: 1) a national policy shift in 2004, of patient treatment switch from 
being treated abroad in Republic of Serbia to being locally treated; 2) exponential 
increase in Oncology indications incidence. In 2008 there was an introduction of 
public tenders that run every two calendar years, which allowed additional medi-
cations to be purchased by the RS HIF, as well at lower costs and hence it resulted 
in moderate decrease in expenditures, even though there was a steady increase in 
quantities purchased. This resulted in balanced and average expenditure from 2008 
to 2012 of € 9 million. Based on 2005 through 2012 consumption of Oncology medica-
tions, it is derived that over the years to date, top three Oncology indications are: a) 
Metastatic breast cancer, b) Metastatic colorectal cancer, c) Colorectal cancer Stage 
III. cOnclusiOns: Results indicate that most of the patients treated abroad, trans-
ferred back to RS HIF for treatment by 2008. Top three Oncology indications show 
that there is a need for higher public awareness and patient education in RS related 
to them. This is in line with current RS public health care policies and strategies.
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MARKET ACCESS OF CANCER DRUGS IN EUROPEAN COUNTRIES: A MATTER OF 
SETTING PRIORITIES FOR RESOURCE ALLOCATION
Pauwels K., Huys I., De Nys K., Casteels M.R., Simoens S.
KU Leuven, Leuven, Belgium
Objectives: Public health systems need to make well-founded choices in order to 
distribute their scarce resources in the most efficient way. Given the large number 
of cancer patients and their increasing life expectancy, public/private investments 
in oncology research, the growing launches of new anticancer agents and con-
sequent high budget impact of cancer care, market access of cancer drugs has 
become delicate over the last decade. Furthermore, decision makers are challenged 
by ethical considerations and endeavor after fair and equal access to treatments 
for cancer patients. The aim of this study is to generate an overview of price set-
ting and reimbursement procedures for cancer drugs in eight European coun-
tries. MethOds: Belgium, The Netherlands, France, Germany, Italy, Poland, UK and 
Sweden were selected as the countries of interest. Results were collected between 
January and March 2013 through a literature review and a qualitative question-
naire sent to authorities involved in price setting and reimbursement of drugs. 
The specific section of results for each country was validated by experts in the 
field. Results: Diverse measures are introduced to optimize market access of can-
cer drugs such as adjusted cost-effectiveness thresholds and new market access 
agreements. Additionally, innovative cancer drugs are excluded from explicit cost 
control measures in some of the studied countries. Given the fact that each drug 
covered by the limited public health care budget might possibly exclude another 
one from reimbursement, results suggest preferential treatment of cancer drugs 
compared to drugs for other diseases. Besides societal preferences for treatments 
of severe diseases, there is no solid evidence that could justify prioritization of can-
cer. cOnclusiOns: Price setting and reimbursement procedures seem to prioritize 
cancer above other disease areas. Further research needs to address the question if 
society attributes higher value to cancer drugs than to treatments for other diseases.
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A NOvEL ALGORITHM USING CLAIMS DATA TO IDENTIFy PATIENTS wITH 
CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Gorritz M.1, Thompson S.F.2, Lee Y.C.1, Stern L.1, Penson D.F.3
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Objectives: CRPC is an advanced form of prostate cancer with poor prognosis. 
The changing treatment landscape calls for use of real-world data to provide cur-
rent information on disease epidemiology, treatment patterns, comparative effec-
tiveness, and treatment cost. Administrative claims databases are a rich source of 
real-world data; however, they lack clinical values needed to identify CRPC patients. 
As currently there is no standard method to identify CRPC patients when clinical 
variables are unavailable, we developed and validated an algorithm using claims 
data to reliably identify CRPC patients. MethOds: Male patients with an ICD-9 
code for PC between January 1, 2004 and November 30, 2012 were identified from 
IMS pharmacy and medical claims data. Metastatic PC was identified by additional 
tumors on or after the PC diagnosis. Surgical castration was determined using CPT 
and ICD-9 procedure codes for orchiectomy; medical castration was identified using 
codes for hormone therapies. The algorithm identified patients as having CRPC 
if they had any of the following: 1) switch in hormone therapy; 2) new metasta-
ses while on hormone therapy; 3) switch in treatment from any hormone therapy 
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COST OF END OF LIFE PHARMACOTHERAPy IN CANCER PATIENTS: wHERE 
DOES THE BUDGET GO TO?
Hammerman A., Greenberg-Dotan S., Battat E., Bitterman H.
Clalit Health Services Headquarters, Tel-Aviv, Israel
Objectives: Costs of cancer treatment has received increased attention in the last 
decade mainly because of the very high expenses on new biological drugs. Total 
cancer treatment costs vary by tumor type and stage, with the highest costs usually 
incurring in the last year of life. In this study, we characterized the drugs that have 
the highest budget-impact in treating cancer patients in Israel, immediately before 
death. MethOds: Clalit Health Services (CHS), Israel’s largest health-care organiza-
tion with over 4 million members, serves 52% of the total population. Using CHS’s 
comprehensive databases, we identified the three leading fatal cancers in 2012. We 
calculated CHS’s acquisition costs for all pharmaceuticals provided to patients in 
their last three months of life, and extracted the top budget-consuming drugs used 
during this period. Results: The leading fatal cancers in 2012 were colorectal (1551 
deaths), breast (1273) and lung cancer (1174). The drugs with the highest budget-
impact in colorectal cancer patients were (% of total drug-expenditure, # of patients 
treated (% of the total number of patients)): Cetuximab (20.2%, 38 patients (2.5%)), 
Bevacizumab (14.6%, 56 patients (3.6%)), Panitumumab (6.6%, 21 patients (1.4%), 
Fentanyl (6.5%, 278 patients (17.9%)), Irinotecan (4.0%, 77 patients (5.0%)). In breast 
cancer: Trastuzumab (12.0%, 23 patients (1.8%)), Fulverstant (6.4%, 42 patients (3.3%), 
Fentanyl (5.9%, 178 patients (14.0%)), Lapatinib (5.5%, 10 patients (0.8%)), Zoledronic 
acid (4.1%, 59 patients (4.6%)). In lung cancer: Erlotinib (21.4%, 77 patients (6.6%)), 
Gefitinib (12.8%, 42 patients (3.6%)), Pemetrexed (10.5%, 57 patients (4.9%)), Crizotinib 
(6.0%, 8 patients (0.7%)), Fentanyl (4.5%, 298 patients (25.4%)). cOnclusiOns: A 
significant proportion of the pharmaceutical budget was spent on a relatively small 
portion of patients who received expensive novel targeted therapies during their last 
months of life although chances for success were minimal. A much higher portion 
of patients received palliative treatments for a substantially smaller proportion of 
the pharmaceutical expenditure.
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THE GERMAN QUOTA SySTEM AS A MODEL FOR BIOSIMILAR COST SAvINGS IN 
EPOETIN TREATMENT
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Objectives: To demonstrate real-world benefits of biosimilar quota system used 
in Germany. MethOds: Long before recent economic challenges health care costs 
have represented a vast and unsustainable trajectory beyond western economies 
real GDP. Biologics have become a driver of payer expenditure with an 83% increase 
in global spend expected from 2010 to 2020. The introduction of biosimilars since 
2006 represents an opportunity to reduce expenditure on biologics while maintain-
ing the quality of patient care. Uptake of biosimilars and associated cost savings has 
been very different across markets. One mechanism, to encourage utilization of bio-
similars, is to introduce quota style systems as in Germany. Using claims data from 
the KV regions to determine the use of biosimilar epoetin in relation to the quotas 
introduced by the 17 physician based regions in Germany, and the historic spend 
on epoetin treatment to calculate the budget expenditure reduction. Results: 
Driven by the German quota system together with consultancy via KV- and SHI-
pharmacists and physicians, biosimilar epoetins in Germany have obtained 57% 
of the German EPO market by Q3 2012. A reduction of 51% was experienced across 
historic public prices from January 2007 to August 2011. The increased penetration 
of biosimilar epoetin resulted in cumulative savings in Germany of € 551 million. 
German real-world research demonstrated that biosimilar epoetin treatments did 
not experience any significant differences in efficacy and safety when compared 
with the originator. cOnclusiOns: The quota system has become a significant 
driver of biosimilar epoetin uptake in Germany, which has resulted in substantial 
cumulative savings to the German health care system. Additionally this has allowed 
for extensive clinical experience with biosimilars which resulted in confirmation of 
the expected efficacy and safety outcomes. The biosimilar quota system provides 
markets with a mechanism to reduce biologic expenditure, increase patient access 
to biologic medicines and increase physician experience.
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A PROSPECTIvE TIME AND MOTION ANALySIS COMPARING INTRAvENOUS 
(Iv) vESUS SUBCUTANEOUS (SC) BORTEzOMIB IN PATIENTS wITH MULTIPLE 
MyELOMA (MM)
Dranitsaris G.1, Kaura S.2
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Objectives: Bortezomib is an effective therapy for patients with MM. The rec-
ommended dosage is 1.3 mg/m2 IV dosed on days 1, 4, 8 and 11 for eight, three 
week cycles. However, a recent randomized non inferiority trial demonstrated that 
the same dosage of bortezomib administered SC is equally effective, but with an 
improved safety profile. To measure the overall efficiency and cost savings of the SC 
route, a prospective time and motion study was undertaken in MM patients treated 
in a sample of U.S. community oncology clinics. MethOds: Time and motion and 
resource use data were collected from MM patients being treated with bortezomib 
IV (n= 20) or SC (n= 20) in seven U.S. community oncology clinics. Resource use 
and time impact on clinical staff were quantified using unit cost estimates. This 
included costs for drug preparation, wastage, administration, materials and sup-
plies, premedication, patient chair time and all labor costs. Results: The mean 
total time for IV and SC delivery (preparation, administration and total chair time) 
was 76.3 and 39.8 minutes (p = 0.005), with the associated (i.e. drug preparation and 
administration) cost being $U.S.189 and $U.S.90.84 respectively. With the inclusion 
of costs for drug wastage (i.e. mean of 1.2 mg for both IV and SC bortezomib, which 
is 34% of a 3.5 gram vial and costs approximately $U.S.500) and premedication, 
the cost for drug delivery was $U.S.808 (95%CI: $U.S.603 to $U.S.1011) and $U.S.596 
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In Germany, IQWIG has proposed to use correlations between surrogate endpoints 
and patient relevant outcomes to determine value of cancer drugs. Due to increased 
cost pressure on payers, such models are likely to inspire novel reimbursement 
schemes for other branded products. cOnclusiOns: Cancer drug reimbursement 
models are setting new benchmark for payers to manage access and control costs. 
These models have significant implications for other expensive branded products.
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THE RELATIONSHIP BETwEEN SUBMITTED LINE OF THERAPy AND 
REIMBURSEMENT DECISIONS IN SOLID STATE TUMOR CANCER DRUGS
Jao R., Jaksa A., Ho Y.S., Daniel K.
Context Matters, Inc., New York, NY, USA
Objectives: To explore the relationship between lines of therapy and submission 
for reimbursement across disease conditions and types of therapy. MethOds: This 
study looked at 252 Health Technology Assessments from eight agencies: CADTH, 
CCO, HAS, HIS, NICE, PBAC, SMC, and pCODR. The data covered 41 drugs across 
seven solid-state tumor cancer conditions. Results: Of the 41 drugs, 27% (11/41) 
were initially submitted for first-line therapy and 73% (8/11) were recommended 
for reimbursement. Similarly, 32% (13/41) were initially submitted for second-line 
therapy and 77% (10/13) were recommended for reimbursement. Cytotoxic drugs 
were most likely to be reviewed initially for first-line therapy at 35% (7/20) and 
second-line therapy at 25% (5/20); targeted therapies were most likely to be reviewed 
initially for second-line therapy at 38% (8/21) and adjuvant therapy at 24% (5/21). 
The percentage of drugs reviewed for two or more lines of therapy varied greatly 
across conditions. Colorectal Cancer, SCLC, and NSCLC had the greatest percentages 
of drugs reviewed for 2+ lines of therapy with 100% (4/4), 100% (1/1), and 83% (5/6), 
respectively. Melanoma, Prostate Cancer, and Ovarian had the lowest percentages 
with 0% (0/2), 14% (1/7), and 40% (2/5), respectively. Additionally, there was a positive 
correlation (r= 0.9) between the number of drugs reviewed and number of lines of 
therapy covered per disease condition. cOnclusiOns: There was no discernable 
difference in the rate of reimbursement between drugs initially submitted for first-
line therapy or second-line therapy. There were, however, differences in various 
trends across disease conditions and between types of therapy. Future research will 
focus on trends across agencies and will include a larger sample size covering more 
conditions as well as investigational case studies on frequently reviewed drugs.
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CLINICAL AND COST-EFFECTIvENESS OF NON-PEGyLATED LIPOSOMAL 
DOxORUBICIN FOR NON-HODGKIN LyMPHOMA: A SySTEMATIC REvIEw
Burda A.1, Zaremba A.1, Lubonski J.2, Matusewicz W.1
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Objectives: To systematically review the currently available clinical and cost-
effectiveness evidence of non-pegylated liposomal doxorubicin (NPLD) for 
non-Hodgkin lymphoma (nHL). The hypothesis under verification was that the 
administration of NPLD lowers the cardiotoxicity typical for conventional anthra-
cyclines while being able to sustain the clinical effect of treatment. MethOds: 
A systematic literature search was conducted for clinical and cost-effectiveness 
data for the nHL population treated with NPLD, using the main medical data-
bases (PubMed, EMBASE, Cochrane Library). In addition, clinical trial registries 
were searched, reference lists of included studies and reviews were screened for 
missed studies. Searches took place in September 2012. Results: The review 
generated 9 one-arm clinical trials and 1 retrospective study which met the inclu-
sion criteria. One comparative parallel trial comparing R-CHOP with R-COMP in 
the DLBCL population is ongoing, with no results published. Generally, available 
evidence is poor – studies identified are characterized by many limitations, i.e.: 
small and heterogeneous study populations, relatively short observation period, 
not always specified inclusion and exclusion criteria, diversified treatment regi-
mens (with R-CHOP dominating), shortened or/and presented selectively safety 
data. The majority of studies was performed in the DLBCL population. Cumulative 
interpretation of data was hindered due to essential differences in between trials. 
Lowering of LVEF was observed with a frequency of 0% to 31,7% of cases, while 
symptomatic lowering of LVEF with the development of chronic ischemic heart 
disease occurred with the frequency of 0 to 10%. The second most frequent car-
diological event observed was arrhythmia. Clinical efficacy focused on surrogate 
endpoints (radiological responses), defined differently in between trials. No eco-
nomic evaluations studies were found. cOnclusiOns: There is limited evidence 
on the effectiveness and safety of NPLD in patients with nHL due to the lack of 
well-designed and well-reported comparative studies. Further research is needed 
to explore the hypothesis in question.
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IMPACT OF RECOMMENDED PHARMACEUTICALS ON CANCER MORTALITy: 
ANALySIS OF REAL-LIFE DATA
Wilson T., Hamerslag L.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: To ascertain whether there were any trends in cancer mortality after 
hospital admittance and diagnosis that could be linked to recent approval of thera-
pies by the National Institute for Health and Care Excellence (NICE). MethOds: 
Using information provided by Hospital Episode Statistics and the Office of National 
Statistics, yearly mortality data from both the inpatient and outpatient population 
between 2007 and 2010 were extracted. An analysis of 30-, 60-, and 90-day mortal-
ity following admittance to hospital was undertaken for malignancies which had 
seen therapies approved by NICE after 2006. Results: Of the 37 cancer therapies 
assessed by NICE between 2006 and 2010 inclusive, 27 were recommended. Patients 
with lung cancer were found to experience one of the highest mortality rates over-
all. Interestingly, lung cancer also saw the largest number of therapies approved 
between 2006 and 2010 (7), along with a steady decline in the annual 90-day mortal-
ity over the three year period (29.6%, 28.4% and 27.1% in 2007-08, 2008-09 and 2009-
to chemotherapy. The algorithm was validated against a PSA-based definition of 
CRPC (at least two PSA increases following castration or new metastases while 
on hormone therapy). Results: A total of 269 patients met inclusion criteria and 
had 3 or more PSA measurements. The two methods agreed in 88% of patients; 220 
(81.8%) were identified as CRPC by both methods and 17 (6.3%) were identified as not 
castration resistant by both methods. A statistical comparison of the two methods 
yielded a Cohen’s kappa of 0.4491, indicating moderate agreement. cOnclusiOns: 
The algorithm was concordant with a PSA-based definition of CRPC and serves as 
a new tool to identify CRPC patients using claims data. Future validation against a 
different data source is needed.
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INCREASED RISK OF CANCER INCIDENCE ASSOCIATED wITH REPEAT MEDICAL 
IMAGING: DESIGNING BETTER CLINICAL TRIAL PROTOCOLS
Zowall H., Brewer C., Deutsch A.
Zowall Consulting Inc., Westmount, QC, Canada
Objectives: To assess the potential increase in lifetime attributable risk (LAR) 
of cancer incidence due to repeated exposure to medical imaging procedures for 
participants in clinical trials. MethOds: Medical imaging in clinical trials has 
grown exponentially in the last decade. We have developed an individual-based 
state-transition model to estimate the LAR of radiation-related cancer following a 
patient’s exposure history, and site-specific dose according to age and gender. Monte 
Carlo simulations to vary effective doses, risk model coefficients, and the period 
for radiation-related cancer latency were performed. Results: We examined two 
scenarios in a three year hypothetical clinical trial: minimal exposure describing 
a subject’s radiation exposure as one abdominal CT scan per year; and frequent 
exposure consisting of five abdominal CT scans per year. For a 30 year old female the 
LAR of cancer incidence increased from 46 per 100,000 population in the minimal 
exposure scenario to 229 per 100,000 in the frequent exposure scenario. For a 30 
year old male, the risk increased from 36 to 179 per 100,000. At age 30, females had 
a 30% higher risk than males, however, cancer incidence at ages 50, and 70 were 
similar for both sexes. At age 50 the LAR of cancer incidence increased from 31 to 
151 per 100,000. At age 70 the risk increased from 15 to 71 per 100,000. The LAR of 
cancer incidence was one third lower in 70 year olds than in 30 year olds, and half 
the rate of 50 year olds. cOnclusiOns: Although the LAR of cancer incidence of a 
single exposure seems to be relatively small, clinical trials that involve a compara-
tively large number of imaging procedures can lead to significantly higher risks. 
Examinations that deliver relatively high doses of radiation, such as CT, need to 
be clinically justified.
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TRENDS IN CHEMOTHERAPy SETTING AND COSTS FROM 2005 TO 2012: A CASE 
STUDy USING BEvACIzUMAB
Foley K.
Truven Health Analytics, Cambridge, MA, USA
Objectives: The rising costs of cancer care are a major focus for clinicians, payers 
and patients. This analysis examines trends in bevacizumab chemotherapy admin-
istration and drug reimbursement. MethOds: Using the MarketScan© Research 
Databases, administrations of bevacizumab were identified from 1/1/2005 through 
12/31/2012 for patients with commercial or employer-sponsored supplemental 
Medicare insurance. Bevacizumab claims were excluded if the claim had a diagnosis 
related to eye disease or the reimbursed amount was < $100. All claims were iden-
tified as occurring in an office-based setting (OBS), an outpatient hospital setting 
(OHS) or other setting. Results: The percent of bevacizumab claims occurring in OHS 
increased from 6 to 34% among Medicare claims, and from 14 to 42% among commer-
cial claims from 2005 to 2012. Medicare median drug reimbursement was $257 more 
for OHS than OBS in 2005, increasing to a difference of $3,022 in 2009 and declining 
to $1,722 in 2011 before narrowing to $165 in 2012. Medicare median reimbursements 
for chemotherapy administration in OHS were $408 more than OBS in 2005, dropping 
to a difference of $97 in 2008 and ending at $165 in 2012. Commercial differences in 
drug reimbursement for OHS and OBS settings continuously increased from $885 in 
2005 to $3714 in 2011, declining slightly to $3676 in 2012. Differences in chemotherapy 
administration reimbursement were $176 more for OHS than OBS in 2005, the dif-
ference decreasing to $103 in 2007 and increasing to $236 in 2012. cOnclusiOns: 
Although the difference in reimbursements to OHS and OBS has decreased over time 
for Medicare, the differences across settings for commercial insurance increased over 
time with a slight indication that cost increases are slowing. The higher reimburse-
ments in OHS combined with the shift from OBS to OHS over the past 7 years has 
implications for the growth in cancer costs over the past decade.
PCN204
NOvEL MARKET ACCESS MODELS FOR CANCER DRUGS
Aggarwal S., Kumar S., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
Objectives: Cancer drugs are the world’s highest selling category of therapeutic 
products. Due to their premium price and budget impact, several new drug reim-
bursement models have been implemented worldwide by public and private pay-
ers. These models have potential implications for coverage and reimbursement 
of all branded products. This study reviewed recent cancer drug reimbursement 
models and developed lessons and implications for future products. MethOds: 
Reviewed cancer drug reimbursement schemes in developed and emerging markets. 
Interviewed payers and KOLs to develop lessons and implications for future prod-
ucts. Results: Public and private payers worldwide have implemented several new 
models for cancer drug reimbursement to manage budgets and control costs. In the 
US, private payers are piloting single source compendia and third party protocols (eg. 
P4 Oncology) to limit off-label use of cancer drugs. In the UK, NICE has successfully 
negotiated lower price and discounts for first few cycles of therapy. In Italy, AIFA has 
implemented registry based patient access for cancer drugs. In India, several manu-
facturers have implemented novel pricing strategy for first few cycles of therapy. 
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and a combination of tegafur, gimeracil and oteracil. Across these oncology assess-
ments a total of 19 patient subgroups have been evaluated. Eleven subgroups (58%) 
showed an additional benefit according to the G-BA. Eight subgroups (42%) received 
the rating “no additional benefit” or “less benefit than comparator”. The compara-
tors chosen by G-BA within subgroups vary widely depending on the indication. 
Key factors for the positive outcome of these assessments were increased overall 
survival, reduction of symptoms or improved quality of life. Main reasons for the 
G-BA to attest no additional benefit include inappropriate indirect comparison and 
lack of adequate patient subgroup analysis. cOnclusiOns: Analysis of HTA reports 
in oncology shows that while overall survival is a strong end point, also increased 
quality of life and reduced side-effects can be sufficient to achieve a beneficial 
outcome (crizotinib: considerable benefit). Importantly, the provided data must be 
applicable to the German regulations under AMNOG, showing clinical evidence 
against the specified comparator. The amount of the additional benefit plays an 
important role in the reimbursement amount negotiations following the definition 
of the additional benefit by the G-BA.
PCN211
HEALTH TECHNOLOGy ASSESSMENT: IS IT THE RIGHT PIECE FOR THE 
jORDANIAN HEALTH CARE PUzzLE?
Al Rabayah A.A., Jaddoua S.
King Hussien Cancer Center, Amman, AL, Jordan
Objectives: To study the pharmaceutical reimbursement/Coverage decision 
making processes in Jordan to highlight the importance of conducting formalized 
technology assessments MethOds: To review publically available data regarding 
the reimbursement/Coverage decision making processes in Jordan through search-
ing related organization’s websites and publically available regulations. Results: 
Jordan is characterized with a fragmented health care system. Pharmaceutical 
registration and pricing are under the responsibility of the JFDA. Furthermore, it 
is responsible about medication selection for the Rational Drug List (the national 
formulary). The medication supply chain differs between the public and the private 
sectors in term of process and out puts. The medication selection process is not 
governed by criteria and not empowered by an independent review body to support 
decision making by the national appraisal committee (national P&T). The rational 
drug list is publically available but without details of the decision or the processes 
of decision making process. Listing of new medication is wide without indication 
specification or date of listing. The role of cost-effectiveness is limited and the ten-
der prices are not linked to any type of cost effectiveness analysis cOnclusiOns: 
The National Agenda, the National health Policy and the National Drug Policy 
tackled the high health expenditure in Jordan as an essential priority. This chal-
lenged is due to the characteristics of the Jordanian health care system that is 
fragmented with a divided funding system between public and private sectors. A 
more formalized medication selection processes empowered with drug information 
services that provide evidence based data and analysis in the form of technology 
assessment would play a role in decreasing health care expenditures. All of these 
recommendations should move parallel with improving the level of transparency 
and patient engagement.
PCN214
EPIDEMIOLOGy FOR ONCOLOGICAL DRUGS REGARDING THE BENEFIT DOSSIER 
PREPARATION IN GERMANy
Kürschner N., Schmitter S.
Pfizer Deutschland GmbH, Berlin, Germany
Objectives: An early benefit assessment of drugs after launch has been imple-
mented since 2011 in Germany. The Institute for Quality and Efficiency in Health Care 
(IQWiG) assesses the benefit of the drug based on a dossier submitted by the phar-
maceutical manufacturer. Based on this assessment and the statements by industry, 
scientific community and patient organizations the Federal Joint Committee (G-BA) 
reviews and decides on the extent of the additional benefit. The dossier needs also 
to contain information about the number of patients treated with the new drug. The 
objective is to investigate the sources considering the calculation of patient numbers 
for oncological drugs. MethOds: A review of oncological drugs which passed through 
the benefit assessment was conducted to evaluate which data sources and methods 
were used to calculate the potential patient number. The results were compared with 
IQWiG’s assessment and the final decision by G-BA, to detect possible methodologi-
cal difficulties. Results: The data sources regarding German epidemiological data 
were mainly collected through publicly available sources such as national and local 
cancer registries. Difficulties occurred with small cancer entities or when specific 
data regarding patient subpopulations (e.g. through age, tumor stages, ECOG perfor-
mance status or previous therapies) was needed. The pharmaceutical manufacturer’s 
calculations were often challenged by IQWiG and G-BA without suggesting a precise 
alternative or more suited data source. cOnclusiOns: The data collection and data 
availability within the benefit dossier process for oncological drugs is in most cases 
challenging and the efforts needed should not be underestimated. Authorities, indus-
try and medical community should work on a common solution for a more valid and 
reliable calculation of the potential patient number in oncology.
PCN215
ECONOMICAL LOSSES DUE TO DISABLEMENTPARENTS CARRING FOR CHILDREN 
wITH ONCOHEMATOLOGICAL DISEASES
Ganieva D.1, Zhukovskaya E.1, Spichak I.2
1Federal Scientific Centre of Children Hematology, Oncology, Immunologyl, Moskow, Russia, 
2Medical Academy, Chelyabinsk, Russia
Objectives: Socio-economic phenomena, caused by disease of children are reflected 
primarily in the formation of non-medical costs. Methodology for calculation of non-
medical costs includes a number of parameters, including the cost of lost output 
by persons caring for children during the treatment period. MethOds: The study 
involved patients from Oncohematological Chelyabinsk Center for Children and 
Adolescents behalf of prof. V. Gerein been treated in the period from 2008 to 2013. 
10, respectively). Similarly, patients admitted to hospital with oesophageal cancer 
experienced a high 90-day mortality rate, ranging from 22% to 21.9% in 2007-08 and 
2009-10, respectively. However, between 2006 and 2010, no therapies were submitted 
for NICE appraisal for oesophageal cancer, suggesting that there may have been a 
lack of research interest and potentially explaining why there was no substantial 
decrease in mortality from 2007, as compared to indications where therapies had 
been approved, such as lung, colon and breast cancer. cOnclusiOns: The recom-
mendation of therapies and their uptake in the UK may at least partially explain the 
trends noted in this study, although other factors such as delay in therapy uptake 
and off-label use may also need to be taken into account.
PCN208
DO NICE EvIDENCE REvIEw GROUPS (ERG) FOCUS ON DIFFERENT ASPECTS OF 
MANUFACTURER SUBMISSIONS IN ONCOLOGy?
Heemstra L., Sweeney N., Van Engen A.
Quintiles, Hoofddorp, The Netherlands
Objectives: Evidence Review Groups (ERGs) provide a critical appraisal of the manu-
facturer submission in the NICE single technology appraisal (STA) process. As the aca-
demic centres may differ in experience and methodology, the objective of this study was 
to evaluate whether the focus areas and key criticisms differ between ERGs. MethOds: 
The NICE website was searched for all NICE oncology STAs, published between June 
2010 and June 2013. The ERG reports were retrieved, and the main critiques were cat-
egorised for the five centres that performed the most evaluations. The focus areas of the 
ERGs were further studied. Results: A total of 27 STAs were identified with evaluations 
performed by 9 different ERGs. The most evaluations were performed by Liverpool (9), 
followed by Sheffield (4), and PenTAG, West Midlands and York (3 evaluations each). All 
ERGs would report uncertainties related to the extrapolation and gain in overall survival 
(OS), maturity of data, trial comparator, and the quality of life (QoL) data. In addition all 
critiques covered submission quality and disease specific challenges, yet variation was 
found in focus area between ERGs. For example a specific focus area of Liverpool was 
the OS modelling method. Proposed changes to survival modelling included separating 
the survival curves for pre- and post-progression, and removing any survival advan-
tage post-progression where this was considered inappropriate. Comments from other 
agencies on OS were mainly limited to the choice of parametric survival function. Other 
areas that differed between ERGs were the systematic review methods (more often 
reported by Sheffield) and comments on the QoL data (York). cOnclusiOns: Although 
all ERGs focus on uncertainty around the evidence and quality of the manufacturer 
submissions, the focus areas differed between the groups. The key difference seems 
to relate to research focus of the academic centre.
PCN209
REvIEw OF NICE TECHNOLOGy APPRAISALS IN ONCOLOGy: HOw DOES 
CLINICAL EvIDENCE CHANGE OvER TIME?
Dequen P., Cooper N.J., Abrams K.R.
University of Leicester, Leicester, UK
Drug licensing and reimbursement authorities worldwide are considering new 
ways to stimulate market access for innovative medicines such as accelerated 
approval and conditional coverage. Early release of pharmaceuticals calls for more 
responsive decision-making alongside continuous evidence generation through-
out clinical development. We explore whether changing trends in clinical evidence 
considerations for health technology assessment (HTA) by the National Institute 
for Health and Care Excellence (NICE) may help inform future evidence require-
ments for rapid and early HTA. Objectives: We investigate how the submission 
and acceptability of clinical evidence for single, multiple and repeated assessments 
of cancer drugs by NICE have changed in the past decade. MethOds: We reviewed 
technology appraisals published online since February 2002 by NICE for pharma-
ceuticals in oncology. Information regarding the clinical evidence included and the 
methods used to analyse relative treatment effects across relevant comparators 
was extracted. Manufacturer submissions, assessment reports, and final appraisal 
determinations were considered for longitudinal comparison. Results: Out of a 
total of 254 appraisals identified since 2002, 85 assessed cancer drugs and 76 of 
these were included for review based on available documentation. Only 11 prod-
ucts had been re-assessed to date with initial guidance superseded by a multiple 
technology appraisal or clinical guideline. We found a greater reliance on phase 
II and observational data in recent appraisals, particularly for novel therapies in 
areas of high unmet need. Limited data was also accompanied by an increase use 
of surrogate outcomes and extrapolation of observed short-term clinical benefits. 
Recent submissions were also marked by the uptake of network meta-analysis 
methodologies. cOnclusiOns: NICE has previously recommended cancer drugs 
based on immature clinical data allowing for considerable uncertainty in ‘real-
world’ effectiveness estimates. However, these examples remain the exception to 
the rule; moreover our review highlighted a need for methodological development 
to deal with early clinical evidence.
PCN210
G-BA ASSESSMENTS OF ONCOLOGy TRIALS: IS INCREASED OvERALL SURvIvAL 
A “MUST HAvE”?
Schuchardt M.1, Nijhuis T.1, Friedmann B.2
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Mannheim, Germany
Objectives: Objective of this research was to provide an overview of Health 
Technology Assessments (HTAs) in oncology after introduction of AMNOG in 
Germany. MethOds: Quintiles’ HTA database (HTA Watch) has been used to ana-
lyse HTAs in Germany. The timeframe chosen for analysis was 1st of January 2011 
to 24th of June 2013. All reports have been analysed in detail to reveal key factors for 
success or failure, which are presented in the following. Results: Since introduc-
tion of AMNOG in 2011, thirty percent (13 out of 43) of all completed assessments by 
the G-BA (Federal Joint Committee) evaluated cancer drugs. The products assessed 
were abiraterone acetate, axitinib, brentuximab vedotin, cabazitaxel, crizotinib, 
decitabine, eribulin, ipilimumab, pixantrone, ruxolitinib, vandetanib, vemurafenib 
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Objectives: To evaluate European physicians’ treatment preferences for prevent-
ing skeletal-related events (SREs) in patients with bone metastases from solid 
tumors. MethOds: Physicians completed an online discrete-choice experiment 
survey consisting of 10 choices between pairs of hypothetical medication profiles 
for a putative patient. Each profile included five attributes within a pre-defined range 
(based on prescribing information for the available bone-targeted agents [BTA]): 
months until first SRE (10, 18 and 28 months); months until worsening of pain (3, 6 
and 10 months); annual risk of osteonecrosis of the jaw (ONJ; 0, 1 and 5%); annual risk 
of renal impairment (0, 4 and 10%); and mode of administration (oral tablet, subcuta-
neous injection, 15-minute infusion and 120-minute infusion). Choice questions were 
based on an experimental design with known statistical properties. The survey was 
pretested with 8 physicians using open-ended interviews. A separate main-effects 
random parameters logit model was estimated for each country. Results: Physicians 
from France (n= 191), Germany (n= 192) and the UK (n= 197) completed the survey. 
Among the attributes included in the survey, months until first SRE and the risk of 
renal impairement were the most important attributes in France and the UK, whereas 
in Germany months until first SRE and a delay in worsening of pain were the most 
important. For all these attributes, better levels were significantly preferred to worse 
levels (p< 0.05). In all three countries, a 120-minute infusion every 4 weeks was the 
least preferred mode of administration (p< 0.05). The annual risk of ONJ was judged by 
physicians to be the least important attribute in all three countries. cOnclusiOns: 
Physicians generally make treatment decisions regarding choice of BTA for patients 
with bone metastases based on intent to delay the onset of SREs, managing risk of 
renal impairment and preventing the worsening of pain.
PCN219
NURSES’ PREFERENCES FOR BONE METASTASES TREATMENTS IN THE UNITED 
STATES
Mohamed A.F.1, Qian Y.2, Hauber A.B.1, Collins H.2, Hechmati G.3, Gatta F.3, Arellano J.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 
3Amgen (Europe) GmbH, Zug, Switzerland
Objectives: Several bone-targeted agents (BTAs) are approved for the prevention 
of skeletal related events (SREs). Nurses work closely with physicans and patients 
in managing the disease. Whilst influencing treatment decisions, nurses prefer-
ences for alternative treatment options have not been assessed. This study evalu-
ated US nurses’ preferences for treatment attributes in preventing SREs among 
patients with bone metastases from solid tumors. MethOds: Nurses completed a 
web-enabled discrete-choice experiment survey consisting of 10 choices between 
pairs of hypothetical medication and patient profiles. Each profile included six 
medication attributes within a pre-defined range (primarily based on prescribing 
information and real-world practice): months until first SRE (10, 18 and 28 months); 
months until worsening of pain (3, 6 and 10 months); annual risk of osteonecrosis of 
the jaw (ONJ; 0, 1 and 5%); annual risk of renal impairment (0, 4 and 10%); mode of 
administration (subcutaneous injection, 15-minute infusion and 120-minute infu-
sion); and out-of-pocket cost to patients ($25, $75, $150 and $330). Choice questions 
were based on an experimental design with known statistical properties. The survey 
was pretested with 6 nurses using open-ended interviews. A main-effects random 
parameters logit model was estimated. Results: A total of 196 US nurses com-
pleted the survey. Among the attribute levels included in the survey, out-of-pocket 
costs to patients, risk of renal impairement, and months until first SRE were the 
most important attributes. For all attributes, better levels were significantly pre-
ferred to worse levels (p< 0.05) except that no difference was observed between 0% 
and 1% ONJ attribute. Annual risk of ONJ was perceived by nurses to be the least 
important attribute. cOnclusiOns: When working with physicians and patients 
on the choice of BTAs for patients with bone metastases, out-of-pocket costs to 
patients, managing the risk of renal impairment and delaying time to first SRE are 
the primary foci for nurses.
PCN220
PHySICIANS’ PREFERENCES FOR BONE METASTASES TREATMENTS IN THE 
UNITED STATES
Arellano J.1, Mohamed A.F.2, Hauber A.B.2, Collins H.1, Hechmati G.3, Gatta F.3, Qian Y.1
1Amgen Inc., Thousand Oaks, CA, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 
3Amgen (Europe) GmbH, Zug, Switzerland
Objectives: Among the bone-targeted agents (BTAs) currently approved for the pre-
vention of skeletal-related events (SREs), several characteristics may be considered 
by physicians when making treatment decisions. This study evaluated US physi-
cians’ treatment preferences for preventing SREs in patients with bone metastases 
from solid tumors. MethOds: Physicians treating patients with bone metasta-
ses completed a web-enabled discrete-choice experiment survey consisting of 10 
choices between pairs of hypothetical medication and patient profiles. Each profile 
included six medication attributes within a pre-defined range (primarily based on 
prescribing information and real-world practice): months until first SRE (10, 18 and 
28 months); months until worsening of pain (3, 6 and 10 months); annual risk of 
osteonecrosis of the jaw (ONJ; 0%, 1% and 5%); annual risk of renal impairment (0%, 
4% and 10%); mode of administration (subcutaneous injection, 15-minute infusion 
and 120-minute infusion every 4 weeks); and out-of-pocket cost to patients ($25, 
$75, $150 and $330). Choice questions were based on an experimental design with 
known statistical properties. The survey was pretested with 8 physicians using 
open-ended interviews. A main-effects random parameters logit model was esti-
mated. Results: A total of 200 US physicians completed the survey. Among the 
attribute levels included, out-of-pocket cost to patients, months until first SRE and 
the risk of renal impairment were the most important attributes. For those attrib-
utes, better levels (outcomes) were significantly preferred to worse levels (P < 0.05). 
For mode of administration, subcutaneous injection was preferred over 15-minute 
infusion every 4 weeks (P < 0.05). cOnclusiOns: When making treatment deci-
sions regarding choice of BTA for patients with bone metastases, out-of-pocket cost 
to patients, delaying the onset of SREs and managing the risk of renal impairment 
are the primary foci for physicians.
Patient selection was random. The basic condition for inclusion in the study was the 
availability of data necessary to meet the costs. The number of patients at this stage 
of the study was already 42 people. Age at diagnosis was 9 months to 12 years, the 
median age of the patients was 6,4 ± 5,6 years. All of the patients were in the hospi-
tal with their parents of working age. In the calculations have been included: - GRP 
Chelyabinsk region (Gross Regional Product-14 USD per day per capita ) and GDP 
(Gross Domestic Product-44,4 USD per day per capita ), which amounted on average in 
2008-2012. The formula for the calculation of total costs:E $ = Nd x GRP / GDP (Nd-the 
number of days of disability) Results: Comparing the various cost components of 
treatment revealed that the indirect costs are 66% of the total amount of all expenses 
for medical treatment. State losses caused by non-working period of hospitalized for 
care people and non-produced Gross Regional Product are 7758,5 ± 1076,1 USD per 
capita. Losses of GDP are 21449,6 ± 3748,8 USD per capita. cOnclusiOns: The for-
mation of regional budgets should be done with consideration of big loss connected 
with disability of people hospitalized for the care of the a sick child, adjusted for and 
with GRP/GDP taken into account of big potion non-medical costs.
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POPULATION BASED UTILIzATION OF RADIATION THERAPy By A CANADIAN 
BREAST CANCER COHORT
Mittmann N.1, Seung S.J.1, Liu N.1, Porter J.1, Saskin R.1, Hoch J.2, Evans W.3, Leighl N.4, Trudeau 
M.5, Earle C.C.6
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2Cancer Care Ontario, Toronto, ON, 
Canada, 3Juravinski Cancer Centre, Hamilton, ON, Canada, 4Ontario Cancer Institute, Toronto, 
ON, Canada, 5Sunnybrook Health Science Centre, Toronto, ON, Canada, 6Cancer Care Ontario / 
Institute for Cancer Research, Toronto, ON, Canada
Objectives: To examine the trends in radiation therapy (RT) utilization by a popula-
tion based breast cancer cohort in Ontario, Canada. MethOds: The provincial can-
cer registry maintains cancer specific databases and provided a breast cancer cohort 
based on diagnosis dates from April 1, 2005 to March 31, 2010. Staging information 
was also available. The cohort was then linked, by their encrypted health card num-
ber, to linkable administrative datasets that are maintained by the Institute for 
Clinical Evaluative Sciences (ICES) such as RT utilization. Results: An all female 
breast cancer cohort (N= 39,656) was identified over a five-year timeframe and the 
average age was 61.6 ± 14.0 years. Approximately, two thirds (N= 25,225) of patients 
received RT and staging information was available for 22,988 patients (stage I = 
9,541; stage II = 8,516; stage III = 4,050; and stage IV = 881). Patients had an average 
of 1.4 ± 0.7 (stage I) number of RT courses, 1.8 ± 1.1 (stage II), 2.5 ± 1.3 (stage III), and 
2.8 ± 2.4 (stage IV). The percent ratio of conventional RT to intensity modulated RT 
(IMRT) was 70.9%:16.6% (stage I), 71.6%:11.3% (stage II), 74.6%:4.6% (stage III), and 
72.7%:12.6% (stage IV). For the non-IMRT cohort with a primary cancer (N= 30,887), 
the average number of fractions per course was 18.1 ± 9.2. cOnclusiOns: From 
2005 – 2010, almost two thirds of a Canadian female breast cancer cohort received 
RT and the average number of courses increased with stage. A similar trend was 
observed with the type of RT (coventional RT utilization increased with stage) but 
peaked at stage III and decreased at stage IV, likely due to palliation. The next step 
is to apply unit costs to the number of fractions per subgroup and to also obtain 
RT-planning and radiation therapist times.
PCN217
DEFINING ELIGIBLE PATIENT POPULATION IN SãO PAULO STATE BASED ON 
CLEOPATRA TRIAL INCLUSION CRITERIA: A RETROSPECTIvE ANALySIS OF 
FUNDAçãO ONCOCENTRO (FOSP) CANCER PATIENT REGISTRy (REGISTRO 
HOSPITALAR DO CâNCER – RHC)
Tobaruella F.S., Maximo M.F.M., Tsuchiya C.T., Buschinelli C.T., Gonçalves T.M.
Roche Brazil, São Paulo, Brazil
Objectives: Breast cancer (BC) is the most common cancer affecting women and, 
despite advances in treatment, is still the leading cause of cancer death among 
women worldwide. Approximately 20%-25% of the women diagnosed with BC will 
have HER2-positive disease and those with metastatic disease (mBC) have a 5-year 
life expectancy of only 24%. Recently, pertuzumab (P) was approved as a new thera-
peutical option for first line HER2-positive mBC in Brazil. This study aims to define 
the proportion of BC patients that would be eligible for pertuzumab+trastuzumab+
chemotherapy (P+T+C) combination therapy in São Paulo state by analyzing retro-
spectively (2000-March 2013) the Fundação Oncocentro (FOSP) cancer patient registry 
(Registro Hospitalar de Câncer – RHC). MethOds: Raw data of cancer cases reported 
from 2000-March 2013 was taken from the FOSP-RHC and mined according to the 
inclusion criteria of the CLEOPATRA trial. Only women with histologically/cytologi-
cally confirmed diagnosis of BC (ICD-50) and reported TNM classification at diagnosis 
were included in the analysis. P+T+C therapy eligible patients were those reported 
as stage IV at diagnosis (de novo mBC) or stages 0, I, II and III with evidence of pro-
gression at last tumour assessment (recurrent cases), excluding ones with evidence 
of central nervous system (CNS) metastasis. Was considered that all patients in the 
database would test for HER2 status and positivity rate was taken from literature 
(25%). Results: During the analysis period 59,095 BC cases with TNM classification 
at diagnosis were reported. 4,660 cases were considered de novo mBC and 7,378 cases 
were considered as recurrent. According to the positivity rate 3,010 patients would be 
eligible for P+T therapy which accounts for approximately 5.1% of the overall cases 
of BC. cOnclusiOns: First-line HER2-positive mBC is a targeted, clearly defined and 
limited patient population where pertuzumab based regimen provides significant 
and clinically meaningful benefits in overall survival and progression-free-survival.
PCN218
PHySICIANS’ PREFERENCES FOR BONE METASTASES TREATMENTS IN FRANCE, 
GERMANy AND THE UNITED KINGDOM
Qian Y.1, Hechmati G.2, Mohamed A.F.3, Hauber A.B.3, Arellano J.1, Gatta F.2, Haynes I.4, Bahl A.5
1Amgen Inc., Thousand Oaks, CA, USA, 2Amgen (Europe) GmbH, Zug, Switzerland, 3RTI Health 
Solutions, Research Triangle Park, NC, USA, 4Amgen Ltd., Uxbridge, UK, 5University Hospitals 
Bristol, Bristol, UK
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A Bayesian NMA using non-informative priors was conducted, based on linking 
trials with treatment and dose-specific common treatment arms. Assessment of 
model fit and selection of fixed versus random effects was based on the Deviance 
Information Criterion (DIC). Sensitivity analyses assessed the impact of individual 
trials and definition of priors. Consistency between direct and indirect evidence was 
assessed. Results: Ten studies reporting results at 26 weeks +/- 4 weeks were iden-
tified. HbA1c-reduction (D) for CANA 100mg was comparable to DPP-4s (D between 
0.05 and -0.14 versus sitagliptin and linagliptin respectively, with pairwise prob-
abilities (P) of being more effective between 33-88%), and higher for CANA 300mg, 
which was comparable to GLP-1s (D= 0.08;P= 31% and 0.01;P= 53%) versus liraglutide 
1.8mg and exenatide 10µg respectively) and biphasic insulin (D= 0.03;P= 43%). CANA 
300mg had the highest weight reduction with changes between 0.14kg;P= 93% (vs. 
exenatide 10µg) and 5.13kg;P= 100% (vs. biphasic insulin). The odds ratio for hypo-
glycaemia versus long-acting insulin were 0.31 and 0.39 for CANA 100mg and 300mg 
respectively, compared to 0.20-0.41 for other classes. cOnclusiOns: NMA of add-
on therapies to MET+SU suggests that glycaemic reductions for CANA at 26 weeks 
are at least as large for CANA 100 mg and greater for CANA 300 mg compared to 
DPP-4s. CANA 300mg was found to be comparable to liraglutide 1.8mg and biphasic 
insulin. Weight reduction was similar to GLP-1s and substantially higher compared 
to all other classes. All classes showed significantly lower hypoglycaemic event 
rates compared to insulin.
PDB3
COMPARATIvE EFFECTIvENESS OF LIRAGLUTIDE vERSUS SITAGLIPTIN IN TyPE 
2 DIABETES IN THE UNITED KINGDOM: A RETROSPECTIvE STUDy IN PRIMARy 
CARE
Nyeland M.E.1, Ploug U.J.1, Skovgaard R.1, Richards A.1, Bergan E.Q.1, Zammit D.C.2, Evans M.3
1Novo Nordisk A/S, Søborg, Denmark, 2IMS Health, Basel, Switzerland, 3University Hospital 
Llandough, Cardiff, UK
Objectives: Liraglutide is an incretin-based (GLP-1 analog) therapy indicated 
for the treatment of patients with type 2 diabetes (T2DM). This study aimed to 
assess whether phase 3 clinical trial data, showing significantly greater reductions 
in HbA1c and body weight vs. the DPP-IV inhibitor sitagliptin is translated into 
routine clinical practice. MethOds: This was a retrospective database analysis of 
the Clinical Practice Research Datalink (CPRD), a primary care database in the UK. 
Patients (≥ 18 years) diagnosed with T2DM and prescribed liraglutide or sitagliptin 
between July 2009 and July 2012, were included. Patients on insulin or fixed dose 
metformin combinations at therapy initiation were excluded. Outcomes included: 
% of patients achieving ≥ 1% HbA1c reduction; % of patients with HbA1c reduction 
≥ 1% and weight reduction ≥ 3% (NICE criteria); % of patients achieving treatment 
target HbA1c < 7%; absolute change in HbA1c, weight (BMI), systolic blood pres-
sure and blood lipids. Results: Baseline demographics: 294 liraglutide and 2790 
sitagliptin patients with a mean age of 55.7 (SD 10.6) and 62 (SD 11.0) years and 
36.4% and 40.5% female respectively. Patients had a baseline HbA1c of 8.9% (SD 
1.9) and 8.6% (SD 1.5), a baseline BMI of 39.3 (SD 7.1) and 33.3 (SD 6.4) and had been 
diagnosed with diabetes 7.1 and 7.2 years prior to start of current treatment for 
liraglutide and sitagliptin respectively. Comparative effectiveness analysis dem-
onstrated superior reductions for liraglutide vs. sitagliptin in HbA1c (%) (-0.89 
vs. -0.57, p< .01), weight (Kg) (-3.78 vs. -1.12, p< .0001), BMI (-1.3 vs. -0.4, p< .0001) 
and systolic blood pressure (mmHg) (-4.1 vs. -0.37, p< .0005) after 6 months of 
therapy. No statistically significant differences were observed in total cholesterol 
and HDL reductions. cOnclusiOns: The superior control and weight reduction of 
liraglutide vs. sitagliptin observed in clinical trials is reflected in routine primary 
care clinical practice.
PDB4
wEIGHT LOSS OF ≥ 3% IN TyPE II DIABETES PATIENTS IS ASSOCIATED wITH 
wEIGHT CHANGE PROPERTy OF NEwLy PRESCRIBED ANTI-DIABETIC MEDICINE 
IN ANTI-DEPRESSANT USERS OvER A 12-MONTH FOLLOw-UP PERIOD
Lin C.C.1, Mukherjee J.2, Kawabata H.3, Colilla S.3, Wygant G.4
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Bristol-Myers Squibb, 
Wallingford, CT, USA, 3Bristol-Myers Squibb, Hopewell, NJ, USA, 4Bristol-Myers Squibb, Princeton, 
NJ, USA
Objectives: Anti-depressant use could complicate the weight change effect of 
anti-diabetes (AD) medications. This study examined if different newly prescribed 
AD medications were associated with weight loss in a 12-months period in type 
II diabetes (T2D) patients who were on anti-depressants. MethOds: The study 
included patients who were on anti-depressants (selective serotonin reuptake 
inhibitors, SSRI, or tricyclic antidepressants,TCA) and prescribed a new AD dur-
ing 1995-2011 from the UK Clinical Practice Research Datalink (CPRD.) Patients on 
more than one ADs are included if ADs are within same weight-change category, 
categorized as weight-gain agents (WG)(sulfonylureas (SU), thiazolidinediones 
(TZD)) and weight- neutral/ loss agents (WN/L)(metformin(MET), DPP-4 inhibitors 
(DPP-4), GLP-1 agonists (GLP-1). Descriptive analyses and multivariate regression 
examined the association between weight loss ≥ 3% and newly prescribed AD medi-
cations grouped by weight change category. Results: This study included 3,445 
T2D patients, of whom 2,041 were SSRI users and 1,404 were TCA users. Mean (sd) 
age was 60(±13.2) years for SSRI users and 64(±12.0) years for TCA users. Baseline 
mean (sd) weight was 92.86(±22.24) kg for SSRI users and 89.31(±19.86) kg for TCA 
users. At 12 months after initiation of AD therapy, with baseline age, weight, and 
other characteristics controlled, the likelihood of achieving weight loss of ≥ 3% was 
higher for those prescribed a WN/L agents versus those prescribed a WG agents 
regardless of the anti-depressant medicine currently used: For SSRI users OR= 2.84; 
95% CI [1.89, 4.32]; for TCA users OR = 1.51; 95% CI [1.03, 2.23]. cOnclusiOns: T2D 
anti-depressant users prescribed WN/L agents had higher odds of actual weight loss 
of ≥ 3%, compared to those prescribed WG agents. This association holds regardless 
of the anti-depressant medicine patients are currently taking. For T2D patients on 
anti-depressants, considering different weight change effects when initiating anti-
diabetes therapy is needed.
PCN221
IDENTIFICATION OF THE TREATMENT PATHwAy OF METASTATIC CASTRATE-
RESISTANT PROSTATE CANCER IN SCOTLAND: A CHART REvIEw
Maman K.1, Khemiri A.2, Roïz J.1, Naidoo S.3, Baskin-Bey E.3, Holmstrom S.4
1Creativ-Ceutical, London, UK, 2Creativ-Ceutical, Tunis, Tunisia, 3Astellas Pharma Europe Ltd., 
Chertsey, UK, 4Astellas Pharma Europe, Leiderdorp, The Netherlands
Objectives: Chemotherapy with docetaxel was the first therapy approved for 
the treatment of metastatic Castrate-Resistant Prostate Cancer (mCRPC) while 
others came along rather recently. With all the treatment options available now, 
current treatment strategies to appropriately sequence these agents are not known. 
This study aims to describe mCRPC current treatment paradigms, with specific 
attention to docetaxel, in Scotland. MethOds: A retrospective chart review was 
conducted. A panel of Scottish physicians was contacted to identify patients diag-
nosed with mCRPC between 2008 and 2013. Collected data included demographics, 
disease history, sequencing of therapies (type, duration and time-to-event), reason 
for switch or discontinuation, drug-related serious adverse events and hospitali-
sations. Descriptive analyses were performed. Time-to-event was analysed using 
the Kaplan-Meier method. Results: Twelve physicians in Scotland completed the 
survey and 34 patients were included in the analysis. Mean age at mCRPC diagnosis 
was 62 years (range 56-69 years). The mean duration between mCRPC diagnosis and 
the date of last contact was 1.20 years. Postcastration, most patients (19/34, 56%), 
received docetaxel as first-line. The second most frequent first-line was bicaluta-
mide (14/34, 41%), alone (9/14, 64%) or in combination with LHRHa. Abiraterone was 
frequently prescribed as next (second or third) line of therapy after docetaxel (6/21, 
29%). The median time to switch was 105 days (range 20-235 days) and did not differ 
between patients with docetaxel versus other as first-line (p = 0.17). Most patients 
switched after radiographic progression or PSA rise. Serious adverse events and hos-
pitalisations were rarely reported. cOnclusiOns: These findings provide insights 
into the treatment pathway of mCRPC patients in Scotland. Chemotherapy with 
docetaxel and hormonal agents appear to be the most utilised therapies. Switch 
from first-line treatment occurred in approximately 3.5 months and was facilitated 
by radiographic progression or PSA rise. A larger retrospective chart review is needed 
to confirm these results.
DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies
PDB1
EvALUATION OF ACUTE PANCREATITIS SIGNALS wITH INCRETIN ENHANCERS: 
REvISITING DISPROPORTIONALITy ANALySIS OF THE ADvERSE EvENT 
REPORTING SySTEM
Ali A.K.
Eli Lilly and Company, Indianapolis, IN, USA
Objectives: There has been a rising concern about the association between incre-
tin enhancers and acute pancreatitis (AP). Previous research showed conflicting 
findings, and this analysis of the FDA Adverse Event Reporting System (FAERS) 
aims at investigating signals of AP across pharmacological classes of anti-diabe-
tes medications (ADM) and within incretin enhancers class. MethOds: Adverse 
event reports submitted to FAERS between 1997Q3-2012Q1 were analyzed. The out-
come was defined by MedDRA Preferred Term (PT) “pancreatitis acute”; exposures 
were defined by generic names of ADM. Sensitivity analyses were conducted by 
creating a custom term (CT) for outcome: “autoimmune pancreatitis”, “ischemic 
pancreatitis”, “pancreatitis”, “pancreatitis acute”, “pancreatitis hemorrhagic”, and 
“pancreatitis necrotizing”. Reports of other pancreatic disorders were excluded. 
Disproportionality analysis by proportional reporting ratio (PRR) and 95% confi-
dence interval (LL05-UL95) is applied to detect AP signals compared to all ADM. 
Associations with LL05≥ 2 are significant signals. Results: A total of1183 AP 
PT and 4481 CT reports for ADM were identified (incretin enhancers, n= 912 and 
n= 3,704, respectively). Corresponding PRR and (LL05-UL95) were: metformin 0.98 
(0.83-1.16) and 0.52 (0.47-0.59); sulfonylureas 0.53 (0.37-0.75) and 0.35 (0.28-0.43); 
thiazolidinediones 0.12 (0.09-0.16) and 0.12 (0.10-0.14); meglitinides 0.54 (0.31-0.93) 
and 0.39 (0.28-0.54); incretin enhancers 1.94 (1.87-2.00) and 2.09 (2.06-2.12); and 
combinations 0.65 (0.47-0.88) and 0.81 (0.70-0.93). Compared to all ADM, estimates 
for incretin enhancers were: exenatide 1.46 (1.37-1.55) and 1.54 (1.49-1.59); liraglutide 
4.90 (4.37-5.48) and 4.00 (2.73-4.28); saxagliptin 4.47 (3.00-6.67) and 4.60 (3.73-5.67); 
and sitagliptin 2.33 (1.95-2.78) and 4.02 (3.75-4.31). There were no reports of AP PT 
for linagliptin, but 39 reports of CT with estimates of 6.41 (4.64-8.85) were identi-
fied. cOnclusiOns: Compared to other ADM, incretin enhancers are associated 
with higher than expected reporting of AP. Prescribers should monitor patients 
with diabetes for signs and symptoms of pancreatitis while treated with incretin 
enhancers. Given limitations of spontaneous reporting systems, pharmacoepide-
miological studies are required to test the generated hypothesis and to draw clini-
cally rigorous conclusions.
PDB2
BAyESIAN NETwORK META-ANALySIS TO ASSESS THE RELATIvE EFFICACy 
AND SAFETy OF CANAGLIFLOzIN IN PATIENTS wITH TyPE 2 DIABETES 
MELLITUS (T2DM) INADEQUATELy CONTROLLED ON METFORMIN AND 
SULPHONyLUREA (MET+SU)
Pacou M.1, Taieb V.1, Abrams K.R.2, Diels J.3, van Sanden S.4, Garg M.5, Schroeder M.6, Kaur V.7, 
Nielsen A.T.N.5, Nuhoho S.6, Neslusan C.8, Hemels M.5
1Amaris, London, UK, 2The Institute of Cancer Research, Sutton, UK, 3Janssen Pharmaceutica, 
Beerse, Belgium, 4EMEA HEMAR Analytics, Janssen EMEA, Beerse, Belgium, 5Janssen Cilag, 
Birkerød, Denmark, 6Janssen UK, High Wycombe, UK, 7Consultant, Mumbai, India, 8Janssen Global 
Services LLC, Raritan, NJ, USA
Objectives: To assess the relative efficacy and safety of canagliflozin (CANA), a 
sodium-glucose co-transporter inhibitor, as an add-on to MET+SU, versus DPP-4 
inhibitors, GLP-1 agonists and insulin, using Bayesian network meta-analysis 
(NMA). MethOds: A systematic literature review was conducted according to 
NICE guidelines. Outcomes of interest included HbA1c, weight and hypoglycaemia. 
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(29%) met BP targets (< 130/80mmHg), 50% had BP ≥ 140/90mmHg. HbA1c, LDL and 
BP were well-controlled in approximately 7.2%, 41.2%, and 8.6% of patients, respec-
tively, while 59.2%, 7.8% and 21.3% of patients were never-controlled, respectively. 
The proportion of patients who were never-controlled for HbA1c increased with 
T2DM duration. cOnclusiOns: Nearly 75% of patients met targets and over 40% 
were well-controlled for LDL; however, rates of control for HbA1c and BP were lower. 
Given the increased risk of complications associated with poor control, achieving 
higher rates of control could reduce the burden of T2DM in the UAE.
PDB8
A SySTEMATIC REvIEw AND NETwORK META-ANALySIS OF SECOND-LINE 
ANTI-DIABETES TREATMENTS FOR THOSE wITH TyPE 2 DIABETES MELLITUS 
INADEQUATELy CONTROLLED By SULFONyLUREA MONOTHERAPy
Orme M.E.1, Fenici P.2, Duprat Lomon I.2, Wygant G.3, Townsend R.4, Roudaut M.2
1ICERA Consulting Ltd., Swindon, UK, 2Bristol-Myers Squibb, Rueil-Malmaison, France, 3Bristol-
Myers Squibb, Princeton, NJ, USA, 4AstraZeneca, Brussels, Belgium
Objectives: To assess the efficacy and safety of EU-licensed anti-diabetes agents 
when added to sulfonylurea (SU). MethOds: A systematic review was conducted in 
MEDLINE, EMBASE and CENTRAL to identify randomised controlled trials in patients 
with type 2 diabetes mellitus inadequately controlled by a stable dose of SU mono-
therapy. Direct meta-analysis, Bucher indirect comparisons and Bayesian network 
meta-analysis (NMA) using WinBUGs were conducted. The effect of potentially con-
founding baseline factors was explored through covariate analyses. Results: The 
search identified 2,976 articles of which 2,945 were excluded based on title/abstract. 
On reviewing remaining full-text articles, 5 studies were selected for analysis at 24 
(+/- 6) weeks follow-up. All studies were comparable in terms of baseline charac-
teristics, including: HbA1c, age and BMI. Three classes of agents had sufficient data 
for meta-analysis: DPP4 inhibitors (‘DPP4s’), GLP1 analogues (‘GLP1s’) and SGLT2 
inhibitors (‘SGLT2s’; only dapagliflozin has an EU licence in this class). Based on the 
fixed-effect NMA, all three classes of treatment resulted in statistically significantly 
lower HbA1c at follow-up compared to placebo (based on the 95% credible interval 
[CrI]). SGLT2 treatment resulted in significantly lower weight at follow-up compared 
to placebo (–1.54 kg; 95% CrI –2.16, –0.92), which is in contrast to treatment with 
GLP1s (-0.65kg; 95% CrI -1.37, 0.07) and DPP4s (0.57 kg; 95% CrI 0.09, 1.06). The odds 
of hypoglycaemia for SGLT2 and DPP4 add-on treatment were similar to placebo, but 
significantly greater than placebo for GLP1 add-on treatment (10.89; 95% CrI 4.24, 
38.28). Assessment of NMA model heterogeneity was hindered by the low number 
of studies within the network. cOnclusiOns: All three classes of treatments used 
as add-on therapy to SU provided better short-term glycaemic control compared to 
SU monotherapy. However, DPP4s, GLP1s and SGLT2s may show variation in terms 
of impact on weight and incidence of hypoglycaemia.
PDB9
REAL LIFE EFFECTS OF LIRAGLUTIDE SUPPORTS THOSE SHOwN IN RCTS
Karasik A.1, Heymann A.D.2, Sternberg P.3, Leshno M.4, Todorova L.5, Goldshtein I.6,  
Bergan E.Q.7
1Tel Aviv University, Tel Hashomer, Israel, Israel, 2Tel Aviv University, Tel Aviv, Israel, 3Novo 
Nordisk Ltd., Kfar Saba, Israel, 4Faculty of Management, Tel-Aviv , Israel, 5Novo Nordisk 
International Operations, Zurich, Switzerland, 6Maccabi Healthcare Services, Tel Aviv, Israel, 
7Novo Nordisk A/S, Søborg, Denmark
Objectives: In RCTs performed in patients with T2DM liraglutide reduced HbA1c 
by 1.0-1.5%-point and weight up to 3.7kg. Patients had disease duration of 7.7 years 
on average, baseline HbA1c of 8.4%. We assessed the effectiveness of liraglutide 
prescribed per guidelines in the analyzed cohort. MethOds: Patients from an Israeli 
HMO (Maccabi) treated with liraglutide ≥ 6 months during 2010-2012 were included. 
Prescription rules were BMI> 30; HbA1c> 8.0% after use of 2 oral hypoglycemic 
agents. Data was extracted from electronic records included in a registry of > 90,000 
diabetes patients. Assessments were performed within 180 days before the date of 
first prescription and at 6 months +/- 90 days. Results: A total of 462 insulin naïve 
patients treated with liraglutide were identified. 52% males; age was 61.0 years (SD 
8.67); diabetes duration was 10.5 years (SD 3.53). HbA1c decreased by 0.93%-points 
(SD 1.17) (p< 0.0001 95% CI 0.82-1.03), down from 8.6% (SD 1.20). Mean time between 
HbA1c measurements was 222 days (SD 52.39). In 170 patients with available data, 
weight decreased by 2.5kg (SD 5.09) (p< 0.0001 95% CI 1.71-3.2) from 99.9kg (18.17). 
Time between measurements of weight was 202 days (SD 63.2). Diabetes duration, 
HbA1c levels and change of the group with weight data were similar to the main 
cohort. 202 patients (43.7%) achieved ≥ 1%-point HbA1c reduction. In 31.2% (48 of 
170), the reduction was without weight gain. 26 (16.9%) achieved the NICE criteria 
(decrease of HbA1c≥ 1% and weight≥ 3%). Baseline HbA1c and amount of liraglutide 
prescribed correlated with the degree of HbA1c reduction. cOnclusiOns: Real life 
use of liraglutide significantly reduced HbA1c and weight, showing similar outcomes 
as those observed in RCTs. Compared to the RCTs patients in this cohort had more 
severe diabetes and were more obese, yet liraglutide retained its effects.
PDB10
A BAyESIAN MULTIPLE TREATMENT COMPARISON OF DULOxETINE, 
PREGABALIN, GABAPENTIN, AMITRIPTyLINE, AND THEIR COMBINATIONS FOR 
PAINFUL PERIPHERAL NEUROPATHy BASED ON PAIN REDUCTION REPORTED IN 
CLINICAL TRAILS
Chinthammit C., Malone D.
University of Arizona, Tucson, AZ, USA
Objectives: To compare the performance of treatment of painful diabetic periph-
eral neuropathy (PDPN) — duloxetine, pregabalin, gabapentin, amitriptyline, and 
their combinations based upon pain reduction reported in clinical trials, and inform 
a revised treatment algorithm. MethOds: Published studies of PDPN treatment 
through May 2012 were identified from MEDLINE(PubMed) database and extended 
manual search was conducted based on citations from identified studies. Inclusion 
criteria was restricted to randomized controlled trials lasting at least 5 weeks and at 
most 12 weeks and studies examining 30% pain reduction or equivalent. Direct and 
PDB5
ECONOMIC IMPACT OF IMPROvING THE ACCURACy OF BLOOD GLUCOSE SELF-
MONITORING ON THE SPANISH HEALTH SERvICE
Sanz-Granda Á1, Hidalgo A.2, Vieta A.3, Graefenhain de C.odes R3
1Weber Economía y Salud, Majadahonda (Madrid), Spain, 2University of Castilla La Mancha, 
Toledo, Spain, 3Bayer, Barcelona, Spain
Objectives: The 15197:2003 ISO states that 95% of the glucose results shall fall within 
±15 mg/dl of the concentrations ≤ 75 mg/dl and ±20% at those > 75 mg/dl. The objec-
tive was to estimate the 1-year economic impact for the Spanish Health System of 
blood glucose self-monitoring by using glucose meters with different degrees of accu-
racy MethOds: A probabilistic model was designed to estimate the clinical and eco-
nomic outcomes of a type 2 (T2D) or type 1 diabetes (T1D) cohort. A second-order Monte 
Carlo simulation was run, in order to estimate the frequency of non-detected hypoglyce-
mia and hyperglycemia cases. The frequency of macro and microvascular events, associ-
ated with the non-detected readings, was calculated. Finally, the economic impact was 
assessed for better accuracy levels (±15; ±5%) Results: We estimated a total prevalence 
of 96,169 type 1 and 3,115,866 type 2 treated diabetic patients in Spain. We included all 
the T1D patients and those insulin dependents T2D (23.4%). The average annual cost of 
associated events and those of monitoring blood glucose were estimated at 95,987,193 
€ for T2D and 11,501,292 € for T1D with a ±20% accuracy. When an accuracy of ±15% 
was analyzed, the annual costs for T2D were reduced to 88,349,485 € and to 9,180,317 € 
for T1D, showing a total saving of 9,958,682 € a year. If the accuracy rose up to ±5%, the 
results were 80,067,179 € in T2D and 6,084,776 € in T1D, for a total saving of 21,336.530 
€ a year. The total costs reduced by 9.3%, 15.4% and 19.9% with accuracy of ±15%, ±10% 
and ±5%, respectively, respect of the initial ±20% cOnclusiOns: This study shows that 
if the accuracy of the glucose meters raises, several macrovascular and microvascular 
events and hypoglycemic episodes could be avoided. That can improve patients’ quality 
of life and reduce significantly the associated costs
PDB6
BASELINE CHARACTERISTICS, wEIGHT AND GLyCAEMIC CHANGE AMONG 
PATIENTS IN THE UNITED KINGDOM wITH TyPE 2 DIABETES MELLITUS (T2DM) 
PRESCRIBED A NEw ANTIDIABETIC TREATMENT CLASS IN A REAL wORLD 
SETTING
Blak B.T.1, Rigney U.1, Ycas J.2, Racketa J.2, Hammar N.3
1AstraZeneca UK Ltd., Luton, UK, 2AstraZeneca Pharmaceuticals US, Wilmington, DE, USA, 
3AstraZeneca Sweden, Mölndal, Sweden
Objectives: Patients with T2DM have an increased risk of comorbidities associ-
ated with weight gain. Depending on patients’ weight, treatment guidelines give 
preference to treatments that have favourable weight profiles, with weight gain 
being an important adverse event to avoid. This study aims to characterize baseline 
characteristics, weight and glycaemic change in patients prescribed new antidia-
betic treatment. MethOds: Patients with T2DM diagnosis and receiving first new 
antidiabetic treatment class (index) between 01/01/05-01/01/12 were identified in 
UK CPRD primary care records. Index class could be first-line, switch or add-on. 
Demographics, baseline weight and glycosylated haemoglobin (HbA1c), and change 
at 6 months were described by index class. Results: Of 23,987 included (of whom 
133 were lost to follow-up) 64.7% initiated metformin (MET), 15.5% sulfonylureas 
(SU), (14.0%) thiazolidinediones (TZD), 2.1% dipeptidyl-peptidase-4-inhibitors (DPP4), 
1.9% insulin, 0.7% glucagon-like-peptide-1-agonists (GLP-1), 0.6% ‘other’, 0.5% acar-
bose. About 57% were men; baseline mean age for different index classes ranged 
between 56.5 (insulin) and 63.1 years (acarbose). Mean baseline weight ranged 
between 88.0 (SU) and 112.4 kg (GLP-1) and mean baseline HbA1c between 72.6 
mmol/mol (8.8%) (acarbose) and 84.7 mmol/mol (9.9%) (insulin). Among 14,438 
patients with six-month follow-up data an increase in weight was found for sub-
jects initiating SU (2.1%;95%CI: 1.9;2.4,n= 2,223), TZD (1.9%;95%CI: 1.7;2.1,n= 2,034) 
and insulin (1.8% ;95%CI: 1.0;2.6,n= 285). A reduction in weight was observed for 
patients on GLP-1 (-3.4%;95%CI: -4.3;-2.5,n= 119), DPP4 (-0.9%;95%CI: -1.4;-0.4,n= 347) 
and MET (-0.8%;95%CI: -0.9;-0.7,n= 9,278). A mean reduction in HbA1c over the six 
month period was seen for all antidiabetic classes but was not statistical significant 
for GLP-1 and ‘other’. cOnclusiOns: These results indicate that initiation of anti-
diabetic agents such as SU, TZD and insulin frequently are associated with weight 
gain. This underscores the need to choose agents with favourable weight profiles for 
overweight or obese patients, as recommended by UK T2DM treatment guidelines.
PDB7
GLyCEMIC, LIPID, AND BLOOD PRESSURE CONTROL AMONG TyPE 2 DIABETES 
MELLITUS PATIENTS IN DUBAI
Szabo S.M.1, Osenenko K.M.1, Donato B.M.K.2, Korol E.E.1, Qatami L.3, Al Madani A.4, Al Awadi 
F.4, Al Ansari J.4, Maclean R.5, Levy A.R.1
1Oxford Outcomes Ltd., Vancouver, BC, Canada, 2Bristol-Myers Squibb Company, Wallingford, 
CT, USA, 3Bristol-Myers Squibb Company, Dubai, United Arab Emirates, 4Dubai Hospital, Dubai, 
United Arab Emirates, 5Bristol-Myers Squibb, Plainsboro, NJ, USA
Objectives: Inadequate glycemic, blood pressure (BP), and lipid control among 
type 2 diabetes mellitus (T2DM) patients is associated with increased risk of T2DM-
related complications. Few data on these outcomes are available from the United 
Arab Emirates (UAE). The objective was to estimate the proportion of T2DM patients 
with glycemic, lipid, and BP control at a large centre in Dubai. MethOds: Charts 
from T2DM patients aged ≥ 18 years that visited the Dubai Hospital from October 
2009 to March 2010 (enrolment period) were systematically sampled until the target 
(n= 250) was reached. Results of haemoglobin A1c (HbA1c), low-density lipoprotein 
(LDL), and BP tests conducted from enrolment to September 2011 were abstracted 
from patient charts. The most recent test values were compared to guideline targets. 
The proportion of well-controlled (target met on all tests) and never-controlled 
patients (target not met on any test) over the study period was calculated. All analy-
ses were stratified by T2DM duration. Results: Thirty-three percent of the sample 
was male, and at enrolment, the mean (SD) age was 58 years (12), and T2DM dura-
tion, 14 years (8). At the most recent assessment, 58 patients (23%) had HbA1c < 7%, 
68 (27%) had HbA1c ≥ 9%, and 173 (71%) had LDL < 100mg/dL. Although 74 patients 
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Objectives: To assess the effectiveness, tolerability and maintenance of vildaglip-
tin in type 2 diabetes (T2D) patients under real-life conditions in France, requested 
by the French Health Technology Agency. MethOds: A representative sample of 
T2D patients initiating a treatment with vildagliptin was enrolled in a 2 years fol-
low-up observational cohort in 2010 by a national sample of endocrinologists and 
general practitioners. Results: A total of 482 GPs and 84 endocrinologists included 
1,700 patients. 60% were males, mean age= 63 (±9) years, mean disease duration= 7 
(±6.5) years. Follow up visits were available for 96.3%, 90.7%, 86.5% and 81.8% of 
patients at respectively 6, 12 18 and 24 months. Mean HbA1c level decreased from 
7.8% (sd= 1.3) before vildagliptin prescription to 7.0% (sd= 1.0) 0 to 6 months after 
vildagliptin initiation and remained stable thereafter: 7.0% (sd= 1.0), 7.0% (sd= 0.9) 
and 7.0% (sd= 1.0) 6 to 12 months, 12 to 18 months and 18 to 24 months after vilda-
gliptin initiation. The percentages of patients with alanine and/or aspartate ami-
notransferase above 120 UI were 0.5% before vildagliptin prescription and 0.3%, 0.5%, 
0.1%, 0.0% at 0-6 months, 6-12 months, 12-18 months and 18-24 months after vilda-
gliptin prescription. The mean glomerular filtration rate (MDRD formula) was 82.0 
ml/minute before vildagliptin prescription and 82.4, 84.1, and 83.6 and 82.8, at 0-6 
months, 6-12 months, 12-18 months and 18-24 months after vildagliptin prescrip-
tion. The incidence of severe hypoglycemia (requiring third party assistance) has 
been estimated at 0.30/100 vildagliptin treated patients years (CI95%= [0.15,0.55]). 
All occurred in patients also treated with insulin and/or sulfamide The proportion 
of patients treated with vildagliptin remained high over the course of the study: 
96.5% (CI95%[95.6,97.4]) after 6 months, 92.5% (CI95%= [91.2%,93.8%]) after one year 
and 88.8% (CI95%= [87.2%,90.4%]) after 2 years. cOnclusiOns: Vildagliptin showed 
sustained effectiveness in terms of reduction in HbA1c over 24 months, with a low 
incidence of hypoglycemia.
PDB14
CLINICAL OUTCOMES AND HEALTH CARE COSTS EvALUATION OF 
SULFONAMIDES AND THIAzOLIDINEDIONES COMPARED wITH DIPEPTIDyL 
PEPTIDASE 4 INHIBITORS FOR THE TREATMENT OF UNCONTROLLED DIABETES
Degli Esposti L., Saragoni S., Buda S., Degli Esposti E.
CliCon Srl, Ravenna, Italy
Objectives: To compare clinical outcomes and the health care costs across 
two cohorts of uncontrolled diabetic patients who initiated treatment with 
Sulfonamides or Thiazolidinediones (SU/TZD) or Dipeptidyl Peptidase 4 (DPP-4) 
Inhibitors in a clinical practice setting. MethOds: A retrospective analysis using a 
large administrative database and a clinical registry containing laboratory results 
of three Italian Local Health Units was performed. The index-period ranged from 
July, 2008 and June, 2010. Patients were treatment naïve to SU/TZD or to DPP-4, 
but already treated with other oral antidiabetic agents. Demographics, concomi-
tant therapies, Charlson comorbidity index, glycemic and lipid control level and 
previous hospitalizations were assessed at baseline. Adherence was measured 
by Medication Possession Ratio (MPR). We calculated unadjusted rates and used a 
Poisson regression model to estimate risk ratios for diabetes-related hospitaliza-
tions occurred during the 18-months follow-up period. Total annual costs included 
all the pharmacological treatments and the direct costs due to hospitalizations 
and outpatient services. Results: We identified 1384 patients treated with SU/
TZD and 199 treated with DPP-4. DPP-4 patients were significantly younger (mean 
age 59.2 years and 65.0 years; p< 0.001) and with less previous hospital discharges 
for diabetes-related diseases. Baseline mean HbA1c was 8.1% for SU/TZD and 
8.2% for DPP-4 patients. DPP-4 naïve resulted more adherent (MPR≥ 80%) than SU/
TZD naïve (70.9% and 55.8%; p< 0.001). The SU/TZD group showed a significant 
increased risk of diabetes-related hospitalizations (unadjusted rate was 9,17 vs 
3,47 per 100 person-years, p= 0.002; adjusted incidence rate ratio 1.83; p= 0.028). 
The higher hospitalization rate resulted in higher total annual direct costs per 
patient (€ 2.719 vs € 2.462 of those treated with DPP-4). cOnclusiOns: Results 
indicate that uncontrolled diabetic patients who initiated treatment with DPP-4, 
compared with those initiating with SU/TZD, are associated with a reduced risk 
of diabetes-related hospitalizations and consequently with a lower overall total 
annual cost per patient.
PDB15
THE PRESENCE OF METABOLIC AND OTHER RISK FACTORS IN ADRENAL 
INSUFFICIENCy PATIENTS COMPARED TO AN UNMATCHED BACKGROUND 
POPULATION FROM THE SAME REGION IN THE UNITED KINGDOM
Teneishvili M.1, Marelli C.2, Lee D.3
1ViroPharma LTD., Maidenhead, UK, 2ViroPharma SPRL, Maidenhead, UK, 3BresMed, Sheffield, UK
Objectives: To describe epidemiological characteristics among adrenal insufficiency 
(AI) patients and describe the prevalence of risk factors in primary and secondary AI 
(PAI; SAI) and an unmatched, non-AI population. These analyses explore metabolic 
morbidity in AI, which literature suggests may be associated to a non-physiological 
cortisol profile. MethOds: Initial aggregated data from the FARSITE database were 
analysed. The prevalence of risk factors was evaluated, including hypertension, BMI, 
diabetes and depression, and compared across PAI, SAI and non-AI populations. 
Characteristics of non-AI patients were not matched with AI patients. Results: A 
total of 261,638 patients were included; 62 PAI and 191 SAI. Prevalence of hypertension 
was 32% in PAI, 22% in SAI and 13% non-AI. 26% of hypertension in SAI was not on 
target according to QOF criteria (14% non-AI; 10% PAI). Hypercholesterolemia occurred 
in 13% of PAI and 6% of SAI patients (3% non-AI). Among SAI patients, 69% were over-
weight (BMI> 25) or obese (BMI> 30) (63% PAI; 39% non-AI). Diabetes (Type 1 and 2) was 
prevalent in 13% of PAI and 10% of SAI (5% non-AI), with HbA1c not controlled accord-
ing to QOF criteria in 75% of PAI and 74% of SAI patients. Psychological risk factors 
were more prevalent among AI patients; 24% of PAI and 14% of SAI patients recently 
received anti-anxiety/depression treatment (6% non-AI). Hypnotics were recently 
prescribed to 6% of SAI patients (1% non-AI; PAI not reported). Bisphosphonates are 
used by 21% of PAI and 8% of SAI patients (2% non-AI). The hospital admission rate 
was 3% for SAI patients (1% non-AI; PAI not reported). cOnclusiOns: The preva-
lence of metabolic and other risk factors is considerably higher among AI patients 
indirect pairwise odds ratios (OR) were obtained. The study used Bayesian Analysis 
Using Gibbs Sampling in Windows (WinBUGS) version 1.4.3. and Monte Carlo 
Simulations to conduct a multiple treatment comparison. Results are reported in 
OR with 95% credible intervals (CI) and the median of ranking. Results: There were 
a total of 10 studies with 23 treatment arms, representing 2,885 subjects enrolled, 
that were included in the analysis. The results from fix effects model indicated 
that duloxetine, pregabalin, gabapentin, and co-administration of duloxetine and 
gabapentin were significantly better than amitriptyline (OR= 3.22[95%CI, 1.54-7.17], 
OR = 2.53[95%CI, 1.11-5.94], OR = 4.00[95%CI, 1.33-11.69], OR = 2.86[95%CI, 1.09-7.48], 
respectively). The results from random effects model suggested that only duloxetine 
and pregabalin were significantly better than placebo (OR = 2.61[95%CI, 1.37-4.95] 
and OR = 1.97[95%CI, 1.01-3.62], respectively). There was no significant difference 
between amitriptyline and placebo in either fixed or random effects models. With 
regard to the median ranking, gabapentin was ranked first, followed by duloxetine, 
co-administration of duloxetine and gabapentin, pregabalin, placebo, and amitrip-
tyline from the fix effects model. cOnclusiOns: Treatment of PDPN with amitrip-
tyline does not appear to be significantly different from placebo. Duloxetine and 
pregabalin appear to be better than both amitriptyline and placebo.
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RESULTS OF GALATA STUDy: GALvUS EFFICACy AND SAFETy ASSESSMENT IN 
TURKISH POPULATION
Keskin L.1, Dokmetas H.S.2, Akin F.3, Ayvaz G.4, Boz M.5, Canberk A.6, Tasan E.7, Guler S.8, 
Delibasi T.9, Sahin M.10, Uren E.11
1Malatya State Hospital, Malatya, Turkey, 2Cumhuriyet University School of Medicine, Sivas, 
Turkey, 3Pamukkale University School of Medicine, Denizli, Turkey, 4Gazi University School of 
Medicine, Ankara, Turkmenistan, 5Istanbul Training and Research Hospital, Istanbul, Turkey, 
6Istanbul University, Istanbul School of Medicine, Istanbul, Turkey, 7Bezmialem Foundation 
University Hospital, Istanbul, Turkey, 8Numune Training and Research Hospital, Ankara, Turkey, 
9Diskapi Training and Research Hospital, Ankara, Turkey, 10Ankara University School of Medicine, 
Ankara, Turkey, 11Novartis Pharma AG, Istanbul, Turkey
Objectives: The GALATA study was the first observational study on DPP-4 inhibitors in 
Turkey and aimed to evaluate the efficacy, safety and tolerability of vildagliptin and met-
formin combination (VMc) in patients with type 2 diabetes mellitus (T2DM). MethOds: 
A total of 648 of the 682 screened T2DM outpatients (age > 18 years) on VMc for at least 
4 weeks prior to enrollment were included in this 24-week, multicenter, observational 
study. Results: Of the 648 patients, 382 (59.0%) were female. The mean (standard devi-
ation-SD-) age was 55.2 (10.2) years, the mean (SD) T2DM duration was 4.8 (5.2) years and 
220 (34.0%) patients had T2DM for more than 5 years. Patients were followed for median 
(inter-quartile range-IQR-) 184.0 (74.0) days at median (IQR) 4.0 (2.0) visits. Median vilda-
gliptin and metformin doses were 100.0 mg and 2000 mg, respectively. HbA1c decreased 
from 7.8% to 7.0% (p< 0.001). A similar reduction in HbA1c from 7.6% to 7.1% was also seen 
in elderly patients (> 65 years, 18.1% of patients) (p< 0.001). The proportion of patients 
with HbA1c ≤ 6.5% increased from 13.3% to 42.7% (p< 0.001) and those with HbA1c ≤ 7.0% 
increased from 26.6% to 65.3% (p< 0.001). Mean fasting plasma glucose (FPG) decreased 
from 153.1 mg/dL to 136.5 mg/dL (p< 0.001), whereas mean post-prandial plasma glucose 
(PPG) decreased from 217.6 mg/dL to 182.1 mg/dL (p< 0.001). Eighty (12.3%) patients expe-
rienced 122 adverse events (AEs) including 3 serious AEs; 2 SAEs were not suspected to 
be related to VMc. AEs were mostly (94.3%) mild or moderate in severity and no action 
was taken for 44.3% of them; 76.2% of AEs resolved during follow-up. cOnclusiOns: 
The results of the GALATA study suggested that VMc significantly decreased HbA1c, FPG 
and PPG, achieved glycemic control targets even in elderly patients and demonstrated 
good overall safety and tolerability in T2DM patients.
PDB12
EFFICACy AND SAFETy OF TREATMENTS OF TyPE 2 DIABETES MELLITUS 
(T2DM): A SySTEMATIC REvIEw (SLR)
Pettré S.1, Selya-Hammer C.1, Ho S.1, Garg M.2, Schroeder M.3, Kaur V.4, Hemels M.2
1Amaris, London, UK, 2Janssen Cilag, Birkerød, Denmark, 3Janssen UK, High Wycombe, UK, 
4Consultant, Mumbai, India
Objectives: Collect randomized clinical evidence on the efficacy and safety of anti-
diabetic agents used in dual or triple therapy or add-on to insulin to provide a qualita-
tive overview of the available evidence and undertake a meta-analysis. MethOds: 
A SLR was conducted in line with NICE guidelines to identify randomised controlled 
trials assessing agents received in combination with metformin (MET), a sulphony-
lurea (SU), MET+SU, MET+pioglitazone, or insulin. Interventions of interest included 
SGLT-2 inhibitors (canagliflozin and dapagliflozin), sulphonylureas, pioglitazone, 
DDP-4 inhibitors, GLP-1 analogues and insulin. Electronic searches were undertaken 
using Medline, Medline-in-process, Embase, and the Cochrane Library and supple-
mented with hand searches. An ad hoc search was conducted to identify the most 
recent data at 104 weeks. Results: A total of 159 clinical trials met inclusion criteria. 
The frequency of studies by background therapy was as follows: MET (38%), mixed 
(trials containing treatment arms with different background therapies; 25%), insulin 
(21%), MET+SU (9%), and SU alone (8%). One study (assessing canagliflozin) featured 
a background of MET+pioglitazone. Studies varied in terms of treatment duration (12 
to 104 weeks), presence and duration of run-in periods (57% studies with run-in, from 
0.7 to 18 weeks), HbA1c eligibility criteria (minimum from 6% to 7%), body mass index 
(BMI; 37 studies focused on overweight and obese patients, two studies focused on 
obese patients) and age for inclusion (from ≥ 18 to ≤ 85 years). cOnclusiOns: The 
outcome of this SLR will serve as input-data in a meta-analysis, to assess relative 
efficacy of T2DM treatments in different background therapy settings.
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RESULTS OF THE POST-MARKETING SURvEy OF vILDAGLIPTIN IN FRANCE
Eschwège E.1, Attali C.2, Bringer J.3, Simon D.4, Bouee S.5, Kind B.6, Quere S.7, Dejager S.7, 
Detournay B.5
1INSERM, Villejuif, France, 2Cabinet Médical de Groupe, Epinay sous sénart, France, 3CHRU 
Montpellier, Montpellier, France, 4Hôpital de la Pitié, Paris, France, 5Cemka, Bourg la Reine, France, 
6Novartis, Rueil-Malmaison, France, 7Novartis Pharma, Rueil Malmaison, France
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tion was built (Tableau 8) to visualize the information to be easily communicated to 
local authorities and clinicians. Results: A middle-sized Finnish municipality with 
74 168 inhabitants (Joensuu) was chosen as a case-example. The estimated num-
ber of diabetic patients was 2267, out of which 1678 had T2D. Within three years 
among patients with T2D, the predicted number of CHD events would be 73 and 
57 for HbA1c levels 6.5% and 8.0%, respectively, resulting total of 16 avoidable CHD 
events. cOnclusiOns: By bringing the understanding of epidemiology and treat-
ment effects to local level, there is a possibility to show the positive outcomes of good 
diabetes care in real practice. This information may be used to help budget holders 
in resource allocation and to motivate authorities, clinicians (and patients) to follow 
the diabetes treatments guidelines.
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RESULTS FROM A TwO-STAGE DELPHI PROCESS TO IDENTIFy 
CARDIOMETABOLIC RISK FACTORS IN ADRENAL INSUFFICIENCy PATIENTS AND 
UNDERSTAND CURRENT TREATMENT IN ITALy
Elvidge J.1, Anelli M.2, Lee D.1, Marelli C.3, Teneishvili M.4
1BresMed, Sheffield, UK, 2Keypharma srl, Milan, Italy, 3ViroPharma SPRL, Maidenhead, UK, 
4ViroPharma LTD., Maidenhead, UK
Objectives: To obtain information regarding the presence of cardiometabolic risk 
factors among adrenal insufficiency (AI) patients in Italy. To understand treatment 
patterns and goals and to gain consensus regarding how effectively existing therapies 
meet these goals. MethOds: A two-stage Delphi process was conducted with four 
Italian key opinion leaders (KOLs). Each KOL completed an electronic survey eliciting 
information regarding AI management and the prevalence and importance of risk 
factors. To reach a consensus on the key issues, the results were discussed at a face-
to-face meeting. Results: The KOLs agreed that avoiding adrenal crisis is the main 
treatment goal, and that quality of life and avoiding fatigue are most important to 
patients. Patients typically receive 20–30 mg cortisone acetate or hydrocortisone daily 
in 2-3 administrations. A consensus was reached that cardiometabolic risk factors 
are not hallmarks of AI, but are related to its glucocorticoid replacement treatment 
(GC) either due to overtreatment or non-physiological replacement of serum cortisol. 
In agreement with the available evidence in the literature they suggested that the 
increase risk may be associated with the non-physiological cortisol peaks and troughs 
that are characteristic of the existing GC replacement therapies. They established that 
50% of AI patients are over treated, often to minimise the risk of adrenal crisis and all 
patients currently face non-physiological cortisol replacement, given the available 
treatments. GC replacement–related risks included (prevalence in AI in parenthe-
ses): hypertension (10–30%), abdominal obesity (15–35%), dyslipidaemia (33%) and 
metabolic syndrome (30–35%). cOnclusiOns: The prevalence of cardiometabolic 
risk factors is associated with the treatment of AI, not AI itself. Over-treatment and 
non-physiological cortisol replacement may explain cardiometabolic risks. A physi-
ological alternative to existing treatments would be welcomed in Italy.
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INCIDENCE/PREvALENCE, RISK FACTORS AND COMPLICATIONS OF TyPE 2 
DIABETES MELLITUS IN INDIAN PATIENTS: A SySTEMATIC REvIEw AND META-
ANALySIS
Likhar N., Nair S.R., Rai M.K., Goyal R., Shaikh S., Verma R.K.
Capita India Pvt. Ltd., Mumbai, India
Objectives: Type 2 Diabetes mellitus (T2DM) is becoming a major chronic disease 
burden worldwide. Indians are known to have an increased predisposition for diabetes 
which has become an important health concern. The current analysis is aimed to 
systematically review medical literature on T2DM, its prevalence and complications in 
India and also explore the differential risk factors in sub-groups. MethOds: Studies 
are being retrieved from Pubmed, Cochrane and Embase databases using relevant 
search strategies. Search limits are: articles in English, in human adults and published 
since year 2001. Pre-specified inclusion/exclusion criteria will identify study types, 
such as randomized controlled trials (RCTs), observational and retrospective studies 
reporting incidence/prevalence, risk factors and complications of T2DM patients in 
India. Two researchers will independently extract the data and analysis of comparable 
outcomes will be carried out as per appropriate statistics along with critical appraisal 
of the studies. Meta-analysis will be done using RevMan (v5.0) Results: Though 
there have been several studies assessing incidence/prevalence, complications and 
risk factors for T2DM, a systematic review/meta-analysis of the evidence is lacking 
in the Indian scenario. This study aims to provide the much-needed evidence link-
ing incidence/prevalence, complication and risk factors in different groups of T2DM 
patients. This study hopes to demonstrate association of various risk factors with 
disease progression and with complications of T2DM. cOnclusiOns: The prevalence 
of T2DM has been increasing over the years. The data from published studies will 
hopefully answer some of the prevailing variations and trends in prevalence of T2DM 
between different subgroups of T2DM patients and their association with risk factors.
PDB21
EARLy LIFE DETERMINANTS OF METABOLIC SyNDROME AND DIABETES 
MELLITUS IN SOUTH ASIAN POPULATION LIvING IN EUROPE: A SySTEMATIC 
REvIEw
Callejo D.1, Díaz-Cuervo H.1, Cuervo J.1, Rebollo P.1, Hussain A.2, Hitman G.A.3
1LASER Analytica, Oviedo, Spain, 2University of Oslo, Oslo, Norway, 3Queen Mary University of 
London, London, UK
Objectives: To review lifestyle and genetic factors during pregnancy and early child-
hood in South Asian population living in Europe that may influence later risks of 
insulin resistance, metabolic syndrome, T2DM and CVD MethOds: A systematic 
search, using controlled and free terms (i.e.- metabolic-syndrome, glucose-intol-
erance, diabetes-mellitus, pregnancy, foetal development, life-style, nutrition) was 
conducted in Medline, Centre for Reviews and Dissemination and Cochrane Library 
databases. It was completed by pearling and hand-searching. Two reviewers assessed 
independently the results retrieved in the search, to adopt a decision on inclusion/
exclusion. The quality of included papers was appraised with STROBE checklist for 
than the non-AI population. Since the comparison was unmatched, results should be 
interpreted with caution. Ongoing analysis will include a detailed data assessment, 
with a stronger comparison against matched non-AI populations.
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REAL wORLD INCIDENCE OF TyPE 2 DIABETES (T2D) COMPLICATIONS LEADING 
TO HOSPITALIzATION IN FRANCE: THE RECODE STUDy
Bouee S.1, Cochinaire A.1, Godard C.2, Sabater F.J.2, Amelineau E.2, Emery C.3, Cotté F.E.2
1Cemka, Bourg la Reine, France, 2Bristol-Myers Squibb, Rueil-Malmaison, France, 3Cemka Eval, 
Bourg La Reine, France
Objectives: To estimate the cumulative incidence and cost of cardiovascular (CV) 
complications (stroke, acute coronary syndrome (ACS), acute heart failure (AHF) 
and peripheral vascular disease (PVD)) leading to hospitalization in T2D patients 
with a CV complication history in France. MethOds: We conducted an analysis of 
the Program for a Medicalized Information System (PMSI) databases which record 
all hospitalizations occurring in France including rehabilitation care. We identi-
fied all patients with a T2D diagnosis and hospitalized for any reason in 2006-2008 
and selected patients with a documented CV complication history. We analyzed 
those patients as a retrospective cohort followed-up for 3 years from the index 
date (January 1st 2009) and calculated cumulative incidences of new CV complica-
tions. We considered death as a competing event. Mean hospital and rehabilitation 
costs were based on the National Scale of Costs. Results: A total of 1,114,182 T2D 
patients were hospitalized in France in 2006-2008. Among them, 30.5% (n= 339,328) 
had a CV complication history. Mean age was 70.6 (+/-11.1), and 61.9% were males. 
Hypertension, dyslipidemia, renal impairment and obesity were reported in 
80.1%, 45.0%, 33.3% and 29.2% of the patients, respectively. The 3-year cumulative 
incidences for one or more new CV complication were: 3.6% [95%CI:3.5%;3.7%] for 
stroke, 5.6% [95%CI:5.5%;5.7%] for ACS, 6.8% [95%CI:6.7%;6.9%] for AHF and 15.0% 
[95%CI:14.9%;15.1%] for PVD with a mean cost per event of € 5,724, € 5 315, € 4 726, € 4 
766, respectively. 21.8%, 10.5%, 11.4% and 9.5% of patients required rehabilitation 
care for stroke, ACS, AHF and PVD, at an additional mean cost of € 12,000, € 6 233, € 6 
987 and € 9 219 per patient, respectively. cOnclusiOns: CV complications represent 
an important burden for T2D patients and the health system in France. These results 
would be helpful for health technology assessment and for economic evaluation of 
upcoming interventions which reduce CV risk in T2D patients.
PDB17
STUDy AND EvALUATION OF MEDICATION ERRORS IN DIABETIC PATIENTS IN 
MEDICINE wARD OF A SECONDARy CARE COMMUNITy HOSPITAL AT MUMBAI, 
INDIA
Lokhande A.K.1, Patidar D.2, Patil U.K.3
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 2Indore Institute 
of pharmaceutical Sciences, Indore, India, 3People’s University, Bhopal, India
Objectives: While concerning to diabetic treatment, any suboptimum therapy may 
lead to medication error (ME). Objective of study was to report the causes, severity, 
increase in cost of therapy and outcomes of ME in patients undergone treatment for 
diabetes in medicine ward of a community hospital. MethOds: Prospective obser-
vational study (8 months). In-patients with type-II diabetes mellitus were chosen 
randomly and the details were followed till discharge. Results: Incidences of 504 
MEs were observed in 164 out of total patient pool of 230. The notable trends in MEs 
identified were- erroneous prescriptions 101(20.03%), inappropriate dosage-form 
93(18.4%), incorrect-route 63 (12.5%), incident of drug interactions 129 on 55 patients 
(10.09%), failure to monitor lab levels 27(5.30%), failure to adjust doses according to 
lab levels 37(7.14%) and 21(4.16%) cases of incorrect-indications. On severity scale, 
MEs were classified as 143(28.37%) severe, 256(50.79%) moderate and 105(20.8%) mild. 
Predicted error outcome of 164 incidences which were reaches to patient classified 
as- no serious 85(51.8%), moderately serious 61(37.19%), 9(5.3%) life threatening and 
9(5.35%) death (predicted). We observed fair degree of linear correlation between 
increasing age and occurrence of ME 0.99 (rcritical value-0.878). Female sex was found 
to be at higher risk of MEs than male (X2= 6.73, P-value= 0.01). There was a linear 
correlation observed between the polypharmacy and ME 0.95 ( rcriticalvalue-0.44). It 
was observed that, out of total 129 drug interactions identified; only 35(27.13%) were 
moderate, while 72(55.81%) were severe and 22(17.05%) found mild. Significant incre-
ment in the length of stay in hospital and direct drug cost were observed among the 
severe, moderately severe and in mild cases. cOnclusiOns: The observed finding 
of ME defines specific clinical domains and patient subgroups for which aggressive 
efforts needed to reduce MEs. Through information dissemination and education, 
managed health care professionals should play more active role in ME-reduction.
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ESTIMATING THE HEALTH OUTCOME OF TREATING TyPE 2 DIABETIC 
POPULATION TO TARGET IN LOCAL MUNICIPALITy LEvEL
Säävuori N.1, Tyrväinen V.2, Purmonen T.3
1Oy Medfiles Ltd., Vantaa, Finland, 2Proper Ltd., Joensuu, Finland, 3Oy Medfiles Ltd., Kuopio, 
Finland
Objectives: Type 2 diabetes (T2D) and its consequences are largely studied world-
wide. The number of diabetic patients is increasing and thus, a growing number 
of health care resources are needed to cover the treatment of this population. It is 
also known that in spite of the national treatment guidelines, the recommended 
HbA1c level (< 6.5%/48 mmol/mol) is not always achieved. In order to allocate the 
resources effectively, local information concerning epidemiological and demographic 
differences across different jurisdictions must be available. MethOds: A national 
population-based study (Finriski 2007) was used to estimate the prevalence of dia-
betes in different geographical areas. The estimated prevalence rates and number 
of T2D patients were extrapolated to municipal level using demographic data from 
the official statistics. UKPDS risk equation was used to predict the number of cardio-
vascular events with and without proper treatment in each municipality. Local risk 
profile and different HbA1c levels (6.5% (48 mmol/mol) and 8.0% (64 mmol/mol)) were 
used to illustrate the importance of treating patients to target. A map-based applica-
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Objectives: In Type 1 diabetic (T1D) patients high values of glycated hemoglobin 
(HbA1c) have been shown to be associated with higher risk of complications 
leading to high costs to the National Health Care System (NHS). The aim of this 
analysis is to evaluate the economic impact of poor glycaemic control, and the 
potential savings associated with better glycemic control in the Italian T1D popula-
tion. MethOds: A probabilistic model using published risk-curves was developed 
to project incidence and progression of diabetes-related complications associated 
with different HbA1c levels over 1-year and 5-year time-horizon in T1D patients. 
Associated cost of retinopathy, nephropathy, neuropathy, cardiovascular disease, 
diabetic ketoacidosis and severe hypoglycemia in the Italian setting were used to 
estimate the economic impact of complications in each HbA1c interval form the 
NHS perspective. Subsequently the results of the simulation were translated to 
the entire Italian T1D population stratified by HbA1c level accordingly to published 
2012 data. Results: Estimated cost per patients of diabetes-related complica-
tions in the first year of occurrence, stratified by HbA1c intervals, ranged from 
4,463€ for HbA1c ≥ 10% to 2,006€ for HbA1c between 7% and 8%. A 5 year follow 
up analysis was also conducted. A treatment strategy able to reduce HbA1c level 
from ≥ 10% to 9% could lead to potential savings of 1,342€ per patients in the first 
year of treatment. Considering the total T1D Italian population, improving HbA1c 
to < 8% in the first year would results in a potential savings of about 17 million 
euros. cOnclusiOns: The economic impact of diabetes-related complications in 
the Italian setting is significant. Consequently the potential savings for the NHS 
derived from the implementation of strategies aimed at improving HbA1c in T1 
should be considered. Moreover the greater the reduction of Hba1c obtained the 
greater the associated savings.
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COST-COMPARISON BETwEEN DIFFERENT TREATMENT REGIMENS IN DIABETES 
MELLITUS IN GERMANy BASED ON LONG ACTING INSULINS
Anderten H.1, Dippel F.W.2, Schneider T.2
1Ambulatory Care, Hildesheim, Germany, 2Sanofi, Berlin, Germany
Objectives: Cost comparison between different basal insulin regimens (Glargine 
vs. Detemir vs. NPH-insulin) in diabetic patients in Germany under real-life condi-
tions. MethOds: The analysis is based on IMS LRx-database (2011). This repre-
sentative patient tracking tool covers nearly 60 million insurants and includes 
more than 500 million drug prescriptions per year (including consumables) 
Patients with at least two prescriptions of basal insulin (Glargine, Detemir or 
NPH-insulin) in 2011 (January – December) and at least one prescription of any 
type in 2010 and 2012 were considered eligible. Costs included basal and bolus 
insulin, oral antidiabetic drugs, test strips, needles and lancets and were esti-
mated by ex pharmacy prices (Lauer Taxe) minus legally defined rebates according 
to §130 a of social security code (SGB V). Results: A total of 542.438 patients 
were allocated to either Glargine (207.506 patients) or Detemir (90.671 patients) 
or NPH (244.261 patients). The mean annual treatment costs per patient are 1.211 
€ (Glargine), 1.224 € (NPH insulin) and 1.572 € (Detemir). A breakdown at the level 
of different sick funds shows a similar pattern of annual treatment costs per 
patient of the three basal insulin regimens. The acquisition costs of basal insu-
lin is considerably higher for Glargine (380 € ) and Detemir (448 € ) compared to 
NPH-Insulin (253 € ). The cost of bolus insulin is lower in the Glargine group (305 
€ ) compared to NPH-insulin (419 € ) and Detemir (493 € ). Costs of consumables 
(test strips, needles, lancets) are lowest in the in the Glargine group (395 € ) due 
fewer insulin applications compared to Detemir (509 € ) and NPH insulin (461 
€ .) cOnclusiOns: Mean annual treatment costs are lowest with Glargine fol-
lowed by NPH-insulin, whereas Detemir based regimens are 30% more expensive 
under real life conditions. The results are in line with previous cost analyses in 
diabetic patients in Germany [1-3]
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Objectives: To assess the economic burden and health care utilizations of 
diabetes in the U.S. veteran population. MethOds: Adult (≥ 18 years of age) 
patients diagnosed with diabetes (International Classification of Disease 9th 
Revision Clinical Modification [ICD-9-CM] code 250.x0 or 250.x2) were identi-
fied from the dataset between October 1, 2009 through September 30, 2011. The 
first diagnosis date was designated as the index date. A comparator group was 
created consisting of patients without diabetes but of the same age, region, 
gender and index year, and matched by baseline Charlson Comorbidity Index. 
The index date for the comparator group was randomly selected to minimize 
selection bias. Continuous medical and pharmacy benefits 1 year pre- and 1 year 
post-index date were required for patients in both groups. One-to-one propensity 
score matching (PSM) was applied to compare health care costs and utiliza-
tions during the follow-up period between the diabetes and comparator groups, 
adjusted for baseline demographic and clinical characteristics. Results: A total 
of 1,427,948 patients were identified for the diabetes and comparator cohorts. 
After applying 1:1 PSM matching, a total of 340,933 patients were matched from 
each group, ensuring well-balanced baseline characteristics. Patients diagnosed 
with diabetes were more likely to report inpatient (8.93% vs. 2.09%, p< 0.01), emer-
gency room (13.66% vs. 5.61%, p< 0.01), outpatient (99.63% vs. 53.78%, p< 0.01), 
and pharmacy visits (87.13% vs. 52.69%, p< 0.01). They also incurred higher 
health care costs, including inpatient ($3,031 vs. $582, p< 0.01), emergency room 
($137 vs. $51, p< 0.01), outpatient ($3,375 vs. $1,272, p< 0.01), pharmacy ($708 vs. 
$293, p< 0.01) and total costs ($7,113 vs. $2,148, p< 0.01) than the comparator 
group. cOnclusiOns: U.S. veteran patients diagnosed with diabetes reported 
a significantly higher economic burden compared to the matched controls over 
a 12-month period.
observational studies and Centre for Evidence Based Medicine checklists for any 
other study design. The present review is part of the GIFTS project funded by Seventh 
Framework Programme of European Commission. Results: A total of 349 papers 
were identified, after title and abstract revision 76 full text were retrieved plus 8 
identified through pearling. To date 67 full texts have been assessed, 49 excluded and 
18 included. 14 (78%) were conducted in the UK. South Asian pregnant women were 
at higher risk of developing GDM (OR ranged 2-5.6) and intrauterine growth retarda-
tion (OR ranged 2-5) than European counterparts. These factors contributed to higher 
rates of stillbirth, perinatal and neonatal mortality and congenital anomalies detected 
in South Asian origin women. As well as higher rates of babies with vitamin D defi-
ciency, hypocalcaemia, hyperinsulinemia, dyslipidaemia, hypoglycaemia and lower 
birthweight. Also higher risk of rapid weight gain between 12 to 24 months and 3 to 
5 years in Asian infants was reported in two different papers. cOnclusiOns: There 
are differences between Asian women living in Europe and European women during 
pregnancy, and their offspring, which as early life factors might explain higher preva-
lence of later metabolic syndrome and type 2 diabetes in Asian migrant population.
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Objectives: Recent studies have quantified the resource implications associated 
with severe hypoglycaemia episodes (SHE) and non-severe hypoglycaemia episodes 
(NSHE). The objective of this study was to characterize the relationship between the 
frequency of SHE/NSHE and patient/therapy characteristics in insulin treated type-2 
diabetes mellitus (T2DM) patients. MethOds: We conducted a literature review of 
the MEDLINE database for insulin-based T2DM clinical trials where sulfonylurea usage 
was also reported between June 1, 2007 and June 1, 2012. Patient demographics, treat-
ments effects and treatment type were extracted and the SHE/NSHE rate per 100 
patient years (PY) was modeled via a log-linear regression model using R. Results: 
Data were extracted from 82 studies for a total of 155 trial arms meeting the search 
criteria; treatment regimes were categorized into basal analog (30%); bolus analog 
(4%); basal bolus (24%); biphasic analog (25%); biphasic human (8%) and NPH (10%). 
Mean (standard deviation) age was 57.9 (3.8) years; 10.2 (2.4) years duration of diabe-
tes; 8.8% (0.7)baseline and 7.5% (0.5) end-of-study HbA1c respectively. Mean reported 
NSHE/100 PYs was 929.8. The final regression model was NSHE/100PY= exp(14.771 
- 0.088 × age - 0.667 × baseline HbA1c + 0.427 × HbA1c reduction + 0.189 × duration 
diabetes + 0.007 × % study allowed sulphonylurea – 0.545 × basal analog insulin) with 
an R2 goodness of fit of 0.226. Mean reported SHE/100 PYs was 5.9. The final regression 
model was SHE/100PY= exp(10.794 - 0.101 × age - 0.723 × baseline HbA1c + 0.638 × 
HbA1c reduction + 0.163 × duration diabetes + 0.768 × biphasic insulin )-1 with an 
R2of 0.219. cOnclusiOns: This study provides a basis for predicting the number of 
SHE and NSHE in insulin treated T2DM subjects. When linked to resource and quality 
life, these equations may facilitate the improved estimation of the health economic 
burden associated with SHEs and NSHEs.
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Objectives: Severe (requiring assistance from another individual) hypoglycaemic 
events (SHEs) are important from both clinical and economic perspectives. The aim 
was to assess treatment-related SHEs risk in different treatment regimens in type 1 
and 2 diabetes. MethOds: Anti-diabetic treatments were stratified into six groups: 
basal-bolus (BB); basal in combination with oral therapy (BOT); insulin pumps; bipha-
sic insulin; sulfonylureas; other than SU oral antidiabetic drugs (OADs). Insulin treat-
ments were further split into analogues (IA) and human insulins (HI). The systematic 
review of Medline, EMBASE and Cochrane databases was conducted for recent (≤ 10 
years), large (n ≥ 100), observational studies. Data on time horizon, participants num-
ber and SHEs occurrence were extracted. Using a random effects Poisson model within 
MCMC framework we estimated the SHEs rates. Results: In the systematic review 
5220 publications were found, 525 full texts evaluated and 101 articles included (55 
trials). The following average SHE/year (No of studies; 95%CI) were estimated: Type 1: 
BB with IA as the basal component: 0.53 (7; 0.29–1.18); BB with HI: 1.10 (6; 0.58–2.71); 
pump treatment: 0.18 (14; 0.13–0.25); biphasic insulin: 1.10 (0.58–2.71). Type 2: BOT 
with IA as the basal component: 0.13 (11; 0.04–1.17); BOT with HI: 0.21 (7; 0.08–0.88); 
BB with IA: 0.01 (6; 0.003–0.25); BB with HI: 0.56 (3; 0.16–9.65); biphasic IA: 0.10 (12; 
0.05–0.26); biphasic HI: 0.20 (6; 0.07–0.93); sulfonylureas: 0.05 (6; 0.02–0.14); OADs: 0.01 
(0.001–0.008). The differences in the SHEs risk among regimens were significant at a 
95% level. cOnclusiOns: The SHEs risk differs in both type 1 and 2 diabetes across 
various treatment regimens. HI was found to increase the SHEs risk compared to IA. 
Limited availability of studies and heterogeneous data make it difficult to come up 
with precise rate estimation for typical anti-diabetic treatment regimens.
DIABETES/ENDOCRINE DISORDERS – Cost Studies
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ments. In addition, diabetic patients with low education level cost 2.341€ cost more 
on average in comparison to better educated patients. cOnclusiOns: T2DM is an 
expensive to treat disease and in the era of limited resources and escalating costs 
it is critical to implement sound public health policies in order to achieve patient’s 
good glycemic control and consequently less burden to health care budgets.
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Chauhan R.1, Lee D.2
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Objectives: To calculate the cost of illness (COI) associated with adrenal insuffi-
ciency (AI) in the UK. AI patients do not produce cortisol and require glucocorticoid 
replacement therapy (RT) to survive, which is predominantly immediate-release 
hydrocortisone in the UK. With current therapy, AI patients have increased mor-
bidity and premature mortality, and suffer reduced quality-of-life. MethOds: The 
COI determines the direct and indirect costs over a 1-year period. The COI includes 
the cost of RT, primary and secondary care costs (GP and outpatient appointments; 
admissions for adrenal crises; diagnosis and management of AI) and those associ-
ated with reduced productivity (absenteeism). Direct costs were estimated using 
national reference costs, Payment by Results tariffs and other published data. AI 
prevalence and adrenal crises data were taken from published literature and activity 
data (hospital admissions for management of AI) from Hospital Episode Statistics 
(HES) data. A 2012 worldwide survey of AI patients was used to determine days 
taken off work and clinical expert opinion was sought to determine total outpatient 
appointments per year. The costs associated with premature mortality, the treat-
ment and management of co-morbidities and the burden associated with reduced 
quality of life were not included due to lack of data. Results: There are ~20,000 AI 
patients in the UK. Based upon the burden of disease calculations, the estimated 
COI associated with AI is £1,922 per patient or £39.7 million over 1 year: RT, £21.7 
million; GP appointments, £1.8 million; secondary care, £4.4 million; and reduced 
productivity, £11.8 million. cOnclusiOns: The high health care and social costs 
associated with AI highlight the clinical and economic need to improve RT. Indeed, 
as some consequences of the disease were not included in the calculations, £39.7 
million is likely a considerable underestimate of the true burden of disease.
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Objectives: To assess the direct costs associated to type I and II diabetes mellitus 
(DM) from a health care perspective in Spain. MethOds: We performed a cost of ill-
ness study considering the prevalence approach. The use of resources was estimated 
from the existing Spanish health care databases and bibliographic references. Costs 
evaluated were: hospital costs (including outpatient care), primary care costs, drugs 
costs, consumables costs and additional tests costs. All costs were updated to 2012 
euros. Results: The total direct annual cost of DM was 5,809 million euros repre-
senting 8.2% of the total Spanish health expenditure. The total drug cost accounted 
for 2,232 million euros (38%) and was mainly due to the elevated contribution of 
non-antidiabetic drugs (24%). Hospital costs represented 1,934 million € (33%) and 
were mainly driven by the acute and chronic complications (17%). Cardiovascular 
disease cost (521 million € ) and peripheral vascular disease costs (127 million € ) 
were the most important complications cost drivers. The contribution of monitoring 
strips to the total cost was only 118 million € (2%). Total complications cost repre-
sented 2,143 million € (37% of the total direct cost). cOnclusiOns: DM total direct 
costs are strongly conditioned by DM complications cost and have a considerable 
economic impact on Spanish health expenditure. In order to reduce the health and 
economic impact generated by DM, the introduction of measures and strategies 
focused on improving the efficiency of the treatment of the disease are crucial.
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Objectives: There have been a number of studies quantifying the direct and indi-
rect resource implications associated with severe hypoglycaemia episodes (SHE) 
and non-severe hypoglycaemia episodes (NSHE). The objective of this study was to 
calculate the total direct and indirect economic burden associated with SHE and 
NSHE in insulin treated type 2 diabetes mellitus (T2DM) subjects. MethOds: We 
conducted two literature reviews of the MEDLINE database for studies published 
between June 1, 2007 and June 1, 2012. The first assessed the direct (primary and 
secondary care and treatment related) and indirect resource implications (lost pro-
ductivity) associated with SHE and NSHE; the second established the frequency of 
NSHE and SHE in insulin-based clinical trials where sulfonylurea usage was also 
reported in T2DM. An economic model written in Microsoft Excel was developed to 
predict the expected annual per-patient cost (using 2011 US costs) associated with 
the incidence of hypoglycaemia. Results: Resource utilisation from 6 studies and 
data characterising hypoglycaemia frequency were extracted from 82 studies for a 
total of 155 trial arms where the search criteria were met. Mean annual hypoglycae-
mia event rates were 16.4, 8.9, 4.8 and 2.6 for NSHE and 0.083, 0.039, 0.015 and 0.003 
for SHE associated with baseline HbA1c levels of 6%, 7%, 8% and 9% respectively.
Total expected annual per-patient hypoglycaemia costs were $929, $471, $237 and 
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Objectives: Severe hypoglycaemias occurring in diabetes care are associated with 
a major economic burden on health care systems, with a major part of the direct 
costs resulting from the small proportion of patients who are admitted to hospital. 
We assessed the inpatients costs of severe hypoglycaemic events in Type 1 and 2 
diabetes (SHE) patients in France. MethOds: The study was done using the 2012 
French National Database on hospital care (PMSI). This comprehensive database 
covers all hospital stays in the French population (over 20 million hospital stays per 
year). SHE were identified using ICD10 codes of hypoglycaemias (E160, E161, E162, 
T383) in combination with diabetes codes (E11, E10, E13, E14, N083) and excluding 
gestational diabetes. Directs costs to the health care system were estimated using 
the French National Costs study (2011 values). Results: Overall, in 2012, 17,835 
stays for diabetes related hypoglycaemias were identified in the database corre-
sponding to 16,406 patients. 8.7% of patients were hospitalized twice in the year for 
SHE, 51% were male and aged 66.7 years on average (SD 19.7). 90% of stays occurred 
in public hospitals and mean length of stay was 8.1 days (median 7.0). The mean 
direct cost of one SHE hospital stay was € 4,360. Extrapolated to the whole country 
the direct cost of hospitalized SHE was € 77.7 million which roughly correspond to 
1.2% of the overall diabetes costs for the health care system. Such value would be 
considered a conservative estimate due to potential underreporting of cases in the 
database. cOnclusiOns: Our study confirmed that hypoglycaemic events lead to 
substantial costs for the community even it was limited to direct costs in inpatient 
setting. As the short-term and long term consequences of hypoglycaemia begin to 
be better understood, more studies have to be done to estimate the full economic 
burden of this disease.
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Objectives: Health expenditure to treat and prevent T2DM and its complications 
was estimated at USD 345 million for OECD countries in 2010. These costs pose 
great burden to national health system’s budget, which is already under pres-
sure. In Greece there are no studies that provide information on the costs of T2DM 
patients including the cost of complications, hospitalizations and co-morbidities. 
The current study aimed to estimate the total cost of T2DM patients from a third 
party payer perspective. MethOds: A retrospective research study was performed 
in four major hospital diabetes centers and 211 patients with at least 10 years 
of T2DM from diagnosis. Patients were categorized in two groups, controlled and 
uncontrolled. Hospitalization and management of complications was based on DRG 
cost. Pharmaceutical and diagnosis cost was based on official NHS prices. Health 
care cost corresponds to 2012 Euros and the perspective used was of the Social 
Security Fund. Subgroup analysis was performed in order to evaluate the cost dif-
ference between controlled vs. uncontrolled, obese non-obese and various other 
subgroups. Results: The mean age of patients was 72.9±8.1 years with mean T2DM 
duration 21.2±7.5 years, and mean HbA1c 7.3±1.0%. The mean average yearly cost of 
T2DM was € 7.111 whereas only the18.8% was attributed to cost of antidiabetic drugs. 
Controlled patients (HbA1c ≤ 7) cost on average 6.366 and uncontrolled (HbA1c> 7) 
€ 7.783. The mean hospitalization and complication cost was € 2.456. It was found 
no difference of mean hospitalization and complication cost between controlled 
and uncontrolled patients (p= 0.09). Co-morbidities cost absorbs the majority of the 
budget and was the differentiating factor between two groups. Few patients (21.8%) 
reported admission to hospital with similar hospitalization rates on number and 
duration between the two groups. cOnclusiOns: T2DM is an expensive to treat 
disease with very high cost complications with economic and societal burden.
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Objectives: Health expenditure to treat and prevent T2DM and its complications 
was estimated at USD 345 million for OECD countries in 2010. These costs pose a 
great burden to the national health system’s budget, which is already under pres-
sure. In Greece there are no studies that provide information on the costs of T2DM 
patients including the cost of complications, hospitalizations and co-morbidities. 
The current study aimed to estimate the total cost of T2DM patients from a third 
party payer perspective. MethOds: A retrospective research study was performed 
in four major hospital diabetes centers and 211 patients with at least 10 years 
of T2DM since diagnosis. Patients were categorized in two groups, controlled and 
uncontrolled. Hospitalization and management of complications was based on DRG 
cost. Pharmaceutical and diagnosis cost was based on official NHS prices. Health 
care cost corresponds to 2012 Euros and the perspective used was of the Social 
Security Fund. Subgroup analysis was performed in order to evaluate the cost differ-
ence between controlled vs. uncontrolled, obese non-obese and various other sub-
groups. Results: The mean average yearly cost of T2DM was € 7.111 whereas only 
18.8% was attributed to cost of antidiabetic drugs. Diabetic men cost 2.222€ more per 
year in comparison to diabetic women, whereas obese diabetics cost 1.460€ more 
per year in comparison to overweight and normal patients. These may be explained 
by the higher levels of HbA1c, co-morbidities and the number of antidiabetic treat-
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cular complications- 41%. In the type 1 diabetes group the cost was equal to 15 364 
EUR with the following split: 63% due to (general) diabetes, 19% due to microvascular 
complications, and 18% due to macrovascular complications. cOnclusiOns: Type 
2 diabetes is more costly than type 1 when hospitalizations occur. People with type 
2 diabetes pay high cost for macrovascular complications than for microvascular 
probably due to high hypertension prevalence. The difference in costs between type 
1 and 2 may result from different patients’ characteristics.
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UKRAINE
Vadziuk I.
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Objectives: Due to the preparation for the transition to health insurance in Ukraine 
and because of the significant increase in thyroid disease it is important to assess a 
range of medicines included to the Ukrainian National Formulary (UNF). MethOds: It 
was compared the range of drugs for treatment of thyroid disease which are included 
to the Ukrainian National Formulary with the WHO Model list of Essential Medicines. 
Also it was calculated the annual cost of treatment by each medication considering 
the usual maintenance dose. Results: In accordance to WHO Model List of Essential 
Medicines it was established that Ukrainian National Formulary includes thyroid 
hormones and antithyroid medicines for thyroid disease treatment such as: levothy-
roxine sodium and potassium iodide. Also it was found that there are no propylthi-
ouracil medications in UNF. The dosage of levothyroxine sodium tablets satisfies the 
norms of World Health Organization, which are: 25 micrograms, 50 micrograms and 
100 micrograms. Potassium iodide tablets in dose of 100 micrograms, 200 micrograms, 
1 mg does not comply the norm. According to WHO Model list of Essential Medicines 
dosage of potassium iodide in tablets should be 60 mg. The cheapest annual cost of 
treatment by levothyroxine per patient is EUR 10,95 (The EUR/UAH conversion rate: 1 
EUR = 10,52 UAH (Average 2013)), the most expensive is EUR 80,30. The most expensive 
annual cost of treatment by potassium iodide per patient is EUR 31,32, the cheapest is 
EUR 2,85. cOnclusiOns: Propylthiouracil should be included to Ukrainian National 
Formulary. The cost difference of thyroid disease treatment by essential medicines 
caused by presence of foreign products in the pharmaceutical market of Ukraine.
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Objectives: The randomized controlled ABACUS study assessed the impact of 
using the automated insulin bolus advisor within the Accu-Chek Aviva Expert sys-
tem in combination with intensive diabetes therapy on glycemic control in patients 
treated with MDI therapy. This analysis assessed the potential incremental eco-
nomic benefit of using this automated bolus advisor device on the short-term health 
care costs (SHC). MethOds: The study outcome parameter was “achieving the goal 
of an at least 0.5% reduction in HbA1c”. The economic analysis was performed with a 
spreadsheet-model from a UK payer’s direct cost perspective and based on ABACUS 
outcomes. Data on correlation between HbA1c change and expected cost are based 
on published literature. Model outputs include expected impact on SHC and sen-
sitivity analysis. Results: A total of 56% of patients in the intervention group (IG) 
achieved the goal, in the control group (CG) 34% respectively. Goal achievement led 
to an average HbA1c reduction of 1.2%, irrespective of group. There was no clinically 
relevant HbA1c effect in the remaining patients. Goal achievement correlates with 
an expected reduction in SHC of £189 per person / per year (PPY). The expected 
SHC reduction is £104 PPY in the IG and £74 PPY in the CG. The goal-achievement-
rate increased by 63%, driving a comparative economic benefit of £30 PPY for an 
automated insulin bolus advisor supported approach. There were no significant dif-
ferences in complications or in intervention cost. cOnclusiOns: An MDI therapy 
in diabetes care that is supported by the Accu-Chek Aviva Expert systems with its 
automated bolus advisor leads to a 63% higher rate of goal achievement. This is 
expected to result in an incremental reduction in short-term health care costs of 
£30 PPY. Hence automated bolus calculation improved the cost-effectiveness of 
self-monitoring of blood glucose in this study population.
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Objectives: Type 2 diabetes mellitus (DM) is widely spread in Russia, counting 
about 10 million. New drugs are highly effective and carry a high cost for health 
care. The results of clinical trials are not enough to assess long term efficacy 
and safety of treatment. Modeling is a tool for making long term economic and 
outcome prognosis and comparing treatment strategies. The main goal of the pre-
sented study was to develop a predictive model of type 2 DM outcomes validated 
in Russian clinical conditions and to perform pharmacoeconomic evaluation of 
glucose lowering therapies. MethOds: Existing type 2 DM models were evalu-
ated. Risk equations for type 2 DM complications were compiled from EAGLE and 
UKPDS DM models. Demographic (age, sex, height, weight, DM duration, smok-
ing), biochemical (HbA1c, lipids) and clinical (blood pressure) patient parameters 
were used as inputs. Glucose lowering drug effectiveness was incorporated into 
$117 associated with HbA1c levls of 6%, 7%, 8% and 9% respectively. cOnclusiOns: 
In insulin treated T2DM subjects lower HbA1c is associated with higher frequency of 
hypoglycaemia and associated costs. Failing to account for the cost burden associ-
ated with hypoglycaemia may underestimate the value of diabetes management 
strategies that minimize hypoglycaemia risk.
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COMPARATIvE ANALySIS OF THE COST AND METABOLIC CONTROL IN 
DIABETIC CHILDREN USING INSULIN PUMPS
Petkova V.1, Petrova G.2, Petkova E.1
1Medical University, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University of Sofia, Sofia, 
Bulgaria
Objectives: To assess the cost and metabolic outcomes in children with diabetes 
mellitus treated with CSII or with human insulin. MethOds: It is a cost-conse-
quence analysis. Retrospectively were observed patients dossier and health care 
resources used during the period 1999 – 2012. The study sample included 34 chil-
dren aged 3 to 18 years with type 1 diabetes. Seventeen of the children are using 
continuous subcutaneous insulin infusion (CSII) therapy and 17 using intensified 
dosage regime of human insulin. The duration of the disease, diabetic control, HbA1c 
deviation scores, height and weight were observed. Cost of pharmacotherapy, test 
strips were calculated and compared with the therapeutic outcomes in both studied 
groups. The average improvement of HbA (1c) after the CSII introduction was chosen 
as therapeutic outcome. Results: Subcutaneous insulin infusion (CSII) systems are 
not a standard treatment for the Bulgarian children; they are of a limited usage and 
are not reimbursed. From the 34 children with diabetes type 1 observed 17 were on 
CSII (mean age 10 years, mean duration of diabetes - 7 years, average usage of CSII - 3 
years). The test stripes costs 533 Euro/ year and their average cost according to the 
duration of the disease is 3779.45 Euro since diagnosis. The blood glucose monitor-
ing system costs 20 Euro and for the duration of the disease - 4.96 Euro per patient 
per year. The CSII price is 3896 Euro and it costs 1292 euro per patient per year. The 
average improvement of HbA (1c) after the CSII introduction is 1.85. In the group 
treated while human insulin the average cost per children is 925 Euro and improve-
ment of HbA (1c) human insulin is 0.28 for the same period. cOnclusiOns: The 
treatment with CSII leads to significant improvement in glycemic control compared 
to the treatment with human insulin at the comparable costs.
PDB34
A COST ANALySIS OF MEDICATION FOR PATIENTS wITH TyPE 2 DIABETES 
MELLITUS (T2DM) – HOw THIS vARIES ACCORDING TO BODy MASS INDEx (BMI) 
STATUS, AGE, GENDER AND CO-MORBIDITy
Queally M.B.
National University of Ireland Galway, Galway, Ireland
Objectives: The rising prevalence of overweight and obesity has led to an increase 
in related metabolic disorders; most notably t2dm. We sought to determine how 
the cost of medication for this condition varies within a cohort of patients attend-
ing Galway University Hospital, according to age, gender, BMI and co-morbidity 
status. MethOds: We identified a subgroup of 185 adult type 2 diabetes patients 
attending our university hospital-based diabetes clinic, for whom detailed informa-
tion about drug therapy and comorbidities (obesity, hypertension, dyslipidaemia) 
was available. We modelled the lifetime costs of medications for each patient, taking 
account of age, gender and comorbidity. The analysis compares the lifetime cost of 
medication of those patients who are obese relative to those who are overweight 
and of those with fewer to those with more co-morbidities; specifically obesity, 
hypertension and dyslipidaemia. Results: We found that obesity is associated with 
a higher cost of medication relative to being overweight. Those with a BMI range of 
35-39.9 had the highest mean cost of medication, costing on average € 615 more than 
those who are overweight (p< .01). The highest cost of medication was associated 
with those aged 50-65- non-significant. Among those having all three co-morbidities 
compared to those having only t2dm there was a significant difference in the cost 
of medication costing on average an extra € 418 (p< .05). cOnclusiOns: These 
results suggest that the health economic costs associated with t2dm are differential 
with respect to the BMI status of affected individuals. These findings are of use in 
understanding the drug related burden of illness associated with obesity, t2dm and 
also the burden associated with being obese when one has t2dm compared to not 
being obese and having it. This study generated interesting data which will need to 
be replicated in larger prospective multicentre cohort studies.
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COST OF MICROvASCULAR AND MACROvASCULAR COMPLICATIONS IN 
PEOPLES wITH DIABETES TyPE 1 AND TyPE 2 IN BULGARIA
Dimitrova M.1, Doneva M.1, Vulov V.2, Manova M.1, Savova A.1, Petrova G.3, Czech M.4
1Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2NovoNordisk, Sofia, Bulgaria, 
3Medical University of Sofia, Sofia, Bulgaria, 4Novo Nordisk Pharma Sp z.o.o., Warsaw, Poland
Objectives: It has been shown that people with diabetes have a high prevalence of 
microvascular (neuropathy, nephropathy, retinopathy, diabetic angiopathy) and mac-
rovascular (hypertension, stroke, myocardial infarction, heart failure and coronary 
artery disease) complications leading to hospitalizations. The objective of the present 
study is to evaluate the cost of hospitalizations due to micro- and macrovascular 
complications in an observed cohort of 433 patients with type 1 and 2 diabetes treated 
with insulin. MethOds: The evaluation is based on data from a 6 months com-
bined retrospective and prospective observational study. People were separated in two 
groups depending on the type of diabetes and further into subgroups depending on 
the reason of hospitalization. The total costs for each subgroup of people were calcu-
lated and compared to the total costs of treatment for the observed period. Results: 
In the group of people with type 2 diabetes (n= 255) 128 people with complications 
were observed, whereas in people with type 1 diabetes it was only 70 people out of 
178. The cost of hospitalizations in the type 2 diabetes group was in total 35 367 EUR 
for the people enrolled in the 6 months study with the following division of reported 
reasons: (general) diabetes- 43%, microvascular complications- 16%, and macrovas-
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Asturias, Alcalá de Henares, Madrid, Spain, 4Oblikue Consulting, Barcelona, Spain, 5Merck, S.L, 
Madrid, Spain
Objectives: Hypothyroidism in pregnancy can lead to adverse obstetri-
cal outcomes. Universal screening in pregnant women for thyroid disease 
allows diagnose and treat cases of overt and subclinical hypothyroidism that 
are potentially missed when screening only women at high risk. The objec-
tive of the study was to assess the cost-effectiveness of universal screening 
as an alternative to high risk screening and no screening for thyroid disease 
in pregnant women in Spain. MethOds: The model compared the incre-
mental cost per quality adjusted life-year (QALY) of universal screening ver-
sus high risk screening and versus no screening. A decision analytic model 
was used for the pregnancy and post-partum period. Probabilities from ran-
domized controlled trials were considered for adverse obstetrical outcomes. 
A Markov model was used to assess the lifetime period after the first post-
partum year and accounted for the development of overt hypothyroidism. Main 
assumptions of the model and the use of resources were validated by local 
clinical experts. The analysis considered only direct health care costs (euros 
2013). A 3% discount was applied to costs and QALYs for the period beyond one 
year. Results: Universal screening gained 0.011 QALYs over high risk screening 
and 0.014 QALYS over no screening. Total direct costs per patient were € 5,791 
for universal screening, € 5,796 for high risk screening and € 5,786 for no screen-
ing. Universal screening was dominant compared to risk-based screening and 
highly cost-effective alternative compared to no screening with an ICER of € 374 
per QALY. cOnclusiOns: Universal screening of pregnant women in the first 
trimester for thyroid disease is dominant in Spain compared to the current 
type of screening which is risk-based, as well as cost-effective compared to 
no screening.
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COST-EFFECTIvENESS OF COMBINED TREATMENT OF METFORMIN AND 
FENOFIBRATE ON RETINOPATHy PROGRESSION
Hren R.1, Cerovic R.2
1University of Ljubljana, Ljubljana, Slovenia, 2Health Insurance Fund - Republic of Serbia, 
Belgrade, Serbia and Montenegro
Objectives: To evaluate the cost-effectiveness of intensive glycemic control 
(metformin) combined with fenofibrate in its impact on retinopathy progres-
sion compared to the treatment with metformin only in patients with type 2 
diabetes. MethOds: Design: Markov decision model of retinopathy progression. 
Population: 40-year old patient with type 2 diabetes followed for 29 years. Main 
outcome measures: Risk of visual impairment; incremental cost-effeciveness 
ratio (ICER) for the two treatment options: one combining metformin and fenofi-
brate, and one using solely metformin. Results: Combined tretament of met-
formin and fenofibrate resulted in ICER of -133.06 GBP per QALY which means 
that the intervention is not only effective but is also potentially saving money to 
the National Health Service; tretament solely with metformin is therefore domi-
nated. cOnclusiOns: Results of our study suggest that patients suffering from 
type 2 diabetes will receive from additional treatment with fenofibrate substantial 
benefits of protection against early microvascular complications related to retin-
opathy, including blindness. The favorable cost-effectiveness of intensive glycemic 
control combined with fenofibrate will likely be further increased if other major 
microvascular complications (e.g., non-traumatic amputations) and macrovascular 
complications (e.g., total cardiovascular events) of type 2 diabetes are taken into 
account. Our study is one of the first to compare cost-effectiveness of combined 
treatment of metformin and fenofibrate with current intensive glycemic control 
using solely metformin in its impact on retinopathy progression. Our study also 
provides evidence which may be useful in shaping the current clinical practice in 
the UK and European Union.
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REAL wORLD OUTCOMES IN TyPE 2 DIABETES: LOwER COST OF TREATING 
PATIENTS TO A1C< 7% wITH LIRAGLUTIDE vERSUS ExENATIDE
Dekoven M.1, Lee W.C.1, Bouchard J.R.2, Massoudi M.2, Langer J.2
1IMS Health, Alexandria, VA, USA, 2Novo Nordisk Inc., Plainsboro, NJ, USA
Objectives: Type 2 diabetes (T2D) is characterized by progressive β -cell failure 
in the presence of insulin resistance. The LEAD-6 (Liraglutide Effect and Action 
in Diabetes) clinical trial program compared the efficacy and safety of liraglutide 
once-daily (LIRA) to exenatide twice-daily (EXEN). Few studies have explored the 
real-world effectiveness, and associated costs, of these comparators. Glycemic goal 
attainment of A1C< 7% and total diabetes-related pharmacy costs in clinical practice 
were assessed over 6 months follow-up. MethOds: A retrospective cohort study 
using integrated medical and pharmacy claims and linked A1C results from the 
IMS Patient-Centric Integrated Data Warehouse was conducted. T2D patients ≥ 18 
years naïve to GLP-1, DPP-IV and insulin use during a 6 months pre-index period, 
with evidence of ≥ 1 prescription for LIRA (N= 234) or EXEN (N= 182) between January 
2010 and December 2010 were identified. Only patients who were persistent on 
their index treatment during a 6 months post-index period were included in the 
analysis. The percentage of patients achieving A1C< 7% and total diabetes-related 
pharmacy costs were estimated using multivariable modelling to control for con-
founding effects. The cost per successfully treated patient was calculated as total 
diabetes-related pharmacy costs divided by the percentage of patients achiev-
ing A1C< 7%. Results: The percentage of patients reaching A1C< 7% was 64.4% 
and 53.6% for LIRA and EXEN, respectively (p< 0.05) (baseline A1C mean: 7.8% for 
both LIRA and EXEN). Average total diabetes-related pharmacy costs per patient 
at 6 months were higher for LIRA than EXEN ($2,002 vs $1,799, p< 0.001) but when 
assessed as cost per patient successfully reaching A1C< 7%, LIRA was cost-effective 
compared to EXEN ($3,108 vs $3,354, p< 0.0001). cOnclusiOns: The average cost 
of treating a patient to A1C< 7% at 6 months follow-up was lower with LIRA than 
EXEN. This suggests LIRA to be a cost-effective treatment option compared to EXEN 
in the management of T2D.
the model as to its ability to modify input parameters. The model was externally 
validated against epidemiological data from Russia. Mortality and complications 
risk equations coefficients were modified in accordance with mortality rates due 
to complications in Russia. Cost-effectiveness analysis was performed. Results: 
The developed model allows assessing the risk of more than 15 type 2 DM compli-
cations in 5 years in patients with predefined risk factors. Among comparison of 5 
strategies of type 2 DM therapies (no therapy, vildagliptin, sitagliptin, liraglutide, 
and exenatide) liraglutide was considered the cost-effective strategy with ICER/
QALY - 470120.40 RUR, which is 51% of the willingness-to-pay threshold in Russia. 
With the lowest complication treatment costs inside the total direct costs, liraglu-
tide monotherapy demonstrated the most long-term sustainable blood glucose 
control and HbA1c goal parameters. cOnclusiOns: The developed model allows 
increase in compliance of therapy. Possibility of individual choice of the most 
cost-effective treatment regimen for each patient leads to so-called “personal-
ized” therapies.
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HEALTH CARE RESOURCE UTILIzATION AND COSTS ASSOCIATED wITH 
TREATMENT OF POLISH ACROMEGALIC PATIENTS wITH LANREOTIDE AUTOGEL 
120 MG – A RETROSPECTIvE OBSERvATIONAL COHORT ANALySIS
Orlewska E.1, Kos-Kudla B.2, Sowinski J.3, Sworczak K.4, Zgliczynski W.5
1Centre for Pharmacoeconomics, Warsaw, Poland, 2Silesian Medical University, Katowice, Poland, 
3Poznan Medical University, Poznan, Poland, 4Medical University Gdansk, Gdansk, Poland, 
5Medical Center of Postgraduate Education, Warsaw, Poland
Objectives: To estimate the resource utilization and related costs for Polish acro-
megalic patients treated with lanreotide AUTOGEL 120 mg (ATG120) in routine 
clinical practice MethOds: Medical care resource (dosage regimens, diagnostic 
procedures, hospitalizations, out-patient visits, any treatment changes) were col-
lected during 1-year retrospective phase of non-intreventional, observational study 
(Lanro-Study). The study population consisted of acromegalic patients treated for 
at least three injections with ATG120. The endpoints were: proportion of patients 
treated for acromegaly with a given pharmaceutical in a given dosing interval, 
resource utilization, costs per patient/month or year. Costs were calculated in 
PLN from the public health-care payer perspective for the year 2013 (1 EURO = 4.2 
PLN). Results: A otal of 143 patients were included in the analysis (72% women, 
80% macroadenoma, 72% previous pituitary surgery). Changes in the treatment 
scheme were reported in 54 patients. The mean cost of treatment in patients who 
switched from octreotide LAR (LAR) to ATG120 (n= 26) was 6060.01 PLN/patient/
month with LAR and 4047.96/patient/month PLN when switched to ATG120. At the 
time all patients entered the prospective phase, and were receiving ATG120, the 
mean cost of treatment with ATG120 was estimated at 3941.84 PLN/patient/month. 
Most patients (n= 100; 70%) received ATG120 at dosing intervals less frequent than 
every 4 weeks. Patients were predominantly treated in out-patient setting with 4.77 
physician visits/patient/year, most common control examinations were magnetic 
resonance imaging of brain and brain stem (0.57/patient/year), ultrasound of neck 
(0.55/patient/year), and IGF-1 (1.96/patient/year), GH (1.49/patient/year), glycemia 
(0.91/patient/year), pituitary-thyroid axis hormones (TSH- 0.45/patient/year, T4-0.49/
patient/year). Only 7.7% patients were hospitalized. The mean medical cost, exclud-
ing pharmacotherapy, was 1002 PLN/patient/year. cOnclusiOns: These results 
represent the current use of ATG120 in the population of Polish acromegalic patients 
in a realistic clinical settings and indicate that this therapy may provide cost saving 
in comparison to octreotide LAR.
PDB40
ASSESSMENT OF REAL-wORLD USAGE OF LANREOTIDE (SOMATULINE 
AUTOGEL) 120 MG IN POLISH ACROMEGALIC PATIENTS – RESULTS FROM 1 yEAR 
PROSPECTIvE PHASE OF LANRO-STUDy
Orlewska E.1, Kos-Kudla B.2, Sowinski J.3, Sworczak K.4, Zgliczynski W.5
1Centre for Pharmacoeconomics, Warsaw, Poland, 2Silesian Medical University, Katowice, Poland, 
3Poznan Medical University, Poznan, Poland, 4Medical University Gdansk, Gdansk, Poland, 
5Medical Center of Postgraduate Education, Warsaw, Poland
Objectives: To assess the treatment pattern, dosage and costs of lanreotide 
AUTOGEL 120 (L-ATG120) administered as part of routine acromegaly care in 
Poland. MethOds: Lanro-Study is a multicenter, non-interventional, observa-
tional study on resource utilization in the population of Polish acromegalic patients 
treated with L-ATG120 at 4 weeks or extended (> 4 weeks) dosing interval. The study 
recruited adult acromegalic patients treated medically for ≥ 1 year, including at least 
3 injections of L-ATG120. Data on dosing interval and aspects of administration were 
collected prospectively during 12-months (interim analysis). Costs were calculated 
in PLN from the public health care payer perspective for the year 2013 (1 EURO = 
4.2 PLN). Results: A total of 139 patients were included in the analysis. Changes 
in dosing regimen were reported in 14 (9.4% ) patients, polytherapy was used in 11 
(8%) patients. 70 patients (50%) received L-ATG120 at an extended dosing interval (> 
4 weeks), the mean number of days between injections was 35.56 (SD 8.4). L-ATG120 
was predominantly administered in out-patient setting (77%), by health care profes-
sionalists (94%). Mean time needed for preparation and administration was 4.33 and 
1.58 min., respectively, mean product wastage – 0.13 mg. The cost of L-ATG120 was 
estimated at 4103.87 PLN/patient/month cOnclusiOns: These results represent 
the current use of L-ATG120 in the population of Polish acromegalic patients in a 
realistic clinical settings. Findings that 50% of patients could be treated with dose 
intervals of longer than 28 days support the potential for L-ATG120 of reducing 
treatment burden.
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COST-EFFECTIvENESS OF UNIvERSAL SCREENING FOR THyROID DISEASE IN 
PREGNANT wOMEN IN SPAIN
Donnay S.1, Balsa J.A.2, Alvarez J.3, Crespo C.4, Pérez-Alcántara F.4, Villacampa A.4, Polanco C.5
1Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain, 2Hospital Universitario 
Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain, 3Hospital Universitario Príncipe de 
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were updated to € 2013. Results: The primary analysis compared dapagliflozin 
with sulfonylureas resulting in 0.525 additional QALYs and € 1,835 additional cost 
(cost-effectiveness ratio of € 3,496/QALY). The higher drug cost of dapagliflozin was 
partially offset by lower costs of complications, hypoglycemia and the cost associ-
ated with weight gain. In the secondary analyses, dapagliflozin was a cost-effective 
option compared with thiazolidinediones and DPP4, resulting in a cost per QALY 
gained of € 20,183 and € 487, respectively. The univariate and probabilistic sensitivity 
analyses confirmed the robustness of the results. cOnclusiOns: Dapagliflozin in 
combination with metformin proved to be a cost-effective alternative compared to 
sulfonylureas, thiazolidinediones and DPP4 inhibitors in the treatment of T2DM.
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A BUDGET IMPACT AND COST-EFFECTIvENESS ANALySIS OF BLOOD GLUCOSE 
MONITORING SySTEM IN ONE ITALIAN REGION
Colombo G.L.1, Cremascoli C.2, Perrone F.3, Garcia - Valero J.4, Schauf M.5
1University of Pavia, Pavia, Italy, 2Johnson & Johnson, LifeScan, Milano, Italy, 3Johnson & Johnson 
Medical, Pomezia (Roma), Italy, 4Johnson & Johnson, LifeScan, Madrid, Spain, 5Johnson & Johnson, 
LifeScan EMEA, Zug, Switzerland
Objectives: Diabetes is a chronic disease and associated with significant health 
care expenditures. Increasing costs are mainly related to long-term complications. 
Identifying patterns of hypoglycemia by means of a blood glucose monitoring sys-
tem (BGMS) can be used to support diabetes management efficiently. MethOds: 
An economic analysis was carried out to estimate the life-time cost-effectiveness 
(CEA) of blood glucose monitoring system (BGMS) with pattern alert technology vs. 
standard BGMS for the prevention of Severe Hypoglycaemia (SH) in insulin-treated 
type 1 (DM1) and type 2 patients (DM2). The cost-effectiveness analysis was based 
on a literature review and cost data (direct and indirect) from the Emilia Romagna 
region; a decision tree was developed to calculate the incremental cost per addi-
tional quality of life. The BIA (Budget Impact Analysis) estimated the cost of using 
the new pattern alert technology in the Italian Healthcare System. Results: For 
the base-case scenario, the utilization of BGMS with pattern alert technology was 
less costly and more effective compared to standard BGMS. Life time cost savings 
for the prevention of SH were 300 euro for DM1 and DM2 patients using pattern 
alert technology. The difference in life time QALYs was 0,17. cOnclusiOns: BGMS 
with pattern alert technology, monitoring individual blood glucose levels are cost 
effective in preventing SH for DM1 and insulin-treated DM2 patients, as well as in 
detecting blood glucose trends and patterns. Nevertheless, empirical data on the 
probability of reducing Severe Hypoglycemia is necessary in order to reach any 
firm conclusions.
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INCRETIN THERAPy FOR PATIENTS wITH TyPE 2 DIABETES IN SPAIN: A COST-
EFFECTIvENESS ANALySIS OF LIRAGLUTIDE vERSUS SITAGLIPTIN
Ramirez de Arellano A.1, Hunt B.2, Mezquita Raya P.3, Briones T.1, Pérez A.4, Valentine W.J.2
1Novo Nordisk, Madrid, Spain, 2Ossian Health Economics and Communications, Basel, 
Switzerland, 3Hospital Torrecardenas, Clinica San Pedro, Almería, Spain, 4Hospital de la Santa 
Creu I Sant Pau, Barcelona, Spain
Objectives: Diabetes mellitus represents a significant challenge to health care 
providers in Spain, with a national prevalence of over 8% and approximately 20,000 
diabetes-related deaths annually. Treatment with GLP-1 receptor agonists and DPP-4 
inhibitors, which target the incretin axis, has the potential to improve glycemic 
control without the weight gain associated with traditional therapies. To evaluate 
the relative cost-effectiveness of incretin therapies, the present study compared the 
long-term clinical and cost implications associated with liraglutide and sitagliptin in 
type 2 diabetes patients in Spain. MethOds: Data were taken from a randomized, 
controlled trial (NCT00700817) in which adults with type 2 diabetes (mean age 55 
years, HbA1c 8.4%, BMI 33kg/m2) failing metformin monotherapy were randomly 
allocated to receive either 1.2mg liraglutide or 100mg sitagliptin daily in addition 
to metformin. Liraglutide was associated with greater improvements from baseline 
HbA1c (–1.24% vs. –0.9%) and BMI (–0.99kg/m2 vs. –0.33kg/m2). Long-term projec-
tions of clinical outcomes and direct costs (2012 EUR) were made using a published 
and validated model of type 2 diabetes and assumed patients switched to insulin 
after five years. Results: Liraglutide was associated with improved life expec-
tancy (14.05 years vs. 13.91 years) and quality-adjusted life expectancy (9.04 quality-
adjusted life years [QALYs] vs. 8.87 QALYs) compared to sitagliptin. Improved clinical 
outcomes were driven by improved glycemic control, leading to a reduced incidence 
of diabetes-related complications, including renal disease, cardiovascular disease, 
ophthalmic and diabetic foot complications. Mean cost savings as a result of avoided 
complications were EUR 1,827 per patient. Overall, liraglutide was associated with 
increased direct costs of EUR 2,297, yielding an incremental cost-effectiveness ratio 
of EUR 13,266 per QALY gained versus sitagliptin. cOnclusiOns: Liraglutide was 
projected to improve life expectancy, quality-adjusted life expectancy and reduce 
incidence of diabetes-related complication. Liraglutide is likely to be cost-effective 
from a health care payer perspective in Spain.
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HEALTH-ECONOMIC COMPARISON OF CONTINUOUS SUBCUTANEOUS INSULIN 
INFUSION vERSUS MULTIPLE DAILy INjECTIONS FOR THE TREATMENT OF TyPE 
1 DIABETES IN KAzAKHSTAN CHILDREN
Roze S.1, Demessinov A.2, Zeityn M.2, Toktarova N.3, Abduakhassova G.4, Sissemaliev R.5, 
Karamalis M.6, Dunne N.6, Muratalina A.5, Klots M.6, Lynch P.6
1HEVA HEOR, Lyon, France, 2Republican Centre for Health Development, Astana, Kazakhstan, 
3National Scientific Medical Centre, Astana, Kazakhstan, 4National Scientific Centre of Maternity 
and Childhood, Astana, Kazakhstan, 5Medtronic, Almaty, Kazakhstan, 6Medtronic, Tolochenaz, 
Switzerland
Objectives: To project the long-term costs and outcomes of continuous subcu-
taneous insulin infusion (CSII) compared with multiple daily injections (MDI) in 
children with Type 1 diabetes in KAZAKHSTAN. MethOds: The CORE Diabetes 
Model is a peer-reviewed, validated model, which employs standard Markov/Monte 
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Objectives: To project the long-term costs and outcomes of continuous sub-
cutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) 
in adult patients with Type 1 diabetes in KAZAKHSTAN. MethOds: The CORE 
Diabetes Model is a peer-reviewed, validated model, which employs standard 
Markov techniques to describe the long-term incidence and progression of diabe-
tes-related complications. It was used to simulate disease progression in a cohort 
of adult patients with baseline characteristics and costs taken from primary data 
collection in KAZAKHSTAN (mean age 39.7 years, duration of diabetes 10.1 years 
and mean HbA1c 8.5%). Clinical outcomes (HbA1c and hypoglycemic events) were 
taken from a published meta-analysis of CSII studies. Direct costs for 2013 were 
calculated from a third-party payer perspective. Discount rates of 5% per annum 
were applied to costs and 3% to clinical outcomes. Results: Treatment with CSII 
was associated with an improvement in mean quality adjusted life expectancy 
(QALE) of 0.745 years compared with MDI and incidence of any diabetes related 
complication was delayed on average by 1 year with CSII. This produced an incre-
mental cost-effectiveness ratio (ICER) of KZT 4’784’971 per quality-adjusted life 
year (QALY) gained with CSII vs. MDI. CSII related therapy costs were partially 
offset by the savings due to the reduction in long-term complications. CSII treat-
ment also delayed the average onset of complications such as ESRD (1.9 years) and 
blindness (2.1 years). Extensive sensitivity analyses showed the robustness of the 
results. cOnclusiOns: Improvements in glycemic control associated with CSII 
over MDI led to improved QALE owing to reduced incidence of diabetes-related 
complications. CSII was associated with ICERs representing good value for money 
by current standards in KAZAKHSTAN (using a WTP threshold of 6,330,000 KZT 
[3x GDP]) from a payer’s perspective. CSII would be even more attractive from a 
societal perspective when including indirect costs.
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COST OF ACHIEvING RELEvANT COMPOSITE ENDPOINT OF HBA1C< 7%, 
NO HyPOGLyCAEMIA AND wEIGHT LOSS OF ≥ 3% IN A 52 wEEK POST-HOC 
ANALySIS OF DAPAGLIFLOzIN vERSUS GLIPIzIDE
Bergenheim K.1, Grandy S.2, Wygant G.D.3
1AstraZeneca, Mölndal, Sweden, 2AstraZeneca, Wilmington, DE, USA, 3Bristol-Myers Squibb, 
Princeton, NJ, USA
Objectives: Dapagliflozin (DAPA), a selective SGLT2 inhibitor, reduces hypergly-
caemia in an insulin-independent manner by increasing urinary glucose excretion. 
Glipizide (sulphonylurea) reduces hyperglycemia by increasing beta cell insulin 
secretion. We conducted an analysis of the cost of treating patients to a clinically 
relevant composite endpoint of HbA1c < 7%, no major or minor hypoglycaemic 
events and weight loss ≥ 3%. MethOds: The Cardiff Diabetes model was used to 
estimate the cost of treating patients to the composite endpoint of HbA1c < 7%, 
no major or minor hypoglycaemic events and weight loss ≥ 3% in the UK using 
52 week data from a previously published double-blind randomised clinical trial 
of DAPA vs glipizide (GLIP) in combination with metformin (NCT 00660907). The 
cost of treating one patient to the composite endpoint using DAPA or GLIP over 
52 weeks was calculated as total cost per treatment arm divided by number of 
patients that reached the composite endpoint in that treatment arm. Calculation 
of costs included drug acquisition costs, cost for adverse events, and costs related 
to the patient’s BMI level. Results: The number needed to treat was 5 on DAPA 
and 54 on GLIP for one patient to achieve the composite endpoint. The overall cost 
of treating one patient over 52 weeks to the composite endpoint of HbA1c < 7%, no 
major or minor hypoglycaemic events and ≥ 3% weight loss was £3296 on DAPA 
and £13620 on GLIP. cOnclusiOns: The cost of treating one patient to composite 
endpoint of HbA1c < 7%, no major/minor hypoglycaemic events and ≥ 3% weight 
loss was approximately 4 times higher with GLIP compared to DAPA. These results 
demonstrate that when multiple treatment goals, including weight loss and reduc-
tion of hypoglycaemic events are targeted, the cost of treating patients with DAPA 
is lower compared to GLIP.
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Objectives: To analyse the cost-effectiveness of dapagliflozin in combination with 
metformin in the treatment of type 2 diabetes (T2DM) in comparison with sulfo-
nylureas, thiazolidinediones and DPP4 inhibitors also combined with metformin 
in Spain. MethOds: The analysis was based on the results of the available clinical 
trials in order to estimate the quality-adjusted life years (QALY) and economic con-
sequences of managing the disease and its complications. An economic model was 
used to simulate the natural history of 10,000 T2DM patients with each treatment 
option. The analysis was performed from the National Health System perspective 
considering direct costs (pharmacological costs, adverse events, T2DM complica-
tions, hypoglycaemias and costs related to weight gain) and patient’s entire life 
as time horizon. A discount rate of 3% was applied to costs and benefits. All costs 
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Objectives: With new classes of T2DM medications offering weight reduction in 
addition to better glycaemic control, HTA agencies expect fuller accounting of the 
impact of post-trial weight trajectory assumptions on cost-effectiveness. Four alter-
native scenarios were examined using the example of the novel SGLT-2 inhibitor 
canagliflozin (CANA) in the UK treatment setting. MethOds: The importance of 
alternative assumptions was illustrated using CANA 300mg versus glimepiride (GLIM; 
1mg titrated to 6mg or 8mg) in dual therapy with metformin simulated over 40 years 
using the ECHO-T2DM model loaded with patient characteristics, treatment effects, 
and adverse event rates from the DIA3009 trial, in which CANA 300mg reduced body 
weight by –5.7% versus GLIM over 52 weeks. HbA1c was assumed to drift annually by 
0.14% for CANA (similar to metformin in ADOPT), 0.24% for GLIM (as sulphonylurea 
in ADOPT), and 0.15% for rescue therapy with insulin (initiated when HbA1c > 7.5%). 
Upon treatment discontinuation, four alternative weight-trajectory assumptions were 
applied: (A) weight change maintained permanently; (B) CANA weight reduction dis-
appears fully at treatment discontinuation, GLIM weight-gain permanent; (C) GLIM 
weight-gain permanent, forced convergence of weight upon CANA discontinuation; 
(D) weight changes disappear fully at discontinuation for both treatments. A weight 
increase was applied when insulin was initiated and proportional weight changes 
were applied when insulin dose was titrated upwards. Results: CANA 300mg gener-
ated more QALYs at modest incremental cost, resulting in ICERs of £2,766 to £4,317 in 
the scenarios. Maintaining the benefits permanently (A) generated the largest QALY 
gain (0.243); complete elimination of benefits at discontinuation (D) offered the small-
est (0.198). The proportions of incremental QALYs attributable to weight differences 
were 34.4%, 19.5%, 18.9% and 17.4% for Scenarios A to D, respectively. cOnclusiOns: 
CANA 300mg was cost-effective in each of four weight scenarios following discon-
tinuation. Further work is required to define the most clinically plausible scenarios.
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Objectives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
inhibitor (SGLT-2) approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 
2 diabetes mellitus (T2DM). This study evaluates the cost-effectiveness of dapagli-
flozin compared with a dipeptidyl-peptidase-IV (DPP-4) inhibitor when added to 
metformin in patients inadequately controlled on metformin alone. MethOds: 
The published and validated CARDIFF diabetes model was used to conduct the 
analysis. Clinical inputs were derived from a systematic review and network meta-
analysis. Based on clinical inputs and the United Kingdom Prospective Diabetes 
Study (UKPDS) equations, the model predicts disease progression and the number 
of micro- and macro-vascular complications, along with diabetes-specific and all-
cause mortality. The perspective of the National Health Service in England and Wales 
was adopted over a lifetime horizon. Local unit costs and utility data were assigned 
to the appropriate model parameters to calculate total Quality-Adjusted-Life-Years 
(QALYs) and costs. Univariate and probabilistic sensitivity analyses (PSA) were con-
ducted. Results: Compared to a DPP-4 inhibitor, dapagliflozin was associated with 
0.076 incremental QALYs (95%CI: –0.028; 0.146) at an additional cost of £412 (95%CI: 
-£212; £853); resulting in an incremental cost-effectiveness ratio (ICER) of £5,455 
per QALY gained. The univariate analyses showed that no input parameter change 
inflated the ICER above £15,000 per QALY. The PSA estimated that dapagliflozin 
has a 81% chance to increase QALYs and costs, a 9% chance to increase QALYs 
and save costs, a 4% chance to reduce QALYs and costs and a 6% chance to reduce 
QALYs and increase costs. At a willingness-to-pay threshold of £20,000 per QALY 
gained, dapagliflozin strategy had an 86% probability to be cost-effective in this 
setting. cOnclusiOns: Dapagliflozin in combination with metformin was shown 
to be a cost-effective treatment option for T2DM patients who are inadequately 
controlled with metformin mono-therapy.
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Objectives: The NICE reference case for T2DM requires cost-utility analysis with a 
lifetime horizon. The denominator in cost-utility outcomes is the incremental QALY, 
which is driven in most T2DM economic models by several key features, includ-
ing: life extension, micro- and macrovascular events, treatment and treatment-
related adverse events (AEs), and excess bodyweight. The aim of this analysis is to 
determine which factors most impact QALY gains in an analysis of CANA 300mg 
versus SITA 100mg when combined with metformin and sulphonylurea in the UK 
treatment setting. MethOds: The ECHO-T2DM model was used to simulate CANA 
versus SITA over 40 years. ECHO-T2DM was loaded with patient characteristics, 
treatment effects, and AE rates from the DIA3015 trial. HbA1c was assumed to drift 
upwards at an annual rate of 0.14% for CANA and SITA (similar to metformin in 
the ADOPT trial). CANA and SITA were discontinued and insulin initiated (annual 
drift 0.15% as in UKPDS) when patients failed to maintain HbA1c under 58 mmol/
mol (7.5%). Results: Hypothetical patients experienced 0.039 more QALYs when 
treated with CANA 300mg versus SITA 100mg. Because SITA had lower initial HbA1c 
lowering, it was associated with greater use of rescue medication. Patients treated 
initially with SITA, thus, had greater insulin-mediated HbA1c lowering over time so 
HbA1c values converged asymptotically (limiting differences in rates of microvas-
cular complications). There were relatively modest QALY benefits related to macro-
Carlo simulation techniques to describe the long-term incidence and progression 
of diabetes-related complications. It was used to simulate disease progression in 
a cohort of pediatric patients with baseline characteristics taken from published 
KAZAKHSTAN studies (mean age 10.4 years, duration of diabetes 4.1 years, mean 
HbA1c > 7.5%). Direct costs for 2013 were calculated from a third-party payer per-
spective. Discount rates of 5% per annum were applied to costs and 3% to clinical 
outcomes. Results: Mean undiscounted life expectancy of patients using CSII vs. 
MDI was increased by 3.58 years. The Incremental-Cost-Effectiveness-Ratio (ICER) 
for CSII was 3,935,375KZT per Quality-Adjusted-Life-Year gained based on direct 
costs only. CSII related therapy costs were partially offset by the savings due to the 
reduction in long-term complications, i.e.638,744KZT, mainly due to cardiovascu-
lar and renal diseases. Cumulative incidences of proliferative diabetic retinopathy, 
blindness, ESRD, and GRP were decreased by 25.3%, 5.6%, 28.3%, and 17.7%, respec-
tively. CSII treatment also delayed the average onset of ESRD (3.9 years), blindness 
(3.7 years), PVD (3.5 years), CHF (3.6 years), Neuropathy (3.4 years), first ulcer (4.0 
years), amputation (3.7 years), MI (3.5 years), and stroke (3.5 years). Extensive sensi-
tivity analyses showed the robustness of the results. cOnclusiOns: Using a payer’s 
perspective, our analysis showed that CSII is cost-effective over a lifetime horizon 
in children with Type 1 Diabetes in Kazakhstan (using a WTP threshold of 6,330,000 
KZT [3x GDP]) and can lead to an increase in life expectancy as well as delay and 
reduce long-term complications. When including indirect costs, CSII would be even 
more attractive from a societal perspective.
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Objectives: To assess the cost-effectiveness of using intralesional injection of 
recombinant human epidermal growth factor (rhEGF) for the treatment of severe 
non-healing diabetic foot ulcers (DFU) in highly-specialized inpatient department 
in Russian setting. MethOds: We developed a cost-effectiveness model based on 
hypothesis that use of intralesional injection of rhEGF in addition to standard treat-
ment of severe DFU (Wagner grade 3-4) would reduce the rate of amputations and 
related increased mortality in population of amputated DFU patients. For model 
inputs we used published data on the rates of amputation from retrospective study 
of intralesional injection of rhEGF and survival rates for patients with DFU with and 
without major amputations. Cost data was derived from the Russian retrospective 
study of real practice of inpatient treatment of severe DFU and reimbursement rates 
in Russian compulsory medical insurance system, cost of rhEGF treatment was pro-
vided by the manufacturer. Based on the model outputs we calculated incremental 
cost-effectiveness ratio (ICER) as the difference in costs to the difference in years 
lived during the 5-year period of observation by two cohorts of patients treated with 
only standard methods and with addition of rhEGF. Results: The use of rhEGF 
intralesional injection treatment may prevent 52 amputations and save 29.54 years 
of life in a cohort of 100 patients with severe DFU during subsequent 5-year period of 
observation. The ICER for rhEGF is estimated at EURO 27,200 per life year saved and 
does not exceed the acceptable threshold of three GDP per capita as recommended 
by WHO. The sensitivity analysis demonstrated that the results are most sensitive 
to the cost of rhEGF. cOnclusiOns: The model has demonstrated the acceptability 
of adoption of intralesional injection of rhEGF in addition to standard treatment for 
DFU in highly specialized inpatient departments.
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Objectives: To assess the cost-effectiveness of oral hypoglycaemic agents (micro-
nized glibenclamide, gliclazide, glimepiride and repaglinide) in the treatment of 
Russian patients with type 2 diabetes mellitus. MethOds: Based on the data from 
comparative studies (B. Wolffenbuttel et al., 1999; A. Holstein et al., 2001; O. Reshetko 
et al., 2007) the pharmacoeconomic profiles of glibenclamide and repaglinide, gliben-
clamide and glimepiride, glibenclamide and gliclazide were compared. It was revealed 
that glibenclamide and repaglinide, glibenclamide and gliclazide have equal efficacy 
and safety, so the cost-minimization analysis was performed. The cost-effective-
ness of glibenclamide and glimepiride was measured as total costs of medicines 
and expenses for ambulance calls for severe hypoglycemia per one patient without 
hypoglycaemic events. A one-year time horizon was adopted in the models. One-
way sensitivity analysis (SA) was carried out to assess the robustness of the results 
. Results: Compared to repaglinide and gliclazide, treatment with glibenclamide 
was associated with substantial budget savings (22,699.35 RUB and 3,566.05 RUB per 
one patient, respectively). Costs per one patient without hypoglycaemic events were 
1,137.17 RUB and 5,549.85 RUB in glibenclamide and glimepiride groups, respectively. 
Sensitivity analysis demonstrated that results are robust. cOnclusiOns: The pre-
sent study has demonstrated that administration of micronized glibenclamide is 
the most economically effective strategy in the treatment of Russian patients with 
type 2 diabetes mellitus. Treatment with micronized glibenclamide is associated 
with considerably lower costs as compared to repaglinide, glimepiride and gliclazide.
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combination with insulin versus insulin alone for patients who are inadequately 
controlled despite high doses of insulin. MethOds: The published and vali-
dated CARDIFF diabetes model was used to conduct the analysis. Clinical inputs 
were derived from a randomized clinical trial comparing dapagliflozin add-on to 
insulin with insulin regimens. Based on clinical inputs and the United Kingdom 
Prospective Diabetes Study (UKPDS) equations, the model predicts disease pro-
gression and the number of micro- and macro-vascular complications, along with 
diabetes-specific and all-cause mortality. The perspective of the National Health 
Service in England and Wales was adopted over a lifetime horizon. Local unit 
costs and utility data were assigned to the appropriate model parameters to cal-
culate total Quality-Adjusted-Life-Years (QALYs) and total costs. Univariate and 
probabilistic sensitivity analyses (PSA) were conducted. Results: Compared to 
insulin, dapagliflozin added to insulin was associated with 0.342 incremental 
QALYs (95%CI: 0.288; 0.480) at an additional cost of £1,813 (95%CI: £1,165; £2,381), 
resulting in an incremental cost-effectiveness ratio (ICER) point estimate of 
£5,295 per QALY gained. The univariate analyses showed that no input 
parameter change inflated the ICER above £15,000 per QALY. At a willingness-to-
pay threshold of £20,000 per QALY gained, the dapagliflozin treatment strategy 
was estimated to have a 100% probability of being cost-effective when compared 
to the insulin treatment strategy. These findings were shown to be robust with all 
sensitivity analyses. cOnclusiOns: Dapagliflozin was shown to be a cost-effec-
tive treatment option in combination with insulin for patients who are inad-
equately controlled with insulin alone within established UK cost-effectiveness 
thresholds.
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Objectives: To evaluate uncertainty, the NICE reference case requires estimation 
of cost-effectiveness using alternative parameter values. Because models of T2DM 
necessarily include many parameters, NICE requirements dictate a large number 
of simulations. This study assesses the relative importance of common sensitivity 
analyses by identifying key drivers of the incremental cost-effectiveness ratio (ICER) 
using the example of CANA 300mg versus GLIM (titrated from 1mg to 6mg or 8mg), 
in combination with metformin in dual therapy. MethOds: The ECHO-T2DM model 
was used to simulate CANA versus GLIM over 40 years. ECHO-T2DM was loaded 
with patient characteristics, treatment effects, and adverse event rates from the 
DIA3009 trial. HbA1c was assumed to drift annually by 0.14% for CANA (similar to 
metformin in ADOPT), 0.24% for GLIM (as sulphonylurea in ADOPT), and 0.15% for 
rescue therapy with insulin (initiated when HbA1c > 7.5%). Twenty-four one-way 
sensitivity analyses assessed the impact of drug durability, macrovascular risk equa-
tions, utility weights, and HbA1c goals. Results: In the base case, CANA 300mg 
was associated with 0.21 greater QALYs at an incremental cost of £828, generating 
an ICER of £4,050/QALY. QALY gains were driven by fewer hypoglycaemic events 
and a better weight profile. The low acquisition cost of GLIM was partially offset by 
a greater need for insulin rescue therapy earlier in treatment, more hypoglycaemic 
events, and more macrovascular complications. Assuming no difference in durabil-
ity for CANA and GLIM had the greatest impact on the ICER (£49,717), followed by 
no disutility for hypoglycaemic events (£15,733). The only other scenario having a 
noticeable impact was an HbA1c goal of 9.0% (£9,718). Alternative macrovascular 
risk engines had little impact on the ICER. cOnclusiOns: The ICER was robust 
under a large number of scenarios. Only the difference in assumed long-term GLIM 
durability reversed the interpretation of CANA as cost-effective versus GLIM using 
NICE criteria.
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Objectives: The NICE reference case for T2DM requires cost-utility analysis with a 
lifetime horizon. The denominator in cost-utility outcomes is the incremental QALY, 
which is driven in most T2DM economic models by several key features, including: 
life extension, micro- and macrovascular events, treatment and treatment-related 
adverse events (AEs), and excess bodyweight. This analysis aims to determine which 
factors most impact QALY gains using the example of CANA 300mg versus GLIM 
(titrated from 1mg to 6mg or 8mg) when combined with metformin. MethOds: The 
ECHO-T2DM model was used to simulate CANA versus GLIM over 40 years. ECHO-
T2DM was loaded with patient characteristics, treatment effects, and AE rates from 
the DIA3009 trial. HbA1c was assumed to drift upwards at an annual rate of 0.14% 
for CANA (similar to metformin in the ADOPT trial) and 0.24% for GLIM (as sulpho-
nylurea in ADOPT). CANA and GLIM were discontinued and insulin initiated (annual 
drift 0.15% as in UKPDS) when patients failed to maintain HbA1c under 58 mmol/mol 
(7.5%). Results: Hypothetical patients experienced 0.21 more QALYs when treated 
with CANA 300mg versus GLIM. Because GLIM was associated with greater use of 
rescue medication (and extra insulin-mediated HbA1c lowering) in the simulation, 
HbA1c values converged asymptotically limiting the differences in microvascular 
complications. However, lower blood pressure for patients on CANA versus GLIM was 
associated with reductions of 2.2% to 4.1% for the rates of macrovascular outcomes 
(although associated QALY gains were small due to discounting). Differences in weight 
and especially hypoglycaemic events, related both to GLIM and to earlier initiation of 
insulin, were associated with improvements in utility (0.04 and 0.16 QALYs, respec-
vascular events, but substantial benefits attributable to weight (0.020) and especially 
hypoglycaemic events (0.024), related to CANA’s better weight-lowering and longer 
time to initiation of insulin. cOnclusiOns: Patients treated with CANA in triple 
therapy experienced an additional 0.039 QALY’s over 40 years versus patients treated 
with SITA. The primary drivers were improved weight while on agent and fewer 
hypoglycaemic events.
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Objectives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
(SGLT-2) inhibitor approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 
2 diabetes mellitus. This study investigates the cost-effectiveness of dapagliflo-
zin compared with a sulphonylurea (SU) when added to metformin in patients 
inadequately controlled with metformin mono-therapy. MethOds: The published 
and validated CARDIFF diabetes model was used to conduct the analysis. Clinical 
inputs were derived from a randomized clinical trial comparing dapagliflozin and 
glipizide in combination with metformin. Based on these clinical inputs and the 
United Kingdom Prospective Diabetes Study (UKPDS) equations, the model predicts 
disease progression and the number of micro- and macro-vascular complications, 
along with diabetes-specific and all-cause mortality. The perspective of the National 
Health Service in England and Wales was adopted over a lifetime horizon. Local 
unit costs and utility data were assigned to the appropriate model parameters to 
calculate total Quality-Adjusted-Life-Years (QALYs) and total costs. Univariate and 
probabilistic sensitivity analyses (PSA) were conducted. Results: Compared to 
SU added to metformin, dapagliflozin add-on to metformin was associated with 
an incremental benefit of 0.467 QALYs (95%CI: 0.420; 0.665) at an additional cost of 
£1,246 (95%CI: £613; £1,637), resulting in an ICER point estimate of £2,671 per QALY 
gained. The univariate analyses showed that no input parameter change inflated the 
ICER above £15,000 per QALY. The PSA showed that at a willingness-to-pay threshold 
of £20,000 per QALY gained, dapagliflozin treatment had an estimated 100% prob-
ability to be cost-effective compared to an SU treatment strategy. These findings 
were shown to be robust with all sensitivity analyses. cOnclusiOns: Dapagliflozin 
in combination with metformin was shown to be a cost-effective treatment option 
for patients who are inadequately controlled with metformin mono-therapy within 
established UK cost-effectiveness thresholds.
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Objectives: Insulin, often combined with metformin, is usually the last therapy 
option for patients with type 2 diabetes Mellitus (T2DM) who are uncontrolled on 
oral anti-diabetic drugs. Dutch guidelines recommend up-titration of insulin until 
patients maintain an HbA1c < 7%, yet in practice many patients never reach this tar-
get. Clinical evidence shows that dapagliflozin – a highly selective sodium-glucose 
cotransporter 2 (SGLT2) inhibitor – meets a need for these patients, i.e. by reduc-
ing HbA1c and weight. We studied the cost-effectiveness of dapagliflozin added to 
insulin (vs. not adding dapagliflozin) for patients with T2DM who have inadequate 
glycaemic control while on insulin. MethOds: We used the Cardiff Diabetes model 
to evaluate cost and effects of dapagliflozin added to insulin using direct compara-
tive efficacy data from a randomized placebo-controlled trial (NCT00673231). In this 
trial up-titration of insulin was allowed in case of severe glycaemic imbalance. Risk 
factor progression and occurrence of future vascular events were estimated using 
the UKPDS 68 risk equations. Costs and utilities were derived from the literature. 
The analysis was conducted from a Dutch societal perspective using a lifetime hori-
zon. Results: The overall incidence of vascular complications was lower, and life 
expectancy was higher (19.43 LYs vs. 19.35 LYs) in those patients receiving dapagli-
flozin compared to patients not receiving dapagliflozin. Patients in the dapagliflozin 
arm obtained an incremental benefit of 0.42 QALYs. The lifetime incremental cost 
per patient in the dapagliflozin arm was € 2,293, resulting in an incremental cost-
effectiveness ratio of € 27,779 per LYG and an incremental cost-utility ratio of € 5,502 
per QALY gained. Sensitivity and scenario analyses showed that the results were 
robust to variation in modelling assumptions and input variables. cOnclusiOns: 
This analysis shows that dapagliflozin increases the quality of life of T2DM patients 
compared to current practice (up-titration of insulin), and is cost-effective in a 
Dutch health care setting.
PDB58
THE COST-EFFECTIvENESS OF DAPAGLIFLOzIN (FORxIGA®) vERSUS INSULIN 
IN THE TREATMENT OF TyPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND 
wALES
Charokopou M.1, McEwan P.2, Lister S.3, Callan L.4, Bergenheim K.5, Tolley K.6, Roudaut M.7
1Pharmerit International, Rotterdam, The Netherlands, 2HEOR Consulting, Monmouth, UK, 
3Bristol-Myers Squibb, Uxbridge, UK, 4AstraZeneca UK Ltd., Luton, UK, 5AstraZeneca, Mölndal, 
Sweden, 6Tolley Health Economics, Buxton, UK, 7Bristol-Myers Squibb, Rueil-Malmaison, France
Objectives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
(SGLT-2) inhibitor approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 2 
diabetes mellitus. This study assesses the costs-effectiveness of dapagliflozin in 
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discounted at 5% annually. Sensitivity analyses were performed. Results: Fenofibrate 
monotherapy improved mean quality-adjusted life expectancy by 0.09 QALYs versus 
placebo due to fenofibrate patients spending more time in mild DR states. Direct medi-
cal costs were AUD 898 higher for fenofibrate monotherapy, with additional treatment 
costs partially offset by reduced cost associated with advanced DR (e.g. ophthalmolo-
gist time and laser treatment), leading to an ICER of AUD 10,221 per QALY gained. 
Similarly, fenofibrate+statin led to an improvement of 0.05 QALYs versus statin alone 
with an incremental direct cost of AUD 1,707. The ICER for fenofibrate+statin was AUD 
33,350 per QALY gained versus statin alone. Sensitivity analysis showed that results 
were relatively insensitive to changes in a range of assumptions. cOnclusiOns: The 
reduced risk of DR progression associated with fenofibrate treatment was projected 
to improve quality-adjusted life expectancy, with treatment costs partially offset by 
reduced costs of retinopathy care. ICERs indicated that fenofibrate therapy was in the 
range likely to be considered cost-effective in Australia.
PDB64
COST-EFFECTIvENESS OF INSULIN DEGLUDEC COMPARED wITH INSULIN 
GLARGINE IN A BASAL-BOLUS REGIMEN IN PATIENTS wITH TyPE 1 DIABETES 
MELLITUS IN THE UNITED KINGDOM
Chubb B.1, Evans M.2, Wolden M.3, Christensen T.3, Gundgaard J.3
1Novo Nordisk Ltd., Crawley, UK, 2University Hospital Llandough, Cardiff, UK, 3Novo Nordisk A/S, 
Søborg, Denmark
Objectives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for the management of patients with type 1 (T1DM) and patients 
with type 2 (T2DM) diabetes. IDeg has demonstrated effective blood glucose con-
trol with less hypoglycaemic events and with an option for flexibility in dose time 
compared to insulin glargine (IGlar). The aim of this analysis was to evaluate the 
cost-effectiveness of IDeg versus IGlar in adults with T1DM in the UK. MethOds: 
Meta-analysis data from two phase III clinical studies were used to populate a 
simple, transparent short-term model. The analysis was conducted from the UK 
National Health Service perspective and costs and benefits were calculated over 
a 12-month period. Sensitivity analyses were conducted to assess the degree of 
uncertainty around the results. In order to test the robustness of the results, two 
versions of the model were used. One applied disutilities derived from the SF-36 
questionnaire used in the clinical trials, the other applied disutilities associated with 
the occurrence of hypoglycaemic events. In both approaches an additional utility 
gain was attributed to the benefit of dosing flexibility. Baseline incidence of hypogly-
caemia was taken from a real-life study from the UK. Resource use associated with 
hypoglycaemia was documented in the clinical trials. Published tariffs were used 
as unit costs. Results: The base-case ICERs were £12,637/QALY and £13,349/QALY 
in the two modelling approaches, which are below commonly accepted thresholds 
for cost-effectiveness. The results were robust and largely insensitive to changes in 
input parameters. cOnclusiOns: This short-term modelling approach allows the 
economic evaluation of newer insulin analogues when advanced long-term model-
ling based on HbA1c differences is inappropriate due to the treat-to-target nature of 
the clinical trials resulting in equivalent HbA1c levels. For patients in the UK with 
T1DM IDeg is a cost-effective treatment option compared with IGlar.
PDB65
COST-EFFECTIvENESS OF INSULIN DEGLUDEC COMPARED wITH INSULIN 
GLARGINE FOR PATIENTS wITH TyPE 2 DIABETES MELLITUS INITIATING 
INSULIN THERAPy IN THE UNITED KINGDOM
Evans M.1, Chubb B.2, Christensen T.3, Gundgaard J.3, Wolden M.3
1University Hospital Llandough, Cardiff, UK, 2Novo Nordisk Ltd., Crawley, UK, 3Novo Nordisk A/S, 
Søborg, Denmark
Objectives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for management of patients with type 1 (T1DM) and patients with 
type 2 (T2DM) diabetes. IDeg has demonstrated effective blood glucose control with 
less hypoglycaemic events and an option for flexibility in dose time compared to 
insulin glargine (IGlar). The aim of this analysis was to evaluate the cost-effec-
tiveness of IDeg versus IGlar in adults with T2DM initiating insulin therapy in the 
UK. MethOds: Meta-analysis data from three clinical studies were used to populate 
a 1-year cost-utility model. The analysis was conducted from the UK National Health 
Service perspective. Sensitivity analyses were conducted to assess the robustness 
of results. Two versions of the model were tested, one applied disutilities derived 
from the SF-36 questionnaire used in the clinical trials, the other applied disutili-
ties associated with the occurrence of hypoglycaemic events. In both approaches 
an additional utility gain was attributed to the benefit of dosing flexibility. Baseline 
incidence of hypoglycaemia was derived from a UK real-life study. Resource use 
associated with hypoglycaemia was documented in the clinical studies. Official 
tariffs were used as unit costs. Results: Base-case ICERs were £15,705/QALY and 
£13,003/QALY in the two modelling approaches. Results were robust, with baseline 
rate of hypoglycaemia a key driver of results. Using hypoglycaemia rates from a 
subgroup of patients who experienced ≥ 1 hypoglycaemic event per year IDeg was 
highly cost-effective versus IGlar; with estimated ICERS of £4,706/QALY and £2,528/
QALY. cOnclusiOns: This short-term modelling approach allows the economic 
evaluation of newer insulin analogues when advanced long-term modelling based 
on HbA1c differences is inappropriate due to treat-to-target trial design. For patients 
with T2DM on a basal-only insulin regimen, IDeg is cost-effective compared with 
IGlar and offers additional benefits to subgroups of patients, such as those suffering 
from recurrent hypoglycaemia.
PDB66
THE COST-UTILITy OF INSULIN DEGLUDEC COMPARED wITH CURRENT 
STANDARD OF CARE IN THE MANAGEMENT OF TyPE ONE AND TyPE TwO 
DIABETES MELLITUS IN BELGIUM
Jugrin A.V.1, Lamotte M.1, Malfait M.2, Vandebrouck T.3
1IMS Health HEOR, Vilvoorde, Belgium, 2sa Novo Nordisk Pharma nv, Brussels, Belgium, 3Novo 
Nordisk Pharma, Brussels, Belgium
tively). cOnclusiOns: Patients treated with CANA in dual therapy experienced an 
additional 0.21 QALYs over 40 years versus patients treated with GLIM. The primary 
drivers were improved weight while on agent and fewer hypoglycaemic events.
PDB61
COST-EFFECTIvENESS OF INSULIN DETEMIR IN T2DM PATIENTS POORLy 
CONTROLLED wITH NPH INSULIN IN POLAND
Kaczor M.P.1, Pawlik D.2, Wójcik R.2, Jurkiewicz B.3
1Jagiellonian University Medical College, Kraków, Poland, 2Aestimo s.c., Kraków, Poland, 3Novo 
Nordisk Pharma, Warszawa, Poland
Objectives: In Poland, where long acting insulin analogues (LAA) are not currently 
reimbursed in T2DM, it is crucial to select a group of patients for whom LAA may 
be particularly preferred. Based on NICE recommendation such patients are those 
treated with human insulin (NPH) but not achieving glycaemic control. Thus the aim 
of this study was to evaluate the cost-effectiveness of insulin detemir (IDet) when 
compared to NPH in subpopulation of poorly controlled T2DM as defined by HbA1c 
≥ 8% and/or ≥ 1 episode of severe or nocturnal hypoglycemia recorded during ≥ 6 
months of NPH treatment. MethOds: A validated computer simulation of diabetes 
model (IMS-CORE) was used to project long-term clinical and economic outcomes. 
Clinical effects in HbA1c improvement, BMI change and reduction in hypoglycemic 
episodes were modelled. Analysis was based on findings from the subgroups of the 
PREDICTIVE study – a real-world data trial – that closely reflects the defined target 
population. Two distinct insulin therapy regimens with IDet and NPH were evalu-
ated: basal-supported oral therapy (BOT) and a basal-bolus (BB) regimen. Baseline 
cohort characteristics, disease progression and utility estimates were obtained from 
systematic literature review. Costs were obtained from Polish published data. The 
analysis was conducted from a public payer and patient perspective over a lifetime 
time horizon. Discount rates were 5% (costs) and 3.5% (outcomes). Results: The 
mean QALY gain resulting from treatment initiation with IDet compared with NPH 
was 0,311 (BOT) and 0,451 (BB). Base-case incremental cost-effectiveness ratios 
(ICERs) were 38,136 PLN/QALY (9,113€ ) and 13,726 PLN/QALY (3,280€ ), respectively. 
At the current ICER threshold of 105,801 PLN/QALY (25,281€ ) in Poland, probability 
of IDet being cost-effective compared to NPH is 95% (BOT) and approaching 100% 
(BB). cOnclusiOns: Based on generally accepted cost/QALY threshold values in 
the Polish settings, IDet was found to be a cost-effective option for T2DM patients 
with inadequately controlled diabetes.
PDB62
COST-EFFECTIvENESS ANALySIS OF INSULIN DEGLUDEC COMPARED wITH 
CURRENT STANDARD OF CARE IN THE MANAGEMENT OF TyPE 1 AND TyPE 2 
DIABETES MELLITUS IN THE SPANISH HEALTH SySTEM
Ramirez de Arellano A.1, Orozco-Beltran D.2, Mezquita-Raya P.3, Pérez A.4, Galan M.5
1Novo Nordisk Pharma, Madrid, Spain, 2University Miguel Hernández, Department of Clinical 
Medicine, Alicante, Spain, 3Hospital Torrecardenas, Clinica San Pedro, Almeria, Spain, 4Hospital de 
la Santa Creu I Sant Pau, Barcelona, Spain, 5Novo Nordisk, Madrid, Spain
Objectives: Insulin degludec (IDeg) is a basal insulin with an ultra-long duration 
of action for management of patients with type 1 (T1DM) and patients with type 
2 (T2DM) diabetes. IDeg have demonstrated efficacious blood glucose control with 
less hypoglycaemic events and with an option for flexibility in dose time compared 
insulin glargine (IGlar). The objective was to assess the cost-effectiveness of IDeg in 
Spain, compared with IGlar. The analysis focused on subgroups of patients within 
three treatment regimens: T1DM, T2DM treated with basal insulin in combination 
with oral anti-diabetics (BOT) and T2DM treated with basal-bolus (BB). MethOds: 
A one-year cost-utility model driven by differences in hypoglycaemia was used. Two 
alternative utility approaches were used: in the first case, the utility gain was elicited 
from the clinical trials. In the second, published dis-utilities for hypoglycaemic 
events and self-monitoring blood glucose tests were used to calculate QALYs. Cost 
and utilities were also estimated for potential use of less blood glucose test strips. 
Three subgroups were analysed: those using twice daily IGlar, those with high risk 
of severe hypoglycaemia, and those obtaining extra utility from dosing flexibility. 
Unit costs pertained to public tariffs and reflected the payer perspective. Baseline 
incidence rates of hypoglycaemia and related resource use was derived from a 
Spanish observational study. Results: IDeg was dominant for T1DM, T2DM BOT 
and T2DM BB switching from twice daily. T2DM BOT with high risk of hypoglycaemia 
was also dominant. As for patients benefiting from dosing flexibility the cost/QALY 
were 6,921€ /QALY in T1DM, 9,244€ /QALY in T2DM BOT, and 33,099€ /QALY in T2DM 
BB. The use of the two different utility methods gave similar results. Univariate and 
probabilistic sensitivity analyses confirmed robust results. cOnclusiOns: This 
analysis demonstrates that IDeg is a cost-effective option in Spain, when used in 
sub-groups of patients currently treated with long-acting insulin.
PDB63
EvALUATING THE COST-UTILITy OF FENOFIBRATE TREATMENT OF DIABETIC 
RETINOPATHy IN AUSTRALIA
Valentine W.J.1, Pollock R.F.1, Carr E.2, Aubonnet P.2, Mitchell P.3, Keech A.3
1Ossian Health Economics and Communications, Basel, Switzerland, 2Abbott Laboratories, 
Allschwil, Switzerland, 3University of Sydney, Sydney, Australia
Objectives: Evidence from the landmark trials FIELD and ACCORD demonstrated 
that fenofibrate significantly reduces rates of diabetic retinopathy (DR) progression 
in type 2 diabetes patients (T2DM). This study evaluates the long-term cost-effective-
ness of fenofibrate mono- and combination therapy for DR in Australia. MethOds: A 
seven-state Markov model simulated progression of DR based on data from the Blue 
Mountain Eye Study. Risk reductions for retinopathy progression were derived from 
FIELD for fenofibrate monotherapy (vs. placebo) and ACCORD for fenofibrate+statin 
(vs. statin alone). No additional benefits were assumed beyond 5 years (DR progression 
was the same with/without fenofibrate after year 5). Quality-adjusted life expectancy, 
direct costs and incremental cost-effectiveness ratios (ICERs) were reported over 10 
years. Unit costs (2012 Australian dollars, AUD), resource use and utilities were taken 
from country-specific sources/expert opinion. Future costs and clinical benefits were 
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PRODUCTIvITy LOSS IN POPULATION OF INFORMAL CAREGIvERS TO DIABETIC 
FOOT SyNDROME PATIENTS IN POLAND
Macioch T.1, Sobol E.2, Mrozikiewicz-Rakowska B.1, Krakowiecki A.1, Mienicka A.2, 
Mlynarczuk M.2, Kasprowicz M.1, Paweska J.1, Hermanowski T.R.1, Karnafel W.1
1Medical University of Warsaw, Warsaw, Poland, 2Medical University of Warsaw Central Clinical 
Hospital, Warsaw, Poland
Objectives: Foot ulceration is a major cause of disability in diabetic patients. 
Disability of patients with diabetic foot ulceration (DFS – Diabetic Foot Syndrome) 
concerns not only patients themselves, but also the informal caregivers, mainly 
their close relatives. The aim of this study was to estimate lost productivity in 
a population of family caregivers of patients with diabetic foot ulceration in 
Poland. MethOds: A survey among 189 patients with DFS (treated in ambulatory 
care) and their families was conducted. To assess the impact of diabetic ulceration 
on productivity of caregivers to DFS patients the modified questionnaire WPAI-CG 
was used. The PEDIS scale was used to classify severity of ulceration. Results: A 
total of 116 out of 189 questionnaires were collected, and data on 93 responders 
(25 males) were included in the analysis (23 questionnaires were returned empty 
or concluded that informal care is not provided to DFS patients). Fifty-two (13 
males) out of 93 caregivers were employed at the time of the survey. Mean age 
of the population of caregivers was 45.9±11.2 years. Most were close relatives of 
DFS patients (58% spouses, 27% children). Almost half caregivers were employed 
in private sector (46%). Most had higher (50%) or secondary (48%) education. The 
average weekly work time declared was 40.4±13.1 hours. Approximately 70% of 
caregivers were urban population. The average percentage of work time missed 
and the percentage of working impairment while working due to informal care 
of DFS patients were estimated at 11.9% and 25.0%, respectively. The percentage 
of overall work impairment due to informal care of DFS patients was 32.2%. This 
amounts to weekly average time of the absence of 13.0 hours. cOnclusiOns: 
The lost productivity due to informal care on DFS patients is substantial and may 
have important implications for the economy.
PDB70
UTILISATION PATTERN OF GLP-1 AGONISTS IN COMBINATION wITH BASAL 
INSULIN IN PATIENTS wITH T2DM IN THE NORwEGIAN SETTING IN ONE yEAR
Levorsen A.1, Jespersen S.1, Chou E.2
1Sanofi, Lysaker, Norway, 2Sanofi, Bridgewater, NJ, USA
Objectives: GLP-1 agonists in combination with basal insulin (BI) have demon-
strated additional improvement of glycemic control in uncontrolled T2DM patients 
in clinical trials. It is therefore important to assess the real-world utilisation of 
GLP-1 agonists in combination with BI in T2DM patients. MethOds: Retrospective 
cohort analysis (2010 to 2012) to assess GLP-1 agonist utilisation in T2DM patients 
based on the Norwegian Institute of Public Health Prescription Database (NorPD). 
Both ICPC= T90 and ICD-10= E11 were applied to identify T2DM patients. Patients 
who had ≥ 2 GLP-1 dispensed within 6-month in Year-2011, with 1-year pre-Base-
line/post- Follow-up GLP-1 initiation were included in the analysis. Baseline anti-
diabetic drug use and combination use of GLP-1 and BI at Follow-up were also 
assessed. Results: Of the 1,500 GLP-1 initiators identified (mean age= 57; 52% 
male) at Baseline, 77% were on OADs, 19% on BI, 2% on prandial insulin (no BI) 
and 2% on other/no anti-diabetic drug. During 1-year Follow-up of GLP-1 adding 
on OADs patient population, 56% used GLP-1 continuously including 50% who 
used GLP-1 alone and 6% added BI. In total, 15% had either combined with or 
switched to BI, 4 months after the first GLP-1 was dispensed. Of those GLP-adding 
on BI patient population, 53% continuously used GLP-1 including 26% had both 
GLP-1 and BI dispensed throughout the Follow-up. About 52% had either BI inter-
rupted or discontinued approximately 2 months after the first GLP-1 was dis-
pensed. In total, 27% had insulin bolus dispensed; of which 58% either interrupted 
or discontinued GLP-1. cOnclusiOns: About 1/3 of GLP-1 initiators were in com-
bination with BI. In BI treated T2DM patients > 25% remained on both GLP-1 and 
BI, while another > 25% required treatment augmentation or switched to bolus. 
The data suggests an unmet treatment need, particularly in T2DM patients treated 
with BI.
PDB71
REvIEw OF COST OF DIABETES COMPLICATIONS IN FOUR EUROPEAN 
COUNTRIES
Beaudet A.1, Grabbi E.2, Maurel F.3, Ramos M.4, Lebioda A.5
1IMS Health, Basel, Switzerland, 2IMS Health, London, UK, 3IMS Health, La Défense, France, 4IMS 
Health, Barcelona, Spain, 5IMS Health, Munich, Germany
Objectives: To provide a comprehensive and coherent reference document of 
published cost data for diabetic complications in France, Germany, Italy and Spain 
for use in economic diabetes modeling. MethOds: A search for published cost of 
diabetes complications data from a health care payer perspective was performed 
on government websites, in peer-reviewed journals and local cost experts. All costs 
were inflated to 2013 Euros (€ ). Results: First year costs of myocardial infarction 
varied between € 3,041 in France and € 9,690 in Germany. Heart failure costs were 
similar across countries: € 3,104 in France; € 2,791 in Germany; € 4,000 in Italy and 
€ 3,316 in Spain. Costs of non-fatal stroke were higher in Germany (€ 16,441) than in 
other countries (Spain € 8,016; Italy € 6,073; France € 5,447). Everywhere, the cost of 
haemodialysis was higher than peritoneal dialysis € 35,972 versus € 21,255 in Spain, 
€ 21,552 versus € 18,485 in Italy, € 34,290 versus € 34,069 in Germany € 71,683 versus 
€ 48,752 in France. Renal transplant cost was estimated to € 84,114 in France, € 34,858 
in Germany, € 38,528 in Italy and € 26,618 in Spain. The cost of a major hypoglycemia 
requiring medical care was € 4,275 in Spain, € 2,561 in Germany, € 1,391 in Italy and 
€ 1,165 in France. Neuropathy complication costs varied widely: € 3,808 (France); 
€ 16,762 (Germany); € 4,290 (Italy); and € 5,330 (Spain) for foot ulcers and € 6,056 (Italy); 
€ 7,754 (Germany); € 9,578 (France); and € 12,118 (Spain) for lower-extremity ampu-
tation. cOnclusiOns: This study provides a coherent set of costs for diabetes 
complications in four European countries. Due to the differences in health care 
Objectives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for management of patients with type 1 (T1DM) and patients with 
type 2 (T2DM) diabetes. IDeg has demonstrated efficacious blood glucose control, 
with less hypoglycaemic events, and with an option for flexibility in dose time, 
compared with insulin glargine (IGlar). The objective was to assess the cost-
effectiveness of IDeg in Belgium, compared with IGlar. The analysis focused on 
patients in three treatment regimens: T1DM, T2DM treated with basal insulin in 
combination with oral anti-diabetics (BOT) and T2DM treated with basal-bolus 
(BB). MethOds: A one-year cost-utility model driven by differences in hypogly-
caemia was used. Published dis-utilities for hypoglycaemic events were multiplied 
by the rate of hypoglycaemia to calculate quality-adjusted life years (QALYs). Costs 
and utilities were also calculated for potential use of less blood glucose test strips. 
A utility gain was attributed to the additional benefit of dosing flexibility. Unit 
costs pertained to public tariffs and reflected the payer perspective in Belgium. 
Baseline incidence rates of hypoglycaemic events and related resource utilization 
pertained to a Belgian patient-reported outcomes study. Hospitalization costs 
following severe hypoglycaemia were estimated using the IMS Hospital Disease 
Database. Results: IDeg was associated with an incremental cost-effectiveness 
ratio of 14,677€ /QALY in T1DM, 4,976€ /QALY in T2DM BOT, and 12,930€ /QALY in 
T2DM BB. Univariate and probabilistic sensitivity analyses confirmed robust 
results. Results were most sensitive to variations in number of IGlar doses per 
day, and number of glucose-monitoring tests. At a willingness to pay threshold of 
30,000€ /QALY, IDeg would be cost-effective in 54%, 100% and 93% of the cases in the 
T1DM, T2DM BOT or T2DM BB treatment regimens respectively. cOnclusiOns: 
These analyses demonstrate that IDeg is cost-effective in Belgium, when used 
in patients with T1DM and T2DM currently treated with long-acting insulin ana-
logues.
PDB67
ECONOMIC EvALUATION OF LIRAGLUTIDE FOR TREATMENT OF TyPE 2 
DIABETES MELLITUS IN THE RUSSIAN FEDERATION
Yagudina R., Kulikov A., Novikov I.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: The analysis goal is to determine the cost-effectiveness of liraglutide 
as add-on to metformin in for patients with type 2 diabetes in condition of the 
Russian health care system. Total medical expenses and effectiveness in terms of 
QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combina-
tion with metformin, and metformin monotherapy. MethOds: Data were sourced 
from a clinical trial comparing liraglutide vs. glimepiride (in combination with 
metformin), and a clinical trial comparing liraglutide vs. rosiglitazone (as add-on to 
metformin). From them data on clinical effectiveness in form of impact on HbA1(c), 
body mass index and blood pressure are extracted. Utility values are mostly taken 
from the UK Prospective Diabetes Studies supplemented with other published 
sources. The analysis is conducted from the perspective of the Russian health care 
system. Respectively the cost of the following resources is accounted: comparing 
of alternatives, concomitant pharmacotherapy, cost of medical manipulation, cost 
of ambulatory visits. Both future costs and clinical benefits are discounted at 3 
percent. Sensitivity analysis is performed. Results of this analysis are shown in the 
incremental cost-utility rate (ICUR). Results: The data of the analysis illustrates 
that liraglutide therapy for type 2 diabetes patients provides a significant health 
improvement from the perspective of quality adjusted life-years. Simultaneously 
liraglutide demonstrates better cost-effectiveness than the compared alternatives. 
The ICUR index of 1.2 mg liraglutide in combination with metformin equal to 1 
348368 rub, 1 161874 rub and 537331 rub for QALY in comparison with metformin 
monotherapy, glimepiride and rosiglitazone, both in combination with metformin, 
respectively. cOnclusiOns: Liraglutide has turned to be cost-effective therapeu-
tic alternative for treatment of type 2 diabetes in adult patients in conditions of 
Russian health care system over a 10-year time horizon.
PDB68
ECONOMIC EvALUATION OF SITAGLIPTIN IN DIABETES MELLITUS TREATMENT 
IN CHINA
Chen W., Zhu J.
Fudan University, Shanghai, China
Objectives: To evaluate the long-term cost effectiveness of sitagliptin com-
pared to glimepiride and acarbose in the treatment of type 2 diabetes mellitus in 
China. MethOds: Sitagliptin, as add-on therapy to metformin, was compared to 
glimepiride and acarbose, and as monotherapy was also compared to acarbose. 
The validated UKPDS Outcomes Model was used to estimate the direct medical 
costs and outcomes (life years and QALYs gained). The demographic characteris-
tics and clinical data were taken from published literature. The quality of life data 
was obtained from published literature and re-confirmed through a questionnaire 
survey from a clinical expert panel of 20 diabetes specialists. The cost of drugs 
was calculated based on government guidance price or actual market price. The 
annual cost of complications was estimated based on expert opinions. Patients’ 
outcomes were modeled for 40 years and incremental cost-effectiveness ratios 
were calculated. Both future costs and clinical benefits were discounted at 3 
percent. A probabilistic sensitivity analysis was performed to understand the key 
drivers and general sensitivity of the model. Results: The results showed that, 
compared to the treatment of glimepiride and acarbose plus metformin therapy, 
the add-on of sitagliptin provided a gain of 0.02 and 0.95 QALYs per patient, and 
the incremental cost-effectiveness ratios were USD 9,470 and USD 399, respec-
tively. The results also showed that compared to acarbose monotherapy (100mg 
t.i.d and 200mg t.i.d), the sitagliptin monotherapy (100mg/d and 200mg/d) was 
dominant, with higher QALYs (0.58 and 0.92) and years of life (0.72 and 1.23) 
gained and lower cost (USD 90 and USD 185). cOnclusiOns: According to the 
China’s GDP per capita in 2011 (USD 5,674), the results demonstrate that sitag-
liptin is more cost-effective than glimepiride and acarbose in the treatment of 
diabetes mellitus in China.
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sulphonylureas were less likely to be persistent than those initiated on metformin 
(OR= 0.50; 95%CI= 0.45 to 0.54; p< .0001). cOnclusiOns: Persistence amongst newly 
treated T2DM patients appears to be low. Type of OHM, age and scheme were all 
significantly associated with persistence. Prescribers should pay particular atten-
tion to newly treated patients covered under the GMS scheme, at the extremes of 
age and those initiated on sulphonylureas.
PDB75
THE IMPACT OF MEMORy PROBLEMS ON DIABETES TREATMENT IN CANADA
Brod M.1, Kongso J.2, Bushnell D.M.3
1The Brod Group, Mill Valley, CA, USA, 2Novo Nordisk A/S, DK-2860 Soborg, Denmark, 3Health 
Research Associates, Inc., Seattle, WA, USA
Objectives: The impact of memory problems (MPs) on patient’s insulin taking 
behavior, functioning, well-being and diabetes management is not well under-
stood. MethOds: A 5 country web-based survey was conducted. MPs were defined 
as: unintentionally forgetting (UF) to take insulin, questioning whether or not 
insulin had been taken (QT), or questioning how much insulin dose was taken 
(QD). Data from Canadian respondents were analyzed and compared to the other 
countries (US, UK, Germany, and China). Results: A total of 350 respondents in 
Canada completed the survey (74.0% Type 1, 52.0% male, mean age of 37.1 years, 
mean age of diabetes onset of 24.2). The prevalence of MPs was 60.6% (UF), 76.3% 
(QT) and 44.6% (QD) in the past month with only approximately 1/3 being confi-
dent they knew what to do when having an MP. Between 21.5% (QT) and 37.4%(UF) 
tested their blood glucose and 32.6% (QD) – 51.6% (QT) skipped their insulin dose 
and waited for next scheduled dose when experiencing a MP, requiring, on aver-
age, between 8.5 (QT)–19.1 (UF) hours for return to normal blood glucose ranges. 
Patients conducted between 1.9 (QT) –5.0 (UF) extra BG monitoring tests the week 
following the MP and reported moderate negative impacts on their ability to 
work, physical and emotional functioning. Up to 13.7% missed a work day (UF) 
and between 10.8% (QT) and 16.8% (UF) visited their health care provider as a 
result of MP Compared to respondents in the other countries (N= 1404), Canadian 
respondents were reported significantly longer recovery times for returning to 
normal blood glucose levels following a MP and were significantly more likely 
to experience hyperglycemia following UF/QD than patients in other countries 
(p< .05). cOnclusiOns: These findings suggest that MPs have economic implica-
tions, impact patients’ functioning and well-being and may be serious obstacles 
to optimal diabetes control.
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THE IMPACT OF MEMORy PROBLEMS ON DIABETES TREATMENT IN THE UNITED 
KINGDOM
Brod M.1, Kongso J.2, Bushnell D.M.3
1The Brod Group, Mill Valley, CA, USA, 2Novo Nordisk A/S, DK-2860 Soborg, Denmark, 3Health 
Research Associates, Inc., Seattle, WA, USA
Objectives: The impact of memory problems (MPs) on patient functioning, well-
being and diabetes management is not well understood. The purpose of this study 
was to examine these impacts in the UK and compare these findings to data 
from US, Germany, Canada, and China). MethOds: A 5 country web-based survey 
examining MPs was conducted. MPs were defined as: unintentionally forgetting 
(UF) to take insulin, questioning whether or not insulin had been taken (QT), or 
questioning amount of insulin dose (QD). Results: A total of 350 UK respondents 
(52.0% Type 1), 49.1% male, mean age of 40.3, mean age of diabetes onset of 25.5 
completed the survey. The prevalence of MPs was 66.6% (UF) forgetting, 84.9% (QT) 
56.9% (QD). MPs occurred most frequently when relaxing or doing household jobs. 
Between 13.7% (UF) – 32.6% (QT) of respondents skipped their insulin dose due 
to a MP and required between 1.4 (QD)–13.1 (UF) hours, on average, to return to 
normal blood glucose range. As a result of a MP, patients conducted between 1.7 
(QT) –6.8 (UF) extra BG monitoring tests , reported a moderate negative impact on 
their physical and emotional functioning, as well as their ability to go to or func-
tion optimally at work and between 8.1% (QT) and 20.0% (UF) visited/contacted 
their health care provider . Economic implications include cost of additional BG 
strips, lost work productivity and health care resource utilization. Compared to 
respondents in the US, Germany, China and Canada (N= 1404), UK respondents 
conducted significantly more BG tests during the week following a missed dose 
of insulin were more likely to take a dose of insulin following a MP without test-
ing their BG. cOnclusiOns: These findings suggest that MPs in the UK carry 
financial burden, impact patients’ daily functioning and well-being and may be 
serious obstacles to optimal diabetes control.
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DO FIxED-DOSE COMBINATIONS IMPROvE ANTIDIABETIC TREATMENT 
COMPLIANCE? A STUDy BASED ON FRENCH IMS LIFELINK DISEASE ANALyzER 
DATABASE
Grandfils N., Le Jeunne P., Maillard C., Solomiac A., Besson A.
IMS Health, PARIS LA DEFENSE, France
Objectives: To compare antidiabetic treatment compliance with regards to the 
fixed or free treatments combination. MethOds: A retrospective study based on 
the IMS LifeLinkTM Diabetes Cohort linked to IMS Disease Analyzer, a longitudinal 
patient database containing the electronic health records of patients followed-up 
by a representative panel of French general practitioners. Two cohorts of patients 
treated both with metformin and DPPIV were constituted, the first one treated with 
fixed associations (“fixed cohort”), the second one treated with free associations 
(“free cohort”). Study investigated patients’ demographic and clinical character-
istics, conditions of use, persistence rates, medication possession ratio (MPR) and 
proportion of days covered (PDC) of the two cohorts. Results: Respectively 2 234 
and 8220 patients have been treated with free and fixed antidiabetic associations 
between 2007 and 2013. Patients are significantly older (66 vs. 64 years, p< 0.01) in 
the free cohort where the proportion of men is significantly lower (56% vs. 63%, 
p< 0.0001). Nevertheless diabetes oldness is the same (about 10 years) in both 
system structure and in cost transparency, the cost estimation methodology varied 
among countries. One limitation of this study is that diagnostic related group (DRG) 
tariffs were used to estimate several costs, which may not accurately represent the 
burden of a specific complication nor take into account the full burden of follow-up 
after an acute event.
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THE COST OF SPECIALIzED HOSPITAL CARE FOR PATIENTS wITH DIABETIC 
FOOT ULCERS IN RUSSIA
Ignatyeva V.1, Avxentyeva M.1, Omelyanovsky V.V.1, Galstyan G.R.2
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia, 2The Endocrinological Scientific Center, Moscow, Russia
Objectives: To assess the direct medical costs for aggressive limb preservation 
treatment of diabetic foot ulcer (DFU) in a highly-specialized hospital setting in 
Russia MethOds: A retrospective data analysis of 156 admissions during 1-year 
period was done to get direct costs (associated with hospital stay, conservative 
and surgical treatment and laboratory testing) for treatment of DFU in a highly-
specialized inpatient department in Russian setting (Federal Endocrinology 
Centre). Results: The median cost of hospital treatment was 2270 EUR and 
increased with severity level, defined according to Wagner classification, ranging 
from 1590 EUR (grades 0-2) to 3812 EUR (grade 3) and 7683 EUR (grade 4), the differ-
ence was statistically significant. The length of stay in a hospital also correlated 
with the severity level starting with 14 days for grade 1 and reaching 39 days for 
grade 4. The costs of treatment were significantly higher for patients with inad-
equate vascular status requiring surgery – the median was 6185 EUR for cases with 
only angioplastic surgery and 8622 EUR for cases with both angioplastic and foot 
surgery provided. cOnclusiOns: Treatment of DFU aimed at limb preservation is 
resource consuming, costs for treating severe stage ulcer are 4,8 times higher than 
are those for treating low-stage ulcer. The high costs of treating severe stages of 
DFU in a specialized hospital setting emphasize the value of intensive outpatient 
interventions designed to prevent ulcer progression.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes &  
Patient Preference Studies
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RISK FACTORS FOR DISCONTINUATION OF INSULIN PUMP THERAPy IN 
PEDIATRIC AND yOUNG ADULT PATIENT GROUPS
Kostev K.1, Rockel T.1, Rex J.1, Mergenthaler U.1, Rosenbauer J.2, Rathmann W.2
1IMS Health, Frankfurt am Main, Germany, 2German Diabetes Center, Duesseldorf, Germany
Objectives: Previous studies have shown that only a small number of pediatric and 
young adult patients discontinue pump therapy, but risk factors for discontinuation 
are unclear. Aim of this study was to identify characteristics of pediatric and young 
adult patients with pump therapy which are associated with discontinuation of 
treatment. MethOds: Retrospective cohort study using a representative nation-
wide database (LRx; IMS Health) in Germany covering > 80% of all prescriptions to 
members of statutory health insurances in 2008-2011. All patients (age groups: < 6, 
6-< 12, 12-< 18, 18-< 25 years) with new prescriptions of insulin pumps or related 
material were identified (2009-2011) and were followed for ≥ 12 months. Results: 
Overall, 3057 new pump users were identified, of whom 177 (5.8%) switched to other 
forms of insulin therapy within 12 months. Discontinuation was lowest in the age 
group < 6 years (2.1%) and was highest in adolescents (12-< 18 years: 7.5%) (p< 0.01). 
In age-adjusted logistic regression, usage of steel needles (Odds ratio, OR, 95%CI: 
1.69; 1.20-2.44) and prescriptions of antiepileptics (3.14; 1.49-6.59) were related to 
pump discontinuation. In younger age groups only, discontinuation was signifi-
cantly higher in patients with thyroid therapy as a surrogate measure for thyroid 
autoimmunity (< 6 years: 14.3%; 6-< 12 years: 25.0%) (p< 0.01). cOnclusiOns: About 
94% of pediatric and young adult patients maintained insulin pump therapy within 
12 months. Adolescence (12-18 years), usage of steel needles and prescriptions of 
antiepiletic drugs are independent predictors of discontinuation. In younger age 
groups (< 12 years) also thyroid therapy (indicating autoimmunity) was related to a 
higher risk of discontinuation.
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PERSISTENCE PATTERNS wITH ORAL HyPOGLyCAEMIC MEDICINES (OHM) IN 
NEwLy TREATED IRISH PATIENTS wITH TyPE 2 DIABETES MELLITUS (T2DM)
Grimes R.1, Tilson L.2, Usher C.2, Henman M.1, Bennett K.3
1Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland, 
3Trinity Centre for Health Sciences, Dublin, Ireland
Objectives: To describe persistence patterns to OHM in newly treated Irish patients 
with T2DM. The study also investigated the effect of age, gender, reimbursement 
scheme and type of OHM on persistence. MethOds: A population based retrospec-
tive cohort study was conducted using national pharmacy claims databases, includ-
ing two community drugs schemes; Long Term Illness, (LTI, non-means tested) and 
General Medical Services (GMS, means tested). Newly treated T2DM patients were 
identified for 2008-2009, having received no OHM in the previous year, and followed 
up until Nov-2012. Patients who subsequently switched or received additional OHM 
were excluded. Non-persistence was defined as a prescription gap of > 12 weeks 
and within 1 year of initiating treatment. Logistic regression examined associations 
of age, gender, scheme and type of OHM with persistence with results presented 
as odds ratios (OR) and 95% confidence intervals (CI). Results: A total of 15,174 
persons were eligible for the study. Most patients were initiated on metformin 
(79.4%) and sulphonylureas (19.1%). Persistence at 1 year was 60.9%. The median 
overall time to non-persistence was 51.5 days. Men were slightly more likely to 
be persistent than women (OR= 1.08; 95%CI= 1.001 to1.15; p= 0.0025). Patients aged 
16-44 and 75+ were less likely to be persistent than patients aged 55-64 (OR= 0.18; 
95%CI= 0.16-0.21; p< 0.0001 and OR= 0.67; 95%CI= 0.60-0.75; p< 0.0001 respectively). 
Patients registered with the LTI Scheme were more likely to be persistent than 
from the GMS Scheme (OR= 1.35; 95%CI= 1.20-1.51; p< 0.0001). Patients initiated on 
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daytime and nocturnal hypoglycaemia. Non-linear regression curves were fitted 
to the total disutility of different frequencies of hypoglycaemic events. A weight-
ing scheme was used to allow each data point (one event quarterly, one monthly, 
one weekly or three weekly) to reflect the range of hypoglycaemic frequencies the 
data point represented. Non-parametric bootstrapping was applied to character-
ise the uncertainty of the marginal disutility. Results: Power function regres-
sion curves were estimated at Ud= 0.0141x0.3393 and Ud= 0.0221x0.3277, where Ud is 
disutility and x is the annual hypoglycaemic event rate, for non-severe day-
time and non-severe nocturnal events. An increase from 0 to 1 hypoglycaemic 
events per year, produced a utility decrease of 0.0141 for non-severe daytime, 
and 0.0221 for non-severe nocturnal, whereas an increase of one hypoglycaemic 
event per year for a patient who experiences 25 hypoglycaemic events per year 
produces a marginal impact of 0.0006 and 0.0008 for non-severe daytime and 
non-severe nocturnal, respectively. cOnclusiOns: If patient-level data are avail-
able, non-linear functions estimated with TTO data might improve the precision 
of the measured impact of hypoglycaemic events. The results seen here illustrate 
diminishing marginal disutility with increasing numbers of hypoglycaemic events. 
This fits with the phenomenon of “first being worst” with regards to hypogly-
caemia.
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QUALITy OF LIFE IN PATIENTS wITH TyPE 2 DIABETES IN POLAND: 
COMPARISON wITH GENERAL POPULATION USING EQ-5D QUESTIONNAIRE
Golicki D.1, Dudzinska M.2, Zwolak A.3, Tarach J.S.2
1Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, 
Poland, 2Department of Endocrinology, Medical University of Lublin, Lublin, Poland, 3Chair of 
Internal Medicine and Department of Internal Medicine in Nursing, Medical University of Lublin, 
Lublin, Poland
Objectives: To compare the health related quality of life (HRQoL) in Polish patients 
with type 2 diabetes (T2D) and in matched sample from the general popula-
tion. MethOds: Data on HRQoL came from two non-interventional studies: pro-
spective study of patients with T2D and EQ-5D Polish general population norms 
study. Analysis of HRQoL was conducted in four separate age groups: 32–44, 45–54, 
55–64 and above 65 years. We analyzed: an subjective and objective assessment 
of HRQoL (EQ VAS and EQ-5D index) and the presence of restrictions within five 
dimensions of the EQ-5D descriptive part. Results: A total of 274 patients with T2D 
and 214 representatives from population norms study, were included. EQ VAS was 
systematically lower in diabetic patients compared to the general population, and 
decreased with age (68.2 vs 83.9, 62.4 vs 79.2; 54.9 vs 78.1, 50.2 vs. 69.8 in consecutive 
age groups). A similar relationship was observed with EQ-5D index. The largest mean 
differences were observed among subjects aged 55-64 years (EQ VAS: 23.2, EQ-5D 
index: 0.085). In three domains: self-care, usual activities and anxiety/depression, 
patients with diabetes above 45 years of age, reported significantly more problems 
than respondents from the general population. cOnclusiOns: Both subjective 
and objective HRQoL in patients with T2D is lower than in respondents of similar 
age from the general population. Compared with type 2 diabetic populations from 
other countries, Polish patients characterize by a relatively high HRQoL objective 
assessment and very low subjective assessment.
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UTILITIES FOR TyPE 2 DIABETES MELLITUS AND ASSOCIATED COMPLICATIONS
Shingler S.L.1, Fordham B.1, Evans M.2, Thompson G.3, Schroeder M.3, Lloyd A.J.1
1Oxford Outcomes, An ICON plc Company, Oxford, UK, 2University Hospital Llandough, Cardiff, 
UK, 3Janssen UK, High Wycombe, UK
Objectives: The impact of Type 2 diabetes mellitus (T2DM) on health related quality 
of life (HRQL) is complex due to the burden of disease, lifelong treatment require-
ments and comorbidities. This study aimed to capture UK societal utility values for 
health states associated with T2DM and treatment-related adverse events (AEs) to 
assess the burden of the disease and common AEs. MethOds: Nine health state 
descriptions were developed (from a literature review and patient and clinician 
qualitative input) depicting the burden associated with T2DM and treatment related 
AEs. These were mild/moderate urinary tract infection (UTI); severe UTI; mycotic 
infection; moderate hypoglycaemic events; severe hypoglycaemic events; fear of 
hypoglycaemia; gastrointestinal symptoms; and hypovolaemic events. Members 
of the UK general public (n= 100) valued these states using the time trade-off (TTO) 
methodology to elicit utility values (between 0= dead, 1= full health). Regression 
analysis was conducted to understand influence of age and gender. Results: All 
treatment-related AEs were found to have a significant effect on utility. From the 
T2DM baseline state (0.92), the experience of AEs was associated with the follow-
ing disutility: T2DM with hypovolaemic events (0.08); T2DM with mild/ moderate 
UTIs (0.09); T2DM with moderate hypoglycaemic events (0.11); T2DM with severe 
hypoglycaemic events (0.15); T2DM with fear of hypoglycaemia (0.15); T2DM with 
severe UTIs (0.19); T2DM with GI symptoms (0.24); andT2DM with mycotic infection 
(0.25); Males consistently scored the states with significantly lower utility values, but 
no significant age effects emerged. cOnclusiOns: Findings suggest that adverse 
events in T2DM can be a burden for some individuals. The study indicates the poten-
tial importance of including information regarding AEs in economic evaluations. 
Although some states were rated severely in terms of utility, in reality, many of 
these only last a few days, therefore having a minimal quality adjusted life year 
(QALY) impact.
PDB84
HEALTH-RELATED QUALITy OF LIFE AND UTILITy IN PATIENTS wITH DIABETIC 
FOOT SyNDROME - AN EQ-5D SURvEy IN POLAND
Sobol E.1, Macioch T.2, Krakowiecki A.2, Mrozikiewicz-Rakowska B.2, Mienicka A.1, 
Mlynarczuk M.1, Kasprowicz M.2, Paweska J.2, Karnafel W.2, Hermanowski T.R.2
1Medical University of Warsaw Central Clinical Hospital, Warsaw, Poland, 2Medical University of 
Warsaw, Warsaw, Poland
cohorts. Daily number of prescribed tablets whatever the therapeutic classes is 
significantly higher in the free cohort (4.4 per day vs. 3.1, p< 0.01). At the end of the 
first treatment year, significantly more patients of the fixed cohort are still treated 
by the same association regardless daily dosages or potential add-on treatments 
(85% vs. 72%, p< 0.0001); moreover MPR is the same in both free and fixed cohort 
(64% and 66% without statistical difference) while PDC is significantly higher in 
the fixed cohort (60% vs. 54%, P< 0.0001). cOnclusiOns: Patients treated by fixed 
antidiabetic treatments associations seem to be more persistent than these 
treated by free ones at the end of the first year of treatment. These results will be 
consolidated soon by comparing two similar sub-cohorts with the same medical 
profile.
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IMPACT OF DOSAGE AND SEvEN OTHER FACTORS IN THE ADHERENCE TO ORAL 
MEDICATION IN PEOPLE wITH DIABETES TyPE 2 IN GERMANy
Pleguezuelo W.itte M
IMS Health, London, UK
Objectives: Low adherence to medications in chronic diseases is a well docu-
mented problem that diminishes drug actions. Understanding the factors that 
can impact adherence is a priority in order to improve it. Diabetes adherence can 
be influenced by the complexity of administration of some medications as well 
as patients’ attitudes and doctor/patients interaction. This study evaluates the 
influence of the following variables in the adherence of people with diabetes: 
Dosage, patient age, gender, substance, price of drug, pack size, pack strength 
and doctor specialty. MethOds: Adherence was calculated using the medical 
possession ratio (MPR) = unique days of therapy/available days. A logistic regres-
sion was conducted to explore the multiple variables affecting the MPR. Results: 
The analyses included 25 months (from July 2009 to July 2011) of longitudinal 
prescription data for Germany for the ATC class A10 (oral antidiabetic). We found 
significant effects on adherence for age groups 55-64 (0.0909 p< 0.01), 65-74 (0.1266, 
p< 0.0004) and > 75 (0.0868, p< 0.0155), dosage (-0.7646, p< 0.0001), gender (-0.0493 
p< 0.001), pack size (0.0119, p < 0.0001), doctor specialty (0.0251, p< 0.0286) and 78% 
of all substances. cOnclusiOns: Adherence seems to be negatively influence 
by dosage and younger age groups. Price does not seem to have an influence. 
Perhaps this is because the health care system in Germany reimbursed all oral 
antidiabetics. Metformin has the greater odds for poor adherence aside from the 
substances “glitazones”. Lower adherence rate might be negatively influenced 
by the recent warnings for Glitazones. Gender is a weak predictor for adherence. 
When comparing specialists with general practitioners, the odds of adherence are 
not very different between them (slightly positive towards the specialist group_ 
coeff 0.0251, p< 0.0286). This could be related to the diabetes management plan 
that exists in Germany since 2003, which has several aspects, from support to 
clinicians to training of patients.
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PSyCHOSOCIAL ADjUSTMENT IN DIABETIC PATIENTS wITH AND wITHOUT 
DIABETIC FOOT-ULCERS-A COMPARATIvE STUDy
Prabhu V.A.1, Doddapaneni S.1, Roy R.T.1, Rodrigues G.S.2, Unnikrishnan M.K.1, Sekhar S.M.1
1Manipal College of Pharmaceutical Sciences, Manipal, India, 2Kasturba Medical college and 
hospital, Manipal, India
Objectives: Diabetes is a chronic illness and 15% of diabetic will develop foot 
ulceration at some point of their life. Poor psychosocial states have been identi-
fied as one of the major risk factors for foot ulcers. Good, regular foot care, strict 
metabolic control and better adjustment to illness can prevent or reduce suffering 
effect of the illness. The purpose of this study was to compare the psychosocial 
adjustment to illness between diabetic patients with and without diabetic foot ulcer 
(DFU). MethOds: A case-control study was conducted in a tertiary care teaching 
hospital in South India for a period of one year. Psychosocial Adjustment to Illness 
Scale-Self Report ( PAIS-SR) were used to assess psychosocial adjustment to illness. 
DFU patients (Case) who admitted in the surgery units were included. Diabetic 
patients without foot ulcers (control) were selected from medicine units during the 
same period. Results: The study participants were 84 people with diabetic foot 
ulceration and 84 people without diabetic foot ulceration. There were no significant 
differences between the two groups for gender, age and marital status. A significant 
difference was found between two groups for education level (p= 0.001) occupational 
status (p= 0.045). A significant difference was found between the groups in relation 
to smoking (p= 0.000) and drinking (p= 0.000). There were a significant difference 
seen in PAISSR scores ( lower scores means better adjustments) between the two 
groups (p= 0.000) representing subjects without DFU had better psychosocial adjust-
ment than subjects with DFU. cOnclusiOns: The study concluded that compared 
to patients without DFU, patients with diabetic foot ulcer had poorer metabolic 
control, low educational level, bad social habits. Longer duration of diabetes, longer 
period of hospitalization, low level of disease knowledge and more incidence of 
comorbid conditions.
PDB81
DIMINISHING MARGINAL DISUTILITy OF HyPOGLyCAEMIC EvENTS
Lauridsen J.T.1, Lønborg J.2, Gundgaard J.3, Jensen H.H.2
1Centre of Health Economics Research (COHERE), Department of Business and Economics, 
University of Southern Denmark, Odense, Denmark, 2Incentive Partners, Holte, Denmark, 3Novo 
Nordisk A/S, Søborg, Denmark
Objectives: Hypoglycaemic events are proven to have a negative impact on 
the health-related quality of life (HRQoL) of patients with diabetes. The negative 
impact of hypoglycaemia on HRQoL may be evaluated via disutility scores. The 
aim of this study was to assess the marginal impact of non-severe hypoglycaemic 
events on HRQoL and to investigate the functional form of the disutility of hypo-
glycaemic events. MethOds: Published disutility values from a large-scale, web-
based time-trade-off study (TTO) conducted in UK, USA, Canada, Germany and 
Sweden with 8,286 respondents, were used as a basis for the analysis of non-severe 
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THE DIABETIC PERIPHERAL NEUROPATHIC PAIN IMPACT (DPNPI) MEASURE 
– PSyCHOMETRIC vALIDATION OF A NEw PATIENT REPORTED OUTCOME 
MEASURE
Brod M.1, Ramasamy A.2, Bushnell D.M.3, Blum S.I.2
1The Brod Group, Mill Valley, CA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Health 
Research Associates, Inc., Seattle, WA, USA
Objectives: The Diabetic Peripheral Neuropathic Pain Impact (DPNPI) Measure is a 
patient-reported outcome (PRO) measure developed in accordance with the FDA PRO 
guidance for assessing the impacts of living with Diabetic Peripheral Neuropathic 
Pain (DPNP). A validation study was conducted to evaluate the measurement model 
and properties of the 27-item draft version of the DPNPI. MethOds: A non-inter-
ventional, observational, survey-based validation study enrolled outpatients from 
clinical sites in the United States. Recruitment included diagnosed DPNP patients 
(aged 18-80) both treated and untreated with prescription agents. Subjects com-
pleted a retest survey via mail two weeks after their in-clinic assessment. Analyses 
included assessment of the measurement model (factor analysis), reliability (inter-
nal consistency, test-retest) and validity (content, known-groups) of the DPNPI. IRT 
was utilized to evaluate item fit and function. Results: Out of 124 subjects (56% 
male, mean age 62.8),105 completed the retest survey. Nine items from the draft 
version were deleted due to conceptual issues and/or redundancy. Factor analysis 
confirmed the three hypothesized domains: Physical/Mobility Function; Daily Life; 
Sleep. All domains and the total score were internally consistent (0.91 to 0.96) and 
reproducible (0.84 to 0.91). All a priori convergent validity hypotheses were confirmed 
(p< .001) with moderate-strong association between the total and/or subscale scores 
on the DPNPI measure and other logically related measures (range 0.43 to 0.79). 
Additionally, all a priori hypothesized associations for content and known-group 
validity of domains and total score were confirmed (p< .001) and IRT fit statistics 
were within acceptable range. cOnclusiOns: The final 18-item version of the 
DPNPI can be considered a well-designed, valid and reliable measure of the impact 
of DPNP on patients’ daily lives and physical functioning. This measure can be used 
as an endpoint in clinical trials to assess impacts related to DPNP. Further study is 
needed to understand the responsiveness of the DPNPI.
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HOw HyPOGLyCEMIA IMPACTS QUALITy OF LIFE AND TREATMENT 
SATISFACTION IN TyPE 2 DIABETES MELLITUS PATIENTS ON BASAL-BOLUS 
INSULIN THERAPy?
Ionova T.I.1, Odin V.I.2, Nikitina T.P.1, Kurbatova K.A.1, Shablovskaya N.E.1
1Multinational Center for Quality of Life Research, Saint-Petersburg, Russia, 2Military Medical 
Academy, Saint-Petersburg, Russia
Objectives: Hypoglycemia burden is the most common problem in patients with 
type 2 diabetes mellitus (T2DM) receiving insulin treatment. However, how hypogly-
cemia affects quality of life (QoL) and treatment satisfaction in this patient popula-
tion is less clear. We aimed to study the QoL and treatment satisfaction in T2DM 
patients on basal-bolus insulin therapy with the absence and presence of different 
types of hypoglycemia. MethOds: A total of 500 T2DM patients receiving basal-
bolus insulin therapy for at least 6 months were enrolled in the survey: male/female 
122/378; mean (SD) age 61.8 (8.4) yrs; mean (SD) time from T2DM diagnosis 12.8 (6.9) 
yrs. Mean HbA1c level was 8.3%. Patients were classified as with no, non-severe, 
severe and nocturnal hypoglycemia events during the last month. Patients filled 
out SF-36 and Patient Treatment Satisfaction Questionnaire. The impact of hypo-
glycemia on QoL and treatment satisfaction was examined through multivariate 
regression, adjusting for sociodemographics and disease status. QoL and treatment 
satisfaction scores were analyzed using t-test, ANOVA, Chi-square test. Results: 
After adjustment, QoL and treatment satisfaction decreased with the increase of 
hypoglycemia events (p< 0.05). Patients with hypoglycemia had significantly lower 
QoL scores for 6 out of 8 SF-36 scales as compared to those without hypoglyce-
mia (p< 0.05). Treatment satisfaction was higher in patients without hypoglycemia 
than in those with hypoglycemia (mean score 7.25 vs 8.0; p= 0.01). Patients with 
nocturnal and severe hypoglycemia had significant reduction of role-physical, 
social functioning, vitality and pain as compared to patients with non-severe 
hypoglycemia (p< 0.05). The percentage of patients who were completely dissatis-
fied or poorly satisfied with treatment was higher in the group with severe or/and 
nocturnal hypoglycemia than in those with non-severe hypoglycemia (20% vs 8%; 
p= 0.002). cOnclusiOns: Hypoglycemia has negative impact on QoL and treatment 
satisfaction in T2DM patients. Severe and nocturnal hypoglycemia significantly 
decreases QoL and reduces treatment satisfaction.
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ASSESSING QUALITy OF LIFE IN ADULT GROwTH HORMONE DEFICIENCy: 
FURTHER DEvELOPMENT OF THE QOL-AGHDA
Graham J.E., McKenna S., Wilburn J., Twiss J.
Galen Research Ltd., Manchester, UK
Objectives: The QoL-AGHDA assesses quality of life (QoL) specific to adults with 
Growth Hormone Deficiency (GHD). Questionnaire content was derived from quali-
tative interviews conducted with individuals who had the condition. Since its devel-
opment a number of new language adaptations have been made for Europe (9), 
Eastern Europe (4), and Central and South America (2). New language versions of 
the measure were required for use in two major new multinational clinical trials. 
These were for Greece, Hungary, Israel, Romania, Russia, Slovakia, Ukraine and the 
US (Spanish). MethOds: The dual-panel methodology was employed to translate 
each of these measures. This approach has been used in the adaptation of all needs-
based QoL measures. Two panels are held. The first employs local people who are 
also proficient in English who agree the most appropriate translation for the instruc-
tions and items. The second panel involves lay people who ensure that the level of 
language is appropriate and will be understood by future respondents. Following 
translation, cognitive debriefing interviews were conducted with adults with GHD 
in each country. Results: No major difficulties were experienced in producing 
Objectives: Foot ulceration is a major cause of disability in diabetes. The aim 
of this study was to estimate influence of severity of diabetic foot ulceration on 
HRQoL. MethOds: A survey among DFS (Diabetic Foot Syndrome) patients with 
active foot ulceration treated in ambulatory care was conducted. The PEDIS scale 
was used to classify severity of ulceration. To assess the impact of diabetic ulcera-
tion on HRQoL in DFS patients the EQ-5D-3L questionnaire was used. Utility scores 
were calculated based on Polish EQ-5D value set (Golicki et al.) Results: Between 
April 2012 and May 2013 185 patients were questioned directly. 179 of them (131 
males) completed the EQ-5D questionnaire and had full record on ulceration sever-
ity (the PEDIS scale). The mean age of patients was 61.9±10.6 years. Diabetes type 
2 was diagnosed in 150 (83.8%) patients while diabetes type 1 in 26 (14.5%). Other 
type of diabetes was diagnosed in 2 persons and data on one were missing. Mean 
time from the diagnosis of diabetes was 18.0±11.1 years. 99 (55%) and 69 (39%) 
patients had grade 1 and 2 perfusion, respectively. The mean ulceration size was 
6.2±13.4 cm2. 74 (41.3%), 65 (36.3%) and 40 (22.3%) patients had grade 1, 2 and 3 
depth/tissue loss respectively. 84 (46.9%), 55 (30.7%) and 36 (20.1%) patients had 
grade 1, 2 and 3 infection, respectively. Most patients (89.4%) had loss of protective 
sensation (grade 2 sensation). Mean utility value in overall population was esti-
mated at 0.618±0.320. Very week negative correlation was found between ulcera-
tion size and utility value. Despite some differences in utility value in patients 
with different perfusion grade no strict correlations between severity of ulceration 
and utility values were found. cOnclusiOns: There is little or no strict correla-
tion between severity of ulceration measured with the PEDIS scale and HRQoL 
measured with the EQ-5D.
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DIABETIC PATIENTS IN PRIMARy CARE: SELF-PERCEPTION AND SATISFACTION. 
COMPARATIvE STUDy SPAIN vERSUS EUROPE
Sánchez-Piedra C., García-Pérez S., Sarría S.antamera A
Agencia de Evaluación de Tecnologías Sanitarias (AETS), Madrid, Spain
Objectives: EUprimecare is an European Union project aimed at analyzing the 
costs and quality of the different models of primary care (PC) in Europe. The aim 
of this study is to analyze the management of diabetic patients in PC services in 
Spain compared to other European countries, the satisfaction of these patients 
with PC services and their self-perceived health status. MethOds: We conducted 
a population survey by telephone among PC users in each of the consortium 
countries (Germany, Spain, Estonia, Finland, Hungary, Italy and Lithuania). The 
questionnaire included information on sociodemographic characteristics, health 
status, satisfaction, utilization of PC services, and frequency of some interven-
tions carried out by PC professionals. The survey was conducted to 431-432 PC 
users in each country (Ntotal = 3020). Results: The percentage of diabetic 
patients in Spain was 6.7% (N = 29), lower than the overall average (9.1%). Eighty 
three percent of patients living in Spain were diagnosed by their PC physicians 
compared with 73% of the European average. Eighty six percent of patients in 
Spain said that they were being treated for diabetes (EU average = 84%) and in 
88% of these cases the treatment was prescribed by their PC doctor (EU average 
= 70%). Only 6.9% of patients said their health was poor or very poor, the lowest 
proportion of all countries assessed. The overall satisfaction with PC services 
among diabetic patients was 4.10 points on a scale of 1 to 5. Satisfaction in Spain 
was below the global average for all the items measured. cOnclusiOns: Diabetic 
patients in Spain are more frequently controlled by PC professionals than in 
other European countries. These patients have a better self-perceived health 
status and the results of this study suggest a lower level of dissatisfaction with 
the services provided by PC.
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PATIENTS PREFERENCES REGARDING THE TREATMENT OF TyPE II DIABETES 
MELLITUS: COMPARISON OF BEST-wORST SCALING AND ANALyTIC 
HIERARCHy PROCESS
Mühlbacher A.C., Bethge S., Kaczynski A., Juhnke C.
Hochschule Neubrandenburg, Neubrandenburg, Germany
Objectives: There is limited evidence available regarding patient preferences 
for treatment alternatives, including those treatment characteristics that have 
greatest influence on the perceived value, and how this knowledge can be used 
in health care decision-making. The objective of this study was to identify and 
elicit patient preferences for treatments in Type-II-Diabetes in different patient 
groups. MethOds: In order to elicit patient preferences this study used an 
explorative qualitative approach in combination with quantitative survey tech-
niques. Literature research and semi-structured interviews (N= 15) were the basis 
of quantitative elicitations (N= 388) using Analytic-Hierarchy-Process (AHP) and 
Best-Worst-Scaling (BWS). The study aimed at the determination of the relative 
importance of patient-relevant decision criteria as well as to compare two meth-
ods of measuring preference. In total, seven therapy-related attributes (three lev-
els each) were tested. The sample contained patients receiving oral anti-diabetics 
(OAD) (N= 200) or insulin (N= 188). Results: The qualitative study identified 22 
patient-relevant treatment-characteristics. Out of these the seven most impor-
tant were included in AHP and BWS. The AHP- as well as BWS-surveys resulted in 
a dominance of the attribute “HbA1c-Level”, for both OAD- and Insulin-patients. 
In the OAD-group AHP and BWS independently showed the same ranking of the 
three attributes: “Delay of Insulin-Therapy” (Rank 2), “Occurrence of hypoglyce-
mia” (Rank 3) and “Weight changes” (Rank 4). In the Insulin-group “Occurrence 
of hypoglycemia” was ranked second using AHP and third within BWS. “Weight 
changes” were ranked equally in both methods. However their relevance among 
different patient groups changed. cOnclusiOns: In both patient-groups AHP 
and BWS show similar results. Nonetheless both groups have different horizons 
of experience and differ in the ranking of decision criteria. For the first time the 
methods of AHP and BWS were used to assess patients’ preferences for different 
characteristics of treatment in Type-II-Diabetes, as well as the influence of those 
criteria on the patient benefit.
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Objectives: Acromegaly is a rare, chronic, hormonal disorder caused by excessive 
growth hormone (GH) and insulin-like growth factor 1 (IGF-1) production resulting 
predominantly from pituitary adenoma. The objective was to test endocrinologist 
acceptability of the newly developed SAGIT tool in clinical practice. MethOds: 
SAGIT (Signs and symptoms - Associated comorbidities - GH concentration level 
– IGF-1 – Tumour) is a Clinician-Reported Outcomes (ClinROs) tool developed with 
international experts in acromegaly; it allows patient classification and descrip-
tion in a standardised manner. The tool was pre-tested for acceptability, under-
standing and ease of use with practicing endocrinologists in France, Germany, UK, 
Spain, Italy and Brazil (n= 2 per country) using the PRAgmatic Content and face 
validity Test (PRAC-Test). The endocrinologists completed the SAGIT tool prior to 
and following an intervention (therapeutics or surgery) for three patients each 
(n= 36). Once completed, a one-hour phone interview was conducted with each 
endocrinologist to collect their feedback on the tool. Results: The tool was well 
accepted and deemed concise (n= 11) and informative (n= 10) by the endocrinolo-
gists. Several points were raised that illustrate its usefulness in clinical practice, 
including the removal of the subjectivity when assessing the disease severity, the 
possibility of rapid evaluation of the control/progression of acromegaly or of a 
treatment response, and the possibility for standardisation across countries. Key 
recommendations for improvements were the need to include: 1) instructions to 
facilitate the understanding and the use of the tool; 2) definitions of rules and 
recommendations for patient management; and 3) addition of other signs and 
symptoms and further details about tumour size to better reflect their clinical 
cases. cOnclusiOns: SAGIT is a useful tool for endocrinologists to accurately 
stage and classify acromegaly patients in clinical practice. It is currently being 
piloted in a cross-sectional study. Validation of scoring rules will confirm the utility 
of the tool to improve patient management.
PDB93
A DISCRETE CHOICE ExPERIMENT TO EvALUATE BLOOD GLUCOSE METER 
PREFERENCES IN PEOPLE wITH TyPE 1 AND TyPE 2 DIABETES IN THE UNITED 
KINGDOM
Perard R.1, Orme M.E.2
1Montpellier University, Montpellier, France, 2ICERA Consulting Ltd., Swindon, UK
Objectives: Regular self-monitoring of using a blood glucose meter helps diabetic 
patients to adjust their management strategies proactively, thus avoiding diabetic 
complications which place a burden on health care resources. The aim of this study 
was to elicit diabetic patients’ preferences for different blood glucose meter attrib-
utes. MethOds: A cross-sectional, web-based survey of UK patients with Type 1 and 
type 2 diabetes was conducted in January 2013 and preferences for five key attributes 
associated with blood glucose meters were estimated using a discrete choice experi-
ment (DCE) framework. A foldover design and optimised orthogonal differences 
were considered, but the final choice experiment was a Bayesian d-efficient design. 
Responses were analysed using a conditional logit model in STATA 12.1. Results: 
Out of 447 responses, 406 (90.83%) patients were suitable for inclusion in the DCE 
analysis. Statistically significant differences (p< 0.05) were found between the Type 1 
and Type 2 sub-groups when comparing responder characteristics (years diagnosed, 
age, tests per day, number of comorbidities). Regarding glucose meter attributes, 
Type 1 respondents considered the ‘time to test’ to be the most critical factor and 
were willing to trade a compact device (2.61 units), or convenience (1.37 units) for 
a device that could produce test results in under 30 seconds. Type 2 respondents 
preferred the low maintenance attribute and were most willing to trade a compact 
device (2.72 units) or convenience (1.37 units) for this attribute. cOnclusiOns: This 
is the first DCE to examine the impact of blood glucose meter attributes on blood 
glucose meter choice and adherence. Devices that provide value added features such 
as offline storage of data and additional data analysis will be valued by both Type 1 
and Type 2 patients whereas a compact device is less valued.
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GROwTH MIxTURE MODELING (GMM) TO DETERMINE TREATMENT EFFECTS OF 
CANAGLIFLOzIN vERSUS SITAGLIPTIN ON wEIGHT-RELATED QUALITy OF LIFE 
(wRQOL) IN SUBjECTS wITH TyPE 2 DIABETES MELLITUS (T2DM)
Stull D.E.1, Houghton K.1, Traina S.B.2
1RTI Health Solutions, Didsbury, Manchester, UK, 2Janssen Global Services, LLC, Raritan, NJ, USA
Objectives: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed 
for T2DM. GMM was used to evaluate the effects of canagliflozin versus sitaglip-
tin on WRQoL in subjects with T2DM. MethOds: Data were from 2 multinational, 
randomised, double-blind, Phase 3 trials: 1) subjects inadequately controlled with 
metformin (N= 1,284) receiving canagliflozin 100 or 300 mg, sitagliptin 100 mg, or 
placebo for 26 weeks with a 26-week extension (placebo switched to sitagliptin; 
dual therapy); and 2) subjects inadequately controlled with metformin plus a sul-
phonylurea (N= 755) receiving canagliflozin 300 mg or SITA 100 mg for 52 weeks 
(triple therapy). WRQoL was assessed using the Impact of Weight on Quality of 
Life-Lite (IWQOL-Lite) questionnaire. GMM was used to assess heterogeneity within 
samples to identify data-driven subgroups with differential changes in IWQOL-Lite 
total scores. Results: In both trials, GMM identified 2 subgroups per treatment 
arm: “subgroup 1” (81% and 87% of total trial samples) started with high scores 
(~85 points), while “subgroup 2” (19% and 13% of total trial samples) started with 
low scores (44-53 points). Subgroup 1 scores remained high throughout both tri-
als for all treatments. For the dual-therapy trial, subgroup 2 subjects treated with 
canagliflozin 100 or 300 mg had improvement (2.1 and 5.4 points, respectively), 
while those treated with sitagliptin 100 mg had declining scores (–4.0 points) over 
the course of the trial (P < 0.05). For the triple therapy trial, all subgroup 2 subjects 
improved; improvement was significantly greater with canagliflozin 300 mg versus 
sitagliptin 100 mg (19.6 vs 4.8 points; P< 0.05). In both trials, there were significant 
differences between the subgroups based upon baseline demographic, clinical, and 
patient-reported characteristics. cOnclusiOns: GMM applied to these trial data 
enabled identification of treatment effects that were masked by standard statisti-
cal techniques. Heterogeneity should be considered when analysing WRQoL data.
the translations. Ten to fifteen cognitive debriefing interviews were conducted 
in each country. Interviewees reported the measure to be easy to understand 
and complete and that the content was relevant without missing important 
issues. cOnclusiOns: The standards set by the existing UK version of the QoL-
AGHDA are high with internal consistency and test-retest reliability above 0.90. 
Construct validity was also demonstrated by the measure’s ability to distinguish 
between patients according to self-perceived general health and by correlating 
scores with those on the General Well Being Index (> 0.70). Completed validations 
have obtained a similar psychometric quality. Similar studies are underway to evalu-
ate the formal construct validity and reproducibility of these new language versions.
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USEFULNESS OF THE HyPOGLyCEMIA PERSPECTIvES QUESTIONNAIRE (HPQ) IN 
MANAGEMENT OF PATIENTS wITH TyPE 2 DIABETES
Ionova T.I., Nikitina T.P., Kurbatova K.A., Shablovskaya N.E.
Multinational Center for Quality of Life Research, Saint-Petersburg, Russia
Objectives: Assessment of patient’s perspectives of hypoglycemia burden may 
be of value to provide adequate management of type 2 diabetes (T2D) patients. 
The Hypoglycemia Perspectives Questionnaire (HPQ) is a new multidimensional 
instrument assessing patient’s experience of hypoglycemia. The goal of this study 
was to test the practicability and utility of HPQ-Russian version (HPQ-R) by means 
of its psychometric performance. MethOds: A total of 200 T2D patients receiving 
oral hypoglycemic therapy (59% – metformin; 41% – metformin plus vildagliptin or 
sulphonylureas, SU) were enrolled in the study: male/female 71/129; mean age – 
58.7 yrs; mean disease duration – 4.1 yrs. Mean HbA1c level was 7%. All the patients 
completed HPQ-R at baseline and after 2-3 months of treatment. Patients and physi-
cians were interviewed to test practicability of the instrument. Construct validity, 
reliability and sensitivity of the HPQ-R were assessed to provide its utility. Results: 
Both patients and physicians acknowledged the comprehensiveness of the tool for 
revealing hypoglycemia-related problems; physicians used information from it for 
their decision-making. It was easily understood by, and administered to patients: 
2.8% of missing values. An exploratory factor analysis revealed a strongly dimen-
sional instrument (explained 70% of total pooled variance), with Chronbach alphas 
≥ 0.9 for 6 out of 7 scales. Reproducibility of the tool was shown by comparing 
HPQ-R scores at two time-points for patients with effective HbA1c control receiving 
metformin plus vildagliptin: r= 0.53–0.87 for 5 scales (p< 0.05). HPQ-R scores were 
lower in patients with hypoglycemia events than in patients without hypoglycemia 
as well as in patients with severe hypoglycemia than in patients with non-severe 
hypoglycemia (p< 0.05). Increased occurrence of hypoglycemia events and worsening 
of scores for 4 HPQ scales was shown after switch from monotherapy to therapy 
metformin plus SU (p< 0.05). cOnclusiOns: Thus, the HPQ-R is a practical and use-
ful tool for comprehensive assessment of hypoglycemia experience in T2D patients.
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BENEFITS OF vILDAGLIPTIN PLUS METFORMIN COMBINATION THERAPy IN 
TyPE 2 DIABETES MELLITUS (T2DM) FROM PATIENT’S PERSPECTIvE: QUALITy 
OF LIFE (QOL) AND HyPOGLyCEMIA BURDEN ANALySIS
Ionova T.I.1, Odin V.I.2, Nikitina T.P.1, Kurbatova K.A.1, Shablovskaya N.E.1
1Multinational Center for Quality of Life Research, Saint-Petersburg, Russia, 2Military Medical 
Academy, Saint-Petersburg, Russia
Objectives: Patients’ preferences and evaluation of treatment benefits/risks from 
patient’s perspective are increasingly being considered in decision-making regard-
ing treatment option. The goal of this prospective, open, observational study was to 
evaluate QoL and hypoglycemia burden in T2DM patients treated with vildagliptin 
and metformin as compared to those treated with sulphonylureas (SU) and met-
formin. MethOds: A total of 194 T2DM patients previously on oral monotherapy 
were enrolled in the study. 111 patients were selected by their treating physician to 
receive vildagliptin and metformin (cohort 1 – mean age 58 yrs; male/female 43/68) 
and 83 patients – SU and metformin (cohort 2– mean age 58.6 yrs; male/female 
27/56). Patient-reported outcomes were assessed at base-line and after approxi-
mately 3 mo using the SF-36 and the Hypoglycemia Perspectives Questionnaire 
(HPQ). For comparisons adjustment for age, sex, disease duration, complications 
and comorbidities was made. Results: QoL parameters for all SF-36 scales were 
significantly higher in cohort 1 as compared to cohort 2 after 3 mo of therapy 
(p< 0.01). Switch to vildagliptin plus metformin therapy was accompanied with 
remarkable increase of Integral QoL Index (p< 0.0001) whereas no changes of 
Integral QoL Index were observed after switch to SU plus metformin. After 3 mo 
of combination therapy the number of self-reported symptomatic hypoglycemic 
events was 16% in cohort 1 versus 70% in cohort 2; 12% of pts had severe hypogly-
cemic events in cohort 2. SU plus metformin therapy was accompanied with sig-
nificant hypoglycemia burden – after switching worries, awareness and symptom 
concern increased (p< 0.001). No changes were observed in cohort 1. The changes 
in glycemic control were the same in both cohorts: DHbA1c= 0.8%. cOnclusiOns: 
Benefits of vildagliptin plus metformin combination therapy in terms of improved 
QoL and reduced hypoglycemia burden in T2DM patients were shown. This therapy 
is an effective and preferable treatment in daily medical practice from patient’s 
perspective.
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PRELIMINARy TESTING OF THE SAGIT TOOL: A TOOL TO HELP 
ENDOCRINOLOGISTS IN THEIR MANAGEMENT OF PATIENTS wITH 
ACROMEGALy IN CLINICAL PRACTICE
Giustina A.1, Bevan J.2, Bronstein M.3, Casanueva F.4, Chanson P.5, Petersenn S.6, Truong 
Thanh X.M.7, Massien C.7, Dias Barbosa C.8, Guillemin I.8, Arnould B.8, Melmed S.9
1Piazzale Spedali Civili, Brescia, Italy, 2Aberdeen Royal Infirmary, Aberdeen, UK, 3Hospital das 
Clinicas, Sao Paulo, Brazil, 4Universidad de Santiago de Compostela, Santiago de Compostela, 
Spain, 5Hôpital Bicêtre, Kremlin-Bicêtre, France, 6ENDOC Center for Endocrine Tumors, Hamburg, 
Germany, 7Ipsen Pharma, Boulogne Billancourt Cedex, France, 8Mapi, Lyon, France, 9Cedars Sinai 
Medical Center, Los Angeles, CA, USA
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p-value < 0.001) cOnclusiOns: BMI was negatively associated with HRQoL based 
on the multivariate regression analysis among Korean diabetic patients with HbA1c 
≥ 6.5, after adjusting for confounding factors. This finding alerts diabetic patients to 
the danger of the weight gain as it is related to the lower quality of life.
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HEALTH-RELATED QUALITy OF LIFE IN PATIENTS wITH TyPE 1 DIABETES AND 
IMPAIRED HyPOGLyCAEMIA AwARENESS: THE ROLE OF SENSOR-AUGMENTED 
INSULIN PUMP THERAPy wITH AUTOMATED INSULIN SUSPENSION
McBride M.1, Eggleston A.S.2, Jones T.3, Ly T.3
1Medtronic Australasia Ltd., North Ryde, NSW, Australia, 2*Medtronic International Ltd., North 
Ryde, Australia, 3Princess Margaret Hospital for Children, Perth, WA, Australia
intROductiOn: Compared with multiple daily injections, insulin pump therapy 
(continuous subcutaneous insulin infusion - CSII) improves glucose control in 
patients with type 1 diabetes mellitus (T1DM). When CSII is combined with continu-
ous glucose monitoring (CGM) with automated low glucose insulin suspension (LGS), 
exposure to hypoglycaemia is significantly reduced. Patients with impaired hypogly-
caemia awareness (IHA) are at increased risk of severe hypoglycaemia, so the ben-
efits of this technology should be evident in patient reported health-related quality 
of life (HRQoL). Objectives: To compare HRQoL in T1DM patients with IHA treated 
with CSII alone or CSII with CGM + LGS in this 6 month, prospective, single centre 
RCT. MethOds: T1DM patients with IHA and CSII experience were randomised to 
either CSII alone (control, n= 49) or CSII with CGM + LGS (treatment, n= 46). Patients 
> 12 years were included in this analysis (n= 64, male 50%, age 23.2 ± 11.9 years, 
diabetes duration 13.8 ± 9.5 years, CSII duration 4.9 ± 3.6 years, Hypoglycaemia 
Awareness score 6.2 ± 1.4). Hypoglycaemia Fear survey (HFS) and HRQoL (EQ5D) 
were analysed using ANCOVA least-squares mean change from baseline to 6 months 
post-randomisation. Results: Enrolled patients were not appreciably impaired at 
baseline (EQ5D Utility mean +SD 0.96+0.07), but overall gains in treatment group 
(+0.038) and decrements in control (-0.035) over 6 months produced a significant 
comparative utility gain for the intervention (LS mean difference 0.073, 95% CI: 
0.008-0.139, p= 0.028). Although not statistically significant, supporting trends were 
noted in EQ5D VAS and HFS (Worry subscale). cOnclusiOns: Success of T1DM 
treatment relies upon effective and compliant self-management, so the patient 
perspective is relevant when evaluating treatment options and determining the 
impact on aspects of daily life. This analysis further supports the important role of 
insulin pump therapy plus CGM with automated LGS in the effective management 
of T1DM patients with IHA.
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QUALITy OF LIFE (QOL) AND RESOURCES CONSUMPTION IN INSULIN-
DEPENDENT DIABETIC PATIENTS wITH A1CNOw+ AND CONTOUR USB. COMET 
STUDy
Graefenhain R., Vieta A.
Bayer, Barcelona, Spain
Objectives: To analyse the quality of life in insulin-dependent patients and 
resource consumption due to poor metabolic control after the standarization of 
glycated hemoglobin measure with A1CNOW+ and the glycemia measure with 
CONTOUR USB. MethOds: An observational, prospective, multicentre study in 
patients with diabetes, insulin-dependent, with poor metabolic control has been 
conducted. Distribution of the ESDQOL questionnaire which contains the domains 
satisfaction, impact, social /vocational, concern regarding diabetes and degree of 
perception of QoL at baseline, at 3 and 6 months. The score of the domains and the 
full questionnaire is measured on a scale 0-100; where lower scores indicate a higher 
QoL. Also, Visual Analogic Scale was used to assess the patient’s own perception 
of their quality of life. The resource consumption is analysed for urgent attention 
due to poor metabolic control, the use of resources included are visits to emergency 
department, income, length of hospital stay and additional consultations. Results: 
The evolution of the domains in satisfaction goes from 35.9 at baseline to 31.5 at 
6 months. The impact improves from 27.9 at baseline to 26.0 at 6 months, social/
vocational concern 25, 8 to 22.4 as well as concerns related to diabetes from 37.7 
to 33, 1. Also the degree of perceived improvement in VAS was 2.1 points. All ana-
lysed results were statistically significant. At baseline there were 26 patients (7.9%) 
who required urgent attention due to poor metabolic control in the previous 3 
months versus 9 patients (2.8) who requested urgent attention on data collected at 
6 months. cOnclusiOns: CONTOUR USB device to measure glycemia and A1CNow 
device to measure HbA1C improve the quality of life of patients and reduce the use 
of resources due to poor control.
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IMPACT OF NOCTURNAL AND DAyTIME NON-SEvERE HyPOGLyCAEMIC 
EvENTS ON PEOPLE wITH DIABETES IN SOUTH AFRICA
Snyman J.1, Todorova L.2
1Agility Global Health Solutions, Centurion, South Africa, 2Novo Nordisk International Operations, 
Zurich, Switzerland
Objectives: Two surveys aimed to understand the impact of nocturnal and daytime 
non-severe hypoglycaemic events on health care system utilisation and patient 
quality of life. MethOds: People with diabetes from six countries who had expe-
rienced a non-severe hypoglycaemic event in the 4 weeks prior to the survey were 
eligible (n= 300/survey). In South Africa, surveys were conducted online. Results: 
In the South African nocturnal (N)/daytime (D) hypoglycaemia cohorts (n= 50/sur-
vey), 80% and 80% (N/D) had type 2 diabetes; 30%/24% (N/D) were male; mean age 
45/43 years (N/D); mean diabetes duration 11.1/9.4 years (N/D); 93/93% (N/D) insu-
lin users. 34/40% (N/D) experienced ≥ 1 non-severe hypoglycaemia events/week. 
Most respondents (70/76% [N/D]) were unemployed, which could skew the observed 
impact of hypoglycaemia on productivity. Both surveys revealed that, following 
an event, it took 20 min (median) for acute symptoms to disappear and 60 min 
(median) for the respondent to function at their normal level. After an event, 11/11% 
(N/D) decreased insulin dose, 14/12% (N/D) modified insulin administration time 
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wEIGHT- AND HEALTH-RELATED QUALITy OF LIFE (wRQOL AND HRQOL) wITH 
CANAGLIFLOzIN (CANA) vERSUS SITAGLIPTIN (SITA) IN SUBjECTS wITH TyPE 2 
DIABETES MELLITUS (T2DM) ON BACKGROUND METFORMIN
Traina S.B.1, Ho K.F.2
1Janssen Global Services, LLC, Raritan, NJ, USA, 2STAT-TU Inc., Toronto, ON, Canada
Objectives: CANA is a sodium glucose co-transporter 2 inhibitor developed for 
the treatment of T2DM. In a Phase 3 multi-national, randomised, double-blind, 
placebo- and active-controlled study, CANA improved glycaemia and reduced body 
weight and systolic blood pressure compared with placebo and SITA in subjects 
with T2DM on background metformin. Herein we report post-hoc analyses of the 
HRQoL and WRQoL data. MethOds: WRQoL and HRQoL were measured using the 
Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and the 36-item Short Form 
(SF-36) at baseline, Week 26, and Week 52; with both instruments, higher scores 
indicate better quality of life. Data were analysed for CANA 100 (n= 368) and 300 
mg (n= 367), and SITA 100 mg (n= 366). Least-squares mean changes were evaluated 
using ANCOVA models; gender, anti-hyperglycaemic adjustment, baseline score, 
and treatment as covariates. Results: Improvements from baseline to Weeks 26 
and 52 were detected for WRQoL total, physical function, and self-esteem scores in 
the CANA (both doses) and SITA groups (95% CI excludes zero), and for the other 
WRQoL domains, there was either improvement or no difference. A comparison 
of CANA 300 mg versus SITA at Week 26 suggests a difference in physical function 
(p= 0.0374). Improvements from baseline to Weeks 26 and 52 were also detected 
for HRQoL general health scores in the CANA (both doses) and SITA groups (95% 
CI excludes zero), and for other domains, there was either improvement or no 
difference. Other HRQoL results suggest possible differences in bodily pain (Week 
26, CANA 100 mg vs. SITA, p= 0.0518) and the mental component summary score 
(Week 52, CANA 300 mg vs. SITA, p= 0.0908). cOnclusiOns: CANA and SITA were 
associated with improvements in WRQoL and HRQoL over 1 year in dual therapy. 
Results suggest that CANA is associated with a greater positive impact on patients 
versus SITA.
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ASSESSING THE RELATIONSHIP BETwEEN THE DIABETES HEALTH PROFILE 
AND DIABETES SPECIFIC CLINICAL INDICATORS: CASE FOR TAILORED 
THERAPEUTICS
Mulhern B.1, Meadows K.2, Churchman D.3
1University of Sheffield, Sheffield, UK, 2DHP Research & Consultancy Ltd., Banbury, UK, 
3University of Oxford, Oxford, UK
Objectives: With the increasing use of patient reported outcome measures in 
diabetes, it is important to understand which dimensions are most relevant to 
clinical indicators, and are the most predictive when assessing clinical change over 
time. This is important as the PROM scores can help inform the development of 
tailored therapeutics by highlighting the psychosocial functioning and quality of life 
impacts of different treatments. The aim of this study is to assess the relationship 
between the Diabetes Health Profile (DHP-18) and diabetes specific clinical vari-
ables to investigate how the measure can be used in the assessment of the impacts 
of different related complications and treatments. MethOds: The relationship 
between the DHP-18 and a number of variables, including diabetes specific and co-
morbid health complications and length of time diagnosed were assessed. This was 
done cross-sectionally and longitudinally using a large dataset of Type 1 and Type 
2 people with diabetes (n= 1,802) collected in one United Kingdom health authority 
area. The analysis was carried out using Ordinary Least Squares and Logit regres-
sion. Results: The Psychological distress domain is significantly associated with 
eye and foot related complications, and a number of co-morbid conditions including 
depression. The Barriers to activity domain is significantly associated with eye and 
foot related complications, duration of diabetes and a range of co-morbid conditions. 
The Disinhibited eating domain is related to duration of diabetes and co morbid 
conditions such as bone and lung disease. The number of associated problems was 
also a key predictive variable. cOnclusiOns: The findings indicate that there is 
relationship between psychosocial functioning as measured by the DHP-18 and a 
range of clinical indicators. Tailored therapeutics can be used to change or reduce 
clinical concerns while also impacting on a patient’s psychosocial functioning and 
quality of life, and the DHP can be used to efficiently measure this.
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A RELATIONSHIP BETwEEN BODy MASS INDEx AND HEALTH-RELATED 
QUALITy OF LIFE AMONG KOREANS wITH DIABETES: THE KOREA NATIONAL 
HEALTH AND NUTRITION ExAMINATION SURvEy
Lee J.Y., Lee E.K.
Sungkyunkwan University, Suwon-si, Gyeonggi-do, South Korea
Objectives: Little is known about the impact of body mass index (BMI) on health-
related quality of life (HRQoL) for diabetics in the Korean population. The aim of 
this study was to estimate the association between BMI and HRQoL of type 2 dia-
betic patients in Korea. MethOds: This study is a cross-sectional analysis of adults 
who participated in 4th (2007-2009) and 5th (2010-2011) Korean National Health and 
Nutritional Examination Survey(total, 42,347 participants). HRQoL was measured 
by EuroQoL five-dimension (EQ-5D) and its association with BMI was investigated 
in Korean diabetic patients, especially those who did not have adequate control of 
blood glucose (HbA1c ≥ 6.5). Multivariate linear regression was performed at p-value 
of 0.05 with the use of SAS software, version 9.2. Results: Out of 42,347 partici-
pants, 9.04% had diagnosed of diabetes. Among 2,726 diabetic patients in Korea, 
we assessed the association in 1,838 patients (median age 63) whose diabetes was 
not adequately controlled. We found that BMI was significantly negative associated 
with HRQoL(-0.0038, p-value < 0.001), after adjusting for age, sex, education, income, 
marital status, smoking status, alcohol, HbA1c, insulin treatment status, oral anti-
diabetic drug therapy, history of hypertension/high cholesterol/high triglyceride 
prevalence, stress level, and depression for more than two weeks. EQ-5D index 
decreased with rising BMI in Korean diabetic patients with HbA1c ≥ 6.5(-0.0038, 
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Objectives: Since 2008, the Caisse Nationale d’Assurance Maladie des Travailleurs 
Salariéshas set up a diabetic patient support programme in ten pilot depart-
ments in France. In addition to written advice, programme members also have 
access to telephone support from health education nurses. In 2010, the sophia 
programme was extended to another nine departments and, at the beginning of 
2013, it was generalized to all French departments. The present study evaluated 
the health economics impact of the programme after a follow-up of 3 years. This 
analysis follows a preliminary assessment that demonstrated positive results 
after 1 year. MethOds: The variation of various health care use indicators as 
well as outpatient and inpatient costs was compared between three cohorts: 
members of pilot departments, non-members, and a control group of diabetic 
patients living in departments in which sophia was not available. Results are 
adjusted for between-group differences observed at the beginning of the pro-
gramme. Results: Adjusted analysis showed that, after matching for all other 
characteristics, compliance with recommended examinations improved to a much 
greater extent among programme members than among control subjects and 
non-members. Although all health care costs continued to increase in each cohort, 
outpatient and inpatient expenditure was € 226 lower for programme members 
than for controls for the period 2009-2011: -€ 54 for outpatient care and -€ 172 
for inpatient care. Although the outpatient expenditure of programme members 
was higher (+€ 40) for outpatient visits and medical procedures, their paramedical 
expenditure was lower (-€ 89). Hospitalization rates for diabetes were significantly 
lower among members than among controls. cOnclusiOns: These results con-
firm the significant impact of the sophia programme on compliance with clinical 
practice guidelines in diabetology, hospitalization rates, and the 3-year growth of 
outpatient and inpatient costs. An assessment of the impact of the sophia pro-
gramme on clinical parameters will be conducted in the near future.
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CONSISTENCy OF CURRENT TyPE 2 DIABETES (T2DM) TREATMENT PATTERNS 
IN GENERAL PRACTICE vERSUS THE 2013 FRENCH HAS T2DM GUIDELINES: A 
TRANSvERSAL STUDy BASED ON THE FRENCH IMS LIFELINKTM PROSPECTIvE 
DIABETES COHORT
Larger E.1, Ansolabehere X.2, Le Jeunne P.2, Grandfils N.2, Briand Y.3, Gibelin B.3
1Hotel Dieu Paris, PARIS, France, 2IMS Health, PARIS LA DEFENSE, France, 3Boehringer Ingelheim 
France, PARIS, France
Objectives: To evaluate the consistency of T2DM management by French GPs in 
2012 versus 2013 HAS guidelines that recommend modulating glycaemic objec-
tives depending on patient’s profile. To assess current treatment need for T2DM 
patients. MethOds: A transversal study, based on the IMS LifeLinkTM prospective 
Diabetes Cohort linked to Electronic Medical Records database (Disease Analyzer) 
was used to investigate patients’ profiles (age, disease history and complications, 
renal impairment, cardiovascular events, co-morbidities), HbA1c, hypoglycaemic 
risk, self monitoring of blood glucose (SMBG), and BMI evolution, linked to the cur-
rent treatment. Results: A total of 6680 T2DM patients (56% men) were included 
in the 2012 study cohort. The mean age was 66.6 years (25% of patients above 75 
years); 19% had moderate to severe renal impairment and 56% had cardiovascular 
history. The new HAS guidelines split patients into several categories with associ-
ated HbA1c objectives varying from 6.5% to 9% based on age, frailty, diabetes history, 
and co-morbidities. 4%, 35%, 43%, and 18% of diabetic patients were eligible for the 
6.5%, 7%, 8%, and 9% HbA1c objectives respectively. It appears that 55% of the dia-
betic population were at risk of hypoglycaemia, age and long diabetes history being 
the major risk factors. Given the modulation of glycaemic objectives more patients 
reached the new HbA1c objectives (74% of patients) vs. previous guidelines (about 
55%). In this representative cohort, SU were prescribed with no dosage adjustment 
to all patients and even more frequently to patients at risk of hypoglycaemia (60.6%) 
while DDP4i were prescribed to “healthy patients” mostly not at risk of hypoglycae-
mia (51.5%). cOnclusiOns: A minority of T2DM patients (39%) are eligible for an 
HbA1c objective of 7% or below, highlighting their frailty. This survey also shows that 
more patients are reaching their HbA1c target. However many of them are receiving 
treatments they should not due to high risk of hypoglycaemia.
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THE IMPACT OF MEMORy PROBLEMS ON DIABETES TREATMENT IN GERMANy
Brod M.1, Kongso J.2, Bushnell D.M.3
1The Brod Group, Mill Valley, CA, USA, 2Novo Nordisk A/S, DK-2860 Soborg, Denmark, 3Health 
Research Associates, Inc., Seattle, WA, USA
Objectives: The impact of memory problems (MPs) on patient functioning, well-
being and diabetes management is not well understood. This study examines 
these impacts in Germany and compares findings to data from US, UK, Canada 
and China. MethOds: A 5 country web-based survey was conducted. MPs were 
defined as: unintentionally forgetting to take insulin (UF), questioning if insulin 
had been taken (QT), or questioning amount of dose (QD). Results: A total of 350 
German respondents (60.0% Type 1) completed the survey, 61.1% male, mean age of 
39.5 (±13.3) and mean age of diabetes onset 30.2 (±12.6). The prevalence of MPs in the 
past month was: 74.0% UF, 82.0% QT and 68.3% QD. MPs occurred most frequently 
when waking in the morning or when relaxing. Between 27.9% (UF) – 48.3% (QD) of 
respondents skipped their insulin dose and waited for next scheduled dose when 
experiencing a MP. Patients experiencing MPs required between 2.0 (QT)–8.7 (UF) 
hours, on average, to return to normal blood glucose range, conducted between 1.2 
(QT) –4.4 (UF) extra BG monitoring tests, reported a moderate negative impact on 
their physical and emotional functioning, work absenteeism or reduced ability to 
function optimally when at work and between 3.6% (QT) and 13.8% (QD) visited/
contacted their health care provider due to MPs. Compared to the total sample 
(N= 1404), German respondents were more likely to report that their diabetes was 
very well/well controlled and that they were very/extremely confident in knowing 
what to do when they had an MP compared to respondents and were less likely 
than patients in other countries to have contact with a physician or other health 
care professional following a MP. cOnclusiOns: These findings suggest that MPs 
and 14/12% (N/D) contacted a health care professional. In the week after an event, 
respondents added an average of 2.8/3.6 (N/D) blood glucose tests to an average of 
18.8/17.4 (N/D) tests in a normal week. Nocturnal events had a high impact on sleep 
quality (46% of respondents) and social life (24%), and 84% of respondents felt tired 
and/or fatigued the next day. In the daytime survey, about 26% reported the event 
highly impacted daily activities (outside of work). Also, 40/18% (N/D) of respondents 
indicated that the event had a high impact on their fear of hypoglycaemia. The 
majority ascribed hypoglycaemia to stress (50%/58% [N/D]) or irregular/insufficient 
food intake (50%/40% [N/D]). cOnclusiOns: Both nocturnal and daytime hypogly-
caemic events had an impact on patients’ use of health care system, quality of life 
and daily productivity.
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CLINICAL SIGNIFICANCE OF CHANGE IN THE QUALITy OF LIFE-ASSESSMENT 
OF GROwTH HORMONE DEFICIENCy IN ADULTS (QOL-AGHDA) SCORE IN ADULT 
GROwTH HORMONE DEFICIENCy (AGHD)
Wiid Z.1, Pleil A.2, Ho K.3, Holdaway I.4, Cutfield W.5, Bullinger M.6, Koltowska-Häggström M.7, 
Mardekian J.8
1Pfizer Australia, West Ryde, Australia, 2Pfizer, Inc., San Diego, CA, USA, 3Centres for Health 
Research, Brisbane, Australia, 4Greenlane and Auckland Hospitals, Auckland, New Zealand, 
5Director Liggins Institute, Auckland, New Zealand, 6Hamburg University, Hamburg, Germany, 
7Pfizer Inc., Sollentuna, Sweden, 8Pfizer, Inc., New York, NY, USA
Objectives: To investigate the clinical significance of change in QoL-AGHDA 
score after 1 year of growth hormone (GH) replacement. MethOds: Observational 
data were obtained from KIMS (Pfizer International Metabolic Database). Minimal 
important differences (MID) for the QoL-AGHDA score and its five domains (mem-
ory and concentration, tenseness, tiredness, self-confidence, and social isolation) 
were calculated using an anchor-based approach with a rating of patient-perceived 
treatment benefit and patient-reported change in need for assistance. Perception 
of treatment benefit was measured using the KIMS Patient Life Situation Form 
(PLSF), a 5-point ordinal assessment of change (much improved, a little improved, 
no change, a little worse, much worse). The effect of baseline (BL) scores on MID 
was analysed using the QoL-AGHDA thresholds included in the New Zealand (≥ 16) 
and England (≥ 11) reimbursement criteria. Results: Data from 1404 patients 
(52% female, 96% Caucasian, mean age [SD] of 45 [14] years) were included in the 
analysis. Mean GH dose [SD]was 0.20 [0.14] mg/day at BL and 0.32 [0.16] mg/day 
during Year 1. The Spearman correlation between change in QoL-AGHDA score 
and perception of treatment benefit was moderately positive (0.45; p < 0.01). The 
correlation was stronger for females and for patients with more impaired (higher) 
BL QoL-AGHDA scores. Using the anchor-based approach with patient-perceived 
treatment benefit, the MID for the QoL-AGHDA score was -4.61 at Year 1. Self-
confidence was most sensitive and tenseness least sensitive of the domains in 
predicting patient-perceived treatment benefit. Patients requiring assistance at 
BL and not at Year 1 experienced the largest mean improvement in QoL-AGHDA 
score. cOnclusiOns: Several national reimbursement authorities currently 
include the QoL-AGHDA score in eligibility criteria for access to reimbursed GH 
replacement. This is the first study to calculate the MID for the QoL-AGHDA score. 
Findings indicate that change in QoL-AGHDA score is positively correlated with 
patient-perceived treatment benefit.
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THE IMPACT OF DAyTIME AND NOCTURNAL NON-SEvERE HyPOGLyCAEMIC 
EvENTS ON PEOPLE wITH DIABETES IN BRAzIL
Fraige Filho F.1, Todorova L.2
1ABC Faculdade de Medicina SP Brasil, Sao Paulo, Brazil, 2Novo Nordisk International Operations, 
Zurich, Switzerland
Objectives: This study examined the effects of nocturnal and daytime non-severe 
hypoglycaemic events on utilisation of health care services and patient quality of 
life in Brazil. MethOds: People with diabetes from six different countries who 
had experienced a non-severe hypoglycaemic event in the past 4 weeks were 
asked to take part in a nocturnal and/or daytime hypoglycaemia survey. In the 
Brazilian subgroup, 86 people responded (50 respondents per survey). The sur-
veys were conducted either face to face or online; hypoglycaemic events were 
self-reported. Results: In the Brazilian cohort (nocturnal [N]/daytime [D] survey, 
respectively), 80% (N)/76% (D) had type 2 diabetes, 46%/38% (N/D) were male, mean 
age was 41(N)/40(D) years and mean weight was 82.4 kg(N)/81.8 kg (D). Participants 
received treatment with insulin (53%/70% [N/D]), oral medication (61%/60% [N/D]), 
GLP-1 (0%/8% [N/D]) and/or diet and exercise (32%/45% [N/D]). Approximately a 
quarter of respondents (26%/22% [N/D]) reported that they generally experienced 
a hypoglycaemic episode at least once a week. After the non-severe nocturnal (N)/
daytime (D) hypoglycaemic event, 29% and 53% (N/D) decreased their insulin dose 
and 38% and 50%, respectively, contacted a health care professional. Participants 
used on average 13.0 or 11.5 (N/D) extra blood glucose tests the following week and 
56%/32% (N/D) of the surveyed reported a high level of fear of a hypoglycaemic event. 
Among the 44/43 (N/D) respondents who worked for pay, 48%/35% (N/D) went to 
work late or left early; 23%/9% (N/D) missed ≥ 1 full days due to the non-severe event 
and 55%/26% (N/D) said that the event highly impacted upon their productivity at 
work. cOnclusiOns: In Brazil, nocturnal and daytime non-severe hypoglycaemic 
events severely impact upon patients’ quality of life and work productivity, with half 
of patients surveyed decreasing their insulin dose and/or contacting their health 
care provider after a non-severe event.
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HEALTH ECONOMICS ASSESSMENT OF THE CNAMTS SOPHIA DIABETIC 
PATIENT SUPPORT PROGRAMME: RESULTS OF THE FIRST 4 yEARS
Aguadé A.S., Martin C., Saugnac C., Gastaldi-Menager C., Prieur J.P., Gomez E.
CNAMTS (National Health Insurance), Paris Cedex 20, France
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analysis of phase III registration trials (full-publication if available, and Clinical 
Trial report/study Synopsis) and EPARs of commonly used short-acting (Insulin 
Aspart and Insulin Glulisine) and pre-mix (Biphasic Insulin Aspart) insulin ana-
logues. Results: Therapy adjustments based on SMBG data were documented 
in 5/24 Insulin Aspart-, 3/18 Insulin Glulisine- and 4/15 Biphasic Insulin Aspart 
phase III registration trials. The EPARs of all three insulin analogues recommend 
the use of SMBG to adjust the insulin doses, repeatedly and throughout all sections 
in EPAR. cOnclusiOns: Overall, in 12/57 phase III registration trials the dose of 
insulin analogues was regularly adjusted based on SMBG data, and the EPARs of all 
insulin analogues explicitly recommend the use of SMBG to adjust the insulin doses. 
Therefore, the demonstrated safety and efficacy of these insulin analogues are the 
result of a complex intervention including insulin analogues, their dose adjust-
ments based on SMBG data as well as training rather than the insulin analogues 
alone. This is not consequently reflected in reimbursement schemes, in particular 
in emerging countries. Full study reports were not available for further analysis. 
These potentially would have provided deeper insights on how SMBG was used in 
the remaining 45/57 trials.
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DIFFERENT INjECTION FREQUENCIES OF BASAL INSULINS IN TyPE 2 DIABETES 
PATIENTS UNDER REAL-LIFE CONDITIONS: A RETROSPECTIvE DATABASE 
ANALySIS
Kostev K.1, Dippel F.W.2, Rathmann W.3
1IMS Health, Frankfurt am Main, Germany, 2Sanofi, Berlin, Germany, 3German Diabetes Center, 
Duesseldorf, Germany
Objectives: Little is known about routine use of basal insulins (Glargine, Detemir, 
NPH) in primary care patients with type 2 diabetes. The aim was to compare 
injection frequencies of basal insulins in type 2 diabetes (T2D) in primary care 
practices, both for basal-supported oral (BOT) and basal-bolus (ICT) treatment regi-
mens. MethOds: Primary care data from 4,503 Glargine (BOT/ICT: 2,247/1,964), 
1,373 Detemir (490/800), and 4,072 NPH-insulin (1,331/2,425) users were retrospec-
tively analysed (05/2009-04/2012). The Disease Analyzer database (IMS HEALTH) 
assembles drug prescriptions, diagnoses, basic medical and demographic data 
obtained from the practice computer system of general practitioners and special-
ists throughout Germany. The Charlson Comorbidity Index was used as generic 
marker of comorbidity. Logistic regression (> 1 daily injection) and propensitiy scores 
were used to adjust for various confounders (age, sex, type of physician, dosage, 
BMI, HbA1c). Results: Overall, more than one daily injections were observed in 
7.5% of Glargine users (BOT: 6.2%, ICT: 9.0%), which was lower than for Detemir 
(overall: 25.4%; BOT: 22.0%, ICT: 27.4%) and NPH-insulin (25.4%; BOT: 23.9%, ICT: 
27.2%) (all p< 0.001). The adjusted odds of having more than one injection was lower 
for Glargine compared to Detemir (OR; 95% CI: 0.26; 0.22-0.32) and NPH-insulin 
(0.20; 0.17-0.23). Similar results were found for BOT (Glargine vs. Detemir: 0.23; 
0.17-0.32; Glargine vs. NPH-insulin: 0.16; 0.13-0.21) and for ICT (Glargine vs. Detemir: 
0.27; 0.21-0.35; Glargine vs. NPH-insulin: 0.22; 0.18-0.27). Finally, after matching the 
groups for the propensity score, the odds for more than one daily injection was also 
significantly reduced in the Glargine group both compared to Detemir (OR; 95%CI: 
0.30; 0.24-0.37) and NPH insulin (0.25; 0.22-0.29). cOnclusiOns: Glargine is associ-
ated with significant lower injection frequencies than other basal insulins. These 
findings might impact treatment satisfaction and as a consequence quality of life, 
persistence and economic aspects of diabetes treatment.
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ORAL HyPOGLyCAEMIC MEDICINE (OHM) INITIATION IN NEwLy TREATED 
TyPE 2 DIABETES MELLITUS (T2DM) IN IRELAND: AN ANALySIS OF TREATMENT 
INTENSIFICATION AND SwITCHING PATTERNS
Grimes R.1, Tilson L.2, Usher C.2, Henman M.1, Bennett K.3
1Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland, 
3Trinity Centre for Health Sciences, Dublin, Ireland
Objectives: To examine treatment intensification and switching patterns of 
individuals with T2DM initiating OHM. The results are compared to international 
guidelines issued in 2009. MethOds: Data were analysed using a population-based 
pharmacy claims database from January 2008 to November 2012. Incident users of 
OHM were identified for 2008-2009 as not having received OHM in the previous 12 
months. Patients dispensed insulin, > one OHM, or < 16 years were excluded from 
the study. Patients were followed until Nov-2012. Treatment intensification was 
defined as receiving an additional one, or two hypoglycaemic medicines (double or 
triple-therapy respectively). Treatment switching was defined as OHM monotherapy 
discontinuation with initiation on alternative monotherapy. Results: A total of 
24,869 patients were included in the study. Most were initiated on metformin (76.4%) 
or sulphonylureas (21.6%). Treatment intensification: 25.8% of patients initiated 
on metformin progressed to double-therapy. Sulphonylureas (61.5%), DPP-4 inhibi-
tors (23.9%) and GLP-1 agonists (6.2%) were the most frequently prescribed add-on 
treatment (median time to add-on OHM= 424days). Of those initiated on sulpho-
nylureas 32.4% progressed to double-therapy; metformin (78.4%), DPP-4 inhibitors 
(9.3%) and long-acting insulin (5%) were the most frequently prescribed (median 
time to add-on= 295days). 14.3% of patients on double-therapy progressed to triple-
therapy (median time to add-on= 434days). 26.6% of patients did not receive the 
recommended double-therapy and 64.3% received agents in their triple-therapy 
that were not recommended. Treatment Switching: Overall 7.1% switched medi-
cation. The most frequent switches were metformin to sulphonylureas (46.5%, 
median time to switch= 226days), sulphonylureas to metformin (22.5%, median 
time to switch= 330days) and metformin to DPP-4 inhibitors (6.9%, median time 
to switch= 577days). Initial OHM was significantly associated with time to switch 
(p< .0001). cOnclusiOns: Initial drug treatment followed guidelines. However, 
evidence-based practice was not closely followed for treatment intensification 
suggesting prescribers may be unaware of treatment guidelines. This data may be 
useful for assessing the potential place in therapy, and cost-effectiveness of new 
hypoglycaemic medicines.
carry financial burden, impact patients’ daily functioning and well-being and may 
be serious obstacles to optimal diabetes control. This burden may be some lower in 
Germany than other countries.
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TREATMENT PATTERNS AND HEALTH CARE RESOURCE UTILIzATION OF 
PATIENTS wITH ACROMEGALy IN THE UNITED STATES
Chuang C.C.1, Dinet J.2, Bhurke S.1, Chen S.Y.1, Brulais S.2, Gabriel S.2
1Evidera, Lexington, MA, USA, 2IPSEN Pharma, Boulogne Billancourt, France
Objectives: To examine patient characteristics, treatment patterns, and health 
care resource utilization of patients with acromegaly in the US. MethOds: Using 
a large US claims database, adult individuals with commercial insurance newly 
diagnosed with acromegaly (ICD-9-CM: 253.0) between 07/01/2007 and 12/31/2010 
were identified (the first observed diagnosis was the index date). Patients were 
required to have 6-month pre-index and 12-month post-index continuous enroll-
ment. Descriptive analysis was performed to describe demographic and clini-
cal characteristics, treatment patterns of acromegaly, and health care resource 
utilization during the post-index period. Similar analysis was conducted for 
Medicare-eligible patients with supplemental private insurance. Results: This 
study included 930 commercially-insured patients (mean age: 47.2 years; 52.0% 
female) and 104 Medicare-eligible patients (mean age: 72.8 years; 36.5% female) 
with acromegaly. For the commercial population, of the comorbidities evaluated, 
hypertension (38.2%), diabetes (25.9%), and anthropathy/arthralgia/synovitis 
(23.7%) had the highest prevalence. More than half of the patients (57.3%) received 
no treatment; 21.7% received tumor resection surgery and 21.0% received medi-
cal therapy as the first-line treatment. During the 12-month post-index period, 
one-third had inpatient hospitalization and 23.2% had emergency room visit; 
the mean physician office visit was 17.1. For the Medicare population, hyperten-
sion (67.3%), diabetes (36.5%), and anthropathy/arthralgia/synovitis (29.8%) were 
most prevalent comorbidities. About two-thirds (63.5%) received no treatment; 
8.7% received tumor resection surgery and 27.9% received medical therapy 
as the first-line treatment. More than one-third (34.6%) had inpatient hospitaliza-
tion and 26.9% had emergency room visit during the 12-month post-index period; 
the mean physician office visit was 21.1. cOnclusiOns: Our findings suggest 
high unmet needs in the population with more than half of patients with acro-
megaly being untreated. Efforts should be made to understand this untreated 
population to provide better care. Future research should investigate different 
treatment options as well as their impact on health care costs and health care 
resource utilization.
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UK QUALITy OUTCOMES FRAMEwORK (QOF) THRESHOLDS AND ELEvATED 
HBA1C LEvELS AMONG PATIENTS wITH TyPE II DIABETES - A LONGITUDINAL 
STUDy USING THE CLINICAL PRACTICE RESEARCH DATALINK (CPRD)
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Objectives: HbA1c concentrations predict the risk of complications in patients 
with type 2 diabetes mellitus (T2DM). This study assessed temporal trends in ele-
vated HbA1c levels in the UK primary care setting. MethOds: T2DM was identi-
fied by medical diagnosis, prescribing, elevated blood glucose and/or prescribing of 
monitoring devices. Patients had ≥ 12 months of CPRD history, with data available 
for the entire year of observation. T2DM patients prescribed insulin were excluded. 
Mean HbA1c levels and proportion of patients with elevated HbA1c were assessed 
across six years (01/04/2006–31/03/2012). Elevated HbA1c was defined according to 
the UK Quality and Outcomes Framework (QOF) threshold: > 7.5% for all years except 
2009/2010 (> 7.0%). Estimates were stratified by age-band, gender, T2DM-status and 
treatment categories. Results: Mean HbA1c levels among 176,428 patients were 
relatively stable and below threshold across the study period (2006/2007: 7.05%; 
2011/2012: 7.16%), with the exception of 2009/2010 (7.09%). Nonetheless, > 20% of 
patients had a record of elevated HbA1c in each year (36.7% in 2009/2010). Elevations 
were more common among males than females (20%-25.0% vs. 18%-20%) and among 
patients 40-59 years (27.2%-33.7 %) vs. those ≥ 60 years (15.9%-23.3%). Although 
elevations were similar among prevalent (20%-23%) and incident-T2DM (22%-23%), 
prevalent-T2DM showed an increasing trend in the proportions with an elevation 
over time, whilst incident-T2DM showed a decreasing trend. The proportion with 
elevated HbA1c varied by treatment: diet and exercise 4.8%-6.1%; monotherapy 24%; 
dual therapy 32.7%-38.0%, and; triple therapy 42%-50%. Over 80% of patients with 
elevated HbA1c were overweight or obese, > 20% had a 10-year Framingham Risk 
score > 20% (patients without existing CVD) and 17%-21% of patients had history of 
chronic renal failure. cOnclusiOns: Although mean HbA1c concentrations were 
below target (apart from 2009/2010), elevated HbA1c was present in > 20% patients 
across all years. Further efforts are needed to help patients to achieve adequate 
glycaemic control.
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SELF-MONITORING OF BLOOD GLUCOSE wITH INSULIN ANALOGUES: NICE TO 
HAvE OR NEED TO HAvE? ANALySIS OF PHASE III REGISTRATION TRIALS AND 
EUROPEAN PUBLIC ASSESSMENT REPORTS OF INSULIN ANALOGUES
Caruso A., Hilsdorf H.L., Mast O.
Roche Diagnostics GmbH, Mannheim, Germany
Objectives: Registration trials’ purpose is to show safety and efficacy of insulin 
therapy. They are the basis of subsequent insulin reimbursement decisions. Insulin 
dosing is typically individualized: a safe and efficacious insulin therapy requires 
upfront dose finding and regular dose adjustments. These adjustments are based 
on data from Self-Monitoring of Blood Glucose (SMBG). However, some countries 
reimburse insulin analogues, but not blood glucose test strips. This analysis inves-
tigates the use of SMBG in Phase III registration trials of selected insulin analogues 
and if consequently the European Public Assessment Reports (EPARs) recommend 
the use of SMBG as part of the insulin therapy. MethOds: Systematic search and 
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2,134,870 (per patient mean 55) primary care contacts; 1,200,142 (31) laboratory 
tests and 24,656 (0.63) hospitalizations. Mean annual resource use almost doubled 
the first year after diagnosis and remained on a higher level than before diagnosis 
throughout the study period. This pattern was seen in primary care as well as for 
hospitalizations. Furthermore, obesity at baseline appeared to be correlated with a 
higher level of resource use. The relationship between resource use, baseline weight 
and weight changes appears complex. cOnclusiOns: Data from 183,614 patient 
years of follow-up show that T2DM diagnosis is associated with increased long-term 
resource use. Quantifying resource utilization using data from clinical practice set-
ting may provide an important input to diabetes cost-effectiveness modeling and 
resource allocation decisions.
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THE IMPACT OF THE POLISH HUMAN INSULIN (GENSULIN) ON PUBLIC PAyER’S 
ExPENDITURE IN 2001-2013
Orlewski J.1, Orlewski P.M.2, Orlewska E.3
1Medical University of Warsaw, Warsaw, Poland, 2Warsaw University of Technology, Warsaw, 
Poland, 3Centre for Pharmacoeconomics, Warsaw, Poland
Objectives: Reference pricing (RP) – an approach where a payer sets payment 
for a group of similar drugs using benchmark based on a lower-priced option is a 
strategy commonly used to control drug expenditures. The aim of this study was to 
determine the impact of Polish human insulin (Gensulin, BIOTON) on public payer’s 
expenditure in 2001-2013. MethOds: We analyse published data on insulin con-
sumption and changes in reimbursement limits between October 2001 and February 
2013. An Excel-based model was developed to compare scenario with (1) and without 
(2) Gensulin on the Polish pharmaceutical market. The reimbursement limit for 
insulin in (1) was determined by Gensulin (the lowest priced product within a group 
of human insulins), in (2) was fixed at 151 PLN/1500 i.u (A) or decreased to 134.99 
from April 2002 (B). In the calculation all products containing 1500 i.u.insulin/pack 
or only pen were considered. Cost was adjusted for inflation and reported in PLN at 
2013 prices (1 Euro= 4.2 PLN). Results were presented as total and incremental cost 
in subsequent years and over the entire period. Results: Between 2002-2012 the 
consumption of human insulins in Poland incresead from 3.8 mln to 5.6 mln pack a 
1500 i.u. The reimbursement limit in PLN/pack decreased gradually from 151 in 2001 
to 98.57 in 2013 (scenario 1). Overall for the 12.5-year period the total public payer 
savings resulting from setting the reimbursement limit by Gensulin were 3 157 114 
474 and 2 039 163 591 PLN in A and B, respectively. If only pens were considered RP 
policy led to a saving of 2 719 053 565 PLN in (A) and 1 777 711 973 PLN in (B) over 
12.5 years. cOnclusiOns: The launch of Gensulin and RP resulted in considerable 
reduction of public resources spent on human insulin in Poland
PDB117
wHO KNOwS BETTER? A KNOwLEDGE, ATTITUDE AND PRACTICE SURvEy 
OF OSTEOPOROSIS PRESCREENING TOOLS AMONG PHARMACISTS AND 
PHySICIANS
Khan Y., Sharriff A., Khan A.H.
Universiti Sains Malaysia, Minden, Malaysia
Objectives: Although osteoporosis is preventable, still its prevalence is escalating 
to endemic proportions. The reason for this massive incidence of osteoporosis is lack 
of identification of high risk individuals. In order to overcome this scenario and to 
cut cost associated with bone scanning; various prescreening tools were developed 
in 1990’s. The purpose of such tools is to select high risk individuals for bone densi-
tometry. The objective of current study is to analyze knowledge, attitude and prac-
tices of both physicians and pharmacist towards prescreening tool and to evaluate 
possible reasons for non-implementation of existing prescreening tools. MethOds: 
Using convenience sampling method, an explorative cross sectional survey was con-
ducted in Penang, Malaysia. A pre-validated self- administered questionnaire was 
used to carry out the study among community pharmacists (n= 83) and physicians 
(n= 87). Results: There was a statistically significant difference between mean rank 
score of pharmacist (137.55) and physicians (78.05). Although, pharmacists scored 
higher than physicians in all three domains of questionnaire but still both showed poor 
knowledge and practices regarding prescreening tools. Pharmacists considered low 
awareness regarding availability of such tools as the main factor that pose hindrance 
in implementation of such tools while physician suggested lack of time ,on their part, 
as the main reason. cOnclusiOns: Participants showed general lack of awareness 
regarding osteoporosis pre-screening tools but in order to save cost associated with 
bone densitometry majority showed willingness to utilize such tools in future.
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REAL LIFE APPLICATIONS OF SOCIAL SECURITy INSTITUTION (SSI) 
REGULATIONS; A CASE STUDy OF DPP4 INHIBITORS IN TREATMENT OF 
DIABETES IN TURKISH HEALTH CARE SySTEM
Kececioglu S.1, Ulus P.2, Cukadar F.3, Ozkan M.3, Urganci B.3
1Boehringer Ingelheim Turkey, Istanbul, Turkey, 2Boehringer Ingelheim Turkey, ISTANBUL, 
TURKEY, Turkey, 3Boehringer Ingelheim Turkey, ISTANBUL, Turkey
Objectives: Analyze real life applications of SSI regulations via a case study: 
patient access to DPP4 inhibitors (ProductA*&Product B**) for Diabetes treatment, 
in Turkish health care system (2010-2012). MethOds: Regulation analysis is com-
pleted to define access conditions to DPP4 inhibitors. IMS Medical Index is used 
for prescription data analysis (patient age, sex, diagnosis, localization, medica-
tions, etc.). Calculations and process modelling are completed by Microsoft Excel-
2007. Results: Patient access to DPP4 inhibitors is possible if glycemic control 
cannot be sustained after use of maximum tolerable doses of metformin and/or sul-
phonylurea. This new requirement is being applied since April 2011. This study eval-
uates two comparable timeframes T1 and T2 (before and after regulation update); 
T1: 2010 (Q1/Q2/Q3/Q4) & 2011 (Q1) and T2: 2011 (Q2/Q3/Q4) & 2012 (Q1/Q2). From T1 
to T2, Product A percentages of monotherapy, w-biguanides and w-sulphonylurea 
prescriptions changed from 32% to 35% (+3%), 51% to 42% (-9%) and 17% to 23% 
(+6%), whereas for Product B presciptions changed from 10% to 37% (+27%), 68% to 
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THREE-yEAR HEALTH CARE ExPENDITURES IN DIABETIC PATIENTS RECEIvING 
RAPID-ACTING INSULIN ANALOGUES vERSUS THOSE ON HUMAN REGULAR 
INSULIN
Cammarota S.1, Bruzzese D.2, Catapano A.L.3, Citarella A.4, De Luca L.1, Manzoli L.5, Masulli 
M.6, Menditto E.1, Mezzetti A.7, Riegler S.8, Riccardi G.6
1CIRFF- Center of Pharmacoeconomics, Naples, Italy, 2Federico II University Hospital School of 
Medicine, Naples, Italy, 3University of Milan, Milan, Italy, 4Karolinska Institutet, Stockholm, 
Sweden, 5“G. D’Annunzio” University Foundation, Chieti, Italy, 6University of Naples, Naples, 
Italy, 7University , Chieti, Italy, 8CIRFF, Federico II University, Naples, Italy
Objectives: To compare health care expenditures following rapid-acting insulin 
analogues or human regular insulin utilization in a cohort of diabetic patients through 
the analysis of administrative databases. MethOds: A population-based cohort 
study was conducted using administrative data from four local health authorities 
in the Abruzzo Region (900,000 inhabitants). Diabetic patients free of macrovascular 
disease at baseline and treated either with human regular insulin or rapid-acting 
insulin analogues were followed for a maximum of 3 years. Propensity score matching 
was used to adjust for significant differences in the baseline characteristics between 
the two treatment groups. The direct cost was calculated as the sum of drug use, 
financial compensation by hospital DRG and outpatient activities (laboratory tests, 
services use and specialistic consultations), all regulated by government contracts. 
Generalised linear mixed models under gamma distribution were used to evaluate 
the costs. In case of cost variables with a large proportion of zeros, a two part model 
(logistic regression and glm with gamma distribution) was employed. Results: After 
PS approach, 566 patients treated with human regular insulin were matched with 
an equal number of patients receiving rapid-acting insulin analogues. During the 
3-year follow-up, the average number of hospitalizations was higher (0.54 vs. 0.47; 
P= 0.028), and the average length of stay was 4,7 days longer (P < 0.004), among patients 
receiving human regular insulin in comparison with those receiving rapid-acting 
insulin analogues. The annualized total health care costs were significantly lower in 
the rapid-acting insulin analogues group than human regular insulin group with an 
estimated difference between the two groups of 1336.7 € per patient per year (P= 0.001) 
. cOnclusiOns: This analysis from real-world clinical practice suggests that rapid-
acting insulin analogue is associated with lower rates of hospitalizations and lower 
overall health care costs in diabetic patients.
PDB114
HEALTH CARE COST AvOIDANCE DUE TO INSULIN GLARGINE FOR TyPE 2 
DIABETIC PATIENTS IN HONG KONG AS COMPARED TO NPH INSULIN
Lee K.K.1, Wu D.B.C.2
1Monash University Sunway Campus, Selangor, Malaysia, 2Monash University Sunway Campus, 
Kuala Lumpur, Malaysia
Objectives: Many studies have shown that insulin glargine (IG) is associated with 
a better glycemic control and less incidents of hypoglycemia. The objective of this 
study is to examine the potential cost avoidance arising from reduced hypoglycemic 
episodes by IG vs NPH insulin in T2DM patients receiving insulin in Hong Kong. 
The findings will fill a knowledge gap as no data is available before. MethOds: 
A decision analytic model was developed using local and international data to 
evaluate the potential health and economic impact of routine use of IG over a 
1-year horizon. The study was conducted from a payer perspective. Probability of 
IG and NPH causing severe hypoglycemia was derived from the LEAD (LANTUS 
Evaluation in Asian Diabetics) study. Disease epidemiology and costs were all Hong 
Kong-specific. One-way sensitivity analysis was performed to test the robustness 
of model assumptions. Results: The use of IG over a 1-year period is estimated to 
result in a substantial 81.9% reduction of hospitalization cost (HKD313,572,521) and 
a 29% reduction of emergency room cost (HKD1,184,312) which together accounts 
for about 0.7% of the overall annual public hospital budget of HK. In addition, IG is 
expected to prevent 23,755 cases of severe hypoglycemia events and to avert 95,022 
hospitalization-days over 1 year. The overall incremental cost using IG vs. NPH is 
HKD126,843,257. cOnclusiOns: The use of IG in T2DM patients receiving insulin 
in Hong Kong is likely to substantially reduce health care costs in hospitalization 
and emergency room visits due to severe hypoglycemia compared with NPH. The 
results of this study are considered as conservative because if improvement in 
clinical outcomes of IG over NPH is included, the additional clinical benefit will 
translate into larger long term health savings.
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HEALTH CARE UTILIzATION FOLLOwING NEwLy-DIAGNOSED TyPE-2 DIABETES 
IN SwEDEN: A FOLLOw-UP OF 38,956 PATIENTS IN A REAL CLINICAL SETTING
Sabale U.1, Bodegård J.1, Sundström J.2, Svennblad B.3, Östgren C.J.4, Nilsson P.5, Johansson 
G.3, Henriksson M.1
1AstraZeneca Nordic-Baltic, Södertälje, Sweden, 2George Institute for Global Health, Sydney, 
Australia, 3Uppsala University, Uppsala, Sweden, 4Linköping University, Linköping, Sweden, 
5Lund University, Malmö, Sweden
Objectives: The growing prevalence of diabetes leads to increased pressure on 
national health care budgets. Despite the high prevalence the long-term health 
care costs of diabetes patients are not widely studied in a clinical practice set-
ting. The study objective was to quantify and describe health care resource utili-
zation following newly-diagnosed type-2 diabetes mellitus (T2DM) patients over 
time. MethOds: Newly diagnosed T2DM patients were identified from 84 primary 
care centers in Sweden between 1999 and 2009, and followed for a maximum of 9 
years. Resource use data were extracted from electronic patient records (primary 
care contacts and laboratory tests) and a national patient register (hospitalizations). 
Data were linked using unique social security numbers. Resource use patterns are 
reported for the full study period and by partitioned time periods to investigate 
trends in resource use over time. The relationship between weight and resource 
use was also investigated. Results: The study included 38,956 T2DM patients 
(women, 45%; mean age, 64 years; HbA1c, 5.7%; mean BMI, 29.8) with a total num-
ber of 183,614 observation years. Over a mean follow-up of 4.7 years there were 
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of about 25,000 hospitalizations from 180,000 diabetic patients were analyzed over a 
five year period. Results: Study population of statutorily insured diabetic patients 
is representative as it is comparable to the overall German population by age, gender, 
mortality and morbidity. Treatment of most diabetic patients on oral anti-diabetic 
drugs remained unchanged before and after a hospital stay (55.8%). A smaller part of 
diabetic patients (37.6%) is admitted and discharged with the same insulin regimen. 
In 15% of the cases where patients are discharged with insulin, insulin treatment 
was initiated or changed during hospitalization. 53% of these patients received a 
first prescription of insulin. Basal supported oral therapy (BOT) and conventional 
insulin treatment (CT) regimens made up the largest fraction of all insulin initiations 
(62%). If a BOT was initiated, insulin glargine was favored (60%) compared to all other 
long acting insulin formulations such as human insulin (30%) and insulin detemir 
(10%). In 21% of the cases initiation results in a basal-bolus regimen (ICT) and in 
17% in a prandial insulin therapy (SIT). cOnclusiOns: Insulin treatment was first 
prescribed or switched during hospitalization in 15% of the cases where patients 
are discharged with insulin. Initiation of BOT and CT regimens turned out to be the 
overall preferred therapies in the underlying analysis. Given the fact that 26.7% of 
the German diabetic population has suboptimal HbA1c-values more of them should 
receive an adequate adjustment of antidiabetic therapy during hospitalization.
PDB122
TREATMENT PATTERNS AND BURDEN OF ILLNESS OF CUSHING’S DISEASE IN 
THE UNITED KINGDOM: REAL wORLD (Rw) DATA FROM CLINICAL PRACTICE 
RESEARCH DATALINK (CPRD)
Murray R.D.1, Forsythe A.2, Siva V.3, Oliver N.3, Rojas-Farreras S.4, Roset M.4
1Leeds Teaching Hospitals NHS Trust, West Yorkshire, UK, 2Novartis Oncology, Florham Park, NJ, 
USA, 3Novartis Pharmaceuticals UK Limited, GB- Frimley/Camberley, Surrey, UK, 4IMS Health, 
Barcelona, Spain
Objectives: Cushing’s disease (CD) is an extremely debilitating endocrine condition 
caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma. 
CD has a significant impact on patients’ health, as well as on their physical, cogni-
tive, emotional, and social well-being. Treatment of CD is complex involving sur-
gery, radiotherapy and medication; however, there are limited published real world 
data on treatment patterns. MethOds: A retrospective database analysis study 
using CPRD linked with Hospital Episode Statistics (HES) was conducted. Patient 
population included patients enrolled after January 1956 up to March 2012 with at 
least two CD diagnosis or Cushing’s Syndrome diagnosis and one of the following: 
transsphenoidal surgery, benign pituitary neoplasm or pituitary disorder. Data was 
collected from 510 general practitioners (GPs). Patients’ characteristics, treatment 
history, and comorbidities were analysed. Cortisol values (urinary free or serum) 
were expressed as ULN-fold based on patient specific lab norms. Standardized 
Mortality Ratio (SMR) was calculated and compared to general age/gender matched 
UK population. Results: A total of 258 patients with CD were identified (227 alive 
and 31 dead) ). Among alive patients, mean age (SD) was 54(15) years old, 76% female, 
mean age at diagnosis was 38(15). Comorbidities were: infections (63%), hyperten-
sion (47%), fractures (30%), depression (25%), diabetes mellitus (22%), osteoporosis 
(22%) and obesity (18%); 65% of patients had treatment records. Among those: 48% 
received TSS, 41% adrenalectomy, 24% radiotherapy and 42% oral medications. A 
total of 32% of 1stline TSS and 34% of 1stline radiotherapy patients received further 
treatment; 26% of adrenalectomy patients were treated with radiotherapy and/
or surgery for Nelson’s syndrome. Among patients on oral medications, majority 
received metyrapone (79%) or ketoconazole (32%). 69% of patients with cortisol 
measurements (n= 92) were not controlled. SMR was 7.4, 5.1 and 3.1 at 5, 10 and 15 
years respectively. cOnclusiOns: This study demonstrated significant mortality 
and morbidity burden of CD in the UK primary practice.
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SySTEMATIC REvIEw ON THE COST-EFFECTIvENESS OF THERAPEUTIC 
EDUCATION TO PREvENT THE DEvELOPMENT AND PROGRESSION OF TyPE 2 
DIABETES
Odnoletkova I.1, Goderis G.1, Pil L.2, Nobels F.3, Aertgeerts B.1, Annemans L.4, Ramaekers D.1
1University of Leuven, Leuven, Belgium, 2Ghent University, Gent, Belgium, 3Aalst Hospital, Aalst, 
Belgium, 4Ghent University & Brussels University, Ghent, Belgium
Objectives: To critically appraise current evidence on the cost-effectiveness (CE) 
of therapeutic education for people with type 2 diabetes (T2D) and prediabetes 
compared to usual care. MethOds: We conducted a systematic review of eco-
nomic evaluations of educational programs for people with T2D or prediabetes 
which were based on randomized controlled trials and published between 2002 
and 2012. The quality of the clinical and the health economic evidence was ranked 
high, moderate, low or very low after critical appraisal by means of the Cochrane 
Collaboration’s tool for assessing risk of bias and the Consensus Health Economic 
Criteria List. Interventions were classified based on the reported incremental 
cost-effectiveness ratios (ICERs). Results: The search yielded 1.886 publications. 
Fourteen met the inclusion criteria. In prediabetes, patient education was found 
to be cost-saving in two out of five studies. The reported ICERs were € 850; € 24.400; 
€ 110.850 per quality adjusted life-year (QALY) gained from the payer’s perspec-
tive and € 6.800; € 40.000; € 48.500 per QALY gained from the societal perspective. 
In T2D, the CE of patient education varied from cost-saving to not cost-effective 
and had a mean ICER of € 44.500 (range: € 6.380; € 83.000) per QALY gained from 
the payer’s perspective. The quality of the health economic evidence was mainly 
moderate or low in studies on prediabetes, and very low in studies on T2D. The 
uncertainty analysis were not exhaustive in most studies. In the modeling stud-
ies (n = 10), the models’ structural assumptions and validation methods were in 
general not properly reported. cOnclusiOns: Current evidence on CE of thera-
peutic education of people with prediabetes and T2D is limited in volume and 
quality but consistently suggests that investing in patient education may offer 
good value for money. Studies of better quality are needed to reconfirm these 
findings. Commonly accepted methodologies for performance and assessment 
of health economic evaluations should guide further research.
47% (-21%) and 22% to 16% (-6%), respectively. cOnclusiOns: For Product A, after 
the regulation update, prescription rate for w-biguanides is decreased, while that 
for w-sulphonylurea and monotherapy options are increased. However, for Product 
B, prescription rate for w-sulphonylurea is decreased, while those for w-biguanides 
and monotherapy options are increased. For both products, prescription rate for 
monotherapy is increased. Limitation of this study is level of comprehensiveness for 
the system variables (market dynamics, patient profiles, etc.) This study concludes 
that, regardless regulation updates, there is an unmet need, which results in physi-
cians’ preference of innovative treatment options in clinical practice for treatment 
of Diabetes. *ProductA= Sitagliptin, **ProductB= Vildagliptin
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THE POTENTIAL IMPACT OF AMNOG-TRIGGERED INTERNATIONAL REFERENC 
PRICING: A SCENARIO FROM DPP-Iv INHIBITORS
Ando G.1, Van Mol C.2, Reinaud F.3, Honoré A.C.4
1IHS, London, UK, 2Alliance Concepts, Schilde, UK, 3IHS, Paris, France, 4IHS, Zurich, Switzerland
Objectives: 1) International reference pricing (IRP) is a complex cost containment 
policy which has an often unclearly defined ripple effect across countries; 2) The 
aim of this study was to quantify by simulation what the ripple effect through IRP 
would be if prices of DPP-IV inhibitors in Germany dropped post-AMNOG benefit 
assessment because of either internal referencing or subject to the specific AMNOG 
provisions under which the IRP process can be deployed; and 3) A secondary objec-
tive was to draw initial conclusions over the evolution of IRP. MethOds: 1) The IRP 
landscape was studied using primary and secondary payer research on the basket of 
countries formally or informally employed in 40 countries, specifying a) those which 
reference Germany directly and b) identifying a cascading “indirect wave” of those 
which reference the countries that reference Germany, and 2) We examined current 
pharmaceutical pricing data and employed an industry validated proprietary simu-
lation model for assessing the impact of selected AMNOG-triggered price decline 
scenarios. Results: 1) In the universe of 32 countries where the 2 DPP-IV inhibitors 
studied are on the market, 25 countries are potentially affected by a price decrease in 
Germany: 16 countries that reference Germany directly and 9 via a secondary phase 
of IRP, and 2) The resulting interdependent price impact - solely from IRP - in the 
diverse afflicted countries is quantified for each model scenario. cOnclusiOns: 
1) As more countries explore the possibility or already deploy IRP as a pricing poli-
cies, it will become increasingly crucial for pharmaceutical companies to gauge 
the full impact of evolving international referencing and cross-referencing – and 
integrate this early on in their pricing strategy; 2) The results demonstrate that he 
composition itself of the basket of reference countries is driving the pricing impact; 
and 3) IRP and value-based or market pricing could be complementary and need 
not necessarily be diametrically opposed.
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TREATMENT PATTERNS AND BURDEN OF ILLNESS OF ACROMEGALy IN THE 
UNITED KINGDOM: REAL wORLD (Rw) DATA FROM CLINICAL PRACTICE 
RESEARCH DATALINK (CPRD)
Murray R.D.1, Forsythe A.2, Roset M.3, Siva V.4, Oliver N.4, Rojas-Farreras S.3, Ayuk J.5
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NJ, USA, 3IMS Health, Barcelona, Spain, 4Novartis Pharmaceuticals UK Limited, GB- Frimley/
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Birmingham, UK
Objectives: Acromegaly is a rare slowly progressing endocrine disorder character-
ized by abnormally elevated levels of growth hormone (GH) and insulin-like growth 
factor-1 (IGF-1). Acromegaly has a significant impact on patients’ health, as well as 
on their physical, cognitive, emotional, and social well-being. Treatment of acro-
megaly is complex involving surgery, radiotherapy and medication; however, there 
are limited published real world data on treatment patterns. MethOds: A retro-
spective database analysis study using CPRD linked with Hospital Episode Statistics 
(HES) was conducted. Patient population included patients enrolled between January 
1956 and March 2012 with Acromegaly diagnosis at two timepoints or Acromegaly 
diagnosis and either GH or IGF-1 test. Data was collected from 500 general practi-
tioners (GPs). Patients’ characteristics, treatment history, comorbidities and disease 
control were analysed. Biochemical control was defined as an age/gender adjusted 
IGF-1≤ ULN and GH≤ 2.5mg/l. Standardized Mortality Ratio (SMR) was calculated 
and compared to general age/gender matched UK population. Results: A total 
of 822 patients with Acromegaly were identified (580 alive and 242 dead at March 
2012). Among alive patients, mean age (SD) was 63(15) years old, 52% male, mean 
age at diagnosis was 48(14). Comorbidities included: hypertension (46%), osteopo-
rosis (31%), arthralgia/synovitis (21%), diabetes (18%), carpal tunnel (13%) and sleep 
apnea (11%); 31% of patients had no treatment records. Among treated patients: 38% 
received TSS, 29% radiotherapy, 45% somatostatin analogs (SSAs), and 45% dopamine 
agonists (DAs). A total of 45% of TSS 1st line and 52% of radiotherapy 1st line patients 
received further treatment; 22% of SSAs patients and 34% of DAs patients switched 
to/added 2nd line medical therapy. 64% of patients with GH+IGF-1 data (n= 109) 
were not controlled. SMR was 4.6, 3.4 and 2.5 at 5, 10 and 15 years after diagnosis 
respectively. cOnclusiOns: This study demonstrated significant mortality and 
morbidity burden of Acromegaly in the UK GP practice.
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HOw DOES HOSPITALIzATION IMPACT INSULIN TREATMENT IN DIABETES 
MELLITUS? RESULTS OF A RETROSPECTIvE GERMAN DATABASE ANALySIS
Schmidt J.1, Dippel F.W.2, Steinmeier T.3
1Technical University, Garching, Germany, 2University, Leipzig, Germany, 3Sanofi, Berlin, Germany
Objectives: One important aspect for patients suffering from diabetes is an appro-
priate metabolic control to avoid micro- and macrovascular complications. There is 
a lack of information about adjustment of antidiabetic treatment during hospitali-
zation. MethOds: To identify a change in medication in patients suffering from 
diabetes, treatment regimens before and after hospitalization were investigated 
retrospectively. Information was taken from 2006 to 2010 German claims data. Data 
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patients using CSII and CGM; and 5)Results are more sensitive to reimbursement for 
routine physician care and lifestyle modification services. cOnclusiOns: 1) Seven 
American professional societies comprising the Diabetes Working Group (DWG) 
concur delivering high-quality, guideline-based diabetes care unrealistic given cur-
rent care and payment paradigms; 2) DWG recommends alternative approaches 
in 3 areas: care management, payment reform, and workforce supply, to mitigate 
increasing medical and financial impact of this epidemic chronic illness; 3) Model 
can be used internationally to support public policy efforts.
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GLP1 AND INSULIN GLARGINE TREATMENT PATTERNS AMONG TyPE 2 
DIABETES PATIENTS IN MAjOR EU MARKETS
Divino V.1, Hallinan S.1, Dekoven M.1, Varol N.2, Lee W.C.1, Reaney M.D.2
1IMS Health, Alexandria, VA, USA, 2Eli Lilly and Company, Windlesham, Surrey, UK
Objectives: Evaluate treatment patterns of Type 2 diabetes (T2D) patients initiat-
ing glucagon-like peptide-1 receptor agonists (GLP1) or insulin glargine in Germany 
(GE) and UK. MethOds: Adult T2D patients initiating exenatide twice-daily (exBID), 
liraglutide (LIRA) or glargine (1/10-12/11), or exenatide once-weekly (exQW) (1/10-
6/12), were identified using the IMS LifeLink™ EMR-EU databases (exQW in GE 
only). Therapy initiation date was termed ‘index date’. Eligible patients were naïve 
to index therapy class and had ≥ 180 days pre- and ≥ 360 days post-index data (180 
post-index exQW only). Treatment modification was evaluated over 180-day and 
total post-index period. Patients were required to have non-missing prescription 
data. Results: 6,171 GE (300 exBID/174 exQW/906 LIRA/4,791 glargine) and 1,042 UK 
(249 exBID/306 LIRA/487 glargine) patients were included. Approximately half were 
male (GE/UK% 53.9/51.9). At index, mean age in GE/UK was 57.6/57.6 among GLP1 
initiators; 67.4/63.1 among glargine initiators. Incidence of treatment modification 
(discontinuation, switch or augmentation) over 180-day post-index varied by treat-
ment and country (GE/UK,%): exBID (58.0/41.4), LIRA (54.1/39.2), exQW (40.8/NA), 
glargine (13.7/29.2). Augmentation as first modification was rare among exBID and 
LIRA patients (GE/UK,% of those with modification); 11.5/6.8 and 10.0/7.5, respec-
tively, compared to exQW (26.8/NA) and glargine (66.1/45.1). Discontinuation rates 
(i.e., stopping index therapy without switch to a new therapy) were higher than 
switching rates throughout the 180-day period for GLP1 and glargine users (GE/UK,% 
of those with modification): GLP1 74.4/75.3 discontinuation & 13.6/17.5 switch; glar-
gine 32.9/52.8 discontinuation and 1.1/2.1 switch. Using all available post-index data, 
mean follow-up was (GE/UK, months): exBID 24.5/25.6, LIRA 24.0/21.8, exQW 10.6/
NA, and glargine 24.4/25.4; proportions with treatment modification were (GE/UK,%): 
exBID 91.0/81.5, LIRA 80.1/71.6, exQW 57.5/NA, glargine 69.8/72.1. cOnclusiOns: 
Treatment patterns varied among GLP1 and glargine patients. Longer-term data 
would be useful to further elucidate practice patterns associated with these medi-
cines, particularly exQW.
PDB128
TREATMENT PATTERNS AMONG TyPE 2 DIABETES MELLITUS PATIENTS IN 
DUBAI
Osenenko K.M.1, Szabo S.M.1, Donato B.M.K.2, Korol E.E.1, Qatami L.3, Al Madani A.4,  
Al Awadi F.4, Al Ansari J.4, Maclean R.5, Levy A.R.1
1Oxford Outcomes Ltd., Vancouver, BC, Canada, 2Bristol-Myers Squibb Company, Wallingford, 
CT, USA, 3Bristol-Myers Squibb Company, Dubai, United Arab Emirates, 4Dubai Hospital, Dubai, 
United Arab Emirates, 5Bristol-Myers Squibb, Plainsboro, NJ, USA
Objectives: The United Arab Emirates (UAE) has among the highest prevalence 
(25%) of type 2 diabetes mellitus (T2DM) globally; however, few data are available 
on how patients are managed in clinical practice. The objective was to characterize 
recent treatment patterns among T2DM patients in Dubai. MethOds: Charts from 
T2DM patients aged ≥ 18 years that visited the Dubai Hospital between October 
2009 and March 2010 (enrolment period) were systematically sampled until the tar-
get (n= 250) was reached. Treatment data from enrolment to September 2011 were 
abstracted from patient charts, as well as treatments received before enrolment. 
Treatment regimens, their frequency of use, and the number of switches (drug 
replacement/removal/addition) over the study period were calculated. Analyses 
were stratified by T2DM duration, and data for those recently-diagnosed (< 5 years; 
n= 29) and with longstanding disease (≥ 20 years; n= 67) are presented. Results: 
Mean age at enrolment was 58 years (SD: 12 years), 33% were male, and mean 
T2DM duration was 14 years (SD: 8 years). At enrolment, 74% of patients had 
received prior insulin treatment (recently-diagnosed: 55%; longstanding disease: 
84%). During the study period, the most common regimens were insulin+oral 
combination therapy (55%) and oral combination therapy (39%). Overall, 67% 
received any insulin therapy during the study period (recently-diagnosed: 45%; 
longstanding disease: 87%). By study end, 78% had received insulin therapy at 
any time (recently-diagnosed: 62%; longstanding disease: 88%). On average, T2DM 
patients had two treatment switches; little variation was seen by T2DM dura-
tion. cOnclusiOns: Most patients had longstanding T2DM and received treat-
ment with insulin. Patients had an average of two treatment switches over the 
relatively short study period, indicating modification was attempted to improve 
T2DM control. Novel therapies may improve clinical outcomes among T2DM 
patients and this study provides valuable baseline data with which to compare 
the effectiveness of new T2DM treatments in Dubai.
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HOw CO-PAyMENT MECHANISM HAS CHANGED PATIENTS’ PERCEPTION 
TOwARDS OTC-TyPE PRODUCTS?
Deger C.C., Tuna E., Ozdemir Z., Ozel M.O., Parali E., Sumer F., Yilmaz Z.S.
Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey
PDB124
IMPACT OF vALUE COMMUNICATION IN DECISION MAKING: AN APPROACH TO 
THE TREATMENT OF TyPE 2 DIABETES IN PORTUGAL
Viriato D.1, Antunes M.2
1Novartis, Sintra, Portugal, 2Faculdade de Ciências da Universidade de Lisboa, 1749-016, Portugal
The increasing budgetary constraints faced by health care payers have made the 
access decision increasingly complex and decentralized processes a growing trend. 
Thus, demonstration of new health technologies value has become critical to ensure 
patients’ access to innovation.Objectives: To identify the most important value 
messages within decision making process in the treatment of Type 2 Diabetes 
Mellitus (T2DM) among General Practitioners (GP) coordinating Primary Care 
Centers. MethOds: Regional meetings based on Health Economics training held 
(during 2013) with GPs, including the presentation of a cost-effectiveness analysis of 
vildagliptin vs sulphonilureas (SU) and a budget impact tool that enables the estima-
tion of meaningful impacts of T2DM. Two surveys were developed to be applied at 
beginning and end of training to characterize the learning insights and identify the 
factors considered in the decision process. Results: Partial results based on a 51 
GPs sample are presented. The positive impact of the training in HE concepts was 
statistically significant (p= 0.000) with an 89.4% average rate of correct answers. More 
than 50% of GPs considered the increasing prevalence of T2DM, cost of macrovascu-
lar and microvascular complications and the impact of hipoglycaemias in patients’ 
quality of life (QoL) and costs, as the most important factors in the decision process. 
The key decision factor to use vildagliptin is the improvement of patients’ QoL. The 
use of SU is explained due to its fast response, mainly in patients with Hb1Ac level 
above 7.5%. Majority of GPs (87.5%) chose vildagliptin as the preferred therapeutic 
for T2DM patients not controlled with metformin. cOnclusiOns: This analysis 
demonstrated that both epidemiological and economic factors are important at 
local decision process. Clinically, patients’ QoL is the most relevant achievement. 
Most GPs prefer vildagliptin to control T2DM, considering QoL improvements its 
greatest benefit.
PDB125
QUALITy OF CARE FOR TyPE 2 DIABETES MELLITUS PATIENTS IN DUBAI
Donato B.M.K.1, Osenenko K.M.2, Korol E.E.2, Szabo S.M.2, Qatami L.3, Al Madani A.4, Al Awadi 
F.4, Al Ansari J.4, Maclean R.5, Levy A.R.2
1Bristol-Myers Squibb Company, Wallingford, CT, USA, 2Oxford Outcomes Ltd., Vancouver, BC, 
Canada, 3Bristol-Myers Squibb Company, Dubai, United Arab Emirates, 4Dubai Hospital, Dubai, 
United Arab Emirates, 5Bristol-Myers Squibb, Plainsboro, NJ, USA
Objectives: Despite the high prevalence (25%) of type 2 diabetes mellitus (T2DM) in 
the United Arab Emirates (UAE), few data are available on the types and quality of care 
administered. Quality of care is an important determinant of whether clinical targets 
can be met, and serious complications avoided. The objective was to estimate the 
proportion of T2DM patients receiving recommended monitoring of clinical measures 
in Dubai, over one year. MethOds: Charts from T2DM patients aged ≥ 18 years that 
visited the Dubai Hospital between October 2009 and March 2010 (enrolment period) 
were systematically sampled until the target (n= 250) was reached. Quality of care 
was assessed from April 2010 to March 2011, adapted from the United States (US) 
Healthcare Effectiveness Data and Information Set (HEDIS) Comprehensive Diabetes 
Care measures. Measures included: glycosylated haemoglobin (HbA1c) screening, 
control (< 8%) and poor control (> 9%); low-density lipoprotein (LDL) screening and 
control (< 100mg/dL); blood pressure (BP) control (< 140/90mmHg); retinopathy screen-
ing; and medical attention for nephropathy. Patients were classified as having control 
based on their latest test in the period. Results: Mean age at enrolment was 58 years 
(standard deviation (SD): 12 years), 33% were male, and mean T2DM duration was 14 
years (SD: 8 years). Over the 12-month period, 98% underwent HbA1c screening (54% 
had control and 26% displayed poor control); 90% underwent LDL screening (64% 
had control); 43% had BP control; 32% had retinopathy screening; and 16% attention 
for nephropathy. Two-hundred and eleven patients (84%) were screened for BP, LDL 
and HbA1c measures over the period. cOnclusiOns: Guideline monitoring was 
conducted for most patients; rates of compliance were comparable to or higher than 
US benchmarks for HbA1c and LDL monitoring. Greater understanding of the factors 
leading to high adherence to the guidelines would be useful for other areas of preven-
tive care, and other hospitals and jurisdictions.
PDB126
USING A “STANDARDS OF CARE ECONOMIC MODEL” TO QUANTIFy BARRIERS 
AND POTENTIAL SOLUTIONS TO PROvIDING OPTIMAL GUIDELINE-DRIvEN 
CARE TO PATIENTS wITH DIABETES MELLITUS IN THE UNITED STATES
Hughes K.E.
Avalere Health LLC, Washington, DC, USA
Objectives: 1) Build economic model to estimate resources to deliver current 
standards of care to US diabetes patients, and 2) Evaluate provider costs to meet 
standards, assess patient outcomes specified in guidelines relative to reimburse-
ment. MethOds: Build model: 1) Integrate 3 national standard sets (ADA, AACE, 
and TES) into 28 consolidated standards of optimal care; 2) Develop provider matrix 
for rendering care; 3) Draft 6 clinical vignettes: 3 each T1DM and T2DM; 4) Convene 
3 multidisciplinary panels of 4-7 care professionals; with facilitator, estimate mini-
mum/maximum time to achieve care standards/patient type – baseline/best cases; 
5) Convene separate panel estimating time to start/follow patients using CSII or 
CGM; 6) Multiply provider time by average wage and overhead amounts to deter-
mine visit cost; 7) Map activities to CPT and HCPCS billing codes and payment 
rates; 8) Compute reimbursement per expected payer mix; and 9) Note gaps in 
reimbursement compared to costs on unit and total basis. Populate model; perform 
analytics: Repeat Steps 4-9 with data from national provider survey and national 
database. Results: 1) Baseline scenarios show provider costs exceed reimburse-
ments for all type patients; best case indicates same in 5 of 6 scenarios; 2) In dif-
ferent scenarios costs of treating adults exceed reimbursement by > $750,000 per 
year; practices would require 19%-64% increase to breakeven; 3) In pediatric prac-
tice, costs exceed reimbursement by > $471,000 per year; 4) Gaps are increased for 
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THE ROLE OF COMMUNICATION AND HEALTH LITERACy ON PATIENT SAFETy 
IN PUBLIC PHARMACIES IN THE REPUBLIC OF SRPSKA
Janjic Z.1, Tasic L.2, Rados L.3, Krajnovic D.2, Medic G.4
1Pharmacies “Zdravlje Pharm”, Bijeljina, Republic of Srpska, Bosnia, 2University of Belgrade – 
Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 3Pharmacy Zrenjanin, Zrenjanin, Serbia 
and Montenegro, 4Mapi - HEOR & Strategic Market Access, 3995 AX Houten, The Netherlands
Health literacy is the skill (social and cognitive) that determines the motivation 
and ability of the person to receive, understand and use information in order 
to improve and maintain good health. Communication between patients and 
pharmacist is essential for optimal patient safety.Objectives: To highlight the 
importance and present the results of conducted research and to give recom-
mendations for improving the health literacy among patients and pharmacists’ 
communication skills. MethOds: The study was conducted in June 2013 in 5 
selected branches of pharmacy-chain “Zdravlje Pharm” in Bijeljina, Republic of 
Srpska, Bosnia and Herzegovina. The sample consisted of 219 patients selected 
randomly, of whom 195 accepted the survey, and 24 rejected to participate. The 
instrument was previously validated and adjusted questionnaire of Pharmacy 
Zrenjanin, Serbia, related to patient satisfaction with pharmacy services, but 
also conceived needs of the thesis, with 32 close-type questions, except one. 
Health literacy of patients and communication with pharmacists were fol-
lowed. The analysis was done in Excel, and the results are given in tables and 
graphs. Results: About 90% of patients reported that pharmacists give clear 
information during consultations and the advices helped them. A total of 65% 
reported to easily remember the information from the pharmacists, which shows 
a good level of patient health literacy; but the rest can have uncertain outcomes 
of the therapy and be exposed to greater safety risks. cOnclusiOns: There is a 
place for improvement of aspects which can contribute to better patient safety. 
That can be achieved by applying certification standards throughout the health 
care system in the Republic of Srpska.
PHP5
ARE THE BIOTECHNOLOGy AND PHARMACEUTICAL SECTORS DEFENSIvE 
RELATIvE TO THE S&P 500?
Furnback W., Wang B., Magyar A.F.
Alliance Life Sciences, Somerset, NJ, USA
Objectives: The health care sector is widely regarded as a defensive play in the 
stock market. We analyzed the performance of a pharmaceutical and a biotechnol-
ogy index from March 2000 through April 2013 alongside the S&P 500. MethOds: 
We categorized the S&P 500 from March 2000 through April 2013 into bull and bear 
markets. During this time there were three bull markets and three bear markets. 
Bull and bear markets were defined as changes in the S&P 500 of more than 20%. 
We followed the AMEX Pharmaceutical (^DRG) and Biotechnology (^BTK) Indices to 
represent their sectors. We compared the returns of the sectors with the overall mar-
ket and also calculated their correlated volatility (beta) with the S&P 500. Results: 
For the entire analysis period, the S&P 500 returned 4.59% while ^DRG and ^BTK 
returned 25.43% and 252.83%, respectively. During the bear markets, the S&P 500 
lost at an average annual rate of 27.17%, while ^DRG and ^BTK lost at annual rates 
of 12.16% and 21.99%, respectively. Though ^DRG performed best during the bear 
markets, it was a laggard in the bull market gaining 8.15% annually, while the S&P 
500 and ^ BTK had 22.04% and 31.97% annual returns, respectively. The overall beta 
during our analysis period was 0.63 for ^DRG and 1.07 for ^BTK. cOnclusiOns: 
Both the AMEX Pharmaceutical and Biotechnology Indices fell at a lesser rate than 
the S&P 500 during bear markets. The Pharmaceutical Index may be the more defen-
sive play as it lost at an average annual rate of more than two times less than the 
S&P 500. However, the Biotechnology Index gained almost four times more than the 
Pharmaceutical Index in bull markets and also outperformed the S&P 500 by almost 
10 percentage points during bull markets.
HEALTH CARE USE & POLICy STUDIES – Diagnosis Related Group
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COMPARISON OF DEvELOPMENT DIAGNOSIS RELATED GROUPS BASE RATE IN 
HUNGARy AND GERMANy
Ágoston I.1, Bordi K.2, Sebestyén A.3, Szarka E.1, Schaefer J.4, Boncz I.1
1University of Pécs, Pécs, Hungary, 2AGAPLESION gAG, Frankfurt am Main, Germany, 3National 
Health Insurance Fund Administration, Pécs, Hungary, 4AGAPLESION FRANKFURTER DIAKONIE 
KLINIKEN gGmbH, Frankfurt am Main, Germany
Objectives: Diagnosis Related Groups (DRG) based methods was introduced for 
acute hospital care reimbursement in 1993 in Hungary (H-DRG) and in 2003 in 
Germany (G-DRG). The aim of our study is to compare the development of DRG 
base rate in Germany and Hungary. MethOds: The Hungarian data derive from the 
financial database of the Hungarian National Health Insurance Fund Administration 
(NHIFA), the only health care financing agency in Hungary. German data derive 
from German DRG Institute. We analyzed how the uniform, nationwide DRG base 
rate has been introduced in both countries. Results: The German DRG system 
consists of 1200 disease groups, while the Hungarian contains ca. 736 groups. The 
German DRG base rate was hospital specific between 2003-2004. From 2005 to 2009 
hospital-specific base rates converged to a state-wide base rate. From 2010 to 2014, 
the state-wide base rates should converge to a nationwide base rate. The German 
hospital specific base rate varied between EUR2200-3200. In Hungary, a hospital 
groups specific base rate was applied for 16 groups of hospitals between 1993-
1998 with a gradual converge of base rates. Middle level (county or regional) base 
rate was not introduced in Hungary. The nationwide uniform DRG base rate was 
set up in 1998 in Hungary. The Hungarian uniform DRG base rate was EUR518 in 
2012. cOnclusiOns: Both Hungary and Germany applied a gradual implementa-
tion of uniform DRG base rate. Germany took three steps (hospital, Lander and 
nationwide), while Hungary took two steps (hospital group, nationwide) in reaching 
the nationwide uniform DRG base rate.
Objectives: Turkish health care system has developed in terms of quality, access, 
equity and efficiency with the introduction of a number of reforms under “Health 
Transformation Program” since 2003. However, these have created significant 
financial burden to the government. In order to contain expenditures, avoid over-
use, misuse and abuse; government has implemented certain cost sharing tools. 
Our objective is to define how co-payment mechanism has affected patients’ 
purchasing behavior regarding OTC-type products. MethOds: Regulations and 
reports published by Ministry of Health and Social Security Institution, “Health 
Systems in Transition Turkey 2011” and “IMS Market Prognosis 2012-2016” reports 
are examined. Results: In Turkey, family physicians do not act like gatekeepers 
since a formal referral system does not exist. Therefore, patients could directly 
apply to secondary/tertiary health care services without co-pay. At secondary/
tertiary health care levels, co-payment rate is 5 TL and 12 TL for outpatient care 
in public and private hospitals respectively, 3 TL for prescription fee and extra 
1 TL for each product exceeding 3 products per prescription. All active workers 
pay 20% while retirees pay 10% of total amount of the prescriptions as co-pay. 
Patients with chronic conditions requiring medical report are exempt from co-
pay. Considering different co-payment rates and number of visits/prescriptions 
recorded in hospitals, it is calculated that patients paid approximately 3 billion 
TL in total outpatient care as co-payment in 2012. cOnclusiOns: Minimum 9 
TL in total is required as a co-payment for outpatient care and prescription, if 
patient visits a public hospital. Therefore, for products with a lower price than 
10 TL, patients rather go directly to pharmacies. This behavioral change of out-
of-pocket payments might be explained by improved purchasing power and 
increased co-pay rates.
PHP2
METHODOLOGICAL CHALLENGES IN MULTI-CRITERIA DECISION ANALySIS 
(MCDA) FOR HEALTH POLICy DECISION-MAKING: A SySTEMATIC REvIEw
Wahlster P.1, Goetghebeur M.M.2, Kriza C.1, Niederländer C.S.1, Kolominsky-Rabas P.L.1
1Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of 
Erlangen-Nuremberg, Erlangen, Germany, 2LASER Analytica, Dorval, QC, Canada
Objectives: Decision making about health technologies from research and 
development to reimbursement is affected by heterogeneous opinion and cri-
teria of participating stakeholders. There is a lack of systematic consideration 
of stakeholders’ preferences in current health policy. Multi-criteria decision 
analysis (MCDA) offers a solution to take preferences into account. This study 
gives an overview about the applications of MCDA methods in health economic 
decision-making. MethOds: A systematic review of the health care literature 
was performed to identify original research articles. Using predefined categories, 
data was systematically extracted for the type of policy applications, MCDA 
methodology, criteria used and how they were defined. Results: Twenty-one 
studies were included in the analysis. 12 studies (67%) used indirect approaches 
and nine studies (43%) used direct MCDA approaches. Four studies (19%) focused 
on technologies in the early innovation process. The majority of 17 studies (81%) 
examined a technology on the level of reimbursement decision. Eight studies 
(38%) resulted into implementation, which means that an official committee 
considered the MCDA results. Other studies were conducted in an explorative 
manner. MCDA decision criteria used were obtained from literature research and 
context-specific studies, expert opinions, and group discussions. The number of 
criteria ranged from three up to 15. The most prominent criteria described health 
outcomes (71%), disease impact (62%), and implementation of the intervention 
(38%). cOnclusiOns: MCDA is used at different levels of medical innovation 
and can increase transparency for involved stakeholders by explicitly structuring 
decision criteria. Further research is needed to understand existing variability 
of the number of criteria used and ensure that models are robust regarding 
potential criteria overlaps, performance scales and operationalizability aligned 
with evidence needs.
PHP3
SUPPLEMENTARy HEALTH INSURANCE IN TURKEy
Deger C.C., Tuna E., Ozdemir Z., Ozel M.O., Parali E., Sumer F., Yilmaz Z.S.
Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey
Objectives: In Turkey, almost everyone is covered by General Health Insurance 
Scheme (GHIS) under Social Security Institution (SSI). GHIS provides a Basic 
Benefit Package (BBP) for patients to benefit from both public and private health 
care providers contracted with SSI. Patients are obliged to pay certain level co-
pays for extra services as defined in the regulation. Besides GHIS, patients could 
benefit from private health insurances(PHI) by paying relatively high level of pre-
miums for different types of PHI packages. Supplementary Health Insurance(SHI) 
law has been enacted in June 2012 and patients started to benefit from SHI by 
paying relatively lower premiums for health care services that are not covered 
or partially covered by BBP. The objective is to evaluate the significance and 
potential of SHI in Turkey. MethOds: Regulations of SSI, OECD publications, 
International Investors Association’s Turkey Report and database of Insurance 
Association of Turkey are examined. Results: Number of private hospitals has 
increased by 50% over 5 years and reached out 500 by 2012. Parallel with this 
growth, PHI sector market share has also increased. By 2012, number of people 
covered by PHI has reached out more than 2 million and the PHI market is 
expected to reach nearly USD 2 billion in 2015. Meanwhile, approximately 20 
thousand people has covered by SHI since November 2012 and SHI is expected to 
reach 5 million people next 5 years. cOnclusiOns: Public health care expendi-
ture is continuously rising due to increased health demand, increased coverage 
and demographic changes. In order to assure a financially sustainable health 
care system, PHI could be an option and create source of funding for the health 
care expenditure. In this context, SHI will reduce the pressure on public health 
budget, create an area of growth for the private health insurance sector, allowing 
health care providers supplying both public and private health care to become 
more effective.
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cost benefit analysis and 3 BIAs. Key assessment criteria that the other studies did not 
meet were consideration of all relevant costs and execution of a sensitivity analysis. 
Of the best quality studies, 3 reported net economic benefits from implementing 
SEDs, at least in the base case analysis. cOnclusiOns: Investment in SEDs gener-
ates economic benefits from savings in managing medical sharps injuries and their 
sequelae. Future economic evaluations need to carefully assess all important and 
pertinent costs to enable well-informed decision making about the implementation 
of SEDs in the health care workplace.
PHP12
A PRICE COMPARISON STUDy OF RECENT DRUGS IN EU5, 2008-2012
Le Pen C.1, Vigier D.2, Grandfils N.2
1Université Paris Dauphine, PARIS, France, 2IMS Health, PARIS LA DEFENSE, France
Objectives: To compare prices of new drugs between France and the other 
EU4. MethOds: Study used IMS MIDAS database for economic data such as prices 
and sales volume and LEEM database (French association of the pharmaceutical 
manufacturers) for the ASMR scale (HAS assessment of the drug’s added value/
innovation). All the products applying for the first time for reimbursement by the 
French Public health insurance between January 2008 and June 2012 were included 
in the study (except those restricted to hospital use in France) and having an ASMR 
rating and an official price in June 2012. Paasche and Laspeyres price-index were 
calculated for drugs with: a) high ASMR, b) ASMR IV, c) ASMR V and d) all drugs. A 
sensitivity analysis was conducted to measure the effect of different weighting 
options. Results: A total of 107 products (245 dosages) were included in this study. 
Fifty-one (48%) have been found available in the community pharmacies of all the 5 
countries. The availability analysis by pair of countries (France + another) is higher: 
94 for Germany, 79 for UK, 71 for Spain and 69 for Italy (Italy often restricts drug’s 
access to hospitals only). French prices are generally equal to or lower than prices 
in the four other markets, which shows a relative price index decrease for France 
since 2008 studies. The only significant exception are UK prices for products ranked 
in France ASMR 1-2-3 (20% less expensive). Prices are regularly and significantly 
higher in Germany than in all other countries. Interestingly, the highest disparities 
in prices occur for the ones ranked as most innovative in France – while ASMR IV 
have surprisingly consistent prices across EU5. cOnclusiOns: European patients 
don’t have consistent access to the same drugs in retail market, and the drugs 
considered innovative in France show a large price index disparity across EU5, with 
UK prices being 20% lower.
PHP13
TO wHAT ExTENT CAN BIOSIMILARS COMPETE wITH BRAND NAME 
BIOLOGICS? A EU-5 GRANULOCyTE-COLONy STIMULATING FACTORS MARKETS 
ANALySIS
Bocquet F.1, Paubel P.2, Fusier I.3, Cordonnier A.L.3, Le Pen C.1, Sinègre M.3
1Dauphine University, Paris, France, 2Paris Descartes University, Paris, France, 3General Agency of 
Equipment and Health Products (AGEPS), AP-HP, Paris, France
Objectives: To determine the ability of biosimilars (copies of branded biologics) to 
compete with brand name biologics within the same therapeutic class by analyz-
ing EU-5 G-CSF (Granulocyte-Colony Stimulating Factors) markets and the factors 
affecting the G-CSF biosimilar uptakes, particularly that of biosimilar prices relative 
to reference G-CSFs. MethOds: Data on medicine volumes, values and ex-manu-
facturer prices for all G-CSF categories were provided by IMS Health. Volumes were 
calculated in DDD (Defined Daily Doses) and prices in euros per DDD. In the EU-5 
countries biosimilar G-CSFs benefit from a 5-year experience. Data were available 
from 2007 until 2011. Results: There are two G-CSF market profiles: i) countries 
with a high retail market distribution which are the largest G-CSF markets with low 
global G-CSF biosimilar uptakes (5.4% in France and 8.5% in Germany in 2011); ii) 
countries with a dominant hospital channel which are the smallest markets with 
higher G-CSF biosimilar uptakes (12.4% in Spain and 20.4% in the UK). The G-CSF 
biosimilar uptakes depend critically on their market access at a local/regional level. 
The more the decisions are decentralized (hospitals, local purchasing structures) 
the more their uptakes are high (28.3% of the hospital market in France in 2011 
and 20.4% in the UK). The price difference between G-CSF biosimilars and their 
reference plays a marginal role at a global level (+13.3% in the UK and -20.4% in 
France). cOnclusiOns: The competition with G-CSF biosimilars varies signifi-
cantly between EU-5 countries due to distribution channel differences. Currently, 
this competition is not mainly based on prices, but on local political options to 
stimulate tendering between them and other most recently branded products. In 
countries with dominant retail markets, a prerequisite for the success of biosimilar 
G-CSFs is that governments approve their substitution in the same way generics 
are authorized by introducing them case-by-case.
PHP14
CHARACTERISING PRELIMINARy PROFILE PARAMATERS FOR FDA 
BREAKTHROUGH THERAPy CANDIDATES
Labban M., Izmirlieva M., Ando G.
IHS, London, UK
Objectives: Since the new Breakthrough Therapy (BT) designation was introduced 
with the new Food and Drug Administration Safety and Innovation Act (FDASIA) 
on 9 July 2012, the FDA has received over 50 requests, and has issued over 20 such 
designations to various candidates in various indications based on preliminary 
evidence that the investigational drugs fulfill a highly unmet medical need where no 
alternatives exist, or demonstrate a significant improvement over existing therapies. 
We have set out to examine the key parameters that characterise a “Breakthrough” 
candidate, and to determine the likelihood of an investigational therapy being 
granted the status. MethOds: Using the FDA listing of BT designation statistics, 
publicly available information, as well as IHS Global Insight data, we identified a 
list of currently approved BT candidates between 9 July 2012 and 14 June 2013 and 
determined their preliminary profile characteristics. Results: To date, nearly 75% 
of the designations have been publicly announced by the pharmaceuticals firms 
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THE ASSOCIATION BETwEEN EUROPEAN MEDICINES AGENCy APPROvAL AND 
HEALTH TECHNOLOGy ASSESSMENT RECOMMENDATION
Lipska I.1, Hövels A.M.2, McAuslane N.1
1Centre for Innovation in Regulatory Science, London, UK, 2Utrecht University, Utrecht, The 
Netherlands
Objectives: To find the association between duration of the process of market-
ing authorization (MA) approval at European Medicines Agency (EMA) and health 
technology assessment (HTA) recommendations in European Union (EU) coun-
tries. MethOds: EMA MA timing for new active substances (NASs) during 2007-
2009 were analyzed based on publicly available information. HTA recommendations 
(positive, positive with restrictions, negative, not assessed) issued for the same 
medications in 6 EU countries (SMC, Scotland; AOTM Poland; CVZ, The Netherlands; 
HAS, France; NICE, UK; INFARMED, Portugal) were also analyzed based on public 
information. Hypothesizing that EMA approval process timing might be an indica-
tor of complexity and potential issues in the dossier, the potential for longer EMA 
approval times being associated with less beneficial HTA recommendation was 
investigated. Analyses were performed per country as EMA decisions are centralized 
but HTA recommendations are taken independently by member states. Results: 
A total of 86 NAS were approved by EMA in 2007-2009; mean time of approval was 
460 days (median 423 days). In total, we expected 516 HTA recommendations (86 
drugs assessed by 6 organizations). We found in total 138 positive, 77 positive with 
restrictions, 67 negative recommendations. 234 expected recommendations for 6 
HTA included in this study were not assessed (45,3% of all expected recommenda-
tions). The association between HTA recommendation and approval time (in days) 
was analyzed using Spearman’s rho rank correlation. There was statistically signifi-
cant negative correlation between approval time and HTA recommendation in The 
Netherlands. More time needed for EMA approval was associated with less beneficial 
HTA recommendations. Correlations in other countries were not statistically signifi-
cant. cOnclusiOns: Our research indicates that a longer EMA approval process is 
associated with a less beneficial HTA recommendation in The Netherlands. Further 
research is required whether this indicates that the same issues that cause delays 
at EMA are reconsidered at HTA authorities.
PHP9
THE IMPACT OF INDICATION ExTENSIONS ON PHARMACEUTICAL PRICES
Genane C.1, Marinoni G.2, Ando G.2, Reinaud F.1
1IHS, Paris, France, 2IHS, London, UK
Objectives: To assess the impact of an indication extension on pharmaceutical 
prices in 9 markets: Australia, Brazil, France, Germany, Italy, Japan, Spain, Turkey, 
and the UK. MethOds: Websites of the EMA and national regulatory agencies 
were surveyed to indentify medicines granted an indication extension between 
2007 and 2013. Eight case studies (bevacizumab, trastuzumab, sunitinib, ivabradine, 
telmisartan, aripiprazole, paliperidone, and omalizumab) were selected based on 
market share and availability across the geographies of interest. The list prices, at 
ex-manufacturer levels, of these eight drugs and those of the medicines belong-
ing to their therapeutic class (at ATC level 3) were collected for the period 2007-13. 
Price movements for these eight medicines were compared to the price evolution 
within their therapeutic class over the period. Results: Based on the selected 
case studies, there is ambivalent synchrony between indication extensions and 
pharmaceutical list price movements in the countries analysed. The data show that 
list prices tend to remain stable following an indication extension. When list prices 
changed subsequent to an indication extension, the movements could not directly 
be linked to the indication extension, as external factors such as a class trend or a 
wider pricing and reimbursement process (e.g. blanket price cuts) could also play a 
role. cOnclusiOns: There is inconclusive evidence that indication extensions lead 
to list price changes in the countries analysed. Moreover, the impact of commercial 
agreements and discounts should be taken into account as secondary indications 
may be subject to separate pricing arrangements (e.g., patient access schemes). As 
such, the selection of the indication for the first marketing-authorisation filing (such 
as a high medical need, niche indication, commanding a premium price) is pivotal 
for the commercial success of a medicine, as its launch price seems unlikely to be 
reviewed following subsequent approvals in broader patient populations.
PHP10
ECONOMIC ANALySIS OF THE PREvENTION OF MEDICAL SHARPS INjURIES 
wITH SAFETy-ENGINEERED DEvICES: A SySTEMATIC REvIEw
Barnett G.S.1, Maclaine G.D.H.2
1Gillian Barnett & Associates Ltd., Dunfanaghy, County Donegal, Ireland, 2Becton, Dickinson UK 
Ltd., Oxford, UK
Objectives: To protect health care workers from risk of needlestick injury, preven-
tive safety measures are increasingly mandated in the health care environment, 
which may include the use of safety-engineered medical sharp devices (SEDs) spe-
cifically designed to prevent sharps injuries. We undertook a systematic review of 
the literature to understand the economic impact of replacing conventional sharps 
devices with SEDs. MethOds: We conducted searches of electronic databases includ-
ing Embase/MEDLINE, PubMed, CINAHL Plus, HEED, NHS EED, the Cochrane Library, 
ProQuest Nursing and Allied Health Source, and the Tufts CEA Registry. Databases of 
the WHO and HTA agencies, reference lists of identified studies, conference abstract 
books and the internet were also searched. The time horizon covered January 1990 to 
March 2013. Two reviewers independently screened titles and abstracts, applied inclu-
sion criteria to full text papers and extracted data from identified studies according to 
an a priori defined data set. Differences were resolved by consensus. Study quality was 
assessed using a published 10-point checklist. Results: From 19621 records, 21 stud-
ies met the review criteria and were selected. Most studies (16) were budget impact 
analyses (BIAs). Reductions in sharps injuries with SEDs ranging from 12% to 100% 
were reported. Just 4 studies were assessed as providing the best quality evidence: a 
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representative drug dispensing data from ambulatory care). The statistical analy-
sis was performed using SAS Enterprise Guide 4.1. Results: The average price of 
medicines in the NHS market reduced significantly. Until March 2013, the average 
price of generics reduced 59.0% and brands 12.9%. The margins of pharmacies and 
wholesalers decreased in 2012. As a consequence, the outpatient pharmaceutical 
market decreased € 752 million and the NHS expenditure € 468.1 million, between 
2010 and 2012. However, hospital market in 2012 remains at the same level observed 
in 2010. In the first quarter of 2013, outpatient market reduced another 90.3 million 
€ and NHS expenditure € 49.7 M, of which 21% is due to the reduction of distribution 
margins. cOnclusiOns: Even before the MoU, several changes led to a great reduc-
tion of the public expenditure in 2011. This impact worsened after the MoU, with 
direct effects on the reduction of the remuneration of pharmacies and wholesalers. 
Urgent strategies that ensure the access of patients to medicines while preserving 
the sustainability of both the NHS and the network of pharmacies are required, as 
well as policies to monitor the prescribing, dispensing and utilization of medicines 
and concrete changes in the inpatient NHS expenditure.
PHP19
UTILIzING STORyTELLING TO PROMOTE RATIONAL ANTIBIOTIC USE IN 9-11 
yEARS OLD SCHOOL CHILDREN IN IRAN
Soleymani F.1, Mohammadhosseini N.2, Mohammadzadeh S.2, Kazemi M.2
1Tehran University of Medical Sciences and Ministry of Health, Tehran, Iran, 2National Committee 
on Rational Drug use, Tehran, Iran
Objectives: Antimicrobial resistance is still a growing health problem which 
increases morbidity, mortality, and health costs and has been associated with inap-
propriate antibiotic use. In Iran antibiotic prescription rates are high in children and 
antibiotics are the most common medication prescribed. Teaching children about 
the different types of microbes and the increasing problems of antibiotic resistance 
with unnecessary and inappropriate use of antibiotics should not only raise aware-
ness in our future generation of antibiotic users but also in the family environment. 
This study aimed to evaluate the effectiveness of the story telling in improving 
children’s knowledge about rational antibiotic use. MethOds: Junior (9–11 years) 
school classes were divided into either control or intervention groups for evaluation 
of the story telling. Students were required to complete identical knowledge ques-
tionnaires at three time points (before, immediately after and 4 weeks after teach-
ing), to assess knowledge change and retention. Teaching, using story books which 
provided by National Committee on Rational Drug Use (NCRUD), was given by junior 
school teachers. Results: A total of 164 junior students, 95 were intervention and 
69 control groups, were studied. The junior story telling demonstrated a significant 
improvement in student’s knowledge (34.5% of change) and there was no significant 
decrease in student knowledge observed after a 4 week period. cOnclusiOns: 
Availability of information on the effectiveness of intervention for improving and 
promoting appropriate antibiotics use can facilitate implementation of strategies in 
this field. Regarding the effectiveness of storytelling, it is therefore recommended 
that decison-maker place greater emphasis on the use of such interventions.
PHP20
RELEvANT DECISION-MAKING CRITERIA IN GERMAN HOSPITAL FORMULARIES
Rübesam T.1, Jain M.2, Pioch E.1
1University of Gloucestershire, Cheltenham, UK, 2BioMarin Europe Limited, London, UK
Objectives: Hospital formularies are usually the gatekeepers for pharmaceutical 
drugs. Typical majority members of hospital formularies are physicians, although 
most of the time the formulary is chaired by a pharmacist. As German hospitals 
are struggling with a difficult economic environment the question arises: what 
kind of decision-making criteria are applied when pharmaceutical drugs should 
be added to the formulary list? Information regarding this topic is scarce due to 
the sensitive topic of decision-making. Only one study (Thürmann et al., 1997) is 
looking into this for Germany. MethOds: a total of 588 public, private and ecclesi-
astic hospitals in Germany have been contacted to participate in an online-survey 
regarding the structure of their hospital formulary, roles of members and applied 
decision-making criteria. Results: Thirty-five of 588 hospitals (6%) have finally 
participated and filled out the complete questionnaire. Out of the 35 participants, 
29 were pharmacists (82.9%) and 6 were physicians (17.1%). 34.3% of the hospitals 
have no guidelines for their decision-making and 65.7% of the hospitals with guide-
lines have written (48.6%) or verbal (17.1%) guidelines. Out of these, 78.3% discuss 
decision-making criteria, but only 47.8% talk about the relative importance of the 
discussed decision-making criteria. Budget impact (82.6%), clinical studies (69.6%) 
and price (65.2%) are the most often mentioned decision-making criteria in the 
guidelines. cOnclusiOns: A third of the participating hospitals do not have guide-
lines for their decision-making process and only half of the guidelines discussing 
decision-making criteria also talk about the relative importance. Hospital formular-
ies in Germany do not seem to be transparent in their decision-making process. In 
addition the top 3 decision criteria in the existing guidelines include 2 economical 
criteria which lead to the question of dominance of economical versus medical or 
other criteria. Further research needs to look at the real applied decision-making 
criteria and how much impact economical criteria have on decision-making in 
German hospital formularies.
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2.5 yEARS OF AMNOG IN GERMANy – AN ANALySIS OF BENEFIT ASSESSMENT 
AND NET PRICE NEGOTIATION TRENDS
Dehnen J., Schmoeller M.
IMS Consulting Group, Muenchen, Germany
Objectives: In 2011, the AMNOG law changed the price-setting procedure for drugs 
in Germany. Manufacturers are now required to submit a dossier to the Federal 
Joint Committee (GBA) for newly launched or, upon specific request, already market 
products. The GBA decides on the level of additional benefit which impacts the reim-
bursement price negotiations with German sick funds. The objectives of this study 
were thus to: 1) identify ways in which manufacturers can optimize the benefit 
developing the candidates, with investigational oncology drugs representing the 
largest proportion (53%). Orphan diseases make up the second largest group with 
over a third of publicly disclosed BT therapies. In therapeutic areas with already 
available treatment options, such as Hepatitis C Virus infections and advanced mela-
noma, there is still potential for drug candidates to gain BT designation if they can 
be shown to provide an alternative to effectively treat patients that fail to respond 
to the current standard of care. cOnclusiOns: Our investigation has highlighted 
the FDA’s focus on finding breakthrough candidates within oncology as well as 
rare genetic or orphan diseases that do not currently have adequate treatment 
options. Additionally, candidates offering alternative options to non-responders 
have also secured a place on the list, which is likely to grow as increased interest 
and awareness is generated.
PHP16
MEDICO-ECONOMIC EvALUATION IN FRANCE: METHODOLOGy AND IMPACT 
ON THE PRICING AND REIMBURSEMENT SySTEM
Furet J.1, Marinoni G.2, Ando G.2
1IHS Global, Paris, France, 2IHS, London, UK
Objectives: From October 2013, some pharmaceutical products will be required 
to undergo a medico-economic evaluation in France. The aim of this study was to 
interview key stakeholders involved in this conceptual change in order to under-
stand how this reform will be implemented and how it will affect market access 
in France. MethOds: Primary research was conducted between April and June 
2013 with stakeholders from the French National Authority for Health (HAS), the 
Economic and Public Health Evaluation Commission (CEESP), the Transparency 
Commission (TC) and relevant French ministries. Interviews lasted between 45 
and 75 minutes and focused on the methodology for medico-economic assess-
ment and its implications on the French pharmaceutical pricing and reimbursement 
(P&R) process. Results: Medico-economic evaluation in France will be based on 
cost-utility or cost-effectiveness analyses, depending on whether or not quality 
of life is an important outcome. Cost-utility analyses will rely on QALYs (quality-
adjusted life years), whereas cost-effectiveness analyses will rely on survival. The 
medico-economic assessments will inform pricing negotiations, on the one hand, 
and potentially the development of prescribing guidelines, on the other. Medicines 
will be subjected to a medico-economic assessment based on their level of innova-
tion and/or on their financial impact on the health care budget. cOnclusiOns: 
France is formally introducing the QALY into its P&R system; however, this reform 
will come with a twist on the Anglo-Saxon approach, as there will be no associated 
ICER (incremental cost-effectiveness ratio) above which the medicine will not be 
reimbursed. While there is still some level of uncertainty with regards to the medi-
cines that will be subjected to this assessment (as stakeholders have yet to put a 
quantitative value on a “significant impact” on the health care budget), the direction 
of travel is toward greater pressure on pharmaceutical prices.
PHP17
OvERCOMING THE HTA HURDLE IN GERMANy: KEy CONSIDERATIONS FOR A 
MANUFACTURER’S PRICING AND MARKET ACCESS STRATEGy
Ratcliffe M., Ralston S., Chetty M.
PHMR Associates, London, UK
Objectives: In 2011, we saw the introduction of an evidence-based pricing 
approach to new branded pharmaceuticals in Germany. The process arose from the 
Act of the Reform of the Market for Medicinal Products (AMNOG) and all new drugs 
must undergo clinical benefit assessment by the Federal Joint Committee (GBA) fol-
lowed by price negotiation with the German sick fund (GKV-SV) heads depending on 
whether additional benefit has been demonstrated. A review of the final GBA assess-
ments published to date was undertaken and the aim was to evaluate the implica-
tions for manufacturers considering Germany as a launch country. MethOds: The 
GBA and IQWIG websites were searched for AMNOG evaluations performed between 
January 2011 to May 2013. Where appropriate the approach taken in the GBA assess-
ment was compared with that of other HTA groups in Europe. Results: The most 
important consideration for a manufacturer is choosing the right comparator in 
their submission, the core evidence document in this process. A number of drugs 
have been compared to the wrong treatment and subsequently were found to have 
no additional benefit. Some submissions chose the appropriate comparator but 
only for certain subgroups, leading to a reduced overall benefit for the new drug. 
Like most HTA groups, the preference is for mortality, morbidity and side effects 
evidence from head-to-head trials, however GBA appear to give little considera-
tion to quality of life evidence. The review also revealed that GBA make decisions 
that are independent of other HTA bodies and sometimes reject recommendations 
of its own evidence review group, IQWIG. cOnclusiOns: Early engagement with 
GBA to agree an appropriate comparator, patient population and clinical outcome 
measures is very important to improve chances of a positive assessment. However, 
the requirements of the GBA process should be balanced with those of other key 
markets as part of the drug’s global PRA strategy.
PHP18
TROIKA IN PORTUGAL: PHARMACEUTICAL SECTOR FROM PAPER TO REALITy
Teixeira I., Mendes Z., Guerreiro J.P., Costa S.
Centre of Health Research & Evaluation (CEFAR), National Association of Pharmacies (ANF), 
Lisbon, Portugal
Objectives: The Memorandum of Understanding signed in May 2011, between the 
Portuguese Government and the International Authorities, increased requirements 
to reduce the public expenditure with medicines. These measures included the 
major change in margins distribution system. This study aims to: 1) describe the 
MoU measures related to medicines; 2) analyze public expenditure and impact of 
distribution margins reductions on medicines public expenditure, due to MoU and 
legislative changes in Portugal. MethOds: Descriptive study with updates to the 
MoU and published legislation. Market analysis and simulations were computed 
based on the Pharmacy Sales Information System (a nationwide database with 
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and European countries. MethOds: Comparison of miligram based prices analy-
sis between European countries done by Intelligent Health System(IHS) was used. 
The analysis of IHS included Germany, France, United Kingdom(UK), Spain and 
Italy(EU5). Comparison was done with taken row data of analysis EU5 and Turkey 
average milligram retail prices of Ceftriaxone, Clopidogrel, Esomeprazole, Fentanyl, 
Lamotrigine, Levofloxacin, Metformin, Venlafaxine, Letrozole and Olanzapine 
molecules. Results: It has been reported that compared 10 molecules highest 
average miligram based prices of Esomeprazole(0,043 € ), Levofloxacin(0,058 € ) and 
Clopidogrel(0,0083 € ) molecules belong to Turkey, Lamotrigine(0,01 € ) belongs to 
Germany. The highest average miligram based prices of other 6 molecules belong 
to UK with following; Ceftriaxone(0,0196 € ), Fentanyl(0,186 € ), Letrozole(1,24 € ), 
Metformine(0,00013 € ), Venlafaxine(0,0074 € ), Olanzapine(0,261 € ). cOnclusiOns: 
It has known that because of UK used free pricing mechanism on drugs, prices of 
drugs are higher than other compared countries. This sitiuation established on the 
anaylsis. But despite of Turkish Government policy decisions; it is important indicia-
tion that 3 drugs represents highest prices out 10 drugs. Reference pricing system 
applied based on box price. Better control mechanism may achievable if miligram 
based pricing apply in Turkey. On the other hand because of the study only consist 
retail sales prices the evaluation should be done from point of reimbursement 
prices on future studies.
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CONSUMPTION OF BIOSIMILAR DRUGS IN CAMPANIA REGION IN THE yEARS 
2009-2012
Menditto E.1, Cammarota S.1, Putignano D.1, Orlando V.1, Fiorentino F.2
1CIRFF-Center of Pharmacoeconomics, Naples, Italy, 2Regional Health Authority of Campania 
region, Naples, Italy
Objectives: The expiration of biotech drugs patent has led to the creation of drugs 
copies of originator products, defined ‘biosimilars’. No European country allows 
automatic substitution between the originator and the biosimilar. In Italy, due to 
the lack of a national legislation, some Regions have issued directives to encour-
age the use of biosimilars, recognizing a potential saving of resources. Campania 
Region was the first region to legislate on the matter, (decree no. 15 of 11.30.2009) 
supporting the prescription of biosimilars to the naive patient. The aim of our 
study is to describe trends in biosimilars consumption in Campania region and 
evaluate how biosimilar products are replacing the originators in the respective 
markets. MethOds: IMS Health regional database was used to analyze biosimi-
lar drugs consumption patterns (erythropoietins, G-CSF, somatropin) in the years 
2009- 2012. Information was retrieved about different distribution channels (retail, 
direct distribution, hospital). Consumptions are expressed in Counting Units (CU) 
and trends have been calculated using Compound Average Grow Rate (CAGR). The 
study especially focused on consumption trends of erythropoietin (ATC B03XA) in 
the years 2009-2012. Results: In 2012 the penetration rate of biosimilars was 40.1% 
(evaluated as the biosimilars share of the total erythropoietins, G-CSF, somatropin 
market). These values are double than those at national level, that are estimated to 
be 19.7% of consumption. Focus on erythropoietin trends showed a strong increase 
in biosimilars consumption (451 CU in 2009 vs 140,327 CU in 2012) after the introduc-
tion of regional measures to promote the prescription of biosimilars to the naive 
patient. In 2012, biosimilar erythropoietins and reference drugs show similar market 
shares (37.0% and 33.7% of the total erythropietins market respectively) showing 
a high substitution effect. cOnclusiOns: Our analysis outlines the significant 
effects of regional measures on market penetration rates of biosimilars.
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INDIRECT AND DIRECT SAvINGS RESULTED FROM PARALLEL TRADE OF 
PHARMACEUTICALS IN POLAND – RESULTS OF vALUATION SALES DATA FROM 
PUBLIC PHARMACIES
Baran-Lewandowska I., Hermanowski T.
Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
Objectives: Estimation of the direct and indirect savings generated by parallel 
importing (PI) of pharmaceutical products in public pharmacies in Poland, and esti-
mation of the savings for the payer in the case of reimbursed drugs. MethOds: IMS 
Health Poland National Sales Data (2005-2012) and data from respective reimburse-
ment lists were used for all calculations. Direct savings were estimated considering 
all PI products sold in public pharmacies(433 products, 1550 SKUs). To avoid overes-
timation, only 18 products that passed restrictive criteria were used for calculations 
of indirect savings. Twenty-seven reimbursed products were used for the payer 
savings calculations. Direct savings were calculated as a difference between PI and 
reference product prices multiplied by the number of packs of PI product. Indirect 
savings were calculated as a difference between the reference product price and 
the theoretical reference product price (i.e. prices in a hypothetical situation where 
there is no price pressure caused by PI – calculated using linear regression). Indirect 
savings considered only those products which met the criteria of the reference 
product’s price decrease of at least 5% within 3 months prior to, or after, the appear-
ance of the PI product. Results: Study revealed that the savings generated by the 
PI of pharmaceuticals in Poland between 2005-2012 may be estimated at the level 
of EUR 146m (direct savings EUR 46m and indirect savings EUR 100m). Savings for 
the payer calculated for reimbursed products between 2008-2012 reached the level 
of EUR 0.06m. cOnclusiOns: This is the first study estimating direct and indirect 
savings coming from PI phenomena covering all years since PI was reinforced by 
Poland’s accession to the EU. It has been found very interesting that indirect sav-
ings tend to be substantially higher that direct ones. This indicates that high price 
pressure is created by PI, and affects the prices of reference products.
PHP27
PRICING OF “FOLLOw-ON” DRUGS AND COMPETITION wITHIN 
PHARMACEUTICAL CLASSES: EvIDENCE FROM GERMANy 1993-2008
Mueller M.T.1, Frenzel A.2
1Universität Witten/Herdecke, Witten, Germany, 2IMS Health, Frankfurt/Main, Germany
assessment outcomes, 2) analyze correlations between additional benefit, budget 
impact and negotiated rebate. MethOds: To achieve objective 1, assessments by 
the GBA and the IQWiG (Institute for Quality and Efficiency in Healthcare) (source: 
GBA website) were scanned for key trends. To achieve objective 2, list and post-
negotiation prices were extracted from the Lauer-Taxe (German price database). 
For the 10 agents that had so far completed price negotiations, these were mapped 
against additional benefit and the budget impact (annual therapy costs as stated 
in GBA assessment). Results: The results linked to objective 1, which were more 
qualitative in nature, allowed for the extraction of 5 key learnings for manufacturers 
to keep in mind. The results associated with objective 2 showed no link between 
additional benefits granted and negotiated rebate but did reveal price impacting 
parameters apart from budget impact. cOnclusiOns: Concerning objective 1, the 
ways in which manufacturers can attempt to optimize benefit outcomes include: 1. 
Focus on comparator choice, 2. Focus on hard endpoints, 3. Make patient segmenta-
tion more solid, 4. Expect independent action of GBA and IQWiG and 5. Accept that 
there is no methodological standard for the definition of an additional benefit. 
Regarding objective 2, we concluded that budget impact, influenced primarily by 
target population size, annual therapy costs and drug price, is an – if not the most 
important driver in the negotiation.
PHP22
IS DRUG INNOvATION STILL REwARDED IN THE TOP 5 EUROPEAN 
PHARMACEUTIAL MARKETS?
Reinaud F.1, Ando G.2
1IHS, Paris, France, 2IHS, London, UK
Objectives: To assess how drug innovation is rewarded and how it is impacted 
by cost-containment policies. MethOds: Manufacturer prices per unit of pack-
age and strengths were compared and assessed in a basket of 97 innovative drugs 
approved by the European Medicines Agency (EMA) since 2000. The products were 
still patent protected, and available in each of the top 5 European pharmaceutical 
markets. Results: Prices of innovative drugs in Germany were still the highest and 
had a benchmark price index of 100. In France, when drugs were deemed innova-
tive, premium prices were granted – resulting in a price index of 94 – but signifi-
cantly decreased over time. While prices at launch in Italy, Spain and the UK were 
commonly lower – with price indexes of 89, 88 and 86 respectively - they tended 
to remain constant over time. cOnclusiOns: Despite the fact that governments 
in developed markets are attempting to lower prices, differences still exist across 
the largest markets, enabling pharmaceutical companies to implement differential 
and protective pricing strategies. In Germany, time to market is comparatively fast 
and premium prices at launch have been granted. In future, the AMNOG reform 
will complicate this picture, although pricing premiums have still been achieved 
for drugs deemed innovative that have gone through the full AMNOG process. In 
France, although prices are relatively high at launch, they drop at time of renewal 
and innovation is granted to a limited number of drugs. Prices have been compara-
tively low at launch but remain constant in Italy and Spain, reflecting the fact that 
price cuts in those countries have often been directed towards generics, although 
these are still considered high-risk markets. In the UK, it remains to be seen how 
the value-based pricing reform will impact prices.
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ACCESSIBILITy OF ORPHAN DRUGS IN FRANCE, UNITED KINGDOM AND 
GERMANy: DIFFERENT APPROACHES wITH REGARD TO HTA AND PRICES
Grandfils N., Hounkanlin H., Troubat A.
IMS Health, PARIS LA DEFENSE, France
Objectives: To describe availability of orphan drugs in France, UK and Germany and 
to compare agencies’ assessments and prices. MethOds: All the products designated 
as orphan drugs by the European Commission and commercialized at least in one of 
the three countries were included in the study. Comparison of prices is made per dos-
age and is based on prices per standard unit, using IMS MIDAS database. Comparison 
of assessments is based on Transparency Committee opinions, NICE guidances and 
IQWIG benefit assessments. Results: Sixty-two products (103 dosages/forms) were 
included in this study; 47 (76%; 84 dosages/forms) are commercialized in the 3 coun-
tries, 8 (13%) products in only 2 countries (6 both in Germany and UK and 2 both in 
Germany and France) and 7 (11%) only in 1 country (6 in Germany only and 1 in France 
only). Among the 84 products/dosage/forms available in the three countries, most of 
them are available at hospital (respectively 68, 70 and 77 in Germany, France and UK) 
but those available through retail pharmacists are much numerous in Germany (72 of 
them) than in France (29) or UK (30). German and UK manufacturer March 2013 retail 
prices more often higher than French one, despite the fact that among the 49 orphan 
drugs commercialized in France, 31 are innovative products (ASMR rate I to III). For 
instance, French assessment of pirfenidone was less favorable than the Germans’one, 
and German price is thus +65.2% higher than French price. French and UK HTA assess-
ments for azacitidine were both positive and led to similar prices. cOnclusiOns: 
Most orphan drugs are available in the three studied countries but accessibility to 
them seems to be different and depends on HTA results.
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COMPARISON RETAIL PRICES OF DRUG PRICES BETwEEN TURKEy AND 
EUROPEAN COUNTRIES
Kockaya G.1, Atikeler K.2, Esen A.3, Tuna E.2
1Health Economics and Policy Association, Ankara, Turkey, 2Hacettepe University, Ankara, Turkey, 
3Yeditepe University, Istanbul, Turkey
Objectives: The reference pricing system is used for setting drug prices in Turkey 
since 2006. There are 5 reference countries following; Spain, Italy, Germany, France 
and Greece. Except those countries, manufactured or imported countries may be 
used as reference countries. Reference prices are reviewed time by time and may 
be subject to certain alterations, but evaluation of box prices may be different if 
evaluation made based on milligram. The aim of this study is to evaluate differ-
ences of average milligram sales prices of some generic medicines between Turkey 
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The margin index was 21% in 2009 and 20% in 2010. Since all drugs were Rx 
(margin was set up to 12%, VAT was fixed to 8%), this was completely expected. At 
the end of 2010, two medicines: levonorgestrel (1,5mg) and orlistat (60mg), were 
authorised as OTC medicines (free pricing, margin:25%, VAT:18%). cOnclusiOns: 
“Lifestyle-medicines” are difficult to define. Market success depends on prod-
uct characteristics, effectiveness, tolerability, convenient drug-delivery format, 
simple dosing regimen, good safety profile, first-to-market position, premium 
prices, sustained media attention, Rx-OTC switch potential and reimbursement 
potential. Although more new “lifestyle-medicines” will be authorised in Serbia, 
market share is expected to decrease because of low purchasing power and low 
reimbursement potential.
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IS ExTERNAL PRICE REFERENCING AN APPROPRIATE DRUG POLICy FROM AN 
EFFICIENCy, EQUITy, AND QUALITy PERSPECTIvE?
Wouters O.J., Kanavos P.
London School of Economics and Political Science, London, UK
Objectives: Different external price referencing (EPR) configurations are applied 
by countries worldwide. Depending on how EPR schemes are implemented, 
they may have varying effects on short- and long-run prices, market dynam-
ics, key stakeholders, and other relevant endpoints. This research evaluated 
the merits and demerits of EPR from an efficiency, equity, and quality perspec-
tive. MethOds: A theoretical and empirical analysis of the effectiveness of 
EPR was conducted, based on a systematic review of the literature and stake-
holder interviews. As EPR has been most common in Europe, the study focused 
on this region. Results: The systematic review identified 100 relevant articles. 
The articles were categorised according to study characteristics and four major 
themes were identified; these findings were confirmed by the interviewees. The 
evidence suggests that EPR schemes often generate disproportionate price lev-
els in relation to national abilities to pay; this is likely due to the reliance on 
foreign list prices which do not reflect negotiated discounts. If manufacturers 
apply launch strategies to exert upward pressure on prices (e.g. launch delays or 
product withdrawals), it may also limit patient access to life-saving medicines. 
In addition, the bureaucratic complexity of many EPR schemes may undermine 
the objectives of EPR use (i.e. cost containment and macroeconomic efficiency). 
Finally, widespread EPR application may stifle pharmaceutical and biomedical 
innovation. cOnclusiOns: A national pricing policy should provide an effec-
tive, predictable, transparent, and stable pricing environment for pharmaceutical 
products. It should internalise national priorities for health and industrial policy, 
including cost containment, employment, innovation, and trade promotion. EPR 
is associated with important short- and long-term issues. If EPR is going to con-
tinue to be applied by EU Member States and other countries, then it is necessary 
to establish guiding principles to govern EPR use across jurisdictions. Still, dif-
ferential pricing and risk-sharing agreements may represent more sustainable 
policy options.
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DOES EUROPE REwARD REFORMULATIONS? A DATA DRIvEN ANALySIS OF 
vALUE PRESERvATION THROUGH REFORMULATION
Hughes A.L.H.1, Luft D.1, Lions I.2, Flostrand S.J.A.3
1IMS Consulting Group, London, UK, 2IMS Consulting Group, Basel, Switzerland, 3IMS Consulting 
Group, La Défense Cedex, France
Objectives: Reformulating existing drugs can improve patient convenience, com-
pliance and create new uses for the product. However, reformulations cost millions 
of Euros - a risky investment without guaranteed exclusivity or returns. This study 
assessed whether markets reward incremental value creation through reformu-
lation by comparing sales performance close to patent expiry for reformulated 
and non-reformulated products. MethOds: IMS MIDAS data was interrogated to 
identify 829 small molecule, non-generic products which had peak sales above € 5M 
and lost patent protection between 2001 and 2010 in EU-5 (France, Germany, Italy, 
Spain and UK). Ex-manufacturer sales value (€ ) 2 years after patent expiry was 
compared with sales value 4 years earlier to calculate percentage value erosion 
for each of the 829 products. A subset of 133 products which launched at least 1 
reformulation close to patent protection expiry (launch between 3 years before 
and 1 year after patent protection expiry) were analysed to assess whether value 
erosion varied across countries or therapy areas. Results: Mean ex-manufacturer 
sales value erosion of reformulated products (24%) was significantly less than 
non-reformulated products (37%, P< 0.01). Reformulated product value erosion 
varied with country and therapy area. Germany saw highest number of reformu-
lations launched yet only reformulations launched in Italy showed significantly 
less value erosion than non-reformulated products (P< 0.01). Across therapy areas, 
reformulations were most common in nervous system, metabolism and anti-
infective categories. However, reformulated anti-infective product value erosion 
was pronounced while musculoskeletal and nervous system products experi-
enced significantly less value erosion than for non-reformulated products (both 
P< 0.05). cOnclusiOns: Overall, reformulated products do maintain more value 
than non-reformulated products following loss of patent protection. Chronic 
disorders e.g. nervous and musculoskeletal system disorders appear to be the 
most promising areas for reformulating. Future reformulation potential is tightly 
linked to country-specific pricing and market access policy decisions to recognise 
incremental value products.
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CONSTRUCTING AN INDEx OF INTERNATIONAL PHARMACEUTICAL PRICES. A 
COMPARISON OF PHARMACEUTICAL PRICES IN 56 COUNTRIES
Davey P.
Macquarie University, Sydney, Australia
Objectives: To construct a number of pharmaceutical price indices for a broad set 
of countries, covering a range of regions, including countries with different levels 
Objectives: Competition within therapeutic drug classes from “follow-on” drugs 
has been a highly controversial issue. Manufacturers launching new molecules 
in existing drug classes have often been criticized for inflating health systems’ 
expenses, but it has been argued that such drugs increase therapeutic options. 
Economic theory suggests that follow-on drugs induce price competition. We con-
tribute to this discussion by addressing the topic of pricing at market entry and 
price development in the German market with the distinct focus on competition 
within already existing drug classes. MethOds: We measure determinants of 
price strategies of follow-on drugs using regression analyses, considering all new 
molecules launched in the German market in the period from 1993-2008. Prices of 
products are standardized on Defined Daily Dosages controlling for sales volumes 
based on data from the IMS Health DPM database, a census audit of pharmaceutical 
sales in Germany, and for the therapeutic quality of a new product using ratings 
by Fricke/Klaus as a proxy for innovation. Results: We identify prices correlating 
with therapeutic value at market entry. While the first two molecules engage in 
quality competition by offering more therapeutic options, price discounts below the 
market price can be observed from the third entrant on. Price discounts are even 
more distinct in development races with several drugs entering the market within 
two years and in classes with a low degree of therapeutic differentiation. Prices 
remain relatively constant over time. cOnclusiOns: This study contributes to 
assessments of competition in pharmaceutical markets focusing on price strategies 
of new market entrants. After an initial phase of market building, further follow-on 
products induce price competition. Largely unchanged prices after 4 years may be 
interpreted as quality competition and can be attributed to prices in Germany being 
anchor point for international price referencing.
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THE IMPACT OF GENERIC SUBSTITUTION ON HEALTH OUTCOMES AND COSTS: 
A SySTEMATIC REvIEw
Schall I.1, Saverno K.2, Luzak A.1, Mitrovic M.1, Gothe H.3, Brixner D.4, Siebert U.5
1UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, 
2Department of Pharmacotherapy, University of Utah / UMIT – University for Health Sciences, 
Medical Informatics and Technology, Salt Lake City, UT, USA / Hall i.T., Austria, 3UMIT - 
University for Health Sciences, Medical Informatics and Technology / ONCOTYROL - Center for 
Personalized Cancer Medicine, Hall i. T. / Innsbruck, Austria, 4UMIT, Salt Lake City, UT, USA / 
Hall i.T., Austria, 5UMIT – University for Health Sciences, Medical Informatics and Technology / 
ONCOTYROL / Harvard University, Hall i. T./ Innsbruck / Boston, Austria
Objectives: Although generic drugs are considered to be therapeutically equivalent 
to their off-patent (branded) counterparts, the overall impact of generic substitu-
tion on clinical and economic outcomes has not been comprehensively evaluated. 
The goal of this study was to test whether 1) generics and branded products yield 
the same health outcomes; and 2) generic therapies save economic resources ver-
sus branded therapies for de-novo patients and patients on maintenance ther-
apy. MethOds: We performed a systematic literature review in Medline, Cochrane 
Database of Systematic Reviews and Embase (2000-2012) to identify original research 
studies on clinical or economic outcomes with either independent or pre-post com-
parator groups. Data were aggregated using a standardized extraction form. For 
each included study, outcomes were categorized as favoring or opposing generic 
drug substitution. As we compared different outcomes, one publication could 
contribute to multiple outcome comparisons. Results: We included 40 studies 
that led to 121 outcome comparisons. Similar clinical effects were found in 74% 
of all studies in which patients were initiating therapy (de novo) and 64% of all 
studies involving maintenance therapy comparisons. 100% of the economic analy-
ses of de novo patients and 56% of comparisons of maintenance therapy patients 
showed lower costs associated with the use of original brand. Overall, 66% of the 
outcome comparisons reported similar clinical outcomes and 64% suggested that 
brand products lower costs compared to generic substitution. cOnclusiOns: Our 
analyses suggested that clinical effects were mainly similar, whereas economic 
savings of brand to generic drug substitution may be overstated, particularly in 
sensitive therapeutic areas such as anti-epileptic drugs or immunosuppressives. 
More systematic research comparing clinical and cost outcomes with or without 
generic substitution is needed to inform policy on the use of generic substitu-
tion. AcknOWledgeMents: We would like to thank Anke-Peggy Holtorf and 
Zoltán Kaló for their scientific input.
PHP29
PRICING AND REIMBURSEMENT ANALySIS OF LIFESTyLE MEDICINES IN SERBIA
Baltezarevic D.1, Petrova G.I.2, Medic G.3, Samardzic J.4
1Pharmacoeconomics Section of the Pharmaceutical Association of Serbia, Belgrade, Serbia and 
Montenegro, 2Medical University, Faculty of Pharmacy, Sofia, Bulgaria, 3Mapi - HEOR & Strategic 
Market Access, 3995 AX Houten, The Netherlands, 4University of Belgrade, Medical Faculty, 
Belgrade, Serbia and Montenegro
Objectives: To determine whether there was a difference between wholesale 
prices, utilization and market share, as well as to explain Rx-OTC switches and 
reimbursement possibilities of “lifestyle-medicines”, in 2009 and 2010, before and 
after the adoption of new Medicines Law, in Serbia. MethOds: We investigated 
how many potential “lifestyle-medicines”, satisfying the previously determined 
criteria, were authorised for sale. Utilization, price changes and reimbursement 
status were monitored. Price index and margin index were calculated using the 
formula: I= QxP (index(I),quantity(Q),price(P)). To compare the differences in prices 
and utilization, non-parametric Mann-Whitney test was used. To test difference 
in market shares, T-test of proportion was used. Results: There were 21 regis-
tered “lifestyle-medicines”. Five medicines (oral contraceptives) were listed. In 
2009, there were 1,763,030 units dispensed worth 16,074,922€ . In 2010, 1,814,405 
units were dispensed while total value was 14,129,792€ . The average sales(€ ) were 
higher in 2009, which is not in line with the expected growth trend, but observed 
difference was not statistically significant. The wholesale price-index 2009/2010 
was -13%. This means that prices were 13% lower in 2010. In fact, during 2010, 
prices remained the same in national currency, which weakened against euro. 
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INTRODUCTION OF INNOvATIONS INTO THE GERMAN STATUTATORy 
REIMBRUSMENT SySTEM – FACTORS FOR SUCCESS
Krensel M.
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Objectives: Innovations are fundamental for progress and improvement in health 
care and medicine. In German hospitals provision of all kind of services is allowed, 
since it is not forbidden explicitly. But it is paid only if it is represented in the reim-
bursement system. For integration of innovations into this system applications must 
be addressed by each hospital which wants to provide a special innovative service in 
each year separately to the German institute for reimbursement in hospitals which 
decides about (additional) payments. The objective is to determine which factors 
influence the chance for innovations being incorporated. Results can be used by hos-
pitals to assess if certain innovations have good chances to be afforded. MethOds: 
Data about applications, their approval and assessment, number of hospitals and 
years in which approvals were made were obtained from the German institute for 
reimbursement systems in hospitals from 2005 to 2011. Innovations have been 
classified into types of methods. Applications made by medical associations and 
for orphan drugs were identified. Associations between each variable and success 
of application were calculated. In all analyses Bonferroni correction was conducted. 
Finally intercorrelation of variables was assessed. Results: Chance of integration 
was best for innovations with the following characteristics: Applications were made 
by medical associations, innovations were applied over a period of 6 years and by 
more than 100 hospitals, subjects were drugs (especially orphan drugs) and they 
belong to gynecology, oncology or cardiology and vascular medicine. Intercorrelation 
between these independent variables is also a predictor of success in some constel-
lations. cOnclusiOns: The success of integration of a new method depends on all 
analyzed variables. Therefor all of them have to be taken into account when decision 
is made about what innovation should be applied.
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THE IMPACT OF AMNOG ON DRUG REIMBURSEMENT IN GERMANy
Heeg B.1, Schoeman O.2, Mueller S.3, Wilke T.3
1Pharmerit International, Rotterdam, The Netherlands, 2Pharmerit International, Berlin, Germany, 
3IPAM - Institut für Pharmakooekonomie und Arzneimittellogistik, Wismar, Germany
Objectives: There are three main governmental stakeholders in the German 
AMNOG process: The IQWiG assesses the AMNOG drug manufacturer’s submission 
and provides advice on any additional benefit to the GBA who makes the final deci-
sion. Following confirmation of additional benefit, manufacturers start price nego-
tiations with the GKV-Spitzenverband (association of German sickness funds). The 
aim of this research is to assess the AMNOG-decisions so far. MethOds: All AMNOG 
decisions up to December 2012 were analyzed in terms of additional benefit deci-
sion, reason for additional benefit decision, reimbursed price versus manufacturer 
set price, and consistency in IQWiG-recommendation and GBA-decision. Results: 
In total AMNOG decisions of 41 drugs (60 subgroups) were identified. IQWiG rec-
ommendations were as follows: 22 cases demonstrated no additional benefit, 2 
unquantifiable benefit, 3 slight benefit, 7 significant benefit, and 7 additional benefit 
due to orphan-drug status. In 6 cases, the GBA upgraded IQWIG’s recommenda-
tions. In 3 cases it downgraded it. The following reasons were identified for GBA 
“additional benefit decisions” (multiple reasons apply for some decisions): No or 
non-quantifiable additional benefit (18 cases); no reliable clinical data (14 cases; 3 
cases no submission), wrong comparator (5 cases); additional benefit in any form 
(23 cases): mortality advantages (7 cases), orphan drug status (7 cases), morbidity 
advantages (8 cases), and QoL advantages (3 cases). The negotiated price rebates 
varied from 4.7% to 70.7% based on manufacturer set price; the rebates show limited 
correlation to the degree of additional benefit so far. cOnclusiOns: Key factors for 
positive AMNOG decisions are conducting superiority trials on mortality or at least 
morbidity/QoL against active comparators. If benefits are based on soft end-points, 
it is crucial to demonstrate these on high quality, preferably German data. Indirect 
comparisons seem to be challenged as proof of additional benefits.
PHP37
EU PAyER AND DECISION MAKER USE OF OBSERvATIONAL STUDIES FOR 
HEALTH CARE REIMBURSEMENT DECISIONS
Hogue S.1, Hollis K.2, McLeod L.2, Brogan A.1, Heyes A.E.3
1RTI-Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Research Triangle 
Park, NC, USA, 3RTI Health Solutions, Manchester, UK
Objectives: As cost-containment pressures across Europe intensify, evidentiary 
hurdles to justify new drugs will continue to grow. Data from clinical trials alone are 
no longer adequate to meet the needs of all health care decision makers (e.g., payers 
and health technology assessment [HTA] agencies, physicians and patients), driving 
a need for robust, complementary data. However, perceived need to collect real-world 
clinical, patient-centered, and/or economic outcomes through observational studies 
varies across countries, stakeholders and organizations. The objective was to better 
understand how decision makers use observational studies to inform reimburse-
ment and/or market access decisions for new products. MethOds: Desktop research 
identified the types of observational studies most valuable for reimbursement deci-
sion making. This project extends a United States (US) payer study by conducting 
qualitative one-on-one interviews with decision makers across Europe to review the 
need for real-world evidence. Participants represented national and regional decision 
makers from several European countries, to identify specific evidence requirements 
and design attributes most accepted by payers/ HTA advisors and to understand 
how real-world evidence contributes to the value of a new drug from the decison-
makers’ perspectives. Results: Data from observational studies are used to describe 
patient segments, understand treatment patterns, resource utilization, and provide 
effectiveness data that supplement clinical trial data as well as inform risk sharing 
schemes. Observational studies help inform payer decision making but the valid-
ity and robustness of the results is often scrutinized. Publication of observational 
data in a Tier 1, peer-reviewed journal lends critical credibility to real-world study 
of economic development and a representative sample of medicines. MethOds: 
The indices were developed using the Fisher EKS method. In order to construct 
an index the products needed to be defined as like. The definition of like in this 
study was based on molecules which are deemed to deliver equivalent health 
outcomes. This is a very broad definition and allows a large number of coun-
tries and molecules to be included in the indices. Two price indices have been 
constructed. The first compares prices of mostly off-patent medicines across 56 
countries over the period from 2005 to 2011 and included 42 molecules which 
were sold in each country for the period. The second examined on-patent medi-
cines across 17 countries and 9 molecules. Results: The results showed prices 
varied significantly between regions and that prices of genericised medicines 
both fell and converged over time. For the mostly generic drugs index the regions 
from lowest to highest price were - Region of the Americas A; South-East Asian 
Region D; South-East Asian Region B; European Region B; Western Pacific Region A; 
European Region A; African Region E; European Region C; Western Pacific Region 
B; Eastern Mediterranean Region D; Region of the Americas D; Region of the 
Americas B and Eastern Mediterranean Region B. Prices tended to be similar 
within each region. These results will be presented in detail. cOnclusiOns: This 
research makes a unique contribution to our understanding of drug prices. It is 
the largest international comparison of pharmaceutical prices ever undertaken; 
employs new method to pharmaceutical pricing indices through the Fisher EKS 
method and outcomes based definitions of equivalence and examines genericised 
and on-patent markets separately.
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TRANSPARENCy OF THE MEDICINES REIMBURSEMENT SySTEM IN IRELAND: A 
QUANTATIvE ANALySIS OF THE INFLUENCES ON REIMBURSEMENT DECISIONS 
[2006-2013]
Mahon S., Redmond S., Carney P.
GlaxoSmithKline, Dublin, Ireland
Objectives: To identify what process and technology related characteristics influ-
ence reimbursement decisions in Ireland. MethOds: Using publically available 
data compiled from the NCPE and HSE websites from 2006 to 2013, we examined sev-
eral variables (disease area; transparency; and, assessment and judgement of effect 
and CE), as defined in Fischer (2013), to identify what influences reimbursement 
decisions made through the community drugs schemes (i.e. GMS, and High Tech 
schemes). Analyses included, Spearman’s Rank Correlation (SRC), Kruskal-Wallis 
and Fishers exact tests in the univariate analyses, and a step-wise multivariate 
regression. Results: For technology features most disease areas were found not 
to have a significant influence on reimbursement decisions (SRC: max 0.30, Fishers 
Exact: p> 0.10; and, regression analysis p> 0.10). However, treatments for endocrine 
conditions were significant (p< 0.10). For process features the availability, quantity, 
and type of assessment information were strongly correlated with reimbursement 
decision (SRC: ≥ 0.73). Judgement of effect and cost-effectiveness were significant 
(p< 0.05), and the multivariate regression showed “transparency”, “judgement of 
effect” and “judgement of CE” to be statistically significant (odds ratios: 0.095, 
2.752, and 3.657 respectively; p< 0.10). cOnclusiOns: Overall, increased trans-
parency (i.e. publically available documentation of the decision rationale) has a 
negative influence on the likelihood of reimbursement. This can be explained by 
the Rapid Review process, whereby products are initially screened and selected for 
further HTA analysis. As expected, those not selected for HTA are more likely to 
be reimbursed, but have less documentation supporting the decision, introducing 
less transparency overall. Where a HTA has been conducted, judgement of effec-
tiveness and cost-effectiveness has strong positive influence on reimbursement, 
with cost-effectiveness being the strongest positive influence. Fisher (2013) found 
stakeholder involvement to be an important influence; this could not be tested in 
the Irish context as the numbers of stakeholders known to be involved are constant 
across all observations.
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RELEvANCE OF A NATIONAL FORECAST GROwTH RATE, AS A REGULATION 
TOOL OF THE ExPENSIvE HOSPITAL DRUG SPENDING, IN FRANCE
Monnier R., Degrassat-Théas A., Parent de Curzon O., Sinègre M.
General Agency of Equipment and Health Products (AGEPS), PUBLIC WELFARE HOSPITAL OF 
PARIS (AP-HP), PARIS, France
Objectives: In France, a forecast growth rate in spending related to the list of 
expensive hospital drugs, funded in addition to DRG-based payment, is determined 
annually (2% in 2012). If hospitals exceed the rate, they will be controlled, based on 
the proper use of drugs. The objective is to question the relevance of this national 
growth rate as a regulation tool. MethOds: This study used 2011/2012 data from 
“medicalized information system program”. Expensive drug expenditures are 
aggregated by each type of French hospitals (without private sector): cancer cent-
ers (CC= 19), university hospitals (UH= 32), hospitals centers (HC= 415) and private 
non-profit hospitals (PNPH= 104). In order to identify their specificities, we analyzed 
the expenditures of the first therapeutic class in value by hospital type and how 
much the top 3 drugs, that drive the overall growth, contribute to their respective 
growth. Results: Overall spending grew by 4.95% in 2012. Antineoplastic drugs (1% 
of decrease) represent 48% of overall expenditures. Their market share varies from 
34% in UH expenditures to 95% in CC, the only hospital type that meet the forecast 
rate. The top 3 drugs (2 immunosuppressant drugs and 1 replacement enzyme; 
17% of overall expenditures) contribute to 3.93 points of the total growth. Their 
contribution to the growth of each hospital types is uneven: from -0.02 point out of 
-6% in CC to 5.35 points out of 9.03% in UH. cOnclusiOns: There is a divergence 
in the growth of spending for the different hospital types because of their specific 
characteristics leading to different consumption profiles. Therefore, some hospitals 
are more impacted by changes in the spending structure, as CC for antineoplastic 
drugs. A regulation by an annual growth rate is useful because of its flexibility. But 
relevance of a single national rate does not reflect the care’s offer heterogeneity 
and needs local analyses.
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to result in any great changes, although in certain areas, price reductions can be 
expected. cOnclusiOns: Some downward pressure on prices in other EU markets 
is likely as Croatia becomes a reference market for IRP, although this is likely to be 
limited in scope in the short term, with only particular products and therapeu-
tic groups affected. Over the longer term, as more markets add Croatia to their 
reference-pricing baskets, this pressure is likely to intensify.
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GENERIC SUBSTITUTION IN IRELAND – THE vIEwS OF KEy STAKEHOLDERS
O’Leary A.1, Usher C.2, Lynch M.1, Interns and tutors1
1Royal College of Surgeons in Ireland, Dublin, Ireland, 2National Centre for Pharmacoeconomics, 
Dublin, Ireland
Objectives: The Health (Pricing and Supply of Medical Goods) Act 2013 passed in 
June 2013 provides for generic substitution in Ireland. The aim of the study was to 
ascertain the views of the stakeholders i.e. patients, pharmacists and prescribers on 
generic substitution,prior to the Act’s introduction. MethOds: Three stakeholder 
specific surveys were developed to assess knowledge of and attitudes to generic 
substitution. Convenience samples of health care professionals and patients were 
gathered until data saturation was achieved. Descriptive quantitative and qualita-
tive analysis was undertaken. Results: A total of 742 health care professionals 
and 330 patients responded. The study highlighted 4 areas where prescribers and 
pharmacists differed; (1) Prescribers ranked cost-savings as the most important 
information to impart to patients while pharmacists advocated therapeutic equiva-
lence as highest. (2) Pharmacists considered that more patients would be agreeable 
to generic substitution (52%) as compared to 41% of prescribers. (3) Prescribers 
considered that generic substitution would have a greater effect (25%) on patient 
care than pharmacists (14%). (4) 19% of prescribers supported generic substitution in 
all cases and 76% with some exceptions, compared to 16% and 84% for pharmacists 
respectively. More than 80% of patients were on between 1 and 8 medicines daily, 
and of these > 50% reported that they were on generic medicines. More than 80% 
would be happy with generic substitution, while more 75% of those interviewed 
considered generic drugs to contain the same drug, to be as effective and as safe 
as branded medicines. cOnclusiOns: To prevent possible confusion and concern 
among patients it is important that health care professionals acquire the necessary 
tools and knowledge to manage transition into and rollout of this new system, so 
that they can work together to ensure the obvious benefits of the new system are 
maximised.
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AN ANALySIS OF PRISCRIPTION AND REIMBURSEMENT OF POTENTIALLy 
INAPPROPRIATE MEDICATION (PIM) IN A GERMAN PRACTICE NETwORK
Pohl-Dernick K.1, Meier F.1, Maryschok M.1, Wambach V.2, Lindenthal J.2, Wunder S.3, 
Schöffski O.1, Emmert M.1
1Friedrich-Alexander-University Erlangen-Nuremberg, Nuremberg, Germany, 2Practice network 
“Qualität und Effizienz eG”, Nuremberg, Germany, 3AOK Bavaria, German Statutory Health 
Insurance, Nuremberg, Germany
Objectives: Potentially inappropriate medication (PIM) in the elderly increases 
the risk of adverse drug reactions (ADR) and consequently has an impact on both 
patients’ quality of life and health care costs. In 2010, the PRISCUS list was published 
in Germany to identify PIM and to propose adequate substitution medication. The 
objective of the study was to assess both the prevalence and reimbursement of 
PIM in a German practice network applying the PRISCUS list. Moreover, costs for 
proposed surrogates were evaluated. MethOds: Patients fulfilling the following 
criteria were included: (1) insured at the local health fund AOK Bavaria, (2) treated 
by physicians of the practice network, and (3) aged ≥ 65. Data was provided from 
AOK Bavaria and contained 214,177 anonymized prescriptions between Q1/2009 
and Q4/2011. Information included age, gender, date of prescription and ATC-Code. 
Since no information on dosage or package size was given, medication and its 
application duration were differentiated in acute and long-term medication by 
expert opinion. Costs were calculated by applying the concept of DDD. Results: 
On average, 16.0% of the patients received at least one PIM prescription each quarter. 
13,736 prescriptions were classified as PIM (6.4%; 68.7% to women). Out of these, 
psycholeptics such as Zopiclon (11.8%) and calcium antagonists such as Nifedipin 
(7.9%) were prescribed most frequently. Total costs of PIM-prescriptions were cal-
culated to be 446,430€ (mean 40,585€ per quarter; min. 32,869€ ; max. 50,024€ ). 
When assuming prescription of surrogates, costs varied between 267,990€ and 
935,826€ . cOnclusiOns: PIM represents both a medical and economic burden to 
the German health care system. From an economic perspective, substitution of PIM 
may result in cost disadvantages. Thus, there is little economic incentive for health 
insurances to further promote the substitution of PIM. Future research should take 
a broader perspective and include costs of PIM-related ADR to fully evaluate the 
economic impact of PIM in the elderly.
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HOw DOES PRESCRIPTION OF GENERIC DRUGS SPREAD OUT?: DATA MINING 
AND vISUALIzATION By USING PRESCRIPTION DATA FORM ACUTE CARE 
HOSPITALS NATIONwIDE
Shimizu S.1, Ishikawa K.B.2, Ikeda S.3, Fushimi K.4
1Institue for Health Economics and Policy, minato-ku, Japan, 2National Cancer Center, Tokyo, 
Japan, 3International University of Health and Welfare, Ohtawara-City, Japan, 4Tokyo Medical and 
Dental University Graduate School of Medicine, bunkyo-ku, Tokyo, Japan
Objectives: To clarify the spread with prescription of generic drugs and the shift 
from brand drug market by using nationwide administrative data. MethOds: For 
the sample, out of 30 drugs seen as the parameter for generic drugs in France, 27 
have been selected after considering their availability in Japan. For those drugs 
unapproved in Japan, they were replaced by other drugs with the same effects, 
and anticancer agents as well as radio contrast agents were added. New drugs 
listed to National Health Insurance list around the same time were also included 
for comparison. Database was created by extracting the data of patients who were 
results. cOnclusiOns: The current study extends the evaluation into Europe to 
confirm that as reimbursement decision makers continue to rigorously review new 
drug therapies, accurate, robust, peer-reviewed published and generalisable real-
world data will become particularly important for outcomes- or performance-based 
access schemes and health care budget management both in the US and Europe.
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THE SURvEy OF THE jAPAN-STyLE PREMIUM SCHEME IN PHARMACEUTICAL 
PRICING DECISIONS
Kamae I.1, Murata T.2, Suman D.3, Yamabe K.4, Sugimoto T.3, Kobayashi M.5
1The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, 2Crecon Research & 
Consulting Inc., Tokyo, Japan, 3The University of Tokyo, Tokyo, Japan, 4MSD.K.K. & HTA and Public 
Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan, 5CRECON Research 
& Consulting Inc, Tokyo, Japan
Objectives: To review the new drugs which were listed in the past on the Medical 
Fee Schedule of Japan, and to clarify the profile of the quasi value-based pricing 
in the Japan-style premium scheme. MethOds: The information on pricing deci-
sions with premium was searched, extracted, and analyzed from the government 
documents open to public on the website of the Ministry of Health, Labour and 
Welfare in Japan. The four drug categories were focused due to data availability: 1) 
antihypertensive; 2) antidiabetic; 3) antibiotic; and 4) psychotropic, listed from April 
1998 through April 2013. The information relevant to the premium decision included 
listing dates, drug prices, premium categories, premium rates, and also clinical evi-
dence that could be associated with the premium decision. Results: Among total 
106 of new drugs, 27 have been identified with premium, whilst 79 with no premium. 
For each category, there existed 12 antihypertensive (single agent), 25 antidiabetic, 52 
antibiotic, 17 psychotropic. That is, the acquisition rate of premium for each category 
was 17%, 20%, 31% and 24%, respectively. The high proportion, 85%,of the rewarded 
premium categories was recognized in the category of “Usefulness II”, i.e., the 3rd 
ranked premium, while only one drug obtained the premium of innovativeness, the 
highest ranked premium. Regarding the benefit associated with the premium, both 
of clinical and humanistic outcomes seemed to be accepted for decision-making 
although the criteria for the decisions were not clearly indicated. cOnclusiOns: 
The profile of the Japan-style premium scheme was clarified based on the survey 
over the new drugs listed in 1998 to 2013. The information extracted in our study 
will be useful for further investigations to improve the Japanese quasi value-based 
pricing methods.
PHP39
THE STRUCTURE AND PROCESS OF wORK OF SPANISH REGIONAL COMITTEES 
ASSESSING MEDICINES: PRELIMINARy RESULTS
Sarría-Santamera A., Polo M., Gacía S.
Institute of Health Carlos III (ISCIII), MADRID, Spain
Objectives: Spain has a decentralized health care systems with several levels of 
decision-making. After a drug is approved by the Spanish Agencia del Medicamento, 
regional committees (RC) conduct evaluate and assess those drugs for their use 
in ambulatory settings making recommendations to health professionals within 
its territory. The objective of this study is to analyze the structure and process of 
work of those RC. MethOds: RC were contacted by phone and informed about 
this study. A web based questionnaire was ellabored including questions on: 1) 
General information of the RC; 2) Procedure of work of RC; and 3) Criteria used for 
the selection of medicines to asess and the procedures followed to. A link was sent 
by email to contact persons of the RC of the Spanish 17 Autonomous Comunities 
(AC). Results: To this date 10 RC (59%) have submitted their answers and 3 regions 
(18%) have responded indicating the absence of this type of structure or process in 
their region. These 3 regions, though, make recommendations usually conducting 
their own assessments or using assessments conducted by other regions. 7 RC 
have a normalized process of work (5 is open to the public). 8 RC have more than 8 
members. All RC evaluate medicines prescribed for outpatients purchased through 
pharmacies (5 of them exclusively), and 5 conduct also assessments of drugs used 
in hospitals. 9 RC use as comparator the standard treatment for a given indication. 
Economic evaluation is performed through budget impact (6 RC), cost-effectiveness 
(5 RC); and cost-minimization (2 RC). 6 RC make public their assessments through 
public web pages and 2 using electronic bullletins. cOnclusiOns: Preliminary data 
indicate that the majority of Spanish regions conduct their own drug assessments, 
and most of them have established RC, whose structure and process of work show 
some variability and indicate certain degree of duplication.
PHP40
CROATIA’S EU ACCESSION IN THE CONTExT OF INTERNATIONAL 
REFERENCE PRICING: wHAT wILL BE THE wIDER IMPACT FOR PRICING AND 
REIMBURSEMENT?
Melck B., Izmirlieva M., Ando G.
IHS, London, UK
Objectives: To assess the implications of Croatia’s accession to the European Union 
for the pricing and reimbursement landscape both in Croatia and other EU member 
states, focusing on international reference pricing. MethOds: Changes to Croatia’s 
laws governing drug pricing and reimbursement were examined in detail, in rela-
tion to their likely effects on drug prices in Croatia and in other EU member states 
through international reference pricing. The IHS International Reference Pricing 
Matrix was used to determine impact of Croatian prices on other markets likely 
to include Croatia in their reference pricing basket. Interviews were conducted 
with representatives of the pharmaceutical industry in Croatia, and regulators in 
Croatia and other EU member states, to gauge their views. Results: The exist-
ence of comparatively low prices of medicines in Croatia is likely to result in some 
downward pressure on pricing in countries which include all EU countries in the 
IRP basket of countries. However, this impact is not likely to be felt immediately, 
and only for the few therapeutic areas where Croatia’s prices are among the lowest 
in Europe. Changes to Croatia’s international reference pricing basket are unlikely 
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the 646 records found, 108 studies met the inclusion criteria (29 cost-effectiveness 
studies (CES) and 81 systematic reviews on effectiveness (SRE)). The majority of 
CES addressed adherence (55%), followed by inappropriate prescribing (31%) and 
prescribing errors (28%). No studies addressed the full medicines pathway. A simi-
lar picture emerged for SRE at 67%, 15 and 11 respectively. Among the 15 types of 
outcomes used in CES, the top three were clinical (31%) measures of adherence 
(21%) and quality-adjusted life years (17%). In SRE, hospitalisations (43%), measures 
of adherence (23%) and mortality (21%) were the most frequent. cOnclusiOns: 
Interventions to improve suboptimal use of medicines tend to be specific to a par-
ticular aspect of the pathway and/or to a particular disease area. Little considera-
tion is made on how to improve medicines use in patients with co-morbidities and 
poly-medication. The medicines pathway is rarely examined holistically but in a 
fragmented manner, making it difficult to draw conclusions on which aspect of 
suboptimal use of medicines should be prioritised for investment.
PHP48
THE EFFECT OF REDUCED OR REMOvED COPAyMENTS FOR PRESCRIPTION 
MEDICINES ON ADHERENCE – A SySTEMATIC REvIEw
Sinnott S.J., Sinnott C.M., Whelton H.
University College Cork, Cork, Ireland
Objectives: To examine the effect of removal or reduction in prescription copay-
ments, in the absence of disease management plans, on adherence to prescription 
medications. MethOds: Six electronic databases were systematically searched 
for relevant articles, along with hand searches of references in review articles and 
the included studies. Studies were included if they involved an intervention which 
reduced or removed copayments and if the outcome was objectively measured 
adherence. Study designs permitted were randomised controlled trials, time series 
analyses, controlled before/after studies and cohort studies. Studies were excluded 
if the intervention was part of a disease management plan. Study exclusion, data 
extraction and quality appraisal were carried out by two independent reviewers. 
Data were qualitatively synthesised. Results: Nine out of 40 studies were included. 
One study was an RCT; the remainder were all controlled before/after studies. 
There were 144,991 cases and 125,057 controls in this review. The mean age was 
54.39yrs and 55.21yrs for the cases and controls respectively. 44.79% of the cases 
were female, whereas 49.54% of the controls were female. Four studies analysed the 
effect of reduced copayment, 4 studies analysed the effect of a removed copayment 
and 1 study analysed both. Only one study received a strong quality assessment, 
one study was rated as moderate, and the remainder were rated as weak. Seven 
studies showed a significant improvement in adherence. Two studies did not show 
an improvement in adherence. cOnclusiOns: This review concludes that there 
is some evidence of small increases in adherence on the removal or reduction of 
copayments. However, confounders and biases between the included studies were 
variable. Future studies should concentrate on establishing associations between 
reduced cost-sharing and clinical and economic outcomes.
PHP49
PREvALENCE OF PHySICIANS CAUSING POTENTIAL DRUG INTERACTIONS IN 
AMBULATORy CARE IN SwITzERLAND: A REPRESENTATIvE NATIONAL SURvEy
Bucher H.C.
Basel Institute for Clinical Epidemiology & Biostatistics, Basel, Switzerland
Objectives: No representative data on the quality of drug prescription exist in 
Switzerland. We analysed potential drug interactions (PDI) in primary care based 
on prescription data from 2010 from three large health insurers. MethOds: In our 
study population we identified based on the national drug formulary 494 drug-
drug interactions (DDI) classes. Of those, 41 were from drug interaction severity 
classes I (contraindicated) and II (potentially contraindicated) and classified as PDI. 
PDI were calculated for two indicators with different denominators, 1) the total 
number of DDI and 2) the total number of patients potentially exposed to a PDI. 
For each physician we calculated the probability that the number of caused PDI 
was unlikely (p-value between 0.05 and 0.01; ‘problematic prescription behaviour’) 
and very unlikely (p-value < 0.01; ‘likely problematic prescription behaviour’) to be 
explained by chance. Results: Of 3.13 million individuals 1.34% were exposed to 
at least one PDI; figures increased to 3.78% and 4.40% in females and males aged 
≥ 70 years. Of 20,710 physicians 42% caused at least one PDI. With DDI being the 
denominator 6.2% und 3.4% of general practitioners and 0.9% und 0.5% of specialists 
were classified with a ‘problematic’ and ‘likely problematic prescription behaviour’. 
With the patient population being the denominator between 0.96% and 6.22% of 
physicians from all specialty groups had caused a PDI that was classified as ‘likely 
problematic’ (p-value < 0.01). When combining both indicators 457 of 20‘720 physi-
cians (2.2%) had a prescription behaviour causing a PDI that in comparison to peers 
was highly unlikely to be explained by chance (p-value < 0.01). cOnclusiOns: A 
total of 2.2% of physicians in primary care prescribe during one year at least one 
drug combination that is classified as PDI. A linkage to other data sources would 
be needed to further classify PDI that put patients at serious risk for adverse drug 
reactions.
PHP50
A SySTEMATIC EvALUATION OF DRUG-DRUG INTERACTIONS IN 
PRESCRIPTIONS; FACTS AND COMPARISONS
Ahmad M., Arshad W., Usman Minhas M.
The Islamia University of Bahawalpur, Bahawalpur, Pakistan
Objectives: The study focus was to evaluate and compare the prescriptions for 
the encountered potential drug-drug interactions (pDDIs) and their different levels 
on the basis of onset, severity and documentation status, in a tertiary care hos-
pital and community pharmacies in Bahawalpur, Pakistan. MethOds: Total 800 
prescriptions, 400 from a tertiary care teaching hospital and 400 from community 
pharmacies, fulfilling inclusion criteria were collected thrice a week during a period 
of three months and were analyzed for potential drug-drug interactions using dug 
digest database, drug interaction checker of www.drugs.com and reference text 
prescribed those drugs from DPC/PDPS data collected between 1st April 2010 and 
31st March 2012 at 1139 of acute care hospitals in Japan. Hospitals were classified 
into five categories (university, private, publi, social insurance group, and others). 
SQL Server 2008 R2 was used for data handling, R for data analysis, and ArcGIS for 
statistical analysis of geography. Results: Generic drugs were least used amongst 
almost all types of drugs in university hospital and social insurance group. For 
prescription of generic drugs, private hospital was the most proactive, followed 
by public hospital. It was revealed, thorough comparison between 20% of medical 
care institutions that are the most proactive towards introduction of generic drugs 
and 20% of the least proactive, that the shifting progress was slower in bigger size 
medical care institutions. cOnclusiOns: This study indicated that for effective 
promotion of generic drugs, it is important to establish plans for changing the policy 
of medical care institutes, which are amongst the bottom 20% of introduction rate, 
where a policy maker does not shift to generic drugs even in the area of expensive 
drugs such as anti anticancer agents and radio contrast agents.
PHP45
HEALTH TRANSFORMATION PROGRAM IMPACT ON IMPORT AND LOCAL 
PHARMACEUTICAL CONSUMPTION IN TURKEy
Ufuktepe B.1, Kockaya G.2
1Istanbul University, Istanbul, Turkey, 2Health Economics and Policy Association, Ankara, Turkey
Objectives: Health Transformation Program(HTP) started in year 2003 by MoH of 
Turkey. All health system changed dramatically. It had impact on all health con-
sumptions and expenditures. The aim of this study is to show the impact of HTP 
on the imported pharmaceuticals(IP) and local manufactured pharmaceutical(LMS) 
sales in Turkey. MethOds: Pharmaceutical retail sales data in units and 
volume(US$) from year 1998 to 2012 were retrieved from IMS Dataview. Local and 
import consumption trends were reviewed. The data was analyzed with Microsoft 
Excel 2010. Results: Total unit sales were 689M in 1998, 698M in 2002 and 1768 M 
in 2012; after 10 years of HTP. Total sales were 1937M, 2526M and 8000 M USD for 
the same years, respectively. Between 1998 and 2012, CAGR(Cumulative Annual 
Growth Rate) of unit sales was 7%, while the majority of this growth came from 
HTP(9,7% after HTP vs 0,3% before HTP). There was no significant change in unit 
sales between 1998 and 2002; total CAGR was 0,3%. Sales between 1998 and 2012 in 
USD had an average growth rate of 10,7%. Comparing CAGR for before and after HTP; 
LMP was 1,5% before and 7% after while IP showed an inverse ratio with the total 
and LMP values and was 23,5% and 13,1% before and after. In the beginning of the 
15 years period market share for local manufacturing 92,6% in units and 80,8% in 
USD; in 2002 dropped down to 88,8% in units and 65,7% in USD, and finally in 2012 to 
75,2% in units and 49,8% in USD. cOnclusiOns: The percentage of IP both in units 
and volume increased in years. This increase may be caused by different reasons, 
particularly new oncology and biotechnology molecules. It was observed that the 
volume increase in IP or decrease in LMP was limited by the HTP.
PHP46
UNDERSTANDING PATTERNS OF MONITORING OF APPROPRIATE PRESCRIBING 
IN EUROPE
Schroeder C.1, Keja J.2, Hughes B.2, Toussi M.3
1IMS Health, Munich, Germany, 2IMS Health, London, UK, 3IMS Health, Paris La Défense, France
Objectives: To analyse the current requirements and patterns for drug use moni-
toring in Europe and highlight new ways for pharmaceutical companies to meet 
these requirements MethOds: We combined three methods of data collection to 
characterise current requirements and patterns for drug use monitoring: 1) review of 
official reports by European agencies; 2) analysis of data elements on the European 
Medicines Agency (EMA) website; and 3) interviews with experts from pharma-
ceutical companies, facing requirements for conducting drug utilisation studies 
(DUS). Results: The recent Good Vigilance Practice (GVP) established a clear regula-
tory framework for drug safety monitoring and calls for the assessment of the effec-
tiveness of risk minimisation measures (RMMs). This should include the evaluation 
of their implementation and outcome. DUS provide simple metrics for monitoring 
of appropriate drug use, and thus the implementation of RMMs. We identified 28 
drugs with DUS in their risk management plan and an additional 23 DUS requested 
by EMA. We observed a top total number of requests for DUS in the fields of contra-
ception (n= 10), infectious diseases (mainly HIV and hepatitis) (n= 8) and diseases 
of the metabolism (mainly diabetes) (n= 6) and less for other therapeutic areas. The 
main reasons for DUS requests were monitoring of off-label use (n= 30) and new 
safety concerns (n= 27). Experts confirmed an increasing demand for DUS. In order 
to optimise the RMMs, repetitive DUS in different points in time are necessary. This 
study analyses DUS’ critical data elements allowing for the automation of such 
measurements. cOnclusiOns: Current and future EMA practice for DUS seems 
to focus on new active substances, particularly in diseases of high public health 
relevance and infectious diseases. To meet this demand, pharmaceutical compa-
nies are required to propose more repetitive measurements of the drug use. This 
study identifies data elements allowing for the automation of such measurements.
PHP47
CATCHING THE LOw-HANGING FRUIT IN MEDICINES OPTIMISATION
Faria R., Sculpher M.J.
Centre for Health Economics, York, UK
Objectives: The medicines bill in high income countries accounts for approxi-
mately 17% of total health care expenditure. However, around $500 million could 
be saved a year worldwide by optimising medicines use. This study aims to scope 
the evidence on the effectiveness and cost-effectiveness of interventions to 
address suboptimal use of medicines and pinpoint the evidence gaps to prioritise 
future research. MethOds: Systematic searches (up to February 2013) of the NHS 
Economic Evaluation Database, the Cochrane Database of Systematic Reviews and 
the Database of Abstracts of Reviews of Effects for systematic reviews on effec-
tiveness or cost-effectiveness and for primary research on cost-effectiveness of 
interventions. Studies in English set in any country were included. Results: Of 
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geographical barriers while 63.5% and 58.5 % of them are in front of economic and 
waiting list barriers, respectively. More likely to face economic barriers in access are 
unemployed patients [coef.0.55; 95% CI (0.1, 1)] and patients with low income [-0.2; 
95% CI (-0.26,-0.13)] and lower educational level [-0.04; 95% CI (-0.08, 0)]. Women 
[0.22; 95% CI(0.02,0.42)], low-income patients [-0.13 ; 95% CI(-0.2, -0.06)], and patients 
with lower health status [-0.02 ; 95% CI(-0.02,-0.01)] are more likely to be in front 
of geographical barriers in access. Moreover, all occupational categories examined, 
demonstrate a statistically significant positive relationship with the probability of 
geographical barriers occurrence. In addition, unemployed patients [0.51; 95% CI 
(0.06, 1)], public or private sector employees [0.45; 95% CI (0.09, 0.81)] and low income 
patients [-0.086; 95% CI (-0.15, 0.02)] are more likely to deal with barriers attributed 
to waiting lists. cOnclusiOns: Chronic patients face extensive barriers in access, 
which can mainly be explained by the fall of income, the rise of unemployment 
and the policy of decreasing the supply of certain health services in order to reduce 
health expenditure. If such barriers won’t be minimized inequalities will be enlarged 
and chronic patients’ health status will be worsened which might lead to increased 
future costs and adverse effects on health expenditures.
PHP54
QUALITy ASSURANCE OF FOURTH HURDLE CONCERNING TO DRUGS AND 
MEDICAL DEvICES
Tesar T.1, Babela R.2
1Union Health Insurance Fund, Bratislava, Slovak Republic, 2St. Elizabeth University of Health and 
Social Sciences, Bratislava, Slovak Republic
Objectives: From 2011, there are basic thresholds (λ 1= 24 x average monthly sal-
ary € / QALY and λ 2 = 35 x average monthly salary € / QALY) defined directly in the 
Slovak legislation reflecting the benefits displaced elsewhere in the Slovak health 
care system when funds are allocated to new medicines and medical devices. The 
objective of this study was to analyse the quality of submitted economic studies, 
related critical appraisals process and impacts of the new legislation on the access 
to medicines and medical devices. MethOds: We created a working group to review 
previously submitted economic evaluations and related critical appraisals in order 
to identify potential technical and methodological problems. The working group 
scrutinized previous submissions and critical appraisals, concerning to chosen ATC 
groups of drugs and groups of medical devices, published between June 2012 and 
June 2013 at the webside of MoH. Results: Pharmacoeconomic evaluations of drugs 
and medical devices within decision making process concerning to reimbursement 
are mandatory but the quality of studies are very often rather poor. The concept “the 
QALY is a tool not a rule” was slightly modified in Slovakia. Our analysis shows that 
implicit thresholds included into the Slovak legislation have influenced decision-
making process concerning to drugs and medical devices. In the defined time period 
4 drugs exceeded the basic thresholds described in the Slovak legislation, however 
108 drugs and medical devices were refused to include into the reimbursement 
list, because of the poor quality of provided pharmacoeconomic studies from the 
side of applicants. cOnclusiOns: The transparent method of HTA can improve 
the consistency of reimbursement decisions making related to drugs and medical 
devices in Slovakia. However significant improvements in the quality of submitted 
pharmacoeconomic dossiers have to be the first step towards the better access to 
drugs and medical devices for the Slovak patients.
PHP55
THE HyBRID PURCHASER-PROvIDER SPLIT IN ENGLAND: SHOULD EUROPE 
FOLLOw SUIT?
Sewak N.P.S., Devienne E., Karia R.
Double Helix Consulting, London, UK
Objectives: Developed countries have embraced the purchaser-provider split as 
a mechanism to improve health resource allocation and outcomes. With the emer-
gence of Clinical Commissioning Groups (CCGs) as both buyers and providers of 
health services a hybrid purchaser-provider model is being explored. This research 
explored the opportunities and challenges of this model and analysed the impli-
cations for NHS England and Europe. MethOds: Eighty influential regional and 
national payers involved in the NHS England reforms took part in 1-hour tele-depth 
interviews to better understand the changes and uncertainties before the reforms 
were implemented. This research was re-visited three months post implementa-
tion in an advisory board setting to externally validate our findings and identify 
case studies for further analysis. Results: NHS payers stated that they were still 
‘broadly optimistic’ about the re-allocation of purchaser responsibilities to CCGs. 
One case study illustrated that greater clinician involvement provided opportuni-
ties to redesign services like respiratory care and allocate funding more efficiently 
between acute and primary care. Initial success stories include the creation of 
primary care diabetes clinics and Pharma-NHS local partnerships to help reduce 
hospital activity. Within the advisory board, payers voiced concerns with this hybrid 
model. Questions raised from the meeting included: 1) How do we equip GP commis-
sioners with the right skill set to draft and negotiate hospital contracts? 2) How can 
we help GP commissioners and GP providers to help minimise potential conflicts of 
interest? cOnclusiOns: The purchaser-provider model implemented in England 
presents a new way to tackle reduced financial budgets and need to improve health 
outcomes. The results of this research suggest that the purchaser-provider model 
has the potential to make a difference for patient care. A number of challenges 
appear to still be present and it will be important to address these in order for the 
UK and other countries to further explore its benefits.
PHP56
CURRENT STATUS AND EvIDENCE OF EFFECTS OF E-PRESCRIBING 
IMPLEMENTATION IN UNITED KINGDOM, ITALy, GERMANy, DENMARK, POLAND 
AND UNITED STATES
Hermanowski T.R.1, Kowalczyk M.1, Szafraniec-Burylo S.I.2, Krancberg A.N.1, Pashos C.L.3
1Medical University of Warsaw, Warsaw, Poland, 2National Institute of Public Health – National 
Institute of Hygiene, Warsaw, Poland, 3Evidera, Lexington, MA, USA
Drug Interaction Facts. Results: A highly significant difference was observed 
between the prevalence of pDDIs in prescriptions from hospital (45%; 180 out of 
400 prescriptions with at least 1 pDDI) and community pharmacies (29.25%; 117 
out of 400 prescriptions with atleast 1 pDDI). On the whole, out of total 543 pDDIs 
(hospital = 337; community = 206) majority of them were of delayed onset (hospital 
= 50.44%, community = 44.66%), moderate severity (hospital = 57.87%, community 
= 42.72%), suspected type (hospital = 27.6%) and possible documentation (com-
munity = 14.08%). Most of the prescriptions (hospital = 80%; community = 83%) 
contained 2-4 medicines. The interacting combinations such as aspirin-clopidogrel 
omeprazole-clopidogrel and digoxin-furosemide (in hospital); isoniazid-rifampin 
and tramadol-escitalopram were found to be frequently involved in major inter-
actions. The findings showed that cardiovascular drugs were involved in most of 
the rapid pDDIs (in hospital = 32.46%; in community = 33.33%) and respiratory 
system drugs were associated with majority of established documented pDDIs (in 
hospital = 16.67%; in community = 42.86%). cOnclusiOns: Drug-drug interac-
tions in prescription medicines were observed in high percentage both in hospitals 
and community pharmacies. Clinical practices must be standardized as rational 
prescribing practices.
HEALTH CARE USE & POLICy STUDIES – Equity and Access
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UNMET HEALTH NEEDS OF IMMIGRANTS LIvING IN GREECE DURING THE 
ECONOMIC CRISIS: THE LONG-TERM IMPACT FOR THE HEALTH CARE SySTEM
Kaitelidou D.1, Galanis P.1, Zikos D.2, Lemonidou C.1, Chrysopoulou E.1, Bellali T.3, Vafeiadis 
J.4, Siskou O.2, Velonakis E.1
1National and Kapodistrian University of Athens, Athens, Greece, 2Center for Health Services 
Management and Evaluation, National and Kapodistrian University of Athens, Athens, Greece, 
3Alexander Technological Educational Institute of Thessaloniki, Thessaloniki, Greece, 4National 
Organization for the Provision of Health Services (EOPYY), Marousi, Greece
Objectives: To examine access of migrants in health care services, their unmet 
health needs, and the factors associated with these. MethOds: A cross-sectional 
pilot study was conducted from January to May 2013. The study population consisted 
of 231 recent immigrants living in Greece. A questionnaire was developed including 
information about demographics, health status, difficulties in health services access 
etc. Statistical analysis included Pearson’s x2 test, x2test for trend, student’s t-test, 
analysis of variance and Pearson’s correlation coefficient. Results: Almost half of the 
participants (n= 115, 49.7%) used public health services in the last 12 months in Greece. 
Among them, 56.8% (n= 131) used emergency department services. A considerable 
proportion of the participants (n= 144,62.3%), during the last year, needed at least one 
time to use health services but they could not afford it. The most important reasons 
for that were high cost of health care (n= 80, 34.5%) and the long waiting lists (n= 29, 
12.6%). More than half of the participants (n= 122, 52.9%) reported that they had major 
difficulties in accessing health services. Increased family monthly income was associ-
ated with decreased difficulties in access in health services (x2 test for trend= 32.1, 
p< 0.001). The use of preventive services has been limited since more than 60% of 
the women 40+ reported not having conducted a pap test or a mammography, while 
more than 30% of the respondents were not subjected to a blood test or a cholesterol 
examination. cOnclusiOns: Barriers to health services access for migrants may 
lead to decreased use of health services, especially primary, and thus lead to increased 
hospitalizations and higher cost in the longer-run. Formulation of policies to improve 
access and use of health care services are necessary.
PHP52
IMPORTANCE OF SUBGROUP ANALySES FOR HEALTH TECHNOLOGy 
ASSESSMENTS
Aggarwal S., Topaloglu H., Kumar S.
Novel Health Strategies, Bethesda, MD, USA
Objectives: Cost effectiveness analyses play a critical role in determining coverage 
of novel drugs and devices. Increasingly, payers are demanding subgroup analyses 
to determine indications which would be covered by the national health system or 
insurance agency. MethOds: To understand and review trends in the use of subgroup 
cost effectiveness analysis, we analyzed NICE HTAs for products approved between 
2011-2012. Manufacturer submissions for CEA were compared to final review and 
decision by HTA agency. Analogs were identified and case studies were developed 
to further understand the use of subgroup analyses and cost effectiveness mod-
els. Results: Decisions made by NICE in 2011-2012 show increasing trends towards 
the use of subgroup analysis for determining indications for coverage by national 
payer bodies. Between 2011-2012, 80% of the assessments included subgroup analy-
ses. Approximately half of them included cost effectiveness analyses for various 
subgroups. Interestingly, the ICER values estimated by NICE for the same subgroups 
showed a large variation (1X-3X fold difference) compared to ICER values estimated 
by manufacturers. Selected case studies highlighted that for several products, NICE is 
recommending treatments only for subgroups whose ICER values are within the cost 
effectiveness threshold. cOnclusiOns: New products need robust broader popula-
tion and subgroup analyses for insurance coverage.
PHP53
CHRONIC PATIENTS’ ACCESS TO PHySICIANS SERvICES IN TIMES OF ECONOMIC 
CRISIS
Kyriopoulos I.I.1, Skroumpelos A.1, Mylona K.1, Anastasiou L.2, Pavi E.1
1National School of Public Health, Athens, Greece, 2Novartis Hellas, Metamorfosi, Greece
Objectives: To explore the magnitude of certain access barriers to physician ser-
vices that chronic patients are in front of as well as which patients are more vul-
nerable to such restrictions. MethOds: A cross-sectional study was conducted in 
1600 chronic patients suffering from diabetes, hypertension, COPD and Alzheimer. 
Logistic regression analysis was carried out in order to explore the factors related 
to economic and geographical barriers in access, as well as the determinants of 
barriers imposed by waiting lists. Results: A total of 25% of chronic patients face 
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wHICH ARE THE ATTITUDES OF PRIMARy HEALTH SERvICES USERS 
CONCERNING COST SHARING MEASURES IN A PERIOD OF ECONOMIC CRISIS IN 
GREECE?
Siskou O.1, Galanis P.1, Kouli E.1, Tsavalias K.1, Kaitelidou D.1, Theodorou M.2, Prezerakos P.3, 
Spinthouri M.1, Vafeiadis J.4, Kalogeropoulou M.1
1National and Kapodistrian University of Athens, Athens, Greece, 2Open University of Cyprus, 
Latsia, Cyprus, 3University of Peloponnese, Sparta, Greece, 4National Organization for the 
Provision of Health Services (EOPYY), Marousi, Greece
Objectives: To identify the extent to which patients accept the measure of cost 
sharing fee (5€ ) in public primary health care units (health centers and hospitals’ 
outpatient departments) as well as to investigate whether patients perceive the 
potential benefits of the measure for the quality improvement of provided health 
care. MethOds: The study population consisted of 1260 people, who used public 
primary health care units. A structured questionnaire was used, including ques-
tions for patients’ demographic characteristics, their attitude regarding the cost 
sharing mechanism (compliance, perception of the benefits for health services 
upgrade etc), and their level of satisfaction with the provided services. Results: 
The implementation of cost sharing mechanism was positively accepted by 30% 
of respondents. Approximately 90% of the respondents, who expressed positive 
opinion for the implementation of the mechanism, considered that it would provide 
financial support to health units. Among the respondents who expressed negative 
opinion for the measure, 95% believed that health services should be public and free 
for everyone, 83% expressed lack of confidence that the measure aims at upgrading 
the provided services, 78% believed that the insurance contributions they already 
pay are high and 67% stated no financial comfort. The negative opinions were more 
frequent among people with lower socio-economic profile and those who have used 
health centers (p< 0.06). Respondents with higher socio-economic profile, coming 
from urban areas and respondents who were very satisfied with health services 
had statistically significantly greater possibility to express positive opinion for the 
measure. cOnclusiOns: Low socio-economic profile is negatively associated with 
the acceptance of the implementation of cost sharing mechanism, while high satis-
faction with services is positively associated with the acceptance of the mechanism. 
The majority of those, who expressed positive opinion for the measure, consider it 
as a contribution to the enhancement of health services.
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FINANCIAL INCENTIvES IN HEALTH CARE: EvIDENCE OF UNINTENDED 
CONSEQUENCES
Jensen S.O.1, Amelung V.E.1, Hermanowski T.R.2, Krauth C.1
1Hannover Medical School, Hannover, Germany, 2Medical University of Warsaw, Warsaw, Poland
Objectives: Financial incentives or Pay-for-Performance (P4P) have become a 
common approach to improve the quality in health care. Although the effective-
ness is mixed, more and more P4P initiatives are implemented. Besides the desired 
effects of quality improvement, a growing number of evaluations show that finan-
cial incentives lead to unintended consequences. Therefore this study analyses 
negative effects of P4P. MethOds: On the basis of a systematic review of system-
atic reviews regarding P4P in health care (nine systematic reviews included that 
evaluate 75 different primary studies; Methodological quality assessment using the 
AMSTAR checklist) an additional hand search was conducted to identify evidence of 
unintended consequences of P4P. Results: Both theory and evidence of financial 
incentives demonstrate the potential of negative effects. Risk selection is identified 
in six reviews: Patients could get selected due to their severity of illness in order 
to achieve quality targets with minimum effort (cherry picking); Physicians will 
focus on indicators or aspects of care that are linked to payments (teaching to the 
test). Focussing on incentivized indicators could lead to quality decrease in non-
incentivized indicators (negative spillover effects), assessed in four reviews. Five 
reviews show that physicians could game the P4P program by reporting incorrect 
results and therefore increase their payments (gaming). Furthermore, improvements 
can be the result of better documentation and not actual quality improvements (four 
reviews). Finally one review identified crowding out of intrinsic motivation due to 
financial incentives. cOnclusiOns: The available evidence shows that P4P can 
result in unintended consequences. Evaluations of P4P should include these effects 
in order to assess an overall effect and thereby determine the effectiveness of P4P. 
To avoid negative effects it is important to consider the potential of unintended 
consequences and develop appropriate solutions.
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GEOGRAPHICAL INEQUALITIES IN THE ACCESS TO AND UTILIzATION OF HOME 
CARE (NURSING) SERvICES IN HUNGARy
Cs. Horváth Z.1, Molics B.2, Ágoston I.2, Sebestyén A.3, Boncz I.2
1National Institute for Quality- and Organizational Development in Healthcare and Medicines, 
Pécs, Hungary, 2University of Pécs, Pécs, Hungary, 3National Health Insurance Fund 
Administration, Pécs, Hungary
Objectives: Home care (nursing) was introduced into the Hungarian basic health 
insurance package in 1996. The aim of our study is to analyze the geographical ine-
qualities in the access to and utilization of that services in Hungary. MethOds: Data 
were derived from the nationwide administrative dataset of the National Health 
Insurance Fund Administration (OEP), the only health care financing agency in 
Hungary. The geographical inequalities in home care (nursing) services were meas-
ured by the number patients, visits and reimbursement according to 20 Hungarian 
counties. We analyzed the year 2011. Results: The national average number of 
patients was 51 patients / 10000 population. We found the highest patient number 
in county Zala (67), Jász-Nagykun-Szolnok (63) and Baranya (62), while the lowest 
number in county Békés (43), Somogy (43) and Szabolcs-Szatmár-Bereg (28). The 
national average number of home visits was 1193 visits / 10000 population. We found 
the highest number of visits in county Nógrád (1494), Tolna (1385) and Fejér (1377), 
while the lowest number in county Somogy (1138), Csongrád (1106) and Szabolcs-
Szatmár-Bereg (678). The national average of reimbursement per patient was 65345 
Objectives: Electronic-prescribing (E-prescribing) in comparison to manual (“by 
hand”) generation, transmission and filling of prescriptions is thought to substan-
tially lower the risks of inaccuracy and therefore reduce associated health care 
resource use and costs. The purpose of this work is to describe the current state of 
e-prescribing systems implementation in Denmark, Germany, Italy, Poland, United 
Kingdom (UK) and United States (USA), and to assess present evidence of its influ-
ence on health care. MethOds: A systematic review supplemented by additional 
hand-search was conducted to find relevant articles. Medline, Embase, The Cochrane 
Library and Scopus were searched. Quality was assessed on the basis of PRISMA, 
MOOSE and STROBE checklists and West 2002 recommendations. Results: Thirty-
one relevant full texts were identified during systematic review, and then as a result 
of hand-search, 5 publications were added. E-prescribing varies considerably across 
these countries. It is currently voluntary in Germany, Italy and United States. In 
United Kingdom the system is implemented except for electronic signature. In 
Denmark e-prescribing is mandatory for primary care providers. Model implemen-
tation in Poland is expected to take place in 2014. Of these 36 sources, 4 articles 
assessing e-prescribing were of the highest quality, as judged using the assessment 
methods. Positive influence on medical visits frequency, quality of care, patient 
satisfaction, prescription errors frequency, and prescriber-pharmacy-patient com-
munication was described in literature; most studies were conducted in the UK 
and USA. No data about effects of implementation for Germany, Italy, Denmark and 
Poland were found. cOnclusiOns: Implementation of e-prescribing is in process 
in the majority of described countries. Although few studies exist that definitely 
demonstrate positive impact of e-prescribing on health care, gathered papers do 
indicate positive effects. More comprehensive assessments would be valuable in 
showing the attributes of e-prescribing that are most valuable, and those that may 
be strengthened.
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MODELS OF DRUG SAFETy MONITORING IN ENGLAND, POLAND, ITALy, 
GERMANy, DENMARK AND UNITED STATES
Hermanowski T.R.1, Krancberg A.N.1, Szafraniec-Burylo S.I.2
1Medical University of Warsaw, Warsaw, Poland, 2National Institute of Public Health – National 
Institute of Hygiene, Warsaw, Poland
Objectives: To review, describe and assess models of drug safety monitoring in 
England, Poland, Italy, Germany, Denmark and in the United States and prepare 
recommendations useful in health authorities decision-making process. MethOds: 
A review of documents, materials and information published on national medicines 
agencies as well as WHO’s statements was conducted, supplemented by hand-
search of literature. Results: The advantages and disadvantages of described phar-
macovigilance schemes in selected countries has been discussed. The gathered data, 
related i.a. to the level of adverse drug reaction reporting in different countries, was 
used to assess the efficacy of national reporting process. Moreover our research 
allowed us to value the formula of pharmacovigilance schemes as well as the atti-
tudes of health care professionals and patients towards it. cOnclusiOns: Although 
the majority of compared countries are European Union members bound to respect 
the same acts of European law, there are still many significant differences met in 
Pharmacovigilance practice reflecting in the level of adverse reaction reporting. 
These differences may be found as the treatment of newly registered medicines, 
data availability and transparency of procedures within the agencies or the relation-
ship between health authorities and potential reporters. A set of recommendations 
has been prepared related to special treatment of new medicines, creating aware-
ness of importance of pharmacovigilance in health care (hospitals, pharmacies), 
changing the attitude to risk aspects, transparency of safety monitoring practice 
and patients’ enrollment. The implication of our proposals could help to amend the 
pharmacovigilance systems in all discussed countries.
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SPECIFIC ATTRIBUTES OF PHARMACEUTICAL CARE IN ENGLAND, POLAND, 
GERMANy, DENMARK, ITALy AND UNITED STATES
Hermanowski T.R.1, Duleba D.1, Krancberg A.N.1, Szafraniec-Burylo S.I.2, Pashos C.L.3
1Medical University of Warsaw, Warsaw, Poland, 2National Institute of Public Health – National 
Institute of Hygiene, Warsaw, Poland, 3Evidera, Lexington, MA, USA
Objectives: To describe existing models of pharmaceutical care (PC) in England, 
Poland, Germany, Denmark, Italy and United States and to indicate similarities 
and specific attributes meant as differences (from the whole system point of view), 
identifying possibly promising solutions (promising means having preliminary or 
probably positive results described in found literature). MethOds: A systematic 
and non-systematic literature review in Medline, Embase, Scopus and the Cochrane 
Library was performed. Quality of publications was critically appraised. Results: 
The review identified 48 full texts. The majority of papers were of moderate quality 
(PRISMA, MOOSE or STROBE checklists) and intermediate consistency, coherence 
and strength (West 2002). In chosen countries differences in the definition of PC 
have been noticed and therefore often it is difficult to find similarities. Although in 
some countries like England and the US, PC is firmly established and comparable 
with one another, in other it is very heterogeneous. Mainly in Central and Eastern 
Europe (CEE), especially in Poland, it is offered to a very limited extent or only pilot 
implementations exist. Four types of PC models have been distinguished: Anglo-
Saxon, Scandinavian, German and Italian. Specific attribute of English PC is division 
into essential, advanced and enhanced services. American pharmacists provid-
ing this service must be highly specialized. Danish system focuses on identifying, 
solving and prevention of drug-related problems. In Germany family pharmacy 
concept emerged. Pivotal point of Italian system is hospital PC. Identified promis-
ing solutions found in some countries were i.a. Drug Utilization Review, disease 
management programs or medicines use review. cOnclusiOns: Identical PC con-
cept may be difficult to introduce in all EU Member States, due to differences in 
health systems. However, some identified, promising actions should be considered 
by decision makers and providers, as well as implementing PC to a sufficient extent 
in CEE countries.
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(100%), Abbott (100%), Bayer (83%), Gilead (80%), and Boehringer-Ingelheim (80%). 
The average time to receive a CDR recommendation varied from 170 days to 248 
days. The manufacturers with the fastest time to recommendation are GSK, Abbott, 
Roche, Boehringer-Ingelheim, and Watson. Time to reimbursement / formulary list-
ings in all provinces ranged from 123 days to 593 days. cOnclusiOns: This is the 
first analysis to describe the success rate of pharmaceutical manufacturers through 
the CDR. There appears to high variability in all the metrics that were measured and 
further research into the determinants of variability is warranted.
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IMPACT OF MEDICARE PART D ON PRESCRIPTION USE, HEALTH CARE 
ExPENDITURES, AND HEALTH SERvICES UTILIzATION: NATIONAL ESTIMATES 
FOR MEDICARE BENEFICIARIES, 2002 TO 2009
Cheng L.I.1, Rascati K.L.2
1Amgen, Thousand Oaks, CA, USA, 2The University of Texas at Austin, Austin, TX, USA
Objectives: To investigate the impact of Medicare Part D on prescription utilization, 
health services utilization, and health care expenditures in the general Medicare 
population. MethOds: A retrospective analysis of Medicare beneficiaries (N= 32,228) 
was conducted using the Medical Expenditure Panel Survey 2002 to 2009 data. 
Multivariable quantile regression was used to estimate the following outcomes at 
the 25th, 50th, 75th, and 90th percentiles, adjusting for socio-demographic charac-
teristics: 1) number of prescription fills; 2) out-of-pocket (OOP) drug expenditures; 3) 
total drug expenditures; 4) OOP health care expenditures; 5) total health care expen-
ditures; 6) number of hospitalizations; and 7) number of emergency department 
(ED) visits between the pre-Part D (2002-2005) and post-Part D (2006-2009) periods. 
All expenditures were inflation-adjusted to 2009 dollars. Results: In the general 
Medicare population, Part D was associated with decreases in OOP drug expenditures 
(-25.7% to -33.6%; p< 0.0001) and OOP health care expenditures (-22.1% to -24.3%; 
p< 0.0001) across all percentiles. Part D was associated with increases in the number 
of prescription fills across all percentiles (5.8% to 8.4%; p< 0.0001) but only at the 
75th and 90th percentiles for increases in total drug expenditures (75th percentile: 
5.5%; 90th percentile: 10.2%; p< 0.0001). Part D was not associated with changes in 
total health care expenditures, hospitalizations, or ED visits in the general Medicare 
population. cOnclusiOns: Part D resulted in increases in medication utilization 
and reductions in OOP drug and OOP health care expenditures among Medicare 
beneficiaries, but was not associated with differences in total health care spending, 
hospitalizations, or ED visits.
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THE IMPLICATIONS OF DEMOGRAPHIC CHANGES FOR GMS COSTS IN IRELAND 
THROUGH TO 2026
Conway A.1, Kenneally M.1, Thummel A.2, Woods N.1, Ryan M.1
1University College Cork, Cork, Ireland, 2Darmstadt University, Darmstadt, Germany
Objectives: The General Medical Services (GMS) scheme presently covers around 
40% of the Irish population and entitles them, inter alia, to free prescription drugs and 
appliances. This paper projects the effects of future changes in population, coverage, 
claims rates and average claims cost on GMS costs in Ireland. MethOds: Data on 
GMS coverage, claims rates and average cost per claim are drawn from the Primary 
Care Reimbursement Service (PCRS) and combined with Central Statistics Office (CSO) 
(Regional and National Population Projections through to 2026). A Monte Carlo Model 
is used to simulate the effects demographic change (by region, age, gender, coverage, 
claims rates and average claims cost) will have on GMS prescribing costs in 2016, 
2021 and 2026 under different scenarios. Results: A total of 100,000 Monte Carlo 
simulations indicate that GMS medicines costs could rise to € 1.9bn by 2026 and will 
likely fall in the € 1.7bn to € 2.3bn region. Population is projected to grow by 32% by 
2026 and by 96% for the over 70s. The Eastern region is estimated to grow by 3% over 
the lifetime of the projections at the expense of most other regions. The Monte Carlo 
simulations project that females will be a bigger driver of GMS costs than males. Those 
aged 70 and over and children under 12 will be significant drivers of GMS costs with 
the impending demographic changes. cOnclusiOns: GMS coverage is increasing 
in tandem with falling public health budgets and poses a threat going forward to the 
sustainability and funding of the GMS scheme. Our projections and simulations map 
the likely evolution of GMS cost, given existing policies and demographic trends.
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vARIABILITy IN PUBLICALLy-PRESCRIBED DRUG COSTS: THE ROLE OF REGION, 
AGE AND GENDER
O Céilleachair A.J., Woods N., O’Sullivan K., Kenneally M.
University College Cork, Cork, Ireland
Objectives: Ireland currently has one of the highest levels of public drug spending 
per capita in Europe. As budget retrenchment efforts continue, publically-funded 
drug schemes such as the General Medical Scheme have been the subject of several 
initiatives to reduce costs in recent years. However, little is known about the regional 
and socio-demographic factors that may influence variations in prescribing across 
the state. The objective of this study was to identify these factors. MethOds: Using 
a 192,000-strong sample of PCRS data drawn from monthly GMS returns for 2007, 
we constructed an ANOVA model that included the main effects of age, gender and 
region together with their second order and third order interactive terms in an 
interactive effects regression model examining the role of gender, age category and 
region of residence in explaining variation in prescribing costs for Ireland. Results: 
Mean cost per person per month was € 102. Men were on average more expensive 
than women (€ 109 vs. € 94) and cost increased with age group (€ 34 for those 0-12yrs 
and € 169 for those over 75). The most expensive region was the Midlands HSE region 
(€ 103) while the North West (€ 90) was the least costly. Most of the variation in pre-
scribing costs was explained by age, though the relationship between prescribing 
cost and age category was not constant. A significant three-way interaction was 
found between age category, gender and region. cOnclusiOns: The regional and 
Hungarian Forint (HUF) or 234 Euro (EUR) / patient. We found the highest reimburse-
ment per patient in county Nógrád (87879 HUF, 315 EUR), Fejér (80851 HUF, 290 EUR) 
and Békés (77643 HUF, 278 EUR), while the lowest reimbursement county Budapest 
(58859 HUF, 211 EUR), Jász-Nagykun-Szolnok (55757 HUF, 200 EUR) and Zala (54924 HUF, 
197 EUR). cOnclusiOns: We found significant differences measured by all the three 
indicators in home care (nursing) services in Hungary. Our results revealed that there 
are important inequalities both in the access to and utilization of home care services.
PHP62
SELF-REPORTED POPULATION HEALTH: AN INTERNATIONAL PERSPECTIvE 
BASED ON EQ-5D
Szende A.1, Janssen M.B.2, Cabasés J.M.3, Ramos Goñi J.M.2
1Covance, Leeds, UK, 2EuroQol Group, Rotterdam, The Netherlands, 3Public University of Navarra, 
Pamplona, Spain
Objectives: General population EQ-5D health surveys have been accumulated 
in the EuroQol Group’s archive over the past two decades. Using the database as a 
source of standardized measure of self-reported health, the objective was to esti-
mate the level of health (EQ-5D population norms) and the distribution of health 
within populations along socio-demographic characteristics. MethOds: Analyses 
captured EQ-5D data on 163,838 individuals from 18 countries with nationally repre-
sentative population surveys. Descriptive statistics were used to provide EQ-5D-3L 
population norms by age and gender categories for EQ VAS, EQ-5D index values, 
and for the 5 dimensions for each country. Odds ratios and the health concentra-
tion index methodology were used in the socio-demographic analysis of EQ-5D 
data. Results: The mean EQ-VAS rating varied from 71.1 to 83.7 and from 70.4 to 
83.3 across countries without and with age standardization, respectively. Statistically 
significant inequalities existed in all samples (p< 0.01) with the EQ-VAS based health 
concentration index varying from 0.090 to 0.157 across countries. Among the soci-
odemographic factors, age had generally the largest contributing share, while edu-
cation also had a consistent role in explaining lower levels of self-reported health. 
Among the 5 dimensions, usual activities and pain/discomfort were the highest 
contributors to overall inequalities in most countries. cOnclusiOns: EQ-5D norms 
can be used as reference data to compare patients with specific conditions and to 
assess the burden of the disease in question. Inequalities in self-assessed health 
exist in all countries with different social and cultural backgrounds, deserving the 
attention of policy makers within each country.
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ANALySIS OF ADvERSE REACTIONS OF MEDICINE IN UKRAINE
Zalis’ka O., Maksymovych N., Zaliskyy O.
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Objectives: In Ukraine the pharmacovigilance system for adverse reactions is 
working. In 2008 was received 7,115, 2009 – 8291, 2010 – 8673, 2012- 11674 card-
reports of adverse reactions (AR) drugs. MoH conducted a detailed analysis of these 
reports found that 13% of them experienced serious adverse events, and 0.7% of the 
cards with the unexpected AR. MethOds: We analyzed the side effects depending 
on the ATC-group drugs. Results: We found that antimicrobial agents for sys-
temic use the largest number of reports received on AR (75.4%), which in most 
cases manifested anaphylactic AR. Further analysis showed that AR often were 
drugs (by INN): ceftriaxone (12.6%), amoxicillin in combination with clavulanic 
acid (8.0%), levofloxacin (6.3%). Among the cardiovascular drugs, reports AR often 
came on enalapril (10.0%), pentoxifylline (9.7%) and amlodipine (8.1%).Among the 
drugs affecting the nervous system, haloperidol (7.4%), metamizol sodium (7.4%) 
and paracetamol (7.0%). The analysis showed that the ratio of serious not serious 
AR under anti-neoplastic drugs and antiretroviral drugs is 1:2, anti-TB drugs - 1:3, 
and those affecting the cardiovascular system, gastrointestinal tract, respiratory 
system - under 1:9, 1 : 6, 1:6. Thus, the frequency of serious AR is much higher in 
the application of anti-neoplastic, anti-HIV and anti-TB drugs.The greatest risk 
AR was for children aged 28 days - 11 years, especially boys, and adults, especially 
women aged 46-60 years. cOnclusiOns: Results of the analysis of AR indicate 
that needed pharmaceutical care when dispensing antiretrovirals, anti-tuberculosis, 
anti-neoplastic drugs that meet the requirements of Good pharmacy practice in 
Ukraine. Implementation of training courses and programs for pharmacists on the 
subject of safe use of drugs to treat infectious diseases, tuberculosis and HIV / 
AIDS is essential. As well as acquiring skills pharmaceutical care and prevent AR 
in dispensing drugs to children and women 45-60 years.
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A 10-yEAR REvIEw OF THE CANADIAN COMMON DRUG REvIEw: 
PHARMACEUTICAL MANUFACTURERS’ SUCCESS RATE
Shum D.1, Wyatt G.2, Siu E.2, Mills F.2
1Hoffmann-La Roche Limited, Mississauga, ON, Canada, 2Wyatt Health Management, Oakville, 
ON, Canada
Objectives: The Canadian Common Drug Review (CDR) is a national HTA agency 
that has been in existence for 10 years. During this, the CDR has reviewed the 
clinical and cost-effectiveness of 188 drugs and provided 269 recommendations to 
the publically funded drug plans. Of all the drugs reviewed over the past 10 years, 
50.4% have received a positive recommendation and 49.6% have received a negative 
recommendation. The objective of this analysis was to describe the success rate of 
each pharmaceutical manufacturer in terms of type of recommendation, time to 
recommendation, and time to listing in the provincial formularies. MethOds: The 
CDR Tracker database was used to analyze all CDR drug reviews from 2003 to the end 
of 2012. There were a total of 189 reviews during this 10 year period. All manufactur-
ers that had three or more submissions with CDR were included in the analysis; 
29 companies met this criterion. Results: Of the 189 reviews and 29 companies 
analyzed, the positive recommendation rates ranged from 100% to 17%. The top 5 
most successful manufactures in terms of positive recommendations were Roche 
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is similar for males and females. Growing inequality generally increases GMS cover-
age but pushes some persons aged over 70 above the qualifying income threshold. 
Repeating 2010 average income in 2011 would increase the 2011 GMS medicines 
cost by around € 110m; repeating the 2010 inequality changes would increase it by 
a further € 105m, ceteris paribus. cOnclusiOns: Fiscal cutbacks during recession 
induce countervailing increases in the medical card population and the public cost 
of its medicines. These are the first systematic and detailed estimates – by age, 
gender and region – of whose medical access is affected and how much the offset-
ting public cost will increase.
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THE BURDEN OF DISEASE ATTRIBUTABLE TO PHySICAL INACTIvITy IN THE 
AUSTRIAN REGION OF BURGENLAND
Walter E.1, Dragosits A.1, Gollner E.2, Szabo B.2, Schnabl F.2
1Institute for Pharmaeconomic Research, Vienna, Austria, 2University of applied science 
Burgenland, Pinkafeld, Austria
Objectives: About 52.6% or 125,434 people of the population in Burgenland is 
physical inactive. As a risk factor for several chronic diseases like cardiovascular 
diseases, type 2 diabetes, osteoporosis, depression, back-pain, hypertension, breast 
cancer and colorectal carcinoma physical inactivity can potentially be a substantial 
public health burden. Furthermore, it is one of the greatest risk factors for global 
mortality. Hence, the aim of the analysis was to estimate the direct health-care costs 
saved, the number of diseases and premature death saved each year attributable to 
a health promotion program focusing on walking (“3,000 steps” more). MethOds: 
The evaluation of the health-economic impact was performed using a cost-of-illness 
analysis. We have used relative risk (RR) estimates from the literature to evaluate 
the effects of physical inactivity on the above mentioned diseases. Afterwards, the 
population-attributable fraction (PAF) for each illness to estimate the risk factor on 
the given disease was computed. Direct medical costs were considered from the 
health care system perspective. Costs were calculated bottom-up for the year 2012. 
We have calculated effects of a reduction in inactivity level by 10,000 physical inac-
tive people in Burgenland. Results: Results show that physical inactivity causes 
27,542 cases of illness as well as 50 premature deaths in population of Burgenland, 
leading to a total cost-of-illness of 58.9 million Euro (6.3% of total health expendi-
ture). Reducing the inactive group by 10,000 people, 2,221 cases of illness and cases 
of death will be reduced by four. Moreover the cost of illness could be reduced by 
6.40 million Euro each year of which 5.03 million Euro are directly related to dimin-
ish physical inactivity. cOnclusiOns: Physical inactivity represents an important 
public health burden in Austria. Even modest reductions in inactivity levels could 
result in substantial cost savings.
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THE IMPACT OF THE BLIND BID PROCEDURE IN HUNGARy
Komáromi T., Gyáni G., Andriska P.
Healthware Consulting Ltd., Budapest, Hungary
Objectives: The modified reference price procedure, which was introduced 
in October 2011, caused significant savings in the Health Insurance Fund’s 
Pharmaceutical budget. In our analysis we aim to give an insight into the effects 
of this measure on the drug consumption and on the sales of the pharmaceutical 
companies as well as measure the generated savings and losses on the side of the 
industry. In the course of the analysis we examine the change in the demand of 
the related drugs and in their composition, from the aspect of industry, financer 
and patients. We explore which are the price strategies of the companies and are 
they managed to increase the sales or decrease the losses with them. The proper 
knowledge of the effects of blind bid will support the decision making of the con-
cerned market actors as well as the further rulemaking. MethOds: A retrospec-
tive data analysis was conducted on the official NHIFA (national Health Insurance 
Fund) monthly data-base between October 2011 and March 2013. Results: In 
the blind bid procedure 90 companies, 169 active substances and more than 2100 
product were involved. The relevant products market share is almost 30% of the 
total Hungarian Pharmaceutical budget, which is almost 1 billion € annually. 
As we found, the blind bid process has a significant saving effect for the 
financer. The cumulative savings on the 18 months period reached 113 millions 
€ for the financer. It means 24% reduction on the average reimbursement level, 
whilst the average manufacturer price decreased 16% and a minimal 3% savings 
was realized on the co-payment side. cOnclusiOns: Huge savings were real-
ized with this new reference pricing method, where the financer realized the 
most of the savings.
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COST-EFFECTIvENESS OF AN INTERFACE GERIATRIC INTERvENTION: ACUTE 
MEDICAL UNIT COMPREHENSIvE GERIATRIC ASSESSMENT INTERvENTION 
STUDy (AMIGOS)
Tanajewski L.1, Franklin M.1, Gkountouras G.1, Berdunov V.1, Edmans J.1, Conroy S.2, 
Bradshaw L.1, Gladman J.1, Elliott R.A.1
1University of Nottingham, Nottingham, UK, 2University of Leicester, Leicester, UK
Objectives: Older people (> 70) with high risk of future health problems discharged 
from acute medical units (AMU) within 72 hours, in Nottingham and Leicester, 
England, were included in an RCT of an interface geriatric intervention (IGI) compris-
ing geriatrician assessment and further specialist management. The objective was 
to assess cost-effectiveness of IGI compared to standard care. MethOds: In the 
trial-based economic evaluation, 417 participants (IGI: 205) were analysed at 90-day 
follow-up. Health (inpatient, day-case, outpatient), social care and IGI resource-use 
data were collected and combined with unit costs to estimate total cost. Quality-
adjusted life years (QALY), based on EQ-5D valuations at baseline and follow-up, 
were obtained for 254 (60.9%) participants. Multiple imputation by chained equa-
tions was applied to deal with missing QALY values. Cost and QALYs were adjusted 
by baseline characteristics using regression methods, and probabilistic incremental 
cost-effectiveness ratios (ICER) were constructed. Sub-group analysis was carried 
demographic factors underlying the cost of GMS prescribing in Ireland are complex 
and inter-related. Alternative solutions to the question GMS coverage in the elderly 
may need to be found soon that prove fiscally and economically sustainable. The 
large gap in GMS prescribing costs between men and women in early adulthood 
requires further investigation.
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THE TRANSPARENCy OF NATIONAL HEALTH CARE COSTS IN THE ‘EUROPEAN 
UNION FIvE (EU-5)’
Firth Z.A., Smith T.A.
Mapi, London, UK
Objectives: Cost-effectiveness analyses play a key role in the reimbursement of 
health care technologies and require health care resource use (HRU) cost inputs. 
Inaccuracies in inputs can lead to potentially significant differences in results. Thus, 
the availability of HRU costs is vital for decision-making. This study’s objective is to 
assess the transparency and ease of access to HRU costs in France, Germany, Italy, 
Spain and the UK. MethOds: A targeted search and contact with country-specific 
representatives highlighted existing national documentation. A cross-sectional 
selection of costs were searched for including GP and nurse costs; hospital bed and 
overhead costs; drug prices; follow-up/out-patient visit costs; and the availability of 
Diagnosis-Related Group (DRG) codes and tariffs. The transparency and availability 
of costs were assessed using the following criteria: the date, access restrictions and 
the need for assumptions to generate cost estimates. Results: DRG tariffs were 
identified for all countries, but the availability of other data varied. Drug prices were 
obtainable online (such as the website MedicPrix, France), but others required paid 
registration (Giofil, Italy). The UK had the most accessible primary and secondary 
care HRU cost data through PSSRU. Italy was the least transparent however AIFA 
informed us a website reform will increase access to data in 2014. Where not explicit, 
HRU costs can be indirectly derived from total procedure codes (for example through 
ATIH, France). Spain and Italy’s regional structure made sourcing national cost data 
challenging, resulting in wide ranges in input costs in published cost-effectiveness 
analyses. cOnclusiOns: Whilst some nations provided transparent HRU cost data, 
others did not, causing inconsistent inputs across cost-effectiveness analyses. To 
minimise inconsistency we propose a hierarchy of evidence for use when sourc-
ing costs: 1) Govt/health service official sources; 2) Official international websites 
(OECD/WHO); 3) Published economic studies; 4) Published non-economic studies; 
5) National expert opinion; and 6) Unofficial websites/sources.
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A RETROSPECTIvE ANALySIS OF DRUG REIMBURSEMENT DECISIONS IN 
IRELAND: A MULTI CRITERIA DECISION ANALySIS APPROACH
Schmitz S.1, McCullagh L.2, Adams R.2, Barry M.2, Walsh C.1
1Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland
Objectives: Standard approaches to economic evaluations based on cost utility 
analysis are increasingly considered inadequate. While simple and intuitive, it is 
acknowledged that the QALY alone does not capture all aspects of health benefit. 
Multi Criteria Decision Analysis (MCDA) has been proposed as a way of incorporat-
ing multiple factors influencing the value of a health technology. The objective of 
this study was to analyse past reimbursement recommendations by the National 
Centre for Pharmacoeconomics (NCPE) in Ireland in order to identify factors which 
have influenced decisions in the past. MethOds: Based on published literature, 
national guidelines and experience, a list of potentially influencing criteria was 
identified. Information on each criterion was extracted for each full pharmacoeco-
nomic assessment conducted by the NCPE. Logistic regression was used to estimate 
the impact each of these criteria has had on past recommendations. Model fit was 
assessed using the Deviance Information Criterion and the best fit model was cho-
sen using backwards stepwise regression. Results: Between 2006 and May 2013 the 
NCPE conducted 54 full pharmacoeconomic assessments. Each of these was scored 
against 14 criteria, which can be grouped into clinical utility, consumer demand, 
economic incentives, societal perspective and efficiency/affordability. The model 
of choice identified criteria of each group which impact on reimbursement recom-
mendations. cOnclusiOns: This analysis shows that factors other than cost per 
QALY have impacted on past valuations of health technologies in Ireland. Since the 
analysis was carried out retrospectively, these factors have influenced decisions in 
an informal manner and do not necessary represent the factors which should influ-
ence future reimbursement decisions. This approach contrasts with methods used 
elsewhere to estimate weights for the criteria. The results of this analysis provide 
a basis for the development of a MCDA approach to HTA in Ireland, which has the 
potential to improve consistent and transparent decision making.
PHP71
MEDICAL CARDS DURING RECESSION: HOw MANy, FOR wHOM AND HOw 
MUCH?
Kenneally M.
University College Cork, Cork, Ireland
Objectives: To model the age, gender and regional pattern of GMS coverage rates 
as they are key determinants of public spending on GMS medicines. MethOds: 
We used PCRS (Primary Care Reimbursement Service) and CSO (Central Statistics 
Office) databases to estimate GMS coverage rates by age, gender and region in 2010 
and 2011. Assuming log-normally distributed incomes we used CSO SILC data to 
estimate GMS coverage semi-elasticities in 2010. We estimated how much GMS 
male and female coverage rates in 7 adult age categories and 8 Irish regions in 
2010 responded to changing average income levels, income inequality and income 
thresholds. We tracked how well our predicted GMS coverage rates fitted actual 
rates in 2011. We simulated the 2011 GMS medicines cost burden of a ceteris 
paribus repeat of the 2010 changes in income and income-inequality. Results: 
Our modelled coverage rates have high goodness of fit compared to conventional 
econometric estimates. Coverage income-semi-elasticity ranges from .7 to 2.3, is 
highest for elderly age cohorts and in the South-East and South-West regions and 
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data collection is used for the same resource items. MethOds: Articles citing 
38 trial-based resource use instruments catalogued in the MRC-funded Database 
of Instruments for Resource Use Measurement (www.DIRUM.org) were identified 
using Google Scholar, ISI Web of Science and Scopus, and screened according to 
resource use measure usage. Data were extracted on: the method of administra-
tion, resources measured, rates of return and the nature of the other methods 
of resource use measurement. Results: A total of 146/1503 citations met the 
screening criteria. Nearly all (143/146) used resource use instruments derived from 
Beecham and Knapp’s Client Service Receipt Inventory. Most instruments relied 
on patient- or proxy-recall (126/146) generally administered during researcher 
interviews. Primary and secondary care usage were the most widely asked items 
(136/146) with 75 using no supplementary supporting data such as from hospital 
notes. Twelve studies compared one or more method of data collection for the 
same resource items with 8 indicating good agreement between medical records 
and patient/carer recall, 1 indicating the greater reliability of case notes and 3 were 
not evaluable. cOnclusiOns: Resource use instruments based on patient recall 
are valuable complements to other methods and essential for certain items (e.g. 
out of pocket costs, non-medical costs). However, there remains inappropriate use 
in circumstances where more objective measures are available.
PHP78
BEyOND PATENT ExPIRy: DEvELOPMENT OF A MODEL FOR PRICING GENERIC 
DRUGS IN SOUTH AFRICA
Keele M.G.1, Butkow N.1, Venter D.2
1University of the Witwatersrand, Johannesburg, South Africa, 2Nelson Mandela Metropolitan 
University, Port Elizabeth, South Africa
Objectives: Generic drugs provide a safe, effective and affordable alternative to 
medicines whose patent protection has expired. Generics have to meet the same 
quality standards as the innovator drugs; the only substantive difference is the price. 
Generic manufacturers compete ‘on a knife-edge’ of narrow margins of profitability. 
The generic pharmaceutical industry is risky and complex, success depends on the 
number of other generic drug manufacturers on the market, which affects the profit 
margins and volumes that each company could realize. The objective of the current 
study was to develop a model that explains the effect of generic drug entry on price 
competition after patent expiration in the pharmaceutical industry. MethOds: 
Innovators and their generics selected from all the chemical entities whose pat-
ents expired from 1999 through 2009. Data were obtained from IMS Health (Market 
Segmentation Report) and National Department of Health (Database of Medicine 
Prices) for the patents’ expiration dates, prices, sales volume, therapeutic group, 
schedule, and dosage forms of drugs in the sample. Results: A year after pat-
ent expiration, the innovators’ products retained an average of 59% of the market 
share; the generic-to-innovator price ratio was at an average of 65%. By the end of 
the first year after patent expiration, an average of 2 generics was registered per 
innovators’ product. cOnclusiOns: Generic entry is commercially driven; it is 
influenced by the market size of the innovator product prior to the expiry of the 
patent protection. Generic penetration is slow, only intensifies after 5 years since 
the loss of patent protection. The price erosion of the innovator product is strongly 
influenced by generic penetration. The cost of drugs in South Africa is not coming 
down fast enough.
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HOSPITAL RESOURCE USE IN CHRONIC DISEASE COMBINATIONS: IS IT ENOUGH 
TO jUST ADD THEM UP?
Seah J.Z., Harris A., Lorgelly P.K.
Monash University, Victoria, Australia
Objectives: Economic evaluations often ignore the possibility of non-linear 
health care costs when chronic diseases occur in combination. This paper aims 
to quantify the comparative effect of single and multiple chronic diseases on hos-
pital resource use. MethOds: Using records of all admissions to public hospitals 
in the state of Victoria, Australia in 2010-2011 we estimate multiple regression 
models of hospital length of stay (and total annual discharges) for combinations 
of 11 chronic diseases. For length of stay we run separate models for same-day 
and overnight stays, adjusting for observed and unobserved characteristics of 
patients. Results: A higher chronic disease count decreases the odds of a same-
day hospitalization (day-case) exponentially while some disease combinations 
increased these odds. Having ischemic heart disease (IHD) & dementia doubled the 
odds of a day-case compared to a patient with dementia only. Among overnight 
stays, having a mental disease had the highest single disease effect on length 
of stay (LOS) – increasing LOS by 3-4 days. Some disease combinations had non-
additive effects (i.e. their combined effect was greater/less than the sum of their 
single disease effects) on LOS while others were additive. The interaction effect in 
a depression-renal failure combination added 3 days to its single disease effects, 
while in cancer-osteoporosis it was -2 days. Disease combinations that produced 
a positive interaction effect were usually unrelated diseases. We found disease 
count to be positively correlated with number of admissions. Having a combina-
tion of diseases was generally found to have a less-than-additive effect on the 
number of admissions. cOnclusiOns: Patients with chronic diseases have a 
resource use pattern that includes longer lengths of stays and more admissions. 
Combinations of unrelated diseases are particularly correlated with longer lengths 
of stay therefore it is the disease and combination type that is associated with 
higher lengths of stay and admitted episodes.
PHP80
PHARMACEUTICAL ExPENDITURE, CLINICAL OUTCOMES AND ExPENDITURES 
ON OTHER HEALTH SERvICES
Siskou O.1, Galanis P.1, Tsavalias K.1, Kalogeropoulou M.1, Kaitelidou D.1, Pasaloglou S.2, 
Schneider M.3, Liaropoulos L.1
1National and Kapodistrian University of Athens, Athens, Greece, 2Novartis Hellas, Metamorfosi, 
Greece, 3BASYS, Augsburg, Germany
out for patients who had not been hospitalized within six months prior to index 
AMU admission. Results: In the whole group, total cost for IGI was higher (£207.4, 
95%CI: £94.8-£331.2) with no QALY gain (-0.001, 95%CI: -0.009-0.007); IGI was domi-
nated by standard care (3%-probability of ICER< £30,000/QALY). In the sub-group 
of 209 patients (IGI: 106) without a hospital stay in the previous six months, total 
cost for IGI was lower (-£274.2, 95%CI: -£480.4--£46.3) with non-significant QALY 
gain (0.001, 95%CI: -0.011-0.013), and 49%-probability of IGI being dominant (90%- 
probability of ICER≤ £30,000/QALY). In the whole group (sub-group), inpatient cost 
was lower by £212 (£778), and social care cost was higher (lower) by £220 (£141), 
comparing IGI to standard care. cOnclusiOns: The IGI for high-risk older people 
discharged from AMU was not cost-effective for all patients, but was cost-effective in 
patients without a hospital stay in the previous six months. This suggests targeting 
the intervention is required.
PHP75
ANALySIS OF TOTAL TREATMENT COSTS OF ORGANOPHOSPHOROUS 
POISONING IN A TERTIARy CARE HOSPITAL
Pariti B.1, Thunga G.2, MK U.2, Nikhil B.2
1Manipal University, Manipal, India, 2Manipal College of Pharmaceutical Sciences, Manipal 
University, Manipal, India
Objectives: . To establish the correlation of log mean cost with respect to APACHE 
II score, pre-hospitalization and length of hospital stay, and to determine the intra-
group variance of log mean treatment costs in different parameters. MethOds: 
Categorical data was presented as frequencies with percentages and was analyzed 
by Chi-square test, log regression and Pearson correlation. A logarithmic trans-
formation was used for total cost to convert into normal distribution. Geometric 
mean and Geometric SD was used to summarize total cost. One way ANOVA was 
used to compare the mean of log (total cost) across various categorical variables. 
Multiple linear regression was used to find the factors associated with total cost 
of hospitalization of OPP. Correlations was used for measuring the strength of 
linear relationship between total cost and APACHE II score. Results: A significant 
variance in log mean treatment costs was observed in different parameters like 
pseudocholinesterase levels, type of poison consumed, anticholinergics admin-
istered and incidence of intermediate syndrome. A high mean cost was observed 
in patients with a pseudocholinesterase level of less than 2000 and those who 
consumed WHO class Ib pesticide. A cost difference of INR 25,000 was noted in 
patients who developed intermediate syndrome. The APACHE II Score, pre-hos-
pitalization period and length of hospital stay had significant correlation with 
log cost. Among the variables, length of hospitalization had strong correlation 
with log cost (r= 0.673, p< 0.001). For every one-unit increase in pre-hospitalization 
period, APACHE II score and length of hospital stay, the log cost increases by INR 
1.01, 1.27 and 1.5 respectively. cOnclusiOns: High costs of treatment coupled 
with a proportionately great loss of man-days, make OPP an extremely important 
area for pharmacoeconomic evaluation and for framing appropriate policies for 
remedial measures. Hence studies evaluating treatment regimens with respect 
to costs and outcome are highly desirable.
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COST OF INTENSIvE CARE STAy IN TURKEy: IN THE vIEw OF PAyER AND 
HEALTH CARE PROvIDER
Daylan Kockaya P.1, Kavuncubasi S.2, Kockaya G.3
1Zirve University, Gaziantep, Turkey, 2Baskent University, Ankara, Turkey, 3Health Economics and 
Policy Association, Ankara, Turkey
Objectives: The demand for intensive care units has risen in the recent years 
as the increasing aged population in all countries and in Turkey. The aim of the 
study is to calculate the average cost of intensive care stay(ICS) and to compare 
the cost with the reimbursement amount depending on a public hospital data 
in Turkey. MethOds: The records of ICSed patients from a public hospital in 
Ankara were evaluated retrospectively between November 2011 and January 2012. 
The hospital cost and reimbursement amount were calculated depending on the 
data. Results: A total of 104 patients stayed in the given time line. Four patients 
excluded due to the missing data in files. The average cost of pharmaceuticals, 
medical devices, laboratory, health care and total cost per patient were calculated 
as 1209.16 TL± 492.46, 137.48 TL± 41.08, 422.35 TL± 108.70, 873.10 TL± 247.82 and 
2992.43 TL± 994.06, respectively. The average reimbursement amount per patient 
was calculated as 2846.59 TL± 842.60. The average profit or deficit of the hospital 
were calculated for the 1st,2nd,3rd,4th, 5th,6th, 7th,8th,9-15th,16-29th and 30-51st 
days as 34.90 TL± 49.69, -75.48 TL± 671.39, -23.25 TL± 315.41, 382.80 TL± 368.58, 283.09 
TL± 628.57, -266.13 TL± 612.81, 312.45 TL± 416.11, 118.99 TL± 729.00, -916.58 TL± 
1430.94, -1500.57 TL± 3217.87 and -2054.55 TL± 3204.79, respectively. The profit and 
deficit trend line was calculated with the number of ICS days as “y = -51,889x2 + 
446,98x - 631,73” (y= profit or deficit, x= hospital stay days). cOnclusiOns: It was 
concluded that the average daily cost of ICS increased depending on the length of 
stay. The patients in critical state who needed more ICS days may have caused this. 
On the other hand, it was observed that the fixed daily reimbursement amount is 
inadequate for prolonged ICS. As a result this leads to the deficits of the hospitals 
in the prolonged ICS.
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REvIEw OF THE USE OF RESOURCE USE INSTRUMENTS BASED ON PATIENT 
RECALL IN RELATION TO OTHER METHODS OF COST ESTIMATION
Ridyard C., Linck P., Hughes D.A.
Bangor University, Bangor, UK
Objectives: Instruments for resource use measurement based on patient-recall 
(e.g. questionnaires, logs and diaries) are used extensively in trial-based economic 
evaluations; sometimes on their own and sometimes alongside other methods 
for estimating costs. The aims were to assess: 1) how resource use instruments 
are used in practice; 2) which items of resource use are based most frequently 
on patient-recall; and 3) how estimates compare if more than one method of 
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COST-OUTCOME DESCRIPTION OF CLINICAL PHARMACIST INTERvENTIONS IN 
A UNIvERSITy TEACHING HOSPITAL
Gallagher J.1, Mc Carthy S.1, Lynch D.2, Woods N.1, Byrne S.1
1University College Cork, Cork, Ireland, 2Cork University Hospital, Cork, Ireland
Objectives: Clinical pharmacist interventions are actions which aim to improve 
a patient’s pharmaceutical care. The primary objective of this study is to esti-
mate the cost savings achieved by clinical pharmacists through the prevention of 
adverse drug events (ADE) in a hospital setting. Previous studies have estimated 
the benefit of these interventions over shorter periods of time and in specific 
hospital areas. This study will encompass a longer time period and a complete 
hospital system. MethOds: This study was a retrospective analysis of a data-
base detailing pharmacist interventions on patient therapies at Cork University 
Hospital. Period examined was from January 2012 to December 2012 inclusive. 
Cost savings were calculated based on the probability that an ADE would have 
occurred in the absence of the proposed pharmacist intervention (Average cost 
of ADE = € 970). Input costs were calculated based on the time required for phar-
macists (n = 17) to enact interventions. One way sensitivity analysis incorporated 
published ranges for intervention time, pharmacist salary and probability an ADE 
would have occurred. Alternative costs for an ADE were also included in analysis. 
Cost savings are from the perspective of the health care institution. Costs are 
presented in 2012 € values. Results: A total of 4,247 interventions were docu-
mented. Base case analysis resulted in net cost benefit of € 590,000 per annum 
and a cost benefit ratio of 10.4:1. Cost savings of € 650,000 were generated and 
the cost of providing the service was estimated at € 60,000. Sensitivity analysis 
resulted in cost benefit ratio varying from 5.2 – 64.8 (minimum – maximum). 
The most prevalent pharmacist intervention was the identification of drug omis-
sions (n= 1820, 42.9%). cOnclusiOns: Cost benefit ratio remained positive in all 
situations examined. This study has added to the body of evidence that clinical 
pharmacist interventions are cost effective over extended time periods and entire 
hospital settings.
PHP84
DIFFERENTIAL DISCOUTING: CAPTURING THE vALUE OF LIvING LONGER AND 
BETTER
Ralston S., Floyd D., Ratcliffe M.
PHMR Associates, London, UK
Objectives: Discounting future cost and health benefits is standard in phar-
macoeconomic evaluations. Using different discount rates for costs and benefits 
remains controversial, although there is a case for lowering the health effect 
discount rate as the general population benefits from better health over a longer 
period of time. The implications of differential discounting on the likely duration 
of health benefits was assessed. MethOds: An extensive literature review sourced 
current discount rates for European countries, including the justification for those 
rates where available. Using a specific example (mifamurtide [Mepact, Takeda] for 
the treatment of osteosarcoma) the time to loss of health benefits for equal and 
differential discount rates using a UK reference case was assessed. Results: 
Like most of Europe, the UK National Institute for Clinical Excellence (NICE) has 
been using a discount rate of 3.5% for both costs and health effects. However, it 
has recently adopted a differential reference case where health effects are sus-
tained over a period of 30 years or more: 1.5% for health effects and 3.5% for costs. 
Taking the example of mifamurtide and using the original rate of 3.5% for health 
effects, all benefit would be discounted away after just 22 years. By adopting the 
lower rate, the effects will not be discounted away until 49 years after treatment. 
In this case, the discount rates used to for mifamurtide are particularly sensitive 
because all costs are borne in the first year, yet benefits of treatment can be over a 
patient’s lifetime. cOnclusiOns: Adopting differential discounting rates reflects 
the potential long-term benefits of new health care technologies. However, most 
European countries, with the exceptions of Belgium, The Netherlands and now 
the UK in specific circumstances, continue to use the same discount rate for costs 
and health effects, thereby potentially undervaluing the long-term benefits cur-
rent and new treatments.
PHP85
ADvANCED BUDGET NOTIFICATION (ABN): IS THERE A wIN:wIN FOR 
MANUFACTURERS AND PAyERS GIvEN THE CURRENT AUSTERITy MEASURES 
ACROSS THE EU
Mallinson M.
Access Partnership, London, UK
Objectives: The mature health economies across the EU are severely fiscally 
challenged, and yet manufacturers of innovative medicines are where the legisla-
tion permits expected to give a notifiable ‘warning’ of expected budget impact. A 
survey was undertaken amongst payers to ascertain their real world expectations 
in terms of advanced warning and how realistically a collaborative approach to 
access could be achieved. MethOds: Manufacturers of innovative technologies 
are where legislation permits advised to supply payers and budget holders with 
information that will assist the aforesaid bodies with sufficient information to 
decide on the managed entry of that technology; historically manufacturers are 
in two minds about the value of this process. A study was undertaken with payers 
as to their perceived interest and interaction with manufacturers who willingly 
entered into ABN. Payers at a regional and national level were interviewed to gauge 
their opinions. Results: There appears to be a dichotomy of opinion amongst 
payers as to the value of the legislation; ‘damned if you do, damned if you don’t’, 
however it clearly is in the interest of both parties to work together. Payers value 
the contact and information provision from Manufacturers, Manufactures seek to 
garner the approval of payers. cOnclusiOns: The EU is in the worst economic 
depression since the 1930’s, affordability is the key watchword. New technologies 
need to continue to be presented to payers in a manner which allows them to plan 
for fiscal pressure and service redesign.
Objectives: The study examined: a) the relationship between pharma care and 
health outcomes, b) the influence of expenditure on drugs to the level of expendi-
ture on other forms of care c) the impact of providers on the level of pharma 
expenditure. MethOds: We conducted linear multiple regression analysis with 
pharma expenditure as independent variable, and dependent variables such as 
clinical indicators and expenditure of other categories. Also, we conducted analy-
ses with number of physicians and pharmacists as independent variables and 
pharma expenditure as dependent. Analyses were conducted for all Eurozone 
countries (2003-2011). All tests of statistical significance were two-tailed, and 
p-values of less than 0.05 were considered significant. Results: Increased total 
per capita outpatient pharma expenditure (in US $ PPP’s) by 10% was related to 
increase in life expectancy: a) at birth for men by 0.41% (p= 0.07), b) for men 65+ by 
2.35% (p= 0.004), and c) at birth for women by 0.37% (p= 0.03). Moreover, increased 
public pharma expenditure as a % of total current public expenditure by 10% was 
related to a reduction of public current health expenditure (as a % of GDP) by 
2.8% (p< 0.001). A 10% increase of total pharma expenditure as a % of total cur-
rent health expenditure as a % of GDP, was related to a reduction of total current 
health expenditure as a % of GDP by 3.3% (p= 0.045). Finally, an increase in the 
number of pharmacists/100,000 population by 10% was related to an increase of 
total per capita pharmaceutical expenditure by 0.93% (p= 0.07). cOnclusiOns: 
Overall drug expenditure is positively related to population health and negatively 
connected with the level of total health expenditure, a finding that should influ-
ence political decisions on public insurance coverage. The accuracy of our results 
will be further enhanced by similar research in the future, when longer time 
series data are available.
PHP81
BIOSIMILAR AND ORIGINATOR BIOLOGIC PRICING DyNAMICS IN EMERGING 
MARKETS
Lockwood C.1, Reinaud F.2, Marinoni G.1, Ando G.1
1IHS, London, UK, 2IHS, Paris, France
Objectives: To characterise pricing dynamics between originator biologics and 
biosimilar products in a number of emerging markets, namely Brazil, China, India, 
Mexico, Russia, South Korea and Turkey. MethOds: Prices for the products con-
cerned were based on calculations of ex-manufacturing prices. Prices at time of 
biosimilar launch and from the most recent time point available were selected for 
the respective biosimilar and originator products, and converted to a price-per-unit 
basis. Average prices were then calculated per brand name, where more than one 
strength or formulation of a product existed. In addition, primary and secondary 
research were utilised to obtain further manufacturer and/or retail-level price data 
where possible. Results: At the time of launch, biosimilar products in emerging 
markets exhibit a manufacturer-level price representing an approximately 30% 
discount, on average, over that of the originator biologic. There are a number of 
exceptions, with evidence that some biosimilar products are priced at a mere 40% 
of the originator at time of launch. The more typical 30% differential appears to 
narrow significantly with time, as evidenced across a number of markets that have 
seen activity in the first generation of biosimilar products (e.g., erythropoietins, 
granulocyte colony-stimulating factor, etc). cOnclusiOns: At time of launch, the 
pricing dynamic between originator biologics and their respective biosimilars in 
emerging markets appears to mimic the scenario which has thus far been observed 
in Europe. However, there are exceptions, with some products associated with sig-
nificantly larger discounts at time of launch in certain emerging markets. Over 
time, there tends to be dramatic price erosion for both originators and biosimilars 
as a function of the original originator price. This erosion is driven by competitive 
entry into the market of subsequent biosimilars, coupled with widespread use of 
tendering in the public markets.
PHP82
EvALUATION OF THE POLICIES IMPLEMENTED TO MONITOR PRESCRIPTION 
AND REDUCE PHARMACEUTICAL ExPENDITURE AT THE UNIvERSITy GENERAL 
HOSPITAL OF PATRAS, GREECE
Tsiata K.1, Letsios A.1, Kousoulakou H.2, Geitona M.2
1University General Hospital of Patra, Patra, Greece, 2University of Peloponnese, Corinth, Greece
Objectives: The University Hospital of Patras (GPNP) has implemented a series of 
prescription monitoring measures that aim at reducing the hospital’s pharmaceu-
tical expenditure. The objective of this study was to evaluate the results of those 
policies. MethOds: Analysis of the 2011 and 2012 economic data of the GPNP on 
purchase and consumption (in terms of quantity and value) of pharmaceutical prod-
ucts, both in the inpatient and outpatient settings, was conducted. Data on the total 
number of outpatient prescriptions and high-cost drugs were also analyzed. The 
subgroup of high-cost drugs was further investigated, by performing a breakdown 
analysis of the expenditure of high-cost drugs by disease area. Results: The cost 
containment measures implemented by the GPNP (which include, among others, 
the development of guidelines on rationalizing the use of pharmaceutical products, 
and a hospital formulary, which took into consideration both clinical and cost data), 
have resulted in a reduction of the total pharmaceutical consumption by 11.5% 
in 2012 (€ 29.4 million) compared to 2011(€ 33.2 million). Although total outpatient 
prescriptions and the related quantity of pharmaceutical products prescribed were 
increased by 8.1% and 10.5%, respectively, the pharmaceutical cost of outpatient care 
was reduced by almost 28%, indicating a significant increase in the prescription of 
lower cost pharmaceuticals. Indeed, the high-cost hospital medicines prescribed to 
outpatients was reduced by almost 21% in 2012. In the inpatient setting, the total 
expenditure on high-cost hospital medicines was reduced by 12.9%. The expenditure 
on cytostatic drugs, which accounts for more than 70% of the total expenditure 
for high-cost drugs in the inpatient setting, was reduced by almost 10%, while the 
number of patients hospitalized was reduced by only 1.6%. cOnclusiOns: The 
policies implemented by the GPNP were successful in reallocating pharmaceutical 
budget towards more innovative medicines in order to ensure patients’ access to 
new therapies.
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of the case mix of the hospital activity. As a consequence, it could be a useful model 
to increase the awareness of the economic impact and to allow a more informed 
management at hospital and regional level.
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COST ANALySIS OF AN INTENSIvE CARE UNIT
Putignano D.1, Di Maio F.F.1, Orlando V.1, Cammarota S.1, De Nicola A.2, Menditto E.1
1CIRFF-Center of Pharmacoeconomics, Naples, Italy, 2Presidio Ospedaliero San Leonardo - 
Castellammare di Stabia, Castellammare di Stabia, Italy
Objectives: The aim of our study is to analyze the costs incurred by hospitalized 
patients in 2010, in the intensive care unit (ICU) of San Leonardo Hospital (Southern-
Italy). MethOds: A retrospective cost analysis was performed on patients with a 
length of stay longer than 24 hours. Direct medical costs were estimated (hospi-
talization, surgical procedures, devices). The costs of hospitalizations and surgical 
procedures were calculated based on the 24.0 version of the tariff system DRG 
(Diagnosis Related Group). The data on the costs of the devices were provided by 
the management of the hospital pharmacy. To evaluate the burden of the diagnostic 
groups two indicators were used: cost per surviving patient (total resources used / 
total survivors) and money loss per patient (total resources used for dead patients 
/ total patients) [Rossi et al. Intensive Care Med. 2006]. Results: A total of 201 
patients hospitalized in the ICU in 2010 were selected and analyzed depending on 
their diagnostic group. Hospitalized patients who had a hospital stay longer than 
or equal to 24 hours, were 95% of the sample. Most frequent diagnostic groups have 
been: edema (16.4%), left heart failure (13.9%) and COPD (9.0%). There is a wide vari-
ation between the average costs per patient probably due to the difference in the 
duration of hospitalization (from a minimum of € 2,777 in stroke, to a maximum 
of 7,227 euros in nephro-urological disease). Intracranial bleeding is the disease 
causing the highest costs per dead or survived patient. The nephro-urological and 
neurological diseases are characterized by the lowest costs, for dead and survived 
patients, indicating a better efficiency. cOnclusiOns: The results are a starting 
point for further investigations aimed at the exploitation of resources absorbed 
by ICU opposed to the need to provide patients with the best possible health care.
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HEALTH ECONOMIC EvIDENCE FOR MEDICAL NUTRITIONS: ARE THESE 
INTERvENTIONS vALUE FOR MONEy?
Walzer S.1, Droeschel D.2, Nuijten M.J.C.3, Chevrou-Severac H.4
1State University Baden-Wuerttemberg, Loerrach, Germany, 2Swiss Tropical and Public Health 
Institute, Basel, Switzerland, 3Ars Accessus Medica, Jisp, The Netherlands, 4Nestlé Health Science, 
Vevey, Switzerland
Objectives: Medical nutrition (MN) targets patients with malnutrition or with 
specific disease such as Crohn’s disease (CD) to support their recovery. Efficacy of 
MN has been demonstrated in malnutrition, as well as in paediatric CD or gastro-
intestinal (GI) cancer surgery. However, its health economic evidence is less known. 
This article summarizes the findings of a systematic literature search on health 
economics evidence of MN in order to understand what the value for money of 
MN interventions is. MethOds: A systematic literature search was performed to 
identify publications related to health economics evidence of MN. The result of it 
was communicated elsewhere. For selected articles, the clinical background, basis 
of the analysis, health economic design and results were extracted and summa-
rized by relevant disease areas. Results: Among the 32 articles found, 11 covered 
malnutrition, 9 related to GI surgery, 6 studied cow milk allergies (CMA), whereas 
the remaining focused on various diseases. When targeting malnutrition, MN was 
accepted as being cost-effective and/or cost-savings from budget impact analyses. 
In GI surgery, when taking into account the full episode of care, oral and enteral 
nutrition was assessed as good value-for-money. In CMA, there was a significant 
health care budget impact of using MN to treat symptoms of this allergy. In the 
remaining indications, the use of enteral tube feeding was demonstrated as being 
cost-saving compared to parenteral nutrition. cOnclusiOns: Based on a system-
atic literature search, MN interventions showed value for money in different health 
care settings. Although few studies calculated an incremental cost-effectiveness 
ratio (ICER), those calculated were all below thresholds applied in medical settings. 
In addition, most of the times MN was more effective and cost saving, thus a domi-
nant option. However, more research is needed to strengthen economic modelling 
for medical nutrition interventions.
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IMPACT OF PHARMACOECONOMICS MODELLING ON REIMBURSEMENT OF 
MEDICINES IN SERBIA
Medic G.1, Baltezarevic D.2, Novakovic T.2
1Mapi - HEOR & Strategic Market Access, Houten, The Netherlands, 2Pharmacoeconomics Section 
of the Pharmaceutical Association of Serbia, Belgrade, Serbia and Montenegro
Objectives: To assess the impact of recently published (2011) Guidelines for 
Pharmacoeconomic Evaluations for Serbia and ISPOR Guidelines (2013) on the 
methods and the conduct of budget impact analysis (BIA) during reimbursement 
submission. MethOds: We investigated how many reimbursement submissions 
were made with an accompanying BIA to the Health Insurance Fund in Serbia from 
2012 till June 2013. Results: There were 306 submissions in 2012 and 2013 and none 
of those had a thorough and complete BIA submitted. There were 65 new drugs 
(international non-proprietary names (INNs)) added to the Reimbursement list in 
2012 and 5 new drugs (INNs) in April 2013. Possible reason for a non-complete BIAs 
was that it is not an obligatory part of the submission dossier. It is recommended 
at this moment, but the plan is to make it an obligatory part. BIA simply quantifies 
the financial consequences of using health-care services, comparing reference with 
anticipated scenario. Currently there is no template for the BIA, just recommenda-
tions how to address time horizon, target population, costing, scenarios and dis-
counting. This could be one of the reasons why most of the submissions had almost 
complete pharmacoeconomics evaluation. cOnclusiOns: The availability of a 
template for BIA would increase transparency, the quality of submissions and pro-
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PHARMACOECONOMIC ANALySIS OF IOvERSOL vERSUS IOHExOL FOR 
DIAGNOSTIC PROCEDURES
Ivakhnenko O.1, Khachatryan G.1, Avxentyeva M.2, Rebrova O.3, Müller-York A.4
1Autonomous non-profit organization “National Centre for Health Technology Assessment”, 
Moscow, Russia, 2The Russian Presidential Academy of National Economy and Public 
Administration, Moscow, Russia, 3Pirogov Russian National Research Medical University, Moscow, 
Russia, 4Mallinckrodt Deutschland GmbH, Neustadt an der Donau, Germany
Contrast-induced nephropathy (CIN) is a clinically significant and costly com-
plication related to the use of iodine-based contrast media (CM). The hypothesis 
regarding the advantages of isoosmolar CM compared to low-osmolar CM was not 
confirmed in recent meta-analyses; still, there may be safety differences between 
individual CM. Objectives: To perform a pharmacoeconomic comparison of the 
CM ioversol and iohexol used for x-ray procedures in Russia. MethOds: We cal-
culated the costs for using ioversol and iohexol taking into account the risk of 
the occurrence of CIN and CIN-associated complications. Data for the model were 
extracted from published clinical trials and reviews. We performed an indirect com-
parison of both CM to calculate the relative risk (RR) of CIN (via the CM iodixanol as 
a mutual control). This RR value was used in the model to simulate the impact of 
potential safety differences between both CM on the costs. Direct medical costs were 
calculated based on the Russian health care system setting. Related costs for CM 
and for CIN-associated complications (e.g. cardiovascular complications, respiratory 
distress syndrome and hemodialysis for acute kidney injury) were also taken into 
account. Cost calculations were performed separately for patients with low, medium 
and high risk for CIN. One-way sensitivity analysis was performed. Results: RR of 
CIN was 0.26 (95% confidence interval 0.12-0.58) for ioversol vs iohexol in the indirect 
comparison. Direct medical costs were higher for iohexol than for ioversol due to 
the slightly higher rate of CIN, thus, CIN-associated complications: net benefits 
were 469.16; 752.88 and 3313.13 rubles (~11.03; 17.70; 77.91 Euros) per patient with 
low, medium and high risk of CIN correspondingly. Still, results were sensitive to 
the price of both CM. cOnclusiOns: In the Russian health care setting, the use 
of ioversol seems to be more cost efficient than iohexol due to slightly favorable 
renal safety.
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ECONOMIC EvALUATION OF INTRAvENOUS IODINATED CONTRAST MEDIA IN 
ITALy
Iannazzo S.1, Vandekerckhove S.2, De Francesco M.1, Nayak A.3, Morana G.4, Valentino M.5, 
Ronco C.3
1IMS Health, Milan, Italy, 2IMS Health HEOR, Vilvoorde, Belgium, 3San Bortolo Hospital, Vicenza, 
Italy, 4Ca’ Foncello Hospital, Treviso, Italy, 5S. Antonio Abate Hospital, Tolmezzo, Italy
Objectives: Contrast-induced acute kidney injury (CI-AKI) is defined as a dete-
rioration in renal function after administration of radiologic iodinated contrast 
media (CM). Iodixanol, showed a lower CI-AKI incidence than low-osmolar contract 
media (LOCM). A cost-effectiveness analysis was performed comparing iodixanol 
and LOCM in intravenous (IV) setting in Italy. MethOds: A Markov model was 
developed. Patients moved across four health states, CI-AKI free, CI-AKI, myocar-
dial infarction and death. The simulation horizon was lifetime with one-month 
cycles. Costs and outcomes were discounted at 3.5% rate. CI-AKI incidence was 
considered from published literature across different definitions. Cost-effectiveness 
of iodixanol was assessed in terms of incremental cost per life year gained. Net 
monetary benefit (NMB) was also calculated. Both deterministic and probabilistic 
sensitivity analysis were performed. Results: Base-case results showed an aver-
age survival increase of 0.51 LYs and a saving of € 7.25 for iodixanol vs. LOCM. The 
cost-effectiveness of iodixanol was confirmed when other scenarios were explored, 
such as varying CI-AKI definition, sub-populations with specified risk factors, CM 
hospital bids prices and inclusion of adverse drug reactions of allergic nature. A NMB 
ranging between € 6,007.25 and € 30,007.25 was calculated. cOnclusiOns: base-
case results are showing that IV iodixanol is cost-effective compared to LOCM in 
the Italian clinical setting of hospital CT radiology practice. However, some caution 
is due, mainly linked to inherent limitations of the modelling technique and to the 
lack of agreement on CI-AKI incidence data in the clinical literature.
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A DETERMINISTIC MODEL TO EvALUATE THE COSTS FOR SURGICAL 
PROCEDURES: THE wIN-wIN MODEL
Velleca M.1, Mauro E.1, Belarbi S.2, Perrone F.1
1Johnson & Johnson Medical, Pomezia (RM), Italy, 2Ethicon Surgical Care, a Johnson & Johnson 
company, Issy les Moulineaux, France
Objectives: The Italian National Health Service (Servizio Sanitario Nazionale-SSN)is 
financed at hospital level by DRG (Diagnosis Related Group): the classification is 
defined at national level and the tariffs at regional level. Each region could define 
different tariffs for different types of hospital, choosing different criteria to identify 
them. The aim of this study is to analyze the incidence of the different types of 
costs for different surgical procedures and to evaluate the impact of the case mix 
on the total hospital costs. MethOds: We developed an excel model, the Win-Win, 
in order to analyze the incidence of different types of costs using the hospital per-
spective: length of stay, operating room time, personnel, materials. We identified 8 
surgical procedures, based on the International Classification of Disease 9-Clinical 
Modification, and for each one, we collected all the data from a survey based on 
different clinical practices in different types of hospitals. The model has been set 
up with the possibility to customize each type of data, consumptions and unit 
costs. Results: We calculated the average (AVG) and the confidence interval (IC) 
for the incidence of each type of cost among the different surgical procedures. For 
the length of stay we observed the highest average incidence (35,1%; IC95% 24,4-
39,9), followed by the cost of materials with an average of 34,9% (IC95% 30,1-43,1), 
the operating room cost (avg 20,6%; IC95% 18,8-22,8), and the personnel (avg 9,4%; 
IC95% 7,2-11,1). cOnclusiOns: Through the Win-Win Model it is possible to ana-
lyze the costs of each type of surgical procedure and evaluate the economic impact 
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by the government budget. Results: Sixty-two DRGs were identified as suitable for 
day cases. The majority of these were procedures of the eye (16%), the ear, nose and 
throat (11.3%), the myoskeletal system (9.7%), the kidney and the urinary tract (9.7%) 
and the female reproductive system (9.7%). The hospital marginal cost of an increase 
in the length of stay by one day was estimated at 563.32 euros (95%CI: 541.6–585.1). 
The annual savings were estimated at 93.7 million euros for the SI and when labor 
opportunity cost is included the amount saved exceeds 225 million. cOnclusiOns: 
In light of the economic crisis and the continuously reduced health care budget, 
the health system should adopt cost-effective intervention in order to preserve a 
satisfactory level of health services output. As this study concludes, day surgery can 
save a great amount of resources and according to the international literature can 
also guarantee patients’ safety and satisfaction.
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CHRONIC PATIENTS’ PERCEPTIONS ABOUT GENERIC MEDICINES IN GREECE: 
FINDINGS FROM A CROSS SECTIONAL SURvEy
Mylona K.1, Skroumpelos A.1, Zavras D.1, Pasaloglou S.2, Pavi E.1, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Novartis Hellas, Metamorfosi, Greece
Objectives: The Greek authorities implemented mandatory generic substitution 
trying to expand the use of generics, due to reasons of cost-containment. However, 
Greece lacks a strong, established generics culture. This study aims to investigate 
chronic patients’ perceptions on generics in Greece. MethOds: We carried out 
a cross-sectional study among 1600 patients from four chronic illness groups 
(HTN, Diabetes, COPD and Alzheimer mild to moderate stage). Logistic regression 
analysis was used to determine the factors associated with chronic patients’ per-
ceptions. Results: Of 1600 patients, 1594 responded to the survey (99.6%). Only 
67% has used generics in the past. 39.3% considers them safe, 34.3% thinks that 
the generics have the same quality standards as the originals and 37.3% believes 
that they have the same treatment outcomes. 63% expressed concern on potential 
adverse effects from generics. 58% argues that the drug’s country of origin affects its 
safety. Statistical analysis revealed that generics quality has a statistical significant 
relationship with patient’s income (OR 1.24; 95% CI 1.00-1.19), age (OR 0.99; 95% CI 
0.98-1.00), gender (OR 0.73; 95% CI 0.57-0.94) and health status (OR 1.00; 95% CI 1.00-
1.02) while generics effectiveness was positively related with the patient’s income 
(OR 1.10; 95% CI 1.02-1.20), gender (OR 0.70, 95% CI 0.55-0.90) and health (OR 1.00, 
95% CI 1.00-1.01). Women and the elderly are less likely to consider that the gener-
ics have the same standards as the originals. cOnclusiOns: Our findings reveal 
that chronic patients express reservations towards generic medicines which in an 
extent can probably explain the low generic market share in Greece. Perceptions 
about generics were found significant related mostly with patients’ demographic 
characteristic. The latter can be considered as useful information as it assists stake-
holders to identify on which chronic patients groups should direct campaigns in 
order to encourage generic drug use as a means to control expenditures and to save 
resources for innovative drugs.
PHP97
ANALySIS OF SPANISH GENERIC MEDICINES MARKET: RECOMMENDATIONS TO 
ENHANCE LONG-TERM SUSTAINABILITy
Dylst P.1, Simoens S.1, Vulto A.2
1KU Leuven, Leuven, Belgium, 2Erasmus University Medical Center, Hospital Pharmacy, 
Rotterdam, The Netherlands
Objectives: To provide an overview of the Spanish generic medicines retail market 
and to identify policy measures which impede its development. Finally, recommen-
dations to increase both the efficiency of health care with regards to pharmaceuti-
cals in general and the sustainability of the Spanish generic medicines retail market 
are put forwards. MethOds: A literature review has been carried out to explore the 
current situation of the Spanish generic medicines market. In addition, a survey 
has been developed and interviews have been conducted to validate the infor-
mation obtained from the literature review. Results: The Spanish government’s 
focus on the price level of generic medicines in the past has decreased prices of 
generic medicines drastically. The current reference pricing system (since 2011) has 
eroded price differentials between originator and generic medicines in more than 
90% of the reference groups. Differing policies at the demand-side have resulted 
in differing generic market shares between the autonomous communities. Policies 
are needed to increase both the efficiency of the health care system with regards 
to pharmaceuticals (e.g. electronic prescribing, prescribing by international non-
proprietary name, etc.) and the sustainability of the Spanish generic medicines retail 
market (e.g. creating price difference between originator and generic medicines, 
accelerating market entrance, building and improving trust for generic medicines 
in patients and physicians, etc.). cOnclusiOns: The low volume of generic medi-
cines used in Spain combined with the continuous pressure on the price level of 
generic medicines threatens the sustainability of the generic medicines industry. 
The reduced price difference between originator and generic medicines tends to 
be an important barrier for the development of a generic medicines market. The 
unique experience in the Spanish market shows the importance of demand-side 
policies on the use of generic medicines.
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ACCEPTABILITy OF INDIRECT EvIDENCE TO SUPPORT DRUG REIMBURSEMENT 
IN AUSTRALIA
O’Leary B.A., McKenna S.J., Cheng Y.Y., McElroy H.J.
Covance Pty Ltd., North Ryde, Australia
Objectives: When there are no direct head-to-head trials versus an appropriate 
comparator, indirect comparisons are commonly performed to support a clinical 
claim and relative pricing. In Australia, Public Summary Documents (PSDs), report-
ing on the Pharmaceutical Benefits Advisory Committee’s (PBAC) decision-making 
process relating to government reimbursement of medicines, have been published 
since July 2005. A review of PSDs specific to drugs where the primary claim was 
based on indirect evidence was undertaken to assess the success of the approach and 
mote its use. The audience includes those who develop, submit or use budget impact 
models and committees who evaluate reimbursement submissions. With a use 
of Guidelines for Pharmacoeconomic Evaluations, ISPOR Guidelines and proposed 
BIA template (which will be published in the updated version of the Guidelines for 
Pharmacoeconomic Evaluations) the quality of submissions to the HIF in Serbia 
would be raised and the decision time could be reduced.
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THE SUSTAINABILITy OF IRISH PHARMACEUTICAL ExPENDITURE
Walshe V.1, Kenneally M.2
1Health Service Executive, Cork, Ireland, 2University College Cork, Cork, Ireland
Objectives: The recent economic crisis has threatened the sustainability of many 
international economies as well as their health care systems. The objective of this 
paper was to quantify recent cost containment measures used to reduce Irish pub-
lic pharmaceutical expenditure in light of the ongoing fiscal restrain. MethOds: 
Pharmaceutical expenditure across the EU was briefly examined using the most 
current OECD data. The main pharmaceutical cost containment measures recently 
adopted in Ireland were identified under the headings of drug prices, fees/mark-ups 
and coverage/co-payments with full year 2011 public savings estimated. Results: 
EU pharmaceutical expenditure was estimated at € 190 billion in 2010, almost one 
fifth of all health expenditure. At € 528, Ireland spent more on pharmaceuticals 
than any other European country on a per capita basis and 50% more than the 
average across EU member states. Governments under pressure to maintain a sus-
tainable national health system and reduce deficits, while still preserving acute 
care levels, are cutting pharmaceutical expenditure. Many European countries, 
including Ireland, have increased the use of cost containment measures including 
a mix of price and volume controls. Collectively, these measures were estimated 
to have reduced Irish public pharmaceutical expenditure by € 380m in 2011. The 
main cost containment measures used involved addressing; 1) the ex-factory price 
of drugs including price cuts of up to 40% on off-patent and generic drugs leading 
to an estimated € 200m saving, 2) pharmacy dispensing fees and mark-ups via a 
new dispensing fee structure and reducing both retail and wholesale mark-ups 
with a € 100m saving, and 3) scheme coverage and patient co-payments including 
restricting scheme coverage for persons over 70 years and increasing the level of 
co-payments with savings of € 80m. cOnclusiOns: There use of pharmaceutical 
cost containment measures to decrease health expenditure is a trend that is likely 
to continue for some time yet.
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BASIC ATTITUDE TOwARDS HEALTH CARE RESOURCE ALLOCATION DECISION 
MAKING IN jAPANESE PEOPLE -UTILITARIANISM OR EGALITARIANISM?
Saito S.1, Shiroiwa T.2, Shimozuma K.3, Kodama S.4, Noto S.5, Fukuda T.2
1Okayama University, Okayama, Japan, 2National Institute of Public Health, Saitama, Japan, 
3Ritsumeikan University, Kusatsu, Japan, 4Kyoto University, Kyoto, Japan, 5Niigata University of 
Health and Welfare, Niigata, Japan
Objectives: Japan is now confronting budget constraints and trying to introduce 
economic evaluation into health care resource allocation. To clarify the basic atti-
tude towards health care resource allocation in Japanese people, a national survey 
was conducted. MethOds: A survey was carried out in a face-to-face manner with 
random sampling on the 50 municipalities in Japan, adjusting for age and sex, 
between March and April 2013. The questionnaire consisted of two scenarios; ques-
tion 1:”Imagine that there are two clinical examinations (A: less expensive with 
low power; B: more expensive with high power) and choose from the following two 
options: option 1: all subjects receive examination A and subsequently the death of 
1,000 people is prevented; option 2: a half of the subjects is selected by lottery and 
receives examination B, preventing the death of 1,100 people as a consequence.” ; 
question 2:” Imagine that two types of diseases differing the treatment cost(A: 10 
million per patient; B: 2 million per patient), and allocate 100 million yens to these 
diseases.” Results: Out of 1143 respondents, 601 chose the option 1 in question 1. 
In question 2, 217 chose the least utilitarian combination(A;8, B;10), 139 chose 2nd 
combination(A;6, B;20), 289 chose 3rd one(A;4, B;30), 67 chose 4th one(A;2, B;40), and 
379 chose the most utilitarian option(A;0, B;50). The weak correlation was observed 
in the utilitarian trend and age (r= 0.29, p < 0.01). Utilitarian tendency to maximize 
the health benefit varied among respondents with different educational back-
grounds. cOnclusiOns: We investigated the basic attitude towards health care 
resource allocation in Japanese people by answering to specific scenarios, which 
revealed fairly extreme utilitarian selection was the most popular. This utilitarian 
tendency correlated with age and education. It seems that the discussion on the 
priority setting in health care resource allocation in Japan based on this kind of 
empirical data become important.
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RESOURCES SAvED By THE INTRODUCTION OF DAy SURGERy IN THE GREEK 
NATIONAL HEALTH SySTEM
Skroumpelos A.1, Mylona K.1, Naoum P.1, Kyriopoulos D.1, Oikonomidou R.2, Thireos E.3,  
Pavi E.1
1National School of Public Health, Athens, Greece, 2Health Center Kallikrateia, Thessaloniki, 
Greece, 3Greek NHS, Athens, Greece
Objectives: Day surgery has been introduced in numerous heath care systems and 
has been proved able to save resources and promote efficiency and effectiveness. 
The aim of this study is to estimate the savings that can be realized by the adoption 
of day surgery by the Greek National Health System. MethOds: Surgery procedures 
were classified according to the type of anesthesia and the post-operative care they 
require. The procedures identified as suitable for day surgery, according to the above 
criteria, were matched to the Greek Diagnostics Related Groups (DRGs). The possible 
savings were calculated on the basis of the marginal cost these procedures impose 
to hospitals when treating them as inpatient surgeries. Savings were estimated for 
both the social insurance(SI) and for the government budget due to the fact that SI 
reimburses the capital production factor of each DRG while the labor cost is funded 
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Objectives: To define and develop risk - and more specifically market access risk– 
as a framework towards understanding and evaluating stability in market access 
systems at an individual country level. MethOds: We created a combination model 
of rating quantitative and qualitative variables which affect a country’s ability and 
willingness to pay for new drugs. The criterion for selection of variables is based 
on relevance, availability and uniformity in our model. We included a total of 42 
variables categorised under three verticals - quantitative, qualitative and measures 
of stability. In order to derive a non-recursive model of ratings, we fit the regression 
equation for quantitative and qualitative variables as: Y(1) = α i + ∑β i*Xi + ε (Equation 
1.1) Y(2) = α j + ∑β j*Xj + ε (Equation 1.2) where Y(1) and Y(2) are the market access risk 
ratings for quantitative and qualitative variables, Xi and Xj are vectors of independ-
ent quantitative and qualitative variables, and ε is the error term. The final score 
was derived by taking the geometric mean of the two ratings together with ratings 
for the measures of stability and is described as below: Total Risk Score = √Y(1)^2* 
Weight of Y(1) + Y(2)^2*Weight of Y(2) + Risk Rating (Measures of Stability)^2*Weight 
of (Measures of Stability). Results: We decided to aggregate risk scores from dif-
ferent countries into defined clusters – such as BRICS (Brazil, Russia, India, China 
and South Africa), BRICS-MT (Brazil, Russia, India, China, South Africa, Mexico and 
Turkey), and Emerging Europe (Czech Republic, Hungary and Poland) - for easier 
comparison. Their respective risk scores were 4.17, 4.96 and 3.30. cOnclusiOns: 
Market Access Risk ratings could serve as a starting point for crafting tailored 
strategies to fully capitalise new opportunities. These ratings could also serve as a 
benchmark for a country to improve its overall access to pharmaceutical products 
and improve quality of care.
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CAN vARIATION IN HOSPITAL PROCEDURE RATES IDENTIFy CANDIDATES FOR 
HEALTH TECHNOLOGy REASSESSMENT AND DISINvESTMENT?
Hollingworth W., Busby J., Jones H., Sterne J.
University of Bristol, Bristol, UK
Objectives: The process of disinvestment from inefficient health care involves 
identification and prioritisation of candidates, a health technology reassessment 
(HTR)of evidence, implementation and monitoring of discontinuance. We evalu-
ate whether variation in procedure rates is a useful tool for identifying potential 
candidates for HTR and disinvestment. MethOds: We used English Hospital 
Episode Statistics (HES) data to identify inpatient procedures. We selected the 181 
most frequent interventional procedures for analysis. For each procedure we used 
Poisson regression to estimate the variance in procedure rates, adjusting for age, 
gender and other proxies of clinical need, between Primary Care Trusts in England. 
We conducted multivariate regression analyses to examine factors that might be 
associated with high variation in procedure rates (e.g. coding uncertainty, evolving 
evidence). Results: The degree of inter-PCT variation in procedure rates differed 
vastly from procedure to procedure. Among the five procedures with the highest 
inter-PCT variance, the procedure rate was more than thirty times higher in the 
PCT at the ninetieth percentile than the PCT at the tenth percentile. The multivari-
able analysis provided strong evidence that large increases in procedure use, large 
decreases in procedure use, the presence of a substitute procedure, and shorter 
length of stay were all associated with higher inter-PCT variation in procedure 
rates. cOnclusiOns: The widespread geographic variation in hospital procedure 
rates in England are not solely due to variance in clinical need and are likely to 
reflect clinical uncertainty about appropriate procedure use which might be reduced 
by HTR. The relevant HTR questions often concern the appropriate procedure setting 
and patient subgroups or the relative value of two alternative procedures rather 
than the value of a single procedure per se. In some circumstances knowledge of 
geographic variation might lead to NHS savings and disinvestment or discontinu-
ation of inefficiently used procedures.
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INFERENCE ON INCREMENTAL COST EFFECTIvENESS THRESHOLDS 
INFLUENCING NICE DECISIONS: A BAyESIAN ANALySIS
Cao X.1, Yin D.D.2, Mavros P.2
1Temple University, Philadelphia, NJ, USA, 2Merck & Co., Inc., Whitehouse Station, NJ, USA
Objectives: NICE has been issuing health technology guidance based on cost-
effectiveness evidence alongside other factors since 2000. Previous studies have 
shown that technologies with higher incremental cost-effectiveness ratio (ICER) 
were more likely to be rejected; however none drew direct inference on the ICER 
threshold(s). Our aim is to directly estimate the ICER threshold(s) as well as the 
possible range. MethOds: Data were abstracted from the technology apprais-
als (TA) published from 03/2000 to 12/2012. For each decision to ‘recommend’ 
or ‘reject’ a technology we collected: ICER, publish date, disease area, technol-
ogy type, comparator, reason for rejection if rejected, population and end of life 
(EOL) criteria (applies only to TAs after January 2009). Cancer related technolo-
gies which had been evaluated for EOL criteria were classified as satisfying or 
not satisfying the criteria. A Bayesian hierarchical model was implemented to 
estimate the overall threshold as well as the thresholds in different technology 
categories. Results: A total of 270 TA’s were evaluated. After excluding those 
updated or terminated, a total of 187 appraisals with 323 decisions entered the 
final analysis. Non-informative priors were given to all the model parameters. The 
unadjusted estimate of the ICER threshold was £46,850 (95% CI: £40,420-£55,570). 
After adjusting for disease area, cancer related technologies had an estimated 
threshold of £48,550, (95% CI: £36,550-£63,200) compared to non-cancer related 
technologies’ estimated threshold of £43,430, (95% CI: £35,440-£52,300). Among 
the 37 technologies evaluated for end of life criteria, the estimated ICER thresh-
old was £56,160, (95% CI: £39,020-£79,970) and £33,100, (95% CI: £19,180-£49,620) 
for those satisfying and not satisfying the criteria respectively. cOnclusiOns: 
Preliminary assessment of NICE appraisals and associated ICER indicates that a 
likely ICER threshold exceeds the £20K-£30K quoted in the NICE Methods Guide. 
Additional analyses are needed to assess the impact of other factors on the likely 
variability of ICER thresholds.
identify the PBAC’s main concerns relating to the methodology. MethOds: All PSDs 
published between July 2005 and November 2012 where the primary evidence was 
based on an indirect comparison, either as simple or a mixed treatment comparison, 
were reviewed. Data relating to comparator, clinical claim, economic analysis, and 
PBAC concerns were extracted and analysed. Results: PSDs relating to 105 products 
using an indirect comparison as the primary analysis were reviewed. A total of 70 
(67%) submissions were recommended; the remaining submissions were rejected (32, 
30%) or deferred (3, 3%). An indirect comparison was used to support a non-inferiority 
claim in 84 (80%) submissions and superiority claim in 21 (20%) submissions. Of those 
claiming non-inferiority, 60 (71%) submissions were recommended by the PBAC. Of 
those claiming superiority, the PBAC accepted the clinical claim for 10 (48%) submis-
sions; 6 (29%) received a price premium. The PBAC expressed concerns relating to the 
indirect comparisons in 56 (53%) PSDs. The key issues related to the exchangeability 
of the trials as a consequence of different patient populations (25%), quality of tri-
als (24%), and dosing (18%). cOnclusiOns: Clinical comparisons based on indirect 
evidence are associated with increased uncertainty related to the exchangeability of 
the trials. The PBAC usually accepts evidence to support a claim of non–inferiority, 
but rarely the same in regards to superiority.
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INvESTIGATING THE ECONOMIC IMPACTS OF NEw PUBLIC PHARMACEUTICAL 
POLICIES IN GREECE
Siskou O.1, Litsa P.2, Georgiadou G.3, Paterakis P.2, Alexopoulou E.2, Argyri S.3, Kaitelidou D.1, 
Liaropoulos L.1
1National and Kapodistrian University of Athens, Athens, Greece, 2National Organization for the 
Provision of Health Care Services, Athens, Greece, 3Ministry of Labour and Social Security, Athens, 
Greece
Objectives: Since 2010, cost contaiment efforts in Greece focused on the reduction 
of public pharmaceutical expenditure. Changes in cost sharing levels (dementia/alz-
heimer & epilepsy 0%-10%, osteoporosis & copd: 10-25% etc.), reductions in prices and 
generics substitution are some of the measures implemented after the second quar-
ter of 2012. The aim of the study is to investigate the economic impact of the above 
measures for public funds and households. MethOds: Data on volume and values 
for prescribed drugs for each therapeutic category and cost sharing level were derived 
from EOPYY, the main reimbursement agency (95% of population). The periods com-
pared were January to February 2012 vs. January to February 2013. Results: During 
2009-2011, public pharmaceutical expenditure in Greece declined by 23%, while for 
2009-2014 the decline is projected at 61%.During 2013, 2014 targets are € 2.44billion or 
1.3% of GDP and 1.935 billion or 1% of GDP. In 2013, only 8.2% of prescribed drugs boxes 
were provided free of charge, vs 13.6% in 2012 A 25% cost sharing level was imposed 
to 76.4% of prescribed medicines in 2013 compared to 51.4% in 2012. Consequently, 
the mean cost-sharing burden for pharmaceuticals in 2013 was estimated at 18% vs 
13.1% in 2012. Monthly savings in public expenditures from changes of cost–sharing 
patterns was estimated at € 18-€ 20 mil. Average price per package declined in 2013 
by 23%, from € 18 in 2012 to € 14 in 2013. Public funds savings, because of consump-
tion of cheaper drugs, were estimated at € 55-€ 60 mil.per month. Major savings for 
public funds were achieved through cardiovascular diseases drugs cOnclusiOns: 
The economic results of the measures for third party payers are positive. However, 
the measures should be reconsidered and examined more closely also taking in mind 
social effects, in terms of accessibility of users and especially for vulnerable groups 
who in need of essential pharmaceutical care.
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CHRONIC PATIENTS RESPONSE TO THE IMPLEMENTATION OF INTERNATIONAL 
NON-PROPRIETARy NAME (INN) PRESCRIBING IN GREECE
Mylona K.1, Skroumpelos A.1, Zavras D.1, Pasaloglou S.2, Pavi E.1, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Novartis Hellas, Metamorfosi, Greece
Objectives: Under the pressure of fiscal consolidation and pharmaceutical spending 
decrease in Greece, mandatory generic substitution and compulsory prescription by 
international non-proprietary name (INN)were recently introduced as reimbursement 
drivers in Greece. This study aims to investigate the implications of INN implementa-
tion regarding chronic patients’ choices and their willingness to switch to an alter-
native pharmaceutical treatment. MethOds: A cross-sectional study was carried 
out among 1600 patients from four chronic disease groups(HTN, Diabetes,COPD and 
Alzheimer). Logistic regression analysis was used to investigate the factors asso-
ciated with chronic patients’ choices. Results: Out of 1600 patients approached, 
1594responded to the survey(99.6%). 69% of them stated that they were aware of 
the new reimbursement system. After the implementation of INN prescribing, only 
few(11%) have changed their usual drug. 43% were totally certain that an original 
drug is more effective than a generic, while 67% have never used generics in the 
past. Most patients(82%) preferred to be prescribed their usual medicine, despite of 
the extra cost they had to bear. This choice was a co-decision with their physician 
as 58% of them stated. The average additional amount that they would be willing to 
spend in order not to switch to another medicine was estimated at € 17.8. These results 
showed a significant statistical correlation with patients’ income, educational level 
and occupation category. cOnclusiOns: According to this study chronic patients 
are not willing to change their usual drug and switch to a generic, despite the cost 
this choice imposes. Consequently INN prescribing may decrease public expenditures 
on pharmaceuticals but it will lead to higher private expenditure. Given that due to 
economic crisis incomes are continuously decreasing and unemployment rate is 
rising, the measure might eventually result in lower adherence to medication and 
consequently in adverse effects on patients health status and future public expendi-
ture for treating possible complications.
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MARKET ACCESS RISK SCORING: A UNIFIED FRAMEwORK FOR CROSS COUNTRy 
COMPARISON OF DIvERSE MARKET ACCESS SySTEMS AND PROCESSES
Mehta P., Ando G.
IHS, London, UK
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for the intention to use the EMR. For nurses this attribute was followed by support 
from supervisor, presence of performance feedback from the EMR and presence o 
f decisions support. While for physicians this ordering differed since presence of 
decision support was relatively more important than performance feedback and 
support from the supervisor. cOnclusiOns: Considering the prominent wish of all 
the intended users for a flexible interface, currently used EMRs only partially comply 
with the needs of the users, indicating the need for closer incorporation of user 
needs during development stages of EMRs. The differences in priorities amongst 
nurses and physicians show that different users have different needs during the 
implementation of innovations. Hospital management may use this information to 
design implementation trajectories to fit the needs of various user groups.
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EvALUATE THE STATUS OF PHARMACOECONOMIC RESEARCH DEvELOPMENT 
IN CHINA FROM 2002 TO 2013
Chen C.I.1, Huang Y.2
1Pfizer China, Beijing, China, 2University of Florida, Gainesville, FL, USA
Objectives: To describe the current status of Pharmacoeconomic (PE) research 
in China from Jan 2002 through June 2013. MethOds: We conducted a review of 
pharmacoeconomic studies performed in China during Jan 2002 to June 2013. Using 
the Wanfang Chinese Database, we identified a total of 1338 articles. Keywords used 
are ‘Pharmacoeconomics’ or ‘Cost-Effectiveness Analysis’ or ‘Cost-Benefit Analysis’ 
or ‘Cost-Utility Analysis’ or ‘Cost’ or ‘Cost Study’ or ‘Economics Analysis’ all following 
by ‘(Healthcare and Medical Care)’ to exclude animal and other studies. Through a 
manual review, we excluded another 52 articles that did not align with study objec-
tives. Article types selected are Journals, Academic Essays and Conference Essays. 
Descriptive analyses were performed to identify current trends, including number 
of articles by year, type of studies, and type of studies by year. Results: A total of 
1286 articles were conducted in China from 2002 to 2013. In general, the number of 
articles per year has been on the rise since 2002and appears to approach a steady 
state after 2007. Numbers of articles by year are 91 in 2002, 84 in 2003, 107 in 2004, 
110 in 2005, 136 in 2006, 132 in 2007, 121 in 2008, 120 in 2009, 130 in 2010, 116 in 2011, 
112 in 2012 and 27 during first half of 2013. The most common type of studies found 
were economic analyses (n= 908/1286), of which cost-benefit analyses (n= 395) were 
most commonly conducted. Two other common research types included treatment 
use (n= 48) and application of PE (n= 146), namely the role of PE to help determine 
price and inform health care management decisions. cOnclusiOns: The devel-
opment of Pharmacoeconomic research in China has been on a steady rise since 
2002 with most output focused on economic modeling, followed by application of 
PE and treatment use.
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LONG-TERM SURvIvAL AFTER INTENSIvE CARE UNIT DISCHARGE IN 
THAILAND: A RETROSPECTIvE STUDy
Luangasanatip N.1, Hongsuwan M.1, Lubell Y.1, Limmathurotsakul D.1, Teparrukkul P.2, 
Chaowarat S.2, Day N.P.1, Graves N.3, Cooper B.S.1
1Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand, 2Sappasithiprasong 
Hospital, Ubon Ratchatani, Thailand, 3Queensland University of Technology, Brisbane, Australia
Objectives: Economic evaluations of interventions in the hospital setting often 
rely on the estimated long-term impact on patient survival. Estimates of mortality 
rates and long-term outcomes among patients discharged alive from the inten-
sive care unit (ICU) are lacking from lower and middle-income countries. This 
study aimed to assess the long-term survival, life expectancy (LE) and the quality-
adjusted life expectancy (QALE) amongst post-ICU patients in a middle-income 
country. MethOds: In this retrospective cohort study, data from a regional tertiary 
hospital in northeast Thailand and the regional death registry were linked and used 
to assess patient survival time after ICU discharge. Adult ICU patients aged at least 
15 years who had been discharged alive from an ICU between 1anuary 1, 2004 and 
December 31, 2005 were included in the study, and the death registry was used to 
determine deaths occurring in this cohort up to December 31, 2010. These data 
were used in conjunction with standard mortality life tables to estimate annual 
mortality and LE. Results: A total of 10,321 ICU patients were included in this 
analysis; 3,251 patients (31.5%) died during ICU admission. Of 7,070 patients dis-
charged alive, 2,527 (35.7%) were known to have died within the five-year follow-up 
period, a mortality rate 2.5 times higher than that in the Thai general population 
(age- and sex-matched). The mean LE was estimated as 18.3 years compared with 
25.2 years in the general population. Given the range of the Health Related Quality 
of Life (HRQOL) from the published literature, the mean QALE of post-ICU patients 
would range from 10.2 to 16.1. cOnclusiOns: Post-ICU patients experienced much 
higher rates of mortality than members of the general population over the five-year 
follow-up period, particularly in the first year after discharge. Further work assess-
ing HRQOL in both post-ICU patients and in the general population in developing 
countries is needed.
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INvESTIGATING SAFETy-APPRAOCH IN SAUDI ARABIA MINISTRy OF HEALTH 
HOSPITALS
Alkelya M.A.1, Haleem R.M.2
1King Abdullah International Medical Research Center (KAIMRC); King Saud Bin Abdulaziz 
University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia, 2King Abdullah international 
medical research center, Riyadh, Saudi Arabia
Joint commission (JCI) International Patient centered standards-2011 promotes 
improvements in patient safety(ISPG) & Medication Management Use (MMU). 
Objectives: To investigate historical changes of patient-safety approach in Saudi 
Arabia, create comparison baseline for future studies. MethOds: Cross-sectional 
2003 survey sent to pharmacy managers of 127 hospitals of Ministry of Health(MOH); 
67.7% responded; data of 63.7% hospitals were valid for analysis. 19 hospitals were 
chosen deliberately according to their level of development, their data was tested 
against selected criteria. Due to limitations of data; only 2 criteria were selected: 
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DRIvERS OF CLINICIAN PRESCRIBING DECISIONS AND THE ECONOMICS OF 
INFORMATION
Parkinson B., Viney R., Goodall S., Haas M.
University of Technology, Sydney, Ultimo, Australia
Objectives: Policy decision makers require accurate forecasts of the financial 
implications of funding a new drug. They may also wish to influence adoption to 
ensure the most cost-effective pattern of care. The seminal theory regarding the 
adoption of innovations was published by Rogers in 1962; but there are several 
reasons why health care may be a special case. This paper assesses the applicabil-
ity of Rogers’s theory to the adoption of new drugs, and identifies how it could 
be extended using economic theories of information. MethOds: The empirical 
literature on drug adoption was reviewed to determine the consistency of findings 
with Rogers’s theory and the economic theories of information. Results: Overall 
74 empirical studies were reviewed. Clinicians consider a broad range of attributes 
when adopting a new drug, with their relative importance dependent on the patient 
and therapeutic area. Consistent with Rogers’s theory, interpersonal communication 
channels are the most important information source, with clinicians, especially GPs, 
more likely to rely on advice from specialists or pharmaceutical representatives than 
peer-reviewed publications. Moreover, clinicians are influenced by ‘norm’ prescrib-
ing behaviour. These findings can be further explained using economic theories of 
information. Obtaining information via peer-reviewed publications requires more 
effort compared to specialists and pharmaceutical representatives. As patients can-
not observe the effort expended, there is a potential for moral hazard in terms of 
reduced effort and thus an increased reliance on pharmaceutical representatives. 
Clinical evidence is often uncertain and not always directly applicable to current 
practice, which can lead to following ‘norm’ prescribing behaviour and persistent 
prescribing when combined with risk-aversion. cOnclusiOns: Rogers’s theory 
only partially explains drug adoption. An expanded framework regarding drug adop-
tion is proposed, incorporating agency relationships, moral hazard, uncertainty 
and risk-aversion.
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HEALTH ECONOMIC ANALySES IN MEDICAL NUTRITION: A SySTEMATIC 
LITERATURE REvIEw
Walzer S.1, Droeschel D.2, Nuijten M.J.C.3, Chevrou-Severac H.4
1State University Baden-Wuerttemberg, Loerrach, Germany, 2Swiss Tropical and Public Health 
Institute, Basel, Switzerland, 3Ars Accessus Medica, Jisp, The Netherlands, 4Nestlé Health Science, 
Vevey, Switzerland
Objectives: Medical nutrition is dedicated to patients with some nutritional defi-
ciencies or inability to eat normally. When used on top of normal diet in patients 
or in Crohn’s disease, medical nutrition can improve patient’s recovery or have a 
therapeutic effect. Although efficacy studies of medical nutrition exist, it is unclear 
regarding health economic analysis. This research assessed the current health eco-
nomic evidence published on medical nutrition. MethOds: A systematic literature 
search was performed using PubMed, the Health Technology Assessment Database, 
and the NHS Economic Evaluation Database. For selected articles, the clinical back-
ground and basis of the analysis, health economic design and results were extracted. 
Finally for health economic modeling studies, the Drummond checklist was applied 
to validate their quality; whereas for systematic reviews the AMSTAR checklist 
was used. Results: Fifty-three articles were identified and obtained via PubMed. 
Among them, 32 articles have been included in a thorough data extraction proce-
dure. Among these articles, only few health economic models have been found: Most 
of the articles were modelling analyses and economic trials. Overall only 8 health 
economic models were validated applying the Drummond checklist. Anyhow, most 
included models have been carried out with a quite high quality standard even 
though some areas were identified for further improvement. Within the two iden-
tified reviews of health economic studies one review achieved the highest quality 
scores applying the AMSTAR checklist. cOnclusiOns: Reasons for finding only few 
modeling studies but quite a large number of clinical trials with health economic 
endpoints might have different reasons. Until recently, health economics wasn’t 
required in reimbursement or coverage decisions for medical nutrition interven-
tions; and there might be specificities of medical nutrition which might not allow 
easy modeling. Further research is warranted to understand the specifics of medical 
nutrition and its applicability for health economic modelling.
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PREFERENCE STRUCTURE OF CLINICIANS IN THE USE OF ELECTRONIC MEDICAL 
RECORDS; QUANTIFyING THE RELATIvE IMPORTANCE OF BARRIERS AND 
FACILITATORS OF AN INNOvATION
Struik M.H.L.1, Koster K.2, Veldwijk J.3, Schuit A.J.4, Lambooij M.S.5
1VU University Amsterdam, Amsterdam, The Netherlands, 2Erasmus University Rotterdam, 
Rotterdam, The Netherlands, 3National institute for public health and the environment, Bilthoven, 
The Netherlands, 4National Institute for Public Health and the Environment, Bilthoven, The 
Netherlands, 5National Institute of Public Health and the Environment, Bilthoven, The Netherlands
Objectives: Electronic medical records (EMRs) in hospitals are potentially ben-
eficial for quality and safety of care, but diffuse slowly. Many of the barriers and 
facilitators of the adoption of EMRs are identified, but the relative importance of 
these factors is still undetermined. This paper quantifies the relative importance 
of known barriers and facilitators of EMR, experienced by the users (i.e., nurses and 
physicians in hospitals). MethOds: A d-efficiently designed discrete choice experi-
ment (DCE) was conducted among physicians and nurses. Participants answered ten 
choice sets containing two scenarios. Each scenario included attributes that were 
based on previously identified barriers in the literature and the model of the Unified 
Theory of Acceptance and Use of Technology (UTAUT), namely : data entry hardware, 
technical support, supervisor attitude, performance feedback, flexibility of interface 
and decision support. Panel Mixed Multinomial Logit analysis was used to determine 
the relative importance of the attributes. Results: Data on 148 nurses and 150 phy-
sicians showed that high flexibility of the interface was the most important factor 
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PRE-FINANCING FUNCTION OF THE PHARMACEUTICAL FULL-LINE wHOLESALE 
SECTOR IN THE EUROPEAN UNION
Said M., Dragosits A., Walter E.
Institute for Pharmaeconomic Research, Vienna, Austria
Objectives: Pharmaceutical full-line wholesalers carry out a variety of main func-
tions. One of these is the financing function. Pharmaceutical full-line wholesal-
ers stock and distribute the complete assortment of products in range and depth. 
Moreover, they acquire ownership over the medicinal products when purchasing 
them from the manufacturers and pass on ownership to pharmacies when they 
are delivered. Thus, the analysis aims to draw a comprehensive picture of the pre-
financing function, expressed in terms of working capital, of the pharmaceutical 
wholesale sector in Europe. MethOds: The necessary data was provided by the 
European Association of Pharmaceutical Full-line Wholesalers (GIRP). The study 
analysed core indicators representative for all countries of the European Union 
plus Croatia, Norway and Switzerland (EU-25 + 3), with the exception of Malta and 
Cyprus as no full-line wholesalers are operating in the latter. Results: In the ana-
lysed countries, 935 pharmaceutical full-line wholesalers operate 1,220 warehouses, 
serving 171,767 retail and hospital pharmacies and dispensing doctors and sup-
ply 520 million people. In 2012, pharmaceutical full-line wholesalers generated a 
total turnover of € 130 billion in the EU-25 + 3. Pharmaceutical full-line wholesalers 
assume a pre-financing function towards manufacturers and pharmacies that is 
not offered by other distribution models. In the EU-25 + 3 alone they pre-financed 
on average € 12.2 billion over a period of 35 days. In total, this sum is pre-financed 
approximately ten times per year. cOnclusiOns: Pharmaceutical full-line whole-
salers pre-finance the entire retail market of medicinal products, guarantee the 
continuous supply of all medicinal products and secure the cash flow of social 
insurers. The funding and holding of buffer stocks, the resulting working capital 
and ownership that goes with wholesaling services are vital for an effective and 
efficient functioning of the health care industry in Europe.
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ESTIMATING MARKET POTENTIAL FOR BIOSIMILAR INTRODUCTION
Paglia R.1, Bache G.2, Rossi C.3
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Objectives: The global biopharmaceutical industry is facing a biologics “pat-
ent cliff” between 2013 and 2020, which will leave approximately $54 billion in 
drug revenue, without patent protection. In order to achieve success with these 
biosimilar agents, it is critical that manufacturers/marketers target the highest 
potential global markets. The objective of this research is to provide a framework 
for identifying the markets with the highest potential for biosimilar adoption and 
utilization. MethOds: A review of literature, research reports, and review articles 
was conducted, along with a panel discussion of industry thought leaders in bio-
similars. Key indicators of biosimilar market potential were identified, evaluated, 
and prioritized. A systematic approach was developed to score each key indicator, 
and a mathematical approach adopted to aggregate the market scores. A series 
of 20 country markets were evaluated and ranked in order of biosimilar market 
potential. Results: Key indicators of biosimilar market potential were separated 
into three categories: 1.) Originator-drug indicators including originator sales, 
reimbursement level, and reimbursement status. 2.) Market indicators including 
rate of uptake of currently available biosimilars, payer cost-containment mecha-
nisms, and future biosimilar outlook. 3.) Regulatory indicators including barriers 
to marketing authorization based on the complexity of required data packages, 
and the risks associated with the development of clinical programs. Secondary 
research of public domain information was conducted on each of 20 countries, in 
order to obtain the data to populate the key indicators for market potential. Each 
country achieved a score based on the data, and was ranked based on biosimilar 
market potential. cOnclusiOns: The process demonstrates a rational approach 
to identifying and sequencing of biosimilar market potential, which can be used to 
inform clinical-development and market-access plans. Also, in practical applica-
tion for a manufacturer/marketer, “resource indicators” of market-specific assets 
should be included.
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CONFIDENTIAL PATIENT ACCESS SCHEMES IN THE UNITED KINGDOM – DO 
THEy AFFECT PRICES IN OTHER MARKETS?
Nijhuis T.1, Haigh J.2, Van Engen A.1
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Reading, UK
Objectives: To investigate whether trends exist in drug prices of products approved 
by the UK NICE with a Patient Access Scheme in other key EU countries in the last 
2 years. MethOds: Expensive new pharmaceuticals that are not deemed cost-
effective by NICE in the first instance, can often still become recommended with 
a Patient Access Scheme. It is a trend that the type of scheme offered is becoming 
purely financial-based, with the last 17 schemes approved offering a simple dis-
count. Although these discounts are ‘commercial in confidence’, the company’s 
willingness to negotiate is obvious. To investigate if NICE recommended drugs with 
simple discount schemes affect pricing elsewhere in Europe, we compared their list 
prices in France, Germany, Italy and the UK. The analysis focused on pharmaceu-
ticals recommended after 1 January 2011. Results: Since 2011, 20 therapies were 
recommended by NICE with a PAS based on a simple discount. In all except one case, 
the UK list price was the lowest among available list prices in all countries analysed. 
Where an Italian list price was available it was usually the highest. When compar-
ing the prices on an ex-manufactory level, the UK prices remain the lowest, but the 
German prices are generally the most expensive in this scenario. Of the countries 
analysed, only Italy has a risk sharing framework in place besides the UK. Out of the 
20 therapies analysed here, only 3 were under an Italian scheme. cOnclusiOns: 
The analysis shows that even before a PAS discount is applied, the UK price is 
already low, usually the lowest in the 4 EU countries analysed. There were no clear 
IPSG.1; identify patients correctly (criteria 1) and MMU.1& MMU.7; identify medi-
cation use & monitoring (criteria 2) Average for conforming to both criteria was 
calculated for each hospital. Correlation was tested between compliance to both 
criteria and hospital characteristics which were hospital type; general/tertiary & 
hospital geographical location; urban/rural. For each criterion; several measurables 
were selected from literature; and their average was calculated accordingly. Criteria 
1; 1 measurable, composed of 2 components of which there average was calcu-
lated. Criteria 2; 2 measurables; measurable for MMU.1 composed of 3 components, 
while measurable for MMU.7 composed of 2 components. Average of averages was 
calculated. Results: A total of 89.47% were complying to criteria 1 &10.53% non-
complying with 10 hospitals 100% conforming. 52.63% were complying to criteria 
2& 47.37% non-complying. Average compliance percentage with criteria 1 was 97.75, 
85.91& 98.25 for general rural, general urban and tertiary urban hospitals respec-
tively. In case of criteria 2, it was 28.75, 27.18& 20.5 for general rural, general urban 
and tertiary urban hospitals respectively. Correlations could not be established, no 
significant difference in means of compliance between or within criteria for dif-
ferent geographical locations or different hospital types; this can be contributed to 
the small sample size. cOnclusiOns: A baseline for comparison of compliance 
to safety-related approach in Saudi Arabia was established which can be used for 
comparison in future studies.
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PHARMACISTS’ SATISFACTION wITH DIFFERENT PHARMACEUTICAL 
DISTRIBUTION MODELS IN FIvE EUROPEAN COUNTRIES
Dragosits A., Said M., Walter E.
Institute for Pharmaeconomic Research, Vienna, Austria
Objectives: Serving 172,709 dispensing points, the pharmaceutical wholesale-
industry is a vital branch. One of the major business-objectives is total-customer-
satisfaction. Thus, a questionnaire aimed to draw a comprehensive picture of 
the level of satisfaction (including delivery-times and country-specific-issues) of 
pharmacists with pharmaceutical-full-line and short-line wholesalers, Direct-
sales from manufacturers, Direct-to-Pharmacies (DTP) and Reduced-Wholesale-
Arrangements (RWA) in Europe, focusing on Germany, UK., France, Spain and 
The Netherlands. MethOds: The necessary data was obtained from an online-
questionnaire (March 2011-October 2011) which was directed to pharmacies 
(n= 473). Results: The majority of the observed countries (99% in Spain to 72% 
in the UK) of the respondent pharmacists were satisfied with the distribution 
through pharmaceutical-full-line-wholesalers. With regard to the delivery-time 
offered by pharmaceutical-full-line wholesalers the satisfaction ranged from 97% 
in Spain to 76% in the UK. With regard to the distribution through short-line-
wholesalers 62.50% of the German pharmacists were satisfied. With their delivery-
time 56.30% of the pharmacists were satisfied, whereas 50.00% (distribution) and 
38.90% (delivery-time) of the Dutch-participants showed satisfaction. Less than 
half of the respondents (58% in Spain to 12% in the UK) in four out of the five 
countries observed showed satisfaction with the distribution through Direct-sales 
from manufactures. 80% of the pharmacists in the UK were unsatisfied with this 
kind of distribution-system. Concerning the delivery-time pharmacists in the 
majority of the observed countries answered with neutral. Pharmacists in the 
UK (76%) were unsatisfied with Direct-sales from manufacturer. Pharmacists in 
the UK were unsatisfied with Direct-to-Pharmacy and the Reduced-Wholesale-
Arrangements (DTP: 89.70% distribution vs. 75.90% delivery-time; RWA: 90.80% 
distribution vs. 58.50% delivery-time). Country-specific-issues mentioned were 
lack-of-availability of medicinal-products, stock-problems (UK), out-of-stocks 
problems (NL), shortages, supply-problems (ES) and decrease in discount-rates 
(DE). cOnclusiOns: The satisfaction of pharmacists varies greatly between dif-
ferent distribution-models. Responding pharmacists in the countries observed 
receiving their medicinal-products through pharmaceutical full-line-wholesalers 
showed overall-satisfaction with this kind of distribution-system.
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THE FUTURE OF INDIvIDUAL FUNDING REQUESTS IN CLINICAL 
COMMISSIONING GROUPS ERA
Chaudhari S.D.
PAREXEL International, Uxbridge, Middlesex, UK
Objectives: Until March 2013,decisions on Individual funding requests (IFRs) had 
been the job of the primary care trusts to decide upon such requests. It has been 
widely acknowledged that IFRs to fund particular treatments have caused PCTs 
some thorny problems (with the rate of acceptance of IFRs having fallen from 59% in 
2008/09 to 46% in 2010/11). However, with the Clinical Commissioning Groups (CCGs) 
formally assuming commissioning responsibilities for their local populations since 
April 2013, it is expected that health services and care pathways will become more 
patient focussed. The objective of this study was to assess whether IFRs will enjoy 
better success under the so-called ‘patient centred’ CCG leadership. MethOds: 
This research was based on a combination of secondary and primary research to 
assess the CCGs attitudes and expertise to cope with IFRs. Secondary research of 
published data such as current IFR policies and overall CCG health care priorities 
contributed towards a framework to understand the key factors affecting success-
ful management of IFRs, which was then validated through a telephone survey 
of health care stakeholders. Results: CCGs understand the importance and the 
value of having a clear and robust IFR policy. Learning from PCTs, CCGs also realise 
that having a clear IFR standard operating procedures and clear timeframes would 
mean spending significantly less time considering and defending decisions on IFRs. 
Some CCGs also believe that public conversation may be required IFRs are to be 
managed effectively. cOnclusiOns: While CCGs realise that IFRs would be one 
of complicated bit of commissioning responsibilities, their real challenge is avoid 
making the same mistakes as PCTs. Early engagement with local populations about 
commissioning priorities is perceived to be crucial. Also the success of IFRs depends 
on organisations such as NHS Clinical Commissioners due to their dual role as CCG 
supporter and a body accountable to government.
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comparator before entering negotiations. The negotiated price was between 0% and 
56% lower compared to the price listed in the AMNOG dossier, regardless of the level 
of additional benefit. The number of eligible patients for each drug (141 - 214,000) 
tends to correlate with the negotiated rebate. cOnclusiOns: An additional benefit 
is necessary for a reimbursement beyond the reference group price. Despite the 
small number of observations it might be concluded, that the reimbursed price 
inversely correlates with disease incidence. The highest rebate on reimbursement 
price resulted from the decision of the arbitration board.
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INFORMING THE AFFORDABILITy OF vACCINES wITH DIFFERENT HEALTH CARE 
FINANCING MECHANISMS
Varghese L., Li X., Sauboin C., Standaert B.
GlaxoSmithKline Vaccines, Wavre, Belgium
Objectives: Budget impact analysis is the traditional approach of assessing the 
affordability of new interventions. While vaccination has been shown to be one of 
the most cost-effective means to improve health, budget requirements can be a 
barrier. This study aims at comparing an affordability indicator of a new vaccine in 
countries with similar Gross Domestic Product (GDP) per capita, but different health 
care financing mechanisms. MethOds: Based on National Health Accounts data, 
analyses of Total Health Expenditures (THE) and share of Public Health Expenditures 
(PHE) of various middle income countries were performed. Brazil and Turkey were 
selected for in-depth analysis as they had comparable GDPs and health care 
expenditures per capita. Health care access and financing data were also obtained 
from various government sources for a quantitative analysis. The budget require-
ments for a new vaccine costing $40 Purchasing Power Parity (PPP) per immunized 
child covering 80% of the birth cohort were calculated and expressed as a share of 
PHE. Results: THE per capita doubled over 10 years in both countries since 2001, 
reaching $1,037 (PPP) for Brazil and $1,160 for Turkey in 2011. However, the share of 
PHE is vastly different; 46% in Brazil compared to 75% in Turkey. Implementing the 
new vaccine would require an additional budget of $97Million and $42Million. While 
large in absolute values they represent only 0.11% of the PHE in Brazil and 0.07% in 
Turkey. The higher affordability in Turkey can be explained by a different financing 
mechanism. cOnclusiOns: While the implementation of a new vaccine in com-
parable countries in terms of wealth and THE per capita would require significant 
additional national spending in absolute terms, it represents only a small fraction 
of the PHE. The underlying health care financing mechanisms is an important factor 
affecting the affordability of a new vaccination program.
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IQwIG’S EFFICIENCy FRONTIER APPROACH: FIT FOR PURPOSE!
Sandmann F.G., Gerber A., Lhachimi S.K.
Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
Objectives: Since its adoption by the Institute for Quality and Efficiency in Health 
Care (IQWiG) in 2009, the Efficiency Frontier (EF) approach is criticized by the phar-
maceutical industry, key opinion leaders and national organizations. In a German 
context, we aim to verify the accuracy of those concerns. MethOds: Review of the 
most commonly stated arguments against the EF-approach published within the 
scientific community and given as stakeholders’ response on IQWiG’s first cost-
effectiveness analysis of antidepressants. Results: Often stated objections against 
the EF include: 1) no international health economic standard, 2) merely disease 
specific without prioritization across disease areas, 3) no fixed threshold, and 4) 
avoiding the quality-adjusted life year (QALY). Ad 1): IQWiG adopted the EF-approach 
to inform setting appropriate reimbursement caps (since 2011 to inform negotia-
tions for appropriate reimbursement caps with an interquartile-range as basis). 
In other jurisdictions, an appropriate price need not be determined; decisions (or 
recommendations) are made regarding whether or not the cost-effectiveness of 
a drug supports (restricted) reimbursement. Ad 2+3): Although prioritizing funds 
is no primary aim in Germany, the EF can still be applied equally across indica-
tions. Within indications, the reimbursement cap may not distort competition by 
disadvantaging a manufacturer unfairly and needs to be appropriate when com-
pared with other available interventions. Contrary to the EF-approach, determining 
prices based on arbitrary fixed thresholds may not stand up in court. Ad 4): Despite 
methodological doubts concerning QALYs, they are not antecedently excluded as 
possible patient-relevant outcome measure when using the EF in Germany. Only 
a fixed cost/QALY-threshold was rejected. cOnclusiOns: The EF fits the purpose 
of decision-making in Germany. Most objections are flawed or originate from a 
profound misunderstanding of the concept or the German (legal) context, where 
the EF is necessary and viable. The EF’s prime distinction remains: Deriving flexible, 
non-arbitrary thresholds for disease areas.
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A SySTEMATIC COMPARISON OF MARKET ACCESS AND REIMBURSEMENT 
PATHwAyS FOR DIAGNOSTIC TESTS IN GERMANy, UNITED KINGDOM AND THE 
UNITED STATES
Walzer S.1, Gartemann J.2
1MArS Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany, 2Roche Diagnostics 
International Ltd., Rotkreuz, Switzerland
Objectives: A diagnostic test is any kind of medical test performed to aid in the 
diagnosis or detection of disease and is becoming a key component of Personalized 
Health Care (PHC). The market access and reimbursement pathways for pharmaceu-
ticals are well described however such pathways are missing for diagnostics in many 
countries and similarities between countries are not well understood. MethOds: A 
targeted literature review has been executed on top of reviews from market access 
and reimbursement authorities in Germany, the UK and the US. Existing pathways 
were plotted and key decision criteria have been evaluated in terms of comparability 
and health care decison-maker impact. Results: In Germany inpatient reimburse-
ment is being differentiated from outpatient with inpatient access being easier to be 
achieved (DRG, OPS coding). The outpatient pathway includes a full evidence pack-
signs that a potential discount had lowered a list price in one of the other countries, 
but is it clear that despite the external reference price systems in Europe prices of 
high-priced therapies vary considerably.
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PUBLIC PREFERENCE ELICITATION IN DRUG REIMBURSEMENT USING MULTI-
CRITERIA DECISION ANALySIS (MCDA) FOR UNIvERSAL HEALTH INSURANCE 
SySTEM IN SOUTH KOREA
Cho H.Y., Lee E.K.
Sungkyunkwan University, Suwon, South Korea
Objectives: To elicit public preference for drug reimbursement criteria in Korea’s 
universal health insurance system using three commonly used weighting methods 
in Multi-Criteria Decision-Analysis (MCDA). MethOds: Based on literature review, 
we established five criteria in drugs reimbursement decision-making: disease 
impacts, context of reimbursement, improvement of health outcomes, economics 
and quality of evidence. We evaluated the relative importance of five criteria using 
three weighting methods of direct rating (DR), SWING and analytic hierarchy process 
(AHP). 283 people were selected across the country by quota sampling and asked to 
assess the weights of five criteria with all three weighting methods repeatedly. The 
survey was self-administered by the participants with help of the trained interview-
ers. Results: It was revealed that improvement of health outcomes and disease 
impacts have relatively higher weights than other three criteria in all weighting 
methods. Survey participants considered improvement of health outcomes the 
most important with DR (Mean [SD]: 0.210 [0.033]) and AHP (0.271 [0.127]), whereas 
disease impacts with SWING (0.231 [0.050]). Meanwhile, no coherence was shown 
in the low-ranked three criteria (context of reimbursement, economics, and quality 
of evidence) over three weighting methods. Quality of evidence ranked the third 
with DR (0.200 [0.035]), the fifth with SWING (0.165 [0.041]) and the fourth with AHP 
(0.160 [0.121]). Economics ranked the fourth with DR (0.197 [0.035]) and the third 
with SWING (0.192 [0.045]) and AHP (0.207 [0.118]). Lastly, context of reimbursement 
ranked the fifth with DR (0.188 [0.035]) and AHP (0.112 [0.090]) and the fourth with 
SWING (0.189 [0.045]). cOnclusiOns: In this study, it was discovered that the sur-
vey participants considered improvement of health outcomes and disease impacts 
relatively more important than economics, context of reimbursement and quality 
of evidence in drug reimbursement decision making.
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DIFFUSION OF THE EFFICIENCy FRONTIER APPROACH wITHIN HEALTH 
ECONOMIC EvALUATION: CURRENT AND FUTURE APPLICATIONS
Sandmann F.G., Lhachimi S.K., Gerber A.
Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
Objectives: This study explores current applications (and potential future use) 
of the Efficiency Frontier (EF) in health economic evaluation. MethOds: We per-
formed desk research on pharmacoeconomic guidelines for current usage of the 
EF and investigated possibilities for future use. Results: Currently, the EF is offi-
cially used in 3 European countries. In Germany, since the enforcement of the ‘Act 
on the Reform of the Market for Medicinal Products’ (AMNOG) in January 2011, 
IQWiG applies the EF to determine non-arbitrary flexible thresholds across disease 
areas to ultimately determine an appropriate reimbursement price of new drugs 
(including interquartile-range to display uncertainty) in negotiations on request of 
the decision maker or manufacturer. In Belgium, the updated KCE guidelines dated 
July 2012 request the EF to identify the appropriate comparator among all relevant 
alternatives. In France, the updated HAS guidelines dated October 2012 require 
health interventions to be plotted on the EF to inform decision-making. In the 
future, the EF-approach could also be used to check on prices of national reference 
pricing clusters. Furthermore, the EF could help with priority setting (as suggested 
by the World Health Organization guide to cost-effectiveness analysis in 2003) and 
guiding or informing potential future (dis)investment decisions. The EF may also be 
combined with other approaches (e.g. making reimbursement decisions up to an 
ex ante fixed cost/outcome-threshold but setting prices beyond that level with the 
flexible EF). Lastly, it should not be overlooked that the EF can be applied for multiple 
purposes simultaneously. cOnclusiOns: Since its first use to measure hospital 
efficiency, the EF is a valuable tool in health economics. Currently, its use diffuses 
within health economic evaluation and reimbursement decision-making. Yet, the 
full potential of the approach has not been exploited so far and the EF-approach 
remains under-researched by the scientific community.
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IMPACT OF THE GERMAN AMNOG EvALUATION ON DRUG PRICES: 
CORRELATION OF REBATE?
Neeser K., Loeffler D., Schmidt E., Muller E.
LASER Analytica, Loerrach, Germany
Objectives: In January 2011 the new German law on the reorganization of the 
pharmaceutical market (AMNOG) came into force with the intention to reduce drug 
prices in Germany. Up to June 2013 44 dossiers completely evaluated and for 16 drugs 
(excluding orphan drugs) a price has been negotiated between the manufacturer and 
the National Association of Statutory Health Insurance Funds (GKV-SV). Since previ-
ous analyses have shown no correlation of negotiated price and the extent of clinical 
benefit, the underlying analysis aims to identify further parameters potentially 
influencing the reimbursed price of a new drug. MethOds: Evaluated drugs with 
completed price negotiation between manufacturers and the GKV-SV were selected 
from the website of the Federal Joint Committee (G-BA). The manufacturer free 
price was analyzed for potential interactions with following parameters extracted 
from module 3 of the AMNOG dossier: number of eligible patients, annual drug cost 
of the evaluated intervention and appropriate comparator, and the final price as 
listed in the Lauer-Taxe (official German drug price index). Results: The 16 drugs, 
for which a negotiated reimbursement price was available, showed a minor (n= 8), 
considerable (n= 5), not quantifiable (n= 2) or no additional clinical benefit (n= 1).The 
investigated drug price was between 0,73 and 71 times the price of its appropriate 
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Objectives: Moldova is a country where expenditure on pharmaceuticals is already 
very high and exceeds several times the prices in the region. Drugs expenditure 
represents 70% of direct health expenditure of a household and is the main factor 
that reduces the financial protection of health care services. The objective of the 
study was to assess affordability of reimbursement medicines and to evaluate the 
National Health Insurance Company (NHIC) impact on ensuring economic accessibil-
ity. MethOds: To determine the affordability of medicines was used the methodology 
recommended by the World Health Organization. Have been analyzed data concern-
ing price of drugs, the amounts paid by patients and the amounts paid by the NHIC 
for partially reimbursed drugs for 5 years (2008-2012). Was calculated: the median 
price for each drug international common name dependent’s on strength; duration of 
treatment and number of units needed for treatment (for chronic disease); number of 
working days required for a treatment cure depending on minimum wage and aver-
age wage in economy. Available treatment is considered, the cost of which is 1 or less 
than the cost of one working day. Based on these results has been also determined 
the impact of the NHIC. Results: Number of economically accessible reimbursed 
drugs depending on minimum wage was: 2008-24 (42%), 2009-34 (60%), 2010-43 (53%), 
2011-48 (58%), and 2012-71 (86%); depending on average wage in economy: 2008-50 
(87%), 2009-50 (87%), 2010-66 (81%), 2011-73 (88%), and 2012-77(94%). The average num-
ber of working days compensated by NHIC based on the minimum wage: 2008-6.23, 
2009-3.5, 2010-3.7, 2011-2.92, and 2012-1.03; based on average wage in economy: 2008-
0.98, 2009-0.76, 2010-0.75, 2011-0.55, and 2012-0.38. cOnclusiOns: Compensation 
of drugs by NHIC, doesn’t significantly affect the affordability of reimbursement 
medicines. Patients feels no real benefit from NHIC, drugs expenditure within the 
households practically remain unchanged even if it get reimbursed medicines.
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ASSESSMENT OF METHODOLOGICAL QUALITy OF ECONOMIC EvALUATIONS IN 
BELGIAN DRUG REIMBURSEMENT APPLICATIONS
Simoens S.
KU Leuven, Leuven, Belgium
Objectives: To assess the methodological quality of economic evaluations included 
in Belgian reimbursement applications for Class 1 drugs. MethOds: For 19 reim-
bursement applications submitted during 2011 and Spring 2012, a descriptive analy-
sis assessed the methodological quality of the economic evaluation, evaluated the 
assessment of that economic evaluation by the Drug Reimbursement Committee 
and the response to that assessment by the company. Compliance with methodo-
logical guidelines issued by the Belgian Healthcare Knowledge Centre was assessed 
using a detailed checklist of 23 methodological items. The rate of compliance was 
calculated based on the number of economic evaluations for which the item was 
applicable. Results: Economic evaluations tended to comply with guidelines 
regarding perspective, target population, subgroup analyses, comparator, use of 
comparative clinical data and final outcome measures, calculation of costs, incre-
mental analysis, discounting and time horizon. However, more attention needs to 
be paid to the description of limitations of indirect comparisons, the choice of an 
appropriate analytic technique, the expression of unit costs in values for the cur-
rent year, the estimation and valuation of outcomes, the presentation of results of 
sensitivity analyses, and testing the face validity of model inputs and outputs. Also, 
a large variation was observed in the scope and depth of the quality assessment by 
the Drug Reimbursement Committee. cOnclusiOns: Although general guidelines 
exist, pharmaceutical companies and the Drug Reimbursement Committee would 
benefit from the existence of a more detailed checklist of methodological items that 
need to be reported in an economic evaluation.
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PRICING AND REIMBURSEMENT SySTEM OF ORPHAN DRUGS IN THE CzECH 
REPUBLIC
Prochazkova M.1, Kubickova P.1, Mazelova J.2, Hambalek J.2, Heislerova M.2
1Ministry of Health, Prague, Czech Republic, 2State Institute for Drug Control, Prague, Czech 
Republic
Objectives: In the CZ, orphan drugs so-called highly innovative drugs first enter 
a temporary reimbursement period of three years. Having proven their cost-effec-
tiveness they later become permanently reimbursed. The objective of the study 
was to determine how successfully orphan drugs enter the database of reimbursed 
drugs. MethOds: The EMA list of orphan drugs was compared to the Czech data-
base of reimbursed drugs to the date of 1-Jul-2013. For each detected drug the date 
of entering the database was found. In drugs reimbursed after 2008, submissions 
of cost effectiveness analyses were recorded. Although CZ has no willingness to 
pay threshold, interpretation of cost effectiveness analyses results could improve 
the process of HTA of drugs. Results: To the date of 1-Apr-2013 the EMA has 
registered 65 orphan drugs. Out of these, 28 have been assigned a maximum and 
reimbursement price in the CZ. To this date, 27 drugs have not applied for reimburse-
ment price. Starting from 2008, 30 drugs have applied: in 20 products the decision 
is legally effective, in 2 cases only hospital use has been approved, in 7 cases (3 
appeals, 4 unfinished proceedings) the proceedings are still in process and in one 
case the application was withdrawn. In about a third of cases a cost effectiveness 
analysis was submitted and accepted by SUKL. The upper limit of the ICER of the 
submitted analyses exceeds by far the cost-effectiveness level recommended by the 
WHO. cOnclusiOns: The results imply that in almost in all cases the submitted 
applications for maximum and reimbursement price are approved by SUKL. In some 
cases, however, the health insurance companies hinder reimbursement of drugs 
by filing an appeal. However, the assessment of cost effectiveness of drugs should 
be performed at an earlier level – during the administrative proceedings. This calls 
for necessary emphasis on health technology assessment.
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PRICING AND REIMBURSMENT OF PHARMACEUTICALS IN IRAN
Moradi M.
Corvinus University of Budapest, Budapest, Hungary
age including clinical and health economic data and takes on average more than 
two years. In the UK the process is largely based on three different PCT payment 
and the various NHS value for money mechanisms combined with procurement 
systems. The value-based pricing system might change the current situation. Finally, 
in the US CPT codes are similarly being applied as DRG codes in Germany with 
a different pathway of application. In comparison the health economic evidence 
plays a larger role in the UK, even though (still) not in a systematic manner as for 
pharmaceuticals. The clinical evidence plays an important role in all countries, 
however it was identified that for diagnostic tests the access routes and especially 
the coding process is more dependent on consistency on applicability of existing 
codes and technology argumentation. cOnclusiOns: In the different countries 
the evidence base for market access and reimbursement pathways for diagnostics 
differs significantly. Instead, having a unified approach might ease a value based 
market access argumentation for diagnostics.
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A COMPARATIvE STUDy OF THE ROLE OF DISEASE SEvERITy IN DRUG 
REIMBURSEMENT DECISION MAKING IN BELGIUM, FRANCE, THE NETHERLANDS 
AND SwEDEN
Franken M., Koopmanschap M.
Erasmus University, Rotterdam, The Netherlands
Objectives: Considerations beyond (cost-) effectiveness are increasingly important 
in reimbursement decision-making. We investigated the importance of disease sever-
ity relatively to other decision criteria in drug reimbursement decision-making in four 
European countries. MethOds: The importance of disease severity and its operation-
alization was assessed in Belgium, France, The Netherlands and Sweden. We investi-
gated scientific literature, policy documents, reimbursement reports, and conducted 
three interviews in each country (four in The Netherlands) with policymakers involved 
in drug reimbursement. Results: All interviewees acknowledged that disease sever-
ity is, especially in case of high severity, an important criterion while considering 
a drug’s (cost-) effectiveness. However, its relative importance compared to other 
decision criteria remains implicit in the decision-making process. Although rarity of 
the disease is not a criterion as such, interviewees indicated difficulties in separating 
rarity from severity and the availability of alternative treatments. Only Belgium and 
France explicitly show societal willingness to pay by using reimbursement levels 
depending on the severity of the disease. In Sweden, ‘need and solidarity’ is one 
of the three prioritizing principles. The Netherlands is the only country that quan-
titatively operationalized disease severity using the proportional shortfall method 
and suggesting a cost-effectiveness threshold range depending on disease severity 
(which was never formalised by the minister). Although interviewees acknowledged 
that quantitative information, besides a qualitative description of the disease, may 
provide additional decision information, none of them considered such information 
to be of decisive importance. cOnclusiOns: Disease severity is, especially in case 
of high severity, an important decision criterion in all four countries. However, all 
countries seem to struggle in making its actual role explicit. The operationalization 
differs across countries. While Belgium and France are most explicit by using the 
severity of the disease in setting reimbursement levels, all countries could improve 
transparency of its actual importance relatively to other decision criteria.
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CLINICAL AND HEALTH ECONOMIC EvIDENCE REQUIREMENTS FOR OBTAINING 
HEALTH INSURANCE COvERAGE FOR INNOvATIvE MEDICAL DEvICES IN 
GERMANy
Schwander B.1, Krone F.A.2, Walzer S.3
1AHEAD GmbH, Loerrach, Germany, 2Baden-Wuerttemberg Cooperative State University, Lörrach, 
Germany, 3MArS Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany
Objectives: To evaluate the clinical and health economic evidence requirements 
for obtaining statutory health insurance coverage for innovative medical devices 
(MDs) in Germany. MethOds: We have assessed the requirements for innovative 
MDs in Germany according to the available reimbursement pathways and grouped 
them by the application setting as this had a significant impact on the research 
question. Results: According to the German statutory rules in the inpatient care 
setting (reservation of prohibition; ‘Verbotsvorbehalt’) all innovative MDs can be 
applied once they have received marketing approval for Germany (CE mark) whereas 
a positive voting from the federal joint committee is required before MDs can be 
applied in the outpatient setting (reservation of authorization; ‚Erlaubnisvorbehalt’). 
The reimbursement coverage in the inpatient setting depends on the available cod-
ing and grouping mechanisms that define specific diagnoses related groups and 
their reimbursement value. If this value is not adequate or an adequate coding/
grouping is not possible specific applications can be made, that require no specific 
clinical and health economic evidence; only a detailed (additional) cost estimation 
of the new procedure and a rationale of the innovative character are required. In 
contrast the outpatient reimbursement of the statutory health insurance shows 
very strict requirements as a detailed clinical evidence reporting (e.g. randomized-
controlled trials) and a full health economic evaluation (e.g. cost-effectiveness and 
budget impact assessment) need to be provided for obtaining reimbursement cov-
erage. There are recent political streams that claim that the regulatory and reim-
bursement process of MDs should be adapted comparable to the more restrictive 
regulations for pharmaceuticals which might have a major impact on the evidence 
requirements for the inpatient sector. cOnclusiOns: Currently MDs applied in the 
inpatient setting require no specific evidence whereas strong clinical and health 
economic evidence is required for MDs applied in the outpatient setting.
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IMPACT OF REIMBURSEMENT OF MEDICINES ON ECONOMIC ACCESSIBILITy 
LEvEL FOR wORKING POPULATION IN REPUBLIC OF MOLDOvA
Chitan E.1, Brumarel M.2
1State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldova, 2State 
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take into account confidential discounts under patient access schemes. Finally, 
the threshold probability of cost effectiveness seems to lie between 30% and 60%.
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PARAMETER UNCERTAINTy IN vALUE BASED MULTI CRITERIA DECISION 
ANALySIS: A SySTEMATIC REvIEw OF METHODS
Groothuis-Oudshoorn C.G.M.1, Broekhuizen H.1, Hummel J.2, van Til J.1, Ijzerman M.1
1University of Twente, Enschede, The Netherlands, 2University Twente, Enschede, The Netherlands
Objectives: Multi criteria decision analysis (MCDA) aims to support decision-mak-
ing where decisions are based on multiple criteria. In disciplines like engineering 
and environmental policy, MCDA is widely accepted and routinely used. The use of 
MCDA in HTA priority setting and reimbursement decisions is growing, but mostly 
limited to research projects. A factor that might influence acceptance is a perceived 
difficulty to value an MCDA’s outcome when its inputs and outputs contain uncer-
tainties. When this is the case, decision makers might not feel confident in accept-
ing or rejecting its outcome. The objective of this study is to systematically review 
how parameter uncertainty is taken into account in value-based MCDA methods 
in general, and to discuss which of the approaches is appropriate for the setting of 
reimbursement decision making in health care. MethOds: A systematic literature 
review was conducted using the Scopus database. Found abstracts were categorized 
by MCDA method used. Then, themes and families of methods were identified by 
two independent reviewers. Selected full text articles were read to identify methodo-
logical details. Results: The search strategy identified 635 abstracts, mostly from 
engineering and environmental journals and only 1.6% in health journals. Identified 
themes were fuzzy set theory (n= 223), probabilistic framework (n= 68), deterministic 
sensitivity analysis (n= 140), Dempster-Shafer theory (n= 14), Bayesian framework 
(n= 7) and Grey theory (n= 8). A large number of papers considered the Analytic 
Hierarchy Process in combination with fuzzy set theory (n= 155). cOnclusiOns: 
In the health literature there is little attention for parameter uncertainty. Methods 
to deal with parameter uncertainty in MCDA must strike a balance between com-
prehensibility and understandability. Several complex methods are developed for 
parameter uncertainty, but there seems to be a gap between the theory and the 
implementation of those methods. For simple applications, methods like deter-
ministic sensitivity analysis are likely to be sufficient.
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AMNOG BENEFIT ASSESSMENT: TIME DELAy OF MARKET ACCESS FOR 
PHARMACEUTICALS IN GERMANy?
Neubauer A.S., Voss P., Gmeiner A., Neubauer G.
IfG Institute for Health Economics (www.ifg-muenchen.com), München, Germany
Objectives: To investigate quantitatively, if and to which extent the German 
Arzneimittelmarkt-Neuordnungs-Gesetz (AMNOG) delays market access of phar-
maceuticals. Secondary objective was to potentially identify predictors for access 
delay. MethOds: All AMNOG assessment procedures that were completed at the 
level of the joint federal committee (G-BA) by May 15 2013 were included (web-
site www.g-ba.de). Time delay to dossier submission was calculated between the 
approval date of the European Medicines Agency (EMA) and the mandatory AMNOG 
dossier submission date. Submission date usually occurs when pharmaceuticals are 
made available and is decided upon by the manufacturer. We also included in the 
analysis the ordinal level classification and evidence certainty level for each product 
as assessed by Institute for Quality and Efficiency in Health Care (IQWiG) and G-BA 
as well as the ATC code. Results: In n= 17 (49%) of N= 35 investigated pharmaceu-
ticals a small time delay greater than 1.1 months (which is usually feasible) after 
EMA approval was observed, but only 20% had a delay > 2 months. A negative cor-
relation existed between the amount of time delay to dossier submission and the 
benefit level outcome as assessed by IQWIG (r= -0.258, n.s.) and the final result by 
G-BA (r= -0.484, p= 0.003). Benefit assessment outcomes between IQWiG and G-BA 
were correlated moderately with r= 0.442 (p< 0.008). For both, IQWiG (r= 0.841) and 
G-BA (r= 0.773) certainty of evidence correlated highly with the benefit level out-
come. cOnclusiOns: This analysis highlights the impact of AMNOG on the market 
access of pharmaceuticals in Germany. Overall, only small time delays existed for 
most products. Time delay in market access correlated significantly with a nega-
tive assessment of additional benefit by G-BA. Evidence certainty clearly correlated 
with benefit outcomes.
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A COMPARISON OF COvERAGE AND REIMBURSEMENT DECISIONS IN GERMANy 
(AMNOG) AND SCOTLAND (SMC)
Charokopou M.1, Heeg B.1, Schoeman O.2, Mueller S.3, Tempest M.J.4, Schlagmüller S.C.1, 
Wilke T.3
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Objectives: In Scotland, drug reimbursement is predominantly based on cost-
effectiveness in contrast to the corresponding German AMNOG process. The study 
compares the reimbursement and pricing process in Germany (AMNOG), as reformed 
in 2011, and Scotland (SMC) based on reimbursement assessments. MethOds: All 
AMNOG and SMC appraisal decisions made in 2011-2012 were identified. Matching 
AMNOG-SMC cases were found and compared in terms of final appraisal decision 
and rationale. Results: For 2011-2012, forty-one AMNOG cases over 60 subgroups 
and 193 SMC cases were identified; twenty five matching cases were compared 
as these were assessed by both organizations. Regarding these 25 cases, AMNOG 
deemed ten cases demonstrated no additional benefit, in two cases the additional 
benefit was unquantifiable, slight benefit was acknowledged in seven cases and 
in six there were significant benefits. Based on the benefit assessment the negoti-
ated price rebates ranged from 4.7% to 70.7% based on manufacturer set price. No 
restrictions to subgroups were opposed to any reimbursement decision. The SMC 
reimbursed 18 products (72%), of which four were restricted to a certain population 
due to cost-effectiveness. SMC rejected 7 cases (28%) based on weak economic evi-
Objectives: To investigate the problem of pricing and reimbursement of pharma-
ceuticals in Iran. A large amount of country’s Health care expenditures, including 
insurance organizations’ expenses, are spent for pharmaceutical products. However, 
the high amount of capital spent by the users for purchasing pharmaceuticals 
indicates a serious flaw in the system. As will be shown, this flaw is due to the struc-
tures, policies, and regulations of Iranian medical insurance system. MethOds: 
This is a descriptive study and, therefore, ethnographic site and fieldwork were used 
as the main source of information. Furthermore, information on the Internet and 
several Iranian online databases has been used for comparison purposes. Results: 
Ministry of Health and Medical Education (MOHME) is the main responsible body 
for pharmaceuticals in Iran. However, different government organizations such 
as Ministry of Commerce, the Central Bank of Iran, and National Industries 
Organizations are involved in policy-making in this sector. MOHME decides how 
to allocate governmental supports and foreign currency quotas, to various related 
industries. This is done due to the fact that MOHME decides which pharmaceuti-
cals should be covered and distributed in the country. However, prices are set by 
insurance organizations due to their bargaining power over MOHME. Insurance 
companies pay approximately 70-90% of the final price of a product. However, for 
purchasing expensive products, confirmation from insurance companies is needed. 
The reimbursed price is set at the level of the lowest priced equivalent on the mar-
ket. cOnclusiOns: These flaws and loopholes arise because of system’s negligence 
on research and development methods and, therefore, lack of standard regulations 
on reimbursement decisions and priority settings. Inflexible profit margins for dif-
ferent products with different unit costs, incomplete support for vulnerable groups 
and patients with chronic diseases, and absence of rational pharmaceutical usage 
campaigns can be named as other major problems.
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PERSONALIzED HEALTH CARE IN FRANCE, GERMANy AND THE UNITED 
KINGDOM: ARE HEALTH TECHNOLOGy ASSESSMENT AGENCIES READy?
Walzer S.1, Gartemann J.2, Zoellner Y.F.3, Towse A.4, Garrison L.5
1MArS Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany, 2Roche Diagnostics 
International Ltd., Rotkreuz, Switzerland, 3Hamburg University of Applied Sciences, Hamburg, 
Germany, 4Office of Health Economics, London, UK, 5University of Washington School of Pharmacy, 
Seattle, WA, USA
Objectives: Personalized health care (PHC) is a treatment model that customizes 
health care based on biomarker-based prediction of likely response. It is increas-
ingly being prioritized by politicians and payers—one recent example is the pub-
lished strategy plan by the German Federal Ministry of Education and Research. 
A key policy question remains whether health care systems and health tech-
nology assessment (HTA) bodies are adequately prepared evaluating these new 
treatment options. MethOds: Existing HTA evaluation methods for therapies in 
France, Germany, and the UK were reviewed with respect to the applicability to 
PHC products based on information provided by decision-making bodies and the 
literature. Results: Current HTA evaluation methods being applied to medical 
therapies, in general, need to be modified when applied to PHC. For example, tra-
ditional benefit evaluations that require randomized clinical trials are standard 
but cannot always be fulfilled in PHC. Furthermore, combined benefit assessments 
for typical PHC treatment—e.g., a pharmaceutical combined with a diagnostic 
test—lack experience about appropriate evaluation methods to use. Today, decison 
makers and manufacturers rarely make use of the opportunity to re-assess or for 
joint evidence generation. Finally, reimbursement for PHC is inflexible and does 
not fully reflect the value of targeting, including the reduction in uncertainty and 
greater appropriate use. Among these three, the UK seems the most open to PHC 
funding. HTA in France and Germany does not recognize the special economic and 
evidence features of PHC, though the French system is more open to innovative 
market access. cOnclusiOns: If the largest EU health care systems are to secure 
the full benefits of PHC, they will need to provide for full and flexible reimbursement 
for innovative technologies and services based on value. Currently, the importance 
of PHC by health care politicians is not being reflected in the evaluation tools or 
reimbursement methods being applied.
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TRENDS IN REIMBURSEMENT DECISIONS IN IRELAND: AN ANALySIS OF THE 
NCPE DATABASE FROM AN INDUSTRy PERSPECTIvE
Redmond S., Mahon S., Carney P.
GlaxoSmithKline, Dublin, Ireland
Objectives: To analyse trends in reimbursement in Ireland to help in the planning 
of HTAs from an industry perspective. MethOds: A database of all NCPE deci-
sions and reimbursement for drugs from 2006 to April 2013 was developed from 
publically available NCPE reports and HSE websites. A descriptive analysis of the 
database was undertaken. Results: From 2006 to April 2013 37% of drugs were 
reimbursed without a HTA and 63% were recommended for HTA (N= 126). There 
were three HTAs undertaken in 2006 compared to 26 in 2012. High Tech (HT) drugs 
were more likely to attract a HTA compared to General Medical Services (GMS) drugs 
(83% vs. 51%). Of the HTAs completed, 57% resulted in a positive reimbursement 
recommendation within a median time from HTA submission to reimbursement 
of 7.9 months (min 3.9, max 16.3). The median time was 7.1 and 9.8 months for 
GMS and HT drugs respectively. Dominance almost perfectly predicted reimburse-
ment; 83% reimbursed. Of the ICERs in the north-east quadrant, 54% resulted in 
a positive reimbursement recommendation (average ICER around € 60,000/QALY). 
The cost per QALY for those not reimbursed in this quadrant was almost twice this 
at around € 110,000. Finally, the average probability of cost effectiveness for reim-
bursed and non-reimbursed drugs were 60% and 30% respectively. cOnclusiOns: 
Companies can expect more requests for HTAs especially for HT drugs. When HTAs 
are requested the probability of success is around 60% with an expected timeline 
of 8 months from submission to launch. Budget impact does have an important 
role to play as dominance is a strong predictor of reimbursement. The average cost 
per QALY for reimbursed drugs is above the € 45,000/QALY threshold but does not 
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recession and the IPHA agreement on the rate of positive reimbursement made by 
the NCPE. We also tested whether the new agreement had an impact on the time-
to-reimbursement using a linear regression model. Results: The results of the 
logit model suggest that neither the economic recession nor the agreement had 
any statistically significant impact on the probability of reimbursement. However, 
there was some evidence that the time-to-reimbursement was reduced after the 
agreement (p< 0.10). cOnclusiOns: Although the analysis suggests that these two 
events had no impact on the rate of reimbursement it is possible that the reimburse-
ment price of new drugs may have decreased over this period which could have 
facilitated reimbursement. Unfortunately, details of the final price of medicines are 
not always known in the Irish system and it is therefore not possible to test this 
hypothesis using currently available data. Our analysis of time-to-reimbursement 
suggests that the new agreement may have satisfied one of its main objectives in 
getting new medicines onto the market sooner.
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MODELLING THE HEALTH TECHNOLOGy ASSESSMENT (HTA) PROCESS FOR 
INNOvATIvE DRUG TECHNOLOGIES (IDTS) IN THE TURKISH HEALTH CARE 
SySTEM
Kececioglu S.1, Ulus P.2, Cukadar F.3, Ozkan M.3, Urganci B.3
1Boehringer Ingelheim Turkey, Istanbul, Turkey, 2Boehringer Ingelheim Turkey, ISTANBUL, 
TURKEY, Turkey, 3Boehringer Ingelheim Turkey, ISTANBUL, Turkey
Objectives: Offering a standardized HTA process model through economic evalu-
ation of IDTs in the Turkish health care system. MethOds: Current regulations on 
evaluation of innovative drug technologies through the reimbursement process are 
defined via a process flow scheme. A stepwise model is proposed to cover a stand-
ardized HTA system within the economic evaluation through an independent HTA 
body (Model HTA Authority). Results: In the current system, economic evaluation 
content of a reimbursement application dossier is evaluated by Social Security 
Institution (SSI) through Technical and Main Commissions respectively. However 
this evaluation process is not standardized with respect to main variables such as 
scientific methodologies, timelines and responsibilities. This study offers a model, 
which initiates a re-defined application step for economic evaluation content 
of a IDT reimbursement dossier; parallel application to SSI and an independent 
HTA body (Model HTA Authority). Therefore, the Main Commission in SSI will be 
able to combine a general evaluation from the Technical Commission and an HTA 
report of the IDT by an independent HTA body. These reports will be available to 
owners of reimbursement applications until announcement of a final decision of 
SSI, and will become publicly available afterwards. cOnclusiOns: IDTs are not 
involved in a standardized HTA process in the current Turkish health care system. 
However, pharmacoeconomic analysis reports are requested by SSI for reimburse-
ment applications of IDTs. This study offers a model, which includes a standard-
ized HTA process for IDT in the Turkish health care system. Applicability of this 
model may be tested through pilot projects and further steps may be defined for 
further excellence.
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CANADIAN PRIvATE PAyERS’ PERCEPTIONS AND ExPECTATIONS OF 
SUBMISSION REQUESTS FOR DRUG REIMBURSEMENT SUBMITTED By THE 
PHARMACEUTICAL INDUSTRy
Charaan M.
University of Montreal, Montreal, QC, Canada
Objectives: To identify, from a private payer’s perspective, the required elements 
to include in a pharmacoeconomic model and a budget impact analysis and com-
pare them to that of the public payers’ requirements. The secondary objective was 
to determine the preferred components to present in a submission regarding pri-
vate payers. MethOds: A survey was sent to 21 submission reviewers from 14 
private insurance companies offering drug reimbursement, using an online sur-
vey builder, KwikSurveys. The survey included 15 questions divided in 5 sections: 
General information, Clinical information, Pharmacoeconomic evaluation, Budget 
impact analysis and General appreciations. Results: Nine reviewers from eight 
different companies, which represent 80% of the Canadian private payer market 
shares, responded to the survey. Results showed that 67% of participants follow the 
Canadian Agency for Drugs and Technologies in Health (CADTH) guidelines for eco-
nomic evaluations. 88% of participants prefer a cost-effectiveness evaluation, while 
75% prefer a cost-benefit evaluation. 100% of the participants would like direct drug 
costs and the indirect costs related to loss of productivity due to reduced working 
capacity to be included in the pharmacoeconomic model. 75% would like the costs 
to employer to hire and train replacement worker, the costs of premiums paid to, 
as well as benefits received from, private insurers to also be included in the model. 
63% of the participants would like to see a population data-based model for their 
budget impact analysis. Similarly, 63% of the participants prefer a time horizon 
of 3 years for the budget impact analysis. cOnclusiOns: The parameters to be 
considered in a submission sent to private payers are different from public payers’ 
requirements. The perspective of the pharmacoeconomic model should be that of 
a private payer and the budget impact analysis should only consider a population 
covered by private payers.
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POINT OF CARE TESTS: THE LONG AND wINDING ROAD TO REIMBURSEMENT
Hogue S.1, Brogan A.1, Heyes A.2
1RTI-Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Manchester, UK
Objectives: Market access for innovative new technologies can be complex 
and time consuming. As cost-containment pressures in the European Union (EU) 
intensify, evidentiary hurdles to justify new point-of-care (POC) tests continue to 
grow. Decentralized health care decision making can also be a significant hurdle. 
This study aimed to characterize the process and identify challenges for Health 
Technology Assessment (HTA), pricing, reimbursement, and market access for a 
new POC test in the EU-5 countries. MethOds: We conducted desktop research of 
dence. Both organizations reached the same assessment regarding clinical benefit 
in only 13 cases (52%). cOnclusiOns: AMNOG implements a more rigorous process 
with respect to clinical evidence assessment compared to SMC. All AMNOG deci-
sions are positive; however final prices may resemble generic prices for products 
that demonstrate low additional benefit (“Festbetragsgruppen”). In comparison, 
a negative decision by SMC warrants re-submission and re-assessment of the set 
price for successful drug reimbursement. Orphan drugs are assessed as normal 
products in Scotland and may be rejected on the grounds of economic evidence, 
while in Germany the additional benefit is presumed and price negotiation starts 
automatically. Furthermore, the SMC assessment process starts later than the 
AMNOG process.
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ACCESSING THE PHARMACEUTICAL MARKETS OF BRAzIL, RUSSIA, INDIA AND 
CHINA
Faria-Billinton E.C.1, Murray G.C.1, Raza S.A.2, Grubert N.3, Pickering L.4
1Abacus International, Manchester, UK, 2Abacus International, East Delhi, India, 3Decision 
Resources, London, UK, 4Decision Resources, Burlington, MA, USA
While pharmaceutical sales in mature economies are declining, in emerging mar-
kets they have been expanding rapidly, with growth rates in double figures. Here we 
focus on market access in BRIC (Brazil, Russia, India and China) which together rep-
resent just over 40% of the world population.Objectives: To identify the processes 
and key stakeholders involved in gaining market access in BRIC; to assess the impor-
tance of health technology assessment (HTA) in gaining reimbursement in these 
countries; to identify opportunities and challenges to market access. MethOds: 
A review was conducted to identify the current processes and key stakeholders in 
market access in the BRIC countries and to identify favourable and unfavourable fac-
tors to market access. Results: The licensing and reimbursement processes vary 
in the BRIC countries. Brazil follows processes similar to those in Western Europe, 
including HTA and public consultation as part of the reimbursement application. In 
China, the licensing process can take 4-6 years, though fast-tracking for innovative 
drugs has recently been introduced. Russia, China and India do not yet rely on HTA 
for reimbursement decisions. In India plans to use “pharmacoeconomic principles” 
in setting prices of new molecules have been announced. Opportunities in all these 
countries result from increasing affluence and life expectancy and the diseases 
associated with these. Some challenges to market access are: poor IP protection; 
protectionist measures; compulsory licensing; drive to use generics or biosimilars, 
often produced locally; price controls; variable health insurance/NHS coverage; 
and limited budgets for prescription drugs. cOnclusiOns: HTA is now common 
practice in Brazil, but not yet in Russia, India or China. Although demand for new 
drugs is increasing in these markets, protectionism measures, competition from 
generics and budget constraints due to the increased burden and requirement for 
new high priced drugs present a challenge when accessing the pharmaceutical 
market in BRIC countries.
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PLACEBO-CONTROLLED TRIALS: ARE THEy ACCEPTABLE TO HEALTH 
TECHNOLOGy ASSESSMENT BODIES?
Casamayor M., Ivanescu C., Van Engen A.
Quintiles, Hoofddorp, The Netherlands
Objectives: The gold-standard pivotal trial design has three arms with experi-
mental medicine, placebo and active control however, often marketing authorisa-
tion is granted on placebo controlled (PLAc) trial(s). While PLAc trials are often 
still acceptable to the European Clinical Trials Directive and European Medicines 
Agency (EMA), they are less acceptable to Health Technology Assessment (HTA) 
bodies. The latter request an (in)direct comparison vs. the relevant active 
comparator(s) (AC) to demonstrate the added value of existing standard of care. 
We have investigated the hurdles encountered during HTA assessments for those 
drugs with marketing authorization based solely on PLAc studies. MethOds: We 
identified those drugs approved since 2010 by EMA based only on PLAc trials. We 
then reviewed the HTA assessments for these drugs in France (HAS), Germany 
(G-BA) and the UK (NICE and SMC) and compared these HTA assessments to others 
where the trial included an AC. Results: Applications for 41 (45 indications) of the 
220 drugs approved by EMA between 2010 and end of 2012 were based exclusively 
on PLAc trials. The number of indications already assessed and recommended 
(percentage) by HTA bodies are 19 and 11 (58%) for NICE, 33 and 18 (55%) for SMC, 
24 and 20 (83%) for HAS, and 18 and 12 (67%) for G-BA. When compared to all 
HTAs irrespective of comparator being placebo or AC assessed since 2010, lack of 
an AC seemed to have no impact in HAS (83% vs 75% favorable opinion among all 
assessments) and G-BA (67% vs 58%) assessments but had a negative impact on 
SMC (55% vs 85%) and NICE (58% vs 64%) recommendations. cOnclusiOns: The 
impact of no direct comparison with an AC varies across countries. The analysis 
seems to indicate that in absence of head-to-head data HTA agencies will accept 
indirect evidence against the right AC.
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THE IMPACT OF THE ECONOMIC RECESSION AND PHARMACEUTICAL-HEALTH 
SERvICE AGREEMENT ON THE PROBABILITy AND TIME OF REIMBURSEMENT OF 
NEw MEDICINES IN IRELAND
Carney P., Redmond S., Mahon S., Barry C.
GlaxoSmithKline, Dublin, Ireland
Objectives: To assess the impact of the Irish economic recession (September, 2008) 
and the Irish Pharmaceutical Healthcare Association agreement (IPHA; November, 
2012) on the probability of reimbursement decided by the National Centre for 
Pharmacoeconomic Evaluation (NCPE). We also aim to test whether the new IPHA 
agreement reduced the time-to-reimbursement for new medicines in the General 
Medical Services (GMS) and High Tech Drug Scheme (HTDS). MethOds: A database 
of all NCPE decisions since 2006 to present was compiled from publically available 
NCPE decision reports and a logistic model was used to test the occurrence of the 
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jAPANESE REPRESENTATION IN LEADING GENERAL MEDICINE AND BASIC 
SCIENCE jOURNALS: A COMPARISON OF TwO DECADES
Takahashi O.
St.Luke’s International Hospital, Tokyo, Japan
Objectives: During 1991-2000, Japan contribution to the top basic and clinical sci-
ence journals was less than 1% and 3%, respectively. The objective of this study was 
to compare the Japanese representation in 7 major general medicine journals and 
6 basic science journals between the years 1991-2000 and 2001-2010. MethOds: 
Retrospective observational study. We measured the frequency of journal article 
publications in PubMed from Japan in both seven high-impact general medical and 
internal medicine journals and six high-impact basic science journals using Boolean 
operators to connect name of the journal, year of publication and corresponding 
authors’ affiliation with different universities, cities and places in Japan. Results: 
Japan represented 0.66% (260/39,255) and 0.74% (265/36,038) of journal articles in 7 
of the top general medicine journals during 1991-2000 and 2001-2010, respectively. 
In contrast, the respective representation in 6 of the top basic science journals was 
2.51% (849/33,779) and 3.60% (1364/37,908), respectively. Overall, we observed that 
the proportion of Japan-originated articles published in the top general medicine 
journals during 2001-2010 remained unchanged compared to 1991-2000 (P= 0.255). 
However, the Japanese representation in basic science journals during 2001-2010 
increased significantly compared to 1991-2000 (P< 0.001). Japanese representation in 
basic science journals had an upward trend during the 1991-2000 period (P< 0.001) 
but remained flat during 2001-2010 (P= 0.177). In contrast, the trend of Japanese 
representation in general medicine journals remained flat during the period of 
1991-2000 (P= 0.273) but exhibited a marginally downward trend during 2001-2010 
(P= 0.073). cOnclusiOns: Overall, the Japanese representation in top general 
medicine journals has remained negligible and unchanged over the last two dec-
ades. Representation in basic science journals remained unchanged during the 
time period of 2001-2010, although it had shown an upward trend during the years 
1991-2000. Interventional measures are needed to address these trends.
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DETERMINANTS OF PROMPT ACCESS TO HEALTH CARE IN CHPS PROGRAMME 
IN RURAL COMMUNITIES OF BAwjIASE, GHANA
Nuamah Buruwaa G.1, Agyei-Baffour P.2
1Korle Bu Teaching Hospital, Accra, Ghana, 2Kwame Nkrumah Univeristy of Science and 
Technology, Kumasi, Ghana
Objectives: Prompt access to effective health care is a priority in the develop-
mental agenda of Ghana yet only 20% of people who actually need health care have 
it. Evidence on the determinants of prompt access to health care in these CHPS 
programme is woefully inadequate. The study sought to assess the factors that 
influence prompt access to health care in CHPS settings. MethOds: A descriptive 
cross sectional study was conducted in 2011 with 230 respondents within the CHPS 
zones of Bawjiase Sub-district, Central region of Ghana. Data was collected on using 
structured questionnaire and analyzed using SPSS version 19 software. Logistic 
regression was run to access the correlation of the determinants on prompt access 
to health care in CHPS settings at 95% confidence interval. Results: We identi-
fied that, factors which play a major role in prompt access of CHPS programme 
within the CHPS zones of Bawjiase sub - district include geographical accessibility 
(chi square = 33.57; p = 0.000) and service characteristics (chi square = 19.17; p = 
0.001). Economic accessibility however, had no influence (chi square = 123; p = 
0.975) on prompt access to CHPS programme. Factors which had strong influence 
on prompt access of CHPS programmes were age (chi square = 12.39; p = 0.015), 
sex (chi square = 15.25; p = 0.000), marital status (chi square = 31.56; p = 0.000), 
education level (chi square = 28.49; p = 0.000) and occupation (chi square = 33.56; p 
= 0.000). cOnclusiOns: The study concludes that geographical proximity, service 
characteristics and individuals’ background factors influence prompt access to qual-
ity health care in rural CHPS setting.
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ASTROLOGICAL SIGNS AND HEALTH PROBLEMS; DEMONSTRATING THE 
MULTIPLE COMPARISONS PROBLEM
Vegter S., van Boven J.F., Pechlivanoglou P., Rozenbaum M.H., Stevanovic J., Le H.H.
University of Groningen, Groningen, The Netherlands
Objectives: Astrological signs have been linked to numerous health problems, 
not only in pseudoscientific but also in high impact, peer-reviewed scientific lit-
erature. The aim of this study was to use a large prescription database to assess 
associations between astrological star signs and health problems. This study may 
demonstrate important statistical issues that arise when doing multiple compari-
sons. MethOds: For this cross-sectional study, patient and drug data were collected 
from a large prescription database in The Netherlands. Patients were followed for 
one year, starting from their birthday in 2010. Outcomes were drug prescriptions 
for one of four health problems: cardiovascular disease, depression, erectile dys-
function in men and fertility problems in women. The “determinant” was patients’ 
astrological sign (based on Western-culture horoscope). Differences in prevalence 
rates between star signs were tested using logistic regression, adjusted for age 
and gender. Significance was set at P= 0.05. Results: Almost 300,000 persons were 
included for analysis. In our analysis, persons born under the star sign Aquarius 
were less likely to suffer from cardiovascular disease (P= 0.001), whereas patients 
born under Scorpio or Sagittarius were more likely (P= 0.011 and P= 0.017). There were 
no effects on depression or erection dysfunctions. Women born under Gemini were 
37% less likely to use fertility drugs (P= 0.016). cOnclusiOns: This study found 
several associations between star signs and health problems, none of which had any 
biologic plausibility. Interestingly, datasets filled with randomly generated star sign 
data also resulted in significant findings. Multiple comparisons without prespeci-
fied hypotheses, biological plausibility and adjustments for familywise error rates, 
can lead to false-positive findings. Multiple comparisons are common in outcomes 
research, appropriate use of statistics therefore is important.
published literature, HTA reports, and third-party websites, to identify the critical 
path and data most valuable to reimbursement decision making. We conducted 26 
qualitative one-on-one interviews with payer decision makers in the EU-5: 12 key 
opinion leaders, 4 laboratory directors, and 10 academic health economists and HTA 
advisors. Results: Reimbursement is critical to rapid adoption of new technolo-
gies. There are multiple appropriate access pathways for various theatres of care 
(e.g., outpatient office/clinic, inpatient, emergency), all with varying requirements 
and value drivers. Payment for new diagnostic tests typically is handled regionally 
or locally; treating physicians and medical societies can influence these budget 
decisions. Shared financial agreements or risk-sharing scenarios may speed intro-
duction of a new POC test. Test reimbursement processes may differ for inpatient 
versus outpatient use. Currently, the evidence hurdle for a POC test is not as high 
as for prescription medicines. cOnclusiOns: Market access for a POC test varies 
across and within countries; adequate data to meet decision makers’ needs is not 
well understood. No roadmap exists for navigation of the critical path for POC tests, 
and evidence requirements in the EU are not well established. Access for a POC test 
will be complex; regardless of pathway, decisions regarding reimbursement and 
adoption of new technology are diverse and dispersed across and within countries 
with varying levels of required evidence.
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vALUE OF LIFE: AS PERCEIvED By PHySICIANS AND THE GENERAL PUBLIC
Tichopad A., Zigmond J.
CEEOR s.r.o., Prague, Czech Republic
Objectives: With the advancing process of HTA in the Czech Republic question 
emerged such as what is the willingness to pay (WTP) for health and life as well 
as what is the general awareness of the national health care policy and health 
economics. So far all estimations of WTP were largely based on academic deduc-
tions, thus we adopted a previously published approach to estimate the empirical 
WTP. MethOds: A total of 381 doctors of 15 specializations and 500 respondents 
from general population, both matching the CZ demography, were interviewed 
online. Doctors were asked directly to suggest reasonable WTP per equivalent of 
QALY. The general public was interview using the dichotomous double bounded 
choice method. The value of WTP, including 95% confidence interval, was deter-
mined using proc lifereg of the SAS system that allowed estimating averages for 
interval data. Optimal parametric extrapolation of the data was chosen based on 
the minimum value of Akaike’s information criterion (AIC). Results: Economics 
is the last criterion considered as important by doctors following the quality of life, 
clinical parameters and ethical/social aspects. Doctors not rejecting the concept 
of paying for health (28%) produced median of CZK 700,000 (EUR 27,129) to be an 
adequate payment for an extra year in full health, representing one QALY. General 
population suggested CZK 18.4 million (EUR 731,110) as an adequate WTP to be paid 
by the national health insurance fund, largely in contrast to only CZK 177,000 (EUR 
6859) as suggested for the pay-of-pocket WTP. cOnclusiOns: The awareness about 
health economics and its methodology is rather low among doctors and general 
public. While those medical doctors who expressed understanding for the concept 
of WTP and QALY suggested a value similar with the implicit WTP of CZK 1,000,000 
(EUR 38,756) general public suggested extreme WTP from public budget, reflecting 
distant position of the public.
HEALTH CARE USE & POLICy STUDIES – Health Care Research & Education
PHP144
TOwARDS EvIDENCE-BASED EUROPEAN POLICy IN CLINICAL TRIALS THE 
SURvEy OF ATTITUDES TOwARDS TRIAL SITES IN EUROPE - THE SAT-EU 
STUDyTM
Gehring M.1, Taylor R.2, Casteels B.3, Piazzi A.4, Mellody M.4, Gensini G.F.5, Ambrosio G.6
1sbg Healthcare Consulting, Pully, Switzerland, 2Peninsula Medical School, Exeter, UK, 3BC 
Consulting & Solutions Sàrl, Lausanne, Switzerland, 4Virtuoso Sàrl, Grand Saconnex, Switzerland, 
5University of Florence, Florence, Italy, 6University of Perugia, Perugia, Italy
Objectives: Applications to run clinical trials in Europe have been falling 
since 2007. Costs, speed of approvals, and shortcomings of European Clinical 
Trial Directive (CTD) are commonly held responsible. However, there is no hard 
evidence on the actual weight of these factors, nor are policy recommenda-
tions typically founded on a research-based understanding of factors impact-
ing trial site selection. Indeed, borrowing from the rigour of its own discipline, 
medical policy decisions ought to be “evidence-based”. MethOds: The SAT-EU 
StudyTM was an anonymous, cross-sectional Web-based survey designed to 
systematically assess factors impacting European clinical trial site selection. 
It explored 19 factors across investigator-, hospital-, and environment-driven 
criteria, and costs. It also surveyed perceptions of the European trial environ-
ment. Clinical Research Organizations (CROs), academic Clinical Trial Units 
(CTUs), and Industry were invited to respond. OUTCOME MEASURES: Primary: 
Weight assigned to each factor hypothesized to impact trial site selection and 
trial incidence; Secondary: Desirability of twelve European countries to run 
clinical trials Results: Responses were obtained from 485 professionals in 34 
countries: 49% from BioPharma, 40% from CTUs or CROs. Investigator-, environ-
ment-, and hospital-dependent factors were rated highly important, costs being 
less important (P< 0.0001). Within environment-driven criteria, pool of eligible 
patients, speed of approvals, and presence of disease-management networks 
were significantly more important than costs or government financial incentives 
(P< 0.0001). Germany, UK, and The Netherlands were rated the best trial markets 
(P< 0.0001). cOnclusiOns: Fostering European clinical research does not require 
additional government spending or a revamping of the clinical trial cost structure. 
Rather, it requires greater visibility of centres of excellence and the harmonised 
national adoption of recently approved revisions to the CTD. Carefully crafted 
harmonization of approvals, including aligned hospital contracting, speedier trial 
authorization and greater visibility of disease networks may bring significantly 
more clinical research to Europe and stimulate growth.
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as a readmissions reduction strategy may be ineffective, unless the specific need and 
care content of these additional days is assured.
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MEDICATION ERRORS-INCIDENCE, CAUSES AND POSSIBLE PREvENTION 
STRATEGIES IN INDIAN HEALTH CARE SETTING
Patel H., Parthasarathi G., Shashank C., Adithyanath B., Shwetha D., Doney J.
JSS College of Pharmacy, JSS University, Mysore, India
Objectives: Medication errors (MEs) frequently contribute for patient’s morbidity 
and mortality in health care settings. The present study was aimed to identify and 
assess the pattern of occurrence of MEs and to develop strategies to prevent these 
MEs. MethOds: It was a prospective study conducted in a teaching hospital over 
a period of 6 months. Trainee clinical pharmacists followed the patients admitted 
to general surgery (GS) wards. MEs occurred and the cause for ME was identified 
by reviewing medical records, interviewing patients and concerned health care 
professionals (HCPs). All identified MEs were documented electronically and were 
evaluated for its nature, extent, cause and outcome. Prevention strategies were 
developed accordingly. Results: A total of 417 MEs were identified in 313 patients 
from 1125 patients followed. Calculated incidence of MEs in GS wards was 27.8%. The 
majority of them were prescribing errors (60.4%), followed by administration errors 
(38.6%) and dispensing errors (9.8%). The common reasons observed for MEs were 
omission error (25%), incorrect drug selection (14%), wrong frequency (10%), poor 
patient adherence to medicines (7%), drug use without indication (7%), improper 
dose (6%), wrong administration (4%) and wrong time (3%). Pantoprazole (27.5%), 
Ceftriaxone (9.8%), Piperacillin-Tazobactum (6.7%), Diclofenac (6.4%) and Tramadol 
(6.2%) were drugs commonly involved in MEs. Majority of MEs (96%) that reached 
to patients were not harmful but 32% of them needed monitoring/intervention to 
ensure patient safety. Around 60% of MEs were due to inappropriate prescribing 
by clinicians followed by patient non-adherence to therapy (14%), improper follow 
up by ward clinical pharmacists (15%) and nursing workload (11%). Strategies were 
designed to prevent commonly identified MEs. cOnclusiOns: MEs can be mini-
mized if patients are monitored correctly on time. Appropriate team work from all 
HCPs can certainly reduce the occurrence of MEs.
PHP152
THE RELATIONSHIP BETwEEN SCIENTIFIC RESEARCH, CLINICAL TRIALS AND 
FDA DRUG APPROvAL
Burgon J.1, Hamerslag L.2
1Costello Medical Consulting Ltd., Cambridge, UK, 2Costello Medical Consulting Ltd., Cambridge, 
UK
Objectives: An important aim of medical research is often to identify potential 
novel therapeutic targets for disease treatment. Here we investigated whether 
the amount of scientific research (measured as papers published) in a given dis-
ease area correlated with the number of clinical trials, and whether an increased 
amount of research in a disease area resulted in a higher number of FDA approved 
drugs. MethOds: FDA drugs approved between 2000-2013 were identified using the 
online database ‘CenterWatch’, and the number of papers and clinical trials for each 
disease area was established by running comprehensive searches on PubMed from 
1975-2013, and ClinicalTrials.gov from 1999-2013, respectively. The total numbers of 
approved drugs, published papers and clinical trials were compared for each of 17 
disease areas and, to analyse the correlations between these factors, simple regres-
sion analyses were performed. Results: Analysis for correlation between the num-
ber of papers published and the number of clinical trials per disease area revealed 
a strong correlation between these two variables (R square: 0.69, p< 0.001); thus, 
increasing numbers of published papers were associated with increasing numbers 
of clinical trials. Further analyses were carried out to investigate the relationship 
between the number of papers published, or clinical trials, and the number of drugs 
approved by the FDA. Interestingly, these analyses revealed that both clinical trials (R 
square: 0.05, p= 0.41) and published papers (R square: 0.09, p= 0.25) correlated poorly 
with the number of FDA approved drugs per disease area. cOnclusiOns: These 
data suggest that the amount of research significantly correlates with the number 
of clinical trials in a given disease area. However, neither research nor clinical trials 
correlated with the number of drugs approved by the FDA. This may suggest that 
some disease areas could face a bottle neck at the drug approval stage, perhaps 
through difficulties in demonstrating efficacy.
PHP153
EFFECTS OF CHANGING HEALTH POLICy ON PHARMACOECONOMICS AND 
HEALTH OUTCOME STUDIES FROM 2000 TO 2012 IN TURKEy
Kockaya G.1, Daylan Kockaya P.2, Ergin G.1
1Health Economics and Policy Association, Ankara, Turkey, 2Zirve University, Gaziantep, Turkey
Objectives: Health policy chances may effect the conducted studies in all 
fields. Pharmacoeconomics dossiers for the reimbursement applications for new 
medicines were not mandatory before year 2008. New molecules need to show cost-
effectiveness and possible budget effect with their applications for reimbursement 
to Social Security Institution from 2008. This policy changing may effect pharmaco-
economics and health outcome studies in Turkey. The aim of the study is to evaluate 
the improvement of pharmacoeconomics and health outcome studies which are 
specific for Turkey in years. MethOds: Database of ISPOR Outcome Research Digest 
were searched online from the begining of database (1998) to 2011 with the key 
words “Turkey” and “Turkish”. The inclusion criteria were taken as study must be 
specific for Turkey and first author must be from Turkey. Included abstract evaluated 
for increasing in years, distribution in study topics and diseases areas. Results: 
121 abstracts were matched with inclusion criteria. First abstracts were published 
in 2000. There were only 16 abstracts in total until 2008. After year 2008, published 
abstracts numbers were increased year by year and reached up to 40 per year in 
2012. 58.7% of all abstracts were Cost Studies(CS). It was followed by Health Care 
Use & Policy Studies(HP) (15.7%) and Patient Reported Outcomes & Preference-Based 
Studies (PRO) (12,7%). 49.3% of all Cost Studies were Cost-Effectiveness studies. 
PHP148
SELF- ASSESMENT OF HEALTH PROFESSIONALS’ COMMUNICATION SKILLS 
wITH PATIENTS
Jocic D., Krajnovic D., Tadic I.
University of Belgrade – Faculty of Pharmacy, Belgrade, Serbia and Montenegro
Objectives: Effective communication helps us to clearly understand patients or 
situation and enable us to make differences, build trust and respect. If a health 
professional does not have communication skills, it may reduce compliance and 
decrease the quality of health care. The aim of this study was to self-assess the 
communication skills during daily work in delivering care to patients by phar-
macists and physicians at community settings. MethOds: This study is a pilot 
project of an ongoing Research Project aiming to investigate social and behavioral 
insights of pharmaciesy and physicians working in community settings in Serbia, 
started in November 2011. The rating scale is used to test pharmacists’ skills and 
in-patient communication designed for the needs of the research consisted of 31 
claims. Results: The questionnaire completed 157 health professionals (physician, 
pharmacists) from the southeastern and central part of Serbia (75.3 % of which 
were females). The average age of participants were 40.42±9.38 and the average 
years of work experience were 12.92 ± 9.10 years.There is a correlation between the 
age of pharmacists and the following variables: assertiveness (r = 0.456, p < 0.01), 
active listening skills of patient (r = 0.443, p < 0.01), questioning patient (r = 0.455, 
p < 0.01), rhetoric skills (r = 0.540, p< 0.01). ANOVA examined the effects of age on 
empathy (F (4.64) = 1.52, p = 0.01), assertiveness (F (4.64) = 3.54, p = 0.01), rhetoric 
skills (F (4.64) = 2.48, p = 0.01) and adherence to ethical principles (F (4.64) = 1.53, p 
= 0.01). cOnclusiOns: Elder health professionals with greater empathy are more 
assertive having better rhetoric skills and adherence to ethical principles in com-
munication. There is a need to improve the communication skills of young health 
professionals.
PHP149
REGULATORy AND GENERAL EPIDEMIOLOGICAL KNOwLEDGE ABOUT RARE 
DISEASES AND ACCESS TO TREATMENT FOR RARE DISEASES: HEALTH 
PROFESSIONALS’ vIEw IN SERBIA
Krajnovic D.1, Jocic D.1, Arsic J.2, Petrova G.3, Tadic I.1, Tasic L.1, Jocic-Milosavljevic B.4
1University of Belgrade – Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 2Apoteka 
Vranje, Vranje, Serbia and Montenegro, 3Medical University in Sofia - Faculty of Pharmacy, Sofia, 
Bulgaria, 4Apoteka Pancevo, Belgrade, Serbia and Montenegro
Objectives: To assess the knowledge of health professionals about epidemiological 
and national regulatory issues concerning rare diseases (RD) and access to orphan 
drugs. MethOds: This paper reports some of the results from an ongoing KAP 
study on rare diseases and orphan drugs in the Republic of Serbia (RS). A prospective 
cross-sectional study was conducted from May to June 2013, on a convenient sample 
of licensed pharmacists and physicians from two, large cities’ and its suburbies in 
the central parts of RS. A specially designed KAP instrument in a form of three-part 
questionnaire was applied and these results were related to the assessment of 
concerning knowledge (8 multiple-choice questions) and self-assessment of the 
participants (one question). Results: The study population included 214 health 
workers (151 pharmacists and 63 physicians); the average age of participants was 
40.80±9.45 and the average years of professional practice was 13.14 ± 9.68. Majority 
of the participants (57%) knew the true prevalence of RD and slightly less than third 
of the samples (26.2%) responded correctly to the question of the extent of European 
population suffering from RD. There are major differences in regulatory knowledge 
about access to treatment for rare diseases, as participants answered correctly in 
a wide range of 21% to 67.4%. Most of the health professionals self-estimated that 
possessed little (31.3%) or enough (43.5%) knowledge related to general epidemio-
logical and legislative issues concerning RD and orphan drugs. The average level of 
overall knowledge assessment for all questions and self-assessmentin general was 
3.53 ± 1.58 and 2.04± 0.87 respectively. cOnclusiOns: The majority of respondents 
estimated that possess less knowledge on RD (general information) and drugs to 
treat RD, or insufficiently. The average level of respondents’ knowledge on RD and 
drugs to treat RD was below the average.
PHP150
TIMING OF DISCHARGE MAKES A DIFFERENCE: THE EFFECTS OF LENGTH OF 
STAy AND DAy OF DISCHARGE ON 30-DAy READMISSIONS
Flaks-Manov N.1, Shadmi E.2, Bitterman H.3, Balicer R.D.4
1Clalit Health Services, Tel-Aviv, Israel, 2University of Haifa, Haifa, Israel, 3Clalit Health Sevi, 
Technion City, Haifa, Israel, 4Clalit Health Services, Tel Aviv, Israel
Objectives: The evidence on the influence of timing of discharge on readmission 
risk is inconsistent, showing that both increased length of stay (LOS) and early dis-
charge are associated with an increased risk of readmission. We aimed to test whether 
LOS and day of discharge (i.e., weekend vs. work days) are associated with the risk 
of 30-day emergency readmission. MethOds: Data on first admission to internal 
medicine departments during January – March 2010 was retrieved from Clalit Health 
Services’ data warehouse. Inclusion criteria: LOS of > = 2 nights, age 18+, readmitted 
to an internal medicine demartment or ICU. Predictors: LOS, ACG morbidity categories, 
age, socioeconomic status, and prior health care use. Logistic regression was used to 
model the effect of discharge day and LOS on 30-day emergency readmission, con-
trolling for known risk factors. Results: After adjustment for morbidity, clinical and 
demographic factors, there is an increased risk for 30-day readmissions associated 
with increased length of stay (OR= 1.56 when LOS is 8+ days vs. 2-3 days, p< 0.001). 
Focusing on 2-7 day hospitalizations, the same association is found (OR= 1.47 for LOS 
> 5 days, p< 0.001). Being discharged over the weekend increases the odds of readmis-
sion by 11% (p= 0.04), controlling for all known risk factors. Modeling for an outcome 
of readmission or death, or for a 7-day readmission outcome, resulted in similar find-
ings. cOnclusiOns: Our study showed that contrary to some of the evidence, longer 
hospital stays were associated with increased risk of unplanned readmission. Being 
discharged over the weekend incurs mild additional risk for readmission, especially 
at shorter LOS. These findings suggest that despite short LOS in Israel, increasing LOS 
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ing patients with rare diseases, and studying attitudes and behaviours relating to 
taboo subjects. SM may also increase recruitment into research studies, especially 
from hard-to-reach groups.
PHP157
PHARMACO-ECONOMIC EDUCATION NEEDS INvESTIGATED By ISPOR CHAPTER 
– ExAMPLE FROM BULGARIA
Nikolov I.1, Petrova G.2
1Glaxo SmithKline, Sofia, Bulgaria, 2Medical University of Sofia, Sofia, Bulgaria
Objectives: Education in pharmacoeconomics is one of the primary goals of ISPOR. 
This study is aiming to explore the needs for pharmacoeconomic educations by 
national chapter among different pharmaceutical stakeholders. MethOds: Inquiry 
research was performed among the participants in 2 educational initiatives of the 
Bulgarian ISPOR chapter. In both seminars attended representatives of payers - 
Bulgarian government (MoH, NHIF), as well as from pharmaceutical business, non- 
governmental organizations and academia. On total 48 individuals left feedback from 
over 60 participants in both seminars. The questionnaires focused on the topics cov-
ered in the seminars, organizational matters and needs of new educational themes. 
Preferred themes were assessed and results are consolidated Results: Both semi-
nars target the same groups of individuals – institutions, academia, pharmaceutical 
business, and non-governmental organizations. The first seminar was focused mainly 
on the pricing and reimbursement of the pharmaceuticals with international lectur-
ers, while the second one covered basic pharmacoeconomic methods with national 
lectures. The overall satisfaction score from both seminars was very high (25%) and 
excellent (55%). The most preferred topic was the pricing and reimbursement of phar-
maceuticals by 53%, followed by different modeling techniques (47%). Participants 
wanted to know more about the way of regulatory usage of pharmacoeconomics in 
pricing and reimbursement (70%). Focus groups discussion (98%) and practical of 
pharmacoeconomic were also a matter of high preference (30%). cOnclusiOns: This 
study proves the necessity for education in the field of pharmacoeconomic, modeling, 
core models explanations and pharmaceuticals assessment. They also pointed out 
the place of national chapters as providers of education and independent organizers 
able to gather different stakeholders’ point of view in non-formal discussions. Having 
in mind that BG is in the beginning of the HTA process obviously willingness to be 
educated among the whole Pharma environment is definitely high.
PHP158
PHARMACOECONOMIC EDUCATION FOR HEALTH CARE STUDENTS IN BOSNIA 
AND HERzEGOvINA
Catic T.
ISPOR Bosnia and Herzegovina, Sarajevo, Bosnia
Objectives: In order to examine the current situation related to education in the 
field of pharmacoeconomics and Health-economics, we investigate which uni-
versities and colleges provide such training. The study included pharmaceutical, 
medical and dentistry faculties and departments as well as the health care col-
leges. Information on health care colleges and faculties in B&H are taken from State 
register of accredited higher education institutions. MethOds: We have analyzed 
the on-line availability of the curricula at official websites of health care faculties, 
its content for each program of study at the undergraduate and postgraduate level. 
All programs are qualitatively analyzed in terms if they include pharmacoeco-
nomics/health economics as a separate subject (mandatory or elective) Results: 
Twenty-two high health care institutions are identified; 5 medical, 4 dentistry, 9 
pharmaceutical faculties, 13 nursing and 6 othe. Seventeen of them have on-line 
available curricula, 3 are not available and 2 faculties do not have available web-
sites, so we included 77,7% of all health care faculties program. In undergraduate 
courses pharmacoeconomics/health-economics is included in curricula at 5 facul-
ties. Pharmacoeconomics as separate mandatory subject is included in curricula 
at 1 medical and 1 pharmacy faculty while at 3 health care colleges this area is 
covered through health-economics or health-management courses. In postgraduate 
programs (master and doctoral studies) just 3 faculties included health economics 
in its curricula; 1 medical faculty as mandatory subject, and 2 medical colleges 
as elective subject. cOnclusiOns: Pharmacoeconomic education for health care 
students in Bosnia and Herzegovina is poorly organized and not satisfactory. There 
is growing need to educate health care professional and stakeholders in this field to 
ensure proper understanding and implementation in practice and decision-making 
process. Limitation of this study is that detail programs and structure of courses 
could not be examined since it is not on-line available. Further research is recom-
mended to get deep insight into curricula.
HEALTH CARE USE & POLICy STUDIES – Health Technology Assessment  
Programs
PHP159
wORKSHOP IN PHARMACOECONOMICS: AN ITALIAN ExPERIENCE OF MULTI-
STAKEHOLDER HTA CONSENSUS
Cicchetti A.1, Gasbarrini A.2, Ruggeri M.1, Sacchini D.2, Lanati E.P.3
1Università Cattolica del Sacro Cuore, Rome, Italy, 2Università Cattolica del Sacro Cuore, Rome, 
Italy, Italy, 3MA Provider, Milano, Italy, Italy
Objectives: To validate an innovative experience that aims at being recognized 
by Institutions as a national and independent HTA assessor, thus supporting both 
national and regional health care decison makers. This experience consists of 
a multi-stakeholder working group that, in the field of new technologies pro-
posed for critical clinical areas, discusses and develops guide-lines and decision 
rules and comparatively examines local data. MethOds: The working method 
consists of a series of meetings (4 per year) of a scientific board (composed 
by high-profile experts covering all HTA domains) that carries out a nationwide 
analysis of the topic under examination and focuses on the main clinical, eco-
nomic, organizational, social, and ethical aspects. Questionnaire-based surveys 
and Delphi panel are the main operational tools. WEF adopts standard HTA pro-
17.4% of all abstracts were in the Alergy diseases area. It was followed by Multiple 
Diseases (14%). cOnclusiOns: It was shown that the policy changing in 2008 as 
to require pharmacoeconomics dossiers in the reimbursement application effected 
Turkey specific pharmacoeconomic and health outcome studies positively. In other 
words, pharmaceutical ýndustry and the government started to invest in pharma-
coeconomics and health outcome studies after 2008.
PHP154
LONG TERM ANALISyS OF THE HUNGARIAN HOSPITAL BED CAPACITIES
Ágoston I., Szarka E., Endrei D., Zemplényi A., Molics B., Vas G., Boncz I.
University of Pécs, Pécs, Hungary
Objectives: To provide a long term analysis of the Hungarian hospital bed capaci-
ties. MethOds: During the preparation we performed bibliographic review includ-
ing research of related statistical data collections, historical hospital works. Data 
were derived from the database of the Hungarian Central Statistical Office and 
from historical documents. The study covered the period between 1800-2010. The 
following indicators were used: number of hospitals and hospital beds. Results: 
The first data available for hospital statistics dates back to 1800 and showed that 
there were 34 hospitals and 1590 hospital beds in Hungary. For 1867 the number of 
hospitals and hospital beds increased up to 46 and 4684 respectively. Shortly after 
the introduction of compulsory health insurance in 1891, the number of hospitals 
was 344 and the number of hospital beds was 16497 in 1895. After the First World 
War hospital number decreased to 183, and bed number increased to 26451. Since 
1945 to 1990 the number of hospitals varied between 147-287, while the number 
of hospital beds continuously increased from 33162 to 105097. After the social and 
political changes in 1990, hospital bed number showed strong decrease to 71216 in 
2010 with varying number of hospitals between 148-174. As a consequence in the 
changes of numbers of hospitals and hospital beds, the average bed number per 
one hospital continuously increased from 47 in 1800, 107 in 1915, 182 in 1950 and 
710 in 1990. cOnclusiOns: The definition and function of hospitals significantly 
changed during the past 200 years in Hungary. The former old fashioned small poor 
houses of the early 19th century have been replaced by hospitals with large number 
of hospital beds by 1990. After social and political changes in 1990, the number of 
hospitals beds in Hungary decreased and got closer to EU average.
PHP155
‘BIG DATA’ IN HEALTH CARE. wHAT DOES IT MEAN AND wILL IT MAKE A 
DIFFERENCE?
Velthuis E.J.1, Malka E.S.2, Richards M.S.2
1PPD, Bennekom, The Netherlands, 2PPD, Morrisville, NC, USA
bAckgROund: With the evolution from data on paper into electronically available 
data, the term Big Data has made its entrance. This term is widely used and refers 
to the four V’s: Volume, Velocity, Variety and Veracity. Big Data is being used in many 
sectors such as retail and banking, and also in the health care sector. However, within 
the health care sector, this term is ill defined. Objectives: The main purpose of this 
study is to get an understanding of the definition of Big Data in health care. Further, 
it’s value and challenges will be explored. MethOds: : First, an attempt has been 
made to clarify the term Big Data in health care using the term “Big Data” in combina-
tion with ‘health’ in PubMed searches. Also, the internet and social media have been 
searched for definitions of Big Data in health care. Further, the potential use of Big 
Data in health care has been reviewed using these sources. Results: In the medical 
literature, the term Big Data is rarely used in health care research and no standard 
definitions of Big Data big data are available. The term is used in combination with 
electronic health care records (EHR), claims data, registries, pharmacy utilization 
records, and linkages between these databases. On the internet and social media, 
various definitions for Big Data in the health care sector can be found.” Values are: 
increased medical knowledge, improved quality of care, improved personalized medi-
cine, better health outcome prediction, and lower costs. Challenges with Big Data in 
Healthcare are of technical (different data structures), ethical (patient privacy) and 
scientific (quality issues, biases, causality assessment) magnitude. cOnclusiOns: 
Healthcare Big Data has poorly been defined. Use of Big Data can be beneficial in terms 
of better care and lower costs despite the challenges to be faced.
PHP156
DISEASE BECOMES SOCIAL. HEALTH RESEARCH CONDUCTED ON, OR USING, 
wEB 2.0 MEDIA: A SySTEMATIC REvIEw
Martin A., Lombard L.
Evidera, London, UK
Objectives: To assess the range and focus of health research that has involved 
interactive internet and mobile technology (“social media”; SM). MethOds: We 
conducted a systematic review of studies that investigated the use of SM, or used 
SM as a research tool, published in English since 2003 and indexed in MEDLINE 
and EMBASE. Results: We identified 3,773 unique studies, of which 304 reported 
primary research or were systematic reviews of such studies. Of these, 192 (63%) 
were surveys of actual or potential users of SM, including health care professionals 
(20%), patients with a specific disease or problem (46%), or the general public (34%); 
40 (13%) were articles describing SM tools or sites; 71 (23%) assessed the potential 
of SM to increase knowledge or improve clinical outcomes, of which 22 compared 
SM with more traditional support or information; 71 (23%) described SM users; 
53 (17%) sought their views on the benefits of SM; 24 (8%) discussed the potential 
harm its use could do to professional-patient relationships; and 25 (8%) analysed 
SM content. SM were also used as a tool to recruit participants into research (85 
articles, 28%), especially on topics such as sexual practices, intimate partner vio-
lence, or substance abuse, or involving groups typically underrepresented in clinical 
research. Of the various types of SM studied or used to recruit participants into 
research, Facebook was cited in 73 articles (24%); mobile apps in 40 papers (13%); 
PatientsLikeMe and Twitter in 13 articles (4%) each; MySpace in 3 articles (1%); and 
other online forums in 70 articles (23%). cOnclusiOns: SM is a rich source of data 
on patients and health care professionals. It may be particularly useful in target-
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but rather where list prices are lower than in comparable countries. Objectives: 
The aim of this research is to understand the impact of H2H data on the Service 
Médical Rendu (SMR) and Amélioration du Service Médical Rendu (ASMR) ratings fol-
lowing passage of the law. MethOds: Transparency Commission (TC) reports for new 
drugs or indication expansions of existing drugs published between January 1, 2012 
and March 31, 2013 were reviewed. The following data were gathered: 1) study type 
(placebo-controlled vs active H2H comparator); 2) comparator (if H2H); 3) availability 
of appropriate comparators in the marketplace; and 4) SMR/ASMR ratings. Results: 
A total of 110 TC assessments of 88 drugs were identified and examined. Ninety-four 
of the 110 assessments were of drugs where an appropriate comparator existed in the 
marketplace. Of these 94 assessments, H2H trials were conducted in 54 assessments. 
The percentage of assessments in the H2H group obtaining an SMR of important (78%) 
was similar to those that did not conduct H2H trials (75%). In contrast, the percent-
age of assessments in the H2H group obtaining an ASMR of III or IV was greater than 
the non-H2H group (15% vs. 26%). cOnclusiOns: The conduct of H2H trials does 
not guarantee an SMR of important for new drugs or indication extensions, but may 
improve ASMR rating. Although the TC mentions the lack of comparative data as a 
major contributing factor for an SMR of insufficient in their assessments of some 
products (Daxas, Xiapex), other factors, such as adverse events or efficacy data vs 
placebo are equally important.
PHP163
INFLUENCE OF PATIENT-REPORTED OUTCOMES ON HTA REIMBURSEMENT 
DECISIONS
Kulich K.1, Versoza L.2, Jaksa A.2, Demuro-Mercon C.3, Gnanasakthy A.4
1Novartis Pharma AG, Basel, Switzerland, 2Context Matters, Inc., New York, NY, USA, 3RTI Health 
Solutions, Research Triangle Park, NC, USA, 4Novartis Pharmaceuticals, East Hanover, NJ, USA
Objectives: To understand how patient-reported outcomes (PROs) influence deci-
sions made by Health Technology Assessment (HTA) agencies. MethOds: Reports 
from five HTA agencies that make reimbursement decisions (NICE, HAS, SMC, PBAC 
and CADTH’s CDR) were selected. The reports, taken from January 2005-April 2013, 
cover disease conditions in neurological and respiratory therapeutic areas. PROs 
within the HTA reports were identified and four analysts independently examined 
the stated rationales for the agencies’ decisions to determine whether PROs had a 
positive, negative, or neutral influence on the decision. Discrepancies between the 
analysts were discussed in-depth until consensus was reached. Results: A total of 
262 HTA reports were analyzed from the five agencies selected. PROs were mentioned 
in 34% of the HTA reports, and were the primary endpoint in 6%. Twenty-five (10%) 
reports mentioned PRO in the clinical rationale for their decisions. Twelve of the 25 
HTA reports (48%) contained PRO as a primary outcome, indicating that a PRO is more 
likely to influence the decision-making process if it is a primary outcome (p < 0.001). In 
12 out of the 25 HTA reports, the clinical rationale for the decision stated that, for the 
PRO, the drug performed better than placebo or comparator. Ten (83%) of these reports 
resulted in a positive decision. In eight reports, the drug compared equivalently or 
unfavorably to placebo or comparator for the PRO and resulted in four (50%) positive 
decisions. There was no significant difference in agency decisions between the reports 
that positively reported PROs and the reports with negative or similar PRO results 
(p= 0.16). cOnclusiOns: In respiratory and neurological diseases, the use of PROs 
is more likely to influence decision-making by HTA agency when PROs are specified 
as primary outcomes. Future research directions include comparing these findings 
to the effect other clinical outcomes have on reimbursement decisions.
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HEALTH ECONOMIC (HE) DATA REQUIREMENTS AND AvAILABILITy IN THE 
EUROPEAN UNION. RESULTS OF A SURvEy
Skoupa J.1, Annemans L.2, Hájek P.3
11st Medical Faculty, Charles University, Prague, Czech Republic, 2Ghent University & Brussels 
University, Ghent, Belgium, 3Pfizer, Praha, Czech Republic
Objectives: To compare data requirements and their availability for HE evaluations 
in 5 countries in Central/Eastern Europe - Poland, Czech Republic, Slovakia, Hungary, 
Romania (CEE) and 5 in Western Europe – UK, France, Germany, The Netherlands, 
Sweden (WE). MethOds: A questionnaire was developed and distributed to market 
access representatives from Pfizer who were asked to complete the questionnaire 
with opinion leader’s support. The questionnaire focused on the obligation to con-
duct HE assessment for reimbursement submissions, local HE guidelines, applied 
discount rates for future costs and effects, willingness to pay (WTP) thresholds 
and available data sources. Results: HE is mandatory in all CEE and 3 WE par-
ticipating countries for reimbursement applications of innovative drugs. Usually 
cost-effectiveness (CEA) and budget-impact (BIA) analyses are required. The pre-
ferred outcome of CEA is quality-adjusted-life years. In Romania, France and Czech 
Republic guidelines could not be identified at the time of the survey. HE evaluations 
are usually prepared by the applicant; in Sweden, UK, The Netherlands and Poland 
unlocked models have to be presented for scrutiny. Discount rates vary from 1.5% 
to 5%; usually the same for costs and outcomes (except in The Netherlands and 
Poland). Only UK, Poland and Slovakia have an explicit WTP threshold. In Poland 
it is based on GDP per capita, in Slovakia on multiples of average monthly wages. 
Differences were found on data availability. In WE data can be acquired easier com-
pared to CEE. Health insurance funds do not provide their data, unless they were 
published. Patient registries are either not available in CEE or difficult to access, so 
applicants mostly rely on retrospective medical chart data, hospital information 
systems or expert panels. cOnclusiOns: We found similar requirements for HE 
analyses in CEE and WE but differences in data availability. This results in less 
accurate inputs across the CEE influencing analyses’ outcomes.
PHP165
KEy DRIvERS OF PBAC DECISIONS FOR THE REIMBURSEMENT OF ORPHAN 
DRUGS ON THE LIFE SAvING DRUGS PROGRAM
Maguire B., Tilden D.
THEMA Consulting Pty. Limited, Pyrmont, Australia
cedures according to the EUnetHTA Core Model. To avoid any conflict of interests, 
no fee is paid to any member. Results: Since 2011, three HTA reports have been 
completed focusing in 2011-2012 on hepatology (HCV/HBV screening and treat-
ments) and extending in 2013 to other topics including hepatocellular carcinoma 
and inflammatory bowel diseases; HIV is coming up next year. Along with 4 pub-
lications in international journals (mean impact factor 5.73), there have been 
auditions at the Italian Drug Agency (AIFA) and at the Healthcare Commission 
in Parliament that have facilitated the approval of new HCV drugs. Furthermore, 
delays in approvals by regional formularies have been reduced by about 65% 
(from 212 days after national marketing authorization to 74 days; Farmindustria 
data). cOnclusiOns: This new multidisciplinary and multistakeholder approach 
proved to be well-accepted, and the “WEF method” is already recognized as a 
milestone in the Italian HTA landscape, by both Institutions (e.g. AIFA and Italian 
MoH) and Scientific Societies, thus helping payers in making rational decisions 
based on HTA methods.
PHP160
ExPLORING THE KEy DECISION DRIvERS PROvIDED By HTA AGENCIES 
ACCEPTING SUBMISSIONS wITH ICERS HIGHER THAN THE THRESHOLD
Goodrich K., Walsh S.C.M.
HERON Evidence Development Ltd., London, UK
Objectives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold, generally understood to be £30,000 for 
NICE (England), £20,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), 
and AUS$42,000 for PBAC (Australia). To help inform future submissions, we 
assessed the rationale provided by the four HTA agencies when submissions 
were accepted despite the reported ICERs being higher than these thresh-
olds. MethOds: All HTA appraisals from January 2000 to May 2013 from NICE, 
SMC, CADTH, and PBAC were included in the analysis. Multiple technology apprais-
als, resubmissions, vaccination programmes, requests for advice, and submissions 
for which an ICER could not be determined were excluded from the analysis. The 
full responses of the remaining appraisals were reviewed, with the submitted 
ICER (with and without proposed PAS), recommendation, and reasoning behind 
the recommendation extracted. Results: A total of 594 submissions met the 
inclusion criteria and 240 included a higher-than-threshold ICER, with 75 (31.6%) 
accepted. The key rationale for acceptance was a lack of alternative treatments 
(25/75). Submissions were also accepted based on the inclusion of a PAS (21/75), a 
demonstrated cost-effectiveness in a restricted patient population (16/75), and a 
robust economic evaluation resulting in a certain ICER (13/75). The agencies con-
sistently based their rationale on clinical need and cost-effectiveness, although 
the proportions varied between the agencies: NICE (53.3%), SMC (59.4%), CADTH 
(70.0%), PBAC (81.8%). cOnclusiOns: The majority of submissions reporting 
ICERs greater than the threshold ICER were rejected. ICERs over the threshold ICER 
were either brought in line with the threshold ICER through PASs or restricting 
the patient population; or accepted in spite of the high ICER based a clear clinical 
need or a robust and certain economic analysis. This highlights the importance 
for manufacturers to provide robust and appropriately justified economic evalu-
ations, even at the expense of an ICER lower than threshold.
PHP161
ARE CONDITIONALLy APPROvED THERAPIES SUCCESSFUL IN GAINING MARKET 
ACCESS?
Sweeney N.1, Nijhuis T.1, Haigh J.2
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Reading, UK
Objectives: To evaluate all medicines that received a conditional regulatory approval 
in Europe and to compare these decisions with the products current market access 
status through the evaluation of Health Technology Assessments (HTAs). MethOds: 
A manual search of the European Medicines Agencies (EMA) website was carried out 
to identify all pharmaceuticals that received a conditional approval (January 2007 to 
May 2013). Of the medicines identified, the statutory funding status was checked by 
reviewing the websites of the key HTA agencies in the EU 5 countries-: HAS (France), 
G-BA (Germany), AIFA (Italy), DGFPS (Spain) and AWMSG, NICE, SMC (UK). Results: 
A total of 15 pharmaceuticals were found that had received an EMA conditional 
approval. Of these, 10 met the inclusion criteria and were analysed further: etra-
virine, everolimus, fampridine, lapatinib, ofatumumab, panitumumab, pixantrone, 
pazopanib, stiripentol and vandetanib. Of the 10 pharmaceuticals, a total of 50 HTA 
assessments were conducted by the 7 agencies, with 31 (62%) of the HTAs reaching a 
positive funding decision. Both NICE and AWMSG recommended only 1 of the condi-
tionally approved drugs for funding, G-BA recommended 2, SMC 3, DGFPS 6, AIFA 6 and 
HAS 8. Of the 10 drugs, everolimus was the most successful and is funded by 6 (of the 
7) HTA agencies. The key reasons for the success of everolimus were due to convincing 
efficacy (prolonging progression-free survival), combined with an economic case that 
was considered demonstrated despite some uncertainties. cOnclusiOns: Whilst 
regulatory bodies recognise the need to grant marketing authorisation on the basis 
of less complete data, this does not necessarily mean a straight forward path through 
market access. Although the majority of HTA agencies did provide a positive funding 
decision; sound health economic evidence remains essential for new medicines to 
increase the chances of market access approval.
PHP162
ARE HEAD-TO-HEAD DATA NECESSARy TO GAIN REIMBURSEMENT IN THE 
FRENCH NATIONAL HEALTH CARE SySTEM?
Patel A.1, Grosfeld D.1, Conti C.C.2, Zaidi Q.1, Furniss S.J.3
1GfK Bridgehead, New York, NY, USA, 2GfK Bridgehead, London, UK, 3GfK Bridgehead, Melton 
Mowbray, UK
bAckgROund: Since December 2011, pharmaceutical companies are required by 
law to provide the Haute Autorité de Santé with head-to-head (H2H) data against 
standard of care when available to be entitled for reimbursement. However, France 
is a market where health authorities rarely deny reimbursement to innovative drugs 
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documentation of the searches is crucial to ensure the best possible acceptance of 
evidence in the AMNOG process.
PHP168
ANALySIS OF PUBLISHED HEALTH TECHNOLOGy ASSESSMENTS (HTA) IN 
RUSSIA AND ITS PLACE IN RUSSIAN REIMBURSEMENT SySTEM
Kalbasko A., Heemstra L., Nijhuis T.
Quintiles, Hoofddorp, The Netherlands
Objectives: Currently there is no formal HTA agency in Russia, although the need 
for HTA as an evidence tool for policy makers is increasing due to budget constraints. 
However, there are HTA bodies which to some extent influence decison makers 
through publications of pharmacoeconomic studies. The objective of the present 
study was to gain insights into the current activities of existing HTA organizations 
and research trends in developing HTA in Russia. MethOds: A manual search of 
four Russian HTA organizations’ websites was conducted to find pharmacoeco-
nomic assessments published from 1998 onwards. Per agency, all relevant reports 
were categorized by therapeutic area and publication date. Any revealed patterns 
in the HTA topics were in-depth analyzed and compared with the World Health 
Organization (WHO) country profile of Russia. Results: In total, 180 pharmaco-
economic assessments published by four Russian HTA organizations were identi-
fied. Overall, the majority of studies were performed in cardiovascular (n= 45; 25%) 
and oncology (n= 32; 18%) disease areas, which are according to the WHO, the two 
leading causes of death, both in Russia and globally. The total number of pharma-
coeconomic publications per year has been constantly increasing from one study in 
1998 to 26 in 2009, however with fewer reports published in 2010-2013 (32 HTAs in 
three years). When reported, the potential willingness-to-pay (WTP) threshold for 
cost-effectiveness was suggested to be 3*Gross Domestic Product (GDP) per capita 
as recommended by WHO, which equals to approximately 30,000 euro per Quality 
Adjusted Life Year (QALY) gained. cOnclusiOns: Although formally Russia does 
not have a transparent HTA based reimbursement process, existing HTA organiza-
tions are constantly developing and gaining HTA experience by conducting assess-
ments in the therapeutic areas with the highest burden on Russian population. 
These areas of interest, as well as an approach to define WTP threshold, match with 
WHO data and recommendations.
PHP169
SySTEMATIC LITERATURE REvIEwS AT THE HEART OF HEALTH TECHNOLOGy 
ASSESSMENT: A COMPARISON ACROSS MARKETS
Rycroft C.E.1, Fernandez M.2, Copley-Merriman C.3
1RTI Health Solutions, Manchester, UK, 2RTI Health Solutions, RTP, NC, USA, 3RTI Health 
Solutions, Ann Arbor, MI, USA
Objectives: Requirements for systematic literature reviews (SLRs) within a 
Health Technology Assessment (HTA) submission vary across the world. The objec-
tive of this study is to compare clinical and economic SLR requirements issued 
by eight HTA agencies in the UK (England and Wales, Wales, Scotland), Ireland, 
Germany, Sweden, Canada, and Australia. MethOds: SLR requirements issued by 
the National Institute for Health and Care Excellence (NICE), All Wales Medicines 
Strategy Group (AWMSG), Scottish Medicines Consortium (SMC), National Centre 
for Pharmacoeconomics (NCPE), Gemeinsamer Bundesausschuss (G-BA) (Federal 
Joint Committee), The Dental and Pharmaceutical Benefits Agency (TLV), Canadian 
Agency for Drugs and Technologies in Health (CADTH), and Pharmaceutical Benefits 
Advisory Committee (PBAC) were compared, and a checklist of requirements was 
compiled. Results: SLRs of the clinical and economic evidence underpin the HTA 
process. However, HTA agencies vary on the specific requirements for each and the 
need for critical appraisal of identified clinical studies and economic analyses. NICE 
requirements are the most prescriptive, whereas AWMSG and TLV have few stated 
SLR requirements. All agencies require a clinical SLR, although AWMSG does not 
specify outright but requires a clinical SLR to determine economic model inputs. 
Four agencies require both a clinical SLR and critical appraisal of the included stud-
ies (NICE, NCPE, G-BA, and PBAC), although recommended appraisal tools vary. NICE 
and CADTH require both an SLR and a critical appraisal of existing economic evalu-
ations for the intervention of interest; PBAC requires an SLR of only economic evalu-
ations. NICE, SMC, AWMSG, and NCPE require an SLR of utility data, and only NICE 
and SMC specify the need for an SLR of cost and resource use data. A more detailed 
analysis of specific methodology requirements will be presented. cOnclusiOns: 
Although SLR requirements vary between HTA agencies, a clinical SLR is a key 
requirement for all eight agencies investigated.
PHP170
ANALySIS OF TRANSPARENCy AMONGST INTERNATIONAL HEALTH 
TECHNOLOGy ASSESSMENT ORGANIzATIONS
Jebrail F.1, Duong M.2, Shum D.2
1University of Toronto, Toronto, ON, Canada, 2Hoffmann-La Roche Limited, Mississauga, ON, 
Canada
Objectives: To assess the level of transparency of health technology assessment 
(HTA) organizations in eight countries (Australia, Canada, Brazil, France, Germany, 
Italy, Spain, and the UK). MethOds: Nine national review bodies carrying out HTAs 
for the purposes of reimbursement and funding decisions within their respective 
countries were assessed according to 33 transparency parameters. The parameters 
were designed to assess the level of transparency in the HTA processes, clinical and 
economic reviews, and stakeholder involvement. Using a modified Delphi process, 
each parameter was weighted based on its importance to transparency and given a 
score from one to ten. A review of each national body was conducted to determine 
whether or not they included each of the 33 parameters. Data from public sources 
(i.e., organization websites) were utilized and interviews with international experts 
were conducted to verify the information. Total scores were calculated and con-
verted to a transparency index, with 100% being the most transparent. The score was 
adjusted for review bodies that did not require economic evaluations for their HTA 
process. Results: The level of transparency varies greatly amongst the HTA organi-
Objectives: In Australia, the decision process for the reimbursement of orphan 
drugs on the Life-Saving Drugs Program (LSDP) is centred on a drug’s ability to 
meet strict criteria as specified and assessed by both the Pharmaceutical Benefits 
Advisory Committee (PBAC) and the LSDP Advisory Committees. The objective of this 
research was to investigate the key determinants of PBAC decisions with respect to 
the LSDP criteria in order to understand the key challenges facing new treatments 
seeking LSDP funding. MethOds: A systematic search was conducted of all avail-
able Public Summary Documents (PSDs) from July 2005 to April 2013, to identify 
products that have sought listing on the LSDP. The selected PSDs were reviewed 
and data extracted according to categories defined by the LSDP criteria. Data were 
then qualitatively analysed within and across categories to identify key themes 
and concepts influencing decisions. Quantitative analyses were also conducted on 
the number of submissions, rejections, deferrals and the time from when a product 
first sought reimbursement to when funding was initiated. Results: Since the 
LSDP was created in 1995 only 12 products have sought LSDP funding, 10 are cur-
rently reimbursed covering 7 disease areas. Of the applications reviewed, 58% of 
submissions were immediately referred from the PBAC to LSDP for funding, 17% 
were initially rejected and after subsequent submissions have been funded, and 
25% of applications are yet to receive funding. The average time from the first PBAC 
consideration of a product until funding on the LSDP is 19.7months. The most com-
mon reason for rejection was around uncertainty in a drug’s ability to significantly 
prolong life and the appropriateness of surrogate outcomes to accurately predict 
long-term survival. cOnclusiOns: This analysis shows there is a pathway to reim-
bursement of high cost orphan drugs when there is a reasonable level of evidence 
supporting survival gains.
PHP166
HOw DOES THE UNCERTAINTy AROUND THE ExPECTED ICER AFFECT NICE 
DECISIONS?
Barber R., Steeves S., Kusel J., Wilson T., Hamerslag L.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: In the UK, NICE assesses health technologies based on clinical 
and cost-effectiveness evidence. Recommendations ensure NHS patients have 
access to the most clinically effective treatments, whilst using NHS resources 
cost-effectively. Nevertheless, cost-effectiveness analyses are susceptible to limi-
tations which make the true value of a technology uncertain. This study investi-
gates what other factors NICE considers when making recommendations under 
uncertainty. MethOds: All Single Technology Appraisals (STAs) published by NICE 
between 2011-2013 inclusive were reviewed. Recommendations were identified 
as being made under uncertainty if there was a less than 50% probability that the 
intervention was cost-effective at a willingness-to-pay threshold of £20,000 per 
QALY gained. NICE committee reports for these appraisals were reviewed to deter-
mine the factors taken into account when making a recommendation. Results: 
Of 64 STAs published in the studied period, 31 interventions were identified with 
uncertainty at the willingness-to-pay threshold of £20,000, of which 18 (58%) were 
recommended by NICE. Moreover, only 4 (22%) recommended STAs with uncer-
tainty at £20,000 had a greater than 50% probability of being cost-effective at a 
threshold of £30,000. Of the STAs recommended under uncertainty, 13 (72%) had a 
patient access scheme (PAS) in place, while 3 (17%) fulfilled end-of-life treatment 
criteria. Health-related benefits not captured in the manufacturer’s economic 
model that were likely to lower the ICER, innovative technologies, or interven-
tions satisfying an unmet clinical need were also taken into account. For exam-
ple, fingolimod was recommended by NICE for treatment of multiple sclerosis 
based on its oral rather than intravenous formulation and because benefits from 
a reduced caregiving need were not accounted for in the manufacturer’s economic 
model. cOnclusiOns: Even under uncertainty, NICE often recommends new 
technologies, particularly if a PAS is in place or if additional costs are deemed to 
be justified by the benefit provided to patients or their families.
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ANALySIS OF THE IQwIG COMMENTS ON THE EvIDENCE SEARCHES OF 
DOSSIERS IN THE GERMAN AMNOG PROCESS
Witt B.1, Bakker K.2, Volmer T.1
1SmartStep Consulting GmbH, Hamburg, Germany, 2Hochschule Fresenius, University of Applied 
Sciences, Hamburg, Germany
Objectives: The benefit assessment of new drugs in Germany requires the sub-
mission of a value dossier including systematic searches. The majority of dossiers 
are methodically inspected and assessed by the German Institute for Quality and 
Efficiency in Healthcare (IQWiG). The study’s objective was the analysis of com-
mon deficiencies in systematic searches and their consequences for the IQWiG 
assessment. MethOds: A total of 37 IQWiG assessment reports were analysed 
with regard to all comments made on the presented systematic searches in the 
dossier of the pharmaceutical company. A distinction was made between literature 
and study searches. The respective IQWiG comments were categorized and listed. 
Inadequate searches were examined in terms of consequences for the assessment 
by the IQWiG. Consequences were divided into those affecting the search required 
for the substance itself and those carried out for indirect comparisons/ further 
investigations. Results: A total of 4 of the 37 dossiers passed the IQWiG assess-
ment without deficiencies. Out of all analysed searches a total of 104 deficiencies 
were found, of which the most frequent ones referred to the search strings (32%) and 
the documentation of the search (25%). In the consistency check on the number of 
hits deviations were found by the IQWiG in 13%; 92% of the inconsistencies occurred 
in study-registry versus 8% in literature searches. There were no consequences in 
62% (23/37) for the substance-search and in 22% (8/37) for indirect comparisons/ 
further investigations. Non-consideration of study results, which was the most 
frequent consequence of an inadequate search, occurred in 24% for the substance-
search and in 32% for indirect comparisons/further analyses. cOnclusiOns: The 
methodological requirements for systematic searches to be accepted by the IQWiG 
are not achieved in the majority of dossiers. An adequate design and a careful 
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workbook. Results: Of the 71 STAs published, ACDs were produced for 60 technolo-
gies, while 11 (15%) proceeded straight to FAD. All submissions which proceeded 
directly to FAD were recommended (full or optimised) in the final guidance. Twelve 
STAs (20%) received a “minded no” at ACD; however, 11 of these (92%) were reversed 
within the FAD on the basis of additional data provided by the manufacturers in 
the form of economic analyses (n= 5) or patient access schemes (PAS) (n= 6). Of the 
35 “not recommended” at ACD, 15 (43%) were ultimately recommended within the 
FAD through the introduction or revision of a PAS and/or submission of additional 
analyses. cOnclusiOns: If manufacturers can demonstrate a robust clinical and 
economic argument in their initial submission the chances of a FAD being produced 
without the requirement of an ACD are greatly increased. Furthermore, ACD deci-
sions can also be overturned; technologies which receive a “minded no” or “not 
recommended” at ACD stage can achieve a recommendation at FAD by presenting 
additional analyses or introducing/modifying a PAS.
PHP174
COMPARISON OF DRUG ASSESSMENTS IN FRANCE, GERMANy AND THE UNITED 
KINGDOM: IS EUROPEAN HTA A REALITy?
Troubat A., Perrin L.
IMS Health, PARIS LA DEFENSE, France
Objectives: In 2006, the EUnetHTA project was launched. One of its main strategic 
objectives was to strengthen the link between HTA and health care policy making 
in the EU. Seven years after EUnetHTA establishment, the objective of this study 
was to compare HTA agencies’ assessments in France, Germany and UK, focusing 
on method and outcomes. MethOds: Scope of the study was all the products 
getting a positive opinion from CHMP during two years, starting at January 1, 2011. 
Comparison between assessments was made for products assessed by the three 
HTA agencies: IQWiG, NICE, and HAS. Results: A total of 87 drugs were included in 
this study. 11 (13%) have been assessed by the three agencies. Among these drugs, 
more than 50% (6) were cancer treatment. HAS was the first to assess drug in 6 cases 
(mean delay between CHMP positive opinion and assessment: 223 days), followed 
closely by IQWiG (242 days), then by NICE (354 days). IQWiG segmented the patient 
population defined by the manufacturer into different sub-populations in 6 assess-
ments, HAS in 2, NICE never. NICE was the only agency who did not recommend a 
drug for cost-effectiveness reasons (2 assessments). In three assessments, IQWiG 
concluded that there was no benefit proven for the whole population; regarding 
the same drugs, HAS concluded there was minor improvement in actual benefit 
twice. cOnclusiOns: Some major trends emerge in the assessments studied: use 
of indirect comparisons, added therapeutic value weighted by severity and fre-
quency of side effects and uncertainty. Nevertheless, comparator choices, perception 
of clinical benefits and risks, budget impact and overall method still differ between 
the three HTA agencies studied, leading to different outcomes for drugs assessed.
PHP175
USING THE DELPHI METHOD FOR SELECTING MEDICAL TECHNOLOGIES UNDER 
BUDGET CONSTRAINTS: A FEASIBILITy STUDy
Daichman S.1, Greenberg D.2, Triki N.3, Hammerman A.4, Luxenburg O.5, Pliskin J.S.6
1SCE- Shamoon College of Engineering, Beer-Sheva, Israel, 2Ben-Gurion University of the 
Negev, Beer-Sheva, Israel, 3Maccabi Healthcare Services, Tel Aviv, Israel, 4Clalit Health Services 
Headquarters, Tel Aviv, Israel, 5Ministry of Health, Jerusalem, Israel, 6Ben Gurion University of the 
Negev, Beer-Sheva, Israel
Objectives: To examine whether the Delphi method can provide a convenient 
tool for selecting medical technologies for inclusion in the National List of Health 
Services (NLHS) in Israel under a pre-defined budget constraint. MethOds: The 
Delphi method was applied in two groups: medical specialists (oncologists and 
cardiologists) and observers in the NLHS committee. Participants in each group 
were anonymously asked to choose five of ten suggested technologies from the list 
of technologies submitted for inclusion in the 2012 NLHS and rank them accord-
ing to importance. Subsequently, the participants repeated the experiment after 
receiving aggregated feedback on the relative ranking of each technology within the 
same group after the first round. Comparison of the results was performed using 
descriptive statistics and non-parametric tests. Results: After two rounds of the 
experiment, observers and medical specialists reached agreement on four of the 
five highest ranked technologies in each field (oncology and cardiology) regarding 
their importance to be included in the NLHS. Three of these four technologies were 
indeed included in the NLHS for 2012. cOnclusiOns: The Delphi method is one of 
the best-known techniques to control group interaction and reach a consensus by 
utilizing the expertise of committee members. The study demonstrated the feasibil-
ity using the Delphi method for ranking health care technologies.
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wHICH SHOULD BE THE CORRECT NMA TO BE USED? A REvIEw OF HTA 
RECOMMENDATIONS
Solozabal M.1, Roset M.1, Rojas-Farreras S.1, González-Rojas N.2, Gil A.2
1IMS Health, Barcelona, Spain, 2Boehringer Ingelheim, Sant Cugat del Vallès (Barcelona), Spain
Objectives: In the lack of head-to-head comparative trials to demonstrate the effi-
cacy of new treatments, it is common to use network meta-analysis (NMA), includ-
ing indirect treatment comparison (ITC) or combine direct and indirect evidence 
through mixed treatment comparison (MTC). Due to the increasing number of drugs 
approved for the same indication and the increasing complexity of networks for 
treatments comparisons, new methods of MTC taking into account all the com-
parisons have aroused. Health Technology Assessment (HTA) bodies increasingly 
demand NMA although different recommendations about the methodologies to be 
applied exist. This study aims to review recommendations regarding ITCs and MTCs 
among the main HTA bodies. MethOds: A review of methodologies for drug com-
parison recommended by the main HTA bodies was performed. Recommendations 
related to evidence identification methods, assessment of homogeneity of studies 
and populations to be combined and statistical approach for the analysis were also 
reviewed. Results: A systematic literature search is a prerequisite for most HTA bod-
zations studied. The transparency index scores were as follows: Institut für Qualität 
und Wirtschaftlichkeit im Gesundheitswesen/Gemeinsamen Bundesausschusses 
(Germany), National Institute for Health and Care Excellence (UK), pan-Canadian 
Oncology Drug Review (Canada), Common Drug Review (Canada), Pharmaceutical 
Benefits Advisory Committee (Australia), Comissão Nacional de Incorporação 
de Tecnologias (Brazil), Haute Autorité de Santé (France), Agencia de Evaluación 
de Tecnologias Sanitarias (Spain), and Agenzia Italiana del Farmaco (Italy) were 
97%, 96%, 91%, 83%, 78%, 70%, 67%, 53%, and 25%, respectively. cOnclusiOns: 
Transparency amongst HTA organizations is progressively becoming the interna-
tional standard. However, the extent of transparent processes and procedures proves 
to be heterogeneous amongst international review organizations.
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ExPLORING THE KEy DECISION DRIvERS PROvIDED By HTA AGENCIES 
REjECTING SUBMISSIONS wITH ICERS LOwER THAN THE THRESHOLD
Walsh S.C.M., Goodrich K.
HERON Evidence Development Ltd., London, UK
Objectives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold generally understood to be £30,000 for NICE 
(England), £20,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), and 
AUS$42,000 for PBAC (Australia). To help inform future submissions, we assessed 
the rationale provided by the four HTA agencies when submissions were rejected 
despite the reported ICERs being lower than these thresholds. MethOds: All HTA 
appraisals from January 2000 to May 2013 from NICE, SMC, CADTH, and PBAC were 
included in the analysis. Multiple technology appraisals, resubmissions, vaccination 
programmes, requests for advice, and submissions for which an ICER could not be 
determined were excluded from the analysis. The full responses of the remaining 
appraisals were reviewed, with the submitted ICER, recommendation, and reason-
ing behind the recommendation extracted. Results: A total of 594 submissions 
met the inclusion criteria. 354 submissions across the four HTA bodies included a 
lower-than-threshold ICER, with 107 (30.2%) of these submissions rejected. Across 
the agencies, the most common reasons for rejection were use of an inappropriate 
patient population or comparator (45/107), uncertainty regarding the clinical ben-
efits (32/107), and use of economic evidence that was not sufficiently robust (40/107). 
The reasons for rejection were consistent across the four agencies, with a similar 
proportion basing their decision at least partly on one of the three reasons provided 
above: NICE (92.9%), SMC (92.0%), CADTH (93.3%), PBAC (93.8%). cOnclusiOns: A 
large proportion of submissions were rejected despite ICERs below the threshold. 
In instances where decisions went against the ICER thresholds, there was a clear 
tendency for identifiable problems with the clinical and economic assumptions to 
diminish the reliability of the ICERs presented. This result highlights that a lower-
than-threshold ICER is not enough for a positive recommendation and manufac-
turers must support their submission with accurate and reliable data to achieve a 
favourable outcome.
PHP172
CROSS-MARKETS vARIABILITy OF INNOvATION BENEFIT’S EvALUATIONS. HOw 
ITALy COMPARES TO FRANCE, GERMANy AND THE UNITED STATES
Savi L., Conti C.C., Tangari M., Lim A.
GfK Bridgehead, London, UK
Objectives: A new drugs’ innovation benefit is commonly evaluated, both in 
Europe and the USA. Most of the new pharmaceutical launches have to be evalu-
ated on the level of innovation that they offer as part of the market access process. 
The objective of this abstract is to give an example of the variability that emerges 
in the innovation scores given by the Italian agency, AIFA, as compared to those of 
France, Germany and the USA. MethOds: Drugs listed on the AIFA website as show-
ing potential or important innovation, were used as a benchmark to measure how 
innovation benefit assessments performed in France, Germany and the USA deviate. 
The innovation benefit was measured through: the ASMR score (Amélioration du 
Service Médical Rendu) in France, as published on the HAS website (Haute Autorite’ 
de Sante’); the level of additional benefit in Germany, as published on the G-BA 
website (Gemeinsame Bundesausschuss); the type of approval procedure as pub-
lished on the FDA (Food and Drug administration) website. In the case of the USA, 
standard approval vs. priority review was used as a proxy measure of the level of 
innovation. Results: The results of the innovation benefit’s evaluations performed 
in France, Germany and the USA differ from those performed by AIFA in 74%, 33% 
and 58% of cases respectively. The lower percentage in Germany is due to lim-
ited available information compared to other markets. cOnclusiOns: The level 
of variability that exists between the outcomes of the innovativeness evaluation 
performed in different countries suggests that although the definition of innova-
tion may appear straightforward, it is open to different interpretations by different 
health care systems.
PHP173
NICE STA DECISIONS: AN ANALySIS OF HOw ADvICE DIFFERS BETwEEN 
PRELIMINARy AND FINAL GUIDANCE
Murray G., McLeod C., Howells R.
Abacus International, Manchester, UK
Objectives: The National Institute for Health and Care Excellence (NICE) estab-
lished the Single Technology Appraisal (STA) programme to evaluate the clinical 
and cost-effectiveness of medical technologies and provide mandatory guidance 
on how they should be used within the National Health Service (NHS) in the UK. The 
objective of this analysis is to explore how NICE advice differs between preliminary 
and final guidance in the STA process and identify actions manufacturers could 
take to increase their chances of a successful submission. MethOds: For STAs 
published between February 2010 and May 2013, the appraisal consultation docu-
ment (ACD) and final appraisal determination (FAD) were identified. The guidance 
issued in these documents was compared and contrasted, and the key clinical and 
economic evidence that affected recommendations were extracted into an Excel 
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the assessments with an ASMR I, II or III. 70% (n = 49) of the remaining evaluations 
where ASMR IV or V. cOnclusiOns: In the first six years mAbs were perceived as 
a disruptive innovation to a significant proportion of ASMRs between I and III as 
a reward for research and development efforts of the manufacturer. This research 
suggest that mAbs manufacturers no longer benefit from a ‘first mover’ advantage 
and may face higher scrutiny from the TC and greater price pressure from the 
French pricing committee.
PHP180
HEALTH TECHNOLOGy ASSESSMENTS OF MEDICAL DEvICES: IS HELP OUT 
THERE?
Green W., Wood H.
University of York, York, UK
Objectives: Small-Medium Enterprises (SMEs) should assess the potential profit-
ability of new medical devices early in their development. This can be achieved 
via early-stage health technology assessments (HTAs). However, many SMEs 
will not have the skills necessary to undertake these HTAs, so tools and frame-
works that aid this process are likely to be beneficial. A systematic review of the 
literature was undertaken to identify resources that can facilitate early-stage 
HTAs. MethOds: Electronic databases, such as MEDLINE and ECONLIT, were 
searched in February 2013. Papers were included if they met all of the five selec-
tion criteria used. Results: Of the 4729 papers identified, ten were included in 
the final analysis. Only one interactive tool, a decision analytic model which is 
operational via Microsoft Excel, was identified. Of the remaining nine articles, five 
were classified as frameworks. Of these five articles, the most comprehensive out-
lines a multi-criteria decision analysis (MCDA) value matrix. The final three articles 
included in the final analysis contained descriptive methods with information that 
was considered useful. cOnclusiOns: The resources available to aid the undertak-
ing of early-stage HTAs is very limited. Ideally, an interactive spreadsheet tool that 
generates intuitive results would be available. However, the one identified tool is 
too inflexible and most users would struggle to find accurate data to populate it. 
Unfortunately, these issues are likely to be endemic to any interactive tool for early 
modelling. As such other guidance, including frameworks, may be more useful if 
they are comprehensive. Only the MCDA framework article contained methods that 
the authors of this article considered comprehensive, and the use of MCDA for early-
stage HTAs has its own issues. Therefore, there may be a place in the literature for 
more complete pieces of guidance to undertaking early-stage HTAs.
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THE NICE MEDICAL TECHNOLOGy EvALUATION PROGRAMME (MTEP) – 
INSIGHTS FOR MANUFACTURERS CONSIDERING NOTIFICATION
McLeod C.1, Howells R.1, Harrison L.2
1Abacus International, Manchester, UK, 2Abacus International, Bicester, UK
Objectives: The Medical Technologies Evaluation Programme (MTEP) was 
established to promote the uptake of innovative medical technologies through the 
publication of Medical Technology Guidance (MTG) by the National Institute for Health 
and Care Excellence (NICE) to the National Health Service (NHS) in the UK. The objec-
tive of this analysis is to report data on the MTEP, which are not currently collated 
on the NICE website, in order to provide insights to manufacturers on the process, 
outcomes and implementation of guidance. MethOds: Information published on 
the NICE website was used to identify notified technologies, the proportion routed to 
the MTEP, and the subsequent NICE recommendations. Results: Between January 
2010 and December 2012, 102 technologies were notified to the MTEP. Of these noti-
fications, 21 technologies were routed to MTEP and 15 were routed to the diagnostics 
assessment programme (DAP), giving a routing rate of 20% and 15%, respectively. Of 
the 21 technologies routed to MTEP, 13 technologies have had guidance issued: 10 
(77%) had a positive recommendation and 3 (23%) were not recommended for use in 
the NHS. Whilst a positive recommendation for use is likely to encourage uptake, it is 
not guaranteed. Following a positive MTEP recommendation for CardioQ-oesophageal 
doppler monitor (ODM), the implementation levels were relatively low (31% increase 
in use). cOnclusiOns: Many of the notified technologies are not selected at notifi-
cation stage. However, once selected and routed to MTEP, most technologies receive 
some form of positive recommendation. Evidence on implementation levels following 
a positive recommendation by the NICE MTEP indicates that the implementation of 
guidance by the NHS may not always be optimal. The new NICE Health Technology 
Adoption Programme should help to improve implementation levels in the future. 
To ensure optimal implementation, manufacturers should consider developing tools 
to support the uptake of technologies alongside a NICE positive recommendation.
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NUMBER OF SUBMISSIONS NEEDED TO REACH A POSITIvE REIMBURSEMENT 
DECISION FROM SMC, CADTH, AND PBAC
Jaksa A., Ho Y.S., Daniel K.
Context Matters, Inc., New York, NY, USA
Objectives: Often positive reimbursement decisions are only achieved after 
multiple submissions. Multiple submissions can delay patient access to neces-
sary therapies and be costly for the manufacturer. This study analyzes the number 
of submissions needed to gain a positive decision and determines the lag time 
between the first submission and the positive decision. MethOds: The data cov-
ered three agencies: SMC, PBAC, and CADTH’s Common Drug Review. The reviews 
spanned 23 disease conditions and included 396 Health Technology Assessments 
(HTAs). Results: A positive decision was achieved after the first submission in 50% 
of the HTAs analyzed. At 1.57 submissions, PBAC had the highest average number of 
submissions needed to achieve a positive decision. PBAC’s average was statistically 
higher than that of both CADTH and SMC (p< 0.001). On average, CADTH and SMC 
needed 1.17 and 1.16 submissions, respectively, to obtain a positive decision. Also, 
for drugs that were resubmitted, it took on average 430, 924 and 1,189 days to gain a 
positive decision from SMC, CADTH, and PBAC. For CADTH and SMC, there appears 
to be a modest linear relationship between the number of resubmissions needed 
ies, as well as demonstrating homogeneity and consistency among studies. Regarding 
to the statistical analysis, Bucher’s method is the most commonly used and is recom-
mended by most HTA bodies for indirect comparisons. Nevertheless, some HTA bodies 
(e.g. HAS, SMC), EUnetHTA and ISPOR Task Force on Indirect Treatment Comparisons 
consider that even if some direct evidence is available it is appropriate to validate the 
results using MTCs. According to these institutions, Bucher’s method is not appropri-
ate for the analysis of complex networks, while Bayesian approach is a more com-
prehensive method that can include meta-regression and study-level covariates. The 
use of the non-appropriate methods can derive to biased results. cOnclusiOns: 
Methodology used for NMA should include all available evidence. Due to the increas-
ing complexity of network patterns, Bayesian analysis better meets HTA needs than 
the Bucher’s method, and is also a stronger evidence-deriving tool.
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SCANDINAvIAN DRUG REIMBURSEMENT AND COvERAGE DECISIONS: THE ROLE 
OF HTA
Grepstad M.L.1, Kanavos P.2
1London School of Economics and Political Science, London, UK, 2London School of Economics and 
Political Science, London, UK
Objectives: To examine and explain differences and similarities in coverage 
decisions for outpatient pharmaceuticals in Denmark, Norway and Sweden, and 
to provide a better understanding of the current and future role of HTA in these 
countries. MethOds: A comparative analysis of all outpatient drug appraisals 
carried out between 2009 and 2012, including an analysis of divergent coverage 
decisions for outpatient drug-indication pairs appraised by all three countries was 
performed. Agreement levels between HTA agencies were measured using kappa 
scores. Primary data collection through consultation with decision makers and 
academics in the three countries was carried out to obtain insight on how coverage 
decisions are made and why reimbursement outcomes differ in the three coun-
tries. Results: A total of 19 outpatient drug-indication pairs appraised in each of 
the three countries were identified, of which six pairs (32%) had divergent coverage 
decisions. An uneven distribution of coverage decisions was observed, with the 
highest number of overlap in appraisals in Norway and Sweden (freemarginal kappa 
0.89). Similarities were found in the criteria for reimbursement and the reasoning for 
coverage decisions. Differences in the appraisal methods applied and the interpreta-
tion of the evidence considered may explain divergent decisions. cOnclusiOns: 
The study suggests that Norway and Sweden employ similar methods for outpatient 
drug appraisals and have less divergent reimbursement outcomes, while health 
economic evaluation is less prominent in Danish outpatient drug appraisal, leading 
to a lower percentage of reimbursements with restrictions or criteria.
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THE IMPORTANCE OF SAFETy ASPECTS IN THE AMNOG PROCESS IN GERMANy: 
IS THE G-BA ASSESSMENT CONSISTENT wITH THAT OF THE CHMP?
Kuphal L., Witt B., Volmer T.
SmartStep Consulting GmbH, Hamburg, Germany
Objectives: To assess the role of safety aspects in the overall AMNOG benefit 
assessment in Germany. Special attention was given to two aspects: (1) Are adverse 
events (AE) used systematically to change the benefit assessment in any direction? 
(2) Are safety aspects considered in the assessment in accordance with the scien-
tific CHMP opinion? MethOds: Twenty-six benefit assessments decided and pub-
lished by the Federal Joint Committee (G-BA) between Jan 1st 2011 and Jun 6th2013 
were analyzed regarding the extent of harm. For each drug the extent of harm 
included with the consecutive influence on the overall benefit rating including 
potential changes in the overall rating scores was determined. Additionally, the 
safety aspects considered in the G-BA decision were compared to the CHMP assess-
ments. Results: For 19 of 26 drugs (73.1%), a greater or less harm vs. the compara-
tor determined by the G-BA was considered. In 12 of these 19 substances (63.2%) the 
rating of the additional benefit drawn from efficacy results remained unaltered due 
to safety aspects. In 5 procedures (26.3%) the G-BA rated the additional benefit solely 
on the basis of less harm vs. the comparator. In 2 procedures (10.5%) the G-BA found 
a greater harm vs. the comparator which negatively impacted the overall rating. 
Statistically significant results of ‘overall incidence of AE’, ‘AE grade 3-4’, ‘serious AE’ 
and ‘AE leading to study withdrawal’ were always considered by the G-BA. In 8 cases 
(42.0%), the G-BA weighted safety aspects differently from the EMA in its overall 
rating process. cOnclusiOns: The AE profile is of major importance in the AMNOG 
process. It changed in more than one third of the drug assessments (7 cases; 36.8%) 
the efficacy based benefit ratings. In 8 cases (42.0%) the G-BA assessment deviated 
from the conclusions considered by the EMA.
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ARE MONOCLONAL ANTIBODIES STILL CONSIDERED AS INNOvATIvE By THE 
FRENCH HEALTH CARE SySTEM? A RETROSPECTIvE ANALySIS 2000-2012
Conti C.C.1, Kostakis A.1, Furniss S.J.2
1GfK Bridgehead, London, UK, 2GfK Bridgehead, Melton Mowbray, UK
Objectives: To understand the dynamics of the Transparency Committee (TC) 
assessments of monoclonal Antibodies (mAbs) through the improvement in ther-
apeutic benefit (known as “ASMR”) ratings from 2000 to 2012. ASMR ratings are 
divided into two main groups by the French health care system. ASMR I to III allow 
manufacturers to notify price to the pricing committee based on the innovative 
character of the product and on the improvement provided over standard of care. 
This allows pricing at the “European” level. ASMR IV and V are given to non-inno-
vative products adding at best minor improvement to standard of care. MethOds: 
mAbs (excluding radiotherapeutics) online published reports from the TC from 2000 
to 2012, including new indications and reassessments, were analysed. The TC has 
evaluated a total of 26 mAbs, leading to 105 ASMR ratings during the period stud-
ied. Results: From 2000 to 2006, 83% (n = 29) of the TC evaluations of mAbs led 
to ASMR I, II or III and only 17% of the TC evaluation lead to ASMR IV or V (n = 6). 
During the following period, from 2006 to 2012, the TC granted only 30% (n = 21) of 
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comes to the choice of the method of analysis. Cases of disagreement between 
G-BA and IQWiG are rarer in this area. In the case of Belimumab, the manufacturer 
chose to demonstrate the additional benefit by showing the add-on effect of the 
agent on-top of the appropriate comparator and not against it. This resulted in 
diverging benefit assessment by IQWiG and G-BA. cOnclusiOns: The analysis 
of the assessment for all new active agents shows disparities between the assess-
ments of all parties involved. The AMNOG legislation has been in place for about 
two years and still, there are uncertainties in the choice of patient-relevant end-
points, comparators and method of analysis in the German benefit assessment 
process. Discussion is necessary to resolve diverging expectations about required 
methods and following assessments.
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THE IMPACT OF COST EFFECTIvENESS ON REIMBURSEMENT APPROvALS IN 
FRANCE: A COMPARISON OF FRANCE AND THE UNITED KINGDOM
Purchase J.L.1, Nijhuis T.2
1Quintiles, Reading, UK, 2Quintiles, Hoofddorp, The Netherlands
Objectives: To estimate the potential impact of the new health economic assess-
ment requirement on innovative products that came into law in October 2012 in 
France, by comparing the outcomes of recent Health Technology Assessments 
(HTA) in France (HAS) and the UK (NICE, SMC, AWMSG, JCVI). The hypothesis is 
that reimbursed products that achieved a high benefit score in France may have 
been rejected if the health economic case had to be demonstrated, as is required in 
the UK. MethOds: A search was conducted to identify all therapies evaluated by 
HAS which were given a significant, important or moderate therapeutic improve-
ment score (ASMR I, II or III) between January 2010-June 2013. We then identified 
the assessments of the same product in the UK and compared the outcome of the 
assessment and the role of the economic evidence that was submitted. Results: 
Thirty-six therapies rated an ASMR I-III by HAS were found. Out of these 36, 19 
products had not (yet) been evaluated in the UK. For the remaining 17 that had 
been assessed by both countries, only one was not recommended by at least one of 
the UK agencies. NICE’s primary reason for rejecting the said intervention was due 
to the ‘clinical and cost effectiveness’. Similarly the SMC stated the economic case 
of the drug had ‘not been demonstrated’, and the long term clinical effect remains 
unknown. cOnclusiOns: Initially, it doesn’t appear that economic evaluations 
based on QALYs considerably influence the outcomes of HTAs. Only one assessment 
was rejected by both UK agencies based on economic grounds but was awarded an 
ASMR III. Since most products have been endorsed by the UK agencies, the French 
system’s incorporation of health economics will not necessarily be an additional 
hurdle that cannot be overcome.
PHP187
wEB-BASED OF TOPIC SELECTION FOR COMPARATIvE EFFECTIvENESS 
RESEARCH IN KOREA
Kim H.S., Lee D.S., You J.H.
National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea
Objectives: As the only health technology evaluation institution in Korea, National 
Evidence-based Healthcare Collaborating Agency has made efforts to establish the 
topic selection model of comparative effectiveness research which corresponds to 
Korean situations in order to revitalize it since 2012. MethOds: As a result of pre-
paring thetopic selection process of the comparative effectiveness research accord-
ing to these efforts and of conducting model operations in 2012, solution to access 
to the proposal process of research topics and a close examination of research 
methodologies was proposed as improvement point. Results: Accordingly, web-
based research topic proposal systems(www.necacer.re.kr) were designed in order 
to solve access to the proposal process of research topics and to increase trans-
parency of the early stage of research in 2013. To make a close examination of 
the possibility of research performance in multidisciplinary fashion, evaluation 
systems of three stages were divided to operate but web-based design which is the 
same as topic proposal systems was done reflecting the evaluator’s geographical 
access etc. Concretely, web-systems for topic proposal are composed of writing 
proposed research topic, writing proposed content of a topic, and confirming and 
submitting stages after writing basic information after login, and evaluative web 
systems were composed as follows: Step 1 is composed of quantitative evalua-
tion based on 6 standards, step 2 qualitative evaluation based on 6 standards, and 
step 3 investigation process based on 4 standards in relation to research topics 
refined. cOnclusiOns: It is conceived that Korean web-based topic selection sys-
tems of comparative effectiveness research prepared systematically taking Korean 
situation into consideration will be able to contribute to improving qualitative 
aspects of research and enhancing researchers’ credibility by transparent opening 
the whole process of proposing, selecting and confirming topics.
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RELEvANCE OF INDIRECT COMPARISONS IN THE GERMAN EARLy BENEFIT 
ASSESSMENT (AMNOG)
Lebioda A.1, Gasche D.1, Dippel F.W.2, Plantör S.1
1IMS Health GmbH & Co. OHG, Munich, Germany, 2Universität Leipzig, Leipzig, Germany
Objectives: Early benefit assessment in Germany under the AMNOG legislation 
requires a direct comparison with the appropriate comparator determined by the 
Federal Joint Committee (G-BA). In case no head-to-head studies are available, sub-
mission of indirect comparisons is permitted to assess the additional benefit of the 
new drug. The aim of this study was to comprehensively analyze the submissions 
of indirect comparisons reviewed so far by the Institute for Quality and Efficiency 
in Health Care (IQWiG) from January 2011 until May 2013. MethOds: A systematic 
review of all 48 published assessment reports was performed. Results: There is 
a mismatch between the original intention of the early benefit assessment and 
its actual outcome. Until May 2013, 14 indirect comparisons have been conducted 
and submitted by manufacturers regarding the early benefit assessment. Only one 
indirect comparison has been accepted in a subindication by the IQWiG. However 
to obtain a positive decision and the number of unique drugs reviewed within the 
disease condition (r= .46 and .41, respectively). This relationship was not observed 
for PBAC (r= 0.01). cOnclusiOns: PBAC required a greater number of submissions 
to gain a positive decision and the lag time to a positive decision is longer compared 
to SMC and CADTH. The number of submissions needed to gain a positive decision 
by CADTH and SMC were similar, but CADTH’s lag time was double that of SMC. For 
both SMC and CADTH, the number of drugs reviewed in a disease condition was 
positively correlated with the number of times a drug had to be submitted in order 
to gain a positive decision.
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DRAFT vERSUS FINAL GUIDANCE IN NICE’S DRUG TECHNOLOGy APPRAISAL 
PROCESS
McGee M.A.1, Izmirlieva M.2, Ando G.2
1IHS Global Insight, London, UK, 2IHS, London, UK
Objectives: The study sought to establish the pattern by which draft versus final 
technology appraisal’s (TA) for drugs have been issued by UK’s NICE. In particular, 
the study focused on variations between the draft versus final guidance, and the 
rationale for any changed recommendations during the appraisal process. MethOds: 
The current study is based on a review of NICE’s 13 draft guidance and subse-
quent final guidance issued over the time period from November 2010 to mid June 
2013. Results: NICE issued five recommendations, four rejections and four rec-
ommendations subject to restriction, on drugs for use within the NHS in England 
and Wales. Four out of the five final recommendations had been overturned from 
an initial non- recommendation, to gaining a positive decision in final guidance. 
Meanwhile, all four final rejections corresponded to the recommendations made in 
its respective draft guidance. With one exception, all recommended drugs had an 
ICER below GBP30,000. None of the drugs rejected in the final guidance had a Patient 
Access Scheme offered. cOnclusiOns: One-third of the 13 decisions were positive 
recommendations, a trend that is significantly lower than the average between 1 
March 2000 to 31 May 2013, when 62% of TA’s gained a positive final recommendation. 
Aside from clinical issues, the overriding rationale for the rejections were attributed 
to the high ICERs, coupled with the lack of PAS. This is compared to the case of, for 
example, ipilimumab, where a PAS offered in the final guidance lowered the ICER 
from GBP54,000 - GBP70,000 per QALY gained to GBP42,200 and essentially overturned 
NICEs initial non-recommendation. As seen in half of the initial rejections, NICE has 
overturned several decisions in favour of the manufacturer prior to final guidance.
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ACCEPTANCE OF SURROGATE ENDPOINTS By HTA AGENCIES IN EUROPE
Es-Skali I.J., Nijhuis T.
Quintiles, Hoofddorp, The Netherlands
Objectives: To compare how different European HTA agencies assess surrogate 
endpoints to demonstrate efficacy. MethOds: We identified 8 therapies with sur-
rogate endpoints that were evaluated in the last 6 years by NICE and/or SMC (UK), 
HAS (France) and G-BA (Germany). The acceptability of the use of surrogate end-
points and any specific comments made by these agencies were analysed. Results: 
Commonly used surrogate endpoints such as glycated haemoglobin (HbA1c) in 
diabetes, progression free survival (PFS) in oncology and forced expiratory volume 
(FEV1) for respiratory diseases have been generally accepted as sufficient evidence 
to gain reimbursement by HTA agencies. Especially when a surrogate endpoint 
has been accepted by EMA, it is usually considered a valid outcome measure. Less 
well-accepted were several surrogate cardiovascular endpoints such as 6 minute 
walk test, blood pressure and LDL cholesterol. For G-BA it is important that sur-
rogate endpoints have been properly validated and are patient relevant but they 
did accept endpoints such as sustained virological response (SVR) for hepatitis 
treatments, FEV1 and body mass index (BMI) based on minor evidence. NICE and 
SMC also strongly value evidence to demonstrate the correlation between surro-
gate endpoints and clinical outcomes. Interestingly SMC has recently become more 
cautious in accepting widely established endpoints such as HbA1c. With regards 
to the HAS, they often did not comment on the use of surrogate endpoints at all 
in their published reports. cOnclusiOns: The use of surrogate endpoints in the 
assessment of clinical benefit is still controversial; however, attempts are made to 
establish clearer regulations such as the recently published EUnetHTA guidelines 
regarding surrogate endpoints. In the absence of evidence on final patient-relevant 
clinical endpoints, several commonly used biomarkers and intermediate endpoints 
will be considered as valid surrogate endpoints by HTA agencies. Newer, less estab-
lished surrogate endpoints will be more subject to strict validation requirements.
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A COMPARISON OF GERMAN BENEFIT ASSESSMENTS By G-BA, IQwIG AND 
MANUFACTURERS
Eheberg D.1, Lebioda A.2, Hülsebeck M.2, Plantör S.2
1IMS Health, Munich, Germany, 2IMS Health GmbH & Co. OHG, Munich, Germany
Objectives: In the German HTA process (AMNOG) the choice of the patient-
relevant endpoint, the appropriate comparator and the method of analysis are 
known to be decisive for the G-BA’s resolution of an additional benefit. Therefore, 
we aimed to analyze differences between manufacturer’s dossiers and G-BA / 
IQWiG assessments. MethOds: The analysis will take into account all completed 
AMNOG assessment procedures. We analyzed all G-BA resolutions in compari-
son to IQWiG assessments and the manufacturer. Results: One major point of 
discrepancies occurred in the declaration of patient-relevant endpoints. By June 
2013, 58 surrogate endpoints were declared by IQWiG and manufacturers mainly 
in the indications oncology, infectious diseases and diabetes. The G-BA clearly 
states that only valid patient relevant endpoints are to be considered. However, 
there remains uncertainty around the term “patient-relevant” and which criteria 
have to be met for the IQWiG to accept an endpoint as patient-relevant. To date, 
54 comparisons were made in the dossiers to show an additional benefit of a new 
agent. The pharmaceutical manufacturer and the IQWiG often disagree when it 
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Classification) group of drugs was prescribed. Our composite health index, CHI, 
is a coverage-weighted average of the separate indices we construct for persons 
covered by each community drug scheme in each region. Results: Respiratory 
health status varies most across Irish regions but Cardiovascular, Central Nervous 
System and ‘Other’ health conditions have higher CHI weights and contribute more 
to overall regional health disparities. The Midlands region had the poorest health 
status in 2010 (8% below the national average); the Eastern region had the best 
(6% above average), followed closely by the Mid-West. The Mid-West has a better 
health status than the Midlands despite having lower income and a larger elderly 
population share. The health status of the Eastern region is just 2% higher than the 
Mid-West even though its income is 6% higher and the percentage of its population 
aged over 65 is 1.8 percentage points lower. Simple economic and demographic 
variables - mean income and the elderly population share – correlate well with 
health status. cOnclusiOns: Our index maps significant regional disparities and 
paves the way for complementary epidemiological studies to trace their underlying 
lifestyle and medical causes and inform regional health policy.
HEALTH CARE USE & POLICy STUDIES – Prescribing Behavior & Treatment 
Guidelines
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FEASIBILITy OF MEDICINES REvIEw TO REDUCE POTENTIALLy INAPPROPRIATE 
MEDICINES IN THE ELDERLy: THE OPTI-SCRIPT CLUSTER RANDOMIzED 
CONTROLLED TRIAL
Clyne B.1, Hughes C.2, Smith S.M.1, Fahey T.1
1Royal College of Surgeons in Ireland, Dublin, Ireland, 2Queens University Belfast, Belfast, UK
Objectives: Potentially inappropriate medicines (PIMs) can result in increased 
morbidity, adverse drug events and hospitalizations. Polypharmacy is the strongest 
predictor of PIMs,the prevalence of which was 36% in 2007 in those aged ≥ 70 years 
, with an associated expenditure of over € 45 million. Medicines review may have 
the potential to improve patient outcomes and reduce prescribing costs. This study 
aims to assess the feasibility of introducing medicines review to reduce PIMs in older 
patients. MethOds: OPTI-SCRIPT is a cluster randomized controlled trial (RCT), that 
aims to assess the effectiveness of a complex intervention incorporating academic 
detailing, a medicines review with web-based pharmaceutical treatment algorithms 
that provide recommended alternative treatments, and tailored patient information 
leaflets in reducing PIMs. A qualitative evaluation is being conducted to determine the 
feasibility and acceptability of the intervention. Results: Twenty-one GP practices 
(response rate 32.3%) participated. Identifying patients with a PIM required consider-
able time and expertise. Practices screened all patients aged ≥ 70 years to identify 
those suitable to participate. A pharmacist reviewed their repeat medications, identi-
fying patients with a PIM who were then invited to participate. Despite being offered 
a once off review of their current prescriptions with their GP, only 37.4% (196) agreed 
to participate. Preliminary qualitative findings indicate that intervention group GPs 
valued the review process as an opportunity to reflect on their prescribing practice. 
Some GPs highlighted that conducting routine structured reviews with older patients 
wouldn’t be feasible due to the time, resources and funding available to them cur-
rently in primary care. Participating patients placed a high value on their medicines 
review. cOnclusiOns: Preliminary findings illustrate that implementing a system of 
structured reivews for older patients with a PIM is challenging. However, participating 
GPs and older patients saw the value of conducting medicines reviews, but formal 
resourcing of such services would need to be considered.
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USE OF CLINICAL PRACTICE GUIDELINES By PHySICIANS IN jAPAN
Shimbo T.1, Suzuki T.1, Takahashi O.2, Tanaka Y.1
1National Center for Global Health and Medicine, Shinjuku-ku, Japan, 2St.Lule Life Science 
Institute, Chuo-ku, Japan
Objectives: The present study aimed to determine the proportion of physicians 
in Japan who use clinical practice guidelines, as well as factors influencing this 
choice. MethOds: We conducted an on-line cross-sectional survey throughout 
Japan on general internists, gastroenterologists, cardiologists, endocrinologists and 
general surgeons, including gastrointestinal or breast surgeons, who registered for 
marketing research. Questions addressed their usage of CPGs in practice, education, 
and research, as well as their attitudes toward CPGs. We then investigated associa-
tions between usage and characteristics of the respondents. Results: We received 
responses from 1342 physicians, 1222 (91.1%) of whom were male (mean age (SD), 46.5 
(9.6) years). The proportion of respondents who always or often use CPGs in several 
practice settings, such as when providing explanations to patients based on CPGs, 
ranged from 27.7% to 54.6%. Among them, 822 respondents (61.3%) applied 1 to 4 CPGs, 
and 381 (28.4%) applied 5 to 9. Usage differed according to age group, subspecialty, 
and workplace. After multivariate adjustment, the mean probability (95% confidence 
interval) of a high usage of CPGs when providing explanations to patients was 65% 
(60% - 71%) and 40% (30% - 50%) for those aged < 40 y and ≥ 60 y, respectively, 44% 
(38% - 50%) for general internists, 65% (59% - 71%) for surgeons, and 51% (46% - 57%) 
and 65% (58% - 72%) for those working in clinics and university hospitals, respectively. 
Attitudes towards the trustworthiness and convenience of CPGs were associated 
with usage, although this was unable to explain all differences in usage among sub-
groups. cOnclusiOns: A substantial proportion of Japanese physicians use CPGs 
in clinical practice. Age, subspecialty, and workplace were independently associated 
with CPG usage. This should be considered during the process of CPG implementation.
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SySTEMATIC REvIEw ON USE OF ECONOMIC EvIDENCE By CLINICAL 
GUIDELINES
Aggarwal S., McGrane M., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
Objectives: The recent reforms and policy changes have increased the cost pres-
sures on all health care stakeholders, including clinical experts. In the past, clini-
the results did not cause an added value of the drug in this respective application. 
In seven cases the indirect comparison was declined due to a different comparator 
as determined by the G-BA. Three indirect comparisons were declined because of 
methodological deficiencies and another three indirect comparisons were declined 
because non-adjusted indirect comparisons were performed. cOnclusiOns: The 
IQWiG only accepts adjusted indirect comparisons. The application of the correct 
methodology is necessary to gain valid results and shall not be questioned. The 
IQWiG approach is accurate with regard to contents and correct in a legal sense. 
However the procedure shows, that the external preconditions and methodologi-
cal requirements are demanding and almost impossible to fulfill. Main reason for 
denial is the divergence from the prespecified appropriate comparator set by the 
G-BA. To get back to the original aim of the early benefit assessment, a more realistic 
and reasonable determination of the appropriate comparator would be desirable.
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THE ADOPTION OF HEALTH TECHNOLOGIES: A SURvEy OF BRAzILIAN POLICy 
MAKERS
Elias F.T.S.1, Souza K.M.2, Silva M.T.3, Willer A.C.D.M.4, Gonçalves L.5
1Oswaldo Cruz Foundation MoH, Brasília, Brazil, 2Brazilian MoH, Brasilia, Brazil, 3Brazilian 
Ministry of Health, Brasília, DF, Brazil, 4CNPq, Brasília, Brazil, 5Brazilian Ministry of Health, 
Brasília-DF, Brazil
Objectives: Policy makers of municipalities decided to adopt health technol-
ogy into the Brazilian Public Health System (SUS). This group met during national 
conferences. The last conference, “The XXVIII National Congress of Municipal 
Health Secretariats (CONASEMS)”, took place during June 11 to 14, 2012. The aim 
was describe the views of participants at the CONASEMS event regarding technol-
ogy assessment criteria for the Brazilian Public Health System (SUS). MethOds: 
A survey applied at the Ministry of Health’s exhibition booth, June 11 to 14, 2012. 
Three variables were studied for the survey: “Participant Profile”, “Knowledge of 
Health Technology Assessment for Adoption by the SUS” and pre-selected criteria for 
assessing health technologies (where 1= most important and up to 9= least impor-
tant) Results: The survey encompassed 5.6% (244/4.328) of all conference partici-
pants. Of these, 43% represented policy makers; 35% health professionals and 22% 
others. Of the total amount of participants, 67% have little or average knowledge of 
HTA and 14% declared having no knowledge of the area. The values in the adoption 
of health technologies were ranked by delegates. The score of one was: evidence on 
patient safety, improved quality of life and patient survival, impact on the popula-
tion’s health. The score nine was: relationship between benefits and costs, health 
system costs and patient costs. cOnclusiOns: Considering the results, the value 
related to criteria regarding quality of life and survival were the most important in 
detriment to cost criteria. It is important to involve the Brazilian Network for Health 
Technology Assessment (REBRATS) as an additional contribution to the application 
of the new Brazilian law regarding the incorporation of health technologies.
PHP190
ORPHAN DRUGS IN THE GERMAN EARLy BENEFIT ASSESSMENT– REAL wORLD 
vERSUS G-BA BUREAUCRACy
Lebioda A., Hülsebeck M., Plantör S.
IMS Health GmbH & Co. OHG, Munich, Germany
Objectives: Early benefit assessment pursuant to AMNOG was introduced to cut 
costs and illustrate the additional benefit of new pharmaceuticals including orphan 
drugs at launch in Germany. In this process orphan drugs have a special status. The 
EMA orphan drug designation implies the assumption that at least a not-quanti-
fiable additional benefit is set by law. However the extent of the additional benefit 
still has to be demonstrated by the manufacturer. MethOds: By June 2013 seven 
orphan drug dossiers have been submitted and assessed. Only one product has been 
admitted an important additional benefit. Four substances had a minor additional 
benefit and two substances had a not-quantifiable additional benefit. Results: An 
additional benefit needs to be proven against a comparator. But the G-BA will not 
define an appropriate comparator as for non-orphan drugs. Instead, the assessment 
of orphan drugs is based on the pivotal trial; the comparator will be derived from 
this trial. Due to the early phase of pivotal trials in rare diseases, using a compara-
tor is not common. Furthermore, phase II trials often do not meet requirements in 
terms of evidence level requested: randomized controlled trials with large patient 
populations are unusual in orphan diseases as well as investigation of valid patient 
relevant endpoints or validated surrogate endpoints. cOnclusiOns: The G-BA 
requirements for HTA assessments are drawn from phase III trials and demonstra-
tion of an additional benefit over an appropriate comparator, which also serves as 
price benchmark. The requirements derived for all newly launched products do not 
reflect orphan drug reality, which is indication and not agent based. In summary 
the EMA declaration of early admission of orphan drugs in phase II conflicts with 
the G-BA’s methodological requirements for the quantification of an additional 
benefit. In fact, manufacturers of orphan drugs face an additional barrier before 
launch in Germany.
HEALTH CARE USE & POLICy STUDIES – Population Health
PHP191
vARIATIONS IN THE HEALTH STATUS OF IRISH REGIONS
Kenneally M., Lynch B.
University College Cork, Cork, Ireland
Objectives: This paper constructs a composite index that is sufficiently compre-
hensive to rank the overall health status of Irish regions and sufficiently detailed to 
identify the principal sources of varying regional health status. MethOds: We draw 
on the CSO (Central Statistics Office), PCRS (Primary Care Reimbursement Service) 
and IPH (Institute of Public Health) health and medicines databases to construct 
a composite index of the health status of the 8 HSE regions in Ireland in 2010. Our 
composite health index (CHI) has 6 component indices. Each maps the regional 
prevalence of major health conditions for which an ATC (Anatomical Therapeutic 
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significantly reduced by using the ETHICON SECURESTRAP™ Open fixation device 
compared with suture fixation of IPOM mesh. This shows promise of reducing open 
IPOM procedure time which may realize related patient benefits of reduced anesthe-
sia time, infection risks, costs etc. Also, reduction in surgical stress could potentially 
offer improvement in surgical performance – benefiting the surgeon, the patient 
and the health care system.
HEALTH CARE USE & POLICy STUDIES – Regulation of Health Care Sector
PHP198
COST SAvINGS IN THE HUNGARIAN CARE MANAGING PROGRAMME
Ágoston I., Vajda R., Jankó-Király A., Lampek K., Boncz I.
University of Pécs, Pécs, Hungary
Objectives: A pilot care managing programme was introduced in Hungary in 1999. 
The conceptual foundations of the Hungarian implementation of managed care is 
closer to what was called the GP fundholding in the UK than HMOs in the USA. The 
purpose of the study is to analyse the cost savings realized within the Hungarian 
care managing programme. MethOds: The data derive from the financial data-
base of the Hungarian National Health Insurance Fund Administration (NHIFA) 
covering the period 1999-2007. We identified the annual cost savings realized by 
the Care Managing Organizations. The Hungarian CMOs was financed through 
a risk adjusted capitation fee and the health services covered by CMOs were 
defined in legal regulations. Cost saving was defined as the difference between 
the annual revenues (capitation fee) and expenditures (real utilization) of care 
managing organizations. Results: During the study period the total number of 
persons covered by the care managing programme increased from 1.5 % of the 
Hungarian population to its peak of 19.4 % in 2005. The cost saving of the care 
managing programme was 63138000 Hungarian Forint (HUF) or 249756 Euro (EUR) 
in 1999; 457662600 HUF (1759945 EUR) in 2000, 1109442300 HUF (4322246 EUR) in 
2001; 2710926900 HUF (11157503 EUR) in 2002; 1452041100 HUF (5727683 EUR) in 
2003, 3799000306 HUF (15094804 EUR) in 2004; 3709400000 HUF (14954510 EUR) in 
2005; 4964600000 HUF (18786048 EUR) in 2006 and 3669000000 HUF (14599437 EUR) 
in 2007. These amounts resulted in the following annual savings rate: 1999: 3.6%; 
2000: 10.4%; 2001: 6.5%; 2002: 8.7%; 2003: 3.4%; 2004: 4.0%; 2005: 2.1%; 2006: 2.9% and 
2007: 2.9%. cOnclusiOns: With the development of the Hungarian care managing 
system, the average number of enrolees increased. Cost savings of Care Managing 
Organizations varied between 2.1-4.0 % during the mature period of this programme.
PHP199
SySTEMATIC REvIEw ON THE IMPACTS OF STRICT PHARMACEUTICAL PRICE 
CONTROLS
Relakis J.1, Maniadakis N.1, Kourlaba G.2, Shen J.3, Holtorf A.P.4
1National School of Public Health, Athens, Greece, 2National and Kapodistrian University of 
Athens School of Medicine, Athens, Greece, 3Abbott, Basel, Switzerland, 4Health Outcomes 
Strategies LLC, Basel, Switzerland
Objectives: To systematically review and synthesize published evidence on the 
impact of pharmaceutical price controls, such as price cuts, price caps, price freezes 
or international price referencing. MethOds: A literature search was conducted 
in Medline, Scopus, Econlit, Web of Science and ABI/INFORM to identify relevant 
studies published in English to March 2013. Results: Forty-seven out of 3787 initial 
studies were included. Price caps and price reductions were most commonly studied 
in the literature, followed by reference pricing and price freezes. The evidence indi-
cates that price controls reduce company profits and have a detrimental effect on 
pharmaceutical research and development, pipeline productivity and investment. 
They may also inhibit, reduce or delay new product launches, increase parallel 
exports and diminish availability of generics due to disincentives and, hence, may 
reduce product availability, increase withdrawals and shortages. In terms of public 
expenditure about half of the studies indicate realized savings, but the other half 
indicate no effect or even increases in expenditure. In terms of effects on patients, 
studies indicate in the short term welfare gains due to lower cost and better access, 
but also losses due to drug shortages and availability issues. Long-term effects 
appear to be welfare losses due to reductions of discoveries, resulting from the 
disinvestment associated with the lower revenues. cOnclusiOns: Effects of price 
controls are ambiguous in the case of pharmaceuticals. Price controls reduce drug 
acquisition cost and increase access in the short run. On the other hand, they may 
decrease patient welfare and access as they can cause product shortages, withdraw-
als and launch delays. Moreover, they may reduce the likelihood for new product dis-
coveries. Contrary to common beliefs, price controls not always reduce expenditure. 
Thus careful consideration is needed in designing drug price policies. Value based 
pricing approaches may be more effective alternatives compared to price cutting.
PHP200
GUIDANCE FOR PARTNERSHIP wORKING BETwEEN CATSALUT AND THE 
PHARMACEUTICAL INDUSTRy
Gilabert A., Espinosa C., Mora R., Santos J.
Catalan Autonomous Region Health Service, Barcelona, Spain
Objectives: Relationships between National/Regional Health care Systems (NHS) 
and pharmaceutical companies can and should be based on a cooperative venture, 
built on the expertise of each side, that best meets clearly defined public needs 
through the appropiate allocation of resources, risks and rewards, while preserv-
ing transparency and its independence. However, joint working can be difficult to 
initiate due to the number of parties involved and the lack of clear shared objec-
tives. Guidelines can be very useful to support the NHS/Pharmaceutical Partner’s 
commitment. To our knowledge, there are no such published guidelines in Spain. 
This first guidance in Spain was designed with the main aim of identifying and 
simplifying the initiation, the start-up phase and the remainder of joint working 
projects between the Catalan Heath System (CatSalut) and pharmaceutical com-
panies. MethOds: A flowchart was designed to describe the standard steps and 
timelines suggested to start, implement, monitor and evaluate a Joint Working pro-
cal guidelines were developed independent of cost or economic considerations. 
However, increasingly, more clinical guidelines are mentioning cost concerns and 
referring to economic data in new recommendations. The objective of this study was 
to analyze trends in the use of health economic information for developing clinical 
guidelines. MethOds: To understand trends in use of health economic information 
we conducted targeted search for clinical guidelines, expert recommendations, and 
consensus statements with specific mention of “cost” or “economic” or related terms. 
A systematic literature search was undertaken for the databases Pubmed, Google 
Scholar and Cochrane. The guidelines published between 2003-2012 were included. 
For guidelines which met the search criteria, data was collected for the name of the 
authors, indication, year of publication, country/region, and context of use of cost/eco-
nomic evidence. Results: Sixteen clinical guidelines published between 2003-2012 
met the inclusion criteria for specific mention of cost/economic evidence. More than 
50% of these guidelines were published between 2006-2012. For indication, 3 out of 
16 guidelines were for diabetes, while the rest were for different indications. In these 
16 guidelines “cost effectiveness” was mentioned 14 times, either referencing cost-
effectiveness data or to mention the importance of such data for selecting treatment 
options. The guidelines commonly cite high cost of disease or high economic burden 
as one of the considerations for developing new recommendations (11 out of 16). 
Another term that was commonly used by these guidelines was “cost-benefit,” which 
was mentioned 5 times in these guidelines. Notably, QALY was rarely mentioned (1 
out of 16 times) in these guidelines. cOnclusiOns: This analysis suggests that some 
clinical experts groups are increasingly showing willingness to use and incorporate 
health economic information for developing new recommendations.
PHP195
REASONS GIvEN By THE EUROPEAN MEDICINES AGENCy FOR REvISING 
DISEASE-SPECIFIC SCIENTIFIC GUIDELINES
Caron M., Acquadro C.
Mapi Research Trust, Lyon, France
Objectives: To review all the reasons provided by the European Medicines Agency 
(EMA) to substantiate the need for revisions to or updates of disease-specific scien-
tific guidelines developed by the Committee for Medicinal Products for Human Use 
(CHMP). MethOds: All the scientific guidelines issued by the CHMP were reviewed 
on the EMA’s website. The guidelines not focusing on disease-specific issues were 
not selected, i.e., guidelines listed in the following sections: Clinical Pharmacology 
and pharmacokinetics, General, Herbal Medicinal products, Information on medici-
nal products, and Radiopharmaceutical and diagnostic agents. Results: A total of 
182 disease-specific scientific guidelines were reviewed. The review identified 21 
concept papers developed with the intent of revision (11.5% of specific guidelines). 
The analysis of the concept papers revealed that four main reasons were claimed: 
1) Clarifications needed for pediatric development [10 concept papers: acute heart 
failure, asthma, Crohn’s disease, hepatitis C, hypertension, glucocorticoid-induced 
osteoporosis, irritable bowel syndrome (IBS), multiple sclerosis, pain, and ulcerative 
colitis); 2) Evolution in the field and treatments (n= 9); 3) Clarifications on endpoints 
identification and measurement (n= 7); and 4) Safety aspects (n= 6). For instance, 
in asthma, one of the critical aspects to be discussed regarding endpoints was “the 
need to reinforce the use of clinical measurements (symptoms) and patient-reported outcome 
measures to complement lung-function parameters.” In IBS, regulators asked that “An 
evaluation whether more clear recommendations as regards the use of certain 
scales or newly developed PROs can be made is also desirable.” cOnclusiOns: The 
main reason for the EMA to revise disease-specific guidelines is the need for provid-
ing guidance in pediatric issues. This is in line with the introduction of Pediatric 
Investigation Plans (PIPs) by the European Commission in January 2007 to help 
ensure that medicines for children are included in the mainstream drug develop-
ment process in Europe.
HEALTH CARE USE & POLICy STUDIES – Quality of Care
PHP197
REDUCTION IN FIxATION TIME AND RELATED SURGICAL STRESS wITH THE 
USE OF ETHICON SECURESTRAP™ OPEN ABSORBABLE STRAP FIxATION DEvICE 
IN THE DEPLOyMENT OF INTRA-PERITONEAL ONLAy MESH (IPOM) FOR OPEN 
vENTRAL HERNIA REPAIR
Roy S.1, Shnoda P.2, Savidge S.2, Hammond J.2, Panish J.1, Wilson M.3
1Johnson & Johnson Global Surgery Group, Somerville, NJ, USA, 2Ethicon, Somerville, NJ, USA, 
3University of Exeter, Exeter, UK
Objectives: This study compared fixation time using ETHICON SECURESTRAP™ 
Open device to suture fixation of IPOM mesh in ventral/ incisional hernia repair. It 
also assesses surgeon-reported levels of task load experienced during the two fixa-
tion approaches. MethOds: Nine surgeons inserted skirted mesh using IPOM tech-
nique on created incisional defects in live swine models. Each surgeon performed 
two suture (using their standard technique) and two ETHICON SECURESTRAP™ 
Open fixation procedures. The duration of fixation procedure starting from mesh 
preparation through the last firing or suture knot was recorded. Surgical work-
load was measured using the validated Surgery Task Load Index (SURG-TLX) 
questionnaire. Time savings and task load reduction were determined by the 
lower limit of the two-sided 95% confidence interval for the difference between 
suture fixation and ETHICON SECURESTRAP™ Open groups. Results: A total of 
38 IPOM fixation procedures were performed with equal numbers using suture 
and ETHICON SECURESTRAP™ Open. 89% reduction in mean fixation time was 
observed from suture to mechanical fixation with ETHICON SECURESTRAP™ Open 
[mean reduction: 34.9 minutes (SD: 17.9 minutes); p< 0.0001]. Similarly, 55% reduc-
tion in perceived overall workload was observed with SECURESTRAP™ Open com-
pared to suture fixation [mean reduction: 22.17 (SD: 15.12); p= 0.0003]. ETHICON 
SECURESTRAP™ Open demonstrated significantly lower ratings in five of the six ele-
ments of surgical task load, namely – Mental Demand, Physical Demand, Situational 
Stress, Task Complexity, and Temporal Demand [p< 0.05 for all] compared to suture 
fixation. cOnclusiOns: Time for fixation and related surgical task load can be 
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when and for what type of service use publicly financed health care. MethOds: 
Data was retrieved from National Health Insurance Fund Administration of Hungary 
(NHIFA) and Central Statistical Office. Current study’s base was processing the last 
five years’ statistical data (2007-2012), concerning health care of third country 
citizens permanently living in Hungary. We analyzed the volume, place and medi-
cal specialty of these services. Results: In the last 5 years third country citizens 
required inpatient care 9414 times (61% in Budapest), emergency care 11776 times 
(63% in Budapest), out-patient care 72306 times (57% in Budapest). Patient accessed 
health care providers due to medical problems in the following medical fields: 
obstetrics (19%), surgery (18%), laboratory (18%), pediatrics (7%), and ophthalmol-
ogy (6%). Most of the patients are from Ukraine (42 %), China (22 %), Vietnam (11 %), 
ex-Yugoslavia (6 %) and Russia (6 %). Analysis by nationalities shows that Chinese 
population requires health care relatively few times (for instance, 2011: 5%, in 2012: 
6%) and even these are almost exclusively done in Budapest. In contrast USA citizens 
see doctors relatively often (2011: 8%, 2012: 8%), mainly in relation to diagnostics and 
curative surgery. From the neighboring non-EU states (23095 people, 31%) Ukrainian 
and (5709 people, 7%) ex-Yugoslavian citizens needed health care in the investigated 
period. Despite previous expectations, need for health care is not the characteristics 
of border regions but the capital city. cOnclusiOns: Utilization of the Hungarian 
publicly financed health care system is significant by third country citizens. When 
planning health care capacity, this crucial fact must be taken into consideration.
PHP204
PHARMACEUTICAL REGULATION IN EUROPE AND ITS IMPACT ON CORPORATE 
R&D
Mahlich J.1, Eger S.2
1University of Vienna, Vienna, Austria, 2Medical University of Vienna, Vienna, Austria
Objectives: Many European countries regulate drug prices in order to cope with 
rising health expenditures. On the other hand, price regulation distorts incentives to 
invest in pharmaceutical R&D. This study aims at empirically assessing the impact 
of price regulation on pharmaceutical R&D expenditures. MethOds: We analyze 
a sample of 20 leading pharmaceutical companies between 2000 and 2008. The 
share of sales in Europe serves as a proxy for the degree of price regulation. We 
control for other determinants of R&D such as cash flow, company size, leverage 
ratio, growth rate, and Tobin’s q. Results: Our results suggest a nonlinear rela-
tionship between European sales ratio and R&D intensity. Beyond a threshold of 
33% of sales generated in Europe, a higher presence in Europe is associated with 
lower R&D investments. cOnclusiOns: Price regulation has a negative impact 
on pharmaceutical R&D investments. Policy makers must take long term effects 
of regulation into account.
PHP205
ELICITING THE RELATIvE IMPORTANCE OF KEy ELEMENTS FOR BENEFIT-
RISK ASSESSMENT: A COMPARISON AMONG GENERAL POPULATION, HEALTH 
AUTHORITy AND MEDICAL DOCTORS
Ha J.H.1, Na H.S.1, Chung M.W.1, Byun J.H.2, Kwon S.H.2, Park E.J.3, Lee E.K.2
1Ministry of Food and Drug Safety, Chungcheongbuk-do, South Korea, 2Sungkyunkwan University, 
Suwon, South Korea, 3Korea Institute for Health and Social Affairs, Seoul, South Korea
Objectives: This research was designed to find out the key attribute for ben-
efit-risk assessment using swing weight method in general population, health 
authority and hospital doctors. MethOds: We selected six important elements 
for each benefit and risk assessment based on previous study. The elements of 
benefit assessment consisted of disease severity, size of population affected by 
disease, clinical guidelines recommendation, comparative interventions limita-
tion, improvement of efficacy/effectiveness, improvement of quality of life. The 
attributes of risk assessment contained overall incidence of adverse events, 
overall incidence of serious adverse events, discontinuation rate due to adverse 
events, drug or food interactions, drugs of potential misuse, risk management. 
583 subjects constituted 3 groups (general population, health authority and hos-
pital doctors) were selected across the country by quota sampling method and 
performed survey to evaluate preference of each elements with the swing methods 
repeatedly. The trained interviewers assisted participant successfully completed 
survey. Results: Improvement of efficacy/effectiveness and overall incidence 
of serious adverse events were revealed as the most important attributes than 
others for benefit- risk assessment in all three groups. Health authority group 
outweighed the improvement of efficacy/effectiveness [Mean (±SD): 0.208(±0.04)] 
and overall incidence of serious adverse events [Mean (±SD): 0.220(±0.05)], while 
0.204(±0.03), 0.216(±0.04) in doctor group and 0.197(±0.04), 0.185(±0.04) in general 
population respectively. In six benefit attributes, the lowest preference score was 
clinical guidelines recommendation [0.114(±0.04)] in health authority group and 
[0.144(±0.04)] in general population while size of population affected by disease 
[0.126(±0.04)] in hospital doctor group. Among six risk elements, the lowest prefer-
ence was drugs of potential misuse showed in health authority [0.117(±0.04)] and 
in hospital doctors [0.121(±0.04)] while risk management [0.121(±0.04)] in general 
population. cOnclusiOns: This shows that improvement of efficacy/effective-
ness among benefit attributes and overall incidence of serious adverse events 
among risk attributes are key elements for benefit-risk assessment.
HEALTH CARE USE & POLICy STUDIES – Risk Sharing/Performance-Based  
Agreements
PHP206
COvERAGE wITH EvIDENCE DEvELOPMENT IN SwEDEN – FORMALITy OR 
EFFECTIvE wAy TO REDUCE UNCERTAINTy?
Kornfeld A.1, Schroeder M.2, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Copenhagen, Denmark, 3University Claude 
Bernard Lyon 1, Lyon, France
Objectives: TLV (formerly LFN) is responsible for reimbursement decisions in 
Sweden. They regularly give temporary reimbursement with request for additional 
ject, applicable to both single and multi-company projects. Any obligatory internal 
processes should be completed in tandem. Results: Health outcomes studies, 
pharmacoeconomic evaluations, and risk sharing agreements for the access of new 
pharmaceuticals were identified as projects of high priority to implement in the 
following years. cOnclusiOns: The steps outlined in this guidance, although not 
compulsory, will provide useful practical tips for how to go about setting up a Joint 
Working project in Catalonia (Spain), and to assist through the remainder of it. This 
guide is not a substitute for suitable regulatory or legal advice.
PHP201
MAPPING AND ANALySING PHARMACEUTICAL POLICy SETTINGS wORLDwIDE
Maniadakis N.1, Kourlaba G.2, Shen J.3, Holtorf A.P.4, Kalo Z.5
1National School of Public Health, Athens, Greece, 2National and Kapodistrian University of 
Athens School of Medicine, Athens, Greece, 3Abbott, Basel, Switzerland, 4Health Outcomes 
Strategies LLC, Basel, Switzerland, 5Syreon Research Institute, Budapest, Hungary
Objectives: In the context of increasing demand and expenditure for health 
services it is important to elaborate policies which maximise efficiency. 
Pharmaceuticals account for about a fifth of total health care expenditure and are 
often target of health care efficiency policies. The aim of this study is to classify 
and grade pharmaceutical supply and demand control policies across the globe 
and cluster systems by regulatory rigidity. MethOds: Pharmaceutical policies and 
market data across 65 countries were researched in the literature with emphasis 
on pricing, reimbursement, dispensing, expenditure and demand control domains. 
Policies were classified by domains and graded through a multi-country expert sur-
vey for the degree of regulation. Cluster analysis helped to group countries by policy 
types. Results: Pricing policies for on-patent products (with increasing degree 
of regulation) include: free pricing, direct negotiations, value-based-pricing, cost-
plus-pricing, conditional-pricing, reference-pricing, state dictates and tenders. Cost 
control policies include: discounts, rebates, risk-sharing agreements, price-volume 
agreements, profit controls, pay-backs, claw-backs, margin cuts, price cuts, freezes, 
and tenders. Reimbursement policies include: variants of ATC5-based internal refer-
encing, variants of statutory copayments, and variants of ATC4-based internal refer-
encing. Dispensing policies were: no restrictions, indicative substitution, mandated 
or compulsory substitution. Demand controls include: educational campaigns, 
prescription aids, indicative prescription guidelines, indicative INN prescription, 
prescription monitoring, quotas, targets, predefined budgets, compulsory INN pre-
scription, mandatory electronic prescription, compulsory prescription guidelines, 
prior/posterior approvals, sanctions and incentives for target/guidelines adherence. 
Cluster analysis identified a set of countries using an intermediate regulation policy 
approach and another with a more rigid approach. These did not differ significantly 
(p: 0.20) concerning pharmaceutical expenditure as % of GDP. cOnclusiOns: A 
variety of policies were used in recent years for controlling pharmaceutical expen-
ditures. Countries fall into two subsets based on the intensity of the regulation. 
More regulated systems do not appear to be associated with lower pharmaceutical 
expenditure.
PHP202
THE COST-EFFECTIvENESS OF PERIODIC SAFETy UPDATE REPORTS (PSURS) FOR 
BIOLOGICALS IN EUROPE
Bouvy J.1, Ebbers H.2, Schellekens H.2, Koopmanschap M.A.3
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Utrecht University, Utrecht, The 
Netherlands, 3Erasmus University, Rotterdam, The Netherlands
Objectives: The safety profile of new drugs is usually not fully established upon 
market entry, giving cause for Europe’s comprehensive pharmacovigilance sys-
tem. A key regulatory vehicle to communicate the outcomes of pharmacovigilance 
activities is the Periodic Safety Update Report (PSUR), which summarizes a prod-
uct’s worldwide safety data and facilitates periodic assessment of its benefit-risk 
profile. We assessed the cost-effectiveness of all PSURs submitted in Europe during 
1995-2009 for biologicals, using a societal perspective. MethOds: We evaluated 
two regulatory scenarios: Full Regulation (pharmacovigilance including PSURs) and 
Limited Regulation (pharmacovigilance without PSURs). We assessed the source 
of regulatory action for all urgent safety issues that were identified for biologicals 
during 1995-2009. In two out of 24 urgent safety issues (systemic spread of botu-
linum toxin and edema after use of dibotermin-alfa), PSURs were the regulatory 
instrument that identified the safety issue and we assumed these issues would 
have been discovered five years later under limited regulation. Estimates from the 
literature and Markov-chain life tables were used to calculate costs and effects 
of PSURs for biologicals. Results: The incremental cost-effectiveness ratio (ICER) 
of Full Regulation versus Limited Regulation was € 342,110 per quality-adjusted 
life year gained. Extensive sensitivity analyses indicated a low probability of the 
Full Regulation scenario being cost-effective. Only two parameters resulted in a 
more favorable ICER: a 100% risk reduction after identification of the urgent safety 
issues (base-case assumption was 25%) and a high risk (1 in 1,000 patients) of severe 
systemic spread after therapeutic use of botulinum toxin (base-case assumption 
1 in 10,000 patients). cOnclusiOns: Regulatory cost-effectiveness analysis is a 
feasible instrument for assessing the (added) value of parts of the drug regulatory 
framework. In light of high costs of regulatory compliance, cost-effectiveness should 
be a consideration in deciding whether or not safety-related regulatory actions 
are required.
PHP203
UTILIzATION OF THE HUNGARIAN PUBLICLy FINANCED HEALTH CARE SySTEM 
By THIRD (NON EU) COUNTRy CITIzENS
Kovács G.1, Boncz I.2, Gyeney L.3
1Széchenyi István University, Győr, Hungary, 2University of Pécs, Pécs, Hungary, 3Pázmány Péter 
Catholic University, Budapest, Hungary
Objectives: The number of citizens from third countries (outside of European 
Union or stateless) permanently living in Hungary is 205 000, and annually ca. 23000 
people get permit to settle. Current study aims at exploring what group of foreigners, 
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systematically collected through visiting social health insurance bureau websites, 
literature review and key informant interview. Case study and comparison analy-
sis were conducted among these schemes. Results: Two kinds of risk sharing 
schemes, performance based scheme and financial based scheme, were employed 
in sampling provinces and cities, with the latter model more often implemented. 
Performance based scheme has only been developed in one city (Guangzhou) for a 
non-small-cell lung cancer drug. Patients eligible for inclusion criteria and treated 
in one of three designated hospitals could be qualified to reimburse for more than 
one year treatment if they were responsive to the drug. Other provinces and cities 
has adopted the financial based scheme, mainly focusing on increasing patients 
access to expensive drugs, usually for breast cancer, leukemia and non-small-cell 
lung cancer and not covered by health insurance schemes. For instance, local health 
insurance fund of Zhejiang and Jiangsu province would only reimburse patients’ five 
to six months treatment and pharmaceutical company should sponsor patients’ 
treatment for the next six months. Besides, cities like Qingdao and Chengdu imple-
mented the price volume scheme for special drugs and medical materials in order to 
control fund expenditure. cOnclusiOns: By risk sharing scheme, some innovative 
drugs, previously not covered by social health insurance, can be reimbursed, which 
will increase patients’ access, reduce patients economic burden, and help expend-
ing pharmaceutical companies’ market share. However, as risk sharing scheme in 
China has only been adopted for only one or two years, long-term impact still needs 
to be observed and evaluated.
PHP210
SQUARING THE CIRCLE: INNOvATIvE CONTRACTING TO ACHIEvE MARKET 
ACCESS FOR INNOvATIvE PRODUCTS
Street-Docherty L.M., Morrison S.
GfK Bridgehead, Melton Mowbray, UK
In an increasingly resource-constrained environment, a variety of innovative 
contracting arrangements exist, representing an alternative to conventional pric-
ing and reimbursement agreements between payer and manufacturer. There are 
various tools and resources that may influence funding with which payers and 
prescribers would welcome support from manufacturers. Objectives: To gain 
an overview of contractual agreements currently used within the pharmaceu-
tical sector and to uncover how innovative contracting has, and continues to, 
evolve. MethOds: Secondary research was conducted to identify examples of 
innovative contracting, highlighting elements that work and associated hur-
dles, in order to understand issues relating to transparency and implementa-
tion. Results: Sixteen markets worldwide embrace innovative schemes with 
a further 5 markets beginning to show uptake. In the past, agreements were 
predominantly performance-based. However, companies are increasingly moving 
towards financial schemes such as product bundling, confidential discounts and 
fixed price treatments. The most common elements of risk-sharing agreements 
are price volume agreements (39%), requirement for data collection (29.5%), and 
access limited only to eligible patients (13.1%). Innovative contracts are predomi-
nantly used for drugs that relate to high cost or high performance with oncology 
being the therapeutic area that dominates these agreements. cOnclusiOns: 
Innovative contracting schemes can aid manufacturers with market access, help 
to maintain price and increase usage. However, the current design of many agree-
ments is suboptimal, and there are hurdles which need to be overcome. It is 
important that there is a balance between risk and incentive for all stakeholders, 
and this balance between the benefits and cost implications must be carefully 
considered.
HEALTH CARE USE & POLICy STUDIES – Conceptual Papers
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THE HEALTH OF HEALTH TECHNOLOGy ASSESSMENT IN IRELAND: FIvE POINTS 
FOR IMPROvEMENT
O’Mahony J.1, O’Neill C.2
1Trinity College Dublin, Dublin, Ireland, 2National University of Ireland Galway, Galway City, 
Ireland
This study critically appraises the contribution of cost-effectiveness analysis (CEA) 
in improving the rational allocation of health care resources in Ireland. While Ireland 
has successfully established some of the institutional infrastructure for CEA, there 
remain key areas for improvement: 1) Ireland has an explicit cost-effectiveness 
threshold of € 45,000/QALY. It resulted from negotiations between the pharmaceu-
tical industry and the public health service and only applies to pharmaceutical 
interventions. If Ireland is to use a threshold, it would be better served by an empiri-
cally determined threshold that applies to all interventions. 2) The threshold has 
recently been exceeded by a number of expensive drugs, in some cases by a very 
large margin. Conversely, despite being highly cost-effective, colorectal screening 
remains unimplemented due to a failure to allocate resources. In the absence of 
clarity around these decisions, the allocations appear to indicate that considera-
tions of budget impact are dominating rather than complementing those of cost-
effectiveness. 3) Recent CEAs by Ireland’s statutory health technology assessment 
authority, the Health Information and Quality Authority (HIQA), appear to confuse 
average cost-effectiveness ratios with incremental cost-effectiveness ratios (ICERs). 
Clarity around the interpretation of cost-effectiveness evidence is required to instil 
confidence in the process. 4) Ireland has an established CEA process to appraise 
new drugs. However, this process has been bypassed in recent cases, as some costly 
cancer drugs have been approved before being subject to CEA, despite recommen-
dations that these drugs be assessed. Consistency in approach is required to instil 
confidence in the process. (5) Greater transparency around reimbursement decisions 
would be desirable, whereby the relevant bodies issue documentation explaining 
their decisions and deliberations. In conclusion, CEA could make a greater contri-
bution to rational resource allocation in Ireland if more rigorous and consistent 
decision rules were applied. Greater accountability of the decision making process 
should further that goal.
data: Coverage with Evidence Development (CED). The objective of this study was 
to review the outcomes of the CEDs granted by TLV during the years 2005 to 2012, 
and to appreciate if it is an effective way to manage uncertainty. MethOds: All 
decisions published from January 2005 to December 2012 on the TLV website were 
screened. All decisions that included a CED were reviewed and the information 
on the initial decision for a CED and the final decision based on the evidence 
developed were extracted in a standardized way. The information was then ana-
lyzed. Results: During the period TLV issued 38 decisions with a CED, 4 in 2012, 
5 in 2011, 11 in 2010, 3 in 2009, 2in 2008, 8 in 2007, 5 in 2006 and none in 2005. For 
10 CEDs issued 2010 to 2012 the time for evaluation had to yet been reached. For 
12 CED decision taken from 2006 to 2010 the time for evaluation was reached but 
no decision had been taken and the products continue to be reimbursed accord-
ing to the conditions in the temporary reimbursement decision. 7 products were 
granted general reimbursement and 9 limited reimbursement based on the evalu-
ation of the evidence. No product was rejected reimbursement. cOnclusiOns: 
Although it is early to draw any final conclusions, a significant number of CED 
decisions were not followed up with a final decision, which leads to continued 
reimbursement. The risk of de-reimbursement based on a CED seems minimal in 
Sweden. Therefore it is unclear if CED will actually contribute to manage uncer-
tainty in Sweden.
PHP207
vARIANCES IN INDIvIDUALS’ PRESCRIPTION DRUG COSTS IN IRELAND
Walshe V.1, Kenneally M.2, Buckley G.2
1Health Service Executive, Cork, Ireland, 2University College Cork, Cork, Ireland
Objectives: To assess the average individual’s drug costs prescribed under the 
main community drug scheme in Ireland over time, by age cohort and by geo-
graphical region. It also examined regional costs having standardized for age and 
sex. MethOds: The 2002 to 2012 average pharmacy payment per eligible person, 
number of items prescribed per person and the average cost per item prescribed 
were calculated. The most recent average individual cost of medicines was exam-
ined for each of the 4 health regions and 32 sub-regions by 22 age and sex cohorts. 
Regional age and sex adjustments were made by applying the scheme’s national 
age and sex weights to each region’s costs. This produced regional cost estimates 
independent of age and sex variations. Results: Community drug expenditure 
has undergone substantial growth in the past 10 years with costs more than dou-
bling and the number of persons covered by the main scheme increasing by nearly 
60%. Nationally an individual’s average cost of medicines was € 713 in 2011, varying 
from € 670 (-6%) in HSE-West to € 762 (+7%) in HSE-South. Sub-regional LHO (local 
health office) cost variances were significantly greater ranging from € 200 to € 1,200. 
Average cost increases with age and for persons over 75 was nearly 4 times those 
aged 35 to 44 (€ 1,689 versus € 446). Removing the impact of age and sex increases 
cost variances marginally overall, restraining some regions costs and promoting 
others. cOnclusiOns: Individuals’ prescription drug costs vary significantly by 
age and sex however regional cost differences are not explained by variances in age 
and sex and may be a result of other factors such as prevalence of chronic health 
conditions and GP prescribing patterns.
PHP208
ANALySIS AND CLASSIFICATION OF RISK-SHARING SCHEMES PROPOSED IN 
REIMBURSEMENT APPLICATION RECEIvED By AHTAPOL IN 2012
Zawodnik S.1, Iwanczuk T.1, Hermanowski T.2, Matusewicz W.3
1Agency for Health Technology Assessment in Poland, Warsaw, Poland, 2Department of 
Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, 3Agency for Health 
Technology Assessment in Poland (AOTM), Warsaw, Poland
Objectives: To analyze and classify the Risk-Sharing Schemes (RSSs) proposed in 
reimbursement applications received by Agency for Health Technology Assessment 
in Poland (AHTAPol) in 2012. MethOds: Risk-Sharing Schemes proposed in reim-
bursement applications received by AHTAPol in 2012 were quantitatively and 
qualitatively analyzed. The classification of the RSSs was also conducted based 
on both Carlson’s approach and the Polish Act on Reimbursement of medicinal 
products. Results: In the studied period, 52 reimbursement applications with 26 
proposed RSSs were received by AHTAPol. They were classified into 5 categories 
according to the Act on Reimbursement. The most common category was making 
the official sales price dependent on the applicant providing supplies at a reduced 
price, as specified in the negotiations on the price of the medicine (34.61%). Further 
categories were: making the official sales price dependent ona pay-back of a part 
of the reimbursement obtained to the entity which is obliged to finance bene-
fits with public funds (23.08%), making the official sales price dependent on the 
level of turnover of the medicine (11.54%) and making the level of the applicant’s 
revenues dependent on the health effects achieved (3.85%). RSSs classified as 
others constituted 26.92% of all. Among 26 proposed RSSs only 8 of them could be 
classified according to the Carlson’s approach (1 proposition included more than 
one category). As a results, 4 Price Volume Agreements, 4 Manufacturer Funded 
Treatment Initiation and 1 Conditional Treatment Continuationwere identi-
fied. cOnclusiOns: Most of the propositions should not be considered as RSS 
according to the Carlson’s approach. The most common propositions were related 
to medicinal product’s price reduction and did not include any risk sharing. There 
is a strong need for further research.
PHP209
RISK SHARING FOR INNOvATIvE PHARMACEUTICALS wITHIN SOCIAL HEALTH 
INSURANCE: ExPERIENCES FROM CHINA
Chen W.1, Zhang L.1, Fan W.2
1Fudan University, Shanghai, China, 2School of Public Health, Fudan University, Shanghai, China
Objectives: To understand current risk sharing scheme landscape for innova-
tive pharmaceuticals in some typical provinces and cities of China. MethOds: 
Risk sharing schemes for pharmaceuticals in four provinces (Guangdong, Zhejiang, 
Jiangsu and Sichuan) and three cities (Guangzhou, Hangzhou and Chengdu) were 
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ing doesn’t tell us why some country like UK perform well while others like France 
don’t. cOnclusiOns: Our results underline the country difference of arbitration 
between public policies such as public health, and industrial or innovation policy. 
Among tested variables, it appears that the regulation of drug pricing and market 
access, or the macroeconomic impact of pharmaceutical industry in a country con-
tribute to determine the scope of HTA policies.
PHP215
CLINICAL, EPIDEMIOLOGICAL AND ECONOMIC METRICS DIFFERENCE BETwEEN 
HPv-RELATED AND TRADITIONAL HEAD AND NECK CANCERS
Coughlan D.
NUI Galway, Galway, Ireland
Excessive smoking and alcohol consumption were the traditional causal factors in 
many head and neck cancers in the United States and Western Europe. However, 
the Human papilloma Virsus (HPV) is now responsible for up to 80% of cancers of 
the oropharynx. HPV-related oropharyngeal cancers are a distinct clinical, epide-
miological and molecular entity. This poster will show that the metrics used to 
describe the burden of a cancer to policy makers are very nuanced. As the patients 
with HPV-associated oropharyngeal cancers are younger and healthier individuals, 
they have been shown to have a better prognosis than traditional head and neck 
cancers. The goal of treatment has shifted from mortality to morbidity in these can-
cers. Measures of morbidity (functional status) are now important considerations in 
treatment options. This poster will compare and contrast various epidemiological 
measures - Incidence /100,000, Prevalence, Years of Life Lost, Mortality to Incidence 
Ratio with respect to HPV-related and unrelated head and neck cancers. Finally, 
we will discuss the economic metrics (e.g. Disability adjusted life years, Years of 
working age lost) used to portray a cancer and make a link with research funding 
in various countries. The question posed is whether mortality or morbidity should 
predominate in resource/research allocation decisions?
PHP216
COMPARING THE vALUE OF DIFFERENT HTA DECISION MAKING PROCESS: 
EvALUATING THE EvALUATORS
Johannesen K.M.1, Claxton K.1, Sculpher M.J.1, Wailoo A.J.2
1University of York, York, UK, 2University of Sheffield, Sheffield, UK
Objectives: How health care decision makers arrange their appraisal process of 
new health care technologies have direct impact on population health. However, 
no consensus exists on how the appraisal process should be designed to maxim-
ise population health or societal welfare. The purpose of this work is to develop 
a simple analytic framework that enables analysis of the different stakeholders’ 
(decision makers and manufacturers) payoffs from alternative appraisal pro-
cesses. MethOds: The analytic framework outlined in the paper is based on 
viewing the appraisal processes as a diagnostic test aimed at identifying cost-
effective (true positives) and cost-ineffective (true negative) technologies. Based 
on this characterisation pay-off functions are formalised to analyse how design 
and operation of the appraisal process impacts population health and manufac-
turers’ earnings. Results: The framework identifies those factors that have the 
greatest influence on population health and manufactures payoffs and illustrates 
how this leads to conflicting interests towards how the appraisal process should 
be set up and operated. It is demonstrated that there is no uniquely optimal way 
to design and operate the appraisal of new health care technologies, since optimal 
design and operation depends on the price of technologies that undergo appraisal. 
The analysis also shows that operating a given reimbursement system implies a 
trade-off between incentivising cost-effective pricing (pricing below the threshold/
willingness to pay) and rejecting more cost-effective technologies (increasing the 
proportion of false negatives). It is further demonstrated how the framework can 
be used to gain insight into current policy questions including who should bear the 
burden of proof and how rigorous the process should be. cOnclusiOns: There is 
no unique way to design and operate the appraisal of health care technologies in 
order to maximise population health or societal welfare. Improving health or soci-
etal welfare through the appraisal process requires careful consideration of payoffs 
and incentives of all stakeholders.
PHP217
THE FRAMEwORK FOR HEALTH ECONOMIC MODELING AND MULTI-CRITERIA 
DECISION ANALySIS (MCDA) ON THE ExAMPLE OF THE MOBILE STROKE UNIT 
(MSU)
Wahlster P., Niederländer C.S., Kriza C., Kolominsky-Rabas P.L.
Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of Erlangen-
Nuremberg, Erlangen, Germany
Objectives: The generation of evidence in the early development of a technology 
is a bottle neck for uncertainty in decision making. Health economic modeling can 
support the assessment of early innovation, but complex modeling approaches are 
criticized for being “black boxes” which in turn reduce their acceptance in health 
policy. MethOds: MCDA can address the gap about what matters to health care 
decision makers and data collection by explicitly structuring decision criteria. The 
combination of MCDA modeling and health economic modeling implies a potential 
for gaining efficiency. The simulation model of the intervention for stroke, the MSU, 
is analyzed regarding application of MCDA. Results: Experts and stakeholders can 
support the: 1) Definition of model factors e.g. outcome parameter, which is gener-
ally accepted (Barthel-Index for Stroke outcome); 2) Evidence collection e.g. is the 
data valid? (outcome of thrombolysis); 3) Model structure e.g. interrelation between 
input parameters (stroke incidence, risk factors and population); 4) Validation of 
a model e.g. reassessment of step 1-3; and 5) Final analysis by using MCDA e.g. 
importance of economic vs. medical benefit. cOnclusiOns: The methodological 
combination is advantageous because simulation modeling as well as MCDA have 
a similar sequence of events. The simulation output, which is commonly validated 
by technical and medical experts, can gain validity by the heterogeneous perspec-
tives of participating stakeholders in the validation process. For example, this raises 
PHP212
OBTAINING OPTIMAL PERSONALIzED SURvEILLANCE STRATEGIES FOR 
PATIENTS wITH SCREEN-DETECTED COLORECTAL ADENOMAS USING 
DISCRETE EvENT SIMULATION
Comas M.1, Andreu M.2, Castells A.3, Buron A.1, Sala M.1, Binefa G.4, Garcia M.4, Rue M.5, 
Castells X.1
1IMIM (Hospital del Mar Medical Research Institute; Red de Investigación en Servicios de Salud en 
Enfermedades Crónicas (REDISSEC), Barcelona, Spain, 2IMIM (Hospital del Mar Medical Research 
Institute), Barcelona, Spain, 3Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 
Hospital Clínic, Barcelona, Spain, 4Institut Català d’Oncologia (ICO), Institut d’Investigació 
Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Spain, 5Biomedical Research Institute 
of Lleida (IRBLLEIDA), University of Lleida. Red de Investigación en Servicios de Salud en 
Enfermedades Crónicas (REDISSEC), Lleida, Spain
bAckgROund: Colorectal cancer (CRC) screening in Spain uses a fecal-occult 
blood test (FOBT) for screening and colonoscopy as diagnostic tool. Adenomas 
constitute the most frequent findings of this colonoscopy, and the removal of 
these premalignant lesions is considered the main contributor to the reduction 
of mortality and incidence of CRC. There is no clear agreement regarding the 
risk classification of adenomas as well as the optimal surveillance strategy for 
each degree of risk. Genomics may contribute to further delineate individual risk, 
and its characterization is crucial for improving the effectiveness of surveillance 
strategies by targeting individuals who would benefit the most. Objective: To 
optimize, within a CRC screening program, surveillance of premalignant lesions 
using individual risk-based strategies, based on genetic analysis, that take into 
account benefits, harms and costs. MethOds: A discrete-event simulation model 
that reproduces the process of screening and takes into account the costs at every 
stage, from invitation to screening to surveillance of findings will be upgraded. 
The natural history of the disease will be included, with special emphasis on the 
events after adenoma detection at screening colonoscopy. Based on the results of a 
study aimed at identifying common genetic variants associated with an increased 
susceptibility to develop colorectal adenomas, the risk of developing cancer or 
recurrent adenomas according to the clinical characteristics of the patients will 
be included in the model. The interval between surveillance colonoscopies will 
be optimized with the objective of minimizing the number of colonoscopies while 
keeping the same level of effectiveness, defined as the impact on incidence of 
advanced adenomas and cancer over time. IMPLICATIONS: Simulation models 
can help in the design of personalized screening strategies. Personalizing CRC 
screening through surveillance strategies may improve allocation of resources 
under cost constraints, minimize harms and maximize benefits of population-
based programs, affecting millions of people.
PHP213
FIxED REFERENCE PRICING OR BENEFIT ASSESSMENT OF ESTABLISHED 
PRODUCTS – FROM THE FRyING PAN INTO THE FIRE?
Vosgerau S.1, Eheberg D.2, Plantör S.1, Lebioda A.1
1IMS Health GmbH & Co. OHG, Munich, Germany, 2IMS Health, Munich, Germany
For nearly 25 years, the most effective tool for containing public spending on 
pharmaceutical drugs in Germany is the formation of fixed reference price groups 
(FRPG) - the annual savings have continuously risen from 0.31 billion Euros in 1990 
to 4.32 billion Euros in 2009. Hereunder, the so-called “jumbo groups” (patent-free 
and patented substances) that were introduced with the SHI Modernization Act 
of 2004 have been of high importance. With the recently published, first-time call 
for benefit assessments of substances in the established market (April 2013), the 
Federal Joint Committee (FJC) has yet launched another potent mean of reducing 
costs. Unlike the early benefit assessment of new active ingredients where several 
substances have undergone scrutiny since January 2011, it is unclear what the 
outlook is for the substances in the established market. Therefore, the objective of 
the presentation is to assess whether a FRPG or a benefit assessment is to be pre-
ferred by pharmaceutical companies for established substances. Fixed reference 
price scenarios are calculated for therapeutically comparable substance classes 
within the call for benefit assessment of substances in the established German 
drug market. For the established substances, a risk assessment and benchmark 
is performed based on the criteria in the code of procedure of the FJC and the 
assessment of new active ingredients, respectively. The results of the ongoing FRPG 
scenario evaluation will be displayed as bar charts by savings in € . The risk assess-
ment is displayed in a tabular format. Apart from discussing the results of the 
FRPG calculations compared to the benefit assessment of established substances, 
the presentation discusses implications for international reference pricing, since 
the German market has been regarded as the last bastion of free pharmaceutical 
pricing for a long time.
PHP214
HTA NATIONAL PUBLIC POLICy AND THEIR SOCIO-ECONOMIC ENvIRONMENT: 
A EUROPEAN PERSPECTIvE
Benoit C.1, Gorry P.2
1Sciences Po Bordeaux, Pessac, France, 2Université Montesquieu - Bordeaux IV, Pessac, France
Objectives: Socioeconomic factors are important components of Health 
Technology Assessment’s (HTA) institutionalization. If most of the countries 
have established HTA agencies, they required scientific expertise to emerge and 
become institutionalized. In a previous scientometric work, we did an analysis 
of scientific conditions of HTA emergence in the scientific literature. Our obser-
vation allowed us to link HTA research capacity and HTA institutionalization in 
a given country. MethOds: In order to explore endogenous as well exogenous 
factors sustaining HTA expertise, we undertake a principal component analysis 
as multivariate analysis technique in order to establish which variable are more 
appropriate for the assessment of scientific expertise in the context of HTA public 
policy. Results: HTA national public policy could be ranked according to their 
academic expertise. Country HTA publications productivity matched in comparison 
with health expenses & gross product in several countries. Nevertheless this rank-
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reflects a preference on behalf of the decision maker. Reality does not always match 
the ideal of a fixed threshold.
PHP221
DOES HTA PROCESS HELP TO ACHIEvE THE HEALTH OBjECTIvES OF THE 
MILLENNIUM? A SOUTH AMERICAN ANALySIS
Sansone D.1, Decimoni T.C.1, Etto H.1, Santos A.M.1, Araújo G.2, Fonseca E.3, Fonseca M.2
1Axia.Bio Consulting, São Paulo, Brazil, 2Federal University of São Paulo / Axia.Bio Consulting, 
São Paulo, Brazil, 3Federal University of São Paulo, São Paulo, Brazil
Objectives: South America (SA) is a continent with 400 million people and occu-
pies 12% of the world’s territory. It is composed by 12 countries and 6.75% of its 
population is below the poverty line, as defined by UN. The proper distribution of 
financial health resources, through an HTA process in public systems is potentially 
essential to improve the quality of health care expenditure. The objective of this 
study is to understand the incorporation process of new health technologies and 
compare the general health status in each country, regarding the Objectives of 
the Millennium (OM). MethOds: A public data collection was performed in offi-
cial sources linked to UN, to governments of SA and the Unión de las Naciones 
Suramericana (UNASUR). Results: The public health financing in SA countries 
was between 2.43% and 6.20% of the GDP. An HTA process in an institutionalized 
and specialized form is in place in only 3 countries (Argentina, Brazil and Peru). 
Bolivia, Chile, Colombia, Paraguay and Venezuela do not have a specialized HTA 
process and the other four countries have no HTA process at all. Regarding the OM 
the decrease in child mortality, increase in vaccination, increase in malaria and 
tuberculosis treatments are among the closest to be achieved in all countries. There 
is a linear positive correlation of OM with the Human Development Index and with 
the percentage of GDP invested in public health but not with having a HTA process 
in place. cOnclusiOn: At this moment, there is no evidence that an HTA process 
in place helps SA countries to achieve the OM.
PHP222
THE NEw ITALIAN HEALTH CARE REFORM: INTRODUCING NEw MEASURES TO 
SPEED UP MARKET ACCESS
Palombi M.1, Urbinati D.2, Lo Muto R.1, D’Ausilio A.1
1Creativ-Ceutical, Milan, Italy, 2Creativ-Ceutical, Luxembourg, Luxembourg
Objective: The Balduzzi law (189/2012) introduced several changes aimed at pro-
moting the country’s development through a higher level of health protection and 
at bridging the gap left by the rationing of health care resource from the Spending 
Review (135/2012). Reducing the time to drug market access is one of the main pur-
poses. The aim of the research is a critical analysis of this law to understand its actual 
and future impact on the health care scenario. MethOds: An evaluation of the laws 
issued in the last three years that aimed at regulating the drug market was carried out. 
To build a future scenario analysis, we focused our attention on the Balduzzi law and 
two of its articles (11 and 12) and on the new drugs approved by AIFA and commercial-
ized under the new regulation. Results: The changes that will have a major impact 
on the drug market are: the allocation of the medicines approved under centralized 
procedure in the non-negotiated C Class within 60 days from the publication in the 
Official Gazzette of the European Union and the direct placement of generics and bio-
similars in the reimbursement class of the originator without any price negotiation. As 
of now, a total number of 49 drugs have been included in the non-negotiated C Class, 
within this new group there are 15 first drug authorizations. cOnclusiOn: The new 
reform can be potentially an interesting innovation to speed up market access, though 
the impact of including new drugs in the C class (at patient charge) before the price 
negotiation is still under debate. The increased competitiveness coming from having 
a faster introduction in the market of generics/biosimilars could lead to important 
savings for the National Healthcare System over the next years.
PHP223
INvESTING IN EUROPEAN HEALTH R&D – A PATHwAy TO SUSTAINED 
INNOvATION AND STRONGER ECONOMIES
Pasmans R.1, Saka Ö1, Urbina-Valdespino E.1, Delwart V.2, Gijssels S.2
1Deloitte, Diegem, Belgium, 2Janssen Pharmaceutica NV, Bersee, Belgium
A large number of factors point to an unavoidable rise in health care expenditure to 
13%-18% of Europe’s GDP by 2030, even with policy interventions or budget caps that 
aim to counterbalance these pressures. This growth in health care costs need not be 
undesirable especially so when higher spending on health care leads to improved health 
care quality and life expectancy. Therefore, the challenge is not “how do we reverse the 
growth of health care costs?” but “how can we best deploy the increasing resources spent 
on health care to create optimal benefits for the European population?” Health R&D is 
the key to being able to respond to this dilemma. Increased investment in R&D leads to 
improved health outcomes, long term efficiency gains, better productivity and high eco-
nomic yields. However, the outlook for Europe is not as positive as it could be. Recently, 
there has been a stagnation or even decline in European private and public investment 
in R&D, which is in sharp contrast with the much higher investments in the US. Private 
biopharmaceutical investments in health R&D, which are double the size of public health 
R&D, in 2011 actually decreased in absolute terms. Public R&D investments declined or 
stagnated in most European countries and will be further under pressure in the near 
future due to public budget deficits. Janssen commissioned the Deloitte European Center 
on Health Economics and Outcomes Research to set out the arguments in support of 
increased investment in health R&D in Europe. The paper demonstrates that, even in 
times of austerity, policymakers need to prioritise approaches that will enhance public 
R&D investments and adopt strategies that produce incentives for private enterprises 
so that the current decline in private sector investment is halted.
PHP224
HOw DO ONCOLOGy DRUG PRICES vARy ACROSS EU5, THE UNITED STATES, 
AND BRIC MARKETS?
Patel P., Donze B., Zaganelli D.
Alliance Life Sciences Consulting Group, Somerset, NJ, USA
questions about priority and importance of certain outcome parameters like the 
thrombolysis rates vs. the independence of patients after 3 months. Finally, the com-
bination of MCDA and simulation modeling contributes to a transparent analytic 
process and results in a more complex understanding of the technology.
PHP218
MECHANISM OF COORDINATED ACCESS TO ORPHAN DRUGS
DeRidder H., Arickx F., Adriaens C., Quanten A., Mortier M., Kleinermans D.
NIHDI, Brussels, Belgium
Although the EU Council stated that “All health systems in the EU aim to make provision, 
which is patient-centered and responsive to individual need”, unacceptable differences in 
access to orphan medicinal products (OMP) in the Member States of the European 
Union are identified. In the context of the 2010 Belgian EU presidency initiative 
on ‘Innovation and Solidarity’ and within the framework of the process on corpo-
rate responsibility in the field of pharmaceuticals, EU Commissioner Tajani there-
fore launched the project Mechanism of Coordinated Access to OMP.Objectives: 
Designing a operational mechanism of coordinated access to OMP for patients, stake-
holders and Member States to provide, irrespective of the local conditions, access for 
patients with unmet medical needs and for whom these solutions would otherwise 
be out of reach – in an affordable and sustainable way (“real life access”). MethOds: 
The project is managed by Belgium (NIHDI), supported by the European Commission 
and Eminet. Thirteen Member States participated, with the stakeholders (AIM, EPF, 
ESIP, Eurordis, CPME, EFPIA, EGA, EuropaBio, GIRP). Three Workpackages cover the 
different aspects of granting effective access to medicines: Identifying and assess-
ing a relevant orphan drug (assessment/evaluation) - Selection of target population 
and mechanisms of funding (structural access) - Treatment (individual access). 
Feasibility at present and opportunities for near future development of desirable 
activities were studied, and no-go solutions were documented and rejected in order 
to develop implementable scenarios for pilot projects and policy recommendations. 
Discussion: Although coordinated access at an European level will be organized on a 
voluntary basis, some sort of commitment from the participating partners is required. 
Moreover, it is crucial that the subsidiarity principle is not jeopardized or compro-
mised. Duplication of efforts will be avoided and previously made investments – in 
terms of financial and human resources, expertise and experience - (ex. by EUnet 
HTA, EMA COMP, EUCERD, CAVOD,…) will be valorized.
PHP219
THE FUNDING OF ORPHAN MEDICINES IN EUROPE: PAyERS ACHILLES’ HEEL?
Rietveld A., Brown C., Johnson N., Spoors J.
RJW & Partners, Royston, UK
Objectives: To look at the affordability of orphan medications across Europe and 
whether payer attitudes to high-price medications are changing in the face of ris-
ing health care expenditure and tighter budgets. MethOds: A detailed review of 
7 EU markets (France, Germany, Italy, The Netherlands, Poland, Spain, UK) looking 
at payer attitudes and funding decisions for key orphan drugs and the political, 
economic and societal impact of these. A key focus of the research was insight into 
payer attitudes towards the evidence base for the purpose of pricing negotiations 
and how anecdotal evidence, such as Patient Reported Outcomes (PROs) and patient 
case studies, have an impact on decision-making. Detailed research was also under-
taken to ascertain the pricing levels achieved for a number of orphan drugs across 
Europe looking at payer thresholds and the implications of these for the purpose 
of reimbursement. Results: The research demonstrates that there is considerable 
variation in pricing levels across the European markets and difference in payer 
attitudes towards the way orphan drugs are funded. Overcoming evidence chal-
lenges in orphan diseases remains a headache for payers and scepticism remains 
around dosing, innovation and whether approaches such as “coverage with evidence 
development” are adequate and/or sustainable in the long-term following initial 
approval. cOnclusiOns: The environment for orphan medicines in Europe is 
changing; and as the financial performance of European countries begins to diverge, 
so do attitudes towards the funding of orphan medicines. Orphan medicine prices 
are rarely justified on the basis of traditional cost-effectiveness thresholds and most 
markets still differentiate them from other pharmaceuticals. However, payers are 
afraid of uncertainty and, given the increasing number of orphan drugs and the 
often tentative evidence base at launch, may be forced by overwhelming financial 
necessity to make tougher decisions on funding.
PHP220
BUDGET IMPACT AND THRESHOLDS: HOw ARE REAL DECISIONS MADE? - 
ExPECTED UTILITy OR PROSPECT THEORy?
Adams R.1, Gray E.1, McCullagh L.1, Schmitz S.2, Barry M.1, Walsh C.2
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland
Decision making rules in health technology assessments are often based on a fixed 
willingness to pay threshold for the incremental cost effectiveness. This may be 
thought of as consistent with expected utility – with utility here defined in terms of 
Incremental Net Benefit (INB) – a combination of QALY gain and the threshold value. 
Alternative methods such as multi criteria decision analysis allow incorporation 
of other dimensions into the decision space. These seek to explore whether utility 
may be driven by factors other than simple QALY gain. Prospect theory suggests 
that decision makers are concerned in practice with the ‘size’ of a given decision. 
Also, they handle investment and disinvestment differently. In the Irish State, every 
new drug is examined. In order to look at actual decisions, lifetime QALY gains were 
extracted from completed economic evaluations submitted to the Irish health care 
payer. Total spend on these was calculated using a combination of the payer reim-
bursement database and predicted budget impact. Real choices indicate that where 
the budget impact is relatively small the drug is more likely to be reimbursed even 
with a comparatively small QALY gain. Technologies in areas of cancer and orphan 
diseases often lie outside of the threshold where a technology would be accepted. 
Decision makers are faced with choices with varying degrees of risk. Choices asso-
ciated with a low budget impact are deemed to be less risky. This is pragmatic; it 
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sure by demanding early decisions and rapid access. Decision makers may unduly 
delay potential benefits to patients by waiting for stronger evidence, or may endorse 
medicines that later turn out to have a less robust benefit-risk ratio, to be ineffective, 
cost-ineffective, or even harmful. Hence, many countries have developed mechanisms 
that allow temporary access to promising medicines while concurrently requesting the 
generation of additional evidence to reduce uncertainty. Their objective is an optimal 
trade-off between different stakeholder needs, flexibility, responsiveness, and rigor as 
well as the flexibility to revise decisions on access when new evidence becomes avail-
able. The ENCePP WG on HTA has the potential to become a capacity building tool for 
regulatory and HTA agencies to develop research structures aimed at complementing 
the evidence generation for MA and market access. Post-authorisation studies devel-
oped under the auspices of ENCePP could provide new safety and clinical effectiveness 
information of marketed medicines. ENCePP expertise, research experience and health 
care databases may also contribute to the coordination, methodological guidance and 
data sourcing for the enhancement of HTA processes.
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HEALTH TECHNOLOGy ASSESSMENT OF HIGH-vALUE THERAPIES
Hegyi R.1, Tóth E.1, Érsek K.1, Nagy B.2
1Healthware Consulting Ltd., Budapest, Hungary, 2Healthware Ltd., Budapest, Hungary
Objectives: Main function of a health system is to prevent diseases, restore health 
status and reduce health impairment. Health systems are mainly organized on effi-
cacy based decisions, but sometimes their social functions modulate this principle. 
In case of small patient groups, end-stage status and unmet health needs, usually 
decision are made on the basis of equity, instead of efficacy. These demands create 
special development conditions; eventuate in high prices on the supply side, therefore 
cost-effectiveness cannot be guaranteed, not even with substantial health benefits. 
Numerous expensive drug therapies are available in Hungary with reimbursement, 
but due to fiscal restrictions, new therapies are not able to access reimbursement. 
These tendencies create a paradox situation, since equity is implemented occasionally 
in absence of objective criteria. Due to the huge differences among these therapies, a 
standardized decision-making principle does not exist, but a general framework can 
be developed. In our study, methods and techniques are introduced, which can help to 
assess these therapies and organize a transparent system. MethOds: For the general 
assessment of therapies, many methods are available. In our research, we reviewed 
these tools and investigated their combinability in the special situation of “high-
value” therapies. Results: A wide range of evidences (clinical trials, meta-analysis, 
health-economy analysis, HTAs) provide a robust background to compare high-value 
therapies between different therapeutic areas. Outputs (LYG, OS, QALY, costs etc.) 
show a significant variation following different clarification process. A standard-
ized process needed to earn comparable outputs from evidences. cOnclusiOns: As 
we found, these tools could help decision making on prioritizing therapies, allocate 
resources with a higher control and reduce the risk of reimbursement.
PHP228
ORPHAN DRUG LEGISLATIONS: HEyDAy OR HAD THEIR DAy?
Palmer M., Hughes D.A.
Bangor University, Bangor, UK
Orphan Drug Legislation incentivises the development of treatments for rare dis-
eases that would otherwise not be profitable investment opportunities. However, 
with budgets squeezed and diseases increasingly stratified, we question whether 
this legislation is fit for purpose. Segmenting diseases into genetically-defined sub-
groups, most notably among some cancers, has enabled increased pharmacological 
targeting. Common diseases are thus being reconsidered as multiple rare conditions, 
each eligible for orphan designation, entitling the treatments to the economic ben-
efits afforded by legislation. Stratification also occurs in diseases which are already 
rare (e.g. cystic fibrosis), and new treatments, such as ivacaftor, are being developed 
to target specific mutations. Orphan status for a drug is maintained regardless of 
whether the overall population size, for which the drug is licensed, exceeds prevalence 
thresholds enabling companies to take a strategic approach to development. The high 
prices of orphan drugs impact on access. However, typical cost-effectiveness thresh-
olds are often waived suggesting that greater value is placed on treatments for rare 
conditions, compared with prevalent diseases that are equally severe and debilitating. 
Population surveys indicate that funding policies that take resources from elsewhere 
in health economy budgets to fund these treatments are not in the public interest. 
At the same time, research and development into certain common diseases such as 
stroke, where the burden is much higher, has been somewhat neglected. We believe 
it is time to revisit orphan drug legislation. Regulators should be able to limit the 
benefits of orphan designation should the cumulative eligible population exceed a 
certain threshold. More robust criteria need to be applied for defining a “medically 
plausible subset” and pricing should to be brought closer in line with drugs for non-
rare diseases. Furthermore, the focus of incentives should move more towards areas 
of unmet need where disease burden is greatest.
PHP229
REvIEw OF ECONOMIC PRINCIPLES OF BRANDED “ME-TOO” DRUGS MARKET
Hren R.
University of Ljubljana, Ljubljana, Slovenia
In this paper, we review a well-known phenomenon of »me-too« drugs in the pharma-
ceutical branded markets, which has gained wide attention during the recent years. 
A branded “me-too” drug is deemed having somewhat similar therapeutic effect as 
the “breakthrough” drug, although from an intellectual property right perspective, 
there is no difference between the two. Definition of “me-too” drugs has yet to reach 
consensus and it would likely be ferociously disputed by the branded firms. When the 
first branded »me-too« drug enters the market, we are dealing with oligopoly, or more 
precisely, duopoly, described by Cournot model. From an oligopoly model, we would 
expect at Nash equilibrium both price to decrease and total volume to increase com-
pared to shared monopoly conditions. An oligopolistic structure of a »me-too« phar-
maceutical market puts substantial emphasis on branding and promotion (to achieve 
Objective: Pharmaceutical pricing is characterized by a consistent variability across 
markets. Social and economic differences represent only the easiest-to-predict reason 
for such variability. Stricter regulatory hurdles, market landscape, challenging nego-
tiation processes, varying business strategies, and sometimes unplanned outcomes 
of pharma launch decisions concur in the final price for a specific drug. A better 
understanding of price trends and out-patterns is a useful insight to help improving 
pricing strategies by targeting realistic pricing expectations, and studying competi-
tors’ pricing mistakes and successes. This paper shows the price variability of ten 
different pharmaceuticals in ten key markets (France, Germany, UK, Italy, Spain, US, 
Brazil, Russia, India, and China). Common trends, similarities and particularities are 
discussed. MethOds: Using PRICENTRICTM data, we collected ex-factory prices for 
various oncology products, and we defined whether a country fell into a HTA sys-
tem or free pricing group. We also compared the product prices to GDP per capita 
(International Monetary Fund 2012) to investigate trends between the two parameters. 
The analysis investigates two key areas: 1. Difference in price depends on social, eco-
nomic considerations but also by the nature and complexity of market access process 
2. The relationship between prices and GDP per capita across countries. Results: The 
US and Germany have the highest prices of all studied countries. They are also the 
only two countries where prices are freely set by manufacturers. Prices are slightly 
higher in countries having a high GDP per capita. However, countries like France and 
UK having strong HTA authorities and pricing regulations do have a small correlation 
to this trend line. cOnclusiOn: Our analysis shows that pricing and pharma strate-
gies can be based on countries’ economic situation. Nevertheless, formal established 
HTA bodies with clear pricing rules help controlling pricing.
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A SySTEMS-THINKING APPROACH FOR THE HEALTH CARE INDUSTRy: 
STRATEGIES AND INSIGHTS FOR BIOPHARMA, PAyERS AND PROvIDERS
Hoschander S.1, Doyle J.J.2, Istas A.3
1Quintiles Global Consulting, Hawthorne, NY, USA, 2Quintiles, Hawthorne, NY, USA, 3Quintiles, 
Durham, NC, USA
Collaboration with health care stakeholders is a fundamental component of a sys-
tems-based health care economy, and it will become the dominate business model 
going forward. Yet most health care industry stakeholders are failing to accept this 
inevitable transition. While many acknowledge the need to move toward a more 
integrated “systems thinking” approach – one that maps influence patterns, ampli-
fies interdependencies, and drives collective outcomes, they struggle with actual 
implementation. A viable and sustainable information network provides the struc-
ture, aligned incentives and competitive collaboration the bricks and mortar, and 
trust the cornerstone. Until they can build that and foster a culture of transparency, 
they won’t achieve the cost and innovation benefits inherent in these cross-industry 
partnerships. Although health care stakeholders know they need to partner with 
others to be successful in this new systems-thinking economy, they need actionable 
strategies to demonstrate how the benefits of ongoing collaborations far outweigh 
the risks. This podium presentation will present original research aimed to qualify 
stakeholder perceptions on alignment and collaboration around the delivery of health 
care, in addition to critical hurdles they must overcome. A recent survey of close to 
300 Biopharma executives, EU and US Payers, and US providers provides insight into 
their needs, their disparate perceptions, and their levels of confidence in the ability to 
shift to a systems-thinking collaborative culture. Approximately 25% of respondents 
stated they were not aligned with other stakeholders, though agree they need better 
alignment and foresee closer collaboration in the future. Over 70% of stakeholders 
believe data transparency and information-sharing is critically important to a suc-
cessful and interoperable health care system, yet very few from each group were 
willing to demonstrate such transparency. Further detail will be given on insights and 
challenges gleaned from interviewing large and small stakeholders as well as practical 
strategies to guide the transformation to a systems-thinking industry.
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INTRODUCING THE ENCEPP wORKING GROUP (wG) ON HEALTH TECHNOLOGy 
ASSESSMENT (HTA): ENHANCING THE GENERATION OF ADDITIONAL EvIDENCE 
FOR HTA PROCESSES
Sinclair M.1, Lis Y.2, Van Engen A.3, Van Ganse E.4, Autier P.5, Daumer M.6, Ehrenstein V.7, 
Qizilbash N.8, Méndez I.9, Engel P.10, Bergman U.11, Fusco D.12, Pasterk M.5, Postma M.J.13, 
Smulders M.14, van Staa T.15, Pariente A.16, Ruether E.17, Toussi M.18, Moore N.19, Meyer F.20, 
Prieto L.21
1University of Ulster, Newtownabbey, United Kingdom, 2PAREXEL International, Uxbridge, United 
Kingdom, 3Quintiles, Hoofddorp, The Netherlands, 4Université Lyon 1, Lyon, France, 5International 
Prevention Research Institute, Lyon, France, 6Sylvia Lawry Centre for Multiple Sclerosis Research, 
Munich, Germany, 7Aarhus University Hospital, Aarhus N, Denmark, 8OXON Epidemiology 
Limited and Department of Primary Care and Public Health, Imperial College, London, United 
Kingdom, 9Oxon Epidemiology Limited, Madrid, Madrid, Spain, 10Quintiles, Levallois-Perred 
Cedex, France, 11Karolinska Institutet, Stockholm, Sweden, 12Department of Epidemiology Lazio 
Region, Rome, Italy, 13University of Groningen, Groningen, The Netherlands, 14IMS Health, London, 
United Kingdom, 15GPRD, London, United Kingdom, 16Universite de Bordeaux, Bordeaux, France, 
17University of Munich, Munich, Germany, 18IMS Health, Paris La Défense, France, 19University 
of Bordeaux, Bordeaux, France, 20Haute Autorité de Santé, Saint-Denis La Plaine Cedex, France, 
21European Medicines Agency, London, United Kingdom
The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance 
(ENCePP) is a project led by the European Medicines Agency aimed at further strength-
ening the post-authorisation monitoring of medicinal products in Europe by facilitat-
ing the conduct of multi-centre, independent post-authorisation studies focusing on 
safety and benefit/risk assessment. ENCePP has recently established a WG on HTA 
to develop methodological guidance to supplement the efficacy and safety aspects 
of medicines known at the time of marketing authorisation (MA) and to bridge the 
needs of HTA and post-marketing benefit-risk assessments. Decision makers are often 
faced with the challenge that long-term, real-world data on safety and effectiveness is 
lacking at the time of MA. This creates uncertainty around the medicines’ risk-benefit 
profile while manufacturers, health care providers, and patient groups exert pres-
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essary duplication of effort must be eliminated. However, doing so is difficult due to 
the current culture of data protectionism and a lack of suitable software that enables 
convenient and useful sharing of the intermediate results. AppROAch: Building on 
our previously published reviews of software for systematic review and trial analyt-
ics, the talk identifies the technical and cultural challenges to be met. We propose 
that a web-based solution enabling the global research community to contribute 
their intermediate results in exchange for access to the data contributed by others 
could rapidly gain momentum. Such a system would challenge data protectionism by 
greatly reducing the level of investment required for data acquisition. cOnclusiOn: 
A disruptive web-based system enabling a massively collaborative approach to sys-
tematic reviewing can make data protectionism obsolete and eliminate much of the 
effort required for future systematic reviews.
PHP233
vALUE-BASED PRICING IN THE UK AND POTENTIAL PATIENT ACCESS HURDLES 
TO INNOvATIvE DRUGS
Papadopoulou K., Grosvenor A.
PriceSpective, London, UK
The UK government plans to introduce value-based pricing (VBP) for medicines in 
England and Wales from January 2014, and one of the key tenets of the scheme is 
to improve patient access to new innovative drugs. This poster aims to explore the 
extent to which VBP is likely to achieve this goal. To meet this objective, an in-depth 
review of available literature (including white papers from key stakeholders and sci-
entific publications) was conducted. Targeted interviews with five leading thought-
leaders in the implementation of VBP were also conducted to support analysis. 
Research identified a number of areas of uncertainty in VBP implementation that 
could detrimentally impact patient access to new drugs. First, the timeline for the 
VBP negotiation process remains unclear. Currently, it takes NICE on average 48 
weeks to issue guidance on a single technology appraisal, which could be extended 
if a technology is not considered cost-effective. Under VBP, manufacturers will still 
be required to negotiate their price with the Department of Health if the calculated 
VBP price by NICE is unfavorable, and the VBP HTA methodology itself could be more 
complex than the current cost-per-QALY approach. Protracted negotiations could 
also delay access in Scotland and Northern Ireland. Equally, manufacturers may 
postpone launch in the UK if they consider VBP a threat in their price corridor in 
other markets. Finally, it is not clear if additional regional or local level negotiations 
will take place, which could further delay access. In conclusion, although there is 
potential for the new adjustable QALY threshold (which remains to be confirmed) 
to foster innovation, the ability of the new VBP process to expedite patient access 
remains uncertain.
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A CHOICE OF BUSINESS FOR THE PHARMACEUTICAL INDUSTRy “SEGURO 
POPULAR” IN MExICO
Vilchis S.
Sistema de Proteccion Social en Salud Mexico, Mexico, Mexico
A choice of business for the pharmaceutical industry “Seguro Popular” in Mexico. 
Abstract Mexico has various providers of health services each one determined to 
a sector of the population where we can find the Mexican Social Security Institute 
(IMSS) that is specifically for workers in the private sector employees and their 
families, the Institute for security and services social of the State workers (ISSSTE) 
for workers in the service of the State or public sector and their families starting 
2003 ushered to the Seguro Popular that extends to the population without social 
security or in State of helplessness in these three mentioned health are emerg-
ing as institutions providing health services larger Mexico insomuch that by 2013 
the Seguro Popular has approximately 54 million affiliates number of successful 
membership in less than 10 years in a country where there is little more than 110 
million of people Seguro Popular is placed, on par with the historic and hegemonic 
IMSS, as the largest buyer of drugs, aware of this are his consumption figures that 
since 2008 has been made public, in such data can find that from 2008 to 2012 they 
have bought 1,241,637,748.68 US Dlls only in drugs consumption regularly since the 
Seguro Popular has several portfolios of services where separate regular conditions 
of sufferings of low frequency and high cost and conditions of very low frequency 
and high cost for children under 5 years who in turn have specific budgets.
DISEASE-SPECIFIC STUDIES 
GASTROINTESTINAL DISORDERS – Clinical Outcomes Studies
PGI1
UNDERSTANDING THE EFFECT OF CLOSTRIDIUM DIFFICILE INFECTION ON 
HOSPITAL MORTALITy IN ENGLAND, THE NETHERLANDS, AND SPAIN
Wasserman M., Jones C., Roberts G., Latif F.
Double Helix Consulting, London, UK
Objectives: Increasing rates of Clostridium Difficile Infection (CDI), a hospital-acquired 
infection, has stimulated a number of financial incentives and government spon-
sored initiatives to quell the spread of the disease. Previous research has shown the 
impact of CDI on hospital length of stay to attempt to quantify the resource impli-
cations. The purpose of this study is to evaluate the impact of CDI on in-hospital 
mortality. MethOds: Data were obtained from national hospital episode databases 
in England, The Netherlands, and Spain. Only patients over the age of 50 and those 
diagnosed with diabetes, chronic kidney disease, heart failure, and chronic obstructive 
pulmonary disease (COPD) were included in the analysis. Cases of CDI were stratified 
between hospital-onset and community-onset cases. Only those that were assumed 
to be hospital-onset were included in the analysis. A logistical regression was used to 
predict the relative effect hospital-onset CDI had on in-hospital mortality. A number 
of covariates were controlled for including: age, sex, comorbidities, and length of stay 
but varied between countries depending on the availability of data. Results: Patients 
with hospital-onset CDI had an overall higher mortality rate compared to those who 
horizontal differentiation), which is often cited (beside R&D costs) as the second barrier 
to entry to the branded market. Here, we have discussed several examples of Cournot 
model within various ATC4 groups and jurisdictions. We have also critically examined 
preponderance of »me-too« entries, particularly in the light of an R&D investment of 
the branded firms. Historically, »me-too« drugs are more ubiquitous than often real-
ized by regulatory agencies, payers, and also the pharmaceutical industry itself. This 
unfortunately presents an inefficient use of resources as the breakthough innovation 
is nowadays, in the time of austerity measures, a real necessity. The models that would 
give incentives to the industry to invest in R&D for breaktrough therapies are possible 
and would not only contribute to optimization of societal welfare but would also in 
the long run increase an R&D productivity of branded firms.
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CELL THERAPIES: ASSESSING THE PATIENT ACCESS OPPORTUNITIES AND 
CHALLENGES THAT LIE AHEAD
Walker R.1, Mackenzie A.2
1PriceSpective, London, UK, 2PriceSpective, Cambridge, MA, USA
This poster seeks to highlight the key challenges and opportunities surrounding patient 
access to innovative cell therapies in the EU5 and US. The findings are based on second-
ary research of commercialised cell therapies as well as primary research with payers 
in EU5 and US. Cell therapies have a unique opportunity to improve patient outcomes 
but face their own set of challenges due to being cell based. As many of these thera-
pies involve manipulation of the patients’ own cells before being reintroduced (e.g., 
ChondroCelect), the associated side effects are likely to be minimal. Other therapies 
(e.g., gene therapy, Glybera) involve the introduction of foreign genetic material but 
provide a potential long-term cure. However, there are some important challenges that 
must be assessed when considering how to commercialise such therapies. In the case of 
therapies where a patient’s cells are manipulated ex vivo, who bears the risk if the patient 
does not receive their individualised treatment? For those therapies that purport to cure 
disease, how much are health care systems willing to pay for them and what evidence 
would be required in order to justify a high price? Moreover, for all therapies, there is the 
uncertainty regarding access pathways: will cell therapies necessarily undergo an HTA 
evaluation to gain access in the EU? What are the criteria that will be used to determine 
whether such a therapy is deemed a product (and, hence, undergo an assessment like 
a regular biopharmaceutical) or a procedure (and likely bypass a national evaluation)? 
In conclusion, cell therapies face uncertainties in market access and funding due to 
unestablished pathways for the spectrum of interventions that fit under the cell therapy 
umbrella. Until frameworks have been put in place, each cell therapy should be assessed 
individually in order to determine likely pathway to patient access.
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THE IMPACT OF RECENT GENERIC DRUG PRICE POLICIES ON PHARMACEUTICAL 
INNOvATION: A THEORETICAL RATIONALE AND PROPOSAL OF A METHOD 
SUPPORTING INNOvATION IN AREAS OF UNMET MEDICAL NEED
Dionne P.A.1, Ali F.1, Grobler M.2
1Pfizer Canada, Kirkland, QC, Canada, 2Pfizer Australia, West Ryde, NSW, Australia
New discoveries are a critical priority for the pharmaceutical industry, for which 
the primary aim should be to address unmet medical needs. However, the use of 
fixed cost-effectiveness (ICER) thresholds for health technology assessment (HTA) 
may tend to decrease incentives to innovate and affect future treatment options. 
This presentation highlights, using a case study, the impact of recent generic drug 
price policies on pharmaceutical innovation in the context of fixed ICER thresh-
olds and proposes a new consideration for the cost-effectiveness analysis (CEA). 
There is a direct causal relationship between HTA and the market price of a drug; 
in jurisdictions where HTA agencies apply fixed ICER thresholds as an important 
reimbursement listing criterion, the incremental cost of a new drug is expected to be 
proportional to its incremental benefit over the comparator. However, the compara-
tor price is subject to market forces or sudden policies and may change markedly 
affecting the cost-effectiveness assessment (e.g. where the comparator patent has 
expired). Since recent generic price regulations (e.g. 18% or 25% of the innovative 
price in Canada) increased the price gap between drugs’ generic and patented ver-
sions, it is harder to achieve a sufficient level of incremental benefits in order to 
offset incremental prices of new treatments. This analysis thus demonstrates that 
with recent changes in generic drug prices in Canada and other jurisdictions, even 
promising drugs will have challenges to show attractive ICERs. Traditional decision-
making process should be adapted to reflect these changes and to promote innova-
tion in therapeutic fields with unmet medical needs. A compromise would be to 
include the comparator’s patented price in the CEA instead of the generic drug in 
certain areas of unmet needs. By identifying the relevant disease areas, decison 
makers and HTA authorities could convey the importance of investing in these 
therapeutic areas to manufacturers.
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THE ExPANDING SCOPE OF COMPARATIvE EFFECTIvENESS REvIEwS REQUIRES 
COLLABORATIvE INFORMATION SySTEMS SOLUTIONS
van Valkenhoef G.
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
bAckgROund: The scope of systematic reviews and health technology assessments 
is rapidly expanding due to increasing demand for more complex models that account 
for patient, treatment, and trial characteristics, network meta-analyses that include 
more interventions, and the growing number of clinical trials. By the year 2000, the 
effort required to publish a typical systematic review had already reached the thou-
sands of person-hours, which were predominantly spent on data acquisition tasks. 
Innovative solutions are required to prevent the costs of comparative effectiveness 
research from ballooning out of proportion. pRObleM: Typically only the end product 
of systematic reviewing, a report summarizing the evidence, is made widely avail-
able. However, capturing the intermediate results of literature searching, publication 
screening, and data extraction has the potential to greatly enhance the efficiency of 
future reviews. In the face of the increasing scope of systematic reviews, this unnec-
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literature review was performed to identify relevant randomized controlled trials 
(RCTs). Data were extracted on study design and patient characteristics. Endpoints 
concerning efficacy were evaluated using network meta-analyses. Clinical response 
was defined as a decrease in Mayo score of ≥ 30% and ≥ 3 points, accompanied by a 
decrease in rectal bleeding score of ≥ 1 point or rectal bleeding score of 0 or 1. Clinical 
remission was defined as a total Mayo score of 2 points or lower, with no individ-
ual subscore exceeding 1 point. Mucosal healing was defined as absolute subscore 
for endoscopy of 0 or 1. Bayesian network meta-analyses (NMA) were conducted 
to evaluate each efficacy endpoint for TNF-naïve patients at the end of induction. 
All analyses were conducted using the OpenBUGS software package. Results: Six 
RCTs were identified from the literature. Similar clinical response was observed 
between the IFX and GOL treatment regimens (IFX 5mg: OR= 2.74, 95%Crl [1.48-5.1], 
IFX 10mg: 2.54 [1.37-4.73], GOL 200/100mg: OR= 1.7 [0.93-3.14], GOL 400/200mg: 1.95 
[1.05-3.58]) when compared to ADA 160/80mg. These similarities were also seen for 
mucosal healing (IFX 5mg: 2.66 [1.43-4.94], IFX 10mg: 2.57 [1.38-4.77], GOL 200/100mg: 
1.54 [0.83-2.85], GOL 400/200mg: 1.68 [0.91-3.10]). IFX demonstrated slightly greater 
clinical remission than GOL (IFX 5mg: 1.96 [0.80-4.65], IFX 10mg: 1.51 [0.61-3.62], GOL 
200/100mg: 1.55, 0.59-4.06], GOL 400/200mg: 1.47 [0.56-3.84]) when compared to ADA 
160/80mg. cOnclusiOns: The NMA allowed the estimation and comparisons of 
clinical response, remission, and mucosal healing of interventions for UC evaluated in 
different RCTs. The findings suggest that the greatest induction of response in moder-
ate to severe UC patients is most likely achieved with IFX and GOL compared to ADA.
PGI5
NETwORK META-ANALySIS OF APPROvED BIOLOGIC INTERvENTIONS FOR THE 
MAINTENANCE OF RESPONSE IN ULCERATIvE COLITIS
Chen M.1, Black C.M.2, Gurunath S.1, Jansen J.P.3, Chaudhary M.A.4, Fan T.5
1Mapi Group, Boston, NJ, USA, 2Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 
Whitehouse Station, NJ, USA, 3Mapi / Tufts University School of Medicine, Boston, MA, USA, 4Merck 
Research Laboratories, North Wales, PA, USA, 5Merck & Co. Inc., Whitehouse Station, NJ, USA
Objectives: To evaluate the comparative long-term efficacy of approved bio-
logic treatments for ulcerative colitis (UC), with a focus on golimumab(GOL), 
adalimumab(ADA), and infliximab(IFX). MethOds: A systematic literature review 
identified 4 randomized controlled trials (RCTs) assessing the efficacy of IFX (5mg, 
10mg), ADA (160/80/40mg) and GOL (100mg, 50mg) as maintenance treatment for 
moderate to severe UC. Data were extracted on study design and patient character-
istics. Endpoints concerning efficacy were evaluated using network meta-analyses 
(NMA) within a Bayesian framework. Analyses were conducted to evaluate sus-
tained response to therapy at both the mid-point (week 30/36) and completion 
(week 52/54/60) of each trial. An additional sub-analysis was conducted because 
the PURSUIT trial design included a re-randomization of induction responders 
to placebo, GOL 50mg or GOL 100mg. This sub-analysis was limited to patients 
who received an induction regimen of GOL 200/100mg followed by 100mg during 
the maintenance period and induction non-responders who received 100mg as 
per protocol. All analyses were conducted using the OpenBUGS software pack-
age. Results: 4 RCTs were identified from the literature. Overall, IFX and GOL 
showed greater sustained response, remission and mucosal healing when compared 
to ADA 160/80/40mg. Between IFX and GOL, IFX doses showed greater remission at 
trial’s completion (IFX5mg OR= 2.04, 95%Crl 0.6-7.03; IFX10mg 1.96, 0.6-6.8; GOL50mg 
1.24, 0.4-3.9; GOL100mg 1.79, 0.6-5.4), response (IFX5mg 1.88,0.8-4.4; IFX10mg 1.73, 
0.7-4.1; GOL50mg, 1.38, 0.6-3.1; GOL100mg 1.45, 0.6-3.3) and mucosal healing (IFX5mg 
1.51,0.7-3.4; IFX10mg 1.53, 0.7-3.5; GOL50mg, 1.38, 0.6-3.3; GOL100mg 1.38, 0.6-3.2. 
During the sub-analyses, GOL100mg and both IFX doses demonstrated greater sus-
tained response and sustained remission when compared to ADA 160/80/40mg. 
Sustained mucosal response increased for IFX 5mg and IFX10mg but decreased for 
GOL100mg. cOnclusiOns: Based on indirect comparison of RCT evidence, IFX 
and GOL are more efficacious to induce and maintain long term response than ADA 
among moderate to severe UC patients.
PGI6
A SySTEMATIC REvIEw OF ANTIDEPRESSANTS IN IRRITABLE BOwEL 
SyNDROME: A QUALITATIvE ANALySIS
Lindner L.1, O’Neill I.D.2, McManus A.2, Rance M.3
1Almirall S.A., Barcelona, Spain, 2Edge Communications, Dorking, UK, 3Almirall UK, Uxbridge, UK
Objectives: To systematically identify and review published evidence on the efficacy 
of antidepressants (tricyclic antidepressants (TCA) and selective serotonin inhibi-
tors (SSRI)) for irritable bowel syndrome (IBS). MethOds: A systematic search of the 
medical literature was conducted using PubMed, Embase, and Cochrane databases. 
Search terms included ‘irritable bowel syndrome’, ‘spastic colon’, ‘irritable colon’, 
‘functional diseases, colon’ and a mixture of agent terms – including antidepressants, 
tricyclic, and SSRIs. Randomised placebo-controlled trials evaluating the efficacy of 
antidepressants (SSRIs and TCAs) in adult patients with IBS were eligible for inclusion. 
Exclusion criteria included absence of placebo arm, patients< 18 years of age, and dual 
publication. Results: A total of 628 unique titles and abstracts were retrieved; 579 
records were excluded upon title (or abstract) review and 31 upon full-text review. The 
final review included 17 studies, 10 reporting on TCAs, 6 on SSRIs, and 1 comparing 
both an SSRI and a TCA vs. placebo, and assessed the methodological compliance of 
each included study with that used in regulatory submissions. In these studies, the 
majority of patients had diarrhea, and only one study, (on SSRIs) reported specifically 
on IBS-C. Treatment duration ranged from 4-12 weeks. A range of outcomes were 
reported, most commonly global symptom relief, and improvements in abdominal 
pain/discomfort. Three studies reported on quality of life, while no studies reported 
specifically on treatment satisfaction. Most outcomes did not align well with those 
now required for FDA and EMA regulatory approval. Across all studies, patient drop-
outs were common, and reporting on per-protocol and intention-to-treat (ITT) popu-
lations varied and in many cases was not explicitly reported. cOnclusiOns: The 
evidence base was of low quality, making estimates of effect very uncertain. Data for 
the efficacy of antidepressants in IBS subtypes is especially limited. Further studies 
are required to support the off-label use of antidepressants in IBS-C.
did not have the disease, demonstrated by a crude relative risk of 6.06 in England 
(37.6% vs. 6.2%), 2.68 in The Netherlands (19.0% vs. 7.1%), and 1.97 in Spain (14.9% vs. 
7.5%). When controlling for covariates, predictive models found a considerable impact 
of hospital-onset CDI on mortality with odds ratios of 2.57 for England (p< 0.001), 
1.88 for The Netherlands (p< 0.001) and 1.33 for Spain (p< 0.001). cOnclusiOns: This 
research demonstrates the significant impact of CDI on hospital mortality and the 
need for more preventative measures within the hospital setting. Further research 
using death certificate data could improve the predictive results of models by ensur-
ing that causal effects of CDI are accurately accounted for.
PGI2
RULING OUT IBD IN THE UNITED KINGDOM AND SPAIN: IS THE USAGE OF 
F-CALPROTECTIN IN PRIMARy CARE COST-EFFECTIvE?
Mascialino B.1, Hermansson L.L.1, Larsson A.2
1Thermo Fisher Scientific, Phadia, Uppsala, Sweden, 2Uppsala University, Uppsala, Sweden
Objectives: The inflammatory bowel diseases (IBD) are characterized by chronic 
inflammation of the gastrointestinal tract; the irritable bowel syndrome (IBS) is a func-
tional disorder (prevalence 10%-20%). They present overlapping symptoms, making 
diagnosis difficult in primary care. Endoscopy is the gold standard for IBD, but it often 
turns negative due to IBD’s low prevalence, it is expensive, uncomfortable and risky 
for the patient. F-Calprotectin is a marker of intestine inflammation: as IBD patients 
exhibit levels higher than the general population and IBS patients, F-Calprotectin can 
be used to rule out IBD. The only CE evaluation on F-Calprotectin has been published 
by NHS (CEP09041, 2010); based on new evidence, we propose a refined model to 
evaluate the CE of F-Calprotectin compared to the standard pre-endoscopic sero-
logic test (CRP+ESR) to distinguish IBD from IBS in the UK and Spain. MethOds: 
F-Calprotectin sensitivity (0.96) and specificity (0.96) were evaluated from a meta-
analysis performed in March 2013; CRP+ESR sensitivity (0.35) and specificity (0.73), 
and the costs come from CEP09041. Published HRQoL values for IBD and IBS were 
transformed in QALYs with transfer-to-utility techniques. The outcomes included 
cost savings, cost per QALY. Uncertainty was addressed with a probabilistic sensitiv-
ity analysis. Results: Results for UK show that F-Calprotectin is CE with respect 
to CRP+ESR: a) it results in more corrected IBD diagnoses at a lower price (it costs 
113£ and 85€ less per patient); b) it reduces the number of unnecessary endoscopies, 
increasing the number of correctly diagnosed IBD (N= 59) and IBS (N= 195) patients; 
c) it brings about a QALY gain per patient equal to 0.0034QALYs; in the UK, the ICER 
of the CRP+ESR diagnostic strategy is 47,783£ (25,941€ for Spain), falling well outside 
the cost-effectiveness bounds (20,000–30,000£ per additional QALY). cOnclusiOns: 
F-Calprotectin is CE to rule out IBD in primary care in UK and Spain.
PGI3
DIAGNOSIS OF PANCREATIC ExOCRINE INSUFFICIENCy IN CHRONIC 
PANCREATITIS, PANCREATIC CANCER AND GASTROINTESTINAL OR 
PANCREATIC SURGERy PATIENTS: A SySTEMATIC LITERATURE REvIEw AND 
ExPERT CONSENSUS ON THE ACCURACy OF DIAGNOSTIC TEST USED IN SPAIN
De Madaria E.1, Gonzalez-Carro P.2, Boadas J.3, Puig de la Bellacasa J.4, Carr E.5, Labrador E.4, 
Paz S.6, Lizán L.6, Schwander B.7, Dominguez M.uñoz E8
1Hospital General Universitario de Alicante, Alicante, Spain, 2Complejo Hospitalario La Mancha 
Centro, Alcazar de San Juan, Spain, 3Consorci Sanitari de Terrasa, Terrasa, Spain, 4Abbott 
Laboratories, Madrid, Spain, 5Abbott Laboratories, Allschwil, Switzerland, 6Outcomes 10, 
Castellon, Spain, 7AHEAD GmbH, Loerrach, Germany, 8Hospital Universitario de Santiago de 
Compostela, Santiago de Compostela, Spain
Objectives: To systematically appraise the literature on the accuracy of four widely 
used tests to diagnose Pancreatic Exocrine Insufficiency (PEI) secondary to chronic 
pancreatitis (CP), gastrointestinal/pancreatic surgery or pancreatic cancer in Spain, 
namely: coefficient of fat absorption (CFA); mixed 13C-triglyceride breath test (MTG); 
fecal elastase-I (FE-I); and serum nutritional markers (SNM). MethOds: A system-
atic review of the literature (March, 2013) was performed (MedLine/PubMed, Cochrane 
Library, CRD, MEDION, ARIF, MEDES, IBECS, ISI WOK, SCOPUS), based on the Cochrane 
and NHS Centre for Reviews and Dissemination recommendations for reviewing 
diagnostic test accuracy studies. Expert validation of the review strategy and results 
were achieved by two consensus meetings. Results: Out of 13.379 publications, 16 
from the systematic search and 3 from hand-search were reviewed: 11 in CP and 8 
in cancer/surgery patients. Fourteen of these used the secretin/cerulein test as the 
reference standard. According to experts, CFA is the gold standard for PEI diagnosis 
(assumed accuracy 100%). 4 publications using CFA as the reference standard were 
selected: FE-I sensitivity and specificity in 58 CP (cutoff < 218μ g/g) and 40 cancer/
surgery patients (cutoff 200μ g/g) were 68% and 98%, and 91% and 35%, respectively. 
MTG was ≥ 90% sensitive and specific in all populations (63 patients), experts con-
sidered this a good reference standard. Sensitivity and specificity for SNM vs. MTG 
were 80% and 81%, respectively and considered by experts as similarly accurate in 
the cancer/surgery population. cOnclusiOns: This is the first systematic review 
to confirm the accuracy of four diagnostic tests for PEI in CP and cancer/surgery 
patients, with the final selection of results being based on expert consensus to 
ensure that the data are representative of Spanish clinical practice. These data, 
together with resource use and cost information from clinical practice will feed an 
economic tool to assess the cost of PEI diagnosis in Spain.
PGI4
NETwORK META-ANALySIS OF APPROvED BIOLOGIC INTERvENTIONS FOR THE 
INDUCTION OF RESPONSE IN ULCERATIvE COLITIS
Chen M.1, Black C.M.2, Gurunath S.1, Jansen J.P.3, Chaudhary M.A.4, Fan T.5
1Mapi Group, Boston, NJ, USA, 2Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 
Whitehouse Station, NJ, USA, 3Mapi / Tufts University School of Medicine, Boston, MA, USA, 
4Merck Research Laboratories, North Wales, PA, USA, 5Merck & Co. Inc., Whitehouse Station, NJ, 
USA
Objectives: To evaluate the comparative efficacy of approved biologic treatments 
for ulcerative colitis (UC), with a focus on golimumab(GOL), adalimumab(ADA), and 
infliximab(IFX) in the induction periods of clinical trials. MethOds: A systematic 
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by colostomy, 0.9% by image guided drainage, 0.7% by washout, 0.62% by abscess, 
0.42% by re-anastomsis, and 0.01% by stent. Patients with leaks tended to be slightly 
younger and male, had higher Charlson Co-morbidity Index, and more likely admit-
ted through emergency vs. elective surgery (p< 0.05). cOnclusiOns: Our study 
indicated an incidence rate of 6.38% for post-operative anastomotic leaks among 
patients undergoing colorectal surgeries in UK, compared to 6.18% leak rate seen 
in the US study. The results highlight the importance of future study in evaluating 
the impact of anastomotic leaks on patient’s clinical and economic outcomes in UK.
PGI10
RESOURCE USE AND DISEASE PROGRESSION AMONG HCv-POSITIvE PATIENTS
Degli Esposti L.1, Sangiorgi D.1, Rizzardini G.2, Perno C.F.3, Buda S.1
1CliCon Srl, Ravenna, Italy, 2“L. Sacco” Hospital Authority, Milano, Milano, Italy, 3University 
Hospital Tor Vergata, Rome, Italy
Objectives: Hepatitis C is an infectious disease affecting the liver; chronic infection 
can lead to cirrhosis. The actual standard of care in Italy is Peginterferon+ribavirin. 
Our aim was to describe treatment patterns, disease progression and resource use 
in HCV. MethOds: An observational retrospective cohort analysis based on 4 Local 
Health Units administrative and laboratory databases was conducted. HCV-positive 
patients between January 1, 2009- December 31, 2010 were included and followed-up 
for one year. To explore which covariates were associated to disease progression 
(cirrhosis, hepatocellular carcinoma -HCC-, death for any cause), Cox proportional 
hazards models were performed. Results: A total of 9514 patients were analyzed, 
55.6% male, age 58.1±16.1; 5.8% had HIV, 3.0% HBV, 1.6% HCV+HBV+HIV, 26.1% cir-
rhosis, 4.3% HCC. Genotypes frequencies were 1a (17%), 1b (34%), 2 (24%), 3 (19%), 4 
(5%). Antiviral treatment was not administered to the majority of patients (79%); the 
main factors affecting this decision were: age > 65 years (44%), females (46% VS 40% 
of treated), cirrhosis (30%), normal liver enzymes (28%), ongoing substance/alcohol 
abuse (7%), HCC (5%). Disease progression in the observed timeframe was less fre-
quent among treated patients (incidence rate per 100 patients/year: cirrhosis 2.1±0.7 
VS 13.0±1.0, HCC 0.5±0.3 VS 3.6±0.5, death for any cause 0.5±0.3 VS 6.4±0.7); at multi-
variable Cox regression models, hazard ratios were, respectively, 0.30 (0.21-0.43), 0.41 
(0.19-0.92) and 0.24 (0.12-0.48) (all p< 0.05). For genotype1 subgroup, results were not 
statistically different between Peginterferon+ribavirin treated and untreated (cir-
rhosis: HR= 0.82 (0.32-2.11), p= 0.682). The annual expenditure for HCV management 
(drugs, hospitalizations, outpatient services) was € 4,700 per patient. cOnclusiOns: 
Actual standard of care was not widely used, especially for sensitive subgroups such 
as women and the elderly; in this context, there is an urgent need for treatment, 
but current therapies do not appear to be adequate for all patients, especially those 
with genotype1, which represents 60% of the Italian HCV population.
GASTROINTESTINAL DISORDERS – Cost Studies
PGI11
PERITONITIS FLUID TREATMENT IN RUSSIAN FEDERATION: EvALUATION OF 
ECONOMICAL BURDEN IN REAL CLINICAL PRACTICE
Yagudina R., Kulikov A., Murashko M.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: Peritonitis is an inflammation of the parietal and visceral peritoneum 
which is accompanied by severe general condition of the body. Peritonitis as a com-
plication of acute inflammatory diseases of the abdominal cavity is found in 15-20% 
of clinical observation and about 6% of all surgical procedures on the abdominal 
cavity. The research is conducted in regard to 4 technologies of fluid treatment, 
including: Reamberin, Ringer’s solution, Plasma-Lyte and Sterofundin. MethOds: 
Retrospective researches analysis is considered as a source of data on real effective-
ness. The decree of the RF Ministry of Health No 669 of October 15, 2007 is considered 
as a source of data on commonly used drugs and medical services. The price-list of 
the Clinical Center of the First MSMU charges for medical services is incorporated 
as the source of data on the price of medical services. Results: The calculation 
is made for the hypothetical group of 100 patients with the peritonitis disease. 
During the cost of illness analysis of peritonitis the direct costs are estimated. They 
include: medical services and pharmacotherapy in the period of the residence in the 
in-patient department(euro per patient: 9 241 for Reamberin, 10 554,8 for Ringer’s 
solution, 9 755,7 for Plasma-Lyte and 9 756,4 for Sterofundin). The cost-effectiveness 
analysis(CEA) results are the following: 10 241 euro for Reamberin, 12 639 euro for 
Ringer’s solution, 12 302 for Plasma-Lyte and 11 683 euro for Sterofundin. The budget 
impact analysis(BIA) show that the 100% switching patients from Ringer’s solution, 
Plasma-Lyte and Sterofundin to Reamberin saves respectively: 131 377 euro, 51 465 
euro and 51 538 euro. cOnclusiOns: Cost of illness analysis, CEA and BIA of peri-
tonitis indicate that the scheme of therapy including Reamberin is the dominant 
one. Total costs are 9 241 euro per patient, CER is 10 241 euro per saved live.
PGI12
ORGANIzATIONAL AND ECONOMIC ISSUES RELATED TO THE INTRODUCTION 
OF BOCEPREvIR IN THE TREATMENT OF PATIENTS wITH GENOTyPE 1 CHRONIC 
HEPATITIS C IN ITALy
La Torre G.1, Miele L.2, Mannocci A.3, Saulle R.3, Giraldi G.3, Unim B.3, Ursillo P.3, Semyonov L.3, 
Colamesta V.3, Melcarne R.3, Biolato M.2, Cecchi R.1, Villari P.3, De G.iusti M3
1Sapienza University of Rome, Rome, Italy, 2Catholic University of Sacred heart, Rome, Italy, 
3Sapienza University of Roma, Roma, Italy
Objectives: To present the critical points concerning organizational and economic 
issues of the introduction of boceprevir in the treatment of patients with genotype 1 
chronic hepatitis C in Italy. MethOds: A budget impact analysis was conducted adapt-
ing the NICE (UK) scheme for this drug, using the Italian epidemiological context and the 
perspective of the National Health Service. The cost-utility analysis (CUA) was carried out 
using a Markov model comparing the triple therapy (TT) with peginterferon alfa, ribavirin 
and boceprevir to the double therapy (DT) with peginterferon alfa and ribavirin. Available 
Italian published scientific literature provided data source. The main outcome of the 
CUA was the incremental cost-effectiveness ratio (ICER). The organizational aspects 
PGI7
CHARACTERISTICS OF CHILDREN AND ADOLESCENTS USING PROTON PUMP 
INHIBITORS OR HISTAMINE-2-RECEPTOR ANTAGONISTS: ANALySIS OF THIN 
AND PHARMO DATABASES
Ruigómez A.1, Houweling L.M.A.2, García-Rodríguez L.A.1, Penning-van Beest F.J.A.2,  
Herings R.M.C.2
1Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain, 2PHARMO Institute 
for Drug Outcomes Research, Utrecht, The Netherlands
Objectives: To describe demographics and co-morbidities of children starting 
PPI or H2RA use. MethOds: Data were obtained from The Health Improvement 
Network (THIN, a UK primary care database) and the Dutch PHARMO Database 
Network (including outpatient pharmacy and hospital databases). Children (< 19 
years) starting a PPI or H2RA between 2009–2012 (THIN) and 2008–2010 (PHARMO) 
were selected. Demographics, medical history, co-morbidities and co-medication 
were assessed. Results: The study included 15782 PPI starters (THIN, n= 5957; 
PHARMO, n= 9825) and 8980 H2RA starters (THIN, n= 5696; PHARMO, n= 3284). The 
proportion of males was similar between PPI and H2RA starters in each database 
(THIN, 41% vs 48%; PHARMO, 44% vs 48%). H2RA starters more often were < 12 years 
of age (THIN, 73% vs 26%; PHARMO, 58% vs 36%) and PPI starters more often had 
received other prior acid-suppressing treatment (THIN, 9% vs 2%; PHARMO, 10% vs 
7%). In THIN, a history of infectious or respiratory disease was more common in PPI 
starters: infectious disease, 89% vs 65% (odds ratio (OR) 1.20; 95% confidence interval 
(CI) 1.05–1.37); respiratory disease, 77% vs 49% (OR 1.20; 95%CI 1.08–1.34). In PHARMO, 
PPI starters were also more likely to suffer from asthma/chronic obstructive pulmo-
nary disease (8% vs 6% (OR 1.35; 95%CI 1.14–1.60)) and more often used antibiotics 
(20% vs 13% (OR 1.53; 95%CI 1.37–1.72)) and non-steroidal anti-inflammatory drugs 
(25% vs 5% (OR 4.48; 95%CI 3.80–5.29)). PPI starters in PHARMO were also more likely 
to have a history of diabetes or epilepsy (diabetes, 1% vs < 0.5% (OR 5.00; 95%CI 
2.33–10.73); epilepsy, 2% vs 1% (OR 1.69; 95%CI 1.16–2.45)). cOnclusiOns: Results 
from both databases indicated that H2RA starters were younger than PPI starters. PPI 
starters were more likely to have received other prior acid-suppressing treatment 
and had more co-morbidities than H2RA starters.
PGI8
HEPATOCELLULAR CARCINOMA: AN EPIDEMIOLOGICAL AND MANAGEMENT 
SURvEy-BASED ANALySIS IN ITALy
Cicchetti A.1, Gasbarrini A.2, Ruggeri M.1, Sacchini D.2
1Università Cattolica del Sacro Cuore, Rome, Italy, 2Università Cattolica del Sacro Cuore, Rome, 
Italy, Italy
Objectives: To verify how Hepatocellular Carcinoma (HCC) management is carried 
out in Italy and to point out the organizational key variables useful for an economic 
assessment, considering that Italy is among the European States with the highest 
incidence of HCC according to recent published data and that HCC is the final and 
highest cost health state along the natural history of liver diseases. MethOds: A 
questionnaire was set up jointly by clinicians (hepatologists and infectivologists), 
pharmacoeconomists and HTA experts, and submitted to 9 centers in order to col-
lect epidemiology and management data. The survey consisted of a series of ques-
tions regarding HCC patients: gender and age, HCC etiology, BCLC (Barcelona Clinic 
Liver Cancer) staging at diagnosis, current treatments, hospitalization regimens, 
number and description of diagnostic/outpatient procedures, other relevant concur-
rent pathologies. The survey was administered to patients in four Italian centers 
of excellence for liver diseases with well-established experience in treating HCC 
patients. Results: A total of 596 questionnaires were collected, the majority of 
which regarding male patients (79%), with a mean age of 67. Etiology proved to be 
mainly HCV-related (56%) and most patients underwent full hospitalization (81%) 
with a mean duration of 16.5 days, with a wide variability among centers, concern-
ing both diagnostic procedures (CT, MRI, ecography…) and treatments (surgery, liver 
transplantation, drugs…). cOnclusiOns: The collected data show a major hetero-
geneity, linked to the different etiology and epidemiology of the disease along the 
peninsula, well characterized by a number of published studies, but prove to be very 
helpful in describing the current situation regarding HCC in Italy. This descriptive 
analysis will be useful to set up a prospective study with the aim to implement an 
economic model able to compare different treatments and diagnostic procedures, 
and including organizational aspects in accordance to a cluster-randomized logic.
PGI9
INCIDENCE OF ANASTOMOTIC LEAKS AFTER COLORECTAL SURGERIES USING 
HOSPITAL EPISODE STATISTICS IN THE UNITED KINGDOM
Riebman J.1, Lim S.1, Gao X.2, Delatore P.1, Wan Y.2
1Ethicon, Inc, Somerville, NJ, USA, 2Pharmerit International, Bethesda, MD, USA
Objectives: Reported incidence of gastrointestinal anastomotic leaks after colorec-
tal surgeries varies across regions, mainly due to different definitions of anastomotic 
leaks. A recent study using Premier Perspective administrative database reported 
6.18% incidence of post-operative anastomotic leaks in US. The objective of this 
study is to apply a similar definition of anastomotic leaks from the US study and 
estimate incidence of anastomotic leaks after colorectal surgeries in UK. MethOds: 
Hospital Episode Statistics database was used to identify patients receiving colo-
rectal surgeries from January 2007 to December 2011. The index colorectal sur-
geries included colectomy, hemicolectomy, sigmoid colectomy, and low anterior 
resection identified by OPCS-4 codes. The anastomotic leak event was defined by 
re-intervention (OPCS-4 codes) or diagnosis (ICD-10 codes) within 30-day window 
following index colorectal surgeries. The re-intervention included re-operation, re-
anastomosis, stent, colostomy, image guided drainage, abscess, and washout. The 
diagnosis was generalized acute peritonitis. Chi-square and t tests were used to 
compare demographic characteristics between patients who had leaks and those 
who did not. Results: A total of 132,045 patients (mean age: 65 years, 50% male) 
received colorectal surgeries during 2007-2011. Of these, 8,434 (6.38%) had anas-
tomotic leaks within 30 days of the colorectal surgeries. 2.63% leak cases were 
defined by reoperation, 1.82% by diagnosis of generalized acute peritonitis, 1.24% 
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treated. The savings mainly resulted from shorter operating time (13 Minutes) and 
decreased hospital stay (0.7 days). cOnclusiOns: Although the instrument cost 
is higher for the ultrasonic device, the total procedural cost is lower compared 
to electrosurgery. Utilization of the Harmonic® ultrasonic device in laparoscopic 
cholecystectomy can lead to substantial cost savings for US hospitals.
PGI16
MORTALITy AND MEDICAL COSTS ASSOCIATED wITH LIvER-RELATED 
DISEASES AMONG PATIENTS wITH HEPATITIS C vIRUS(HCv) INFECTION IN 
TAIwAN
Tang C.H., Huang K.C., Huang S.Y., Wu Y.T., Lin K.D.
Taipei Medical University, Taipei, Taiwan
Objectives: To examine the mortality and medical costs during the first and the 
2nd year following the onset of the five liver-related diseases, i.e. HCV infection, 
compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carci-
noma (HCC), or liver transplantation. MethOds: Patients with HCV infection and 
patients who transitioned to the health state of liver-related disease were identi-
fied from the National Health Insurance Research Database (NHIRD) during 2008-
2010 if any outpatient/inpatient service with primary diagnosis code of 070.54 for 
HCV infection or 571.5 for CC occurred, or if patients registered in the Registry of 
Catastrophic Illness with diagnosis code of 571.5 for DCC, 155 for HCC or V42.7 for 
post liver transplantation. Dual infection patients with diagnosis code of 070.30 for 
HBV or 042-044 for HIV were excluded. The date that the outpatient visit/admission 
with the diagnosis code associated with each health state of liver-related disease 
firstly occurred was defined as the index date. Regression-adjusted medical costs 
associated with each health state of liver-related disease within 1st year and 2ndyear 
after the index date were estimated by generalized linear regression model. Excess 
risks of death for patients with DCC, HCC, or liver transplantation were assessed 
by Cox proportional hazard model. Results: First year total medical costs associ-
ated with HCV infection, CC, DCC, HCC and liver transplantation were NT$25,345, 
NT$49,793, NT$187,428, NT$197,835, NT$487,816, respectively. The 2nd year total 
medical costs associated with DCC, HCC and liver transplant were NT$194,016, 
NT$176,167 and NT$270,009, respectively. Patients in the health states of DCC, HCC 
and liver transplantation posed higher risk of death with hazard ratio of 14.5when 
compared with their matched control counterparts. cOnclusiOns: Liver-related 
diseases followed by HCV infection impose substantial economic burdens to the 
National Health Insurance in Taiwan. Effective treatment for HCV infection may 
imply potential savings to the society.
PGI17
RESOURCE UTILIzATION AND COSTS FOR PATIENTS wITH INFLAMMATORy 
BOwEL DISEASES IN ITALy: A POPULATION-BASED ASSESSMENT
Madotto F.1, Fornari C.1, Fiorino G.2, Ardizzone S.2, Bortoli A.2, Caprioli F.2, Cestari R.2,  
Conti S.1, Cortelezzi C.2, Mantovani L.G.3, Massari A.2, Meucci G.2, Ravelli P.2, Vecchi M.2, 
Danese S.2, Cesana G.1
1University of Milano - Bicocca, Monza, Italy, 2EPICO MICI LOMBARDIA Project, Milano, Italy, 
3Federico II University of Naples, Naples, Italy
Objectives: To describe health care resource utilization in treating patients 
affected by inflammatory bowel diseases (IBD) and to assess the related direct costs 
to the Italian health care system (HS) in its most populated region. MethOds: A 
retrospective observational study was conducted using data from DENALI, a data 
warehouse that organizes and integrates the health care administrative databases 
of the national HS in Lombardy (northern Italy) with a probabilistic approach. The 
Italian HS provides universal coverage and records the accesses to health care ser-
vices at regional level. We enrolled adult patients with Ulcerative Colitis (UC) or 
Crohn’s Disease (CD) diagnosed during the period 2003-2009. Patients were classi-
fied in two cohorts in relation to the type of IBD and were followed until December 
31st, 2009 to assess the mean annual consumption of resources (hospitalizations, 
pharmaceutical prescriptions, outpatient services) and the related costs incurred by 
HS. Results: We identified 5,523 patients with UC and 3,321 with CD and the mean 
annual cost per-capita was € 2,386 (95%CI: 2,241-2,516) and € 2,699 (95%CI: 2,538-
2,914) respectively. The breakdown of expense was similar in the cohorts: pharma-
cological treatments accounted for 37% , hospitalizations for 47% and outpatient 
services for 16%. Use of mesalamine was high in patients with UC and CD:94% and 
88% of subjects was respectively prescribed at least one package during follow-up. 
High adherence (≥ 70%) to oral mesalamine was observed in 39% of patients with 
UC and in 24% of CD cohort. Less than 6% of patients used biologics, which were 
used only from 2008. cOnclusiOns: This study confirms that patients with IBD 
represent a considerable economic burden for the Italian HS: prescribed drugs, 
especially mesalamine, account for a substantial proportion of health care costs. 
The results underline the importance of administrative databases and the need 
for further research, since the recent widespread use of biologics for treating IBD.
PGI18
UTILISATION AND COSTS OF INPATIENT AND OUTPATIENT SERvICES AMONG 
PATIENTS wITH IRRITABLE BOwEL SyNDROME- A STUDy USING THE CLINICAL 
PRACTICE RESEARCH DATALINK (CPRD)
Murray-Thomas T.1, Dedman D.1, Canavan C.2, West J.2, Card T.2
1Medicines and Healthcare Products Regulatory Agency, London, UK, 2University of Nottingham, 
Nottingham, UK
Objectives: Irritable bowel syndrome (IBS) is a common functional gastrointestinal 
disorder. We assessed utilisation of secondary care services and associated costs 
among patients with IBS. MethOds: IBS was identified by medical diagnosis and/
or prescribing in the UK primary care setting. Patients had ≥ 12 months of medical 
history prior to diagnosis. Absolute resource use and expenditure were assessed 
post IBS and over four years (01/04/2008-31/03/2012) using Hospital Episode Statistic 
data. Inpatient admission, outpatient attendance and length of stay for any cause 
including IBS related conditions were assessed. Inpatient costs for the period were 
estimated using allocated Health Resource Group coded data. Outpatient costs 
considered were: clinical management of patient with HCV chronic infection, access 
modalities, outpatient visit, planned and unplanned visits, hospital admission, role of 
the general practitioner (GP). Results: The budget impact analysis shows that, consid-
ering both naïve and previously treated patients, the treatment with boceprevir has an 
impact on the National Health Service of almost € 66 million for the first year. Compared 
to treatment with DT, the cost-utility analysis shows for the boceprevir-based treatment 
strategy an ICER of € 8.622,00. The management of TT for its intrinsic complexity requires 
monthly outpatients visits, at least at the beginning of treatment, for monitoring the 
compliance to treatment, efficacy and side effects. A critical organizational point is 
potentially the request for boceprevir for each single patient by the medical prescriptor, 
who needs to fill in detailed form from the Italian Agency of Drug (AIFA). cOnclusiOns: 
The impact of the introduction of boceprevir on the budget is high, even if the ICER is 
favourable. Patients’ management is particularly complex and there is the need for an 
alliance between the patients, their relatives, GPs and specialized centers.
PGI13
ENTERAL DIETS (ED): A COST-COMPARISON ANALySIS FOR IN-HOSPITAL 
PREPARATIONS BASED ON REAL wORLD OBSERvATION
Clark O.A.C.1, Paladini L.1, Nishikawa A.M.1, Borges L.1, Arraiz A.2
1Evidencias, Campinas, Brazil, 2Danone Medical Nutrition, São Paulo, Brazil
Objectives: ED can be administered based on three different systems – powder 
based (Po), open, liquid (Op), and a completely closed (Cl). There are differences in the 
preparation, installation and delivery and in the diarrhea rates among them. Our aim 
was to measure the total costs for each system, considering the resources needed to 
prepare, delivery administer and discard of each system (hidden costs). MethOds: 
We measured the human (nurse, nutritionist, auxiliary personnel) resources involved 
in ED preparations in three hospitals of Brazil. Then, we calculated the costs of the 
process, based on the minimum official wage for each professional category. After, we 
added the costs of the diets and materials needed to the infusion. We used as base 
case a daily need of 1 000Kcal / patient. Additional analyses were performed to include 
the side effects of ED system. Results: There were differences among the human 
resources needed for each system. Hidden costs were 63% of the total for Op, 58% for Po 
and 53% for Cl. Particularly, the nurse time varied from 18 minutes for Po and Op and 5 
min for Cl for each infusion. Considering that and average patient would require daily 
4 infusions of Po or Op, that represents a total of 72min of nurse time to these systems, 
against 5 min to Cl. Total daily costs, were Op US$ 62.05; Po US$ 50.75 and Cl US$48.03. 
If we consider the costs of side effects, such as diarrhea, the costs are: Op US$ 73.42; 
Po US$ 62.15 and Cl 56.35. This increase in the difference amog the costs is due to a 
lower incidence of diarrhea in Cl systems. cOnclusiOns: There are many hidden 
costs on the ED systems. If we consider them Cl systems are less costly than Op and Po.
PGI14
COST ANALySIS OF PROTON PUMP INHIBITORS IN THE TREATMENT OF ULCER 
DUODENUM IN UKRAINE
Iakovlieva L., Gerasymovà O., Mishchenko O., Kuznetsov I., Kyrychenko O., Tkachova O.
National University of Pharmacy, Kharkiv, Ukraine
Objectives: Proton pump inhibitors (PPIs) are essential components schemes of 
antyhelicobacter therapy (AT) of peptic ulcer disease. The aim of research - to deter-
mine the costs of the use of PPIs in the traditional triple schemes AT (first and second 
line) of the working age patients with a duodenal ulcer in Ukraine. The objects of 
research - preparations of omeprazole, pantoprazole, rabeprazole, lansoprozol, ezome-
prazol, which are present in Ukraine. MethOds: Cost analysis on the use of PPIs in 
the schemes of AT was performed per one patient for 14 days with the daily doses of 
drugs: omeprazole - 40 mg, pantoprazole - 80 mg, rabeprazole - 40 mg, lansoprozol - 60 
mg, ezomeprazol - 40 mg (according to the recommendations of the “Maastricht IV”, 
2010). For determining the costs only the costs of the PPIs were taken into account. 
The prices of drugs were taken from the information system “Drugs” of Company 
“Morion” (December, 2012). The currency ratio of UAH to dollar (USA) on 10.12.12 was 
7.99:1. To determine the range of costs for use of PPIs determined their trade names 
with the minimum and maximum costs for the AT. Results: The range of costs for 
use of PPIs in the traditional triple schemes AT in Ukraine is wide enough, respectively: 
omeprazole - 1.15 - 19.15 $, pantoprazole - 5.11 - 49.28 $, lansoprozol - 5.14 - 10.66 $, 
rabeprazole - 4.27 - 63.40$, ezomeprazol 1.81 - 36.42$. cOnclusiOns: Costs only for 
the use of PPIs in the schemes of AT of duodenal ulcer can be quite high in Ukraine. 
In this regard, the choice of PPIs for inclusion in the schemes of AT is advisable to use 
the results of pharmacoeconomic studies that will optimize the costs of the payer.
PGI15
ECONOMIC ANALySIS OF USE OF HARMONIC DEvICES IN INPATIENT 
LAPAROSCOPIC CHOLECySTECTOMy IN THE UNITED STATES
Cheng H.1, Hinoul P.1, Clymer J.1, Vaughn B.2
1Johnson & Johnson(Ethicon Endo Surgery, Inc), Cincinnati, OH, USA, 2Johnson and 
Johnson(Ethicon, Inc), Somerville, NJ, USA
Objectives: Harmonic® ultrasonic energy devices have been developed as a safer 
and more efficient alternative to traditional electrosurgery (monopolar and bipolar) 
in laparoscopic cholecystectomy. However, the economic impact on hospital cost 
has not yet been assessed in the United States. The aim of the study is to evaluate 
the total cost of laparoscopic cholecystectomy performed with an ultrasonic device 
versus electrosurgery from a hospital perspective. MethOds: A literature review 
was performed to identify publications via EMBASE and MEDLINE database. Nine 
randomized controlled studies were included in this analysis based on inclusion 
criteria. The clinical results were weighted based on No. of patients to calculate 
averages for both energy devices. The total departmental cost data for electrosurgery 
group were obtained from a large US payor (PREMIER database) to apply the clini-
cal findings to calculate the cost for the Harmonic group. The total cost in laparo-
scopic cholecystectomy with two energy devices was compared to determine which 
modality is more cost effective. Results: The total case cost using an ultrasonic 
device in an inpatient laparoscopic cholecystectomy is $7701 v.s. electrosurgery is 
$8637. The use of an ultrasonic device provides a hospital savings of $936 per patient 
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part of the gastrointestinal tract. Although most people with CD lead active lives, five 
years after onset 15% to 20% of patients are disabled by their disease to some degree. 
The purpose of the current review was to evaluate recent data from the literature on 
the economic burden of CD in European countries in adults and in children, using US 
data as a benchmark. MethOds: A systematic review of the data on economic and 
humanistic burden for adults and children in Germany, France, UK, Italy, Spain and 
the US was performed covering the period 2000 to 2012. The methods followed rec-
ommendations and guidance published by the Centre for Reviews & Dissemination, 
York, UK. Results: Of the 425 publications identified on the economic burden of 
CD, 92 were suitable for further evaluation, and 39 were selected. Among these 
studies, five presented total costs of CD management in adults, ranging from € 1,425 
to € 15,521 per patient depending on the country. Most of the direct costs were due 
to hospitalisations, surgeries or use of biologic drugs. Patients with severe disease 
and those requiring hospitalisation had disproportionately higher costs (5.6 times 
higher) compared to those with milder disease. Direct costs were more important 
for relapsing disease than quiescent disease. Only one European study focused on 
children using biologic drugs as maintenance treatment. cOnclusiOns: Research 
on the economic burden of CD management has been mainly published on adults 
in the US and UK, with limited data from Germany, Spain and Italy. Similar data for 
paediatric CD is almost non-existent. More research is needed to better understand 
the economic and humanistic burden faced by paediatric CD patients in Europe.
PGI22
ECONOMIC CONSEQUENCES OF NONALCOHOLIC STEATOHEPATITIS IN THE 
UNITED STATES
Lin F.1, Thomas S.2, Gruenberger J.B.3, Calado F.3
1Novartis, East Hanover, NJ, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 
3Novartis Pharma AG, Basel, Switzerland
Objectives: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-
alcoholic fatty liver disease that becomes increasingly prevalent with the growing 
epidemic of obesity and diabetes in the United States. An estimated 3% of adults in the 
US have NASH and are at high risk of severe liver complications, including cirrhosis, 
liver failure, and hepatocellular carcinoma (HCC). Despite the rising prevalence, data 
on its economic and clinical consequences are limited. The objective of this study 
was to predict the long-term clinical and economic consequences associated with 
the adult NASH patients in the US over the next 20 years, including NASH-related 
complications, morbidity, mortality and health care costs. MethOds: We developed 
a Markov cohort model to estimate the consequences of NASH, which included six 
Markov states: NASH, compensated cirrhosis, decompensated cirrhosis, HCC, liver 
transplantation, and death. We estimated the number of liver complications, their 
associated health care costs, and NASH-related mortality. Results: By 2033, 53.1% 
and 32.8% of NASH patients would progress to compensated and decompensated cir-
rhosis, respectively. An estimated 13.7% of patients developed HCC, and 13.3% eventu-
ally underwent liver transplantation. Among NASH patients, 16% had Type II diabetes 
and 44.8% and 23.8% would develop decompensated cirrhosis and HCC. The model 
predicted hepatic-related mortality of 24.2% and 12.6% for patients with and without 
diabetes, while the cardiovascular-related mortality was estimated to be 12.1% and 
8.8% for NASH patients with and without diabetes. The direct health care cost was 
estimated at $72,170 and $120,165 for patients with and without diabetes, resulting in 
a total of $574 billion health care cost over the next 20 years. cOnclusiOns: NASH 
patients were expected to have substantial risks for chronic liver failure and result 
in an increasing financial burden on the US health care system.
PGI23
ECONOMIC EvALUATION OF TIPS COMPARED TO LARGE vOLUME 
PARACENTESIS IN PATIENTS wITH REFRACTORy ASCITES
Burke M.1, Hacking N.2, Wright M.2, Iqbal K.3, Craig J.4
1NICE, Manchester, UK, 2Southampton General Hospital, Southampton, UK, 3WL Gore & 
Associates Ltd., Livingstone, UK, 4York Health Economics Consortium Limited, York, UK
Objectives: Undertake an economic evaluation of transjugular intrahepatic por-
tosystemic shunts (TIPS) compared to large volume paracentesis (LVP) in patients 
with refractory ascites. Paracentesis, although the standard treatment for refractory 
ascites, does not treat the underlying portal hypertension. According to a meta-
analysis of individual patient data, using TIPS with bare metal stents (BMS) rather 
than LVP showed improved survival and lower recurrence of ascites although with 
a higher number of hepatic encephalopathy episodes (Salerno 2007). MethOds: A 
Markov economic model was developed to measure the incremental resources and 
costs associated with TIPS, using costs for ePTFE covered stent-grafts configured 
for TIPS (SG), compared to LVP over two years. Clinical data came mainly from the 
meta-analysis, whilst health care costs were from UK national databases. Results: 
Use of TIPS rather than LVP to manage refractory ascites was estimated to save 
almost £1,600 per patient over 2 years. Total costs for the treatment pathway were 
£8,310 with TIPS and £9,907 with LVP treatments. The TIPS implantation, together 
with the associated costs of re-intervention & complications cost £6,760 but there 
were estimated savings of £8,360 from avoided LVP procedures. Using TIPS to man-
age refractory ascites, rather than LVP, was cost saving under all the sensitivity 
analyses undertaken. cOnclusiOns: The economic model demonstrated a total 
cost reduction of £1,600 per patient from TIPS with SG compared to LVP. Actual cost 
reduction may be greater as clinical data used from the meta-analysis was for BMS. 
Compared to BMS, SG have improved patency resulting in fewer reinterventions 
(Bureau 2007) which may reduce overall costs.
PGI24
AN ECONOMIC EvALUATION COMPARING EPTFE COvERED STENT-GRAFTS 
CONFIGURED FOR TIPS wITH BARE METAL STENTS IN PROCEDURES FOR THE 
TREATMENT OF PORTAL HyPERTENSION COMPLICATIONS
Burke M.1, Hacking N.2, Wright M.2, Iqbal K.3, Craig J.4
1NICE, Manchester, UK, 2Southampton General Hospital, Southampton, UK, 3WL Gore & 
Associates Ltd., Livingstone, UK, 4York Health Economics Consortium Limited, York, UK
were estimated using national average reference costs based on treatment speci-
ality. Costs of medications prescribed in secondary care were not included. Total, 
mean and annual visits and costs were estimated and stratified by gender, age and 
treatment speciality. Prices were adjusted to 2011/2012. Results: We identified 
79,303 patients with IBS with an average follow-up of 3.38 years. Of these patients, 
46,814(59%) had ≥ 1 contact with secondary care for any cause; 22,685(48.5%) patients 
attended outpatient services only. Patients using secondary care had about 2 hos-
pitalizations on average and 3-4 outpatient visits annually. Mean inpatient stay 
declined from 4 days in 2008/2009 to 3 days in 2011/2012. The total cost of hospi-
talisation during the period was over £114 million, including about £35(30%) million 
for emergency inpatient admissions and £33.8 million for outpatient attendance. 
Digestive disorders accounted for around 30% of inpatient admissions and 21% of 
expenditure incurred. Mean cost of inpatient admissions for digestive conditions 
was £1,993, average costs per patient was £4,871 and £2,779 for elective and emer-
gency visits respectively. cOnclusiOns: Utilisation and costs of secondary care 
among IBS patients is substantial, not only for the management of IBS and related 
conditions, but also for other co-morbid medical conditions.
PGI19
INTERIM RESULTS FROM THE BURDEN OF BOwEL DySFUNCTION IN SPINAL 
CORD INjURy STUDy
Mittmann N.1, Bannon G.1, Hassan S.1, Seung S.J.1, Kee P.1, Cartolano N.S.1, Pinto P.M.1,  
Smith K.2, Craven C.3, Wolfe D.4
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2Providence Care, Kingston, ON, 
Canada, 3Toronto Rehabilitation Institute, Toronto, ON, Canada, 4Parkwood Hospital, St. Joseph’s 
Health Care, London, ON, Canada
Objectives: There are approximately 40,000 Canadians living with spinal cord 
injury (SCI). Most individuals with SCI experience some type of bowel dysfunction 
(BD), which can contribute to a high burden in individuals and caregivers, and a 
decrease in quality of life. This study aims to identify and measure resources, costs, 
health preference and quality of life associated with BD and its management in a 
cohort of SCI individuals living in a community setting in Ontario over a 6-month 
period. MethOds: This study is a prospective, observational study with 80 adult 
participants being recruited at three SCI clinics in Ontario, Canada. Questionnaires 
are completed by participants over a 6-month period (baseline, three weekly and 
five monthly). Information related to demographics, BD (e.g., neurogenic bowel 
dysfunction score), health preference (e.g., Health Utility Index (HUI) Mark 3) and 
resource utilization (e.g., physician, medication, caregiver burden, etc.) attributed 
to BD is being collected. Results: Results from three clinics are being evaluated. 
45 participants have completed the questionnaires to-date. The majority of partici-
pants are male (60.00%). Mean time since SCI was 20.2±13.7 (2 – 42) years. Twenty 
(44.4%) participants were employed. At baseline, the mean neurogenic BD score was 
14.37±6.05 (0 – 31). At 6 months, the score was 12.9±6.6 (2 – 28). The mean HUI-3 score 
at baseline was 0.17±0.31 (-0.37 – 0.95). At 6 months the score was 0.19±0.33 (-0.37 – 
1). The mean number of visits to primary care physicians by participants was 8.3 ± 
8.6 (0 – 33) times over 6 months. 52.21% of participants required caregiver assistance. 
12.50% of participants required a mean 1.21±0.67 (0.3 – 2) hours daily assistance 
with their bowel routines. cOnclusiOns: Results from the 45 SCI individuals with 
BD indicate a variety of health resources are being utilized over a 6-month period. 
Future results will have resources associated with BD quantified.
PGI20
A COST-OF-ILLNESS ANALySIS OF HEPATITIS C IN GREECE
Athanasakis K.1, Arzoumanidou D.1, Petrakis I.1, Karampli E.1, Theodoropoulou T.2,  
Retsa M.P.2, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2MSD Hellas, Athens, Greece
Objectives: Hepatitis C virus infection is accompanied by significant disease and 
economic burden internationally. In absence of data, the objective of this study 
was to estimate the annual cost of hepatitis C treatment and follow-up, in Greece, 
according to disease severity. MethOds: Resource utilization for “typical patient” 
scenarios, according to disease stage, was elicited via an expert panel (gastroen-
terologists and hepatologists from major hospital units of the Greek NHS). Patients 
were stratified based on disease stages; (a) fibrosis stage F0 to F3, (METAVIR score) (b) 
compensated cirrhosis (c) decompensated cirrhosis – first year (d) decompensated 
cirrhosis – subsequent years (e) hepatocellular carcinoma (HCC) (f) liver transplant 
(LT) – first year (g) LT – subsequent years. Direct cost categories included yearly 
costs of consultations, laboratory and PCR tests, medications and hospitalization. 
Cost calculations were based on 2012 fixed fees and prices, from a Social Security 
perspective. Results: The average direct annual cost per patient for F0-F3 patients 
was estimated at 642.7€ , excluding the cost of medications or 12,685.1€ , includ-
ing the cost of standard of care with PegIFN/ribavirin regimen. Respective annual 
costs for states (b) to (g) were: 636.7€ (compensated cirrhosis), 2,250.1€ and 5,934.5€ 
(decompensated first and subsequent years), 21,890.1€ (HCC), 35,051.1€ and 4,001.5€ 
(LT first and subsequent years). Main cost variables were hospitalizations [48.9%, 
53.3% and 88.2% of the total cost for states (c) (d) and (g)], medications [93.2% and 
50.1% of the total cost for states (e) and (g)] and laboratory tests [89.1% and 83.0% 
of the total cost for states (a) and (b)]. cOnclusiOns: This cost analysis of chronic 
hepatitis C in the Greek health care system has shown that there is a substantial 
economic burden, significantly increasing in advanced liver disease. Standard and 
new interventions that slow disease progression or achieve virus eradication are 
deemed necessary from a clinical and economic perspective.
PGI21
SySTEMATIC REvIEw: THE ECONOMIC BURDEN OF CROHN’S DISEASE IN 
EUROPE IN ADULTS AND CHILDREN
Floyd D.1, Langham S.1, Chevrou-Severac H.2
1PHMR Associates, London, UK, 2Nestlé Health Science, Vevey, Switzerland
Objectives: Crohn’s Disease (CD) is an immune-mediated disorder characterised by 
recurrent chronic uncontrolled inflammation on the intestinal mucosa affecting any 
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COST-EFFECTIvENESS OF LINACLOTIDE COMPARED TO ANTIDEPRESSANTS IN 
THE TREATMENT OF IRRITABLE BOwEL SyNDROME wITH CONSTIPATION IN 
SCOTLAND
Fisher M.1, Falqués M.2, Rance M.3, Taylor D.C.A.4, Lindner L.2
1WG Consulting Healthcare Limited, High Wycombe, UK, 2Almirall S.A., Barcelona, Spain, 
3Almirall UK, Uxbridge, UK, 4Ironwood Pharmaceuticals, Cambridge, MA, USA
Objectives: Presently, linaclotide is the only EMA approved therapy indicated for 
the treatment of irritable bowel syndrome with constipation (IBS-C). This study 
sought to determine the cost-effectiveness of linaclotide compared to antidepres-
sants for the treatment of adults with moderate to severe IBS-C who have previ-
ously received antispasmodics and/or laxatives from the perspective of the Scottish 
National Health System (NHS). MethOds: A Markov model was created to estimate 
costs and QALYs over a 5-year time horizon from the perspective of NHS Scotland. 
Health states were based on treatment satisfaction (satisfied, moderately satisfied, 
not satisfied) and death. Transitions between states were based on satisfaction data 
from the linaclotide pivotal studies (MCP-103-302 and LIN-MD-31) and Scottish 
general all-cause mortality statistics. Treatment costs were calculated from the 
British National Formulary. NHS resource use and disease-related costs for each 
health state were estimated from Scottish clinician interviews in combination with 
NHS Reference costs. Quality of life was based on EQ-5D data collected from the 
pivotal studies. Costs and QALYs were discounted at 3.5% per annum. Uncertainty 
was explored through extensive deterministic and probabilistic sensitivity analy-
ses. Results: Over a 5-year time horizon, the additional costs and QALYs with 
linaclotide were £659 and 0.089, resulting in an incremental cost-effectiveness ratio 
of £7,370 per QALY versus antidepressants. Results were most sensitive to health 
state transitions probabilities, NHS resource use assumptions and health state 
utilities. Threshold analyses showed that the effectiveness of linaclotide would 
have to be at least 11% lower than the base case to exceed a willingness-to-pay 
threshold (WTP) of £20,000 per QALY. Based on the probabilistic sensitivity analysis, 
the likelihood that linaclotide was cost-effective at a WTP of £20,000 per QALY was 
74%. cOnclusiOns: Linaclotide is a cost-effective treatment for adults with mod-
erate to severe IBS-C who have previously received antispasmodics and/or laxatives.
PGI28
COST-EFFECTIvENESS OF HEPATITIS C vIRUS (HCv) TREATMENT wITH 
TELAPREvIR/PEGyLATED INTERFERON ALPHA/RIBAvIRIN TRIPLE THERAPy 
vERSUS wAITING FOR NEw REGIMENS IN FRANCE
Lee A.1, Granados D.2, Hulbert E.3, McGarry L.4, Fleischmann J.5
1OptumInsight, Burlington, ON, Canada, 2Janssen France, Issy les Moulineaux, France, 
3OptumInsight, Eden Prairie, MN, USA, 4OptumInsight, Cambridge, MA, USA, 5Janssen EMEA 
HEMAR, Neuss, Germany
Objectives: To assess the cost-effectiveness of treating chronic HCV infection 
(genotype 1) with currently available telaprevir+pegylated interferon alpha/ribavirin 
(TPR) compared to waiting for new regimens with improved efficacy (hypothetical 
treatment assumed) currently in development from the French health care perspec-
tive. MethOds: A Markov model tracked the adult naïve HCV+ French population 
over a lifetime horizon. Model health-states are defined by METAVIR fibrosis stage 
(F0-F4) and complications of advanced HCV (decompensated cirrhosis, hepatocel-
lular carcinoma, liver transplant, and death). During each 1-year cycle, individu-
als may remain in the current health-state, respond to treatment or progress, at 
probabilities determined by disease status, age at infection, current age, gender, 
and treatment received. Individuals were eligible for treatment in F2-F4. Transition 
probabilities, treatment efficacy, health-state utilities, resource utilization and costs 
were derived from published literature and standard French sources. The efficacy 
of a new hypothetical treatment regimen was based on currently published results; 
cost for the new treatment was assumed at € 50,000 for a full treatment (excluding 
PR backbone). Results: A treatment lag of 1, 2, and 3 years resulted in 142,777 indi-
viduals, 140,417 individuals, and 137,930 individuals being treated by the new regi-
men, respectively, versus 145,010 with immediate TPR treatment. The new treatment 
option resulted in additional life years saved (range 11,230-27,536), QALYs gained 
(range 12,528-29,359), and prevented more HCV-related deaths (range 3,839-5,756). 
Total costs incurred were higher for the new regimen versus TPR, from the health 
care perspective. ICERs were € 58,294.49/QALY, € 73,295.59/QALY, and € 107,403.02/
QALY gained for a 1, 2, and 3 year treatment lag, respectively. cOnclusiOns: These 
findings suggest waiting for new regimens currently in development should not be 
the most efficient choice to be considered by French Health care system. Waiting 
for new treatments should yield better clinical outcomes, but with higher costs and 
ICERS that may be challenging for the payer.
PGI29
CROHN’S DISEASE: AN ECONOMIC ASSESSMENT OF BIOLOGICAL DRUGS IN 
ITALy
Cicchetti A.1, Gasbarrini A.2, Ruggeri M.1
1Università Cattolica del Sacro Cuore, Rome, Italy, 2Università Cattolica del Sacro Cuore, Rome, 
Italy, Italy
Objectives: This study had a dual objective: verify the improvements in qual-
ity of life (QoL) due to biological drugs administration and evaluate their cost-
effeffectiveness versus the standard steroid-based therapy in Crohn’s Disease 
(CD). High-cost biological drugs’ efficacy is well-established, but they still lack of 
cost-effectiveness studies. MethOds: A survey was prepared with clinicians and 
pharmacoeconomists and administered in 9 centers in Italy. The questionnaire 
was set up to detect QoL through a Visual Analogue Scale and EQ-5D and to assess 
patients’ profile (age, gender, job) and clinical features (time-to-first diagnosis, cur-
rent and at-diagnosis Montreal classification, current and at-diagnosis treatments, 
past surgical procedures, hospitalizations). Collected data were then used in a sta-
tistical regression model and an economic assessment complete of probabilistic 
sensitivity analysis was performed comparing costs and utilities of the considered 
treatments. Results: A total of 348 questionnaires were collected, giving back a 
Objectives: Establish the potential resource and cost savings from using ePTFE 
covered stent-grafts configured for TIPS (SG) compared to bare metal stents (BMS). 
Most centres have adopted SGs to treat portal hypertension because of their 
reduced re-intervention rates, elimination of regular monitoring of patency and 
improved survival. However there is no published economic analysis identifying 
the related cost consequences. Understanding the improved efficiencies is essen-
tial in the current financial environment. MethOds: A Markov economic model 
was developed to measure the incremental costs of the initial procedure and 
re-interventions with SG compared to BMS. Re-intervention procedures included 
angioplasty (67%), introducing a balloon expandable stent (22%) or a second stent 
(10%). The adverse events were hepatic encephalopathy and clinical relapse. 
Clinical data came mainly from a published RCT (Bureau 2007), whilst health care 
costs were from UK national databases. Results: Compared to BMS, using SG in 
TIPS resulted in a cost saving of over £1,150 per patient over 2 years. Modelling 100 
patients, compared to BMS, the SG cohort had 25 fewer re-interventions including 
angioplasties, saving 41 hours staff time in theatre and 16 inpatient days; with 
fewer cases of encephalopathy (16), recurrent ascites (8), variceal bleeds (5) and a 
markedly reduced mortality (13). cOnclusiOns: The model showed that ePTFE 
covered stent-grafts configured for TIPS reduced mortality and re-interventions, 
saved theatre time and bed-days, and reduced overall costs despite the higher 
initial device cost.
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AN ECONOMIC EvALUATION OF THE TRIPLE HCv TREATMENT REGIMEN FOR G1 
NAïvE PATIENTS IN THE GREEK HEALTH CARE SySTEM
Athanasiadis A.1, Konstantopoulou T.2, Koulouris S.3
1Foundation for Economic & Industrial Research (IOBE), Athens, Greece, 2Roche (Hellas), Greece, 
Athens, Greece, 3Roche (Hellas), Athens, Greece
Objectives: In 2011 EMA approved Boceprevir and Telaprevir with PegIFN and 
Ribavirin for the treatment of Genotype 1 Chronic Hepatitis C patients. In 2013 
the Greek and other European HCV Guidelines recommend treatment alloca-
tion in G1 naïve patients according to the IL28B genotype or the RVR profile. 
Local studies indicate that the IL28B-CC and the RVR (+) rates are approximately 
30%. The objective of this study was to implement this guidance and examine 
whether triple therapy with PegIFNa-2a+RBV and the two protease inhibitors, 
Boceprevir or Telaprevir, constitutes a cost-saving option for the treatment of 
naïve G1 patients in the Greek health care setting. MethOds: For the needs 
of this analysis, a cost-consequence model was utilized, to compare the costs 
incurred when: i) patients with IL28B CC aplotype (30%) were treated with SoC 
(PegIFN alfa-2a + RBV) and patients with IL28B non-CC aplotypes (70%) were 
treated with triple therapy and ii) all patients are treated with triple therapy. 
The economic inputs are based on official and publically available sources while 
the clinical inputs are taken from published clinical trial results. The number of 
patients treated per year was provided by local bibliography. Results: The total 
cost to treat 509 naïve patients with triple therapy was € 13,8 million compared to 
€ 10.9 million to treat based on IL28B allocation, maintaining the same SVR rate 
of 70% for either of the treatment strategies. cOnclusiOns: This personalized 
approach based on a baseline predictor of response such as the IL28B profile was 
proven to be a cost-saving resource allocation choice compared to the option 
of treating all treatment naive patients with triple therapy, providing SVR rates 
of 70% and a constrain of cost for the Greek health care system of € 2,9 million/
year (aprox.25%).
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COST-EFFECTIvENESS OF EARLy vERSUS DELAyED HEPATITIS C vIRUS (HCv) 
TREATMENT wITH TELAPREvIR/PEGyLATED INTERFERON ALPHA/RIBAvIRIN 
TRIPLE THERAPy IN ADULTS AGED 40+ IN FRANCE
Lee A.1, Granados D.2, Hulbert E.3, McGarry L.4, Fleischmann J.5
1OptumInsight, Burlington, ON, Canada, 2Janssen France, Issy les Moulineaux, France, 
3OptumInsight, Eden Prairie, MN, USA, 4OptumInsight, Cambridge, MA, USA, 5Janssen EMEA 
HEMAR, Neuss, Germany
Objectives: To assess the cost-effectiveness of treating HCV infection (geno-
type 1) with telaprevir/pegylated interferon alpha/ribavirin (TPR) at METAVIR 
fibrosis stage F2 (“early”) versus delaying treatment until progression to F3 
(“delayed”) from the French health care perspective. MethOds: A Markov 
model tracked the HCV+ French population aged 40+ over a lifetime horizon to 
compare outcomes of early versus delayed treatment. Model health states are 
defined by fibrosis stage (F0-F4) and complications of advanced HCV includ-
ing decompensated cirrhosis, hepatocellular carcinoma, liver transplant, and 
death. During each 1-year cycle, individuals may remain in the current health 
state, respond to treatment or progress, at probabilities determined by disease 
status, age at infection, current age, gender, and treatment received. Transition 
probabilities, treatment efficacy, health-state utilities, resource utilization and 
costs were derived from published literature and standard French sources. Costs 
and outcomes were discounted at 4.0% for 30 years and 2% thereafter. Cost-
effectiveness was assessed as incremental cost per life year gained (LYG) and 
QALY gained. Results: An estimated 203,644 French residents aged 40+ years 
are diagnosed with HCV in 2013. Treating with TPR at F2 versus F3 is projected 
to result in 135,240 versus 113,728 individuals treated, at an incremental life-
time cost of € 654.65M from the French health care perspective. Early treatment 
avoided 2,205 HCV-related deaths and saved 11,384 life-years, and 17,599 QALYs, 
at a cost of € 57,506/LYG and € 37,197/QALY gained. Results are most sensitive to 
efficacy parameters, time horizon, and discount rates and least sensitive to diag-
nosis and treatment parameters. cOnclusiOns: Treating HCV-infected indi-
viduals at F2 is expected to results in better clinical outcomes but at higher cost 
compared to delaying treatment until the individual progresses to F3. Earlier 
treatment with TPR should be considered as an efficient choice by the French 
health care system based on its estimated incremental cost-effectiveness ratio 
of € 37,197/QALY gained.
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which provided monthly EQ-5D measures, treatment duration, adverse events (diar-
rhoea) and responder status (abdominal pain/discomfort improvement ≥ 30% from 
baseline). Belgian EQ-5D tariffs were used to estimate utilities and trapezoidal rule 
to estimate QALYs. A Delphi panel including 6 general practitioners and 5 gastro-
enterologists provided the resource use for IBS-C patients in different treatment 
phases: controlled with 2nd line or new drug else non-responders. Patient-level 
costs were applied using first-order Monte-Carlo simulation (gamma distribution 
function; per treatment arm and responder status; health care payer perspective). 
A stopping rule was implemented at 4 weeks for linaclotide non-responders. A 
non-parametric bootstrap with 1000 replications was performed. The 2012 Belgian 
GDP per capita (€ 34,000) was used as willingness-to-pay threshold. Results: The 
responder rate at 4 weeks was 54.6% with linaclotide vs. 35.5% with SoC. There 
was on average 0.0129 QALYs gained per linaclotide patient vs SoC at 6 months 
(0.385 vs. 0.372), with an incremental cost of € 95 (€ 1,376 vs. € 1,280). The incremental 
cost-effectiveness ratio of was € 7,364/QALY. The diarrhoea costs were higher with 
linaclotide (+€ 19.4) while savings were observed in clinical management (-€ 132.2) 
compared to SoC. Using a willingness-to-pay threshold of € 34,000/QALY, 66% of the 
simulations were cost-effective. cOnclusiOns: Due to improvements in abdomi-
nal pain/discomfort complaints in patients receiving linaclotide, savings were gen-
erated in the clinical management of IBS-C compared to SoC. Using the GDP per 
capita as willingness-to-pay threshold, linaclotide seems a cost-effective alternative 
to today SoC of IBS-C in Belgium.
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COST-EFFECTIvENESS OF CAPSULE ENDOSCOPy (PILLCAM®) IN THE DIAGNOSIS 
OF SMALL BOwEL CROHN’S DISEASE
Makino K.1, Arora N.1, Tilden D.1, Bingham W.2
1THEMA Consulting Pty. Ltd., Pyrmont, Australia, 2Given Imaging ANZ, North Ryde, Australia
Objectives: Capsule endoscopy (CE) is a minimally invasive endoscopic tech-
nology that uses a disposable capsule containing a small camera to monitor 
and diagnose disorders of the gastrointestinal tract such as Crohn’s disease and 
obscure gastrointestinal bleeding. This study examines cost-effectiveness of CE 
(PillCam®, Given Imaging) for the diagnosis of small bowel Crohn’s disease in 
Australia. MethOds: A modelled cost-utility analysis of CE vs. no CE followed 
by empiric treatment is performed. The population under consideration consists 
of patients with a clinical suspicion of Crohn’s disease despite non-confirmatory 
results with prior endoscopic/radiologic tests. Due to a lack of alternative diagnos-
tic options, many of these patients currently receive empiric treatment, whereby 
a diagnosis is achieved based on long-term response to therapy for Crohn’s dis-
ease. CE increases the proportion of patients who receive a confirmed diagnosis 
for Crohn’s disease or for other bowel conditions (represented by irritable bowel 
syndrome in the model), thereby allowing more patients to promptly receive 
a correct treatment and thus improving the down-stream treatment effective-
ness. The administration of correct and effective treatment, as aided by CE, thus 
produces additional QALYs and potential cost savings, which are captured by the 
current model. The model has a 12-month time horizon and takes the perspec-
tive of Australian health care system. Results: CE is estimated to produce 0.057 
additional QALYs over the 12-month period. The additional cost of CE is in part 
offset by cost savings arising from the improved treatment selection. The incre-
mental cost-effectiveness ratio (ICER) is estimated to be $23,672 per additional 
QALY. cOnclusiOns: The current model suggests CE is highly cost-effective. 
Importantly, the target patient population currently experience a unique and 
special unmet clinical need because the currently funded endoscopic/radiologic 
technologies are unable to provide a confirmed diagnosis. The evidence for cost-
effectiveness clearly supports that CE represents good value for money.
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THE COST-UTILITy OF FIDAxOMICIN AS COMPARED TO CURRENT STANDARD 
TREATMENT IN THE MANAGEMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS 
IN BELGIUM
Lamotte M.1, Vellopoulou K.2, Richir K.3, Smets J.3, Grabe K.4, Coppens K.3
1IMS Health HEOR, Vilvoorde, Belgium, 2IMS Health, Vilvoorde, Belgium, 3Astellas, Brussels, 
Belgium, 4Astellas Pharma Europe Ltd., Chertsey, UK
Objectives: Clostridium difficile infection (CDI) is one of the most common hos-
pital acquired infections in industrialised countries. CDI is responsible for severe 
morbidity, partly driven by the high proportion of patients experiencing a recur-
rence after an initial successful response to treatment. In Belgium, CDI incidence 
and mortality has more than doubled between 1998 and 2007. The aim of this study 
was to assess the cost-utility of fidaxomicin as compared to current standard treat-
ment for managing CDI in Belgium. MethOds: A Markov model with a 1-year time 
horizon and 10-day cycles was developed to compare fidaxomicin, metronidazole 
and vancomycin in patients with all CDI and two subpopulations (severe CDI and 
first recurrence of CDI). Clinical data from two pooled published phase-3 trials 
(fidaxomicin vs. vancomycin) were used along a mixed treatment comparison of 
fidaxomicin vs. metronidazole. Treatment paths and data input were approved dur-
ing an advisory board. Costs of first episode and recurrent CDI hospitalizations were 
taken from the IMS Hospital Disease Database. Cost per quality-adjusted life-year 
(QALY) gained was calculated from the health care payer perspective. Results: The 
model showed cost savings and QALY gained versus vancomycin and metronida-
zole. Fidaxomicin versus an average of these comparators delivered benefits for all 
CDI patients (-1,100€ ; 0.008 QALY), for severe CDI (-1,300€ ; 0.009 QALY) and for first 
recurrence CDI (-1,500€ ; 0.009 QALY). One-way sensitivity analyses revealed that 
time horizon and the odds ratio of recurrence with fidaxomicin had most affect 
on the results. Applying a cost-effectiveness threshold of € 30,000 per QALY gained, 
probabilistic sensitivity analysis showed acceptable cost-effectiveness in 80% of all 
CDI cases. cOnclusiOns: Based on the available clinical data the model showed 
that fidaxomicin dominates vancomycin and metronidazole generating additional 
QALYs with cost-savings not only in patients with all CDI, but also in subpopulations 
with severe CDI or a first recurrence.
population with a mean age of 42, 52% male, 58% actively working, 52% undergone 
surgical interventions, and 66% being already administered previous therapies. 
The mean number of outpatients visits was 4.15/year, with 0.23 hospitalizations/
year. At diagnosis, the 55% of patients were treated with steroids, while only the 
3% with biological drugs. At the time of survey administration, the 9% of patients 
were treated with steroids, and the 50% with biological drugs. The statistical model 
showed a significant QoL improvement due to biological drugs therapy of about 6%. 
The economic assessment showed biological drugs to be cost-effective only in more 
severe settings of patients (€ 26.000 – 38.000 /QALY), but not in mild and moderate 
CD (€ 58.000 to 328.000 /QALY). cOnclusiOns: The results of the analysis, based 
on simulation models and real practice data, are consistent with evidences from 
other countries and thus biological drugs can be considered a good health care 
investment in severe cases of CD.
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IS THE USE OF ESOMEPRAzOLE IN GASTROESOPHAGEAL REFLUx DISEASE A 
COST-EFFECTIvE OPTION IN POLAND?
Petryszyn P., Staniak A.
Wroclaw University of Medicine, Wroclaw, Poland
Objectives: To compare the cost-effectiveness of therapy of different forms of GERD 
with esomeprazole and other proton pump inhibitors (PPIs) in Poland. MethOds: 
Results of clinical trials with esomeprazole in comparison with equivalent doses of 
other PPIs in the treatment of erosive esophagitis (EE - 6 RCTs), non-erosive reflux 
disease (NERD – 1 RCT) and GERD maintenance therapy (2 RCTs) were systemati-
cally reviewed. Meta-analysis was conducted as appropriate, relative risk values 
were calculated. Cost data derived from Polish Ministry of Health and pharma-
cies in Wroclaw. Cost effectiveness ratios and incremental cost effectiveness ratios 
were assessed for 100 patients. Results: In the treatment of EE esomeprazole 
was significantly more effective than other PPIs. For 4 weeks therapy ICER values 
(esomeprazole 40 mg vs. omeprazole 20 mg and pantoprazole 40 mg) were 614 PLN 
and 906.33 PLN respectively if original and generic esomeprazole products were 
taken into account and 118.22 PLN and 162.67 for generics. For 8 weeks therapy 
ICER values (esomeprazole 40 mg vs. omeprazole 20 mg, lansoprazole 30 mg and 
pantoprazole 40 mg) were: 430.45 PLN, 329.47 PLN and 325.33 PLN (for generics 
and original esomeprazole) and 1869.58 PLN, 2677.89 PLN and 1812.67, respectively 
for generics. Differences in effectiveness of NERD therapy with esomeprazole and 
other PPIs were not statistically significant. The replacement of pantoprazole 20 mg 
with more effective esomeprazole 20 mg in the 6-month maintenance therapy was 
associated with a marginal cost of 3078.01 PLN (only generics included) and 4590.91 
PLN (for original esomeprazole and generics) respectively. cOnclusiOns: 1) For 
4 and 8 weeks therapy of EE esomeprazole has to be recognized as a cost-effective 
option. 2) In the NERD treatment the choice of PPI should be based on the price of 
medicament. 3) The use of esomeprazole in GERD maintenance therapy is associ-
ated with a very high ICER.
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COMPARATIvE ECONOMIC ANALySIS OF RETREATMENT STRATEGIES FOR HCv 
GENOTyPE 1 PATIENTS IN RUSSIA
Ivakhnenko O.1, Omelyanovsky V.V.2, Rebrova O.3, Khachatryan G.1
1Autonomous non-profit organization “National Centre for Health Technology Assessment”, 
Moscow, Russia, 2The Russian Presidential Academy of National Economy and Public 
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Objectives: To assess the cost-effectiveness of retreatment with pegylated inter-
feron and ribavirin in combination with boceprevir of HCV genotype 1 patients, who 
failed to respond to previous treatment, in comparison with absence of retreatment 
and retreatment with pegylated interferon and ribavirin. MethOds: We performed 
cost-effectiveness analysis. Based on the published data we modeled the number 
of long-term unfavorable outcomes of HCV (liver cirrhosis, hepatocellular carci-
noma and death) in the hypothetic cohort of HCV genotype 1 patients following 
one of three retreatment strategies: “no treatment” (NT), “peginterferon+ribavirin” 
(PR) and “peginterferon + ribavirin + boceprevir” (PRB). We have evaluated direct 
medical costs for a short-term (only cost of HCV retreament) and for a long-term 
(costs of medical care for adverse outcomes) periods for all strategies. Costs were 
estimated on the basis of average price for the drugs and reimbursement rates 
for medical services in the compulsory medical insurance system. Incremental 
cost-effectiveness ratio (ICER) for PR and PRB strategies vs NT were calculated as 
additional cost per unfavorable outcome avoided. Results: It is expected that in 
hypothetic cohort of 10000 HCV genotype 1 patients 58,1% would fail to respond to 
the treatment. The estimated costs of retreatment for this group were EURO 69,07 
mln in case of PR strategy and EURO 235,58 mln for PRB. The cumulative number 
of unfavorable outcomes of HCV during 25-year period would be 5075 cases for NT 
strategy, 4262 for PR and 2012 for PRB. The long-term costs of NT strategy were EURO 
205,35 mln, EURO 168,37 mln in case of PR strategy and EURO 81,4 mln for PRB. ICER 
for PR strategy was EURO 44532 and for PRB - EURO 36379 per unfavorable outcome 
avoided. cOnclusiOns: The use of PRB strategy is efficient as it allows reducing 
the number of unfavorable outcomes of HCV at a lesser cost.
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COST-UTILITy ANALySIS OF LINACLOTIDE IN THE TREATMENT OF IRRITABLE 
BOwEL SyNDROME wITH CONSTIPATION IN BELGIUM
Gerlier L.1, Caekelbergh K.1, Lamotte M.1, Kinoo D.2, Meurgey F.3, Berdeaux G.1
1IMS Health HEOR, Vilvoorde, Belgium, 2Almirall, Vilvoorde, Belgium, 3Oukelos sprl, Brussels, 
Belgium
Objectives: Linaclotide is the first drug that received EMA approval in the man-
agement of irritable bowel syndrome in its constipation form (IBS-C). We aimed 
at estimating the cost-utility of linaclotide, compared to standard of care (SoC) 
in Belgium. MethOds: The analysis was conducted using data from a 6-month 
randomized trial of linaclotide 290µg once daily (N= 401) versus placebo (N= 403), 
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1.25 hospitalizations. Diagnostic tests were also more frequent (rectosigmoidoscopy: 
49.3%; abdominal echography: 43.6%) except thyroid function (70.0%). The annual 
cost of second line was € 2,114 [1,509;2,819] versus € 2,920 [2,072;3,917] after second 
line failure. Hospitalizations accounted for about 75% of the costs. cOnclusiOns: 
IBS with constipation leads to significant resource use and high costs certainly in 
case of second line treatment failure.
GASTROINTESTINAL DISORDERS – Patient-Reported Outcomes & Patient  
Preference Studies
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AGREEMENT BETwEEN CHILD AND PARENT SyMPTOM DIARy RESPONSES 
IN CHRONIC CONSTIPATION (CC) AND IRRITABLE BOwEL SyNDROME wITH 
CONSTIPATION (IBS-C): IMPLICATIONS FOR THE MEASUREMENT OF SyMPTOMS 
IN yOUNG CHILDREN
Holloway L.1, Arbuckle R.1, Carson R.T.2, Dennee-Sommers B.3, Abetz-Webb L.1
1Adelphi Values, Bollington, UK, 2Forest Research Institute, Jersey City, NJ, USA, 3Endpoint 
Outcomes, Boston, MA, USA
Objectives: Using patient-reported and observer-reported outcome measures to 
assess symptoms in children is challenging. While the child is arguably the most 
‘valid’ reporter, parents may provide more reliable responses. Our aim was to 
assess the agreement in child and parent ratings of CC/IBS-C symptoms collected 
through an electronic daily diary (eDiary). MethOds: Separate child and parent 
eDiaries were developed to assess CC/IBS-C symptoms based on concept elicita-
tion interviews with 64 children and 75 parents. The eDiaries were completed by 
36 children (aged 6-11) and 30 parents for 5-9 days prior to cognitive debriefing 
interviews. eDiary data were compared for five symptoms: abdominal pain, bowel 
movement (BM) frequency, stool form/consistency, straining and rectal pain during 
defecation. Results: There were moderate to high levels of agreement (children/
parents selecting the same level of response on a given day) for all items, including 
66.9% agreement for BM frequency; 70.2% for stool form and 72.5% for rectal pain. 
Children’s reports of their ‘tummy hurting’ were consistent with parents seeing 
their child holding his/her tummy (68.5% agreement) and parents being told by the 
child that his/her tummy hurt (76.4% agreement). Children’s reports of straining 
were consistent with parents observing their child making a face (60.4% agree-
ment) and hearing their child grunt (52.3% agreement) during defecation. Across 
all symptoms, agreement was higher for 6-8 year old children and their parents 
(mean 76.9% agreement) compared to 9-11 year old children and their parents (mean 
58.4%). cOnclusiOns: The results present evidence of moderate to strong agree-
ment between children’s and parents’ reports of core CC/IBS-C symptoms. Lower 
levels of agreement in ratings amongst 9-11 year old children and their parents may 
be due to parents being less aware of their child’s symptoms.
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vALIDATING THE UNIDIMENSIONAL FATIGUE IMPACT SCALE (U-FIS) FOR USE IN 
CROHN’S DISEASE
Wilburn J.1, McKenna S.1, Twiss J.1, Kemp K.2, Campbell S.2
1Galen Research Ltd., Manchester, UK, 2Manchester Royal Infirmary, Manchester, UK
Objectives: Fatigue is usually defined as a feeling of exhaustion, lack of energy 
or tiredness and affects many aspects of daily living. Crohn’s Disease (CD) is often 
associated with severe fatigue. The Fatigue Impact Scale (FIS) was developed to 
determine the mental and physical impacts of fatigue. It has been simplified and 
shortened to 22 items and shown by Rasch analysis to be unidimensional. This 
version is called the U-FIS. The study was designed to determine the validity of the 
U-FIS when used with CD patients. MethOds: CD patients were asked to com-
plete the U-FIS and a subset of respondents completed it again two weeks later to 
assess test-retest reliability. Rasch analysis was applied to U-FIS data to determine 
unidimensionality. Construct validity was further assessed by relating scores on 
the U-FIS to those on the Crohn’s Life Impact Scale (CLIQ) and the Nottingham 
Health Profile (NHP). Results: A total of 158 CD patients (36.1% female; aged 16-79 
years (mean: 42.4; SD 15.0)) completed the U-FIS, with 103 completing it a second 
time. Overall fit to the Rasch model was confirmed (p = 0.61) and no items misfit. 
Internal consistency (0.98) and reproducibility (test-retest reliability = 0.88) for the 
U-FIS were good. U-FIS scores correlated 0.79 with those on the CLIQ indicating the 
importance of fatigue to quality of life. U-FIS scores were also related as expected 
with NHP section scores. cOnclusiOns: The U-FIS is a reliable and valid instru-
ment for measuring fatigue in Crohn’s Disease. These findings replicate those found 
with the use of the measure with patients who have Multiple Sclerosis. The U-FIS 
is valuable as it provides a holistic index of the impact of fatigue from the patient’s 
perspective. The measure may prove valuable for use with patients who have a wide 
variety of chronic conditions.
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vALIDATION OF THE CROHN’S LIFE IMPACT QUESTIONNAIRE (CLIQ), THE FIRST 
PATIENT-REPORTED OUTCOME MEASURE SPECIFIC TO ADULTS wITH CROHN’S 
DISEASE
Wilburn J.1, McKenna S.1, Twiss J.1, Kemp K.2, Campbell S.2
1Galen Research Ltd., Manchester, UK, 2Manchester Royal Infirmary, Manchester, UK
Objectives: The study was designed to identify the final CLIQ – the first patient-
reported outcome measure specific to adults with Crohn’s Disease (CD) and deter-
mine its unidimensionality, reproducibility and construct validity. The measure has 
two scales; Activity limitations and needs-based Quality of Life (QoL). MethOds: 
CD patients were sent a package consisting of the CLIQ, the Nottingham Health 
Profile (NHP), the Unidimensional Fatigue Impact Scale (U-FIS) and a demographic 
questionnaire. A subset of respondents received a second questionnaire package 
2 weeks later. Rasch analysis was applied to responses for item reduction and 
assessment of unidimensionality. Assessments of internal consistency, test-retest 
reliability and construct validity were also undertaken. Results: The CLIQ was 
completed by 273 CD patients (65.6% female; aged 16-79 years (mean: 43.9; SD 15.1). 
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THE COST EFFECTIvENESS OF PEGINTERFERON ALFA AND RIBAvIRIN FOR THE 
TREATMENT OF HEPATITIS C IN CHILDREN AND yOUNG PEOPLE
Cooper K.1, Baxter L.2, Loveman E.1, Hartwell D.1, Frampton G.1
1University of Southampton, Southampton, UK, 2London School of Hygiene, London, UK
Objectives: To assess the cost-effectiveness of peginterferon α -2a and peginter-
feron α -2b in combination with ribavirin compared to best supportive care (BSC), for 
the treatment of chronic hepatitis C virus (HCV) in children and young people aged 3 
to 17 years. MethOds: A Markov state-transition economic model of chronic HCV 
in children and young people was developed that extrapolated the impact of sus-
tained virological response (SVR) on life expectancy, quality-adjusted life expectancy 
and lifetime costs. The model was adapted from one previously developed for adults. 
A systematic review was conducted of the clinical effectiveness of the treatments, 
and the health related quality of life for patients with hepatitis C. Uncertainty was 
explored through probabilistic and deterministic sensitivity analyses. Results: 
Seven studies were identified that were relatively small and of generally poor qual-
ity. Estimates of SVR were similar for peginterferon α -2a (60%) and peginterferon 
α -2b (58%), whilst the SVR for no treatment was assumed to be zero. From this 
model, peginterferon alfa (α -2a or α -2b) in combination with ribavirin was more 
effective and cheaper than BSC. Sensitivity analyses suggest that the results were 
generally robust to all changes to the structural assumptions and input parameters. 
The model results were most sensitive to changes to the discount rate, time hori-
zon, SVR and baseline fibrosis of the cohort. cOnclusiOns: Treatment of children 
and young people with peginterferon alfa (α -2a or α -2b) and ribavirin may be an 
effective therapy. Peginterferon alfa (α -2a or α -2b) in combination with ribavirin is 
cost-effective compared with BSC. However, the available evidence is of poor quality. 
The views expressed in this paper are those of the authors and do not necessarily 
represent the views or policies of the UK HTA programme or Department of Health.
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COST-UTILITy ANALySIS OF TELAPREvIR IN COMBINATION wITH 
PEGINTERFERON ALPHA AND RIBAvIRIN IN PREvIOUSLy UNTREATED PATIENTS 
wITH CHRONIC HEPATITIS IN A ROMANIAN SETTING
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Objectives: To estimate the cost-effectiveness in Romanian setting of triple ther-
apy with Telaprevir and Peginterferon/Ribavirin (TVR+PR) compared with PR alone 
in previously untreated patients with hepatitis C virus (HCV) infection from the 
third payer - National Health Insurance Agency (NHIA). MethOds: We used the 
published data of efficacy from large international trials and published Markov 
models to estimate the cost-effectiveness of this new HCV serine protease inhibi-
tor (telaprevir) using the specific local cost and epidemiological data. The superior 
results shown by Jacobson IM et all in ADVANCE trial - (Telaprevir for previously 
untreated chronic hepatitis C virus infection) for telaprevir - 75% sustained virologic 
response compared with 44% for PR alone. The discount rate was 3% for both cost 
and efficacy. Cost were extracted from NIHA tarrifs, Minister of Health drugs price 
catalog and from previous published data. The reference patient was a 45-year-old 
male with chronic liver disease due to chronic HCV infection. Time horizon was set 
patient life time. The clinical outcomes and Utilities for all health states were taken 
from ADVANCE phase-3 trial. The comparator was Peginterferon 2alfa with ribavirin. 
The effectiveness was measured in quality-adjusted life years (QALY).The cost of 
secondary drug reactions were not included in the model. Results: Incremental 
cost effectiveness ratio (ICER) for telaprevir in combination with PR compared to PR 
alone was 23291 € /1 gained QALY. cOnclusiOns: As in Romania HTA is only at the 
beginning, health authorities has to evaluate the most cost-effective strategy to fol-
low for treatment of patients with chronic hepatitis as ICER of telaprevir in combina-
tion with PR compared with PR alone is reaching or is above the level recommended 
by Word Health Organisation as upper threshold (3 GDP/capita – Romania’s GDP/
capita is 6200Euro). Further CUA should be performed, including for guided therapy 
and treatment designated to previous treated patients.
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THE CURRENT MANAGEMENT AND COSTS OF IRRITABLE BOwEL SyNDROME 
wITH CONSTIPATION IN BELGIUM: A 2-ROUND ExPERT SURvEy
Caekelbergh K.1, Gerlier L.1, Lamotte M.1, Kinoo D.2, Meurgey F.3, Berdeaux G.1
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Objectives: Patients suffering from irritable bowel syndrome (IBS) with constipa-
tion (IBS-C) receive laxatives as first line therapy. In spite of these laxatives most 
of them experience failure. We aimed at describing the current management and 
its costs of Belgian IBS-C patients who failed first line treatment. MethOds: A 
2-round Delphi panel was conducted including general practitioners (GP) and 
gastroenterologists. The type and frequency of medical resources used per year 
as second-line IBS-C therapy (consultations, exams/tests, drugs, hospitalizations) 
were collected, reflecting the expert’s own practice in the first round and find-
ing a Belgian consensus in the second round. Two patients’ profiles were defined: 
second line current management and third line management in case of second 
line failure. Unit costs (2012 INAMI/RIZIV tariffs) were assigned to the resources 
used to calculate a cost per patient-year and a range based on the distribution of 
experts’ answers. Results: Eleven experts participated (6 GPs/5 gastroenterolo-
gists). The drugs prescribed in second line were laxatives (71.4%, mainly osmotics), 
spasmolytics (72.2%), pain killers (11.5%) and antidepressants (6.0%). There were 
7.7 consultations per patient-year on average (GP: 5.3; specialists: 2.4). Emergency 
room visits occurred in 10.4% and diagnostic tests included thyroid function (79.1%), 
rectosigmoidoscopy (39.8%) and abdominal echography (36.8%). There were 0.97 IBS-
related admissions to hospital per patient-year. After a second line failure, resource 
use increased with more laxatives (75.5%), antidepressants (24.6%) and pain killers 
(17.3%), 11.6 consultations (GP: 7.5; specialist: 4.1), 14.5% emergency room visits and 
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ECONOMIC AND QUALITy-OF-LIFE BURDEN OF MODERATE TO SEvERE 
IRRITABLE BOwEL SyNDROME wITH CONSTIPATION (IBS-C) IN SPAIN: INTERIM 
ANALySIS OF THE IBIS-C STUDy
Mearin F.1, Fortea J.2, Valveny N.3, Cortes X.2, Lindner L.2, Prior M.2
1Centro médico Teknon, Barcelona, Spain, 2Laboratorios Almirall S.A., Barcelona, Spain, 3TFS, 
Barcelona, Spain
Objectives: The IBIS-C study, currently ongoing, is the first to assess the burden 
of IBS-C in 6 European countries (France, Germany, Italy, Spain, Sweden, UK) . We 
present an interim analysis of the retrospective data from Spain. MethOds: This is 
an observational, retrospective-prospective (±6-months(m)) study in patients diag-
nosed in the last five years of IBS-C (Rome-III criteria) of moderate-to-severe degree 
(IBS-Symptom Severity Score(IBS-SSS)≥ 175). Quality-of-life(QoL) was assessed 
with the EuroQoL-5D(EQ-5D) and IBS-QoL. Results: We included 46 patients (62% 
severe, mean(±SD) 44.6±12.2 years, 83% women, time since diagnosis 2.8±3.6 years). 
According to IBS-SSS, 94% had abdominal pain in the last month (62% of time) and 
85% abdominal distention. Other prevalent symptoms were: constipation (96%), 
abdominal discomfort (72%) and bloating (59%). Mean IBS-QoL was 46±23, on a scale 
0-100 (worst QoL), and the most affected domains were “food avoidance” (mean:64) 
and “health worry” (60). Mean EQ-5D was 51±20, on a scale 0-100 (best QoL), and 93% 
and 70% of patients, respectively, reported problems in pain/discomfort and anxiety/
depression. In the previous 6m, 83% of patients consulted a primary care physi-
cian, and 89% a specialist (mostly a gastroenterologist)(mean(95%CI):2.8(1.4-4.3) 
and 2.0(0.9-3.1) visits, respectively). 20% of patients required emergency depart-
ment visits or hospitalization (mean stay:1.3(0.6-1.9) days). 76% of patients under-
went a diagnostic test (mean:2.1(1.3-2.9) tests). 89% of patients took medication 
(63% prescription drugs and 54% OTC medications), 26% received complementary 
therapies. The mean direct costs per patient for the National Health System(NHS) 
were € 1,025/6m(549-1627) and the mean costs for the patient were € 200/6m. 17% 
of patients had sick leave(mean:3.5 leaves; mean duration:58 days) and 46% had 
productivity losses(mean:49 hours). Mean indirect costs were € 991/6m. Total costs 
amounted to € 2216/6m. cOnclusiOns: Moderate-to-severe IBS-C has a great 
impact on health care resource utilization and productivity of patients, and the 
results suggest significant costs to the NHS and society. QoL can be severely affected.
PGI45
HEALTH-RELATED QUALITy OF LIFE (HRQL) IN CHRONIC HEPATITIS C (CH-C)  
PATIENTS TREATED wITH SOFOSBUvIR CONTAINING INTERFERON-FREE 
REGIMENS
Younossi Z.M.1, Stepanova M.1, Nelson D.2, Lawitz E.3, Nader F.1, Hunt S.4
1Inova Fairfax Hospital, Falls Church, VA, USA, 2University of Florida, Gainesvillle, FL, USA, 
3Texas Liver Institute, San Antonio, TX, USA, 4Inova Health System, Falls Church, VA, USA
Objectives: Interferon-containing regimens for treatment of CH-C are associated 
with substantial side effects and significant impairment in HRQL. The aim of this 
study is to evaluate the effect of Interferon-free regimens on HRQL. MethOds: 
Three validated HRQL instruments, namely, Medical Outcomes Study-Short Form 
36 (SF-36), CLDQ-HCV (Chronic Liver Disease Questionnaire-HCV) and FACIT-F 
(Functional Assessment of Chronic Illness Therapy-Fatigue) were administered to 
previously untreated CH-C patients (N= 201) treated with interferon-free regimen 
(Sofosbuvir+Ribavirin) at baseline, during, and after treatment. Patients were ran-
domized to receive 16 weeks of active treatment or 12 weeks of active treatment 
followed by 4 weeks of blinded placebo. Historical data for interferon containing 
regimens were available for all these questionnaires. Results: Small decrements in 
most of the domains of all HRQL metrics were noted at weeks 4, 12, and 16 of active 
treatment regardless of the study arm (maximum observed decrements in HRQL 
summary scores between 3.3% and 8.8% compared to baseline, p< 0.05). There were 
no differences between the study arms at all time points (p> 0.05). These decrements 
were substantially better than historical data available for interferon-containing 
regimens (between 10.4% and 15.2% for the same scores, p< 0.0001). By week 4 of 
follow-up after treatment, some of the social and emotional well-being-related 
domains of FACIT-F improved significantly compared to their own baseline (by 4.9-
6.0%, p< 0.05). At the end of 12-week follow-up, all those domains as well as domains 
of CLDQ-HCV (activity, emotional, worry, systemic domains) further improved (by 
3.8-11.2%, p< 0.05), while physical and functional well-being-related domains of 
FACIT-F and SF-36 returned to their baseline levels or improved moderately (by 3.1-
8.3%, p< 0.05). cOnclusiOns: The impairment in HRQL in CH-C patients treated 
with an interferon-free regimen is minimal and diminishes soon after the end of 
treatment. This interferon-free regimen is associated with substantially better HRQL 
as compared to interferon-containing regimens.
GASTROINTESTINAL DISORDERS – Health Care Use & Policy Studies
PGI46
SySTEMATIC LITERATURE REvIEw IN MODERATE TO SEvERE ULCERATIvE 
COLITIS
Huisman E., Medic G., Eijgelshoven I., Weijers L., Karabis A.
Mapi - HEOR & Strategic Market Access, Houten, The Netherlands
Objectives: Ulcerative colitis (UC) is a chronic inflammatory bowel disease. The 
objective of this systematic literature review (SLR) was to examine the evidence on 
the efficacy and safety of all available pharmacological interventions for moderate 
to severe UC. MethOds: A systematic literature search using a predefined strategy 
was performed in Medline®, EMBASE®, Medline-In-Process, Cochrane Library and 
BIOSIS from 1966 to 2013, to identify randomized controlled trials (RCTs) concern-
ing the efficacy and safety of available treatments in adult patients with moderate 
to severe UC. Studies reporting on mild-moderate UC patients were included if 
they reported results for the moderate subgroup separately. No language restric-
tions were applied to the search. Results: A total of 4344 abstracts were screened 
based on the predefined selection criteria, of which 4279 were excluded. In total, 
65 publications, reporting results from 65 RCTs were included (49 double blind), 
101 patients completed and returned the second package. Both scales had good 
overall fit to Rasch model (Chi2 p = 0.35; Chi2 p = 0.13 for activity limitations and 
QoL respectively) and unidimensionality of the scales was confirmed. No evidence 
of DIF by age or gender was found and the scales had good coverage of the meas-
urement constructs. Internal consistency was 0.91 for the QoL scale and 0.93 for 
Activity limitations. Good reproducibility was observed (QoL 0.91, Activity limita-
tions 0.89) and both scales were able to distinguish between self-perceived disease 
severity and general health status groups (p< .01). cOnclusiOns: The CLIQ is the 
first CD-specific PRO and is truly patient-based as its content was generated directly 
from CD patients. It is well accepted, completed by patients and is easy to score. 
Both scales measure a clear unidimensional construct and generate valid total 
scores. The scales have good consistency, reproducibility and promising construct 
validity. Studies are planned to assess responsiveness. The CLIQ will prove to be an 
important tool for assessing Activity limitations and QoL in clinical audit, practice 
and trials.
PGI42
THE RELATIONSHIP BETwEEN IRRITABLE BOwEL SyNDROME wITH 
CONSTIPATION SyMPTOMS AND HEALTH-RELATED QUALITy OF LIFE
Buono J.L.1, Taylor D.C.A.2, Spalding W.M.2, Carson R.T.1
1Forest Research Institute, Jersey City, NJ, USA, 2Ironwood Pharmaceuticals, Inc., Cambridge, MA, 
USA
Objectives: To identify symptoms significantly impacting health-related qual-
ity of life (HRQOL) and how changes in symptoms explain variability in HRQOL 
among adult patients with irritable bowel syndrome with constipation (IBS-
C). MethOds: IBS-C symptom and HRQOL data were pooled from two Phase 3 
trials (n= 1602) assessing efficacy and safety of linaclotide, a guanylate cyclase-C 
agonist approved for adult treatment of IBS-C in the US and moderate to severe 
IBS-C in Europe. IBS-C symptoms measured included abdominal (bloating, cramp-
ing, discomfort, fullness, pain) and bowel (spontaneous bowel movement [SBM] 
and complete SBM [CSBM] frequency, stool consistency, and straining) symptoms. 
HRQOL measures included: a disease-specific Irritable Bowel Syndrome-Quality 
of Life questionnaire (IBS-QOL), and generic HRQOL measures, the EuroQol-5D 
(EQ-5D) and Short Form-12 (SF-12). Analysis of variance evaluated relationships 
between Week 12 change from baseline in IBS-C symptoms and HRQOL, con-
trolling for demographics and baseline HRQOL. Results: Changes in IBS-QOL 
overall score were most significantly impacted by changes in abdominal fullness, 
cramping, and straining (beta coefficients: -1.1, -1.3, -1.7, respectively). The full 
model explained nearly half of the changes in IBS-QOL (R-Square: 0.42). Changes 
in EQ-5D were primarily driven by changes in abdominal bloating, cramping, and 
straining (beta coefficients: -0.009, -0.009, -0.011, respectively, R-Square: 0.49). 
Changes in SF-12 physical and mental component summaries (PCS and MCS) 
were best explained by changes in bloating, cramping, and straining (beta coef-
ficients: -0.41, -0.34, -0.53, respectively; R-square: 0.42), and abdominal fullness 
and CSBM frequency (beta coefficients: -0.59 and 0.26, respectively; R-square: 
0.35), respectively. cOnclusiOns: Improvements in abdominal cramping and 
straining at Week 12 compared to baseline were associated with improvements 
in HRQOL as measured by the IBS-QOL, EQ-5D and SF-12 PCS. Improvements in 
abdominal bloating and fullness, and increases in CSBMs were also associated 
with HRQOL improvements. Targeting improvement in specific IBS-C symptoms 
may result in increased patient HRQOL.
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THE IMPACT OF TyPE OF LIvER CONDITIONS ON THE PATIENTS’ HEALTH 
RELATED QUALITy OF LIFE
Cortesi P.A.1, Scalone L.1, Ciampichini R.2, Cozzolino P.2, Cesana G.1, Mantovani L.G.3, 
Okolicsanyi S.1, Ciaccio A.1, Rota M.1, Valsecchi M.G.1, Gentiluomo M.4, Gemma M.1,  
Grisola A.5, Scripo R.1, Pecere S.5, Pontisso P.6, Burra P.6, Mondelli M.7, Fabris L.6, Colledan M.5, 
Fagiuoli S.5, Belli L.S.4, Strazzabosco M.1
1University of Milano - Bicocca, Monza, Italy, 2Charta Foundation, Milan, Italy, 3Federico II 
University of Naples, Naples, Italy, 4Niguarda Hospital, Milan, Italy, 5Azienda Ospedaliera Papa 
Giovanni XXIII, Bergamo, Italy, 6University of Padua, Padua, Italy, 7Fondazione IRCCS Policlinico 
San Matteo, Pavia, Italy
Objectives: Liver diseases (LDs) have a high impact on morbidity, mortality and 
health-related quality of life (HRQoL). LDs may have different impact on patients’ 
HRQoL. The aim of our study was to evaluate HRQoL in the major liver conditions: 
hepatitis B(HBV), hepatitis C(HCV), cirrhosis(compensated and decompensated), 
hepatocellular carcinoma(HCC), autoimmune hepatitis(AIH), primary biliary 
cirrhosis(PBC), primary sclerosing cholangitis(PSC), NAFLD/NASH, patients in the 
liver transplant list and post-transplant. MethOds: A naturalistic, prospective, 
multicenter study has been conducted to generate and validate a set of health care 
outcomes indicators for the major liver conditions. LDs patients (age> 18 years) were 
enrolled in 3 major Italian medical centers and are still being followed up (median 
f-up:13 months). Within this study, socio-demographic, clinical and HRQoL were 
collected using the EQ-5D-3L. The HRQoL data was analyzed dividing the patients 
in sub-groups according to the most recently diagnosed and most severe condi-
tion. Results: We enrolled 3,217 patients, 64.8% male, aged 19-91 (median= 61) 
years; 95.0% of them filled in the EQ-5D at baseline visit. Patients in the HCC group 
were 22.6%; while in the AIH group were 1.6%. The highest percentage of problems 
in Mobility dimension (39.2%) was reported by decompensated cirrhosis sub-group, 
the highest percentage in Self-care (22.6%) and Usual Activities (47.1%) by patients 
in liver transplant list, in Pain/Discomfort (59.2%) by AIH and in Anxiety/Depression 
(57.8%) by PBC. The HBV sub-group reported the best HRQoL with a mean EQ-5D 
VAS of 77.8; while AIH and listed for liver transplant patients reported the worst 
HRQoL levels (mean EQ-5D VAS= 67.7 and 63.5, respectively). cOnclusiOns: our 
study shows how HRQoL is different between LDs and how it is negatively related 
with the clinical severity. Understanding the different impact of LDs on the patients’ 
HRQoL could help physicians and decision makers to better estimate the burden of 
these conditions and to improve the quality of care.
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and adalimumab (Subcutaneous). The objective of this study was to compare the 
dispensation channel of anti-TNFs used in IBD across European (EU) top 5 coun-
tries. MethOds: We analyzed dispensation conditions using IMS data from 2011 
and official local official websites, France (Haute Autorité de Santé and Health insur-
ance drugs database), Italy (Agenzia Italiana del Farmaco), Spain (Ministerio de 
Sanidad Servicios Sociales e Igualdad), Germany (Gemeinsamer Bundesausschuss), 
United Kingdom (Department of Health). Results: In UK, Spain, Italy, both inflixi-
mab and adalimumab dispensation were restricted to hospital channel. In Germany, 
both infliximab and adalimumab can either be dispensed through retail and hos-
pital channels. In France, adalimumab was available either in hospital and retail 
channels under exceptional status, and infliximab was dispensed through hospital 
channels only. The differences across countries could not be related to products 
labels as they are all approved under European Medicines Agency (EMA) centralized 
procedure. cOnclusiOns: It is unlikely that the gaps observed are only related to 
differences in health care services organization but rather budget constraint like 
in UK, Italy and Spain. In Germany and France, the two leading EU pharmaceuticals 
markets this is not yet the case. Hospital dispensation channel of biologics and 
biosimilars is a new way to generate savings mainly through tenders.
PGI50
PAEDIATRIC GASTROENTERITIS: DISEASE BURDEN, COST AND LOSS OF 
PRODUCTIvITy OF MALAySIAN AND vIETNAMESE PARENTS
Azmi S.1, Reginald P.2
1Veras Research, Petaling Jaya, Malaysia, 2Azmi Burhani Consulting, Petaling Jaya, Malaysia
Objectives: The cost of paediatric gastroenteritis is poorly documented in Asia. 
This analysis reports findings of a survey on disease burden, cost and productivity 
loss caused by paediatric gastroenteritis in Malaysia and Viet Nam. MethOds: A 
survey was conducted between August 2012 and April 2013 targeting respondents 
in public spaces in Hanoi and Bac Giang, Viet Nam and Klang Valley, Malaysia. The 
surveys were self-administered and collected information on demographics, disease 
burden, cost and productivity loss. Descriptive analysis was conducted to report the 
overall findings using STATA SE 11.2. Results: Survey questionnaires were com-
pleted by 245 and 307 respondents from Malaysia and Viet Nam, respectively. Over 
90% of the respondents were parents of children below 10. Overall, 69% reported 
that their children experienced gastroenteritis requiring physician visits and 28% 
reported episodes requiring hospital admissions. Differences were noted in the 
treatment seeking patterns between the two countries. These differences influenced 
cost and productivity loss to the families of affected children. In Malaysia, a large 
proportion of parents (41.2%) reported hospitalisation cost to be more than USD 350 
whereas in Viet Nam, a majority (74.6%) reported hospitalisation cost less than USD 
34. Among these, 52.9% and 30.5% of Malaysian and Vietnamese parents paid out-of-
pocket for hospital admission, respectively. The majority reported days off work of 2 
to 5 days, however more parents in Viet Nam (23.7%) required greater than 6 days off 
work to care for their affected child compared to Malaysia (3.9%). cOnclusiOns: 
Gastroenteritis has an impact on cost and productivity loss to parents of affected 
children in Malaysia and Viet Nam. However, there were several differences noted 
likely due to differences in GDP, health system and cultural factors.
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INFLAMMATORy BOwEL DISEASES IN ITALy: INCIDENCE TRENDS AND 
PATIENTS’ CHARACTERISTICS
Fornari C.1, Madotto F.1, Fiorino G.2, Ardizzone S.2, Bortoli A.2, Caprioli F.2, Cestari R.2,  
Conti S.1, Cortelezzi C.2, Mantovani L.G.3, Massari A.2, Meucci G.2, Ravelli P.2, Vecchi M.2, 
Danese S.2, Cesana G.1
1University of Milano - Bicocca, Monza, Italy, 2EPICO MICI LOMBARDIA Project, Milano, Italy, 
3Federico II University of Naples, Naples, Italy
Objectives: To assess the impact of inflammatory bowel diseases (IBD) in the 
Italian general population: incidence and time trends from 2003 to 2009, as well 
as population characteristics. MethOds: A retrospective observational study was 
conducted in Lombardy, an Italian region with about 10 million of inhabitants, using 
health care administrative databases of the national health care system (HS) which 
provides universal coverage. The main administrative databases were integrated in 
a data warehouse called DENALI using probabilistic record linkage. New cases of 
Crohn’s Disease (CD) and Ulcerative Colitis (UC) were identified in the adult popu-
lation between January 1, 2003 and December 31, 2009. Annual age-standardized 
incidence rates were computed separately for CD and UC using the population 
living in Lombardy at 2001 census. Moreover we evaluated patients’ baseline main 
characteristics, coexisting chronic conditions and survival at December 31, 2009.  
Results: The annual incidence rate per 100,000 person-years of IBD was 15.6 (95%CI 
15.2-15.9); UC and CD incidences were 9.7 (9.4-10.0) and 5.9 (5.7-6.1) respectively. 
Incidence rates of both diseases were higher in men than in women. CD incidence 
was highest in subjects aged 20-24 (9.2, 95%CI 8.1-10.2) and decreased with age, 
while UC incidence was stable in the 20-65 year-old population. No time trends in 
UC and CD incidences were observed from 2003 to 2009, both in the whole study 
population and in gender and age-specific subgroups. The mean age at CD diag-
nosis was 44 years (±16.6 sd), which was lower than that at UC diagnosis (46 ± 16.6, 
p< 0.0001). During a mean follow-up time of 3.4 years (± 2.0) 2.2% of IBD patients 
died. cOnclusiOns: Our study provides updated estimates on current epidemiol-
ogy of IBD in Italy. IBD incidence in Lombardy is lower than in northern Europe and 
the data confirm that UC incidence is higher than that of CD.
SENSORy SySTEMS DISORDERS – Clinical Outcomes Studies
PSS1
INDIRECT COMPARISON OF THE EFFECT OF BIOLOGICS IN PATIENTS wITH 
PSORIASIS; A META-ANALySIS OF RANDOMIzED, DOUBLE BLIND CLINICAL 
TRIALS IN BAyESIAN FRAMEwORK
Brodszky V., Mo M., Gulacsi L., Baji P., Balogh O., Péntek M.
Corvinus University of Budapest, Budapest, Hungary
examining aminosalicylates (n= 23), corticosteroids (n= 10), immunosuppressants 
(n= 15), biologics (n= 16) and kinase inhibitors (n= 1). Baseline patient characteristics, 
study design and outcomes were extracted, including: adverse events (AE) (reported 
in n= 24 studies), serious AE (n= 25), deaths (n= 23), clinical remission (n= 49), clini-
cal response (n= 33) and mucosal healing (n= 11). Eleven different disease activity 
scales and four different endoscopic scales were used. The mean age of included 
patients ranged from 27 to 51, and the percentage of males from 28.6% to 87.5%. Due 
to large differences and different scales used for reporting efficacy it is not feasible 
to report the range across different scales. Safety endpoints were also reported 
inconsistently. The results per outcome are presented in a narrative way per treat-
ment class. cOnclusiOns: A comprehensive SLR performed which identified 65 
RCT reporting on the efficacy and safety of pharmacological treatments in moderate 
to severe UC patients. Differences in patient population, disease severity, disease 
activity scales and trial duration are explored and presented.
PGI47
HOw THE PRICING STRATEGy OF 2ND GENERATION HCv DIRECT ANTIvIRAL 
AGENTS CAN AFFECT THE NUMBER OF TREATED PATIENTS IN ITALy AND THE 
NATIONAL DRUG BUDGET
Lanati E.P.1, Lidonnici D.1, Cammà C.2
1MA Provider Srl, Milan, Italy, 2University of Palermo, Palermo, Italy
Objectives: To assess the impact of new HCV drugs pricing strategy on the number 
of potential treated/cured patients and on the Italian Healthcare Service budget, 
using a simplistic model to design different scenarios for second generation direct 
antiviral agents (DAAs). MethOds: We calculated the HCV drugs budget and the 
number of patients for setting a base case by summing a) AIFA values for HCV 
dual therapy drugs to assess the number of patients currently treated; b) triple 
therapy number of patients estimated from AIFA budget (210.000.000€ in total). 
We performed budget scenarios on two variables: 1) pricing strategy of more effec-
tive DAAs; 2) total HCV drugs budget. We calculated the number of treated and 
responder patients, considering only genotype 1 HCV to maintain a comparability 
between base case and future scenarios with new DAAs. Results: The number of 
patients to be cured with stable budget vs base case are: 1) 9.000 (+56% vs. base case) 
with parity price vs. triple therapy; 2) 7.500 (+30% vs. base case) in case of a 20% 
premium price that would allow 8.300 patients to be treated. Assuming to double 
the allocated budget from payers (420.000.000€ ) and to reduce the new DAAs price 
by a 20%, 25.000 patients will be treated and 22.500 (+291% vs. base case) will be 
cured. cOnclusiOns: This simplified analysis shows that more effective drugs can 
significantly increase the number of patients who could be treated and cured. In 
order to support these results, efforts from both payers (higher budget) and pharma 
companies (lower prices) are needed.
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ExPLAINING THE INCREASED HEALTH CARE ExPENDITURES AMONG 
INDIvIDUALS wITH CO-OCCURRING CHRONIC OBSTRUCTIvE PULMONARy 
DISEASE AND GASTROESOPHAGEAL REFLUx DISEASE: A COST-
DECOMPOSITION ANALySIS
Ajmera M.R.1, Raval A.D.1, Shen C.2, Sambamoorthi U.3
1West Virginia University, Morgantown, WV, USA, 2The University of Texas MD Anderson Cancer 
Center, Houston, TX, USA, 3West Virginia University School of Pharmacy, Morgantown, WV, USA
Objectives: The objective of this study is to examine health care expenditures asso-
ciated with Gastro-esophageal Reflux Disease (GERD) among elderly with Chronic 
Obstructive Pulmonary Disease (COPD) and understand the explanatory factors 
associated with incremental expenditures associated with (GERD). MethOds: The 
study utilized retrospective cross-sectional design. Data were extracted from multiple 
years (2006-2009) of the Medicare Current Beneficiaries Survey (MCBS). The analytical 
sample consisted of community dwelling elderly individuals with COPD (n = 3,821) 
identified using appropriate International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes. The key independent variable was defined 
as presence or absence of GERD. T-tests and ordinary least squares regressions (OLS) 
on log-transformed total health care expenditures were performed to analyze the 
association between health care expenditures with GERD among individuals with 
COPD. Blinder-Oaxaca decomposition analysis was performed to estimate contribu-
tion of factors towards explaining the excess health care expenditures. Results: 
Among elderly individuals with COPD, the annual average health care expenditures 
were higher for those with GERD ($36,793 ± $1,387) as compared to those without 
GERD ($24,722 ± $800). Individuals with GERD had poorer health status, low physi-
cal activity profile, and higher rates of obesity. Furthermore, the rates of depression 
and anxiety were significantly higher among individuals with GERD compared to 
those without GERD. A decomposition technique revealed that nearly 30.9% of the 
incremental health care spending associated with GERD was due to the differences in 
characteristics such as Charlson’s comorbitity score (17.5%), perceived health status 
(7.13%) and depression (5.85%). cOnclusiOns: Our findings highlight the burden 
of comorbid conditions among those with COPD and GERD. This study reinforces the 
need to modify the care-delivery model from single-disease care approach to inte-
grated/ multiple diseases care approach to manage the complex comorbid diseases, 
which may ultimately reduce the excess health care expenditures.
PGI49
DISPENSATION CHANNELS OF ANTI-TNFS IN INFLAMMATORy BOwEL DISEASE
Thivolet M.1, Rémuzat C.2, Kornfeld A.1, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical France, Paris, France, 3University Claude 
Bernard Lyon 1, Lyon, France
Objectives: In The Netherlands, the funding for some high cost drugs and particu-
larly biologics was transferred in 2012 to hospital pharmacy dispensation channel. A 
European study forecast (2012-2016) shown hospital dispensation as a very effective 
policy to reduce budget impact of branded biologics and increase savings related 
to biosimilars. Two biologics (anti-TNFs) are indicated for Inflammatory Bowel 
Disease (IBD) in EU with different mode of administration: infliximab (Intravenous) 
A502  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
versus those with associated MH. This analysis establishes the representativeness 
of the MIVI-TRUST patient population in the context of clinical practice.
PSS4
ATOPIC DERMATITIS: EvALUATION OF 2 DIFFERENT DRUG RELATED 
MANAGEMENTS
Taieb C.
CREES PFSA, Paris, France
Objectives: Atopic Dermatitis (AD) is a chronic relapsing skin condition and one 
of the most common skin diseases worldwide. Nowadays, the prevalence of AD is 
estimated to be between 5%-and-30% in children. AD onset is commonly before 
5years old in children. Therapeutic treatments include topical corticosteroids (CS) 
and long-term emollients as first-line therapy, followed by topical calcineurin inhibi-
tors. Emollients represent one of the cornerstones of treatments for patients with 
AD. The aims of this study were to compare the drug related management and 
the drug related costs between children with AD treated by at least an emollient 
(composed-of-Glycerol [15 gr], Vaseline [8 gr] and liquid-paraffin [2gr] per 100 gr) 
and children not treated by emollient. MethOds: This was a retrospective analysis 
of data extracted from the “Disease Analyzer™” database, including anonymized 
data from medical files of the patients seen by a representative sample of FrenchGP. 
Children with AD diagnosed before 1 year old were tracked for 12-months after the 
date of diagnosis. Only children monitored at least 1 year after the diagnosis were 
included in the analysis. Costs of AD treatments were calculated from a societal 
perspective. Results: 49 children with AD were treated by the emollient (group 1) 
and 59 were not (group 2). 59.2% of children of group 1 were treated by CS vs 72.9% in 
group 2; the same trend was found for the prescription of antiseptic (24.5%-vs-27.1%) 
and antibiotic (10.2%-vs-13.6%). On the contrary, healing was more prescribed in the 
emollient group (32.7%-vs-25.4%). Average annual cost of prescribed dermatological 
drugs was estimated to be 139.8 € in the emollient group and 146.4 € in the other 
group. cOnclusiOns: These preliminary results suggest that CS, which may have 
negative effects (skin fragility, infection, addiction and impact on growth), are less 
prescribed in the emollient group. Studies considering larger samples are warranted 
to confirm this trend.
PSS5
BASELINE PATIENT, OCULAR FEATURES AND MANAGEMENT OF A PATIENT 
POPULATION DIAGNOSED wITH vITREOMACULAR TRACTION: AN 
OBSERvATIONAL STUDy IN FLANDERS
Lescrauwaet B.1, Spaepen E.2, Vriens I.3, Stalmans P.3
1Xintera Consulting, Leuven, Belgium, 2SBD Analytics BVBA/SPRL, Bekkevoort, Belgium, 
3Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Objectives: Limited data is published on baseline characteristics of patients diag-
nosed with vitreomacular traction (VMT) or different macular hole (MH) stages. Aim 
of our study was to describe the baseline patient and ocular characteristics, and 
the management of patients diagnosed with diseases of the vitreomacular inter-
face. MethOds: This was an observational study with retrospective design. The study 
sample included patients from a large tertiary care ophthalmology center in Flanders, 
who had at least 1 outpatient visit at the study center between July 2009 and May 
2013. Patients presented with or without visual symptoms and were examined using 
optical coherence tomography (OCT) in both eyes. Patients diagnosed with other 
retinal diseases were excluded from this study. This analysis reports on the VMT 
cohort only. Results: The study sample included a total of 509 patients of which 
156 patients (191 eyes) presented with VMT. Mean (SD) age was 72.8 (9.8); 59% were 
female. Majority (73%) was referred by an ophthalmologist for symptoms of general 
vision loss (60%) and/or metamorphopsia (23%). Mean follow-up was 1.64 years. Eyes 
in which a vitrectomy was performed (n= 41) presented with worse visual acuity 
(VA) compared with eyes managed through observation (0.43 versus 0.55; p= 0.029). 
However, VA in fellow eye was significantly better in eyes managed with vitrectomy 
(0.7 versus 0.56, p= 0.039). Metamorphopsia (61% versus 37%, p= 0.005) and concomi-
tant ERM (20% versus 9%, p= 0.049) were significantly more prevalent in eyes man-
aged through vitrectomy compared with observation. cOnclusiOns: In a real-life 
population, visiting the outpatient clinic of a large tertiary care ophthalmology center, 
31% of patients presented with VMT. Patients were predominantly managed though 
observation. Worse visual acuity of fellow eye, and presence of metamorphopsia or 
ERM were significantly associated with occurrence of vitrectomy.
PSS6
CHILDREN wITH ATOPIC DERMATITIS: MONITORING A FRENCH COHORT OvER 
A NINE-yEAR PERIOD
Taieb C.
CREES PFSA, Paris, France
Objectives: To assess the diseases associated with AD or that take over during 
the years following the diagnosis of the infant and to calculate the annual cost of 
treating these children. MethOds: The cohort includes infants with AD who have 
undergone consultation with their general practitioners between the beginning of 
2000 to the end of 2003. The data gathered through the IMS database was entered by 
general practitioners, enabling tracking of patients. The tracking period was started 
after diagnosis. Only infants who were monitored for a minimum of one-year were 
included. A control group comprising infants without AD and who were monitored 
for at least a year was created. Results: A total of 723 infants who met the criteria 
outlined were identified. In the first year following their birth, infants with AD had 
significantly more concomitant disorders, particularly respiratory disorders (85% 
vs. 76%), and asthma (8.9% vs 4.6%) or other types of dermatosis (46.9% vs. 28.2%) 
among others. During the nine-years of monitoring, the children of the AD cohort 
consumed more dermatological products than the children of the control-group did 
in terms of emollients or topical corticosteroids. As well, the AD group consumed 
more antiseptic products than the control group did in the first year (27.6% vs 14%). 
Children with AD were observed to consume more anti-asthma drugs, with a peak 
occurring at age 4. cOnclusiOns: From an epidemiological perspective, this study 
Objectives: The main aims of this systematic review were to identify all relevant 
literature on clinical efficacy for biological medications in patients with psoriasis 
and to conduct an up-to-date meta-analysis. MethOds: The following compara-
tors were considered for this analysis: adalimumab, etanercept, infliximab, and 
ustekinumab. A MEDLINE search was conducted until March 2013. The Cochrane 
Highly Sensitive Search Strategy was applied to identify randomized controlled 
publications and was combined with ‘psoriasis’ MeSH terms and drug names. 
Randomized, controlled, clinical trials with adults with moderate-to-severe pso-
riasis where the full paper can be obtained were included. Evidences were com-
bined in a mixed treatment comparisons in a Bayesian framework. Efficacy was 
measured by the 75% and 90% improvement of Psoriasis Area Severity Index (PASI) 
at three months were analysed. Results: Nineteen trials were included in this 
indirect comparison; treatment arms with off-label dosages were excluded. Each 
biologic showed significantly more favourable effect than placebo with respect to 
any level of PASI response. Significantly more patients on infliximab treatment 
met PASI75 endpoint than on etanercept, adalimumab or ustekinumab, combined 
odds ratios (95% confidence intervals) were 5.34 (2.29-12.50), 7.49 (3.31-16.92) and 
3.64 (1.62-8.20) respectively. Similarly, significantly more patients on infliximab 
treatment met PASI90 endpoint than on adalimumab or etanercept, odds ratios 
were 6.12 (1.07-34.86) and 7.78 (1.02-59.01). No significant differences in terms of 
PASI75 and PASI90 improvements were observed between adalimumab, etanercept 
or ustekinumab. cOnclusiOns: All biologics demonstrated statistically significant 
improvements compared to placebo. This review also showed that infliximab was 
significantly more efficacious than other biologics.
PSS2
COMPARATIvE EFFECTIvENESS OF PEAK AND TROUGH EFFECTS OF 
BIMATOPROST 0.03%/TIMOLOL 0.5% PRESERvATIvE-FREE FIxED COMBINATION 
FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OCULAR 
HyPERTENSION
Harvey B.1, Stradwick S.1, Brereton N.J.1, Shergill S.2, Wong W.3
1BresMed, Sheffield, UK, 2Allergan Ltd., Marlow, UK, 3Allergan Inc., Irvine, CA, USA
Objectives: To evaluate the comparative effectiveness of bimatoprost 0.03%/
timolol (BTFC) 0.5% preservative-free (PF) fixed combination solution in single 
dose vials (BTFC PF) for the treatment of glaucoma/ocular hypertension (OHT) 
compared to alternative combination therapies accounting for fluctuations in 
intraocular pressure (IOP). MethOds: A systematic review was conducted to iden-
tify randomised controlled trials investigating efficacy of combination therapies 
for the treatment of glaucoma/OHT; where efficacy is defined as IOP change from 
baseline. Maximum and minimum changes in IOP were used as a representa-
tion of peak and trough effects of medication. Prostaglandin/prostamide analog 
and timolol monotherapy trials were also included as key connectors. A Bayesian 
mixed treatment comparison (MTC) analysis was used to synthesise the resulting 
evidence base. Supportive probability of best and rankogram summary analysis 
were used to position treatments within the network based on efficacy. Results: 
A total of 136 studies met the pre-determined MTC inclusion criteria in total; 
representing 24 unique treatment arms. BTFC PF was numerically superior to all 
treatments (monotherapies and combination therapies; preserved and PF thera-
pies) in lowering IOP efficacy in both peak and trough analyses. This superiority 
was statistically significant (p< 0.05) for 18/23 comparisons in both analyses. Lack 
of evidence is the likely reason for non-significance in remaining comparisons. The 
probability of the BTFC formulations (preserved or PF) being the best treatments 
in the network was 0.94 (94% chance) in the peak analysis and 0.90 (90% chance) 
in the trough analysis; BTFC PF specifically had a 57% chance in the peak analysis 
and 62% chance in the trough analysis. No other treatments had > 6% chance. 
Overall ranking of BTFC PF and BTFC preserved in terms of IOP-lowering efficacy 
was 1st and 2nd respectively. cOnclusiOns: BTFC PF showed the greatest clinical 
efficacy of any combination- or mono-therapy in reducing IOP from baseline in 
patients with glaucoma and/or OHT.
PSS3
BASELINE CHARACTERISTICS AND vITREORETINAL INTERFACE FEATURES IN 
PATIENTS wITH vITREOMACULAR TRACTION AND MACULAR HOLE FROM THE 
MIvI-TRUST CLINICAL PROGRAM
Lescrauwaet B.1, Koshy Z.2, Labourette A.3, Duchateau L.4
1Xintera Consulting, Leuven, Belgium, 2University Hospital Ayr, Ayr, UK, 34Clinics, Paris, France, 
4Ghent University, Ghent, Belgium
Objectives: There is limited published evidence on demographic and vitreoretinal 
interface (VRI) characteristics of patients with vitreomacular traction (VMT), includ-
ing when associated with macular hole (VMT+MH). Establishing insights into the 
characteristics of untreated VMT patients may contribute to a better understanding 
of the burden of VMT disease. The objective of our analysis is to describe baseline 
patient characteristics and VRI features in patients with persistent VMT included in 
the phase 3 ocriplasmin studies. This analysis reports on VMT patients without MH 
(VMT) and VMT patients with MH (VMT+MH). MethOds: Two randomized, double-
masked, placebo-controlled trials designed to determine efficacy and safety of ocri-
plasmin for the treatment of VMT comprising of 652 patients (VMT n= 499; VMT+MH 
n= 153). Baseline characteristics included patient demographics (age, gender); eye-
disorder characteristics (time since diagnosis, visual acuity (VA) in study eye (SE); VA 
in non-study eye (NSE), presence of pseudophakia and/or ERM; VRI features (focal 
adhesion ≤ 1500 microns; min-max MH width), VFQ-25 composite score. Results: 
Baseline characteristics for VMT vs. VMT+MH patients were respectively: 72.6 ver-
sus 68.7 years; 62.7% versus 75.8% female. Time since diagnosis: 268 days versus 
62 days; VA: SE 66.8 versus 55.9, NSE 73.5 versus 77.8. Pseudophakes: 38.7% ver-
sus 20.9%, concomitant ERM: 46.3 % versus 15.8%. The majority of VMT patients 
presented with focal adhesion ≤ 1500 microns (69%) while VMT+MH patients pre-
sented with a min-max hole width of 272.7 microns. VFQ-25 composite score: 78.0 
vs. 80.3. cOnclusiOns: Baseline characteristics of the MIVI-TRUST ocriplasmin 
patient population show differentiations between patients with persistent VMT 
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(vPDT) fell from 93% to 68%. In the ‘without ranibizumab’ scenario, only vPDT was 
administered. Costs of treatment, administration, monitoring, bilateral disease and 
management of recurrences were included. Results: An estimated 2045 patients 
were eligible for treatment at year 1 and 2119 at year 5. In the ‘with ranibizumab’ 
scenario, 143 patients received ranibizumab at year 1, increasing to 678 at year 5; 
1902 patients received vPDT at year 1 and 1441 at year 5. ‘With ranibizumab’ annual 
costs were higher in years 1–2 than ‘without ranibizumab’ costs. During years 3, 
4 and 5, cost savings occurred with ranibizumab (£3867, £121 584 and £232 467, 
respectively), owing to lower total costs of treatment and monitoring than with 
vPDT. The total 5-year saving ‘with ranibizumab’ over ‘without ranibizumab’ was 
£227 086. cOnclusiOns: Treating visual impairment due to CNV secondary to PM 
with ranibizumab rather than vPDT is estimated to provide significant cost savings 
in England and Wales over 5 years.
PSS10
PHARMACOECONOMIC ASSESSMENT OF RANIBIzUMAB IN THE TREATMENT OF 
THE DIABETIC RETINOPATHy IN THE RUSSIAN FEDERATION
Serpik V.G., Yagudina R., Kulikov A.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Diabetic retinopathy (DR) is one of the main reasons of vision loss. Traditional 
treatment provides insufficient control of disease and adverse events. New drug 
ranibizumab usage in treatment of DR opens new opportunities in treatment of DR. 
Objectives: To provide pharmacoeconomic assessment of ranibizumab in DR treat-
ment in the Russian Federation. MethOds: Comparative modeling cost-effective-
ness (CEA) and budget impact (BIA) analyses based on clinical trials results were 
conducted. CEA with 1 year time horizon for basic group patients and BIA with 
5 year time horizon for high risk vision loss patient group. CEA considered only 
direct costs (DC), while BIA dealt with both DC and indirect costs (IC). 1 EURO = 40 
RUB. Results: Annual total costs (TC) per patient (PP) for ranibizumab treatment (8 
injections on the average) approached 9786 EURO. Annual TC for LC treatment were 
440 EURO PP. Ranibizumab provides 6,1 letters vision improvement on the average, 
while LC – 0,8 letters. Cost-effectiveness ratio (CER) for ranibizumab was 1604 EURO 
per letter, for LC CER was 550 EURO per letter. ICER was 1764 EURO per additional 
letter. Second scenario included DR patients going blind in 5 years on LC treatment, 
while on ranibizumab treatment they could keep their eyesight. TC over 5 years for 
ranibizumab treatment (13 injections on the average) were 15225 EURO PP. TC over 
5 years on LC were 27327 EURO PP, including IC due to vision loss – 25250 EURO. BIA 
results have shown that ranibizumab treatment for high-risk vision loss DR patients 
group provided 9 616 EURO (discounted at 3,5%) cost-saving PP in comparison with 
LC treatment. cOnclusiOns: Ranibizumab is highly effective costly treatment 
that demands additional consideration for administration in common DR patient 
group, while it seems to be cost-saving in DR patient group of high-risk vision loss.
PSS11
EvALUATION OF THE HERPES zOSTER IMPACT AS COMORBIDITy FACTOR IN 5 
PATHOLOGIES FRENCH HOSPITAL CARE AMONG ADULTS AGED 50 AND OLDER
Blein C.1, Gavazzi G.2, Paccalin M.3, Baptiste C.4, Vainchtock A.5
1HEVA, Lyon, France, 2Hopital de la TRONCHE, LA TRONCHE, France, 3CHU la Milétrie, POITIERS, 
France, 4SANOFI PASTEUR MSD, LYON, France, 5HEVA, LYON, France
Objectives: To evaluate the impact of Herpes Zoster (HZ) as associated diagnosis 
on hospitalizations for an other main health problem, using 3 evaluation crite-
ria: length of stay, number of death and cost from the national health insurance 
perspective. MethOds: The hospitalizations of people aged 50 years and more 
were selected from the French national hospital database (PMSI) 2011 using ICD 
10 diagnosis code: HZ (B02*) in associated diagnosis (DAS), and excluding codes of 
immunosuppressive conditions (D8* or B20*-B24*). The 5 main categories of diseases 
leading to hospitalization distribution allowed us to select, in decreasing order of 
importance: circulatory (I0*-I5* & I7*-I9*), respiratory (J0*-J9*), digestive (K0*-K9*), 
osteo-articular systems (M0*-M9*), and diabetes (E1*). For each of the 5 categories, a 
retrospective case-control has been realized. The cases are defined by hospitaliza-
tions with HZ in DAS and controls were hospitalizations without HZ in DAS matched 
on age and sex to the cases. Statistical non parametric analyses (Wilcoxon-Mann-
Whitney) in each of the five categories have been realized to evaluate the difference 
in length of stay, death rate, and cost. Results: In each of the five categories, cases 
presented a statistically significant length of stay compared to the controls. Median 
differences varying of 3 days for osteo-articular system (+50%) to 6 days for diges-
tive system (+300%). None difference in the death rates has been observed. The 
study also demonstrated a statistically significant cost of cases compared to the 
controls median differences varying of 857€ for circulatory system (+25%), 922€ for 
osteo-articular system (+26%), 945€ for respiratory system (+26%), 987€ for diabetes 
(+39%), and 2011€ for digestive system (+126%). cOnclusiOns: When present as 
an associated diagnosis in hospitalizations of people 50+ for other medical reasons, 
HZ significantly increases the length of stay at hospital and subsequent economic 
burden for the French health system.
PSS12
SPECTACLE INDEPENDENCE AND vISION-RELATED QUALITy OF LIFE IN 
CATARACT SURGERy PATIENTS FOLLOwING IMPLANTATION OF A MULTIFOCAL 
INTRAOCULAR LENS
Samiian A.1, Carones F.2
1Alcon Labs, Geneve, Switzerland, 2Centro Oftalmo Chirurgico Carones, Milano, Italy
Objectives: The aim of this study was to compare spectacle independence and 
vision-related quality of life following implantation of a multifocal intraocular 
lens (IOL: ReSTOR®) or monofocal IOLs. MethOds: This prospective observational 
study involved 206 cataract surgery patients (median age 71 years, range 51–90 
years) receiving either the multifocal IOL or monofocal IOLs. The primary outcome 
measures were the proportion of patients with a postoperative improvement in 
uncorrected visual acuity of 0.1 logMAR or better, the proportion of patients achiev-
ing spectacle independence, and vision-related quality of life assessed using the 
was in line with current data. Pulmonary symptoms call for vigilance in monitoring 
children. Chronic ocular inflammation sometimes is the cause of long-term cata-
racts in patients with atopic disorders. Early ocular symptoms found in this cohort 
must be specified and suggest that an opthamological follow-up may be required 
in some cases. In addition, the abnormally high consumption of antiseptics - and 
also often the source of irritation - raises concerns about children’s treatment.
PSS7
BURDEN OF ACTINIC KERATOSIS IN GERMANy-RESULTS OF A LITERATURE 
RESEARCH
Pfiffner C.1, Macheleidt O.2, Batscheider A.1, Ehlken B.1, Greiner R.A.1, Schroeder C.1, Hutt H.J.2
1IMS Health, Munich, Germany, 2LEO Pharma GmbH, Neu-Isenburg, Germany
Objectives: Actinic keratoses (AK) are dermatological conditions with the risk-
potential becoming squamous cell carcinoma (SCC). Descriptions of AK-epidemiology 
and cost-of-illness are currently necessary when submitting an AMNOG dossier for an 
AK-product in Germany. MethOds: To describe AK-epidemiology a targeted litera-
ture research was conducted in PubMed in 2012, using the search terms (epidemiology 
OR incidence OR prevalence). To find relevant cost-of-illness information the following 
search terms were used (cost OR costs OR burden OR econom* OR pharmacoeconom* 
OR financ* OR budget OR reimburs* OR (resource NEAR (use OR utilization))). Both 
searches were combined with AND ((actinic OR solar OR senil*) AND (keratos* OR 
cheilitis)) AND Germany. PubMed research was supplemented by additional searches 
in guidelines and the World Wide Web for publications in German/English. Results: 
The screening of the epidemiology results (36 in PubMed) identified two relevant 
publications of four studies investigating AK-prevalence in Germany (Schäfer epub 
ahead of print 2012, Lichte 2010). An additional search for the German phrase “nicht 
melanozytäre Hautkarzinome” identified a publication on the cost-benefit of skin-
cancer-screening, including data on prevalence of AK (Guther 2011). The study results 
demonstrate a prevalence range between 2.0% and 7.4% with increasing prevalence 
by age. So far no cost-of-illness data of AK were identified for Germany (5 hits in 
pubmed). In an expert survey from Augustin and Kornek (2012) one important cost-
factor was seen in the progression of AK into SCC and its prevention might reduce 
treatment cost and burden of disease for patients. Citation tracking of this expert-
survey identified an additional prevalence-study in Germany (prevalence 2%, Augustin 
2011). cOnclusiOns: No data of AK-incidence in Germany are available. Prevalence 
data of AK in Germany have a broad range from 2.0% - 7.4%. Cost-of-illness data are 
needed for Germany to demonstrate the cost saving aspect of AK-prevention as seen 
in cost-of-illness studies of other countries.
PSS8
PREvALENCE AND RISK FACTORS OF ACTINIC KERATOSES
Schaefer I.1, Kornek T.1, Spehr C.1, Reusch M.2, Augustin M.1
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Dermatology Center 
Tibarg, Hamburg, Hamburg, Germany
Objectives: In Europe only few and inconsistent data on the prevalence and 
treatment of Actinic Keratoses (AK) are available. Objective of this study was to 
determine the prevalence of AK in Germany, to identify potential predictors and to 
estimate the number of AK cases treated in dermatologic practices. MethOds: In a 
multiple-source-approach, prevalence was assessed from whole-body-examinations 
in a cohort of 90.800 employees and from nationwide statutory health insurance 
(SHI) data of 2008. c) The number of cases documented in dermatological offices was 
estimated from statistics of a SHI Physicians Association. Results: Standardized 
prevalence of AK from dermatological examinations was 2.7%; the rate increased 
with age (11.5% in the group 60-70 years) and was higher for men (3.9%) than for 
women (1.5%). Significant associations were also identified for skin phototype I, 
sunburns in childhood and solar lentigines. Vitiligo and a history of melanoma were 
also but not significantly associated with AK. In the SHI data analysis standardized 
AK prevalence was 1.8%. Age-specific rates were below 1.5% up to 60 years and rose 
to 8.2% (13.2% in men) in the group 80-89 years. The prevalence from these large 
data sets - which is at the lower limit of studies from other countries – suggests 
about 1.7 Mio. estimated AK cases in Germany. In 2011 AK accounted for 8.3% of the 
hundred most frequently treated dermatological outpatient diagnoses. The propor-
tion of AK cases has risen almost continuously over the last 10 years. Estimated 
annual number of AK cases documented by dermatologists in Germany is about 
1.7 Mio. cOnclusiOns: AK is a frequent condition in higher age groups and more 
prevalent in men; a relevant need for health care evident. Predictors and risk factors 
for AK are easy to identify in the population, which could also help to detect groups 
with special need for preventive measures.
SENSORy SySTEMS DISORDERS – Cost Studies
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THE BUDGET IMPACT OF INTRODUCING RANIBIzUMAB IN ENGLAND AND 
wALES FOR THE TREATMENT OF vISUAL IMPAIRMENT DUE TO CHOROIDAL 
NEOvASCULARIzATION SECONDARy TO PATHOLOGIC MyOPIA
Malcolm W.A.1, Leteneux C.2, Claxton L.3, Taylor M.3, Rathi H.4
1Novartis UK, Frimley, UK, 2Novartis Pharma AG, Basel, Switzerland, 3York Health Economics 
Consortium, York, UK, 4Novartis Healthcare Pvt.Ltd., Hyderabad, India
Objectives: To evaluate the budget impact of introducing ranibizumab. MethOds: 
Cumulative costs were assessed using an open cohort model with a 5-year time 
horizon and NHS perspective. The number of eligible patients was based on: the 
estimated prevalence of pathologic myopia (PM) in the population > 40 years old 
(1.2%); the incidence of choroidal neovascularization (CNV) in patients with PM 
(0.98%); the proportion of patients eligible for pharmacotherapy (81%) and bilateral 
disease prevalence (5.5%). Treatment and diagnosis rates were estimated at 80% and 
83–86% respectively. Treatment frequency was based on RADIANCE trial data. The 
model compared two scenarios. In the ‘with ranibizumab’ scenario, the proportion 
of eligible patients treated with ranibizumab was estimated as 7% at year 1, increas-
ing to 32% at year 5; the proportion receiving verteporfin photodynamic therapy 
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of psoriasis. MethOds: A systematic literature search was conducted and studies 
were identified from PubMed and conference proceedings. Studies published in 
English language between January 2001 and May 2013, and reporting direct and 
indirect economic burden of psoriasis were identified using search strategies. A 
total of 1,181 abstracts were screened by two researchers; any discrepancy was 
resolved by a third researcher. Results: Forty studies (34 primary articles and 6 
conference abstracts) from 12 countries including 19 from the US, 4 from Canada, 3 
from Germany, 2 each from Italy, The Netherlands and the UK, 1 each from Australia, 
Brazil, Israel, Spain, Sweden and Switzerland, and 2 multinational studies met the 
inclusion criteria. Overall, 27 studies assessed direct costs, 3 studies assessed 
indirect costs, and 10 studies evaluated both. Major contributors of direct costs 
included medication costs, office visits, hospitalization costs and monitoring costs. 
Productivity loss, patient and caregiver work days lost, and restricted activity days 
were key drivers of indirect costs. Among the European countries, the most recent 
studies reported an annual total cost (direct and indirect cost) per patient of € 11,928 
in Sweden, € 8,372 in Italy, and € 2,866 - € 6,707 in Germany based on treatment type. 
In US and Canada, the annual direct and indirect economic burden of psoriasis was 
$1.4 billion and CDN$1.7 billion respectively. cOnclusiOns: Costs associated with 
chronic plaque psoriasis are high in many countries indicating a continued need 
for new treatments.
PSS16
CANADIAN BURDEN OF CHOROIDAL NEOvASCULARIzATION SECONDARy TO 
PATHOLOGIC MyOPIA: BASELINE CHARACTERISTICS OF PATIENTS
Zaour N.1, Heisel O.2, Barbeau M.1, Ma P.3
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2Syreon Corporation, Vancouver, BC, 
Canada, 3University of British Columbia, Vancouver, BC, Canada
Objectives: To identify the real world standard of care, treatment patterns, medi-
cal history, resource use and costs of patients with choroidal neovascularization 
(CNV) secondary to pathologic myopia (PM) in Canada. MethOds: With enroll-
ment still ongoing, 85 patients with Myopic CNV were recruited by ophthalmolo-
gists and retina specialists from 16 centres across Canada to participate in this 
retrospective, multicenter study. Medical records covering at least one year of fol-
low up data from the CNV diagnosis, and up to two years, were analyzed to gather 
all information related to Myopic CNV. Results: Data from 67 study participants 
was analyzed. Patients had a mean age of 55.4 years (range: 27 – 80 years) at the 
time of their PM diagnosis (CNV affected eye), and 56.0 years (range: 29 - 82 years) 
at the time of their first lifetime CNV episode. The analysis showed that 71.6% 
of participants were female, 71.6% were Caucasian, 61.2% had subfoveal CNV in 
the affected eye and 31.3% had more than one lifetime CNV episode reported. 
Based on their visual acuity at the time of CNV diagnosis at the beginning of the 
chart review period, they were grouped by the Snellen score of the affected eye 
into 7 groups: 20/32-20/20 (n= 5), 20/50-20/32 (n= 5), 20/80-20/50 (n= 15), 20/125-
20/80 (n= 12), 20/200-20/125 (n= 2), 20/320-20/200 (n= 7) and < = 20/320 (n= 21). The 
approximate mean Snellen score was 20/160 in the affected eye and 20/63 in the 
fellow eye. The proportion of patients that had both eyes affected with PM was 
58.2%. cOnclusiOns: Information on Myopic CNV is very limited in the literature. 
The baseline characteristics of Canadian patients presented here are aligned with 
other few data available in the public domain. This is the first study worldwide 
investigating the burden of Myopic CNV and the final results, will help us better 
understand this debilitating disease.
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COSTS OF INCIDENCE-BASED CENTRAL RETINAL vEIN OCCLUSION IN FRANCE
Girmens J.F.1, Koerber C.2, Miadi-Fargier H.3, Wittrup-Jensen K.U.4
1CHNO des Quinze-Vingts, Paris, France, 2Bayer Santé S.A.S, Loos, France, 3Bayer Santé S.A.S., 
Loos, Nord, France, 4Bayer Pharma AG, Berlin, Germany
Objectives: Retinal vein occlusion (RVO) is the most common retinal vascular dis-
order with the potential for significant vision-related morbidity. The societal costs 
associated with CRVO are little known. Only a few studies reports on the burden of 
retinal vein occlusion or the resource use and cost of Central Retinal Vein Occlusion 
(CRVO). No specific burden of illness study is available that describes the situation in 
France. The purpose of the current study was to create a model that enables study of 
the societal costs of CRVO in France. The perspective of the model was prepared from 
a societal perspective. MethOds: The input for health care utilisation input, were 
derived from a client survey conducted among French clinical experts in ophthal-
mology. An incidence-based model was constructed, which included the following 
parameters: direct and indirect costs, including treatment with drugs, non-drug 
treatments (e.g., grid laser photocoagulation and pan retinal photocoagulation), 
monitoring of the disease, adverse events, lost productivity, transportation and the 
cost of blindness. Results: In France the incidence of people suffering from CRVO 
was estimated to 10,471 (2011). The average annual contribution from each patient 
to the overall cost of CRVO was calculated to 11,434€ . The yearly direct and indirect 
costs were estimated to app. 120mill Euros. The contributing factors driving the 
cost of CRVO, in France, are, cost of blindness 29%, drug treatment cost 26%, cost of 
adverse events 25% and cost from monitoring 14%. cOnclusiOns: Despite CRVO 
being a uncommon disease, the annual costs to the French society, based on the 
incidence of CRVO, are substantial. The cost of blindness account for 26% of the 
total annual costs indicating that there is a potential for reducing those costs with 
improved treatment options in CRVO.
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COSTS OF BEST SUPPORTIvE CARE IN THE TREATMENT OF MODERATE-TO-
SEvERE PSORIASIS IN THE UNITED STATES
Tencer T., Li S., Zhang F.
Celgene Corporation, Summit, NJ, USA
Objectives: To describe the best supportive care costs of psoriasis patients follow-
ing discontinuation of conventional systemic or biologic therapy. MethOds: Adult 
patients with ≥ 2 psoriasis diagnoses (from office visits) with continuous insurance 
5-dimension National Eye Institute Refractive Error Quality of Life (NEI-RQL)-42 
scale; expenditure on spectacles was also measured. Results: The proportion of 
patients with a postoperative improvement in visual acuity of 0.1 logMAR or better 
was significantly higher with the multifocal IOL than with monofocal lenses (45.7% 
vs. 2.1%, respectively; P< 0.0001), as was the proportion of patients achieving spec-
tacle independence (73.3% vs. 25.3%, P< 0.0001). At 6 months, the group difference 
in NEI-RQL-42 scores for dependence on correction significantly favoured the mul-
tifocal IOL (mean difference 37.3, 95% confidence interval 28.7–46.0, P< 0.0001), but 
there were no significant differences between the groups in scores for the other four 
dimensions (near vision, appearance, limitation in activity, and satisfaction with 
correction). The mean costs of spectacles in patients with multifocal or monofocal 
IOLs were € 154.42 and € 267.21, respectively, for lenses and € 66.59 and € 74.35, respec-
tively, for frames. cOnclusiOns: Compared with monofocal IOLs, the multifocal 
IOL resulted in greater spectacle independence and lower expenditure on glasses. 
These findings are consistent with those of a previous economic modelling study, 
which showed that the use of this lens resulted in significant cost savings due to a 
reduced need for spectacles.
PSS13
COSTS COMPARISON OF CUTANEOUS DRUG REACTIONS TREATMENT DIvIDED 
By DIAGNOSIS GROUPS
Wisniewska N.1, Szkultecka-Debek M.2, Owczarek W.1, Paluchowska E.B.1, Jahnz-Rozyk K.M.1
1Military Institute of Medicine, Warsaw, Poland, 2Department of Dermatology, Military Institute of 
Medicine, Warsaw, Poland
Objectives: The aim was to analyze the total direct costs of treatment of cutane-
ous drug reactions (CDR) from health care provider and public payer perspective 
divided by diagnosis groups. MethOds: We analyzed retrospectively data from 
164 patients (57 men, 107 women) hospitalized in the Department of Dermatology, 
Military Medical Institute in Warsaw (from 2002 to 2012) due to CDR. Total direct 
costs from the public payer and health care provider were calculated for different 
diagnoses (based on ICD 10 codes). The analysis was based on data derived from 
the patients’ medical charts, daily medication logs, and cost data provided by the 
hospital organization and accounting department. The services paid by National 
Health Fund (NHF) were grouped based on ICD-10 and DRG system. For the pur-
pose of the analysis the hospitalization costs were calculated based on the prices 
for medical services established by the NHF on the basis of a contract with the 
selected health institution. Results: In the study group 3 CDR groups were iden-
tified: J38-severe skin disease (generalized rash) J39-large dermatological diseases 
(erythema multiforme) J49-gentle dermatological diseases (urticaria). From NHF 
perspective the most expensive procedure is J 38 – 962 € per patient (1€ = 4.24 PLN), 
the lower cost is for J39 and J 49 (476€ and 331€ respectively). From health care 
provider’s perspective the total direct costs equal: J38 – 630 € , J 39 – 552 € , J49 – 375€ . 
Differences in costs could be due to high costs of the clinically severe diseases treat-
ment incurred by the provider while according to the NHF, these units are classified 
as large dermatological diseases and thereby direct treatment costs are much lower 
than real provider’s costs. cOnclusiOns: The analysis results suggest taking into 
consideration reclassification of the services by NHF or better estimation of DRG 
groups by the public payer.
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COSTS OF PREvALENCE-BASED CENTRAL RETINAL vEIN OCCLUSION (CRvO) IN 
THE UNITED KINGDOM
Priaulx J.1, Wittrup-Jensen K.U.2
1Bayer HealthCare, New Bury, UK, 2Bayer Pharma AG, Berlin, Germany
Objectives: The societal costs associated with CRVO are little known. Only a few 
studies report on the burden of retinal vein occlusion, the resource use and cost of 
CRVO. No specific burden of illness study is available that describes the situation in 
the UK. The purpose of this study was to create a model that enabled the calcula-
tion of the societal costs of CRVO in the UK. MethOds: The health care utilisation 
inputs for the model were derived from a survey conducted among UK ophthalmol-
ogy experts. The model included parameters that contribute to the costs of illness 
of CRVO and is based on the prevalence of CRVO in the UK. These were direct and 
indirect costs including drug treatment, non-drug treatment (e.g. grid laser photo-
coagulation and pan retinal photocoagulation), monitoring of the disease, adverse 
events, lost productivity, transportation and the cost of blindness. Results: In 
the UK, the average annual contribution from each patient to the overall cost of 
CRVO was calculated to £14,692. The annual cost for the UK society was estimated 
to be almost £700 million. The main part of the cost, 42%, was from monitoring of 
the disease. Also, 20% was from the cost of blindness, 16% from the drug treatment 
and 15% from treatment of adverse events. cOnclusiOns: Despite CRVO being an 
uncommon disease, the annual costs to the UK society are substantial. The total 
burden of CRVO is most sensitive to changes in the cost associated with interven-
tions, with the number of hospital visits, ophthalmoscopy examinations and the 
number of optical coherence tomography (OCT) procedures as the dominating fac-
tors. By reducing the cost and/or the number of interventions by 25%, the overall 
burden of CRVO decreases from £14,692 to £13,147 per patient, which corresponds 
to a societal saving of almost £73 million per year.
PSS15
SySTEMATIC LITERATURE REvIEw OF ECONOMIC BURDEN OF CHRONIC 
PLAQUE PSORIASIS
Feldman S.R.1, Burudpakdee C.2, Gala S.2, Mallya U.3
1Wake Forest University, Winston-Salem, NC, USA, 2MKTXS, Raritan, NJ, USA, 3Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
Objectives: Psoriasis is a significant economic burden to both patients and pay-
ers in terms of direct and indirect costs. Previous systematic reviews have been 
limited with regards to geographical region of assessment and type of economic 
outcomes reported. Hence, the objective of this systematic review is to provide a 
global comprehensive understanding of the direct and indirect economic burden 
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treatment, shortening “patient paths” and establishing centers of wound treat-
ment would be recommended in Hungary.
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THE COST-EFFECTIvENESS OF INTRAvITREAL AFLIBERCEPT (IvT-AFL) IN 
TREATING NEOvASCULAR AGE-RELATED MACULAR DEGENERATION IN AN 
ITALIAN SETTING
D’Ausilio A.1, Midena E.2, Pilotto E.2, Calligari N.3, Bianchi C.3, Wittrup-Jensen K.U.4
1Creativ Ceutical, Luxembourg, Luxembourg, 2University of Padova, Padova, Italy, 3Bayer Pharma, 
Milano, Italy, 4Bayer Pharma AG, Berlin, Germany
Objectives: In Italy, standard treatment care of patients with neovascular (“wet”) 
age-related macular degeneration (wAMD) is currently performed with ranibi-
zumab (RBZ) on as-needed basis (PRN). The objective of this study was to assess 
the cost-effectiveness of intravitreal aflibercept (IVT-AFL), administered every 
other month vs. RBZ PRN treatment, in the Italian treatment setting. MethOds: 
A Markov model was built to compare IVT-AFL compared to RBZ PRN in wAMD. 
Health states were based on visual acuity in the better-seeing eye. In the model, 
patients may remain in the same status (same visual acuity), progress to another 
status or die. A proportion of patients may also discontinue treatment monthly 
or upon becoming blind. Parameters were estimated from two randomized phase 
III studies VIEW 1/VIEW 2, published literature or expert opinions. Analyses were 
performed from the Italian Healthcare perspective, using a 20-year time hori-
zon (starting age was 77 years). The simulation model calculated costs (drug, 
administration, monitoring, vision impairment and adverse events), quality-
adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs), all 
discounted at 3% annually. Deterministic and probabilistic sensitivity analyses 
(SA) were performed to test the robustness of the results. Results: IVT-AFL 
costs 30,852€ compared with 33,636€ for RBZ PRN; QALYs totaled 2.651 for IVT-
AFL and 2.638 for RBZ-PRN respectively. IVT-AFL is associated with less cost and 
more QALYs gained than RBZ-PRN and hence dominates RBZ PRN. Deterministic 
SA showed that the results were most sensitive to changes in efficacy and time 
horizon, while probabilistic SA showed that 90% of the iterations fell within the 
cost-effectiveness threshold deemed acceptable for Italian Payers (for example 
€ 40,000). cOnclusiOns: Results indicate that, within the Italian treatment set-
ting, attainment of maximal visual gains via IVT-AFL is cost-saving that means less 
costly and more effective (more QALYs gained) compared to RBZ PRN.
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COST-EFFECTIvENESS OF RANIBIzUMAB FOR THE TREATMENT OF vISUAL 
IMPAIRMENT DUE TO CHOROIDAL NEOvASCULARIzATION SECONDARy TO 
PATHOLOGIC MyOPIA IN THE UNITED KINGDOM
Leteneux C.1, Claxton L.2, Malcolm W.A.3, Taylor M.2, Rathi H.4
1Novartis Pharma AG, Basel, Switzerland, 2York Health Economics Consortium, York, UK, 
3Novartis UK, Frimley, UK, 4Novartis Healthcare Pvt.Ltd., Hyderabad, India
Objectives: To evaluate the cost-effectiveness of ranibizumab compared with 
verteporfin photodynamic therapy (vPDT) for the treatment of patients with visual 
impairment due to choroidal neovascularization (CNV) secondary to pathologic 
myopia (PM). MethOds: A Markov model with a 3-month cycle length and health 
states defined by best-corrected visual acuity (BCVA) was developed from the UK 
health care provider perspective. A lifetime time horizon was applied, and future 
costs and outcomes were discounted at 3.5%/year. Baseline characteristics were 
derived from the phase 3 RADIANCE study; year 1 health state transitions and 
treatment frequency were based on the RADIANCE study and a vPDT study (VIP). 
Treatment was given beyond year 2 only in cases of mCNV recurrence (6%/year). 
Existing literature was used to estimate BCVA transitions beyond 12 months. Health 
states were based on the visual acuity of the study eye, which could be each patient’s 
better-seeing eye (BSE) or worse-seeing eye (WSE). BSE utility values came from a 
published source. Results: The mean lifetime cost of ranibizumab treatment was 
slightly lower than the cost of vPDT. Ranibizumab was associated with higher life-
time quality-adjusted life-years (QALYs) than vPDT (relative gain of 0.43), reflecting 
higher utility values and reduced mortality with ranibizumab. Ranibizumab there-
fore dominated vPDT. Ranibizumab had a 100% probability of being cost-effective 
compared with vPDT at a willingness-to-pay threshold of £20 000 per QALY. The 
model was sensitive to the number of ranibizumab injections in year 1. Ranibizumab 
remained cost-effective even when the mean number of ranibizumab injections 
increased from 3.5 (base case) to 12 and the mean number of vPDT treatments 
remained constant (3.4) in year 1. cOnclusiOns: Ranibizumab is less costly and 
is associated with a gain in QALYs relative to vPDT for the treatment of patients 
with visual impairment due to CNV secondary to PM in the UK.
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COST-EFFECTIvENESS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF 
MODERATE TO SEvERE PSORIASIS IN THE UNITED KINGDOM
Betts K.A.1, Sundaram M.2, Mughal F.3, Yan S.Y.1, Signorovitch J.1, Wang K.2, Wu E.Q.1
1Analysis Group, Inc., Boston, MA, USA, 2AbbVie Inc., North Chicago, IL, USA, 3AbbVie Ltd., 
Maidenhead, Berkshire, UK
Objectives: To evaluate the cost-effectiveness of biologic treatments for moderate 
to severe psoriasis in the UK. MethOds: A decision model similar to those utilized 
in NICE appraisals TA103, TA134, TA146, and TA180 was constructed consisting of 
2 distinct periods, the trial and treatment periods. Clinical efficacy was estimated 
during the trial period based on the relative probabilities of achieving Psoriasis Area 
and Severity Index (PASI) response (50/75/90) obtained via a network meta-analysis 
of 15 randomized controlled trials of adalimumab, etanercept, infliximab, and usteki-
numab. Weight-based dosing was calculated for infliximab and ustekinumab to reflect 
licensed use. Only patients who achieved PASI 75 response in the trial period contin-
ued into the treatment period. Treatment benefits were determined by the relation-
ship between predicted PASI response and the EQ-5D health utility measure. Costs 
(2011 British pounds) were assessed from a UK National Health Services perspec-
tive and included drug acquisition, administration, monitoring and hospitalization 
coverage ≥ 6 months before (baseline period) and ≥ 12 months post-index date were 
selected from the MarketScan Commercial and Medicare Claims database (2005-2009). 
The index date was defined as the last day of conventional systemic or biologic drug 
coverage. Discontinuation was defined as no systemic or no biologic treatment for ≥ 
12 consecutive months from the last day of systemic or biologic prescription coverage. 
Patients were classified as having discontinued from a biologic if there was evidence 
of biologic drug use during the baseline period; otherwise they were defined as hav-
ing discontinued from non-biologic systemic therapy. Twelve-month average costs 
following discontinuation were reported. Results: A total of 4,720 psoriasis patients 
met the selection criteria; 67.4% discontinued from non-biologic systemic therapy 
and 32.6% from biologic therapy. Over the 12-month period following discontinu-
ation, total costs were $10,577 (SD: 19,910) and $9,001 (SD: 16,401) for biologic and 
non-biologic discontinuers, respectively (p= 0.004). Outpatient and medication costs 
were significantly higher for the biologic discontinuers compared to the non-biologic 
discontinuers ($5,283 vs. $4,449, p= 0.003, and $2,738 vs. $2,470, p= 0.022, respec-
tively). There was no statistically significant difference in hospital/ER costs ($2,556 
vs. $2,083, p= 0.214, respectively). Outpatient costs accounted for approximately 50% 
of total costs for both cohorts. cOnclusiOns: This study suggests that outpatient 
costs account for a substantial proportion of health care costs in psoriasis patients 
who discontinued from systemic or biologic therapy. Patients who had discontinued 
from biologic therapy incurred significantly higher outpatient and medication costs 
compared to patients who had discontinued from conventional systemic therapy.
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AN INNOvATIvE METHOD: APPLICATION OF NEGATIvE PRESSURE wOUND 
THERAPy IN THE TREATMENT OF CHRONIC LEG ULCERS – MEDICAL AND 
HEALTH ECONOMICS ASPECTS
Kovács L.A.1, Kádár Z.1, Várszegi D.1, Sebestyén A.2
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Pécs, 
Hungary
Objectives: Chronic leg ulcers without healing tendency present a serious public 
health and socio-economic issue. Rationally combinig causal and conservative treat-
ments with innovative methods, it would be beneficial to improve the effectivity of 
wound treatment, thus reducing its financial impacts. The aim of study was to inves-
tigate the cost of conservative treatment and an innovative Negative Pressure Wound 
Therapy (NPWT). MethOds: The authors present cases of dermatological patients 
with severe, chronic leg ulcers of various etiologies resistant to conservative therapy 
(Patients-1: fasciitis necrotisans; Patients-2: ulcer associated with chronic venous 
insufficiency; Patients-3: pyoderma gangrenosum), thus comparing the costs of con-
servative treatment (social insurance subsidies on bandages) and NPWT (not financed 
by social insurance) in each patient. Furthermore, the authors compare costs of NPWT 
cases with other cases (Patient-4: fasciitis necrotisans; Patient-5: ulcer associated with 
chronic venous insufficiency; Patient-6: ulcer associated with rheumatoid arthritis), 
in which no NPWT was applied thus far due to financial reasons. (1USD$= 225 HUF, 
Hungarian Forint). Results: Social insurance subsidies on bandages/patient (USD) 
in treatment period: Patient-1.: $1324; Patient-2.: $15495; Patient-3.: $412; Patient-4.: 
$11376; Patient-5.: $10557; Patient-6.: $7306. Cost of NPWT/patient and proportion of 
social insurance subsidies on bandages/patient: Patient 1.: $1405 (106%); Patient 2.: 
$667 (4.3%), Patient 3.: $778 (188.9%). The cost of NPWT is relatively high, however, 
NWPT-treated leg ulcers have healed compared to cases receiving conservative treat-
ment, which can be attributed to NPWT stimulating wound healing. cOnclusiOns: 
Treatment of the disease resulting leg ulcer – causal therapy combined with NPWT – is 
beneficial in wound healing, reducing high costs of wound treament, shortening the 
time of wound healing, improving the patient’s quality of life. Application of NPWT 
in specialized centers of wound treatment and financing by social insurance would 
be recommended for cases not responding to conservative treatment in Hungary.
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DIFFERENTIAL DIAGNOSIS OF LEG ULCERS – MEDICAL AND HEALTH 
ECONOMICS ASPECTS
Kovács L.A.1, Várszegi D.1, Kálmán E.1, Sebestyén A.2
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Pécs, 
Hungary
Objectives: Incidence of chronic leg ulcers without healing tendency exceeds 1% 
among adults and 3-5% among people over 65 years. The burden of diseases caused 
by wounds without healing tendencies can only be estimated. Complications of 
chronic wounds are severe, life-threatening. Total social insurance subsidies on 
bandages in Hungary is 22-26 million USD/year. Using case studies the authors 
emphasize the importance of (differential) diagnosis, mistakes of wound treat-
ment affecting healing and increasing costs of treatment, in contrast to therapy 
costs. MethOds: The authors present leg ulcer cases of various etiologies referred 
to the dermatological clinic, seeking mistakes of wound treatment, examining 
social insurance subsidies on bandages, based on bandage prescriptions. Patients 
1-4.: Ulcus cruris due to chronic venous insufficiency; Patient 5.: Leg ulcer caused 
by lymphoedema; Patients 6-8.: Ulcerous malignancies treated as leg ulcers; 
Patient 9.: Ulcus cruris+myeloproliferative disease; Patient 10.: Bilateral leg ulcers 
resulting from cardial decompensation and diabetes mellitus. (1USD$= 225 HUF, 
Hungarian Forint). Results: Social insurance subsidies (USD) on bandages per 
patients and mistakes in wound therapy: Patient 1.: $1857; Patient 2.: $1639; Patient 
3.: $1787; Patient 4.: $53329, lack of compression therapy and lymphatic massage; 
Patient 5.: $12.567, lack of lymphatic massage; Patient 6.: $213; Patient 7.: $294; 
Patient 8.: $2143, lack of correct diagnosis; Patient 9.: $2993, no treatment of con-
comitant hematologic disease; Patient 10.: insufficient therapy of co-morbidities: 
diabetes, obesity, cardial decompensation. cOnclusiOns: Modern treatment of 
leg ulcers mainly aims at determining primary causes, treating diseases causing 
wound healing disorders, namely causal therapy. Inefficient wound treatment 
is costly, application of modern bandages without principles, not treating co-
morbidities and treating on inadequete levels cause financial problems to both the 
patient and the social insurance. Introducing professional guidelines for wound 
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was adapted to the Portuguese setting to evaluate the cost-effectiveness (CEA) of 
linezolid vs.vancomycin in MRSA cSSTI. MethOds: Published Bayesian evidence 
synthesis results were used to populate efficacy parameters of the model. Resource 
utilization and MRSA prevalence rates were obtained through an expert panel of 
Portuguese clinicians and costs from published sources were applied to resource 
units. Analyses were done from the Portuguese NHS perspective. Both univariate 
and probabilistic sensitivity analyses were performed to test the robustness of model 
results. Results: Average cost per patient for linezolid and vancomycin treatments 
were 15,195€ and 17,345€ respectively. Average effectiveness gained with linezolid 
treatment was 0.002QALYs. Average saving obtained with linezolid treatment was 
2150€ per patient. cOnclusiOns: Linezolid is a dominant strategy compared to 
vancomycin: less costly and more effective. Compared to vancomycin, linezolid is 
expected to result in lower total costs that offset its higher acquisition cost in cSSTI 
in Portugal.
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ECONOMIC EvALUATION OF RANIBUzUMAB FOR THE TREATMENT OF MyOPIC 
CHOROIDAL NEOvASCULARIzATION IN CANADA
Lee A.1, Zaour N.2, Becker D.L.1, Leteneux C.3, Barbeau M.2
1OptumInsight, Burlington, ON, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, 
Canada, 3Novartis Pharma AG, Basel, Switzerland
Objectives: To assess the cost-effectiveness of ranibizumab compared to verteporfin 
in photodynamic therapy (vPDT) for the treatment of myopic choroidal neovasculari-
zation (mCNV) from the Canadian health care and societal perspectives. MethOds: 
A Markov model was used to follow a cohort of 55-year old patients with mCNV over 
a lifetime horizon. The model included 8 health states based on best corrected visual 
acuity (BCVA) and an absorbing death state. Patients were allowed to remain in their 
current health state, or transition to other health states or death every 3 months. 
Results from the RADIANCE trial were used to inform the first year transitions for 
patients receiving ranibizumab, and the first 3 months for those on vPDT. The VIP 
trial was used to estimate month 4-12 transitions for vPDT. Patients transitioned 
according to natural progression from year 2 onwards. Health state utilities were 
derived from a Canadian utility study and published sources. Resource use and costs 
were collected from clinical trials, published literature, expert opinion, and standard 
Canadian sources. Results: From the health care perspective, patients receiving 
ranibizumab for mCNV incurred less health care costs compared to those on vPDT 
(cost savings of $3,939). This was achieved while accruing an additional 0.07 life years 
(LYs) and 0.37 quality-adjusted life years (QALYs). Thus ranibizumab dominated vPDT. 
Similar findings were observed from the societal perspective (cost saving of $14,217). 
The average BCVA score remained consistently higher with ranibizumab compared to 
vPDT over the entire time horizon. cOnclusiOns: From a cost-effectiveness stand-
point, ranibizumab dominated vPDT in the treatment of mCNV, from both Canadian 
health care and societal perspectives. Patients on ranibizumab realized more QALYs 
and LYs at a lower cost compared to vPDT.
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COST-EFFECTIvENESS OF INTRAvITREAL AFLIBERCEPT IN TREATING 
NEOvASCULAR AGE-RELATED MACULAR DEGENERATION IN SwEDEN
Clements K.M.1, Hulbert E.M.2, Panchmatia H.R.1, Eriksson M.3, Wittrup-Jensen K.U.4,  
Nilsson J.5, Weinstein M.C.6
1OptumInsight, Cambridge, MA, USA, 2OptumInsight, Eden Prairie, MN, USA, 3Bayer AB, Solna, 
Sweden, 4Bayer Pharma AG, Berlin, Germany, 5OptumInsight, Stockholm, Sweden, 6Harvard 
School of Public Health, Boston, MA, USA
Objectives: Monthly dosing with ranibizumab (RBZ) is needed to achieve maxi-
mal sustained visual gains in patients with neovascular (“wet”) age-related macular 
degeneration (wAMD). In Sweden dosing is on an as-needed (PRN) basis, resulting in 
suboptimal efficacy. Intravitreal aflibercept dosed every 2 months (IVT-AFL) demon-
strated clinically equivalent efficacy compared to RBZ monthly dosing (RBZ Q4) in a 
randomized clinical trial setting. We assessed the cost-effectiveness of IVT-AFL vs. 
RBZ Q4 and RBZ PRN real-life data, in a Swedish setting. MethOds: A Markov model 
compared wAMD treatment over two years with either IVT-AFL, RBZ Q4 or real-life 
RBZ PRN. Health states were based on visual acuity in the better-seeing eye; a propor-
tion discontinued treatment monthly or upon visual acuity < 20/400. Parameters were 
estimated from trial data, published literature, or expert opinion. Analyses were per-
formed from a societal perspective with a lifetime horizon (starting age 77 years). The 
model calculated costs (drug, administration, monitoring, vision impairment, adverse 
events, caregiver), quality-adjusted life-years (QALYs), and incremental cost-effec-
tiveness ratios (ICERs), all discounted 3% annually. Deterministic and probabilistic 
sensitivity analyses were performed. Results: IVT-AFL cost 578,400 SEK, compared 
with 686,600 SEK for RBZ Q4 and 565,700 SEK for real-life RBZ PRN; QALYs totaled 4.58 
for IVT-AFL, 4.59 for RBZ Q4, and 4.43 for real-life RBZ PRN. Compared with real-life 
RBZ PRN, IVT-AFL cost 80,000 SEK/QALY gained. RBZ Q4 cost over 20 million SEK/
QALY gained, compared with IVT-AFL Q8. The model was most sensitive to IVT-AFL 
efficacy and patient age. IVT-AFL had a 42% probability of dominating RBZ Q4 and a 
100% probability of being cost-effective vs. RBZ PRN, at an assumed willingness-to-pay 
threshold of 500,000 SEK. cOnclusiOns: Results suggest that, in Sweden, attainment 
of maximal visual gains via IVT-AFL is cost-effective compared with real-life RBZ PRN 
dosing. RBZ Q4 is not cost-effective relative to IVT-AFL.
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THE COST-EFFECTIvENESS OF BIMATOPROST 0.03%/TIMOLOL 0.05% 
PRESERvATIvE-FREE FIxED COMBINATION COMPARED wITH DORzOLAMIDE/
TIMOLOL PRESERvATIvE-FREE FIxED COMBINATION AND 2-BOTTLE UNFIxED 
COMBINATIONS FOR THE TREATMENT OF PRIMARy OPEN-ANGLE GLAUCOMA 
IN THE UNITED KINGDOM
Hirst A.1, Almond C.1, Brereton N.J.1, Shergill S.2, Wong W.3
1BresMed, Sheffield, UK, 2Allergan Ltd., Marlow, UK, 3Allergan Inc., Irvine, CA, USA
Objectives: To evaluate the cost-effectiveness of bimatoprost 0.03%/timolol 0.05% 
(BTFC) preservative-free (PF) fixed combination compared with dorzolamide/timolol 
costs. Drug acquisition cost for ustekinumab reflected the manufacturers’ UK Patient 
Access Scheme. Incremental cost-effectiveness ratios (ICERs) were calculated and 
treatments were ranked relative to supportive care. One-way sensitivity analyses, 
using alternative plausible values for key parameters, explored uncertainty in the 
results. Results: Infliximab provided the most additional quality-adjusted life-years 
(QALYs) vs. supportive care (0.186) followed by ustekinumab (0.174) and adalimumab 
(0.169). In the base case, adalimumab was the most cost-effective biologic (£19,082/
QALY vs. supportive care), followed by ustekinumab (£20,964/QALY), etanercept 25 mg 
BIW (£26,580/QALY), etanercept 50 mg BIW during the trial period followed by 25mg 
BIW (£28,719 per QALY), and infliximab (£46,844 per QALY). ICERs for ustekinumab 
and infliximab compared with adalimumab were £87,625 and £332,015, respectively. 
Adalimumab remained the most cost-effective in the majority of the sensitivity analy-
ses. cOnclusiOns: In this decision-model analysis, adalimumab was the most cost-
effective biologic treatment for moderate to severe psoriasis in the UK.
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A COST-EFFECTIvENESS ANALySIS OF INGENOL MEBUTATE GEL FOR THE 
TREATMENT OF ACTINIC KERATOSIS: A SCOTTISH PERSPECTIvE
Tolley K.1, Kemmett D.2, Thybo S.3, Nasr R.4, Gillingham H.5
1Tolley Health Economics, Buxton, UK, 2Royal Informary of Edinburgh, Edinburgh, UK, 3Leo 
Pharma A/S, Ballerup, Denmark, 4LEO Laboratories Limited, Princes Risborough, UK, 5Abacus 
International, Bicester, UK
Objectives: Ingenol mebutate gel is a recently developed, topical, 2 or 3 days patient-
administered AK therapy. The objective was to compare the cost-effectiveness of ingenol 
mebutate gel with diclofenac gel and other available therapies for the first-line treat-
ment of AK in adult patients, from the perspective of the National Health Service (NHS) 
in Scotland. MethOds: A cost-utility analysis was conducted using a decision tree 
approach to calculate the costs and benefits of different treatment strategies for AK over 
a 12-month time horizon. Data on the relative efficacy of treatment was derived from a 
systematic review of RCTs and a subsequent mixed-treatment comparison (MTC). Utility 
scores and resource use data were obtained from published sources. Due to the uncer-
tainty surrounding the impact of AEs on HRQoL and costs, AEs were modelled in a sce-
nario analysis. Results: In the primary comparison, ingenol mebutate 150 mcg/g gel and 
500 mcg/g gel were associated with ICERs of £44 and £114 per QALY gained, respectively 
compared with diclofenac (3%) for 8 weeks and £36 and £74, respectively compared with 
diclofenac (3%) for 12 weeks. In the secondary comparisons, ingenol mebutate 150 mcg/g 
gel and 500 mcg/g gel were associated with ICERs of £47 and £134, respectively compared 
with 5-FU/salicylic acid (0.5%/10%) cutaneous solution and dominated cryotherapy (i.e. 
were cheaper and more effective). Ingenol mebutate 150 mcg/g gel and 500 mcg/g gel were 
cheaper and less effective than 5-FU (5%) cream. Ingenol mebutate 150 mcg/g gel, but not 
ingenol mebutate 500 mcg/g gel, was cost-effective assuming a decision making will-
ingness-to-pay threshold of £20,000/QALY (for one additional QALY gained, there would 
be an incremental cost of £26,525 incurred for 5-FU (5%) cream vs ingenol mebu-
tate gel). cOnclusiOns: Ingenol mebutate gel is a fast-acting, convenient 
and, relative to most comparators, cost-effective therapy for the first-line treatment 
of AK.
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COST EFFECTIvENESS OF ANTI-OxIDANT vITAMIN + zINC TREATMENT TO 
PREvENT THE PROGRESSION OF INTERMEDIATE AGE RELATED MACULAR 
DEGENERATION TO ITS wET FORM. A SINGAPORE PERSPECTIvE
Saxena N.1, George P.P.1, Heng B.H.1, Lim T.H.2, Yong S.O.2
1National Healthcare Group, Singapore, Singapore, 2Tan Tock Seng Hospital, Sinapore, Singapore
Objectives: To determine if providing high dose anti-oxidant vitamins + Zinc 
treatment to intermediate Age Related Macular Degeneration (AMD) patients 
aged 40-79 years from Singapore is cost effective in preventing progression to Wet 
AMD. MethOds: We estimated the number of AMD patients aged 40 to 79 years 
(Category 3 and 4) in the Singaporean resident population. This hypothetical cohort 
was followed for 5 calendar years to determine the number of patients who would 
progress to wet AMD given the following four treatment scenarios: a) Vitamins 
+Zn followed by Ranibizumab (as needed) for wet AMD; b) Placebo followed by 
Ranibizumab (as needed) for wet AMD; c) Vitamins + Zn followed by Bevacizumab 
(monthly) for wet AMD; and d) Placebo followed by Bevacizumab (monthly) for wet 
AMD. Costs were estimated for the above scenarios from the providers’ perspective 
and cost effectiveness was measured by cost per disability adjusted life year (DALY) 
averted with a disability weight of 0.22 for wet AMD. Crude annual mortality rate 
was incorporated into the model. Results: Over 5400 patients could be prevented 
from progressing to Wet AMD cumulatively over five years if preventive anti-oxidant 
vitamins +Zn treatment were prescribed. Vitamins + Zn followed by ranibizumab 
(as needed) or bevacizumab (monthly) was cost effective compared to placebo fol-
lowed by either drug (cost per DALY averted: $1885.8 - well within the threshold 
suggesting it is cost effective). However, bevacizumab (monthly 1 injection) alone 
was cost effective. Cost savings as a result of prescribing anti-oxidant vitamins +Zn 
were $ 46.7M for ranibizumab arm over 5 years. cOnclusiOns: Prophylactic treat-
ment with high dose anti-oxidant vitamins + Zn for intermediate AMD patients, 
followed by ranibizumab for patients who progressed to wet AMD was found to be 
cost-effective. These findings have implications for intermediate AMD screening, 
treatment and health care planning in Singapore.
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COST-EFFECTIvENESS ANALySIS OF LINEzOLID AND vANCOMyCIN IN 
PATIENTS wITH COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS CAUSED 
By METHICILIN-RESISTANT STAPHyLOCOCCUS IN PORTUGAL
Inês M.1, Saramago P.2, Pinto A.3
1Pfizer Portugal, Porto Salvo, Oeiras, Portugal, 2University of York, York, UK, 3Pfizer Portugal, Porto 
Salvo, Portugal
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) complicated skin 
and soft-tissue infection (cSSTI) is an infection associated with high health expendi-
ture for the Portuguese National Health Service (NHS). A decision analytic model 
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Objectives: The value of ranibizumab monotherapy and laser combination therapy 
compared to laser photocoagulation was assessed within the framework of a cost-
utility analysis from the Quebec health care and societal perspectives. MethOds: 
A Markov model followed a cohort of patients with diabetic macular edema over 
a lifetime time horizon. The model included 8 heath states as defined by best-
corrected visual acuity and one absorbing state for death. All transition probabilities 
in Year 1 were based on the RESTORE trial. For Years 2 and 3 data from the RESTORE 
Extension trial was used to inform ranibizumab monotherapy and combination 
therapy transition probabilities. For laser photocoagulation, Years 2 and 3 transition 
probabilities were based on data from DRCR.net trials. From Year 4 onwards, all tran-
sition probabilities were based on the natural history of disease. Health state utilities 
were derived from the literature (for the best-seeing eye) and a Canadian utility 
study in RVO patients (for the worse-seeing eye). Resource use and costs were col-
lected from published literature and standard Quebec sources. Costs and outcomes 
were discounted at 5% as recommended by Canadian guidelines. Results: From 
the health care perspective, patients receiving ranibizumab monotherapy accrued 
an additional 0.40 quality-adjusted life years (QALYs) and an incremental cost of 
CAD$9,790, resulting in $24,345 per QALY gained. Patients receiving combination 
therapy accrued an additional 0.32 QALYS and an incremental cost of $11,387, result-
ing in $36,148 per QALY gained. At a willingness-to-pay threshold of $50,000, ranibi-
zumab monotherapy and combination therapy had a 75.2% and 59.3% probability 
of being cost-effective (CE), respectively. From the societal perspective, considering 
costs from productivity losses, ranibizumab monotherapy and combination therapy 
dominated laser photocoagulation and had an 88.2% and 78.8% probability of being 
CE, respectively. cOnclusiOns: Compared to laser photocoagulation, ranibizumab 
monotherapy and combination therapy for 3 years show cost-effectiveness from 
health care and societal perspectives.
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A COST-UTILITy ANALySIS OF RANIBIzUMAB IN AGE-RELATED MACULAR 
DEGENERATION BASED ON REAL-LIFE OBSERvATIONAL DATA IN FRANCE
de Pouvourville G.1, Lafuma A.2, Moeremans K.3, Nivelle E.3, Umuhire D.4, Gerlier L.3,  
Maurel F.5, Ponthieux A.6
1ESSEC Chair of Health Systems, Cergy, France, 2Cemka Eval, Bourg La Reine, France, 3IMS Health 
HEOR, Vilvoorde, Belgium, 4IMS Health, La Défense Cedex, France, 5IMS Health, La Défense, 
France, 6Novartis Pharma S.A.S., Rueil-Malmaison Cedex, France
Objectives: To calculate the cost-effectiveness of ranibizumab versus licensed 
comparators in wet age-related macular degeneration (AMD) from a French soci-
etal perspective based on real-life observational data. MethOds: A Markov model 
was developed containing 5 health states defined by visual acuity (VA) of the 
treated eye and a death state. The model time horizon covered 2 years of treat-
ment followed by 8 years of best supportive care (BSC). Medical and non-medical 
resource use and efficacy during treatment were based on observational patient-
level data with ranibizumab (LUEUR and LUMIERE studies) or verteporfin (OPV 
study). No observational data were available for pegaptanib. Efficacy was obtained 
per VA level to control for population differences in baseline VA. The base-case 
analysis reflects 1st line therapy. Mutual to both comparators, BSC was modelled 
with clinical trial placebo data and resource use estimates. Annual discount rates 
were 4% for costs (€ 2011) and outcomes. Utilities reflected general population 
preference (UK) using time-trade-off methods. Results: Compared to verteporfin, 
1st line ranibizumab provided a gain of 0.20 QALYs and avoided 0.63 years of 
vision impairment (YVI). The total incremental cost was € 3,843. The cost-utility 
was € 19,088/QALY, the cost per YVI avoided was € 6,114. Similar outcomes were 
obtained when including pre-treated patients. Ranibizumab was cost-effective 
with a probability of 62.8% and 78.2% at willingness to pay thresholds of € 20,000/
QALY and € 30,000/QALY respectively. cOnclusiOns: Based on real-life observa-
tional studies, 2-year treatment with ranibizumab was associated with improved 
vision-related health outcomes and a cost-utility ratio below commonly applied 
willingness to pay thresholds.
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COST-EFFECTIvENESS OF SEQUENCES OF BIOLOGIC TREATMENTS FOR 
MODERATE-TO-SEvERE PSORIASIS IN FINLAND
Asseburg C.1, Valgardsson S.2, Soini E.J.1
1ESiOR Oy, Kuopio, Finland, 2Janssen-Cilag, Lysaker, Norway
bAckgROund: Little is known about the health-economic properties of sequences 
of biologics agents for the treatment of moderate-to-severe psoriasis. These are 
available to patients who have failed to achieve therapeutic goals on the tradi-
tional systemics such as methotrexate and ciclosporin. Objectives: To predict 
the five-year costs and health outcomes associated with different sequences of 
biologic psoriasis treatments (adalimumab, etanercept, infliximab, and usteki-
numab), and to evaluate their cost-effectiveness from a Finnish societal per-
spective. MethOds: The Psoriasis Area Severity Index (PASI) was chosen as the 
main efficacy measure and results of a published meta-analysis were re-run 
to provide relative efficacy of the biologics in the short term. A fully stochas-
tic Markov cohort model was developed that represents patient health in terms 
of PASI, Dermatology Life Quality Index (DLQI), and quality-adjusted life-years 
(QALY). Failure to achieve efficacy targets, serious adverse events and other rea-
sons of withdrawal led to switch to the next treatment in the sequence, and 
eventually methotrexate maintenance. Costs included direct medical and related 
direct costs as well as productivity losses. Costs and QALYs were discounted at 
3% per annum. Results: At a willingness-to-pay threshold of EUR 50,000 per 
QALY gained, only four of the 60 potential sequences had non-zero probability of 
being cost-effective. The sequence most likely to be cost-effective was first-line 
ustekinumab followed by adalimumab followed by maintenance. Its incremental 
cost-effectiveness ratio (ICER) per QALY gained relative to the cheapest sequence 
(etanercept followed by adalimumab) was estimated at EUR 8,253. Some model-
ling assumptions tested in the sensitivity analyses may be influential in driving 
the results, but others, for example inclusion of an anti-TNF class effect, made 
PF fixed combination (DTFC PF), and tafluprost PF/timolol PF unfixed-combination 
(TTUF PF) for the treatment of primary open-angle glaucoma (POAG). MethOds: A 
cost-effectiveness and cost-utility model was developed to estimate lifetime costs 
and outcomes. The analysis was performed from a UK NHS perspective. No head-to-
head evidence was available for BTFC PF and the comparators; therefore effectiveness 
estimates in terms of the mean lowering of intraocular pressure (IOP) at Week 12 
were estimated using a mixed treatment comparison (MTC). Estimates of visual field 
progression were taken from the literature and modelled by an irreversible decrease 
in patients’ mean deviation (MD) score in each 12-week cycle. Resource use levels for 
each of the health states were obtained using a clinician survey. All costs and utili-
ties were obtained from literature or NHS cost sources. Outcomes were reported in 
terms of cost per mmHg IOP gained and cost per quality-adjusted-life-year (QALY). 
Deterministic and probabilistic sensitivity analyses were performed. Results: The 
cost-effectiveness results indicated that BTFC PF dominates DTFC PF and TTUF PF, 
with patients treated with BTFC PF having a greater IOP reduction (1.6 mmHg) and 
incurring lower lifetime costs (£2,294 vs. DTFC PF, £2,919 vs. TTUF PF). The cost-utility 
results indicate BTFC PF dominates DTFC PF and TTUF as well with an incremen-
tal gain of 0.03 QALYs. Deterministic sensitivity analyses indicate the results are 
most sensitive to the rate of visual field progression. Probabilistic sensitivity analysis 
indicates that BTFC PF has a 98.8% probability of being cost-effective at a threshold 
of £20,000/QALY. cOnclusiOns: BTFC PF is considered a cost-effective treatment 
option for the treatment of POAG when compared with DTFC PF and TTUF PF from 
a UK NHS perspective.
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COST-MINIMIzATION ANALySIS OF INTRAvITREAL AFLIBERCEPT (IvT-AFL) FOR 
NEOvASCULAR AGE-RELATED MACULAR DEGENERATION IN SPAIN
Garcia-Layana A.1, Ortega A.2, Ruiz-Moreno J.M.1, Figueroa M.S.3, Farres J.4, Mendivil J.4, 
Altemark A.5, Wittrup-Jensen K.U.5
1Clínica Universidad de Navarra, Pamplona, Spain, 2Clínica Universitaria de Navarra, Pamplona, 
Spain, 3Hospital Universitario Ramón y Cajal, Madrid, Spain, 4Bayer Hispania, S.L., Barcelona, NE, 
Spain, 5Bayer Pharma AG, Berlin, Germany
Objectives: Anti-VEGF therapy improves visual acuity in patients with neovascu-
lar (“wet”) age-related macular degeneration (wAMD). By comparing different treat-
ment regimen scenarios, based on data from available randomized clinical studies, 
the objective was to compare costs for intravitreal aflibercept (IVT-AFL) treatment 
with Ranibizumab treatment when treating wAMD patients in a Spanish set-
ting. MethOds: A Markov model, describing wAMD treatment was estimated, cal-
culating the direct medical costs based on 2-year clinical trial data. Parameters were 
estimated from trial data, published literature, and expert opinion. Costs, discounted 
at 3% per year, were calculated over a five-year horizon. Alternative scenarios and 
deterministic sensitivity analyses were performed and reported. Results: IVT-AFL, 
dosed every two months in Year 1 and modified quarterly dosing in year two, was 
least expensive, € 13,519, followed by IVT-AFL every second month, for two years, 
€ 16,085. Cost of Ranibizumab monthly (RBZ Q4) regimens ranged from € 17,284 (12.6 
injections over two years) to € 26,457 (monthly injections over two years). Results 
were driven by less frequent IVT-AFL dosing and monitoring. The model was most 
sensitive to RBZ Q4 Year 1 efficacy and Year 2 injection frequency. cOnclusiOns: 
IVT-AFL is less expensive than Ranibizumab when treating wAMD in Spain, due to 
less frequent dosing with IVT-AFL and lower monitoring costs.
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COST-MINIMIzATION ANALySIS OF MULTIFOCAL AND MONOFOCAL 
INTRAOCULAR LENSES IN CATARACT SURGERy IN THE CzECH REPUBLIC
Kruntoradova K., Klimes J., Dolezal T., Vocelka M.
Institute of Health Economics and Technology Assessment, Prague, Czech Republic
Objectives: To model the lifetime cost attributed to intraocular lenses (multifo-
cal vs. monofocal) implantation during cataract surgery from patient’s perspec-
tive. MethOds: The Markov model was developed with 28-day cycle length 
projecting life-time costs of patients undergoing cataract surgery of both eyes at 65 
years. Patients move among four health states which occur after cataract surgery. 
Patients become independent on the spectacles or need them after cataract surgery 
with probabilities derived from literature. In the model, we assume that new glasses 
are bought by patients, who wear glasses after surgery, every three years. Patient 
may die from each health state with probability derived from Czech life-tables there 
was no difference in mortality specific for particular intraocular lenses. Resource 
utilization was received by an expert panel and unit costs were derived from current 
pricing list. Costs of cataract surgery with multifocal and monofocal lenses implanta-
tion were 1,200EUR and 9.9EUR, respectively. Mean costs of spectacles were 48.9EUR 
and 82.5EUR after the intervention of implanting multifocal and monofocal lenses, 
respectively and monthly costs of ophthalmologist visit, maintenance and service 
of spectacles was 0.4EUR. Discount rate of 3% was applied. One-Way Sensitivity 
Analysis was performed. Results: After cataract surgery with multifocal lenses 
implantation, patients purchase on average by 4.4 spectacles less compare to patients 
undergoing monofocal intraocular lenses implantation (i.e. 5.9). The initial patient’s 
investment of 1,190EUR into multifocal IOLs is in the lifetime horizon partially off-
set by saving of 364EUR attributed to lower number of new spectacles purchased 
and their maintenance. Costs on spectacles after cataract surgery with monofocal 
lenses and level of reimbursement of multifocal lenses were the biggest driver of the 
results. cOnclusiOns: Bilateral multifocal IOL implants decrease patient’s depend-
ence on spectacles. From patient’s perspective, the initial investment into multifocal 
lenses is partially compensated by saving of spectacles costs and its maintenance.
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A QUEBEC ECONOMIC EvALUATION FOR 36 MONTHS OF RANIBIzUMAB FOR 
THE TREATMENT OF DIABETIC MACULAR EDEMA
Haig J.1, Barbeau M.2, Ferreira A.3, Pickering M.2
1Optum, Burlington, ON, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 
3Novartis Pharma AG, Basel, Switzerland
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Understanding patient preferences will help physicians to manage their patients’ 
disease most effectively and potentially ensure greater adherence to therapy. 
Further research is warranted to understand patient preferences quantitatively.
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PSORIASIS PATIENTS’ TOLERANCE FOR THERAPEUTIC RISKS IN RETURN FOR 
SyMPTOM IMPROvEMENT IN THE UNITED KINGDOM
González J.M.1, Johnson F.R.1, Mughal F.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2AbbVie Ltd., Maidenhead, Berkshire, UK
Objectives: To quantify UK psoriasis patients’ tolerance for serious side-effect 
risks associated with biologic treatments relative to the value of symptom improve-
ments. MethOds: Members of a UK psoriasis patient organization were invited to 
complete an on-line conjoint-analysis survey which evaluated efficacy and safety 
features of biologic treatments for psoriasis. Patients’ trade-off preferences for 
improvements in the severity and coverage of psoriatic lesions were elicited, as well 
as treatment-related risks of tuberculosis (TB), serious infections, and lymphoma. 
The choice pattern observed in the data was used to estimate preference weights 
which indicated patients’ relative trade-off preferences among treatment outcomes.
Preference weights were used to derive maximum levels of side-effect risks that 
patients would accept for various improvements in psoriasis symptoms. The DLQI 
was used to assess the impact of psoriasis on patients’ quality of life. Results: A 
total of 159 people with a self-reported physician diagnosis of psoriasis completed 
the survey. Mean age was 39 years and most respondents reported having psoriasis 
for at least 5 years. Also, the mean DLQI score was 11. Respondents would accept up 
to 0.39% of treatment-related risks of lymphoma for reducing the area covered by a 
severe lesion from 25% to 10% of their torso, and up to 0.60% if lesions were on their 
arms or legs.For the same improvement in symptoms, respondents would accept up 
to a 2.3% risk of TB or 3.3% risk of serious infections if the lesions were on their torso, 
and a 3.6% risk of TB or 5.2% risk of serious infections if the lesions were on their arms 
and legs. cOnclusiOns: Psoriasis patients’ tolerance for side-effect risks varies with 
side-effect severity and location of lesions. Estimates of patients’ risk tolerance for 
serious side-effects indicate that patients value psoriasis symptom control further 
confirming that psoriasis has a significant effect on patients’ quality of life.
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ATOPIC DERMATITIS IN ADULTS: DESIGN AND vALIDATION OF A SPECIFIC 
BURDEN QUESTIONNAIRE
Taieb C.
CREES PFSA, Paris, France
Objectives: Atopic Dermatitis (AD) is a common skin condition, even in adults. 
On the contrary of quality of life questionnaires, the notion of individual burden 
associated with a disease has been introduced to determine the “disability” in 
the broadest sense. The aim of the current study was to develop and validate 
the Atopic dermatitis Burden Scale questionnaire for Adults (ABS-A) following 
Classical Test Theory method (CTT). MethOds: The questionnaire was developed 
by a working group composed of individuals with expertise in PRO development, 
dermatologists, and patients from patients’ association. Subsequently, this ques-
tionnaire was sent to 900 people with AD. ABS-A was refined via exploratory factor 
analysis (EFA). Internal consistency was determined by calculating the Cronbach’s 
alpha, concurrent validity by calculating the Spearman’s rank coefficient correla-
tion between ABS-A, SF-12 and Dermatology Life Quality Index (DLQI) question-
naires. Discriminant validity was analysed according to the severity degrees of AD 
assessed by the Patient Oriented SCORing index of AD questionnaire. Results: 
A total of 128 individuals filled out the ABS-A entirely and were then evaluated. 
68.8% of them were men and almost 50% of them were aged between 35 and 64 
years old. Based on the results of the EFA, 1 item was removed due to cross-loading 
on factors. Consequently, the questionnaire consisted of 18 items grouped into 
4 domains. ABS-A showed good internal coherence (Cronbach’s á: 0.89). ABS was 
significantly correlated to both components of the SF-12 (r(PCS)= -0.36, p< 0.0001; 
r(MCS)= -0.52 , p< 0.0001). A higher coefficient correlation has been found between 
ABS-A and DLQI (r= 0.78; p< 0.0001). Significant differences between severity 
degrees of AD have been shown. cOnclusiOns: These preliminary results 
suggest the validity of the ABS-A questionnaire. However, since recruitment of 
patients is not achieved, performing analyses of the other stages of CTT, and 
Confirmatory Factor analysis or Rash analysis are warranted. Comparison between 
both methods may be valuable.
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THE BURDEN IMPOSED By ATOPIC DERMATITIS ON FAMILIES: CREATION OF A 
SPECIFIC QUESTIONNAIRE
Taieb C.1, Branchoux S.2
1CREES PFSA, Paris, France, 2Pierre Fabre, Boulogne Billancourt, France
Objectives: The notion of individual burden, associated with the disease, has been 
introduced recently to determine the “disability” caused by the pathology in the 
broadest sense of the word (psychological-social-economic-physical). MethOds: 
The ABS questionnaire (Atopy Burden Score Q) consists of 19 items, structured 
around 5 components. It was distributed to a random sample of families consulting 
at the Necker Hospital, staying at the Avène Hydrotherapy Center, and members of 
the patient-association. The ABS was accompanied by SF12 and PGWBI, to confirm 
internal and external validation, and by the PO-SCORAD to assess the level of sever-
ity. Results: A total of 58 Q were considered evaluable. 51% of the AD children 
were girls. The PO-SCORAD established the level of severity of the AD: 14%, 50% and 
36% of children had mild, moderate or severe AD respectively. Internal-validity was 
measured by Cronbach’s alpha, which is equal to 0.81, reflecting a good homogeneity 
of the 19 items. The mean PGWBI score is 51.82±14.28. The score reflecting the most 
important deterioration is found among parents of children with severe atopy. In 
contrast, the scores associated with moderate and mild atopy are not correlated 
with severity. Families’ QoL, measured using the SF12, revealed no deterioration 
in the physical component. The ABS score is correlated with the scores of the Q 
little difference. cOnclusiOns: Using a sequence model of biologic therapies in 
psoriasis, first-line ustekinumab was found to be cost-effective in the treatment 
of moderate-to-severe psoriasis in Finland.
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COST-UTILITy OF PEDIATRIC COCHLEAR IMPLANTATION IN HUNGARy
Hashim M.S., Dozsa C.
Corvinus University, Budapest, Hungary
Objectives: To calculate the Cost-Utility of unilateral pediatric Cochlear Implantation 
in Hungary. Parallel to that, we aim to provide an assessment of currently served cases 
and epidemiological demand. MethOds: Cost accounting of direct medical costs, 
from public purchaser perspective, covering medical resources sacrificed for unilateral 
implant in 1 year children, with a 60 year life expectancy. Cost-utility is calculated 
based on direct costs and QALY gain retrieved from literature, both to be discounted 
at 3% annually. Prevalence of eligible newborns to undergo Cochlear Implantation 
versus served cases is reported. Results: Draft estimation of total direct costs is 
12.26 million HUF (25,288 EUR) and when discounted it would be 7.3 million HUF 
(24,219 EUR). This is divided into 2.1% preoperative, 53.8% operative (including cost 
of implant) and 44% post operative. Based on health utility reported by Cheng, dis-
counted QALY gain ranges from 6.1 to 10.8 life years. Therefore, Cost-utility of uni-
lateral CI would range from 679,433 HUF (2,343 EUR) to 1,204,449 HUF (4,153 EUR) per 
discounted QALY gain. Currently in Hungary, about 90 cases are operated per year 
(0.1 % of crude birth rate). From 220 to 250 new cases, 2.5 to 3 times currently served, 
every year (0.24 – 0.37 % of crude birth rate), would be necessary for providing equal 
access to care. cOnclusiOns: This study provides an overview to Hungarian policy 
makers and other stakeholders about cost-utility, direct costs and estimated effect, 
and also of the possible full capacity of such costly intervention. Unilateral Cochlear 
Implantation appears to be reasonable if direct costs per QALY are compared to GDP 
in Hungary. Hungarian values are compared with international values.
SENSORy SySTEMS DISORDERS – Patient-Reported Outcomes & Patient  
Preference Studies
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UTILITy AND RESOURCE USE OF AN AUSTRALIAN POPULATION OF PSORIASIS 
PATIENTS
Wilson J.L., Porter A., Price N., Dowling H.
AbbVie Pty Ltd., Sydney, Australia
Objectives: Psoriasis is a chronic, systemic immune-mediated disorder char-
acterised by skin and often joint involvement affecting 2.3% of the Australian 
population. While psoriasis has traditionally been viewed as a non-serious skin 
condition, it is now recognised as a systemic inflammatory disease with a growing 
body of evidence linking the condition with a number of serious co-morbidities. 
The objective of this study was to determine the burden, in terms of disutility and 
resource use, that co-morbidities have on patients with psoriasis. MethOds: A 
large-scale, multi-centre, cross-sectional study of Australian adults with psoria-
sis was conducted during 2011. The survey contained 43 questions and focused 
primarily on comorbidity, health care resource use and the impact of psoriasis 
on disutility as assessed by EQ-5D. Results: A total of 330 patients responded 
to the survey. Three-quarters of respondents reported having at least two or 
more concomitant medical conditions, with only 8% reporting no comorbidities. 
Combined, joint-related conditions such as joint pain (46%) and psoriatic arthritis 
(28%) represented the largest proportion of medical comorbidities reported. The 
mean EQ-5D score for the cohort was 0.73. Utility decreased as the number of co-
morbidities increased, ranging from 0.88 for patients with no co-morbidities to 
0.36 for patients with 9 co-morbidities. Resource use and out of pocket expenses 
also increased with increasing number of co-morbidities. cOnclusiOns: This 
study highlights the co-morbid nature of psoriasis with most respondents report-
ing having two or more concomitant conditions. Furthermore, based on the mean 
EQ-5D health status score, psoriasis has a considerable impact on patient quality 
of life comparable with other chronic diseases.
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PATIENT PREFERENCES REGARDING MONITORING AND TREATMENT FOR THE 
MANAGEMENT OF NEOvASCULAR AGE-RELATED MACULAR DEGENERATION
Ferreira A.1, Lall A.2, Squire A.1, Gregg L.3, Graham A.3
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Healthcare Pvt. Ltd., Hyderabad, India, 
3Adelphi, Bollington, Macclesfield, UK
Objectives: To investigate qualitatively patient preferences for monitoring and 
treatment in the management of neovascular (wet) age-related macular degen-
eration (wAMD) in different countries. MethOds: The study involved 39 patients 
with wAMD from the UK (n= 9), Canada (n= 10), Germany (n= 10) and Japan (n= 10). 
Subjects participated in a 30-minute semi-structured telephone interview. Data 
were analysed to identify key themes and opinions. Results: Most (74%, n= 29) 
patients were aged ≥ 70 years, 28% (n= 11) required a caregiver to attend clinic visits, 
and 90% (n= 35) had comorbidities. Only 13% (n= 5) of patients were treatment-
naïve, 41% (n= 16) had received ≤ 1 year of therapy and 46% (n= 18) had received > 
1 year of therapy. Most (92%, n= 36) were currently or had previously been receiving 
ranibizumab; 8% (n= 3) were receiving or about to initiate therapy with aflibercept. 
Most patients (62%, n= 24) preferred monthly monitoring with treatment given as 
needed based on disease progression, 26% (n= 10) preferred bimonthly monitoring 
and fixed bimonthly dosing and 13% (n= 5) had no preference. Patients reported 
being very anxious about their sight and tended implicitly to trust their treat-
ing physician to decide on the most appropriate treatment; as a result, patients 
reported being highly adherent to therapy. Many patients reported appreciating 
the reassurance provided by frequent monitoring and were very satisfied with 
their current dosing regimen as chosen by their treating physician. cOnclusiOns: 
The results of this pilot, qualitative study suggest that most patients prefer 
frequent monitoring with dosing based on disease progression to treat their wAMD. 
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all 3 studies were analysed using latent growth models to generate intercepts and 
slopes of change across trials for each patient, irrespective of treatment. Slopes 
of change were correlated to examine how closely DLQI changes mirrored UAS7 
changes. Results: Results indicated that both measures showed large improve-
ments over the course of the trials: UAS7 and DLQI scores were high at the start 
of the study reflecting moderate-severe CSU/CIU (UAS7) and a very large effect on 
patient’s life (DLQI). Correlations between changes in DLQI and changes in UAS7 by 
study end were 0.88, 0.85, and 0.88, indicating high correspondence between the two 
measures. cOnclusiOns: These results suggest that collecting DLQI information 
in-clinic can provide an excellent indication of the weekly UAS7 score, and is more 
efficient for clinical practice routine in assessing CSU/CIU patients.
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ETANERCEPT PROvIDES IMPROvED QUALITy OF LIFE REGARDLESS OF THE 
PRESENCE OF PSORIATRIC ARTHRITIS IN MODERATE/SEvERE PSORIASIS 
SUBjECTS FROM CENTRAL AND EASTERN EUROPE, LATIN AMERICA AND ASIA
Kemeny L.1, Amaya M.2, Cetkovska P.3, Lee W.R.4, Galimberti L.R.5, Mahgoub E.6, Rahman M.6, 
Marshall L.6, Pedersen R.6, Tang B.7
1University of Szeged, Szeged, Hungary, 2Hospital San Lucas, Monterrey, Mexico, 3University 
Hospital, Plzeò, Czech Republic, 4Shuang Ho Hospital, New Taipei City, Taiwan, 5Hospital Italiano, 
Buenos Aires, Argentina, 6Pfizer Inc, Collegeville, PA, USA, 7Pfizer, Inc., New York, NY, USA
Objectives: Some psoriasis patients also have psoriatic arthritis (PsA), which 
increases disease burden and further reduces quality-of-life (QoL). Our objective 
was to compare QoL of subjects with both psoriasis and PsA to those with psoriasis 
alone, and to evaluate improvement on etanercept (ETN) therapy in specific coun-
tries of Central and Eastern Europe, Latin America, and Asia where data are lim-
ited. MethOds: Patients with moderate/severe psoriasis were randomized to 50mg 
ETN QW (once weekly) or 50mg ETN BIW (twice weekly, weeks 1-12), followed by 50mg 
QW (weeks 13-24). The following post-hoc assessments were included: EuroQoL-5D 
(EQ-5D); Dermatology Quality of Life Index (DLQI); Functional Assessment of Chronic 
Illness Therapy (FACIT)-Fatigue; Hospital Anxiety and Depression Scale (HADS); 
Medical Outcomes Study (MOS)-Sleep; and Work Productivity and Activity Impairment 
(WPAI). Subjects with and without PsA were pooled across ETN groups for compari-
sons of changes in scores from baseline to week 24, which were based on independent 
sample t-tests. Results: Of 171 subjects analysed, 64 (37.4%) had PsA. Baseline demo-
graphic characteristics and QoL measures were similar in PsA and psoriasis-alone 
groups. EQ-5D scores improved significantly over time with ETN treatment in both 
subjects with and without PsA (P< 0.0001) with similar adjusted mean improvement 
in both groups after 24 weeks (0.2 vs 0.2; P= 0.6202). Improvement in EQ-5D greater 
than MID (change ≥ 0.05) at week 24 was observed in a greater proportion of PsA than 
psoriasis-alone subjects (74.6% vs 63.8%; P= 0.174). Significant improvements from 
baseline in both PsA and psoriasis-alone groups were also observed after 24 weeks in 
DLQI (both P< 0.0001), FACIT (both P< 0.01) and HADS anxiety (both P< 0.0001) scores. 
Improvements of other patient-reported outcomes were also observed at weeks 24 in 
both disease subgroups. cOnclusiOns: ETN in both dose regimens provided signifi-
cant improvement in QoL measures in subjects with moderate-to-severe psoriasis, 
regardless of the presence of PsA.
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QUALITy OF LIFE IMPROvEMENT wITH ETANERCEPT IN PATIENTS wITH 
MODERATE/SEvERE PSORIASIS FROM CENTRAL AND EASTERN EUROPE, LATIN 
AMERICA AND ASIA
Kemeny L.1, Amaya M.2, Cetkovska P.3, Lee W.R.4, Galimberti L.R.5, Mahgoub E.6, Rahman M.6, 
Marshall L.6, Tang B.7
1University of Szeged, Szeged, Hungary, 2Hospital San Lucas, Monterrey, Mexico, 3University 
Hospital, Plzeò, Czech Republic, 4Shuang Ho Hospital, New Taipei City, Taiwan, 5Hospital Italiano, 
Buenos Aires, Argentina, 6Pfizer Inc, Collegeville, PA, USA, 7Pfizer, Inc., New York, NY, USA
Objectives: To assess the impact of etanercept (ETN) on quality-of-life (QoL) through 
24 weeks in patients with moderate/severe psoriasis in specific countries of Central 
and Eastern Europe, Latin America, and Asia where data are limited. MethOds: 
Patients with moderate/severe psoriasis were randomized to 50mg ETN QW (once 
weekly) or 50mg ETN BIW (twice weekly, weeks 1-12), followed by 50mg QW (weeks 
13-24). Patients completed the Dermatology Life Quality Index (DLQI) EuroQoL 5D (EQ-
5D), FACT-Fatigue, HADS Anxiety Score, Psoriasis Subject Satisfaction Questionnaire, 
and Work Productivity Activity Impairment (WPAI) at baseline and subsequent vis-
its. Results: Of 171 patients analysed, 85 were randomised to ETN BIW and 86 to ETN 
50 QW. Baseline DLQI scores were 14.8 in both treatment groups suggesting severe 
QoL impairment. Significant improvements in DLQI from baseline were observed 
at weeks 12 and 24 in both groups (all p< 0.0001); mean improvement at week 12 for 
ETN BIW was greater than for ETN QW (10.8 vs 8.4, p= 0.001), but was similar between 
groups at week 24 (11.0 vs 9.5, p= 0.063). EQ-5D utility was significantly improved 
from baseline in both groups at weeks 12 and 24 (all p< 0.0001), with mean improve-
ment significantly greater for the higher dose at both time-points (week 12: 0.3 vs. 
0.2, p= 0.029; week 24: 0.3 vs. 0.2, p= 0.027). Mean EQ-5D improvement at week 24 
was greater than MID (change ≥ 0.05) in a significantly greater proportion of patients 
receiving BIW than QW (77.1% vs 58.8%; p= 0.013). Improvements of other patient-
reported outcomes from baseline were observed at weeks 12 and 24 in both treat-
ment groups. cOnclusiOns: At baseline, patients had severely impaired QoL, and 
improvement in QoL was achieved with both ETN regimens. Improvements observed 
with ETN BIW were significantly greater than with ETN QW for both DLQI and EQ-5D 
utility at week 12, but only for EQ-5D at week 24.
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QUALITy OF LIFE OF PATIENTS SUFFERING FROM ExUDATIvE AGE-RELATED 
MACULAR DEGENERATION AND TREATED By INTRAvITREAL INjECTIONS AND 
ITS PREDICTORS: THE EQUADE STUDy
Leveziel N.1, Joubert M.2, Hermans M.3, Moser E.3, Le Picard S.3, Maurel F.4
1CHU de Poitiers, Poitiers, France, 2Association DMLA, Saint-Cloud Cedex, France, 3Retina France, 
Colomiers cedex, France, 4IMS Health, La Défense, France
used, thus confirming external validity. The mean score calculated from the ABS 
is 48.17±18.36. The score increases with the severity of the AD. A statistically sig-
nificant difference is observed between the 3 severity-groups, i.e. mild, moderate 
and severe, with scores of 30.63, 42.55 and 62.62 respectively. cOnclusiOns: The 
internal and external validity of our Q were confirmed. ABS is correlated with the 
severity of AD. Hence, we have a short, easy-to-use, validated tool for assessing the 
burden imposed by atopy on families. Following cultural and linguistic validation, 
the ABS is now available in US English, Spanish, German and Italian.
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HEMANGIOMA FAMILy BURDEN: CREATION OF A SPECIFIC QUESTIONNAIRE
Taieb C.1, Boccara O.2
1CREES PFSA, Paris, France, 2Necker Hospital, Paris, France
Objectives: The notion of individual burden, associated with the disease, has 
been introduced recently to determine the “disability” caused by the pathology in 
the broadest sense of the word (psychological-social-economic-physical). The aim 
of our study is to develop a specific questionnaire for assessing the burden on fami-
lies of children with HI. MethOds: A “Hemangioma Family Burden” questionnaire 
(HFB) consisting of 22 items, The score increases with the heaviness of the burden. It 
was distributed accompanied by 2 validated QoL questionnaires (SF12 and PGWBI) 
to obtain internal and external validation Results: A total of 58 evaluable Q were 
returned. One parent from each family described how they perceived the effects of 
the disease, which led to the creation of 6 severity groups, paired together for size 
reasons: “not-very-far-reaching” and “somew-hat-far-reaching”; “quite-far-reaching” 
and “far-reaching”; “very far-reaching” and “extremely far-reaching”. Internal validity 
was measured by Cronbach’s alpha, which is equal to 0.95, reflecting a good homoge-
neity of the 22 Q items. The mean scores of the physical and mental components are 
54.93±5.12 and 40.49±11.28 respectively. Hence, the HFB score is correlated with these 
2 components, thus confirming external validity. The mean score calculated from the 
HFB is 23.42±19.93. The score increases with the “severity score” of the parents. In 
fact, a statistically significant difference is observed between the 3 severity groups: 
5.28±6.8 for those reporting the smallest extent to 41.0±18.71 for those reporting the 
greatest extent, and 27.7±16.96 for a moderate extent. This confirms the sensitivity of 
the HFB cOnclusiOns: During the evaluation, internal and external validity were 
confirmed. The HFB is correlated with the extent felt by parents, a feeling deemed 
relevant because it is often the cause of consultation and demand for treatment. 
We now have an easy-to-use, validated IH tool for assessing the disability caused. 
Following cultural and linguistic validation, the HFB is now available in US English, 
Spanish, German and Italian.
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A SySTEMATIC REvIEw OF PATIENT REPORTED OUTCOMES IN GLAUCOMA
Aggarwal S., Segal J., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
Objectives: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show improve-
ments in health-related quality of life (HRQoL). Glaucoma is a chronic disease 
with high importance for patient HRQoL. The objective of this study was to review, 
analyze, and understand trends in the PRO instruments used in patients with 
Glaucoma. MethOds: A systematic literature search for Glaucoma trials with 
PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, Google 
Scholar and Cochrane. Data was collected for the study size, interventions, year, 
PRO instrument and results for PROs. Analysis for conducted to identify trends 
in commonly used PRO instruments and categorize results as positive, neutral or 
negative. Results: A total of 31 studies with a total of 9819 patients were identi-
fied. In these studies there were eleven different PROs instruments were identified 
that were Glaucoma health perception index, Glaucoma quality of life question-
naire (Glau-QoL), Glaucoma utility index, Impact of vision impairment, Low vision 
quality of life questionnaire, National eye institute visual function index-19 items, 
National eye institute visual function index-51 items, Nursing home vision quality 
of life questionnaire, Quality of life and visual function questionnaire, Vision core 
module 1, and Vision quality of life index. The most commonly used instruments 
were Impact of vision impairment (used in 7 studies) and Low vision quality of life 
questionnaire (used in 4 studies). cOnclusiOns: Patients with glaucoma have 
significant impairment in their QoL, hence collection of such data is important 
for new medical products. PRO instruments such as Impact of vision impairment 
and Low vision quality of life questionnaire have been commonly used to generate 
evidence to show which therapies improve patient QoL.
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CORRELATIONS BETwEEN CHANGES IN THE URTICARIA ACTIvITy SCORE 
(UAS7) AND THE DERMATOLOGy LIFE QUALITy INDEx (DLQI) FROM BASELINE 
TO 28 OR 40 wEEKS: COMPARISONS OF TRAjECTORIES OF CHANGE IN PATIENTS 
wITH CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA (CSU/CIU)
Stull D.E.1, McBride D.2, Balp M.M.3, Gnanasakthy A.4
1RTI Health Solutions, Didsbury, Manchester, UK, 2RTI Health Solutions, Manchester, UK, 
3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals, East Hanover, NJ, USA
Objectives: The UAS7 is a patient-reported measure of urticaria symptoms. Daily 
pruritus scores and number of hives are summed over 7 days for a weekly score. The 
DLQI was developed as a brief (10-item) patient-reported measure with one-week 
recall for routine clinical use to assess the psychosocial effects of skin disease. The 
objective of this analysis was to examine changes in the UAS7 with those of the 
DLQI to see if the DLQI could be used in a clinic visit in lieu of collecting one week 
of UAS7 diary data. MethOds: Data come from three pivotal, phase 3 clinical tri-
als investigating the effects of omalizumab for patients with refractory CSU/CIU 
(publication available elsewhere). DLQI data were collected at baseline and weeks 
4, 12, 24, and 40 (ASTERIA I and GLACIAL), and baseline and weeks 4, 12, and 28 
(ASTERIA II). UAS7 score was reported at baseline and every four weeks but data 
from the same weeks as the DLQI were used for these analyses. Pooled data from 
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1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2St. Joseph’s Health Care, London, 
ON, Canada
Objectives: To assess the yearly frequency of ranibizumab injections for the treat-
ment of wet Age-Related Macular Degeneration (wAMD) in two large Canadian 
public drug plans: Ontario Public Drug Program (OPDP) and Régie de l’assurance-
maladie du Québec (RAMQ). MethOds: Pharmastat database (IMS Health Canada 
Inc.) was used to assess the mean annual number of ranibizumab injections for 
wAMD patients covered by the OPDP or RAMQ drug plans (1 injection was defined 
as 1 claim). Only wAMD treatment-naïve patients were included and the index 
date was defined as the date of the first ranibizumab claim. The analysis looked 
at monthly data from March 2008 to November 2012 for OPDP patients and from 
January 2008 to May 2012 for RAMQ patients and tracked the mean number of 
claims during the patient’s first, second, third and fourth year of ranibizumab 
therapy. Results: For the OPDP, the mean number of ranibizumab injections was 
6.0, 5.4, 5.5 and 5.6 for year 1 (N= 26,606), year 2 (N= 19,466), year 3 (N= 12,708), and 
year 4 (N= 6,681), respectively. For the RAMQ, the mean number of injections was 
5.4, 4.7, 5.2 and 5.7 for year 1 (N= 3,457), year 2 (N= 2,185), year 3 (N= 1,178), and year 
4 (N= 349), respectively. cOnclusiOns: These results suggest that many Ontario 
and Quebec retina specialists and ophthalmologists do not treat monthly but rather 
adopt an individualized ranibizumab treatment regimen to manage their patients’ 
wAMD. In addition, these results provide information on the real-world utilization of 
ranibizumab in wAMD for up to four years of treatment. The analyses, conclusions, 
opinions and statements expressed are those of Novartis Pharmaceuticals Canada 
Inc., and not those of IMS Health Canada Inc.
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DEFINING THE PATIENT jOURNEy vIA CLAIMS ANALySIS IN AN ORPHAN 
OPHTHALMIC CONDITION: IS THERE A STANDARD OF CARE?
Gavaghan M.1, Abraham J.1, Pauer L.2
1GfK Bridgehead, Wayland, MA, USA, 2Santen, Inc., Emeryville, CA, USA
Objectives: To date, there has not been extensive study on the economics or estab-
lished treatment guidelines in patients with non-infectious posterior uveitis (NIPU). 
Current treatment is mostly topical/systemic/injection corticosteroids, though treat-
ment is associated with significant side effects. We undertook a secondary research 
analysis of MarketScan claims data to better understand the patient journey and the 
current treatment standard of care for NIPU patients. MethOds: We analyzed the 
MarketScan dataset to identify NIPU patients from a defined list of ICD-9 codes. We 
then identified patients with 30 months of continuous enrollment data, 6 months 
prior and 24 months post initial diagnosis. Patients were assessed for number of 
office visits/procedures, number of diagnostic tests, number of inpatient stays, and 
number and frequency of drug treatment (corticosteroids, corticosteroid injections, 
immunomodulators, and biologics). Results: Of the 56 million lives in the claims 
dataset, 34,827 had an ICD-9 code consistent with NIPU. Of these unique patients, 
33,386 were analyzed. 78.8% of patients came from the commercial dataset, 59% 
of patients were female, and the average age at diagnosis was 51.5 years. Prior to 
diagnosis, 5,775 patients were treated for NIPU at an average cost of $185.43 per 
patient (58.0% topical/systemic corticosteroids, 22.7% corticosteroid injections, 
15.7% immunomodulators, 3.7% biologics). In the 24 months post-diagnosis, the 
number of treated patients increased to 11,570 patients at an average cost of $249.01 
per patient (45.7% topical/systemic corticosteroids, 37.4% corticosteroid injections, 
16.4% immunomodulators, 3.2% biologics). Examining each six-month period post-
diagnosis, the number of treated patients decreased, but the share of treatments 
remained the same. cOnclusiOns: Patients with NIPU are engaging the health 
care system and being treated for NIPU at least six months prior to an official 
diagnosis. Efforts should be made to better identify patients with NIPU to ensure 
proper diagnosis and treatment.
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wAITING TIMES AND SCHEDULING IN DERMATOLOGICAL PRACTICES IN 
GERMANy
Krensel M.1, Augustin M.1, Reusch M.2, Rosenbach T.3
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Dermatology Center 
Tibarg, Hamburg, Hamburg, Germany, 3Dermatology Center Osnabrück, Osnabrück, Germany
Objectives: Waiting time for medical consultation is an important quality indi-
cator of health systems. International studies have shown that there is consider-
able variation of waiting time between countries. It may also vary within countries 
depending on the degree of emergency, indication, and way of reimbursement. Our 
objective was to assess practice organization and waiting times in German derma-
tological practices. MethOds: A one page questionnaire was sent to be returned 
anonymously by fax to 2,644 German office base dermatologists randomly selected. 
Included were items on organization of practice, region and specific average waiting 
times for selected diagnoses. The postal codes obtained from the practices were 
mapped to the 17 German regions of physicians association of statutory health 
insurance. Results: Data sets were obtained from 681 practices. A total of 4.3% of 
practices rarely or never gave fixed appointments, 36.3% only gave fixed appoint-
ments. The percentage of treatment at fixed appointments varied by regions from 
71.1% in Bremen and Brandenburg to 90.0% in Hessen. Moreover, private practices 
not being associated with the statutory health system showed a higher rate of timed 
appointments with 94.8% compared to 83.0%. Average waiting time in practices 
treating also patients with statutory health insurance is 5 weeks and thus 4 times 
higher compared to waiting time in practices treating private insured patients only 
(1.2 weeks). There was large variation in waiting time for the first appointment 
between different indications. Patients with acute eczema or pigmented lesions 
specific for melanoma were given appointments after 1.7 or 1.2 weeks, respec-
tively; for skin cancer screening, patients had to wait for 5.7 weeks on average. 
There was only small geographic variation regarding this pattern. cOnclusiOns: 
Patients with risky and acute indications are treated with low waiting times whereas 
patients with less threating skin diseases have to wait longer for appointments at 
dermatological offices.
Objectives: To assess the quality of life (QoL) of patients with an exudative Age-
Related Macular Degeneration (AMD) treated by intravitreal Anti-VEGF (vascular 
endothelial growth factor) and determine its drivers in a real-life setting. MethOds: 
A self-reported survey was carried out among AMD patients belonging to 2 French 
associations. Only patients with exudative AMD and under active intravitreal anti-
VEGF treatment over the last 6 months were included. Data on demographics, 
disease parameters, past and ongoing treatments were collected. One validated 
vision-specific QoL instrument was also considered: the NEI-VFQ-25. Patients were 
stratified into four groups of visual acuity (VA). A multivariate model was performed 
to identify the QoL drivers. Results: Out of the 1,888 questionnaires mailed 32.4% 
were returned and 24.7% fulfilled the inclusions criteria and were fully completed 
for analyses. Patients’ mean age was 78.0 years (SD 7.6). A total of 70.5% were 
women. A total of 60.4% had bilateral disease. The mean duration of symptomatic 
exudative AMD was respectively of 7.2 (SD 5) and 2.3 years (SD 3) for the first and the 
second eye. Most of anti-VEGF treated eyes (n= 641) were treated for more than 1 year 
(77.4%). The mean annual number of anti-VEGF injections was 4.7 (SD 2.7). The mean 
NEI-VFQ-25 global score was 53.4 (SD 21.5). A decrease of this score was positively 
correlated to VA decrease (0.63;p< .0001). This correlation was observed for 11 sub-
scales out of 12. The main risk factor associated to the lower Qol score was the worst 
VA category, with an odds ratio of 5.2 (CI95%[2.6-10.4];p< .0001). cOnclusiOns: In 
a real-life survey of patients treated and followed for exudative AMD, VA decrease 
was the strongest factor linked to QoL worsening. Other factors such as the number 
of Anti-VEGF injections were not correlated to QoL in this study. Then, preservation 
of useful VA still remains a major concern to improve patients’ QoL.
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ASSESSMENT AND CAUSAL LINK BETwEEN vISION-RELATED QUALITy OF LIFE 
AND GENERAL HEALTH RELATED QUALITy OF LIFE IN DRy EyE PATIENTS
Ernst F.
Santen GmbH, Munich, Germany
Objectives: This abstract describes attempts to evaluate the burden of dry eye dis-
ease with regards to vision-related quality of life (QoL) and the causal link to general 
health related quality of life. Recent increased awareness of dry eye disease (DED) 
by both health care professional and patients has been accompanied by improved 
recognition that it is a chronic disorder often requiring long-term treatment and 
management. DED, frequently associated with symptoms of discomfort and visual 
disturbance, also impairs general health status and general quality of life, including 
aspects of physical, social, and psychological functioning. This abstract summarizes 
the available research on the burden of DED and the impact on QoL. MethOds: 
The research included systematic literature search on clinical relevant DED litera-
ture based on HTA relevant requirements, in order to identify potential differences 
within DED. Correlations with socio- demographic characteristics, clinical param-
eters, and psychological status were evaluated. Results: A relative small amount 
of data supporting the effectiveness of DED treatments as assessed by QoL measures 
exists (such as DEQLQ, IDEEL etc.). Dry eye treatments have been associated with 
improvements in symptoms measured by OSDI (Ocular Surface Disease Index), and 
in ophthalmology-disease-specific measurement of QoL, and with enhancement of 
patients’ ratings regarding their ability to perform activities of daily life. Significant 
correlations were found between symptoms score and QoL scores and patient anxi-
ety, especially depression levels which correlates to general health. cOnclusiOns: 
Vision-related QoL in dry eye patients was correlated with general health status, 
especially with anxiety and depression. DED has further implication on general 
public health and deserves an increased attention and resources.
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PHySICIAN ExPERIENCE wITH RITUxIMAB TO TREAT PEMPHIGUS vULGARIS IN 
CANADA: A QUESTIONNAIRE-BASED STUDy
Mittmann N., Knowles S., Heelan K., Bannon G., Seung S.J., Shear N.
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Objectives: To examine the experience of physicians who treat patients with 
pemphigus vulgaris (PV) in Canada as well as the utilization and access of the drug 
rituximab (Rtx). MethOds: An online questionnaire was created in SurveyMonkey® 
to collect data from participants based on a convenience sample size of 10 English-
speaking dermatologists. Consent was implied once the dermatologist completed the 
questionnaire. Non-identifying information for both dermatologists and PV patients 
was collected. Results: The 10 participating dermatologists have been treating PV 
patients an average of 20.9 ± 10.7 (5 – 45) years in which 28.8 ± 58.3 (0 – 200) was the 
mean number in their practice. Experience with Rtx is based on an average of 4.1 ± 
3.8 (0 – 10) years and 13.1 ± 29.2 (0 – 100) PV patients treated with Rtx. All participants 
answered that “failure of conventional therapy for at least six months” was the pri-
mary reason for using Rtx and that azathioprine, intravenous immunoglobulin and 
mycophenolate mofetil were the most popular treatments used to treat PV patients 
prior to Rtx. On average, it takes 3.2 ± 2.2 (0 – 6) months for a remission to be induced 
after Rtx treatment and 90% of the dermatologists were concerned that infections 
would be an adverse event. Lastly, 6.3 ± 12.3 (0 – 40) was the mean number of Rtx drug 
reimbursement letters that the dermatologists had written on behalf of PV patients 
in which 1.9 ± 2.5 (0 – 6) letters were successful in securing Rtx drug reimburse-
ments. cOnclusiOns: A recent survey of 10 Canadian dermatologists experienced 
with treating PV patients found that Rtx utilization is still new, disease remission is 
achieved within a short period of time, and the drug reimbursement process remains 
a barrier based on the low number of letters written by the dermatologists.
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REAL-wORLD UTILIzATION DATA OvER 4 yEARS OF RANIBIzUMAB INjECTIONS 
FOR THE TREATMENT OF wET AGE-RELATED MACULAR DEGENERATION IN 
CANADA
Lebel K.1, Gonder J.2, Davies B.1, Zaour N.1
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Moreover, HrQoL (DLQI) improved by 65% from inclusion. The conventional system-
ics cohort showed comparable reduction in PASI= 3.1 (77%) but less improvement 
in DLQI= 3.1 (49%). cOnclusiOns: PsoBest provides long-term real-world data on 
psoriasis care in Germany. The results show the high burden of psoriasis patients 
entering the registry and also the high quality of care and patient benefit after 
initiation of systemic treatment.
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RECRUTING PHySICIANS FOR HEALTH OUTCOME AND POST-APPROvAL 
STUDIES: BENEFITS OF A MANAGED PHySICIAN PANEL
Potthoff P.1, Güther B.1, Brown C.2, Eichmann F.1
1Kantar Health Germany, Munich, Germany, 2All Global, London, UK
Objectives: Access to multi-country physician panels is an alternative option to 
recruit medical sites for health outcome or post-approval studies, compared to the 
conventional approach of individually recruiting clinical expert sites. The objec-
tive of our study was to assess the potential of physician panels for site recruit-
ment. MethOds: In 2012, a representative survey among members of a managed 
physician panel (All Global’s managed panel of ophtalmologists in US, UK, GER, FR, 
IT and SP) was conducted. The survey assessed the willingness of the physicians 
to participate in post-approval studies. Information about former participation in 
those studies and commitment to special requests for post-approval studies (e.g. 
ethical committee involvement, advent reporting to sponsor, security of patient’s 
informed consent) were also collected. Results: A total of 200 opthalmologists 
participated in the survey. Since no special incentive was offered for participation 
the response rate of more than 25% was satisfactory. 79 (39,5%) of the physicians 
formerly participated in clinical trials and 95 (47,5%) in post-approval studies. 54,5% 
of the ophtalmologists were willing to participate in future studies. More than 80% 
of this group was ready to ask their hospital or other legal authorities for permission 
to participate in studies of this kind, to report serious adverse events to the spon-
sor of the study and to ask patients for written informed consent. cOnclusiOns: 
Managed physician panels are a valuable alternative option to recruit medical sites 
for post-approval or health outcome studies. Every second ophtalmologist from 
panels is experienced in this kind of studies and most of them are willing fullfil all 
necessary legal and quality requirements. In addition to timing and cost factors, an 
adavantage of physician panels is the better representation of daily medical routine-
practice, adding to the epidemiological validity of respective projects.
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LyMPHEDEMA – THE LONG wAy TO DIAGNOSIS AND THERAPy
Blome C.1, Herberger K.1, Sandner A.1, Augustin M.2
1University Medical Center Hamburg, Hamburg, Germany, 2University Medical Center Hamburg-
Eppendorf, Hamburg, Germany
Objectives: Clinical experience indicates that edema often remain undiagnosed. 
The aim of this study was to examine how much time passes between impor-
tant events in the ‘patient journey’ and what predicts late consultation and diag-
nosis. MethOds: Sixty-five patients with secondary arm lymphedema and 161 
patients with primary or secondary leg lymphedema were interviewed. The follow-
ing latency times were computed: time between 1) first symptoms and first visit 
to physician; 2) visit to physician and diagnosis; 3) diagnosis and lymph drainage 
therapy; and 4) diagnosis and compression therapy. Associations of latency times 
with patient and clinical characteristics were analysed using t tests and multivari-
ate linear regression. Results: All arm edema patients had consulted a physician 
in the year after first symptoms at the latest, and everyone except two received the 
diagnosis in the following year at the latest. For secondary leg edema, the average 
latency until physician consultation was also short with 0.5 ± 1.8 years, and latency 
until diagnosis was 1.7 ± 3.8 years. In contrast, latencies in primary leg edema 
were significantly longer: The average time between first symptoms and physician 
consultation was 5.2 ± 11.0 years, and edema diagnosis was made after further 6.7 
± 11.4 years. On average, it took 13.5 years from first symptoms to lymph drainage 
therapy in these patients and 13.7 years until compression therapy. Predictors of 
late consultation and late diagnosis in primary leg edema were age< 40, positive 
family anamnesis, and female gender. cOnclusiOns: Primary leg lymphedema 
are diagnosed late in many cases, especially in younger women.
PSS57
ADHERENCE By SPANISH RETINOLOGISTS TO THE GUIDANCE FOR 
THE MANAGEMENT OF PATIENTS wITH wET AGE-RELATED MACULAR 
DEGENERATION
Colomé A.1, Balaña M.1, Ruiz Moreno J.M.2, Roura M.1
1Novartis Farmacéutica, S.A., Barcelona, Spain, 2Instituto Oftalmológico Alicante (VISSUM) y 
Universidad de Castilla la Mancha, Alicante, Spain
Objectives: To assess the adherence by Spanish retinologists to the recommenda-
tions for the management of age-related macular degeneration (AMD) published by 
the Spanish Society of Retina and Vitreous (SERV). MethOds: Non-interventional, 
retrospective and multicenter study, involving 59 researchers from different Spanish 
Ophthalmology Services that collected medical records from 346 patients aged ≥ 50 
years and diagnosed with exudative AMD. Results: Adherence to SERV-guidelines 
by Spanish retinologists was high concerning diagnostic (96.8%) and control items 
(98.6%) of AMD patients, slightly lower for therapeutic issues (84.4%), and much 
lower on patient follow-up and retreatment criteria (46.9%). When focusing on diag-
nostic, first symptoms indicative of wet AMD were sharp and progressive loss of 
visual acuity (64.7%), followed by metamorphopsia (distorted vision) (33.8%) and 
central scotoma (23.1%). Main diagnostic confirmatory tests were visual acuity 
(97.1%), OCT (93.4%), biomicroscopy (92.2%) and fluorescein angiography (71.1%). 
For therapeutic issues, first choice treatment was based on anti-VEGF-drugs (99.1%), 
mainly ranibizumab (96.8%) as a loading dose of three injections (88.1%). Main 
patient follow-up tests were: visual acuity tests (98.0%), optical coherence tomog-
raphy (96.0%), biomicroscopy (91.9%). Most common control schemes during the 
first year of treatment were every-two-months (35.8%) or monthly (30.4%) visits; 
PSS52
SAFETy IN NATIONAL CARE - REAL wORLD DATA FROM THE GERMAN 
PSORIASIS-REGISTRy “PSOBEST”
Rustenbach S.J.1, Purwins S.1, Spehr C.1, Radtke M.A.1, Reich K.2, Augustin M.1
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Dermatologikum 
Hamburg, Hamburg, Germany
Objectives: The registry “PsoBest” observes systemic therapy of moderate and 
severe psoriasis/psoriasis-arthritis in Germany since 2008. The registry is supported 
by the German society for dermatologists, the association of dermatologists, phar-
maceutical manufactures, dermatologists and patients. It is located at CVderm and 
documents safety, effectiveness and patient benefit in routine health care. One 
purpose of PsoBest is to monitor the safety of systemic antipsoriatics. MethOds: 
Patients receiving first time a conventional systemic or biologic treatment are 
observed for 5 years, regardless of therapy switches. Standardised questionnaires 
for physicians and patients are compiled. Adverse and serious adverse events (AE/
SAE) are coded in MedDRA and analyzed twice a year. Results: Pharmacovigilance 
after 42 months on 1984 patients with 800 expositions to biologics (1196 patient 
years) and 1430 to systemics (1548 patient years) resulted in 187 SAE codings in 
121 patients (6.1%). A total of 105 SAE were observed under biologic and 95 under 
conventional systemic treatment (8.9 and 4.5%, respectively). Of these, 20 SAE in 14 
patients were observed in combined treatment. By system-organ-classes, general 
disorders and administration site conditions were observed for 2.3% of biologic 
(1.51 events/100 patient years) and 1.3% systemic patients (1.32 events/100 patient 
years). The rates for cardiac disorders were 0.92 (1.4% of patients) and 0.84 (0.9% 
of systemic patients), respectively. For infections and infestations the rates were 
0.84 (1.3%) and 0.52(0.8%) and for neoplasms benign, malignant and unspecified 
(incl. cysts and polyps) 0.67 (1.0%) and 0.71 (0.8%). cOnclusiOns: PsoBest provides 
urgently needed long-term safety data in the systemic treatment of psoriasis and 
psoriatic-arthritis from routine care in Germany. To date, no safety concern emerged 
from the registry. To raise the power for signal detection, verification, analysis and 
assessment, PsoBest is proactively contributing to the European surveillance of 
effectiveness and safety of systemic psoriasis therapy (ENCEPP-network psonet).
PSS53
AFLIBERCEPT IN NEOvASCULAR (wET) AGE-RELATED MACULAR 
DEGENERATION: AN ANALySIS OF THE PAyER DECISION LANDSCAPE
Brown A.1, Ferreira A.2, Lamle S.2, Milnes F.2
1Abacus International, Manchester, UK, 2Novartis Pharma AG, Basel, Switzerland
Objectives: To investigate and analyse decisions of Health Technology Assessment 
or national drug reimbursement agencies for aflibercept in neovascular (wet) aged-
related macular degeneration, including decision outcomes, the rationale for these, 
the data package and any payer critique of the manufacturer approach. MethOds: 
A search of decision-making agency websites in key European markets, Canada and 
Australia was conducted to identify relevant decisions. Data were extracted and used 
to conduct a qualitative analysis of decisions. Results: Five decisions were identi-
fied; from NICE (England & Wales), SMC (Scotland), HAS (France), G-BA (Germany) and 
PBAC (Australia). In all instances, the clinical and economic arguments, where appli-
cable, were based on demonstration of non-inferiority of aflibercept to an existing 
therapy, ranibizumab. These arguments were supported by two key trials of aflibercept 
vs. ranibizumab: VIEW 1 and 2, and also indirect comparisons and network meta-
analyses. In all decisions, aflibercept was either recommended for the full licensed 
indication or recommended with restrictions. All agencies commented that the key 
trials were well conducted and unbiased; however, they also state that the dosing 
schedule for ranibizumab did not reflect the license or clinical practice in respective 
markets, and it was unclear if there would be any difference in the frequency of 
injections between therapies in the clinical setting. Furthermore, for the economic 
models for NICE, SMC and PBAC, the respective agencies thought the frequency of 
injections and number of clinician visits for ranibizumab were overestimated. All 
agencies concluded that aflibercept demonstrated no additional clinical benefit over 
ranibizumab. For example, HAS in France granted an ASMR level V: no improvement 
in clinical benefit, while NICE recommended that aflibercept be used in accordance 
with their recommendations for ranibizumab. cOnclusiOns: While aflibercept is 
an effective alternative therapy to ranibizumab, payers have concluded that it offers 
no demonstrable added clinical benefit compared with ranibizumab.
PSS54
HEALTH RELATED QUALITy OF LIFE-OUTCOME IN NATIONAL CARE - REAL 
wORLD DATA FROM THE GERMAN PSORIASIS-REGISTRy “PSOBEST”
Purwins S.1, Spehr C.1, Augustin M.1, Radtke M.A.1, Reich K.2, Rustenbach S.J.1
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Dermatologikum 
Hamburg, Hamburg, Germany
Objectives: The registry “PsoBest” observes systemic therapy of moderate and 
severe psoriasis/psoriasis-arthritis in Germany since 2008. The registry is supported 
by the German society for dermatologists, the association of dermatologists, phar-
maceutical manufactures, dermatologists and patients. It is located at CVderm and 
records efficacy, safety, and patient benefit in routine health care. One purpose of 
PsoBest is to monitor health related quality of life (HrQoL) and severity of psoria-
sis in the process of care. MethOds: Patients receiving first time a conventional 
systemic or biologic therapeutic are observed for 5 years, independent of further 
treatment. Standardised questionnaires for physicians and patients are compiled. 
Main outcomes are severity (PASI), affected body surface area (BSA) and HrQoL (DLQI 
and EQ-5D). Results: A total of 1,984 patients were enrolled up to July 2012 (60% 
male, mean age of 47 years); mean duration of illness was 19±14 years. Patients on 
biologics (n= 686) tended to be male (63 v. 58%), older (48.1 v. 46.7 years) as patients 
on conventional systemics (n= 1,298) and had a longer history of psoriasis (21.9 v. 
16.8 years). The biologic cohort showed more nail involvement (64 v. 52%), signs 
of arthritis (47 v. 17%), higher severity (PASI: 15.6 v. 14.6; BSA: 22. v. 21.5) and lower 
HrQoL (DLQI: 11.7 v. 11.0; EQ-5D VAS: 50.6 v. 55.7). For the biologics cohort, mean 
PASI improved to 4.5 between 12 and 24 months (reduction of 70% from baseline). 
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nel during standard-of-care visits. Although this is the traditional approach, it has 
several practical shortcomings: infrequent or irregular standard-of-care visits; 
patients switching health care providers; transient nature of some safety events; 
treatment at non-study sites, and the lack of care-seeking for the safety events. An 
alternative study design that overcomes several of these shortcomings includes 
direct-to-patient contact (DPC) and follow-up. Objectives: The purpose of this 
study is to describe patients’ short and long term management patterns including 
the detection and verification of events of interest by contacting patients’ event 
treating physician (ETP). MethOds: This is multinational multicenter observational 
prospective longitudinal cohort study involving 10,600 patients in Europe and South 
America. Patients were enrolled at hospital and followed up by telephone by a spe-
cialized DPC unit at 6 weeks then quarterly up to 2 years after hospital discharge. 
Data collected include clinical outcomes, safety events of interest, economic bur-
den and quality of life. Results: A total of 88,276 phone calls to patients were 
performed, achieving a reachable rate of 88.5% and an interview successful rate of 
84.6%. 87.2% of the initial sample completed the 2-year follow-up period: 5.7% of 
the sample died, 6.0% voluntarily withdrew and 0.9% was withdrawn to participate 
to a clinical trial. Only 19 patients were never reached (0.2%). In total, 2144 events of 
interest were detected and a medical verification from ETPs was obtained in 72.3% of 
the case. cOnclusiOns: This study demonstrates that DPC along with a proactive 
pharmacovigilance system achieved very high response rates from both patients 
and ETPs. It represents an effective alternative methodology to collect patients data, 
including safety data, in real life settings.
PCv3
ANTITHROMBOTIC STRATEGIES AND ADvERSE OUTCOMES IN ACUTE 
CORONARy SyNDROME AND ATRIAL FIBRILLATION: A COMMUNITy STUDy
Chamberlain A.M.1, Gersh B.J.1, Klaskala W.2, Mills R.M.2, Alonso A.3, Weston S.A.1, Roger V.L.1
1Mayo Clinic, Rochester, MN, USA, 2Janssen Research & Development, LLC, Raritan, NJ, USA, 
3University of Minnesota School of Public Health, Minneapolis, MN, USA
Objectives: Atrial fibrillation (AF) is frequent in acute coronary syndromes (ACS) 
and impacts the need for subsequent antithrombotic treatment. However, whether 
associations of antithrombotic treatment with strokes, bleeding, and death differ 
between ACS patients with and without AF remains uncertain. MethOds: Olmsted 
County, MN residents with incident myocardial infarction or unstable angina during 
2005-2010 were classified according to AF status prior to or during the index ACS 
hospitalization. Antithrombotic strategy at discharge was categorized into double/
triple vs. no/single and warfarin vs. no warfarin therapy. Cox regression was used 
to examine associations between treatment and strokes, bleeding, and mortality 
and to test whether AF differentially impacted these associations. Models were 
age- and sex-adjusted and weighted for the inverse probability of the propensity 
score for therapy. Results: A total of 244 of 1140 incident ACS patients had AF 
(ACS+AF), and of these patients, 49% were discharged on double/triple antithrom-
botic therapy and 33% received warfarin. In 896 ACS patients without AF, 63% were 
discharged on double/triple therapy and 4% on warfarin. Over a median of 4.2 years, 
95 strokes, 297 bleeds, and 255 deaths occurred. Antithrombotic strategy was not 
associated with the risk of stroke or bleeding. Among all ACS patients, mortality 
was similar between strategies; however, ACS+AF patients on double/triple therapy 
(vs. no/single therapy) showed a trend toward a lower risk of death [HR (95% CI): 
0.64 (0.41-1.02) for ACS+AF, 1.25 (0.83-1.87) for those without AF; pinteraction= 0.03]. 
For warfarin vs. no warfarin, those with AF exhibited a lower mortality risk with 
warfarin [HR (95% CI): 0.46 (0.29-0.73) for ACS+AF, 2.01 (0.94-4.32) for those with-
out AF; pinteraction< 0.01]. cOnclusiOns: Altogether, in community ACS patients, 
antithrombotic strategy is not associated with the risk of stroke, bleeding, or death. 
However, in the subset of ACS patients with AF, a warfarin strategy is associated 
with a lower risk of death.
PCv4
COMORBIDITy INFLUENCE IN THE CONTROL OF ARTERIAL HyPERTENSION
Sicras-Mainar A.1, Fernandez J.L.2
1Badalona Serveis Assistencials, Badalona, Spain, 2Primary Care Center Doctor Vicenç Papaceit, La 
Roca del Valles, Spain
Objectives: Determine the impact of co-morbidity in controlling arterial hyperten-
sion in clinical practice situation. MethOds: Cross-sectional study, conducted from 
retrospective review of patient records obtained from primary care. We included 
patients’ ≥ 30 years who demanded attention during the year 2012. The main meas-
ures were: demographics, control (≤ 140/90 mmHg) blood pressure (BP), evolution 
time, co-morbidity (general and specific) protocol using cardiovascular events (CVE), 
visits and referrals to specialists. Statistical analysis and multiple linear regression 
for correction of the models, p< 0.05. Results: We recruited 900 patients (mean age 
67.4 years, women: 51.1%). The 64.8% (CI: 61.7% -67.9%) of subjects had a proper 
control of the BP. The average duration of hypertension was 6.0 years and use 4.6 
protocol entries / year. The average number of visits was 15.3 and 0.7 referrals. The 
years of evolution were associated with age (r = 0.323). The control patients showed 
a higher average BP of ischemic heart disease (11.1% vs. 6.9%) and CVE (19.4% vs. 
14.8%), p < 0.05. The BP control was associated with women (OR = 1.4) and the pres-
ence of CVE (OR = 1.8), p < 0.02. The number of diagnoses (morbidity) was associated 
with age (ß = 0.14) and the number of referrals (ß = 0.08), p < 0.05 (coefficient R2= 
40%). cOnclusiOns: Optimal control of BP is high. The profile of these patients is 
women in a situation of secondary prevention.
PCv5
HIGH DOSAGES OF STATINS IN HIGH CARDIOvASCULAR RISK PATIENTS IN A 
REAL wORLD SETTING: TREATMENT PATTERNS AND OUTCOMES
Degli Esposti L., Sangiorgi D., Buda S.
CliCon Srl, Ravenna, Italy
Objectives: International guidelines recommend the use of high dosages statins 
(in particular, Rosuvastatin and Atorvastatin) in high cardiovascular (CV) risk 
patients. The aim of this study was to assess the degree of implementation of the 
while after first year of treatment, controls tend to become less frequent, mostly 
every-three-months (39.9%). When recurrence occurs, main retreatment criteria 
were: presence of macular fluid (93.5%), loss of ETDRS letters (50.5%; 68.8% with 
≥ 5 letters), macular hemorrhage (46.3%) and increase of central-retinal-thickness 
(45.4%). Single injection of anti-VEGF retreatments was applied in 48.6% of recur-
rences, while 23.6% were not treated with anti-VEGF. cOnclusiOns: A relatively 
high adherence to SERV guidelines was followed by Spanish retinologists regarding 
diagnosis, treatment and control of AMD. However, limitations have been identified 
on patterns of follow-up and retreatment criteria that may compromise therapeutic 
and clinical outcomes.
PSS58
TREATMENT PATTERNS OF RANIBIzUMAB AND AFLIBERCEPT FOR THE 
MANAGEMENT OF wET AGE-RELATED MACULAR DEGENERATION IN ROUTINE 
CLINICAL PRACTICE IN THE UNITED STATES
Ferreira A.1, Sagkriotis A.1, Milnes F.1, Olson M.1, Hill J.2, Lu J.2, Makin C.2
1Novartis Pharma AG, Basel, Switzerland, 2IMS Health, Plymouth Meeting, PA, USA
Objectives: To compare the frequency of injections for ranibizumab and afliber-
cept for the treatment of wet age-related macular degeneration (wAMD) in a real-
world setting. MethOds: Claims from the IMS Integrated Data Warehouse were 
used to identify treatment-naïve patients with wAMD receiving ≥ 1 prescription for 
ranibizumab or aflibercept between 1 November 2011 and 31 March 2012 and with 
a follow-up of 365 days. Patients were considered to be treatment-naïve if they had 
received no anti-VEGF treatment for > 180 days prior to the index date. Mean number 
of injections received within 365 days of treatment initiation and the proportion of 
patients receiving 3 loading doses within 3 months were calculated and compared 
for patients starting therapy with ranibizumab or aflibercept. No adjustments for 
bilateral treatment were performed. Results: Patient characteristics were similar 
for patients receiving ranibizumab (N= 2,799) or aflibercept (N= 117) at the index 
date (median age: 82 years; % male, 36%). The mean (±SD) number of anti-VEGF 
injections received by patients starting on ranibizumab or starting on aflibercept 
was similar: 5.6±3.5 and 5.4±2.8, respectively (p= 0.6593). In patients continuously 
treated with the same agent for 12 months, the mean number of injections was 
also similar across ranibizumab and aflibercept: 4.9±3.4 (n= 1,898) vs 5.2±2.6 (n= 87), 
respectively (p= 0.2705). Approximately two-thirds of patients with more than 3 
injections received 3 loading doses within the first 3 months (ranibizumab, 65.6%; 
aflibercept, 64.3%). Results for patients who were treatment-naïve for 365 days were 
consistent with the above results. cOnclusiOns: There are limited data regard-
ing real-world treatment patterns with aflibercept for the management of wAMD. 
Our results suggest that in routine clinical practice patients receive a comparable 
number of injections in the first year of treatment with both ranibizumab and 
aflibercept. Analysis of data from larger patient populations and for longer follow-
up is warranted when these data become available.
RESEARCH POSTER PRESENTATIONS – SESSION Iv 
DISEASE-SPECIFIC STUDIES 
CARDIOvASCULAR DISORDERS – Clinical Outcomes Studies
PCv1
APPLICATION OF LOGISTIC REGRESSION FOR SIGNAL DETECTION AND RISK 
ASSESSMENT OF MACROLIDE-ASSOCIATED TORSADE DE POINTES
Ali A.K.
Eli Lilly and Company, Indianapolis, IN, USA
Objectives: Torsade de pointes (TdP) is an identified risk for antibacterial treat-
ment with macrolides, but the risk might vary across individual macrolides. This 
study evaluates the association between macrolides and TdP from the FDA Adverse 
Event Reporting System (FAERS). MethOds: Disproportionality analysis of FAERS 
between 1997 and 2012 was conducted for azithromycin, clarithromycin, erythro-
mycin and Telithromycin with TdP preferred term of the Medical Dictionary for 
Regulatory Activities using logistic regression. Logistic reporting odds ratio (LROR) 
and corresponding 95% confidence intervals (CIs; LR05-LR95) are estimated for 
individual macrolides. Estimates are compared with Multi-Item Gamma Poisson 
Shrinker data mining algorithm. Estimates ≥ 2 yield significant safety signals. Lack 
of overlap between estimate-specific CIs indicates efficient approach for signal 
detection. Results: A total of 318 TdP events were reported for macrolides. The 
majority of reports were for erythromycin (n= 122) and clarithromycin (n= 114), fol-
lowed by azithromycin (n= 74) and telithromycin (n= 8). Most of events were reported 
for females with median age of 62.8 years. 98% of TdP were serious events (10% of 
those were deaths). Death contributed to 18%, 10% and 5% of serious TdP events 
for azithromycin, erythromycin and clarithromycin, respectively. Telithromycin 
didn’t have death TdP reports. Significant TdP signals were identified for mac-
rolides. LROR (LR05-LR95) were: erythromycin 48.1 (40.4-55.9); clarithromycin 15.3 
(12.1-19.1); azithromycin 13.9 (11.1-17.2); and telithromycin 6.79 (3.20-13.5). Except 
for telithromycin, no overlap was observed between estimate-specific CIs between 
analysis methods. cOnclusiOns: Macrolides are associated with more than 
expected reporting of TdP compared to other drugs and events in the database; 
however, the risk was highest in erythromycin and lowest in telithromycin. Fatal TdP 
was highest in azithromycin, and telithromycin didn’t have fatal TdP. The findings 
show differential risk of TdP across macrolide antibiotics, emphasizing the need for 
monitoring cardiac rhythms in patients treated with macrolides.
PCv2
DIRECT-TO-PATIENT CONTACT AND PROACTIvE PHARMACOvIGILANCE 
SySTEM: A CASE STUDy
Wiederkehr S., Seux M., Michel J., Fournie X.
Mapi, Lyon, France
Post-authorization non-interventional safety studies typically enroll patients at 
sites and safety events are reported and collected as appropriate by site person-
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A513
patients, riociguat increased the proportion fulfilling criteria defining a positive 
response to therapy.
PCv8
PATIENT REPORTED OUTCOMES ASSSESMENT OF THAI CHRONIC STABLE 
ANGINA PECTORIS(CSAP)
Rojkajornnaphalai S.
Chest Hospital, Nonthaburi, Thailand
Objectives: A pilot test to assess patient-centered outcomes in daily manage-
ment of coronary artery disease at cardiology clinics in Thailand. MethOds: A 
Delphi method was used for development of PRO questionnaire assessing along 
with ivabradine treatment from randomly selected CSAP patients under the Health 
Authorities’ pharmacovigilance monitoring program. A 15-items short-form health 
survey with 5 response choices adopted with permission from validity-tested PRO 
used in medical outcomes study in Thai patients, four health dimensions included 
general, physical, social function role limiting and mental health dimensions with 
1, 6, 5 and 3 items each respectively. Standardized scoring was calculated with 
the lowest(0) to highest(100). Field tests among healthy volunteers performed.The 
reliability test employed inter-item and intra-item consistency using Cronbach’s 
alpha coefficient. All 15 items of survey were evaluated at initiation and after 
four months clinical intervention. The treatment acceptability was further 
assessed from patient interviews. Results: Of 162 patients randomly selected 
for PRO evaluation, 85(53%) was men, all patients mean(SD) age of 67.3(11.7) years 
whom 97(59.5%)was > 65 years, 9(5.5%) was smokers and 81(49.7%) had a Body 
Mass Index ≥ 25 kg/m2. Forty-three (26.4%) of patients had previous intervention 
and 63(39%) had heart failure(HF). The internal consistency of the score for all 
15 items, for physical, social function role limiting and mental health dimen-
sions, reflected Chronbach’s alpha coefficient of 0.888, 0.771, 0.702 and 0.807 at 
baseline. After 4-month, Cronbach’s alpha coefficient were of 0.735, 0.715, 0.661 
and 0.519. All mean scores(SD) of these four health dimensions, were signifi-
cantly improved from 47.59(11.50) to 54.91(9.45), from 50.33(12.11) to 54.91(10.42), 
from 39.53(10.35) to 52.68(10.32) and from 45.88(17.08) to 54.88(18.49) respectively 
(P< 0.001). cOnclusiOns: This pilot development confirms reliability of 15-items 
short-form health survey, score is consistent overtime. Thai CSAP patients who 
were prescribed ivabradine reported a highly significant improvement in qual-
ity of life including all health dimensions general, physical, social function role 
limiting and mental health. Patient-reported outcomes questionnaires could be 
recommended alongside clinical treatment.
PCv9
ATTAINMENT OF LOw-DENSITy LIPOPROTEIN CHOLESTEROL GOALS IN 
PATIENTS AT vERy HIGH CARDIOvASCULAR RISK IN THE UNITED KINGDOM: 
RESULTS FROM A GENERAL PRACTICE POPULATION STUDy
Ray K.K.1, Foody J.2, Khan I.3, Lewis B.E.4
1St George’s University of London, London, UK, 2Brigham and Women’s Hospital, Boston, MA, 
USA, 3Sanofi, Bridgewater, NJ, USA, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Objectives: European guidelines support LDL-C goals based on an individual’s 
absolute cardiovascular (CV) risk and have established a goal of < 70 mg/dL in very 
high CV risk patients. The objective of this study was to estimate the proportion of 
individuals that attain these goals and assess the determinants of any observed 
variation. MethOds: Patients in The Health Improvement Network (THIN) UK 
general practice database with an LDL-C measurement during 2011 and at very 
high risk of CV risk events were identified and further categorized as recent acute 
coronary syndrome (ACS, within 6 months pre LDL-C measurement), prior coronary 
events, stroke, and peripheral vascular disease (PVD). Lipid-lowering therapy (LLT) 
was categorized as high-potency statin, standard-potency statin, non-statin LLT, 
and no LLT. Results: In total, 25,535 patients met the inclusion criterion. Median 
(inter-quartile range [IQR]) age was 71 (62 to 79) years, 63.5% were male, and median 
(IQR) LDL-C was 108 (83 to 139) mg/dL. Across the total cohort, 6.3%, 61.3%, 17.8%, and 
14.6% had evidence of recent ACS, prior coronary events, stroke, and PVD. Patients 
with LDL-C < 70 mg/dL within these categories were 18.9%, 13.5%, 14.5%, and 11.4%. 
Across the total cohort, 16.0%, 52.5%, 0.5%, and 31.0% were on high-potency statin, 
standard-potency statin, non-statin LLT, and no LLT. Patients with LDL-C < 70 mg/
dL within these LLT categories were 18.3%, 15.4%, 11.6%, and 8.5%. cOnclusiOns: 
In a large, contemporary cohort of very high CV risk patients, few achieved the 
optimal LDL-C goal of < 70 mg/dL. One third were not on any LLT, < 20% were on 
high-potency statin, and > 80% of those receiving high-potency statins were not at 
LDL-C goal. These data suggest the need for ongoing efforts to improve prescribing 
of appropriate LLT as well as identifying new therapies to improve goal attainment 
among very high CV risk patients.
PCv10
vENOUS THROMBOEMBOLISM IN GyNAE-ONCOLOGy PATIENTS POST SURGERy 
– IS TINzAPARIN PROPHyLAxIS AN EFFECTIvE ANTICOAGULANT?
Ibrahim N.1, Norris L.2, O’Toole S.3, Gleeson N.1
1Dept of Gynaecology-oncology, St. James’s Hospital. Dept of Obstetrics and Gynaecology, Trinity 
Centre for Health Sciences, St. James’s Hospital, Dublin, Ireland, DUBLIN4, Ireland, 2Dept of 
GynaecologDept of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s 
Hospital, Dublin, Ireland, DUBLIN8, Ireland, 3Dept of Gynaecology-oncology, St. James’s Hospital. 
Dept of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital, 
Dublin, Ireland, DUBLIN5, Ireland
Objectives: Venous thromboembolism (VTE) is a relatively common post-operative 
complication in cancer patients associated with high mortality rates. Gynae-oncology 
patients are predisposed to developing VTE due to the presence of a number of high 
risk factors. Current thromboprophylactic protocols for LMWH dosage and duration 
may be insufficient as a significant percentage of VTEs in gynae-oncology patients 
occur despite LMWH prophylaxis. The aim of this study is to investigate the antico-
agulant (anti-Xa) activity of Tinzaparin prophylaxis in the immediate post-operative 
period in gynae-oncology patients. MethOds: All patients attending St. James’s 
recommended therapeutic strategies and clinical outcomes as a function of the 
therapeutic strategies in a real world setting. MethOds: An observational retro-
spective cohort analysis based on 4 Local Health Units administrative databases 
was conducted. High CV risk patients who filled at least one prescription for high 
dosages statins between January 1, 2007-December 31, 2007 (enrolment period) 
were included. Patients were followed-up for 24 months. Patients were defined as 
adherent if they had > 80% of follow up period covered by drugs dispensation. To 
correct for potential confounders, a multivariable proportional hazards Cox regres-
sion model considering age, gender, type of statin, adherence to treatment and 
stay on treatment was assessed. Stay on treatment was defined as no switch or 
down titration during the follow up period. Results: Among 36,327 (3% of the 
population) high CV risk patients, Rosuvastatin 40mg (R40) and Atorvastatin 80mg 
(A80) were not used (0.1% each treatment); 625 (2%) patients used R20 and 908 (2%) 
A40. Stay on treatment was similar across treatments: 61% for R20 and 60% for A40 
(p= 0.583). 2.6 (1.7-3.5) CV events per 100 patients/year for R20 and 4.4 (3.4-5.4) for 
A40 were observed (p= 0.014). At the multivariable Cox regression analysis, risk of 
CV event was lower for R20, as compared to A40 (HR= 0.60, 95%CI 0.39-0.91, p= 0.017). 
Other statistically significant covariates were adherence (HR= 0.50, 95%CI 0.29-0.87, 
p= 0.015) and stay on treatment (HR= 0.58, 95%CI 0.40-0.85, p= 0.006). cOnclusiOns: 
Despite guidelines recommendations, high dosages statins are poorly used in real 
practice. Stay on treatment was similar among those treated with R20 and A40, even 
though R20 showed a lower incidence of cardiovascular events.
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MODELING THE CARDIOvASCULAR EFFECTS OF SwITCHING PATIENTS FROM 
ROSUvASTATIN TO ATORvASTATIN
Folse H.1, Schuetz C.A.1, Rengarajan B.1, Sternhufvud C.2, Gandhi S.K.3
1Archimedes, Inc., San Francisco, CA, USA, 2AstraZeneca R&D, Mölndal, Sweden, 3AstraZeneca 
Pharmaceuticals LP, Wilmington, DE, USA
Objectives: This analysis estimates the impact of switching from rosuvastatin 
to atorvastatin on cardiovascular (CV) events. MethOds: Using the Archimedes 
model, a discrete-event simulation, we evaluated a simulated population of 50,038 
patients aged 45–70 years with dyslipidemia and adherent to rosuvastatin. The 
virtual population was created based on matched biomarker profiles of patients 
in the National Health and Nutrition Examination Survey (NHANES). Statin treat-
ment models were based on data from published studies, including STELLAR, 
JUPITER, CARDS, ASCOT, and TNT. Patients were started on a rosuvastatin dose 
based on their LDL-C and ATP-III goal. Treatment prevalence was calibrated to 
match distributions of statin use observed in U.S. pharmacy claims data. In the 
experimental arm, patients switched to twice the mg atorvastatin dose as their 
rosuvastatin dose at their first follow-up visit (no switching occurred in the con-
trol arm). Patients were monitored for 5 years, during which time they received 
regular visits, with the opportunity to increase their dosage if they were above 
their LDL-C goal. Rate of first occurrence of MI, stroke, or CV death (MACE) for 
each arm was estimated. Results: After 5 years, when all patients switched to 
atorvastatin, 4.8% fewer patients reached goal, and mean LDL-C increased by 7.1 
mg/dL. The 5-year relative risk of MACE was 1.117 (95% CI 1.098–1.135), and the 
number needed to harm (NNH) to incur one additional MACE was 262, favoring 
rosuvastatin. For diabetics, the relative risk of MACE was 1.128 (95% CI 1.096–1.159), 
and the NNH to incur one additional MACE was 195, indicating greater risk for dia-
betics. The results were insensitive to assumptions of adherence rates and LDL-C 
goal values. cOnclusiOns: In this simulation, switching from rosuvastatin to 
atorvastatin led to fewer patients attaining LDL-C goal, higher mean LDL-C values, 
and greater risk of MACE over 5 years.
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RIOCIGUAT FOR THE TREATMENT OF PATIENTS wITH PULMONARy ARTERIAL 
HyPERTENSION (PAH): RESPONDER ANALySIS OF wHO FUNCTIONAL CLASS III 
PATIENTS FROM THE PATENT-1 STUDy
Grünig E.1, Sikirica M.2, Curram J.3, Davie N.4, Ghofrani H.A.5
1Centre for Pulmonary Hypertension at the Thoraxclinic of University Hospital Heidelberg, 
Heidelberg, Germany, 2Global HEOR, Bayer HealthCare Pharmaceuticals, Berlin, Germany, 
3Clinical Statistics EU, Bayer HealthCare Pharmaceuticals, Newbury, UK, 4Global Clinical 
Development, Bayer HealthCare Pharmaceuticals, Wuppertal, Germany, 5University of Giessen 
and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), 
Giessen, Germany
Objectives: Indications for PAH medications vary between countries, and prod-
ucts may have restricted reimbursement based on policies limiting treatment to 
WHO functional class (FC) III patients. In the PATENT-1 study, the novel soluble 
guanylate cyclase stimulator riociguat significantly improved 6-minute walking 
distance (6MWD) and a range of secondary endpoints in patients with PAH. This 
subgroup analysis of PATENT-1 investigated the proportion of FC III/IV patients 
achieving threshold criteria. MethOds: PATENT-1 was a double-blind, randomized 
Phase III study in which patients with PAH received 12 weeks’ oral treatment with 
placebo, an individual titration of riociguat (up to 2.5 mg tid), or a capped titration 
of riociguat (up to 1.5 mg tid). Increase in 6MWD ≥ 40 m, 6MWD ≥ 380 m, cardiac 
index (CI) ≥ 2.5 L/min/m2, pulmonary vascular resistance (PVR) < 500 dyn·s·cm−5, 
mixed venous oxygen saturation (SvO2) ≥ 65%, FC I/II, absence of clinical worsen-
ing events, and NT-proBNP < 1800 pg/mL were chosen as positive response criteria 
based on studies showing their prognostic relevance at baseline and after targeted 
therapy. Results: At baseline, 241 patients were in FC III/IV (FC IV n= 4) across 
the three treatment groups, and similar proportions met selected criteria in the 
riociguat individual titration (n= 141) and placebo groups (n= 61). At Week 12/last 
visit, the proportion of patients fulfilling these criteria was higher in the riociguat 
individual titration group than the placebo group for all parameters: increase in 
6MWD ≥ 40m (44% vs 15%), 6MWD ≥ 380m (49% vs 36%), CI ≥ 2.5 L/min/m2 (75% vs 
43%), PVR < 500 dyn·s·cm−5 (52% vs 27%), SvO2 ≥ 65% (68% vs 35%), FC I/II (33% vs 
23%), absence of clinical worsening events (99% vs 90%), and NT-proBNP < 1800 pg/
mL (84% vs 64%). cOnclusiOns: In this population of predominantly FC III PAH 
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Objectives: Management with vitamin K antagonists (VKAs) has been an effec-
tive and cost-effective strategy for stroke prevention in atrial fibrillation (AF) but 
is associated with shortcomings. Novel oral anticoagulants (NOACs) were devel-
oped with the aims of no monitoring requirement and improved effectiveness 
and safety profiles. Economic evaluations require the comparison of all relevant 
options. However, there are no randomized controlled trials (RCTs) directly compar-
ing these agents. In such cases, indirect treatment comparison (ITC) can be used to 
synthesize indirect comparative evidence. Through ITC-based evidence synthesis, 
the cost-effectiveness of all available NOACs for stroke prevention in AF patients 
may be evaluated. MethOds: ITC models were based on RCTs data comparing 
dabigratran, rivaroxaban, or apixaban with VKA treatment. Relative effectiveness 
was estimated for stroke/systemic embolism, intracranial hemorrhage, myocar-
dial infarction, extracranial hemorrhage, and minor bleeding. A Markov model was 
developed using ITC-synthesized evidence with VKA as the baseline. Health utili-
ties were collected from international sources whereas costs and mortality data 
were extracted from Dutch sources. Univariate and probabilistic sensitivity analy-
ses (PSA) were conducted on the base-case incremental cost-effectiveness ratio 
(ICER). Results: The ICERs for dabigatran, apixaban, and rivaroxaban compared to 
VKA were € 12,146/QALY, € 12,488/QALY, and € 24,124/QALY, respectively. Sensitivity 
analysis using the upper and lower limits of the 95% confidence interval for abso-
lute stroke risk with VKA treatment resulted in ICERs that varied drastically from 
dominance for VKA to being dominated by all NOACs. This is likely due to the large 
uncertainty observed between the baseline risk profiles of the VKA arms in the 
three RCTs. The options with the highest probabilities of cost-effectiveness in PSA 
were VKA at thresholds under € 13,000/QALY and dabigatran or apixaban at thresh-
olds above this mark. cOnclusiOns: Dabigatran and apixaban were shown to be 
cost-effective options for AF patients in The Netherlands. However, these results 
were strongly influenced by uncertainty around stroke risk with VKA treatment.
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ESTIMATING THE CARDIOvASCULAR BENEFITS OF DPP-4 INHIBITORS:  
A SIMULATED STUDy
Schuetz C.A.1, Ong S.H.2, Yeung T.1, Blüher M.3
1Archimedes, Inc., San Francisco, CA, USA, 2Novartis Pharma AG, Basel, Switzerland, 3University 
of Leipzig, Leipzig, Germany
Objectives: Outcomes trials are currently underway to establish the effects of 
DPP-4 inhibitors on major adverse cardiovascular events (MACE), but to-date no 
major clinical trial has published results. Using simulations, we evaluated the 
effectiveness of DPP-4 inhibitors in preventing MACE in two populations with type 
2 diabetes, relative to the standard of care. MethOds: We used the Archimedes 
ARCHeS platform to simulate two clinical trials of virtual individuals with diag-
nosed type 2 diabetes (N= 11,000 each). The DPP-4 class was modeled with a meta-
analysis of HbA1c and weight change, pooling results from published trials. The 
study treatments were added-on to standard care. The first simulated trial examined 
subjects with elevated cardiovascular (CV) risk, based on established CV disease 
or multiple risk factors. The second considered individuals on metformin mono-
therapy with HbA1c ≥ 7%. We tracked changes in biomarkers and outcomes for 
20 years. Results: The DPP-4 class was associated with HbA1c drops of 0.66% 
[0.71% , 0.62% ] in the elevated CV risk population and 0.71% [0.75%,0.67%] in the 
metformin add-on population; and a weight drop of 0.14 [0.36,-0.07] kg in both 
cohorts. The biomarker benefits produced a relative risk (RR) for MACE at 5 years 
of 0.977 [0.968, 0.986] and 0.962 [0.949, 0.975] for the elevated CV risk population 
and metformin add-on population, respectively. The number needed to treat to 
prevent one occurrence of MACE at 5 years was 327 [233,550] in the elevated CV risk 
population. cOnclusiOns: Our simulated study suggests that DPP-4 inhibitors do 
not increase the risk of MACE relative to the standard of care in a population with 
elevated CV risk, and a representative diabetic metformin monotherapy population. 
This study provides insights on the long term benefits of DPP-4 inhibitors, and will 
support interpretation of the CV safety trial results likely to be published soon.
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INDIRECT COMPARISONS OF NOvEL ORAL ANTICOAGULANTS FOR THE 
PREvENTION OF STROKE IN PATIENTS wITH NONvALvULAR ATRIAL 
FIBRILLATION: A SySTEMATIC LITERATURE REvIEw
Claflin A.B.1, Liu X.2, Phatak H.3
1Pfizer Inc, New York, NY, USA, 2Pfizer, Inc., New York, NY, USA, 3Bristol-Myers Squibb Company, 
Princeton, NJ, USA
Objectives: Given the absence of head-to-head studies, this review summarized 
indirect treatment comparison studies of oral anticoagulants (OACs) for the pre-
vention of stroke in patients with nonvalvular atrial fibrillation (NVAF). MethOds: 
Eligible English-language studies published up to May 31, 2013 were identified 
from electronic databases, Medline, EMBASE and Cochrane Library. Studies were 
included if the indirect comparison involved at least two OACs currently on the 
market with the common comparator warfarin. The search yielded ten pub-
lished studies and one in press study was obtained. Results: Eleven indirect 
comparison studies, based on data from three phase III (RE-LY, ROCKET-AF, and 
ARISTOTLE) and one phase II (PETRO) clinical trial, was reviewed. Six pairwise 
comparisons were reviewed across studies: any/all OACs vs. warfarin, apixaban 
vs. dabigatran 110mg, apixaban vs. dabigatran 150mg, apixaban vs. rivaroxaban, 
dabigatran 110mg vs. rivaroxaban, and dabigatran 110mg vs. rivaroxaban. OACs as 
a whole were found to have significantly better bleeding and efficacy endpoints 
when compared with warfarin. Apixaban and dabigatran 110mg were found to 
have significantly reduced risk of multiple bleeding endpoints when compared 
with rivaroxaban and dabigatran 150mg. Dabigatran 150mg was found to have 
significantly decreased risk of multiple efficacy endpoints when compared with 
rivaroxaban. Three studies compared discontinuation rates. Apixaban and rivar-
oxaban were found to have significantly lower discontinuation rates compared 
with both doses of dabigatran. Apixaban was also found to have a significantly 
lower discontinuation rate compared with rivaroxaban. cOnclusiOns: Apixaban, 
Hospital with suspected gynaecological malignancy and who fulfilled the inclu-
sion criteria were recruited for the study. All patients with BMI less than 35 received 
Tinzaparin (4500 IU) once daily injection while those with BMI more than 35 received a 
higher dose (7500 IU). Two days post surgery; venous blood samples were collected for 
anti-Xa analysis 4 hours post Tinzaparin injection. Results: The majority of patients 
received Tinzaparin of 4500 IU. The mean anti-Xa level in the malignant group was 
0.191 IU/ml while in the benign group the level was 0.1740 IU/ml. There was no dif-
ference between the two groups. In the malignant group, the number of cases with 
peak anti-Xa levels below 0.1IU/ml was slightly higher than in the benign group. One 
patient with malignant disease developed VTE, in the immediate postoperative period 
and showed a low peak anti-Xa level (0.06IU/ml). cOnclusiOns: The results of this 
study show that Tinzaparin prophylaxis provides adequate peak anti-Xa levels in the 
majority of gynae-oncology patients post surgery and is unlikely to be responsible 
for the high rates of VTE in cancer patients in the immediate post operative period. 
Larger studies are required to confirm this.
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IMPACT OF PILL-SPLITTING TRAINING ON DRUG PHySIOCHEMICAL 
PROPERTIES, COMPLIANCE AND CLINICAL OUTCOMES IN ELDERLy 
POPULATION: A CROSS-OvER COHORT STUDy
Lee V.W.Y.1, Yu Y.1, Tang L.1, Yan B.2
1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2The Chinese University of Hong 
Kong, Shatin, Hong Kong
Objectives: Pill splitting is a common problem in Hong Kong public hospitals for 
flexible dose adjustment and cost containment, especially for chronic diseases’ 
treatments such as hypertension, diabetes mellitus. The current study aimed 
to determine the importance of education on the proper way of pill splitting for 
elderly in Hong Kong by exploring their habits of pill splitting, evaluating their 
knowledge on pill cutting and investigating the impact of improper pill cutting 
habit. MethOds: Survey was conducted on elderly taking selected drugs require 
splitting (Metformin, Atenolol and Amlodipine) in 5 elderly centers. The survey 
focuses on habits and knowledge regarding pill cutting. Elderly subjects were asked 
to cut 3 pills that they were currently taking in their own ways. After proper educa-
tion, they were asked to cut another 3 pills with a pill cutter. The collected sample 
were then weighed and analyzed. The result was then compared with ideal value 
of half of the whole pill. Results: From the survey, 72% of the elderly have never 
received any education on pill cutting. Above half consider pill cutting troublesome. 
About half thought that all kinds of pills can be cut without affecting the expected 
effect. 80% cut pills for more than one dose each time, including 44% cut pills for 7 
days’ doses each time. From the experiment, the results of Metformin and Atenolol 
show that the cut drug samples’ weights deviate a lot from the ideal value (50% of 
the whole pill) before education. After education, the samples’ weights get closer 
to the ideal value. However, the result of Amlodipine does not show significant dif-
ference. cOnclusiOns: Education can improve the accuracy of dose in regimen 
require pill splitting. Elderly in Hong Kong do not receive enough education on the 
proper way of pill splitting from the health care giver.
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TOTAL AND LOw-DENSITy LIPOPROTEIN CHOLESTEROL LEvELS IN HIGH RISK 
PATIENTS TREATED wITH ATORvASTATIN MONOTHERAPy IN THE UNITED 
KINGDOM
Jameson K.1, D’Oca K.2, Zhao C.3, Ramey D.3, Tershakovec A.M.3, Marrett E.3
1MSD Ltd., Hoddesdon, UK, 2MSD, London, UK, 3Merck Sharp & Dohme Corp., Whitehouse Station, 
NJ, USA
Objectives: European guidelines recommend statins as first-line treatment for 
elevated cholesterol in patients at high cardiovascular (CV) risk; however, many 
patients do not attain guideline-recommended goals on statin monotherapy. As 
atorvastatin is now generically-available and its use is likely to increase, we exam-
ined recommended total cholesterol (TC) and low-density lipoprotein cholesterol 
(LDL-C) levels in high-risk patients treated with atorvastatin monotherapy in the 
UK. MethOds: In this retrospective UK general practice database study, included 
were patients with a prescription for atorvastatin monotherapy (IndexRx) between 
November 30, 2008-November 30, 30, 2011, who had evidence of coronary heart dis-
ease (CHD), atherosclerotic vascular disease (AVD), diabetes mellitus (DM), or familial 
hypercholesterolemia, ≥ 1 TC and LDL-C measurement 3-12 months post-IndexRx, 
and an atorvastatin prescription (to determine the daily dose) within 45 days of lipid 
measurements. Endpoints included proportions of patients (overall and by dose) 
below guideline-specific thresholds: TC< 5.0, TC< 4.0, and for patients with CHD/
AVD+DM, TC< 4.0 or LDL< 2.0 mmol/L. Results: Of 2999 high-risk patients (60.2% 
males, mean age 67.9 years [SD 10.6]) meeting selection criteria, 23.9, 28.2, 36.2, and 
11.6% received prescriptions for 10-mg, 20-mg, 40-mg, and 80-mg atorvastatin, respec-
tively. Further, 27.6% of patients were newly initiated with atorvastatin monotherapy 
at index date. Overall, mean follow-up TC was 4.08 (SD 0.80) and LDL-C was 2.08 (SD 
0.65) mmol/L. The proportion of patients with TC< 5.0 and < 4.0 mmol/L was 88.8% 
and 45.8%, respectively. For those with CHD/AVD+DM, 63.7% had TC< 4.0 or LDL-C< 2.0 
mmol/L. Generally, more patients were below lipid thresholds with higher atorvastatin 
doses. cOnclusiOns: In UK patients at high CV risk, a substantial proportion did 
not achieve guideline-recommended lipid levels. Less than half of patients achieved 
TC< 4.0 mmol/L, and only two-thirds of patients with CHD/AVD+DM were below rec-
ommended levels for either TC or LDL-C. More effective lipid-lowering strategies may 
be needed to achieve optimal TC and LDL-C levels in high-risk patients.
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INDIRECT TREATMENT COMPARISON AND ECONOMIC EvALUATION OF NOvEL 
ORAL ANTICOAGULANTS FOR THE PREvENTION OF STROKE IN PATIENTS wITH 
ATRIAL FIBRILLATION IN THE NETHERLANDS
Le H.H.1, Pechlivanoglou P.2, Postma M.J.1
1University of Groningen, Groningen, The Netherlands, 2University of Toronto, Toronto, ON, 
Canada
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total number of patients with stable angina who have indications for ivabradine 
was 17559 people. The number of prevented cases of non-fatal myocardial infarc-
tion and unstable angina was 244 cases per year. The number of prevented cases 
of cardiovascular death was 95 cases per year. The number of prevented cases of 
surgical revascularization was 260 cases per year. cOnclusiOns: The analysis 
allowed to identify Belarusian patients in need of ivabradine use by estimating 
the size of the target group of patients with stable angina and elevated heart 
rate for whom antianginal therapy is inadequate or impossible and who need an 
ivabradine prescription and potentially could make the most effective reaction 
to the therapy.
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EvIDENCE THRESHOLDS IN THE ABSENCE OF EFFECTIvE ALTERNATIvES: THE 
CASE OF INTERMITTENT COMPRESSION IN CRITICAL LIMB ISCHEMIA
Moran P., Teljeur C., Harrington P., Ryan M.
Health Information and Quality Authority, Dublin, Ireland
Objectives: Intermittent pneumatic compression (IPC) is proposed as an adjunct 
to medical care for people with critical limb ischemia (CLI) who are unsuitable for 
revascularisation. Given the lack of treatment options for these patients, a safe 
therapy that can be shown to provide even a modest clinical improvement may 
make a significant contribution to the management of this condition. This research 
aims to synthesise and critically appraise the evidence supporting the use of this 
technology in this cohort. MethOds: A systematic review of the clinical effective-
ness of IPC in non-reconstructable CLI was performed. Medline, Embase and trial 
registries were searched for randomised controlled trials (RCTs), non-randomised 
controlled trials (nRCTs) and controlled before-and-after (CBA) studies compar-
ing IPC plus medical care to medical care only. Results: No RCTs or nRCTs were 
identified. Two CBA studies, both with a high risk of bias, found that IPC was asso-
ciated with improved limb salvage and wound healing (OR 7, 95% CI 1.82 to 26.89, 
p< 0.05 for both outcomes) as well as improved quality of life scores in bodily pain 
(mean difference [MD] 32.7, 95% CI 29.4 to 36.0, p< 0.05) and physical functioning 
(MD 18.8, 95% CI 14.1 to 23.6, p< 0.05). Improvements were also reported for initial 
and absolute claudication distances (MD 26.9m, 95% CI 21.7 to 32.1, p< 0.05; MD 
52.9m, 95% CI 42.2 to 63.6, p< 0.05, respectively). No serious adverse events were 
reported. cOnclusiOns: Despite some promising results there is a lack of high-
quality evidence demonstrating the effectiveness of IPC in addition to medical 
management in non-reconstructable CLI. Where findings are equivocal a question 
arises as to the minimum level of evidence required to support the introduction of 
a technology when no effective alternatives exist. Competing interpretations of the 
balance of risks and benefits between different stakeholders in the decision-making 
process in these circumstances are discussed.
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EFFECTS OF ExCESS USE OF CORONARy ANGIOGRAPHy AND ITS ASSOCIATION 
wITH MORTALITy RATES, HEALTH CARE COSTS AND HOSPITAL QUALITy IN 
TURKEy
Baser O.1, Burkan A.2, Baser E.3, Koselerli R.2, Ertugay E.2, Altinbas A.4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Social Security 
Institution, Ankara, Turkey, 3STATinMED Research, Ankara, Turkey, 4Diskapi Yildirim Beyazi 
Education and Research Hospital, Gastroenterology Clinic, and STATinMED Research, Ankara, 
Turkey
Objectives: To evaluate excess use of coronary angiography prior to coronary 
artery bypass graft (CABG) surgery and its association with mortality, health care 
costs and hospital quality in Turkey. MethOds: MEDULA, a nationwide integrated 
system shared between general health insurance and health care providers in 
Turkey was used to analyze coronary angiography utilization. Patients age 18–99 
years who underwent CABG surgery between April 1, 2009 and October 1, 2010 were 
identified and assigned to “standard-therapy” or “excess-use” groups based on 
whether they had one or more coronary angiography, respectively, within 3 months 
of the first CABG diagnosis date (index date) during the identification period. 
Survival rates and annual health care costs of patients in the coronary angiog-
raphy standard-therapy and excess-use groups were compared using propensity 
score matching. The empirical Bayes approach was used to combine mortality 
and hospital volume for quality index. Chi-squared tests were used to assess the 
relationship between hospital quality and excess use of coronary angiography 
excess use. Results: From a total of 20,126 identified patients, 7.27% underwent 
excessive coronary angiography procedures, at average annual costs that were 
9.7% higher than patients with a single angiography (p< 0.01). Operational mortal-
ity associated with excessive use was significantly higher as well (7.4% vs. 5.4%, 
p< 0.02). Use of coronary angiography across cities and hospitals varied. Patients 
who underwent cardiac surgery in high-quality hospitals were less likely to have 
excessive angiography use than those in low-quality hospitals (7.0% vs. 9.5%, 
p< 0.01). cOnclusiOns: In Turkey, excess use of coronary angiography prior to 
CABG surgery is associated with higher operational mortality, higher expenditures 
and lower hospital quality.
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ANTICOAGULANT USE IN HOSPITALIzED PATIENTS wITH ACUTE vENOUS 
THROMBOEMBOLISM IN THE UNITED STATES
Liu X.1, Xie L.2, Phatak H.3, Mardekian J.1, Tan W.1, Baser O.4, Schneider R.F.1, Ramacciotti E.3
1Pfizer, Inc., New York, NY, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3Bristol-Myers 
Squibb Company, Princeton, NJ, USA, 4STATinMED Research/The University of Michigan, Ann 
Arbor, MI, USA
Objectives: To examined anticoagulant use and associated factors in hospitalized 
patients with acute venous thromboembolism (VTE) in the US clinical practice set-
ting. MethOds: Adult VTE patients were selected from the linked MarketScan and 
Hospital Drug database in an inpatient setting between 07/01/2006-12/31/2011. The 
first hospitalization with a diagnosis of VTE was designated index hospitalization 
(IH). Patients were required to have at least 6 months continuous enrollment and 
dabigatran and rivaroxaban appear to have better safety and efficacy profiles when 
compared with warfarin. Apixaban and dabigatran 110mg consistently demon-
strated reduced risk of bleeding when compared with rivaroxaban and dabigatran 
150mg. Dabigatran150mg demonstrated increased efficacy on multiple endpoints 
when compared with rivaroxaban, while discontinuation rates were increased. 
Head-to-head studies would help clarify any differences among these medicines 
for efficacy and bleeding.
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META-ANALySIS OF SAFETy OF DABIGATRAN AND wARFARIN FOR TREATMENT 
OF ATRIAL FIBRILLATION
Aggarwal S., Segal J.
Novel Health Strategies, Bethesda, MD, USA
Objectives: Atrial fibrillation (AF) is an irregular and often rapid heart rate that 
commonly causes poor blood flow to the body. Dabigatran and Warfarin have 
shown safety and efficacy for treatment of AF. The objective of this study was 
to conduct meta-analysis and present evidence for safety of Dabigatran versus 
Warfarin for treatment of AF. MethOds: For this meta-analysis we included 
randomized controlled trials (RCTs) evaluating Dabigatran for the treatment of 
AF. We included studies that were: (1) a RCT in humans; (2) an investigation of 
patients with nonvalvular atrial fibrillation; (3) an evaluation of dabigatran com-
pared with warfarin or each other; and (4) a report of results of stroke or systemic 
emboli and major bleeding. A systematic literature search for dabigatran trials 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and 
Cochrane. Data was collected for the study size, interventions, year and total 
bleeding events. For meta-analysis, random effects and fixed effects models were 
used to obtain cumulative statistics. Results: Two RCTs with a total of 12,268 
patients were identified. The pooled event rate for Dabigatran for total bleeding 
events was 31.9% (95% CI 31%-33%). The pooled response rate for Warfarin for 
total bleeding events was 35.1% (95% CI 34%-37%). The cumulative relative risk 
for total bleeding events with Dabigatran versus Warfarin was 0.91 (95% CI 0.89-
0.93) cOnclusiOns: Meta-analysis shows Dabigatran has a slightly lower rate 
of total bleeding events compared to Warfarin.
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EFFECT OF IvABRADINE ON THAI CHRONIC STABLE ANGINA PECTORIS 
PATIENTS
Rojkajornnaphalai S.
Chest Hospital, Nonthaburi, Thailand
Objectives: To evaluate efficacy/safety of ivabradine in chronic stable angina 
pectoris(CSAP) Thai patients. MethOds: Ivabradine 5-7.5 mg bid was prescribed 
to CSAP patients. Hemodynamic parameters including systolic/diastolic blood 
pressure(SBP/DBP) in mmHg and heart rate(HR) in beats per minute(bpm) were 
recorded at entry and after 1,4 months follow-up. A standardized digital device 
was used to monitor BP and HR. Acceptability was evaluated in patient inter-
views. Results: A total of 256 patients, men/women ratio of 1.04, mean(SD) age 
67.1(12.4) years, 149(58%) were > 65 years old, 64(25%) and 76(29.7%) of patients 
had previous intervention and heart failure(HF). 127(50%)&51(20%) received beta-
blockers&nitrate as initial medication. Patients’ assessment was made using 
Canadian Cardiology Society angina pectoris classification(CCS). At entry, 34.9%, 
52.2% and 10.8% of patients were found with CCS grades 3, 2 and 1. Among 76 HF 
patients, 35.8%, 58.2% and 6.0% were found with stage 3, 2 and 1 of NYHA classifica-
tion. In overall population, mean(SD) baseline HR was 86.9(11.2) bpm and SBP/DBP 
137.8(24.6)/81.7(15.9) mmHg. After 4 months, mean(SD), HR significantly reduced to 
69.96(7.13)bpm (p< 0.001) and SBP/DBP lowered to 126.5(12.9)/73.9(8.9) mmHg, while 
mean arterial pressure(MAP)was optimally maintained at 100.4(17.6) mmHg. The 
highly significant drop in mean difference(SE) HR of 16.9(0.7) was observed with 
95% CI between 15.5-18.3 bpm. No significant mean difference(SE),[95% CI] SBP 
drop, between patients with/without HF, and with/without previous intervention 
of 7.32(1.17),[4.99-9.64] and 8.15(2.07),[4.02-12.2764], or 8.14(1.27),[5.61-10.67] and 
7.46(0.89),[5.69-9.22] (p= 0.502, p= 0.691) respectively. Improvement for CCS 3 and 
CCS 2 angina class, reduced to 1.9% and 36.1% whereas the NYHA classification 
for stage 3&2 reduced to 3.2%&56.4%(p< 0.001). Common AE reported were palpita-
tion(2.5%) and nausea(1%). cOnclusiOns: Ivabradine is a well-tolerated heart rate 
reducing agent, effective for both chronic stable angina pectoris and heart failure. 
It effectively reduces elevated heart rate without affecting other hemodynamic 
parameters. In this Thai setting, ivabradine significantly improves CCS and NYHA 
classifications with minimal side effects being reported.
PCv19
EvALUATION OF THE POTENTIAL EFFICACy OF IvABRADINE IN HEALTH CARE 
OF THE REPUBLIC OF BELARUS
Kozhanova I.1, Romanova I.1, Gavrilenko L.1, Sachek M.2
1Belarusian State Medical University, Minsk, Belarus, 2The Belarusian Center for Medical 
Technologies, Computer Systems, Administration and Management of Health, Minsk, Belarus
Objectives: To determine the potential population of patients with stable angina 
pectoris in Belarus who need prescription of ivabradine and setting the amount of 
the effect of the drug in this group of patients. MethOds: In the research phar-
macoeconomic Markov model of ivabradine application in patients with stable 
angina, national surveillance data, analysis of literature have been used. Patients 
with stable angina after revascularization, patients with contraindications to 
beta-blocker use, not applying the dihydropyridines and having a contraindica-
tion to ivabradine use have been used to determine the target population. The 
number of prevented or postponed events – PPE - (nonfatal myocardial infarction 
and unstable angina, cardiovascular death, the number of surgical revasculariza-
tion) has been calculated. For the potential efficacy of ivabradine use in patients 
with stable angina and heart rate ≥ 70 bpm calculating the data about efficacy in 
accordance with the results of the Beautiful study were used Results: The total 
number of patients with stable angina pectoris in Belarus in 2011 was 242943. The 
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ANTICOAGULATION TREATMENT wITH vKA IN FRANCE, ITALy, GERMANy, 
SPAIN AND UNITED KINGDOM. RESULTS FROM THE REACT AF STUDy
Carrasco J.1, Cotté F.E.2, Duprat Lomon I.3, Letierce A.4, Huguet M.5, Marchant N.6
1Bristol-Myers Squibb Company, Paço de Arcos, Portugal, 2Bristol-Myers Squibb, Paris, France, 
3Bristol-Myers Squibb, Rueil-Malmaison, France, 4Cegedim strategic Data, Boulogne-Billancourt, 
France, 5Cegedim Strategic Data, Boulogne-Billancourt, France, 6Pfizer Ltd., Surrey, UK
Objectives: This study investigated the outcomes and management associated 
with stroke prevention treatments in patients with non-valvular atrial fibrilla-
tion (NVAF) in Europe. The primary objective of this analysis was to assess the 
management of patients treated with vitamin K antagonists (VKA). MethOds: 
We conducted an observational retrospective cohort study of patients with NVAF 
in the Longitudinal Patient Database (CEGEDIM) in France, Italy, the UK, Spain and 
Germany. The analysis included patients > = 18 years old with recorded AF diag-
nosis, treated with VKA, and without rheumatic valvular disease or prosthetic 
valves prior to the index date (date of 1stvisit during inclusion period – May 2010 
- April 2012 - , or date for first AF diagnosis, if this falls during this period. Only 
patients with > = 1 year of data were included to ensure adequate data avail-
ability. Using recorded INR measures, we estimated the average time within 
therapeutic range (TTR), INR between 2 and 3 for patients eligible to apply the 
Rosendaal Method. Results: In France 1,110 patients were assessed, in Germany 
1,208, in Italy 1,230, & the UK 2,702. Insufficient data were retrieved in Spain 
(n= 12). INR was measured 9.6 times/year in France, 9.5 times/year in Germany, 
9.8times/year in Italy, and 13.1 times/year in the UK. In France, 48% of the patients 
had TTR > = 70% of their time; in Germany, 44%; in Italy, 46%, and in the UK, 
65%. cOnclusiOns: Treatment outcomes with VKAs, in particular stroke and 
bleeding, depend on maintaining patients’ INR values within recommended 
range. The results show that the majority of patients in France, Germany and 
Italy, & 1/3 of patients in UK did not achieve recommended TTR and therefore 
were at increased risk of stroke or major bleeding. Further research is needed 
to demonstrate the correlation between these estimates and stroke and major 
bleeding rates within countries.
PCv26
PHARMACOEPIDEMIOLOGICAL STUDy OF HMG COA REDUCTASE INHIBITOR 
PRESCRIBING: IMPACT OF GENERIC PRESCRIBING ON COST
Truter I.
Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
Objectives: To investigate the prescribing of hypolipidaemic agents with specific 
emphasis on the effect of generic prescribing on HMG-CoA reductase inhibitor (statin) 
costs. MethOds: A retrospective, cross-sectional pharmacoepidemiological study 
was conducted on 2011 medical insurance claims data in South Africa. Results: A 
total of 4805 patients (56.88% males) were prescribed 38373 hypolipidaemic agents. 
The average age of patients was 56.07 (SD= 13.32) years. Statins accounted for 93.85% 
of all prescriptions and 83.44% of cost, followed by fibrates (3.61% of prescribing fre-
quency and 7.72% of cost). Simvastatin was the most frequently prescribed statin 
(accounting for 62.59% of all prescriptions), followed by atorvastatin (17.04%) and 
rosuvastatin (11.68%). Simvastatin was also the active ingredient with the lowest aver-
age cost per product of R46.43. Simvastatin was prescribed under 16, atorvastatin six 
and pravastatin four different trade names. Fluvastatin, lovastatin and rosuvastatin 
only had one trade name under which they were prescribed. Only one cholesterol 
absorption inhibitor drug was prescribed (ezetimibe) accounting for 1.64% of prescrip-
tions. This product had the highest average cost per prescription of R416.37. Other 
hypolipidaemic agents prescribed accounted for only 0.89% and consisted of the com-
bination of ezetimibe and simvastatin, and cholestyramine. The fibrates constituted 
3.61% of prescribing, with most prescriptions for bezafibrate. Dosages for the statins 
were investigated and it was found that the average Prescribed Daily Doses (PDDs) 
were generally lower or in agreement with the Defined Daily Doses (DDDs). The aver-
age PDD of simvastatin was 23.70 (DDD= 30 mg), pravastatin 25.35 mg (DDD= 30 mg), 
lovastatin 26.31 mg (DDD= 45 mg), atorvastatin 20.91 (DDD= 20 mg) and fluvastatin 
57.29 mg (DDD= 60 mg). cOnclusiOns: There are a variety of generic equivalents 
available for the statins on the South African market. It was clear that products with 
more generic equivalents had a lower average cost per prescription compared to the 
innovator products.
PCv27
USE OF CALCIUM CHANNEL BLOCKERS IN SERBIA IN THE PERIOD FROM 2007 TO 
2011 yEAR
Milijasevic D., Milijasevic B., Tomic N., Sabo A., Raskovic A., Horvat O.
Faculty of Medicine, University of Novi Sad, Serbia, Novi Sad, Serbia and Montenegro
Objectives: Calcium channel blockers are drugs of first choice in the treatment 
of hypertension. The aim of this study was to analyze the consumption of calcium 
channel blockers in Serbia in the period from 2007 to 2011 year. MethOds: The data 
about the use of drugs were taken from the Agency for Drugs and Medical Devices 
of the Serbia. Results: The most frequently used drug from this group with mainly 
vascular effects was amlodipine. During this observed five years the consumption 
of amlodipine is in steadily increased. In 2007. it was 21.25DDD/1000 inh/day, at the 
end of 2011. year the consumption was 72.97DDD/1000 inh/day. On the second place 
in drug consumption in the same group of drugs was nifedipine. Contrary to amlodi-
pine, nifedipine recorded a decline in consumption. From the calcium channel 
blockers with direct cardiac effects the most frequently used drugs were verapamil 
and diltiazem. The consumption of verapamil in the observed years was uneven. At 
the and of 2011. consumption of this drug was reduced by 50%. The consumption 
of diltiazem in observed five years is in constantly decreasing. cOnclusiOns: In 
Serbia, in the observed period the consumption of calcium channel blockers been 
uneven. In 2010 and 2011 the consumption of calcium channel blockers marks a 
positive trend. This research was supported by Provincial Secretariat for Science 
and Technological Development, Autonomous Province of Vojvodina project No 
114-451-2458/2011 and by Ministry of Science, Republic of Serbia, project no 41012.
have no VTE diagnosis in the 6 months prior to IH. Parenteral and oral anticoagu-
lants used during IH were identified. Multivariate logistic regression was used to 
examine factors associated with anticoagulant use. Results: A total of 957 VTE 
patients were eligible for the study. Mean age was 62.8 years, and 45.1% were male. 
Mean length of stay was 8.7 days. During index hospitalization, 45.4% patients 
were treated with parenteral anticoagulants (PA) and warfarin, 24.6% with warfa-
rin only, and 13.6% with PA only. Among patients treated with PA, low molecular 
weight heparin accounted for 93.4%. Chemotherapy (OR= 2.24), respiratory disease 
(OR= 1.44), and pulmonary embolism (PE) vs deep vein thrombosis (DVT) (OR= 1.42) 
were significantly associated with PA use, while prior stroke (OR= 0.43) and renal 
disease (OR= 0.58) were associated with less likelihood of PA use. DVT plus PE 
vs DVT (OR= 3.87), obesity (OR= 2.57), chemotherapy (OR= 2.23), and PE vs DVT 
(OR= 2.19) were significantly associated with warfarin use, while bleeding history 
(OR= 0.41), diabetes (OR= 0.64), and heart disease (OR= 0.67) were associated with 
less likelihood of warfarin use. cOnclusiOns: Less than half of VTE patients dur-
ing hospitalization were prescribed PA and warfarin, 25% warfarin only, and 14% 
PA only. Clinical factors including VTE type, stroke and bleeding history, comorbid 
respiratory disease, diabetes, heart disease, obesity, and chemotherapy were asso-
ciated with anticoagulant use. Further research needs to examine characteristics 
and health outcomes of patients who did not receive parenteral anticoagulants 
during hospitalization.
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THE USE OF ORAL ANTICOAGULATION DRUGS FOR STROKE PREvENTION IN 
NONvALvULAR ATRIAL FIBRILATION IN FRANCE, ITALy, GERMANy, SPAIN AND 
THE UNITED KINGDOM: IS CURRENT PRACTICE CONSISTENT wITH THE 2012 
ESC RECOMMENDATIONS?
Carrasco J.1, Cotté F.E.2, Duprat Lomon I.3, Marchant N.4, Letierce A.5, Huguet M.6
1Bristol-Myers Squibb Company, Paço de Arcos, Portugal, 2Bristol-Myers Squibb, Rueil-Malmaison, 
France, 3Bristol-Myers Squibb, Rueil-Malmaison, France, 4Pfizer Ltd., Surrey, UK, 5Cegedim 
strategic Data, Boulogne-Billancourt, France, 6Cegedim Strategic Data, Boulogne-Billancourt, 
France
Objectives: The REACT AF study investigated the outcomes and management 
associated with stroke prevention treatments in patients with non-valvular atrial 
fibrillation (NVAF) in Europe. This analysis assessed 1) the use of oral anticoagulation 
drugs (OACs) and 2) whether current practice is consistent with the 2012 European 
Society of Cardiology (ESC) recommendations. MethOds: We conducted an obser-
vational retrospective cohort study of patients with NVAF in the Longitudinal Patient 
Database (CEGEDIM) in France, Italy, UK, Spain and Germany. The analysis included 
patients > = 18 years old, with AF diagnosis, and without rheumatic valvular disease 
or prosthetic valves. Patients had to be in the database for ≥ 1 year before date of 1st 
visit (index date) during the inclusion period (May 2010-April 2012). We calculated 
patients’ CHA2DS2-VASc score at index date for untreated patients and at the time of 
the current OAC initiation for treated patients. We evaluated patients’ requirement 
for stroke prevention therapy based on the 2012 ESC recommendations and calcu-
lated the percentage of patients for whom treatment initiation and OAC use were 
consistent with recommendations. Results: In France 53% of the OAC patients 
(total= 16,329) were treated consistently with the 2012 ESC recommendations (treat-
ment requirement and choice of OAC); 46% in Germany (total= 13,468), 58% in Spain 
(total= 12,357); 39% in Italy (total= 22,447); and 36% in the UK (total= 19,956). The per-
centage of patients (CHA2DS2-Vasc> 1, if not alone due to female gender) not receiv-
ing the required treatment (either not treated or treated with a non-recommended 
OAC) was 36% in France; 48% in Germany; 34% in Spain; 52% in Italy; and 48% in 
the UK. cOnclusiOns: The study findings indicate there is a discrepancy between 
current practice regarding OAC prescribing and the 2012 ESC recommendations. 
Special attention must be given to time of treatment initiation and choice of OAC 
to correctly follow ESC recommendations.
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ADHERENCE TO TREATMENT AND PERSISTENCy IN PATIENTS TREATED wITH 
vKA IN FRANCE, ITALy, GERMANy, SPAIN AND THE UNITED KINGDOM
Carrasco J.1, Cotté F.E.2, Duprat Lomon I.3, Letierce A.4, Huguet M.5, Marchant N.6
1Bristol-Myers Squibb Company, Paço de Arcos, Portugal, 2Bristol-Myers Squibb, Paris, France, 
3Bristol-Myers Squibb, Rueil-Malmaison, France, 4Cegedim strategic Data, Boulogne-Billancourt, 
France, 5Cegedim Strategic Data, Boulogne-Billancourt, France, 6Pfizer Ltd., Surrey, UK
Objectives: This study investigated the outcomes and management associated 
with stroke prevention treatments in patients with non-valvular atrial fibrillation 
(NVAF) in Europe. This analysis estimated persistence and adherence to treatment 
with VKA. MethOds: We conducted an observational retrospective cohort study 
of patients with NVAF in the Longitudinal Patient Database (CEGEDIM) in France, Italy, 
the UK, Spain and Germany. The analysis included patients > = 18 years old, with 
AF diagnosis, treated with VKA and without rheumatic valvular disease or pros-
thetic valves. Patients had to be in the database for > = 1 year before date of 1stvisit 
during inclusion period (May 2010/April 2012). We estimated persistence (time to 
VKA discontinuation) as the time from first prescription to last prescription before 
discontinuation, defining discontinuation as switch or absence of renewal within 
3 months, using the Kaplan-Meier method. We measured adherence to treatment 
by the Medication Possession Ratio (MPR) during the inclusion period. Results: 
Median time to treatment discontinuation was 0.78 year in Germany (n= 6,386), 1.00 
year in Italy (n= 8,774), 1.34 years in France (n= 9,184), 1.99 years in Spain (n= 7,526), 
and 1.92 years in the UK (n= 7,731). Persistence at 5 years was 12% in Germany, 20% 
in Italy, 24% in France, 26% in Spain, and 25% in the UK. Concerning adherence the 
mean MPR was 0.54 in Spain, 0.56 in Italy, 0.57 in France, and 0.59 in Germany. There 
was insufficient data to estimate adherence in the UK. cOnclusiOns: MPR > = 0.80 
is used to define good adherence. The results show adherence to treatment with 
VKA is low in the countries studied. Results were consistent across countries, which 
suggest that low adherence is not country specific. Low adherence to treatment with 
VKA can affect the maintenance of patients within recommended range of INR, and 
therefore may increase the risk of stroke.
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Objectives: To describe current real-world data on in-hospital/long-term mor-
tality and morbidity outcomes in patients in the western world with acute coro-
nary syndromes (ACS). MethOds: We conducted a review of publications from 
international registries: GRACE (Global Registry of Acute Coronary Events) and 
GRACE expanded (both worldwide); GRACE UK-Belgium; and EuroHeart survey II/III 
(Europe/Mediterranean basin). The most recent data on in-hospital/long-term out-
comes were stratified by ACS type: ST-elevation myocardial infarction (STEMI) and 
non-ST elevation Acute Coronary Syndromes (NSTE ACS), which includes unstable 
angina (UA) and the non-ST elevation myocardial infarction (NSTEMI). Results: 
In-hospital mortality rates were 4.6–7.8% in STEMI patients, 2.2–5.9% in NSTEMI 
patients, and 0.8–2.7% in UA patients. At 6 months post-discharge, mortality rates 
were 4.5–4.8% in STEMI patients, 6.2% in NSTEMI patients, and 3.6% in patients 
with UA. These rates increased to 19%, 22%, and 18% in STEMI, NSTEMI, and UA, 
respectively, at 5 years post-discharge. The most common morbidities were in-hos-
pital congestive heart failure (STEMI, 11–15%; NSTEMI, 6.1–10%; and UA, 6%) and 
in-hospital myocardial (re)infarction (STEMI, 2–2.8%; and NSTE-ACS, 1.7–2.4%). Six 
months post-discharge myocardial (re)infarction rates were 2% in STEMI patients 
and 2.9% in NSTE-ACS patients, which are lower than previously reported in clini-
cal trials. cOnclusiOns: Despite current treatments, a substantial proportion 
of patients with ACS still suffer death and serious morbidities in the acute phase 
of the disease and longer term. Further research is needed to improve acute and 
long-term therapies.
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INTERRUPTION/BRIDGING OF vKA TREATMENT OF PATIENTS wITH ATRIAL 
FIBRILLATION: ANALySIS OF INCIDENCE AND CLINICAL OUTCOMES BASED ON 
A GERMAN CLAIMS BASED DATA SET
Wilke T.1, Groth A.2, Müller S.2, Hastedt C.3, Fuchs A.4, Maywald U.4
1IPAM - Institut für Pharmakooekonomie und Arzneimittellogistik, Wismar, Germany, 2IPAM 
Wismar, Wismar, Germany, 3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, 
Germany, 4AOK Plus, Dresden, Germany
Objectives: For patients with atrial fibrillation (AF) undergoing a surgery, guidelines 
recommend the interruption of VKA-treatment combined with LMWH/UFH bridging. 
As a result, patients may be placed at higher risk for thromboembolic events during 
this time. This study investigates the incidence of such perioperative management 
situations and describes clinical event rates. MethOds: Claims data from a large 
German statutory health insurance (period 01/01/2007-31/12/2011) was analysed. 
AF-patients who started VKA-treatment within this period and continued ther-apy 
until 31/12/2011 were included. VKA-interruption/bridging was assumed when the 
patient was admitted to a hospital due to an inpatient surgical procedure (case 1) or 
the patient experienced an outpatient surgery, combined with an outpatient pre-
scription of a LMWH/UFH within 10 days after surgery (case 2). Clinical events of 
interest were cardiovascular (strokes, TIA, embolism, myocardial infarctions) and 
bleedings leading to inpatient hospitalization. Daily event rates during regular VKA 
usage days were compared to those 5 days before/30 days after surgery (“interruption/
bridging days”). Results: 41,170 patients were included (mean age 74.8 years; 50.8% 
male; average CHA2DS2-VASc score 5.2). 11,695 (28.4%) VKA-patients experienced 
a hospital admission due to a surgery (case 1). 464 patients (1.1%) experienced an 
outpatient surgery with outpatient LMWH prescription (case 2). Overall (both cases) 
potential interruption/bridging occurred 0.24 times per person-year. The daily car-
diovascular/bleeding event risk during potential VKA-interruption/bridging was 
about 10fold/25fold higher than during a regular VKA-usage day (0.08%/0.21% vs. 
0.0078%/0.0083%, vs. (p< 0.0001)). About half of the bleedings were coded by treat-
ing physicians as due to anticoagulation therapy. cOnclusiOns: Periods in which 
VKA-interruption/bridging due to surgery was required frequently occur during 
the VKA-treatment of AF patients. The cardiovascular/bleeding event risk of VKA-
patients is significantly higher during such periods compared to periods of regular 
VKA-treatment. Whether this is due to VKA-interruption/bridging or the surgical 
procedures themselves needs to be analysed in future.
PCv33
USING A CAUSE-OF-DEATH-BASED MORTALITy MODEL TO IDENTIFy THE 
INDIvIDUALS wHO wOULD BENEFIT MOST FROM PRIMARy PREvENTION wITH 
STATINS
Martin C.1, Pichardo-Almarza C.2
1Crystallise Limited, London, UK, 2InScilico Ltd., London, UK
Objectives: To explore the use of a cause-of-death-based mortality model to 
identify those individuals most likely to benefit from taking statins for primary 
prevention of cardiovascular disease (CVD). MethOds: A cause-of-death-based, 
deterministic Markov model of all-cause mortality was developed. The baseline 
population average mortality rates for CVD, COPD, other respiratory disease, and 
cancer were adjusted by referencing individual risk factor values to population 
averages. Risk factors that were used as model inputs included cigarette consump-
tion per day (CPD), systolic blood pressure (SBP), body mass index (BMI), total 
cholesterol (TC), and high density lipoprotein (HDL). A total of 11,520 scenarios 
were modelled encompassing all combinations of high and low values for these 
risk factors, in men and women, and younger (35 years) and older (65 years) age 
categories. Results: Using an arbitrary threshold for a meaningful clinical ben-
efit of 6 months’ increased life expectancy per 10 years of treatment, individuals 
who are on the cusp of benefiting from statin therapy include: men aged 35 with 
SBP of 150 mmHg, BMI of 20 kg/m2, smoking 15 cigarettes per day, with a TC:HDL 
ratio of 3.5; men aged 70 with SBP of 140 mmHg, BMI of 20 kg/m2, smoking 10 
cigarettes per day, with a TC:HDL ratio of 2.8; women aged 35 with SBP of 135 
mmHg, BMI of 20 kg/m2, smoking 15 cigarettes per day, with a TC:HDL ratio of 4.2 
or higher; and women aged 65 with SBP of 140 mmHg, BMI of 30 kg/m2, who are 
non-smokers, with a TC:HDL ratio of 4.2. cOnclusiOns: The model facilitates 
decision-making about when to start preventive treatment and highlights that 
this is a multi-dimensional problem that renders rules-of-thumb inadequate in 
determining who most benefits from therapy.
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USE OF DIURETICS IN SERBIA IN THE PERIOD FROM 2007 TO 2011 yEAR
Tomic Z., Sabo A., Mikov M., Milijasevic D., Vukmirovic S., Milijasevic B.
Faculty of Medicine, University of Novi Sad, Serbia, Novi Sad, Serbia and Montenegro
Objectives: Diuretics are drugs of first choice in the treatment of hypertension. The 
aim of this study was to analyze the consumption of diuretics in Serbia in the period 
from 2007 to 2011 year. MethOds: The data about the use of drugs were taken 
from the Agency for Drugs and Medical Devices of the Serbia. Results: The use of 
diuretics during the observed period in Serbia is quite small and it ranged from 5 to 
6% of the total consumption of all drugs from the C group. Furosemide was the most 
frequently used diuretic. In the five year period furosemide consumption ranged 
from 33-55% of the total consumption of all diuretics. The second largest consupm-
tion during first four years of the study is belonged to the indapamide. Indapamide 
consumption in the fifth year was at the fourth position. At the third position in drug 
consumption in the first four years was hydrochlorothiazide. Use of hydrochloro-
thiazide in 2011 took second place. Spironolactone has occupied the fourth position 
in the first four years. During the last years of the period spironolactone occupied 
the third position. Consumption of all other diuretics was small. cOnclusiOns: 
In Serbia, in the observed period, consumption of diuterics is two to three times 
lower in comparison with the consumption of diuretics in Norway and Finland. 
This research was supported by Provincial Secretariat for Science and Technological 
Development, Autonomous Province of Vojvodina project No 114-451-2458/2011 and 
by Ministry of Science, Republic of Serbia, project no 41012.
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USE OF BETA BLOCKING AGENTS IN SERBIA IN THE PERIOD FROM 2007 TO 2011 
yEAR
Milijasevic B., Tomic N., Milijasevic D., Sabo A., Stilinovic N., Mikov M.
Faculty of Medicine, University of Novi Sad, Serbia, Novi Sad, Serbia and Montenegro
Objectives: Beta blocking agents are drugs of first choice in the treatment of 
hypertension. The aim of this study was to analyze the consumption of beta block-
ing agents in Serbia in the period from 2007 to 2011 year. MethOds: The data about 
the use of drugs were taken from the Agency for Drugs and Medical Devices of the 
Serbia. Results: During the observed period in Serbia the consumption of selective 
beta blocking agents were dominant. The most frequently used drug from this group 
was metoprolol. During this five years the consumption of metoprolol is in steadily 
decreased. In 2007. it was 37.73 DDD/1000 inh/day, at the end of 2011. year the con-
sumption was 22.13 DDD/1000 inh/day. On the second place in drug consumption in 
the same group of drugs was atenolol. Atenolol also recorded a decline in consump-
tion. On the third place in drug consumption was bisoprolol. At the beginning of 2007. 
consumption of this drug was very small, gradually grew and reached its maximum 
in 2011. From the unselective beta blocking agents the most frequently used was pro-
pranolol and his consumption in the observed years was constant. cOnclusiOns: 
In Serbia, in the observed period the consumption of beta blocking agents been 
mostly constant. From all drugs in C07 group the most frequently used group of 
drugs was C07AB. This research was supported by Provincial Secretariat for Science 
and Technological Development, Autonomous Province of Vojvodina project No 114-
451-2458/2011 and by Ministry of Science, Republic of Serbia, project no 41012.
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IN PREGNANT wOMEN: A SySTEMATIC REvIEw
Kourlaba G.1, Milonas C.2, Kontodimas S.3, Holm M.V.4, Maniadakis N.5
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Objectives: To systematically review the humanistic and economic burden of 
pregnancy-related venous thromboembolism (VTE). MethOds: Pubmed, Cochrane 
Central Register of Controlled Trials, Econlit, Science Direct, JSTOR, Oxford Journals 
and Cambridge Journals were searched using combinations of a considerable number 
of relevant words. Humanistic studies published from January 2000 to December 2012 
were eligible for inclusion in the review. The reference lists of all relevant papers 
retrieved from the original search were manually screened to identify additional 
studies. The identified studies were independently reviewed by two reviewers against 
pre-determined criteria. A quality assessment of the selected studies was also con-
ducted by using standard methods. The data of selected studies were extracted onto 
a data extraction form and consequently synthesized. Results: Twenty studies were 
included in our review. The overall pregnancy-related VTE incidence rate per 1,000 
deliveries ranged between 1 and 1.72. This rate was higher in the postpartum period 
compared to the antenatal period. Events were spread across the 3 trimesters, with 
the majority of events occurring in the third trimester of pregnancy. Limited data is 
available on mortality due to pregnancy-related VTE, with one study reporting an over-
all mortality rate of 1.1/100,000 deliveries due to pregnancy-related VTE. Recurrence 
rate was found to be higher in the postpartum period compared to the pregnancy 
period. Poorer quality of life (QoL) was identified in women with pregnancy-related 
VTE in comparison to their counterparts with no VTE. Data regarding the economic 
burden of VTE in this specific population was lacking. cOnclusiOns: The present 
systematic review showed that women are under a substantially increased risk of 
VTE events during pregnancy and VTE strongly affect their QoL. Despite the expected 
economic burden imposed by the pregnancy-related VTEs, no relevant studies were 
found. Therefore, further research is required to evaluate the humanistic and eco-
nomic burden of VTE in pregnant women.
PCv31
IN-HOSPITAL AND LONG-TERM MORTALITy AND MORBIDITy BURDENS IN 
PATIENTS wITH ACUTE CORONARy SyNDROMES
Zeymer U.1, Domenger C.2, Zakouri B.3
1Institut für Herzinfarktforschung, Ludwigshafen, Germany, 2Sanofi, Paris, France, 3Sanofi 
Research and Development, Chilly-Mazarin, France
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were women. The control group was selected to show an optimal comparability in 
terms of demographic and morbidity measures between the two groups. The inter-
vention group showed better compliance (87.9% vs. 71.4%, p= 0.001). BP control was 
52.5 vs. 53.1% (p= NS) initially and 63.2% vs. 55.6% at the end of the study (p< 0.001) 
for the intervention group vs. control, respectively. The follow-up average cost per 
patient and year was € 377.9 vs. € 442.4, p< 0.001 (reduction in intervention group: 
66 € ). 82% of health care professionals and 91% of patients were satisfied with 
the DMP. cOnclusiOns: The DMP has improved adherence to treatment and BP 
control and has reduced health care management costs. If the study results were 
extrapolated to the overall population of Badalona, a potential saving of 1.7 million 
per year would be achieved.
PCv37
BUDGET IMPACT ANALySIS OF APIxABAN FOR THE PREvENTION OF vENOUS 
THROMBO-EMBOLISM IN PATIENTS UNDERGOING ORTHOPEDIC REPLACEMENT 
SURGERy IN ITALy
Mantovani L.G.1, Furneri G.2, Di M.inno G3
1Federico II University of Naples, Naples, Italy, 2Charta Foundation, Milan, Italy, 3giovanni.
diminno@unina.it, Naples, Italy
Objectives: Venous thromboembolism (VTE) is a common cardiovascular condition, 
frequently leading to severe complications and requiring high-cost health care interven-
tions. New oral anticoagulants (nOACs) have demonstrated to be efficacious and safe 
in VTE prevention of patients undergoing total hip replacement (THR) and total knee 
replacement (TKR). This analysis is aimed present article aims to evaluate its economic 
impact in the perspective of the Italian SSN. MethOds: We conducted a budget impact 
analysis to estimate clinical outcomes and economic consequences associated to the 
reimbursement of apixaban in the prevention of VTE as a consequence of major ortho-
pedic surgery, over a three-year time horizon. The analysis compared two alternative sce-
narios, with apixaban either reimbursed (Scenario B) or not reimbursed (Scenario A) by 
the Italian SSN. Only direct health care costs have been considered. Results: According 
to market assumptions, it is estimated that 1.2%, 3.7%, and 6.5% of THR patients, and 
1.2%, 3.8% and 6.7% of TKR patients, would be treated with apixaban over the first three 
years since launch. The introduction of apixaban, at the estimated daily cost of € 2.48/
die, would translate into a budget impact of € 14.3 mln, € 45.5 mln, and € 81.4 mln at years 
1, 2 and 3 since launch, respectively. This expenditure would be more than offset by sav-
ings, due to: i) reduction of prescriptions of alternative treatment options (other nOACs, 
low-molecular weight heparins, fondaparinux); ii) reduction of the economic burden 
attributable of CV complications of VTE. Finally, Scenario B resulted slightly favourable 
compared to Scenario A, leading to economic savings for about € 50 thousands over 
three years. cOnclusiOns: Reimbursement of apixaban does not determine a budget 
impact increase for Italian SSN, and offers an additional option to prevent high-cost 
event provoked by VTE. Its usage may be considered fully sustainable from a pharmaco-
economic viewpoint.
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ASSESSMENT OF THE BUDGETARy IMPACT OF IMPROvING THE USE OF 
EvIDENCE-BASED MEDICINE IN THE TREATMENT OF PATIENTS wITH HEART 
FAILURE AND LEFT vENTRICULAR DySFUNCTION IN ENGLAND
Underhill S.M.1, Branscombe N.2, Jofre-Bonet M.3
1Servier Laboratories Ltd., Slough, UK, 2Les Laboratoires Servier, Suresnes, France, 3City 
University London, London, UK
Objectives: Heart failure places a significant burden on the resources of the NHS. 
The aim of this study was to compare from a budgetary perspective the current treat-
ment of patients with heart failure and left ventricular dysfunction with an estimate 
of what could be achieved if the use of evidence-based medicine was optimised in 
accordance with national guidance. MethOds: Quality and Outcomes Framework 
prevalence and Hospital Episode Statistics data 2011/12 were analysed to determine 
the number of hospital admissions associated with patients with a diagnosis of heart 
failure for each Clinical Commissioning Group (CCG) and GP Practice in England. These 
data were adjusted for patients with left ventricular dysfunction who were in sinus 
rhythm and hospitalisation costs were applied. This was combined with the cost 
associated with the current use of evidence-based medicine to determine the total 
cost associated with this condition. This was compared with an estimate of total costs 
(hospitalisation and medication) if patients received the levels of evidence-based 
therapy, and outcomes, reported in the SHIFT trial. SHIFT was chosen as the largest 
and most recent contemporary trial in heart failure and left ventricular dysfunction, 
which reflects the optimal use of recommended therapies. Data for each CCG and 
GP practice in England is available via a model presented in Microsoft excel® or 
Apple numbers®. Results: Increasing the use of evidence-based therapy to the 
levels achieved in the SHIFT trial can potentially release estimated funding of up to 
£175m for the population of England, £810,000 for a CCG with a population of 250,000 
and £32,000 for a GP practice with a list size of 10,000. cOnclusiOns: If the use of 
evidence-based therapy for patient’s heart failure and left-ventricular dysfunction is 
increased from current levels, significant improvements in terms of patient outcomes 
and the use of NHS funding can be achieved.
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A BUDGET IMPACT ANALySIS TO ESTIMATE THE ECONOMIC IMPACT OF DRUG 
ELUTING BALLOON FOR THE TREATMENT OF PERIPHERAL vASCULAR DISEASE
Corbo M.1, Beccagutti G.1, Manda B.2
1Medtronic Italia, Sesto San Giovanni, Italy, 2Medtronic Vascular Inc., Santa Rosa, CA, USA
Objectives: Drug Eluting Balloon (DEB) is a promising alternative for the treat-
ment of patients with peripheral arterial disease, due to the potential reduction 
in re-intervention rates and cost-savings compared to other technologies com-
monly used. The objective of this analysis was to assess the economic impact of 
DEB and other endovascular therapies for patients with femoral-popliteal dis-
ease. MethOds: A budget impact model was developed to compare the relative 
impact in Italy of four different index procedure treatments (PTA with regular bal-
loons, DEB, bare metal stents (BMS) and drug eluting stents (DES)) based on the 
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THE EFFECTIvENESS OF STATINS IN THE TREATMENT OF CARDIOvASCULAR 
DISEASE: CROSS-SECTIONAL STUDy wITH PAIRED GROUPS FROM ELECTRONIC 
PATIENT RECORDS
Abrahão M.T., Nobre M.R., Gutierrez M.A.
INCOR - HCFMUSP, Sao Paulo, Brazil
Objectives: Electronic Patient Record has proven useful to assess the benefits, 
harms and costs in the real world. To describe the association between the use 
of statins and cardiovascular events in patients with myocardial ischemia by 
means an Electronic Patient Record (ePR) as the basis for a retrospective cohort 
study. MethOds: To evaluate the association between the use of statins and car-
diovascular events, we conducted a cross-sectional study with patients in the ePR 
of the Heart Institute (InCor) - University of São Paulo Medical School. Patients were 
considered for the period between 2004 and 2012 and evaluated in terms of the 
association between the use of statins with prevalence of percutaneous coronary 
intervention (PCI), coronary artery bypass graft (CABG) and inpatient mortality. A 
total of 46,757 patients were randomly selected and matched for gender, age group 
(18-49/50-59/60-69/> 70), and category of cardiovascular disease diagnosis, being 
from three ICD-10 groupings, I20-I25/I63-I69/G45/I70. The pairing resulted in two 
groups, each of them with 14,654 patients, a group with prescription of statin (SG) 
and a group for comparison (CG) without statin. Results: A total of 67.4% of the 
patients registered in the ePR used statins. The presence of reverse causality, very 
common in cross-sectional studies, was observed in patients submitted to revascu-
larization procedures. Revascularization was made present in 14% of CG versus 42% 
of SG, which is justified by the drug administration for care of patients undergoing 
those procedures. Mortality was 5.8% in CG and 4.7% in SG, with prevalence rates 
of 80%. The absolute reduction in the prevalence of death between groups was 
1.1% (95%CI:0,6-1,6%) in favor of the use of statins. cOnclusiOns: Statins were not 
prescribed to approximately one third of the patients, the use of statins was higher 
in patients undergoing revascularization procedures and, was also associated with 
a 20% reduction in the occurrence of mortality.
CARDIOvASCULAR DISORDERS – Cost Studies
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BUDGET IMPACT ANALySIS OF ROUTINE GENTAMICIN-COLLAGEN IMPLANTS 
FOR THE PREvENTION OF SURGICAL SITE INFECTION (SSI) IN HIGH RISK 
CARDIOTHORACIC SURGERy PATIENTS
Satherley A.W.1, Sayers J.2, Fitzsimons E.2
1GfK Bridgehead, Melton Mowbray, UK, 2EUSA Pharma, Stevenage, UK
Objectives: The SSI rate after cardiothoracic surgery is estimated at 7.3% by the 
UK Health Protection Agency (HPA) for high risk patients. This represents a burden 
on resources, through greater risk of in-hospital mortality and increased length 
of hospital stay (mean 22.1 extra days for deep SSI). Treatment guidelines recom-
mend IV antibiotic prophylaxis before surgery; however a challenge in high-BMI 
and diabetic patients (high risk) is the inability of systemic antibiotics to suffi-
ciently penetrate target tissue. It is however estimated that 40%-60% of SSIs are 
avoidable, with clinical data supporting additional use of local gentamicin-collagen 
for SSI prevention. The purpose of this study was to examine the budget impact 
case from a UK NHS perspective of routinely administering gentamicin-collagen 
local prophylaxis against SSI in high risk patients undergoing cardiothoracic sur-
gery. MethOds: A literature review was undertaken regarding gentamicin-collagen 
efficacy in reducing SSI in cardiothoracic patients, NHS costs of SSI, and annual UK 
cardiothoracic patient numbers. The SSI rate in cardiothoracic surgery was obtained 
from HPA data. Findings were incorporated into a decision tree budget impact model 
to analyse potential savings from routine use of gentamicin-collagen in high risk 
cardiothoracic patients. Results: Considering a cohort of 3710 high-risk cardio-
thoracic patients, annual NHS costs of SSI are £2,164,316. Administration of two 
gentamicin-collagen implants to each high risk patient would cost £200 per patient. 
Assuming a 59% reduction in SSI; this would prevent 197 sternal wound infections, 
with direct savings of £1,590,882 per year, a net saving of £229 per cardiothoracic 
surgery patient. cOnclusiOns: Significant NHS and hospital trust savings may 
be achievable through routine use of gentamicin-collagen implants in high risk 
cardiothoracic surgery patients. A conservative estimate of high-risk patient num-
bers was used in the analysis, suggesting the scope for budgetary savings could 
exceed reported findings.
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EvALUATION OF TELEMEDICINE PROGRAM (ITHACA): INNOvATION IN THE 
TREATMENT OF ARTERIAL HyPERTENSION INCREASING THE COMPLIANCE AND 
ADHERENCE IN THE SECOND yEAR OF ITS IMPLEMENTATION (2011-2012)
Sicras A.1, Ibañez J.2
1Badalona Serveis Assistencials, Badalona, Spain, 2Badalona Serveis Assistencials, Badalona, 
Barcelona, Spain
Objectives: To evaluate effectiveness of an interventional strategy (disease man-
agement program (DMP)) supported by a telemedicine platform in patients with 
mild/moderate hypertension. MethOds: Quasi-experimental design, paired data 
with control group (1:2, patients were matched by age and gender). Study pop-
ulation and follow-up period: patients from 6 primary care centers in Badalona 
(Barcelona, Spain) were followed-up during 2011 and 2012. Study groups: interven-
tion group (telemedicine program) and control group (usual clinical practice). The 
intervention consisted on establishing a permanent channel of interaction with 
the patient (telemedicine platform) and providing the patient with educational 
materials, clinical monitoring, SMS, phone calls, etc. Main measures: Demographic, 
co-morbidity, anthropometric and biochemical parameters, adherence to treat-
ment, blood pressure control (BP: 140/90 mmHg), associated health care man-
agement costs and satisfaction surveys to professionals and patients. Statistical 
significance:p< 0.05. Results: A total of 750 patients were included (intervention 
group n= 250, control group n= 500). Mean age was of 64.2 years old 52.1% of patients 
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for treatment with dabigatran. It is assumed that all diagnosed AF patients eligible 
for oral anticoagulation currently receive warfarin and that all patients switch to 
dabigatran in Year 1, regardless of International Normalised Ratio (INR) control 
amongst warfarin patients. Differences in numbers of clinical events expected to 
occur based on a patient’s antithrombotic treatment were estimated by applying 
event rates from literature sources. Costs were estimated from a HSE perspective and 
included costs of clinical events, disability costs and medication costs. Results: 
A total of 28,332 Irish patients are estimated to have been diagnosed with AF and 
are eligible for dabigatran. Switching these patients from warfarin to dabigatran 
may avoid: 657 strokes; 792 major bleeds; 1,437 deaths. By Year 5, cumulative dabi-
gatran drug costs were estimated at € 7,670,870. Cost savings due to clinical events 
avoided amounted to € 2,894,743 and savings on disability costs at € 5,563,349, giving 
a total cost saving with dabigatran of € 787,223. cOnclusiOns: Use of dabigatran 
as compared to warfarin for stroke prevention in AF in the Irish setting may avoid 
a significant number of clinical events and result in overall cost savings.
PCv44
ECONOMIC BURDEN OF vENOUS THROMBOEMOBLISM ACROSS PATIENT 
POPULATIONS: A LITERATURE REvIEw
Claflin A.B.1, Mitchell C.R.2, Liu X.1, Phatak H.3, Mitchell S.A.2
1Pfizer, Inc., New York, NY, USA, 2Abacus International, Bicester, UK, 3Bristol-Myers Squibb 
Company, Princeton, NJ, USA
Objectives: To conduct a literature review on the economic burden of venous throm-
boembolism (VTE) (encompassing deep vein thrombosis (DVT) and pulmonary embo-
lism (PE)) and related complications. MethOds: Eligible English-language studies 
published post-1990 were identified from electronic databases (Medline, EMBASE 
and Cochrane Library: accessed December 2012) and conference proceedings with 
no restriction on geographical location or patient population. All costs are reported 
in US$ adjusted to 2013 levels. Results: Twenty-nine studies met eligibility criteria: 
United States (n= 17), Canada (n= 2), Australia (n= 1), South America (n= 1) and Europe 
(n= 8). The estimated annual cost of VTE treatment is in excess of $2 billion in the 
USA and Europe and $153 million in Australia. This figure rises to $15.6–$34.8 billion 
in the US and to $1.78 billion in Australia on inclusion of complications, productivity 
loss and other societal costs. The cost of treating PE per patient ($12,567-$20,488) is 
higher than that of treating DVT ($2,912-$13,299). Hospitalisation is the main cost 
driver for VTE treatment, accounting for 56%-89% of all treatment costs. For patients 
with cancer, costs were 30-50% higher for those with VTE compared with those with-
out VTE. VTE-related complications incur additional costs including: bleeding (up to 
$23,963 per patient with a major bleed); recurrent VTE (up to $18,122 per patient); 
post-thrombotic syndrome (increase of up to 75% in treatment cost); chronic throm-
boembolic pulmonary hypertension (up to $6,708 per patient); and heparin-induced 
thrombocytopenia (up to $18,779 per patient). cOnclusiOns: Incident VTE events 
and related complications are associated with significant economic burden across 
several patient populations. Treating PE may cost up to five times more than treating 
DVT, with hospitalisation reported as the major cost driver of VTE treatment. Effective 
and convenient therapies associated with both a reduced incidence of bleeding and 
complications are required to further reduce the cost burden associated with VTE.
PCv45
PHARMACOECONOMIC ASPECTS OF ACTOvEGIN AND SOLCOSERyL IN THE 
TREATMENT OF RUSSIAN PATIENTS wITH ACUTE CEREBROvASCULAR 
ACCIDENTS
Ryazhenov V.V.1, Gorokhova S.G.1, Emchenko I.V.1, Matveev N.V.2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2N.I. Pirogov Russian 
National Research Medical University, Moscow, Russia
Objectives: To assess the cost-effectiveness of actovegin and solcoseryl in the treat-
ment of Russian patients with acute ischemic stroke and predict potential budget 
impact of the implementation of actovegin in routine clinical practice. MethOds: 
The pharmacoeconomic model was developed based on the data from Russian 
clinical trial performed by A. Fedin et al. (2000). Two groups of patients (100 persons 
each) hospitalized with acute ischemic stroke were included in the model. The first 
group of patients received conventional therapy + actovegin and the second group 
received conventional therapy + solcoseryl. Based on the reported by A. Fedin et al. 
time-dependent mortality reduction in actovegin-treated patients (mortality rate 
was 7% in patients started actovegin within the first 6 hours after stroke onset, 
10% – in those started actovegin within the first 24 hours, 14% – in those started 
actovegin after more than 24 hours, and it was much higher in the control group – 
21%) cost-effectiveness ratios (CERs) and indicator of economic rationality of costs 
of previous periods (IRPP) were calculated and compared. Results: Estimated CERs 
varied from 46,348.82 to 50,121.40 RUB per one survivor in the actovegin group and 
from 50,900.56 to 53,585.17 RUB per one survivor in the solcoseryl group. Inefficient 
expenditures (IRPP) varied from 301,730.83 RUB to 603,461.67 RUB in the actovegin 
group, and were 873,453.57 RUB in the solcoseryl group. cOnclusiOns: The study 
has demonstrated the preferred cost-effectiveness profile of actovegin as compared 
to solcoseryl in patients with acute ischemic stroke.
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PHARMACOECONOMIC BENEFITS OF CITICOLINE IN THE TREATMENT OF ACUTE 
ISCHEMIC STROKE IN RUSSIA
Ryazhenov V.V., Gorokhova S.G.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To assess the cost-effectiveness of citicoline in the treatment of Russian 
patients with acute ischemic stroke and identify potential budget impact of the imple-
mentation of citicoline in routine clinical practice. MethOds: The pharmacoeco-
nomic model was developed based on the data of meta-analysis performed by A. 
Davalos et al. (2002). Two groups of 100 patients each were included in the model: the 
first group of patients received conventional therapy and the second group (active 
treatment group) additionally received citicoline. It was assumed that citicoline was 
given to patients in the active treatment group in the following way: during the first 
repeat procedure rates (TLR - target lesion revascularization) over 1 year. The model 
was developed from a Italian national health care system (NHS) perspective with 
a 5-year time horizon. A systematic literature review was carried out on TLR rates 
in patients with femoral-popliteal disease treated with one of the four treatment 
choices. Costs associated to each treatment are derived from the average DRG tariffs 
used for peripheral angioplasty procedures. A decision analytic model was devel-
oped to estimate total costs over 12 months of index procedures and possible revas-
cularizations. Results: Pooled 12-month TLR rates show clear patients benefit with 
DEB compared to PTA (8,6% vs 28,6%) and non-inferiority of DEB vs DES (9,4%) and 
BMS (11,5%). Total Italian DRG payments for index and repeat interventions (based 
on TLR rates estimation) across treatments showed that DEB was the least costly 
treatment strategy over 1 year, with saving of almost € 1,000 per patient with DEB 
vs PTA. Based on these per-patient savings, the potential total savings amounted 
to approximately € 2 million for an assumed annual increase of 5% in DEB adoption 
rate over 5 years. cOnclusiOns: The analysis suggests clear patient benefit for 
DEB. Despite initial higher investments, DEB represents a cost-saving alternative 
to other technologies according to the NHS perspective.
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BUDGET IMPACT ANALySIS OF RIvAROxABAN IN THE PREvENTION OF STROKE 
IN NON-vALvULAR ATRIAL FIBRILLATION PATIENTS IN ITALy
Capri S.1, Veneziano M.2, Ricciardi W.G.3, D’Ausilio A.4, Pedone M.P5, Bianchi C.5
1Institute of Economics, Castellanza, Italy, 2Catholic University of Sacred Heart, Roma, Italy, 
3Catholic University of Sacred Heart, Rome, Italy, 4Creativ Ceutical, Luxembourg, Luxembourg, 
5Bayer Pharma, Milano, Italy
Objectives: In Italy about 500,000 non-valvular atrial fibrillation (NVAF) patients 
have a major unmet medical need as they do not receive adequate anticoagulation 
therapy for stroke prophylaxis: many patients receive antiplatelet therapy, even 
when the guidelines recommend vitamin-K antagonists (VKA), or are not treated at 
all or have international normalized ratio inadequate control despite treatment with 
VKA. The purpose of this study was to perform a budget impact analysis of rivaroxa-
ban - a novel oral anticoagulant (NOAC) - in NVAF patients with the highest unmet 
medical need from the Italian health care system (SSN) perspective. MethOds: 
Two scenarios were compared within a three-year timeframe: the actual scenario, 
where patients are treated according to current clinical practice (46% with VKA, 
38% with antiplatelets, 17% non-treated) and a scenario where Rivaroxaban is pre-
sent with increasing market shares. The event risks (ischemic and haemorrhagic 
stroke, systemic embolism, myocardial infarction and bleedings) were retrieved 
from the ROCKET-AF trial or from a network meta-analysis. Resource consumption 
was computed using mean regional tariffs. Since Rivaroxaban price is not officially 
published, the daily cost used ranges from € 2.10 (price of the first NOAC approved in 
this indication in Italy) and the lowest Rivaroxaban price available in Europe (€ 1.94). 
The results of the analysis are displayed as a total costs difference between the two 
scenarios. Results: A reduction in the total number of events and costs at SSN 
charge is shown since the first year from rivaroxaban introduction. The increase in 
pharmaceutical expenditure is offset by savings from a lower number of events to 
treat and absence of routine coagulation monitoring. cOnclusiOns: The introduc-
tion of rivaroxaban in the national scenario is beneficial because it will provide a 
substantial reduction in the disease burden for patients and in costs for the SSN.
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COMPARISON OF DABIGATRAN ETExILATE vERSUS wARFARIN, ASPRIN & NO 
TREATMENT FOR STROKE PREvENTION IN ATRIAL FIBRILLATION IN ENGLAND, 
UNITED KINGDOM, OvER 5 yEARS
Sunderland T.J.1, Zah V.2, McCarron C.1
1Boehringer Ingelheim, Berkshire, UK, 2ZRx Outcomes Research Inc., Mississauga, ON, Canada
Objectives: To estimate the number of clinical events and costs of these events 
for dabigatran etexilate (dabigatran) versus a combination of warfarin, aspirin and 
no treatment for stroke prevention in atrial fibrillation (AF) patients in an England, 
UK, setting over 5 years. MethOds: An interactive model was built in Microsoft 
Excel to calculate the following: • Total number of AF patients eligible for dabi-
gatran • Number of clinical events for dabigatran, warfarin, aspirin and no treat-
ment patients over a 5 year time horizon. Clinical events included were stroke 
(ischaemic, haemorrhagic, systemic embolism); major bleeding (intracranial and 
extracranial); all cause mortality; acute myocardial infarction • Total costs of clini-
cal events for each treatment. The total cost per day for dabigatran is £2.20 per day; 
warfarin is £1.18; aspirin is £0.09; no treatment is £0.00. Warfarin had a TTR of 55% 
(from Jones et al 2005); aspirin and no treatment clinical event rates were from 
Roskell et al (2010). Dabigatran data was from the RE-LY trial Results: The model 
estimates there are 822,527 patients with AF in England, of which 78% are eligible 
for dabigatran (641,571). After 5 years, patients treated with dabigatran versus 80% 
with warfarin; 10% aspirin; 10% no treatment are associated with: 1) 27,357 fewer 
strokes (16,938 fewer ischaemic storkes); 2) 14,413 fewer major bleeding events; 
and 3) An increase of £268,167,861 in drug budget; however there is an overall cost 
saving of £11,240,201. The overall cost saving is predominantly driven by savings in 
disability following stroke. cOnclusiOns: Study indicates that due to a superior 
clinical profile, dabigatran may more than offset the increase drug budgets, result-
ing in cost savings, if used preferentially versus warfarin, aspirin or no treatment.
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COMPARISON OF DABIGATRAN ETExILATE vERSUS wARFARIN FOR STROKE 
PREvENTION IN ATRIAL FIBRILLATION IN IRELAND OvER 5 yEARS
McCarron C.1, Sunderland T.J.1, Zah V.2
1Boehringer Ingelheim, Berkshire, UK, 2ZRx Outcomes Research Inc., Mississauga, ON, Canada
Objectives: To estimate numbers of clinical events (strokes, major bleeds, acute 
myocardial infarctions and deaths) and health care costs over a five year period 
in Ireland following a switch of antithrombotic therapy for atrial fibrillation (AF) 
from warfarin to dabigatran. MethOds: A model was built in Microsoft Excel and 
included an estimate of the number of Irish patients diagnosed with AF and eligible 
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the National Health Care system perspective. Results: Preoperative characteris-
tics and risk scores of the 2 groups were comparable. Hospital mortality was 3.7% 
in Sutured and 2.4% in Sutureless (p= 0.65). Aortic cross-clamp, cardiopulmonary 
bypass time and operation time were 20%, 23% and 16% shorter in Sutureless (each 
one p< 0.001).Sutureless required less blood transfusion (1.2±1.3 vs 2.5±3.7 units, 
p= 0.005) with a similar incidence of postoperative bleeding (2 patients vs 5, p= 0.221). 
Sutureless had a shorter intensive care unit stay (2.0±1.72vs 2.8±1.3 days, p< 0.001), 
a shorter hospital stay (11.4±3.9 vs 17.3±13.7 days, p< 0.001) and a shorter intuba-
tion time (9.5±4.6 vs 16.6±6.4 hours, p< 0.001). A neurological event was recorded in 
3 sutureless patients and in 6 sutures (p= 0.248). Sutured has an higher incidence 
of postoperative atrial fibrillation, pleura effusions and respiratory insufficiency (p 
0.015, 0.024 and 0.016, respectively). Reduced risk of post operative complication 
resulted in a dramatic reduction of resources consumption in the sutureless group 
allowing a saving of 50% of the complication related resource use. cOnclusiOns: 
Shorter procedural times resulting from sutureless aortic valve replacement are 
associated with better outcomes and lower costs. Sutureless valve may be consid-
ered as the first-line treatment for patients underwent aortic valve replacement 
with a bioprosthesis.
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TRENDS IN THE COST-EFFECTIvENESS OF STROKE CARE
Urbina-Valdespino E.1, Saka Ö1, Crichton S.2, Rudd A.2, Mcguire A.3, Wolfe C.2
1Deloitte, Diegem, Belgium, 2King’s College London, London, UK, 3London School of Economics, 
London, UK
Objectives: To assess the annual average costs and quality adjusted life years 
(QALYs) of stroke services in the UK before and after the introduction of the National 
Stroke Strategy (period: 2006-2011). MethOds: Data from the South London Stroke 
Register (SLSR) from 2006 to 2011 were used to populate a discrete event simulation 
(DES) model. Parameters, such as daily probability of survival and length of stay, 
included in the model were calculated by using Cox proportional hazard model and 
multivariate regression methods respectively. Barthel Index was used as proxy for 
measures of quality of life. Treatment costs were introduced in the model in order 
to calculate the total costs based on resource usage. The model simulated the stroke 
care delivery from stroke onset with 10-year follow up. Average cost and QALYs 
were calculated for every year from 2006 to 2011. Results: The average total costs 
per treating a stroke patient decreased from £30,745 to £27,086 between 2006 and 
2011 (p-value for trend < 0.001). This is mainly as a result of savings achieved in the 
inpatient phase due to a shorter LOS and a higher proportion of patients with mild 
disability. Per patient QALY’s also increased from 2.2 to 3.1 during the same period 
(p-value for trend < 0.001), this is due to a higher proportion of patients having 
access to better organised stroke care. cOnclusiOns: This study has demonstrated 
that stroke services in the UK have improved their value for money over time with 
constant gains in efficiency. The use of DES together with SLSR data allows the test-
ing of the costs and outcomes of a whole stroke provision system or components 
of it and provide opportunities for retrospective (as done in this study) as well as 
prospective analysis (in the case of health technology assessment studies).
PCv52
DISCRETE EvENT SIMULATION MODEL OF PRIMARy PREvENTION OF STROKE: 
BENEFITS OF INCREASING COvERAGE TO UNSERvED PATIENTS
Urbina-Valdespino E.1, Saka Ö1, Kleintjens J.1, Rudd A.2, Wolfe C.2
1Deloitte, Diegem, Belgium, 2King’s College London, London, UK
Objectives: To assess the impact of a hypothetical increase in the stroke primary 
preventive care coverage in the UK. Productivity gains, using resource utilization 
as proxy, and monetary benefits were calculated. MethOds: Data from the South 
London Stroke Register (SLSR) from 2009 to 2011 were used to create a hypothetical 
cohort to populate a discrete event simulation (DES) model. The model simulated 
the stroke care delivery from primary preventive stroke care until discharge from 
stroke unit or general medical ward. Primary preventive care was defined as taking 
medications to control hypertension, high-cholesterol and also anticoagulants in 
patients with atrial fibrillation in order to prevent strokes. Treatment costs were 
introduced in the model in order to calculate the total costs based on resource usage. 
Hypothetical scenarios consisting in 10% incremental increase of primary preven-
tive care for high-risk factors were tested. The reduction of strokes was given by 
relative risk reduction ratios extracted from clinical trials. Results: Our findings 
indicate that for every 10% increase in the number of patients undergoing primary 
prevention treatment the number of strokes would be reduced by 1.2%. In a scenario 
where 50% of the untreated patients receive primary prevention 7,232 strokes would 
be reduced per year. For the same scenario, 47 hyper acute beds, 359 acute beds and 
47 general medical ward beds could be saved in average. In total this would yield in 
£42.2 million of savings in the inpatient phase of stroke care. cOnclusiOns: Our 
findings suggest that by enhancing primary prevention of stroke care in the UK, 
significant benefits can be achieved in terms of reductions in resource consumption 
and monetary savings as a result of averted strokes. The generation and analysis 
of these retrospective hypothetical scenarios, using real-world evidence on stroke, 
help evaluate policy choices in stroke care in the UK.
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THE BURDEN OF RESISTANT HyPERTENSION IN 5 EUROPEAN COUNTRIES
Sapoval M.1, Hale B.C.2, Armstrong S.3, Da Deppo L.4, Hertz D.3, Briggs A.5
1Interventional Radiology Department, Assistance Publique des Hôpitaux de Paris, Georges 
Pompidou European Hospital, Paris, France, 2Boston Scientific, Natick, MA, USA, 3GfK Bridgehead, 
Wayland, MA, USA, 4Boston Scientific, Milan, Italy, 5University of Glasgow, Glasgow, UK
Objectives: Greater than 40% of Europeans over age 25 have hypertension, and 10% 
of those have medication resistant hypertension (RHT). In EU5 (France, Germany, 
Italy, Spain, UK) that results in 9.4 million persons with blood pressure above goal, 
despite treatment with 3+ medications. These patients have a greater than 30% 
risk of cardiovascular disease (CVD) over 10 years and an increased risk of end-
stage renal disease (ESRD). This analysis sought to quantify the burden of RHT 
10 days since acute stroke onset, 2,000 mg was administered intravenously; from day 
11 to the end of the treatment periods (74 days), 1,000 mg was administered per os. 
The time horizon adopted in the model was 12 weeks. Based on the data on effective-
ness of citicoline in complete patient recovery after 3 months reported by A. Davalos 
et al., the cost-effectiveness ratios (CERs) were calculated and compared. Results: 
Estimated CERs were 513,099.20 RUB per one patient recovered in control group and 
435,368.00 RUB per one patient recovered in citicoline group. Furthermore, the costs 
of rehabilitation of patients were lower in the citicoline group as compared to control 
group, cost savings were estimated to be about 1,719,610.00 RUB. cOnclusiOns: The 
study has demonstrated that the treatment of acute ischemic stroke with citicoline 
was more cost-effective and had the potential to reduce the rehabilitation expenses.
PCv48
REMOTE PATIENT MONITORING IN CRT-D RECIPIENTS MAy REDUCE USE OF 
HOSPITAL-BASED CARE
Stern S.1, Kansal A.R.1, Amorosi S.L.2, de Lissovoy G.3
1Evidera, Bethesda, MD, USA, 2Boston Scientific, Natick, MA, USA, 3Johns Hopkins University, 
Baltimore, MD, USA
Objectives: Heart failure (HF) is a costly disease imposing a substantial health 
burden which affects 1-2% of Europeans. Hospital readmission for HF is a common 
occurrence with 25% of all patients readmitted within 30-days following initial 
hospitalization. Reducing readmission is an important component of managing HF 
costs and increasingly being targeted with health care policy reforms. The objec-
tive of this study is to examine how remote patient monitoring (RPM) may affect 
health care costs following the placement of a CRT-D device for patients with HF 
through the use of a simulation model. MethOds: The analysis was an individual 
patient event-based simulation from a US payer perspective based on a sample 
of patients from RAPID-RF, a multi-center prospective single-arm registry which 
enrolled 889 patients who received a CRT-D and RPM system (LATITUDE® Boston 
Scientific). The modeled population consisted of patients that had at least one alert 
for weight change, atrial tachycardia or ICD shock with a subsequent interven-
tion (N= 128). The population was limited to this subset to focus on the costs of 
changes in management due to RPM. A non-RPM control group was created by 
cloning each trial patient and simulating their response in the absence of RPM to the 
conditions that triggered each alert in the trial over one year using a decision tree 
which computed rates of hospitalization and physician contacts based on literature 
data. Event and hospitalization costs were estimated per Medicare (CMS) national 
average payment. Results: RPM reduced total costs after the index procedure by 
$323/patient driven by a reduction in costs related to hospitalization admissions. 
The decrease in hospital admission cost was partially offset by RPM’s increase in 
physician visits and telephone counseling. cOnclusiOns: RPM has the potential 
to shift HF-related care from an inpatient setting to office-based care, resulting in 
cost savings to national payers.
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DABIGATRAN ETExILATE IN PREvENTION OF STROKE FOR NONvALvULAR 
ATRIAL FIBRILLATION PATIENTS IN TURKISH HEALTH CARE SETTING; A STUDy 
ON COST CONTAINMENT OF SOCIAL SECURITy INSTITUTION (SSI)
Kececioglu S.1, Ulus P.2, Cukadar F.3, Ozkan M.3, Urganci B.3
1Boehringer Ingelheim Turkey, Istanbul, Turkey, 2Boehringer Ingelheim Turkey, ISTANBUL, 
TURKEY, Turkey, 3Boehringer Ingelheim Turkey, ISTANBUL, Turkey
Objectives: Analysis of cost containment of SSI via use of Dabigatran Etexilate 
(150MG) versus current standard of care (Warfarin) in prevention of stroke for non 
valvular atrial fibrillation patients in Turkish health care setting. MethOds: All 
calculations are performed for a group of 1000 patients in each treatment arm per 
year (Treatment arms; Dabigatran 150MG & Warfarin 5MG – results are represented 
as “cost per patient per day”). Available clinical data is analyzed for calculation of 
event costs in each treatment arm (RE-LY study). Local costs of events are included 
from local literature. Microsoft Excel (2007) is used for calculations and construc-
tion of data tables. Results: Direct cost of SSI (indirect costs are not included in 
this analysis) is calculated in each treatment arm. Difference of daily medication 
cost between Dabigatran Etexilate and Warfarin treatments is +3.12 TL/Day*Patient 
however, this difference is calculated as -3.34 TL/Day*Patient when medication 
cost is combined with total treatment cost (costs of thromboembolic&adverse 
events, INR monitoring, impairment). Dabigatran Etexilate offers a cost contain-
ment (saving) of 0.22 TL/Day*Patient in prevention of stroke for non valvular atrial 
fibrillation patients in Turkish health care setting. cOnclusiOns: Limitation of 
this study is covering only direct cost data due to lack of local literature on indirect 
costs. Further analysis may be performed by non-interventional studies, which 
will define cost containment data via real life cost and effectiveness values. This 
study demonstrates that Dabigatran Etexilate treatment may sustain cost contain-
ment (saving) via reduction of direct cost of SSI with respect to current standard of 
care, in prevention of stroke in patients with atrial fibrillation in current Turkish 
health care system.
PCv50
COST SAvING AFTER SUTURELESS REPLACEMENT IN AORTIC vALvE STENOSIS: 
RESULTS FROM A PROPENSITy-MATCHED SCORE ANALySIS IN GERMANy
Santarpino G.1, Giardina S.2, Pollari F.1, Vogt F.1, Pfeiffer S.1, Fischlein T.1
1Klinikum Nurnberg, Nurnberg, Germany, 2Sorin Group, Milano, Italy
Objectives: New sutureless aortic valve prostheses reduce the surgical time. 
Objective of this study is to asses if shorter operative times may also result in 
improved patient outcomes and the impact on the hospital costs. MethOds: 
Records of 547 patients that underwent aortic valve replacement with a biopros-
thesis from March 2009 and May 2013 were identified. Based on a propensity score 
analysis 2 groups (Sutureless and Sutured) with 82 matched pairs were created from 
the 112 patients received a Perceval sutureless bioprosthesis and the 435 patients 
received a sutured valve. Hospital and follow up outcomes, resources consumption 
was recorded and compared between groups. Analysis was performed according 
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estimate the burden of illness in PAH patients. MethOds: Data came from a large 
commercial claims database. PAH patients were identified based on having > 2 medi-
cal claims for primary pulmonary hypertension (ICD-9 code:416.0), and either one 
claim for right heart catheterization or one claim of echocardiogram and diagnosed 
by a pulmonologist/cardiologist within 12 months of the medical claim. The first 
medical claim during this period served as in the index date with 12 months prior 
to this event as baseline and 12 months post as follow-up period. Demographic 
variables were extracted at a patient level from administrative files and economic 
variables, which included health care utilization and costs for outpatient, inpatient, 
emergency and pharmacy services came from the respective medical and pharmacy 
claim files and summarized at a per-patient-per-month (PPPM). Five controls were 
randomly picked and matched to each PAH patient on demographic characteristics. 
Incremental burden of PAH was estimated using non-parametric statistical tests 
between controls and PAH group. All costs were adjusted to 2012 base year using 
consumer price index. Results: A total of 2,245 PAH patients were identified and 
matched to 11,225 controls. PAH group had significantly higher (p< 0.001) PPPM 
health care utilization compared to the matched control across all drivers: outpa-
tient (2.6 vs. 1.5), inpatient (0.08 vs. 0.02), emergency room (0.1 vs. 0.04), and phar-
macy services (4.2 vs. 2.6). The increase in utilization translated in higher (p< 0.001) 
total PPPM incremental costs of $3,193 in the PAH group with inpatient ($1,665 
vs. $345) and pharmacy costs ($790 vs. $178) being as much as five times greater 
compared to controls. cOnclusiOns: Health care resource use and costs for PAH 
patients is high from a managed care perspective.
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COSTS OF ACUTE HEART FAILURE IN FRANCE
Bouee S.1, Laurendeau C.2, Detournay B.1, Kind B.3, Deschaseaux C.4, Ong S.H.4, Lecomte P.4
1Cemka, Bourg la Reine, France, 2Cemka-Eval, Bourg la Reine, France, 3Novartis, Rueil-Malmaison, 
France, 4Novartis Pharma AG, Basel, Switzerland
Objectives: To describe the incidence and profile of patients hospitalised for acute 
heart failure (AHF); to assess the trajectories of patients before and after hospitaliza-
tion; and to estimate the cost of AHF inpatients stays. MethOds: Patients with AHF 
were identified over a 5-year period (2006 - 2010) from the French PMSI (Programme 
de Médicalisation des Systèmes d’Information), a national disease-related group 
inpatient database. The PMSI database contains data related to all private and public 
hospital stays in France (about 20 millions/year). Heart failure was identified with 
the ICD-10, code I50. Results: The numbers of patients hospitalised at least once 
per year for AHF increased from 144,043 in 2006 to 158,623 in 2010. These num-
bers lead to incidence rates of 2.28‰ in 2006 and 2.45‰ in 2010. The proportion of 
patients aged ≥ 75 increased from 71.0% in 2006 to 74.3% in 2010. Half of patients 
were male. The mean number of comorbidities was 9.6 in 2010. The mean length of 
stay was 9.5 days and 12.6 days per year (2010), as mean re-hospitalization for AHF 
within the same year was 22%. The mean annual number of AHF hospitalisations 
per patient was 1.3. The mean cost for an AHF hospitalisation in the acute setting 
was 4,713€ in 2010. The mean annual cost for all hospitalisations occurring for a 
patient hospitalised at least once in a year (2010) for AHF was 6,253€ . Mean costs 
per hospital stay was higher if the patient died during hospitalisation (5,722€ vs. 
4,627€ , p< 0.001). Extrapolation to the whole country leads to a yearly cost of nearly 
a billion of euros (991 millions). cOnclusiOns: Incidence of AHF hospitalisation 
increased in the recent years. This analysis highlighted the high economic hospital 
burden of AHF in France.
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DISEASE BURDEN OF ISCHEMIC STROKE ALONG FIRST yEAR POST-STROKE IN 
SPAIN
Álvarez Sabín J.1, Masjuan J.2, Yébenes M.3, Mar J.4, Oliva J.5, González-Rojas N.6
1Hospital Vall D’Hebrón, Barcelona, Spain, 2Hospital Ramón y Cajal, Madrid, Spain, 
3Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 4Hospital Alto Deba, 
Mondragon, Spain, 5Castilla-La Mancha University, Toledo, Spain, 6Boehringer Ingelheim, Sant 
Cugat del Vallès (Barcelona), Spain
Objectives: Stroke has catastrophic consequences resulting in death or disability 
in 80% of patients and representing a substantial burden on the health care system, 
as well as on patients, family, and society. Stroke is considered as the 2ndcause of 
burden of disease in Europe and ischemic stroke (IS) represents a high percent-
age of total strokes. The objective of the present study was to analyze the first 
year post-stroke burden of IS in Spain. MethOds: We performed an observational, 
multicenter, naturalistic and prospective study that included 16 hospitals (stroke 
units of National Health System hospitals) of 16 Spain regions. We took into con-
sideration consumption of health care resources, social burden, productivity lost 
and health-related quality of live of patient and caregiver during the first year 
post-stroke. Results: A total of 321 stroke patients were recruited. Mean age 72 
years, 54.8% male. Basal NIH stroke scale was 9.11 and 28.9% presented moderate-
high disability. 291 (90.7%) patients presented IS. Overall 1-year cost per IS was 
27,596.53€ . Direct health care costs were 8,623.35€ (31.25%), direct intrahospital 
health care costs supposed 69% (5,926.21€ ) of these costs. Direct non-health care 
costs were 18,377.75€ (66.59%), of which 16,515.09€ (59.84%) were informal care 
costs. Productivity lost was 595.43€ (2.16%). cOnclusiOns: IS were the majority 
of total strokes in the study and represent a high burden on health care system and 
society, mainly due to hospitalization and informal care costs. Intrahospital costs 
were double than the published DRGs in Spain. Other diseases like Alzheimer or 
dementia represent a lower burden than stroke.
PCv59
FOLLOw-ON HEALTH CARE COSTS IN PATIENTS wITH ACUTE CORONARy 
SyNDROME (ACS)
Berger A.1, LaPensee K.2, Oster G.1
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2The Medicines Company, Parsippany, NJ, USA
Objectives: To review published estimates of post-acute-care costs over one year 
in patients with acute coronary syndrome (ACS). MethOds: Using the Medline and 
in EU5, a subject about which nothing has been published to date. MethOds: A 
burden of illness model was constructed to examine the impact of RHT in EU5, 
specifically the incremental incidence, mortality and direct medical costs of CVD, 
which includes: coronary heart disease (CHD), congestive heart failure (CHF) and 
stroke. Framingham risk equations which included a coefficient for treatment resist-
ance and SCORE risk charts were used to estimate the risk of CVD for patients 
with and without RHT. Transition probability data were taken from the literature 
to estimate the risk of death from CVD events, subsequent CVD events and ESRD. 
Direct costs for these events and their long-term consequences were taken from 
the literature and from country-specific drug and acute inpatient costs. Results: 
The total direct medical cost of RHT in EU5 is estimated to be € 3.9 billion in 2013. 
This does not include the cost for drugs to treat RHT, or other costs such as lost 
productivity not directly borne by the health care system. RHT will contribute to 
188,000 cases of CHD, 57,400 strokes, 31,500 CHF and 1,400 ESRD and 30,000 deaths 
in 2013. cOnclusiOns: The burden of RHT due to the increased incidence of CVD 
and ESRD is high. Reducing the incidence of CVD and ESRD through better blood 
pressure control should be a priority for health care decision makers.
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RETROSPECTIvE COSTING STUDy TO ESTIMATE BURDEN OF HEART FAILURE 
IN SPAIN
Llorens P.1, Crespo C.2, Pérez-Alcántara F.2
1Hospital General Universitario, Alicante, Spain, 2Oblikue Consulting, Barcelona, Spain
Objectives: To analyze and estimate resource utilization and associated costs, 
one year following an acute episode of heart failure (HF) in Spain. MethOds: 
Patient-flow data after index hospitalization for acute HF (AHF) were obtained 
from EAHFE database, an emergency (ER)-based registry containing records of all 
AHF patients treated in 29 Spanish hospitals (over 5,800 cases). Estimated medical 
resource utilization data during patients’ ER and other wards stay, hospitalization, 
and first-year follow-up was collected from medical specialists through question-
naire. AHF episodes and hospitalizations incident rates were estimated through 
literature review and disease statistics in official sources. Cost data was retrieved 
from Spanish Pharmacists official sources and a national health care costs database 
(Euros, 2013). To assess uncertainty, sensitivity analysis was carried out. Results: 
A total of 111,803 annual hospital admissions are estimated in Spain (2013). 92% 
of patients suffering an AHF episode are discharged alive and of these 90% survive 
the first month; 23% of these patients are discharged directly from ER, while the 
majority of those who are hospitalized, are admitted to Internal Medicine (53%) or 
Cardiology (17%) wards. On an average, patients are re-admitted 0.41 times within 1 
year. Total direct costs in the first year following an AHF episode averages € 6,822, of 
which 88% are incurred in hospital, with drugs and diagnostic tests accounting for 
less than 5% of all hospital costs. Follow-up costs, in average, split equally between 
drugs and outpatient visits/tests, but vary widely depending on local HF protocols. 
Extrapolation of results to the Spanish population suggests that the total burden of 
HF is more than € 542 million per year. cOnclusiOns: Treating HF patients within 
Spain is resource intensive. Costs are primarily incurred in hospital and are mostly 
driven by the length of stay.
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THE BURDEN OF ILLNESS OF CHRONIC THROMBOEMBOLIC PULMONARy 
HyPERTENSION: A MANAGED CARE PERSPECTIvE IN THE UNITED STATES
Joish V.N.1, Muccino D.1, Kreilick C.2, Kamalakar R.2, Yao J.2, Mathai S.3
1Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 2Bayer HealthCare, Wayne, NJ, USA, 
3Johns Hopkins University School of Medicine, Baltimore, MD, USA
Objectives: Chronic thromboembolic hypertension (CTEPH) is associated with 
considerable morbidity and mortality. The objective of this study was to describe the 
burden of illness in patients with CTEPH. MethOds: Data for this study came from 
a large commercial claims database. CTEPH patients were identified based on having 
> 2 medical claims for either primary pulmonary hypertension (ICD-9 code:416.0) or 
chronic pulmonary heart disease (ICD-9 code:416.8), history of pulmonary embolism 
in the past one year (ICD-9 code:415.1, V12.51, 38.7; CPT-4 codes:36010, 37620, 75825, 
75940; HCPCS codes:C1880) and either one claim for right heart catheterization 
or one claim of echocardiogram and diagnosed by a pulmonologist/cardiologist 
within 12 months of the medical claim. Demographic variables were extracted at 
a patient level from administrative files and economic variables, which included 
health care utilization and costs for outpatient, inpatient, emergency and pharmacy 
services came from the respective medical and pharmacy claim files and sum-
marized at a per-patient-per-month (PPPM). Five controls were randomly picked 
and matched to each CTEPH patient on demographic characteristics. Incremental 
burden of CTEPH was estimated using non-parametric statistical tests between 
controls and CTEPH group. All costs were adjusted to 2012 base year using consumer 
price index. Results: A total of 191 CTEPH patients were identified and matched 
to 955 controls. CTEPH group had significantly higher (p< 0.001) PPPM health care 
utilization compared to the matched control across all drivers: outpatient (3.1 vs. 
1.5), inpatient (0.13 vs. 0.02), emergency room (0.16 vs. 0.04), and pharmacy services 
(4.5 vs. 2.6). The increase in utilization translated in higher (p< 0.001) total PPPM 
incremental costs of $5,007 in the CTEPH group with inpatient ($3,909 vs. $332) and 
pharmacy costs ($607 vs. $180) being as much as twelve and three times greater 
compared to controls. cOnclusiOns: Health care resource use and costs for CTEPH 
patients is high from a managed care perspective.
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THE BURDEN OF ILLNESS OF PULMONARy ARTERIAL HyPERTENSION: A 
MANAGED CARE PERSPECTIvE IN THE UNITED STATES
Joish V.N.1, Muccino D.1, Kreilick C.2, Kamalakar R.2, Yao J.2, Mathai S.3
1Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 2Bayer HealthCare, Wayne, NJ, USA, 
3Johns Hopkins University School of Medicine, Baltimore, MD, USA
Objectives: Pulmonary arterial hypertension (PAH) is a progressive disease result-
ing in high health care resource use and costs. The objective of this study was to 
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A COMPARISON OF THE ECONOMIC BURDEN AND HEALTH CARE UTILIzATIONS 
OF vETERAN PATIENTS DIAGNOSED wITH HyPERTENSION IN THE UNITED 
STATES
Wang L.1, Xie L.2, Du J.2, Li L.1, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA
Objectives: To compare the economic burden and health care utilizations of U.S. 
veteran patients diagnosed with hypertension. MethOds: A retrospective database 
analysis was performed using the Veterans Health Administration Medical SAS 
datasets from October 1, 2008 to September 30, 2012. Patients diagnosed with hyper-
tension were identified using International Classification of Disease 9th Revision 
Clinical Modification (ICD-9-CM) diagnosis codes 401.x, 402.xx, 403.xx, and 404.
xx, with the first diagnosis date designated as the index date. A comparison group 
of patients without hypertension but of the same age, region, gender and index 
year were identified and matched by baseline Charlson Comorbidity Index. The 
index date for the comparator group was randomly chosen to reduce selection bias. 
Patients in both groups were required to be at least 18 years old, and have continu-
ous medical and pharmacy benefits 1 year pre- and 1 year post-index date. Study 
outcomes, including health care costs and utilizations, were compared between 
the disease and comparator groups using 1:1 propensity score matching. Results: 
A total of 2,422,810 patients were included in the hypertension and comparison 
cohorts. After 1:1 matching, a total of 748,857 patients were matched from each 
group, and baseline characteristics were well-balanced. Patients diagnosed with 
hypertension utilized more health care resources for inpatient (8.21% vs. 1.01%, 
p< 0.01), emergency room (ER) (12.78% vs. 3.60%, p< 0.01), physician office (99.43% 
vs. 39.45%, p< 0.01), outpatient visits (99.61% vs. 40.14%, p< 0.01), and pharmacy 
visits (85.51% vs. 35.66%, p< 0.01). The disease group also had higher patient expen-
ditures for inpatient ($2,568 vs. $289, p< 0.01), ER ($121 vs. $30, p< 0.01), physician 
office ($2,541 vs. $767, p< 0.01), outpatient visit ($2,844 vs. $853) and pharmacy visits 
($544 vs. $191, p< 0.01) than the comparison group. cOnclusiOns: Results suggest 
that patients diagnosed with hypertension incurred significantly higher health care 
utilizations and costs compared to those without.
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THE COSTS OF SURGICAL AORTIC vALvE REPLACEMENT IN FRANCE
Goodall G., Candolfi P.
Edwards Lifesciences, Nyon, Switzerland
Objectives: Surgical aortic valve replacement (sAVR) represents the gold stand-
ard for treatment in patients who require valve replacement therapy. However, 
the risks and costs are not uniform across all patients. We have examined the 
national hospital costs database of France to detail the variability of outcomes 
and costs in an attempt to allow improved decision making when deciding on 
appropriate interventions. MethOds: The Programme de Médicalisation des 
Systèmes d’Information (PMSI) hospital database for 2010 was examined and all 
discharge records retrieved for patients undergoing aortic valve replacement. In 
addition to the discharge costs information on hospital length of stay, mortality 
and Charlson risk score were also obtained. Results: The mean cost for all 12,512 
recorded sAVR procedures (defined as Groupe homogène de maladies (GHM) codes 
05C02 and 05C03) in 2010 was € 19,029 (median € 17,349). Overall hospital mortal-
ity was 5.94% but increased to 26.06% depending on severity level and GHM code. 
Corresponding total costs increased if patients died prior to discharge by € 11,007 
and € 9,200 for 05C02 and 05C03 respectively but also differed by severity, generally 
increasing together with mortality up to a maximum mean of € 42,063. Hospital 
length of stay (LoS) also varied by severity levels with means of between 10.74 
and 27.91 days dependent on severity. cOnclusiOns: The costs and outcomes of 
sAVR vary enormously and a single point estimate cannot be used to adequately 
to reflect them. Therapeutic choices must be tailored to the individual patient and 
has the potential to generate substantial cost reductions for the payer by avoid-
ing mortality and reducing LoS. We present this in the context of new treatment 
options for aortic valve replacement.
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ECONOMIC IMPACT OF STROKE EPISODE IN PATIENTS PREvIOUS DIAGNOSED 
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Objectives: Evaluate the costs of patients with known diagnosis of atrial fibril-
lation who received medical care related to stroke episodes, under the Private 
Healthcare system perspective. MethOds: A retrospective evaluation of a data-
base with 3 million individuals was conducted to identify patients diagnosed with 
Atrial Fibrillation (AF) using the International Classification of Diseases version 
10 (ICD10) I48 code (Flutter and atrial fibrillation) between 2009 and 2010. From 
the identified cohort, patients presenting the following codes: ICD10 I64, I63, I66 
and I69, were further analyzed from 2009 to 2012. Costs associated to the episodes 
such as medications, exams, procedures, hospitalizations and others were evalu-
ated. Results: From 1898 patients presenting the AF diagnose identified in the 
database, 66 Presented a diagnosis of stroke. The 66 patients cost BRL 2,325,250.61 
to the supplemental health service, being BRL 2,193,185.50 spent with 21 patients 
hospitalizations due to stroke. cOnclusiOns: If not controlled, AF may impose 
a significant morbidity due to increased susceptibility for thromboembolic events 
such as stroke and its complications, causing important spending beyond hos-
pitalizations and other significant direct and indirect costs to the private health 
care system.
Embase databases, we identified published reports of direct health care costs in ACS 
patients in the US; we limited attention to studies published in English between 
January 1, 2003 and July 30, 2012. Reference lists of all such studies also were scanned 
to identify additional sources. We abstracted information from all relevant reports on 
costs of recurrent events (e.g., myocardial infarction [MI], stroke, ACS-related readmis-
sions) and cardiac procedures, as well as costs of cardiac-related outpatient visits 
and pharmacotherapy and total health care costs, in the year following ACS onset. 
As appropriate, estimates were converted to 2011 US dollars, using the medical-care 
component of the US Consumer Price Index. Results: A total of 16 studies were 
identified that met all selection criteria. For persons with private health insurance 
coverage, estimated cost per recurrent event was lowest for bleeding ($7951) and high-
est for MI (range = $17,081 - $20,348); the cost of ACS-related admissions ranged from 
$6818 to $34,089. For Medicare beneficiaries, cost per recurrent event was lowest for 
other cardiovascular events ($4542 - $14,360) and highest for MI ($10,082 - $11,347); the 
cost of ACS-related admissions was $13,683. Mean total health care costs for patients 
with private insurance coverage ranged from $21,319 to $40,062 in the year following 
ACS onset; similar estimate was identified for Medicare beneficiaries. cOnclusiOns: 
Costs of follow-on care are high in patients with ACS, due to recurrent events, revascu-
larization, and routine follow-on care. In general, costs were higher for patients with 
private health insurance coverage than those with Medicare coverage.
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Objectives: Few studies have undertaken a global review of major cardiovascular 
conditions and events. This review summarizes the current literature for costs of: 
major cardiovascular diseases/events (angina, myocardial infarction, heart failure, 
stroke/transient ischemic attack, peripheral arterial disease); revascularization 
(coronary, cerebral, or peripheral); coronary heart disease mortality; and cerebro-
vascular mortality. MethOds: A systematic search of the scientific literature from 
2007 through 2012 was conducted. English language articles reporting per-patient 
average direct medical costs of any cardiovascular event of interest in any country 
were included. Cost-effectiveness studies and primary prevention interventions 
were excluded. Cost of the event including initial hospitalization (“acute cost”) and 
any re-hospitalizations or post-event follow-up (“follow-up cost”) along with meth-
odologies of each study were abstracted. Results: A total of 176 articles represent-
ing 30 countries were abstracted. Coronary revascularization (N= 46), stroke (N= 43), 
and heart failure (N= 31) articles were heavily represented. Acute cost estimates 
varied widely for all conditions/events (2013 USD): angina ($1,004-8,380); myocar-
dial infarction ($570-$31,321); coronary revascularizations ($240-$129,747); heart 
failure ($536-$28,176); stroke ($577-$167,378); cerebral revascularizations ($7037-
$57,884) peripheral arterial disease ($1241-23,144); peripheral revascularizations 
($2297-$129,865); coronary heart disease inpatient mortality ($7,030-$25,556); cer-
ebrovascular disease inpatient mortality ($6,197-$40,141). Similarly, wide variation 
was found for follow-up cost estimates, based on time horizons that range from 
30-day re-hospitalization to the remainder of life post-initial event. The major-
ity of studies were specific to the United States; for countries other than the US, 
cost estimates for each event were much less robust. Methodological differences 
between articles limit comparability of costs. cOnclusiOns: Though estimates 
vary, the significant economic burden of these cardiovascular events is evident. A 
lack of robust literature in some conditions and countries combined with significant 
heterogeneity of study design and reporting makes comparison of cardiovascular 
event costs difficult. New research should identify a representative sample using 
study designs that allow for comparability.
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Objectives: Atrial Fibrilation (AF) 5-folds stroke risk, which results in death or dis-
ability in 80% of individuals and the one-year mortality approaches 50%. The objec-
tive of the present study was to determine first year post-stroke costs in patients 
with or without AF. MethOds: We performed an observational, multicenter, natu-
ralistic and prospective study that included 16 hospitals (stroke units of National 
Health System hospitals) of 16 Spain regions. We took into consideration all costs 
related to stroke: direct health care costs (inpatient and outpatient), societal cots 
(formal and informal care), and indirect costs (productivity lost) during the first year 
post-stroke. Results: A total of 321 stroke patients were recruited, 291 (90.7%) with 
ischemic stroke (IS) and 30 (9.34%) with intracraneal hemorraghe (ICH); 160 with and 
161 without AF. The mean age was 72±13 years, 54.8% was male, basal NIH stroke 
scale was 9.11±6.79 and 28.9% presented moderate-high disability. The overall cost 
per year was 27,711.10€ . Direct health care costs: 8,491.22€ (30.64%), intrahospital 
costs were 68.8% (5,838.41€ ) of direct health care costs. Direct non-health care costs 
were 18,643.50€ (67.3% of total costs), and informal care supposed 89.5% of these 
costs. Indirect costs were 576.39€ (2.1% of total costs). ICH costs were higher than IS 
costs (28,895.04€ vs 27,596.53€ ). AF costs were higher than non AF but only formal 
care costs were statistically significant. The most explicative variables were age, 
male sex, NIH stroke scale, arterial hypertension comorbidity, and exitus along 
study. cOnclusiOns: Stroke and its consequences represent an important use of 
health care and social resources during first year post-stroke, total costs of stroke 
represent more than 5% of public health care costs in Spain. Several studies from 
other countries showed similar health care costs but lower informal care costs, 
which where more than two-thirds of total costs in our study, with a very high 
burden over the family or informal carer.
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nated: rivaroxaban and dabigatran 150mg. The efficiency frontier was constructed 
by connecting the remaining strategies: warfarin and apixaban. Apixaban resulted 
in an incremental additional cost of 2,870€ and an incremental QALY of 0.189, cor-
responding to an ICER of 15,157€ /QALY versus warfarin. The PSA indicated that the 
probabilities for apixaban being cost-effective versus warfarin were respectively 80% 
and 90% at the informal willing-to-pay thresholds of 30,000€ and 50,000€ . Sensitivity 
analysis identified stroke risk with apixaban and intracranial hemorrhage risk with 
warfarin as the variables most influencing the results. cOnclusiOns: Apixaban 
may be the most economically efficient alternative to warfarin in NVAF patients 
eligible for stroke prevention in France. All other strategies are dominated. However, 
uncertainty surrounding these results should be investigated through real life data.
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Liem A.H.4, Hoes A.W.1, Koffijberg H.1
1University Medical Center Utrecht, Utrecht, The Netherlands, 2Center for Diagnostic Support in 
Primary Care, Etten-Leur, The Netherlands, 3Meander Hospital, Leusden, The Netherlands, 4Sint 
Franciscus Gasthuis Rotterdam, Rotterdam, The Netherlands
Objectives: Heart failure is quite common in elderly patients with type 2-diabetes. 
Screening could potentially improve health outcomes at acceptable costs through 
early detection and adherence to current prescription guidelines. Based on a pro-
spective study the cost-effectiveness of different screening strategies to detect heart 
failure in patients aged 60 years with type 2-diabetes was assessed. MethOds: 
Data obtained from our prospective study and literature were used in a Markov 
model with a lifetime horizon to evaluate the incremental cost-effectiveness ratio 
of five increasingly extensive screening strategies. Differences in survival rates 
estimated by the Seattle Heart Failure Model between patients with undetected 
versus detected heart failure, induced by medication use, were used to adjust input 
parameters for health states related to undetected heart failure. Estimates for costs, 
utilities, and transition probabilities were additionally adjusted to age and NYHA 
class. Scenario analyses were performed to evaluate the impact of screening age 
and medication prescription and effectiveness. Probabilistic sensitivity analysis 
was performed to assess robustness of the results. Results: For both men and 
women usual care (no screening) had the highest probability of being cost-effective 
when the willingness to pay (WTP) was small. For WTP values in the range of € 4,600/
QALY-€ 27,000/QALY for men and € 5,200/QALY-€ 40,000/QALY for women evaluation 
of the electronic medical record and symptoms had the highest probability of 
being cost-effective. For higher WTP values echocardiography was the preferred 
strategy. For all screening strategies cost-effectiveness improved if prescription of 
heart failure medication was optimal or screening was started at the age of 70 
years. cOnclusiOns: Screening for heart failure through evaluation of electronic 
medical record and symptoms has favorable cost-effectiveness and echocardiog-
raphy may also be acceptable at higher WTP values. The benefits from screening 
could be much larger than currently identified when test outcomes would more 
often lead to proper medication prescription.
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Objectives: To assess the cost-effectiveness of apixaban versus rivaroxaban in 
the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) in 
Spain. MethOds: A Markov model was developed to simulate the evolution of 
NVAF patients throughout their lifetime. Cycle’s length was 6 weeks and 10 health 
states such as stroke, bleeding and other cardiovascular complications were defined. 
Drug’s safety and efficacy outcomes were obtained from a meta-analysis of pairwise 
indirect comparisons. The analysis was made from the Spanish National Health 
System (NHS) and the societal perspective. Apixaban and rivaroxaban pharmaco-
logical costs were calculated according to their recommended doses (5 mg twice 
daily (BID) and 20 mg once-a-day (QD), respectively). The cost of NVAF complications 
and disease management were obtained from Spanish sources. An annual discount 
rate of 3.5% for costs and health outcomes was applied. Results: Model results 
illustrate that 1,000 patients with NVAF treated with apixaban during their lifetime 
could avoid numerous complications versus rivaroxaban (9 strokes, 10 intracranial 
bleedings, 1 systemic embolism, 32 major bleedings, 52 clinically relevant non major 
bleedings and 12 related deaths). The use of apixaban was associated with 0.062 life 
years (LYG) and 0.049 quality-adjusted life-years (QALYs) gained when compared to 
rivaroxaban. Due to the lower expected mortality of patients, apixaban generated 
more costs per patient vs. rivaroxaban from the NHS perspective (115 € ), but savings 
would arise from the societal perspective (-241 € ). Incremental cost-effectiveness 
ratio results were 1,855 € per LYG and 2,347 € per QALY gained for the NHS analysis. 
Apixaban was dominant (more effective and less costly than rivaroxaban) from the 
societal perspective. Deterministic and probabilistic sensitivity analyses confirmed 
these results. cOnclusiOns: According to this analysis, apixaban is a cost-effective 
treatment compared with rivaroxaban for the prevention of stroke in patients with 
NVAF in Spain.
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Objectives: To calculate treatment costs for patients hospitalised for heart fail-
ure (HF) and analyse associated medical resource utilisation in a real-life care set-
ting. MethOds: The study was designed as a retrospective medical record review of 
a cohort of 478 patients diagnosed and hospitalised for HF (as the primary diagnosis 
for hospitalisation with ICD-10 codes I11, I13 and I50 meeting the inclusion and 
exclusion criteria of RELAX-AHF, a randomised, placebo-controlled phase III-trial 
in acute HF) in three German hospitals. Costs and medical resource utilisation for 
HF treatment were extracted from datasets according to §21 KHEntgG (Hospital 
Reimbursement Act) and patient medical records from the full year of 2011. Costs 
of HF treatment were determined according to the cost calculation scheme of the 
German Institute for the Hospital Remuneration System (InEK). A multivariate 
regression model was developed to detect incremental effects. Results: The mean 
cost per hospital stay was 3,518 € [3,203 € ; 3,833 € ; 95%CI 315 € ]. Differences in costs 
between male and female patients were not significant. The mean length of stay 
(LOS) was 8.55 days [8.0; 9.1; 95%CI 0.55] with in-hospital mortality being 5.4% (26 
of 478 patients). A total of 637 different active pharmaceutical agents and agent 
combinations were used. The percentage of patients treated with loop diuretics 
was 84%. About 8% of patients received nitrates (all formulations). The regression 
model showed a positive correlation for treatment costs with LOS and the amount 
of daily drug doses. cOnclusiOns: This analysis highlights that HF is a condition 
that imposes considerable costs to the German health care system. Data suggests 
that there is a high use of diuretics and a low use of nitrates in a real-life care setting.
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Objectives: To assess the cost-effectiveness of apixaban vs. dabigatran in 
stroke prevention in patients with non-valvular atrial (NVAF) fibrillation in 
Spain. MethOds: A Markov model was developed, with cycles of 6 weeks, through-
out the patient’s life and 10 health states. The analysis was made from the Spanish 
National Health System (NHS) and the societal perspective. The safety and efficacy 
of the drugs was obtained from a meta-analysis of pairwise indirect comparisons. 
Drug costs, (apixaban: 5 mg twice daily (BID); dabigatran: 110 mg BID or 150 mg 
BID), NVAF complications and disease management costs were obtained from 
Spanish sources. An annual discount rate of 3.5% for costs and health outcomes 
was applied. Results: In a cohort of 1,000 patients with NVAF, apixaban could 
avoid numerous complications versus dabigatran during their lifetime (24 ischemic 
strokes and 28 related deaths vs. dabigatran 110 mg; 11 ischemic strokes, 29 bleed-
ings and 19 deaths vs. dabigatran 150 mg). The use of apixaban was associated with 
0.126 life years (LYG) and 0.107 quality-adjusted life-years (QALYs) gained when 
compared to dabigatran 110 and 150 mg, respectively. Apixaban was estimated to 
generate more costs per patient vs. dabigatran 110 mg from the NHS perspective 
(139 € ) but overall savings could arise from the societal perspective (-524 € ), with a 
cost per QALY gained of 1,299 € for the NHS. Apixaban was dominant (more effective 
and less costly than dabigatran 110 mg) from the societal perspective. The cost per 
QALY gained, from the NHS and societal perspective, compared with dabigatran 
150 mg BID was 6,591 € and 10,676 € , respectively. Deterministic and probabilistic 
sensitivity analyses confirmed the stability of these results. cOnclusiOns: Results 
suggest that apixaban is cost-effective versus dabigatran for the prevention of stroke 
in patients with NVAF in Spain.
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Objectives: To evaluate the cost-effectiveness of apixaban in the prevention of 
stroke in patients with non-valvular atrial fibrillation (NVAF) from a French payer 
perspective. MethOds: A Markov model was developed in accordance to the new 
French guidelines of the Commission for Economic Evaluation and Public Health 
(CEESP) that also recommends applying efficiency frontier. A hypothetical cohort of 
patients with NVAF, 70 years old eligible for stroke preventive treatment (CHADS2≥ 1) 
was simulated over lifetime. Clinical events modeled included strokes, systemic 
embolism, intracranial hemorrhage, other major bleeds, clinically relevant non-
major bleeds and myocardial infarction. Treatment efficacy and bleeding data was 
obtained from ARISTOTLE. Efficacy data are from published indirect comparisons. 
Acute medical costs of stroke and hemorrhage were obtained from a dedicated 
analysis of the French national hospitalization database (PMSI). Long-term medical 
costs and utility data were derived from the literature. Univariate and probabilistic 
sensitivity analyses (PSA) were also performed to assess the robustness of the model 
projections. Results: Three strategies were strictly dominated: aspirin, dabigatran 
110mg, and dabigatran in sequential dosages. Two others were extendidly domi-
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of ivabradine plus standard therapy being cost-effective at a threshold of € 36,000/
QALY was found to be 96% in both within trial and lifetime analysis. This result is 
driven by a reduction in mortality and hospitalisations and the associated costs of 
care. cOnclusiOns: Ivabradine added to standard care could be a cost-effective 
treatment for the treatment in CHF patients in Greece.
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With 7 million deaths per year, ischaemic heart disease is the leading cause 
of mortality worldwide. In Acute Coronary Syndrome (ACS), the vast majority 
of fatal cardiovascular events occur after hospital discharge. Guidelines recom-
mend antithrombotic treatment for secondary prevention after ACS. Objectives: 
To assess the cost-effectiveness of rivaroxaban 2.5mg BID in combination with 
standard antiplatelet therapy (ASA alone or in combination with a thienopyri-
dine [clopidogrel or ticlopidine]) versus standard antiplatelet therapy alone for 
prevention of secondary events in ACS patients from a Swedish societal perspec-
tive. MethOds: A Markov model is used to capture single and multiple events, 
costs and utilities based on the time since index event to reflect clinical practice. 
For the first 2 years the model uses data from the ATLAS ACS 2-TIMI 51 clinical 
trial including efficacy, safety, treatment discontinuation and average patient 
age. After 2 years, transition probabilities were extrapolated using an exponen-
tial function method. Estimates for life expectancy, drug acquisition costs and 
other medical and indirect costs were derived from published Swedish sources. 
Cost and effects are discounted at 3.0%. Univariate and probabilistic sensitivity 
analyses were conducted with an assumed willingness to pay (WTP) threshold of 
SEK 500,000. Results: For the base case scenario, incremental life time costs are 
estimated at SEK 10,000.44 (€ 1,156), incremental QALYs at 0.14, and incremental 
cost per QALY at SEK 71,245.76 (€ 8,236). Univariate sensitivity analyses indicate 
that the results are sensitive to changes in the cost of rivaroxaban and baseline 
utility value. At an assumed WTP of SEK 500,000, rivaroxaban in combination with 
standard antiplatelet therapy is expected to be cost-effective. cOnclusiOns: 
From a Swedish societal perspective, secondary prevention with rivaroxaban 
2.5mg BID in combination with standard antiplatelet therapy can be considered 
a cost-effective option for patients with ACS. Sensitivity analyses demonstrated 
that the results are robust.
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Objectives: The most common cardiac arrhythmia (atrial fibrillation, AF) 
increases the risk of morbidity and mortality. We estimated the health and eco-
nomic consequences of the use of apixaban compared with warfarin reducing the 
risk of stroke in patients with AF, from the perspective of the Instituto Mexicano 
del Seguro Social (IMSS). MethOds: We performed a cost-effectiveness analysis 
using a Markov model (17 health states, six-week cycles), which simulates patients 
treated with warfarin (fixed dose: 5mg/day) or apixaban (10mg/day). Patients enter 
the model at age 70 and remain there until death (disease-related or according to 
Mexican life tables). Safety, efficacy and utilities were extracted from published 
sources. The costs of warfarin and AF-related clinical events were extracted from 
IMSS sources. The cost of apixaban was provided by the manufacturer. Costs are 
expressed in US$, 2013 and a 5% per-year discount rate was applied. Years of 
life and quality adjusted life years (QALYs) gained were the health outcomes. 
Univariate and probabilistic sensitivity analyzes were performed. Results: The 
model estimated 7.645 life years and 5.454 QALYs in the apixaban arm, which 
means 0.147 and 0.160 gained life years and QALY’s, respectively (regarding war-
farin). The costs of apixaban and warfarin were US$14,943 and US$15,042, respec-
tively (apixaban is a dominant alternative). Health gains with apixaban are driven 
by fewer event-related deaths (10/1000 patients at risk) as well as fewer hemor-
rhagic strokes (12) and bleeding (13 major bleeds, 41 clinically non-major bleeds) 
compared to warfarin-treated patients. Treatment costs are driven by drug acqui-
sition cost (apixaban) and monitoring cost (warfarin). cOnclusiOns: Apixaban 
is more effective and safer than warfarin reducing the risk of stroke associated 
with AF, as well as bleeding events. To achieve this improvement, no additional 
economic resources need to be invested, which makes apixaban a cost-saving 
intervention in the context of the IMSS.
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Objectives: Apixaban is an oral anticoagulant that has demonstrated a supe-
rior clinical profile compared to warfarin and aspirin in the management of 
patients with non-valvular Atrial Fibrilation (NVAF) and at least one additional 
risk factor for stroke. The objective of the present analysis was to assess the 
cost-effectiveness of apixaban against warfarin and aspirin for the preven-
tion of stroke in patients with NVAF in Greece. MethOds: A Markov model 
that evaluated clinical events, quality adjusted life expectancy and costs for 
patients treated with apixaban and warfarin or aspirin (VKA-suitable and 
Henriksson reported that surgery plus medical management can be considered 
cost effective as a treatment of asymptomatic carotid stenosis in 65 year-old men. 
He assumed a surgery relative risk reduction of 65.5%, or approximately an abso-
lute risk reduction (ARR) of 8% in this population. However, data for the compara-
tor arm (medical management alone) were dated and did not reflect efficacies 
of current medical therapies. Objectives: To analyze using Bayesian methods, 
asymptomatic carotid stenosis clinical trial data, and more current medical therapy 
data the probability of achieving this 8% ARR and an incremental cost per QALY 
of approximately $50,000 (US, inflated - 2013 dollars). MethOds: The outcome of 
interest from the clinical trials was the mean difference in the probability of any 
stroke or perioperative death between surgery (carotid endarterectomy [CEA]) and 
aggressive medical management (MM). The CEA data came from the Asymptomatic 
Carotid Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery Trial 
(ACST). The updated medical management data came from a systematic review 
published in the journal Stroke (Abbott, 2009). The Bayesian analysis employed a 
Beta-Binomial Model. Results: The posterior distribution of the Bayesian analysis 
representing the ARR of CEA versus MM had a mean of 0.008 with an essentially 
zero probability of achieving the Henriksson assumption of 8% ARR. Using the mean 
of this posterior distribution, the resulting incremental cost per QALY exceeded 
$500,000 in 65 year-old men – a value unlikely to be considered cost effective in any 
country. cOnclusiOns: Bayesian analysis allows the prediction of the probability 
that a treatment alternative exceeds a predefined threshold. A powerful feature of 
Bayesian analysis is the ability to incorporate additional and/or newer data. This 
newer data can drastically alter assumptions about the cost effectiveness of treat-
ment alternatives.
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Objectives: Aortic stenosis is the most common valvular heart disease in the 
elderly –its prevalence is estimated to be up to 5% in individuals over 75 years. 
Surgical replacement of aortic valve is considered the standard care and in the 
absence of serious coexisting conditions, the procedure is associated with low 
operative mortality. However, a significant proportion of patients cannot undergo 
surgery due to high surgical risk associated with advanced age or presence of 
multiple coexisting conditions. Treatment with transcatheter aortic-valve implan-
tation (TAVI) is a therapy with potentially lower peri-procedure risk and has been 
used as a therapeutic option in this group considered inoperable. This study aims 
to develop a cost-effectiveness analysis of TAVI in patients with severe aortic 
stenosis who are not suitable for surgical treatment according to Brazilian Private 
System Perspective. MethOds: A Markov model was developed to compare TAVI 
versus standard therapy (drug treatment with or without aortic balloon valvulo-
plasty) with a 5-year time horizon. Outcomes in the model were based on safety 
and effectiveness (as measured by clinical outcomes of chance of successful 
implantation procedure and survival from PARTNER cohort B trial). Resource use 
included early perioperative complications (30 days) and late events. Cost data 
were obtained from Brazilian public lists (CMED/SIMPRO/CBHPM). Results were 
expressed as incremental cost-effectiveness ratio (ICER) per life years gained 
(LYG). Probabilistic sensitivity analysis was performed to confirm robustness of 
results. Results: Compared with standard therapy with or without aortic balloon 
valvuloplasty, use of TAVI improves survival in 0.97 life years with an incremental 
cost of US$43,602, resulting an ICER of US$45,080/LYG. In an alternative scenario 
considering 10-year time horizon, ICER was 27,565/LYG. cOnclusiOns: Use of 
TAVI results in improved survival with a low risk of serious adverse events, and 
demonstrates a cost-effectiveness profile when compared to other technologies 
already incorporated in Brazil.
PCv72
ECONOMIC EvALUATION OF IvABRADINE IN CHRONIC HEART FAILURE IN 
GREECE
Kourlaba G.1, Parissis J.2, Karavidas A.3, Beletsi A.4, Milonas C.5, Maniadakis N.6
1National and Kapodistrian University of Athens School of Medicine, Athens, Greece, 2Attikon 
University Hospital, Athens, Greece, 3Athens General Hospital, Athens, Greece, 4SERVIER HELLAS 
Pharmaceuticals Ltd., Athens, Greece, 5National School of Public Health, Athens, Athens, Greece, 
6National School of Public Health, Athens, Greece
Objectives: In the SHIFT trial, ivabradine administered to chronic heart failure 
(CHF) patients in combination with standard therapy significantly reduced cardio-
vascular death and hospital admission for cardiovascular problems. An economic 
evaluation of ivabradine plus standard care against standard care alone, for the 
management CHF in patients with a baseline heart rate ≥ 75b.p.m. was conducted 
from the Greek third party-payer perspective. MethOds: An existing Markov model 
consisting of two health states for CHF NYHA classes I to IV (i.e. alive, dead) was 
adapted to the Greek health care setting. In each one month cycle, patients can 
either remain alive or die, during their life span or 29 months (i.e. within SHIFT 
trial period). Health state utilities were estimated from EQ-5D index scores obtained 
from the SHIFT clinical trial and using appropriate modeling techniques the data 
were extrapolated beyond the trial period. All costing data reflects the year 2013. 
Probabilistic sensitivity analyses (PSA) were conducted. Both cost and outcomes 
were discounted at 3.5% per year. Results: Results for within trial analysis 
revealed that ivabradine had an incremental cost and incremental QALY of € 905 
and 0.05 respectively, leading to an incremental cost per QALY gained of € 16,635/
QALY. Ivabradine was a cost-effective alternative at a willingness to pay thresh-
old of € 36,000 per QALY gained Moreover, the cumulated lifetime analysis showed 
incremental cost of € 2,792 and incremental QALY of 0.28. The ICER for ivabradine 
was calculated to be € 9,986 per QALY gained. The PSA showed that the likelihood 
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PHARMACOECONOMIC EvALUATION ACCEPTABILITy OF CLOPIDOGREL vERSUS 
ACETyLSALICyLIC ACID IN PATIENTS wITH CARDIOvASCULAR DISEASE FOR 
STROKE PREvENTION IN UKRAINE
Mishchenko O., Iakovlieva L., Adonkina V., Kyrychenko O., Gerasymovà O.
National University of Pharmacy, Kharkiv, Ukraine
Objectives: The results of many clinical trials demonstrate the benefit of long-
term antiplatelet therapy in reducing the risk of cardio- and cerebrovascular com-
plications. Both acetylsalicylic acid (ASA) and clopidogrel are effective, but have 
potentially serious side effects, and clopidogrel is more expensive than ASA. The 
purpose of the study is to evaluate the pharmacoeconomic acceptance of clopi-
dogrel versus ASA in patients with atherosclerotic vascular disease manifested 
as either recent ischaemic stroke, recent myocardial infarction, or symptomatic 
peripheral arterial disease to prevent non-fatal stroke and death rate according to 
the clinical trial CAPRIE from Ukrainian perspective. MethOds: Outcomes of the 
clinical study CAPRIE, modeling “decision tree” and analysis “cost-effectiveness” 
were used. Results: The results of the clinical trial CAPRIE study showed, that 
clopidogrel is more effective versus ASA for reducing the risk of nonfatal stroke: 
absolute risk reduction is -2.7%. Model “decision tree” was built using the probabili-
ties of events (nonfatal stroke and death) from the study CAPRIE. Direct costs were 
calculated taking into account the costs of antiplatelet therapy, of nonfatal stroke 
treatment (drugs, diagnosis, patient’s stay in hospital) and the cost of rehabilita-
tion after stroke. Indirect costs are not taken into account because the patients 
were of retirement age (62.5 years old). As a result of calculations it was found, 
that antiplatelet therapy with clopidogrel is more expensive and more effective (2 
additional lives saved per 1000 patients over 1.91 years) compared with ASA. Due 
to the threshold of society “willingness to pay” per 1 life saved, or 1 QALY, use of 
clopidogrel as antiplatelet agent in patients with cardiovascular disease is economi-
cally profitable for Ukraine. cOnclusiOns: The use of clopidogrel as an antiplatelet 
agent in patients with cardiovascular disease to prevent nonfatal stroke compared 
to the ASA is economically profitable for Ukraine.
PCv79
AN ANALySIS OF THE COST EFFECTIvENESS OF LEFT ATRIAL APPENDAGE 
CLOSURE FOR THE PREvENTION OF STROKE IN PATIENTS wITH ATRIAL 
FIBRILLATION AND ABSOLUTE CONTRAINDICATIONS TO wARFARIN THERAPy
Reddy V.Y.1, Akehurst R.L.2, Amorosi S.L.3, Armstrong S.4, Holmes D.R.5
1Mount Sinai School of Medicine, New York, NY, USA, 2University of Sheffield, Sheffield, UK, 
3Boston Scientific, Natick, MA, USA, 4GfK Bridgehead, Wayland, MA, USA, 5Mayo Clinic, 
Rochester, MN, USA
Objectives: Stroke and its associated disability costs the European Union an esti-
mated € 62 billion per year. Warfarin is the mainstay for stroke prevention in atrial 
fibrillation (AF), but many patients have absolute contraindications to this drug. The 
Watchman device for left atrial appendage closure (LAAC) received CE mark for stroke 
prevention in AF patients with contraindications to warfarin. This analysis sought to 
estimate the cost effectiveness of treating warfarin-ineligible AF patients with LAAC 
as compared to standard aspirin therapy. MethOds: A Markov model was developed 
comparing clinical outcomes and total costs between patients treated with LAAC or 
aspirin over 5 and 10 years based largely on clinical outcomes from the Aspirin and 
Plavix Registry (ASAP) and ACTIVE trials. Clinical events included ischemic stroke, 
TIA, systemic embolism, bleeding, and acute myocardial infarction as well as proce-
dure-related events. Germany was chosen as the country of analysis because of its 
unique DRG for the LAAC procedure. Acute costs were taken from German DRGs and 
long-term disability costs were taken from the Berlin Acute Stroke Study. Sensitivity 
analysis was performed on clinical and cost inputs; the model was most sensitive 
to changes in the rate of ischemic stroke. Results: LAAC demonstrated a benefit 
in terms of ischemic strokes and mortality avoided. The cost per ischemic stroke 
avoided was € 91,020 and € 24,722 at 5 and 10 years, respectively. The cost per life year 
gained for LAAC versus aspirin was € 22,694 at 5 years and decreased to € 5,859 at 
10 years. cOnclusiOns: LAAC is a cost-effective alternative to aspirin therapy in 
patients with contraindications to warfarin. Cost offsets achieved with LAAC become 
considerably more pronounced over time. This analysis highlights the importance of 
considering the lifetime costs of stroke prevention in AF, especially as the probability 
of both stroke and bleeding increases with patient age.
PCv80
COST-EFFECTIvENESS OF RIvAROxABAN IN THE PREvENTION OF STROKE IN 
NON-vALvULAR ATRIAL FIBRILLATION PATIENTS IN ITALy
Capri S.1, Veneziano M.2, Ricciardi W.G.2, D’Ausilio A.3, Pedone M.P.4, Bianchi C.4
1Institute of Economics, Castellanza, Italy, 2Catholic University of Sacred Heart, Rome, Italy, 
3Creativ Ceutical, Luxembourg, Luxembourg, 4Bayer Pharma, Milano, Italy
Objectives: To perform a cost-effectiveness analysis of rivaroxaban (once-daily) in 
the prevention of stroke and systemic embolism of patients with non-valvular atrial 
fibrillation (NVAF) and in patients sub-groups from the perspective of the Italian 
health care system (SSN). MethOds: A Markov model was developed with a life-
time timeframe where a hypothetic NVAF patients’ cohort is treated with Vitamin-K 
antagonists (VKAs), antiplatelet drugs (ASA) or no therapy. Patients remain stable 
or progress towards other health states (ischemic or hemorrhagic stroke, myocar-
dial infarction and bleedings) until death. The base case compares rivaroxaban 
with VKAs. In subgroup analyses, rivaroxaban is compared with patients at highest 
unmet medical need: 1. VKA patients with poor INR control, 2. patients under ASA 
or 3. not treated. Clinical data were derived from ROCKET-AF trial or a network 
meta-analysis. Utility data were retrieved from published literature. Health care 
resources consumption was valued using average regional tariffs in Italy. Since 
rivaroxaban price is not officially published, the price of the first novel oral antico-
agulant approved in this indication in Italy was considered. Model outcomes are 
expressed in terms of incremental cost per quality adjusted life year (QALY) gained 
(ICER). Univariate and probabilistic sensitivity analyses were performed Results: 
In the base case, rivaroxaban showed to be cost-effective compared to VKA with an 
VKA-unsuitable, respectively) formed the basis of the analysis. Clinical events 
(ischemic strokes, hemorrhagic strokes, intracranial hemorrhages, other major 
bleeds, clinically relevant non-major bleeds, myocardial infarctions and car-
diovascular hospitalizations) were modeled over a lifetime horizon based on 
the clinical efficacy of each comparator, as reported by two phase-III clini-
cal trials (ARISTOTLE and AVERROES). Resource use with regards to patient 
monitoring was elicited via an experts’ panel (cardiologists & internists). 
Cost calculations reflect the local clinical setting, and followed a third-party 
payer perspective (Euros, year 2013, discounted at 3%). Results: Apixaban 
was projected to reduce the occurrence of clinical events and increase quality 
adjusted life expectancy compared to warfarin and aspirin (an incremental 
increase of 0.225 and 0.274 QALYs per patient, respectively). Taking into account 
costs of medications, treatment and management of events, the incremental 
cost-effectiveness ratio for apixaban versus warfarin and aspirin was esti-
mated at 12,154.6 € /QALY and 5,980.6 € /QALY gained, respectively. Extensive 
sensitivity analyses indicated that results were robust over a wide range of 
inputs. cOnclusiOns: Based on the results of this analysis, apixaban can 
be a cost-effective alternative to warfarin and aspirin for the management of 
VKA-suitable and VKA-unsuitable patients with NVAF, respectively, in Greece.
PCv76
TOTAL COSTS AND OUTCOMES OF DRUG-ELUTING STENT PLACEMENT wITH 
INTRAvASCULAR ULTRASOUND (IvUS) COMPARED wITH ANGIOGRAPHy 
ALONE: A COST-EFFECTIvENESS ANALySIS FROM THE PERSPECTIvE OF THE 
ITALIAN HEALTH SySTEM
Wasserman M.1, Priest V.2, Alberti A.3, Gelera A.4, Stefanini L.4, Simmonds M.5
1Double Helix Consulting, London, UK, 2Double Helix Consulting (APAC), Singapore, Singapore, 
3Istituto Clinico Sant’Ambrogio, Milan, Italy, 4Boston Scientific, Milan, Italy, 5Boston Scientific, 
Sydney, Australia
Objectives: Intravascular ultra-sound (IVUS) allows physicians to generate a supe-
rior image of coronary arteries during percutaneous coronary interventions (PCI), 
providing a tomographic, 360-degree view of the arterial wall from the inside, which 
allows a more accurate and complete assessment than is possible with angiography. 
The purpose of this study was to understand the cost-effectiveness of IVUS com-
pared with traditional angiography techniques in drug-eluting stent (DES) implanta-
tion, from the perspective of the Italian health system. MethOds: A Markov model 
was developed to extrapolate the comparative costs and outcomes of a theoretical 
population of 1000 patients undergoing DES implantation with traditional angiogra-
phy alone, or in conjunction with IVUS. The model assesses cardiac events, including 
revascularisations and myocardial infarctions from a health system perspective. 
Outcomes with and without IVUS were based on a meta-analysis by Zhang et al 
(2013). Because of limited clinical evidence to inform the long-term outcomes of 
IVUS compared with angiography, the model either assumes the benefit of IVUS 
is conferred only in the first year of treatment, or that the benefit is maintained 
permanently. Results: Using IVUS during PCI cost an average of € 542 per patient, 
and yields an additional 0.022 quality adjusted life years (QALYs) per patient. In a 
population of 1,000 patients, IVUS led to a reduction of 6.7 revascularisations and 
5.9 less myocardial infarctions (MI) over the lifetime of a patient. When the revas-
cularisation and MI benefit of IVUS is assumed to extend for the patient’s lifetime, 
angiography with IVUS costs € 38 per patient and yields an additional 0.09 QALYs 
over a patient’s lifetime; avoiding 13.4 MIs and 12.3 revascularisations per 1,000 
patients. cOnclusiOns: IVUS appears to be a cost-effective addition to traditional 
angiography in DES placement in Italy, with the increased upfront cost of IVUS offset 
by reduced cardiac events in IVUS-treated patients over time.
PCv77
COST-EFFECTIvENESS OF APIxABAN vERSUS OTHER NEw ORAL 
ANTICOAGULANTS FOR THE PREvENTION OF STROKE: AN ANALySIS OF 
PATIENTS wITH ATRIAL FIBRILLATION IN GREECE
Athanasakis K.1, Arzoumanidou D.1, Karampli E.1, Armelidou E.2, Giovas P.2, Petrikkou E.3, 
Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Pfizer Hellas, Athens, Greece, 3BMS Hellas, 
Athens, Greece
Objectives: Apixaban, dabigatran (150 mg BID and 110 mg BID) and rivaroxaban 
are three novel oral anticoagulants (NOACs) currently approved for stroke preven-
tion and systemic embolism in non-valvular atrial fibrillation (NVAF) patients. 
The objective of this analysis was to assess the cost-effectiveness (CE) of apixa-
ban against other NOACs for the prevention of stroke in patients with NVAF in 
Greece. MethOds: A Markov model that evaluated clinical events, quality adjusted 
life expectancy and costs for patients treated with apixaban or other NOACs formed 
the basis of the analysis. Clinical events (ischemic strokes, hemorrhagic strokes, 
intracranial hemorrhages, other major bleeds, clinically relevant non-major bleeds, 
myocardial infarctions and cardiovascular hospitalizations) were modeled for a 
lifetime horizon. Due to lack of head-to-head comparisons, efficacy and safety data 
was derived from an indirect treatment comparison (ITC). The key pivotal trials, 
ARISTOTLE, ROCKET-AF and RE-LY, all included warfarin as a comparator therefore 
allowing for an ITC. Resource use with regards to patient monitoring was elic-
ited via a panel of experts (cardiologists & internists). Cost calculations reflect the 
local clinical setting and followed a third-party payer perspective (Euros, year 2013, 
discounted at 3%). Results: Apixaban was projected to reduce the occurrence of 
clinical events and increase quality-adjusted life expectancy and costs of treatment 
compared to other NOACs. Taking into account costs of medications, treatment 
and management of events, the incremental cost-effectiveness ratios for apixaban 
5 mg BID versus dabigatran 150 mg BID, dabigatran 110 mg BID and rivaroxaban 
20 mg QD were estimated at 15,403€ /QALY, 4,955€ /QALY and 10,130 € /QALY gained, 
respectively. Extensive sensitivity analyses indicated that results were robust over a 
wide range of inputs. cOnclusiOns: Based on the results of this analysis, apixaban 
can be a cost-effective alternative to other NOACs, for the prevention of strokes in 
patients with NVAF in Greece.
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using the UKPDS risk engine. Statin adherence was measured as pill days cov-
ered (PDC) in the IADB.nl pharmacy research database. Cost-effectiveness was 
measured in costs per quality-adjusted life-year (QALY) form the health care-
payers’ perspective. Results: For an average patient aged 60 at diagnosis, statin 
treatment was highly cost-effective at around € 2,300 per QALY. Favourable cost-
effectiveness was robust in sensitivity analysis. Differences in age and 10-year 
cardiovascular risk showed large differences in cost-effectiveness from more 
than € 100,000 per QALY to almost being cost saving. For the average patient aged 
40 at diabetes diagnosis, statin treatment for primary prevention was not cost-effec-
tive. cOnclusiOns: Despite the non-adherence levels observed in actual practice, 
statin treatment is cost-effective for primary prevention in patients newly diagnosed 
with type 2 diabetes. Due to large differences in cost-effectiveness according to differ-
ent risk and age groups, the efficiency of the treatment could be increased by targeting 
patients with relatively higher cardiovascular risk and higher ages.
PCv84
DEvELOPMENT OF NOvEL IMAGING TESTS TO SELECT PATIENTS FOR 
INDIvIDUALIzED THERAPIES: ARE THEy wORTH FURTHER INvESTMENT?
Buisman L.R., Rijnsburger A.J., Redekop W.K.
Erasmus University Rotterdam, Rotterdam, The Netherlands
Objectives: Patients with a recent transient ischemic attack (TIA) or minor ischemic 
stroke who receive medicines have a 10-year risk of about 16% for any recurrent 
stroke. Non-invasive molecular imaging technologies are currently being developed 
to improve individual stroke risk prediction. We estimated the potential lifetime cost-
effectiveness of a novel imaging test for stroke prediction in an early stage of develop-
ment. MethOds: Decision modelling was used to estimate the potential value of an 
add-on test that could identify which patients with a recent TIA or minor ischemic 
stroke should undergo surgery instead of receive medicines. The comparator was 
patient management according to Dutch guidelines. Test sensitivity and specificity 
were varied from 0-100% and its cost was set at € 350. Different age- and gender-spe-
cific subgroups were examined to see how much cost-effectiveness varied. Results: 
A perfect add-on test (100% sensitivity and specificity) for 60-year-old men appears to 
be cost-effective versus Dutch guidelines, with an estimated 0.61 QALY gain, € 3,986 
cost increase, and an incremental cost-effectiveness ratio (ICER) of € 6,534/QALY 
gained. A test with sensitivity= 60% and specificity= 100% increases both health (0.14 
QALYs) and costs (€ 2,888), resulting in an ICER of € 20,338/QALY gained. Similarly, a 
test with sensitivity= 100% and specificity= 60% increases both health (0.29 QALYs) 
and costs (€ 5,784), resulting in an ICER of € 19,946/QALY gained. cOnclusiOns: An 
imaging test that improves risk prediction and therefore treatment decisions for 
patients with a recent TIA or minor ischemic stroke has the potential to optimize cost-
effectiveness by reducing the risk of recurrent stroke. However, reduced sensitivity 
or specificity of the test reduces its cost-effectiveness versus the Dutch guidelines. 
Developers must consider if the minimum level of accuracy required to be cost-effec-
tive is close to the maximum capability of the test. Model-based analyses are valu-
able in facilitating decisions about investments in the further development of a test.
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PERSONALIzED TREATMENT IN HEART FAILURE DISEASE MANAGEMENT 
IMPROvES OUTCOMES AND REDUCES COSTS
Cao Q., Postmus D., Hillege H.L., Buskens E.
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Objectives: At the population level, disease management programs (DMPs) for heart 
failure (HF) have proven to be effective in increasing quality-adjusted survival and 
reducing the rate of hospital readmission. However, a systematic assessment as to 
whether these outcomes could still be improved upon by tailoring the content and 
structure of such DMPs to the risk profile of the individual patient has not yet been 
conducted. Using data from a previously conducted randomized controlled trial, the 
purpose of this study was to explore the clinical and health economic consequences 
of assigning different DMPs to different risk categories of HF patient. MethOds: The 
analysis was conducted alongside the COACH study, in which 1023 patients were ran-
domly assigned to one of three DMPs: care-as-usual (routine follow-up by a cardiolo-
gist), basic additional support by a nurse specialized in HF management (HF-nurse), 
and intensive additional support by an HF-nurse. The Subpopulation Treatment Effect 
Pattern Plot (STEPP) methodology was applied to graphically establish suitable cut-
offs for stratifying patients into different risk categories based on their predicted 
18-month mortality risk. Separate cost-effectiveness analyses were subsequently 
performed within each of these strata to determine per risk category the DMP that 
would be optimal in terms of survival time and costs. Results: Based on the STEPP 
analysis, a cut-off of 0.17 was selected to classify 346 (33.8%) patients as low risk and 
677 (66.2%) patients as high risk. At a threshold value of € 10,000 per life-year, this 
resulted in an 82.9% probability that intensive support would be optimal for low-risk 
patients and an 83.6% probability that basic support would be optimal for high-risk 
patients. cOnclusiOns: Assigning different DMPs to different risk groups of patient 
improved outcomes and reduced costs. Tailoring the content and structure of such 
programs to the risk profile of the individual patient seems therefore desired.
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THE COST-EFFECTIvENESS OF DABIGATRAN AND THE OPPORTUNITy COST OF 
DELAyED SUBSIDISED ACCESS IN AUSTRALIA
Tilden D.1, Germanos P.2, Gordon J.2, Tocchini L.1
1THEMA Consulting Pty. Limited, Pyrmont, Australia, 2Boehringer Ingelheim Pty Limited, North 
Ryde, NSW, Australia
Objectives: Dabigatran was recommended by the Pharmaceutical Benefits 
Advisory Committee (PBAC) in March 2011 for the treatment of non-valvular atrial 
fibrillation (NVAF) but was not listed on the Pharmaceutical Benefits Scheme (PBS) 
for over two years. This analysis examines the cost-effectiveness of dabigatran 
and the opportunity cost of delayed reimbursement from a societal perspec-
tive. MethOds: This analysis estimated the costs for dabigatran compared with 
warfarin and a mixed comparator (warfarin/aspirin/untreated) reflective of current 
ICER of € 11,000/QALY which is below the threshold deemed acceptable from Italian 
payers (25.000€ -40.000€ ). In the subgroups analyses, rivaroxaban demonstrated to 
be a dominant strategy (more effective and less costly). Sensitivity analyses showed 
the robustness of the results. cOnclusiOns: Rivaroxaban is a cost-effective alter-
native to VKA and is cost-saving for the SSN in the treatment of NVAF patients at 
highest unmet medical need.
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COST-EFFECTIvENESS OF DABIGATRAN ETExILATE FOR THE SECONDARy 
PREvENTION OF RECURRENT DEEP vEIN THROMBOSIS AND PULMONARy 
EMBOLISM IN THE UNITED KINGDOM
Wolowacz S.1, Brockbank J.2, Sunderland T.J.3, Gonschior A.K.4
1RTI Health Solutions, Manchester, UK, 2RTI Health Solutions, Didsbury, UK, 3Boehringer 
Ingelheim, Berkshire, UK, 4Boehringer-Ingelheim GmbH, Ingelheim Am Rhein, Germany
Objectives: To estimate the cost-effectiveness of dabigatran etexilate (dabigatran) 
for the secondary prevention of deep vein thrombosis (DVT) and pulmonary embo-
lism (PE) from the perspective of the UK National Health Service. MethOds: A 
Markov model was developed to estimate costs and outcomes over the lifetime of 
a cohort of patients receiving either dabigatran (150mg given orally, twice daily) 
or placebo for 6 months after having completed 6 to 18 months of anticoagulation 
treatment for a DVT or PE. Modelled events included recurrent DVT and PE, major 
bleeding (including long-term disability from intracranial haemorrhage), clinically 
relevant non-major bleeding, myocardial infarction, unstable angina, pulmonary 
hypertension, severe postthrombotic syndrome, and death. Efficacy and safety 
parameters were based on the RE-SONATE study; the period of follow-up was 6 
months with an extension to 18 months. Probabilities of recurrent DVT and PE after 
trial follow-up were based on a prospective cohort study of 1,626 patients followed-
up for a median of 50 months and were assumed to be equivalent in both treatment 
groups. Utility estimates were based on EQ-5D data collected in dabigatran trials and 
published literature. The mean duration of therapy was based on the RE-SONATE 
study; other costs were based on NHS Reference Costs and published literature. 
Costs and outcomes were discounted at 3.5% per annum. Univariate and probabilis-
tic sensitivity analyses were performed. Results: In the base-case analysis, mean 
total costs for dabigatran and placebo patients were £7,147 and £7,520 respectively; 
mean QALYs were 13.089 and 13.070 respectively. Dabigatran was dominant; the 
probability of cost-effectiveness at a willingness-to-pay threshold of £20,000 per 
QALY was 63%. In univariate sensitivity analysis, dabigatran was dominant in all 
analyses. cOnclusiOns: This analysis suggests that dabigatran is likely to be cost-
saving compared to placebo for the secondary prevention of DVT and PE in the UK.
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A HEALTH ECONOMIC EvALUATION OF FENOFIBRIC ACID IN COMBINATION 
wITH STATINS IN THE PREvENTION OF CARDIOvASCULAR DISEASE IN 
TAIwANESE MIxED HyPERLIPIDEMIA PATIENTS
Ramos M.1, Vellopoulou K.2, Lamotte M.3, Chang C.J.4, Carr E.5
1IMS Health, Barcelona, Spain, 2IMS Health, Vilvoorde, Belgium, 3IMS Health HEOR, Vilvoorde, 
Belgium, 4Chang Gung University, Tao-Yuan, Taiwan, 5Abbott Laboratories, Allschwil, Switzerland
Objectives: Statins are the standard treatment for cardiovascular disease (CVD) 
prevention however, with limited effect on triglyceride (TG) and high-density lipo-
protein-cholesterol (HDL-C) in mixed hyperlipidemia. Fenofibric acid (FA) is approved 
for co-administration with statins to reduce TG and increase HDL-C in patients with 
mixed hyperlipidemia at goal for LDL-C with statins. This study assesses the cost-
effectiveness of FA combined with low (LDS) or medium (MDS) dose statins versus 
low, medium or high (HDS) dose statins alone in the prevention of CVD in Taiwanese 
patients with type 2 diabetes and mixed hyperlipidemia. MethOds: A 5-health-
state Markov model for diabetic patients with mixed hyperlipidemia already 
treated with statin (TG:250mg/dl; HDL-C:35mg/dl; LDL-C:115mg/dl; TC:200mg/dl) 
was developed, using a lifetime horizon with annual cycles. PROCAM (first event) 
and Framingham (subsequent event) risk equations were used. Effects on TG, HDL-C 
and TC for each comparator were derived from pooled simvastatin, atrovastatin 
and rosuvastatin trials. Drug and event costs were based on official national data-
bases. Annual discounting (5%) was applied to outcomes and costs. Incremental cost 
(€ ) per Quality of Life Gained (QALYG) was calculated from the Taiwanese Bureau 
of National Health Insurance perspective. Results: Compared to LDS and MDS, 
treatment with FA+LDS resulted in higher costs (€ 2,225; € 1,676) but more QALYG 
(0.311; 0.064), resulting in an incremental cost-effectiveness ratio of € 7,161/QALYG 
and € 26,375/QALYG respectively. Compared to HDS, FA+LDS costs were lower with 
slightly less QALYG (ICER: € 183,490/QALYG). Compared to FA+MDS, FA+LDS was 
dominant with lower costs (-€ 900) and higher QALYG (0.004). Sensitivity analyses 
showed robustness of the results. The probability for FA+LDS being cost-effective 
(< GDP threshold € 45,400) is 100% for both, LDS and MDS. cOnclusiOns: In this 
specific mixed hyperlipidemia population, FA+LDS is likely to be a cost-effective 
alternative to LDS or MDS alone, potentially allowing for lower statin doses in pre-
venting CVD.
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COST-EFFECTIvENESS OF STATINS FOR PRIMARy PREvENTION IN NEwLy 
DIAGNOSED TyPE 2 DIABETES PATIENTS IN THE NETHERLANDS
de Vries F.M.1, Denig P.2, Visser S.T.1, Hak E.1, Postma M.J.1
1University of Groningen, Groningen, The Netherlands, 2University Groningen, Groningen, The 
Netherlands
Objectives: Statins reduce the risk of cardiovascular events in patients 
with diabetes. The aim of this study is to determine whether statin treatment 
for primary prevention in newly diagnosed type 2 diabetes is cost-effective, 
taking non-adherence, baseline risk, and age into account. MethOds: A cost-
effectiveness analysis was performed using a Markov model with a time horizon 
of 10 years. The baseline 10-year cardiovascular risk was estimated in a Dutch 
population of primary prevention patients with newly diagnosed diabetes from 
the Groningen Initiative to Analyse Type 2 Diabetes Treatment database (GIANTT), 
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patients with a recent ischemic stroke/TIA. The purpose of this study was to esti-
mate the cost-effectiveness of two screening methods for detection of silent AF, 
brief intermittent long-term ECG recordings at regular time intervals and short-
term 24-hours continuous ECG (Holter-ECG) and to compare them to a no screening 
alternative in patients with a recent ischemic stroke. MethOds: The long-term 
(20 year) costs and effects of brief intermittent long-term ECG recordings at regular 
time intervals and short term continuous ECG are estimated with a decision ana-
lytic model combining the result of a clinical study and epidemiological data. The 
structure of a cost-effectiveness analysis was used in this study. The short term 
decision tree model analyzed the screening procedure until the onset of antico-
agulant treatment. The second part of the decision model follows a Markov design 
simulating the patients for 20 years. Results: Continuous 24 h ECG recording was 
dominated by intermittent ECG due to lower sensitivity and higher costs. The base 
case analysis compared intermittent-ECG screening with no screening of patients 
with recent stroke. The implementation of the screening program on 1000 patients 
resulted in 10,9 avoided strokes and the gain of 29,2 life years or 22,7 QALYs and 
cost savings of € 55 000. cOnclusiOns: Screening of silent AF by intermittent ECG 
recordings in patients with a recent ischaemic stroke is cost-effective use of health 
care resources saving costs, lives and quality of life.
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ISSUES wITH COST-EFFECTIvENESS MODELLING OF DIAGNOSTIC TESTS – CASE 
STUDy OF ISCHAEMIC CARDIOMyOPATHy
Thokala P., Thomas S., Campbell F.
University of Sheffield, Sheffield, UK
Objectives: To estimate the cost-effectiveness of diagnostic pathways for assessing 
patients with ischaemic cardiomyopathy to identify patients with viable myocar-
dium with a view to revascularisation. MethOds: A decision analytic model was 
developed to estimate the cost-effectiveness of diagnostic strategies for assessing 
patients with ischaemic cardiomyopathy. The different diagnostic pathways were 
applied to a hypothetical cohort of patients with ischaemic cardiomyopathy and the 
probability of successful identification of viable myocardium and non-viable myo-
cardium was determined by the accuracy of the diagnostic pathway. It was assumed 
that patients diagnosed with viable myocardium would be managed promptly by 
revascularisation and that the patients diagnosed with non-viable myocardium 
would be on medical therapy. The model assigned each patient a risk of death and 
rehospitalisation depending upon whether they are truly viable and whether they 
had revascularisation or not. Each patient then accrued lifetime QALYs. Health care 
costs were also accrued through measuring diagnostic costs and treatment costs, 
depending on the pathway and their treatment status. Results: All the diagnostic 
pathways are cost-effective when compared with no testing at current NICE thresh-
old, this suggests that all the current services for diagnosing viable myocardium 
are a cost effective use of NHS resources irrespective of the diagnostic pathway 
used. For services that need to decide the most cost-effective strategy starting from 
scratch, then Stress CMR is the most cost-effective strategy. cOnclusiOns: There 
are a number of issues with abstracting the data for cost-effectiveness modelling 
of diagnostic tests. For example, the diagnostic accuracy depends upon the type of 
index test, gold standard test and threshold used. Furthermore, the benefits of treat-
ments after diagnosis are not always clear and might be linked to the type of diag-
nostic test. Appropriate caution needs to be taken when evaluating diagnostic tests.
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ECONOMIC EvALUATION OF IvABRADINE FOR CHRONIC HEART FAILURE NyHA 
II TO Iv CLASS wITH SySTOLIC DySFUNCTION IN IRELAND
Lacey L.1, McAuliffe A.2, Poisson M.3
1Lacey Solutions Ltd., Skerries, Ireland, 2Servier Ireland, Dun Laoghaire, Ireland, 3Laboratoires 
SERVIER, Suresnes, France
Objectives: Ivabradine is approved by the European Medicine Agency for the treat-
ment of Chronic Heart Failure (CHF) NYHA II to IV class with systolic dysfunction 
in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with 
standard therapy including beta-blocker therapy or when beta-blocker therapy is 
contraindicated or not tolerated. The study objective was to perform a cost-effective-
ness analysis of ivabradine based on the outcomes of the SHIFT clinical trial from 
the perspective of the Irish Health Service Executive (HSE). MethOds: A six health 
state Markov model with health states for CHF NYHA classes I to IV, alive, and dead 
was adapted to the Irish health care setting. The economic evaluation compared 
the cost-effectiveness of ivabradine in combination with standard therapy versus 
standard therapy alone. A lifetime horizon was chosen in the base case analysis. 
Costs and effects were discounted at 4% per year. Deterministic and probabilistic 
sensitivity analyses were performed. Health state utilities were estimated from 
EQ-5D index scores obtained from the SHIFT clinical trial. The base case analysis 
was based on heart failure outcomes and associated costs. Results: When used 
in addition to standard therapy, ivabradine increased discounted health care costs 
by € 2169 for a 0.23 QALY gain, resulting in an incremental cost per QALY gained of 
€ 9,426. In no case of the deterministic sensitivity analysis did the cost per QALY 
gained increase above € 20,000. The probability of the cost-effectiveness of ivabradine 
at a willingness to pay threshold of € 45,000 per QALY gained was estimated to be 
approx. 100%. cOnclusiOns: When used in addition to standard therapy, based 
on heart failure outcomes and associated costs, ivabradine had an incremental cost 
per QALY gained of € 9,426 with an approximately 100% probability of being cost-
effective at a willingness to pay threshold of € 45,000 per QALY gained.
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THE COST-UTILITy OF CATHETER-BASED RENAL DENERvATION AS COMPARED 
TO CURRENT STANDARD OF CARE FOR RESISTANT HyPERTENSION IN BELGIUM
Jugrin A.V.1, Caekelbergh K.1, Vanacker J.2, Vancauwenberghe L.2, Lamotte M.1
1IMS Health HEOR, Vilvoorde, Belgium, 2MEDTRONIC INC., Brussels, Belgium
Objectives: Hypertension affects 41% of male and 31% of female adults in Belgium; 
13% of these are believed to be refractory to standard hypertension treatment (uncon-
practice. A societal perspective incorporated the following indirect costs: formal and 
informal long term care costs for stroke, productivity losses associated with stroke 
and carers, and productivity, out of pocket and travel costs associated with INR 
testing in both metropolitan and rural settings. The opportunity cost of a delayed 
dabigatran PBS listing was estimated over a 2 year period. Estimates were derived 
using the economic model presented to the PBAC. Results: When incorporating a 
societal perspective, dabigatran was cost saving versus both warfarin and the mixed 
comparator. Dabigatran is estimated to save an average of $2,011 and $3,994 per 
patient per year for patients in metropolitan and rural settings respectively com-
pared with current practice. In the more than two years since the initial PBAC rec-
ommendation of dabigatran it is estimated over 150,000 patients have been denied 
affordable access to treatment, resulting in $47.9 million in costs to Medicare, $5.2 
million in patient out of pocket costs and 470,000 hours of lost productivity due to 
avoidable INR testing. Importantly, 4,059 strokes and 902 resultant deaths could have 
been avoided in this time compared to current practice. cOnclusiOns: Dabigatran 
is a cost-effective treatment for stroke prevention in patients with NVAF in Australia 
and is cost saving compared to current therapy (warfarin, aspirin and no treatment) 
when a societal perspective is taken.
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COMPREHENSIvE OvERvIEw: EFFICACy, TOLERABILITy AND COST- 
EFFECTIvENESS OF IRBESARTAN
Gialama F.1, Maniadakis N.2
1National School of Public Health, ATHENS, Greece, 2National School of Public Health, Athens, 
Greece
Objectives: Hypertension represents a major health problem, affecting more than 1 
billion adults worldwide. Irbesartan, an angiotensin II receptor blocker, is considered 
to be a highly effective treatment in the management of hypertension. Therefore 
this study aims to evaluate the efficacy, safety and tolerability profile, as well as 
the cost-effectiveness of irbesartan in the treatment of hypertension. MethOds: 
A review of the literature was conducted using the electronic databases Medline, 
Cochrane and HEED of search terms relating to irbesartan efficacy, tolerability and 
cost-effectiveness and the results were synthesized. Results: Findings from the 
present analysis show that irbesartan either as monotherapy or in combination 
with other agents can have significant reductions in Blood Pressure, both systolic 
and diastolic, when compared to other alternative treatment options. Irbesartan 
was also found to have a renoprotective effect, independent of its blood pressure 
lowering effect in patients with type 2 diabetes and nephropathy. Irbesartan also 
delayed onset of end-stage renal disease (ESRD) and reduced the cumulative inci-
dence of ESRD. Furthermore, Irbesartan demonstrated an excellent safety and toler-
ability profile. Overall adverse event incidence with irbesartan was comparable with 
other antihypertensive drugs. Most common adverse events were headache, fatigue 
and dizziness. In terms of economic analyses, compared to other antihypertensive 
therapy alternatives, irbesartan increased life expectancy and lead to substantial 
cost savings. cOnclusiOns: Evidence indicates that treating patients with hyper-
tension alone or with type II diabetes and nephropathy, can control hypertension, 
prolong life and reduce costs, in relation to other existing alternatives.
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INDIvIDUALLy TAILORED ELASTIC COMPRESSION THERAPy FOR THE 
PREvENTION OF POST THROMBOTIC SyNDROME
Bouman A.C.1, ten Cate-Hoek A.J.1, ten Cate H.1, Joore M.A.2
1Laboratory for Thrombosis and Hemostasis, Department of Internal Medicine, Maastricht 
University Medical Centre, Maastricht University, The Netherlands, Maastricht, The Netherlands, 
2Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical 
Centre; CAPHRI, Maastricht University, Maastricht, The Netherlands
Post thrombotic syndrome (PTS) is a chronic condition that develops in up to 50% of 
patients after deep vein thrombosis and is characterized by debilitating complaints 
of the leg. Two randomized controlled trials (RCT) showed that elastic compression 
stocking (ECS) therapy for 2 years after DVT reduces the PTS incidence by approxi-
mately 50%. A recent management study showed that tailored duration of ECS ther-
apy on individual patient characteristics may result in a reduction of ECS therapy of 
18 months for 50% of patients with an even lower incidence of PTS. However, these 
results may be biased. Objectives: To explore the cost-effectiveness of individually 
tailored ECS therapy (IND) compared with a standard duration of 2 years ECS therapy 
(STANDARD), from a health care perspective in order to inform the design of an RCT 
comparing the two treatment options. MethOds: A decision-analytic probabilistic 
Markov model with lifelong time horizon was used. Health states in the model are: 
No PTS with stocking, No PTS without stocking, Mild to moderate PTS, Severe PTS, 
and Death. Transition probabilities, costs, and utilities were obtained from litera-
ture. The incidence of PTS was taken from the trials (STANDARD: 2-year incidence 
24.5%) and the management study (IND: 2-year incidence 21.1%). The delta for non-
inferiority of a future RCT was determined, and uncertainty was assessed in value 
of information analyses. Results: Based on current evidence IND saves € 2,292 and 
gains 0.14 quality adjusted life years (QALY) per patient compared to STANDARD. 
This result is however highly uncertain, and future research is valuable. The savings 
of IND amount to € 306 when assuming equal incidence of PTS. If PTS incidence is 
7% higher in IND, the treatment seizes to be cost-effective. cOnclusiOns: Based 
on current limited evidence, IND may dominate STANDARD. Future research is 
worthwhile, and may be informed by this modeling study.
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THE COST-EFFECTIvENESS OF SCREENING FOR SILENT ATRIAL FIBRILLATION 
AFTER ISCHAEMIC STROKE
Levin L.Å1, Husberg M.1, Rosenqvist M.2, Sobosinski-Doliwa P.2, Friberg L.2, Frykman-Kull V.2, 
Davidson T.1
1Linköping University, Linköping, Sweden, 2Karolinska Institutet, Stockholm, Sweden
Objectives: Prolonged brief intermittent arrhythmia screening has been suggested 
to substantially improve detection of silent paroxysmal atrial fibrillation (AF) in 
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Objectives: Asymptomatic Peripheral Arterial Disease (PAD) is associated with 
greater risk of acute cardiovascular events. American heart association and American 
college of cardiology clinical practice guidelines recommend low dose aspirin to 
reduce the cardiovascular events and mortality in PAD patients. As asymptomatic 
PAD often remains undiagnosed, opportunities for secondary prevention are missed 
in primary care. Therefore, there is a clinical need of early detection of asympto-
matic PAD and to initiate the appropriate preventive treatment. United States pre-
ventive services task force’s recommendation against screening is heavily criticized 
and expansion of the evidence base for PAD screening is recommended in 2011 in 
a focussed update of the guidelines. This study aims to determine the value of PAD 
screening using ankle brachial index test in high risk individuals using decision 
analytic modelling. MethOds: A Markov model was developed to evaluate the cost 
effectiveness of selective PAD screening in high risk individuals followed by preventive 
treatment compared to no screening and no preventive treatment. The analysis was 
conducted from the societal perspective using a lifetime time horizon. To address the 
parameter uncertainty, probabilistic sensitivity analysis was performed. Results: 
Screening and preventive treatment of identified PAD patients with low dose aspirin 
is a dominant strategy producing higher mean quality adjusted life years per patient 
for a lower lifetime cost. The cost effectiveness acceptability curves show that 100% 
simulations favour screening followed by preventive treatment at a willingness to 
pay threshold of 400 Euros. cOnclusiOns: This decision analysis suggests that the 
targeted screening and secondary prevention of cardiovascular events in the identi-
fied patients, is a highly cost effective public health intervention. This study results 
may provide one of the building blocks of evidence expansion for advocating PAD 
screening and to promote its more widespread use to detect and treat PAD patients.
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COST-EFFECTIvENESS OF INCREASING STATIN ADHERENCE FOR PRIMARy AND 
SECONDARy PREvENTION IN COMMUNITy PHARMACIES
Vegter S.1, Oosterhof P.1, van Boven J.F.1, Stuurman-Bieze A.G.G.2, Hiddink E.G.2, Postma M.J.1
1University of Groningen, Groningen, The Netherlands, 2Health Base Foundation, Houten, The 
Netherlands
Objectives: Therapy persistence is important to achieve optimal clinical benefits 
of statin therapy. The aim of this study was to determine the cost-effectiveness 
of pharmaceutical care in community pharmacies, aimed to increase persistence 
with statin therapy for both primary and secondary prevention of cardiovascular 
events (CVEs). MethOds: The effectiveness of the Dutch pharmaceutical care pro-
gram MeMO on improving statin therapy persistence was measured in 500 patients 
and compared to 502 control patients. Time-investments of the program were also 
collected. Markov models with lifelong time-horizons were developed to estimate 
the influence of the program on CVEs: stroke, myocardial infarction (MI), revascu-
larization and mortality. The efficacy of statins, taken from large clinical trials in 
primary and secondary prevention, were adjusted for therapy persistence. A Dutch 
health care provider’s perspective was adopted for the analysis and probabilistic 
sensitivity analyses were performed. Results: Patients in the MeMO program had 
a lower risk for non-persistence, RR = 0.50 (0.40-0.63), the effect was similar in 
primary and secondary prevention. In a cohort of 1,000 patients, 60% of whom had 
a history of CVE, the MeMO program resulted in a reduction of 8 non-fatal strokes, 
2 fatal strokes, 16 non-fatal MIs, 7 fatal MIs and 14 revascularizations. Additional 
medication, disease management and intervention costs in the MeMO program 
were € 375,000; the cost-savings due to reduced CVEs were € 450,000. Thus, the MeMO 
program resulted in 83 quality-adjusted life-years (QALYs) gained and cost-savings 
of € 75,000. Clinical benefits and cost-savings were highest in the secondary preven-
tion population. cOnclusiOns: Pharmaceutical care in community pharmacies 
can improve statin therapy persistence, resulting in more optimal prevention of 
CVEs. The MeMO program resulted in considerable clinical benefits and overall 
cost-savings. Persistence and adherence improving programs in community phar-
macies may provide good value for money and health care insurers should consider 
reimbursing these activities in The Netherlands.
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COST-EFFECTIvENESS ANALySIS OF IvABRADINE IN CHRONIC HEART FAILURE 
IN THE POLISH SETTING
Borowiec L.1, Faluta T.1, Filipiak K.J.2, Niewada M.3, Wrona W.4
1Medical Department, Servier Poland, Warsaw, Poland, 21st Chair and Department of Cardiology, 
Medical University of Warsaw, Warsaw, Poland, 3Department of Experimental and Clinical 
Pharmacology, Medical University of Warsaw, Warsaw, Poland, 4HealthQuest Sp z o.o. Sp. k., 
Warsaw, Poland
Objectives: To estimate cost-effectiveness of ivabradine used in treatment of 
chronic heart failure in Poland, using model based on individual patient data from 
pivotal SHIFT trial adapted using contemporary real-life epidemiology, treatment 
pattern and cost country-specific data. MethOds: Economic model based on SHIFT 
trial was originally developed for the UK setting and published. Based on the model, 
in November 2012 NICE gave its positive guidance for the analysed technology in 
line with EMA registered indication, acknowledging a range of conservative assump-
tions. Current study utilizes the NICE model populated with most recently published 
local data. General mortality was estimated from Polish life tables for the year 
2010. Unit cost and expected rate of hospitalizations on standard treatment was 
based on publication in Polish Heart Journal. Standard treatment cost was based 
on official listing of reimbursed drugs. Average cost of ivabradine (5mg and 7.5mg, 
56 tabs) was based on popular drug database (Kamsoft, April 2013). Exchange rate 
of National Bank of Poland 1 EUR= 4.1759 PLN was applied (May 2013). Results: 
At current pharmacy price (55.60 EUR / 56 tabs), incremental cost-utility ratio for 
ivabradine on top of standard treatment vs standard treatment alone is estimated 
at 10 230 EUR / QALY, well below the official cost-effectiveness threshold defined at 
3*DGP per capita (25 336 EUR). Sensitivity analysis revealed that in order to exceed 
the cost-effectiveness threshold, price would have to be increased to 113.60 EUR 
(+104%). cOnclusiOns: Conservative analysis shows that ivabradine used on top 
of standard treatment (ACE inhibitor, beta-blocker, MR antagonist, ±diuretics) in 
trolled with ≥ 3 different classes of antihypertensive therapy). Catheter-based renal 
denervation (RDN) is a novel, minimally invasive therapy for treatment-resistant 
hypertension. The aim of this study was to assess the cost-utility of RDN as compared 
to current standard of care (SoC) for refractory hypertension in Belgium. MethOds: 
A lifetime state-transition, Markov model was used, with health-states encompass-
ing possible long-term consequences of hypertension: stroke, myocardial infarction, 
angina, heart failure, end-stage renal disease. Risk equations were used to calculate 
the risk of events with changing systolic blood pressure (SBP). Reductions in SBP 
following RDN vs. SoC pertain to the results of the Symplicity HTN-2 randomized 
controlled trial. The underlying modeled cohort was defined similar to the same trial: 
mean baseline SBP 178 mmHg, mean age 58 years, 34% with diabetes mellitus. Costs 
pertained to published economic evaluations or public tariffs and reflected the Belgian 
payer perspective. Costs and health outcomes were discounted at a rate of 3%, and 
1.5% respectively. Results: Projected lifetime costs were 21,743€ and 24,558€ in the 
SoC and RDN arms respectively, while total projected life years were 16.43 and 17.23. 
RDN increased patients’ quality of life with 0.93 quality-adjusted life years (QALYs) vs. 
SoC. This resulted in an incremental cost-utility ratio (ICUR) of 3,020€ /QALY. Results 
were most sensitive to changes in SBP reductions, and the cost of RDN procedure, but 
remained under a willingness to pay (WTP) threshold of 20,000€ /QALY. Probabilistic 
sensitivity analyses showed acceptable cost-effectiveness in 100% of cases, under a 
WTP threshold of 20,000€ /QALY. cOnclusiOns: Results of these analyses suggest 
that, under the current model settings, catheter-based RDN procedure could be a 
cost-effective strategy for resistant hypertension in Belgium.
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COST-EFFECTIvENESS ANALySIS OF ATORvASTATIN COMPARED TO 
SIMvASTATIN IN THE PREvENTION OF CARDIOvASCULAR DISEASES IN THE 
CzECH REPUBLIC
Klimes J., Vocelka M., Dolezal T., Kruntoradova K.
Institute of Health Economics and Technology Assessment, Prague, Czech Republic
Objectives: To assess the impact of atorvastatin compared to simvastatin use in the 
Czech Republic on cardiovascular diseases (CVD), Life-Years Gained (LYG) and Quality-
Adjusted Life Years (QALY), based on the real proportional consumption of both statins 
in particular strengths (10 mg, 20 mg, 40 mg). MethOds: Life-time cost-effectiveness 
Markov cohort model was developed with 1 year cycle length and 5 health sates, i.e. 
Alive without CVD, Alive with experience of CVD, Non-fatal CVD, Fatal CVD and Death. 
The probability of transition among health states were derived from Framingham 
equations or from SCORE equations (probability of the first non/fatal CVD), Czech 
life-tables (background mortality) and international cohort studies (probability of 
subsequent CVD). Patients enter the model with base-line risk characteristics: age, 
proportions of males, diabetics, smokers, level of systolic blood pressure and choles-
terol (total and HDL) level. The efficacy data for particular statin and its strength were 
derived from latest meta-analyses. Drug acquisition costs of atorvastatin 10 mg and 
20 mg were 10% higher compared to simvastatin 20 mg and 40 mg. The costs of fatal, 
non-fatal CVD and one-year follow-up after CVD were 1,410 EUR, 1,460 EUR and 580 
EUR. Probabilistic sensitivity analysis (PSA) using a willingness to pay (WTP) threshold 
equal to 1 times GDP per capita (14,300 EUR) was applied. Results: Over a life-time 
horizon, atorvastatin compared to simvastatin provides 8.14 QALYs vs. 8.07 QALYs, 
11.33 LYG vs. 11,24 LYG, 44.8% vs. 46.3% of non-fatal CVD and 28.2% vs. 29.4% of fatal 
CVD. The increment of total costs was 330 EUR for atorvastatin, ICER for atorvastatin 
vs. simvastatin was then 4,720 EUR/ QALY. cOnclusiOns: The use of atorvastatin 
generates 0.07 QALYs more compared to simvastatin per patient in the Czech Republic. 
There is a 98.5% probability of atorvastatin being cost-effective at the selected WTP.
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NOvEL ORAL ANTICOAGULANTS vERSUS wARFARIN – A BUSINESS CASE 
ANALySIS
You J.
The Chinese University of Hong Kong, Shatin, Hong Kong
Objectives: The decision on whether to use more expensive novel oral antico-
agulants (NOACs) or invest resources for quality improvement of warfarin therapy 
requires inputs of both clinical and economic outcome analyses. Outcomes of NOACs 
comparing to warfarin therapy at various levels of patient-time in therapeutic range 
(TTR) in patients with atrial fibrillation were examined from health care provider’s 
perspective. MethOds: A Markov model was designed to compare life-long eco-
nomic and treatment outcomes of warfarin and NOACs in a hypothetical cohort of 
65-year-old atrial fibrillation patients with CHADS2score 2 or above. Model inputs were 
derived from clinical trials published in literature. Outcome measure was incremental 
cost per quality-adjusted life-year (QALY) gained (ICER). Results: Expected cost and 
QALYs of NOACs were USD96,602 and 9.957, correspondingly, in base-case analysis. 
Using USD50,000 as the threshold of willingness-to-pay per QALY, NOACs therapy was 
cost-effective when TTR of warfarin therapy was 60%, or monthly cost of warfarin 
management increased by 1.5-fold or above to achieve 70% TTR. Warfarin therapy 
was cost-effective when TTR of warfarin was 70% with no increment in monthly cost 
of care, or when TTR reached 75% with monthly cost of warfarin care increased up 
to 2.5-fold. At TTR 60%, 70% and 75%, NOACs was cost-effective when monthly drug 
cost was < USD208, < USD135-200 and < USD96-160, respectively. 10,000 Monte Carlo 
simulations showed NOACs to be cost-effective in 77.2%, 52.7% and 31.7% of time at 
TTR of 60%, 70% and 75%, respectively. cOnclusiOns: Acceptance of NOACs as cost-
effective was highly depended upon drug cost, anticoagulation control for warfarin, 
and anticoagulation service cost.
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SCREEN OR NOT TO SCREEN FOR PERIPHERAL ARTERIAL DISEASE: GUIDANCE 
FROM A DECISION MODEL
Vaidya A.1, Joore M.A.2, tenCate-Hoek A.J.1, tenCate H.1, Severens J.L.3
1Maastricht University, Maastricht, The Netherlands, 2Clinical Epidemiology and Medical 
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COST ANALySIS OF ALPROSTADIL (PROSTAvASIN®) AS TREATMENT FOR 
PATIENTS wITH PERIPHERAL ARTERIAL DISEASE STAGES III AND Iv COMPARED 
wITH LUMBAR SyMPATHECTOMy IN MExICO
Carlos F.1, Gasca R.1, Aguirre A.2, Naranjo M.2
1R A C Salud Consultores S.A. de C.V., Mexico City, Mexico, 2UCB de Mexico, S.A. de C.V., Mexico, 
D.F., Mexico
Objectives: Peripheral arterial disease is associated with significant adverse out-
comes, especially in patients with critical limb ischemia (CLI; stages III and IV). At 
6 months, the risk of amputation is 35%, and mortality 20%. In patients unsuitable 
for interventional therapy, treatment with prostanoids may help reduce the risk of 
adverse outcomes. We aimed to assess the average cost of alprostadil (prostaglan-
din E1) as treatment for patients with CLI compared with lumbar sympathectomy 
from the perspective of The Mexican Social Security Institute (IMSS). MethOds: 
In a clinical trial, alprostadil and lumbar sympathectomy showed similar response 
rates (Petronella P, et al. Nutr Metab Cardiovasc Dis 2004;14:186–92).Therefore, we 
conducted a cost minimization analysis based on the direct medical costs of alpros-
tadil (40 µg twice-daily or 60 µg once-daily) administered over 28 days versus lumbar 
sympathectomy. Relevant costs included acquisition and infusion for alprostadil, 
and surgical procedure besides hospitalization (9 days) for lumbar sympathectomy. 
Unit cost for infusion was assumed to be equivalent to an emergency visit at first 
level of care at IMSS; unit cost of the surgical procedure and standard hospital stay 
(per day) correspond to the official values for these items at the second level of care 
at IMSS. UCB Pharma provided the cost for alprostadil. All costs are in 2013 Mexican 
pesos (MXN; 12.88 MXN = 1 USD, 17.23 MXN = 1 Euro). Results: Costs per patient 
would be lower with both alprostadil 40 µg twice-daily ($59,640) and alprostadil 
60 µg once-daily ($37,884) than with lumbar sympathectomy ($66,084), leading to 
savings of $6,444 (9.8%) and $28,200 (42.7%), respectively. Alprostadil use remained 
cost-saving versus lumbar sympathectomy in most of the scenarios evaluated 
through sensitivity analysis. cOnclusiOns: These results suggest alprostadil is a 
cost saving intervention when compared with lumbar sympathectomy for patients 
with CLI from the Mexican public health care perspective.
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THE COST-EFFECTIvENESS OF APIxABAN COMPARED TO wARFARIN, ASPIRIN, 
RIvAROxABAN AND DABIGATRAN IN IRELAND
Kelly J.1, Griffith G.2, Fortune P.3, Lister S.4
1Pfizer Healthcare Ireland, Dublin, Ireland, 2Pfizer UK, Tadworth, UK, 3Bristol-Myers Squibb 
Ireland, Dublin, Ireland, 4Bristol-Myers Squibb, Uxbridge, UK
Objectives: The objective of this pharmacoeconomic evaluation was to determine 
whether apixaban, compared to warfarin, dabigatran and rivaroxaban in patients 
suitable for vitamin K antagonists (VKA), or to aspirin in VKA-unsuitable patients, 
is a cost-effective treatment for the prevention of stroke or systemic embolism (SE) 
in adult patients with non-valvular atrial fibrillation (AF) with one or more risk fac-
tors. MethOds: A Markov model was constructed consisting of 18 health states, 
using a 6-week cycle length and a lifetime time horizon. Baseline characteristics were 
taken from a 2011 GPRD study. Clinical inputs were derived from a network meta-anal-
ysis of the efficacy and bleeding outcomes from the three warfarin-controlled trials 
ARISTOTLE, RE-LY and ROCKET-AF, and the single aspirin-controlled trial AVERROES. 
Local unit costs and utility data were assigned to the appropriate model health states 
to calculate total Quality-Adjusted Life Years (QALYs) and costs. Univariate and proba-
bilistic sensitivity analyses (PSA) were conducted. Results: Apixaban was associated 
with an ICER vs warfarin of € 11,087. Against the less-commonly used anti-coagulants, 
apixaban was cost-effective against each at the € 45,000 willingness-to-pay thresh-
old. Apixaban provided more QALYs than all other therapies. Compared to warfarin, 
apixaban produced savings in avoided cost of stroke, intracranial haemorrhage, INR 
monitoring, and bleeding. Apixaban was cost-effective across all patient subgroups 
of INR control (centre Time in Therapeutic Range) and CHADS2stroke risk categories 
1 and 2. One-way sensitivity analyses, scenario analyses, and probabilistic sensitivity 
analyses confirmed that the findings were robust to changes in key parameters. The 
probability that apixaban was the most cost-effective therapy at a willingness-to-
pay threshold of € 45,000 per QALY was 93% and 100% in the VKA-suitable and VKA-
unsuitable populations, respectively. cOnclusiOns: Apixaban can be considered 
cost-effective for the prevention of stroke and SE in people with non-valvular AF, at 
a threshold of € 45,000/QALY, under standard decision rules.
PCv103
ECONOMIC EvALUATION OF APIxABAN FOR THE PREvENTION OF STROKE IN 
ATRIAL FIBRILLATION IN THE NETHERLANDS
Stevanovic J.1, Pompen M.2, Le H.H.1, Rozenbaum M.H.3, Postma M.J.1
1University of Groningen, Groningen, The Netherlands, 2Bristol-Myers Squibb, Woerden, The 
Netherlands, 3Pfizer Nederland, Capelle aan den Ijssel, The Netherlands
Objectives: Stroke prevention is the main goal in treating patients with atrial 
fibrillation (AF). Treatment with anticoagulants, such as vitamin-K antagonists 
(VKAs; e.g. warfarin and cumarines), was demonstrated to be an effective strat-
egy. However, even though VKAs are the current standard therapy recommended 
by different guidelines, the significant risk of bleeding and the requirement for 
a regular monitoring are limiting its use. Apixaban is a novel oral anticoagulant 
(NOAC) associated with significantly lower hazard rates for stroke/systemic embo-
lism, major hemorrhage and discontinuations, compared to VKAs. This study evalu-
ated the cost-effectiveness (CE) of apixaban compared to VKAs in the base-case 
analysis and alternatively to other NOACs for stroke prevention in non-valvular 
AF patients in The Netherlands. MethOds: A global Markov model developed by 
United BioSource Corporation was modified to reflect the use of oral anticoagulants 
in The Netherlands. The model used efficacy data from a published indirect treat-
ment comparison of NOACs and cost data from Dutch costing studies as inputs. 
Following health states were included in the model: non-valvular AF, primary and 
recurrent ischemic and hemorrhagic stroke, systemic embolism, myocardial infarc-
tion, intracranial hemorrhage, other major and non-major bleedings, treatment 
patients suffering from chronic heart failure is a highly cost-effective health tech-
nology in the Polish setting, according to the criterion defined in Reimbursement 
Law. Robustness of this finding is demonstrated by the fact that cost-effectiveness 
is retained even at a price double vs base-case.
PCv98
STATIN COST-EFFECTIvENESS IN PATIENTS wITH PREvIOUS CORONARy HEART 
DISEASE: A SySTEMATIC REvIEw OF THE COST-EFFECTIvENESS ANALySIS 
DERIvED FROM SINGLE RANDOMISED CLINICAL TRIALS
Luque A.1, Nobre M.R.C.2
1Sao Paulo University, Sao Paulo, Brazil, 2InCor - HCFMUSP, São Paulo, Brazil
Objectives: Large randomized clinical trials (RCT) evidenced the benefits of statins 
in reducing major cardiovascular events in patients with established coronary heart 
disease (CHD). These multinational trials are likely to provide internally valid evi-
dence. Cost-effectiveness analysis based on single trials costs and effects are common 
and represent the potential net benefit of an intervention in a well-controlled environ-
ment. The aim of this study is to systematically review the cost-effectiveness studies 
based on statins single trials in patients with previous CHD. MethOds: We searched 
to identify all literature relating to the cost-effectiveness of statins in the secondary 
prevention in patients with established CHD. Only studies with the effectiveness data 
extracted from a single RCT and clinical outcomes such as quality assessment, mor-
tality or cardiovascular events rate were included. The cost per QALY was classified 
according to the WHO, following three categories of cost-effectiveness, Highly cost-
effective, Cost-effective and Not cost-effective, adjusted with GDP per capita based 
on purchasing power parity (constant 2005 international USD). Results: Twenty-one 
studies were included in the final analysis, covering a period range from 1996 to 
2009. 7 large RCTs represented the origin of efficacy data. Most of studies assumed 
a full compliance, the Markov models were used in 11 out 21 studies. Time horizon 
ranged from 5 years to time life, with 10 years being the predominant choice. 9 studies 
performed a cost-utility analysis and showed the average cost per QALY, 8 of them 
classified as highly cost-effective and 1 cost-effective. Cost per QALY was sensitive for 
drug price, time horizon and event rates, 6 of this models models worked with com-
posite endpoints. cOnclusiOns: Statins are highly cost-effective in patients with 
CHD when effect size came from single well designed RCTs. Models heterogeneity 
and composite endpoints can decrease the robustness of the results.
PCv99
THE COST-EFFECTIvENESS OF CATHETER ABLATION AS FIRST-LINE 
TREATMENT
Aronsson M., Walfridsson H., Janzon M., Walfridsson U., Levin L.Å
Linköping University, Linköping, Sweden
Objectives: It has been suggested that radiofrequency catheter ablation could take 
priority over antiarrhythmic drugs as first-line treatment of paroxysmal AF, due to 
better efficiency, and fewer serious side effects. The objective of this study was to 
evaluate the cost-effectiveness of treating paroxysmal atrial fibrillation with radi-
ofrequency catheter ablation as first-line treatment. MethOds: A decision-analytic 
Markov model was developed to study long-term effects and costs of catheter abla-
tion compared to antiarrhythmic drugs as first-line treatment. Results: Small, 
positive clinical effects were found in the overall population, a gain of an average 
0.06 quality-adjusted life years (QALYs) to an incremental cost of € 3033, resulting in 
an incremental cost-effectiveness ratio of € 50 570/QALY. However, the incremental 
cost-effectiveness ratio of a 45-year-old patient was approximately € 3434/QALY, 
while a 65-year-old costs € 108 937 per QALY. cOnclusiOns: Radio-frequency cath-
eter ablation as first-line treatment is a cost-effective strategy for younger patients 
with paroxysmal atrial fibrillation. However, the cost-effectiveness of using catheter 
ablation as first-line therapy in older patients is uncertain, and in most of these 
cases antiarrhythmic drug therapy should be attempted before catheter ablation.
PCv100
ACTIvE-IMPLANTABLE CARDIAC DEvICES: IS THERE ROOM FOR COST SAvINGS 
IN PORTUGUESE HOSPITALS?
Pelicano-Romano J.1, Oliveira-Martins S.1, Mota-Filipe H.2, Cabrita J.1
1Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal, 2INFARMED – National Authority of 
Medicines and Health Products, IP, Lisbon, Portugal
Objectives: Portugal is facing an economic crisis that demands a tight control over 
all hospitals’ expenditures, namely with medical devices, whose market price is not 
yet regulated or documented. This study aims to describe the number and value of 
the Active-Implantable Cardiac Devices (AICD) bought by Portuguese hospitals in 
2011, as well as to quantify potential savings that can be obtained shifting utilisation 
from higher to lower prices. MethOds: In February 2012, 42 hospitals were asked 
by INFARMED – National Authority of Medicines and Health Products, IP, about the 
number, type and value of the AICD acquired, using an ad-hoc developed software. 
Potential savings analysis was performed at two levels: AICD sub-groups (according 
to Portuguese Medical Device Nomenclature) and individual device reference. Within 
each level, three cost-minimization scenarios were conceptualized based on the 
minimum price reported (scenario 1), the average between the average price and 
the minimum one (scenario 2) and the average price (scenario 3). Results: During 
2011, 73.8% of the hospitals enrolled (n= 31) bought AICD, comprising 16,815 devices, 
at a cost of 40,217,411 euros. In numbers, the most common AICD were pacemakers 
(44.8%), whereas cardioverter-defibrillators were related to a higher expenditure 
ratio (51.5% of total cost). Based on the AICD sub-groups analysis, the potential sav-
ings were 14.5 million euros in scenario 1 (44.1% of total cost), 7.4 million euros in 
scenario 2 (22.5%) and 1.8 million euros in scenario 3 (5.3%). Following this scenario 
order, the device reference approach estimated savings of 6.2 million euros (18.8%), 
3.4 million euros (10.3%) and 1.1 million euros (3.3%), respectively. cOnclusiOns: 
Significant potential savings were found, being greater when analysing AICD sub-
groups, assuming equal efficiency and safety for all devices within these clusters. 
Despite scenario 1 higher savings, scenario 2 seems the most realistic and feasible, 
when trying to accomplish a sustainable health care system.
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and literature sources. Two price scenarios were evaluated, one in which the sutureless 
valve is sold at the double, and one at the triple price of its comparator. Future costs and 
outcomes are discounted at a yearly 3.5% rate. Results: In the first cost scenario, the 
model predicts that on average MiAVR with Perceval S instead of traditional sutured 
valves in FS would yield incremental 0.29 LYs (0.20 QALYs) and savings for about 3,000 
€ and 3,250 £, in France and UK, respectively. In the second cost scenario, Perceval S 
in MiAVR still remains dominant, with savings for 550 € and 740 £, in France and UK, 
respectively. Deterministic threshold analysis indicates that the sutureless valve would 
retain acceptable cost-effectiveness (at willingness-to-pay thresholds of 30,000€ and 
20,000£ per QALY) as long as its price does not exceed 5.6 and 4.9 times that of the 
traditional valve, in France and UK, respectively. cOnclusiOns: The sutureless valve 
in combination with MiAVR offers the opportunity to improve outcomes in isolated 
AVR at a reduced cost to the third party payers.
PCv107
COST UTILITy ANALySIS OF SCREENING AND TREATMENT OF HyPERLIPIDEMIA 
IN CHINESE ADULTS AGED 45 AND ABOvE
Zhang X.G.1, Wu J.J.1, Chen C.I.2, Xie X.P.2, Liu L.3, Yang L.1
1Peking University, Beijing, China, 2Pfizer China, Beijing, China, 3Pfizer Inc. and Weill Medical 
College of Cornell University, New York, NY, USA
Serum total and LDL cholesterol levels are high (13.9% for borderline high LDL- choles-
terol) and increasing in China. Hyperlipidemia is a main risk factor for cardiovascular 
and cerebrovascular diseases. Screening is one of the effective prevention methods; 
however, there has been no appraisal of the cost-effectiveness of blood lipid screen-
ing in China. Objectives: To determine the cost-utility of blood lipid screening and 
subsequent interventions versus no screening for the prevention and treatment of 
hyperlipidemia and its complication. MethOds: Cost utility analysis based on a 
Markov model was conducted for a cohort of Chinese adults aged 45 and abovefrom 
screening to death. Published clinical trials and epidemiological studies retrieved from 
electronic bibliographic databases; supplementary data obtained from CVD patients 
survey in China. Markov model simulated the long term effects of screening and no 
screening strategies from the aspects of cost and effectiveness. The model assumed a 
30 year time horizon, and costs and benefits were discounted at 5%. The willingness-
to-pay threshold is ¥100,000/QALY. Sensitivity analyses were conducted to evaluate 
assumptions of the model and to identify which model inputs had most impact on the 
results. Results: Estimated costs for each quality adjusted life year (QALY) gained 
among no screening population were ¥6325.8, with cumulative costs of ¥77112 and 
cumulative utility of 12.19, and ¥5783.5 for screened population with cumulative costs 
of ¥72178 and cumulative utility of 12.48, respectively. The results showed the blood 
lipid screening was associated with increased QALY and potentially cost-saving as 
compared with no screening. Sensitivity analyses demonstrated robustness of the 
results. cOnclusiOns: Based on this Markov model, blood lipid screening is likely 
to be cost-effective option compared with no screening for the prevention and treat-
ment of hyperlipidemia and its complication among Chinese aged 45 and above.
PCv108
COST-EFFECTIvENESS OF DRUG-ELUTING STENTS vERSUS BARE METAL 
STENTS IN EGyPTIAN DIABETIC PATIENTS
ElSisi G., Ragab S., Ashraf R., Elmahdawy M.
Central Administration for Pharmaceutical Affairs, Cairo, Egypt
Objectives: Cost-effectiveness of Drug eluting stents (DES) versus bare metal stents 
(BMS) in Egyptian diabetic patients with chronic coronary artery disease from a 
patient perspective was evaluated over a time horizon of 3 years. MethOds: A cohort 
Markov process model with five health states: stent, coronary artery bypass surgery 
(CABG), non-fatal myocardial infarction (MI), percutaneous coronary intervention 
(PCI) and death was derived from published data. The transition probabilities from the 
index procedure to death, MI, PCI, and CABG were derived from an updated, previously 
published meta-analysis of RCTs comparing DES with BMS in patients with coronary 
artery disease. Relative risk reduction, restenosis risks, mortality rates, utilities were 
derived using published sources. Direct Medical costs were obtained from 4 top-rated 
cardiology hospitals in Egypt. All costs and effects were discounted at 3.5% annually. 
All costs were reported in Egyptian pounds of the financial year 2013. Deterministic 
sensitivity analysis was conducted. Results: In the overall population, total costs for 
DES and BMS were 20,664 EGP and 11,957 EGP respectively. Total QALYs for DES and 
BMS were 2.26 and 2.05 respectively. The incremental cost-effectiveness ratio (ICER) 
for DES versus BMS was 41,616 EGP/QALY. DES is cost effective because it is less than 
3 times GDP/capita in Egypt (57,566 EGP). Results between DES and BMS were most 
sensitive to the Mortality rate of both DES and BMS. cOnclusiOns: World Health 
Organization recommends that interventions that cost more than 3 times GDP/capita 
for one Disability Adjusted Life Year (DALY) avoided should not be reimbursed. Despite 
DALY is different from QALY but we can assume that they are similar to be able to put 
a value on the outcome. DES represents a good value for money compared to BMS in 
Egyptian diabetic patients with chronic coronary artery disease.
PCv109
COST-UTILITy ANALySIS OF CORONARy ARTERy CALCIUM SCORE TO GUIDE 
STATIN THERAPy IN PATIENTS wITH ELEvATED C-REACTIvE PROTEIN AND 
LOw LDL CHOLESTEROL LEvELS
Silva Miguel L.1, Ferreira A.M.2
1CISEP (Research Centre on the Portuguese Economy), Lisbon, Portugal, 2Hospital de Santa Cruz 
and Hospital da Luz, Carnaxide and Lisbon, Portugal
Objectives: Using statins in primary prevention is controversial given the low event 
rate and the difficulty to identify patients who really benefit. Coronary calcium score 
has been identified as a strong predictor of cardiovascular events, being recom-
mended for risk stratification in intermediate risk individuals. This study aims to 
assess, from the Portuguese societal perspective, the cost-utility of determining coro-
nary calcium score to guide the use of statins in individuals with elevated C-reactive 
protein and low LDL cholesterol. Three strategies are compared: no treatment, test 
and treat accordingly, and treat every patient with rosuvastatin 20mg. MethOds: 
discontinuations and death. Main outcomes were quality adjusted life years (QALY) 
and costs. Univariate and probabilistic sensitivity analyses (PSA) were conducted on 
the incremental cost-effectiveness ratio (ICER). Results: In the base-case analysis, 
apixaban treatment compared to VKAs has an ICER well below an informal mini-
mal willingness-to-pay threshold of € 20,000/QALY for The Netherlands (i.e. around 
€ 7,000/QALY). PSA showed that the results of the base-case analysis were quite 
robust. Potentials exist for apixaban to be dominant over the other NOACs, rivaroxa-
ban and dabigatran depending on hazard ratios, risks for complications and local 
price levels. patients in The Netherlands. cOnclusiOns: In patients with AF, we 
found apixaban to be a cost-effective option in The Netherlands, compared to VKAs.
PCv104
A SOCIETAL PERSPECTIvE COST-UTILITy ANALySIS OF RIvAROxABAN 
COMPARED wITH ENOxAPARIN SODIUM IN PATIENTS UNDERGOING TOTAL HIP 
OR TOTAL KNEE REPLACEMENT SURGERy
Stollenwerk B.1, Le L.1, Zindel S.1, Müller D.2, Klug F.1, Stock S.2
1Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, 
Germany, 2University of Cologne, Cologne, Germany
Objectives: Several cost-effectiveness analyses exist that compare rivaroxaban 
with enoxaparin sodium as thrombosis prophylaxis in patients undergoing total 
hip replacement (THR) or total knee replacement (TKR) surgery. However, none of 
these refers to a societal perspective, and thus indirect costs have so far not yet 
been included. The objective of this research was to conduct a cost-utility analysis 
from the German societal perspective, based on a life-time horizon. MethOds: A 
decision-tree was used to calculate the short term consequences of treatmentby 
classifying whether subjects experienced a deep a vein thrombosis, a pulmonary 
embolism, a major bleeding, death due to the surgery, or no event. Furthermore, 
we designed a Markov model to quantify the long-term consequences. The main 
health effect was based on the RECORD 1 and RECORD 3 trials. A semi-micro simu-
lation approach was applied to reflect the age and gender distribution of the target 
population. Probabilistic, deterministic and structural sensitivity analyses were per-
formed to assess the robustness of the results. Results: Rivaroxaban dominated 
enoxaparin sodium in the case of TKR. This dominance was robust within sensitivity 
analysis. In contrast, the point estimate of the cost-effectiveness ratio in the case of 
THR was € 867,018 per quality-adjusted life year (QALY). However, there was a wide 
variation within the probabilistic sensitivity analysis: the dots were substantially 
scattered over three quadrants of the cost-effectiveness plane. Compared to previ-
ous analyses, the selection of effectiveness data seems to have a significant impact 
of the results. cOnclusiOns: Rivaroxaban was found to dominate enoxaparin 
sodium after TKR, whereas the evidence regarding THR is unclear. Results were 
similar to previous analyses from the third-party payer perspective.
PCv105
TELEMONITORING AFTER DISCHARGE FROM HOSPITAL wITH HEART FAILURE – 
COST-EFFECTIvENESS MODELLING OF ALTERNATIvE SERvICE DESIGNS
Thokala P., Baalbaki H., Brennan A.
University of Sheffield, Sheffield, UK
Objectives: To estimate the cost-effectiveness of home telemonitoring (TM) or 
structured telephone support (STS) strategies versus usual care for adults recently 
discharged (within 28 days) after a heart failure (HF) exacerbation in England and 
Wales. MethOds: A Markov model was used to evaluate a) STS via human to 
machine (HM) interface, b) STS via human to human (HH) contact, and c) TM, against 
d) usual care. Given heterogeneity in the interventions, cost-effectiveness analysis 
was performed using bottom up costing scenarios regarding costs of devices, moni-
toring and medical care to deal with alerts. Costs and quality adjusted life years 
(QALYs) over a 30 year (patient lifetime) horizon were estimated based on monthly 
probabilities of death and monthly risks of hospitalisations (HF-related complica-
tions or other causes) estimated from clinical effectiveness parameters computed 
using a network meta-analysis of randomised controlled trials. Results: Base case 
monthly costs per patient were: £27 for usual care, £119 for STS HM, £179 for STS HH 
and £175 for TM. TM was the most cost-effective strategy in the scenario using these 
base case costs. Compared with usual care, TM had an estimated incremental cost 
effectiveness ratio (ICER) of £9,552/QALY, whereas STS HH had an ICER of £63,240/
QALY against TM. STS HM was dominated by usual care. Probabilistic sensitivity 
analysis (PSA) showed 44% chance of TM being cost-effective at a willingness to 
pay threshold of £20,000 per QALY, with STS HH 36%, STS HM 18% and usual care 
2%, respectively. Scenario analyses performed using higher costs of usual care, 
higher costs of STS HH and lower costs of TM do not substantially change the con-
clusions. cOnclusiOns: Cost-effectiveness analyses suggest TM was an optimal 
strategy in most scenarios, but there is considerable uncertainty in relation to clear 
descriptions of the interventions and robust estimation of costs.
PCv106
LIFETIME COST-EFFECTIvENESS OF ISOLATED AORTIC vALvE REPLACEMENTS 
ASSOCIATED wITH THE MINI-INvASIvE IMPLANTATION OF A NEw 
SUTURELESS AND COLLAPSED vALvE IN FRANCE AND UNITED KINGDOM
Pradelli L.1, Giardina S.2, Ranucci M.3
1AdRes HE&OR, Turin, Italy, 2Sorin Group, Milano, Italy, 3IRCSS Policlinico San Donato, San 
Donato Milanese, Italy
Objectives: Mini-invasive aortic valve replacement (MiAVR) has several advantages 
over full sternotomy (FS), mainly less surgical trauma, decreased blood loss, lower 
mortality and faster recovery. Perceval S is an aortic valve which is implanted without 
need for suturing and a collapsed profile, thus allowing a significant reduction of cross-
clamping times, an independent risk factor for worse outcomes, allowing to expand 
the pool of operable patients with MiAVR. MethOds: A patient-level simulation model 
fully coded in WinBugs was updated and extended to predict lifetime effectiveness 
and costs of isolated AVR procedures associated with this new valve in France and 
UK, as compared to traditional valve implants, from the cost perspective of the third 
party payer. Unit costs and health state-specific utilities were retrieved from official 
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formed to determine economic advisability of its applying in Belarus. MethOds: 
Markov model with 12-month cycle duration and 10-year time horizon has been 
constructed on the basis of a systematic review of literature, national surveillance 
data, local health services market and drugs market estimation. Four conditions 
were included: stable process, non-fatal event (cardiac infraction or unstable 
angina), surgical revascularization, death. Number of patients with stable angina 
who stayed alive and QALY till the end of the last analyzed cycle of the model has 
been used as a measure of efficiency and utility. One-sided determinate sensitiv-
ity analysis has been conducted. Incremental values have been calculated. Direct 
medical expenses have been evaluated. Value of triple GDP per capita per year (10790 
euro) has been used as threshold. Results: Research showed clinical advantage of 
treatment scheme with ivabradine as compared to “traditional therapy” concern-
ing the amount of patients who stayed alive by the end of the last cycle of model 
(7275 vs. 6421 persons in total population and 8136 vs 6993 in patients with heart 
rate > 70 pbm) and QALY number (77635 vs. 69253 in total population and 84138 vs. 
73031 in patients with heart rate > 70 pbm years). The sensitivity analysis showed 
that in 9.09% of cases ivabradine was the prevailing technology, in 90.91% the cost 
per QALY did not exceed the threshold. The average counted incremental cost per 
QALY was 3836 Euro. cOnclusiOns: The analysis showed the pharmacoeconomic 
acceptability of ivabradine use by patients with stable angina with left ventricular 
systolic disfunction and heart rate ≥ 70 bpm at prescription of the medication in 
optimal dosage which ensures minimal market value of the medication.
PCv113
LIFETIME COST-EFFECTIvENESS OF CONCOMITANT AORTIC vALvE 
REPLACEMENTS IN FRANCE AND THE UNITED KINGDOM
Pradelli L.1, Giardina S.2, Ranucci M.3
1AdRes HE&OR, Turin, Italy, 2Sorin Group, Milano, Italy, 3IRCSS Policlinico San Donato, San 
Donato Milanese, Italy
Objectives: Aortic valve replacement (AVR) is the most common heart valve opera-
tion, accounting for a conspicuous part of all valve surgery performed in the elderly. 
Prolonged aortic cross-clamping times are an independent risk factor for worse out-
comes. Perceval S is a new aortic valve which is implanted without need for sutur-
ing and a collapsed profile, thus allowing a significant reduction of cross-clamping 
times. MethOds: A patient-level simulation model fully coded in WinBugs was 
updated and extended to predict lifetime effectiveness and costs of concomitant 
AVR procedures associated with this new valve in France and UK, as compared to 
traditional valve implants, from the cost perspective of the third party payer. Two price 
scenarios were evaluated, one in which the sutureless valve is sold at the double, and 
one at the triple price of its comparator. Unit costs and health state-specific utilities 
were retrieved from official and literature sources. Future costs and outcomes are 
discounted at a yearly 3.5% rate. Uncertainty is evaluated through the incorporated 
probabilistic sensitivity analysis and deterministic threshold analyses. Results: The 
model predicts that on average the use of the Perceval S valve instead of traditional 
sutured valves would yield incremental 0.21 LYs (0.16 QALYs) per patient, with an 
associated saving of about 5,100 € and 4,400 £ in France and UK, respectively, in 
the first scenario, and of 2,600 € and 1,900 £, in the second. Deterministic threshold 
analysis indicates that the sutureless valve would remain averagely dominant as long 
as its price does not exceed 4.1 and 3.8 times that of the traditional valve, in France 
and UK, respectively. cOnclusiOns: The sutureless valve offers the opportunity to 
improve outcomes in concomitant AVR at a reduced cost to the third party payers.
PCv114
IMPACT OF CARDIOvASCULAR DISEASE ON LABOUR FORCE PARTICIPATION: 
BIvARIATE PROBIT ANALySIS
Civil E.F.1, Ilhan M.N.1, Yildirim J.2
1Gazi University Faculty of Medicine, Ankara, Turkey, 2TED University, Ankara, Turkey
Objectives: Health status plays an important role in individuals’ labour supply 
decision. Chronic diseases, such as cancer, diabetes mellitus, cardiovascular disease, 
mental illness and disabilities are reported to have strongest effect on individual 
transitions on the labour market. Among them, cardiovascular disease (CVD), in addi-
tion to being the leading cause of death, is likely to affect individuals’ employment 
decision. The aim of this study is to investigate the impact of clinically diagnosed car-
diovascular disease on labour supply, taking account of the observed and unobserved 
factors that influence the risk of cardiovascular disease and labour force participa-
tion. MethOds: Study subjects were randomly selected from Gazi University general 
internal medicine outpatient clinic. Demographic, health and employment status 
data have been compiled for five hundred and fifteen study subjects who applied to 
the clinic between December 2012 and February 2013. The bivariate probit method 
has been utilized to investigate the impact of incidence of cardiovascular disease on 
employment status. Results: Empirical results indicate that cardiovascular disease 
have a strong negative impact on labour market outcomes, particularly for men, and 
that education level, gender, hypertension have significant indirect effects on labour 
force participation. Analysis results suggest that there is a correlation between the 
labour force participation and the incidence of cardiovascular disease, revealing that 
single equation models might be misspecified. cOnclusiOns: As cardiovascular dis-
ease has a significant negative impact on employment status, public health programs 
need to address this issue and provide treatment strategies and prevention efforts to 
alleviate the destructive impact on societal productivity.
PCv115
REAL wORLD RESOURCE USE ASSOCIATED wITH TRANSCATHETER AORTIC 
vALvE IMPLANTATION AND CONvENTIONAL AORTIC vALvE REPLACEMENT 
SURGERy
Awad W.1, Mathur A.1, Baldock L.2, Oliver S.2, Kennon S.1
1The London Chest Hospital, London, UK, 2pH Associates Ltd., Marlow, UK
Objectives: To define hospital and post discharge-related resource use for patients 
undergoing Transcatheter Aortic Valve Implantation (TAVI) and conventional Aortic 
Valve Replacement (AVR) surgery within a single UK hospital. MethOds: A local 
A Markov model was developed to predict the occurrence of myocardial infarction, 
stroke, coronary revascularization and death. The model considers a lifetime horizon 
and a 3.5% discount rate. Clinical inputs were derived from the JUPITER trial and 
from a cohort of the MESA study fulfilling JUPITER inclusion criteria. Event costs 
were obtained from the literature. Rosuvastatin 20mg cost incorporates a discount to 
reflect the introduction of generics within a maximum of 5 years. Results: Coronary 
calcium score determination and subsequent primary prevention in individuals 
with a score exceeding 100 dominates no treatment. Implementing primary preven-
tion in those patients with positive score, and not just those with score above 100, 
implies a willingness to pay around 40,000€ per QALY. Finally, primary prevention in 
all individuals is not cost-effective when compared to primary prevention in those 
with positive calcium score as it is associated with a cost per QALY of more than 
600,000€ . cOnclusiOns: Determination of coronary calcium score is cost-effective 
as it allows to identify those patients that will benefit most from primary preven-
tion. Primary prevention in patients with calcium score greater than 100 should be 
implemented. The implementation of this strategy in other patients with positive 
calcium score depends on the willingness to pay for a QALY.
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LIFETIME COST-EFFECTIvENESS OF ISOLATED AND CONCOMITANT AORTIC 
vALvE REPLACEMENTS IN GERMANy
Pradelli L.1, Giardina S.2, Ranucci M.3
1AdRes HE&OR, Turin, Italy, 2Sorin Group, Milano, Italy, 3IRCSS Policlinico San Donato, San 
Donato Milanese, Italy
Objectives: Aortic valve replacement (AVR) is the most common heart valve 
operation, accounting for a conspicuous part of all valve surgery performed in 
the elderly. Prolonged aortic cross-clamping times are an independent risk factor. 
Perceval S is a new aortic valve which is implanted without need for suturing and a 
collapsed profile, thus allowing a significant reduction of cross-clamping times and 
to expand the pool of patients operable with mini-invasive aortic valve replacement 
(MiAVR) among isolated AVR candidates. Aim of this simulation study was to predict 
costs and outcomes of isolated AVR procedures associated with this new valve in 
Germany, as compared to traditional valve implants, from the cost perspective of 
the third party payer. MethOds: A previously published probabilistic, patient-level 
simulation model fully coded in WinBugs was updated with new clinical data and 
the evaluation extended to evaluate lifetime cost-effectiveness from the perspective 
of the third party payer. Unit costs and health state-specific utilities were retrieved 
from official and literature sources; the price of the sutureless valve is hypothesised 
twice as much as for traditional valves. Future costs and outcomes are discounted 
at a yearly 3.5% rate. Results: The model predicts that on average the use of the 
Perceval S in MiAVR instead of traditional sutured valves in full sternotomy among 
isolated AVR candidates, would yield incremental 0.29 LYs (0.20 QALYs) per patient, 
with an associated saving around 3,500 € , thus representing a dominant option 
when compared to traditional surgical AVRs. In concomitant procedures, on aver-
age the use of the Perceval S valve instead of traditional sutured valves is expected 
to yield incremental 0.21 LYs (0.16 QALYs) per patient, with an associated saving of 
over 4,400 € , also representing a dominant alternative. cOnclusiOns: Sutureless 
valves may improve outcomes in AVR at a reduced cost to the third party payers.
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STROKE PREvENTION IN NON-vALvULAR ATRIAL FIBRILLATION: SySTEMATIC 
REvIEw OF COST-EFFECTIvENESS STUDIES
Costa S., Ramos J.C., Braga A.C., Pereira J.
Universidade Nova de Lisboa, National School of Public Health, Lisboa, Portugal
Objectives: To conduct a systematic review of cost-effectiveness studies of newer 
oral anticoagulants for stroke prevention in atrial fibrillation versus warfarin and 
understand its implications for policy and for further research. MethOds: We 
searched DARE, Cochrane, NICE, Tufts, NHS EED, Science Direct and PubMed through 
May 2013 to identify studies of oral anticoagulants dabigatran, rivaroxaban and 
apixaban versus warfarin for stroke prevention in non-valvular atrial fibrillation 
in patients at a moderate-to-high risk of stroke initiating anticoagulation for/near 
lifetime using either a societal or health care perspective. A separate analysis was 
performed for ISPOR abstracts. Results: Ten studies were identified, most based 
on one randomized trial per therapy, 3 reported an ICER above commonly accepted 
WTP levels. ICERs ranged from $9,099–$86,000 for dabigatran and $3,190–$55,757 for 
rivaroxaban. Apixaban was found to be cost-effective $11,400–$24,312. Upon PSA, 
dabigatran was cost-effective 40% to 98%, apixaban 44.1% to 60%, and rivaroxaban 
2.1% to 80% of the time, for the lowest reported WTP. Variations in ICERs occurred 
between studies that used the same efficacy data. Key variables influencing vari-
ations include differences in costs; assumptions for INR monitoring and utiliza-
tion of health care resources; and the probabilities of adverse event. Effectiveness, 
compliance, adverse events and INR management were derived from clinical tri-
als. Additional data from recent abstracts reported similar trends. cOnclusiOns: 
For this indication, novel agents seem to be cost-effective alternatives to warfarin, 
despite variations across countries. However, cost-effectiveness may depend on: 
prices of medicines in each country; the proportion of actual patients’ time within 
the INR therapeutic range; and the actual real-world effectiveness, safety, and utili-
zation of these therapies. More head-to-head RCTs and pragmatic trials are required. 
Future cost-effectiveness studies of these new therapies should be periodically 
repeated during the lifecycle of medicines under real-world utilization and should 
also incorporate budget impact analysis.
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PHARMACOECONOMIC ANALySIS OF IvABRADINE USE IN BELARUS
Kozhanova I.1, Romanova I.1, Gavrilenko L.1, Sachek M.2
1Belarusian State Medical University, Minsk, Belarus, 2The Belarusian Center for Medical 
Technologies, Computer Systems, Administration and Management of Health, Minsk, Belarus
Objectives: Cost-effectiveness and cost-utility analysis of ivabradine use in 
patients with stable angina with left ventricular systolic dysfunction has been per-
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TwO SIMPLE METHODS OF MEASURING ADHERENCE IN HyPERTENSIvE 
PATIENTS ARE PREDICTIvE OF BLOOD PRESSURE CONTROL: POOLED ANALySIS 
OF 17,516 PATIENTS FROM SEvEN vALSARTAN STUDIES
Villa L.1, MacDonald K.2, Denhaerynck K.3, Sun D.4, Vancayzeele S.5, Brié H.5, Aerts A.6, 
Abraham I.7
1Universidad de Concepcion, Concepcion, Chile, 2Matrix45 LLC, Earlysville, VA, USA, 3Matrix45, 
Basel, Switzerland, 4University of Arizona, Tucson, AZ, USA, 5Novartis Pharma AG, Vilvoorde, 
Belgium, 6Novartis Pharma, Vilvoorde, Flemish Brabant, Belgium, 7University of Arizona College 
of Pharmacy Center for Health Outcomes and PharmacoEconomic Research/ Matrix45 LLC, 
Earlysville, VA, USA
Objectives: Hypertension is a common chronic disease and risk factor for many 
other conditions. Despite effective treatments, few patients achieve recommended 
blood pressure targets. Among the variables related with poor antihypertensive 
outcomes, patient adherence appears to be especially influential. Adherence 
assessment should fit seamlessly into the clinical encounter, which requires sim-
ple methods. We evaluated whether adherence assessments through a single-item 
query and a visual analogue scale (VAS) are independent predictors of controlled 
systolic (SBP), diastolic (DBP), and combined systolic/diastolic (SBP/DBP) blood pres-
sure (BP). MethOds: Pooled analysis of 17,516 patients treated with valsartan as 
second-line therapy from seven Belgian studies. Adherence was assessed at baseline 
and 90 days using two methods: a single query derived from the Basel Assessment 
of Adherence Scale (“Do you recall not having taken your medication sometime in 
the past four weeks?”) and a physician-rated VAS (0-100 range). Logistic regression 
was used to model BP control as a function of these two measures. Controlled 
BP was defined as < 140mm/90mmHg (< 130/80mmHg for diabetics). Results: BP 
control rates at 90 days were 39.3% for SBP, 59.4% for DBP, and 33.8% for SBP/DBP. 
79% of patients identified as adherent under the single query reached BP control, 
with odds ratios of 0.66 (95%CI= 0.62-0.71, p< 0.001) for SBP, 0.68 (95%CI= 0.63-0.73, 
p< 0.001) for DBP, and 0.64 (95%CI= 0.59-0.70, p< 0.001) for SBP/DBP. Of those patients 
with a physician-rated VAS adherence score of 80 or more, 81% reached BP control, 
with odds ratios of 0.93 (95%CI= 0.86-1.00, p< 0.001) for SBP, 0.79 (95%CI= 0.73-0.85, 
p< 0.001) for DBP, and 0.91 (95%CI= 0.84-0.99, p< 0.001) for SBP/DBP. cOnclusiOns: 
The two simple methods of measuring adherence, the single query and VAS, are 
independent predictors of blood pressure control. These measures can be integrated 
seamlessly into routine clinical practice. These findings must be validated in other 
health conditions and therapeutic areas.
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vALIDITy OF SELF-REPORTED DOSE OF PATIENTS USING wAFARIN IN CLINICAL 
PRACTICE
Dumas S.1, Rouleau Mailloux E.2, Tardif J.C.2, Talajic M.3, Dubé M.P.2, Perreault S.1
1Université de Montréal, Montreal, QC, Canada, 2Université de Montréal, Montréal, QC, Canada, 
3Montreal Heart Institute, Montreal, QC, Canada
Objectives: Warfarin is an oral anticoagulant used for the prevention of throm-
bosis, and many adjustments are needed to achieve a therapeutic INR. The dose 
of warfarin is important to establish an association between clinical and safety 
outcomes and the exposure. To evaluate the validity of the weekly dose of warfarin 
as reported by the patient compared to the weekly prescribed dose. MethOds: 
This study was based on an ongoing prospective cohort of new warfarin-users to 
assess the genetic and clinical risks associated with the effectiveness and safety 
of warfarin. Demographic and clinical data were collected from 219 patients who 
began the treatment between May 1st, 2010 and Oct. 31st, 2011 at the Montreal 
Heart Institute. They were followed-up each three months for a year. The primary 
outcome is the concordance between the reported and prescribed weekly dose of 
warfarin. The secondary outcome is the difference between the means of reported 
and prescribed warfarin weekly doses. A t-test and a Pearson correlation are used for 
the secondary outcome and a generalized mixed linear model with repeated meas-
ures is used for the primary outcome. Results: Patients had a mean age of 67.7, 
58.9% were men and 70.3% had atrial fibrillation. No significant difference between 
the means of reported and prescribed warfarin weekly dose (Pearson coefficient = 
0.969). However, we observed that the correlation was weak at 3 months for patients 
in the low dose group and in the high dose group (Pearson coefficient = 0.806 and 
0.829, respectively). Mixed linear model analysis detected no association between 
the covariates and the concordance. cOnclusiOns: This study demonstrates that 
the weekly reported dose correlates well with the prescribed dose patients in a 
prospective cohort study. Furthermore, the effect was similar whether measured 
in new-onset users of warfarin and up to 12 months of use.
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EFFECTS OF THE OCCURRENCE OF A FIRST CARDIOvASCULAR EvENT ON 
STATIN ADHERENCE IN TyPE 2 DIABETES: A MATCHED COHORT DESIGN
de Vries F.M.1, Denig P.2, Vegter S.1, Bos H.J.1, Postma M.J.1, Hak E.1
1University of Groningen, Groningen, The Netherlands, 2University Groningen, Groningen, The 
Netherlands
Objectives: Adherence to statin therapy is important for an effective reduction 
in cardiovascular events. We aimed to assess the effect of the occurrence of a first 
cardiovascular event on adherence rates in type 2 diabetes patients using a matched 
cohort design. MethOds: A matched cohort study was performed within the IADB.
nl pharmacy database among type 2 diabetes patients, who initiated statin treat-
ment for primary prevention. Index patients experienced a first event (index date) 
after initiation whereas reference patients did not. Index and reference patients 
were matched on gender, age at statin initiation, statin initiation date, adherence 
level before the index date and follow-up period. Adherence was measured as per-
centages of days covered and classified into: non-adherent, partial-adherent or 
full-adherent. Adherence rates were measured from statin initiation until the index 
date, and from the index date until end of follow-up, for reference patients in both 
cases the same follow-up period was used. Mean adherence rates between index 
and reference before and after were compared by the use of an independent samples 
service evaluation of patients undergoing TAVI or AVR between January 2011 and 
May 2012 captured data until 6-months post-procedure, collected from hospital 
records and via a General Practitioner questionnaire. The main endpoints were 
mortality, hospital length of stay (LoS), discharge destination, readmission and 
post-discharge resource use. Subgroup analyses were performed for AVR patients 
aged ≥ 80 (AVR≥ 80) and with Euroscore of ≥ 10 (AVR≥ 10). Results: Results given as 
means (standard deviation) for TAVI (n= 51), AVR (n= 188), AVR≥ 80 (n= 48) and AVR≥ 10 
(n= 47) respectively, unless otherwise stated. Age in years was 83 (3.06), 71 (13.11), 84 
(2.72), 79 (7.12), Logistic Euroscore1 was 24.74 (11.90), 8.07 (6.44), 12.01 (6.04), 16.45 
(6.58) and post-operative LoS in days was 11.51 (11.16), 10.88 (10.82), 14.31 (16.66), 
15.19 (17.67). For patients discharged alive, 0 of 48 (0%), 13 of 180 (7%), 6 of 46 (13%) 
and 4 of 44 (9%), had an unplanned cardiac-related readmission within 30-days of 
discharge. Time to readmission was 74.6 (52.9), 31.1 (37.2), 15.4 (10.5) and 16.7 (12.8) 
days. cOnclusiOns: Despite TAVI being performed in an older, higher risk popula-
tion the LoS is similar to AVR. Most strikingly there were no cardiac-related readmis-
sions within 30-days for TAVI and time to first readmission was significantly longer. 
This evaluation suggests that TAVI is clinically appropriate and provides economic 
advantages in both the hospital and post discharge setting in this high risk group. 
Many patients undergoing TAVI are considered unfit for surgery and hence TAVI 
offers a treatment that delivers similar results to traditional AVR surgery without 
the high risk associated with surgery.
CARDIOvASCULAR DISORDERS – Patient-Reported Outcomes & Patient  
Preference Studies
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PERSISTENCE wITH MEDICATIONS: A DISCRETE CHOICE ExPERIMENT OF 
PREFERENCES AMONG HyPERTENSIvE PATIENTS
Fargher E.A., Morrison V., Plumpton C.O., Hughes D.A.
Bangor University, Bangor, UK
Objectives: To examine patients’ stated preferences for persisting with medications 
using a discrete choice experiment (DCE) and to explore the relationship with clinical, 
demographic and psycho-social variables. MethOds: A 4-attribute DCE (mild side-
effects, potentially life-threatening but rare side-effects, dose frequency, treatment 
benefits) with 3-levels identified from literature and expert opinion was developed 
using a fractional factorial design. Scenarios were folded into nine forced binary 
choices: Which medicine would you be most likely to continue taking? The survey was 
translated, piloted and approved for eleven European countries. Target sample was 
100≤ n≤ 323 patients prescribed anti-hypertensives per country, recruited by posters 
in community pharmacies or general practices. Results were analysed in STATA using 
a random effects logit model. Results: A total of 2856 patients from Austria (n= 323), 
Belgium (n= 180), England (n= 323), Germany (n= 265), Greece (n= 289), Hungary (n= 323), 
The Netherlands (n= 237), Poland (n= 323) and Wales (n= 323) completed the online 
questionnaire. All four attributes influenced persistence with treatment (p< 0.01). 
Patients were willing to forego chance of improvements in treatment benefits (%) 
in order to improve other attributes: -36.10% (95% CI: -41.24 to -32.94) for a very rare 
risk of life-threatening side-effects; -18.66% (95% CI: -21.51 to -16.67) for once daily 
dose frequency; -0.74% (95% CI: -0.85 to -0.67) to reduce the risk of mild ADR by 1%. 
Likelihood ratio tests showed that models controlling for clinical, demographic and 
psycho-social variables were significantly different from the base-case. There was 
limited evidence that self-reported adherence influenced stated preferences to per-
sist. cOnclusiOns: Patients were willing to trade potential benefits, harms, and 
convenience in responding that they would persist with treatment. Clinical, demo-
graphic and psycho-social factors influence the extent of the trade-offs between 
these attributes. Persistence may therefore be enhanced directly, through selection 
of medicines meeting preferred levels of attributes, or indirectly through targeting 
modifiable psycho-social factors that affect trade-off choices.
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ILLUSTRATION OF THE COMBINED EFFECT OF PATIENT’S ADHERENCE AND 
INDIvIDUAL BIOLOGICAL CHARACTERISTICS ON BLOOD PRESSURE
Tousset E.1, Lowy A.2, Ong S.H.2, Vrijens B.1
1MWV Healthcare, Visé, Belgium, 2Novartis Pharma AG, Basel, Switzerland
Objectives: With the recognition that adherence is commonly imperfect, even with 
once daily regimen, ‘forgiveness’ is becoming acknowledged as an important char-
acteristic in predicting real-world effectiveness. Forgiveness is typically reported 
as a group average value, ignoring person-to-person variability. Here we illustrate 
an alternative way of estimating and presenting information on drug forgiveness 
which allows the estimation of the combined effect of imperfect adherence and 
variable forgiveness. MethOds: Adherence data from 4783 patients with hyper-
tension were used in these simulations. A projected dosing history over 365 days 
was obtained from each of these individual adherence profiles. Longitudinal clinic 
systolic blood pressure (SBP) collected from 4879 patients after drug withdrawal 
were analysed using non linear mixed effect models, allowing the estimation of the 
between-patient variability in the loss of effect (the ‘offset’). Projected SBP profiles 
were obtained by combining each dosing history with 100 offset curves randomly 
sampled from the variance-covariance matrix estimated in the previous step. 
Re-samplings were performed in the resulting dataset using two adherence distri-
butions described in the literature to estimate the proportion of time patients who 
achieved the maximal effect on SBP over a treatment period of 365 days. Results: 
In the first population, 90% of the patients achieved the maximal effect during 95% 
of the time, whereas, in the population presenting a lower adherence, about 80 % 
maintained the maximal effect during 95% of the time. cOnclusiOns: The impact 
imperfect adherence on response is mitigated by drug forgiveness. This methodol-
ogy reveals the person-to-person variability in clinical effectiveness which is hidden 
when forgiveness is considered as a group-average quantity, and shows that the 
agent studied provides a reliable clinical effectiveness despite imperfect adherence. 
Ultimately, this approach could be used to compare drugs with different levels of 
forgiveness and/or regimens in the presence of non-adherence.
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Objectives: SHIFT examined the effect of adding ivabradine, a heart rate lower-
ing therapy, to optimised standard therapy in chronic heart failure (HF) patients 
(n= 6505). This study reports methods and results for an analysis of SHIFT patient 
quality of life data used to inform the UK cost-effectiveness analysis for ivabra-
dine. MethOds: EQ-5D quality of life data were collected for patients in coun-
tries with a validated questionnaire (n= 5313). EQ-5D data were analysed using 
regression techniques appropriate for repeated observations across individuals 
over time. Results: Ivabradine was associated with a significant gain in patient 
quality of life (utility). Utility values were estimated to range between 0.82-0.46 
[standard care, New York Heart Association (NYHA) class I-IV] and between 0.84-
0.47 (ivabradine, NYHA I-IV). Hospitalisations were strongly associated with a 
reduction in utility, this reduction varied according to NYHA class from -0.07 
(NYHA I) to -0.21 (NYHA IV). Patients with more severe heart failure symptoms 
(NYHA III and IV), were found to suffer a greater loss in utility given a hospi-
talisation than patients with milder symptoms (NYHA I and II). cOnclusiOns: 
Ivabradine was associated with a significant improvement in quality of life. In 
addition, hospitalisation was found to significantly reduce patient quality of life; 
ivabradine is consequently expected to convey further quality of life benefits by 
avoiding the temporary utility loss associated with hospitalisations. Cumulatively, 
over a patient’s life time, this may generate important gains in quality of life for 
ivabradine versus standard care.
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HEALTH OUTCOMES AT 6 TO 120 MONTHS SINCE HEART TRANSPLANT IN 
SPAIN: CLINICAL STATUS, HEALTH RELATED-QUALITy OF LIFE AND UTILITy 
ASSESSMENT
Cuervo J.1, Delgado J.F.2, Crespo M.G.3, Crespo M.A.1, Rebollo P.1
1LASER Analytica, Oviedo, Spain, 2Hospital 12 de Octubre, Madrid, Spain, 3Complejo Hospitalario 
A Coruña, A Coruña, Spain
Objectives: To evaluate the outcomes related to heart transplantation in adult 
recipients at 6±1 (Group I),12±2 (Group II), 36±6 (Group III), 60±10 (Group IV) or 120±20 
(Group V) months after receiving the allograft. MethOds: A multicenter, cross-sec-
tional study was conducted in different transplant units from Spain (n= 14). Patients 
(aged > 18 years) with a heart transplant (HTx) due to congestive heart failure and 
living with a single functioning graft were proposed to participate. Clinical status 
was assessed with the New York Heart Association Scale. Besides, participants com-
pleted the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the EQ-5D. Other 
measures of social support and caregivers’ burden were also included. Differences 
between groups were studied (Chi-squared, Kruskal-Wallis and Mann-Whitney U 
with Bonferroni correction tests). Multivariate regression analyses were applied to 
examine the association of clinical and socio-demographic variables with question-
naires’ scores. Results: A total of 303 transplant recipients (77.9% males) with a 
mean age(SD) of 56.4(11.4) years were included. High levels of health-related quality 
of life (HRQoL) were found at all stages after transplant. However, a slight decrement 
was detected after 10 years since transplantation (p≤ 0.033). EQ-5D utility mean(SEM) 
scores were: Group I-0.81(0.03)-; Group II-0.82(0.03)-; Group III-0.85(0.03)-; Group 
IV-0.86(0.02)-; Group V-0.75(0.03)--). VAS values (EQ-5D) were close to those of the 
general population, with the exception of patients at 10 years since transplanta-
tion whose scores were lower. Multivariate analyses showed that this decrement 
in well-being was related to comorbid medical conditions, severe vascular disease 
of allograft and the number of hospitalizations (EQ-5D: 48.4% of explained vari-
ance, F4,164= 38.46, p< 0.001; KCCQ-overall functional score-: 45.0% F3,198= 54.073, 
p< 0.001). cOnclusiOns: : HTx outcomes in Spain seem to be satisfactory with 
good achievements in HRQoL and utility scores.
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THE RELATION BETwEEN THE MODIFIED RANKIN SCALE (MRS) SCORES AND 
UTILITy wEIGHTS: RESULTS FROM A SURvEy AMONG COMMUNITy DwELLING 
LONG TERM STROKE SURvIvORS
Greenberg D.1, Ginsberg G.2, Ziv A.3, Litmanovitch-Goldstein D.3, Tanne D.4, Chodick G.5, 
Balicer R.D.6, Dankner R.3
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Ministry of Health, Jerusalem, Israel, 
3The Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer, Israel,  
4Tel-Aviv University, Tel-Aviv, Israel, 5Maccabi Healthcare Services, Tel Aviv, Israel,  
6Clalit Health Services, Tel Aviv, Israel
Objectives: The modified Rankin Scale (mRS) is frequently used in clinical stud-
ies to measure the level of disability following stroke and TIA. As the mRS is a 
disease-specific instrument, it can not be easily translated into preference-based 
utility-weights to be used in cost-effectiveness analyses (CEAs). Data on utility-
weights by the mRS disability level are limited. We estimated the relation between 
mRS scores and utility-weights in a convenience sample of “real-world” stroke 
survivors. MethOds: During a personal interview of 148 community dwelling 
long-term stroke survivors attending day-care rehabilitation centers through-
out Israel, we estimated the level of disability using the mRS, ranging from: no 
symptoms/disability (mRS= 0), to severe disability (mRS= 5). Patients also com-
pleted the EuroQoL (EQ-5D) questionnaire, the most commonly used instrument 
for obtaining utility values. Utility-weights were calculated using the EQ-5D UK 
tariffs. Health states may range from -0.594 to 1, where 1.0 is defined as per-
fect health and zero represents death. Results: Mean age (±SD) of patients was 
65.8±9.8, ranging from 28-85 years, with male predominance of 73.6%. Over 80% 
of patients were married, living with their spouse or family. The vast majority 
(92%) of patients did not work at the time of interview, mainly due to the stroke. 
Mean time from first stroke was 7.2±5.9 years and 1/3 of respondents experienced 
> 1 stroke events. Mean utility-weights (±SD) were as follows: mRS 0-1(N= 31), 
0.748±0.231; mRS 2-3 (N= 78), 0.395±0.317; mRS 4-5 (N= 38), 0.055±0.277. Nineteen 
percent of patients had a utility-weight < 0 representing a health state considered 
worse than death. cOnclusiOns: While utility-weights of stroke survivors with 
no symptoms/no significant disability (mRS 0-1), are comparable to those used 
in published CEAs, patients with moderate and severe disability (mRS 4-5) show 
T-test. Results: From the 855 index patients 375 could be matched to a reference 
patient. Mean adherence rates before the index date were 79% for both groups. 
After the index date, mean adherence rates were 81% for index patients and 71% for 
reference patients (p-value < 0.001). Index patients were more likely to become full-
adherent and less likely to become non-adherent. 26% of the index patients used 
more statins after the event than before whereas 20% used less. cOnclusiOns: 
Patients receiving a statin are likely to become more adherent after the occurrence 
of a cardiovascular event during statin treatment. One in five of these patients, how-
ever, become less adherent showing there are still important health and economic 
benefits to achieve by tailoring the management of individual patients.
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HEALTH STATE IN PATIENTS wITH ATRIAL FIBRILLATION ON NEw ORAL 
ANTICOAGULANTS AS ASSESSED wITH THE NEw EQ-5D-5L QUESTIONNAIRE: 
PREFER IN AF REGISTRy
Brüggenjürgen B.1, Ammentorp B.2, Darius H.3, De Caterina R.4, Le-Heuzey J.Y.5, Pittrow D.6, 
Reimitz P.E.2, Schilling R.J.7, Schwertfeger M.2, Zamorano J.L.8, Kirchhof P.9
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Germany, 7Barts and St Thomas Hospital, London, UK, 8University Hospital Ramón y Cajal, 
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Objectives: New oral anticoagulants (NOACs) have the promise to change the man-
agement of patients with atrial fibrillation (AF), and can be used in lieu of vitamin K 
antagonists (VKAs) or antiplatelet drugs (AP). We aimed to obtain contemporary data 
on the health state of AF patients under everyday practice conditions at the time of 
introduction of NOACs. MethOds: PREFER in AF is a non-interventional study that 
prospectively documents AF patients in terms of clinical characteristics, manage-
ment, quality of life and other outcome parameters. The new EuroQol EQ-5D-5L 
descriptive system was applied in PREFER in AF to obtain patient-reported generic 
health-related quality of life information and utility scores to inform resource allo-
cation decisions. Results: Of the 7243 AF patients (63.1% males, mean age 71.5 ± 
10.7 years), 2159 (30.0%) had paroxysmal, 1731 (24.0%) persistent, 517 (7.2%) long-
standing persistent, and 2793 (38.8%) permanent AF. Comorbidities were highly prev-
alent. On the visual analogue scale, the mean score in 5674 patients (78.3% EQ-5D 
participation rate) was 67.7 ±18.4 points, with no major differences between patients 
on NOACs (68.4), VKAs (67.6), AP (69.7), or VKAs+AP (65.5), respectively. Problems of 
any severity were reported for mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression in 50.1%, 20.7%, 45.0%, 55.4%, and 47.1%. The overall utility 
index was 0.85 ±0.17. The 319 patients on NOACs had the same utility index as the 
182 patients without VKAs or AP (0.80 in both groups), whereas the 2937 patients 
on VKAs, the 342 on AP or the 425 patients on VKAs+AP had lower indices (0.77 vs. 
0.77 vs. 074). cOnclusiOns: Patients with AF present with reduced self-reported 
quality of life compared to the general population. Patients receiving NOACs had 
a slightly higher quality of life, possibly illustrating that this type of treatment 
is initially given to “healthier” populations compared to established VKA therapy.
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QUALITy OF LIFE IN PATIENTS wITH vENOUS THROMBOEMOBLISM: A 
SySTEMATIC LITERATURE REvIEw
Rao N.1, Liu X.2, Claflin A.B.2, Phatak H.3, Mitchell S.A.1
1Abacus International, Bicester, UK, 2Pfizer, Inc., New York, NY, USA, 3Bristol-Myers Squibb 
Company, Princeton, NJ, USA
Objectives: A systematic review was conducted to determine the quality of life 
(QoL) in patients with venous thromboembolism (VTE). VTE encompasses deep 
vein thrombosis (DVT) and pulmonary embolism (PE) and may be associated with 
long-term complications including post-thrombotic syndrome (PTS) in up to 50% of 
patients following symptomatic DVT. MethOds: Eligible English language studies 
reporting QoL and utility scores for VTE (published since 1990 from any geographical 
location) were identified from electronic databases (Medline, EMBASE and Cochrane 
Library: accessed December 2012) and conference proceedings. Results: Thirty 
studies (VTE= 4; DVT= 23; PE= 3) that were eligible for inclusion were conducted 
in Europe (n= 11), Canada (n= 9), United States (n= 7), or were multinational (n= 3). 
A total of 14 unique generic (n= 8) and disease-specific (n= 6) instruments were 
reported. The generic SF-36 (n= 18), and the disease-specific VEINES QoL/Sym (n= 12) 
were the most frequently used instruments. In general, the QoL of patients with 
VTE was significantly impaired in all domains – physical, social and psychological 
– compared with the general population, measured using both disease-specific and 
generic instruments. QoL scores tended to improve during follow-up with the great-
est improvement reported between 1–4 months following an initial event. Factors 
associated with poor QoL were identified: older age, obesity, female gender, comor-
bidities, and recurrent VTE events. Patients with PTS reported long-term worsening 
of QoL and functional disability compared with patients without PTS following 
an initial VTE event, with the impact on QoL increasing with severity of disease. 
However, in contrast to disease-specific QoL instruments, the impact of PTS on QoL 
was not consistently reported with generic questionnaires. cOnclusiOns: Initial 
VTE events and long-term complications, such as PTS, are significantly associated 
with reduced patients’ QoL in physical, psychological, and social domains. Disease-
specific measurements should be further developed to assess the long-term impact 
of VTE recurrence, PTS, and bleeding associated with anticoagulant use.
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AN ANALySIS OF EQ-5D QUALITy OF LIFE DATA FOR A COST-EFFECTIvENESS 
ANALySIS OF IvABRADINE PLUS STANDARD CARE vERSUS STANDARD CARE 
ALONE IN CHRONIC HF
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days post-stroke) and early patients. Models accounting for patient health utility 
were significantly different (p< 0.05). cOnclusiOns: These findings complement 
the more descriptive summaries of a comprehensive matrix of sources of support 
within regions and localities (Department of Health, 2007), with which people living 
with stroke may interact. Exploring what patients and carers consider important 
in the provision of stroke support services, will ensure that service re-design is 
user-focused to maximum utility.
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PATIENTS PREFERENCES FOR LONG-TERM TREATMENT AFTER ACUTE 
CORONARy SyNDROME: A DISCRETE-CHOICE ExPERIMENT AND ANALyTIC 
HIERARCHy PROCESS
Mühlbacher A.C., Bethge S., Kaczynski A., Juhnke C.
Hochschule Neubrandenburg, Neubrandenburg, Germany
Objectives: Diseases of the cardiovascular system are the main causes of death in 
Germany and other industrial countries. Different therapeutic approaches exist as 
well as several treatment options. How people who have suffered from an acute cor-
onary syndrome, value aspects of their medical treatment is not very well analyzed 
until today. The objective of this empirical investigation was to evaluate patient’s 
preferences regarding different antiplatelet medication options following an acute 
coronary syndrome. MethOds: Primary method was a Discrete-Choice-Experiment 
that included 6 patient-relevant attributes. Furthermore an Analytic-Hierarchy 
Process (AHP) was used to test the applicability of the method and to compare the 
results. The Discrete-Choice-Experiment (DCE) was conducted using a fractional 
factorial NGene-design with priors and the statistical data analysis used a random 
effect logit model. AHP was conducted using the eigenvalue method. Results: The 
preference analysis of N= 683 patients showed a clear dominance for the attribute 
“reduction of the risk of death” (DCE coef.: 0.803; AHP coef.: 0.402.). Rank 2 in AHP 
the “reduction of heart attack risk” (DCE coef: 0.464; AHP coef.: 0.272.) and in the 
DCE was “shortness of breath” (DCE coef.: 0.550; AHP coef.: 0.165.). The side effect 
of “bleeding” (DCE coef.: 0.400; AHP coef.: 0.117.) joined accordingly. The “frequency 
of administration” was less important in DCE and AHP (DCE coef: 0.025; AHP coef. 
0,044.). cOnclusiOns: The results of both methods generated an almost equal 
ranking of the included features. The highest value for patients within a treatment 
decision was the mortality reduction. The consideration of patient preferences in 
therapeutic decisions implies stronger patient focus and can at the same time be 
used for the development of effective therapies after acute coronary syndrome. 
The preference data generated can be used for health care decision makers and 
stakeholders to represent the patient’s benefit at the same time.
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COMPARING THE PERFORMANCE OF THE EQ-5D-5L wITH THE EQ-5D-3L IN 
STROKE PATIENTS IN jAPAN
Noto S.1, Izumi R.1, Moriwaki K.1, Igarashi A.2, Ikeda S.3, Fukuda T.4, Shiroiwa T.4,  
Kobayashi M.5, Saito S.6, Shimozuma K.7
1Niigata University of Health and Welfare, Niigata, Japan, 2Tokyo Univ. Faculty of Pharmacy, 
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Objectives: To assess the performance of the EQ-5D-5L Japanese version com-
pared with the EQ-5D-3L in clinical setting targeted at patients with stroke in 
Japan. MethOds: The stroke patients were recruited from six rehabilitation hos-
pitals in Japan. The proxy of the patients completed a questionnaire including the 
two versions of the EQ-5D. We tested the inconsistency, the redistribution proper-
ties, and the ceiling effect. Results: A total 533 patients were recruited: 61% male, 
15-99 (mean= 67) years old. Diagnoses of patients were infarction (54.6%), hemor-
rhage (35.5%), and other (9.9%). The proportion of inconsistent responses (i.e., 3L 
responses that were at least two levels away from the 5L responses) was 3.6%. In 
particular the proportion in MOBILTY was 14.6%. Regarding redistribution, 52-61% 
of the patients answering level 2 with the 3L version redistributed their responses 
to levels 2 or 4 with the 5L version. A relative 3% reduction of the ceiling effect was 
found. cOnclusiOns: Our findings suggest that the EQ-5D-5L Japanese version 
performs better in at least some properties analyzed. Further study is necessary to 
clarify other psychometric properties.
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A RETROSPECTIvE STUDy COMPARING COMPLIANCE, PERSISTENCE, AND 
BLOOD PRESSURE CONTROL BETwEEN FREE-DRUG AND SINGLE-PILL 
COMBINATION THERAPIES IN KOREAN HyPERTENSIvE PATIENTS
Hong J.M.1, Kim E.G.1, Min K.2, Min J.3, Shin K.4, Yang B.M.1
1Seoul National University, Seoul, South Korea, 2Ajou University School of Medicine, Suwon, 
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Objectives: Existing evidences indicate that single-pill antihypertensive combina-
tions (SPC) have greater rates of adherence and more effective lowering of blood 
pressure than free-drug combinations (FC). SPC therapy has been used in Korea for 
the purpose of achieving optimal blood pressure control. However it is questioned 
whether such existing positive evidence toward SPC from western countries can 
be found in the Korean population. MethOds: This study compared compliance, 
persistence and blood pressure change of SPC versus FC using the medical charts of 
1,940 patients from 17 Korean general hospitals (GH1-17). The hypertensive patients 
with SPC or FC prescription, more than 40 years old, no history of hospitalization, 
visited GH1-17 from January 1, 2010 to December 31, 2011 were included. Compliance 
was compared using the Medication Progression Ratio (MPR), calculated as the ratio 
between the days medication was taken and days in a time interval. Persistence was 
measured as the number of days from the index date to the therapy discontinuation 
date. The blood pressure (BP) change was calculated as the difference between the first 
and the last visit. Results: Overall compliance measured by MPR was 0.71 for the 
SPC group and 0.69 for the FC group, with the difference being statistically significant. 
an extremely low quality of life. These findings should be considered in future 
planning of interventions in stroke patients.
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Objectives: To determine the feasibility of using the Experience Sampling Method 
(ESM) to obtain accounts of the momentary experience of Health Related Quality 
of Life (HRQOL) and compare these to retrospective global measures of HRQOL and 
utilities derived from choice under uncertainty. MethOds: An experience-sampling 
study of 139 participants from three different patient groups and a control sample 
examined the momentary experience of HRQOL (mom-HRQOL). Global retrospec-
tive HRQOL measures were also administered. Feasibility of was determined by 
assessing willingness to participate in the study and by analysing the percentage 
of drop-outs and the number of completed beep questionnaires. Bivariate correla-
tions between mom-HRQOL and momentary positive affect (PA), negative affect (NA) 
and physical symptoms (PS) for each participant were determined. Furthermore, 
correlations between mom-HRQOL, PA, NA and PS on the one hand and retrospec-
tive global health (EQ-VAS), the EQ-5D utility, the SF-6D utility and the TTO on the 
other hand were determined. Results: The overall participation rate was low but 
there were no drop-outs and the number of completed beeps was comparable to 
other studies. For most participants, the correlation between mom-HRQOL and 
momentary PA, NA and PS was in the expected direction. Correlations between 
ESM data on HRQOL, PA, NA and PS and retrospective measures were moderate to 
high, with the exception of the TTO. cOnclusiOns: Overall, this study extends our 
knowledge of the similarities and differences between ESM data on HRQOL, feelings 
and symptoms and retrospective measures of HRQOL, which may aid future health 
care research and decision making.
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PATIENTS wITH HyPERTENSION IN PRIMARy CARE IN SPAIN: MANAGEMENT, 
SELF-PERCEPTION AND SATISFACTION
Sánchez-Piedra C., García-Pérez S., Sarría S.antamera A
Agencia de Evaluación de Tecnologías Sanitarias (AETS), Madrid, Spain
Objectives: EUprimecare is a European Union project aimed at analyzing the costs 
and quality of the different models of primary care (PC) in Europe. The aim of this 
paper is to analyze the management of patients with hypertension in PC services 
in Spain compared to other European countries, the satisfaction of these patients 
with PC services and their self-perceived health status. MethOds: Cross-sectional 
study. We conducted a population survey by telephone among PC users in each of 
the consortium countries (Germany, Spain, Estonia, Finland, Hungary, Italy and 
Lithuania). The questionnaire included information on sociodemographic charac-
teristics, health status, satisfaction, utilization of PC services, and frequency of 
some interventions carried out by PC professionals. The survey was conducted to 
431-432 PC users in each country (Ntotal = 3020). We use satisfaction, health status 
and sociodemographic variables to consider the situation of patients with hyperten-
sion in PC. Results: The percentage of users of primary care services who reported 
having hypertension in Spain was 21.6% (N = 93), lower than the overall average 
(34.9%). 97% of patients resident in Spain were diagnosed by their primary care 
physicians versus 82.6% of the European average. The 91.4% of patients in Spain 
claimed to be in treatment to hypertension (EU average= 92.3%) and in 92.9% of 
cases the treatment was prescribed by their PC doctors (EU average= 84.5%). Only 
7.5% of patients claimed that their health was poor or very poor, the lowest propor-
tion of all countries evaluated. cOnclusiOns: The patient with hypertension in 
Spain is diagnosed and managed by PC professionals more frequently than in other 
European countries. The self-perception of these patients in Spain is good and they 
were satisfied with the services of AP. The overall satisfaction of the patients with 
AP services was high but not significantly different from other countries.
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USER PREFERENCES FOR STROKE SERvICES IN wALES
Fargher E.A., Plumpton C.O., Roberts G.W., Owen H., Burton C.R.
Bangor University, Bangor, UK
Objectives: To investigate patient and family carer preferences for stroke support 
services. MethOds: Discrete choice experiment (DCE) using a fractional factorial 
design, folded into nine binary choices, containing four attributes: format of service 
(group, individual); service provider (hospital stroke team, primary care, voluntary 
sector); provision of additional social and leisure activities (provided, not provided); 
and time to plan and make the journey (1,2,4 hours). Attributes and levels were 
defined by a review of policy documentation and two workshops with patients and 
family carers (n= 8). Patients (six months post-stroke) and their family carers were 
recruited from four stroke-services in Wales, to complete a paper questionnaire 
including the DCE and validated instruments to facilitate pre-specified sub-group 
analyses. Data were analysed in STATA using a random effects logit model. Marginal 
rate of substitution (MRS) used journey time as the value attribute. Results: A total 
of 144/474 (30%) eligible patients requested the questionnaire, 80 (56%) completed 
(mean age 70.8 years (sd 11.1). A total of 34/74 family carers who requested the 
questionnaire completed. All four attributes were significant for patients (p< 0.05), 
only format of service and journey for carers. Patients preferred support services on 
an individual basis (p= 0.00, MRS= 128.61 minutes), with additional social and leisure 
activities (p= 0.00, MRS= 64.07 minutes). Family carers were willing to trade more 
journey time for services provided on an individual basis (p= 0.00, MRS= 273.73 min-
utes). Sub-group analysis showed significant differences between established (> 315 
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Objectives: There are few studies in Spain about outcomes at six months in 
terms of health-related quality of life (HRQoL) in patients hospitalized by heart 
failure (HF). The objective of the study was to evaluate changes in HRQoL from 
baseline to six months post discharge in patients with HF through three ques-
tionnaires, SF-12, EQ-5D-3L and Minnesota Living with Heart Failure questionnaire 
(MLHFQ). MethOds: This is a prospective study with 976 patients admitted by HF. 
Patients completed questionnaires during their hospitalization and at six months. 
The MLHFQ is a specific instrument which has 21 items with an overall scale, physi-
cal (8 items) and emotional (5 items) subscales. MLHFQ items are scoring from 0 
(best) to 5 (worse). Total score ranges from 0 to 105, physical domain from 0 to 40 
and emotional from 0 to 25. SF-12 has two dimensions, Physical Summary Score 
(PCS) and Mental Summary Score (MSC) which scores range from 0 (worst) to 100 
(best). EQ-5D has been measured according to the Spanish tariffs by time trade-off 
and the visual analogic scale. We used general linear model to study gains in each 
dimension adjusted by baseline score, age, gender and readmissions in the previous 
6 months. Results: Mean age was 76.0 (SD= 10.4), there were a 53.3% of men and 
33.1% of readmissions in the previous six months. Regarding all questionnaires and 
dimensions, baseline status influence in gains, the worse the baseline the more 
the gains. Likewise men have greater gains and patients readmitted lower in all 
domains. Age has an influence in all domains but emotional dimension of MLHFQ 
and MSC of SF-12. cOnclusiOns: Adjusted by baseline score and readmissions, 
men have greater improvements in all domains of MLHFQ, SF-12 and EQ-5D. On the 
other hand, the younger the patients the higher the improvement is, however age 
does not have any influence in psychological domains.
PCv135
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Objectives: Warfarin anticoagulation is monitored using international normal-
ized ratio (INR); specified with the narrow/wide 2.0–3.0/1.9–3.5 therapeutic target 
range, and converted to time in the therapeutic range (TTR, total percentage of 
time the INR reading is within the INR therapeutic range). We explored the impact 
of I) INR monitoring and II) TTR on patients’ quality of life (QoL). MethOds: A 
total of 647 unselected patients visiting 3 health centres in Pirkanmaa district 
(31.01–11.02.2011), Finland participated to prospective study. To assess INR moni-
toring or TTR and QoL, Beta regressions were applied in Stata and EQ-5D-3L-based 
QoL (Smithson&Verkuilen transformation) 3 months after the baseline visit was 
the dependent variable. The covariates were CHADS2(congestive heart failure, 
hypertension, age> 75, diabetes mellitus, stroke) score, other comorbidities, 
baseline QoL, time difference (days) between dependent variable measurement 
and mean TTR time point (subgroup model), and INR monitoring (yes/no in total 
population) or TTR % (subgroup model). Results: A total of 28 patients (46.43% 
male; means: age 73.21 years, CHADS2-score 2.39, other comorbidities amount 
1.71, baseline QoL 0.8334, INR tests 4.21, 66.31%/82.86% INR measurements on 
the narrow/wide range) had INR measurements (“warfarinization group”) during 
the 3 months follow-up. 27 patients had calculable TTR (Rosendaal method) that 
was 69.29%/86.66% on the narrow/wide range. In the beta regression (N 393, +1 
marginal change), CHADS2-score (-0.021), other comorbidities amount (-0.030), 
baseline QoL (+0.350), and INR monitoring (p= 0.299, -0.042, SE 0.044) predicted QoL. 
The mean adjusted QoL with/without INR monitoring in the warfarinization-like 
group was 0.794/0.836. In subgroup Beta regression including only warfariniza-
tion patients, higher TTR levels predicted lower QoL (p< 0.050, +1 %-unit marginal 
change -0.006 [SE 0.007]; discrete change -0.284 in the wide range from 35.3% to 
100.0%). cOnclusiOns: INR monitoring may predict QoL loss and, surprisingly, 
higher TTR predicts lower QoL. Larger studies are needed to confirm the potential 
relationship between TTR and QoL.
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CORONARy ARTERy DISEASE, DIABETES, AND HEALTH-RELATED QUALITy OF 
LIFE: FINDINGS OF A COHORT STUDy FROM INDIA
Shah B.S.1, Deshpande S.S.2
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Objectives: Assess health-related quality of life (HRQoL) of patients with 
CAD. MethOds: The main observational study cohort enrolled consecutive patients 
admitted in ICU at tertiary care hospital and diagnosed with CAD. Demographic 
information, risk factors for CAD, and angiographic findings were collected. EQ-5D 
was administered at 1-year follow-up. EQ-5D levels were dichotomized: ‘no prob-
lems’ (level 1), ‘any problem’ (levels 2 and 3). Linear stepwise regression was used 
to assess predictors of all 5 health states (mobility, self-care, usual activities, pain/
discomfort, anxiety/depression). The independent variables studied include age, 
hypertension, diabetes, CHF, gender, prior MI, final diagnosis, MI type, and final 
treatment. Respondents reporting problems EQ-5D dimensions were stratified by 
presence of diabetes and compared. Results: Of 960 CAD patients enrolled for the 
main cohort study (30% diabetic), 306 (male, 230; diabetics, 64) responded HRQoL 
questionnaire at 1-year. On liner regression, presence of diabetes was independent 
predictor of 4/5 EQ-5D HRQoL dimensions: mobility (p= 0.019), problems performing 
usual activities (p= 0.041), pain/discomfort (p< 0.001); anxiety/depression (p= 0.001). 
At 1-year, mean EQ-5D utility index score and VAS score were significantly lower 
for diabetes vs non-diabetics (0.76±0.13 vs. 0.83±0.15, p= 0.0003 and 67.8 ± 8.8 vs. 
73.6±5.4, p= 0.0001, respectively) with more problems with performing usual activi-
ties (56.3% vs. 41.3%, p= 0.04), pain or discomfort (51.6% vs. 17.8%, p= 0.0001) as 
well as anxiety/depression (32.8% vs 14.9%, p= 0.002). cOnclusiOns: Among CAD 
This was especially evident for SPC patients in the 40~64 year age group (0.71 for SPC, 
0.69 for FC) and patients with two or more comorbidities (0.73 for SPC, 0.69 for FC) (P= 
0.0011). However, no statistical significance was observed for the difference both in 
persistence and the BP change between the two groups. cOnclusiOns: Our study 
suggests that compliance tends to be improved by the use of SPC compared with 
FC. Unlike the previous western studies, it was hard to find a significant increase in 
persistence or BP change with SPC therapy in this study.
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Objectives: Telemedical systems (TMS) and data management for implantable 
cardioverter-defibrillators (ICD) promise to reduce costs and optimize patient 
care. Depressive symptoms are common among patients with an ICD and the 
health related quality of life (HRQoL) is affected by the underlying disease and the 
implanted device, respectively. TMS might improve the HRQoL of patients and ICDs 
acceptance due to closer monitoring and, thereby, an increased level of perceived 
safety. In this RCT, changes in the level of depression, HRQoL and ICD-acceptance 
over a period of six months after ICD-implantation were investigated. MethOds: 
A total of 161 patients (80.7% male; age: 64,1±14,6; 82% with coronary disease, 11% 
with DCM) with an ICD were randomized at the day of implantation into interven-
tion (n= 82) or control group (n= 79). The intervention group was equipped with a 
telemonitoring-system that transferred ICD-data from the patients’ home to the 
medical practitioner. The control group received regular care. Patients were asked to 
fill out three questionnaires (the generic EQ-5D, the depression specific HADS and 
the device specific FPAS); the follow-up period was six month, with postal surveys 
on a monthly basis. Results: Nine patients dropped out before survey comple-
tion. A total of 140 patients filled out at least two sets of questionnaires and were 
included in the analyses. After six months the mean improvement in the HRQoL 
(EQ-5D-Index) in the telemonitoring group was 10.7 points compared to baseline 
(p= .006) while the mean change in HRQoL in the control group was 5.5 (p= .138). FPAS 
and HADS-D showed small but non-significant advantage for the telemonitoring 
group. cOnclusiOns: Preliminary results suggest that TMS have the ability to 
improve HRQoL of patients with ICDs. Results on effects towards depression and 
anxiety and enhancement of ICDs acceptance are also promising. Since ICDs are 
used in chronic diseases a longer follow-up period seems to be required to validate 
the effects.
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Objectives: To assess convergent and divergent validity of a new questionnaire 
(SAFUCA) developed to measure satisfaction with medical care in patients with 
non valvular atrial fibrillation. MethOds: The 25-item reduced version instru-
ment was administered along with the Treatment Satisfaction Questionnaire for 
Medication (TSQM), and 5 Visual Analog Scales (VAS) measuring: Health Related 
Quality of Life (HRQoL), Effectiveness and Overall Satisfaction assessed by the 
patient; and Effectiveness and Tolerability assessed by the clinician. A convenience 
sample of 230 patients recruited at 7 health centers (5 hospitals and 2 primary care 
centers) in Spain was used. Second Order Exploratory Factor Analysis (SO-EFA) and 
correlation with VAS scales were computed. Results: SAFUCA dimensions cor-
related (p< 0.001) higher with corresponding TSQM dimensions (e.g.: Effectiveness 
r= 0.450, Convenience r= 0.457, Undesired Effects r= -0.340, Overall satisfaction 
r= 0.651), while SO-EFA made evident differences regarding the assessment of 
satisfaction with INR controls, interference in QoL and Medical Care. Correlation 
pattern between VAS scores was significantly different between primary care cent-
ers and hospitals, with a higher correlation between patient and clinician scores 
observed in primary care (e.g.: Effectiveness rPC= 0.430 vs. rH= 0.057). Similarly, 
correlation patterns between VAS concurrent scales and SAFUCA dimensions 
differed between center types. While high correlations between Effectiveness 
dimension and patient satisfaction VAS were observed in both cases (rPC= 0.521 
vs. rH= 0.516), correlation of Tolerability with Undesired Effects differed between 
centers (rPC= -0.474 vs. rH= -0.085). cOnclusiOns: The 25-item questionnaire 
exhibits good convergent and divergent validity values. Differences between 
types of health care centers in correlation patterns were meaningful and worth 
of further research.
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(NOACs), 5.2% on antiplatelets (AP) and 11.0% on VKA+AP combinations. In the 
“convenience” dimension, the overall score (0-100 range) was 82.9 ±17.3. The score 
was higher in the NOAC group (88.1 ± 13.0) compared to the VKA (82.1 ± 17.5), AP (87.0 
± 17.9) or VKA +AP groups (83.2 ± 16.8), respectively. In the “anticoagulant treatment 
satisfaction” dimension of the PACT-Q2, the overall score was 63.4 ±15.9. Again, 
this score was higher in the NOAC group (66.6 ±16.6) compared to the VKA (63.2 
±15.9), AP (63.7 ±16.8), or VKA + AP groups (62.8 ±15.0), respectively. cOnclusiOns: 
Overall, patients on current anticoagulation achieve relatively high values on the 
convenience scale, but moderate values on the satisfaction scale. While differences 
in group size and patient characteristics need to be taken into account, patients 
on NOACs compared to patients on VKAs tend to rate their convenience and treat-
ment satisfaction higher.
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CHRONIC PATIENTS’ wILLINGNESS TO PAy FOR AN ALTERNATIvE DRUG wITH 
INNOvATIvE CHARACTERISTICS
Skroumpelos A.1, Kyriopoulos I.I.1, Mylona K.1, Anastasiou L.2, Pavi E.1
1National School of Public Health, Athens, Greece, 2Novartis Hellas, Metamorfosi, Greece
Objectives: Aim of the study was to investigate whether chronic patients are 
willing to pay an extra amount of money in order to switch to another drug that it 
is either on patent, more effective or simpler in dose. MethOds: A cross-sectional 
study was conducted among 1600 chronic patients suffering from diabetes, hyper-
tension, COPD and Alzheimer. Logistic regression analysis was carried out to explore 
the factors that influence patients’ decision on willingness to pay (WTP) for an 
alternative drug with innovative characteristics. Results: Of the 1600 patients 
approached, 1594 responded to the survey (99.6%). A total of 40% stated that they 
would be willing to pay more for a patent drug, 57.5% for a more effective drug and 
37.5% for a simpler in dose drug. The average additional amount per month that 
they would be willing to spend was estimated at 23.6€ for a patent drug, 24.1€ for a 
more effective drug and 21.9€ for a simpler in dose drug. Statistical analysis revealed 
that WTP for a patent drug was statistically significant related with the patient’s 
income (OR,1.24;95%CI, 1.14-1.34) while WTP for a more effective or a simpler in dose 
drug was positively related with the patient’s income (OR,1.25;95%CI, 1,13-1,39 and 
OR, 1,14;95%CI, 1.05-1.24 respectively) and educational level (OR,1.06;95%CI, 1,01-
1.13 and OR, 1.06;95%CI, 1.01-1.13, respectively). cOnclusiOns: Half of chronic 
patients demonstrate absolute willingness to increase spending for an innovative 
drug, which highlights the significance they attribute to pharmaceuticals for the 
management of their condition. The remaining’s 50% reluctance may be attributed 
to the extended trust on their current pharmaceutical treatment and to the efforts 
and money spent in order to control their condition. However, patients with higher 
socioeconomic status are more likely to express WTP which reflects the economic 
burden imposed by chronic conditions, and the role of education in shaping patient 
attitudes.
CARDIOvASCULAR DISORDERS – Health Care Use & Policy Studies
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EvALUATION OF THE LENGTH OF HOSPITAL STAy FOR PATIENTS wITH ATRIAL 
FIBRILLATION
Volz F.1, Kloss S.1, Muschaweck F.2, Wilke M.3, Leverkus F.1
1Pfizer Deutschland GmbH, Berlin, Germany, 2Bristol-Myers Squibb GmbH & Co. KGaA, Munich, 
Germany, 3Dr. Wilke GmbH, Munich, Germany
Objectives: Identification of differences in the length of hospital stay for patients 
with atrial fibrillation (AF) with and without oral anticoagulation (OA). Longer 
stays of patients could lead to an economical burden for the hospital because 
of the Diagnosis Related Groups (DRG) system in Germany and the compensa-
tion with case-based lump sum. MethOds: We conducted a retrospective study 
using an electronic DRG benchmarking database. This database contains DRG 
data from 208 hospitals in Germany with over 2,800,000 inpatient cases per year. 
In total, 10,912,922 cases from the year 2010 to 2012 were analyzed. 661,845 cases 
fulfilled the inclusion criteria and were analyzed according the statistical analy-
sis plan including matched pair analyses. Results: Cases with AF and surgical 
intervention compared to cases without AF and with surgical intervention have 
a significantly longer pre-operation length of stay (+0.74 days) and a significantly 
longer hospital stay (+1.5 days). Furthermore cases with chronic AF (= AF+OA) 
have a significantly longer total length of stay in the hospital (+0.86 days). For 
the cases with AF and bleeding vs. cases without bleeding, there is no significant 
difference in the total length of stay, but there is a significantly longer stay of 0.82 
days compared to the average length of stay in the DRG-catalogue. cOnclusiOns: 
Patients with AF and with or without OA could be an economic burden for the 
hospital, because the increased length of stay in hospital leads to higher costs 
whereas the existing compensation diagnosis-based lump sum is not affected by 
increased treatment days. The new oral anticoagulants could lead to shorter stays 
of patients with AF by shortening the bridging periods compared to OA like vitamin 
K antagonists. Further studies should be conducted to figure out the causes for 
longer hospital stays of patients with AF.
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ADHERENCE TO wARFARIN TREATMENT IN BRAzIL: SySTEMATIC REvIEw OF 
THE LITERATURE
Feijo L.F.1, Clark O.A.C.2, Monteiro R.C.3, Fujii R.K.4, Donato B.M.K.5, Bernardino G.D.R.3,  
Barbieri D.E.6, Mould J.7, Manfrin D.F.4
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patients with diabetes, HRQoL was lower across all health dimensions measured 
by the EQ-5D; except mobility and self-care. Individualised therapeutic manage-
ment programs could be considered in order to improve the HRQoL of CAD patients 
with diabetes.
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TRANSLATION AND CULTURAL ADAPTATION OF PATIENT PERCEPTION OF 
ARRHyTHMIA QUESTIONNAIRE IN POLAND
Farkowski M.M.1, Golicki D.2, Pytkowski M.1, Szumowski L.1, Wood K.A.3, Szwed H.1
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Objectives: Patient Perception of Arrhythmia Questionnaire (PPAQ) is a disease-
specific questionnaire designed to measure symptoms and health-related quality of 
life in patients suffering from a group of arrhythmias collectively called supraven-
tricular tachycardias (SVT). There is no valid translation of PPAQ available in Poland, 
which hinders research in this area with Polish arrhythmia patients. The aim of 
this study was to conduct initial content validity testing through translation and 
cultural adaptation of the English language version of the PPAQ to the Polish lan-
guage. MethOds: The whole project was conducted according to ISPOR Principles 
of Good Practice for the Translation and Cultural Adaptation Process for Patient-
Reported Outcomes (PRO) Measures published in 2005. Results: In 2011, the PPAQ 
was translated into Polish and cultural adaptation was performed on 20 patients 
with SVT (12 male, age 54.9±17.4). Issues concerning close meanings of symptom 
names and language-dependant gender-related distinctions were identified. The 
former was solved by cooperation with experts in arrhythmia and latter by incor-
porating patients’ preferences during cognitive debriefing. cOnclusiOns: The 
Polish translation was well accepted by patients during this translation and initial 
content validity testing. Issues arisen during the translation process may recur in 
other translations and be resolved in similar manner.
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HEALTH-RELATED QUALITy OF LIFE IN PATIENTS ALONG FIRST yEAR 
POSTSTROKE IN SPAIN
Álvarez Sabín J.1, Masjuan J.2, Torres C.3, Mar J.4, Oliva J.5, González-Rojas N.6
1Hospital Vall D’Hebrón, Barcelona, Spain, 2Hospital Ramón y Cajal, Madrid, Spain, 
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Objectives: Atrial fibrillation (AF) 5-folds stroke risk, which results in death or dis-
ability in 80% of individuals and one-year mortality approaches 50%. The objective of 
the present study was to analyze the health-related quality of live (HRQoL) one year 
post-stroke in patients with or without AF and the burden of caregivers. MethOds: 
We performed an observational, multicenter, naturalistic and prospective study that 
included 16 stroke units from different Spanish regions. We used EQ-5D and VAS to 
test patients HRQoL and Zarit Burden Inventory to estimate the caregiver burden. 
We collected information at hospital entry for patients, 3 and 12 months post-
stroke both for patients and carers through direct physician interviews. Results: 
A total of 321 stroke patients were recruited, 160 with and 161 without AF. EQ-5D 
was completed by 274 patients - 127 with AF and 147 without AF -, and VAS by 249 
- 113 with and 136 without AF -. The average utility scores of EQ-5D were 0.57, 0.62, 
and 0.65. We found a statistically significant difference between AF and non-AF 
obtained at hospital entry (p= 0.029) and 12 months post-stroke (p= 0.023). There 
were no differences between hospital visits (p= 0.112). If we took into consideration 
the age of patients, the absence or presence of AF in EQ-5D scores, lost its signifi-
cance (p= 0.099). VAS average scores were 45.81, 44.15 and 45.74. VAS results showed 
non-significant differences neither by AF presence (p= 0.396) nor time (p= 0.613). 
Caregiver burden was higher in AF than non-AF patientes (46.47 vs 40.93 2nd visit 
and 45.29 vs 38.73 3rd visit) and the difference was statistically significant (p= 0.007 
and p= 0.002). cOnclusiOns: Stroke has a deep impact on patients HRQoL with 
no improvement over time. In the same line, caregivers also support an important 
burden related to stroke and specially in AF patients.
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Germany, 7Barts and St Thomas Hospital, London, UK, 8University Hospital Ramón y Cajal, 
Madrid, Spain, 9University of Birmingham Centre for Cardiovascular Sciences and SWBH NHS 
Trust, Birmingham, UK
Objectives: The great majority of patients with atrial fibrillation (AF) require anti-
coagulation in order to prevent strokes or other thromboembolic events. We aimed 
at obtaining detailed and current information on patients’ satisfaction with their 
ongoing anticoagulation treatment. MethOds: PREFER in AF (The PREvention oF 
thromboembolic events – European Registry in Atrial Fibrillation) is a current non-
interventional study performed in France, Germany, Austria, Switzerland, Italy, 
Spain and UK. A total of 7243 consecutive patients with ECG-confirmed AF in the 
previous 12 months are followed up prospectively. The ‘Perception of Anticoagulant 
Treatment Questionnaire’ is a valid and reliable instrument that allows the assess-
ment of patients’ expectations (PACT-Q1) and satisfaction regarding anticoagu-
lant treatment, as well as patients’ opinion about treatment convenience of use 
(PACT-Q2). Results: A total of 5049 patients (69.7%) received antithrombotic treat-
ment and were willing to fill out the PACT-Q2 questionnaire at baseline. 77.1% 
of these were on vitamin K antagonists (VKAs), 6.4% on new oral anticoagulants 
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Objectives: Price erosion is considered the key success criterion of generic 
drug policies. For chronic drug therapy, however, persistence with the original 
drug substance is equally important. Low persistence may result in poor health 
outcomes, lead to increased health care costs. Our objective was to estimate the 
impact of switching drug therapy on health and economic outcomes as a conse-
quence of the Hungarian drug policy in hypertension. MethOds: We retrieved 
4-year medical records of hypertensive patients, who had at least 10 prescriptions 
of original losartan or losartan HCT in the 12 months prior to patent expiry. We 
allocated patients to 3 groups based on switching history in the 12 months after 
patent expiry. Group 1 patients were switched to another patented antihyperten-
sive product without risk for generic substitution (n= 953). Group 2 patients were 
switched to generic losartan or losartan HCT, but did not change the generic brand 
in 12 months (n= 630). Group 3 patients were switched at least twice among differ-
ent generic brands in 12 months (n= 1144). We calculated the incidence of major 
cardiovascular events (MACE) and overall health care cost (289.42 HUF/EUR 2012 
average exchange rate) in each group. Results: Total 3-year health care costs were 
€ 9,728, € 6,594, € 8,227, the incidence of MACEs was 13.3%, 9.8%, 12.3% in Group 1, 2 
and 3 respectively. cOnclusiOns: In chronic diseases switching to generic drugs 
reduces health care costs. However, frequent switching among generic brands may 
result in negative health outcomes and increased health care costs. Suboptimal 
implementation of generic drug policies in chronic diseases may compromise 
expected benefits (i.e. same health gain at lower costs). Potential confounding fac-
tors may limit the generalizability of our conclusions.
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ASSESSMENT OF GENERIC DRUG POLICy IMPLEMENTATION By MEASURING 
PERSISTENCE wITH ANTIHyPERTENSIvE DRUG THERAPIES AFTER PATENT 
ExPIRy
Abonyi-Tóth Z.1, Kalo Z.2, Ágh T.3, Inotai A.3, Katona L.4, Rokszin G.1, Jozwiak-Hagymásy J.3
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Objectives: There are two important success criteria of generic drug policies in 
chronic diseases after patent expiry: price erosion and persistence. Our objective 
was to assess the implementation of generic drug policies on these criteria between 
2007-2011 in Hungary by comparing the continuation of angiotensin receptor block-
ers after patent expiry of original therapies. MethOds: In Hungary the first generic 
losartan was launched in 2007; losartan HCT in 2009; valsartan/valsartan HCT in 
2011. From the National Health Insurance Fund database, we selected prescription 
records of hypertensive patients with at least 10 prescriptions of original losar-
tan (Group 1; n= 2637), losartan HCT (Group 2; n= 7598) and valsartan/valsartan 
HCT (Group 3; n= 38098) in the last 12 months prior to patent expiry. We compared 
antihypertensive therapies in 12 months after the reimbursement of first generic 
drug in each group. Antihypertensives were categorized into preferred (continued 
antihypertensive therapy with same active ingredient generic drugs), and non-pre-
ferred (continuation on original drug therapy; switching to other patented drug(s) 
without risk for generic substitution; switching to generic drugs with other active 
ingredient(s); discontinuation of reimbursed antihypertensive drug therapies) policy 
outcomes. Results: After patent expiry 76.2% and 68.9% of Group 1&2 patients 
continued the original losartan or losartan HCT therapy for 12 months, and only 
3.9% and 8.5% were switched to generic losartan/losartan HCT. In Group 3, 33.6% 
of patients were switched to generic valsartan/valsartan HCT, 42.8% received other 
generic drugs or drug combinations, whilst 14.5% were switched to other patented 
products. cOnclusiOns: Despite significant changes in the generic drug policies 
in Hungary in 2007, 2009 and 2011 not more than one-third of hypertensive patients 
changed to generic drugs during 12 months after first generic entry. These findings 
indicate suboptimal generic drug policy in a chronic disease with significant public 
health implications.
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CROSS-COUNTRy COMPARISON OF PRESCRIBING PATTERNS vERSUS PORTUGAL 
AND POTENTIAL COST-SAvINGS
Costa S., Guerreiro J.P., Baptista A., Teixeira I., Torre C.
Centre of Health Research & Evaluation (CEFAR), National Association of Pharmacies (ANF), 
Lisbon, Portugal
Objectives: To review the consumption pattern of ambulatory high expenditure 
therapeutic groups in Portugal following prescribing guidelines set forth by the 
Memorandum of Understanding; to perform a cross-country comparison of utili-
zation patterns focusing on quality prescribing indicators identified by the EURO-
MED-STAT and/or major international prescribing guidelines; and to perform a 
cost-saving scenario analysis if more rational European prescribing patterns were 
undertaken in Portugal. MethOds: Cross-national drug utilization study with 
data from seven European countries: Portugal, Denmark, England, Finland, The 
Netherlands, Norway and Sweden. Data from Portugal retrieved from hmR Pharmacy 
Sales Information System, a nationwide database with representative pharmacy 
dispensing data. Data from other countries was selected from published literature 
and/or public databases. Cost-saving analysis with assumptions: average annual 
cost per defined daily dose (DDD) from Portugal and simulations to measure the 
impact on total expenditure of international utilization patterns (DDD proportion) 
versus Portuguese pattern. Results: Portugal has the highest consumption of 
oral antidiabetic combinations (19.3% in 2010), of Antagonists Reception Blockers 
(ARBs) (31% in 2009), and of rosuvastatin (22.2% in 2011). A total of 236 Million euro 
annual cost-savings was estimated in scenarios of more rational prescribing: 100 
Million euro (58% decrease in costs of antidiabetic agents in 2010) when simulating 
the Dutch oral antidiabetic prescribing pattern; 106 Million euro when simulating 
the Danish antihypertensive prescribing pattern (20% decrease in antihypertensive 
costs in 2009); and 26 Million euro when simulating the UK statin prescribing pat-
tern (13% decrease in statin costs in 2011). cOnclusiOns: It is crucial to optimize 
prescribing patterns in Portugal, in order to achieve a more rational use of medi-
cines and a sustained control of pharmaceutical expenditure. Besides prescribing 
Objectives: To review the literature about adherence to warfarin treatment 
in Brazil. MethOds: A systematic review of the literature and a wide search 
in LILACS (Literatura Latino Americana e do Caribe em Ciências da Saúde) and 
MEDLINE (Medlars On Line) electronic databases were conducted to identify 
studies with the key words: “warfarin” and “Brazil”. The combination of terms 
was used as reference for the analysis. Search was restricted to randomized con-
trolled trials (RCT), systematic reviews, meta-analysis and prospective clinical 
trials (PCT). Results: A total of 77 studies were identified, from which only 22 
met inclusion criteria: 1 meta-analysis, 5 RCTs, 8 systematic reviews and 8 PCTs. 
Only 1 study described adherence to treatment. From a total of 229 randomized 
patients, 119 received warfarin. Adherence to treatment was observed in 42% 
(p= 0.001) of patients using warfarin considering an average of 57+-18 months 
of follow-up, INR < 2 in 37.54 % and INR > 2 in 11.18 %. Multivariate analysis 
estimated that every 1% of INR < 2, the risk of a thromboembolic event increases 
8.4%. cOnclusiOns: The systematic review of the literature showed lack of 
data regarding Brazilian patients under warfarin treatment. The only available 
study did not define adherence and it did not investigate the underlying causes 
of non-adherence. Thus, it is recommended the conduction of further studies 
in order to provide better understanding of anticoagulant therapies compliance 
in Brazilian patients.
PCv145
COMPLIANCE wITH PREvENTIvE RECOMMENDATIONS IN PRIMARy CARE AND 
RATE OF POTENTIALLy AvOIDED HOSPITALIzATIONS By DIABETES, CHRONIC 
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Objectives: Potentially avoidable hospitalizations (PAH) are increasing in Spain 
and account for more than 3% of all the discharges. One of the hypothesis to 
explain PAH lies on the suboptimal management of chronic disease at ambulatory 
level of care. In this study we aim at explaining the association between compli-
ance with preventive recommendations in primary care and observed rate of 
PAH. MethOds: Compliance with evidence-based preventive recommendations 
regarding diabetes mellitus (DM), chronic heart failure (CHF) and chronic obstruc-
tive pulmonary disease (COPD) was calculated for the 1,350 general practition-
ers of the Basque Health Service and compared with the annual (2011) observed 
rate of PAH between their patients’ panel (mean panel≈1,500 adults; population 
covered= 1,942,873). PAH was defined by a restrictive set of ICD-9 criteria follow-
ing recommendations of the Spanish group of studies on Variability in Medical 
Practice. Multilevel poisson regression was used and age, sex, status socioeco-
nomic (SSE) and hospital of reference were entered as covariates. Results: After 
adjusting by all the covariates, higher compliance of recommendations such as 
periodical spirometry or assessment of the correct use of bronchodilator inhalers 
shows association with lower rates of PAH by COPD (p< 0.05). Periodical foot care, 
oftalmological exam or assessment of the cardiovascular risk is non-significantly 
(0.15≥ p≥ 0.05) but consistently associated to lower rates of PAH by DM. No link was 
observed between compliance or recommendations for CHF and PAH due to this 
cause. The independent effect of the SSE was strong in all the diseases (p< 0.001) 
(higher rates as privation increases). Variations regarding the hospital of refer-
ence were also observed. cOnclusiOns: Adequate compliance of evidence-based 
recommendations limits, modestly but consistently, the incidence of PAH due to 
DM or COPD. The SSE and the hospital of reference explain part of the observed 
variability in hospitalization by chronic disease.
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vALUE CHAIN ANALySIS FOR CARDIAC DEvICES
Lucas F.1, Tsai P.2
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Objectives: We investigated opportunities to cost-effectively improve health out-
comes for patients eligible for ICD, sICD and CRT-D devices. This area was chosen 
because of the high cost of these devices and the significant amount of uncertainty 
on how to use them in a cost effective way. Also, we aimed to explore value-added 
services to patients and physicians, and the area appeared to have potential for 
this. MethOds: We conducted a value chain analysis. The first step was to clarify 
the care pathway and identify places where outcome or efficiency were poor; the 
second step was to prioritise the associated problems based on their importance 
(health/cost impact) and the feasibility of addressing the root causes in the short to 
medium term; the third step was to propose ways to address the priority problems 
and add value in the care pathway. To do this, we conducted secondary research, and 
primary research mainly focused on the UK (20 in-depth discussions with cardiolo-
gists, patients and manufacturers). Results: A core issue was the lack of good evi-
dence-based criteria to identify which patients would benefit most from the various 
devices. Referral to device implantation and funding were seen as below the levels 
expected given current clinical and HTA guidelines; the gap might even increase 
given the expectation that future guidelines may call for higher implantation rates. 
The proposed solutions focused on increasing awareness of the guidelines for more 
effective referral to specialist centres, supporting more flexibility in local funding, 
and taking advantage of the rich, continuous data that the devices themselves could 
provide with a view to eventually improve eligibility criteria. cOnclusiOns: It 
is increasingly difficult to achieve health gains through new therapies. Therefore, 
focusing on improving referral and delivery pathways of current therapies may be 
quite effective at increasing health gains and/or efficiency.
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were on polytherapy, 41% on monotherapy, and 4% had no antihypertensive treat-
ment. Polytherapy was more predominant with age, duration of diabetes, duration of 
hypertension, and comorbid complications. cOnclusiOns: Although prescribing 
pattern of antihypertensive showed adherence to existing evidence-based guide-
lines, higher proportion of uncontrolled hypertensive patients was found.
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THROMBOEMBOLISM AND IMPAIRED RENAL FUNCTION: RESULTS OF AN 
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Objectives: Patients undergoing initial therapeutic anticoagulation after a venous 
thromboembolic event (VTE) with severely impaired renal function (RI-VTE-patients) 
are at high risk of accumulating the anticoagulants resulting in an increased risk of 
bleeding events. Current guidelines/approved summary of product characteristics 
(SPC) recommend usage of specific anticoagulants only, monitoring of aXa-activity, 
and/or dose-adjustment (in the case of enoxaparin) for initial therapeutic anticoagu-
lation of RI-VTE-patients. This study investigates the treatment of German RI-VTE-
patients and evaluates whether guideline/SPC recommendations are implemented 
in the practice of real life care. MethOds: We conducted a chart review in 5 German 
hospitals. All VTE patients treated in these hospitals from 01/01/2007-31/12/2011 
were included. RI was defined as CrCl< 30ml/min. Treatment did not conform to the 
recommendations in guidelines/SPCs, if: a) A drug was used that is contraindicated 
according to the SPC; b) The recorded daily dose of enoxaparin was higher than the 
recommended weight-adjusted dose. Results: Of 5,263 VTE patients identified, 709 
(13.5%) cases could not be documented due to missing charts (601) or no documented 
creatinine serum levels (108). Of the remaining 4,554 patients (mean age ±SD 67.4 
years ±15.7; 53.0% female; weight 80.2 kg ±20.0; 54.5% deep VT), 337 (7.4%) had a mean 
estimated GFR< 30ml/min; additionally 1,630 (35.8%) had a minimum eGFR< 60ml/
min. In 19 (5.6%) of these cases, patients were treated with a drug not recommended 
for use, 21 (6.2%) did not receive any initial anticoagulation treatment and 91 (27.0%) 
received a higher than recommended dosage of enoxaparin. Additionally, for 22 
patients (6.5%) receiving enoxaparin, no weight information was recorded and it 
is therefore unlikely that the dosage was adjusted correctly. cOnclusiOns: VTE 
treatment in RI-VTE-patients differs remarkably from labelled recommendations; 
over-dosage of enoxaparin is common. It seems fair to assume that these patients are 
facing a higher risk of adverse reactions in particular bleeding events.
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ATTITUDES OF PHySICIANS TOwARD IMPLEMENTING SHARED MEDICAL 
APPOINTMENTS AT NATIONAL GUARD FAMILy MEDICINE CENTERS IN RIyADH
Alhowimel M.H.
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Objectives: To determine the attitude of physicians in three family medicine centers 
(FMCs) at the National Guard Health Affairs (NGHA) toward the implementation of 
the Shared Medical Appointment (SMA) approach compared to the current individual 
appointment approach. MethOds: A cross-sectional survey study was conducted 
by distributing a structured questionnaire among the 79 FMCs’ physicians at NGHA 
in Riyadh, Saudi Arabia. The first part of the questionnaire was an introduction, the 
second part has requested socio-demographic information, and the third part con-
sisted of 12 statements measuring physicians’ attitude toward implementing SMA 
and the current individual appointment approach. Responses were measured using 
5-points Likert Scale. Seventy-nine self-administered questionnaires were distributed 
to physicians’ mail-boxes and the completed questionnaires were collected from 
mail-boxes at each clinic. Data collection was done from December 10 to 15, 2011. 
Data were entered and analyzed by the Statistical Package for Social Science (SPSS.16). 
Descriptive analysis was conducted using frequencies, percentages, and mean (SD). 
Inferential analysis was conducted using one way ANOVA and Mann-Whitney tests 
to detect statistically significant differences in responses. A significance level of 
0.05 was used. The validity and reliability of the instrument was measured using 
Pearson’s correlation and Cronbach’s Alpha, respectively. Results: A totla of 78 valid 
questionnaires were returned yielding a response rate of 99 %. The average attitude 
scores were 3.75 toward the SMA approach and 2.98 toward the current Individual 
Appointment approach. The average attitude scores were significantly different at all 
dimensions (Mann Whtiney P-value < 0.001) in favor of SMA except for patient privacy 
which was in favor of current individual appointment approach. Subgroup analysis by 
socio-demographic variables indicated that males and Saudi national physicians have 
higher positive attitude toward SMA. cOnclusiOns: There is positive attitude of all 
physicians toward SMA compared to the current individual appointment approach. 
This attitude was affected by gender and nationality.
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ANALySIS OF RE-HOSPITALISATIONS FOR STROKE AND TRANSIENT ISCHEMIA 
RECURRENCE AND ASSOCIATED COSTS IN THE BURGUNDy REGION IN FRANCE
Marty R.1, Jouaneton B.2, Giroud M.3, Mougin P.4, Roze S.1
1HEVA HEOR, Lyon, France, 2HEVA, Lyon, France, 3CHU Dijon, Dijon, France, 4Bayer HealthCare 
Pharmaceuticals, Loos, France
Objectives: To assess the re-hospitalisations rates for stroke (ST) and transient 
ischemia (TI) recurrences as well as related inpatient costs through the French 
national Hospitals Medical Health Information database (PMSI). MethOds: A ret-
rospective hospital administrative-claims analysis was carried out based on the 
Diagnoses Related Groups (DRG)-data of four hospitals within the Burgundy region 
along the 2006-2011 period. In each of the four hospitals, three cohorts were fol-
lowed up over two years. Patients were excluded if any related hospitalisation for ST 
or TI occurred in the preceding two-years (identification through ICD-10 diagnosis 
codes). One and two-year re-hospitalisations rates for ST and/or IT were calculated. 
guidelines, health prevention / monitoring strategies, involving coordinated actions 
between primary care and pharmacies, are valuable resources to consider.
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A REvIEw OF THE APPLICATION OF INTERNATIONAL REFERENCE PRICING IN 
UKRAINE’S PILOT HyPERTENSION REIMBURSEMENT SCHEME
Rainova K., Izmirlieva M., Ando G.
IHS, London, UK
Objectives: The Ukrainian government has been considering ways to improve the 
population’s access to medicines by offering limited reimbursement access. For this 
purpose, the government has expressed its interest in implementing International 
reference pricing (IRP). The pilot hypertension programme, which introduced a sys-
tem of IRP for certain hypertension drugs, was introduced in mid-2012. The govern-
ment is currently looking to revise the pricing and reimbursement mechanism and 
to expand the list of drugs eligible for reimbursement under the scheme. This study 
examines the pilot hypertension programme and its impact in terms of achieving its 
objectives so far. MethOds: Secondary research focused on analysing the current 
pharmaceutical market and health care situation in Ukraine, with a specific focus on 
the hypertension market. The study then assessed the pricing and reimbursement 
methodology which is currently in place, the programme’s objectives, and its impact 
on volume and value of the antihypertensives market. Results: Hypertension 
was chosen for the pilot programme due to the high prevalence of the condition in 
the country. While, for the full year 2012, the weighted average cost per package in 
the antihypertensive drug segment decreased by 1.4% compared to the previous 
year, the volume of retail sales increased 16.8%. Furthermore, as of January 2013, 
the prices of these drugs had been falling every month from July till December 
2012 compared to the corresponding months of 2011. cOnclusiOns: With the 
pilot hypertension programme, the government is hoping to lower drug prices and 
thereby improve affordability. Considering that the pilot scheme could be followed 
by programmes in other therapeutic areas, including a government proposal to 
include IRP for insulin treatments, the structure and effectiveness of the hyperten-
sion programme, and the subsequent amendments to it, could substantially impact 
the development of any other potential programmes in the future.
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HOw COMPLEx IS THE COMPETITION IN REGULATED PHARMACEUTICAL 
MARKETS?
Colak B.1, Timur A.2
1University of South Florida, Tampa, FL, USA, 2Hodges University, Johnson School of Business, 
Naples, FL, USA
Objectives: This paper constitutes an attempt at investigating processes of 
dynamic competition in pharmaceuticals, with reference to the nature and intensity 
of price competition in relation to patent expiry and different regulatory regimes. 
The paper uses comprehensive data on a selection of in-patent and off-patent 
(generic) cardiovascular medicines from IMS from the five largest European phar-
maceutical markets - UK, Germany, France, Italy, Spain - to analyze the impact that 
pricing and reimbursement regulation and product differentiation have on market 
structure, diffusion and prices. MethOds: The paper develops a panel data model 
to explain the determinants of brand-name prices and generic prices both before 
and after patent expiry, the impact of generic entry and generic penetration on 
market share and prices of brand-name drugs, the competition patterns in their 
off-patent sector, the determinants of generic diffusion in the presence of generic 
competition, and the relationship between originator branded and generic prices 
under different regulatory regimes. The structure of the data allows these ques-
tions to be explored at molecule level and at product level. At all levels the origi-
nator and generic markets are observable. Results: Despite the proliferation of 
generic policies in many countries, prices in the off-patent sector do not decline as 
fast as originally thought. Entry into the generic market is positively influenced by 
regulation through reference pricing and opportunities for product differentiation. 
Elements of product differentiation within generics promote diffusion, but do not 
reduce prices. And, health insurance does not capitalize fully on the cost advantage 
of generic medicines. cOnclusiOns: The results suggest that the relationships 
between the dynamics of original drug prices, patent expiry, and generic competi-
tion are complex and differentiated across countries. The level of generic penetra-
tion remains low in some of them and a sharp contrast exists between countries.
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PRESCRIPTION PATTERNS OF ANTIHyPERTENSIvE AGENTS IN T2DM PATIENTS 
vISITING TERTIARy CARE CENTRE IN NORTH INDIA
Raval A.1, Dhanaraj E.2, Bhansali A.3, Yadav R.2
1West Virginia University, Morgantown, WV, USA, 2National Institute of Pharmaceutical 
Education and Research, Mohali, India, 3Post-Graduate Institute of Medical Education and 
Research, Chandigarh, India
Objectives: Hypertension management is of a paramount importance in diabetic 
patients for cardiovascular risk reduction. Hence, we evaluated prescribing pattern 
of antihypertensive in T2DM (type 2 diabetes) patients and compare with existing 
recent guidelines. MethOds: A cross-sectional study involving evaluation of all 
T2DM patients referred to endocrinology unit at tertiary care centre for hyperten-
sion, comorbid complications, and recording prescription. Utilization of 5 different 
antihypertensive drug classes was compared for all patients receiving 1, 2, 3, 4, or 
more drugs. Logistical regression was used to assess likelihood of prescription of 
drugs and/or therapy for specific conditions mentioned in the guidelines. Results: 
Out of 1358, T2DM enrolled patients 1186 (87%) had hypertension (males 52%, 
females 48%). The median duration (IQ) of hypertension diabetics was 4 (1-10) years. 
A total of 25% patients had controlled BP and 75% with uncontrolled blood pressure 
(13% isolated systolic hypertension, 6% isolated diastolic hypertension, and 55% 
both elevated). Overall, ACE inhibitors (ACEIs) were prescribed the highest (59%) 
followed by angiotensin receptor blockers (ARBs) (52%), calcium channel blockers 
(CCBs) (29%), diuretics (27%), and beta-blockers (14%). Overall, 55% of T2DM patients 
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of an anti-hypertensive medication combination and compared with current care 
(23.9% BP control rate). 100,000 hypertensive simulated individuals were modeled 
over a 10 year time horizon. Outcomes of major adverse cardiovascular events; stroke, 
myocardial infarction (MI) and CV death were reported. Direct health care costs of 
strokes and MIs were derived from official Russian statistics and price lists. Results: 
To achieve SBP control rates of 30%, 40%, 50%, and 60%, adherence rates to the anti- 
hypertensive treatment program were 11.1%, 29.4%, 47.6%, and 65.9% respectively. CV 
death relative risk reductions were 5.0%, 13.2%, 21.4%, and 29.6%, respectively. For the 
current estimated 43,855,000 person Russian hypertensive population, each control 
rate scenario resulted in an absolute reduction of 398,097, 1,050,715, 1,703,334 and 
2,355,952 CV deaths, and a reduction of 458,781, 1,210,881, 1,962,981, and 2,715,081 
stroke/MI diagnoses. Averted direct costs from current care (225,781) were 12,834, 
33,873, 54,913 and 75,952 million Rubles, respectively. cOnclusiOns: Our simulation 
implies that a clinically significant number of CV events in the Russian hypertensive 
population may be prevented by achieving BP control through an antihypertensive 
drug combination. Averted costs may be re-allocated to strengthen evidence-based, 
preventive interventions.
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wHAT FACTORS PREDICT THE DECISION TO TREAT ACUTE CORONARy 
SyNDROME INvASIvELy? EvIDENCE FROM CLINICAL PRACTICE
Fakhouri W.K.1, Belger M.1, Larkin L.2, McCollam P.L.3, Rennie K.L.4, Donaldson R.4,  
Di Tanna G.L.4, Neasham D.4
1Eli Lilly & Company, Surrey, UK, 2Lilly UK, Hampshire, UK, 3Eli Lilly & Co, Indianapolis, IN, USA, 
4Evidera, London, UK
Objectives: To describe UK patients with acute coronary syndrome (ACS) who 
receive percutaneous coronary intervention (PCI) or are medically managed only 
(MM) and evaluate factors affecting approaches to treatment. MethOds: Patients 
registered with a general practice participating in the Clinical Practice Research 
Datalink (CPRD) with Hospital Episode Statistics (HES)-linked data were included 
if they had an ACS-related hospitalization (January 2008-December 2009). Logistic 
regression analyses were used to assess what characteristics at ACS-related hospi-
talization date were associated with PCI or MM classified at 30-days post-hospital-
isation date (30DHD). Results: A total of 10,753 ACS patients were identified (60% 
male, 67% aged ≥ 65, 81% had NSTEMI or UA at index date); 30DHD, 74% were MM 
and 26% had PCI. Factors associated with receiving PCI were STEMI at hospitalization 
(OR 3.73, 95% CI 3.30, 4.22); patients with previous PCI pre-hospitalization (OR 1.29, CI 
1.07, 1.55) and current smokers (OR 1.16, CI 1.02, 1.32). Patients less likely to receive 
PCI included women (OR 0.67, CI 0.60, 0.75), those with previous ACS hospitaliza-
tion (OR 0.69, CI 0.59, 0.80), those prescribed: statins 12 months pre-hospitalization 
date (OR 0.75, CI 0.67, 0.85), diuretics (OR 0.72, CI 0.61, 0.85), ACE inhibitors (OR 
0.84, CI 0.75, 0.95), proton pump inhibitors (OR 0.86, CI 0.77, 0.96), those previously 
diagnosed with congestive heart disease (OR 0.54, CI 0.42, 0.71), atrial fibrillation 
(OR 0.67, CI 0.54, 0.83), stroke/TIA (OR 0.77, CI 0.63, 0.93) or renal disease (OR 0.82, 
CI 0.71, 0.95). Age and BMI were significant as continuous variables with non-linear 
effects. cOnclusiOns: This is the first large-scale UK study using real-world data 
to assess socio-demographic and clinical predictors for PCI in ACS, and indicates 
that NSTE-ACS patients and those with comorbidities are more likely to be MM. This 
will be discussed in light of current treatment of STEMI and NSTE-ACS in the EU.
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THE PHARMACOECONOMIC OF CARDIOLOGy IN RUSSIA
Popov V.V.1, Gorokhova S.G.2, Gorokhov V.D.1, Ryazhenov V.V.2
1Scientific Clinical Center of JSC Russian Railways, Moscow, Russia, 2I.M. Sechenov First Moscow 
State Medical University, Moscow, Russia
Objectives: To analyze the current state and the trends of pharmacoeconomic 
research in cardiology in Russia. MethOds: We have reviewed all main databases 
of scientific publications (PubMed, eLibrary.ru etc.) as well as individual journals, 
conference abstracts and web-sites for the period 2007–2013. Results: It was found 
that cardiology becomes one of the most popular topics for pharmacoeconomists, 
partly because of its significance for public health and the growing amount of state 
funding for the prevention of CVD in recent years. Cardiovascular problems make up 
16-25% of congress abstracts and 26% of applications for Da.Signa, the only award in 
pharmacoeconomics in Russia. Most publications in our analysis dealt with arterial 
hypertension (44%), coronary heart disease (16%) and chronic heart failure (7%). A 
wide range of original and generic drugs were included into these researches, how-
ever in most cases there was a prevalence of cost-efficiency analysis and modeling 
methods based on the results of non-Russian clinical trials and meta-analyses. 
Overwhelming majority of the results were published in Russian and therefore are 
not available for the non-Russian-speaking reader. cOnclusiOns: During the last 
five years, a great number of pharmacoeconomic research in cardiology have been 
performed and published. However, there is a need of clinical trials that would con-
sider the Russian specifics and health care standards. Pharmacoeconomic analysis 
should become an integral part of clinical trials, especially in case of drug therapy 
of myocardial infarction, stroke and other conditions, where the differences exist 
between the Russian and foreign practice. Some of the analyzed publications should 
be updated because of the recent changes in health care standards.
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THE vOLUME-OUTCOME RELATIONSHIP AND MINIMUM vOLUME STANDARDS – 
EMPIRICAL EvIDENCE FOR GERMANy
Mennicken R., Hentschker C.
Rheinisch-Westfälisches Institut für Wirtschaftsforschung e.V., Essen, Germany
Objectives: To analyze the volume-outcome relationship for patients with intact 
abdominal aortic aneurysm (AAA) and hip fracture (HIP) and define hypothetical 
minimum volume standards to assess changes in access. MethOds: The analy-
sis is based on administrative data coming from the German system of diagnosis 
related groups of about 18.6 million hospital cases of 1780 German hospitals for the 
year 2007. The data includes detailed information on patient characteristics used for 
Re-hospitalisations were taken into account if they occurred after one month fol-
lowing inclusion and regardless of the location of the hospital at the national level. 
Alternatively, ‘all’ re-hospitalisations rates regardless the related diagnosis were also 
assessed. Inpatient costs were valued based on reference tariffs according to French 
National Social Health Payer perspective. Results: Around 1750 patients were fol-
lowed per cohort across the four hospitals starting from 2009, 2010 and 2011. One-
year re-hospitalisations rates for ST and TI ranged from 2.9% to 7.1%. The median 
time to re-hospitalisation ranged between 1.5 to 9.3 months. Two-year re-hospitali-
sations rates for ST and TI ranged from 4.5% to 10.4%. Two-year re-hospitalisations 
rates regardless of related diagnosis in acute and/or rehabilitative settings ranged 
between 45.5% to 65.1%. Mean costs (+/-SD) per inpatient stay for ST and TI were 
4’645€ (+/-3’821) in acute setting (2013 EUR). When excluding TI, mean costs were 
5’293€ +/-4’225€ . Hospitalization costs varied depending on sub-type of stroke, sever-
ity, co-morbidities and also year of costing. cOnclusiOns: Such short term data 
on recurrence rates and inpatient costs might be useful when estimating potential 
benefits of any secondary prevention intervention aiming at reducing stroke relapses.
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STATINS IN CANADA: THE CASE FOR DISINvESTMENT
Richter T., Amegatse W., Lee K.
CADTH, Ottawa, ON, Canada
Objectives: We examined the economic consequences of generic switching within 
the statin market for public plans in Canada between 2000 and 2012. MethOds: 
We extracted data (number of units, costs, and claims) for all statins reimbursed 
by Canadian public drug plans for the period 2000-2012 (sources: IMS Brogan and 
Canadian Institute for Health Information). Results: Public plans paid $11.2 BN to 
reimburse statins for 2 MM patients between 2000 and 2012. The annual cost of reim-
bursing statins peaked at $1.3 BN in 2009. Generic atorvastatin was listed by public 
plans in 2010, and the proportion of statin reimbursement attributable to generics 
increased from 18% in 2009 to 75% in 2012, reflecting a 76% increase in generic switch-
ing. During the same period, the unit cost of brands and generics fell by 25% and 49%, 
respectively. The combined effect of increased generic switching and lower unit costs 
resulted in a 55% decrease in the total cost of statins, from $1.3 BN in 2009 to $582 MM 
in 2012. Annual savings attributable to generic switching increased 10-fold between 
2000 and 2012, from $7 to $709 MM. The efficiency at which potential savings has been 
captured through generic switching increased from 8% to 74% from 2000 to 2012; we 
project that this will generate savings of ~$800 MM annually through 2015. Increasing 
generic switching to 100% could generate up to an average of $135 MM annually in 
additional savings cOnclusiOns: Although substantial savings have been gener-
ated by generic switching within the statin class, increasing generic switching could 
generate additional savings. One strategy to capture these additional savings would 
be disinvestment: if branded statins were de-listed from public plans if a generic ver-
sion were available, this would increase generic switching, increase the efficiency at 
which potential savings are captured, and increase total savings.
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ATRIAL FIBRILLATION’S BURDEN OF DISEASE IN PORTUGAL
Gouveia M.1, Borges M.2, Alarcão J.2, Caldeira D.2, Pinheiro L.2, Sousa R.2, Ascenção R.2,  
Costa J.3, Vaz-Carneiro A.2
1Católica Lisbon School of Business and Economics, Lisbon, Portugal, 2Center for Evidence Based 
Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 3Institute of Molecular 
Medicine, Lisbon, Portugal
Objectives: To estimate the Disability Adjusted Life-Years (DALY) attributable to 
Atrial Fibrillation (AF) during 2010 in Portugal, including both AF and AF related 
stroke. MethOds: The analysis requires two types of data. The first is an extended 
set of epidemiological data, which resulted from a compilation of the prevalence and 
mortality data for AF and for stroke in Portugal. For the distribution of mortality by 
age, gender and cause of death the WHO Europe mortality database was used. The 
analysis also uses the results of FAMA, a study of the prevalence of AF in Portugal. 
Incidence rates were estimated from a review of the international literature. The 
second type of data concerns the relative risk (RR) of stroke for patients with AF. 
RR values by age group from the Framingham Study were used. Disability weights 
were taken from the Global Burden of Disease 2010. Results: A total of 3863 deaths 
in Portugal in 2010 were related to AF, with 813 having AF listed as cause of death 
and the remaining 3.050 being stroke deaths attributable to AF. The AF attributable 
deaths are roughly 3.6% of total deaths in the country. The estimate total DALYs 
was 9.814 (2.251 for AF listed as the cause of death and 7.563 for stroke as cause of 
death attributed to AF). cOnclusiOns: AF is an important cause of disease burden 
in Portugal. As reference, AF DALYs are roughly twice the estimated DALYs for skin 
cancer. AF should receive adequate attention from policy makers.
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SIMULATING THE POTENTIAL IMPACT OF IMPROvED BLOOD PRESSURE 
CONTROL ON CLINICAL AND ECONOMIC OUTCOMES IN RUSSIA
Kontsevaya A.1, Alperin P.2, Shum K.3, Eriksson J.A.4, Vigdorchik A.5, Shalnova S.1, Boytsov S.1, 
Hughes D.6
1National Research Center for Preventive Medicine, Moscow, Russia, 2Archimedes, Inc., San 
Francisco, CA, USA, 3Archimedes Inc., San Francisco, CA, USA, 4OptumInsight, Stockholm, 
Sweden, 5Novartis Russia Pharma LLC, Moscow, Russia, 6Novartis International AG, Basel, 
Switzerland
Objectives: Russia faces a high burden of cardiovascular (CV) disease. Prevalence 
of all CV risk factors, especially hypertension, is high. Elevated blood pressure (BP) 
is generally poorly controlled, and medication usage is suboptimal. With a disease 
model simulation we assessed the impact of improved systolic blood pressure (SBP) 
control on the number and costs of CV events potentially averted in the hypertensive 
Russian population. MethOds: The Archimedes Model, a detailed computer model 
of human physiology, disease progression, and health care delivery was adapted to 
the Russian setting. Intervention scenarios of achieving SBP control rates (defined as 
SBP < 140) of 30%, 40%, 50%, and 60% were simulated by modifying adherence rates 
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level. The development of the performance measures over time may be attributed 
to changes in organization and management of the system. MethOds: As routine 
data the ATHIS 2006/2007 (a standardized health interview survey), the cause of 
death registry 2006 and 2007, the hospital discharge datasets from the Austrian 
DRG system 2006/2007 (KDok/DLD) and diagnoses for the outpatient sector derived 
from pharmaceutical claims data 2006/2007 (ATC→ICD) - are used to describe the 
burden of disease regarding Ischemic Heart Disease (ICD9 410–414) with differ-
ent regional granularity. Methods and results are compared with epidemiological 
data extracted from a literature search on this topic. To explore the similarity 
of the results of these different methods of measurement a systematic review of 
regional correlation is being elaborated. Correlations pointing to a high analogy of 
the findings in spite of the differences in dimensions measured on the one hand and 
contra intuitive correlations on the other hand were further explored. Results: The 
review of regional correlation indicates promising close links between the burden 
of disease derived from ATC→ICD, ATHIS and cause of death registry data. Hospital 
discharge data, however, show some contra-intuitive relations towards the other 
data sets. cOnclusiOns: The use of routine data yields promising opportunities 
for monitoring the Austrian health care system in a timely and comprehensible 
way. It enables different aggregation levels regarding regions and periods and leads 
the way to further research addressing underlying causes for the observed regional 
variation. The methodology can be transferred to other areas of diseases.
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ASSESSING THE IMPACT OF ORGANIzED SCREENING FOR ABDOMINAL AORTA 
ANEURySMS IN AUSTRIA – FOLLOwING EUNETHTA CORE INFORMATION
Urach C.1, Zauner G.2, Wilbacher I.3, Endel G.3, Miksch F.2, Breitenecker F.1
1Vienna University of Technology, Vienna, Austria, 2dwh Simulation Services, Vienna, Austria, 
3Main Association of Austrian Social Security Institutions, Vienna, Austria
Objectives: Abdominal Aorta Aneurysms (AAAs) refers to distension of the abdominal 
aorta. It is a common disease among 65+ year old people with increasing importance due 
to overageing of the population. Currently, AAAs in Austria are only incidentally detected 
and due to its asymptomatic course often overlooked therefore the impact of an organ-
ized screening program in Austria was evaluated. MethOds: An agent based simulation 
model for Austria’s population was developed. Each agent represents a person which 
has an individual development of its aorta depending on age, sex, and smoking habits. 
Identification of risk factors and parameterization of the model was performed in the 
IFEDH project (FFG grant number 827347). The observed persons are 65 years old at 
simulation start and the observed time horizon is 20 years. The chosen screening strat-
egy which is compared to current practice corresponds to the EUnetHTA scheme with 
an assumed 40% participation. Results: Events like ruptures, deaths or treatment are 
recorded and accumulated over the whole simulation time. Additionally, because many 
figures of the model depend on probabilities, the point in time when patients benefit 
from the intervention with 95% probability is calculated. Ruptures are reduced from 786 
to 531, death cases from 571 to 433 whereas the costs per life year gained are about 7500 
€ . Significant differences can be observed after about four years. Although incidence 
is much higher among men, it is remarkable that screening is more cost-effective for 
women due to higher risk of rupture and life expectancy. cOnclusiOns: The agent 
based simulation model allows detailed analysis of groups with specific properties, e.g. 
smokers, other age groups and different screening strategies. It also allows decision 
makers to estimate when the impact of the intervention, in this case organized screen-
ing, can be observed or measured within the real population.
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ADDED vALUE AND FUTURE ADOPTION OF A NEw MEDICAL IMAGING 
TECHNOLOGy FOR INTERvENTIONAL CARDIOLOGy
Meeks M.D.M.E.1, Steuten L.M.C2, Sahyoun C.1, Ijzerman M.J.2
1Philips Healthcare, Best, The Netherlands, 2University of Twente, Enschede, The Netherlands
Objectives: To estimate the potential added value of an ultrasound-fluoroscopy 
fusion technology and to support product development and marketing positioning 
of the technology in interventional cardiology, using a combination of research 
methods. MethOds: Stakeholder analysis was carried out to determine the profes-
sionals involved in the adoption process. Literature search indicated which proce-
dures could benefit most from the imaging technology. Subsequently, the current 
workflow and associated resource use of those procedures was compared with the 
expected workflow after potential technology adoption. Decision criteria to adopt 
the new imaging technology were evaluated with the analytical hierarchy process 
(AHP). Finally, a value based pricing approach was used to estimate the value of the 
technology to specific types of hospitals. Results: Intervention cardiologists were 
identified as key stakeholders in the adoption of technology. The AHP showed that 
reduction in complication rates is the most important criterion for adopting a new 
imaging technology, whereas the purchase price seemed less important. Various 
procedures could benefit from the new technology, as this may shorten procedural 
times and facilitate communication between intervention cardiologists and imag-
ing professionals. Value based pricing analysis showed that cost savings could be 
expected as a result of reduced procedure times, especially in centers of expertise 
with medium to high procedure volumes. cOnclusiOns: The ultrasound-fluoros-
copy fusion technology can provide added value in specific cardiac interventions, 
especially in hospitals with medium to high procedure volumes. Early assessment 
of potential added value and adoption criteria timely and effectively supported the 
product development phase. It informed various decision makers on the factors 
influencing the expected value of and uncertainties surrounding a future adoption 
of the technology.
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DIvERGENCE OF HTA DECISIONS ACROSS COUNTRIES: CASE ANALySIS OF 
IvABRADINE
Thivolet M.1, Rémuzat C.2, Kornfeld A.1, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical France, Paris, France, 3University Claude 
Bernard Lyon 1, Lyon, France
risk-adjustment. Furthermore, we have a ZIP-code for each patient and the exact 
address for every hospital. Addresses of hospitals and the centroids of all German ZIP 
codes were geo-coded. For the empirical analysis, we use multiple logistic regression 
analysis. We supplement our analysis by showing changes in access to hospitals if a 
minimum volume standard is introduced. Results: Patients with hip fracture who 
are treated in hospitals with less than 58 cases per year have an average probability of 
death of 5.1 % compared to an average mortality of 3.1 % for patients who are treated 
in hospitals with more than 151 cases. For patients with AAA the case volume effect 
is lower. However, compared to patients treated in hospitals with less than 15 cases 
per year, the average probability of death for patients treated in hospitals with more 
than 68 cases is 1.0 percentage points less. We show that minimum volume standards 
seem possible without compromising overall access. cOnclusiOns: The estima-
tion results suggest that around 380 deaths could have been presumably avoided, 
if around 20,000 patients in the smallest hospitals would have been treated in the 
largest hospitals instead. Furthermore, we show that minimum volume standards 
do not compromise overall access measured in travel times. However, to ensure an 
adequate access in all areas, a few “sole providers” in some regions seem necessary.
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THE SHORT-TERM IMPACT OF PARTICULATE MATTER ExPOSURE ON THE RISK 
OF PRESCRIPTION OF CARDIORESPIRATORy DRUGS IN ITALy
Conti S., Lafranconi A., Fornari C., Madotto F., Cesana G.
University of Milano - Bicocca, Monza, Italy
Objectives: Drug prescriptions recorded in health care administrative databases 
(HADs) can be an indicator of moderate health outcomes (undetectable through hos-
pitalization or death registries) correlated to particulate matter (PM) exposure. This 
study is aimed at assessing the short-term effect of PM10 exposure on the risk of car-
diorespiratory drug prescription in Lombardy, a region in northern Italy. MethOds: 
For each resident in seven cities of Lombardy, we identified all prescriptions of 
selected respiratory, cardiovascular and antidiabetic treatments recorded during 
2005-2006 in data warehouse DENALI, which gathers HADs of Lombardy health 
system. The Regional Environmental Protection Agency of Lombardy provided time-
series of daily mean PM10 concentration. We applied a time-stratified case-crossover 
design matched by day of week and fitted separate Cox proportional hazard models 
for each respiratory and cardiovascular treatment. Confounding was accounted for 
using a method, which we developed, based on the time-series of prescription of 
antidiabetics. Analyses were replicated for delayed effects of PM up to 6 days and 
for warm and cold season. Results: The study area counted 470,300 residents, 
requiring 655,805 prescriptions. Mean PM10 concentration was 48µg/m
3 (SD 32µg/
m3). Overall, we estimated that rises in PM10 concentration were associated with 
an immediate increment in the risk of prescription of inhalant adrenergics (0.32% 
for increments of 10µg/m3 in PM10 concentration; 95%CI:0.00,0.65), antiarrhythmics 
(0.52%; 95%CI:0.16,0.87) and nitrates (0.51%; 95%CI:0.27,0.76). Increased PM10 expo-
sure was also positively associated with the prescription of inhalant glucocorticoids 
during the warm season and of inhalant adrenergics, antiarrhythmics and nitrates 
during the cold season. cOnclusiOns: The significant association that we detected 
between PM concentration and drug prescriptions suggests that PM exposure may 
impact public health not only through severe but also through moderate adverse 
events. Further investigation is needed and given the usual difficulty retrieving 
information on moderate outcomes, HADs represent a valuable data source.
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HyPERCHOLESTEROLEMIA’S BURDEN OF DISEASE IN PORTUGAL
Gouveia M.1, Borges M.2, Augusto M.2, Caldeira D.2, Alarcão J.2, Pinheiro L.2, Sousa R.2, 
Fareleira F.2, Ascenção R.2, Costa J.2, Laires P.3, Fiuza M.4, Dias N.C.4, Martins S.4, Belo A.4,  
Vaz C.arneiro A2
1Católica Lisbon School of Business and Economics, Lisbon, Portugal, 2Center for Evidence Based 
Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 3Merck, Sharp & Dohme, 
Oeiras, Portugal, 4Sociedade Portuguesa de Cardiologia, Lisbon, Portugal
Objectives: To estimate the impact of hypercholesterolemia (HYP) on population 
health in Portugal. MethOds: We estimate the Disability Adjusted Life-Years (DALY) 
attributable to HYP in 2010. The DALY include both years lost to premature death and 
years lost to disability. HYP is a risk factor for Acute Myocardial Infarction (ICD 9 410), 
other Coronary Heart Diseases (ICD 9 411-414) and for Ischemic Stroke (ICD 9 433-434). 
In order to estimate the attributable fractions to HYP of the diseases considered a 
microsimulation approach was used by using Framingham equations on data from 
individual observations in the VALSIM database. A total cholesterol equal to the mean 
for observations above 200 mg/dL was imputed to all individuals under statin treat-
ment. In a counterfactual scenario HYP was eliminated (reducing total cholesterol to 
200 mg/dL and increasing HDL to 40 mg/dL in all cases with HYP). The resulting pro-
portional change in the probability of events was taken as the HYP attributable fraction 
of the diseases studied. Results: In Portugal the prevalence of HYP in 2010 was esti-
mated at 55,5% of the population over 18 (56,7% male and 54,5% female). In 2010 there 
were 1689 deaths attributable to HYP. This number can be broken down by gender (640 
males and 1050 females) or by disease (481 from Acute Myocardial Infarction, 235 from 
other ischemic heart disease and 974 from ischemic stroke). DALY for premature death 
were estimated at 7263, and DALY for disability at 8239. Of the total 15502 DALY attrib-
utable to HYP 6132 were for ischemic stroke and 9369 for coronary disease. Gender 
decomposition of this total was 8012 for males and 7489 for females. cOnclusiOns: 
The analysis suggests that HYP is an important cause of disease burden in Portugal 
and that it should remain a major target for health policy interventions.
PCv164
UTILIzATION OF ROUTINE DATA FOR REGIONALIzED EPIDEMIOLOGy IN 
AUSTRIA - THE ExAMPLE OF ISCHEMIC HEART DISEASE (ICD9 410-414)
Endel G.1, Fülöp G.2
1Main Association of Austrian Social Security Institutions, Vienna, Austria, 2Gesundheit Österreich 
GmbH - GÖG, Vienna, Austria
Objectives: Monitoring the performance of the health care system requires 
timely and robust information highlighting the burden of disease on a regional 
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over other LAIs in terms of discontinuation due to AEs. This study provides support 
for formulary decision-making in the absence of head-to-head data.
PMH2
RISK OF PSyCHIATRIC AND NEUROLOGICAL DISEASES IN PATIENTS wITH 
wORKSPACE MOBBING ExPERIENCE IN GERMANy: A RETROSPECTIvE 
DATABASE ANALySIS
Kostev K.1, Rex J1, Schröder-Bernhardi D1, Mergenthaler U.1, Waehlert L.2
1IMS Health, Frankfurt am Main, Germany, 2Fresenius University of applied sciences, Idstein, 
Germany
Objectives: In recent years workplace mobbing attracts notice in public and sci-
ence. Victims of workplace mobbing frequently suffer from depressions, somatic 
symptoms, may develop alcoholism or other substance abuse disorders and show 
increased risk of suicidal behavior. The aim of this study was to calculate the 
number of patients with a workspace mobbing documentation and their diagnosis 
profile in general practices in Germany between 2003 and 2012 based on the data 
from a large epidemiological database. MethOds: This retrospective study ana-
lysed longitudinal routine care data collected by general practitioners in Germany 
(IMS® Disease Analyzer). Data from patients with notice as workplace mobbing 
(N= 2653) and without such notice (N= 2653) from 199 general medical practices 
in Germany (Disease Analyzer database; 01/2003 to 12/2012) were matched for 
age (41 ± 13 years), gender (male: 33%), health insurance (private: 5%) and retro-
spectively analyzed. Odds Ratio (OR; Logistic regression) for depression, anxiety, 
somatoform disorder, migraine and sleep disorder (follow-up: 3 years) were calcu-
lated. Results: In 2003, 24 (projected to national level: 2448) patients were docu-
mented as mobbing victims; this number continuously increased to 429 (projected 
to national level: 43758) in 2012. Shares of female patients and mean age have not 
significantly changed from 2003 till 2012. In workspace mobbing persons there 
was a increased risk of depression (OR: 4.11, p< 0.001), anxiety (OR: 2.76, p< 0.001), 
somatoform disorder (OR: 3.51, p< 0.001), migraine (OR: 1.41, p= 0.003) and sleep 
disorder (OR: 2.32, p< 0.001). cOnclusiOns: This retrospective database analysis 
showed that experience of workspace mobbing was associated with increased 
prevalence of psychiatric and neurological problems. Further research is required 
to understand this complex issue.
PMH3
POINTS TO CONSIDER IN MULTIREGIONAL TRIALS USING PHQ-9: A META-
ANALySIS ON PHQ-9
Ueki H., Kaneko M., Narukawa M.
Kitasato University, Graduate School of Pharmaceutical Science, Tokyo, Japan
Objectives: As the cultural adaptation process of PROs (Patient Reported 
Outcome instruments), every version of PROs should be validated. However, little 
is known whether those validated PROs are identical in terms of the test perfor-
mance (operating characteristics). In this study, we investigated PHQ-9 (Patient 
Health Questionnaire-9 for depression) using the meta-analysis. MethOds: We 
searched PubMed for studies examining diagnostic accuracy of PHQ-9. Then we 
extracted or retrieved 2 x 2 data from each study and meta-analysis was performed 
using Bivariate model (Reitsma et al. 2005). As the language versions of PHQ-9 
and regions where the studies were conducted would be potential confounding 
factors, we performed meta-regression. Bivariate meta-analysis of the subgroup 
(region, language) was explored. Results: Twenty-eight studies met our inclu-
sion criteria. Univariate meta-regression showed that all the covariates assessed 
such as language, region significantly contributed to the heterogeneity of sensi-
tivity (I^2= 82.7) and specificity (I^2= 92.5) among the studies. Meta-analysis of 
subgroup of the regions and languages was made using bivariate model; studies 
conducted in North America (6 studies), Europe (13 studies), or Asia & others 
(9 studies); LogitSe of North America, Europe and Asia& other were 1.66, 1.45, 
and 1.48, respectively. Logit Sp of these regions was 1.87, 1.90 and 2.22, respec-
tively. cOnclusiOns: Results suggest that operational characteristics would 
influenced by the regions, language version of PHQ-9. Therefore, when considering 
a multiregional study using PHQ-9 as screening tool, there would be a chance of 
some imbalance among regions. Therefore, before initiation of the clinical studies, 
efforts need to minimize the heterogeneity of the definite diagnosis, e.g. training 
to the investigators, or central diagnosis.
PMH4
RESULTS FROM THE “AUTOR” STUDy, A EUROPEAN OBSERvATIONAL STUDy IN 
PEDIATRIC PATIENTS wITH ATTENTION-DEFICIT/HyPERACTIvITy DISORDER
Haynes V.1, Lopez-Romero P.2, Anand H.3
1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Madrid, Spain, 3Eli Lilly and 
Company, Surrey, UK
Objectives: To investigate factors associated with changes in attention-defi-
cit/hyperactivity disorder (ADHD) symptom severity and quality of life (QoL) in 
patients who were responders and stable on their pharmacotherapy at study 
entry. MethOds: “AUTOR” is a European prospective, observational study inves-
tigating factors associated with ADHD severity changes during a 2-year follow-up 
period in patients aged 6-17 years. At baseline, patients had received the same 
pharmacotherapy for 3-8 months and had a Clinical Global Impression (CGI)-ADHD-
Severity score of mild or lower and a CGI-ADHD-improvement score of improved/
very much improved since treatment initiation. Data were collected at naturally 
occurring visits coinciding with observation windows (postbaseline): 0, 3, 6, 9, 12, 
18, and 24 months, and ±6 weeks. ADHD symptom severity worsening was defined 
as a ≥ 2-point increase from baseline in CGI-ADHD-Severity score. The Child Health 
Profile-Child Edition (CHIP-CE) was used to measure QoL. Multivariate logistic 
regression was used to assess the association of different factors with changes 
in ADHD severity at any time postbaseline. Mixed-model repeated measures 
(MMRM) regression was used to estimate adjusted differences between treatments. 
Propensity scoring was used to adjust for imbalanced covariates before treatment 
comparisons. Results: Data were analyzed from 704 patients (mean [standard 
Objectives: In 2012, ivabradine was centrally approved by the EMA for Chronic 
Heart Failure treatment. Through ivabradine NICE and HAS decisions analysis, the 
objective of this policy research is to illustrate the divergence of HTA decisions 
despite a consistent efficacy, effectiveness and economics information. MethOds: 
NICE and HAS reports were fully reviewed with a focus on decisions outcomes. 
Then, convergences and divergences between HAS and NICE decisions were high-
lighted. Results: NICE recommended for use ivabradine for patient with NYHA 
class II to IV with systolic dysfunction, with sinus rhythm with a heart rate ≥ 75 
bpm, in combination with standard therapy or when beta-blocker therapy is con-
traindicated or not tolerated, and with a left ventricular ejection fraction ≤ 35%. 
Decision made by NICE was mainly based on results of one subgroup defined post 
hoc on the request of EMA. HAS rated the actual benefit of ivabradine as impor-
tant for the labelled indication, nevertheless HAS distinguishes 2 subpopulations: 
one with minor improvement of actual benefit - patient with NYHA class II to III 
with systolic dysfunction in sinus rhythm with the heart rate ≥ 77 bpm and in 
which beta-blockers are contraindicated or not tolerated- for the other patients, 
HAS stated that ivabradine does not provide improvement in actual benefit. HAS 
based its decision mainly on the results of one subgroup defined a priori in which 
ivabradine was superior to each individual components of the primary combined 
endpoint. cOnclusiOns: While EUnetHTA attempts to provide a coordinated opin-
ion on comparative effectiveness, HTA decisions continue to be divergent across 
Europe. Ivabradine NICE and HAS decisions divergences exemplify once more the 
inconsistency of HTA decisions and highlight the obstacle for the establishment 
of a jointed EUHTA body.
PCv168
QUALITy IMPROvEMENT INITIATIvES FOR PATIENTS ON wARFARIN IN 
PRIMARy CARE
Molony S.1, O’Leary A.2, Usher C.2, Molony D.3
1Royal College of Surgeons in Ireland, Dublin, Ireland, 2National Centre for Pharmacoeconomics, 
Dublin, Ireland, 3Mallow Primary Healthcare Centre, Mallow, Ireland
Objectives: The primary objective of this study was to report the clinical out-
comes, i.e. routine calculation of time in therapeutic range (TTR), bleed events and 
thromboembolic events for patients on warfarin in a general practice following 
the introduction of quality improvement initiatives. A secondary objective was 
to estimate the cost of care of these patients managed from the perspective of 
the general practice. MethOds: Clinical data were analysed annually using a 
General Practice database, adapted to allow calculation of TTR for all patients pre-
scribed warfarin for the years 2009 (baseline), to 2011 (Year 2). Decision trees were 
constructed to reflect typical episodes of care for patients with atrial fibrillation 
(AF). Resource use and unit cost data were applied to each node in the decision 
tree. The probabilities of events occurring were derived from the literature and 
expert clinical opinion. A 60% TTR was used as a reference criterion for patient 
outcomes. Ethical approval for the study was obtained. Analysis was performed 
in SPSS®. Results: The TTR at baseline was 54%, rising to 61% in Year 1 and 63% 
in Year 2. One patient suffered a haemorrhagic stroke in the baseline year (TTR 
71%), and in the same year there were 4 thromboembolic events. No major haem-
orrhagic or thromboembolic events have been recorded in the follow-up years. 
The median cost per patient with AF was € 276 (using a median of 12 INR tests per 
annum). cOnclusiOns: The introduction of routine assessment of TTR in the 
practice has resulted in a significant improvement in care as demonstrated by the 
rise in TTR values, and adherence to international best-practice criteria. Clinically 
significant outcomes on patient care are also evident with the absence of major 
bleed events or thromboembolic breakthrough events. The study highlights the 
feasibility and benefits of enhanced care at local level.
MENTAL HEALTH – Clinical Outcomes Studies
PMH1
EFFICACy OF LONG-ACTING INjECTABLE ANTIPSyCHOTIC THERAPIES IN 
MAINTENANCE TREATMENT OF SCHIzOPHRENIA: A MIxED TREATMENT 
COMPARISON (MTC) OF DOUBLE-BLIND RANDOMIzED CLINICAL TRIALS
Majer I.M.1, Gaughran F.2, Sapin C.3, Beillat M.3, Hennequin M.1, Treur M.1
1Pharmerit International, Rotterdam, The Netherlands, 2South London and Maudsley NHS 
Foundation Trust, London, UK, 3Lundbeck SAS, Issy les Moulineaux, France
Objectives: Treatment with antipsychotic medication is an important element of 
relapse prevention in the management of schizophrenia. However, approximately 
50% of patients with schizophrenia miss taking > 30% of their medication, there-
fore the use of long-acting injectable (LAI) formulations is an important option for 
patients partially or non-adherent to oral formulations. This study aimed to com-
pare LAIs in terms of efficacy and safety. MethOds: A systematic literature review 
in PubMed, EMBASE, Cochrane, PsychINFO and conference abstracts was conducted 
to identify relevant randomized controlled trials of LAIs in maintenance treatment 
in schizophrenia. Selection criteria included long-term follow-up, stable patients 
and minimamilly one LAI treatment arm. The primary efficacy outcome was relapse 
rate; rate of discontinuation due to treatment-related adverse events (AEs) was also 
considered in this analysis. Data on discontinuation parameters were analyzed by 
applying a MTC competing risks model appropriate for multinomial distribution 
of data using WinBUGS. Results: Six trials (study follow-up from 24 to 53 weeks) 
were identified, allowing comparisons of aripiprazole (oral and LAI), risperidone 
LAI, paliperidone LAI, olanzapine (oral and LAI), haloperidol LAI and placebo. The 
total patient number was 3402, of which 534 (16%) received aripiprazole. Compared 
to placebo the risk of relapse was the smallest for aripiprazole LAI (mean hazard 
ratio [HR]= 0.26, 95% confidence interval [CI] 0.12-0.50) and risperidone LAI (HR= 0.29, 
95% 0.05-0.83). The risk of discontinuation due to AEs was lower than placebo for 
aripiprazole LAI (HR= 0.72) and higher than placebo for the other LAIs (paliperidone 
LAI: HR= 5.08, risperidone LAI: HR= 12.06, olanzapine LAI: HR= 6.58, haloperidol LAI: 
HR= 4.19). cOnclusiOns: The MTC suggests that aripiprazole LAI is at least as effi-
cacious in the management of relapse prevention as other LAIs with an advantage 
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Kragujevac, Kragujevac, Serbia and Montenegro, 9School of Health Sciences & Practice, New York 
Medical College, U.S.A., NY 10595, NY, USA, 10Center for Children and Childhood Studies, Rutgers 
University, Camden, NY, USA
Objectives: To assess health care professional’s judgments on economic con-
sequences of prescribed medical interventions and their responsiveness of 
different health care policy measures aiming for increasing their cost-conscious-
ness. MethOds: The design encompassed the nation-wide-cross-sectional hier-
archical levels of health care facilities across the geographical regions. Authors 
used validated and standardized Likert scale of Health Economic Awareness (HEA) 
adjusted for local setting to evaluate health care professionals by face-to-face inter-
views. The questionnaire comprehended clinician’sattitudes on: Clinical-Decision-
Making-Alternative-Interventions (CDMAI); Quality-of –Health-care (QHC); and 
Cost-Containment-Policy (CCP). This survey was conducted in two waves before 
and after policy intervention in 40 hospitals and primary care facilities in fifteen 
cities in Serbia from January 2010-December 2012. A total of 649 participants were 
interviewed before the intervention and 651 after the intervention. Core Republican 
Health Insurance Fund adopted and disseminated the package of cost containment 
measures through the Nation-wide pharmacoeconomic guidelines which princi-
pally targeted at prescribers. Pharmacists, physicians and dentists were examined 
by the scores of CDMAI, QHC, CCP and HEA. Results: Pharmacists and dentists 
had a higher average score (mean±s.d.) of CDMAI by the pharmacists (1.200±0.421) 
and the dentists (1.195±0.560) than the score of physicians (1.017±0.453). Dentists 
had the highest average score of CCP (2.127±0.598) and then the score of physicians 
(1.976±0.529). The score of pharmacists was the lowest (1.854±0.461).There were no 
impacts of the interventions on the professional behaviors regarding the scores 
of QHQ, CDMAI, CCP, and HEA. cOnclusiOns: Health economic awareness has 
differed substantially among of different health care professionals. Health policy 
measures were implemented to reduce non-cost-effective prescribing behaviors 
but the effects are non-clear-cut evidences. This experimental study is a pioneering 
effort in the wider Balkans region.
PMH8
EFFICACy AND SAFETy OF AGOMELATINE IN DEPRESSED THAI PATIENTS 
INCLUDING THE ELDERLy DEPRESSED POPULATION
Suraaroonsamrit B.
Somdet Chaopraya Institute of Psychiatry, Somdet Chaopraya Hospital, Bangkok, Thailand
Objectives: To assess the efficacy and safety of agomelatine using pharma-
covigilance during 12-week follow-up. MethOds: Agomelatine 25-50 mg was pre-
scribed open label to patients with depressive disorders diagnosed by psychiatrists 
based on DSM-IV/ICD-10 criteria. Treatment options were intent-to-treat. All 480 
patients, including 97 elderly patients were followed up at week 2 if dose titra-
tion was necessary. Efficacy was assessed using Montgomery-Äsberg Depression 
Rating Scale(MÄDRS) and clinical global impression of improvement (CGI-I) and of 
severity (CGI-S) scales, at weeks 2, 6, and 12. Data on adverse effects and for reports 
were gathered through patient interviews. Results: Of 480 patients, 20-86 years 
(mean[SD] 49.6[14.5]), 247(51.5%) were men and 97(20.2%) were elderly (65 to 86; 
mean[SD] 71.1[5.0]). Among all patients, 225(46.9%) and 255(53.1%) were depressed 
with a single episode and recurrent episodes. Patients with recurrent episodes were 
taking various classes of antidepressants, including selective serotonin reuptake 
inhibitors in 328(50.9%) patients. Generalized anxiety disorder was a concurrent 
diagnosis in 95(24.3%) of patients. The respective mean(SD) baseline CGI-S, CGI-I, 
and MADRS scores of 3.90(0.68), 4.15(0.76), and 22.59(3.77) were reduced to 2.1(0.31), 
1.11(0.37), and 9.19(2.03), with respective reductions in mean(SD; 95% CI) scores of 
1.78(0.75;1.72-1.85), 2.98(0.78;2.91-3.05), and 13.39(4.36; 13.00-13.78). Similar efficacy 
was evidenced for elderly depressed patients (N= 97), in whom mean(SD) MADRS 
score at baseline 22.37(4.79) was consistently significantly reduced to 14.61(3.04), 
10.76(3.04), and 8.72(1.91) at weeks 2, 6, and 12, respectively. After 12 weeks, over-
all remission (MADRS score < 10) was seen in 68.4% of patients with moderate to 
severe (MADRS > 25) depression and in 73.4% of elderly depressed patients. The 
mild adverse events reported were dizziness(9.5%), headache(7.4%), difficulty sleep-
ing(6.3%), and nausea(3.1%). There were no cases reported of alanine transaminase 
levels three times above upper limit of normal. cOnclusiOns: Agomelatine has 
proven to be a safe and effective new antidepressant in intent-to-treat analysis of 
depressed, including elderly, patients in daily clinical practice in Thailand.
PMH9
COMPARATIvE EFFICACy AND METABOLIC SIDE EFFECTS OF LURASIDONE FOR 
THE MANAGEMENT OF ACUTE SCHIzOPHRENIA: A SySTEMATIC LITERATURE 
REvIEw AND MIxED TREATMENT COMPARISON wITH FIRST AND SECOND 
GENERATION ANTIPSyCHOTICS
Guelfucci F.1, Watt M.1, Vimont A.2, Roïz J.3, Cadi-Soussi N.4
1Creativ Ceutical, London, UK, 2Creativ-Ceutical, Paris, France, 3Creativ-Ceutical, London, UK, 
4Takeda Pharmaceuticals International GmbH, Glattpark-Opfikon (Zurich), Switzerland
Objectives: Second generation antipsychotics (SGA) are associated with increased 
risk of metabolic side effects. A systematic literature review and mixed treatment 
comparisons (MTC) were performed to assess the efficacy and the metabolic side 
effects of antipsychotics, and more especially to compare lurasidone to other widely 
used antipsychotics in patient with acute schizophrenia. MethOds: This review 
included short-term (≤ 12 weeks) randomised controlled trials (RCTs) in patients 
with an acute phase of schizophrenia. The literature search was based on the 
NICE guidelines on treatment for schizophrenia published in 2010. A systematic 
search in the most comprehensive medical databases of peer-reviewed articles 
(MEDLINE, EMBASE, CENTRAL) was conducted until June 2012 to update the evi-
dence. In addition to lurasidone, eight comparators were considered: amisulpride, 
aripiprazole, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone and pla-
cebo. A Bayesian ramdom effect MTC was performed on efficacy outcomes (PANSS 
total score and CGI-S score) and metabolic side effects (weight, triglycerides, total 
cholesterol level and fasting glucose level). Results: Thirty-nine RCTs involving 
12,721 patients were included. Results showed that lurasidone had similar efficacy 
deviation] age 10.7 [2.75] years, 99% Caucasian, 82% male, 76% combined ADHD 
subtype). Variables associated with worsening severity were: baseline parental 
occupation (P= .003), poorer school outcomes (P< .001), and use of psychoeducation 
(P= .004). Initial use of nonstimulants (vs. stimulants) was associated with significant 
improvement on the CHIP-CE total score at 3 months and 9-24 months postbaseline. 
The estimated adjusted difference between treatments was −6.0 (95% confidence 
interval: −7.9, −4.1) at 24 months postbaseline. cOnclusiOns: In this observational 
study, worsening of ADHD symptoms was associated with initial use of psychoe-
ducation, parental occupation, and poorer school outcomes. Initial treatment with 
nonstimulants (vs. stimulants) was associated with improved QoL.
PMH5
CLINICAL OUTCOMES IN SCHIzOPHRENIA TREATED wITH DONEPEzIL IN 
COMBINATION wITH ANTIPSyCHOTICS
Ballesteros J.1, Guillen V.1, Zabala A.1, Santos B.1, Rueda J.R.2, Solà I.3
1University of the Basque Country UPV/EHU, Leioa, Spain, 2University of the Basque Country, 
UPV/EHU, Leioa, Spain, 3Iberoamerican Cochrane Center, Barcelona, Spain
Objectives: To assess the efficacy of a cognitive enhancer, donepezil, as an adju-
vant treatment to antipsychotics on clinical outcomes of schizophrenia. MethOds: 
Systematic review with meta-analysis to obtain appropriate evidence from rand-
omized clinical trials (RCTs) on the efficacy of donepezil plus antipsychotics versus 
placebo plus antipsychotics in patients diagnosed with schizophrenia for the follow-
ing outcomes: general psychopathology, positive/negative symptoms, and depres-
sive symptoms. Effect size estimates corrected for small sample size trials (Hedges’ 
g) were calculated for parallel trials and cross-over trials. Negative values for Hedges’ 
g denote an effect favouring the combined treatment. When needed, values for the 
cross-over correlation were imputed from available individual data to obtain the 
Hedges’ g estimates. The individual estimates were pooled with a random-effects 
meta-analysis. Results: Seven trials (4 cross-over, 3 parallel) were included. Four 
trials provided data on the Positive and Negative Syndrome Scale (PANSS) for total 
and general psychopathology scores. Three trials provided data for PANSS positive 
scores and 5 trials provided data for PANSS negative scores. Three trials provided 
data on depression scores. The combined treatment did not show differences in 
any of the assessed outcomes: PANSS total scores (g = -0.57, 95% CI = -2.11 to 0.96, 
I2 = 67%); PANSS General Psychopathology scores (g = -0.20, 95% CI = -0.74 to 0.34, 
I2 = 0%); PANSS positive symptoms (g = -0.06, 95% CI = -0.73 to 0.60, I2 = 0%); PANSS 
negative symptoms (g = -0.43, 95% CI = -1.98 to 1.12, I2 = 86%); depression scores (g = 
-0.35, 95% CI = -1.20 to 0.49, I2 = 0%). cOnclusiOns: The combination of donepezil 
with antipsychotic treatment does not improve clinical outcomes in schizophrenia.
PMH6
RESPONDER ANALySIS OF FUNCTIONAL HEALTH AND wELL-BEING IN MDD: 
A POOLED ANALySIS OF SF-36 RESULTS FROM THREE PHASE III TRIALS wITH 
LEvOMILNACIPRAN SR
Blum S.I., Hallman L.A., Tourkodimitris S., Gommoll C.
Forest Research Institute, Jersey City, NJ, USA
Objectives: Levomilnacipran (1S,2R-milnacipran) is a potent and selective seroto-
nin and norepinephrine reuptake inhibitor (SNRI) with approximately 2-fold greater 
potency for reuptake inhibition of norepinephrine than serotonin. Levomilnacipran 
SR is in late-stage clinical development for the treatment of major depressive dis-
order (MDD) in adults. A pooled analysis of Phase III studies was conducted to 
evaluate the effects of levomilnacipran SR treatment on functional health and 
well-being. MethOds: Pooled analysis of three double-blind, placebo-controlled, 
Phase III randomized clinical trials (Clinicaltrials.gov #NCT00969709, NCT00969150, 
NCT01034462), which included one fixed-dose (levomilnacipran SR 40, 80 or 120 mg/
day or placebo) and two flexible-dose (levomilnacipran SR 40-120 mg/day or placebo) 
studies that included the acute version of the SF-36v2 health survey. Percentage of 
responders following 8-weeks of treatment (observed cases) with levomilnacipran 
SR or placebo were compared for each individual health domain and the Physical 
(PCS) and Mental (MCS) Component Summary scores based on individual patient-
level responder criteria for minimally important differences. Estimates of odds 
ratios, 95% confidence intervals and p-values were from a logistic regression model 
with study and treatment as factors, baseline score as covariate and a study-by-
treatment interaction term. Results: Compared with placebo-treated patients, 
a greater percentage of patients who were treated with levomilnacipran SR were 
considered as responders. Homogeneity of OR could be assumed for the individual 
health domains and component summary scores except for the Bodily Pain scale 
(study-by-treatment interaction p-value= 0.0123). Pooled OR [95%-CI] for being a 
responder were as follows: MCS= 1.705 [1.292-2.250]; PCS= 1.285 [0.972-1.700]; General 
Health= 2.324 [1.763-3.064]; Social Functioning= 1.698 [1.295-2.226]; Vitality= 1.608 
[1.250-2.068]; Mental Health= 1.579 [1.203-2.072]; Role-Emotional= 1.453 [1.121-1.882]; 
Physical Functioning= 1.382 [1.032-1.850]; and Role-Physical= 1.341 [1.005-1.788]. All 
OR (except PCS) were statistically significant (p< 0.05). cOnclusiOns: Compared 
with placebo, patients who are treated with levomilnacipran SR are more likely to 
achieve meaningful improvement in multiple domains of health as measured by 
the SF-36 Health Survey.
PMH7
DO POLICy MEASURES IMPACT ON COST CONSCIOUSNESS OF HEALTH CARE 
PROFESSIONALS?
Jakovljevic M.1, Vukovic M.2, Antunovic M.1, Dragojevic Simic V.3, Velickovic Radovanovic R.4, 
Siladji-Mladenovic D.5, Jankovic N.6, Rankovic A.7, Kovacevic A.3, Antunovic M.3,  
Markovic V.8, Chia-Ching C.9, Tetsuji Y.10
1Faculty of medical Science, Kragujevac, Serbia and Montenegro, 2Health Centre, Valjevo, Serbia 
and Montenegro, 3Military Medical Academy Belgrade, Belgrade, Serbia and Montenegro, 4The 
Faculty of Medicine, University of Nis, Nis, Serbia and Montenegro, 5University Clinical Center 
Vojvodina, Novi Sad,, Novi Sad, Serbia and Montenegro, 6The Faculty of Medical Sciences 
University of Kragujevac, Kragujevac, Serbia and Montenegro, 7University Clinical Center 
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with newly diagnosed depressive disorder. The patients were followed up for one 
year after the index date (the first date of diagnosis). Psychotropic drugs used to 
treat depressive disorder included first- and/or second-generation antidepressant, 
benzodiazepine, sulpiride, and antipsychotics. The treatment duration and time to 
treatment by gender and age were evaluated by Cox regression model. Results: 
A total of 5,464 patients (men: 3,483, mean age: 36.1±9.9) with depressive disorder 
was identified. Median treatment duration was 123 days (men: 150 days, women 
92 days). 90.1% of patients was prescribed at least one psychotropic drug within 
30 days from the first date of diagnosis (84.5% in women and 93.1% in men). The 
proportion of patients who were prescribed at least one psychotropic drug for the 
first time after 6 months from the index date was 5.6% (men: 3.8%, women: 9.1%). 
The result showed that older patients were more likely to be treated longer period. 
In addition, men tend to be prescribed at least one psychotropic drug in a shorter 
period of time from the index date compared to that in women. cOnclusiOns: 
This study suggested the trend of treatment disparity between men and women as 
well as age in working population with regard to treatment duration and time to 
prescription. Further study is needed for generalizability.
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THE BURDEN OF TREATMENT CHANGE IN MAjOR DEPRESSIvE DISORDER: 
COMPARISON OF SwITCH vERSUS NON-SwITCH PATIENTS IN THE PERFORM 
STUDy
Boulenger J.P.1, Haro J.M.2, Lamy F.X.3, Brignone M.3, Caillou H.4, Rive B.3, Saragoussi D.3
1CHU de Montpellier, Montpellier, France, 2Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat 
de Barcelona, Barcelona, Spain, 3Lundbeck S.A.S., Issy-les-Moulineaux, France, 4Inferential, Paris, 
France
Objectives: PERFORM (Prospective Epidemiological Research on Functioning 
Outcomes Related to Major depressive disorder) is a 2-year prospective observa-
tional cohort study conducted in Europe (France, Germany, Spain, Sweden and UK). 
Objectives are to describe the functioning of patients with major depressive disorder 
(MDD) and factors associated with functional impairment. Here we compare charac-
teristics and outcomes of patients switching antidepressant treatment (ADT) with 
those initiating ADT at baseline, on an interim 1000-patient dataset. MethOds: 
Outpatients were recruited from primary or secondary care. Inclusion criteria were: 
DSM-IV-TR diagnosis of MDD, age 18-65 years, initiation or first switch to an ADT, in 
monotherapy. In addition to socio-demographics and disease history, data collec-
tion included clinician assessments (MADRS and CGI-S) and patient-rated scales 
evaluating depression (PHQ-9), functioning (SDS), work productivity (WPAI-SHP) 
and quality of life (QoL - EQ-5D). Results: Of 947 analysable patients at inclusion, 
213 (23%) patients were switching (76% for lack of efficacy), versus 716 (77%) initi-
ating ADT. Switchers were slightly older (mean age 46 versus 43 years) and more 
often female (77% vs. 72% women). Switching patients had more severe symptom 
profiles: more had previous depressive episodes (34% vs. 24%) and previous suicide 
attempts (16% vs. 12%). Severity of current episode was greater for switchers (46% 
vs. 36% with a CGI-S score above “markedly ill”; 48% versus 38% with a PHQ-9 score 
above the severe depression threshold). MADRS scores were similar: 18.1 versus 
17.6. QoL was poorer for switchers (EQ-5D: 0.449 vs. 0.567), as was overall patient 
functioning (47% vs. 36% with an SDS total score in the highest quartile), while no 
difference was found for absenteeism (35% vs. 34%) and presenteeism (49% vs. 50%) 
(WPAI-SHP). cOnclusiOns: Patients switching ADT had more severe symptom 
profiles, lower quality of life and higher functional impairment, compared to non-
switching patients.
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PATIENT-REPORTED COGNITIvE DySFUNCTION NEGATIvELy IMPACTS 
FUNCTIONING IN PATIENTS wITH MAjOR DEPRESSIvE DISORDER – 
PRELIMINARy FINDINGS FROM THE PERFORM STUDy
Saragoussi D.1, Haro J.M.2, Boulenger J.P.3, Jönsson B.4, Knapp M.5, Caillou H.6, Chalem Y.1, 
Milea D.7, François C.1
1Lundbeck S.A.S., Issy-les-Moulineaux, France, 2Parc Sanitari Sant Joan de Déu, CIBERSAM, 
Universitat de Barcelona, Barcelona, Spain, 3CHU de Montpellier, Montpellier, France, 4Stockholm 
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Objectives: PERFORM (Prospective Epidemiological Research on Functioning 
Outcomes Related to Major depressive disorder) is a 2-year prospective observa-
tional cohort study conducted in Europe to describe the functioning of patients 
with major depressive disorder (MDD) and factors associated with functional 
impairment. Here we report the impact of patient-reported cognitive dysfunc-
tion (PRCD) on quality of life (QoL), work and overall functioning at baseline, on 
a preliminary 1000-patient dataset. MethOds: Outpatients were recruited from 
primary or secondary care. Inclusion criteria were: DSM-IV-TR diagnosis of MDD, 
18-65 years old, initiation or first switch to an antidepressant, in monotherapy. 
Functioning was assessed by the SDS (Sheehan Disability Scale), work productiv-
ity by the WPAI-SHP (Work Productivity and Activity Impairment Questionnaire) 
and QoL by the EQ-5D (EuroQol-5 Dimensions) and SF-12 (12-Item Short-Form 
Health Survey). PRCD was assessed by the Perceived Deficit Questionnaire 5-item 
(PDQ-5). Descriptive analyses stratified on PDQ-5 quartiles were complemented 
with ANCOVA adjusted for severity of depression. Results: At inclusion, over 947 
analysable patients, mean PDQ-5 score (ranging from 0 to 20) was 11.5 (SD= 4.4). 
PRCD was associated with impairment of overall functioning, QoL and productiv-
ity. SDS total scores were 14.4, 18.5, 20.2, and 23.6 (first to fourth PDQ-5 quartiles, 
respectively) (p< 0.001). Similar patterns were observed for WPAI-SHP presentee-
ism scores (impairment while working: from 36.9% in first quartile to 64.4% in 
fourth quartile, p< 0.001; overall work impairment: from 41.5% to 71.3%, p< 0.001). 
These associations remained statistically significant after adjustment for baseline 
depression severity in multivariate analyses. A negative impact of PRCD was also 
observed on sick-leave length and on QoL. cOnclusiOns: At inclusion, subjective 
cognitive dysfunction in depressed patients was associated with poorer function-
ing, work productivity and QoL. This is in addition to any negative impact of the 
to others antipsychotics in terms of PANSS total score and CGI-S score and a similar 
effect as compared to placebo on all metabolic outcomes. The probability to have 
a lower impact than aripiprazole on weight increase and fasting glucose level was 
respectively 75.5% and 65.9%. Probabilities to have a lower impact on cholesterol 
level and triglycerides compared to olanzapine, quetiapine or riperidone varied 
from 98% to 100%. cOnclusiOns: Efficacy has been demonstrated for all reviewed 
treatments vs. placebo, with a similar effect. Lurasidone had a similar effect as 
compared to placebo and a less negative impact than olanzapine, quetiapine and 
risperidone on weight increase, triglycerides, total cholesterol level and than olan-
zapine on fasting glucose level.
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RELATIvE EFFICACy AND ACCEPTABILITy OF vORTIOxETINE vERSUS 
MARKETED ANTIDEPRESSANTS
Llorca P.M.1, Lançon C.2, Brignone M.3, Rive B.3, Salah S.4, François C.5
1Centre Hospitalier Universitaire, Clermont-Ferrand, France, 2Hopital Sainte-Marguerite CHU, 
Marseille, France, 3Lundbeck S.A.S., Paris, France, 4Keyrus Biopharma, Paris, France, 5Lundbeck 
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Objectives: Vortioxetine (Lu AA21004) is an investigative multimodal antide-
pressant which demonstrated efficacy, safety and tolerability in Major Depressive 
Episode (MDE). The comparison of vortioxetine to marketed antidepressants guides 
decison makers and clinicians in their choice of treatment. The main study objective 
was to generate comparative evidence for the efficacy and acceptability of vortiox-
etine in MDE. MethOds: Indirect comparisons were performed by meta-regression 
analysis, an extension of classical random-effect meta-analyses, to compare vorti-
oxetine to agomelatine, escitalopram, duloxetine, sertraline, venlafaxine IR/XR and 
vilazodone. To ensure comparability between studies, in terms of selection of patient 
population and exposure to treatment, only investigational drug and placebo arms 
from pre-registration placebo-controlled studies were included in the base case 
analyses. The main outcomes were efficacy, measured as the standardized mean dif-
ference between active treatment and placebo control in the change from baseline 
to 2 months of the primary endpoint (MADRS or HAM-D total score), and accept-
ability (the withdrawal rate due to adverse events) and expressed as the logarithm of 
the odds ratio (OR) between active treatment and placebo. Sensitivity analyses were 
performed with the inclusion of post-marketing authorization studies, adjustment 
for age/gender and on response and remission. Results: For efficacy, treatment 
effect estimates and p-values for vortioxetine versus comparators were: -0.16(0.11) 
versus agomelatine (negative effect favours vortioxetine); 0.09(0.42) versus dulox-
etine; -0.05(0.70) versus escitalopram; -0.04(0.83) versus sertraline; 0.12(0.33) versus 
venlafaxine IR/XR and -0.24(0.11) versus vilazodone. For acceptability, all but one OR 
(< 1) favoured vortioxetine: 1.77(0.03) versus agomelatine; 0.75(0.26) versus dulox-
etine; 0.67(0.28) versus escitalopram; 0.30(0.01) versus sertraline; 0.47(0.01) versus 
venlafaxine and 0.64(0.18) versus vilazodone. Meta-regression adjusted for age and 
gender demonstrated the robustness of the estimated differences between treat-
ments, as did sensitivity analyses including post-marketing trials. cOnclusiOns: 
Vortioxetine is a promising intervention with efficacy comparable to marketed anti-
depressants in MDE and a favourable acceptability profile.
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DRUG TREATMENT OF ATTENTION-DEFICIT/HyPERACTIvITy DISORDER (ADHD) 
IN AUSTRIA
Hinteregger M.1, Füzi J.2, Reichardt B.3
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Objectives: The therapy of Attention Deficit/Hyperactivity Disorder (ADHD) with 
methylphenidate or atomoxetine, formerly only related to children and adolescents, 
is now extended to the adult population. Little is known about treatment patterns 
in Austria. The aim of this study was to evaluate the medication patterns of ADHD 
in 2012 in Austria, stratified by age and sex. MethOds: The data analysis refers to 
the accounting data of the 13 major Austrian health insurance funds, covering more 
than 97% of the Austrian population. Provided in a pseudonymised manner, with 
availability of the individual patient parameters age and sex, all dispensed medica-
tion of methylphenidate or atomoxetine is included in the descriptive analysis. The 
prevalence of ADHD medication is evaluated regarding age and sex. Furthermore the 
prescribed daily dose in relation to the defined daily dose is pointed out. Results: 
A total of 9120 patients with ADHD medication in 2012 are included in the analy-
sis (22% female). One per cent of all patients with ADHD medication is in the age 
cohort of under 6 years, 47% are between 6 and 13, 22% are between 14 and 17, and 
30% are adults (18+). The relation between the defined daily dose (ddd) to the pre-
scribed daily dose (pdd) shows that 86% of children and adolescents have less than 
366 pdd in the whole year and only 1% has more than 732 pdd. 81% of the adults 
have less than 366 pdd and 6% have more than 732 pdd. cOnclusiOns: While the 
variety of prescribed daily dose per patient is homogeneous during childhood and 
adolescence, this parameter spreads widely in adults. This could be an indicator of 
overuse or misuse. As the results reflect the prescription reality they can be used 
as a solid basis for further discussions, future evaluations and interventions about 
ADHD medication in Austria.
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TREATMENT DISPARITy AMONG PATIENTS DIAGNOSED wITH DEPRESSIvE 
DISORDER IN wORKING POPULATION BASED ON CLAIMS DATABASE IN jAPAN
Onishi Y.1, Furukawa T.A.1, Hinotsu S.2, Kawakami K.1
1Kyoto University, Kyoto, Japan, 2Okayama University, Okayama, Japan
Objectives: Treatment disparity by gender and age among patients with depres-
sive disorder in working population has not been examined in Japan. This study 
examined treatment disparity by gender and age among patients newly diagnosed 
with depressive disorder based on the claims database of health insurance socie-
ties between 2008 and 2011 in Japan. MethOds: Retrospective cohort database 
(N= 600,000) was followed up for four years to identify patients (18 ≤ age ≤ 65) 
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exclusion criteria. The combined odds ratio was 1.72 (95% CI: 1.432 to 2.070), indicating 
the odds of fetal malformation is higher among women taking antidepressants than 
those not receiving SSRIs. In the pairwise analysis, 2 of the 14 pairwise comparisons 
were statistically significant: fluoxetine compared to control (OR 1.774, 95% CI 1.008 
to 2.925); paroxetine compared to control (OR 1.752, 95% CI 1.057 to 2.953). The result-
ing pairwise odds ratios suggested a lowest odds of malformation to highest odds 
was citalopram, sertraline, paroxetine, fluoxetine. cOnclusiOns: The risk of mal-
formation is an important consideration when treating pregnant women. This study 
suggests that there is an increase in the odds of fetal malformation when exposed 
to SSRIs in utero during the period of organogenesis. The risk appears to be highest 
with fluoxetine and paroxetine, and lower for citalopram.
MENTAL HEALTH – Cost Studies
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BUDGET IMPACT OF PALIPERIDONE PALMITATE IN AUSTRIA
Ransmayr S.1, Mehnert A.2, Mahlich J.C.3
1University of Vienna, Vienna, Austria, 2Janssen Pharmaceutica NV, Beerse, Belgium, 3Janssen-
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Objectives: The costs of schizophrenia in Austria are high and new long acting 
injectable (LAI) antipsychotics might be able to reduce costs due to a reduction 
of hospital stays. We aim to estimate budget effects of the introduction of a new 
LAI (Paliperidone Palmitate) in Austria. MethOds: A budget impact analysis was 
conducted that took direct costs of illness into account (i.e. costs for inpatient 
and outpatient services and drug costs). We used official Austrian remuneration 
prices as input parameters. The robustness of the model was checked by means 
of deterministic sensitivity analyses with regard to switch rates to Paliperidone 
Palmitate and rehospitalisation rates. Results: According to our calculations, 
direct total costs of schizophrenia in Austria reach € 254.36 million a year. The 
drug costs are € 26.14 million and the costs for inpatient and outpatient services 
are € 228.22 million. Within the next five years, drug costs will slightly decrease to 
€ 25.77 million due to a bigger market share of generic Quetiapine which offsets 
the higher drug costs of Paliperidon palmitate. The use of Quetiapine is associ-
ated with a higher rate of rehospitalisation. Therefore, costs for inpatient and 
outpatient services will increase to € 228.65 million, which results in an overall 
effect of € 60,000 additional costs compared to the situation without paliperidone 
palmitate. cOnclusiOns: The introduction of a new treatment of schizophrenia 
in Austria is budget neutral.
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ASSOCIATION BETwEEN COGNITIvE FUNCTION AND 3 MONTH HEALTH CARE 
COSTS AMONG PATIENTS INITIATING AN ANTIDEPRESSANT FOR DEPRESSIvE 
DISORDER IN AN AMBULATORy CARE SETTING
Kurlander J.L.1, Walker V.1, Essoi B.1, Samp J.2, Akhras K.S.2, Yang J.2
1OptumInsight, Eden Prairie, IL, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, 
USA
Objectives: Depression is associated with reduced cognitive function and signifi-
cant health care costs; however, the extent to which these two are related remains 
unclear. This study compared follow-up health care costs for major depressive dis-
order patients with and without cognitive dysfunction after antidepressant (AD) 
initiation. MethOds: A large US health plan affiliated with OptumInsight was used 
to identify depressed patients with a newly prescribed AD who could be surveyed 
to assess cognitive function. Patients with neurological diseases associated with 
cognitive dysfunction were excluded. Patients were mailed a survey invitation and 
consent form. Patients maintained eligibility by confirming a depressive diagno-
sis and no excluding diagnoses. Consenting, eligible patients were interviewed by 
telephone and completed 4 cognitive function tests. Patients were classified as 
“cognitive normal (CN)” or “cognitive dysfunction (CD)” based on test scores relative 
to normative data. All-cause health care costs in the 3 months post-AD initiation 
were calculated from pharmacy and medical claims. T-tests compared 3-month 
costs of CN versus CD. Gamma models with log link compared health care costs 
between CD and CN patients, adjusting for race, sex, age, education, employment, 
depression severity, and comorbidities. Results: A total of 13,537 patients were 
invited to participate in the study and 564 patients maintained eligibility and com-
pleted the study. Patients were mostly female (80%), mean age was 41 years, 98% 
had a high school degree or higher, and 84% were employed. A total of 45% (n= 255) 
met criteria for CD. Mean health care costs were $4,996 for all patients. Costs were 
$6,457 for the CD group compared to $3,787 for the CN (p = 0.038). In the gamma 
models with costs as the outcome, CD patients had costs 1.43 times higher than CN 
patients (95% CI: 1.13, 1.81). cOnclusiOns: In this study population, health care 
costs were significantly higher in patients with cognitive dysfunction compared to 
those without cognitive dysfunction.
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ASSESSING THE ECONOMIC BURDEN AND HEALTH CARE UTILIzATIONS OF 
vETERAN PATIENTS DIAGNOSED wITH POST-TRAUMATIC STRESS DISORDER IN 
THE UNITED STATES
Xie L.1, Dysinger A.H.1, Wang L.2, Du J.1, Huang A.2, Baser O.3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 
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Objectives: To assess the economic burden and health care utilizations of 
patients diagnosed with post-traumatic stress disorder (PTSD) in the U.S. veteran 
population. MethOds: Patients diagnosed with PTSD were identified (International 
Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis 
code 309.81) from the Veterans Health Administration (VHA) dataset from October 
01, 2009 through September 30, 2011. The first diagnosis date was designated as the 
index date. A comparator group was created by identifying patients without PTSD 
but with the same age, region, gender and index year, and who were matched by 
baseline Charlson Comorbidity Index. A randomly chosen index date served to 
severity of depression on these outcomes. These preliminary results need to be 
confirmed on the full dataset.
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FACTORS ASSOCIATED wITH EARLy RESPONSE TO OLANzAPINE AND 
CLINICAL AND FUNCTIONAL OUTCOMES OF EARLy RESPONDERS TREATED FOR 
SCHIzOPHRENIA IN CHINA
Ye W.W.1, Montgomery W.2, Kadziola Z.3, Liu L.L.1, Xue H.B.H.1, Treuer T.4
1Lilly Suzhou Pharmaceutical Co., Ltd. Shanghai Branch, Shanghai, China, 2Eli Lilly Australia 
Pty Ltd., West Ryde, Australia, 3Eli Lilly GmbH, Vienna, Austria, 4Eli Lilly & Company, Budapest, 
Hungary
Objectives: To identify factors associated with early response at 4 weeks of treat-
ment with olanzapine and to assess whether early response is associated with 
better longer-term outcomes for patients with schizophrenia in China. MethOds: 
A post-hoc analysis was conducted using data from the Chinese schizophrenia 
subgroup (n= 330) of a multicountry, 6-month, prospective, observational study of 
outpatients with schizophrenia/bipolar mania who were initiated or switched to oral 
olanzapine. Stepwise logistic regression controlling for baseline clinical character-
istics, participation in weight education program at baseline, and compliance with 
antipsychotics over first 4 weeks of olanzapine treatment was used to identify fac-
tors associated with early response. Mixed Models Repeated Measures with baseline 
covariates were used to compare outcomes over time between early responders and 
early non-responders to olanzapine. Results: A total of 130 patients (40%) achieved 
early response. The models revealed that significant factors associated with a higher 
likelihood of achieving early response were higher CGI-Sevirity score (OR= 1.51, 95% 
CI: 1.15-1.97), fewer years since first diagnosis (OR= 0.94, 95% CI: 0.90-0.98), a greater 
number of social interactions (OR= 1.22, 95% CI: 1.05-1.40), participation in a weight 
education program (OR= 1.81, 95% CI: 1.04-3.15) at study entry, and high medication 
compliance with antipsychotics during the first 4 weeks of treatment (OR= 2.98, 95% 
CI: 1.59-5.58). When compared to early non-responders, early responders achieved a 
significantly higher endpoint response and significantly greater symptom improve-
ment at end point (CGI-Severity) and a greater improvement in level of functional 
outcomes (all p< 0.05). cOnclusiOns: High levels of compliance to prescribed 
antipsychotic and participation in a weight education program were associated with 
early response in schizophrenia patients in China. Early response was associated 
with greater improvement in symptomatic, functional and quality-of-life outcomes 
at 6 months compared to early non-response. Current findings are consistent with 
previous research outside of China.
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FACTORS ASSOCIATED wITH PAIN PERSISTENCE IN PATIENT wITH 
DEPRESSION DURING A 3 –MONTH FOLLOw-UP PERIOD
Novick D.1, Montgomery W.2, Aguado J.3, Kadziola Z.4, Peng X.5, Brugnoli R.6, Haro J.M.7
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Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain
Objectives: Patients with major depressive disorder (MDD) frequently suffer from 
concomitant pain symptoms, which are associated with higher depression sever-
ity and worse quality of life. We describe the baseline factors associated with pain 
persistence in patients with MDD during a 3-month follow-up period. MethOds: 
Patients from Asia (n= 909) presenting with a new or first episode of MDD were 
enrolled in a 3-month prospective observational study. This report analyzes the 
709 (78%) patients assessed at baseline and 3 months. Demographics, depressive 
symptoms (Hamilton Depression Scale), overall severity (Clinical Global Impression 
Severity score), somatic symptoms (Somatic Symptom Inventory) and quality of 
life (Euro QOL -5D) were assessed. Logistic regression models were fitted to assess 
the relationship between baseline factors and pain persistence during follow-
up. Results: Of the 709 patients analyzed , 349 (49%) had pain at baseline. Forty 
three per cent of the patients (151) having pain at baseline still presented with pain 
at 3-months. Patients with persistent pain had more frequently suffered from previ-
ous MDD episodes (54% vs 39%) , were less likely to be older than 60 (11 vs. 21%), and 
had a higher number of medical comorbid conditions (14% vs 5% with two or more 
co-morbidities). The logistic model adjusting for other baseline covariates confirmed 
these results. cOnclusiOns: A high proportion of patients with depression who 
presented with pain at baseline still suffered from pain symptoms at 3 months. A 
history of depression and the presence of other medical conditions were risk factors 
for pain persistence at 3-months.
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BAyESIAN ANALySIS OF MALFORMATION OUTCOME IN SELECTIvE SEROTONIN 
REUPTAKE INHIBITOR (SSRI) USE DURING PREGNANCy: AN INDIRECT 
COMPARISON OF CITALOPRAM, FLUOxETINE, PAROxETINE, AND SERTRALINE
Ip Q., Smith K.W., Malone D.C.
University of Arizona, Tucson, AZ, USA
Objectives: Assessing the safety of selective serotonin reuptake inhibitor (SSRI) 
use during pregnancy is complicated, especially given the array of treatment option. 
The objective of this study was to evaluate the risks of fetal malformation of SSRI 
use during pregnancy. MethOds: A search for prospective studies evaluating fetal 
malformation with maternal use of citalopram, fluoxetine, paroxetine, or sertraline 
was conducted using the databases of MEDLINE, PsycINFO and EMBASE for the period 
of 1974 to March 21, 2013. The key terms used were: ‘serotonin reuptake inhibitors’, 
‘pregnancy’, ‘prospective studies’. The inclusion criteria in addition to prospective 
studies included: 1) malformation outcome; 2) citalopram, fluoxetine, paroxetine, 
and/or sertraline; 3) drug exposure in first trimester; and 4) compared to control 
group of either ‘no SSRI exposure’ or ‘nonteratogenic agents’. The exclusion criteria 
included: 1) evaluation of SSRI as a drug class, and 2) venlafaxine or bupropion. A 
Bayesian random-effects indirect treatment comparison model was used to perform 
the analysis. Results: The search resulted in 64 articles. Eight articles met inclusion/
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Objectives: To estimate the direct total and component medical costs for inpatient 
and outpatient care for patients with schizophrenia in Tianjin, China. MethOds: 
Data were extracted from the Tianjin Urban Employee Basic Medical Insurance data-
base. Patients (N= 2125) who were aged ≥ 18 years, at least 1 diagnosis of schizophre-
nia and 12-month continuous enrollment after their first observed schizophrenia 
diagnosis between 2008 and 2010 were included. Psychiatric-related inpatient and 
outpatient direct medical costs were estimated. Results: During the study period, 
60.8% of patients had at least one inpatient admission and 39.2% used only outpa-
tient services. The mean (± SD) total annual cost for inpatients was $2771.9±2175.6, 
with 88.9% ($2465.4±2022.5) due to non-drug medical costs and 11.1% ($306.6±461.7) 
for medications. Total annual costs for the outpatient only group were $230.6±487.3 
with 4.4% ($10.1±40.8) for non-drug medical costs and 95.6% ($220.5±470.3) for medi-
cations. Antipsychotics accounted for 50.4% of the total annual medication costs 
in the inpatient group and 60.0% in outpatient only group. On average, inpatients 
had 2.2 psychiatric hospitalizations and 2.2 outpatient visits. Outpatient only group 
had 5.9 outpatient visits. The highest costs per psychiatric-related inpatient admis-
sion were general care and non-drug treatment (49.8%), followed by examinations 
(21.6%), bed fee (14.6%), and medications (7.8%). The majority of costs for outpatient 
visits were due to medications (96.2%). cOnclusiOns: Patients who were hospital-
ized for schizophrenia incurred considerably more costs than those who were only 
treated at outpatient setting in Tianjin China, primarily driven by non-drug medical 
care. This suggests that the use of more effective treatments to minimize the risk 
of hospitalization could lead to reduced total health care costs.
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HEALTH CARE RESOURCE UTILIzATION AND DIRECT MEDICAL COSTS AMONG 
PATIENTS wITH SCHIzOPHRENIA IN TIANjIN, CHINA
He X.1, Wu J.1, Liu L.L.2, Montgomery W.3, Ye W.W.2, Xue H.B.H.2
1Tianjin University, Tianjin, China, 2Lilly Suzhou Pharmaceutical Co., Ltd. Shanghai Branch, 
Shanghai, China, 3Eli Lilly Australia Pty Ltd., West Ryde, Australia
Objectives: To estimate the health care resource utilization and direct medi-
cal costs of patients with schizophrenia in Tianjin, China. MethOds: Data were 
obtained from the Tianjin Urban Employee Basic Medical Insurance database. Adult 
patients with ≥ 1 diagnosis of schizophrenia and 12-month continuous enroll-
ment after the first observed schizophrenia diagnosis between 2008 and 2010 were 
included. Both all-cause and psychiatric-related resource utilization and direct 
medical costs were estimated. Two-sample t-test was used to assess cost differ-
ence. A multiple linear regression model was applied to identify factors associated 
with total cost. Results: A total of 2125 patients were included, with mean age 
of 52.3 years, 49.3% male and 55.7% retired. 60.8% of the patients experienced ≥ 1 
psychiatric-related hospitalizations during the study period. Median (min-max) 
length of stay was 88 (1-365) days per admission and 91 (1-365) days per patient-
year. 58.9% of the patients experienced ≥ 1 psychiatric related outpatient visits. 
Median number of outpatient visits was 4 (1-82). Mean (±SD) total all-cause and 
psychiatric-related direct medical costs were $2863.5±2638.4 and $1774.5±2123.3 
per patient-year respectively, with significant difference between hospitalized and 
non-hospitalized patients ($3953.0 vs. $1176.9, p< 0.001; $2771.9 vs. $230.6, p< 0.001). 
The regression model revealed that patients with more hospitalizations/outpatient 
visits and non-retired patients were more likely to incur higher psychiatric-related 
annual costs. cOnclusiOns: Costs related to treatment with schizophrenia was 
considerable in Tianjin China, driven mainly by psychiatric hospitalizations. Patients 
with psychiatric-related hospitalizations used more medical resources and had 
higher direct medical cost than patients who were not hospitalized.
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SOCIO-ECONOMIC IMPACT OF ALzHEIMER’S DISEASE IN GREECE: PILOT STUDy
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Objectives: The economic burden of Alzheimer disease goes beyond the direct 
health cost as the disease has significant economic and social impact on both 
patients themselves and their families (carers). Despite the fact that Greece is 
plagued by the economic crisis, with major cuts in health expenditure, very little 
is known about the cost of chronic diseases and the most cost-effective ways to 
manage them. The study’s’ aim is to estimate, for the first time in Greece, the cost of 
Alzheimer’s disease, per each severity stage, evaluating apart from the direct costs 
of disease, the cost of carers. MethOds: The pilot sample was 46 patients from 
two Alzheimer centers. A cost analysis was conducted from the socio-economic 
perspective. Data regarding the carers’ time were collected via a questionnaire 
developed by the researchers of this study and was partly based on the research 
tool CATS (Caregiver Activities Time Survey) as it was adopted by Jacobsen et al. 
(2011). Results: The total annual cost of the disease was estimated at € 12,140 (SD: 
6,555.9) for the mild stage (MMSE* 30-21), at € 13,735 (SD: 7,858.7) for the moderate 
stage (MMSE 20-11), and € 22,666 (SD: 8,467.2) for the severe stage (MMSE 10-0) (for 
outpatient cases), 87% higher compared to the mild stage of disease. On average, 
from the total cost of disease, 77% was the cost of the primary and the second-
ary caregiver, 8.7% is the cost of medication and 5% is the hospitalization cost. 
Productivity loss of the primary caregiver exceeds 5% of the total cost per patient in 
mild stage. cOnclusiOns: As the patient gets worse and goes from mild to more 
severe stages, the total health care cost increase. It is important, when possible, to 
prolong the stay of patients in the early stages of the disease.
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SCHIzOPHRENIA AND NEGATIvE SyMPTOMS – BURDEN OF THE DISEASE IN 
SEvEN CENTRAL AND EASTERN EUROPEAN (CEE) COUNTRIES: THE RESULTS OF 
THE LITERATURE REvIEw
Walczak J.1, Augustyńska J.1, Miernik K.1, Stelmachowski J.1, Pieniazek I.1, Obrzut G.1, 
minimize selection bias. Patients in both groups were required to be at least 18 years 
old, and have continuous medical and pharmacy benefits 1 year pre- and 1 year 
post-index date. One-to-one propensity score matching was applied to compare 
follow-up health care costs and utilizations between patients with and without 
PTSD. Results: A total of 938,138 patients were identified for the PTSD and com-
parison cohorts. After 1:1 matching, a total of 333,303 of patients were matched from 
each group, and baseline characteristics were balanced. Patients diagnosed with 
PTSD used more health care resources for inpatient (8.57% vs. 2.58%, p< 0.01), emer-
gency room (13.45% vs. 7.15%, p< 0.01), physician office (99.59% vs. 55.67%, p< 0.01), 
outpatient (99.64% vs. 56.46%, p< 0.01), and pharmacy visits (89.97% vs. 56.47%, 
p< 0.01) than patients in the comparator cohort. The PTSD cohort also incurred 
higher health care costs for inpatient ($2,587 vs. $719, p< 0.01), emergency room 
($133 vs. $66, p< 0.01), physician office ($3,404 vs. $1,254, p< 0.01), outpatient ($3,735 
vs. $1,430) and pharmacy visits ($629 vs. $362, p< 0.01). cOnclusiOns: Study results 
suggest that the economic burden and health care utilizations were significantly 
higher for patients with PTSD versus those without.
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COMPARING THE HEALTH CARE COSTS AND UTILIzATIONS BETwEEN 
PATIENTS wITH ANxIETy vERSUS THOSE wITHOUT
Xie L.1, Wang L.2, Du J.1, Li L.2, Baser O.3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 
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Objectives: To compare health care costs and utilizations between patients with 
anxiety versus those without in the U.S. veteran population. MethOds: A retro-
spective database analysis was performed using the Veterans Health Administration 
(VHA) Medical SAS datasets (01OCT2008-30SEP2012). Patients diagnosed with anxi-
ety were identified (ICD-9-CM: 300.xx) from October 01, 2009 through September 30, 
2011. The first diagnosis date was designated as the index date for the anxiety group. 
A group of non-anxiety patients of the same age, region, gender and index year 
were identified and matched by baseline Charlson Comorbidity Index (CCI) as the 
comparison group. The index date for the comparator group was randomly chosen 
to reduce the selection bias. Patients in both groups were required to be at least 18 
years old, and have continuous medical and pharmacy benefits 1 year before and 
1 year after the index date. One-to-one propensity score matching was applied to 
compare the health care costs and utilizations during the follow-up period between 
the anxiety and comparison groups, adjusted for baseline demographic and clinical 
characteristics. Results: A total of 928,724 patients were identified for the anxiety 
and comparison cohorts. After 1:1 matching, 338,373 of patients were matched from 
each group and the baseline characteristics were well-balanced. Patients with anxi-
ety had higher percentages of inpatient (11.03% vs. 2.74%, p< 0.01), emergency room 
(18.64% vs. 7.50%, p< 0.01), physician office (99.53% vs. 59.16%, p< 0.01), outpatient 
(99.68% vs. 59.91, p< 0.01) and pharmacy visits (91.42% vs. 59.13%, p< 0.01). The anxi-
ety group had higher expenditures in inpatient ($3,347 vs. $782, p< 0.01), emergency 
room ($204 vs. $68, p< 0.01), physician office ($3,527 vs. $1,435, p< 0.01), outpatient 
($3,948 vs. $1,621) and pharmacy visits ($745 vs. $429, p< 0.01) than the comparison 
group. cOnclusiOns: Results suggest that patients diagnosed with anxiety used 
significantly more health care resources and incurred significantly higher health 
care costs compared to patients without.
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METHODOLOGICAL CHALLENGES OF COST-OF-ILLNESS STUDIES ON 
DEMENTIA: AN INTERNATIONAL SySTEMATIC REvIEw
Schaller S.U.1, Mauskopf J.A.2, Kriza C.1, Wahlster P.1, Kolominsky-Rabas P.L.1
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Objectives: Increasing prevalence of dementia highlights the need for a better 
understanding of the cost burden for health policy makers. By descriptive analysis 
of specific cost impacts, cost-of-illness (COI) studies are an essential instrument 
for decision making and planning of health care services. Therefore the purpose of 
this study was to review COI studies of dementia in order to analyze cost compo-
nents and underlying methods in an international context. MethOds: A system-
atic review according to the PRISMA-guidelines was conducted from 2002-2012 in 
order to identify COI studies related to dementia, searching the PubMed, Cochrane, 
EMBASE and NHS Economics Evaluations databases. Annual outcomes per patients 
were analyzed for total, direct, indirect and informal costs. Results: In total 25 
studies were evaluated. Total costs showed an annual range from USD 3.512 to USD 
59.526 in 14 health care systems. This is due to the fact, that the composition of cost 
components and corresponding methods indicated a large heterogeneity in terms 
of both – study characteristics (e.g. diagnosis, care setting, disease stratification) 
and composition of cost components. The majority of studies (92%, n= 23) included 
direct costs, however different cost components and underlying measurements 
were applied. Almost two thirds (60%, n= 15) of the studies included informal costs, 
whereas 9 used the replacement cost approach and 6 studies the opportunity cost 
approach. cOnclusiOns: Outcomes of COI studies in dementia indicate a large 
range, due to differences in health care systems, but also because of methodo-
logical approaches and cost components included. Dementia as a long-lasting and 
progressive disease affects multiple cost dimensions and thereby poses a complex 
challenge for policy makers. In addition, international guidelines on cost analysis 
of dementia are lacking. Standards regarding the methodology of COI studies in 
dementia by the scientific community would be useful. Funded by the European 
Commission, ICT-FP7, project-ID-287509.
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DIFFERENTIAL RESOURCE USE AND COSTS AMONG INPATIENTS AND 
OUTPATIENTS wITH SCHIzOPHRENIA IN TIANjIN, CHINA
Liu L.L.1, Ye W.W.1, He X.2, Wu J.2, Montgomery W.3, Xue H.B.H.1
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PPP to 69,231 US-$ PPP. A co-morbid conduct disorder was reported to be the most 
influential factor for increased health care costs. All CEA analysed psychotherapy 
interventions. While CEA reporting cost per avoided parasuicide event indicated 
favourable incremental cost effectiveness ratios, CEA reporting cost per quality-
adjusted life years (QALY) indicated just weak cost-effectiveness. cOnclusiOns: 
BPD is associated with high costs. Available COI provide a first insight into the 
structure of cost and its predictors. There are no CEA regarding medication for 
BPD. Evidence regarding the cost-effectiveness of psychotherapy interventions is 
ambiguous. Future research should promote the understanding of the economic 
aspects of BPD and determine the societal value of its treatment. In this context 
high methodical standards are particularly important.
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HEALTH INSURANCE COST OF EPILEPSy IN HUNGARy: A COST OF ILLNESS 
STUDy
Oberfrank F.1, Donka-Verebes É2, Boncz I.3
1Institute of Experimental Medicine (IEM)., Budapest, Hungary, 2Integra Consulting zRt., 
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Objectives: To calculate the annual health insurance treatment cost of epilepsy 
disease in Hungary. MethOds: The data derive from the financial database of the 
Hungarian National Health Insurance Fund Administration (NHIFA), the only health 
care financing agency in Hungary. We analyzed the health insurance treatment 
cost and the number of patients for the year 2010. The following cost categories 
were included into the study: out-patient care, in-patient care, CT-MRI, PET, home 
care, transportation, general practitioner, drugs and medical devices. Results: 
The Hungarian National Health Insurance Fund Administration spent 6.341 billion 
Hungarian Forint (HUF) (23.026 million EUR) for the treatment of epilepsy patients. 
The annual average expenditure per patient was 41900 HUF (152.1 EUR) while the 
average expenditure per one inhabitant was 633 HUF (2.3 EUR). Major cost drivers 
were pharmaceuticals (6.3 % of total health insurance costs), general practitioners 
(13.1 %) and acute inpatient care (11.4 %). The number of patients with epilepsy was 
151 per 100000 populations. We found the highest patient number in pharmaceuti-
cal budget (151357 patients), out-patient care (131280 patients) and general practi-
tioners (86704 patients). cOnclusiOns: Epilepsy disease represents a significant 
burden for the health insurance system. Pharmaceutical treatment is the major 
cost driver for epilepsy disease in Hungary.
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HEALTH CARE RESOURCE UTILIzATION AND COSTS ASSOCIATED wITH 
ATyPICAL ANTIPSyCHOTICS USE IN CHILDREN AND ADOLESCENTS wITH 
ATTENTION DEFICIT/HyPERACTIvITy DISORDER IN QUEBEC, CANADA
Lachaine J.1, Sikirica V.2, De G.3, van Stralen J.4, BenAmor L.1, Hodgkins P.2, Yang H.5, Heroux 
J.6
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Objectives: To compare health care resource utilization (HRU) and costs among 
children/adolescents with attention deficit/hyperactivity disorder (ADHD) in Quebec, 
Canada, who received an atypical antipsychotic (AAP) as either augmentation or 
alternative therapy to stimulant, before vs. after initiating the AAP. MethOds: 
Patients (6–17 years) with ≥ 2 documented ADHD diagnoses (ICD-9 codes: 314.0–
314.9), who used stimulants for ≥ 30 days and either switched to an AAP or aug-
mented stimulants with an AAP, were identified in Quebec’s health care database, 
the Régie de l’assurance maladie du Québec between 03/2007 and 02/2012. Patients 
with a documented diagnosis for which AAPs are indicated were excluded. All-
cause and ADHD-related HRU and costs (from a public payer’s perspective in 2012 
Canadian dollars) were compared between the 6-month period before (pre-index) 
and after (post-index) patients’ first AAP prescription claim. Results: A total of 453 
children/adolescents met the inclusion criteria (54.5% switched from stimulants to 
AAPs and 45.5% augmented stimulants with AAPs). The mean age was 10.4 years 
(SD= 2.5) and 25.4% were female. The most prevalent documented mental comorbidi-
ties in the pre-index period were adjustment reaction (7.1%), anxiety disorder (5.1%), 
and learning disability (4.4%). Risperidone (81.7%) and quetiapine (16.3%) were the 
most common AAPs initiated. Compared to the pre-index period, patients incurred, 
on average, more all-cause outpatient visits and costs (3.2 vs. 4.6; $207 vs. $303), 
prescription fills and costs (13.3 vs. 22.2; $710 vs. $889), total medical costs ($644 vs. 
$1,096), and total health care costs ($1,354 vs. $1,985) (all p< 0.05) during the post-
index period. Similarly, ADHD-related total health care costs ($835 vs. $1,269; p< 0.05) 
were higher during the post-index period; all-cause and ADHD-related total health 
care costs increased by 46.6% and 52.0%, respectively. cOnclusiOns: Children/
adolescents with ADHD, who received an AAP as either augmentation or alternative 
therapy to stimulant, incurred higher HRU and costs after AAP initiation, mostly 
through ADHD-related HRU.
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REGISTER BASED ANALySIS OF TREATMENT COSTS OF SECOND GENERATION 
ANTIPSyCHOTICS IN SCHIzOPHRENIA
Borsi A., Takacs P., Feher L.
Janssen Cilag Hungary, Budapest, Hungary
Objectives: The goal of our research was to assess and calculate the costs of 
antipsychotic treatment of schizophrenia patients in Hungary, using the database 
of the National Health Insurance Fund (NHIF). Based on the results of a recently 
published study using real world data (Bitter et al. 2013.) we focused especially on 
the costs linked to the early medication discontinuation and poor adherence of 
schizophrenia patients. MethOds: In Hungary all medicines which are purchased 
with reimbursement are documented in the centralized register of the NHIF since 
1998. We analyzed the Payer’s database taking into account the time to treatment 
discontinuation results of the Bitter et al. study. We calculated the yearly aver-
age costs of schizophrenia treatment both per patient, and both per substance 
Pogroszewska A.1, Szkultecka-Debek M.2, Paulic G.3, Maric D.3, Sinisa A.3, Pecenak J.4,  
Tavcar R.5, Indrikson A.6, Jankovic S.7, Pulay A.J.8, Rimay J.9, Varga M.9, Sulkova I.10
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Croatia, 4Faculty of Medicine, Comenius University, Bratislava, Slovak Republic, 5University 
Psychiatric Hospital, Ljubljana, Slovenia, 6Roche Eesti OÜ, Estonia, Tallinn, Estonia, 7Faculty of 
Medical Science, Univercity of Kragujevac, Kragujevac, Serbia and Montenegro, 8Semmelweis 
University, Budapest, Hungary, 9Roche (Magyarorszag) Kft, Hungary, Budaörs, Hungary, 10Roche 
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Objectives: To gather data concerning burden of schizophrenia in seven Central 
and Eastern European (CEE) countries (Croatia, Estonia, Hungary, Poland, Serbia, 
Slovakia, Slovenia) taking into account: epidemiology, clinical guidelines and rec-
ommendations, current standards of care, costs of illness, resource utilisation, 
health-related quality of life (HRQoL), stigmatisation and discrimination related 
to schizophrenia. The project focused on negative symptoms (NS). MethOds: A 
targeted search was performed focused on publications issued from 1995 onwards 
and indexed in the following databases: PubMed, Cochrane Library, and Centre for 
Review and Dissemination. Moreover, searches for literature in local languages 
from each country of interest were conducted. Results: Fourteen reviews related 
to schizophrenia epidemiology were identified and revealed that the mean inci-
dence of schizophrenia varied greatly from 0.04 to 0.58 per 1,000 population and 
lifetime prevalence from 0.4% to 1.4%. At least one negative symptom was found 
to be present in 57.6% of schizophrenia patients and in 50–90% of individuals expe-
riencing their first schizophrenia episode. Primary NS were observed in 10–30% 
of patients. Mortality of schizophrenia patients was greater than in the general 
population (Standardised Mortality Ratio varies between 2.58 and 4.3), potentially 
due to increased suicide risk, effect of illness on lifestyle and environment, and 
side effects of disease treatment. Identified guidelines indicate a role for second-
generation antipsychotics in NS treatment, nevertheless the development of novel 
therapeutic approaches should be pursued actively. Thirty-seven primary publica-
tions identified from the seven CEE countries which relate to HRQoL of patients 
and caregivers revealed that the disease greatly affects HRQoL of hospitalised 
patients and has a significant negative impact on caregivers’ QoL. cOnclusiOns: 
The literature review confirmed that schizophrenia is one of the most common 
and burdensome mental illnesses, with NS present in a relatively large percent-
age of patients.
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Objectives: To assess the excess direct medical costs associated with a diagnosis of 
attention-deficit/hyperactivity disorder (ADHD) in Germany. MethOds: Nordbaden 
is a region in Southwestern Germany with a population of 2.74 million. Regional 
sociodemographics and health care provider density are well understood and reflect, 
with few exceptions, respective national averages. The Nordbaden database cov-
ers the total regional population insured by SHI (2.24 million lives), integrating 
administrative data from the organization of physicians registered with statutory 
health insurance (SHI) and SHI, allowing patient-centered evaluation of health care 
utilization and direct medical cost for years 2003 to 2009. Patients with a diagnosis 
of ADHD were compared to a control group matched by age, gender, and type of 
health insurance within SHI. Here we report on years 2006-2009, as nonpharmaco-
logical therapy-related cost data were not fully available for earlier years. Results: 
Average annual total cost per ADHD patient increased from € 897 in 2006 to € 1,006 in 
2009 (controls, € 261 in 2006 and € 337 in 2009). Cost per patient correlated positively 
with age, and female patients were generally more costly than males (total as well as 
excess costs). Increasing severity and comorbidity were also associated with higher 
costs per patient. Physician services constituted the major cost component (on 
average, overall, € 653 per case in 2009), followed by pharmacological therapy (€ 330 
in 2009). cOnclusiOns: The average excess cost (from the perspective of German 
SHI) per ADHD patient (over all age groups and irrespective of gender, compared 
to matched controls) was € 669 per year in 2009. Extrapolation from the regional to 
the national level suggests annual outpatient treatment costs attributable to ADHD 
in the magnitude of € 500 million (2009), from the payer’s perspective of SHI. This 
estimate compares to total annual expenditures for health services by German SHI 
of € 160 billion in 2009.
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A SySTEMATIC REvIEw OF COST-OF-ILLNESS STUDIES AND COST-
EFFECTIvENESS ANALySES IN BORDERLINE PERSONALITy DISORDER
Brettschneider C.1, Riedel-Heller S.2, König H.H.1
1University Medical Center Hamburg, Hamburg, Germany, 2University of Leipzig, Leipzig, 
Germany
Objectives: The borderline personality disorder (BPD) is a common mental dis-
order. It is frequently associated with various mental co-morbidities and causes a 
fundamental loss of functioning. Furthermore, economically relevant consequences 
such as high utilization of inpatient and emergency room treatment or reduced 
productivity at work have been reported. The aim of this study is to present the 
existing health economic evidence regarding BPD and to point out implications 
for further research. MethOds: We performed a systematic literature search in 
MEDLINE, EMBASE, PsycInfo and NHSEED to identify cost-of-illness studies (COI), 
cost-effectiveness analyses (CEA) and other cost studies (OCS) regarding BPD. Cost 
data were inflated to the year 2010 and converted into US-$ using purchasing power 
parities (PPP). Quality assessment of the studies was performed by means of a 
standardised quality checklist. Results: We identified three COI, eight CEA and 
six OCS. The methodical quality was moderate. Depending on study perspective 
and considered cost categories cost per patient and year ranged from 18,306 US-$ 
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treatment option as compared with escitalopram,sertraline, and venlafaxine in 
a matrix comparator, with regard to side effects especially sexual dysfunction, 
agomelatine should be considered as the most cost-effective option for treat-
ment of depression.
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COST-EFFECTIvENESS OF PALIPERIDONE PALMITATE FOR THE TREATMENT OF 
SCHIzOPHRENIA IN GERMANy
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Objectives: Treatment with antipsychotic medication is an important element of 
relapse prevention in the management of schizophrenia and can reduce inpatient 
stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting 
injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment 
of schizophrenia in Germany. The study aims at estimating, based on a previously 
published model, the cost-effectiveness of paliperidone long-acting injections com-
pared to other common antipsychotic treatment strategies in patients diagnosed 
with schizophrenia in Germany. MethOds: A Markov decision analytic model was 
adapted to the German health care system. The model considers the cost-effective-
ness for PLAI as a maintenance treatment for patients with schizophrenia from the 
payer perspective. The patients transition between eight health states on a monthly 
basis over a 5-year time horizon. As therapeutic strategies PLAI, quetiapine, risperi-
done long-acting injections (RLAI), oral olanzapine, oral risperidone, zuclopenthixol 
decanoate, olanzapine long-acting injections (OLAI), oral typical and oral atypical 
were compared. Probability of relapse, level of adherence, side effects and treatment 
discontinuation were derived from the Swedish original model. Input factors regard-
ing resource use and costs were estimated and adjusted for the German health care 
system. A probabilistic sensitivity analyses using cost-effectiveness scatter plots 
was performed to visualize the robustness of the results. Results: In base case 
scenario PLAI is superior to RLAI in gained quality adjusted life years (QALYs) and 
avoided relapses. Relative to all other treatment strategies PLAI is more effective 
with regard to gained QALYs and avoided relapses but results in higher treatment 
costs over a 5-year horizon in base case scenario. The results were tested in proba-
bilistic sensitivity analyses cOnclusiOns: PLAI dominates RLAI and compared to 
the other treatment strategies PLAI has shown to be more effective but results in 
higher costs in base case scenario.
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COST EFFECTIvENESS ANALySIS FOR THE USE OF ExTENDED RELEASE 
QUETIAPINE AS ADjUNCTIvE THERAPy IN MExICAN ADULT PATIENTS wITH 
MAjOR DEPRESSIvE DISORDER NON-RESPONDERS TO ANTIDEPRESSANT 
TREATMENT
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Depression is present in 10% of patients attending primary care services and is 
generally not identified. In Mexico it is estimated a prevalence of 12% to 20% among 
adults between 18-65 years old. Up to 75% of patients treated with a selective inhibi-
tor of serotonin reuptake (SSRIs) are not responding adequately. Atypical antipsy-
chotics are an effective alternative for these patients. Objectives: To evaluate the 
cost-effectiveness (CE) of extended release (XR) quetiapine as adjunctive therapy 
(AT) in patients with major depressive disorder (MDD) that doesn’t respond to 
antidepressant treatment (AD), compared with other antipsychotics listed in the 
Mexican Formulary (aripiprazole and olanzapine). MethOds: A Markov model 
was developed to perform and incremental analysis with weekly cycles during 
eight weeks time horizon, based on the meta-analysis developed by Komossa et.al 
in 2010. Health states: remission, relapse and discontinuation of treatment. The 
model estimates the remission time gained (RG) by each AT alternative. The analy-
sis was done from society perspective, considered direct costs, and reported in 
2013 US dollars. Results: Patients with AT with quetiapine XR had 1.83 weeks 
of RG, while patients under aripiprazole and olanzapine obtained 1.5 and 1.72 
weeks of RG, respectively. Quetiapine XR compared to olanzapine generated an 
additional cost per patient of $94.70, with additional RG of 0.11 weeks and ICER 
of $881.73. Quetiapine XR dominated extendedly to aripiprazole. Robustness of 
results were confirmed by additional deterministic and probabilistic sensitivity 
analysis. cOnclusiOns: The use of quetiapine XR as adjuvant treatment for non-
responders patients is a cost-effective compared to aripiprazole and olanzapine, 
and could be considered as an option in an institutional setting.
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Objectives: Sexual dysfunctions (SD) is a common adverse event of antidepressants. 
It has a lasting impact on quality of life and is associated with an increased risk of 
early treatment discontinuation. Using an open-source Discrete Event Simulation 
model (https://open-model-mdd.org/), we performed a cost-effectiveness analysis 
comparing alternative sequences of treatments, to determine whether an antidepres-
sant with moderate efficacy and reduced risk of SD should be positioned before or 
after a treatment with high efficacy and average risk of SD. MethOds: The model 
used was designed to simulate costs and QALYs in cohorts of patients with major 
depressive disorder (MDD), under alternative treatment strategies over 5 years. 
Each strategy consisted of up to 4 lines of treatment, with possibility to switch to 
different drugs when a patient experienced adverse events or lack of efficacy. We 
between 2006 and 2012. Results: Our findings indicate that in the assessed time 
period an average yearly amount of approximately € 5,5 million (calculation based 
on yearly average EUR/HUF exchange rates) is spent on second generation antip-
sychotics, which are prescribed and purchased with reimbursement but finally 
not used by the patients due to early medication discontinuation. Based on our 
calculations, the average yearly treatment costs of antipsychotics increased from 
€ 612 (2006) to € 974 (2012) per patient in the assessed time period. The analysis of 
the NHIF database resulted, that the average yearly expenditure on different antip-
sychotics, varied between € 173 and € 2420 per patient. cOnclusiOns: All-cause 
medication discontinuation is a major concern in the treatment of schizophrenia 
both from a clinical and both from a health economic perspective. In order to 
ensure resources are spent cost-effectively, it is crucial to identify methods which 
can improve treatment continuation and adherence of schizophrenia patients 
in the future.
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ADjUNCTIvE THERAPy wITH PREGABALIN IN GENERALIzED ANxIETy 
DISORDER PATIENTS wITH PARTIAL RESPONSE TO SSRI TREATMENT: A COST-
CONSEQUENCES ANALySIS IN MEDICAL PRACTICE IN SPAIN
Carrasco J.L.1, Olivares J.M.2, Alvarez E.3, Pérez M.4, López-Gómez V.4, Rejas J.5
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Objectives: To compare the effect of adjunctive therapy with pregabalin versus 
usual care (UC) on health care costs and clinical and patients consequences in 
Generalized Anxiety Disorder (GAD) subjects with partial response (PR) to previous 
SSRI course in medical practice in Spain. MethOds: Post-hoc analysis of patients 
with PR to SSRI monotherapy enrolled in a prospective 6-month naturalistic study. 
PR was defined as a Clinical-Global-Impression scale score > 3 and insufficient 
response with persistence of anxiety symptoms > 16 in the Hamilton-Anxiety scale. 
Two groups (based on psychiatrist judgment) were analyzed 1) adjunctive therapy 
(AT) with pregabalin (150-600 mg/day) to existing therapy; or 2) usual care (switching 
to a different SSRI or adding another anxiolytic different than pregabalin). Costs 
estimation used year-2009 prices for GAD related health care resources utilization. 
Consequences were a health profile based on the combination of psychiatrist-based-
measurements [HAM-A, CGI and Montgomery-Asberg-Depression-Rating (MADRS) 
scales], and patient-reported-outcomes [sleep (MOS-sleep), disability (WHO-DAAS 
II) and quality-of-life/quality-adjusted-life-year gain (EQ-5D)]. Changes in both 
health care costs and scale scores were compared separately at end-of-trial visit 
by a general-linear-model with covariates. Results: Four-hundred-eighty-six 
newly prescribed pregabalin and 239 UC GAD patients [mean (SD) HAM-A 26.7 (6.9) 
and CGI 4.1 (0.5)] were analyzed. Adding pregabalin was associated with signifi-
cantly higher mean (95% CI) score reductions vs. UC in HAM-A [-14.9(-15.6;-14.2) vs. 
-11.2(-12.2;-10.2), p< 0.001] and MADRS [-11.6(-12.2;-10.9) vs. -7.8(-8.7;-6.8), p< 0.001]. 
Changes in all patient-reported-outcomes favored significantly patients receiving 
pregabalin, including QALY gain; 0.13(0.12;0.14) vs. 0.09(0.07;0.10), p< 0.001. Health 
care costs were significantly reduced in both cohorts yielding similar 6-month costs; 
€ 1543 (1375;1711) UC and € 1497 (1380;1614) pregabalin, p= 0.661. The effect of sex on 
costs and consequences were negligible. cOnclusiOns: In medical practice, GAD 
patients with PR to SSRI experienced greater consequences improvements with 
adjunctive therapy with pregabalin versus UC, without increasing health care cost. 
The effect of pregabalin was independent of patient gender.
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COST-EFFECTIvENESS OF ANTIDEPRESSANT AFTER 24 MONTHS OF 
TREATMENT BASED ON DISCRETE EvENT SIMULATION MODELING (DESM): 
AGOMELATINE vERSUS MATRIx COMPARATOR OF ESCITALOPRAM, SERTRALINE 
AND vENLAFAxINE IN A THAI SETTING
Satra T., Ngamthipwatthana T.
Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Objectives: To compare cost-effectiveness of agomelatine versus an escitalo-
pram-sertraline-venlafaxine matrix comparator. MethOds: A DESM describes 
course of depressive disorders with acute , continuation, and maintenance treat-
ment of depression in Thai setting for 24 months. A sample of 250,000 patients 
with 100 simulations were assumed with Exigo® model. Antidepressants were 
analyzed for treatment of episodes(12-24 weeks),continuation phase(6-9 months), 
maintenance phase over 2 years follow-up. Data inputs included Thai data on 
disease parameters; Cost included antidepressants, drugs for insomnia, sexual 
side-effects, cognitive behavioral therapy(CBT), electroconvulsive therapy(ECT) 
and mean cost of psychiatric visits. Impact measures were derived from a sys-
temic review. Results were presented as cost(Thai-Baht currency-THB) per Life-
Year-Remission(LYR) averted and Quality-Adjusted Life Year(QALY) compared with 
branded antidepressants in the matrix comparator (46%escitalopram, 33%ser-
traline, 21%venlafaxine). Model simulation initiated with either agomelatine 
25mg or comparators(escitalopram10mg,sertraline100mg,venlafaxine 150mg 
by random selection). Relapse cases required dose increase fro each antidepres-
sant, addition of CBT and ECT. Data on impact of treatment on quality of life in 
patients free from relapse, sexual side effects, insomnia were taken from cochrane 
database. Results: During 24 months, patients treated with agomelatine cost 
15,814.2THB and 20,232.0THB per LYR and QALY gains, whereas with compara-
tor cost 17,999.6THB and 23,431.7THB per LYR and QALY gains. As a result, the 
incremental cost-effectiveness ratio(ICER) shows that agomelatine is the most 
cost-effective antidepressant for episodic treatment with/without continua-
tion or maintenance phase, its cost being lower than comparator by 153,283 and 
83,645 THB per LYR and QALY. These results were robust, probability sensitiv-
ity analysis suggested that agomelatine was effective for a willingness-to-pay 
of 300,000THB,95%CI of -146,120.4 to -179,651.0THB per QALY, with probability of 
> 0.90. cOnclusiOns: Based on the model, agomelatine is the most cost-effective 
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tions (CVC). A number of models are available for the evaluation of the economic 
impact of antipsychotics in schizophrenia, but few of them properly consider 
metabolic syndrome and associated complications. The objective of this study 
was to build a new model to reflect the real patient therapeutic management of 
patients with schizophrenia. MethOds: An expert meeting was set up to vali-
date the design of the model, and to list all outcomes that should be included 
in the model structure. The model was programmed in Excel 2010, with VBA 
coding. Results: The expert meeting validated the premise that the aim of the 
treatment is to prevent relapses, affecting patients’ quality of life and generating 
substantial costs. A patient-level Markov model structure was used, to simulate 
a cohort of patients with schizophrenia over lifetime, with 6-month cycles. Five 
lines of treatments are considered in the model. With up to 3 comparators in 
the first cycle, it models patients’ treatment adjustment, and provides the flex-
ibility to specify at any line of treatment a specific distribution of antipsychotics. 
The model considers treatment response, associated side effects (weight gain, 
sexual dysfunction, EPS and sedation), diabetes diagnosis and CVC (coronary 
heart disease and stroke). Non-response and compliance (based on side effects) 
drive relapse and hospitalization. Each relapse is assumed to require a treatment 
switch. Patients are also allowed to escape from the health care system, or to die, 
due to natural death, suicide or CVC-related death. Finally, extensive determinis-
tic and probabilistic sensitivity analyses are also implemented. cOnclusiOns: 
This new economic model allows taking into account all key features of schizo-
phrenia, in a transparent way.
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COST-EFFECTIvENESS OF ASENAPINE vERSUS ATyPICAL ANTIPSyCHOTICS 
USED IN TURKEy IN THE TREATMENT OF SCHIzOPHRENIA
Pala M.1, Özdemir S.1, Ozdemir O.2
1Lundbeck, Istanbul, Turkey, 2Yorum Consultancy Ltd., Istanbul, Turkey
Objectives: Asenapine is a new atypical antipsychotic approved in Turkey for the 
treatment of schizophrenia and bipolar I disorder. Asenapine has demonstrated 
comparable efficacy over olanzapine in controlling both positive and negative symp-
toms of schizophrenia in the long-term. However, unlike olanzapine, asenapine is 
associated with a favorable metabolic profile as well as with a minimal weight gain. 
Post-hoc analyses of a clinical study vs. olanzapine illustrated higher incidence of 
developing metabolic syndrome (MetS) with olanzapine than with asenapine after 
52 weeks of treatment. The aim of this study is to assess the cost-effectiveness of 
asenapine in schizophrenia compared with the most widely used atypical antip-
sychotics in Turkey with a focus on the long-term consequences of MetS which 
increases the risk of diabetes and cardiovascular diseases (CVD). MethOds: 
Perspective of National Pharmaceutical Reimbursement Authority was applied and 
life expectancy horizon was adopted. Annual risks of metabolic syndrome were 
derived from randomized clinical studies of asenapine and indirect comparison of 
other atypical antipsychotics vs. olanzapine. Risks of developing diabetes and CVD 
were based on published risk models. Treatment costs associated with metabolic 
consequences as well as cost of atypical antipsychotics were derived from local 
sources. Number of diabetes and CVD avoided is used as effectiveness measure in 
the model. Results: Asenapine dominates (more effective and less expensive) all 
atypical antipsychotics in the treatment of schizophrenia. Compared to olanzapine, 
quetiapine, aripiprazole, risperidone and paliperidone (all genericized except pali-
peridone), asenapine was associated with incremental total costs of 1908 TL, 1298 TL, 
314 TL, 841 TL and 1958 TL; and associated with incremental total number of diabetes 
& CVD avoided of 0.046, 0.029, 0.001, 0.028 and 0.028 respectively. cOnclusiOns: 
The lower incidence of developing MetS associated with asenapine compared to 
olanzapine and other atypicals is associated with lower treatment costs and lower 
incidence of diabetes and CVD in Turkey.
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COST-EFFECTIvENESS OF ASENAPINE vERSUS ATyPICAL ANTIPSyCHOTICS 
USED IN TURKEy IN THE TREATMENT OF BIPOLAR I DISORDER
Pala M.1, Özdemir S.1, Ozdemir O.2
1Lundbeck, Istanbul, Turkey, 2Yorum Consultancy Ltd., Istanbul, Turkey
Objectives: Asenapine is a new atypical antipsychotic approved in Turkey for the 
treatment of bipolar I disorder (BD-I) and schizophrenia. Asenapine has demon-
strated comparable antimanic efficacy over olanzapine in a head-to-head study. 
However, unlike olanzapine, asenapine is associated with a favorable metabolic 
profile as well as with a minimal weight gain. Post-hoc analyses of a clinical study 
vs. olanzapine illustrated higher incidence of developing metabolic syndrome 
(MetS) with olanzapine than with asenapine after 52 weeks of treatment. The 
aim of this study is to assess the cost-effectiveness of asenapine in the treat-
ment of BD-I compared with the most widely used atypical antipsychotics with 
a focus on the long-term consequences of MetS which increases the risk of dia-
betes and cardiovascular diseases (CVD). MethOds: Perspective of National 
Pharmaceutical Reimbursement Authority was applied and life expectancy hori-
zon was adopted. Risks of metabolic syndrome after 52 weeks of treatment were 
derived from randomized clinical studies of asenapine and indirect comparison of 
other atypical antipsychotics vs olanzapine. Risks of developing diabetes and CVD 
were based on published risk models. Treatment costs associated with metabolic 
consequences as well as cost of atypical antipsychotics were derived from local 
sources. Number of diabetes and CVD avoided is used as effectiveness measure 
in the model. Results: Asenapine dominates (more effective and less expensive) 
all atypical antipsychotics in the treatment of BD-I. Compared to olanzapine, 
quetiapine, aripiprazole, risperidone and paliperidone (all genericized), asenapine 
was associated with incremental total costs of 2418 TL, 1786 TL, 804 TL and 877 
TL; and associated with incremental total number of diabetes & CVD avoided of 
0.054, 0.038, 0.010 and 0.037 respectively. cOnclusiOns: The lower incidence of 
developing MetS associated with asenapine compared to olanzapine and other 
atypicals is associated with lower treatment costs and lower incidence of diabetes 
and CVD in Turkey.
compared two strategies based on hypothetical treatments: under strategy A, an 
antidepressant with high response rate/high SD rate was prescribed in first-line and 
an antidepressant with moderate response rate/low SD rate available in second-line; 
under strategy B, the positions of these two drugs were reversed. Efficacy and safety 
parameters were obtained from a meta-analysis and other parameters, from the 
literature. Costs were estimated for the UK, from payer perspective. Results: The 
numbers of QALYs were estimated at 3.660 QALYs (SE= 0.013) and 3.649 (SE= 0.012) 
under strategies A and B respectively. Costs were estimated at £3,894 (SE= 60) and 
£3,918 (SE= 61). cOnclusiOns: Positioning an antidepressant with moderate efficacy 
and reduced risk of SD before or after a treatment with high efficacy and average risk 
of SD had no significant impact in terms of average costs and QALYs. Thus, differences 
in efficacy and tolerability can offset each other. In practice, the choice of first-line 
treatment should take account of patient preferences.
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COST-EFFECTIvENESS OF INjECTABLE ATyPICAL LONG-ACTING 
ANTIPSyCHOTICS FOR CHRONIC SCHIzOPHRENIA IN POLAND
Hemels M.1, Einarson T.R.2, Zilbershtein R.3, Schubert A.4, Skrzekowska-Baran I.5,  
Van Impe K.6
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Objectives: To determine the cost-effectiveness of paliperidone palmitate (PP-LAI; 
paliperidone long-acting injectable), a new once-monthly long-acting antipsychotic 
therapy, compared with risperidone long-acting injectable (RLAI) administered 
biweekly for treating chronic schizophrenia in Poland from the National Health 
Fund (NHF) perspective. MethOds: We adapted a 1-year decision tree model to 
the Polish health care system with literature-derived data (e.g., length of stay in 
hospital, treatment patterns, resource utilization) and clinical expert inputs. Costs 
in 2012 euros were obtained from published sources or in case of non-reimbursed 
drug price, directly from producer. Drugs compared were PP-LAI, a new treatment 
option, and RLAI, the established treatment for Polish patients. Clinical rates were 
derived from published trials. Model outputs included expected cost/patient as 
well as rates of hospitalization, emergency room visits, days free of symptoms, and 
quality-adjusted life-years (QALYs). One-way sensitivity analyses were applied to 
major inputs. As well, all inputs were varied simultaneously in probabilistic sensitiv-
ity analyses using 10,000 iterations. Results: Despite its higher acquisition cost, 
PP-LAI had a lower expected cost per patient treated when the benefits are included 
in the estimation model. PP-LAI was associated with 0.824 QALYS, 323 days with 
stable disease and 44.6% hospitalization. RIS-LAI had 0.817 QALY, 317 stable days and 
51.3% hospitalizations. PP-LAI dominated RIS-LAI in the base case and in 55.0% of 
10,000 simulations, and was cost-effective in 76.6%. However, cost-effectiveness was 
sensitive; it was lost with modest increases for PP-LAI or decreases for comparison 
drugs with respect to drug prices, relapse rates and adherence rates. Because it is 
injected monthly as opposed to biweekly, it saves caregiver time. cOnclusiOns: 
From the viewpoint of the National Health Fund of Poland, as compared with RLAI, 
PP-LAI is a cost-effective drug that has the potential to reduce health care costs.
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MOOD STABILIzERS AND ATyPICAL ANTIPSyCHOTICS IN MAINTENANCE 
THERAPy FOR BIPOLAR DISORDER: A COST-EFFECTIvENESS ANALySIS
Zimmermann I.R.1, Kiyomoto H.D.2, Alexandre R.F.2, Nobre M.R.C.3, Diaz M.D.M.4
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Objectives: To evaluate the cost-effectiveness of using a combination of atypical 
antipsychotic agents and mood stabilizers in maintenance treatment of bipolar dis-
order in Brazil MethOds: Analyzing cost-effectiveness, taking direct costs, from the 
perspective of Brazil’s Ministry of Health and its public health system (local acro-
nym SUS), using a Markov model with transitions between possible states: euthy-
mia, mania, depression, discontinuation and death. Efficacy data to populate the 
model were extracted from clinical trials and prospective cohort studies while direct 
cost data came from the public health system’s databases (current values of 2012, 
exchange rate: US$ 1 = R$ 2.21). For a hypothetical cohort of 2000 euthymic individu-
als aged 40, maintenance therapy costs and outcomes were simulated over quarterly 
cycles through a timeframe that reached an effectiveness of < 1 day in remission, for 
up to 30 years. Discount rates and half-cycle correction were applied, also, sensitiv-
ity analyses were run. Results: The available efficacy data enabled the analysis to 
include only a combination with quetiapine. After twelve years (48 cycles) tracking the 
hypothetical cohort, there were 512 acute episodes (285 depression and 227 mania) for 
monotherapy against 306 (166 depression and 139 mania) for the quetiapine combina-
tion. The incremental cost-effectiveness ratio (ICER) for the quetiapine combination 
therapy was US$ 565.64 per additional month in remission. The sensitivity analysis 
with all variables demonstrated the model’s robustness, while dosage and quetiapine-
price variations had most impact, showing an ICER ranging from US$ 381.88 to US$ 
811.24 per additional month in remission. cOnclusiOns: Maintaining the euthymia 
in bipolar disorder has a clinical relevance, especially, because of its impact on func-
tional capacity in this population. In this context, in specific populations, the ICER 
shown may justify the use of the therapeutic strategy presented here. This reimburse-
ment by public systems should also consider its budget impact.
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PATIENT-LEvEL MARKOv MODEL TO ASSESS ECONOMIC IMPACT OF NEw 
ANTIPSyCHOTICS INTRODUCTION IN SCHIzOPHRENIA
Millier A.1, Vimont A.1, Cadi-Soussi N.2, Murthy V.3, Toumi M.4
1Creativ-Ceutical, Paris, France, 2Takeda Pharmaceuticals International GmbH, Glattpark-Opfikon 
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Objectives: Antipsychotic treatments can cause several side effects, such as 
weight gain, metabolic syndrome, which could lead to cardiovascular complica-
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ated with a lower total cost (€ 1,562) and a larger health gain (QALYs) at one year 
(0.732) per patient, and dominated the other treatment strategies since more QALYs 
were achieved at a lower total cost. Sensitivity analyses support the robustness of 
the model. cOnclusiOns: The results indicate that escitalopram is the most cost-
effective pharmacological treatment strategy for the Italian health service compared 
with other SSRIs and all SNRIs used in the first-line treatment of MDD.
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COST EFFECTIvENESS OF PALIPERIDONE PALMITATE IN NATIONAL HEALTH 
SERvICE (NHS) wALES: A COST UTILITy ANALySIS BASED ON THE NATIONAL 
INSTITUTE FOR HEALTH AND CARE ExCELLENCE (NICE) CORE MODEL FOR THE 
MANAGEMENT OF SCHIzOPHRENIA
Lee J.1, Jiang Y.2, Gauthier A.2, Curtis S.3, Musingarimi P.1, Price M.1
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Objectives: Paliperidone palmitate has demonstrated non-inferior efficacy to 
risperidone long acting injectable (LAI) for the treatment of schizophrenia in previ-
ous studies. The objective of this analysis was to assess the cost effectiveness of 
paliperidone palmitate relative to risperidone LAI, based on the cost-utility analysis 
described in the current NICE Guidelines for the Management of Schizophrenia. The 
analysis was undertaken from the perspective of NHS Wales and was submitted to 
the All Wales Medicines Strategy Group for evaluation. MethOds: A decision-ana-
lytic Markov model was developed to estimate the cost-utility of paliperidone palmi-
tate relative to risperidone LAI. The model adopted an annual cycle length. Patients 
who entered the model initiated either paliperidone palmitate or risperidone LAI 
and could subsequently transition between five health states during each annual 
cycle. AEs associated with each intervention were derived from literature. Utility 
values were derived from a community-based study, using trade-off technique to 
elicit HRQoL for schizophrenia according to frequency of injections. Resource use 
data was sourced from the NICE core model/guidelines, Welsh clinical experts, and 
a UK Delphi panel. Unit costs were derived from the British National Formulary, NHS 
reference costs, and the Personal Social Services Research Unit reports. Costs and 
outcomes were evaluated over a 10-year horizon, and discounted at 3.5%. Results 
were presented as incremental costs/QALY. Uncertainty was addressed via deter-
ministic and probabilistic sensitivity analyses. Results: The base case analyses 
demonstrated that paliperidone palmitate would incur lower costs (-£3,773) and 
generate more quality adjusted life years (QALYs) (+0.13) than risperidone LAI. This 
indicated that paliperidone palmitate ‘dominated’ risperidone LAI. Extensive sce-
nario/sensitivity analyses confirmed the robustness of the results cOnclusiOns: 
Compared with risperidone LAI, paliperidone palmitate is a cost-effective therapy 
for the treatment of schizophrenia in adult patients in NHS Wales.
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COST-UTILITy ANALySES OF COGNITIvE-BEHAvIORAL THERAPy FOR MAjOR 
DEPRESSIvE DISORDER – A SySTEMATIC REvIEw
Brettschneider C., König H.H.
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Objectives: Major depressive disorder (MDD) causes a massive health and eco-
nomic burden for societies worldwide. Cognitive behavioural therapy (CBT) is an 
inherent part of the treatment of MDD and is recommended for children, adoles-
cents and adults. Cost-Utility-Analysis (CUA) is an important instrument to sup-
port decision-making on resource allocation and health policy as it permits the 
comparison of interventions for different diseases. The objective of our study was 
to systematically review CUAs related to CBT in the treatment of patients suffering 
from MDD. MethOds: We conducted a systematic literature search in MEDLINE, 
EMBASE, PsycINFO and NHSEED. We included all original studies reporting CUA of 
CBT for patients suffering from MDD. Cost data were inflated to the year 2011 and 
converted into US-$ using purchasing power parities (US-$ PPP) to ensure compa-
rability of the data. Quality assessment of the studies was performed by means of 
a standardised quality checklist. Results: We identified 22 CUAs. The methodo-
logical quality was fair. Two studies considered a lifetime horizon. The mean time 
horizon of the remaining studies was 19.2 months (SD = 12.6). In most instances 
individual and group CBT as well as CBT for maintenance showed acceptable cost-
utility ratios (ICER < 50.000 US-$-PPP / QALY). The results of CUAs of CBT provided 
for children and adolescents or by computer were inconsistent. In comparison 
to medication CBT tends to be more cost effective as stand-alone therapy and in 
combination with medication. cOnclusiOns: Individual and group CBT is a cost 
effective treatment for MDD. Further research to determine the cost effectiveness 
of computerized CBT and of CBT for specific populations like children, adolescents 
or the elderly is required. Furthermore there is a need for long term evidence of 
cost effectiveness of CBT.
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COMPARISON OF HEALTH CARE RESOURCE UTILIzATION AND COSTS AMONG 
CHILDREN AND ADOLESCENTS wITH ATTENTION DEFICIT HyPERACTIvITy 
DISORDER IN GERMANy wHO INITIATED TREATMENT wITH ATOMOxETINE OR 
LONG-ACTING METHyLPHENIDATE
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Objectives: This study compared health care resource utilization (HRU) and costs 
among children/adolescents with attention deficit/hyperactivity disorder (ADHD) 
in Germany who initiated treatment with atomoxetine (ATX) or long-acting meth-
ylphenidate (LA-MPH). MethOds: A retrospective propensity score matched cohort 
analysis was conducted using the IMS electronic medical record database compris-
ing > 15 million patient records from ~3,000 German physicians. Included patients 
were aged 6-17 years, with a first (index) ATX or LA-MPH prescription in 2006-2010; 
≥ 1 ADHD diagnoses 12-month before (pre-index) and after (post-index) index; and 
≥ 1 index medication prescription post-index. Patients in the ATX and LA-MPH 
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Objectives: An economic analysis was conducted from the United Kingdom’s 
(UK’s) National Health Service (NHS) perspective to evaluate the cost-effectiveness 
of lisdexamfetamine (LDX) versus atomoxetine (ATX) in treating children and 
adolescents with attention-deficit/hyperactivity disorder (ADHD) who have had 
an inadequate response to methylphenidate (MPH). MethOds: A 1-year proba-
bilistic decision-analytic model with a Markov structure of nested decision trees 
was constructed. Health states included “response”, “non-response”, and “unable 
to tolerate”. Key model assumptions were adapted from a technology assessment 
for ADHD products by the National Institute for Health and Care Excellence. The 
analysis used clinical data from a head-to-head randomized controlled trial in inad-
equate responders to MPH. Response to treatment was defined as a score of 1 (much 
improved) or 2 (improved) on the Clinical Global Impression-Improvement scale. 
Tolerability was assessed by rates of discontinuation due to adverse events. Utility 
weights were identified via a systematic literature review. Health care resource use 
estimates for responders and non-responders were obtained via a survey of UK spe-
cialists. Unit costs from national sources were applied to estimate the correspond-
ing health-state costs. Daily drug costs were based on mean doses reported in the 
trial. One-way and probabilistic sensitivity analyses were performed. Results: The 
comparison of LDX and ATX, using head-to-head data, resulted in an incremental 
cost-effectiveness ratio (ICER) of £1,802 per quality-adjusted life year (QALY). At a 
willingness to pay of £20,000 per QALY, LDX had an 86% probability of being cost-
effective compared with ATX. In 38% of sensitivity analysis runs, LDX was a domi-
nant strategy over ATX. The model was slightly sensitive to changes in assumptions 
about drug costing and to lengthening the titration period for ATX. cOnclusiOns: 
From the perspective of the UK NHS, LDX provides a cost-effective treatment option 
for children and adolescents with ADHD who are inadequate responders to MPH.
PMH43
COST-EFFECTIvENESS OF ASENAPINE IN THE TREATMENT OF BIPOLAR 
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Objectives: The cost-effectiveness of second-generation antipsychotic drugs 
is well established in the treatment of patients experiencing a manic episode 
associated with bipolar I disorder. However, no studies demonstrating the value of 
these drugs in patients with mixed episodes according to DSM-IV have so far been 
undertaken. The aim of this study was to assess the cost-effectiveness of asenapine 
versus olanzapine in the treatment of this costly subgroup of patients. MethOds: 
A 9-week acute phase model was developed, during which patients receive up to 
three lines of treatment: asenapine or olanzapine alone, then adjunctive valproate, 
and finally a switch to adjunctive lithium. Patients can respond during any 3-week 
period and non-responders move to the next treatment in the sequence. Efficacy of 
asenapine (46.3%) and olanzapine (37.5%) was informed by a post-hoc analysis of 
two short-term clinical trials, where response was measured as a composite YMRS 
and MADRS endpoint. Following initial treatment, patients entered a 5-year main-
tenance Markov model during which they faced probabilities of treatment discon-
tinuation, recurrent manic, mixed and depressive symptoms and death. Direct costs 
(year 2012-13 values), including drug, monitoring costs and resource use related to 
bipolar disorder and selected adverse events, were assessed from a UK NHS per-
spective. Benefits were measured as quality-adjusted life years (QALYs). Results: 
For patients with a mixed episode, asenapine was a more effective and less costly 
treatment strategy compared with olanzapine over a 5-year period. Greater health 
benefits and cost savings were driven by earlier response to asenapine treatment 
during the acute phase and were well maintained during longer-term follow-up. 
These results were robust to changes in key parameters including short and longer-
term efficacy, unit cost and utility values. cOnclusiOns: Compared with olanzap-
ine, results of this analysis suggest that asenapine generates greater health benefits 
at lower cost in the treatment of patients experiencing mixed episodes associated 
with bipolar I disorder.
PMH44
C-QUALITy: A COST AND QUALITy OF LIFE PHARMACOECONOMIC ANALySIS 
OF ANTIDEPRESSANTS IN MAjOR DEPRESSIvE DISORDER IN ITALy
Katz P., Heiman F., Ripellino C.
CSD Medical Research S.r.l., Milan, Italy
Objectives: To assess the cost-effectiveness (€ per quality-adjusted life year [QALY]) 
of all Selective serotonin reuptake inhibitors (SSRIs) and all Serotonin-norepinephrine 
reuptake inhibitors (SNRIs) for the treatment of Major Depressive Disorder (MDD) in 
Italy. MethOds: A decision analytic model was adapted from the Swedish Dental 
and Pharmaceutical Benefits agency model to reflect current clinical practice in the 
treatment of MDD in the largest Italian regions. This adaptation was possible thanks 
to the collaboration of an expert panel of Italian psychiatrists and health economists. 
The model evaluated patients with a first diagnosis of MDD and initiating an SSRI 
or an SNRI for the first time. The time horizon was 12 months. Efficacy and utility 
data for the model were retrieved from the literature and validated by the expert 
panel. Local data were considered for resource utilization and for treatment costs 
based on each regional health service perspective. Population-weighted regional 
data were used to define a national model. Scenario simulations, one-way sensitiv-
ity analyses, and Monte Carlo simulations were performed to test the robustness of 
the model. Results: The base case analysis showed that escitalopram was associ-
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Objectives: To evaluate functional outcomes of aripiprazole once-monthly 
(ARI-OM) 400 mg (ARI-OM-400) versus a sub-therapeutic dose of ARI-OM (50 mg; 
ARI-OM-50), oral aripiprazole (ARI), and placebo, in two trials of stable patients with 
schizophrenia. MethOds: Detailed study designs have been reported previously. 
Results are reported for the double-blind, randomized phase of each study. ARI-OM 
is an extended-release injectable suspension given at 400 mg in the gluteal muscle. 
Functional outcome was measured using the Personal and Social Performance scale 
(PSP) and statistically analyzed using analysis of covariance with last observation 
carried forward. Results: A total of 403 patients were randomized to ARI-OM-400 
(n= 269) or placebo (n= 134) in the first (246) trial. PSP scores at endpoint significantly 
worsened with placebo (-6.2) versus ARI-OM-400 (-1.7; p= 0.0002). In the second 
study (247), 662 patients were randomized to: ARI-OM-400 (n= 265); ARI (n= 266); 
or ARI-OM-50 (n= 131). PSP scores with sub-therapeutic ARI-OM-50 significantly 
worsened (-2.39) versus ARI-OM-400 (+0.45; p= 0.03). Similar functional stability 
was observed with ARI (+0.08). cOnclusiOns: Patient functioning, as assessed 
by PSP, was maintained with ARI-OM in both studies but deteriorated in patients 
randomized to either sub-therapeutic doses or placebo, confirming the benefits of 
adequately dosed antipsychotic therapy in preserving functional stability in long-
term management of schizophrenia.
PMH51
THE DEvELOPMENT AND vALIDATION OF A QUALITy OF LIFE MEASURE FOR 
PEOPLE wITH MILD COGNITIvE IMPAIRMENT (THE MCQ)
Dean K.1, Walker Z.2, Churchman D.3, Wilcock G.4, Jenkinson C.4
1Royal Berkshire NHS Foundation Trust, London, UK, 2University College London, London, UK, 3Isis 
Outcomes, Oxford, UK, 4University of Oxford, Oxford, UK
Objectives: Mild cognitive impairment (MCI) is a state that lies between normal 
cognition and dementia, and the number of cases with the condition is rising as the 
population ages. However, to date, no validated patient reported outcome measure 
(PRO) exists specifically in MCI. We report on a study to develop a PRO for use in 
MCI. MethOds: Semi-structured in-depth interviews were carried out with peo-
ple with MCI in order to determine the questionnaire items. These interviews were 
audio-recorded, transcribed and content analysed. The draft questionnaire was 
refined following feedback from a focus group of patients with a diagnosis of MCI. 
Questionnaires were posted to subjects recruited from memory clinics and research 
databases, the completed questionnaires were analysed using factor analytic tech-
niques to produce the final measure; construct validity was assessed by correlation 
with a generic patient reported outcome measure, the SF-12. Results: Interviews 
were carried out with 23 people with MCI. 280 questionnaires were sent to subjects, 
with a response rate of 56% i.e.146 were included in the analysis. Factor analysis 
produced a 13 item measure tapping two domains of patient reported quality of life 
(‘Emotional Effects’ and ‘Practical Concerns’ ). Internal consistency reliability was high 
for both domains (alpha was 0.91 and 0.85 respectively). Both dimensions were found 
to be highly and significantly correlated with the Mental Component Summary score 
of the SF-12. cOnclusiOns: The Mild Cognitive Impairment Questionnaire (MCQ) is 
a short 13 item measure developed specifically to measure patient reported outcomes 
in people with MCI. It was created on the basis of patient report, and has been shown 
to have good psychometric properties. It is likely to prove valuable in the evaluation 
of treatment regimes in this important and growing patient group.
PMH52
SCORING THE CENTER FOR EPIDEMIOLOGIC STUDIES – DEPRESSION SCALE: 
wHICH ITEMS GO wHERE?
Cole J.C., Atkinson M.J., Nokela M.
Covance Market Access Services, Inc., San Diego, CA, USA
Objectives: To guide researchers on the best way to score the Center for 
Epidemiologic Studies – Depression scale (CES-D) by comparing competing mod-
els in the literature. MethOds: Radloff (19777), the original CES-D author, first 
provided scoring for four uncorrelated factors of depression: negative affect 
(NA), positive affect (PA), interpersonal (I), and somatic (S). Sheehan et al. (1995) 
validated four correlated factors in the CES-D. However, Radloff and Sheehan 
results may have differed because Radloff ascribed items of failure and fearfulto 
NA whereas Sheehan assigned a value of I. Following Sheehan’s scoring, Cole et 
al. (2004) presumed a hierarchical factor of depressed mood that included all four 
previously identified factors and posited a 10-item short-form of the CES-D. These 
four models were compared using structural equation modeling for parametric 
models with Bollen-Stine bootstraps to control for multivariate nonnormality in 
225 community-residing subjects, structural validity of the models were com-
pared. Results: Fit statistics for the four models were: Radloff comparative fit 
index (CFI) = .790 & root mean square error of approximation (RMEA) = .011; 
Sheehan CFI = .926 & RMSEA = .053, Cole hierarchical CFI = .927 & RMSEA = 
.052; Cole 10-item CFI = .979 & RMSEA = .041 cOnclusiOns: The uncorrelated 
Radloff model was the poorest fit the day. Both Sheehan and Cole 20-item models 
were decently fit to the data and nearly identical to each other in fit. Finally, the 
10-item Cole short-form of the CES-D was the best fit model to the data. Given 
the brevity of this form and strong fit with the theoretical structure postulated 
by Radloff, researchers may want to consider this form of the CES-D for research 
on depressed mood.
PMH53
PREvALENCE AND RISK FACTORS OF DEPRESSION IN PATIENTS wITH CHRONIC 
OBSTRUCTIvE PULMONARy DISEASE IN INDIA
Negi H.1, Raval A.2, Malay M.3
1Post Graduate Institute of Medical Education & Research, Chandigarh, India, 2West Virginia 
University, Morgantown, WV, USA, 3Indira Gandhi Medical College, Shimla HP, India
Objectives: Although depression is a significant co-morbid condition in chronic 
illness, little is known about the prevalence or risk factors for depressive symp-
cohorts were matched 1:1 using “nearest neighbor” greedy match propensity score 
method. HRU (inpatient, outpatient, and medications) and costs were compared 
between the two cohorts. Unit costs were identified from German Diagnosis-related 
Group for inpatient, Einheitlicher Bewertungsmassstab doctor fee scale for out-
patient, and Rote Liste®for medication costs. Direct medical costs over the post-
index period were reported in 2011 Euros. Chi-square for categorical variables and 
t-test or Wilcoxon-Mann-Whitney for continuous variables were used to test for 
differences between cohorts (alpha= 0.05). Generalized linear models with nega-
tive binomial (for HRU) and gamma (for cost) distributions were used to address 
residual differences between matched cohorts. Results: Of 4705 eligible patients, 
737 with ATX (mean age= 10.9 years, 20.8% female) were identified and matched 
1:1 with LA-MPH patients (mean age= 11.2 years, 18.6% female). Patients initiating 
ATX had higher HRU and spending per-patient than patients initiating LA-MPH 
over the post-index: 20.9 (SD= 11.5) vs. 15.7 (SD= 9.0) outpatient prescriptions, 10.1 
(SD= 6.3) vs. 8.3 (SD= 5.3) outpatient visits, € 1029 (SD= 574) vs. € 496 (SD= 334) in retail 
pharmacy costs, and € 1,258 (SD= 739) vs. € 684 (SD= 515) in total all-cause costs (all 
p= < .0001). cOnclusiOns: Among children/adolescents with ADHD in Germany, 
ATX initiators consumed significantly more health care resources and were associ-
ated with significantly higher direct medical costs compared with LA-MPH initiators.
MENTAL HEALTH – Patient-Reported Outcomes & Patient Preference Studies
PMH48
FACTORS ASSOCIATED wITH POOR ADHERENCE IN PATIENTS INITIATING 
MEDICATION FOR MAjOR DEPRESSIvE DISORDER: INTERIM RESULTS FROM A 
PROSPECTIvE, LONGITUDINAL STUDy
Lenderking W.R.1, Samp J.2, Hanlon J.1, Hsieh R.3, Akhras K.S.2, Revicki D.A.3
1Evidera, Lexington, MA, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 
3Evidera, Bethesda, MD, USA
Objectives: To examine factors associated with low adherence in Major Depressive 
Disorder (MDD) patients initiating antidepressant medication (ADM) over a 12-week 
period. MethOds: MDD patients initiating an ADM (with no ADM claim in the 6 
months prior) were identified from a large pharmacy benefits manager database. 
Patients completed paper or online assessments including demographics at baseline 
and patient-reported assessments at baseline, Week 4 and Week 12. Participants were 
classified as having low, medium, or high adherence based on the modified Morisky 
Adherence Scale, with the medium and high adherence groups combined for analysis. 
Logistic regression analyses were run to evaluate the association between adherence 
and age, gender, and patient-reported assessments of depression and sexual dysfunc-
tion (SD), weight gain, sleep problems, nausea, and anxiety. Results: Of 2412 patients 
screened, 591 enrolled and completed baseline assessments. Mean age was 40.4 years 
(standard deviation= 12.1), 82.4% were women, and 87.6% were white. There were 483 
who completed Week 4 and 425 who completed Week 12 assessments. At Week 12, 
39.6% were high adherers, 20.6% were medium adherers, and 39.8% were low adher-
ers. Thirty-eight percent of low adherers had actually discontinued ADM. Among dis-
continuers, 40.6% discontinued due to ADM side effects. In logistic regression models, 
low adherence at Week 4 was significantly associated with weight change ≥ 5 pounds 
(OR= 2.10, 95% CI: 1.32–3.35), anxiety (OR= 1.73, 95% CI: 1.06-2.8) and nausea (OR= 2.31, 
95% CI: 1.06–5.02). Age, gender, depression severity, sexual dysfunction, and insomnia 
were not significant in the logistic model. No factors were significantly associated 
with adherence at Week 12. cOnclusiOns: In this real-world study of patients with 
MDD, nearly 40% of patients were low adherers. Weight change, anxiety, and nausea 
were associated with low adherence at Week 4, but not at Week 12.
PMH49
ADHERENCE, SwITCHING, AND DISCONTINUATION DURING THE 12 wEEKS 
FOLLOwING ANTIDEPRESSANT INITIATION IN PATIENTS wITH DEPRESSIvE 
DISORDER: RESULTS OF A PROSPECTIvE, LONGITUDINAL STUDy
Lenderking W.R.1, Samp J.2, Hanlon J.1, Hsieh R.3, Revicki D.A.3, Akhras K.S.2
1Evidera, Lexington, MA, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 
3Evidera, Bethesda, MD, USA
Objectives: This study examined patterns of adherence, switching, and discontinu-
ation, in major depressive disorder (MDD) patients initiating antidepressant medica-
tion (ADM) therapy. MethOds: Depressed patients recently initiating an ADM were 
identified from a large pharmacy benefits manager database. Eligible patients were 
invited to participate by phone or mail and enrolled patients completed. Results: 
Of 2,412 patients screened, 591 were enrolled. Average age was 40.4 years (standard 
deviation= 12.1), 82.4% of participants were women, and 87.6% were white. At Week 
4 (n= 483), 39.4% were classified as low adherers with 31 (6.4%) patients having 
discontinued ADM for reasons including side effects (n= 14, 45.2%), feeling better 
(n= 5, 16.1%), cost (n= 5, 16.1%), and lack of efficacy (n= 4, 12.9%). There were 27 (5.6%) 
patients who switched by Week 4. Of these, 12 (44.4%) switched due to side effects, 
11 (40.7%) due to lack of efficacy, and 3 (11%) due to cost. By week 12 (n= 425), 33 
additional patients had discontinued ADM citing similar reasons as those at Week 
4. Of 43 patients who reported switching at Week 4 or Week 12, 15 (34.9%) cited side 
effects, 16 (37.2%) cited lack of efficacy, and 4 (9.3%) cited cost. cOnclusiOns: In 
this real-world, 12-week study of MDD patients initiating ADM, adherence to ADM 
was low. Switching and discontinuing ADM were common within the 12-weeks 
period and were primarily attributed to side effects and lack of efficacy.
PMH50
FUNCTIONAL OUTCOMES wITH ARIPIPRAzOLE ONCE-MONTHLy IN TwO 
DOUBLE-BLIND, PLACEBO- AND ACTIvE-CONTROLLED STUDIES (ASPIRE US 246 
AND ASPIRE EU 247) FOR THE TREATMENT OF SCHIzOPHRENIA
Fleischhacker W.W.1, Perry P.2, Sanchez R.2, Jin N.3, Peters-Strickland T.2, Johnson B.2,  
Baker R.2, Eramo A.4, McQuade R.D.2, Carson W.H.2, Kane J.M.5
1Department of Psychiatry and Psychotherapy, Medical University, Innsbruck, Austria, 
2Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA, 3Otsuka 
Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA, 4H. Lundbeck A/S, 
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PMH56
HEALTH-RELATED QUALITy OF LIFE OF PATIENTS ON OPIATE REPLACEMENT 
THERAPy
Adams R.
National Centre for Pharmacoeconomics, Dublin, Ireland
Objectives: To evaluate health-related quality of life (HRQOL) and contributing 
factors in individuals receiving opiate replacement therapy. MethOds: This was 
a cross-sectional study of patients attending for methadone therapy in an inner 
city drug treatment centre. EQ-5D, SF-36, SF-6D, Hospital Anxiety Depression Scale 
(HADs) were assessed, along with substance abuse via the Treatment Outcomes 
Profile (TOPs). Mean values, ranges and standard deviations were calculated and 
utility scores were derived. Analysis was performed using Spearman’s correlation 
and t-test to determine any significant correlations. Results: A total of 115 patients 
were included, 72% were male and the mean age was 35 years. 63% were HCV-PCR 
positive and 49% admitted to using drugs in the past month. 57% of patients had 
high levels of anxiety with the mean score being 11.14 (anxious). 35% were depressed 
with the mean score being 8.40 (borderline depressed). The mean EQ-5D utility 
score was 0.56 with 7% having a utility score that was worse than death. The mean 
SF-36 utility score was 0.55. The mean SF-36 physical component score was 44.25 
and the mean mental component score was 33.18. cOnclusiOns: HRQOL was 
reduced in this opiate replacement therapy cohort. HCV, gender and injecting drug 
use did not affect HRQOL but anxiety, depression and use of crack cocaine had a 
significant impact.
MENTAL HEALTH – Health Care Use & Policy Studies
PMH57
NATURALISTIC DISEASE MANAGEMENT STUDy OF PATIENTS wITH ALCOHOL 
DEPENDENCE IN THE PRIMARy CARE SETTING IN THE UNITED KINGDOM 
(STREAM)
Coste F.1, Chalem Y.1, François C.1, Wallace P.2
1Lundbeck S.A.S., Issy-les-Moulineaux, France, 2NIHR, London, UK
Objectives: Describe the management of alcohol dependence at general practitioner 
(GP) level. MethOds: STREAM is a non-interventional, 6-month prospective study of 
adult patients undergoing targeted alcohol screening during routine consultation by 
GPs throughout England and Scotland, for whom alcohol problems were either known 
or suspected on the basis of clinical signs or patient’s report. Inclusion criteria were an 
AUDIT score > = 8 and consent. At baseline, diagnosis of dependence was made using 
the DSM-IV criteria and data were collected on socio-demographic characteristics, co-
morbidities, alcohol consumption with the timeline follow-back method, previous and 
current alcohol treatment, treatment goal (abstinence or reduction of alcohol consump-
tion). The data were analyzed descriptively. Results: A total of 218 patients screened 
positive and were included in 26 sites. A total of 79% of patients fulfilled the DSM-IV 
criteria for alcohol dependence; 74% were men, the mean age was 50 years and only 
29% were working full or part-time. 40% of patients had a history of alcohol treatment 
(almost always counseling), 20% had a history of detoxification and 9% a history of 
pharmacological treatment. At inclusion, the proportion of patients with ongoing treat-
ment for alcohol addiction was 28% and these patients were drinking in average 63 g/
day compared to 89 g/d in untreated patients. Of those patients on treatment or about 
to initiate it, alcohol reduction was more frequently the treatment goal than abstinence 
(51% vs. 45%). cOnclusiOns: Targeted screening is an effective way for GPs to identify 
patients with alcohol dependence opportunistically. Many such patients have a history 
of counseling but few have received pharmacological interventions. Only a minority of 
those with alcohol dependence have ever received any form of treatment. For the major-
ity of those in treatment, alcohol reduction is the treatment goal of choice. Consumption 
levels in patients with dependence tend to be high, irrespective of treatment status.
PMH58
ARE PUBLIC SUBSIDIES EFFECTIvE TO REDUCE HOSPITALIzATIONS
Rapp T., Sirven N., Chauvin P.
University of Paris Descartes, Paris, France
Objectives: Elderly people facing dependence are exposed to the financial risk of 
long lasting care expenditures. This risk is high for people facing cognitive, func-
tional and behavioral problems. In the short-term, dependent elderly people face 
increased non-medical care expenditures. In the long-term, they face increase medi-
cal care expenditures, driven by extended hospital stays. In France, providing public 
financial assistance has been showed to improve dependent people’s access to 
non-medical care services. However, the long-term impact of public financial assis-
tance on care trajectories has not been explored yet. Our study aims at determining 
whether financial assistance on non-medical care provision decreases hospital stays 
rates. MethOds: We run Fixed Effects Poisson regression models using longitudinal 
data of 574 French patients diagnosed with Alzheimer’s disease. We use instrumen-
tal variables to reduce the presence of a potential endogeneity bias. Results: We 
find that beneficiaries of home care subsidies have a 34% lower rate of hospitaliza-
tion than non-beneficiaries. cOnclusiOns: Providing public financial assistance 
is effective to reduce hospitalizations in Alzheimer’s disease.
PMH59
DEvELOPING AN INDIvIDUALIzED E-HEALTH DECISION SUPPORT SySTEM FOR 
DEMENTIA TREATMENT AND CARE: THE FP7 EU-PROjECT E-HEALTH MONITOR 
(EHM)
Schaller S.U., Kriza C., Niederländer C., Wahlster P., Kolominsky-Rabas P.L.
Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of Erlangen-
Nuremberg, Erlangen, Germany
Objectives: The increasing prevalence of dementia worldwide highlights the need 
for effective and individualized support systems for dementia treatment and care. 
Facing the reality of increasing internet usage as well as the large availability of 
digitalized information, there is a high potential for ehealth interventions. Therefore 
one purpose of this project is to provide a ‘Personal eHealth Knowledge Space’ (PeKS) 
toms in chronic obstructive pulmonary disease (COPD) in India. A study was 
undertaken to investigate the prevalence and risk factors of depression in the 
Indian COPD patients. MethOds: COPD was classified according to GOLD stages 
based on forced expiratory volume in one second (FEV1) in 126 stable patients. 
Depression was examined by administering the nine-item Hindi version of Patient 
Health Questionnaire-9 (PHQ-9). Linear regression model was used to examine 
association between predictor variables and risk of depression with adjustment 
of age and sex. Cronbach alpha was calculated to assess internal consistency of 
PHQ-9. Results: Patients with stable COPD (n= 126) were evaluated (73.8% male 
and 26.2% female). In the study population as whole, 33.3% patients showed mod-
erate to severe depressive symptoms whereas 20.6% patients had major depressive 
disorder on PHQ-9 Scale. Educational and occupational status, body mass index, 
FEV1, respiratory symptoms, physical impairment and dyspnea were found to be 
potential predictors of depression in COPD patients. cOnclusiOns: One-fifth of 
the patients with COPD had severe symptoms of related to depression, which was 
especially higher with severity of COPD. Hence, the patients with COPD should 
focus on management of these two conditions. Further, future studies should be 
conducted to assess the role of depression management and timely treatment of 
it in the patients with COPD.
PMH54
PATIENT FUNCTIONING IN GENERALIzED ANxIETy DISORDER SUBjECTS wITH 
PARTIAL RESPONSE TO PRIOR SSRI TREATMENT: THE EFFECT OF ADjUNCTIvE 
THERAPy wITH PREGABALIN IN DAILy MEDICAL PRACTICE
Carrasco J.L.1, Olivares J.M.2, Alvarez E.3, Pérez M.4, López-Gómez V.4, Rejas J.5
1Department of Psychiatry, Hospital Clínico San Carlos, Madrid, Spain, 2Hospital Meixoeiro, 
Complejo Hospitalario Universitario, Vigo, Spain, 3Department of Psychiatry, Hospital de la 
Santa Creu i San Pau, Barcelona, Spain, 4Pfizer S.L.U., Alcobendas, Madrid, Spain, 5Pfizer S.L.U., 
Alcobendas/Madrid, Spain
Objectives: To analyze the effect of adding pregabalin or usual care (UC) on 
patient functioning in GAD subjects with partial response (PR) to previous SSRI 
course in daily medical practice. MethOds: Post-hoc analysis of patients with PR 
to SSRI monotherapy enrolled in a prospective 6-month naturalistic study. PR was 
defined as a Clinical Global Impression scale score > 3 and persistence of anxiety 
symptoms > 16 in the Hamilton-Anxiety scale. Two groups (based on psychiatrist 
judgment) were analyzed: adjunctive therapy (AT) with pregabalin (150-600 mg/
day) to existing therapy; or usual care (switching to a different SSRI or adding 
another anxiolytic different than pregabalin). Patient functioning was assessed by 
mean of the disability WHO-DAS-II scale [range 0 (no disability) to 100 (completely 
unable)]. Changes in domains scale scores were compared at end-of-trial visit by 
a general linear model with covariates. Results: Four-hundred-eighty-six newly 
prescribed pregabalin and 239 UC patients [mean (SD) HAM-A 26.7 (6.9) and CGI 4.1 
(0.5)] were analyzed. AT with pregabalin was associated with significantly higher 
mean (95% CI) reductions vs. UC in all the domains of the WHO-DAS-II scale. 
Differences between groups were statistically significant (effect sizes were moder-
ate): understanding and communication [-6.9(-9.8;-4.0), p< 0.001], getting around 
[-5.2(-8.0;-2.8), p< 0.001], self-care [-3.6(-5.5;-1.8), p< 0.001], getting along with oth-
ers [-5.0(-8.6;-1.3), p= 0.007], household [-5.3(-9.6;-1.0), p= 0.015], work activities 
[-6.5(-11.2;-1.8), p= 0.007], and participation in society [-6.3(-9.7;-2.9), p< 0.001]. The 
overall disability score was significantly more reduced in pregabalin group vs. 
UC: -21.7(-23.3;-20.1) vs. -15.3(-17.5;-13.1), p< 0.001. Gender effect was negligible 
(no interaction) in all the dimensions analyzed except household functioning 
(higher reduction in women). cOnclusiOns: In medical practice, GAD patients 
with partial response to prior course of a SSRI experienced greater and meaningful 
functioning improvements with adjunctive therapy with pregabalin in comparison 
with usual care. The effect of pregabalin was independent of patient gender except 
for household functioning.
PMH55
wORK IMPAIRMENT BURDEN OF ANxIETy AND DEPRESSION IN GERMANy
Pisa G.1, DiBonaventura M.2
1Kantar Health GmbH, Munich, Germany, 2Kantar Health, New York, NY, USA
Objectives: The effect of mental disorders on absenteeism in Germany has stead-
ily increased. They are now the third-most common reason for sick leave after 
musculoskeletal and respiratory conditions. The aim of this study was to provide 
current estimates of the effect of anxiety and depression on both absenteeism 
and presenteeism in Germany. MethOds: Data from the German respondents 
(N= 15,001) of the 2011 National Health and Wellness Survey were used in the 
analysis. Outcome measures included the Short Form-12v2 (mental and physi-
cal component summary [MCS and PCS] and health utility scores) and the Work 
Productivity and Activity Impairment questionnaire. Respondents who reported 
a diagnosis of anxiety and, separately, a diagnosis of depression were compared 
with respective matched controls (matched on demographic and health his-
tory variables using propensity score matching). Results: A total of 904 (6.0%) 
respondents reported a diagnosis of anxiety (62.6% female, mean age= 44.6 years) 
and 1574 (10.5%) respondents reported a diagnosis of depression (60.2% female; 
mean age= 44.9 years). Compared with matched controls, respondents with anxi-
ety reported significantly greater absenteeism (17.9% vs. 8.1%) and presenteeism 
(36.3% vs. 19.4%) (all p< .05). Similar findings were observed for depression (absen-
teeism: 17%.3 vs. 7.6%; presenteeism: 36.1% vs. 17.1%; all p< .05). These findings 
translated to an incremental 60.7 and 61.1 days lost per year due to absenteeism 
alone for anxiety and depression, respectively. Respondents with anxiety and 
depression also reported significantly lower levels of health status compared 
with matched controls (anxiety: 33.0 vs. 45.7 and 43.5 vs. 46.6 for MCS and PCS, 
respectively, all p< .05; depression: 33.3 vs. 46.6 and 43.8 vs. 47.1 for MCS and PCS, 
respectively, all p< .05). cOnclusiOns: Anxiety and depression were associated 
with significant work impairment along with reduced mental and physical health 
status in Germany. These results suggest greater awareness and early treatment 
could reduce the social and economic burden of these conditions.
A552  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
change in MPR observed for patients initiating GXR while on LA stimulants alone 
versus those on SA or SA+LA stimulants.
PMH62
PATIENTS’ CHARACTERISTICS AND PATTERNS OF USE OF DEPOT 
ANTIPSyCHOTICS IN GERMAN PATIENTS wITH SCHIzOPHRENIA
Rouleau A.1, Depont F.2, Klora M.3, Messer T.4, Braun S.5, Zeidler J.3, Milea D.6
1Lundbeck SAS, Issy-les-Moulineaux, France, 2SC Partners, Paris, France, 3Leibniz University 
Hannover, Hannover, Germany, 4Danuvius Klinik GmbH, Pfaffenhofen, Germany, 5HERESCON 
GmbH, Hannover, Germany, 6Lundbeck Singapore PTE LTD., Singapore, Singapore
Objectives: To describe patients’ characteristics and patterns of use of depot antip-
sychotics in patients with a diagnosis of schizophrenia in Germany. MethOds: 
Claims data were analysed from German patients covered by Elsevier Health Risk 
Research Database between 2009-2011 (approx 7.6 million insured persons). The 
study sample consisted of adult patients who initiated a given depot antipsychotic 
for schizophrenia (F20) or schizoaffective disorder (F25) in 2010. Baseline clinical 
characteristics of patients were searched over the year prior to depot initiation. 
Persistence (treatment duration) with depot treatment was assessed using a 
Kaplan-Meier survival analysis until discontinuation or end of the study period (31 
December 2011). Results: A total of 2,240 patients with a diagnosis of schizophre-
nia or schizoaffective disorder (mean age 50.7 years, 48.8% male) were included. At 
baseline, the main psychiatric comorbidities were major depressive disorder (38% of 
patients), substance use disorders (29%) and anxiety disorders (13%). Main somatic 
conditions were cardiovascular diseases (37%), neurological disorders (33%) and 
hyperlipidemia (27%). Depot antipsychotics prescribed were mainly risperidone 
long acting (32%), flupentixol (31%) and haloperidol decanoate (17%). Prescribers 
were psychiatrists/neurologists (58%), GPs (16%), other/unknown (26%). Median per-
sistence to depot antipsychotic treatment was 156 days. cOnclusiOns: To our 
knowledge, this is the first large database study conducted in Germany aiming at 
describing the patients’ characteristics and treatment patterns of schizophrenic 
patients treated with depot antipsychotics. It is notable that the current sub-popu-
lation of schizophrenic patients treated with depot showed substantial psychiatric 
and cardiovascular co-morbidities.
PMH63
vARIATION IN TREATMENT PATTERNS AND OUTCOMES IN CHILDREN AND 
ADOLESCENTS wITH ATTENTION-DEFICIT/HyPERACTIvITy DISORDER ACROSS 
EUROPEAN COUNTRIES
Setyawan J.1, Grebla R.1, Nam S.1, Fridman M.2, Supina D.1
1Shire, Wayne, PA, USA, 2AMF Consulting, Los Angeles, CA, USA
Objectives: To visualize heterogeneity in treatment pathways and outcomes 
among children and adolescents with ADHD in Europe. MethOds: Retrospective 
chart review of 779 ADHD patients (aged 6–17 years) diagnosed by 340 clinicians 
between 2004 and 2007 in six European countries. Receipt of ADHD medication 
and/or behavioural therapy (BT) was evaluated across the study period. Patient 
characteristics, treatment patterns, physician-reported satisfaction and symp-
tom control were analysed in the total population and among patients with at 
least one switch in ADHD therapy during follow-up (switchers). Optimal treatment 
success (OTS) was defined as high satisfaction and complete symptom control 
at chart review. Results: Most patients treated with ADHD medication (89.5%) 
received methylphenidate. Among 386 patients (49.6%) who remained on their 
initial treatment throughout the chart review period, the majority (86.3%) were 
treated with ADHD medication alone or in combination with BT. Switchers (n= 393; 
50.4%) did not differ significantly at baseline from non-switchers. Few patients 
(n= 98; 12.6%) switched more than once. The most common types of switch (first 
and last treatments considered) were from one monotherapy to another (n= 91; 
23.2%) or change of medication co-administered with BT (n= 54; 13.7%). The most 
common reasons for last switch were suboptimal response (40.2%), duration of 
action (18.1%) or both (14.5%). At review, among those who switched, 11.7% discon-
tinued all ADHD treatment and 5.1% received only BT. Overall, OTS was 27.4% with 
no significant difference between switchers and non-switchers (29.1% vs 25.5%; 
p= 0.281). cOnclusiOns: About half the patients switched from their initial treat-
ment during chart review, mostly due to suboptimal response, with many (16.8%) 
discontinuing ADHD medications. Furthermore, OTS remained low regardless of 
whether a patient switched ADHD therapies. Together, these observations suggest 
currently available ADHD treatments are inadequate for achieving OTS among chil-
dren and adolescents in Europe.
PMH64
PATIENTS’ CHARACTERISTICS AND PATTERNS OF USE OF DEPOT 
ANTIPSyCHOTICS IN SwEDISH PATIENTS wITH SCHIzOPHRENIA
Depont F.1, Rouleau A.2, Osby U.3, Sobocki P.4, Milea D.5
1SC Partners, Paris, France, 2Lundbeck SAS, Issy-les-Moulineaux, France, 3Karolinska Institutet, 
Stockholm, Sweden, 4Pygargus AB, Stockholm, Sweden, 5Lundbeck Singapore PTE LTD., Singapore, 
Singapore
Objectives: To describe patients’ characteristics and patterns of use of depot 
antipsychotics in patients with a diagnosis of schizophrenia in Sweden. MethOds: 
A retrospective analysis was conducted based on longitudinal and population-
based data in the Swedish national health registries. The study sample con-
sisted of adult patients who initiated a treatment with any depot antipsychotic 
for schizophrenia (F20) or schizoaffective disorder (F25) in 2009-2010. Baseline 
clinical characteristics of patients were searched over the year prior to depot 
initiation. Persistence (treatment duration) with depot treatment was assessed 
using a Kaplan-Meier survival analysis until discontinuation or end of the study 
period (31 December 2011). Results: A total of 2,879 patients with a diagno-
sis of schizophrenia or schizoaffective disorder were included. Mean age was 
50.0 years and 54.4% of the patients were male. At baseline, the main psychiatric 
comorbidities were other psychotic disorders (17% of patients), substance use 
disorders (11%) and major depressive disorders (3%). Somatic conditions were 
for dementia patients, caregivers and medical professionals on the basis of a web-
based platform. MethOds: Within the PeKS, involved endusers will be provided 
disease- as well as situation-specific information from existing, evidence-based 
digital information (links, PDFs, videos) but also from local and regional informa-
tion sources. The overall aim is to enable increased knowledge and competence by 
providing situation-specific and on time information. On the other hand, the PeKS 
includes an interactive monitoring tool, thus enhancing (shared) medical decision 
support by connecting patients/caregivers and medical professionals. After the tech-
nical integration of the concept, a running prototype will be available. Results: The 
developed prototype of the ‘Personal eHealth Knowledge Space’ is realized by inte-
grating service-oriented architecture, knowledge engineering, multiagent systems, 
and wearable/portable device technologies. An interactive monitoring tool, based 
on information provided by caregivers will be realized by integrating the ‘Nurses’ 
Observation Scale for Geriatric Patients (NOSGER)’. Individualized information is 
going to be provided through push- and pull mechanisms. cOnclusiOns: Health 
support systems addressing individual dementia patients/caregiver needs have a 
large potential, however they are scarce. eHealthMonitor’s overall objective is to 
significantly increase the individualization of personal eHealth services and thereby 
the quality and patients’ acceptance of electronic health care services for preven-
tion, treatment and care. The research is funded by the European Commission, ICT 
FP7, project ID 287509.
PMH60
PSyCHOACTIvE DRUG USE, POLyPHARMACy AND CO-MORBIDITIES IN NEwLy 
DIAGNOSED PATIENTS wITH PERvASIvE DEvELOPMENT DISORDER IN THE 
PROvINCE OF QUEBEC
Croteau C.1, Dorais M.2, Tarride J.E.3, Mottron L.4, Perreault S.1
1Université de Montréal, Montreal, QC, Canada, 2StatSciences Inc., N.-D. de l Île-Perrot, QC, 
Canada, 3McMaster University, Hamilton, ON, Canada, 4Hôpital Rivière des Prairies, Montreal, 
QC, Canada
Objectives: A number of medication surveys conducted in the U.S. have demon-
strated a high level of psychotropic drug use in patients diagnosed with pervasive 
development disorder (PDD). Medication use is of interest as not many products 
are approved for treatment in autism. Describe drug use in subjects newly diag-
nosed with PDD in Quebec province. MethOds: A cohort study was built by using 
Quebec RAMQ and Med-Echo databases for subjects having a new PDD diagnosis 
(ICD-9 codes: 299.0-299.9) between January 1998 and December 2010. Cohort entry 
date was the date of a first diagnosis confirmed by the absence of PDD diagnosis 
in previous 2 years, and aged less than 26 years. Descriptive analyses of patient 
characteristics were done at cohort entry and drug use profiles were done the 
year prior to, and within the 3 years following diagnosis. Results: A cohort of 
4684 subjects was identified; 78% of patients were male and the age ranges were 
as follows: 41.9% (1-5 years), 31.2% (6-12 years), 12.3% (13-17 years), 14.7% (18-
25 years). Prior to being diagnosed with PDD, 35% received at least 1 psychoac-
tive drug. Methylphenidate was most common in 6-12 year olds (36%) whereas 
antipsychotics were most common in the 13-17 group (28.6%) and in the adult 
population (51.7%). Antipsychotic use was also present in younger children: 5.7% 
in 1-5 year olds and 23% in 6-12 year olds, 1 year after diagnosis. Antipsychotic, 
antidepressant and anticonvulsant usage increased in the 3 years following diag-
nosis, and also with age. cOnclusiOns: Prior to PDD diagnosis, more than a third 
of the patients were on psychotropic medications, a practice that continued and 
increased after diagnosis. Psychoactive drug utilization is high and could be of 
concern if used to compensate for limited access to other treatment modalities 
such as educational and allied health therapies.
PMH61
IS ADjUNCTIvE GUANFACINE-ExTENDED RELEASE ASSOCIATED wITH 
CHANGES IN STIMULANT ADHERENCE AMONG CHILDREN AND ADOLESCENTS 
wITH ATTENTION DEFICIT/HyPERACTIvITy DISORDER IN A MANAGED CARE 
SETTING?
Gajria K.1, Candrilli S.D.2, Meyers J.2, Fridman M.3, Farrand K.1, Hodgkins P.1, Sikirica V.1
1Shire, Wayne, PA, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3AMF 
Consulting, Los Angeles, CA, USA
Objectives: To assess stimulant adherence among pediatric patients with 
attention-deficit/hyperactivity disorder (ADHD) after adding guanfacine extended-
release (GXR) as adjunctive therapy to stimulants in a US managed care set-
ting. MethOds: Data from the MarketScan Commercial Claims and Encounters 
insurance claims database (2009-2011) were used. Patient inclusion criteria were: 
6-17 years old; ≥ 1 ADHD diagnosis (ICD-9-CM code 314.00 or 314.01); ≥ 1 long-acting 
(LA) and/or short-acting (SA) stimulant prescription; continued stimulant therapy 
for ≥ 30 days and ≥ 6 months of continuous insurance coverage pre- and post-
GXR initiation; and nonadherent to stimulant treatment pre-GXR. Adherence was 
assessed using the medication possession ratio [MPR] (range= 0.0-1.0), with MPR 
< 0.80 considered nonadherent. Change in stimulant adherence pre- to post-GXR 
initiation was assessed using an OLS multivariable model, adjusting for patient 
age, sex, and geographic region; GXR dose (last observed), adherence, dose sta-
bilization, and year of initiation; number of non-ADHD prescriptions pre-GXR; 
stimulant MPR pre-GXR; and stimulant received (LA, SA, SA+LA). Results: A total 
of 238 patients nonadherent to stimulants prior to initiating GXR were analyzed; 
38% were female, mean (SD) age was 10.3 (3.3) years, unadjusted pre- and post-
GXR stimulant MPR was 0.51 (0.16) and 0.82 (0.25), respectively, and the change 
in MPR was 0.31 (0.28). Among LA patients (n= 162), mean unadjusted pre-GXR 
stimulant MPR was 0.50, and 0.80 post-GXR; among SA and SA+LA patients (n= 76), 
this was 0.53 (pre-GXR) and 0.88 (post-GXR). The mean adjusted (i.e., post-model 
estimation) change in MPR was 0.29 (95% CI: 0.27-0.32) for LA patients versus 
0.34 (95% CI: 0.31-0.38) for combined SA and SA+LA patients (difference= 0.05; 
P= 0.013). cOnclusiOns: Among patients nonadherent to stimulant treatment, 
prior to initiating adjunctive GXR, adding GXR was associated with positive 
changes in stimulant adherence, with statistically significant differences in the 
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delay dependence. Few studies have explored such a relationship in Continental 
Europe. MethOds: We use data from the DEP-FR study. We ran ordered logisitic and 
heckman regressions. Results: We provide evidence: that there is a positive and 
significant correlation between cognitive, functional and behavioral declines and 
dependence on others, that an increase in dependence on others is associated with 
a decrease in informal care providers’ satisfaction, that there is a linear relationship 
between dependence on others and informal and formal care use. cOnclusiOns: 
Our results provide two main dependence policies perspectives. First, public inter-
ventions should try to reduce dependence through its three main dimensions of 
dependence on others (cognitive, behavioral and functional), and not only focus 
on the functional dimension of dependence. Second, specific measures should be 
implemented to the release of informal caregivers’ burden, which increases with 
dependence on others.
PMH68
HOw wELL DO wE UNDERSTAND THE ECONOMIC BURDEN ASSOCIATED 
wITH DEMENTIA? A FOCUS ON TRENDS IN CARE HOME COSTS AND FUTURE 
PERSPECTIvES IN THE UNITED KINGDOM
Griffiths M., Hamerslag L., Wilson T., Kusel J.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: The prevalence and economic burden of dementia is increasing, and 
in 2007 the UK government declared dementia a national priority. This research 
aims to evaluate trends in care home costs for dementia patients following this 
announcement, and to discuss the implications for the future economic burden 
of dementia. MethOds: PubMed was searched for terms related to ‘cost’, ‘care 
homes’ and ‘dementia’. Horizon scanning was additionally performed for costs 
of care home data in the context of the wider economic burden of dementia. Only 
UK studies published after 2007 were considered, and information from a range of 
sources was assimilated to understand future implications for the economic burden 
of dementia. Results: Four relevant PubMed articles and an additional twelve 
publications from horizon scanning were identified. It was reported that two-thirds 
of care home patients have dementia and that accommodation costs represent the 
major contributor to the cost of dementia (41%). The average annual cost of a care 
room had risen from £25,953 in 2011 to £27,404 in 2012 and this was accompanied 
by a 3.9% deficit in local authority payment increases for care home residents from 
2010 to 2012. It is estimated that by 2043, more than double the current number of 
care home places will be required to match the increase in dementia prevalence, 
and the economic dependency ratio is expected to increase from 24% to 30% over 
the next 15 years. cOnclusiOns: A considerable proportion of dementia patients 
are treated in care homes and, considering the disparity between the rising costs of 
care homes and funding increases, the burden borne by patients and their families 
is increasing. There is therefore an imminent need to develop cost-effective service 
provision for dementia patients; the new remit of NICE in social care may represent 
an important step towards this.
PMH69
ExAMINING THE EFFECTS OF A FUNCTIONAL RESTORATION AND PAIN 
MANAGEMENT PROGRAM AMONG CHRONIC PAIN PATIENTS IN THE TExAS 
wORKERS COMPENSATION SySTEM: PILOT STUDy – PART I
Nwokeji E.D.1, Rascati K.L.1, Nemeth W.C.2, Jordan K.D.2, Novak S.1, Adeyemi A.O.1
1The University of Texas at Austin, Austin, TX, USA, 2RestoreFX, Austin, TX, USA
Objectives: Management of chronic nonmalignant pain (CNMP) is important in 
both primary care and rehabilitative medicine however, the relationships between 
CNMP and the diverse types of addiction and chemical dependency are often 
complex and clinically relevant. The objective of this pilot study was to examine 
the impact of the Functional Restoration and Pain Management (FRPM) Program 
on pain severity outcomes and controlled medication use among CNMP patients 
enrolled in the Texas Workers Compensation (TWC) benefit program. MethOds: 
A retrospective cohort analysis of administrative claims and medical records data 
was conducted among TWC chronic pain patients enrolled in the FRPM Program 
receiving buprenorphine therapy. Prescription utilization patterns and pain severity 
outcomes during a 12-month observation period were examined. Eligible patients 
were ≥ 18 years of age, continuously enrolled as TWC beneficiaries, had a history 
of utilization of chronic pain medications at enrollment, placed on buprenorphine 
therapy, and received services through the FRPM program within the observation 
period defined as date from patient entry into the program to 12 months post-
enrollment. Results: The mean age of eligible participants (N= 18) enrolled in the 
pilot study was 49.6 years ±9.5. A majority of patients were male (61%), white (61%), 
had a chronic pain lumbar diagnosis (45%), depression comorbidity (78%), and a 
substance abuse disorder (39%). Overall, patients showed a significant reduction in 
pain scores (p= 0.032) at month 12 compared to baseline. For controlled medication 
utilization, there was a significant difference in narcotic pain medication use reduc-
tion in Hispanics/Latinos (p= 0.033) compared to other racial/ethnic groups (i.e., 
Whites and African-Americans) at month 12 compared to baseline. cOnclusiOns: 
Though a pilot study, the results suggest that the FRPM program has the potential 
of improving health outcomes of patients with chronic pain, while reducing their 
use of controlled medications. A larger follow-up study is needed to validate and 
expand on these preliminary findings.
PMH70
IMPACT OF AUTISM SPECTRUM DISORDERS ON THE FAMILy – A NATIONAL 
PERSPECTIvE
Vohra R., Madhavan S., Sambamoorthi U.
West Virginia University School of Pharmacy, Morgantown, WV, USA
Objectives: To examine caregiver reported impact of ASD on family as compared 
to impact of other developmental disabilities (DD) and mental health conditions 
(MHC) on family. MethOds: A cross-sectional study using 2009-2010 National 
Survey of Children with Special Health Care Needs on caregivers of children aged 
3-17 years with either ASD, DD, MHC, or both DD and MHC diagnosis (N = 18,136) 
infrequent (4% diabetes and 3% neurological disorders). The most common depot 
antipsychotics prescribed were zuclopentixol (32%), perphenazine (28%) and risp-
eridone LAI (19%). These were prescribed primarily by psychiatrists (85%). Median 
persistence to depot treatment was 195 days. cOnclusiOns: To our knowledge, 
this is the first large database study conducted in Sweden aiming at describing 
the patients’ characteristics and treatment patterns of schizophrenic patients 
treated with depot antipsychotics. It is notable that the current sub-population of 
schizophrenic patients treated with depot does not show substantial psychiatric 
and somatic co-morbidities, possibly due to under-diagnosing of co-morbidities, 
especially somatic diseases, by psychiatrists.
PMH65
ASSESSING THE ECONOMIC BURDEN AND HEALTH CARE UTILIzATIONS OF THE 
UNITED STATES vETERAN PATIENTS DIAGNOSED wITH SCHIzOPHRENIA
Wang L.1, Xie L.2, Li L.1, Kariburyo M.F.2, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
Objectives: To examine the economic burden and health care utilizations of 
schizophrenia in the U.S. veteran population. MethOds: A retrospective database 
analysis was performed using the Veterans Health Administration (VHA) Medical 
SAS datasets from October 1, 2008 to September 30, 2012. Patients diagnosed with 
schizophrenia were identified using International Classification of Disease 9thRevi-
sion Clinical Modification (ICD-9-CM) diagnosis codes 295.xx, and the first diagnosis 
date was designated as the index date. A group of patients without schizophrenia 
of the same age, region, gender and index year were identified and matched by 
baseline Charlson Comorbidity Index (CCI) as the comparison group. Patients in 
both groups were required to be at least 18 years old and have continuous medical 
and pharmacy benefits 1 year pre- and 1 year post-index date. One-to-one propen-
sity score matching was used to compare health care costs and utilizations during 
the follow-up period between the schizophrenia and comparison group patients, 
adjusted for baseline demographic and clinical characteristics. Results: A total of 
171,086 eligible patients were identified for the schizophrenia and control cohorts. 
After 1:1 matching, a total of 70,045 patients were matched from each cohort with 
well-balanced baseline characteristics. Patients diagnosed with schizophrenia had 
significantly higher health care utilization in inpatient (18.12% vs. 2.30%, p< 0.01), 
emergency room (19.67% vs. 6.46%, p< 0.01), office (98.32% vs. 53.26%, p< 0.01), and 
outpatient visits (98.53% vs. 54.16%, p< 0.01). Higher health care utilizations trans-
lated into higher costs for schizophrenic patients including inpatient ($7,228 vs. 
$613, p< 0.01), pharmacy ($1,012 vs. $343, p< 0.01), outpatient ($3,998 vs. $1,302, 
p< 0.01), and total costs ($12,238 vs. $2,260, p< 0.01) relative to patients in the com-
parison group. cOnclusiOns: Schizophrenic patients were associated with a sub-
stantial economic burden compared to their matched controls.
PMH66
DIFFERENCES IN HEALTH CARE RESOURCE UTILIzATION AND ExPENDITURES 
AMONG SCHIzOPHRENIC PATIENTS IN THE UNITED STATES By HEALTH 
INSURANCE STATUS, 2007-2008
Rohwer R., de Moor C.
Mapi Real World Evidence, Lexington, KY, USA
Objectives: To compare health care resource utilization (HRU) among schizo-
phrenic patients in the United States by the type of health insurance and estimate 
the annual expenditures. MethOds: The 2007 National Health and Interview 
Survey (NHIS) data were used for this study (150 schizophrenia cases). Multivariate 
regression was conducted to compare HRU (hospitalizations, physician visits, ER vis-
its) by type of health of insurance (any private, public only, and none). Additionally, 
2008 Medical Expenditure Panel Survey (MEPS) data were linked with the NHIS data 
(29 of the NHIS cases). Means, SE and 95% confidence intervals of prescription and 
total health care annual expenditures were calculated for schizophrenic patients 
by insurance type. Results: Multivariate analysis indicated a significant associa-
tion between the number of hospitalizations, physician visits and ER visits over 
12 months and any private insurance (β = -2.06, SE= 0.84, p= 0.01; -19.69, 8.92, 0.03; 
-22.35, 9.55, 0.02, respectively) compared to no insurance (referent). These same 
associations were not significant for the public only insurance (-0.30, 0.44, 0.16; 
-5.89, 3.91, 0.13; -7.72, 4.09, 0.06, respectively). Mean, SE [95% confidence interval] 
prescription expenditures for schizophrenic patients are similar between private 
insurance holders ($737, 215.3 [312.3-1161.6]) and those without insurance ($718, 
237.0 [249.7-1186.3]), but were higher for public insurance holders ($3781, 897.2 
[2008.1-5553.0]). Mean total health care expenditures for schizophrenic patients are 
similar between private insurance holders ($4000, 1382.4 [1273.9-6726.7]) and those 
without insurance ($4318, 2215.4 [0-8696.6]), but were higher for public insurance 
holders ($12,584, 2452.2 [7739.6-17,428.8]). cOnclusiOns: Private insurance HRU 
for schizophrenic patients is lower than public only insurance holders, followed 
by those without insurance. Seemingly contradictory, a higher expenditure among 
public insurance holders was observed. This observation could be the result of the 
more severe schizophrenic cases having only public insurance. Caution should be 
employed in the use of the expenditure calculations due to the small numbers of 
patients.
PMH67
ExPLORING DEPENDENCE ON OTHERS IN ALzHEIMER’S DISEASE
Rapp T.1, Lacey L.2, Orgogozo J.M.3, Vellas B.4
1University of Paris Descartes, Paris, France, 2JANSSEN Alzheimer Immunotherapy, Dublin, 
Dublin, Ireland, 3Université Bordeaux, Bordeaux, France, 4Gérontopole Toulouse, Toulouse, France
Objectives: The increasing economic importance of dependence on others in the 
elderly population is a major problem in Europe. This problem is very concern-
ing for patients with Alzheimer’s disease, who heavily rely on informal caregivers’ 
assistance. Exploring the relationship between patients’ dependence on others 
and care expenditures is very important when planning future resources for the 
elderly and for predicting the economic consequences of interventions which may 
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MEDICATION USE PATTERNS AND ADHERENCE AFTER INITIATING 
ANTIPSyCHOTICS TREATMENT FOR PATIENTS wITH SCHIzOPHRENIA IN 
TIANjIN, CHINA
Yao X.1, Wu J.1, Liu L.L.2, Ye W.W.2, Xue H.B.H.2, Montgomery W.3
1Tianjin University, Tianjin, China, 2Lilly Suzhou Pharmaceutical Co., Ltd. Shanghai Branch, 
Shanghai, China, 3Eli Lilly Australia Pty Ltd., West Ryde, Australia
Objectives: To describe medication use patterns and adherence rates for 
schizophrenia patients after initiating antipsychotic treatment in Tianjin, 
China. MethOds: Data were extracted from the Tianjin Urban Employee Basic 
Medical Insurance database (2008-2010). Adult patients with a schizophrenia 
diagnosis, newly initiating or restarting antipsychotics (no antipsychotics during 
previous 90 days) with 12-month continuous enrollment after their first observed 
antipsychotic prescription were included. Patients’ medication prescribing patterns 
and antipsychotic adherence are described. Results: A total of 1216 patients were 
identified, with a mean (SD) age of 51.43 (12.48) years, 54.11% female. 83.14% of 
patients initiated with one antipsychotic and 16.86% with ≥ 2 antipsychotics. 37.99% 
of patients were initiated on typical antipsychotics, 52.06% on atypicals, and 9.95% 
on both. A higher portion of typical initiators were co-prescribed antianxiety and 
anticholinergic medications than atypical starters (both p< 0.001). During the follow-
ing 12 months, the majority of patients remained on medications from their initial 
antipsychotic class (80.74% of typical initiators vs. 86.41% of atypical initiators) or 
the same medication (66.45% of typical initiators vs. 70.93% of atypical initiators). 
More typical initiators switched to, or augmented with, atypical antipsychotics than 
atypical initiators to/with typical antipsychotics (19.26% vs. 13.59%, P= 0.011). During 
the following 3, 6 and 12 months, antipsychotic continuation rates (≤ 30 days gap) 
were 50.33%, 23.60%, and 8.88%, respectively. Medication Possession Ratios were low, 
with means (SD) of 0.58 (0.32), 0.44 (0.30), and 0.34 (0.27) for the 3, 6 and 12 months, 
respectively. cOnclusiOns: More individuals with schizophrenia were treated 
with atypicals rather than typical antipsychotics. The majority of patients tended 
to stay with one antipsychotic drug class or the same medication. Patients’ adher-
ence to prescribed antipsychotics was low. This study highlights the importance 
of selecting an effective medication when starting antipsychotic therapy in China. 
However much could be done to improve treatment adherence.
MUSCULAR-SKELETAL DISORDERS – Clinical Outcomes Studies
PMS1
THE IMPACT OF COMORBIDITIES ON UTILITy CHANGES IN LOwER-LIMB 
OSTEOARTHRITIS : KHOALA STUDy
Hosseini K.1, Gaujoux-Viala C.2, Baertschi A.3, Oudot J.3, Rat A.C.1, Guillemin F.1
1CHU Nancy, Clinical Epidemiology and Evaluation; Université de Lorraine, Paris Descartes 
University, APEMAC, EA 4360, Nancy, France, 2• Montpellier I University, Nîmes University 
Hospital, Rheumatology, France • EA 2415, Montpellier I University, Nîmes University Hospital, 
Rheumatology Department, France, Paris, France, 3CHU Nancy, Clinical Epidemiology and 
Evaluation, Nancy, France
Objectives: 1) To determine the minimal important change (MID) of indirect util-
ity score for patients with osteoarthritis (OA) over 3-year follow up, and 2)Estimate 
the impact of comorbidity for patients reaching the MID. MethOds: A total of 878 
patients with symptomatic knee or/and hip OA of KHOALA cohort were included. 
Comorbidity were assessed by Functional Comorbidity Index (FCI). Utility score 
was assessed using SF-6D, and limitation in activities by WOMAC function score 
(0-100,0 is better), at baseline and 3-year. The MID of utility was assessed using 
standard error of measurement (SEM). According to MID, patients were classified as 
negative/positive change or unchanged. Two separate multinomial logistic models 
were fitted to determine predictors of positive or negative change over the MID 
threshold. Both models included sociodemographic characteristics and the mean 
difference of WOMAC score between baseline and 3-year. Results: A total of 650 
OA patients completed the questionnaire at both times. The mean (SD) utility was 
0.664 (±0.110) at baseline and 0.667 (±0.110) at 3-year. Patients have on average 2.5 
(±1.94) comorbidities and a signifcant (p< .0001) decrease of the WOMAC function 
score at 3-year. The MID of SF-6D utility score was 0.067: 147 patients classified with 
negative and 156 with a positive change. In the first model including the number 
of comorbidities, patients with a decrease of the WOMAC function score had an 
increased utility (OR= 0.95; p< .0001). In the second model, patients with pneumo-
logic (OR= 1.88; p= 0.03) or neurologic (OR= 2.73;p= 0.047) disease were likely to have 
improved utility, while patients having a psychiatric disease were less likely to have 
an improvement (OR= 0.54;p= 0.029). cOnclusiOns: According to MID, about half 
of patients had a positive or negative change in their utility score. Compared to 
functional severity of OA, comorbidities have a relatively marginal impact on indi-
rect utility score. This suggests that clinically, considering the functional severity 
of OA remains a first priority.
PMS2
THE IMPACT OF COMMODITIES AND ExTRA-ARTICULAR MANIFESTATIONS IN 
RHEUMATOID ARTHRITIS PATIENTS
Doddapaneni S.1, Khera K.1, Prabhu V.A.1, Nagappa A.N.2, Rau N.R.3
1Manipal College of Pharmaceutical Sciences, Manipal, India, 2Manipal University, MCOPS, 
Manipal, India, 3Kasturba Medical College & Hospital, Manipal, India
Objectives: Rheumatoid arthritis (RA) is a chronic, systemic disease associated 
with comorbidities and extra-articular manifestations (EAM) . The main objective 
of the study was to estimate the frequency and impact of comorbidities and EAM in 
well-defined RA patients. MethOds: A prospective study was conducted at a ter-
tiary care hospital between the years 2009 & 2012. Patients (age ≥ 18 years) with RA, 
fulfilling the revised criteria of the American college of rheumatology (1987 & 2010), 
were enrolled in the study. Standard clinical, laboratory and radiological measures 
of RA and details of comorbidities and EAM were recorded using patient hospital 
records. Results: Of 602 RA patients, 481 (79.9%) females and 121 (20.1%) males 
were present. Mean age of 47.57±12.78 years, mean disease duration of 4.52±4.75 
was conducted. Family impact was assessed as: Financial burden, Employment 
Burden, and Time-related burden. Binary and multinomial logistic regressions 
were conducted to compare likelihood of adverse family impact across ASD, DD 
without ASD, MHC without ASD, and DD and MHC without ASD, after adjust-
ing for socio-demographics, number of special children in the household, child’s 
functional ability, and presence of a physical condition. Results: Majority of 
the sample were older children (6-17 years), Whites, caregivers with ≥ 200% FPL 
income and greater than high school education. Sixteen percent (n= 2,801) of the 
caregivers had a child with an ASD diagnosis. Caregivers of children with ASD 
were more likely to have financial burden than caregivers of children with DD 
(AOR= 1.45, 95% CI= 1.10-1.91) and MHC (AOR= 1.59, 95% CI= 1.33-1.91). There were 
no significant differences in financial burden reports between caregivers of chil-
dren with ASD and those with both DD and MHC. Caregivers of children with ASD 
were also more likely to leave a job (employment), as compared to caregivers of 
children with DD (AOR= 1.57, 95% CI= 1.23-2.00), MHC (AOR= 3.06, 95% CI= 2.51-3.74), 
or both (AOR= 1.73, 95% CI= 1.36-2.20). Caregivers of children with ASD were more 
likely to report time-related burden as compared to caregivers of children with 
MHC (AOR= 2.87, 95% CI= 2.18-3.78) and DD and MHC (AOR= 1.80, 95% CI= 1.32-
2.44). cOnclusiOns: Caregivers of children with ASD are more likely to report 
an adverse family impact as compared to caregivers of children with DD, MHC, 
or both.
PMH71
DEvELOPING A POPULATION-BASED DEMENTIA REGISTRy FOCUSING ON 
PATIENTS AND CARER NEEDS: METHODOLOGICAL CHALLENGES
Gobin J.1, Marinova-Schmidt V.1, Schaller S.U.1, Luttenberger K.2, Richter-Schmidinger T.2, 
Maler J.M.2, Gräßel E.2, Kolominsky-Rabas P.L.1
1Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of 
Erlangen-Nuremberg, Erlangen, Germany, 2University Hospital, Erlangen, Germany
Objectives: With increasing prevalence of dementia worldwide the interest in the 
dementia burden and impact on the health care system is rising. Yet comprehensive 
information about long-term needs and patterns of care of dementia patients and 
informal caregivers is scarce. Dementia specific registries provide an opportunity 
to investigate these aspects by long-term-data analysis. However, so far no inter-
national standards exist for developing a dementia registry. MethOds: An inter-
disciplinary team (psychiatry, public health, psychology, medical sociology, health 
economics and gerontology) established a registry structure in 2012. In the concep-
tion phase, existing registries, studies of dementia and best practice scenarios were 
identified. Features were combined in our concept and inclusion criteria, time for 
follow-up, fields of particular relevance and instruments were determined. A ques-
tionnaire was built and tested in exemplar sites. Results: The pilot study started 
with prospective interviews in January 2013 to evaluate the concept. The inclusion 
criterion is a dementia diagnosis according to ICD-10. Patients are recruited from 
the regional memory clinic during the process of diagnosis. Patient drop outs occur 
after initial inclusion because of other ensured diagnosis such as depression. Both 
patients and caregivers are interviewed separately with internationally approved 
valid instruments. The follow-up will take place after 6, 12 months and annually 
until death or loss to follow-up. cOnclusiOns: Existing dementia registries are 
very rare and heterogeneous in their structure, with currently no standards on 
quality indicators and processes. However, the complexity of dementia requires a 
sophisticated organizational structure for covering all aspects of dementia. Despite 
the challenges, our dementia registry structure provides essential, comprehensive 
and long-term information about the dementia care setting. The research is funded 
by the European Commission, ICT FP7, project ID 287509.
PMH72
EFFECT OF NURSE-LED MEDICATION REvIEwS IN PSyCHIATRIC PATIENTS – AN 
INTERvENTIONAL STUDy
Soerensen A.L.1, Nielsen L.P.2, Lisby M.3, Poulsen B.K.2, Mainz J.4
1Aalborg University, Aalborg, Denmark, 2Aarhus University Hospital, Aarhus, Denmark, 3Aarhus 
University Hospital & Aarhus University, Aarhus, Denmark, 4Aalborg Psychiatric University 
Hospital, Aalborg, Denmark
Objectives: There is an increasing demand for medication reviews to improve 
the quality of prescribing for patients with chronic illness such as psychiatric 
patients. Traditionally, this has been undertaken by physicians. Pharmacists have 
also proven to be a resource in this field but registered nurses are the health profes-
sionals spending most time directly with the patient and very few studies inves-
tigate nurses’ role and potential in improving the appropriateness of medication. 
Therefore, the objective of this study is to investigate the effect of educating nurses 
in general pharmacology and conducting systematic medication reviews using 
computer based screening. The effect is evaluated in a controlled interventional 
study. MethOds: An interventional study including 2 acute psychiatric wards. In 
one ward nurses’ will receive pharmacological training and the other ward will func-
tion as a control. The nurses will perform approximately 250 medication reviews 
followed by medication reviews performed by pharmacologists. Primary outcomes 
are the respective frequencies, types and severity of potential inappropriate pre-
scriptions identified by the nurses and pharmacologists and an estimation of the 
interratervariability between the two professions. Results: The hypothesis is that 
nurse-led medication reviews will reduce potential inappropriate prescribing and 
that training will increase nurses’ ability to identify and report potential inappropri-
ate prescribing. It is assumed that this intervention, in addition to a more appropri-
ate prescribing, will lead to a reduction in length of hospitalization for psychiatric 
patients. cOnclusiOns: The perspective for this study is to add knowledge about 
frequency, types and potential severity of potential inappropriate prescribing for 
psychiatric patients. The study will contribute with information regarding the effect 
of pharmacological training of nurses and possibly improve medication safety for 
psychiatric patients. Results from this study could serve as evidence, when hospital 
management makes decisions on how to accede the need for medication reviews 
as part of an ongoing accreditation process.
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with first oBP prescription (index event) between January 2004–December 2007, 
≥ 50 years of age, with no history of cancer and a minimum of 12 months’ data 
before and 6 months’ after the index event. Follow-up for any osteoporotic frac-
ture was until December 2008. Persistence was defined as duration of continuous 
oBP use with no gaps > 3 months; compliance was assessed using the medica-
tion possession ratio (MPR; proportion of time with treatment available). HRU 
was evaluated using total primary care contact (including prescriptions), and all 
specialist referrals and hospitalisations. Analyses were stratified by persistence 
and compliance. Results: A total of 21,717 patients were included (mean age, 
73.5 years). Between 2004–2007, fracture rates per patient–year were: 0.14 (95% CI: 
0.12, 0.16; group with MPR < 80%) and 0.11 (0.10, 0.12; MPR ≥ 80%) for patients with 
12–24 months’ persistence vs 0.09 (0.08, 0.10) and 0.07 (0.06, 0.08), respectively, 
for patients with ≥ 36 months’ persistence. Hospitalisation rates were 0.38 (0.34, 
0.42; MPR < 80%) and 0.30 (0.29, 0.32; MPR ≥ 80%) for patients with 12–24 months’ 
persistence vs 0.55 (0.52, 0.59) and 0.18 (0.17, 0.19), respectively, for patients with 
≥ 36 months’ persistence. Among patients who discontinued oBPs and had < 12 
months’ persistence and MPR ≥ 80% before discontinuation, fracture rates were 
0.02 (0.01, 0.03) and 0.09 (0.07, 0.12) in the first and second 6 months following 
discontinuation, respectively, and hospitalisation rates were 0.09 (0.07, 0.11) and 
0.48 (0.42, 0.55), respectively. cOnclusiOns: Outcomes associated with oBPs were 
improved with longer persistence and higher compliance. However, in patients 
with < 12 months’ persistence, protection against fractures and hospitalisation 
diminished 6 months after discontinuation of oBPs.
PMS6
INDIRECT COMPARISON OF jOINT DAMAGE PREvENTION wITH ADALIMUMAB 
v. ABATACEPT, EACH IN COMBINATION wITH METHOTRExATE, IN EARLy 
RHEUMATOID ARTHRITIS
Wu E.Q.1, Cifaldi M.2, Diener M.3, Kaltenboeck A.3, Ganguli A.2, Bergman M.4
1Analysis Group, Inc., Boston, MA, USA, 2AbbVie Inc., North Chicago, IL, USA, 3Analysis Group, 
Inc., New York, NY, USA, 4Taylor Hospital, Ridley Park, PA, USA
Objectives: The AMPLE trial concluded comparable efficacy of adalimumab (ADA) 
and abatacept (ABA) after one-year methotrexate (MTX) combination treatment for 
rheumatoid arthritis (RA). This study compared effects of adalimumab v. abatacept, 
each in MTX combination, on progressive RA joint damage, adjusting for study 
population characteristics. MethOds: Two placebo-controlled trials in early RA, 
PREMIER (ADA+MTX v. MTX) and AGREE (ABA+MTX v. MTX) were selected based on 
design and comparability of enrollment criteria. Patient-level data from PREMIER 
were adjusted, using propensity score weighting, to match average baseline char-
acteristics from AGREE, including RA duration and clinical measures. Radiographic 
progression (RP) was a change in total Sharp score (TSS) > 0 (modified TSS in 
PREMIER and Genant-modified TSS in AGREE). Joint space narrowing (JSN) and joint 
erosion (JE) scores in PREMIER were scaled to proportion with AGREE measures. 
After re-weighting, one-year incremental effects were compared for ADA+MTX vs. 
ABA+MTX, including RP rates, mean JSN and JE score changes from baseline, disease 
activity score (DAS28) remission rates, and American College of Rheumatology 50% 
improvement (ACR50). Results: Compared to AGREE patients, PREMIER patients 
were slightly older, more likely to be Caucasian, had longer RA duration, higher 
C-reactive protein levels, more severe joint damage, and lower functional impair-
ment at baseline. After re-weighting, more ADA+MTX patients had no RP after one 
year compared to ABA+MTX patients (27.0% v. 8.3%; p= 0.02). Mean improvements in 
JSN (-1.41 v. -0.04) and JE (-1.54 v. -0.39) scores from baseline were numerically greater 
with ADA+MTX; statistical significance could not be assessed as standard errors 
were not published for AGREE. No statistically significant differences were observed 
in DAS28 remission rates (p= 0.47) and ACR50 responses (p= 0.72). cOnclusiOns: 
Although both combination therapies yielded similar disease activity measures at 
one year in early RA patients, ADA+MTX offered greater protection against radio-
graphically-confirmed joint damage than ABA+MTX.
PMS7
META-ANALySIS OF EFFICACy OF ETANERCEPT FOR TREATMENT OF PSORIATIC 
ARTHRITIS
Aggarwal S., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
Objectives: Psoriatic arthritis (PA) is an inflammatory disease affecting joints and 
connective tissues. The anti-tumor necrosis factor (TNF) biologics are increasingly 
being used in patients who have failed traditional disease-modifying antirheu-
matic drugs. Etanercept has shown efficacy in treatment of PA. The objective of 
this study was to conduct meta-analysis and present total evidence for etanercept 
in treatment of PA. MethOds: For this meta-analysis we included randomized 
controlled trials (RCTs)evaluating etanercept for the treatment of PS. RCTs study-
ing adult populations with active and progressive PA with an inadequate response 
to previous DMARD therapy were eligible. Trials conducted among PA populations 
with prior experience with anti-TNF agents, including an inadequate response, 
were excluded. A systematic literature search for Etanercept trials was undertaken 
for the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was 
collected for the study size, interventions, year, and the three outcomes HAQ, PASI 
and PsARC. For meta-analysis, random effects and fixed effects models were used 
to obtain cumulative statistics. Results: Two RCTs with a total of 131 patients 
were identified. The pooled response rates for Etanercept for PsARC were 75% (95% 
CI 60%-90%), for HAQ were 59% (95% CI 46%-72%), and for PASI were 24% (95% CI 
13%-34%). The pooled response rates for placebo for PsARC were 30% (95% CI 26%-
35%), for HAQ were 5% (95% CI 1%-9%), and for PASI were 3% (95% CI 0%-7%). For 
PsARC the cumulative relative risk with Etanercept versus placebo was 0.40 (95% 
CI 33%-48%). For HAQ, the cumulative relative risk with placebo versus Etanercept 
was 0.08 (95% CI 5%-12%). For PASI, the cumulative relative risk with placebo ver-
sus Etanercept was 0.14 (95% CI 8%-20%). cOnclusiOns: Meta-analysis shows 
Etanercept offers patients with psoriatic arthritis an effective therapeutic option 
for control of their disease.
years and mean days of hospitalization 6.44±4.47 were observed. Disease duration 
of more than 2 years was observed in 336 (55.8%) patients. RA alone, RA with 1 
comorbidity, RA with 2 comorbidities, RA with 3 comorbidities, RA with 4 comorbidi-
ties, RA with 5 comorbidities, were present in 227 (37.7%), 171 (28.4%), 118 (19.6%), 
58 (9.6%), 19 (3.2%), 9 (1.5%) patients respectively. The most common comorbidities 
were diabetes mellitus 114 (18.94%), hypertension 104 (17.28%) and EAM was anemia 
351 (58.30%). cOnclusiOns: Comorbidities and EAM were present in substantial 
proportion of RA patients. Diabetes mellitus, hypertension and anemia were found 
to be most common in our setting. Early diagnosis and management are necessary 
to reduce their impact on therapeutic outcomes in RA.
PMS3
IMPACT OF COMORBIDITy BURDEN ON REAL-wORLD HEALTH CARE COSTS OF 
RHEUMATOID ARTHRITIS PATIENTS IN TURKEy
Baser O.1, Burkan A.2, Baser E.3, Koselerli R.2, Ertugay E.2, Altinbas A.4
1STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA, 2Social 
Security Institution, Ankara, Turkey, 3STATinMED Research, Ankara, Turkey, 4Diskapi Yildirim 
Beyazi Education and Research Hospital, Gastroenterology Clinic, and STATinMED Research, 
Ankara, Turkey
Objectives: To determine the impact of comorbidity burden on real-world health 
care costs of rheumatoid arthritis (RA) patients in Turkey, using nationwide real-
world data. MethOds: Study data was obtained from MEDULA (2009-2011). Using 
International Classification of Disease Tenth Revision Clinical Modification (ICD-
10-CM) codes, adult RA patients (ages 18-99) were identified for the identification 
period (June 1, 2010 - December 31, 2010). Patients were required to have two RA 
diagnoses at least 60 days apart, and were grouped as prevalent and incident cases. 
The date of the first RA claim was identified for each patient and designated as 
the index date. Total health care costs were examined over the 12-month period 
following the index date. To control for clinical characteristics, a comorbidity 
index score for each patient during the baseline period was calculated using the 
Elixhauser method. This index is the sum of a comprehensive set of 30 present 
comorbid conditions, and is widely-used in the outcomes research field to deter-
mine patient health status. Individual comorbidities, such as diabetes, respira-
tory diseases, allergy and cardiovascular diseases, were identified using ICD-10 
codes. Results: A total of 2,613 patients met all inclusion criteria (693 incident; 
1,920 prevalent patients). Prevalent patients had higher comorbidity index scores 
relative to incident patients. Nearly 35% of incident and 40% of prevalent patients 
had at least one cardiovascular, diabetic, respiratory, or allergy comorbid condi-
tion prior to the diagnosis. The mean Elixhauser Comorbidity Index score was 
calculated as 5.31 for incident and 5.7 for prevalent patients. Prevalent patients 
with respiratory and cardiovascular comorbid conditions incurred additional 
health care costs of € 302 and € 283 respectively. For incident patients, respiratory 
comorbid conditions increased the health care costs with € 916. cOnclusiOns: 
Respiratory comorbid conditions were associated with health care costs for both 
prevalent and incident RA patients in Turkey.
PMS4
EFFECTS OF CLAIMS-BASED RHEUMATOID ARTHRITIS SEvERITy ON BIOLOGIC 
THERAPy USE AND HEALTH CARE COSTS IN TURKEy
Baser O.1, Baser E.2, Altinbas A.3, Burkan A.4
1STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA, 2STATinMED 
Research, Ankara, Turkey, 3Diskapi Yildirim Beyazi Education and Research Hospital, 
Gastroenterology Clinic, and STATinMED Research, Ankara, Turkey, 4Social Security Institution, 
Ankara, Turkey
Objectives: To apply a previously validated claims-based severity index for rheu-
matoid arthritis (SIFRA) to prevalent rheumatoid arthritis (RA) groups in Turkey 
and assess the effect of claims-based RA severity on health care costs and bio-
logic use. MethOds: The Turkish national health insurance database MEDULA 
(01JUN2009-31DEC2011) was used for the study. Prevalent RA patients were required to 
be age 18-99 with two RA diagnoses ≥ 60 days apart and continuous enrollment 1 year 
pre- (baseline period) and post-index date (follow-up), which was the first RA claim 
during the identification period (01JUN2010-31DEC2010). SIFRA was calculated for the 
baseline period. For the follow-up period, total health care costs and biologic use were 
examined. To determine health care costs, generalized linear models were applied, 
and multivariate logistic regression determined the effect of SIFRA on outcome meas-
ures for biologic use. Results: A total of 1,920 RA patients were identified. The mean 
SIFRA score was 14.21. There was a significant variation in scores across cities. Study 
results confirmed increased biologic use in more severe patients. After adjusting for 
differences in age, gender, region and comorbidity index, patients in the high SIFRA 
tercile were 5.16 times more likely to be prescribed biologics (p< 0.001, confidence 
interval [CI]: 3.46-7.69), and incurred more annual health care costs in the amount of 
€ 2,091 (p< 0.001, CI: € 1,557-€ 2,625) than those in the low SIFRA tercile. cOnclusiOns: 
This study showed that RA severity is a significant determinant of health care costs 
and biologic therapy use. Biologic use was positively correlated with the severity score. 
According to severity scores, the total medical costs of RA patients in Turkey ranged 
from € 1,435 to € 3,275. Since statistically omitting a variable from population models 
provides biased and inconsistent estimates, any comparative effectiveness studies 
on RA treatment should include severity scores in the analysis.
PMS5
THE IMPACT OF PERSISTENCE AND COMPLIANCE wITH ORAL 
BISPHOSPHONATES ON FRACTURE RATES ASSESSED USING THE CLINICAL 
PRACTICE RESEARCH DATALINK (CPRD) IN THE UNITED KINGDOM
Feudjo Tepie M.1, Taylor A.2, Roddam A.1, Critchlow C.3, Iqbal M.2, Ferguson S.1, Bayly J.4
1Amgen Ltd., Uxbridge, UK, 2Amgen Ltd., Cambridge, UK, 3Amgen Inc, Thousand Oaks, CA, USA, 
4University of Derby, Derby, UK
Objectives: To assess the impact of persistence and compliance on fracture 
rates and health care resource use (HRU) in women treated with oral bispho-
sphonates (oBPs). MethOds: This analysis of the UK CPRD included women 
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intraoperative revision for malplaced screws during the index procedure. Results 
of 10 case series and a European registry show rates of pedicle screw placement 
accuracy (0 mm to ≤ 2 mm) between 95% and 100% with 3D O-arm surgical imag-
ing with navigation compared to 84% - 95% reported for various current practice 
options from multiple meta-analyses. In addition, accuracy rates of between 72% 
and 92% have been reported for 2D C-arm without navigation. Economic studies 
demonstrated 3D O-arm surgical imaging with navigation has the potential to 
reduce the cost of fusion procedures in Europe and the USA by negating the need 
for pre-operative and post-operative imaging associated with current standard-
of-care, reducing the need for reoperations for screw revision, shortening length 
of procedures and OR time. It has been estimated that it could reduce the cost 
of hospitalization for spinal surgery by at least 3.8%. cOnclusiOns: Current 
evidence shows 3D O-arm surgical imaging with navigation substantially reduces 
the human and financial burden of patients during spinal stabilization surgery 
compared with standard practice.
PMS11
EvALUATING THE EFFICACy OF BIOSIMILAR INFLIxIMAB wITH THE ACR50 
RESPONSE IN PATIENTS wITH RHEUMATOID ARTHRITIS; A META-ANALySIS IN 
BAyESIAN FRAMEwORK
Brodszky V., Gulacsi L., Balogh O., V. Hevér N., Baji P., Péntek M.
Corvinus University of Budapest, Budapest, Hungary
Objectives: To identify all relevant literature on clinical efficacy and safety evi-
dence for biosimilar infliximab (CT-P13) and comparator biological medications in 
rheumatoid arthritis and to conduct an up-to-date meta-analysis. MethOds: The 
following comparators were considered for this analysis: abatacept, adalimumab, 
certolizumab, etanercept, golimumab, infliximab, rituximab and tocilizumab. A 
MEDLINE search was conducted until March 2013. The Cochrane Highly Sensitive 
Search Strategy was applied to identify randomized controlled publications and was 
combined with ‘arthritis, rheumatoid’ MeSH terms and drug names. Randomized, 
controlled, clinical trials with adults with moderate-to-severe RA and reporting end-
points for 6 months where the full paper can be obtained were included. Direct and 
indirect evidences were combined in a mixed treatment comparisons in a Bayesian 
framework. Efficacy measured by ACR50 endpoint and frequency of serious adverse 
events at 24-30 weeks were analysed. Results: Altogether 41 trials were included 
into current meta-analysis. The relative odds ratios (and 95% credible intervals) for 
ACR50 of biosimilar infliximab treatments compared to abatacept, adalimumab, cer-
tolizumab, etanercept, golimumab, rituximab, tocilizumab and infliximab were 1.0 
(0.3-3.8), 0.9 (0.2-3.4), 0.3 (0.1-1.4), 1.0 (0.2-4.2), 1.2 (0.3-5.1), 0.9 (0.2-3.6), 0.5 (0.1-2.2), 
1.0 (0.3-3.2), respectively. Similarly, relative odds ratios for serious adverse events 
were 1.9 (0.8-4.8), 2.0 (0.6-5.8), 0.7 (0.2-2.1), 2.0 (0.8-5.7), 1.5 (0.5-4.2), 1.1 (0.7-2.0), 1.3 
(0.8-2.2), 1.3 (0.8-2.1), respectively. cOnclusiOns: The results showed that efficacy 
and safety of biosimilar infliximab is not significantly different from innovator 
infliximab and from other biologics.
PMS12
SySTEMATIC REvIEw COMPARING THE EFFICACy AND SAFETy OF 
COLLAGENASE CLOSTRIDIUM HISTOLyTICUM (xIAFLEx®) INjECTION 
wITH SURGICAL FASCIECTOMy FOR THE TREATMENT OF DUPUyTREN’S 
CONTRACTURE
Sugden P.1, Cottrell S.1, Tilden D.1, Ballmer A.2
1THEMA Consulting Pty. Limited, Pyrmont, Australia, 2Actelion Pharmaceuticals Australia, 
Belrose, Australia
Objectives: To compare the efficacy and safety of collagenase clostridium his-
tolyticum (CCH, Xiaflex®) injection with surgical fasciectomy for the treatment 
of Dupuytren’s contracture (DC). MethOds: Systematic review and qualitative 
synthesis of comparative and non-comparative studies reporting efficacy (clini-
cal success, recurrence of contracture) and safety (complication) outcomes for 
patients undergoing fasciectomy for DC. Informal non-statistical comparison with 
outcomes from 3 pivotal placebo controlled trials and a long term follow-up study 
of DC patients treated with CCH. Results: Sixty-eight studies of fasciectomy were 
identified for inclusion in the review: 61 case series (52 retrospective; 9 prospec-
tive); 3 randomised controlled trials (RCTs), none of which permitted either a direct 
comparison with CCH or an indirect comparison via a common comparator; 1 RCT 
follow-up study; 2 prospective uncontrolled studies; 1 postal survey. Studies varied 
in terms of fasciectomy technique employed. Follow-up ranged from only immedi-
ately post-operatively up to 35 years post-operatively. Definitions of surgical success 
and recurrence varied, and were frequently ill-defined or less stringent than the 
robust definitions used in the CCH trials. In studies of fasciectomy where defini-
tions were judged as reasonably comparable to those used in the CCH trials (clinical 
success: 14 studies; recurrence: 40 studies), clinical success and recurrence rates for 
CCH and fasciectomy were comparable (clinical success: 63% vs 69% respectively, 
recurrence: 28% vs 21% at 4 years, respectively). Complication rates were greater 
for fasciectomy than for CCH. These included digital nerve or artery injury (3.3% vs 
0%), complex regional pain syndrome (3.6% vs 0.04%), joint stiffening (8.9% vs 0%), 
wound infection (6.2% vs 0%), and paraesthesia (4.3% vs 0%). Tendon ruptures were 
reported with CCH, but were infrequent (0.07%). cOnclusiOns: CCH and surgical 
fasciectomy can be reasonably considered as comparable in terms of efficacy for 
the treatment of DC and superior in terms of safety.
PMS13
COMPARATIvE EFFECTIvENESS OF ACTIvE vERSUS SHAM ACUPUNCTURE 
vERSUS USUAL CARE IN THE MANAGEMENT OF CHRONIC, NON-CANCER PAIN 
IN PRIMARy CARE
Saramago P.1, Weatherly H.1, Manca A.2, Sculpher M.J.1, MacPherson H.1
1University of York, York, UK, 2University of York, Heslington, UK
Objectives: To examine the effectiveness of acupuncture net of sham effect and 
usual care, measured using EQ-5D, in the management of chronic, non-cancer pain 
in primary care. Systematic reviews of acupuncture for the conditions osteoarthritis 
PMS8
EQ-5D UTILITy wEIGHTS ASSOCIATED wITH RESPONSE TO TREATMENT wITH 
MATRIx APPLIED AUTOLOGOUS CULTURED CHONDROCyTES (MACI) IMPLANT 
AND MICROFRACTURE FOR CARTILAGE DEFECTS OF THE KNEE
Saris D.1, Brittberg M.2, Mehin N.3, Dehle F.4, Dowton D.4, Kili S.5, Price A.6
1University Medical Center Utrecht, Utrecht, The Netherlands, 2Region Halland Orthopaedics, 
Kungsbacka, Sweden, 3Sanofi Biosurgery, Paris, France, 4OptumInsight, Sydney, Australia, 5Sanofi 
Biosurgery, Oxford, UK, 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal 
Sciences (NDORMS), Oxford, UK
Objectives: SUMMIT, a 2-year, multicenter, randomised trial, demonstrated signifi-
cant improvements in pain and function with matrix applied autologous cultured 
chondrocytes (MACI) implant versus microfracture in patients with symptomatic 
knee cartilage defects (NCT00719576). We present post-hoc results of the impact of 
treatment response on EQ-5D utility scores, and the overall incremental impact of 
treatment with MACI compared with microfracture over 2 years. MethOds: Patients 
(aged 18-55) with Outerbridge Grade III/IV focal cartilage defect ≥ 3.0cm2were ran-
domised to receive MACI implant (n= 72) or microfracture (n= 72). Response to treat-
ment was defined as ≥ 10-point improvement from baseline in both the Knee Injury 
and Osteoarthritis Outcome (KOOS) pain and function scores at year 2. EQ-5D was 
evaluated at baseline, and years 1 and 2. Patients’ EQ-5D responses were scored using 
UK-tariffs. Utility values associated with responders and non-responders were esti-
mated based on results from both treatment arms combined. Incremental quality-
adjusted life year (QALY) gains were derived by multiplying the difference in response 
rates between the treatments with the difference in utility between responders and 
non-responders. Results: The mean utility score for all patients (n= 142) at base-
line was 0.481±0.296. Responders (n= 111) had an improvement in mean utility score 
from baseline of 0.352 (0.833-0.481) compared with 0.033 for non-responders (n= 29; 
0.514-0.481) at year 2. Significantly more patients treated with MACI responded to 
treatment than with microfracture (87.5% vs. 68.1%, respectively; p= 0.016), result-
ing in an incremental QALY gain of 0.11 for MACI compared with microfracture over 
2 years. cOnclusiOns: At baseline, patients with chondral defects experienced a 
substantially reduced HRQoL. Significantly more patients responded to treatment 
with MACI versus microfracture, and this response was associated with substantial 
improvements in HRQoL. In this population, the higher response rate for MACI resulted 
in an incremental QALY gain of 0.11 compared with microfracture over 2 years.
PMS9
EARLy RESPONSE TO CERTOLIzUMAB PEGOL IN RHEUMATOID ARTHRITIS 
PREDICTS OUTCOME AT ONE yEAR
Berenbaum F.1, Pham T.2, Fautrel B.3, Joubert J.M.4, De Chalus T.4, Riou França L.5, 
Claudepierre P.6
1CHU Saint-Antoine, Paris, France, 2CHU Sainte-Marguerite, Marseille, France, 3CHU Pitié-
Salpétrière, Paris, France, 4UCB Pharma, Colombes, France, 5Phisquare Institute, Paris, France, 
6Groupe Hospitalier Henri Mondor, Créteil, France
Objectives: Treat-to-target strategies for the treatment of rheumatoid arthritis 
(RA), as recommended in current treatment guidelines, require the use of reliable 
early markers of treatment response in order to adapt therapy in a timely way in 
patients with insufficient response. The objective of this study was to evaluate 
and compare the performance of different clinical indicators in predicting clini-
cal response at one year. MethOds: This was a post-hocanalysis of data from the 
RAPID1 randomised, placebo-controlled Phase III study. A total of 382 severe RA 
patients treated with certolizumab pegol 200mg and no prior TNF inhibitor were 
assessed by Week 12 (bW12) and at Week 52 (W52). “Insufficient response” was 
defined using the ACR response criteria, compared to baseline, DAS28 score (Δ < 1.2), 
HAQ score (Δ < 0.22) and CDAI (score< 22). The ability of insufficient response to 
these markers bW12 to predict failure to achieve ACR50 at W52, was compared in 
terms of positive predictive value (PPV), specificity and sensitivity. Results: At 
W52, 149 (38.1%) patients met the ACR50 response criterion. For all bW12 outcome 
indicators, the specificity and the PPV was > 80%. The higher PPVs were observed 
for bW12 ACR20 non response (1.00 [95%CI: 0.93-1.00]), bW12 reduction in DAS28 
(0.95 [95%CI: 0.82-0.99]) and bW12 CDAI score (0.93 [95%CI: 0.85-0.97]). For bW12 
ACR20 non response, bW12 reduction in DAS28 and bW12 CDAI score, specificities 
were respectively 1.00 (95%CI: 0.97-1.00), 0.99 (95%CI: 0.94-1.00) and 0.95 (95%CI: 
0.90-0.98). The highest sensitivity was observed for the bW12 ACR50 (0.70 [95%CI: 
0.63-0.76]). cOnclusiOns: All these early response markers have high PPV and 
high specificity but low-to-moderate sensitivity: 80% to 100% of patients identified 
as “insufficient-responders” by W12 would fail to fulfil the ACR50 response at W52. 
Such predictability data for certolizumab pegol should help physicians to make early 
decisions about the potential discontinuation of the treatment.
PMS10
THE 3D O-ARM SURGICAL IMAGING SySTEM wITH NAvIGATION EFFECTIvELy 
AND ECONOMICALLy ADDRESSES THE CHALLENGES OF SPINAL STABILIzATION 
PROCEDURES
Annoni E.1, Joedicke H.1, Barnett G.S.2
1Medtronic International, Tolochenaz, Switzerland, 2Gillian Barnett & Associates Ltd., 
Dunfanaghy, County Donegal, Ireland
bAckgROund: Inaccurate pedicle screw placement and neurological or vascu-
lar injury during spinal instrumentation procedures is both costly and prevent-
able. Objectives: To determine the comparative efficacy or effectiveness and 
value for money of the 3D O-arm Surgical Imaging System with Navigation during 
spinal stabilization surgery compared with standard practice. MethOds: A search 
of Medical and Health Economic electronic databases (Embase, PubMed, HEED, 
NHS EED, Cochrane) and conference abstracts up to Nov. 2012 was conducted to 
identify studies evaluating the effectiveness, efficacy and economics of 3D surgical 
imaging with navigation. No time or language restrictions were applied. Results: 
Compared with current practice options, the 3D O-arm surgical imaging with navi-
gation was shown to significantly increase the accuracy of instrument placement, 
reduce surgeons’ and patients’ exposure to radiation, and offer the opportunity for 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A557
PMS16
UPTAKE OF DENOSUMAB IN THE TREATMENT OF OSTEOPOROSIS IN THE CzECH 
REPUBLIC
Fuksa L., Vytrisalova M.
Charles University, Faculty of Pharmacy, Hradec Kralove, Czech Republic
Objectives: The objective was to analyze current trends in consumption as well 
as prescription practice pattern of the new anti-RANKL monoclonal antibody 
denosumab in the treatment of osteoporosis since its introduction onto the mar-
ket in the Czech Republic in 2011. MethOds: The prescription-based database of 
the General Health Insurance Company (VZP) of the CR that covers approximately 
62% of the Czech population was used as the data source. An insured person with 
a recorded prescription for denosumab in the period of interest was defined as a 
patient. The obtained epidemiological and costing data were also confronted with 
the prediction in the budget impact analysis in the public reimbursement dossier 
accessible in the State Institute for Drug Control files. Results: A total of 3119 (158) 
patients (men) treated with denosumab were identified in the first year, i.e. between 
August 2011 and July 2012. The median age of patients was 73 years. Of the patients 
prescribed denosumab in the first half-year, 84% received the second dose within 
the observed period of one year, of which 85% within the authorized period of 6 
months (+-1 month). This new drug was most often prescribed by physicians trained 
in internal medicine (47%) and rheumatology (30%). The cumulative costs for VZP 
of the drug were CZK 27.3 mil (EUR 1.1. mil) in the first year. cOnclusiOns: The 
uptake of denosumab has been rapid and agrees with the predictions presented by 
the manufacturer before the launch of the drug. This preliminary data also suggest 
that both the prescribing doctors and the patients filling the prescriptions follow 
the dosing schedule.
PMS17
THE USE OF BIOLOGIC DRUGS FOR THE TREATMENT OF RHEUMATOID 
ARTHRITIS IN ITALy
Heiman F.1, Katz P.1, Pegoraro V.1, Di V.irgilio R2
1CSD Medical Research S.r.l., Milan, Italy, 2Pfizer Pharmaceuticals, Rome, Italy
Objectives: To describe the clinical profile of patients with rheumatoid arthri-
tis (RA) treated with biologic agents within the former Italian centers “Antares” 
where autoimmune diseases are treated. MethOds: This study analyzed data from 
patient diaries (PDS), which involved 70 rheumatologists that are regular prescribers 
of biological treatments for rheumatoid arthritis and were recruited by telephone. 
The patient diaries were completed via web. Results: Study population consisted 
of 206 (45.9%) patients with RA, 160 (35.6%) with psoriatic arthritis, 61 (13.6%) with 
ankylosing spondylitis, 14 (3.1%) with Juvenile idiopathic arthritis and 8 (1.8%) with 
early RA. Female gender prevailed, while the most numerous age group was the 
one that ranged from 50 to 60 years. The disease was mostly diagnosed before 50 
years old and, despite in the group of patients treated with biologic drugs for more 
than 3 months the percentage of subjects with a value of HAQ less than 1 is higher 
when compared with those of patients whose treatment has begun more recently, 
the proportion of patients with a value of HAQ between 2 and 3 is still 40.0%. The 
same, half of the subjects treated for more than 3 months still have a moderate or 
high disease activity (DAS28 ≥ 3.2). cOnclusiOns: The study sample was in line 
with the literature concluding that it is representative of the Italian context. The 
fact that there is a proportion of patients treated with biological therapy for more 
than three months, as well as an important number of patients who have been 
treated with more than one biologic drugs, and that have a perception of quality of 
life rather low and / or a disease activity state rather active, leads to conclude that 
there is still a type of patient for which new therapeutic options should be evaluated.
PMS18
ESTIMATED OSTEOPOROTIC POPULATION AND THE RELATED MEDICATION 
CONSUMPTION IN MUNICIPALITy LEvEL – DISCREPANCIES OBSERvED 
THROUGH DATA vISUALIzATION APPROACH
Säävuori N.1, Tyrväinen V.2, Purmonen T.3
1Oy Medfiles Ltd., Vantaa, Finland, 2Proper Ltd., Joensuu, Finland, 3Oy Medfiles Ltd., Kuopio, 
Finland
Objectives: Osteoporosis is a common health problem among elderly popula-
tion. Patients with osteoporosis are exposed to low-energy fractures. The preva-
lence of the disease varies significantly throughout the country due to the strong 
correlation with demographic factors. National guidelines recommend secondary 
prevention for all osteoporosis patients suffering from low-energy fractures. The 
aim of treatment is to prevent further fractures. In order to effectively allocate the 
resources needed for osteoporosis treatment, it is essential to know the number 
of patients and treatment practices in local level. MethOds: Local registry data 
was used to estimate the total population with low-energy fractures, as well as 
to recognize the differences in treatment of osteoporosis in each hospital district 
(n= 21) and municipality (n= 320). Data on hip fractures from year 2009 was extrapo-
lated to year 2012 using demographic data. The overall prevalence of low-energy 
fractures was estimated trough a distribution of different fracture types available 
from literature. A map-based application was built (Tableau 8) to visualize the dif-
ferences in the prevalence and treatment of osteoporosis across Finland. The model 
enables comparison between municipalities or hospital districts. Results: The 
estimated number of osteoporotic fractures was 1733, in a hospital district with 
250,000 inhabitants (Northern-Savo). The estimated prevalence rates in different 
municipalities within the hospital district varied between 0.52–1.7/100 inhabit-
ants. Simultaneously, basic reimbursement for medical treatment (ATC:M05B) was 
paid for 1.2/100 inhabitants - the range among elderly population (> 65y) was 3.21– 
6.56/100 inhabitants. cOnclusiOns: There are significant local differences in the 
prevalence of osteoporosis as well as in its treatment. The population demographics 
do not explain the observed differences in the consumption of osteoporosis medica-
tion between different municipalities. The developed map-based application gives 
multiple possibilities to analyze these issues through data visualization. With this 
approach the interventions may be targeted to areas needing it the most.
of the knee, musculoskeletal pain and headache have been published however no 
reviews have incorporated the latest trial evidence from the recent large scale high 
quality RCTs to generate EQ-5D scores. MethOds: An individual patient level data 
(IPD) based Mixed Treatment Comparison (MTC) was undertaken using a database 
of 28 recent, high quality RCTs containing observations for over 18,000 patients. 
The analysis evaluated the effectiveness of acupuncture in terms of continuous 
outcomes, for each of the three conditions over a three month time horizon, map-
ping generic and disease-specific measures to generate EQ-5D scores and using 
published mapping algorithms unless none were available. Results: Acupuncture, 
net of sham, is more effective in that it generates greater EQ-5D scores compared to 
usual care in the management of chronic, non-cancer pain in primary care. Using 
a random effects IPD MTC, the change in EQ-5D scores from baseline to 3 months 
was mean 0.0419 (95% credibility interval 0.0066 to 0.0765) for acupuncture net 
of sham and 0.0573 (95% credibility interval 0.0139 to 0.1006) for acupuncture vs 
usual care. cOnclusiOns: Based on EQ-5D scores, this analysis suggests that 
acupuncture, is the most effective option. The analyses synthesise effectiveness 
evidence using MTC of IPD whilst controlling for sham effect. This analysis is an 
intermediate step to inform a full cost-effectiveness analysis to support decision-
making in the UK.
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APPLICATION OF A DATA vISUALIzATION TOOL: TREATMENT PATTERNS OF 
vETERAN PATIENTS wITH ANKyLOSING SPONDyLITIS
Baser O.1, Wang L.2, Li L.2, Huang A.2, Xie L.3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, 
Dallas, TX, USA, 3STATinMED Research, Ann Arbor, MI, USA
Objectives: As outcomes research methodologies advance, they should increas-
ingly allow access by different disciplines as clinicians, epidemiologists, econo-
mists, and statisticians interact frequently. A data visualization tool can present 
complex patterns effectively to a diverse audience. The objective of this study 
was to present treatment patterns among Veterans Health Administration (VHA) 
patients diagnosed with ankylosing spondylitis (AS) using advanced data visuali-
zation techniques. MethOds: Using the VHA Medical SAS®dataset, adult patients 
with at least one AS diagnosis (ICD-9-CM: 720.0) were selected. Prescriptions for 
anti-tumor necrosis factor (anti-TNF) and non-TNF agents were identified. For 2 
years after the date of the first prescription (initiation date), drug switches and 
discontinuation were examined. Using a processing language, a data visualization 
tool was developed to demonstrate changes in treatment patterns after the first 
and second treatment switches. Results: A total of 1,021 AS patients initiated 
therapy with TNF, of which 13.52% switched to another TNF, 0.20% switched to a 
non-TNF, 49.56% discontinued therapy and 36.73% continued their initial therapy. 
Among patients who switched to another TNF, 60.87% remained on the switched 
therapy, while 31.16% discontinued therapy, 7.97% switched to another TNF, and 
no patients switched to a non-TNF. 81.82% of patients who made a second switch 
to a TNF medication remained on this TNF, while 9.09% discontinued treatment. 
A total of 84 AS patients initiated therapy with a non-TNF. 4.76% of these patients 
switched to a TNF, 1.19% switched to another non-TNF, 93.61% discontinued therapy 
and no patients continued treatment. Of those patients whose first switch was to a 
TNF, 50% continued therapy while the remaining 50% discontinued. There were no 
second switches. cOnclusiOns: When analyzing several years of data including 
treatment (dis)continuation and switches, treatment patterns can be difficult to 
capture. Data visualization tools help present complicated flows effectively for a 
diverse research audience.
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IMPROvEMENT IN DISEASE ACTIvITy SCORES ASSOCIATED wITH EARLy 
vERSUS LATE INITIATION OF BIOLOGIC THERAPy IN PATIENTS wITH 
RHEUMATOID ARTHRITIS: RESULTS OF A EUROPEAN CHART REvIEw STUDy
Emery P.1, Solem C.T.2, Macahilig C.P.3, Majer I.M.4, Stephens J.M.2, Cappelleri J.C.5, Tarallo M.6
1University of Leeds School of Medicine, Leeds, UK, 2Pharmerit International, Bethesda, MD, 
USA, 3Medical Data Analytics, Parsippany, NJ, USA, 4Pharmerit International, Rotterdam, The 
Netherlands, 5Pfizer Inc., New York, NY, USA, 6Pfizer Italia, Rome, Italy
Objectives: Recent research has suggested that patients may have a “window of 
opportunity” to reverse immune dysregulation associated with RA onset through 
aggressive early treatment. This study aimed to evaluate the outcomes associ-
ated with early versus late biologic treatment in RA. MethOds: Adults (≥ 18 
years) with confirmed RA diagnosis between January 2008 and December 2010, 
who received biologic therapy for ≥ 3 months and had ≥ 12 months follow-up 
were included in this retrospective, observational medical chart review study in 
Spain, Germany, and United Kingdom. Physicians abstracted outcomes including 
28-joint disease activity scores (DAS28) alongside treatment received. Patients 
were classified as receiving early biologic treatment if started within 1 year of 
RA diagnosis. Outcomes included DAS28 reduction of ≥ 1.2 from scores at biologic 
start and remission (DAS28< 2.6). Time to reaching these outcomes was evaluated 
using Kaplan-Meier survival curves and log rank tests. Results: Of 328 patients 
included, 310 (178 early; 132 late) had DAS28 measurements and were demographi-
cally similar between early vs. late treatment (overall: mean age 47.9 at diagno-
sis, 71.0% female, 96.1% white). Overall, 73.5% of patients had a DAS28 decrease 
≥ 1.2 points and 44.5% achieved remission. More early versus late biologic treated 
patients had a DAS28 decrease ≥ 1.2 (79.2% vs 65.9%, p= 0.009) but there was no 
significant difference in the time to this decrease. More early vs. late biologic 
treated patients achieved remission (51.1% vs. 35.6%, p= 0.009), with a significant 
difference in survival curves when indexing on time since RA diagnosis (p< 0.001) 
and biologic start (p= 0.024). There were no significant differences outcomes across 
countries. cOnclusiOns: This chart review contributes to the growing literature 
surrounding outcomes associated with early biologic treatment. Within this study, 
RA patients who were treated early were more likely to achieve clinically signifi-
cant improvement and to reach remission earlier in their RA disease trajectory 
than those treated later.
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model. Results: Over the entire 3-year period with gradually interchanging 80% of 
infliximab patients to biosimilar infliximab is expected to leading to a net benefit of 
29,810,000 euros compared to the scenario in which biosimilar infliximab would not 
be available. In the scenario in which interchangeabilty was disallowed the budget 
savings was 18,765,000 euros. If budget savings were spent on reimbursement of 
additional biosimilar treatments, approximately 1,615 or 1,025 more patients could 
be treated in the six countries, respectively. cOnclusiOns: This budget impact 
analysis indicates that introducing biosimilar infliximab might result significant 
budget savings or increasing of the number of patient access to biological therapy. 
Interchanging by prescribing physicians could substantially increase budget savings.
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INTRODUCTION OF AN INFLIxIMAB BIOSIMILAR (CT-P13): A FIvE-yEAR BUDGET 
IMPACT ANALySIS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN 
IRELAND
McCarthy G.1, Ebel Bitoun C.2, Guy H.3
1Mater Misericordiae University Hospital, Dublin, Ireland, 2Hospira, Meudon La Foret, France, 
3WG Consulting Healthcare Limited, High Wycombe, UK
Objectives: Biosimilars have similar efficacy and safety profiles to the originator 
biologics such that their introduction into Ireland is expected to increase competi-
tion, lower prices and improve the affordability of costly therapies. The objective 
of this study sought to estimate the budget impact of introducing an infliximab 
biosimilar (CT-P13) as a treatment option for rheumatoid arthritis (RA) patients 
in Ireland. MethOds: An Excel-based budget impact model was developed over 
a five-year time horizon. The annual population in Ireland receiving treatment 
with a biologic was based on national population statistics and published litera-
ture including: prevalence and incidence of RA; proportion of patients eligible for 
treatment with a biologic; and proportion of patients receiving treatment with a 
biologic. After the first year, an annual population growth rate of 1.1% was assumed. 
Maximum conversion of all existing and new infliximab patients to the infliximab 
biosimilar was assumed for years one to five. The total cost/patient was based on 
published literature and included drug acquisition, administration, and monitoring 
costs. Outcomes are reported as the annual and cumulative budget impact over five 
years. Results: In year one, 3,776 prevalent and 119 incident patients entered the 
model. Of these, 13% received the infliximab biosimilar with the total cost/patient 
calculated as € 15,754 in the first year of treatment and € 12,789 in subsequent years. 
The drug acquisition cost for the infliximab biosimilar was assumed to discount 
infliximab by 20%. Annual budget saving estimations following introduction of the 
infliximab biosimilar were € 579,631, € 1,165,400, € 1,177,553, € 1,189,463 and € 1,201,137 
for years one to five, with a cumulative budget saving of € 5,313,184. cOnclusiOns: 
Introducing an infliximab biosimilar as a treatment option for RA patients in Ireland 
represents a cost saving of up to € 5,313,184 over five years; equivalent to treating 
an extra 337 new patients with a biosimilar for one year.
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DEMINERALISED BONE MATRIx (DBM) vERSUS ILIAC CREST BONE GRAFT (ICBG) 
FOR LUMBAR SPINAL FUSION PROCEDURES IN THE UNITED KINGDOM;  
A BUDGET-IMPACT ANALySIS
Carlqvist P.1, Dawson S.2, Jeppsson K.3, Borgman B.4
1Heron AB, Stockholm, Sweden, 2HERON Evidence Development AB, Stockholm, Sweden, 3HERON 
Evidence Development Ltd., London, UK, 4Medtronic Trading Sàrl., Tolochenaz, Switzerland
Objectives: Iliac Crest Bone Graft (ICBG) is a commonly used bone graft material 
in lumbar spinal fusion procedures. Demineralised Bone Matrix (DBM) added to 
supplement Local Bone (LB) provides an alternative graft material that does not 
require a secondary surgery site to harvest iliac crest bone. The objective of this 
study was to investigate the economic impact associated with the use of DBM in 
lumbar spinal fusion procedures in the UK. MethOds: A decision tree model was 
developed to evaluate the two-year budget impact associated with adding DBM 
as an alternative bone graft material in the lumbar spinal fusion surgical proce-
dure. The model structure was based on previously published economic models, 
identified via a structured literature search, and compares surgical treatment with 
either ICBG or DBM added to the LB procedure. The model includes the costs of the 
surgical procedures, for adverse events and for treatment failure (reoperations). 
Further, the model was validated by UK clinical experts to ensure its adherence to 
UK clinical practice. The model population included UK-based patients with lumbar 
degenerative disc disease (LDDD) considered eligible for lumbar spinal fusion with 
either LB or ICBG. In the model’s base-case analysis, ICBG was compared with DBM 
added to LB. Results: The model predicts cost-savings of £44 467 over two years 
when adding DBM to LB compared with using ICBG alone for the lumbar spinal 
fusion procedure in a hypothetical population of 100 patients. The cost-savings 
are realised through reduced surgical time and fewer adverse events associated 
with surgery. cOnclusiOns: In a defined population of spinal fusion patients 
in the UK that would otherwise be treated with ICBG, the addition of DBM to LB 
presents an economically viable and potentially cost-saving clinically appropriate 
treatment option.
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POTENTIAL ECONOMIC IMPACT OF USING SUGAMMADEx FOR THE ROUTINE 
REvERSAL OF NEUROMUSCULAR BLOCKADE IN RUSSIAN HEALTH CARE 
SETTING
Derkach E.V.1, Avxentyeva M.V.2, Omelyanovsky V.V.2
1Autonomous Non-profit Organization “National Centre for Health Technology Assessment”, 
Moscow, Russia, 2The Russian Presidential Academy of National Economy and Public 
Administration, Moscow, Russia
Objectives: To evaluate the potential economic impact of sugammadex used for 
reversal of rocuronium-induced neuromuscular blockade (NMB) in comparison 
with neostigmine and spontaneous reversion of NMB in Russian health care set-
ting. MethOds: We constructed the model to compare two scenarios of general 
anesthesia with rocuronium-induced NMB: 1) routine practice (70% spontaneous 
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COMPARISONS OF THE RISK FOR vENOUS THROMBOEMBOLISM BETwEEN HIP 
AND KNEE ARTHROPLASTy USING KOREA NATIONAL HEALTH INSURANCE 
CLAIMS DATABASE
Kim Y.J.1, Ahn J.H.1, Jang E.J.1, Jung Y.J.1, Yoo J.J.2, Yoon P.W.2, Lee S.H.2
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Seoul 
National University College of Medicine, Seoul, South Korea
Objectives: Venous thromboembolism (VTE) including deep vein thrombosis (DVT) 
and pulmonary embolism (PE) occurs most often in patients undergoing major joint 
arthroplasty and major surgical procedures (such as hip arthroplasty, HA or knee 
arthroplasty, KA). The prevalence of clinically relevant VTE, DVT and PE after hip 
and knee arthroplasty in nationwide database of Korea were 1.7%, 1.1% and 0.5%, 
respectively. The aim of this study was to compare the risk for VTE (including DVT 
and PE) between hip and knee arthroplasty in the Korean population. MethOds: A 
retrospective cohort study was conducted using nationwide claim registry obtained 
from the Korean Health Insurance Review and Assessment Service (HIRA), which 
includes medical claims records for 97.0% of South Koreans. We retrospectively 
identified patients who underwent HA or KA between January 1 and December 31 
in 2010. VTE after arthroplasty were identified by diagnostic code (ICD-10: PE - I26, 
I26.99, DVT - I80, I82, I82.2) within 90days after surgery. Patients’ characteristics 
including sex, age and preoperative comobidities were defined using the HIRA 
database from 2007 to 2010. We compare the risk for VTE between hip and knee 
arthroplasty using logistic regression model in patients without VTE history and VTE 
chemoprophylaxis use . Results: A total of 38,024 patients had HA or KA arthro-
plasty in Korea in 2010 (HA 11,908 patients, KA 26,116 patients). KA was associated 
with an increased risk of DVT [aOR= 1.3; 95% CI= (1-1.7), p-value= 0.048], but KA was 
associated with a decreased risk of PE compared with HA [aOR= 0.5; 95% CI= (0.3-0.7), 
p-value< 0.001]. cOnclusiOns: This study suggest that the risk of PE was high in 
HA rather than KA, but the risk of DVT was high in KA rather than HA. These results 
were due to differences in pathogenesis of DVT or PE.
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CORRELATION BETwEEN PROGNOSTIC FACTORS AND NON PROSTHETIC 
FURTHER FRACTURE RELATED TREATMENT AFTER FEMORAL NECK FRACTURE 
UNDERwENT INTERNAL FIxATION IN ELDERLy
Sebestyén A.1, Gajdácsi J.2, Molics B.3, Vámhidy L.3, Patczai B.3, Kovács L.A.3, Boncz I.3
1National Health Insurance Fund Administration, Pécs, Hungary, 2National Health Insurance Fund 
Administration, Budapest, Hungary, 3University of Pécs, Pécs, Hungary
Objectives: To investigate the correlation between prognostic factors and non 
prosthetic fracture related treatments following internal fixation of femoral neck 
fractures in elderly patients. MethOds: This retrospective observational cohort 
study data were collected from the Hungarian National Health Insurance Fund 
Administration and from the health care provider institutes based on S7200 ICD-10 
codes. The patients with femoral neck fractures following internal fixation aged 60 
years or older were provided in 2000. The secondary non prosthetic fracture related 
treatments during the 8 year follow-up period were registered. Of the prognostic 
factors, age, gender, type of fracture and surgical intervention, season and day of 
the primary surgery, surgical delay and the accompanying diseases were evaluated. 
Statistical analyses were performed using multivariate Cox regression models and 
Kaplan Meier survival methods. Results: A total of 3306 patients met the criteria. 
The mean of age was 78.04 years (SD:8.59). The non-prosthetic fracture related treat-
ment was performed in 307 patients (9.3%). With Cox regression analysis, significant 
correlation was revealed between the incidence of non prosthetic treatment and 
younger age (year, HR= 0.978), surgical delay (12-24h vs 0-6h, HR= 1.730; 24h+ vs 0-6h, 
HR= 1.578), season of primary osteosynthesis (winter vs summer, HR= 0.707; fall vs 
summer, HR= 0.638), type of primary surgical intervention (screw vs DHS fixation, 
HR= 2.096; femoral neck nailing vs DHS fixation, HR= 3.223; Ender nailing vs DHS 
fixation, HR= 4.515) and type of femoral neck fracture (intracapsular displaced vs 
intracapsular undisplaced, HR= 1.360; extracapsular vs intracapsular undisplaced, 
HR= 1.634). There was no significant effect of the day of primary surgery, the gender 
and the presence of comorbidities on the incidence of further surgical interven-
tions. cOnclusiOns: We have demonstrated that summertime primary surgical 
intervention, delay of surgery longer than 12 hours, type of femoral neck fracture 
and method of fixation are independent predictors of non prosthetic further treat-
ment of femoral neck fractures.
MUSCULAR-SKELETAL DISORDERS – Cost Studies
PMS21
BUDGET IMPACT ANALySIS OF BIOSIMILAR INFLIxIMAB TREATMENT FOR 
RHEUMATOID ARTHRITIS IN SIx CENTRAL EUROPEAN COUNTRIES
Brodszky V.1, Péntek M.2, Baji P.1, Balogh O.1, V. Hevér N.1, Gulacsi L.1
1Corvinus University of Budapest, Budapest, Hungary, 2Corvinus University, Budapest, Hungary
Objectives: To analyse the budget impact of introducing biosimilar infliximab 
for the treatment of rheumatoid arthritis in six central European countries’ –
Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia - health care 
systems. MethOds: This budget impact model estimates the potential impact of 
the biosimilar infliximab on the health care budget over a three year time frame. 
The model considers third-party payer perspective. A spreadsheet-based country 
specific dynamic population model was developed. The model functioned in quarter 
year time units according to the three months long evaluation period. The model 
tracked the movement of the RA population between main states: 1) on synthetic 
DMARD; 2) on infliximab; 3) on biosimilar infliximab; 4) TNF inhibitors other than 
infliximab; and 5) biologics other than TNF inhibitor. Switching between biologics 
and biosimilar infliximab was taken into consideration too. Scenario analyses were 
conducted, different rate of interchanging and switching were considered. A -25% 
percentage price difference was assumed for biosimilar infliximab compared to 
originator infliximab. The budget impact was calculated as the difference in the 
total cost of the scenarios with and without biosimilar infliximab in each year of the 
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demonstrated efficacy of biologics for moderate RA. However, access to biologics 
varies substantially by country, in part due to differing eligibility criteria of reim-
bursement policies. Here we investigated the proportion of patients who receive 
biologics, and whether eligibility criteria were correlated with total costs per RA 
patient across a range of countries. MethOds: PubMed searches were performed to 
establish which countries reimburse biologics for RA treatment. Eligibility require-
ments, percentage of patients who received biologics and cost per patient were 
extracted from a variety of sources. Simple regression analysis was used to com-
pare total cost of RA treatment per patient and severity of RA (DAS score) required 
for biologic access. Results: Regarding eligibility criteria, 16 out of 21 countries 
restricted biologics to patients with severe RA (DAS score > 5.1) and/or who failed 2 
previous DMARDs. Eligibility was linked to reimbursement policy for 14 countries. 
New Zealand had the most stringent reimbursement criteria, with only 1 biologic 
reimbursed and limiting eligibility to severe, active erosive RA > 6 months, 4 failed 
DMARDs including MTX, and DAS score > 5.1. Taking into account the relative preva-
lence of RA, 20% of RA patients received biologics in Norway and Belgium, 10% 
in the UK, 9% in Australia, 5% in Germany and Italy and only 3% in New Zealand 
and Austria. Out of 14 countries, there was poor correlation between total cost of 
RA treatment per patient and the severity of RA required for biologics access (R 
Square: 0.09, p= 0.29). cOnclusiOns: Reimbursement policies for biologics in RA 
vary substantially between countries, as does the proportion of RA patients who 
receive biologics. No significant correlation was found between cost per patient and 
DAS score required for biologics treatment.
PMS28
ASSESMENT OF THE COST OF BIOLOGICAL THERAPy IN RHEUMATIC DISEASES: 
ECONOMIC IMPACT OF DOSAGE MODIFICATION IN CLINICAL PRACTICE
Manrique-Arija S., Ureña I., Jimenez- Nuñez F.G., Ordóñez- Cañizares M.C.,  
Romero- Barco C.M., Rodriguez- García V., Nieves L., Cano L., Irigoyen M.V.,  
Fernandez-Nebro A.
HRU CARLOS HAYA. UNIVERSITY OF MALAGA. IBIMA, Malaga, Spain
Objectives: To evaluate the real annual cost of biological therapies (BT) in rheu-
matic diseases in a tertiary hospital in 2012 and to compare the real annual spend-
ing, in daily clinical practice, with theoretical costs with conventional doses. To 
analysis the reduction of costs after creating BT outpatient clinic. MethOds: 
Cost minimization analysis based on an observational, cross-sectional study.
Patients with different rheumatic diseases in follow-up by Rheumatology service 
in Hospital Carlos Haya(Spain) who have been treated with BT under conventional 
and modified doses were included. Outcome 1º: Annual average cost (in Euros) of BT 
in patients with rheumatic diseases in clinical practice compared with theoretical 
cost.Secondary Variables: cost reduction in Euros after implantation of a specialized 
outpatient clinic of BT. Dose reduction protocol: After 6 months with label dose activity 
disease is assessed, if DAS28< 2,6 or BASDAI< 4, we reduce the standard dose and 
we reevaluate every 6 month. We performed a descriptive analysis of the sample. 
Cost minimization analysis to evaluate annual costs were carried out. Results: 
A total of 478 patients were treated with BT in our service in 2012. Most of them 
were Reumatoid arthritis(265,55.4%). Theoretical annual cost in 2012, it would be of 
5,647,969.35 Euros (11,791.17 Euros patient-year). However, during 2012 32 patients 
reduced doses of their biological therapy in clinical practice. This represented a 
saving of 146,129.67 Euros in 2012. From December 2012 until June 2013 in our out-
patient clinic of BT, 76 patients went into remission or low disease activity and the 
biological drug dose was reduced. This dose modification resulted in a reduction 
of the total cost of 159, 004 Euros in 6 months associated with adequate disease 
control cOnclusiOns: It is possible to reduce doses and associated costs of BT. 
The follow-up of patients in a specialized outpatient clinic leads to a better patient 
management and a cost reduction
PMS29
BURDEN OF INFUSION-RELATED COSTS AND STAFF TIME FOR RHEUMATOID 
ARTHRITIS IN THE HOSPITAL SETTING
Ogden K.1, Cifaldi M.2, Quock T.1, Ganguli A.3
1ICON plc, San Francisco, CA, USA, 2AbbVie Inc., North Chicago, IL, USA, 3AbbVie, North Chicago, 
IL, USA
Objectives: Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting 
0.6% of the population in the US. Current RA infusion therapy incurs substantial 
cost and time to the hospital and patient. The purpose of this study was to model 
the infusion and related staff costs within a hospital center to better understand 
the economic and time burden of RA infusion therapy. MethOds: We developed 
an Excel model to estimate the annual time and cost burden associated with RA 
infusion services in a hypothetical hospital center. We assumed patients received 
abatacept, tocilizumab, or rituximab monotherapy. Product package inserts 
informed the number of annual maintenance infusions (13 infusions for abatacept 
[30 minutes each] and tocilizumab [60 minutes each]; 4 infusions for rituximab 
[195 minutes each]) per patient. The model projected annual direct costs and total 
value of staff time for infusion drug administration, infusion-related services, 
facility-related services, laboratory tests, and patient/caregiver costs. Costs were 
derived from the literature and adjusted to 2012 USD; 29.5% allocated overhead 
was applied to laboratory, facility and infusion service costs. Time estimates were 
obtained from the literature and survey data, converted to annual wages using 
BLS data, and adjusted to 2012 USD. Results: The baseline model estimated 
total infusion drug and service-related costs to be $24,645 for abatacept, $27,840 
for rituximab, and $31,339 for tocilizumab. Roughly 54%, 62% and 58% of these 
annual costs are associated with hospital labor, respectively. Patient/caregiver 
costs, comprising of lost wages and indirect medical costs, were estimated to be 
$788 for abatacept, $793 for rituximab, and $1,063 for tocilizumab. cOnclusiOns: 
Our findings show that direct and infusion-related contribute to a substantial eco-
nomic and time burden to both the hospital and patient. These findings can help 
decison makers assess the relative benefits and cost implications of administering 
infusion drugs to RA patients.
reversal from NMB, 30% use of neostigmine), and 2) sugammadex used in all cases. 
We estimated costs associated with NMB and time when operation rooms are occu-
pied. Calculations were made for a typical Russian hospital providing 5000 surgeries 
per year, 160 of them performed with rocuronium-induced NMB. The model inputs 
included current practice patterns derived from the survey of experts, data on the 
recovery time from NMB and rates of residual NMB and its complications were taken 
from published sources. Costs were estimated on the basis of data on governmental 
tenders and reimbursement rates for services in the compulsory medical insurance 
system. Results: Introduction of sugammadex can decrease number of residual 
NMB cases by 93,6% and save 70 hours in operation room due to shorter period till 
extubation in comparison with base case scenario. The overall spending related to 
general anesthesia increased by EURO 20,510. In case of rational hospital management 
saved operating time could be used for providing extra surgeries that will generate 
additional revenue of EURO 14,395 – 48,041 for a hospital, depending on the type of 
surgery provided in a saved time. cOnclusiOns: The reduction of recovery time 
with sugammadex may generate additional revenue for the hospital and improve 
access to health care for public. Still optimization of workflow processes is necessary.
PMS25
BUDGET IMPACT ANALySIS OF BIOLOGIC DRUGS FOR TREATMENT OF 
POLIARTICULAR jUvENILE RHEUMATOID ARTHRITIS IN RUSSIA
Ignatyeva V.1, Goryaynov S.2, Avxentyeva M.1
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia, 2Autonomous non-profit organization “National Centre for Health Technology 
Assessment”, Moscow, Russia
Objectives: To assess impact on the 3-year health care budget of 3 biologic drugs 
(BD) – abatacept, adalimumab and etanercept – provided for all eligible children 
with poliarticular juvenile rheumatoid arthritis (JRA) not responding to the standard 
therapy MethOds: The indirect comparison of the results of randomized controlled 
trials (RCT) demonstrated that compared BD have approximately the same effect 
on the rate of disease flares in children with poliarticular JRA. We developed four 
scenarios assessing direct costs (drugs, medical services and sick leave payments 
for parents caring for children) bared by the government during 3-years period in 
base case and in cases of provision of one of compared BD for all children with 
poliarticular JRA. The hypothesis was that introduction of BD decreases the rate of 
disease flares and thus reduces related costs. The potential reduction of costs related 
to disability was not assessed due to the lack of data. The model inputs were derived 
from Russian cost of illness analysis of JRA and RCTs on the efficacy of BD. The costs 
estimation was based on the average wholesale price of BD and reimbursement 
rates in the compulsory medical insurance system. Results: The lowest costs are 
expected in the scenario with abatacept – EURO 63 mln in comparison with EURO 
81.62 mln for etanercept and EURO 134.18 mln for adalimumab. Adoption of BD 
would reduce the costs of hospital treatment and sick leave payments for the caring 
parents by 14-17%. Overall the increase of budget spending during 3 year period per 
1 patient receiving BD varies from EURO 10,328 (abatacept) to EURO 23,255 (adali-
mumab). cOnclusiOns: Supplying with BD all eligible children with JRA requires 
high additional spending of the health care budget, the least burden is imposed by 
the adoption of abatacept in comparison with etanercept and adalimumab.
PMS26
STRATAFIxTM KNOTLESS TISSUE CONTROL DEvICE: A BUDGET IMPACT 
ANALySIS FROM ITALIAN HEALTH SERvICE PERSPECTIvE
Perrone F.1, Muehlendyck C.2, Velleca M.1
1Johnson & Johnson Medical, Pomezia (RM), Italy, 2Johnson & Johnson Medical Gmbh, Norderstedt, 
Germany
Objectives: STRATAFIX™ Knotless Tissue Control Device is a new medical device. 
With significantly more points of fixation than traditional sutures, STRATAFIX™ 
gives surgeons more consistent tension control over every pass, and combine the 
strength and security of interrupted closure with more efficiency than continu-
ous closure. A Budget impact analysis was developed to estimate the cost saving 
associated with use of new technology from the Italian Health Service perspec-
tive over a 1 year time horizon. MethOds: A literature review was conducted to 
evaluate the time savings in different procedures: hysterectomy and myomectomy 
(Gynecology), breast reconstruction and abdominoplasty (Plastic Surgery), pros-
tatectomy and nephrectomy (Urology), hip and knee replacement (Orthopedics). 
Moreover, a survey with clinicians was conducted to estimate the number of sutures 
used for the different procedures. The means and 95% confidence interval (95%-CI) 
for the budget impact were estimated using bootstrap methods (10.000 simulations) 
assuming lognormal distribution for costs and time data, and beta distribution for 
percentage data. Results: Cost savings per procedure with STRATAFIX™ would 
be 217 € and 227 € for hysterectomy and myomectomy respectively, 274 € and 60 
€ for breast reconstruction and abdominoplasty, 56 € and 230 € for prostatectomy 
and nephrectomy, 48 € and 50 € for hip and knee replacement. Considering the 
evolution of annual procedures performed with the introduction of STRATAFIX™, 
the cost saving associated will be about 1.340.129 € (95%-CI: 218.530- 3.089.771 
€ ): 30% for myomectomy, 26% for breast reconstruction and 22% for hysterec-
tomy. cOnclusiOns: The additional costs for this new medical device permits 
to generate appropriateness and to reallocate staff and operation rooms for other 
activities. STRATAFIX™ technology appears cost-saving for the reduction of pro-
cedure time. The results were consistent according to the developed probabilistic 
sensitivity analysis, STRATAFIX™ leads to cost savings in 99% of the simulation.
PMS27
GLOBAL vARIATIONS IN BIOLOGICS ACCESS AND RHEUMATOID ARTHRITIS 
TREATMENT COSTS
Miles G.1, Bell J.H.1, Wilson T.J.2, Hamerslag L.2, Kusel J.2
1Costello Medical Consulting, Cambridge, UK, 2Costello Medical Consulting Ltd., Cambridge, UK
Objectives: Biological therapy is effective at slowing disease progression in 
Rheumatoid Arthritis (RA), particularly in severe RA. Recent clinical trials also 
A560  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
in three Romanian cities participated. A total of 140 patients were included: 60 
(42.8%) with hip, 68 (48.6%) with vertebral and 12 (8.6%) with wrist osteoporotic 
fractures. The mean [95% CI] total cost of osteoporotic fracture management was 
€ 1,155 [€ 1,044 - € 1,304] per patient. Medications (mean [95% CI], € 544 [€ 477 - € 624]) 
and hospital care (€ 447 [€ 393 - € 512]) were the major cost drivers, accounting for 
47.1% and 42.8% of the average total cost respectively. Hip fractures were more 
costly than vertebral and wrist fractures (mean [95% CI]: € 1,384 [€ 1,186 - € 1,643]; 
€ 991 [€ 852 - € 1,172]; and € 934 [€ 659 - € 1,177], respectively). cOnclusiOns: This 
study provides the first estimates of the direct cost of osteoporotic fractures in the 
Romanian health care system. The results suggest that osteoporotic fractures pose 
a significant burden on both drug and hospital budgets. Effective treatment strategy 
to avoid such fractures may reduce this burden.
PMS33
MEDICAL COSTS OF PATIENTS wITH RHEUMATOID ARTHRITIS AND 
ASSOCIATION wITH GLOBAL DISEASE ACTIvITy IN TURKEy
Hamuryudan V.1, Direskeneli H.2, Ertenli I.3, Inanc M.4, Karaaslan Y.5, Oksel F.6, Ozbek S.7, Pay 
S.8, Terzioglu E.9, Durguner B.10, Baser O.11, Akkoç N.12
1Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 2Marmara University 
Faculty of Medicine, Istanbul, Turkey, 3Hacettepe University Faculty of Medicine, Ankara, Turkey, 
4Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, 5Ankara Numune Training 
and Research Hospital, Ankara, Turkey, 6Ege University, Izmir, Turkey, 7Cukurova University 
Faculty of Medicine, Adana, Adana, Turkey, 8Gulhane Military Medical Academy, Ankara, Turkey, 
9Akdeniz University, Antalya, Turkey, 10Pfizer Pharmaceuticals, Istanbul, Turkey, 11The University 
of Michigan, Ann Arbor, Michigan, MI, USA, 12Dokuz Eylül University, Izmir, Turkey
Objectives: To identify factors associated with the cost of RA care and calculated 
risk-adjusted costs associated with RA in Turkey. The relationships between costs 
of RA treatment and disease activity was also examined. MethOds: This cross-
sectional study was performed in 10 tertiary rheumatology centers. Eligible patients 
were ≥ 18 years of age diagnosed as having RA for at least 12 months according to the 
American College of Rheumatology (ACR) 1987 criteria. Overall costs were catego-
rized as inpatient, outpatient and pharmacy costs. Generalized linear models were 
used to calculate risk-adjusted direct costs. Results: A total of 698 patients were 
studied. Patients’ visual analog scale (VAS), patient’s global disease activity (GDA) 
and routine assessment of patient index data 3 (RAPID-3) scores were on average 
44.15, 5.19 and 5.10 respectively. Most patients were prescribed immunosuppres-
sive medications and glucorticoids (87.8% and 61.2%, respectively). After adjusting 
all variables, total annual medical cost was € 2,671. The most significant portion of 
overall expenditures was due to pharmaceutical costs € 1,987, while outpatient costs 
were € 303, inpatient costs were € 360 and co-payments were € 21. 14% of patients 
experienced work loss due to RA. On average, annual costs due to workday loss were 
€ 480. 5.4% of patients also had other RA-related consultations, which were not cov-
ered by insurance, bringing the average annual burden to € 1,600 for these patients. 
6.5% of RA patients had additional costs related to their condition such as the 
need for a new car, apartment or special equipment, spending an additional € 1,640 
in 1 year. 13.7% of patients required caregivers. The average annual out-of-pocket 
amount paid to caregivers was € 624. cOnclusiOns: The annual medical cost of 
RA in Turkey, although significantly lower compared to European estimates, causes 
considerable economic burden. Drug costs constitute the major part of annual cost 
for RA followed by indirect costs.
PMS34
PATIENTS AS A SOURCE FOR COST OF RHEUMATOID ARTHRITIS STUDy
Marinov L.1, Petrova G.2
1Medical University, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University of Sofia, Sofia, 
Bulgaria
Objectives: To perform the cost of rheumatoid arthritis analysis based on inquiry 
study with patients. MethOds: It is a micro costing study which was conducted 
between August and December 2012. The information was gathered with the sup-
port of the Association of patients with rheumatoid arthritis. The questionnaire 
was made and distributed to patients waiting in front the physicians’ offices. 
Clarification in case of missing data was made by phone. The questions aimed 
to gather basic information about the characteristics of the patients, their phar-
macotherapy, frequency of physicians’ visits, hospitalizations, and their health 
status self- evaluation. The direct health costs were calculated based on patients’ 
answers and insurance fund tariff. Results: A total of 119 patients participated in 
the study, and nineteen were excluded due to insufficient information. Twenty-two 
patients were male and 78 were female aged 54.78 years on average. Almost half of 
the patients (42 patients) were employed. Thirty-four of patients had duration of 
the RA less than 5 years, 19 had duration between 5-7 years, another 14 patients 
had duration of between 7-10 years and 33 patients had duration more than 10 
years. The total cost for the treatment of the patients for one month was 82 523 
BGN (per patient, per month on average 825 BGN). To one quarter of the patients 
a biological treatment was prescribed with a total cost of 74 026 BGN per year. 
Ninety-two of the patients answered that they are strictly taking their medicines. 
Our study shows that most of the patients doesn’t knows what medicines they are 
taking or even doesn’t knows their dossing regime. cOnclusiOns: The percent-
age of the patients that are not following the doctor’s prescription is very high 
and their reliability as a source of cost studies is not sufficient that impose the 
need of patient education.
PMS35
wORK PRODUCTIvITy LOSS DUE TO RHEUMATOID ARTHRITIS IN POLAND. 
RESULTS OF CROSS-SECTIONAL STUDy OF OUTPATIENTS wITH CHRONIC 
INFLAMMATORy DISEASES AND COMPARISON wITH SELECTED STUDIES
Wladysiuk M., Bebrysz M., Rutkowski J., Haldas M., Fedyna M.
Central and Eastern European Society of Technology Assessment in Health Care, Krakow, Poland
Objectives: To measure productivity loss of RA patients in Poland compared 
to results of selected studies. MethOds: In this study consecutive patients in 
PMS30
COST ANALySIS OF THE USE OF AN OPERATING ROOM wITH FULL-ROTATION 
3-D INTRAOPERATIvE IMAGING AND NAvIGATION IN DIFFERENT SPINE 
SURGERIES
Rodríguez D., Gonzalez P.
Medtronic Iberica S.A., Madrid, Spain
Objectives: The use of navigation and intraoperative imaging permits to perform 
a large number of procedures more accurately and safely. The aim of this study was 
to estimate the cost savings achieved by an integrated operating room with full 
rotation 3-D intraoperative imaging and navigation (NT) compared with a stand-
ard operating room in three types of surgery: balloon kyphoplasty, lumbar fusion, 
and fusion cervical. MethOds: We developed a cost analysis through a published 
literature review of full rotation 3-D intraoperative imaging and navigation stud-
ies, taking into account a hospital perspective. We identified the studies with data 
related to hospital resource savings when compared with a standard operating 
room (imaging test outside the operating room). Subsequently, potential savings 
per patient were estimated for each surgery and were updated to euros 2013. Cost 
data were taken from e-Salud database and Spanish regional tariffs. Results: The 
use of full rotation 3-D intraoperative imaging and NT versus a standard operating 
room increases surgical process efficiency due to: avoid post surgery computer 
tomographies to confirm the success of the procedure, increase the accuracy of sur-
gical interventions, avoid complications and reduce the need for re-interventions, 
reduce the operating room time, faster patient recovery and reduce hospital length 
of stay. Potential savings by type of surgery were € 615, € 3,242, and € 4,458 for balloon 
kyphoplasty, posterior cervical fusion, lumbar fusion, respectively. cOnclusiOns: 
The use of full rotation 3-D intraoperative imaging and NT leads to improved clinical 
outcomes and increased hospital efficiency in surgeries carried out with it. A 3-D 
intraoperative imaging system is a cost-saving strategy for balloon kyphoplasty, 
lumbar fusion, and cervical fusion surgeries from a hospital perspective.
PMS31
HEALTH CARE UTILIzATION AND ExPENDITURES OF OSTEOPOROSIS PATIENTS 
TREATED wITH ORAL BISPHOSPHONATE IN TIANjIN, CHINA
Yu Q.1, Wu J.1, Ma F.1, Liu J.2, Jin L.3, Lin M.4, Chang J.4
1Tianjin University, Tianjin, China, 2Tianjin Medical Insurance Research Association, Tianjin, 
China, 3Bureau of Human Resource and Social Security, Tianjin, China, 4Beijing Novartis Pharma 
Co., Ltd., Beijing, China
Objectives: To estimate the health care utilization and expenditures for osteo-
porosis patients treated with oral bisphosphonate in Tianjin, China and examine 
factors associated with health care expenditures. MethOds: Data were obtained 
from Tianjin Urban Employee Basic Medical Insurance database (2008-2010) with 
30% random sample of enrollees. The index date was the first pharmacy claim 
date of oral bisphosphonate in 2009. Patients of 40 years of age or older, continu-
ously enrolled for 12 months prior to and following the index date, were included if 
osteoporosis was diagnosed and oral bisphosphonate (alendronate and etidronate) 
was claimed accordingly. All-cause cost, osteoporosis-related cost, drug cost, and 
related health care utilization were estimated at 2009 dollars. Logistic regression 
analysis was applied to identify factors associated with expenditures. Results: 
Of 853 patients identified, 64.6% were for women. The mean age was 64.6 (±10.4) 
years. Of $2039.2 (±2782.6) all-cause cost per person per year, out-of-pocket cost 
accounted for 2.1%; drug cost accounted for 61.1%; osteoporosis-related cost 
accounted for 37.9%. Of $1026.5 (±1108.8) all-cause outpatient cost per person per 
year, drug cost accounted for 82.3%; osteoporosis-related cost accounted for 14.6%. 
Of $1012.7 (±2586.2) all-cause inpatient cost per person per year, drug cost accounted 
for 39.6%; osteoporosis-related cost accounted for 61.5%. An average of 7.0 (±3.7) 
outpatient visits and 0.4 (±0.8) hospitalization admissions were found. Regression 
results demonstrated that patients with diabetes mellitus and nephropathy had 
higher all-cause cost; female patients and patients with pre-fracture had higher 
osteoporosis-related cost. cOnclusiOns: The economic burden of osteoporosis is 
high for osteoporosis patients and is expected to increase considering the increment 
of life expectancy and the increasing number of elderly population. Greater empha-
sis and policy guidance should be given to the impact of osteoporosis prevention 
and treatment in elderly population.
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THE COST OF OSTEOPOROTIC FRACTURES IN THE ROMANIAN 
POSTMENOPAUSAL wOMEN POPULATION
Mihalache M.1, Berghea F.2, Botez I.3, Dumitru C.4, Grigorie D.5, Ionescu R.6, Lupescu O.7, 
Opris D.6, Poiana C.5, Stanciu S.8, Psachoulia E.9, Intorcia M.9
1Amgen Romania SRL, Bucharest, Romania, 2Carol Davila University Of Medicine and Pharmacy, 
Bucharest, Romania, 3Spitalul Clinic de Recuperare Iasi, Iasi, Romania, 4Spitalul Municipal 
Ploiesti, Ploiesti, Romania, 5Institutul National de Endocrinologie “C.I. Parhon”, Bucharest, 
Romania, 6Spitalul Sf. Maria, Bucharest, Romania, 7Spitalul Clinic de Urgenta Floreasca, 
Bucharest, Romania, 8Spitalul Judetean de Urgenta Ploiesti, Ploiesti, Romania, 9Amgen (Europe) 
GmbH, Zug, Switzerland
Objectives: Little data are available regarding the economic burden of osteoporosis 
on the Romanian (public payer) health care system. This retrospective chart review 
estimated the direct costs of osteoporotic fractures in postmenopausal women in 
Romania. MethOds: Women aged > 65 years diagnosed with osteoporosis, who 
sustained an osteoporotic hip, wrist or vertebral fracture between December 1, 
2007 and November 1, 2011 (and 1-5 years prior to study enrolment), admitted as 
inpatients to a sample of Romanian general and specialist hospitals were eligible; 
patients with multiple fractures or fractures resulting from co-morbidities were 
excluded. The duration of post-fracture follow-up was one year. The cost perspective 
included direct costs incurred by the Romanian national health insurance agency 
and the patients’ own budgets. Health care utilization was recorded from hospital 
and primary care resources, and then multiplied with national tariffs to obtain 
total costs. Bootstrapping was conducted to generate bias corrected and accelerated 
confidence intervals. Results: Five general hospitals and two specialist hospitals 
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OUTPATIENT MEDICAL COSTS, INDIRECT COSTS, AND FAMILy BURDEN OF 
OSTEOPOROSIS FRACTURE IN CHINA
Yang Y.1, Du F.2, Lu T.3, Xie Z.4, Xu W.5, Huang Q.4, Ye W.W.6, Burge R.7
1Eli Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai Branch, Shanghai, China, 2Beijing Brainpower 
Pharma Consulting Co. Ltd., Beijing, China, 3Beijing Chaoyang Hospital, Capital Medical 
University, Beijing, China, 4Southwest Hospital, Third Military Medical University, Chongqing, 
China, 5Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 
Wuhan, China, 6Lilly Suzhou Pharmaceutical Co., Ltd. Shanghai Branch, Shanghai, China, 7Eli 
Lilly and Company, Indianapolis, IN, USA
Objectives: The prevalence of osteoporosis fractures is anticipated to increase 
rapidly due to China’s aging population. However, representative data on the eco-
nomic burden of osteoporosis fractures are lacking. The aims of this study were to 
estimate direct outpatient medical costs, indirect costs and family burden associ-
ated with patients with osteoporosis fractures in China. MethOds: One hundred 
and fifty osteoporosis fracture patients and/or care-givers were interviewed within 
149 days [median] post-fracture in three tertiary hospitals in Beijing, Wuhan and 
Chongqing representing eastern, middle and western China. Fracture patients were 
discharged from hospital between January 2011 and January 2013. The survey col-
lected data on demographics; ambulatory status; outpatient services and costs 
(emergency room, drugs, other outpatient); indirect medical services and supplies 
and costs (nursing, transportation, rehabilitation, devices, etc.); and lost work time 
from caregivers. Results: Of the 123 valid respondents (female: 64.2%; mean age: 
71.3 years), 62.6% were hip fractures, followed by vertebral fracture (34.1%), non-
vertebral/non-hip fracture (2.4%), and multiple fracture (0.8%). All patients received 
surgical treatment, 8.9% had historical fractures, 80.5% had comorbidities and 82.9% 
of patients had post-discharge outpatient visits. The most frequent comorbidities 
were hypertension (61.0%), rheumatoid arthritis (41.5%), high cholesterol (35.0%) and 
cardiovascular disease (34.2%). Reported disability (walk w/aid or could not walk) 
increased from 13% pre-fracture to 36% post-fracture. Average post-acute outpatient 
care costs and indirect medical costs were 2084 RMB and 3526 RMB, respectively. 
Care-givers reported an average of 33.2 days lost from work. Using median income 
from the three regions, the estimated average lost income for caregivers was 5910 
RMB (weighted by share of responders per region). cOnclusiOns: The study sug-
gests the economic burden of osteoporosis fractures is considerable in terms of 
outpatient medical costs, indirect medical costs and family burden. Osteoporosis-
related fractures may pose a significant burden to China due to the aging population.
PMS39
ANNUAL ExPENDITURE ON ANTI-TNF TREATMENT OF RHEUMATOID 
ARTHRITIS FOR THE PUBLIC HEALTH SySTEM IN BRAzIL
Nobre M.R.C.1, Costa F.M.1, Taino B.1, Kiyomoto H.D.2, Rosa G.F.2
1INCOR -HCFMUSP, sao Paulo, Brazil, 2Cognos - Health Education, sao Paulo, Brazil
Objectives: Provide clinically relevant evidence and drug expenditure informa-
tion for brazilian public health system management. MethOds: We performed a 
systematic review on the use of anti-TNF biological agents, infliximab, adalimumab 
and etanercept in the treatment of patients with rheumatoid arthritis, using the 
precepts of evidence-based medicine, ensuring methodological quality of clinical 
studies, prioritizing clinical outcomes. Clinical evidence was retrieved in PubMed, 
Central Cochrane, EMBASE and medicine purchase costs in July 2010. Results: 
Twenty-three randomized trials met the eligibility criteria, six on infliximab, nine 
on adalimumab and eight on etanercept. Adalimumab and etanercept showed no 
benefits when not associated with methotrexate. The ACR50 response to infliximab 
(NNT = 6) and adalimumab (NNT = 5) were similar while the results for etanercept 
were considered heterogeneous. The annual cost of infliximab to treat six patients 
and get ACR50 response in a single patient was US$ 125,997.00 while for adalimumab 
to treat five was US$ 186,990.00. The ACR70 response was similar between etanercept 
(NNT = 9) and adalimumab (NNT = 10), being lower in the recommended dose of 
infliximab (NNT = 12). The most favorable annual cost of acquisition was observed 
with adalimumab which US$ 311,651.00 is needed to treat 10 patients and get ACR70 
response in a single one, compared to expense of US$ 365,107.00 with etanercept 
(NNT = 9). The unusual infliximab dose of 10mg/kg showed similar results (NNT 
= 9), however with the most unfavorable spent of US$ 680,385.00. cOnclusiOns: 
Adalimumab was the agent who showed the most favorable annual expenditure 
for medicine purchase from the perspective of the public health system in Brazil, 
considering the most clinically relevant response.
PMS40
BIOLOGICAL TREATMENT PATTERNS AND ASSOCIATED COSTS FOR PATIENTS 
wITH RHEUMATOID ARTHRITIS IN TAIwAN
Wu C.H., Chuang P.Y., Tang C.H.
Taipei Medical University, Taipei, Taiwan
Objectives: To examine the pattern of biological treatment and the medical costs 
for patients with rheumatoid arthritis (RA). MethOds: A longitudinal dataset that 
includes the claims of service used by a cohort of RA patients from the Bureau of 
National Health Insurance was used for this study. The inclusion criteria for the 
study cases were patients who: 1) were holding the Catastrophic Illness Card with 
RA; 2) had the 1stline TNF-α antagonist treatments for at least 6 months; 3) were aged 
over 17. Treatment patterns were defined based on their TNF-α Antagonist within 
12 months after the initial 6-month treatment period. Wilcoxon signed rank tests 
were performed to compare differences in service costs and service uses between 
the pre- and post-biological treatment periods. Results: In total, 2425 patients 
were eligible for analysis. In the first year after TNF-α initial 6-month treatment, 94% 
remained using the same TNF-α antagonist, 3% had switched from one to another 
TNF-α antagonist, and 3% discontinued use of TNF-α antagonist. RA patients treated 
with TNF-α antagonist were significantly associated with reductions in emergency 
room visits (p < 0.001), hospital days (p < 0.01) and total medication costs (excluding 
biologics) (p < 0.01). However, total RA-related outpatient visits and overall medi-
cation costs went up significantly (p < 0.001). Reduction in services use was not 
productive age (18-60 for women and 18-65 for men) were recruited at regionally 
stratified sample of rheumatology outpatient centers around the country and 
were offered a questionnaire including Work Productivity and Activity Impairment 
(WPAI) instrument (a standardized tool for loss of work productivity estimation). 
The survey was complemented by disease activity assessment questionnaire 
filled out by specialists who were also responsible for patients recruitment dur-
ing the routine visits. Employed patients were estimating i.a. the absenteeism 
and presenteeism rates (% of work time missed due to health and % of impair-
ment while working). Subsequently, systematic review of Medline database was 
conducted. Two studies using WPAI questionnaire were found (Bansbrack 2012, 
Zhang 2010). Results: In the study, mean age of RA patients was 49 (mean age 
at RA onset was about 39), mean DAS28 result 3,77 (moderate disease). 40% of the 
group had first symptoms for less than 5 years (mean duration since symptoms 
onset was 90 months). Meanwhile, in Bansbrack 2012 mean age at RA onset was 
48 and mean duration since onset of symptoms was 48.6 months. Mean age of 
patients described in Zhang 2010 was 51, 45.8% had disease duration of less than 
5 years. The participants had a low function disability level and moderate arthritis. 
In the study absenteeism rate was 18%, while presenteeism rate reached 27%. The 
corresponding values in Bansbrack 2012 were 8.7% and 24%. In Zhang 2010 only 
presenteeism rate was analyzed and equaled 17.8%. cOnclusiOns: RA reduces 
work ability and lower work productivity in people in productive age both in Poland 
and in other countries. Differences in patients characteristics are probably the 
cause of results variation between studies.
PMS36
HEALTH CARE RESOURCE USAGE, TREATMENT AND COSTS AMONG PATIENTS 
wITH HIP FRACTURE IN THE UNITED KINGDOM
Lambrelli D.1, Burge R.2, Raluy M.1, Karlsdotter K.1, Chen S.Y.3, Wu N.3, Schoenfeld M.2
1Evidera, London, UK, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Evidera, Lexington, MA, 
USA
Objectives: Available data on economic impact of hip fractures in the U.K. are 
mostly derived from clinical trials or published before the year 2000; recent esti-
mates are lacking. This study examined health care resource usage, treatment and 
costs among patients with hip fracture in the U.K. MethOds: The study used data 
from the Clinical Practice Research Datalink (CPRD) linked to the Hospital Episode 
Statistics (HES). Adult patients hospitalised for hip fracture (ICD-10: S72 or M84.4; 
admission date as index date between January 1, 2006—March 31, 2011) and no pre-
vious hip fracture 7 days to 1 year pre- index, and computerised data available 1 year 
pre and 1 year post-index were identified in HES. Hip fracture-related inpatient and 
outpatient visits and pharmaceutical treatments were estimated for pre- and post-
index periods. Associated costs were calculated by multiplying resource units by 
official publicly available costs from the NHS perspective. Results: A total of 8,028 
hip fracture patients were identified (mean age 79; 27% age 85+; 75.8% female; mean 
Charlson comorbidity index score 2.1). The most common comorbidities were osteo-
arthritis (42%), pulmonary disease (25%), and renal disease (23%). Pre-index, aver-
age resource use per patient included 1 inpatient stay (mean 5.7 days), 7.4 General 
surgery visits, 4.4 blood tests, and 0.76 General Practice phone consults. Average 
overall costs pre-index were £3122. For the index hospitalisation, mean length-
of-stay and costs were 19.5 days and £14223, respectively; 18% were discharged to 
another hospital; and 39% and 5% had partial or total hip arthroplasty procedures 
performed. Post-index frequent medications included acetaminophen (56%), opioids 
(46%), and bisphosphonates (46%); 51% had hospital stays; and 5.7% had subsequent 
hip fractures. Average post-index overall costs were £7359. cOnclusiOns: Our 
study provides recent estimates of resource usage, treatment and costs among 
U.K. hip fracture patients. This information can be useful in burden of illness and 
economic analyses.
PMS37
RESOURCE UTILISATION AND COSTS OF TOTAL HIP ARTHROPLASTy IN THE 
UNITED KINGDOM: A DESCRIPTIvE ANALySIS
Raluy M.1, Burge R.2, Lambrelli D.3, MacLachlan S.1, Wu N.4, Chen S.Y.4, Schoenfeld M.2
1Evidera, London, UK, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Evidera, UK, 4Evidera, 
Lexington, MA, USA
Objectives: Total hip arthroplasty (THA) is a commonly performed surgical proce-
dure in the elderly, projected to increase substantially due to the aging population. 
Newer resource use and cost estimates are needed to understand the potential THA 
burden. The study objective was to estimate health care resource use and costs in 
THA patients in the U.K. MethOds: The Clinical Practice Research Datalink (CPRD) 
linked to the Hospital Episode Statistics (HES) was used to estimate resource use in 
THA patients. Inclusion criteria were: first inpatient stay for THA (OPCS procedure 
code W37-W39, W46-W48, W93-W95) (index event between 1/1/2006--3/31/2011); 
no THA diagnosis/procedure 7 days to one year pre-index date; 1-year pre and 
1-year post-index of computerised data available; age 18+. Inpatient, outpatient 
and pharmacy THA-related costs were calculated by multiplying resource units 
by official publicly available costs (British Pound Sterling, 2012) from the NHS per-
spective. Results: THA patients identified (n= 15,288) were mostly female (66%), 
elderly (mean age 72; 45%> 75), and 84% had osteoarthritis. Pre-index, the most 
common medications were opioids (53%), NSAIDs (41%), and acetaminophen (35%); 
95% had General surgery visits; 64% had inpatient stays; 36% had x-ray; and overall 
costs (std. dev) were £4,556 (7850). The index hospital event average length-of-stay 
(LOS) was 9 days and mean costs were £11,321. Post-index medication usage for 
opioids, NSAIDs, and acetaminophen was 49%, 29%, and 45%, respectively. The 
most frequent resources were General surgery visits (94%), hospital stays (39%), 
and General Practice phone consults (35%). For patients with utilisation, means per 
patient were 7.4 for General surgery visits, 5.4 days for hospitalisations. Mean (std. 
dev) overall post-index costs were £3,567 (9612), comprised mostly of inpatient costs 
(85%). cOnclusiOns: This study described resource utilisation, pain medications 
usage and associated costs for THA patients. These estimates may offer a better 
understanding of the economic burden.
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eligible for surgery, shows that HA viscosupplementation has the most favorable 
outcome, both from a clinical and economic point of view.
PMS44
COST-EFFECTIvENESS MODELLING OF A 3-MONTH TIGHT CONTROL PATIENT 
MANAGEMENT OF RHEUMATOID ARTHRITIS wITH CERTOLIzUMAB PEGOL IN 
FRANCE
Fagnani F.1, Pham T.2, Claudepierre P.3, Berenbaum F.4, De Chalus T.5, Saadoun C.5,  
Joubert J.M.5, Fautrel B.6
1Cemka-Eval, Bourg la Reine, France, 2CHU Sainte-Marguerite, Marseille, France, 3Groupe 
Hospitalier Henri Mondor, Créteil, France, 4CHU Saint-Antoine, Paris, France, 5UCB Pharma, 
Colombes, France, 6CHU Pitié-Salpétrière, Paris, France
Objectives: European registries of Rheumatoid Arthritis (RA) patients treated by 
biological agents suggest that 70-80% are maintained in first line at 1 year despite 
potential insufficient efficacy. Post hoc analyses of certolizumab pegol (CZP) stud-
ies indicate that a 3 month clinical response had a high predictive value of the 1 
year outcome. The objective was to examine the efficiency of a strategy consisting 
of early switching from CZP to a second line TNF inhibitor in case of insufficient 
clinical response at 3 months (3M) in the French setting versus current clinical 
practices. MethOds: A decision-tree model was built to estimate the clinical 
outcomes (ACR50 cumulated time) and the direct costs of different cohorts of RA 
patients over a 2 year period. ACR50 was considered as an RA satisfying clinical 
outcome. The “3M tight control” strategy consisted of stopping CZP at 3 months in 
patients not achieving the ACR50 criterion and switching them to other biologics. 
Three reference cohorts treated with first line CZP, etanercept or adalimumab, 
respectively, according to current clinical practices were considered as compara-
tors (reference). All TNF inhibitors were assumed to have equal efficacy in first line. 
Costs were estimated at 2013 French public prices. Results: The proportion of 
patients achieving ACR50 after a 2 year follow-up was 58% in all reference cohorts 
and 75% in the “3M tight control” CZP strategy cohort. The costs per patient-year 
in ACR50 were € 19,326 with the “3M tight control” strategy cohort and € 23,588, 
€ 26,774 and € 30,285 for the CZP, etanercept and adalimumab reference cohorts, 
respectively. The strategy “3M tight control” had an incremental cost-effectiveness 
ratio of € 5,605/patient-year in ACR50 versus CZP reference, and was dominant 
versus etanercept or adalimumab reference. cOnclusiOns: A 3-month tight con-
trol management of RA patients with CZP as first line treatment is cost-effective 
compared to alternatives.
PMS45
COST-PER-RESPONDER ANALySIS OF BIOLOGICAL AGENTS FOR THE 
TREATMENT OF ACTIvE ANKyLOSING SPONDyLITIS IN GERMANy
Betts K.A.1, Joshi A.D.2, Yan S.Y.1, Zhou Z.1, Rao S.2, Wolff M.3, Cifaldi M.2
1Analysis Group, Inc., Boston, MA, USA, 2AbbVie Inc., North Chicago, IL, USA, 3AbbVie 
Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Objectives: To conduct a cost-per-responder analysis of biologic treatments 
(adalimumab, etanercept, golimumab, and infliximab) for the treatment of active 
ankylosing spondylitis (AS) from the German Statutory Health Insurants (SHI) 
perspective. MethOds: A systematic literature review was conducted to identify 
randomized clinical trials for biologic treatments for active AS. The clinical efficacy 
of biologic therapies and standard of care was evaluated using Assessment of 
SpondyloArthritis international Society (ASAS) 20 response, which is defined as at 
least 20% improvement from baseline using ASAS criteria. The relative probability 
of achieving ASAS 20 at Week 12 with each biologic therapy was estimated via net-
work meta-analysis. Evaluation was conducted in terms of cost-per-incremental 
ASAS 20 responder. Twelve-week costs were assessed in terms of 2012 euros, and 
included drug acquisition, administration, laboratory tests, and clinic visits based 
on German treatment guidelines. Weight-based dosing for infliximab assumed 
an average weight of 78.6 kg. Results: Thirteen randomized controlled trials of 
active AS with a minimal duration of 12 weeks were identified; 10 reported ASAS 
20 at Week 12. The estimated rates of ASAS 20 response at Week 12 were not sta-
tistically different between infliximab (70.8%), adalimumab (62.9%), golimumab 
(61.2%), and etanercept (60.5%). However, all 4 biologic therapies were significantly 
better than the standard of care (27.1%). In the base case, adalimumab had the 
lowest cost-per-incremental ASAS 20 responder compared with standard of care 
(€ 13,282 per incremental ASAS 20 responder), followed by golimumab (€ 13,947), 
etanercept (€ 14,221), and infliximab (€ 22,838). These rankings were unchanged 
in sensitivity analyses based on ASAS 40 response rates (estimated from 6 tri-
als). cOnclusiOns: All 4 biologic treatments were more efficacious in terms of 
ASAS 20 response than the standard of care. Among biologics, adalimumab showed 
the lowest cost per incremental ASAS 20 responder at Week 12 for active AS from 
the German SHI perspective.
PMS46
COST-EFFECTIvENESS ANALySIS OF BIOLOGICAL DISEASE-MODIFyING 
ANTIRHEUMATIC DRUGS IN THE TREATMENT OF RUSSIAN PATIENTS wITH 
RHEUMATOID ARTHRITIS wHO FAILED PREvIOUS ANTI-TNF-ALFA THERAPy
Ryazhenov V.V., Emchenko I.V.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To assess the cost-effectiveness of rituximab and anti-TNF-alfa 
agents in the treatment of Russian patients with rheumatoid arthritis (RA) who 
failed previous anti-TNF-alfa therapy. MethOds: The pharmacoeconomic model 
was developed based on the data from multicentre prospective 3-year observa-
tional MIRAR-study (J. Gomez-Reino et al., 2012). A one-year time horizon was 
adopted in the model. The cost analysis included costs of medicines and expenses 
for the day care services. The efficacy of therapies was defined as a reduction of 
disease activity score in 28 joints (DAS28) and proportion of patients achieved 
EULAR good or moderate response after 6, 9 and 12 months since biological 
therapy was started. To assess the robustness of the results, one-way sensitivity 
analysis (SA) was carried out. Results: Treatment with rituximab was associated 
significantly observed among patients who switched during their TNF-α antago-
nist treatment. cOnclusiOns: RA with biological treatment was associated with 
reductions of service uses; however, overall service costs were compromised by 
costs incurred from increased utilization of outpatient service and TNF-α antagonist 
medication costs under the context of health care in Taiwan.
PMS41
REDUCTION IN NSAIDS CONSUMPTION AFTER vISCOSUPPLEMENTATION wITH 
HA: IS IT COSTS SAvING?
Migliore A.1, Massafra U.1, Bizzi E.1, Tormenta S.1, Giordan N.2
1S. Pietro Fatebenefratelli Hospital, Rome, Italy, 2Fidia Farmaceutici S.p.A, Abano Terme (PD), Italy
Objectives: Multicentric, open, retrospective study to determine whether NSAID 
consumption may be reduced by the use of US-guided Intra-articular injection 
(USGIAI) of hyaluronic acid (HA), in hip joint in patients affected by symptomatic 
hip OA. MethOds: Patients affected by mono or bilateral hip OA entered the study 
and were administered with a single HA (HyalOne-Hyalubrix 60) injection every six 
months. As primary endpoint, consumption of NSAIDs was evaluated by recording 
the number of days a month the patient used NSAID during the month previous to 
the visit, reported at each visit during the 24 months follow-up period, while second-
ary endpoints was represented by the percentage of patients assuming NSAIDs at 
baseline and at each control visit. Results: A total of 755 patients entered the study 
from 2008 to 2013. Consumption of NSAIDs was reduced from a consumption rate 
mean of 21,3 to a mean of 5,08 at the third month; this reduction further improved 
at 12th and 24th month with a reduction respectively to 4,14 and 3,79. Percentage 
of patients not taking NSAIDs at baseline was 45%; this percentage raised to 57% at 
12 months and remained stable (58%) at 24 months. We performed an evaluation of 
costs of therapies for hip OA for two hypothetic populations of 1000 patients each, 
the first one undergoing to HA USGIAI every six months for a total of 4 injections 
in 2 years, and the second one of 1000 patients undergoing to chronic daily NSAIDs 
therapy, both for two years. Our results confirmed in the USGIAI population a cost 
savings in comparison with the NSAIDs population. cOnclusiOns: HA USGIAI, 
administered every 6 months, reduce the assumption of NSAIDs in patients affected 
by hip OA, reflecting its efficacy on pain relief and cost saving.
PMS42
PHARMACOTHERAPEUTIC MONITORING OF PATIENTS USING 
IMMUNOBIOLOGICAL IN A HEALTH INSURANCE COMPANy IN BRAzIL: TO 
KNOw TO BETTER MANAGE
Reis H.P.L.C.1, Vieira J.B.2, Fonseca D.B.2, Magalhães D.D.P.2, Sartori D.P.2, Viana A.D.J.R.2, Barsi 
U.D.2, Alencar J.L.L.2, Maciel J.A.P.2, Filho A.E.A.M.2, Alcantara A.C.D.C.2
1UFC, Fortaleza, Brazil, 2Unimed Fortaleza, Fortaleza, Brazil
Objectives: To determine the clinical and pharmacoeconomic indicators from 
pharmacotherapeutic monitoring of patients using immunobiological (IMB) in 
a Health Insurance Company in Fortaleza - Brazil. MethOds: Cross-sectional 
study in two hospitals accredited Insurance, from March/2012 to May 2013 (n = 96 
patients). Data were recorded by medical (rheumatologist) in computerized manage-
ment system (Sabius ®) performed after the query. Later, these were entered into 
Microsoft Excell 2007 and analyzed by clinical pharmacists auditors. The cost was 
calculated from the unit value in the book Brasíndice 765, using the Consumer Price 
Maximum and average weight of 70 kg in standard doses. Results: Most patients 
were women (66, 68.75%), averaging 67 kg, aged between 30-59 years (62.50%) and 
higher incidence of rheumatoid arthritis among the diseases treated (45; 46.88%). 
The higher costs per capita were checked with Infliximab (R$ 62,459.40) and abata-
cept (R$ 41,989.55), while Adalimumab (R$ 16,614.60) and golimumab (R$ 10,385.05) 
represented the lowest cost per capita. There was a significant difference between 
the average cost per capita of IMB intravenous (91, R$ 48,975.27) and subcutaneous 
(11, R$ 10,695.49). The average cost for treatment / dose first line was R$ 6,068.91 
and the second line was R $ 9,590.06, resulting in an incremental cost / dose of R $ 
3,521.16 (36.72%). cOnclusiOns: The pharmacotherapeutic monitoring becomes 
important for planning strategies aimed at streamlining and optimization of these 
drugs and pharmacoeconomic clinical management.
PMS43
DELAy OF TOTAL HIP REPLACEMENT (THR) USING HA 
vISCOSUPPLEMENTATION: IS COST EFFECTIvE?
Migliore A.1, Massafra U.1, Bizzi E.1, Tormenta S.1, Giordan N.2, Belisari A.3
1S. Pietro Fatebenefratelli Hospital, Rome, Italy, 2Fidia Farmaceutici S.p.A, Abano Terme (PD), Italy, 
3Fondazione CHARTA, Milan, Italy
Objectives: Retrospective study to determine whether THR may be delayed by the 
use of US-guided Intra-articular injection (USGIAI) of hyaluronic acid (HA), in hip 
joint in patients affected by hip OA. MethOds: We evaluate the delaying in the 
THR considering 176 patients suffering from hip OA and treated with HA USGIAI, 
candidates for THR according to the judgment of six orthopaedics. Then, we imag-
ing two hypothetic populations of 1000 patients each candidates to THR, the first 
undergoing to 1 injection of HA (HyalOne-Hyalubrix 60) USGIAI and the second one 
undergoing to THR for a follow-up period of one year and four years. We performed 
the cost evaluation on hip surgery, eventual revision of the prosthesis, post-oper-
ative complications and mortality, rehabilitation, lost working days. Results: At 
24 months, 159 out of 76 (90 %) patients did not undergo to THR. At 48 months, 82 
% (N = 144) of the study population treated with HA USGIAI avoided THR. In the 
group of 93 patients candidates for THR (that is, in which 4, 5, or 6 orthopaedic 
surgeons agreed that the patient was a suitable candidate for THR), only 17 had 
undergone THR, with survival results of 82 % at 24 months. At 48 months, this 
percentage reduced to 66 % in this group. Results show that the treatment with 
HA USGIAI is the most favorable option, from a clinical and economic perspective, 
and also considering the social impact (higher value of quality-adjusted life-years 
(QALYs)). Analyzing hospital perspective, there are even higher benefits, estimated 
to be between approximately 940,000 euros in one year and 580,000 euros after 4 
years. cOnclusiOns: Data simulation comparing HA USGIAI vs THR in patients 
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Objectives: Several technologies are currently being developed for better 
stratifying individuals at risk of developing Rheumatoid Arthritis (RA) to patient-
tailored treatment. We assessed the potential cost-effectiveness of four technolo-
gies (MRI, il6-serum test, RNA B-cell signature, genetic assay) applied to patients 
with intermediate risk for RA (3-5 points on ACR/EULAR) using an one-year hori-
zon. MethOds: The cost-effectiveness was simulated with a decision model 
using data from the Rotterdam Early Arthritis Cohort (prevalence of RA: 55%). 
The comparator was 2010 ACR/EULAR classification criteria. Test properties (sen-
sitivity (se), specificity (sp) and costs) were based on literature and expert opinion. 
Patients were classified true positive (TP) if they score > = 6 points on the criteria 
or were test positive and used MTX at 12 months. True negative (TN) patients were 
those who that scored < 6 points or were test negative and did not use MTX at 
12 months. Utility changes within one year were assigned to TP (+0.1), TN (+0.1), 
false positive (+0.05), and false negative (-0.05). Results: RNA B-cell signature 
(se: 0.60; sp: 0.90; costs: € 150) has the largest net benefit (Δ TP-Δ FP) (45%) and is 
most cost-effective with an incremental cost effectiveness ratio (ICER) of € 13,939. 
The il-6 serum test (se 0.70; sp: 0.53; costs: € 100) has an ICER of € 17,343. The MRI 
and genetic assay have ICERs of € 38,541 and € 70,347 due to the higher incremen-
tal costs of these strategies. To stay below a willingness to pay (WTP) threshold 
of € 20,000/QALY gained (given current utility assumptions), the extra test costs 
of the new test strategy can maximally be € 230. cOnclusiOns: The RNA B-cell 
signature or il6-serum tests have most potential to be cost-effective in patients 
with intermediate risk of developing RA.
PMS50
INvESTIGATING THE vALUE OF ABATACEPT Iv IN THE TREATMENT OF 
RHEUMATOID ARTHRITIS: A SySTEMATIC REvIEw OF COST-EFFECTIvENESS 
STUDIES
Athanasakis K., Petrakis I., Kyriopoulos J.
National School of Public Health, Athens, Greece
Objectives: Rheumatoid arthritis is a progressive inflammatory disease that 
affects greatly patients’ quality of life and demands for aggressive manage-
ment early on during the course of the disease. The emergence of biologics has 
equipped rheumatologists with evolutionary treatment tools but it has also influ-
enced the costs of the disease, thus highlighting the necessity of cost-effective-
ness data. In this light, the purpose of this study was to conduct a systematic 
review of cost-effectiveness data for abatacept i.v. in the treatment of moderate 
to severe rheumatoid arthritis. MethOds: Pubmed, the International Society 
for Pharmacoeconomics and Outcomes Research Outcomes Research Digest, 
the National Health System Economic Evaluation Database, and the Database 
of Abstracts of Reviews of Effects were searched for papers published in the last 
decade (2002-2012). An initial search using the keywords “abatacept, cost effec-
tiveness, and rheumatoid arthritis” was followed by a search of related citations. 
The quality of independent economic evaluation studies was evaluated in accord-
ance to the Centre for Reviews and Dissemination set of guidelines. Results: In 
total 301 studies were identified and 42 met the inclusion criteria. The majority 
of rejected studies were due to lack of cost data, failure to include abatacept as 
a comparator to other biologic agents, and failure to include RA as a treatment 
indication. Half of the selected studies evaluated abatacept in the treatment 
of rheumatoid arthritis, after failure of or intolerance to tumor necrosis factor 
alpha inhibitors. Of those, 82% were in favor of abatacept as a cost-effective or 
dominant strategy versus varying alternatives, whereas 18% favored other treat-
ments. cOnclusiOns: The majority of evidence from the published literature 
supports that abatacept IV can be a cost-effective alternative in the treatment of 
moderate to severe rheumatoid arthritis.
PMS51
PHARMACOECONOMIC ASPECTS OF THE FIRST-LINE BIOLOGIC THERAPIES IN 
RUSSIAN PATIENTS wITH RHEUMATOID ARTHRITIS
Ryazhenov V.V., Gorokhova S.G., Emchenko I.V.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To assess the cost-effectiveness of tocilizumab and TNF-alfa inhibi-
tors in the treatment of Russian patients with rheumatoid arthritis (RA) and 
intolerance or inadequate response to disease-modifying antirheumatic drugs 
(DMARDs) or for whom continuation of DMARDs was deemed inappropri-
ate. MethOds: Based on the data from ADACTA-trial and the results of indirect 
comparison of tocilizumab and anti-TNF-alfa agents (G. Bergman et al., 2010) 
two pharmacoeconomic models were developed. A six-month time horizon was 
adopted in the models. Cost-effectiveness of tocilizumab and adalimumab was 
estimated in the first model. In the second model, cost-effectiveness of toci-
lizumab was compared to the cost-effectiveness of antirheumatic therapy in 
the mixed treatment group, which included patients who received infliximab, 
etanercept and adalimumab in proportion 1:1:1. The cost analysis included 
costs of medicines and expenses for the day care services. The efficacy of the 
treatment was defined as a DAS28-reduction, proportion of patients achieved 
a low or moderate DAS28, EULAR good or moderate response (was considered 
only in the first model) and ACR20, ACR50, ACR70 responses. Sensitivity analysis 
(SA) was performed by changing costs of medicines and relative proportions of 
patients received infliximab, etanercept and adalimumab in the mixed treat-
ment group. Results: Despite the higher cost of treatment with tocilizumab 
(591,112.92 RUB as compared to 488,735.00 RUB for adalimumab), it had the bet-
ter cost-effectiveness ratios (CERs): 179,125.04 RUB vs 271,519.44 RUB per unit of 
DAS28-reduction, respectively. The similar results were observed for the CERs 
estimated per one patient with clinical response. Compared to the mixed treat-
ment group, tocilizumab also had better CERs. SA confirmed the robustness of 
the model. cOnclusiOns: The study has demonstrated that tocilizumab is an 
economically effective strategy in the treatment of Russian patients with RA 
and intolerance or inadequate response to DMARDs or for whom continuation 
of DMARDs was deemed inappropriate.
with the lowest total costs (437,620.24 RUB per one patient). The costs further 
increased in the row: etanercept (554,912.15 RUB), adalimumab (977,470.00 RUB), 
and infliximab (1,039,363.68 RUB). It should be noted that in the infliximab group 
the bulk of the costs (more than 60% of total) incurred within first six month of 
therapy. This may potentially increase the financial losses associated with inad-
equate response to infliximab. The estimated cost-effectiveness ratios (CERs) were 
241,779.14 RUB, 334,284.43 RUB, 630,625.81 RUB, and 670,557.21 RUB per unit of 
DAS28-reduction in the rituximab, etanercept, adalimumab and infliximab groups, 
respectively. The similar results were observed for the CERs estimated per one 
patient with EULAR good or moderate response (533,683.22 RUB, 730,147.57 RUB, 
1,286,144.74 RUB, and 1,367,583.79, respectively). SA demonstrated that results are 
robust. cOnclusiOns: The present study has demonstrated that administration 
of rituximab is economically effective strategy in the treatment of Russian patients 
with rheumatoid arthritis who failed previous anti-TNF-alfa therapy. Furthermore, 
treatment with rituximab is associated with considerably lower costs as compared 
to etanercept, adalimumab and infliximab.
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COST-EFFECTIvENESS ANALySIS OF TOCILIzUMAB IN RHEUMATOID 
ARTHRITIS, IN COLOMBIA
Gamboa O.1, Bárbosa D.2, Parada L.3, Latorre M.4
1IECAS, Bogotá, Colombia, 2F. Hoffmann-La Roche, Bogotá D.C, Colombia, 3Roche Colombia, 
Bogotá, D.C, Colombia, 4Productos Roche Colombia, Bogota, Colombia
Objectives: Assess the cost-effectiveness of first-line tocilizumab bio-
logical treatment as monotherapy or in combination with methotrexate, in 
patients with rheumatoid arthritis (RA) refractory to treatment with non-
biological DMARDs. MethOds: A markov model was used of the natural his-
tory of RA to assess: tocilizumab, tocilizumab+methotrexate, adalimumab, 
adalimimab+methotrexate, etanercept, etanercept + methotrexate and 
infliximab+methotrexate. The systematic review of literature don’t show results 
for infliximab in monotherapy. The strategies were evaluated in combination with 
methotrexate in the first or second line, for a total of 11 strategies evaluated. 
Outcomes were measured as quality adjusted life years (QALYs). Analysis from 
the payer perspective, only direct costs were considered, COP 2012. Ratios were 
calculated cost-effectiveness and incremental cost-effectiveness, and sensitivity 
analyzes deterministic and probabilistic were conducted. For the RA chronicity, 
was used time horizon until life expectancy used discount rate of 3% for both costs 
and health outcomes. Results: Tocilizumab was one of the least expensive strat-
egy in first and second-line treatment. For life expectancy horizon monotherapy 
with tocilizumab followed by infliximab in second line are efficient frontier with 
an ICER per QALY gained of COP $165,918,610.58. The ICER is sensible to price 
of medicaments, with a inferiority limit, the results change to COP $106.160.64. 
The probabilistic analysis indicates that a threshold to willingness to pay of COP 
$ 150 million higher than monotherapy with tocilizumab, be cost-effective in 
Colombia. cOnclusiOns: The use of tocilizumab in first and second line like 
monotherapy and in combination strategy remains lower costs per benefit gained; 
in that sense, can be considered as an efficient therapy in the Colombian context.
PMS48
A MODEL TO EvALUATE THE IMMUNOGENICITy COSTS OF TUMOUR NECROSIS 
FACTOR-ALPHA INHIBITORS IN PATIENTS wITH RHEUMATOID ARTHRITIS
Heeg B.1, Majer I.1, Stephens J.M.2, Tarallo M.3
1Pharmerit International, Rotterdam, The Netherlands, 2Pharmerit International, Bethesda, MD, 
USA, 3Pfizer Italia, Rome, Italy
Objectives: The prognosis of rheumatoid arthritis (RA) has improved dramati-
cally with the development of tumour necrosis factor-alpha (TNFα ) inhibitors. 
However, some patients develop immunogenicity to TNFα inhibitors that can result 
in treatment failure and higher costs. In addition, immunogenicity to one TNFα 
inhibitor may create cross-resistance to others. Previous studies have shown the 
TNFα inhibitor etanercept (ETN) is less immunogenic than adalimumab (ADA) and 
infliximab (INF). The objective of this study was to determine the costs incurred 
due to the immunogenicity of ETN, ADA, and INF. MethOds: A Markov model 
was created using data from previously published studies (i.e. the proportions 
of patients developing antibodies against ADA and INF; the size of increase of 
dose or drug administration frequency in patients receiving ADA and INF if treat-
ment failed; and the rate of effective dose escalation in patients with and without 
immunogenicity) and from expert opinion (i.e. physician visit intervals). It was 
assumed that patients receiving ETN did not develop immunogenicity. Patients 
initially started ETN, ADA, or INF were allowed to switch treatment to a second 
or third TNFα inhibitor if treatment failed. Costs due to immunogenicity were 
calculated from: drug usage after treatment failure, dose or frequency increase 
after treatment failures, and additional visits due to lack of response. Results: 
Initiating treatment with ETN resulted in the highest proportion of patients still 
receiving first-line therapy after 5 years, compared with ADA or INF. Assuming 
15,000 patients (1% prevalence of RA in The Netherlands) treated for 5 years, 
the immunogenicity costs incurred with different sequential treatment strat-
egies were: ETN-ADA-INF € 4,937,176, ETN-INF-ADA € 5,409,593, ADA-ETN-INF 
€ 10,140,206, INF-ETN-ADA € 11,160,699, ADA-INF-ETN € 14,735,996, and INF-ADA-
ETN € 15,980,783. cOnclusiOns: The 5-year results of our model showed initiat-
ing treatment with ETN rather than ADA or INF resulted in higher adherence to 
first-line therapy and lower immunogenicity costs.
PMS49
COST-EFFECTIvENESS ANALySIS OF DIAGNOSTIC TESTS IN THE wORK-UP 
OF PATIENTS wITH INTERMEDIATE RISK OF DEvELOPING RHEUMATOID 
ARTHRITIS
Buisman L.R.1, Luime J.J.2, Oppe M.1, Hazes J.M.2, Rutten-van Mölken M.P.M.H.1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus MC, Rotterdam, The 
Netherlands
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THREE TNF-A-INHIBITORS FOR TREATMENT OF RHEUMATOID ARTHRITIS, 
ANKyLOSING SPONDyLITIS AND PSORIATIC ARTHRITIS
Ivakhnenko O.1, Rebrova O.2, Avxentyeva M.3, Khachatryan G.1
1Autonomous non-profit organization “National Centre for Health Technology Assessment”, 
Moscow, Russia, 2Pirogov Russian National Research Medical University, Moscow, Russia, 3The 
Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia
Objectives: To perform pharmacoeconomic analysis of golimumab (GOL) vs 
adalimumab (ADA) and infiliximab (INF) for rheumatoid arthritis (RA), ankylosing 
spondylitis (AS) and psoriatic arthritis (PA) in Russia MethOds: Indirect compar-
ison demonstrated that compared drugs have similar efficacy and safety. Cost-
minimization analysis was performed to compare the cost for 1-year treatment with 
GOL, ADA and INF in doses according to the approved recommendations. Expected 
cost for treating all eligible patients with RA, AS and PA with TNF-α -inhibitors in 
Russia were calculated in a model, assuming that INF is used in the 1st line therapy 
during one year and ADA or GOL in the 2d line therapy during the 2d year. Number 
of patients to be treated with TNF-α -inhibitors was calculated based on state sta-
tistical data and data on the percentage of patients who do not respond to therapy 
with synthetic disease-modifying antirheumatic drugs (DMARDs) and first-line 
biologic DMARDs from clinical trials. Results: INF dosing regimen is different 
for RA and other rheumatic diseases, 1 year treatment with INF costs € 16,212 for 
RA and € 24,319 for AS and PA. GOL and ADA have the same dosing regimen for all 
rheumatic diseases and costs € 16,544 and € 24,243 per year correspondingly. If all 
eligible patients with rheumatic diseases in Russia receive biologic DMARDs when 
necessary, treatment with GOL in the 2d line is less expensive than ADA, difference 
in costs is € 89,062,427 (for all eligible patients per year). It allows treating additional 
4959 patients RA, 278 AS patients and 147 PA patients per year. cOnclusiOns: GOL 
is cost-saving vs ADA for the 2d line therapy of rheumatic diseases in Russia. 1-year 
treatment with GOL is less expensive that INF for AS and PA and may be considered 
as the 1st line option.
PMS56
PHARMACOECONOMIC ANALySIS OF ABATACEPT FOR TREATMENT OF ADULTS 
wITH RHEUMATOID ARTHRITIS IN RUSSIA
Gerasimova K.1, Avxentyeva M.2, Goryaynov S.3, Rebrova O.4
1The First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia, 2The 
Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, 
3Autonomous non-profit organization “National Centre for Health Technology Assessment”, 
Moscow, Russia, 4Pirogov Russian National Research Medical University, Moscow, Russia
Objectives: to conduct a pharmacoeconomic analysis of abatacept vs etaner-
cept, tocilizumab and adalimumab for rheumatoid arthritis (RA) in adult patients, 
resistant to methotrexate therapy, in Russia. MethOds: Indirect comparison of 
clinical efficacy of abatacept, etanercept, tocilizumab and adalimumab was per-
formed. Data on safety from clinical studies and meta-analysis was analyzed. The 
differences in the direct medical costs for compared biological drugs (BD) in adult 
patients with RA were calculated using the cost-minimisation analysis. The cost 
of abatacept vs etanercept and tocilizumab were calculated on the basis of the 
registered manufacture’s prices for vital and essential drugs (VED) in 2012. The 
costs of abatacept vs adalimumab were calculated based on the price of tender 
purchases in 2011 (adalimumab is not included into the VED List, and its price is 
not registered). The costs of day care for patients during the BD administration 
were calculated based on the cost norms per volume of medical care approved by 
the Program of State Guarantees for the provision of free medical care to Russian 
citizens in 2012. The calculations were performed over the BD application period 
for 2 years. Results: Indirect comparison showed no statistically significant dif-
ferences in the efficacy of compared BD. There was no data about clinically mean-
ingful differences in safety. The use of abatacept is less costly than etanercept 
and tocilizumab when registered manufacture’s prices are used for cost estima-
tion. The difference in costs (in favor of abatacept) amounted to 1431.34 EUR and 
16058.34 EUR per patient per 2 years respectively. Abatacept is less costly than 
adalimumab (the costs are calculated based on prices of tender purchases in 2011): 
the difference in costs amounted to 1502.07 EUR per patient per 2 years in favor 
of abatacept. cOnclusiOns: Abatacept is a cost-saving option compared with 
etanercept, tocilizumab and adalimumab.
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CURRENT AND FUTURE STRATEGy FOR OSTEOPOROSIS SCREENING AND 
DIAGNOSTICS: COST-EFFECTIvENESS OF FRAx wITH OR wITHOUT PULSE-
ECHO ULTRASOUND MEASUREMENT OF BONE MINERAL DENSITy AND DxA ON 
DEMAND
Asseburg C.1, Riekkinen O.2, Karjalainen J.K.2, Kröger H.3, Soini E.J.1
1ESiOR Oy, Kuopio, Finland, 2Bone Index Finland, Kuopio, Finland, 3Kuopio University Hospital, 
Kuopio, Finland
Objectives: Over 75% of osteoporotic patients are not diagnosed with osteoporo-
sis and do not receive treatment because effective on-site diagnostics is lacking in 
primary care facilities. We compare the cost-effectiveness of two pathways of osteo-
porosis diagnosis: 1) Fracture Risk Assessment Tool (FRAX) followed by pocket size 
pulse-echo ultrasound device (Bindex®) followed by Dual-energy X-ray absorptiom-
etry (DXA) when needed (“proposed”), and 2) FRAX followed by DXA when needed 
(“guideline”). MethOds: A new Markov model of preventive osteoporosis treatment 
(assumptions: generic alendronate treatment; efficacy based on published meta-
analysis and modified by compliance/persistence; wrist, vertebral, hip and other frac-
tures included; Finnish health care payer perspective with 10-year timeframe and 3% 
discounting per annum) was extended to include the proposed pathway and osteo-
porosis screening/diagnosis in terms of sensitivity/specificity. FRAX with body mass 
index and age dependent National Osteoporosis Guideline Group thresholds was the 
initial screening tool common to both pathways. Bindex® was calibrated to 90% sen-
sitivity and specificity thresholds (International Society for Clinical Densitometry). In 
the proposed pathway, only the patients with Bindex result between these calibration 
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ASSESSMENT OF THE ECONOMIC IMPACT OF BELIMUMAB FOR THE TREATMENT 
OF SySTEMIC LUPUS ERITHEMATOSUS IN THE ITALIAN SETTING: A COST-
EFFECTIvENESS ANALySIS
Turchetti G.1, Pierotti F.1, Palla I.1, Stragliotto E.2, Porcasi R.2, Pippo L.2
1Scuola Superiore Sant’Anna, Pisa, Italy, 2GlaxoSmithKline, Verona, Italy
Objectives: Systemic Lupus Erythematosus (SLE) is a chronic non-organ spe-
cific autoimmune disease and is characterized by a dysregulation of the immune 
system that involves many organs and systems. It affects about 28,500 people 
in Italy, especially women of childbearing age (female-male ratio 9:1) that may 
have a compromised functional state and a decreased quality of life. The purpose 
of this analysis is to determine the cost-effectiveness of belimumab, a new bio-
logical treatment specifically developed for the treatment of SLE, in the Italian 
setting. MethOds: A cost-effectiveness micro simulation model with a lifetime 
horizon was adapted to the Italian setting. The analysis compares the standard 
of care (SoC) alone vs belimumab plus SoC from the perspective of the National 
Healthcare System. Clinical-economic consequences of the therapy and of the 
development of organ damage were calculated. When available, Italian data were 
used, otherwise UK costs were transformed into euros using the purchasing-power 
parity approach. The utility values were based on the EQ-5D of belimumab clini-
cal trials (BLISS 52 and 76). The results were discounted by 3% for both costs and 
effects. It was considered a duration of treatment with belimumab of 6 years and 
it was assumed that the drug is used with wastage. Results: The results of the 
cost-effective analysis in terms of cost per life year gained (ICER) and cost per QALY 
(ICUR) were € 22,990 and € 32,859 respectively. These values drop to € 20,119 and 
€ 28,754 respectively when indirect costs are included. cOnclusiOns: In this 
analysis, the results of ICER and ICUR show that belimumab is cost-effective in 
the Italian setting, according to the guidelines of the Italian Association of Health 
Economics (€ 25-40,000/QALY).
PMS53
TOCILIzUMAB IN POLyARTICULAR jUvENILE IDIOPATHIC ARTHRITIS – A COST-
UTILITy MODEL FOR THE UNITED KINGDOM
Chang S.1, Sawyer L.1, Dejonckheere F.2, van Suijlekom-Smit L.W.3, Anink J.3, 
Diamantopoulos A.1
1Symmetron Limited, Elstree, UK, 2F. Hoffmann-La Roche Ltd., Basel, Switzerland, 3Erasmus MC 
Sophia Childrens Hospital, Rotterdam, The Netherlands
Objectives: To evaluate the cost-effectiveness of tocilizumab (TCZ) in the treat-
ment of polyarticular juvenile idiopathic arthritis (pJIA) in the United Kingdom 
(UK). MethOds: An individual sampling model was developed to reflect the health 
care system and treatment pathway in the UK. Benefits were measured in terms of 
Quality Adjusted Life years (QALYs) and were derived from HUI3 data collected by 
the Dutch Arthritis and Biologicals in Children (ABC) Register [Prince et al., 2011]. 
Costs were calculated from a National Health Service and Personal Social Services 
perspective. The analysis calculated incremental costs and benefits associated with 
the addition of first line TCZ to the standard care pathway involving etanercept 
(ETN), adalimumab (ADA), and abatacept (ABA). The economic model used efficacy 
inputs derived from an indirect comparison of TCZ and ADA [Sawyer et al., 2013]. 
Due to fundamental differences in the clinical trial populations and trial design, it 
was not possible to compare the response rates of TCZ with ETN and ABA. Therefore 
in the absence comparative data, the economic analysis assumed response rates 
for ETN and ABA were similar to ADA. Longer-term treatment discontinuation was 
linked to level of response and assumed to be independent of treatment. Results: 
Base case results estimated incremental costs of approximately £1,750 and incre-
mental QALYs of 0.1011. The incremental cost-effectiveness ratio (ICER) was £17,000 
per QALY gained. cOnclusiOns: The results of this analysis suggest that TCZ rep-
resents an efficacious and cost-effective addition to the current standard of care for 
treating pJIA patients in the UK.
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COST-MINIMIzATION ANALySIS OF SUBCUTANEOUS ABATACEPT IN THE 
TREATMENT OF RHEUMATOID ARTHRITIS IN SPAIN
Ariza-Ariza R.1, van Walsem A.2, Canal Fontcuberta C.3, Roldán Acevedo C.4,  
Betegón Nicolás L.3, Oyagüez Martín I.4, Janssen K.2
1Hospital Universitario Virgen Macarena, Sevilla, Spain, 2Mapi, Houten, Spain, 3Bristol-Myers 
Squibb, Madrid, Spain, 4Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
Objectives: To compare the cost of using subcutaneous abatacept (SC ABA) versus 
other first-line biological disease-modifying antirheumatic drugs (DMARDs) avail-
able in Spain, in the treatment of patients with rheumatoid arthritis (RA) who have 
failed an initial treatment with methotrexate (MTX). MethOds: With regards to 
efficacy and safety outcomes, SC ABA was considered non-inferior vs intravenous 
ABA (IV ABA), adalimumab (ADA), certolizumab pegol (CZP), etanercept (ETN), goli-
mumab (GLM), infliximab (IFX) and tocilizumab (TCZ), based on results of an indirect 
comparison using mixed treatment analysis. Therefore a cost- minimization analy-
sis for a 3 year time horizon was developed. The perspective was that of the Spanish 
National Health System (NHS). Pharmaceutical and administration costs (€ , 2013) of 
all biological DMARDs which are available in Spain as first-line treatment after MTX 
were considered. Drug costs were included in terms of ex-factory price with man-
datory rebate. Administration costs were obtained from local published data. The 
analysis was developed for an average patient weight of 70 kg. A 3% annual discount 
rate was applied. Deterministic and probabilistic sensitivity analyses were per-
formed. Results: SC ABA treatment was associated with a yearly cost of € 11,521.36 
per patient during the first year of treatment and € 11,002.23 in subsequent years. 
The total 3-year cost of SC ABA was € 32,138.43 per patient, proving to be cost saving 
versus most of the other biological DMARDs. In all cases, pharmaceutical costs lead 
to more than 85% of total disease management costs. Sensitivity analyses proved 
the model to be robust. cOnclusiOns: According to these results, SC ABA would 
lead to cost-savings versus IV ABA, ADA, CZP, ETN, GLM and TZC in the management 
of RA patients initiating treatment with biological DMARDs.
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modifying antirheumatic drugs (tDMARDs) and are intolerant or contraindicated 
to methotrexate (MTX). MethOds: A patient-level simulation model was applied 
to project lifetime costs and outcomes for 10.000 patients from a payer’s perspec-
tive. The analysis compared a standard treatment pathway (STP) (adalimumab, 
etanercept and palliative care) with a similar pathway initialized with tocilizumab 
(TCZ). Disease severity was reflected by Health Assessment Questionnaire (HAQ) 
scores. As primary efficacy outcomes, American College of Rheumatology (ACR) 
response rates were used. Patient characteristics (age, gender and baseline HAQ 
score) and TCZ efficacy data were derived from the ADACTA trial, whereas effi-
cacy data for the remaining DMARDs were derived from a network meta-analysis 
of each medication’s trial outcomes. A mapping model transformed HAQ scores 
into QALYs. Clinical practice standards were defined by an expert panel of Greek 
Rheumatologists. Costs for pharmaceuticals and resource unit costs were obtained 
from official (Social Insurance) price lists. A discount rate of 3% was used for both 
costs and QALYs. Results: Results indicate that a treatment sequence starting 
with TCZ yields 1.17 more QALYs (9.38 vs. 8.21) for an additional cost of € 33,145 
(€ 125,409 vs. € 92,264) compared to the STP. The Incremental Cost – Effectiveness 
Ratio (ICER) was 28,325.5€ /QALY gained. Sensitivity Analysis confirms robustness 
of findings below a threshold of € 45.000. cOnclusiOns: The results of the analy-
sis suggest that TCZ as a first-line biologic drug can be a cost-effective treatment 
option for the management of active RA in patients intolerant or contraindicated 
to MTX.
PMS61
HEALTH ECONOMIC MODELLING OF SEQUENTIAL THERAPIES FOR 
RHEUMATOID ARTHRITIS: A SySTEMATIC REvIEw
Tosh J., Stevenson M., Akehurst R.
University of Sheffield, Sheffield, UK
Objectives: A systematic review was conducted to: 1) Identify economic evalu-
ations of therapies for rheumatoid arthritis (RA), and 2) assess and critique how 
sequential therapies were modelled and evaluated. MethOds: Systematic 
searches of ten databases were undertaken to identify published economic evalua-
tions of disease modifying therapies for RA. Searches were undertaken in February 
2013, with no date restriction. Studies were included if they reported a full compar-
ative economic evaluation. Identified studies were appraised using the Drummond 
economic evaluation checklist. Data extracted included economic evaluation data, 
along with data relating to sequential treatments. Data on the modelling methods 
used were also extracted, to identify how data sources were synthesised. The 
systematic review was conducted to the PRISMA standards. Results: Fifty-seven 
studies were identified. 43 (75%) were cost-utility analyses. 11 (19%) had a UK 
perspective, and 11 (19%) had a US perspective. The remainder were mainly under-
taken within Europe (26 (46%) studies). There was a distinction between studies 
in recent-onset RA (14 (25%)), and those in established RA (42 (74%)). One study 
(1%) was unclear. The review identified approximately 30 RA treatments. Using 
individual level modelling was associated with improved quality of the evaluation 
and the ability to evaluate sequences. Reporting about the impact of future treat-
ments on costs and health benefits was poor. When downstream treatments were 
modelled, the evidence used was often poorly reported. No study considered iden-
tifying the optimal sequence of treatments given a set of alternative treatments. 
Where models have been developed that consider a lifelong time horizon and 
downstream treatment sequences, evidence gaps were identified. cOnclusiOns: 
The review has identified that methods have not been consistently applied, which 
has led to varied estimates of cost-effectiveness. Sequences of treatments have 
not been appropriately considered and modelled, potentially biasing estimates 
of cost-effectiveness.
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COST-UTILITy ANALySIS OF TOCILIzUMAB IN COMBINATION wITH 
METHOTRExATE vERSUS STANDARD OF CARE FOR THE TREATMENT OF 
RHEUMATOID ARTHRITIS IN GREECE
Athanasakis K.1, Konstantopoulou T.2, Tarantilis F.1, Tsalapati K.1, Vritzali E.3, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Roche (Hellas), Greece, Athens, Greece, 3Roche 
(Hellas), Athens, Greece
Objectives: Rheumatoid Arthritis (RA) is a chronic, inflammatory disease affecting 
0.68% of the adult population in Greece. RA is associated with a lowered quality of 
life and a serious economic burden. This study aims to evaluate the cost-effective-
ness of adding tocilizumab to a treatment sequence on a background of methotrex-
ate (MTX) for patients with active RA, who had an inadequate response to one or 
more traditional disease-modifying antirheumatic drugs (tDMARDs). MethOds: A 
patient-level simulation model was applied to project lifetime costs and outcomes 
for 10.000 patients from a payer’s perspective. The analysis compared a standard 
treatment pathway (STP) (Adalimumab, Etanercept, Abatacept and Palliative care 
along with MTX) with a similar pathway initialized with Tocilizumab (TCZ). Disease 
severity was reflected by Health Assessment Questionnaire (HAQ) scores. As pri-
mary efficacy outcomes American College of Rheumatology (ACR) response rates 
were used . Patient characteristics (age, gender and baseline HAQ score) and drug 
efficacy for TCZ were obtained by an analysis of pooled data from three phase-III 
clinical trials. Efficacy data for comparators were derived from indirect compari-
sons. A mapping model transformed HAQ scores into QALYs. Standards regard-
ing clinical practice were defined by an expert panel of Greek Rheumatologists. 
Costs for pharmaceuticals and resource unit costs were derived from official (Social 
Insurance) price lists. A discount rate of 3% was used for costs and QALYs. Results: 
Results indicate that a treatment sequence starting with TCZ yields 0.79 more 
QALYs (11.68 vs. 10.89) for an additional cost of € 21,174 (€ 168,963 vs. € 147,788) 
compared to STP. The Incremental Cost – Effectiveness Ratio was 26,686€ /QALY 
gained. Sensitivity Analysis confirms robustness of findings below a threshold of 
€ 45.000. cOnclusiOns: The results of the analysis suggest that TCZ, combined 
with MTX, as a first-line biologic drug can be a cost-effective treatment option for 
the management of active RA compared to STP.
thresholds (32,6% of the patients) required a DXA measurement to verify the diagnosis 
of osteoporosis. Cost-effectiveness was assessed in five patient cohorts: women (BMI 
24 kg/m2) aged 65 years with previous fracture and 75 or 85 years with and without 
previous fracture. Results: Among the cohorts modeled, the average screening cost 
saved with Bindex® including proposed pathway in comparison to current guideline 
pathway were around € 230/patient. At a cost of € 50/screen, the probability that the 
pathway including Bindex® was cost-effective compared to the current pathway was 
100% in all patient cohorts. Bindex® including pathway appeared to be cost-effective 
at prices as high as € 100/screen. cOnclusiOns: Bindex® including pathway appears 
to be cost-saving strategy compared to the current and recommended Finnish osteo-
porosis diagnosis and care pathway.
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A MODEL OF THE COST EFFECTIvENESS OF INFLIxIMAB FOR THE TREATMENT 
OF SEvERELy ACTIvE ULCERATIvE COLITIS, IN CHILDREN AND ADOLESCENTS 
AGED 6 TO 17 yEARS, wHO HAvE HAD AN INADEQUATE RESPONSE TO 
CONvENTIONAL THERAPy
Farrell J.1, Jiang Y.2, Chaudhary M.A.3, Sheppard O.1, Gathany T.4, Fan T.5
1MSD, Hoddesdon, UK, 2Amaris, London, UK, 3Merck Research Laboratories, North Wales, PA, 
USA, 4Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 5Merck & Co., Inc., 
Whitehouse Station, NJ, USA
Objectives: To evaluate the cost-effectiveness of Infliximab (IFX) treatment in severe, 
active paediatric ulcerative colitis (pUC). MethOds: A Markov model was constructed 
based upon the literature, to model the progression of a cohort of pUC patients treated 
with IFX and ciclosporin (CIC) used off-label in the rescue therapy setting. The transi-
tion probabilities were estimated from the IFX phase III trials (T72, ACT1 and ACT2).
The comparative efficacy was incorporated by using the odds ratio for IFX vs. CIC from 
a head to head trial in adults (Laharie et al). Utility weights from observational studies 
(SOLUTION and Arseneau et al) were assigned to the health states within the Markov 
process. Incremental cost-effectiveness ratios (ICERs) were estimated with a one year 
time horizon. Uncertainty around key variables was explored through deterministic 
sensitivity analysis. Results: Compared to CIC in the rescue therapy setting, IFX 
was a dominant treatment option (produced more QALYs at a lower cost). The results 
were sensitive to the number of days patients were hospitalised for each treatment, 
the comparative rates of adverse events and altering the odds ratio for comparative 
effectiveness. cOnclusiOns: IFX is a highly effective and well-tolerated therapy 
for the treatment of paediatric patients with severely active ulcerative colitis. IFX is 
the only biologic treatment licensed for this population, and is cost-effective when 
compared to the commonly used off-licence treatment CIC.
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COST-UTILITy OF RHEUMATOID ARTHRITIS MONOTHERAPy wITH 
TOCILIzUMAB IN SPAIN
Benito Ruiz P.1, Navarro Sarabia F.2, Gomez Reino J.3, Poveda J.4, Alvaro Gracia J.5,  
Rubio-Rodríguez D.6, Ruiz-Beato E.7
1Hospital del Mar, Barcelona, Spain, 2Hospital Virgen de la Macarena, Sevilla, Spain, 3Complejo 
Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 4Hospital Universitario La 
Fe, Valencia, Spain, 5Hospital Universitario de La Princesa, Madrid, Spain, 6Health Value, Madrid, 
Spain, 7Roche Farma, S.A., Madrid, Spain
Objectives: Analyze Tocilizumab (TCZ) monotherapy cost-utility for moderate/ 
severe rheumatoid arthritis in patients who are intolerant/contraindicated to MTX, com-
pared with two standard treatment sequences: comparison 1: Etanercept-Adalimumab-
Certolizumab-Support treatment vs. Tocilizumab-Etanercept-Adalimumab-Support 
treatment, and comparison 2: Adalimumab-Etanercept-Certolizumab- Support treat-
ment vs. Tocilizumab-Adalimumab-Etanercept-Support treatment. MethOds: A life 
time micro-simulation model with 6 months cycles was performed in order to 
calculate the incremental cost-effectiveness ratio of the TCZ treatment sequences 
vs. standards sequences, which were determined by an expert panel of Spanish 
rheumatologists. Demographic data on age, HAQ score and sex were obtained 
from the ADACTA trial, while body weight data was obtained from the PRAXIS 
study. The efficacy data (ACR clinical response) were obtained from the pivotal 
clinical trial of each drug. Utilities were calculated from the relationship between 
ACR response, HAQ score and EQ5D instrument, according to the VACAR study, 
conducted in the Spanish population. The analysis was done from National Health 
System (NHS) perspective. Unit costs (€ ; 2012) were obtained from Spanish sources. 
Annual discount rate was 3.5% for costs and outcomes. Probabilistic sensitivity 
analyses were performed. Results: TCZ sequences generated more costs per 
patient than the standard sequence (€ 7,107 in comparison 1; € 6,087 in comparison 
2). However, the TCZ sequence generated more QALYs than the standard sequence 
(0.330 in comparison 1 and 0.297 in comparison 2). The cost of gaining a QALY with 
TCZ sequences versus the standard sequence was € 21,529 (comparison 1) and € 
20,496 (comparison 2). According to probabilistic sensitivity analyses, the prob-
ability that the TCZ sequences are cost effective is 86.8% for the comparison 1 and 
86.1% for the comparison 2. cOnclusiOns: In both comparisons, the analysis 
results indicate that the inclusion of TCZ monotherapy as first-line represents 
an effective and cost-effective alternative in Spain versus the current sequences 
used for the treatment of patients with rheumatoid arthritis and MTX intoler-
ance/contraindication.
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COST-UTILITy ANALySIS OF TOCILIzUMAB MONOTHERAPy vERSUS STANDARD 
OF CARE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN GREECE
Athanasakis K.1, Konstantopoulou T.2, Tarantilis F.1, Tsalapati K.1, Vritzali E.2, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Roche (Hellas), Athens, Greece
Objectives: Rheumatoid Arthritis (RA) is a chronic, inflammatory disease 
affecting 0.68% of the adult population in Greece. RA is associated with a lowered 
quality of life and a serious economic burden. This study aims to evaluate the 
cost-effectiveness of adding tocilizumab to a treatment sequence for patients with 
active RA, who had an inadequate response to one or more traditional disease-
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ductivity and daily activities was assessed at study baseline, using the validated 
arthritis-specific Work Productivity Survey (WPS). Results: At baseline, pts had a 
mean age of 48 years and 55% were female; 61.6% had psoriasis skin involvement 
≥ 3% body surface area. 59.5% of pts were employed, 14.0% work disabled due to 
PsA, and 13.5% retired. Overall, a high burden of PsA on workplace and household 
productivity and on social activities was reported, with on average > 1 week (wk) of 
paid work affected and > 2 wks of household duties or social activities affected per 
month. Household productivity losses were on average, up to 2 to 3 times higher in 
non-employed or disease work disabled pts vs employed pts: on average household 
duties were affected 18 days or 26 days vs 10 days/month, respectively. Employed pts 
with manual jobs reported higher productivity losses at work and within the home 
vs those with non-manual jobs. Overall, 41.8% of pts required regular assistance 
from relatives, friends or paid caregivers in their usual activities because of PsA. 
These pts reported on average 2 to 3 times higher workplace and household produc-
tivity losses vs pts who did not require help. cOnclusiOns: PsA is associated with 
a high burden of disease on workplace and household productivity that could lead 
to large financial burden for pts and society. Effective PsA treatments are needed 
to prevent disability and work losses, and reduce economic burden of the disease.
PMS66
ECONOMIC BURDEN OF AxIAL SPONDyLOARTHRITIS RELATED TO PAID wORK 
AND HOUSEHOLD PRODUCTIvITy AT BASELINE IN THE RAPID-AxSPA STUDy: 
DIFFERENCES AND SIMILARITIES BETwEEN ANKyLOSING SPONDyLITIS AND 
NON-RADIOGRAPHIC AxIAL SPONDyLOARTHRITIS
van der Heijde D.1, Purcaru O.2, Kavanaugh A.3
1Leiden University Medical Centre, Leiden, The Netherlands, 2UCB Pharma, Brussels, Belgium, 
3UCSD, San Diego, CA, USA
Objectives: To estimate the economic burden of axial spondyloarthritis (axSpA) and 
directly compare ankylosing spondylitis (AS) and axSpA with no definitive sacroiliitis 
on X-ray (non-radiographic axSpA, nr-axSpA) in terms of workplace and household 
productivity losses. MethOds: The ongoing Phase 3 RAPID-axSpA trial (NCT01087762) 
recruited patients (pts) with adult-onset active axSpA according to ASAS criteria, and 
included AS and nr-axSpA pts. The impact of axSpA on workplace and household 
productivity was assessed at study baseline (BL), using the arthritis-specific Work 
Productivity Survey (WPS). Results: At BL, 69.2% of axSpA, 67.4% AS and 71.4% nr-
axSpA pts were employed outside the home. A high burden of axSpA on workplace and 
household productivity and on social activities was reported, with slightly higher burden 
in nr-axSpA vs AS pts. More AS vs nr-axSpA pts were unable to work (15.7% vs 8.2%). On 
average, axSpA pts reported > 1 wk of paid work and > 2 wks of household duties or social 
activities affected/month. Household productivity losses were up to 2–3 times higher in 
non-employed and disease work disabled vs employed pts. Employed pts with manual 
jobs reported higher losses at paid work and within household vs pts with non-manual 
jobs. 39.1% of axSpA pts required regular assistance in their usual activities (42.1% in 
AS vs. 35.4% in nr-axSpA) and reported higher workplace and household productivity 
losses vs those who did not require help. Similar patterns were observed in AS and nr-
axSpA. cOnclusiOns: A similarly high burden of disease on workplace and household 
productivity was seen in AS and nr-axSpA pts that could lead to large financial burden 
for pts and society. Effective axSpA treatments are needed to prevent disability and work 
losses and to reduce the economic burden of axSpA.
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LOSS OF PRODUCTIvITy IN POLISH PATIENTS wITH RHEUMATOID ARTHRITIS
Szafraniec-Burylo S.I.1, Orlewska E.2, Rupinski R.3, Filipowicz-Sosnowska A.3
1National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland, 2Centre for 
Pharmacoeconomics, Warsaw, Poland, 3Institute of Rheumatology, Warsaw, Poland
Objectives: To assess loss of paid productivity in Polish rheumatoid arthritis (RA) 
patients according to disease activity and disability. MethOds: We conducted a 
prospective one-center observational study with 6-month time horizon. The sample 
consisted of 109 RA patients of working age (women:< 60 years; men:< 65 years), 
stratified according to Disease Activity Score (DAS28-CRP) and disability index of 
the Health Assessment Questionnaire (HAQ-DI). Productivity loss was expressed 
by absenteeism and employment status changes: reduced work hours (part-time), 
unemployed and/or early retirement due to RA. Spearman rang correlation coef-
ficient test was used to investigate the relationship of productivity loss with disease 
activity and disability. Results: Patients were on average 48.5 years of age, had a 
mean disease duration of 8.5 years, and 85% were female. DAS28-CRP was ≤ 5.1 in 
52 patients (group A) and > 5.1 in 57 patients (group B). HAQ-DI was > 2 in 22 patients 
(group I), > 1 and ≤ 2 in 54 patients (group II), ≤ 1 in 33 patients (group III). Number of 
patients who lost productivity was 94 (86%) (79% in A vs. 93% in B, 100%, 94% and 
63.6% in I, II and III, respectively). Of them 63 (58%) patients received disability pen-
sion due to RA (48% in A vs. 67% in B, 77%, 76% and 15% in I, II and III, respectively). 
Mean number of working days lost was 120.7 (97.2 in A vs. 142.9 in B; 157.3, 143.1 
and 59.8 in I, II and III, respectively). Proportion of patients with productivity loss 
and number of working days lost were correlated with disease activity (p< 0.01 
and p< 0.001, respectively) and disability index (both p< 0.001). cOnclusiOns: This 
study indicates high impact of disease activity and disability on productivity loss 
in RA patients. Treatment aiming at reducing disease activity decreases disability 
progress and may enhance productivity in Polish patients with RA.
PMS68
RESOURCE USE DUE TO DISABILITy IN POLISH RHEUMATOID ARTHRITIS 
PATIENTS: SIGNIFICANT INCREASE OF TRANSPORTATION NEEDS AND HOME 
vISITS
Szafraniec-Burylo S.I.1, Orlewska E.2, Rupinski R.3, Filipowicz-Sosnowska A.3
1National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland, 2Centre for 
Pharmacoeconomics, Warsaw, Poland, 3Institute of Rheumatology, Warsaw, Poland
Objectives: To assess transportation needs and number of home visits in rela-
tion to disease activity (DAS-28CRP) and disability index of the Health Assessment 
Questionnaire (HAQ-DI) in Polish patients with rheumatoid arthritis (RA) MethOds: 
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COST-UTILITy OF FIRST-LINE ADALIMUMAB AND TOCILIzUMAB 
MONOTHERAPIES IN RHEUMATOID ARTHRITIS BASED ON HEAD-TO-HEAD 
DATA
Soini E.J.1, Hallinen T.1, Vihervaara V.2, Kauppi M.J.3
1ESiOR Oy, Kuopio, Finland, 2Roche Oy, Espoo, Finland, 3Päijät-Häme Central Hospital, Lahti, 
Finland
Objectives: Until recently, large-scale head-to-head randomized clinical trials (RCT) 
involving biologic drugs in the treatment of rheumatoid arthritis (RA) have been lack-
ing. In addition, most evidence of biologic RA treatments has relied on combination 
treatment with methotrexate. The RCT ADACTA compared adalimumab vs. tocili-
zumab monotherapies as the 1st biologic treatments for severe RA, and demonstrated 
tozilizumab’s clinical superiority over adalimumab. Based on this evidence, we assess 
the cost-utility of adalimumab and tocilizumab monotherapy in RA after the failure 
of traditional disease modifying antirheumatic drug(s) (tDMARD). MethOds: Two 
sequences, namely adalimumab or tocilizumab followed by etanercept followed by 
best supportive care (BSC) including tDMARDs, were implemented in a probabilistic, 
individual sampling (microsimulation model) setting in order to compare the results 
among 1,230 Finnish RA patients in a lifetime scenario (based on the Finnish social 
insurance institution reimbursement data, 1,230 [42.6%] of anti-TNF users purchased 
anti-TNF without tDMARD in 2012). Clinical outcomes (no ACR20, ACR20, ACR50 and 
ACR70 responses, and their impact on Health Assessment Questionnaire, HAQ) were 
obtained from ADACTA and drug survivals from literature. HAQ-scores were linked 
non-linearly to EQ-5D scores based on the tocilizumab trials, and to hospitaliza-
tions and lost production days through literature data. All resources were valued 
with Finnish unit costs (drugs 4/2013, other costs 2012 real value). Analyses were 
performed from the Finnish payer perspective (excluding productivity loss) and 
societal perspective including 3% annual discount rate. Results: A QALY gained 
with the tocilizumab sequence costs € 14,294 (€ 9,111) compared with the adalimumab 
sequence from the payer (societal) perspective. The respective expected value of per-
fect information (EVPI) for the payer was € 996/patient. Population EVPI was € 121,770 
with € 20,000/QALY gained. According to cost-effectiveness acceptability frontier, the 
tocilizumab sequence had 89% probability for cost-effectiveness at € 20,000/QALY 
gained. cOnclusiOns: After tDMARD(s) failure, tocilizumab monotherapy was cost-
effective in comparison to adalimumab monotherapy.
PMS64
LONG TERM COSTS AND OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS NOT 
RESPONDING TO CONvENTIONAL THERAPy TREATED wITH TUMOR NECROSIS 
FACTOR INHIBITORS: THE ExTENSION OF PSORIATIC ARTHRITIS COST 
EvALUATION (PACE) STUDy
Cortesi P.A.1, Olivieri I.2, de Portu S.3, Salvarani C.4, Cauli A.5, Lubrano E.6, Spadaro A.7, 
Cantini F.8, Cutro M.2, Mathieu A.5, Matucci-Cerinic M.9, Pappone N.10, Punzi L.11, Scarpa R.12, 
Mantovani L.G.13
1University of Milano - Bicocca, Monza, Italy, 2San Carlo Hospital of Potenza and Madonna 
delle Grazie Hospital, Potenza and Matera, Italy, 3Medtronic International Sàrl, Tolochenaz, 
Switzerland, 4Arcispedale S. Maria Nuova, Reggio Emilia, Italy, 5University of Cagliari, 
Monserrato, Italy, 6University of Molise, Campobasso, Italy, 7Università di Roma “La Sapienza”, 
Rome, Italy, 8Prato Hospital, Prato, Italy, 9University of Florence, Florence, Italy, 10Fondazione 
Maugeri IRCCS, Telese Terme, Italy, 11University of Padova, Padova, Italy, 12University Federico II 
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Objectives: Poor information on long term outcomes and costs on Tumor Necrosis 
Factor-α (TNF-α ) inhibitors in Psoriatic Arthritis (PsA) are available. Our aim was 
to evaluate long-term costs, benefits and cost-effectiveness of TNF-α inhibitors in 
PsA patients with inadequate response to conventional treatment with traditional 
disease-modifying antirheumatic drugs (DMARDs). MethOds: A total of 55 of the 
107 enrolled patients included in the study at one year, completed the 5 years follow 
up period (2005-2010). Patients aged older than 18 years, with different forms of PsA 
and failure or intolerance to DMARDs therapy were treated with anti-TNF agents. 
Information on resource use, quality of life, disease activity, function and laboratory 
values were collected at baseline and through the 5 years of therapy. Costs (expressed 
in Euro 2011) and utility (measured by EQ-5D instrument) before and after TNF-α 
inhibitorstherapy were compared in order to estimate the incremental cost per qual-
ity adjusted life year (QALY) gained. The cost-effectiveness acceptability-curve was 
also calculated. Results: Thirty-four patients were males (61.8%), aged mean(SD)= 
48.94(11.09) years. The majority of patients (83.6%) had a predominant or exclusive 
peripheral arthritis. At the end of the 5 years, there was a significant increase in direct 
costs due to an increase of drug cost caused by TNF-α inhibitors that was partially 
offset by the decrease in indirect costs. The incremental cost estimated and the util-
ity gained of 0.22 gave an incremental cost-effectiveness ratio of 39,678.6 € per QALY 
gained for the society. The acceptability curve showed there would be a 90% likeli-
hood that anti-TNF therapy would be considered cost-effective at willingness-to-pay 
threshold of € 60,000 per QALY gained. cOnclusiOns: Cost-effectiveness ratios are 
within the commonly accepted Italian willingness-to-pay threshold. These results 
show how TNF-α inhibitors could be long-term cost-effectiveness treatment. Our 
results need to be confirmed in larger samples of patients.
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HIGH ECONOMIC BURDEN OF MODERATE TO SEvERE PSORIATIC ARTHRITIS ON 
PAID wORK AND HOUSEHOLD PRODUCTIvITy: BASELINE RESULTS FROM THE 
RAPID-PSA STUDy
Kavanaugh A.1, Mease P.J.2, Purcaru O.3, van der Heijde D.4
1UCSD, San Diego, CA, USA, 2Swedish Medical Center and University of Washington, Seattle, 
WA, USA, 3UCB Pharma, Brussels, Belgium, 4Leiden University Medical Centre, Leiden, The 
Netherlands
Objectives: To estimate the economic burden of moderate to severe psoriatic 
arthritis (PsA) on workplace and household productivity using data from RAPID-
PsA. MethOds: The ongoing Phase 3 RAPID-PsA trial (NCT01087788) recruited 
patients (pts) with active PsA. Impact of PsA on workplace and household pro-
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Objectives: Compliance to osteoporosis drugs is frequently very low, leading to 
an increased fracture risk. We investigated the factors associated with fracture 
risk in women with postmenopausal osteoporosis (PMO) in Hungary, with a focus 
on compliance. MethOds: This retrospective analysis of data from the National 
Health Insurance Fund Administration included women aged ≥ 50 years with a 
diagnosis of osteoporosis (ICD-10 codes, M80 or 81), who started an osteoporosis 
drug prescription between Jan 2004–Dec 2012 (index event) and had a 13-month 
non-treatment period prior to this prescription. The relationship between all 
factors (covariates) and fracture risk was assessed using a dynamic Cox regres-
sion model and Andersen-Gill analysis, estimating 95% confidence intervals. 
Compliance was measured using the medication possession ratio (MPR); MPR≥ 80% 
at 1 year was considered compliant. Results: A total of 181,239 patients matched 
the inclusion criteria; 40.4% of patients were > 70 years old and 12.2% had prior 
fractures in the 36-month period before each index date. Compliant patients had a 
35% (RR= 0.65, CI= 0.59-0.72) fracture risk reduction versus non-compliant patients. 
Patients aged 70-79 years, and > 80 years, had an increased fracture risk of 71% 
(RR= 1.71, CI= 1.54-1.90) and 118% (RR= 2.18, CI= 1.94-2.46), respectively, compared 
to patients aged 50-60 years. Prior fractures were associated with a 32% increased 
risk of one new fracture (RR= 1.32, CI= 1.18-1.49), and with a 90% increased fracture 
risk (RR= 1.90, CI= 1.64-2.19) in patients with 2+ prior fractures, respectively, com-
pared to patients with no prior fractures. There was also a relationship between 
any co-medication and fracture risk, with a 12% (RR= 1.12, CI= 1.03-1.22) increase 
with one co-medication and an 11% (RR= 1.11, CI= 1.01-1.21) increase with 2+ co-
medications compared to none. cOnclusiOns: Compliance was associated with 
protection against fracture (reduction of relative fracture risk). However, age, any 
co-medication and prior fractures were associated with an increased relative risk 
of fracture.
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TREATMENT PERSISTENCE IN SwEDISH wOMEN INITIATING DENOSUMAB 
TREATMENT FOR POSTMENOPAUSAL OSTEOPOROSIS
Karlsson L.1, Lundkvist J.2, Intorcia M.3, Psachoulia E.3, Ström O.1
1Quantify Research, Stockholm, Sweden, 2Amgen AB, Solna, Sweden, 3Amgen (Europe) GmbH, 
Zug, Switzerland
Objectives: Persistence to orally and/or frequently administered osteoporosis 
treatments is poor. Indeed, previous retrospective research has shown that approx-
imately 50% of patients discontinue oral treatments within one year. Denosumab 
is administrated as a treatment for postmenopausal osteoporosis (PMO) via a sub-
cutaneous injection once every 6 months, and better persistence with denosumab 
has been shown in randomized trials. The current study estimated treatment 
persistence among women initiating denosumab for PMO in Sweden. MethOds: 
The study included post-menopausal women who initiated denosumab between 
May 2010 and July 2012 in the Swedish National Prescription Register. One injection 
of denosumab was defined as 6 months of persistence. Patients were considered 
persistent for an additional 6 months if they filled their next denosumab prescrip-
tion within 6 months + 56 days (permissible gap). Subgroup analyses included 
comparisons of pre-treated vs. treatment-naïve patients to other osteoporosis 
treatments, and of patients initiating denosumab treatment in 2010/2011 vs. 
2012. Results: The study identified 2,315 incident users of denosumab. Mean (SD) 
age was 73.7 (9.0) years and 60.7% were pre-treated. 83% (CI95:81-84) of patients 
were persistent at 12 months, 69% (CI95:67-71) at 18 months and 62% (CI95:60-65) at 
24 months. Increasing the permissible gap to 90 or 180 days resulted in 12-month-
persistence of 85% and 91%, respectively. Pre-treated patients were more persistent 
than treatment-naïve patients after 18 (71% vs. 67%) and 24 months (65% vs. 58%), 
but not at 12 months. No difference was observed between patients starting their 
treatment during 2010/2011 and 2012. cOnclusiOns: Among Swedish women 
with PMO, persistence to denosumab treatment is high, and pre-treated patients 
are more persistent than treatment-naïve patients. Given the poor persistence to 
oral osteoporosis treatments, denosumab treatment could, in these patients, be 
considered a relevant alternative to increases persistence and hence optimizes 
outcomes in PMO.
PMS73
PERSISTENCE & COMPLIANCE TO TREATMENT FOR OSTEOPOROSIS IN 
POSTMENOPAUSAL wOMEN IN HUNGARy: A RETROSPECTIvE COHORT STUDy
Lakatos P.1, Tóth E.2, Cina Z.2, Lang Z.2, Psachoulia E.3, Intorcia M.3
1Semmelweis University, Budapest, Hungary, 2Healthware Consulting Ltd., Budapest, Hungary, 
3Amgen (Europe) GmbH, Zug, Switzerland
Objectives: Persistence and compliance with prescribed medication are 
important factors in treatment success. This study calculated persistence and 
compliance to treatment among postmenopausal women with osteoporosis in 
Hungary. MethOds: This retrospective analysis of data from the National Health 
Insurance Fund Administration included women aged ≥ 50 years with a diagnosis 
of osteoporosis (ICD-10 codes, M80 or 81), who started an osteoporosis prescription 
(including bisphosphonates, strontium ranelate, hormone replacement therapy, 
parathormone and denosumab) between January 2004 to December 2012. We esti-
mated 12- and 24-month persistence per active substance and administration type, 
with an 8-week grace period; and measured compliance using the medication pos-
session ratio (MPR; MPR≥ 80% at 12-months considered compliant). Results: A 
total of 288,194 patients matched the inclusion criteria;43.8% were aged > 70 years 
and 6.6% had prior fractures at first index date; 84.4% and 3.1% were receiving 
oral and intravenous bisphosphonates, respectively, and 12.5% other osteoporosis 
therapies. 12-month persistence to oral and injectable drugs was 31% and 76%, 
respectively. 12-month persistence was lowest for daily (23%) and monthly (27%) 
versus quarterly (58%) and half-yearly (84%) administration (100% persistence and 
compliance assumed for yearly administration), declining at 24 months to 10%, 
10%, 36% and 44% for daily, monthly, quarterly and yearly drugs, respectively (24-
month persistence to half-yearly drugs not available). Only 46% of patients were 
compliant with treatment, with compliance higher for injectable (daily, quarterly, 
Prospective data on distance covered due to RA (paid and non-paid, self and car-
egiver’s transport) and about number of medical home visits were gathered during 
6 months observation after discharge of non-selected RA patients from one tertiary 
academic hospital. Patients were stratified according to their DAS28-CRP and HAQ-DI. 
Spearman rang correlation coefficient test was used for statistical analysis. Results: 
A total of 205 consecutive RA patients included into the study were stratified in 5 
groups: A: DAS-28CRP ≤ 5.1 (89 patients), B: DAS28-CRP > 5.1 (116 patients), I: HAQ-DI 
≤ 1 (51 patients), II: HAQ-DI ≤ 2 and > 1 (88 patients) and III: HAQ-DI > 2 (66 patients). 
In the whole study group 157 (77%) patients used transport for a mean distance of 
461 kilometers in 6 months. Corresponding values for group A, B, I, II and III were 
as follows: 67% for 329 km, 84% for 563 km in B, 55% for 159 km in I, 81% for 528 km 
in II and 88% for 605 km in III. 7 patients used home visits (3% for a mean number 
of 0.1 visits - 2% for 0.2, 4% for 0.2, 0% for 0, 1% for 0.3 and 9% for 0.3 in A, B, I, II and 
III, respectively). There was significant positive correlation between disability and 
both proportion of patients using transport and distance covered (both p< 0.0001), 
between disability and home visits and between disease activity and transport (both 
p< 0.01). cOnclusiOns: Problems with moving around and need for travelling due to 
the disease result in significant resource use in RA patients. Comprehensive services 
meeting these needs may diminish the burden of disease in Poland.
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BURDEN OF INFORMAL CARE IN RELATION TO DISEASE ACTIvITy AND 
DISABILITy IN POLISH PATIENTS wITH RHEUMATOID ARTHRITIS
Szafraniec-Burylo S.I.1, Orlewska E.2, Rupinski R.3, Filipowicz-Sosnowska A.3
1National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland, 2Centre for 
Pharmacoeconomics, Warsaw, Poland, 3Institute of Rheumatology, Warsaw, Poland
Objectives: To assess informal care use in relation to disease activity (DAS-28CRP) 
and disability index of the Health Assessment Questionnaire (HAQ-DI) in Polish 
patients with rheumatoid arthritis (RA). MethOds: Data on amount of time con-
sumed for informal care (unpaid assistance of family member or other caregiver) 
was collected during a prospective one center cohort observational study of non-
selected RA patients discharged from tertiary academic hospital. At enrollment 
patients were divided according to DAS28-CRP and HAQ-DI. Observational period 
was 6 months. Spearman rang correlation coefficient test was used to investigate 
the relationship between informal care and disability. Results: A total of 205 
patients were included in the analysis: 89 with DAS-28CRP ≤ 5.1 (group A), 116 with 
DAS28-CRP > 5.1 (group B), 51 with HAQ-DI ≤ 1 (group I), 88 - with HAQ-DI ≤ 2 and > 1 
(group II) and 66 patients with HAQ-DI > 2 (group III). 164 (80%) patients have been 
looked after by informal caregivers (64% and 92% in A and B, respectively, and 47%, 
89% and 94% in I, II and III, respectively). Mean number of hours of informal care per 
patient during 6 months was 467 (336, 567, 153, 412 and 783 hours in A, B, I, II and 
III, respectively). There were significant (p< 0.0001) positive correlations between 
both disease activity and disability index and both number of patients being looked 
after by informal caregivers and number of hours of informal care. cOnclusiOns: 
Informal care involves substantial time inputs depending on disease activity and 
functional status of the care receiving RA patients. On one side, improving access to 
formal caregiving might be a good solution to improve quality of life and enhance 
productivity of present informal caregivers in Poland. On the other side slowing 
down the disease process might reduce the need of informal care for RA patients.
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THE USE OF DExA SCANS IN POSTMENOPAUSAL OSTEOPOROSIS IS 
ASSOCIATED wITH REDUCED LONG TERM FRACTURE RISK
Burke T.P., de Courcy J., Milligan G.
Adelphi Real World, Bollington, UK
Objectives: Postmenopausal osteoporosis (PMO) leads to an increased risk of 
fractures, which in turn is associated with high resource utilisation. DEXA scans 
measure the patient’s bone mineral density and are an important tool in assess-
ing fracture risk. We aim to determine if the monitoring of PMO patients using 
DEXA scans is associated with lower incidence of fracture. MethOds: Analysis 
was undertaken using data from the 2012 Adelphi Osteoporosis Disease Specific 
Programme (DSP), a cross-sectional survey of patients with osteoporosis across the 
EU5 and the US. Physicians completed a detailed patient record form (PRF) for the 
next 10 consulting osteoporosis patients. The PRF captured patient information 
which included age, BMI and physician-perceived severity of the patient’s osteo-
porosis as well information on fracture history, DEXA scans received and date of 
diagnosis. Bootstrapped survival time regression using an exponential distribu-
tion on time to fracture was used to determine the hazard ratio (relative fracture 
risk) for those that had received a DEXA scan, compared with those that had not. 
Other covariates in the model were age, BMI, severity, and the possibility that the 
likelihood of a DEXA scan increases with duration of time since diagnosis. Results: 
Of the 2508 PMO patients with complete information required for the analysis, 1107 
had received a DEXA scan (and had associated treatment intervention) and 1401 
had received no DEXA scan. Patients who had received a DEXA scan had 59% (0.594, 
p= 0.006) of the fracture risk of those who had received no DEXA scan, adjusted by 
possible confounders (ceteris paribus). cOnclusiOns: Patients tested with DEXA 
scans were associated with a significantly lower risk of fracture than those patients 
who were not. Over time increased use of DEXA testing could lead to a reduction in 
fractures and subsequently lower resource use and disease burden.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes & Patient 
Preference Studies
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COMPLIANCE PROTECTS AGAINST FRACTURE IN wOMEN wITH 
POSTMENOPAUSAL OSTEOPOROSIS IN HUNGARy
Lakatos P.1, Tóth E.2, Cina Z.2, Lang Z.2, Psachoulia E.3, Intorcia M.3
1Semmelweis University, Budapest, Hungary, 2Healthware Consulting Ltd., Budapest, Hungary, 
3Amgen (Europe) GmbH, Zug, Switzerland
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mated, where EQ-5D was regressed on 1) eight SF-36 scores; 2) as per 1) plus squared 
and pair-wise interaction terms, 3) as per 1) plus clinical characteristics; and 4) as 
per 3) plus squared and pair-wise interaction terms, respectively. Model 2 and 4 were 
developed by using stepwise regression analyses. Model goodness of fit was examined 
by using Akaike information criterion (AIC), R2, and adjusted R2. Predictive perfor-
mance was evaluated by using root mean square error (RMSE). Results: Model 1 with 
eight SF-36 scores explained more than 59% of the variation in EQ-5D utility values. 
The best-performing model based on goodness of fit and predictive performance was 
model 4 (AIC= ◽-200.4, R2= 0.767, adjusted R2= 0.709, RMSE= 0.090). The model included 
four SF-36 scores (GH, MH, PF, and RP), five squared terms, twelve pair-wise interaction 
terms, and log transformed simplified disease activity index (SDAI). Also model 2, 
which included no clinical characteristics, had similar predictive ability (AIC= ◽-195.0, 
R2= 0.764, adjusted R2= 0.699, RMSE= 0.093). cOnclusiOns: EQ-5D utility values can be 
predicted from SF-36 scores and SDAI with Japanese patients with RA. The mapping 
model can be applied to SF-36 datasets to produce utility scores for economic evalua-
tion of RA treatments from the perspective of Japan health care system.
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HEALTH-STATE UTILITIES IN MEASURING HEALTH-RELATED QUALITy OF LIFE 
AMONG PATIENTS wITH RHEUMATOID ARTHRITIS IN TAIwAN
Tang C.H.1, Hsu P.N.2, Hsu J.Y.1, Fang C.H.3
1Taipei Medical University, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan, 3Pfizer, 
New Taipei City, Taiwan
Objectives: Rheumatoid arthritis is (RA) associated with numerous comorbidities 
that have major impacts on patients’ quality of life. The purpose of this study is 
of twofold, first, to measure the health related utilities on patients with RA using 
time trade-off (TTO) and EQ-5D and to examine how these different measures were 
related to a disease specific measure, Health Assessment Questionnaire (HAQ) and 
disability level of RA. Second, to investigate absenteeism and presenteeism using 
Work Productivity and Activity Impairment Questionnaire for Patients with RA 
(WPAI-RA). MethOds: Face-to-face patient interviews on patients with mild RA 
(DAS < 3.2), moderate RA (3.2< = DAS< 5.1) and severe RA (DAS> = 5.1) have been car-
ried out since June 2013 at rheumatology outpatient clinics at four hospitals located 
in northern, central and southern Taiwan, and will be continued until the desired 
sample size of 120 is attained. Health state utilities were elicited using time trade-
off (TTO), visual analogue scale (VAS) and EQ-5D. Productivity losses and activity 
limitation were measured by WPAI-RA. The mean value of the total HAQ score is 
the mean of the scores for the eight categories: dressing, rising, eating, walking, 
hygiene, reach, grip and usual activities. Results: Based upon the preliminary 
sample collected, the mean age was 54.5 years, mean history of disease was 8.16 
years, and 77% were female in the study patients. The mean health utility was 0.87 
(EQ-5D), 0.72 (VAS) and 0.75 (TTO). The mean value of the total HAQ score is 0.83. 
Employed patients reported 10% reduced work productivity in the previous week, as 
well as 21.0% reduced productivity in daily activities (all patients). cOnclusiOns: 
EQ-5D and VAS are consistent measures for HAQ and have high potentials for use 
in assessing the well-being of the patients with RA in Taiwan. Productivity losses 
associated with absenteeism and presenteeism are substantial.
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PATIENT PREFERENCE FOR ORAL vERSUS INjECTABLE AND INTRAvENOUS 
METHODS OF TREATMENT FOR RHEUMATOID ARTHRITIS
Barclay N.1, Tarallo M.2, Hendrikx T.3, Marett S.1
1The Research Partnership Ltd., London, UK, 2Pfizer Italia, Rome, Italy, 3Pfizer bv, Capelle aan den 
IJssel, The Netherlands
Objectives: For patients with rheumatoid arthritis (RA), convenience, frequency 
of dosing, and invasiveness vary greatly across different administration routes and 
may influence their everyday lives. The objective of this study was to investigate 
the impact of administration method on patients’ quality of life, understand their 
resulting unmet needs, and establish an overall preference for method of admin-
istration for RA treatment. MethOds: Patients from France, UK, Germany, Italy, 
Spain, Belgium, Sweden, and The Netherlands diagnosed with RA by a physician and 
taking prescription medication – disease-modifying anti-rheumatic drug (DMARD) 
monotherapy, biologic monotherapy, or DMARD and biologic combination therapy 
– completed a 20-minute online survey. Patients were asked about: 1) benefits and 
drawbacks of their current treatment administration method; 2) their preference 
for twice-daily oral therapy versus injection or intravenous (IV) infusion therapy if it 
met their safety and efficacy expectations; 3) if told by their doctor that they needed 
to change their current RA therapy, would they switch to twice-daily oral tablets, 
injections, or IV infusion if efficacy and safety requirements were met. Results: 
1400 patients were included: n= 250 patients in each of France, UK, Germany, Italy, 
and Spain and n= 50 in each of Sweden, Belgium, and The Netherlands. Oral DMARDs 
were seen as having more benefits and fewer drawbacks than DMARD injections, 
biologic injections, and IV therapy. The majority of patients (79%) would prefer a 
twice-daily oral tablet than an injection or IV infusion (21%) if it met efficacy and 
safety expectations. If told by their doctor that they needed to change their current 
RA therapy, 83% of all patients would prefer switching to twice-daily oral tablets over 
injection (13%) or IV infusion (4%). cOnclusiOns: Oral therapy can meet some of 
the key practical and emotional unmet needs RA patients face with injectable or IV 
infusion therapy, providing efficacy and safety requirements are met.
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ARE PATIENTS’ PREFERENCES FOR OSTEOPOROSIS DRUG TREATMENT 
TRANSFERABLE BETwEEN COUNTRIES? RESULTS FROM A DISCRETE-CHOICE 
ExPERIMENT CONDUCTED IN TwO EUROPEAN COUNTRIES
Hiligsmann M.1, Dellaert B.2, Dirksen C.1, Van der Weijden T.1, Goemaere S.3, McGowan B.4, 
Reginster J.Y.5, Watson V.6, Boonen A.1
1Maastricht University, Maastricht, The Netherlands, 2Erasmus University Rotterdam, Rotterdam, 
The Netherlands, 3Ghent University Hospital, Ghent, Belgium, 4Trinity Centre for Health Sciences, 
Dublin, Ireland, 5University of Liège, Liège, Belgium, 6University of Aberdeen, Aberdeen, UK
half-yearly or yearly) (78%) versus oral (daily, weekly, or monthly) drugs (35%). The 
lowest compliance was observed with daily (24%) and monthly (34%) drugs. Less 
frequently administered drugs (except yearly) had the highest compliance with 
quarterly drugs having 63% and half-yearly drugs 70%. cOnclusiOns: This analy-
sis shows that persistence and compliance to osteoporosis treatment is very low 
in postmenopausal women in Hungary. However, higher persistence and better 
compliance was observed for injectable, less frequently administered drugs, which 
may lead to better outcomes.
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vALIDATION OF THE FRENCH TRANSLATED vERSION OF THE OSTEOPOROSIS 
SPECIFIC MORISKy MEDICATION ADHERENCE SCALE (OS-MMAS) IN FRANCE
Feudjo Tepie M.1, Kempf C.2, Letierce A.3, Ferreira I.4, Kalouche-Khalil L.5, Roddam A.1, 
Guillemin F.6
1Amgen Ltd., Uxbridge, UK, 2Cegedim Strategic Data, Boulogne-Billancourt, Île-de-France, France, 
3Cegedim strategic Data, Boulogne-Billancourt, France, 4Amgen, Cambridge, Cambridge, UK, 
5Amgen, ZUG, Switzerland, 6University of Lorraine, Nancy, France
Objectives: The OS-MMAS is a disease-specific 8 item self-reported measure of 
adherence for osteoporosis patients. This study evaluated the measurement prop-
erties of its French translated version. MethOds: A cohort of women aged 55 or 
older, with post-menopausal osteoporosis (PMO) residing in France and treated with 
daily or weekly oral bisphosphonates (OBPs) were selected based on their historical 
data from the French Longitudinal Patient Database; following their visit to one of 
the participating practices. Eligible patients were given an OS-MMAS questionnaire 
for completion at home. Internal consistency was evaluated using the Cronbach’s 
coefficient and construct validity using confirmatory one factor analysis (CFA). 
Convergence validity was assessed using agreement between patients’ medication 
procession ratio (MPR) and their total score from OS-MMAS. To assess reproducibility, 
a subset of respondents received a second questionnaire approximately 3 months 
later. Reproducibility was tested using the intra-class correlation (ICC). Results: 
From a network of 1200 French general practices, 117 participated; 687 eligible 
women visited these practices during the period 20-Jul-2012 to 31-Dec-2012. Of 
these women, 218 (mean 73.2 years; SD= 8.1) completed ≥ 1 OS-MMAS. The 6 and 
12 month MPR was less than 80% for 25.7% patients and 59.1% patients, respec-
tively. Cronbach’s alpha coefficient was 0.76 and varied between 0.71 and 0.79 with 
the deletion of one item. The Chi-Square test of association between MPR (< 80%, 
> 80%) and OS-MMAS scores (< 6; 6-8; 8+) was statistically significant at 6 months 
(p= 0.025), but not at 12 months (p-value= 0.059). CFA reported a standardized root 
mean square residual of 0.06. The ICC on 70 patients was 0.24 with 95% confidence 
interval [0.01-0.45]. cOnclusiOns: This study demonstrated acceptable agreement 
between classification of patient’s adherence to OBPs assessed using French trans-
lated OS-MMAS and that using historical 6 months MPR; but also indicated that the 
construct of the OS-MMAS could be improved.
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CHANGE OF BURDEN OF DISEASE IN GERMAN RHEUMATOID ARTHRITIS 
PATIENTS SINCE THE UPTAKE OF TNF-INHIBITORS: A LITERATURE REvIEw OF 
GERMAN REAL LIFE DATA
Wolff M.1, Kleine H.2, Wittig B.2, Mentrup S.2
1AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 2AbbVie Deutschland GmbH & 
Co. KG, Wiesbaden, Germany
Objectives: To obtain a comprehensive overview of the impact of TNF-inhibitors on 
the components of the burden of Rheumatoid Arthritis (RA) in Germany. MethOds: 
A systematic literature research in EMBASE, Medline, grey literature including rheu-
matology congress abstracts (ACR, EULAR, DGRh), German RA registry homepages, 
and the Information System of the Federal Health Monitoring (2002-2012) was per-
formed. Published data on the effect of TNF-inhibitors on mortality, morbidity, and 
health care resource utilization (HCRU) was included. Results: Overall, 15 partially 
overlapping full-text articles (0 mortality, 12 morbidity, 5 HCRU), 6 additional unique 
abstracts excluding encore publications (1 mortality, 4 morbidity, 1 HCRU) and two 
other sources (1 morbidity, 1 HCRU) were included in the final review. Reviewed lit-
erature reported an association of TNF-inhibitor use with a 35% lower mortality rate 
(HR= 0.65; p= 0.0004) compared to synthetic disease modifying antirheumatic drugs 
(DMARDs). Disease severity based on symptoms decreased over time in Germany: the 
chances of reaching DAS28 remission (OR= 1.97; 95%-CI: [1.20-3.21]) and functional 
remission (OR= 2.21; 95%-CI: [1.06-4.63]) were doubled, the odds of functional independ-
ence were quadrupled (OR= 4.09; 95%-CI: [1.80-9.29]) with TNF-inhibitor treatment. 
All SF-36 domains and fatigue scores increased significantly after treatment initia-
tion. TNF-inhibitor treatment is associated with fewer limitations in daily activities 
(OR= 0.77; 95%-CI: [0.65-0.90] and less perseverant limitations (OR= 0.82; 95%-CI: [0.68-
0.98]. Standardized disability pension ratios in patients with biologics use decreased 
over time from 12.5 (2001–2003) to 3.4 (2010-2011). Frequency and average duration of 
hospitalization have fallen from 2001 (19% of patients hospitalized with average dura-
tion of 19 days) to 2011 (12%, 12 days). No HRCU data was available for the outpatient 
sector or surgery. cOnclusiOns: Based on available German data, treatment with 
TNF-inhibitors is associated with lower mortality, increasing likelihood to reach clinical 
remission, better symptom control, functional status, work ability and quality of life.
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PREDICTING EQ-5D UTILITy SCORES FROM SF-36 SCORES IN PATIENTS wITH 
RHEUMATOID ARTHRITIS IN jAPAN
Moriwaki K.1, Ito S.2, Kobayashi D.2, Noto S.1, Yanagisawa S.3, Toujou T.1, Murasawa A.2
1Niigata University of Health and Welfare, Niigata, Japan, 2Niigata Rheumatic Center, Shibata, 
Japan, 3Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Japan
Objectives: To develop a mapping model for estimating EuroQol 5D (EQ-5D) utility 
values from Short Form 36 (SF-36) scores in Japanese patients with rheumatoid arthri-
tis (RA), with or without clinical characteristics. MethOds: Linear regression models 
were applied to a cross-sectional data set of 112 patients with RA collected from a 
regional hospital in Niigata prefecture, Japan. Four model specifications were esti-
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nent summary (Wk24: 8.4 and 7.6; Wk48: 8.6 and 8.4) and mental component sum-
mary (Wk24: 5.5 and 3.5; Wk48: 4.8 and 3.2), PsAQoL (Wk24: -4.4 and -3.3; Wk48: -4.8 
and -3.5), and DLQI (Wk24: -6.3 and -5.2; Wk48: -6.2 and -5.6) for CZP 200mg Q2W 
and 400mg Q4W patients, respectively. cOnclusiOns: Improvements in generic 
and disease-specific PROs observed over 24 wks were sustained over 48 wks in 
CZP-treated PsA pts. Improvements were observed regardless of CZP dose regimen.
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ExPANDING THE MEASUREMENT OF TREATMENT BENEFIT IN RHEUMATOID 
ARTHRITIS: THE ROLE OF THE PATIENT-REPORTED OUTCOME CONSORTIUM’S 
RA wORKING GROUP
Naegeli A.N.1, Nikaï E.2, Burke L.B.3, Coons S.J.4, Strand V.5, Simon L.S.6, Piault E.7, Hayes R.P.1
1Eli Lilly and Company, Indianapolis, IN, USA, 2UCB Pharma S.A., Brussels, Belgium, 3CDER FDA, 
Silver Spring, MD, USA, 4Critical Path Institute, Tucson, AZ, USA, 5Stanford University, Palo Alto, 
CA, USA, 6SDG LLC, Cambridge, MA, USA, 7Genentech, San Francisco, CA, USA
Objectives: To develop a patient-reported outcome (PRO) instrument that can 
be qualified by the Food and Drug Administration (FDA) for use in rheumatoid 
arthritis (RA) randomized controlled trials (RCTs) to support treatment ben-
efit claims. MethOds: On August 28, 2012, a consensus development workshop 
was held by the RA Working Group (WG) within the Critical Path Institute’s PRO 
Consortium to identify RA-related PRO concepts to determine their potential role 
in the documentation of treatment benefit in RA RCTs. Key stakeholders partici-
pated in this one-day meeting, including RA patients, representatives from the FDA 
(Division of Pulmonary, Allergy, and Rheumatology Products [DPARP] and Study 
Endpoints and Labeling Development [SEALD]), experts from the American College 
of Rheumatology (ACR), European League Against Rheumatism (EULAR), Outcome 
Measures in Rheumatology (OMERACT), National Institutes of Health (NIH, NIAMS) 
and the pharmaceutical industry (RA WG members). Results: Over the course of 
the workshop, a consensus emerged that there are several outcomes important to 
RA patients not explicitly assessed by the ACR response criteria (i.e., fatigue, stiff-
ness, and social participation). Finally, consensus amongst the various stakeholders 
was reached that any new measure needs to provide information over and above 
what is currently captured by the traditional primary composite endpoints and 
the priority would be to focus on FDA qualification of a PRO measure evaluating 
RA-related fatigue. cOnclusiOns: The RA WG is initiating a collaboration with 
clinical experts through OMERACT to provide an operational definition of fatigue 
and to develop a conceptual framework to support its measurement in clinical trials. 
Following this preliminary step, qualitative and quantitative steps will be launched 
to develop the fatigue measure.
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SHORT RUN DyNAMICS OF INADEQUATE PAIN RELIEF (IPR): EvIDENCE FROM A 
EUROPEAN MULTINATIONAL SURvEy OF REAL wORLD THERAPIES (SORT)
Mavros P.1, Black C.M.1, Peloso P.M.1, Stokes L.2, Philips C.3, Moore A.4, Conaghan P.5, 
 Rannou F.6, Arden N.7, van de Laar M.8, Taylor S.D.1
1Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA, 
2Merck & Co., Inc., Whitehouse Station, NJ, USA, 3Swansea University, Wales, UK, 4University of 
Oxford, Oxford, UK, 5University of Leeds, Leeds, UK, 6University of Paris, Paris, France, 7University 
of Southampton, Southampton, UK, UK, 8University of Twente, Enschede, The Netherlands
Osteoarthritis (OA) is the most prevalent musculoskeletal disorder and has been 
associated with poorer quality of life for patients who experience heightened pain 
and decreased functionality. Despite the importance of OA management in clinical 
practice settings, there has been limited evidence confirming the adequacy of pain 
relief in patients with knee OA who take analgesics to manage their symptoms. 
Objectives: To assess changes in pain relief states in the short run (30 days) and 
evaluate associated changes in outcome measures: SF-12, Brief Pain Inventory (BPI) 
and WOMAC in participants with knee OA. MethOds: The Survey of Real World 
Therapies (SORT), a 12-month prospective study across 6 EU countries (N= 1,254), 
enrolled participants > 50 years old with knee OA who were prescribed analgesics. 
Patient-reported outcomes measures were collected at baseline and one month post 
baseline: BPI, SF-12 and WOMAC. Inadequate pain relief (IPR) was defined as BPI 
pain score of “moderate or greater pain” (> 4). Results: A total of 1153 participants 
were included: 67.3% women; mean age 68 years (SD= 9.4); mean OA duration 5.9 
years (SD= 6.2). 54% of participants reported experiencing IPR. After 30 days, 28% 
of participants reported changes in pain relief, which was equally distributed (14% 
each) between the two baseline pain-relief states. Changes in IPR states were sig-
nificantly associated with changes in SF-12 composite summary scores and WOMAC 
subscales. Patients who reported improvements in pain scores showed statistically 
significant improvements in average pain (2.7 points) and both QOL composite 
measures (p< 0.01): WOMAC subscales improvement ranged from 8-11 points and 
the Physical and Mental Component Summaries scores decreased 1.83 and 1.79 
points, respectively. Those who experienced worsening pain had an increase in aver-
age pain of 2.7 points on the BPI. These participants showed statistically significant 
decreases in QOL - WOMAC scores decreased between 4-9 points and PCS and MCS 
scores increased 2.10 and 2.27 points, respectively. cOnclusiOns: Changes in pain 
states were significantly associated with overall quality of life and physical function.
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HEALTH OUTCOMES AND ECONOMIC BURDEN OF POST-KNEE REPLACEMENT 
SURGERy IN OSTEOARTHRITIS PATIENTS: COMPARISON wITH MATCHED 
CONTROLS
Pignot M.1, DiBonaventura M.2
1Kantar Health, München, Germany, 2Kantar Health, New York, NY, USA
Objectives: Osteoarthritis (OA), a degenerative condition of the articular cartilage, 
primarily affects the knee joint and surgery is often required for late-stage patients. 
The number of total knee arthroplasties (TKAs) is expected to grow to 3.48 million 
procedures by 2030 in the US alone. However, the devices lack an ideal safety profile. 
The objective of this study was to examine real-world outcomes among OA patients 
post-knee replacement. MethOds: Data from the 2012 U.S. National Health and 
Objectives: To evaluate the preferences of osteoporotic patients for medication 
attributes in Belgium and Ireland, and to assess whether preferences are transferable 
across these jurisdictions. MethOds: A discrete-choice experiment was designed 
in which patients were asked to choose between two unlabelled drug alternatives 
(and an opt-out option), which vary in five attributes: efficacy in reducing the risk of 
fracture, type of potential common side-effects, mode and frequency of administra-
tion and out-of-pocket costs. An efficient experimental design was used to construct 
the sets of treatment options and a mixed logit panel data model was employed to 
estimate patients’ preferences. To assess the significance of the differences between 
countries, a joint model was estimated using interaction terms. Results: A total of 
257 Belgian and 200 Irish osteoporotic patients completed the experiment. In both 
countries, patients preferred a drug treatment with a higher risk reduction and a lower 
cost. They disliked more being at risk of gastro-intestinal disorders than at risk of 
skin reactions and flu-like symptoms and preferred 6-month subcutaneous injection 
compared with weekly oral tablets. In Belgium, patients also preferred oral monthly 
tablet over weekly tablets, while Irish patients preferred yearly intravenous over 
weekly tablets. Some differences between countries were significant. Irish patients 
attached higher value to being at risk for skin reactions or flu-like symptoms, and the 
parameter of yearly intravenous was higher (and significant) in Ireland. In addition, 
higher costs are more acceptable for Irish patients. These differences were generally 
robust in subgroups analyses including patients over 65 years, with prior fracture, high 
income or high education. cOnclusiOns: In this study, the preferences of osteo-
porosis patients for drug therapy did not substantially differ between two European 
countries. Only for levels of some attributes significant differences were observed, 
which could not only be related to health and socio-demographic factors.
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LONG-TERM MAINTENANCE OF IMPROvEMENTS IN PATIENT-REPORTED 
OUTCOMES wITH CERTOLIzUMAB PEGOL IN PATIENTS wITH AxIAL 
SPONDyLOARTHRITIS, INCLUDING ANKyLOSING SPONDyLITIS AND NON-
RADIOGRAPHIC AxIAL SPONDyLOARTHRITIS: 48-wEEK RESULTS OF THE 
RAPID-AxSPA STUDy
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Objectives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in axial spondyloarthritis (axSpA), 
including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), over 
48 weeks (wks) in the RAPID-axSpA trial. MethOds: The ongoing RAPID-axSpA trial 
(NCT01087762) is double-blind and placebo (PBO)-controlled to Wk24 and dose-blind 
to Wk48. Patient (pts) fulfilled ASAS criteria and had active axSpA. Pts originally 
randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at 
Wks 0, 2, 4) continued on their assigned dose in dose-blind phase; PBO pts enter-
ing dose-blind phase were re-randomized to CZP loading dose followed by CZP 
200mg Q2W or 400mg Q4W. We report efficacy data for the full analysis set (FAS) 
originally randomized to CZP. PRO endpoints included physical function (BASFI), 
total spinal pain, fatigue (from BASDAI), ASQoL, Sleep Problems Index II domain 
of MOS Sleep scale, and SF-36. Missing data were imputed by LOCF. Results: Of 
111 and 107 pts randomized to CZP 200mg Q2W and 400mg Q4W, 105(94.6%) and 
98(91.6%) completed the double-blind period, and 98(88.3%) and 93(86.9%) completed 
the dose-blind period. Rapid improvements from baseline to Wk24 were maintained 
to Wk48, for both CZP 200mg Q2W and 400mg Q2W, in total spinal pain (Wk24: -3.3 
and -3.2; Wk48: -3.6 and -3.5), fatigue (Wk24: -2.6 and -2.8; Wk48: -2.8 and -2.9), BASFI 
(Wk24: -2.4 and -2.3; Wk48: -2.6 and -2.4), ASQoL (Wk24: -5.1 and -5.1; Wk48: -6.0 and 
-5.6) and sleep (Wk24: -12.7 and -12.9; Wk48: -14.7 and -14.2). CZP-treated pts also 
maintained improvements in SF-36 components and domains. Similar outcomes 
were seen in AS and nr-axSpA populations. cOnclusiOns: Improvements in PROs 
observed with both CZP dosing regimens were maintained over 48 wks, including 
those in pain, fatigue, physical function and HRQoL. Maintenance was observed in 
both AS and nr-axSpA pts.
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PSORIATIC ARTHRITIS wITH CERTOLIzUMAB PEGOL: 48-wEEK PATIENT-
REPORTED OUTCOME RESULTS OF THE RAPID-PSA STUDy
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Objectives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) over 
48 weeks (wks) in the RAPID-PsA trial. MethOds: The ongoing RAPID-PsA trial 
(NCT01087788) is double-blind and placebo-controlled to Wk24 and dose-blind to 
Wk48. Patients (pts) had active PsA and had failed ≥ 1 DMARD. Pts originally rand-
omized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at Wks 
0, 2, 4) continued on their assigned dose in dose-blind phase; placebo pts entering 
dose-blind phase were re-randomized to CZP loading dose followed by CZP 200mg 
Q2W or 400mg Q4W. We report efficacy data for the randomised set (RS) of pts 
originally randomized to CZP. Mean changes from baseline in patient assessment of 
pain (VAS), fatigue assessment scale (NRS), HAQ-DI, SF-36, PsAQoL and Dermatology 
Life Quality Index (DLQI) were assessed with LOCF imputation. Results: Of 138 
and 135 pts randomized to CZP 200mg Q2W and 400mg Q4W, 128 (92.8%) and 120 
(88.9%) completed the double-blind period, and 123 (89.1%) and 114 (84.4%) com-
pleted the dose-blind period, respectively. Rapid improvements from baseline to 
Wk24 observed in double-blind period were maintained to Wk48 for pain (Wk24: 
-28.6 and -28.4; Wk48: -31.6 and -29.5), fatigue (Wk24: -2.2 and -1.9; Wk48: -2.4 and 
-2.0), HAQ-DI (Wk24: -0.52 and -0.43; Wk48: -0.56 and -0.49), SF-36 physical compo-
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days with ≥ 50% decreased household productivity (mean BL:10.5, C/W:1.2), RA inter-
ference with household productivity (mean BL:6.2, C/W:2.0) and days missed per 
month of family/social/leisure activity (mean BL:5.8, C/W:0.7). cOnclusiOns: In 
the RAPID1 OLE, CZP Q2W plus MTX maintained improvements in workplace and 
household productivity and increased social activity participation over > 4yrs.
PMS87
CONTINUED IMPROvEMENTS IN wORKPLACE AND HOUSEHOLD PRODUCTIvITy 
wITH CERTOLIzUMAB PEGOL TREATMENT IN AxIAL SPONDyLOARTHRITIS, 
INCLUDING ANKyLOSING SPONDyLITIS AND NON-RADIOGRAPHIC AxIAL 
SPONDyLOARTHRITIS: 48-wEEK RESULTS FROM THE RAPID-AxSPA STUDy
van der Heijde D.1, Braun J.2, Rudwaleit M.3, Purcaru O.4, Kavanaugh A.5
1Leiden University Medical Centre, Leiden, The Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, 
Germany, 3Endokrinologikum Berlin, Berlin, Germany, 4UCB Pharma, Brussels, Belgium, 5UCSD, 
San Diego, CA, USA
Objectives: Investigate certolizumab pegol (CZP) effect on workplace and house-
hold productivity up to 48 weeks (wks) in patients (pts) with axial spondyloarthritis 
(axSpA), including ankylosing spondylitis (AS, meeting modified New York criteria) 
and non-radiographic axSpA (nr-axSpA). MethOds: The ongoing RAPID-axSpA 
trial (NCT01087762) is double-blind and placebo-controlled to Wk24 and dose-
blind to Wk48. Pts had active axSpA, according to ASAS criteria, including AS and 
nr-axSpA. Pts originally randomized to CZP (200mg Q2W or 400mg Q4W, following 
400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in dose-blind 
phase; placebo pts entering dose-blind phase were re-randomized to CZP loading 
dose, followed by CZP 200mg Q2W or 400mg Q4W. The validated arthritis-specific 
Work Productivity Survey (WPS; administered Q4W) assessed the impact of axSpA 
on workplace and household productivity. WPS responses (LOCF imputation) in 
pts originally randomized to CZP in the full analysis set (FAS) are summarized 
descriptively over 48 wks. Results: A total of 325 pts were randomized, of which 
218 were assigned to CZP 200mg Q2W or CZP 400mg Q4W. 69.4% and 74.9% of pts 
were employed at baseline (BL) in the CZP 200mg Q2W and CZP 400mg Q4W groups, 
respectively. By Wk48, employed CZP pts reported reduced workplace absenteeism 
(Wk48: mean 0.4 and 0.1 days missed/month for CZP 200 mg Q2W and 400 mg 
Q4W, respectively vs BL: mean 2.3 and 1.4 days/month) and presenteeism (Wk48: 
mean 1.0 and 1.6 days with reduced productivity/month vs BL: mean 5.8 and 4.7 
days/month). Continued improvements in both CZP groups to Wk48 were also 
observed in household productivity and participation in social/leisure activities. 
Similar improvements were seen in AS and nr-axSpA populations. cOnclusiOns: 
The initial improvements with CZP in workplace and household productivity and 
increased participation in social/leisure activities observed over 24 wks were con-
tinued to Wk48 in axSpA, AS and nr-axSpA pts.
PMS88
SUSTAINED IMPROvEMENTS IN PRODUCTIvITy AT PAID wORK AND wITHIN 
HOUSEHOLD, AND INCREASED PARTICIPATION IN DAILy ACTIvITIES OvER TIME 
wITH CERTOLIzUMAB PEGOL IN PATIENTS wITH PSORIATIC ARTHRITIS:  
48-wEEK RESULTS FROM THE RAPID-PSA STUDy
Kavanaugh A.1, Gladman D.2, van der Heijde D.3, Purcaru O.4, Mease P.J.5
1UCSD, San Diego, CA, USA, 2University of Toronto, Toronto, ON, Canada, 3Leiden University 
Medical Centre, Leiden, The Netherlands, 4UCB Pharma, Brussels, Belgium, 5Swedish Medical 
Center and University of Washington, Seattle, WA, USA
Objectives: To examine the effect of certolizumab pegol (CZP) on workplace and 
household productivity up to 48 weeks (wks), in patients (pts) with active psoriatic 
arthritis (PsA). MethOds: The ongoing RAPID-PsA trial (NCT01087788) is double-blind 
and placebo-controlled to Wk24 and dose-blind to Wk48. Pts had active PsA and had 
failed ≥ 1 DMARD. Pts originally randomized to CZP (200mg Q2W or 400mg Q4W, follow-
ing 400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in dose-blind 
phase; placebo pts entering dose-blind phase were re-randomized to CZP loading dose, 
followed by CZP 200mg Q2W or CZP 400mg Q4W. This publication reports data for pts in 
the randomised set (RS) originally randomized to CZP. The validated arthritis-specific 
Work Productivity Survey (WPS), administered Q4W from baseline (BL), assessed the 
impact of PsA on workplace and household productivity. WPS responses (LOCF impu-
tation) in both CZP groups are summarized descriptively over 48 wks. Results: 409 
pts were randomized, of which 273 were assigned to CZP 200mg Q2W or CZP 400mg 
Q4W. 87% of patients randomized to CZP completed to Wk48. 60.1% and 61.5% were 
employed at BL in the CZP 200mg Q2W and CZP 400mg Q4W groups, respectively. 
By Wk48, employed CZP pts reported reduced workplace absenteeism (Wk48: mean 
0.1 and 0.6 days missed/month for CZP 200mg Q2W and 400mg Q4W, respectively vs 
BL: mean 2.0 and 1.6 days/month) and presenteeism (Wk48: mean 0.8 and 1.9 days 
with reduced productivity/month vs BL: mean 5.2 and 5.1 days/month). CZP groups 
also reported improvements in household productivity and increased participation 
in social/leisure activities up to Wk48. cOnclusiOns: The initial improvements with 
CZP in workplace and household productivity, and participation in social/leisure activi-
ties observed over 24 wks were maintained over 48 wks in PsA pts.
PMS89
FACTORS ASSOCIATED wITH ABSENTEEISM IN RHEUMATOID ARTHRITIS 
PATIENTS IN EMPLOyMENT: RESULTS OF A SURvEy AMONG FRENCH PATIENTS
Fagnani F.1, Duburcq A.1, Woronoff A.S.2, Chauvin P.3, Cukierman G.4, Tropé-Chirol S.2, 
Joubert J.M.4, Bertin P.5
1Cemka-Eval, Bourg la Reine, France, 2ANDAR, Paris, France, 3INSERM, Paris, France, 4UCB 
Pharma, Colombes, France, 5CHU Dupuytren, Limoges, France
Objectives: To investigate the contribution of different socio-economic and clinical 
factors to absenteeism in the workplace in a population of Rheumatoid Arthritis (RA) 
patients currently in employment. MethOds: A national retrospective survey was 
conducted in French RA patients (age < 60, either employed or unemployed) recruited 
by rheumatologists or who were members of a patients’ association (ANDAR). Patient-
reported outcomes, socio-economic characteristics and various measures of pro-
ductivity loss were collected using structured telephone interviews. Multivariate 
Wellness Survey, an Internet health survey administered to a representative sample 
of adults, were used. Respondents who reported experiencing OA, with the knee 
being the only joint affected, and who reported having had joint surgery in the past 
year were considered to have had a knee replacement. A matched control group was 
identified as a comparator to the knee replacement group by using a propensity 
score matching method (matching variables include demographics and health his-
tory). Knee replacement respondents and matched controls were compared with 
respect to the Short Form-36v2, activity impairment (from the Work Productivity 
and Activity Impairment questionnaire), and health care resource utilization using 
ANOVA tests. Results: A total of 102 respondents were identified as part of the 
knee replacement group (52.0% male, 57.9 years). Compared with matched con-
trols (n= 102), those in the knee replacement group reported significantly worse 
physical health status (42.5 vs. 47.6, p< .05) though equivalent mental health status 
(49.7 vs. 49.0, p= .67). Levels of activity impairment (38.0% vs. 27.0% impairment, 
p< .05) and health care resource utilization (physician visits: 7.3 vs. 4.5, p< .05; emer-
gency room visits: 0.6 vs. 0.2, p< .05; and hospitalizations: 0.6 vs. 0.2, p< .05) were 
all significantly higher among the knee replacement group relative to matched 
controls. cOnclusiOns: These results suggest a significant burden among knee 
replacement respondents across both health status and economic outcomes. 
Improved management of these patients may have significant societal benefits.
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COMPARING HEALTH-RELATED QUALITy OF LIFE ACROSS RHEUMATOID 
ARTHRITIS, PSORIATIC ARTHRITIS AND AxIAL SPONDyLOARTHRITIS: 
ANALySES FROM CERTOLIzUMAB PEGOL CLINICAL TRIAL BASELINE DATA
Mease P.J.1, van Tubergen A.2, Deodhar A.3, Coteur G.4, Nurminen T.5, van der Heijde D.6
1Swedish Medical Center and University of Washington, Seattle, WA, USA, 2Maastricht University 
Medical Center, Maastricht, The Netherlands, 3Oregon Health and Science University, Portland, 
OR, USA, 4UCB Pharma, Brussels, Belgium, 5UCB Pharma, Monheim, Germany, 6Leiden University 
Medical Centre, Leiden, The Netherlands
Objectives: Inflammatory diseases such as rheumatoid arthritis (RA), psoriatic 
arthritis (PsA) and axial spondyloarthritis (axSpA) are associated with significant 
burden on patients’ (pts) health-related quality of life (HRQoL). The objective was to 
compare HRQoL across RA, PsA and axSpA populations. MethOds: Baseline data 
used from: RA pooled RAPID1 (NCT00152386) and RAPID2 (NCT00160602), RAPID-
PsA (NCT01087788) and RAPID-axSpA (NCT01087762). Differences between SF-36 
HRQoL scores and US general population age/gender-matched population norms 
were calculated and descriptively compared between the overall RA, PsA and axSpA 
populations, PsA subpopulations with skin involvement (≥ 3% body surface area) and 
without, and axSpA subpopulations of ankylosing spondylitis (AS) and non-radio-
graphic axSpA (nr-axSpA). Physical function was assessed using HAQ-DI in RA and 
PsA, and was also compared between PsA subpopulations. Results: Comparison of 
SF-36 score decrement vs population norms (mean±SD) revealed axSpA pts (N= 317) 
experienced a higher burden on overall physical HRQoL (-19.3±7.5) compared to RA 
(N= 1535; -17.4±7.0) and PsA (N= 403; -16.6±8.0) pts, while RA pts reported a higher 
psychological burden (-11.3±11.2) compared to axSpA (-9.3±12.3) and PsA (-8.6±12.2) 
pts. Comparison of HAQ-DI scores revealed RA pts experienced greater difficulties in 
all physical function aspects assessed, compared to PsA pts. For axSpA pts, the burden 
of disease (SF-36 scores) was similar between AS and nr-axSpA subgroups. For PsA pts, 
comparison of HRQoL scores confirmed that skin involvement does not significantly 
add to the physical health burden of disease but adds to some of the psycho-social 
aspects (eg. social function). cOnclusiOns: Trends suggested axSpA had the high-
est burden on overall physical HRQoL followed by RA and PsA, while the burden on 
overall mental HRQoL was highest in RA followed by axSpA and PsA. HRQoL burden 
in axSpA did not appear different between subpopulations, however the presence 
of skin involvement in PsA was associated with a higher burden on social function.
PMS86
LONG-TERM BENEFITS OvER MORE THAN 4 yEARS OF CERTOLIzUMAB PEGOL 
COMBINATION THERAPy ON wORKPLACE AND HOUSEHOLD PRODUCTIvITy, 
AND PARTICIPATION IN SOCIAL ACTIvITIES IN RHEUMATOID ARTHRITIS: 
RESULTS FROM THE OPEN-LABEL ExTENSION STUDy OF RAPID1
Kavanaugh A.1, Smolen J.S.2, Emery P.3, Keystone E.4, Strand V.5, Purcaru O.6,  
van Vollenhoven R.7
1UCSD, San Diego, CA, USA, 2Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 
3University of Leeds School of Medicine, Leeds, UK, 4University of Toronto, Toronto, ON, Canada, 
5Stanford University, Palo Alto, CA, USA, 6UCB Pharma, Brussels, Belgium, 7Karolinska Institute, 
Stockholm, Sweden
Objectives: In the RAPID1 randomized controlled trial (RCT; NCT00152386), certoli-
zumab pegol (CZP) every 2 weeks (Q2W) plus MTX provided rapid improvements in 
clinical measures, and workplace and household productivity over 52 weeks (wks) 
in patients (pts) with active rheumatoid arthritis (RA). We report the long-term effect 
of CZP+MTX Q2W on workplace and household productivity and social participation 
in RA pts from the RAPID1 open-label extension (OLE; NCT00175877). MethOds: 
RAPID1 52-wk Completers and Wk16 Withdrawers were eligible for treatment in OLE 
with CZP 400mg Q2W +MTX, reduced per study protocol to 200mg Q2W +MTX after 
≥ 6 months in OLE. Workplace and household productivity were assessed through 
the validated RA-specific Work Productivity Survey (WPS-RA). WPS-RA responses 
(observed cases) are summarized for CZP RCT Completers who enrolled in OLE and 
completed WPS-RA at OLE completion/withdrawal visit (C/W). Results: Of CZP 
Completers who enrolled in OLE (N= 508), 388 remained at Wk208 (4yrs) and a subset 
of 290 completed WPS-RA at OLE C/W (after minimum 4.3 and maximum 6.2 years 
CZP treatment from RCT baseline [BL]). Of these pts at RCT BL (N= 267), 49% were 
employed outside the home, 21% were RA work-disabled, 14% were homemakers 
and 13% were retired. Employed pts reported long-term reductions in absenteeism 
[mean BL:3.7 (N= 131), C/W:0.1 (N= 129)], number of days with decreased productiv-
ity (presenteeism) (mean BL:7.8, C/W:0.4) and level of RA interference with work 
productivity (mean BL:5.0, C/W:1.3, on 0–10 scale) per month. Similar decreases 
were reported in the number of household work days missed (mean BL:8.1, C/W:1.0), 
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private practices to collect de-identified data on patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status. Physicians from the 
US were screened for duration of practice and patient volume and recruited from a 
large panel to be geographically representative. Eligible patient charts (> 6 biologic 
patients, > 2 biologic-suitable (and yet biologic-naïve) patients per physician judg-
ment) were randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Results: Ninety-seven physicians 
abstracted 726 eligible RA patient charts; 378(52%) patients were on their first bio-
logic and 175(24%) patients have never experienced biologic but were considered 
suitable for one. Mean age was: 1st line-52.8yrs, biologic-suitable-51.5yrs; Female: 
1st line-73%, biologic-suitable-76%. Disease severity at diagnosis and current dis-
ease severity (both per physician judgment) (mild:moderate:severe) were: 1st line 
– 6%:74%:14% and 67%:29%:3%, biologic-suitable – 11%,74%, 10% and 25%:66%:9% 
respectively. Current drug class usage differed between the two groups (1st line/
biologic-suitable): non-biological-DMARD (57%/88%), steroids (19%/36%), NSAIDs-
COX2-inhibitors (6%/10%), NSAIDs- non-COX2-inhibitors (14%/22%), and analge-
sics (11%/12%). Key lab measures were (1st line/biologic-suitable): ESR(24.2/40.0 
mm/h) and CRP(2.5mg/5.6 dl). Current ACR-scores were (1st line/biologic-suita-
ble): no response(2%/19%), ACR20(12%/36%), ACR50(18%/15%), ACR70(20%/5%), 
ACR90(26%/1%). Among patients with available data, current HAQ (1st line-0.7, 
biological-suitable-1.1), DAS28 (1st line-2.5, biological-suitable-4.1), 100mmVAS 
(1st line-2.3, biological-suitable-4.6), Swollen Joint Count (1st line-2.0, biological-
suitable-5.9) and Tender Joint Count (1st line-2.8, biological-suitable-7.0) differed 
between the patient groups. cOnclusiOns: Compared to the patients currently 
treated with 1st line biologic, RA biologic-naïve but suitable patients (per physician 
judgment) had relatively higher disease burden. Reasons for non-initiation of bio-
logic treatment among ‘biologic-suitable’ patients warrant further investigation to 
alleviate disease burden.
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COMPARISON OF DISEASE STATUS, TREATMENTS AND OUTCOMES OF 
PATIENTS wITH PSORIATIC ARTHRITIS RECEIvING THEIR FIRST BIOLOGIC IN 
THE EUROPEAN UNION AND UNITED STATES
Narayanan S.1, Baskett A.2, Lu Y.2, Hutchings R.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To compare the disease status and outcomes of patients with PsA 
receiving their first biologic in UK, Germany, France, Italy and Spain (5EU) with 
the US. MethOds: A multi-country multi-center medical chart-review study of 
PsA patients was conducted among physicians (majority: rheumatologists) in 
hospitals/private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians were screened 
for duration of practice and patient volume and recruited from a large panel to 
be geographically representative in each country. Eligible PsA patient charts 
(> 3) were randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient diag-
nosis, treatment patterns/dynamics and patient symptomatology/disease status/
outcomes. Results: In 4Q2012, 434 physicians (5EU:337, US:97) abstracted 790 
eligible PsA patient charts (5EU:606, US:184); 674 (85%) (5EU:527, US:147) patients 
were on their first biologic (mean-age: 5EU:47.4yrs, US:47.6yrs; female: 5EU:48.6%, 
US:44.9%). Time-to-1st biologic from diagnosis (5EU:41.0months, US:27.2months) 
and time-on-current biologic (5EU:23.2months, US:36.7months) differed between 
regions. Top-2 biologic treatments observed were adalimumab (5EU:47%, US:47%) 
and etanercept (5EU:36%, US:32%). Among the top-4 reasons for biologic treatment 
initiation, ‘mechanism of action’, ‘improve signs/symptoms’, ‘positive personal 
experience’ and ‘prevention of structural damage’ were observed in both the 5EU 
and US. Key lab measures documented were: ESR (5EU:20.6mm/h, US:23.7mm/h) and 
CRP (5EU:9.4mg/dl, US:2.8mg/dl). Current disease severity per physician-judgment 
(mild:moderate:severe) was: 5EU-61%:33%:5%, US-73%:26%:1%. Among patients with 
available data, current HAQ (5EU:1.3, US:0.6), VAS provider score (5EU:3.1, US:2.6), 
VAS patient score (5EU:3.4, US:2.7) and Swollen Joint Count (5EU:2.0, US:1.7) differed 
across regions. cOnclusiOns: Among PsA patients receiving their first biologic, 
disease severity and outcomes differed between 5EU and US, with patients in 5EU 
with relatively higher burden and poorer outcomes.
PMS94
PATTERNS OF DISEASE REMISSION AMONG PATIENTS wITH RHEUMATOID 
ARTHRITIS RECEIvING THEIR FIRST BIOLOGIC IN EUROPEAN UNION
Narayanan S.1, Baskett A.2, Lu Y.2, Hutchings R.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess the patterns of disease remission among RA patients receiv-
ing their first biologic in 5-EU countries, namely, UK, Germany(DE), France(FR), 
Italy(IT) & Spain(SP). MethOds: A multi-country multi-center medical chart-review 
study of RA patients was conducted among physicians (majority: rheumatologists) 
in hospitals/private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians were screened 
for practice-duration and patient-volume and recruited from a large panel to be 
geographically representative in each country. Patient charts (> = 5) were randomly 
selected within each center/practice. Physicians abstracted patient diagnosis, 
treatment patterns/dynamics and patient symptomatology/disease status (incl. 
assessment of ‘disease remission’, per physician clinical judgment). Results: In 
4Q2011, 370 physicians abstracted 2208 eligible RA patient charts (UK:410, FR:499, 
DE:404, IT:415, SP:480); patient mean-age:51yrs, female:71%; 75% and 20% were on 
1st line and 2nd line biologic respectively. Overall, 53% of patients were in remis-
sion (UK:54%, FR:56%, DE:61%, IT:41%, SP:53%). Remission-rates differed by biologic 
lines: 1st-line:53%, 2nd-line:53%, 3rd-line:46%, 4th-line:42%, 5th-line:38%. Among those 
with lab measures, results differed between those in remission vs. those who were 
not: mean ESR(mm/h): 17.0vs.32.1, mean CRP(mg/dl): 7.0vs.15.6, mean MMP3(ng/
ml): 2.8-vs-4.7, Rheumatoid Factor (% positive): 83%-vs-86% and Anti-CCP (% posi-
tive): 75%-vs-79%. Among those with data, recent (mean) disease severity scores 
regression analyses were performed to identify the contributing factors to absentee-
ism. Results: A sample of 503 patients agreed to participate, of which 488 were 
evaluable. 364 patients (74.6%) were in employment, 31 (6.4%) were unemployed and 
93 (19.1%) were out of the labor market. Among the 364 patients currently in employ-
ment, 102 (28.0%), 138 (37.9%) and 124 (34.1%) were in ACR functional class of I, II and 
III/IV, respectively. The mean HAQ scores were 0.6, 1.4 and 1.5 (p< 0.0001), and 2.9%, 
16.7% and 29.0% (p< 0.0001), respectively, had an occupational disability status. An 
overall proportion of 48.3% patients declared an RA associated work absence over the 
last year. This proportion increased from 28.4% in ACR I to 62% in ACR III/IV group, 
and from 7.8% to 31.4% (p< 0.0001), respectively, for absence > 1 month. Despite a high 
uptake of biologic agents (60.4%) among these patients, RA was active for a significant 
period of time; mean 2.2 (±3.2) months in ACR I group and 4.8 (±4.2) months in ACR 
III/IV group. Regression analyses suggested that ACR functional class and frequencies 
and duration of flares were the major factors contributing to absenteeism, far ahead 
of any other socio-economic characteristics. cOnclusiOns: Loss of productivity due 
to RA could be further reduced through better control of disease activity.
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A REvIEw OF COST-EFFECTIvENESS EvALUATIONS AS PART OF NATIONAL HTA 
ASSESSMENTS OF BIOLOGIC DMARDS IN THE TREATMENT OF RHEUMATOID 
ARTHRITIS
Iannazzo S.1, De Francesco M.2, Gomez-Ulloa D.3, Benucci M.4
1IMS Health, Milano, Italy, 2IMS Health, Milan, Italy, 3IMS Health, Barcelona, Spain, 4Hospital S. 
Giovanni di Dio, Florence, Italy
Objectives: Rheumatoid arthritis is an autoimmune chronic disease which is 
associated with an increasing disability of patients and high socioeconomic bur-
den. Given the large number of economic evaluations considered by national HTAs, 
this review attempts to clarify whether biologic DMARDs cost-effectiveness and 
cost-utility results form the basis for official recommendation by national HTA 
agencies. MethOds: Both older biologic anti-TNFα drugs (etanercept, infliximab 
and adalimumab) and novel bDMARDs (abatacept, tocilizumab, certolizumab, goli-
mumab and rituximab) were considered. All main HTA agencies were searched 
for published economic evaluations up to 2012. Documents were selected if they 
included cost-effectiveness or cost-utility as outcome, if they referred to at least 
one of the drugs of interest, if they were published in English and if they were not 
superseded by other analysis. PICO statements were used to define exclusion crite-
ria. Results: Of the 65 documents initially identified through the search strategy, 
20 documents were selected. The associated HTA agencies were PBAC (Australia), 
CADTH (Canada), SMC (Scotland) and NICE (England). In relation to older anti-TNFα , 
documents published by NICE were found to be the only explicitly recommending 
the drugs on the basis of obtained cost-utility results. Economic evaluations of 
novel bDMARDs published by SMC and NICE appeared to inform HTA decisions not 
to recommend abatacept and to list all other drugs conditional on price facilitation 
and following failure of rituximab. By contrast, cost-utility analysis published by 
PBAC and CADTH did not appear to influence official recommendations on novel 
biologic DMARDs. cOnclusiOns: Cost-effectiveness and cost-utility evidence was 
not equally perceived by decison makers and did not have equal weight in defining 
the official listing of biologic DMARDs for the treatment of RA. Further research 
should therefore address methods for a greater integration between health eco-
nomic analysis and final decisions taken by National HTA agencies.
PMS91
COST-EFFECTIvENESS ANALySIS OF ALENDRONATE THERAPy FOR SECONDARy 
PREvENTION OF OSTEOPOROTIC FRACTURES
Moriwaki K.1, Komaba H.2, Noto S.1, Yanagisawa S.3, Takiguchi T.1, Toujo T.1, Inoue H.1, 
Fukagawa M.2, Takahashi H.E.1
1Niigata University of Health and Welfare, Niigata, Japan, 2Tokai University School of Medicine, 
Isehara, Japan, 3Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Japan
Objectives: Although osteoporotic fractures impose a heavy financial burden on 
society as a whole, only 20% of patients with osteoporosis and in risk of fracture 
are being treated. The purpose of this study was to estimate the cost-effective-
ness of alendronate therapy for secondary prevention of osteoporotic fractures in 
Japan. MethOds: A patient-level simulation model with nine health states was 
developed to predict lifetime costs and quality-adjusted life years (QALYs) of five 
years of alendronate therapy versus no preventive treatment for Japanese women 
with osteoporosis, who have a history of hip fracture. Fracture risk associated with 
age and bone mineral density (BMD) was derived from epidemiologic studies in 
Japan. We ran the model with different combinations of age (50, 60, and 70), BMD 
(T-score of −2.5 and −2.0), and BMD-independent fracture risk factors. Results: 
For patients with T-score of -2.0 having no additional risk factors, the incremental 
cost-effectiveness ratio (ICER) of alendronate was $3,023 and $7,389 per QALY gained 
for those aged 60 and 70 years, respectively. In all other situations, alendronate 
was dominant over no preventive treatment, with lifetime cost savings ranging 
from $30,849 to $1,498,961. These results were fairly robust to variations in model 
parameters. cOnclusiOns: Alendronate therapy for secondary fracture prevention 
in Japanese women with osteoporosis provided good value for money.
PMS92
COMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS wITH 
RHEUMATOID ARTHRITIS RECEIvING THEIR FIRST BIOLOGIC AND BIOLOGIC-
NAïvE PATIENTS CONSIDERED BIOLOGIC-SUITABLE IN THE UNITED STATES
Narayanan S.1, Baskett A.2, Lu Y.2, Hutchings R.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess clinical characteristics of RA patients considered suitable 
for biologic therapy (by their physicians) in comparison to those currently treated 
with 1st line biologics in the US. MethOds: A medical chart-review study of RA 
patients was conducted among physicians (primarily rheumatologists) in hospitals/
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chart-review study of PsA patients was conducted among physicians in hospitals/
private practices to collect de-identified data on patients recently treated with a 
biologic as part of usual care. Physicians from UK/Germany/France/Italy/Spain (5EU) 
were screened for practice-duration and patient-volume and recruited from a large 
panel to be geographically representative in each country. Eligible patient charts (> 2) 
were randomly selected from a sample of prospective patients visiting each center/
practice during the screening period. Physicians abstracted patient diagnosis, treat-
ment patterns/dynamics and patient symptomatology/disease status. Results: 
Between Jan2011-Dec2012, 454 PsA patients (mean age:48.8yrs;female:49.6%) on 
2nd-line biologic after 1st-line anti-TNF failure were identified. Mean time-to-1st-
line anti-TNF from diagnosis was 51.6months; mean time on 1st-line anti-TNF was 
18.3months (patients < 6/7-12/13-24/> 24months:33%/21%/19%/27%). Top-3 1st line 
anti-TNFs observed were: etanercept(38%), adalimumab(32%), and infliximab(27%). 
The top-5 reasons for 1st-line anti-TNF discontinuation were ‘long-term efficacy 
failure’, ‘disease worsened’, ‘side-effects not tolerated’, ‘insufficient-improve-
ment’, and ‘initial failure of efficacy’. Mean time on current 2nd-line biologic was 
18.5months (patients < 6/7-12/13-24/> 24months:28%/21%/25%/27%). Current 2nd-
line biologics (top-5) included: adalimumab(39%)/etanercept(31%)/infliximab(14%)/
golimumab(11%)/abatacept(2%). Top-5 reasons for choice of 2nd-line biologic were 
‘mechanism of action’, ‘prevention of structural damage’, ‘improve signs/symp-
toms’, ‘disease worsened’, ‘positive personal experience’. Key lab measures docu-
mented were: ESR-21.7mm/h and CRP-8.3mg/dl. Among patients with available 
data, current HAQ was 1.1, Swollen Joint Count was 1.9 and Tender Joint Count 
was 3.4. Current disease severity per physician judgment (mild:moderate:severe) 
were: 48%:47%:5%. Current disease severity (mild:moderate:severe) by time on 1stline 
anti-TNF biologic (< 6/7-12/13-24/> 24months) were 47%:48%:5% / 55%:42%:3% / 
49%:48%:4% / 44%:49%:7% respectively. cOnclusiOns: Among PsA pts on their 2nd 
biologic who experienced anti-TNF failure, 54% discontinued their 1st line anti-TNF 
regimen within 12months of initiation and continue to have considerable disease 
burden despite current 2nd line biologic.
PMS98
ECONOMIC IMPACT ASSOCIATED wITH A BIOLOGICAL THERAPy 
PRIORITIzATION PROTOCOL IN RHEUMATOID ARTHRITIS PATIENTS IN THE 
HOSPITAL OF SAGUNTO
Borrás-Blasco J.1, Gracia-Pérez A.1, Castera D.E.1, Rosique J.D.1, Abad F.J.1, González Álvarez A2
1Hospital de Sagunto, Sagunto, Spain, 2Hospital Obispo Polanco, Teruel, Spain
Objectives: Until 2010 the cost of biological treatments in Rheumatoid Arthritis 
(RA) was increased annually by 15% in our hospital. In 1stJanuary 2011, a Hospital 
Commission and Protocol of Biological Therapies were created to improve the 
cost-effectiveness usage of biological drugs in RA. To evaluate the economic impact 
associated with a biological therapy prioritization Protocol for RA patients in the 
Hospital of Sagunto. MethOds: Observational, ambispective study comparing 
the associated cost of biotreated RA patients pre-protocol (2009-2010) versus 
post-protocol periods (2011-2012). Inclusion criteria: RA patients treated with 
Abatacept (ABA) Adalimumab (ADA), Etanercept (ETN) or Infliximab (IFX) for at 
least 6 months during the study period (2009-2012). ETN was selected as 1st line 
therapy because our successful experience of ETN 25 mg/weekly in certain RA 
patients, its subcutaneous administration and lowest theoretical cost per patient 
in Spain. Cost savings and economic impact were calculated using Spanish offi-
cial prices. Results: In the pre-protocol period (2009-2010), total expenses were 
increased by 110,000€ , up to 1,761,000€ in 2010 (11,362€ pat/year). After protocol 
implementation, total expenses decreased by 53,676€ on the 2010-2011 period, and 
149,200€ on the 2011-2012 period. On the 2010-2011 period the cost of biological 
therapy per patient-year decreased 355€ (11,007€ pat/year) and additional 653€ (up 
to 10,354€ pat/year) by 2012, with a cumulative effect of the protocol implementa-
tion of 1,008€ per patient-year. In the pre-protocol period, the annual cost/patient 
was 10.812€ with ETN, 10.942€ with IFX, 12.961€ with ADA and 12.739€ with ABA. 
By 1st Jan 2013, the annual cost per patient was 9,469€ with ETN, 10,579€ with 
IFX, 11,117€ with ADA and 13,540€ with ABA. cOnclusiOns: The creation of our 
Commission of Biological Therapies is key to rational management of RA patients 
and optimization of resources, allowing us to save 200,000€ after 2-year efficiency 
protocol implementation.
PMS99
REAL wORLD UTILIzATION OF BIOLOGICAL AGENTS IN RHEUMATOID 
ARTHRITIS PATIENTS: A FRENCH NATIONAL CLAIMS DATABASE ANALySIS 
OvER THE PERIOD 2009-2011
Fautrel B.1, Laurendeau C.2, Joubert J.M.3, Cukierman G.3, Gourmelen J.4, Fagnani F.2
1CHU Pitié-Salpétrière, Paris, France, 2Cemka-Eval, Bourg la Reine, France, 3UCB Pharma, 
Colombes, France, 4INSERM, Villejuif, France
Objectives: To describe the current medical management of Rheumatoid 
Arthritis (RA) patients in routine practice in a national representative sample of 
patients, focusing on biological agents (BA) uptake. MethOds: The EGB database 
is a 1/97 representative sample of the national claims database covering the whole 
French population. RA patients were identified as adults (age > 18) benefiting from 
full coverage (“ALD” eligibility criteria) for RA (ICD-10 codes M05-06) on January 1, 
2009. Patients treated by BA were defined as RA patients with at least one claim 
for at least one BA over the period. BA-naïve treated patients were identified by 
the absence of a BA claim during the first 3 months of the study period, followed 
by at least one BA claim. Results: Over the 3-year period, 236 patients had a BA 
reimbursed and 5,336 deliveries by pharmacists were observed. The proportion 
of BA users, either alone or in combination, was 14.0% in 2009, and 70 patients 
(32.7%) used a BA in combination with methotrexate. Among patients treated by 
BA, 85.2% used at least one TNF inhibitor during the study period. Etanercept had 
the highest delivery record (58.1%), followed by adalimumab (28.8%) and infliximab 
(15.3%). Among the whole group of patients treated by BA, 13.6% were delivered 
rituximab at least once. Over the period, a proportion of 73.3% of patients had one 
BA agent only, 19.1% experienced one switch and 7.6% had two or more switches. 
differed between those in remission vs. those who were not: Tender Joint Count: 
2.3-vs-6.1, Swollen Joint Count: 1.2-vs-4.2, 100mm VAS score: 18.6-vs-42.8, HAQ: 
0.7-vs-1.6 and DAS28: 2.6-vs-4.4. cOnclusiOns: More than half of the patients 
were not in remission in this diverse cohort of RA patients in 5-EU and they experi-
enced disproportionate level of disease burden. As the line of treatment increased, 
proportion of individuals achieving remission decreased. These observed patterns 
warrant further scrutiny to determine the best practices and improve remission 
rates, thereby alleviating patient burden.
PMS95
COMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS wITH 
RHEUMATOID ARTHRITIS RECEIvING THEIR FIRST BIOLOGIC IN EUROPE UNION 
AND THE UNITED STATES
Narayanan S.1, Baskett A.2, Lu Y.2, Hutchings R.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess the clinical characteristics of patients with RA receiving their 
first biologic in EU and the US. MethOds: A multi-country medical chart-review 
study of RA patients was conducted among physicians (majority: rheumatologists) 
in hospitals and private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians from UK, Germany, 
France, Italy and Spain (5EU) and the US were screened for duration of practice and 
patient volume and recruited from a large panel to be geographically representa-
tive in each country. Eligible RA patient charts (> 5) were randomly selected from 
a sample of prospective patients visiting each center/practice during the screen-
ing period. Physicians abstracted patient diagnosis, treatment patterns/dynamics 
and patient symptomatology/disease status. Results: In 4Q2012, 434 physicians 
(5EU:337; US:97) abstracted 2085 (5EU:1534; US:551) eligible RA patient charts; cur-
rent biologic patterns (5EU/US) were: 1st line (78%/69%), 2nd line (16%/21%) & 3rd+ 
line (6%/11%). 1577 (5EU:1199; US: 378) patients were on their first biologic. Mean 
age – 5EU:50.8yrs, US:52.8yrs; female – 5EU:73%; US:73%. Mean time-to-1st biologic 
(5EU/US) from diagnosis was 40/28 months; mean time on current 1st biologic (5EU/
US) was 24/34 months. Top-3 biologic treatments observed were – etanercept (5EU/
US:37%/42%), adalimumab (5EU/US:34%/32%), and infliximab (5EU/US:8%/10%). 
The top-5 reasons for biologic treatment initiation were the same across 5EU/US 
(‘mechanism of action’, ‘improve signs/symptoms’, ‘prevent structural damage’, 
‘positive personal experience’, ‘inhibits disease progression’). Key lab measures 
documented were (5EU/US): ESR (22.7/24.2mm/h) and CRP (10.9/2.5mg/dl). Current 
disease severity per physician judgment (mild:moderate:severe) were: 5EU-
57%:37%:6%, US-67%:29%:3%. Among patients with available data, current HAQ 
(5EU:1.2/US:0.7), DAS28 (5EU:3.4/US:2.5), 100mmVAS (5EU:3.5/US:2.3), Swollen Joint 
Count (SWC) (5EU:2.6/US:2.0) and Tender Joint Count (TJC) (5EU:3.9/US:2.8) differed 
within between 5EU and US. cOnclusiOns: Among RA patients receiving their 
first biologic, disease severity differed between 5EU and US, with patients in 5EU 
with relatively higher burden.
PMS96
PATIENT ELIGIBILITy AND USE OF BIOLOGICS IN RHEUMATOID ARTHRITIS, 
ANKyLOSING SPONDyLITIS AND PSORIATIC ARTHRITIS IN THE UNITED STATES
Narayanan S.1, Baskett A.2, Lu Y.2, Hutchings R.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To evaluate physician assessment of patient eligibility and even-
tual use of biologics in RA, AS, and PsA in the US. MethOds: A multi-country 
cross-sectional survey of physicians (primarily rheumatologists) was conducted 
in the US. Physicians were screened for biologic patient volume (> 2RA biologic 
patients/week, > 5AS biologic patients/month, > 5PsA biologic patients/month) 
and recruited from a large physician-panel to be geographically representative. 
Practice characteristics, patient-volume, physician perceptions and practice pat-
terns were assessed; physicians’ target patient population was grouped into 2 
categories, based on physician input: Group1 – patients perceived to be eligible 
for biologics, Group2 – patients who ended up receiving biologics within Group1. 
Summary statistics across the US are reported. Results: In 4Q2012, 97 physicians 
participated in the study. Mean age: 47.6yrs; female: 30%. Main practice: private 
office (non-hospital):46%. Patient volume per physician was: total-1904, RA-419, 
AS-82, PsA-145. Average frequency of patient encounters were (RA/AS/PsA; weeks): 
11/12/11. Physician judgment of patient disease severity were (average across their 
patients): RA – mild:28%/moderate:47%/severe:25%, AS – mild:31%/moderate:43%/
severe:26% and PsA – mild:30%/moderate:44%/severe:27%. Physician assess-
ment of patient eligibility and use of biologics were: within RA-mild-patients – 
Group1:21%/Group2:14%, within RA-moderate-patients – Group1:63%/Group2:51%, 
within RA-severe-patients – Group1:81%/Group2:70%; within AS-mild-patients – 
Group1:32%/Group2:24%, within AS-moderate-patients – Group1:66%/Group2:55%, 
within AS-severe-patients – Group1:79%/Group2:69%; within PsA-mild-patients – 
Group1:30%/Group2:23%, within PsA-moderate-patients – Group1:66%/Group2:55%, 
within PsA-severe-patients – Group1:81%/Group2:71%. Among the top-3 biologic 
treatments used, etanercept, adalimumab, and infliximab were observed throughout 
RA, AS and PsA. cOnclusiOns: Across the markets, between 30-45% of biologic 
eligible patients (per physician perception) within moderate/severe disease sever-
ity groups did not end up receiving a biologic therapy across RA/AS/PsA cohorts. 
Reasons behind these patterns and the impact on subsequent patient outcomes 
warrant further scrutiny.
PMS97
DISEASE BURDEN AMONG PATIENTS wITH PSORIATIC ARTHRITIS wHO HAvE 
ExPERIENCED FIRST LINE TUMOR NECROSIS FACTOR INHIBITOR REGIMEN 
FAILURE IN THE EUROPEAN UNION
Narayanan S.1, Lu Y.2, Hutchings R.2, Baskett A.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess treatment patterns and disease burden among PsA patients 
on 2nd-line biologics after 1st-line anti-TNF failure. MethOds: A multi-country 
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was inadequate response from traditional disease-modifying anti-rheumatic drugs 
(DMARDs) alone (54.9%), followed by symptom control (13.4%). Among the remaining 
responses, clinical data (e.g., results from clinical trials) was cited most frequently in 
the UK (17.1%) compared to Germany/Spain (9.0%/4.7%), while personal experience 
was cited most in Germany (15.3%) vs. UK/Spain (2.7%/0.9%). Inadequate response 
to DMARDs was most frequently reported for adalimumab (61.5%) vs. etanercept 
(46.9%) or other biologics (40.2%); inadequate DMARD symptom control was more 
cited for etanercept (18.8%) vs. adalimumab (11.1%) or other biologics (9.8%). Among 
the 23 patients who switched to a second biologic agent, 72.7% were switched due 
to inadequate response to the first biologic agent. cOnclusiOns: Across the 
three study countries, prescribers most frequently initiated biologic therapy due 
to inadequate response or lack of symptom control on traditional DMARDs. Other 
reasons varied by country, however differences across biologic agents prescribed 
were minimal.
PMS103
BURDEN OF DISEASE OF CERvICAL DySTONIA IN THE UNITED KINGDOM
Raluy M.1, Kurth H.2, Wang M.1, Dinet J.2, MacLachlan S.1, Gabriel S.2, Wasiak R.1
1Evidera, London, UK, 2IPSEN Pharma, Boulogne Billancourt, France
Objectives: Cervical Dystonia (CD), the most common adult-onset dystonia, is 
characterised by involuntary contractions of the cervical muscles that result in 
abnormal, sustained, and painful postures of the head, neck and shoulders. Annual 
prevalence rate of CD in Europe is approximately 117 per million. To date, very 
few studies assessed the burden of the disease, and those published focused on 
costs of specific treatments. The objective of this study was to describe health care 
resource utilisation of patients with CD during the first year after diagnosis in 
the UK. MethOds: In this retrospective cohort study, adult patients with a first 
ever diagnosis of primary or secondary CD (Read code: F138200 Spasmodic torti-
collis) between January 2007 and December 2011 were selected from The Health 
Improvement Network (THIN), a large UK Primary Care database. Patients were 
required to have a follow-up time of at least 24 months after diagnosis. Analyses 
performed described demographic and clinical characteristics at diagnosis and 
all-cause utilization of CD-related health care resources including treatment dur-
ing follow up. Results: This study included 4,497 patients, 65.40% were female, 
median age at diagnosis was 41 years old and 8.05% were diagnosed with depression. 
During that first year, patients had on average 6 visits to the GP (SD: 5.45) and were 
newly referred most frequently to the orthopaedist (5.09%); less than 2% of patients 
had an all-cause hospitalisation and less than 1% underwent neurosurgery; 80.23% 
were managed with pharmacological treatment for CD, and the most commonly 
prescribed drugs were analgesics (69.85%) and benzodiazepines (41.23%); 14.65% 
received physical therapy. cOnclusiOns: This study provides first-time estimates 
of the health care resource utilisation related to management of patients with CD 
in UK during the first year. To describe the complete burden of CD further research 
will have to investigate secondary care data and longer time horizon.
PMS104
THE COST SAvING POTENTIAL OF UTILIzING BIOSIMILAR MEDICINES IN 
BIOLOGIC NAIvE SEvERE RHEUMATOID ARTHRITIS PATIENTS
Whitehouse J.1, Walsh K.2, Papandrikopoulou A.2, Hoad R.1
1GfK Bridgehead, Melton Mowbray, UK, 2Sandoz Biopharmaceuticals, Holzkirchen, Germany
Objectives: To analyze the potential cost savings associated with utilization of 
a quota for biosimilar RA medicines in a biologic naïve but potentially biologic 
eligible population (those defined as severe). MethOds: High patient numbers 
in rheumatoid arthritis (RA) and biologic therapy costs place significant pressures 
on health care budgets. Currently biologic therapies are underutilized in severe RA 
(DAS Score ≥ 3.7) patient populations that may be eligible for treatment. Biosimilar 
treatments are expected to reach the market (for the top 3 molecules adalimumab, 
etanercept and infliximab) by 2017 and may provide an avenue to reduce treatment 
costs and increase patient access to these agents. Biologic naïve RA populations 
were estimated for France, Germany and the UK as severe RA patients are assumed 
to be eligible for biologic therapy. Total cost of applying biologic treatment to a 
50% quota of the estimated eligible patient population was compared to a situa-
tion of initiating patients on a biosimilar equivalent with a price point 30% lower 
than the originator. Reinvestment potential was calculated, defining how many 
more patients could be treated with yearly savings. Results: By 2017, when all 3 
biosimilars are expected to be available, the assumed 50% quota resulted in yearly 
savings of € 98 million for the UK, € 351 million for Germany and € 26 million for 
France compared to the budget impact of using the originator. If these savings were 
reinvested potentially 40%, 36% and 39% of the remaining biologic naïve patients 
could be initiated on biosimilar treatment in the UK, Germany and France respec-
tively. cOnclusiOns: The cost savings from biosimilar adoption in naive severe 
RA patients presented potentially increase access by removing budgetary pressures 
from health care systems. Proactive payer encouragement for biosimilar utilization 
is necessary through the use of guidelines and prescription quotas so that health 
care systems can realize significant savings.
PMS105
THE RESOURCE USE RELATED TO HIP FRACTURES BASED ON DATA FROM 
ICUROS
Wintzell V.1, Ivergård M.1, Tankó L.B.2, Barghout V.2, Svedbom A.1, Alekna V.3, Bianchi M.L.4, 
Clark P.5, Díaz Curiel M.6, Dimai H.P.7, Jürisson M.8, Lesnyak O.9, McCloskey E.10,  
Sanders K.M.11, Thomas T.12, Borgström F.13, Kanis J.A.14
1OptumInsight, Stockholm, Sweden, 2Novartis Pharma AG, Basel, Switzerland, 3Vilnius University, 
Faculty of Medicine, Vilnius, Lithuania, 4Bone Metabolism Unit, Istituto Auxologico Italiano 
IRCCS, Milan, Italy, 5Clinical Epidemiology Unit, Hospital Infantil Federico Gómez and Faculty of 
Medicine UNAM, Mexico city, Mexico, 6Catedra de Enfermedades Metabolicas Óseas, Universidad 
Autonoma, Madrid, Spain, 7Department of Internal Medicine, Division of Endocrinology and 
Metabolism, Medical University of Graz, Graz, Austria, 8Faculty of Medicine, Tartu University, 
Tartu, Estonia, 9Ural State Medical Academy, Yekaterinburg, Russia, 10Academic Unit of Bone 
At 18 months, drug survival rate of the mix of first-line biologics was 71.8% [95% 
CI: 60.1% - 80.6%]. cOnclusiOns: Claims database is a useful tool to describe the 
medical management of RA patients. These observations suggest that BA clinical 
use in RA disease management in France is similar to other existing European 
registries data.
PMS100
ETANERCEPT 25 MG ONCE wEEKLy COULD BE A COST-EFFECTIvE OPTION FOR 
RHEUMATOLOGy PATIENTS IN SUSTAINED CLINICAL REMISSION
Borrás-Blasco J.1, Gracia-Pérez A.1, Casterá D.E.1, Abad F.J.1, Rosique-Robles J.D.1,  
González Álvarez A.2, Gimeno-Mallench L.1
1Hospital de Sagunto, Sagunto, Spain, 2Hospital Obispo Polanco, Teruel, Spain
Objectives: Etanercept 50mg/week (ETN50) has demonstrated efficacy in rheu-
matoid arthritis (RA), psoriatic arthropathy (PA) and ankylosing spondylitis (AS) 
patients. In certain patients in sustained clinical remission, a dose reduction to 
etanercept 25 mg/week (ETN25) could be done. Determine the economic impact 
of ETN25 in RA, PA and AS patients in sustained clinical remission. MethOds: 
Observational, retrospective cohort of patients treated with ETN50 that achieve 
and maintain clinical remission (DAS28< 2.6 or BASDAI< 2) during 1 year and slow 
worsening of structural changes, enrolled in an off-label program (January 2006-June 
2013) to switch ETN50 to ETN25. Economical impact was assessed using Enbrel® 
Spanish official prices. Results: From January 2006 to June 1, 2013, 98 RA, 40 PA, 
47 AS patients were treated with ETN50; 39 (24%) patients (18 women; age 53±7 
years; 24 RA, 7 PA, 8 AS) received ETN25 for at least 0.5 years (2.6±2.0 years; range 
0.5-7.3 years). At June 1, 2013, 29 (74%) patients continued on ETN25. RA patients: 17 
continued on ETN25, 5 patients discontinued due to reactivation of RA (4 switched to 
ETN50 and 1 switched to adalimumab, all regained clinical remission) and 2 patients 
due to adverse reactions. PA patients: 4 continued on ETN25, 2 patients discontinued 
due to reactivation of PA (switched to ETN50 regaining clinical remission) and 1 
patient due to adverse reaction. All AS patients continued on ETN25. Total associ-
ated savings with ETN 25 throughout the 7-year observation period were 622.073€ , 
leading to treat 52 additional patients with ETN50 for a year without increasing ETN 
total costs. cOnclusiOns: ETN25 produces cost savings when used in patients 
in clinical remission for at least 1 year with ETN50. At a time when therapy cost is 
an unavoidable component of health care treatment decisions, ETN25 could be a 
cost-effective option for selected RA, PA and AS patients.
PMS101
BURDEN OF DOSE ESCALATION wITH BIOLOGICS IN RHEUMATOID ARTHRITIS: 
A REvIEw OF FREQUENCy AND COSTS
Moots R.1, Mays R.2, Li C.2, Stephens J.2, Tarallo M.3
1University of Liverpool Academic Rheumatology Unit, Liverpool, UK, 2Pharmerit International, 
Bethesda, MD, USA, 3Pfizer Italia, Rome, Italy
Objectives: Switching or dose escalation of TNF inhibitors is an option for rheu-
matoid arthritis (RA) patients unresponsive or with a partial response to first-line 
treatment. Drug costs increase with higher dosing but the frequency and impact 
of dose escalation on other costs is not well known. A literature review of biologic 
dose escalation in RA was conducted to assess how often it occurs and the economic 
impact to payers. MethOds: A search of PubMed, EMBASE, Cochrane, and Centre of 
Disseminated Reviews was conducted for TNF inhibitors in inflammatory arthritis 
diseases. Searches were focused on dose escalation and economic terms in RA. 
Limits were Human, English and time frame (2003 to 2013). A weighted proportion 
of dose escalators in RA was calculated for each drug as an alternative to reporting 
ranges. Results: Forty-one publications were identified with 36 reporting values 
for dose escalation in RA. The proportion of dose escalators varied widely: adali-
mumab 7.5 to 36%, etanercept 0 to 22%, and infliximab 0 to 80%. Various definitions 
of dose escalation led to the wide range. The weighted proportion of dose escalators 
for each drug was adalimumab 14.9%, etanercept 4.9%, and infliximab 41.7%. Six 
studies reported economic data comparing dose escalators to non-dose escalators. 
Adalimumab drug costs increased 27 to 43% with total costs increasing 28 to 34%; 
infliximab drugs costs increased 6 to 75%, RA-related costs increased 25 to 54%, 
and total costs increased 15% to 35%. Lowest costs were reported with etanercept: 
drug costs increased 3.2 to 19%, RA-related costs increased 4.5%, and total costs 
increased 2.2 to 15%. cOnclusiOns: Pooled results demonstrated dose escalation 
in RA occurred most frequently with infliximab and least frequently with etaner-
cept. Not only were biologic costs increased, but also RA-related and total costs. 
Etanercept was associated with the lowest cost increases.
PMS102
RATIONALE FOR INITIATING AND SwITCHING BIOLOGIC THERAPy IN PATIENTS 
wITH RHEUMATOID ARTHRITIS: RESULTS OF A EUROPEAN CHART REvIEw 
STUDy
Emery P.1, Solem C.T.2, Macahilig C.P.3, Corman S.2, Majer I.M.4, McGuire M.3, Cappelleri J.C.5, 
Tarallo M.6
1University of Leeds School of Medicine, Leeds, UK, 2Pharmerit North America, LLC, Bethesda, MD, 
USA, 3Medical Data Analytics, Parsippany, NJ, USA, 4Pharmerit International, Rotterdam, The 
Netherlands, 5Pfizer, Inc., Groton, CT, USA, 6Pfizer Italia, Rome, Italy
Objectives: This study aimed to describe the rationale for selection of initial bio-
logic therapy and changes in biologic therapy among patients with RA in Germany, 
Spain, and the United Kingdom (UK). MethOds: This retrospective, observational 
medical chart review captured patient data via 118 Spanish, German, and British 
rheumatologists. Patients( ≥ 18 years) had a confirmed diagnosis of RA between 
January 2008 and December 2010, and received a biologic therapy for ≥ 3 months and 
had ≥ 12 months of follow-up. Physicians recorded all RA regimens and rationale for 
drug selection. Results: The 656 patients (n= 328; Germany: n= 111, Spain: n= 106, 
UK: n= 111) were 71.3% female, had a mean (standard deviation) age of 48.3 (12.6) 
years at diagnosis and mean 28-joint Disease Activity Score of 5.1±1.2 at biologic 
initiation. Patients most frequently initiated biologic therapy with adalimumab 
(41%) or etanercept (38%). The most common reason for initial biologic treatment 
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by age groups of 60 to 74. cOnclusiOns: The physiotherapy services occurred with 
the highest incidence in cases of the ‘diseases of the musculoskeletal system and 
connective tissue’ ICD group. The dorsopathia diseases at the ICD groups show the 
highest prevalence, indicating the importance of prevention.
PMS108
AGE AND GENDER DISTRIBUTION OF OUTPATIENT CARE PHySIOTHERAPy 
SERvICES FOR HIP AND THIGH INjURIES IN HUNGARy IN 2009
Molics B.1, Sebestyén A.2, Kránicz J.1, Schmidt B.3, Nőt L.1, Zemplényi A.1, Boncz I.1
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Pécs, 
Hungary, 3University of Pécs, Zalaegerszeg, Hungary
Objectives: The medical aspects of injuries of the lower extremity is well known, 
however, limited information is available on physiotherapy treatment of these dis-
eases. The aim of our study is to assess amount and frequency of the physiotherapy 
services in hip and thigh injuries based on age and gender distribution. MethOds: 
Data were derived from the countrywide database of Hungarian Health Insurance 
Administration (HHIA), based on official reports of outpatient care institutes in 
2009. The total numbers of different physiotherapy services were determined by 
selecting the reported specific diagnoses codes and counting the number treatments 
provided for that specific diagnosis code. The different types of treatment codes 
are listed in the chapter of the Guidelines of HHIA for ‘Physiotherapists, massage-
therapists, conductors and other physiotherapy practices’. The number of cases 
in physiotherapy activities related to for hip and thigh injuries (BNO S70-79) were 
determined per 10,000 persons by age and gender in outpatient care. Results: 
The total number of the 151 different physiotherapy services was 353.260 cases at 
the hip and thigh injuries in the year of 2009 at the. In 2009 the average number of 
cases of physiotherapy activities per 10,000 persons accounted for 351.91 cases. The 
average number of cases per 10,000 persons for males and females were 443.7 cases 
for males and 249.75 cases for females. The number of cases of the hip and thigh 
injuries were higher in the 15-49 age group in males, and in the age group of elderly 
females. cOnclusiOns: In case of the hip and thigh injuries, the highest demand 
of the outpatient care physiotherapy services occurred older injured patients. The 
differences in young males vary with the physical activity and the type of recreation 
activities, and with the condition of osteoporosis in elderly females.
PMS109
BONE EvALUATION STUDy (BEST): PREvALENCE AND TREATMENT RATES OF 
MALE PATIENTS wITH OSTEOPOROSIS (OP) IN GERMANy
Hadji P.1, Steinle T.2, Eisen C.2, Linder R.3, Klein S.4, Schmid T.2
1Universityhospital of Giessen and Marburg GmbH, Marburg, Germany, 2Amgen (Europe) GmbH, 
Munich, Germany, 3WINEG | Wissenschaftliches Institut der TK, Hamburg, Germany, 4IGES 
Institut GmbH, Berlin, Germany
Objectives: With an aging population, prevalence of OP and OP-attributable frac-
tures (OAF) is expected to rise dramatically. We evaluated prevalence and treatment 
rates for male OP (MOP) in Germany. MethOds: BEST, a retrospective analysis of 
de-identified claims data from a German sickness fund, included male and female 
OP patients, aged ≥ 50 years and insured ≥ 1 day between 01/2006−12/2009. Two 
populations were defined. Inclusion criteria for population B were: 1) OP diagno-
sis (M80.x, M81.x), and/or 2) prescription for OP-related medication (OPM), and 3) 
exclusion of diagnoses M88.x, E83.5x, and M90.7x (ICD-10). Population A included 
population B plus patients solely experiencing OAF. Results: Population A included 
104,938 men. In 2009, prevalence of MOP was 6%. While 67% of men experienced 
≥ 1 OAF during observation period, with the highest rate in those aged 50-54 years 
(78%), only 15% received OPM. Population B included 47,694 men. In 2009 prevalence 
of MOP was 4.8%. 27.2% of those diagnosed experienced ≥ 1 OAF, with the highest 
rate in men aged ≥ 75 years (2006-2009). Only 41.8% of men with ≥ 1 OAF received 
OPM during the observation period. cOnclusiOns: While prevalence of MOP is 
lower than that of postmenopausal OP (6% vs. 24% in 2009), high fracture rates 
in OP-patients represent a significant burden to the German health care system. 
The low treatment rates reported may lead to suboptimal outcomes, and must be 
optimized to reduce risk of follow-up fractures in MOP.
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PRM1
THE BENEFIT-HARM FRONTIER OF DIFFERENT PRIMARy SCREENING 
STRATEGIES FOR CERvICAL CANCER IN GERMANy
Sroczynski G.1, Esteban E.1, Engel J.2, Hillemanns P.3, Petry K.-U4, Krämer A.5,  
Schnell-Inderst P.1, Mühlberger N.1, Siebert U.6
1UMIT - University for Health Sciences, Medical Informatics and Technology/ ONCOTYROL 
- Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria, 2Munich Cancer 
Registry of the Munich Cancer Centre, Clinic Grosshadern, Ludwig-Maximilians-University, 
Munich, Germany, 3Hannover Medical School, Hanover, Germany, 4Department of Obstetrics and 
Gynecology, Hanover Medical School, Hanover, Germany, 5School of Public Health, University of 
Bielefeld, Bielefeld, Germany, 6UMIT – University for Health Sciences, Medical Informatics and 
Technology / ONCOTYROL / Harvard University, Hall i. T./ Innsbruck / Boston, Austria
Objectives: Using a benefit-harm frontier (BHF) approach, we systematically com-
pared benefits and harms of different HPV- and cytology-based primary cervical can-
cer screening strategies in Germany. MethOds: A previously validated and published 
Markov modelwas used to analyze the trade-off between benefits and harms of differ-
ent screening strategies differing by length of screening interval and test algorithms, 
including cytology alone, HPV testing alone, in combination with cytology or with 
cytological triage of HPV-positives. We used published German clinical, epidemio-
logical and international test accuracy data from meta-analyses. Predicted outcomes 
included reduction in cervical cancer incidence and unnecessary treatment (defined 
as conizations of lesions < CIN3). Results: Overall, comparing identical screening 
Metabolism, Metabolic Bone Centre, University of Sheffield, Sheffield, UK, 11Department of 
Medicine, NorthWest Academic Centre, The University of Melbourne, Melbourne, Australia, 
12INSERM U1059, CHU-St-Etienne, Saint Etienne, France, 13LIME/MMC, Karolinska Institutet, 
Stockholm, Sweden, 14WHO Collaborating Centre for Metabolic Bone Diseases, University of 
Sheffield, Sheffield, UK
Objectives: The International Costs and Utilities Related to Osteoporotic fractures 
Study (ICUROS) is an ongoing 18 months prospective observational study with the 
objective of estimating resource use and health related quality of life related to 
osteoporotic fractures. This study aims to describe the resource utilization for hip 
fractures (sustained during 2007-2012) pooled from 10 countries: Australia, Austria, 
Estonia, France, Italy, Lithuania, Mexico, Russia, Spain, and the UK. MethOds: 
Patients studied were ≥ 50 years and lived at home prior to fracture. Data were col-
lected through patient interviews and review of medical records: at baseline and 4, 
12, and 18 months after fracture. Only resource use related to the fracture event was 
collected. Results: There were 1,795, 1,435, 1,256 patients available for analysis at 4, 
12 and 18 months follow-up, respectively. The mean age (±SD) at fracture was 77±10 
years and 79% were women. 96% of patients were hospitalized. Mean hospital length 
of stay (LoS) (±SD) was 17.2±20.4 days during months 0-4 and 1.2±6.8 during months 
5-18. Mean LoS varied from 9.3 days to 26.5 days during months 0-4 across countries. 
The mean number of physician visits (±SD) was 2.8±3.1 during months 0-4 and 
2.5±5.6 between months 5-18. The mean number of nurse visits (±SD) was 2.4±9.6 
and 3.8±31.9 during corresponding periods, respectively. During months 0-4, 65% of 
patients used analgesics, 41% calcium/vitamin D, and 27% pharmacological inter-
ventions for osteoporosis. The respective uptakes for months 5-18 were 47%, 46% 
and 25%. cOnclusiOns: Almost all patients were hospitalized after fracture and 
the mean number of inpatient days is high, although there is a large variation. The 
vast majority of health care consumption in relation to fracture occurs during the 
first 4 months but substantial consumption persists up to 18 months after fracture.
PMS106
METHODOLOGy OF AN OBSERvATIONAL STUDy TO EvALUATE THE CARE MAP 
OF wOMEN wITH POSTMENOPAUSAL OSTEOPOROSIS (PMO) IN SwITzERLAND
Lippuner K.1, Pendl G.2, Biteeva I.2, Murigande C.2, Schwenkglenks M.3
1Policlinic for Osteoporosis, Bern, Switzerland, 2Amgen Switzerland Ag, Zug, Switzerland, 
3Institute of Pharmaceutical Medicine/ European Center of Pharmaceutical Medicine, University of 
Basel, Basel, Switzerland
Objectives: The diagnosis and management of PMO involves multiple special-
ists and referrals. To better understand patient management, an ongoing obser-
vational study will evaluate the care map of women with PMO treated in routine 
clinical practice in Switzerland, and estimate the 2-year treatment cost of parenter-
ally administered medications (denosumab, ibandronate, zoledronate). Here, we 
describe the study design and methodology. MethOds: Of 52 specialist centers 
across Switzerland operating a DXA machine, 22 agreed to participate in the study. 
Women diagnosed with PMO and initiated on parenteral antiresorptive treatment 
were enrolled in the study between June 18, 2012 and May 31, 2013. To minimize 
selection bias, treatment initiation must have occurred within 6 months before 
study initiation visit at the participating center. The planned follow-up period is 24 
months. Patients may be followed by the specialist or referred back to the general 
practitioner. Where available, the following data will be collected: demographics and 
patient history, co-morbidities and co-medications, DXA T-scores, osteoporosis risk 
factors, PMO treatment and rationale, bone turnover markers, vitamin D level, and 
costs related to PMO diagnosis and treatment. These parameters will be recorded 
at baseline and at any visit in the 24-month observation period as available from 
routine practice. Continuous outcomes will be summarized by descriptive statistics. 
For categorical outcomes, the number and percentage of patients in each category 
will be presented. Baseline covariates (demographic, patient characteristics and site 
characteristics) will be described overall and by treatment received. Results: As 
of May 31, 2013 at least 280 eligible women were enrolled into the study. Full study 
results will be reported at a later date. cOnclusiOns: The recruited number of 
patients confirms the feasibility of the planned methodology. Data from this study 
will provide valuable information regarding the care map of women with PMO in 
routine clinical practice in Switzerland.
PMS107
AGE AND GENDER DISTRIBUTION OF OUTPATIENT CARE PHySIOTHERAPy 
SERvICES FOR DORSOPATHIA DISEASES IN HUNGARy
Molics B.1, Hanzel A.1, Kránicz J.1, Schmidt B.2, Horváth Z.3, Boncz I.1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3National Institute 
for Quality- and Organizational Development in Healthcare and Medicines (GYEMSZI), Pécs, 
Hungary
Objectives: To assess the utilization of out-patient care physiotherapy services 
related to dorsopathia diseases of the musculoskeletal and connective tissue dis-
eases according to age and gender. MethOds: The data come from the financial 
data base of the National Health Insurance Fund Administration (in Hungarian: 
OEP) involving the year of 2009. The activity list was provided by the rulebook on 
the application of the activity code list in out-patient care. The dorsopathia dis-
eases of musculoskeletal and connective tissue diseases (M00-M99) are listed in the 
International Classification of Diseases (ICD) with code of M40–M54. The number 
of cases in physiotherapy activities were determined per 10,000 persons by age 
and gender in outpatient care. Results: The total number of the provided 151 dif-
ferent types WHO-classified physiotherapy services was 32.318.413 in the year of 
2009; 19.095.614 (59,09%) of them with the musculoskeletal and connective tissue 
diseases. The prevalence of the dorsopathia diseases were 51,17% in the group of 
the muskuloskeletal and connective tissue diseases. The average number of cases 
of physiotherapy activities per 10,000 persons accounted for 12.015 cases in 2009. 
The average number of cases per 10,000 persons for males and females were 15.589 
cases for males and 8.061 cases for females. The number of cases increase from 
the 20. age groups in the men and women patients. The highest number of physi-
otherapy treatment is provided for both gender in the age group 50 to 59 followed 
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Objectives: There is a growing interest from health technology assessment agen-
cies in determining the clinical outcomes assessments and endpoint strategies 
that can establish treatment benefits. We describe a systematic literature review 
of endpoints and outcomes used in schizophrenia trials to determine treatment 
benefit. MethOds: The therapies selected in the search strategy included pharma-
cological interventions, cognitive-behavioural therapies, family intervention, and 
music therapy. These were chosen to reflect the range of interventions in current 
use, and to allow comparison between outcomes reported for different therapies. 
The search terms were designed to include all outcomes for each therapy area, and 
were used to search four electronic databases for published English language stud-
ies. Randomised controlled trials (RCTs) were retrieved if they included patients 
with schizophrenia treated with the chosen therapies, and clinical outcomes from 
a predefined list (e.g. symptom improvement, functionality, quality of life, remission 
rates, response rates, and recovery). Results: Of 2,221 RCTs identified, 271 pro-
gressed to data extraction; 225 assessed pharmacological interventions and 46 non-
pharmacological interventions. Approximately 76 outcomes were measured across 
the trials. The most common scale used in pharmacological trials was the Positive 
and Negative Syndrome Scale (PANSS) total score (76.9%), and the PANSS positive 
subscale in non-pharmacological trials (50%). However, even within the common 
outcomes, the specified level of reduction to define a relevant response varied; 
among trials reporting PANSS total, five different levels of reduction were defined 
(≥ 20%, ≥ 25%, ≥ 30%, ≥ 40%, ≥ 50%). Common outcomes were also measured differ-
ently in terms of improvement from baseline and proportion achieving response/
remission, with little consensus on clinical meaningfulness. cOnclusiOns: The 
RCTs included in this review reported a broad range of outcomes, making com-
parison of different therapies a complex task. The disparity in outcomes between 
pharmacological and non-pharmacological outcomes scales highlights the chal-
lenges in designing trials to demonstrate clinical benefit.
PRM5
MULTI-DIMENSIONAL CAPTURE OF PATIENT-RELEvANT ENDPOINTS 
IN REGULATORy TRIALS AND HEALTH TECHNOLOGy ASSESSMENTS IN 
ONCOLOGy TwO yEARS AFTER INTRODUCTION OF THE GERMAN AMNOG 
HEALTH CARE REFORM
Dintsios C.M.1, Knoerzer D.2, Duenne A.A.2, Schwartz F.W.3, Ruof J.2
1German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany, 2Roche 
Pharma, Grenzach-Wyhlen, Germany, 3Hannover Medical School, Hannover, Germany
Objectives: With the introduction of AMNOG in January 2011, an early benefit 
assessment (EBA) was required for new medicines in Germany. EBAs are based on 
the additional therapeutic benefit of a drug on patient-relevant endpoints (PREs). 
We compared the acceptance of PREs for oncology in regulatory trials, and in EBAs 
conducted by German health technology assessment (HTA) bodies. MethOds: EBAs 
on oncology drugs and the respective regulatory trials were reviewed. The Federal 
Joint Committee (G-BA) website was used to obtain manufacturers’ value dossiers, 
Institute for Quality and Efficiency in Health Care (IQWiG) assessments, and G-BA 
resolutions. Acceptance of endpoints in the dimensions of mortality, morbidity 
and quality of life (QoL) by HTA bodies, IQWiG and G-BA, were compared to those 
accepted for regulatory trials. Data on endpoints used in regulatory trials were 
obtained from the manufacturers’ value dossiers. Results: Overall survival (OS) 
and measures of disease morbidity, such as progression-free survival (PFS), were 
generally accepted in regulatory trials. OS was accepted by IQWiG and G-BA as a 
mortality endpoint for evaluating additional benefit. Widely accepted morbidity 
endpoints such as PFS were not deemed patient-relevant by IQWiG and G-BA. In 
general, QoL questionnaires used in regulatory trials were accepted by the HTA 
bodies, although minor variability between questionnaires led to some exclusions 
from the HTA evaluations and the obtained QoL data revealed a number of missing 
values. cOnclusiOns: HTA and regulatory bodies largely agree on the accept-
ance of mortality and QoL endpoints typically evaluated in oncology. Considerable 
variability was observed in the acceptance of PREs in morbidity. Evaluating addi-
tional benefit based only on mortality and QoL endpoints underestimate the poten-
tial value of new drugs. Multiple endpoints, which capture all three dimensions, 
should be evaluated in regulatory trials and accepted by IQWiG and G-BA to confirm 
patient-relevant additional benefit.
PRM6
THRESHOLD SELECTION IN BIOMARKERS USING COx REGRESSION. AN 
APPLICATION TO NON-SMALL-CELL LUNG CANCER
Luaces P.1, Sánchez L.1, Ballesteros J.2, García B.1, Rodríguez P.C.1, Viada C.1, Popa X.1,  
Crombet T.1, Lage A.1
1Center of Molecular Immunology, Havana, Cuba, 2University of the Basque Country UPV/EHU, 
Leioa, Spain
Objectives: To select thresholds for predictive biomarkers using Cox regres-
sion. MethOds: We used data from a Cuban trial designed to assess the efficacy 
of immunotherapy against the epidermal growth factor (EGF) to test our approach. 
The trial included 122 patients diagnosed with non-small-cell lung cancer (NSCLC) 
who had basal EGF concentration available. The EGF concentration was analysed as 
a predictor of immunotherapy success over the range of all possible values of the 
biomarker (w [a,b]). For each wi, patients with w > wi0 were selected and a Cox model 
adjusted to assess survival. We then identified the w0s with significant treatment 
results to find (a) the lowest biomarker threshold where the effect of treatment was 
significant and also to find (b) the biomarker threshold that reflected the highest 
difference between treatments. Results: For NSCLC we observed that EGF concen-
tration thresholds range from 870 pg/ml to 2000 pg/ml were significant. At the lowest 
threshold (870 pg/ml) the immunotherapy group showed a 6-month difference for 
the median survival (p = 0.022) whereas at the threshold that showed the maximum 
difference between treatments (EGF = 1750 pg/ml) the immunotherapy group pre-
sented a 10-month difference for the median survival (p = 0.004). cOnclusiOns: 
The evaluation of p-values of the effect of treatment for each w0 [a,b] allows the 
selection of the thresholds where the treatment result is significant. Whereas the 
intervals HPV-based screening was more effective than cytology alone, with a rela-
tive reduction in cervical cancer incidence of 49%-90% compared to 33%-80% with 
cytology alone (depending on screening intervals). In HPV- compared to cytology 
screening the incremental gain in effectiveness was higher with extended screening 
intervals and the increase in harms lower. Based on the BHF, 12 of 17 screening strate-
gies were dominated, including annual cytology, the current recommended standard 
in Germany. Biennial HPV-screening was similarly effective as annual cytology and 
reduced unnecessary treatment. Moving from biennial HPV- with cytological triage 
to annual HPV-screening alone results in an incremental harm-benefit ratio of 15-533 
unnecessary treatments per additional prevented cervical cancer case (depending on 
screening adherence rate). cOnclusiOns: The benefit-harm frontier is a useful tool 
to demonstrate the trade-off between expected gains and risks of different screening 
strategies. Based on our analyses, HPV-based cervical cancer screening is more effec-
tive than cytology alone, but has a higher risk of overtreatment when used in annual 
screening. In the German health care context, depending on screening adherence 
rates biennial or triennial HPV-screening for women ≥ 30 years is similarly effective 
as annual cytology with significantly reduced unnecessary treatments.
PRM2
EvALUATING wHETHER INCONSISTENCIES ARE PRESENT IN A MIxED 
TREATMENT COMPARISON OF TROUGH FORCED ExPIRATORy vOLUME IN  
1 SECOND AT 12 wEEKS
Buckley F.1, Baldwin M.2, Keininger D.3, Jansen J.1, Cope S.4
1Mapi, Boston, MA, USA, 2Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, UK, 
3Novartis Pharma AG, Basel, Switzerland, 4Mapi, Toronto, ON, Canada
Objectives: To evaluate whether there are inconsistencies in the network of ran-
domized controlled trials (RCTs) used for a network meta-analysis (NMA) compar-
ing alternative long-acting bronchodilators among patients with moderate to severe 
chronic obstructive pulmonary disease (COPD) in terms of trough forced expiratory 
volume in 1 second (FEV1) at 12 weeks. MethOds: The change from baseline (CFB) 
in FEV as observed with placebo, tiotropium 18µg/5µg once daily (OD), salmeterol 
50µg twice daily (BID), formoterol 12µg BID, aclidinium 400µg BID, glycopyrronium 
50µg OD, indacaterol 75/150/300µg OD, formoterol 12µg+ tiotroipum 18µg BID/OD, 
indacaterol 150µg+ tiotropium 18µg OD, and indacaterol 110µg+ glycopyrronium 50µg 
OD in RCTs identified with a systematic literature review were synthesized with a 
NMA. Where possible, treatment estimates from fixed effect (FE) and random effects 
(RE) NMA models (assuming consistency between direct and indirect evidence) and 
independent means (IM) models (pooled direct evidence) were compared to assess 
whether any inconsistencies in the network were present. Results: Thirty-two 
RCTs identified through a systematic literature review were included in the analysis. 
Direct evidence was available for the monotherapies versus placebo, the combination 
therapies versus tiotropium, for indacaterol+ glycopyrronium versus placebo, and for 
tiotropium versus salmeterol. The largest differences between the estimated treatment 
effect estimates from the NMA and the IM models were observed for the compari-
sons between indacaterol 150µg versus tiotropium (FE difference= 0.025 [95% Credible 
Intervals (95%CrI): 0.002, 0.047]; RE difference= 0.027 [95%CrI: -0.007, 0.61]), indacaterol+ 
glycopyrronium versus placebo (FE difference= -0.022 [95%CrI: -0.053, 0.008]; RE differ-
ence= -0.018 [95%CrI: -0.059, 0.022]), and indacaterol+ glycopyrronium versus tiotro-
pium (FE difference= 0.011 [95%CrI: -0.014, 0.036]; RE difference= 0.015 [95%CrI: -0.024, 
0.053]). cOnclusiOns: Based on a comparison of the findings of a NMA and IM mod-
els, some minor inconsistencies in treatment effects for trough FEV1 at 12 weeks were 
identified that will be explored through additional sensitivity analyses.
PRM3
TESTING THE EUNETHTA INTERNAL vALIDITy OF RANDOMIzED CONTROLLED 
TRIALS GUIDELINE AND TOOL IN HUNGARy
Huszti Z., Juhasz J.
National Institute for Quality- and Organizational Development in Healthcare and Medicines, 
Budapest, Hungary
Objectives: The reliability of the results of a randomized trial depends on the extent 
to which potential sources of bias have been avoided. We tested the EUnetHTA Internal 
Validity guideline so that to harmonize our risk of bias assessments with the European 
standard and finally to improve the reliability of relative efficacy and cost effectiveness 
assessments for decision makers in Hungary. MethOds: We translated the risk of bias 
standardized assessment questions of the EUnetHTA Internal Validity (of randomized 
controlled trials) into Hungarian. We first chose ten studies for internal validity testing 
from the ones that were submitted for reimbursement at the beginning of 2012, and 
their results were used for health economy assessment. Results: We found adequate 
randomization sequence generation in seven studies and we marked it unclear in 
three trials (e.g.: lack of information, age related sequence generation). The allocation 
concealment was labeled suitable in six studies (e.g.: IVRS, IWRS) and unclear in four 
trials. All studies could be classified according the the type of blinding. We found 
selective reporting in one trial where the non-inferiority results in the per-protocol 
population were not published. We rated the risk of bias low for eight trials and high for 
two trials due to unclear sequence generation and publication bias. We also evaluated 
77 endpoints and we labelled 22 endpoints with high risk of bias. The most common 
reasons for high risk ratings were the not appropriately implemented ITT principle 
and selective reporting. cOnclusiOns: The EUnetHTA guideline gives an opportu-
nity to estimate the risk of bias of randomized controlled trials in a structured and 
harmonized way without leaving out any important considerations. The results of the 
internal validity evaluation can lead the focus of interest to those endpoints where 
the sensitivity analysis is requisite in the health economic models.
PRM4
CLINICAL OUTCOMES ASSESSMENTS IN SCHIzOPHRENIA: A SySTEMATIC 
LITERATURE REvIEw
Cooke C.1, Heatley R.2, Galani Berardo C.3, Johnson K.I.2, Kasper S.4
1Complete Clarity, Macclesfield, UK, 2Complete Clarity, Macclesfield, Cheshire, UK, 3F. Hoffman La 
Roche, Basel, Switzerland, 4Medical University of Vienna, Vienna, Austria
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strategy reduces the risk of overestimating adherence. For prescriptions extending 
beyond the end of the analysis period, days’ supply is truncated at the end of the 
period. Patients in each study sample are stratified into 5 categories based on their 
adherence score: 1–19%, 20–39%, 40–59%, 60–79%, or 80–100 %. Results: High level 
of medication adherence was associated with lower hospitalization and exacerba-
tion rates. cOnclusiOns: Increased drug utilization can provide a net economic 
return when it is driven by improved adherence.
PRM10
USING SATURN PLOTS TO DESCRIBE CO-MORBIDITy PATTERNS wITHIN 
COHORTS
Juneau P.
Truven Health Analytics, Boyds, MD, USA
Objectives: It is a common practice in outcomes research studies to examine 
several co-morbidities over two or more cohorts to develop some intuition about 
the health status of each group. It is also a common practice in claims data to record 
the co-morbid condition as a binary variable (i.e., absence or presence of the co-
morbidity). If an investigator is interested in studying the absence or presence of 
10 co-morbidities, he or she will have to consider 210= 1024 possible co-morbidity 
patterns, a seemingly daunting task. The common current practice is to construct 
summary tables and examine them to understand cohort co-morbidity patterns. 
Even with this summarization, it is difficult to deduce what the composition is for 
the cohort over all co-morbidities simultaneously. Once again, this can be a daunt-
ing task. The objective of this research is to develop a means of summarizing these 
rich and somewhat complex data to enhance clinical decision making. MethOds: 
Graphical approaches for the summarization of data enable geometry, scaling, shad-
ing, and or color to describe such “high dimensional” data. The author will introduce 
a novel means of plotting the co-morbid conditions that will afford investigators 
the ability to study patterns of co-morbidities simultaneously and understand the 
relative frequencies of their occurrence in one display. Results: The use of a novel 
graphical procedure (a Saturn plot) allows an investigator to examine co-morbidity 
patterns readily when the number of binary co-morbidities is 10 without having to 
resort to poring over several tables or one large table partitioned into smaller ones 
based on co-morbidities. cOnclusiOns: A newly developed graphical data sum-
mary called a Saturn plot allows investigators to indentify the relative frequency of 
various subgroups (as defined by their co-morbidity pattern) within a cohort without 
the need to study large sets of tables.
PRM11
DESIGN OF A RANDOMIzED CONTROLLED TRIAL (RCT) EvALUATING OUTCOME 
AND COST-EFFECTIvENESS OF A LOCAL CASE MANAGEMENT INTERvENTION 
OF PATIENTS SUFFERING FROM CHRONIC OBSTRUCTIvE PULMONARy DISEASE 
(COPD)
Sørensen S.S.1, Pedersen K.M.2, Ehlers L.1
1Aalborg University, Aalborg, Denmark, 2University of Southern Denmark, Odense M, Denmark
Objectives: In December 2011 the Danish Government issued a new plan of action 
for chronic disease management in the Danish counties and DKK 100 million were 
granted to set up new positions as case managers to help vulnerable elderly patients. 
No precise job description was provided, however, and the Danish counties request 
evidence for the effect of case management (CM). The aim of this study was to 1) 
design a job description for a case manager, and 2) design a RCT evaluating conse-
quences and costs of providing local CM to patients with COPD. MethOds: By use 
of the UK Medical Research Councils (MRC) framework for development of complex 
interventions, the design of the case manager job description and the RCT was 
determined through a systematic literature review, interviews with key persons and 
discussions in a specialist-comprised steering group. Results: CM was designed to 
encompass coordination of care, facilitation of relevant health- and social services 
and promotion of patient self-care through advocacy and education. The RCT was 
powered to detect the effect of CM on hospital admissions. Secondary measures 
include mortality, quality of life, self-care and cost-effectiveness of CM versus usual 
care. 150 COPD patients are randomized into two groups after referral to pulmo-
nary rehabilitation at the local rehabilitation center in Aalborg County, Denmark. 
The control group will receive usual care, whereas the interventional group will 
receive CM besides their usual care. Each patient is followed for 12 months. The 
questionnaires SF-12, EQ-5D, Sct. George-Respiratory-Questionnaire (SG-RQ) and 
The Patient-Activation-Measure (PAM-13) are completed at baseline and 12 months. 
Prospectively collected data from national population-based medical registries are 
used to estimate events and resource usage. cOnclusiOns: The study is expected 
to provide further insight to the future organization of CM, and if being cost-effec-
tive, the intervention could be applied to comparable health care settings.
PRM12
REvIEw OF META-ANALySIS METHODS FOR MULTINOMIAL DATA
Bennison C.1, van Beurden-Tan C.2, Buyukkaramikli C.2, Heeg B.2
1Pharmerit Ltd., York, UK, 2Pharmerit International, Rotterdam, The Netherlands
Objectives: Indirect comparisons are often based on binary outcomes (e.g. relapse / 
remission) or continuous outcomes. In these cases logistic or linear models are applied 
to make the indirect comparisons. However, sometimes datasets contain multino-
mial outcomes, such as ‘complete’, ‘partial’ and ‘no’ response in oncology, that need 
to be indirectly compared. With multinomial data, different indirect comparisons 
methods may be required to answer different research questions. Our goal was to 
identify and qualitatively compare the different techniques that have been used to 
model multinomial data in an indirect comparison framework. MethOds: A system-
atic review of the PubMed database was conducted to identify different methods for 
handling multinomial data in a meta-analysis. Key words included ‘meta-analysis’, 
‘ordinal’, ‘ordered’, ‘multinomial’ and ‘proportional odds’, in various combinations. 
Models were qualitatively compared according to their assumptions, flexibility and 
complexity. Results: The systematic review identified three methods: a proportional 
odds model, an ordered logistic model, and a multinomial model. The proportional 
lowest threshold where the effect of treatment is significant allows the selection 
of patients that could be mostly benefited with the treatment, the selection of the 
threshold with the minimum p-value will reflect the higher difference between 
treatments.
PRM7
SySTEMATIC LITERATURE REvIEw AND vALIDITy EvALUATION OF THE 
ExPANDED DISABILITy STATUS SCALE (EDSS) AND THE MULTIPLE SCLEROSIS 
FUNCTIONAL COMPOSITE (MSFC) IN PATIENTS wITH MULTIPLE SCLEROSIS
Meyer-Moock S.1, Feng Y.Y.S.1, Dippel F.W.2, Kohlmann T.1
1University Medicine Greifswald, Greifswald, Germany, 2Sanofi, Berlin, Germany
Objectives: There are a number of instruments to describe severity and progres-
sion of multiple sclerosis, which are increasingly used as endpoints to assess the 
effectiveness of therapeutic interventions. We examined to what extent the psy-
chometric properties of the two accepted instruments - EDSS and MSFC – meet the 
methodological standards and what value they have in clinical trials. MethOds: We 
conducted a systematic literature search in relevant databases [MEDLINE (PubMed), 
ISI Web of Science, EMBASE, PsycINFO & PSYNDEX, CINAHL] yielding 3,860 results. 
The identification of relevant full-text publications was conducted using abstract 
and then full-text reviews. Results: For evaluation of psychometric properties 
(validity, reliability, sensitivity of change) of EDSS and MSFC, 120 relevant full-text 
publications were identified, 54 of them assessed the EDSS, 26 the MSFC and 40 
included both instruments. The EDSS has some documented weaknesses in reli-
ability and sensitivity to change. For the MSFC, the main limitations are the learn-
ing effects and the z-scores method used to calculate the total score. However, the 
methodological criterion of validity applies sufficiently for both instruments. For 
use in clinical studies, we found that the EDSS has been preferred as a primary and 
secondary outcome measure in recent studies (50 EDSS, 9 MSFC). cOnclusiOns: 
Recognizing their strengths and weaknesses, both EDSS and MSFC are suitable 
to detect the effectiveness of clinical interventions and to monitor the disease 
progress. Almost all publications identify the EDSS as the most widely used tool to 
measure disease outcomes in clinical trials. Despite some limitations, both instru-
ments are accepted to generate “hard endpoints”. In no publication, EDSS or MSFC 
are discussed as surrogate parameters. A great advantage of the EDSS is the inter-
national acceptance (e.g. by EMA) as a primary endpoint in clinical trials and its 
broad use in trials, enabling cross-study comparisons.
PRM8
IMPACT OF MEDICATION ADHERENCE ON HEALTH CARE COST IN ASTHMA
Nagy B.1, Tóth E.2, Komáromi T.2, Lang Z.2, Molnár D.3, Kalmár J.3, Marusakova E.4, Helbich M.5
1Healthware Ltd., Budapest, Hungary, 2Healthware Consulting Ltd., Budapest, Hungary, 3GSK 
Hungary, Budapest, Hungary, 4GlaxoSmithKline Slovakia, Bratislava, Slovak Republic, 5Caldera 
s.r.o., Slovakia, Banská Štiavnica, Slovak Republic
Objectives: To evaluate the impact of medication adherence on health care utili-
zation and costs of the patients with asthma in Hungary. MethOds: The authors 
conducted a retrospective observation of the patients continuously enrolled in med-
ical and prescription benefit plans from July 2007 to June 2012. The study is based 
on patient attendance data of Hungarian National Health Insurance Fund -NHIFA. 
The accessible resource uniquely contains the detailed provision data (medicine, 
out- and inpatient services) about the whole 10 millions Hungarian populations. 
Inclusion criterion for the patients was at least one diagnosis of asthma in inpa-
tient or outpatient care (ICD code J45) and at least one relevant asthma therapy 
prescription in a twelve months period, and at least one relevant asthma therapy 
prescription during the following twelve months period. Disease-related and all-
cause related medical costs, drug costs, and hospitalization risk were measured. 
These measures were modeled at varying levels of medication adherence using 
regression analysis. Adherence (Sokol, 2005) was defined as the percentage of days 
during the analysis period that patients had a supply of 1 or more maintenance 
medications for the condition. The days of supply are calculated based on WHO 
DDD’s. This measurement strategy reduces the risk of overestimating adherence. 
For prescriptions extending beyond the end of the analysis period, days’ supply is 
truncated at the end of the period. Patients in each study sample are stratified into 
5 categories based on their adherence score: 1–19%, 20–39%, 40–59%, 60–79%, or 
80–100 %. Results: High level of medication adherence was associated with lower 
hospitalization and exacerbation rates. cOnclusiOns: Increased drug utilization 
can provide a net economic return when it is driven by improved adherence.
PRM9
IMPACT OF MEDICATION ADHERENCE ON HEALTH CARE COST IN COPD
Nagy B.1, Tóth E.2, Komáromi T.2, Lang Z.2, Molnár D.3, Kalmár J.3, Helbich M.4, Marusakova E.5
1Healthware Ltd., Budapest, Hungary, 2Healthware Consulting Ltd., Budapest, Hungary, 3GSK 
Hungary, Budapest, Hungary, 4Caldera s.r.o., Slovakia, Banská Štiavnica, Slovak Republic, 
5GlaxoSmithKline Slovakia, Bratislava, Slovak Republic
Objectives: To evaluate the impact of medication adherence on health care utiliza-
tion and costs of the patients with COPD in Hungary. MethOds: The authors con-
ducted a retrospective observation of the patients continuously enrolled in medical 
and prescription benefit plans from July 2007 to June 2012. The study is based on 
patient attendance data of Hungarian National Health Insurance Fund - NHIFA. 
The accessible resource uniquely contains the detailed provision data (medicine, 
out- and inpatient services) about the whole 10 millions Hungarian populations. 
Inclusion criterion for the patients was at least one diagnosis of COPD in inpatient 
or outpatient care (ICD code J44) and at least one relevant COPD therapy prescrip-
tion in a twelve months period, and at least one relevant COPD therapy prescription 
during the following twelve months period. Disease-related and all-cause related 
medical costs, drug costs, and hospitalization risk were measured. These measures 
were modeled at varying levels of medication adherence using regression analysis. 
Adherence (Sokol, 2005) was defined as the percentage of days during the analysis 
period that patients had a supply of 1 or more maintenance medications for the con-
dition. The days of supply are calculated based on WHO DDD’s. This measurement 
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Objectives: To build an Excel calculator, including demographic and clinical char-
acteristics of Ankylosing Spondylitis (AS) patients, and estimate annual health 
care costs of AS patients in Turkey. MethOds: The study data was obtained from 
the Turkish national health insurance database, MEDULA (2009-2011). Adult AS 
patients (ages 18-99) were identified for the identification period (June 1, 2010 - 
December 31, 2010) through the use of International Classification of Disease Tenth 
Revision Clinical Modification (ICD-10-CM) codes. Patients were required to have 
two AS diagnoses at least 60 days apart, with at least 1 year of continuous health 
plan enrollment for the baseline and follow-up years. Patients were grouped as 
prevalent and incident cases, and generalized linear models (GLMs) were used to 
estimate risk-adjusted total annual costs for prevalent and incident cases. The 
expected annual cost value was based on patient demographic and clinical char-
acteristics. Coefficients of patients’ demographic and clinical characteristics were 
built in the Excel calculator. Using the calculation, a marginal effects table was 
created after GLM estimation. Results: A total of 2986 patients met all inclusion 
criteria (603 incident; 2383 prevalent patients). Demographic and clinical char-
acteristics of the patients were entered into the Excel calculator. Risk-adjusted 
annual total costs were calculated as € 3307 for prevalent cases and € 2000 for 
incident cases. Prior biologic use significantly contributed to total medical costs 
for both prevalent and incident AS patients (p< 0.001). For incidence cases, the cost 
of care was lower for the 18-39 age group when controlling for other factors. For 
prevalent cases, there were no differences in health care costs in terms of region, 
gender, age, comorbidities, or prior non-steroidal anti-inflammatory drug (NSAID) 
or disease-modifying anti-rheumatic drug (DMARD) use. cOnclusiOns: An Excel 
calculator is an important tool to estimate and compare AS-related health care 
costs in outcomes research.
PRM16
DERIvATION OF SEvERITy INDEx FOR RHEUMATOID ARTHRITIS
Baser O.1, Baser E.2, Altinbas A.3, Burkan A.4
1STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA, 2STATinMED 
Research, Ankara, Turkey, 3Diskapi Yildirim Beyazi Education and Research Hospital, 
Gastroenterology Clinic, and STATinMED Research, Ankara, Turkey, 4Social Security Institution, 
Ankara, Turkey
Objectives: To derive a claims-based severity index for rheumatoid arthritis 
(SIFRA) and examine its impact on prevalent rheumatoid arthritis (RA) patients in 
Turkey. MethOds: Using the Turkish national health insurance database MEDULA 
(01JUN2009-31DEC2011), prevalent RA patients were identified. Patients were 
required to be age 18-99, have two RA diagnoses ≥ 60 days apart and be continu-
ously enrolled 1 year pre- (baseline period) and post-index date (follow-up), which 
was the first RA claim during the identification period (01JUN2010-31DEC2010). The 
SIFRA score was derived for each patient. RA-related indicators were sub-grouped as 
clinical and functional status, extra-articular manifestations, surgical history and 
medications. The strength of each relationship was measured from 0= no relation-
ship to 6= perfect relationship, and assessed by six board-certified, clinically active 
rheumatologists according to the Delphi panel method. The index was previously 
validated and applied to the U.S. Department of Veteran Affairs, Veterans Health 
Administration (VHA) data. Results: For the total of 1,920 identified RA patients, 
SIFRA scores ranged between 0 and 69.40, with a mean value of 14.21, and a standard 
deviation (SD) of 10.26. Mean SIFRA scores were 7.05 (49.57%), which consisted of 
clinical and functional status variables, followed by 6.32 (44.47%) for medications, 
0.48 (3.40%) for radiology and laboratory findings, 0.32 (2.25%) for extra-articular 
manifestations (pulmonary nodules, subcutaneous nodules, vasculitis ever, Felty’s 
syndrome ever), and 0.04 (0.31%) for surgical history (cervical spine fusion, hand/
foot joint replacement, foot joint/ankle/wrist fusion, total hip/knee/elbow/shoulder 
replacement). cOnclusiOns: SIFRA demonstrated evidence of being a significant 
determinant for health care costs and biologic therapy use. This study suggests 
that SIFRA could be an important methodological tool to control for severity in 
RA-related outcomes research. Any comparative effectiveness studies in RA treat-
ment should include severity scores in the analysis.
PRM17
PHySICIAN PANELS SUPPORTING CLINICAL TRIALS AND POST-APPROvAL 
STUDIES IN ONCOLOGy: A wILLINGNESS-TO-PARTICIPATE STUDy
Potthoff P.1, Brown C.2, Güther B.3, Eichmann F.3
1Kantar Health GmbH, München, Germany, 2All Global, London, UK, 3Kantar Health Germany, 
Munich, Germany
Objectives: Clinical oncology research projects require participation of oncolo-
gists and/or hematologists to recruit patients and/or assess clinical outcomes. A 
variety of methods is used to recruit office or hospital based physicans. Specifically 
for studies with an epidemiological aspect, the study should not rely on the typi-
cal clinical expert sites, thus, alternative recruitment pathways are increasingly 
considered. The objective of our study was thus to assess the benefits of using 
physician panels for site recruitment. MethOds: In 2012, a representative survey 
among members of a managed physician panel (All Global’s managed panel of 
oncologists and hematologists in US, UK, GER, FR, IT and SP) was conducted. A 
Sample of oncologists and hematologists was selected. The panel was stratified by 
country and within the strata physicians were randomly selected. 335 out of 1.303 
oncologists and hematologists in the sample (25,7%) reported about their former 
experience with clinical trials and post-approval studies, their willingness to par-
ticipate in future studies and their adherence to aspects of GCP rules. Results: A 
total of 284 (84,7%) of the physicians have formerly participated in clinical trials and 
276 (67,2%) in post-approval studies. A total of 88,9% of the experienced oncologists 
and hematologists were willing to participate in future studies. More than 80% of 
this group was ready to be named as principal investigator to an ethical commit-
tee, to report serious adverse events to the sponsor of the study and to ask patients 
for written informed consent. No substantial difference between countries was 
detected. cOnclusiOns: Since no special incentive was offered for participation 
the response rate was satisfactory Managed oncologist panels are a cost-effective, 
odds model has a natural interpretation of the treatment effect, is flexible in terms of 
handling data with different numbers of categories, but relies on the proportional odds 
assumption. The ordered logistic model also has a natural interpretation of the treat-
ment effect, but increases in complexity when handling data with a large number of 
categories. The multinomial model’s interpretation for the treatment effect is difficult, 
but it can model a large number of categories and can handle unordered competing 
risks and time dependent data. cOnclusiOns: There are three methods for incor-
porating multinomial data in a meta-analysis framework with various advantages 
and disadvantages. Selection of the appropriate model appears to be most dependent 
on the characteristics of the dataset. We determine that there is sufficient cause for 
future research focusing on a quantitative comparison of these different methods.
PRM13
EASING DECISION-MAKING By ExPANDING METHODS OF MULTIPLE 
TREATMENT COMPARISON META-ANALySIS – INCORPORATING NON-
COMPARATIvE STUDIES vIA INFORMATIvE PRIORS
Thorlund K.1, Kanters S.2, Mills E.3
1McMaster University, Hamilton, ON, Canada, 2University of British Columbia, Vancouver, BC, 
Canada, 3Stanford University, Palo Alto, CA, USA
Objectives: While multiple treatment comparisons (MTC) generally provide strong 
evidence, many are accompanied with uncertainty that makes life challenging for 
decison makers. Seeking reduction in uncertainty from non-comparative trial can ease 
decision-making, but the validity of this approach must be tested. Using an example of 
treatments for cryptococcal meningitis (CM), our objective was to assess the value and 
validity of incorporating non-comparative trial evidence via prior distributions in the 
Bayesian MTC framework. MethOds: We conducted a Bayesian MTC meta-analysis 
with and without informative priors and reported odds ratios (OR) with 95% credible 
intervals (CrI). Non-comparative data were incorporated in a two-stage approach. First 
meta-analysis for proportions was used to pool all relevant non-comparative outcomes 
for each treatment. Second, these results were used to construct informative priors for 
the comparative treatment effect parameters (the log odds ratios) in the Bayesian MTC. 
Treatments considered were amphotericin (AmB)-based therapy coupled with either 
flucytosine (5FC) or fluconazole (Azole). Results: Twenty-seven studies (N= 1,938), 15 
head-to-head drug comparison trials and 12 studies evaluating a single drug, described 
early mortality. Twenty-nine studies, 17 head-to-head and 12 single-arm studies, 
described late mortality. Incorporating non-comparative trials via informative priors 
improved the precision of several comparisons. For early mortality for example, the 
OR for AmB+Azole vs AmB+5FC was 0.26 (95%CrI 0.04-1.26) with a conventional MTC, 
and 0.24 (0.04-0.98) with informative priors. Use of informative priors reduced the DIC 
by 38% and the heterogeneity by 28%, indicating a better model fit. Moreover, evidence 
from the non-comparative studies was coherent with the randomized evidence, add-
ing to the validity of the approach. cOnclusiOns: Incorporating non-comparative 
studies as informative priors in Bayesian MTCs appears a viable approach for reducing 
the uncertainty in MTCs, and thus easing decision making.
PRM14
DEvELOPMENT OF THE SCHIzOPHRENIA CAREGIvER QUESTIONNAIRE: 
MODIFICATION OF THE zARIT BURDEN INTERvIEw INFORMED By 
QUALITATIvE INSIGHTS
Gater A.1, Rofail D.2, Tolley C.1, Marshall C.1, Abetz-Webb L.1, Zarit S.H.3, Galani B.erardo C4
1Adelphi Values, Bollington, UK, 2Roche Products Ltd., Welwyn Garden City, UK, 3Pennsylvania 
State University, University Park, PA, USA, 4F. Hoffmann-La Roche LTD., Basel, Switzerland
Objectives: Understanding the impact of caring for a person with schizophrenia 
on caregivers’ lives and emotional and physical well-being is of increasing interest 
for health care decison makers. The Zarit Burden Interview (ZBI) is an established 
measure of caregiver impact for Alzheimer’s disease. Face and content validity 
of the ZBI have not yet been established in schizophrenia and were explored in 
this study based on qualitative insights from caregivers of people with schizo-
phrenia. MethOds: A targeted literature review and consideration of best practice 
guidelines for development of self-report questionnaires informed initial ZBI modi-
fications. Face and content validity of the newly labelled Schizophrenia Caregiver 
Questionnaire (SCQ) were assessed via comprehensive semi-structured interviews 
with a diverse range of 19 US caregivers of people with schizophrenia. Interviews 
were initially open-ended and explored caregivers’ experience of caring for a per-
son with schizophrenia (concept elicitation). Cognitive debriefing of the draft SCQ 
then assessed relevance and understanding. Results: Initial review of the ZBI 
informed changes to item wording, recall period, and response scales to improve 
face validity. The qualitative literature review and concept elicitation interviews 
informed ten additional items assessing concepts important to caregivers, not 
included in the ZBI: tiredness, stress, disturbed sleep, sadness, medication admin-
istration issues, worries about future episodes, worsening symptoms, frustration, 
emotional highs and lows, and impact on work. Following cognitive debriefing inter-
views, five items were modified to improve relevance and understanding; otherwise, 
caregiver feedback supported the content validity and comprehensiveness of the 
resulting SCQ. cOnclusiOns: SCQ demonstrated good face and content validity 
for the assessment of caregiver impact in schizophrenia and is a promising tool for 
communication of caregiver outcomes to health care decision makers. Tiredness, 
disturbed sleep and sadness are included in depression scales hence there may be 
overlap if depression is assessed). Further work determining final SCQ content/
scoring and psychometric properties is ongoing.
PRM15
USING AN ExCEL CALCULATOR TO ESTIMATE ANKyLOSING SPONDyLITIS 
COSTS IN TURKEy
Baser O.1, Burkan A.2, Baser E.3, Koselerli R.2, Ertugay E.2, Altinbas A.4
1STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA, 2Social 
Security Institution, Ankara, Turkey, 3STATinMED Research, Ankara, Turkey, 4Diskapi Yildirim 
Beyazi Education and Research Hospital, Gastroenterology Clinic, and STATinMED Research, 
Ankara, Turkey
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graft required for transplantation to remain cost saving compared to dialysis; the 
number of future transplants or improvement in graft survival required to avoid the 
transplant waiting list increasing. The study utilises UK costs and future costs and 
benefits were discounted at 3.5% Results: Over a 10-year projected time horizon 
the total per-patient cost saving associated with remaining on dialysis compared 
to transplant was £276,330; however, a cost saving was conditional upon achieving 
at least 3-years of functioning graft. In order to maintain the transplant waiting list 
at approximately 7,000, the number of annual transplants conducted would need to 
increase from 2,645 in 2010 to 3,640 by 2022 (a 37.6 % increase). At current activity 
levels the transplant waiting list is projected to increase by approximately 1,983; 
improvement in graft survival could potentially reduce this by 941. cOnclusiOns: 
For kidney transplantation to be cost saving recipients must maintain at least 3 
years of functioning graft. As early graft failure also impacts on future transplant 
waiting time, management strategies that maximize graft survival will reduce costs 
and improve service delivery targets.
PRM21
COMPARISON OF ALTERNATIvE METHODS OF RESOURCE-USE DATA 
COLLECTION FOR THE ECONOMIC EvALUATION OF HEALTH CARE 
INTERvENTIONS: A CASE STUDy IN FRAIL OLDER PEOPLE
Franklin M., Gkountouras G., Berdunov V., Tanajewski L., Gladman J., Elliott R.A.
University of Nottingham, Nottingham, UK
Objectives: Economic evaluations require patient-level resource-use to estimate 
patient costs. The National Programme for IT (2002) prompted UK health and 
social care to record patient-level resource-use using Electronic Administration 
Records (EAR’s). Retrieving EAR’s is labour intensive, but may provide better infor-
mation than self-report methods, such as the Client Service Receipt Inventory 
(CSRI), particularly in cognitively impaired people. Study objectives are to examine 
agreement, and associated cost estimates, between resource-use obtained from 
EAR's or CSRI in frail older (≥70) participants. MethOds: Health and social care 
data for 247 patients (193 cognitively impaired) were sought retrospectively six 
months post-index hospital admission. Resource-use data were collected using 
a self/proxy-reported modified CSRI, and EAR systems for primary (PC), second-
ary (SC), and social (SoC) care. Lin’s coefficient (ρc) assessed agreement between 
methods, where <0.4 = poor agreement. Results: Agreement between EAR and 
CSRI ‘per contact’ resource-use was: good, primary care (ρc = 0.60); fair, outpa-
tient care (ρc = 0.53). Agreement was incomparable for social care due to different 
resource-use recording formats; CSRI’s inpatient care question was removed due 
to the preferred detailed information available in EAR’s. EAR data provided detailed 
patient care information, such as diagnosis and procedure type, allowing improved 
allocation of unit costs. Difference in mean cost per patient between methods 
varied by service (CSRI/EAR (£): PC = 61/433; SC = 7281/7833; SoC = 252/886); CSRI 
inpatient costs were simulated assuming perfect agreement with EAR, but using 
level of information outlined within the CSRI. cOnclusiOns: EAR’s provided 
more complete patient costs. Using EAR’s reduces burden upon participants, which 
is important for frail and cognitively impaired people. Although the CSRI can be 
modified and simple to administer, poor recall and inadequate detail about patient 
care contacts prevented accurate patient-level cost estimation. Gaining access to 
EAR’s is labour intensive, but recommended in cognitively impaired participants.
PRM22
CARBON COST-EFFECTIvENESS OF COCOONING IMMUNIzATION AGAINST 
PERTUSSIS IN ENGLAND AND wALES: AN ECOLOGICAL PERSPECTIvE
Terlinden A.1, Renson B.2, Ponder C.3, Poirrier J.E.2, Curran D.2
1Navigha, Tervuren, Belgium, 2GSK Vaccines, Wavre, Belgium, 3GSK, Research Triangle Park, NC, 
USA
Objectives: The cost-effectiveness of pertussis vaccination has been demonstrated 
for various vaccination strategies. However, beyond financial cost expressed in mon-
etary terms vaccines also incur environmental cost expressed in CO2equivalent 
(CO2e) emission. By preventing disease, this cost might be offset by avoided events 
such as doctors’ visits, hospital bed stays, medication, amongst other items. In 
this exercise we examine the CO2e savings of a pertussis (dTpa) booster dose for 
cocooning in England and Wales. We propose a complementary measure to the 
classical Incremental Cost-Effectiveness Ratio that includes environmental cost 
instead of monetary cost. MethOds: The cradle to gate carbon footprint (from 
raw material extraction, to manufacturing, to disposal) for a typical dTpa vaccine 
dose was assessed to estimate the total amount of CO2e emitted (“carbon cost”). 
A previously published static epidemiological model was used to account for the 
reduction in incidence of pertussis. Two scenarios were compared: the current per-
tussis vaccination schedule and the same schedule with additionally a cocooning 
strategy. Results: For each dose of a dTpa vaccine manufactured, results show 
approximately 1kg of CO2e was emitted. The model shows cocooning immuniza-
tion against pertussis is projected to reduce the reported incidence of pertussis in 
young infants. Results also show that due to the reduction in emitted CO2e after 
the introduction of a cocooning strategy, vaccination is an acceptable alternative 
to the current strategy to control pertussis infection. cOnclusiOns: The method 
presented demonstrates how traditional economic models can be utilized to model 
environment features. Assessment of the cradle to gate carbon footprint of a vaccine 
provides a preliminary view of both the impact on the environmental in general 
and on the environment profile of health care in the UK.
PRM23
MODELLING THE COST-EFFECTIvENESS OF FIRST-LINE BIOLOGICS FOR 
RHEUMATOID ARTHRITIS IN ENGLAND AND wALES
Righetti C.1, Lebmeier M.1, Pennington B.2, Brereton N.J.2
1Bristol-Myers Squibb Pharmaceuticals Ltd., Uxbridge, UK, 2BresMed, Sheffield, UK
Objectives: In 2012, NICE initiated a multiple treatment assessment reviewing all 
licensed biologics for the treatment of rheumatoid arthritis (RA) previously treated 
experienced and high-quality source for post-approval studies. Elaborated manage-
ment processes in multi-country panels guarantee a constant quality of the panel 
over geographies.
PRM18
CLASSIFICATION OF COGNITIvE DySFUNCTION AND COGNITIvE NORMAL 
USING SCORES FROM FOUR COGNITIvE ASSESSMENTS IN PATIENTS wITH 
DEPRESSIvE DISORDER
Maruff P.1, Walker V.2, Samp J.3, Essoi B.2, Kurlander J.L.2, Akhras K.S.3
1CogState, New Haven, CT, USA, 2OptumInsight, Eden Prairie, IL, USA, 3Takeda Pharmaceuticals 
International, Inc., Deerfield, IL, USA
Objectives: Cognitive functioning is a multidimensional attribute comprising 
various domains including attention, memory, executive function, and psycho-
motor speed. The number of impacted domains and magnitude of deficits that 
equate to a classification of cognitive dysfunction (CD) are unclear. This analysis 
examined criteria used for CD classification in an observational study of depressed 
patients. MethOds: A large US health plan was used to identify depressed patients 
with a newly prescribed antidepressant. Consenting, eligible patients were inter-
viewed by telephone and completed a structured assessment of cognitive function 
measuring 4 domains: verbal episodic memory (Hopkins Verbal Learning Test-
Revised), attention (Digit Span Forward), working memory (Digit Span Backward), 
and executive function (D-KEFS-Letter Fluency Test). Patients were classified into 2 
groups based on test scores relative to normative data. “CD” was defined as patients 
with ≥ 2 scores that were ≥ 1.5 standard deviations (SD) below the normative mean 
(criterion 1) or patients with ≥ 3 scores that were ≥ 1.0 SD below the normative 
mean (criterion 2). Patients not meeting either of these were classified as “cognitive 
normal (CN).” T-tests compared differences between the groups across cognitive 
domains. Results: Of 564 eligible patients who completed the study, 45% met 
criteria for CD. Among these, 63% met both criteria for classification of CD, 19% met 
only criterion 1, and 18% met only criterion 2. The percentage of patients with scores 
≥ 1.0 SD below the mean and ≥ 1.5 SD below the mean were significantly higher in the 
CD group compared to the CN for all 4 tests. Mean scores on all domains were signifi-
cantly lower (P < 0.001) in the CD group compared to the CN group. cOnclusiOns: 
Among patients with depression, those with cognitive dysfunction had significantly 
worse functioning across all domains. This suggests that the criteria appropriately 
identified a subset of patients with impaired cognitive functioning.
RESEARCH ON METHODS – Cost Methods
PRM19
TIME DEPENDENT RESOURCE USE AND COSTS ASSOCIATED wITH DIFFERENT 
STATES OF DISEASE IN PATIENTS DIAGNOSED wITH HER-2 POSITIvE 
METASTATIC BREAST CANCER
Frederix G.W.1, Severens J.L.2, Hövels A.M.1, van Hasselt J.G.3, Raaijmakers J.A.4, Schellens J.H.5
1Utrecht University, Utrecht, The Netherlands, 2Erasmus University Rotterdam, Rotterdam, The 
Netherlands, 3Slotervaart Hospital & Netherlands Cancer Institute, Amsterdam, The Netherlands, 
4Utrecht University & GlaxoSmithKline, Utrecht, The Netherlands, 5Netherlands Cancer Institute & 
Utrecht University, Amsterdam, The Netherlands
Objectives: Adequate reflection of disease progression and costs over time is 
essential in cost-effectiveness analyses (CEAs) based on health state transition mod-
els. However costing studies normally investigate the burden of metastatic breast 
cancer (MBC) without explicitly examining impact of specific disease states on 
health care costs over time. The objective of this study was to assess time-dependent 
costs of different health states of human epidermal receptor 2 (HER-2) positive 
MBC and the factors contributing to these costs. MethOds: In The Netherlands, 
HER-2 positive MBC patients were identified in three different hospitals. Resource 
use was collected during 24 months, which was linked to unit costs and related 
to time with respect to date of MBC diagnosis, disease progression and death for 
each individual patient. Subsequently, monthly costs for different health states 
were calculated. Finally, a nonlinear mixed effect modelling approach was used 
to provide a quantitative description of the time course of cumulative progression 
costs. Results: Costs during stable disease were constant over time with a mean 
of € 3,236. In contrast, monthly costs for progressive disease demonstrated a change 
over time with the largest costs in the first two months after diagnosis (p< 0.005). The 
developed mixed effect model adequately described cumulative cost time course 
and associated variability. During the last months of life, costs varied over time, with 
the last month of life as the most expensive one with a mean of € 4,522 per patient 
per month. cOnclusiOns: To reflect costs of HER-2 positive MBC accurately in 
Markov models, costs stable disease can be defined time-independent, however, 
costs of progressive disease should be defined time dependent, and costs related to 
the final months of life should be modeled as such. The mixed effect model we have 
developed could now be considered for adequate description of the time-dependent 
cost of progressive disease.
PRM20
ASSESSING THE FUTURE BURDEN OF RENAL REPLACEMENT THERAPy IN THE 
UNITED KINGDOM
McEwan P.1, Ward T.1, Righetti C.2, Brenner M.2, Lebmeier M.2
1HEOR Consulting, Monmouth, UK, 2Bristol-Myers Squibb Pharmaceuticals Ltd., Uxbridge, UK
Objectives: The UK has an ageing and growing population and the prevalence 
of renal replacement therapy (RRT) has grown by 5.0% annually since 2000. RRT 
accounts for over 2% of the current NHS expenditure. Transplantation increases 
survival, improves quality of life and maintenance costs are less than dialysis. 
Despite increasing rates of transplantation, an estimated 7,000 patients remain 
on the waiting list. The objective of this study was to quantify the relationship 
between graft survival time, total estimated cost and the number of projected 
patients on the transplant waiting list. MethOds: We utilized a population based 
simulation model with published disease progression, incidence and prevalence 
parameters specific to the UK. We evaluated the number of years of functioning 
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PRM26
IMPACT OF USING EITHER MULTIPLICATIvE OR ADDITIvE UTILITy 
DECREMENTS IN DECISION MODELS
Cure S.1, Despiégel N.2, Guerra I.1
1OptumInsight, Uxbridge, UK, 2OptumInsight, Nanterre, France
Objectives: In cost-utility analyses (CUAs) it is common to estimate the utility 
of patients while on treatment or when experiencing comorbidities by adjusting 
their baseline utility with the treatment/comorbidity-related utility decrement. 
This study assessed the impact of adjusting patients’ baseline utility with additive 
versus multiplicative utility decrements on the lifetime quality-adjusted life years 
(QALYs) in CUAs for two chronic illnesses. MethOds: Two Markov models were 
developed. In the first model, utility during treatment was obtained by adjust-
ing the baseline utility with the treatment-related utility decrement; treatment 
was given for one year. In the second model, utilities with comorbidities were 
obtained from external sources and were combined with the health state utilities 
by considering the lowest value. In both models, the response of the multiplicative, 
additive and the combined approach was investigated by comparing the number 
of QALYs gained over a lifetime. Results: In the first model, as treatment was 
only given during the first year, the impact on the number of QALYs gained over 
a lifetime was minimal. Thus, a similar incremental cost-effectiveness ratio per 
QALY (ICER/QALY) was obtained with all the approaches. In contrast, for the second 
model, the number of QALYs gained over a lifetime between the approaches was 
significantly different. This is because comorbidities were experienced during a 
longer period of time. Consequently, the difference in ICER/QALY was also substan-
tial. cOnclusiOns: When developing CUA, either a multiplicative or combined, 
rather than additive, approach should be used to calculate the utility of patients 
during treatment or with comorbidities, using utility decrements, if consider-
able uncertainty is present in the baseline utility. However, if QALYs gained with 
treatment or with comorbidities represent only a small fraction of the overall 
QALYs gained, the difference between the approaches is not expected to have a 
significant impact on the results.
PRM27
UNCHARTERED TERRITORy – ANALySIS OF CROSS-BORDER SERvICE PROvISION 
wITHIN PUBLIC HEALTH SySTEMS
Moran P., Teljeur C., Murphy L., O’Neill M., Harrington P., Ryan M.
Health Information and Quality Authority, Dublin, Ireland
Objectives: The European Union’s (EU) 2011 Directive on cross-border health care 
establishes the right of EU citizens to receive treatment abroad and be reimbursed 
in their home country. While the focus has been on patient mobility and access, it 
may also facilitate international outsourcing of services between countries. This 
research examines the methodological challenges in evaluating the costs and 
consequences of cross-border service provision. MethOds: Using the example 
of deep brain stimulation (DBS) treatment in Ireland, we conducted an economic 
analysis of the provision of cross-border services from the perspective of the public 
health system. This included an analysis of clinical and cost-effectiveness, ethical 
and societal implications and the challenges of integrating care between sepa-
rate health systems. Results: Accurate modelling of the provision of a new or 
expanded service serves as the basis for evaluating costs, impact on patients and 
potential gaps in continuity of care. Cost minimisation analysis may be appropriate 
under some circumstances, with due regard to the importance of patient selec-
tion and follow up. Cross-border services may have significant implications for 
equity of access, with potential negative consequences for those most in need of 
treatment. Results of the economic analysis indicate that a national DBS service 
in Ireland would cost an additional € 20,900 per patient over 10 years. The potential 
for anomalies within health systems with a mixture of private and public funders 
is highlighted, with the difference being reduced to € 4,100 per patient in a single 
payer scenario. cOnclusiOns: Health care funding structures can impact signifi-
cantly on the cost-effectiveness of cross-border services, even when differences in 
the actual cost of care are minimal. Given the externalities involved, analysis from 
the payer perspective may be too narrow for the economic evaluation of routine 
cross-border provision of elective services.
PRM28
EMPIRICAL EvIDENCE FOR THE vALIDITy AND RELIABILITy OF RESOURCE-USE 
MEASURES BASED ON PATIENT RECALL: A SySTEMATIC REvIEw
Thorn J., Noble S., Moore T., Hollingworth W.
University of Bristol, Bristol, UK
Objectives: Accurate measurement of resource use is required for economic 
evaluations alongside clinical trials. Patient-completed questionnaires are com-
monly employed as a means of collecting data; however, concerns over data qual-
ity persist, and there is little certainty about best practice. This review collates the 
evidence concerning the validity and reliability of resource-use measures based 
on patient recall with the aim of aiding health economists in developing better 
measures. MethOds: A search strategy incorporating terms covering health care 
resources, utilisation, patient-reported measures and validation/reliability con-
cepts was applied to the MEDLINE, EMBASE and PsycINFO bibliographic databases. 
Studies were included if they reported original research to inform costing studies, 
and were about patient or proxy self-reports of direct health care-related resource 
use in which a comparator (to assess validity or reliability) was specified. Studies 
were excluded if they were not in English or if they assessed general population 
surveys. Reference and citation lists of included studies were hand searched to 
identify additional studies. Data on study and population characteristics, type of 
instrument, recall period and sample size were extracted. Results and conclusions 
concerning the validity and reliability of reports of types of resource use consumed 
(e.g.medication, inpatient stays) were also extracted. Results: A total of 13,367 
abstracts were identified as potentially relevant through the database searches. 
Following abstract and full-text screening, 60 articles were deemed relevant, with a 
further 9 identified through hand searching. The majority focused on adults (60/69), 
with conventional DMARDs only. The sequence of treatments used after the fail-
ure of first biologic treatment was to be included as part of the cost-effectiveness 
modelling. We therefore built a model to match the treatment pathway for first-line 
biologics and beyond. MethOds: We researched the treatment pathway and exist-
ing cost-effectiveness models in order to create an appropriate model. We rebuilt 
the model used by the technology assessment group in TA195, which considered 
second-line biologics and beyond. We adapted this model to reflect the current 
treatment pathway and consider first line biologics. Results: We created a patient 
simulation model, which generated a cohort of virtual patients and tracked their 
costs and QALYs over the pathway. Patients began treatment with a biologic, and 
could discontinue at month 6 due to an adverse event (AE), in which case they 
switched to a different biologic, with first-line efficacy. Patients who did not have 
an AE discontinued at month 6 if their DAS 28 improvement was insufficient. After 
discontinuation at month 6, or later, patients next received rituximab, unless con-
traindicated. If rituximab was contraindicated, or the patient had an AE by month 
6, they moved onto another biologic treatment, after which they received a DMARD 
treatment sequence (including palliative care). Patients who had insufficient DAS28 
response on rituximab at month 6 switched to tocilizumab (unless received previ-
ously), after which they received the DMARD sequence. Patients who had sufficient 
DAS28 improvement with rituximab remained on rituximab long-term, until they 
received the DMARD treatment sequence. Patients could exit the model at any point 
if they died. cOnclusiOns: We used robust methodology and clinical rationale to 
assess the cost-effectiveness of licenced treatments reflected across NICE’s recom-
mended treatment pathway for RA.
PRM24
MODELLING THE COST-EFFECTIvENESS OF FIRST LINE BIOLOGICS FOR 
RHEUMATOID ARTHRITIS IN IRELAND
Righetti C.1, Lebmeier M.1, Pennington B.2, Brereton N.J.2
1Bristol-Myers Squibb Pharmaceuticals Ltd., Uxbridge, UK, 2BresMed, Sheffield, UK
Objectives: In 2013, NCPE assessed the cost-effectiveness of subcutaneous (SC) 
abatacept as a first line biologic for the treatment of rheumatoid arthritis (RA), 
compared to existing biologics. It was necessary to consider the treatment path-
way beyond first line biologics. We therefore built a model to match the treatment 
pathway for first line biologics and beyond. MethOds: We used our individual 
patient sampling model for England and Wales as a starting point to create a model 
which considers biologic cycling, to match the treatment pathway in Ireland. We 
differentiated between the efficacy of a biologic at first line, and at second line 
or later. Results: We created a model which could be used to calculate the cost-
effectiveness of biologics for the treatment of RA in Ireland. Patients first received 
treatment with SC abatacept, intravenous abatacept, adalimumab, etanercept, 
infliximab, certolizumab pegol or golimumab. If they experienced an adverse event 
(AE) on that treatment within 6 months, they switched to another biologic at first 
line efficacy. If not, their response to treatment was tested using the DAS28: if this 
improved by 1.2 or more, their time on treatment was sampled from a Weibull 
distribution, otherwise they discontinued at month 6. The patient then moved onto 
a randomly sampled second line biologic, which was either one of the first line bio-
logics or rituximab. The time on second line biologic was sampled from a Weibull 
distribution, and then the patient moved onto a third line biologics (second line 
biologics and tocilizumab). The patient cycled through the biologics until they died, 
or had received all 8 treatments. After 8 biologics, remaining patients received 
leflunomide, cyclosporin, azathioprine and palliative care. cOnclusiOns: We 
used robust methodology and clinical rationale to model the treatment pathway of 
biologics for RA in Ireland and facilitated cost-effectiveness comparison between 
first line biologics.
PRM25
A SySTEMATIC REvIEw OF ECONOMIC EvIDENCE IN HEPATITIS C: METHODS 
USED IN RECENT ECONOMIC EvALUATIONS
Woods M.S.1, Kiri S.2, Ling C.1, McCrink L.1, Zimovetz E.1, Hass B.3
1RTI Health Solutions, Manchester, UK, 2Boehringer Ingelheim Ltd., Bracknell, UK, 3Boehringer 
Ingelheim GmbH, Ingelheim, Germany
Objectives: To perform a systematic literature review of economic evidence 
for genotype 1 hepatitis C virus (HCV) treatments and to summarise and assess 
the methods used in recent economic evaluations. MethOds: Multiple data-
bases were searched to identify economic evaluations in patients with genotype 
1 HCV. Detailed review methods are presented elsewhere. Results: 53 economic 
analyses and 17 Health Technology Assessment (HTA) documents were identified. 
Most economic analyses were performed using lifetime horizon Markov models, all 
for interferon-containing regimens. Most were performed in the United Kingdom 
(UK) (n = 13), United States (n = 13), or Germany (n = 7). Two recent National 
Institute for Health and Care Excellence (NICE) submissions were included: tel-
aprevir triple therapy (with peginterferon plus ribavirin) and boceprevir triple 
therapy, for previously treated and untreated patients. The models used were 
different; however their structures and some inputs were based on previous 
NICE appraisals for peginterferon plus ribavirin. There were a number of limita-
tions found in the included economic evaluations, which may have affected the 
cost-effectiveness outcomes: 1) The models did not adequately capture all health 
benefits and costs in their quality-adjusted life-year calculations; 2) The models 
did not account for the possibility of benefits caused by reduced transmission of 
HCV; 3) The models did not incorporate patient factors that may influence disease 
progression; 4) Modelling of subgroups may have been insufficient, particularly 
as the understanding of patient and viral factors that predict treatment response 
grows; and 5) Some made generalisations for the compensated cirrhosis popula-
tion that were not comparable with the UK population. cOnclusiOns: Recent 
economic models have generally adhered to previous iterations of HCV models and 
have not evolved with our knowledge of the disease. In light of upcoming treat-
ment alternatives, model refinement may be necessary to capture the increasingly 
complex treatment decisions that will be required.
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studies, including and in addition to the EQ-5D, are extracted and added to the data-
base record to create a searchable index of instruments. A beta version of the data-
base, using bespoke software to improve functionality, is currently undergoing ad hoc 
testing. Results: The alpha version of the database contains over 3,500 potentially 
relevant studies identified by the search process. Several hundred studies have been 
data extracted and indexed. The names of over 50 instruments, including quality of 
life, disease specific and generic preference-based measures have been added to the 
index. A programme of sifting, data extraction and indexing is ongoing. Public access 
to the beta version of the database is planned for Autumn 2013. cOnclusiOns: 
The purpose of the health utilities database is to improve access to HSUV evidence, 
in the first instance in studies using the EQ-5D with a view to including all major 
preference-based utility measures.
PRM33
THE REvIEw OF PUBLICATIONS OF PHARMACOECONOMIC RESEARCH IN 
RUSSIA DURING 2007-2012
Yagudina R.1, Kulikov A.1, Mirkasimova G.1, Litvinenko M.2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2First Moscow State 
Medical University named after I. M. Sechenov, Moscow, Russia
Objectives: To analyze the publications on methodology and normative regu-
lations of pharmacoeconomic studies, including materials providing results of 
conducted researches in Russia or translated international publications, as well 
as to analysis the dynamics of publications and identify the structure of meth-
odological approaches in Russia. MethOds: The screening of publications from 
the data of the Central Medical Scientific Library of the First MSMU was conducted 
based on the key words - “pharmacoeconomic*” and “pharmacoeconomical*” with 
corresponding endings. The time horizon of the study was 6 years (from 2007-
2012). Results: By the beginning of 2013, 280 literature sources were found and 
analyzed in the timeline from 2007 to 2013. It was found that the most common 
type of publications for the reporting period have been the inaugural dissertations 
showing the researches results - they are accounted for about 47% of all studies, 
followed by further research reports, accounted for 44%, methodical publications 
- 5%, dissertations devoted to the methodology of the pharmacoeconomics- 3%, 
regulatory guidance documents and translations of foreign studies - 1%. The most 
common structure of published researches was monocenter (56%), with a retro-
spective time-restricted directivity (74%). Russian authors use the methodology of 
the “cost-effectiveness” analyzing in their works the most frequently (48%). 64% of 
Russian researchers take into account only direct costs, 32% of researchers analyze 
their studies based on indirect costs. cOnclusiOns: Based on our review of the 
published works from 2007 to 2012, we can make a conclusion on the formation 
and development of high-grade pharmacoeconomics as an independent research 
area in the Russian Federation.
PRM34
EvALUATING DIFFERENT MODES OF RADIOTHERAPy BASED ON A PATIENT-
LEvEL SIMULATION MODEL
Quik E.H.1, Feenstra T.L.1, Postmus D.1, Krabbe P.F.M.1, Langendijk H.2
1University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 
2UMCG, Groningen, The Netherlands
Objectives: Use of proton instead of photon radiation therapy for head and neck 
cancer reduces the primary tumor and damage to adjacent organs risk, which 
results in fewer complications. These complications decrease quality of life (QOL). To 
support better decision making concerning which patients benefit most from pro-
ton therapy, a patient-level simulation model is developed and applied to compare 
outcomes. MethOds: Model estimates, such as patient and tumor characteristics, 
follow-up time, and survival, were based on patient-level data containing patients 
treated with radiation therapy as first line therapy for head and neck tumor in The 
Netherlands between 1980–2010 at the UMC Groningen (n= 277) and VU Amsterdam 
(n= 736). In silico radiation treatment planning schemes for both proton and photon 
therapy allowed to compare a priori expected health benefits and cost consequences 
for both therapy modes to support a patient tailored choice. Results: Patients 
experienced their first event at a median time of 30 (0-270, SD 34) months’ time. 
Loco-regional recurrency in 29%, distant metastasis in 4.2%, both combined in 1% 
and dead in 13.3% of patients. Cost per year for photon was estimated € 15000, proton 
€ 30000, disease free state € 190, local regional recurrence € 28000, metastases € 35000, 
and both € 35000. For the complication sticky saliva costs per year of an average 
patient were € 31, xerostomia € 194, dysphagia € 57, tube feeding € 4262, and hypothy-
roidism € 117. Proton radiation therapy leads to less complications and improved 
QOL. cOnclusiOns: Given the high costs of proton therapy, this was found not 
to be cost-effective compared to best photon therapy in an average patient with 
head and neck cancer. However, the outcomes vary substantially between patients. 
Depending on patient and tumor characteristics for selected patients with high 
complication risks, proton therapy can be a better option.
PRM35
THE ECONOMIC FOOTPRINT OF THE GREEK PHARMACEUTICAL INDUSTRy
Tserkezis E., Paratsiokas N., Tsakanikas A., Athanasiadis A.
Foundation for Economic & Industrial Research (IOBE), Athens, Greece
Objectives: To assess the overall impact of the production and distribution of 
pharmaceutical products in the Greek economy, in terms of Value Added, GDP, 
employment and tax revenues. MethOds: The overall impact in the Greek econ-
omy is estimated as an exogenous change in the economic activity by using the 
Leontief input-output model. Results: The results indicate that the direct effect 
of the industry on domestic economic activity is € 1.5 billion in terms of GDP. The 
indirect effect, which represents the value created by auxiliary sectors as (main 
suppliers) of the pharma industry is € 2.2 billion. Finally, the induced effect, which 
is the impact from the final consumption, as a result of the wages and salaries 
gained by employees across the production chain of the specific industry is € 3.8 
billion. Hence, the overall effect on GDP is approximately € 7.5 billion, which repre-
and nearly half originated from north America (31/69). Emerging themes suggest 
that better accuracy is achieved when patients are answering questions about inpa-
tient and specialist care. cOnclusiOns: There is only a limited amount of valid-
ity and reliability information available to inform best practice for resource-use 
measurement in clinical trials. This ongoing review will identify the gaps, giving a 
clearer view of where research efforts should be concentrated.
PRM30
FUTURE COSTS INCLUSION IN PUBLISHED ECONOMIC EvALUATIONS: wHAT IS 
THE CURRENT SITUATION?
Gros B.1, Soto J.2, Casado M.A.1
1Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 2Carlos III University of Madrid, 
Madrid, Spain
Objectives: Nowadays, there is a general agreement about the need of includ-
ing future related medical costs in life years gained while no consensus has been 
achieved about future unrelated medical costs (indirect medical costs) and future 
non-medical costs. The aim of this study has been to assess the extension of 
published economic evaluations that incorporated future costs and what types 
of future cost were included. MethOds: Three general health economic journals 
(Pharmacoeconomics, Value in Health and European Journal of Health Economics) were 
reviewed to identify economic evaluations from 2008 to 2011. Only complete eco-
nomic evaluations were accepted for this research. From each selected article, future 
cost inclusion was evaluated along with the type of future costs included. Results: 
A total of 148 articles were founded from the three journals fulfilling the inclusion 
criteria; 67 of them (45.27 %) incorporated future related medical costs, 9 (6.08 %) 
included also future unrelated medical costs and none included future non-medical 
costs. Percentage of articles including future costs increased from 2008 (33 %) to 
2011(57 %) and no differences were detected between the three journals in the pro-
portion of economic evaluations incorporating future costs. cOnclusiOns: Despite 
most of health economic guidelines advice the need of incorporating future costs in 
l economic evaluations, less than the half of articles reviewed incorporated them. 
Moreover, the inclusion of future unrelated medical costs and future non-medical 
costs was much lower. Results of economic evaluations can change dramatically 
depending on future costs inclusion. It is necessary to change the current practice 
and systematically include future related medical costs in the base case of economic 
evaluations and future unrelated medical costs and future non medical costs at 
least in sensitivity analysis.
PRM31
CHALLENGES OF CONDUCTING ECONOMIC EvALUATIONS USING LINKED 
ELECTRONIC HEALTH RECORDS - CPRD AND HES IN THE UNITED KINGDOM
Asaria M.1, Walker S.1, Sculpher M.J.2, Palmer S.1, Manca A.3, Abrams K.R.4, Hemingway H.5, 
Denaxas S.5, Morley K.I.5, Shah A.5, Timmis A.6, Gale C.7
1University of York, York, UK, 2Centre for Health Economics, York, UK, 3University of York, 
Heslington, UK, 4The Institute of Cancer Research, Sutton, UK, 5UCL, London, UK, 6Barts and the 
London School of Medicine and Dentistry,, London, UK, 7Leeds University, Leeds, UK
Objectives: A range of linked electronic health records (LEHR) datasets are 
becoming available in the NHS in England. Understanding the benefits such large 
LEHR datasets can offer when performing cost-effectiveness analysis and over-
coming the challenges inherent in utilising such datasets using as a case study: 
the CALIBER (Cardiovascular Disease Research using Linked Bespoke Studies and 
Electronic Records) dataset to assess the cost-effectiveness of treatment of patients 
with chronic stable angina. MethOds: The CALIBER dataset links primary care 
data from CPRD with secondary care data from HES, mortality data from ONS and 
disease-specific data from MINAP. This dataset is used to provide a generalisable 
baseline for cost-effectiveness models and to provide effectiveness estimates for 
treatments observed in the dataset. It is also used to explore decisions that, due 
to ethical concerns, could not be researched through RCTs - for example, optimal 
durations and combinations of treatments used in current practice. The statistical 
methods of matching, differences in differences and instrumental variables are 
used to overcome the selection bias problems associated with inferring treatment 
effects using observational data. The models are also combined with RCT results 
for novel treatments to assess their cost-effectiveness in a real world as opposed to 
trial setting. Results: There were significant challenges involved in working with 
LEHR ranging from correctly linking the data to plausibly imputing missing data 
and correcting for selection bias in estimates. Having addressed these challenges 
we were left with a rich dataset, from which to estimate costs, risks of health events 
and treatment effects in a generalisable real world setting. cOnclusiOns: While 
the selection biases associated with the use of LEHR within the NHS makes them 
challenging to work with, the large sample sizes, generalisability of the results 
and relatively low cost of the research makes them a hugely valuable resource for 
economic evaluation.
PRM32
DEvELOPMENT OF THE SCHARR HUD (HEALTH UTILITIES DATABASE)
Rees A., Paisley S., Brazier J., Cantrell A., Poku E., Williams K.
University of Sheffield, Sheffield, UK
Objectives: The retrieval of studies containing evidence of health state utility val-
ues (HSUVs) is currently problematic using generic bibliographic databases such as 
Medline. This is due to a lack of standardised search vocabulary and inadequate and 
inconsistent indexing. The objective of this project is to develop a bibliographic data-
base providing access to details of research studies containing health state utility val-
ues generated using the EQ-5D and other preference-based instruments. MethOds: 
The initial phase of the project has focussed on the EQ-5D. An alpha version of the 
database was created using Mendeley reference management software. A corpus of 
potentially relevant studies was identified by searching Medline and by sifting the 
reference lists of systematic reviews of HSUVs in a range of diseases and conditions. 
The sifting of retrieved studies is an ongoing process. Studies are included in the 
database if they contain estimates of HSUVs. The names of instruments used in the 
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2012. The aim of this study is to understand which of the validation methods recom-
mended in health economics and financial guidelines are practically used across 
different disease areas and business fields. MethOds: For this study we reviewed 
guidelines, economic models for diabetes, cardiovascular diseases, and cancers, as 
well as risk-prediction models. The identified validation methods were collected 
and categorized into three groups: face validity, internal verification, and cross 
validity. Results: Twenty-two (22) economic models, 8 risk prediction models, 5 
financial and 7 health economics guidelines were identified. In the guidelines we 
found 3, 14 and 5 methods within the face validity, internal verification, and external 
validity categories respectively. Almost three quarters of the 22 methods identi-
fied were also described in the ISPOR guideline on model validation and the other 
guidelines described 5 to 15 methods. External validation was done for 14 out of the 
22 economic models reviewed in which (part of) the model results were compared 
against other clinical/epidemiology studies (14 models) or other validated models 
(10 models). Internal verification was mainly done through comparison against the 
trials that the models were built on (10 models). Out of the remaining 13 internal 
verification methods only 3 were performed for the economic models. Face valida-
tion was only performed for 3 economic models. cOnclusiOns: This study found 
that there is a substantial gap between the validation steps recommended and those 
actually performed. Hence a more consistent and pragmatic approach needs to be 
taken to validate economic models. In addition, the validation methods performed 
need to be consistently reported.
PRM39
ANALySIS OF HEALTH CARE COSTS IN ELDERLy PATIENTS wITH MULTIPLE 
CHRONIC CONDITIONS USING A FINITE MIxTURE OF GENERALIzED LINEAR 
MODELS
Eckardt M., Brettschneider C., van den Bussche H., König H.H.
University Medical Center Hamburg, Hamburg, Germany
Objectives: Multimorbid individuals consume a disproportionally large share 
of health care resources. Usually standard (1-component) regression techniques 
are applied to analyse costs in samples of patients with multiple chronic condi-
tions. However, the patient specific number and combination of co-occurring single 
diseases results in inhomogeneous data leading to biased estimates when using 
traditional regression techniques. In this study we analyse health care costs in a 
sample of patients suffering from multimorbidity using a more elaborate approach 
to address this heterogeneity. MethOds: We used a subsample of N= 1050 patients 
from a multicentre prospective cohort study of multimorbid primary care patients 
aged 65 to 85 years in Germany who completed a questionnaire on health care utili-
zation covering a 6-month-period. We applied a finite mixture of generalized linear 
models, which belongs to the group of statistical learning algorithms, in order to 
control for unobserved heterogeneity of patient level health care costs focussing on 
the identification of multimorbidity patterns. Results: We detected four different 
groups of patients with regard to total costs. The effect of the presence of an addi-
tional disease on costs differs between these groups. Two diametrically opposed cost 
trends were detected with respect to the number of co-occurring diseases. While in 
one group containing hypertension, joint arthrosis, diabetes, gout, anxiety and lower 
limb varicosis cost increased with the number of co-occurring diseases, in a sec-
ond group including severe hearing loss, asthma/COPD, osteoporosis, neuropathies, 
Parkinson’s disease and chronic ischemic heart disease cost decreased. Diversities 
between groups were also found in the results indicated by diametrically opposed 
influence of single diseases. cOnclusiOns: Our results indicate existing unob-
served heterogeneity in costs among patients suffering from multimorbidity with 
different combinations of single diseases which would remain unconsidered using 
standard regression techniques. Especially different costs trends were detected with 
regard to the number and nature of co-existing diseases.
RESEARCH ON METHODS – Databases & Management Methods
PRM40
USE OF THE CLINICAL PRACTICE RESEARCH DATALINK (CPRD) TO ASSESS 
‘REAL-wORLD’ MANAGEMENT OF TUBEROUS SCLEROSIS COMPLEx (TSC) IN THE 
UNITED KINGDOM
Demuth D.1, Nasuti P.1, Richards C.1, Gray L.2, Price L.2, Magestro M.3
1IMS Health, London, UK, 2Novartis Pharmaceuticals UK Limited, Frimley, UK, 3Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
Objectives: TSC is a multi-system genetic disorder associated with benign lesions 
throughout the body, neurological manifestations, and impaired cognition. As many 
as 8000 people in the UK may have TSC; many cases likely go undiagnosed. Long-
term morbidity and treatment burden associated with TSC are significant, suggest-
ing substantial economic burden. This preliminary study assessed presentation 
patterns of select TSC manifestations in CPRD. MethOds: TSC patients were retro-
spectively identified in CPRD (Read: PK5.00) and linked Hospital Episodes Statistics 
(HES; ICD-10: Q85.1) databases. CPRD includes over 5 million active patients from UK 
primary care practices (~8% coverage). A total of 55% of practices (375) are linked to 
HES, allowing events in secondary care to be analysed (e.g. hospitalisations, proce-
dures). Patients not linked to HES were excluded. Available history was extracted for 
each patient; descriptive statistics for select TSC-related diagnoses and procedures 
are presented. All ages reported below are median values. Results: A total of 244 
patients (49% male) with a TSC diagnosis were identified; age at diagnosis was 8 
years, with 70% under 18 years. Patient data history was 20 years; 3 and 11 years 
pre/post initial TSC diagnosis. By age 4, 72% had a record of epilepsy; by 16 years, 
9% had a record of subependymal giant-cell astrocytoma (SEGA); by 18 years, 1% 
had obstructive hydrocephalus; by 43 years, 4% had renal angiomyolipoma (AML) 
[median age at initial recorded diagnosis]. cOnclusiOns: Preliminary analyses 
affirm the utility of CPRD in a real-world study of TSC, and the many emergent TSC-
related manifestations, in a longitudinal fashion. Data are suggestive of evolving 
diagnostic and treatment patterns (30% adults) and may highlight a need for better 
coordination of adult care. Relatively low prevalence of AML was unexpected and 
sents almost 3.4% of the country’s GDP (2010). In terms of employment 23.000 are 
directly employed in the sector, while the total benefit for the Greek economy (both 
direct and indirect) is estimated to approximately 132.000 jobs. Finally, the industry 
accounts for nearly € 400 million tax revenue, half of which affects the economy 
directly. cOnclusiOns: Taking these effects in consideration it stems that for every 
€ 1 of Value added in the production / distribution of the pharmaceutical sector some 
€ 2.6 of Value added is created as an indirect effect and € 5.3 as an induced effect. 
Additionally every job position in the sector in the pharmaceutical (production / 
distribution) sector supports 2.5 jobs due to indirect effects and almost 6 jobs in the 
economy. Finally, for every € 1 in tax revenue provided by the sector, an additional 
€ 1.6 is generated though indirect effect and a total of € 2.2 if the induced effect is 
taken into consideration.
PRM36
AN ASSESSMENT OF THE USE OF UTILITy DATA IN LONG-TERM COST-
EFFECTIvENESS MODELS OF LIPID LOwERING THERAPIES
Kuan R.K.1, Wang A.1, Cong Z.2, Zolfaghari S.1, Gandra S.R.2, Nordyke R.1
1PriceSpective LLC, El Segundo, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA
Objectives: To determine through a literature review how economic evaluations 
incorporate utility data into models when estimating long-term cost-effectiveness 
of lipid lowering therapies in primary and/or secondary cardiovascular disease 
(CVD) prevention. MethOds: We used MEDLINE to identify published articles 
reporting cost-effectiveness models. Inclusion criteria included: English language 
articles published from 2000-2013, studies in adults ≥ 18 years old, studies assess-
ing statins or ezetimibe for primary and/or secondary CVD prevention, and studies 
in the US, Canada, UK, Spain, Germany, Australia, Sweden, France, and Italy. Two 
researchers independently identified articles and disagreements were resolved by 
consensus. Results: Sixty-one studies fulfilled the inclusion criteria. Forty-eight 
studies assessed the long-term cost-effectiveness (≥ 10 years) of lipid-lowering ther-
apy— 20 studies were in primary CVD prevention, 19 were in secondary prevention, 
and 9 were in both primary and secondary prevention. 36/48 studies incorporated 
utility parameters into their models. 23/36 models differentiated short-term ver-
sus long-term utility impact of cardiovascular events. Eleven models were able 
to differentiate between short-term and long-term utilities through model struc-
ture, where separate health states were created for events versus post-events (e.g., 
stroke versus post-stroke), and utility values could be assigned to these health states 
accordingly. Twelve models were able to differentiate short-term versus long-term 
utilities by changing the model inputs, where different utility values were applied 
to a health state according to length of time after the event (e.g., event year versus 
subsequent years for a health state, or < 6 months versus > 6 months from time of 
event). Eleven models accounted for the occurrence of multiple events by applying 
disutilities or combining utilities multiplicatively for patients experiencing ≥ 1 event 
over time. cOnclusiOns: Around two-thirds of the published long-term models 
differentiated short-term versus long-term utility impacts of cardiovascular events 
through model structure or utility inputs, which should be incorporated into future 
models on this topic.
PRM37
AN ExCEL CALCULATOR TO ESTIMATE RHEUMATOID ARTHRITIS COSTS IN 
TURKEy
Baser O.1, Burkan A.2, Baser E.3, Koselerli R.2, Ertugay E.2, Altinbas A.4
1STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA, 2Social 
Security Institution, Ankara, Turkey, 3STATinMED Research, Ankara, Turkey, 4Diskapi Yildirim 
Beyazi Education and Research Hospital, Gastroenterology Clinic, and STATinMED Research, 
Ankara, Turkey
Objectives: To build an Excel calculator, taking demographic and clinical charac-
teristics of rheumatoid arthritis (RA) patients in Turkey, and estimate the annual 
health care costs. MethOds: 2009-2011 data from MEDULA, the Turkish national 
health insurance database, was used for the study. RA patients (ages 18-99) were 
identified for the identification period (June 1, 2010 - December 31, 2010) using 
International Classification of Disease Tenth Revision Clinical Modification (ICD-
10-CM) codes. Patients were grouped as prevalent and incident cases and required 
to have two RA diagnoses at least 60 days apart. In order to estimate risk-adjusted 
total annual costs for prevalent and incident cases, generalized linear models 
(GLMs) were used. Patients’ demographic and clinical characteristics were factors 
to determine the expected annual cost value, with coefficients of the charac-
teristics built in the Excel calculator. A marginal effects table was created after 
GLM estimation by using such calculation. Results: A total of 2,613 patients 
met all inclusion criteria, of which 693 were incident and 1,920 prevalent cases. 
Patients’ demographic and clinical characteristics were entered into the Excel 
calculator. Risk-adjusted annual total costs were calculated at € 2,021 for prevalent 
cases and € 1,818 for incident cases. The most expensive contributor to annual 
expenditures was prior biologic use for both groups. Prevalent patients who were 
prescribed disease-modifying anti-rheumatic drugs (DMARDs) in the baseline 
period incurred € 5,898 more costs than those who were not. For incident cases, 
male patients incurred lower costs (€ 1,818 - € 708 = € 1,110), whereas respiratory 
comorbid conditions increased the total expected health care cost of incident RA 
patients by € 916 (€ 1,818 + € 916 = € 2,734). cOnclusiOns: In outcomes research, an 
Excel calculator serves as an important tool to estimate and compare RA-related 
health care costs.
PRM38
UNCOvERING THE GAP BETwEEN MODEL vALIDATION RECOMMENDATIONS 
AND PRACTICE
Kleintjens J., Akpo H.
Deloitte, Diegem, Belgium
Objectives: Health technology agencies and payers rely on economic models to 
evaluate the value of new treatments. It is therefore critical to ensure the scientific 
credibility of these models through validation, which is also required by NICE since 
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visit combined with extended treatment (starting 0–30 days after outpatient visit) 
with ≥ 1 of the following: a further course of intravenous corticosteroids > 7 days 
after the first course; a course of oral corticosteroids > 7 days after the intravenous 
course; intravenous immunoglobulins or plasma exchange. Algorithms for identify-
ing atypical relapses were also developed. cOnclusiOns: General and outpatient 
ARRs are consistent between the two distinct claims databases and are similar to 
those reported in the literature. Differences in inpatient ARRs may indicate differ-
ences between clinical practices in the two systems. Further investigation in the 
real-world setting is required.
PRM44
COMPARISON OF METHODS TO IDENTIFy STAGE IIIB OR Iv METASTATIC LUNG 
CANCER PATIENTS FROM ELECTRONIC MEDICAL RECORDS
Stafkey-Mailey D., Landsman-Blumberg P., Farrelly E., Eaddy M.
Xcenda, Palm Harbor, FL, USA
Objectives: Increased use of electronic medical records (EMR) has necessitated 
efficient ways to identify patients with certain clinical characteristics. This study 
compared use of standard fields and standard language recognition of progress 
notes to identify patients with metastatic lung cancer within an oncology-specific 
EMR. MethOds: Lung cancer patients (ICD-9-CM: 162.2 - 162.9) with second line 
erlotinib treatment were identified from a proprietary EMR. Method 1 identified 
metastatic disease using standard data fields for diagnoses (196.x – 198.x) and/
or stage (3B/IIIB or 4/IV); Method 2 utilized keyword searches for indications of 
metastases or stage within progress notes. Chart reviews were used to confirm 
advanced disease. Positive and negative predictive values (PPV and NPV) were then 
compared across methods. Results: A total of 740 patients were identified with 
suspected metastatic disease; 60.1% (n= 448) using Method 1. Of the remaining 292 
patients, 282 (96.5%) were identified by metastases and 117 (40.1%) by stage key-
words (Method 2). Overall, 671 (86.6%) were confirmed “metastatic” with chart review 
and 5 patients excluded for evidence of other cancers. Overall, PPV was 100% and 
NPV 6.3%. Of those identified as metastatic using the standard fields, the PPV for 
metastases and stage were 65.5% and 66.3% respectively and 99.3% combined. The 
PPV and NPV among the 287 patients identified only by keyword searches, was 
98.2% and 8.7% respectively for metastases and 49.3% and 89.9% respectively for 
stage. cOnclusiOns: Utilization of standard EMR fields for diagnosis and disease 
stage, when used together, resulted in identification of large numbers of confirmed 
metastatic lung cancer patients. However, for those patients requiring text searches 
for metastases and stage, neither separately nor in combination, could adequately 
identify metastatic disease patients. Further standardization of EMRs and consistent 
entry within oncology practices could reduce the need for labor-intensive, costly 
human chart review in real-world oncology research.
PRM45
ASSESSMENT OF A CANADIAN PRIMARy CARE ELECTRONIC MEDICAL RECORD 
DATABASE FOR USE IN OBSERvATIONAL STUDIES
Frise S.1, Reidel K.2, Tarride J.E.1, Corner N.2, Dziarmaga A.1
1AstraZeneca Canada Inc., Mississauga, ON, Canada, 2IMS Brogan Canada, Kirkland, QC, Canada
Objectives: Observational data derived from clinical practice is becoming increas-
ingly important to answer questions that cannot be addressed by RCTs. Although 
there are a number of administrative databases in Canada, access to more com-
prehensive, longitudinal clinical data such as smoking status, body weight and 
laboratory values in the primary care setting is limited. The objective of this study 
was to evaluate a Primary Care EMR (Electronic Medical Record) system to deter-
mine its feasibility for use in observational studies. MethOds: We analyzed de-
identified patient data from primary Health Care Professionals (HCPs) including 
General Practitioners from 2009-2011. Comprehensiveness and completeness of 
each variable by visit were evaluated. First steps were taken to understand how the 
patient population compares to data from published sources. Results: There were 
3,019,954 patient visits observed by 255,274 active patients (≥ 1 visit). The patient vis-
its were entered by 497 HCPs (152 physicians). Data are available for demographics, 
vitals, smoking status, laboratory values, prescriptions, medical history, diagnosis 
(ICD-9), short term absences and referrals. Completeness of each variable by visit 
ranged from 26% for pulse to 100% for age, sex, lab results and referrals. Initial 
assessment revealed that 85.6% of written prescriptions and 88% of diagnoses were 
recorded using structured fields. The median age of patients in the EMR was 37.2 
years compared to 39.9 years reported by Statistics Canada (July 2011). Younger 
age groups were overrepresented, with the largest difference found in those 20-29 
years; no difference was observed for sex. cOnclusiOns: The status of electronic 
primary care health records in Canada is still in its infancy. The research suggests 
this is a valuable new addition to support observational studies in Canada. Disease 
specific validation studies will be required prior to further analysis. Further research 
is being undertaken to review quality measures.
PRM46
EvALUATION OF DISSEMINATION OF BRAzILIAN NETwORK FOR HEALTH 
TECHNOLOGy ASSESSMENT (REBRATS)
Gonçalves L.1, Souza K.M.2, Elias F.T.S.3
1Brazilian Ministry of Health, Brasília-DF, Brazil, 2Brazilian Ministry of Health, Brasília, Brazil, 
3Oswaldo Cruz Foundation MoH, Brasília, Brazil
Objectives: The Brazilian Network for Health Technology Assessment (REBRATS) 
is composed of universities, hospitals and managing institutions who have among 
their goals the objective to elaborate and disseminate HTA information. The net-
work’s website and database are found at the http://www.saude.gov.br/rebrats and 
are tools to disseminate the policies and methodological guidelines of the network’s 
institutional organization and the studies produced by its members. To evaluate 
the degree of the network’s dissemination on national and international levels by 
analyzing the level of access and the rate of return from site users. MethOds: To 
analyze the number of visits to the REBRATS site registered through the Google 
Analytics monitoring and data extraction tool, with the intention of identifying 
warrants further investigation. Robust analyses are planned to comprehensively 
describe the clinical and economic burden of TSC in the UK.
PRM41
ExPLORING THE IDENTIFICATION OF MULTIPLE SCLEROSIS INCIDENT COHORTS 
IN CLAIMS DATABASES: METHODOLOGy AND CHALLENGES
Capkun-Niggli G.1, Lahoz R.1, Nordstrom B.2, Fraeman K.2, Chen W.3, Simeone J.C.2, Dickinson S.1
1Novartis Pharma AG, Basel, Switzerland, 2Evidera, Lexington, MA, USA, 3Novartis Pharma Co. 
Ltd., Shanghai, China
Objectives: To explore whether multiple sclerosis (MS) incident cohorts can be 
identified in claims databases. MethOds: We used several approaches to try 
and identify MS incident cohorts in the US Department of Defense (DOD) and 
MarketScan® databases, based on diagnostic and treatment history. Patients were 
first identified with 1 year of no MS claims or treatment before their first MS 
claim. Sensitivity analyses identified patients with 1–4 years of no MS claims or 
treatment before their first MS claim. Results: In patients with a 1-year baseline 
history with no MS claims or treatment, age and baseline characteristics were 
similar to all MS patients. The mean age at index date (second MS claim) was ~50 
years, in contrast with previous research reporting a mean age at diagnosis of 
25–40 years. Patients aged ≤ 65 years with ≥ 1 MS claim and 4 years of continuous 
baseline enrolment were identified in the DOD (n= 16 444) and MarketScan® (n= 16 
352) databases. With increasing years of baseline history, more patients showed 
evidence of pre-existing MS; the percentage of total patients with no MS claim or 
treatment before the first MS claim decreased from 53.3% (1 year history) to 42.2% 
(4 years history) in the DOD database, and from 23.5% to 15.5% in MarketScan®. 
Despite the decrease in patient numbers, the mean age at index date remained 
high (44–49 years). cOnclusiOns: Results indicate that > 4 years of patient his-
tory is needed to define an incident MS cohort in claims databases. However, the 
4-year claim and treatment-free cohort may be useful for studying treatment 
patterns and their impact on outcomes in recently treatment-naïve MS patients. 
There are substantial challenges in retrospectively identifying incident cohorts 
of MS patients using claims databases and a need for additional, large, real-world 
data sources to study newly diagnosed MS patients.
PRM42
SCREENING CHARACTERISTICS AND DIABETES BIOMARKERS IN FRENCH AND 
UK PATIENT-LEvEL DATABASES
Cabrera C.1, Le Jeunne P.2, Lee A.3, Thomas F.4, Mian N.3, McDonell A.5
1AstraZeneca, Mölndal, Sweden, 2IMS Health, Paris, France, 3AstraZeneca GMD UK, Cheshire, UK, 
4AstraZeneca France, GMD, Paris, France, 5IMS, London, UK
Objectives: Describe the patient characteristics and diabetes markers of type 
2 diabetes (T2D) patients in the newly launched IMS LifeLink Diabetes Cohort in 
France. Monitor the data quality through comparison of measures with a French 
national survey of diabetes patients (ENTRED), the UK National Diabetes Audit (NDA) 
where possible, and the “gold standard” UK Clinical Practice Research Datalink 
(CPRD). MethOds: The IMS Diabetes cohort in France supplements patient-level 
data from general practitioners with additional patient data via pop-up technol-
ogy within electronic medical records to facilitate robust epidemiological studies. 
This study compares the T2D patients in the Diabetes Cohort with similar popula-
tions in terms of gender, age, disease duration, and proportion of patients meet-
ing key disease-specific targets (data presented as summary statistics). Results: 
Patient characteristics and diabetes markers were analyzed for T2D patients in the 
Diabetes Cohort (n= 5,142), ENTRED (n= 3,894), UK NDA (n= 1,909,494), and UK CPRD 
(n= 268,618). The mean (SD) age in years was 66 (12.58) in the Diabetes Cohort, 66 
in ENTRED, and 61 (15.35) in CPRD. The mean (SD) time since T2D diagnosis was 
8 (7.7), 11, and 7.7 (6.2) years in the Diabetes Cohort, ENTRED, and CPRD, respec-
tively. Mean (SD) BMI was 30.5 (5.76) in the Diabetes Cohort, 29.5 in ENTRED, and 
30.8 (6.51) in CPRD. HbA1c target level of ≤ 6.5% was met by 32.5%, 34%, 23.5%, 
and 26% of the patients in the Diabetes Cohort, ENTRED, CPRD, and NDA, respec-
tively. cOnclusiOns: Health care systems and data collection methods vary across 
EU countries in general. Data monitoring helps assess data quality and robust-
ness. Based on comparison of patient characteristics and diabetes markers, the 
IMS Diabetes Cohort population does not appear to differ from the ENTRED popula-
tion. Although some differences between the Diabetes Cohort and CPRD data were 
noted, this unique French Diabetes Cohort appears appropriate for epidemiological 
research.
PRM43
MEDICAL AND PHARMACy CLAIMS-BASED ALGORITHMS FOR IDENTIFyING 
RELAPSES IN PATIENTS wITH MULTIPLE SCLEROSIS
Capkun-Niggli G.1, Lahoz R.1, Verdun E.1, Dickinson S.1, Lowy A.1, Nordstrom B.2, Dahlke F.1
1Novartis Pharma AG, Basel, Switzerland, 2Evidera, Lexington, MA, USA
Objectives: To develop appropriate algorithms for identifying and classifying 
relapses among patients with multiple sclerosis in claims databases. MethOds: 
Algorithms for detecting relapses in claims databases were identified by literature 
searches and refined by neurologists and database experts to identify relapses in 
inpatient and outpatient settings. Definitions were used in the US Department of 
Defense (DOD) and MarketScan® databases to determine annualized relapse rates 
(ARR) occurring after index date (date of second MS medical claim separated by ≥ 30 
days, following ≥ 12 months of continuous enrollment) during the 12-month and all 
available follow-up time. Results: A relapse was defined as an inpatient visit with 
a primary ICD-9-CM diagnosis code 340.xx or both an outpatient visit with any 340.
xx diagnosis code and oral or intravenous corticosteroid use ≤ 7 days of the outpa-
tient visit. ARR estimates in the DOD (N= 15,447) and MarketScan® (N= 35,134) data-
bases were 0.25–0.30 and 0.20–0.27, respectively. For inpatient relapses, estimates 
were 0.04–0.06 in the DOD database and 0.02–0.03 in the MarketScan® database. The 
corresponding estimates for outpatient relapses were 0.20–0.23 and 0.18–0.24. Severe 
relapses required an inpatient visit plus additional evidence of brain or spinal mag-
netic resonance imaging ≤ 7 days before or during hospitalization, or an outpatient 
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include = > 1 cohorts, retrospective or prospective data collection, disease or treat-
ment-based inclusion criteria, various outcomes (safety, prescription pattern or 
off-label use, comparative effectiveness, quality of life or other patient-reported 
outcomes[PRO], health economics, or other objectives), site/investigator selection 
(in-house, commercial, professional organization, or government databases), and 
country-specific requirements. MethOds: Studies that used integrated and non-
integrated DM systems were evaluated to identify criteria for use and associated 
protocol template language (PTL), including required, preferred, or optional text 
based on various study designs and objectives. Results: Multiple DM systems were 
evaluated and algorithms created with use criteria. For integrated DM systems that 
combined data capture and trial management, simplified PTL was identified. DM 
PTL was adjusted to include paper or electronic data capture (EDC) methods, paper/
electronic-based PROs, paper/electronic case report forms (CRFs), data (eg. subject/
physician entered, site or aggregate, medical or laboratory records) and appropriate 
subject data protection. For non-integrated systems that required separate DM and 
trial management, additional PTL was identified for these complex DM systems. The 
templates denoted minimum required language and suggested extended language 
for more elaborate designs. To support the numerous NIS study design types, we 
included decision trees to account for various study goals, associated outcomes, 
and data collection requirement. Our data collection decision tree summarized the 
variety of potential study designs with frequently used study goals/outcomes and 
associated data collection techniques. cOnclusiOns: Integrated DM systems pro-
vided the most flexibility and simplicity of protocol template language. All template 
language was created as adjustable to meet the typical study designs encountered 
in PASS studies. This additional information was to support the protocol devel-
opment team in creating the final protocol in a timely manner and in reviewing 
client-provided templates.
PRM50
BUILDING A REAL wORLD PRACTICE-BASED NETwORK DATA PLATFORM TO 
LINK RARE DISEASE PATIENTS: CASE STUDy OF MyELOFIBROSIS PATIENTS IN 
THE UNITED STATES
Lee A.1, Iqbal S.U.1, Hess G.2, Fonseca E.3, Redmond S.3, Wang H.4, Rose M.5, Neumann F.6, 
Cohen P.6
1Sanofi, Cambridge, MA, USA, 2Leonard Davis Institute, University of Penn, Philadelphia, PA, 
USA, 3IMS Health, Plymouth Meeting, PA, USA, 4Sanofi, Bridgewater, NJ, USA, 5Sanofi, Chilly-
Mazarin , Cedex, France, 6Sanofi Oncology, Cambridge, MA, USA
Objectives: Conducting real world evidence (RWE) research on patients with rare 
diseases is particularly challenging when using only one type of data (e.g. insur-
ance claims). Myelofibrosis (MF) is a rare, hematological cancer with global annual 
incidence rate of < 1 - 2.4 cases per 100,000 patients. MF is characterized by the 
reduced ability of bone marrow to synthesize blood cells which can result in anemia, 
thrombocytopenia, and higher risk of infection. Absent adequate, recent data on MF 
patients, a practice-based network (PBN) data platform was developed to facilitate 
RWE research on MF patients. MethOds: MF patients observed in IMS Health data-
bases between November 2010 to October 2012 were identified. Academic centers of 
excellence and large community oncology practices treating MF patients were then 
identified to link additional patients into the platform using a HIPAA-compliant 
patient de-identification algorithm. Patient demographics and attributes of dis-
pensed prescriptions, private practitioner visits, and electronic medical record data 
including laboratory information were collected across patients from January 2000 
to March 2013. Descriptive analyses of demographic and clinical characteristics were 
conducted to assess the generalizability of the sample versus literature. Results: 
A total of 6362 U.S. MF patients were identified in the platform. Mean (SD) age was 
67 (12.6) and 45% of patients were female. Mean (SD) Charlson Comorbidity Index 
was 4.36 (2.4). Among the subset of 529 patients with laboratory results, 63% were 
identified as anemic and 34% had platelet counts 50,000 - 100,000 / microL. All U.S. 
geographic regions were represented. cOnclusiOns: Demographic and clinical 
results suggest that this large sample of MF patients is comparable to prior esti-
mates of the broader MF population. This case study of U.S. MF patients suggests it 
is important to look beyond any one data source and to build PBN platforms with 
key clinical domains spanning multiple geographic regions when conducting RWE 
research on patients with rare diseases.
PRM51
FROM CLINICAL TRIAL TO REAL-wORLD EvIDENCE: A SySTEMATIC APPROACH 
TO IDENTIFyING DATA SOURCES FOR OBSERvATIONAL RESEARCH
Parasuraman B.1, Tomic K.S.2, Winchester C.C.3, Westergaard M.1, Johansson S.4
1AstraZeneca R&D, Wilmington, DE, USA, 2Oxford PharmaGenesis™ Inc., Newtown, PA, USA, 
3Oxford PharmaGenesis™ Ltd., Oxford, UK, 4AstraZeneca R&D, Mölndal, Sweden
Objectives: Observational studies are often planned on an ad hoc basis, with 
the risk that methods are inconsistent and that aims overlap rather than comple-
ment each other. Our objective was to develop a systematic approach for identify-
ing observational data sources for an integrated global programme of real-world 
evidence gathering, to support an important new indication for an antiplatelet 
drug. MethOds: Systematic literature and Web searches, supplemented with email 
and telephone contact with data owners, were used to identify and characterize 
registries and health care databases suitable for use in observational studies of 
myocardial infarction and acute coronary syndromes. The ability to identify patients 
across data sources was also assessed. Data were captured and evaluation criteria 
applied, including compatibility with aspects of an ongoing randomized clinical 
trial (patient population, treatments, outcomes, and length of follow-up [≥ 3 years]). 
Selection criteria included accessibility; availability of inpatient, outpatient, cardiac 
event, and drug data; and generalizability. Results: Over 2700 publications were 
screened; we identified 216 registries and 380 databases (primarily of administra-
tive claims and electronic medical records). Of these, 12 registries, and 21 databases 
met the evaluation criteria and were assessed in depth. After application of the 
selection criteria, 5 registries and 12 databases were recommended. Recommended 
data sources ranged in size, each capturing data on between 4000 and 11 million 
the user’s behavior upon navigating the site. Results: Since the site began to get 
monitored on July 1, 2012 and up until June 25, 2013, 19.738 hits were registered, with 
a monthly average of 1.661 hits. More than 65 countries accessed the site, the major-
ity coming from the USA, UK and Portugal. Brazil leads with 93%. The rate of return 
of people who frequently accessed the site was 24,7%. Upon navigating the site, 
more than 45.000 visualizations of the web page were registered. cOnclusiOns: 
This monitoring began in 2012 and therefore no previous years exist to serve as a 
basis for comparison. The results show that a considerable number of users have 
access to the site and consequently know about REBRATS. From the perspective of 
the website, the number of hits is still low, however, considering that the HTA field 
is a recent one in Brazil, its growth has been gradual. On an international level, 
new dissemination strategies are necessary in order to create greater visibility and 
promotion of the network.
PRM47
DESCRIPTION OF TREATMENT PATHwAyS IN CHRONIC DISEASES USING LARGE 
GENERAL PRACTITIONER LONGITUDINAL DATA: THE ExAMPLE OF PHARMACO-
THERAPy IN PARKINSON’S DISEASE IN THE UNITED KINGDOM
Guelfucci F.1, Neine M.2, Bineau S.3, Milea D.3, Aballea S.2
1EPHE Sorbonne, Paris, France, 2Creativ-Ceutical, Paris, France, 3Lundbeck S.A.S., Issy-Les-
Moulineaux, France
Objectives: Identifying treatment pathways based on administrative data or elec-
tronic medical records is generally a complex task, as many incidental events may 
hide the key trends. The purpose of this study was to propose a transparent method-
ology for defining treatment pathways using a large longitudinal real life database. 
The application of two alternative algorithms with different variants in Parkinson’s 
disease (PD) was described. MethOds: In the first method, a new treatment line 
was assumed to start when a pre-specified number of consecutive prescriptions of 
drugs from the same PD drug class or combination of classes (rasagiline, selegiline, 
dopa agonists, COMT inhibitors, levodopa and derivatives) occurred. In the second 
method, start and end dates of continuous treatment periods (i.e. without gaps 
higher than six months between prescriptions) were determined for each drug class 
independently of each other. Combinations were assumed to be used when differ-
ent treatment periods overlapped. Algorithms were tested using medical records 
of patients with Parkinson’s disease (PD) extracted from the UK Clinical Practice 
Research Datalink (CPRD). The outputs of the different algorithms were described 
in details for ten patients, randomly selected. The sensitivity of the algorithms to 
changes in assumptions was tested. Results: The first algorithm did not systemat-
ically capture the addition of a new drug to the current treatment as combined drugs 
were not necessarily prescribed or renewed during the same consultations. However, 
the second method well captured the treatment lines observed but sometimes cre-
ated undue treatment lines from isolated prescriptions. This issue was overcome 
by deleting short lines lasting less than three months. cOnclusiOns: The second 
algorithm developed in this study provided an accurate description of the treatment 
strategies developed by prescribers in Parkinson’s disease in the UK using a limited 
number of assumptions and may be useful for other chronic diseases.
PRM48
IDENTIFICATION AND QUALITATIvE ASSESSMENT OF REAL wORLD DATA 
SOURCES: ExAMPLE OF LyMPHOMA AND MULTIPLE MyELOMA IN EUROPE
Noibi S.O.1, Bertwistle D.1, MacDougall F.1, Berger K.1, Mehta J.2, Trask P.C.2
1IMS Health, London, UK, 2Sanofi, Cambridge, MA, USA
Objectives: To identify and assess real world data sources for observational 
research on lymphoma and multiple myeloma (myeloma) in Europe. MethOds: 
Structured (EMBASE and MedLine) and grey literature searches were conducted 
to identify relevant European data sources. Identified data sources were screened 
based on the following criteria: inclusion of patient-level data and patients with 
NHL, HL, or MM diagnoses, possession of data dictionaries, and ongoing data accrual. 
Where regional registries were proven to feed data into national registries, only 
the national data source was retained for evaluation. Data sources passing initial 
screening were subjected to further evaluation based on publicly reported infor-
mation, questionnaires and / or interviews with data source owners, and informed 
by lymphoma and myeloma treatment pathway analysis. Results: One hundred 
eighty-six data sources from 21 countries were identified; of which cancer regis-
tries (R) accounted for 65%. The remaining 35% non-registry (NR) sources included 
biobanks, clinical audits, data linkage initiatives, drug databases and electronic 
medical records. Screening removed 101 sources. Of the 85 sources retained after 
screening, roughly half (52%) were NR sources and a majority (74%) were from six 
countries: France, Germany, Spain, Sweden, The Netherlands, and The UK. NR data 
sources generally collected more data attributes than R data sources. These data 
attributes included symptoms (collected by 52% NR, and 21% R data sources), treat-
ment regimens (81% NR, 40% R), and resource use (49% NR, 8% R). cOnclusiOns: 
Compared with disease registries, non-registry data sources in Europe typically have 
more diverse data attributes and are therefore potentially better for lymphoma and 
myeloma research. This result may guide the selection of data sources for observa-
tional research. As scrutiny of real-world outcomes for reimbursement of oncology 
drugs increases, much work remains to be done to increase the visibility and utility 
of data sources for health care payers and providers.
PRM49
COvERING THE PASS: DEvELOPMENT OF PROTOCOL TEMPLATE LANGUAGE 
(PTL) FOR DATA COLLECTION AND DATA MANAGEMENT (DM) IN POST-
AUTHORIzATION SAFETy STUDIES (PASS)
Oberthur Johnson L.1, Watts H.1, Krishnan S.1, Zarotsky V.2, Spannheimer A.3, Siebenaler J.1, 
Gulyas S.1, Clark S.1
1OptumInsight, Eden Prairie, MN, USA, 2Optum, Eden Prairie, MN, USA, 3OptumInsight 
(Deutschland) GMBH, Munchen, Germany
Objectives: To address non-interventional study (NIS) protocol DM and data 
collection requirements in PASS observational study designs. These studies may 
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Objectives: Access to large-scale public health claims databases is limited due 
to privacy concerns and lack of a unique identifier in Japan. Since such databases 
were not originally designed for outcomes research, we assessed the usefulness 
of one of the commercial databases in identifying treatment patterns in routine 
clinical practice. MethOds: Treatment patterns for patients with exudative age-
related macular degeneration (AMD) using anti-vascular endothelial growth factor 
(anti-VEGF) was selected as an example to enhance our understanding of real-
world clinical practice. A retrospective open-cohort study of patients diagnosed 
with AMD and treated from January 2010 to December 2012 at community hospitals 
employing Diagnostic Procedure Combination payment system was conducted by 
using hospital claims database provided by Medical Data Vision, Co., Ltd. Strengths 
and weaknesses of using the database were also identified. Results: During the 
study period, 248 patients were diagnosed with AMD and received ranibizumab, 
19 patients received pegaptanib, and two patients received aflibercept. Among the 
patients who received ranibizumab, the average number of ranibizumab injec-
tions per year was 3.21±2.38. The strength of the database was granularity of 
data including daily medication and medical procedural histories that allow us to 
obtain key parameters of analyzing treatment patterns. A major weakness was no 
unique identifier for patients; thus, a patient would be recorded as two different 
entries in the database if s/he visited two different hospitals. cOnclusiOns: 
The results show that the commercial hospital claims database was useful to 
understand treatment patterns of exudative AMD at non-university hospital set-
tings. Since treatment guidelines are usually written based on published clinical 
trial evidence, this type of database research provides an understanding of real 
life clinical practice and its associated patient outcomes, contributing to better 
adherence and future updates of treatment guidelines.
PRM55
COMPARISON OF THE PRICES USED IN THE MANUFACTURERS’ BUDGET IMPACT 
ANALySES AND THE PRICES FROM REIMBURSED DRUGS LIST
Iwanczuk T., Zawodnik S., Misiak J., Chodacka A., Sejbuk K.
Agency for Health Technology Assessment in Poland, Warsaw, Poland
Objectives: To compare official prices and refunding limits of the selected drugs 
with the prices and limits used in the manufacturers’ Budget Impact Analyses 
(BIAs) submitted in the reimbursement applications and in the manufactur-
ers’ documentations from request for removing, altering the level or method of 
financing of medicines to AHTAPol and to verify the accuracy of their assump-
tions. MethOds: Prices and limits proposed in BIAs in years 2007-2011 and 
official prices and limits for the same medicine were compared. Only BIAs for 
medicines which had been reimbursed for at least one year were included in 
the analysis. The official prices and limits were obtained from reimbursed drugs 
list published in Ministry of Health’s Orders. Results: In the studied period, 
72 drugs were included in the analysis. Among them, 51,39% (37/72) were from 
reimbursement applications and 48,61% (35/72) were from requests for remov-
ing, altering the level or method of financing of medicines, respectively. As 
a result, 13% (9/72) of the prices proposed in the BIAs were underestimated. 
Median and mean difference (MD) between official prices and prices used in 
BIAs for the same medicine were 95% and 91% respectively. The overestimation 
was found in 39% BIAs (28/72); median = 117%, MD = 124%. Rest of the prices 
were equal 49% (35/72). Limits were underestimated in 8% (6/72) of the BIAs. 
Median and mean difference between official prices and prices used in BIAs 
were 97% and 98% respectively. Overestimation of the limits was found in 57% 
(41/72) of the BIAs; median = 133%, MD = 117%. Rest of the limits were equal 35% 
(25/72). cOnclusiOns: Among the contradictory prices and limits official ones 
were higher than the prices assumed in BIAs for the same medicines. There is a 
strong need for further research.
PRM56
DEvELOPING A PUBLICATION STRATEGy IN THE CONTExT OF OUTCOME 
RESEARCH: A REvIEw OF THE LITERATURE
Laloyaux C., Boyer M., Delbecque L.
Business & Decision Life Sciences, Brussels, Belgium
Objectives: Many public health decisions are made based on information con-
tained in medical publications. Therefore developing a publication strategy is a 
benefit for the pharmaceutical industry as it ensures an efficient dissemination of 
drug efficacy and safety evidence and an ethic development of the publications. In 
the context of outcome research, a publication strategy should take into considera-
tion specific aspects related to the field (e.g., dealing with local, regional and global 
levels) and is important to ensure that unbiased information is provided to medical 
decision makers on time for the good of public health. A literature review was con-
ducted to investigate if published guidelines on the development of a publication 
strategy in the context of outcome research exist. MethOds: A literature search 
of English articles was conducted on MEDLINE and Scopus. Search terms included 
“publication strategy” OR “publication planning” OR “publication coordination” 
AND “health economics” OR “health outcome” OR “outcome research” OR “medical 
economics”. Independent extraction of articles was performed using predefined 
data fields. Results: The search provided four citations; all were discarded after 
reviewing the abstracts. However, a simple search for the keywords “publication 
strategy” OR “publication planning” returned 85 hits in fields as various as psychol-
ogy, political science, environmental science and medicine. None of the citations 
was specific to outcome research. cOnclusiOns: The results of the literature 
search showed that the development of a publication strategy is an important 
concept through many different domains. However, no published guideline on 
the development of a publication strategy in the context of outcome research 
was found. A publication strategy specific to outcome research publications will 
be presented including recommendations regarding the key aspects that should 
be covered in an efficient outcome research publication strategy such as a criti-
cal assessment of published literature, identification of gaps, and development 
of a strategic plan.
patients, and were geographically diverse, representing populations in Europe, the 
USA, and Australia. Each recommended data source had unique strengths and limi-
tations for use in real-world evidence studies, and together they had the potential 
to provide consistent and complementary information. The study output provided 
a valuable tool for global and local investigators. cOnclusiOns: Observational 
data sources are diverse. A systematic understanding of real-world evidence can 
guide the development of a coherent strategy for designing observational studies 
to support clinical research.
PRM52
FEASIBILITy OF USE OF MEDICAL TRANSCRIPTION DATA FOR REAL wORLD 
EvIDENCE GENERATION IN THE UNITED STATES: A PILOT STUDy OF PATIENTS 
wITH SySTEMIC LUPUS ERyTHEMATOSUS INITIATED ON BELIMUMAB
Narayanan S.
Ipsos Healthcare, Gaithersburg, MD, USA
Objectives: To assess the feasibility of use of medical-transcription data for 
real-world clinical evidence generation in the US. MethOds: Majority of clini-
cal practices in the US are experimenting digitization of patient medical records 
for two reasons: patient-management/care-delivery and billing/administrative/
legal documentation purposes. Increasingly, physicians are using medical-tran-
scription services, where physicians dictate details of patient visits and send the 
voice-recording-device to medical-transcription organization which processes 
voice-data and delivers electronic-files back to clinics; physicians review/revise/
append the electronic-documentation and adds data to their patient-database-
repository for future use. This pilot study assessed the utility of de-identified med-
ical-transcription data in evaluating patient-physician dynamics and real-world 
treatment patterns/outcomes and documented adverse-events(AEs) using random 
set of adult SLE patients who initiated belimumab (a recently-launched biologic) 
within the past 2years as part of usual care. SLE was chosen specifically because of 
its complex clinical management issues. Results: Nineteen belimumab patient 
transcription-records (de-identified) were reviewed (mean age:39.4yrs; female:95%). 
Top-4 clinical-manifestations at belimumab-start were: musculoskeletal(68%)/
mucocutaneous(53%)/constitutional(42%)/renal(21%). Physicians discussed beli-
mumab-attributes (specifically, infection-risks/AEs/etc), asked patients to do their 
own research on belimumab, and cited insurance/reimbursement-issues prior to 
belimumab-start in 58%, 26% & 26% of cases respectively; 11% of patients asked for 
belimumab. Top-3 documented-reasons for belimumab-start were: steroid-spar-
ing(32%), control autoimmune diathesis(11%), control SLE-flares(16%). In 47% of 
patients, belimumab (at initiation) replaced another medication (majority:steroids/
immunosuppressants); concomitant SLE-medications were: antimalarials(84%)/
oral-steroids(68%)/Immunosuppressants(47%). Average belimumab-duration was 
8.1months (overall data availability/patient:23.8months). During the observation 
period, 42% had > = 1AE (e.g., diarrhea/rash/bronchiolitis/alopecia/upper-respira-
tory-track-infection), 42% discontinued belimumab (but 26% re-started) and 47% 
had some physician-documented improvement in outcomes (e.g., joint-pain/
rash/energy level/fatigue). One patient had documented steroid-stoppage post-
belimumab initiation. cOnclusiOns: Medical-transcription data may provide 
documented real-world evidence of treatment dynamics and clinical status/out-
comes associated with patient care. In this random cohort of SLE patients using 
belimumab, belimumab appears to provide some demonstrable benefits in almost 
half of the patients.
PRM53
UPDATE OF THE PATIENT-REPORTED OUTCOME AND QUALITy OF LIFE 
INSTRUMENTS DATABASE (PROQOLID): INCLUSION OF E-PRO INFORMATION
Caron M., Perrier L.L., Acquadro C.
Mapi Research Trust, Lyon, France
Objectives: In 2002, PROQOLID was launched to provide an overview of existing 
PRO instruments and a facilitated access to the instruments and their develop-
ers through the structured presentation of synthesized, reliable, and constantly 
updated data. With the constant growth of electronic capture of patient-reported 
outcomes, detailing information about modes of data collection (i.e., paper vs. 
electronic) in PROQOLID might become a crucial step in updating the database. 
The objective of this study was: (1) To review how e-PROs are currently reported 
in PROQOLID; and (2) To propose (if needed) ways of clarifying and updating e-PRO 
information. MethOds: PROQOLID was searched to retrieve current information 
about e-PROs using an advanced search engine. Results: The e-PRO information 
was found under the category “mode of administration.” Three options could be 
chosen: computer-administered, electronic-administered, and IVR (Interactive Voice 
Response) version. Out of the 751 instruments in the database, 37 (5%) were reported 
with e-PRO information. Information about existing translations of electronic ver-
sions was clearly specified for three questionnaires. To clarify and update e-PRO 
information in PROQOLID, several recommendations are proposed: (1) To create 
a new category, i.e., mode of data collection, in order to differentiate it from the 
“mode of administration” category; (2) To categorize each mode of data collection 
into five subcategories [i.e., Hand-Held Device, IVR, Internet web-data capture, Pen, 
and Tablet]; and (3) To provide a list of all translations available in each mode of 
data collection. cOnclusiOns: This review has shown that PROQOLID already 
includes e-PRO information. Recommendations are given on how to modify the 
organization and content of the database to present the information on electronic 
capture of PROs.
PRM54
USEFULNESS OF A COMMERCIAL HOSPITAL CLAIMS DATABASE TO IDENTIFy 
CURRENT ANTI-vASCULAR ENDOTHELIAL GROwTH FACTOR TREATMENT 
PATTERNS IN PATIENTS wITH ExUDATIvE AGE-RELATED MACULAR 
DEGENERATION IN jAPAN
Narimatsu A., Adachi K., Wang E.C.Y.
Bayer Yakuhin, Ltd., Tokyo, Japan
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similar difference was observed for Protocol-B. This finding showed non-weighted 
sampling from the SF would cause biases in CTS. At the same time, this result 
suggested that various CTS’s assumptions by weighted sampling might be useful. 
Further evaluation is recommended. cOnclusiOns: The present study provides 
relevant information that there is considerable similarity in the demographics 
between SFs from Japanese HDB and Japanese CTs, suggesting usefulness of HDB 
with application of weighted sampling with CTS.
RESEARCH ON METHODS – Modeling Methods
PRM60
DOES IT MATTER? DISCOUNTING AND ITS ROLE IN ANALySING THE COST-
EFFECTIvENESS OF PREvENTATIvE INTERvENTIONS
Starkie Camejo H.J.1, Van Kriekinge G.2, Li X.3
1GlaxoSmithKline, Uxbridge, UK, 2GlaxoSmithKline Vaccines, 1300 Wavre, Belgium, 
3GlaxoSmithKline Vaccines, Wavre, Belgium
Objectives: The UK runs a human papillomavirus (HPV) vaccination programme 
for girls aged 12-13 years to protect them from cervical cancer (CC). When long-
term health benefits such as these occur, with costs occurring at the outset, cost-
effectiveness analyses are very sensitive to the discount rate used. In view of this, 
the National Institute for Health and Care Excellence (NICE) will consider analyses 
with discount rates of 1.5% for costs and outcomes. Therefore, we modelled the 
cost-effectiveness of vaccination with the AS04-adjuvanted HVP-16/18 vaccine 
(BV) compared with HPV-6/11/16/18 (QV) with discount rates of 1.5%. MethOds: 
A published lifetime Markov cohort model replicating the natural history of onco-
genic and low-risk HPV infection was adapted to the UK and run for a cohort of 
100,000 girls aged 12. Vaccine efficacy against vaccine-type and non-vaccine type 
HPV was obtained from each vaccine’s respective clinical trials. Lifetime protec-
tion was assumed for both vaccines. Input data were obtained from the literature, 
public databases and expert opinion. All costs were updated to 2012 values and 
reflected an NHS perspective. The incremental cost effectiveness ratio (ICER) of 
vaccinating with the BV vs. the QV was evaluated. Sensitivity analyses were per-
formed on key variables. Results: The model estimated that compared with QV, 
BV saved an additional 277 CIN1 cases, 1,460 CIN2/3 cases, 53 CC cases and 23 
deaths, but did not protect against 7,747 GW cases. Discounting at 1.5% results 
in +54 QALYs gained and £2.4 million saved. However, applying a discount rate 
of 3.5% results in -52 QALYs and £1.1 million saved. Sensitivity analyses showed 
results were robust. cOnclusiOns: Applying a discount rate of 1.5% for both costs 
and outcomes focuses the appraisal on the long-term outcomes, such as CC and 
CC-death, of the vaccination programme, and to the finding that the BV was shown 
to dominate QV.
PRM61
INvESTIGATING THE vALIDITy OF THE UKPDS OUTCOMES EQUATIONS IN 
CURRENT CLINICAL PRACTICE
McEwan P.1, Ward T.2, Bergenheim K.3
1Swansea University, Cardiff, UK, 2HEOR Consulting, Monmouth, UK, 3AstraZeneca, Mölndal, 
Sweden
Objectives: The UKPDS 68 equations are routinely used to assess the benefits 
associated with glucose control in type 2 diabetes mellitus (T2DM) cohorts. Their 
validity has been questioned because they were derived from a cohort of newly 
diagnosed T2DM subjects and diabetes management practices have evolved consid-
erably. The objective of this study was to re-calibrate the equations to contemporary 
health care data and assess their continued relevance. MethOds: We utilized data 
from The Health Improvement Network (THIN) database over the period 1/1/2004 
to 31/12/2009. We selected patients either aged > 64 years with HbA1c > 7.5% and 
diabetes duration > 10 years or aged > 55 years with at least 1 established cardiovas-
cular risk factor. Weibull survival equations were fitted to the following endpoints; 
myocardial infarction (MI), stroke, congestive heart failure (CHF), ischemic heart 
disease (IHD), amputation, blindness and end-stage renal disease (ESRD) using R. 
Missing data was modeled using multiple imputation. Results: Data were available 
on 68,990 T2DM subjects meeting the inclusion criteria with mean age 66.1 years, 
46% female, 8.8 years duration of diabetes; with mean body mass index (29.7m/kg2), 
HbA1c (8.0%), systolic blood pressure (147.5mmHg), total cholesterol (5.1mmol/l) 
and HDL cholesterol (1.3mmol/l). Log hazards (standard error) associated with unit 
changes HbA1c were 0.097(0.011) for MI, 0.084 (0.008) for CHF, 0.051 (0.009) for stroke, 
0.112(0.02) for blindness, 0.043 (0.007) for ESRD and 0.225 (0.017) for amputation. 
These estimates were statistically consistent (at the 95% level) with the original 
UKPDS log hazards except for IHD (non-significant in the THIN database) and ESRD 
(non-significant in UKPDS). cOnclusiOns: In general, the UKPDS equations retain 
their validity for assessing the relationship between HbA1c and macrovascular and 
microvascular complications. It is likely that use of UKPDS equations will overesti-
mate the incidence of IHD and under-estimate the incidence of ESRD.
PRM62
vARIANCE REDUCTION THROUGH ANTITHETIC vARIATES AS A MEANS OF 
DEvELOPING COMPLEx vBA MODELS wITH REASONABLE COMPUTATION 
TIMES
Bennett H., Tetlow A.P., McEwan P.
Swansea University, Cardiff, UK
Objectives: Modelling chronic conditions such as diabetes necessitates the 
development of complex models, raising issues of computational intensity 
and execution time. While the use of compiled languages such as C++ is more 
computationally efficient, concerns may exist regarding their transparency 
compared to commonly used VBA in Microsoft Excel. This study investigates the 
application of antithetic variates to the pseudo-random numbers of Monte Carlo 
simulation, to provide reductions in stochastic uncertainty, through the introduc-
tion of negatively correlated pairs of simulation replicates, as a means of devel-
oping complex VBA models with reasonable computation times. MethOds: A 
PRM57
TELLING THE INSIDE STORy: ACTIvITy AND PERFORMANCE METRICS FOR 
A TyPICAL INTERNATIONAL MULTI-LANGUAGE MULTI-CENTER NON-
INTERvENTIONAL STUDy wITH THE INTRIAL DATA CAPATURE SySTEM
Eichmann F.1, Hausner S.1, Schwunk M.1, Faber S.1, Potthoff P.2
1Kantar Health Germany, Munich, Germany, 2Kantar Health GmbH, München, Germany
Objectives: Getting insight into the technical and logistical challenges of a typi-
cal global non-interventional EDC study by analyzing the pure log file numbers: 
from application scalability to data handling and processing. MethOds: To analyze 
EDC activity and performance metrics, a global oncological observational study 
managed via the INTrial EDC application was selected. System log files were used 
for quantitative and qualitative performance/workflow-related aspects and time 
measurements. Results: Study parameters: The study ran for 4 years and was 
conducted in 39 countries with 6 languages, 382 sites, 3395 patients and 1612 users. 
The electronic Case Report Form for a single patient consisted of up to 2513 fields 
with a total number of 1,574,627 filled-in fields for the whole study. 24,382 transla-
tions were imported into the EDC system. Using 845 possible system queries per 
patient, 163,703 of these were commented and resolved, 30,451 manual queries were 
inserted. In total, 4,938,215 page calls took place for reading purpose and 582,052 for 
writing purpose (average of 3,781 page calls per day, 2.6 calls per minute). 6,060,981 
field entries or changes (value or status) were carried out (average: 4,151 changes 
per day). Performance: Time between real data collection and data entry by site: 
25% within 5 days, 22% from 6 to 20 days and 24% from 21 to 60 days. 92% of all 
manual queries had been commented by the site. Average time for resolving site 
comments for system queries: 29 days. Average time for translation processing: 19 
days. cOnclusiOns: A suitable technical system like INTrial can help to improve 
and optimize the study workflows. Easy to use data entry and data management 
functionalities and additional tools like multi language support, translation import 
or archiving are substantial – always in combination with a well trained and enthu-
siastic study team and established procedures.
PRM58
4-vALENT vACCINE PATIENTS – STATISTICAL ASSESSMENT OF A NEw 
ESTIMATION METHODOLOGy
Schroeder-Bernhardi D.1, Grunow S.2, Zoellner Y.F.3
1IMS HEALTH, Frankfurt am Main, Germany, 2IMS Health, Frankfurt am Main, Germany, 
3Hamburg University of Applied Sciences, Hamburg, Germany
Objectives: The objective was to estimate the number of patients in Germany who 
received a 4-valent vaccine in 2011. This estimation was based on data collected 
through a sample of GP/Pediatrician practices (Vaccine Analyzer [VA] sample (0.43%; 
1.13%). MethOds: The VA-sample was compared to the German population by age/
gender. This comparison shows a disproportional distribution of the VA-sample. A 
disproportional sample distribution may result in biases of final estimates. Hence, 
we opted for a methodology to mitigate estimation biases that would result from 
a straight-forward projection methodology. The VA-sample was restricted to eli-
gible practices. For the projection of the patient sample counts to the universe, a 
specific formula was used. The assumption is that the sampling ratio in terms of 
doses equals the sampling ratio in terms of patients. This assumption is theoreti-
cally valid as per medical recommendation one dose per patient shall be used. In 
summary, the estimation of total number of universe patients can be considered 
feasible from statistical point of view. Results: The methodology to estimate total 
patient numbers is statistically valid and utilizes data sources in an efficient way. 
The assumption with regard to the conversion of patients into doses is in line with 
empirical findings. The stratified projection caters to disproportional distribution 
of VA-sample doctors. cOnclusiOns: The usage of patient age information from 
the VA-sample is theoretically feasible. The empirical validation with indepen-
dently sourced German Longitudial Prescription data of statutory insured patients 
shows differences, which is a certain weakness. As most vaccine-prescriptions are 
not patient-based the coverage is only 0.07% at paediatricians and 0.39% at GPs. 
However, VA-age distributions show an overall correlation of 80% which let the 
usage of VA-age distribution appears feasible. The suggested estimation method is 
methodologically sound and delivers results confirmed by observation, and statis-
tically preferable to straightforward projection methods which are prone to bias.
PRM59
APPLICABILITy OF jAPANESE HEALTH CARE DATABASE TO CLINICAL TRIAL 
PLANNING FOR DySLIPIDAEMIA DRUG
Yamamoto Y.1, Nagayasu S.1, Tomosugi T.1, Matsuoka N.2, Takata A.2, Kanmuri K.2, Imai K.2, 
Fujimoto Y.2
1MinaCare co.Ltd., Tokyo, Japan, 2Pfizer Japan Inc, Tokyo, Japan
Objectives: Clinical trial simulation (CTS) is encouraged to prevent clinical tri-
als (CT) from failing. Health care database (HDB) is a potential source for baseline 
characteristics in CTS. The study evaluates, 1) overlapping between distribution of 
baseline characteristics extracted from Japanese HDB and also from two Japanese 
CTs for dyslipidaemia drugs, and 2) applicability of HDB as a sampling frame (SF) for 
baseline data in CTS for dyslipidaemia drug development. MethOds: We extracted 
data from MinaCare HDB which contains both insurance claims and health check-
ups of people insured by employment-based insurances as of April 2013 and built 
two SFs according to eligibility criteria of the protocol in two CTs (Protocol-A and 
Protocol-B) conducted by Pfizer Japan Inc. Distribution of patient characteristics 
at screening, such as body mass index (BMI) and low density lipoprotein choles-
terol (LDL-C) levels, were compared between SFs (n= 1663 for Protocol-A, n= 5011 
for Protocol-B) from MinaCare HDB and CTs, for Protocol-A (n= 165) and Protocol-B 
(n= 459), respectively. Results: For both two protocols, we found similar distri-
bution of age, sex, weight, and BMI when comparing descriptive statistics (e.g., 
mean, standard deviation (SD)). However, LDL-C in CTs was higher than in SFs; e.g., 
in Protocol-A, patients without prescription for dyslipidaemia showed LDL-C 
(mg/dL) of 169.9±19.2 from the CT vs. 160.2±16.5 from the SF. Among the patients 
with prescription, LDL-C was 132.3±31.0 from the CT vs. 118.4±31.0 from the SF. A 
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Objectives: In developing probabilistic models to analyse cost-effectiveness, it 
is possible to control many model parameters using random seeds so that output 
differences should be due to the interventions being modelled rather than due to 
chance differences in the model parameters. However, at the point of intervention, 
the simulated patient effectively enters a parallel universe where outcomes may 
legitimately be better or worse irrespective of the intervention. The purpose of this 
study was to present an example of reduced health outcomes contrary to expec-
tation. MethOds: Using a model developed to evaluate the impact of different 
MRI-based breast cancer surveillance strategies, the total benefits measured for 
individual simulated patients were compared between surveillance and no sur-
veillance. Random seeds were used to ensure model parameters were matched 
between different model runs. Model structure ensured that later detection of 
cancer could not be associated with a better outcome. For breast cancer occur-
rence, random seeds were matched until the first incidence. Individuals could 
have multiple cancers. Results: Across 7 surveillance strategies, compared to a 
situation of no surveillance, life expectancy was unchanged for between 97.7% 
and 99.0% of individuals. Depending on the surveillance strategy, between 0.98% 
and 2.2% of individuals had increased life expectancy, and between 0.04% and 
0.1% of simulated individuals experienced a reduced life expectancy. A larger 
number of individuals had reduced life expectancy due to surveillance, but this is 
attributable to the detection of DCIS which does not always develop into invasive 
cancer. cOnclusiOns: When comparing interventions using probabilistic models, 
chance variation can result in poorer outcomes despite the intervention. Although 
these anomalies are not apparent in summary figures as there may be an “on aver-
age” benefit, their occurrence is legitimate and should not be artificially prevented.
PRM66
ADHERENCE TO DISEASE-SPECIFIC RECOMMENDATIONS FOR 
PHARMACOECONOMIC STUDIES IN RHEUMATOID ARTHRITIS
Makady A.1, Frederix G.W.2, Hövels A.M.2
1Utrecht University, Zeist, The Netherlands, 2Utrecht University, Utrecht, The Netherlands
Objectives: Previous research has demonstrated wide varieties in modelling 
methods of pharmacoeconomic (PE) studies focussing on biological drugs for the 
treatment of rheumatoid arthritis (RA). To eradicate this variety, disease specific 
guidelines were presented in 2002 by OMERACT-ILAC. The objective of this study 
is to assess whether recently published PE studies adhered to these recommen-
dations. MethOds: A literature review was conducted for PE studies evaluating 
TNF-α inhibitors use in RA. Four different databases (e.g. Embase, NIHR-EED) were 
searched for PE studies published that focus on Adalimumab between October 
2003 and May 2013. Methodological quality of included studies was checked 
against the CHEC-checklist. Data extraction forms were used to retrieve informa-
tion such as study outcomes (QALY’s, costs, ICER) and modelling methods and 
parameters (e.g. time horizon, sources for costs and effectiveness data). Finally, 
information retrieved from all studies was compared to recommendations pro-
posed by the OMERACT-ILAR guideline to assess adherence to these recommenda-
tions. Results: Nine studies were identified that met all inclusion criteria and 
were included in our analysis. All studies met at least 12 of the 19 items of the 
CHEC checklist for quality and 3 studies met all 19 items. Study outcomes varied 
considerably in QALY’s calculated, costs and ICER’s. Patient subtypes, modelling 
methods, sources for cost and effectiveness data also varied significantly. Only 
2 of the 12 recommendations published in the OMERACT-ILAR guideline were 
unanimously implemented in all 9 studies of our review. Only 1 study was found 
to contain all elements of guideline recommendations, albeit with some limita-
tions cOnclusiOns: We demonstrate that modelling methods still widely differ 
and adherence to disease-specific guidelines for the conduct of PE studies in RA is 
very low. Development of strict disease-specific guidelines in RA and subsequent 
adoption by re-imbursement agencies is vital to ensure comparability,validity and 
credibility of future PE studies.
PRM67
MODELING A SwITCH FROM TRIvALENT TO QUADRIvALENT INFLUENzA 
vACCINE IN CANADA AND THE UNITED KINGDOM
Thommes E.W.1, Ismaila A.2, Meier G.3, Bauch C.T.4
1GlaxoSmithKline Canada, Mississauga, ON, Canada, 2GlaxoSmithKline, Mississauga, ON, 
Canada, 3GlaxoSmithKline Vaccines, Wavre, Belgium, 4University of Guelph, Guelph, ON, Canada
Objectives: Current trivalent influenza vaccines (TIVs) contain only one of the 
two currently circulating influenza B lineages (Victoria and Yamagata). Worldwide, 
in about half of all influenza seasons since co-circulation of the two B lineages 
commenced, the dominant B lineage did not match the one chosen for inclusion in 
the TIV. Quadrivalent influenza vaccines (QIVs) would help address this problem by 
including both B lineages each season. We modeled the impact of a country-wide 
switch from TIV to QIV on the yearly population-wide rates of influenza cases and 
influenza-associated events, in both Canada and the UK. MethOds: We calculated 
projections using a dynamic transmission model which incorporates four interact-
ing influenza strains, transmission-rate seasonality and age-specific mixing within 
the population, run over a 40-year time horizon. Influenza vaccine coverage rates in 
Canada and the UK were taken from public sources, TIV efficacy was obtained from 
a meta-analysis (Tricco et al., in press), and QIV efficacy was assumed to be similar 
to TIV without B lineage mismatch. Results: Across Canada, the model estimates 
that a switch from TIV to QIV would, in an average influenza season, avert 9% (rela-
tive) of influenza cases (= 237,000 cases), 9% (= 86,000) of general practitioner (GP) 
visits, 9% (= 12,000) of emergency room (ER) visits, 8% (= 2,500) of hospitalizations, 
and 7% (= 330) of deaths. Across the UK, the model estimates that 0.7% (= 70,000) 
of influenza cases, 0.8% (= 19,000) of GP visits, 0.8% (= 600) of ER visits, 0.8% (= 800) 
of hospitalizations, and 3% (= 270) of deaths would be averted. cOnclusiOns: In 
both Canada and the UK, a country-wide TIV-QIV switch is predicted to bring about 
a clear reduction in the burden of influenza. The relatively greater impact of the 
switch in Canada is due principally to that country’s higher vaccine uptake among 
people younger than 65 years.
simulation model of type 2 diabetes, based on the UKPDS 68 outcomes equations, 
was executed with and without the application of antithetic variates. The impact 
of the technique was evaluated through comparison of total cost and benefit esti-
mates, predicted over a long-term horizon of 40 years. Results: An approximate 
four-fold reduction was observed in the Monte Carlo Error (MCE) associated with 
estimated mean incremental costs and benefits, when antithetic variates were 
applied over 1,000 simulations of 1,000 individuals. For a fixed number of runs 
(1,000), the number of replicated individuals required to achieve 99% accuracy 
(MCE/mean< 1%) in incremental cost and benefit estimates fell from approximately 
500 and 550 respectively, to fewer than 50 with antithetic variates. Similarly, for 
a fixed cohort size (1,000) the same level of precision was produced with fewer 
than 10% of the simulation runs required otherwise. cOnclusiOns: The use 
of antithetic variates can improve the precision of modelling output; reducing 
the number of simulation runs and thus computation time required to perform 
analyses. The use of such variance reduction techniques should be pursued in the 
simulation of chronic conditions, as a means of achieving manageable run times 
and facilitating the extensive scenario and sensitivity analyses required as part 
of economic evaluations.
PRM63
MODELLING THE ADENOMA AND SERRATED PATHwAy TO COLORECTAL 
CANCER (ASCCA)
Greuter M.J.1, Xu X.M.2, Lew J.B.2, Dekker E.3, Kuipers E.J.4, Canfell K.2, Meijer G.A.1, Coupe V.M.1
1VU University, Amsterdam, The Netherlands, 2University of New South Wales, Sydney, Australia, 
3Academic Medical Center, Amsterdam, The Netherlands, 4Erasmus MC University Medical 
Center, Rotterdam, The Netherlands
Objectives: Most models developed for colorectal cancer (CRC) screening evalua-
tions are based on the adenoma-carcinoma pathway only. Currently, there is increas-
ing evidence that serrated lesions can also develop into CRC. This study aimed to 
develop a model that reflects both the adenoma-carcinoma pathway and the ser-
rated pathway to CRC and that includes characteristics of polyps. MethOds: The 
Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) model was built using 
the scientific literature, expert opinion, data from the Dutch COCOS trial and Dutch 
cancer registry data. A flexible model structure was chosen to examine the impact 
of two alternative natural history assumptions: (i) all CRCs arise from adenomas and 
(ii) 15% of CRCs arise from serrated lesions. The two model versions were calibrated 
manually using a systematic, step-by-step approach. Results: Calibration resulted 
in 19 parameter sets for the adenoma-carcinoma pathway and 13 for the serrated 
pathway, matching the age- and sex-specific adenoma and serrated lesion prevalence 
in the COCOS trial and several other intermediate model outcomes. For the first natu-
ral history assumption, progression rates from advanced adenoma to CRC between 
1.6% and 2.7% were found to produce model-based age-standardized incidence rates 
within the 95% confidence interval of the Dutch incidence in 2009. For the second 
assumption, these progression rates were between 1.3% and 2.2%. Mean duration 
from adenoma to CRC was 24 years. cOnclusiOns: The ASCCA model will be used 
to evaluate the (cost-)effectiveness of different screening and surveillance strategies 
for CRC. Future analyses will evaluate the upcoming Dutch screening program using 
the two calibrated model versions. The implication of different test accuracies for 
different types of polyps with their characteristics can be taken into account in a 
straightforward manner. Furthermore, the impact of structural as well as parametric 
assumptions concerning the serrated pathway can be addressed.
PRM64
MICROSIMULATION OR COHORT MODELLING? A CASE STUDy IN CHRONIC 
OBSTRUCTIvE PULMONARy DISEASE (COPD)
Lin F.1, Thomas S.2, Baldwin M.3
1Novartis, East Hanover, NJ, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 
3Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, UK
Objectives: Markov models are commonly used to study time dependent disease 
progression. While most models are cohort based, due to their limitation of dealing 
with heterogeneities, continuous variables, and dynamic strategies, individual-based 
microsimulation is being increasingly used. The objective was to compare microsimu-
lation to cohort approach in modeling COPD, while validating the two approaches 
against findings from TORCH trial. MethOds: We developed both models to study 
COPD progression in a cohort defined by the characteristics of TORCH patients. The 
microsimulation randomly generated a large number of patients and tracked each 
patient’s the lung function (FEV1), exacerbations, and mortality, based on individual’s 
characteristics and disease history. The cohort model included four COPD stages 
and death; it modeled exacerbations as events, assuming no impact on transitions 
or future exacerbations. Both models were populated by published data and results 
were compared against TORCH findings. Results: The mean decline in FEV1 over 
3-year was 126 ml in microsimulation, 49 ml in cohort model, compared to 117 ml in 
TORCH. The annual rates of moderate and severe exacerbations were 0.94 and 0.18 in 
microsimulation, 1.12 and 0.18 in cohort model, compared to 1.13 and 0.19 in TORCH. 
The 3-year mortality was 17.4% in microsimulation, 12.2% in cohort model, and 15.2% 
in TORCH. Microsimulation required simulating at least 3500 patients to obtain stable 
estimates, which took 4 minutes to run each scenario. It would take 300 hours to 
run 5000 scenarios for sensitivity analysis, while the cohort model took less than 1 
minute. cOnclusiOns: In COPD, patient heterogeneity and disease history can be 
conveniently captured in microsimulation, while parameter uncertainties are easily 
assessed using cohort approach. The cohort approach is simple to develop, but its 
inherent Markovian property cannot fully represent COPD pathology. Microsimulation 
is flexible in mimicking COPD progression, but it is computational expensive.
PRM65
SIMULATING PATIENT POPULATIONS – DIFFICULTIES IN CONTROLLING THE 
ROLL OF THE DICE
Teljeur C., O’Neill M., Murphy L., Harrington P., Ryan M.
Health Information and Quality Authority, Dublin, Ireland
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close to the Willingness to Pay threshold, Markov models should be analyzed with 
shorter cycle length or a DES approach adopted to ensure conclusions are robust.
PRM71
MODEL-BASED ECONOMIC EvALUATIONS IN ALzHEIMER’S DISEASE : A REvIEw 
OF MODELING METHODS
Marty R., Roze S.
HEVA HEOR, Lyon, France
Objectives: To review the modeling-based economic evaluations (MB2E) of 
acetylcholinesterase inhibitors (ACE) and memantine (MEM) used in the field of 
Alzheimer’s disease (AD). MethOds: A systematic literature search was carried 
out based on several electronic databases such as Medline or the Cochrane Library 
up to November 2012. Modeling frameworks used to depict the natural history of 
AD and incorporation of treatment effects were qualitatively described and com-
pared. Results: More than thirty MB2E were identified with several local adapta-
tions based on ten original modeling frameworks. First published MB2E were either 
Markov state-transitions models or partition failure time survival models while 
most recent MB2E relied on discrete events simulations. The hallmark of the disease, 
the cognitive dimension, was first introduced to model the disease progression 
mainly based on the Mini Mental State Examination (MMSE) scale. The two other 
fundamental-functional and behavioral-dimensions were taken into account as 
a second step. Models relied on distinct clinical milestones and risk equations to 
extrapolate intermediate clinical endpoints from clinical trials (mainly on cognition 
and function) into long-term final endpoints. These latter were delay in severity, 
loss of patient autonomy, institutionalization, burden of care and quality-adjusted 
life years. Differences occurred as well on the way inter-patient heterogeneity was 
incorporated with a trend towards more micro-simulations technics. Eventually, 
predictors and inter-relations between the several dimensions of the natural history 
of the disease seemed not to be fully captured in the model structures with chal-
lenging needs to assess the resulting potential biases. cOnclusiOns: Advanced 
modeling methods in the field of AD were being introduced to better capture the 
continuous, progressive and multivariate natural history of AD. Further work is war-
ranted given the emerging early diagnosis technics, neuropathological biomarkers 
and targeting therapies.
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THE COST-EFFECTIvENESS OF SEQUENTIAL FIRST- AND SECOND-LINE 
TREATMENTS IN METASTATIC RENAL CELL CARCINOMA USING REAL-wORLD 
DATA AND A PATIENT-LEvEL SIMULATION MODEL
de Groot S.1, Blommestein H.1, Redekop W.1, Oosterwijk E.2, Kiemeney L.2, Uyl- de G.root C1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Radboud University Medical 
Centre, Nijmegen, The Netherlands
Objectives: Previous cost-effectiveness analyses of targeted therapies in meta-
static renal cell carcinoma (mRCC) have been based on randomised trials and 
evaluate just one single treatment-line. The aim of this study was to estimate 
the real-world cost-effectiveness of sequential first- and second-line treatments 
for patients with mRCC using a patient-level simulation (PLS) model. MethOds: 
Based on patient-level data from a Dutch population-based registry, a PLS model 
was developed that comprised entities (i.e. patients with mRCC), attributes 
assigned to the entities (i.e. prognostic factors), and events (i.e. second-line treat-
ment or death). Patients were repeatedly simulated from the model and time-to-
event was estimated using a lognormal distribution. A separate sampling process 
was used to determine which type of event occurred. Time to death following 
second-line treatment was modelled using a Weibull distribution. Lifetime health 
care costs were modelled using patient-level data from the registry. Results: In 
current daily practice, 50% (341/686) of patients did not receive any targeted ther-
apy and 42% (291/686) received sunitinib as first-line therapy. In the second line, 
31% (33/107) were treated with sorafenib and 31% (33/107) with everolimus. Mean 
overall survival (OS) was 13.6 months and mean costs were € 69,622 for all patients. 
In a strategy where all patients are treated according to clinical guidelines, mean 
OS was 15.2 months and costs were € 91,059. This meant an increase in OS (1.6 
months) and costs (€ 21,437) compared to current practice, with an incremental 
cost-effectiveness ratio of € 159,107 per life-year gained. Probabilistic sensitiv-
ity analyses showed the robustness of these results. cOnclusiOns: A complete 
disease model and real-world data are essential in estimating real-world cost-
effectiveness. Our PLS model allows comparisons between treatment strategies 
spanning multiple treatment lines, which will ultimately help to reveal the optimal 
strategy. For example, guidelines-based treatment appears to increase both OS and 
costs compared to current daily practice.
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THE ROLE OF SIMULATION MODELING IN PLANNING LONG-TERM CLINICAL 
TRIALS IN TyPE 2 DIABETES
Foos V.1, Grant D.2, Palmer J.L.3, Lamotte M.4, McEwan P.5
1IMS Health, Basel, Switzerland, 2IMS Health, London, UK, 3IMS Health, Allschwil, Basel-
Landschaft, Switzerland, 4IMS Health HEOR, Vilvoorde, Belgium, 5Swansea University, Cardiff, UK
Objectives: Long-term cardiovascular outcomes studies are routinely under-
taken to demonstrate safety in all new diabetes therapies. Given that diabetes 
models are extensively validated to contemporary outcomes trials they offer the 
potential to inform on design of new trials. The objective of this study was to 
use an established diabetes model to explore the relationship between levels 
of glycaemic control, major adverse cardiovascular events (MACE) and sample 
size. MethOds: The IMS CORE Diabetes Model (CDM) a validated and widely used 
simulation model was initiated with patient level data (PLD) drawn from NHANES. 
The model was run with a five-year time horizon and the sample sizes required 
to detect a difference in MACE (defined as myocardial infarction, stroke or CV 
death) at the 5% level as a function of change in HbA1c evaluated. Results: PLD 
from NHANES was available on 1853 subjects with mean (SD) age 63.6(12.1) years, 
53% male, duration of diabetes 9.6(8.5) years, baseline HbA1c 7.4% (1.8), systolic 
PRM68
HEALTH ECONOMIC ANALySIS OF PNEUMOCOCCAL vACCINATION – ExAMPLE 
FROM BULGARIA
Manova M.1, Savova A.1, Petrova G.2
1Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University of Sofia, Sofia, 
Bulgaria
Objectives: To evaluate cost-effectiveness of pneumococcal vaccination of 
children with 10-valent (PHiD-CV) compared with 13-valent pneumococcal con-
jugate vaccine (PCV-13). MethOds: A Markov cohort model which simulates in 
a Bulgarian birth cohort the disease process of invasive disease (ID) (meningitis 
and bacteremia), community acquired pneumonia (CAP), and acute otitis media 
(AOM) over life-time caused by S. pneumoniae and non-typeable Haemophilus 
Influenzae (NTHi). The cohort model essentially considers the perspective of the 
health care payer. Bulgarian specific epidemiological and demographic data and 
data from other country sources were obtained for the model. Base case assump-
tions include estimates of pneumococcal and NTHi infection rates as well as vaccine 
efficacy based on published literature, 94% vaccine coverage, herd protection and a 
(3+1) vaccination schedule. One-way sensitivity analyses performed to assess the 
impact of changes in key model assumptions. Results: PHiD-CV and PCV-13 are 
projected to prevent 29.4 and 29.9 cases of invasive diseases respectively and 437 
and 434 bacteremia hospitalizations respectively . PHiD-CV in comparison with 
PCV-13 is projected to prevent additional 9393 cases of AOM, 426 myringotomies 
and 2801 GP visits. Vaccinating a birth cohort with PHiD-CV is expected to gener-
ate 41 more QALYs compared to PCV-13. The estimated total savings for health 
care system are 1.77 mil Euro. The PHiD-CV is dominant in comparison with PCV-
13. Sensitivity analyses indicate that GP visits for AOM and efficacy vs. AOM due 
to Streptococcus Pneumonia non-Vaccine Types Sp nVT have biggest impact on 
results. cOnclusiOns: Overall, PHiD-CV is expected to have betterI impact and 
under the given assumptions, PHiD-CV dominates PCV-13 because it also has a 
larger cost offsets.
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CORRELATING COST EFFECTIvENESS OUTPUT wITH PATIENT LEvEL DATA 
INPUT vIA THE IMS CORE DIABETES MODEL (CDM)
McEwan P.1, Foos V.2, Palmer J.L.3, Lamotte M.4, Grant D.5
1Swansea University, Cardiff, UK, 2IMS Health, Basel, Switzerland, 3IMS Health, Allschwil, Basel-
Landschaft, Switzerland, 4IMS Health HEOR, Vilvoorde, Belgium, 5IMS Health, London, UK
Objectives: Analysing patient level data (PLD) within cost-effectiveness (CE) mod-
els offers the potential to better understand patient profiles associated with greatest 
health economic benefit. The objective of this study was to contrast the application 
of average treatment efficacy profiles compared to patient level treatment efficacy in 
assessing the CE of insulin glargine (IG) versus Neutral protamine Hagedorn (NPH) in 
Type 2 diabetes mellitus (T2DM) MethOds: This study used the IMS Core Diabetes 
Model (CDM), a validated and established diabetes model to evaluate the CE of 
switching to IG from NPH using published effectiveness data from a large population 
based cohort. Average HbA1c reduction after switching from NPH was -0.18% and 
weight gain was 0.5kg. Annual diabetes specific therapy cost was £573 (IG) versus 
£320 (NPH). A PLD extract was obtained from NHANES and the CE of IG versus NPH 
assessed applying (a) overall mean treatment effects (MTE) and (b) baseline HbA1c, 
BMI and sex adjusted treatment effects (ATE). Costs (2012 UK£) and benefits were 
discounted at 3.5%. Results: For the MTE and ATE scenarios, the incremental cost 
effectiveness ratio (ICER) was £28,925 and £57,279 respectively. For MTE scenario, 
765 (41.1%) of subjects were CE at the £20,000 willingness to pay (WTP) and 47 IG 
subjects (6.1%) were both cost saving with increased health benefit. Using ATE, 
525 (28.2%) were CE at the £20,000 WTP threshold with 164 (31.2%) of IG subjects 
identified as both cost saving with increased health benefit. The odds ratio (OR) of 
being both cost saving with greater health benefit was significantly associated with 
age, OR= 0.89(0.87-0.93) and baseline HbA1c, OR= 6.11 (4.64-8.03). cOnclusiOns: 
The identification of patient characteristics associated with greater potential for 
health gain and reduced cost is an important goal. The analysis of PLD alongside 
simulation model output provides an additional mechanism for informing health 
care decision-making.
PRM70
COMPARISON OF MARKOv AND DISCRETE EvENT SIMULATION MODELING 
TECHNIQUES wITH APPLICATION TO COST EFFECTIvENESS ANALySES
Chrosny W.(1, Stevenson M.2, Munzer A.1
1TreeAge Software, Inc, Williamstown, MA, USA, 2University of Sheffield, Sheffield, UK
Objectives: To assess the bias introduced to absolute costs, absolute QALYs and 
the incremental cost effectiveness ratio (ICER) associated with Markov models, 
compared with discrete event simulation (DES) models. To investigate how such 
biases are a function of cycle length and half-cycle correction. MethOds: A hypo-
thetical three health state model was constructed using both Markovian and DES 
approaches. Costs and utility were assigned to each health state and the ICERs 
between two treatment strategies were estimated. Six Markov models using dif-
ferent cycle lengths (1 month, 3 month, 1 year), and with and without half cycle 
correction were constructed. Differences in the absolute costs and QALYs generated 
between each Markov model were compared with the DES approach and the ICERs 
generated by each model were compared. Results: Markov model simulation was 
shown to introduce biases in the absolute costs and QALYs when compared with a 
DES approach. The bias was related to the duration of the time cycle with the results 
converging to the DES values as the time cycle was reduced. The initial bias in cost 
fell from 14% to less than 1%; QALY bias was consistently below 1%. The ICERs show 
bias between 2.4% and 9.6% when using a 1 year cycle and between 0.6% - 5.4% when 
using a 1 month cycle. The half-cycle correction reduced absolute bias between 2% 
- 10%, the ICERs were not affected. The time cycle duration was the primary param-
eter in reducing bias. cOnclusiOns: Markov models introduce bias due to the 
simplifying assumptions of fixed cycle length and half cycle correction; DES models 
do not suffer the same biases. It is suggested that when the ICERs produced are 
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structural equation models (ESEM), a method that can be considered a strong 
alternative to the exclusive use of exploratory factor analysis (EFA) and confirma-
tory factor analysis (CFA) in patient related outcomes measurement. By combining 
the steps of EFA and CFA in one unified approach, ESEM saves significant time 
and effort usually invested in separate iterations of EFA and CFA. MethOds: 
One hundred replications of ESEM models were carried out for variations of sam-
ple size and latent factors. Simulation study 1 examined the behavior of ESEM 
parameter estimates by changing the values of rotation constant (0.01, 0.001 and 
0.0001) in Geomin rotation for a three-factor single group model and for N= 300 and 
1000. Simulation study 2 evaluated the behavior of ESEM parameter estimates for 
multi-group models using three- and four-factor models for N= 150 and 500 per 
group. Bias, Mean Square Errors (MSE) and standard errors were used to evaluate 
accuracy of parameter recovery. Item parameters were generated from 27 items 
belonging to a pilot graduate creativity instrument. Results: For study 1, Geomin 
rotated parameter estimates of factor loadings, means and covariances produce 
higher MSEs than the follow up Target rotations. In study 2, the parameter esti-
mates for ESEM Geomin show small sample size bias for some parameters while 
the standard errors produced correct coverage for all parameters under Target 
rotation method for large N= 500 per group. cOnclusiOns: Overall, there was 
accurate recovery of parameter estimates in the smallest sample of 300 especially 
in the multi-group models specifically when Geomin rotations were employed. 
This bodes well for analysis of real data and for the study of measurement invari-
ance across groups. Future studies could include the examination of number of 
items affecting recovery of parameter estimates.
PRM77
METHODOLOGICAL APPROACHES FOR MODELING CARDIOvASCULAR EvENTS 
IN COST-EFFECTIvENESS ANALySES BASED ON OUTCOME TRIALS
Kansal A.R.1, Zheng Y.1, Palencia R.2, Ruffolo A.2, Hass B.2, Sorensen S.1
1Evidera, Bethesda, MD, USA, 2Boehringer Ingelheim GmbH, Ingelheim, Germany
Objectives: Historically, cardiovascular (CV) endpoints, including myocardial 
infarction and stroke, have often been included indirectly in cost-effectiveness 
analyses (CEA) based on surrogate endpoints from clinical trials, such as cho-
lesterol levels, blood pressure or glycemic control. With the availability of out-
comes trials sufficiently powered to show differences in CV endpoints, there 
is an increasing need to incorporate these data directly into CEA. This study 
investigated approaches available in the published literature for modeling CV 
endpoints directly based on outcomes data. MethOds: A systematic review of 
cost-effectiveness models for cardiovascular interventions published in the past 
5 years was conducted in PubMed and Embase using a predefined search strategy. 
Only studies in English language directly integrating trial data on CV endpoints 
from randomized clinical trials were considered. For each study that met the 
inclusion criteria, clinical input characteristics and the modeling approach were 
summarized and evaluated. Results: Twenty-three papers were identified for 
final review, including studies of antithrombotic, heart failure, and lipid lowering 
therapies. Methodologically, decision trees, Markov models (cohort and individual 
patient), discrete event simulations as well as hybrids of these approaches were 
used. Event rates were incorporated either as constant rates, time-dependent 
risks, or risk equations based on patient characteristics. Although potentially more 
accurately reflecting the trial data, risks dependent on time and/or patient charac-
teristics were only used where feasible (major event rates > 1%/year) and practical 
(models with fewer than seven health states). Models incorporating data from 
infrequent events or with numerous health states generally preferred constant 
event rates. cOnclusiOns: When the risk of CV events is low and/or the disease 
state is explicitly modeled in detail, constant events rates were most common. 
For heterogeneous populations or when CV event risk is high, simpler model 
structures were generally accompanied by patient- or time-dependent event rates 
where permitted by the available data.
PRM78
TwO-wAy SENSITIvITy ANALySIS: SHOwING THE IMPACT OF CORRELATED 
PARAMETERS IN COST-EFFECTIvENESS ANALySES
Heemstra L.1, Skaltsa K.2, Van Engen A.1
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Barcelona, Spain
Objectives: Correlated parameters are a common feature in economic 
models, but no standard sensitivity analysis (SA) exists to show their impact on 
cost-effectiveness. The one-way SA only varies one parameter at a time and ignores 
correlation while the probabilistic SA is typically used to address overall uncertainty. 
The objective of this study is to propose a standard method for visualising the 
impact of one variable consisting of two correlated parameters in cost-effectiveness 
analysis. MethOds: A model evaluating the cost-effectiveness of a cancer product 
was used. Using the Cholesky decomposition, 1,000 correlated random draws were 
generated from the distributions of the intercept and slope of a linear function 
determining survival in the model. Each pair was inputted in the model to yield the 
percentage of simulations below accepted thresholds. Results were visualised using 
R in a scatter plot with both parameters on a separate axis. Shaded areas repre-
sented the percentage of simulations below accepted cost-effectiveness thresholds 
and an ellipse was added representing 80% of the simulated parameter combina-
tions. A conventional one-way SA was performed for comparison. Results: The 
one way SA found wide ranges of incremental cost-effectiveness ratios (ICER) for 
the intercept and slope parameters (£10,000 - £50,000 per QALY gained). The method 
described above found that 78% of the simulated pairs resulted in ICERs below 
£20,000 per QALY gained, and 93% in ICERs below £30,000. The scatter plot visualised 
the combined uncertainty and their impact on the ICER. A limitation is that the 
visualisation only allows for 2 correlated parameters. Also, the use of R to generate 
the graph complicates incorporation of this SA in Excel models. cOnclusiOns: 
A method was demonstrated to show the impact of correlated parameters in cost-
effectiveness analyses. This method may be especially helpful when assessing the 
uncertainty around parametric survival fits.
blood pressure 134.9mmHg (22.0) and total cholesterol of 189.8 mg/dl (48.7). The 
expected five-year cumulative MACE event rate was 9.2% and HbA1c reductions 
of 0.5%, 1.0% and 1.5% produced relative risk reductions of 7.5%, 9.0% and 10.6% 
respectively. At the 5% level, the number of patients required to detect a signifi-
cant reduction in MACE events was 17,786, 11,758 and 1,912 for HbA1c reductions 
of 0.5%, 1.0% and 1.5% respectively. On average, each half-unit change in HbA1c 
required an additional 7,937 subjects to detect a significant difference in MACE 
event rate. cOnclusiOns: Given the requirement to extensively validate health 
economic models to contemporary outcomes studies it is an obvious extension 
to use these models to inform on the design of clinical trials. These models offer 
considerable flexibility in the evaluation of sample size requirements in terms of 
expected changes in modifiable risk factors.
PRM74
DEvELOPING REALISTIC PATHwAyS IN COST-EFFECTIvENESS MODELS FOR 
PSORIASIS: wHAT TO DO wHEN A BIOLOGIC FAILS
Mauskopf J.A.1, McBride D.2, Mallya U.3, Feldman S.R.4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Manchester, 
UK, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Wake Forest University, 
Winston-Salem, NC, USA
Objectives: Clinical studies indicate switching to a second biologic or combination 
therapy with an immunosuppressant after failure of first biologic can be effective 
in patients with moderate to severe plaque psoriasis not responding to the first bio-
logic. MethOds: A systematic literature review was performed to assess treatment 
pathways included in cost-effectiveness (CE) estimates of biologic treatments of mod-
erate to severe psoriasis and compare these pathways with those recommended 
in psoriasis treatment guidelines. Results: Twenty-one CE modeling studies were 
identified. Of these 10 estimated incremental cost per responder for > = 1 biologics 
over time horizons varying from 12 weeks to 18 months. Treatment pathways were 
considered not relevant in these studies. In 11 studies with time horizons up to 10 
years where treatment pathways were considered, 5 studies included a switch to non-
systemic therapy or best supportive care after failure of the initial biologic. In 6 of 11 
studies, failure of the initial biologic was followed by monotherapy with a second-line 
biologic - one of the recommendations in current treatment guidelines. In only 1 of 
6 studies that considered treatment sequencing was the efficacy of the second-line 
biologic adjusted downwards compared to first line treatment. None of the cost-
effectiveness analyses included dose titration with the first-line biologic or combina-
tion therapy with a biologic plus methotrexate or phototherapy after failure of the 
first-line biologic as recommended in some treatment guidelines. cOnclusiOns: 
In most long term CE studies, failure of the first biologic was followed by biologic 
monotherapy of the second, without efficacy adjustment. Some treatment guidelines 
support dose titration or combination treatment after failure of a first-line biologic. 
Nevertheless, these options were not included in the published CE models with time 
horizons up to 10 years. For decision makers there may be a need for more extensive 
models where such strategies are allowed.
PRM75
DECISION ANALyTIC MODELS USED IN ESTIMATING THE COST-EFFECTIvENESS 
OF DRUG-ELUTING STENTS vERSUS BARE-METAL STENTS: A SySTEMATIC 
REvIEw
Burgers L.T., Redekop W.K., Severens J.L.
Erasmus University Rotterdam, Rotterdam, The Netherlands
Objectives: Drug-eluting stents (DES) and bare-metal stents (BMS) are both used 
widely in percutaneous coronary interventions. However, cost-effectiveness analy-
ses of DES versus BMS conflict about whether the reduction in repeat revascu-
larizations of DES versus BMS offsets the initial higher treatment costs of DES. A 
systematic review was performed to examine whether modelling methods influ-
enced the cost-effectiveness of DES versus BMS. MethOds: We reviewed modelling 
studies published until January 2012 that compared the costs and consequences 
of DES versus BMS. General information (e.g. funding) and modelling methods 
used, related to the framing of the economic evaluation (e.g. population and inter-
vention characteristics, time horizon) and parameterisation of the models were 
extracted from the relevant studies for each of the individual analyses performed 
in the studies. Associations between these characteristics and the incremental 
costs and effectiveness were explored using regression analysis. We also exam-
ined whether the results were associated with the quality of the models based on 
the Philips et al. (2006) checklist. Results: Fifteen eligible studies accounted for 
498 separate analyses, in which the incremental cost-effectiveness ratios ranged 
from DES being dominated by BMS to DES being dominant. The most important 
predictors significantly associated with these differences were several population 
and procedure characteristics, funding and assumptions concerning stent efficacy. 
The results and conclusions of individual studies corresponded with the findings 
of this meta-level systematic review. Overall quality of the models was moderate 
(55%±17%) and significantly negatively associated with repeat revascularizations 
avoided. cOnclusiOns: Models are important to obtain valid estimates of the 
cost-effectiveness of DES versus BMS, and framing decisions (e.g. time horizon) 
and quality of the models both influence incremental costs and effects. The most 
influential parameters are identified with this systematic review and we showed 
the need of examining those parameters and of performing a quality check when 
interpreting the results.
PRM76
ExPLORATORy STRUCTURAL EQUATION MODELS: A SIMULATION STUDy 
ExPLORING GEOMIN AND TARGET ROTATION TECHNIQUES ON vARIATIONS OF 
ESEM MODELS
Sen R.
Adelphi Values, Boston, MA, USA
Objectives: This simulation study evaluates the impact of Geomin and Target 
rotation criteria on factor loading matrices in the recently developed exploratory 
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cost-effectiveness frontier generated by the average costs and benefits of each 
technology may mask inter-dependencies between technologies. Parameter val-
ues that render one technology efficient may render another inefficient, and vice 
versa. There can also be uncertainty about which interventions appear on the 
frontier, and the adoption of approaches to select competing interventions solely 
on the basis of being on the efficiency frontier may be unreasonable.
PRM82
vALIDATING AN INDOLENT NON-HODGKIN’S LyMPHOMA (NHL) COST-
EFFECTIvENESS ANALySIS MODEL USING TwO SOFTwARE TOOLS: KEy 
IMPLEMENTATION CONSIDERATIONS AND RESULTS
Wehler E.A.1, Bilir S.P.2, Bertwistle D.3, Leyva V.4, Munakata J.2
1IMS Health, Alexandria, VA, USA, 2IMS Health, San Francisco, CA, USA, 3IMS Health, London, 
UK, 4IMS Health, Mexico City, Mexico
Objectives: The ISPOR-SMDM Modeling Good Research Practices Task Force 
highlights the importance of model transparency and validation, including 
cross validation, as a means to establishing trust and confidence in economic 
models. (1) To investigate how a technical model validation can be conducted by 
reconstructing a previously-developed Microsoft Excel cost-effectiveness model 
using TreeAge; and, (2) to validate the model by comparing the results of two 
implementations. MethOds: An Excel-based cohort model on indolent NHL was 
reconstructed in in TreeAge using the same model structure, clinical inputs, and 
costing assumptions. Lifetime costs, life-years, quality-adjusted life-years, and 
incremental cost-effectiveness ratios (ICERs) were projected and compared for 
bendamustine-rituximab (Ben-R) versus fludarabine-rituximab (Fdb-R) in relapsed 
indolent NHL patients in Colombia. All costs were in 2013 Colombian pesos. The 
base-case results and sensitivity analyses were compared between the two soft-
ware tools and key implementation considerations were identified. Results: 
Key differences in the two software tools were identified and implementation 
differences will be described, including handling of survival inputs and applica-
tion of one-time and per-cycle costs. The TreeAge model produced more favorable 
results compared to the Excel model. The total costs for Ben-R and Fdb-R were 
$223,400,660 and $208,115,352 in the TreeAge model, respectively, while in the 
Excel model they were $291,192,912 and $260,463,392. The ICERs were $11,582,974/
LY and $13,815,417/QALY in the TreeAge model and $23,286,360/LY and $27,956,124/
QALY in the Excel model. However, once the differences between the two models 
were accounted for in implementation, the reconstructed TreeAge model produced 
approximately the same results compared to the original Excel model (23,381,795/
LY vs. $23,286,360/LY). cOnclusiOns: There are inherent differences in model 
implementation in Excel vs. TreeAge that should be considered when performing 
double implementation and when interpreting the model results. Model valida-
tion using two software tools is a practical way to ensure proper and intended 
implementation.
PRM83
RELATIONSHIP BETwEEN MODELLING APPROACH AND REPORTED OUTCOMES: 
CASE STUDIES OF MODELS FOR THE TREATMENT OF SCHIzOPHRENIA
von Schéele B.1, Mauskopf J.A.2, Brodtkorb T.H.1, Ainsworth C.3, Galani Berardo C.4, Patel A.5
1RTI Health Solutions, Lund, Sweden, 2RTI Health Solutions, Research Triangle Park, NC, USA, 
3RTI Health Solutions, Manchester, UK, 4F. Hoffmann - La Roche Ltd., Basel, Switzerland, 5King’s 
College London, London, UK
Objectives: Different modeling approaches have been used to estimate the cost-
effectiveness of antipsychotics used to reduce psychotic symptoms of schizo-
phrenia. This study systematically reviewed schizophrenia modelling studies, to 
examine the relationship between the modeling approach used in schizophrenia 
studies and their reported outcomes. MethOds: A systematic literature review of 
MEDLINE, EconLit, Embase, and the Cochrane Library and an Internet search iden-
tified published results of schizophrenia modeling studies from 2000 to 2011. Two 
independent reviewers performed searches according to a prespecified protocol 
limited to English-language articles from any country. Results: Eighty-three pub-
lications reported 80 individual modelling studies that met the inclusion criteria. 
Fifty-seven studies reported results of 71 pairs of antipsychotic drug comparisons 
(drug A vs. drug B) as incremental cost-effectiveness ratios (ICERs), such as cost per 
quality-adjusted life-year (QALY), which allowed a comparison of results. The major-
ity of the economic evaluations used a Markov (23 studies) or decision-tree model 
23 studies); 9 studies used a discrete-event simulation (DES) model, and 2 studies used 
a microsimulation model. Among the 11 comparisons with contradictory results, we 
focused on the following drug comparisons of atypical antipsychotics with the most 
studies: risperidone long-acting injection versus oral olanzapine, oral risperidone ver-
sus oral olanzapine, oral risperidone or oral olanzapine versus ziprasidone, and oral 
olanzapine versus oral aripiprazole. Overall, model structure, time horizon, and patient 
population did not affect study results. Differences among studies with contradictory 
results generally reflected definition of response and relapse rates in the health states, 
validity of clinical data sources for transition probabilities, and assignment of utilities 
to estimate QALYs. cOnclusiOns: The cost-effectiveness results of the majority of 
models were in agreement regardless of the model structure. In models with contra-
dictory results, most differences could be explained by definition of response, relapse, 
discontinuation, or adverse-event rates and/or by the selection of sources.
PRM84
LITERATURE REvIEw AND ASSESSMENT TO POPULATE A DECISION-ANALyTIC 
MODEL EvALUATING A NOvEL PROGNOSTIC IN EARLy LUNG CANCER
Stenehjem D.1, Jiao T.2, Rhien T.2, Bellows B.K.2, Kaldate R.R.3, Jones J.3, Brixner D.4
1University of Utah/ University of Utah Hospitals & Clinics, Salt Lake City, UT, USA, 2Department 
of Pharmacotherapy, University of Utah, Salt Lake City, Utah, USA, Salt Lake City, UT, USA, 
3Myriad Genetic Laboratories, Inc., Salt Lake City, UT, USA, 4University of Utah, Salt Lake City, 
UT, USA
Objectives: A novel prognostic test is being developed to predict cancer-related 
mortality in early non-small cell lung cancer (NSCLC) to inform the use of adju-
PRM79
ASSESSING THE SIGNIFICANCE OF HBA1C DURABILITy IN COST 
EFFECTIvENESS ANALySIS OF 2ND LINE ORAL THERAPIES IN THE 
MANAGEMENT OF TyPE 2 DIABETES
Foos V.1, McEwan P.2, Palmer J.L.3, Lamotte M.4, Grant D.5
1IMS Health, Basel, Switzerland, 2Swansea University, Cardiff, UK, 3IMS Health, Allschwil, Basel-
Landschaft, Switzerland, 4IMS Health HEOR, Vilvoorde, Belgium, 5IMS Health, London, UK
Objectives: Due to the progressive nature of type 2 diabetes mellitus (T2DM), 
therapy escalation or intensification is often required to maintain acceptable 
levels of glycaemic control. The objective of this study was to assess how dif-
ferential dual therapy failure rates influence the cost effectiveness (CE) results in 
T2DM. MethOds: This study used the IMS Core Diabetes Model (CDM), a validated 
and established diabetes model, to evaluate the CE of metformin+ sulphonylurea 
(M+S) compared to metformin + DPP-4 (M+D). Efficacy data for dual therapy was 
sourced from a published systematic review; HbA1c and BMI change of -0.8% and 
0.199kg/m2 (M+D) and -0.79% and 0.707kg/m2 (M+S) respectively were applied. 
Rates of severe hypoglycaemia were 0.1612 and 1.538 per 100 patient years and 
4.596 and 68.769 per 100 patient years for non-severe events in M+D and M+S 
respectively. Insulin rescue therapy was initiated at an HbA1c threshold of 7.5%. 
Base case analysis assumed M+D and M+S had the same HbA1c durability; lifetime 
CE was assessed assuming improvement in durability favouring M+D applied 
in 10% increments with costs (US$) and benefits discounted at 3.5%. Results: 
In the base case analysis, annual HbA1c increase was 0.26% with mean time 
to therapy escalation of 5 years; and a predicted cost per quality adjusted life 
year (QALY) of $211,948. Mean annual increments in HbA1c for M+D of 0.182%, 
0.13% and 0.1% were necessary to achieve costs effectiveness at willingness to 
pay (WTP) thresholds of $100,000, $70,000 and $50,000 respectively. Published 
HbA1c durability for M+D of 0.052% per year was associated with a cost per QALY 
of $33,427. cOnclusiOns: This analysis demonstrates that the annual rate of 
increase in HbA1c exerts considerable influence over predicted CE and is therefore 
an important variable to study when assessing the CE of new interventions for 
the management of T2DM.
PRM80
NUTRIECONOMIC ExPLORATORy ASSESSMENT OF A DAILy CONSUMPTION OF 
PLANT STEROLS-ENRICHED DAIRy PRODUCTS ON STATIN’S INITIATION DELAy: 
A CONSUMER PERSPECTIvE APPROACH
Bruckert E.1, Durand-Zaleski I.2, Emery C.3, Lafuma A.3, Gagneau M.4
1APHP Pitié-Salpetrière, Paris, France, 2Santé Publique URCEco APHP, Créteil, France, 3Cemka 
Eval, Bourg La Reine, France, 4Danone Research, Palaiseau, France
The efficacy of plant sterols in reducing plasma LDL-cholesterol has been dem-
onstrated. In 2009, the European Food Safety Agency stated that for an intake of 
1.5-2.4g/day plant sterols, an average reduction of LDL blood cholesterol from 7% 
to 10.5% can be expected and such a reduction is of biological significance in terms 
of reduced risk of coronary heart disease. In France, the consumption of plant-
sterols enriched products (PSEP) was part of the official dietary recommendations 
for hypercholesterolemic subjects when the study was designed. Objectives: 
The objective was to assess the cost-effectiveness of a daily consumption of PSEP, 
in the context of a healthy diet, on statin’s initiation delay from the consumer 
perspective, in the eligibleat risk French population. MethOds: A 1 year cycle 
Markov model was built to estimate the benefit (i.e. delay/avoid statins’ initiation) 
in a French population aged between 45 and 65 years and at risk of drug treatment 
according to the French Drug Agency recommendations. Information on the evolu-
tion of cholesterol level and the different cardiovascular disease risk factors was 
retrieved in the literature. Costs of statin treatment duration avoidance (i.e. price 
of PSEP fully paid by the consumers) was estimated according to age and gen-
der. Results: The eligiblepopulation included in the model was respectively 49% 
and 66% among the French male and female population between [45;65 y]. Based 
on the selected assumptions, and assuming that healthy diet is already integrated 
in lifestyle habits, daily cost per statin free life year due to substitution of usual 
dairy product by a PSEP was estimated at 0.71€ /day and 1.01€ /day respectively for 
male and female. cOnclusiOns: This exploratory work allowed getting a first 
estimation of the cost-effectiveness of the daily consumption of PSEP, from the 
consumer perspective in accordance with official dietary recommendations for 
cholesterol management.
PRM81
GENERATING THE COST-EFFECTIvENESS FRONTIER wHEN COSTS AND/OR 
BENEFITS ARE CORRELATED ACROSS STRATEGIES
Teljeur C., O’Neill M., Harrington P., Ryan M.
Health Information and Quality Authority, Dublin, Ireland
Objectives: The cost-effectiveness efficiency frontier is typically generated by 
plotting the costs and benefits for a variety of technologies, often summarised 
as the mean across a large number of simulations. However, the mean across 
simulations may mask correlations between technologies within simulations. We 
sought to investigate these issues using a HTA comparing 19 different interven-
tions. MethOds: We compared 19 different breast cancer surveillance strategies 
for women aged less than 50 years with a BRCA1 mutation. We calculated the 
cost-effectiveness efficiency frontier for 5,000 simulations and also based on the 
mean costs and benefits for each strategy. We also investigated the probability 
of a strategy appearing on the frontier and correlations between whether or not 
different strategies appeared on the frontier. Results: The efficiency frontier 
based on means included 6 strategies. This was the cost-effectiveness efficiency 
frontier in only 22 (0.44%) of 5,000 simulations. Forty four other frontiers were more 
likely to be generated by simulations. Two strategies not on the frontier of means 
had a substantial probability of being on the frontier. Some strategies were nega-
tively correlated such that the appearance of one strategy on the frontier never 
or seldom co-occurred with another. These negative correlations also occurred 
between strategies that appeared on the frontier of means. cOnclusiOns: The 
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ExTERNAL vALIDATION OF THE SyREON DIABETES MODEL
Zsólyom A.1, Merész G.2, Nagyjánosi L.2, Nagyistók S.2, Nagy B.1, Kaló Z.1, Vokó Z.2
1Eötvös Loránd University, Budapest, Hungary, 2Syreon Research Institute, Budapest, Hungary
Objectives: The Syreon model was developed to predict the long term effects 
of screening, treatment and control of type 2 diabetes. After a successful internal 
validation the model’s outcomes needs to be compared to outcomes of cohorts that 
were not used for the modeling exercise. The objective of this study was to demon-
strate the methods and results of the external validation. MethOds: As a first step, 
we identified the applicable clinical trials and cohort studies which had not been 
used to build the model and simulated the patient cohorts for each study according 
to the published demographic, epidemiologic characteristics and treatment pat-
terns. The incidence rates of the predicted and observed outcomes were calculated 
for comparison and the results were evaluated using statistical methods and expert 
opinion. Results: 92 validation analyses were performed. The differences between 
the estimated and measured values of the incidences were within the range of 
44% and -100%. The slope of the fitted linear regression line was 0.5326 while the 
R2 value was 0.6956. The macular oedema submodel presented the best fit and the 
estimated values from the foot ulcer submodel had the lowest accuracy compared 
to values observed in other studies. cOnclusiOns: In overall the model performed 
well, however it frequently underestimated the incidence of the outcomes observed 
in the studies. This is most likely due to the limited information about the patient 
characteristics from the studies under evaluation. In most cases the information 
published about the population characteristics, treatment patterns and effective-
ness were not sufficiently detailed to precisely match the model’s input parameters. 
Without sufficient information average values were used as input parameters, and 
this way the model presumably simulated healthier patient cohorts than the ones 
participated in the studies.
PRM88
DISENTANGLING EFFECTS ON FATAL AND NON-FATAL CARDIOvASCULAR 
EvENTS OvER TIME
Thurston S., Van Hout B.
Pharmerit Ltd., York, UK
Objectives: Within acute coronary syndromes (ACS), the risk of experiencing fatal 
and non-fatal cardiac events is highest immediately after diagnosis and decreases 
over time. Visual inspection of survival curves from pivotal ACS trials suggest three 
potential risk periods. The highest risk (unstable disease) period typically lasts up to 
10 days from diagnosis. Patients then become more stable but are still at a high risk 
of events until approximately 30 days from diagnosis. Beyond 30 days patients are 
considered stable and at a lower risk of events. Different agents may be best suitable 
for different periods and may affect different events. The objective of this research is 
to estimate a model which enables the effects on fatal and non-fatal events follow-
ing an ACS episode to be disentangled and that distinguishes between periods of dis-
ease without accurately knowing how long these periods are. MethOds: A Markov 
model is estimated which distinguishes between three time periods and between 
fatal and non-fatal events. A likelihood function is derived as well as a Bayesian pro-
cedure to estimate the model parameters. The approach is tested using simulated 
data. Subsequently, event free survival data and overall survival data comparing 
ticagrelor with clopidogrel are taken from the Kaplan-Meier curves presented in the 
publication of the PLATO trial and model parameters are estimated based on these 
data. Results: Using simulated data the model mimics the data generating process 
perfectly and the approach seems quite powerful in distinguishing periods and dif-
ferences with patient numbers of 500 and above. cOnclusiOns: When applied to 
the PLATO study we conclude from the model that ticagrelor lowers the probability 
to experience an event in the unstable and stable high risk disease periods.
PRM89
A DE NOvO ECONOMIC MODEL TO ASSESS THE COST AND QUALITy OF LIFE 
CONSEQUENCES OF AN INTERvENTION FOR LEvODOPA INDUCED DySKINESIA 
AMONGST PATIENTS wITH PARKINSON’S DISEASE
Bhattacharyya S.1, Sacco P.2, Shirore R.M.1, Sonathi V.1, Thomas S.2
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA
Objectives: Emergence of long-term side effects of treating Parkinson’s disease 
(PD) patients with levodopa, particularly dyskinesia (levodopa induced dyskinesia - 
LID), limit the ability to optimally treat symptoms and consequences of PD. PD-LID 
interferes with performance of activities of daily living, ambulation and balance 
and increases health care costs. There are no approved treatments and no stud-
ies examining cost-effectiveness of an intervention for PD-LID. Objective of the 
present study is to develop a de-novo economic model to identify the value drivers 
for a drug to be cost-effective for treatment of PD-LID. MethOds: The model com-
bines a short-term (6 months) decision tree, to determine initial response to the 
drug, with a long-term Markov approach to model transition of patients across LID 
severity over lifetime. The model classifies LID severity using modified Abnormal 
Involuntary Movement scale (mAIMS) with disease states defined as mild (0-12), 
moderate (13-18) and severe (19-24). Disease state specific costs included costs 
of drug treatments, consultations/visits, paramedical services, laboratory tests, 
radiological examinations, hospitalizations, community/social services and 
unpaid services. State specific utilities were calculated and assigned based on 
literature. Results: The model suggests that initial response to the treatment, 
ability to improve and halt worsening dyskinesia health states are the greatest 
value drivers of the treatment for PD-LID. More than 90% of costs were driven 
by medical costs. A treatment for PD-LID that results in 6-month response rate 
of at least 50%, 25% increase in the probability of dyskinesia improving and 25% 
reduction in the probability of dyskinesia worsening results in a 0.28 QALY gain 
per patient. cOnclusiOns: This economic analysis suggests that a health care 
intervention that could improve the clinical parameters of dyskinesia can have 
significant beneficial impact on costs and utilities. Further studies are required 
vant chemotherapy (ACT). The collection and assessment of data inputs for a U.S. 
economic model evaluating this prognostic will be reported. MethOds: Medline 
and Tuft’s CEA Registry were searched for model parameters using the following 
terms and MeSH headings: NSCLC, adjuvant chemotherapy, recurrence, utilization, 
economics, cost, quality of life, utility, cost-effectiveness/-utility/-benefit. Inclusion 
criteria were randomized controlled trials (RCTs), meta-analyses, heath technology 
assessments, North American and European studies, quality of life analyses, and 
early lung cancer. Results were limited to full text and English articles. We also 
assessed relevant references listed in these articles. Results: The search yielded 
one meta-analysis and 7 RCTs assessing ACT in resected NSCLC. These studies 
report survival (HR 0.75-0.95 favoring ACT), ACT toxicity (30-85% experiencing grade 
3-4 toxicity), and stage distribution (Stage IA-7.6%, IB-29.9%, II-35.3%, III-27.2%). They 
also include disease free survival (HR 0.66-0.93 favoring ACT), but not stratified by 
NSCLC stage. Monthly cost of NSCLC was found in two studies (initial $5,255-11,496, 
continuing $2,602-3,733, terminal $9399-16,470). Two studies reported the U.S. cost of 
ACT toxicity ($4,629-9,516 per grade 3-4 event). Three studies reported utility values 
specific to early NSCLC including one with values related to ACT and toxicity with 
values varying from 0.60 to 0.75. Data reporting current U.S. ACT utilization was not 
identified. cOnclusiOns: Early NSCLC literature contains the majority of data 
inputs necessary for this model. Limitations exist, specifically regarding recurrence 
by stage, current ACT utilization and cost of health care resources. These limitations 
can be overcome using expert opinion, assumptions for guideline adherence and/
or conducting observational studies to inform the model.
PRM85
ANALySIS OF CAUSAL RELATIONS IN STROKE REGISTRy DATA
Jakubczyk M.1, Niewada M.2
1Institute of Econometrics, Warsaw School of Economics, Warsaw, Poland, 2Department of 
Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
Objectives: Stroke–one of the leading causes of death and disability–represents 
substantial clinical and economic burden. Understanding treatment patterns and 
causative relations may help e.g. to identify outcomes predictors and cost driv-
ers. MethOds: We used Polish Hospital Stroke Registry data on patient baseline 
characteristics (demographics, risk factors, prestroke disability, stroke severity), 
hospital management, treatment outcomes and drugs (pre-admission, during hos-
pitalisation, and prescribed at discharge). We used inferred causation approach that 
deducts causal (not associative) interpretations from patterns of (conditional) inde-
pendence. In this primary analysis we used 5000 observations from 2007/2008 year, 
binary variables and assumed no hidden variables. We used Tetrad 4.3.10-6 with PC 
algorithm. Variables were grouped into five tiers, a priori forbidding some directions 
of causal influence. Large number of variables led us to a restrictive significance 
level (α = 0.0001). Results: New insight can be gained from existence, lack of, and 
the direction of causal relations. Our results: confirmed (without imposing prior 
knowledge) the use of cardiovascular drugs in relation with underlying risk factors 
and natural sequence of drug management (drugs used prior to, in acute stroke 
and at discharge); surprisingly suggested no causal relation between some clinical 
characteristics and drug use (e.g. history of stroke/diabetes and oral anticoagulants) 
or acute stroke treatment (e.g. aspirin, thrombolysis, stroke unit based treatment) 
and mortality/post-stroke disability; determined the causal direction between 
some risk factors (e.g hypertension and diabetes, gender and AF) or patient history 
and prestroke disability (history of stroke or age over 75 and impaired disability); 
could not unambiguously discover the causal-relation between stroke unit based 
treatment and unproven efficacy drugs use. cOnclusiOns: Apart from statistical 
or econometric approach, causal-type reasoning can be used both to confirm the 
intuition, and to detect new patterns in data. Further research should include the 
possibility of hidden variables and try to quantify the causal relations.
PRM86
HOw TO SELECT THE RIGHT COST-EFFECTIvENESS MODEL? A SySTEMATIC 
REvIEw AND STEPwISE APPROACH FOR TRANSFERRING AN ExISTING HEALTH 
ECONOMIC MODEL FOR RHEUMATOID ARTHRITIS
van Haalen H.G.M.1, Tran-Duy A.2, Boonen A.2, Severens J.L.1
1Erasmus University, Rotterdam, The Netherlands, 2Maastricht University Medical Center, 
Maastricht, The Netherlands
Objectives: To a) to perform a systematic literature review to identify existing 
models for cost-effectiveness analysis of disease modifying anti rheumatic drugs 
in Rheumatoid Arthritis, and b) to develop and test a method for the selection of 
a model that is transferable to the Dutch health care setting by simple adapta-
tion. MethOds: We searched Medline and Embase to identify relevant studies in 
the English language between 1-1-2002 and 31-8-2012. For studies that met the 
inclusion criteria, we applied a 3-step approach in model selection. First, models 
that did not meet all minimal methodological requirements based on the OMERACT 
criteria were excluded. Second, the models were assessed based on their fit when 
transferred to the Dutch health care setting. Transferability factors as published by 
Welte et al., except for those that were deemed transferable by simple adaptation, 
were used for this ranking procedure. Finally, the remaining models underwent 
a general quality check using the Philips checklist. Models showing good fit and 
high quality were considered to be transferable to the Dutch health care setting 
using simple adaptation. Results: The systematic literature search resulted in 498 
papers, which included 33 unique health economic models. Only six models passed 
the OMERACT methodological requirements. Two of these models had imperfect 
transferability fit according to Welte. The remaining four models were, according 
to Philips, of good quality and were expected to be transferable by a simple adapta-
tion. cOnclusiOns: This study introduces a stepwise approach to the identifica-
tion and selection of health economic models that are transferable by a simple 
adaptation. This approach can be applied in various therapeutic areas, provided that 
the minimal methodological requirements are defined accordingly. Availability of 
health economic models coupled with structured model selection could improve 
the efficiency, quality and comparability of health economic evaluations.
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number of scenarios where the EVPI curve takes a different form compared to the 
one illustrated in the typical ‘textbook’ example. For example, when the majority of 
the plotted outcomes are spread over the northern quadrants the traditional EVPI 
peak is absent, and this could be explained by the fact that the reduction in decision 
uncertainty does not outweigh the increased value of opportunity loss. Further, plots 
spread over the eastern quadrants present a maximum EVPI at zero λ which then 
gradually decreases. This study may inform the interpretation of EVPI curves, and 
add value to the analysis of the value of additional research.
PRM93
MODELING MEDICATION ADHERENCE IN COMPARATIvE EFFECTIvENESS 
RESEARCH
Slejko J.F.1, Campbell J.D.2
1University of Washington, Seattle, WA, USA, 2University of Colorado Anschutz Medical Campus, 
School of Pharmacy, Aurora, CO, USA
Objectives: Real-world patients do not exhibit the level of medication adherence 
seen in clinical trials. Hence, the effectiveness of medications in routine practice 
may differ. It is important to understand the manifestations of suboptimal medi-
cation adherence in a population to assess the potential of adherence-improving 
interventions and the real-world value of medications. The objective of our study 
was to compare the clinical outcomes of an adherence naïve framework versus 
a dynamic adherence framework using the case of statins for primary preven-
tion of cardiovascular disease versus no statin use. MethOds: Statin adherence 
was categorized as PDC≤ .20, .20< PDC< .80 and PDC≥ .80 based on a longitudinal 
epidemiological cohort study of US medical and pharmacy claims. Yearly adher-
ence transitions were incorporated into a Markov microsimulation using Treeage 
software. Tracker variables were used to store adherence transitions which were 
then used to adjust probabilities of cardiovascular events (MI, stroke, acute angina) 
over the patient’s lifetime. Statin effectiveness was adjusted between 0% and 
100% of trial-based risk reduction. A total of 10,000 microsimulations were used 
to estimate incremental effectiveness as CV events avoided and quality-adjusted 
life-years (QALYs). Results: In the 10,000-patient statin user cohort simulated 
by the adherence-naïve model, it was estimated that statin use resulted in 1,162 
CV events avoided and 0.39 QALYs gained over a lifetime horizon. The dynamic 
adherence model estimated that 42% of patients exhibited highest adherence, 40% 
exhibited intermediate adherence and 18% exhibited low adherence. This model 
simulated that overall, statin use resulted in 366 events were avoided and 0.18 QALYs 
gained. cOnclusiOns: A Markov microsimulation used to simulate changes in 
patients’ medication adherence over time reveals differential risk reduction and 
effectiveness in terms of CV events and QALYs gained. The framework presented 
here is useful for comparing drugs in which optimal effectiveness and costs may 
be similar, but differential adherence may affect outcomes.
PRM94
CAUSAL ANALySIS OF LONGITUDINAL PATIENT TURNOvER DATA AT 
HEPATITIS-C
Lang Z., Bacskai M., Tóth E., Rakonczai P.
Healthware Consulting Ltd., Budapest, Hungary
Objectives: In recent years the financer in Hungary (NHIFA) has established a 
detailed and stabile patient turnover database, which reflects time dependent 
changes. Meanwhile, statistical methods of longitudinal data revealing causal 
relationship have been becoming widespread. By these new methods, analyses 
similar to assessment of randomized clinical trials have become available. In 
our research we studied the causal effects of the strategy of treatment, espe-
cially the frequency of retreatment of responder patients on features of status, 
events and costs of patients diagnosed Hepatitis C. MethOds: Causal infer-
ence on longitudinal (e.g. patient path) data is possible using the methods of 
Robins (1999). It makes therapy history exogenous, i.e. independent of the actual 
status of the patient via dynamical, time dependent reweighting of individual 
patient paths. Consequently, patient paths can be analyzed similarly to cohort 
data assessment of randomized clinical trials. The method can be used to con-
firm the results of RCTs. It can substitute RCTs, too, e.g. if RCTs are ethically 
impossible. Results: We obtained by applying Robins’ method that repeated 
combination therapies decreased the risk of liver related complications and the 
development of hepatocellular carcinoma. The method applied to cost analysis 
revealed that despite repeated therapies the costs of newly developed cirrhosis 
and tumor are higher than the corresponding costs of patients with sustained 
viral response. cOnclusiOns: Robins’method is appropriate for measuring the 
causal effects of certain factors of care on patient pathways, especially if patient 
turnover data are supplemented with physiologic, diagnostic and lab information 
found in clinical registers.
PRM95
APPROPRIATE EvIDENCE SOURCES FOR POPULATING DECISION ANALyTIC 
MODELS wITHIN HEALTH TECHNOLOGy ASSESSMENT (HTA): A SySTEMATIC 
REvIEw OF HTA MANUALS AND HEALTH ECONOMIC GUIDELINES
Zechmeister-Koss I.1, Schnell-Inderst P.2, Zauner G.3
1Ludwig Boltzmann Institut for Health Technology Assessment, Vienna, Austria, 2UMIT - 
University for Health Sciences, Medical Informatics and Technology, Hall i. T.; Innsbruck, Austria, 
3Drahtwarenhandlung Simulation Services, Vienna, Austria
Objectives: Decision analytic modellers use numerous types of evidence for 
populating model parameters. Detailed methodological advice on which type of 
data is to be used for what type of model parameter is required. We aim at review-
ing existing HTA manuals and health economic (modelling) guidelines in order to 
gain advice on appropriate evidence sources for populating models. MethOds: 
We identified manuals and guidelines via the International Network of Agencies 
for Health Technology Assessment (INAHTA) and by hand search. We included 
documents from Europe, the USA, Canada, Australia and New Zealand as well as 
transnational guidelines written in English or German. We systematically sum-
to characterize the underlying disease progression parameters and strengthen 
these assessments.
PRM90
OvERvIEw OF HEALTH ECONOMIC MODELS IN TyPE 2 DIABETES MELLITUS 
(T2DM); A SySTEMATIC LITERATURE REvIEw
Charokopou M.1, Sabater F.J.2, Townsend R.3, Roudaut M.2, Verheggen B.G.1
1Pharmerit International, Rotterdam, The Netherlands, 2Bristol-Myers Squibb, Rueil-Malmaison, 
France, 3AstraZeneca, Brussels, Belgium
Objectives: To identify and compare economic models developed to evaluate the 
cost-effectiveness of treatments for type 2 diabetes mellitus (T2DM), and their use 
in health care decision-making. MethOds: This research updates two previously 
published systematic reviews. The current systematic literature review was per-
formed according to a pre-defined search strategy and review criteria in six com-
monly used databases from September 2008 to January 2013. In addition, websites 
of Health Technology Assessment (HTA) organizations across nine countries and 
major disease conferences’ proceedings were also reviewed. For each identified 
model, key information was extracted and assessed. Results: Overall, 2262 cita-
tions were identified; 122 full text publications, 169 conference proceedings and 106 
HTA reports met the pre-defined inclusion criteria. Among these, 27 models were 
identified; 6 from full text publications, 18 models from conference proceedings, and 
3 models from HTA reports. Most of the included models applied a similar model 
structure, either using Markov-modelling or micro-simulation techniques, and were 
based on similar key data sources. A key challenge of T2DM economic modelling is to 
appropriately predict the long-term progression of relevant risk factors and translate 
these into clinical and economical consequences of diabetes-related complications. 
In line with previous findings, the UKPDS risk equations were most commonly used 
for the above purposes in the newly identified models. Among published studies and 
HTA submissions, T2DM economic models that are widely published and accepted 
by HTAs include CARDIFF and CORE. cOnclusiOns: The most commonly employed 
models in HTA submissions, namely CARDIFF and CORE, have similar techniques 
to forecast future costs and health outcomes. Hence, the focus for decision makers 
should be to consider the appropriateness of the critical assumptions regarding 
data inputs that impact the results.
PRM91
NETwORK META-ANALySIS wITH FRACTIONAL POLyNOMIALS FOR REPEATED 
TROUGH FEv1 MEASURES IN COPD: ACLIDINIUM BROMIDE 400 μG BID vERSUS 
TIOTROPIUM 18 μG QD
Karabis A.1, Jansen J.P.2, Lindner L.3
1Mapi, Houten, The Netherlands, 2Mapi / Tufts University School of Medicine, Boston, MA, USA, 
3Almirall UK, Uxbridge, UK
Objectives: To estimate the relative efficacy of aclidinium bromide 400 µg 
BID (AB400), to tiotropium bromide 18 µg QD (TIO18) by means of lung function 
in patients with COPD, within the first 24 weeks of treatment and illustrate the 
repeated measures network meta-analysis (NMA) models. MethOds: A system-
atic literature search using a predefined strategy in MEDLINE, EMBASE and the 
Cochrane Library identified 16 unique placebo-controlled RCTs reporting FEV1 
trough: TIO18 (n= 13) and AB400 (n= 3). The development of trough FEV1over time 
for AB400, TIO18 and placebo (PLA) was modeled with fractional polynomials, and 
the difference between the parameters of these polynomials within a trial were 
synthesized across studies with a Bayesian NMA. This type of NMA allows for the 
simultaneous analysis of outcomes at multiple time points. The within-trial cor-
relation was not available from the publications of the included studies, and as 
such a sensitivity analyses was performed assuming different values for the cor-
relation. Results: Given the fractional polynomial parameters obtained with the 
NMA model, the corresponding treatment effects over time for AB400 vs TIO18, 
AB400 vs PLA and TIO vs PLA were estimated. The model with t-0.5and log(t) had 
the best fit according to the deviance information criterion (DIC). These polynomi-
als and within study correlation were used for the modeling of the outcomes over 
time. AB400 is equally efficacious compared to TIO18 during the first 24 weeks, as 
the 95% CrI of the difference in CFB between the treatments includes zero while 
the mean is < 15mL. Furthermore, the probability that each treatment was best was 
calculated as a function of time. cOnclusiOns: This analysis demonstrates the 
use of the proposed NMA models and suggests that maintenance treatment with 
AB400 results in comparable improvements in lung function, as TIO18 in COPD 
patients over a 24 weeks period.
PRM92
EvPI CURvES IN PRACTICE
Jeppsson K.1, Posnett J.2, Carlqvist P.3
1HERON Evidence Development Ltd., London, UK, 2Heron Evidence Development, Ltd., London, UK, 
3Heron AB, Stockholm, Sweden
When making decisions about the allocation of scarce health-care resources it’s 
not only important to consider the estimated cost-effectiveness (CE) with current 
evidence, but also the value of additional research. Expected value of perfect infor-
mation (EVPI) is the amount a decision maker should be willing to pay to eliminate 
uncertainty surrounding the decision about which option is optimal for different 
levels of the CE threshold (λ ). Although EVPI analysis is being requested increasingly 
by reimbursement agencies there is still limited literature on the interpretation 
of EVPI curves. The typical ‘textbook’ example represents just one of the possi-
ble shapes that the curve can take. Objectives: To explore and explain different 
shapes of EVPI curves based on the position of alternative treatment choices on 
the incremental cost-effectiveness plane. MethOds: A hypothetical probabilistic 
decision model was developed in which two interventions were compared. Key 
input parameters were varied to force the model outcomes into different quad-
rants on the incremental CE plane. The population EVPI, based on a hypothetical 
number of future patients and the estimated lifetime of the new intervention, was 
plotted. Results And cOnclusiOns: The result of this study demonstrates a 
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escalation thresholds influences predicted costs and quality adjusted life expec-
tancy (QALE) in T2DM economic evaluations. MethOds: This study used the IMS 
Core Diabetes Model (CDM), a validated and established diabetes model, to evaluate 
the cost effectiveness of metformin+ sulphonylurea (M+S) compared to metformin 
+ DPP-4 (M+D). Baseline HbA1c was set to 8.0% (non-sampled scenario) with stand-
ard error of 0.8 (sampled scenario). Efficacy data for dual therapy was sourced from a 
published systematic review; HbA1c and BMI changes of -0.8% and 0.199kg/m2 (M+D) 
and -0.79% and 0.707kg/m2 (M+S) respectively were applied. Insulin rescue therapy 
was applied to both arms at HbA1c thresholds of 6.5%, 7.0% 7.5%. The model was 
run over a lifetime and costs (US$) and benefits were discounted at 3.5%. Results: 
Total incremental costs were $7,667, $9,571 and $11,644 for M+D versus M+S using 
sampled baseline HbA1c for therapy escalation thresholds of 6.5%, 7.0% 7.5% respec-
tively; and were $5,258, $2311 and $206 lower using non-sampled values, respec-
tively. A similar pattern was observed for QALE, in which incremental QALE gains 
were 85%, 42% and 1% lower with non-sampled compared to sampled baseline 
HbA1c for escalation thresholds of 6.5%, 7.0% 7.5% respectively. cOnclusiOns: 
The importance of probabilistic analysis within cost effectiveness models extends 
beyond quantifying the effects of parameter uncertainty. When treatment decision 
rules are dependent on patient attributes that are subject to variability (such as 
HbA1c) then failing to accommodate this within the model can significantly bias 
predicted costs and QALE.
PRM99
MARKOv MODELS IN NON METASTATIC PROSTATE CANCER – AvAILABILITy OF 
INPUT FACTORS AND STRUCTURURAL UNCERTAINTy
Jacobsen J.
LSHTM, Nevlunghavn, Norway
Objectives: This study aims at reviewing structural differences in Markov Models 
comparing different treatment strategies for Non-Metastatic Prostate Cancer related 
to scope, time-horizon, perspective, assumptions and the selection of parameters 
for the model. MethOds: There is an abundant literature on Prostate Cancer. There 
are however few well performed RCT’s comparing different options for management 
for NMPCa.[1] Due to the lack of conclusive clinical evidence on the best treatment 
for localised prostate there has been a considerable interest in the modelling of 
prostate cancer in decision analytic models and economic evaluation.[2] The lit-
erature review in this paper focuses on the limited number of papers on economic 
evaluation related to the condition. In addition there are several articles presenting 
Markov Models. The evaluation was based on selected items from “Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS)”. Results: In NMPCa 
there are Markov models ranging from two to five health states [9]. The choice of 
model originates from the underlying assumptions, the aim/scope of the study or 
the availability of data to feed into the model. The insufficient clinical evidence 
and few preference based studies of health state values where the most influen-
tial elements in structuring the models Little attention is paid to the structural 
differences in the analysis and the discussions in the available papers. Structural 
uncertainty is viewed as external to the model and difficult to evaluate unless the 
structural choices are made transparent.[10]. cOnclusiOns: Models in NMPCa 
differ in complexity and structure. The ability to evaluate the use of different models 
is highly dependent on transparency in the different building blocks. The CHEERS 
framework provided a useful tool in the evaluation input factors and the different 
Markov Model structures,
PRM100
BAyESIAN EvIDENCE SyNTHESIS OF SAFETy DATA: A ROBUST OPTION?
Amzal B.1, Nikodem M.2
1LASER Analytica, London, UK, 2LASER Analytica, Krakow, Poland
Objectives: Particularly in the context of HTA evaluations where both post-mar-
keting and pre-marketing data may be considered, the evidence to be synthesized 
can be sparse, partial and heterogeneous for safety outcomes. The Bayesian option 
has increasingly appeared as an unrivalled option for such challenging evidence 
synthesis cases but implementation in practice may be questioned. This work aims 
at determining how Bayesian meta-analysis or mixed treatment comparison of 
safety data can be optimized especially regarding the choice of prior distributions 
and model parameterization. MethOds: Based on the latest developments from 
the DIA working group on Bayesian methods for safety data applied to specific 
real-world cases of both direct meta-analysis and mixed treatment comparisons 
(MTC), different model parameterizations and different forms of informative and 
non-informative prior distributions are tested, with various weights allocated to the 
clinical data vs. the observational information. Results: As opposed to the NICE 
parameterization of network meta-analysis, the 2-way predictor parameterization 
of MTC as proposed by the DIA working group provides more robust analysis based 
on non-informative priors. In the case of informative prior results, the most robust 
option was seen for equal total weight of clinical vs. observational data. Results 
of all meta-analyses appeared to be consistent across different model and prior 
specifications, even with low number of studies (< 10). cOnclusiOns: Bayesian evi-
dence synthesis can leverage all available information in a robust manner for both 
direct and indirect comparisons, with fair quantification of uncertainty. Specific 
guidance on MTC model parameterization for safety data could complement the 
current NICE guidelines.
PRM101
THE ROLE OF HALF-CyCLE CORRECTION IN THE MODELS USED FOR HEALTH 
TECHNOLOGy ASSESSMENT
Nemeth B., Vincziczki Á
National Institute for Quality- and Organizational Development in Healthcare and Medicines, 
Budapest, Hungary
Objectives: To analyse the half-cycle correction and its effect on the final results 
of Markov models. MethOds: In our analysis we focus on the half-cycle correction, 
which is a method used to deal with the inaccuracy caused by inadequate cycle 
marised recommendations on appropriate evidence sources for different model 
parameters in a narrative manner. Additionally, information on advantages and 
disadvantages of sources, on evidence identification methods and on data quality 
issues was extracted. Results: Twenty-eight documents fulfilled our inclusion 
criteria. We identified a large variety of evidence sources for informing model 
parameters on clinical effect size, natural history of disease, resource use, unit 
costs and health state utility values. They comprise research and non-research 
based sources. The documents do not provide structured advice on the hierarchy 
of evidence and on the limitations of evidence sources. The information is pre-
sented fragmentarily and is not tailored to specific model types. cOnclusiOns: 
The usability of guidelines and manuals for modelling could be improved by 
addressing the issue of appropriate evidence sources in a more structured and 
comprehensive format.
PRM96
MODELLING UNCERTAIN FUTURE EvENTS IN COST-EFFECTIvENESS ANALySIS
Mahon R.
University of York, York, UK
Objectives: When the appropriate time horizon exceeds the evidence time 
horizon in a cost-effectiveness decision model, numerous uncertainties arise. 
One potential source of uncertainty is that of a possible future event that may 
affect one or more model parameters, e.g. a price shock or the emergence of 
a new comparator. These uncertain future events (UFEs) are rarely accounted 
for in health technology assessment and there is a dearth of guidance regard-
ing how they should be modelled. The objective of this study is to describe the 
circumstances under which UFEs could meaningfully impact cost-effectiveness 
estimates and to explore and demonstrate appropriate modelling techniques 
using a motivating example. MethOds: Drawing on examples from HTA and 
other relevant literature, a framework is proposed to outline: when to take 
explicit account of uncertain future events for the purposes of reimbursement 
decisions, how different future events may affect value-of-information analysis 
and what modelling methods are likely to be useful when incorporating UFEs. 
Taking the example of a decision model seeking to estimate the cost-effective-
ness of an early interventional strategy for patients with non-ST-elevation acute 
coronary syndrome, a future price change is simulated and the framework is 
applied. Results: UFEs are shown to impact ‘accept or reject’ reimbursement 
decisions only in very specific circumstances where there is the potential to 
incur irrecoverable costs, whereas their role in value-of-information analysis is 
invariable. The applied example shows that the reimbursement recommenda-
tion for future populations may change with the occurrence of the future event 
and that there is value in reducing the uncertainty regarding the nature of the 
future event. cOnclusiOns: UFEs will only impact expected costs-effectiveness 
sunder specific and rare circumstances. When it is appropriate to include a future 
event in a decision model, the uncertainty surrounding its likelihood, timing and 
magnitude should also be quantified.
PRM97
TECHNICAL ERRORS IN COST-EFFECTIvENESS MODELS: EvIDENCE FROM THE 
SINGLE TECHNOLOGy APPRAISAL PROGRAMME IN ENGLAND AND wALES
Trueman D., Livings C.
Abacus International, Bicester, UK
Objectives: Modelling for cost-effectiveness studies often relies upon the use of 
spreadsheets. However, research has shown that approximately 90% of spread-
sheets contain technical errors. Furthermore, cost-effectiveness models rely on 
accurate transcription between many data sources, which increases the risk of 
errors further. The objective of this analysis was to ascertain the incidence of 
reported technical errors in cost-effectiveness models submitted to NICE as part of 
the Single Technology Assessment (STA) programme, which are subject to rigorous 
assessment by Evidence Review Groups (ERGs). MethOds: NICE guidance docu-
ments were searched for a wide range of technical error types using the HTAinsite 
database. Reports were included if the ERG had identified technical errors in the 
manufacturer’s submission and this had been noted at committee level. Included 
appraisals were analysed to identify categories of errors identified. Results: Of 
the 102 completed STA Guidance documents searched, 39 appraisals met the inclu-
sion criteria of the study, representing a technical error incidence of 38.2% (95% CI: 
28.8 – 48.4%). Within these studies, 47 errors were identified in the following areas: 
computation (47%), logic (17%), transcription (13%) and data handling (9%). Error 
causes could not be determined in 15% of cases. The magnitude of effect caused by 
technical errors was difficult to determine, because corrected models often include 
additional changes to parameters or model structure. cOnclusiOns: The inci-
dence of technical errors identified in the STA programme was lower than has 
previously been observed in studies of spreadsheet validity although this analysis 
assumes that ERG groups will identify all technical errors. The true incidence of 
errors may be higher than reported by this analysis. Use of best-practice methods 
and increased awareness of the causes and identification of technical errors may 
help to reduce their pervasiveness.
PRM98
THERAPy ESCALATION THRESHOLDS AND THE POTENTIAL FOR BIASED COST 
EFFECTIvENESS ANALySIS wHEN FAILING TO SAMPLE BASELINE HBA1C IN 
TyPE 2 DIABETES
McEwan P.1, Foos V.2, Palmer J.L.3, Lamotte M.4, Grant D.5
1Swansea University, Cardiff, UK, 2IMS Health, Basel, Switzerland, 3IMS Health, Allschwil, Basel-
Landschaft, Switzerland, 4IMS Health HEOR, Vilvoorde, Belgium, 5IMS Health, London, UK
Objectives: Due to the progressive nature of type 2 diabetes mellitus (T2DM), 
patients inevitably require therapy escalation or intensification. In health economic 
analyses, sampling input parameters is routinely undertaken for probabilistic analy-
sis but non-sampled analysis (mean values) is still commonplace. The objective of 
this study was to assess how sampling baseline HbA1c in combination with therapy 
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to assess the cost effectiveness of CML interventions were identified in MEDLINE 
and EMBASE. The studies were reviewed to map the method employed, how and why 
these approaches were selected, and lessons learned by the authors. Results: A 
total of unique CML models were reviewed. The large majority of these models were 
published in the last 10 years, with almost half being published in 2011. All but 1 of 
the models adopted a Markov structure, based around the following health states: 
chronic phase; accelerated phase; blast phase; and death. In line with best practice 
recommendations, over 75% of studies modeled progression and survival based on 
response to treatment. Extrapolation of trial data used a wide range of statistical 
models. Contrary to best practice recommendations, the fit of these models to the 
trial data and the validity of the extrapolation were not always tested. A variety of 
approaches were employed to estimate the health related quality of life associate 
with health states, including the direct valuation of health states, the use of stand-
ard health instruments (such as EQ5D), and mapping methods. cOnclusiOns: 
Several approaches to the economic modeling of CML interventions were identified 
in the literature. A number of examples of good practice were identified, including 
the use of disease response outcomes when modeling progression and survival, and 
the systematic testing of the fit of survival distributions to trial data. Key challenges 
facing CML modeling are the validity of extrapolations of trial data given the long 
time periods over which these extrapolations are required, and the lack of data 
against which to validate them.
PRM105
MODELLING THE NATURAL HISTORy OF SCHIzOPHRENIA: COMPARISON OF 
NAïvE vERSUS ADvANCED STATISTICAL METHODS
Millier A.1, Lenert L.2, Sadikhov S.3, Moreno S.3, Toumi M.4
1Creativ-Ceutical, Paris, France, 2University of Utah School of Medicine, Salt Lake City, UT, USA,  
3F. Hoffmann-La Roche Ltd., Basel, Switzerland, 4University Claude Bernard Lyon 1, Lyon, France
Objectives: The literature provides little guidance on statistical methods for esti-
mating parameters of Markov models using longitudinal data. We compared the 
commonly used naïve (based on raw data) and advanced approaches to estimate 
two model parameters: transition probabilities and hospitalisation rates. Both 
the naïve and advanced approaches were applied using data from the European 
Schizophrenia Cohort (EuroSC) to populate a Markov model in schizophre-
nia. MethOds: EuroSC is a 2-year observational study of patients with schizo-
phrenia (n= 1,208), with 5 visits at 6-month intervals. Patients were classified into 
8 health states at each visit according to severity of symptoms assessed using the 
Positive and Negative Syndrome Scale (PANSS). For each health state, both model 
parameters (hospitalisation days and transition probabilities) were estimated 
based on raw data by pooling all time intervals (i.e. naïve approach). Similarly, 
for advanced methods, transition probabilities were estimated using multi-state 
models while hospitalisation days were estimated using two-part Generalised 
Estimating Equations (GEEs). Advanced methods adjusted for patient character-
istics and included random effects to account for repeated measures. Results: 
The naïve approach showed that the average number of hospitalisation days in 
a 6-month interval ranged from 4.20 in health state 1 to 19.43 in health state 8. 
Results from the two-part GEEs provided a range from 4.21 in health state 1 to 
14.7 in health state 8. GEEs tended to provide narrower confidence intervals. With 
regards to transition probabilities, differences between the naïve approach and the 
multi-state model were mostly seen in the second decimal place. cOnclusiOns: 
While the naïve approach is frequently used for its simplicity, it has a number of 
shortcomings including: not accounting for repeated measures and not allowing 
for adjustment of patient characteristics. To increase the robustness of results, we 
recommend using statistical models that recognise and account for the unique 
distributional characteristics of data.
PRM106
SURvIvAL ANALySIS wITH COvARIATES IN COMBINATION wITH 
MULTINOMIAL ANALySIS TO PARAMETRIzE TIME TO EvENT FOR MULTI-STATE 
MODELS
Feenstra T.L.1, Postmus D.2, Quik E.H.3, Langendijk H.4, Krabbe P.F.M.3
1University Medical Centre Groningen, Groningen, The Netherlands, 2University Medical Center 
Groningen, Groningen, The Netherlands, 3University of Groningen, University Medical Center 
Groningen, Groningen, The Netherlands, 4UMCG, Groningen, The Netherlands
Objectives: Recent ISPOR Good practice guidelines as well as literature encourage 
to use a single distribution rather than the latent failure approach to model time to 
event for patient level simulation models with multiple competing outcomes. Aim 
was to apply the preferred method of a single distribution on time to event in combi-
nation with a multinomial distribution on type of event for parameterizing the pri-
mary tumor component of a patient level head and neck cancer model. MethOds: 
Data on patients treated with radiation therapy as first line therapy for head and 
neck tumor at two university hospitals in The Netherlands between 25-02-1980– 
13-12-2010 was used (nUMCG= 277 & nVUMC= 736). Several distributions were 
tested for model fit, using QQ-plots, AIC, and simulated versus actual data plots 
to judge best fit. Covariates tested for inclusion were age, gender, tumor location 
dummies, nstage and tstage. The final model was applied in the patient simulation 
model. Multinomial regression with the same covariates and time of event added 
as a covariate was applied on type of event, distinguishing death, loco regional 
recurrence and metastasis as events. All analyses were performed in R. Results: 
The LogNormal distribution showed best fit. The final model had the following 
coefficients for the location parameter (se in brackets): Intercept, 8.2 (0.38), Age 
-0.026 (0.0053), Tstage -0.38 ( 0.062), Nstage -0.21 (0.076), Locd1 -0.91 (0.22) , Locd2 
-0.28 (0.15), Locd3 -0.72 (0.22). Locd refers to location dummies. The estimated 
value for Log(sd) was -0.44 (0.038). The multinomial model had age, tstage and 
time of event as significant covariates cOnclusiOns: A disadvantage of this 
method is that a single distribution has to be fit to a time of event which is the 
result of different interacting stochastic processes. The resulting distributions 
showed acceptable fit and could be implemented straightforwardly in the patient 
level simulation model.
length in Markov models. The benefits of half-cycle correction has been widely 
published in the international literature. We measured the importance of half-cycle 
correction in the models submitted to the Hungarian HTA Office. We examined 
when it is adequate to use half-cycle correction and how big role should it have in 
the process of modelling. Results: Our experience shows that only 11% of the sub-
mitted models incorporated half-cycle correction. In more than half of these cases 
the value of the incremental cost-effectiveness ratio (ICER) changed by less than 1% 
when half-cycle correction was used compared to the base-case scenario. We also 
found the possibility that in some cases the added benefit of half-cycle correction 
is not considerable. cOnclusiOns: The necessity of using half-cycle correction is 
essential in models, when the cycle length is half year or longer and if the number 
of the cycles of the models is less than 200. In most cases the half-cycle correction 
results in only a little change in the cost-effectiveness ratio of the submitted models, 
therefore half-cycle correction should be executed carefully.
PRM102
A REvIEw OF CLINICAL TRIAL SIMULATION METHODS
Schuetz C.A.1, Ong S.H.2
1Archimedes, Inc., San Francisco, CA, USA, 2Novartis Pharma AG, Basel, Switzerland
Objectives: Randomized controlled clinical trials are the gold standard for deter-
mining causal inference. However, trials are expensive, and the results can be 
difficult to interpret. Our objective was to evaluate methods for clinical trial simu-
lation to understand how the simulation approach can be used for improved trial 
planning and interpretation of trial results. Our primary focus was trials of type 2 
diabetes and cardiovascular disease. MethOds: We systematically searched the 
MEDLINE database for clinical trial simulation studies. We used the MeSH terms: 
Markov model, Markov chains, simulation, simulation model, microsimulation, 
computer model, and required type 2 diabetes mellitus and cardiovascular dis-
eases. We restricted the search to studies of humans published in English and 
found 92 publications. We also considered innovative clinical trial simulation 
methods from other areas to gain context. Results: A number of established 
techniques — notably, the Archimedes Model, Markov models, and observational 
analyses— are used for clinical trial simulation. Markov model-based simulations 
are widely employed, but have structural limitations with regard to the physiologi-
cal detail they can capture (e.g. multiple comorbidities). Retrospective, observa-
tional methods for clinical trial simulation are gaining utility as more databases 
become available. However, observational methods remain vulnerable to unknown 
biases. Finally, large-scale simulation models (such as the Archimedes model), with 
physiological underpinnings, provide accurate and clinically detailed trial simula-
tions. These models are used to simulate trials of therapies not yet marketed, or to 
forecast late stage trials. Model-based simulations require validations to ensure 
accuracy. cOnclusiOns: Clinical trial simulation is an increasingly powerful 
tool, complementing real-world clinical trials. Large scale simulation modeling 
has been shown to be valuable for estimating and interpreting clinical findings. 
Recent studies suggest that future developments will leverage both large-scale 
simulation models and increasingly rich real-world evidence.
PRM103
PROTOTyPE MODEL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER 
(MCRPC): A TOOL TO POSITION NEw TREATMENTS IN THE PATIENT PATHwAy?
Karcher H.1, Dinet J.2, Amzal B.1, Marteau F.3, Obrzut G.4, Pieniazek I.4, Brulais S.5, Gabriel S.2
1LASER Analytica, London, UK, 2IPSEN Pharma, Boulogne-Billancourt, France, 3Ipsen Pharma 
SAS, Boulogne-Billancourt, France, 4LASER Analytica, Krakow, Poland, 5Ipsen pharma, Boulogne-
Billancourt, France
Objectives: New treatments registered in mCRPC are expected to alter the way 
patients are currently treated. It is hence essential for developers of any new treat-
ment not only to position it within the current therapeutic landscape, but also to 
anticipate what this landscape will resemble at time of launch. To address this issue, 
we developed a modeling tool that recast a new treatment’s value into the evolving 
therapeutic landscape. MethOds: We conducted a literature review of existing 
health economic models in mCRPC, including recent HTA reports and conference 
abstracts. Technical and contextual elements were leveraged to build a flexible pro-
totype economic model for new treatments. The model encompasses disease man-
agement from asymptomatic mCRPC to patient’s death. It aims at describing the 
future management of mCRPC in including the current way patients are treated and 
the following innovative features: flexibility to alter the target population definition 
and size and to add new therapies. New therapies’ effectiveness and their expected 
positioning within the treatment pathway of mCRPC patients are assessed through 
the model. Results: We have created a dynamic prototype model to position new 
options in the current and future therapeutic landscape for treatment of mCRPC 
in Europe. Economic models identified in literature were addressing specific reim-
bursement questions and were not flexible enough to be re-used for our purpose of 
assessing therapeutic landscape evolution. However, some technical elements on 
costs and effectiveness could be leveraged for our model. The tool itself enabled to 
identify information gaps: epidemiology and real-life data were missing for some 
new treatments. These could be simulated and introduced in our easily-actualizable 
tool. cOnclusiOns: An actualizable modeling and simulation tool was developed 
in mCRPC. This tool enables dynamic identification of the best public health and 
economic outcomes out of a new potential therapeutic alternative.
PRM104
A REvIEw OF METHODS USED IN HEALTH ECONOMIC MODELS OF CHRONIC 
MyELOID LEUKEMIA INTERvENTIONS
Marsh K.1, Xu P.2, Orfanos P.1, Benedict A.3, Desai K.1, Griebsch I.4
1Evidera, London, UK, 2Evidera, Lexington, MA, USA, 3Evidera, Budapest, Hungary, 4Boehringer 
Ingelheim Pharma GmbH, Ingelheim am Rhein, Germany
Objectives: To describe the methods adopted by economic models of CML inter-
ventions, assess their strengths and limitations, and develop best practice recom-
mendations. MethOds: Examples of different economic modeling approaches used 
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marketing activity by brand name drugs. Estimates were small, significant, and 
positive (feed-forward neural networks indicated an even stronger positive relation-
ship between brand and generic approvals), suggesting that the presence of generic 
drugs might further innovation. cOnclusiOns: It was shown that market size does 
affect the rates at which pharmaceuticals aim to bring their products to the market. 
While brand manufacturers react positively to increased market size, weak property 
rights do not appear to affect innovation output negatively.
PRM110
CROSSOvER ADjUSTMENT IN ONCOLOGy TRIALS USING A RANK PRESERvING 
STRUCTURAL FAILURE TIME MODEL (RPSFTM): wRAPPING BOOTSTRAPS 
AROUND ESTIMATES OF LIFE ExPECTANCy FOR CE MODELS
Ray J., Bennett I., Wright E.
F. Hoffmann-La Roche Ltd., Basel, Switzerland
Objectives: Oncology trials increasingly permit switching from standard care (SC) 
to the new treatment following disease progression. Methods to remove the effect 
of the active treatment in the SC arm are used by HTA agencies to estimate what 
the effect of the SC would’ve been had crossover not occurred. One method is using 
RPSFT models to derive counterfactual survival times without crossover. For CE 
modeling, these counterfactual survival times need to be parametrically extrapo-
lated to estimate life expectancy. It is known that the RPSFT approach introduces 
additional uncertainty and e.g. the standard error of a hazard ratio calculated from 
counterfactual survival times needs to be inflated. Traditional methods of para-
metric survival analysis don’t account for this increased uncertainty which could 
influence allocation decisions. MethOds: A dataset of 400 patients was simulated 
assuming a Weibull distribution for PFS and OS with 70% of the patients in the SC 
arm switching after progression. Life expectancy was calculated in two scenarios. In 
scenario 1 the RPSFTM adjusted OS had Weibull parameter estimates and covariance 
calculated directly from the counterfactual survival times. In scenario 2 the data 
was bootstrapped 1000 times. For each iteration a new RPSFT model, associated 
counterfactual survival times and Weibull functions were fitted. The mean and 
covariance of these 1000 parameter estimates was taken. Results: Mean incre-
mental life expectancy after adjusting for cross-over was the same with and without 
bootstrapping. When PSA was run, larger confidence intervals in the scenario with 
bootstrapping indicated, the traditional approach failed to account for the increased 
uncertainty and underestimated the probability of the new treatment being less 
efficacious (0.4% without compared to 13.4% with bootstrapping). cOnclusiOns: 
Failing to appropriately reflect the uncertainty underlying parameter estimates of 
crossover adjusted survival times could impact HTA decisions when appraisals are 
based on the likelihood of a treatment being cost effective.
PRM111
THE USE OF DATA FROM PUBLISHED KAPLAN-MEIER SURvIvAL CURvES IN NICE 
HTAS
Taylor M.1, Lewis L.2, Yellowlees A.3, Fleetwood K.3
1York Health Economics Consortium, York, UK, 2York Health Economics Consortium, University of 
York, York, UK, 3Quantics Consulting Ltd., Edinburgh, UK
Objectives: Reporting of survival outcomes from clinical trials is often limited to 
median survival times, hazard ratios, Kaplan-Meier curves and numbers at risk. 
The numerical results are not always sufficient for meta-analysis and cost-effec-
tiveness analysis. Further information can be obtained by digitizing and analysing 
the Kaplan-Meier curves. The most basic analysis approach is to fit a non-linear 
model to the Kaplan-Meier curve and use this to estimate parameters such as the 
mean survival time. Methods have recently been developed for estimating individual 
patient data (IPD) from Kaplan-Meier curves. Once individual patient data is esti-
mated, standard survival analysis approaches can be used to estimate parameters 
and also provide estimates of uncertainty in the curve fits. The objective of this 
study was to review the methods commonly used and assess the impact of the 
improved methods, where IPD is estimated, on the inferences drawn. MethOds: 
We conducted a systematic review of the methods that have been used in NICE HTAs 
to obtain data from published Kaplan-Meier curves. We examined the frequency 
of each method, how results were used and any feedback from Evidence Review 
Groups. Improved methods, estimating IPD, were applied to a selection of studies 
where this was not conducted in the original analysis. The impact of the improved 
methods on the conclusions of the studies was assessed. Results: The review 
showed that most HTAs used non-linear models to approximate the Kaplan-Meier 
curves. It also showed that the improved methods, estimating IPD, can have a sig-
nificant impact on conclusions drawn from survival results. cOnclusiOns: The 
estimation of IPD from Kaplan-Meier curves is a valuable method that is currently 
underutilised. It has the potential to provide better estimates of survival param-
eters and to improve the characterisation of uncertainty in such estimates. This is 
especially important when survival curves are extrapolated.
PRM112
A BAyESIAN DyNAMIC MODEL OF ASTHMA IN THE REAL LIFE
Amzal B.1, Timmaraju V.2, Castelnuovo E.3, Boucot I.4, Pribil C.5, Nachbaur G.6
1LASER Analytica, London, UK, 2LA-SER Analytica, London, UK, 3GlaxoSmithKline, London, UK, 
4GlaxoSmithKline, Marly-le-Roi, France, 5GSK France, Marly le roi, France, France, 6GSK France, 
Marly le roi, France
Objectives: Evolution of asthma disease severity over time can be highly depend-
ent on the prescription patterns and drug compliance of patients. The purpose of 
the modeling is to analyze longitudinal observational data of cohort of asthma 
patients to describe and quantify the dynamics of adherence, prescriptions, and 
outcomes and their interaction over time. MethOds: We explored and analyzed 
5 different observational studies following asthma patients in France over up to 
2 years. Main patients’ demographics along with prescriptions, ACT and 3-level 
GINA control scores could be defined every quarter and exacerbations at a given 
quarter were adjucated based on hospital admissions. Medication possession 
ratios could be defined quarterly and used as a proxy for adherence. A patient-
PRM107
ExTRAPOLATING SURvIvAL IN A HETEROGENEOUS PATIENT POPULATION 
wITH METASTATIC MELANOMA; A CASE STUDy OF INTEGRATING STATISTICAL 
AND CLINICAL CONSIDERATION
Majer I.M.1, Gueron B.2, Kotapati S.3, Van Hout B.4
1Pharmerit International, Rotterdam, The Netherlands, 2Bristol-Myers Squibb, Rueil Malmaison, 
France, 3Bristol-Myers Squibb Pharmaceuticals, Wallingford, CT, USA, 4Pharmerit Ltd., York, UK
Objectives: While the follow-up time on Ipilimumab trials is in excess of 4 years, 
HTA models often require survival to be extrapolated to 10 years and beyond. 
However, patient level data on prognostic factors are rarely available; hence 
extrapolation methods assume a homogeneous study population and are based 
on statistical considerations only. Such approaches are criticized for disregarding 
clinical reality and may be biased. In this study a survival extrapolation model 
that accounted for heterogeneity was developed based on both statistically and 
clinically relevant considerations. The method was applied on survival data in 
patients with Metastatic Melanoma. MethOds: Survival data were taken from 
a randomized controlled clinical trial that compared dacarbazine plus placebo 
versus dacarbazine plus ipilimumab. Two parametric models were explored to 
extrapolate survival: a model assuming no heterogeneity in patients and another 
model that divided patients into three subgroups based on cancer stage observed 
at baseline and additionally included subpopulations of a priori unobserved long-
term survivors. Survival of the subpopulations was extrapolated and summed 
to obtain survival in the overall population. Subgroup formation was guided by 
expert opinion of oncologists. The statistical and clinical validity of the models 
were assessed. Results: Among commonly used distributions (exponential, 
Weibull, lognormal) the lognormal distribution fitted the survival data best in 
the no-heterogeneity model whereas Weibull distribution was used for the het-
erogeneity model. For statistical validity, both models fitted the data reasonably 
well. However, the no-heterogeneity model underestimated the long tail of the 
survival curves. The no-heterogeneity model implied decreasing mortality over 
time while the heterogeneity model implied increasing mortality, which is more 
clinically relevant. cOnclusiOns: The no-heterogeneity model fitted the data 
reasonably well but was not relevant for extrapolation from a clinical perspective. 
The heterogeneity model captured the long tail of the survival curve best, and 
provided a statistically and clinically relevant model.
PRM108
BIvARIATE INDIRECT COMPARISON META-ANALySIS MODEL IN ECONOMIC 
EvALUATION OF CANCER TREATMENTS
Tan S.H., Bujkiewicz S., Abrams K.R.
University of Leicester, Leicester, UK
Objectives: A three-state Markov model for cost-effectiveness analysis of cancer 
treatments requires information on both progression-free survival (PFS) and over-
all survival (OS). However, data is not always available on both of these outcomes. 
The objective of this study is to perform a Bayesian bivariate indirect comparison 
meta-analysis (BICMA) to obtain estimates of both PFS and OS for use in a cost-
effectiveness analysis when data on these outcomes is incomplete. MethOds: In 
a UK Health Technology Assessment report on cost-effectiveness assessment of 
docetaxel with prednisone/prednisolone for the treatment of hormone-refractory 
metastatic prostate cancer, a two-state Markov model was specified using OS data 
from a single randomised controlled trial that did not report PFS. We propose the 
use of a Bayesian BICMA model that jointly estimates OS and PFS, and which in turn 
allows for the specification of a three-state Markov model incorporating a post-pro-
gression phase. Survival data for the trials included in the BICMA were reconstructed 
from survival curves, presented in the articles reporting the trials, using the method 
proposed by Guyot et. al. (BMC Med Res Methodol 2012;12:9) using the DigitizeIt and 
R software. Results: The Bayesian BICMA model was designed to jointly model 
the correlated outcomes: OS and PFS using either non-informative or informative 
prior distribution on the correlation between the outcomes. An informative prior 
distribution on the correlation between PFS and OS was based on external evidence 
using prostate cancer trials presented in Halabi et. al. (Clin Oncol 2009;27(17):2766-
71). Modelling the correlated outcomes jointly using this bivariate model allows 
prediction of PFS for the comparison of interest. cOnclusiOns: In the absence of 
evidence on PFS, required for the specification of a three-state Markov model, the 
proposed method allows PFS to be constructed thus eliminating the need to reduce 
the cost-effectiveness analysis to a two-state Markov model.
PRM109
THE DETERMINANTS OF INNOvATION – A BRIEF STUDy OF ISSUES 
INFLUENCING INNOvATION IN THE PHARMACEUTICAL INDUSTRy
Ghouse R.
Curo Consulting, Marlow, UK
Objectives: To examine factors determining the level of innovation in an organisa-
tion, examining two factors – market size and the strength of intellectual property 
rights for a particular drug class MethOds: The pharmaceutical industry is used 
as a case study as it not only relies heavily on R&D, but, with the division between 
brand name and generic drugs, can provide insight into how the removal of intel-
lectual property rights might affect innovation. The estimation models were based 
on an economic model for innovation and market size developed by Acemoglu and 
Linn (2004). Drug approval data obtained from the US FDA was used for the innova-
tion variable; a measure for market size was constructed using prescribed medi-
cines expenditure data from the US Medical Expenditure Panel Survey. The analysis 
focussed on examining the relationships between the variables using various statis-
tical estimation techniques, starting with a simple OLS log-log model, more general 
negative binomial and gamma models, as well as fully flexible non-linear smoothing 
regressions in the form of feed-forward neural networks. Results: Brand name 
approvals increased by 2.64% and generic approvals by 4.2% for a 1% increase in 
income-based market size. The presence of generic drugs and, thus, weak intel-
lectual property rights did not appear to have a negative effect on research and 
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influence the outcome of treatment. The objective was to assess patient preferences 
on treatments for ED by applying Conjoint Analysis. MethOds: Seven attributes 
were selected through a literature review and a consultation with 25 patients treated 
of ED and 5 experts: effectiveness (E), rapidity of onset (R), duration of effect (D), 
adverse events (AE), methods of administration (MA), price (P) and interaction with 
alcohol and food (I). 3 groups of scenarios were selected using “Orthogonal Design”: 
Phase 1, 9 scenarios with 4 attributes (R, D, MA, I); Phase 2, 16 scenarios with the 7 
attributes; Phase 3, 9 scenarios with 4 attributes (E, MA, P, I). It was applied the “Order 
of simulated preference” method by using cards with symbols and text. Interactions 
of age, comorbidity and frequency of sexual intercourses with preferences were 
studied. Results: The set of 16 scenarios was very difficult for patients. A total 
of 314 patients participated in Phase 1, 99 in Phase 2 and 178 in Phase 3. Order of 
preferred attributes: Phase 1: MA (57.99%), D (16.68%), I (14.57%) y R (10.76%); Phase 
2: MA (40.53%),E (21.98%), R (8.98%), P (8.11%), D (7.46%), AE (6.67%),I (6.25%); Phase 
3: MA (53.9%), I (22.45%), P (12.50%), E (11.14%). The preferred MA in the 3 phases 
was the orodispersible tablet with reference to pill and injectable. No statistically 
significant associations were found with age, comorbidity and frequency of sex-
ual intercourse. cOnclusiOns: . Patients gave more importance to the attribute 
“method of administration” in any of the three phases performed. The preferred 
MA was orodispersible tablet over pill and injectable.
PRM116
CHOOSING HEALTH STATES FOR ELICITATION OF POPULATION PREFERENCES 
FOR THE EQ-5D
Adams R.1, Reddy B.1, Kind P.2, Barry M.1, Walsh C.3
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2University of York, York, UK, 3Trinity 
College Dublin, Dublin, Ireland
Objectives: The EQ-5D-3L descriptive classification defines a total of 243 health 
states which presents a problem when seeking to establish social preferences. As 
it would be challenging to value all 243 health states, a subset is chosen but the 
basis for this selection varies across national valuation studies. The aim of this 
study was to choose health states based on the most commonly found health states 
experienced by the Irish population. MethOds: EQ-5D data from four different 
datasets were combined to determine what health states are prevalent in Ireland. 
Data from a general population study of health (SLAN), an over 70 population cohort, 
a rheumatoid arthritis and psoriatic arthritis cohort. The most commonly experi-
enced health states were determined and these were arranged on a 5 dimensional 
lattice. Health states were chosen using the Manhattan distance metric. Results: 
A total of 12,520 ratings of self-reported EQ-5D health states were included. Fifty 
two per cent of the cohort had perfect health (11111). Ninety five per cent of states 
include at least one ‘1’ and no ‘3’. 126/243 health states were not experienced in 
these datasets. The Manhattan distance between health states was measured. The 
imposition of such a metric facilitated the identification of clusters of states and 
associated centroids. Distance sampling was used to identify states within the clus-
ters. A simple random sampling strategy was also used across the lattice to ensure 
coverage of health states outside of the cluster cOnclusiOns: Previous population 
preference elicitation studies have used theoretical approaches to health states 
elicitation, which could lead to health states being directly valued which are rarely 
experienced in the population. The approach presented here uses the information 
already known about the population, to inform choice of health states for population 
valuation of health using the EQ-5D.
PRM117
HEALTH UTILITIES INDEx (HUI®): POPULATION REFERENCE STATISTICS
Horsman J.R.1, Furlong W.J.1, Feeny D.H.2, Torrance G.3
1Health Utilities Inc., Dundas, ON, Canada, 2University of Alberta, Portland, OR, USA, 3McMaster 
University, Toronto, ON, Canada
Objectives: To describe HUI reference statistics available from clinical and general 
population health studies. MethOds: Reviews of published literature, unpublished 
reports and corporate databases were used to identify summary statistics or data 
available for calculation of summary statistics. Published examples illustrate the use 
of HUI reference statistics for health-related quality of life (HRQL) scores to assess the 
health of patients relative to general populations and of general populations between 
countries. Results: Summary statistics of HRQL scores were compiled from pub-
lished clinical studies (n= 5), population health surveys (n= 6), or provided by investiga-
tors of individual studies (n= 3). Statistics from four sets of published results were used 
to identify health problems among patients treated for acute lymphoblastic leukemia 
in childhood in a recently published study. Results from the Joint Canada/US Survey of 
Health (JCUSH), conducted at the same time in both countries using the same survey 
methodology are presented here in brief. The mean HUI3 score in Canada (0.88) was 
slightly higher than in the US (0.87) (p< 0.05). However, the mean HUI3 score for those 
with less than a high school education in Canada (0.81) was much higher than the 
mean for the same group in the US (0.74) (p< 0.05). HUI Mark2 (HUI2) and HUI Mark3 
(HUI3) summary statistics by country, gender, race and age groups are presented in 
43 tables on the HUI web-site (www.healthutilities.com). cOnclusiOns: The results 
highlight the usefulness of continuous preference-based measures of population 
health such as the HUI3. Population reference data enable international comparisons 
of population health and provide normative data with which to interpret results from 
clinical studies. The publicly available summary statistics of interval-scale preference-
based measures for the HRQL of reference populations provide valid, reliable and 
cost-effective results for clinical and general population studies.
PRM118
PATIENT PREFERENCES IN THE CHOICE OF DISEASE MODIFyING DRUGS FOR 
MULTIPLE SCLEROSIS
Bergmann A.1, Lang M.1, Bischoff C.1, Schicklmaier P.2, Schiffhorst G.3, Nolting H.D.3,  
Rellecke J.3, Kunz E.2
1NTD study group, Neuburg/Donau, Germany, 2Biogen Idec GmbH, Ismaning, Germany, 3IGES 
Institut GmbH, Berlin, Germany
level dynamic Bayesian inhomogeneous Markov model with quarterly time-step 
was then developed to jointly describe prescriptions and outcomes over time 
in relation with adherence proxy using medication possession ratio, adjusting 
for patients demographics and seasonality. Internal and external validation was 
performed. Results: . Such Bayesian model could be fitted to the available data 
with different parameters informed by one or another data source. Treatment 
switches were associated with severity at the previous quarter while adherence 
was significantly improved when patients are switched and when they are less 
controlled in the previous quarter. Risk of exacerbations was depending on the 
control score and season at the present quarter and on the risk of exacerbation 
at the previous quarter. Control was significantly improved by a better adherence 
and to a lesser extent by a treatment escalation and improved severity at the previ-
ous quarter. cOnclusiOns: This Bayesian dynamic model allowed quantifying 
the most important interactions between drug uses and effects on control and 
exacerbations over time, hence providing a powerful tool for real-world outcomes 
predictions in asthma patients.
PRM113
UNCERTAINTy QUANTIFICATION OF LARGE-SCALE HEALTH ECONOMIC 
SIMULATION MODELS
Zheng P., Dinh T.
Archimedes Inc., San Francisco, CA, USA
Objectives: Large scale simulation models (e.g. Archimedes Model, MISCAN) are 
increasingly used to predict cost-effectiveness of medical interventions and to 
drive reimbursement decisions. These models are complex and involve hundreds 
of parameters and inputs. Quantification of parameter uncertainties using tradi-
tional sampling-based approaches (e.g., Monte Carlo sampling and its variants) can 
be prohibitively expensive for these models. MethOds: We overcome the limita-
tions of traditional probabilistic sensitivity analysis through a 4-step process. First, 
we conduct a thorough survey of all parameters and their confidence intervals. 
Second, we use local sensitivity analysis to evaluate the effects of each parameter 
on the outcome of interest. Third, based on results from single-parameter sensitivity 
analysis, we rank and identify a group of parameters that have the largest effects 
on the outcome. We then employ response surface (RS) approximation methods 
to create a mathematical model of the model predictions for these parameters. 
We use Latin Hypercube sampling (LHS) to generate data points and multivariate 
adaptive regression splines (MARS) to build the response surface approximations. 
Fourth, we sample parameters from their joint distributions, and then use the con-
structed response surface to calculate the probability distribution of the predicted 
outcomes. Results: We apply the above methodology to quantify uncertainties 
in predictions of the Archimedes Model for effectiveness of colorectal cancer (CRC) 
screening by colonoscopy (COLO) and fecal immunological test (FIT). We started out 
with 200 parameters and identified 20 parameters that have significant influences 
on predicted effectiveness of CRC screening. We conclude that there is a 89% chance 
that COLO will save more life years FIT, after accounting for parameter uncertainties. 
Similarly we estimate that there is a 61% probability that FIT is more cost effective 
than colonoscopy. cOnclusiOns: We have developed a robust and efficient meth-
odology for quantifying parameter uncertainties of large-scale simulation models 
used for cost-effectiveness analysis.
RESEARCH ON METHODS – Patient-Reported Outcomes Studies
PRM114
CATALOGUE OF EQ-5D SCORES FOR CHRONIC CONDITIONS IN DENMARK
Hvidberg M.F., Ehlers L., Petersen K.D.
Aalborg University, Aalborg, Denmark
Objectives: EQ-5D catalogues have been developed and tested in US and UK. The 
current study aims to develop a Danish preference-based EQ-5D 3L scores cata-
logue for around a hundred of the most common monitored chronic conditions. The 
development is based on experiences from the US and UK, but adding new factors of 
importance such as health habits, BMI, social networks and stress. MethOds: The 
marginal disutility estimates will be calculated using CLAD and OLS regression on a 
single source population from a random sample: the National Danish Health Survey 
Data from 2010 which is a self-administrated survey with approx. 38.000 respond-
ents age ≥ 16. The survey data is combined with data from national registers contain-
ing individual health data e.g. diagnosed chronic conditions during hospitalization, 
medication, use of hospitals as well as socio-economic data. The catalogue differs 
from UK and US catalogues’ by adding health habits information and by using ICD-
10 classifications from registers as well as it is based on Danish EQ-5D tariffs. The 
marginal disutility is calculated for each chronic condition controlling for age, gen-
der, ethnicity, income, education and comorbidity etc. Results: Marginal disutility 
estimates (EQ-5D) for around a hundred ICD-10 chronic conditions are presented 
and compared. It is expected that this new knowledge will contribute and qualify 
prioritization debate, when results are published and combined with knowledge of 
for example factors of importance and burden of disease in costs. cOnclusiOns: 
The catalogue will provide scientist with an “off-the-shelf” tool for use in health eco-
nomic evaluations. Marginal disutilities estimates can be used to estimate QALY’s 
in CEA for a wide variety of conditions in Denmark.
PRM115
PATIENT PREFERENCES ON TREATMENTS FOR ERECTIL DySFUNCTION 
DEFINED By MEANS OF DIFFERENT ATTRIBUTE GROUPS: THE METHOD OF 
ADMINISTRATION IS THE MOST vALUED ATTRIBUTE AND THE ORODISPERSIBLE 
TABLET IS THE MOST PREFERRED LEvEL
Gutiérrez P.1, Rebollo P.2, Mendivil J.3, Vera V.2, Cazorla D.3, Rodríguez-Aguilella A.2, Osorio G.3
1Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, 2LASER Analytica, 
Oviedo, Spain, 3Bayer HealthCare, Barcelona, Spain
Objectives: Phosphodiesterase type 5 inhibitors (PDE5i) for the treatment of erec-
tile dysfunction (ED) have similar pharmacologic profile. Patient preferences may 
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for use in diabetes (n = 11; 13%) ), then 7 pain instruments (8%), 5 respiratory question-
naires (6%), 2 urological questionnaires (2%) and 2 treatment specific instruments 
(2%). The remaining 30 (34%) instruments covered individual conditions ranging from 
anaemia to osteoporosis. cOnclusiOns: There are at least 88 patient’s treatment 
satisfaction/preference instruments published for possible use in clinical trials; 31 of 
which are useful for evaluating satisfaction / preference for drug therapies without 
reference to a specific therapy area. For those disease-specific measures, assessment 
of content validity and psychometric properties should be assessed before chosing 
the most appropriate measure for a given study.
PRM121
DUAL BACK TRANSLATION vERSUS SINGLE BACK-TRANSLATION 
METHODOLOGy wHEN TRANSLATING PATIENT REPORTED OUTCOMES (PRO)
Talbert M.1, Brandt B.A.2, McKown S.1, Gawlicki M.C.2, Heinzman A.3, Polltiz A.4
1Corporate Translations Inc., Chicago, IL, USA, 2Corporate Translations, Inc., East Hartford, CT, 
USA, 3Corporate Translations Inc., East Hartford, CT, USA, 4Corporate Translations, Inc., Chicago, 
IL, USA
Objectives: To determine whether dual back-translators improve the transla-
tion process for Patient Report Outcomes (PRO). MethOds: Four (4) PROs were 
translated using dual back-translators. The two back-translators worked indepen-
dently, possessing no knowledge of the other’s back-translation. The translated PROs 
were: a physical assessment questionnaire containing 1507 words with medical 
terminology, a physical assessment questionnaire with simple terminology con-
taining 593 words, a COPD questionnaire containing medical concepts with 713 
words, and a cancer treatment questionnaire containing colloquial terminology 
and 403 words. Instances of the following scenario were tallied during analysis: 
one back-translation accurately reflected the source, the other back-translation 
inaccurately reflected the source, but revealed an error in the forward translation. 
The same PROs were analyzed again, focusing only on one of the back-translators 
to compare the number of forward translation revisions that occur when using a 
single back-translator. Results: After analysis, 184 forward translation revisions 
occurred when using dual back-translators. 11 out of the 184 were a revision to a 
forward translation where one back-translation was correct despite the other back-
translation being incorrect. This occurred 4 times amongst Slavic family languages, 
3 times amongst Indian languages, 3 times amongst Southeast Asian languages, and 
once with Chinese. No such revisions occurred amongst Latin and Germanic lan-
guage families. After analysis of the translated PROs with just one back-translator, 
a total of 180 forward translation revisions occurred. cOnclusiOns: A second 
back-translation improves the translation process if the readability of the text of 
higher difficulty, and if Slavic, Asian and Indian language translations are required. 
However, the low number of revisions resulting from one incorrect back-transla-
tion, while using dual back-translators, demonstrates that one back-translator is 
acceptable. Since dual back-translators revealed the need for only 4 more forward 
translation revisions than the single back-translator, the quality output is similar.
PRM122
MOBILE PHONE USE IN PATIENT REPORTED OUTCOMES – A LITERATURE 
SEARCH
O’Gorman H.
Exco InTouch, Nottingham, UK
Objectives: To demonstrate the increased use of mobile phones to collect patient 
reported outcomes in research and to show that they are a valid method of data col-
lection. MethOds: A literature search was conducted looking at articles published 
between 2009 and 2013 that referenced electronic diaries of some description. Articles 
were pulled out that specifically referenced mobile or cellular phones. Results: 
Twenty-four of out of 157 articles found specifically referenced mobile. The studies 
referenced in these articles were carried out on populations with an age range of 8 
years up to 70 and were split into 12 therapy areas including metabolic and genetic 
disorders, pain, weight management, sexual activity, respiratory and alcohol related. 
Population size ranged from 15 to 994 (mean 145.6; SD-180), and subjects reported 
for a minimum of 7 days (up to 6 reports per day) to a maximum of 365 days (mean 
107.9 days; SD-112.6). Notably, 17 out of the 24 studies allowed the subjects to use 
their own mobile phone for the reporting and 11 referenced smartphones specifi-
cally. cOnclusiOns: All concluded that mobile phones were suited to collect data 
from subjects. It was noted that the use of mobiles was acceptable as they are used 
them in everyday life and found to be convenient; the technology was also inexpen-
sive to implement. The fact that 70.8% of the studies allowed the subjects to use their 
own mobile phones for the reporting emphasises the practicality of using mobile 
phones in patient reported outcomes. Although the mean age of all the studies was 
relatively low, the age range was very wide and researchers can be confident that 
older populations could use mobile phones to collect these data. The rapid adoption 
and technical evolution of mobile technologies and ubiquitous nature show that this 
technology is a valid means to collect patient reported outcomes.
PRM124
ExPLORING THE FEASIBILITy OF THE INSTRUMENT USED IN DETERMINATION 
OF wILLINGNESS-TO-PAy PER QUALITy-ADjUSTED LIFE-yEAR IN MALAySIA
Lim Y.W., Shafie A.A., Hassali M.A.A., Chua G.N.
Universiti Sains Malaysia, Penang, Malaysia
Objectives: The lack of empirical and well-accepted cost-effectiveness (CE) thresh-
old is recognized as one of the most important barriers in using Health technology 
assessment (HTA) in policy decisions and this is no exception in Asia Pacific region. 
HTAsiaLink, a network of HTA organizations in Asia has embarked on first collabora-
tive research on determining the CE threshold across 4 countries in Asia Pacific region 
namely Korea, Japan, Malaysia, and Thailand. This pilot study aimed 1)to explore 
the feasibility of the instrument/methods used 2)to examine the value of a quality-
adjusted life-year (QALY) associated with improving quality of life in mild, moderate 
and severe health condition, and extending life during terminal illness. MethOds: 
Five EQ-5D health states with different health severity (11121, 11212, 11323, 11223 
Objectives: There is a variety of disease modifying drugs available for the 
treatment of multiple sclerosis (MS). These drugs are associated with different 
characteristics in key attributes such as side effects, mode of administration etc. 
The current study was carried out to assess the importance of treatment charac-
teristics for patients’ preferences in an ecologically valid design. MethOds: In 
a discrete choice experiment (DCE), MS patients from 38 neurological practices 
in Germany (n= 1,153) were asked to choose the most and the least preferred 
drug (best-worst-scaling) among hypothetical multi-attribute alternatives with 
varying levels of the following key attributes: mode of administration, local and 
systemic side effects, frequency of administration, and required monitoring of the 
patient. This design (Case-3, multi-profile case) simulates a real choice situation 
between different hypothetical multi-attribute pharmaceutical treatment alterna-
tives. Results: On average, patients (~75% female) were 42 years of age with 9.6 
years of disease duration, and ~90% reporting prior experience with parenteral 
modes of administration. Count analysis (Flynn & Louviere, 1992; Orme, 2009) 
yielded that mode of administration was the most important attribute guiding 
patients’ preferences, with ‘oral application’ being most desired (selected as best 
option in 63% of the cases). Notably, the studied systemic side effects, such as 
flu-like symptoms or gastrointestinal disorders were only half as important as 
mode of administration for patients’ choice. The second most relevant attribute 
was frequency of administration, with ‘administration once a week’ being the most 
preferred attribute level (in 47% of the cases). cOnclusiOns: Our data indicate 
that for MS patients, the most important attributes of MS disease modifying drugs 
are route of administration (oral being the number one choice by majority) and 
frequency of administration (with intake once a week being the most preferred), 
probably because these aspects meet the patients’ need for low treatment burden 
in daily life.
PRM119
RELIABILITy AND vALIDITy OF A THAI vERSION OF LAM EMPLOyMENT 
ABSENCE AND PRODUCTIvITy SCALE (LEAPS)
Pumpaisalchai W.1, Ruengorn C.2, Karahong K.3, Jamroenkhajonsuk P.4, Pongdoung T.1, 
Udombhornprabha A.5
1Suanprung Hospital, Chiang Mai, Thailand, 2Faculty of Pharmacy,Chiang Mai University, Chiang 
Mai, Thailand, 3Omkoi Hospital, Chiang Mai, Thailand, 4Sobprab Hospital, Lampang, Thailand, 
5College of Public Health Science, Chulalongkorn University, Bangkok, Thailand
Objectives: Work-loss disability from ailments especially depression become 
shortcoming in economic development thus demands early reverts. No reliable tool 
to evaluate work-loss diability in Thai developed. We assessed reliability and validity 
of Thai version of Lam Employment Absence and Productivity Scale (LEAPS),direct 
patient report outcome subsequent to ailments. MethOds: An original LEAPS 
was officially acquired,validated by language experts, distributed to field-test 
from patients age above 18 years with ailments seeking treatment at hospital. The 
scale reliability employed item-scale and inter-item consistency with standardized 
Chronbach’s alpha coefficient. The scale discrimination for patient with income or 
non-income job was determined and compared using area under curve for Receiver 
Operating Characteristics (AuROC) with Chi-square test. Results: There were 
seven main LEAPS items with five responder choices. Of 201 patients, 86(42.8%) 
male,115(57.2%) female, mean (SD)age of 39.6(15.2) years recruited from 3 hospitals. 
132(65.7%) and 69(34.3%) patients were classed in income job and non-income job 
respectively. Background education were graduate 76(38%), vocational certificate 
35(17.5%), high school 42 (21%) and primary education 42(21%). 74 (37.2%) of patients 
had been diagnosed with co-morbidities whom 13(18%) and 61(82%) were psycho-
logical and physical illness respectively. Overall 120(60%) of patients complained 
about their health problems which demanded medical treatment within one week, 
where 58(29%) reported the condition not interfere with daily activities whereas 
36(18%) indicated that the conditions were severe and needed hospitalization. 
The responder to LEAPS was 94.5%. Reliability test for overall internal consistency 
Chronbach’s alpha coefficient were 0.834 with AuROC of 0.78,95%CI:0.72-0.85. The 
AuROC for non-income generating vs income-generating group of 0.82,95%CI:0.71-
0.92 vs 0.77,95%CI:0.69-0.86 were not significant different (p= 0.528) with correspond-
ing Chronbach’s alpha coefficient of 0.811 vs 0.842 (p= 0.667). cOnclusiOns: Thai 
version Lam Employment Absence and Productivity Scale(LEAPS) is reliable to use 
among Thai patients. The scale is robust with consistency among Thai patients with 
employment and loss productivity regardless of income-generating job and highly 
predictive for work-loss disability.
PRM120
A SySTEMATIC REvIEw OF PATIENTS’ TREATMENT SATISFACTION AND/OR 
PREFERENCE PATIENT-REPORTED OUCOMES MEASURES USED IN CLINICAL 
TRIALS
Pease S.1, Savre I.2, Rudell K.3, Perret C.2, Symonds T.4
1Pfizer Inc, Whitmore Lake, MI, USA, 2MAPI Research Trust, Lyon, France, 3Pfizer Limited, 
Tadworth, UK, 4Pfizer Ltd., Surrey, UK
Objectives: To determine the availability of Patient Reported Outcome (PRO) 
instruments measuring Patient’s Treatment Satisfaction and/or Preference for drug 
therapies. MethOds: The authors conducted a systematic review of the published 
literature using established biomedical literature databases (Medline and Embase), 
ClinicalTrials.gov as well as a PRO specific database (PROQOLID). The instruments 
identified through the various sources were selected according to specific criteria: 1) 
Include: PRO instruments of Treatment Satisfaction or Preference as a sole concept OR 
PRO instruments with at least two domains of Treatment Satisfaction or Preference; 2) 
Exclude: Evaluation of biomarker control OR No information found on the PRO instru-
ments. Results: The systematic literature review identified a total of 720 articles on 
biomedical databases and 1634 closed clinical trials on Clinicaltrials.gov. The search 
in PROQOLID identified ten PRO instruments. From an initial review, 130 instruments 
were considered of particular relevance. Upon detailed review, 88 PRO instruments 
met selection criteria - nine of which were solely designed for a specific study. Of these 
88 PRO instruments, 31 were generic (35%). The most disease-specific measures were 
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Objectives: Haemophilia A treatment involves replacement of missing clotting 
factor (FVIII) by intravenous infusion prophylactically or on-demand. Treatment 
adherence is influenced by patients’ beliefs about their condition, treatment and 
side effects; mode of administration can also be a significant barrier. This study 
aimed to assess the psychometric properties of a survey evaluating patient percep-
tion and preference for haemophilia A treatment. MethOds: A 40-item survey 
(derived from existing literature) was developed to assess patient perception and 
preference for haemophilia A treatment and delivery systems in five European 
countries. Item refinement and analyses involved: 1) item response and dimen-
sionality analyses using classical test theory; 2) finalisation of items based on data 
analysis and clinical relevance; 3) scoring development; 4) psychometric testing of 
the resulting scores including 4a) Rasch analysis, factor analysis, item-level discri-
minant validity tests and item response distributions; 4b) internal consistency reli-
ability; and 4c) known-groups validity. Results: A total of 273 male patients with 
haemophilia A completed the survey. The results support the survey’s construct, 
known-groups; item-level convergent and divergent validity; and internal consist-
ency reliability. A five-factor solution was observed with the following subscales: 1) 
Ease of using clotting factor treatment; 2) Impact of clotting factor treatment; 3) Risk 
associated with clotting factor treatment; 4) Burden of clotting factor treatment; and 
5) Influence of others on treatment choices. Twenty-seven items were deleted based 
on redundancy identified through poor psychometric performance and low clinical 
relevance, and one item was added (to provide a rating on ease of use of treatment 
which was considered missing from a content validity perspective) resulting in a 
14-item scale. cOnclusiOns: A sequential process of item evaluation and reduc-
tion resulted in a short, patient-completed ‘Perceptions of clotting factor treatment’ 
survey - a brief, psychometrically tested method assessing patient perceptions and 
preference for clotting factor treatment in haemophilia A.
PRM128
vALIDATION OF THE MULTIPLE SCLEROSIS INTERNATIONAL QUALITy OF LIFE 
QUESTIONNAIRE IN ELECTRONIC FORM USING ITEM RESPONSE THEORy
Gupta S.1, DiBonaventura M.2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA
Objectives: The Multiple Sclerosis International Quality of Life Questionnaire 
(MusiQoL) has been validated in paper and pencil form. Validating patient-reported 
outcomes using Item Response Theory (IRT) along with Classical Test Theory (CCT) 
methods are becoming progressively more common. The current study examined 
the psychometric properties of the MusiQoL among patients diagnosed with multi-
ple sclerosis (MS) using an online version of the instrument. MethOds: Data were 
used from a 2012 US survey of patients self-reporting a diagnosis of MS (N= 1,000). 
The online survey collected information on patients’ demographics, disease and 
treatment history, and health outcomes. Participants also completed the Multiple 
Sclerosis Rating Scale Revised (MSRS-R) and the abbreviated Treatment Satisfaction 
Questionnaire for Medication (TSQM-9). Internal consistency and concurrent valid-
ity were examined for the domain-specific scores and the composite total score 
of the MusiQoL. IRT (one and two-parameter graded response models) analyses 
evaluated item discrimination and item difficulty. Results: Among 1000 patients 
with MS, 82.8% were female, the mean age was 48.7 (SD = 11.29), and 76.7% were 
currently using a disease-modifying medication. Internal consistency (Cronbach’s 
α ) of the total scale of the MusiQoL was 0.913 and the domain scores ranged from 
0.824 to 0.944. The total score of the MusiQoL were moderately-to-strongly correlated 
with MSRS-R (r= -0.551), and adequately correlated with the subscales of the TSQM-9 
(r= 0.138 to 0.348). Items varied in their discrimination (range: 1.507 to 4.814) and dif-
ficulty (range: -2.875 to 2.362) parameters. Majority of the MusiQoL domains best dis-
criminated at lower levels of health-related quality of life (HRQoL). cOnclusiOns: 
IRT and CCT are both helpful means for evaluating the psychometric properties 
of the MusiQoL. The MusiQoL in electronic form is reliable and valid for evaluat-
ing HRQoL in patients with MS, but performs best when discriminating among 
respondents with poorer HRQoL.
PRM129
FUNCTIONAL OBSERvATION wITH TTO IN CHRONIC DISEASES
Kövér K., Meszaros A.
Semmelweis University, Budapest, Hungary
Objectives: Ageing population will result in an increased social burden of 
chronic diseases. Therefore we evaluate the impact of three chronic diseases 
(Diabetes Mellitus;DM, Hypertension;HT, Rheumatoid Arthritis;RA) on quality of 
life (QoL) in Hungary with EuroQoL-5D-3L (EQ-5D) EuroQoL-Visual Analogue Scale 
(EQ-VAS) and Time Trade Off (TTO). TTO is useful in health planning, economic 
evaluation as it is a utility measure when health state is based on the willingness 
to trade off lifetime MethOds: A total of 468 patients were interviewed with 
EQ-5D, EQ-VAS and TTO. 253 patients with RA, 110 patients with DM and 105 
patients with hypertension filled out the questionnaires. In TTO patients need to 
choose between two alternatives: living with the actual health state for ten years 
or living with perfect health state for Y years. We used the ping-pong method 
to find the minimum Z period of time which is offered in exchange for perfect 
health. Results: The EQ-5D mean scores were according to our expectations: RA 
had lowest (0,525;SD:0,32); DM had 0,73;SD:0,26 and HT had highest (0,769;SD:0,26). 
In contrast TTO was lowest in DM (0,74;SD:0,24); RA was 0,769;SD:0,21 and HT was 
0,815;SD:0,21. TTO results are higher than EQ-5D index scores in all disorders. 
Moderate correlation (0.2< r< 0.7) was observed in all cases between EQ-5D, VAS 
and TTO at 0.01 significance-level opposed to HT where correlation was lower 
(r= 0,18). cOnclusiOns: The low correlation between EQ-5D and TTO in HT could 
be due to the lacking disease awareness in many subjects, TTO needs special con-
sideration in such patients. TTO is an easy method to use but some of the patient 
could not understand the question or they had difficulties to accept the concept 
of giving up life-years, some needed longer explanation. The answer on the EQ-5D 
depend only on patient’s health state however the answer of the TTO depend on 
health, social state and religion.
and 22332) were used. For improving quality of life scenarios, willingness-to-pay 
(WTP) to avoid being in the given health state for a given duration was determined 
to ensure the similar magnitude of QALY gained (0.2 and 0.4QALYs) across health 
conditions. Similarly, in extending life during terminal illness and life saving sce-
narios, WTP for increasing life expectancy for given 0.2 and 0.4QALYs were examined. 
Data were analysed using Predictive Analytics Software (PASW v18.0). Results: The 
mean WTP/QALY value for 199 adult was estimated at MYR10,505 (SD:17311) for mild, 
MYR10,906 (SD:15,101) for moderate and MYR14,981 (SD:21,774) for severe health con-
dition. For terminal illness with extended life scenario, it was estimated at MYR19,611 
(SD:27,054). Participants took mean of 29.74 minutes (SD:6.77) to response. One-third 
(32.2%) of the respondents felt the questionnaire was difficult to answer and 7% rated 
it as very difficult. cOnclusiOns: The instrument used was feasible for determin-
ing the value of WTP/QALY. However, further revision of the questionnaire may be 
required to simplify the research task. This study also suggested that the threshold 
for Malaysia to be MYR10,505(0.35GDP)–MYR19,611(0.66GDP) per QALY.
PRM125
EPRO MIGRATION AND USABILITy TESTING OF PATIENT-REPORTED OUTCOME 
(PRO) MEASURES
Wilkins G.1, Two R.1, Churchman D.2, Jenkinson C.3, Dawson J.4
1PharmaQuest Ltd., Banbury, UK, 2Isis Outcomes, Oxford, UK, 3University of Oxford, Oxford, UK, 
4Health Services Research Unit, Department of Public Health, University of Oxford, Headington, 
UK
Objectives: In recent years there has been an increase in interest surrounding the 
adaptation of traditional paper-based PRO measures to create ‘ePRO’ (electronic PRO) 
versions. Questionnaires in this format are intended to be administered to patients 
via a tablet or PDA device, website or other electronic media. In collaboration with 
Isis Outcomes, PharmaQuest Ltd. has managed a series of ePRO migration and trans-
lation studies. The aim of the study presented here was to produce versions of the 
Oxford Hip Score (OHS) and Oxford Knee Score (OKS) that can easily be completed 
by patients through electronic media, and that are conceptually equivalent to the 
original paper-based measures. MethOds: The adaptation process consisted of 3 
main steps. Firstly a draft ePRO version was produced and discussed to resolve any 
formatting issues. The draft was then tested for conceptual equivalence with the 
paper-based measure via cognitive debriefing interviews with patients from the 
target population. Finally, a series of usability questions were used to assess the 
patients’ experience of completing the ePRO measure. Results: Overall, no com-
prehension issues were reported during the cognitive debriefing step for these ques-
tionnaires, although the clarity of some instructions was questioned. The feedback 
from usability testing varied predominantly by age group, with older respondents 
generally reporting more difficulty in using the ePRO device. However, a large major-
ity of respondents reported that the ePRO version was preferable to a paper ques-
tionnaire. cOnclusiOns: Cognitive debriefing feedback confirmed that the ePRO 
versions presented here were conceptually equivalent to the paper questionnaires. 
The ePRO versions were generally well received by patients, although the usability 
testing highlighted the importance of clear instructions and intuitive software.
PRM126
LOCALIzATION OF ACTIvITIES AND EQUIvALENCE OF MOvEMENT IN CLINICAL 
OUTCOMES ASSESSMENTS
Talbert M.1, McKown S.1, Gawlicki M.C.2, Brandt B.A.2, Angun C.3, Schulz C.2
1Corporate Translations Inc., Chicago, IL, USA, 2Corporate Translations, Inc., East Hartford, CT, 
USA, 3Corporate Translations Inc., Odunpazarı, Eskişehir, Turkey
Objectives: Clinical Outcomes Assessments (COAs) frequently include questions 
to assess patients’ ability to perform specific activities. Some activities may not be 
applicable in the target country, necessitating adaptation during translation. When 
requiring adaptation, a tendency exists to substitute an equally recognizable, but 
non-equivalent, activity. Consideration of movements and exertion, as well as cul-
tural appropriateness, is imperative. Failure to do so can impede data pooling across 
languages in multinational trials. MethOds: Languages observed were Eastern 
European, Indian, Middle Eastern, Asian, and Southeast Asian, all of which presented 
difficulties in adapting “Western” activities. The activities analyzed appeared in 
actual patient questionnaires that underwent linguistic validation. Alternatives 
were recommended by linguists and cognitive debriefing subjects. Results: In 
Arabic for Egypt, “bocce” was deemed inapplicable. “Billiards” was suggested as an 
appropriate alternative as both require standing and light exertion. “Bocce” also 
posed difficulties for Indian languages. The initial alternative was “cricket,” however, 
cricket requires higher exertion and running. A suitable alternative was “playing 
marbles,” as the Indian version requires standing, light movement, and no running. 
Questionnaires also may assess one’s ability to complete personal hygiene tasks, 
such as “getting in and out of a bathtub.” In Indian languages, cognitive debriefing 
subjects did not understand “bathtub,” as a majority of the target sample do not have 
“bathtubs” at home. A suitable alternative was “to sit on and get up from a small 
stool in order to take a bath with a tumbler.” This activity replicated both the source 
movement and exertion with a culturally appropriate activity. cOnclusiOns: 
Adaptation of Western activities in COAs requires consideration of the movement 
and exertion involved in the source, as well as maintaining cultural appropriate-
ness and familiarity to the respondent. This is essential when creating a localized 
questionnaire that will yield sound data across languages.
PRM127
ITEM REFINEMENT AND PSyCHOMETRIC TESTING OF A NOvEL SURvEy FOR 
EvALUATING PATIENT PERCEPTION AND PREFERENCE FOR HAEMOPHILIA A 
TREATMENT
Teal S.A.1, Brohan E.2, Hettema Y.3, Humphrey L.4, Willgoss T.4, Hudgens S.5, Westfeld M.3, 
Cappelleri J.C.6
1Pfizer Ltd., Tadworth, UK, 2Adelphi Values Ltd., Manchester, UK, 3Pfizer Italia srl, Rome, Italy, 
4Adelphi Values, Bollington, UK, 5Clinical Outcome Solutions, Tucson, AZ, USA, 6Pfizer Inc., New 
York, NY, USA
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erties of the questionnaire, but, due to VCP’s transversal design, the full process 
hasn’t been achieved.
PRM133
PATIENT REPORTED OUTCOMES wITH MULTIPLE SCLEROSIS IN SLOvAKIA
Tomekova K.1, Tomek D.2, Bielik J.3, Visnansky M.4
1Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, 2Pharmaceutical Faculty at 
Comenius University, Bratislava, Slovak Republic, 3Trencin University, Trencin, Slovak Republic, 
4SLOVAHTA, Bratislava, Slovak Republic
Objectives: The current prevalence of Multiple Sclerosis (MS) in Slovakia ranges 
from 100 till 150 cases per 100 000, actualized by 112 cases with insurance data. 
There are approx. 6 100 MS diagnosed MS patients. The objective of this paper was to 
find out all possible data about patients and for patients. MethOds: We conducted 
a research in collaboration with MS patient organizations. No HCP were involved, 
patient investigators were trained. A. Demography, treatment and socioeconomics 
(53 items), B. Specific questionnaire (31 items). We disseminated 500 questionnaires, 
356 valid questionnaires were at the end evaluated, 78% women, 20% men (2% n. a.), 
average age 48.5 ± 11.9 , range 23-78 y, median 49.5 y, 52% college/gymnasium, 24% 
university, equal w + m (p= 0.460). Results: First symptoms related to SM raised 
average in the age of 30.9 ± 9.2 y (median 30 y), 12% before the age of 20, 18% after 40 
, 41% were diagnosed until 6 months of the first visit by physician, another 21% in 
1 y. 30% were diagnosed after more than 2 y. 45% EDSS 4-6.5, 33% EDSS 0-3 and 16% 
EDSS 7-9.5 (6% did not announced), 60% impaired with walking, 10% wheelchair, 2% 
in bed, 51% with assistance by daily activities, 9% by any activity. With rising EDSS 
MS therapy declines and other therapy is rising. cOnclusiOns: The patients with 
MS in Slovakia, even with a relatively generous support from health care and social 
care and with available conventional or disease modifying therapy (DMT) suffer a 
significant decrease of their QoL.
PRM134
RELIABILITy AND vALIDITy OF THE PEDIATRIC QUALITy OF LIFE INvENTORy 
GENERIC CORE SCALES FOR DUTCH CHILDREN wITH FUNCTIONAL 
CONSTIPATION
Hartman E.E.1, Pawaskar M.2, Dubois D.3, Benninga M.A.4, Joseph A.5
1Tilburg University, Tilburg, The Netherlands, 2Shire, Wayne, PA, USA, 3ULB, Brussels, Belgium, 
4Emma Children’s Hospital/Academic Medical Center, Amsterdam, The Netherlands, 5Shire 
Switzerland, Eysins, Switzerland
Objectives: Although psychometric properties of the Quality of Life InventoryTM 
(PedsQL) version 4.0 Generic Core Scales have been established in different pedi-
atric populations, it has not been validated in patients with functional consti-
pation (FC). The primary objective of the current study was to determine the 
reliability and validity of the Dutch translation of PedsQL in children with FC 
in The Netherlands. MethOds: The PedsQL was administered to 189 children 
and adolescents (aged 5-18 yrs) who met the Rome III diagnosis criteria for FC 
and 257 parents (of patients aged 2-18 yrs) recruited from 12 hospitals. Missing 
responses, internal consistency and reliability (Cronbach’s alpha), discriminant 
validity (t-test comparisons between children with FC and a separate sample of 
healthy children [from the literature]) and construct validity (Pearson correlation 
between a-priorihypothesized relationships between the PedsQL and disease-
specific indicators, including the GI-module and the Defecation Disorder List), and 
inter-rater reliability between self- and parent-reports (Intraclass Correlations 
Coefficients, ICC) were assessed. Results: The PedsQL showed minimal missing 
responses (5% child-, 0% parent-report) and achieved good to excellent internal 
consistency reliability for the Total Score (α 0.86 child, 0.88 parent), Physical Health 
Summary Score (α 0.75 child, 0.83 parent), and Psychosocial Health Summary 
Score (α 0.79 child, 0.85 parent). It also distinguished between healthy references 
and children with FC (d= 0.28-0.57 child, 0.49-0.85 parent). The PedsQL was cor-
related to disease-specific reference measures (r varied from 0.23 to 0.57 child, 
0.25 to 0.45 parent) consistent with the a-priori hypotheses. ICC’s between child 
and parent-reports ranged from 0.70 to 0.72. cOnclusiOns: The results showed 
good initial measurement properties of the Dutch version of the PedsQL generic 
core scales in patients with FC. It could be considered as a valuable tool for 
measuring health related quality of life in Dutch speaking patients aged 2 to 18 
years with FC.
PRM135
PILOT TESTING OF THE POLISH PRE-FINAL vERSION OF “DISABILITIES OF THE 
ARM, SHOULDER AND HAND” (DASH) QUESTIONNAIRE
Golicki D.1, Krzysiak M.2, Strzelczyk P.3
1Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, 
Poland, 2Oddzial Rehabilitacji Dziennej, MCR Stocer, Konstancin Jeziorna, Poland, 3The Kosciuszko 
Foundation scholar, New York, NY, USA
Objectives: To perform a pilot testing of the translated and culturally adapted 
Polish pre-final version of the DASH questionnaire in a population from a target 
setting. MethOds: Thirty patients (20 men), medium age 41.1 years (range 13 
-79) from Rehabilitation Centre STOCER (Konstancin-Jeziorna) took part in pilot 
testing. The studied population was heterogeneous in terms of side affected (right: 
13, left:13, both: 4), diagnosis (20 different diagnoses, most common - brachial 
plexus injury, n= 6) and treatment (both conservative and surgical). Subjects com-
pleted questionnaires and were asked if there were questions that were difficult to 
respond or difficult to understand. After that each patients had to explain in his/
her own words the meaning of five randomly chosen questions and their answers. 
We analyzed: number of missing items by question, number of missing items by 
patients and distribution of responses for each item. Results: Understanding of 
randomly chosen questions and answers was appropriate. All items, except one, 
had high frequency of present answers (86.7% - 100%). Item 21 (sexual activity) was 
omitted by 60% of respondents. Number of missing items by patients ranged from 
0 to 6. Five patients (16.7%) had more than 10 percent of the items left blank. Three 
from these persons were 60 years of age and over and could characterize with 
PRM130
vALIDATION OF THE wHOQOL-OLD IN TAIwAN
Yao G., Chien C.C.
National Taiwan University (Dept. of Psychology), Taipei, Taiwan
Objectives: To examine the psychometric properties of the WHOQOL-OLD in 
Taiwan. MethOds: Five questionnaires including the WHOQOL-BREF, WHOQOL-
OLD, Geriatric Depression Scale (GDS-15), Barthel Index (BI), and Mini-Mental State 
Examination (MMSE) were used. A total of 524 participants (M = 76.2, SD = 7.5, 
ages ranged from 60 to 99) from northern and southern Taiwan completed these 
questionnaires. Cronbach’s alpha, correlation analysis, and factor analysis were 
conducted to examine internal consistency reliability, content validity, criterion 
validity, and construct validity. Results: Among the participants, 180 (34.4%) were 
male, and 344 (65.6%) were female. The results showed that the originally designed 
6-factor model of the WHOQOL-OLD was supported. Fit indices (CFI = 0.93, IFI = 
0.93, NNFI = 0.92 and RMSEA = 0.06) were acceptable. The internal consistency 
coefficients (Cronbach’s alpha) ranged from 0.72 to 0.95 for the 6 domains. Content 
validity coefficients were in the range of 0.41 to 0.80 for item-associated domain 
correlations. Except for the DAD domain (Death and dying), other domains showed 
moderate to high inter-domain correlations (Pearson’s correlation ranges from 0.24 
to 0.70) and provided good criterion related validity with GDS-15 and WHOQOL-BREF 
(Pearson’s correlation ranges from 0.23 to 0.55). cOnclusiOns: The results showed 
that the psychometric properties of WHOQOL-OLD were acceptable. The WHOQOL-
OLD module is a useful instrument for the old people in Taiwan.
PRM131
DEvELOPMENT OF AN INTERvIEwER-ADMINISTERED vERSION OF THE 
ASTHMA CONTROL QUESTIONNAIRE (ACQ-IA) FOR 6-10 yEAR OLD PATIENTS IN 
11 LANGUAGES
Juniper E.1, Mear I.2, Kaschinski D.3
1McMaster University, Hamilton, ON, Canada, 2Mapi, Lyon, France, 3Boehringer Ingelheim GmbH, 
Ingelheim am Rhein, Germany
Objectives: The Asthma Control Questionnaire (ACQ) was developed and validated 
to measure the adequacy of asthma control in patients 11-70 years. Since younger 
children may have difficulty reading and understanding the instructions, questions 
and response options, an interviewer version (ACQ-IA) for 6-10 year old patients was 
developed and validated in UK English. If children had difficulty understanding an 
ACQ question, standardised alternative wording was added (in UK English, alterna-
tives were needed for questions 2-4 and 6). The objective was to develop the ACQ-IA 
in a further 11 languages [English (Australia), French (Belgium), Korean, Norwegian, 
Portuguese (Brazil, Portugal), Spanish (Argentina, Guatemala, Peru and the USA), 
and Swedish] based on the adult ACQ versions, using the methodology developed 
for the UK ACQ-IA. MethOds: First, the concept of each question was defined. For 
each language there was: (1) forward/backward translation of ACQ-IA instructions; 
(2) testing of instructions with interviewers; (3) Cognitive interviews with children 
(6-10yr) with symptomatic asthma (n= 5) to identify questions difficult to compre-
hend; (4) Development of alternative wording for these questions; (5) Testing of the 
alternatives on a different sample of children (n= 5). Results: In all languages at 
least three questions required alternative wording. Most frequently children had 
problems understanding medical terms such as “asthma,” “symptoms,” “wheeze,” 
and “short-acting bronchodilator.” “Asthma” was usually replaced by “difficulty in 
breathing” and “symptoms” was followed by examples in brackets (hard to breathe, 
cough, wheeze). For “wheeze”, “whistling sound when you breathe” was the most 
common alternative. Children usually know their “short-acting bronchodilator” as 
their “rescue” or “emergency” medicine. cOnclusiOns: Cognitive interviews with 
children were crucial for identifying ACQ questions difficult for 6-10 year olds to 
understand and for formulating the alternative wording in each language. The valid-
ity of this novel methodology for the ACQ-IA cultural adaptation has been further 
supported by these successful adaptations.
PRM132
STRUCTURAL vALIDATION OF THE CHRONIC vENOUS INSUFFICIENCy QUALITy 
OF LIFE QUESTIONNAIRE-14 (CIvIQ-14) : A CONFIRMATORy FACTOR ANALySIS
Le Moine J.G., Katumba K.R., Launois R.
Rees France, Paris, France
Objectives: The aim of this study was to confirm the factorial structure of 
the short version of the CIVIQ questionnaire using Vein Consult Program (VCP) 
results. MethOds: The VCP was an international study aiming to evaluate the 
impact of chronic venous disease (CVD) on cost and quality of life. The factorial 
structure of CIVIQ-14 was evaluated using two methods: confirmatory factor 
analysis (CFA) and multitrait/multi-items matrix. CFA was performed based on the 
3-dimensional structure of CIVIQ-14 established in a previous study. 6 indices from 
CFA were used to assess stability: Chi², Root Mean Square Approximation (RMSEA), 
Adjusted Goodness-of-Fit Index (AGFI), Standardized Root Mean square Residual 
(SRMR), Normed-Fit Index (NFI) and Comparative-Fit Index (CFI). In addition, VCP 
results were also used to evaluate the psychometric properties of the questionnaire. 
Prior to data analysis, missing data were replaced using multiple imputation and 
a bootstrap was conduct to take the country-effect into account. Results: A total 
of 47149 questionnaires from 17 countries were available in the VCP, of which 1438 
were excluded for more than 50% missing values. Results from the CFA showed 
an acceptable adjustment of the CVIQ-14’s 3-dimensional structure to VCP data. 
Within absolute-fit indices, both AGFI and SRMR proved the model to be relevant 
(AGFI= 0.905; SRMR= 0.034) while RMSEA was slightly over threshold (RMSEA= 0.079; 
threshold= 0.07). Relative-fit indices were consistent with absolute indices, with 
NFI= 0.95 and CFI= 0.95. Multitrait/mutli-items analysis agreed with CFA, showing all 
items to be more correlated to their dimensions score, with correlation coefficient 
superior to 0.4. Evaluating psychometric properties of the scale, Cronbach’s alpha 
proved internal consistency (α > 0.8 in all dimension). cOnclusiOns: Confirmatory 
factor analysis on VCP data supported the stability of the CIVIQ-14 questionnaire 
factorial structure. An attempt has been made to evaluate the psychometric prop-
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should take caution when mapping EQ-5D values from algorithms that have not 
been externally validated, especially where these algorithms have used clinical 
outcomes or disease-specific measures of health-related quality of life. Our results 
suggest that mapping from generic outcome measures might be reasonable.
PRM139
LOST IN TRANSLATION: TRANSLATABILITy OF PSyCHIATRIC TERMS – THE 
ExAMPLE OF THE MINI–INTERNATIONAL NEUROPSyCHIATRIC INTERvIEw 
(M.I.N.I.)
Boudrot A.1, Sheehan D.2, Acquadro C.3
1Mapi, Lyon, France, 2University of South Florida College of Medicine, Tampa, France, 3Mapi 
Research Trust, Lyon, France
Objectives: The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a short, 
structured diagnostic interview, developed by psychiatrists and clinicians in the 
USA and Europe, for DSM-IV and ICD-10 psychiatric disorders. The objectives of our 
study were: 1) To determine if the psychiatric terms used in the M.I.N.I. are trans-
latable worldwide, especially in non-western countries, and 2) To review strategies 
used to culturally adapt psychiatric terms. MethOds: We reviewed the records 
of all linguistic validation projects involving the M.I.N.I. Results: We retrieved 
67 language versions, representing 47 countries. The analysis of the translations’ 
content revealed three types of results, depending on the existence (or not) of cor-
responding psychiatric terminology in the target languages. The standard meth-
odology (forward/backward and clinician review) was used in all countries and 
adapted, depending on the context. In all western and westernized countries (e.g., 
Europe, Russia, etc., totaling 49 languages), the psychiatric terms used in the M.I.N.I. 
were easily translated (i.e., existence of an agreed-upon corresponding terminol-
ogy). In languages where psychiatric terms do not exist (e.g., certain Sub-Saharan 
languages), all the clinician-directed parts (titles and clinician-directed instruc-
tions/algorithms), which are capitalized in the original instrument, were left in 
English, and the patient-directed parts were translated in the target languages. In 
languages where there is a partially agreed-upon terminology (e.g., Thai), the titles 
as well as the algorithms were translated with corresponding English equivalents 
between brackets, when necessary. Moreover, in order to follow the typographical 
conventions of the M.I.N.I., in languages with no capital letters (such as Kannada 
or Malayalam), the translations used bigger font size. cOnclusiOns: This review 
showed that terms used to describe psychiatric disorders had no equivalents in 
some countries, especially in Africa. Translation was not always possible and was 
even judged to be culturally and linguistically irrelevant in countries where psy-
chiatry is only taught in English.
PRM140
HEALTH-RELATED QUALITy OF LIFE (HRQOL) IN PATIENTS TREATED By NOvEL 
ORAL ANTICOAGULANTS (NOACS): REDUCED vERSION OF THE SAwICKI 
QUESTIONNAIRE
Rodríguez-Aguilella A.1, Viñolas Prat X.2, Campillo-Álvarez Á1, Martínez Sande J.L.3,  
Alegret Colomé J.M.4, Castejón N.1, Osorio F.ernández G5
1LASER Analytica, Oviedo, Spain, 2Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 3Hospital 
Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 4Hospital 
Universitario Sant Joan de Reus, Reus, Spain, 5Bayer Hispania SL, Barcelona, Spain
Objectives: Sawicki questionnaire is a 32-item specific measure for the evalu-
ation of the change in the measure of the Quality of Health Related Life (HRQOL) 
experienced by patients treated by Novel Oral Anticoagulants (NOACs) versus tra-
ditional Oral Anticoagulant Therapies (OAT). The objective of this research focuses 
on the application of the Rasch model in selecting the most appropriate items of 
Sawicki questionnaire. MethOds: Sample was composed of 689 Atrial Fibrillation 
(AF) patients in whom an attempt of electrical or pharmacological cardioversion 
was scheduled within a 4 months inclusion period from baseline (CARDIOVERSE 
study). Data were analyzed with WinSteps version 3.75 using the Rasch Partial 
Credit Model. Statistical criteria taken into account for the selection of those 
items with better psychometric properties were: model-fit and separation statis-
tics, Differential Item Functioning (DIF), unexpected responses and item content. 
The results were compared with those of the original version of the question-
naire in CARDIOVERSE sample. Results: Misfiting items were deleted, resulting in 
a 12 items version rated on a 4-point Likert-scale. This short form of the ques-
tionnaire showed good model fit and represented an accurate measure of the 
construct. Infit MNSQ ranged from 0.90 to 1.15 (M= 1.02; SD= 0.09) and outfit MNSQ 
ranged from 0.90 to 1.18 (M= 1.02; SD= 0.08). Person separation index and item 
reliability were 2.11 and 0.99 respectively and item-person map showed that the 
test was on-target and covered the wide range of the ability scale. Finally, the 
criterion validity of the short version by age, sex and risk groups was similar to 
the original version of the questionnaire. cOnclusiOns: Short version of Sawicki 
questionnaire has adequate psychometric properties in terms of goodness-of-
fit-test and reliability. This version makes it possible to have a new short and 
appropriate HRQoL measure for the study of the effect in QoL experienced by 
patients treated by NOACs.
PRM141
vALIDITy OF QOL IMPACT ATTRIBUTIONS TO SPECIFIC DISEASES:  
A MULTITRAIT-MULTIMETHOD COMPARISON
Ware J.E.1, Guyer R.2
1John Ware Research Group, Inc., Worcester, MA, USA, 2John Ware Research Group, Worcester, 
MA, USA
Objectives: To test convergent-discriminant validity of quality of life (QOL) 
impact attributions to arthritis and respiratory conditions using the multitrait-
multimethod (MTMM) approach. MethOds: Chronically-ill adults (N= 601) with 
osteoarthritis (OA) and respiratory (asthma, COPD) disease completed Internet-
based surveys. Ages ranged from 18-93 (median= 58), 66.5% female and 20.7% non-
white. QOL impact was measured using 3 methods: QOL Disease Impact Scale 
(QDIS) and disease severity with specific attribution to each condition, specific 
worse cognitive function. Fifteen items had responses with ≥ 35% frequency and 
three items (turning a key, recreational activities with force, recreational activities 
with moving arm freely) had responses with ≥ 50% frequency. cOnclusiOns: 
Patients had no complaints about understanding or difficulty of the adapted ver-
sion of the questionnaire. Still, there were some items with missing answers (most 
often - sexual activity). Although, we provide some evidence of content validity, 
additional testing for the retention of psychometric properties of the translated 
questionnaire is recommended.
PRM136
IMPACT ON THE ESTIMATED ICER OF INCLUDING AGE-SPECIFIC BASELINE 
HRQOL IN A MODEL
Teljeur C.1, Adams R.C.2, Harrington P.1, Ryan M.1
1Health Information and Quality Authority, Dublin, Ireland, 2National Centre for 
Pharmacoeconomics, Dublin, Ireland
Objectives: For models that simulate patients over a long span, such as from birth 
to life expectancy, the baseline HRQoL can be incorporated. Typically this means 
that younger people have a higher utility than older people. The aim of this study 
was to investigate the impact of including age-specific baseline utilities in a model 
that simulated women at elevated risk of developing breast cancer from ages 20 to 
85. MethOds: A model was developed to evaluate the impact on costs and benefits 
of breast cancer surveillance in a population of women with a BRCA1 mutation. 
Women were modelled from age 20 to 85. QALY reductions were associated with the 
treatment of cancer and were stage-specific. The model was evaluated incorporat-
ing age-specific baseline QALYs and also where all ages had a baseline QALY of 1. 
The impact of age-specific baseline QALY inclusion was evaluated in terms of the 
ICERs for different surveillance strategies. Results: The incremental cost of each 
intervention and the interventions included in the cost-effectiveness efficiency 
frontier were unaffected by the choice of baseline HRQoL. However, both the average 
and incremental cost-effectiveness ratios were changed. For interventions on the 
cost-effectiveness efficiency frontier, all ICERs were less than € 100,000/QALY when 
age-specific baseline HRQoL values were used. ICERs reduced by an average € 11,520 
when a uniform baseline HRQoL was used. cOnclusiOns: The use of age-specific 
baseline HRQoL in a cost-effectiveness model needs to be carefully considered. 
Inclusion of age-specific baseline HRQoL can favour interventions with an impact 
at a younger age. Whether age-specific or uniform baseline data are used in a model, 
the alternative should be considered in a sensitivity analysis.
PRM137
EQ-5D-5L CROSSwALK vALUE SET FOR POLAND
Golicki D., Niewada M.
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, 
Poland
Objectives: To estimate EQ-5D-5L crosswalk value set for Poland, based on 
Crosswalk methodology developed by EuroQol Group. MethOds: Based on the data 
from 3691 respondents from 6 European countries, EuroQol Group has developed 
a method of obtaining interim values sets for the EQ-5D-5L by means of map-
ping to the available EQ-5D-3L values sets (“crosswalk” methodology). A significant 
part of the data in this study came from Polish respondents (n= 972; 26.3%). Poland 
is the first Central European country with EQ-5D-3L time trade-off based social 
values set published. In order to obtain interim EQ-5D-5L values set, we applied 
Crosswalk methodology, developed by EuroQol Group, to available Polish EQ-5D-3L 
values set. Results: Estimated Polish values for 3125 EQ-5D-5L health states will 
be presented. Both, EQ-5D-5L and EQ-5D-3L values sets have the same range (from 
-0.523 to 1.000), but different means (0.448 vs. 0.380) and medians (0.483 vs. 0.403), 
respectively. Participation of states worse than dead is less in EQ-5D-5L (5.38%), 
than in EQ-5D-3L (13.17%) values set. cOnclusiOns: As long as value set based on 
preferences directly elicited from representative Polish general population sample 
is not available, estimated crosswalk values set should be used in EQ-5D-5L studies 
in Poland in order to calculate health state utilities.
PRM138
CROSS (-wALK) AT yOUR OwN PERIL! COMPARING AND CONTRASTING CEA 
RESULTS wHEN INDIvIDUAL-LEvEL UTILITIES ARE DERIvED FROM ExTERNAL 
MAPPING ALGORITHMS RATHER THAN ACTUALLy OBSERvED RESPONSES
Patton T.1, Manca A.1, Palmer S.2, Sculpher M.J.1
1University of York, York, UK, 2Centre for Health Economics, York, UK
Objectives: Existing studies exploring the validity of using mapping algorithms 
to predict utilities in external datasets have found mixed results. We apply a series 
of published EQ-5D mapping algorithms to individual patient level data from a 
trial which in fact collected this outcome, with a view to assess the impact of 
using predicted versus actual EQ-5D values on the results of a cost-effectiveness 
model. MethOds: The RITA-3 trial compared early interventional strategy for 
patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) against 
a conservative strategy. EQ-5D data were collected at baseline, 4 months, 12 
months and yearly thereafter. A range of other clinical and quality of life out-
comes were also collected including the Seattle Angina Questionnaire (SAQ), 
SF-36 and the Canadian Cardiovascular Society (CCS) Functional Classification of 
Angina. Using mapping algorithms found in the published literature, we predicted 
EQ-5D scores using these outcome measures. We then explored what effect the 
predicted utilities had upon cost-effectiveness estimates in a model compared 
to those with the actual EQ-5D data. The comparisons were made across five 
patient subgroups. Results: The cost-effectiveness estimates varied according to 
the original outcome measure used to map and the patient subgroup. The EQ-5D 
values predicted using CCS scores produced cost-effectiveness estimates much 
higher than those with the actual EQ-5D data in the trial, whilst the estimates 
using EQ-5D values predicted using SAQ scores were lower. The values predicted 
using SF-36 scores gave cost-effectiveness estimates very similar to those with 
the EQ-5D data, irrespective of the patient subgroup. cOnclusiOns: Analysts 
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THE ‘wOUND-QOL’: A SHORT QUESTIONNAIRE MEASURING QUALITy OF LIFE 
IN PATIENTS wITH CHRONIC wOUNDS
Blome C.1, Baade K.1, Price P.2, Debus S.1, Augustin M.3
1University Medical Center Hamburg, Hamburg, Germany, 2Cardiff University, Cardiff, UK, 
3University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Objectives: To develop a short questionnaire measuring health-related quality of 
life (HRQoL) in patients with chronic wounds. MethOds: Three validated instru-
ments assessing HRQoL in chronic wounds, the Freiburg Life Quality Assessment 
for wounds (FLQA-w), the Cardiff Wound Impact Schedule (CWIS), and the Würzburg 
Wound Score (WWS), were filled in by 154 leg ulcer patients in a prospective 
study under routine care. For implementation in the new, shorter questionnaire 
Wound-QoL, those of all 92 items were selected that covered the core content of 
the three questionnaires and showed good psychometric properties (e. g. num-
ber of missing values, inter-item correlations). Internal consistency, convergent 
validity regarding four generic HRQoL measures such as the EQ-5D, and respon-
siveness of the Wound-QoL were analysed using the longitudinal study data on 
the selected items (so-called virtual validation). Subscales were determined with 
factor analysis. Item, instruction, and response scale wording of the Wound-QoL 
were harmonized. Results: Seventeen items were included in the Wound-QoL 
questionnaire which could be attributed to three subscales on everyday life, body, 
and psyche. Both global score and subscale scores were internally consistent with 
Cronbach’s alpha values between 0.71 and 0.91. The global score showed significant 
convergent validity (r= 0.48 to 0.69, depending on the criterion) and responsive-
ness regarding change in generic HRQoL (r= 0.18 to 0.52); the same was true for 
the subscale scores. cOnclusiOns: The Wound-QoL for measurement of HRQoL 
in chronic wounds proved to be internally consistent, valid, and responsive in the 
virtual validation analysis.
PRM145
MAPPING FROM PDQ-39 AND PDQ-8 ONTO EQ-5D UTILITy INDEx IN PATIENTS 
wITH PARKINSON’S DISEASE: ExTENDED ANALySIS
Kalabina S.1, Curry A.S.1, Milligan G.2, Jackson J.2, Merikle E.3, Filipovic I.1
1AbbVie Ltd., Maidenhead, UK, 2Adelphi Real World, Bollington, UK, 3AbbVie Inc, North Chicago, 
IL, USA
Objectives: To develop an algorithm for mapping of disease-specific health related 
quality of life scores to the EQ-5D utility index for patients with PD. MethOds: 
EQ-5D and Parkinson’s disease Questionnaire (PDQ) data were obtained for 117 
UK PD patients (HY stages 1-4) via a cross-sectional survey of practicing clinicians 
and their patients. The EQ-5D utility index (UK Tariff) was regressed on PDQ-39/
PDQ-8 summary indices (SI) and PDQ-39 domains/PDQ-8 questions using OLS 
regression. Analysis on PDQ-39 domains/PDQ-8 questions was repeated using 
OLS with backward elimination. Two-part models (TPM) were conducted on PDQ-
39/8 SI and domains/questions respectively consisting of a logistic regression on 
whether EQ-5D< 1 followed by either OLS, GLM with gamma distribution and log 
link or identity link functions and GLM with Gaussian distribution with log link 
for the remainder. Mapping equations were used to predict utilities which were 
subsequently compared to those observed. Models were compared using RMSE 
values. Results: Compared to simple OLS [RMSE 0.1685-0.1924], a model with back-
ward elimination of variables did not improve predictive power. Out of the TPMs the 
best fitting models were GLM with gamma distribution and identity link function 
[RMSE 0.1666-0.1929] and GLM with Gaussian distribution and log link function 
[RMSE 0.1683-0.1912]. All models produced better results utilising the domains of 
PDQ-39 or individual questions of PDQ-8 than with the SI. cOnclusiOns: All map-
ping algorithms estimated utilities for patients with HY stage 1-4 with reasonable 
accuracy. Therefore, mapping functions reported could be used for predicting EQ-5D 
scores from either PDQ-39 or PDQ-8 when EQ-5D data were not collected. However, 
simple OLS, TPMs with gamma family and identity function and Gaussian family 
and log functions resulted in the best prediction and the smallest RMSE values. 
Further validation is needed to ascertain whether these mapping functions perform 
well for more advanced patients in HY stage 5.
PRM146
PATIENT-REPORTED OUTCOME MEASURES FOR SySTEMIC LUPUS 
ERyTHEMATOSUS CLINICAL TRIALS: A CONTENT vALIDITy AND 
PSyCHOMETRIC PERFORMANCE REvIEw
Humphrey L.1, Heron L.1, Pilling C.1, Holloway L.1, Højbjerre L.2, Strandberg-Larsen M.2, 
Hansen B.B.2
1Adelphi Values, Bollington, UK, 2Novo Nordisk A/S, Søborg, Denmark
Objectives: Patients with Systemic Lupus Erythematosus (SLE) experience unmet 
medical needs and many inflammatory symptoms resulting in humanistic and 
economic burden. This study aimed to create a conceptual model of patient and eco-
nomic burden, and review patient-reported outcomes (PROs) used to measure such 
concepts in SLE clinical trials. MethOds: An SLE conceptual model was developed 
from structured review of published articles from 2007-June 2012 identified from 
literature databases (MEDLINE, PsycINFO, EconLit) plus other sources (PROLabels, 
FDA/EMA websites, Clinicaltrials.gov). PROs targeting key symptom/impact were 
identified from the literature. In the context of FDA guidance, the PROs were subject 
to in-depth review and assessed for face and content validity, and psychomet-
ric properties to determine appropriateness for use in SLE trials. Results: Pain, 
fatigue, cognition, daily activities, emotional well-being, physical/social functioning, 
and work productivity were in the conceptual model identified as key SLE concepts. 
Of the 63 articles reviewed, 31 reported PRO data. From these and the other sources, 
14 PROs were selected for review including SLE-specific health-related quality of life 
(HRQoL) measures (n= 3), work productivity (n= 1), and generic measures of fatigue 
(n= 3), pain (n= 2), depression (n= 2) and HRQoL (n= 3) as these were deemed salient 
for patients with SLE in the literature. The FACIT-Fatigue, BPI-SF (pain) and LupusQoL 
demonstrated the strongest face validity, conceptual coverage and psychometric 
properties measuring key concepts in the conceptual model. All PROs reviewed, 
symptoms (joint pain, shortness of breath), and generic physical (PCS) and men-
tal (MCS) summary measures (SF-36). The resulting 10X10 correlation matrix (3 
disease-specific, 2 generic) for each disease was evaluated to test convergent 
validity (correlations > 0.40 between different methods of measuring the same 
disease) and discriminant validity (significantly lower correlations between dif-
ferent diseases measured by the same method). The MTMM matrix was also ana-
lyzed using principal component analysis (PCA) to test for disease versus methods 
factors. Results: The MTMM matrix yielded strong evidence that patients dis-
criminated the impact of one condition from the other. In support of convergent 
validity, disease specific QOL impact, severity and symptom measures (joint pain 
for OA, SOB for respiratory) correlated substantially for asthma (0.516 - 0.765) 
and OA (0.465 - 0.774). In support of discriminant validity, different diseases 
measured by the same method correlated significantly lower (0.264 - 0.286). 
PCA yielded two disease-specific factors (OA and respiratory) with high loadings 
across methods for OA (0.748 - 0.871 and respiratory (0.687 - 0.890) and low sec-
ondary loadings (0.085 - 0.262). Generic PCS and MCS measures correlated lower 
than disease-specific measures, as hypothesized. 2-method (QOL impact, sever-
ity) MTMM validations replicated these results across 37 pairs of over-sampled 
comorbid conditions. cOnclusiOns: Results strongly support the convergent-
discriminant validity of survey measures of QOL impact based on attributions to 
OA and respiratory disease and suggest that disease-specific attributions may 
improve the validity of QOL impact attributions for other common pairs of comor-
bid conditions.
PRM142
ESTIMATING THE ASSOCIATION BETwEEN THE OxFORD HIP SCORE (OHS) AND 
EQ-5D UTILITy vALUES USING DIRECT AND RESPONSE MAPPING METHODS
Rivero-Arias O.1, Chiocchia V.2, Field P.3, Pinedo-Villanueva R.1
1Oxford University, Oxford, UK, 2Oxford Brookes University, Oxford, UK, 3Oxford Pharmagenesis 
Ltd., Oxford, UK
Objectives: Mapping algorithms can translate disease-specific or generic 
health-related quality of life measurements into values obtained from prefer-
ence-based instruments such as the EuroQol 5-dimension questionnaire (EQ-
5D). The Oxford Hip Score (OHS) is a disease-specific instrument widely used by 
orthopaedic surgeons to assess outcomes from hip surgery. There is an algorithm 
for estimating mean EQ-5D scores from the OHS, but this was developed using 
early response mapping methods and has limited external validation. We have 
developed a new mapping algorithm to translate OHS results into EQ-5D domain 
responses and utilities in a large UK dataset using direct and response mapping 
methods. MethOds: OHS and EQ-5D responses were extracted from the publicly 
available National Patient Reported Outcomes Measures (PROMs) database. The 
sample of complete data pairs (n= 126 862) was split into estimating (n= 51 800, 
years 2009–10) and external validation (n= 75 062, years 2010–12) samples. EQ-5D 
utilities were estimated directly using ordinary least squares regression and two-
part models. EQ-5D responses were estimated using ordered and multinomial logit 
models. For the two-part and the multinomial logit models, the expected value 
method was used to calculate utilities. Performance was evaluated using mean 
square error (MSE) and mean absolute error (MAE). Results: The two-part models 
and the ordered or multinomial regressions performed better than ordinary least 
square regression. In external validation, the MSE (MAE) was 0.0319 (0.1286) for 
the two-part model and 0.0315 (0.1249) for response mapping. For EQ-5D index 
values > 0.5 (better health states), response mapping predictions had a slightly 
smaller MSE and MAE than direct method predictions. Both indirect and direct 
approaches predicted higher MSE and MAE when EQ-5D < 0.5. cOnclusiOns: 
Response mapping between OHS and EQ-5D was similar or slightly more predic-
tive than direct mapping. Further research is needed to improve the performance 
of these techniques in poorer health states.
PRM143
META-ANALySIS OF QUALITy OF LIFE IN CORONARy HEART DISEASE
Stevanovic J.1, Pechlivanoglou P.2, Kampinga M.1, Krabbe P.F.M.3, Postma M.J.1
1University of Groningen, Groningen, The Netherlands, 2Toronto Health Economics and Technology 
Assessment (THETA), Toronto, ON, Canada, 3University of Groningen, University Medical Center 
Groningen, Groningen, The Netherlands
Objectives: A large number of quality of life (QoL) values for patients with coro-
nary heart disease (CHD) are available in the literature. From the abundance of QoL 
values in CHD, only preference-based values can be directly applied in cost-utility 
analysis (CUA). In this study we performed a multivariate meta-regression analysis 
of the preference-based QoL values in CHD. Our aim was to obtain a summarized 
QoL estimate while accounting for study-level covariates and for the correlation 
between multiple outcomes both within and between studies. MethOds: Studies 
were considered eligible for this analysis if they reported mean QoL values, standard 
deviations and the instrument for measuring QoL (e.g. EQ-5D, SF-6D). Additionally, 
studies reporting separate values of SF-36 and SF-12 QoL instruments were included. 
The scores of the SF-36 and SF-12 QoL were mapped onto EQ-5D and SF-6D values. 
Mapped preference-based values were added to the base-case data set that con-
sisted only of published preference-based QoL values. Finally, a multivariate meta-
regression model was used in order to estimate pooled, instrument-specific QoL 
in CHD. Results: Our systematic search identified 35 eligible studies reporting 43 
preference-based QoL values in CHD as well as 46 studies reporting QoL scores of 
SF-36 and SF-12. Following instrument-specific QoL estimates were obtained when 
conducting the analysis on the base-case data set: 0.77 (EQ-5D UK), 0.79 (EQ-5D 
US), 0.65 (SF-6D), 0.85 (15D), 0.44 (HUI3) and 0.63 (QWB). Age was the only study-
level covariate that showed an influence on instrument-specific QoL estimates. 
Significant heterogeneity was observed when the analysis was conducted on the 
expanded data set. cOnclusiOns: This study represents the first meta-analysis 
of QoL in CHD. Given the abundance of QoL values in CHD on the one hand and 
the requirement for single, accurate QoL values in CUA on the other hand, pooled 
estimates of QoL could be highly applicable in CUA.
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sample of patients who participated in at least 1 clinical trial that included patient 
diaries in the past 2 years. The survey asked questions about the most recent trial 
with a diary focusing on the patient’s diary experience. Results: A total of 398 
patients provided complete responses. On a scale of 1-7 (1= Very Bad; 7= Very Good), 
mean satisfaction rating= 5.4. Satisfaction was categorized for sub-group analysis 
purposes: Positive Satisfaction (75%); Ok Satisfaction (16%); Negative Satisfaction 
(9%). Time per diary entry had the biggest impact on satisfaction. Those whose 
diaries took < = 30 minutes had the highest percentage of positive satisfaction 
(78%) and those whose diaries took > 30 minutes had the lowest percentage of 
positive satisfaction (46%), p< 0.001. Patients who were negatively satisfied had the 
highest percentage (44%) of reporting dropping out or considering dropping out 
due to diary effort, p< .0001. Patients who were negatively satisfied had the highest 
percentage (67%) of reporting non-compliance with completing diaries (p< 0.01). 
Time per diary entry impacted compliance where those patients whose diaries 
took > 30 minutes had the highest percentage of reporting non-compliance (68%), 
p= 0.03. cOnclusiOns: When planning patient diaries, it is important to consider 
the patient population and preferences. As the results show that satisfaction is 
linked to drop out and compliance, it is important to keep patients satisfied. As 
time per diary was found to impact satisfaction, it is important to keep patient 
burden and their experience in mind when developing ePRO instruments and 
selecting mode of administration. . Satisfied patients lead to higher compliance, 
retention and data quality.
PRM150
CAN wE USE THE EQ-5D ONLy FOR ASSESSING THE QUALITy OF LIFE OF 
PATIENTS wITH OSTEOPOROSIS?
Tadic I.1, Lakic D.1, Odalovic M.1, Tasic L.2, Vujasinovic Stupar N.3, Stevanovic D.4, Petrova G.5, 
Krajnovic D.1
1University of Belgrade Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 2University of 
Belgrade – Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 3University of Belgrade School 
of Medicine, Belgrade, Serbia and Montenegro, 4General Hospital Sombor, Sombor, Serbia and 
Montenegro, 5Medical University of Sofia, Sofia, Bulgaria
Objectives: Osteoporosis is a chronic disease which has impact on specific 
aspects of health such as pain, physical functioning, social and mental functioning 
and loss of personal independence. Generic questionnaire EQ-5D explores similar 
dimensions and therefore is usually used as a questionnaire for assessing the con-
current validity of the specific osteoporosis questionnaires. The objective of this 
study was to explore for a potential correlation between the similar dimensions 
of the specific osteoporosis questionnaire QUALEFFO-41 and EQ-5D. MethOds: 
Analyzed data were a part of the study that included 50 patients with osteoporosis 
and vertebral fractures conducted during the period June 2010 - October 2011. 
The correlation between the questionnaires was assessed using the Spearman’s 
correlation coefficient. Results: Strong correlations were found between EQ-5D 
index / VAS score and QUALEFFO-41 total score (ρ = -0.73 and ρ = -0.57, p< 0.001, 
respectively). The EQ-5D dimensions “Pain/discomfort”, “Mobility”, “Activities”, 
“Anxiety/Depression” similar to QUALEFFO-41 dimensions “Pain”, “Physical func-
tion”, “Leisure, social activities”, “Mental function” were also strongly correlated 
(ρ = 0.42, ρ = 0.76, ρ = 0.46 and ρ = 0.32, p< 0.001, respectively). cOnclusiOns: Strong 
correlations between similar dimensions of the compared questionnaires were 
notified. Negative values of the Spearman’s correlation coefficient indicated that 
total score of the QUALEFFO-41 were scored in the reverse order. There was only 
one QUALEFFO-41 dimension (“General health perception”) that is not similar to 
any of the EQ-5D dimensions. Although there was a strong correlation between 
the total scores of compared questionnaires, the results of the EQ-5D question-
naire should be observed with caution, because it does not contain all important 
dimensions that osteoporosis affects.
PRM151
vALIDITy, RESPONSIvENESS AND RELIABILITy OF THE ARTHRITIS-SPECIFIC 
wORK PRODUCTIvITy SURvEy ASSESSING wORK PRODUCTIvITy wITHIN AND 
OUTSIDE THE HOME IN PATIENTS wITH PSORIATIC ARTHRITIS
Osterhaus J.1, Purcaru O.2
1Wasatch Health Outcomes, Park City, UT, USA, 2UCB Pharma, Brussels, Belgium
Objectives: The arthritis-specific Work Productivity Survey (WPS) estimates arthri-
tis-related productivity limitations at workplace and within home, and on social 
activities, during the preceding month. There is an unmet need for an instrument 
assessing similar limitations in psoriatic arthritis (PsA). Following its validation in 
rheumatoid arthritis, this analysis aimed to assess the psychometric properties of 
WPS in adult-onset active PsA. MethOds: WPS comprises 9 questions evaluating 
employment status, workplace and household productivity. Psychometric proper-
ties were assessed using data from RAPID-PsA (NCT01087788). The WPS was com-
pleted at baseline and every 4 weeks (wks) until Wk24. Validity was evaluated via 
known-groups approach, comparing patients (pts) with a worse vs better health 
state, defined by the 1st and 3rdquartiles cut-off of pt scores to DAS28(CRP), HAQ-DI, 
SF-36 and PsAQoL. The responsiveness and reliability were assessed comparing 
WPS mean changes in ACR20 or HAQ-DI MCID= 0.3 responders vs non-responders at 
Wk12. Comparisons were conducted in the Randomized Set (observed cases) using a 
non-parametric bootstrap-t method. Results: Results confirmed the discriminant 
validity of WPS. Compared to pts with a better health state, pts with a worse health 
state had significantly more days of household work lost, household work with 
reduced productivity, social activities missed, outside help hired and a significantly 
higher interference rate of arthritis. Similarly, employed pts with a worse health 
state had significantly more work days lost or with productivity reduced by ≥ 50%, 
and higher interference of arthritis on work productivity. WPS was also responsive 
to clinical changes, with responders reporting significantly larger improvements at 
Wk12 in WPS scores vs non-responders. The effect sizes for changes in productiv-
ity in responders were moderate (0.5< SRM< 0.8) or small. cOnclusiOns: These 
analyses demonstrate that the WPS is a valid, responsive and reliable instrument 
for measurement of productivity within and outside the home in adult-onset PsA.
except for the Lupus-specific HRQoL measures, lacked SLE patient involvement 
during development limiting their content validity. The HADS, SF-36v2, EQ-5D-3L 
and WPAI:Lupus showed suitability for SLE economic models. cOnclusiOns: SLE 
is a condition associated with clear unmet medical needs and considerable burden 
to patients. This review highlights the current availability and future need for both 
disease-specific and generic patient-reported measures of relevant domains of dis-
ease signs and symptoms, HRQoL and work productivity.
PRM147
MODE EQUIvALENCE OF INTERACTIvE vOICE RESPONSE (IvR) AND PAPER 
vERSIONS OF THE BRIEF PAIN INvENTORy (BPI) “wORST PAIN” ITEM IN 
METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) EvALUATED 
CONCEPTUALLy USING QUALITATIvE METHODS
Bennett A.1, Eremenco S.2, Heon N.3, Scheffold C.4, Schimmoller F.4, Weitzman A.4, Basch E.1
1University of North Carolina, Chapel Hill, NC, USA, 2Evidera, Bethesda, MD, USA, 3Memorial 
Sloan-Kettering Cancer Center, New York, NY, USA, 4Exelixis Inc, South San Francisco, CA, USA
Objectives: The BPI “pain at its worst in the last 24 hours” item is often admin-
istered as a primary or key secondary endpoint in clinical trials using an IVR daily 
diary. However, evidence of equivalence between the validated paper version and 
IVR has not been published. This study evaluated conceptual equivalence between 
IVR and paper version of this item using qualitative methods. MethOds: Twenty-
six patients with mCRPC in a non-randomized expansion cohort (N= 144) of phase 
2 study XL184-203 were interviewed to confirm their comprehension of the BPI 
“worst pain” item administered using an IVR simulation by the interviewer and 
presented on paper. Patient interpretation of the item’s meaning in both modes 
was elicited and compared to identify similarities between the modes. Patients 
were also interviewed regarding the usability of IVR during the trial. Results: 
Patients (median age = 68; range 44-81) had ECOG performance status of 0 (38%) and 
1 (62%). Nearly all patients answered the IVR version of the question as intended – 
by considering the past 24 hours (72%; 18% did not specify); including non-cancer 
related pain (96%); and reporting pain experienced with analgesia (100%). Patients 
did not interpret the paper version of the pain question differently from the IVR 
version; 4 patients spontaneously stated that the paper version was the same as 
the IVR version they had used. All patients reported that the IVR was easy to use to 
answer the diary. cOnclusiOns: This study provides important qualitative sup-
port of conceptual equivalence between an IVR and paper version of the BPI “worst 
pain” item. These results confirm that this item is well understood by patients, and 
that they interpret the question similarly whether administered via IVR or on paper. 
The results also show good usability and acceptability of IVR administration of this 
important item in clinical trials.
PRM148
A COMPARISON OF THE RELATIvE wEIGHTS OF HEALTH DOMAINS ON GLOBAL 
RETROSPECTIvE AND ExPERIENCED HEALTH AND wELL-BEING
Joore M.A.1, Delespaul P.A.2, White M.P.3, Maes I.4
1Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical 
Centre; CAPHRI, Maastricht University, Maastricht, The Netherlands, 2Maastricht University, 
Maastricht, The Netherlands, 3University of Plymouth, Plymouth, UK, 4Clinical and Medical 
Technology Assessment, Maastricht University Medical Centre; CAPHRI, Maastricht University, 
Maastricht, The Netherlands
Objectives: Are the relative weights of different dimensions of health differ-
ent when determined by their impact on subjective well-being (SWB; 2 types of 
self-report: retrospective global evaluation, momentary experience) and health (3 
types of self-report: retrospective global evaluation, future prospect, momentary 
experience). MethOds: The study population consisted of persons experiencing 
psychosomatic, psychological and somatic illness, and members from public. The 
experience sampling study took 6 days, during which momentary self-reports of 
health and SWB were obtained. In addition, participants completed retrospective 
global evaluations of health (EQ-5D), SWB (Life Satisfaction Scale) and preference 
for a future prospect of health (time trade-off). Regression analysis was used to 
determine relative weights of EQ-5D dimensions on the outcomes. Results: A 
total of 139 participants were included. Some/moderate problems in usual-activities 
and anxiety/depression were associated with the largest drop in health for all three 
types of self-report. Moderate anxiety/depression had a larger impact than moderate 
problems in usual-activities in momentary as compared to retrospective health-
reports. Moderate problems in usual-activities and anxiety/depression and self-
care were associated with a drop in retrospective and momentary SWB. Moderate 
problems in usual-activities was associated with the largest drop in retrospective 
SWB, while moderate anxiety/depression was associated with the largest drop in 
momentary SWB. Comparing the relative weights, it was shown that anxiety/depres-
sion was more important relative to usual-activities in momentary experiences than 
in retrospective evaluations. cOnclusiOns: Relative weights of health domains 
are different, depending on the type of self-report (global or momentary) and con-
cept of value (health or SWB) used. Most notably, the relative weight of anxiety/
depression is larger when using a momentary measure, and when taking SWB as 
the outcome of interest. This finding warrants further discussion and research on 
the place and value of momentary measures of experience and SWB as outcome in 
health (economic) evaluation.
PRM149
PATIENT SURvEy: INvESTIGATION ON wHAT IMPACTS PATIENT 
SATISFACTION, DROP-OUT AND COMPLIANCE IN PATIENT DIARIES
Ross J., Holzbaur E., Ross E.
Almac Clinical Technologies, Souderton, PA, USA
Objectives: Patient Reported Outcomes (PROs) play an important role in patient-
centered research where compliance is important. To better understand patient 
preferences when participating in PROs, survey research was conducted in 2013. 
This presentation investigates what impacts patient satisfaction, drop-out and 
compliance. MethOds: An internet-based survey was administered to a global 
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of health inequality in society and for evaluating the overall impact of population 
health interventions on health inequality.
PRM155
USING STRUCTURAL EQUATION MODELING TO DETECT RESPONSE SHIFT AND 
TRUE CHANGE IN HEALTH-RELATED QUALITy-OF-LIFE SCORES OF BREAST 
CANCER PATIENTS AFTER SURGERy
Nakamura K.1, Shimozuma K.1, Suzukamo Y.2, Taira N.3, Shiroiwa T.4, Shibahara H.1, Saito S.5
1Ritsumeikan University, Kusatsu, Japan, 2Tohoku Universitiy, Seidai, Japan, 3Okayama University 
Hospital, Okayama, Okayama, Japan, 4National Institute of Public Health, Saitama, Japan, 
5Okayama University, Okayama, Japan
Objectives: This study aimed to capture response shift and true change in 
health-related quality of life (HRQOL) scores of breast cancer patients after sur-
gery. MethOds: A data set from a prospective study to identify predictive factors 
of HRQOL (Taira N, Shimozuma K, et al: Breast Cancer Res Treat, 2011) was analyzed, 
which included HRQOL scores of physical well-being (PWB) and emotional well-
being (EWB) scales of the FACT-G in 191 female breast cancer patients during a 
two-year postoperative period (at baseline [1 month after surgery]), 6, 12, and 24 
months postoperatively). Oort’s structural equation modeling approach was used to 
investigate three aspects of response shift: (a) a change in the respondent’s internal 
standards of measurement (i.e., recalibration); (b) a change in the respondent’s 
importance of values (i.e., reprioritization) and (c) a redefinition of the target con-
struct (i.e., reconceptualization). Results: All three aspects of response shift were 
observed. Recalibration and reprioritization were occurred in three items of PWB 
(‘nausea’, ‘trouble with family’, ‘side effects’). Reconceptualization was observed 
from PWB to EWB in two items (‘nausea’ and ‘pain’) and from EWB to PWB in two 
items (‘sadness’ and ‘nervousness’). True change, which was calculated after adjust-
ment of response shift, was observed in PWB (the across occasion difference of 
common factor mean [alpha] = 0.238, P < 0.001) during first 6 months, and in PWB 
(alpha = 0.605, P < 0.001) and EWB (alpha = 0.234, P < 0.05) during first 12 months, 
while observed data analyses indicated statistically significant change in PWB and 
EWB during first 12 months. cOnclusiOns: Captured response shifts in this study 
may be affected by various pre- and post-operative events such as notification of 
cancer and/or received treatments. These results will help improve reliability of 
HRQOL measurements in a longitudinal study.
PRM156
FACTORIAL INvARIANCE OF THE wHOQOL-OLD ACROSS GENDER, AGE, AND 
RESIDENT AREA IN TAIwAN
Yao G., Chien C.C.
National Taiwan University (Dept. of Psychology), Taipei, Taiwan
Objectives: To examine the factor invariance of the WHOQOL-OLD across gender, 
age, and resident area for the old people in Taiwan. MethOds: Data were collected 
from 512 Taiwan elderly people (M = 76.2, SD = 7.5, ages ranged from 60 to 99) includ-
ing 177 males and 335 females. 232 aged from 60 to 75 and 279 aged from 76 to 99. 
334 live in the southern rural area and 176 live in the northern metropolitan area. 
To examine the factorial invariance of the WHOQOL-OLD, the sample was divided 
into two groups on different gender, age, and resident area. First, a baseline six-
factor model was tested for different gender, age, and resident area respectively. 
Second, multi-sample analysis was conducted across gender, resident area, and 
age. Specifically, equal constrains on factor loadings, error variances, and factor 
variances were imposed. Model comparisons by using Chi-square difference tests 
were conducted to examine the factor invariance across gender, age, and resident 
area. Results: Multi-sample analysis revealed that the factor loadings were invari-
ant across different gender, age, and resident area groups respectively. Besides, 
when imposing equal constrains on the factor loadings, item variances and factor 
variances, the model fit indices revealed that the only complete factor invariance 
model was across gender but not age and resident area groups. cOnclusiOns: This 
study suggests the underlying factor construct of the WHOQOL-OLD are similar to 
different degree across different gender, age, and resident area groups. We conclude 
that the WHOQOL-OLD is a practical measurement tool for different gender, age, 
and location groups for the old people in Taiwan.
PRM157
A REvIEw OF COGNITIvE INTERvIEwING METHODOLOGIES DURING 
LINGUISTIC vALIDATION OF CLINICAL OUTCOME ASSESSMENTS (COAS)
Simon M.1, Sweeney E.1, Moravec H.2
1TransPerfect, New York, NY, USA, 2TransPerfect, San Francisco, CA, USA
Objectives: Per ISPOR and FDA guidelines, conducting cognitive interviews during 
the linguistic validation of COAs is recommended to increase comprehension and 
conceptual equivalence between language versions. However, multiple methods are 
available to conduct cognitive interviews, partially enabled by the increased avail-
ability and ease of technology to facilitate the interviews. This poster will review the 
various methodologies that can be used to conduct cognitive interviews. MethOds: 
A review of cognitive interview methodologies from past projects as well as potential 
alternative methods was conducted, including: 1) in-person interviews, 2) telephone 
interviews, and 3) interviews via video conferencing. Consideration was given to 
ease of scheduling, cost, and quality/comphrensiveness of feedback. Results: Each 
methodology presented pros and cons, including: 1) in-person interviews enable the 
interviewer to gauge the respondent’s body language, signaling where he/she may 
be having difficulty with an item but are unable to verbalize feedback; however, the 
interviews are more costly and present organizational challenges (i.e. scheduling, 
travel, etc.); 2) telephone interviews enable easier scheduling of interviews and 
reduce cost, but do not allow the interviewer to gauge the body language of the 
respondent and respondents may not feel comfortable providing feedback over the 
telephone; 3) interviews via video conferencing may enable easier scheduling of 
interviews, allow an interviewer to gauge the body language of the respondent, and 
provide a lower-cost alternative, but the availability of the technology can present 
challenges in certain regions. cOnclusiOns: There are various ways of conduct-
PRM152
TRANSLATION AND CULTURAL ADAPTATION OF THE POLISH vERSION OF 
“DISABILITIES OF THE ARM, SHOULDER AND HAND” (DASH) AND QUICKDASH 
QUESTIONNAIRES
Golicki D.1, Krzysiak M.2, Strzelczyk P.3
1Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, 
Poland, 2Oddzial Rehabilitacji Dziennej, MCR Stocer, Konstancin Jeziorna, Poland, 3The Kosciuszko 
Foundation scholar, New York, NY, USA
Objectives: To translate into Polish and adapt culturally DASH and QuickDASH out-
come measures. MethOds: We followed recommendations issued by Insitute for 
Work and Health (IWH, 2007). Two forward translations were made – by an informed 
(T1) and uninformed translator (T2). Discrepancies were discussed and resolved with 
participation of the third unbiased investigator and a synthesis of translations was 
produced (T12). Two native speakers, totally blind to the original version, translated 
back T12 version into English (BT1 and BT2). Eight experts: 2 orthopedic surgeons, 
physiotherapist, sworn translator, 2 English native speakers, psychologist and a 
Polish language specialist formed an Expert Committee (EC). Committee consoli-
dated all the versions, review all the translations and reached a consensus on any 
discrepancy found. Decisions were made to achieve semantic, idiomatic, experien-
tial and conceptual equivalence with the original version. Results: We report 65 
discrepancies raised by Expert Committee members and their solutions. The Polish 
pre-final versions of DASH and QuickDASH questionnaires, ready for pilot testing, 
were produced. Written reports from all stages of the process were submitted to the 
IWH Cross-Cultural Adaptation Review Committee for approval. cOnclusiOns: 
Numerous translation discrepancies were resolved by discussion by Expert 
Committee. The Polish pre-final versions of DASH and QuickDASH questionnaires 
were produced and used in pilot testing.
PRM153
LINGUISTIC TRANSLATION AND CULTURAL ADAPTATION OF FUNCTIONAL 
ASSESSMENT OF CHRONIC ILLNESS THERAPy-TUBERCULOSIS INSTRUMENT 
INTO ARABIC LANGUAGE
Dujaili J.A.1, Syed Sulaiman S.A.1, Hassali M.A.2, Awaisu A.3, Blebil A.Q.1, Dujaili M.A.4,  
Bredle J.5
1Universiti Sains Malaysia, Minden, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia, 
3Qatar University, Doha, Qatar, 4Baghdad Medical City, Baghdad, Iraq, 5FACITtrans, Elmhurst, 
IL, USA
Objectives: Functional Assessment of Cancer Therapy- General (FACT-G) was 
adapted to develop a disease specific subscale for pulmonary tuberculosis (PTB) 
patients in Iraq. The current study aimed to linguistically validate Functional 
Assessment of Chronic Illness Therapy- Tuberculosis (FACIT-TB) measurement 
scale into Arabic language and to produce a translated version which was con-
ceptually equivalent to the original U.S. English version for use in clinical practice 
and research. MethOds: The linguistic validation process comprised of general 
procedures derived from internationally accepted guideline for linguistic valida-
tion and cultural adaptation of FACIT measurement system; including 1) Forward 
translation, 2) Reconciliation, 3) Back translation, 4) Review, 5) Spelling and gram-
matical verification. Furthermore, the translated questionnaire was pretested at 
Thoracic and Respiratory Diseases Specialist Center in Baghdad, Iraq. Results: 
Issues encountered during the linguistic validation process of FACIT-TB into Arabic 
language pertained to linguistic and semantic nuance were resolved. Pretesting was 
completed in seven Arabic-speaking TB patients with a mean age of 40.14 years. In 
addition, respondent need about 15.35 minutes (range 10-20 minutes) to complete 
the questionnaire. In general, respondent reported no significant problem with 
understanding the content of the Arabic version of FACIT-TB. Furthermore, they 
reported no culturally-irrelevant item. The instrument was found to be compre-
hensible, clear and relevant to the value of PTB patients in Iraq. cOnclusiOns: 
Linguistic validation of FACIT-TB into Arabic language was completed according to 
a recognized and rigorous double-back translation method to achieve, to the great-
est degree possible, equivalence of meaning and measurement between the two 
different country versions. It will provide an additional parameter to evaluate the 
effectiveness of TB program for patients in Iraq. Health care providers in the national 
TB control program should make a judicious utilization of this instrument in help-
ing patients to cope with their illness and in predicting TB treatment outcomes.
PRM154
ESTIMATING THE SOCIAL DISTRIBUTION OF HEALTH IN ENGLAND
Asaria M., Griffin S., Cookson R., Koh J.
University of York, York, UK
Objectives: To develop a model of quality adjusted life expectancy (QALE) in 
England and estimate the social distribution of both mortality and morbidity by 
socio-economic characteristics such as gender, ethnicity and deprivation. METHODS 
The 2011 wave of the Health Survey for England (HSE) is used to model EQ-5D as 
a function of gender, ethnicity, index of multiple deprivation and other relevant 
characteristics using appropriate regression techniques to account for the skewness 
of the EQ-5D distribution. Previous waves of the HSE are used to validate the model. 
ONS life tables and the ONS longitudinal study data are used to model life expec-
tancy as a function of the same characteristics. The two models are combined to give 
a multivariate prediction model for QALE as a function of these characteristics. This 
prediction model is combined with population level aggregate data on the key char-
acteristics and used to estimate a population QALE distribution. Results: There 
is a substantial social gradient in the health distribution as represented by QALE in 
England. The QALE differential between most and least disadvantaged fifths of the 
social distribution is 12 years, compared with a difference of 5 years in life expec-
tancy when morbidity differentials are not taken into account. cOnclusiOns: 
The QALE prediction model allows us to estimate quality adjusted life expectancy 
distributions for various subsets of the population, and shows that focusing on life 
expectancy alone substantially underestimates the degree of health inequality. Our 
model can be used both for obtaining a more accurate picture of the overall level 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A603
effect was the least important attribute in both datasets, the relative importance of 
the other attributes differed. All results differed by educational level. Estimated and 
observed choices showed higher correlation in the word dataset. cOnclusiOns: 
The presentation of the choice tasks by either using words or graphics influences 
study outcomes. The use of graphics to present attribute levels in choice tasks seems 
less preferred by respondents and showed a reduced validity. Besides extensive pilot 
testing, discussions about the presentation of the choice tasks should be included in 
the focus group stage of the designing process. Extensive research on respondents’ 
interpretation of choice tasks should be conducted to enable the formation of choice 
task presentation guidelines.
PRM161
SIMILARITIES AND DIFFERENCES ACROSS SAME LANGUAGE QUESTIONNAIRES 
FOR DIFFERENT COUNTRIES: LINGUISTIC vALIDATION OF THE ASTHMA 
SyMPTOM DIARy (ASD) AND KIDNEy DISEASE AND QUALITy OF LIFE  
(KD-QOL-36)
Neewoor S., Scharf L.
ICON PLC, Oxford, UK
Objectives: Prior to use in an international study, the Asthma Symptom Diary 
and Kidney Disease and Quality of Life underwent linguistic validation into over 
30 languages. This involved linguistic validation work on common languages tar-
geted for different countries via the forward / backward translations or adaptation 
steps and cognitive debriefing step. This study aims to investigate similarities and 
differences in the translation of key terms and wordings and determine potential 
patterns across groups of languages. MethOds: This investigation was carried out 
as follows: 1) Identification of key terms and words; 2) Collation and comparison of 
the translations across the same language versions; 3) Identification of similarities 
and differences; and 4) Review of discussions and issues from the translation pro-
cess. Results: The linguistic validation process was shown to be able to identify and 
resolve important cross-cultural differences. Key findings included the identifica-
tion of potential recurring translation issues between same language groups. Within 
the German, French and Spanish languages, technical terminology was translated 
alike whilst there were differences in the way non-technical, socially constructed 
wordings, emotions and symptoms were translated due to such factors as idiomatic 
formulations and cultural differences. Across the English languages, the text was 
simplified or elaborated as part of the adaptation process. Across the Russian and 
Chinese languages there were differences in the way technical and disease-specific 
terms were translated. cOnclusiOns: With the insight of the linguistic validation 
process, important differences were identified and resolved between technical terms 
and general wordings across same language groups. Cognitive debriefing is highly 
recommended and this will ensure appropriate comprehension across cultures and 
facilitate International comparison and pooling of data.
PRM244
DETERMINING THE MAGNITUDE OF A DETECTABLE AND A RELEvANT 
TREATMENT BENEFIT IN AESTHETIC MEDICINE USING A PHOTOGUIDE AND 
THE INTERNET
Pleil A1, Bushmakin A.G.2, Shields A.3, Jensen J.1, Cappelleri J.C.4
1Pfizer, Inc., San Diego, CA, USA, 2Pfizer Global Research and Development, Groton, 
CT, USA, 3Adelphi Values, Boston, MA, USA, 4Pfizer Global Pharmaceuticals,  
New York, NY, USA
Objectives: Photoguides are used as measures of treatment effect. To interpret 
the results, an understanding of what change is “enough” is required. The purpose 
of this study was to determine the Patient Detectable Difference (PDD) and Patient 
Relevant Difference (PRD) in scar severity using a discrete choice experiment with 
paired comparisons of scar photos via the internet. MethOds: Patients were asked 
to select the scar most like their own from a 5-photo photoguide as the referent. 
Each patient was then presented with a randomly selected scar from a scar library 
previously scored on severity by clinicians. For the PDD, patients were asked if the 
random scar was better, worse, or about the same. For the PRD, patients were asked 
if they would undergo treatment to “get” the random scar as opposed to keeping 
the referent scar. Each exercise was repeated five times. Optimal cutoff scores for 
PDD and PRD were based on a random intercept logistic model (RILM). Results: 
Using a series of RILM estimations across 514 participants, the PDD was calcu-
lated as 15.4 points on a 100-point scale (area under curve = 0.85, sensitivity = 
0.83, specificity = 0.73). In subgroup analyses by gender and scar source, the PDD 
ranged from 9.5 to 22.0 points. The replicate analysis adjusting for directionality 
of preference (improvement only) showed a PRD of 26.9 points (area under curve 
= 0.97, sensitivity = 0.90, specificity = 0.93), which ranged from 19.5 to 32.0 in the 
subgroups. cOnclusiOns: Results show that, as expected, scar patients report 
detectable differences in scar severity that are smaller than what they report as 
relevant differences necessary to choose treatment. The Internet-based approach 
using a discrete choice experiment is a novel method to quantify the threshold of 
detectable and relevant differences in scar severity using a photoguide.
PRM162
PARENT RATINGS OF ABILITy TO CONSENT FOR CLINICAL TRIALS IN FRAGILE 
x SyNDROME
Bailey D.1, Raspa M.1, Wheeler A.2
1RTI International, Research Triangle Park, NC, USA, 2University of North Carolina at Chapel Hill, 
Chapel Hill, NC, USA
Objectives: Advances in understanding the neural underpinnings of intellectual 
disabilities (ID) such as fragile X syndrome (FXS) have led to clinical trials testing 
medications addressing disease-specific targets. Individuals with ID ought to have 
a voice in consenting for clinical trials, but the extent to which they are capable 
of doing so is unknown. We discuss the importance of involving individuals with 
ID in the consent process and report results from a study of parents’ perceptions 
of their child’s ability to consent. MethOds: A survey was conducted with 422 
families who had a child with FXS. Parents rated items assessing their child’s abil-
ing cognitive interviews during the linguistic validation process of COAs. Further 
research is required to develop industry guidelines to ensure that the interviews 
are able to achieve their purpose: garnering accurate and meaningful feedback from 
respondents in order to increase comprehension and cross-cultural equivalence of 
multiple language versions.
PRM158
DEFINING STANDARDS OF CLINICIAN QUALIFICATIONS FOR THE LINGUISTIC 
vALIDATION OF CLINICAL OUTCOME ASSESSMENTS (COAS)
Sweeney E., Nakonechny A.
TransPerfect, New York, NY, USA
Objectives: As the linguistic validation of COA instruments often includes a review 
of medical terminology, it is important to confirm that the in-country clinician 
reviewer has sufficient qualifications to ensure quality as well as to elicit the highest 
level of conceptual equivalence in a linguistic validation project. This poster will 
consider each type of COA (Clinical Outcomes Assessment) and recommend guide-
lines for the qualifications of medical reviewers. MethOds: An examination was 
conducted of past linguistic validation projects involving an in-country review step 
with a medical professional. A review was completed of COAs (Clinician-Reported, 
Caregiver-Reported, as well as Patient-Reported questionnaires and diaries) within 
various therapeutic areas. This review also included an analysis of the specific 
background of each in-country clinician reviewer. Results: In the examination 
of linguistic validation projects that included a medical review step, it was deter-
mined that the experience level of clinician reviewers varied between projects. 
In an effort to standardize this step, a minimum experience requirement based 
on study needs and project type is proposed. cOnclusiOns: After a thorough 
review of past linguistic validation projects, it is suggested that an in-county clini-
cian reviewer should, at a minimum, encompass the following qualifications: 1) 
2+ years experience diagnosing and/or treating the patient population; 2) M.D. or 
relevant equivalent in the target country; 3) Native-language and/or advanced medi-
cal terminology training in the target language/country. Implementing minimum 
qualifications standards will help to ensure that an in-country medical reviewer 
will conduct a high-quality review for linguistically validated COAs.
PRM159
EvALUATION OF THE PSORIASIS AREA AND SEvERITy INDEx (PASI) AS PATIENT 
RELEvANT OUTCOME IN THE BENEFIT ASSESSMENT OF PSORIASIS THERAPIES
Gutknecht M., Augustin M., Rustenbach S.J., Schäfer I.
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Objectives: Psoriasis vulgaris is one of the most frequent chronic diseases in der-
matology and can cause a high disease burden and reduction of quality of life. The 
severity of psoriasis is determined by the clinical parameter PASI (Psoriasis Area and 
Severity Index). It is the most often cited measurement to determine the efficacy of 
therapies. Since the assessment of patient relevant treatment benefit gains impor-
tance in treatment evaluation, the objective of the study was to test to what extent 
PASI improvements agree with patient relevant benefit parameter. MethOds: A 
multicenter longitudinal observational study was conducted in n = 218 patients with 
psoriasis vulgaris. Data collection took place at the beginning of psoriasis treatment 
and between three and eight weeks after treatment. In addition to PASI, physician 
and patient data were collected, e.g. socio-demographics, clinical features, derma-
tological quality of life (DLQI), and assessment of treatment. Results: Each level of 
PASI (50, 75, 90) showed relevant improvements in patient reported outcomes. The 
satisfaction with the treatment and the patient benefit was greater, the higher PASI 
was reached. This effect was not seen for DLQI. However, improvements were only 
significant for PBI for all levels of PASI. Furthermore, results showed that not only 
changes in PASI but also its absolute value at the end of treatment has an impact for 
the patient reported assessment of therapy. Values < 3 in comparison to < 5 resulted 
in better values of PBI and higher treatment satisfaction. cOnclusiOns: The clini-
cal reduction of the severity of psoriasis vulgaris correlates with the improvement 
of the quality of life and with the patient defined treatment benefit. However, the 
PASI does not completely reflect the patient relevant outcome in the benefit assess-
ment. Therefore, it is recommended to make additional elicitation of patient defined 
objectives and benefits in the evaluation of psoriasis therapies.
PRM160
THE INFLUENCE OF CHOICE TASK LAyOUT ON THE OUTCOMES OF A DISCRETE 
CHOICE ExPERIMENT
Veldwijk J.1, Lambooij M.S.2, van Til J.A.3, Smit H.A.4, de Wit G.A.5
1National institute for public health and the environment, Bilthoven, The Netherlands, 2National 
Institute of Public Health and the Environment, Bilthoven, The Netherlands, 3University of 
Twente, Enschede, Overijssel, The Netherlands, 4University Medical Center Utrecht, Utrecht, 
The Netherlands, 5National Institute for Public Health and the Environment, Bilthoven, The 
Netherlands
Objectives: To test to what extent the presentation of choice tasks contrasting 
display in words or graphics, influences the attribute estimates, relative importance 
and participation probability and the conclusions drawn from a Discrete Choice 
Experiment (DCE). MethOds: A DCE questionnaire was sent to the parents of 
2,500 newborn babies aged 6 weeks at maximum. Each questionnaire contained 
two versions of the same 9 choice tasks, one in which the levels were presented in 
words, and one with graphic attribute levels. The DCE consisted of five attributes: 
vaccine effectiveness, frequency of severe side effects, protection duration, location 
of vaccine administration, out-of-pocket costs. Choice consistency was estimated, 
panel-mixed logit models were conducted to estimate the relative importance of 
the attributes and internal sample validation was calculated. Results: In total 13% 
answered consistent on all choice tasks, 19% answered inconsistently in one choice 
task, and 51% answered inconsistently in more than two choice tasks. Respondents 
who were presented with word choice tasks at first were significantly more consist-
ent compared to respondents that were presented with graphic choice tasks at first. 
Although out-of-pocket costs was the most important and frequency of severe side 
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the two scales on different patients can be compared or integrated across stud-
ies. MethOds: Data were taken from the 2011 and 2012 US National Health and 
Wellness Survey (NHWS). The NHWS is a large cross-sectional survey representative 
of the total adult population in several major markets; current analyses were limited 
to the US (n~75,000/year). Respondents self-reported physician diagnosis of various 
health conditions, including 9,633 who reported a diagnosis of IBS. Adherence was 
measured with MMAS-4 in 2011 and MMAS-8 in 2012. The two adherence scales 
were evaluated by comparing the frequency distributions of the MMAS scores in the 
two scales, Cronbach’s alpha and inter-item correlations, and the creation of a new 
4-item scale including the questions in MMAS-8 that best matched the questions 
in MMAS-4. Results: In IBS patients, both MMAS-4 and -8 scores are Poisson-like 
distributed, with median at zero (high adherence). Chronbach’s alpha was 0.64 for 
MMAS-4 and 0.70 for MMAS-8, while average item-test correlations were 0.70 and 
0.59, respectively. The reduced 4-item scale created out of MMAS-8 is also Poisson-
like distributed, Cronbach’s alpha was 0.67 and the average item-test correlation was 
0.71. cOnclusiOns: Data obtained with the two MMAS show similar qualitative 
and quantitative characteristics, suggesting that it may be appropriate to integrate 
data sources using the two different versions, particularly when the responses to 
the subset of 4 MMAS-8 items are available. Future research should confirm that 
the scales can be integrated in different therapeutic areas.
PRM166
USING FEEDBACK FROM PATIENTS IN DETERMINING SUITABILITy OF THE 
PERCEIvED DEFICITS QUESTIONNAIRE (PDQ) AND THE RESOURCE UTILIzATION 
IN DEMENTIA-LITE (RUD-LITE) FOR USE IN CLINICAL TRIALS IN PRODROMAL 
ALzHEIMER’S DISEASE
Lenderking W.R.1, Steenrod A.2, Rudell K.3, Klapper S.2, Howard K.2, Gaudig M.4
1Evidera, Lexington, MA, USA, 2Evidera, Bethesda, MD, USA, 3Pfizer Limited, Tadworth, UK, 
4Janssen Alzheimer Immunotherapy, Neuss, Germany
Objectives: Many instruments used to assess outcomes of treatment for Alzheimer’s 
disease (AD) have no published evidence for their content validity in mild cognitive 
impairment (MCI) or prodromal AD (pAD). The objective of this project was to evalu-
ate the content validity of AD patient reported outcome (PRO) instruments in this 
population. MethOds: Two waves of interviews were conducted: First, 11 patients 
with MCI and their informants/ (carers) evaluated several AD PROs (Alzheimer’s 
Disease Medication Administration Questionnaire (ADMAQ), Abbreviated Resource 
Utilization in Dementia-Lite (RUD-Lite), Perceived Deficits Questionnaire (PDQ), and 
Abbreviated Dependence Scale (AB DS); Second, 8 patients with pAD reviewed the 
modified PDQ, and their carers reviewed the RUD Lite. Interviews were transcribed 
and analysed. Results: Results of Wave 1 identified the PDQ and the RUD-Lite as 
the most promising measures for this cohort. Some minor modifications were sug-
gested for the PDQ, and a separate section was added to the RUD-Lite. Results of Wave 
2 showed pAD carers viewed the content of the RUD- Lite as less relevant because 
the patients are not functionally restricted enough to utilize resources at this early 
stage of the disease, although the newly added domain for the pAD population was 
understood and applicable. The modified PDQ was more acceptable to pAD patients 
than the original version. cOnclusiOns: Even well-established measures for AD 
patients should have their content validity evaluated prior to their use in pAD or MCI 
populations. In this study, we found that the PDQ and RUD –Lite needed modifications 
to be more relevant in early stage patients.
PRM167
RECOMMENDATIONS FOR THE SUCCESSFUL LINGUISTIC vALIDATION OF 
CLINICAL OUTCOME ASSESSMENTS FOR LIMITED PATIENT POPULATIONS
Moravec H.1, Chulis C.2, Sweeney E.2
1TransPerfect, San Francisco, CA, USA, 2TransPerfect, New York, NY, USA
Objectives: Timeline and budget considerations for the linguistic validation of 
Clinical Outcome Assessments (COAs) can vary substantially depending on patient 
population requirements and target locales. Rare diagnoses and/or small popula-
tions of native speakers of a language can lead to a small pool of eligible patients 
for cognitive debriefing respondents. This review highlights considerations neces-
sary to promote successful linguistic validation projects and mitigate the potential 
impact of small patient populations that, in turn, can affect study timelines as a 
whole. MethOds: To assess possible steps to take during study planning and the 
linguistic validation process, a literature review and examination of past linguistic 
validation projects were completed. This focused on trials in which a small patient 
population limited the number of eligible cognitive interviewing respondents, and 
the issues and solutions associated with each project. Results: In order to meet 
timeline and budget requirements, it is crucial that sufficient steps are taken to 
ensure cognitive interviewing populations are fully evaluated during a trial’s plan-
ning stages. Solutions for helping achieve this include: 1) Identification and possible 
inclusion of broader patient populations with conditions with similar symptoms; 2) 
Extended timeline consideration for rare diseases or small native-speaking popula-
tions at study start; 3) Selection of more general COAs (e.g. not specific to the diag-
nosis in the case of rare conditions) so cognitive interviewing may be performed on 
healthy respondents or a broader group of patients. cOnclusiOns: When choosing 
COAs for global use, an analysis of the intended patient population – including 
prevalence rates of the condition and size of the native-speaking population – is 
recommended in order to integrate projected linguistic validation timelines into 
the overall study plan. It is also recommended that study teams discuss this with 
their language services team for guidance on timelines and assistance in planning 
to ensure targeted study milestones are met.
PRM168
USING MOBILE TECHNOLOGy (MHEALTH) TO DEvELOP THE vALUE STORy FOR 
NEw DRUGS, DEvICES AND THERAPIES: OPTIMISING USER ENGAGEMENT AND 
ADDRESSING PAyER CONCERNS
Tran J.B.1, Hugh-Jones C.2
1Double Helix Consulting, London, UK, 2McCann Health, London, UK
ity to understand and complete six consent tasks. They also provided information 
about themselves (maternal education, willingness to enroll child in a clinical trial) 
and their child (age, autism status, thinking/reasoning ability, gender). Results: 
Factor analysis confirmed that the six items comprise a single factor. However, we 
found a clear hierarchy of difficulty; the least difficult tasks were “understands that 
this medication is different from his/her regular treatment” and “realizes that he/
she can choose to participate in the study or withdraw at any time.” The most dif-
ficult were “can make a decision about study participation” and “understands and 
weighs potential benefits and risks of participating in the study.” Although 29% of 
parents reported that their son was not at all capable of participating, the remainder 
exhibited a range of decisional skills. Factors associated with this variability include 
gender, autism, cognitive ability, age, and parents’ willingness to enroll their child 
in clinical trials. cOnclusiOns: Parents rate many individuals with FXS as able to 
participate in the consent process, but they will likely need support to maximize 
effective participation. We conclude with a brief review of strategies to support more 
inclusive participation in the consent process for people with ID.
PRM163
RESULTS OF A STUDy USING A TABLET PC TO COLLECT PROS IN ELDERLy 
POPULATION
Pau D.1, Nguyen L.1, Pibre S.1, Gokou S.1, Paget J.2
1Roche, Boulogne-Billancourt, France, 2Lincoln, Boulogne Billancourt, France
Objectives: Primary objective of the Percepolis study was to look at patient’s percep-
tion regarding their Erythropoiesis Stimulating Agents (ESA) treatment of anemia in 
chronic kidney disease. Many discussions arose at the set-up of the study regarding 
the best collection method of PROs as target population was old. The following fac-
tors helped to make a decision towards ePRO: - Clinical data were collected using 
an eCRF and previous experience of studies using PROs showed it was difficult to 
mix method of collecting data, - PRO was the primary endpoint of this study and 
needed to be carefully monitored, - Most elderly people use new technologies (cellular 
phone, PC), - Twenty questionnaires needed to be equally distributed. MethOds: 
This is a 6-month multicenter prospective Non-Interventional Study (NIS). Patients 
had to complete questionnaires at baseline and around 6-month in order to analyze 
the importance they gave to their ESA treatment characteristics. Technology used 
was the Tablet PC Samsung Galaxy Tab and specific interface was developed on the 
Operating System (O.S.) Android to maximize ease of use of the device for patients 
and investigators. For example, patients only had to select an answer on the screen 
to display the next question using the tactile functionnalities of the device. When 
connecting to the electronic data capture system, O.S. was detected in order to fit the 
screen’s display of the HTML pages. Results: A total of 789 patients were included, 
93% patients answered at least one questionnaire at baseline, 87% after 6 months 
of treatment. Mean age of the study population was 73 years old (± 13 years). Most 
PROs (95%) were answered using the Tablet PC. cOnclusiOns: ePROs can be used in 
elderly population as long as tools are adequately developed to simplify use of devices. 
ePROs also allowed following online study recruitment and questionnaires data entry.
PRM164
HOw BURDENSOME IS COMPLETION OF ELECTRONIC PATIENT-REPORTED 
OUTCOMES (EPRO)? ITEM COMPLETION TIMES AND QUALITATIvE EvIDENCE 
FROM STUDIES IN FOUR DIFFERENT HEALTH CONDITIONS
Arbuckle R.1, Tolley C.1, Burbridge C.2
1Adelphi Values, Bollington, UK, 2Pfizer Ltd., Surrey, UK
Objectives: The patient burden of completing large numbers of patient-reported 
outcome (PRO) items is often a concern; particularly when PROs must be completed 
daily, or at multiple timepoints over long studies. However, as ePRO and mPRO 
(technology that utilizes patients’ personal tablets and smartphones) methods 
advance, PRO completion becomes quicker and easier. How long does it actually 
take patients to complete ePROs? How burdensome do patients find ePRO comple-
tion? MethOds: ePRO allows collection of the time taken to complete a set of PRO 
items. We summarise data from four qualitative studies across a range of health 
conditions (fibromyalgia, a women’s health condition, pediatric constipation and 
pediatric irritable bowel syndrome). In all four studies, small samples of patients 
(n= 20-65) completed an ePRO diary daily for 5-9 days during pilot testing prior to 
cognitive debriefing. Completion times and missed days were collected. During 
the cognitive debriefing interviews patients were asked how burdensome the PRO 
completion was and if they had difficulty fitting it into their daily routine. Results: 
The PROs being developed had 15-35 items, but two included skip patterns, reducing 
the item burden. Average completion times ranged from 2.5-5.5 minutes per diary. 
For diaries without skip patterns, mean ‘per item’ completion times were calculated 
to range from 9.4-15.7 seconds. The majority of patients (93-100%) reported that the 
PRO was quick and easy to complete and not burdensome. Missed diary rates were 
consistently low with only 0-12% of patients missing more than one diary comple-
tion in the two studies where this information was collected. cOnclusiOns: These 
data provide evidence that patients (including children) can complete ePRO diaries 
very quickly, don’t find this burdensome, and are happy to complete relatively large 
numbers of items daily. If ePROs are carefully designed, using skip-patterns and 
event driven items, completion burden can be reduced even further.
PRM165
HARMONIzING MEASUREMENT OF ADHERENCE ACROSS THE 4-ITEM AND 
8-ITEM MORISKy MEDICATION ADHERENCE SCALE USING CROSS-SECTIONAL 
DATA FROM PATIENTS TREATED FOR IRRITABLE BOwEL SyNDROME
Pedersini R.1, Isherwood G.2, Vietri J.3
1Kantar Health, Epsom, UK, 2Kantar Health, Epsom, Surrey, UK, 3Kantar Health, Milan, Italy
Objectives: The 4-item Morisky Medication Adherence Scale (MMAS-4) and the 
more recent 8-item version (MMAS-8) have been both validated, and their concur-
rent validity has been assessed among hypertensive patients, but the extent to 
which the two scales can be compared against one another has not been deter-
mined. The current analysis assessed whether adherence scores obtained with 
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THE E-HEALTH IMPACT QUESTIONNAIRE: DEvELOPING A TOOL TO MEASURE 
THE EFFECTS OF USING HEALTH-RELATED wEBSITES
Kelly L., Ziebland S., Jenkinson C.
University of Oxford, Oxford, UK
Objectives: The internet is a valuable resource for accessing health information 
and support. This study aimed to develop a tool (the eHIQ) to measure the impact 
of using health-related websites which contain experiential and factual informa-
tion. MethOds: A multi-method study with four stages. Stage 1: Themes concern-
ing the impact of using health-related websites were identified through qualitative 
secondary analysis of interviews exploring patient and carer experiences of health 
and a relevant literature review. Stage 2: Questionnaire items based upon identified 
themes were constructed and assessed using expert and patient opinion. Stage 
3: Items were administered online and subjected to exploratory factor analysis. 
Stage 4: The reduced questionnaire and appropriate reference measures were 
administered online to test convergent validity and external reliability. Results: 
Sixty-seven items were constructed according to the key themes identified through 
relevant literature and qualitative analysis. Following expert and patient refinement, 
two independent item pools were entered into psychometric testing. The first item 
pool (eHIQ-Part 1) related to general views of using the internet in relation to health 
and second item pool (eHIQ-Part2) related to the impact of using a specific health-
related website. Analysis confirmed three domains present in eHIQ-Part 1 and six 
domains present in eHIQ-Part 2. These domains were tested further during Stage 4 
and were found to have high convergent validity, internal consistency and good test-
retest reliability. cOnclusiOns: Developing the eHIQ through the use of qualitative 
analysis and patient-expert opinion enhanced face and content validity. The eHIQ 
demonstrates good psychometric properties and will enable the measurement of 
the effects of using health-related websites across a range conditions.
PRM172
DESIGN OF LUPUS IMPACT TRACKER (LIT) vALIDATION STUDy IN FIvE 
EUROPEAN CLINICAL PRACTICE SETTINGS
Schneider M.1, Mosca M.2, Pego-Reigosa J.M.3, Koscielny V.4, Moore-Ramdin L.4, Devilliers H.5
1Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, 2University of Pisa, Pisa, Italy, 
3Hospital do Meixoeiro, Vigo, Spain, 4GlaxoSmithKline, London, UK, 5Dijon University Hospital, 
Dijon, France
Objectives: Physicians treating systemic lupus erythematosus (SLE) use a variety 
of tools to monitor disease activity and organ damage however these do not capture 
the functional burden experienced by patients. Studies suggest that communication 
between physicians and patients need to be optimized. The Lupus Impact Tracker 
(LIT), a brief, disease specific 10-item patient reported outcome tool, was developed 
to assess the impact of SLE on patients daily functioning and well-being. This study 
aims to evaluate the cross-cultural validity, acceptability and feasibility of the LIT in 
European clinical practice settings. Potential effect of LIT on communication during 
the consultation will also be assessed. MethOds: This is a prospective, observa-
tional, multicenter cross-sectional validation study of SLE patients on standard of 
care from hospital/clinical settings in five European countries (France, Germany, 
Italy, Spain and Sweden). 625 patients enrolled to obtain at least 500 evaluable cases 
irrespective of disease severity. Before the visit, patients will complete self-reported 
questionnaires: SF-36, Global Evaluation of Change (GEC), care satisfaction and LIT. 
During visits, physicians will record patient data, assess disease activity using the 
SELENA-SLEDAI and Physician Global Assessment (PGA), and disease damage using 
the SLICC/ACR damage index. After the visit patients and physicians complete LIT 
feedback questionnaires. Analyses will be performed using descriptive statistical 
methods with no specific hypothesis suggested. Results: Psychometric evalua-
tion of LIT in US clinical settings found the tool reliable and valid. Evaluation for 
use in European clinical practice settings is thus needed. Cross-cultural validity 
of LIT across countries will be analyzed using differential item functioning (DIF) 
analysis. Data from the Lupus Impact Tracker-(Patient and Physician) Feedback 
Questionnaires will be tabulated and summarized. cOnclusiOns: We need 
improvement of the patient/physician interaction in lupus care. The LIT may be 
a valid and acceptable tool for use with SLE patients in European clinical practice 
settings.
PRM173
DEvELOPMENT OF A QUESTIONNAIRE TO EvALUATE FOOD-RELATED  
wELL-BEING
Guillemin I.1, Allaert F.A.2, Arnould B.1, Capuron L.3, Dupuy A.4, Ginon E.5, Lecerf J.M.6,  
Prost M.7, Rogeaux M.8, Urdapiletta I.9, Marrel A.1
1Mapi, Lyon, France, 2CEN Biotech/CEN Nutriment, Dijon, France, 3Université Bordeaux 
II, Bordeaux, France, 4Université de Toulouse II – Le Mirail, Toulouse, France, 5Laboratoire 
d’Expérimentation en Sciences Sociales et Analyse des Comportements (LESSAC); ESC Dijon 
Bourgogne, Dijon, France, 6Institut Pasteur de Lille, Lille, France, 7Laboratoire de recherches 
Appliquées Spiral (SPIRAL), Couternon, France, 8Danone, Palaiseau, France, 9Laboratoire Parisien 
de Psychologie Sociale - Universités de Paris 8 & Paris 10, Saint-Denis, France
Objectives: To screen food-related products and support allegation demands, evalu-
ating food-related concepts with appropriate tools is essential. In the absence of such 
a tool, we developed a specific questionnaire providing insight into the way a person 
links food to well-being in terms of pleasure, joint comfort, digestive comfort, pre-
vention and immunity. MethOds: Semi-directive interviews were conducted with 
40 healthy subjects to explore three themes: food, well-being and food-related well-
being, and determine the basis of the interview guide for focus group discussions. 
Twenty-four group discussions (199 subjects in total) were conducted with healthy 
subjects (n= 12) and subjects with joint, digestive or repetitive infection complaints 
(n= 4 per complaint), to investigate definition and experience of food-related well-
being. Qualitative analysis was performed to identify concepts of interest. Based on 
the designed conceptual model and discussion with the scientific committee, items 
were generated using subjects’ verbatim expression. Face-to-face cognitive interviews 
were conducted with 29 healthy subjects to ensure comprehension and appropri-
Objectives: This research explored the feasibility of using mobile technology 
(mHealth) to capture data such as resource utilisation and patient reported 
outcomes to support the market access of new products. The main objectives 
were to understand best practices in engaging end users to optimise data col-
lection, and to explore payer opinions on the validity of using mHealth for 
data collection and its usefulness in the decision making process. MethOds: 
Secondary research was conducted to identify best practices in optimising 
end user engagement with mHealth solutions. Studies that led to success-
ful outcomes were analysed in detail to understand the key engagement suc-
cess factors. Qualitative primary payer interviews were conducted in several 
key European markets to understand the validity of using mHealth to collect 
data including perceived challenges of leveraging this data to support market 
access decisions. Results: Research showed that interventions that are person-
alised through data, analytics and behaviour change methodologies are most 
successful in engaging end users when using mHealth. Payers highlighted sev-
eral key concerns of using mHealth; namely, data quality and sustainability/ 
scalability. These concerns should be considered and addressed by health care 
companies who wish to use mHealth as a data platform to support payer deci-
sions. cOnclusiOns: mHealth is a tool that holds promise for many different 
parts of the health care value chain. This includes leveraging mHealth to support 
the market access targets of new products, by collecting and using data to enhance 
the communication of the products’ value. The findings from this research high-
light best practices to engage users in order to optimise data collection as well as 
provide insights from payers on the key concerns of doing so.
PRM169
THE INFLUENCE OF HAQ UTILITy MAPPING ALGORITHMS ON THE 
COST-EFFECTIvENESS OF SECOND LINE BIOLOGICS FOR TREATMENT OF 
RHEUMATOID ARTHRITIS
Pennington B.
BresMed, Sheffield, UK
Objectives: In 2010, the National Institute for Health and Clinical Excellence 
(NICE) performed a multiple technology assessment for second line biologic 
treatments (following the failure of a TNF inhibitor and disease modifying anti-
rheumatic drugs (DMARDs)) for the treatment of rheumatoid arthritis (RA). The 
Birmingham RA Model (BRAM) was used to obtain incremental cost-effectiveness 
ratios (ICERs) of £21,100/quality-adjusted life year (QALY) for rituximab versus 
DMARDs and £130,600 for abatacept versus rituximab. Adalimumab, etanercept 
and infliximab were dominated by rituximab. NICE recommended rituximab, 
unless contraindicated, in which case all the other biologics were recommended. 
The BRAM used in the NICE assessment used a linear regression model to trans-
late Health Assessment Questionnaire (HAQ) scores into EQ-5D scores, however 
other algorithms exist. The objective of this study was to understand how the 
algorithm used to map from HAQ to EQ-5D affects the ICERs generated by the 
model. MethOds: The BRAM used in the NICE assessment used a linear regres-
sion model to translate Health Assessment Questionnaire (HAQ) scores into EQ-5D 
scores, however other algorithms exist. The objective of this study was to under-
stand how the algorithm used to map from HAQ to EQ-5D affects the ICERs gen-
erated by the model. Results: The ordering of the effectiveness of treatments 
did not change with the mapping algorithm used, however there was substantial 
variation in the magnitude of the ICER. The ICER for rituximab versus DMARDs 
varied from £21,594/QALY to £32,039/QALY depending on the exact algorithm used. 
The ICER for abatacept versus rituximab varied from £124,776/QALY to £167,687/
QALY. cOnclusiOns: The cost-effectiveness results of the BRAM are heavily 
influenced by the choice of mapping algorithm. In future modelling, the choice 
of algorithm should be justified, and appropriate sensitivity analyses presented. 
Further research is needed to identify the most appropriate algorithm(s) for use 
in health technology assessment.
PRM170
USING RASCH ANALySIS TO CO-CALIBRATE SCORES FROM OUTCOME 
MEASURES SPECIFIC TO ASTHMA (ALIS), CHRONIC OBSTRUCTIvE PULMONARy 
DISEASE (LCOPD) AND PULMONARy HyPERTENSION (CAMPHOR)
Twiss J., McKenna S., Rouse M.
Galen Research Ltd., Manchester, UK
Objectives: Disease-specific patient-reported outcomes (PROs) are designed to 
be highly relevant to a single disease. It is widely believed that comparisons of 
outcomes between patients with different diseases is only possible using generic 
PRO measures. The present study employs a novel method of using Rasch analy-
sis to co-calibrate scores from different disease-specific PROs allowing scores to 
be compared across diseases. MethOds: Three samples of patients completed 
the Asthma Life Impact Scale (ALIS), the Living with COPD scale (LCOPD) or the 
Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), depending on 
their illness. Each scale utilises the needs-based model of QoL and the scales 
share 8 common items. The three samples were analysed separately for fit to 
the Rasch model and then combined and re-analysed. Results: The ALIS was 
completed by 140 asthma patients (mean age= 50.6, males = 29.3%); the LCOPD 
by 162 COPD patients (mean age= 69.3, males = 43.8%) and the CAMPHOR by 91 
patients (mean age= 52.6, males = 29.7%). Each of the scales fit the Rasch model 
individually (ALIS Chi2 = 0.05; LCOPD Chi2 = 0.32; CAMPHOR Chi2 = 0.92). The com-
bined dataset also fit the Rasch model at first run (Chi2 = 0.24). One common item 
showed misfit (Chi2< 0.001) and non-uniform differential item functioning (DIF) 
by disease (Chi2< 0.001). This item was removed from the analysis and the final 
co-calibrated scale showed good fit to the Rasch model (Chi2= 0.48) with minimal 
DIF by age, gender or disease. cOnclusiOns: The results showed that it was pos-
sible to co-calibrate scores on the ALIS, LCOPD and CAMPHOR. As disease-specific 
measurement has advantages over generic assessment related to relevance and 
reproducibility, the results have the potential to enhance PRO measurement in 
respiratory research.
A606  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
Objectives: The use of pharmacoeconomic evaluations, e.g. cost-utility analysis 
(CUA), in resource allocation is gaining attention in Arabic –speaking countries. The 
Short Form-6D (SF-6D) is a generic preference-based measure of health-related 
quality of life (HRQoL) that can be used to generate health-state utilities for use in 
CUAs. The objective of this study is to translate and culturally-adapt the SF-6D for 
use in Arabic-speaking countries, with particular focus on Egypt and the United 
Arab Emirates. MethOds: The study followed the International Quality of Life 
Assessment (IQOLA) methodology. Two forward translations, one consensus and 
one backward translation were undertaken. The translators (professional linguists 
and bilingual pharmacoeconomists) reported the difficulties encountered in the 
translation process. An advisory committee of six researchers and three clini-
cians, who are native Arabic speakers and proficient in English language, assessed 
the consensus version for accuracy, cultural compatibility and cognitive burden. 
The difficulties encountered during the process were categorized as grammati-
cal, idiomatic, semantic/conceptual, and cultural. The backward translation was 
completed by a professional medical translator, reviewed and assessed by the com-
mittee. Results: Five items raised discussion during the process for grammatical 
(1 item), semantic (1 item), idiomatic (1 item) and cultural (2 items). For example, 
“emotional problems” had to be culturally adapted and “down-hearted and low” 
had to be substituted. The committee members approved the forward translation as 
linguistically and grammatically accurate. Minor changes were made to the forward 
translation to improve cultural appropriateness. The Backward translation did not 
reveal major problems and equivalence to the original was confirmed following 
committee review. cOnclusiOns: The translation and cultural adaptation of the 
SF-6D into Arabic resulted in a conceptually equivalent and culturally appropriate 
version. Psychometric validation and a valuation survey will be needed to assess 
its validity for use in the target populations.
PRM177
ASSESSING MEASUREMENT EQUIvALENCE OF DIFFERENT FORMS OF 
ADMINISTRATION OF THE CAMBRIDGE PULMONARy HyPERTENSION OUTCOME 
REvIEw (CAMPHOR) USING RASCH ANALySIS
Twiss J.1, McKenna S.1, Graham J.E.1, Swetz K.M.2, Sloan J.2, Gomberg-Maitland M.3
1Galen Research Ltd., Manchester, UK, 2Mayo Clinic, Rochester, MN, USA, 3University of Chicago 
Medicine, Chicago, IL, USA
Objectives: Electronic formats of patient-reported outcome (PRO) measures 
are now routinely used in clinical trials. Their use promises a range of benefits 
such as improving access to patients, increasing compliance, reducing miss-
ing data and avoiding errors associated with data entry. When changing from 
paper and pen to an electronic administration it is necessary to establish their 
equivalence. This is the first study to evaluate the use of Rasch analysis for 
this purpose. MethOds: Three groups of US patients with pulmonary hyper-
tension participated. A clinical sample completed an electronic version of the 
CAMPHOR (e-sample) and two different samples completed the pen and paper 
administration (pp1 and pp2). Analyses were conducted on the CAMPHOR activity 
limitations and quality of life (QoL) scales. The three databases were analysed 
separately for fit to the Rasch model. Data were then combined, re-analysed and 
assessed for differential item functioning (DIF). Results: The three datasets 
were matched randomly for sample size (n= 147). Mean age (years) and percent-
age male respondents were as follows: e-sample (51.7, 16.0%); pp1 (50.0, 14.0%); 
pp2 (55.5, 40.4%). After minor adjustments to the three datasets, fit to the Rasch 
model was achieved (Chi2 values for activity limitations and QoL respectively 
were e-sample (0.11, 0.07); pp1 (0.18, 0.12); pp2 (0.40, 0.30)). Fit was also achieved 
for the combined sample after minor adjustments (activity limitations Chi2 = 
0.21, QoL Chi2 = 0.12). Importantly, no evidence of DIF by mode of administration 
was found. cOnclusiOns: Equivalence of the electronic and pen and paper 
administrations of the CAMPHOR was established. The results showed how the 
Rasch model can be utilized to determine the equivalence of alternative formats 
of PRO measures. This methodology has the added advantage of avoiding the 
need for complex study designs such as matching samples for disease severity 
or repeated administration of alternative formats of questionnaires.
PRM178
MODELLING THE RELATIONSHIP BETwEEN THE wOMAC OSTEOARTHRITIS 
INDEx AND EQ-5D
Wailoo A.J.1, Hernández M.1, Escobar M.artinez A2
1University of Sheffield, Sheffield, UK, 2Hospital Universitario Basurto, Bilbao, Spain
Objectives: Economic evaluation typically is conducted using health state 
utilities to estimate treatment benefits. However, such outcomes are often miss-
ing from studies of clinical effectiveness. This study aims to bridge that gap by 
providing appropriate methods to link values from the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) to the EQ-5D utility instru-
ment. MethOds: Patients from a large registry of Spanish patients (n= 7072 obser-
vations) with knee or hip osteoarthritis who completed both WOMAC and EQ-5D 
was used. A mixture model approach was used based on distributions bespoke to 
the EQ-5D UK value set to estimate EQ-5D as a function of WOMAC pain, stiffness 
and function subscores. Results: A five class mixture model provides very close 
fit to the observed data at all levels of disease severity. The overall mean (0.542 vs 
0.542), median (0.620 vs 0.636) and the percentage of observations at full health 
(15 vs 14.8) were very similar between the observed data and the estimated model 
respectively. Stiffness has limited relationship to EQ-5D, whereas functional disabil-
ity and pain are strong predictors. cOnclusiOns: EQ-5D can be reliably estimated 
from WOMAC subscale scores without any systematic bias using the results based 
on a bespoke mixture model method.
PRM179
DIFFERENTIAL ITEM FUNCTIONING IN A SATISFACTION ITEM BANK
Campillo-Álvarez Á, Rodríguez-Aguilella A., Castejón N., Cuervo J., Rebollo P.
LASER Analytica, Oviedo, Spain
ateness of the resulting test questionnaire. After revision, the pilot questionnaire 
was created. Results: Concepts elicited during group discussions revolved around 
pleasure and health. The test questionnaire consisted of 199 items divided into six 
modules: “grocery shopping”, “cooking”, “places where meals are eaten”, “convivial-
ity”, “eating and drinking”, and “eating habits and health”. Items within the first 
five modules assess subject behaviour and benefits (pleasure, psychology, digestion, 
physical condition); the module “eating habits and health” assesses beliefs. Cognitive 
interviews led to minor rewordings, removal and addition of items. The resulting pilot 
questionnaire consisted of 174 items distributed across the 6 aforementioned mod-
ules. cOnclusiOns: We developed a unique tool that comprehensively assesses the 
full picture of well-being related to food and eating habits in the general population. A 
validation study is underway to establish the scoring and ascertain the psychometrics 
of the instrument before it can be used in clinical studies.
PRM174
METHODOLOGy AND DEvELOPMENT OF ‘POLISH DICTIONARy OF QUALITy OF 
LIFE TERMS’
Golicki D.1, Farkowski M.M.2, Grabowska-Krawiec P.3, Szkultecka-Debek M.4, Zawodnik S.5, 
Baran J.6, Borowiec L.7, Czech M.5
1Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, 
Poland, 2Institute of Cardiology, Warsaw, Poland, 3Department of Immunology and Clinical 
Allergology, Military Institute of Medicine, Warsaw, Poland, 4Department of Dermatology, Military 
Institute of Medicine, Warsaw, Poland, 5Department of Pharmacoeconomics, Medical University of 
Warsaw, Warsaw, Poland, 6Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland, 
7Servier Polska Sp. z o.o., Warsaw, Poland
Lack of an established Polish terminology is a serious limitation of the development 
of health-related quality of life (HRQoL) studies in Poland. Objectives: To develop 
Polish dictionary of terms used in the studies of HRQoL. MethOds: In February 2012, 
HRQoL Special Interest Group of ISPOR Poland Chapter took on the task of preparing 
Polish dictionary of HRQoL terms. Following steps were planned: (1) preparation of 
a list of target English-language terms, (2) preparation of a reference list of transla-
tions typically used in Polish literature, (3) step-by-step translation of English terms 
by individual experts (4) analysis and approval of proposed translations by Expert 
Committee, (5) re-analysis of key terms, (6) preparation of pre-final vocabulary, (7) 
reviews by Review Committee, (8) preparation and publication of the final version. 
The list of English terms was based on following sources: popular English-language 
HRQoL textbooks, key words from papers published in leading peer-reviewed jour-
nals in the field, ISPOR guidelines concerning patient-reported outcomes, websites of 
generic HRQoL instruments. The reference lists of translations used in Polish literature 
was based on pharmacoeconomics and psychology textbooks, EBM dictionaries and 
HRQoL papers published in Polish peer-reviewed journals. Expert Committee was 
comprised of seven Polish investigators with vast experience in the field of HRQoL 
studies. Review Committee was formed by three authorities in the field of psycho-
metrics, statistics and epidemiology. Results: Till June 2013, there were 13 meetings 
of Expert Committee: three focused on the development of methodology and ten - on 
analysis and approval of proposed translations. Initially, we identified 1640 English 
terms from different sources. After removal of duplicates, final English list comprised 
of 1314 terms. Pre-final version of vocabulary, ready for peer-review, consists of 1051 
proposed Polish translations. cOnclusiOns: We anticipate, that dictionary prepared 
by the ISPOR Poland Chapter will support practical usage of PRO in Poland.
PRM175
MAPPING THE OxFORD HIP SCORE (OHS) TO EQ-5D: A TEST OF MODEL 
PERFORMANCE
Sungher D.K., Diamantopoulos A.
Symmetron Limited, Elstree, UK
Objectives: The lack of preference-based utility data places great importance 
on the accuracy of mapping functions. The objective of this study is to assess the 
predictive accuracy of statistical models which address the unique properties of 
EQ-5D. MethOds: A large dataset from the Patient Reported Outcome Measures 
(PROMs) programme reporting EQ-5D and OHS values for patients who have under-
gone total hip replacement, during April 2010 and March 2011, was used to develop 
6 mapping functions using different statistical methods: Ordinary Least Squares 
(OLS), standard Tobit, adjusted Tobit, two-part logit (TPL), response-mapping and 
censored least absolute deviation (CLAD). Three different model specifications 
were investigated, including the total OHS, individual item score and individual 
item responses. Each model specification was examined using goodness-of fit 
measures. The predictive accuracy of each model was analysed using the mean 
absolute error (MAE) and mean squared error (MSE). Model performance was com-
pared in an internal and external validation. Results: The OHS individual item 
response variables proved to give the best model fit and were therefore used 
across all models. The OLS and TPL models consistently demonstrated the highest 
predictive accuracy, providing the lowest MSE and the closest estimation of the 
mean EQ-5D. The response-mapping approach was the poorest predictor in esti-
mating individual values; however it was able to predict the median with perfect 
precision. Models using Tobit and CLAD frameworks provided the poorest predic-
tions. cOnclusiOns: The OLS and TPL models proved to be the most accurate 
in predicting EQ-5D on an individual level, whilst the response-mapping model 
is recommended for predicting the median. Using inaccurate mapping functions 
such as the Tobit models developed in this study can have a substantial impact 
on CEA results and reimbursement decisions.
PRM176
TRANSLATION AND CULTURAL ADAPTATION OF THE SF-6D QUESTIONNAIRE 
FOR USE IN ARABIC-SPEAKING COUNTRIES
Dawoud D.M.1, Soliman A.M.2, Alhyas L.3, Amin M.E.K.4, Hussein M.5, Mohamed O.4
1Cairo University, Cairo, Egypt, 2AbbVie Inc., Libertyville, IL, USA, 3Ministry of Health, Abu Dhabi, 
United Arab Emirates, 4University of Wisconsin-Madison, Madison, WI, USA, 5University of 
Tennessee, College of Pharmacy, Memphis, TN, USA
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testing also provides preliminary quantitative item performance data and important 
insights about the usability of eDiaries.
PRM182
THE IMPACT OF DSM-5 ON THE DEvELOPMENT OF DRUGS TO TREAT AUTISM 
SPECTRUM DISORDER
Meyers O.I.
Truven Health Analytics, Cleveland, OH, USA
Objectives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) which 
is a classification and diagnostic system for psychiatric and certain neurologic con-
ditions. DSM-5 brings significant changes to many of the diagnostic categories as 
compared to the previous edition of the manual. The objective of this review was 
to examine the changes in the Autism Spectrum Disorder (ASD) criteria and dis-
cuss the impact of these changes for industry. MethOds: A line-by-line review 
of the DSM-5 criteria for Autism Spectrum Disorder and the DSM-IV criteria for 
Pervasive Developmental Disorders was undertaken. Significant changes were 
highlighted and discussed from the point of view of sponsors of clinical trials for 
psychopharmacologic agents being developed to treat these conditions. Results: 
The changes to the diagnostic criteria for what were known in DSM-IV as pervasive 
developmental disorders (PDD) are sweeping. ASD, now in a section of the DSM 
titled “Neurodevelopmental Disorders,” is a single entity in DSM-5 with several 
levels of severity that effectively replaces the five PDDs that were separately clas-
sified in DSM-IV. Notable changes include the addition of severity levels to the ASD 
criteria, changes to the social interaction and social communication criteria, and 
the addition of hyper- or hyporeactivity to sensory input or unusual interest in sen-
sory aspects of the environment, as an illustrative example of restrictive, repetitive 
patterns of behavior, interests, or activities. cOnclusiOns: The numerous and 
significant changes in DSM-5 pose both challenges and opportunities to industry. We 
need to take a careful look at DSM-5 to understand what the changes mean for how 
we go about developing medical products to treat psychiatric disorders. This means 
the need for investment in research, education, and new ways of approaching the 
development of endpoints and outcome assessments in clinical trials.
PRM183
ESTIMATING THE IMPACT OF ENDOGENOUS SUBSTANCE ABUSE ON  
SELF-REPORTED HEALTH STATUS
Gu N.Y.
University of New Mexico, Albuquerque, NM, USA
Objectives: The impact of addictive substance abuse (SA) on overall well-being, 
such as patient’s self-reported health status, may suffer from endogeneity bias. The 
purpose of this study is to estimate the impact of SA on patient’s health status using 
the instrumental variable (IV) approach. MethOds: The sample was extracted from 
the 2011 Substance Abuse and Mental Health Services Administration (SAMHSA) 
data for 36,347 adult US respondents who indicated SA status. Treating SA as exog-
enous, a single-equation probit model was used. Treating SA as endogenous, bivari-
ate probit models were employed using different IVs. The outcome variable was the 
self-reported health status (1= better than good; 0= fair or poor). Other exogenous 
variables controlled in the model were respondents’ age, gender, race, marital status, 
education level, employment status and family income. IVs were respondents’ age 
at SA initiation, SA frequency and substance availability. Exogeneity, over-iden-
tification and weak instrument tests were performed to ensure the validity and 
appropriateness of the IVs. Results: About 50% of the respondents were between 
18-25 years old. Over 56% indicated SA and approximately 36% had initiated SA 
before age 18. The single-equation probit suggested that SA was associated with 
at least a 2% decrease in overall health status (p< 0.01), compared those who never 
had SA. After adjusting for endogeneity bias, the negative relation between SA and 
health status increased by at least two-fold (p< 0.01). All tests indicated that the 
IVs used were valid and the results were significant. cOnclusiOns: The findings 
suggest that estimating the impact of SA on health status should consider adjust-
ing the endogeneity bias induced by individual characteristics and environmental 
factors such as age at SA initiation, frequency of SA use and substance availability 
in the community. Further investigations on the effect of SA abstinence durations 
on health status should be explored to strengthen their associations.
PRM184
THE IMPACT OF DSM-5 ON THE DEvELOPMENT OF DRUGS TO TREAT 
ATTENTION-DEFICIT/HyPERACTIvITy DISORDER
Meyers O.I.
Truven Health Analytics, Cleveland, OH, USA
Objectives: In May 2013, the American Psychiatric Association released the 
fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 
which is a classification system for psychiatric and certain neurologic conditions. 
DSM-5 brings significant changes to many diagnostic categories as compared to 
the previous edition of the manual. The objective of this review was to examine the 
changes in the Attention-Deficit/Hyperactivity Disorder (ADHD) criteria and discuss 
the impact these changes may have for industry. MethOds: A line-by-line review 
of the DSM-5 and DSM-IV criteria for ADHD was undertaken. Significant changes 
were highlighted and discussed from the point of view of sponsors of clinical trials 
for psychopharmacologic agents being developed to treat ADHD. Results: One of 
the more notable changes to ADHD criteria in DSM-5 is in the age of onset cutoff. 
To meet DSM-IV criteria, symptoms had to be present before age 7. In DSM-5 this 
was changed to 12. Additionally, symptoms present before the age of onset cutoff 
had to cause impairment to meet the DSM-IV criteria, but in DSM-5 there is no 
such requirement. Another significant change lies in the fact that while DSM-IV 
did not make a distinction between childhood and adult ADHD, in DSM-5, from 
age 17 on, only 5 of 9 symptoms in one or both categories are required, rather than 
6. Several other changes related to differential diagnosis and functional impair-
ment were noted as well. cOnclusiOns: The significant changes in DSM-5 pose 
Objectives: In the last years, the assessment of patient satisfaction has become 
an area of great interest due to its implications, especially in the management of 
chronic diseases. Across the board, satisfied patients tend to have better adher-
ence to medication. It affects a patient’s prognosis and treatment costs. High-risk 
hypertension and Diabetes Mellitus (DM) (types I and II) are two chronic diseases 
with high prevalence. The objective of this research was to examine Differential 
Item Functioning in a previously developed Satisfaction with Treatment item bank 
between these chronic diseases as a first step to improve the item bank. MethOds: 
The sample consisted of a total of 283 patients diagnosed with DM and 1.517 high or 
very high-risk hypertensive patients. Uniform DIF between both samples was inves-
tigated using Winsteps. The presence of DIF in thirteen items from a satisfaction 
bank was analyzed. Results: Ceiling effect was detected and an item-person map 
showed that the test was off-target and didn’t cover the highest range of the ability 
scale. DIF was present between patients with Diabetes Mellitus (I and II) and high-
risk hypertensive patients. Differences above one logit were found in three items, 
two related to adverse-events, which diabetes patients found harder to endorse, and 
one to oversights, harder to endorse for high-risk hypertensive patients. A differ-
ence in the same direction was found in two more items pertaining to convenience, 
with differences in this case larger than 0.75 logits. cOnclusiOns: This study 
represents a psychometrically valid initial effort to improve patients with chronic 
diseases satisfaction assessment. The DIF analysis has allowed improving the item 
satisfaction bank, selecting those items which could provide better information in 
order to develop a satisfaction questionnaire better tailored to specific patients. 
Future research is recommended considering different chronic pathologies and to 
reduce the ceiling effect associated with the satisfaction measures.
PRM180
THE IMPACT OF DSM-5 ON THE DEvELOPMENT OF DRUGS TO TREAT 
SCHIzOPHRENIA
Meyers O.I.
Truven Health Analytics, Cleveland, OH, USA
Objectives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a 
classification system for psychiatric and certain neurologic conditions. DSM-5 
brings significant changes to many diagnostic categories as compared to the 
previous DSM-IV-TR. The objective of this review was to examine the changes 
in the Schizophrenia criteria and discuss the impact these changes may have 
for industry. MethOds: A line-by-line review of the DSM-5 and DSM-IV criteria 
was undertaken. Significant changes were highlighted and discussed from the 
point of view of sponsors of clinical trials for psychopharmacologic agents being 
developed to treat Schizophrenia. Results: The primary diagnostic criteria for 
Schizophrenia in DSM-5 are little changed. The major change in the so-called 
“active-phase symptoms” is with the mix of symptoms that can meet this crite-
rion. Five key symptom areas must be present to meet criteria. In DSM-IV, any two 
symptoms were sufficient and in some limited cases, even just one was enough 
(bizarre delusions or Schneiderian first-rank auditory hallucinations – convers-
ing voices). According to the DSM-5 criteria, there always must be at least two 
symptoms to meet Criterion A, and one of the two must be either delusions, hal-
lucinations, or disorganized speech. Other important changes include changes to 
the course specifiers, the elimination of Schizophrenia subtypes, and the addition 
of an optional framework for clinicians to rate the severity of the primary symp-
toms. cOnclusiOns: The changes in DSM-5 pose both challenges and opportu-
nities for industry. The changes in the DSM-5 criteria may translate into changes 
for how we go about developing medical products to treat psychiatric disorders, 
including Schizophrenia. There will need to be an investment in research and edu-
cation, and sponsors must examine the possibility of developing new endpoints 
and outcome assessments for use in clinical trials.
PRM181
THE vALUE OF PILOT TESTING PRO SyMPTOM DIARIES PRIOR TO CONDUCTING 
COGNITIvE DEBRIEFING INTERvIEwS IN CHILDREN/ADOLESCENTS: 
QUALITATIvE AND QUANTITATIvE INSIGHTS
Arbuckle R.1, Holloway L.1, Carson R.T.2, Dennee-Sommers B.3, Abetz-Webb L.1
1Adelphi Values, Bollington, UK, 2Forest Research Institute, Jersey City, NJ, USA, 3Endpoint 
Outcomes, Boston, MA, USA
Objectives: To pilot test daily electronic symptom diaries in pediatric chronic 
constipation (CC) and irritable bowel syndrome with constipation (IBS-C) for approx-
imately one week prior to cognitive debriefing interviews. MethOds: Separate 
child and parent eDiary measures of CC/IBS-C symptoms were developed based 
on concept elicitation interviews with children with CC/IBS-C and their parents. 
The eDiaries were completed by 36 children/adolescents (aged 6-17 years) with 
CC/IBS-C and 30 parents (of 6 month-11 year old children with CC/IBS-C) for 5-9 
days prior to cognitive debriefing. Children and parents were trained to use the 
eDiary and following the pilot test, children and parents were interviewed sepa-
rately about their experiences completing the eDiaries and the symptom items. 
Item descriptive statistics were calculated using the eDiary data collected during the 
pilot test. Results: Both eDiaries were well understood, all items were considered 
relevant, and no symptoms were identified as missing from the eDiaries. During 
cognitive debriefing, the children were able to reflect on their experiences of com-
pleting the eDiary as opposed to considering hypothetical scenarios to debrief the 
items. Although 9 children and 15 parents reported challenges with transmitting 
data, mean compliance rates were high (94% and 92%, respectively), indicating low 
levels of missing data and that the eDiaries were easy to use overall. Mean comple-
tion times were 3.72 minutes for children and 3.96 minutes for parents, provid-
ing further evidence of low burden. All item responses were normally distributed 
and demonstrated expected patterns of response (e.g., most reported 0 or 1 bowel 
movement daily). cOnclusiOns: Pilot testing eDiaries prior to cognitive debrief-
ing interviews, especially with children, provides respondents with the experience 
of completing the eDiary, facilitating a more informed qualitative interview. Pilot 
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matrix of likely sample size based on these values ranged from 44 to 193 per group. 
Based on this DPP, a sample of 120 per group was selected as the sample size that 
would deliver clinically meaningful results. cOnclusiOns: A DPP is useful in late 
phase research to define appropriate sample size where no data exist. It is important 
to note that DPP methods do not require significance testing, but the benefit is no 
need for a correction for multiple comparisons at the time of the final analysis.
PRM188
FAULTy CONNECTIONS: CAN CRITICISMS OF NETwORK META-ANALySIS IN 
NICE SUBMISSIONS BE AvOIDED?
Martin A., Rizzo M., Iheanacho I.
Evidera, London, UK
Objectives: To assess 1) how network meta-analyses (NMAs) included within 
manufacturer submissions to the National Institute for Health and Care Excellence 
(NICE) have been criticised by its Evidence Review Groups (ERGs); 2) how some 
of these criticisms might be avoided in future submissions; and 3) the extent to 
which such avoidance might increase the likelihood of a new intervention being 
approved. MethOds: We reviewed the ERG reports of all NICE technology appraisals 
published since January 2007 to identify those where the manufacturer’s submission 
included an NMA. Subsequently, all criticisms made by the ERG of such analyses 
were analysed to seek common themes; and assess how often any one type of 
criticism was associated with a rejection by NICE. Results: A total of 181 NICE 
technology appraisal reports were evaluated. These covered 243 separate interven-
tions, 83 (34%) of which were drugs for cancer. Overall 37–64% of submissions cited 
NMAs, of which 43–83% were criticised, with this proportion having increased over 
time. Avoidable criticisms related to flaws in the systematic review methodology 
used to identify relevant RCTs for the analysis; inappropriate pooling of data from 
heterogeneous studies; and use of suboptimal statistical approaches in conducting 
the NMA. Unavoidable criticisms related to the lack of RCTs available for competitor 
drugs in the population of interest. However, no association was found between 
flaws in the NMA and a decision by NICE not to approve the use of the intervention. 
Instead, such rejection was associated mainly with a lack of evidence of clinical 
efficacy or cost-effectiveness in the target population. cOnclusiOns: Most criti-
cisms of NMAs could be avoided by a more rigorous and transparent approach to 
conducting and reporting the underlying systematic review and statistical analysis. 
However, rejection of submissions remains a considerable risk where the underly-
ing evidence is weak.
PRM189
METHODOLOGICAL CHALLENGES IN COMPARING TOPICAL THERAPIES IN 
DERMATOLOGy IN THE ABSENCE OF HEAD TO HEAD STUDIES
Greiner R.A.1, Batscheider A.1, Eheberg D.1, Gohlke A.1, Pfiffner C.1, Ehlken B.1,  
Macheleidt O.2, Hutt H.J.2
1IMS Health, Munich, Germany, 2LEO Pharma GmbH, Neu-Isenburg, Germany
Objectives: German HTA agency requires evidence about the additional benefit of 
a new pharmaceutical versus an appropriate comparator as basis for price negotia-
tions. This is challenging when head-to-head studies (H2HS) or randomized placebo-
controlled trials (RPCTs) are missing and particularly in dermatology, where topical 
therapies in registration trials are usually compared to their individual vehicle. The 
aim of this research was to describe different approaches to assess the additional 
benefit of a new topical therapy under these limitations. MethOds: For ingen-
olmebutate-gel (IMG) and the appropriate comparator diclofenac-hyaluronic-acid 
(DHA) bibliographic literature search was conducted for RCTs followed by sequential 
screening on H2HS, comparable endpoints, RPCTs, common bridge comparator, 
H2HS of vehicles alone, RPCTs of vehicles. The similarity of vehicles was assessed 
by comparison of efficacy and safety profile. The lack of H2HS demands to conduct 
the following approaches depending on the comparability of vehicles: 1. An adjusted 
indirect comparison due to Bucher 1997 (vehicles are placebo-like or adequately 
similar) 2. Linkage of direct comparisons due to Wells 2009 (possible when H2HS or 
RPCTs of vehicles are available) 3. Mixed treatment comparison (MTC) (prerequisites 
as mentioned for Bucher). Results: 5 RCTs for IMG versus 3 RCTs for DHA were 
identified with comparable endpoints. No RPCTs for topical therapies or for their 
vehicles, no H2HS of vehicles, no bridge comparator and no clear evidence for the 
adequate similarity of both vehicles could be detected. Therefore, the prerequisites 
of all available statistical methods are not met and cannot thoroughly be applied. 
Notwithstanding these limitations, Bucher (RR[95%KI]: 4.14[2.03;8.47]) and MTC both 
favor IMG significantly while Wells showed non-inferiority (RR[95%KI]: 0.8[2,03;8,47]) 
in the primary endpoint of IMG versus DHA. cOnclusiOns: A definition of ade-
quate similarity for vehicles by German HTA agencies is needed to enable the use of 
methodologically sound indirect comparisons or MTCs in reimbursement dossiers.
PRM190
USE OF MULTIvARIATE BAyESIAN EvIDENCE SyNTHESIS TO REDUCE 
UNCERTAINTy AROUND CLINICAL EFFECTIvENESS AND QUALITy OF LIFE 
ESTIMATES
Bujkiewicz S.1, Thompson J.1, Sutton A.1, Cooper N.1, Harrison M.2, Symmons D.P.2,  
Abrams K.R.1
1University of Leicester, Leicester, UK, 2University of Manchester, Manchester, UK
Objectives: In health technology assessment, decisions about reimbursement 
of new health technologies are largely based on effectiveness estimates. These 
estimates are sometimes also used to predict the health-related quality of life 
outcomes, such as EQ-5D, as part of economic evaluation. However, sometimes 
these effectiveness estimates are not readily available. When many alternative 
instruments measuring these outcomes are being used (and are not all reported) 
or an extended follow-up time of clinical trials is needed to evaluate long-term 
endpoints (and drug development is at an early stage), data on relevant outcomes 
may be limited. The aim of this study was to develop methodology that would allow 
synthesis of all available evidence to assess interventions early and reduce uncer-
tainty around relevant outcomes. MethOds: Bayesian multivariate meta-analysis 
both challenges and opportunities for industry. The changes in the DSM-5 criteria 
may translate into changes for how we go about developing medical products to 
treat psychiatric disorders, including ADHD. There will need to be an investment in 
research and education, and sponsors must examine the possibility of developing 
new endpoints and outcome assessments for use in clinical trials.
PRM185
THE IMPACT OF DSM-5 ON THE DEvELOPMENT OF DRUGS TO TREAT MAjOR 
DEPRESSIvE DISORDER
Meyers O.I.
Truven Health Analytics, Cleveland, OH, USA
Objectives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a 
classification system for psychiatric conditions. DSM-5 brings significant changes 
to many diagnostic categories as compared to the previous edition. The objective 
of this review was to examine the changes in the Major Depressive Disorder (MDD) 
criteria and discuss the impact these changes may have for industry. MethOds: 
A line-by-line review of the DSM-5 and DSM-IV criteria for MDD was undertaken. 
Significant changes were highlighted and discussed from the point of view of spon-
sors of clinical trials for psychopharmacologic agents being developed to treat 
MDD. Results: The primary symptom criterion for MDD remains unchanged, 
requiring five of nine symptoms, over a two-week period. The changes of note 
have to do with the differential diagnoses and specifiers. One change that received 
significant attention in the time leading up to the publication of DSM-5 was the 
elimination of the bereavement exclusion, which discounted bereavement after the 
loss a loved one within the first two months as part of the normal grief process. In 
terms of specifiers, a new addition in MDD is “with anxious distress,” referring to 
episodes of depression characterized by at least two of five symptoms of anxiety. 
DSM-5 notes that this is associated with “greater likelihood of treatment nonre-
sponse.” Therefore, this is a factor sponsors may wish to consider in developing their 
trial inclusion/exclusion criteria. cOnclusiOns: The significant changes in DSM-5 
pose both challenges and opportunities for industry. The changes in the DSM-5 
criteria translate into changes for how we go about developing medical products to 
treat psychiatric disorders, including MDD. There will need to be an investment in 
research and education, and sponsors must examine the possibility of developing 
new endpoints and outcome assessments for use in clinical trials.
PRM186
PATIENT NETwORKS AS A DATA SOURCE FOR PATIENT REPORTED OUTCOMES 
RESEARCH. CARENITy ExPERIENCE
Castejón N.1, Chekroun M.2, Martínez García J.1, Gay C.H.2, Rebollo P.1
1LASER Analytica, Oviedo, Spain, 2carenity.com, Paris, France
Objectives: To explore the potential of online patient networks (PN) as a viable 
source of PRO data for clinical research. Several PNs have emerged in the last few 
years in different European countries, and as a natural meeting point for chronic 
patients with an active engaged with their communities, they represent a promising 
source of patient reported data. In this original, the experience with the French PN 
“Carenity” is described. MethOds: Given the great heterogeneity of the users of 
“Carenity”, and the fact that the test was computer-led by definition, a Computer 
Adaptive Test (CAT) was considered the best choice. The authors decided to use a 
culturally adapted version of CAT-Health system, which measures generic health-
related quality of life (HRQoL). However, in absence of a calibration for the French 
population, a selection of the best items was used, using the Spanish calibration 
as a reference. All patients in the PN were invited to participate in the test. A score 
was estimated for the test using the Spanish parameters, as a rough approxima-
tion of the real score. Age, sex and the main pathology of the subjects were also 
collected. Results: Preliminary results from the first week of data collection show 
601 patients answered (Women: 404, Men: 140). The most frequent reported patholo-
gies and their t-scores were multiple sclerosis (N:92,M:37.91,SD:5.85), fibromyalgia 
(N:81,M:36.65,SD:4.99), ankylosing spondylitis(N:60,M:37.74,SD:5.32) and both types 
of diabetes (I: N:53,M:50.38,SD:10.94, II: N:41,M:48.12,SD:10.04). Significant differ-
ences (p< 0.05) were found in diabetes patients by sex, and between both types 
of diabetes and the other 3 most common pathologies. cOnclusiOns: Carenity 
PN seems to be a fast way to obtain PRO scores directly from patients. Preliminary 
results show differences in the expected direction.
RESEARCH ON METHODS – Statistical Methods
PRM187
DEFINING THE PROPER METHODOLOGy TO USE IN A DATA-PEEK FOR POwER 
(DPP)
Eisenberg D., Wasser T.
HealthCore, Inc., Wilmington, DE, USA
Objectives: Late phase research is conducted outside the RCT setting where there 
is uncertainty as to how many subjects are needed to find differences between 
groups. Due to the lack of real-world information (non-RCT) in late phase designs, 
there are no tangible inputs for power calculations. This research defines a bias-free 
method to examine data while determining sample size. MethOds: As an example 
of the application of a DPP, a study examining the decrease of HGbA1c values in two 
different insulin delivery methods was examined in patients with several comor-
bid conditions. Literature examined found little to no data and a DPP was used to 
determine effect size (ES) and standard deviations (SDs) once 30 patients had been 
enrolled in each group. The DPP procedure was: 1) Determine the test statistic; 2) 
Identify the power formula most appropriate to the test statistic; 3) Determine the 
ES, variation and assumptions needed for the data-peek in the form required by the 
formula; 4) Construct a matrix of possible sample size values; and 5) Select a sample 
size that is obtainable and answers the research question. Results: Data for group 
A demonstrated a mean reduction of 2.75% ±0.760, group B mean reduction of 3.01% 
±0.636. Exact power analysis showed 113 subjects per group would be needed. A 
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1Amaris, London, UK, 2The Institute of Cancer Research, Sutton, UK, 3Janssen Pharmaceutica, 
Beerse, Belgium, 4EMEA HEMAR Analytics, Janssen EMEA, Beerse, Belgium, 5Janssen Cilag, 
Birkerød, Denmark, 6Janssen UK, High Wycombe, UK, 7Consultant, Mumbai, India, 8Janssen Global 
Services LLC, Raritan, NJ, USA
Objectives: To assess the relative efficacy and safety of canagliflozin (CANA), a sodium-
glucose co-transporter (SGLT) inhibitor, as add-on to metformin, compared to sulpho-
nylureas (SU), pioglitazone, DPP-4s, GLP-1s and dapagliflozin. MethOds: Bayesian 
network meta-analysis was conducted based on a systematic literature review described 
separately. Outcomes of interest included HbA1c, weight and hypoglycaemia. Networks 
were based on treatment- and dose-specific nodes where possible. Non-informative 
priors were used; selection of fixed versus random-effect model was based on DIC. 
Studies causing inconsistency (identified through the comparison of direct and indirect 
evidence in the network) were identified with a clinical expert and excluded from the 
base case. Results: 25/17/7 studies reported results at 26/52/104 weeks (w) respectively. 
HbA1c-reduction (2) at 26w/52w was best for exenatide 2mg and liraglutide 1.8mg. CANA 
300mg had a higher reduction versus DPP-4s (h= -0.11 to -0.39) and dapagliflozin 10mg 
(= = -0.12 to -0.38) across all time points; while CANA 100mg conferred at least as large 
reductions (= = 0.01 to -0.30 and 0.00 to -0.26 respectively). The analysis at 104w was 
conducted based on the pooling of SUs. CANA 300mg and 100mg ranked first/second 
before liraglutide 1.2mg/1.8mg (s= -0.11/-0.13 and -0.02/-0.04 respectively). Both CANA 
doses had higher weight-reductions than SU, DPP-4s and pioglitazone, and provided 
reductions comparable to GLP-1s and dapagliflozin. Odds ratios for hypoglycaemia ver-
sus SU ranged from 0.03 to 0.11 for DPP-4 and SGLT. cOnclusiOns: NMA of add-on 
therapies to metformin suggests that CANA 300mg is associated with increased HbA1c-
reduction versus DPP-4s and dapagliflozin while CANA 100mg provides at least similar 
effects. Additionally, results suggest increasing relative efficacy of CANA over time versus 
liraglutide and CANA reached at least as large HbA1c reductions as liraglutide at 104w. 
Weight reduction was comparable to GLP-1s and substantially higher than all other 
classes. All classes showed significantly less risk of hypoglycaemia compared to SU.
PRM194
ESTIMATING CHRONIC DISEASE PREvALENCE FROM CLAIMS DATA: REDUCING 
BIAS By ACCOUNTING FOR DISEASED INDIvIDUALS wHO DO NOT GENERATE 
CLAIMS
Signorovitch J.1, De G.2, Drabo E.3, Guerin A.4
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3University of 
Southern California, Los Angeles, CA, USA, 4Analysis Group, Ltee., Montreal, QC, Canada
Objectives: Claims data are often used to estimate the prevalence of chronic dis-
eases, typically by dividing the number of patients with disease-related claims 
(e.g., ≥ 1 or ≥ 2 claims) by the number of studied individuals. Such estimates will 
have a downward bias because not all diseased patients will generate disease-
related claims within their enrollment period. This downward bias can be sub-
stantial for underserved diseases that lack effective treatments. We explored 
whether an empirical Bayes estimator for the number of diseased individuals who 
do not generate claims could improve the accuracy of claims-based prevalence 
estimates. MethOds: As an example, we studied the prevalence of a rare der-
matological condition without any FDA-approved therapies. After accounting for 
enrollment time, individuals in a large nation-wide claims database were identified 
as having 0, 1, 2, 3, etc., disease-related claims. These counts were modeled using a 
mixture of Poisson distributions, with an unknown mixing distribution. Empirical 
Bayes approaches, which are frequently used to estimate numbers of unobserved 
species in ecological experiments, were used to estimate the number of diseased 
individuals without claims, and to provide adjusted prevalence estimates. Results: 
Out of over 4 million individuals with at least one year of continuous enrollment, 
n= 2,026 had disease-related claims, comprised of n= 1,422 with one claim, n= 317 
with two claims, n= 134 with 3 claims, etc. The traditional method for estimating 
prevalence identified 4.9 cases per 10,000 persons. After applying the empirical 
Bayes approach, the estimated prevalence increased to 7.9 cases per 10,000 persons, 
and became closer to published prevalence estimates based on non-claims data 
sources. cOnclusiOns: In this example application, prevalence estimates based 
on claims data were increased by over 60% by using empirical Bayes approaches to 
account for large numbers of diseased individuals who did not generate claims. The 
increased prevalence estimates were more consistent with the published literature.
PRM195
APPLICATION OF COPULAS IN ECONOMIC EvALUATION
Crespo C.1, Monleon A.1, Díaz W.2, Rodriguez C.1, Brosa M.3, Rios M.1
1University of Barcelona, Barcelona, Spain, 2Universidad de Antioquia, Medellin, Colombia, 
3Oblikue Consulting, Barcelona, Spain
Objectives: To analyse the applicability of copulas distribution in economic evalu-
ation. MethOds: We have analyzed data from an observational prospective study 
of patients with allergic rhinitis in Spain (n= 498). Main data were direct cost (€ 2012) 
and Health Related Quality of Life (SF-12). We have calculated the goodness of fit 
for copulas (Gumbel copula, Clayton Copula, Frank Copula, Normal Copula, Plackett 
Copula and T copula) based on the empirical process comparing the empirical cop-
ula with a parametric estimate of the copula derived under the null hypothesis. We 
have used inversion of Kendall’s tau method to fit copulas. A multivariate independ-
ence sample was generated to compare with copulas results. This process was rep-
licated for a 100 times to obtain p-values by bootstrap method. Results: Marginal 
distribution of direct cost was a 3-parameter Gamma distribution (shape= 1.856, 
scale= 0.00324, location= 10.97). Marginal distribution of Health Related Quality of 
Life was associated to a 1- gamma (shape 2.9253 and scale 0.16104). P-value range 
were 0.093 to 0.144 for independent distribution, 0.004 to 0.031 for Gumbel copula, 
0.246 to 0.522 for Clayton Copula, 0.545 to 0.814 for Frank Copula, 0.463 to 0.716 for 
Normal Copula, 0.373 to 0.628 for T Copula and 0.549 to 0.847 for Plackett Copula. 
Frank Copula and Plackett Copula had the best goodness of fit. Kendall’s Tau for 
Fran Copula showed a correlation of -0.4212. cOnclusiOns: Copulas distribution 
allows us to adjust better the non-lineal relation between cost and effectiveness. 
Furthermore, this kind of approach could improve probabilistic sensitivity analyses.
methods have been developed for synthesis of diverse sources of evidence: multiple 
outcomes (including surrogate, potentially short-term endpoints) and other exter-
nal evidence. These methods were applied to an example in rheumatoid arthritis 
where outcomes such as the Health Assessment Questionnaire (HAQ), the Disease 
Activity Score (DAS-28) and the American College of Rheumatology (ACR20) are 
synthesized. External information about correlations between the outcomes was 
included in the form of informative prior distributions. Estimates of HAQ were then 
mapped onto EQ-5D. Also in an alternative approach, the multivariate framework 
was applied to model jointly the utility estimates and the clinical effectiveness out-
comes. Results: The use of multivariate meta-analysis led to reduced uncertainty 
around the effectiveness and utility estimates. Combining the HAQ with DAS-28 
gave a 19% reduction in the uncertainty around the estimate of HAQ and also 16% 
around the estimate of EQ-5D. cOnclusiOns: By allowing all relevant data to be 
incorporated in economic evaluations of new health technologies, this multivariate 
approach to meta-analysis can lead to reduced uncertainty and hence more efficient 
decision-making in health care.
PRM191
NETwORK META-ANALySIS OF MULTIPLE OUTCOMES: A SIMULATION STUDy 
AND APPLICATION
Achana F., Dequen P., Gray L., Cooper N.J., Abrams K.R., Owen R.K.
University of Leicester, Leicester, UK
The usefulness of a multivariate approach to compare treatments in the context of 
pairwise meta-analysis has been widely demonstrated in the literature. However, 
this approach has not yet been considered for multiple treatment comparisons. 
We believe that extending such methodology to network meta-analysis (NMA) 
will increase the primary evidence base allowing us to compare more interven-
tions across multiple outcomes measures. Borrowing strength between outcome 
measures using multivariate NMA can also potentially increase the precision of 
relative treatment effect estimates and reduce the impact of outcome reporting 
bias.Objectives: To extend standard NMA to incorporate multiple outcomes of 
interest and evaluate the use of multivariate NMA models through simulated and 
real datasets. MethOds: We developed a random effects multivariate NMA model 
to account for the correlation between multiple outcome measures. The potential 
benefits of this method were demonstrated in a simulated example comparing uni-
variate and bivariate NMAs for continuous outcome measures. We further explored 
the application of our multivariate NMA model using a case study comparing anti-
obesity pharmacological interventions for waist circumference, weight change and 
BMI change from baseline. Results: The simulation study showed that through 
use of multivariate NMA the precision in mean relative treatment effects increased 
compared to a standard univariate NMA. This held true under multiple scenarios 
testing model parameters including both within- and between-outcome correla-
tions. Similar findings were obtained from the application to the example data-
set in obesity. cOnclusiOns: Our method proves particularly useful in reducing 
uncertainty around relative effectiveness estimates when the outcomes included 
for analysis are highly correlated. However, the advantages of the multivariate NMA 
are limited where there is little correlation between outcome measures. Further 
work will explore the applicability of multivariate NMA methods to different types 
of outcomes such as binary outcome measures.
PRM192
HANDLING vARIABILITy IN TIME ENDPOINTS IN MULTI-CENTRE TIME AND 
MOTION (T&M) STUDIES: A CASE STUDy OF ERyTHROPOIESIS-STIMULATING 
AGENTS FOR ANAEMIA MANAGEMENT IN 13 CENTRES IN ITALy
Kritikou P.1, De Cock E.2, Proskorovsky I.3, Payne K.A.3, Tomic R.4
1Evidera, London, UK, 2Evidera, Barcelona, Spain, 3Evidera, Dorval, QC, Canada, 4Roche S.p.A., 
Monza, Italy
Objectives: In multi-centre Time and Motion (T&M) studies, time endpoints can 
be highly variable due to differences in centre practices. Our aim was to assess the 
impact of the type of analysis employed on the results of a T&M study. MethOds: 
Data from 13 centres were analyzed in relation to each of the following: drug prepa-
ration, distribution, and injection, using three methods. Base case methodology 
included a random intercept generalized linear mixed effect model assuming 
gamma distribution with log link function to account for potential centre cluster-
ing effect and non-normality of the outcome measure. The two alternative methods 
were: standard linear regression (assuming time data are normally distributed) and 
gamma regression with log link function (assuming time data are positively skewed), 
both of which do not account for centre clustering effect. Sample means and vari-
ability as measured by 95% confidence interval (CI)) were also compared. Results: 
For the base case, mean time was 0.53 min (95% CI: 0.33-0.85) for “preparation”, 0.30 
min (95% CI: 0.22-0.40) for “distribution”, and 0.81 min (95% CI: 0.59-1.11) for “injec-
tion”. Mean time resulting from the standard linear regression was markedly higher 
for “preparation”: 0.66 (95% CI: 0.59-0.73), and similar for “distribution” and “injec-
tion”: 0.34 (95% CI: 0.30-0.37) and 0.84 minutes (95% CI: 0.79-0.88), respectively. Using 
the gamma regression yielded similar results to standard linear regression: 0.65 (95% 
CI: 0.59-0.71), 0.31 (95% CI: 0.29-0.34), and 0.83 minutes (95% CI: 0.79-0.88), respec-
tively. The base case scenario detected a “centre-clustering” effect, hence producing 
substantially wider CIs compared to both alternative methods which ignore depend-
ence in the data. cOnclusiOns: Although mean task times remained relatively 
stable across the various methods, 95% CIs were substantially wider for random 
intercept model. If “centre-clustering” is detected, random effects regression models 
must be employed to produce valid confidence intervals around point estimates.
PRM193
BAyESIAN NETwORK META-ANALySIS TO ASSESS RELATIvE EFFICACy AND 
SAFETy OF CANAGLIFLOzIN IN PATIENTS wITH TyPE 2 DIABETES MELLITUS 
(T2DM) INADEQUATELy CONTROLLED wITH METFORMIN
Pacou M.1, Taieb V.1, Abrams K.R.2, Diels J.3, van Sanden S.4, Garg M.5, Schroeder M.6, Kaur V.7, 
Nielsen A.T.N.5, Nuhoho S.6, Neslusan C.8, Hemels M.5
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observational, and 14% employed hybrid methods, including chart review or survey. 
Only 20% used independent observers. Three quarters (76%) reported descriptive 
statistics. Of 9 multi-centre studies, one used a random effects regression model to 
account for “centre clustering”, and 8 reported pooled data (3 of which used a “mean 
of centre averages” approach). Eleven studies (52%) compared two groups, of which 3 
applied an analytical design aiming to defect statistical differences, and 2 reported 
a sample size calculation. cOnclusiOns: This review of T&M studies revealed that 
descriptive designs are most common (analytical designs using power calculations 
seem rare). Multi-centre comparator studies rarely use random effects regression 
models to account for “centre clustering”, though considered the method of choice 
to produce valid confidence intervals around point estimates. In general, statistical 
methodology is scarcely reported, affecting overall study credibility.
PRM199
THREE TOOLS TO REDUCE THE IMPACT OF COMMON DECISION-MAKING BIASES 
wHEN CONSIDERING SUBGROUP ANALySES
Hawkins N.1, Fletcher C.A.2
1Oxford Outcomes Ltd., Oxford, UK, 2Amgen Ltd., Cambridge, UK
Objectives: Subgroup analyses of randomized trial data are performed to provide 
estimates of average treatment effects for patients with specific characteristics. They 
inform adoption and re-imbursement decisions by identifying groups of patients 
with favourable risk-benefit or cost-effectiveness ratios. They may also inform deci-
sions regarding the conduct and design of future clinical studies. However, subgroup 
analyses are essentially observational (patients are not randomized between sub-
groups) and there is a risk that the differences observed between subgroups may 
be due to chance rather than reflecting true effects. This risk is exacerbated as 
typically the same data are used to both select relevant subgroups and to estimate 
subgroups effects leading to biased estimates and underestimation of uncertainty. 
This tendency increases as the number of subgroups tested increases. A number of 
measures are recommended to reduce the risk of bias including: pre-specification, 
consideration of biological plausibility, and correction of inference for multiple 
testing. However, the risk of bias is not obviated by pre-specification, correction 
for multiplicity may lead to discounting of true subgroup effects, and biological 
plausibility may not be a particularly specific test. In addition, common cognitive 
and process biases associated with decision-making such as the action impera-
tive, optimism bias, anchoring, and group think may further lead to the inherent 
uncertainty in subgroup analyses to be effectively underestimated.  MethOds And 
Results: We demonstrate three techniques that may help to counteract these 
biases: graphical inference methods clearly illustrate the inherent uncertainty in 
subgroup analysis; Bayesian shrinkage estimation can reduce the effect of anchoring 
on the observed subgroup effects and encourage consideration of regression to the 
mean; and reframing exercises (for example, considering the credibility of biological 
plausibility arguments as if they had been mooted a priori) may counter optimism 
bias. cOnclusiOns: These techniques are illustrated using a published subgroup 
analysis from the PLATO trial (NCT00391872)
PRM200
PARAMETER IMPORTANCE ASSESSMENT IN A HEALTH ECONOMIC EvALUATION 
MODEL FOR HEART FAILURE
Cagdas B.uyukkaramikli N
Technical University of Eindhoven and Contemporary Analytics, Eindhoven, The Netherlands
Objectives: Along with uncertainty around the parameters and the initial param-
eter value assumptions used in health-economic evaluation models, an analy-
sis of the uncertainty around the model inputs/outputs is essential. Parameter 
importance analysis (PIA) provides an explicit framework to quantitatively iden-
tify the contribution of each uncertain input to the output uncertainty. There are 
several methods available to be used in PIA. The objectives of this research were 
to investigate different PIA methods with the pros and cons of each method and 
identify the most robust method with respect to different initial parameter value 
assumptions. MethOds: A health economic model for heart failure is developed 
to serve as a basis to implement different PIA methods. Six alternative methods 
are applied: One-way sensitivity analysis, rank correlation analysis, analysis of 
covariance (ANCOVA), dominance analysis, standardized regression analysis and 
expected value of perfect parameter information (EVPPI) analysis. Initial parameter 
assumptions are varied and the robustness of each method is assessed with respect 
to how close the parameter importance rankings are with different initial param-
eter assumptions. Results: Each technique/initial parameter values’ assumption 
combination generates a different ranking for the importance of the parameters that 
explain the uncertainty around the expected net monetary benefit with £20,000/
QALY. EVPPI is the most robust method with respect to different initial parameter 
assumptions. However it is the most demanding method in terms of computation 
time. On the opposite side, one-way sensitivity analysis is the least computation 
time demanding method; however the importance rankings are very susceptible 
to change with different initial assumptions. Other Monte-Carlo simulation based 
methods (e.g. ANCOVA, dominance, standardized regression and rank correlation 
analysis) are alternative PIA methods, which generate rather robust rankings with 
different initial parameter assumptions. These alternative methods require sub-
stantially less computation times compared to EVPPI with high consistency and 
robustness to different initial value assumptions.
PRM201
ADjUSTING FOR TREATMENT SwITCHING IN CLINICAL TRIALS wHEN ONLy 
SUMMARy DATA ARE AvAILABLE – AN EvALUATION OF POTENTIAL METHODS
Boucher R.1, Abrams K.R.1, Crowther M.J.1, Lambert P.C.1, Wailoo A.J.2, Latimer N.R.2
1University of Leicester, Leicester, UK, 2University of Sheffield, Sheffield, UK
Objectives: Treatment switching is an important problem in Health Technology 
Assessment (HTA), particularly in oncology, which can often bias trial results. 
Although a variety of statistical approaches have been advocated for adjusting 
trials subject to treatment switching these all assume that Individual Patient Data 
PRM196
vALIDATION OF DISEASE STATES IN SCHIzOPHRENIA: COMPARISON 
OF CLUSTER ANALySIS BETwEEN THE UNITED STATES AND EUROPEAN 
POPULATIONS
Thokagevistk K.1, Millier A.2, Lenert L.3, Sadikhov S.4, Moreno S.4
1Creativ-Ceutical, Chicago, IL, USA, 2Creativ-Ceutical, Paris, France, 3University of Utah School of 
Medicine, Salt Lake City, UT, USA, 4F. Hoffmann-La Roche Ltd., Basel, Switzerland
Objectives: A set of disease states for patients with schizophrenia was previ-
ously published using a statistical clustering method, applied to Positive and 
Negative Syndrome Scale (PANSS) data from US patients. While factor analyses of 
the PANSS have shown remarkable stability of the structure across international 
populations, it is unknown whether similar multidimensional disease states would 
also be stable. Using data from the European Schizophrenia Cohort (EuroSC), a 
2-year observational study in 1,208 schizophrenia patients, we examined the fac-
tor structure of the PANSS and identified disease states using the same clustering 
method as previously. MethOds: A principal component analysis (PCA) was con-
ducted using the Kaiser criterion and varimax rotation on PANSS items, followed 
by a k-means cluster analysis on PANSS scores for items most strongly correlated 
with the PCA domains. For each cluster, a level (low, moderate, high) was assigned 
to each domain based on the cluster centres values. Kappa statistics were used 
to measure the agreement in assignment between the published and the derived 
states sets. Results: Five factors accounting for 56% of total variance were obtained 
from the PCA (positive symptoms, negative symptoms, cognitive impairment, mood 
disorder, and hostility). As in the analysis of patients in the initial US study, rates 
of change in root mean squared distance became small after six clusters. When 
assigning the two sets of states based on levels of positive, negative, and cognitive 
impairment, the simple, Cicchetti-Allison, and Fleiss-Cohen weighted Kappa sta-
tistics (95% CI) were, 0.418 (0.401-0.435), 0.568 (0.553-0.584), and 0.692 (0.676-0.709), 
respectively. cOnclusiOns: The factor structure, number of discrete states, and 
combinations of levels of symptoms in states were similar in US and European 
populations. Resulting moderate-to-substantial agreement in assignment suggests 
that disease states obtained using k-means clustering from the PANSS generalise 
across international populations.
PRM197
EvALUATING OvERALL SURvIvAL IN ONCOLOGy TRIALS wITH SUBSEQUENT 
THERAPIES: A METHODOLOGICAL REvIEw AND APPLICATION IN NON-SMALL 
CELL LUNG CANCER
Jonsson L.1, Fleischer F.2, Bluhmki E.2, Griebsch I.2
1OptumInsight, Stockholm, Sweden, 2Boehringer Ingelheim Pharma GmbH, Ingelheim am Rhein, 
Germany
Objectives: The use of subsequent therapies has the potential to confound assess-
ment of overall survival (OS) in oncology trials, in particular for trials in early lines 
of therapy and for malignancies with several registered or investigational treatment 
options. Standard intent-to-treat analysis is biased, since treatment choices are 
likely to be influenced by events associated with mortality risk, such as disease pro-
gression. We review and compare available statistical methods to obtain unbiased 
estimates of OS effects in presence of subsequent therapies. MethOds: Marginal 
structural modeling methods include inverse-probability of censoring weighting 
(IPCW) and inverse-probability of treatment weighting (IPTW). These methods 
explicitly model both treatment choices and effects of treatments on mortality. 
Rank-preserving structural failure time models (RPSFT) instead depend on paramet-
ric assumptions regarding the effect of investigational and subsequent therapies 
on survival, and require non-standard estimation methods such as G-estimation 
or iterative parameter estimation (IPE). We compare the results with the different 
methods with data from the Lux Lung 1 trial of the tyrosine kinase inhibitor afatinib 
in non-small cell lung cancer. Results: IPCW and IPTW require detailed informa-
tion on covariates that influence treatment choices and are sensitive to model 
misspecification. RPSFT may not yield a single estimate of treatment effects due 
to limitations of the G-estimation procedure. All methods were consistent with a 
potential OS benefit from afatinib, but the hazard ratio varied from 0.583 (p= 0.038) 
with the pre-specified IPCW method to 0.894 (0.281) with RPSFT/IPE. cOnclusiOns: 
The proposed methods for obtaining unbiased OS estimates in presence of sub-
sequent therapies rest on assumptions that cannot be tested empirically. There 
is currently no accepted standard method; pre-specification of model choice is of 
importance as well as testing alternative methods. Care should be taken to avoid 
unbalance in subsequent therapy and to record specific information on adminis-
tered treatments with potential OS effects.
PRM198
QUANTIFyING HEALTH CARE EFFICIENCy: A REvIEw OF PUBLISHED TIME AND 
MOTION STUDy DESIGN PARAMETERS REFERENCED IN PUBMED BETwEEN 
2008-2013
Kritikou P.1, Bassel M.2, De Cock E.3, Payne K.A.2
1Evidera, London, UK, 2Evidera, Dorval, QC, Canada, 3Evidera, Barcelona, Spain
Objectives: To review design characteristics of T&M studies applied to health care, 
with a focus on choice of study design, statistical methodology, and handling of 
multi-centre data. MethOds: A PubMed search was performed using key search 
terms including “time and motion” (MeSH Term) AND any of the following: cost 
(analysis), (health) economics, observation(al), and prospective. Articles (English; 
2008 or later) were selected based on the following criteria: (1) observational study 
using T&M methodology; and (2) task-based data collection. Studies that measured 
broad aggregate health care professional tasks/hospital workflows, in the absence of 
task- or event-specific timings, were excluded. Results: Of 191 identified abstracts, 
151 were excluded during screening; upon review, 21 of 40 remaining were retained 
for detailed assessment. Half (48%) were applicable to Europe, of which 2 were 
multi-country studies. Medical interventions studied were: drug (48%), diagnostic 
process (14%), medical procedure (24%), and IT systems to improve clinical manage-
ment (e.g. EMR) (14%). The majority (86%) of studies were hospital-based, 86% were 
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Objectives: Whether new medical technology is implemented may depend 
on the balance between costs and effects, but also on practical constraints. 
Examples are a fixed health care budget and a maximum clinically acceptable 
risk of adverse events. However, the impact of compliance with such constraints 
cannot be handled explicitly in the current value of information (VOI) framework. 
Our objective was to demonstrate proper handling of constraints by extending 
the VOI framework through separation of cost, effect, and constraint compo-
nents. MethOds: The proposed VOI extension was investigated in a simulation 
study comparing two hypothetical drugs and their side effects. The VOI exten-
sion was also applied to a clinical study concerning the cost-effectiveness of 
carotid intima-media thickness measurements to improve treatment guidance 
of patients at high risk of cardiovascular disease. Results of the standard VOI 
analysis, considering only costs and effects, were compared with results from the 
extended VOI analysis explicitly considering constraints. Results: Standard VOI 
results may under- or overestimate the value of additional research compared 
to extended VOI results. In our clinical example, with penalties of $2 and $5 
per dollar budget exceedance, standard values for the Expected Value of Perfect 
Information (EVPI) of $24, and $1,490 were found, with corresponding values of 
$239, and $565 for the extended EVPI. Ignoring the budget constraint in the stand-
ard EVPI analysis therefore resulted in a underestimation of $214 ($2 penalty) and 
an overestimation of $925 ($5 penalty) of the EVPI per patient. cOnclusiOns: 
When decision-maker’s criteria go beyond costs and effects, standard VOI results 
may not reflect the actual value of additional research accurately and may there-
fore jeopardize optimal research prioritization. Determination of the extended 
VOI, through separation of cost, effect, and constraint components, is straightfor-
ward and can support optimal research prioritization regardless of the complexity 
of the decision criteria considered.
PRM205
MEASURING TREATMENT EFFECTS ON RARE EvENTS USING META-ANALySIS: 
AN ASSESSMENT OF ExISTING METHODS
Jamotte A., Roïz J.
Creativ-Ceutical, London, UK
Objectives: Meta-analysis combines results from independent studies to pro-
duce robust statistical estimates. This technique is widely used in health care 
to synthesise treatment effects from clinical studies. However, when dealing 
with rare events such as rare adverse events, existing meta-analysis methods 
might not produce good treatment effect estimates, especially when there is no 
event occurrence in one or both arms of a study. The objective of this study is to 
compare the performance of various methods in estimating effect size for rare 
events. MethOds: An assessment of meta-analysis methods providing pooled 
odds-ratios as effect size estimates was conducted for different scenarios. The 
Inverse Variance Weighted, Peto, Mantel-Haenszel and logistic methods were 
assessed, with constant, “treatment arm” or empirical continuity corrections 
added when needed. The scenarios were created using different values of odds-
ratio, baseline risk, and group imbalance. For each scenario 5,000 simulations of 
10 studies were generated using R software. Coverage, bias and statistical power 
were used to compare the methods. Results: The most commonly used conti-
nuity correction is outperformed in every scenario by the two other corrections. 
The inverse variance method, most commonly used in meta-analysis, performs 
poorly when the event probability is smaller than 0.10: it is not recommended for 
sparse data. Peto’s method performs well in some scenarios but leads to biased 
results with high odds ratios and high imbalance. The logistic method is highly 
biased when baseline risk is low and true odds ratio is high. Under other scenarios 
it performs well but is most often outperformed by other methods. The Mantel-
Haenszel method with empirical correction performs constantly well over the 
scenarios. cOnclusiOns: These findings may be used to develop guidelines on 
when to use which method for conducting meta-analysis with rare events. Next 
steps will be to assess the use of mixed models and Bayesian techniques.
PRM206
METHODOLOGy FOR ESTABLISHING INTERNAL AND ExTERNAL vALIDITy 
wHEN PROPENSITy SCORE MATCHING IS USED
Eisenberg D.1, Wasser T.1, Placzek H.2, Luthra R.1
1HealthCore, Inc., Wilmington, DE, USA, 2HealthCore, Inc., Andover, MA, USA
Objectives: Propensity score matching (PSM) is an approach commonly used 
when treatment and control groups are thought to be different on key study vari-
ables. When the control group is larger than the treatment group, (as large as 20:1) 
a good match might be easy to obtain. However, differences may exist between the 
matched controls and the unmatched controls, indicating poor generalizability 
of study results. MethOds: Groups for the analysis are the unmatched controls 
(UM), the matched controls (MC) and the treatment cohort (TRT). Analysis methods 
for these groups in a fully crossed method and interpretation of the results will 
determine internal (IV) and external validity (EV). Analysis comparing the groups 
against the outcomes variable will determine if variables need to be controlled 
for in models that may be developed. Results: After the PSM is conducted MC 
and TRT groups should be compared on the matched variables. Differences at this 
stage would indicate a poor match and a low level of IV. MC and UM should also 
be compared on the variables used for matching, as well as the outcome variables 
of interest. Significant differences on the matched variables would indicate low 
EV and poor generalizability of results, while differences of MC and UM groups 
and UM and TRT groups on the outcome variables would indicate that statisti-
cal models would need to address covariates as potential confounding effects 
would be present. Analysis methods can be fit statistics (chi-square or equiva-
lence tests) or typical inferential methods with adjusted p-values greater than 
0.05. cOnclusiOns: It is important that research studies maintain good IV and 
EV. This is often complicated in research where the controls vastly outnumber the 
treatment group. Proper statistical analysis can go a long way to test and clarify 
data to make the results as meaningful as possible.
(IPD) is available. In many situations, especially when Indirect Comparison (IC) 
methods are required to estimate head-to-head effects, it is often the case that 
IPD is only available for one trial, and summary data for the other. A variety of 
potential methods are evaluated for the adjustment of such summary data using 
simulation methodology. MethOds: A review of HTA submissions to NICE in 
which both ICs were used and in which trials were subject to treatment switch-
ing was undertaken. A series of simulation studies were undertaken to assess the 
potential level of bias associated with the methods that are most commonly used 
for the analysis of such trials. Two broad approaches to adjusting summary data 
for treatment switching were then evaluated on the simulated data – calculation of 
Adjustment Factors (AFs), and re-creation and analysis (including bootstrapping) 
of IPD using scanned survival curves. Results: The most commonly reported 
methods of analysis for studies only presenting summary data were Intention-
to-Treat (ITT) and Per Protocol (PP) analyses. Results from the simulation stud-
ies indicated that these may be subject to between 0.5% and 140% levels of bias 
depending on trial characteristics, and that the use of AFs or re-created IPD had 
potential scope for reducing this. cOnclusiOns: Treatment switching can be 
associated with considerable levels of bias, and methods for adjusting using sum-
mary data, can go some way to compensating for this when IPD is not available 
as is often the case in Indirect Comparisons (IC). Further extension to a Network 
Meta-Analysis (NMA) setting is under investigation.
PRM202
MULTIPLE IMPUTATION TECHNIQUES FOR SURvEy DATA wITH MULTIPLE 
RATING SCALES
Plumpton C.O.1, Hughes D.A.1, White I.R.2
1Bangor University, Bangor, UK, 2MRC Biostatistics Unit, Cambridge, UK
Objectives: Large scale survey data presents a number of challenges to imputa-
tion, not least the high number of variables and complexity of the data set. Data 
may suffer from sparsity in responses, and some questions may be conditional 
upon previous responses. In addition, survey data commonly contain results from 
multiple rating scales, which are summed (either directly or weighted) during 
analysis. We aim to develop a method for the multiple imputation of missing 
data from complex surveys. MethOds: We propose an adaptation of multiple 
imputation for survey data which contains multiple rating scales, whereby scale 
summary scores are used within the prediction models. The method is applied to 
data gathered from a large multinational survey, with data sets from 9 countries. 
Analysis uses a logistic regression model on each of the 9 data sets, and results 
are compared from a complete case analysis approach with those from multiple 
imputation. Results: The proposed approach reduces the size of the prediction 
models from 135 predictors to a maximum of 72. Distributions of imputed data are 
seen to be consistent with observed data. Results from the regression analysis with 
multiple imputation are similar to, but show lower standard errors than, results 
for complete case analysis; for the same regression models a 39% reduction in 
the standard error is observed. cOnclusiOns: Our adaptation makes multiple 
imputation practical for large scale survey data with multiple rating scales. For 
the data considered, analysis of the multiply imputed data shows greater power 
and efficiency than complete case analysis. The adaptation of multiple imputation 
makes better use of available data and can yield substantively different results 
from simpler, less valid techniques.
PRM203
STRUCTURAL FAILURE TIME MODELING OF OvERALL SURvIvAL EFFECTS IN 
ONCOLOGy TRIALS wITH SUBSEQUENT THERAPIES
Jonsson L.1, Fleischer F.2, Bluhmki E.2, Griebsch I.2
1OptumInsight, Stockholm, Sweden, 2Boehringer Ingelheim Pharma GmbH, Ingelheim am Rhein, 
Germany
Objectives: Subsequent therapies can confound the evaluation of overall survival 
(OS) in oncology trials. We evaluated the application of rank-preserving structural 
failure time modeling for the estimation of OS effects in presence of subsequent 
therapies through Monte Carlo simulations. Results were demonstrated for a clini-
cal trial: the Lux Lung 1 study of afatinib vs. placebo in non-small cell lung can-
cer. MethOds: In accelerated failure time models, covariates are assumed to affect 
survival times rather than hazard rates. Counterfactual survival times can therefore 
be computed, i.e. how long patients would have survived without the investigational 
or subsequent therapies. The parameters of structural failure time models can be 
obtained by G-estimation, whereby counterfactual survival times are calculated 
with hypothetical treatment effects and OS is compared between treatment arms. 
The G-estimate is the set of hypothetical effects that generate the most similar 
survival in both study arms. Branson & Whitehead (2002) developed an alternative 
estimation method for trials with cross-in from placebo to active treatment based 
on iterative parametric regressions; we extend this framework to the application 
with subsequent therapies. Results: Simulation showed that standard methods 
are biased in the presence of subsequent therapies affecting overall survival. This 
includes intent-to-treat analysis, censoring at start of subsequent therapies and 
subgroup analysis in patients never receiving subsequent therapy. G-estimation 
often failed to identify parameter values when more than one treatment effect was 
included in the model. Iterative parameter estimation produced unbiased estimates 
in simulation studies and predicted a small numeric but non-significant survival 
benefit of afatinib. cOnclusiOns: Structural failure time models can be useful to 
obtain unbiased estimates of OS in presence of subsequent therapies. However the 
assumption of proportionality in survival times cannot be tested empirically and 
non-standard estimation procedures are required.
PRM204
THERE IS MORE TO DECISION MAKING THAN COSTS AND EFFECTS: HANDLING 
PRACTICAL CONSTRAINTS IN THE vALUE OF INFORMATION FRAMEwORK
Koffijberg H., Janssen M.
University Medical Center Utrecht, Utrecht, The Netherlands
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characteristics. The checklist suggests that a quality network meta-analysis of 
this data should exclude one study with high risk of bias, avoid grouping sham 
procedures and optimal pain management, and control for baseline pain-score 
to address imbalance across arms. Meta-regression to control for differences in 
endpoint definitions or inclusion criteria would likely have been infeasible given 
the low number of studies. cOnclusiOns: Applying the checklist improved our 
ability to identify sources of confounding to be addressed or highlighted as caveats 
in a meta-analysis.
PRM210
IMPLEMENTATION OF INTERNATIONAL CHART REvIEw STUDIES: AN 
ASSESSMENT OF KEy DESIGN AND OPERATIONAL CONSIDERATIONS FOR 
SUCCESSFUL CONDUCT
Jean-Mary J.1, Stein D.2, Payne K.A.2
1Evidera, Hammersmith, UK, 2Evidera, Dorval, QC, Canada
Objectives: There is an increased need to conduct international chart review 
studies (chart reviews) since health care databases with required information are 
not consistently available. Chart reviews offer an alternative for the effective cap-
ture and analysis of real-world patient-level data on patient characteristics and 
outcomes, treatment patterns, treatment effectiveness and safety. For successful 
implementation, awareness of significant multi-national design and operational 
considerations is necessary. MethOds: A critical review of 13 recent chart reviews 
conducted in Europe and North America on treatment patterns, clinical outcomes 
and/or drug utilization and safety was undertaken. Design and operational chal-
lenges, opportunities, and learnings are delineated. Results: All studies collected 
data retrospectively. Two studies collected certain information prospectively. Four 
studies were categorized as post authorization safety studies. Therapeutic areas 
varied across the studies with 8 studies being in oncology. Sample size ranged 
from 20-2,000 patients, number of countries ranged from 1-6, and number of sites 
ranged from 4-375. All studies included at least 1 European country. Across studies, 
key design considerations include confirming the eligibility and study periods that 
permit evaluations of recent care patterns yet allow for sufficient follow-up time, 
case ascertainment and sampling frame methodologies, and safety reporting in the 
context of retrospective source data. Additionally, key operational considerations 
include balancing science and practicality in site selection, ambiguous multina-
tional ethical/regulatory requirements, country variations for informed consent, 
data collection designed to minimize site burden, and effective yet cost-efficient site 
management for quality data. cOnclusiOns: International chart reviews are prov-
ing to be an effective methodology for capturing tailored, patient-level data. These 
studies can be used to address a myriad of research objectives. Through conduct 
and assessment of recent chart reviews, the design and operational considerations 
involved can be understood with opportunities for improvement learned. These 
lessons will help for better planning and overcoming these challenges.
PRM211
GENERATING AND MAINTAINING MOMENTUM IN POST-AUTHORISATION 
STUDIES
Vinken A.1, Lis Y.2, Coward G.2
1PAREXEL International, Amsterdam, The Netherlands, 2PAREXEL International, Uxbridge, UK
Objectives: Some observational studies fail to gain momentum while others move 
smoothly to successful completion. This study set out to determine which factors 
drive physician motivation in prospective observational studies. MethOds: A web 
based survey was designed using input from structured literature review, investiga-
tors and experienced observational study researchers. It comprised 35 questions 
covering: Scientific and clinical factors (7), Study requirements (11), Operational 
considerations (6), Financial and legal considerations (4), Personal and professional 
factors (7). Respondents were asked to rate factors on a scale -5 to +5 (+5 represented 
very motivational and -5 very de-motivational). Free form comments were also 
invited. The survey was e-mailed to investigators (n= 1160) identified from Citeline® 
as having performed both prospective observational studies and clinical trials in the 
last 5 years. Results: Overall response was 15% (n= 174), Europe (55%) and North 
America (45%) covering Community care (34%), University hospitals (29%), General 
hospitals (24%) and dedicated research facilities (13%). Most respondents had experi-
ence of > 5 clinical trials in the last 5 years (81%) but fewer had similar experience 
with observational studies (40%). Responses indicate that not all physicians are 
equally motivated by the same factors. However most important motivational fac-
tors were in the scientific and clinical, financial and legal domains including studies 
which advance medical knowledge and / or patient management and acceptable 
honoraria. Less important factors were in the personal and professional domain 
including opportunities to speak at conferences or publish the data. Investigators 
more experienced in observational research placed greater motivational value on 
advancing medical knowledge and/ or patient management than less experienced 
colleagues. cOnclusiOns: The findings provide good insight into which factors 
really motivate physicians and more customised motivational approaches are likely 
to minimise study risks. Further sub analyses of the survey data may identify more 
detailed strategies to pursue.
PRM212
RESEARCH IN HAEMOPHILIA B – STUDIES IN A RARE DISEASE IN TIMES OF 
REQUIREMENTS FOR HIGH EvIDENCE LEvELS
Schopohl D.1, Berger K.1, Schramm W.2
1University Hospital of Munich, Muenchen, Germany, 2Rudolf-Marx-Stiftung, Bluterbetreuung 
Bayern, Muenchen, Germany
Objectives: Haemophilia B (HB), a rare disease, occurs in approximately 1:30,000 
males and requires individualized therapy with factor IX (FIX) concentrate. Payers 
in European countries request studies with high levels of evidence for decision 
making. The objective was to determine the status quo of current studies con-
cerning HB, new FIX products and new therapeutic modalities regarding clinical 
and real-life evidence. MethOds: A systematic literature research was conducted 
PRM207
NOvEL USE OF MULTIvARIATE jOINT MODELLING TO IDENTIFy PATIENT LEvEL 
FACTORS ASSOCIATED wITH TREATMENT FAILURE – ExAMPLE OF BOTOx 
TREATMENT FOR PATIENTS wITH OvERACTIvE BLADDER
Owen R.K., Crowther M.J., Tincello D.G., Abrams K.R.
University of Leicester, Leicester, UK
Detrusor overactivity (DO) is characterised by the symptoms of overactive bladder 
(OAB) including incontinence, urgency, and voiding episodes; though, identifica-
tion of a cardinal symptom still remains unclear, where treatment efficacy is often 
evaluated across multiple outcomes. As a result, ascertainment of the most patient 
impacting symptom is crucial. Joint modelling allows us to evaluate the association 
between surrogate outcome measures such as patients’ symptom profiles and time 
to perceived treatment failure. Objectives: To determine the most associated OAB 
symptom with patients’ perceived time of treatment failure using a novel applica-
tion of a joint modelling framework. MethOds: To account for the potential cor-
relation between symptoms, we applied a joint model of multivariate longitudinal 
and time-to-event data to a randomised clinical trial of patients receiving botulinum 
toxin for DO. We investigate the association of incontinence, urgency and voiding 
episodes collected at baseline, 6 weeks, 3 months, and 6 months, on patients’ per-
ceived time of treatment failure. Results: The multivariate joint model was applied 
to 122 patients (270 data points) with 69 (56.6%) patients reporting treatment failure. 
The results identified urgency as the most impactful surrogate measure on patients’ 
perceived time of treatment failure, with an estimated hazard ratio of 1.26 (95% CI: 
0.97 to 1.64) for every additional urgency episode. Incontinence, voiding episodes 
and the interaction between symptom measures had a non-significant association. 
However, in this example, sensitivity to the model choice produced inconsistent 
estimates due to the limited nature of the data set and therefore results should be 
interpreted cautiously. cOnclusiOns: This approach illustrates the advantage of 
applying a joint modelling framework to identify symptoms most associated with 
time to treatment failure. With an increasing need to identify and assess core symp-
toms for varying medical conditions, the novel use of a joint modelling approach 
would appear to be extremely promising.
PRM208
USING MULTI-CRITERIA DECISION ANALySIS TO SUPPORT ALLOCATION 
DECISIONS IN LARGE TRANSLATIONAL RESEARCH PROjECTS
De Graaf G., Postmus D.
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Objectives: Large translational research projects often have abstract objectives, 
such as reducing the burden of disease and health care costs from type-2 diabetes 
(T2DM). Such an abstract objective entails: i) a very large number of possible strate-
gies to reach the objective and ii) a lack of detailed data and high levels in uncer-
tainty. Currently, no methods to support project selection and resource allocation 
decisions in such a setting are available. MethOds: As a case study, we supported 
a resource allocation decision for the remaining funds in a large Dutch translational 
research consortium with the aforementioned objective, and compared the results 
to the decision made at the start of the project. We used the problem structuring, 
model building methods from multi-criteria decision analysis to identify four dif-
ferent alternative research strategies, and a set of evaluation criteria. Consequently, 
we used a combination of judgment from experts involved in the project and pre-
viously published data on the burden of disease and health care costs to evalu-
ate the alternatives. Finally, a decision analysis was performed using Stochastic 
Multicriteria Acceptability Analysis for ordinal data (SMAA-O), which allows for 
the combined use of quantitative and qualitative (ranked) data. Results: Using 
our method, it was decided to allocate remaining resources to the identification of 
biomarkers and development of technologies that can be used in the prevention of 
macrovascular complications in T2DM patients. This decision differed from the one 
made at the start of the project, which was not supported by any formal decision 
analysis. cOnclusiOns: Our study shows that our method using SMAA-O can be a 
practical and valuable tool to support decisions on the allocation of research funds 
within large translational research consortia.
RESEARCH ON METHODS – Study Design
PRM209
CONFRONTING HETEROGENEITy: USING SySTEMATIC REvIEw EFFECTIvELy 
FOR META-ANALySIS
Quigley J.M., Woods B., Thompson J., Bryden P.A., Scott D.A.
Oxford Outcomes Ltd., Oxford, UK
Objectives: The pooling of treatment effects estimated from several trials via 
meta-analysis or network meta-analysis can be confounded by differences across 
studies; however, advanced methodologies are available to address many of these 
issues. Systematic reviews of interventions typically generate a large volume of 
data and lead to assimilation of a large amount of knowledge by the reviewers. 
Identifying key variances between trials can be difficult and important nuances 
can be missed by a meta-analyst. We have designed a novel checklist that high-
lights key areas of heterogeneity to be considered when designing and undertaking 
meta-analysis. MethOds: It is important to identify differences early on; hence 
we have developed a checklist that can be applied to the results of a systematic 
review of randomised controlled clinical trials. Components of the checklist fall 
into four domains where heterogeneity may be present: population, interventions, 
outcomes, and risk of bias. Sections documenting the feasibility of network meta-
analysis and recommendations for analysis design are also included. The checklist 
has been retrospectively applied to a recent NICE technology appraisal; percuta-
neous vertebroplasty and percutaneous balloon kyphoplasty for the treatment 
of osteoporotic vertebral compression fractures (TA279). Results: The checklist 
identified the following sources of heterogeneity in the nine included studies: 
inclusion criteria, endpoint definitions, endpoint reporting, presence of cross-over, 
differences in interventions, risk of bias; and within-trial imbalances in baseline 
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Assessment, Development and Evaluation) MethOds: We evaluated the primary 
endpoint of a random sample from efficacy and effectiveness studies included in 
a systematic review on the treatment of rheumatoid arthritis with anti-TNFs. The 
quality assessment was conducted in accordance with the recommendations of the 
GRADE Working Group available at: www.gradeworkinggroup.org/toolbox/index.
htm. It assigns at first high quality for trials and low quality for observational stud-
ies. Results: The assessment of 8 efficacy and 8 effectiveness studies showed 
respectively that the quality of evidence were high in 5 and 0; moderate in 3 and 
2; low in 0 and 2; and very low in 0 and 4. The risk of bias was present in 3 and 5; 
imprecision results in 0 and 5; elevated magnitude of effect in 6 and 4; controlled 
confounding bias in 0 and 3; presence of dose-response gradient in 0 and 1. Indirect 
evidence and inconsistencies were not found in any of the studies. cOnclusiOns: 
The quality of evidence of 3 trials and 4 observational studies were downgraded, while 
2 observational studies had the quality assessment increased.
PRM216
wHAT vALUE CAN OPERATIONAL FEASIBILITy STUDIES BRING TO POST 
MARKETING OBSERvATIONAL STUDIES (PMOS)? ExAMPLE OF FEASIBILITy 
STUDy PERFORMED IN EASTERN EUROPE TO ASSESS HEPATITIS C vIRAL 
DISEASE/PATIENT MANAGEMENT IN REAL wORLD SETTING
El Kebir S., Bayle D., Gauchoux R.
Mapi, Real World Evidence, Lyon, France
Objectives: Operational feasibility studies provide a good opportunity to assess 
practicality of large full-scale studies. They are an almost essential pre-requisite and 
should be well designed with clear objectives. Conducting a pilot study can enhance 
the likelihood of success of PMOS and potentially help to avoid serious design flaws. 
The objective of this research is to assess the value of feasibility studies prior to 
PMOS implementation and highlight the importance of local physicians’ feed-
back. MethOds: A feasibility study in 6 Eastern European countries was conducted 
via collection of physician surveys to assess local standard of care. The feasibility 
questionnaire was developed to assess operational aspects, such as availability of 
patient population, site experience and time and willingness to participate. The 37 
physicians who received the questionnaire were selected through PubMed; they 
were all experts who have published regarding HCV infection and were provided 
with the protocol synopsis Results: Out of the 37 selected physicians, 18 gastro-
enterologists, hepatologists, and infectious disease specialists in Bulgaria, Croatia, 
The Czech Republic, Hungary, Poland and Romania completed the questionnaire. 
The participating Physicians were working exclusively in public institutions. The 
average number of HCV patients seen by year is 140 and out of them 78 are treated 
by Interferon. They specified that they can enrol 2 eligible patients per month on 
average. They see their patients frequently during treatment initiation (bi-weekly 
or monthly). However, the follow-up varies from one country to another (quarterly 
or semi-annually). Physicians indicated that patient records and data regarding 
blood tests and procedures are accessible for 100% of the cases. Over 60% of the 
sites were familiar with Patient Reported Outcomes. Overall, 12 physicians were 
interested in participating in the Study. cOnclusiOns: The result of this survey 
helped us documenting routine medical practice and confirming the study design 
and methodology to be implemented.
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USE OF SURROGATE OUTCOMES IN HEALTH TECHNOLOGy ASSESSMENTS 
(HTAS)
Jaksa A., Ho Y.S., Daniel K.
Context Matters, Inc., New York, NY, USA
Objectives: This study analyzes how frequently surrogate outcomes are used 
in HTAs and if the validity of these outcomes are discussed and reported within 
the HTAs. A surrogate outcome is defined by the National Institutes of Health as 
a biomarker intended to substitute for a clinical endpoint. A surrogate outcome 
is used when a clinical endpoint of interest is not ideal or does not occur often 
enough to perform meaningful statistical analysis. It is appropriate to use a sur-
rogate outcome only when there is a strong correlation with the clinical endpoint. 
Before using surrogate outcomes researchers should confirm that the surrogate 
outcome is biologically plausible, has a magnitude of association with the clini-
cal endpoint, and reflects changes in the relevant clinical endpoint. MethOds: 
Context Matters (CM) analyzed 1,056 HTAs spanning 38 disease conditions. Each 
HTA had a primary outcome that could be classified as either a surrogate outcome 
or a clinical endpoint. Data was analyzed for eight HTA agencies: AHRQ, DERP, 
SMC, HAS, PBAC, NICE, CADTH, and HIS Scotland. For those HTAs using a sur-
rogate outcome as the primary outcome, CM then determined if the HTA agency 
reported the use of the surrogate and/or discussed the surrogate outcome’s valid-
ity. Results: Ninety-one percent of HTAs used a surrogate outcome (966 HTAs), 
but only 11% (109 HTAs) identified it as a surrogate outcome and/or discussed 
its validity. The agencies that discussed the use of the surrogate outcome most 
often were AHRQ, DERP, and HIS Scotland at 48.1%, 28.6%, and 29.0% of the time, 
respectively. cOnclusiOns: Surrogate endpoints are prevalent in HTAs, but the 
agencies rarely discuss the validity of these endpoints. All agencies failed to dis-
cuss the use of the surrogate endpoint in over 50% of their reviews. HTA agencies 
are not following best practice use of surrogate outcomes.
RESEARCH ON METHODS – Conceptual Papers
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PROPOSAL OF ECONOMIC EvALUATION GUIDELINE IN jAPAN
Fukuda T.1, Akazawa M.2, Fukuda H.3, Igarashi A.4, Ikeda S.5, Ishida H.6, Kobayashi M.7, 
Moriwaki K.8, Noto S.8, Sakamaki H.9, Saito S.10, Shimozuma K.11, Shiroiwa T.1, Takura T.12, 
Tomita N.13
1National Institute of Public Health, Saitama, Japan, 2Meiji Pharmaceutical University, Tokyo, 
Japan, 3Institute for Health Economics and Policy, Tokyo, Japan, 4Tokyo Univ. Faculty of Pharmacy, 
Tokyo, Japan, 5International University of Health and Welfare, Otawara City, Tochigi, Japan, 
in EMBASE and MEDLINE, search terms ‚hemophilia B‘ and ‚FIX‘. Inclusion crite-
ria: journal articles (JA), conference abstracts (CA), English language, published 
between January 2009 and March 2013, studies only. Screening of titles, abstracts 
and full texts was performed subsequently. Registered trials (RT) concerning HB 
or FIX were identified in ClinicalTrials.gov. Analysis comprised age group, spon-
sor, research topic, recruitment status, and study design. Results: Screening of 
1,639 hits yielded 31 JA describing 35 studies, and 62 CA. FIX was the topic of 21 
studies (60.0%) and 29 CA (46.8%). A total of 7 studies focused on various aspects 
of HB, 6 on haemophilia studies with separate data on HB. Gene therapy was the 
main focus of 2 JA and 11 CA (17.7%). Screening of 173 hits from ClinicalTrials.gov 
yielded 47 RT, 42 unpublished. Overall 32 unpublished RT (76.2%) concerned FIX, and 
4 (9.5%) gene therapy. Randomized study design was described in one study (2.9%) 
and 4 RT (9.5%), and 3 studies (8.6%) and 7 RT (16.7%) were prospective observa-
tional comparative. cOnclusiOns: Randomized study design or comparator arms 
were uncommon, and payers’ requirements for evidence were not met. Therefore, 
randomization, comparison to standard of care and documentation of outcome 
should be discussed. Development of refined statistical methods and exploitation 
of complementary data like real-life data may help to fill actual evidence gaps in 
rare diseases.
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THE ROLE OF DSM IN THE EMA AND FDA AUTHORIzATION PROCESS FOR 
PSyCHIATRIC DRUGS
Meyers O.I.
Truven Health Analytics, Cleveland, OH, USA
Objectives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). This 
is significant for clinicians, researchers, and developers of psychopharmacologic 
drugs. The previous version of the DSM, the DSM-IV-TR, was published in 2000 and 
the last time the diagnostic criteria were revised was in 1994, when the DSM-IV 
was published. The objective of this review was to determine how much of a role 
DSM has played in the drug approval process in Europe and the US. MethOds: For 
drugs authorized since 2000, summaries of product characteristics (SPCs; EMA) and 
approved labels (FDA) were reviewed to determine how frequently the DSM is men-
tioned in the “clinical particulars” or “indications” sections and how frequently DSM 
criteria are mentioned in the clinical trials sections of the SPCs or labels. The review 
focused on schizophrenia and psychotic disorders, mood disorders, and for the 
FDA, attention-deficit/hyperactivity disorder as well. Results: For EMA-authorized 
products, 8 EPARs met the criteria with 10 indications in total. The DSM was never 
mentioned in the indications or posology sections, but in 7 (70%) of the descriptions 
of pharmacodynamic properties (section 5.1), DSM criteria were cited as the study 
inclusion criteria. For FDA-approved products, 17 labels with 22 indications met the 
review criteria. The DSM was mentioned in 10 of the indications sections (45%) and 
DSM criteria were cited as inclusion criteria in 20 instances (91%). cOnclusiOns: 
Regulators in Europe and the US rely heavily on DSM diagnostic criteria, in the 
sense that these often serve as inclusion criteria for pivotal clinical trials. Given 
significant changes to the criteria in many diagnostic categories, regulators and 
sponsors need to familiarize themselves with the document and evaluate their use 
of DSM criteria going forward.
PRM214
PODCASTS AS A LEARNING TOOL IN A RESEARCH METHODS COURSE FOR 
PHARMACy STUDENTS
Nguyen T.L., Lovett A.W., Lundquist L.M., Bonner C.L.
Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, USA
Objectives: Podcasts (recorded lectures) can be beneficial for all students, particu-
larly English as a second language students who face language barriers when learn-
ing in another language. There is limited study on pharmacy student perceptions 
and podcasts, none from an international perspective. The primary objective was 
to describe pharmacy students’ perceptions on the usefulness of podcasting and a 
secondary objective was to compare perceptions between native versus non-native 
English speakers in a pharmacy research course. MethOds: All first year phar-
macy students (n= 157) attending a Research Methods course in 2012 were invited 
to participate in a survey, which utilized a 4-point Likert Scale (1= strongly disagree, 
2= disagree, 3= agree, and 4= strongly agree). Podcasts covered all course topics such 
as Applied Statistics, Odds Ratio and Relative Risk, Case Reports, Observational 
Studies, Randomized Controlled Trials, and Economic Evaluations. Descriptive sta-
tistics and t-tests were utilized to analyze the data in SPSS. The study was approved 
by the Institutional Review Board. Results: A total of 73% of the class completed 
the survey (40.2% Caucasian, 32% Asian and 25% African American). A total of 24.1% 
identified themselves as non-native English speakers, 94.6% lived in the US for 
greater or equal to 5 years and 66.1% communicated in English at home. The major-
ity of students agreed/strongly agreed that podcasts helped them to prepare for 
exams (92.9%), podcasts were a useful learning tool (91.2%), promoted understand-
ing of course material (89.3%), helped with missed concepts (96.4%), and facilitated 
note-taking at their own pace (92.2%) with mean scores 3.34, 3.27, 3.27, 3.48 and 3.48, 
respectively. Results of the t-test revealed that there is no statistically significant 
difference between native versus non-native English speaking students in their 
perceptions of podcast usefulness (p> .05). cOnclusiOns: Podcasts are beneficial to 
a majority of students, despite their language background. Podcasts have the poten-
tial to be a valuable learning tool for students taking a research methods course.
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GRADE FOR QUALITy ASSESSMENT OF EFFICACy AND EFFECTIvENESS 
STUDIES ON ANTI-TNFS TREATMENT OF RHEUMATOID ARTHRITIS
Taino B, Nobre M.R.C
INCOR - HCFMUSP, Sao Paulo, Brazil
Objectives: Assess the quality of evidence on experimental and observational clini-
cal research through the same approach named GRADE (Grading of Recommendations 
A614  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
by critical evaluation against traditional CEA (Cost Effective Analysis) via a scien-
tific process. Patient and Public Involvement (PPI) in HTA is associated with a low 
evidence base potentially limiting its value. Research presented at ISPOR 2012 by 
the same authors concluded a need to improve and standardize PAG input integra-
tion in HTA decision making. To investigate the way different forms of knowledge / 
experience are used by PAGs in NICE HTA for guideline development and new tech-
nology review. We will look at: 1) Influence of PAG structure, resource capability, 
internal process and the impact of PAG advisory board physician representatives 
on scientific validation of patient input in HTA participation, and 2) Part I results 
will inform further research into selection and ranking criteria of social derived 
data compared with CEA. An iterative PPI best practice approach will be followed. 
Selection criteria: Five UK PAG groups (Neurological, Autoimmune, Rare disease, 
Cardiovascular and Oncology) will be invited to participate. The NICE PPI Unit will 
nominate groups when needed. Inclusion criteria: 1) willingness to participate, 
2) prior involvement in guideline / new technology assessments; and 3) pres-
ence of medical advisory board. Research elements: Application of GRIPP criteria 
(Guidance Reporting Involvement Patient Public) to ensure a strong evidence base 
will guide development of an on-line survey and subsequent focus groups and 
interviews. The survey, designed for SAP review, will study: size of PAG, internal 
process for HTA involvement, previous HTA involvement, data submitted, PAG 
knowledge gaps and involvement of medical advisory board. Follow up by focus 
groups and interviews with PAG and advisory board members to identify insights/ 
themes.
PRM222
jUGGLING jURISDICTIONS: METHODS FOR CONDUCTING MODULAR 
SySTEMATIC REvIEwS?
Thompson J., Hawkins N.
Oxford Outcomes Ltd., Oxford, UK
A crucial component of a systematic review is a clear description of the disposi-
tion of studies throughout the various steps of the review process (de-duplication, 
abstract review, full paper review and final inclusion). This is commonly achieved 
using a PRISMA diagram that shows the number of inclusions and exclusions at 
each stage of the review. This may be supplemented with details of the reasons for 
exclusion. To create the PRISMA diagram it is necessary to keep an on-going count of 
exclusions and inclusions throughout the review process. However, this can pose a 
challenge where the scope of a systematic review changes from the original specifi-
cation. This may happen where the set of licensed treatments or HTA requirements 
vary between jurisdictions or over time. In these cases, it may be time consuming to 
recreate the on-going counts of exclusions that correspond to the modified scope. 
We present a methodology for conducting a modular systematic review in which 
PRISMA diagrams and other descriptions of study disposition can be generated 
corresponding to any subsequent changes of scope. This is achieved by splitting 
the review into a set of ‘component-reviews’ defined by mutually exclusive treat-
ment search terms that comprise the full set of possible intersections between the 
individual treatments. Throughout the systematic review process separate counts of 
abstracts, papers and studies are maintained for each of these component-reviews. 
The results from the component-reviews can then be combined to reflect any final 
review scope (based on individual treatments). We will illustrate the methodology 
with an example review of the comparative efficacy of licenced thiazolidinedione’s 
(TZDs) versus placebo in patients with type 2 diabetes mellitus (T2DM) where there 
are two TZDs licensed in the USA (pioglitazone and rosiglitazone) but only one in 
Europe (pioglitazone).
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SOCIAL NETwORK ANALySIS OF AUTHORSHIP NETwORKS AND THE 
IDENTIFICATION OF ExPERT ADvISORS
Stoddart S.D.R.1, Siddiqui M.K.2
1HERON Evidence Development Ltd., London, UK, 2Heron Health Private Ltd., Chandigarh, India
Objectives: Systematic reviews are often supplemented with the use of external 
experts to provide guidance on the nuances of the area. This can help add context 
if a review is used to support trial design or health economic model development. 
The ideal expert would have a deep understanding of the area and be well con-
nected to those individuals conducting trials. The aim of the current research 
was to assess whether social network analysis of coauthor networks could be 
used to rapidly and objectively identify individuals with the qualities desired in 
an external expert. MethOds: Publication lists from a recent systematic review 
of rheumatoid arthritis were used to produce a list of links between authors and 
publications. This was then imported into the Gephi program for social network 
analysis. Within Gephi, matrix multiplication was used to transform this net-
work into a coauthorship network. Eigenvector centrality was then used to infer 
the amount of access individual authors have to the research community as a 
whole. The use of eigenvector centrality as a measure of influence within the 
author network was then validated by correlating the centrality scores of a random 
sample of authors against independent ratings of desirability of those individu-
als’ expertise. Results: The coauthor network for rheumatoid arthritis, while 
not completely connected, showed a high degree of connectivity (mean degree: 
26, network diameter: 5). Eigenvector centrality allowed the identification of key 
experts, with the highest scoring experts each providing direct access to approxi-
mately half of the whole network. Eigenvector centrality measures were a reli-
able predictor of mean desirability scores from ten raters (F(1,9)= 20.35, p= 0.0015, 
R-squared= 0.69). cOnclusiOns: Social network analysis of coauthor networks 
provides an efficient and robust method for the identification of expertise, and 
can be used as part of the systematic review process.
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SySTEMATIC REvIEw APPROACHES FOR HTA: HORSES FOR COURSES?
Kenworthy J., Langham J., Chetty M.
PHMR Associates, London, UK
6Yamaguchi University Hospital, Ube, Yamaguchi, Japan, 7CRECON Research & Consulting 
Inc, Tokyo, Japan, 8Niigata University of Health and Welfare, Niigata, Japan, 9Meijo University, 
Nagoya, Japan, 10Okayama University, Okayama, Japan, 11Ritsumeikan University, Kusatsu, 
Japan, 12Osaka University, Osaka, Japan, 13National Institute of Public Health, Wako, Japan
Objectives: Use of economic evaluation of health care technologies is intensively 
discussed in the government in Japan. In order to make evaluation results compa-
rable, standardized method of evaluation is required. We proposed an economic 
evaluation guideline in Japan. MethOds: We organized a research team for devel-
oping guideline. After reviewing guidelines in HTA agencies in the world and cur-
rent debate on issues, we investigated HTA reports and methodology of economic 
evaluation studies in several drugs, devices and procedures. Based on the review of 
these information, the research group discussed and proposed economic evalua-
tion guideline suitable for Japan. Results: Proposed guideline consist of 13 items: 
1) Objective; 2) Perspective of analysis; 3) Comparators; 4) Method of analysis; 
5) Time horizon; 6)Choice of outcomes; 7) Source of clinical data; 8) Costs; 9) 
Productivity loss; 10) Discounting; 11) Modeling; 12) Uncertainty; and 13) Budget 
impact analysis. Guideline sentences are classified into 3 levels, principal, recom-
mended, and optional. cOnclusiOn: This guideline is a proposal by a research 
team. However, it will be needed in the near future for using economic evalua-
tion of health care technologies. Proposed guideline should be tested by adopting 
individual studies.
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DEALING wITH zERO CELLS IN SPARSE NETwORKS IN BAyESIAN NETwORK 
META-ANALySIS
Ivanescu C.1, Skaltsa K.2, Heemstra L.1, Van Engen A.1
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Barcelona, Spain
Objectives: Bayesian Network Meta-Analysis (NMA) models for binary data 
are well established and special precautions do not usually need to be taken in 
the case of zero cell counts. Furthermore, trials with zero cells in both arms are 
usually excluded from the analysis. However, in sparse networks with only one 
trial per comparison and zero cells in unique link studies, their inclusion may 
be mandatory. Zero frequencies may result in numerical instability and/or large 
variances. The objective of this study was to investigate the effect of different 
methods dealing with zero cells in sparse networks in Bayesian NMA. MethOds: 
A review was conducted to identify methods dealing with zero cells for binary 
outcomes in sparse networks in a Bayesian setting. The identified methods were 
applied to a sparse network with six treatments and one study per comparison. 
The outcome was grade 3+ Adverse Events and measured by Odds Ratio. A fixed 
effects model was fitted with binomial likelihood. The performance of the meth-
ods was assessed by the residual deviance and the Credible Intervals’ (CrI) width 
was compared. Results: We identified three methods: apply a continuity cor-
rection (a constant factor of 0.5 or the reciprocal of the opposite treatment size), 
use of informative priors on treatment effects and placing a distribution on the 
baseline model. We applied all methods and combinations of them. The model 
fit was adequate for all methods (residual deviance [10;12.3] for 12 datapoints). 
The use of different informative priors improved the variability estimates. CrI 
widths were reduced up to 15 times with respect to the original model with vague 
priors. cOnclusiOns: Although the debate on the inclusion of studies with zero 
events in NMA is still open, our research shows that methods are available to 
address this issue. However, no clear recommendations can be provided.
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QUALITy ASSESSMENT OF OBSERvATIONAL STUDIES FOR SySTEMATIC 
REvIEwS
Kiss N., Tongbram V., Fortier K.J.
Oxford Outcomes, Morristown, NJ, USA
Observational studies are frequently included in systematic reviews, especially in 
those disease areas where RCTs are limited. While there are very specific tools for 
and guidance on assessing the quality of RCTs, the assessment of observational 
studies is less standardized. OBJECTIVE: To understand and assess the different tools 
used to review the quality of observational studies and to make recommendations 
based on our evaluation. MethOds: First, a systematic review of literature from 
2005-present was conducted in Embase and Medline to determine the frequency 
of use of quality assessment for observational studies and the type of tools used to 
conduct the assessment. Second, we reviewed documentation from NHS guidance 
on quality assessment of non-randomized studies. Finally, we reviewed two years of 
approved HTA submissions to see what methods of assessment have been used for 
submissions. Results: A total of 1429 articles were screened. Compared to a similar 
study on older literature, our review found an increase in the use of quality assess-
ment for observational studies. However, we found that many studies continue to 
devise their own tool or adapt existing tools rather than use a tool in its entirety. 
Downs and Black, MOOSE, and STROBE were the most referenced tools, although 
STROBE was not originally intended for such use. Guidelines centered on “non-ran-
domized” studies were mixed and were not always found to be applicable to obser-
vational studies, but instead mostly to single-armed clinical trials. cOnclusiOns: 
There is still a need for guidance and standardization for observational studies 
assessment for use in systematic literature reviews. Although quality assessment 
of observational studies is still not standardized, there are a few methods becom-
ing more frequent in the literature but are difficult to compare across systematic 
literature reviews because they have often been adapted by each author.
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AN APPROACH FOR QUANTIFICATION OF PATIENT ADvOCACy GROUP INPUT IN 
THE HTA PROCESS
Hicks N.1, Toumi M.2
1Commutateur, Paris, France, 2University Claude Bernard Lyon 1, Lyon, France
Patient input in HTA pathways by the appropriate disease Patient Advocacy Group 
(PAG) uses principally humanistic and social studies as an evidence base followed 
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SIMULATED TREATMENT COMPARISONS – AN ALTERNATIvE APPROACH TO 
INDIRECT COMPARISON wHEN STANDARD METHODS ARE NOT FEASIBLE OR 
APPROPRIATE
Ishak K.J.1, Proskorovsky I.1, Benedict A.2, Chen C.3
1Evidera, Dorval, QC, Canada, 2Evidera, Budapest, Hungary, 3Pfizer Global Pharmaceuticals, New 
York, NY, USA
Health technology assessments (HTAs) rely on comparative evidence about new 
treatments and competing therapies, which are typically derived using indirect or 
mixed treatment comparisons (ITC/MTCs). These are not always feasible or appro-
priate, particularly in rapidly evolving therapeutic areas, like oncology. For instance, 
some comparisons may not be possible due to incomplete evidence networks; or, 
heterogeneity between studies due to differences in design or population may 
make an MTC inappropriate. There is, therefore, a need for alternative techniques, 
such as Simulated Treatment Comparisons (STCs). This technique is designed to 
derive comparisons between treatments after adjustment for differences between 
the populations of the two studies. This targeted comparison requires individual 
patient-level data (IPD) for at least one of the treatments (the index), and are appro-
priate when the trials used for the comparison are sufficiently comparable in design 
and methods, but differ in the profiles of their population in measured risk factors. 
The differences can be adjusted analytically using IPD via regression equations. This 
produces endpoint estimates for the index treatment that reflect the profile of the 
comparator population. These can then be contrasted with published results for 
the comparator to obtain a measure of difference between treatments. Since only 
measured risk factors can be included in the adjustment, the potential for residual 
confounding remains. Another potential bias is a possible “study effect” whereby 
other differences between studies distort the comparisons. This can be assessed 
using the reference groups of the trials, if these received the same treatment. STCs 
have been used in HTA submissions, and it is likely that its use and that of other 
alternative techniques will increase particularly in areas with rapid drug develop-
ment. In the presence of heterogeneity or incomplete evidence networks, STCs can 
provide comparative evidence where these may be otherwise deemed unavailable 
due to limitations of ITCs/MTCs.
PRM229
THE USE OF EUROPEAN ELECTRONIC HEALTH RECORDS TO INvESTIGATE 
CANCER TREATMENT PATHwAyS
Langham J., Langham S., Weir S., Ralston S.
PHMR Associates, London, UK
RCTs remain the gold standard for evaluation of drug efficacy and safety. However, 
the only way of identifying treatment pathways and improving understanding of 
costs and outcomes at different stages of care is via longitudinal observational 
studies. Observational data from electronic health records (EHRs) are increas-
ingly being used to support pharmaco-epidemiological research. Coverage, data 
quality and validity of UK EHR databases such as the Clinical Practice Research 
Datalink (CPRD) have improved in recent years, and many papers confirm the 
validity of data in diagnoses such as cancer. Published data show that recording 
of cancer diagnosis and mortality in primary care electronic records is generally 
consistent with Cancer Registry (CR) data in England. The use of “read codes” in 
CPRD to identify an event (cancer diagnosis or referral to secondary care) and 
the possibility of anonymous linkage to secondary care databases (e.g. Hospital 
Episode Statistics [HES] for information about hospital management as an in- or 
out-patient, to other CR data, and accurate mortality tracking by the Office for 
National Statistics [ONS]) allows the data and diagnosis to be validated against 
multiple sources, as well as identifying treatment pathways in both secondary 
and primary care. There are some limitations, e.g. not all patients identified in GP 
practices via the CPRD are linked to other databases. Management data such as 
secondary care prescribing are difficult to access (not available in HES) but may 
be available from reviewing anonymized patient notes or by connecting to other 
datasets. For example, IMS Health links CPRD data with hospital pharmacy audit 
data and HES data. However these data have only become available recently, are 
expensive to access and currently patient population coverage is low. We will 
provide a detailed description of the possibilities for integrated database use to 
map treatment pathways for cancer patients.
PRM230
SHOULD THERE BE AN OPTION TO “UNREFER” NICE SINGLE TECHNOLOGy 
APPRAISALS: CASE STUDy OF ARIPIPRAzOLE FOR BIPOLAR I DISORDER IN 
ADOLESCENTS
Uttley L., Kearns B., Stevenson M.
University of Sheffield, Sheffield, UK
Single technology appraisals (STAs) are a key component of the development of 
NICE technology appraisals guidance, but are a time and resource intensive process. 
Societal costs are incurred during STAs by holding the NICE Appraisal Committee, 
via payment to the evidence review group (ERG) and in the opportunity costs of 
other technologies which are not appraised. In addition, the drug manufacturer 
also incurs substantial costs in preparation of their submission and throughout 
the STA process. Recently aripiprazole, an atypical antipsychotic drug for the treat-
ment of manic episodes in adolescent bipolar I disorder, was subjected to an STA 
and received positive guidance. It was apparent to the ERG from the outset of the 
appraisal that the conclusion would be positive as: the drug had a small acquisi-
tion cost; was already in widespread use; would shortly be going generic; and had 
a profile similar to its comparators. As the budget impact over a 5-year period esti-
mated by the manufacturer was less than the payment received by the ERG, it was 
unlikely that the STA represented efficient use of resources. Given a fundamental 
role of NICE is in assessing cost-effectiveness, the option of un-referring STAs in 
rare circumstances has appeal. It is proposed that if certain criteria are met then 
it would be more cost-effective to not proceed with an STA. These include: small 
patient population, commonly used in current clinical practice, patent expiring in 
Systematic reviews aim to identify, select, synthesize and appraise all high qual-
ity research evidence relevant to a particular research question, and are widely 
accepted as the gold standard for providing the best evidence for use in decision 
making. They are essential, routine components of submission data packages 
for health technology assessments (HTAs) of products undergoing evaluation 
for reimbursement and market access. Additionally, systematic reviews are 
often the source for clinical evidence used in health economic modelling to 
evaluate cost-effectiveness. Thus, they represent a substantial investment of 
resources, and incorrect or incomplete reviews could invalidate the proposed 
clinical and economic value of a product set out in a health technology submis-
sion and result in unfavourable reimbursement decisions and/or delayed market 
access. There are a number of best practice criteria set down for systematic 
reviews; the most widely recognised being from the Cochrane group. However, 
when carrying out a systematic review for HTA purposes researchers should 
be aware of the additional requirements set out by each agency. The Cochrane, 
UK National Institute for Clinical Excellence (NICE) and Germany’s Institut für 
Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWIG) methodologi-
cal guidelines for conducting and reporting systematic reviews were analysed 
and an ‘inclusive’ checklist of requirements was developed to ensure the sys-
tematic review and meta-analysis met the broad set of HTA requirements and 
minimise the risk of having to repeat the procedure or create the need for a 
HTA review group to carry out its own review, which could potentially lead to 
an unfavourable reimbursement decision or a restriction on use. An aware-
ness of specific HTA systematic review requirements can help optimise the 
preparation of a data package for HTA submission and hence maximise the 
chances of success.
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CAN A MULTI-CRITERIA DECISION (MCD) OPTIMISATION MODEL HELP 
DECISION MAKERS IN THE OPTIMAL SELECTION OF vACCINES wHEN 
ExPANDING THEIR UNIvERSAL MASS vACCINATION PROGRAMME? THE  
CASE OF POLAND
Topachevskyi O.1, Standaert B.1, Van Bellinghen L.A.2, Van Vlaenderen I.2
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2CHESS, Ternat, Belgium
Objectives: The model aims to determine the optimal allocation of financial 
resources amongst various paediatric vaccines accounting for changes in budget 
and availability of new vaccines over time. This approach aims to inform decision 
makers who are seeking to extend their national immunisation programmes 
about the optimal mix of vaccines and sequence of their introduction, meanwhile 
accounting for their preferences in clinical and cost outcomes. MethOds: An 
MCD optimisation model was developed in Microsoft Excel that considered avail-
ability of new vaccines and budget changes over time, optimal mix of vaccines 
in previous years, budget investment time horizon, cumulative outcomes time 
horizon, maximal achievable vaccination coverage, specific target populations. 
The optimal mix of vaccines within an available portfolio was determined by 
manually programmed linear optimisation based on a defined objective func-
tion and budget constraints. The objective function includes maximisation of 
prevention of disease cases, GP visits, hospitalisations, deaths, and cost sav-
ings in disease management. A multi-criteria approach allows for redistributing 
weights across clinical and cost outcomes in the objective function. Vaccination 
against rotavirus, varicella, influenza and pneumococcal disease was evaluated, 
based on disease incidences and direct medical costs from Poland. Relative risk 
reductions induced by vaccination were based on randomised controlled trials 
and post-marketing surveillance data. Results: Dependent on the definition of 
objective function, the allocation of budget across a portfolio of vaccines resulted 
in different recommendations. If deaths-avoided was weighted at maximum, 
pneumococcal vaccine was ranked first, followed by rotavirus and influenza vac-
cination. If cost savings received the maximum preference, vaccination against 
influenza was ranked first, rotavirus second, pneumococcal third, and varicella 
fourth. The use of a weighted objective function resulted in different vaccines 
introduction sequences. cOnclusiOns: The use of an MCD optimisation model 
provides a tool to inform decision makers about the optimal allocation of finan-
cial resources over time.
PRM226
DON’T MAKE ME wAIT: THE vARIANCE REDUCTION TECHNIQUE FOR FASTER 
MONTE CARLO SIMULATIONS IN COST EFFECTIvENESS MODELS ON wEB
Kutepov G.1, Kostiuk A.2
1Modelate LLC, Kaiserslautern, Germany, 2University of Kaiserslautern, Kaiserslautern, Germany
With the rapid pervasion of internet technologies, demand for making health 
economic evidence, such as mathematical models, accessible through the web 
increases. Long running computations such as Monte Carlo simulation can impair 
user experience because of longer waiting time. Our aim is to employ mathematical 
techniques to reduce the computation time of probabilistic cost effectiveness Monte 
Carlo models, thus increasing their acceptance when used on the web. We employ 
the variance reduction technique to reduce computation time while obtaining out-
comes with the same Monte Carlo error. The control variate approach is applied. 
It utilizes information about errors in estimates of known mean Net Monetary 
Benefit (NMB) quantities to reduce errors in estimation of the cost-effectiveness 
acceptability curve. The NMB mean value is calculated based on the deterministic 
counterpart of the model. The said technique has been applied to the published 
probabilistic decision tree-based Excel model for evaluating cost-effectiveness of 
breast cancer screening. In this model, different types of probability distributions 
can be chosen to model uncertainty of disease incidence, mortality rate and inter-
vention effectiveness. By applying the control variate approach we were able to 
achieve outcome with the same error while performing 50% less simulations as 
compared to the plain Monte Carlo method. Such performance improvement is yet 
another step towards increasing user acceptance of web based health economic 
models with Monte Carlo simulations.
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patient subgroups. For example, in oncology, markers such as KRAS, HER-2/neu and 
BRCA 1,2 are used for prognosis and to direct treatment. To reflect this evolution, 
comparative effectiveness research programme designs and analytical methods 
must be able to detect important treatment effects and outcomes for specific patient 
subgroups. The emergence of patient-centered care adds further complexity to HTA 
data requirements. The systematic collection of patient-reported outcomes (PROs) 
and their application to medicine is far from standard in clinical practice, although 
many clinical trial programmes now include the collection of PROs. For products 
in development, data generation plans must reflect ongoing changes and evolving 
complexities. We will review the growing range of methods employed in clinical 
effectiveness research, and show how personalised medicine and patient outcome 
programmes can strengthen HTA data packages.
PRM234
AN ANALySIS OF HOw NOT TO USE COST-EFFECTIvENESS ANALySIS FOR 
PRICE-SETTING
Standaert B.1, Ethgen O.2, Emerson R.A.3, Postma M.J.4
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2University of Liege, Liege, Belgium, 3Emerson 
Consulting c/o GlaxoSmithKline Vaccines, Wavre, Belgium, 4University of Groningen, Groningen, 
The Netherlands
Objectives: Cost-effectiveness Analysis (CEA) and the calculation of the 
Incremental Cost-Effectiveness Ratio (ICER) together with its comparison with a 
threshold such as Gross Domestic Product (GDP)/capita, have long been used to 
assess the value for money of a new intervention compared with a comparator 
that this new intervention precisely seeks to displace. In this paper we show the 
paradoxical increase in cost-effective price using data from middle, low and very 
low income settings. MethOds: Using the introduction of rotavirus vaccination 
compared with no-vaccination as the example. We create a theoretical framework 
for calculating the ICER by gradually decreasing the investment for treatment of 
rotavirus related disease (the ‘no-vaccination comparator’) representing different 
countries with different GDP levels and decreasing levels of existing health care 
investment. We compare these results with an analysis of cost-effectiveness using 
real data from 9 countries representing a range of different GDP levels. Results: 
The theoretical framework works well in situations where the GDP/capita exceeds 
$10,000 – as expected the cost-effective price decreases with a decrease in the 
GDP/capita. Below this the scant investment in health care infrastructure, thereby 
reducing potential cost-offsets, coupled with the significant increase in the poten-
tial effect gain, results in a much wider margin between a cost-neutral and cost-
effective price that could effectively be set using this approach. cOnclusiOns: 
Although Cost-Effectiveness Analysis is widely used to assess the value for money 
of a new intervention for a particular price, we would argue that where investment 
in health care is low and disease burden is high, the use of CEA leads to paradoxes 
in price-setting.
PRM235
RE-ENGINEERING OF THE DISTRIBUTION OF DRUGS IN THE HOSPITAL.  
TOC APPLICATION AND TRz
Alonso H.erreros J
HOSPITAL GENERAL REINA SOFIA, MURCIA, Spain
Objectives: Presents a reengineering process of the distribution of drugs into the 
hospital, analyzing all the options available in the market, and looking for alterna-
tive solutions that may be more cost-effective. MethOd: The processes and sub-
processes in the cycle from prescribing, distribution, and drug administration, are 
defined and discussed based on studies of medication errors (ME). The differential 
analysis is performed on the subprocesses. As technique for finding creative solu-
tions (new cost-effective alternatives) apply the Theory of Constraints (TOC), and the 
TRIZ methodology. Results: Since patient safety can distinguish four processes: 
prescription (about 40% of ME), transcription, distribution (about 10% each), and 
administration (about 40% of ME). In the administration, avoided ME before they 
reach the patient are minimal (only 2%). In the prescription/transcription there 
are 4 options: manual prescription, preprinted sheets, electronic prescription, 
and assisted prescription. In the distribution has 3 options: clasical SUD, filling 
carts using automated carousels, and automated dispensing systems (ADS). For 
administration there are other 3 options: manual record, electronic registration, and 
registration across the barcode. The most expensive option would be the introduc-
tion of ADS in all plants (1.4 million€ for a hospital of 280 beds). But these teams 
only reduces errors about 10% of all ME. Applying the TOC and TRIZ, investment in 
electronic prescribing, and administration with barcodes is the most cost-effective. 
Dose-day (sending medication for one day but not rated by patient) could be the 
most efficient system by simplifying processes. The error difference between Dose-
day, and SDU can be annulled by the advantages of the assisted prescription, and 
administration with barcode cOnclusiOns: It is surprising to invest large sums in 
improving distribution processes (ADS) - where the fewest mistakes occurs - instead 
of prescribing and administration. The dose-day with barcode administration would 
be the most cost-effective theoretical-model.
PRM236
HOw CAN HEALTH ECONOMIC ASSESSMENT METHODS HELP DECISION 
MAKING IN PORTFOLIO DEvELOPMENT
Akpo H., Popa C., Saka Ö
Deloitte, Diegem, Belgium
Objectives: The R&D costs of a new drug approximate $1.3 billion and are increas-
ing due partly to regulatory hurdles and development costs. There is a need for 
smarter investments, which consider the requirements of regulatory bodies, 
increasing the chances of securing market access and high return on investment. We 
describe how health economic methods could support capital investment decisions 
in funding, valuing and bringing new pharmaceuticals to market. MethOds: A lit-
erature review was performed on health economic and capital investment methods. 
The different analyses were mapped to the commercial roadmap and R&D pipeline 
the near future, and similar levels of efficacy and acquisition cost as key compara-
tors In rare circumstances conducting an STA may not be cost-effective. It is possible 
that this can be predicted early in the STA process and we propose criteria to aid in 
this decision. When these criteria are met the possibility of “unreferring” the topic 
is likely to be the most cost-effective option.
PRM231
THE 2013 REvISION TO NICE’S DISCOUNTING GUIDELINES: DIFFERENTIAL 
DISCOUNTING HAS GONE BUT UNjUSTIFIED SELECTIvE APPLICATION REMAINS
Paulden M.1, O’Mahony J.2
1University of Alberta, Edmonton, AB, Canada, 2Trinity College Dublin, Dublin, Ireland
Objectives: To call attention to the problems resulting from the National Institute 
for Health and Care Excellence’s (NICE) recent revision to their methods guidance 
on discounting, which recommends applying a lower discount rate than the refer-
ence case rate in selected cases. MethOds: NICE’s reference case discount rate for 
costs and health effects is 3.5%. In 2011 NICE amended their economic appraisal 
guidelines recommending differential discounting of costs and health effects at 
3.5% and 1.5% respectively in selected cases. A recently published article in Value in 
Health criticised this amendment on a number of grounds, including ambiguity over 
what are the eligible selected cases; the lack of rationale for selective application 
of differential discounting; the apparent inconsistencies that unjustified selective 
application give rise to; and, the size of the differential between the two discount 
rates. In April 2013 NICE published a comprehensive revision of their methods guide-
lines, in which equal discounting of costs and effects at 1.5% in selected cases is 
now recommended. Results: While NICE’s new 2013 guidance no longer includes 
an unjustified differential between the discount rate on costs and health effects, 
it still recommends the application of lower discount rates in selected cases. The 
revised guidance still offers no rationale for such selective application of lower dis-
count rates. This means that many of problems described in the recently published 
critique of the 2011 amendment still apply to the new 2013 guidance, including a 
particularly worrying potential for age discrimination. cOnclusiOns: NICE’s selec-
tive application of lower discount rates in certain cases is not justified and leads to 
inconsistencies in the appraisal of different interventions. NICE is urged to again 
revise their discounting guidance, this time ensuring all interventions are treated 
equally and are subject to the same discount rates.
PRM232
A FLExIBLE MULTI-STATE MODELLING FRAMEwORK FOR THE SIMULATION OF 
CANCER PROGRESSION AND CANCER CARE
van der Meijde E.1, van den Eertwegh A.J.1, Uyl - de Groot C.A.2, Coupe V.M.H.1
1VU University Medical Center, Amsterdam, The Netherlands, 2Institute for Medical Technology 
Assessment, Rotterdam, The Netherlands
Most cost-effectiveness models for evaluation of cancer care compare interventions 
within a single treatment line. However, to investigate the full impact of a new 
treatment, also downstream effects must be taken into account. Furthermore, most 
models are based on observed clinical states, whilst these observations depend on 
the timing of examinations and the choice of diagnostic test. To evaluate the poten-
tial of new treatments and diagnostics, the underlying disease process needs to be 
modeled including the interaction with diagnostics and treatment.Objectives: 
To build a flexible framework for a disease model, that simulates cancer progres-
sion to obtain clinical, patient and economic outcomes, while taking diagnostics 
treatment pathways and surveillance schedules into account . MethOds: The 
modeling framework discerns two levels to describe disease progression, the level 
of the patient and the tumor. At the patient level, an individual is characterized 
by clinical states; “primary tumor only”, “local recurrence”, “regional recurrence”, 
“distant metastasis, stable”, “distant metastasis, progressing” and “death”. The 
clinical state is derived from disease development at the tumor level. Seven tumor 
growth states are defined: “absent tumor”, “dormant tumor”, “micro tumor”, “small 
macro tumor”, “medium macro tumor”, “large macro tumor”, “symptomatic tumor”. 
Melanoma progression was used as a case study. The model simulates, in parallel, 
11 possible tumor sites, ranging from “local” to “regional” and “distant metastatic” 
locations. Sites were chosen because they are associated with different treatment 
and prognosis. The disease model is complemented with a treatment and surveil-
lance module. In this module, treatment choices in each of the clinical states are 
specified. Treatment choice may depend on patient and tumor features, and subse-
quently influences rate of transitioning between tumor growth states. For surveil-
lance, timing of surveillance visits, techniques used and their detection rate(s) are 
specified. cOnclusiOns: The proposed framework provides a flexible and widely 
applicable cancer modeling design.
PRM233
HOLISTIC DATA GENERATION AND SyNTHESIS FOR HTA ASSESSMENT: 
BRINGING TOGETHER COMPARATIvE EFFECTIvENESS RESEARCH, 
PERSONALISED MEDICINE AND PATIENT-CENTRED OUTCOMES RESEARCH
Langham S., Ratcliffe M., Floyd D.
PHMR Associates, London, UK
Defining value and generating innovation in health care relies increasingly on real 
world evidence. Consequently, there is an ongoing evolution in the data needs for 
health technology assessment (HTA). Three key elements of data generation are 
comparative effectiveness, personalised medicine and patient-centred outcomes. 
Integrating these three to support synthesis via systematic reviews, meta-analyses 
and modeling is necessary to maximise value and drive innovation. Effectiveness 
is not just about reduced morbidity and mortality. It now covers quality of life, 
patient satisfaction, intermediate endpoints, and screening/diagnosis/monitoring. 
Additionally, there is a shift away from effectiveness versus placebo to compara-
tive effectiveness versus other technologies or standards of care in the real world, 
focusing on the effect on health outcomes in defined patient populations based on 
ethnicity, comorbidities or age. Personalised medicine signals another shift of focus 
away from broad, homogenous patient populations to small, more-or-less defined 
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data on the general population. Specific examples of large systematic reviews con-
ducted for estimating food safety accounting for population variability and inter-
actions between food contaminants and drugs are also presented. Details on the 
model-based meta-analyses of such safety data are described and discussed for the 
purpose of regulator’s decision making. Systematic reviews have been to the context 
of food and nutritional epidemiology requiring more stringent quality assessment 
and more advanced management of variability. This resulted in a Bayesian random 
effect model accounting for population variability. Metabolic interactions between 
food and drugs were evidenced and variability metrics could be explicated in terms of 
“uncertainty factors” to be used by the food regulators to assess safety limits for food 
ingredients, contaminants or drugs and their combined use. Food regulator in EU is 
aligning and even sometimes anticipating drug regulators in terms of evidence-based 
safety assessment in the real life. Common tools for model-based evidence synthesis 
can be applied to quantify safety signals and interaction in the general population.
PRM240
COMPARATIvE EFFICIENCy RESEARCH: META-ANALySIS OF COST-
EFFECTIvENESS STUDIES
Crespo C.1, Monleon A.1, Díaz W.2, Rodriguez C.1, Brosa M.3, Rios M.1
1University of Barcelona, Barcelona, Spain, 2Universidad de Antioquia, Medellin, Colombia, 
3Oblikue Consulting, Barcelona, Spain
Objectives: Cost-effectiveness analyses (CEA) have become widely used in several 
pathologies. Currently, new CEA studies comparing active vs control treatment have 
been incorporated each year. For this reason, the combination of CEA studies could 
give a more consistent and accurate estimate of an intervention’s efficiency than 
one study alone. The aim of study was to develop a new method to do compara-
tive efficiency research (COMER) based in individual patient data. MethOds: After, 
adjusted the marginal distribution and copula distribution of a hypothetical cohort, 
we stated the parameters and distribution estimated like our unknown theoretical 
distribution. We conducted an iterative analysis of a random Frank Copula distribu-
tion with a different range of sample size. We performed a comparison between 
samples and theoretical distribution in terms of incremental cost-effectiveness ratio 
(ICER), incremental monetary benefit(IMB) fixed a threshold (k= 20.000 monetary 
units) and goodness of fit for Frank copula, assuming a tolerance. Results: The 
Theoretical distribution fixed, showed a cost of 604.34 monetary units for active and 
516.12 monetary units for control, and a utilities of 0.529 for active and 0.492 for 
control. ICER for theoretical cohort was 2,380 monetary units per quality-adjusted 
life year gained and IMB was 653. With a tolerance of 500 monetary units for ICER 
and 50 monetary units for IMB, only 15.52% of simulations were near the theoretical 
ICER and only 6.12% of IMB. The amount of individual patients simulated was more 
than 500 patients per treatment to fit Frank Copula. cOnclusiOns: Preliminary 
results showed that COMER based in individual patients’ data could allow decision 
maker to know real add-value of a new intervention.
PRM241
EvALUATING THE ECONOMIC IMPACT OF TECHNOLOGICAL ADvANCES 
IN DIAGNOSTICS: THE CASE OF HIGH THROUGHPUT SEQUENCING FOR 
HEREDITARy BREAST CANCER
Jacob I., Payne K.
University of Manchester, Manchester, UK
Benefits of diagnostics tests generally centre on test accuracy measures. However, 
additional benefits of diagnostics may include: reduced laboratory time, reduced time 
to results and increases in the capacity of a laboratory to deliver more tests. New tech-
nological developments, such as high throughput sequencing (HTS) are challenging the 
current methods used in establishing the case for the introduction into clinical practice 
terms of economic impact. This is evident in the case study developed here examining 
BRCA1/2 genetic testing in providing information on the risk of development of breast 
cancer. Current BRCA1/2 testing technologies are limited by long (up to one-year) turna-
round times, which together with limited resources to increase the volume of tests 
and associated genetic counselling, has driven the use of a ‘risk threshold’ to target 
women eligible for testing. HTS offers the opportunity of decreased turnaround time 
and increased volume of BRCA1/2 tests, which will impact on the benefits and costs 
associated with the diagnostic service. Systematic reviews have identified Markov-type 
models as the dominant modeling methodology for the assessment of genetic testing. 
We propose that discrete event simulation (DES) is the appropriate model type to quan-
tify the economic impact of HTS BRCA1/2 testing as it allows evaluation of the impact 
of capacity constraints and increased turnaround time on the costs and benefits of 
this new diagnostic technology. Importantly, DES also allows for the assessment of 
structural uncertainty by considering changes in patient pathways when using a new 
diagnostic technology. While DES may be the most appropriate modeling methodology 
in assessing the economic impact of novel genetic tests; typically the type of data and 
information required to popuate these models in lacking. We conclude by highlighting 
the type of data required to both population appropriate models and to adequately 
assess the economic impact of these novel genetic tests.
PRM242
THE IMPORTANCE OF SENSITIvITy ANALySES IN HEALTH TECHNOLOGy 
ASSESSMENTS
Hren R.
University of Ljubljana, Ljubljana, Slovenia
In this paper, we critically evaulated analytical design of health technology assess-
ment methodologies, particularly related to sensitivity analyses and willingness-
to-pay thresholds. To this end, we have used two studies: the first one analyzing 
cost-effectiveness of a human papillomavirus vaccination of boys at age 12 against 
oropharyngeal carcinoma and anogenital warts and the second one examining 
cost-effectiveness of a universal programme of vaccinating children against pneu-
mococcal disease. We have shown – as expected – that the impact of variation of 
parameters can be substantial, however, outcomes of sensitivity analyses are often 
understated both by marketing authorization holders and authorities. Few would 
of a biopharmaceutical company. An approach based on real options valuation 
model was proposed to support investment and market decisions and to predict the 
potential net present value (NPV) of a drug. The conceptual structure of the model 
was face-validated by health economic and valuation experts. Results: A deci-
sion-tree based valuation method, populated partially by information from health 
economic tools, was adopted to analyse and clearly communicate R&D investment 
opportunities, to capture management flexibility and to improve strategic thinking. 
A feedback loop can be built into the model to analyse resiliency to assumption 
changes. In early phases, headroom and multi-criteria decision analyses indicate 
the likelihood of an investment being cost-effective. Phase I and II trials provide 
early evidence on drug efficacy and tolerability and initial cost estimates. Based 
on value of information, cost-effectiveness and budget impact models, only drugs 
deemed to meet authority requirements would be selected. Market intelligence 
and uncertainties and clinical success probability further enable identification of 
the optimal portfolio containing drug candidates that maximize NPV for given risk 
levels. cOnclusiOns: Health economic methods are commonly applied during 
late stage development, but if implemented alongside capital investment tools from 
earliest R&D stages they could increase the likelihood of selecting the right products 
to compose an effective investment portfolio.
PRM237
MULTIvARIATE NETwORK META-ANALySIS OF PROGRESSION FREE SURvIvAL 
AND OvERALL SURvIvAL
Jansen J.P.1, Trikalinos T.2
1Mapi / Tufts University School of Medicine, Boston, MA, USA, 2Brown University, Providence, RI, 
USA
Cancer treatment effectiveness is often quantified by analyzing time from treat-
ment initiation to the occurrence of a particular event. Very commonly studies 
report data on overall survival (OS), where the event is death from any cause, and on 
progression-free survival (PFS), where the event is death from any cause or disease 
progression, whichever occurred first. Both OS and PFS can inform decision making. 
Separate meta-analyses of OS and of PFS data ignore the correlation between the 
outcomes. We introduce a method for the joint meta-analysis of OS and PFS that is 
based on a tri-state transition model with time-varying hazard rates modeled with 
fractional polynomials. In English, we assume that, at any time, patients can be in 
one of three health states: “alive but not progressed”, “alive and progressed”, and 
“dead”. PFS corresponds to time spent in the first state, and OS to time spent in the 
two alive states. The proposed approach allows the joint network meta-analysis 
of OS and PFS, relaxes the proportional hazards assumption, extends to a network 
of more than two treatments, and simplifies the parameterization of decision and 
cost-effectiveness analyses. The data needed to run these analyses can be extracted 
directly from published survival curves. We demonstrate use by applying the meth-
odology to a network of trials for the treatment of non-small cell lung cancer.
PRM238
USING LOwER COST, LOwER EFFICACy INTERvENTIONS CAN IMPROvE 
POPULATION HEALTH OUTCOMES UNDER BUDGET CONSTRAINTS
Arbel R., Greenberg D.
Ben-Gurion University of the Negev, Beer-Sheva, Israel
bAckgROund: The global economic crisis imposes severe restrictions on budgets 
allocated to health care. Innovative technologies in medicine may improve patient 
outcomes but such improvements come at a substantial cost, thus limiting the num-
ber of patients that may benefit from them. According to current cost-effectiveness 
analyses (CEA), most innovative interventions are associated with a higher efficacy 
and higher costs compared with the standard of care. These analyses do not account 
for the budget impact associated with implementing the interventions on all eligible 
patients. Even when a new intervention is highly cost-effective, health care systems 
may not be able to adopt it due to substantial budgetary impacts. Implementing a 
substantially lower-cost intervention to a substantially wider population, accept-
ing inferior per-patient outcomes, may improve overall health outcomes under a 
restricted budget. Objectives: Develop an innovative health technology assess-
ment (HTA) model that combines CEA and budget-impact analyses, thus enabling to 
compare the impact of intervention alternatives on the entire intended use popula-
tion, under a pre-specified budget constraint. MethOds: We identified the follow-
ing steps to be included in the model formulation: 1) Define the intended use and the 
target population. 2) Define two or more interventions, one of them at higher cost 
and better per-patient outcome, and the second with lower cost and inferior per-
patient outcome. 3) Forecast the diffusion of the alternatives into the entire intended 
use population, under a pre-defined budget, in order to estimate the treated and 
untreated populations. 4) Calculate the clinical impact of each alternative on the 
treated population. 5) Calculate the clinical impact of no therapy on the untreated 
population 6) Compare the aggregated clinical impact of each alternative on the 
entire intended use population – both treated and untreated. Using the proposed 
population-based model may result in improved health care outcomes, especially 
in times of economic downturn and austerity.
PRM239
EvIDENCE-BASED METHODS IN FOOD SCIENCES AND NUTRITION
Quignot N.1, Amzal B.2
1LA-SER Analytica, Paris, France, 2LASER Analytica, London, UK
Evidence-based medicine has emerged as the bottom line of Health Technology 
Assessments for drug evaluations. Over the last decade, evidence-based assessment 
of food and nutritional products has accelerated. Specific quantitative tools to syn-
thetize evidence have been increasingly developed, and used for decision support. 
This work aims at highlighting the critical role of systematic reviews and model-based 
evidence synthesis in the field of food sciences and nutrition, especially with the view 
of safety assessment. To first set the scene of food assessment in Europe, the latest 
Guidelines on Systematic Reviews published by the European Food Safety Authority 
(EFSA) (EFSA, 2010) are described with the approach on how to handle observational 
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and matched for age, gender and geographic location. The index date was defined 
as the date of the first AD diagnosis or the first script for AD medication whichever 
comes first. Prevalence of diseases and treatment exposures in the years preceding 
the index date were analyzed according to the occurrence of diseases (ICD-9 codes) 
and medication utilization (AHFS codification) between AD patients and the control 
group. Results: Data were obtained for a random sample of 34,086 AD patients 
(mean age of 78.5 years [SD= 8.0], 65.2% females). A higher proportion of patients 
had a diagnosis of organic psychotic conditions (49.6% vs. 9.2%, p< 0.001), other 
psychoses (21.9% vs. 8.6%, p< 0.001) and neurotic disorders, personality disorders 
and other nonpsychotic mental disorders (69.1% vs. 55.4%, p< 0.001) in the AD group 
compared to the control group. Furthermore, a greater number of patients used psy-
chotropic drugs (53.5% vs. 35.9%, p< 0.001) and anxiolytics, sedatives and hypnotics 
(70.3% vs. 65.9%, p< 0.001) in the AD group than in the control group. cOnclusiOns: 
Comorbidities’ frequency was higher in AD patients for several diseases and treat-
ments, particularly for mental disorders-related diagnoses and medications.
PND3
EFFICACy OF FINGOLIMOD IN DELAyING CONFIRMED DISABILITy 
PROGRESSION IN PATIENTS FAILING PRIOR TREATMENT: A MARKOv MODEL 
APPLICATION TO ESTIMATE TIME TO DISABILITy HEALTH STATES
Bergvall N.1, Rathi H.2, Nixon R.M.1, Thom H.H.Z.3
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Healthcare Pvt.Ltd., Hyderabad, India, 3MRC 
Biostatistics Unit, Cambridge, UK
Objectives: To estimate the efficacy of fingolimod versus placebo on confirmed 
disability progression (CDP) and on time to severe disability health states in 
patients with relapsing–remitting multiple sclerosis (RRMS) failing prior treat-
ment. MethOds: Patients failing prior treatment were defined as: 1) ≥ 1 relapse 
in the previous year and either ≥ 1 gadolinium-enhancing T1 lesion or a T2 lesion 
count ≥ 9 at baseline, or 2) equal or more relapses in the year prior to baseline 
compared with the previous year. Hazard ratios (HR) for 3-month and 6-month CDP, 
measured using Expanded Disability Status Scale (EDSS) scores, were estimated 
using Cox proportional hazards models. Both per-protocol definitions of CDP and 
revised definitions used in other trials were analysed. Time from EDSS score 0 to 
scores of 4 or 6 and to conversion to secondary progressive MS (SPMS) were esti-
mated by fitting a multi-state Markov Transition model to individual patient data 
from the pooled FREEDOMS placebo groups (HRs accounted for treatment effects) 
and the London Ontario cohort (SPMS and RRMS–SPMS transitions). Results: 
Using both definitions of treatment failure, fingolimod reduced the risk of 3-month 
CDP (per-protocol) by 35% (definition 1: HR: 0.65; p< 0.05) and 34% (definition 2: 
HR: 0.66; p< 0.05) versus placebo. The corresponding HRs for 6-month CDP were 
0.61 (p= 0.06) and 0.60 (p< 0.05). HRs were generally lower using the revised CDP 
definition. The Markov Transition model, assuming a 40% reduction, estimated 
that fingolimod delays the median time to EDSS 4 (2.2 years, 61% increase), EDSS 
6 (3.3 years, 52% increase) and SPMS (4.5 years, 62% increase) compared with pla-
cebo. cOnclusiOns: Fingolimod is highly efficacious in delaying CDP in patients 
failing prior treatment, and our modeling approach suggests that this translates 
into a meaningful delay in time to severe disability health states.
PND4
COMPARING THE EFFICACy OF FIRST AND SECOND GENERATION DISEASE-
MODIFyING THERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS:  
A NETwORK META-ANALySIS
Fogarty E.1, Schmitz S.2, Walsh C.2, Barry M.1
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland
Objectives: As the number of available disease-modifying therapies (DMT) for 
relapsing-remitting multiple sclerosis (RRMS) expands, consideration of all evidence 
on comparative efficacy of newer second generation therapies with established 
first generation therapies is required to inform clinical care and health policy. This 
network meta-analysis (NMA) estimates the relative efficacy of DMT in reducing 
relapses and slowing short-term progression of disability in RRMS. MethOds: A 
systematic review of RCTs of interferon-beta, glatiramer acetate (first generation 
DMTs), natalizumab, alemtuzumab, fingolimod, teriflunomide, laquinimod, and 
BG-12 (second generation DMTs) compared with each other or with placebo for the 
treatment of RRMS, identified 20 eligible RCTs (n= 14610). A random-effects NMA 
model was used to calculate relative annualized relapse rate (ARR) and hazard 
ratio (HR) of short-term disability progression. Results: Statistically significant 
reductions in ARR versus placebo, between 24% - 69% for second generation DMTs 
and 16% - 33% for first generation DMTs were found. Alemtuzumab, natalizumab, 
fingolimod, and BG-12 were significantly more efficacious than other DMTs in 
reducing ARR. There was greater uncertainty associated with DMT efficacy in reduc-
ing short-term disability progression. Significant improvements over placebo in 
reducing short-term disability progression were restricted to second generation 
DMTs alemtuzumab, natalizumab, fingolimod, laquinimod, BG-12, and terifluno-
mide 14mg (HR 0.27 - 0.54). No statistically significant improvements in short-term 
disability progression were exhibited by first generation DMTs and teriflunomide 
7mg. cOnclusiOns: The growing number of innovative second generation DMTs 
offers the potential of therapeutic advances in reducing relapse rates in RRMS, with 
less certain benefits on short-term disability progression. Despite these potential 
advantages, the relative position of second generation DMTs on the RRMS treatment 
landscape remains to be defined, due to potentially serious side effects, limited 
long-term safety data and their high cost.
PND5
EFFECTIvENESS OF THE EARLy PSyCHOSOCIAL INTERvENTION ON 
INSTITUTIONALIzATION OF PATIENTS wITH MILD ALzHEIMER’S DISEASE AND 
CAREGIvERS’ QUALITy OF LIFE – AN ALSOvA STUDy
Martikainen J.A.1, Kautiainen H.2, Väätäinen S.1, Välimäki T.1, Hongisto K.1, Hallikainen I.1, 
Sivenius J.1, Soininen H.1, Koivisto A.1
1University of Eastern Finland, Kuopio, Finland, 2Medcare Foundation, Äänekoski, Finland
disagree that innovation in health care is worthwhile; the tremendous technological 
success in pharmacological treatment of HIV patients is a case in point. On the other 
hand, a relatively large number of “me-too” entries in the pharmaceutical market 
and the diminishing productivity of R&D sector call for robust methodologies, which 
could distinguish high-value, breakthrough products. Sensitivity analyses of cost-
effectiveness studies should be made pivotal in decision-making process in order 
to ensure efficient diffusion of innovation.
PRM243
SURvEy DESIGN IN THE ASSESSMENT OF THE IMPLEMENTATION OF RISK 
MINIMISATION MEASURES FOR MEDICINAL PRODUCTS
Prieto L., Hidalgo-Simon A., Arlett P.
European Medicines Agency, London, UK
The introduction of the risk management plan (RMP) has ensured greater proactivity 
to the pharmacovigilance and post-authorisation benefit risk assessment of human 
medicines. An RMP may include risk minimisation measures (RMM), public health 
interventions intended to prevent the occurrence, or reduce the impact of adverse 
drug reactions associated with the exposure to a drug. The new EU legislation on 
pharmacovigilance explicitly requires the active monitoring of the outcome of RMM, 
placing obligations on regulators and industry for this purpose. In this respect, the 
European Medicines Agency’s good pharmacovigilance practices module dedicated 
to the practical implementation of the legislation on the evaluation of the effective-
ness of RMM foresees a dual evidence approach. This approach builds on the assess-
ment of two distinct levels of evidence: the actual implementation of the RMM, and 
the attainment of its final objective(s). The approach requires research encompass-
ing analysis of implementation (process indicators), and traditional epidemiological 
research addressing the attainment (final outcome indicators) of RMM. Surveys 
are usually involved in the assessment of process indicators, in particular when 
RMM imply the provision of educational information to health care professionals 
(HCP) and the surveys are intended to measure what the HCP have learned. This 
paper aims to conceptualise the construction of surveys designed for the analysis of 
implementation of RMM. Such surveys should be developed following the principles 
of content validation. This requires a body of relevant questions (items), the sample 
population to which it will be administered, and a test plan. The test plan includes 
the type of items to be used, the number of items, the length of administration, 
how it is to be administered, and how it is to be scored and analysed in terms of 
item difficulty and discrimination. The paper concludes with a checklist to assist 
stakeholders in designing surveys for RMM assessment purposes.
DISEASE-SPECIFIC STUDIES
NEUROLOGICAL DISORDERS – Clinical Outcomes Studies
PND1
DISEASE BURDEN IN EPILEPSy ASSOCIATED wITH TUBEROUS SCLEROSIS 
COMPLEx: SySTEMATIC REvIEw
Blieden M.1, Parker L.1, Foster T.1, Segal S.2, Magestro M.2
1Evidera, Lexington, MA, USA, 2Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA
Objectives: To summarize literature on the burden of epilepsy in tuberous sclero-
sis complex (TSC); TSC is a genetic disease characterized by behavioral disorders, 
benign tumors in multiple organs, and neurological manifestations including epi-
lepsy. MethOds: A systematic search of keywords for TSC and burden of illness 
was conducted in MEDLINE- and EMBASE-indexed publications from 5/2000-1/2013, 
and non-indexed materials. Results: In total, 83 articles on TSC-associated epi-
lepsy were included. Up to 93% of TSC patients have epilepsy, with severe forms 
more common than in non-TSC epilepsy patients (infantile spasms, 35-57% vs. 9%; 
generalized tonic-clonic or grand mal seizures, 37% vs. 7%; complex focal seizures, 
87% vs. 33%). Seizure onset is early (median age: 7 months, 82% by age 3). TSC2 
gene mutations and cortical tubers, common brain malformations in TSC, are risk 
factors for early onset and greater severity of seizures. TSC-epilepsy patients have 
significant disabilities, including high rates of autism spectrum disorders (13-30%) 
and cognitive impairment/delay (62-80%). Although data are not available on long-
term outcomes, early seizure control may reduce cognitive impairment and autism 
symptoms. Vigabatrin is a first-line treatment option for TSC-associated infantile 
spasms and focal seizures in infants, but poses a risk of serious retinal toxicity. 
Other anti-epileptic drugs are available as second-line options; most patients still 
require polytherapy, and 62% have refractory epilepsy that can necessitate surgery. 
With high rates of medication use, hospitalizations, and surgeries, TSC-epilepsy 
patients may consume substantial health care resources, particularly during the 
first 5 years post-diagnosis. Longitudinal trends in resource use, direct and indirect 
costs, and treatment patterns for TSC-epilepsy are largely absent from the litera-
ture. cOnclusiOns: TSC-epilepsy is common and may be severe, with presenta-
tion early in childhood and long-term morbidity. True disease burden to patients, 
caregivers, and payers remains unknown given substantial data gaps in longitudinal 
clinical outcomes, treatment patterns, and costs.
PND2
POTENTIAL PREDICTORS OF ALzHEIMER’S DISEASE: AN ANALySIS wITH THE 
QUEBEC PROvINCIAL DRUG REIMBURSEMENT PROGRAM DATABASE
Lachaine J.1, Lambert-Obry V.1, Dionne P.A.2
1University of Montreal, Montreal, QC, Canada, 2Pfizer Canada, Kirkland, QC, Canada
Objectives: To identify potential determinants of Alzheimer’s disease (AD) by ana-
lyzing past medical history in terms of previous diseases or treatment exposures 
of patients with AD compared to patients without the disease, using the Quebec 
provincial drug reimbursement program database (RAMQ). MethOds: This ret-
rospective study included patients covered by the RAMQ who had at least one 
diagnosis of AD (ICD-9 code 3310) or have received at least one script for an AD 
medication (donepezil, rivastigmine, galantamine or memantine) from January, 1985 
to December, 2011. A control group of patients without AD was created on a 1:1 ratio 
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on naïve and exposed populations was available for colistin and colistin-P, respec-
tively. cOnclusiOns: By conducting an alternative approach where the naïve and 
exposed arms were considered separate treatment-by-population groups, the full 
evidence base could be evaluated, including the data for the dry-powder colis-
timethate sodium inhaler. This will provide relevant information to support clinical 
decision making in CF.
PND8
CLINICAL EFFECTIvENESS OF LACOSAMIDE AND ITS IMPACT ON 
CONCOMITANT ANTIEPILEPTIC DRUGS CONSUMPTION IN THE CzECH 
REPUBLIC
Klimes J.1, Vocelka M.1, Dolezal T.1, Foitova H.2
1VALUE OUTCOMES, s.r.o., Prague 2, Czech Republic, 2UCB, s.r.o., Prague 8, Czech Republic
Objectives: To gather data on clinical effectiveness of lacosamide add-on ther-
apy to standard antiepileptic drugs (AEDs) in the Czech Republic. These data were 
intended as inputs for a cost-effectiveness analysis. MethOds: A retrospective 
multicenter (n= 40) data collection of patients with epilepsy treated with lacosamide 
for 6 months in clinical practice was performed. Information on the number of sei-
zures and concomitant AEDs before and after lacosamide treatment was observed. 
In this analysis patients reporting at least a 50% reduction in seizure number 3 
months after lacosamide treatment were considered responders. Adverse events 
reported after initiating lacosamide treatment were collected. Results: In total, 
data from 409 patients were collected, 403 had complete data that were analyzed. 
Mean (SD) age was 40.4 (±14.2) years and the mean (SD) time since diagnosis 18.7 
(±12.8) years. In 91% of patients lacosamide treatment was initiated because of 
resistance to previous AEDs. Most patients suffered from partial (44.2%), second-
ary generalized (20.1%) or both (34.0%) types of seizures, or other (1.7%). Following 
lacosamide administration the mean (median) number of seizures decreased from 
baseline of 40.3 (12.0) to 25.9 (7.0) (per 3 months). Median (mean) number of sei-
zure reduction was equal to 41% (30%), and 45% were responders. Adverse events 
occurred in 79 pts (19.6%), with somnolence (6.2%) and dizziness (5.5%) most fre-
quently reported. During lacosamide administration, a decrease in concomitant 
AEDs number was observed. The mean number per patient decreased from 2.2 to 
1.7, as did concomitant AEDs used before and after lacosamide administration: 
levetiracetam (39% vs. 33%), lamotrigine (38% vs. 32%), carbamazepine (34% vs. 
29%), valproate (33% vs. 28%) and zonisamide (17% vs. 8%). cOnclusiOns: Results 
confirm the effectiveness of lacosamide in the reduction of seizure frequency in 
clinical practice. In addition, findings suggest that adding lacosamide may lead to 
a reduced use of other concomitant AEDs.
PND9
COST ANALySIS OF ANTI-MIGRAINE PRESCRIBING USING A CLAIMS DATABASE
Truter I.
Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
Objectives: To analyse the cost of different anti-migraine products to determine 
price differences and the impact of generic prescribing. MethOds: A retrospective 
drug utilisation study was conducted on South African medical insurance claims 
data for 2011. No clinical information was available. Results: A total of 797 patients 
received 1583 anti-migraine products during 2011. The majority of patients (70.14%) 
were females and 47.05% of patients were between 30 and 49 years old. Only 13.96% 
of patients claimed their anti-migraine products from the chronic plan of their 
medical insurance schemes. The average age of patients was 41.61 (SD= 14.91) years, 
with females on average slightly older than males (41.89 years vs. 40.96 years). 
Clonidine was the most frequently prescribed active ingredient (accounting for 
49.21% of the number of prescriptions, yet only for 25.70% of the amount claimed for 
anti-migraine products). Triptans (selective serotonin (5-HT1B/1D)-receptor agonists) 
accounted for 27.98% of all anti-migraine prescriptions, but accounted for 45.92% 
of cost. Five different triptans were prescribed. The average cost per sumatriptan 
prescription was the lowest (R177.64) of all the triptans. Sumatriptan was the only 
triptan with generic equivalents. Rizatriptan was the most often prescribed triptan, 
accounting for 18.51% of prescribing frequency and 29.15% of the amount claimed. 
Tablets and wafers were the preferred dosage forms. Only 0.32% of prescriptions 
were for triptan nasal sprays and they were on average the most expensive dos-
age form prescribed (R428.82 per prescription). cOnclusiOns: The results of this 
study were in agreement with the findings of previous South African studies. The 
cost saving implications of generic prescribing were clear in this study. Migraine is 
an expensive condition to treat and is also affecting the economically active sec-
tor of the population. Studies investigating the economic impact of migraine will 
therefore yield valuable results.
PND10
PRACTICE OF CEREBROPROTECTORS CONSUMPTION IN UKRAINE
Kuznetsov I., Iakovlieva L., Ribka A., Vasileva A., Kyrychenko O.
National University of Pharmacy, Kharkiv, Ukraine
Objectives: Despite the lack of evidence-based efficacy of cerebroprotective drugs, 
one-third of Europe’s population uses of these drugs (WHO statistics). The pur-
pose of the study - to research the dynamics of cerebroprotectors consumption in 
Ukraine. MethOds: Determination of cerebroprotectors consumption by means of 
frequency analysis, ATC/DDD-methodology during 6 months in 2012 in Ukraine. The 
consumption of cerebroprotective drugs in money term does not give a true picture 
about the volume of pharmacotherapy using these drugs, that is why ATC/DDD-
methodology was used. As a unit of consumption DDD and PDD were used. Results: 
A comparison of outpatient and inpatient cerebroprotective drugs consumption 
during 6 months in a neurological hospital and in a drugstore in Kharkov, it was 
found, that 58 trade names (TN) of drugs in the amount of $ 28218 (the rate of $ 1: 
8,16 UAH on 1.10.12), in the hospital 17 TNs were used in the amount of $1518. It is 
shown, that the inpatient consumption of cerebroprotectors is much higher, than 
outpatient consumption, for example, vincamine - 2,32 DDDs/100 patients and 1,66 
DDDs/100 bed–days; piracetam - 2,59 DDDs /100 patients and 0, 15 DDDs/100 bed-
Objectives: To assess the effects of early psychosocial intervention on delaying the 
institutionalization of patients with mild Alzheimer’s disease (AD) and on caregiv-
ers’ health-related quality of life (HRQOL). MethOds: Totally, 240 patient-caregiver 
dyads were recruited to a pragmatic, controlled, and randomized (1:2) clinical trial 
in 3 hospital districts in Finland between 2002-2006. A primary outcome measure 
was the intervention’s impact on cumulative risk of institutionalization over 36 
months of follow up. In the analysis of the primary outcome, Fine & Gray’s (1999) 
proportional subhazards (sHR) model was applied to adjust the impact of compet-
ing risk (i.e., death). Main secondary outcome measures were caregivers’ global 
burden (measured by Global Health Questionnaire GHQ) and HRQOL measured by 
the 15D. The secondary outcomes were analyzed using generalized linear mixed 
models (GLMM) with hierarchical structure to account for repeated measures and 
possible clustering by the hospital district. Results: After 36 months of follow 
up, cumulative competing risk adjusted incidence of institutionalization rates 
(95% CI) were 21.2% (12.5% – 29.9%) and 16.1% (10.3% - 21.9%) in the intervention 
and usual care groups, respectively. Age and sex adjusted sHR was 1.37 (95%CI 
0.75 – 2.52). No statistical significant differences in the secondary outcomes were 
found. cOnclusiOns: The early psychosocial intervention for patients with mild 
AD and their caregivers did not delay time to nursing home placement. The results 
of the present study are consistent with a recently published study (Waldorff et al. 
2012 BMJ) reporting no effect of semi-tailored intervention for patients with mild 
AD and their caregivers. Even if the present study did not manage to show differ-
ences between the study groups, it provides the valuable longitudinal dataset for 
studying long-term disease progression (in terms of correlated cognitive, behavioral, 
and functional disabilities) and its economic and quality of life consequences for 
patients with AD and their caregivers.
PND6
MODELING THE IMPACT OF DISEASE MODIFyING TREATMENT ON TIME TO 
DISABILITy HEALTH STATES IN MULTIPLE SCLEROSIS: AN EvALUATION 
OF ORAL THERAPIES THROUGH INDIRECT COMPARISONS OF 6-MONTH 
CONFIRMED DISABILITy PROGRESSION
Bergvall N.1, Rathi H.2, Nixon R.M.1, Thom H.H.Z.3, Alsop J.4, Dunsire L.4
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Healthcare Pvt.Ltd., Hyderabad, India, 3MRC 
Biostatistics Unit, Cambridge, UK, 4Numerus Ltd., Wokingham, UK
Objectives: To estimate the comparative efficacy of oral therapies (fingolimod, dime-
thyl fumarate [DMF] and teriflunomide) in delaying progression to disability health 
states in patients with relapsing–remitting multiple sclerosis (RRMS). MethOds: Cox 
proportional hazards regression models were used to analyse 6-month confirmed 
disability progression (CDP; based on Expanded Disability Status Scale [EDSS] scores) 
in the pooled fingolimod FREEDOMS trials. Initial models were constructed with eight 
baseline covariates as main and treatment-interaction effects and final models with 
the most predictive covariates were selected using a stepwise algorithm. Models 
predicted hazard ratios (HRs) for 6-month CDP for fingolimod 0.5mg versus placebo 
for average TEMSO (teriflunomide trial) and pooled DEFINE/CONFIRM (DMF trials) 
patients. Time from EDSS score 0 to scores of 4 or 6 and to conversion to secondary 
progressive multiple sclerosis (SPMS) were estimated by fitting a multi-state Markov 
Transition model to individual patient data from the pooled FREEDOMS placebo 
groups (HRs accounted for treatment effects) and the London Ontario cohort (SPMS 
and RRMS–SPMS transitions). Results: Without covariate adjustment, the HR for 
CDP for fingolimod versus placebo in the pooled FREEDOMS trials was numerically 
lower (i.e. fingolimod more efficacious) than that for DMF twice daily versus placebo 
in DEFINE/CONFIRM (0.62 vs. 0.71). In adjusted comparisons, the predicted HR for 
fingolimod versus placebo in the DEFINE/CONFIRM population was lower than in the 
FREEDOMS population (initial model, 0.51; final model, 0.60). Fingolimod increased 
median time to disability health states (EDSS 4, 1.0 years; EDSS 6, 1.5 years) and SPMS 
(1.9 years) compared with DMF. Comparisons with teriflunomide also showed fingoli-
mod increased times to disability health states. cOnclusiOns: Fingolimod is the 
only oral treatment that has demonstrated a significant effect on 6-month CDP in a 
clinical trial and our modeling approach suggests that progression to severe disability 
health states is delayed by fingolimod.
PND7
EFFICACy OF INHALED ANTIBIOTICS IN CF PATIENTS wITH CHRONIC  
P. AERUGINOSA INFECTION: A NETwORK META-ANALySIS
Janssen K.J.1, Higashi K.1, Jansen J.2, Doering G.3, Elborn S.4, Calado F.5, Sagkriotis A.5, 
Angyalosi G.5, Balp M.M.5
1Mapi, Houten, The Netherlands, 2Mapi, Boston, MA, USA, 3Tübingen University, Tübingen, 
Germany, 4Queens University Belfas, Belfast, UK, 5Novartis Pharma AG, Basel, Switzerland
Objectives: To compare the efficacy of tobramycin powder for inhalation (TIP) rela-
tive to tobramycin inhalation solution containing 300 mg/5ml of tobramycin (TIS-T) 
and 300mg/4ml of tobramycin (TIS-B), aztreonam lysine inhalation solution (AZLI), 
colistimethate sodium solution (colistin) and colistin inhalation powder (colistin-
P) for cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosainfection, 
by updating a systematic literature review (SLR) and network meta-analysis (NMA) 
with recently published evidence. MethOds: The updated SLR was conducted in 
Medline, Medline in Process, Embase and the Cochrane Library up to 2012. Individual 
study results were synthesized and indirectly compared with a Bayesian NMA. As 
some trials included naïve patients (previously not exposed to the treatment) in one 
arm, and previously exposed patients to the treatment in the other arm, the naïve 
and exposed arms were considered separate treatment-by-population groups in 
the network. Results: Three new trials were identified and analysed with eleven 
trials identified in the previous SLR. In naïve populations, TIP is expected to have 
similar efficacy as TIS-T, TIS-B, and AZLI (difference in % change in FEV1 predicted 
at week 4 respectively -1.97 (95% Credible Interval -11.84, 8.03), -2.38 (-12.71, 7.98), 
and 1.53 (-7.04, 10.00)). Compared to colistin-P, TIP is expected to have similar effi-
cacy, however the point estimate is in favour of TIP (11.36 (-1.75, 24.31)). In exposed 
populations, TIP is expected to have similar efficacy as TIS-T, TIS-B and colistin 
(respectively -0.78 (-7.65, 5.99), 0.01 (-10.42, 10.46), and -5.75 (-21.23, 9.89)). No data 
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or best supportive care (BSC). MethOds: The BIM was developed from the UK 
NHS (National Health Service) and Personal and Social Services (PSS) perspective. 
The status quo scenario assumed the three BoNT-As, Dysport® (abobotulinum-
toxinA), Botox® (onabotulinumtoxinA), or Xeomin® (incobotulinumtoxinA), are 
used in 33%, 52% and 15%, respectively, of patients with ULS receiving BoNT-A 
in the UK. The new market share scenario assumed an increased proportional 
use of abobotulinumtoxinA (to 73% in year 5) compared to other interventions. 
The patients were modelled over a 5-year horizon. Epidemiologic data inputs 
were from published sources. Unit costs for BoNT-As, other health care costs and 
non-medical costs came from the British National Formularyand PSS. Resource-use 
inputs were obtained from UK clinicians. One-way sensitivity analyses for model 
inputs were conducted. Results: Total care costs were decreased by between 
£425,765 in year 2 and £1,854,601 in year 5 by shifting market share to abobo-
tulinumtoxinA. In the base-case scenario, BSC (no BoNT-A treatment) or with 
incobotulinumtoxinA or onabotulinumtoxinA cost more per patient per year than 
abobotulinumtoxinA. Sensitivity analyses showed that number of patients treated 
with BoNT-As, time-to-re-injection, and dose per injection of abobotulinumtoxinA 
and onabotulinumtoxinA were the most influential parameters on budget impact, 
impacting both drug acquisition costs and physician visits. cOnclusiOns: Study 
findings suggest that increased use of abobotulinumtoxinA compared with inco-
botulinumtoxinA and onabotulinumtoxinA for ULS in the UK could potentially 
reduce total treatment costs.
PND14
THE BUDGET IMPACT OF INTRODUCING BG-12 (DIMETHyL FUMARATE) FOR 
TREATMENT OF RELAPSE-REMITTING MULTIPLE SCLEROSIS (RRMS) IN CANADA
Dorman E.1, Kansal A.R.1, Sarda S.2
1Evidera, Bethesda, MD, USA, 2Biogen Idec, Weston, MA, USA
Objectives: Multiple sclerosis causes significant disability and mortality globally 
and is especially prevalent in Canada and across Europe. BG-12 is an orally admin-
istered disease modifying treatment for relapsing-remitting MS (RRMS) patients 
currently on the market in the United States and Canada and under review in 
Europe. A budget impact model (BIM) was developed to assess the financial con-
sequences of introducing BG-12 for the treatment of RRMS in Canada. MethOds: 
A BIM calculated the financial consequences of introducing BG-12 in Canada over 
three years based on RRMS prevalence, treatment market share, and clinical effects. 
RRMS prevalence in Canada was derived from published literature and natural 
relapse rates and disease state distribution from clinical trial data. It was conserva-
tively assumed that 100% of RRMS patients were treated with a disease modifying 
treatment. BG-12 was assumed to absorb market share proportionally from the 
following current treatments: interferon beta-1a IM, interferon beta-1a SC, inter-
feron beta-1b, glatiramer acetate, natalizumab, and fingolimod. Treatment efficacy, 
in terms of reductions in relapse rate, and treatment discontinuation rates were 
determined from a mixed treatment comparison. Treatment costs (including costs 
of acquisition, monitoring, and administration) and the cost of relapse were con-
sidered. Deterministic one-way sensitivity analyses were conducted to assess the 
most sensitive input parameters. Results: Over three years, the introduction of 
BG-12 resulted in an average annual increase of CAD279 per treated patient per year, 
with reductions in costs associated with relapses (CAD192/patient/year) partially 
offsetting increased drug acquisition costs (CAD471/patient/year). On a popula-
tion level, the average annual cost increase was CAD16,494,850. The main drivers 
of budget impact were cost of BG-12, drop-out rates, proportion of RRMS patients 
treated, and market share assumptions. cOnclusiOns: The acquisition costs of 
BG-12 for treatment of RRMS are predicted to be partially offset by reduced costs of 
relapses in the Canadian health care system.
PND15
BUDGET IMPACT OF EvEROLIMUS FOR TUBEROUS SCLEROSIS COMPLEx (TSC) 
RELATED ANGIOMyOLIPOMA (AML): UNITED KINGDOM PERSPECTIvE
Whalen J.D.1, Srivastava B.2, Ozer-Stillman I.1, Gray L.3, Price L.3, Magestro M.2
1Evidera, Lexington, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 
3Novartis Pharmaceuticals UK Limited, Frimley, UK
Objectives: AMLs are benign tumors common in patients with TSC, associated 
with high morbidity (aneurysm, hemorrhage, chronic kidney disease), and can 
result in death. Complication risk may correlate with increased AML volume. 
Historically, AMLs were treated surgically with embolization or tissue-sparing 
resection. In the EXIST-2 trial, everolimus significantly reduced AML volume in 
TSC patients. This analysis estimates the cost of reimbursing everolimus for TSC-
related AML to the UK health care system. MethOds: A Markov model was built to 
analyze budget impact over five years. The treated population is estimated using 
TSC and AML prevalence. Adult patients with growing AML ≥ 3 cm are assumed 
eligible for everolimus. Treatment reference costs are from the UK, resource utili-
zation data from The Netherlands, efficacy and safety assumptions from EXIST-2. 
The model assumed one-year treatment duration. Responding patients (≥ 30% 
AML volume reduction) may restart everolimus upon AML regrowth. Costs are 
discounted at 3.5% per annum. Sensitivity analyses were conducted. Results: 
Up to 1,474 adults in the UK have TSC-related AML; 30% are assumed eligible 
for everolimus. On average, 165 patients are estimated to be treated annually 
with everolimus (Year 1: 88; Year 5: 233) at an average cost of £4,600,000 (Year 
1: £2,700,000; Year 5: £6,200,000). Over five years, AML-related medical spending 
decreased £54,000. Annual per patient treatment cost with everolimus is £31,000. 
Results were most sensitive to patient prevalence, percent eligible for everolimus, 
and the percent experiencing ≥ 30% AML volume reduction. cOnclusiOns: TSC 
is a relatively rare genetic disease for which everolimus is the only non-surgical 
treatment that has demonstrated efficacy in reducing AML volume. Reducing AML 
volume may prevent long-term complications and avoid surgeries, resulting in 
decreased AML-related medical costs. Further long-term studies are needed to 
better understand the benefits of everolimus in preventing AML-related morbidity 
and the associated costs.
days, respectively. By frequency of outpatient appointments a combined generic drug 
fezam (234 appointments, prise $ 5.1), and outpatient cavinton (19 appointments, 
prise $ 17.27) were used often. cOnclusiOns: In Ukraine, outpatient cerebroprotec-
tive drugs consumption is greater than their consumption in hospital due to the lack 
of prescriptions control.
PND11
UTILIzATION OF ANTI SPASTICITy DRUGS IN MULTIPLE SCLEROSIS: ANALySIS 
FROM AN ITALIAN ADMINISTRATIvE DATABASE
Mantovani L.G.1, Furneri G.2, Scalone L.3, Ciampichini R.2, Cortesi P.A.3, Fornari C.3,  
Madotto F.3, Chiodini V.3, Cesana G.3
1Federico II University of Naples, Naples, Italy, 2Charta Foundation, Milan, Italy, 3University of 
Milano - Bicocca, Monza, Italy
Objectives: Spasticity is a common condition among patients with progres-
sive and/or relapsing forms of multiple sclerosis (MS). Current therapies seem to 
partially control spasticity symptoms, and patients often receive multiple treat-
ments or switch to new treatments to achieve a better control. The objective of 
this analysis was to assess the current usage of spasticity drugs and relative 
patterns of utilization among patients with MS, through administrative database 
analysis. MethOds: Using DENALI datawarehouse, we detected MS patients 
who, during the period January 2000 – December 2009, had at least one disease 
modifying agent (DMA) prescription Then the usage of drugs commonly used 
in spasticity (muscle relaxant drugs, baclofen, tizanidine, clonidine, dantrolene) 
was evaluated in this cohort of patients, in terms of number of subjects receiving 
at least one prescription, and number of DDD (defined daily doses) per patient 
per year. Results: From 2000 to 2009, the annual number of patients with MS, 
receiving DMA treatment raised from 10,746 to 12,594. Concomitantly, the annual 
number of patients receiving at least one muscle relaxant prescription raised from 
5.87% (n= 631) to 9.42% (n= 1,186). The most prescribed drug was baclofen with few 
patients receiving other drugs commonly indicated in spasticity (dantrolene, tiza-
nidine and clonidine). A relevant number of patients using muscle relaxants also 
received other drugs for the central nervous system, although its usage achieved 
a peak in 2005 (8% of MS patients). The analysis of DDD per patient/year suggested 
that the usage of muscle relaxant might be almost chronic in these patients (in 
2009, 303 DDD per patients per year). cOnclusiOns: Only 10% of patients with 
MS currently receive active pharmacological treatment, although this condition 
seems affecting more than 20% of MS patients in Europe. Also, there are not rel-
evant alternatives or second line options to baclofen, which is the most commonly 
prescribed drug in this condition.
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USE OF THE FRENCH CLAIMS AND HOSPITALISATIONS DATABASE TO ESTIMATE 
THE PREvALENCE AND INCIDENCE OF PARKINSON’S DISEASE IN FRANCE
Blin P.1, Dureau C.1, Grolleau A.1, Corbillon E.2, Jové J.1, Lassalle R.1, Poutignat N.2,  
Foubert-Samier A.3, Droz C.1, Moore N.4
1INSERM CIC-P 0005, Université Bordeaux, Bordeaux, France, 2Haute Autorité de Santé, Saint 
Denis La Plaine, France, 3INSERM U897, ISPED, Université Bordeaux, CHU de Bordeaux, 33076, 
France, 4INSERM CIC-P 0005, Université de Bordeaux, CHU de Bordeaux, Bordeaux, France
Objectives: Few studies have assessed the prevalence and incidence of Parkinson’s 
disease (PD) in France. The objectives of this study were to estimate the prevalence 
and incidence of PD between 2005 and 2010 using a claims and hospitalisations 
database. MethOds: The EGB database is a 1/97 permanent random sample of 
the French health care insurance system database linked to the national hospital 
discharge summary database. Data for all adults with full insurance coverage for 
PD, or hospitalised with main, related, or associated PD diagnosis, or with at least 3 
antiparkinson agent reimbursements over a one-year period were extracted for the 
years 2004 to 2010. A specific and a sensitive PD criterion were defined: i) patients 
with a medical diagnosis of PD from full insurance coverage or hospitalisation; ii) 
same patients plus those without a PD medical diagnosis in the database but a 
drug pattern compatible with this diagnosis (a second set of at least 3 antiparkin-
son agent reimbursements over another one-year period and no co-medication 
with extrapyramidal side effects, as well as no antiparkinson agent pattern spe-
cific of another indication). EGB estimations were applied to the French population 
with age and gender standardization to estimate the prevalence and incidence in 
France. Results: Prevalence of PD increased from 0.27% in 2005 to 0.33% in 2010 
using the specific definition of disease, and from 0.38% to 0.46% using the sensitive 
definition. The incidence rate per year was 0.03-0.04% using the specific definition 
of disease, and 0.05-0.06% using the sensitive definition. Estimated population size 
was between 180,000 and 255,000 persons in 2010 with approximately 22,000 to 
32,000 new patients per year. cOnclusiOns: The prevalence and incidence of PD 
in France are likely to be within the range of estimations found in the EGB database 
using the specific and sensitive definitions of disease; results are consistent with 
that reported internationally.
NEUROLOGICAL DISORDERS – Cost Studies
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BUDGET IMPACT ANALySIS OF BOTULINUM TOxIN A THERAPy FOR UPPER LIMB 
SPASTICITy IN THE UNITED KINGDOM
Kurth H.1, Remak E.2, Hortobagyl L.3, Desai K.3, Abogunrin S.3, Dinet J.4, Gabriel S.4,  
Bakheit A.M.5
1IPSEN Pharma, Boulogne Billancourt, France, 2Evidera, Budapest, Hungary, 3Evidera, London, UK, 
4IPSEN Pharma, Boulogne-Billancourt, France, 5Moseley Hall Hospital, Birmingham, UK
Objectives: Upper limb spasticity (ULS) secondary to upper motor neurone 
lesions has a considerable patient and caregiver burden, particularly with regards 
to pain, activities of daily living and personal care. BotulinumtoxinA (BoNT-A) 
injections are effective in treating ULS. We developed a budget impact model 
(BIM) to assess different BoNT-A treatments available in the UK for reducing 
ULS. We also assessed annual costs of treating each ULS patient with BoNT-A 
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HEALTH CARE RESOURCE USE AND DIRECT COSTS ASSOCIATED wITH FRAGILE 
x SyNDROME (FxS) IN THE UNITED STATES
Vekeman F.1, Gauthier-Loiselle M.1, Faust E.2, Lefebvre P.1, Lahoz R.3, Duh M.S.2, Sacco P.4
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA, 3Novartis 
Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Objectives: FXS is the most common inherited form of intellectual disability and is 
associated with comorbidities that impair functioning and adaptive behavior. This 
study is aimed at evaluating the incremental direct health care costs and resource uti-
lization associated with FXS using administrative health care claims data. MethOds: 
Using the Optum Health Reporting and Insights Employer database covering 1999-
2012, subjects < 65 years old with ≥ 1 FXS diagnosis (ICD-9-CM: 759.83) and ≥ 6 months 
of continuous enrollment prior to the first observed FXS diagnosis were matched 
with up to 5 non-FXS controls using high-dimensional propensity score matching. 
Individuals were followed until the end of continuous enrollment in the health plan. 
All-cause and FXS-related costs and resource utilization stratified by hospitalizations, 
emergency room (ER), outpatient, and home care visits were examined. Results: 
590 FXS individuals (mean[median] age: 25.7[27]; female: 54.1%; employee: 32%) and 
2,950 non-FXS controls (mean[median] age: 25.7[27]; female: 52.1%; employee: 32%) 
were identified. Significant differences were observed between FXS and non-FXS in 
the all-cause per-patient per-year (PPPY) incidence of hospitalizations (0.414 vs. 0.237; 
incidence rate ratio [IRR] [95% CI]: 1.75[1.51-2.02]), outpatient visits (14.345 vs. 9.078; 
IRR: 1.58[1.54-1.62]), and home care visits (1.817 vs. 0.348; IRR: 5.22[4.80-5.69]). Similar 
results were found for FXS-related hospitalizations (0.206 vs. 0.092; IRR: 2.23[1.80-
2.77]), outpatient visits (4.929 vs. 1.976; IRR: 2.49[2.39-2.61]), and home care visits (0.341 
vs. 0.029; IRR: 11.70[9.09-15.06]). FXS subjects were also associated with significantly 
higher PPPY all-cause health care costs (total[SD]: $14,674[47,163] vs. $5,110[18,378]; 
hospitalization: $4,507[18,141] vs. $1,328[10,203]; outpatient: $4,730[12,538] vs. 
$2,394[10,515]; drugs: $2,331[6,226] vs. $844[2,244]; p< .01 for all) and FXS-related costs 
(total: $5,890[16,541] vs. $1,744[10,149]; hospitalization: $2,730[13,628] vs. $788[9,506]; 
outpatient: $1,799[4,243] vs. $555[1,510]; drugs: $1,008[2,999] vs. $197[1,030]; p< .01 for 
all), compared to non-FXS controls. cOnclusiOns: The economic burden associated 
with FXS is significant and underscores the need to improve outcomes of individu-
als with FXS.
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DIRECT AND INDIRECT COSTS OF MS IN IRELAND
Fogarty E.1, Walsh C.2, McGuigan C.3, Barry M.1, Tubridy N.3
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 
3St. Vincent’s University Hospital, Dublin, Ireland
Objectives: Multiple Sclerosis (MS) has significant financial consequences for 
health care systems, individual patients and households, and the society in general. 
This study examines the distribution of MS costs and resource utilisation across cost 
categories and from various perspectives, as MS disability increases. MethOds: A 
total of 214 patients with MS were recruited from a specialised MS outpatient clinic 
in Dublin, Ireland, to participate in an interview-based study on MS-related resource 
consumption and costs. Mean annual direct medical, direct non-medical and indi-
rect costs per patient were calculated, stratified by MS disability: mild (n= 114), 
moderate (n= 72) and severe (n= 27). Results: Participants were 66% female; mean 
(sd) age 47.6(12.75) years; mean (sd) EDSS score 3.6(2.6); 53% relapsing-remitting 
MS. Mean annual direct costs increased as MS disability increased from ~€ 10,000 
in mild disease, more than five fold to ~€ 56,000 in severe MS. Direct costs exceed 
indirect costs in mild and severe MS, driven by costly disease-modifying therapies 
and professional home-help respectively. In contrast, indirect costs dominate in 
moderate MS (~€ 32,000 indirect vs. ~€ 13,000 direct) due primarily to early retire-
ment. Disease-modifying therapies account for 76% of total direct costs in mild MS. 
A total of 74%-96% of all direct costs are borne by the health care payer in Ireland. 
Remaining costs are incurred by patients, their families or other non-health care 
organisations predominantly relating to non-medical resources such as living-aids, 
home-modifications and home-help. cOnclusiOns: MS is associated with high 
levels of health care resource consumption and costs, which increase with disability. 
The majority of direct costs in our study are borne by the health care payer. However 
out-of-pocket spending at the individual patient level and the contribution of other 
organisations can be significant, particularly in severe disease. There is potential 
to significantly reduce the economic burden of MS through interventions which 
prevent progression to severe disability, support independent living at home and 
maintain labour force participation.
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THE ANNUAL TREATMENT AND REHABILLITATION COSTS OF PATIENTS wITH 
PARAPLEGIA IN THE PRIvATE HEALTH CARE SETTING IN GREECE
Tzovolou K., Geitona M.
University of Peloponnese, Corinth, Greece
Objectives: To examine the annual resource use and related treatment costs for 
patients with paraplegia in Greece in 2011. MethOds: This was a prospective study, 
which recorded data from all inpatient and outpatient visits to Olympion Hospital, a 
private rehabilitation center in Patras, during 2011. Patient files, which recorded the 
patients’ demographic, clinical and economic/ cost data, were created. Direct costs 
included medical and pharmaceutical costs, lab tests and direct non-medical costs, 
which were retrieved through the Center’s IT system. Indirect cost data consisted 
of the loss of individual and family income and were elicited via face-to-face or tel-
ephone interviews with the patients or their relatives. Each patient participating in 
the study signed an informed consent. Results: A total of 300 patients were treated 
in the rehabilitation center in 2011, of which 36 (12%) suffered from paraplegia. Of 
these, 20 were treated in the inpatient setting and 16 in the outpatient setting. The 
total average annual cost of treating patients with paraplegia was estimated at 
€ 101,228; the average costs of the inpatient and outpatient settings were € 86,699 
(€ 74,296 direct cost + € 12,403 indirect cost) and € 14,529 (€ 9,445 direct cost and € 5,084 
indirect cost) respectively. The mean number of hospitalization days for inpatients 
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NATALIzUMAB FOR RAPIDLy EvOLvING SEvERE RELAPSING-REMITTING 
MULTIPLE SCLEROSIS (RESRRMS) PATIENTS: 5-yEAR BUDGET IMPACT ANALySIS 
(BIA) FROM THE BRAzILIAN PUBLIC PAyER PERSPECTIvE
Nishikawa A.M.1, Paladini L.1, Liamas A.L.2, Bueno C.C.1, Clark O.A.C.1
1Evidencias, Campinas, Brazil, 2Biogen Idec Brasil, São Paulo, Brazil
Objectives: Multiple sclerosis (MS) is a neurodegenerative disease associated 
with long-term disability and significant economic impact. With the addition 
of new agents for the treatment of MS (e.g. natalizumab), there is a need to 
evaluate the relative value of newer therapies in terms of cost, given health 
care resource constraints in Brazil. This analysis considered just the indication 
for rapidly evolving severe relapsing-remitting multiple sclerosis (RESRRMS) 
patients (≥ 2 disabling relapses per year, and ≥ 1 gadolinium-enhancing lesions 
on brain magnetic resonance imaging or a significant increase in T2 lesion load). 
Brazilian reimbursement guidelines recommend natalizumab only as 3rd line 
treatment for MS. A budget impact analysis (BIA) has been created to analyze 
the impact of introducing natalizumab in RESRRMS treatment in Brazilian Public 
Healthcare System (SUS). MethOds: BIA was based on a Markov model with 
monthly cycles and 5-year time horizon with MS epidemiological data obtained 
from Brazilian public database (DATASUS). The model compared current MS 
treatment options reimbursed by the Brazilian government – interferons-betas, 
glatiramer acetate and natalizumab (3rd line) with an alternative scenario with 
1st line natalizumab. Results: The number of Brazilian patients eligible for 
REHARRMS treatment was estimated to be 1,574, 532 and 110 patients for 1st, 2nd 
and 3rd line treatment, respectively, in the first year. Compared to the current 
scenario, the inclusion of natalizumab in the reimbursement protocol for 1st 
line shows potential savings of USD 729.1K, 524.6K, 360.3K, 200.6K and 83.6K for 
5 consecutive years. cOnclusiOns: The inclusion of natalizumab as RESRRMS 
treatment option is estimated to yield savings of USD 1.9 M in five years for MS 
treatment in SUS.
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BUDGET IMPACT OF SwITCHING PRAMIPExOLE IMMEDIATE RELEASE TO 
PRAMIPExOLE ExTENDED RELEASE IN TREATMENT OF PARKINSON’S DISEASE; 
PERSPECTIvE OF THE SOCIAL SECURITy INSTITUTION
Kececioglu S.1, Ulus P.2, Cukadar F.3, Urganci B.3, Ozkan M.3
1Boehringer Ingelheim Turkey, Istanbul, Turkey, 2Boehringer Ingelheim Turkey, ISTANBUL, 
TURKEY, Turkey, 3Boehringer Ingelheim Turkey, ISTANBUL, Turkey
Objectives: Budget impact analysis of switching Pramipexole Immediate Release 
(IR) to Pramipexole Extended Release (ER) in treatment of Parkinson’s Disease in 
the Turkish health care setting from a Social Security Institution’s (SSI) perspec-
tive. MethOds: Based upon a literature review demonstrating that, Pramipexole 
ER is similar to Pramipexole IR in efficacy and safety in treatment of Parkinson’s 
Disease (non-inferiority), budget impact analyses were performed using Microsoft 
Excel (2007). Results: The switch from IR to ER was analyzed for the following 
formulations 0.75MG /1.50MG /3.00MG /4.50MG per day and patient. The daily 
pill burden per patient was reduced from 3 to 1 and 6 to 1 for 0,75MG /1,5MG 
/3,0MG and 4,5MG respectively. The total annual treatment cost per patient was 
reduced by 2.91%, 6.25%, 1.74% and 3.30% for 0.75MG, 1.50MG, 3.00MG and 4.50MG 
respectively. cOnclusiOns: The findings of this study indicate that, switching 
Parkinson’s Patients from Pramipexole IR to ER will not result in an additional 
budget impact for the Turkish health care system from a SSI perspective. However, 
further research needs to be conducted in order to explore the potential implica-
tions of compliance benefits and if they can be translated into long-term savings. 
No local effectiveness data was available at the time this analysis was performed. 
Potential benefits in patients’ adherence were not considered.
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HEALTH CARE RESOURCE UTILIzATION AND COST AMONG NATALIzUMAB 
INITIATORS wITH MULTIPLE SCLEROSIS IN THE UNITED STATES
Bonafede M.M.1, Johnson B.H.1, Watson C.2
1Truven Health Analytics, Cambridge, MA, USA, 2Biogen Idec Inc., Weston, MA, USA
Objectives: To evaluate MS-related health care resource utilization and costs 
prior to and after initiating natalizumab in the US. MethOds: A retrospective 
administrative claims analysis was conducted using the Truven Health MarketScan 
Commercial and Medicare supplemental databases to identify adults diagnosed 
with MS (ICD-9-CM 340) who initiated natalizumab between January 1, 2007 and 
December 31, 2010 (first claim is the index date). Patients had ≥ 24 months of 
continuous enrollment (12 months before [pre-period] and 12 months after [post-
period] the index date) and remained on natalizumab for the 12 month post-
period. Patients with and without other disease modifying treatment (DMT) during 
the pre-period were examined. Patient characteristics, MS-related inpatient stays 
and corticosteroid use were described in the pre- and post-periods. Results: The 
1458 patients in this study had a mean age of 45.2 years (standard deviation 10.5) 
and 74% were female. The majority (70.1%) used a DMT during the pre-period. After 
initiating natalizumab, there was a significant reduction in percentage of patients 
with MS-related inpatient stays (7.6% vs. 2.4%, p< 0.001), MS-related inpatient costs 
(median $12,078 vs. $9,784, p< 0.001) and length of stay (7.12 days vs. 6.26 days, 
p= 0.005). Reduction in percentage of patients with MS-related inpatient stays 
and costs were numerically higher for patients without DMTs in the pre-period 
(-6.2% and -$1,496 respectively) compared with those with a DMT in the pre-
period (-4.8% and -$1,262, respectively). Compared to the pre-period, there were 
significant reductions in IV and oral corticosteroid use for natalizumab initiators 
(-60.1% and -52.9%, respectively, p< 0.001 for both). These reductions correspond 
to a mean corticosteroid cost per patient reduction of $101 across all natalizumab 
users (p< 0.001). cOnclusiOns: The initiation of natalizumab was associated with 
significant decreases in MS-related inpatient stays and corticosteroid use with 
corresponding decreases in length of stay and costs among natalizumab users 
with and without DMTs in the prior year.
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Netherlands from a societal perspective. MethOds: Health care, patient and fam-
ily and other use of resources for five different categories of side-effects were 
measured by means of a questionnaire. Respondents were patients with epilepsy 
who experienced at least one side-effect due to antiepileptic treatment in the 
last 12 months. Results: Based on data from 203 chronic epilepsy patients, the 
overall societal costs of common side-effects in 2012 are estimated to be € 20,751 
(CI: 15,049-27,196) per patient per year in the base case analysis. These societal 
costs exist of: mean health care costs (€ 4,458), mean patient and family costs (i.e. 
informal care and out of pocket expenses) (€ 10,526) and mean other costs (i.e. pro-
ductivity and daily routine losses) (€ 5,761). Examining the different categories of 
side-effects separately, ranging from the most to the least expensive category, the 
cost estimates were as follows: other side-effects (€ 13,228), behavioral side-effects 
(€ 9,689), general health side-effects (€ 7,454), cognitive side-effects (€ 7,285) and 
cosmetic side-effects (€ 2,845) per patient per year. Subgroup analyses showed sig-
nificant differences in costs between patients using monotherapy and those using 
polytherapy when looking at cognitive and cosmetic side-effects. cOnclusiOns: 
These estimates should be considered in the overall assessment of the economic 
impact of a pharmacotherapy.
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HEALTH CARE RESOURCES UTILIzATION IN ALzHEIMER’S DISEASE: AN 
ANALySIS wITH THE QUEBEC PROvINCIAL DRUG REIMBURSEMENT PROGRAM 
DATABASE
Lachaine J.1, Lambert-Obry V.1, Dionne P.A.2
1University of Montreal, Montreal, QC, Canada, 2Pfizer Canada, Kirkland, QC, Canada
Objectives: To assess resource utilization before and after the development of 
Alzheimer’s disease (AD), using the Quebec provincial drug reimbursement program 
database (RAMQ). MethOds: This study included patients covered by the RAMQ 
who had at least one diagnosis of AD (ICD-9 code 3310) or have received at least 
one script for an AD medication (donepezil, rivastigmine, galantamine or meman-
tine) from January, 1985 to December, 2011. A control group of patients without AD 
was created on a 1:1 ratio and matched for age, gender and geographic location. 
The index date was defined as the date of the first AD diagnosis or the first script 
for AD medication whichever comes first. Health care resource costs were ana-
lyzed in terms of emergency room, outpatient clinic, intensive care unit and physi-
cian’s visits, hospitalizations and long-term care, plus AD medications and other 
medications costs. Annual health care costs were reported for the 5-years before 
and the 5-years after the index date. Results: Data were obtained for a random 
sample of 34,086 AD patients (mean age of 78.5 years [SD= 8.0], 65.2% females). 
Before the index date, health care costs were similar between AD patients and the 
control group, except for the year preceding AD. Indeed, cost per patient for this 
year increased from CDN$5,126 to CDN$8,839 for the AD group and from CDN$4,466 
to CDN$5,212 for the control group (72.4% vs. 16.7% increase respectively). For the 
5-year period after the index date, costs were significantly higher for AD patients 
with an average cost per patient per year of CDN$9,364 vs. CDN$5,864 for the control 
group (mean difference of CDN$3,500,p< 0.001). cOnclusiOns: AD significantly 
increases health care resource costs, including medical resources and medications. 
Costs generated by AD patients cumulate over time leading to a major difference in 
long-term costs compared to non-AD patients.
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COST EFFECTIvENESS OF APOMORPHINE IN THE TREATMENT OF ADvANCED 
PARKINSON DISEASE IN THE UK AND GERMANy: RESULTS FROM A 
MULTICOUNTy DECISION ANALyTIC MODEL
Walter E., Said M.
Institute for Pharmaeconomic Research, Vienna, Austria
Objectives: Parkinson Disease (PD) is the second commonest cause of neuro-
logical disability and affected approximately 5.2 million men and women world-
wide. Continuous subcutaneous apomorphine (CSAI) represents an alternative 
treatment option of advanced PD with motor fluctuation. The purpose of this 
analysis was to estimate the cost-effectiveness of CSAI compared with Levodopa/
carbidopa intestinal gel (LCIG), Deep-Brain-Stimulation (DBS) and Standard-of-care 
(SOC). MethOds: We developed a multicounty Markov-Model to simulate the long-
term consequences, disease progression (Hoehn&Yahr-stages 3-5, percentage of 
waking-time in the OFF-state), complications and adverse-events. Complications 
are different for the alternatives (e.g. pump problems in case of LCIG, temporary/
permanent complications in case of DBS). We include moderate and severe adverse-
events and death. Monte-Carlo-simulation accounted for uncertainty. The model 
includes 25 health-states. Probabilities were derived from RCT and open-label stud-
ies; direct costs (2012) from published sources from the payer’s perspective (NHS and 
German health care systems). QALYs, life-years (LYs) and costs were projected over 
a life-time horizon and discounted according the national guidelines. Results: UK 
life-time costs associated with CSAI amounts to 70,258 £ and generates 2.85 QALYs 
and 6.28 LYs (106,530 € , 2.92 QALYs and 6.49 LYs for Germany). Costs associated 
with LCIG are 117,121 £, achieves 3.06 QALYs and 6.93 LYs (178,405 € , 3.18 QALYs and 
7.18 LYs for Germany). The incremental-cost per QALY gained (ICER) was 223,052 £ 
(281,089 € ). Costs for DBS are 88,361.61 £, associated with 2.75 QALYs and 6.38 LYs 
(121,988 € , 2.85 QALYs and 6.61 LYs for Germany). CSAI dominates DBS. SOC associ-
ated UK costs are 68,082.92 £; 2.62 QALYs and 5.76 LYs were reached (91,588 € , 2.7 
3QALYs and 6 LYs for Germany). cOnclusiOns: CSAI is a cost-effective treatment 
alternative, reducing OFF-time and improving quality-of-life and is associated with 
a cost-advantage.
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COST-EFFECTIvENESS OF SOMATROPIN ADMINISTRATION wITH INCREASED 
ADHERENCE DUE TO MONITORING COMPARED TO NON-MONITORED 
ADMINISTRATION IN PATIENTS wITH GROwTH HORMONE DEFICIENCy
Vitova V., Tichopad A.
CEEOR s.r.o., Prague, Czech Republic
were 178. The key cost driver for inpatients was daycare (hospitalization, medical 
and nursing care, therapies). cOnclusiOns: The annual cost of treating patients 
with paraplegia in the private health care sector in Greece is high. This study is the 
first cost study in this disease area and additional studies should be undertaken in 
order to acquire a more complete picture of the cost of managing disease, in both 
the private and public health care sectors.
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BURDEN OF L-DOPA-INDUCED DySKINESIA IN PARKINSON’S DISEASE PATIENTS 
(PD-LID) IN FRANCE – THE LIDIA STUDy ECONOMIC ANALySIS (LEvODOPA 
INDUCED DySKINESIA IMPACT EvALUATION)
Kryskowiak P.1, Viallet F.2, Brefel-Courbon C.3, Durif F.4, Ory-Magne F.3, Tison F.5, Bourdeix I.6, 
Rérat K.6, Willemin L.6
1Hôpital Nord, Amiens, France, 2CH du Pays d’Aix, Aix-en-Provence, France, 3Hôpital Purpan, 
Toulouse, France, 4Hôpital Gabriel Montpied, Clermont-Ferrand, France, 5Hôpital Haut-Levêque, 
Bordeaux, France, 6Novartis, Rueil-Malmaison, France
Objectives: PD-LID, a complication of L-Dopa treatment, is associated with inabil-
ity to perform daily living activities, reduction in quality of life and increase in 
health care costs. Limited data are currently available on the burden of this dis-
ease. LIDIA describes medical and non-medical resource utilization and economic 
impact of PD-LID patients from payer and society perspective according to LID 
severity: mild (mAIMS score< 8), moderate (mAIMS [8-12]) and severe (mAIMS> 12) 
patients. MethOds: This observational, prospective, longitudinal, multicentre 6 
month-study was conducted by French neurologists specialized in Parkinson’s dis-
ease (PD). PD patients taking L-dopa for at least 3 years were included, with PD-LID 
present for more than 3 months and for more than 25% of the time. Results: 
Thirty-three neurologists included 186 patients (mean 68 years old, 52% women) 
with mean mAIMS score at 10. PD-LID patients were mainly followed by their neu-
rologists (96%) and general practitioner (GP) (84%) with more non-medical follow-up 
for severe patients. Almost 60% had at least one biological or radiological exami-
nation, only 31% required transport. All patients received L-Dopa (including 32% 
long-acting), and 69% dopaminergic agonists. Only 21% had at least one hospitali-
zation and over 40% needed home layout and mobility equipment. Most patients 
(70%) were assisted by a caregiver (24h/week), 43% required external assistance (6h/
week), 22% received an invalidity allowance. Total costs represent 35117€ , 33640€ and 
43739€ in respectively mild, moderate and severe patients (on average per patient/
year). Non-medical costs (transportations, paid external help, caregivers time, mobil-
ity equipment, home layout) are the major cost drivers (80%), including caregiver 
help (70%), followed by medical (consultations, treatments, hospitalizations)(15%) 
and indirect costs (allowances and work stoppages)(5%). cOnclusiOns: The LIDIA 
study confirms that in this disabling disease, the economic burden is mainly sup-
ported by the patient family, with the payer part being 23%. Economic burden is 
greater in patients with severe dyskinesia.
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HERPES zOSTER IN EUROPE: A REvIEw OF EvIDENCE DOCUMENTING 
HUMANISTIC, ECONOMIC AND SOCIETAL BURDEN
McCool R.1, Gater A.2, Préaud E.3, Baron-Papillon F.3, Largeron N.3
1Adelphi Values, Manchester, UK, 2Adelphi Values, Bollington, UK, 3Sanofi Pasteur MSD, Lyon, 
France
Objectives: Herpes zoster (HZ) and its most common complication post-herpetic 
neuralgia (PHN: pain persisting months after the rash onset) are associated with 
substantial burden of disease. There is a sharp increase in incidence from the 
age of 50, impacting individuals, their relatives and society. The objective of our 
work was to conduct a critical review documenting the Humanistic, Economic and 
Societal Burden of HZ in Europe. MethOds: Systematic searches were conducted in 
Medline, EMBASE, PSYCHINFO, EconLit, HEED and CRD databases, using a combina-
tion of search terms in title and abstracts. Articles, published from 2000 onwards, 
were selected for full review by two independent researchers in accordance with 
predefined eligibility criteria. Results: From a review of 1448 abstracts, 42 eligible 
articles, were identified which reported data concerning health care resource use 
(n= 26), direct costs (n= 21), indirect costs (n= 14), impact on health-related qual-
ity of life (HRQoL) (n= 21) and impact on caregivers (n= 3). Findings across studies 
highlight that levels of pain severity and the presence of PHN are associated with 
greater impairments in HRQoL and higher costs of management. At least 50% of 
employed patients missed work due to the disease. While the incidence of HZ and 
PHN increase with age, age was not a key driver of overall costs for HZ and PHN. 
Specifically, while direct costs (e.g. GP, specialists, medications, hospitalisations) 
tend to be higher for older patients, indirect costs (e.g. work time missed) are higher 
for younger patients. cOnclusiOns: Available evidence highlights that HZ and 
PHN result in significant humanistic and economic burden for patients, health care 
systems and wider societies. There is a tendency to focus upon health care resource 
use and the direct costs of management which may result in an underestimation 
of the true burden of HZ and PHN, which is also expected to grow with the ageing 
European population.
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SIDE-EFFECTS OF ANTIEPILEPTIC DRUGS: THE ECONOMIC BURDEN
de Kinderen R.J.A.1, Evers S.M.1, Postulart D.2, Vader C.I.2, Majoie M.H.2, Aldenkamp A.P.2
1Maastricht University, Maastricht, The Netherlands, 2Epilepsy Center Kempenhaeghe, Heeze, The 
Netherlands
Objectives: Epilepsy is a brain disorder which is characterized by recurrent 
unprovoked seizures. The outward effect of seizures can be as dramatic as a 
wild trashing movement or as mild as a brief loss of awareness. To reduce fre-
quency and severity of seizures, antiepileptic drugs are potentially an effective 
treatment for patients with epilepsy. However, side-effects are common. The 
negative consequences of side-effects can lead to treatment ranging from minor 
care to very expensive hospitalization. This cost analysis has been conducted 
to provide insight into the costs of side-effects due to antiepileptic drugs in The 
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in monotherapy and IFN+GA combined, it may be concluded that the first is a 
dominant strategy.
PND30
ECONOMIC EvALUATION OF THE TREATMENT COMPLIANCE IN PATIENTS wITH 
PARKINSON’S DISEASE RECEIvED DIFFERENT PREPARATIONS OF LEvODOPA
Ryazhenov V.V., Emchenko I.V.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To assess the cost-effectiveness of two conventional combinations 
of levodopa and decarboxylase inhibitors (benserazide or carbidopa) in the treat-
ment of Russian patients with Parkinson’s disease. MethOds: The pharmaco-
economic model was developed based on the data from multicentre randomized 
controlled triple-blind trial (H. Pakkenberg et al., 1976) on the efficacy and toler-
ance of levodopa+benserazide and levodopa+carbidopa in the treatment of patients 
with Parkinson’s disease previously not treated with levodopa. A six-month time 
horizon was adopted in the model. The cost analysis included costs of the original 
preparation of levodopa+benserazide and costs of the available in Russia generic 
preparations of levodopa+carbidopa and considered on-demand antiemetic treat-
ment with domperidone to reduce the incidence of gastrointestinal side effects 
of levodopa. The efficacy of treatment was defined as proportion of patients 
with full compliance to the treatment protocol and proportion of patients with-
out side effects (nausea and vomiting, hyperkinesia). Results: Treatment with 
levodopa+benserazide was associated with significantly lower incidence of patient 
non-compliance (43% as compared to 76% in the levodopa+carbidopa group). Less 
patients in levodopa+benserazide group experienced side effects of levodopa. The 
expenses for antiemetic treatment was 8.7-fold lower in patients treated with 
levodopa+benserazide as compared to those received levodopa+carbidopa. Total 
costs in levodopa+benserazide group were 912,264.90 RUB per 100 patients and 
varied from 682,154.60 RUB to 1,255,226.00 RUB in levodopa+carbidopa groups. The 
cost-effectiveness ratios (CERs) were 15,692.02 RUB and 21,988.11 – 45,866.08 RUB per 
one patient with full compliance to the protocol in the levodopa+benserazide and 
levodopa+carbidopa groups, respectively. The similar results were observed for the 
CERs estimated per one patient without side effects of levodopa. cOnclusiOns: 
The present study has demonstrated that administration of levodopa+benserazide 
is an economically effective strategy in the treatment of Russian patients with 
Parkinson’s disease.
PND31
PHARMACOECONOMIC ANALySIS OF DIFERENT ANTI-PARKINSONIAN DRUGS 
USED IN MONOPHERAPy DURING EARLy STAGES OF PARKINSON DISEASE
Belousov D.Y., Afanasyeva E.V., Efremova E.A.
Pharmacoeconomic research center, Moscow, Russia
Objectives: To evaluate the cost-effectiveness ratio of antiparkinsonian medica-
tion taken as monotherapy in patients with Parkinson’s disease (PD). MethOds: 
A cost-effectiveness analysis (CEA) of therapies including pramipexole ER, prami-
pexole, ropinirole, piribedil and rasagiline has been performed. Direct medical costs 
including costs of medications and treatment of adverse drug effects for 1-year 
therapy of PD have been considered. The clinical effect of selected antiparkinsonian 
medication was assessed in percentage of patients responding to treatment, and 
also by means of the UPDRS II-III scale. All calculations were done in RUR prices 
of 2013 (nominal exchange rate RUR/USD = 30/1). Results: Pramipexole ER has 
the lowest cost-effectiveness ratio (CER) of RUR 57,572 per patient/year respond-
ing to antiparkinsonian therapy. Hence, pramipexole ER was the most effective 
antiparkinsonian preparation studied in pharmacoeconomic terms. Based on cost-
effectiveness ratio, the medications evaluated can be arranged in the following 
order: pramipexole ER (RUR 57,572), pramipexole (RUR 59,548), piribedil (RUR 70,921), 
ropinirole (RUR 71,887), and rasagiline (RUR 91,112). The model results were robust 
to deterministic sensitivity analysis with variable drug costs. Limitations: Absence 
of direct comparative evidence from randomized, double-blind, controlled studies 
makes interpretation of the data difficult. Only short-term studies (up to 24 months) 
were available and hence do not allow to evaluate the influence of pharmacotherapy 
on motor fluctuations as well as other longterm factors. cOnclusiOns: The results 
of the present pharmacoeconomic analysis indicate that pramipexole ER is cost-
effective as first line therapy for the treatment of early stages of Parkinson’s disease 
from a Russian health care perspective. All five formulations evaluated, are well 
below the conditional “willingness to pay ratio” (equal to RUR 1,308607 in 2012). 
Hence, these preparations would qualify for application in the Russian system of 
public reimbursement.
PND32
COST-EFFECTIvENESS ANALySIS OF LACOSAMIDE COMPARED wITH 
STANDARD OF ANTIEPILEPTIC CARE BASED ON CLINICAL PRACTICE DATA
Vocelka M.1, Klimes J.1, Dolezal T.1, Foitova H.2
1VALUE OUTCOMES, s.r.o., Prague 2, Czech Republic, 2UCB, s.r.o., Prague 8, Czech Republic
Objectives: To perform a cost-utility analysis of lacosamide as add-on therapy 
to standard antiepileptic drugs (AEDs) compared to standard AEDs alone based 
on individual patients data derived from actual clinical practice in the Czech 
Republic. MethOds: Based on retrospective data collection of 409 patients with 
epilepsy treated with lacosamide for 6 months in actual clinical practice, we devel-
oped a cost-utility Markov cohort model. The model has 4 basic health states defined 
by number of seizures within 3 months plus 1 state represented by occurrence of 
severe side effects and 1 absorption state; death. Each health state was described 
by utility levels derived from literature. Transition probabilities for the first cycle 
were derived from observational study data and subsequently published literature. 
The model time-horizon was 20 years, 1 cycle length covered 3 months, and a 3% 
discount rate was used for costs and outcomes (Quality adjusted life years (QALYs)). 
Only costs attributed to drug acquisition were calculated, dosing of each AED was 
derived from the retrospective study. We performed probabilistic sensitivity analysis 
(PSA) with 3000 iterations using a willingness to pay (WTP) threshold equal to 3 
Objectives: All recombinant human growth hormones (rhGH) have the same 
molecular structure, therefore providing equal efficacy and safety, and are granted 
the same reimbursement in the Czech Republic (CR). All rhGH are currently 
administered subcutaneously once a day, differing only in applicators. Easypod 
is the only applicator that enables monitoring the dose, time and date of each 
injection and allows feedback control by doctors. The objective was to assess the 
cost-effectiveness of monitored rhGH treatment administered by Easypod with 
an increase in reimbursement of 10% compared to the standard non-monitored 
rhGH administration in CR. MethOds: The interim results (n= 596) of an ongo-
ing multicenter, non-comparative, observational, longitudinal study (ECOS) were 
used to populate deterministic cohort model. The model simulated long-term costs 
and benefits development of rhGH treatment. Evaluation was developed primar-
ily on evidence-based connection (from ECOS) between the monitoring of treat-
ment and patient adherence to the treatment. Increased adherence of monitored 
patients was transferred to the increased effectiveness of the treatment, based on 
published study. Model further transformed the long-term treatment benefits to 
the increased quality of life, using QALY as the target parameter using empirical 
transformation. Costs were expressed from the payer’s perspective. Results: Due 
to an increased adherence in monitored patients, the hypothetical cohort of 10,000 
boys generated 9,517 incremental QALY and CZK1.6 billion incremental costs in a 
lifetime horizon. A hypothetical cohort of 10,000 girls generated 11,504 incremental 
QALY and CZK1.35 billion incremental costs. The average cost per 1 QALY (ICER) is 
approximately CZK157,000 for the patient with GHD. cOnclusiOns: Monitoring 
of the treatment may lead to an increased adherence and more effective treatment 
at relatively low cost, hence being considered cost-effective. Sensitivity analysis 
showed that ICER did not exceed CZK500,000 upon the considered uncertainty.
PND28
THE COST EFFECTIvENESS OF BG-12 (DIMETHyL FUMARATE) FOR THE 
TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA
Su W.1, Walker A.2, Sarda S.3, Kansal A.R.1, Vicente C.4, Deniz B.3
1Evidera, Bethesda, MD, USA, 2Heron Evidence Development Ltd., London, UK, 3Biogen Idec, 
Weston, MA, USA, 4PIVINA Consulting Inc., Mississauga, ON, Canada
Objectives: Multiple sclerosis (MS) causes significant disability and diminished 
quality of life globally. BG-12 is a new oral treatment for relapsing forms of MS 
that is currently approved in the US and Canada and is under regulatory review in 
Europe. A cost-effectiveness model was developed to compare the health economic 
impact of BG-12 against other disease-modifying therapies (DMTs) as first-line 
treatment for relapsing-remitting MS (RRMS) from a Ministry of Health perspec-
tive in Canada. MethOds: A cohort-based Markov model was developed to simu-
late patients’ progression through a series of health states, based on the Kurtzke 
Extended Disability Status Scale (EDSS) over a lime-time horizon. Patients entered 
the model based on a distribution of baseline EDSS scores, from which they could 
either progress/regress to higher/lower EDSS state, or remain in the same state. 
Relapses could occur at any EDSS score. Results from a mixed-treatment comparison 
were used to inform model inputs for disease progression and relapse rates per 
treatment. In addition to the overall discontinuation rates reported in trials, patients 
discontinued treatment on conversion to secondary-progressive MS or reaching 
EDSS 7. Costs included direct medical costs stratified by EDSS score, along with 
relapse, adverse events (AEs), and treatment-related costs. Utilities were accrued 
based on time spent in each EDSS state, adjusted for disutilities associated with 
AEs and caregiver burden. A 5% discount rate was applied. Results: Compared 
with glatiramer acetate, BG-12 yielded 0.396 incremental quality adjusted life years 
(QALYs) at an incremental cost of CAD22,437, resulting in an ICER of CAD56,649. 
Compared with Rebif 44µg, BG-12 resulted in an ICER of CAD10,669. Results were 
consistent across a wide range of one-way and probabilistic sensitivity analy-
ses. cOnclusiOns: Based on traditional cost-effectiveness thresholds in Canada, 
BG-12 can be considered a cost-effective option compared to other first line DMTs.
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COST-EFFECTIvENESS OF GLATIRAMER ACETATE AND INTERFERON BETA-1A 
FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS, BASED ON THE COMBIRx 
STUDy
Darba J.1, Kaskens L.2, Sánchez-de la R.osa R3
1Universitat de Barcelona, Barcelona, Spain, 2BCN HEALTH, Barcelona, Spain, 3TEVA Pharma, 
Madrid, Spain
Objectives: To assess the cost-effectiveness of the Disease Modifying Treatments 
(DMT), Glatiramer Acetate (GA) and Interferon beta-1a (IFN) in monotherapy alone 
and in combination for the prevention of relapses with established Relapsing–
Remitting Multiple Sclerosis (RRMS) among Spanish patients aged between 18 and 
60 years old. MethOds: A Markov model was developed to represent the transition 
of a cohort of patients over a 10 year period using the perspective of the Spanish 
National Health Service (NHS). The model considered five different health states 
with one-year cycles including without relapse, patients with suspect, non-protocol 
defined and protocol defined exacerbations, as well as the category information lost. 
Efficacy data was obtained from the 3-year CombiRx Study. Costs were reported in 
2013 Euros and a 3%discount rate was applied for health and benefits. Deterministic 
results were presented as the annual treatment cost for the number of relapses. 
A probabilistic sensitivity analysis was performed to test the robustness of the 
model. Results: Deterministic results showed that the expected cost per patient 
was lower when treated with GA (€ 13,843) compared with IFN (€ 15,589) and the 
combined treatment with IFN+GA (€ 21,539). The number of relapses were lower in 
the GA cohort with 3.81 versus 4.08 in the IFN cohort and 4.18 in the cohort treated 
with IFN+GA. Results from probabilistic sensitivity analysis showed that GA has a 
higher probability of being cost-effective than the treatment with IFN or IFN+GA 
for threshold values from € 28,000 onwards, independent of the maximum that the 
Spanish NHS is willing to pay for avoiding relapses. cOnclusiOns: GA showed 
to be a cost-effective treatment option for the prevention of relapses in Spanish 
patients diagnosed with RRMS. When GA in monotherapy is compared with INF 
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over the time horizon of a patient’s lifetime were estimated at 20285, 144194, 299279, 
251255 and 69796 USD for symptom management, Avonex, Betaferon, Rebif and 
CinnoVex, respectively. As a result, the incremental cost per QALY for patients 
receiving Avonex, Betaferon, Rebif and CinnoVex was 607397, 1374355, 1166515 
and 1010429 USD, respectively, when compared with symptom management. The 
results were sensitive to changes in time horizon, disease progression and drug 
costs. cOnclusiOns: DMDs in RRMS patients is associated with increased benefits 
compared with symptom management, albeit at higher costs. Because patients 
receiving Avonex incurred slightly higher QALYs than patients receiving other 
DMDs, treatment with Avonex dominate other DMDs in Iran.
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COST-UTILITy ANALySES OF NATALIzUMAB vERSUS INTERFERON BETA-1A 
44 MCG FOR RAPIDLy EvOLvING SEvERE RELAPSING-REMITTING MULTIPLE 
SCLEROSIS (RESRRMS) PATIENTS IN BRAzIL
Nishikawa A.M.1, Paladini L.1, Liamas A.L.2, Bueno C.C.1, Clark O.A.C.1
1Evidencias, Campinas, Brazil, 2Biogen Idec Brasil, São Paulo, Brazil
Objectives: Multiple sclerosis (MS) is a neurologic disease that can dramatically 
affect patients’ quality of life. The aim of this study is to conduct a cost-utility 
analysis of natalizumab (Tysabri®) versus interferon beta-1a 44 mcg (Rebif®) – a 
commonly prescribed 1st line disease modifying therapy – in rapidly evolving severe 
relapsing-remitting MS patients from the Brazilian Public Healthcare System (SUS) 
perspective. MethOds: A Markov model with 20-year time horizon with health 
states based on Expanded Disability Status Scale (EDSS) and disease relapses 
was developed. Since there are no published data evaluating long-term course 
specifically in RESRRMS, it was assumed transition probabilities on EDSS states were 
based on natural history studies in unselected RRMS patients, and relapse prob-
abilities based on a post-hoc analysis of the placebo patients on pivotal natalizumab 
AFFIRM trial. In each monthly cycle, patients can discontinue treatment, remain 
stable, progress to higher EDSS state, experience progressive multifocal leukoen-
cephalopathy (PML) or die. For natalizumab, we assumed efficacy data on disabil-
ity progression and relapse from AFFIRM trial and for interferon beta-1a 44 mcg 
we assumed efficacy data on disability progression and relapse from pivotal trial 
PRISMS. Patients with EDSS score ≥ 7.5 receive best supportive care. Resource use 
and costs were validated by an expert panel and valued using Brazilian public offi-
cial lists (DATASUS and BPS). Costs and outcomes were discounted (5%). Probabilistic 
sensitivity analyses covered variability in efficacy and costs. Results: The use of 
natalizumab was associated with slower EDSS progression and reduced relapse 
burden. The quality-adjusted life years obtained with natalizumab and interferon 
beta-1a 44 mcg were 9.27 and 8.75, and costs were USD119,977 and USD132,446, 
respectively. In the base-case, natalizumab was dominant versus interferon beta-1a 
44 mcg. cOnclusiOns: For a patient with HARRMS, the model shows that natali-
zumab was dominant when compared to interferon beta-1a 44 mcg in the Brazilian 
Public Healthcare System.
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COSTS ASSOCIATED wITH THE IMPACT OF PROGRESSIvE MULTIPLE SCLEROSIS: 
INSIGHTS FROM A THREE yEAR CLINICAL TRIAL (THE CUPID TRIAL)
Green C.1, Shearer J.2, Zajicek J.3
1Exeter University, Exeter, UK, 2Kings College London, London, UK, 3Plymouth University, 
Plymouth, UK
Objectives: To estimate the costs associated with health and social care resource 
use in a UK cohort of people with progressive multiple sclerosis (MS). MethOds: 
Health and social care resource use data were collected prospectively over 33 
months from a cohort of 458 patients with progressive MS enrolled in a UK clinical 
trial (the CUPID Trial). Resource use data are used in combination with unit costs 
(2011 costs) from published UK national sources, and estimates of costs/prices 
where required. Costs for informal (unpaid) care are estimated using equivalent 
hourly home care rates for UK NHS and social care services. Data are presented 
over the 33-month period of follow, and also to allow comparison with other 
studies, against an estimated 6-monthly cost. Regression analyses were used to 
explore the impact on cost estimates from explanatory variables. Results: The 
main component of resource us and costs was informal care provided by friends 
and family, accounting for over 84% of the estimated costs over time. Excluding 
informal care, the most important cost items, within the remaining sub-total of 
costs, were social care (52%), health care services (23%), medications (10%), adapta-
tions (8%), and hospitalisations (6%). From a Payer perspective, the estimated mean 
six-monthly costs of health and social care were £927, but from a broader perspec-
tive the estimated six-monthly cost was £10,737, when private and patient costs 
were included. Regression analyses identified disease severity, as characterised by 
the EDSS, as the main explanatory driver of cost estimates. cOnclusiOns: This 
study presents new information to inform on the impact of progressive multiple 
sclerosis to add to the currently sparse evidence base. Data suggest that costs are 
considerable and fall mainly on patients and carers. The findings also confirm 
the central role of disability status in predicting overall costs associated with the 
impact of progressive MS.
NEUROLOGICAL DISORDERS – Patient-Reported Outcomes & Patient Preference 
Studies
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TREATMENT ADHERENCE AND COSTS IN MULTIPLE SCLEROSIS: A NARRATIvE 
REvIEw OF THE LITERATURE
Paz S., Comellas M., Lizán L.
Outcomes 10, Castellon, Spain
Objectives: To appraise the literature relating adherence and other patients’ 
reported outcomes (PROs) to Multiple Sclerosis (MS) costs. MethOds: Electronic 
databases [MedLine/PubMed, Google Scholar, Congress proceedings] were searched 
to identify publications analyzing MS costs related to adherence, persistence, sat-
times GDP per capita (43,000 EUR) in the Czech Republic. Results: Over a 20 year 
time-horizon, add-on lacosamide generated 11.47 QALYs and costs 33,439 EUR (per 
patient), whereas standard AEDs alone provided 11.09 QALYs and costs 22,916 EUR 
(per patient), respectively. The base-case ICER was calculated as 27,692 EUR/QALY. 
Based on the PSA and its cost-effectiveness acceptability curve (CEAC) we calculated 
that add-on lacosamide has a probability of cost-effectiveness at 43,000 EUR per 
QALY gained of 80.2% compared to standard AEDs alone. cOnclusiOns: Based 
on data from clinical practice lacosamide as add-on treatment in patients with 
partial-onset seizures is cost-effective under the WTP threshold implicitly applied 
in the Czech Republic.
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COST EFFECTIvENESS OF PHARMACOGENETIC SCREENING PRIOR TO 
INITIATION OF CARBAMAzEPINE TREATMENT FOR EPILEPSy
Plumpton C.O.1, Yip V.2, Alfirevic A.2, Marson A.3, Pirmohamed M.2, Hughes D.A.1
1Bangor University, Bangor, UK, 2University of Liverpool, Liverpool, UK, 3Walton Centre for 
Neurology and Neurosurgery Foundation Trust, Liverpool, UK
Objectives: Carbamazepine (CBZ) is a widely-used, first-line treatment in epilepsy. 
However, CBZ is associated with hypersensitivity adverse drug reactions (ADRs) 
ranging from mild rash such as maculopapular exanthema, to hypersensitivity 
syndrome, Steven-Johnson syndrome and toxic epidermal necrolysis (TEN). TEN is 
associated with a mortality rate of up to 30%. The presence of the HLA-A*3101 allele 
is associated with an increased risk of CBZ-induced hypersensitivity reactions [OR 
9.1, 95% CI, 4.0 to 20.7]. HLA-A*3101 is present in 2% - 5% of populations of Northern 
European descent. We aim to investigate the cost effectiveness of pharmacoge-
netic testing for HLA-A*3101prior to initiation of CBZ treatment in patient with 
epilepsy. Patients testing positive for the allele are prescribed an alternative antie-
pileptic drug, lamotrigine. MethOds: A decision analytic model was developed to 
represent the first three months post initiation of anti-epileptic drug, to cover the 
period when the majority of severe ADRs manifest. A Markov model (cycle length 
1 year) was used to simulate costs (from the perspective of the NHS in the UK) and 
utilities incurred in subsequent years. This enables modelling of costs and disutili-
ties from long term sequelae of severe ADRs as well as the effectiveness of treatment 
in terms of remission of seizures. Transition probabilities, costs and utilities were 
sourced from patient level data from the SANAD trial [Lancet 369(9566):1000-15] 
and relevant literature. Results: Compared with no pharmacogenetic testing, and 
prescribing CBZ for all patients, the test results in an incremental cost effective-
ness ratio of £26,684 per QALY gained. The probability that testing is cost-effective 
at a threshold of £30,000 per QALY is 0.55, and the cost of preventing a single ADR 
is £35962. cOnclusiOns: Pharmacogenetic testing for HLA-A*3101 prior to treat-
ment with CBZ might be cost-effective for populations of North European descent.
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COST-MINIMIzATION ANALySIS OF TREATMENT OF SPASTICITy wITH 
BOTULINUM TOxIN TyPE A
Tapias G.1, Crespo C.2, Cuesta M.3, Forne C.3, Garcia-Romero M.4, Pascual-Pascual S.I.4
1Ipsen Pharma, Sant Feliu de Llobregat, Spain, 2University of Barcelona, Barcelona, Spain, 
3Oblikue Consulting, Barcelona, Spain, 4Hospital Universitario La Paz, Madrid, Spain
Objectives: Botulinum toxin type A (BoNT-A) is considered one of the treatments 
of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy 
(CP) patients, two years of age or older by decreasing hyperactivity and increasing 
muscle tone in patients. The aim was to compare the cost of Botox® (Allergan) and 
Dysport® (Ipsen), considering the administered dose per weight (U/kg) in child 
patients with equinus foot CP related. MethOds: We performed an observational, 
longitudinal and retrospective study with data from clinical records from December 
1995 to October 2012. Records included patients younger than 18 years old with 
spasticity treated with BoNT-A at the Pediatric Neurology Service of the Hospital of 
La Paz (Madrid), with recorded birth and visit dates, weight and dose by muscle. Cost 
analysis only evaluated four muscle groups (pronator teres, adductor, semitendi-
nosus and triceps surae) including only direct costs (drug and visit costs). We used 
bootstrap as sensitivity analysis to assess the robustness of results. Costs were in 
euros 2013. Results: A total of 895 patients treated with BoNT-A for spasticity (543 
treated with Botox®, 292 with Dysport® and 60 with both) were included. Baseline 
characteristics and follow-up were similar in both groups. Patients had an average 
dose infiltrated per visit of 5.44 U/kg (SD 2.17) for Botox® and 14.73 U/kg (SD 5.26) 
for Dysport®, and average yearly visits of 3.71 for Botox® and 3.46 for Dysport®. The 
annual total cost per patient was 850 € for Botox® and 636 € for Dysport®. Of these 
total costs, annual visit costs of 362 € for Botox® and 347 € for Dysport®, and annual 
drug costs were 488 € for Botox® and 289 € for Dysport®. cOnclusiOns: Based on 
the real-world management of pediatric spasticity patients with BoNT-A observed 
in our study, Dysport® could reduce annual total costs per patient.
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COST-UTILITy ANALySIS OF DISEASE-MODIFyING DRUGS IN RELAPSING-
REMITTING MULTIPLE SCLEROSIS IN IRAN
Imani A., Golestani M., Tabrizi J.S., Janati A.
Tabriz Medical University, Tabriz, Iran
Objectives: Disease-modifying drugs (DMDs) are a significant expenditure for 
treating multiple sclerosis. However, assessment of the cost-utility of DMDs com-
pared with symptom management in the presence of long-term data has been lim-
ited. To assess the lifetime cost-utility from the Iranian health care perspectives of 4 
disease-modifying drugs relative to symptom management alone in patients with 
relapsing-remitting multiple sclerosis using evidence from long-term published 
studies. MethOds: A Markov model was developed with patients transitioning 
through health states based on Kurtzke expanded disability status scale (EDSS). 
Patient costs included drug costs, other medical and lost worker productivity costs. 
Patient quality of life was considered in the form of utilities. Costs were valued in 
2011 USD, and costs were discounted at 7.2%per annum. Various parameters and 
assumptions were tested in sensitivity analyses. Results: Total costs per patient 
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DyNAMICS OF QUALITy OF LIFE IN CHILDREN wITH CySTIC FIBROSIS AGED 
5-16 yEARS
Simonova O., Gorinova Y., Vinyarskaya I., Samsonova M., Chernikov V.
FSBI Scientific Center of Children’s Health, RAMS, Moscow, Russia
Objectives: For improvement of aiding effectiveness both for clinicians and spe-
cialists in the field of health care system one should know quality of patient’s life 
in different time period rating of the disease. MethOds: 70 cystic fibrosis (CF) 
children from Russia and CIS countries 5-16 years were interviewed using HUI ver-
sion 15Q, while children over 12 years responded on their own (self assessment), 
information about children younger 12 years was obtained from parents (proxy 
assessment) .Version was translated into russian language and adapted. HUI cur-
rently consists of two systems: HUI Mark 2 and HUI Mark 3. Each HUI2 and HUI3 
classification system consists of attributes (domains) of health and 3 to 6 levels of 
functional ability/disability within each attribute and is very responsive to changes 
and to highlight avenues of additional study. Single-attribute utility scores and 
multi-attribute utility scores evaluated corresponding to each system, ranges from 
0 to 1. Results: Mean Mark 2 has a tendency to increase from 0,85 in children 
5 years to 0,95 in children 15 years with reduction in 6 years (0,80), 12 years (0,85) 
and 16 years (0,85). Same tendency was observed in Mark 3: 6 years- 0,75; 12 years- 
0,75; 16 years- 0,77 cOnclusiOns: Decrease of quality of life in above mentioned 
ages is a result of unadequate treatment in children living in some regions of CIS 
and severe complications of CF in older children also.
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HEALTH RELATED QUALITy OF LIFE (HRQL) IN PARKINSON’S DISEASE: THE 
IMPACT OF ‘ON’ AND ‘OFF’ TIME
Kerr C1, Howard C.E1, Johnston K2, Smith H.T.3, Lloyd E3, Cooper J.A3, McIntosh E.4,  
Lloyd A.J.1
1Oxford Outcomes, An ICON plc Company, Oxford, UK, 2Oxford Outcomes, An ICON plc Company, 
Vancouver, BC, Canada, 3GSK, Brentford, UK, 4University of Glasgow, Glasgow, UK
Objectives: Diurnal variation in symptoms and functioning is a feature of 
Parkinson’s disease, referred to as ‘on’ and ‘off time’. Typically patient reported 
outcomes (PROs) don’t capture this variability or its value, instead requesting par-
ticipants report over the last day or week. This study evaluated the impact and value 
of ‘on’ and ‘off time’ for people with Parkinson’s (PwP) by assessing their HRQL and 
strength of preference. MethOds: PwP from UK, Spain, France and Italy (n= 305), 
experiencing ≥ 2 hours ‘off time’ daily, completed EQ-5D-5L assessments for ‘on’ 
and ‘off time’ that day, followed by a discrete choice experiment (DCE) evaluating 5 
treatment attributes: duration of ‘on time’; quality of ‘off time’; predictability of ‘off 
time’; feelings of anxiety/depression, and dosing frequency. The DCE was informed 
by qualitative work with patients (n= 20), carers (n= 6) and health professionals (n= 6) 
in UK and Spain and employed an orthogonal, factorial, fold-over design. Analysis 
used the mixed-logit model and effects coding of categorical levels (predictability of 
off-time attribute). Results: Mean EQ-5D utility values were significantly lower for 
‘off time’ (0.37, 95%CI: 0.33-0.40) than ‘on time’ (0.60, 95%CI: 0.57-0.62). All attributes 
were significant drivers of treatment choice. PwP valued increased duration of ‘on 
time’ (per hour per day: OR= 1.40, 95%CI 1.31-1.45) and predictability of ‘off time’ 
most highly (predictability to within 30 minutes of symptoms returning: OR= 1.42, 
95%CI 1.15-1.57). High disutility was reported for substantial unpredictablility of ‘off 
time’ (OR= 0.67, 95%CI 0.49-0.91). cOnclusiOns: Important differences in quality 
of life between ‘on’ and ‘off time’ were found which could be missed by standard 
PRO assessment, including the relative value that PwP placed on increased dura-
tion of ‘on time’ and predictability of ‘off time’. Assessments and interpretation of 
outcomes in Parkinson’s should consider diurnal variation. Capturing this variation 
and its value may require modifications to PRO design. [Study HO-11-802]
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CULTURAL ADAPTATION AND vALIDATION TO SPANISH OF THE “MS 
TREATMENT CONCERNS QUESTIONNAIRE-MSTCQ”
Galera J.1, Munteis E.2, Navarro G.3, Meca J.4, Maestre A.5, Perez A.6, Gracia J.7, Pato A.8
1Novartis Pharma, Barcelona, Barcelona, Spain, 2Hospital del Mar, Barcelona, Spain, 3Hospital 
Virgen de Macarena, Sevilla, Spain, 4Hospital Virgen de la Arrixaca, Murcia, Spain, 5Hospital de 
Jaén, Jaén, Spain, 6Hospital General de Alicante, Alicante, Spain, 7Hospital de Albacete, Albacete, 
Spain, 8Hospital de POVISA, Vigo, Pontevedra, Spain
Objectives: Albeit effectiveness of subcutaneous treatments for Multiple 
Sclerosis (MS) has been demonstrated, adverse reactions and pain may entail prob-
lems regarding treatment satisfaction and continuity. This study aims to adapt 
and validate the Spanish version of the “Multiple Sclerosis Treatment Concerns 
Questionnaire-MSTCQ”, which evaluates satisfaction with the injection device (ID) 
in 4 dimensions: Injection system (A), Side-effects (B) (flu-like symptoms, reactions, 
and satisfaction), Treatment experience (C) and Benefits (D). MethOds: Two Stages: 
1) Cultural adaptation: Forward-backward translation and expert (n= 6) and patient 
(n= 30) panels; 2) Validation: Observational, cross-sectional, multicenter study. A 
total of 143 adult patients suffering from MS and using an ID were evaluated. Tools 
employed: MSTCQ, Patient-Reported Indices for Multiple Sclerosis (PRIMUS), Treatment 
Satisfaction Questionnaire for Medication (TSQM), Morisky Green and Patient Injection 
Site Reaction (ISR) and Injection Site Pain (ISP). Psychometric properties: Feasibility 
(% valid cases and ground/ceiling effects); Reliability (Cronbach α ) and test-retest 
(41 patients, Intraclass Correlation Coefficient, ICC); as well as construct (Factorial 
analysis of dimensions A and B, FA) and convergent (Spearman MSTCQ vs. TSQM) 
validity. Results: Mean age(SD) in cases was 41,94(10,47) years, 63% female, 88,11% 
suffering from Relapsing-Remitting MS. MSTCQ feasibility was adequate (missing 
0%-2,80%). High internal consistency, total score (A+B) α = 0, 89, by dimensions α (A, 
B and C): 0,76, 0,89 and 0,92, respectively. Furthermore, a concordance was found 
between total (ICC= 0, 98) and by dimensions ICC (A, B and C) scores: 0,82, 0,97 and 
0,89, respectively. The FA confirms dimensions A and B from the original question-
naire. Lastly, the association between total and by dimensions scores, from MSTCQ 
and TSQM was, overall, moderately strong (Rho between-0, 74, y 0, 42) and significant 
isfaction and preferences for MS treatments. Bibliographic references were hand 
searched. English or Spanish studies published between January 2007 and January 
2013 were selected. Results: A total of 398 citations were identified; 12 studies 
accomplished the inclusion criteria. Six referred to PROs and treatment costs; 4 
analyzed satisfaction with disease-modifying therapies (DMTs) and 2 assessed pref-
erences for treatment attributes. An increased adherence and persistence on DMTs 
was associated to higher pharmacy costs and to better clinical outcomes [lower 
relapse risk (OR= 0.71 CI 95%, 0.59-0.85); decreased MS hospitalizations (OR= 0.63, 
CI 95%, 0.47 – 0.83)] leading to a cost reduction of up to 22% patient/year. DMT 
adherent patients had a significantly lower rate of severe relapses (12.5% vs. 19.5%; 
p= 0.0200), lower MS-related or all-causes medical (7.6% vs. 12.5%; p= 0.0447 and 
11.2% vs. 20.0%; p= 0.0027) and emergency visits (8.9% vs. 15.0%; p= 0.0215 and 34.6% 
vs. 43.5%; p= 0.0305) than non-adherent. MS-related and all-cause inpatient costs 
(354.77±2.485.03 vs. 853.13±3,635.48; p= 0.0270 and 648.71±3,753.74 vs. 62.51±265.23; 
p= 0.0018) as well as emergency visit costs (46.46±255.94 vs. 1,740.88±6,127.27; 
p= 0.0076 and 147.82±430.79 vs. 242.42±592.96; p= 0.0044) were significantly lower 
in adherent patients. Self-injection [Visual Analogue Scale (VAS) mean 6.9; range 
0-10] render higher treatment satisfaction. Slower disability progression (efficacy) 
was the most preferred attribute (p< 0,001). Newly developed electronic devices 
that allow adjusting injection settings as well as adherence objective monitoring 
appeal more to patients (VAS mean 7.7; range 0-10) than more traditional methods 
of administration. cOnclusiOns: MS studies assessing adherence and costs are 
scarce. Treatments and devices better tailored to patients’ needs improve adherence, 
enhance clinical outcomes and procure a reduction on MS costs.
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HEALTH STATE (QALy) vALUES FOR MULTIPLE SCLEROSIS: A REPORT USING 
DATA FROM THE UNITED KINGDOM SOUTH wEST IMPACT OF MULTIPLE 
SCLEROSIS (SwIMS) STUDy
Green C.1, Hawton A.1, Zajicek J.2
1Exeter University, Exeter, UK, 2Plymouth University, Plymouth, UK
Objectives: To present health state values (QALY weights) for multiple scle-
rosis (MS) health states using data from a prospective, longitudinal, cohort 
study. MethOds: Data from a large UK cohort study for MS, the South West Impact 
of MS (SWIMS) Study, were used for analysis. SWIMS data comprise six-monthly 
self-report assessments, including EQ-5D and SF-36 health status measures, and 
data on relapse frequency/severity. Self-report data is supplemented with data 
from clinician assessment of disability using the EDSS. Health state valuation data 
are sourced from published UK tariffs (EQ-5D and SF-6D) to present values for MS 
against EDSS, relapse characteristics, and against other disease related characteris-
tics. Results: Analyses of SWIMS data included 1,441 respondents, over an average 
of 8 time-points. Findings on health state values show a health profile that wors-
ens by disease progression, against EDSS stages, using both the EQ-5D and SF-6D 
methods. Health state values estimated from EQ-5D data range from 0.76 at EDSS 
stage 1.0 to 0.03 at EDSS stage 8, with lower values seen for progressive MS. Values 
estimated from SF-36 data reflect the narrower range of values possible on the SF6D 
tariffs, with values from 0.7 to 0.53 across EDSS stages 1.0 to 8. Findings demonstrate 
impact on health state values due to relapse events, with this impact reported at 
0.08 using the EQ-5D and at 0.05 using the SF-6D. The impact of relapse frequency, 
severity and endurance on health has also been assessed. cOnclusiOns: This 
study presents health state valuation data derived from a high quality longitudinal 
cohort study, including values (QALY weights) for features/characteristics of relapse 
events in people with MS. This data can support improvements in the conduct of 
cost-effectiveness analyses of treatments for MS, and can be helpful in a general 
health policy context.
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CAREGIvER BURDEN IN FRAGILE x SyNDROME AS A FUNCTION OF A HEALTH 
STATE UTILITy INDEx IN THE UNITED STATES
Raspa M.1, Bishop E.2, Candrilli S.D.3, Mitra D.3, Sacco P.4, Petrillo J.4, Bailey D.1
1RTI International, Research Triangle Park, NC, USA, 2RTI International, Atlanta, NC, USA, 3RTI 
Health Solutions, Research Triangle Park, NC, USA, 4Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA
Objectives: To assess the association between burden experienced by caregivers 
of patients with fragile X syndrome (FXS) in the United States and a health state 
utilities index derived from the Aberrant Behavior Checklist-Community (ABC-
C). MethOds: A total of 340 US caregivers of children with FXS completed a ques-
tionnaire that captured information on FXS-related burden (i.e., specialist visits, 
medical tests, medications, financial burden, employment status, paid and unpaid 
caregiving, caregiver injuries, and mental health). Using the ABC-Utility Index 
(ABC-UI), an estimate of health-related quality-of-life derived from the ABC-C, five 
utility index categories were created: very low (0.00–0.33); low (0.34–0.66); moderate 
(0.67–0.77); high (0.78–0.89); and very high (0.90–1.00). After controlling for sex, age, 
overall ability level, and income, multivariable regression models documented the 
association between utility score and the nine burden-related outcomes. Results: 
Respondents (283 with FXS male child; 57 with FXS female child) were mostly female 
(91%), Caucasian (92%), and married (84%), with mean age of 50 years. Approximately 
2% of individuals with FXS were in the very low utility category, 30.6% low, 27.1% 
moderate, 37.6% high, and 2.6% very high. The mean utility score was 0.71. Females 
with FXS and adults ≥ 18 years had higher health utilities. Results from regression 
models indicate that increasing utility values reduced the likelihood of ≥ 5 (vs. < 5) 
specialist visits (b= -4.583; p< 0.001) and ≥ 2 (vs. 0 or 1) prescription medications 
used (b= -4.517; p< .001). Similarly, increasing utility score was associated with a 
decreased likelihood of ≥ 8 (vs. < 8) hours of unpaid caregiving (b= -2.723; p= 0.003), 
≥ 1 (vs. 0 or 1) caregiver injuries (b= -7.540; p< 0.001), and ≥ 1 (vs. 0) mental health 
provider visits (b= -2.613; p= 0.002). cOnclusiOns: The ABC-UI appears to function 
well as a health-related quality-of-life indicator in individuals with FXS. Among 
caregivers of patients with FXS in the US, significant differences in burden exist 
across health state utilities.
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A prospective multinational, multicenter (84 centers in 22 countries), observational, 
post-marketing, longitudinal study (ULIS-2), investigating routine use of BoNT-A for 
treating post-stroke ULS. Primary outcome: achievement of the patient’s primary 
goal for treatment using Goal Attainment Scaling (GAS). Goals were set together by 
physicians and patients/caregivers. Patients were able to rate goals for importance. 
Secondary outcome: global assessment of benefits by both physician and patients/
caregiver. Results: Among the 456 adults with post-stroke ULS presenting for 
treatment with BoNT-A, the most commonly selected primary treatment goals were 
passive function (132 (28.9%)), active function (104 (22.8%)), pain (61 (13.4%), and 
impairment (105 (23%)). Patients rated 404/456 primary goals (88.6 %) as “impor-
tant” (395/456 (86.6%) as “very” or “moderately” important), indicating high patient 
involvement in goal-setting. Overall, 363 (79.6%) (95% CI 75.6% to 83.2%) patients 
achieved (or overachieved) their primary goal. GAS T-scores were strongly correlated 
with rating of global benefit and other standard measures (correlations of 0.38 
and 0.63, respectively; p< 0.001). cOnclusiOns: Patient-centered goal setting and 
evaluation using GAS to calculate changes of health-related status is a feasible way 
to capture changes in ULS patient experience. GAS as primary outcome measure in 
ULIS-2 is a step closer to a PRO in ULS patients.
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PATIENT PREFERENCES AND PRIORITIES FOR ANTI-EPILEPTIC DRUG 
TREATMENT
Fargher E.A.1, Marson A.2, Jacoby A.3, Ring A.3, Williamson P.3, Hughes D.A.1
1Bangor University, Bangor, UK, 2Walton Centre for Neurology and Neurosurgery Foundation 
Trust, Liverpool, UK, 3University of Liverpool, Liverpool, UK
Objectives: Clinical trials in epilepsy may not routinely prioritise patient-oriented 
outcomes that consider the harms of treatments in addition to their benefits. To 
date, no systematic empirical research has been undertaken to assess the views of 
people with epilepsy about treatment outcomes. The aim was to identify which out-
comes of drug treatment are considered important to three groups of adults with 
epilepsy: (i) recently diagnosed, (ii) established diagnosis, (iii) women of childbearing 
age. MethOds: Semi-structured individual interviews containing ranking exercise 
were used to explore views and interpretations of benefits, harms, and potential life-
impacts of anti-epileptic drug treatments (n= 41); the feasibility of these findings were 
evaluated in focus groups of health care professionals responsible for prescribing anti-
epileptic drugs (n= 8) . Outcomes ranked 1-4 were scored 4-1. For each group, scores 
were summed and divided by the number of participants. Results: Ten recently diag-
nosed men (mean age 45.9), 13 established (mean age 39.3, 92% male), and 18 women of 
childbearing age (mean age 34.5) participated. Reduction in seizure frequency was the 
most highly ranked outcome of drug treatment across all three subgroups (women of 
childbearing age [score]= 2.5, recent= 2.4, established= 2.23). Adults recently diagnosed 
were most concerned about feelings of aggression (1.6), depression (1.0) and ability to 
work (0.9). Adults with established epilepsy were most concerned with ability to work 
(1.15) negative impacts on relationships (1.0), memory problems (0.69), and social-
life (0.69). Women of childbearing age were concerned about memory (1.22), reduced 
independence (0.78), feeling in control (0.56) and foetal abnormality (0.5). Clinicians 
considered life-impacts (eg work, relationships, independence) as consequences of 
benefits and harms of treatment. cOnclusiOns: The importance of remission from 
seizure was consistent. However, patients’ rankings of unfavourable outcomes of drug-
treatment varied by subgroup. Selection of outcome measures in clinical trials in epi-
lepsy must consider relevant patient-oriented outcomes which differ by population.
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EvALUATING FATIGUE IN FIBROMyALGIA: DEvELOPMENT AND vALIDATION OF 
THE DAILy DIARy OF FATIGUE SyMPTOMS IN FIBROMyALGIA (DFS-FIBRO)
Burbridge C.1, Symonds T.1, Humphrey L.2, Arbuckle R.2, Hirsch I.3, Whelan L.1
1Pfizer Ltd., Surrey, UK, 2Adelphi Values, Bollington, UK, 3Astra Zeneca, Cheshire, UK
Objectives: Despite being recognised as an important symptom in Fibromyalgia 
(FM), existing measures of fatigue are unlikely to meet regulatory standards for clini-
cal trial endpoints. We therefore describe the development and validation of a new, 
electronically administered patient reported outcome (ePRO) measure of fatigue in FM 
- the Daily Diary of Fatigue Symptoms-Fibromyalgia (DFS-Fibro). This was developed in 
accordance with the FDA regulatory guidance and ISPOR good practice recommenda-
tions for the development and validation of PROs. MethOds: Initial item generation 
was based on concept elicitation interviews with 40 FM patients (from the US, Germany 
and France), and clinical relevance of the findings was confirmed by expert clinician 
review. The draft tool was pilot tested with 20 FM patients for 5-9 days, followed by 
cognitive debriefing interviews. A methodology study with 145 FM patients then fol-
lowed, providing data to conduct the psychometric validation of the measure. Both the 
qualitative and quantitative findings were used to finalise the DFS-Fibro. Results: 
Twenty-three items were generated from concept elicitation interviews, including 
items focussed on the physical and cognitive impacts of fatigue as well as fatigue 
‘symptom’ items. Some minor wording revisions were made following pilot testing 
and cognitive debriefing, but none were deleted. All patients found the measure easy 
to understand and use. Initial psychometric analyses supported removing items previ-
ously identified as candidates for deletion in the qualitative work, resulting in a 5-item 
measure focussed on the core symptom of FM fatigue. The psychometric analyses 
were then repeated on the final 5-item measure, which had very high internal consist-
ency (alpha = 0.99), strong test-retest reliability (r > 0.84), and met a priori criteria for 
convergent and known groups validity. cOnclusiOns: The DFS-Fibro development 
followed accepted guidelines and demonstrates strong psychometric properties and 
content validity as a measure of the symptom of fatigue in FM.
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EvALUATING PATIENT ADHERENCE RATES TO APPROvED DISEASE MODIFyING 
THERAPIES (DMT) FOR RELAPSING-REMITTING MS (RRMS): OPERATIONAL 
SETUP FOR A MULTI-COUNTRy, MULTI-CENTER STUDy
Apecechea de Scheffer M., Faber S., Potthoff P., Eichmann F.
Kantar Health Germany, Munich, Germany
(p< 0,05; p< 0,01). cOnclusiOns: The Spanish version of the MSTCQ questionnaire 
is a feasible, reliable and valid tool for the evaluation of satisfaction with the injec-
tion device in the treatment of MS.
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ELICITING PATIENTS’ PREFERENCES FOR EPILEPSy DIAGNOSTICS: A DISCRETE 
CHOICE ExPERIMENT
Wijnen B.F.M.1, de Kinderen R.J.A.1, Colon A.J.2, Dirksen C.D.3, Essers B.A.B.4, Hiligsmann M.1, 
Leijten F.F.S.5, Ossenblok P.P.W.2, Evers S.M.1
1Maastricht University, Maastricht, The Netherlands, 2Epilepsy Centre Kempenhaeghe, Heeze, The 
Netherlands, 3Clinical Epidemiology and Medical Technology Assessment, Maastricht University 
Medical Centre; CAPHRI, Maastricht University, Maastricht, The Netherlands, 4Clinical and 
Medical Technology Assessment, Maastricht University Medical Centre; CAPHRI, Maastricht 
University, Maastricht, The Netherlands, 5Brain Center Rudolf Magnus, University Medical Centre 
Utrecht, Utrecht, The Netherlands
Objectives: Diagnosing epilepsy is a lengthy and burdensome process for patients 
and their family. Although the need for a more patient-centered approach in clini-
cal practice is widely acknowledged, empirical evidence regarding patient prefer-
ences for diagnostic modalities in epilepsy is missing. The objectives of this study 
are 1) to identify to what extent important attributes of diagnostic procedures in 
epilepsy affect preferences for a procedure; 2) to determine the relative importance 
of these attributes; and 3) to calculate overall utility scores for routine electroen-
cephalography (EEG) and magnetoencephalography (MEG) registrations. MethOds: 
A discrete choice experiment was performed to determine patients’ preferences, 
which involved presentation of pair-wise choice tasks regarding hypothetical sce-
narios. Scenarios varied along six attributes: “Way of measuring brain activity”; 
“Duration”; “Freedom of movement”; “Travel time”; “Type of additional examina-
tion”; and “Chance of additional examination”. Choice tasks were constructed using 
a statistically efficient design and the questionnaire contained 15 unique unlabeled 
choice tasks. Mixed multinomial logistic regression was used to estimate patients’ 
preferences. Results: A total of 289 questionnaires were included in the analysis. 
McFadden’s pseudo R2 showed a model fit of 0.28 and all attributes were statistically 
significant. Heterogeneity in preferences was present for all attributes. “Freedom 
of movement” and “Chance of additional examination” were perceived as the most 
important attributes. Overall utility scores marginally differ between MEG and 
routine EEG. cOnclusiOns: Our study suggests that the identified attributes are 
important in determining patients’ preference for epilepsy diagnostics. It can be 
concluded that MEG is not necessarily more patient-friendly than a routine EEG in 
primary diagnostics and, regarding additional diagnostics, patients have a strong 
preference for long-term 24h EEG over EEG after sleep deprivation. Furthermore, 
barring substantial heterogeneity within the parameters in mind, our study sug-
gests that it is important to take individual preferences into account in clinical 
decision-making.
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QUALITy OF LIFE OUTCOMES IN MULTIPLE SCLEROSIS: A REvIEw OF THE 
LITERATURE
Rouse M., McKenna S., Twiss J., Graham J.E., Wilburn J.
Galen Research Ltd., Manchester, UK
Objectives: Multiple sclerosis (MS) is a chronic neurodegenerative disease affecting 
the central nervous system. There are a variety of symptoms and activity limitations 
associated with MS including mobility problems, muscle spasticity, fatigue and 
mental health problems. In order to gain an accurate insight into the impact of MS 
on patients it is important for accurate patient-reported outcome (PRO) instruments 
to be applied. The purpose of this review was to evaluate the available MS-specific 
PRO measures. MethOds: The online literature databases PubMed, Psychinfo and 
Web of Science were used for the search. The search identified all studies that used 
a PRO measure in the study design and was restricted to publications from the 
last fifteen years. Only measures used in at least three clinical trial studies were 
included. The measures identified were evaluated in terms of; source of items, 
item reduction methods, unidimensionality, practicality, responsiveness, reliability, 
internal consistency and face, content and construct validity. Results: The search 
yielded 2317 articles, of which 1066 were duplicates and removed. The review of the 
remaining articles identified six measures that met the review criteria: MSIS-29, 
LMSQoL, MSQoL-54, HAQUAMS, MSQLI and PRIMUS. In addition, the MUSIQoL was 
reviewed because of recent development activity. Most of the measures exhibited 
some weaknesses. Only the PRIMUS performed well on all the review criteria. It 
was the only measure to apply a clear theoretical framework and meet the strict 
measurement requirements of the Rasch model. cOnclusiOns: The PRIMUS is 
recommended for use in clinical trials. The review suggests that many clinical trials 
are using PROs that have not benefitted from the use of Item Response Theory and 
modern psychometric approaches.
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PATIENT-CENTERED OUTCOMES IN UPPER LIMB SPASTICITy: RESULTS FROM A 
LARGE INTERNATIONAL COHORT STUDy (ULIS-2)
Balcaitiene J.1, Kurth H.2, Fheodoroff K.3, Jacinto J.4, Turner-Stokes L.5
1IPSEN Pharma, Boulogne-Billancourt, France, 2IPSEN Pharma, Boulogne Billancourt, France, 
3Gailtal-Klinik, Hermagor, Austria, 4Serviço de Reabilitação de adultos 3, Alcoitão, Portugal, 
5King’s College London, London, UK
Muscle spasticity following stroke may interfere with motor and activity perfor-
mance, cause pain, and lead to secondary complications. Goals of spasticity man-
agement include improving function (active and passive) and body image, and 
facilitating concomitant treatments. The efficacy of BoNT-A in upper limb spasticity 
(ULS) patients focusing on reduction of muscle tone and pain is well established. 
However, there are no specific ULS patient-reported outcome measures (PROs) avail-
able. As patients with ULS are highly heterogeneous, there is a need to develop meas-
ures to capture realistic, patient-specific treatment goals. Objectives: To assess 
effectiveness of BoNTA on ULS considering patient-specific experience. MethOds: 
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36 (-9.50 [-10.97, -8.04; P< 0.0001], n= 584). PRIMUS ALS scores also improved from 
baseline (mean change [95% CI]) to Week 12 (-2.47 [-2.83, -2.11; P< 0.0001], n= 501) 
and Week 36 (-1.53 [-1.96, -1.10; P< 0.0001], n= 437) in patients on treatment. Results 
for the change from baseline to Week 48 for outcomes, including the SF-36 PCS, in 
patients on treatment will be presented. cOnclusiOns: PR-fampridine, which 
improves walking in MS, shows benefits on HRQoL through 36 weeks of treatment.
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QUALITy OF LIFE IN PATIENTS wITH MULTIPLE SCLEROSIS IN SLOvAKIA
Bielik J.1, Tomek D.2, Tomekova K.3, Novak I.4, Andrasova E.4
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4Novartis Slovakia, Bratislava, Slovak Republic
Objectives: The current prevalence of Multiple Sclerosis (MS) in Slovakia ranges 
from 100 till 150 cases per 100 000 population Being a typical chronic disease 
with tendency of progression, MS can have a great impact on quality of life (QoL). 
The objective of this paper was to find out the level of QoL in patients with MS in 
Slovakia. MethOds: The primary method used for the analysis of QoL was the 
presence of disability period and combined questionnaire consisting of 4 parts: 
A. Demography and socioeconomics (13 items), B. Generic questionnaire (SF-36), 
C. Visual scale (4 items), D. Complementary (information and habits, 13 items). There 
were 2 groups of patients. Group A: 41 (29 women, 12 men) patients were treated by 
conventional therapy. Group B: the 41 (32 women, 9 men) patients were treated by 
moderns disease modifying treatment and biological therapy (Betaferon, Avonex, 
Rebif, Tysabri, Gilenya, Copaxone). The average age in the group A was 50.59 vs 
41.82 years in the group B. Results: Disability was 9,39 months per one patient 
per year in group A vs 5,02 in group B, loss of income was 123 vs 165 € per person, 
the expectations of the future was 2,39 vs 2,41 (in the five degrees scale). Present 
level of QoL was identified as 5.29 vs 4,34 on the scale of 10, while in the time of the 
MS diagnosis it was 3,29 vs 2,15. QoL was 8.68 vs 8,17 in the time without SM and 
9,24 vs 8,29 in the total optimal state of health. cOnclusiOns: The treatment of 
MS by conventional or disease modifying therapy (DMT) had a significant impact 
on QoL. The modern DMT had the higher statistical influence as on physical health 
(45,65 vs 28,23) so on mental health (51,65 vs 33,01) in comparison with the patients 
treated by conventional therapy.
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CORRELATION BETwEEN MONTGOMERy-ASBERG DEPRESSION RATING SCALE 
(MADRS) AND THE BECK DEPRESSION INvENTORy II (BDI-II) IN PATIENTS wITH 
FOCAL EPILEPSy
Garcia M.E.1, García I.1, Gil-Nagel A.1, Garcia M.2, Lara N.2
1Hospital Clínico San Carlos., Madrid, Spain, 2IMS Health, Barcelona, Spain
Objectives: To determine the correlation between the Montgomery-Asberg 
Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI-II) 
scores in patients with drug-resistant focal epilepsy (DRE) in comparison with 
patients with controlled focal epilepsy (CFE). MethOds: Observational, cross-
sectional study performed in patients with focal epilepsy (FE) with and without 
DRE, ≥ 18 years. Presence and severity of depression were measured using validated 
Spanish versions of the Montgomery-Asberg Depression Rating Scale (MADRS) and 
the Beck Depression Inventory (BDI-II). In order to know the correlation between 
MADRS and BDI-II, two different criteria were used; degree of association obtained 
on prevalence of depression and correlation between scores from both scales, using 
Pearson correlation coefficient. Results: 515 patients (DRE= 248) were included. 
Using the MADRS scale, prevalence of depression in the DRE group was almost 
double than in the CFE group (59.3% vs. 30.3% using unadjusted data and 62.1% vs. 
32.6% using adjusted data; p< 0.001). Similar results were seen with the BDI, with 
an overall depression rate of 48.1% using the ≥ 10 point threshold, and considerably 
higher rates of depression in the DRE group compared to CFE patients (61.9 % vs. 
35.3% using unadjusted data, and 64.8% vs. 37.2% using adjusted data; p< 0.001). 
Correlation between MADRS and BDI-II was 24,4 % (65/266) in CFE and 51,0% 
(126/247) in DRE patients, according to the degree of association; while the Pearson 
correlation coefficient between the two scales was high, at r= 0.80. cOnclusiOns: 
MADRS and BDI-II showed a positive correlation; the score increment of one scale 
is directly proportional to the increase of the other scale. In both cases, the strong-
est contributor to higher MADRS and BDI-II scores was having a previous clinical 
diagnosis of depression but being untreated for the condition.
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ADDITIONAL CLINICAL BENEFIT FOR PATIENT RELEvANT ENDPOINTS: 
INvESTMENT DISINCENTIvES By AMNOG IN THE ExAMPLE OF PARKINSON’S 
DISEASE
Walzer S.1, Holbein B.2
1MArS Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany, 2University of 
Bremen, Bremen, Germany
Objectives: After the introduction of the new German law AMNOG a statistically 
significant and clinically meaningful difference in patient relevant endpoints are 
required in order to achieve a (significant) clinical benefit for a new (drug) ther-
apy. The question remains if such an incentive is sufficient in all disease areas 
for positive investment decisions for the pharmaceutical industry. MethOds: In 
Parkinson’s disease motor fluctuations and dyskinesias are two major patient rel-
evant outcomes. Different target profiles for a clinical development programme 
of a theoretical new treatment were developed including scenarios following the 
regulatory guidelines only, an efficacy-driven programme and one including the 
above mentioned key patient relevant endpoints. An investment decision model was 
developed based on these profiles with respect to additional clinical benefit by the 
joint federal committee and premium pricing in Germany were assessed. Results: 
Positive investment decisions were possible for the regulatory and efficacy-driven 
Objectives: DMTs constitute an important backbone of MS treatment. To inves-
tigate Health Related Quality of Life (HRQOL) and patient adherence rates to the 
approved DMTs for RRMS among geographically and culturally diverse patient 
populations, a multinational study was to be implemented. Operational and sci-
entific outcomes are presented. MethOds: The study was designed as an obser-
vational, multicenter, multinational post marketing study. Patients and physicians 
received paper questionnaires evaluating adherence to DMTs approved at the time 
of the study. HRQOL (MusiQol) and a Neuropsychological Questionnaire (MSNQ) 
also were applied. Results: The study was implemented in 22 countries. Special 
challenges: cross-cultural CRF design, country-specific recruitment procedures for 
sites and patients, country/site specific contractual arrangements. Ethical approval 
was collected from 70 local and 15 central institutions. Patient recruitment was 
performed via 176 neurologists (hospital and office based). In total, 2.566 patients 
were enrolled within 6 months. Average treatment duration / observational period 
covered 31 months. The study findings revealed that 75% of the patients were adher-
ent (i.e. not missing an injection or changing dose). 12.6% of all patients forgot to 
administer injections compared to 50% of non-adherent patients. Compared to 
non-adherent patients, adherent patients showed shorter disease duration (adher-
ent: median 6.0 yrs; non-adherent: Median 7.0 yrs.), significant shorter treatment 
time (30.0 months vs. 36.0 months; p< 0,001) and a better MSNQ score (18.0 vs. 22.0; 
p< 0,001). cOnclusiOns: For implementing a global multicenter center impor-
tant issues include: linguistic specifics for CRF development, availability of medical 
centers for site recruitment, country specific legal and ethical requirements, care-
ful organization and sharing of responsibilities between the study coordination 
center and local affiliates. Non-adherence to DMT in RRMS was demonstrated to 
be mainly caused by injection problems; adherent patients showed better clinical 
and HRQOL outcomes.
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wELLBEING, LIFE SATISFACTION AND PROGRESSION IN ALzHEIMER’S DISEASE 
– AN ALSOvA FOLLOw-UP STUDy
Väätäinen S., Hongisto K., Hallikainen I., Välimäki T., Martikainen J.A., Koivisto A.
University of Eastern Finland, Kuopio, Finland
Objectives: To examine the quality of life (QoL) of the Alzheimer’s Disease (AD) 
patients in relation to disease progression during the five-year ALSOVA follow-up 
study. MethOds: The baseline sample consisted of 240 subjects with very mild 
or mild AD, 65 years or older, from three Finnish hospital districts. The subjects 
were recruited between 2002 and 2006, and were followed-up for five years. Three 
separate patient-reported wellbeing and life satisfaction instruments were used as 
proxy variables for QoL: a generic, preference-based health-related quality-of-life 
instrument, 15D; an AD -specific wellbeing measure, AD-QOL; and a VAS-based 
life satisfaction scale. AD progression was evaluated with the Clinical Dementia 
Rating (CDR). Both CDR Sum-of-Boxes (CDR-SOB) and global rating were used in the 
analysis. Generalized linear mixed models with hierarchical structure were applied 
to account for repeated measures and possible clustering by the hospital district. 
Data were adjusted for age, sex and years of education. Results: On average, none 
of the three outcome measures demonstrated statistically significant changes over 
time during the five year follow-up. However, when the outcomes were examined 
in relation to AD progression, both CDR-SOB and CDR global rating demonstrated 
statistically significant association between the severity of AD and lower QoL on all 
three outcome measures. However, when using CDR global rating to define disease 
progression, we observed meaningful impairments in QoL variables only in the 
patients with severe AD (CDR 3). cOnclusiOns: Severe AD has a considerable 
impact on patients’ QOL through substantial impairments in wellbeing and life 
satisfaction. Evidence suggest that CDR-SOB is a potential continuous measure of 
AD severity. While CDR-SOB is strongly associated with decrease QoL measures, our 
observations indicate that it is unlikely to be linearly correlated with QoL. Thus, the 
use of CDR-SOB as a determinant of QoL needs to be examined further.
PND51
LONG-TERM PROLONGED-RELEASE FAMPRIDINE TREATMENT AND HEALTH-
RELATED QUALITy OF LIFE OUTCOMES: INTERIM RESULTS OF THE ENABLE 
STUDy
Nagels G.1, Macdonell R.2, Soelberg Sorensen P.3, Pozzilli C.4, Laplaud D.5, de Jong B.6,  
Silva A.M.7, Nicholas R.8, Gaebler J.A.9, Sun J.9, Agarwal S.S.9
1National MS Centre Melsbroek and Vrije Universiteit Brussel, Melsbroek, Belgium, 2Austin 
Health, University of Melbourne, Heidelberg, Victoria, Australia, 3Danish MS Center, Copenhagen 
University Hospital Rigshospitalet, Copenhagen, Denmark, 4Sapienza University, Rome, Italy, 
5CHU de Nantes, Hôpital G. et R. Laennec, Nantes, France, 6Radboud University Nijmegen Med 
Center, Nijmegen, The Netherlands, 7Hospital Santo António-Centro Hospitalar do Porto, Porto, 
Portugal, 8Imperial College, London, UK, 9Biogen Idec, Weston, MA, USA
Objectives: Prolonged-release (PR) fampridine tablets (dalfampridine extended 
release in US) improve walking in some patients with multiple sclerosis (MS). The 
ENABLE study assessed the effect of long-term PR-fampridine treatment on health-
related quality of life (HRQoL) in MS patients with walking impairment. MethOds: 
ENABLE is an open-label, 48-week study to evaluate the effect of PR-fampridine 10 
mg twice daily on HRQoL in MS patients. Patients completed the Timed 25-Foot 
Walk (T25FW) at baseline and Weeks 2 and 4, and the 12-item MS Walking Scale 
(MSWS-12) at baseline and Week 4. Patients with any improvement in T25FW 
speed at both Weeks 2 and 4, and any improvement in MSWS-12 score at Week 
4 remained on treatment. HRQoL measures are assessed at baseline and Weeks 
12, 24, 36, and 48, and include the Short-Form Health Survey (SF-36), Multiple 
Sclerosis Impact Scale (MSIS-29), and the Patient Reported Indices for MS Activity 
Limitations Scale (PRIMUS ALS). The primary endpoint is the change from baseline 
in the SF-36 physical component summary (PCS) score at each visit in patients on 
treatment. Results: At Week 4, 704 patients (78.1% of total enrollment [N= 901]) 
met the criteria to remain on treatment. Interim results at 36 weeks in patients 
on treatment show improvement from baseline (mean change [95% CI]) in MSIS-
29 Physical scores to Week 12 (-12.99 [-14.24, -11.74; P< 0.0001], n= 672) and Week 
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A multi-center retrospective chart-review study of MS patients conducted in United 
Kingdom (UK), France (FR), Germany (DE), Italy (IT), Spain (SP) and US to collect 
de-identified data on diagnosis, clinical status and DM approaches. Health care 
providers (HCPs; 95% neurologists) were screened for duration of practice (> = 3yrs) 
and patient volume (> = 15 MS patients/month) and recruited from a large panel to be 
geographically representative in each country. Medical charts of next 10 consecutive 
MS patients were selected by each physician. Results: A total of 3490 eligible MS 
patient charts were abstracted by 360 HCPs (mean age:47yrs; female: 31%; mean 
practice duration:18yrs; mean # of patients seen per month:63; % working in spe-
cialty MS clinic:45%). Patient mean age: 39yrs; female: 66%; top-5 comorbidities: 
depression (14%), anxiety (10%), hypertension (8%), obesity (7%), migraine/headache 
(6%). Tests used by physicians to diagnose MS varied between the countries (UK/
FR/DE/IT/SP/US: %): History/Neurological exam – 79/88/99/95/97/88, Gadolinium 
MRI – 56/93/66/93/96/89, T1 MRI – 49/89/80/84/93/74, T2 MRI – 65/89/66/91/94/82, 
CSF analysis – 51/82/71/3/90/56, Evoked potentials – 34/48/65/77/80/29. Patients 
with moderate/severe disease and currently on disease modifying treatments 
(DMTs) varied (UK/FR/DE/IT/SP/US: %): 50/45/37/58/50/47 & 52/71/75/77/73/78; cor-
respondingly, tests used by physicians to assess MS disease progression/activity 
also varied between the countries (UK/FR/DE/IT/SP/US: %): EDSS–63/83/84/91/92/40, 
Neurological exam–81/91/88/89/84/86, Gadolinium MRI–33/69/36/90/68/70, T1 MRI–
21/53/53/76/54/54, T2 MRI–29/62/41/89/63/65, Ambulation index–9/13/9/24/16/19, 
Brain atrophy–4/14/6/23/15/18, Nine hole peg test–6/3/10/5/3/1 and PASAT–
1/0/12/5/4/1. cOnclusiOns: UK physicians appear to under-utilize the tests to 
diagnose/manage MS patients, whereas physicians in Spain often used them more 
frequently. Observed trends were not correlated to the patient disease severity 
observed in these settings, warranting further scrutiny of observed patterns to 
optimize MS management.
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DRUG COMPLIANCE AND PERSISTENCE IN PATIENTS wITH PARKINSON’S 
DISEASE TREATED IN PRIMARy CARE IN THE UNITED KINGDOM: A CPRD-BASED 
STUDy
Bineau S.1, Guelfucci F.2, Neine M.3, Aballea S.3, Milea D.1
1Lundbeck S.A.S., Issy-Les-Moulineaux, France, 2EPHE Sorbonne, Paris, France, 3Creativ-Ceutical, 
Paris, France
Objectives: Differences in compliance and persistence between Parkinson’s dis-
ease (PD) drugs were found in a previous US claim database analysis. The objective 
was to apply the same methodology in another setting using the Clinical Practice 
Research Datalink (CPRD) in the UK. MethOds: A retrospective analysis of patients 
starting a new PD drug (rasagiline, selegiline, pramipexole, ropinirole, entacapone, 
tolcapone, levodopa) between January 2009 and January 2012 was conducted using 
CPRD. Patients were categorized as naive to PD therapy (NT) or having prior PD 
therapy (PT), depending on the prescription of other PD drugs within a 12-month 
look-back period. The observation period was 12 months. Compliance was measured 
using the medication possession ratio (MPR) and non-compliance was defined as 
an MPR≤ 80%. Persistence was measured as the duration (days) of uninterrupted 
therapy without gap higher than 45 days. Results: Of the 4,784 patients included 
in the compliance analysis, 3,675 patients (76.8%) had compliance rates > 80%. Mean 
MPRs were generally comparable across PD products (range:84%-90%, all pairwise 
p= NS). Percentage of patients with MPR> 80% was significantly greater with rasagil-
ine (85.6%, all p< 0.05 except vs. ropinirole p= NS). Of the 5,266 patients included in 
the persistence analysis, the highest mean number of persistent days of treatment 
was reported for rasagiline (284 days; all p< 0.05 vs others, except vs. ropinirole 
p= 0.14 and levodopa p= 0.06). Patient persistence at 12 months was significantly 
greater with rasagiline compared with others in NT patients (66.5%, all p< 0.05) 
scenarios even though that the additional clinical benefit profile was uncertain and 
pricing not optimal. When developing potential budget estimates based on sample 
size and complexity of a clinical trial for motor fluctuations or dyskinesias as pri-
mary endpoint a significant clinical benefit was highly likely and premium pricing 
possible. However, a positive investment decision was uncertain due to the high 
development cost. cOnclusiOns: Even though there are incentives to add patient 
relevant endpoints in the development programmes the return on investment could 
potentially not be high enough for a positive investment decision. Target profiling 
including market access and pricing outcomes could optimize investment decisions.
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DISEASE BURDEN AMONG PATIENTS wITH MULTIPLE SCLEROSIS NOT 
RECEIvING DISEASE MODIFyING TREATMENTS IN EUROPE AND THE UNITED 
STATES
Narayanan S.1, Khan H.2, Gabriele S.2, White J.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess clinical characteristics of MS patients not on any DMTs in key 
countries in European Union (EU) and the U.S. MethOds: A multi-country multi-
center medical chart-review study of MS patients was conducted in 4Q2012 among 
Health care providers (HCPs; > 85% neurologists) in hospitals and private practices 
to collect de-identified data. HCPs from UK, Germany, France, Italy and Spain (5EU) 
and the US were screened for duration of practice (> = 3yrs) and patient volume 
(> = 15 MS patients/month) and recruited from a large panel to be geographically 
representative in each country. Medical charts of next 10 consecutive MS patients 
were completed by each physician. HCPs abstracted patient diagnosis, treatment 
patterns and patient symptomatology/disease status. MS patients not on any 
DMTs were analyzed. Results: A total of 967 eligible MS patients were included 
in the analysis (5EU:749; US:218). Mean age (yrs) – 5EU:39.0yrs, US:42.2yrs; Female – 
5EU:69%; US:67%. Key reasons for not receiving DMTs were (5EU/US): mild/early-MS 
(35%/36%), patient refusal (26%/44%), progressive/severe/advanced-MS (20%/17%), 
lack of efficacy of current treatment options (10%/14%), side-effects/tolerance/co-
morbidities (6%/12%), waiting for DMTs to become available (5%/12%) and funding/
authorization/guidelines (4%/7%). Among patients who refused DMTs, more than 
half were not convinced of therapy benefits. Distribution of MS type was (5EU/US): 
Clinically Isolated Syndrome (CIS)-26%/25%, Relapse Remitting MS (RRMS)-44%/49% 
and Secondary Progressive MS (SPMS)-30%/26%. Patients with moderate/severe dis-
ease and those with active/highly active disease (both, per physician judgment) 
were (5EU/US): CIS:10%/11%, RRMS:25%/40%, SPMS:95%/86%, and CIS:31%/44%, 
RRMS:39%/37%, SPMS:36%/32% respectively. Mean Expanded Disability Status Scale 
score were (5EU/US): CIS:0.8/0.7, RRMS:1.8/2.2, SPMS:6.5/5.6); % patients currently 
suffering a relapse were (5EU/US): CIS:20%/29%, RRMS:21%/15%, SPMS:6%/16%; 
% patients with > = 1 relapses in last 12months were (5EU/US): CIS:69%/69%, 
RRMS:52%/58%, SPMS:18%/32%. cOnclusiOns: Among MS patients not on any 
DMTs, disease burden seems substantial. Further research is warranted to scrutinize 
the observed patient management practices to alleviate patient burden.
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DISEASE BURDEN AMONG PATIENTS wITH SECONDARy PROGRESSIvE 
MULTIPLE SCLEROSIS CURRENTLy USING DISEASE MODIFyING TREATMENTS 
IN EUROPE UNION AND THE UNITED STATES
Narayanan S.1, Khan H.2, Gabriele S.2, White J.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess disease burden of SPMS patients treated with DMTs in 
EU and the U.S. MethOds: A multi-country chart-review study of SPMS patients 
was conducted among neurologists in hospitals/private practices to collect de-
identified data. Neurologists from UK/Germany/France/Italy/Spain (5EU) and 
US were screened for practice-duration (> = 3yrs) and patient-volume (> = 15MS 
patients/month) and recruited from a large panel to be geographically representa-
tive in each country. Charts of next 2 consecutive SPMS patients were selected 
by each neurologist. Neurologists abstracted patient diagnosis, treatment pat-
terns and patient symptomatology/disease status. SPMS patients on DMTs were 
analyzed. Results: In 4Q2012, 360 Neurologists (5EU:259; US:101) abstracted 699 
eligible SPMS patient charts (5EU:497; US:202); 420 (5EU:274; US:146) patients were 
managed with DMTs. Mean age – 5EU:46.5yrs, US:49.2yrs; Female – 5EU:58%; US:66%. 
Mean time-to-1st DMT initiation (5EU/US; months) from diagnosis was 21/27; cur-
rent DMT patterns (5EU/US) were: 1st line (25%/34%), 2nd line (39%/38%) & 3rd+ 
line (36%/28%). Interferon beta-1b (5EU) and glatiramer acetate (US) were predomi-
nantly observed in 1st/2nd line; fingolimod and natalizumab use was observed 
in 2nd-line but they dominated later lines. Mean time-to-1stDMT initiation (5EU/
US: months) from diagnosis (1st:45/35, 2nd:13/30, 3rd+:12/10) and mean treatment 
time (5EU/US: months) on current 1st (85/91), 2nd (38/35; prior 1st line: 57/48) and 
3rd+ line (19/24; prior 2nd line: 35/46) differed. Patients with severe disease and 
those with active/highly active disease (both, per physician judgment) were (5EU/
US): 1st:15%/20%, 2nd:20%/18%, 3rd+:35%/37% and 1st:45%/61%, 2nd:63%/73%, 
3rd+:57%/68% respectively; mean Expanded Disability Status Scale scores also dif-
fered (5EU/US): 1st:5.1/5.0, 2nd:5.6/5.5, 3rd+:5.8/6.1. cOnclusiOns: Among SPMS 
patients currently managed with DMTs, the disease burden increased as the line 
of treatment increased, both in 5EU and the US. Patients in 2nd/3rd+line of treat-
ments had progressed through earlier line(s) of treatment quickly. Further research 
is warranted to scrutinize the effectiveness of therapeutic options and sequencing 
strategies to alleviate patient burden.
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PATTERNS OF USE OF TESTS TO DIAGNOSE AND ASSESS DISEASE PROGRESSION 
IN MULTIPLE SCLEROSIS (MS): A MULTICOUNTRy COMPARISON
Narayanan S.1, Khan H.2, Gabriele S.2, White J.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess the patterns of use of tests to diagnose and assess disease 
progression/activity in MS in the European Union and United States (US). MethOds: 
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ment was associated with 38% fewer unplanned admissions (981 vs. 604, X1
2 = 
89.2, p< 0.001) and 58% fewer unplanned bed nights (8,817 vs. 3,681, X12 = 2109.8, 
p< 0.001) in the year following treatment initiation compared with the year before. 
A 14% reduction in all outpatient appointments was also observed, due principally 
to a 25% reduction in neurological outpatient appointments (from 7,826 to 5,901, 
X1
2 = 269.7, p< 0.001). Evidence from this study indicates that duration of treat-
ment is a significant factor in this response; patients receiving between 12 and 
14 doses (n= 1,122) experienced 70% reduction in unplanned admissions and 90% 
reduction in unplanned bed nights. cOnclusiOns: Our data support the notion 
that natalizumab treatment significantly reduces unplanned hospital treatment 
and outpatient attendance.
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PRESCRIBING PATTERNS OF PARKINSON’S DISEASE
Tomita N., Kanatani Y.
National Institute of Public Health, Wako, Japan
Objectives: Parkinson’s disease has the second largest number of patients among 
56 designated diseases/syndrome of the Specified Disease Treatment Research 
Programme for rare and intractable disease programme. The purpose of this study 
were to investigate prescribing patterns of Parkinson’s disease and its pharmaceuti-
cal expenditures. MethOds: We analysed the Social Health Insurance (SHI) claims 
data processed from February to April 2011 provided by the Planning, Review and 
Research Institute for Social Insurance and Medical Program. Results: During the 
three months, 52,851 patients in Social Health Insurance programme received medi-
cal treatments that cost 9,391,451,520 JPY. Average costs for inpatient care without 
meal expense and for outpatient care were 263,782 JPY and 33,209 JPY respectively. 
Except the cases that fell into Diagnosis Procedure Combination (DPC), 37% of the 
total cost, 3,515,091,420 JPY was for pharmaceutical expenditure including dispens-
ing fee. Only 7,437,873 (23.5%) of 31,699,153 dispensed drugs were generics on a 
volume basis. If all the pharmaceutical that have generics had been substituted, 
estimated 899,586,280 JPY would have been saved in the study period by simple 
arithmetic. Generic usage is fewer in the elderly than in the younger generation in 
all therapeutic categories. cOnclusiOns: Percentage of pharmaceutical expend-
iture in total health expenditure for Parkinson’s disease is high. Our study find 
that generic substitution rate is low in general and even lower in the elderly. This 
might be partly related to the medical expense subsidy under the Specified Disease 
Treatment Research Programme, which exempts eligible patients from co-payment 
according to their income. There seems to be a room for prescribing pattern change 
for cost optimization and further study is expected.
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COSTS OF FORMAL AND INFORMAL HOME CARE AND QUALITy OF LIFE OF 
PATIENTS wITH MULTIPLE SCLEROSIS IN SwEDEN
Svensson M.1, Fajutrao L.2
1The Swedish Institute for Health Economics, Lund, Sweden, 2Merck Serono, Solna, Sweden
Objectives: To describe and to estimate costs of formal and informal home care 
and quality of life related to multiple sclerosis. MethOds: A random sample of 
1500 members of the Swedish organization for patients with neurological diseases 
(NHR), specifically MS, were mailed a questionnaire between February-March 2012. 
Collected data included number of hours per month of home care received, type 
of help, productivity losses, quality of life (EQ-5D) and disease characteristics. The 
recall period was one month. Using published Swedish unit cost data, the costs 
for home care were estimated in 2012 euros. A semi-logarithmic linear regres-
sion evaluated other factors that may influence the likelihood of getting home 
care. Results: Of 839 respondents, 65.5% had progressive MS, 24.5% had RRMS 
and 10% had no information. Formal care was given to 27% of respondents at 
an average of 238.7 hrs/month at a mean cost of € 2873 per person with MS per 
month. Informal care was received by 49% of respondents at an average of 47.3 
hrs/month at a mean cost of € 389 per person with MS per month. Based on disease 
severity, the mean total home care costs/patient/month were: mild (EDSS 0-3) = 
€ 63, moderate (EDSS 4-6) = € 461 and severe (EDSS > 6.5) = € 8446. Total home care 
costs were three-fold higher in persons with moderate MS and seven-fold higher 
in persons with severe MS versus mild MS. Total home care costs of patients 
cohabiting with another person were nearly 70% higher compared to people liv-
ing alone. The reported average utility was 0.513 (sd 0.307). Utilities across dis-
ease severity: mild MS= 0.709 (sd 0.233), moderate MS= 0.562 (sd 0.232) and severe 
MS= 0.284(sd 0.283). cOnclusiOns: Total home care costs, of which formal care 
costs accounted for a large proportion, increased with increasing disease severity. 
Informal caregiving contributes significantly to MS home care and is an important 
complement to formal home care in Sweden.
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A COMPARISON OF DEMOGRAPHIC AND CLINICAL vARIABLES OF DOwN 
SyNDROME PATIENTS IN UTAH AND THE UNITED STATES
Jiao T., Liou T.G., Young D., Brixner D.
University of Utah, Salt Lake City, UT, USA
Objectives: To explore the demographics, comorbidities and medication 
exposure of Down Syndrome (DS) patients in Utah compared to a national 
cohort. MethOds: National and local data on adult patients with DS were 
extracted from the General Electric Healthcare National Clinical Data Services 
Warehouse and the University of Utah Healthcare System Enterprise Data, respec-
tively. The ICD-9 code for Down Syndrome (758.0) was used to identify patients, 
alive through 2012, and their associated comorbidities and prescribed medications. 
We used descriptive statistics, t-test, test of proportion and Fisher’s exact test to 
examine relationships between demographics, comorbidities and pharmacothera-
pies and compared results between local and national cohorts. Results: Data was 
extracted on 513 patients in Utah and 11,736 nationally, 98% and 64% of patients 
are adults in cohorts, respectively. Through 2012, adult DS patients in Utah were 
younger (37 vs. 39, p< 0.005), more likely to be female (54.08% vs. 50.47%, p< 0.05) 
and with levodopa in PT patients (72.7%, all p< 0.05). cOnclusiOns: A high and 
comparable level of compliance was observed across PD drugs. Persistence was 
significantly higher than other drugs with rasagiline in treatment-naïve patients 
and with levodopa in previously treated patients.
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DISEASE-MODIFyING THERAPIES (DMT) FOR MULTIPLE SCLEROSIS (MS): 
ANALySIS OF ITS EvOLUTION IN SPAIN BETwEEN 2004 AND 2012
Villoro R.1, Hidalgo A.2
1Instituto Max Weber, Madrid, Spain, 2University of Castilla La Mancha, Toledo, Spain
Objectives: To analyze determinants of recent evolution of DMT consumption for 
MS in Spain. MethOds: Available DMT market data comprised monthly figures 
for the period 2004-2012. Monthly and annual evolution of consumption, treated 
patients and annual cost of treatment were calculated for each DMT. This analy-
sis was replicated for first-line (intramuscular and subcutaneous interferon (IFN) 
β -1a, subcutaneous IFN β -1b, and glatiramer acetate) and second-line therapies 
(natalizumab and fingolimod). Evolution of these variables was analyzed for both 
the whole period 2004-2012 and since 2007 (when second-line therapies become 
available in Spain). Results: DMT expenditure in Spain increased by 147% in 2004-
2012 (from € 115.5M to € 284.9M, 11.95% annually). This evolution can be decomposed 
into: the growth in the figure treated patients (126%; 10.70% annually) and the 
increase in the average annual cost per patient (9%, from € 11,739 to € 12,839; 1.13% 
annually). For 2007-2012 subperiod, DMT spending increased by 73% (11.57% annu-
ally) is attributable to 59% more treated patients (9.73% annually) and an increase 
of 9% (1.68%) in annual cost per patient. Cost per patient in second-line is 70% 
higher (average 2007-2012) than average cost per treated patient (€ 21,074 vs. € 
12,372) and 82% higher than annual cost of first-line therapy (€ 21,074 vs. € 11,549). 
Between 2007 and 2012, second-line therapies accounted 32% of new treatments 
and 48% of incremental cost per patient. By omitting year 2007 from analysis (68 
second-line treatments and € 1.44M associated consumption), second-line therapies 
account for 38% of new treatments and 55% of incremental cost per patient. By 2012 
second-line therapies already represent 50% of new treatments and 67% of DMT 
cost increase. cOnclusiOns: The increase of patients treated with DMT in Spain 
(10.70% annually in 2004-2012), more costly new therapies incorporation and its 
growing consumption are crucial factors in handling hospital pharmacy budgets 
for prevalent diseases such as MS.
PND61
ASSOCIATION BETwEEN NON-MOTOR SyMPTOMS AND HEALTH CARE 
UTILIzATION AMONG PATIENTS wITH PARKINSON’S DISEASE IN THE UNITED 
STATES
Makaroff L.1, Senior E.1, Moran K.2, Kiri V.3, Thieffry S.1
1UCB Pharma, Brussels, Belgium, 2UCB Pharma, Smyrna, GA, USA, 3FV & JK Consulting Ltd., 
Guildford, UK
Objectives: To investigate the characteristics and extent of health care utiliza-
tion among patients with Parkinson’s disease (PD) with and without non-motor 
symptoms (NMS). MethOds: Data were obtained from a US administrative claims 
database (SDI/IMS). Index date was 1 June 2010, and study duration was 12 months. 
Patients were required to have at least two PD diagnoses before the index date. They 
were subsequently matched 1:1 to control patients (no PD diagnoses) based on 
propensity scores derived from age and pre-index Charlson comorbidity index for 
each gender. Results: In total, 127,630 patients with PD were matched to controls. 
Patients with PD had higher annual mean numbers of primary care (16.4 vs 12.3; 
p ≤ 0.0001) and neurologist visits (6.7 vs 0.4; p ≤ 0.0001) compared with matched 
controls. In the PD group, 48,823 patients (38.3%) had a diagnosis for at least one 
NMS, of whom 15,242 (31.2 %) were also treated for at least one NMS. Most fre-
quently reported NMS were pain (27.2%), mood disturbance (depression, anxiety or 
nervousness; 12.7%) and sleep disorder (7.4%). Patients with pain, mood and sleep 
disorders (n= 1,159), had higher total annual primary care and neurologist visits 
than patients with no NMS (50.7 vs. 17.2). Patients who received treatment for pain, 
mood and sleep disorders (n= 118), had a higher total number of annual primary care 
and neurologist visits (66.6) compared with patients treated only for mood (26.0; 
n= 3,233) only for pain (35.6; n= 9,432), or only for sleep (30.6; n= 676). cOnclusiOns: 
Results of the study demonstrate that treatment of NMS increases health care uti-
lization – patients with PD suffering from NMS had a substantially greater number 
of health care visits than those with no NMS. Results also indicate that there are 
substantial levels of undertreatment of NMS among patients with PD, with less 
than a third being treated.
PND62
NATALIzUMAB TREATMENT IS ASSOCIATED wITH REDUCED NEUROLOGy 
OUTPATIENT APPOINTMENTS, UNPLANNED HOSPITAL ADMISSIONS AND 
LENGTH OF STAy
Beadman A, Hanna J
Biogen Idec Limited, Maidenhead, UK
Objectives: Global wellbeing of patients is an important outcome in research and 
clinical practice. Multiple Sclerosis (MS) is a degenerative, neurological condition, 
characterised by progressive disability, affecting approximately 110 per 100,000 
people in England and Wales. Natalizumab is a humanised monoclonal antibody, 
licensed for use in highly active relapsing-remitting MS and administered as an 
IV infusion every 28 days. The purpose of this study was to explore the impact of 
natalizumab on both patients and use of health service resource in clinical practice 
in England. MethOds: Health Episode Statistics (HES) data were used to perform 
a retrospective cohort study. A structured coding search elucidated a compre-
hensive list of natalizumab users by hospital trust. Analysis of health service 
usage, including outpatient appointments and admissions, was undertaken. 
Comparison of use during the year before and after treatment initiation was con-
ducted. Results: A total of 2,196 patients with at least 1 year of available HES 
data after treatment initiation were identified. In this cohort, natalizumab treat-
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Objectives: Diagnosis of urinary tract infection (UTI) in young children is difficult. 
Prompt treatment could alleviate short-term symptoms and prevent serious long-
term sequelae, but over-treatment will increase antibiotic resistance. We evaluated 
the cost-effectiveness of a UTI risk score based on signs, symptoms and dipstick test 
findings compared to clinical judgement in guiding urine sampling and antibiotic 
treatment. MethOds: We developed a risk score based on urine samples collected 
(by clean catch or nappy pad) in a multicentre diagnostic cohort study (DUTY) of 
7,163 children < 5 years presenting to primary care. The diagnostic value of symp-
toms, signs and dipstick test results were evaluated against a reference standard of 
urine culture results from a research laboratory. We constructed decision-analytical 
models comparing the cost-effectiveness of 3 DUTY risk score thresholds (high 
sensitivity, high specificity or intermediate) versus clinical judgement in younger 
(nappy pad) and older (clean catch) children. We explored the role of the dipstick 
in guiding diagnosis. We considered health service costs and patient utilities dur-
ing the initial diagnosis, acute illness and long-term sequelae. Results: The ‘high 
specificity’ DUTY threshold resulted in fewer urine samples than clinical judgement 
(4.8% vs. 9.2%) with similar sensitivity (58.6% vs. 57.1%) and higher specificity (96.1% 
vs. 91.4%). The difference in short-term net benefits between DUTY thresholds was 
small (range £1088 ‘high sensitivity’ to £1091 ‘high specificity’). In younger children 
(nappy pads) the distinction in cost-effectiveness between the DUTY risk score 
and clinical judgement was not clear-cut. Dipstick tests could potentially expedite 
therapy in higher risk children. cOnclusiOns: Clinicians can reduce prescriptions 
and provide more cost effective care by using the DUTY risk score. Clean catch 
samples should be obtained whenever practical. Low UTI prevalence, imperfect NHS 
laboratory tests and an uncertain link between UTI and long-term sequelae mean 
that conservative sampling strategies may be most appropriate.
PUK3
COMPARISONS OF THE CLINICAL EFFECTIvENESS OF TREATMENTS FOR THE 
SyMPTOMS ASSOCIATED wITH OvERACTIvE BLADDER (OAB)
Edwards S.J., Karner C., Trevor N., Barton S., Nherera L.
BMJ Group, London, UK
Objectives: This research was carried out during a review of the manufacturer’s 
submission (MS) to the NICE Single Technology Appraisal programme for the 
selective beta3-adrenoceptor agonist, mirabegron. Antimuscarinics are the main-
stay of treatment for the symptoms of OAB. They may be used at different doses 
and in different formulations (immediate release [IR] or extended release [ER]). 
However, there is limited evidence on their comparative clinical effectiveness 
with each other. This research evaluated the available evidence for mirabegron, 
antimuscarinics, and placebo. MethOds: Randomised controlled trials (RCTs) 
for inclusion were identified using the MS for mirabegron. RCTs were assessed 
for comparability based on diagnosis, patient population, treatment regimen, and 
with outcomes reported at 12 weeks. Mixed treatment comparison (MTC) using 
Bayesian Markov Chain Monte Carlo simulation was used to perform a meta-anal-
ysis of a network of RCTs. Summary statistics used were mean difference (MD) for 
continuous outcomes and odds ratio (OR) for dichotomous outcomes. Results: Of 
the 40 RCTs identified in the MS, 22 met the criteria for inclusion in the analysis. 
No statistically significant differences in frequency of micturition were identi-
fied between any of the active treatments. Compared with mirabegron 50mg, 
statistically significant differences in the remaining outcomes assessed, were: 
fewer incontinence episodes, MD (solifenacin 5mg -0.39, 95%CI: -0.72 to -0.06; 
solifenacin 10mg -0.38, 95%CI: -0.69 to -0.07); increased risk of constipation , OR 
(fesoterodine 8mg 2.12, 95%CI: 1.13 to 3.64; solifenacin 5mg 2.11, 95%CI: 1.16 to 
3.59; solifenacin 10mg 4.52, 95%CI: 2.60 to 7.47; trospium 60mg 7.63, 95%CI: 2.12 to 
22.95); increased risk of discontinuation, OR (oxybutynin 15mg IR 2.67, 95%CI: 1.60 
to 4.22). Mirabegron was associated with significantly lower risk of dry mouth than 
all other active treatments. cOnclusiOns: None of the treatments assessed for 
OAB have a consistently superior efficacy with a reduced risk of adverse events.
PUK4
CONTINUOS RENAL REPLACEMENT THERAPy vERSUS INTERMITTENT 
HEMODIALySIS: SySTEMATIC REvIEw ON PATIENT-ORIENTED OUTCOMES
Nobre M.R.C.1, Monaco C.F.2
1InCor - HCFMUSP, São Paulo, Brazil, 2Centro Universitário São Camilo, São Paulo, Brazil
Objectives: Acute renal failure is responsible for about 1% of hospital admissions, 
and occurs in up to 7% of hospitalized patients and up to 20% of patients admitted to 
intensive care units (ICU’s). When it is severe enough to require dialysis, in-hospital 
mortality rate ranges from 50% to 75% and is also increases risk for chronic and 
terminal kidney diseases. Continuous Renal Replacement Therapy (CRRT) in its 
various forms has theoretical advantages over conventionally done Intermittent 
Hemodialysis (IHD) at significantly higher costs, but these advantages attributed to 
CRRT have not yet been consistently proven in terms of clinical outcomes in con-
trolled trials. MethOds: We have made a literature search in PubMed to identify 
systematic reviews and randomized controlled trials that studied patient-oriented 
outcomes (mortality and renal recovery). Results: We have found five systematic 
reviews published in 2007 and 2008 and conducted our own metanalysis on six trials 
published from 2001 to 2009 (no clinical outcomes oriented trial has been published 
since them). None of the reviews that directly compared CRRT to IHD have shown 
statistically significant advantages of any of them regarding in-hospital or ICU 
mortality or renal function recovery We have analyzed six randomized no-blinded 
clinical trials that met eligibility criteria of evaluating patient-oriented outcomes 
including 1151 patients. Five of them had high to moderate GRADE scores. None 
have shown absolute risk reduction of in hospital, ICU or at 60 days mortality or 
statistically significant renal recovery rates. Overall mortality relative risk of CRRT 
over IHD was 1,01 (95%CI: 0,92 – 1,11). We found moderate heterogeneity and no 
publication bias. cOnclusiOns: Clinical trials published until October 2012 have 
shown no difference in patient-oriented outcomes between the uses of CRRT and 
IHD techniques in adult patients admitted to intensive care units with acute renal 
failure and requiring renal replacement therapy.
and more likely to be Caucasian (64.61% vs. 41.53%, p< 0.001) than national cohort 
patients. DS patients in Utah suffered significantly more comorbidities: autism 
(6.43% vs. 1.12%, p< 0.001), heart problems (2.53% vs. 0.57%, p< 0.001), blood and 
blood-forming problems (14.81% vs. 10.05%, p< 0.001), epilepsy (7.02% vs. 2.23%, 
p< 0.001) and arthritis (28.46% vs. 10.68%, p< 0.001). Higher proportions of Utah 
patients used ulcer drugs (21.64% vs. 16.83%, p< 0.005), majority PPIs (85.6%); 
antidepressants, (17.93% vs. 11.55%, p< 0.001), majority SSRIs (79.3%); analgesics-
NSAIDs (15.59 % vs. 11.13%, p< 0.005), majority NSAIDs (98.8%); multivitamins 
(16.18% vs. 9.02%, p< 0.001), and fluoroquinolones (10.53% vs. 7.45%, p< 0.01) than 
the national cohort. cOnclusiOns: The Utah DS population differs from the 
comparative U.S. Cohort in demographics, comorbidities and medications. These 
results will be incorporated into the development of a Quality of Life scale to value 
new treatments in Down Syndrome.
PND66
TREATMENT PATTERNS FOR PARKINSON’S DISEASE: REAL-wORLD EvIDENCE 
FROM THE EU5 (FRANCE, GERMANy, ITALy, SPAIN, AND THE UNITED KINGDOM)
Sung A.H.1, Kulkarni A.2, Svarvar P.2
1St. John’s University, Queens, NY, USA, 2Merck & Co., Inc., Whitehouse Station, NJ, USA
Objectives: To assess the distribution of initial Parkinson’s Disease (PD) treat-
ment, along with time to and reasons for changes in therapy. MethOds: Adelphi 
Real-World Disease-Specific-Programme (DSP) cross-sectional PD data from 
January 2011 to February 2012 were analyzed. The DSP surveyed 299 physicians 
in the EU5 who completed PD patient reviews (≥ 10 each). Kaplan-Meier estima-
tion was used to evaluate times from initial monotherapy to follow-up therapy 
by treatment. Reasons for adding or switching drug classes were documented 
as efficacy-related, levodopa-related (dyskinesia or on-off fluctuations), due to 
side-effects, and/or other reasons. Results: Of the 3,351 patients included, 60% 
were male; mean age at treatment initiation was 65 years; 55% had mild Hoehn & 
Yahr severity scores (≤ 2.5); and 59% initiated treatment on monotherapy. Overall, 
Dopamine Agonists (DA) were the most common first-line monotherapy (45%; 
mean age 62 years), followed by Levodopa (39%; 71 years), Monoamine-oxidase-B 
Inhibitors (MAOB) (14%; 62 years), and Other (2%; 64 years). The median time 
to change from DA monotherapy was 36 months. Levodopa was the first choice 
add-on (16%) and switch from (5%) DA monotherapy. Reasons for change to 
Levodopa were efficacy-related (92% add-on; 70% switch patients). The median 
time to change from Levodopa monotherapy was 54 months. DA was the first 
choice add-on (13%) and switch from (1.4%) Levodopa monotherapy. Reasons for 
change to DA were efficacy-related (86% add-on; 82% switch patients). The median 
time to change from MAOB monotherapy was 12 months. DA was the first choice 
add-on (32%) and switch from (6%) MAOB monotherapy. Reasons for change to 
DA were efficacy-related (95% add-on; 94% switch patients). cOnclusiOns: This 
EU5 sample represents a levodopa-sparing treatment strategy, favoring initiation 
with DA for younger patients. Initial treatment with Levodopa monotherapy was 
of longer duration than that with DA or MAOB. Physicians predominantly reported 
efficacy-related reasons for treatment changes.
URINARy/KIDNEy DISORDERS – Clinical Outcomes Studies
PUK1
ANALySIS COST EFFECTIvENESS OF PHARMACOLOGICAL PROPHyLAxIS OF 
CONTRAST-INDUCED NEPHROPATHy
Alonso Herreros J.1, Murcia Murcia C.1, Gonzalez C.uello A2
1HOSPITAL GENERAL REINA SOFIA, MURCIA, Spain, 2UNIVERSIDAD DE MURCIA, MURCIA, 
Spain
Objectives: Analyze the cost-effectiveness of the prophylaxis (n-acetylcysteine 
1200mg 4 oral-doses+1/6M bicarbonate 500ml IV) of the contrast-induced 
nephropathy (CIN) at risk patients. The CIN is usually reversible, but may affect 
50% of patients with some risk factors (diabetes, age...) and may favor the 
progressive renal damage. MethOds: Retrospective observational study. The 
population were patients candidates at prophylaxis protocol CIN in a university 
hospital during 2012 (5142 patients). We calculated a sample size of 115 patients 
for a confidence level of 90%, an error of 7.5% and a frequency of CIN equal 40% 
. CIN was considered as the relative elevation of serum creatinine greater than 
or equal to 25% during the 48 hours after the test. For the economic analysis 
were used acquisition-costs of drugs, and the hemodialysis costs described by 
Lorenzo et al (Nephrology2010,30(4):404-412). We consider, according to litera-
ture that at least 35% of risk patients affected by NIC would require a hemodi-
alysis session. Results: Of the patients who received prophylaxis, 3 had CIN 
and 93 no. Of those who received no prophylaxis 5 had CIN, and 14 no. We did a 
Fisher Test being the difference in favor of the protective effect of the protocol 
statistically significant (p < 0.01). The prophylaxis would have prevented 25.26 
CIN. The prophylaxis costs per patient were € 2.29 . The cost of a hemodialysis 
sessions was € 423. Then € 220.42 has been invested to avoid a minimum of € 
3739.74 on hemodialysis. (16.9 € savings per euro spent on prophylaxis. Each 
avoided NIC had cost € 8.73.) cOnclusiOns: The economic analysis is difficult 
because of the diversity of data about CIN. We chose a cost-minimization model, 
considering minor treatment needs found in the literature. In any case this 
prophylaxis is highly cost-effective and should be considered before introduc-
ing other methods.
PUK2
COST EFFECTIvE USE OF URINE SAMPLING AND DIPSTICK TESTING TO 
DIAGNOSE URINARy TRACT INFECTIONS IN PRE-SCHOOL CHILDREN 
PRESENTING TO PRIMARy CARE
Busby J.1, Hay A.1, Butler C.2, Lawton M.1, Sterne J.1, Little P.3, Hood K.2, Harman K.1, 
Hollingworth W.1
1University of Bristol, Bristol, UK, 2Cardiff University, Cardiff, UK, 3University of Southampton, 
Southampton, UK
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on data from a tacrolimus variability study. Cost data were taken primarily from the 
British National Formulary and 2012–13 NHS tariff information and the analysis was 
performed over a 5-year time horizon. Results: The mean cost per patient (includ-
ing tacrolimus, concomitant immunosuppressive medications, dialysis after graft 
failure, and treatment for acute rejection) was GBP 26,958 with Advagraf versus GBP 
30,379 for Prograf over a 5-year period. The total cost saving (GBP 3,421) was driven by 
reduced Advagraf pharmacy costs and lower dialysis costs resulting from the lower 
proportion of patients with high variability in tacrolimus trough concentrations in 
the Advagraf arm, leading to lower risk of graft failure. cOnclusiOns: Converting 
renal transplant recipients from Prograf to Advagraf was associated with lower 
pharmacy and dialysis costs, with the reduction in dialysis costs being driven by the 
lower proportion of Advagraf patients with high tacrolimus trough concentration 
variability and the resultant improvement in graft survival.
PUK9
ECONOMIC EvALUATION OF EPOETIN ALFA HExAL (BINOCRIT) COMPARED 
TO DARBEPOETIN ALFA (ARANESP) IN THE TREATMENT OF CHRONIC 
HAEMODIALySIS (CKD5) PATIENTS IN GERMANy
Turner M.1, Walsh K.1, Maerz M.2, Whitehouse J.3
1Sandoz Biopharmaceuticals, Holzkirchen, Germany, 2Hexal, Holzkirchen, Germany, 3GfK 
Bridgehead, Melton Mowbray, UK
Objectives: To compare the CKD5 budget requirements of utilizing epoetin alfa 
Hexal vs. darbepoetin alfa in the German health care system. MethOds: Chronic 
kidney disease (CKD) is a condition that is prevalent worldwide, and the num-
ber of patients affected continues to increase. ESAs and iron are the mainstays 
of treatment for haemodialysis patients. The purpose of this pharmacoeconomic 
analysis was to evaluate the cost-effectiveness of the short-acting biosimilar ESA 
epoetin-alfa Hexal (EA) 6,000-8,000 IU per week (TIW) vs. long-acting erythropoiesis-
stimulating agent (ESA) darbepoetin alfa (DA) 30-40 mcg weekly (QW), for treating 
chronic haemodialysis patients. A budget impact model was constructed employ-
ing a payer perspective, per patient with 5 year time horizon. The treatment period 
considered was based on 52 weeks and was aligned with real world clinical experi-
ence data from germany1. Model inputs included: medical treatment, outcomes, 
and health care service utilization from published clinical studies2and summary 
of product characteristics recommendation. Effectiveness of therapeutic alterna-
tives was determined by comparing haemoglobin maintenance rates. Costs pre-
sented reflect 2013 prices. The analysis was performed from the perspective of the 
German health care system. Results: The average expected pharmaceutical costs 
per patient were € 3791 to € 5002 for DA QW (30-40mcg weekly) versus € 2690 to € 3520 
for EA TIW (6,000-8,000IU weekly). Cost-savings associated with utilizing EA TIW 
was 41-42% for comparable DA doses. Previous German research has demonstrated 
that ESA consumption of patients on chronic haemodialysis based on DDD is similar 
for biosimilar and originator ESAs1. cOnclusiOns: In the treatment of chronic 
haemodialysis patients in Germany, epoetin alfa Hexal is projected to provide sub-
stantial savings for the health care system when compared to darbepoetin alfa. 
German stakeholders could consider the extent that darbepoetin alfa is utilized in 
haemodialysis patients. [1] Horbrand et al. Eur J Clin Pharmacol 10/2012. [2] Horl et 
al. Clin. Nephrology 1/2012.
PUK10
ECONOMICS OF DIALySIS DEPENDENCE FOLLOwING ACUTE KIDNEy INjURy 
(AKI) IN THE INTENSIvE CARE UNIT (ICU)
Ethgen O.1, Schneider A.2, Bagshaw S.3, Bellomo R.4, Kellum J.5
1University of Liege, Liege, Belgium, 2University of Lausanne, Lausanne, Switzerland, 3University 
of Alberta, Alberta, AB, Canada, 4Austin Hospital, Austin, Australia, 5University of Pittsburgh, 
Pittsburgh, PA, USA
Objectives: AKI is common in the ICU and often necessitates the provision of 
renal replacement therapy (RRT). Two main modalities exist: continuous (CRRT) 
or intermittent (IRRT) therapy. Neither modality has been found superior in terms 
of survival. However, dialysis dependence among survivors remains a significant 
medical and economic issue. A recent meta-analysis showed initial IRRT might be 
associated with higher rates of dialysis dependence than initial CRRT. We performed 
a preliminary cost-utility analysis comparing both modalities based on these recent 
data. MethOds: We assumed a pool of patients who would potentially be eligible 
for either modality and modeled LYG, QALYs gains and costs comparing initial CRRT 
vs. initial IRRT, all else being the same. Using the US perspective, we designed a 
1-year Markov model with daily cycle and 2 health states (dialysis independence/
dependence). Survival for both modalities was fitted from published estimates 
(Weibull regression). The proportion of dialysis independent survivors was fitted 
from published estimates for CRRT (Weibull regression). IRRT dialysis independence 
estimates were obtained by applying the meta-analysis risk-ratio to the fitted CRRT 
estimates. Sensitivity analysis was conducted on the daily implementation cost 
difference between CRRT and IRRT (from $250 to $1,000; basecase: $500) and the 
risk-ratio for dialysis dependence for IRRT as compared to CRRT (from 1.20 to 3.00; 
basecase: 1.99). Results: The QALYs gain was slightly better for CRRT as compared 
to IRRT (0.301 vs. 0.292 respectively). Despite higher hospitalization costs for CRRT 
($86,397 vs. $83,309 for IRRT), the one-year cumulative total cost including the cost 
of dialysis dependence was similar between the two modalities ($94,286 for CRRT 
vs. $94,118 for IRRT). In the basecase analysis, the ICER of CRRT vs. IRRT was $17,562/
QALY. cOnclusiOns: Initial CRRT may actually be cost-effective as compared to 
initial IRRT by reducing the rate of dialysis dependence among AKI survivors.
PUK11
IN-PATIENT HOSPITALIzATIONS FOR CHRONIC KIDNEy DISEASE IN THE 
UNITED STATES
Aggarwal S., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
Objectives: To understand the trends in rate and cost of hospitalizations due to 
Chronic Kidney Disease (CKD) in the U.S. MethOds: We analyzed the last five years 
URINARy/KIDNEy DISORDERS – Cost Studies
PUK5
THE FINANCIAL IMPACT OF INCREASING HOME-BASED HIGH DOSE 
HAEMODIALySIS AND PERITONEAL DIALySIS
Liu F.X.1, Treharne C.2, Culleton B.1, Lees L.2, Arici M.3
1Baxter Healthcare Corporation, Deerfield, IL, USA, 2Abacus International, Bicester, UK, 3Baxter 
Healthcare UK, Berkshire, UK
Objectives: The increasing prevalence of end-stage kidney disease in the UK 
has resulted in a heavy economic burden. The National Institute of Health and 
Care Excellence reported that patients receiving dialysis at home have better 
health outcomes and lower health care resource use. This study aims to assess 
the financial impact of increasing the use of home-based dialyses vs. UK current 
practice. MethOds: A Markov model was constructed to estimate the financial 
impact of different dialysis scenarios from the UK payer perspective. We modelled 
prevalent and incident dialysis patient population over 5 years. The current UK 
dialysis modality distribution of 15% prevalent and 20% incident peritoneal dialysis 
(PD), 82% prevalent and 79% incident in-centre haemodialysis (ICHD), 3% prevalent 
and 1% incident conventional home HD (HHD), and 0% high dose HHD was com-
pared to 3 scenarios: 1) Increase high dose HHD to 10% among prevalent patients; 
2) Increase high dose HHD to 10% and PD to 20% among prevalent patients and 
increase PD to 25% among incident patients; 3) Increase high dose HHD to 10% 
and PD to 25% among prevalent patients and increase PD to 30% among incident 
patients. In each scenario, the proportion of patients on ICHD changes accord-
ingly, while conventional HHD is kept constant. Model inputs were from published 
sources. Results: The base case results show that all 3 scenarios result in lower 
costs versus current UK practice. A prevalent population size of 22,654 patients was 
modelled, accounting for an annual incident population size of 5,393 in England. 
Scenario 1 saves £25 million (£559 per patient). Scenario 2 saves £67 million (£1,526 
per patient). Scenario 3 saves £110 million (£2,493 per patient). Sensitivity analyses 
demonstrate consistent results. cOnclusiOns: Under the current UK national 
tariff, increasing the proportion of patients on home-based dialyses is associated 
with lower total health care costs.
PUK6
BUDGET IMPACT OF SwITCHING FROM AN IMMEDIATE-RELEASE TO A 
PROLONGED-RELEASE FORMULATION OF TACROLIMUS IN RENAL TRANSPLANT 
RECIPIENTS IN THE UK BASED ON DIFFERENCES IN ADHERENCE
Pollock R.F.1, Smith-Palmer J.1, Odeyemi I.A.2, Muduma G.2
1Ossian Health Economics and Communications, Basel, Switzerland, 2Astellas Pharma Europe 
Limited, Chertsey, UK
Objectives: Advagraf® is a once-daily prolonged-release formulation of tacrolimus 
with proven non-inferiority to Prograf®, a twice-daily immediate-release formula-
tion of tacrolimus, in biopsy-proven acute rejection in renal transplant recipients. 
Advagraf is associated with improved adherence compared with Prograf, which may 
ultimately improve long-term outcomes. The present study assessed the budget 
impact of switching patients from Prograf to Advagraf in the UK. MethOds: A 
budget impact model was constructed based on published data on acute rejection, 
graft failure and mortality in the UK setting. Patients were assumed to convert from 
Prograf to Advagraf on a 1:1 mg:mg basis. In a study comparing the adherence rates 
between once-daily versus twice-daily formulations of tacrolimus, the proportion 
of patients taking the prescribed number of daily doses was 88.2% in Advagraf 
patients and 78.8% in Prograf patients. The model applied a relative risk of graft 
failure of 3.47 to non-adherent patients based on data from a 2004 meta-analysis. 
Cost data were taken from the British National Formulary and 2012–13 NHS tariff 
information. The analysis was performed over a 5-year time horizon and future costs 
were not discounted, in line with International Society for Pharmacoeconomic and 
Outcomes Research guidelines. Results: Over a 5-year time horizon, the mean cost 
per patient (including tacrolimus, concomitant immunosuppressive medications, 
dialysis after graft failure, and treatment for acute rejection) was GBP 29,290 for 
Advagraf versus GBP 33,032 for Prograf. The total cost saving of GBP 3,742 was driven 
by reduced Advagraf pharmacy costs and lower dialysis costs arising from the lower 
risk of graft failure in the larger proportion of adherent patients in the Advagraf 
arm. cOnclusiOns: Conversion of renal transplant recipients from Prograf to 
Advagraf was associated with lower pharmacy and dialysis costs, with the reduc-
tion in dialysis costs being driven by improved adherence to Advagraf regimen and 
the consequent improvement in graft survival.
PUK8
AN ANALySIS OF THE COST OF SwITCHING RENAL TRANSPLANT PATIENTS 
FROM AN IMMEDIATE-RELEASE TO A PROLONGED-RELEASE FORMULATION 
OF TACROLIMUS BASED ON DIFFERENCES IN TROUGH CONCENTRATION 
vARIABILITy IN THE UNITED KINGDOM
Pollock R.F.1, Smith-Palmer J.1, Odeyemi I.A.2, Muduma G.2
1Ossian Health Economics and Communications, Basel, Switzerland, 2Astellas Pharma Europe 
Limited, Chertsey, UK
Objectives: Randomized controlled trials have shown that Advagraf®, a once-daily 
prolonged-release tacrolimus formulation, is non-inferior to Prograf®, a twice-daily 
immediate-release tacrolimus formulation, in terms of biopsy-proven acute rejec-
tion in renal transplant recipients. However, relative to Prograf, Advagraf exhibits 
reduced variability in tacrolimus trough concentration, which has been associated 
with reduced graft failure. Based on these data, the present study evaluated the 
cost of switching UK renal transplant patients from Prograf to Advagraf. MethOds: 
UK-specific data on acute rejection, graft failure and mortality were used to 
construct a budget impact model to assess the costs of switching from Prograf 
to Advagraf on a 1:1 mg:mg basis. The model assumed that 3.1% of patients on 
Advagraf had high tacrolimus trough concentration variability compared with 17.4% 
on Prograf, based on a study comparing Advagraf and Prograf pharmacokinetics. The 
model applied a relative risk of graft failure of 2.38 to high variability patients based 
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Objectives: The primary aim of the study was to estimate costs of treatment for the 
first year after renal transplantation from the perspective of health insurance organi-
zations in Iran. MethOds: An Excel-based and a Monte Carlo model were developed 
to determine the treatment costs of current clinical practice in renal transplantation 
therapy (RTT). Inputs were derived from Ministry of Health and insurance organiza-
tions’ database, hospital and pharmacy records, clinical trials and local and interna-
tional literature. According to the model, there were almost 17,000 patients receiving 
RTT in Iran, out of which about 2,200 patients underwent the operation within the 
study year (2011- 2012; n= 2200). Results: The estimated first year total treatment 
cost after renal transplantation was almost $14,000,000. These costs corresponded to 
annual total cost per patient of almost $6500 for the payers. cOnclusiOns: Renal 
transplantation therapy is almost fully reimbursed by government in Iran. However, 
regarding new expensive medicines, cost of medical expenditure is rapidly growing 
and becoming quite unaffordable for the government; therefore, out-of-pocket (OOP) 
payments are dramatically increasing over time. In order to improve reimbursement 
policy making under pressure of current budget constraints, the present study is 
providing decision makers with practical tools make them possible to easily compare 
budgetary impact of the current therapy strategy with the future financial conse-
quences of purchasing newly proposed medicines. In other words having estimation 
of the current budget spending on RTT would help policy makers in making efficient 
resource allocation and decrease quite high OOP expenditures.
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A NON-INTERvENTIONAL RETROSPECTIvE EvALUATION OF RESOURCES 
CONSUMED DURING THE PROvISION OF CARE FOR OvERACTIvE BLADDER 
SyNDROME: A REAL wORLD EvALUATION: GERMAN PERSPECTIvE (THE REDUCE 
STUDy)
Indig M.1, Purdy C.2, Magar R.3, Dalfonso L.3, Walters C.4, Nazir J.4
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Objectives: To evaluate resource utilisation for subjects with overactive 
bladder (OAB) syndrome who are managed with the commonly prescribed oral 
medications: solifenacin succinate, tolterodine tartrate, or trospium chloride from 
the payer perspective. MethOds: Data were abstracted from medical records for 
qualified subjects who were ≥ 18 years, with a diagnosis for OAB (at least one of the 
following: urgency, frequency with or without urgency incontinence) on or before 
December 31, 2010. Subjects must have been on one of the study medications for at 
least 3 months and have at least 12 months of medical records available. The study 
was approved by local ethics committees and all data provided was anonymised. 
Medication costs for Germany are reported for 2013 € . Results: A total of 136 of 
229 subjects were included for the German analysis. The remaining subjects were 
from the Czech Republic to be reported elsewhere. Top 3 reasons for exclusion from 
Germany include: primary diagnosis of urinary tract infection, urologic surgery 
within 6 months of the data collection, and diabetic neuropathy. The annual overall 
mean cost for office visits, specialist visits, investigations, other treatments, medica-
tions and incontinence pad use with solifenacin (5,10mg/day) (N= 60), trospium (IR 
and ER maximum dose of 60mg/day) (N= 51), and tolterodine (IR 2, 4mg/day and ER 
4mg/day) (N= 25), were € 1,059.31, € 1,247.76, and € 1,626.01, respectively. Incontinence 
pad use for weekly frequency with solifenacin, trospium, and tolterodine was, 17.34, 
19.51 and 20.35, respectively. Overall satisfaction with medication as perceived by 
the clinician (very satisfied, satisfied, neutral, dissatisfied, very dissatisfied) for very 
satisfied and satisfied was 97%, 86%, 100%, for solifenacin, trospium, tolterodine, 
respectively. cOnclusiOns: Solifenacin had the lowest annual cost-in-use com-
pared to other study drug annual cost. This was corroborated in part by the lowest 
incontinence pad use for solifenacin compared to trospium and tolterodine and 
the high treatment satisfaction.
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COST AND COST-EFFECTIvENESS OF TREATING URGENCy STRESS 
INCONTINENCE-RESULTS FROM A RANDOMIzED CONTROLLED TRIAL
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Beer-Sheva, Israel, 3Maccabi Healthcare Services, Rishon LeZion, Israel
Objectives: Urgency urinary incontinence (UUI) has a substantial impact on 
patients’ QOL and well-being, and may pose a substantial economic burden on 
patients and health insurers. We assessed the cost and cost-effectiveness of four 
conservative treatment modalities for UUI in Israel. MethOds: A total of 164 
women were randomly allocated to one of four interventions: drug therapy (DT), 
bladder training (BT), pelvic floor muscle-training (PFMT), and combined pelvic floor 
rehabilitation (CPFR) and were followed over a period of 12-months. Resource utili-
zation including physician encounters, dispensed prescriptions, physical therapist 
treatment and any other medical services was estimated for each study participant. 
We also estimated the women’s self-reported utilizations of pads, laundry and new 
underwear. Total costs were calculated by multiplying the volumes of resource uti-
lization by the corresponding unit-prices. We used the bootstrap method to report 
bias-corrected confidence-intervals of cost estimates. Utility weights were elicited 
using the EQ-5D questionnaire at baseline, 3-months and 12-months of follow-
up. Results: Women in all four treatment groups showed improvements in QOL 
from baseline to 12-months (DT:0.87 - 0.93, BT:0.85 to 0.89, PFMT:0.82 - 0.84, CPFR: 
0.82 to 0.86). Changes in QOL summary scores from study enrollment and end of 
follow-up were estimated after correction for potential baseline differences, and 
were not statistically different among study groups. The mean total cost was some-
what lower for the DT group participants ($1,460), as compared with the three other 
interventions (range: $1,760-$1,990). These differences, however, were not statisti-
cally significant. The mean monthly personal costs were significantly reduced from 
baseline to 12-months of follow-up in all treatment groups. cOnclusiOns: The 
four treatment modalities for treating UUI were equally effective and associated 
of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage Renal Disease 
(ESRD). The annual number of hospitalizations for specific diagnosis was obtained 
from AHRQ’s National In-patient Sample (NIS) databases of 2005-2009. Data was 
also analyzed for length of stay (LOS), charges and cost of hospitalization. Results: 
During the last five years the number of hospitalizations with diagnosis of CKD and 
ESRD has increased 4.1 and 4.6 fold, respectively. In 2009, an estimated 1,634,422 
and 931,641 hospitalizations were with diagnosis of CKD and ESRD respectively. The 
mean LOS for patients with CKD increased from 4.9 to 5.5 days between2005-2009. 
The mean LOS for patients with ESRD has remained steady at ~6 days between 2005-
2009. The cost of hospitalization with diagnosis of CKD has increased 31% between 
2005-2009. The cost of hospitalization with diagnosis of ESRD has increased 21% 
between 2005-2009. In 2009, the mean cost of hospitalization for patients with CKD 
and ESRD was $11,209 and $21,358, respectively. cOnclusiOns: Hospitalizations 
due to CKD and ESRD have significantly increased during the last five years. There 
is a need for prevention, treatment, and disease management programs to lower 
the medical and socioeconomic burden of this disease.
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Objectives: To examine the economic burden and health care utilizations of 
patients diagnosed with chronic kidney disease (CKD) in the U.S. veteran popula-
tion. MethOds: A retrospective database analysis was performed using the Veterans 
Health Administration (VHA) Medical SAS datasets (01OCT2008-30SEP2012). Patients 
diagnosed with CKD were identified using International Classification of Disease 9th 
Revision Clinical Modification (ICD-9-CM) diagnosis codes 585.xx, 250.4xx, 791.0x, 583.
xx, and 403.xx. The first diagnosis date was designated as the index date. A group of 
non-CKD patients of the same age, region, gender and index year were identified and 
matched on baseline Charlson Comorbidity Index (CCI) as the comparison group with 
a randomly chosen index date to minimize selection bias. Patients in both groups 
were required to be at least 18 years old, and have continuous health plan benefits 
1 year before and 1 year after the index date. One-to-one propensity score match-
ing was used to compare the health care costs and utilizations during the follow-up 
period between the CKD and comparison groups, adjusted for baseline demographic 
and clinical characteristics. Results: A total of 477,078 patients were identified for 
the CKD cohort and the comparison cohort. After 1:1 matching, 155,324 of patients 
were matched from each group, and the baseline characteristics were well-balanced. 
CKD Patients incurred higher health care utilizations in inpatient (17.00% vs. 2.84%, 
p< 0.01), emergency room (17.81% vs. 6.64%, p< 0.01), physician office (99.28% vs. 67.92%, 
p< 0.01), outpatient (99.36% vs. 68.69%, p< 0.01), and pharmacy visits (91.16% vs. 72.61%, 
p< 0.01). The CKD group also had higher patient expenditures in inpatient ($6,228 vs. 
$802, p< 0.01), emergency room ($194 vs. $62, p< 0.01), physician office ($3,287 vs. $1,516, 
p< 0.01), outpatient ($3,788 vs. $1,715) and pharmacy ($848 vs. $490, p< 0.01) than 
patients in the comparison group. cOnclusiOns: CKD patients had a significantly 
higher burden of illness compared to a similar comparison group of non-CKD patients.
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Objectives: Itchy and dry skin, symptoms of pruritus, are commonly reported by 
patients with end-stage renal disease (ESRD). Previous analyses of a large dialysis 
organization (LDO) suggested that these symptoms are associated with decreased 
quality of life and poorer health outcomes. As a result, these patients may represent 
a higher economic burden to payers. This retrospective cohort study compared direct 
health care resource utilization (HRU) and costs associated with varying degrees of 
self-reported itchiness/dryness skin severity. MethOds: Adult patient data (≥ 18 
years old) from the 2009 United States Renal Disease System (USRDS) dataset were 
combined with corresponding Kidney Disease Quality of Life (KDQOL) survey data 
obtained between January to September 2009, at an LDO. Patients were included if 
they had answered KDQOL itchiness/dryness questions, had KDQOL assessments ≥ 
3 months after starting dialysis, and had Medicare as their primary payer. Patients 
were grouped by their itchiness/dryness severity. All HRU and cost outcomes were 
described over a 3-6 month follow-up period post-KDQOL survey. Patients were 
censored for death, transplant, change in treatment modality, discontinued treat-
ment, or loss of observation during the follow-up period. Results: Study popula-
tion included 1,387 patients. HRU analyses of itchiness showed increased rate of 
hospitalizations (42.5% vs. 28.4%) for patients who were extremely bothered versus 
not bothered by itch. Similar results were observed for dryness (34.3% vs. 27.5%) 
and combined itchiness and dryness (34.2% vs. 28.0%). Extremely bothered patients 
had higher overall health care costs: $33,755 vs. $26,933 for itchiness; $29,801 versus 
$26,321 for dryness; and $29,249 vs. $26,736 for combined itchiness and dryness. 
Dialysis and hospitalization costs contributed the most toward overall health care 
costs. cOnclusiOns: These results suggest an association between increased skin 
itchiness/dryness and increased hospitalizations and health care costs. Additional 
research, adjusting for patient characteristics, is needed to provide more evidence 
for the burden of skin itchiness/dryness in ESRD patients.
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COST OF TREATMENT AFTER RENAL TRANSPLANTATION IN IRAN: SHOULD 
GOvERNMENT CONTINUE PAyING FOR NEw ExPENSIvE IMMUNOSUPPRESSIvE 
DRUGS?
Foroutan N.1, Salamzadeh J.1, Foroutan A.2, Jamshidi H.R.1, Rasekh H.1
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and ER tolterodine patients remained on treatment until week 52, respectively. QALYs 
were higher with fesoterodine than tolterodine (0.762 vs. 0.760). In Spain, fesoterodine 
treatment had higher costs than (generic) ER tolterodine (€ 6 697 vs. € 6 597), resulting 
in a cost of € 15 600/QALY gained. In Finland, fesoterodine was cost-saving relative to 
(non-generic) ER tolterodine (€ 7 885 vs. € 8 024). Sensitivity analysis confirmed these 
findings were robust to the expected price decrease for generic ER tolterodine in 
Finland. In the PSA, fesoterodine was consistently the preferred therapy in Finland 
regardless of the value of a QALY and in Spain for QALY valuations greater than 
€ 15 000. cOnclusiOns: Fesoterodine is cost-effective or cost-saving relative to ER 
tolterodine for the treatment of OAB with UUI in two European countries. Payers and 
prescribers should consider a broad scope of costs in order to make informed cost-
conscious choices of antimuscarinic treatment.
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Objectives: Overactive bladder (OAB) is a chronic condition which affects quality 
of life through the main symptoms of urinary urgency, urinary frequency, and uri-
nary incontinence. Treatments include behavioural therapy, antimuscarinics (AM), 
β 3-adrenoceptor agonsits (mirabegron), botulinum toxin (botox) and sacral nerve stimu-
lation (SNS). The aim of this analysis was to evaluate the costs and outcomes associated 
with different sequences of oral treatments (AM and mirabegron). MethOds: A Markov 
model with monthly cycle length and a time horizon up to 3 years compared two dif-
ferent sequences of up to three lines of oral treatments. Patients who discontinue one 
oral medication may switch to another oral medication, or may discontinue treatment. 
Patients whose symptoms are not improved are considered for botox or SNS. Outcomes 
are measured by (a) number of patients with improved symptoms (< 2 incontinence 
episodes and < 8 micturitions per 24-hours); (b) patients with < 2 incontinence epi-
sodes per 24-hours; and (c) patients with < 8 micturitions per 24-hours. Results: 
Including a third-line oral medication before considering other treatment options 
improved all patient outcomes, irrespective of the particular drugs used. A three-line 
sequence including two generics (oxybutynin (1st line), and tolterodine ER (2nd line)), 
and one branded drug (solifenacin 5mg (3rd line)) resulted in inferior patient outcomes 
and higher cost compared with a sequence of branded drugs (mirabegron (1st line), 
solifenacin 5mg (2nd line), solifenacin 10mg (3rd line)): improved patients (70/1000 
vs. 92/1000); patients with < 2 incontinence episodes (181/1000 vs. 217/1000); patients 
with < 8 micturitions (248/1000 vs. 299/1000). Annual treatment costs were higher in 
the generic sequence (£2659 per patient vs. £2479). cOnclusiOns: Low-cost generic 
treatments are not necessarily more cost-effective than branded drugs. The main rea-
son is that a better efficacy and tolerability balance improves symptoms and quality of 
life, leading to better persistence and lower overall treatment costs.
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Objectives: Mirabegron is a first-in-class beta-3 adrenoceptor agonist for the treat-
ment of overactive bladder (OAB) that demonstrated superior efficacy compared to 
placebo in OAB. The cost-effectiveness of mirabegron 50 mg (MGN) was assessed in 
comparison with tolterodine ER 4 mg (TOL) in the UK. MethOds: A Markov model 
was developed to simulate the therapeutic management, the changes in symptoms 
(micturitions and incontinence), and complications in OAB patients. The model was 
used to predict costs and QALYs over 5 years in cohorts initially treated with MGN 
or TOL, followed by antimuscarinics in case of lack of efficacy or adverse events. 
Transition probabilities and EQ-5D utilities were obtained from regression models, 
estimated from a P3 randomized controlled trial of mirabegron. Costs were evalu-
ated from the UK National Health Service (NHS) perspective and included drug 
acquisition, physician visits, pads and botulinum toxin injections. Subgroup analy-
ses were performed for previously treated, treatment naïve, incontinent, female and 
elderly patients. Results: The MGN strategy was more expensive compared to 
TOL, with a difference of £37.88 per patient, and produced more QALYs (+0.009 per 
patient). The incremental cost-effectiveness ratio (ICER) was estimated at £4,386/
QALY gained. Results of one-way sensitivity analyses showed that in all scenarios, 
except one (the transition probabilities between symptom levels of micturition for 
mirabegron), MGN remained cost-effective or was dominant compared to TOL. Key 
cost-effectiveness drivers included parameters related to efficacy and treatment 
discontinuation. Based on the probabilistic sensitivity analysis, the probability of 
MGN being cost-effective against TOL was 89.4% at a threshold of £20,000 per QALY 
gained. ICERs in subgroups ranged from £3,091 (female subgroup) to £5,736 (elderly 
subgroup). cOnclusiOns: Treatment with mirabegron 50 mg appears to be a cost-
effective strategy compared with tolterodine ER 4 mg for the general OAB population 
and the specified subgroups, from a UK NHS perspective.
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FOR THE TREATMENT OF PATIENTS wITH OvERACTIvE BLADDER IN THE 
UNITED KINGDOM
Maman K.1, Neine M.2, Briquet B.2, Nazir J.3, Odeyemi I.A.O.3, Hakimi Z.4, Garnham A.3, Aballéa S.2
1Creativ-Ceutical, London, UK, 2Creativ-Ceutical, Paris, France, 3Astellas Pharma Europe Ltd., 
Chertsey, UK, 4Astellas Pharma Global Development, Leiden, The Netherlands
with comparable costs. Therefore, an incremental cost-effectiveness ratio was cal-
culated. Due to the possibility of declining adherence to drug therapy over time, 
pelvic floor physical therapy can be considered as the first line treatment for UUI.
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THE COST IMPLICATIONS OF RENAL DENERvATION THERAPy AT THE HOSPITAL 
LEvEL IN THE UNITED KINGDOM
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Objectives: Hypertension is a chronic medical condition and an important risk 
factor in several fatal and debilitating diseases. NICE estimates the cost of pharma-
cologic intervention in the UK for hypertension at £409.8 million. Resistant hyper-
tension arises when blood pressure remains uncontrolled despite antihypertensive 
treatment. Renal denervation is a new procedure aimed at reducing blood pressure 
in resistant hypertension patients by decreasing efferent sympathetic signalling to 
the kidneys. The objective of this research was to review the evidence on the cost of 
renal denervation and to provide a costing model for the procedure. MethOds: A 
targeted review of costing data was performed and information gathered from renal 
denervation experts to establish relevant procedure costs. Once specific health care 
resource use (HRU) and equipment costs were identified, an Excel™ costing model 
was constructed. A further search of NHS costing documents, academic literature, 
and expert consultation provided GBP figures for each cost and identified those that 
were time dependent (e.g. hourly staff costs). Results: The required in-patient 
HRU was identified as staff costs per hour including surgeon costs, nurse costs, 
technician costs and anaesthesiologist costs, all of which vary with procedure time 
depending on the device used (ranging from 20-60 minutes). Catheter lab overhead 
costs per hour and recovery costs (bed days) were also identified. Total HRU costs 
vary between £923.02 and £991.62 (for 20 and 60 minute procedure times respec-
tively). An additional in-hospital recovery day adds £680. Equipment costs were for 
12 items including from syringes to catheters to valves, totaling £281.70 plus the 
cost of the renal denervation therapy device. cOnclusiOns: It is essential the 
cost of the procedure is estimated to fully inform payers and health care providers. 
HRU costs are dependent on procedure time and length of recovery in hospital, thus 
devices that reduce these factors are best for cost savings.
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Objectives: Despite significant improvements in survival and quality of life (QoL) 
of liver transplant (LTx) recipients, patients remain at risk from complications 
related to disease recurrence and long-term use of immunosuppressant (IS). The 
objective was to assess cost, survival, and QoL outcomes of LTx recipients and 
the impact of renal dysfunction on LTx outcomes. MethOds: A de novo cohort 
Markov model was developed to predict long-term outcomes post LTx along two 
independent pathways: 1) liver-related (acute rejection, hepatocellular carcinoma, 
hepatitis C (HCV) recurrence, graft loss), 2) kidney-related (chronic kidney disease, 
dialysis, renal transplantation) and death. All patients, stratified by liver diagno-
sis, entered the model at time of LTx and followed both pathways, allowing for 
multiple combinations of liver and kidney health states. Costs and utilities were 
assigned to each health renal and liver state. Renal complications costs and utility 
decrements were added to those accrued in the liver pathway. The lifetime model 
used an annual cycle length except for the 1st year post LTx (quarterly). Choice of 
immunosuppressant strategy could impact the risk of acute rejection, change in 
renal function and HCV fibrosis progression. A 3% discount rate was applied to 
costs and outcomes. Results: On average, life expectancy post LTx was 13.3 years 
with 10.2 QALYs. Lifetime cost of managing post LTx recipients was USD 550,000 
(excluding LTx procedure): > 50% was related to IS regimen, monitoring and adverse 
events; around 40% to renal complications and 2-7% to liver complications. Patients 
developing renal dysfunction lost 5.2 life-years and 1.5 QALYs. cOnclusiOns: To 
our knowledge, this is the first Markov model simulating lifetime costs and out-
comes post-LTx and the impact of change in renal function on patient survival. A 
health care intervention that could improve or maintain renal function would have 
significant impact on survival and costs.
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COST-EFFECTIvENESS OF FESOTERODINE AND TOLTERODINE FOR THE 
TREATMENT OF OvERACTIvE BLADDER wITH URGE URINARy INCONTINENCE 
IN SPAIN AND FINLAND
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Objectives: To assess the economic value of fesoterodine compared to tolterodine 
for the treatment of overactive bladder (OAB) with urgency urinary incontinence (UUI) 
in Spain and Finland. MethOds: A decision-tree economic model estimated the 
52-week costs and quality-adjusted life years (QALYs) of OAB/UUI patients initiating 
treatment with fesoterodine 4mg/day or extended-release (ER) tolterodine. Treatment 
response (UUI < 1 episode/day) and persistence were evaluated at weeks 4, 12, and 24. 
Titration from fesoterodine 4mg/day to 8mg/day was permitted at week 4. At week 
12, non-responders discontinued treatment permanently. Efficacy, discontinuation, 
and utility data were derived from four clinical trials of fesoterodine. OAB-related 
costs including physician visits, laboratory tests, incontinence pads, and comorbidi-
ties (fracture, skin infection, urinary tract infections, depression, and nursing home) 
were also included. The perspective was that of the National Health Systems (2012€ ). 
Uncertainty surrounding the model parameters was assessed by univariate and prob-
abilistic sensitivity analysis (PSA). Results: A total of 19.5% and 18.0% of fesoterodine 
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Objectives: Elevated serum phosphate (hyperphosphataemia) usually accom-
panies end-stage renal disease and results from the inability of damaged kidneys 
to effectively regulate phosphate levels. Failure to maintain adequate phosphate 
balance has important clinical consequences, with an increased morbidity and 
risk of mortality. When dietary phosphate restriction is inadequate for control, 
administration of phosphate binders may be required. A number of phosphate 
binders are currently available; however, these often require high doses to control 
serum phosphate levels and this may result in lowered patient compliance. The 
objectives of this research were to assess the pill burden associated with phos-
phate binders and highlight any links between pill burden, patient adherence and 
outcomes in terms of serum phosphate levels. MethOds: A literature review 
was performed using the PubMed database using the search term “phosphate 
binders AND adherence”. Twenty six articles were identified in total, with ten 
relevant articles. Results: Six of the ten relevant articles (60%) found that low 
patient adherence or high pill burden were associated with higher mean serum 
phosphate level, whereas only one article (10%) concluded that no link existed. 
Seven articles reported dose increases with phosphate binder treatment or an 
increased number of pills per patient per day over the treatment course, with two 
reporting that the actual dose of phosphate binders in clinical practice was higher 
than those recommended in clinical guidelines. A high pill burden was found to 
lead to low adherence by three of the articles identified (30%), whereas only one 
of the papers identified did not support this hypothesis (10%). cOnclusiOns: 
This research indicates that there is a high pill burden associated with phosphate 
binders, as well as a requirement in clinical practice for high dosages. There is 
a suggestion that these factors are linked to low patient adherence and poorer 
control of serum phosphate levels.
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Objectives: Health economic evaluations of therapeutic interventions in patients 
with CKD and SHPT requiring dialysis (CKD-SHPT) should incorporate the impact of 
major clinical events related to their disease. However, little is known about the disu-
tility (i.e, utility decrease) associated with cardiovascular (CV) and fracture events in 
the context of CKD-SHPT. The purpose of this study was to estimate, via preference-
based valuation completed by general population respondents, the added disutil-
ity of these events beyond the impact of CKD-SHPT. MethOds: One-year health 
states were developed describing CKD-SHPT and related CV/fracture acute events/
procedures. Events with long-term effects (post one year) were also captured in 
chronic health states. General population participants in Canada completed time 
trade-off (TTO) interviews to assess health state utilities. Respondents initially rated 
the CKD-SHPT health state. Then, events and procedures were added to this health 
state: myocardial infarction (MI); unstable angina (UA); heart failure exacerbation; 
peripheral vascular disease (PVD) ± amputation; stable angina (SA); stroke; hip/arm 
fractures; parathyroidectomy; kidney transplant. Each participant was randomly-
assigned 11 of 16 health states to rate. Results: A total of 199 participants (54.8% 
female; mean age = 46.3 years) completed interviews. Each health state had ≥ 130 
valuations. CKD-SHPT had a mean utility of 0.60 (SD= 0.34). For acute events, mean 
utility decrements additional to CKD-SHPT were: MI, -0.06; UA, -0.05; PVD with 
amputation, -0.33; PVD without amputation, -0.11; heart failure, -0.14; stroke -0.30; 
hip fracture, -0.14; arm fracture, -0.04; parathyroidectomy, +0.02; kidney transplant, 
+0.06. Disutilities for chronic effects were: SA, -0.09; stroke -0.27; PVD with ampu-
tation -0.30; PVD without amputation, -0.12; heart failure, -0.14. cOnclusiOns: 
Valuation of health states representing CKD-SHPT plus major clinical events was 
feasible using TTO with a one-year time horizon. These data will assist investiga-
tors in applying appropriate disutilities to clinical events in economic evaluations 
of treatments for patients with CKD-SHPT requiring dialysis.
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COSTS TO MANAGE OvERACTIvE BLADDER
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Objectives: To determine the impact of sacral neuromodulation (SNM) on EQ-5D 
index scores and OAB management costs using an Economic Impact Questionnaire 
(EIQ) in patients who failed at least one anticholinergic medication enrolled in the 
InSite study, an ongoing, prospective, multicenter trial of SNM. MethOds: EQ-5D 
and EIQ were administered at baseline, 3-, 6- and 12-months post-implant. OAB-
related expenses included durable and disposable medical supplies and health 
service utilization (emergency room, hospitalizations and outpatient). A total of 340 
Objectives: Mirabegron is a first-in-class beta-3 adrenoceptor agonist for the 
treatment of overactive bladder (OAB) that demonstrated superior efficacy com-
pared to placebo by reducing OAB symptoms and improving HRQoL. We sought 
to assess the cost-effectiveness of mirabegron 50 mg in comparison with current 
antimuscarinics for the treatment of patients with OAB in the UK. MethOds: 
A Markov model was developed to simulate the therapeutic management, the 
changes in symptoms (micturitions and incontinence), and complications in 
hypothetical cohorts of OAB patients. The model was used to predict costs and 
QALYs over 5 years in cohorts initially treated with antimuscarinics or mirabe-
gron 50mg. Effectiveness and safety data were based on the results from a mixed 
treatment comparison (MTC). A calibration approach was used to derive transition 
probabilities from mean changes in frequency of micturitions and incontinence 
episodes. Other input data were obtained from several sources, including scien-
tific literature and expert opinions. Costs were evaluated from the UK National 
Health Service (NHS) perspective and included costs of drug acquisition, GP visits, 
specialist visit, incontinence pad use and botox injections. Utilities were obtained 
from equations predicting EQ-5D index scores according to symptom severity, 
estimated from a clinical trial of Mirabegron. Results: The Mirabegron strategy 
was slightly more expensive and associated with a greater number of QALYs, as a 
result of improved persistence, related to a lower risk of adverse event compared 
to each antimuscarinic. Mirabegron 50mg was found to be cost-effective com-
pared to each antimuscarinic, with an ICER of £340 vs. solifenacin 10mg, £3,607 
versus fesoterodine 4mg, £3,715 vs. tolterodine ER 4mg, £3,878 vs. oxybutynin ER 
10mg, £8,881 versus trospium chloride MR 60 mg, £12,493 versus solifenacin 5mg, 
and £14,234 oxybutynin IR 10mg. cOnclusiOns: Treatment with mirabegron 
appears to be a cost-effective strategy compared with antimuscarinics from a 
UK NHS perspective.
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Objectives: Intravenous (IV) irons are second line treatments for iron deficien-
cies in severe chronic kidney disease (CKD) patients with iron deficiency anaemia. 
Aim of this study was to compare ferumoxytol, a new agent, against IV ferric 
carboxymaltose (FC) and IV iron sucrose (IS), from a Belgian health care payer (BP) 
and hospital perspective (HP). MethOds: The CKD patients were categorized in 
haemodialysis (HD), peritoneal dialysis (PD), non-dialysis (post-renal transplant 
and non-dialysis) and all patients combined. The available IV irons have a simi-
lar efficacy. Adverse events were not included due to missing comparative data 
and low rates. However, the administration time and number of administrations 
differ among treatments. So a cost-minimization analysis was conducted (time 
horizon: 1 year). The average annual need of IV Iron is 3,500 mg in HD, 2,500 mg in 
PD and 1,500 mg in non-dialysis patients. The hospital perspective was modelled 
by deducting the nurse time cost from the hospital fee per administration (HP). 
For the health care payer the administration cost (hospital fee) and the drug costs 
are included (BP). Other costs were excluded because they did not affect the incre-
mental cost of treatment. Results: The total cost (euro 2012) for all patients was 
€ 676.57, € 819.82 and € 617.34 for ferumoxytol, FC and IS, respectively (BP). In the 
renal transplant and non-dialysis subgroups, ferumoxytol is less costly than FC 
and IS (BP). In the HD subgroup (86.77% of all eligible patients), IS is the least costly 
option (BP). The hospital cost in all patients is higher with IS due to more nurse 
time (€ 101.31, € 7.58 and € 144.19 for ferumoxytol, FC and IS) (HP). cOnclusiOns: 
Hospitals benefit from lower administration costs with ferumoxytol and FC (HP). 
From a Belgian payer perspective, ferumoxytol is less costly than FC and more 
costly than IS.
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Objectives: Anaemia is a frequent complication among patients with Chronic 
Kidney Disease (CKD) and is associated with poor outcomes. European data on the 
patterns of treatment of anaemia in non-dialysed (ND) CKD patients are scarce. 
The aim of this study was to describe the anaemia-associated Health Resource 
Utilization (HRU) in an Italian cohort of ND-CKD patients. MethOds: The admin-
istrative data and clinical laboratory files of 5 Italian Local Health Units from 2006 
to 2011 were used to identify ND patients with CKD (stage3b, 4, 5) and anemia. 
Anaemia-related HRU and associated costs were investigated. Results: A total 
of 1175 patients were included; 790 in CKD stage 3b; 331 in stage 4; 54 in stage 5. 
Anaemia-related medications were prescribed to 31.9% of patients and the per-
centage increased along the CKD stages from 28.9% for stage 3b to 42.6% for stage 
5. Among the drug-treated patients Erythropoiesis-stimulating agents were pre-
scribed to 82.6% of CKD stage 5 patients whereas CKD stage 3b patients received 
mostly oral iron (59.6%). Patients receiving any anaemia-related medications 
had lower per patient-per year cost for almost all studied resources compared to 
patients not receiving any medications. For anaemia-related outpatient services 
[drug-treated and not drug-treated]: stage 3b costs per patient year were € 62.12 
and € 62.32 respectively; stage 4 costs were € 52.23 and € 72.76; stage 5 costs were 
€ 55.83 and € 83.08. For general visits: stage 3b costs were € 168.51 and € 170.28; stage 
4 costs were € 124.17 and € 173.79; stage 5 costs were € 134.49 and € 343.63. For CV 
hospitalizations: stage 3b costs were € 1378.63 and € 1828.60; stage 4 costs were 
€ 1185.17 and € 2155.82; stage 5 costs were € 521.61 and € 514.63. cOnclusiOns: 
Among ND CKD patients drug treatment may help control anaemia-related outpa-
tient services and contain CV hospitalization costs and represents an opportunity 
for health care improvement.
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chologist conducted semi-structured individual interviews with 2 clinical experts 
and 30 patients in the UK recruited through general practitioners. Clinical experts 
were asked to identify key concepts attributable to the overactive bladder (symp-
toms). Patients were asked to describe their symptoms and impact on HRQL and 
rate them. All patient responses were coded using code frequency and bother rat-
ings. Results: Seven men, 23 women were interviewed; the majority of patients 
were older than 65 years. 50% of the patients were incontinent. Preliminary analysis 
suggests that OAB affects the patient’s quality of life on several aspect of their 
life: psychological (embarrassment and worry), occupational limitations, domes-
tic (usual activities) and limitations in leisure activities. All patients reported that 
feeling the need to go ‘‘too often’’ to the bathroom (urgency and frequency) led to 
significant limitations such as avoidance of any unplanned activities. HRQL con-
cepts were similar across the different age group. As expected, patients suffering 
from urgency incontinence reported this symptom as being the most impactful, 
especially in terms of embarrassment and worry. cOnclusiOns: Although the 
impact of all OAB symptoms was found to be significant and similar across all 
patients regardless of their age, the greatest impact or burden of OAB was felt and 
reported by wet patients compared to dry patients.
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Objectives: Bladder cancer (BC) is the fourth most common malignancies among 
men and it has high medical costs per-patient from diagnosis until death. Generally 
little is known about the burden BC imposes on patients’ health-related quality 
of life (HRQL) and the literature lacks detailed utility data for economic evalua-
tions in BC. The authors’ goal was to assess the HRQL and health status utility of 
BC patients. MethOds: A cross sectional survey was performed in three hospital 
based urology centres. Adult patients with BC attending routine care were invited to 
participate in the study. Data on demographics, disease history and co-morbidities 
were obtained, validated versions of the EQ-5D and SF-36 generic questionnaires 
were applied. The UK tarrifs were used to calculate EQ-5D score and the SF-36 was 
converted to SF-6D utilities. Disease-specific HRQL was assessed by the FACT-BL 
questionnaire. Results: Altogether 98 patients (males 63.3%) were involved with 
mean age of 66.4 (SD= 8.6) and disease duration of 3.4 (SD= 3.0) years. The SF-36 
physical and mental health summary measures were 62 (SD= 24), 65 (SD= 24), 
respectively, the scores of the 8 domains were comparable to the > 65 years old 
general population’s results. The average SF-6D, EQ-5D and EQ VAS utility scores 
were 0.705 (SD= 0.145), 0.772 (SD= 0.252) and 68.8 (SD= 19.0). The difference of EQ-5D 
score compared to the age-matched population norm was not significant (p= 0.65). 
The FACT-BL physical, social, emotional and functional well-being scores were 
mean 23.1 (SD= 5.4), 20.6 (SD= 5.7), 18.1 (SD= 5.1) and 19.0 (SD= 6.7), the total score 
was 114.0 (SD= 23.5). cOnclusiOns: According to our knowledge this study is the 
first to assess BC patients’ HRQL using diverse preference based measures. Further 
studies involving larger samples might increase our knowledge on the performance 
of these questionnaires in BC subgroups by disease stage, type of treatment and 
urinary diversion.
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Objectives: The reluctance of those with overactive bladder OAB to seek medical 
advice can leave a considerable part of the population untreated, with significant 
costs for society. The present study investigates the burden of individuals who 
experience symptoms of OAB but are not treated. MethOds: Data were taken 
from the 5EU (France, Germany, Italy, Spain, and UK) 2013 National Health and 
Wellness Survey (NHWS), a cross-sectional survey representative of the total adult 
populations in each 5EU market. 62,000 respondents self-reported physician diag-
nosis of various health conditions, including 1,347 who reported symptoms com-
patible with OAB. These respondents were compared to those who didn’t report 
symptoms of OAB. Variables of interest were demographics (age, gender, marital 
status, education, income and employment status), BMI, alcohol and smoke behav-
iour, health-related quality of life (HR-QoL), work productivity and activity impair-
ment (WPAI). Results: The OAB group, compared to the controls, was older (57 
vs. 47 years), with a lower education level (49.14% went to college vs. 54.49%), less 
were in a relationship (26.43% vs. 31.82%), less were employed (35.04% vs. 58.15%), 
more were obese (31.11% vs. 17.22%), they had lower HR-QoL (SF-36v2, PCS: 42.09 
vs. 51.36; MCS: 42.55 vs. 46.25; Utility: 0.62 vs. 0.73), had lower work productivity 
(overall work impairment of 34.46 vs. 20.03) and higher activity impairment (46.07 
vs. 24.35). All differences were significant (p< 0.001). cOnclusiOns: Respondents 
reporting symptoms compatible with OAB but are not treated and would not be 
captured by clinical studies, are significantly worse-off than the rest of the popu-
lation, e.g. in their quality of life, income and work productivity. It is likely that 
undergoing treatment would benefit them and decrease health care costs.
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patients completed the SNM pre-implant evaluation; data from 265 subjects were 
included in EQ-5D or EIQ analyses. Matched paired t-tests compared EQ-5D scores 
and costs from baseline to each follow-up. Results: Baseline mean EQ-5D index 
score (n= 265) was 0.777. Index scores significantly improved (p< 0.05) from base-
line at each follow-up period [3-months (n= 247)= 0.850, 6-months (n= 246)= 0.828, 
and 12-months (n= 232)= 0.839]; the largest improvement in scores (0.073) was at 
3 months. The proportion of patients reporting no problems on the EQ-5D dimen-
sions of Usual Activities, Anxiety/Depression and Pain/Discomfort and Self-Care 
increased from 61.2% (baseline) to 72.0% (12 months); 57.3% to 69.4%; 40.9% to 50.9%, 
and 93.1% to 95.3%, respectively; the Mobility dimension had a non-significant 
decline (68.5% to 66.4%). At baseline, study subjects reported a 3-month average 
expenditure of $228 (US) for durable and disposable medical supplies and health 
service utilization; 74% of the expenditure was attributed to ER, hospitalization and 
outpatient health services use. Expenditures significantly declined (p< 0.05) by an 
average of $163 per 3-month period post-implant. cOnclusiOns: After receiving 
SNM implant, EQ-5D index scores were significantly improved and self-reported 
durable and disposable medical supplies and health service expenses to manage 
OAB were significantly reduced.
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Objectives: 1) To determine what is the utility change for kidney donors from 
before to 3 months after donation; 2) To determine the minimal important differ-
ence (MID) of a decrease (MIDe) in utility for kidney donors. MethOds: We used 
data from a prospective multicenter observational study, measuring the Health 
Related Quality of Life (HRQoL) of kidney donors before and three months after 
transplantation. Utility scores were estimated using the SF-6D and EQ5D. Two 
methods were used to estimate the MIDe: i) the anchor-based method by the 
Global Rating of Change (GRoC) for donors rating their global health “somewhat 
worse” 3 months after donation; ii) the distribution-based method by the standard 
error of measurement (SEM). Results: In total, 211 donors for the EQ-5D and 192 
for the SF-6D completed the questionnaire. Results showed a significant (p< .0001) 
decrease in utility score at three months. The mean (SD) utility score before trans-
plantation was 0.932 (±0.091) with the EQ5D, and 0.834 (±0.085) using the SF-6D, 
and 0.882 (±0.151) and 0.757 (±0.118) respectively at three months with a significant 
decrease (< .0001). Half of donors (53.9%) rated their global health “about the same” 
and 35 (15.4%) “somewhat worse” at follow up. Using the GRoC method, the MIDe 
was -0.113 units for the EQ-5D and -0.128 units for the SF-6D. By the SEM method, 
MIDe was -0.076 for the EQ5D and -0.073 for the SF6D. More than third of patient 
rechead the MIDe using the SEM method. cOnclusiOns: This study showed a 
significant descrease in utility score three months after donation in most donors 
while reporting their global health “about the same”. The MIDe can be used by 
clinician as a threshold to identify donors with a meaningful decrease in utility 
score in a short run after donation.
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Objectives: Urinary incontinence (UI) is a public health issue with a considerable 
social and economic impact. It affects temporarily or permanently about 400 000-500 
000 adults in Hungary. The purpose of our study was to estimate the prevalence, 
consultation rates and treatment behaviour of the adult population. MethOds: 
In 2012 a 15-item questionnaire survey was performed as a part of a mobile 
health unit screening “The comprehensive health test program of Hungary 2010-
2020”. Results: Altogether 13 355 respondents (60.4% female) completed the ques-
tionnaire, the mean age was 40.2 years (SD 12.2). The prevalence rate of UI was 9.7% 
(n= 786) of women and 3.8% (n= 200) of men. Consultation rates were 22.9% (n= 180) 
for women and 32.5% (n= 65) for men. Seventy-three women (40.6%) consulted a 
gynaecologist, 37 (20.5%) a GP, 46 (25.6%) an urologist and 24 (13.3%) consulted more 
than one physicians. Five men (7.7%) consulted a GP, 44 (67.7%) an urologist and 
16 (24.6%) didn’t answer. Among those who consulted a physician 52.2% (n= 94) of 
women and 66.2% (n= 43) of men found solution for their urinary symptoms. In the 
group of respondents who consulted a doctor (n= 245) the most common therapies 
were medications, surgical treatment, absorbent pads or any combination of the 
foregoing. In the group who self-managed their symptoms without consulting a 
doctor (n= 741) absorbent products and/or pelvic muscle training were the most 
frequently applied therapies. cOnclusiOns: Our prevalence results are in line 
with the international UI screenings. We found low medical consulting rates and 
the majority of the respondents having symptoms used self-management tech-
niques for UI.
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Objectives: To review and identify HRQL dimensions in dry and wet OAB patients 
through literature review and patient interviews. MethOds: A literature review 
on OAB HRQL was performed using the EMBASE database. Specialized forums were 
also searched for relevant HRQL issues reported by OAB patients. A trained psy-
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annual reduction in the number of ESA administrations following conversion to 
C.E.R.A. was 77 (21-138). Average time per patient HD session was 1.54 minutes for 
ESA (95% CI: 1.17-1.90) vs. 1.64 minutes for C.E.R.A. (95% CI: 1.57-2.02). Estimated 
time/patient/year was 137 min (range: 65-277) for ESA and 20 min for C.E.R.A. (range: 
5-51). Assuming a 100% uptake of Q4W C.E.R.A. maintenance therapy, annual time 
savings/centre for frequent anaemia management tasks would be 86% (range: 
62-95%). cOnclusiOns: Substantial annual time savings on frequent anaemia 
management-related tasks were found in HD centres in Italy with 100% uptake of 
Q4W C.E.R.A. maintenance therapy.
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EvALUATION OF A PROCESS OF CARE MODEL FOR OPEN INTRAvESICAL 
URETERAL REIMPLANTATION FROM A CONTEMPORARy HEALTH CARE 
PERSPECTIvE
Ellsworth P., Butler C.
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Objectives: The surgical management of vesicoureteral reflux consists of open 
and minimally invasive approaches. Open approaches are associated with post-
operative hospitalization rates of stay typically 2 to 3 days, varying with the type 
of procedure. We evaluated the impact of a “one night cost-saving stay process of 
care” model for open surgical correction of vesicoureteral reflux on quality of care, 
as defined by return to emergency room or office and/or readmission to the hospital 
within 2 days of discharge. MethOds: An IRB-approved chart review of all open 
uncomplicated ureteral reimplantations for vesicoureteral reflux from the January 
2009 through January 2013 was performed. Length of postoperative stay, emergency 
room records, hospitalizations and office records were reviewed to assess for pres-
entation to the emergency room/office and/or readmission to the hospital within 2 
days of discharge from the ureteral reimplantation. Results: Ninety-five children 
(17 males, 78 females) underwent open ureteral reimplantation. Eighty-four (88.4%) 
were discharged POD #1 , 8 (8.4%) on POD #2 and 3 (3.2%) on the POD #3. Two patients 
presented to the ER within 2 days of discharge, one in the one night stay group and 
one in the three night stay group. No child required readmission within 2 days of 
discharge. Transient ureteral obstruction requiring stent placement occurred in 1 
patient (1.05%) 3 days after discharge. Presentation to the ER > 2 days post-discharge 
was more frequent in those discharged from home POD #1. cOncl usiOns: A pro-
cess of care model decreased the length of stay to one night in 84 of the 95 patients 
(88.4%) and did not appear to increase the risk of early (within 2 days of discharge) 
presentation to the ER/office or readmission. ER/office presentations > 2 days after 
discharge were increased in the POD #1 group.
RESEARCH POSTER PRESENTATIONS – SESSION I
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COSTS OF MANAGEMENT OF PREGNANCy IN OBESE wOMEN ACROSS EUROPE: 
THE DALI ExPERIENCE
Diaz-Cuervo H1, Callejo D1, Cuervo J1, Rebollo P1, Simmons D2, Corcoy R3
1LASER Analytica, Oviedo, Spain, 2Addenbrooke’s Hospital, Cambridge, UK, 3Hospital Sant Pau, 
Barcelona, Spain
Objectives: To assess resource use and costs in the usual clinical management of 
pregnant obese women, considered at high risk for developing GDM. MethOds: 
Information was collected in the framework of the DALI project by means of a 
structured survey about usual clinical practice in the management of obese women 
from week 12 of pregnancy until delivery and a second survey about unit costs of 
related tests and interventions including analytics, imaging tests, follow-up visits 
and delivery. 9 centers in 8 EU countries were included (Austria, Belgium, Denmark, 
Ireland, Italy, The Netherlands, Spain, UK) Unit costs were inflated, using consumer 
price index when needed to 2012 prices and exchanged to US$ using power purchase
parities. Results: According to the reported data, resource utilization according 
to usual practice in management of obese women differed across countries: num-
ber of ultrasound scans ranged 2-6, OGTT 0-3, obstetrician visits 2-10, GP visits 
0-6, nurse/midwife visits 0-12. Follow-up involved different professionals depend-
ing on the country (GPs, obstetricians, nurses, midwives, diabetes educators and 
endocrinologists). Mean costs were 4,624 US$ (SD 2,034), ranging from 2,571 US$ in 
Belgium to 7,682 US$ in Denmark. The main drivers for costs were delivery, health 
care professionals’ follow-up visits and ultrasound scans. When delivery costs were 
excluded mean costs dropped to 722 US$ (SD 226), ranging from 340 US$ in the UK 
to 1052 US$ in Spain. cOncl usiOns: A high heterogeneity in the management 
of obese women during pregnancy and in the unitary costs reported, are observed 
among the centers included in the study, associated with a threefold difference in 
costs across hospitals.
Objectives: To identify and analyze the sensitivity pattern of microorganisms 
isolated and to study the antibiotic utilization pattern in complicated urinary tract 
infection (cUTI) and the outcome of the therapy. MethOds: Retrospective, observa-
tional study conducted in the medicine units of a tertiary care teaching hospital from 
January 2011 to December 2011. Patients who met the inclusion criteria were include 
in the study and patient details like demography, clinical diagnosis, microbiological 
data, antibiotic regimen used and patient outcome were recorded from the medical 
records. Data were analyzed using SPSS 20.0 Results: Out of 297 patients included 
in the study, majority of them were in the age group of 48-59 years. ESBL E. coli 
(61.4%) was the most common causative microorganism isolated, followed by E.coli 
(23.9%). The antibiotic sensitivity profile of microorganisms causing cUTI showed that 
E coli was sensitive to majority of the antibiotics and ESBL producing E. coli was most 
sensitive to cefoperazone-sulbactum followed by amikacin and carbapenems. Dual 
drug regimen was the most preferred choice for the treatment of cUTI compared to 
single or triple or more drug regimens. Among the different category of antibiotics 
used, cephalosporins was the most commonly prescribed while macrolides were the 
least preferred antibiotics. cOnclusiOns: The treatment of ESBL E. coli with dual 
drug regimen showed maximum improvement in outcome (97.2%) followed by single 
drug regimen (89.7%). The organisms isolated were found to be more sensitive to 
cephalosporins, amikacin and carbapenems. Cephalosporins were the most effective 
antibiotic for the treatment of cUTI. The broader outcome of this study would be the 
potential utility of this data in designing strategies both at the level of physicians and 
the administrators for rational prescribing and policy decisions respectively.
PUK34
DIFFERENCE IN INTERDIALyTIC INTERvALS LEADING TO HOSPITAL ADMISSION 
AND MORTALITy IN HEMODIALySIS PATIENTS
Kumar P., Prabhu A. R, Bairy M.
Manipal University, Manipal, India
Objectives: To determine the importance of long and short interdialytic 
interval leading to hospital readmission and mortality in hemodialysis 
patients. MethOds: Reviewed data of 240 patients with 182 male and 58 female 
patients receiving maintenance hemodialysis (HD) twice weekly on a Mon/Thu, 
Tue/Fri, Wed/Sat schedule with prevalent adult’s HD patients on period from 2010 
through2012. Eligible patients were actively recruited who were on chronic HD 
fulfilling the inclusion criteria. Analyzed the patients getting frequent hospitalized 
for Infectious and cardiovascular (CV) admissions were determined by principal 
ICD-9-CM diagnosis codes. Results: A total of 240 patients with End-stage renal 
disease (ESRD) on long term hemodialysis were included the study cohort. The 
mean age was 50.4±13.6 years; 24.2% were women with a mean year of patients 
on hemodialysis of 4.2±2.6. Hypertension was the leading cause of end-stage 
renal disease in 28.8% of the patients, 27.1% of patients with hypertension and 
diabetes, 12% with diabetes and rest were due to Glomerulonephritis, Interstitial 
nephritis, Cystic kidney disease. Over the study period, mortality was 39.6% (95) , 
Cardiac cause 19.2 (46) were high on the day after 3 day interdialytic interval (31 
death vs. 15), Vascular cause 2.5% (6), Infection 7.5% (18), other cause 10.4% (25) 
and readmission was more both on the day after long interdialytic interval and 
day after short interdialytic interval for IHD, stroke, infection. cOnclusiOns: 
Interdialytic interval does not influence mortality and readmission rates for all 
cause cardiovascular and infectious causes.
PUK35
TIME SAvINGS wITH ONCE-MONTHLy C.E.R.A.: A TIME AND MOTION STUDy 
CONDUCTED IN 13 HEMODIALySIS CENTRES IN ITALy
De Cock E.1, Kritikou P.2, Proskorovsky I.3, Tomic R.4
1Evidera, Barcelona, Spain, 2Evidera, London, UK, 3Evidera, Dorval, QC, Canada, 4Roche S.p.A., 
Monza, Italy
Objectives: A major challenge for haemodialysis (HD) centres is to maximise effi-
ciency in care provision while maintaining high standards of care. Our objective was 
to document health care professional (HCP) time for renal anaemia management 
for both shorter-acting erythropoiesis-stimulating agents (ESA) and Mircera, a con-
tinuous erythropoiesis receptor activator (C.E.R.A.) once monthly (Q4W), and model 
time savings with the use of Q4W C.E.R.A. MethOds: This descriptive multi-centre 
Time and Motion (T&M) study was conducted in 13 centres in Italy. The time spent 
on frequent anaemia management-related tasks (preparation, distribution, and 
injection) was recorded for both ESA and C.E.R.A. groups in each centre by trained 
observers. Time/patient/session was used to calculate time/patient/year, time/
centre/year and modelling of potential time savings of a 100% uptake of C.E.R.A. A 
Random intercept generalized linear mixed effect model assuming gamma distri-
bution with log link function to account for the centre clustering effect was fitted 
for each task separately. Results: In all centres, more than 80% of an average 
86 ESRD patients received ESA treatment. The average number of ESA injections/
patient/year, weighted by type of ESA, frequency and route of administration, was 
89 (range: 33-150). The average uptake of C.E.R.A. was 26% (range 11-41%). The mean 
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Metabólicas Asociadas, Barcelona, Spain; Instituto de Salud Carlos III , 
Madrid, Spain 
PDB32 Eli Lilly and Company, Indianapolis, IN, USA 
PDB33 None
PDB34 None
PDB35 NovoNordisk, Sofia, Bulgaria 
PDB36 None
PDB37 Roche, Mannheim, Germany 
PDB38 None
PDB39 Ipsen, Warsaw, Poland
PDB40 Ipsen, Warsaw, Poland
PDB41 Merck, S.L, Madrid, Spain 
PDB42 None
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PDB43 Novo Nordisk Inc., Plainsboro, NJ, USA 
PDB44 Medtronic, Tolochenaz, Switzerland 
PDB45 AstraZeneca, Mölndal, Sweden; Bristol Myers Squibb, Princeton, NJ, USA
PDB47 Brsitol-Myers Squibb, Madrid, Spain; Astra-Zeneca, Madrid, Spain; Oblikue 
Consulting, Barcelona, Spain 
PDB48 Johnson&Johnson, LifeScan EMEA, Zug, Switzerland 
PDB49 Novo Nordisk, Madrid, Spain 
PDB50 Medtronic, Tolochenaz, Switzerland 
PDB51 BC Pharma B.V., Moscow, Russia
PDB52 Berlin-Chemie AG/Menarini Group, Moscow, Russia 
PDB53 Janssen, High Wycombe, UK 
PDB54 Bristol-Myers Squibb , Rueil-Malmaison, France; Bristol-Myers Squibb, 
Uxbridge, UK; AstraZeneca UK Ltd., Luton, UK 
PDB55 Janssen, High Wycombe, UK 
PDB56 Bristol-Myers Squibb , Rueil-Malmaison, France; Bristol-Myers Squibb , 
Uxbridge, UK; AstraZeneca UK Ltd., Luton, UK 
PDB57 AstraZeneca and Bristol-Myers Squibb, Zoetermeer/Woerden, The 
Netherlands 
PDB58 Bristol-Myers Squibb , Rueil-Malmaison, France; Bristol-Myers Squibb, 
Uxbridge, UK; AstraZeneca UK Ltd., Luton, UK 
PDB59 Janssen, High Wycombe, UK 
PDB60 Janssen, High Wycombe, UK 
PDB61 Novo Nordisk Pharma, Warsaw, Poland 
PDB62 Novo Nordisk, Copenhaguen, Denmark 
PDB63 Abbott Laboratories, Allschwil, Switzerland 
PDB64 Novo Nordisk Ltd., Copenhagen, Denmark 
PDB65 Novo Nordisk Ltd., Copenhagen, Denmark 
PDB66 sa Novo Nordisk Pharma nv, Brussels, Belgium 
PDB67 Novo Nordisk, Moscow, Russia
PDB68 Hangzhou MSD Pharmaceutical Company Limited, Hangzhou, China
PDB69 The National Science Centre, Cracow, Poland 
PDB70 Sanofi, Lysaker, Norway 
PDB71 IMS Health, Basel, Switzerland 
PDB72 BC Pharma B.V., Moscow, Russia
PDB73 None 
PDB74 None 
PDB75 Novo Nordisk A/S, Copenhagen, Denmark 
PDB76 Novo Nordisk A/S, Copenhagen, Denmark 
PDB77 None 
PDB78 None 
PDB80 None 
PDB81 Novo Nordisk A/S, Søborg, Denmark 
PDB82 None 
PDB83 Janssen, High Wycombe, UK 
PDB84 The National Science Centre, Cracow, Poland 
PDB85 None 
PDB86 AstraZeneca GmbH, Wedel, Germany; Bristol-Myers Squibb GmbH & Co. 
KGaA, Munich, Germany 
PDB87 Forest Research Institute, Jersey City, NJ, USA 
PDB88 NovoNordisk, Moscow, Russia 
PDB89 None 
PDB90 None 
PDB91 None 
PDB92 IPSEN, Boulogne Billancourt, France 
PDB93 Merck Serono, London, UK 
PDB94 Janssen Global Services, LLC, Raritan, NJ, USA 
PDB95 Janssen Global Services, LLC, Raritan, NJ, USA 
PDB96 None 
PDB97 None 
PDB98 Medtronic Australasia Pty Ltd., North Ryde, NSW, Australia 
PDB100 Bayer, Barcelona, Spain 
PDB101 Novo Nordisk International Operations, Zurich, Switzerland 
PDB102 Pfizer Inc., New York, NY, USA
PDB103 Novo Nordisk International Operations, Zurich, Switzerland 
PDB105 None 
PDB106 Boehringer Ingelheim France, PARIS, France 
PDB107 Novo Nordisk A/S, Copenhagen, Denmark 
PDB108 Ipsen Pharma, Boulogne-Billancourt, France 
PDB109 MSD, Hoddesdon, UK 
PDB110 Roche Diagnostics GmbH, Mannheim, IN, Germany 
PDB111 Sanofi, Berlin, Germany 
PDB112 None 
PDB113 None 
PDB114 None 
PDB115 AstraZeneca, Södertälje, Sweden
PDB116 None 
PDB117 None 
PDB118 None 
PDB119 None 
PDB120 Novartis, Each Hanover, NJ, USA
PDB121 Sanofi, Berlin, Germany 
PDB122 Novartis, Each Hanover, NJ, USA
PDB123 Independant Sickness Funds, Brussels, Belgium 
Reference 
Code Financial Support 
PDB124 None
PDB125 Bristol-Myers Squibb, Princeton, NJ, USA 
PDB126 Abbott Diabetes Care, Alameda, CA, USA; Animas Corporation, a Johnson 
& Johnson Company, West Chester, PA, USA; Bayer HealthCare, Diabetes 
Care, Tarrytown, NY, USA; DexCom, Inc, San Diego, CA, USA; Johnson and 
Johnson, New Brunswick, NJ, USA; LifeScan, Inc., a Johnson & Johnson 
Company, Milpitas, CA, USA; Medtronic Diabetes, Northridge, CA, USA; 
Roche Diagnostics, Indianapolis, IN, USA; Sanofi-Aventis, Bridgewater, NJ, 
USA 
PDB127 Eli Lilly, Windlesham, Surrey, UK 
PDB128 Bristol-Myers Squibb, Princeton, NJ, USA 
PGI1 None
PGI2 Thermo Fisher Scientific, Uppsala, Sweden 
PGI3 Abbott Laboratories S.A., Madrid, Spain 
PGI4 None
PGI5 Merck & co., Inc., Whitehouse Station, NJ, USA 
PGI6 Almirall S.A., Barcelona, Spain 
PGI7 AstraZeneca R&D, Molndal, Sweden 
PGI8 None
PGI9 Ethicon, Somerville, NJ, USA 
PGI10 None
PGI11 None
PGI12 Merck, Rome, Italy
PGI13 Danone, São Paulo, Brazil 
PGI14 None
PGI15 None
PGI16 MSD TAIWAN, Taipei, Taiwan 
PGI17 Takeda SpA, Roma, Italy
PGI18 None
PGI19 Ontario Neurotrauma Foundation, Toronto, ON, Canada
PGI20 MSD Hellas, Athens, Greece 
PGI21 Nestlé Health Science, Vevey, Switzerland 
PGI22 Novartis, East Hanover, NJ, USA 
PGI23 WL Gore & Associates Ltd., Livingstone, UK 
PGI24 WL Gore & Associates Ltd., Livingstone, UK 
PGI25 Roche (Hellas), Athens, Greece 
PGI26 Janssen Pharmaceutica, Beerse, Belgium 
PGI27 Almirall S.A, Barcelona, Spain 
PGI28 Janssen Pharmaceutica, Beerse, Belgium 
PGI29 None
PGI31 None
PGI32 MSD, Moscow, Russia
PGI33 Almirall, Vilvoorde, Belgium 
PGI34 Given Imaging, North Ryde, Australia 
PGI35 Astellas, Brussels, Belgium 
PGI36 National Institute for Health Research Health Technology Assessment (NIHR 
HTA) Programme, London, UK 
PGI37 None
PGI38 Almirall, Vilvoorde, Belgium 
PGI39 Forest Research Institute, Jersey City, NJ, USA 
PGI40 None
PGI41 Crohn's and Colitis UK (NACC), Manchester, UK 
PGI42 Forest Laboratories, Inc., New York, NY, USA; Ironwood Pharmaceuticals, 
Inc., Cambridge, MA, USA 
PGI43 FADE, Milan, Italy
PGI44 Laboratorios Almirall, Barcelona, Spain 
PGI45 Gilead Sciences, Foster City, CA, USA 
PGI46 F. Hoffmann-La Roche Ltd., Basel, Switzerland 
PGI47 None
PGI48 None
PGI49 None
PGI50 None
PGI51 Takeda SpA, Roma, Italy
PHP1 None
PHP2 German Federal Ministry of Education and Research (BMBF), Berlin, 
Germany 
PHP3 None
PHP4 None
PHP5 None
PHP6 None
PHP8 Center for Innovation in Regulatory Science, London, UK
PHP9 None
PHP10 Becton, Dickinson UK Limited, Oxford, UK 
PHP12 LEEM, PARIS, France
PHP13 None
PHP14 None
PHP16 None
PHP17 None
PHP18 ANF, Lisbon, Portugal
PHP19 None
PHP20 Biotest AG, Dreieich, Germany 
PHP21 None
PHP22 None
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PHP23 None 
PHP24 None 
PHP25 None 
PHP26 Ministry of Science and Higher Education, Warsaw, Poland 
PHP27 IMS HEALTH, Frankfurt/Main, Germany 
PHP28 Abbott, Allschwill, Switzerland 
PHP29 None 
PHP30 None 
PHP31 IMS Consulting Group, London, UK 
PHP32 Macquarie University, Sydney, Australia 
PHP33 GlaxoSmithKline, Dublin, Ireland
PHP34 None 
PHP35 None 
PHP36 None 
PHP37 RTI-HS, Durham, NC, USA 
PHP38 None 
PHP39 None 
PHP40 None 
PHP41 None 
PHP42 None 
PHP44 Institue for Health Economics and Polucy, Tokyo, Japan 
PHP45 None 
PHP46 None 
PHP47 Department of Health, London, UK
PHP48 Health Research Board, Dublin, Ireland 
PHP49 Swiss Medical Association, Bern, Switzerland; Santésuisse, Solothurn, 
Switzerland 
PHP50 The Islamia University of Bahawalpur, Bahawalpur, Pakistan
PHP51 co-funded by Greece and the European Union, Athens, Greece
PHP52 None 
PHP53 Novartis, Athens, Greece 
PHP54 None 
PHP55 Double Helix Consulting, London, UK 
PHP56 the 7th Framework Programme (FP7) , Brussel, Belgium 
PHP57 the 7th Framework Programme (FP7), Brussel, Belgium 
PHP58 the 7th Framework Programme (FP7), Brussel, Belgium 
PHP59 Co funded by Greek and EU funds, Athens, Greece 
PHP60 European Union, Brussels, Belgium 
PHP61 None 
PHP62 EuroQol Group, Rotterdam, The Netherlands 
PHP63 None 
PHP64 Roche, Mississauga, ON, Canada
PHP65 None 
PHP66 None 
PHP68 Health Research Board, Dublin, Ireland 
PHP69 None 
PHP70 None 
PHP71 None 
PHP72 None 
PHP73 None 
PHP74 None 
PHP75 None 
PHP76 None 
PHP77 Medical Research Council Network of Hubs for Trial Methodology 
Research, London, UK 
PHP78 University of the Witwatersrand, Johannesburg, South Africa
PHP79 None 
PHP80 NOVARTIS Hellas, METAMORFOSI, Greece 
PHP81 IHS, London, UK 
PHP82 None 
PHP83 None 
PHP84 Takeda, Zurich, Switzerland 
PHP85 None 
PHP87 Covidien (Mallinckrodt), Moscow, Russia 
PHP88 GE Healthcare, Milan, Italy 
PHP89 None 
PHP90 None 
PHP91 Nestlé Health Science, Vevey, Switzerland 
PHP92 None 
PHP93 None 
PHP94 None 
PHP95 None 
PHP96 Novartis Hellas, Athens, Greece
PHP97 None 
PHP98 None 
PHP99 None 
PHP100 Novartis Hellas, Athens, Greece
PHP101 None 
PHP103 National Institute for Health Research, London, UK 
PHP104 Merck & Co., Inc, Whitehouse Station, NJ, USA 
PHP105 University of Technology, Sydney, Sydney, Australia 
PHP106 Nestlé Health Science, Vevey, Switzerland 
PHP107 None 
PHP108 None 
Reference 
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PHP110 None
PHP111 King Abdullah international medical research center, Riyadh, Saudi Arabia
PHP112 GIRP, Brussels, Belgium
PHP113 None
PHP114 GIRP, Brussels, Belgium
PHP115 PAREXEL International, Waltham, MA, USA 
PHP116 None
PHP118 None
PHP120 Institute for Quality and Efficiency in Health Care, Cologne, Germany
PHP122 None
PHP123 GlaxoSmithKline Biologicals SA, Rixensart, Belgium 
PHP124 Institute for Quality and Efficiency in Health Care, Cologne, Germany
PHP125 Roche Diagnostics International Ltd.., Rotkreuz, Switzerland
PHP126 Top Institute Pharma, Leiden, The Netherlands 
PHP127 None
PHP128 None
PHP129 Pharma.be, Brussels, Belgium 
PHP130 None
PHP131 None
PHP132 Roche Diagnostics International Ltd.., Rotkreuz, Switzerland
PHP133 GSK, Ireland, Dublin 16, Ireland 
PHP134 None
PHP135 None
PHP136 None
PHP137 None
PHP138 Quintiles, Hoofddorp, The Netherlands 
PHP139 GSK, Ireland, Dublin, Ireland 
PHP140 None
PHP141 None
PHP142 RTI-HS, Research Triangle Park, NC, USA 
PHP143 None
PHP144 EFPIA, Brussels, Belgium; EuropaBio, Brussels, Belgium; sbg Healthcare 
Consulting, Pully, Switzerland; BC Consulting & Solutions Sàrl, Lausanne, 
Switzerland; Virtuoso, Grand Saconnex, Switzerland 
PHP145 None
PHP146 None
PHP147 None
PHP148 None
PHP149 None
PHP150 None
PHP151 None
PHP152 Costello Medical Consulting Ltd.., Cambridge, UK 
PHP153 None
PHP154 None
PHP155 PPD, Morrisville, NC, USA
PHP156 Evidera, London, UK
PHP157 None
PHP158 None
PHP159 None
PHP160 HERON Evidence Development Ltd., London, UK 
PHP161 None
PHP162 None
PHP163 Novartis, East Hanover, NJ, USA 
PHP164 Pfizer, New York, USA
PHP165 None
PHP166 None
PHP167 SmartStep Consulting GmbH, Hamburg, Germany 
PHP168 None
PHP169 RTI Health Solutions, Manchester, UK 
PHP170 Hoffman La Roche, Mississauga, ON, Canada 
PHP171 HERON Evidence Development Ltd., London, UK 
PHP172 None
PHP173 None
PHP174 None
PHP175 The Israel National Institute for Health Policy and Health Services Research 
(NIHP), Tel Aviv, Israel 
PHP176 Boehringer Ingelheim, Sant Cugat del Vallès (Barcelona), Spain
PHP177 London School of Economics, London, UK 
PHP178 SmartStep Consulting GmbH , Hamburg, Germany 
PHP179 None
PHP180 None
PHP181 None
PHP182 None
PHP183 None
PHP184 None
PHP185 None
PHP186 None
PHP187 None
PHP188 Sanofi, Germany, Berlin, Germany 
PHP189 None
PHP190 None
PHP191 Health Research Board (HRB), Dublin, Ireland 
PHP192 Health Research Board, Dublin, Ireland 
PHP193 None
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PHP194 None 
PHP195 None 
PHP197 Ethicon, Somerville, NJ, USA 
PHP198 SROP-4.2.2.C-11/1/KONV-2012-0005, Well-being in the Information 
Society, Budapest, Hungary 
PHP199 Abbott Products Operations AG, Basel, Switzerland 
PHP200 None 
PHP201 Abbott Products Operations AG, Basel, Switzerland 
PHP202 Top Insitute Pharma, Leiden, QC, The Netherlands 
PHP203 Európai Integrációs Alap, a Belügyminisztérium és a Tullius Kft, Budapest, 
Hungary 
PHP204 None 
PHP205 Ministry of Food and Drug Safety, Chungcheongbuk-do, South Korea
PHP206 None 
PHP207 None 
PHP208 None 
PHP209 None 
PHP210 None 
PHP211 None 
PHP212 Fundación Mútua Madrileña, Madrid, Spain; Fondo de Investigación 
Sanitaria (FIS-ISCIII), Madrid, Spain 
PHP213 None 
PHP214 IDEX Bordeaux, Bordeaux, France
PHP215 None 
PHP216 None 
PHP217 German Federal Ministry of Education and Research (BMBF) , Berlin, 
Germany 
PHP218 None 
PHP219 None 
PHP220 None 
PHP221 None 
PHP222 None 
PHP223 Janssen Pharmaceutica NV, Beerse, Belgium 
PHP224 None 
PHP225 None 
PHP226 None 
PHP227 None 
PHP228 None 
PHP229 None 
PHP230 None 
PHP231 None 
PHP232 None 
PHP233 None 
PHP235 None 
PIH1 Ferring Pharmaceuticals A/S, Copenhagen, Denmark 
PIH2 None 
PIH3 None 
PIH4 None 
PIH6 Bayer Schering, Berlin, Germany
PIH7 Roche Diagnostic, Pleasanton, CA, USA 
PIH8 Johnson & Johnson, Somerville, NJ, USA 
PIH9 Bayer Healthcare Brazil, São Paulo, Brazil 
PIH10 GlaxoSmithKline SpA, Verona, Italy
PIH12 None 
PIH13 GSK s.r.o., Prague, Czech Republic 
PIH14 None 
PIH15 None 
PIH16 European Commission, Brussels, Belgium 
PIH17 None 
PIH18 None 
PIH19 GlaxoSmithKline, Athens, Greece
PIH20 None 
PIH21 Bayer Hispania, S.L., Barcelona, Spain 
PIH22 Kolplast Comérico e Indústria LTD.A, São Paulo, Brazil 
PIH23 Merck & Co., Inc., West Point, PA, USA 
PIH24 Sheffield Teaching Hospitals Charitable Trust, Sheffield, UK
PIH25 None 
PIH26 GSK, Utrecht, The Netherlands
PIH27 Bayer HealthCare Pharmaceuticals, Moscow, Russia 
PIH28 Bayer Healthcare Brazil, São Paulo, Brazil 
PIH29 National Institute for Health Research (NIHR), London, UK 
PIH30 Health Research Board, Dublin, Ireland 
PIH31 None 
PIH32 The Israel National Institute for Health Policy Research, Tel-Aviv, Israel
PIH33 ZonMw, The Hague, The Netherlands 
PIH34 None 
PIH35 Novo Nordisk, Søborg, Denmark
PIH36 None 
PIH37 None 
PIH38 None 
PIH40 Ministry of Health, Labour and Welfare, Tokyo, Japan 
PIH41 None 
PIH42 None 
Reference 
Code Financial Support 
PIH43 Roche, Boulogne-Billancourt, France 
PIH44 Pfizer Inc, Collegeville, PA, USA 
PIH45 None
PIH46 Adelphi Values, Bollington, UK 
PIH47 None
PIH48 Pfizer S.L.U, Alcobendas, Spain 
PIH49 Abbott Laboratories, Abbott Park, IL, USA; GRIDES, São Paulo, Brazil
PIH50 The Israel National Institute for Health Policy Research, Tel-Hashomer, 
Israel 
PIH51 Abbott Laboratories, Abbott Park, IL, USA; GRIDES, São Paulo, Brazil
PIH52 None
PIH53 Gedeon Richter Plc, Budapest, Hungary 
PIH54 European Commission, Brussels, Belgium 
PIH55 Merk S.L., Madrid, Spain
PIH56 None
PIH57 None
PIH58 European Medicines Agency, London, UK 
PIH59 KVBaWue, Stuttgart, Germany; vdek, Stuttgart, Germany; Janssen, Neuss, 
Germany; Shire, Wayne, PA, USA 
PIH60 Swedish council for working life and social research [Forskningsrådet för 
arbetsliv och socialvetenskap, FAS], Stockholm, Sweden 
PIH62 None
PIN1 None
PIN2 Gilead, Foster City, CA, USA 
PIN3 Gilead Sciences, Foster City, CA, USA 
PIN4 Janssen Pharmaceutical NV, Beerse, Belgium 
PIN5 GAP, Bruxelles, Belgium
PIN6 F. Hoffmann-La Roche Ltd., Moscow, Russia 
PIN7 Roche Pharma AG, Grenzach-Wyhlen, Germany 
PIN8 Pfizer S.A de C.V, Mexico City, Mexico 
PIN9 Janssen Pharmaceutica NV, Beerse, Belgium 
PIN10 None
PIN11 Boehringer Ingelheim GmbH, Ingelheim, Germany 
PIN12 Merck & Co. Inc., West Point, PA, USA 
PIN13 NCDC, Tripoli, Libya
PIN14 Sanofi Pasteur MSD, Lyon, France 
PIN15 Sanofi Pasteur MSD, Lyon, France 
PIN16 None
PIN17 None
PIN18 Gilead Sciences, Foster City, CA, USA 
PIN19 GAP, Bruxelles, Belgium
PIN20 Pfizer Hellas, Athens, Greece 
PIN21 Covidien, Ankara, Turkey
PIN22 Roche Spa, Monza, Italy
PIN23 BD, Franklin Lakes, NJ, USA 
PIN24 None
PIN25 Sanofi Pasteur MSD, Maidenhead, UK 
PIN26 F. Hoffmann-La Roche Ltd., Moscow, Russia 
PIN27 Janssen Cilag Farmaceutica, Sao Paulo, Brazil 
PIN28 None
PIN29 ViiV Healthcare, Moscow, Russia 
PIN30 Cepheid, Maurens-Scopont, France 
PIN31 None
PIN32 None
PIN33 GSK Vaccines, Wavre, Belgium 
PIN34 None
PIN35 Novartis Vaccines and Diagnostics, Rueil-Malmaison, France
PIN36 None
PIN37 sanofi pasteur MSD, Stockholm, Sweden 
PIN38 None
PIN39 GlaxoSmithKline Biologicals SA, Rixensart, Belgium 
PIN40 None
PIN41 Novosys Health, Flemington, NJ, USA 
PIN42 None
PIN43 GlaxoSmithKline GmbH & Co. KG, Munich, Germany 
PIN44 Centre for Public Affairs Studies Foundation, Budapest, Hungary
PIN45 None
PIN46 ViiV Healthcare, Brentford, UK 
PIN47 Boehringer Ingelheim GmbH, Ingelheim, Germany 
PIN48 None
PIN49 None
PIN50 Astellas Pharma Europe Ltd., chertsey, UK 
PIN51 Cubist Pharmaceuticals, Lexington, MA, USA 
PIN52 Gilead Sciences Inc, Toronto, ON, Canada 
PIN53 Sanofi Pasteur MSD, Maidenhead, UK 
PIN54 Merck Sharp & Dohme , Madrid, Spain 
PIN55 None
PIN56 The Medicines Company, Parsippany, NJ, USA 
PIN57 Gilead Sciences, Foster City, CA, USA 
PIN58 The Medicines Company, Parsippany, NJ, USA 
PIN59 None
PIN60 None
PIN61 Cepheid, Maurens-Scopont, France 
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PIN62 Robert Koch Institute, Berlin, Germany 
PIN63 Pfizer S.L.U, Alcobendas, Spain
PIN64 Pfizer Central America and the Caribbean, San José, Costa Rica
PIN65 MSD Hellas, Athens, Greece 
PIN66 Janssen Cilag Farmaceutica, Sao Paulo, Brazil 
PIN67 MSD, Hoddesdon, UK 
PIN68 Pfizer , Prague, Czech Republic
PIN69 Astellas Pharma Co Ltd., Dublin, Ireland 
PIN70 GlaxoSmithKline, Wavre, Belgium
PIN71 Copper Development Association, Oxfordshire, UK 
PIN72 Pfizer Spain, Madrid, Spain 
PIN73 None 
PIN74 Pfizer Central America and the Caribbean, San José, Costa Rica
PIN75 Janssen Cilag Farmaceutica, Sao Paulo, Brazil 
PIN76 None 
PIN77 Pfizer Inc., Paris, France 
PIN78 MSD Denmark, Ballerup, Denmark
PIN79 JANSSEN-CILAG S.A., MADRID, Spain 
PIN80 None 
PIN81 None 
PIN82 Pfizer Hellas, Athens, Greece 
PIN83 Sanofi Pasteur MSD, Maidenhead, UK 
PIN84 None 
PIN85 None 
PIN86 None 
PIN87 3M Deutschland GmbH, Neuss, Germany 
PIN88 None 
PIN89 None 
PIN90 None 
PIN91 None 
PIN92 None 
PIN93 None 
PIN94 GlaxoSmithKline, Verona, Italy 
PIN95 None 
PIN96 Gilead Sciences, London, UK 
PIN97 None 
PIN98 None 
PIN99 None 
PIN100 None 
PIN101 2) Basilea Pharmaceutica International Ltd.., Basel, Switzerland
PIN102 ViiV Healthcare, Moscow, Russia
PIN103 Merck , Whitehouse Station, NJ, USA 
PIN104 MSD, Sollentuna, Sweden 
PIN105 None 
PIN106 Janssen, Issy-les-Moulineaux, France 
PIN107 Janssen-Cilag Polska, Warsaw, Poland 
PIN108 Pfizer S.A de C.V, Mexico City, Mexico 
PIN109 1. Eli Lilly (Suzhou) Pharmaceutical Co., Ltd., Shanghai, China
PIN110 Sanofi Pasteur MSD, Lyon, France
PIN111 Abbott Laboratories, Saint-Petersburg, Russia 
PIN112 Sanofi Pasteur MSD, Lyon, France
PIN113 None 
PIN114 Gilead Sciences Inc, Toronto, ON, Canada 
PIN115 Novartis Pharma AG, Basel, Switzerland 
PIN116 Council for Scientific and Humanistic Development Central University of 
Venezuela, Caracas, Venezuela 
PIN117 Gilead Sciences Inc, Toronto, ON, Canada 
PIN118 GSK, London, UK; ViiV Healthcare, London, UK 
PIN119 National Institute for Public Health and the Envoironment, Bilthoven,
 The 
Netherlands 
 
PIN120 Janssen, Beerse, Belgium 
PIN121 None 
PIN122 None 
PIN123 AbbVie, North Chicago, IL, USA
PIN124 AbbVie, Inc, North Chicago, IL, USA 
PIN125 AbbVie, Inc., North Chicago, IL, USA 
PIN126 Janssen, Beerse, Belgium 
PIN127 Sanofi Pasteur MSD, Lyon, France
PIN128 None 
PIN129 None 
PIN130 Merck & Co., West Point, PA, USA
PIN131 Vaccines Europe, European Federation of Pharmaceutical Industries and 
Associations, Brussels, Belgium 
PIN132 Albutran M, Moscow, Russia 
PIN133 Health Research Board, Dublin, Ireland 
PIN134 ViiV Healthcare, Research Triangle Park, NC, USA 
PIN135 Ministry of Higher Education, Putrajaya, Malaysia 
PIN136 GlaxoSmithKline GmbH & Co. KG, Munich, Germany 
PIN137 Context Matters, Inc., New York, NY, USA 
PIN138 French Society of General Medicine, Issy les Moulineaux, France
PIN139 Context Matters, Inc., New York, NY, USA 
PIN140 None 
PMH1 Lundbeck SAS, Paris, France 
Reference 
Code Financial Support 
PMH2 None
PMH3 None
PMH4 Eli Lilly and Company, Indianapolis, IN, USA 
PMH5 None
PMH6 Forest Research Institute, Jersey City, NJ, USA; Pierre Fabre Médicament, 
Toulouse, France 
PMH7 None
PMH8 None
PMH9 Takeda Pharmaceuticals International GmbH, Zurich, Switzerland
PMH10 Lundbeck SAS, Paris, France 
PMH11 None
PMH12 None
PMH13 H.Lundbeck A/S, Valby, Denmark 
PMH14 H.Lundbeck A/S, Valby, Denmark 
PMH15 Eli Lilly and Company, Indianapolis, IN, USA 
PMH16 Eli Lilly and Company, Indianapolis, IN, USA 
PMH17 None
PMH18 None
PMH19 Takeda Pharmaceuticals, Deerfield, IL, USA 
PMH20 None
PMH21 None
PMH22 None
PMH23 Lilly Suzhou Pharmaceutical Company, Ltd.., Shanghai, China
PMH24 Lilly Suzhou Pharmaceutical Company, Ltd.., Shanghai, China
PMH25 sponsored by Novartis Hellas, Metamorfosi, Greece 
PMH26 Roche, Warsaw, Poland
PMH27 KVBaWue, Stuttgart, Germany; vdek, Stuttgart, Germany; Janssen, Neuss, 
Germany; Shire, Wayne, PA, USA 
PMH28 Federal Ministry of Education and Research, Berlin, Germany
PMH29 Richter Gedeon Nyrt., Budapest, Hungary 
PMH30 Shire Development, LLC, Wayne, PA, USA 
PMH31 Janssen Cilag Ltd., Budapest, Hungary 
PMH32 Pfizer S.L.U., Madrid, Spain 
PMH33 None
PMH34 Janssen, Neuss, Germany 
PMH35 AstraZeneca, Mexico city, Mexico 
PMH36 None
PMH37 Janssen EMEA, Beerse, Belgium 
PMH38 Ministry of Health, Brasilia, Brazil 
PMH39 Takeda , Zurich, Switzerland 
PMH40 Lundbeck, Istanbul, Turkey 
PMH41 Lundbeck, Istanbul, Turkey 
PMH42 Shire Development, LLC, Wayne, PA, USA 
PMH43 Lundbeck SAS, Issy les Moulineaux, France 
PMH44 Lundbeck Italia SpA, Milan, Italy 
PMH45 Janssen-Cilag UK Ltd., High Wycombe, England 
PMH46 Federal Ministry of Education and Research, Berlin, Germany
PMH47 Shire Development, LLC, Wayne, PA, USA 
PMH48 Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA
PMH49 Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA
PMH50 H Lundbeck A/S, Valby, Denmark; Otsuka Pharmaceutical Development & 
Commercialization, Inc., Princeton, NJ, USA 
PMH51 None
PMH52 None
PMH53 None
PMH54 Pfizer S.L.U., Madrid, Spain 
PMH55 None
PMH56 None
PMH57 Lundbeck, Issy, France
PMH58 None
PMH59 None
PMH60 None
PMH61 Shire Development, LLC, Wayne, PA, USA 
PMH62 Lundbeck, Valby, Denmark; Otsuka Pharmaceutical Development & 
Commercialization, Princeton, NJ, USA 
PMH63 Shire Development, LLC, Wayne, PA, USA 
PMH64 Lundbeck, Valby, Denmark; Otsuka Pharmaceutical Development & 
Commercialization, Inc, Princeton, NJ, USA 
PMH65 None
PMH66 Mapi, Lexington, KY, USA
PMH67 Janssen Alzheimer Immunotherapy Research & Development, LLC,, Dublin, 
Ireland 
PMH68 None
PMH69 Restore FX, Austin, TX, USA 
PMH70 None
PMH71 None
PMH72 Danish Center for Healthcare Improvement, Aalborg, Denmark; University 
College of Norther n Denmark, Aalborg, Denmark 
PMH73 Lilly Suzhou Pharmaceutical Company, Ltd.., Shanghai, China
PMS1 None
PMS2 None
PMS3 None
PMS4 None
PMS5 Amgen , Uxbridge, UK; GSK, Brentford, UK 
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PMS6 AbbVie Inc., North Chicago, IL, USA 
PMS7 None 
PMS8 Sanofi Biosurgery, Cambridge, MA, USA 
PMS9 UCB Pharma, Colombes, France
PMS10 Medtronic International, Tolochenaz, Switzerland 
PMS11 Egis Pharmaceuticals, Budapest, Hungary 
PMS12 Avtelion Pharmaceuticals Australia, Frenchs Forest, Australia
PMS13 NIHR, UK 
PMS14 None 
PMS15 Pfizer, Collegeville, CT, USA 
PMS16 Faculty of Pharmacy, Charles University in Prague, Hradec Kralove, Czech 
Republic 
PMS17 Pfizer Italy, Milan, Italy 
PMS18 None 
PMS19 None 
PMS20 None 
PMS21 Egis Pharmaceuticals, Budapest, Hungary 
PMS22 Hospira, Royal Leamington Spa, UK 
PMS23 Heron, Stockholm, Sweden; Medtronic, Tolochenaz, Switzerland
PMS24 None 
PMS25 Bristol-Myers Squibb, Moscow, Russia 
PMS26 None 
PMS27 Costello Medical Consulting, Cambridge, England 
PMS28 Pfizer, Malaga, Spain 
PMS29 AbbVie, North Chicago, IL, USA
PMS30 None 
PMS31 Novartis Pharma Co., Ltd., Beijing, China 
PMS32 Amgen Romania SRL, Bucharest, Romania 
PMS33 Pfizer, Istanbul, Turkey 
PMS34 None 
PMS35 Central and Eastern European Society of Technology Assessment in Health 
Care, Krakow, Poland 
PMS36 Eli Lilly and Company, Indianapolis, IN, USA 
PMS37 Eli Lilly and Company, Indianapolis, IN, USA 
PMS38 Eli LIlly, Shanghai, China 
PMS39 CNPQ, Sao Paulo, Brazil 
PMS40 National Science Council, Taiwan, Taiwan 
PMS41 Fidia Farmaceutici SpA, Abano Terme, Italy 
PMS42 None 
PMS43 Fidia Farmaceutici SpA, Abano Terme, Italy 
PMS44 UCB Pharma, Colombes, France
PMS45 AbbVie Inc., North Chicago, IL, USA 
PMS46 F. Hoffmann-La Roche, Moscow, Russia 
PMS47 Products Roche , Bogotá D.C, Colombia 
PMS48 Pfizer, Rome, Italy 
PMS49 None 
PMS50 BMS Hellas, Athens, Greece 
PMS51 F. Hoffmann-La Roche, Moscow, Russia 
PMS52 GlaxoSmithKline, Verona, Italy 
PMS53 F. Hoffman – La Roche, Basel, Swaziland 
PMS54 Bristol-Myers Squibb, Madrid, Spain 
PMS55 MSD, Moscow, Russia 
PMS56 None 
PMS57 Bone Index Finland, Kuopio, Finland 
PMS58 MSD, Hoddesdon, UK 
PMS59 Roche Farma, Madrid, Spain 
PMS60 Roche (Hellas) S.A., Athens, Greece 
PMS61 National Institute for Health Research, London, UK 
PMS62 Roche (Hellas) S.A., Athens, Greece 
PMS63 Roche Oy, Espoo, Finland 
PMS64 Wyeth/Pfizer, Rome, Italy 
PMS65 UCB Pharma, Brussels, Belgium
PMS66 UCB Pharma, Brussels, Belgium
PMS67 Polish Ministry of Science and Higher Education, Warsaw, Poland
PMS68 Polish Ministry of Science and Higher Education, Warsaw, Poland
PMS69 Polish Ministry of Science and Higher Education, Warsaw, Poland
PMS70 None 
PMS71 Amgen (Europe) GmbH, Zug, Switzerland 
PMS72 Amgen (Europe) GmbH, Zug, Switzerland 
PMS73 Amgen (Europe) GmbH, Zug, Switzerland 
PMS74 Amgen Ltd., Uxbridge, UK; GSK, Brentford, UK 
PMS75 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
PMS76 Grant-in-Aid for Young Scientists (B), The Ministry of Education, Culture, 
Sports, Science and Technology(MEXT), Chiyoda-ku, Tokyo, Japan 
PMS77 Pfizer Limited, Taipei, Taiwan 
PMS78 Pfizer, Rome, Italy 
PMS79 Amgen, Zug, Switzerland 
PMS80 UCB Pharma, Brussels, Belgium
PMS81 UCB Pharma, Brussels, Belgium
PMS82 Patient-Reported Outcome Consortium’s RA Working Group, Tuscon, 
 AZ, USA 
PMS83 Merck, Whitehouse Station, NJ, USA 
PMS84 None 
Reference 
Code Financial Support 
PMS85 UCB Pharma, Brussels, Belgium 
PMS86 UCB Pharma, Brussels, Belgium 
PMS87 UCB Pharma, Brussels, Belgium 
PMS88 UCB Pharma, Brussels, Belgium 
PMS89 UCB Pharma, Colombes, France 
PMS90 MSD, Rome, Italy
PMS91 pfizer health research foundation, Shibuya-ku, Tokyo, Japan
PMS92 None
PMS93 None
PMS94 None
PMS95 None
PMS96 None
PMS97 None
PMS98 None
PMS99 UCB Pharma, Colombes, France 
PMS100 None
PMS101 Pfizer, Rome, Italy
PMS102 Pfizer, Collegeville, CT, USA 
PMS103 Ipsen Pharma, Paris, France 
PMS104 Sandoz International GmBH, Holzkirchen, Germany 
PMS105 IOF Invest in Your Bones (IYB), Nyon, Switzerland; Amgen, Thousand Oaks, 
CA, USA; Eli Lilly, Indianapolis, IN, USA; Medtronic, Fridley, MN, USA; 
Novartis, Basel, Switzerland; Sanofi-Aventis, Paris, France; Servier, Neuilly-
sur-Seine, France; Pfizer, New York City, NY, USA 
PMS106 Amgen Switzerland AG, Zug, Switzerland 
PMS107 None
PMS108 None
PMS109 None
PND1 Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA
PND2 Pfizer Canada, Kirkland, QC, Canada 
PND3 Novartis Pharma AG, Basel, Switzerland 
PND4 None
PND5 Yrjö-Jahnsson Foundation, Helsinki, Finland; The Foundation for Municipal 
Development, Helsinki, Finland; Hospital Neuron, Kuopio, Finland; Kuopio 
University Hospital (EVO-grant 5220/5772728), Kuopio, Finland; Novartis 
AG , Basel, Switzerland; the Social Insurance Institute of Finland (Kela), 
Helsinki, Finland 
PND6 Novartis Pharma AG, Basel, Switzerland 
PND7 Novartis Pharma AG, Basel, Switzerland 
PND8 UCB, s.r.o., Prague, Czech Republic 
PND9 NRF, Pretoria, South Africa 
PND10 None
PND11 None
PND12 Haute Autorité de Santé, Saint Denis La Plaine, France
PND13 IPSEN Pharma, Boulogne-Billancourt, France 
PND14 Biogen Idec, Weston, MA, USA 
PND15 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
PND16 Biogen Idec, São Paulo, Brazil 
PND17 None
PND18 Biogen Idec Inc, Weston, MA, USA 
PND19 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
PND20 None
PND21 None
PND22 Novartis Pharma AG, Basel, Switzerland 
PND23 Sanofi Pasteur MSD, Lyon, France 
PND24 None
PND25 Pfizer Canada, Kirkland, QC, Canada 
PND26 EVER Neuro Pharma, Unterach, Austria 
PND27 Merck Serono, Prague, Czech Republic 
PND28 Biogen Idec, Weston, MA, USA 
PND29 TEVA Pharma, Madrid, Spain 
PND30 F. Hoffmann-La Roche Ltd., Moscow, Russia 
PND31 Boehringer Ingelheim, Moscow, Russia 
PND32 UCB s.r.o., Prague, Czech Republic 
PND33 None
PND34 Ipsen Pharma, Barcelona, Spain 
PND35 None
PND36 Biogen Idec, São Paulo, Brazil 
PND37 None
PND38 None
PND39 None
PND40 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
PND41 None
PND42 GSK, Brentford, UK
PND43 Novartis Farmacéutica, S.A, Barcelona, Spain 
PND44 None
PND45 None
PND46 IPSEN Pharma, Boulogne-Billancourt, France 
PND47 NNS National Institute for Health Research, London, UK
PND48 Pfizer Ltd., Walton Oaks, UK 
PND49 BiogeneIdec, Basel, Switzerland 
PND50 Yrjö-Jahnsson Foundation, Helsinki, Finland; The Foundation for Municipal 
Development, Helsinki, Finland; Hospital Neuron, Kuopio, Finland; Kuopio 
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 6 3 7 - A 6 4 8  A645 
 
 
Reference 
Code Financial Support 
University Hospital (EVO-grant 5220/5772728), Kuopio, Finland; Novartis 
AG , Basel, Switzerland; the Social Insurance Institute of Finland (Kela), 
Helsinki, Finland 
PND51 Biogen Idec, Weston, MA, USA
PND52 None 
PND53 Bial Industrial Farmaceutica, Madrid, Spain 
PND54 None 
PND55 None 
PND56 None 
PND57 None 
PND59 LUNDBECK, ISSY-LES-MOULINEAUX, France 
PND60 Merk S.L., Madrid, Spain 
PND61 UCB Pharma, Brussels, Belgium
PND62 Biogen Idec Limited, Maidenhead, UK 
PND63 Ministry of Health, Labour and Welfare, Tokyo, Japan 
PND64 Merck Serono, Stockholm, Sweden; Neurologiskt Handikappades 
Riksförbund, Stockholm, Sweden 
PND65 None 
PND66 Merck & Co., Inc., Whitehouse Station, NJ, USA 
PP1 None 
PP2 EuroQoL, Rotterdam, The Netherlands 
PP3 Evidera, London, UK 
PP4 Quintiles, Reading, UK 
PRM1 None 
PRM2 Novartis Pharma AG, Basel, Switzerland 
PRM3 None 
PRM4 F. Hoffmann-La Roche, Basel, Switzerland 
PRM5 None 
PRM6 None 
PRM7 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 
PRM8 GSK Hungary, Budapest, Hungary
PRM9 GSK Hungary, Budapest, Hungary
PRM10 Truven Health Analytics, Ann Arbor, MI, USA 
PRM11 Region of Northern Jutland, Aalborg, Denmark 
PRM12 None 
PRM13 None 
PRM14 F. Hoffmann La Roche, Basel, Switzerland 
PRM15 None 
PRM16 None 
PRM17 None 
PRM18 Takeda Pharmaceuticals, Deerfield, IL, USA; Lundbeck, Deerfield, IL, USA
PRM19 None 
PRM20 Bristol-Myers Squibb pharmaceuticals Ltd., uxbridge, UK 
PRM21 National Institute for Health Research, London, UK 
PRM22 None 
PRM23 Bristol-Myers Squibb, Uxbridge, UK 
PRM24 Bristol-Myers Squibb, Uxbridge, UK 
PRM25 Boehringer Ingelheim GmbH, Ingelheim, Germany 
PRM26 None 
PRM27 Health Information and Quality Authority, Dublin, Ireland 
PRM28 Medical Research Council, London, UK 
PRM30 None 
PRM31 NIHR, London, UK 
PRM32 NIHR, Sheffield, UK 
PRM33 None 
PRM34 None 
PRM35 Hellenic Association of Pharmaceutical Companies (SFEE), Athens, Greece
PRM36 Amgen, Inc., Thousand Oaks, CA, USA 
PRM37 None 
PRM38 None 
PRM39 Federal Ministry of Education and Research, Berlin, Germany
PRM40 Novartis, East Hanover, NJ, USA
PRM41 Novartis Pharma AG, Basel, Switzerland 
PRM42 AstraZeneca, Alderly Park, England; IMS, London, England 
PRM43 Novartis Pharma AG, Basel, Switzerland 
PRM44 None 
PRM45 AstraZeneca Canada Inc, Mississauga, ON, Canada 
PRM46 None 
PRM47 None 
PRM48 Sanofi, Cambridge, MA, USA 
PRM49 OptumInsight, Eden Prairie, MN, USA 
PRM50 Sanofi, Cambridge, MA, USA 
PRM51 AstraZeneca R&D, Mölndal, Sweden 
PRM52 None 
PRM53 None 
PRM54 Bayer Yakuhin Ltd.., Tokyo, Japan
PRM55 None 
PRM56 Business & Decision Life Sciences, Brussels, Belgium 
PRM57 None 
PRM58 None 
PRM59 None 
PRM60 GlaxoSmithKline, London, UK 
PRM61 AstraZeneca, Molndal, Sweden
PRM62 None 
Reference 
Code Financial Support 
PRM63 None
PRM64 Novartis, East Hanover, NJ, USA 
PRM65 None
PRM66 None
PRM67 GlaxoSmithKline, Mississauga, ON, Canada 
PRM68 GSK, Sofia, Bulgaria
PRM69 IMS Health, Basel, Switzerland 
PRM70 TreeAge Software, Inc (2 authors are employees), Williamstown, MA, USA
PRM71 None
PRM72 The The Netherlands Organisation for Health Research and Development,
The Hague, The Netherlands 
PRM73 IMS Health, Basel, Switzerland 
PRM74 Novartis Pharmaceuticals Corp, East Hanover, NJ, USA
PRM75 Center for Translational Molecular Medicine, Utrecht, The Netherlands; 
Dutch Heart Foundation, Den Haag, The Netherlands 
PRM76 Adelphi Values, Boston, MA, USA 
PRM77 Boehringer Ingelheim GmbH, Ingelheim, Germany 
PRM78 None
PRM79 IMS Health, Basel, Switzerland 
PRM80 Danone Research, Palaiseau, France 
PRM81 None
PRM82 IMS Health, Alexandria, VA, USA 
PRM83 F. Hoffmann - La Roche Ltd.., Basel , Switzerland 
PRM84 Myriad Genetics, Inc., Salt Lake City, UT, USA 
PRM85 None
PRM86 AstraZeneca, Zoetermeer, The Netherlands 
PRM87 None
PRM88 None
PRM89 Novartis AG, Basel, Switzerland 
PRM90 Bristol-Myers Squibb, Rueil-Malmaison, France; AstraZeneca, Brussels, 
Belgium 
PRM91 Almirall, Barcelona, Spain
PRM92 Heron , London, England
PRM93 PhRMA Foundation, Washington, DC, DC, USA 
PRM94 None
PRM95 Austrian Research Promotion Agency, Vienna, Austria 
PRM96 National Institute for Health Research, London, UK 
PRM97 None
PRM98 IMS Health, Basel, Switzerland 
PRM99 None
PRM100 None
PRM101 None
PRM102 Novartis Pharma AG, Basel, Switzerland 
PRM103 Ipsen pharma, Boulogne-Billancourt, France 
PRM104 Boehringer Ingelheim GmbH, Ingelheim, Germany 
PRM105 Roche, Basel, Switzerland 
PRM106 None
PRM107 Bristol-Myers Squibb, Paris, France 
PRM108 University of Leicester, Leicester, UK; National Cancer Centre Singapore, 
Singapore, Singapore 
PRM109 None
PRM110 F. Hoffmann - La Roche, Basel, Switzerland 
PRM111 None
PRM112 GSK, London, UK
PRM113 None
PRM114 None
PRM115 Bayer Hispania, S.L., Barcelona, Spain 
PRM116 None
PRM117 None
PRM118 Biogen Idec GmbH, Ismaning, Germany 
PRM119 None
PRM120 Pfizer Ltd., Tadworth, UK
PRM121 None
PRM122 None
PRM124 None
PRM125 None
PRM126 None
PRM127 Pfizer Italia Srl, Latina, Italy 
PRM128 Kantar Health, New York, NY, USA 
PRM129 None
PRM130 National Science Council, Taipei, Taiwan 
PRM131 None
PRM132 Les Laboratoires Servier, Paris, France 
PRM133 None
PRM134 Shire, Wayne, PA, USA
PRM135 None
PRM136 None
PRM137 None
PRM138 None
PRM139 None
PRM140 None
PRM141 National Institute of Health, Bethesda, MD, USA 
PRM142 Oxford Pharmagenesis Ltd., Tubney, Oxford, UK 
PRM143 None
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PRM144 None 
PRM145 AbbVie Inc, Chicago, IL, USA 
PRM146 Novo Nordisk A/S, Søborg, Denmark 
PRM147 Exelixis, Inc, South San Francisco, CA, USA 
PRM148 None 
PRM149 None 
PRM150 None 
PRM151 UCB Pharma, Brussels, Belgium
PRM152 None 
PRM153 None 
PRM154 None 
PRM155 None 
PRM156 National Science Council, Taipei, Taiwan 
PRM157 TransPerfect, New York, NY, USA
PRM158 TransPerfect, New York, NY, USA
PRM159 AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany
PRM160 National Institute for Public Health and the Envoironment, Bilthoven, The 
Netherlands 
PRM161 ICON PLC, OXFORD, UK 
PRM162 Centers for Disease Control, Atlanta, GA, USA; National Institute of Child 
Health and Human Development, Bethesda, MD, USA 
PRM163 Roche, Boulogne-Billancourt, France 
PRM164 Pfizer Ltd., Tadworth, Surrey, UK
PRM165 Kantar Health, Epsom, UK 
PRM166 Pfizer Ltd., Tadworth, UK; Janssen AI, Neuss, Germany 
PRM167 TransPerfect, New York, NY, USA
PRM168 Double Helix Consulting, London, UK 
PRM169 None 
PRM170 None 
PRM171 National Institute for Health Research, London, UK 
PRM172 GlaxoSmithKline, Brentford, London, UK 
PRM173 European Union (FEDER), Regional Council of Burgundy, General Council, 
Grand Dijon and the BALI consortium of industrials, Dijon, France 
PRM174 None 
PRM175 None 
PRM176 None 
PRM177 None 
PRM178 None 
PRM179 None 
PRM180 None 
PRM181 Forest Research Institute, Jersey City, NJ, USA 
PRM182 None 
PRM183 None 
PRM184 None 
PRM185 None 
PRM186 LA-SER Analytica, Oviedo, Spain; Carenity, Paris, France 
PRM187 None 
PRM188 Evidera, London, UK 
PRM189 LEO Pharma GmbH, Neu-Isenburg, Germany 
PRM190 Medical Research Council, London, UK 
PRM191 NIHR, Leeds, UK 
PRM192 Roche S.p.A., Monza, Italy 
PRM193 Janssen, Copenhaguen, Denmark
PRM194 Analysis Group, Inc., Boston, MA, USA 
PRM195 None 
PRM196 Roche, Basel, Switzerland 
PRM197 Boehringer Ingelheim, Ingelheim, Germany 
PRM198 None 
PRM199 None 
PRM200 None 
PRM201 NIHR, Leeds, UK 
PRM202 MRC funded (MRC Hub for Trial Methodological Research), Liverpool, UK
PRM203 Boehringer Ingelheim, Ingelheim, Germany 
PRM204 None 
PRM205 None 
PRM206 None 
PRM207 NIHR, Leeds, UK 
PRM208 Center for Translational Molecular Medicine (PREDICCT), Eindhoven, The 
Netherlands 
PRM209 None 
PRM210 None 
PRM211 PAREXEL International, Uxbridge, UK 
PRM212 None 
PRM213 None 
PRM214 None 
PRM215 None 
PRM216 None 
PRM217 None 
PRM218 Ministry of Health, Labour and Welfare, Tokyo, Japan 
PRM219 None 
PRM220 None 
PRM221 None 
PRM222 None 
Reference 
Code Financial Support 
PRM223 None
PRM224 None
PRM225 GlaxoSmithKline Biologicals SA, Rixensart, Belgium 
PRM226 None
PRM228 Pfizer Inc., New York, NY, USA 
PRM229 None
PRM230 NICE, London, UK; University of Sheffield, Sheffield, UK
PRM231 None
PRM232 GlaxoSmithKline, ZEIST, The Netherlands 
PRM233 None
PRM234 GlaxoSmithKline Biologicals SA, Rixensart, Belgium 
PRM235 None
PRM236 DELOITTE, Diegem, Belgium 
PRM237 None
PRM238 None
PRM239 None
PRM240 None
PRM241 European Commission, Brussels, Belgium 
PRM242 None
PRM243 None
PRS1 AstraZeneca, Luton, UK
PRS2 None
PRS3 AbbVie Corporation, Montreal, QC, Canada 
PRS4 None
PRS5 AbbVie Corporation, Montreal, QC, Canada 
PRS6 National Institute for Health Research Evaluation, Trials and Studies 
Coordinating Centre, Southampton, UK 
PRS7 Almirall, Barcelona, Spain
PRS8 MSD France, Courbevoie, France 
PRS9 GlaxoSmithKline, Zeist, The Netherlands 
PRS10 Pfizer S.A. de C.V., Mexico City, Mexico 
PRS11 AbbVie Corporation, Montreal, QC, Canada 
PRS12 Mundipharma International Limited, Cambridge, UK 
PRS13 Pfizer S.A. de C.V., Mexico City, Mexico 
PRS14 Fresenius Kabi AG, Bad Homburg, Germany 
PRS15 Chiesi, Barcelona, Spain
PRS16 Almirall S.A., Barcelona, Spain 
PRS17 None
PRS18 None
PRS19 AstraZeneca, Waltham, MA, USA 
PRS20 None
PRS21 Endo Pharmaceuticals, Malvern, PA, USA 
PRS22 Boehringer Ingelheim, Paris, France 
PRS23 GlaxoSmithKline, Tres Cantos (Madrid), Spain 
PRS24 GlaxoSmithKline, Istanbul, Turkey 
PRS25 National Immunisation Advisory Committee, Health Protection Surveillance 
Centre, Ireland 
PRS26 None
PRS27 None
PRS28 Pfizer S.L.U, Madrid, Spain 
PRS29 None
PRS30 None
PRS31 AstraZeneca, Italy, Italy
PRS32 Fresenius Kabi AG, Bad Homburg, Germany 
PRS33 Novartis, Täby, Sweden
PRS34 None
PRS35 AbbVie, Chicago, IL, USA
PRS36 Novartis, Barcelona, Spain 
PRS37 None
PRS38 NIHR Evaluation, Trials and Studies Coordinating Centre, Southampton, UK
PRS39 MSD, Bratislava, Slovak Republic 
PRS40 Philips Research Europe, Eindhoven, The Netherlands 
PRS41 National Institute for Health Research, London, UK 
PRS42 Pfizer S.A de C.V, Mexico City, Mexico 
PRS43 Kantar Health, New York, NY, USA 
PRS44 Instituto Salud Carlos III., Madrid, Spain 
PRS45 Consejeria Salud Junta de Andalucia, Sevilla, Spain 
PRS46 Consejeria de Salud. Juntade Andalucía, Sevilla, Spain 
PRS47 None
PRS48 GlaxoSmithKline, Madrid, Spain 
PRS49 None
PRS50 None
PRS51 None
PRS52 Kantar Health, New York, NY, USA 
PRS53 None
PRS54 None
PRS55 National Heart, Lung and Blood Institute, Bethesda, MD, USA
PRS56 None
PRS57 None
PRS58 None
PRS59 AbbVie Inc., Chicago, IL, USA 
PRS60 Novartis Pharmaceuticals Company, East Hanover, NJ, USA
PRS61 None
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PRS62 None 
PRS63 None 
PRS64 Novartis Pharmaceuticals Company, East Hanover, NJ, USA
PR1 None 
PR2 Abbott Products Operations AG,, Basel, Switzerland 
PR3 IMS Consulting Group, Paris, France 
PR4 None 
PSS1 Egis Pharmaceuticals, Budapest, Hungary 
PSS2 Allergan, Inc, Irvine, CA, USA 
PSS3 ThromboGenics NV, Leuven, Belgium 
PSS4 PFSA, PARIS, France 
PSS5 ThromboGenics NV, Leuven, Belgium 
PSS6 PFSA, PARIS, France 
PSS7 LEO Pharma GmbH, Neu-Isenburg, Germany 
PSS8 German Society of Dermatology (DDG, Berlin, Germany; LEO Pharma, Neu-
Isenburg, Germany; Assoc.Office-Based Dermatol. BVDD, Berlin, Germany; 
Almirall-Hermal, Reinbek, Germany 
PSS9 Novartis Pharma AG, Basel, Switzerland 
PSS10 Novartis, Moscow, Russia 
PSS11 SANOFI PASTEUR MSD, LYON, France 
PSS12 Alcon Labs, Geneve, Switzerland
PSS13 None 
PSS14 Bayer Pharma AG, Berlin, Germany 
PSS15 Novartis Pharmaceuticals Corp., East Hanover, NJ, USA 
PSS16 Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada 
PSS17 Bayer Pharma AG, Berlin, Germany 
PSS18 Celgene Corporation, Warren, NJ, USA 
PSS19 None 
PSS20 None 
PSS21 Bayer Pharma AG, Berlin, Germany 
PSS22 Novartis Pharma AG, Basel, Switzerland 
PSS23 AbbVie Inc., North Chicago, IL, USA 
PSS24 Leo Pharma A/S, Ballerup, Denmark 
PSS25 None 
PSS26 Pfizer, Lisbon, Portugal 
PSS27 Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada 
PSS28 Bayer Pharma Aktiengesellschaft, Berlin, Germany 
PSS29 Allergan, Inc, Irvine, CA, USA 
PSS30 Bayer Pharma AG, Berlin, Germany 
PSS31 None 
PSS32 Novartis, Dorval, QC, Canada 
PSS33 Novartis Pharma S.A.S., Rueil-Malmaison Cedex, France 
PSS34 Janssen-Cilag, Lysaker, Norway
PSS35 None 
PSS36 AbbVie Pty Ltd., Sydney, Australia
PSS37 Novartis Pharma AG, Basel, Switzerland 
PSS38 AbbVie Ltd., Maidenhead, UK 
PSS39 PFSA, Paris, France 
PSS40 PFSA, PARIS, France 
PSS41 PFD, LAVAUR, France 
PSS42 None 
PSS43 Novartis Pharma AG, Basel, Switzerland 
PSS44 Pfizer, Collegeville, PA, USA 
PSS45 Pfizer, Collegeville, PA, USA 
PSS46 Bayer Santé S.A.S., LOOS, France
PSS47 None 
PSS48 Roche Canada, Mississauga, ON, Canada 
PSS49 Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada 
PSS50 Santen Inc., Emeryville, CA, USA
PSS51 LEO Pharma GmbH, Neu-Isenburg, Germany 
PSS52 Abbvie, Wiesbaden, Germany; Biogen-Idec, Ismaning, Germany; Medac, 
Wedel, Germany; Pfizer, Berlin, Germany; Janssen-Cilag, Neuss, Germany; 
MSD Sharp&Dohme, Haar, Germany 
PSS53 Novartis, Basel, Switzerland 
PSS54 AbbVie, Wiesbaden, Germany; Biogen Idec, Ismaning, Germany; medac, 
Wedel, Germany; Pfizer, Berlin, Germany; MSD Sharp & Dohme, München, 
Germany; Janssen-Cilag, Neuss, Germany 
PSS55 None 
PSS56 medi GmbH & Co. KG, Bayreuth, Germany 
PSS57 Novartis Farmacéutica, S.A., Barcelona, Spain 
PSS58 Novartis Pharma AG, Basel, Switzerland 
PSY1 None 
PSY2 Novartis Poland Sp. z o.o., Warsaw, Poland 
PSY3 None 
PSY4 Unimed- Federação Rio de Janeiro, Rio de janeiro, Brazil 
PSY5 Bayer Pharma AG, Berlin, Germany 
PSY6 Janssen-Cilag GmbH, Neuss, Germany 
PSY7 Novartis Pharmaceuticals, East Hanover, NJ, USA 
PSY8 Astellas Pharma Europe Ltd., Chertsey, UK 
PSY9 None 
PSY10 MSD, Rome, Italy 
PSY11 Novartis Poland Sp. z o.o., Warsaw, Poland 
PSY12 None 
PSY13 Novo Nordisk Pharma, Copenhaguen, Denmark 
Reference 
Code Financial Support 
PSY14 Takeda, Moscow, Russia
PSY15 Ethicon Biosurgery, Somerville, NJ, USA 
PSY16 Baxter, Madrid, Spain
PSY17 Eisai Inc., Woodcliff Lake, NJ, USA 
PSY18 Eisai Inc., Woodcliff Lake, NJ, USA 
PSY19 Baxter, Opfikon, Switzerland 
PSY20 Grunenthal, Aachen, Germany 
PSY21 Viropharma, Maidenhead, UK; Adelphi Real World, Bollington, Cheshire, 
UK 
PSY22 ViroPharma SAS, Courbevoie, France 
PSY23 Astellas, Leiden, The Netherlands 
PSY24 Covidien, Istanbul, Turkey
PSY25 Astellas, Leiden, The Netherlands 
PSY26 Pfizer Inc, Walton Oaks, UK 
PSY27 Roche, Mississauga, ON, Canada 
PSY28 Novartis, East Hanover, NJ, USA 
PSY29 Ethicon SAS, Issy les Moulineaux, France 
PSY30 Ariad Pharmaceutical europe Sarl, Lausanne, Switzerland
PSY31 Astellas Pharma Europe Ltd.., Staines, UK 
PSY32 None
PSY33 Orphan Europe, Paris La Défense, France 
PSY34 MSD Ltd., Hoddesdon, UK 
PSY35 Sanofi Pasteur-MSD, Lyon, France 
PSY36 Mundipharma International Limited, Cambridge, UK 
PSY37 The Netherlands organisation for health research and development, The 
Hague, The Netherlands 
PSY38 GlaxoSmithKline, Lisbon, Portugal 
PSY39 Genesis Pharma, Athens, Greece 
PSY40 Novartis, Moscow, Russia 
PSY41 Mundipharma International, Cambridge, England 
PSY42 Sanofi-Aventis, Warsaw, Poland 
PSY43 GSK Services Sp. z o.o., Warsaw, Poland 
PSY44 Novartis Poland Sp. z o.o., Warsaw, Poland 
PSY45 None
PSY46 LighterLife, Harlow, UK
PSY47 Kedrion Spa, Castelvecchio Pascoli , Italy 
PSY48 GlaxoSmithKline Polska, Warsaw, Poland 
PSY49 Pfizer, Inc, Groton, CT, USA 
PSY50 ROcheFarmacêutica Química, Lda, Amadora, Portugal 
PSY51 Astellas Pharma Europe Ltd.., Staines, UK 
PSY52 Plastic Surgery Education Foundation, Arlington Heights, IL, USA
PSY53 Novo Nordisk A/S, Copenhagen, Denmark 
PSY54 FDA, Silver Spring, MD, USA 
PSY55 Pfizer Inc, New York, NY, USA 
PSY56 None
PSY57 None
PSY58 Astellas Pharma Europe Ltd.., Staines, UK 
PSY59 None
PSY60 None
PSY61 Grunenthal, Aachen, Germany 
PSY62 None
PSY63 MSD, Seoul, South Korea
PSY64 None
PSY65 Kantar Health, New York, NY, USA 
PSY66 None
PSY67 None
PSY68 Masaryk University, Brno, Czech Republic 
PSY70 NRF, Pretoria, South Africa 
PSY71 None
PSY72 Mundipharma GmbH, Limburg (Lahn), Germany 
PSY73 Johnson & Johnson Medical, Madrid, Spain 
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BU1
TREATMENT OF TyPE 2 DIABETES wITH SAxAgLIPTIN/METFORMIN 
ExTENDED-RELEASE (xR): BUDgET IMPACT ANALySIS IN ARgENTINA
Elgart J.1, Gonzalez L.1, Aiello E.C.2, Gagliardino J.J.1
1CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, 
Argentina, Buenos Aires, Argentina, 2Bristol-Myers Squibb, Buenos Aires, Argentina
Objectives: To estimate the budget impact of adopting the saxagliptin/metformin 
XR fixed-dose combination, to treat type 2 diabetes (T2DM) in the Social Security 
System of Argentina, compared to the current standard treatment. MethOds: 
We used an Excel-based budget impact model assuming coverage for one mil-
lion people. The time horizon was three years from the perspective of a social 
security organization in Argentina. T2DM prevalence data was obtained from 
the national risk factor survey conducted by the Ministry of Health. Only phar-
maceutical expenditures of oral antidiabetic agents (OAAs) were analyzed. The 
cost of OAAs was obtained from the prices list adjusted to co-payments, and 
expressed in 2012 Argentinean pesos. Asset market-share was taken from the 
QUALIDIAB Database, market studies and data provided by Bristol Myers Squibb. 
The analysis reported findings in terms of budget impact, per-member per-month 
(PMPM) and per-patient per-month (PPPM). Probabilistic Sensitivity Analysis (PSA) 
was performed using Monte-Carlo simulations (10,000 iterations) and included 
parameters of demographic characteristics, price and market-shares. Results: 
The net budget impact estimated that the introduction of saxagliptin/metformin 
XR was $32,930 for the first year, $58,768 for the second year and $85,584 for the 
third year. The cumulative net budget impact was $177,282. PMPM was $0.0027, 
$0.0049 and $0.0071 for the first, second and third year, respectively. PPPM 
was $0.107, $ 0.198 and $0.299 each year, respectively. The cumulative impact 
in the total annual budget for OAAs represented an increase of 0.27%. Monte 
Carlo simulation showed that cumulative budget impact varied from 0.08 to 
0.30%. cOnclusiOns: The introduction of saxagliptin/metformin XR in a social 
security organization as a treatment option for patients with T2DM, has a minimal 
budgetary impact.
BU2
ANáLISE DE IMPACTO ORçAMENTáRIO: QUANTO CUSTARIA AO SISTEMA 
PúBLICO DE SAúDE BRASILEIRO INCREMENTAR, POR MEIO DE TRANSPLANTES, 
O TRATAMENTO DA DOENçA RENAL CRôNICA TERMINAL?
Alvares J., Falleiros D.R., Barbosa M.M., Almeida A.M., Araujo V.E., Guerra Junior A.A., 
Cherchiglia M.L., Acurcio F.D.A.
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
intROduçãO: O transplante renal é apontado na literatura como a terapia de 
substituição renal mais custo-efetiva, permitindo reintegração do paciente as 
atividades cotidianas, aumentando expectativa e qualidade de vida. Entretanto, 
os sistemas públicos de saúde deparam-se com necessidades infinitas, recursos 
finitos, imperativo da qualidade na assistência e gasto e adequação das novas 
tecnologias aos recursos disponíveis. ObjetivOs: Conhecer o impacto orçamen-
tário no Sistema Único de Saúde (SUS)- no âmbito das avaliações de tecnologia em 
saúde - gerado por uma possível ampliação da utilização de transplantes como 
tratamento de pacientes portadores de insuficiência renal crônica. MétOdOs: 
Foram utilizadas informações metodológicas para desenvolvimento de estu-
dos de impacto orçamentário voltados ao SUS disponibilizado pela publicação: 
DIRETRIZES METODOLÓGICAS - Análise de Impacto Orçamentário: Manual 
para o Sistema de Saúde do Brasil. ResultadOs: Em análise temporal de cinco 
anos, considerando-se cenários alternativos que ampliam a utilização de trans-
plante frente a hemodiálise(HD) e diálise peritoneal(DP), dos atuais 3% para 10%; 
20%; 30%, com crescimento esperado de utilização que variam de 20% a 100% 
no período.Considerando a população brasileira, com prevalência da doença 
de 0,047%, incidência de 32% e taxa de mortalidade de 22% para HD+DP e 4,5% 
para transplante, temos que: no Cenário01 (10%)haverá uma queda de 1,2% na 
taxa de mortalidade e em cinco anos um incremento de gasto de R$7bilhões; 
Cenário02(20%) 2,9% e R$6,5bilhões; Cenário03(30%) 4,7% e R$6bilhões. Nesse 
cenário a queda na taxa de mortalidade representa a manutenção de 4.374 vidas, 
mediante um incremento de gasto médio anual da ordem de R$1,2bilhões, já 
considerando a inflação. cOnclusões: O transplante, apesar de ter menor custo 
que HD e DP, por resultar em redução significativa na mortalidade gera impacto 
orçamentário em cinco anos de R1,2bilhões. Esse é o preço a se pagar por aumento 
na sobrevida e na qualidade de vida. Então, quanto vale a vida?
ABSTRACTS
BU3
COSTO E IMPACTO PRESUPUESTAL DEL TRATAMIENTO DE LA ARTRITIS 
REUMATOIDE MODERADA y SEvERA CONSIDERANDO EL USO DE TERAPIAS 
BIOLógICAS EN MéxICO
Aguirre A.1, Peniche-Otero G.2, Jiménez I.2, Baeza G.2, Muciño-Ortega E.3,  
Galindo-Suárez R.M.3
1UCB de Mexico, S.A. de C.V., Mexico, D.F., Mexico, 2Customized Premium Products S.A. de C.V., 
México D.F., Mexico, 3Pfizer S.A. de C.V., Ciudad de México, Mexico
ObjectivOs: El impacto económico del potencial uso de terapias biológicas (TB) 
en el tratamiento de la artritis reumatoide moderada y severa (AR-MS) en el Seguro 
Popular (SP) de México no se ha estimado. Este estudio estuvo enfocado a estimar 
este impacto. MetOdOlOgías: Con datos de la Community Oriented Program for 
Control of Rheumatic Diseases (COPCORD) y registros de casos nuevos en la base 
de datos del Sistema de Información en Salud (Secretaría de Salud), se estimó la 
prevalencia de AR-MS para el 2012. Se estimó la cantidad de pacientes con AR-MS 
candidatos a recibir TB. La estimación de los costos de tratamiento de AR-MS se 
realizó mediante la metodología bottom-up y se expresan en US$ de 2013. Un panel 
de 10 expertos determinó el perfil de uso de recursos: consultas, medicamentos, 
pruebas de laboratorio y gabinete, rehabilitación y manejo de eventos adversos. Los 
costos unitarios se extrajeron de fuentes institucionales. Se realizó un análisis de 
impacto presupuestal en base al Presupuesto de Egresos de la Federación (PEF) para 
2012. ResultadOs: Se estimó que en 2012 había 115,827 pacientes con AR-MS con 
posibilidad de ser tratados con TB en el SP. El costo esperado (anual) de tratamiento 
con TB fue de US$16,880, mientras que sin TB fue de $10,883 (64.5%). El costo de la 
TB está determinado por el costo de adquisición del biológico, mientras que el costo 
de manejo de complicaciones es el rubro más importante en los pacientes sin TB. Si 
se tratase con TB al 5% (5,791) de los pacientes candidatos, el impacto presupuestal 
sería del 0.95% del PEF. cOnclusiOnes: El tratamiento de AR-MS con terapias no 
biológicas representa alrededor de dos terceras partes del costo de tratamiento con TB. 
La introducción progresiva de TB en el SP permitiría controlar el impacto presupuestal 
acorde a la disponibilidad de recursos.
BU4
BUDgET IMPACT ANALySIS OF ABIRATERONE ACETATE IN METASTATIC 
CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREvIOUSLy TREATED 
wITH DOCETAxEL FROM THE PERSPECTIvE OF THE BRAzILIAN PRIvATE 
HEALTH CARE SySTEM
Vitale V.1, Asano E.2, Pereira M.L.1
1Janssen Cilag Farmaceutica, São Paulo, Brazil, 2Janssen-Cilag Farmaceutica, Sao Paulo, Brazil
Objectives: To evaluate the Budget Impact from the perspective of the Brazilian 
Private Health Care System after the introduction of abiraterone acetate (AA) for 
the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients 
previously treated with docetaxel. MethOds: An epidemiological model based on 
reports of Brazilian National Cancer Institute and published literature was developed 
to estimate the incidence of mCRPC patients in the next three years. Budget impact 
was simulated comparing current scenario, where all patients undergo treatment 
with cabazitaxel, and a new scenario with the introduction of AA from the perspec-
tives of the payers (HMOs) and service provider (infusion clinics). Pharmaceutical 
costs were based on official list price applying reimbursement inflators. Costs with 
adverse events and drug administration were obtained from published literature. 
Deterministic sensitivity analysis (DSA) was conducted to determine the impact of 
parameters on results. Results: According to the model, a total of 5,098 patients 
were eligible for treatment with either cabazitaxel or AA over the three years of analy-
sis. In the base case scenario, from the payers’ perspective the introduction of AA 
decreased total treatment costs of the target population by R$47,516,469. If reinvested 
on the treatment of mCRPC patients, these economic savings could allow for the treat-
ment of 692 more patients with AA. For the service provider, assuming reimbursement 
inflator of 10% in cabazitaxel factory price, better financial results per patient are 
achieved in a scenario where reimbursement inflator of AA is set at 15% of factory 
price. In DSA, economic savings from the payers perspective ranged from R$12,454,979 
(assuming mean duration of treatment with AA of 10 months) and R$118,637,890 
(assuming 100% of market share for AA). cOnclusiOns: The introduction of AA 
may generate economic savings for both HMOs and infusion clinics, possibly allowing 
treatment of more patients with mCRPC previously treated with docetaxel.
CARDIOvASCULAR DISEASE OUTCOMES RESEARCH
Cv1
UTILIDAD DE BIOMARCADORES CARDIACOS (POINT OF CARE TESTINg) EN EL 
AREA DE URgENCIAS y SU IMPACTO ECONóMICO
Contreras I.1, Lopez-Perez A.2, Mendez G.F.3, Mejia-Arangure E.4
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mmHg increase: 1.0676, p< .001) as a significant risk factor for stroke in addition to 
age and diabetes, among others. cOnclusiOns: This stroke risk equation shows 
that greater PP is a significant predictive factor for increased stroke risk, even in the 
presence of known risk factors, including SBP. PP should be considered by practi-
tioners along with traditional risk factors in treatment strategies to prevent stroke.
Cv4
ANáLISIS DE COSTO-EFECTIvIDAD DEL USO DE ESTATINAS EN LA PREvENCIóN 
DE EvENTOS CARDIOvASCULARES EN COLOMBIA
Mould J.1, Ordoñez J.2, Gutierrez-Ardila M.V.3, Vargas Zea N.3
1Pfizer, New York, NY, USA, 2Universidad CES, Medellin, Colombia, 3Pfizer S.A.S., Bogotá, 
Colombia
ObjectivOs: Las enfermedades cardiovasculares (ECV) son una de las principales 
causas de muerte precoz en los países occidentales, los fármacos hipolipemiantes 
están indicados para disminuir el riesgo cardiovascular V. El objetivo de este análisis 
es evaluar la costo-efectividad del uso de estatinas en prevención primaria de ECV en 
Colombia. MetOdOlOgías: Se utilizó un modelo compuesto por un árbol de decisión y 
un Markov. El horizonte de tiempo fue la expectativa de vida. Los comparadores fueron: 
atorvastatina (20mg/día) vs. rosuvastatina (20 mg/día). Se simuló una cohorte de 100 
pacientes de 62 años con valor inicial de colesterol LDL de 137.28mg/dL y riesgo anual 
basal de ECV ≤ 3.5%. Se utilizó una tasa de descuento de 3%. Los datos de utilidad, eficacia 
y mortalidad por los eventos fueron tomados de la literatura, ajustados por información 
local. La medida de efectividad empleada fueron los años de vida ganados (AVG), los 
años de vida ajustados por calidad (AVACs) y los casos de ECV evitados. Los precios de 
los medicamentos fueron tomados del SISMED y los costos de una EPS de presencia 
nacional. Se utilizó como umbral de disposición a pagar, el equivalente a 3 PIB per cápita 
≈ US$40,000. ResultadOs: En el horizonte de la expectativa de vida, el ahorro total 
esperado por persona con atorvastatina fue de US$6374 en comparación con rosuvas-
tatina (costos totales: US$8,802 y US$15,176, respectivamente); rosuvastatina obtuvo 
0.0108 AVACs, 0.0127 AVG y 0.0023 casos evitados más que atorvastatina por persona; el 
ICER de rosuvastatina fue de US$507,266/AVAC, US$426,320/AVG y US$2,624,876/casos 
evitados de ECV. cOnclusiOnes: Atorvastatina sería la alternativa de elección en la 
prevención de ECV. El diferencial de AVG, AVACs y casos de ECV de rosuvastatina es muy 
bajo para su costo incremental y su ICER se encuentra por encima del umbral definido, 
por lo que no es una opción costo-efectiva.
HEALTH CARE ExPENDITURE STUDIES
HC1
ADDRESSINg CHILDHOOD-OBESITy IN MExICO: SAvINgS ON HEALTH CARE 
ExPENDITURES FROM REgULATINg FOOD AND BEvERAgE SALES IN BASIC 
EDUCATION SCHOOLS
Guajardo V.1, Gutierrez C.1, Rivera G.2
1Instituto Mexicano del Seguro Social, Mexico, Mexico, 2Secretaría de Salud, Mexico, Mexico
Objectives: Estimate potential direct savings for the Mexican Healthcare System 
generated by the operation of the “Technical Guidelines for the Sale or Distribution 
of Food and Beverages in Establishments of Basic Education”. MethOds: The micro-
simulation model “Chronic Disease Prevention (CDP)” developed by OECD-WHO was 
used for projecting health gains and costs of treatment in a period of 100 years. The 
model was adjusted to accommodate the range 6-14 years old stated in the Guidelines. 
Mexican data on incidence, prevalence, mortality, population at risk, annual unit costs 
and relative risk of selected chronic diseases (diabetes mellitus type 2, hypertension, car-
diovascular, hypercholesterolemia) attributable to obesity and the treatment of obesity 
as disease itself was used. Sensitivity analyses were developed for most variables used 
in the model. Results: Under a base case scenario present value of potential savings 
in total spending on medical care associated with the implementation of the Guidelines 
amount to USD$1052.2 million in 2008. Most savings are derived from averted cases of 
hypertension (32.7%), obesity-overweight (28.6%) and diabetes mellitus type II (17.8%). 
Results are robust to changes in all parameters analyzed. Amounts obtained are an 
underestimation of potential savings as neither expensive complications as renal failure 
nor other chronic diseases attributable to obesity as arthritis, colorectal or breast cancer 
were included. cOnclusiOns: The Guidelines, —developed by the Ministry of Public 
Education in coordination with the Ministry of Health—, represent a good example of 
cooperation among different sectors to solve a complex public health problem. Results 
shows the importance of implementing preventive interventions aimed at reducing 
the prevalence of chronic diseases related to poor eating habits, inadequate physical 
activity and obesity in Mexico. Implementation of the Guidelines involves significant 
direct savings that can be assigned to other health needs of the Mexican population.
HC2
EFFECT OF HEALTH SPENDINg, INCOME INEQUALITy AND MARgINATION 
INDEx ON THE EFFICIENCy OF THE HEALTH SySTEM IN MExICO
Pinzon Florez C.E.1, Reveiz L.2, Idrovo A.J.3, Reyes H.4, Diaz de Leon C.4
1Instituto Nacional de Salud Pública, Cuernavaca, Mexico, 2Organización Panamericana de la 
Salud, Washington, Mexico, 3Fundacion Cardiovascular de Colombia, Bucaramanga, Colombia, 
4Instituto Nacional de Salud Publica, Cuernavaca, Mexico
Objectives: To explore the effect of health spending, income inequality and 
margination on maternal and child health care in México. MethOds: With the 
32 Mexican states an ecological multi spatial study was performed. Correlations 
between maternal and infant mortalities in the total per capita spending (cen-
tral and state governments from 2000 to 2010), Gini and margination indexes 
were computed. Conventional and robust multiple linear regressions were used 
to explore the effects on the technical efficiency of these indicators in the 
State’s health systems. Results: Negative correlations with Spearman rho -0.62 
and -0.28 near to the margination and Gini indexes respectively (p < 0.05), and 
higher than 0.59 for the margination index (p < 0.05) between life expectancy at 
birth for the first and the last infant mortality. The multiple linear regression 
models established the relationship between the deprivation and Gini indexes 
in health indicators. It showed the positive effect of funding from central gov-
1Instituto Mexicano del Seguro Social, México City, Mexico, 2Instituto Mexicano del Seguro Social, 
Los Reyes La Paz, Mexico, 3Instituto Mexicano del Seguro Social, Jalapa, Mexico, 4HOS Health 
Outcomes Solutions S.A de C.V., Mexico, Mexico
ObjectivOs: El síndrome coronario agudo (SCA) representa alta carga de la enfermedad 
para México. Los biomarcadores cardiacos Point of Care Testing (POCT) mejoran la oportu-
nidad diagnóstica, permiten acelerar el tratamiento y reducen la mortalidad. El propósito 
del estudio fue evaluar, desde la perspectiva del proveedor de servicios de salud, su 
impacto clínico y económico en los servicios de urgencias en México. MetOdOlOgías: 
Estudio comparativo, en situaciones habituales, del servicio de urgencias del Hospital 
General de Zona No. 1-A del Instituto Mexicano del Seguro Social (IMSS) en México, 
D.F. Los grupos de comparación fueron: sin disponibilidad de biomarcadores POCT, que 
incluyó pacientes adultos, sin distinción de género, que acudieron al hospital por dolor 
torácico agudo (DTA) entre marzo y abril de 2012; y con disponibilidad de biomarcadores 
POCT, que incluyó pacientes que acudieron entre junio y septiembre de 2012. Se realizó 
seguimiento durante la estancia en urgencias. El resultado de interés fue la identificación 
de pacientes con SCA. Los costos se calcularon con los recursos utilizados durante la 
estancia en urgencias; se expresaron de dólares norteamericanos (tasa de cambio 12.65 
pesos/dólar). ResultadOs: Se incluyeron 336 pacientes, edad promedio 55±18 años, 
52% hombres. El grupo sin POCT incluyó 148 pacientes y con POCT 188. Con POCT se 
identificaron 50 pacientes con SCA (0.27, IC95% 0.20–0.33) vs 21 sin POCT (0.14, IC95% 
0.08–0.19), p= 0.006. El costo promedio de la atención en urgencias con POCT fue US$178 
(IC95% US$161-US$ 340) y sin POCT fue de US$168 (IC95% US$152-US$320), p= 0.93. El 
costo-efectividad promedio para identificar un paciente con SCA sin POCT fue US$1,206 
y con POCT fue US$661. cOnclusiOnes: La disponibilidad de biomarcadores POCT 
en urgencias es costo-efectivo, ya que mejora la probabilidad de identificar SCA en 
pacientes con DTA y no existe diferencia en el costo de su implementación para el IMSS.
Cv2
ESTIMATION OF THE COST-EFFECTIvENESS OF APIxABAN IN NON-vALvULAR 
ATRIAL FIBRILLATION IN ARgENTINA
Giorgi M.A.1, Caroli C.2, Micone P.3, Giglio N.D.4, Aiello E.C.5, Donato B.M.K.6, Mould J.F.7,  
Radero G.8, Casas M.9
1CEMIC, Buenos Aires, Argentina, 2FLENI, Buenos Aires, Argentina, 3universidad austral, Buenos 
Aires, Argentina, 4hospital de niños ricardo gutierrez, Buenos Aires, Argentina, 5Bristol-Myers 
Squibb, Buenos Aires, Argentina, 6Bristol-Myers Squibb Company, Wallingford, CT, USA, 7Pfizer, 
New York, NY, USA, 8Pfizer, Buenos Aires, Argentina, 9Pfizer, buenos aires, Argentina
Objectives: Atrial Fibrillation (AF) affects about 2% of the population and increases 
5-fold the risk of stroke and systemic embolism. This risk is managed with vitamin K 
antagonists (VKA) or aspirin for patients according to their suitability to receive oral 
anticoagulants (OA) but with several limitations. Therefore, novel OAs have become 
a treatment option. Apixaban is the most recent drug approved for thrombotic pre-
vention in AF. Our aim is to estimate the cost-effectiveness (CE) of apixaban in AF in 
Argentina. MethOds: We conducted a literature review of published epidemiologi-
cal AF, and stroke data from Argentina. Data about apixaban, warfarin, rivaroxaban, 
dabigatran and aspirin were obtained from published trials and indirect comparisons. 
Two Delphi Panels, with local experts representing private, public and social security 
health subsectors were held and reviewed and validated data collected and provided 
information on local treatment patterns. Costs, expressed in 2012U$S, were gathered 
from published reports and a local database. Apixaban was compared with each avail-
able AF treatment option allocating them into a simulated cohort of 1,000 patients 
per treatment group (according with their suitability for OA) over a lifetime horizon 
using an MS EXCEL based Markov model. We adopted payer’s perspective reporting 
weighted mean costs for QALY gained. CE threshold for Argentina was considered as 
per WHO-CHOICE and World Bank data (ranging from 9740 to 29220U$S). Results: 
For the suitable population, the cost per QALY gained with apixaban was U$S 9938 and 
1131 versus warfarin and dabigatran 150 mg respectively, and dominant compared 
to dabigatran 110 mg and rivaroxaban. For the unsuitable population, apixaban was 
dominant compared to available alternatives: aspirin, dabigatran 110 mg, dabigatran 
150 mg, and rivaroxaban. cOnclusiOns: on the model using local inputs, apixaban 
is dominant or cost-effective according to local CE thresholds becoming the treatment 
choice in Argentina both in the suitable and unsuitable populations
Cv3
PULSE PRESSURE AND STROkE RISk: DEvELOPMENT AND vALIDATION OF A 
STROkE RISk EQUATION
Ayyagari R.1, Vekeman F.2, Lefebvre P.2, Ong S.H.3, Faust E.1, Trahey A.1, Machnicki G.4,  
Duh M.S.1
1Analysis Group, Inc., Boston, MA, USA, 2Groupe d’analyse, Ltée, Montréal, QC, Canada, 3Novartis 
Pharma AG, Basel, Switzerland, 4Novartis Latin America & Canada, Buenos Aires, Argentina
Objectives: Previous stroke risk equations identified systolic blood pressure (SBP) 
as a key predictive factor. Recent evidence suggests that pulse pressure (PP), defined 
as the difference between SBP and diastolic blood pressure, could be a new risk 
factor. This project aims at developing and validating a new stroke risk equation 
incorporating PP as a potential risk factor. MethOds: Electronic medical records 
including laboratory data of a random sample of 97,237 hypertensive patients from 
a US integrated health delivery system were analyzed (01/2004-05/2012). Patients 
with ≥ 1 peripheral PP (PPP) reading and ≥ 6 months of observation (baseline period) 
prior to the first evidence of hypertension were randomly split into the development 
(two-thirds of sample) and validation (one-third of sample) datasets. Stroke events 
were identified using ICD-9-CM 433.xx-436.xx. Cox proportional hazards models 
assessed time to first stroke event based on baseline risk factors, including PPP, age, 
gender, SBP, smoking status, BMI, diabetes, and cardiac comorbidities. The optimal 
risk equation was selected using the least absolute shrinkage and selection operator 
(LASSO); performance was evaluated by the c-statistic. Results: A total of 30,525 
patients without stroke (mean age 58.2, 48% male) and 4,272 patients with stroke 
(mean age 67.3, 48% male) were selected. Average observation was 3.89 years. PPP 
was higher among patients who developed stroke (mean [SD] PPP, stroke: 62.0 [15.3] 
mmHg; non-stroke: 58.1 [14.0] mmHg, p< .001). The best performing risk equation 
(c-statistic, development: 0.732; validation: 0.722) included PPP (hazard ratio per 10 
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ate the efficacy and safety of new anticoagulants in the treatment of AF. MethOds: 
Health Technology Assessment of multiple technologies. We searched the electronic 
databases Cochrane Library, CRD, Pubmed, Embase and Lilacs, to search for the best 
available evidence assessing the new oral anticoagulants, compared with warfa-
rin in patients with AF. Results: Three randomized controlled trials evaluating 
dabigatran (110mg e 150mg), rivaroxaban 20mg and apixaban 5mg were included, 
all of them compared with warfarin. In this regard, dabigatran 110mg was associ-
ated with similar rates of stroke or systemic embolism and with a 20% relative risk 
reduction (RRR) of major hemorrhage compared with warfarin. Dabigatran 150mg 
was associated with a 34% RRR of stroke or systemic embolism and similar rates 
of major hemorrhage. Rivaroxaban 20mg was associated with similar rates of the 
primary efficacy and safety outcomes. Finally, apixaban was associated with a 21% 
RRR of stroke or systemic embolism and with 31% RRR of major bleeding compared 
with warfarin. cOnclusiOns: There is strong evidence supporting these new tech-
nologies, especially regarding safety. Further studies are needed to support decision 
making, especially with regards to cost-effectiveness issues.
HT2
HEALTH TECHNOLOgy ASSESSMENT REPORT FOR POSITRON EMISSION 
TOMOgRAPHy IN PATIENTS wITH CANCER
Alcaraz A.1, Meza V.2, Glujovsky D.3, Romano M.2, Morelli D.2, Comandé D.3, Garcia Marti S.2, 
Pichon Riviere A.4, Augustovski F.5
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Institute 
for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 3Institute for Clinical 
Effectiveness and Health Policy (IECS), Buenos Aires, Buenos Aires, Argentina, 4IECS - Institute for 
Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 5IECS - Instituto de Efectividad 
Clinica y Sanitaria, Buenos Aires, Argentina
Objectives: Positron Emission Tomography (PET) might be useful for cancer staging 
and follow-up. The objetive was to assess the available evidence on efficacy, safety 
and coverage policies for use of PET in oncology. MethOds: A bibliographic search 
was carried in PubMed, DARE, NHS EED, in health technology assessment (HTA) 
agencies and health insurers. Priority was given to systematic reviews; randomized 
clinical trials (RCTs); HTA; clinical practice guidelines (CPGs) and coverage policies 
(CPs). Results: Thirty-seven systematic reviews, 3 RCTs and 32 observational stud-
ies, 51 CPGs, 15 HTAs and 28 CPs were included. Breast Cancer (17 studies):There 
is no evidence of its use as routine practice. Some CPGs and CPs recommend it for 
suspicious images that could not be clarified through conventional studies. PET is 
not recommended for axillary staging or neodadyuvant response prediction. Lung 
Cancer (44 studies):The accuracy for lung nodule is similar to conventional methods. 
Most CPGs do not recommend the use of PET for lung cancer staging except in some 
non-small cell lung cancer with previous negative tests for metastasis. Colorectal 
Cancer (20 studies): There is no evidence of its use as routine practice. It might be 
used in patients with suspected recurrence and non-conclusive images. Genitourinary 
Tumors (70 studies): PET might be associated with changes in diagnosis or therapeutic 
only in specific cases, such as ovarian cancer with suspected recurrence and nor-
mal conventional images, in residual tumors due to seminoma and cervical cancer 
recurrence eligible for curative treatment. Primary Tumors of the Central Nervous 
System (15 studies):PET is not recommended as routine practice. CPGs, RCTs and CPs 
recognize its usefulness for differential diagnosis between relapse and radionecro-
sis. cOnclusiOns: There is no evidence to support the use of PET in cancer patients 
as routine practice. At present, its use should be restricted to specific patients.
HT3
FORMULATIONS OF AMPHOTERICIN B FOR THE TREATMENT OF FUNgAL 
INFECTIONS IN PATIENTS wITH HIv/AIDS
Costa J.O., Lemos L.L.P., Gomes R.M., Guerra Junior A.A., Acurcio F.A.
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Objectives: To evaluate the efficacy, safety and cost-effectiveness data of lipid 
formulations of amphotericin B to establish which should be used for the treatment 
of systemic fungal infections in patients with HIV/AIDS in Brazil. MethOds: We 
searched The Cochrane Library, Centre for Reviews and Dissemination, Tripdatabase, 
Medline and LILACS databases aiming to find systematic reviews (SRs) and eco-
nomic evaluations (EE) comparing liposomal amphotericin B (L-AmB) or ampho-
tericin B lipid complex (ABLC). Health Technology Assessments (HTA) were searched 
on agencies websites. Quality of the evidence and strength of recommendation 
were evaluated using the GRADE system. Results: We selected five SRs, in which 
one evaluated only safety data, and two economic evaluations. Four SRs were clas-
sified as poor quality and the strength of recommendation was considered weak 
in favor of L-AmB in all studies. In general there were no statistically significant 
differences in terms of survival and response to treatment (p< 0,05). However, L-AmB 
was associated with a lower risk of nephrotoxicity and increased serum creatinine. 
The two economic studies included had conflicting results. In the cost-minimization 
study there was no difference in total costs of the therapies, but the daily cost of 
acquisition and concomitant antifungal therapy and adverse events were lower 
for ABLC (0,002 and 0,027). The incremental cost-effectiveness analysis favored the 
L-AmB (€ 41734 vs. € 51724). Both studies showed important limitations and there 
were no studies considering the Brazilian context. cOnclusiOns: Considering all 
the studies found, as well as their limitations, there is a lack of evidence to support 
the spread use of L-amB in patients with HIV/AIDS affected by fungal infections, 
unless strictly in cases where patients have abnormal renal function. Also, L-AmB 
could be used in case of intolerance to conventional amphotericin B.
HT4
EFICáCIA E SEgURANçA DE RANIBIzUMABE E BEvACIzUMABE NO 
TRATAMENTO DE DEgENERAçãO MACULAR RELACIONADA A IDADE
Saturnino L.T.M.1, Silveira M.R.2, Guerra Junior A.A.3, Acurcio F.D.A.3
1Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil, 2Faculdade de Farmácia daUniversidade 
Federal de Minas Gerais, Belo Horizonte, Brazil, 3Universidade Federal de Minas Gerais, Belo 
Horizonte, Brazil
ernment in better health system performance, as well as the positive effect of 
increased public investment in health over the decade in health indicators and 
process insurance in the last 5 years. cOnclusiOns: The results suggest a 
positive effect of central government spending on health and a negative effect 
of income inequality and margination index on maternal and infant mortali-
ties, clearly mediated by socioeconomic factors characteristic of each state. 
This methodological approach is proposed to evaluate the relationships of the 
different levels of functioning of a health system and the dynamics with the 
social determinants of these levels.
HC3
PAyER AND PHySICIANS EvIDENCE AND DISCOUNT ExPECTATIONS FOR 
BIOSIMILARS IN SIx LATIN AMERICAN COUNTRIES
Sandorff E.1, Severi Bruni D.2, Halbert R.3
1ICON, Blue Bell, PA, USA, 2ICON, El Segundo, CA, USA, 3ICON, PriceSpective LLC, El Segundo, 
CA, USA
Objectives: As follow-up to prior work, investigate what evidence is required 
for reimbursement and prescribing of biosimilar drugs from four key therapy 
areas in six Latin American countries (Argentina, Brazil, Chile, Colombia, 
Mexico and Venezuela). Explore how these requirements may correspond to 
the regulatory pathways across the different countries. MethOds: Conduct 
secondary research to determine any recent changes to biosimilar regulation in 
the six studied countries. Conduct targeted primary research with payers and 
physicians in the six counties exploring: 1) The therapy areas that payers and 
physicians consider most attractive for biosimilars; 2) The baseline evidence 
(bioequivalence, comparative trial data, extrapolation of indications, etc.) that 
stakeholders require across the key therapy areas and across countries; 3) The 
level of discount, below the branded equivalent, that payers and physicians 
would require to consider biosimilars for access or to prescribe to their patients; 
4) The expected access level and prescribing decisions for those biosimilars that 
meet these evidence and discount criteria; and 5) The degree to which payer 
and physician evidence expectations for biosimilars map to our understanding 
of the evolution of biosimilar regulatory environment. Results: Public payers 
across the region see biosimilars as an opportunity to provide broader access to 
needed medications, although some stakeholders are more receptive than oth-
ers and have lower requirements to prove comparability. Clinicians in general 
have concerns about safety and efficacy, however, their willingness to prescribe 
biosimilars correlates inversely with the degree of access and affordability of 
the branded agents. cOnclusiOns: The regulatory and access environment for 
biosimilars in Latin America can be expected to be more favorable than in the 
US but not too dissimilar from Europe. However there are systematic differences 
across countries and therapy areas.
HC4
ANáLISIS DE COSTO-EFECTIvIDAD DE LAS vACUNAS NEUMOCóCICAS 
13-vALENTE y 23-vALENTE PARA ADULTOS DE ALTO RIESgO EN COLOMBIA
Ordoñez Molina J.E.1, Gutierrez-Ardila M.V.2, Vargas Zea N.2
1CES University, Medellin, Colombia, 2Pfizer S.A.S., Bogotá, Colombia
ObjectivOs: El Streptococcus pneumoniae causa una importante morbilidad y 
mortalidad a nivel mundial, tanto en niños como en adultos. El objetivo de este 
análisis es estimar la costo-efectividad de la vacuna conjugada 13-valente (PCV13) 
vs la vacuna neumocócica polisacárida 23-valente (PPSV23) y vs no vacunación en 
los adultos de alto riesgo (inmunocomprometidos) > 50 años en Colombia, desde 
la perspectiva del tercero pagador. MetOdOlOgías: Se adaptó un modelo de 
Markov con horizonte de tiempo de la expectativa de vida y tasa de descuento 3% 
anual. Los comparadores fueron PCV13, PPSV23 y no vacunación (NV), cobertura 
estimada del 70%; revacunación a los 5 años con PPSV23 para > 65 años según 
criterios del CDC. Se utilizó la población > 50 años de alto riesgo en Colombia. 
Las probabilidades de transición, incidencia de enfermedades y efectividades de 
las vacunas fueron extraídas de la literatura (para PCV13 se utilizaron datos de 
PCV7 ajustados por inmunosenescencia), los costos médicos fueron proveídos por 
una EPS de cobertura nacional; los precios de las vacunas fueron tomados de la 
OPS para 2013. Los costos se presentan en US$ 2013. Las medidas de efectividad 
fueron número de casos evitados de enfermedad neumocócica invasiva – ENI 
(meningitis y bacteremia), neumonía invasiva, muertes y años de vida ganados 
(AVG). ResultadOs: Vacunar con PCV13 vs NV y PPSV23 previene 4.389 y 4.134 
casos de ENI; 2594 casos de neumonía invasiva y 550 y 536 muertes respectiva-
mente. PCV13 genera 199 AVG más que PPSV23 y 4.712 AVG más que NV. El ahorro 
total esperado (vacunación + costos médicos) con PCV13 fue US$18,254,171 vs NV 
y US$26,204,251 vs PPSV23. cOnclusiOnes: Vacunar adultos inmunocompro-
metidos > 50 años con PCV13 en Colombia es una alternativa costo-ahorradora en 
comparación con NV y con PPSV23 (US$12.57 y US$18.08 ahorrados por paciente 
respectivamente). Los hallazgos de este estudio soportan una toma de decisión 
a favor de PCV13.
HEALTH TECHNOLOgy ASSESSMENT STUDIES
HT1
EFFICACy AND SAFETy OF NEw ANTICOAgULANTS IN THE TREATMENT OF 
ATRIAL FIBRILLATION: A HEALTH TECHNOLOgy ASSESSMENT
Buehler A.M., Suzumura E.A., Figueiró M.F., Cavalcanti A.B., Berwanger O.
Hospital do Coração, São Paulo, Brazil
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. 
Patients with AF have a 4-5 times larger risk of stroke than age-matched controls. 
Anticoagulation with warfarin is currently the standard of care but the requirement 
for routine monitoring and drug and food interactions, makes its use is suboptimal. 
New anticoagulants were developed to eliminate these barriers and the results are 
promising. However, the incorporation of these technologies within the Brazilian 
Unified Health System (SUS) demands proper consideration. Objectives: To evalu-
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análisis de sensibilidad en los escenarios incluidos, demostrando robustez de los 
resultados del modelo planteado. cOnclusiOnes: El uso de las PTRI como prueba 
inicial de tamizaje para detectar y tratar gestantes con sífilis es costo-efectivo en 
Colombia, evitando casos de sífilis congénita y sus consecuencias.
IN3
ANáLISIS COSTO-EFECTIvIDAD DE INTERvENCIONES PARA EL MANEjO 
DEL TRASTORNO DEPRESIvO MAyOR (TDM) EN PACIENTES CON vIRUS DE 
LA INMUNODEFICIENCIA HUMANA (vIH+) QUE INICIAN TRATAMIENTO 
ANTIRRETROvIRAL DE gRAN ACTIvIDAD (TARgA)
Lemus F.
National Institute of Public Health, Naucalpan, Estado de Mexico, Mexico
intROducción: El Trastorno Depresivo Mayor (TDM) es la comorbilidad psiquiátrica 
de mayor prevalencia en personas con VIH y ocasiona menor adherencia al TARGA, 
lo que a su vez repercute en una mayor progresión de la enfermedad e incrementa 
los costos de atención para el sistema. ObjectivOs: Realizar un estudio de costo-
efectividad de intervenciones para el manejo TDM en una cohorte hipotética de 
pacientes mexicanos con VIH bajo TARGA, desde el punto de vista del Sistema de 
Salud público en México. MetOdOlOgías: Estudio de costo-efectividad medi-
ante un modelo Markov, ciclosmensuales, para estimar la esperanza de vida por 
alternativa evaluada, la ocurrencia de sucesos y costos asociados, en pacientes 
que se encuentran por iniciar TARGA. El modelo está compuesto por los siguientes 
estados de salud: padecer VIH, estar bajo TARGA y presentar TDM; padecer VIH, 
estar bajo TARGA y no presentar TDM; muerte. Los comparadores incluidos son 
el uso de antidepresivos, la Terapia Cognitivo Conductual (TCC), combinación de 
ambas, ninguna intervención. Las probabilidades para la matriz de transición se 
obtuvieron de la literatura; y los costos médicos directos institucionales que se 
midieron son: antidepresivos, consultas especialistas, tratamiento de VIH/SIDA. Se 
corroboró la información con opinión de expertos. El horizonte temporal evaluado 
es la sobrevida del paciente. La tasa de descuento es 5%. Se realizó un análisis de 
costo efectividad incremental y un análisis de sensibilidad. ResultadOs: La TCC 
fue la intervención más costo-efectiva. Las 3 alternativas resultan en un costo por 
año de vida ganado menor a un PIB per cápita y presentan una ganancia en salud 
similar (2.77 años). Costos: TCC ($ 22,622.412); antidepresivos ($24,659.7538) y para 
la combinación de tratamientos ($24,790.722). El análisis de sensibilidad demostró 
la robustez del modelo. cOnclusiOnes: El proporcionar tratamiento contra el 
TDM en pacientes con VIH bajo TARGA ofrece una ganancia en salud y resulta costo-
efectivo para el sistema.
IN4
COSTO-EFECTIvIDAD DE TRES ESTRATEgIAS DIAgNOSTICAS PARA LA 
IDENTIFICACIóN DE INFECCIóN BACTERIANA SEvERA EN LACTANTES FEBRILES 
SIN FOCO
Buendia J.A.1, Urman G.2, Urman E.2, Grosman A.2
1Universidad de Antioquia, Medellin, Colombia, 2Universidad Maimonides, Buenos Aires, 
Argentina
ObjectivOs: Aun sigue siendo controversial el manejo del lactante febril (LFSF) sin 
foco entre uno a tres meses. La introducción de la vacunación contra neumococo ha 
reducido las tasas de bacteriemia oculta y alterado la utilidad de los tests disponi-
bles para detección de infección bacteriana severa (IBS) en LFSF. El objetivo de este 
estudio fue determinar la costo-efectividad de tres pruebas para la detección de IBS 
en LFSF. MetOdOlOgías: Se diseñó un modelo de costo-efectividad utilizando la 
técnica de análisis de decisiones, bajo la perspectiva del financiador (Obra Social) e 
incorporando los costos directos del tratamiento, hospitalización y diagnóstico; para 
comparar la razón de costo efectividad incremental entre la procalcitonina, proteína 
C reactiva y la escala de Rochester en una cohorte hipotética de 10.000 niños entre 
1 a 3 meses con diagnóstico de LFSF. ResultadOs: La proteína C reactiva resulta 
en un costo de AR$5341 por caso correctamente diagnosticado, frente a AR$5376. 
El costo por cada caso correctamente diagnosticado con la procalcitonina frente 
a la proteína C reactiva fue de AR$6127. La proteína C reactiva permanece siendo 
la estrategia más costo efectiva independiente de los valores dentro de los rangos 
declarados que puedan tomar los costos de internación y costo de la proteína C 
reactiva; así como los valores dentro del rango establecido de probabilidad de IBS, 
IBS por neumococo y efectividad vacunal. cOnclusiOnes: La proteína C reactiva 
constituye la estrategia más costo efectiva en la Argentina para la detección de la IBS 
en lactantes que acuden con SFSF. Sin embargo dado las moderadas proporciones 
de casos correctamente diagnosticados (< 80%) aun existentes; estas pruebas deben 
ser interpretadas dentro del contexto clínico del paciente y no como método único 
para la toma de decisiones terapéuticas.
RESEARCH PODIUM PRESENTATIONS – SESSION II
CANCER OUTCOMES RESEARCH
CA1
IMPLICATIONS OF gLOBAL PRICINg POLICIES OF PHARMACEUTICALS FOR 
ACCESS THE INNOvATIvE DRUgS: THE CASE OF TRASTUzUMAB IN SEvEN 
LATIN AMERICAN COUNTRIES
Pichon Riviere A.1, Garay U.1, Augustovski F.2, Vallejos C.3, Huayanay L.4, Navia M.D.P.5, 
Rodríguez A.6, Oliveira C.7, Andrade C.J.8, Buendia J.A.9
1IECS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 2Institute 
for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 3Universidad de La 
Frontera, Temuco, Chile, 4Universidad Peruana Cayetano Heredia, Lima, Peru, 5Universidad de San 
Andres, La Paz, Bolivia, 6Fondo Nacional de Recursos, Montevideo, Uruguay, 7ANVISA, Brasilia, 
Brazil, 8INC, Rio de Janeiro, Brazil, 9Department of Pharmacology .School of Medicine, University of 
Antioquia, Medellin, Colombia
Objectives: Differential pricing (DP) on the basis of countries’ purchasing power 
has been recommended by the WHO to secure more affordably priced medicines. 
However, in developing counties (DC) many innovative drugs have similar or even 
higher prices than in high-income countries (HIC). We conducted a cost-effectiveness 
ObjetivOs: Avaliar e comparar a eficácia e a segurança do ranibizumabe e do 
bevacizumabe para o tratamento da Degeneração Macular Relacionada a Idade 
(DMRI). MétOdOs: Realizou-se uma revisão sistemática / overview utilizando as bases 
The Cochrane Library, Centre for Reviews and Dissemination, Medline e LILACS com o obje-
tivo de encontrar estudos que comparassem ranibizumabe ou bevacizumabe com 
qualquer outra opção terapêutica para o tratamento da DMRI. Os estudos de avaliações 
econômicas foram buscados em sites da Rede Brasileira de Avaliação de Tecnologias e 
Saúde (REBRATS), no National Institute for Clinical Excellence and Health, Health Technology 
Assessment Programme eCanadian Agency for Drugs and Technologies in Health. ResultadOs: 
Foram identificados 643 títulos e destes, 14 foram incluídos sendo 5 revisões sistemáticas 
e 9 avaliações econômicas. A síntese dos resultados das revisões sistemáticas mostrou 
que ambos os medicamentos são eficazes, isso é, evitam a perda progressiva da visão 
e/ou aumentam a acuidade visual sobretudo quando comparados aos demais trata-
mentos disponíveis para a DMRI. Não foram encontrados estudos que comparassem 
diretamente a eficácia do ranibizumabe versus o bevacizumabe o que comprometeu 
uma possível avaliação da superioridade clínica entre eles. Por outro lado, as avaliações 
econômicas apontaram que a vantagem de um medicamento em relação ao outro está 
na diferença dos custos. O ranibizumabe em todos os cenários estudados foi mais caro 
e para torná-lo custo-efetivo é necessário que seu preço diminua. Já o bevacizumabe, 
possui eficácia equivalente e um custo inferior que provavelmente está relacionado 
a sua forma de administração - uma ampola para mais de um paciente - o que tem 
ocasionado uma discussão quanto à sua utilização off label no Brasil. cOnclusões: 
Recomenda-se a utilização do ranibizumabe ou do bevacizumabe para a forma úmida 
da DMRI em pacientes maiores de 50 anos de idade.
INFECTIOUS DISEASE STUDIES
IN1
ASSESSMENT OF BURDEN OF ILLNESS DUE TO HERPES zOSTER IN ARgENTINA: 
A PROSPECTIvE OBSERvATIONAL STUDy
Vujacich C.1, de Wouters L.2, Margari A.3, Gordóvil M.2, Kawai K.4, Lemos E.5, Rampakakis E.6, 
Pollock C.7, White R.8, Acosta C.J.8, Sampalis J.S.6
1Fundación Centro de Estudios Infectológicos (FUNCEI), Buenos Aires, Argentina, 2Hospital 
Privado de la Comunidad, Mar del Plata, Argentina, 3Hospital Naval, Buenos Aires, Argentina, 
4Merck & Co., Inc, West Point, PA, USA, 5MSD Colombia, Bogota, Colombia, 6McGill University & 
JSS Medical Research, St. Laurent, QC, Canada, 7JSS Medical Research, St. Laurent, QC, Canada, 
8Merck & Co., West Point, PA, USA
Objectives: Herpes zoster (HZ) is caused by the re-activation of latent varicella-
zoster virus (VZV) and is characterized by unilateral, vesicular cutaneous eruptions, 
acute neuritis and post-herpetic neuralgia (PHN). To date, data on HZ associated 
pain (ZAP) and its impact on quality of life (QoL) in Argentina are scarce. This study 
assesses the burden of illness associated with HZ in Argentina in a real-life clini-
cal setting. MethOds: This was a prospective, observational, single-cohort study. 
Patients were enrolled at various time points during the course of a zoster episode 
and were followed for ≤ 6 months. ZAP was assessed with the Initial Zoster Impact 
Questionnaire and the Zoster Brief Pain Inventory, while QoL was assessed with the 
EQ-5D instrument using the Hispanic preference weights. Results: A total of 96 
HZ patients were enrolled with a mean (SD) age of 70.14 (10.7) years and 64 (66.7%) 
being females. At baseline, mean (SD) time since rash onset was 15.92 (16.9) days. 
Prior to rash onset (prodrome phase), a significant proportion (59.4%) of patients 
experienced a worst pain score of ≥ 5. ZAP was reported by 92 (95.8%) patients at 
baseline. Mean (SD) worst pain score decreased from 5.47 (3.1) at baseline to 2.94 
(3.0) at 30 days and 0.21 (0.7) at 180 days. PHN (worst pain ≥ 3 after ≥ 90 days since 
rash onset) was experienced by 11 (11.5%) patients. The mean (SD) EQ-5D score sig-
nificantly decreased (P< 0.001) from 0.84 (0.10) before rash onset to 0.63 (0.20) after 
rash onset, increasing thereafter, showing significant (P< 0.05) QoL deterioration 
up to 60 days of follow-up. cOnclusiOns: HZ pain can significantly reduce QoL 
and ability to perform daily activities of people living in Argentina highlighting the 
importance of early intervention or prevention. These findings are consistent with 
observational studies in other countries.
IN2
COSTO-EFECTIvIDAD DEL USO DE PRUEBAS TREPONéMICAS RáPIDAS PARA 
LA DETECCIóN y TRATAMIENTO TEMPRANO DE SíFILIS gESTACIONAL EN 
COLOMBIA
Castañeda Guerrero C.1, Eslava J.1, Ruiz A.1, Diaz J.1, Prieto V.1, Lemos E.V.2
1National University of Colombia, Bogota, Colombia, 2Fundacion para el Desarrollo y Apoyo en 
Salud Internacional (FUDASAI), Bogotá, Colombia
ObjectivOs: Evaluar la costo-efectividad del uso de pruebas treponémicas 
rápidas inmunocromatográficas (PTRI) para el tamizaje de Sífilis gestacional en 
Colombia. MetOdOlOgías: Se desarrolló un árbol de decisiones en una cohorte 
hipotética de pacientes gestantes, las alternativas consideradas fueron: manejo con-
vencional usando prueba no treponémica (VDRL) seguida de treponémica (FTA-ABS) 
frente a una propuesta usando PTRI, Inicio de tratamiento a gestantes positivas y 
prueba confirmatoria con VDRL. Se consideraron varios escenarios: Gestantes tami-
zadas antes de las 24 semanas y a contactos (GT1); Gestantes tamizadas antes de las 
24 semanas sin contactos (GT2); Gestantes tamizadas antes de las 34 semanas con y 
sin contactos respectivamente (GT3), (GT4). La perspectiva fue la del tercer pagador 
y el horizonte temporal 10 meses. Se incluyeron los costos de los medicamentos, la 
estancia hospitalaria, los eventos adversos secundarios al uso de los medicamentos, 
las valoraciones médicas y paraclínicos en su seguimiento. Se realizó análisis de 
sensibilidad determinístico de las variables con mayor incertidumbre. El modelo fue 
desarrollado por un equipo de profesionales de la salud Epidemiólogos, Ginecólogos, 
con asesoría de especialistas en Economía de la Salud en el año 2012. ResultadOs: 
La estrategia propuesta PRTI-VDRL presenta una dominancia absoluta sobre el 
manejo convencional VDRL-FTABS con una disminución de costos de US 210 y un 
aumento de efectividad del 0.18 (18% más de casos evitados de sífilis congénita) en el 
escenario GT1. Esta dominancia absoluta se observó también en los otros escenarios 
estudiados (GT2, GT3, GT4). El resultado de dominancia se mantuvo al realizar el 
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Objectives: Retrospective study of oncology patients with cardiovascular event, in 
order to help an decision. There is evidence regarding the prognosis of cancer patients, 
which is seen as a carrier of a chronic disease that throughout its evolution may have 
acute decompensation, as cardiovascular manifestations. Progress in cancer treatment 
also resulted in increased exposure of patients to cardiovascular risk factors and chemo-
therapy with potential cardiotoxicity and sure for expenses in terms of adding costs of 
care. MethOds: We analised 68 cases collected and registered by the time of cardiology 
and oncology audit, in 2012. Outocmes items used: Costs, cardiovascular events associ-
ated with cancer. Results: Among 68 cases, Breast Cancer is the majority account-
ing 32 ( 47% ). All of them were seen by cardiologist and the total amount spent were 
US$15.000,00 . Thirty one patients were caracterized having a cardio - vascular event 
and the costs were comprise by echocardio, ergo-cardio test, angio tomography and 
coronary cardiac catheterization. The costs of oncology treatment range from $1.500,00 
to $ 6.800,00 USD per cicle, each 21 or 28 days, that means $18.000,00 to $ 120.000,00 USD a 
year . It means that the provisional budget will range from $ 1.224.000,00 to $ 8.160.000,00 
USD a year for the cohort of 68 patients in our institution. So, we will spend 0.18 % to 
1.22 % in cardiac vigilance for the oncologic patients describe above. cOnclusiOns: 
The costs still low, the price of the oncologic cure with an cardiologic event needs more 
studies, details need for further recomendations.
FORMULARy DEvELOPMENT AND PUBLICATION OF COST STUDIES
FD1
RESULTADOS DE LA ENCUESTA “CHANgE PAIN” LATINOAMERICANA: 
DIAgNOSTICO y TRATAMIENTO ACTUAL DE LOS PACIENTES CON DOLOR 
CRóNICO
Amescua C.1, Berenguel M.1, Silvan R.2
1Grunenthal, Latinoamérica, Distrito federal, Mexico, 2Independent Consultant, Distrito federal, 
Mexico
ObjectivOs: La “Change Pain Survey at EFIC 2009- Physian’s perception on manage-
ment of severe chronic non-cancer pain” realizada en países europeos, confirma la 
falta de conocimiento para el dolor neuropático y las variedades de enfoques del 
tratamiento del dolor crónico sin utilizar una guía consistentemente. Aplicando la 
misma encuesta a médicos generales y especialistas en países de América Latina, 
se exploró la percepción y comprensión de la forma de manejo del dolor crónico en 
América Latina. MetOdOlOgías: Se realizaron 2130 encuestas vía electrónica de 
octubre 2012 a marzo 2013, en forma aleatoria a médicos generales y especialistas a 
través de sociedades médicas, fuerza de ventas o aplicadas en congresos médicos de 
15 países de América Latina, poniendo énfasis en la percepción del tipo de dolor para 
elección del tratamiento. ResultadOs: El porcentaje por especialidad fue: 18% trau-
matólogos, 12% médicos generales, 12% de rehabilitación, 13% anestesiólogos, 10% 
algólogos, y otras especialidades menores a 5%. Clasifican el dolor crónico muy heter-
ogéneamente, desde nivel 4 al 9, en una escala del 1-10. Sus objetivos del tratamiento 
del dolor son reducción del dolor (30%) y calidad de vida (27%). La elección terapéutica 
para el dolor la deciden por eficacia (19.28%), tolerabilidad (21.83%), eficacia/equilibrio 
de efectos adversos (24.69), calidad de vida (18.19%) y costo (15.99%). Perciben un cono-
cimiento limitado de las opciones terapéuticas y sobre la diferencia fisiológica entre 
dolor nociceptivo y dolor neuropático. cOnclusiOnes: La encuesta muestra una 
ausencia de estandarización en el tratamiento de dolor crónico y desconocimiento 
de las opciones terapéuticas ideales para el dolor crónico. Existe una necesidad de 
contar con un mejor conocimiento sobre el dolor crónico para lograr un adecuado 
manejo multimodal para su seguimiento y control.
FD2
ESSENTIAL MEDICINE LIST (CUADRO BáSICO) IN MéxICO. IS IT A gUIDELINE 
FOR DECISION MAkINg ON THE CURRENT AND FUTURE HEALTH NEEDS?
Lemus A.1, Marquez R.1, Jimenez P.2
1Universidad de la Salle, MÉXICO D.F., Mexico, 2independent, MÉXICO D.F., Mexico
Objectives: Cuadro Básico is a list of minimum medicines needed for a basic health 
care system, listing the most efficacious, safety and cost-effective medicines for pri-
ority conditions. The importance is to ensure availability of drugs for current and 
future public health relevant diseases. The objective is to describe the characteris-
tics of National List in Mexico and compare it with the Instituto Mexicano Seguro 
Social (IMSS) List in order to hypothesize the relevance of the drugs included on 
both Lists versus current and future health needs in the country. MethOds: It was 
performed a descriptive analysis of the two lists organized by therapeutic area. The 
description includes number of total codes, and number per therapeutic area. The 
information was compared to find the gaps on the number of codes between the two 
Lists. In addition it was identified the top health priorities and prevalence. Results: 
National list has 1631 codes; the therapeutic areas with the majority of codes are 
infectious diseases (222) and Oncology (150). IMSS List has 1145 codes. The biggest 
relative difference between the two lists come from codes available for neurology, 
dermatology and ophthalmology; 57%, 56% and 45% codes are not available at IMSS, 
respectively. The top mortality causes in Mexico are heart disease, diabetes, cancer, 
accidents, liver diseases, stroke and COPD. If the analysis is made by disease, it worth 
mention that COPD only have 3 codes at IMSS and 7 codes at National Listing, while 
Alzheimer disease do not have any code at IMSS. cOnclusiOns: A more extensive 
analysis (already available) brings information about the gaps between health needs 
and the drugs available. Mexico has an increased number of an aging population, 
which requires access to different drugs. The Essential list of WHO has 315 compounds 
versus Mexican which has 1631 codes. Is it a good guideline for decision makers?
FD3
¿PUEDE UN CAMBIO DEL 2003 EN EL REgLAMENTO EN EL CUADRO BáSICO 
(CBM) EN MéxICO IMPACTAR LA CANTIDAD DE ESTUDIOS CIENTíFICOS 
PUBLICADOS DE EvALUACIóN ECONóMICA COMPLETOS DE MEDICAMENTOS 
(EECM) EN LOS úLTIMOS 10 AñOS?
Márquez Cruz M.1, Peralta Bácenas L.A.1, Ibarra Cázares A.E.1, Rodriguez Mendoza M.M.1, 
Pizarro Castellanos M.2, Soto Molina H.1
(CE) analysis to estimate the impact of this pricing policy on the CE of trastuzumab 
in Latin-America (LA). MethOds: Model structure and a common methodology 
for identifying costs and resource use were agreed with country teams. A Markov 
model was designed to evaluate life years (LY), quality adjusted life years (QALYs) 
and costs from a health care sector perspective. A systematic search on effectiveness, 
local epidemiology and costs studies was undertaken to populate the model. A base 
case scenario using transition probabilities from trastuzumab clinical trials, and two 
alternative scenarios with transition probabilities adjusted to reflect breast cancer 
epidemiology in each country, were built to better fit local cancer prognosis. Results: 
Incremental discounted benefits and costs of the trastuzumab strategy ranged from 
0·87 to 1·00 LY, 0·51 to 0·60 QALY and $24,683 to $60,835 (2012 US dollars). Incremental 
CE ratios ranged from $42,104 to $110,283 per QALY, equivalent to 3·6 gross domestic 
products per capita (GDPc) per QALY in Uruguay to up to 35·5 GDPc per QALY in Bolivia. 
The probabilistic sensitivity analysis showed a 0% probability that trastuzumab is CE 
if the willingness-to-pay (WTP) threshold is one GDPpc per QALY, and remains 0% at a 
WTP threshold of three GDPc except in Chile and Uruguay (probability 4·3% and 26·6% 
respectively). cOnclusiOns: Despite its proven CE in other settings, trastuzumab 
was not CE in LA at its current price. Better cooperation between the public and pri-
vate sectors is still needed to make innovative drugs available and affordable in DC.
CA2
NATIONAL SPENDINg wITH SCREENINg, DIAgNOSIS AND TREATMENT OF 
CERvICAL CANCER: ESTIMATES BASED ON HEALTH INFORMATION SySTEMS, 
BRAzIL, 2006
Novaes H.M.D.1, De Soarez P.C.1, Itria A.2, azevedo e Silva G.3, Sartori A.M.C.4, Rama C.5
1University of Sao Paulo, Sao Paulo, Brazil, 2Departamento de Saúde Coletiva do Instituto de 
Patologia Tropical e Saúde Pública, Universidade Federal de Goiás. Pesquisador do Instituto de 
Avaliação de Tecnologia em Saúde (IATS), Goiânia - Goiás, Brazil, 3Universidade Estadual do Rio 
de Janeiro, Rio de Janeiro, Brazil, 4University of Sao Paulo, Sao Paulo, SP, Brazil, 5Secretaria do 
Estado de Saúde de São Paulo, São Paulo, AL, Brazil
Objectives: To estimate national expenditure with procedures of the National 
Cervical Cancer Control Program. MethOds: A cost description study was con-
ducted to develop estimates of expenditures related to care held under the National 
Cervical Cancer Control Program in Brazil. Health Information Systems of the Public 
Health System, SUS (SIH, SIA, APAC, SIAB, and SIGTAP SISCOLO), national survey 
(PNAD 2008), and guidelines of INCA / MS, and reference systems for payments of the 
private system were consulted to construct estimates of direct and indirect costs. 
The estimates were grouped by sets of procedures of the stages of cervical cancer 
care (screening, diagnosis, treatment of precancerous lesions of the cervix - CIN I 
and CIN II / III and treatment of cervical cancer). The study was conducted from the 
perspectives of the health care system and society. Results: The total direct cost 
of SUS in 2006 was estimated at R$ 227,167,515, ambulatory visits were responsible 
for 27% of spending. Screening represented the highest spending. The estimated 
total direct spending to the private sector in 2006 was R$ 938,707,221, ambulatory 
visits were responsible for 68% of spending. The transport costs were estimated at 
R$ 230,533,910. Lost productivity was based on the human capital approach and 
was estimated at R$ 1,463,977,777. The final value of the direct and indirect costs 
estimated and adjusted for the year 2008 was R$ 3,193,335,402. cOnclusiOns: 
Spending with National Cervical Cancer Control Program is very significant. There 
is need for more costing studies in the country, alongside a greater structuring of 
official systems cost data available in order to contribute to the standardization and 
accuracy of the estimates of national costs.
CA3
ANáLISIS DE COSTO-EFECTIvIDAD DE ESTRATEgIAS DE PREvENCIóN 
PRIMARIA y SECUNDARIA PARA CáNCER DE CUELLO UTERINO EN COLOMBIA
Gamboa O.A., Murillo R.H., González M.
Instituto Nacional de Cancerología, Bogotá, DC, Colombia
ObjectivOs: Evaluar la costo-efectividad de estrategias de prevención primaria 
(vacunación) y secundaria (tamización) para la prevención del cáncer de cuello 
uterino en Colombia. MetOdOlOgías: Un modelo de Markov de la historia natural 
del cáncer de cuello uterino fue desarrollado para evaluar las siguientes estrategias: 
no tamización, tamización (citología convencional y en base líquida, pruebas ADN 
VPH, pruebas rápidas de ADN VPH y via vili), vacunación y tamización + vacunación. 
Las estrategias se evaluaron solas o combinadas, para un total de 32 estrategias evalu-
adas. Los años de vida ganados (AVG) fueron usados como medida de efectividad. El 
estudio tuvo la perspectiva del tercero pagador, solo se incluyeron costos directos. 
Se calcularon razones de costo-efectividad y costo-efectividad incremental, se con-
dujeron análisis de sensibilidad determinísticos y probabilísticos. Se aplicó tasa de 
descuento del 3% a los costos y resultados en salud. ResultadOs: Las estrategias 
que quedaron sobre la frontera eficiente fueron: la vacunación, la vacunación más 
las pruebas rápidas de ADN VPH cada 10 años desde los 35 - 50 años, la vacunación 
más la prueba de ADN VPH cada 3 años desde los 30-69 años con triage (via vili) y sin 
triage de las mujeres positivas a la prueba y la vacunación más la citología en base 
líquida en el esquema 1-1-1-3 desde 25-69 años. El costo por año de vida ganado para 
las estrategias arriba mencionadas fue de $US 1.288, $US 6.447, $ US 8.875, $US 14.186 
y $US 94.503 respectivamente. El análisis probabilístico mostró que para umbrales de 
disponibilidad a pagar superiores a $US 13.000 la tamización con prueba de ADN-VPH 
cada 3 años más vacunación es la estrategia más costo-efectiva. cOnclusiOnes: 
La tamización con prueba ADN-VPH cada 3 años más vacunación en mujeres de 12 
años sería una alternativa costo-efectiva para Colombia.
CA4
EMERgINg CARDIOvASCULAR EvENTS ASSOCIATED wITH TARgETED 
ANTICANCER DRUgS. PRELIMINARy RESULTS OF A CARE LINE’S PROgRAM 
BASED ON AUDIT vIgILANCE IN A PRIvATE HEALTH CARE IN BRAzIL
Tanaka E.1, Da Costa E.S.M.2, Santos G.L.2, Michaelis W.2, Miguel Neto C.2, Ribas K.M.D.G.2, 
Mischiatti E.2, Kotze O.H.2
1Curitiba City Health Institute, Curitiba, Brazil, 2ICS, CURITIBA, Brazil
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alternative compared with TOD for collecting, transporting and improving the quality 
of urine specimens in non-pregnant women from the payer perspective in Mexico.
PR3
ANáLISIS COSTO-EFECTIvIDAD DE LINEzOLID COMPARADO CON 
vANCOMICINA EN EL MANEjO DE LA NEUMONíA ASOCIADA A LA vENTILACIóN 
MECANICA EN COLOMBIA
Varon F.A.1, Londoño D.2, Álvarez C.2, Taborda A.2, Prieto Martinez V.3
1Fundación Neumológica Colombiana, Bogotá DC, Colombia, 2Pontificia Universidad Javeriana, 
Bogotá DC, Colombia, 3Pfizer S.A.S., Bogotá DC, Colombia
ObjectivOs: La neumonía asociada a la ventilación mecánica (NAV) es la causa más 
frecuente de morbi-mortalidad en las unidades de cuidado intensivo. La incidencia 
de NAV en Colombia oscila entre 7 y 29 casos por cada 1000 días de intubación orot-
raqueal. Adicionalmente, la ventilación mecánica aumenta el riesgo de infección por 
Staphylococcus aureus resistente a meticilina(SARM). El objetivo de este trabajo es estimar 
la costo-efectividad del tratamiento con linezolid versus con vancomicina en el manejo 
de la NAV causado por SARM en Colombia. MetOdOlOgías: Se construyó un árbol de 
decisión para determinar la razón de costo-efectividad incremental de linezolid (600 mg 
IV/12h) comparado con vancomicina (1g IV/12h) en el tratamiento de NAV por SARM. El 
estudió se llevó a cabo desde la perspectiva del tercer pagador incluyendo solo costos 
directos. Todas las unidades monetarias se expresan en dólares americanos (1 US$ = 
1.785 COP). Se empleó un horizonte temporal de 30 días. La unidad de resultado fueron 
los años de vida ajustados por calidad (AVAC). Los datos de efectividad, seguridad y 
utilidad se tomaron de la literatura, los costos de los procedimientos se obtuvieron del 
manual tarifarios ISS, para medicamentos se utilizó el SISMED y la regulación de precios 
vigente (circular 04 de 2012). Se realizaron análisis de sensibilidad univariados y proba-
bilísticos. ResultadOs: Los costos totales esperados por paciente fueron: linezolid 
(US$ 1589), vancomicina (US$ 1461). Los resultados en términos de AVAC para cada alter-
nativa fueron: Linezolid 0,91; vancomicina 0,87. La razón de costo-efectividad incremen-
tal de Linezolid comparado con vancomicina fue US$ 3090 por AVAC. cOnclusiOnes: 
Asumiendo como umbral el PIB per cápita para Colombia en 2012 (US$ 7104) linezolid 
es una estrategia costo-efectiva en el tratamiento de NAV por SARM.
PR4
ESTUDIO TRANSvERSAL DEL PROCESO DE ACTUALIzACIóN DE 
MEDICAMENTOS EN EL CUADRO BáSICO y CATáLOgO DE INSUMOS DEL 
SECTOR SALUD
Rizo Ríos P., González Rivera A., Rivas Oropeza I., Rivas Bocanegra R., Melchor Martínez F., 
Ruíz Pérez L.C.
Consejo de Salubridad General, Distrito Federal, Mexico
ObjectivOs: Los altos costos generados por el actual perfil epidemiológico y la 
introducción de nuevas tecnologías, impactan en los sistemas públicos, panorama 
que se complica cuando el gasto en salud es bajo, en especial para medicamentos, 
donde la mayor parte de este gasto es de bolsillo. Ello hace ineludible el diseño de 
estrategias para solventar los retos, como fué el fortalecimiento del CBCISS. Este 
estudio describe los resultados del proceso de actualización de medicamentos al 
CBCISS para garantizar la eficacia, seguridad y eficiencia de insumos utilizados en 
las instituciones públicas de salud. MetOdOlOgías: Se realizó un corte transversal 
del proceso de actualización de medicamentos, de septiembre del 2011 a diciem-
bre del 2012, con un análisis descriptivo para cada etapa (valoración, evaluación y 
dictamen). ResultadOs: De 394 solicitudes recibidas y valoradas, 244 (62%) cor-
respondieron a medicamentos, de ellas, 151 (62%) cumplieron los requisitos para 
su evaluación (32% fueron modificaciones y 68% inclusiones), se dictaminaron 
procedentes el 42% (61% de las modificaciones y 33% de las inclusiones). El 73% de 
las inclusiones procedentes fueron por consenso, 12% condicionadas a baja de pre-
cio y 6% por mayoría de votos, esencialmente. Las principales causas de rechazo 
fueron: falta de evidencia clínica (31%) y problemas metodológicos en la evidencia 
económica (27%). cOnclusiOnes: El fortalecimiento del proceso se realizo con rigor 
metodológico basado en análisis crítico de evidencia científica, con transparencia y 
legitimidad bajo un marco legal para favorecer la optimización de recursos. El mayor 
porcentaje de solicitudes fueron para medicamentos, que constituyen la tecnología 
terapéutica más utilizada, que requiere una selección adecuada para garantizar mayor 
beneficio al menor riesgo y costo posible. La evaluación económica fue herramienta 
de apoyo para considerar además del precio, el valor de la salud determinado por 
la calidad de la evidencia, estableciendo un PIB como límite de disposición a pagar.
COST, RISk FACTOR & UNIvERSAL COvERAgE STUDIES
RF1
EFECTO DEL SEgURO POPULAR SALUD SOBRE LA DEMANDA DE SERvICIOS 
PRENATALES EN EL CONTExTO DE LA COBERTURA UNIvERSAL, MéxICO 2012
Servan-Mori E.
National Institute of Public Health, Cuernavaca, Mexico
ObjectivOs: La atención prenatal oportuna es una estrategia efectiva para reducir el 
riesgo de mortalidad materna. En 2003, en México, se creó el Seguro Popular de Salud 
(SP); uno de sus objetivos es contribuir a reducir el riesgo de mortalidad materna, a 
través de intervenciones como la atención profesional del embarazo/parto, incentivar 
el acceso efectivo a servicios de salud y su mayor demanda. Así, el objetivo de este 
estudio fue analizar el efecto del SP sobre la demanda oportuna (DO) de servicios 
prenatales y la demanda de al menos 4 visitas prenatales durante el último embarazo 
(4VP) del mujeres mexicanas. MetOdOlOgías: Se utilizó la Encuesta Nacional de 
Salud y Nutrición de México 2012. El efecto del SP sobre DO y 4VPse estimó a partir de 
métodos no experimentales de pareamiento. Se exploraron además posibles fuentes 
de heterogeneidad de dicho efecto atribuibles a elementos individuales (la escolaridad 
y el nivel socioeconómico, NSE) y de contexto (nivel de desarrollo del lugar de residen-
cia). ResultadOs: El SP incrementó la DO en mujeres de NSE I (RM= 1.88, p< 0.05) y 
la posibilidad de demandar 4VP (RM= 1.65, p< 0.01). No obstante, al incluir la DO como 
predictor de 4VP, el SP perdió importancia en la explicación de este indicador; en este 
modelo la DO incrementó los momios de 4VP (RM= 6.2, p< 0.01). Tanto la DO como 
1Universidad Autónoma Metropolitana, Distrito Federal, Mexico, 2Hospital Infantil Federico 
Gomez, Distrito Federal, Mexico
ObjectivOs: Efectuar una revisión sistemática de los EECM realizados en México 
de 1983 a 2012 y evaluar el impacto que tuvo con la adición del reglamento del 
2003 en CBM. MetOdOlOgías: Se realizó revisión sistemática de artículos 
publicados entre 1983 a 2012 de EECM que cumpliera los siguientes requisitos: 
humanos, idioma español e inglés, realizados en México, no se tomó en cuenta 
resúmenes presentados en congresos. La búsqueda se realizó en Pub Med, CRD, 
ScienceDirect, Imbiomed, Medigraphics y la BSV (OMS). Los estudios EECM fueron 
clasificados de acuerdo a Drummond (2005). Se realizó un análisis de estadística 
descriptivo, por año de publicación, tipo de estudio, fuente de financiamiento, 
especialidad. Asimismo, se ejecutó un análisis de comparación de tres períodos 
continuos (1983/1992, 1993/2002, 2003/2012) para mostrar el crecimiento de EECM 
por el cambio de reglamento del 2003. ResultadOs: Se identificaron un total 
de 154 artículos, de esos 68 (44,16%) son EECM. El tipo de estudio más publicado 
fue costo efectividad (80.88%). Los modelos económicos más utilizados fue el 
árbol de decisiones (36.66%) y markov (35%). Las especialidades donde se publicó 
más fueron infectología (14.7%), oncología y ginecología (11.8%). En el período de 
1983/1992 se publicaron 1 artículo EECM, 1993/2002 6 y 2003/2012 61. La tasa de 
crecimiento de 2003/2012 con respecto al 1993/2002 fue del 916.66%, mientras 
el financiamiento de la industria farmacéutica en ese mismo período creció en 
3,095%. cOnclusiOnes: Debido al cambio del reglamento en el 2003 en el proceso 
de inclusión de medicamentos al sector público, impacto de forma positiva en el 
crecimiento de las publicaciones en EECM en México, siendo su principal fuente 
de financiamiento la industria farmaceútica.
PRICINg STUDIES
PR1
ANáLISIS DEL IMPACTO EN LA DEMANDA DE TECNOLOgíAS INCLUIDAS EN EL 
PLAN DE BENEFICIOS COLOMBIANO (POS) POSTERIOR A SU ACTUALIzACIóN 
EN 2012
Romero M.1, Acero G.1, Marrugo R.1, Alvis N.2, Arango C.3
1Fundacion Salutia, Bogotá, Colombia, 2Universidad de Cartagena, Cartagena de Indias, Bolívar, 
Colombia, 3Fundacion Salutia, Bogotá, Colombia
ObjectivOs: Analizar el impacto de la demanda de tecnologías, tras la actualización 
del plan de beneficios colombiano (Plan Obligatorio de Salud POS) en 2012, como 
indicador del acceso a los servicios de salud. MetOdOlOgías: De una muestra 
aleatoria de 20 medicamentos (37% de las tecnologías incluidas), se analizaron las 
unidades despachadas según el registro del Sistema de Información de Precios de 
Medicamentos (SISMED) para sus canales comerciales e institucionales (farmacias, 
y aseguradoras u hospitales, respectivamente) de 2010 a 2012; estimando lo cam-
bios porcentuales anuales. Las tecnologías que estaban previamente cubiertas en 
el plan, en la misma indicación, fueron incluidas en el análisis. Para el análisis se 
definieron 5 intervalos según el nivel de cambio: < -25%, -25% a 0%, 0% a 50%, 50% a 
100% y > 100%. No se realizó análisis de precios porque durante ese periodo cambió 
la legislación que los regula. ResultadOs: El 60% de las tecnologías incorporadas 
presentó un aumento del doble o más, en sus unidades despachadas; y el 15% 
presentó crecimientos entre el 50% y 100%, mayormente en el canal institucional. 
Los comparadores de uso para patologías específicas, presentaron disminución en 
su participación de mercado, tanto en el canal comercial como institucional. Por 
ejemplo, aciclovir, disminuyó su uso en más del 25%, frente al 2010. El 10% presentó 
disminución de uso con el ingreso al plan. cOnclusiOnes: Aunque los usuarios 
podían acceder a las tecnologías por vías de carácter legal o administrativo, la incor-
poración de las nuevas tecnologías en 2012 mejoró el acceso a los servicios de salud 
entendido como un mayor consumo de tecnologías y se reemplazaron tecnologías 
en uso desde hace más de 10 años. Si bien esto podría ser un efecto del asegurami-
ento, al ser los medicamentos resultado de una atención médica, este incremento 
podría entenderse como pacientes efectivos con mayor acceso.
PR2
ECONOMIC EvALUATION OF AN URINE CLOSED COLLECTION SySTEM vERSUS 
A TRADITIONAL OPEN DEvICE IN NON-PREgNANT wOMEN
Cardona D.P.1, Burbano-Levy X.2, Palacios E.3, Zapata L.3
1Universidad de Antioquia- Facultad De Quimica Farmaceutica, Medellín, Colombia, 2Zilonis 
Health, Inc, Boca Raton, FL, USA, 3Guia Mark, S. A. de C. V., Mexico, DF., Mexico
Objectives: The study assessed the cost-effectiveness (CE) of a medical device, an 
urine collection/transportation system containing or not preservative (UCTS) versus 
the traditional open device (TOD). The evaluated UCTS is used to collect and trans-
port urine specimens, reducing contamination, and providing more accurate test 
results to establish UTI presence in non-pregnant women from the Mexican Institute 
of Social Security (IMSS) perspective. MethOds: The CE analysis was based in a 
decision model, considering a time horizon of two weeks after urine samples were 
collected. The number of correctly diagnosed UTI was the effectiveness measure. 
Data was obtained from available published studies reporting contamination rates. 
To calculate the effectiveness measure of the diagnoses process, a hypothetical cohort 
of 500 patients was simulated and positive/negative predictive values of the labora-
tory tests involved in the process were considered for adjustment. Direct medical 
costs were included and obtained from IMSS available data. CER and ICER were cal-
culated to establish the cost-effectiveness of both medical devices. Univariate and 
multivariate sensitivity analysis, using pricing discounts and effectiveness were per-
formed. Results: Costs of UTI diagnosis in the hypothetical cohort using the UCTS 
were USD1907.40 compared to USD 2163.2 with the TOD. The number of correctly diag-
nosed UTI for each alternative was 25% and 51% respectively. CER were USD 3742.80/
correctly diagnosed UTI and USD 8,597.79/correctly diagnosed UTI with the TOD. 
ICER analyses suggest that UCTS is a cost effective alternative, saving USD 4854.99 
for each correctly diagnosed UTI. The sensitivity analysis confirmed the robustness 
of the modeled parameter estimates. cOnclusiOns: . The results from the analyses 
indicates that UCTS (containing or not preservative) provides a highly cost-effective 
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and quality-adjusted life years (QALYs) were discounted at 3% annually. One-way 
sensitivity analyses were conducted. Results: Using a $20,000/QALY threshold, 
baseline screening with S5 dominated S3 and S4 by reducing overall cost, annual 
cancer incidence, and improving QALYs; and was cost-effective compared to S1 and 
S2. In the 1-year follow-up scenario, S5 was cost-effective compared to all other 
strategies. Detection of HPV 16/18 with S5 resulted in earlier diagnosis of clinically 
relevant CIN 2/3 at the initial visit as well as more efficient use of screening tests 
during follow-up. Sensitivity analyses showed that test sensitivities were the most 
impactful on model results. cOnclusiOns: Incorporating the cobas HPV test with 
HPV 16/18 genotyping was cost-effective compared to various CxCa screening strate-
gies, and resulted in improved protection against CxCa.
TRENDS IN HEALTH CARE STUDIES
TR1
SELF-REPORTED HEALTH STATUS AND EQ-5D-3L vALUES OF THE ARgENTINE 
POPULATION: COMPARINg 2005 vERSUS 2009 NATIONAL RISk FACTOR 
SURvEyS
Augustovski F.1, Rey Ares L.2, Gibbons L.2
1IECS - Instituto de Efectividad Clinica y Sanitaria, Buenos Aires, Argentina, 2Institute for Clinical 
Effectiveness and Health Policy, Buenos Aires, Argentina
Objectives: To describe and compare general population self-reported health 
and EuroQol EQ-5D-3L values in 2005 and 2009 Argentina national risk factors sur-
vey. MethOds: The 2005 and 2009 waves included 41,392 and 34,732 adults, ran-
domly selected from all Argentine provinces with a probabilistic multi-stage sample 
design. We report general population summary data on health status (EQ-5D-3L 
and the general health question of SF-36) as well as of different sociodemographics 
subgroups. Argentine time-trade off (TTO) and visual analog scale (VAS) values (V) 
weights were used. A descriptive analysis was done. 2005 results were compared 
to 2009 using Rao-Scott chi-square or regression analysis. Results: Good or bet-
ter self reported health was similar in 2005 and 2009 (80.1 vs. 80.7%). More people 
reported no limitations in all EQ-5D domains in 2009 vs. 2009 (61 vs. 57%; p< 0.001). 
Mean values in 2005 versus 2009 were: VAS 75.3 vs. 75.9; p= < 0.001; TTO 0.89 vs. 
0.91; p= = < 0.001; VAS-V 0.86 vs. 0.88; p= < .001. 63 vs. 66% of males and 52 vs. 56% of 
females; 71 versuss 77% of 18-24y; and 37 versus 36% of 65+y; 63 versus 69% in the 
higher education category reported no limitations. VAS; TTO; and VAS-V 2005 versus 
2009 in subjects without limitations: 82.4; 1; 1 versus 82.4; 1; 1; while in subjects with 
any limitation figures were 66.5; 0.76; 0.69 versus 66.2; 0.76; 0.69. cOnclusiOns: 
In this analysis of the first two waves of Argentina National Risk Factors Survey, 
we found a small secular trend between 2005 and 2009, showing slightly better 
self reported health in 2009. There are few population surveys in our region that 
incorporated health status measures and did it in a periodic basis. These results can 
serve as a benchmark for future population studies and also as inputs for cost-utility 
analysis of health technologies in Argentina and Latin America.
TR2
ANáLISIS BIBLIOMéTRICO DE LA PRODUCCIóN CIENTíFICA EN ECONOMíA DE 
LA SALUD EN LATINOAMéRICA
Simbaqueba E., Romero M.
Fundacion Salutia, Bogotá, Colombia
ObjetivO: Analizar el nivel de producción científica en economía de la salud 
en Latinoamérica aplicando métodos de valoración cuantitativos de recuento 
y de análisis bibliométrico. MétOdO: La revisión fue hecha a partir de la base 
de datos Scopus, dada su mayor cobertura de acuerdo a Academic Database 
Assesment Tool. Los resultados se analizaron a través de indicadores de produc-
ción, difusión, colaboración y bibliométricos, en los que se contemplaron tenden-
cias de publicación, autores, tipo de documento, área de trabajo, revistas, país 
(Latinoamericanos), número de citaciones, factor de impacto, el índice h, y red de 
difusión. ResultadOs: Se encontraron 860 artículos científicos con autores de 
afiliación institucional en países latinoamericanos. La función de crecimiento anual 
presentó una tendencia exponencial en los últimos veinte años. Brasil, México, 
Argentina, y Chile son los países con mayor impacto y desarrollo en el campo de 
economía de la salud aportando el 80,6% del total de referencias encontradas. La 
producción se encuentra vinculada especialmente a instituciones universitarias y 
grupos de investigación, principalmente la Universidad de Sao Paulo, la Fundación 
Oswaldo Cruz, Universidad de Chile. Las áreas de mayor presencia son: medicina 
(64%); ciencias sociales (7,5%); y ciencias biológicas (5,4%). La economía de la salud 
cuenta con un índice h: 22. cOnclusión: La producción científica en economía de 
la salud en Latinoamérica muestra un creciente desarrollo y arraigo institucional. 
Se espera que el entendimiento y posicionamiento de esta materia cuente como 
herramienta de soporte en la toma de decisiones para los gobiernos de la región y 
en la asignación de recursos para la salud.
TR3
A MULTI-NATIONAL SURvEy ASSESSINg THE RELATIONSHIP BETwEEN 
PROPHyLAxIS TREATMENT AND HEALTH-RELATED QUALITy OF LIFE AMONg 
SEvERE HEMOPHILIA A PATIENTS IN LATIN AMERICA
Perez Bianco P.R.1, Berges A.2, Linares A.3, Moreno B.4, Arvizu J.5, Brabata C.5, Xiong Y.6, Ito D.6
1Instituto de Investigaciones Hematologicas - Academia Nacional de Medicina, Buenos Aires, 
Argentina, 2Instituto Mexicano del Seguro Social. Centro Medico Nacional La Raza Hospital 
General, Azcapotzalco, Mexico, 3Clinica Infantil Colsubsidio, Bogotá, Colombia, 4Fundacion 
Panamena de Hemofilia/Hospital del Nino, Panama City, Panama, 5Baxter Healthcare Corporation, 
Miami, FL, USA, 6Baxter Healthcare Corporation, Westlake Village, CA, USA
Objectives: Research has shown that Hemophilia A patients report lower health-
related quality of life (HRQOL) compared to the general healthy population. While a 
primary prophylaxis (PP) treatment regimen reduces bleed rates, it remains unclear 
if it is associated with improved HRQOL. The objective of this analysis was to deter-
mine if treatment regimen was associated with better HRQOL among hemophilia A 
patients in Latin America based on patient self-report. MethOds: This cross-sec-
4VP se incrementaron con la escolaridad de las mujeres. cOnclusiOnes: Pese a los 
resultados favorables en salud materna atribuibles al SP; es importante redoblar el 
esfuerzo del sistema mexicano de salud por lograr la cobertura efectiva en salud de la 
población más vulnerable de México. El uso eficiente y equitativo de los recursos será 
indispensable para consolidar el acceso universal a la salud en México.
RF2
EPIDEMIOLOgICAL AND ECONOMIC IMPACT OF CHRONIC kIDNEy DISEASE IN 
PATIENTS wITH HyPERTENSION AND DIABETES IN COLOMBIA
Carrasquilla-Sotomayor M., Santos-Ochoa J.J., Alvis-Zakzuk J., Alvis-Zakzuk N.,  
Paternina-Caicedo A., Alvis-Guzmán N.
Universidad de Cartagena, Cartagena de Indias, Colombia
Objectives: Epidemiologic transition from infectious to noncommunicable diseases 
(NCDs) in most countries may increase disease and economic burden. Chronic kidney 
disease (CKD) is a public health problem worldwide. In Colombia, CKD is related to 
catastrophic health expenses in the overall health care system. The aim of this study 
is to assess epidemiological and economic impact of CKD in people with risk factors 
for CKD in Colombia. MethOds: A Markov decision model was carried out to esti-
mate the burden of disease of CKD in Colombia. The Markov model have seven states, 
which followed people with diabetes mellitus (DM) and hypertension from disease 
onset to 90 years old (in 50 annual cycles). Five states went from CKD stage-1 to CKD 
stage-5, one transplant state and one absorbing state (death). Parameters were drawn 
from a literature review. Direct costs were drawn from a sample of patients with 
end-stage CKD from a large insurer in Colombia between 2009 and 2011. Outcome 
measures were: cases of CKD, deaths, disability-adjusted life-years (DALYs), and treat-
ment costs. Results: In Colombia, of 1,899,572 patients with hypertension and DM 
(62.9% were women), 1,083,735 (57.1%) developed CKD. Of all cohort deaths, 55% were 
caused by CKD. 4,413 transplants occurred in the cohort. 6.3 millions DALYs are asso-
ciated to CKD in women, and 10.9 in men, for a total of 17.3 millions. The mean cost 
per patient with end-stage CKD is around I$20.6 dollars (PPP adjusted). This burden 
would represent I$45.8 billions dollars (14.1% of estimated Gross Domestic Product 
of Colombia) if all cases were attended. cOnclusiOns: Despite limitations, this 
study shows the increasing economical and disease burden of NCDs in developing 
countries. This study also highlights the challenge on health systems of increasing 
aging population and risk factors for NCDs in developing countries such as Colombia.
RF3
FACTORES PREDICTORES DE OBSTRUCCIONES CORONARIAS SIgNIFICATIvAS 
EN PACIENTES ADULTOS CON CINEANgIOCORONARIOgRAFíAS REALIzADAS EN 
URUgUAy FINANCIADAS POR EL FONDO NACIONAL DE RECURSOS
Fernandez G., Morales M., Lombide I., Perna A.
Fondo Nacional de Recursos, Montevideo, Uruguay
ObjectivOs: La realización de una cineangiocoronariografía (CACG) es el gold 
Standard para definir la anatomía coronaria. El porcentaje de lesiones coronarias 
no significativas varía según la magnitud de obstrucción definida; siendo del 9 al 
25 % cuando consideramos lesiones menores al 50 %. Existen factores predictores 
como sexo masculino, edad avanzada, diabetes, dislipemia y tabaquismo. El Fondo 
Nacional de Recursos (FNR), financia según normativas de cobertura institucionales, 
prestaciones médicas altamente especializadas en Uruguay, entre ellas las CACG 
de las cuales reúne un registro único nacional. Objetivos: 1) Conocer el porcentaje 
de CACG con lesiones coronarias significativas (mayores al 50 %) realizados entre 
1/07/2011 y 30/06/2012; 2) Identificar el tratamiento elegido luego de su realización; 
3) Describir los factores predictores que permitan identificar pacientes con alto 
riesgo de tener lesiones coronarias significativas. MetOdOlOgías: Estudio retro-
spectivo de una cohorte histórica de pacientes consecutivos mayores de 18 años, con 
CACG realizada en el período establecido . Se excluyeron las solicitadas por enferme-
dad cardíaca no coronaria. ResultadOs: Se incluyen 6.737 CACG, de los cuales son 
de sexo masculino 67,2% , con una media de edad de 64,7 años. El total de CACG 
realizadas con lesiones mayores al 50 % fue 5.737 (85,1%). En 1549 (23 %) se optó por 
el tratamiento médico. Los factores de riesgo retenidos en el modelo de regresión 
logística fueron: edad > 50 años, sexo masculino, procedencia geográfica, diabetes, 
dislipemia, tabaquismo, ausencia de obesidad, oportunidad del procedimiento, y 
tener un infarto trasmural. cOnclusiOnes: El porcentaje de CACG con lesiones 
significativas se encuentra dentro de lo reportado en la bibliografía internacional 
lo que traduce un adecuado proceso de toma de decisiones. La identificación de 
factores de riesgo es de utilidad para este proceso de financiamiento de CACG en 
aquellos pacientes con mayor riesgo de presentar lesiones coronarias significativas.
RF4
COST-EFFECTIvENESS OF vARIOUS COMBINATIONS OF HUMAN 
PAPILLOMAvIRUS (HPv)-BASED PRIMARy SCREENINg TESTINg, INCLUDINg 
gENOTyPINg FOR HPv 16/18, FOR CERvICAL CANCER SCREENINg IN MExICO
Corro A.1, Ramirez A.1, Williams E.2, Huang J.3, Souza F.H.4
1Roche Diagnostics, Mexico, Mexico, 2Xcenda, Palm Harbor, FL, USA, 3Roche Molecular 
Diagnostics, Pleasanton, CA, USA, 4Roche Diagnostics, Sao Paulo, Brazil
Objectives: To determine the cost-effectiveness of various cervical cancer (CxCa) 
screening algorithms including the cobas HPV Test in Mexico, which identifies HPV 
genotypes 16/18 individually while simultaneously detecting the other high-risk 
HPV types. MethOds: A cohort Markov model was developed to compare five CxCa 
screening strategies: (S1) cytology only, (S2) cytology with reflex HPV; (S3) HPV with 
reflex cytology, and (S4) cytology and HPV co-testing; (S5) cobas HPV with genotyp-
ing and reflex cytology. Screening began at age 30 with a routine screening interval 
of every 3 years, and was modeled over a time horizon of 40 years. Performance 
of the overall screening strategies was derived from the ATHENA (Addressing THE 
Need for Advanced HPV Diagnostics) trial. Trial baseline data were used for the 
base case, and 1-year follow-up outcomes were estimated for the alternative sce-
nario, assuming all persistent disease is detected in the subsequent visit. The direct 
costs for screening and treatment of CxCa were estimated using the perspective 
of Mexican Institute of Social Security (IMSS). Costs were in 2010 US dollars. Costs 
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each of the WHO regions: Africa, Americas, Eastern Mediterranean, Europe, South-
East Asia and Western Pacific. A systematic review of the published literature was 
performed through December 2012. Direct information from regulatory agencies 
and Ministries of Heath for each of the countries was extracted. Additionally, key 
informant interviews were performed for validation purposes. Results: Of the 18 
countries selected, only 50% provided an official country level definition for Generic 
drugs. The other 50% were comprised of those devoid of any definition and those 
that refer to the WHO definition of generics. Most countries acknowledge some 
form of Generic Drug Policy following the WHO framework. However, only 65% have 
specific requirements for Generic drugs. The requirements are often associated with 
clinically viable therapeutic interchangeability. Most countries with requirements 
mention Bioequivalence but few require Bioavailability explicitly. At least one third 
of the countries have other terms in their definitions and processes that could be 
associated with Generics. In countries with Generic Drug Policies there is reference 
to patent or protection during the Drug Registration Process. Lack of patent protec-
tion enforcement appears to hinder Generic drug production and utilization despite 
the existence of incentives for the use of Generics. 20% of countries do not mention 
Good Manufacturing Practices as part of the evaluation process. Countries in Africa 
and Eastern Mediterranean Regions appear to have a less developed regulatory 
framework. cOnclusiOns: There is significant variability in the definition and 
classification of generic drugs in emerging markets. Standardization of the defini-
tions is necessary to make international comparisons viable.
PHP4
AçõES DE FARMACOvIgILâNCIA: RELATO DE NOTIFICAçõES DE 
MEDICAMENTOS À AgêNCIA NACIONAL DE vIgILâNCIA SANITáRIA  
(ANvISA) – BRASIL
Costa Paulo P.T.1, Pedrosa M.D.O.2, Melo R.D.F.C.L.R.2, Fernandes A.D.L.V.2
1Universidade Estadual da Paraíba, João Pessoa, Brazil, 2Instituto Cândida Vargas, João Pessoa, 
Brazil
ObjetivOs: Avaliar e quantificar as notificações de medicamentos registra-
das no setor Rede Sentinela do Hospital Instituto Cândida Vargas e enviadas 
à ANVISA (Agência Nacional de Vigilância Sanitária), durante o período de três 
anos. MétOdOs: Realizou-se um estudo descritivo e retrospectivo do período 
de setembro/2009 a setembro/2012 das notificações recebidas, tanto de queixas 
técnicas como de eventos adversos, no setor Rede Sentinela do Hospital Instituto 
Cândida Vargas em João Pessoa-Paraíba. As notificações foram recebidas de forma 
espontânea (encaminhadas pelos profissionais de saúde) ou provenientes da 
busca ativa. Estas notificações foram enviadas via internet, através do Sistema 
de Notificação em Vigilância Sanitária, denominado de NOTIVISA para a 
ANVISA. ResultadOs: No total, foram realizadas 20 (vinte) notificações, sendo 
5% (01) no ano de 2009, 5%(01) no ano de 2010, 45% (09) no ano de 2011 e 45%(09) 
até setembro do ano de 2012. Em relação a forma de recebimento destas noti-
ficações, 14 (70%) foram recebidas de forma espontânea e 06 (30%) através da 
busca ativa. 80% (16) foram de queixas técnicas e 20% (04) de eventos adversos 
em relação ao uso dos medicamentos; o número de queixas técnicas notificados 
de forma espontânea foram 62,5%(10) e de busca ativa 37,5%(06), já o número de 
eventos adversos notificados foi 100% e de forma espontânea. cOnclusões: 
Observou-se um crescimento ano a ano do número de notificações, sendo isto 
uma prática importante e propositiva. A forma de notificação espontânea foi a 
mais freqüente, demonstrando maior envolvimento, conscientização e compro-
metimento da equipe de saúde com o programa de farmacovigilância. Houve 
mais notificações de queixas técnicas do que de eventos adversos, o que já era 
esperado. Conclui-se ainda que o estímulo ao desenvolvimento de programas 
de educação continuada no ambiente de trabalho, buscando identificar os efei-
tos adversos e problemas relacionados aos medicamentos é de fundamental 
importância.
PHP5
ARgENTINA’S gENERIC DRUg LAw: wAS IT SUCCESSFUL?
Lee B.1, Garay O.U.2, Goldhaber-Fiebert J.3, Tang J.1, Lightwood J.1, Wilson L.S.1
1University of California, San Francisco, San Francisco, CA, USA, 2IECS Institute for Clinical 
Effectiveness and Health Policy, Buenos Aires, Argentina, 3Stanford University, Stanford, CA, USA
Objectives: High drug prices present substantial challenges to providing good, 
affordable health care, especially in resource poor settings. To combat rising drug 
prices, in 2002, Argentina implemented “The Generic Law” mandating that pre-
scribers write prescriptions with the International Nonproprietary Name instead 
of brand name to promote generic drug use and lower overall costs. We exam-
ined whether this policy was effective in lowering drug prices. MethOds: We 
used IMS price data of 192 drug products from the WHO essential medicines list in 
Argentina from 1995-2010 along with limited utilization data. The study employed 
a longitudinal interrupted-time-series analysis of price and drug use before and 
after The Generic Law was implemented. We estimated a fixed effects regression 
model both with real price and log of real price as the dependent variable and time, 
policy, number of drug products on the market, and brand or generic status and 
brand policy interaction as independent variables, with residual tests for robust-
ness. Results: The robust pooled log price trends of 192 drug products show that 
prices decreased over all years by 1.1% (CI= 0.0067-0.0151, p< 0.00). We showed a 
robust interaction effect between policy and brand with the policy causing a 7.9% 
decrease (CI= -0.1359--0.0221,p= 0.006) in generic drugs prices over brand prices (1.5 
pesos). The policy by itself did not have a significant effect over all drug prices, 
nor did density of market share. Brand drugs across all time periods had a 27% 
increase (CI= 0.0895-0.4525,p= 0.003) in price (5.13 pesos). Visual inspection of utili-
zation trends indicated that brand utilization decreased while generic use stayed 
stable or increased. cOnclusiOns: Argentina’s generic policy had its intended 
differential effect between brand and generic prices with generic prices decreasing 
significantly with respect to brand prices, although this difference was small. These 
findings provide some evidence supporting implementation of generic drug policies 
in other countries, but should be validated.
tional survey of severe hemophilia A patients ≥ 18 or older, or the parent/caregiver 
of patients aged 2-17 was administered in Argentina, Chile, Colombia, Mexico and 
Panama. A centralized ethics review board approved the study. Eligible, consent-
ing patients completed a questionnaire: from October-November 2009 (Argentina), 
June-August 2011 (Chile, Colombia, Mexico) and September-October 2012 (Panama). 
HRQOL was measured by the Short Form 12 (SF-12) for adults and the Pediatric 
Quality of Life Inventory (PedsQL) for children. Treatment characteristics were also 
assessed. Results: A total of 435 severe hemophilia A patients participated in this 
study, 58% of whom were adults. Overall, 238 (48%) patients were either receiving 
primary or secondary prophylaxis (SP). An ordinary least squares regression was 
performed with SF-12 Physical Component Score (PCS) as the dependent variable, 
and PP, and SP as independent variables. Age and country were included as control 
variables. On average, the PCS score was 8.64 points higher among PP patients com-
pared to on-demand (OD) patients after adjusting for age and country (p= 0.0363). 
A comparable analysis among children using the PedsQL Physical Summary score 
revealed a similar trend: on average, the physical HRQOL score was 7.15 points 
higher among PP patients, compared to OD controlling for age and country, however 
this was not significant. cOnclusiOns: Results suggest that primary prophylaxis 
treatment may be associated with improved physical HRQOL.
TR4
LA PROTECCIóN FINANCIERA y EL gASTO DE BOLSILLO EN SALUD DE LA 
POBLACIóN MExICANA 2002-2010
Rivera G.1, Guajardo V.2, Gutierrez C.2
1Secretaría de Salud, Mexico, Mexico, 2Instituto Mexicano del Seguro Social, Mexico, Mexico
ObjectivOs: Analizar distintos aspectos del gasto de bolsillo en salud de los 
hogares mexicanos para estimar el impacto de la protección financiera del asegu-
ramiento público en salud. MetOdOlOgías: Se estima el porcentaje de hogares 
con gasto catastrófico o empobrecedor en salud y su relación con ingreso, con-
dición de aseguramiento, tipo de localidad y rubro de gasto en salud, usando la 
Encuesta Nacional de Ingreso y Gasto de los Hogares 2002-2010 y una adaptación 
de la metodología de la Organización Mundial de la Salud así como la definición 
oficial mexicana de línea de pobreza alimentaria, de ingresos y gastos corrientes 
totales en los años respectivos. ResultadOs: El porcentaje de hogares con gas-
tos catastróficos en salud presentó una tendencia decreciente a partir de 2006. 
Los hogares con gastos empobrecedores en salud experimentaron una tendencia 
decreciente durante el período analizado. Los hogares con ambos gastos en salud, 
concentrados en localidades rurales, presentan una tendencia decreciente a partir 
del 2006. El gasto de bolsillo en salud por rubro se concentra en los medicamentos 
sin receta y vitaminas, alcanzando un promedio de 57.4% en el periodo anali-
zado, independientemente de la condición de aseguramiento, nivel de ingreso 
y tipo de localidad. cOnclusiOnes: La reducción del gasto catastrófico puede 
estar vinculada con el importante incremento en la protección financiera de la 
población a través del Seguro Popular de Salud. Se requiere analizar a mayor 
detalle la dinámica del gasto de bolsillo en medicamentos para generar políticas 
públicas que incidan en su reducción procurando una mayor protección financiera 
a hogares vulnerables.
RESEARCH POSTER PRESENTATIONS – SESSION I
HEALTH CARE USE & POLICy STUDIES – Consumer Role in Health Care
PHP1
PERFIL DE ADESãO AOS PLANOS DE BENEFíCIO EM MEDICAMENTOS
Santana C.F.S.D.1, Ferreira C.N.2, Paloni E.D.M.P.2, Drago S.3, Salles G.R.D.1, Bonachela F.4,  
Souza C.3, Abreu A.A.3
1Orizon, Sao Paulo, Brazil, 2ORIZON - Companhia Brasileira de Gestão de Serviços, Sao Paulo, 
Brazil, 3ORIZON, Sao Paulo, Brazil, 4Orizon, SAO PAULO, SAO PAULO, Brazil
ObjetivOs: Analisar o comportamento de consumo após implantação de ben-
efícios farmácia para diferentes clientes com variados percentuais de desconto e 
reembolso. MétOdOs: Utilizando a base de dados Orizon, que transaciona cerca 
de 7milhões de medicamentos ano via plano de beneficio medicamentos (PBM), 
selecionou-se quatro planos com subsídios variados e foram analisados o coefi-
ciente de adesão dos planos mês a mês e definido a média de consumo por plano, 
após estes dados estudou-se o tempo médio necessário para atingir a atingir adesão 
linear ao consumo de medicamentos por plano. ResultadOs: Dos quatro planos 
estudados, o Plano 1 que concede subsídios de 40% e 80% de acordo com o medica-
mento, alcançou a média de adesão em 6 meses; o Plano 2 que não oferece subsídios 
aos usuários demorou 13 meses para chegar a média de adesão; os Plano 3 e 4 que 
fornecem subsídios de 80 a 100% aos usuários alcançaram a marca respectivamente 
em 5 e 4 meses. cOnclusões: Observamos que, desde a implantação até a média 
de adesão de consumo, o tempo variou de 4 a 13 meses. Um dos fatores que podem 
explicar esta diferença são os subsídios proporcionados para cada plano, pois o 
Plano 2 que não oferecia subsídio aos usuários apresentou o maior tempo - 13 meses 
- e o que apresentava maiores condições aos usuários levaram apenas até 4 meses. 
Desta forma o subsidio dado aos benefícios faz com que o tratamento seja seguido 
podendo minimizar os custos com sinistralidade por planos de saúde.
HEALTH CARE USE & POLICy STUDIES – Drug/Device/Diagnostic Use & Policy
PHP2
ARE gENERIC DRUgS DEFINED AND CLASSIFIED CONSISTENTLy AROUND THE 
wORLD?
Alfonso-Cristancho R.1, Watanabe J.H.2, Barbosa T.3
1University of Washington, Seattle, WA, USA, 2Western University of Health Sciences, Pomona, 
CA, USA, 3RANDOM Foundation, Bogota, Colombia
Objectives: To systematically identify and compare how generic medications, as 
defined by FDA, WHO, EMA, are classified and defined by regulatory agencies around 
the world. MethOds: We focused on emerging markets and excluded developed 
countries. For country selection, we identified the 3 most populace countries in 
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ment of strategic priorities become essential tools for resource allocation, in order 
to avoid an undesirable technological gap in the country.
PHP9
COMPARATIvE EvALUATION OF THE APPROPRIATENESS OF THE PRESCRIBINg 
IN gERIATRICS INPATIENTS USINg BEERS CRITERIA 2012 AND 2003
Bansal D.1, Undela K.2, Sachdev A.3, D’Cruz S.4
1National Institute of Pharmaceutical Education and Research, Mohali, India, 2JSS College of 
Pharmacy, JSS University, Mysore, IN, India, 3Govt Med Coll Hosp, Chandigarh, India, 4GMCH, 
Chandigarh, India
Objectives: To evaluate appropriateness of prescribing medicines using Beers criteria 
2003 and 2012 and determining predictors of potentially inappropriate medications 
(PIMs) prescribing in elderly in-patients. MethOds: Cross-sectional study was con-
ducted at public hospital and baseline data were collected. Elderly in-patients from 
medicine wards (≥ 60 years) were included. Multivariate logistic regression analysis was 
used to determine the predictors of PIMs prescribing. Results: A total of 500 patients 
were recruited during I year of study period;60% were males and 66% were between 
60-69 years of age with mean (SD) of 68 (7) years. Mean (SD) number of diagnoses and 
medications were 3 (1) and 9 (4), respectively. 81 (16%) patients were prescribed with at 
least ≥ 1 PIMs according to modified AGS updated Beers criteria 2012, compared to 11% 
according to Beers criteria 2003. On multivariate regression, important predictors for the 
PIMs prescribing were found to be age ≥ 80 years (Odds Ratio (OR) 2.46, 95% CI 1.27-3.12; 
p = 0.03), male gender (OR 1.35, 95% CI 1.06-1.84; p = 0.03), more than 3 diagnoses (OR 
2.47, 95% CI 1.59-3.39; p = 0.04), ≥ 6 medications prescribed (OR 1.16, 95% CI 1.02-1.35; p = 
0.03) and ≥ 10 days of hospital stay (OR 1.59, 95% CI 1.09-2.31; p= 0.02). cOnclusiOns: 
Results indicate that PIMs prescribing is common among hospitalized Indian elderly 
patients. It is feasible to reduce this practice through provision of appropriate unbiased 
information to health care professionals. Beers criteria is a well established method for 
evaluating prescribing appropriateness. Results also show the capture of more number 
of PIMs through the use of Beers criteria 2012 due to the addition of new medications in 
the list like spironolactone in heart failure and removal of capping of maximum dose 
of alprazolam, clonazepam and lorazepam from Beers criteria 2003.
HEALTH CARE USE & POLICy STUDIES – Equity and Access
PHP10
ANALySINg THE ACCESS TO PRIORITy HEALTH SERvICES IN THE ADOLESCENT 
POPULATION IN SIx PROvINCES IN NORTHERN ARgENTINA
Maceira D.
Center for State and Society Studies (CEDES), Buenos Aires, Argentina
Objectives: Adolescents present particular issues that may condition their health 
and life, this turns adolescents’ health into a priority. To identify the barriers that hin-
der the access to health by adolescents in order to contribute to the design, orienta-
tion and formulation/reformulation of public policies. MethOds: We implemented a 
self-administered to 5200 secondary public school students in the northern provinces 
of Argentina, Jujuy, Misiones, Tucumán, Santiago del Estero, Catamarca and Chaco. 
On the other hand, we developed in-depth interviews to local referents (Ministries 
of Health, Education, Social Development, etc). Descriptive statistics techniques 
were then applied, together with econometric analysis and qualitative techniques 
of interviews analysis. Results: We identified differences regarding priorities and 
policies oriented to the adolescent population in the six provinces. With regard to 
the teen gaze, 87% of students rate their health as “very good or good”, only half of 
those reporting a health problem consulting the system. Their concerns are linked to 
arguments and emerging problems of their age. “Having to wait long to be attended” 
and “difficulty to get an appointment” are the main barriers they face when access-
ing to the system. cOnclusiOns: The definition of access ceases to be necessarily 
linked with aspects of physical capacity or clinical care, but with the system’s ability 
to orient the question and channel the concerns of young people with social problems 
related to health.
PHP11
URBAN HEALTH NETwORkS AND PERINATAL HEALTH RISk IN ARgENTINA
Maceira D.
Center for State and Society Studies (CEDES), Buenos Aires, Argentina
Objectives: Urban Health Care Networks become a strong limitation to guarantee 
efficient and equitable access, especially in developing countries. Lack of formal 
protocols in referral procedures, insufficient coordination among levels of care and 
limited coordination in human resources across health care system allows dupli-
cation of clinical studies, informality in the decision-making process within the 
network, and higher-than-expected health risks, affecting existing financial protec-
tion mechanisms. In particular, perinatal health care networks involve the analysis 
not only of clinical performance in hospitals and health care centers, but also the 
ability to improve mothers’ behavior during pregnancy, by applying safe preventive 
care procedures. This study analyzes two mayor public hospitals in the Province of 
Buenos Aires, Argentina, searching for quality of referral procedures MethOds: The 
descriptive and logistic analysis identifies three sets of variables: mother’s back-
ground and risk factors, pregnancy characteristics and supply-side infrastructure. 
Using an original database on birth attendance at the hospital head-of-network 
(Perinatal Information System, designed by the World Health Organization) of 
circa 16,500 births, as well as structured questionnaires distributed among human 
resources in both hospitals, the study allows to identify hospital ability to manage 
network risks, failures arising from the health care system and join responsibilities 
between formal health care system and the family. Results: The study allows the 
definition of two sets of observations based on number of medical controls during 
pregnancy, offering the chance of additional comparisons of explanatory variables 
by including test of differences in mean values. cOnclusiOns: Results show the 
presence of multiple failures in urban health care networks, with specific risk factors 
teenage pregnancy and distance to formal health services affecting hospitalization 
rates, newborn risks and counter-reference behavior.
PHP6
UN SEgURO NACIONAL DE ENFERMEDADES CATASTRóFICAS: FUNDAMENTOS 
PARA SU IMPLEMENTACIóN
Tobar F., Olaviaga S., Solano R., Hamilton G.
CIPPEC, Ciudad de Buenos Aires, Argentina
ObjectivOs: Unas pocas enfermedades que afectan a un número reducido de 
personas se llevan una parte cada vez mayor de los recursos de los sistemas de 
salud. Se las denomina enfermedades catastróficas por el impacto económico que 
generan en quienes las padecen y las financian. En la Argentina coexisten seis 
modelos diferentes de cobertura y financiación de estas patologías. Sin embargo, 
constituyen respuestas fragmentadas e inequitativas. La creación de un Seguro 
Nacional de Enfermedades Catastróficas (SENEC) permitiría alcanzar una cobertura 
universal y homogeneizar protecciones de calidad a un costo inferior al actual. 
Esta investigación tiene por objetivo generar evidencia que contribuya a demos-
trar tanto la viabilidad económica y financiera como la factibilidad técnica del 
SENEC. MetOdOlOgías: Para eso, se identifican los tipos de cobertura y financiam-
iento vigentes en el país y se describen algunas experiencias internacionales. Luego 
se exponen diferentes opciones para resolver la protección frente a estas enferme-
dades y se justifica por qué el SENEC es la alternativa más adecuada para el contexto 
argentino. Finalmente, se estiman los costos que conllevaría la creación del seguro 
y se describen cuatro escenarios alternativos de implementación. ResultadOs: 
Los resultados del estudio evidencian que a través del SENEC se puede lograr una 
reducción de hasta el 75% de los costos en cobertura para estas enfermedades. Se 
demuestra que el SENEC en pleno funcionamiento, es decir brindando una cobertura 
explícita y de calidad homogénea a toda la población, tendría un costo menor al 
que hoy deben asumir algunos agentes del seguro (obras sociales nacionales y pre-
pagas). cOnclusiOnes: Esta política pública responde a los desafíos de sustenta-
bilidad económica, calidad y equidad que plantea la cobertura de estas patologías 
al actual sistema sanitario argentino.
PHP7
ANALySIS OF THE PRICINg AND MARkET ACCESS LANDSCAPE OF ORPHAN 
DRUgS IN LATIN AMERICA
Senan Castellano B.1, Severi Bruni D.2, Ziai Buetas A.1
1ICON, London, UK, 2ICON, El Segundo, CA, USA
Objectives: In Latin America, despite the efforts recently implemented to improve 
access for rare diseases, funding remains a challenge due to conflicting priori-
ties to ensure sufficient budget for essential medicines. In this research we aim 
at providing an understanding of the situation in terms of access and funding of 
orphan drugs in Brazil, Mexico and Argentina as well as defining the drivers for 
access in the light of an increasing pressure for drug coverage for orphan con-
ditions. MethOds: Review approval and funding regulation for orphan drugs in 
Brazil, Argentina and Mexico. Selection of 8 orphan drugs differing on a pre-defined 
set of access drivers (Incidence of the disease, severity of the condition, therapeutic 
alternative, level of innovation, affordability, etc.). Develop case studies based on 
HTA reviews and level of access. Formulate hypotheses about the main drivers for 
successful access. Explore and qualitatively validate hypotheses through primary 
research with local payers. Results: 1) Access to orphan drugs is not universal 
- programs starting to be put in place in some countries but limited to selected 
conditions; 2) Brazil and Mexico have implemented a policies for orphan drugs 
expected to facilitate increased access in the future; and 3) Affordability is the main 
driver of access followed by the severity of the disease, although exceptions to this 
rule exist. cOnclusiOns: Whereas regulation for orphan drugs is not available in 
all countries, public funding overall is increasing. Most funding for rare diseases, 
however, focuses on selective, severe, life-threatening conditions, and affordability 
remains a major access barrier. In the medium term, proving value will not be 
enough to obtain access of OD in these markets. Companies seeking access for ODs 
will need selective programs, designed to improve affordability.
PHP8
vALUE jUDgMENTS IN HEALTH TECHNOLOgy ASSESSMENT PROCESS IN 
BRAzIL
Santoro Neto L., Ferraz M.B.
Universidade Federal de São Paulo, Sao Paulo, Brazil
Objectives: To appraise the value judgments in critical decisions involving 
resource allocation and use of technologies in Brazilian health system, through 
the view of health managers and professionals. To evaluate the tendencies of the 
Brazilians’ decision makers when managing the important restriction of financial 
resources. To analyze the influence of health care sectors in the managers and 
professionals’ decisions. MethOds: The research has been conducted through 
a decision-making questionnaire to incorporate health technologies, applied by 
internet. 193 respondents fully answered the research. There was presented four 
scenarios that mimicked real world dilemmas regarding the choice of resource allo-
cation in an environment of severe budget constraint. The decisions should be taken 
regarding the following trade-offs: 1) disease prevalence and reduction/extinction of 
current health programs; 2) disease prevalence and creation of new taxes; 3) patients 
age; and 4) decision among prevention and treatment. Results: The results have 
showed a conservative trend. Most answers were related to lower costs options in 
every scenario, showing the preference in saving resources instead of incorporat-
ing the technologies, in despite of the clinical benefits. The comparison between 
prevention and treatment demonstrates that health managers and professionals 
are suited to a preventive though that indicates the long-term strategy of health 
care policies. It was found different tendencies of answers between the health care 
sectors considered as players of technology assessment process. cOnclusiOns: 
The Brazilian health managers and professionals are significantly influenced by 
economic scarcity when deciding about resource allocation. In search of a paradigm 
for decision-making, most of them have opted for saving resources rather than 
incorporating the technology. With a restricted budget, only few demands can be 
satisfied. Against this background, the cost-effectiveness analysis and the establish-
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como la calidad de las instalaciones e infraestructura, la presencia y calidad de pro-
gramas de capacitación, el apoyo de las autoridades del hospital, la aceptabilidad de 
los servicios por otros profesionales de la salud, el clima laboral y la satisfacción de 
los recursos humanos. cOnclusiOnes: El marco conceptual desarrollado permite 
fundamentar la evaluación de la calidad de SMF’s. El abordaje cualitativo realizado 
permitió identificar aspectos clave en las dimensiones de calidad.
HEALTH CARE USE & POLICy STUDIES – Formulary Development
PHP16
AUDIT OF THE COvERAgE DECISION-MAkINg PROCESS IN A gOvERNMENT 
AgENCy IN URUgUAy: FROM THE gUIDELINES TILL THE PATIENTS
Garcia Marti S.1, Pichon-Riviere A.2, Aruj P.3, Glujovsky D.4, Bardach A.5, Rodríguez A.6
1Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 2Institute for 
Clinical Effectiveness and Health Policy (IECS), BUENOS AIRES, Argentina, 3OSDE, buenos aires, 
Argentina, 4Institute for Clinical Effectiveness and Health Policy (IECS), CABA, Buenos Aires, 
Argentina, 5Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 
6Fondo Nacional de Recursos, Montevideo, Uruguay
Objectives: The National Resources Fund (FNR) is a government agency devoted 
to provide coverage of high cost technologies in Uruguay. A particular characteris-
tic of the FNR is being involved in the whole process of providing access to these 
technologies, from its buying to its patient administration. To guide this process the 
FNR, has some clinical coverage guidelines that are used in the clinical coverage 
decision with each individual patient. During 2009 and 2012 the FNR did an audit 
process of these guidelines and asked IECS (a non profit academic organization) 
from Argentina to implement it. To present the process were 12 of these guidelines 
were audited (colorectal, kidney, CNS and breast cancer, leukemias, cystic fibrosis, 
hepatitis C, diabetes, palivizumab and rituximab, rheumatoid arthritis and multiple 
mieloma) and the coverage decision taken on patients with the corresponding dis-
eases. MethOds: Systematic bibliographic searches were performed to audit the 
guidelines and the clinical record of patients with the corresponding diseases was 
audited summarizing 200 patients in total. Results: Regarding the guidelines it 
was observed that in general there were adequate in its clinical content and updated 
with the actual evidence promoting a better clinical decision coverage process. Only 
some reporting aspects as date of bibliographic searches not reported or not clear 
specification of authors or methodology followed were mentioned. Regarding the 
patients audit, in 198 cases the decision was in concordance with the guideline 
being adequate in almost all the cases. cOnclusiOns: An audit process of the 
coverage decisions implemented in a government agency by an external organism 
as the one described in this study allows to identify potential improvements to the 
process, promotes transparency and at the end a better coverage decision-making 
process and utilization of health resources.
HEALTH CARE USE & POLICy STUDIES – Health Care Costs & Management
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DETERMINANTES DE LOS COSTOS DE ACCIDENTES DE TRáNSITO OCURRIDOS 
EN MEDELLíN (COLOMBIA) 2009-2010
García García H.I., Lugo Agudelo L.H., Castro García P.A., Cano Restrepo B.C., Vélez Jaramillo D.A.
Universidad de Antioquia, Medellín, Colombia
ObjectivOs: Estimar los determinantes de los costos hospitalarios, de rehabili-
tación y del paciente en personas lesionadas en accidentes de tránsito en Medellín 
entre 2009-2010. MetOdOlOgías: Estudio de corte transversal con 375 pacientes 
con lesiones moderadas y graves, según el New Injury Severity Score (NISS), 
a quienes se les aplicó una encuesta en el momento del accidente, 3 y 6 meses 
después. Para estimar los costos de las lesiones se asumió una perspectiva que con-
sideró los costos médicos, del paciente y pérdidas asociadas a la productividad. Los 
costos médicos se valoraron por medio de los precios de los medicamentos sumin-
istrados y las intervenciones realizadas en hospitales de alta complejidad de la ciu-
dad; y los costos del paciente según el salario reportado por él mismo. Se estimó un 
modelo lineal generalizado relacionando el costo total con las variables edad, sexo, 
tipo de vehículo, presencia de alcohol, utilización de elementos de seguridad, locali-
zación de la lesión, rapidez en la atención y condición del accidentado, identificadas 
en la revisión de la literatura y clasificadas en determinantes estructurales y próxi-
mos. ResultadOs: El 80% de los pacientes eran hombres y de éstos el 71% tenían 
entre 21 y 40 años. El costo promedio de atención por paciente fue de USD 8.509. El 
costo de los materiales e insumos representa el 33% del total, seguido por los costos 
de los medicamentos con 20% y el de hospitalización con 18%. El costo asociado 
al uso de motocicleta representó el 80% de los costos totales. cOnclusiOnes: La 
edad, el sexo, el tipo de vehículo y la condición del accidentado se encontraron como 
determinantes fundamentales del costo de atención. La presencia de alcohol y la 
utilización de elementos de seguridad no representaron la carga esperada debido, 
tal vez, al sesgo en la información suministrada por los entrevistados.
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FATORES ASSOCIADOS À COMPRA DE MEDICAMENTOS EM BRASíLIA: 
UMA ANáLISE ECONOMéTRICA COM DADOS TRANSvERSAIS DE BASE 
POPULACIONAL
Andrade C.H.C.D.1, Wichmann R.M.2, Galvao T.F.3, Pereira M.G.4, Silva M.T.2
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Brazilian Ministry of Health, 
Brasilia, Brazil, 3Federal University of Amazonas; University of Brasilia, Brasilia, Brazil, 
4University of Brasilia, Brasilia, Brazil
ObjetivOs: Investigar os fatores associados à compra de medicamentos pela popu-
lação adulta de Brasília. MétOdOs: Estudo transversal com aplicação de questionário 
em pessoas entre 18 a 65 anos, selecionadas por meio de amostragem probabilística em 
dois estágios, com cotas por sexo e idade, para obter representatividade para o Distrito 
Federal. Calculou-se tamanho amostral considerando nível de confiança de 95%, 
margem de erro de 2,5% e frequência de utilização de medicamentos em 50%. Foram 
entrevistadas 1852 pessoas no primeiro semestre de 2012, sendo obtidos dados sociais, 
PHP12
¿LOS FORMULARIOS NACIONALES (CUADROS BáSICOS) PROvOCAN 
OLIgOPOLIOS E INCENTIvAN A TENER PRECIOS ALTOS?
Lechuga D.
ITAM, México D.F., Mexico
ObjectivOs: Demostrar en base a un modelo económico de oligopolio que los for-
mularios provoca oligopolios e incentiva a mantener precios altos. MetOdOlOgías: 
Los formularios son una barrera a la entrada al mercado que desincentiva la com-
petencia. Los medicamentos patentados no son sujetos a competencia directa por 
precio, por lo tanto son sujetos a competir conforme a un modelo de Cournot. Este 
modelo se basa en que los competidores pelean el mercado por cantidades. Los 
productos patentados no son sujetos a licitación si no a adjudicación directa. Se 
toma como supuesto que hay un “n” número de competidores en los formularios 
nacionales, siendo “N” el número total de competidores, cada una con un producto 
que vende a un precio “P”. Los competidores toman decisiones al mismo tiempo. La 
demanda del mercado está dada por P (Q) = a - bQ, siendo “Q” la sumatoria de todas 
las producciones. Hay “X” número de competidores que están fuera del formulario 
nacional. ResultadOs: El precio del productor dependerá, principalmente, de “Q” 
y de “N”. Si incrementa “Q”, y “N” constante, entonces se incrementan los precios. Si 
incrementa “N”, y “Q” constante, bajan los precios. Si no existieran los formularios 
nacionales, no habría barreras a la entrada y la competencia incrementaría en “X” 
que provocaría un menor precio. Si “N” tiende al infinito, entonces el modelo tiende 
a la competencia perfecta. En un caso donde solo un producto ha logrado el acceso al 
formulario nacional formará monopolio. cOnclusiOnes: Las barreras a la entrada 
causada por formularios nacionales mantendrán precios altos hasta que un nuevo 
competidor sea incorporado al formulario. Entre mayor sea el número de oferentes 
se incrementará la competencia y menor será el precio. Se recomienda analizar los 
beneficios de los formularios nacionales y explorar otros métodos de reembolso 
como pagar por el desenlace en salud y no por el producto en sí.
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REACHINg THE MIDDLE OF THE PyRAMID: IMPLICATIONS FOR THE P&MA OF 
PHARMACEUTICAL DRUgS wITH THE ExPANDINg MIDDLE CLASS IN BRASIL, 
CHILE AND COLOMBIA
Severi Bruni D.1, Vidal Pinheiro A.2, Senan Castellano B.2
1ICON, El Segundo, CA, USA, 2ICON, London, UK
Objectives: Sustained economic growth in Latin America in the last decade led 
to an astonishing 50% increase in the middle class. With the empowerment of an 
increasingly educated and wealthier population, governments have been under 
pressure to adapt their health care models to growing expectations for US/EU health 
quality standards. As a result, health care funding balance between patient Out-
Of-Pocket, contributions to private health plans and public via taxation pathways 
is likely to be subjected to sizable shifts in the near/medium future. This work pre-
sents an outlook on the current health care financing and an analysis of potential 
trends and likely implications in terms of P&MA for new drugs in three case study 
countries (Brazil, Chile and Colombia). MethOds: Literature review on health care 
financing distribution from 2003 to 2010. Review of political and private initiatives 
for drug coverage. Hypothesis development on the implications in terms drug’s 
P&MA. Primary research with payers/proxy-payers. Analyze and compare trends 
across countries. Results: 1) Chile saw the lowest growth in overall HC expenditure 
with a clear transfer in the funding distribution from OOP to public sources (39% 
for both to 33% vs. 48%); 2) Brazil overall HC expenditure greatly increased (4.99 
fold), and since 2005 a moderately sustained transfer from OOP to public fund-
ing have been occurring (from 38.6% and 40.1% to 31.6% and 47% in 2010); 3) In 
Colombia, funding is dominated by public spending (74.6%) but OOP expenditure 
has seen the highest growth; 4) HTAs are increasingly involved in drug P&R deci-
sions. cOnclusiOns: Latin American countries are likely to further accommodate 
‘hybrid’ systems for health care financing. However, as Governments are required 
to make decisions for funds allocation, there is increasing need for sophisticated 
tools for drug evaluation and decision making. Increasingly robust HTA agencies 
are expected to be created, implying downward pressures on price pressures and 
increased evidence requirements.
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INTEgRACIóN DE UN MARCO CONCEPTUAL PARA LA EvALUACIóN DE LA 
CALIDAD DE SERvICIOS FARMACéUTICOS HOSPITALARIOS ENFOCADOS A LA 
MEjORA DE LA FARMACOTERAPIA
Diaz de León-Castañeda C., Reyes-Morales H.
Instituto Nacional de Salud Pública, Cuernavaca, Mexico
ObjectivOs: En el contexto de la incorporación del profesional farmacéutico en el 
ámbito hospitalario del sistema de salud mexicano, el objetivo fue integrar un marco 
conceptual para la evaluación de la calidad de servicios farmacéuticos hospitalarios 
enfocados a la mejora de la farmacoterapia (SMF’s). MetOdOlOgías: Se utilizó el 
marco conceptual de Donabedian para la evaluación de la calidad de la atención 
médica como un marco de referencia para el desarrollo del marco conceptual de 
evaluación de la calidad de SMF’s. Asimismo, se utilizó el marco conceptual para la 
identificación, denominación y categorización de acontecimientos adversos a los 
medicamentos (AAM). Dentro de las dimensiones de estructura, proceso y resultado 
se adicionaron diferentes tópicos y variables importantes relacionadas con estas 
dimensiones. Adicionalmente, se realizó un estudio piloto utilizando metodología 
cualitativa para evaluar la calidad de SMF’s de algunos hospitales públicos y priva-
dos de México, que consistió de entrevistas en profundidad a jefes de unidades de 
farmacia hospitalaria o clínica de algunos hospitales públicos o privados de México. 
Las entrevistas se transcribieron y analizaron utilizando una aproximación a la 
metodología de teoría fundamentada. ResultadOs: Se integró un marco concep-
tual para la evaluación de calidad de SMF’s que puede abordarse desde diferentes 
perspectivas metodológicas (cuantitativas o cualitativas). El estudio cualitativo 
piloto permitió utilizar el marco conceptual desarrollado e identificar aspectos 
importantes de estructura, proceso y resultado relacionados con la calidad de SMF’s, 
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se realizó una evaluación económica de iobitridol mediante un análisis de minimi-
zación de costos, que incluye costos de insumos y recursos utilizados en la reali-
zación de urografía, angiografía y escanografía. Para el desarrollo de la evaluación 
se utilizaron los siguientes medios de contraste: iodixanol, iobitridol, iopamidol, 
iohexol, ioversol e iopromide, en todas las concentraciones de yodo disponibles 
en el mercado en Colombia. Los resultados se analizaron para pacientes con peso 
entre 5-110 kg tomando como referencia de uso la dosis promedio de Yodo para 
cada uno de los tres exámenes analizados. Se realizó un análisis de sensibilidad 
univariado de +/- 20%, en los costos de las tecnologías. ResultadOs: Para urografía, 
en el 64% de los casos analizados resultó ahorrativo el uso de iobitridol 300 mg/ml, 
presentando un ahorro de COP$ 4.121 por examen per cápita. Para angiografía, el 
uso de iopamidol de 370 mg/ml es ahorrativo en el 55% de los pesos (kg), frente al 
45% con iobitridol de 300 mg/ml, con un ahorro de 3,44% por examen. Finalmente 
para escanografía, iobitridol de 300 mg/ml se presenta como la tecnología con más 
frecuencia de ahorro en los pesos (kg) de los pacientes, mostrando un ahorro de 
2,87% por examen. El análisis de sensibilidad muestra consistencia del ahorro del 
uso de iobitridol 300 mg/ml e iopamidol 370 mg/ml. cOnclusiOnes: El análisis 
de minimización de costos muestra a iobitridol e iopamidol como tecnologías que 
generan ahorro en urografía, angiografía y escanografía, en concentraciones de 300 
mg/ml y 370 mg/ml respectivamente, dependiendo del peso del paciente.
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DRUg DISTRIBUTION STRATEgIES COST IN BRAzIL
Carraro W.H., Mengue S.S., Haddad E.W.
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Objectives: This research aims to verify the total costs of the medicines that are 
dispensed by pharmacies of the Brazilian Public Health System (SUS) and that are 
also part of the Aqui tem Farmácia Popular program (PAFP). This program is charac-
terized by the powerful link between the government and the private pharmacies 
which provide medicines for free or by co-payment for the population. This work 
also seeks to draft a comparative analysis between the two distribution forms of 
the drugs. MethOds: The direct cost was obtained from the amounts showed on 
the county purchase invoices. The indirect cost was identified as a result of a field 
survey. The sampling selection of visited counties was based on a - non- probabilis-
tic - scenario analysis approach from quality criteria and distributed in each of the 
five country’s regions. Collection was performed by completing a semi-structured 
spreadsheet, by documentary analysis and by participant observation. Data col-
lected correspond to the expenses incurred during 2011. Results: The value of the 
medicines bought by a private pharmacy it is significantly higher than the one paid 
by the SUS pharmacy. It is considered as possible explanations of differential of the 
direct cost between two purchases origins some additional elements that elevate 
the cost of the private pharmacy regarding the one from SUS: purchases volume, 
purchase frequency, presentation, additional costs as logistics, type of packing, costs 
related to the certification of good production practices. cOnclusiOns: From the 
comparative analysis of the SUS pharmacy total cost with the value funded by the 
Ministry of Health for PAFP medicines, it was possible drawing a comparative with 
the analyses provided in the National Accounts Tribunal (TCU) audit report. It was 
observed that the variance shown in the TCU audit report indicates a significant 
difference between the assessed results in this demonstrative.
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ECONOMIC BURDEN OF INPATIENT POST-ADMISSION DEHyDRATION – 
RETROSPECTIvE DATABASE ANALySIS IN US
Pash E., Hashemi L., Parikh N.
Covidien, Mansfield, MA, USA
Objectives: To compare costs and resource utilization of patients experiencing post-
admission dehydration (PAD) to those who do not experience PAD. MethOds: All 
adult inpatient discharges excluding those with suspected dehydration present on 
admission (ICD-9-CM codes for dehydration: 276.0, 276.1, 276.5X present on admis-
sion) were identified from the Premier database(CY2011). Patients with missing infor-
mation on important variables were excluded. PAD patients were identified using 
ICD-9-CM codes. PAD and no PAD(NPAD) groups were matched on propensity score 
adjusting for demographics (age, gender, race, medical, elective patients), patient 
severity (APR-DRG severity scores) and hospital characteristics (geographic loca-
tion, bed-size, teaching and urban hospital). Costs (total and departmental), days 
of stay in hospital(LOS), incidence of mortality and Catheter-Associated Urinary 
Tract Infection(CAUTI) were compared between groups using t-test for continuous 
variables and chi-squared test for categorical variable. Sub-groups of medical and 
surgical population were also matched and analyzed separately. Results: Total of 
86,398(2.1%) of all the selected patients experienced PAD. Post-matching mean total 
cost were significantly higher for the PAD group compared to NPAD group($33,945 
vs. $22,380, p< 0.0001). Mean costs associated with room & board, central supply, sur-
gery, pharmacy and other miscellaneous departments were also significantly higher 
for PAD group(all p< 0.0001). Compared to NPAD group, PAD group had higher mean 
LOS days(12.9 vs. 8.2) and also had a higher incidence of CAUTI(0.6 vs. 0.5%) and in-
hospital mortality(8.6% vs. 7.8%) (all p< 0.05). The results for sub-group analysis were 
also significant for total costs(Medical patients: $22,065 vs. 15,700; Surgical patients: 
$45,728 vs. $32,091) and LOS days(Medical patients: 11.4 vs. 8.3; Surgical patients: 17.8 
vs. 11.4) (all p< 0.05). cOnclusiOns: PAD has a potential to add significant burden 
to hospital costs and resources. Adopting strategies aimed at avoiding PAD may help 
in reducing hospital cost and resource burden and may improve patient outcomes.
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CRESCIMENTO DE óBITOS PóS PARTOS CESARIANOS NO BRASIL vERSUS 
PARTOS NORMAIS
Drago S.1, Ferreira C.N.2, Salles G.R.D.3, Paloni E.D.M.P.2, Santana C.F.S.D.3, Souza C.1,  
Bonachela F.4, Abreu A.A.1
1ORIZON, Sao Paulo, Brazil, 2ORIZON - Companhia Brasileira de Gestão de Serviços, Sao Paulo, 
Brazil, 3Orizon, Sao Paulo, Brazil, 4Orizon, SAO PAULO, SAO PAULO, Brazil
demográficos e econômicos, presença de doenças crônicas, qualidade de vida e a forma 
de aquisição de medicamentos nos últimos sete dias. Um total de 20% das entrevistas 
foram auditadas por telefone quanto a sua autenticidade. O projeto foi aprovado pelo 
Comitê de Ética em Pesquisa da Universidade de Brasília. Para identificar e avaliar os 
determinantes da compra de medicamentos utilizou-se três métodos distintos, Logit, 
Probit e Probabilidade Linear, para elevar a robustez dos resultados. Realizaram-se as 
análises econométricas através dos programas Gretl e R. ResultadOs: Um total de 
1.820 entrevistas válidas, dos quais 59,8% eram mulheres. Foram identificados os poten-
ciais determinantes do consumo de medicamento no DF: classe social, qualidade de 
vida, doenças crônicas, sexo, idade, plano de saúde e consultas médicas. cOnclusões: 
Ter doenças crônicas, ser do sexo feminino, ser mais velho, possuir plano de saúde e ter 
se consultado elevam as chances de comprar medicamentos. Por outro lado, pertencer 
às classes sociais mais baixas e ter melhor qualidade de vida reduz essa chance. Os 
resultados foram qualitativamente equivalentes nos três métodos, além de apresen-
tarem significância estatística próximos de 5%. É possível que os achados estejam 
influenciados pelo viés de suscetibilidade dos sujeitos de pesquisa e de prevalência/
incidência da compra de medicamentos. Entretanto, como diversas características não 
são influenciadas pelo tempo, a validade da informação não é afetada.
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ANáLISIS DEL gASTO SANITARIO ESPAñOL 1980-2010
Crespo C., Brosa M.
Oblikue Consulting, Barcelona, Spain
ObjectivOs: Ilustrar una metodología de distribución del presupuesto sanitario 
público entre las 17 categorías CIE-9-MC (Clasificación Internacional de Enfermedades, 
novena revisión, modificación clínica) y su evolución en el tiempo. MetOdOlOgías: 
La metodología consta de dos fases: una primera fase en la que se realiza una dis-
tribución del presupuesto global por tipo de atención sanitaria (atención hospitalaria, 
ambulatoria o farmacológica), y una segunda fase en que se distribuye el gasto por tipo 
de atención entre las categorías CIE-9-MC. Para esta distribución se utilizan, en la prim-
era fase, informaciones que permitan asignar las diferentes partidas del presupuesto 
a los distintos tipos de atención. Por lo que respecta a la distribución por categorías, 
se utilizan diferentes elementos según el tipo de atención: la estancia hospitalaria, la 
visita ambulatoria o el consumo farmacéutico por subgrupo terapéutico. Se utilizan 
los datos del gasto sanitario en España con propósitos ilustrativos. ResultadOs: El 
análisis del gasto sanitario español entre 1980 y 2010 muestra que la posición relativa 
en cada ámbito no varía demasiado, dominando la atención hospitalaria (58%) en el 
ámbito público y la atención ambulatoria (33%) en el privado. La asistencia farmacéu-
tica incrementa su posición relativa tanto en el ámbito privado como en el público, 2,5 
puntos porcentuales en los dos casos. De análisis de las 17 categorías CIE-9-MC, cabe 
destacar el crecimiento continuo e importante de la categoría VII (enf. del aparato cir-
culatorio, de 10% en 1980 al 17,7% del gasto en 2010) y el decremento de la categoría VIII 
(enf. Respiratorias, del 17,4% al 10,5%). En un segundo término también cabe destacar el 
crecimiento de la categoría II (tumores, del 4,2% al 9,1%) y de la categoría I (infecciosas, 
del 5,2% al 2,31%). cOnclusiOnes: La distribución del presupuesto aporta un punto 
de referencia para la planificación y la gestión sanitarias.
PHP20
IS HOSPITALIzED MULTI-MORBIDITy IN ADULTS DETERMININg COSTS OF  
RE-ADMISSION? EvIDENCE FROM A MULTICENTRIC CROSS SECTIONAL STUDy 
IN ARgENTINA
Insua J.T.1, Villalon R.1, Giunta D.2, Ioli P.3
1Hospital Universitario Austral, Universidad Austral, Derqui, Argentina, 2Hospital Italiando de 
Buenos Aires, Caba, Argentina, 3Hospital Privado de la Comunidad, Fundacion Medica de Mar del 
Plata, Mar del Plata, Buenos Aires, Argentina
Objectives: Multi-morbidity (MM) and readmissions in less than 30 days (ReH) 
require standarized data, diffficult for Argentina. To measure the economic impli-
cations, we evaluated if MM determined direct medical costs of ReH. MethOds: 
In cross sectional study of 1 year hospital discharges (Value in Health;14 (2011):A18), 
of patients ≥ 19 yrs old, primary diagnosis (Dx1) and secondary diagnosis (Dx2), 
total costs (CT$) mean and median per discharge cost ($, 25P-75P-percentiles), in 
international dollars PPP, (UN Data: 1Arg$ = 1.608 I$ PPP, 2008) were obtained. To 
measure of multi-morbidity (MM) we used chronic conditions table in (CC+) counts 
as positive (CC+) per 2Dx. The 30day readmissions (ReH< 30) defined as: 1) any read-
mission within 30 days and 2) the number of stays with at least one subsequent 
hospital stay within 30 days(strict definition) (ReHs). Results: In a universe of 45466 
discharges, we found 7286 ReH < 30 d among adults (≥ 19 yrs old). Total cost of ReH 
TC$ 68 145 431I$; mean cost per discharge ($) was 9629 I$ (SD I$ 23 344); Median 
cost per discharge 4211 I$; (Q1: 1755 -Q3:9291 I$), taken as baseline values for ReH 
(ReHs is N= 6018; with I$ of 10 600 -SD I$ 25271) . Stratified against MM as 2Dx1, 
N= 3357, mean discharge cost was I$ 10823 (SD I$ 24005); 1,12 times the value of all 
ReH. MM at 2Dx5, N= 718, I$ 16538 (SD I$ 36839); 1,72; and when MM was in 2Dx8, 
N= 137, I$ 18785 (SD I$ 34764); 1,95 times baseline (p trend < 0.01). ReHs reduce total 
number of readmissions and produce slightly higher costs (full data not shown), 
e.g. in MM of 2Dx8, ReHs is N= 130, mean discharge cost I$ 19 052 (SD I$ 35591); 1,80 
times baseline. cOnclusiOns: This first estimate of ReH< 30 costs, sensible dura-
tion, and demonstrates impact of multi-morbidity (MM) with the method used.
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ANáLISIS DE MINIMIzACIóN DE COSTOS DE IOBITRIDOL vERSUS OTROS 
MEDIOS DE CONTRASTE IODADOS ISO E HIPO-OSMOLALES EN POBLACIóN 
gENERAL
Simbaqueba E.1, Huerfano L.1, Uriza L.F.2, Romero M.1
1Fundacion Salutia, Bogotá, Colombia, 2Hospital Universitario San Ignacio, Pontificia Universidad 
Javeriana, Bogotá, Colombia
ObjectivOs: Desarrollar una evaluación económica del uso de iobitridol en la 
toma de imágenes diagnósticas versus otros medios de contraste iodados similares 
(seguridad y tolerancia). MetOdOlOgías: Dada la no superioridad ni inferioridad, 
encontrada en la literatura, de los medios de contraste iodados iso e hipo-osmolales, 
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the respondents said they had at least one member of the household experienced 
sickness two weeks prior to the survey. Of those who were sick 15% did not seek 
treatment anywhere, 45% were still sick and 16% had been sick for more than two 
weeks. Sixteen percent of those who sought care took more than one hour to travel 
to the facility. Malaria, ARI, pregnancy related, diarrhea, Aids related and flu were 
mentioned to be the most common diseases the sick were suffering from. Sixty 
percent (681/1137) of the household heads said they were not aware of any com-
munity based referral system for the sick, 66% (467/710) of those who knew about it 
said a community health worker should identify a sick person in the household and 
initiate the referral process to a health facility. A total of 26% said the health facil-
ity should initiate and facilitate the referral process from the household while 3% 
mentioned of self referral to the facility for care when one is sick. cOnclusiOns: 
Despite household members’ knowledge on the diseases they were suffering from, a 
significant proportion did not seek treatment in health facilities even when they had 
been sick for more than two weeks. This finding is significant as it will inform health 
care providers specifically those at lower levels of care to mount behavioral change 
activities aimed to promote early health seeking among household members.
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MODELO PREDICTIvO PARA LA IDENTIFICACIóN TEMPRANA DE POBLACIóN EN 
RIESgO DE CRONIFICAR EN UNA ADMINISTRADORA DE RIESgOS LABORALES 
EN COLOMBIA
Romero M.1, Marrugo R.1, Lopez S.2, Acero G.1, Vivas Consuelo D.3, Palacio D.4, Zapata C.4
1Fundacion Salutia, Bogotá, Colombia, 2Universidad Javeriana, Bogotá, Colombia, 3Universidad 
Politecnica de Valencia UPV, Valencia, Spain, 4ARP SURA, Medellin, Colombia
ObjectivOs: Diseñar un modelo que permita identificar de manera temprana 
los pacientes con riesgo de cronificación basados en un análisis predictivo a par-
tir del gasto farmacéutico, en una administradora de riesgos laborales (ARL) en 
Colombia. MetOdOlOgías: Se revisó el gasto farmacéutico y de atenciones en salud, 
2009-2011 en una ARL, identificando los pacientes con tres o más despachos en un peri-
odo de hasta seis meses (criterio adoptado para definir paciente crónico). Los pacientes 
fueron analizados en 22 grupos de enfermedad basados en la clasificación de enferme-
dades crónicas por prescripciones (Chronic Disease Score CDS). Éstos fueron caracteri-
zados según variables socio-demográficas y con esta información se construyeron dos 
modelos de costos que predicen en el gasto total y farmacéutico. Se estimó un modelo 
logístico binario para predecir el riesgo de llegar a condiciones crónicas. ResultadOs: 
Se identificaron 143.626 pacientes crónicos. Se estableció que el 5,53% de los pacientes 
atendidos, tiende a cronificarse. Con un ajuste global, R^2: 19,1%, se evidenció que 
las variables: edad, salario y número de enfermedades crónicas, generan un impacto 
significativo, positivo y monótono sobre el gasto médico y el farmacológico. El número 
de prescripciones, edad del paciente, tipo de atención y origen del siniestro, tienen un 
impacto positivo sobre la probabilidad de que un paciente llegue a la condición crónica. 
El modelo fue probado sobre los últimos seis meses de datos, mostrando una sensibili-
dad superior al 80%. cOnclusiOnes: El impacto de las enfermedades crónicas sobre el 
gasto total es un factor importante en el resultado económico de las ARL en Colombia. 
El modelo construido permitiría contar mensualmente con un índice de riesgo de cron-
ificación de todos los afiliados, útil en la toma de decisiones, y que permitiría predecir 
de manera más específica el gasto total y farmacéutico.
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COMPARINg QUALITy OF LIFE AND CLINICAL vARIABLES FOR THE PREDICTION 
OF FUTURE MEDICAL EvENTS
Rendas-Baum R., Miller K.
Optum, Lincoln, RI, USA
Objectives: Despite increased recognition that quality-of-life scores correlate with 
health care resource use, their relative predictive value remains understudied. This 
study compares a well-known quality-of-life measure against comorbidity status 
and current medical events in their ability to predict medical events in the subse-
quent 6-month period. MethOds: Data are drawn from panels 10 (n= 12,358; rounds 
2/3) and 11 (n= 13,944; rounds 4/5) of the Medical Expenditures Panel Survey (MEPS), 
collected in 2006 and 2007. The MEPS provides information obtained from medical 
providers on total number of medical events and conditions associated with each 
panel round, as well as the physical component summary (PCS) of the SF-12 (rounds 
2/4), a self-reported health status survey. Three logistic regression models were used 
to estimate the probability of higher resource use (6+ medical events vs. < 6) in the 
subsequent 6 months. Model 1 included the number of comorbidities (none; 1; 2-3; 
4+) and current count of medical events as independent variables. Model 2 included 
just current PCS, and model 3 included all predictors from models 1 and 2. Results: 
Despite being simpler, model 2 (AUC= 0.80, pseudo-R2= 0.11) had explanatory power 
close than that of model 1 (AUC= 0.88, pseudo-R2= 0.20). Model 3 (AUC= 0.90, pseudo-
R2= 0.24) improved slightly on model 1. Under Model 3, a 5-point lower PCS was 
associated with a 33% increase in the odds of having 6+ medical events in the next 
6 months, an association similar to that of having two more medical events (36% 
increase). cOnclusiOns: Our results suggest that as compared to comorbidity 
counts and number of medical events, PCS has a similar ability to predict having 
6+ medical events in the subsequent 6-month period.
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ANáLISIS DE COSTO-EFECTIvIDAD DE LOS PROFESIONALES DE ENFERMERIA 
CON ExPERIENCIA LABORAL EN UCI vERSUS SIN ExPERIENCIA LABORAL 
EN EL ERROR DE LA MEDICACIóN PARENTERAL EN PACIENTES ADULTOS 
HOSPITALIzADOS EN UCI
Beiza C.1, Orrego N.1, Padilla M.F.1, Arriagada M.J.1, Catalan J.1, Fau C.2, Nasabun V.1
1University of Chile, Santiago, Chile, 2Fundacion 2020, Santiago, Chile
ObjectivOs: Determinar la relación de costo-efectividad de los profesionales de 
enfermería con experiencia versus sin experiencia laboral en relación al error de 
tratamiento en la medicación parenteral y los eventos adversos asociados en el 
tratamiento de los pacientes hospitalizados en las unidades de cuidados inten-
sivos (UCI). MetOdOlOgías: Se utilizó un modelo de árbol de decisión de costo-
ObjetivOs: Identificar o crescimento de mortes em partos cesarianas no Brasil e 
compara-las com a quantidade de mortes em partos normais. MétOdOs: Foram 
analisados um banco de dados com 16 milhões de vidas pertencentes à hospi-
tais particulares existentes no Brasil (amostra de 35% do mercado) e analisado a 
quantidade de óbitos pós partos e o tipo de parto realizado todos identificados pelo 
CID-10. ResultadOs: Dado a tendência brasileira o número de partos no Brasil é 
inversamente proporcional a orientação da Organização Mundial de Saúde (15% para 
partos cesarianos e 85% partos normais) a média nacional, de acordo com o Sistema 
de Informações de Nascidos Vivos (Sinasc), do Ministério da Saúde, é de 52,2% e além 
desta tendência nacional verificamos que o número de mortes ocorridas pós partos 
é proporcionalmente maior nas cesariana, além de ter crescido cerca de 135% nos 
últimos 3 anos, sendo que em 2012 o número de mortes foi 186% maior do que as 
mortes em partos normais. cOnclusões: Este estudo é um alerta as organizações 
de Saúde Brasileiras quer seja do ambiente particular quanto público, tanto aos 
elevados números de cesarianas que vem aumentando a cada ano quanto ao riscos 
deste procedimentos tanto para a mãe quanto para o feto. Devendo ser levado em 
consideração outros fatores de custos indiretos como tempo de recuperação.
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HOUSEHOLD FEEDINg PRACTICES FOR THE SICk UNDER FIvE CHILDREN; 
gUCHA SOUTH DISTRICT-kISII COUNTy, kENyA
Mogere D.M.
Great Lakes University of Kisumu, Kisumu, Kenya
Objectives: To examine feeding practices among households with under five sick 
children. MethOds: Household baseline survey was carried out in June 2012 where 
10 sub locations randomly selected were surveyed. A structured questionnaire was 
administered to 983 households with under fives . Mid-Upper-Arm-Circumference 
tapes were administered to under fives, growth monitoring and immunization cards 
were also examined. Results: Fifty-six percent (550/973) fed the sick child less than 
usual, 14% said a child with diarrhea should not be given anything , 64% said child 
should not be given ORS, only 8% said sick child should be given soup and water and 
13% said child should be given breast milk. After taking MUAC tape measurements 
6% could be classified under severely malnourished category. 50% did not have 
growth monitoring cards and only 45% of the eligible children were currently being 
breastfed. Level of education of the mother did not seem to influence breast feeding 
practices, more than three quarters of the widows were not currently breastfeeding, 
while only 27% of salaried, 38% business and 46% farmers women were currently 
breast feeding. Catholic women were leading in currently breast feeding mothers 
with 80% followed by Seventh day Adventist -43%, Indigenous Churches - 42% and 
Anglican -40% respectively. cOnclusiOnes: Majority of the households seem to be 
burdened with child hood sickness. It is worrying that a significant proportion of 64% 
of the respondents said that a child with diarrhea should not be given ORS. Probably 
majority of the households do not know how to manage diarrhea among children 
at home. Significant proportion of the breast feeding children whose mothers were 
engaged in salaried and business employments are disadvantaged because they 
are not being breast fed. Catholic women recorded highest level of breast feeding 
practices compared to their counterparts in other religious affiliations.
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SOCIETAL UNMET NEEDS IN BRAzIL: ExAMININg PREvALENCE, TREATMENT 
RATES, AND HEALTH OUTCOMES
de Renteria J.1, DiBonaventura M.2, Suponcic S.2, Pomerantz D.2
1Kantar Health, Munich, Germany, 2Kantar Health, New York, NY, USA
Objectives: To examine how unmet needs, defined as prevalence rates, treat-
ment rates, and quality of life, compare across the ten most common conditions in 
Brazil. MethOds: Data were obtained from the Brazil 2011 and 2012 National Health 
and Wellness Surveys (NHWS; N= 24,000). The Brazil NHWS is a self-reported nationally 
representative patient survey of the adult Brazilian population (aged 18+), weighted to 
correct for any socioeconomic sampling bias. Among the 10 most prevalent conditions 
in Brazil, prevalence, treatment rates, and health utilities (using the SF-6D algorithm 
from the Short Form-12v2) were examined. Results: Of the conditions respondents 
reported being diagnosed with, eight had prevalence rates greater than 15% (only 
restless leg syndrome (RLS) at 4.74% and arthritis at 4.25% were not among the top ten 
conditions). Despite these prevalence rates, only patients with hypertension (treat-
ment rate= 68.48%) reported a treatment rate greater than 50%. The remaining treat-
ment rates generally varied between 19.30% (insomnia) and 40.47% (high cholesterol); 
patients with RLS reported the lowest treatments rates of all the top ten conditions 
(1.93%). Indeed, many of the debilitating conditions with respect to health utilities had 
particularly suboptimal treatment rates: depression (health utilities= 0.606; treatment 
rate= 39.00%), anxiety (health utilities= 0.639; treatment rate= 23.88%), and insomnia 
(health utilities= 0.640; treatment rate= 19.30%). cOnclusiOns: Despite high preva-
lence rates for a variety of chronic conditions, treatment rates in Brazil are particularly 
poor. One of the exceptions was hypertension, which may be related to the Farmacia 
Popular do Brasil, which allows for the free distribution of medicines for hypertensive 
and diabetic patients. However, many conditions, particularly psychiatric ones, were 
associated with both poor treatment rates as well as significant decrements in health 
utilities. From a public health perspective, more emphasis should be placed on the 
importance of proper chronic disease management in Brazil.
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HEALTH SEEkINg BEHAvIOR AMONg MEMBERS OF THE HOUSEHOLDS; CASE OF 
gUCHA SOUTH DISTRICT, kISII COUNTy, kENyA
Mogere D.M.
Great Lakes University of Kisumu, Kisumu, Kenya
Objectives: To investigate health seeking behavior among households with sick 
persons. MethOds: Household baseline survey was carried out in June 2012 where 
10 sub locations randomly selected were surveyed. A structured questionnaire was 
administered to heads of households. Results: A total of 1427 households were 
surveyed. Questionnaire response rate was 83%. Thirty six percent (423/1181) of 
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100. Results: There were 344 falls including 142 cases (41.3%) with CNDs admin-
istration, and the duration of prescription were 62,622 prescription-days. From 
the viewpoint of length of drug effectiveness, Fall rate for CNDs were 0.16% in 
short-acting CNDs, 0.25% in intermediate-acting CNDs, and 0.26% in long-acting 
CNDs. cOnclusiOns: This result suggested that long-acting CNDs were strongly 
related with falls. To prevent falls within a hospital, hospital personnel including 
nursing staff have to be educated about CNDs.
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SINgLE USE DEvICES IN ARgENTINA: ECONOMIC EvALUATION OF A “REUSE” 
vERSUS A “SINgLE USE” POLICy
Garay O.U.1, Garcia Elorrio E.1, Rodriguez V.1, Spira C.1, Augustovski F.2, Pichon Riviere A.3, 
García Martí S.4
1IECS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 2Institute 
for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 3IECS - Institute 
for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 4Institute for Clinical 
Effectiveness and Health Policy (IECS), CABA, Argentina
Objectives: Several medical devices are labeled for single-use only. The popularity 
of several “off-label” processes - re sterilization, reprocessing and reuse of single 
use devices (SUDs)-is mainly due to the cost saving and environmental benefits, 
but also from scarcity of evidence of adverse safety data. This study objective was 
to compare differential costs of a reuse vs. a single use policy of SUDs and estimate 
its implications considering 4 device types (Trocars, endo-cutters, lineal-cutters 
and harmonic scalpels) from a perspective of an Argentinean private health care 
organization. MethOds: A literature review was performed to identify the clinical 
outcomes after the use of re sterilized SUDs, which was supplemented with a Delphi-
like panel to inform missing parameters. An economic model was built to estimate 
the cost difference between a surgical procedure performed with SUDs or with a 
reused sterilized SUD. Costs were expressed in USD of 2012 and were grouped in three 
categories: device related costs, adverse events, and the incremental surgical time 
associated to reuse of SUD. Deterministic and probabilistic sensitivity analyses were 
performed. Results: A private health care payer in Argentina would expect to spend 
USD 425 per surgery if new trocars are used and USD 244 if sterilized material are 
utilized instead. For endo-cutters the equivalent results were USD 1667 and USD 1102, 
for linear-cutters USD 1228 and USD 1046 and for harmonic scalpels USD 1041 and 
USD 292. Results were robust in the sensitivity and scenario analysis. cOnclusiOns: 
In all the devices and scenarios analyzed, reutilization of SUD resulted less costly than 
using only new material even after considering the additional cost associated with 
potential adverse events related to reuse. If we consider total surgical costs, these 
differences represent savings that range from 2.5% to 14.8%. More research is needed 
to assess effectiveness and safety of these off-label policies.
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SERIOUS ADvERSE EvENTS FOR BIOLOgIC RESPONSE MODIFIERS INDICATED 
FOR THE PROPHyLAxIS AgAINST TRANSPLANT REjECTION. AN INSIgHT FROM 
SPONTANEOUS ADvERSE EvENT REPORTINg SySTEM
Ali A.K.
Eli Lilly and Company, Indianapolis, IN, USA
Objectives: Immunosuppression by biologic response modifiers is essential for 
successful organ transplantation. These medications have safety concerns that com-
plicate organ transplantation. This study aims to identify and characterize safety 
signals of serious adverse events associated with exposure to BRM among organ 
transplant patients. MethOds: Empirica Signal (version 7.3) was used to apply 
pharmacovigilance disproportionality analysis to the FDA Adverse Event Reporting 
System to identify serious adverse events. Associations between drugs and events 
were measured by Empirical Bayes Geometric mean (EBGM) and corresponding 95% 
confidence intervals (EB05-EB95). Associations with EB05 > 1 are considered identi-
fied safety signals, and associations with EBGM ≥ 2 are considered significant safety 
signals that warrants regulatory follow up and possible actions. Results: From Q4 
1997 to Q2 2012, a total of 12,151 serious adverse event reports for biologic response 
modifiers were reported and 15.6% of them met safety signal threshold. About 12% of 
these signals were significant. Sirolimus and Mycophenolate accounted for the major-
ity of all signals, and Antithymocyte Immunoglobulin and Cyclosporine contributed to 
the majority of significant signals. The following significant signals were identified for 
Antithymocyte Immunoglobulin (reduced therapeutic response, pulmonary edema, 
hypotention, serum sickness, infusion related reaction, and anaphylactic reaction); 
for Azathioprine (alternaria infection, fungal skin infection, and lymphoproliferative 
disorder); for Cyclosporine (neurotoxicity, graft versus host disease, and thyroid can-
cer); for Cyclophosphamide (disease progression); for Daclizumab (cytomegalovirus 
infection); and for Tacrolimus (coma and tremor). Approximately 34% of these events 
contributed to patient death; 7% were life-theratening; 32% lead to initial or prolonged 
hospitalization; and 28% contributed to other serious outcomes. cOnclusiOns: 
Exposure to biologic response modifiers for the prophylaxis against transplant rejec-
tion is associated with serious adverse events that could be fatal or life-threatening. 
Pharmacoepidemiological studies are required to evaluate the identified signals to 
help understand the benefit-risk profile of these medications.
PHP40
ASSESSMENT OF ADvERSE EvENTS By USINg TRIggER TOOLS IN SURgERy 
DEPARTMENT OF AN INDIAN TERTIARy CARE TEACHINg HOSPITAL
Vilakkathala R., Mallayasamy S., Konduru S., Rodriques G., Manchanapalli P., Rao A.B.
Manipal University, Manipal, India
Objectives: An adverse event (AE) is defined as ‘unintended physical injury result-
ing from or contributed to by medical care. A Trigger is a clue that helps a health 
care organization to identify adverse events. The objective of this work was to assess 
adverse events by using trigger tools in surgery units of the study hospital to identify 
AEs. MethOds: The study was carried in a tertiary care teaching hospital. Trigger 
list was developed and used to review cases (n= 333). The severity of harm was 
categorized as per National Coordinating Council for Medication Error Reporting 
efectividad para establecer la comparación entre las alternativas: profesionales de 
enfermería con experiencia laboral en UCI (PECE) y profesionales de enfermería 
sin experiencia (PESE), las probabilidades del modelo se determinaron mediante 
una revisión sistemática de la literatura biomédica, la efectividad es cada evento 
adverso evitado (EAE), los costos de los procedimientos fueron calculados en pesos 
chilenos a valor actual desde el punto de vista de una institución de salud, mediante 
un método de microcosteo. Los datos fueron integrados en el modelo y analizados 
mediante el programa DATA 4.0 TreeAge, con los cuales se calculó la razón de costo-
efectividad de cada una de las alternativas de tratamiento. Se realizó un análisis de 
sensibilidad y se calculó la razón de Costo-Efectividad Incremental (ICER) generada 
por una alternativa respecto de la otra. El horizonte de tiempo del análisis fue de un 
año, debido a esto no se utilizaron tasas de descuento. ResultadOs: Los PECE son 
la alternativa dominante del análisis. La efectividad de los PECE fue de 85 EAE, en 
cambio en los PESE fue de 70 EAE. El ICER fue de $17.647 por cada EAE. El análisis de 
sensibilidad mostró que los resultados obtenidos son robustos. cOnclusiOnes: 
Es más costo-efectivo contratar para la atención y el cuidado de los pacientes en las 
UCI a PECE, aun cuando el sueldo de estos profesionales sea un 20% superior al de 
los PESE, ya que por cada EAE se produce un ahorro de $17.647 al sistema de salud.
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TREATMENT AND OUTCOME ANALySIS OF RODENTICIDE POISONINg IN 
TERTIARy CARE HOSPITAL IN SOUTH INDIA
Harika C., Pramoda K., Rohini D., Thunga G.
Manipal College of Pharmacy, Udupi, India
Objectives: To analyze the treatment pattern and outcome of rodenticide poison-
ing in tertiary care hospital. MethOds: A retrospective observational study was 
carried out in a tertiary care teaching hospital on patients admitted due to roden-
ticide poisoning during the period of 2004 to 2012. All the patients who diagnosed 
with rodenticide poisoning were enrolled in the study. Patient data like demography, 
social habits, co-morbid diseases, pre-hospitalization period, type of exposure, type 
of compound consumed, type of treatment given and outcome were collected in case 
record form and analyzed. Results: Total of 137 patients were enrolled in the study. 
Among them 69 (50.4%) patients were male and 68(49.6%) were female. The median 
age of the study population was found to be 24 (11) years. Majority of the poisoning 
were intentional (96%). The median pre-hospitalization period was found to be 3 
(5.75) hours. Among them majority of them consumed zinc phosphide poisoning 
(29.2%). Treatment pattern analysis showed that majority of them received gastric 
lavage(48.2%), charcoal(27.7%), vitamin-k (74.5%), Fresh frozen plasma (37.2%) and 
N-acetyl cysteine (40.1%) as a major course of treatment. Outcome analysis showed 
that gastric lavage and charcoal administration was found to be beneficial as an initial 
course of therapy. Among the other treatment modalities N-acetyl cysteine was found 
to be comparatively beneficial. cOnclusiOns: Gastric lavage and charcoal adminis-
tration were found to increase the survival rate in the initial stages of management. 
N-acetyl cysteine was found to be more effective as a main course of therapy.
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MONITORINg HEALTH PROCESSES IN THE REAL wORLD: AN ITALIAN 
POPULATION DATABASE ExPERIENCE
De Rosa M., Rossi E., Brizuela H.J.
CINECA Interuniversity Consortium, Casalecchio di Reno, Italy
Objectives: To describe a functional approach of a population database for moni-
toring health economics, patient’s outcomes and impact of new drugs. The need to 
use real-world data to support clinical research was the main driver for the Italian 
Inter-university Consortium (CINECA) to set-up a population-based patient cen-
tric database (ARNO Observatory). MethOds: The Italian National Health Service 
(NHS) is a Public Health System, providing health care assistance to all the popu-
lation. Since 1987, ARNO Observatory collects and integrates administrative and 
clinical data for each single patient with high quality and complete information of 
patient demographics, NHS reimbursed drugs dispensed, hospital discharges, lab 
tests prescriptions. Results: ARNO, with its patient centric approach, provides 
comprehensive data from a population of over 11 million of patients of a network 
of 32 Italian Local Health Units. Integration of administrative and clinical data is 
important to study patient care pathways, to evaluate appropriateness of medical 
prescriptions, to evaluate real world outcome and to reduce health expenditure. 
This patient centric approach led to the creation of disease-specific observatories 
such as diabetes, cardiovascular disease, osteoporosis, etc…, with access to data 
tailored on specific user profiles at national or local level. The aim is to examine the 
safety and/or effectiveness of health care products and services in the real-world by 
measuring performance indicators and impact of new drugs. cOnclusiOns: ARNO 
Observatory is an important source of information able to show both economical 
indicators and the good practice of treatment. In particular ARNO enables Health 
Units and Professionals to conduct research projects on disease management, and 
benchmarking and it is a valid instrument for epidemiological and economic plan-
ning for decision making in Italy.
PHP37
RELATIONSHIP BETwEEN FALLS AND CNS DRUgS AT A ACUTE CARE TEACHINg 
HOSPITAL IN jAPAN
Egami K.1, Hirose M.2, Tsuda Y.1, Honda J.1, Shima H.1
1St. Mary’s Hospital, Kurume, Japan, 2Shimane University Hospital, Izumo, Japan
Objectives: Central nervous system drugs (CNSDs) are commonly used at acute 
care settings. However, the relationship between falls and CNSDs has not been 
explored. This study aims to try to address the relationship. MethOds: We used 
data of CNDs prescribed for over fifteen years old in-patients in 2012. There were 
CNSDs including 20 benzodiazepine agents, two non-benzodiazepine agents, one 
barbiturate agents, and five others. With regard to CNDs, we examined duration of 
prescription, duration of administration, and number of patients for falls within 
24 hours after immediately being administered. Falls due to CNDs administration 
is defined as follows: Fall rate for CNDs = number of falls / prescription days x 
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perspective was considered. We considered the following cost components: 
human resources, training, infrastructure, equipment and office supplies, trans-
portation, personal protective equipment (PPE), field and laboratory equipment, 
insecticides and social mobilization, considering capital and recurrent costs. 
Capital costs were estimated for both transmission periods combined. Results: 
The total and monthly recurring costs of the PMCD during the epidemic period 
was R$8.307.590 (US$4.988.345) and R$1.400.819 (US$841.131) respectively; and in 
the endemic period was R$ 5.848.678 (US$ 3.511.876) and R$950.619 (US$570.805), 
with human resources being responsible for the majority of costs in both peri-
ods (83 and 86%, respectively). Capital costs for both periods were R$683,315 
(U.S.$410,301), with a high cost share for transportation (80%) and infrastructure 
(13%) components. The Municipal health department was responsible for 83% 
of total costs, followed by state (13%), and federal (3%) levels. cOnclusiOns: 
Although the estimated costs of the PMCD is under-estimated, we demonstrate a 
significant incremental costs (R$3.050,211 or U.S.$1.831.518) during the epidemic 
period. Our results can provide inputs for cost-effectiveness studies of dengue 
vaccines, which are important to support decision making regarding its introduc-
tion into public health programs.
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THE ECOLOgy OF MEDICAL CARE IN POOR SETTINgS: SELF REPORTED HEALTH 
CARE UTILIzATION IN SANTIAgO DEL ESTERO, ARgENTINA
Insua J.T.
Hospital Universitario Austral, Universidad Austral, Derqui, Argentina
Objectives: Health services utilization in poor provinces in Argentina is poorly 
known, due to data poor environments. We utilized a population based health care 
survey to analyzed the ecology of medical care, and to estimate self reported health 
care services utilization (SRHCU) patterns among adults (≥ 18 years old). MethOds: 
A health Survey was performed, with probabilistic, stratified, polyetapic sampling, 
adding health utilization questions to the National Risk Factor Survey of Argentina 
(ENFR 2009) questionnaire. We obtained SRHCU stratified as ambulatory visits, 
emergency, hospitalizations, stratified into age, sex, rural, urban, health status and 
prior health problem. Analysis was performed with SPSS 17, 95%CI for single pro-
portions was obtained. Results: Among 2064 persons that responded de survey, 
78,9% were urban-21,1% rural, 41,2% males, mean age was 39,9% (SD 15,8) years 
old, age range 18-93. The General Health Status was regular or bad (16,08%) (95%CI 
14,5-17,7%). Likert scale of health status provided Mean = 86,65 (SD 104,35); Median 
80 (25P = 70; 75P = 90). Acute illness events in prior 4 weeks occurred in 24,8% (95%CI 
22,9-26,7%). 70,4% had an ambulatory visit in the prior 6 months (95%CI 68,4-72,4%), 
while, in prior month 17,0% (95%CI 15,4-18,7%) consulted a physician office [gen-
eralist 10,36% (95%CI 9,1-11,7%) and 6,7% specialist (95%CI 5,6-7,8%)]. Office visits 
rate was 261 per 100 persons per year [increased with age 65+ (305), regular or bad 
health (458), and rurality (289), decreased for males (197)]. Emergency visits occurred 
in 106 persons (5,1%) (95%CI 4,18-6,09%); Hospitalization was 10,6% during prior 
year (95%CI 9,3-11,9%), 78% admitted once and 20% readmitted to the hospital in 
the same period. cOnclusiOns: Results provide an estimate of SRHCU data, and 
show lower ambulatory and emergency visit rates, while hospitalization admis-
sions and readmissions is similar to other ecology of medical care studies in other 
areas of the world.
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REvISIóN DE ESTUDIOS DEL COSTE DE LA ENFERMEDAD
Crespo C., Brosa M., Gisbert R.
Oblikue Consulting, Barcelona, Spain
ObjectivOs: Revisar la respuesta que aportan diferentes analistas a la pre-
gunta: ¿qué es lo que obtenemos del sistema sanitario (SS)? MetOdOlOgías: 
Se han revisado las propuestas de la OMS, la OCDE y el enfoque del NHS bri-
tánico. También las aproximaciones de investigadores como D. Cutler y J. Puig-
Junoy. ResultadOs: La OMS combina diferentes dimensiones: resultados en 
salud, equidad, equilibrio financiero y respuesta del sistema sanitario, obteniendo 
un indicador de medida absoluta y proponiendo dos índices relativos de efi-
ciencia: uno relacionado con el nivel de esperanza de vida ajustada por inca-
pacidad y otro que valora la eficiencia del SS en general. En la OCDE consideran 
que debe adjudicarse la prioridad a la medición de la relación costo-efectividad. 
Actualmente sus esfuerzos se orientan a la búsqueda de indicadores de calidad. 
El tercer enfoque estudia la variación de la productividad en el seno del NHS, 
definida como el output obtenido en relación con los inputs utilizados. Se con-
sidera que la efectividad no puede determinarse dado el grado de incertidumbre 
con respecto a los efectos específicos del SS y aboga por ponderar los resultados 
con medidas de calidad. Cutler et al obtuvieron un valor de $19.900 como coste 
por año de vida ganado (C/AVG) en el período 1960-2000 en EEUU, asumiendo que 
el SS es el responsable de la mitad del resultado. Puig-Junoy y Merino-Castelló 
estudiaron para el período 1960-2001 la productividad marginal del gasto sani-
tario en España y obtuvieron un C/AVG entre 10.045 y 12.937. cOnclusiOnes: 
No hay consenso en cuanto al estudio de la efectividad del sistema sanitario. 
La indeterminación que supone la influencia de elementos ajenos al mismo en 
el resultado final supone un inconveniente importante. La incorporación de la 
calidad puede ayudar a superar, en parte, este problema.
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COMPARACIóN DEL TRABAjO EN EQUIPO EN SALAS DE CIRUgíA ENTRE UN 
HOSPITAL PRIvADO y UNO PúBLICO DE BOgOTá, D.C
Amaya Arias A.C., Eslava-Schmalbach J., Barajas Sierra R.
Universidad Nacional de Colombia, Bogotá, Colombia
ObjectivOs: Determinar las diferencias del trabajo en equipo en salas de cirugía 
entre un hospital privado y uno público de Bogotá, D.C. MetOdOlOgías: Estudio 
observacional analítico. Muestra: n= 90 equipos de cirugía, 49 de hospital privado 
(54%) y 41 de hospital público (46%). Criterios de inclusión: Equipos de cirugía 
general de hospitales de tercer nivel de complejidad de la ciudad de Bogotá, D.C. 
and Prevention (NCC MERP) severity scale. Results: When the list of triggers was 
used for the review of AE case reports, 61 triggers were identified in 167 (50.2%) 
cases. Transfusion / use of blood products (15%), infection of any kind (6.9%) were 
the commonly noted triggers in the critical care module. In the surgical module, 
return to surgery (6%) and occurrence of any post surgical complication (6%) were 
predominantly noted. In the medication module, repeated request for lab inves-
tigations (13.2%), use of laxatives (13.2%), pyrexia (10.8%), use of nebuliser/steam 
inhalation (7.5%), use of analgesics (6.6%) and anti-emetics (5.7%) were commonly 
noted. When the harm was studied category E was 24.9% followed by Category F- 
13.8%. cOnclusiOns: The developed trigger list was able to flag 167 case profiles 
with potential adverse events. This tool has potential application in reviewing the 
cases for adverse events.
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EFFECTIvENESS OF DIFFERENT DOSAgE REgIMEN OF PRALIDOxIME IN 
ORgANOPHOSPHORUS POISONINg IN TERTIARy CARE HOSPITAL
Thunga G.1, Pandey S.2
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 2Manipal 
College of Pharmacy, Udupi, India
Objectives: To identify the most appropriate dosage regimen of pralidoxime that 
can be recommended for the management of OP poisoning. MethOds: An open 
labeled cross-sectional, nonrandomized observational study was carried out in 
emergency wards of tertiary care hospital. A total of 256 OP poisoned patients were 
admitted between 2009 to 2013. The basic demographical, clinical characteristics 
and severity were assessed at admission. Based on the pralidoxime dosage regi-
men patients were categorized into 4 different groups viz. control, intermittent, 
500mg/ hour, 1g/ hour groups. The clinical outcome analyzed in terms of hospi-
talization days, ventilatory days, total atropine required, and incidence of inter-
mediate syndrome and outcome were assessed for comparison with pralidoxime 
regimen Results: The results showed that majority of OP poisoned patients were 
in the age group of 21-30 years, and males predominated the females (2.3:1). Clinical 
Severity assessment of these patients showed that most of them had moderate to 
high severity. Outcome analysis showed that patients of continuous infusion of 
pralidoxime had significantly improved recovery rate with least sequel and fatal-
ity rate. The incidence of intermediate syndrome, number of ventilation days, total 
atropine requirement, number of hospitalization days and mortality rate signifi-
cantly reduced in continuous infusion group. cOnclusiOns: Continuous infusion 
of pralidoxime at 500 mg/hour resulted in significantly better clinical outcome than 
other dosing regimens and not associated with adverse derug reactions.
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ANALySIS OF BRAzILIAN PUBLIC FUNDINg PROCESS FOR NEw BIOLOgIC 
DRUgS
Rodrigues T., Izmirlieva M., Ando G.
IHS, London, UK
Objectives: To ascertain if the Brazilian HTA body CONITEC, which replaced CITEC 
in December 2011, is delivering on Ministry of Health (MoH) promises of transpar-
ency and set assessment timelines whilst adopting mandatory evidence require-
ments for new biologic drug funding decisions via the Unified Healthcare System 
(SUS). MethOds: Secondary research based on CONITEC’s final reimbursement 
recommendation reports, evaluating existing and sponsor submitted data. These 
reports include deliberations from a plenary assembly of representatives from the 
MoH, drug regulator ANVISA and supplementary health regulator ANS, as well as 
public consultation contributions. Results: CONITEC has delivered on transpar-
ency with publications of the rationale behind each of its recommendations, thus 
enabling pharmaceutical firms to understand how to respond. The 180 day initial 
analysis phase deadline is being met but evaluation of the implementation phase 
timeline is premature. Out of the final recommendations published to date for bio-
logics, about 40% correspond to a funding rejection. Biologic medicines have been 
denied funding from psoriasis to wet AMD due to lack of cost-effectiveness as well 
as efficacy and safety studies of short duration and small patient populations. The 
rejection of everolimus for a rare brain tumour shows that orphan drugs are not 
being treated differently. Positive endorsements of biologics from breast cancer to 
rheumatoid arthritis come with recommendations of significant price cuts and crea-
tion of clinical guidelines. cOnclusiOns: Manufacturers are struggling to adjust to 
evidence requirements needed in supporting funding applications for new biologics, 
including orphan drugs. Transparency is evident in CONITEC’s analysis phase but is 
absent after a positive recommendation, when the MoH ascertains how the medi-
cine will be offered by SUS. Nonetheless, this is an advance compared to the CITEC 
process, whereby decisions were not made public and there were no clear timelines.
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COSTS OF DENgUE CONTROL AND PREvENTION PROgRAM IN BRAzIL
Santos S.M.1, Amorim F.2, Sousa S.S.3, Ferreira I.A.2, Itria A.4, Siqueira Junior J.B.1, Toscano C.M.1
1Federal University of Goias, Goiânia - Goiás, Brazil, 2Municipal Health Department, Goiânia - 
Goiás, Brazil, 3State Health Department, Goiânia - Goiás, Brazil, 4Departamento de Saúde Coletiva 
do Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás. Pesquisador do 
Instituto de Avaliação de Tecnologia em Saúde (IATS), Goiânia - Goiás, Brazil
The burden of dengue is significant in Brazil. Between 2002 and 2010 approxi-
mately four million probable dengue cases were reported, with significant epi-
demics in 2002, 2008 and 2010. It is expected that a dengue vaccine, currently 
under phase 3 clinical trials, will reduce the number of cases, costs of the disease 
and costs of dengue prevention and control programs, in particular during epi-
demic peaks. Objectives: Estimate the costs of dengue control program (PMCD) 
in the municipality of Goiânia-GO, Brazil. MethOds: We conducted a retrospec-
tive analysis, considering epidemic (October/2009-April/2010), and endemic (May-
September/2010) periods of dengue transmission. The public health care system 
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cos. cOnclusiOnes: Es factible implementar los IMA en 48-72 hs, para responder 
a consultas puntuales acotadas. El perfil fue diferente al de los informes de ETS 
tradicionales. Los IMA más solicitados fueron aquellos relacionados con tecnologías 
terapéuticas, siendo el área oncológica la más frecuente.
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FOLLOwINg THE wESTERN HTA MODEL IN LATIN AMERICA:  
A SELF-FULFILLINg PROPHECy?
Kirpekar S.
Double Helix Consulting, London, UK
Objectives: Health technology assessment in Latin America has been relatively 
more mature than other similarly developed health systems. This research explores 
the trends of development of HTA in the region to understand similarities to the 
European HTA model. It further looks at relevance of having such a model in Latin 
America, the relevance of the complexity of the methodologies and utilities used 
and finally, the implications of these trends. MethOds: The study was conducted 
in Brazil, Mexico, Argentina and Columbia. Opinions of 18 stakeholders were col-
lected via telephone interviews. Respondents included senior clinical oncologists(3), 
academics(4), policy advisors(2), senior bureaucrats in the health ministries(3), senior 
members of HTA bodies(4) and senior executives from manufacturers(2). A scoring 
system was devised to plot the level of complexity and maturity of the HTA systems 
/ agencies both in Latin America and then comparing it with scores of a similar 
study across Europe and Australia. The responses around the relevance of the model 
and implications were analysed qualitatively adding perspective from the author’s 
experience in these countries. Results: The level of maturity of HTA processes in 
all the countries studied was seen to be generally high. The level of association with 
reimbursement processes was seen to vary. There was a split on the relevance of the 
European model to the Latin American context. Majority of the academics (n= 3/4) and 
members of HTA bodies (n= 2/4) felt that following highly complex European models 
was a necessary natural progression to the HTA development curve. This was not 
the observation with the rest of the stakeholders. cOnclusiOns: There is thought 
to be a trend where there is a push by academics and HTA-related professionals 
towards making it similar to the European model, and thus increasingly complex. 
Greater international attention can be a reason, although it must be further explored.
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IT APPLICATION FOR POST MARkETINg DRUg REgISTRIES
De Rosa M., Covezzoli A., Bosio M.A., Ortali M.
CINECA Interuniversity Consortium, Casalecchio di Reno, Italy
Objectives: Establishing an active postmarketing safety surveillance and analysis 
system, used by health professionals, regulatory bodies and sponsors. MethOds: 
The solution consists in making available to the entire community a set of online 
tools aimed to the data collection and analysis on innovative drugs. The introduc-
tion of online integrated environments ensures the appropriate use of drugs, help to 
monitor drug consumption and related costs and improves the real-time reporting 
of suspected adverse drug events. The surveillance system collects patients data in a 
common IT infrastructure within the same network. For 24 antineoplastic drugs the 
system provides also automatic procedures to manage the ‘risk sharing’ & ‘payment 
by result’ approach, that foresees partial or total refund of the cost sustained by 
the hospital pharmacy for the drug in case of progressive disease or unacceptable 
toxicity. Results: This presentation will illustrate the Cineca methodological IT 
approach used also by the Italian National Medicines Agency. The system has been 
used for 70 innovative drugs from eleven different drugs categories: antineoplastic, 
antidiabetics, neurological, dermatological, antiasmatics, ophtalmologic, antireu-
matics and others. More than 500.000 patients were registered by more than 900 
health structures in a timeframe of 7 years. cOnclusiOns: The introduction of 
an online integrated environments ensures a more appropriate drug usage, help to 
monitor drug consumption and related costs and improves the real-time reporting 
of suspected adverse drug events.
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ExPLORINg INCOME INEQUALITy IN SELF-REPORTED HEALTH STATUS IN CHILE 
AFTER THE HEALTH CARE REFORM OF 2005
Cabieses B.1, Espinoza M.A.2
1Universidad del Desarrollo, Santiago, Chile, 2Pontificia Universidad Católica de Chile, Santiago, 
Chile
Objectives: Chile carried out a health care system reform in 2005 aimed at reduc-
ing health and health care inequities. This study assessed whether household 
income-related inequality in adult self-reported health status (SRHS) was reduced 
after this reform. MethOds: Before and after study design using the 2000 and 2009 
CASEN surveys (252 748 and 246 924 participants, respectively) we compared the 
Erreygers concentration index (CI) for SRHS (binary variable: poor= 0, fair/good= 1) 
between these two years. Factors associated with good health were explored using 
weighted logistic regression models. Decomposition analysis of the CIs by “legiti-
mate” (age, sex, marital status, number of household members) and “illegitimate” 
(income, ethnicity, rural/urban, education, occupation, type of health care provision) 
factors was conducted. Results: Results indicated that there was a significant 
concentration of fair/good SRHS favoring the rich people in Chile in both years 
(Erreygers corrected CI for bounded binary variables was 0.165 [Standard Error 0.007] 
in 2000 and 0.053 [0.002] in 2009). We standardized the 2000 and 2009 CIs to assess 
horizontal inequity and decomposed them into “legitimate” factors such as age 
and sex and “illegitimate” factors, mostly socioeconomic conditions. Despite the 
fact that the CIs are not directly comparable between 2000 and 2009, our findings 
suggest that the CI might have decreased after the reform, but good SRHS continued 
Procedimiento: Los datos usados en este estudio hacen parte de la validación del 
instrumento OTAS (Observational Teamwork Assessment for Surgery) en Colombia. 
Una observadora experta en el OTAS ingresó a las salas de cirugía y registró los 
puntajes otorgados a cada subequipo (anestesiólogos, cirujanos, enfermeros e 
instrumentadores quirúrgicos) en cinco comportamientos (comunicación, coordi-
nación, cooperación, liderazgo y conciencia situacional) para las tres fases quirúr-
gicas (pre, intra y post operatorio). Se aplicó la prueba U de Mann-Whitney, se hizo 
la corrección de Bonferroni para el alfa rechazando la hipótesis nula cuando el 
alfa era igual o menor a 0,004, manteniendo así un margen de error para el estudio 
de 5%. ResultadOs: Se encontró que los puntajes obtenidos en el OTAS fueron 
diferentes en la institución privada comparada con la pública (Z= 4,77; p= 0,0000), 
al realizar comparaciones discriminadas se encontraron diferencias significativas 
en los subequipos de anestesiología (Z= 12,17; p= 0,0000), en los comportamientos 
de liderazgo (Z= 3,56; p= 0,0004) y conciencia situacional (Z= 3,20; p= 0,001) y en las 
fases pre quirúrgica (Z= 4,41; p= 0,0000) y post quirúrgica (Z= 4,20; p= 0,0000), en 
todos estos casos los puntajes fueron mayores en los equipos de la institución 
privada. cOnclusiOnes: Teniendo en cuenta el diseño los resultados no pueden 
ser generalizados. Los hallazgos sugieren una diferencia en algunas habilidades 
no técnicas e interacción en los equipos de salud según el tipo de institución, esto 
puede estar relacionado con cumplimiento de protocolos y mayor control de calidad 
implementados en la institución privada.
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APPLICATION OF HEALTH TECHNOLOgy ASSESSMENT AND 
PHARMACOECONOMICS IN THE DECISION-MAkINg PROCESS IN SELECTED EU 
MEMBER STATES
Marusakova E.1, Bielik J.2
1GlaxoSmithKline Slovakia, Bratislava, Slovak Republic, 2Trencin University of Alexander Dubcek, 
Trenèín, Slovak Republic
backgROund: The application of Health Technology Assessment (HTA) and 
Pharmacoeconomics (PE) into real health policies in selected European countries 
(Austria, Bulgaria, Croatia, Czech Republic, Germany, Hungary, Latvia, Poland, 
Romania, Serbia, Slovakia, Slovenia, UK) was analyzed based on the outputs from 
the conference “Optimalization of Methods of PE and HTA: Importance for National 
Health Policy and Cross-Border Cooperation” (Slovakia, 10/2012). Objectives: The 
objective of the paper was to compare the systems and to find the most transpar-
ent one based on the pre-defined criteria. MethOds: The primary method used 
for the analysis was structured evaluation of the outputs from the conference. 
The other relevant information resulted from the systematic review of PUBMED, 
EMBASE and CENTRAL in years 2011-2012 extended to official websites of public 
health institutions and officially published data with the objective to select all 
papers on HTA/Pharmacoeconomics related to selected European countries. We 
evaluated 9 characteristics relevant for the decision-making process: legislative 
background, implementation, binding force, institutionalization, qualified personal 
resources availability, existed methodology/guidelines, clarity of the process, patient 
involvement in the process, and respecting the deadline of 180 days for issuing a 
decision. Results: Resulting from the analysis, of selected countries, the UK was 
shown to have the most transparent system. Germany and Austria ranked second. 
Hungary and Poland ranked third, followed by Slovakia. The least transparent sys-
tem was found in Bulgaria and Romania. cOnclusiOns: One of the criteria was 
qualified personal resources availability that immediately discriminate systems 
in smaller central and eastern European countries. This should result in develop-
ing tailored approaches rather than copying technocratic “western” systems. The 
system prepared in Romania based on multiple criteria decision analysis principle 
could be regarded as a positive example.
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ExPERIENCIA INICIAL CON UN NUEvO TIPO DE DOCUMENTO DE EvALUACIóN 
DE TECNOLOgíA SANITARIA: “INFORMES DE MESA DE AyUDA”
Alcaraz A.1, Augustovski F.2, Garcia Marti S.3, Rey Ares L.3, Pichon Riviere A.4, Meza V.3, 
Lombardo J.1
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2IECS -  
Instituto de Efectividad Clinica y Sanitaria, Buenos Aires, Argentina, 3Institute for Clinical 
Effectiveness and Health Policy, Buenos Aires, Argentina, 4IECS - Institute for Clinical Effectiveness 
and Health Policy, Buenos Aires, Argentina
ObjectivOs: Si bien la utilización de Evaluación de Tecnologías (ETS) para la toma 
de decisiones es cada vez más utilizada en Argentina, es habitual la disociación 
entre el tiempo para la toma de decisiones cotidianas y el que demanda la reali-
zación de informes tradicionales. El Instituto de Efectividad Clínica y Sanitaria 
(IECS), una de las principales agencias de ETS de Latinoamérica, provee informes a 
instituciones públicas, de seguridad social y seguros privados. Se diseñó un nuevo 
tipo de documento orientado a responder una consulta puntual (motivada por 
un caso real), de respuesta en 48-72 hs, denominado Informe de Mesa de Ayuda 
(IMA). El objetivo es describir la experiencia del primer año y evaluar cuáles son las 
tecnologías más solicitadas como IMA por un grupo de decisores de Argentina y 
Uruguay. MetOdOlOgías: Descripción y análisis de las bases de datos de IMA reali-
zados por IECS. ResultadOs: Entre enero de 2011 y febrero de 2013 se realizaron 
110 IMA. El 78% de los pedidos correspondieron tecnologías terapéuticas (54% dis-
positivos, 26% procedimientos y 20% radioterapia), 15% a drogas y 7% a tecnologías 
diagnósticas. Esta distribución fue significativamente diferente a la observada 
en los informes de ETS donde se observa que el 52% de los pedidos correspondi-
eron a tecnologías terapéuticas, 34% a drogas y 14% a tecnologías diagnósticas. En 
cuanto a las áreas de interés el 17% de los IMA fueron relacionados con cáncer, 
el 14% con alteraciones neurológicas, el 12% con patologías traumatológicas, 11% 
gastrointestinal, 11% con trastornos urinarios, siguiendo en frecuencia motivos 
quirúrgicos, cardiovasculares, endocrinológicos, trastornos genéticos y oftalmológi-
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ratio: 2,43; 65-74 yrs old: 4,72%,I$ 25968, age ratio: 1,31; 75-84 yrs old: 8,45%; I$ 15471, age 
ratio: 0,78; 85+ yrs old: 14,09%, I$ 7832, age ratio: 0,39), and sex, males (47,4%) had a I$: 
22679 (M/F I$ ratio: 1,45). In 1 adm.(53% of deaths), mean cost was I$ 23 792; while ReH 
≤ 365 days (47% of deaths), I$ 13 530, cost ratio ReH/1 adm= 0,57 ; and if ReH < 30 days 
(29,5%), I$ 12354, cost ratio ReH< 30/1 adm= 0,52. cOnclusiOns: Understanding the 
economic burden of dying helps promote better and cost-effective ways of promoting 
palliative care, old and readmitted deaths are less costly.
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FROM “gENERIC SCHEME” TO “BRAND-gENERIC SCHEME”: THE EFFECT OF NEw 
POLICy (2003-2004) ON EFFICIENCy OF IRANIAN PHARMACEUTICAL INDUSTRy
Hashemi Meshkini A.1, Varmaghani M.1, Yousefi M.2, Yaghoubifard S.1, Zekri H.3, 
Kebriaeezadeh A.1
1Tehran University of Medical Sciences, Tehran, Iran, 2Tarbiat-Modarres University of Medical 
Sciences, Mashhad, Iran, 3Allameh-Tabatabaee University of Human Sciences, Tehran, Iran
Objectives: Brand-Generic scheme was implemented in Iran to improve the compe-
tition in the market. In this study we aim to assess if this new policy has had any posi-
tive effect on efficiency of Iranian pharmaceutical companies. MethOds: We used 
Data Envelopment Analysis (DEA) to evaluate the relative efficiency of pharmaceutical 
companies for the years 1999-2008. The Wilcoxon matched-pairs signed-rank test and 
also sign test were used to assess the difference between mean relative efficiency of 
companies before and after policy. Results: Although the Wilcoxon matched-pairs 
signed-rank test did not show any significant difference between before and after 
new policy in term of both technical and pure (managerial) efficiency of included 
companies (Pvalue: 0.079 and 0.07, respectively) but the one–sided sign test indicated 
that only relative pure (managerial) efficiency has improved after this policy (Pvalue: 
0.031). cOnclusiOns: The “Brand-Generic scheme” does not seem to be enough 
policy to improve efficiency of pharmaceutical companies in Iran. To achieve this aim, 
paying special attention to infrastructural requirements including non-discriminating 
and transparent laws and regulations for supporting competition, the competitive 
pricing policies, the presence of international companies in the market and full pri-
vatization of companies had to be also considered by policy makers.
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REgULATINg THE ACCESS TO AN ADEQUATE AND AN INTEgRAL ASSISTANCE 
IN BRAzILIAN PRIvATE HEALTH PLANS
Silva F.H.C.V.
Agência Nacional de Saúde Suplementar, Rio de Janeiro, Brazil
Objectives: To describe the main actions promoted by the The Federal Regulatory 
Agency for Private Health Insurance and Plans (ANS) to regulate the access 
of private health plans beneficiaries to an adequate and an integral assis-
tance. MethOds: A retrospective analysis of data about coverage in health plans 
since ANS creation (1999) was done to identify the main actions promoted by the 
agency in this area. It included the set of rules published and ANS periodic publi-
cations. Results: A very important identified mechanism that ANS employs for 
regulating the users access to a full assistance is the elaboration of a list of medical 
procedures. This list constitutes the minimum obligatory coverage for all plans. It 
is periodically reviewed and incorporations and/or exclusions are made according 
to some precepts like: clinical evidence, epidemiological relevance, among oth-
ers. The guidelines implementation is another important instrument identified 
in this study to the improvement of private health assistance. ANS established a 
collaboration term with the Brazilian Medical Association (AMB) to develop guide-
lines, to spread and to monitor their implementation. cOnclusiOns: The actions 
presented are the main one promoted by ANS to regulate the access to an ade-
quate and an integral assistance. They can also improve the sector efficiency along 
with the rational use of techniques and medical technologies. The instruments 
discussed will be a guide to upgrade the health plans management and their 
efficiency. The patients will have safer end more effective treatments and ANS 
keeps the balance and promotion of health in private health with a new model.
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A MEDIAçãO DE CONFLITOS NA AçãO FISCALIzATORIA DO SETOR DE SAúDE 
SUPLEMENTAR BRASILEIRO
Tanaka F.H.R., Franco S.
ANS - Brazilian Private Health Regulatory Agency, Rio de Janeiro, Brazil
ObjetivOs: Demonstrar a eficácia da utilização de meios consensuais de mediação 
de conflitos pela Administração Pública no controle e fiscalização do cumprimento 
das normas que regulam a assistência suplementar à saúde no Brasil. MétOdOs: 
Desde 2010, a ANS – Agência Nacional de Saúde Suplementar implementou o procedi-
mento NIP (Notificação de Investiação Preliminar), cujo objetivo é realizar a mediação 
de conflitos entre operadoras de planos de saúde e consumidores, no que tange a 
situações que envolvem negativa de cobertura assistencial. A NIP é um processo 
totalmente eletrônico, que confere maior celeridade e eficácia na resolução das rec-
lamações dos consumidores, induzindo uma melhora na relação operadora/consu-
midor. Com a NIP, as operadoras têm prazo de 5 dias para solucionar o conflito junto 
ao beneficiário e responder à ANS sobre as medidas tomadas. Após processamento na 
NIP, a reclamação pode ser finalizada por inexistência de infração, reparação de con-
duta ou encaminhada para abertura de processo administrativo, nos casos em que o 
conflito não foi resolvido. ResultadOs: Desde sua implementação, a resolutividade 
dos conflitos na NIP manteve-se acima de 70% do total de reclamações recebidas, o 
que em 2012 significou a conclusão de 42.672 das 54.412 denúncias de negativa de 
cobertura assistencial (78,4% de resolutividade). Antes de seu advento, as reclamações 
eram analisadas por meio de instituição de processo administrativo sancionador, que 
duravam, em média, 18-24 meses para sua conclusão, podendo levar ao arquivamento 
da denúncia ou lavratura de auto de infração contra a operadora. cOnclusões: A 
NIP conferiu maior eficácia ao processo fiscalizatório da ANS, proporcionando maior 
to be concentrated among the rich in both years. Decomposition indicated that 
“illegitimate” factors remained large contributors to income-related inequality in 
SRHS even after the equity-centered reform of 2005. cOnclusiOns: Findings sug-
gest that income-related inequality in SRHS might have decreased in Chile after 
the health care reform. Beyond this observed difference over time, the remaining 
inequality is still largely due to illegitimate factors that should be tackled through 
broader policies in the country.
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PERCEPTION OF USERS OF DRUg DISTRIBUTION PROgRAM IN BRAzIL
Carraro W.H., Mengue S.S., Haddad E.W.
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Objectives: To characterize the users of access to medicines program developed 
in Brazil, known as Aqui Tem Farmácia Popular Program (PAFP), by identifying those 
users who migrated from other supply of basic medicines programs by means of a 
survey explicitly developed for this purpose. This work also seeks to evaluate the 
meeting customers’ needs by the Program and its satisfaction level. MethOds: The 
survey instrument used gathering the users of Aqui Tem Farmácia Popular program 
has been applied in 15 counties from 14 Brazilian states. 1073 interviews com-
posed the sample, in 27 establishments of private pharmacies, during august 2012. 
The collection instrument was composed by three blocks: questions concerning 
the use of the PAFP and other programs of medicines supply; user’s profile infor-
mation; and identification of the medicine supplied. Results: The evaluation of 
the users migration from other programs identified that, before the PAFP, 52% of 
interviewed users was buying the medicines in the private pharmacy and more 
than 30% was using the Public Service in a Health Center of SUS, a piece of 11% 
began the treatment after the PAFP. More than 58% of users would use the service 
of the SUS if there was no PAFP. However, 36% of users reported that they would 
not use the SUS system for withdrawal of medicines. It was observed that 61% of 
users gave out to be economizing while withdrawing the medicines with gratuity 
or at a discount. cOnclusiOns: The conducted survey made possible to character-
ize the users of PAFP showing aspects concerning the participation and the range 
of the program. Generally, it was found that the persons are satisfied and they 
reported to have saved with the program. They also pointed out the convenience 
they have with the possibility of the access to the medicine in any pharmacy with 
the PAFP.
PHP54
A NATIONwIDE SURvEy ON PATIENT SAFETy CULTURE IN jAPAN
Hirose M.1, Egami K.2, Tsuda Y.2, Honda J.2, Shima H.2
1Shimane University Hospital, Izumo, Japan, 2St. Mary’s Hospital, Kurume, Japan
Objectives: To explore safety culture dimensions among health care professionals 
using Hospital Survey on Patient Safety Culture (HSOPSC) by developed by AHRQ 
(Agency for Healthcare Research and Quality). MethOds: We surveyed nationwide 
the situation of patient safety culture in 13 hospitals (5,760 persons) allowed for 
additional costs on patient safety countermeasures under the social insurance med-
ical fee schedule. The questionnaire consists of seven unit-level aspects of safety 
culture including 24 items, three hospital-level including 11 items, and four outcome 
variables including nine items. Results: An average number of beds was 360 beds 
(63 - 1,354 beds). With regard to ownership, 13 hospitals included three municipality 
and local incorporated agency hospitals, one public hospital, two juridical person 
with social insurance hospitals, six medical corporation hospitals, and one other 
hospital. Number of all respondents was 5,118 persons (response rate: 88.9%), and 
included 295 physicians (90.8%), 2,909 nurses (95.5%), and 146 pharmacists (96.7%). 
In terms of 12 dimensions, the overall average positive response rate (RR) for the 
12 patient safety dimensions of the HSOPS was 49.2%, extremely lower than the 
average positive RR for the AHRQ data (61%). In terms of health care professionals, 
the overall average positive RR for pharmacists (46.2%) was lower than that for 
physicians and nurses (49.6% and 49.4%).With regard to pharmacists, the aver-
age positive RRs for 8 dimensions of the 12 dimensions were the lowest among 
three professionals, and three average positive RRs were the highest; Frequency of 
event reporting (pharmacists: physicians: nurses= 73.6%:53.3%:67.9%), Non-punitive 
response to error (48.8%:42.6%:40.4%), and Staffing (29.1%:27.0%:25.4%). cOnclus
iOns: The HSOPSC measurement provides the evidence for assessment of patient 
safety culture in Japan’s hospitals. This result that patient safety culture has been 
in a state of development, compared with the US hospitals.
PHP55
COST AND QUALITy OF DyINg IN HOSPITAL: RESULTS FROM THE ARgENTINE-
HEALTH CARE COST AND UTILIzATION PROjECT (A-HCUP)
Insua J.T.1, Villalon R.1, Giunta D.2, Ioli P.3
1Hospital Universitario Austral, Universidad Austral, Derqui, Argentina, 2Hospital Italiando de 
Buenos Aires, Caba, Argentina, 3Hospital Privado de la Comunidad, Fundacion Medica de Mar del 
Plata, Mar del Plata, Buenos Aires, Argentina
Objectives: Little is known about dying in Argentina, we studied costs and readmis-
sions (ReH) < 30 days of hospital dying adults. MethOds: A cross sectional study of 1 
year hospital discharges, with HCUPs methods, of patients ≥ 19 yrs old. We obtained 
deaths, first admission (1 adm) and ReH ≤ 365 days and ReH < 30 days; total direct 
medical cost (TC I$), mean (I$) (SD), median I$ (Q1-Q3) discharge cost, (in I$ PPP, 2008), 
stratified by age/sex, admissions and ReH < 30 days and < 365 days. Results: Total 
mortality for ≥ 19 yrs old patients was 4,70%. Among 2137 deaths, Total cost of those 
dead in hospital, TC I$: 40 540 842 ; mean cost per discharge (I$) was 19853 (SD 45 599); 
Median cost per discharge I$ 4182; (Q1: 1452-Q3: 17730 I$), comprising 8,31 % of TC I$. 
Among 43321 discharges, TC$ of those alive, TC: 447 300 754 I$; mean cost per discharge 
($) was 10569 I$ (SD 21 217); Median cost per discharge 14 091 I$; (Q1: 2 496- Q3:10 054 
I$). Relative dead /alive I$ was 1,88 times higher. Mean discharge cost of deceased 
stratified by age group (mortality 19-64 yrs. old: 1,52%, I$ 48332, age 19-64/≥ 19 yrs old 
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age of NIPs of individual/family plans, compared to collective ones, may be a reflec-
tion of a greater weakness in consumer-provider relationship in this type of contract.
PHP62
PODER POPULAR y REgULACIóN DEL PRECIO DE LOS MEDICAMENTOS EN 
vENEzUELA
Adesso G.
Universidad Central de Venezuela, Caracas, Venezuela
ObjectivOs: Explorar el rol del Poder Popular en el proceso de regulación del precio 
de los medicamentos en Venezuela, articulado por la Superintendencia Nacional de 
Costos y Precios (SUNDECOP) en conformidad con lo establecido en la Ley de Costos 
y Precios Justos y las Providencias Administrativas relacionadas. MetOdOlOgías: 
Estudio exploratorio documental basado en la búsqueda y revisión de los artículos 
de prensa disponibles y publicados en la página Web oficial de la SUNDECOP. La 
búsqueda y recuperación de la información fue realizada el 10 de marzo de 2012. 
Se tomaron en cuenta para la revisión los artículos que incluían en su contenido 
las palabras: participación o poder popular y regulación del precio de medicamen-
tos. ResultadOs: Se identificaron 172 artículos noticiosos publicados desde 13 julio 
2011 hasta 27 de febrero de 2013. Se revisaron 12 artículos de prensa que cumplían 
con el criterio de inclusión. El 50% de los artículos revisados resaltan la participación 
del Poder Popular en la definición de las políticas de precios y los criterios a tomar 
en cuenta por el Sistema Nacional Integrado de Costos y Precios para la fijación del 
precio de medicamentos, mientras que en 10 de los artículos se desprende el papel del 
Poder Popular como controlador social para vigilar el cumplimiento de la regulación 
una vez sea decretada por la SUNDECOP. cOnclusiOnes: Además de las eventuales 
acciones de inspección y fiscalización, el Poder Popular en Venezuela está aportando 
insumos a la SUNDECOP que serán incorporadas en el proceso de tomas de decisiones 
para fijar el precio a los medicamentos durante el año 2013. Se sugiere profundizar 
en un posterior estudio para conocer y analizar cómo y en qué medida esos aportes 
del Poder Popular están siendo incluidos en el análisis metodológico para establecer 
la definitiva regulación del precio de los medicamentos.
HEALTH CARE USE & POLICy STUDIES – Conceptual Papers
PHP63
NOvEL PRICINg STRATEgIES TO SUPPORT SUSTAINABLE ACCESS TO MEDICINE 
IN LATIN AMERICA
Shankar R., Lindon L., Hooper J., Rowbottom R.C.
IMS Consulting Group, Cambridge, UK
With lower returns from price pressures in developed markets, it is imperative for 
pharma companies to seek growth in emerging markets such as Latin America. 
Simultaneously, with rising incomes, a growing middle class in emerging markets 
is increasing demand for access to innovative medicine, especially in diseases such 
as oncology, CV and diabetes. Achieving commercial expansion as well as increasing 
access to innovative medicine in Latin America needs new pricing strategies and fund-
ing models. We discuss and evaluate alternative pricing strategies and funding models 
to support commercial expansion and increase access to innovative medicines in Latin 
American markets such as Brazil, Argentina, Mexico and Colombia. These include cur-
rent industry strategies, equitable pricing strategies and strategies focused on local 
market conditions. We model the impact of these strategies on both specialty and 
primary care medicines. The modelling is based on insights and assumptions drawn 
from analogue analysis in pharmaceuticals and other industries. It is supplemented by 
interviews with industry experts in Latin American market strategies. For the modelling 
we assume current market and public and private insurance coverage structures. We 
find that in primary care medicines there is considerable opportunity for commercial 
and access gain through more differentiated pricing strategies. These strategies are 
more commercially (revenue and profit) optimal than current industry strategy. At the 
same time, they are also access optimal in terms of the eligible patients they provide 
access to. In the case of specialty medicines, differential pricing strategies can increase 
commercial potential, but there is a gap between commercially optimal and access opti-
mal strategies. This gap can be bridged through increased financing for these medicines. 
Based on this analysis, we suggest a path forward in which pharmaceutical companies 
can collaborate with governments and other stakeholders to achieve increased access 
to innovative medicines in a commercially sustainable manner.
PHP64
ACCESS TO MEDICINES INDEx: MEASURINg HOw wELL COUNTRIES PROvIDE 
ACCESS TO MEDICINES
Shankar R.1, Hickson S.1, Gorokhovich L.2
1IMS Consulting Group, Cambridge, UK, 2IMS Consulting Group, London, UK
Developing countries are now following the steps of developed countries in imple-
menting universal health coverage. Health care systems and policies differ across 
countries resulting in various levels of medicine access. To evaluate which systems 
and policies lead to better access, we need a measure to compare how well countries 
provide access to medicine for their populations. Using IMS proprietary data as well 
as public sources, our analysis proposes a Country Access to Medicines Index that 
compares and ranks countries on access to medicine outcomes across four pillars: 
medicine reimbursement coverage, time to reimbursement, medicine affordability 
and support for innovation. Medicine reimbursement coverage measures private 
or public insurance cover for a representative basket of medicines across major 
communicable and non-communicable diseases. It has three components: share of 
population covered, share of medicines covered and share of costs covered. The time 
to reimbursement pillar measures average time to reimbursement for the selected 
basket. The affordability pillar measures relative cost of medicine basket compared 
to the international average both in absolute terms and as a share of per capita GNI 
in each country. The innovation pillar measures local patents and investment in 
R&D. We used this index to compare and rank more than 30 developed and devel-
oping countries. We then look at the policies in these countries to identify features 
that lead to better index scores. We find that five broad factors can help explain 
satisfação aos beneficiários de planos de saúde. Os dados obtidos na NIP são utilizados 
para monitoramento da garantia de atendimento e acesso às coberturas obrigatórias, 
que podem gerar a suspensão de comercialização dos planos identificados com falhas 
assistencias, bem como instauração de regimes especiais de recuperação pela ANS.
PHP59
CONSTRUCCIóN DE UN MODELO DE PRIORIzACIóN APLICABLE A 
LATINOAMéRICA – EL CASO DE COLOMBIA
Avila A.1, Verbel A.1, Castro H.1, Mejia A.1, Sarria A.2
1Instituto de Evaluación Tecnológica en Salud - IETS, BOGOTÁ, Colombia, 2Agencia Española de 
Evaluación de Tecnologías Sanitarias (AETS) del Instituto de Salud Carlos III, MADRID, Spain
ObjectivOs: Los sistemas de salud deben enfrentar el desafío de hacer uso eficiente 
de recursos limitados ante necesidades crecientes de salud. Colombia no ha sido ajena 
a éste desafío. El Ministerio de Salud ha entendido la importancia de articular un 
sistema de salud que incorpore un sistema de priorización del gasto sistemático, trans-
parente y legítimo. En el marco de lo anterior, fue creado el “Instituto de Evaluación 
Tecnológica en Salud (IETS)”, que tiene como objetivo proporcionar recomendaciones 
sobre tecnologías en salud y mejores prácticas, basadas en evidencia, para el gobierno 
nacional y demás actores, como insumo para la toma de decisiones. En este proceso, 
uno de los primeros pasos es diseñar un proceso para la priorización y selección 
de tecnologías a evaluar. MetOdOlOgías: A partir de una revisión de diferentes 
metodologías de priorización, se propuso un mecanismo de análisis de decisión de 
múltiples criterios, que fue discutido en panel de expertos del gobierno y otros actores. 
Se realizó un piloto de priorización que permitió detectar los principales riesgos y 
desafíos en cada etapa del proceso. A partir de la discusión, construcción colectiva y 
experiencia del piloto, se seleccionaron, definieron y ponderaron los criterios de pri-
orización, y se diseñaron las diferentes etapas e instrumentos para llevar a cabo el pro-
ceso. ResultadOs: Los criterios seleccionados fueron la gravedad de la enfermedad, 
la población afectada, el costo de adquisición de la tecnología, la atención a grupos vul-
nerables, el interés de salud pública y la solicitud de la ciudadanía. cOnclusiOnes: 
Emplear criterios explícitos facilita que la priorización sea un proceso legítimo y trans-
parente. La propuesta permitirá al Ministerio de Salud, como líder del proceso con el 
concurso de otros actores, contar con herramientas para priorizar y seleccionar tec-
nologías para evaluación. La experiencia colombiana dará herramientas metodológicas 
a otros países interesados en la construcción de este tipo de procesos.
PHP60
THE NOTIFICATION OF PRELIMINARy INvESTIgATION (NIP) OF THE FEDERAL 
REgULATORy AgENCy OF PRIvATE HEALTH AND INSURANCE AND PLANS 
(ANS): A TOOL TO FACILITATE THE ACCESS TO THE MANDATORy COvERAgE
Silva F.H.C.V.
Agência Nacional de Saúde Suplementar, Rio de Janeiro, Brazil
Objectives: To describe the instrument NIP (Notification of Preliminary 
Investigation) and it’s role on solving conflicts related to the obligatory cover-
age access, between health plans and patients. MethOds: A critical analysis of 
the rule that created NIP (Regulatory Resolution nº 226/2010), established by The 
Federal Regulatory Agency for Private Health Insurance and Plans (ANS), was done to 
characterize the tool. Results: The Notification of Preliminary Investigation (NIP) 
consists of a communication time to mediate the relationship between consumers 
and providers of health plans in cases of unauthorized procedures by the provider. 
NIP is an electronic process to solve the conflicts before a process that can lead to 
the punishment of the health plan provider. A contact is previously made to notify 
the health plan provider about the problem and it has five business days to answer 
it. This way, the health plan provider has the opportunity to solve the question 
without punishment and the beneficiaries can have a faster access to the procedure 
prescribed by the doctors. If the procedure doesn’t have coverage according to the 
supplementary health rules (it is not listed on ANS Medical List of Procedures), the 
demand is filed. If the provider’s answer is not enough to conclude the question, 
it’s sent to the Inspection Department to a more detailed analysis before being fin-
ished. cOnclusiOns: The NIP is a mediation instrument that can help ANS to solve 
the problems between beneficiaries and health plan providers, giving a fast answer 
to both interested actors of the process. It can be positive because sometimes the 
questions are solved without the provider punishment and the beneficiaries’ injury. 
The conflict mediation by NIP can contribute to the change in the entities attitude 
and culture and can also promotes the interaction and the active participation of 
the actors involved.
PHP61
THE QUALITATIvE PROFILE OF THE COvERAgE COMPLAINTS MADE By HEALTH 
PLAN USERS TO THE FEDERAL REgULATORy AgENCy FOR PRIvATE HEALTH 
INSURANCE AND PLANS (ANS)
Silva F.H.C.V.
Agência Nacional de Saúde Suplementar, Rio de Janeiro, Brazil
Objectives: To define the qualitative profile of the coverage complaints made by 
health plan users, to The Federal Regulatory Agency for Private Health Insurance and 
Plans (ANS). MethOds: A retrospective analysis of the Notification of Preliminary 
Investigation (NIP) registers in 2011 and in the first half of 2012 was performed. The 
data were extracted from Inspection System (SIF). The variables considered were: the 
subject of the coverage complaints (Medical List of Procedures, Time for Coverage 
Access, Managed Care, etc.), the date of the contract (before or after ANS regulation) 
and the type of the plan (individual/ family or collective). Results: The study shows 
a change on predominant coverage subject: In 2011 43,5 % of the complaints were 
about “ Medical List of Procedures”. In 2012, the main subject was “Time for coverage 
access” (36,2% of he coverage complains).” It was possible to verify that, in both years 
considered, there was a prevalence of ANS regulated contracts of individual/familiar 
type (44.8% in 2011 and 47.7% in 2012). cOnclusiOns: This study helped to know the 
qualitative profile of the coverage complaints in brazilian supplementary health. The 
increased number of complaints about “Time for coverage access” in 2012 may indicate 
that the services offered are not being enough to attend the users. The higher percent-
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do usuário, um processo que reconhece o direito de participação nas decisões 
que afetam o cotidiano e promove espaços democráticos para o controle social 
das instituições, representa forma de participação popular mais contemporânea, 
inclusive consoante com a ideologia da LAI. Esse movimento ativo da sociedade, 
demandar o sistema, provoca a percepção por unidades gestoras da importância 
do envolvimento do usuário. Para essa interlocução é necessário adaptar a lin-
guagem para que se disseminem informações compreensíveis e, de fato, úteis à 
sociedade. Com isso, a área de avaliação de tecnologias em saúde do Ministério da 
Saúde teve que se mobilizar para fornecer informações direcionadas aos usuários, 
fortalecendo seu papel de informá-los a respeito do valor relativo das tecnologias 
com informações confiáveis, sólidas e transparentes, inclusive seus impactos ético 
e social. Nesse contexto, a LAI, como instrumento oportuno de participação social, 
é uma ferramenta capaz de direcionar as demandas e ações de saúde, conferindo 
maior transparência ao processo.
PHP68
PATHOLOgICAL gAMBLINg: A gROwINg ADDICTION
Dannon P.
Tel Aviv University, Neer Yaakov, Israel
Gambling is a popular activity of humankind across most cultures and throughout 
history. Gambling disorders affect 0.2–5.3% of adults worldwide. During the last 
decades researchers had found that pathological gamblers (PG) are not a homog-
enous group and some of the patients diagnosed as PG better resemble some other 
categories characteristics: 1-The impulsive subtype is characterized by young adult 
male predominance, high levels of risk taking behavior and lack the ability to plan 
ahead. They tend to lose large sums of money in one sitting and associated with 
attention deficit disorder (ADD), alcohol and other substance abuse and dependence 
and other impulse control disorders. 2-The obsessive- compulsive (OC) subtype, which 
usually prefers slot machines, lottery and scratch tickets, is characterized by female 
predominance which has midlife onset (probably as a response to a perceived psy-
chological trauma) and tend to be associated with higher rate of depression and 
maladaptive coping mechanisms. 3-The addictive subtypeis characterized by betting 
a small amount of gambling at a time in a repetitive and compulsive fashion. In 
this group there is a male predominance and higher rates of alcohol abuse and 
dependence. Various treatment models have been suggested for gambling disorders. 
In general, post-treatment effects were positive for different types of therapy (eg, 
behavioral, and cognitive) and method of therapy However, treatment outcome 
studies that compared GA to CBT have indicated poor outcomes and attendance of 
GA. Treating PG according to its subtype: For the impulsive subtype they suggested 
starting with mood stabilizer. For OC subtype start with SSRI’s, if not effective switch 
to mood stabilizers. For addictive subtype start treatment with bupropion, if not 
effective switch to naltrexone or nalmefen.
DISEASE-SPECIFIC STUDIES
CANCER – Clinical Outcomes Studies
PCN1
TRASTUzUMABE PARA CâNCER DE MAMA COM SUPERExPRESSãO DE HER-2: 
EvIDêNCIA DE EFICáCIA, SEgURANçA E ESTIMATIvA DE CUSTO
Alvares J., Mata A.D., Guerra Junior A.A., Acurcio F.A.
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
ObjetivOs: Trastuzumabe é um anticorpo monoclonal humanizado derivado de 
DNA recombinante, que se liga ao domínio extracelular do receptor do fator de 
crescimento epidérmico humano, HER-2. Esse anticorpo bloqueia o ligante natural 
e infra-regula o receptor. Sua utilização isolada ou em associação com quimioterápi-
cos proporciona desaceleração na progressão do câncer de mama metastático HER-2 
positivo. Este estudo avalia a eficácia, segurança e custo estimado do trastuzumabe 
comparado com outras opções terapêuticas para o tratamento de câncer metas-
tásico com superexpressão HER-2. MétOdOs: Revisões sistemáticas (RS) de ensaios 
clínicos comparando trastuzumabe com outras opções terapêuticas foram pesquisa-
das em The Cochrane Library, Medline, Lilacs, Centre for Reviews and Dissemination 
and Tripdatabase. O custo médio mensal do tratamento foi estimado com base nos 
preços do Banco de Preços em Saúde, do Ministério da Saúde. ResultadOs: Foram 
incluídas nove RS. Todas elas mostraram moderada a alta qualidade de evidência. 
Nas nove RS os principais desfechos avaliados foram sobrevida global, sobrevida 
livre de doença e tempo até a recorrência tardia. Trastuzumabe apresentou melhores 
resultados quando comparado com placebo. Trastuzumabe, em associação com 
taxanos, capecitabina e anastrozol apresentou melhores resultados que os medica-
mentos sem a associação. O risco de desenvolvimento de disfunções cardíacas faz 
com que o uso combinado de antraciclinas com trastuzumabe seja desaconselhado. 
O custo médio mensal do tratamento é de R$34.181,24. cOnclusões: Com base 
na evidência disponível, é recomendado o uso de trastuzumabe no tratamento de 
câncer metastásico com superexpressão HER-2, em associação com paclitaxel ou 
docetaxel. O uso em monoterapia não é indicado.
PCN2
O USO DE TEMOzOLOMIDA NO TRATAMENTO DE ASTROCITOMA DE BAIxO 
gRAU – CâNCER NO CéREBRO
Gomes R.M.1, Ribeiro Júnior N.G.2, Costa J.O.1, Júnior A.A.G.1, Acurcio F.A.1
1Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 2Centro Colaborador do SUS, Belo 
Horizonte, Brazil
ObjectivOs: Avaliar a eficácia e segurança da temozolomida, no tratamento isolado 
ou adjuvante do Astrocitoma de Baixo Grau comparado com outras opções tera-
pêuticas e com a radioterapia – tratamento padrão atual, em resposta às demandas 
judiciais recebidas para o fornecimento deste medicamento para o tratamento do 
Astrocitoma de Baixo Grau no Estado de Minas Gerais, Brasil. MétOdOs: Foram 
pesquisadas as bases The Cochrane Library, Centre for Reviews and Dissemination, 
Medline via Pubmed, LILACS e Clinical Trials. Avaliações de Tecnologias de Saúde 
access to medicines performance. First is the level of health financing. Second is 
a structured and transparent pricing and patient access system that prioritises 
resource allocation to high need diseases and sets economically justifiable or value 
based prices. Third is the development of health care infrastructure. Fourth is the 
provider and pharmacy incentives that promote appropriate use of medicine. And 
finally, a system that protects intellectual property rights.
PHP65
gUIDINg PRINCIPLES FOR EFFECTIvE PRIvATE HEALTH INSURANCE IN 
EMERgINg MARkETS
Shankar R.1, Birkmose J.C.2, Lee S.T.M.1, Colasante W.1
1IMS Consulting Group, Cambridge, UK, 2Novartis, Basel, Switzerland
While emerging market governments are investing more in health care, there is 
still a large gap between demand and supply. The gap can be primary cover in 
some countries; while in others, it can be health care services or costs that are 
not covered publicly. Private health insurance is stepping in to bridge some of 
this gap. We studied private health insurance across major emerging markets in 
Asia, Latin America and Africa to understand current situation and future trends. 
We found that private health insurance is growing across these markets. Its main 
role has been to extend primary cover to certain segments of the population. In 
most cases, these are the relatively affluent or employed segments. However, we 
also see the emergence of community based private health insurance as well as 
public subsidization of private insurance to cover the less well off. However, several 
barriers prevent private insurance from significantly increasing health coverage. 
These are the lack of information to properly assess actuarial risks and make 
proper claims settlements, moral hazard, adverse selection and the non-coverage 
of pre-existing conditions. We then studied specific innovative examples which 
have tried to address some of these barriers. For example, Roche is partnering with 
Swiss Re to provide actuarial expertise to local insurance companies to enable 
affordable premium for cancer medicine coverage in China. India’s Yeshasvini 
community-based health insurance programme provides coverage to rural poor 
through well-speciﬁed procedures for enrollment, treatment and claim settlement 
and monitoring. GSK Brazil increased reimbursement of oncology drugs with some 
health insurance companies through risk-sharing agreements. Learning from such 
cases, we developed specific guiding principles on how private insurance can be 
used to provide increased and effective access to health care in emerging markets. 
These principles can help inform appropriate policy setting on private health 
insurance in emerging markets.
PHP66
THE ECONOMICS OF REPRODUCTION: HOw ‘PRIMACy OF SUCCESSION’ 
HAS INFLUENCED ACCEPTANCE AND PROvISION OF ASSISTED FERTILITy 
TREATMENTS THROUgHOUT HISTORy
Jones C.1, Erten M.Z.1, Sills E.S.2
1University of Vermont - College of Medicine, Burlington, VT, USA, 2Pacific Reproductive Center, 
Irvine, CA, USA
Viewing human history through a medical lens can offer a renewed appreciation for 
today’s vexing reproductive challenges, as some dilemmas encountered in modern 
times are actually continuations of similar economic challenges experienced long 
ago. Succession crises have been an inherent feature of many national systems, 
which can lead to complex rules of inheritance to preserve dynastic patrimony. 
Assuming fertility is unimpaired, this system can work well to maintain market 
stability and intergenerational order. However, on more than one occasion infertil-
ity has disrupted this seamless transition of control; posthumous birth, while less 
common, has also made its own contribution to human culture. The details of an 
individual’s reproductive life are typically impervious to formal study. Yet, archi-
val sources including ancient literature and formal court records do occasionally 
provide evidence of otherwise deeply personal concerns of a different era. This 
survey depicts posthumous birth and infertility as crucial gears in the mechanism 
of economics, demonstrating how each has drawn considerable social interest, occa-
sionally even impacting national security and dynastic succession. This assessment 
describes issues, worries, and desires of patients of antiquity and finds that these 
align closely with contemporary reproductive challenges. Because children and 
family are so central to the human experience, the consequences of reproduction 
(or the lack thereof) make substantial imprints upon the cultural, economic, and 
political landscape—irrespective of civilization or century. This research places 
selected reproductive motifs in a broad historical context to suggest that some 
fundamental tenets in the human condition remain essentially unchanged, despite 
a vast accumulation of knowledge made possible by impressive gains in science 
and technology.
PHP67
A LEI DE ACESSO À INFORMAçãO FORTALECE O PAPEL DA AvALIAçãO DE 
TECNOLOgIAS EM SAúDE (ATS) DE FORNECER INFORMAçõES SóLIDAS E 
TRANSPARENTES AOS USUáRIOS DO SISTEMA úNICO DE SAúDE
Brito G.V., Vidal J.S.
Brazilian Ministry of Health, Brasília, Brazil
ObjetivOs: A Lei de acesso à informação (LAI), lei nº 12.527, de 2011, recentemente 
sancionada no Brasil, tem mudado o cenário jurídico nacional, permitindo uma 
maior participação popular e o controle social das ações governamentais. Essa 
lei regulamenta o direito constitucional de acesso dos cidadãos às informações 
públicas, amplia a participação da sociedade, nas diferentes esferas do governo, e 
permite melhoria na gestão pública. Desde a institucionalização do Sistema Único 
de Saúde (SUS), a participação popular vem sendo um dos pilares da sua organi-
zação. No início, essa participação limitava-se ao envolvimento da sociedade nos 
Conselhos e Conferências de Saúde, conforme a lei nº 8.142, de 1990. Entretanto, 
para garantir o caráter universal e integral imputado ao SUS, é mister que se incor-
pore a participação popular na formulação, fiscalização, execução e manutenção 
de políticas de saúde. Além dos Conselhos e Conferências, o empoderamento 
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Objectives: To evaluate clinical and economic value of ipilimumab in the treat-
ment of advanced melanoma compared with drugs available for the treatment of 
advanced cancer. MethOds: An analysis was performed comparing ipilimumab 
and other drugs for advanced cancer regarding overall survival (OS) and costs 
associated with improvement in survival. Parameters analyzed were: improve-
ment in median/mean OS, improvement on survival rate at 1 year and the number 
needed to treat (NNT) to avoid one death. Monthly costs for improvement in mean 
OS were evaluated. Efficacy data were obtained from clinical trials. Medications 
costs were obtained from official price lists, such as Banco de Dados de Preços 
do Sistema de Saúde do Ministério da Saúde Brasileiro and Lista da Câmara de 
Regulação do Mercado de Medicamentos da Agência Nacional de Vigilância Sanitária 
(CMED). Results: Improvement in median OS ranged from +2.8 (sorafenib) to +4.8 
(transtuzumab), and improvements in mean OS ranged from +1.6 (sorafenib) to +6.1 
(ipilimumab). Only ipilimumab showed better mean OS compared with the median 
OS (6.1 vs. 3.7). This demonstrates the effect of ipilimumab in prolonging OS in long 
term, which is observed in a considerable proportion of patients treated with this 
drug. Major improvement in the survival rate in 1 year occurred with ipilimumab 
(20%). The NNT to prevent 1 death ranged from 7 (ipilimumab) to 61 (bevacizumab 
for lung cancer). Costs per month of mean OS improvement ranged from BRL 34,906 
(sorafenib) to BRL 64,410 (bevacizumab for lung cancer). cOnclusiOns: This com-
parative analysis of drugs used for treatment of advanced cancer used key param-
eters for decision making in health sciences. The results suggest that ipilimumab 
delivers superior clinical and economic benefits when compared with other drugs 
available in Brazil for the treatment of advanced cancer.
CANCER – Cost Studies
PCN6
COMPARINg THE POTENTIAL BUDgET IMPACT OF NOvEL THERAPIES FOR 
ADvANCED MELANOMA IN SECOND-LINE UNDER BRAzILIAN PRIvATE HEALTH 
CARE SySTEM PERSPECTIvE
Tsuchiya C.T., Buschinelli C.T., Tobaruella F.S., Maximo M.F.M., Guzzo M.R., Gonçalves T.M.
Roche Brazil, São Paulo, Brazil
Objectives: Prior to availability of novel agents such as vemurafenib and ipili-
mumab, poor outcomes were associated with advanced melanoma treatment. In 
Brazil, vemurafenib (VEM) is an oral therapy for BRAF-V600E-mutated unresect-
able or metastatic melanoma in all treatment lines meanwhile ipilimumab (IPI) 
is an intravenously administered drug for metastatic melanoma in second-line. 
Whereas IPI is compulsorily reimbursed in private system as labeled, this study 
aims to estimate the potential budget impact of second-line VEM coverage in 
Brazilian Private Healthcare System. MethOds: The study focused in second-line 
setting since IPI has no indication for first-line in Brazil. Based on an epidemio-
logic approach, the potential pool of patients for each drug was estimated. It was 
adopted that private market accounts for 40% oncology patients. BRAF-V600E 
mutation positivity rates of 50% were assumed. Treatment costs were assessed 
evaluating drugs acquisition expenses (considering the ex-factory prices) based 
on labeled posology and when applicable mutation testing costs or infusion fees. 
Mean treatment durations were 6 months (VEM) and 3 months or 4 cycles (IPI). 
Reports were made in Brazilian Reais (BRL1.00~USD0.51 Feb/2013). Results: In 
2013, a potential of 408 advanced melanoma patients in second-line would be 
expected in the private system. Screening all patients and treating those eligi-
ble with VEM (204 patients), would result mean treatment costs per patient of 
BRL110,633 (VEM) and BRL182,852 (IPI). Therefore, system would be charged by 
expenses of BRL59,906,137 instead of BRL74,647,411 in a scenario with no testing 
and all second-line patients treated with IPI. cOnclusiOns: Considering VEM 
availability in private health care system for advanced melanoma in second-line, 
BRL14.7Mio savings could be achieved in 2013. Testing all patients and reimbursing 
VEM seems to be economically advantageous mainly due to lower cost associated 
to VEM and the opportunity of testing patients with BRAF-mutation, identifying 
those who has more chance to respond to the treatment.
PCN7
BUDgET IMPACT ANALySIS FOR THE USE OF vANDETANIB IN MExICAN ADULT 
PATIENT DIAgNOSED wITH ADvANCED UNRESECTABLE MEDULLARy THyROID 
CANCER
Ascencio I.S.I.1, Polanco A.C.1, Ruiz C.2, Pizarro M.3, Soto H.4, Salazar A.2
1AstraZeneca, México, D. F., Mexico, 2Iteliness Consulting, D. F., Mexico, 3Hospital Infantil de 
Mexico Federico Gomez, México D.F., Mexico, 4Health Solutions Consulting, D. F., Mexico
Objectives: Determine the financial impact of including vantedanib in public 
health institutions in Mexico, in the treatment of adult patients with advanced 
or metastatic unresectable medullary thyroid cancer (MTC). MethOds: In order 
to have a greater accuracy of the total population with advanced unresectable 
MTC with social security, we obtained the total population based on the reports in 
Histopathological Registry of Malignant Neoplasms (RHNM), GLOBOCAN and Wells 
2012. All the related care costs were obtained by institutional references and the 
resource use were determined by clinical practice guidances and clinical studies. 
Horizon: 5 years. Comparator: vandetanib and external radiotherapy as palliative 
care, as there are currently no available alternative that has an impact in terms of 
PFS. Discount rate: 5%. The outcome measure was incremental expenditure for the 
use of vandetanib versus external radiotherapy in absolute terms and relative to 
total national health expenditure, in Mexico. Results: The incremental expendi-
ture for the first year was USD$663,558.50 and for the fifth year USD$716,403.10, 
represent 0.0082% and 0.0088% to total national health expenditure respec-
tively. cOnclusiOns: Vandetanib is the only option to patients with advanced 
unresectable MTC, there are no other therapies which can slow the progression of 
advanced disease including radiotherapy and chemotherapy. Because of the low 
prevalence of the disease, the use of vandetanib only represents an average annual 
increase of 0.0086% for total national health expenditure and should be considered 
the optimal choice in this population.
foram pesquisadas em sites de agências nacionais e internacionais. Não houve 
restrição de idiomas na busca das evidências. ResultadOs: Foram incluídas duas 
Revisões Sistemáticas (RS), as quais não compararam o uso da temozolamida com 
outra opção terapêutica e nem com a radioterapia. A primeira RS avaliou a eficácia 
de três diferentes esquemas de administração da temozolomida para tratar Gliomas 
de Baixo Grau entre os quais estão incluídos os Astrocitomas de baixo grau (Grau I 
e II). A segunda RS fez uma análise qualitativa de estudos fase II para criar um guia 
de conduta e prescrição do uso da temozolomida para tratamento dos tumores cer-
ebrais. Os estudos incluídos constituíram um conjunto de evidências classificadas 
como de baixa qualidade. As RS foram consideradas no estudo devido a escassez de 
evidências sobre o tema. Existem quatro ensaios clínicos em desenvolvimento que 
objetivam avaliar o uso de temozolamida isolada ou como adjuvante comparada à 
radioterapia. cOnclusões: Até a presente data não existem evidências disponíveis 
que suportem o uso da temozolomida em Gliomas de Baixo Grau entre os quais 
estão incluídos os Astrocitomas de baixo grau (Grau I e II). Os resultados dos ensaios 
clínicos em andamento serão essenciais para definição da melhor estratégia de 
tratamento para esta condição de saúde.
PCN3
PARECER TéCNICO-CIENTíFICO: EFICáCIA E SEgURANçA DO USO DO 
RITUxIMABE NO TRATAMENTO DE LEUCEMIA LINFOCíTICA CRôNICA
Souza K.M.1, Koury C.D.N.1, Nunes A.A.2
1FIPE -Fundação de Ensino e Pesquisas Econômicas, Brasilia, Brazil, 2University of São Paulo - 
USP, Ribeirão Preto, Brazil
ObjetivOs: Analisar as evidências científicas sobre eficácia e segurança do 
Rituximabe associado à QT convencional com fludarabina + ciclofosfamida 
(RFC) comparado à QT convencional (FC) isolada para o tratamento da Leucemia 
Linfocítica Crônica (LLC). Realizar estimativas de custo de tratamento da LLC com 
FC e FCR em suas indicações terapêuticas por ciclo. MétOdOs: Para a elaboração 
do Parecer Técnico-científico, foram utilizadas as Diretrizes Metodológicas para 
elaboração de PTC do Ministério da Saúde do Brasil. Foi realizada ampla busca 
nas bases de dados Medline (via Pubmed), Embase, Lilacs e CRD que comparassem 
esquemas terapêuticos contendo RFC. A estratégia de busca foi geral e sensível e 
incluiu termos para leucemia linfocítica crônica e rituximabe. Para a estimativa de 
custos, foi considerado o esquema terapêutico com medicamentos oncológicos e 
não oncológicos e o modo de usar para o tratamento do LLC, bem como a apresen-
tação farmacêutica e seu preço obtido de um serviço de onco-hematologia de hos-
pital de ensino público de alta complexidade. ResultadOs: Foram selecionados 
3 estudos e de maneira geral o esquema de tratamento composto pela utilização 
de rituximabe, fludarabina e ciclofosfamida pode melhorar efetivamente a taxa 
de sobrevida global e a remissão completa, além de prolongar a sobrevida livre de 
progressão. Para os desfechos de segurança, o tratamento com RFC apresentou 
maiores eventos adversos comparados à FC. Nas estimativas de custo, verificou-se 
o alto custo para o tratamento com o esquema RFC, chegando aproximadamente a 
R$ 76.155,00 por ano de tratamento em contraste com a QT convencional (FC) de R$ 
30.336,00. cOnclusões: Os estudos selecionados apresentaram baixa qualidade 
metodológica, e os resultados devem ser avaliados com cautela. Além disso, por 
ser uma doença que acomete principalmente pessoas com idade superior a 65 
anos, é necessário avaliar os possíveis impactos causados pela diferença de idade 
e estadiamento da doença.
PCN4
ESTIMACIóN EPIDEMIOLOgICA DEL CáCER DE PULMóN DE CELULAS NO 
PEQUEñAS EN MéxICO
Peniche-Otero G.1, Herrera-Rojas J.1, Gryzbowski E.1, Muciño-Ortega E.2,  
Galindo-Suárez R.M.2
1Customized Premium Products S.A. de C.V., México D.F., Mexico, 2Pfizer S.A. de C.V., Ciudad de 
México, Mexico
ObjectivOs: Estimar la incidencia, prevalencia y mortalidad del cáncer de pulmón 
de células no pequeñas (CPCNP) en México, así como la prevalencia de adenocarci-
nomas y mutaciones EGFR o ALK en este tipo de cáncer. MetOdOlOgías: En base 
a GLOBOCAN 2008 se estimaron la incidencia, prevalencia y mortalidad anual por 
CPCNP en México en 2012. La proporción de casos de CPCNP y de adenocarcinomas 
en CPCNP se extrajo de estudios publicados realizados en México. El porcentaje 
de presentación de metástasis, valoración en la escala del estado funcional de la 
Eastern Cooperative Oncology Group (ECOG) y la presentación de mutaciones EGFR 
o ALK se extrajo de fuentes del Instituto Nacional de Cancerología. ResultadOs: Se 
estimó que la incidencia de CPCNP en 2010 ajustada por sexo fue de 9.28 y de 3.89 
casos por 100,000 habitantes para hombres y mujeres, respectivamente. La inciden-
cia para ambos sexos fue de 6.49 y la incidencia proyectada para 2030 de 11.15. Los 
casos fatales fluctúan entre 7,092 en 2010 a 14,573 en 2030. Los casos prevalentes 
estimados para el 2012 fueron 8,225 y llegan a 15,548 en el 2030. Considerando la 
prevalencia de CPCNP en 2012, los casos esperados del tipo histológico adenocar-
cinoma fueron 4,688, de los cuales 3,985 (85%) presentan ECOG 0 ó 1 (Con síntomas 
que le impiden realizar trabajos arduos, aunque se desempeña normalmente en 
sus actividades cotidianas). El 77% (3,068) presentarían enfermedad metastásica 
y 31% de ellos (951) presentarían una mutación EGFR o ALK. cOnclusiOnes: La 
estimación de la prevalencia de marcadores biológicos EGFR o ALK en pacientes 
con CPCNP del tipo adenocarcinoimoide en México es la base para la estimación 
del impacto presupuestal del uso de terapias blanco en este grupo de pacientes, 
que es un factor a considerar en el diseño de políticas y gestión de programas para 
la atención de estos pacientes.
PCN5
RELATIvE CLINICAL vALUE IN ADvANCED CANCER TREATMENTS
Preto M.C.1, Monteiro R.C.1, Santinho C.S.1, Bernardino G.D.R.1, Donato B.M.K.2, Fanti L.3, Stefani 
S.D.4
1Bristol-Myers Squibb, São Paulo, Brazil, 2Bristol-Myers Squibb Company, Wallingford, CT, USA, 
3Bristol-Myers Squibb, Sao Paulo, Brazil, 4Hospital Mãe de Deus, Porto Alegre, Brazil
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the respective countries were elicited from local experts and clinical guidelines in 
addition to 1L> 2L BEV sequences obtained from the ML18147 trial. Results: When 
1L> 2L BEV replaces sequences which include 1L anti-EGFR regimens, it results in an 
average potential cost reduction of ARS -42,796; $CLP -13,774,258; $COL -8,922,387 
and $MXN-174,606 for Argentina, Chile, Colombia and Mexico respectively. When 
1L> 2L BEV replaces sequences which include 2L anti-EGFR regimens it results in an 
average potential incremental cost of ARS +25,331; $CLP +1,769,387 and $MXN +25,515 
for Argentina, Chile and Mexico. cOnclusiOns: In Argentina, Chile, Colombia and 
Mexico, when 1L> 2L BEV replaces sequences which include 1L anti-EGFR regimens, 
it results in an average potential cost reduction. When 1L> 2L BEV replaces sequences 
which include 2L anti-EGFR regimens, it results in a potential incremental cost which 
allows for the possibility of including a 3L anti-EGFR regimen.
PCN12
COST/BENEFIT ANALySIS OF FIRST LINE CHRONIC LyMPHOCyTIC LEUkEMIA 
(CLL) TREATMENTS IN MExICO
Wehler E.1, Leyva V.2, Bertwistle D.3, Munakata J.4, Valencia A.5, Hernandez A.5,  
de la Torre L.5, Gonzalez L.6
1IMS Health, Alexandria, VA, USA, 2IMS Health, Mexico City, Mexico, 3IMS Health, London, UK, 
4IMS Health, San Francisco, CA, USA, 5Janssen, Mexico City, Mexico, 6Janssen, Raritan, NJ, USA
Objectives: To calculate and compare the costs and costs per PFS and OS for first 
line CLL treatment regimens in Mexico. MethOds: Relevant treatment regimens 
were selected based on KOL input and data availability. Treatment regimen costs 
were calculated using the dose, number of doses per cycle, and number of cycles 
per regimen from published clinical trials. Drug acquisition and administration 
costs were obtained from IMSS. Administration costs were applied once per treat-
ment day, regardless of the number of drugs administered. Progression-free sur-
vival (PFS) and overall survival (OS) benefits for each regimen were calculated by 
applying hazard ratios for PFS and OS from a recent network meta-analysis to the 
median PFS and OS reported for chlorambucil. Cost/ benefit ratios were expressed 
as the regimen cost per month of PFS or OS. Results: Regimens assessed were 
chlorambucil, fludarabine, fludarabine+ cyclophosphamide+ rituximab (FCR) and 
cyclophosphamide+doxorubicin+vincristine+prednisone (CHOP). Costs were esti-
mated in 2012 Mexican pesos. The regimen cost for chlorambucil ($3,101) was 
less than fludarabine, FCR and CHOP ($50,430, $525,481 and $105,246, respec-
tively). Only FCR and CHOP incurred administration costs. The hazard ratios for 
OS and PFS showed FCR was the most effective treatment versus chlorambucil 
(0.24 and 0.73, respectively). The cost/PFS benefit ratio was most favorable for 
chlorambucil ($352/month) versus fludarabine, FCR and CHOP ($4,757, $14,318 
and $18,145, respectively). Chlorambucil also had the lowest cost/OS benefit ratio 
($39/month) versus fludarabine, FCR and CHOP ($639, $4,865 and $1,441, respec-
tively). cOnclusiOns: Chlorambucil was the least costly of the Mexican CLL 
treatment regimens assessed in absolute terms and per benefit. However, there 
is a need for a CLL treatment that provides greater efficacy in terms of PFS and 
OS than chlorambucil, but costs less than FCR. Future studies should focus on the 
incremental cost-effectiveness of new regimens for this indication.
PCN13
THE AFFORDABILITy OF ONCOLOgy AND HIv/AIDS TECHNOLOgIES IN BRAzIL 
COMPARED TO THE UNITED STATES AND OTHER OECD COUNTRIES
Zueger P.1, Becker R.2
1University of Illinois at Chicago, Chicago, IL, USA, 2Russell Becker Consulting, Chicago, IL, USA
Objectives: Brazil’s universal access to health care program has been deemed 
successful by several different measures. However, given limited health care budg-
ets, the affordability of newer, increasingly expensive technologies can become a 
major access barrier. This study compares the affordability of current HIV/AIDS 
and oncology technologies in Brazil to those in the U.S. and other Organization for 
Economic Cooperation and Development (OECD) countries. MethOds: Per patient 
treatment costs for HIV/AIDS and oncology technologies in Brazil, the U.S. and other 
OECD countries were obtained from published studies and datasets. Non-Brazilian 
studies were chosen for their comparability to the Brazilian counterpart studies in 
terms of patient populations, disease characteristics, treatments, and economic 
perspective. Costs compared included drugs, procedures, administrative costs, and 
total cost of treatment. All costs were converted to 2011 U.S. dollars. The two afford-
ability measures utilized included: 1) Cost per gross domestic product (GDP) per 
capita, and 2) cost per health care spending (HCS) per capita. These measures were 
compared between Brazil and other OECD countries to estimate the relative afford-
ability of HIV/AIDS and oncology technologies. Results: A majority of technologies 
assessed were less affordable in Brazil compared to comparator OECD countries 
by both affordability measures. Under the GDP measure, oncology technologies in 
Brazil consumed approximately 2 to 20 times the amount of available resources 
compared to OECD countries. Using the HCS measure, health care resource con-
sumption in oncology was 4 to over 40 times that of OECD countries. Differences in 
relative affordability of HIV/AIDS technologies were generally smaller, with resource 
consumption in each country generally varying by less than 3 times that of the 
comparator country using each affordability measure. cOnclusiOns: Although 
oncology and HIV/AIDS technology access in Brazil has increased in recent years, 
these treatments may be relatively less affordable compared to other developed 
countries given Brazil’s current resource and budget constraints.
PCN14
DIRECT MEDICAL COSTS (DMC) OF TREATINg CHRONIC LyMPHOID LEUkEMIA 
(CLL) PATIENTS IN THE PRIvATE HEALTH CARE SySTEM IN BRAzIL: RESULTS 
FROM A 12-MONTH RETROSPECTIvE ANALySIS OF AN ADMINISTRATIvE 
DATABASE
Paloni E.D.M.P.1, Ferreira C.N.1, Asano E.2, Santana C.F.S.D.3, Pereira M.L.4
1ORIZON - Companhia Brasileira de Gestão de Serviços, Sao Paulo, Brazil, 2Janssen-Cilag 
Farmaceutica, Sao Paulo, Brazil, 3Orizon, Sao Paulo, Brazil, 4Janssen Cilag Farmaceutica, São 
Paulo, Brazil
PCN8
COSTO E IMPACTO PRESUPUESTAL DEL TRATAMIENTO DEL CáNCER DE 
PúLMON DE CELULAS NO PEQUEñAS DEL TIPO ADENOCARCINOMA CON 
gRADO ECOg 0,1,2 EN ESTADIO Iv CON MUTACIóN + (EgFR O ALk) CON 
TERAPIAS BLANCO EN MéxICO
Peniche-Otero G.1, Herrera-Rojas J.1, Gryzbowski E.1, Muciño-Ortega E.2,  
Galindo-Suárez R.M.2
1Customized Premium Products S.A. de C.V., México D.F., Mexico, 2Pfizer S.A. de C.V., Ciudad de 
México, Mexico
ObjectivOs: El impacto económico que tendría en México la incorporación gradual 
de pacientes con cáncer de pulmón de células no pequeñas en estadio IV (tipo 
adenocarcinoma), con mutación EGFR y ALK (CPCNP+), a esquemas basados en tera-
pias blanco no se ha estimado. Este estudio estuvo enfocado a estimar este impacto 
desde la perspectiva del Sector Salud. MetOdOlOgías: Con datos de GLOBOCAN 
2008 se estimó la prevalencia 2012 de pacientes CPCNP+ en México. Un panel de 
expertos (n= 20, 2 centros de alta especialidad) determinó el perfil de uso de recur-
sos para atender a estos pacientes: hospitalización, medicamentos, consulta con 
especialista, administración del medicamento, pruebas de laboratorio y gabinete, 
tamizaje EGFR y/o ALK. Los costos se estimaron mediante metodología bottom-up 
en el Instituto Nacional de Cancerología y se expresan en US$ de 2012. Se realizó 
análisis de impacto presupuestal en base al Presupuesto de Egresos de la Federación 
(PEF) 2012. ResultadOs: Se estimó que en 2012 había 3,068 pacientes candidatos a 
ser sometidos a tamizaje para EGFR y/o ALK, de los cuales 951 (31%) serían positivos 
(candidatos a tratamiento con terapias blanco). El costo esperado anual por paciente 
tratado con terapias blanco fue US$283,180 mientras que el costo correspondiente 
a pacientes que reciben quimioterapia convencional fue US$247,338. Suponiendo 
que el 6% (61) de los pacientes CPCNP+ fueran atendidos con terapias blanco y el 
resto (890) con quimioterapia convencional, el impacto presupuestal hubiera sido 
de 0.1% y 0.65% del PEF 2012, respectivamente. cOnclusiOnes: La prevalencia 
de pacientes CPCNP+ en México es de aproximadamente 8.5/100,000 habitantes. 
La diferencia en el costo esperado de tratamiento entre quimioterapia y terapias 
blanco es de alrededor de 15%. La introducción gradual de terapias blanco por las 
instituciones del Sector Salud es una estrategia que permitiría planificar el impacto 
presupuestal de esta adopción en base a la disponibilidad de recursos.
PCN10
ANáLISE DAS POTENCIALIDADES DE CUSTO-MINIMIzAçãO ATRAvéS DA 
DETERMINAçãO DO MARkET SHARE ENTRE OS QUIMIOTERáPICOS DE 
REFERêNCIA QUE POSSUEM gENéRICOS CADASTRADOS EM UMA OPERADORA 
DE PLANO DE SAúDE
Reis H.P.L.C., Vieira J.B., Magalhães D.D.P., Sartori D.P., Fonseca D.B., Barsi U.D., Filho A.E.A.M., 
Alencar J.L.L., Maciel J.A.P., Viana A.D.J.R., Souza M.I.P.
Unimed Fortaleza, Fortaleza, Brazil
ObjetivOs: Identificar as potencialidades de custo-minimização através da deter-
minação do market shareentre os quimioterápicos de Referência que possuem 
Genéricos cadastrados em uma operadora de Plano de Saúde em Fortaleza, Ceará - 
Brazil. MétOdOs: Estudo de minimização de custos em uma amostragem de medica-
mentos pertencentes à classe dos quimioterápicos (n= 175 códigos). A fonte de dados foi 
a Tabela de Medicamentos padronizados na operadora e utilizados em 2012. Incluiu-se 
na amostra os custos com antineoplásicos pertecentes a classe A (Alto Custo - Curva 
ABC). Foram excluídos os medicamentos utilizados como suporte e hormonioterapia. 
Em seguida, fez-se a classificação das categorias, segundo Agência Nacional de Vigilância 
Sanitária (ANVISA) quanto a Referência, Genérico e Similar. Considerou-se a perspec-
tiva da Operadora de Saúde. ResultadOs: O câncer mais prevalente foi o de Mama 
(n= 203; 31,28%) seguido de Brônquios e Pulmões (n= 55; 8,47%). Quanto ao sexo observou 
maior prevalência em mulheres (n= 442; 68,10%). O custo total com quimioterápicos em 
2012 foi R$ 28.918.397,51, no qual 71,14% (R$ 20.571.337,18) foram com medicamento de 
Referência, seguido de 0,91% (R$ 261.787,42) com Genérico e 0,77% (R$ 222.507,38) Similar. 
Detectou-se que 27,19% (R$ 7.862.765,53) dos com quimioterápicos de Referência tem 
potencialidades de uso de genérico (Docetaxel, Doxorrubicina, Gencitabina, Irinotecano, 
Oxaliplatina, Paclitaxel,). Quanto ao impacto financeiro haveria uma redução 
nos custos por volta de 24,94% (R$ 1.960.973,72), se utilizássemos somente o 
genérico nessas potencialidades de uso, representando o melhor cenário.  
cOnclusões: O mercado de genéricos é hoje uma realidade no país, tendo criado um 
segmento importante no mercado de medicamentos e seu incremento na quimioterapia 
traria economias substanciais nas diferentes instituições de saúde, como as operadoras.
PCN11
ECONOMIC IMPACT OF INCLUDINg SEQUENTIAL BEvACIzUMAB FOR THE 
TREATMENT OF PATIENTS wITH kIRSTEN RAS wILD TyPE UNRESECTABLE 
METASTATIC COLORECTAL CANCER IN FOUR LATIN AMERICAN COUNTRIES
Rautenberg T.1, Tournier C.2, Ngoh C.A.2, Arnaiz F.3, Carrizo M.3, Lewi D.4, Garcia A.5, Mitre N.5, 
Painemal C.6, Parada L.7, Bárbosa D.7, Rosselli D.8, Alva M.9, Torrecillas L.10
1Assessment In Medicine AiM GmbH, Lörrach, Germany, 2F. Hoffmann-La Roche, Basel, 
Switzerland, 3F. Hoffmann-La Roche, Tigre, Argentina, 4Hospital Fernandez, Tigre, Argentina, 
5F. Hoffmann-La Roche, Santiago, Chile, 6Centro Oncológico Integral de Santiago (ONCOISA), 
Santiago, Chile, 7F. Hoffmann-La Roche, Bogotá D.C, Colombia, 8Pontificia Universidad Javeriana, 
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Objectives: To evaluate and compare the economic impact in terms of drug and 
administration cost of first to second line (1L> 2L) sequential bevacizumab (BEV) to 
other sequences of biologics in the treatment of patients with Kirsten Ras wild type 
(KRAS WT) unresectable metastatic colorectal cancer (mCRC) in four Latin American 
countries. MethOds: A previously developed Treatment Sequencing Costing tool 
was adapted for Argentina, Chile, Colombia and Mexico. A private payer perspective 
was adopted for Argentina and Chile and a public payer perspective for Colombia 
and Mexico. Locally sourced drug acquisition and administration costs were included 
in the analysis. Cost of sequences was calculated based on proxy treatment dura-
tions of 6.1 months (1L), 4.0 months (2L) and 2.7 months (3L). Sequences analyzed for 
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COST-EFFECTIvENESS ANALySIS OF INCORPORATION OF THE HPv vACCINE TO 
THE NATIONAL IMMUNIzATION PROgRAM / NIP OF BRAzIL
Novaes H.M.D.1, azevedo e Silva G.2, Ayres A.2, Itria A.3, Rama C.4, Sartori A.M.C.5,  
De Soarez P.C.1, Clark A.6, Resch S.7
1University of Sao Paulo, Sao Paulo, Brazil, 2Universidade Estadual do Rio de Janeiro, Rio de 
Janeiro, Brazil, 3Departamento de Saúde Coletiva do Instituto de Patologia Tropical e Saúde 
Pública, Universidade Federal de Goiás. Pesquisador do Instituto de Avaliação de Tecnologia em 
Saúde (IATS), Goiânia - Goiás, Brazil, 4Secretaria do Estado de Saúde de São Paulo, São Paulo, 
AL, Brazil, 5University of Sao Paulo, Sao Paulo, SP, Brazil, 6London School of Hygiene and Tropical 
Medicine, London, UK, 7Harvard University, Boston, MA, USA
Objectives: To estimate cost-effectiveness of adding human papillomavirus (HPV) 
vaccine to Brazil National Immunization Program, compared with the current strat-
egy for control of cervical cancer, the screening program based on conventional 
Papanicolaou citology. MethOds: We used a static decision tree analysis model, 
CERVIVAC, software developed by PAHO ProVac Initiative. The model compared two 
strategies: 1) a cohort of girls aged 10 years to represent the epidemiological situation, 
current screening, and care of precursor lesions and cancer (without vaccination) with 
2) a cohort of girls aged 10 years who were applied 3 doses of HPV vaccine, maintain-
ing the conditions of screening and care of precursor lesions and cancer, as they are 
currently. National parameters for the epidemiology of cervical cancer, screening 
expenditures and National Cervical Cancer Control Program were estimated in depth. 
The estimates were based on the health information systems of the Public Health 
System, SUS (SIH, SIA, APAC, SIAB, SIGTAP and SISCOLO), national survey (PNAD 2008) 
and relevant national literature. Results: The vaccine introduction would reduce the 
burden of disease. The model estimated 261 deaths avoided and 7595 DALYs averted, 
in each successive cohort to be vaccinated. The ICER per DALY averted R$ 18,121 would 
be considered cost-effective, according to the parameters adopted by WHO. In univari-
ate sensitivity analysis, only a lower discount rate and a high incidence and mortality 
would make the introduction of the vaccine very cost-effective. cOnclusiOns: The 
vaccine introduction should bring benefits for the control of cervical cancer, but it will 
require large investments by the NIP. It should be guaranteed the right conditions for 
the immunization program sustainability and equity in a population perspective as 
well as to improve the screening program.
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ANáLISIS COSTO-EFECTIvIDAD DE EvEROLIMUS MáS ExEMESTANO 
PARA PACIENTES CON CáNCER DE MAMA AvANzADO CON RECEPTORES 
HORMONALES POSITIvOS (RE+), HER2–, QUE FALLARON A LOS INHIBIDORES DE 
AROMATASA NO ESTEROIDEOS (IANES) EN MéxICO
Zhang J.1, Pramanik A.2, Fuentes-Alburo A.3, Anaya P.4, Tinajero-Ayala B.5, Zhou Z.Y.6, Xie J.7, 
Signorovitch J.6, Fan L.6
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ObjectivOs: Evaluar el perfil costo efectividad de everolimus en combinación 
con exemestano en pacientes con cáncer de mama avanzado, RE+, HER2–, que 
fallaron a los IANES. MetOdOlOgías: Se desarrolló un modelo de Markov con 
ciclos mensuales y un horizonte temporal de diez años. El modelo compara a) 
exemestano+everolimus seguido por tres líneas de quimioterapia y mejor tera-
pia de soporte (MTS) con b) tres líneas de quimioterapia más MTS. Se incluyó la 
probabilidad de muerte desde cualquier tratamiento. La secuencia de quimiotera-
pia se definió a través de un panel de expertos. Las probabilidades de transición 
para everolimus+exemestano se obtuvieron del estudio BOLERO-2. Se realizó una 
revisión de la literatura para las probabilidades de transición de las quimioterapias. 
Se incluyeron los costos de los medicamentos y de su administración, los costos 
asociados con eventos adversos, monitoreo y de la MTS. Los resultados se presentan 
en $MXN de 2012 desde una perspectiva del Sistema Público de Salud mexicano. 
Se aplicó una tasa de descuento del 5% para costos y efectividades. Se realizaron 
análisis de sensibilidad probabilístico (ASP) con mil repeticiones y diferentes análisis 
de sensibilidad univariados, incluyendo un análisis con horizonte temporal de por 
vida. ResultadOs: El modelo mostró que everolimus+exemestano resulta en 1.32 
años de vida ganados con un costo incremental de $314,327 dando como resultado 
una razón de costo efectividad incremental (RCEI) de $237,902. El ASP mostró que 
la RCEI está dentro del rango recomendado por la OMS (1 a 3 PIBs per capita) en 
la mayoría de los casos. La RCEI con un horizonte temporal de por vida fue de 
$209,292. cOnclusiOnes: El presente análisis mostró que utilizar everolimus más 
exemestano en pacientes con cáncer de mama avanzado, RE+, HER2–, que fallaron a 
los IANES es una opción costo efectiva de acuerdo a las recomendaciones de la OMS.
PCN19
ANáLISIS DE COSTO-EFECTIvIDAD DE ERLOTINIB EN EL TRATAMIENTO DE 
PACIENTES CON CáNCER PULMONAR DE CéLULAS NO PEQUEñAS, CPCNP, CON 
MUTACIóN DEL gEN EgFR+, EN COLOMBIA
parada Vargas L.A., Barbosa D.A.
Roche Colombia, Bogotá D.C, Colombia
ObjectivOs: Evaluar la costo-efectividad de Erlotinib como tratamiento en primera 
línea (1L) de pacientes con cáncer pulmonar de células no pequeñas, CPCNP estadio 
IIIB/IV, con mutación del gen EGFR+, en comparación con la quimioterapia estándar 
(carboplatino/ Paclitaxel) y con Getinib, desde la perspectiva del Sistema de Salud 
Colombiano. MetOdOlOgías: Se empleó un Modelo de Markov que simula el curso 
del CPCNP, con ciclos mensuales. Los estados de salud considerandos en el modelo 
son: Libre de progresión de enfermedad (LPE), Libre de progresión de enfermedad 
con respuesta (LPER), Progresión de enfermedad (PE); y Muerte. Se consideran cos-
tos directos y eventos adversos en pesos colombianos, años de vida ganados libres 
de enfermedad (AVGLE), para Erlotinib y Gefitinib comparados con quimioterapia 
estándar. Las probabilidades de transición se tomaron de la literatura, los costos se 
obtuvieron a partir de consenso de expertos según la práctica habitual, los costos de 
Objectives: To determine 1-year direct medical costs of treating patients with 
Chronic Lymphoid Leukemia (CLL) from the Brazilian Private Healthcare System 
perspective. MethOds: The Orizon database, an administrative database contain-
ing inpatient and outpatient claims to a pool of 102 HMOs representing 34% of the 
total Private Health System, was reviewed from Jan/2009 to Dec/2012. Eligibility 
criteria were patients starting CLL (ICD-10 code C911) treatment from Apr/2009 to 
Dec/2011. Outcome was direct medical costs (DMC) per patient-year, calculated 
as the sum of the medical claims for each patient included in the analysis, for a 
maximum period of 12-months or death or loss of follow-up, whichever comes 
first. DMC was categorized in chemotherapy, hospitalizations, and other outpa-
tient costs. Further analysis was conducted for chemotherapy and hospitaliza-
tions. Results: From 735 patients with CLL identified in the database, 164 met 
eligibility criteria and were included in the analysis, representing a total of 100 
patients-years. Total DMC in this population was R$ 16,555,421 (mean cost of R$ 
165,827 per patient-year), from which R$ 9,451,124 (57%) are related to chemo-
therapy, R$ 5,341,862 (32%) to hospitalizations and R$ 1,762,434 (11%) to other 
outpatient costs. Outpatient laboratory exams accounted for only a small fraction 
(R$ 176,545, 1%) of DMC, and only one patient had a record of radiotherapy (< 1% 
of DMC). A total of 326 hospitalizations were identified in 79 (48%) patients, with 
an average cost of R$ 16,386 ± 29,185 per hospitalization. Chemotherapy drugs 
accounted for 71% of the total costs with chemotherapy, the rest divided between 
other drugs (12%), disposable devices (6%), hospital facility fees (5%) and other 
costs (6%). cOnclusiOns: Patients with CLL represent a significant economic 
burden to private payers. Chemotherapy and hospitalization costs accounts for 
almost 90% of the total costs.
PCN15
COSTS OF HORMONAL RECEPTOR POSITIvE, HER 2 NEgATIvE METASTATIC 
BREAST CANCER (MBC-HR+) IN BRAzILIAN PRIvATE SySTEM (BPS): A REAL 
wORLD AND PUBLISHED LITERATURE ANALySIS
Clark O.A.C.1, Paladini L.1, Engel T.1, Nishikawa A.M.1, Borges L.1, Caldas A.2, Valentim J.2
1Evidencias, Campinas, Brazil, 2Novartis Biociências SA, São Paulo, Brazil
Objectives: Recently, MBC-HR+ was found to have a diverse pattern of response to 
the treatment compared to other MBC. Our aim is to determine the costs of treat-
ment associated with this disease, from the perspective of BPS. MethOds: A large 
private database of medical claims for chemotherapy (Ch) (Evidencias Database) 
was searched in order to identify MBC-HR+, that were treated in the last two years 
(2011-12). We extracted data regarding treatment received, length of the treatment 
and antropometric data for each MBC-HR+ patient. After, medical literature was 
performed for studies of MBC-HR+ treatments and the same data was extracted. 
Based on the combination of real-world (RW) and published data we constructed 
a decision tree, considering three groups of MBC-HR+, according to the sites of 
metastasis: bone exclusive (B), Visceral exclusive (V) and bone plus visceral (BV). 
For each group, we calculated the costs of the treatment plus adverse events, by a 
micro-costing approach. We simulated a cohort of 100 patients with MBC-HR+ in a 
decision tree, to obtain the costs for each group and a mean cost/ patient. Results: 
RW data showed the following distribution of patients: B 38%, V 42% BV 20%. Lengths 
of treatment (in months) were B: 25.1 to 30.5; V 16.1; BV 14 to 19.6. Most com-
monly used treatments were, B – two hormonal lines, fulvestrant and three lines of 
Ch. V – Four lines of Ch; BV- one hormonal line, fulvestrant, three lines of Ch. Most 
used Ch drugs were docetaxel, paclitaxel and gemcitabine. Mean costs/patient/
group, considering hormones, Ch, bisphosphonates, hospitalization, infusion, evalu-
ations of the disease, radiation therapy and adverse events were: B- R$ 135,744 (US$ 
67,872); V R$ 129,079 (US$64,539) and BV R$ 117,172 (US$58,568). cOnclusiOns: 
MBC-HR+ is associated to a high cost of treatment under the BPS perspective.
PCN16
COST-EFFECTIvENESS OF PAzOPANIB AS FIRST LINE TREATMENT FOR 
METASTATIC RENAL CELL CARCINOMA IN BRAzIL: UPDATED ANALySIS
Pepe C.1, Sedlmayer C.2, Machado M.2
1MedInsight, São Paulo, São Paulo, Brazil, 2GlaxoSmithKline Brazil, Rio de Janeiro, Brazil
Objectives: Targeted therapies shows marked clinical improvements over standard 
treatments such as interferon alfa (IFNa) in the treatment of advanced/metastatic 
renal cell carcinoma (mRCC). We report an updated cost-effectiveness analysis of 
pazopanib, sunitinib, and bevacizumab (the later associated INFa) as first line treat-
ments for mRCC under the Brazilian public health care perspective. In previous 
analysis, taxation was accounted exclusively for pazopanib’s price.[Value Health 
2012;15(4):A218] The present analysis applied ex-factory 0% tax prices, where now 
all comparisons were made under tax waiver programs. MethOds: A Markov model 
was designed to simulate mRCC progression, mortality and costs. The assessed 
time-horizon was 2 years. An indirect comparison estimated the relative efficacy 
and safety of the targeted therapies in mRCC patients. Costs and consequences of 
disease treatment were computed for each comparator. Only direct medical costs 
were considered and reported in 2013 Brazilian currency (1BRL= 0.50USD). Drug 
prices derived from official price list (i.e., CMED). Disease management costs were 
those from a public reimbursement database (i.e., SIGTAP). Costs and outcomes 
were discounted at 5% yearly. Outcomes assessed were progression-free survival 
(PFS) and quality-adjusted life years (QALYs). Stochastic simulations tested model 
robustness. Results: The indirect PFS hazard ratio (< 1 favours pazopanib [95%CI]) 
indicated that pazopanib is not statistically different from sunitinib (0.93 [0.56, 
1.56]) or bevacizumab+IFNa (0.79 [0.48, 1.32]). A recent head-to-head clinical study 
(COMPARZ) of pazopanib versus sunitinib confirmed indirect results. Estimated 
costs and QALYs were BRL 93,389.88 and 0.90 for pazopanib, BRL 124,923.36 and 
0.93 for sunitinib, and BRL 185,942.43 and 0.88 for bevacizumab+INFa. Propabilistic 
analysis showed favourable economic results to pazopanib in > 90% of simula-
tions when compared to sunitinib. Bevacizumab+INFa was dominated in all sce-
narios. cOnclusiOns: Pazopanib reported significantly lower costs and similar 
benefits against studied comparators as first line treatment of patients diagnosed 
with mRCC under the Brazilian public health care perspective.
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Objectives: UHC is the largest hospital in Crete and among the 5 largest hospi-
tals in Greece. With the implementation of the memorandum, all operators were 
asked to reduce their costs, while special emphasis was placed on decreasing 
health care costs. In 2012, in this context, UHC made various attempts to diminish 
its budget. MethOds: Two events happened in 2012: 1) Pharmaceutical companies 
were asked to offer discounts for their products’ price; 2) A central unit for the cyto-
statics drugs’ dilution for all oncologic therapies was founded. Good management 
and economy of scale succeeded in quantity saving of drugs that were re-entered in 
pharmacy’s stock. Results: The effect of these combined actions was examined in 
achieving the goal of reducing the pharmaceutical expenditure. In order for the data 
to be comparable, only the drugs used in the CU were studied. Specifically, there are 
113 medications (62 prototypes, 31 generics and 20 orphan drugs), which derived from 
23 companies. In 2012, 100.000 units were consumed in hospital that worth 10 M€ . 
The combined results were impressive as a budget reduction of 21.4% was achieved 
(15.4% due to discounts and 6% due to the CU). As per the discounts, 82% of cytostat-
ics’ value represents prototypes and expensive drugs, which were limited to the legal 
rebate of 5% discount, while 17% is mostly generics whose discounts varied from 29.5 
to 92.9%. Thus, 73.4% of the value benefit was due to generic and 26.6% due to the 
prototype drugs. As for the CU’s savings, 6000 pieces were returned to the pharmacy. 
A total of 91.7% of the value benefit derived from the prototypes and the remaining 
8.3% from the generic and orphan drugs. cOnclusiOns: Taking into consideration 
that cytostatic drugs’ cost equals 1/3 of the total pharmaceutical expenditure, even 
if only these two events were taking place, a 7.1% budget decrease was achieved.
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EvALUACIóN ECONóMICA DEL USO DE LA PERFUSIóN AISLADA DE 
ExTREMIDAD CON TASONERMIA EN PACIENTES CON SARCOMA DE TEjIDO 
BLANDO IRRESECABLE
Gay J.G.1, Jones K.1, Valencia C.2, Garcia D.2
1TI SALUD, MEXICO, Mexico, 2BOEHRINGER INGELHEIM, MEXICO, Mexico
ObjectivOs: Identificar la relación costo-utilidad de la perfusión aislada de 
extremidad (PAE) con tasonermina (factor de necrosis tumoral 1a (FNTα -1a) y 
quimioterapia, en comparación con amputación, para el control del sarcoma de 
tejidos blandos irresecable en extremidad con la perspectiva de salvamento de la 
extremidad. MetOdOlOgías: El análisis se enfocó en la calidad de vida ganada 
gracias al salvamento de la extremidad en comparación con amputación, en el 
tratamiento del sarcoma de tejidos blandos irresecables. Se desarrolló un modelo 
Markov de cinco años, comparando cinco posibles resultados para PAE con dos 
estados de amputación. Los estados de salud para PAE (pierna y brazo) incluyeron: 
éxito del procedimiento; éxito con pérdida de movilidad y muerte. Las utilidades 
para la población mexicana fueron obtenidas utilizando el método TTO y esta-
dos de salud EQ-5D. Además, utilizando información de distintas dependencias 
públicas, el modelo consideró costos médicos directos y el costo de las compli-
caciones asociadas con el tratamiento. Posteriormente, se realizó un análisis de 
sensibilidad univariado sobre los costos directos, el costo de las complicaciones 
y las tasas de descuento. ResultadOs: Durante el período de análisis, el tratam-
iento más efectivo fue la PAE con tasonermia y quimioterapia, obteniendo una 
ganancia de 2.88 AVACs, en comparación con los 1.39 obtenidos para amputación. 
Además, la RCEI de PAE utilizando tasonermia ascendió a $123,357.78 pesos mexi-
canos. cOnclusiOnes: La PAE utilizando tasonermia en pacientes con sarcoma 
de tejidos blandos irresecable es considerada una alternativa costo-efectiva en el 
contexto mexicano, ya que la RCEI fue inferior a un PIB per cápita. Adicionalmente, 
el impacto positivo que tiene el procedimiento sobre la calidad de vida de los 
pacientes, sin comprometer su esperanza de vida, convierte a tasonermia en una 
opción atractiva para un grupo de pacientes que carecen de opciones de tratamiento.
PCN24
COSTO-UTILIDAD DE INTERvENCIONES PREvENTIvAS CONTRA EL CáNCER DE 
CUELLO UTERINO EN MUjERES PERUANAS
Gutiérrez-Aguado A.
Ministerio de Economía y Finanzas, LIMA, Peru
ObjectivOs: Estimar el costo-utilidad de la vacuna bivalente y tetravalente contra el 
Virus de Papiloma Humano en las mujeres peruanas de 10 años de edad comparando 
el tamizaje de Papanicolau y el no vacunar. MetOdOlOgías: Se realizó una eval-
uación económica de tipo costo-utilidad estructurado sobre un modelo matemático 
de Markov. La población de estudio fue una cohorte hipotética de niñas de 10 años 
de edad para la vacunación y para el caso del tamizaje de Papanicolau, se consideró 
a la población de 30-49 años. Los costos de la vacunación se estimaron desde la 
perspectiva del financiador, con base en estos costos y los años de vida ajustados 
por calidad (QALY) como medidas de resultado de cada una de las intervenciones 
evaluadas, se calcularon las razones costo-utilidad incremental y análisis de sensi-
bilidad utilizando una tasa de descuento del 3%. ResultadOs: El costo anual de la 
vacunación bivalente fue de USD 9’014,006.05, para el tamizaje con Papanicolau fue 
de USD 3’048,448.82 y el costo del CCU fue de USD 16’270,359.3. La Razón incremental 
de costo efectividad (ICER) para la vacunación bivalente fue de 3377 USD/QALY, para el 
tamizaje de Papanicolau fue de 6,554 USD/QALY, para la vacunación tetravalente fue 
de 19,274 USD/QALY y para el no vacunar fue de 30,904 USD/QALY. cOnclusiOnes: 
La vacunación bivalente contra el VPH resultar ser costo-efectiva, en comparación 
con la vacuna tetravalente y el tamizaje de Papanicolau, sin embargo los resultados 
no fueron robustos al incorporar la incertidumbre existente.
CANCER – Health Care Use & Policy Studies
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TRATAMENTO DO CâNCER COLORRETAL METASTáTICO COM BEvACIzUMABE 
E CETUxIMABE: ACESSO E IMPACTO ECONôMICO EM UM HOSPITAL 
UNIvERSITáRIO
Ungari A.Q., Pereira L.R.L., Nunes A.A., Peria F.M.
University of São Paulo - USP, Ribeirão Preto, Brazil
los medicamentos se tomaron de las bases oficiales (SISMED y Circular 04 de 2012). 
Se empleó una tasa de descuento de 3% para costos y beneficios. ResultadOs: El 
costo total para los 60 ciclos de la terapia con Erlotinib fue de $153 millones por 1.55 
AVGLE; frente a la quimioterapia estándar con $122 millones por 1.28 AVGLE; y para 
la terapia con Gefitinib de $158 millones para 1.43 AVGLE. La razón de costo efectivi-
dad incremental de Erlotinib empleado en 1L es de $112 millones por 0,27 AVGLE, con 
respecto al esquema estándar de quimioterapia. La razón de costo efectividad incre-
mental de Gefitinib es de $245 millones para alcanzar 0.14 AVGLE. cOnclusiOnes: 
Erlotinib mantiene el costo por beneficio ganado de la terapia estándar que ya esta 
siendo reembolsada por el Sistema de Salud Colombiano; en ese sentido, se puede 
considerar una terapia eficiente.
PCN20
ANáLISIS DE COSTO-EFECTIvIDAD DE BEvACIzUMAB PARA EL TRATAMIENTO 
DE PRIMERA LíNEA EN PACIENTES CON CáNCER COLORRECTAL METASTáSICO, 
CCRM EN COLOMBIA
parada Vargas L.A., Barbosa D.A.
Roche Colombia, Bogotá D.C, Colombia
ObjectivOs: Realizar un análisis de costo-efectividad (ACE) sobre el uso de 
Bevacizumab vs anticuerpos anti-receptor de factor de crecimiento epidérmico 
(EGFRI), utilizados con esquemas de FOLFIRI o FOLFOX/XELOX en el tratamiento de 
primera línea de los pacientes con CCRm con presencia de KRAS silvestre (WT) en 
Colombia, según la perspectiva del Sistema de Salud Colombiano. MetOdOlOgías: 
Se empleó un Modelo de Markov, con ciclos mensuales, para estimar costos 
Supervivencia Libre de Progresión (SLP) en función del estado KRAS, a partir 
del costo por éxito clínico (Número Necesario a Tratar, NNT, para mantener un 
paciente libre de progresión a 12 meses). Se incluyeron costos directos y even-
tos adversos en pesos colombianos, para: FOLFIRI+Bevacizumab; FOLFIRI+Anti 
EGFR; FOLFOX/XELOX+Bevacizumab; FOLFOX/XELOX+EGFR. Las probabilidades de 
transición se tomaron de la literatura, los costos se obtuvieron a partir de con-
senso de expertos según la práctica habitual, los costos de los medicamentos se 
tomaron de las bases oficiales (SISMED y Circular 04 de 2012). No se empleó tasa 
de descuento por ser un análisis hasta un año. ResultadOs: 1.Costos FOLFOX WT 
($COP): Folfox (10.446.152), Folfox+Anti EGFR (90.221.332), Folfox+Bevacizumab 
(28.238.377). 2. Costos FOLFIRI WT ($COP): Folfiri (16.968.778), Folfiri+Anti EGFR 
(104.049.002), Folfiri+Bevacizumab (45.235.174), Xelox+Anti EGFR (94.513.398), 
Xelox+Bevacizumab (45.488.519). 3. SLP meses WT: Folfox (7.2), Folfox+Anti EGFR 
(7.7), Folfox+Bevacizumab (11.5), Xelox+Bevacizumab (10.6); Folfiri (8.7), Folfiri+Anti 
EGFR (9.9), Folfiri+Bevacizumab (11.5). 5. La Razón de Costo Efectividad Incremental 
mostró que el uso de Bevacizumab + (FOLFOX/XELOX) y FOLFIRI es una terapia 
dominante. cOnclusiOnes: El uso de FOLFIRI/FOLFOX+Bevacizumab resulta ser 
la opción más costo-efectiva para una disposición a pagar de apróximadamente 
COP$36 millones. Los cálculos de costo efectividad estuvieron en linea con los resul-
tados para otras terapias contra el cancer.
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COST-EFFECTIvENESS AND COST-UTILITy ANALySIS OF MIFAMURTIDE 
PLUS COMBINATION CHEMOTHERAPy IN PEDIATRIC PATIENTS wITH 
OSTEOSARCOMA AFTER RESECTION SURgERy
Vargas-Romero J.A.1, Figueroa-Rodriguez A.2, Chiu-Ugalde J.1, Sánchez-Kobashi R.3,  
Gay-Molina J.G.3, López-Alvarenga J.C.4
1Medical Research Department,Takeda-Mexico, Naucalpan, Mexico, 2Market Access and 
Government Sales Department, Takeda-Mexico, Naucalpan, Mexico, 3Tecnología e Informática 
para la Salud, S.A. de C.V., México D.F., Mexico, 4Hospital General de México O.D., México D.F., 
Mexico
Current treatment for high-grade osteosarcoma (HGO) consists in primary tumor 
complete surgical excision and adjuvant multi-agent combined chemotherapy for 
subclinical metastatic disease. In Mexico, osteosarcoma prevalence is ≤ 5 cases 
per 10,000 people; drugs targeting the disease are therefore designated orphan 
medicinal products. This is the case of mifamurtide, a potent monocytes and mac-
rophages inducer. Objectives: This study aimed to determine the most cost-effec-
tive treatment for resectable, non-metastatic HGO in pediatric patients. Therapies 
compared were combined chemotherapy (high doses methotrexate, doxorubicin, 
cisplatin, with or without ifosfamide) vs combined chemotherapy plus mifamur-
tide. MethOds: Efficacy data regarding combination chemotherapy alone or with 
mifamurtide were obtained from the INT-0133 study. A Markov model was designed 
using Excel™ software. According to treatment guidelines, the model considered six 
stages: disease-free; disease progression; recurrence; progression-free after recur-
rence; progression after recurrence; death. The model adopted the Mexican public 
health institutions’ perspective over a 60-year timeframe. Univariate sensitivity 
analyses were conducted to determine the robustness of the model. Average utility 
was calculated from published studies. Costs were from the Mexican Institute of 
Social Security (IMSS). Outcome measures included cost, ICER and ICUR. Results: 
Cost-effectiveness analysis showed that while the chemotherapy combination regi-
men plus mifamurtide was more effective (19.74 vs. 18.17, LYG) it was also more 
costly (USD $102,635.8 vs. $13,148.89), with a discount rate of 3.5%. The ICER is USD 
$56,746.14. The cost-utility analysis found the same results, with the chemotherapy 
plus mifamurtide proving to be most effective treatment (19.55 vs. 17.95 QALY), or 
1.60 additional QALY. The ICER was USD $55,837.7. Sensitivity analyses showed the 
model to be robust. cOnclusiOns: Mifamurtide is a cost-effective treatment for 
pediatric patients with osteosarcoma. The additional 1.60 QALYs are relevant for 
the population, offering longer survival with a better quality of life.
PCN22
HOw UNIvERSITy HOSPITAL OF CRETE SUCCEEDED IN DECREASINg 
CyTOSTATICS’ BUDgET IN 2012?
Gkogkozotou V.K.1, Asithianakis P.2
1UNIVERSITY HOSPITAL OF CRETE, CRETE, Greece, 2UNIVERSITY HOSPITAL OF CRETE (PAGNI), 
CRETE, Greece
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intROductiOn: Actualmente se requieren estrategias para identificar a la 
población en riesgo de padecer cáncer de piel para implementar medidas de pre-
vención y diagnóstico oportuno. No existen instrumentos validados en idioma espa-
ñol que identifiquen el riesgo de cáncer de piel. ObjectivOs: Diseñar y validar un 
cuestionario auto-aplicado para cuantificar el riesgo de cáncer de piel melanoma y 
no melanoma en población mexicana. MetOdOlOgías: Se diseñó un cuestionario 
auto-aplicado para medir factores de riesgo para cáncer de piel, cuya validez de 
apariencia y contenido fue evaluada por cinco expertos. El valor de cada ítem se 
ponderó de acuerdo al riesgo relativo de los factores de riesgo. Se aplicó el instru-
mento a grupos extremos para medir la validez de constructo y la consistencia 
se evaluó mediante “test-retest” a las dos semanas. ResultadOs: Se aplicó el 
cuestionario a pacientes del Centro Dermatológico “Dr. Ladislao de la Pascua” con 
y sin cáncer de piel, 147 y 249 respectivamente. El puntaje total del cuestionario 
fue diferente en ambos grupos (U= 2104.5, p= 0.0001) y mediante curva ROC (área 
0.964, IC95% 0.946-0.981, p= 0.0001) se determinó que 5 o más puntos equivalen a 
riesgo alto para cáncer de piel. La consistencia del instrumento fue de 0.971 (IC95% 
0.943-0.986, p= 0.0001). cOnclusiOnes: Este es el primer instrumento en idioma 
español válido para medir riesgo de cáncer de piel y que aplicado a nivel poblacional 
sería una herramienta útil para identificar a los individuos en riesgo que requieren 
intervenciones preventivas.
PCN29
REQUIREMENT OF CANCER HELP LINES IN INDIA AND THE PERCEPTION OF ALL 
THE STAkE HOLDERS
Kurian S.1, Pariti B.1, Vilakkathala R.1, Mallayasamy S.1, Kumar H.L.2
1Manipal University, Manipal, India, 2MPower institute of Clinical Research, Bangalore, India
Objectives: To analyze the telephonic cancer help lines in India and to determine 
their need and potential application and also evaluate their potential to enhance 
flawless and uniform communication in cancer health delivery. MethOds: A 
Multi-Centre survey was conducted across 9 cities pan India with a structured 
questionnaire. The survey participants were oncologists, paramedical staff, hospi-
tal administrators, patients, their care takers, social workers, government officials 
and medical representatives. Collected data was statistically analyzed. Results: 
A total of 670 people were surveyed across the country. Approximately, only 25% of 
the surveyed subjects were aware of cancer help lines which mainly encompassed 
the educated class. However, almost 97% of the total surveyed people revealed com-
plete willingness for this service and its highest need was perceived in the villages. 
The convenience and comfort of telephone for health education was assessed to 
be 90.70% and 86.20% respectively and 88% perceived it as better than internet for 
personalized information. 92.3% of the oncologists acknowledged it to be useful in 
patient follow-up and for referring physicians for palliative care and majority of the 
other stakeholders recognized it to be useful in rendering better medical, emotional 
and supportive care thereby ultimately benefitting the patients in technologically 
and economically underprivileged countries like India. cOnclusiOns: Owing to 
the health education potential of cancer helplines, and its ability to link all the 
health care sectors, its implementation in developing countries like India that face 
the burden of cancer care, poor patient follow-up and poor psychosocial support 
will contribute towards better and cost-effective treatment approach as well as 
overcome the persistent problem of poor communication in the health care delivery 
and create means for uniform data collection.
PCN30
TRASTUzUMABE NO CâNCER DE MAMA METASTáTICO: UMA REvISãO 
SISTEMáTICA DE ANáLISES CUSTO-EFETIvIDADE
Andrade T.S.D.1, Mosegui G.B.G.1, Miranda E.S.1, Souza T.F.G.D.1, Vianna C.M.D.M.2, Silva F.V.C.3
1Universidade Federal Fluminense, Niterói, Brazil, 2Universidade do Estado do Rio de Janeiro, Rio 
de Janeiro, Brazil, 3Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil
ObjetivOs: Realizar uma revisão sistemática de avaliações de custo-efetividade 
do trastuzumabe em pacientes com câncer de mama metastático. MétOdOs: 
Foi realizada uma revisão sistemática de estudos de custo-efetividade do trastu-
zumabe no câncer de mama metastático, em português, espanhol e inglês, com-
preendendo o período de 2002 a 2013. As buscas foram realizadas em seis bases de 
dados eletrônicas, dois ferramentas de busca na internet e pesquisa de referências 
citadas. Comentários, editoriais, cartas, estudos de caso, artigos de revisão, revisões 
sistemáticas e metanálises foram excluídos. Os estudos foram selecionados por 
dois revisores independentes. ResultadOs: Resultados preliminares indicaram 
a inclusão de 15 estudos. Embora a maioria tenha cumprido com as diretrizes de 
custo-efetividade, a qualidade dos resultados foi limitada. Esquemas de tratamentos 
adotados pelas análises de custo-efetividade foram variados. Finalmente, as análises 
utilizaram diferentes limiares para determinar se o tratamento com o trastuzumabe 
foi custo-efetivo. cOnclusões: O uso de trastuzumabe combinado ou não a taxa-
nos ou capecitabina, foi custo-efetivo em relação a desfechos secundários, porém 
no que se refere ao desfecho primário sobrevida global, houve diferentes conclusões. 
Esses resultados variados são, provavelmente, devido a julgamentos feitos pelos 
autores dos estudos incluídos nesta revisão durante a tradução dos ensaios clínicos 
e por problemas metodológicos para avaliar custos e desfechos. Mais estudos de 
custo-efetividade devem ser realizados com o objetivo de avaliar o uso do trastu-
zumabe no câncer de mama metastático.
DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies
PDB1
COMPARACIóN INDIRECTA DE LA EFECTIvIDAD DE LA COMBINACIóN DE 
HIPOgLUCEMIANTES ASOCIADOS A METFORMINA EN PACIENTES DIABéTICOS 
TIPO 2
Sanchez O., Romero M.
Fundacion Salutia, Bogotá, Colombia
ObjectivOs: Comparar el porcentaje en la reducción de hemoglobina glicosilada 
(HbA1c) posterior al tratamiento en pacientes con Diabetes Mellitus e inadecuado 
ObjetivOs: Avaliar o acesso e o impacto econômico da introdução das terapias-
alvo bevacizumabe e cetuximabe no tratamento do câncer colorretal metástico em 
um hospital universitário após o início do Processo Administrativo (Resolução SS 
54/2012). MétOdOs: Estudo retrospectivo e descritivo realizado de janeiro de 2010 a 
junho de 2012, junto aos pacientes portadores de câncer colorretal metastático em 
seguimento no Serviço de Oncologia Clínica do Hospital das Clínicas da Faculdade 
de Medicina de Ribeirão Preto-USP em uso de tratamento quimioterápico. Foi avali-
ado o número de pacientes atendidos; o tempo médio entre solicitação, avaliação pela 
Secretaria de Estado da Saúde de São Paulo e recebimento dos medicamentos; o inter-
valo médio de tempo entre início de uso do medicamento após seu recebimento; gasto 
financeiro total e o gasto financeiro médio por paciente. ResultadOs: No período 
do estudo foram tratados com bevacizumabe e cetuximabe, respectivamente, 28 e 30 
pacientes. Foi identificado um tempo médio entre o pedido, avaliação pela SES-SP e 
recebimento dos medicamentos de 43 dias; um tempo médio de 14 dias para o iní-
cio do uso após o recebimento dos medicamentos e um gasto financeiro total com 
cetuximabe de R$1.112.145,09 e R$1.157.444,69 com bevacizumabe, sendo o gasto médio 
total de R$37.071,03 por paciente tratado com cetuximabe e R$41.337.31 com bevaci-
zumabe. cOnclusões: O Processo Administrativo proporcionou acesso dos pacientes 
com maior rapidez a estes medicamentos, sendo de extrema importância se conhecer 
os recursos financeiros empregados aos medicamentos disponíveis. A adoção dessa 
medida contribuiu para a garantia do acesso da população à assistência oncológica, 
constituindo-se em um elemento importante para o adequado enfrentamento dos desa-
fios que a progressão da incidência de câncer representa para a saúde pública brasileira.
PCN26
IMPACT OF PUBLIC PAyER CONCENTRATION ON PUBLIC SECTOR DISCOUNTS 
FOR SELECTED CANCER SUPPORTIvE CARE PRODUCTS IN BRAzIL AND MExICO
Sandorff E.1, Ziai Buetas A.2, Severi Bruni D.3
1ICON, Blue Bell, PA, USA, 2ICON, London, UK, 3ICON, El Segundo, CA, USA
Objectives: When contracting with large accounts, manufacturers have long under-
stood the importance of discounting to gain the favor of high-volume customers 
over the competition. The objective of this research is to compare what levels of 
discounting is necessary to sell pharmaceutical products in the highly-competitive 
cancer-supportive care market to the leading public payers in two of Latin America’s 
largest markets, the Sistema Único de Saúde (SUS) of Brazil and the Instituto Mexicano 
del Seguro Social (IMSS) of Mexico. As the level of concentration in terms covered lives 
as a percentage of their respective countries’ total populations varies this will pro-
vide insight into the importance that concentration plays in securing greater dis-
counts. MethOds: Quantitative analysis of SUS and IMSS tender purchase data 
compared with ex-manufacturer prices for selected cancer supportive care agents 
in Brazil and Mexico. Products will be divided into innovative and commoditized 
baskets to provide insight into any differences that level of differentiation may play 
when contracting with these payers. Results: Due to its higher concentration of 
covered lives to total population, discounts on sales for the selected products to SUS 
were greater than on those to IMSS. This was true for innovative as well as commod-
itized products, although differences in coverage policies for higher-cost, innovative 
drugs result in greater variability of data than for the commoditized basket of prod-
ucts. cOnclusiOns: Discounting plays a critical role in securing contracts with large 
accounts, and is even more important with payers that cover a larger proportion of 
their populations. This is especially true for commoditized products, while innova-
tive products show greater ability to avoid more pronounced discounting with even 
the largest public payers in the countries due to their greater level of differentiation.
PCN27
vARIABILIDADE NO TRATAMENTO DO CANCER DE MAMA NO BRASIL
Cherchiglia M.L.1, Pereira J.2, Mateus C.2, Acurcio F.D.A.3, Andrade E.I.3, Machado C.3
1Universidade Federal de Minas Gerais/Escola Nacional de Saúde Pública, Universidade Nova de 
Lisboa, Belo Horizonte/Lisboa, Brazil, 2Escola Nacional de Saúde Pública, Universidade Nova de 
Lisboa, Lisboa, Portugal, 3Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
ObjetivOs: Descrever as taxas de utilização do tratamento para câncer de mama fem-
inino e determinar a variabilidade geográfica no uso desse tratamento. MétOdOs: 
Estudo descritivo ecológico de utilização de tecnologia mediante análise de áreas 
geográficas, cuja fonte de dados foi a Base Onco, desenvolvida por meio de relaciona-
mento probabilístico-determinístico dos registros de autorização para procedimentos 
de radioterapia e/ou quimioterapia e dos registros de internação hospitalar pelo SUS, 
no período de 2000 a 2006. Foram incluídas as pacientes com diagnóstico de câncer de 
mama entre os anos de 2000 a 2005 e com idade entre 19 a 100 anos. Para conhecer a 
magnitude da variação do tratamento para o câncer de mama entre os estados bra-
sileiros foram utilizadas taxas brutas e padronizadas de tratamento oncológico por 
idade por 100.000 mulheres (censo 2000); razão de variação (entre os valores máximos 
e mínimos observados do percentil 5-95), coeficiente de variação e razão de utilização 
padronizada (RUE). ResultadOs: Foram analisadas 104.343 mulheres com idade 
média de 55 anos (DP 13,51), a maioria residia na região sudeste (51%), no momento do 
diagnóstico estava no estadio II e III (73%) e fez quimioterapia e radioterapia exclusi-
vamente (81%). A taxa padronizada para o tratamento oncológico de câncer de mama 
foi de 28,61 por 100.000 mulheres com razão de variação, entre o percentil 5-95, em 
torno de 3,5 vezes. A razão de utilização padronizada apresenta grande discrepância 
entre os estados. Os estados das regiões centro-oeste norte e nordeste - exceto Ceará 
e Rio Grande do Norte, apresentam RUE significativamente inferiores ao esperado 
(2,5 vezes a 15% menos). Os estados do sul e sudeste apresentam taxas superiores de 
RUE (10% a 38%). cOnclusões: As discrepâncias observadas na probabilidade de 
receber um tratamento oncológico para o câncer de mama poderão indicar iniquidade 
no acesso aos serviços públicos de saúde no Brasil.
PCN28
vALIDACIóN DE UN CUESTIONARIO PARA MEDIR RIESgO DE CáNCER DE PIEL
Morales-Sánchez M.A.1, Peralta-Pedrero M.L.2
1Universidad Nacional Autónoma de México, México D.F., Mexico, 2Instituto Mexicano del Seguro 
Social, México D.F., Mexico
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ANáLISIS COMPARATIvO DE INSULINA gLARgINA FRENTE A INSULINA 
DETEMIR: MODELO DE MINIMIzACIóN DE COSTOS PARA COLOMBIA
Fragozo A.1, Misas J.D.2, Jaramillo A.2
1Universidad del Bosque, Bogotá, Colombia, 2Sanofi-aventis de Colombia S.A., Bogotá, Colombia
Las insulinas análogas basales son opciones eficaces en el tratamiento de pacientes 
con DM2. No obstante, el costo del tratamiento, dado su impacto presupuestal desde 
la perspectiva del pagador, puede afectar la elección del medicamento. ObjectivOs: 
Determinar los costos asociados para alcanzar metas glucémicas con el uso de insu-
linas análogas basales, insulina glargina (IG) vs insulina detemir (ID), a través de 
un modelo de minimización de costos. MetOdOlOgías: Búsqueda sistemática de 
literatura en PUBMED de estudios clínicos comparativos entre IG y ID para pacientes 
DM2 insulino-requirentes para extraer datos de uso, efectividad y frecuencia de 
eventos adversos. La meta de control glucémico definida fue HbA1c7%. Los costos 
de insulinas fueron tomados del Sistema Integrado de Precios de Medicamentos 
2011 del Ministerio de Salud y precios de IMS Consulting Group promedio móvil 
anual para noviembre de 2011. Los análisis de sensibilidad se realizaron con simu-
laciones de Monte Carlo en dosis y precios de las insulinas. ResultadOs: Cinco 
publicaciones cumplieron con criterios de inclusión. La diferencia promedio entre 
dosis de IG e ID fue 15,99U (SD10,04U), a favor de IG. El porcentaje promedio de 
pacientes que requirieron dos dosis con ID fue de 56,2% (SD35,7%). No hubo difer-
encias significativas en eventos hipoglicémicos. Para el canal retail, en 4 estudios 
se apreció un mayor costo entre IG vs ID (Rosenstock USD$435, Hollander USD$532, 
Swinnen USD$967 y Currie USD$357 anuales) a favor de IG y solo un estudio mostró 
mayor costo para IG (Raskin USD$69 anuales). Para el canal institucional, en todos 
los estudios, el tratamiento con IG es la modalidad más económica según costos 
anuales. cOnclusiOnes: La diferencia en dosis promedio entre IG e ID genera una 
diferencia significativa en costos anuales a favor de IG. El uso de IG en el manejo del 
paciente DM2-IR es una alternativa costo/efectiva frente a detemir.
PDB5
DIRECT MEDICAL COSTS OF TREATINg DIABETES-RELATED COMPLICATIONS IN 
ARgENTINA
Elgart J.1, De la Llave G.2, Camillucci C.3, Vega-Hernandez G.4, Watkins M.4, Hammerby E.5, 
Nikolajsen A.5, Gagliardino J.J.1
1CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, 
Argentina, Buenos Aires, Argentina, 2Omint Argentina, Buenos Aires, Argentina, 3Hospital Privado 
de Córdoba CMC S.A., Córdoba, Argentina, 4IMS, London, England, 5Novo Nordisk A/S, Søborg, 
Denmark
Objectives: Diabetes is a chronic disease, which when not treated appropriately, 
leads to increased risk of developing preventable complications, increasing the cost 
of care. This represents a heavy burden for the public health budget in Argentina. 
The objective was to collect direct medical costs of treating diabetes-related compli-
cations in Argentina. MethOds: Following a literature review no data on the cost of 
diabetes-related complications were found in Argentina. To obtain robust data, we 
approached 3 local key opinion leaders from both social security (SS) and private (P) 
health care sectors with access to local databases; they covered 3 geographic areas 
of Argentina: Buenos Aires city (P) and Buenos Aires and Cordoba provinces (SS). 
Standardized forms were used for data collection and final values represent average 
cost of the SS and P sectors. Direct costs were classified into 6 groups: disease man-
agement, treatment of acute-events, renal-disease, eye-disease, neuropathy/foot 
ulcers and cardiovascular-complications. Values are presented in 2012 US-dollars 
per “event occurring in the first year” and annual follow up costs (exchange rate 
1USD = 4.89ARS). Results: The diabetes-related complications with highest first 
year average costs were renal-complications (renal transplant 37,833USD; perito-
neal-dialysis 24,655USD and haemodialysis 23,748USD), followed by cardiovascular 
related events (myocardial infarction 5,939USD; congestive heart failure 4,884USD; 
peripheral vascular disease 4,200USD and angina 3,799USD). The cost of an ampu-
tation procedure was 2,727USD while those of prosthesis and post-amputation 
follow up were 3,255USD and 1,470USD, respectively. The cost of eye-laser therapy 
was 449USD while a cataract procedure was 1,186USD. High costs were also associ-
ated with treatment of neuropathy (1,141USD), infected foot ulcer (747USD) and 
gangrene (1,684USD). cOnclusiOns: These findings suggest that implementation 
of prevention strategies to reduce the development of diabetes-related complica-
tions may decrease the diabetes burden on the health care budget. Furthermore the 
data presented will provide useful inputs for economic evaluations in Argentina.
PDB6
DIRECT COSTS OF TyPE 2 DIABETES IN MExICO FROM THE PUBLIC HEALTH 
CARE SECTOR PERSPECTIvE
Chatzitheofilou I.1, Babineaux S.M.2, Ramírez-Gámez J.3, McDonell A.1, Vega-Hernandez G.1
1IMS, London, England, 2Eli Lilly & Company, Indianapolis, IN, USA, 3Eli Lilly and Company, 
México, Mexico
Objectives: To quantify the annual cost of type 2 diabetes mellitus (T2DM) in Mexico 
and explore the relative contributions of different components of cost. MethOds: A 
cost of illness model was developed in Microsoft Excel 2007 to estimate the economic 
burden of T2DM in Mexico from the public health care payer perspective. Cost of rou-
tine management and complications were included in the analysis. Data inputs for 
prevalence of T2DM (weighted to include only patients who are diagnosed and treated) 
and related complications, costs and routine management were sourced from the pub-
lished literature and publicly available databases, where available. Primary research 
approaching local key opinion leaders was performed to fill data gaps. Sensitivity 
analyses were conducted to identify data inputs which were most likely to impact 
overall results when varied. Costs are presented in Mexican pesos 2012. Results: 
The annual cost of T2DM in Mexico is estimated to be $107,343,890,388MXN($8,643,3
48,612USD). This figure represents ~13% of the national health care expenditure. The 
cost of complications were estimated to account for 91% of the total cost of T2DM, 
with cardiovascular and eye complications accounting for 49% and 18% of total costs, 
respectively. Routine management, including drug costs, was estimated to comprise 
control glucémico tratados con diferentes combinaciones de hipoglucemiantes 
orales con metformina. MetOdOlOgías: Mediante una revisión de la literatura se 
identificó y evaluó la efectividad de [vildagliptina, sitagliptina, saxagliptina, lina-
gliptina, glimepiride y glibenclamida] asociados a metformina versus monoterapia 
de metformina (Septiembre 2012). Los estudios encontrados se evaluaron en simili-
tud de diseño y características de los pacientes; y a partir de los resultados de éstos 
se reconstruyeron las distribuciones de Hb1Ac al inicio y a 24 semanas. El análisis 
se hizo por diferencia de medias (reducción de HbaA1c) de acuerdo al método de 
Bacher mediante el software Indirect Treatment Comparison. ResultadOs: Los 
grupos tratado con vildagliptina de 50, 100 mg y glimepiride no eran similares a 
los tratados con las otras combinaciones respecto al nivel de Hb1Ac de inicio (8,4% 
ee 0,08; 8,3% ee 0,07 y 7,7% ee 0,03 respectivamente) limitando su comparabilidad. 
Las comparaciones entre las demás combinaciones de hipoglucemiantes demos-
traron una mayor reducción de la HbA1c frente a la monoterapia con metformina. 
Ninguna de las combinaciones presentó superioridad en el desenlace analizado, 
aunque presentan diferencias en otros aspectos que pudieran modificar el resul-
tado final como adherencia y presentación de hipoglucemia. cOnclusiOnes: Se 
demuestra la mayor efectividad de las combinaciones de hipoglucemiante-met-
formina versus monoterapia de metformina, en pacientes con Diabetes Mellitus 
e inadecuado control glucémico. No existen diferencias de efectividad cuando se 
mide el nivel de cambio de HbA1C a las 24 semanas. Se requieren análisis que 
tengan en cuenta variables a largo plazo como los eventos micro y macro vascu-
lares y otras variables como la tasa de presentación de hipoglucemia que entre 
las tecnologías analizadas.
DIABETES/ENDOCRINE DISORDERS – Cost Studies
PDB2
ANáLISIS DE IMPACTO PRESUPUESTARIO DE LINAgLIPTINA ADICIONADA A 
METFORMINA EN EL TRATAMIENTO DE PACIENTES CON DIABETES MELLITUS 
EN COLOMBIA
Romero M.1, Marrugo R.1, Herran S.2, Di Domenico M.2
1Fundacion Salutia, Bogotá, Colombia, 2Boehringer Ingelheim, Bogotá, Colombia
ObjectivOs: Determinar el impacto sobre la unidad de pago por capitación 
(UPC) de la utilización de linagliptina adicionada a metformina en pacientes con 
Diabetes Mellitus tipo 2 (DM2), con inadecuado control glucémico, en el sistema de 
salud de Colombia. MetOdOlOgías: A partir de un modelo de costo-efectividad 
que muestra el beneficio de uso de linagliptina adicionada a metformina en el 
tratamiento de pacientes con DM2, se realizó un análisis de impacto presupues-
tario para un quinquenio, considerando costos directos en salud asociados a la 
historia natural de la enfermedad, incluyendo eventos macrovasculares y micro-
vasculares, en una cohorte móvil de pacientes. Los costos directos de atención de 
salud se tomaron de Registros Individuales de las Prestaciones de Salud y de ase-
guradores, con un reemplazo del 50% frente a glibenclamida/metformina (incluida 
en el plan de beneficios del sistema de salud). Se hizo un análisis de sensibilidad 
univariado haciendo variar la tasa de reemplazo. ResultadOs: Dada una tasa 
de prevalencia de 0,04 e incidencia de 0,00879 de DM2 en Colombia, y el supuesto 
de que el 10% de los pacientes requiere la intervención, el costo acumulado a 5 
años, sería de US$ 2.143.046.352 tratados solo con glibenclamida/metformina, 
frente a US$ 2.067.111.599 si se usa linagliptina adicionada a metformina, con una 
participación del 50%. En el primer año, el impacto de la inclusión de linagliptina 
sería del 0,21% sobre la UPC. Del segundo al quinto año, se generarían ahorros 
sobre la UPC de 0,004%, 0,13%, 0,27% y 0,41%, respectivamente. Es decir, al cabo 
de cuatro años ya sería ahorrativo. Remplazos mayores a 60% generarían más 
ahorros al sistema. cOnclusiOnes: La introducción de linagliptina adicionadaa 
metformina, en el plan de beneficios del sistema de salud colombianoserá nota-
blemente menos costosa que la actual utilización de glibenclamida/metformina, 
en un periodo de cinco años.
PDB3
LONg-TERM COST COMPARISON BETwEEN PARICALCITOL AND CALCITRIOL 
FOR THE TREATMENT OF SECONDARy HyPERPARATHyROIDISM IN CHRONIC 
kIDNEy DISEASE IN MExICO
Sanchez-Casillas J.L., Ramirez-Lopez-De-N M.G.
Abbvie Inc., Mexico City, Mexico
Objectives: Assess cost burden related to drug usage in a long term treatment 
(5 years) in patients with Secondary hyperparathyroidism (SHPT), considering 
hospitalization cost, erythropoietin (EPO) consumption and other direct health 
care costs from an institutional perspective. MethOds: A statistical model was 
developed to simulate an average Mexican patient resources usage in 5 years’ 
time-frame treated with two alternatives paricalcitol and calcitriol based on clin-
ical data in published literature. Resources usage considered: SHPT treatment 
drugs, EPO, hospitalization costs and medical supplies. Unit costs were collected 
from Mexican Government Databases: Instituto Mexicano del Seguro Social (IMSS) 
official database, Official Journal of the Federation (DOF) and Banco de Mexico. 
Univariable sensibility analysis was executed. Results: SHPT medication treat-
ment cost were US$21.92 with calcitriol and US$10,658.00 with paricalcitol during 
five years, while total costs for paricalcitol patients was US$5,304.20(-8.5%) lower 
compared to calcitriol in this time-frame. Most savings occur in hospitalization 
costs where calcitriol patients require in average US$35,633.36 while paricalcitol 
patients required just US$24,532.88. Erythropoietin consumption costs during 5 
years was also lower by US$4,910.88 in paricalcitol patients compared to calcitriol 
(p< 0.05). During the first two years total costs for the patients treated with pari-
calcitol was slightly higher than those treated with calcitriol, US$441.79(+1.7%), 
due to the initial paricalcitol dosage which is reasonably higher than maintenance 
dosage. cOnclusiOns: Based on this cost comparison model, from institutional 
perspective, paricalcitol treatment is less costly when the patient is treated with 
a middle-term (more than 2 years) or long-term (5 years) perspective at IMSS in 
Mexico.
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costs and Life-years gained (LYG) offset based on incremental survival rate of compared 
therapies. Probabilistic Multivariable sensibility analysis was completed with 5,000 
simulated patients. Results: Survival rate and confidence interval obtained from 
model was 0.63 (0.60, 0.66) for paricalcitol and 0.46 (0.44, 0.48) for PTX. Average survival 
of both therapies resulted in an incremental 0.61 LYG for paricalcitol patients (+18%). 
Average five years treatment cost for Paricalcitol patients was $10,024.25, while PTX 
was US$5,369.74(-46%) resulting in an ICER of US$7,619.94 per LYG, which is 28.2% 
below Mexican Gross Domestic Product (GDP) per capita. Probabilistic analysis shown: 
90.1% of patient treated had a cost-effective outcome and 7.2% of cases had a domi-
nant outcome. cOnclusiOns: According to results obtained and using a threshold 
of US$29,306.29 (3 x GDP per capita), Paricalcitol is a highly cost-effective treatment 
option compared to PTX when treating patients with SHPT at IMSS.
PDB10
COST-EFFECTIvENESS OF FIxED-DOSE COMBINATION (FDC) OF vILDAgLIPTIN/
METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TyPE 2 IN MExICO
Lemus A.1, Jimenez Aranda P.2
1Novartis, Mexico City, Mexico, 2Novartis, Coyoacan, Mexico
Objectives: Type 2 Diabetes is a major public health care problem in Mexico. Some 
patients may require more than one oral antidiabetic treatment to achieve glycemic 
control. Vildagliptin, a DPPIV inhibitor is an option in combination with the stand-
ard treatment of metformin. The objective was to assess the cost-effectiveness of 
Vildagliptin/Metformin FDC versus other oral treatments available in the public 
market. MethOds: Cost-effectiveness analysis of the oral antidiabetic treatments 
available in the public market in Mexico was conducted. The comparisons included 
the following options: Vildagliptin/Metformin FDC, glibenclamide, and thiazolidin-
ediones (Rosiglitazone and pioglitazone). Cost effectiveness analysis versus other 
oral antidiabetics incorporated the incidence and costs of adverse events according 
to Ferrannini 2009 and Gonzalez-Ortíz 2009 for glibenclamide and Motola 2012 for 
thiazolidinediones. Drug costs were elicited from public tenders and health care 
services from unitary costs of the IMSS. The perspective is the public health provider 
and the time horizon is one year. Results: The use of Vildagliptin/Metformin FDC 
(50/500 or 850 mg) BID compared to glibenclamide, is a dominant strategy if the cost 
per hypoglycemia exceeds US$714.03. Vildagliptin/Metformin FDC is dominant ver-
sus pioglitazone,if the cost of fractures incurred by pioglitazone exceeds US$56.56. 
Drug acquisition costs of Vildagliptin/Metformin FDC are 150% cheaper per patient 
treated vs rosiglitazone; additionally rosiglitazone is associated with myocardial 
infarction events. cOnclusiOns: Vildagliptin/Metformin FDC is an opportunity 
for resource optimization in the public sector. This cost effectiveness analysis is 
not considering other potential adherence benefits which are related with having 
two treatments in one pill.
PDB11
PROBABILISTIC SENSITIvITy ANALySIS TO ANALyzE THE COST-EFFECTIvENESS 
OF ORAL HyPOgLyCEMIC AgENTS IN THE INITIAL ORAL DRUg TREATMENT OF 
OUTPATIENTS DIAgNOSED wITH TyPE 2 DIABETES IN PRIMARy CARE
Diaz de León-Castañeda C., Pinzon-Florez C.E., Arredondo A.
Instituto Nacional de Salud Pública, Cuernavaca, Mexico
Objectives: To perform a probabilistic sensitivity analysis to analyze previously 
reported results about the cost-effectiveness of oral hypoglycemic agents (OHA’s) 
in the initial oral drug treatment of patients diagnosed with type 2 diabetes mel-
litus in public primary attention in Mexico. MethOds: A probabilistic sensitivity 
analysis was made in order to analyze results previously reported in which a deter-
ministic sensitivity analysis was performed to study the cost-effectiveness of three 
OHA’s: metformin, glibenclamide and acarbose. We used TreeAge-Pro® software for 
programming and simulating a Markov model of two health states (HbA1C≤ 7% or 
HbA1C> 7%) and twelve cycles of 1 month for a time horizon of 1 year. The parameters 
of monthly success probability as beta distributions and monthly costs as lognormal 
distributions of therapeutic alternatives were computed through a parametrization 
of data. Monte Carlo’s simulations were computed for cohorts of 10,000 patients 
for each treatment option. Results: The results of the Monte Carlo’s simulations 
showed very close iterations clouds for metformin and glibenclamide showing evi-
dent dominance of both over acarbose. In the acceptability curve generated, for a 
willingness to pay (WTP) = 0 the probabilities to be cost-effective were 49.46 %, 43.04 
% and 7.50 % for glibenclamide, metformine and acarbose, respectively, whereas for 
a WTP = 1 mexican GDP per capita (US $ 7876.00 in 2009) were 66.26 %, 26.98 % and 
6.76%. The glibenclamide versus metformin incremental cost-effectiveness analysis 
showed similar results as mentioned before, showing 59.72% of iterations below the 
WTP = 1 mexican GDP per capita line. cOnclusiOns: The probabilistic sensitivity 
analysis showed which the initial drug therapy with glibenclamide or metformin 
have advantage over acarbose. There is not sufficient evidence to say glibenclamide 
has advantage over metformin for WTP near to cero, as in low to middle income 
countries where containment of expenditures is important.
PDB12
A HEALTH ECONOMIC ANALySIS OF THE LONg-TERM OUTCOMES AND COSTS 
ASSOCIATED wITH USINg CANAgLIFLOzIN vERSUS SITAgLIPTIN AS AN 
ADD-ON TO METFORMIN (MET) IN MExICO
Teschemaker A.R.1, Neslusan C.1, Puig A.2, Valencia A.3, Johansen P.4, Willis M.4
1Janssen Global Services LLC, Raritan, NJ, USA, 2Johnson and Johnson World Headquarters, New 
Brunswick, NJ, USA, 3Janssen, Mexico City, Mexico, 4The Swedish Institute for Health Economics, 
Lund, Sweden
Objectives: Canagliflozin (CANA) is a novel inhibitor of the sodium glucose co-
transporter 2 in development for treating patients with type 2 diabetes mellitus 
(T2DM). In a previously reported randomized, double-blind, 4 arm parallel group 
(placebo, CANA 100mg, CANA 300mg and sitagliptin 100mg [SITA]) study of 1284 
subjects inadequately controlled on MET monotherapy, CANA 100mg and 300mg 
significantly decreased HbA1c versus placebo after 26 weeks of therapy by 0.62% and 
0.77%, respectively; SITA decreased HbA1cversus placebo by 0.65%. In this trial, both 
9% of total cost of T2DM. The cost estimate was most sensitive to incidence and event 
cost of peripheral vascular disease, stroke and severe vision loss. cOnclusiOns: 
Based on the present analysis, T2DM places a significant financial burden on the 
health care system in Mexico, with cost of treating related complications being the 
main cost driver. Given the model focuses on diagnosed and treated T2DM patients, 
it is likely this cost is even higher when undiagnosed and untreated patients are 
considered. Delaying the onset of complications could result in a reduction in costs, 
as well as benefits for the patient and health care system.
PDB7
DIRECT COSTS OF TyPE 2 DIABETES FROM THE BRAzILIAN PUBLIC HEALTH 
CARE SECTOR PERSPECTIvE
Hnoosh A.1, Babineaux S.M.2, Piras de Oliveira C.3, McDonell A.1, Vega-Hernandez G.1
1IMS, London, England, 2Eli Lilly & Company, Indianapolis, IN, USA, 3Eli Lilly do Brasil, Sao Paulo, 
Brazil
Objectives: This study aimed to quantify the annual financial cost of type 2 diabe-
tes (T2DM) in Brazil and explore the relative contribution of different components 
of cost. MethOds: A cost of illness model was developed in Microsoft Excel 2007 
to estimate the financial cost of T2DM in Brazil from the public health care payer 
perspective. Cost of routine management and complications were included in the 
analysis. Data inputs for prevalence of T2DM (weighted to include only patients who 
are diagnosed and treated) and related complications, costs and routine management 
were sourced from the published literature and publicly available databases, where 
available. Key opinion leader input was sought to fill data gaps. Sensitivity analyses 
were conducted to identify parameters which were most likely to impact overall 
results when varied. Costs are presented in Brazilian Reals 2012. Results: The annual 
cost of T2DM in Brazil is estimated to be 11,275,921,167 BRL ($5,471,123,022USD) which 
represents 5.3% of national health care expenditure. Costs of complications were 
estimated to account for 56% of the total cost of T2DM. Cardiovascular complica-
tions accounted for 32% of total T2DM cost. Diabetes drug costs were estimated to 
account for 31% of total T2DM health care spending. The overall cost estimate was 
most sensitive to the laser eye surgery, hemodialysis and cardiovascular complica-
tions and the frequency and cost of routine physician consultations. cOnclusiOns: 
The findings indicate that there is a high economic burden of T2DM for the Brazilian 
health care system. Cost of treating related complications was the main driver. An 
even higher burden of the disease is expected if undiagnosed and patients currently 
not being treated start receiving public medical attention. The burden of the disease 
could considerably be reduced if T2DM related complications were avoided, which 
not only benefits the health care system but the patients as well.
PDB8
TRENDS IN HEALTH CARE RESOURCES UTILIzATION, COST AND MEDICATION 
SELECTION IN THE TREATMENT OF DIABETES
Lachaine J., Beauchemin C.
University of Montreal, Montreal, QC, Canada
Objectives: Diabetes is one of the most common chronic diseases in Canada. It 
affects about 6.8% of the Canadian population. Treating and managing the disease 
and its complications is associated with a significant economic burden. The objec-
tive of this study was to analyse trends in terms resource utilization, cost and treat-
ment patterns in the management of diabetes. MethOds: Patients covered by the 
Quebec provincial drug reimbursement program (RAMQ) who had a diagnosis of 
diabetes, in 2005 and were covered continuously by the public drug program for the 
period from January 2006 to December 2010 were selected. Health care resources in 
terms of diabetes medications and physician visits, hospitalization, intensive care 
unit stay, hospital outpatient clinic visits, and emergency room visits associated 
with a diagnosis of diabetes were estimated over a 5-year period, from January 2006 
to December 2010. Trends in the proportion of diabetes medications used each year 
over the 5-year study period were also estimated. Results: A total of 46,194 diabetic 
patients were included in the study. The mean age of the study population was 65.4 
years (SD= 12.3) and proportion of male/female was 47% and 53% respectively. Over 
the study period, annual cost of diabetes medications varied from $320 (SD= 464) in 
2006 to $372 (SD= 546) in 2010 (+16%) while total cost of treatment associated with 
diabetes varied from $627 (SD= 1456) to $715 (SD= 1632) (+14%) during that period. 
Metformine remains the most widely used medication throughout the study period 
with 64.3% of users in 2006 and 65.6% in 2010. Proportion of insulin users increased 
from 15.2% to 22.7% while gliclazide users increased from 4.4% to 11.2% during the 
study period. cOnclusiOns: Over the five-year study period cost of diabetes treat-
ment has increased at a rate similar to inflation, while trends of increased adoption 
of insulin and newer medications is observed.
PDB9
COST-EFFECTIvENESS OF PARICALCITOL vERSUS PARATHyROIDECTOMy 
FOR SECONDARy HyPERPARATHyROIDISM TO CHRONIC kIDNEy DISEASE IN 
MExICO
Sanchez-Casillas J.L., Ramirez-Lopez-De-N M.G.
Abbvie Inc., Mexico City, Mexico
Objectives: Secondary hyperparathyroidism (SHPT) affects one of every two 
Mexicans with chronic kidney disease (CKD) at stage five. The objective of this research 
was to assess cost effectiveness (CE) of Paricalcitol intravenous administration (IV) ver-
sus parathyroidectomy (PTX) from Mexican payer perspective. MethOds: A decision 
tree model was designed to simulate patient resources usage and survival rate in 5 
years time-frame treated with paricalcitol IV and parathyroidectomy based on clinical 
data in recent published literature. Time-frame begins when a patient is refractory 
to Calcitriol therapy and physician decides to treat with Paricalcitol or program PTX. 
Resources usage considered were just directly related to SHPT treatment: drug cost, 
surgery and hospitalization costs and medical supplies linked. Unit costs were col-
lected from Mexican Government Databases: IMSS official database, Diagnosis Related 
Groups from IMSS, Official Journal of the Federation. (Cost considered 5% annual dis-
count rate).Incremental Cost-Effectiveness Ratio (ICER) was calculated with treatment 
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SHORT AND LONg-TERM COST-EFFECTIvENESS OF SwITCHINg THERAPy FROM 
NPH INSULIN TO INSULIN DETEMIR IN PEOPLE wITH TyPE 2 DIABETES
Home P.D.1, Malek R.2, Gálvez G.G.3, Hammerby E.4, Nikolajsen A.4, Henriksen O.5,  
Andersen M.F.B.5
1University of Newcastle upon Tyne, Newcastle upon Tyne, UK, 2Internal Medicine, CHU Setif, 
Sétif, Algeria, 3Instituto Jalisciense de Investigacion en Diabetes y Obesidad, Guadalajara, Mexico, 
4Novo Nordisk A/S, Søborg, Denmark, 5Last Mile P/S, Copenhagen K, Denmark
Objectives: To assess the cost-effectiveness (CE) of switching from NPH insulin 
± oral glucose-lowering drugs (OGLDs) to insulin detemir ± OGLDs in people with 
type 2 diabetes (T2DM) in countries in different economic circumstances based on 
observational data gathered in routine clinical practice. MethOds: The A1chieve
® 
study assessed safety and outcomes over 24 weeks in 66,726 people with T2DM 
starting insulin analog therapy. Most people (96%) stated better glycemic control 
as reason to switching therapy, with 31% also stating hypoglycemia problems as 
a further reason. The CE analyses included data for people switching to detemir 
in South Korea (n= 90) and in seven Arabian Gulf countries (n= 124). Data were col-
lected on clinical effectiveness and adverse events, and health-related quality of 
life using the EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model 
with 1 and 30 year time horizons, with South Korea and Saudi Arabia country-
specific costs for complications and therapies and background mortality rates. CE 
was measured by comparing outcomes at study-end with outcomes at pre-study. 
Incremental cost-effectiveness ratios (ICERs) are expressed as cost per QALY in 
local currencies, USD and in fractions of local GDP per capita. CE was pre-defined 
using the WHO definition of < 3 times GDP per capita. Results: 1-year ICERs were: 
South Korea (KWR 3,236,798; USD 2,980; GDP 0.13), and Saudi Arabia (SAR 27,221; 
USD 7,258; GDP 0.36). 30-year ICERs were: South Korea (KWR 872,589; USD 803; 
GDP 0.04), and Saudi Arabia (SAR 6,349; USD 1,693; GDP 0.08). Sensitivity analyses 
covering cost of self-monitoring, deterioration of glucose control with time, and 
other time horizons showed the results to be robust. cOnclusiOns: Switching 
from NPH±OGLDs to detemir±OGLDs in people with T2DM as performed in the 
A1chieve
® study was found to be cost-effective in both country settings at 1 and 
30 year time horizons.
PDB16
SHORT AND LONg-TERM COST-EFFECTIvENESS OF SwITCHINg THERAPy FROM 
INSULIN gLARgINE TO INSULIN DETEMIR IN PEOPLE wITH TyPE 2 DIABETES
Malek R.1, Gálvez G.G.2, Hammerby E.3, Nikolajsen A.3, Henriksen O.4, Andersen M.F.B.4
1Internal Medicine, CHU Setif, Sétif, Algeria, 2Instituto Jalisciense de Investigacion en Diabetes y 
Obesidad, Guadalajara, Mexico, 3Novo Nordisk A/S, Søborg, Denmark, 4Last Mile P/S, Copenhagen 
K, Denmark
Objectives: To assess the cost-effectiveness (CE) of switching from insulin glargine ± 
oral glucose-lowering drugs (OGLDs) to insulin detemir ± OGLDs in people with type 2 
diabetes (T2DM) in Saudi Arabia, South Korea and Algeria based on observational data 
gathered in routine clinical practice. MethOds: The A1chieve
®study assessed safety 
and outcomes over 24 weeks in 66,726 people with T2DM starting insulin analog ther-
apy. The CE analyses included people switching to detemir in Saudi Arabia (n= 102), 
South Korea (n= 82) and in 3 North-West African countries (n= 94). Data were collected 
on clinical effectiveness and adverse events, and health-related quality of life using 
the EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 
30 year time horizons, with Saudi Arabia, South Korea and Algeria country-specific 
costs for complications and therapies and background mortality rates. Incremental 
cost-effectiveness ratios (ICERs) are expressed as cost per QALY in local currencies, 
USD and in fractions of local GDP per capita. CE was pre-defined using the WHO defi-
nition of < 3 times GDP per capita. Results: The switch was found to be less costly 
and have better outcomes in South Korea after 30 years and in Saudi Arabia at both 
time horizons. 1-year ICERs were: Saudi Arabia (SAR -5,849; USD -1,559; GDP -0.08), 
South Korea (KWR 296,842; USD 273; GDP 0.01), and Algeria (DZD 267,771; USD 3,363; 
GDP 0.80). 30-year ICERs were: Saudi Arabia (SAR -14,839; USD -3,957; GDP -0.19), South 
Korea (KWR -1,133,202; USD -1,043; GDP -0.05), and Algeria (DZD 226,818; USD 2,849; 
GDP 0.68). Sensitivity analyses on the 30 year time horizon showed the findings to be 
robust. cOnclusiOns: Switching from glargine±OGLDs to detemir±OGLDs in T2DM 
as performed in the A1chieve
® study was found to be cost-effective across all country 
settings at 1 and 30 year time horizons.
PDB18
IMPACTO DE LA DIABETES SOBRE LA PRODUCTIvIDAD EN ARgENTINA
Asteazaran S., Elgart J., Gagliardino J.J.
CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, 
Argentina, Buenos Aires, Argentina
ObjectivOs: Estimar y caracterizar el impacto de la enfermedad sobre la productivi-
dad laboral de personas con diabetes (DM) en Argentina. MetOdOlOgías: Estudio 
descriptivo observacional relevando información mediante el cuestionario WPAI-GH 
(Work productivity and activity impairment - General Health version) en personas 
adultas (18 a 75 años) con DM, que concurrieron a su consulta habitual a dos centros 
asistenciales de La Plata. Los encuestados también respondieron sobre aspectos 
socioeconómicos y complicaciones de su enfermedad. La pérdida de productividad 
se estimó por el método del capital humano. Los resultados se presentan como 
media ± desvío estándar (DS) o proporciones. Para las comparaciones se utilizaron 
los test t de student, Kruskal-Wallis y Chi cuadrado, según correspondiera. Se con-
sideró significativo p< 0,05. ResultadOs: Aceptaron participar en el estudio 73 
personas con DM; 54,8% hombres con edad de 57 ± 15 años. El 42,5% poseía estudios 
superiores (nivel terciario o universitario completo). El 60,3% trabajaba, 6.4% estaba 
desempleado y el 33,3% inactivo (jubilado, pensionado). El tiempo promedio de tra-
bajo fue de 43 ± 17 horas/semana y el 38% faltó/retiró de su trabajo por su enferme-
dad. El tiempo de trabajo perdido por ausentismo fue 9.1%, y por disminución de 
la productividad el 22%. La diabetes también disminuyó un 25% la capacidad para 
realizar actividades regulares diarias, afectando más a mujeres que a hombres (30 
y 20,3%, respectivamente). La pérdida de productividad monetaria por ausentismo 
CANA doses and SITA significantly reduced systolic blood pressure (CANA 100mg: 
5.36 mmHg; CANA 300mg: 6.58 mmHg; SITA 3.34 mmHg), however, only CANA sig-
nificantly reduced body weight (CANA 100mg: 2.5%; CANA 300mg: 2.9%) versus 
placebo. The objective of this study was to simulate the health outcomes and associ-
ated costs attributable to using CANA versus SITA in Mexico. MethOds: Forty-year 
outcomes associated with adding CANA 100mg or CANA 300mg versus SITA to 
MET were simulated using ECHO (Economic and Health Outcomes)-T2DM, a vali-
dated micro-simulation model. Treatment effects and patient characteristics were 
sourced from the trial. Simulated treatment was intensified when HbA1cexceeded 
7.5% by adding basal insulin, and subsequently prandial insulin. Disutilities associ-
ated with micro- and macro-vascular events were obtained from the literature and 
costs were adapted to the Mexican setting. Results: Using CANA 300mg versus 
SITA was projected to reduce relative risks for key events (e.g. myocardial infarction 
10.2%; congestive heart failure 6.6%; macroalbuminuria 6.6%; microalbuminuria 
6.2%), improve QALYs (0.046), and result in lower costs per patient ($1927MXN). 
Simulation results of CANA 100mg versus SITA were generally similar, albeit esti-
mates of reductions in relative risks, QALY gains and associated costs differences 
were smaller. cOnclusiOns: These simulations suggest that using CANA versus 
SITA as an add-on to MET could result in improved outcomes and reduced costs 
in Mexico.
PDB13
ECONOMIC EvALUATION OF INSULIN LISPRO MIx 25 wITH gLARgINE IN THE 
TREATMENT OF TyPE 2 DIABETES MELLITUS PATIENTS IN THE MExICAN 
PUBLIC HEALTH CARE SySTEM IN MExICO
Carlos F.1, Ramírez-Gámez J.2
1R A C Salud Consultores S.A. de C.V., México D.F., Mexico, 2Eli Lilly and Company, México, Mexico
Objectives: Compare expected costs and health-outcomes in patients with 
Diabetes Mellitus Type 2 (DMT2) in the Public Sector in Mexico treated with 
glargine or 25%-insulin lispro, 75%-insulin lispro protamine suspension 
(LM25). MethOds: This analysis included a hypothetical cohort of insulin-naïve 
patients with T2DM, aged 30–80, years, with A1C> 7.0% taking antihyperglycemic 
drugs for 90 days. Effectiveness measures included; (1) Percentage of patients with 
A1C< 7.0% levels at 24 weeks, (2) frequency and type of micro and macrovascular 
complications (MMVC) and (3) hypoglycemic events per 1000 patients consider-
ing one-year timeframe. Costs evaluated were: 1) acquisition costs; 2) cost of 
hypoglycemic events; and 3) MMVC. Efficacy measures and mean-daily-dose was 
obtained from DURABLE, parallel, open-label and randomized study comparing 
directly LM25 and Glargine. Incidences of MMVC were estimated using data from 
UKPDS study group and data from Meta-analysis by Quayum following a similar 
process outlined by Grima. Acquisition costs were derived from the transparency 
portal of the Mexican Social Security Institute. Healthcare services utilization 
from hypoglycemic episodes were calculated according to international published 
literature and IMSS Unit Costs updated to 2013 following IMSS methodology, while 
other associated expenses with MMVC complications come from Mexican reports 
and Diagnostic Related Groups (DRG) published by IMSS this data was updated to 
January 2013 using the Bank of Mexico inflation calculator. Costs are expressed 
in 2013 USD (1USD= $12.70MXN) Results: All results consider 1000 patients 
treated in a 1-yeat timeframe. Acquisition costs for LM25 were lower compared 
to glargine ($291,395 vs $383,521, 24% lower), although costs per hypoglycemia 
events were higher for LM25 ($12,242 vs. $3,673). Direct medical costs for MMVC 
were higher for Glargine ($668,027 vs. $754,435) Total medical costs were higher 
for glargine compared to LM25 ($971,663 vs. 1,141,628). cOnclusiOns: Results 
of the present study suggest that compared with LM25, health care costs are 
significantly higher for glargine.
PDB14
HEALTH ECONOMIC BENEFITS OF SENSOR AUgMENTED INSULIN PUMP 
THERAPy IN COLOMBIA
Gomez A.1, Alfonso-Cristancho R.2, Prieto-Salamanca D.3, Valencia J.E.4, Lynch P.5, Roze S.6
1Hospital Universitario de San Ignacio, Bogotá, Colombia, 2University of Washington, Seattle, 
WA, USA, 3RANDOM Foundation, Bogotá D.C., Colombia, 4Medtronic Latinamerica Inc., Bogota, 
Colombia, 5Medtronic, Tolochenaz, Switzerland, 6HEVA HEOR, Lyon, France
Objectives: To estimate the health economic impact of Sensor-Augmented 
Insulin Pump (SAP) Therapy among Insulin-Dependent Diabetes Mellitus (IDDM) 
patients in Colombia. MethOds: The Core Diabetes Model (CDM) is highly vali-
dated, computer simulation model to determine the long-term health outcomes 
and economic consequences of diabetes interventions. A recent real life clinical 
study in Colombia evaluating 217 IDDM patients (average baseline HbA1c of 8.97%, 
mean age 34 years, and average diabetes duration of 14 years) who initiated SAP 
therapy showed that SAP therapy led to a reduction of -1.47% HbA1c as well as a 
significant reduction in severe hypoglycaemic events. The impact of the reduction 
in the fear of hypoglycaemic events on quality of life was also included. Results: 
Life expectancy of patients with SAP was increased by 3.51 years and diabetes 
related complications were delayed on average by 1.74 years. The Incremental-
Cost-Effectiveness-Ratio (ICER) for SAP was $44,889,916COP ($24,939USD) per 
Quality-Adjusted-Life-Year gained based on direct costs only. SAP related ther-
apy costs were partially offset by the savings due to the reduction in long-term 
complications, including proliferative diabetic retinopathy (PDR), Severe Vision 
Loss (SVL), End Stage Renal Disease (ESRD), and Amputations (AMP). The relative 
reduction in incidence of these complications (PDR 42%, SVL 20%, ESRD 46%, AMP 
12%) as well as the average delay in their onset (4.9 years, 4.0 years, 3.8 years, 3.7 
years, respectively) due to SAP therapy is profound. When including indirect costs, 
SAP demonstrated an even lower ICER. Extensive sensitivity analyses showed the 
robustness of the results. cOnclusiOns: Using a payer’s perspective, our analysis 
showed that SAP is cost-effective over a lifetime horizon in IDDM patients in the 
Colombian setting (using a WTP threshold of $60,771,600COP [3x GDP]) and can 
lead to an increase in life expectancy. When using a societal perspective, SAP was 
even more cost-effective.
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was reduced to 22 items. Exploratory and confirmatory factor analysis identified 21 
items contributing to 3 hypoglycemia domains (Symptoms [8 items], Compensatory 
Behaviors [7 items], Worry [6 items]) and a single-item of global symptom awareness. 
HPQ domains had high internal consistency reliability (Cronbach’s alpha= 0.78-0.92). 
Construct validity was demonstrated by significant correlations between HPQ scores 
with HRQoL, treatment satisfaction, and health status. HPQ also demonstrated abil-
ity to discriminate between known groups. Compensatory behaviors and symptom 
awareness were higher for patients with a recent low blood sugar event (p< 0.001) 
and high symptom awareness corresponded to less concern about experiencing 
symptoms of low blood sugar and worry (p< 0.05). cOnclusiOns: These results 
provide preliminary evidence that HPQ is reliable and valid for assessing the experi-
ence and impact of hypoglycemia on T2DM patients.
PDB22
TRANSLATION AND vALIDATION OF HINDI vERSION OF DIABETES QUALITy OF 
LIFE – MEASURE (DQOL-M) IN INDIAN TyPE 2 DIABETES PATIENTS
Pawar S.1, Thakurdesai P.2
1Smt. Kashibai Navale College of Pharmacy, Pune and Research Scholar Karpagam University, 
Coimbatore, Pune, India, 2Indus Biotech Private Limited, Pune, India
Objectives: To test the reliability and validity and of newly translated Hindi version 
of DQOL-M instrument in Indian type 2 diabetic populations. MethOds: Backward 
and forward translation was carried out and intermediate version was compared 
with original instrument to check the linguistic equivalence. After pilot testing the 
final Hindi version of DQOL-M was administered to 250 patients with type 2 dia-
betes twice at the interval of four weeks. Psychometric parameters like treatment 
satisfaction, Impact of treatment, worries of social vocational issues of diabetes 
were assessed. Cronbach alpha for total score was calculated to study the reliability 
of instrument. Results: Internal consistency was assessed using Cronbach alpha 
and value of 0.86 was gained for the summary score. Cronbach alpha for treatment 
satisfaction was found to be 0.77, for Impact of treatment it was 0.73 and for wor-
ries of social vocational issues score of 0.83 was gained. No significant difference 
was observed in test-retest analysis. Pearson correlations were assessed for all the 
four subscales and were found to be significant. cOnclusiOns: This modified 
and final translated version of instrument confirms the linguistic validity of the 
questionnaire for the Hindi language and evaluates the psychometric properties 
of the questionnaire for psychometric validation. Indian Hindi version of DQOL-M 
is valid and reliable instrument for measuring HRQOL of diabetic type 2 patients.
DIABETES/ENDOCRINE DISORDERS – Health Care Use & Policy Studies
PDB23
PHARMACEUTICAL COST ANALySIS OF DIABETES MELLITUS USINg CLINICAL 
RISk gROUPS IN vALENCIAN COMMUNITy
Romero M.1, Uso Talamantes R.2, Vivas Consuelo D.3, De la Poza Plaza E.3,  
Sancho Mestre C.3, Trillo Mata J.L.2, Barrachina I.3
1Fundacion Salutia, Bogotá, Colombia, 2Conselleria de Sanidad, Valencia, Spain, Spain, 
3Universidad Politecnica de Valencia UPV, Valencia, Spain
Objectives: Metabolic agents have the highest expense (130 million Euros per year 
in the Valencian Community) among the top five therapeutic categories of drugs 
for adults aged 18 and over. Treatment of Diabetes Mellitus (DM) is the main cause 
of this. Moreover, diabetes is a chronic illness that requires continuous medical 
care and patient self-management education to prevent acute complications and 
to reduce the risk of long-term complications. Clinical Risk Groups (CRGs) are a 
tool claimed as valid for diabetes patient management. In this context we use this 
methodology to conduct a pharmaceutical cost analysis of diabetes in an Eastern 
Spanish region where the prevalence reaches approximately 8 %. MethOds: A 
database of 5,200,000 subjects was used to analyse the prevalence of patients with 
DM, comorbidity and complications. The patients with DM diagnoses were clas-
sified into CRGs to know their severity levels and pharmaceutical cost was also 
assigned. A multivariable statistical analysis was performed to evaluate the cor-
relation and level of explanation between CRGs’ severity level and pharmaceutical 
expenditure. Results: Identified 300,698 patients with DM type 2 for a prevalence 
of 7.85% in men and 6.77% in women being the 13.2% and 7,98% in unders 50 years 
old, respectively. The 69,1% treated with orals hypoglycemics being combied therapy 
in over 75% of these. The use cosumption ratio glucometer strip, increaes with 
disease progression. It Was posible to identify the presence of complicactions in 
patiens analysed. A high correlation between pharmaceutical costs and CRG severity 
level was found. Comorbidity is a predictor for adjusting the risk of pharmaceuti-
cal expenditure. cOnclusiOns: The model obtained could be a useful tool for 
managing pharmaceutical budget policies and patient management. The use of 
this measurement technique is useful for monitoring the health medical expense.
PDB25
INFLUENCE OF ONE wEEk EDUCATION PROgRAM ON THE kNOwLEDgE AND 
APPROACH OF PHARMACy STUDENTS TOwARDS DIABETES MELLITUS
Khan M.S., Akhtar N., Ali A.
The Islamia University of Bahawalpur, Punjab-Pakistan, Bahawalpur, Pakistan
Objectives: To assess the improvement in knowledge and attitude of Pharmacy stu-
dent towards diabetes by implementing one week education program. MethOds: 
Study was conducted between January 7, 2013 to January 11, 2013 which engaged 
pharmacy students comprising two groups: experimental and control groups. 
Lectures and visual presentations on diabetic education and practice were con-
ducted. Three surveys were performed on two group’s i.e. non intervened control, 
non- intervened experimental and intervened experimental surveys. Questionnaire 
was used as survey tool. Results: Mean score on knowledge about diabetes was 
increased from 68.81% to 88.90% after educational intervention while that of control 
group was 74.75%. General knowledge of diabetes was increased from 66.37% to 
89.90% while that of control was 69.28%. Risk factors knowledge was increased from 
61.05% to 90.20% while that of control was 70.20%. Symptoms knowledge increased 
debido a la DM se estimó en $21,516 ± 8062 año/persona. cOnclusiOnes: La DM 
afecta significativamente la productividad laboral en nuestro medio.
PDB19
COSTO DEL AUTOMONITOREO gLUCéMICO EN PACIENTES EN TRATAMIENTO 
COMBINADO ORAL y CON INSULINA EN ARgENTINA
Elgart J., Gonzalez L., Gagliardino J.J., Rucci E.
CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, 
Argentina, Buenos Aires, Argentina
ObjectivOs: Aunque el automonitoreo glucémico (AMG) es una herramienta útil 
para optimizar el control de la diabetes, no existe en Argentina evidencia de su uso 
e impacto económico. Este estudio trata de estimar en Argentina, el número de tiras 
reactivas (TR) para AMG utilizadas en el Sistema de la Seguridad Social (SSS) y su 
impacto en el costo total de la prescripción terapéutica, en la transición de terapia 
combinada de antidiabéticos orales (ADO) al agregado de insulina. MetOdOlOgías: 
Estudio observacional retrospectivo, utilizando registros de una organización del SSS 
(OSPERYH, consumo de TR de 681 afiliados durante 2012) y de otras dos entidades 
de la SSS, a través de 8.115 recetas anónimas de medicamentos y TR prescriptas 
en el período Febrero-Abril 2012 y registradas por el Colegio Farmacéutico de la 
Provincia de Buenos Aires (COLFARMA). Los resultados representan la media ± des-
vío estándar (DS) o proporciones. Evaluación estadística: utilizamos los test t de 
student, Kruskal-Wallis y Chi cuadrado, según correspondiera. Se consideraron sig-
nificativas diferencias con p< 0,05. ResultadOs: OSPERYH: las TR fueron provistas 
bajo sistema de auditoría que incluye educación diabetológica, tipo de tratamiento y 
grado de control metabólico. Los tipos de tratamiento afectaron significativamente 
el consumo mensual de TR: combinación ADOs 25±12 vs. , ADO+insulina 36±15. El 
costo total combinación ADOs fué $456 vs.ADO+insulina $669 y las TR represen-
taron el 42% y 32% del costo total, respectivamente. COLFARMA: también el tipo de 
terapia afectó significativamente el consumo mensual de TR pero con valores tres 
veces superiores: combinación ADOs 75±47 vs. ADO+insulina 89±63. El costo total 
combinación ADOs fue $711 vs.ADO+insulina $983, y las TR representaron el 63% y 
54% del costo total, respectivamente. cOnclusiOnes: El consumo de TR para AMG 
aumenta en función de la incorporación de insulina al tratamiento y auditorías 
como la descripta optimizan su consumo e impacto económico.
PDB20
RELACIóN DEL íNDICE DE MASA CORPORAL y gASTO EN MEDICAMENTOS EN 
PERSONAS CON DIABETES EN ARgENTINA
Prestes M., Elgart J., Gonzalez L., Gagliardino J.J.
CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, 
Argentina, Buenos Aires, Argentina
ObjectivOs: Evaluar la relación entre el Indice de Masa Corporal (IMC) y el gasto 
en medicamentos de personas con Diabetes (DM) en Argentina. MetOdOlOgías: 
Estudio descriptivo observacional relevando el IMC y el consumo de medicamentos 
de la Base QUALIDIAB. El gasto mensual en medicamentos se determinó mediante 
técnicas de microcosteo, considerándose el precio promedio de las presentaciones 
disponibles en el mercado, sin ajustes. Los valores se expresaron en pesos argen-
tinos (Diciembre 2012). Las personas se estratificaron según IMC de acuerdo a la 
clasificación de la OMS (Normal: ≥ 18,5 y < 25; Sobrepeso: ≥ 25 y < 30; Obesidad: 
IMC≥ 30). Los resultados se expresaron como media ± desvío estándar (DS). Para las 
comparaciones se utilizaron los test t de student, ANOVA y Kruskal-Wallis, según 
correspondiera. Coeficientes de correlación de Pearson (r) se utilizaron para evaluar 
el grado de asociación. Se consideraron significativos p< 0,05. ResultadOs: Se anal-
izaron 1134 registros, edad 63 ± 12 años, 55,4% mujeres. El gasto promedio mensual 
en medicamentos fue de $ 975, el gasto en medicamentos para la DM fue $779, 
para la Hipertensión $ 241 y para la Dislipemia $ 128. El gasto en medicamentos 
aumentó en función del IMC: Normal: $782; Sobrepeso: $936 y Obesidad: $1149. 
El gasto fue significativamente mayor en Hombres ($1045 vs. $919). El gasto total 
de medicamentos se correlacionó significativamente con IMC (r: 0,164), al igual 
que el correspondiente a medicamentos antihipertensivos (r: 0,113) y los utiliza-
dos para controlar la hiperglucemia (r: 0,079). cOnclusiOnes: En pacientes con 
DM en Argentina, el IMC se asocia positivamente con el gasto en medicamentos. 
Estrategias terapéuticas que disminuyan efectivamente el IMC generarían beneficios 
tanto médicos como económicos.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes & Patient 
Preference Studies
PDB21
PSyCHOMETRIC PROPERTIES OF THE HyPOgLyCEMIA PERSPECTIvES 
QUESTIONNAIRE (HPQ) IN TyPE 2 DIABETES MELLITUS
Kawata A.K.1, Ong S.H.2, Therapontos C.3, Mavrogenis P.3, Kulich K.2, Chen W.H.4, Coyne K.4
1Evidera, Bethesda, MD, USA, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharma 
Services Inc. Cyprus, Nicosia, Cyprus, 4Evidera, Bethesda, MD, USA
Objectives: The Hypoglycemia Perspectives Questionnaire (HPQ) was developed 
with clinician and patient input to assess symptoms, behaviors, and impact of 
hypoglycemia on diabetic patients. MethOds: The HPQ was administered to adult 
patients with type 2 diabetes mellitus (T2DM) on antidiabetic treatment as part 
of a cross-sectional, epidemiological study evaluating hypoglycemia and health-
related quality of life (HRQoL) in Cyprus. Demographic and clinical data were col-
lected. Patients also completed the Audit of Diabetes Dependent Quality of Life 
(ADDQoL-19), treatment satisfaction questionnaire, and EuroQol-5 Dimensions (EQ-
5D). The original HPQ consisted of 45 items rating current status or behavior related 
to hypoglycemia on an 11-point numeric rating scale (NRS) and 7 additional descrip-
tive hypoglycemia event frequency items. Analyses included examination of HPQ 
item performance, item reduction, and factor structure. Measurement properties 
(reliability, construct validity, known-groups validity) of the final HPQ were evalu-
ated. Results: A total of 500 T2DM patients completed the HPQ with a mean age 
of 61±10 years; 32.6% women. Based on item evaluation, the original HPQ item pool 
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this study was to evaluate the cost-effectiveness of adding TVR to PR in treatment 
naive and previously treated patients with HCV in Argentina compared to PR alone 
and with the addition of BOC. MethOds: A lifetime Markov model was developed 
including HCV, cirrhosis, liver transplant and death as health states. QALYs as an 
outcome measure, a private health subsector perspective and a 5% discount rate for 
health benefits and costs have been used. Costs are expressed in local currency. A 
review of the literature to obtain epidemiologic and resources utilization data was 
performed and when data were not available or validation was needed a Delphi 
panel with local experts was carried out. Deterministic and probabilistic sensitivity 
analysis was performed. Results: In comparison with PR, TVR avoided 166 cirrho-
sis cases and 13 deaths per 1,000 patients and shown an ICER of $141,922/QALY and 
$74,332/QALY for the naïve and for the previously treated patients respectively. TVR 
presented extended dominance (lower ICER) against BOC in naïve patients and com-
plete dominance (less costly and more efficacious) in most of the previously treated 
ones, except in the partial responders subgroup. Against the WHO criteria TVP ver-
sus PR presented a 42% of probability of being cost effective for naïve and 75% of 
probability of being cost effective for previously treated patients. cOnclusiOns: 
TVR dominated BOC and its ICER against double therapy was slightly above WHO 
3x GDP criteria in Argentina from a private subsector perspective.
PgI3
ANáLISIS DE COSTO EFECTIvIDAD DE ACIDO gADOTERICO FRENTE A OTROS 
MEDIOS DE CONTRASTES BASADOS EN gADOLINIO
Simbaqueba E.1, Uriza L.F.2, Romero M.1, Huerfano L.1
1Fundacion Salutia, Bogotá, Colombia, 2Hospital Universitario San Ignacio, Pontificia Universidad 
Javeriana, Bogotá, Colombia
ObjectivOs: Evaluar la costo efectividad del uso de ácido gadotérico en reso-
nancia magnética para pacientes con insuficiencia renal crónica tipo 4 y 5, ver-
sus otros medios de contraste gadolínicos (gadopentetato de dimeglumina, 
gadoversetamida, gadodiamida, gadobutrol) analizando como desenlace la sobre-
vida del paciente que presenta como evento adverso Fibrosis Sistémica Nefrogénica 
(FSN). MetOdOlOgías: La efectividad de medios de contraste ha sido evaluada en 
términos de seguridad. Al revisar la literatura se encontraron diferencias en la proba-
bilidad de desarrollo (FSN) como principal complicación del uso de estos medios de 
contraste en pacientes con enfermedad renal avanzada, siendo letal en más del 56% 
de los casos. Mediante un modelo de árbol de decisión desde la perspectiva del tercero 
pagador se compararon los diferentes medios de contraste tomando como desenlace 
de análisis la sobrevida medida en años de vida ganados, para una esperanza de vida 
de 64,5 años y una edad promedio de 60 años, sobre las características del caso base. 
Los costos fueron obtenidos de precios de mercado de bases de datos de aseguradoras 
en pesos colombianos, 2012. El costo usado para las tecnologías fue el de la presen-
tación 15 ml. ResultadOs: No se encontraron reportes de casos de FSN con gado-
térico o gadobutrol. El ácido gadotérico mostró un promedio de año de vida de 1,706 
mejor que gadodiamida, gadopentetato de dimeglumina y gadoversetamida; y fue 
el menos costoso frente a todos los analizados (COP$ 132.000) seguido de Gadobutrol 
(COP$ 161.202) siendo dominante en todos los escenarios analizados. En el análisis 
tipo Montecarlo con variaciones de +/-50% mantiene su dominancia en el 95% de las 
iteraciones. cOnclusiOnes: El acido gadotérico es la opción más favorable por su 
dominancia dada por su menor costo, y mejor o igual efectividad frente a los demás 
comparadores, justificando con esta información su mayor preferencia en el uso.
PgI4
RULINg OUT IBD IN THE UNITED kINgDOM AND BRAzIL: IS THE USAgE OF 
F-CALPROTECTIN IN PRIMARy CARE COST-EFFECTIvE?
Mascialino B.1, Hermansson L.L.2, Larsson A.3
1Thermo Fisher Scientific, Phadia, Uppsala, Sweden, 2Thermo Fisher Scientific, Uppsala, Sweden, 
3Uppsala University, Uppsala, Sweden
Objectives: The inflammatory bowel diseases (IBD) are characterized by chronic 
inflammation of the gastrointestinal tract; the irritable bowel syndrome (IBS) is a func-
tional disorder (prevalence 10%-20%). They present overlapping symptoms, making 
diagnosis difficult in primary care. Endoscopy is the gold standard for IBD, but it often 
turns negative due to IBD’s low prevalence, it is expensive, uncomfortable and risky 
for the patient. F-Calprotectin is a marker of intestine inflammation: as IBD patients 
exhibit levels higher than the general population and IBS patients, F-Calprotectin can 
be used to rule out IBD. The only CE evaluation on F-Calprotectin has been published 
by NHS (CEP09041, 2010); based on new evidence, we propose a refined model to evalu-
ate the CE of F-Calprotectin compared to the standard pre-endoscopic serologic test 
(CRP+ESR) to distinguish IBD from IBS in the UK and Brazil. MethOds: F-Calprotectin 
sensitivity (0.96) and specificity (0.96) were evaluated from a meta-analysis performed 
in March 2013; CRP+ESR sensitivity (0.35) and specificity (0.73), and the costs come 
from CEP09041. Published HRQoL values for IBD and IBS were transformed in QALYs 
with transfer-to-utility techniques. The outcomes included cost savings, cost per 
QALY. Uncertainty was addressed with a probabilistic sensitivity analysis. Results: 
Results for UK show that F-Calprotectin is CE with respect to CRP+ESR: a) it results 
in more corrected IBD diagnoses at a lower price (it costs 113£ less per patient); b) it 
reduces the number of unnecessary endoscopies, increasing the number of correctly 
diagnosed IBD (N= 59) and IBS (N= 195) patients; c) it brings about a QALY gain per 
patient equal to 0.0034QALYs; the ICER of the CRP+ESR diagnostic strategy is 47,783£, 
and it falls well outside the cost-effectiveness bounds (20,000–30,000£ per additional 
QALY). Similar results were found for Brazil. cOnclusiOns: F-Calprotectin is CE to 
rule out IBD in primary care in UK and Brazil.
PgI5
COST-EFFECTIvENESS OF TELAPREvIR IN gENOTyPE 1 CHRONIC HEPATITIS C 
vIRUS (HCv) INFECTION IN CHILE
Garcia Marti S.1, Alcaraz A.1, Valanzasca P.1, Garay Ulises U.1, McMullen M.1, Rey Ares L.1, 
Peirano I.2, Oksenberg Reisberg D.3, Soza Ried A.4, Poniachik J.5, Brahm Barril J.R.6, Caporale J.1
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Janssen, 
Buenos Aires, Argentina, 3INDISA Clinica de Familia, Providencia, Chile, 4Pontificia Universidad 
from 80.70% to 95.58% while that of control was 88.56%. Therapeutic complications 
knowledge was increased from 71.58% to 88.57% while that of control was 78.82%. 
Medication knowledge of diabetes was increased from 80.26% to 83.67% while that 
of control was 74.51%. Lifestyle knowledge of diabetes was increased from 72.81% to 
89.80% while that of control was 84.64%. Knowledge about preventions in diabetes 
was increased from 69.47% to 86.53% while that of control was 80.78%. Knowledge 
about diet was increased from 48.68% to 77.55% while that of control was 42.16%. 
Knowledge about monitoring diabetic conditions was increased from 84.21% to 
92.35% while that of control was 86.27. Scores in all diabetic knowledge aspect 
was increased after education intervention and was significantly (P< 0.05) different 
from that of control group. cOnclusiOns: Institutions may ethically help in the 
reinforcement of student’s knowledge by implementing such educational programs 
which may increase the educational skills, efficiency and confidence of pharmacy 
students as well as professionals.
PDB26
ACUTE ExPOSURE OF BISPHENOL-A FROM ELECTRONIC gADgETS DOES NOT 
INDUCE OxIDATIvE STRESS IN THE RAT BRAIN
Kumar N.1, Sharma V.P.2
1Shri Ramswaroop Memorial University, Barabanki, India, 2CSIR-Indian Institute of Toxicology 
Research, Lucknow, India
Objectives: To investigate the effects of BPA on oxidative damage in terms of activ-
ity level of antioxidant enzymes in different regions of the rat brain. MethOds: 
In this study, BPA migration was estimated through physio-chemical parameters 
and leachate (equivalent to 4mg/kg body weight) was used for animal dosing. 
Three groups of Albino Wister rats (190+20grm) were used for control, sham, and 
treated. The antioxidant enzymes including superoxide dismutase (Mn-SOD), cata-
lase (CAT), glutathione peroxidase (GPx) and reduced glutathione level (GSH) were 
measured in different brain regions i.e. corpus striatum, frontal cortex, thalamus 
and midbrain. Results: No significant changes were observed in most of the 
brain regions yet the level of GPx activity in corpus striatum (29.65±0.98 nmoles/
min/mg protein) and level of GSH activity in frontal cortex (2.33±0.12 µmoles/g 
protein) was found to decrease significantly (p< 0.05) when compared to controls. 
In addition, no significant effects were observed for the oxidative damage in brain 
regions of sham group when compared to control group. cOnclusiOns: Thus 
study suggests that acute exposure (4mg/kg body weight per day up to 28 days) of 
BPA does not induce significant oxidative damage in the rat brain. Furthermore, 
study might re-examine before affirm the final remark for subscribers and regula-
tory bodies at similar doses.
gASTROINTESTINAL DISORDERS – Clinical Outcomes Studies
PgI1
COSTS OF PRIMARy BILIARy CIRRHOSIS TREATMENT wITH URSODEOxyCHOLIC 
ACID IN BRAzIL
Lemos L.L.P., Mata A.D., Gomes R.M., Guerra Junior A.A., Acurcio F.A.
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Objectives: To estimate the cost of treatment of primary biliary cirrhosis with 
ursodeoxycholic acid (UDCA) in Brazil and to evaluate the efficacy and safety of 
this treatment. MethOds: We considered the doses of 8, 12 and 15mg/Kg and 
a patient weighing 70Kg to estimate the cost of treatment. We used the maxi-
mum price to the producer in the CMED (Drug Market Regulation Chamber) list 
of 03/15/2013 with 18% of ICMS (Circulating Goods and Services Tax), and applied 
CAP (Adequacy Coefficient of Prices)of 25% . We used Purchasing Power Parity 
of 1,0USD= 1,8BRL. To access efficacy and safety we searched the databases The 
Cochrane Library, CDR, Tripdatabase, MEDLINE and LILACS to identify systematic 
reviews (SR) of clinical trials that reported data on mortality, biochemical improve-
ment measurements and adverse events. Results: The estimated annual cost of 
treatment was USD2,239.24 with the dose of 8mg/Kg; USD3,168.97with the dose 
of 12mg/Kg; and UDS4,098.71 with the dose of 15mg/Kg. We included seven SRs; 
four evaluating UDCA versus placebo/observation; one UDCA versus colchicine; 
one UDCA versus methotrexate; and one UDCA versus bezafibrate. Generally, until 
four years of treatment there were no difference between UDCA and placebo/other 
interventions with respect with mortality, hepatic transplant incidence, wors-
ening or arising of itching and fatigue, and incidence of hepatic complications. 
In the other hand there were improvements in surrogate outcomes like hepatic 
function markers, especially bilirubin. In all studies UDCA was well tolerated by 
patients. cOnclusiOns: Improvements in the blood levels of hepatic markers 
did not match mortality rates or the incidence of transplant. The main symptoms 
of the disease, itching or fatigue, were not altered by the use of UDCA. There is a 
lack of evidence of studies evaluating quality of life of the patients, which perhaps 
could be improved by the use of UDCA. Besides, long observational studies could 
connect biochemical improvement and mortality rate.
gASTROINTESTINAL DISORDERS – Cost Studies
PgI2
COST-EFFECTIvENESS OF TELAPREvIR IN gENOTyPE 1 CHRONIC HEPATITIS C 
vIRUS (HCv) INFECTION IN ARgENTINA
Garcia Marti S.1, Alcaraz A.1, Valanzasca P.1, Garay Ulises U.1, McMullen M.1, Rey Ares L.1, 
Peirano I.2, Bessone F.3, Fainboim H.4, Gadano A.5, Galdame O.5, Vujacich C.6, Caporale J.1
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Janssen, 
Buenos Aires, Argentina, 3Sanatorio Parque, Santa Fe, Argentina, 4Hospital Muñiz, Buenos Aires, 
Argentina, 5Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 6FUNCEI, Buenos Aires, 
Argentina, Buenos Aires, Argentina
Objectives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + RBV (PR) 
are a new therapeutic option with higher rates of sustained virological response 
(SVR) than dual therapy (PR) alone in chronic hepatitis C. Currently, two alternatives 
of DAA, telaprevir (TVR) and boceprevir (BOC), are available in Argentina. The aim of 
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gASTROINTESTINAL DISORDERS – Patient-Reported Outcomes & Patient  
Preference Studies
PgI8
QUALITy OF LIFE IN PATIENTS wITH gASTROESOPHAgEAL REFLUx DISEASE IN 
SLOvAkIA
Bielik J.1, Marusakova E.2, Matisakova I.1, Gerlichova K.3
1Trencin University of Alexander Dubcek, Trencin, Slovak Republic, 2GlaxoSmithKline Slovakia, 
Bratislava, Slovak Republic, 3Trencin University, Trencin, Slovak Republic
Objectives: The estimated prevalence of complicated gastroesophageal reflux dis-
ease (GERD) is approximately 2% in the European population and showing 10-fold 
increase over the past 20 years. The objective of this paper was to find out the level 
of QoL in patients with GERD in Slovakia. MethOds: The primary method used for 
the analysis of QoL was the presence of transient disability period and combined 
questionnaire consisting of 4 parts: A. Demography and socioeconomics (13 items), 
B. Generic questionnaire (SF-36), C. Visual scale (4 items), D. Complementary (infor-
mation and habits, 13 items). The Likert scale was used in closed questions. The 
sample included 100 patients treated in the gastroenterological outpatient clinic 
(34 men and 66 women). Of these, 72 patients were in productive age. The patients 
were chosen according to the order in which they visited the clinic. Results: One 
month and two months of sick days were recorded in 8.3% and 7% of patients, 
respectively; 84,7% of patients did not report any sick days. The loss of money of 
up to 400 € and between 401 and 800 € was recorded in 11.1% and 4.2 % of patients, 
respectively; 84.3 % of did not report any loss of money. Present level of QoL was 
identified as 5.12 on the scale of 10, while in the time of the GERD diagnosis it was 
3.86. QoL was 8.25 in the time without GERD and 8.17 in optimal state of health, 
respectively. Future expectations were perceived as positive in 56% of patients and 
negative in 44% of patients. cOnclusiOns: A total of 95% of patients were well 
and very well informed about its characteristics. Paradoxically, only 48% of them 
used their medications regularly, although regular and occasional administration 
of medications was shown to have positive impact on health status in 56% and 44% 
of patients, respectively.
gASTROINTESTINAL DISORDERS – Health Care Use & Policy Studies
PgI9
A LOw ANTIvIRAL TREATMENT RATE IN CHRONIC HEPTITIS C PATIENTS IN 
TAIwAN- A NATIONwIDE PHySICIAN-BASED SURvEy
Yu M.L.1, Huang J.F.2
1Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan, 2Kaohsiung Municipal Hsiao-
Kang Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan
Objectives: Hepatitis C virus (HCV) infection is the most common cause of liver 
cirrhosis and liver cancer worldwide. In addition to low disease awareness both in 
public and affected patients, a low disease treatment rate remains to be an impor-
tant issue regarding disease control in primary care. The nationwide prevalence 
of anti-HCV seropositivity in Taiwan is 4.4%. However, there are scattered hyper-
endemic areas in Southern Taiwan with an extremely high prevalence rate reaches 
57.9% high. Therefore, several public health strategies with periodic assessment 
aiming to promote liver health have been performed for two decades. MethOds: 
We aimed to elucidate the reasons of lower treatment rate in our country. In this 
hospital-based, physician-oriented study, a proportional sampling based on previous 
documented HCV prevalence of geographic locations in Taiwan was conducted. An 
anonymous questionnaire regarding treatment status in anti-HCV-positive patients 
was collected from these selected physicians. Patient’s information including sex, 
age, anti-HCV therapy, and the reason for not receiving antiviral therapy was 
inquired by their primary care physicians. Results: Seventy-six physicians were 
recruited into this survey (Medical center n= 46; regional hospital n= 23; primary 
clinic n= 7). A total of 2,722 anti-HCV-positive subjects in Taiwan were enrolled into 
this analysis. Among them, 54.5% (1,479/2,722) had ever received anti-HCV treat-
ment before. The treatment rate of medical centers was 63.1%, which was higher 
than 52.7% of regional hospitals, and 33.8% of primary clinics, respectively (p< 0.0001 
for pair-wise chi square test; p< 0.0001 for trend test). Males had a significantly 
higher motivation for receiving antiviral therapy than females (58.6% vs. 50.5%, 
p< 0.0001). The main reason for not receiving anti-HCV therapy was fear of side 
effects (38%), followed by ineligibility for insurance reimbursement (18%), and lack 
of awareness (11%). cOnclusiOns: In Taiwan, half of the HCV-infected patients 
have not received antiviral therapy. The low treatment rate may contribute to HCV 
hyperendemic status.
MENTAL HEALTH – Clinical Outcomes Studies
PMH1
EvALUATION OF FACTORS AFFECTINg TREATMENT RESPONSE AND RISk 
FACTORS FOR PATIENTS DIAgNOSED wITH NON-PSyCHOTIC MAjOR 
DEPRESSIvE DISORDER: A LITERATURE REvIEw
Greene N.1, Greene M.2
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Georgia State 
University, Bethel, MA, USA
Objectives: To conduct a systematic review of literature on factors that are 
affecting patient treatment response and risk factors for patients diagnosed 
with Non-Psychotic Major Depressive Disorder (MDD). MethOds: A literature 
search was performed using relevant search terms to identify articles published 
from 2000 to 2010 on the factors affecting treatment response and risk factors 
for MDD. Studies were identified through electronic Embase, Cochrane, Medline, 
and PubMed databases. Additional parameters were placed on the final search 
strategy to limit the retrieval to articles written in English, involving human 
subjects. Results: The initial search revealed 874 articles for factors affecting 
treatment response and 590 articles for risk factors affecting MDD from PubMed/
Medline/Embase/Cochrane databases. After removing duplicates and non-rele-
Católica de Chile, Santiago de Chile, Chile, 5Hospital Clinico de la Universidad de Chile, Santiago 
de Chile, Chile, 6Hospital Clìnico Universidad de Chile, Santiago de Chile, Chile
Objectives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + RBV 
(PR) are a new therapeutic option with higher rates of sustained virological 
response (SVR) than dual therapy (PR) alone in chronic hepatitis C. Currently, 
two alternatives of DAA, telaprevir (TVR) and boceprevir (BOC), are available in 
Chile. The aim of this study was to evaluate the cost-effectiveness of adding TVR 
to PR in treatment naive and previously treated patients with HCV in Chile com-
pared to PR alone and with the addition of BOC. MethOds: A lifetime Markov 
model was developed including HCV, cirrhosis, liver transplant and death as 
health states. QALYs as an outcome measure, a health care system perspective 
and a 6% discount rate for health benefits and costs have been used. Costs are 
expressed in local currency. A review of the literature to obtain epidemiologic 
and resources utilization data was performed and when data were not avail-
able or validation was needed a Delphi panel with local experts was carried out. 
Deterministic and probabilistic sensitivity analysis was performed. Results: 
In comparison with PR, TVR avoided 174 cirrhosis cases and 16 deaths per 1,000 
patients and shown an ICER of $14,730,736/QALY and $8,300,511/QALY for the 
naïve and for the previously treated patients respectively. TVR dominated BOC 
in naïve patients and in most of the previously treated ones (was less costly 
and more efficacious), except in the partial responders subgroup. Against the 
WHO criteria TVP versus PR presented 80% of probability of being cost effective 
for naïve and 96% of probability of being cost effective for previously treated 
patients. cOnclusiOns: TVR dominated BOC and was cost-effective against 
WHO 3x GDP criteria in comparison to double therapy from the national health 
care system perspective in Chile.
PgI6
ECONOMIC EvALUATION OF DIRECT ACTINg ANTIvIRAL (DAA) TREATMENTS 
FOR HEPATITIS C vIRUS (HCv) INFECTION IN PREvIOUSLy TREATED PATIENTS 
FROM THE PERUvIAN HEALTH CARE SySTEM PERSPECTIvE
Ariza J.G.1, Hinojosa R.2
1Janssen Cilag, Bogotá, Colombia, 2Janssen Cilag Peru, Lima, Peru
Objectives: DAA treatments in addition to Ribavirin (RBV) and peginterferon 
(Peg-INF) (PR), provides the greatest opportunity to fully achieve sustained viro-
logical response (SVR) in HCV infected patients. Currently, two alternatives of 
DAA, telaprevir (TVR) and boceprevir (BOC), are available in Peru. The objective 
of this study is to assess: which is the most efficient DAA treatment to compli-
ment the PR in previously treated patients. MethOds: A Markov model was 
used from the payer perspective to estimate costs and benefits throughout the 
whole life. Transition probabilities, utilities and resources usage were obtained 
from literature and through a mixed treatment comparison. Only direct costs 
were considered as medications, laboratory tests, complications costs and 
adverse events by using tariffs and tender prices from EsSalud. Outcomes were 
measured as SVR, quality adjusted life years (QALY) and events of cirrhosis per 
1,000 treated patients. Two alternatives were assessed: 1) 12 weeks of TVR plus 
PR and 2) 24-44 weeks of BOC plus PR. Discount rate 3% and exchange rate (1 
USD = 2,6 S/). Results: 1) Total costs (USD): TVR plus PR ($56,058), BOC plus PR 
($64,536). 2) Medication costs (USD): TVR plus PR ($47,297), BOC plus PR ($54,649). 
3) SVR: TVR plus PR (76%), BOC plus PR (60%). 4) QALY: TVR plus PR (6,02), BOC 
plus PR (5,87). 5) Cirrhosis per 1,000 treated patients: TVR plus PR (311), BOC plus 
PR (363). Incremental Cost Effectiveness Ratio (ICER) was negative, showing that 
12 weeks of TVR plus PR is a dominant therapy. cOnclusiOns: When a DAA is 
considered, in addition to PR, for previously treated patients, TVR is the preferred 
choice because of its potential cost-savings versus BOC and incremental health 
benefits versus BOC.
PgI7
COST-EFFECTIvENESS OF TELAPREvIR IN gENOTyPE 1 CHRONIC HEPATITIS C 
vIRUS (HCv) INFECTION IN COLOMBIA
Garcia Marti S.1, Alcaraz A.2, Valanzasca P.2, Garay O.U.2, McMullen M.2, Rey Ares L.2,  
Idrovo V.3, Prieto Ortiz J.4, Tapias M.3, Obregon J.5, Ariza J.G.6, Caporale J.2
1Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, 2Institute for Clinical 
Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 3Hospital Universitario Fundación 
Santa Fe, Bogotá, Colombia, 4Clínica del Country, Bogotá, Colombia, 5Hospital Militar Central, 
Bogotá, Colombia, 6Janssen Cilag, Bogotá, Colombia
Objectives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + 
RBV (PR) are a new therapeutic option with higher rates of sustained virologi-
cal response (SVR) than dual therapy (PR) alone in chronic hepatitis C (HCV). 
Currently, two alternatives of DAA, telaprevir (TVR) and boceprevir (BOC), 
are available in Colombia. The aim of this study was to evaluate the cost-
effectiveness of adding TVR to PR in treatment naive and previously treated 
patients with HCV in Colombia compared to PR alone and with the addition 
of BOC. MethOds: A lifetime Markov model was developed including HCV, 
cirrhosis, liver transplant and death as health states. QALYs as an outcome 
measure, a health care system perspective and a 3% discount rate for health 
benefits and costs have been used. Costs are expressed in local currency. A 
review of the literature to obtain epidemiologic and resources utilization data 
was performed and when data were not available or validation was needed a 
Delphi panel with local experts was carried out. Deterministic and probabilis-
tic sensitivity analysis was performed. Results: In comparison with PR, TVR 
avoided 172 cirrhosis cases and 24 deaths per 1,000 patients and shown an ICER 
of $21,260,647/QALY and $8,461,107/QALY for the naïve and for the previously 
treated patients respectively. TVR dominated BOC in naïve patients and in most 
of the previously treated ones (was less costly and more efficacious), except 
in the partial responders subgroup. These results were robust in the sensitiv-
ity analysis. cOnclusiOns: TVR dominated BOC and and was cost-effective 
against WHO 3x GDP criteria in comparison to PR from the national health care 
system perspective in Colombia.
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PMH4
A COMPREHENSIvE REvIEw OF EPIDEMIOLOgy AND ECONOMIC STUDIES FOR 
PATIENTS DIAgNOSED wITH NON-PSyCHOTIC MAjOR DEPRESSIvE DISORDER
Greene N.1, Greene M.2
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Georgia State 
University, Bethel, MA, USA
Objectives: To conduct a systematic review of literature in on epidemiology and 
economic studies for patients diagnosed with Non-Psychotic Major Depressive 
Disorder (MDD). MethOds: The initial search strategy was developed in the 
PubMed/Medline database, and was then translated for the Cochrane and Embase 
database searches. Search strings for epidemiology and economics studies for MDD 
were constructed using varied approaches that included the use of MeSH terms, 
as well as keywords that would afford the best retrieval. Search statements were 
then combined to produce a final search set. Additional parameters were placed on 
the final search strategy to limit the retrieval to articles written in English, involv-
ing human subjects and published between 2000 and 2010. Results: Our search 
revealed 289 articles for epidemiology and 200 articles for economic studies on 
MDD from PubMed/Medline/Embase/Cochrane databases. After removing dupli-
cates and non-relevant articles, 17 for epidemiology and 26 for economic studies 
were included in the final analysis. Fifteen studies on epidemiology were focused 
on MDD prevalence, one study was on cumulative incidence. Prevalence estimates 
were higher for lifetime than past year and ranged between 3.1% and 26.6% for life-
time prevalence and between 1.5% and 11.7% for past-year prevalence. Two studies 
examined burden of illness, one study budgetary impact of MDD, 14 studies exam-
ined cost effectiveness of MDD treatments, 3 studies examined cost utility analysis 
and 6 other studies examined retrospective claims analysis. cOnclusiOns: MDD 
prevalence was higher in the lifetime estimates, when compared to the estimates 
reflecting shorter time frames, although there appeared to be greater variability in 
the lifetime estimates. Overall, the cost of treating MDD varied with type of study, 
study time frame, study perspective, the year in which the costs were calculated, 
and the pharmacotherapy prescribed.
PMH5
EvALUATION OF ASSOCIATIONS AMONg BIOMARkERS, CORRELATES AND 
TREATMENT EFFICACy IN CLINICAL STUDIES IN PATIENTS DIAgNOSED wITH 
NON-PSyCHOTIC MAjOR DEPRESSIvE DISORDER: A LITERATURE REvIEw
Greene N.1, Greene M.2
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Georgia State 
University, Bethel, MA, USA
Objectives: To perform a systematic review of literature in peer-reviewed 
journals on clinical biomarkers, correlates and treatment efficacy in clinical 
studies on patients diagnosed with Non-Psychotic Major Depressive Disorder 
(MDD). MethOds: The initial search strategy was developed in the PubMed/Medline 
database and was then translated for the Cochrane and Embase database searches. 
Search strings for biomarkers, correlates and treatment efficacy in patients with 
MDD were constructed using varied approaches that included the use of MeSH 
terms, as well as keywords that would afford the best retrieval. Also included were 
search terms that used an asterisk as a wildcard applied to a word stem. Search 
statements were then combined to produce a final search set. Additional parameters 
were placed on the final search strategy to limit the retrieval to articles written in 
English, involving human subjects and published between 2000 and 2010. Results: 
The initial search revealed 871 articles from PubMed/Medline/Embase/Cochrane 
databases. After removing duplicates and non-relevant articles, the final articles 
that were included in the review were 131. Forty-eight studies examined biomarkers 
and primarily focused on the relationship between biomarkers and MDD treat-
ment response. Only 29 of the 48 studies found a significant association between a 
biomarker and treatment response. Twenty-nine studies examined MDD correlates 
such as comorbidity or demographic variables. A poorer response to treatment was 
found for those patients who experienced comorbid anxiety, irrespective of the 
type of treatment. Fifty-four studies focused on treatment efficacy and are divided 
into 3 groups: SSRIs only, SNRIs only, and a comparison across SSRIs, SNRIs, and 
bupropion. Overall, the SSRIs showed comparable efficacy when compared to each 
other or placebo. cOnclusiOns: Most of the biomarker studies examined associa-
tions between the serotonin transporter and response to various MDD treatments. 
The majority of efficacy studies found that the treatments that are within the class 
had comparable efficacy.
MENTAL HEALTH – Cost Studies
PMH6
THE IMPACT OF ANTIPSyCHOTICS POLyPHARMACy ON HEALTH CARE COSTS 
OF PEOPLE wITH MENTAL DISORDERS IN SãO PAULO CITy, BRAzIL
Razzouk D., Sousa A., Oliveira G.G., Cardoso A., Mari J.J.
Universidade Federal de Sao Paulo, SAO PAULO, Brazil
Objectives: Antipsychotics polypharmacy (AP) has been associated with more 
adverse drug effects, higher treatment costs, worse clinical outcomes and sudden 
death. Though, the frequency of such practice may reach 50 % in some clinical set-
tings. The aims of this study were to estimate AP costs and its influence on the direct 
costs of health care package in a sample of people with mental disorders in São Paulo 
city, Brazil. MethOds: We used a bottom-up approach for the estimation of direct 
costs according to public health service provider perspective. Direct costs included 
costs with accomodation (residential service), inpatient, outpatient and emergency 
services and treatment received in the previous month, in 147 subjects with mental 
disorders living in twenty residential services during the year 2011. We evaluated 
quality of life, social behavior problems, psychiatric diagnosis, severity of symptoms, 
sociodemographics characteristics and pattern of health service use. Results: AP 
was found in 38% of the sample and it was not related with gender, age, severity of 
psychiatric symptoms, quality of life and social behavior problems. Antipsychotics 
monotherapy costs were related with the type of antipsychotic: Atypical antipsychot-
vant articles, the final articles that were considered for review were 82 for treat-
ment response and 13 for risk factors. Fifty-one studies examined non-genetic 
factors, serotonin-related genetic factors and variety of genes and polymorphism 
biomarkers to determine their association with MDD treatment response. Thirty-
one studies focused on variables that were found to be associated with some 
aspect of MDD and their impact on treatment response and include: comor-
bidity (n= 12), demographic and socioeconomic (n= 6), and depression-related 
(n= 13) variables. Thirteen studies examined the risk factors for MDD. Of these, 2 
studies focused on the role of biomarkers in MDD risk. And, 11 studies focused 
on variables that were found to be associated with some aspect of MDD and 
their impact on MDD risk, and focused on comorbidity (n= 5), demographic and 
socioeconomic (n= 2), depression-related (n= 3), and environmental variables 
(n= 1). cOnclusiOns: The majority of the biomarker studies examined associa-
tions between the serotonin transporter, genes and polymorphisms in response 
to various MDD treatments. With respect to correlate studies, younger age of MDD 
onset, as well as family history of mood disorders, were both associated with a 
longer duration of MDD illness.
PMH2
LENgTH OF STAy AND OUTCOMES FOR ADOLESCENTS TREATED FOR 
SUBSTANCE USE DISORDER: AN ANALySIS OF DOSE RESPOSE USINg 
PROPENSITy SCORES
Ciesla J.1, Mazurek K.2
1Northern Illinois University, DeKalb, IL, USA, 2University of Illinois, Champaign-Urbana, 
Champaign, IL, USA
Objectives: This research uses propensity score methods to identify the relation-
ship between amount of treatment and treatment outcome for adolescents with 
psychoactive substance use disorder (PSUD). The objective is to describe the dose 
response relationship in terms relevant in economic evaluation. Outcomes studies 
in this population show that longer treatment leads to more positive outcomes. 
The standard for residential programs is a minimum of 21 days of treatment and 
ideally up to 90 days. MethOds: The subjects are 377 adolescents who success-
fully completed primary treatment from 2004-2010. All were placed at ASAM level 
III.5 (Clinically-Managed, Medium/High Intensity Residential). The data are from 
treatment records and a 234-item questionnaire. The questionnaire responses were 
matched to variables in treatment records creating a rich source of pre-treatment 
characteristics. This research operationalizes dose with four one-month categories 
(1 dose= 1 month) to capture nonlinearities between service use and outcomes. The 
outcome is three-month post-treatment drug/alcohol abstinence. The categories 
were fairly even and captured 92% of variation in dose. The first stage of statistical 
analysis used multinomial logistic regression to predict dosage with pre-treatment 
variables while adjusting for characteristics influencing both dose and treatment 
outcome. Propensity scores were then created for each dosage category. The dose 
response relationship was assessed using a binomial logistic regression includ-
ing the four dose categories as dummy variables (lowest dose category as refer-
ence). Results: The overall relationship between dose and outcome was significant 
(p= 0.01) as were outcome improvements over the four doses. Improvements were 
significant (p≤ 0.01) decreasing as dose increased—Exp.(B) was1.204 (1.2 times 
more likely to abstain) for one month, 1.532 two months, 1.643 three months, and 
1.794 for four months (% correctly classified= 94.2; – 2LL= 44.712; Cox and Snell 
R2= 0.475.) cOnclusiOns: This research shows a significant dose response rela-
tionship between treatment length and treatment outcome with response dimin-
ishing on the margin.
PMH3
CLINICAL OUTCOMES OF PATIENTS wITH MAjOR DEPRESSIvE DISORDER 
TREATED wITH EITHER DULOxETINE OR SELECTIvE SEROTONIN REUPTAkE 
INHIBITORS IN MExICO
Hong J.1, Novick D.1, Montgomery W.2, Dueñas H.3, Peng X.4, Kadziola Z.5, Haro J.M.6
1Eli Lilly and Company, Windlesham, UK, 2Eli Lilly Australia Pty Ltd, West Ryde, Australia, 3Eli 
Lilly de Mexico, México D.F., Mexico, 4Eli Lilly and Company, Indianapolis, IN, USA, 5Eli Lilly 
GmbH, Vienna, Austria, 6Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, 
Barcelona, Spain
Objectives: To compare treatment outcomes in patients with major depressive dis-
order (MDD) treated with either duloxetine or a selective serotonin reuptake inhibi-
tor (SSRI) for up to 6 months in a naturalistic setting in Mexico. MethOds: Data in 
this post hoc analysis were taken from a 6-month prospective, non-interventional, 
observational study that included a total of 1,549 MDD patients without sexual 
dysfunction in twelve countries (N= 591 in Mexico). Depression severity was meas-
ured using the Clinical Global Impression (CGI) and the 16-item Quick Inventory of 
Depressive Symptomatology Self-Report (QIDS-SR16). Pain was measured using the 
pain related items of the Somatic Symptom Inventory (SSI), and quality of life (QoL) 
was measured using the EQ-5D instrument with the UK population tariff and the 
EQ-VAS. Probabilities of initiating duloxetine (vs. SSRIs), expressed as propensity 
scores, were first constructed using logistic regression. Mixed effects modelling 
with repeated measures (MMRM) analysis was then used to compare treatment 
effectiveness and QoL between the duloxetine (N= 168) and SSRI (N= 413) groups, 
controlling for the propensity scores and other patient characteristics. Results: 
The severity of depression was comparable between the two groups at baseline. 
Duloxetine-treated patients, however, had a higher level of pain severity and a 
lower level of QoL (EQ-5D) than SSRI-treated patients at baseline (p≤ 0.001). Both 
descriptive and MMRM regression analyses showed that patients treated with dulox-
etine had better outcomes during follow-up, compared with patients treated with 
SSRIs. At 6 months, duloxetine-treated patients had lower levels of CGI (2.25 vs. 
2.52, p= 0.005), QIDS-SR16 (3.95 vs. 5.35, p< 0.001), and SSI-pain related (8.52 vs. 9.64, 
p< 0.001), and higher levels of EQ-5D (0.92 vs. 0.87, p< 0.001) and EQ-VAS (64.62 vs. 
57.63, p= 0.006) (MMRM results). cOnclusiOns: Duloxetine-treated patients had 
better 6-months outcomes in terms of depression severity, pain and QoL, compared 
with SSRI-treated patients.
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ance with paliperidone palmitate that is related to less relapses, a better quality of 
life and reduced hospitalization costs.
MENTAL HEALTH – Patient-Reported Outcomes & Patient Preference Studies
PMH10
NEEDS ASSESSMENT OF PATIENTS TREATED IN COMMUNITy PSyCHOSOCIAL 
CENTERS IN SãO PAULO, BRAzIL
Nascimento A.1, Velasco T.M.2, Oliveira M.S.C.1
1Faculdade de Ciências Medicas da Santa Casa de São Paulo, São Paulo, Brazil, 2Hospital Alemão 
Oswaldo Cruz, São Paulo, Brazil
Objectives: To describe the needs of patients treated at community psychosocial 
centers in Sao Paulo, Brazil. MethOds: Cross-sectional study with 373 patients who 
were attending psychosocial care activities at least three times per week in community 
psychosocial centers, during 2007-2008. Needs were assessed using the “Camberwell 
Assessment of Need” (CAN). Psychotic symptoms were assessed using the “Positive 
and Negative Symptom Schedule” (PANSS). Results: Mean age of patients was 40.0 
years (standard deviation, SD = 12.6 years); 57.6% were male, 57.9% had fundamental 
education, 40.5% have schizophrenia, 15.9% have worked during last 12 months and 
14.7% were living alone. Median time attending in community psychosocial centers 
was two years (range of 15 days to 30 years) and mean number of weekly therapeutic 
activities was 3.6 (SD = 2.3). The mean score for the total number of needs was 7.1 
(SD = 2.8), with a range of 0 to 15 (maximum = 22). Basic needs were reported by 38 
(10.2%) patients; at least one social need was reported by 90.9%. At least one function-
ing need was reported by 94.4% patients; 85.5% have at least one health need; 86.3% 
have at least one service need. Women showed higher number of needs than men (p 
= 0.02) and educational until fundamental level was also associated with more needs 
(p = 0.02). We did not observe associations between weekly activities, unemployment, 
age, diagnosis and number of needs. Patients with higher PANSS scores showed more 
needs (p < 0.001). cOnclusiOns: We observed higher number of needs than in stud-
ies conducted in Europe, in all conceptual domains assessed by CAN. Many patients 
showed needs related to health and services, despite the time that they were attending 
in community psychosocial centers. Patients’ needs should take in account in order 
to improve the quality of care offered in mental health services.
MENTAL HEALTH – Health Care Use & Policy Studies
PMH11
CLINICAL PRACTICE gUIDELINE MAjOR DEPRESSIvE DISORDER FOR gENERAL 
PRACTITIONERS
Kongsuk T.
Prasrimahabhodi Psychiatric Hospital, Ubon Ratchathani, Thailand
Objectives: To develop the clinical practice guideline major depressive disorder 
for general practitioners in primary and secondary health care setting included 
the diagnosis, differential diagnosis, severity classification and medical treat-
ments. MethOds: A list of 13 key elements of a CPG development process were 
developed that consisted of 1) setting the review teams; 2) determining the problems; 
3) determining health outcomes;4) evidence based literature review; 5) meeting to 
draft the CPG; 6) formulating draft of CPG; 7) apprising the content of CPG by experts; 
8) trail phase; 9) evaluating for trail phase; 10) developing the curricular for CPG train-
ing; 11) preparing for CPG training; 12) evaluating; and 13) improving the CPG related 
with evaluated results. Results: There were 3 main processes in clinical practice 
guideline major depressive disorder for general practitioners in primary and second-
ary health care setting (CPG-MDD-GP) which were 1) Assessment of major depres-
sive disorder (clinical assessment using 9Q screening tool and DSM-TR diagnostic 
criteria, differential diagnosis, diagnosis for major depressive disorder and coding 
of diagnosis); 2) Management of major depressive disorder; and 3) Management of 
hospitalized patients. General practitioners were satisfied with the CPG-MDD-GP in 
trial phase. A total of 416 general practitioners in all provinces were trained to use 
the CPG-MDD-GP then they would be followed and evaluated. Psychiatrists in psy-
chiatric hospitals/ institutes would be available for consultation from the general 
practitioners. cOnclusiOns: The CPG-MDD-GP should be distributed to all general 
practitioners in primary and secondary health care setting. Next step, it would be 
useful for developing the CPG for MDD in the tertiary health care setting.
PMH12
CONTRIBUTION OF LATIN AMERICA TO MENTAL HEALTH IN PREgNANCy
Lorenzo L.S.1, Einarson A.2, Einarson T.R.3
1Psinapsys Psychiatric Private Center, La Plata, Argentina, 2The Hospital for Sick Children, 
University of Toronto, Toronto, Ontario, Canada, 3University of Toronto, Toronto, ON, Canada
Objectives: To identify and describe published articles dealing with issues of men-
tal health in pregnancy from Latin American counties MethOds: Medline, Embase 
and LILACS databases were searched for published studies originating from Latin 
America regarding mental health issues in pregnancy. Search terms included the 
names of all countries in the United States Census Bureau International Database + 
mental health + pregnancy. We included all research and review articles dealing with 
pregnancy and/or lactation, epidemiology of mental disorders, prevention or treat-
ment of mental disorders, outcomes assessment, and counseling/drug information 
dissemination. Excluded were papers dealing exlusively with postpartum depres-
sion, HIV transmission, induction of abortion, in vitro fertilization, contraception or 
the use of alcohol or drugs of abuse. Data were analyzed descriptively. Results: The 
search identified 701 studies; 110 (16%) met the criteria. The earliest was published 
in 1984 and the contribution has increased exponentially [Y= -1E-125*exp(0.1452X), 
where X is the year; R-squared= 0.97). The majority (n= 80; 73%) consisted of original 
research and the other 27% were reviews (23 overviews, 3 systematic reviews/meta-
analyses, 4 other). Most frequent topics were depression (37%) as well as mixed 
anxiety/depression (6%), mental health during pregnancy (32%;), psychotropic drug 
use in pregnancy (13%), suicidality (6%), and quality of life (1%). By country, 58 (53%) 
were produced by Brazil, followed by Mexico (n= 18, 17%), Chile (n= 10, 9%), Colombia 
ics costs were 167.4 times higher than typical antipsychotic costs. AP mean monthly 
costs per person varied with the type of association between antipsychotics: typical-
atypical associations costs were U$257.5± U$228.5, while mean costs between two 
typical antipsychotics were U$4.36 ± U$4.02. Polypharmacy added U$300.00 dolars per 
person per month to direct costs of health care (excluding accomodation). For each 
additional antipsychotic associated, it was observed an additional montlhy costs per 
person of U$87.5 in the total costs of health care package (health services, treatment 
and accomodation). cOnclusiOns: AP added substantial costs and risks to treat-
ment and to health care costs and quality. This should be taken in account in resource 
allocation in public policies, especially in low-resources settings.
PMH7
MODELIzACIóN ECONóMICA DEL gENOTIPADO DEL CITOCROMO P450 CON EL 
TEST BRAINCHIP EN EL TRATAMIENTO DE LA DEPRESIóN MAyOR
Crespo C., Villacampa A., Brosa M.
Oblikue Consulting, Barcelona, Spain
ObjectivOs: BrainChip es un test genético que predice la respuesta al tratamiento 
farmacológico de la depresión mayor (DM) determinando los polimorfismos de las 
isoenzimas CYP450. El objetivo ha sido valorar la eficienciade la incorporación del 
test BrainChip previa a la prescripción farmacológica en DM tras fallo en primera 
línea. MetOdOlOgías: Se desarrolló un modelo de Markov de ciclos bimensuales para 
cada fármacode una cohorte hipotética depacientes adultos con DM tras fallo en prim-
era línea. La cohorte se adecuó a la distribución del mercado actual y a su modificación 
tras incorporar BrainChip. Los datos de eficacia (no respuesta, respuesta y remisión) 
provienen de revisiones de la literatura y el uso de recursos y costes fue adaptado para 
el análisis inicial a España. Se analizaron los resultados en un horizonte temporal de 1, 3, 
5, 7 y 10 años desde la perspectiva del sistema sanitario aplicando un descuento del 3% 
sobre los efectos y los costes (euros 2011). ResultadOs: BrainChip mejora la remisión 
entre un 9,5%-11,7% y la respuesta entre 5,5%-10,2%, alcanzando a los 10 años una 
respuesta del 72%. Los pacientes con DM mejoran la calidad de vida con BrainChip entre 
0,04 y 0,25 años de vida ajustados por calidad. El coste de Brainchip se compensa a los 
2 años resultando siempre coste-efectivo a corto plazo y dominante a partir del tercer 
año, mostrando ahorros de 1399€ /paciente tras 10 años. cOnclusiOnes: BrainChip 
en DM es dominante, permite prescribir los tratamientos con menos riesgos y costes y 
más eficacia. El modelo desarrollado permitiría la adaptación del análisis a cualquier 
país de Latinoamérica utilizando datos de costos locales.
PMH8
COST EFFECTIvENESS OF PALIPERIDONE PALMITATE vERSUS RISPERIDONE 
LONg-ACTINg INjECTABLE, QUETIAPINE AND OLANzAPINE FOR THE 
TREATMENT OF PATIENTS wITH SCHIzOPHRENIA IN COLOMBIA
Casallas C.1, Ariza J.G.2
1Universidad de la Sabana, Bogotá, Colombia, 2Janssen Cilag, Bogotá, Colombia
Objectives: Schizophrenia is a chronic disorder that requires long-term treatment 
with antipsychotic medication to minimize relapse and provide clinical benefit to 
patients. For patients with schizophrenia, non-adherence to medication is a risk factor 
for relapse and re-hospitalization. Long-acting Injectable (LAI) formulations of atypical 
antipsychotics provide constant medication delivery and the potential for improved 
adherence. The objective of this study is to assess the cost-effectiveness of paliperidone 
palmitate (PP) versus risperidone long acting injectable (RLAI), olanzapine (OP) and que-
tiapine (QP). MethOds: A Markov decision analytic model was developed to simulate 
multi-episode patients transitioning through different states on monthly basis over a 
5 year time horizon from the perspective of the Colombian Health System. Probability 
of relapse, level of adherence, side effects, utilities and treatment discontinuation were 
derived from scientific literature. Only direct costs were considered as medications, 
laboratory tests, relapses and adverse events by using national tariffs and prices from 
Ministry of Health medication database. Outcomes were measured as relapses rate and 
Quality Adjusted Life Years (QALY). Discount rate 3%, exchange rate (1 USD = 1,794 COP) 
and threshold considered 3xPIB per capita (USD 20,066 / QALY). Results: Total costs 
(USD): PP (13,338), RLAI (12,635), OP (11,481) and QP (13,247). Hospitalization relapses costs 
(USD): PP (3,276), RLAI (3,341), OP (4,881) and QP (6,840). QALY: PP (3.09), RLAI (3.00), OP 
(2.93) and QP (2.87). Relapses rate: PP (1.35), RLAI (1.38), OP (2.01) and QP (2.81). Incremental 
Cost Utility Ratios (ICUR: USD / QALY): PP vs. RLAI (4,517), PP vs. OP (6,713) and PP vs. QP 
(230). cOnclusiOns: Considering a willingness to pay of USD 20,066 per QALY, the 
incremental cost of PP versus other alternatives could be compensated by its incremen-
tal benefits in terms of relapses avoided and QALY gained. From Health Care Provider 
perspective, PP demonstrates savings in terms of less hospital setting relapsing costs.
PMH9
THE COST-EFFECTIvENESS AND COST-UTILITy OF PALIPERIDONE PALMITATE 
IN THE TREATMENT OF SCHIzOPHRENIA IN gUATEMALA
Obando C.A.1, Gonzalez L.2, Muschett D.1
1Janssen, Panama City, Panama, 2Janssen, Raritan, NJ, USA
Objectives: To compare from the Guatemaltecan third payer perspective the cost-
effectiveness of paliperidone palmitate with oral quetiapine. MethOds: A Markov 
model was developed to assess the cost-effectiveness and the cost-utility of treat-
ments available for schizophrenia in Guatemala. The model was adjusted to reflect 
the compliance of the patient and the real world effectiveness of both treatments. A 
10 year time horizon was used. All direct medical costs relevant for the third payer 
were included. Four types of side effects were considered in the model: extrapy-
ramidal symptoms, weight gain, diabetes and tardive dyskinesia. Deterministic and 
probabilistic sensitivity analyses were performed. Results: Effectiveness outcomes 
were reported both in QALYs and relapses avoided. The costs were reported in the 
local currency Quetzales and all cost and outcomes were discounted at 5% per year. 
Paliperidone palmitate dominated oral quetiapine by being less expensive (14% less) 
and more effective (44% less relapses and 20% more QALYs). The sensitive analyses 
confirmed the robustness of the results. cOnclusiOns: Paliperidone palmitate 
appeared to be a cost-saving treatment option in comparison with oral quetiapine 
for patients with schizophrenia in Guatemala. The model reflected a better compli-
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budget impact analysys a target population of 550 patients is estimated and three 
scenarios of ustekinumab adoption were assessed: current scenario (13% market 
share), middle penetration scenario (28% market share) and a high penetration 
scenario (50% of market share). No discount rate was used. Exchange rate (1 USD = 
1,794 COP). Results: Total cost per patient (USD): ustekinumab (23,229), etanercept 
(25,079) and adalimumab (23,825). PASI 50 response (% of patients): ustekinumab (90%), 
etanercept (76%) and adalimumab (81%). Cost per responder patient: ustekinumab 
(25,810), etanercept (32,999) and adalimumab (29414). Budget Impact (USD): current 
scenario (13,387,999), middle penetration scenario (13,262,955) and high penetration 
scenario (13,114,969). cOnclusiOns: When a subcutaneous biologic is considered 
as the first line choice of treatment for psoriasis, ustekinumab is the prefered first 
line therapy. Ustekinumab progressive adoption, in the Colombian Health System, 
demonstrates potential savings driven by its better efficacy and less probability of 
requiring a second line more expensive treatment.
PSS3
THE DIRECT COSTS OF DRUg-INDUCED SkIN REACTIONS IN POLAND
Wisniewska N., Szkultecka-Debek M., Owczarek W., Paluchowska B., Jahnz-Rozyk K.
Military Institute of Medicine, Warsaw, Poland
Objectives: Drug-induced skin reactions (DISR) may be a serious medical problem, 
and economical in every country. MethOds: The aim of the study was to analyze 
the direct costs (costs of medication, laboratory costs, costs of physician visits) of 
164 patients (57M, 107 W, mean age 53.7years) hospitalized in the Department of 
Dermatology, Military Institute of Medicine, Poland between 2002 - 2012 due to 
DISR from the public payer (NHF) and hospital perspective. Results: In the group 
of the most common forms of DISR there were toxic - allergic dermatitis (n= 85) 
and erythema multiforme (n= 41). The most common cause of drug-induced skin 
reactions were beta lactam antibiotics, cephalosporins and NSAIDs. Symptoms 
of DISR appeared on an average after 7.4 days of treatment. The average hospi-
tal stay was 4.54 day per patient. Direct average cost of treatment from the NHF 
perspective was 717€ per patient and from the hospital perspective was 680 € per 
patient. cOnclusiOns: Treatment of DISR is expensive, but well priced by the 
public payer in Poland.
PSS4
EvALUACIóN DE COSTO-EFECTIvIDAD DE LA TRABECULOPLASTIA LáSER 
SELECTIvA COMO PRIMERA OPCIóN DE TRATAMIENTO EN gLAUCOMA 
PRIMARIO DE áNgULO ABIERTO EN COLOMBIA
Bernal M.M.1, Organista J.1, Rico A.1, Romero M.2, Barrero J.R.3
1Universidad de Bogotá Jorge Tadeo Lozano, Bogotá, Colombia, 2Fundacion Salutia, Bogotá, 
Colombia, 3Oftalmologo, Bogotá, Colombia
ObjectivOs: Evaluar la costo-efectividad de la Trabeculoplastia Láser Selectiva 
(TLS), como primera opción de tratamiento del Glaucoma Primario de Ángulo 
Abierto (GPAA) sin manejo previo versus el tratamiento médico con latanoprost, 
desde el punto de vista del tercero pagador en Colombia. MetOdOlOgías: Se dis-
eñó un modelo de Markov en ciclos bimestrales que simuló una cohorte hipotética 
de 100 pacientes adultos, con GPAA recientemente diagnosticados y que inician 
tratamiento ya sea con TLS o latanoprost (agonista de la prostaglandina), en un 
horizonte temporal de cinco años, con variaciones de +/-20% en las variables. Con 
este modelo se evaluó el tiempo libre de enfermedad medido en años. Se utilizaron 
probabilidades variables en el tiempo, del estudio cabeza-a-cabeza de Katz 2012. Los 
costos directos de salud fueron estimados con información de dos aseguradoras 
de Colombia. Se asumió una tasa de abandono del tratamiento médico referidas 
por Iskedjian 2011. Se aplicó una tasa de descuento del 3% a costos y desenlaces. 
Finalmente, se realizó un análisis de sensibilidad univariado y multivariado tipo 
Montecarlo. Se estimó que el fallo de primera línea en cualquiera de los dos bra-
zos sería de COP$ 810.596 (umbral propuesto). ResultadOs: El uso de TLS como 
primera línea de tratamiento mostró la mayor efectividad (286,9 años) frente a 
latonoprost (98,3 años) en los 100 pacientes. Al aplicar el descuento la razón de 
costo-efectividad incremental fue de $391.122,24 por año libre de enferemedad 
ganado. El analisis tipo montecarlo mostró que TLS se mantiene costo-efectiva en 
el 100% de los casos. cOnclusiOnes: El uso de TLS mostró ser muy costo efectivo 
frente al uso de latanoprost en las condiciones del caso base y el umbral propuesto. 
Teniendo en cuenta que el costo de la TLS se aplica al inicio del tratamiento, resulta 
conveniente estimar el impacto presupuestario para apoyar la toma de decisión.
PSS5
COSTO-EFECTIvIDAD DEL SCREENINg y TRATAMIENTO DE HIPOACUSIA 
BILATERAL EN RECIéN NACIDOS (RN) EN CHILE
Castillo-Laborde C.1, Loayza S.2, Aravena M.2, Freile B.2, Castillo-Riquelme M.2
1Ministerio de Desarrollo Social, Santiago, Chile, 2Ministerio de Salud, Santiago, Chile
ObjectivOs: El objetivo principal es determinar la costo-efectividad incremental 
de pasar de una estrategia selectiva (RN prematuros) de screening y tratamiento 
oportuno de hipoacusia bilateral congénita a una estrategia de screening univer-
sal. MetOdOlOgías: El análisis se realizó desde la perspectiva del sector público 
y consideró como horizonte temporal la sobrevida de una cohorte de RN. La infor-
mación epidemiológica se obtuvo de fuentes oficiales del Minsal, literatura y de una 
encuesta realizada a expertos. La precisión de los test diagnósticos se obtuvo de la 
literatura y la caracterización del proceso de screening de las Guías Clínicas nacion-
ales. La efectividad de los tratamientos de amplificación se obtuvo por consulta a 
expertos. Para la medición de beneficios se determinaron outcomes intermedios (caso 
pesquisado) y outcomes finales (QALY). Para el análisis de la información se utilizó un 
modelo de árbol de decisión. Se realizaron análisis de sensibilidad determinístico 
(ASD) univariado y análisis de sensibilidad probabilístico (ASP) considerando los 
principales parámetros. ResultadOs: Los costos totales por RN de la estrategia de 
screening selectivo fueron de $26.486,4 (pesos chilenos) y para la estrategia universal 
de $32.620,5, en tanto que la efectividad en QALY fue de 30,0523 y de 30,0708, respec-
tivamente, obteniéndose un ICER $331.368,22. El costo por caso extra de hipoacusia 
bilateral congénita detectado precozmente al pasar de una estrategia a otra es de 
(n= 9, 8%), Peru (n= 5, 5%), Argentina and Ecuador (each with 3, 3%), and one each 
from Costa Rica, Paraguay, and Venezuela. Contributions were positively correlated 
with the size of the population (Spearman’s rho= 0.76, P= 0.03). cOnclusiOns: Latin 
America has begun to make a small but significant contribution to the literature, 
However, more than 50% were from Brazil, so other countries will benefit from 
further research, addressing their unique social and economic needs regarding 
mental health in pregnancy.
PMH14
STANDARDIzED TOOL FOR MEASUREMENT OF HEALTH SERvICES COSTS 
AND UTILIzATION IN A SAMPLE wITH MENTAL DISORDERS: TRANSLATION, 
CULTURAL ADAPTATION AND INTERRATER RELIABILITy OF THE CLIENT 
SOCIODEMOgRAFIC AND SERvICE RECEIPT INvENTORy BRAzILIAN vERSION
Sousa A., Cardoso A., Oliveira G.G., Mari J.J., Razzouk D.
Universidade Federal de Sao Paulo, SAO PAULO, Brazil
Objectives: Information on health service utilization and costs is scarce in the 
mental health. The Client Socio demographic and Service Receipt Inventory (CSSRI), 
developed by Knapp and Chisholm, has been widely used for the measurement 
of health care costs including mental health services. The aims of this study were 
the translation, cultural adaptation and feasibility and the interrater reliability of 
the Brazilian version of the CSSRI. MethOds: CSSRI was translated to Portuguese 
(Inventário Sociodemografico de Utilização e Custos de Serviços ISDUCS) by mental 
health researchers. Structure and cultural adaptations were made according to 
the Brazilian public health system. Two independent researchers applied it in a 
sample of 30 subjects with mental disorders living in residential services in São 
Paulo city, Brazil. Results: The ISDUCS was consisted by six sections and one 
additional annex covering data on: Sociodemographic information; accommoda-
tion, employment and income, medication and services use. Application lasted from 
twenty to sixty minutes. The sample had 50 years on average, with 60% females, 
with 18% illiterates, 51.6 % primary education, with length of psychiatric hospi-
talization of 10 years on average, 45% had severe psychiatric symptoms, 20% had 
moderate symptoms and 35% mild symptoms. Subjects had difficulties to answer 
the following questions: 24.4%, did not know about his/her education level, 76.7% 
did not know about the name of the medication in regular use, 58.8% did not know 
about visit to health professionals in the previous month, 36.4% did not know about 
receiving their benefits. Interrater reliability was calculated using kappa coefficient, 
varying from 0.8 to 1.0 for all items, showing excellent reliability. cOnclusiOns: 
ISDUCS was feasible and reliable to be applied in Brazilian mental health settings. 
Additional sources like medical records and carers information were necessary to 
collect all data probably due to low education and severity of psychiatric symptoms 
of this sample.
SENSORy SySTEMS DISORDERS – Clinical Outcomes Studies
PSS1
EFECTIvIDAD y COSTO-EFECTIvIDAD DE LA FLUORACIóN DEL AgUA EN LA 
PREvENCIóN DE CARIES DENTAL
Zaror C., Vallejos C., de La Puente C., Velasquez M., Corsini G., Bustos L., Reveco R.
Universidad de La Frontera, Temuco, Chile
ObjectivOs: Determinar si la fluoración del agua a concentraciones de 0,6 a 1 ppm 
es más efectiva y costo-efectiva que la no fluoración del agua en la prevención de 
la caries dental. MetOdOlOgías: Se realizó una revisión sistemática de la litera-
tura en MEDLINE, EMBASE, COCHRANE, SCIELO, LILACS, CRD database, BBO, PAHO 
y WHOLIS, limitada desde el 2002 al 2012. Se incluyeron meta-análisis, revisiones 
sistemáticas, cohortes, casos y controles, estudios económicos y corte transversal 
con al menos dos poblaciones comparadas. Dos investigadores de forma inde-
pendiente realizaron una evaluación de la calidad de los artículos seleccionados 
y que cumplieron los criterios de inclusión. ResultadOs: La búsqueda arrojó 468 
artículos de los cuales 27 cumplieron los criterios de inclusión y 8 fueron incluidos 
como evidencia para evaluar la efectividad, y 4 para evaluar costo efectividad. Se 
concluye una reducción del riesgo de caries del 15.4 % (95% CI 10.8%, 20.1%) p< 0.001 
en población infantil y adolescente, y de un 34.6% (95%CI: 12.6%-51.0%) p< 0.001 
en población adulta de acuerdo a las revisiones sistemáticas incluidas. Todos los 
estudios incluidos concluyen que la fluoración del agua es altamente costo-efec-
tiva, con Indices de Costo-efectividad bajos, aun cuando la medida de resultado es 
dimensionada en formas distintas (Daly, Qaly, dólares ahorrados). cOnclusiOnes: 
Existe evidencia tipo I que la fluoración del agua potable, a concentraciones de 
0,6 a 1 ppm, es más efectiva y costo efectiva que la no fluoración del agua en la 
prevención de la caries dental.
SENSORy SySTEMS DISORDERS – Cost Studies
PSS2
A COST–EFFECTIvENESS AND BUDgET IMPACT ANALySIS OF DIFFERENT 
BIOLOgIC TREATMENTS FOR PSORIASIS IN COLOMBIA
Ariza J.G., Nuñez C.
Janssen Cilag, Bogotá, Colombia
Objectives: There are three subcutaneous biologic therapies approved for psoriasis 
in Colombia: ustekinumab, etanercept and adalimumab. A network meta-analysis 
demonstrates a better incremental efficacy of ustekinumab versus the other two 
alternatives. However, considering that the medication cost is higher for usteki-
numab, this analysis evaluates the cost-effectiveness and budget impact of the 
three alternatives assuming the Colombian Health System perspective. MethOds: 
A decision tree was designed from the payer perspective to estimate costs and 
benefits for one year time horizon. Clinical data were obtained from a network 
meta-analysis in order to model treatment response and second line treat-
ment progression. Benefits were measured as probability of achieving a PASI 50 
response at the end of 12 weeks of treatment. Only direct costs were considered 
using national tariffs and prices from Ministry of Health medication database. For 
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El 19,5% (n= 124) de pacientes habían egresado del programa al final de periodo de 
observación. Las causas de egreso fueron: mejoría a TFG > 60 ml/min/año (40,3%), 
muerte (29,0%), ingreso a diálisis (12,1%), suspensión voluntaria (5,7%), otros (12,9%). 
Seguimos a los pacientes 31582 pacientes-mes, equivalente a 2631 pacientes-año y 
la mortalidad fue 0.0137 muertes por paciente-año en el programa. cOnclusiOnes: 
Los meses evitados de diálisis por paciente en ERC 5 son 11. Una proporción sustancial 
de pacientes alcanzaron las metas de progresión de ERC. La principal causa de egreso 
del programa fue por mejoría de la TFG.
PUk2
CLINICAL BENEFITS OF IMMUNOSUPPRESSION THERAPy IN RENAL TRASPLANT 
PATIENTS. SySTEMATIC REvIEw AND META-ANALySIS
Cerezo O.1, Bravo M.G.2, Jimenez Aranda P.3, Lemus E.A.2
1Independient Investigator, Mexico, Mexico, 2Novartis Farmaceutica, México D.F., Mexico, 
3Novartis, Coyoacan, Mexico
Objectives: To study the clinical benefits of immunosuppression therapy for renal 
transplantation, through systematic review and meta-analysis MethOds: Two 
independently searches were performed in biomedical databases: Medline, Embase, 
Cochrane, Health Virtual Library and clinical trials from NIH website. Specific selec-
tion criteria were followed to collect the majority of evidence, items as temporality, 
methodology design, patient population, drug, therapy stage(induction/starting, 
maintenance, acute-rejection treatments), algorithms details and outcomes(acute 
rejection, graft loss, deaths, and rate of infection and malignancy). According to 
“Grades of Recommendation Assessment, Development and Evaluation”(GRADE-
criteria) we assessed the quality of articles in order to run a meta-analysis. Results: 
The study included 9 RCT of basiliximab vs ATG, and after heterogeneity test, the 
meta-analysis was performed with FEM (fixed effects model). In acute rejection, we 
obtained an OR of 1.092 CI95% [0.85–1.4] (in favor of Basiliximab). Infection risk and 
neoplasm development were in favor of basiliximab with (OR 1.6[CI95% 1.1–2.3] and 
OR 3.2[CI95% 1.1–9.4], respectively). Basiliximab vs Non-induction included 5 RCT, 
resulting in OR 1.8 [CI95% 1.4–2.4] and NNT of 8 (in favor of basiliximab) in acute 
rejection, also basiliximab had a better infection risk profile (OR 4.2 [CI95% 3–5.9]). 
Cyclosporine vs Tacrolimus included 26 RCT, with an OR estimate for acute rejec-
tion of 1.9 ([CI 95% 1.6-2.1] in favor of Tacrolimus). Mycophenolate-Sodium(MPS)/
Mycophenolate-Mofetil(MMF) vs azathioprine included 5 RCT (2 with MPS), with 
an OR for acute rejection of 2.2 (CI 95%1.7–2.8) in favor of MPS/MMF, and NNT of 
7 (CI95% 5–10). Additionally, we evaluated the GI AE’s profile of MMF vs MPS, and 
we obtained an OR 0.65 (CI95% 0.5–0.8), in favor of MPS. cOnclusiOns: The pre-
sent study assessed the clinical outcomes of treatments for renal transplantation. 
Basiliximab, Tacrolimus and MMF/MPS proved to have better clinical effects for 
outcomes like acute rejection, infection risk and neoplasm development.
URINARy/kIDNEy DISORDERS – Cost Studies
PUk3
BUDgET IMPACT ANALySIS OF RENAL POST-TRANSPLANT PROPHyLAxIS wITH 
BELATACEPT IN COLOMBIA
Alfonso-Cristancho R.1, Diaz-Sotelo O.D.2, Rosselli D.3, Rueda J.D.3, Garrido Lecca S.4
1University of Washington, Seattle, WA, USA, 2RANDOM Foundation, Bogota, DC, Colombia, 
3Pontificia Universidad Javeriana, Bogotá, Colombia, 4Bristol-Myers Squibb Company, Lima, Peru
Objectives: Renal transplantation is currently the most effective treatment for End 
Stage Renal Disease (ESRD) and its success is linked to effective immunosuppres-
sive regimes. A new immunosuppressive agent, belatacept has recently entered the 
market. The mechanism of action of belatacept focuses on selective blockade of T cell 
activation, improving renal graft survival for a prolonged period of time with less tox-
icity compared to standard immunosuppressive regimes. The objective of this study 
was to estimate the budgetary impact to the health care system in Colombia after 
the introduction of Belatacept for renal post-transplant prophylaxis. MethOds: An 
Excel-based budget impact model was used to estimate over a 5 years period the aver-
age per-member-per-year (PMPY) costs of adding belatacept to the health insurance 
coverage in Colombia. We considered a base case scenario with prevalence of ESRD 
is 0.05%; annual incidence of renal transplant of 3.5% and mortality after transplant 
of 4%. The model considers doses and costs of belatacept, cyclosporine, everolimus, 
sirolimus and tacrolimus, management and costs for adverse events and clinical 
resources used. Data for the model inputs was extracted from published literature 
and local sources. A market share of belatacept increasing from 1% in year one to 10% 
by year five was assumed for this analysis. Results: It was estimated that including 
belatacept in the health insurance coverage would increase health system spending 
for renal post-transplant prophylaxis on COP$7.700 (USD 4.31) PMPY, an aggregated 
budget impact of COP$13 million (USD 7,283) (4.44%) over the five years (additional 
annual investment of COP$2.6 million). Belatacept presents lower adverse events costs 
in comparison with other alternatives. cOnclusiOns: The availability of belatacept 
in post-transplant prophylaxis treatment for patients in Colombia would provide 
a new therapeutic option for immunosuppression with lower adverse events at a 
limited budget impact to the Colombian health care system.
PUk4
IMPACTO PRESUPUESTAL DE LA ENFERMEDAD RENAL TERMINAL EN COLOMBIA 
CON UN INCREMENTO DEL NúMERO DE TRASPLANTES
Rosselli D., Rueda J.D., Díaz C.E.
Pontificia Universidad Javeriana, Bogotá, Colombia
ObjectivOs: La prevalencia de enfermedad renal terminal (ERT) en Colombia viene 
creciendo a cuatro veces el crecimiento poblacional (5% vs. 1,2%). El número de tras-
plantes renales, sinembargo, se viene reduciendo. El objetivo es estimar el impacto 
presupuestal de un incremento en el número de trasplantes. MetOdOlOgías: En 
pesos colombianos y dólares americanos de 2012 (1 USD = 1785 COP), y desde la 
perspectiva del sistema de salud, estimamos los costos asociados a dos escenarios: 
Escenario 1: una reducción progresiva de 2% anual del número de trasplantes (tenden-
cia histórica); o Escenario 2: un aumento gradual (5% anual) del número de trasplantes 
$4.215.913 (US$8.875,61). cOnclusiOnes: El pasar de la estrategia selectiva focali-
zada en RN prematuro a una estrategia universal resulta costo-efectivo. Este resul-
tado no se modificó con la variación de parámetros con incertidumbre asociada en 
los ASD y ASP. Con una disposición a pagar de $6,97 millones (PIB per cápita Chileno) 
la probabilidad de que la ampliación a una estrategia universal de tamizaje resulte 
costo-efectiva es de un 99,3%.
PSS6
ANáLISIS DE MINIMIzACIóN DE COSTOS DEL USO DEL AFLIBERCEPT EN 
DEgENERACION MACULAR RELACIONADA CON LA EDAD EN COLOMBIA
Romero M., Huerfano L., Acero G.
Fundacion Salutia, Bogotá, Colombia
ObjectivOs: Hacer una evaluación económica del uso de aflibercept ver-
sus ranibizumab para el tratamiento de la Degeneracion Macular Relaciona 
con la Edad de tipo exudativa, desde el punto de vista del tercero pagador en 
Colombia. MetOdOlOgías: Se hizo un análisis de minimización de costos par-
tiendo de una revisión de literatura que analizó la efectividad y seguridad entre 
las tecnologías. Se diseñó un modelo de árbol de decisiones basados en la historia 
natural de la enfermedad y el modelo de atención, incluyendo las dosis en cada una 
de las tecnologías y otros costos directos de atención, en un horizonte temporal de 
dos años. Los costos fueron obtenidos de del Sistema de Información de Precios en 
Medicamentos (SISMED) y de los Registros Individuales de la Prestación de Servicios 
de Salud (RIPs) expresados en dólares de 2012. Se efectuó un análisis de sensibilidad 
univariado en una sola vía, modificando la dosis estándar a dosis a demanda, como 
sugiere el estudio de Rosenfeld et al., 2006. ResultadOs: Estudios cabeza a cabeza 
encontrados (VIEW1 y VIEW2) no mostraron diferencias significativas en térmi-
nos de seguridad y efectividad, medida como ganancia en letras; aunque afliber-
cept demostró un 33,4% de ganancia frente al 31,6% de ranibizumab. El modelo 
en un paciente promedio mostró que el uso de aflibercept generaría un ahorro de 
US$11.468,78 a los 2 años. El análisis de sensibilidad del modelo a demanda mues-
tra que aflibercept se mantiene ahorrativo frente a ranibizumab. cOnclusiOnes: 
No se encuentraron diferencias de efectividad entre las tecnologías evaluadas; sin 
embargo, aflibercept se mostró como la tecnología ahorrativa en el tratamiento de la 
Degeneracion Macular Relaciona con la Edad exudativa, desde el punto de vista del 
tercero pagador en Colombia. El menor número de dosis requeridas en el tratami-
ento con aflibercept podría generar adherencia que asegure mayor efectividad.
PSS7
EvALUACIóN ECONóMICA DEL USO DE DOS TRATAMIENTOS 
FARMACOLógICOS EN DEgENERACIóN MACULAR RELACIONADA CON LA EDAD 
DE TIPO ExUDATIvA (DMRE) PARA vENEzUELA
Romero M.1, Bastardo Y.M.2, Sanabria M.1
1Fundacion Salutia, Bogotá, Colombia, 2Universidad Central de Venezuela, Caracas, Venezuela
ObjectivOs: Estimar mediante un modelo de minimización de costos, el precio 
máximo al que sería favorable la inclusión dentro del sistema de salud venezolano el 
uso de aflibercept como tratamiento de la DMRE de tipo exudativa. MetOdOlOgías: 
La revisión de la literatura no mostró diferencias en cuanto a efectividad y seguri-
dad entre al aflibercept y el ranibizumab en los estudios cabeza a cabeza (VIEW1, 
VIEW2). Por lo que mediante un análisis de minimización de costos basado en el 
modelo de atención de la enfermedad y en un horizonte temporal de dos años se 
estimó a las dosis utilizadas en el estudio clínico el precio máximo a que podría 
ingresar el aflibercept al mercado tomando como referencia el precio de ranibizumab 
de $VEF 4.640,83, los costos de atención y del medicamento fueron tomados de infor-
mación proveniente de aseguradores en Bolívares fuertes. Se efectuó un análisis de 
sensibilidad univariado en una sola vía, modificando a dosis por demanda, como lo 
sugiere el estudio de Rosenfeld PJ y colaboradores. ResultadOs: El estudio clínico 
muestra mejor resultado para aflibercept pero las diferencias no son significativas. El 
análisis económico arrojó como costo máximo por dosis de Aflibercept, un valor de 
$VEF 10.598,46; un valor inferior al anterior generaría un ahorro al sistema de salud 
venezolano. El análisis de sensibilidad univariado en una sola vía al utilizarlos por 
demanda determinó que Aflibercept se mantendría como tecnología ahorrativa a 
un precio de $VEF 7.201,13. cOnclusiOnes: Aflibercept sería una opción favorable 
al sistema de salud, por cuanto genera menos dosis de aplicación facilitando una 
mayor adherencia y sería ahorrativo en el tratamiento de la DMRE exudativa para 
Venezuela sí su costo en el mercado se encuentra entre $VEF 7.201,13 y 10.598,46 según 
el esquema de tratamiento que se utilice y de acuerdo a los escenarios evaluados.
URINARy/kIDNEy DISORDERS – Clinical Outcomes Studies
PUk1
EvOLUCIóN CLíNICA DE UNA COHORTE DE PACIENTES CON ENFERMEDAD 
RENAL CRóNICA INTERvENIDOS EN UN PROgRAMA DE SALUD RENAL
Paz J.J.1, Sanabria M.2, Perea D.2, Astudillo K.2, Bunch A.2, Laganis S.2
1Mutual ser EPSS, Cartagena, Colombia, 2Baxter RTS, Bogotá, Colombia
ObjectivOs: El objetivo es describir la velocidad de progresión de la ERC, la perma-
nencia, los meses ahorrados en diálisis, los desenlaces y causas de egreso de una 
cohorte de pacientes en estadíos 3, 4 y 5 que estaban en el programa Clínica de Salud 
Renal (CSR) de RTS Colombia y Mutual Ser entre el periodo comprendido entre diciem-
bre 2010 y diciembre 2012. MetOdOlOgías: En esta cohorte histórica de pacientes 
con ERC se analizan los desenlaces clínicos del programa, en términos de la mediana 
de progresión de la enfermedad renal crónica, medida como delta de tasa de filtración 
glomerular en ml/min/año; se reportan las proporciones de pacientes con velocidad 
de progresión menor que -4 ml/min/año y menor que -2 ml/min/año. Específicamente 
para los pacientes de ERC estadio 5, se calculan los meses trascurridos en estadio 5 
libres de diálisis. Se reporta además la mortalidad de esta cohorte. ResultadOs: En 
diciembre de 2010 habían 634 pacientes en el programa, de estos 510 permanecieron 
en el programa hasta diciembre de 2012 (80,44%). La velocidad de progresión fue 
menor a -4ml/min/año en el 82,2% de los pacientes y en un 60,8% menor de -2ml/min/
año. Los meses ahorrados en diálisis en los pacientes en estadio 5 fueron 11 meses. 
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eralised linear model with log link). Results: Hospitalisation rate was 0.72 hospi-
talisations per patient/year, 6.32 days were spent in hospital per patient/year and 
average hospitalisation rate was 8.68 days. No differences were observed between 
haemodialysis patients and peritoneal dialysis regarding such rates. Average hospi-
talisation bill was $2,567,680. cOnclusiOns: The study population had higher hos-
pitalisation rates and spent less days in hospital than that stated in other reports. 
No differences were observed between HD and PD patients regarding these rates.
PUk9
COSTO-EFECTIvIDAD DE LAS PRUEBAS PARA LA TAMIzACIóN DE BACTERIURIA 
ASINTOMáTICA DURANTE LA gESTACIóN
Chicaiza L.1, Garcia-Molina M.1, Moreno M.2, Urrego J.1, Rincon C.J.3, Amaya J.4, Diaz L.4,  
Rubio J.4, Gomez P.I.4
1Facultad de Ciencias Económicas, Universidad Nacional de Colombia, Bogotá, Colombia, 
2Universidad Nacional de Colombia, Bogotá, Colombia, 3Universidad Nacional de Colombia, 
Bogotá, Colombia, 4Universidad Nacional de Colombia, bogotá, Colombia
ObjectivOs: Estimar la razón de costo-efectividad de las pruebas para tamizar la 
bacteriuria asintomática (BAS) durante la gestación en Colombia. MetOdOlOgías: 
Se diseñaron dos árboles de decisión que presentan como unidad de desenlace 
el número de casos de pielonefritis evitados y el número de partos pretérmino 
evitados, respectivamente. La perspectiva es la del sistema de salud. Las cifras 
monetarias fueron expresadas en pesos colombianos de 2010. Se hicieron análisis 
de sensibilidad univariados y probabilísticos. ResultadOs: La razón de costo-efec-
tividad incremental (RCEI) del urocultivo para pielonefritis evitadas es de $877.494; 
para partos pretérmino evitados es de $13.895.576. La RCEI de la tinción de Gram 
para pielonefritis evitadas es de $314.914 y para partos pretérmino evitados es de 
$.1 399.593. El urocultivo confirmatorio ante resultado positivo del parcial de orina 
es una estrategia dominada en todos los casos. cOnclusiOnes: El urocultivo es la 
alternativa que más casos de pielonefritis y de partos pretérmino evita. Si el umbral 
de disponibilidad a pagar es superior a $970.000 por caso adicional de pielonefritis 
evitado, o superior a $14.550.000 por caso adicional de parto pretérmino evitado, 
el urocultivo será costo-efectivo. Para umbrales entre $350.000 y $970.000 por caso 
adicional de pielonefritis evitada, o entre $2.500.000 y $14.550.000 por caso adicional 
de parto pretérmino evitado, la tinción de Gram será costo-efectiva. Para umbrales 
menores, el parcial de orina sin urocultivo confirmatorio será costo-efectivo.
PUk10
COST-EFFECTIvENESS OF CINACALCET CHRONIC kIDNEy DISEASE PATIENTS 
ON DIALySIS wITH SECONDARy HyPERPARATHyROIDISM IN BRAzILIAN 
PUBLIC HEALTH CARE SySTEM (SUS)
Nishikawa A.M.1, Coutinho M.B.2, Custodio M.R.3, Pecoits-Filho R.F.3, Clark O.A.C.1
1Evidencias, Campinas, Brazil, 2Amgen Brazil, Sao Paulo, Brazil, 3Brazilian Nephrology Society, 
Sao Paulo, Brazil
Objectives: Cinacalcet effectively reduces elevated levels of parathyroid hormone 
(PTH) in patients with CKD and consequently may reduce cardiovascular events, 
mortality and bone metabolism. This study assesses the cost-effectiveness of cina-
calcet plus standard of care for the treatment of SHPT patients on dialysis compared 
to standard of care (SoC) alone, which includes vitamin D and phosphate binders, 
under the SUS perspective. MethOds: A Markov (state transition) cohort model 
with monthly cycles and 10-year time horizon was developed using published data 
from randomized controlled trials. The impact of cinacalcet treatment on mortality, 
cardiovascular events, fractures and parathyroidectomy were calculated based on a 
retrospective analysis. The Markov model consisted of the following health states: 
patient in target according to National Kidney Foundation Kidney Disease Outcomes 
Quality Initiative (KDOQI) targets (SHPT parameters in target range), patient not 
controlled (one or more parameters out target range) and death. Extensive one-way 
sensitivity analysis was conducted. Costs were extracted from official databases of 
prices of SUS. Results: The life years gained (LYG) obtained with cinacalcet plus 
SoC and SoC alone was 4,42 and 3,55, respectively, resulting in an incremental cost-
effectiveness ratio of USD 17,032 in a 10 year time horizon. Additional analysis showed 
that compared to SoC, cinacalcet was associated with more adequate levels of serum 
PTH, reduced the number of cardiovascular events (0,66 vs. 0,70), bone fractures (0,14 
vs. 0,24) and parathyroidectomies performed (0,01 vs. 0,15). The sensitivity analysis 
showed that the main drivers of the result were the mortality probability in each of 
the SoC and cinacalcet groups, and the cost of cinacalcet acquisition. cOnclusiOns: 
This model with data from the Brazilian Public Healthcare System shows that cina-
calcet was cost-effective (cost per LYG gained) when compared to SoC.
PUk11
COST-EFFECTIvENESS ANALySIS OF RABBIT ANTITHyMOCyTE gLOBULIN 
COMPARED TO BASILIxIMAB IN THE INDUCTION OF RENAL TRANSPLANT 
PATIENTS
Escudero P.1, Misas J.D.2, Orozco-Cabal L.F.2
1Nephrology and Transplant Medicine, Bogotá, Colombia, 2Sanofi-aventis de Colombia S.A., 
Bogotá, Colombia
Rabbit antithymocyte immunoglobulin (r-ATG) and basiliximab are used as induction 
treatment for renal transplant patients. Since the cost associated with these proce-
dures is a limiting factor in their availability, it is necessary to determine the cost-effec-
tiveness ratio, given the differences in clinical outcomes among them. Objectives: 
To determine the incremental cost-effectiveness ratio between r-ATG and basiliximab 
for defined clinical outcomes in patients undergoing induction treatment for renal 
transplantation. MethOds: We completed meta-analyses for r-ATG and basiliximab 
in induction treatment. The data was used to define global effectiveness outcome 
measures (i.e. relative risk-RR) necessary to perform a cost-effectiveness analysis 
for Colombia. The attributable risk was calculated using the RR for each clinical out-
come. Results: The quadrant analysis for the cost-effectiveness ratio showed that 
the simulations are in the first quadrant (I), except for the fatal outcome of high-risk 
patients located in quadrant IV. For every other outcome and analysis group, there was 
an increase in effectiveness and cost. The costs of reducing 1% the attributable risk 
durante el período 2013-2017. La prevalencia de ERT se proyectó a partir de datos 
oficiales. Los costos se obtuvieron de distintas fuentes: casos reales para determinar 
uso de recursos, tarifarios oficiales (ISS 2001 ajustado) para procedimientos, y SISMED 
para medicamentos. Todos los datos fueron validados en reuniones de expertos, se 
siguieron las guías ISPOR para impacto presupuestal. ResultadOs: Según nuestros 
estimados, el número de pacientes con ERT pasará de 27.890 en 2013 a 33.900 en 2017. 
En el Escenario1 el costo pasará de COP$837.882 millones (USD$469,4 millones) a 
COP$ 1.009.782 millones (USD$565,7 millones), un crecimiento en pesos constantes 
de 20,5 %. En el Escenario 2 el costo llegaría COP$1.044.883 millones(USD$585,4 mil-
lones), un incremento absoluto de 3 % con respecto al Escenario 1. El número de 
pacientes trasplantados pasaría de 3.601 a 4.145 mientras los muertos en el quin-
quenio se reducirían en 14; ello equivaldría a COP$64,5 millones (USD$36.134) por 
paciente trasplantado adicional o COP$2.507 millones (USD$1,4 millones) por muerte 
evitada. cOnclusiOnes: Un incremento del 5% anual del trasplante renal representa 
un aumento del 3% del costo de la atención de la ERT en Colombia. Parte del “ahorro” 
actual con la diálisis se debe a mayor mortalidad.
PUk5
COST-EFFECTIvENESS OF PARICALCITOL IN END STAgE CHRONIC kIDNEy 
DISEASE SECONDARy HyPERPARATHyROIDISM PATIENTS ON DIALySIS, IN 
BRAzIL
Menezes F.G.1, Nita M.E.1, Peixoto R.B.2
1Abbott Laboratórios do Brasil Ltda., São Paulo, Brazil, 2Abbott, São Paulo, Brazil
Objectives: To understand from the perspective of the Brazilian National Health 
System (SUS) the cost-effectiveness of treating secondary hyperparathyroidism 
with IV paricalcitol versus IV calcitriol in dialysis patients diagnosed with end 
stage chronic kidney disease. MethOds: A decision-analytic Markov model com-
paring the use of IV paricalcitol versus calcitriol. Main outcomes include parathy-
roidectomy, hospitalizations or death, life time costs and the results are reported 
as incremental cost-effectiveness ratios (ICER). The treatment costs are based on 
the DATASUS administrative claim database which includes individuals with an 
end stage chronic kidney disease secondary hyperparathyroidism diagnosis, who 
underwent hemodialysis at SUS, from 2009 to 2012. The main clinical outcomes 
are based on clinical trials or cohort studies reporting those outcomes. Results: 
The reference case analysis was a 5-year time horizon based on a comparison of 
treatment with paricalcitol versus calcitriol, of end stage chronic kidney disease 
secondary hyperparathyroidism dialysis patient. The use of paricalcitol leads to sav-
ings amounting R$ 113.999.601,06 to SUS and an increase in life-years gained (0.52 
years). Paricalcitol was dominant over the comparator (calcitriol), indicating better 
health outcomes and lower costs. One-way sensitivity analyses and probabilistic 
sensitivity analyses confirmed the robustness of the model. cOnclusiOns: In our 
model the substitution of IV calcitriol by IV paricalcitol can be a more cost-effective 
choice in the management of secondary hyperparathyroidism.
PUk6
CATHETER-ASSOCIATED URINARy TRACT INFECTIONS: COST COMPARISON 
STUDy FROM THE PUBLIC PAyER PERSPECTIvE
Tolentino A.C., Schutz V.
Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Objectives: To compare costs of catheter-associated urinary tract infection (CAUTI) 
with the reminding intervention (RI) and without reminding intervention (WRI) 
from the public payer perspective. Urinary catheter (UC) is one of the most invasive 
devices used in health care, and its insertion contributes to the development of 
urinary tract infections (UTI), which accounts for 40% of all nosocomial infections. 
About 12%-16% of patients in the intensive care unit have a UC inserted at some 
point during hospitalization. Unnecessary use of UC may lead to CAUTI, which rep-
resents about 80% of UTI, contributing not only to excess morbidity and mortality, 
but also increasing costs. A prospective study published (Apisarnthanarak 2007) 
evaluated the effectiveness of a program to improve hospital quality, which included 
an intervention to remind physicians to remove unnecessary UC. MethOds: 
Efficacy data was obtained from the literature which compared RI to WRI. Data from 
the Brazilian Hospital Information System (SIH/DATASUS) from 2012 was used to 
define the annual number of high complexity admissions of adult patients in public 
hospitals, assuming WRI as current practice. Resource utilization was estimated 
through published data and unit costs were obtained from Brazilian official price 
lists. Results: A total of 659.934 hospitalizations were identified in the database, 
with a mean length of stay of 6.7 days. According to Apisarnthanarak 2007, RI to WRI 
showed reductions of CAUTI of 9.4%. The estimated consumable costs associated 
were 1,222.45BRL/pacient/7 days of treatment. For all admissions in 2012, the total 
cost of CAUTI represented 247,091,949.90BRL for WRI and 223,865,239.68BRL for RI, 
respectively (medical supplies only). The estimated savings were 23,226,710.22BRL/
year for the Brazilian public system. cOnclusiOns: RI showed that staff education 
generates benefits for the hospital and patients, decreasing costs and unnecessary 
hospitalization. Further researches including other clinical outcomes, longer follow-
up and complications could result in higher savings for the public payer.
PUk8
FRECUENCIA y COSTOS DE HOSPITALIzACIóN EN UNA POBLACIóN DE 
PACIENTES EN DIALISIS EN COLOMBIA
Sanabria M.1, Astudillo K.1, Sanchez R.2, Camargo D.1, Bunch A.1
1Baxter RTS, Bogota, Colombia, 2Universidad Nacional de Colombia, Bogotá, Colombia
Objectives: Chronic renal disease patients are often hospitalised. The present 
study was carried out as no studies have measured such population’s hospitali-
sation frequency and duration in Colombia nor has their economic burden been 
analysed. MethOds:  This was a dynamic retrospective cohort study of 223 patients 
receiving dialysis therapy during 2010. Haemodialysis (HD) and peritoneal dialysis 
(PD hospitalisation frequency was measured, as were the number of days spent in 
hospital, total hospital bill and average cost per day of hospitalisation. Multivariate 
analysis was used for evaluating factors related to hospitalisation cost (i.e. a gen-
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moderados e outros 9(18%) se sentem incapazes de realizar suas atividades habit-
uais. No domínio dor/mal-estar, 33(66%) não refere dores ou mal estar. Sobre ansie-
dade e depressão, 36(72%) não se sentem ansiosos ou deprimidos. O estado de saúde 
autopercebido, medido pela escala analógica visual, mostra uma pontuação mínima 
de 30 e máxima de 100, numa média de 78,5. A grande maioria dos pacientes 24(48%) 
considera sua saúde excelente, 17(34%) afirmam estar com saúde regular. Apenas 
9(18%) da amostra considera sua saúde ruim.Quanto às condições socioeconômicas 
da amostra, 40(80%) pacientes estão em idade produtiva (20-59 anos), média de 41 
anos, sendo a predominância do sexo masculino 34(68%). A maioria dos pacientes 
entrevistados, 27(54%), recebe apenas o salário mínimo como renda individual, 
obtida por aposentadoria ou auxílio doença. cOnclusões: Pelo resultado obtido 
nessa pesquisa infere-se que os pacientes transplantados renais apresentam uma 
boa qualidade de vida nos primeiros meses após transplante. Sugere-se pesquisa 
prospectiva com o intuito de observar sobrevivência e as mudanças na qualidade 
de vida desses pacientes.
PUk15
HEALTH-RELATED QUALITy OF LIFE OF HEMODIALySIS PATIENTS IN 
INDONESIA
Perwitasari D.A.
Ahmad Dahlan University, Yogyakarta, Indonesia
Objectives: Health-Related Quality of Life (HRQoL) is one important outcome that 
should be monitored especially in chronic diseases. The long periode of treatment 
and the progress of diseases can give significant influence to patietns’ HRQoL. 
The study about HRQoL in developing countries will be important as one success 
parameter of treatment outcome. We conducted this study to understand the qual-
ity of life of the hemodialysis patients in Indonesia. MethOds: . We carried out 
observational study in the public hospital during 2 months. The subjects involved 
in this study were chronic renal failure patients which have been at least two times 
hemodialyzed in a public hospital. All of the patients were covered with national 
health insurance to avoid to finance impact of quality of life. The quality of life was 
measured by Indonesian version of WHO-QoL questionnaire which included physi-
cal health function, mental health function, environmental function, and social 
function. The association between quality of life domain and other functions were 
evaluated as well. Results: This study showed that in average the scale of fifty 
hemodialysis patients’ quality of life was 70.38. In the other hand, the scale of physi-
cal, emotional, environtmental and social function were 23.58, 18.10, 14.86 and 7.76, 
respectively. There were positive correlations between the functions and quality of 
life domain. The function that had highest impact on quality of life domain was 
physical function and the function smallest impact on quality life of domain was 
social function. cOnclusiOns: We understand that patients’ physical function 
during hemodialysis could deteriorate their quality of life. Thus the better service 
of health care given to the hemodialysis patients in Indonesia could increase their 
quality of life.
RESEARCH POSTER PRESENTATIONS – SESSION II
RESEARCH ON METHODS
RESEARCH ON METHODS – Clinical Outcomes Methods
PRM1
EFFICACy AND SAFETy OF PULMONARy vEINS ISOLATION wITH CRyO 
TECHNIQUE
Curnis A.1, Cerini M.1, Lipari A.1, Vassanelli F.1, Salghetti F.1, Locantore E.1, Belotti M.1,  
D’Aloia A.1, Vizzardi E.1, Elmaghawry M.2, Raweh A.3, Bontempi L.1
1University of Brescia, Brescia, Italy, 2Aswan Heart Centre, Aswan, Egypt, 3Faculty of Medicine, 
Ludes University, Lugano, Switzerland
Objectives: Pulmoanry vein isolation using cryoablation represents a recently 
developed technology for atrial fibrillation management. Its safety and efficacy 
need to be evaluated. MethOds: From February 2011 to December 2012, 58 patients 
underwent pulmonary veins isolation by cryoablation with Arctic Front Cryoballoon 
(40 men and 15 women) with a mean age of 64.2 ± 11.3 years (range 44-71), sympto-
matic paroxysmal atrial fibrillation refractory to medical therapy and at least two 
antiarrhythmic drugs. In 12 patients (20.6%) there was a normal left atrial diameter, 
while in the remaining 36 (79.4%)there was a documented mild to moderate dilata-
tion (mean diameter 50 mm). The ejection fraction (EF) measured by echocardiogra-
phy was normal in 47 patients (81%, mean FE 58.3%), while in 11 patients (19%) there 
was a moderate left ventricular dysfunction (mean EF 43 %). 76% of patients under-
went 2 cryo applications for pulmonary vein, while in the remaining 24% of patients 
was not possible the cannulation of the lower right pulmonary vein for technical-
anatomical reasons. We performed a clinical follow-up at 3 and 6 months with 24h 
Holter ECG (27 pts) and subcutaneous implant of Loop Recorder (28 pts). Results: 
At the end of follow-up: 51 patients (87.9%) were asymptomatic for palpitations and 
in sinus rhythm, 4 patients (6.9%) went to the emergency department for palpita-
tions with electrocardiographic evidence of typical atrial flutter and underwent 
SVC-tricuspid isthmus ablation and 3 patients (5.21%) experienced episodes of AF 
lasting less than 24 hours. cOnclusiOns: The isolation of pulmonary veins ostium 
by cryoablation with Arctic Front Cryoballoon in our series is a safe and effective 
technique with a low incidence of recurrence of the arrhythmia in the short term.
RESEARCH ON METHODS – Cost Methods
PRM3
ESTUDIOS DEL COSTE DE LA ENFERMEDAD
Crespo C., Gisbert R., Brosa M.
Oblikue Consulting, Barcelona, Spain
ObjectivOs: Analizar la producción de estudios del coste de la enfermedad (CoE) en 
el mundo durante 2000-2010. MetOdOlOgías: Se realizó una revisión de los estu-
dios de “Coste de la enfermedad” en inglés y español en PubMed y otras fuentes. Tras 
for each outcome (incremental cost-effectiveness) using r-ATG vs. basiliximab were: 
acute allograft rejection USD$5,4 (standard-risk) - $8,7 (high-risk); delayed graft func-
tion for high-risk patients USD$57,4; graft failure USD$20 (standard-risk)-$31 (high-
risk); death USD$19,9 (standard-risk) -$39,1 (high-risk). cOnclusiOns: The results 
of the comparative analysis of r-ATG vs. basiliximab in induction of renal transplant 
patients showed that r-ATG is a cost-effective alternative for a significant proportion 
of the population for the examined outcomes in Colombia. The investment necessary 
to reduce the risk of the considered outcomes can be low considering its benefits, 
especially in a context where the availability of donors is limited.
PUk12
COST-EFFECTIvENESS OF BASILIxIMAB AS INDUCTION THERAPy FOR kIDNEy 
TRANSPLANTATION IN MExICO
Lemus A.1, Jimenez Aranda P.2
1Novartis, Mexico City, Mexico, 2Novartis, Coyoacan, Mexico
Objectives: In Mexico 2,200 kidney transplantations were performed in the last 5 
years. The objective of this study was to assess the cost-effectiveness of Basiliximab, 
which is a chimeric interleukin (IL)-2 receptor monoclonal antibody, versus antithy-
mocyte globulins (ATG) or do not apply an induction therapy. MethOds: Cost-
effectiveness analysis of three strategies: Basiliximab, ATG, and no induction, for 
the induction stage of kidney transplantation. Effectiveness was measured by the 
incidence of acute-rejection within 12 months. Time horizon was 1 year, and no dis-
count rate was applied. Brenan D, et al, 2006 showed non-statistically difference in 
efficacy between Basiliximab and ATG. However, Nashan B, et al., 1997 found a dif-
ference on acute-rejection risk in ~17 percentage points (37.9% vs. 54.8%) between 
Basiliximab versus no-induction strategy. The costs included were the drugs cost 
and the kidney transplantation cost that was estimated in US$29,334 according to 
DRGs at IMSS. Drug costs were from public tenders and from public health institu-
tion’s perspective. Results: The induction cost with Basiliximab was US$31,191 and 
US$76,621 with ATG. Basiliximab has the less average cost-effectiveness ratio (C/E) 
per acute rejection avoided with US$512.46 compared to ATG. Basiliximab has the 
similar efficacy as ATG in patients at high risk for acute rejection, but with a lower cost 
which equals to 146% less per patient treated during the induction stage. Basiliximab 
compare to no-induction the Incremental cost-effectiveness ratio (ICER) per rejection 
avoided was US$14,642. cOnclusiOns: The analysis is not considering the whole 
opportunity cost of a kidney transplant beyond the cost of the intervention itself. 
However, Basiliximab represents a cost effective therapy for of acute-rejection in 
kidney transplantation with the lower average cost-effectiveness compared to no-
induction and dominant vs ATG.
PUk13
COSTO-EFECTIvIDAD DEL TRASPLANTE RENAL COMPARADO CON LA DIáLISIS 
EN COLOMBIA
Rosselli D., Rueda J.D., Díaz C.E.
Pontificia Universidad Javeriana, Bogotá, Colombia
ObjectivOs: Evaluar costos, utilidad y efectividad del trasplante renal comparado 
con terapia dialítica en adultos con enfermedad renal terminal en Colombia, desde 
la perspectiva del sistema de salud. MetOdOlOgías: Se diseñó un modelo de 
Markov con 60 ciclos mensuales (horizonte 5 años) y 8 estados, incluyendo muerte 
como estado absorbente. Las transiciones entre estado se obtuvieron de los registros 
internacionales (Collaborative Transplant Study, University of Heidelberg, y US Renal 
Data System). Los costos se presentan en dólares de 2012 (1 USD = COP$ 1785) y 
se obtuvieron de diferentes fuentes locales: casos reales y validación de expertos 
para uso de recursos, tarifarios oficiales (ISS 2001 ajustado) para procedimientos, 
SISMED para medicamentos. Las utilidades, en años de vida ajustados por calidad 
(AVAC), se obtuvieron promediando las reportadas en la literatura. Los datos se 
validaron en reuniones de expertos. Se hicieron análisis de sensibilidad univariados, 
multivariados y probabilísticos. Otros indicadores de efectividad fueron meses de 
vida ganados, meses de diálisis evitados y muertes evitadas. La tasa de descuento 
fue 3% y el umbral de costo-utilidad de 3 veces el PIB = USD$ 20,168. ResultadOs: 
El costo promedio total del paciente trasplantado a 5 años fue de $87,342, y el de 
diálisis $77,451, para una utilidad de 2.9832 y 2.1037 AVAC respectivamente (razón 
de costo-efectividad incremental RCEI = $11,246). Otros resultados fueron $1434 por 
mes de vida ganado, $282 por mes de diálisis evitado y $48,487 por muerte evitada. 
Parte de la diferencia en costos entre las terapias es debida a la mayor sobrevida del 
paciente trasplantado. Si igualamos la mortalidad de ambas terapias los costos se 
igualarían al comenzar el tercer año. cOnclusiOnes: El trasplante renal es más 
costo efectivo, tiene mayor sobrevida y mejor calidad de vida; a partir del tercer año 
es costo-ahorrador al ajustar por mortalidad.
URINARy/kIDNEy DISORDERS – Patient-Reported Outcomes & Patient Preference 
Studies
PUk14
QUALIDADE DE vIDA EM PACIENTESTRANSPLANTADOS RENAIS
Maia R.C.F.1, Monteiro W.M.S.1, Silva M.G.C.2
1Secretaria de Saúde do Estado do Ceará, FORTALEZA, Brazil, 2UECE, Fortaleza, Brazil
ObjetivOs: Descrever o estado de saúde autopercebido e quantificar a qualidade de 
vida relacionada à saúde dos pacientes submetidos a transplante renal em hospitais 
públicosde Fortaleza- Ceará. MétOdOs: A amostra foi composta de 50 pacientes 
submetidos a transplante renal entre 30 a 90 dias de pós-operatório, atendidos nos 
ambulatórios dos hospitais do estudo, no período de janeiro a julho de 2012 e que 
concordaram em participar do estudo. A amostra foi aleatória sendo aplicado o 
Euroqol-5D-5L (EQ-5D-5L) para mensuração indireta de preferências por estados 
de saúde, acrescentado questões sobre perfil sociodemográfico. ResultadOs: Os 
5 domínios de avaliação do instrumento EQ5D mostraram que no item mobili-
dade, 42(84%) pacientes não apresentam problemas, quanto aos cuidados pessoais, 
44(88%) não tem problemas em realizá-los, 22(44%) deles não referiram proble-
mas para realizar suas atividades habituais, enquanto 9(18%) sentem problemas 
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Los costos médicos directos fueron buscados en múltiples fuentes, incluyendo: el 
Sistema de Información de Medicamentos del Ministerio de Salud, manuales tari-
farios oficiales, bases de datos de instituciones prestadoras y aseguradoras en salud 
y bases de datos de precios en farmacias. ResultadOs: Un total de 24 instituciones 
fueron contactadas para obtener información sobre costos médicos directos. Sólo 
6 (25%) suministraron los datos requeridos, que correspondían a costos de hospi-
talización, procedimientos, manejo ambulatorio, pruebas diagnósticas y medica-
mentos asociados con el manejo de la enfermedad. Ninguna de las instituciones 
entregó más del 70% de la información solicitada. La mayor parte de instituciones 
con restricciones de acceso a los datos, adujo políticas internas que no permitían 
hacer pública su información de costos. Las diferencias reportadas en costos para 
el manejo de la Diabetes de las instituciones que suministraron datos fueron: 56% 
en costos de hospitalización, 82% en procedimientos, 88% en manejo ambulatorio, 
59% en pruebas diagnósticas y 91% en medicamentos. cOnclusiOnes: Existen 
dificultades para la consecución de costos y uso de recursos para evaluaciones 
económicas en Colombia y amplia variación en la información obtenida, lo que 
genera altos niveles de incertidumbre y la transparencia y representatividad de los 
resultados puede verse seriamente afectada.
PRM7
USO DE BASES DE DATOS O SISTEMAS DE INFORMACIóN PARA SOPORTAR LA 
TOMA DE DECISIONES EN SALUD EN COLOMBIA
Alfonso-Cristancho R.1, Diaz-Sotelo O.D.2, Maestre K.3, Quijano Arango M.3
1University of Washington, Seattle, WA, USA, 2RANDOM Foundation, Bogota, DC, Colombia, 
3Novartis Pharma AG, Bogotá, DC, Colombia
ObjectivOs: Actualmente existe una tendencia global en el uso de información 
de la vida real para soportar la toma de decisiones en salud. En Colombia, hay 
poca información respecto al uso de la información generada por los diferentes 
actores del sistema de salud. El objetivo de este estudio fue identificar las fuentes 
de información disponibles y su uso actual para soportar la toma de decisiones en 
salud. MetOdOlOgías: Usando una encuesta semi-estructurada auto-diligenciable 
dirigida a diferentes grupos de tomadores de decisiones de instituciones asegurado-
ras y prestadoras de servicios de salud, autoridades de salud, industria farmacéutica 
e instituciones académicas y de investigación, se evaluó la información disponible 
y su uso actual en la toma de decisiones. ResultadOs: Un total de 39 tomadores 
de decisiones en 30 instituciones respondieron la encuesta (40% aseguradores, 17% 
prestadores, 14% industria farmacéutica, 3% entidades gubernamentales y 26% de 
otras entidades). De ellos 95% reportaron tener bases de datos relacionadas con sus 
actividades en el sistema de salud; de éstos, 83% usan datos de costos para soportar 
la toma de decisiones; 58% reportaron que indicadores como años de vida ganados 
por calidad, años de vida perdidos por discapacidad y desenlaces reportados por 
el paciente no se tienen en cuenta para la toma de decisiones. En contraste, el 50% 
de las instituciones usan sistemáticamente indicadores de desempeño y perfiles 
epidemiológicos. cOnclusiOnes: Si bien existen mecanismos de almacenamiento 
y análisis de datos sobre prestación de servicios, eventos de interés en salud pública 
y costos de atención, su uso en Colombia es incipiente, limitando la realización de 
estudios más complejos como evaluaciones económicas o estudios de efectividad 
comparativa, necesarios para favorecer la toma de decisiones mejor informadas. La 
participación activa de los actores en el uso sistemático de esta información, puede 
ser de gran utilidad para mejorar la eficiencia del sistema de salud.
PRM8
áNALISE DE SIgNIFICâNCIA DO BANCO DE DADOS DE HOSPITAIS 
PARTICULARES BRASILEIRO
Ferreira C.N.1, Souza C.2, Bonachela F.3, Abreu A.A.2, Paloni E.D.M.P.1, Drago S.2, Salles G.R.D.4, 
Santana C.F.S.D.4
1ORIZON - Companhia Brasileira de Gestão de Serviços, Sao Paulo, Brazil, 2ORIZON, Sao Paulo, 
Brazil, 3Orizon, SAO PAULO, SAO PAULO, Brazil, 4Orizon, Sao Paulo, Brazil
ObjetivOs: Avaliar o grau de importância do banco de dados da Orizon (informações 
de hospitais particulares) para a sociedade Brasileira. MétOdOs: Foram realizadas 
análises quantitativas e qualitativs da base de dados da Orizon comparada com os 
dados conhecidos da ANS (Agência Nacional de Saúde) que regulamenta os planos 
de saúde no Brasil. Os dados quantitativos analisados foram: número de vidas, tipo 
de operadora existente na base, volume de transações e histórico da base. Quanto 
aos dados qualitativos foram mensurados os tipos e qualidade das informações e 
analisados dados estatístico descritivo. ResultadOs: A Base de dados Orizon possui 
16.161.999 vidas que corresponde à 35% do mercado de saúde suplementar, com-
parado com os dados da ANS por pagador obteve-se a seguinte representatividade: 
autogestão a base possui 24% de todo o mercado, 16% de cooperativa médica, 14% 
filantropia, 8% medicina de grupo e 94% de todas as seguradoras especializas em 
saúde, além de 1.141.316 vidas pertencentes à grupos não regulamentado pela ANS, 
sua distribuição por média nos Estado Brasileiro por beneficiários que possui plano 
de saúde corresponde à 22%. Somente nos dois anos o volume de transações (con-
sultas, internações, cirurgias e exames) correspondeu à 285.353.901. As informações 
existentes são: tipo de internação, motivo da alta, tipo do gasto, tempo de internação, 
descrição do item (material, exame, procedimento, taxa, medicamento e alimento), 
quantidade, valores, localização geográfica, gênero e idade. cOnclusões: No Brasil 
existe somente a base de dados pública do sistema único de saúde (SUS) com infor-
mações do mercado público de saúde não sendo possível mensurar a saúde total 
brasileira, desta forma o banco de dados Orizon vem para auxiliar à mensurar todo 
mercado brasileiros de forma totalmente significante e necessária.
RESEARCH ON METHODS – Modeling Methods
PRM9
ANALySIS OF MANDIBULAR TEST SPECIMENS USED TO EvALUATE BONE 
FIxATION SySTEMS
Passeri L.A.1, Baccarin L.S.1, Casarin R.C.V.2, Silva J.V.L.3
1Unicamp, Campinas, Brazil, 2Paulista University, Sao Paulo, Brazil, 3CTI, Campinas, Brazil
la selección de artículos por el abstract o el título (si no existía abstract), se revisaron 
directamente los artículos. Los criterios de inclusión fueron estudios donde apareci-
era un coste total para la patología o bien un coste por año y paciente siempre que 
no fuera de un estudio de evaluación económica. ResultadOs: Se hallaron 233 
trabajos que cumplían la palabra clave. Esta cifra se redujó a 153 cuando se pasó al 
estudio sobre de los artículos completos. La distribución temporal de los estudios 
es desigual, mostrando 25 en 2009 y 4 en 2000. Las enfermedades del sistema nervi-
oso con 33 (21,6%) trabajos figuran en primer lugar siendo la EPOC con 13 (8,5%) las 
patologías más frecuentes. Se obtuvieron los costes directos en 127 y los indirectos 
en 92, en tres casos se utilizó el enfoque del período de fricción. Se obtuvo el coste 
total en 81 estudios y por paciente-año en 91. Domina el enfoque de la prevalencia 
129 frente al de incidencia 7 y el método “bottom up” 94 frente al “top down” 46, y 
USA, con casi un tercio de los estudios, el país del mundo con mayor peso en este 
tipo de análisis. cOnclusiOnes: Se mantiene –y de hecho crece- el interés por 
CoE con enfoque de prevalencia y “bottom up”, detallando los costes indirectos y 
no sólo los sanitarios.
PRM4
CONSUMPTION PATTERNS, MARkET CHARACTERISTICS AND REgULATION 
IN THE PHARMACEUTICAL INDUSTRy: EvIDENCE FROM TwO THERAPEUTIC 
gROUPS IN INSURED POPULATION IN ARgENTINA
Maceira D.
Center for State and Society Studies (CEDES), Buenos Aires, Argentina
Objectives: Using a theoretical framework based on estimating demand functions 
under uncertainty, this paper proposes to highlight the importance of including 
economic variables of market structure and actors’ strategic organization in the 
design of regulations on the pharmaceutical sector, beyond the relevance of phar-
macological and clinical tools. The specification of regularity standards in social 
health insurance schemes requires of dynamic tools to improve the decision-mak-
ing process within a framework of evidence-based medicine and cost-effectiveness 
analysis. MethOds: With a sample of 9,147 and 27,647 observations on prescrip-
tions by population covered by social insurance in Argentina, the paper two ana-
lyzes therapeutic groups: hypertensive and lipid lowering, respectively. Econometric 
implementation implied classical least squares estimation and logistic models for 
therapeutic group, product and brand. Results: The data provides consistent 
messages about the presence of differentiation mechanisms that overshadow the 
traditional inverse relationship between price and sales. In particular, the interac-
tion between brand and drugs, which can be extended to technological changes in 
a dynamic context, implies a complementary perspective in designing a regulatory 
framework. cOnclusiOns: The power of negotiation and establishment of rules 
of producers must be considered in each particular therapeutic class, allowing coor-
dinated incentives to encourage rational prescription behavior, moving in a pattern 
of more cost-effective and equitable use of resources.
RESEARCH ON METHODS – Databases & Management Methods
PRM5
A EvOLUçãO DA REDE BRASILEIRA DE AvALIAçãO E TECNOLOgIA EM SAúDE
Gonçalves L.1, Souza K.M.2
1Brazilian Ministry of Health, Brasília-DF, Brazil, 2Brazilian Ministry of Health, Brasília, Brazil
ObjetivOs: A Rede Brasileira de Avaliação e Tecnologia em Saúde (REBRATS), com-
posta por 53 membros, atua no incentivo ao acesso livre à informação científica 
através do banco de dados criada em 2009 o SISREBRATS, visando divulgar os estu-
dos em Avaliação de Tecnologias em Saúde (ATS) no Brasil. Além disso, a iniciativa 
destina-se a aumentar a visibilidade das pesquisas, dos pesquisadores, das institu-
ições e da rede e auxiliar a sociedade no processo da educação científica e educação 
em saúde. O objetivo desse estudo é avaliar o crescimento da rede e a evolução da 
disseminação das informações científicas no Brasil através da REBRATS. MétOdOs: 
Levantamento dos dados da base da REBRATS através da contabilização das infor-
mações computadas, do número de usuários, estudos cadastrados e o aumento dos 
membros da rede. ResultadOs: Em uma análise realizada entre de abril de 2010 
e março de 2013, houve expressivo aumento do número de usuários que podem 
incluir estudos no banco de dados, que passou de 29 para 226, são representados 
pelos pesquisadores que fazem parte da REBRATS. Neste mesmo cenário, observa-
se a ampliação dos membros que formam a rede, representando 20,5% de cresci-
mento. Neste mesmo período observou-se aumento de 85,6% de novos cadastros 
dos estudos que são disponíveis para acesso da sociedade e dos gestores de saúde 
do Brasil. cOnclusões: Os resultados demonstraram que houve um crescimento 
significativo de pesquisadores e de instituições na REBRATS. Como consequên-
cia desse aumento, observou-se a ampliação dos estudos cadastrados na base. O 
SISREBRATS é um sistema de acesso livre e com potencial para prover informações 
que podem subsidiar a tomada de decisão dos gestores de saúde do pais. Apesar 
do crescimento, é necessário realizar contínuos esforços para ampliação da base, 
considerando a magnitude e a quantidade de instituições membros da REBRATS.
PRM6
DIFERENCIAS EN LA CONSECUCIóN DE INFORMACIóN SOBRE COSTOS DEL 
MANEjO DE LA DIABETES MELLITUS EN COLOMBIA
Alfonso-Cristancho R.1, Diaz-Sotelo O.D.2, Barbosa T.3, Prieto Salamanca D.3
1University of Washington, Seattle, WA, USA, 2RANDOM Foundation, Bogotá, DC, Colombia, 
3RANDOM Foundation, Bogotá, Colombia
ObjectivOs: La información sobre costos y uso de recursos en salud es indis-
pensable para desarrollar evaluaciones económicas. En Colombia, los diferentes 
actores del sistema de salud tienen fuertes restricciones para brindar acceso a su 
información, la cual en su mayoría no es pública. El objetivo de este análisis fue 
cuantificar el acceso a la información y las diferencias reportadas en la información 
disponible sobre costos de la Diabetes Mellitus en Colombia. MetOdOlOgías: En el 
desarrollo de una evaluación económica, se identificaron los recursos en salud para 
el manejo de la enfermedad a partir de guías nacionales y protocolos institucionales. 
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Objectives: Recent consensus guidelines do not advocate universal thyroid func-
tion screening during pregnancy but recommend testing high-risk pregnant women 
with a personal history of thyroid or other autoimmune disorders or with a family 
history of thyroid disorders. Maternal subclinical hypothyroidism during pregnancy 
is associated with various adverse outcomes. The present study aims to assess 
efficiency of the targeted high-risk case-finding approach in identifying women 
with thyroid dysfunction during early pregnancy. MethOds: A comprehensive lit-
erature search was done in PubMed and EMBASE databases till July 2012 for studies 
related to screening of thyroid dysfunction. Data was extracted from each relevant 
article. The primary estimate was pooled odds ratio with 95% CI. Data analysis was 
done by Comprehensive Meta Analysis software. Heterogeneity was assessed by 
I2 statistics. Publication bias was assessed using Begg and Egger test. Sensitivity 
analysis was also performed. Results: A total of 5 studies (published between 
2007 and 2011) were found to be pertinent after exclusion of irrelevant studies. 
Because of significant heterogeneity, a random effects model was chosen. For the 
effectiveness of universal screening, pooled odds ratio was found to be 2.87 (95% 
CI, 1.60-4.94, p= 0.00). cOnclusiOns: Targeted thyroid function testing of only the 
high-risk group would miss about one third of pregnant women with overt/ sub-
clinical hypothyroidism.
PRM13
DESARROLLO DE UNA ESCALA DE ESTRUCTURAS y PROCESO PARA LA 
EvALUACIóN DE LOS CENTROS DE HEMODIáLISIS
Scarpitta C., Saona G., Leiva G., Gambogi R., Opertti A.
Fondo Nacional de Recursos, Montevideo, Uruguay
ObjectivOs: Desarrollar una escala de indicadores de calidad de estructuras 
y procesos para los centros de hemodiálisis del Uruguay. MetOdOlOgías: Un 
conjunto de expertos nacionales elaboró una lista de indicadores basados en 
estándares que fueron evaluados mediante visitas técnicas en los centros desde 
2004 hasta la actualidad. Mediante el Análisis de Coordenadas Principales (ACoP) 
y la distancia de Gower se estudió el conjunto de indicadores buscando obtener 
un número reducido de factores que expliquen una proporción importante de la 
varianza del sistema de indicadores en el período 2007 a 2010. Se construyó la 
escala de estructuras y procesos empleando como ponderación la mediana de 
la distancia euclidea entre los indicadores para el espacio de factores obtenidos 
en el ACoP. Mediante estadística descriptiva se analizó el comportamiento de la 
escala en el tiempo y respecto de los indicadores originales. Aplicando el criterio 
de Kaiser se seleccionaron los dos primeros factores del ACoP (varianza expli-
cada 37,63%), el análisis presentó un índice de estrés de 0,1646. ResultadOs: La 
escala desarrollada mostró una tendencia temporal de mejora en la calidad de 
las estructuras y procesos brindados por los centros de hemodiálisis. También se 
observó una asociación significativa con varias de las dimensiones de estructuras 
y procesos evaluados. cOnclusiOnes: Se considera que el instrumento desar-
rollado es adecuado para la valoración global de las prestaciones en hemodiálisis 
en las áreas de estructura y procesos.
PRM14
APPLIED COMPARISON OF META-ANALySIS TECHNIQUES
Wang L.1, Lewis-Beck C.2, Baser E.3, Fritschel E.4, Baser O.5
1STATinMED Research, Dallas, TX, USA, 2Freddie Mac (formerly of STATinMED Research, Ann 
Arbor, MI), McLean, VA, USA, 3STATinMED Research, Ankara, Turkey, 4Texas Department of State 
Health Services (formerly of STATinMED Research, Dallas, TX), Austin, TX, USA, 5STATinMED 
Research/The University of Michigan, Ann Arbor, MI, USA
Meta-analysis is an approach that combines findings from similar studies. The 
aggregation of study-level data can provide precise estimates for outcomes of inter-
est, allow for unique treatment comparisons, and explain differences arising from 
conflicting study results. Proper meta-analysis includes five basic steps: identify 
relevant studies; extract summary data; compute study effect sizes, perform statisti-
cal analysis; and interpret and report the results. Objectives: This study aims to 
review meta-analysis methods and their assumptions, apply various meta-tech-
niques to empirical data, and compare the results from each method. MethOds: 
Three different meta-analysis techniques were applied to a dataset examining the 
effects of the bacille Calmette-Guerin (BCG) vaccine on tuberculosis (TB). Fixed-
effect, random-effect modeling and meta-regression were applied for analysis, with 
added study-level covariates. Overall and stratified results, by geographic latitude 
were reported. Results: Estimates of treatment effect differed depending on the 
technique applied. When a fixed effect model was applied to estimate the effect 
of a vaccination against tuberculosis, the log odds ratio was -0.436 (confidence 
interval [CI: -0.528, -0.344]). After testing for heterogeneity and fitting a random 
effects model, the estimate was reduced to -0.741 (CI [-1.12, -0.352]), and the CI 
became wider. When covariates were added to the model to explain the heteroge-
neity, the treatment effect was reduced even further. All three techniques showed 
statistically significant effects from the vaccination. However, once covariates 
were added, efficacy diminished. Independent variables, such as the latitude of 
the location in which the study was performed, appeared to be partially driving the 
results. cOnclusiOns: Meta-analysis is useful to draw general conclusions from 
a variety of studies. However, proper study and model selection are important to 
ensure the correct interpretation of results. Basic meta-analysis models are fixed-
effects, random-effects, and meta-regression.
RESEARCH ON METHODS – Study Design
PRM15
DISPONIBILIDAD y FUENTES DE LA INFORMACIóN PARA LA TOMA DE 
DECISIONES EN REUMATOLOgíA: USO DE LOS ESTUDIOS ECONóMICOS
Guzman Vazquez S.1, Rodriguez Mendoza M.M.2, Pizarro M.3, Soto H.4
1UNAM, México D.F., Mexico, 2Universidad Autónoma Metropolitana, Distrito Federal, Mexico, 
3Hospital Infantil de Mexico Federico Gomez, México D.F., Mexico, 4Health Solutions Consulting, 
D. F., Mexico
Objectives: To evaluate, through biomechanical tests, which synthetic material 
used for the manufacturing of test especimens (ABS plastic, polyamide, and polyure-
thane) shows a better biomechanical behavior for in vitrosimulations of load resist-
ance of a fixation method established to mandibular SSRO [Sagittal Split Ramus 
Osteotomy]. MethOds: 30 synthetic and standardized replicas of human hemimandi-
bles with SSRO were divided into 3 groups of 10 samples each: Group A - ABS plastic, 
Group B - Polyamide, and Group C - Polyurethane. These were fixed by three positional 
bicortical screws (16 mm length, 2.0 mm system), in an inverted “L” pattern, using 
drilling guides and advancement of 5 mm. Each sample was subjected to a vertical 
linear load and the load resistance values recorded at 1, 3, 5, 7, and 10mm displace-
ment. The standard deviations and means were compared using analysis of variance 
(p< 0.05) and Tukey’s test. Results: It was observed a tendency for lower values in 
group B than in groups A and C. In displacements of 3 and 5 mm, there was a differ-
ence between groups A and C to group B (p< 0.05). In displacements of 7 and 10 mm, 
there was a difference among the 3 groups, the highest values being found in group 
C and the lowest ones in group B (p< 0.05). cOnclusiOnes: Taking into considera-
tion the results achieved and the behavior of each material used as substrate, we can 
consider that ABS plastic was very flexible and polyurethane very rigid. On the other 
hand, polyamide samples behaved more likely to the human cortical bone, which 
can be validated to perform load tests, for SSRO, compared to other tested materials.
PRM10
CALIBRATION OF A COST-EFFECTIvENESS MODEL TO EvALUATE THE 
INCORPORATION OF A QUADRIvALENT HPv TyPES 6, 11, 16, 18 vACCINE IN 
ARgENTINA: DISEASE BURDEN COMPONENT
Pichon-Riviere A., Caporale J., Alcaraz A., Bardach A., Klein K., Rey Ares L., Augustovski F.
Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina
Objectives: To calibrate the disease burden component (mortality and incidence 
rates from cervical cancer) of a cost-effectiveness model that aims to evaluate the 
incorporation of a quadrivalent HPV Type 6, 11, 16, 18 vaccine in Argentina. MethOds: 
We adapted a previously developed mathematical model (Elbasha 2010) to evaluate 
the health and economic impact of routine vaccination of 11 years old females. The 
model is a dynamic transmission model which estimates the direct and indirect (via 
herd immunity) health benefits of vaccination. Individuals enter the model as they 
are born; move between successive age groups at an age, gender and sexual activity 
specific rates, and exit the model as they die. A systematic search on effectiveness, 
local epidemiology, resource use and costs was undertaken to populate the model. 
Selected intermediate parameters (probability of transmitting genital HPV infection 
per sexual partnership by HPV genotype, and percent of females with cervical cancer 
that recognize their symptoms and seek treatment) were used for calibration. The 
perspective used was that of the health care system, with a horizontal span of 100 
years and a rate of discount of 5% for costs and health effects. Results: The model 
was properly calibrated with results in a range of +/- 1% as compared to national 
vital statistics and Globocan. The model showed an incidence of 5,285 new cases of 
HPV 16&18 related cervical cancers per year in Argentina and 1,511 deaths for 2013. 
Eighty-seven and 80% of incident cases and deaths were concentrated in the 35 to 85 
age group, and a median age of death of 55 years. cOnclusiOns: The model proved 
to be an evidence-based, internally valid tool for the assessment of the main HPV 
related disease burden and can serve as the basis for the further evaluation of the 
cost-effectiveness of HPV routine vaccination in Argentina.
RESEARCH ON METHODS – Patient-Reported Outcomes Studies
PRM11
MEDICIóN DE LA CALIDAD DE vIDA POR MEDIO DEL “DERMATOLOgy LIFE 
QUALITy INDEx” EN PACIENTES CON PSORIASIS: UNA REvISIóN SISTEMáTICA
Ordoñez Molina J.E.1, Palacios Barahona A.U.1, Londoño Garcia A.M.2, Jimenez Tamayo S.B.1
1CES University, Medellin, Colombia, 2Universidad Pontificia Bolivariana, Medellin, Colombia
ObjectivOs: Evaluar la calidad de vida relacionada con la salud en pacientes con pso-
riasis, medida a través del Dermatology Life Quality Index (DLQI). MetOdOlOgías: 
Se realizó una revisión sistemática en Pubmed, Cochrane Library, Embase y CINAHL 
sobre la calidad de vida relacionada con la salud en pacientes con psoriasis leve, 
moderada y severa. Se incluyeron artículos que evaluarán la calidad de vida en su con-
dición basal mediante la escala DLQI y se reportó el resultado utilizando el Psoriasis 
Assessment and Severity Index (PASI) como resultado secundario. La búsqueda sólo 
incluyó estudios en inglés publicados desde 1994 hasta agosto de 2012. Se excluyeron 
los artículos que comparaban diferentes tipos de tratamiento en términos de mejoría 
de la calidad de vida antes y después de la administración del medicamento, así 
como la evaluación de la calidad de vida en diferentes variantes de la enfermedad 
tales como la artritis psoriática y psoriasis de las uñas. ResultadOs: Se identifi-
caron ocho artículos que cumplieron con los criterios de inclusión y exclusión que 
evaluaban la calidad de vida relacionada con la salud en pacientes con psoriasis leve 
y moderada mediante la escala DLQI. Se evidenció una pérdida de la calidad de vida 
en los pacientes con psoriasis, en sus actividades diarias y de trabajo, así como en la 
vida sexual. El promedio de DLQI estuvo entre 6,4 a 10,8; se observó una gran variabi-
lidad en la duración de la enfermedad entre 17,6 y 28,9 años. Un total de dos estudios 
reportaron el PASI, el cual estuvo entre 6,53 y 10,5, lo que indica enfermedad leve y 
moderada. cOnclusiOnes: La psoriasis afecta la calidad de vida de los pacientes 
que padecen la enfermedad tanto en su forma leve como moderada, y este deterioro 
es superior a los encontrados en enfermedades tales como acné, vitíligo, alopecia y 
urticaria, entre otras enfermedades.
RESEARCH ON METHODS – Statistical Methods
PRM12
THyROID DySFUNCTION DETECTION IN PREgNANCy: UNIvERSAL SCREENINg 
OR TARgETED HIgH-RISk CASE FINDINg? A META-ANALySIS
Gudala K., Bansal D., Kandikatla L.R., Krishna P.S.R.
National Institute of Pharmaceutical Education and Research, Mohali, India
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non-pharmacological cost avoidance assessment we determined that apixaban can 
be a cost saving alternative in the long term. Versus SoC (warfarin), apixaban may 
be the only NOAC with consistent benefit on all relevant events. Consistent with 
trial data, lifetime modeling suggested reduction in the mortality.
PCv2
COMORBIDITIES ASSOCIATED TO ATRIAL FIBRILLATION (AF) IN SELECTED 
LATIN AMERICA COUNTRIES
Leyva-Bravo V.1, Soriano M.A.1, González-Rojas G.L.1, Galindo-Rodriguez J.A.2, Diaz G.F.3
1IMS Health, Mexico City, Mexico, 2Instituto de Salud Dr. Hernan Alessandri, Santiago, Chile, 
3Escuela de Medicina “JM Vargas” Universidad Central de Venezuela, Caracas, Venezuela
Objectives: AF is the most common chronic cardiac arrhythmia worldwide and is 
an important risk factor for morbidity related mainly to an increased risk of cerebro-
vascular events and heart failure. This study examined the prevalence of comor-
bidities among patients receiving treatment for AF in 4 Latin America countries to 
convey a more comprehensive picture of the total disease burden. MethOds: For 
study purposes, co-morbidity was defined as the presence of one or more disorders 
in addition to a primary disease, or the effect of such additional disorders. A 3-step 
process was conducted in order to understand treatment patterns for patients suffer-
ing from AF: 1) health care assessment per country; 2) evaluate patient’s information; 
and 3) data analysis to understand and determine treatment algorithms. Data were 
collected through 59 face-to-face interviews with cardiologists in Argentina, Brazil, 
Chile, and Venezuela. Results: Analysis per country suggested that, in Chile and 
Venezuela, 98% and 94% of patients, respectively, reported at least one co-morbidity. 
In Argentina this pattern was observed in 81% of the patients, whereas in Brazil 
this was 78%. Findings revealed that the main 5 comorbidities associated with AF 
were: 1) Hypertension: LatAm 43%, Argentina 28%, Brazil 45%, Chile 43%, Venezuela 
33%; 2) Dyslipidemia: LatAm 22%, Argentina 11%, Brazil 25%, Chile 21%, Venezuela 
18%; 3) Diabetes: LatAm 13%, Argentina 8%, Brazil 11%, Chile 10%, Venezuela 18%; 
4) Cardiopathies: LatAm 8%, Argentina 4%, Brazil 8%, Chile 8%, Venezuela 9%; 
and 5) Thyroid disease: LatAm 7%, Argentina 4%, Brazil 3%, Chile 12%, Venezuela 
9%. cOnclusiOns: Overall, the analysis suggests that hypertension is the main 
co-morbidity associated with AF, followed by dyslipidemia and diabetes. The health 
burden carried by patients often extends far beyond AF. Physicians should carefully 
consider comorbidities and concomitant medications when managing patients.
PCv3
ICEBERg PHENOMENON OF HEART FAILURE IN HOSPITALIzED PATIENTS:  
A MULTICENTRIC CROSS SECTIONAL STUDy
Insua J.T.1, Villalon R.1, Giunta D.2, Ioli P.3
1Hospital Universitario Austral, Universidad Austral, Derqui, Argentina, 2Hospital Italiando de 
Buenos Aires, Caba, Argentina, 3Hospital Privado de la Comunidad, Fundacion Medica de Mar del 
Plata, Mar del Plata, Buenos Aires, Argentina
Objectives: Heart failure (HF) ranks high in hospital utilization, cost and quality/
safety consequences. We studied occult HF as secondary diagnosis (2Dx) in a multi-
centric study of the A-HCUPs. MethOds: A multi-centric cross sectional study of 1 
year hospital discharges adapted HCUPs for Argentina. We estimated HF by HCUPs’ 
CCS#108 SL (heart failure) in 2Dx to measure submerged HF; obtained HF in first diag-
nosis (1Dx), and 365 day readmissions (ReH), < 30 day ReH, mortality and case fatality. 
2Dx1= in first secondary Dx; 2Dx5= fifth 2Dx, etc. International dollars PPP, (UN Data: 
1Arg$ = 1.608 PPP, 2008) were used. Results: Among 45466 discharges ≥ 19 years 
old, we found 1178 discharges with CCS#108 among 1Dx (incidence: 2,59%*; 95%CI 
2,44-2,74%); mortality 0,24% ** (95%CI 0,20-0,29%); 365 days ReH was 60,9% (95%CI 58,1- 
63,7%) and < 30 day ReH of 18,1% (95%CI 15,9- 20,3%). 864 discharges had CCS #108 (HF) 
among any 2Dx (from 1 to 10 2Dx), (incidence: 1,90%; 95%CI 1,77-2,03%) (p< 0,001 vs*), 
descending from 2Dx1: 316, 2Dx5: 89; and 2Dx8: 36 discharges. HF was one among 
several multi-morbid conditions. Outcomes of discharges with 2Dx1 are 365 day ReH: 
57,3 % (95%CI 51,8-62,7%) and < 30 day ReH: 17,1% (95%CI 12,9- 21,2%), mortality 0,09 
(95%CI 0,06-0,12%,(p< 0,001 vs**), case fatality: 12,66% (95%CI 8,99- 16,32%). Mean cost 
per discharge was 7 907 I$ PPP and median cost 1 917 I$PPP for HF in 1Dx; while mean 
was 23316 I$PPP and median cost 12796 I$PPP for CCS #108 in 2Dx5. cOnclusiOns: 
HF is the leading CCS among several criteria of ranking of discharges. Is one of the 
leading causes of admissions as detected by 1Dx. However, HF is frequently sub-
merged as a 2Dx, causes significant mortality, costs and readmissions (ReH). Quality, 
safety and economic studies should consider HF as secondary diagnosis.
PCv4
PERMANENT TRANSvENOUS LEAD ExTRACTION: FACTORS INFLUENCINg THE 
DIFFICULTy OF THE PROCEDURE
Bontempi L.1, Cerini M.1, Lipari A.1, Vassanelli F.1, Salghetti F.1, Locantore E.1, Belotti M.1, 
D’Aloia A.1, Vizzardi E.1, Raweh A.2, Elmaghawry M.3, Curnis A.1
1University of Brescia, Brescia, Italy, 2Faculty of Medicine, Ludes University, Lugano, Switzerland, 
3Aswan Heart Centre, Aswan, Egypt
Objectives: Transvenous lead extraction is increasingly required. The aim of this 
study was to determine which factors influence the difficulty of a lead extraction 
procedure through the analysis of a high-volume centre database. MethOds: A 
total of 889 permanent leads were extracted from 469 patients. Factors influencing 
the difficulty of a procedure were assessed using a multivariate logistic regres-
sion model. The fluoroscopy time of the procedure was taken as index of diffi-
culty. Results: From January 2003 to December 2012 , 932 of 946 (98.5%) leads were 
completely removed. Major complications occurred in 1.3% patients. No deaths 
occurred. Median fluoro time was 8.4 min (3.2 - 17.1). A procedure was classified as 
difficult when fluoro time was greater then 31.2 min (90th percentile). At a multivari-
ate analysis the predictors of a difficult procedure were the number of extracted 
leads (OR 1.71, 95%CI 1.06 – 2.8), the presence of screw leads (OR 5.68; 95%CI 1.9 
– 16.9), the presence of dual coil shock leads (OR 5.01, 95%CI 1.27 – 19.8), the years 
since the oldest lead was implanted (OR 1.23, 95%CI 1.15 – 1.31), the absence of leads 
with vegetation (OR 6.76, 95%CI 1.35 – 33.3). The female gender, the patient age at 
extraction, the presence of tachy leads, the presence of lead failure weren’t predic-
ObjectivOs: Identificar el impacto de la obligatoriedad de presentar una 
Evaluación Económica (EE) para la inclusión de medicamentos en el Cuadro Básico 
Nacional en las publicaciones de EE relacionada con el área de reumatología en 
México. MetOdOlOgías: Se realizó una búsqueda sistemática de las publi-
caciones de EE y reumatología publicados entre 1995 y 2011. Los estudios de EE 
fueron clasificados por tres expertos en economía de la salud con base a los criterios 
de Drummond, Sí los estudios contemplan comparación de dos o más alterna-
tivas y sí valoran los costos y consecuencias de las alternativas examinadas se 
dice que es un estudio de evaluación económica completa (EEC). Se valoró sí la 
modificación en el año 2003 tuvo impacto significativo en términos de número 
de publicaciones. ResultadOs: Se identificaron un total de 263 artículos de EE 
entre 1995 y 2011, 93(35%) de fueron EEC. En el periodo 1995-2002 se identificaron 
56 estudios, 19(34%) EEC. En el periodo de 2003-2011 (después de la modificación 
del reglamento) se identificaron un total de 207 publicaciones de EE, 74(36%) EEC. El 
79% de las publicaciones se concentra en el periodo 2003-2011, con un total de 207 
publicaciones. Del total de publicaciones las relacionadas con reumatología fueron 
3% (n= 9) de las cuales 33% fueron completas, 67% fueron parciales. Se destaca que 
antes de la modificación del reglamento en 2003 se detectó un estudio de EE/reuma-
tología mientras que después del año 2003 el número de publicaciones ascendió a 8 
artículos. cOnclusiOnes: La EE en México a través del número de publicaciones se 
ha ido desarrollando notablemente, asimismo el hacer obligatorio el presentar un 
estudio de EE para la inclusión de un insumo al Cuadro Básico y Catálogo de Insumos 
del Sector Salud fue un punto de partida para el desarrollo de la EE en México.
RESEARCH ON METHODS – Conceptual Papers
PRM16
A UNIFIED METHODOLOgICAL FRAMEwORk FOR THE ECONOMIC EvALUATION 
OF THERAPEUTIC MEDICAL DEvICES
Iglesias C.P.
University of York, York, UK
To inform policy decisions economic evaluation (EE) studies require the system-
atic identification and (quantitative) synthesis of the relevant evidence base on 
the clinical effectiveness, quality of life (QoL) and costs associated with the use of 
competing health technologies. Existing methods for EE are linked to principles of 
evidence-based medicine and, as such, are geared primarily towards the evaluation 
of pharmaceuticals. Some authors have claimed that medical devices (MDs) cannot 
be evaluated using the same principles. We take the opposite viewpoint and argue 
that used within the right evaluative framework existing EE methods are indeed 
appropriate to assess the cost effectiveness of therapeutic MDs. What makes the 
(economic) evaluation of MDs challenging is the fact that the quantity, quality, and 
characteristics of the evidence base around them, is often fragmented, heteroge-
neous and associated with high levels of uncertainty. In these circumstances it is 
important to acknowledge the value of eliciting and quantitatively summarising 
physicians and other experts’ beliefs regarding the effectiveness and resource use 
demands associated with MDs already in use. Using real life examples this paper 
shows how a Bayesian stepwise iterative approach has helped address some of the 
challenges associated with the EE of MDs, while guiding policy decisions regard-
ing technology adoption, research funding and design. Relevant steps include: a) 
identification of existing evidence base and elicitation of experts’ beliefs on clinical 
effectiveness , QoL and costs - i.e. “a priori evidence base”; b) quantitative synthesis 
of this a priori evidence base to inform the parameters of an EE model; (c) initial 
estimation of the model; d) assessment of the economic value of conducting fur-
ther research (VoI); e) collection of new patient level data (PLD) in a pilot study; 
(f) new evaluation of the EE model updating the prior estimates using primary PLD; 
g) further VoI analysis.
DISEASE-SPECIFIC STUDIES
CARDIOvASCULAR DISORDERS – Clinical Outcomes Studies
PCv1
COSTS AND CONSEQUENCES OF ORAL ANTICOAgULATION IN ATRIAL 
FIBRILLATION IN COLOMBIA
Rosselli D.1, Rueda J.D.1, García Á.A.1, Rodriguez-Morales A.J.2, Garrido Lecca S.3,  
Vargas Zea N.4, Mould J.F.5, Donato B.M.K.6, Juarez Garcia A.7
1Pontificia Universidad Javeriana, Bogotá, Colombia, 2Universidad Tecnológica de Pereira, Pereira, 
Colombia, 3Bristol-Myers Squibb Company, Lima, Peru, 4Pfizer S.A.S., Bogota, Colombia, 5Pfizer, 
New York, NY, USA, 6Bristol-Myers Squibb Company, Wallingford, CT, USA, 7Bristol-Myers Squibb 
Mexico City, México D.F., Mexico
Objectives: To determine the clinical consequences and it’s associated costs of the 
usage of oral anticoagulation therapy for the treatment of atrial fibrillation (AF) in 
Colombia by establishing the cost per disease related event. MethOds: We used a 
6-week cycle length, 17 functional state Markov model of the main clinical outcomes 
in the lifetime of a hypothetical cohort of 1,000 patient with AF per treatment arm. 
The pivotal clinical studies for apixaban, dabigatran, rivaroxaban compared to war-
farin were the source of safety and efficacy data. Data for the analysis was extracted 
from this literature using indirect comparison methods. Costs in Colombian pesos 
2012 are expressed in American dollars (1 US$ = COP$ 1785). To estimate costs, we 
analyzed resource use of a sample of 53 stroke, 148 myocardial infarction, 6 systemic 
embolism patients in San Ignacio University Hospital. Results were validated by an 
expert panel. Results: The number of events associated with each anticoagulant 
therapy (apixaban, dabigatran 110mg, dabigatran 150mg, rivaroxaban and warfarin, 
respectively) were: stroke and systemic embolism 349, 363, 351, 360, 369. ISTH major 
bleedings 235, 212, 233, 280, 277; clinically relevant non major bleedings 342, 337, 357, 
395, 383; myocardial infarctions 102, 114, 116, 101, 104; and event related deaths 459, 
485, 475, 469, 481. Apixaban could be associated with savings in non pharmacological 
cost of $ 360, $170, $145 and $311 per treated patient compared to dabigatran 110mg, 
dabigatran 150mg , rivaroxaban and warfarin, respectively. cOnclusiOns: In this 
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sion was used to estimate the odds ratio of the outcome events for patients whose 
treatment in the week before event date included statins and BBs as compared to 
patients whose treatment included statins and other BPLD(s). Results: Patients on 
statins and BBs showed substantially higher risks for cardiovascular death (OR= 2.12, 
95%CI: 1.81–2.49), all-cause death (OR= 1.64, 95%CI: 1.49–1.81), CVD events (OR= 1.96, 
95%CI: 1.80–2.12) and hospitalization for CVD (OR= 1.99, 95%CI: 1.82–2.17) as com-
pared to patients on statins and other BPLDs. Sensitivity analyses suggest that this 
higher risk is not due to differences in prescription patterns based on perceived 
disease severity (indication bias). cOnclusiOns: In elderly hypertensive patients, 
the concurrent use of statins and BBs is associated with less effective primary 
prevention in comparison to the use of statins in combination with other BPLDs. 
Consequently, the difference observed in the efficacy of different classes of BPLDs 
in elderly populations in primary prevention remains significant in the subpopula-
tion receiving statins. Further studies should be conducted to confirm this finding.
PCv8
DIFFERENCES IN THE wEIgHTED AvERAgE DAILy DOSES OF STATINS IN LATIN 
AMERICA AND THEIR POTENTIAL IMPACT ON CARDIOvASCULAR OUTCOMES
Mould-Quevedo J.F.1, Morehouse L.1, Van Vugt J.2, Liew D.3
1Pfizer, Inc., New York, NY, USA, 2Pfizer, Inc., Capelle Ad IJssel, The Netherlands, 3University of 
Melbourne, Melbourne, Australia
Objectives: We examined the potential clinical implications of prescribing pat-
terns of generic statins within 11 Latin American markets (LA11). In LA11, generic 
versions of pravastatin, simvastatin and atorvastatin are available, however, each 
statin has a different LDL-cholesterol (LDL-C) lowering efficacy that may ulti-
mately result in differences in the incidence of CV events. 2011 LA11 prescription 
data indicate that statins are prescribed at doses that do not yield equivalent 
LDL-C lowering. Thus we calculated the weighted average daily doses (WADDs) 
of pravastatin, simvastatin and atorvastatin within LA11 and estimated the aver-
age LDL lowering with each statin, and the incidence of CV events. MethOds: 
The WADDs of prescribed simvastatin, pravastatin and atorvastatin in LA11 were 
derived from IMS data. The LDL-C modifying potencies of the WADDs were inter-
polated from dose response curves from Nicholls et al (Am J Cardiol, 2010), and 
Law et al (BMJ, 2003). The relationship between LDL-C reduction and the result-
ant impact on cardiovascular events was derived from the Cholesterol Treatment 
Trialists’ Collaboration (CTTC, Lancet 2010), where a 1mmol/L reduction in 
LDL-C, translated to a 22% reduction in major cardiovascular events. Results: 
Across LA11, the WADDs for pravastatin, simvastatin and atorvastatin were 
24.9mg, 22.4mg and 20.6mg, respectively. The corresponding reductions in LDL-C 
at these doses were estimated to be 25.0%, 33.4% and 40.6%. Assuming a pre-
treatment LDL-C of 4.0mmol/L, these lipid changes would lead to reductions 
in the risk of a major coronary/stroke event of 22.0%, 29.4% and 35.8%, respec-
tively. cOnclusiOns: At currently prescribed WADDs in LA11, the real world 
use of atorvastatin provides a superior reduction in LDL-C to either simvastatin 
or pravastatin, and hence would be expected to result in a greater reduction in 
cardiovascular events.
PCv9
ANALySIS OF CONSUMPTION OF DIURETICS IN SERBIA FROM 2006 TO 2010
Tomic Z., Sabo A., Mikov M., Milijasevic B., Milijasevic D., Vukmirovic S.
Faculty of Medicine, University of Novi Sad, Serbia, Novi Sad, Serbia and Montenegro
Objectives: Diuretics are drugs of first choice in the treatment of hypertension. 
The aim of this study was to analyze the consumption of diuretics in Serbia in the 
period from 2006 to 2010 year. MethOds: The data about the use of drugs were 
taken from the Agency for Drugs and Medical Devices of the Serbia. Results: The 
use of diuretics during the observed period in Serbia is quite small and it ranged 
from 5 to 6% of the total consumption of all drugs from the C group. Furosemide 
was the most frequently used diuretic. In the five year period furosemide con-
sumption ranged from 33-55% of the total consumption of all diuretics. The second 
largest consupmtion during first four years of the study was that of indapamide. 
Indapamide consumption in the fifth year was at the fourth position. At the third 
position in drug consumption in the first four years was hydrochlorothiazide. Use 
of hydrochlorothiazide in 2010 took second place. Spironolactone has occupied 
the fourth position in the first four years. During the last years of the period 
spironolactone occupied the third position. Consumption of all other diuretics 
was small and it was only a few percent of the total consumption of all diuret-
ics. cOnclusiOns: In Serbia, in the observed period, consumption of diuterics 
is two to three times lower in comparison with the consumption of diuretics 
in Norway and Finland. This research was supported by Provincial Secretariat 
for Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-2458/2011 and by Ministry of Science, Republic of Serbia, pro-
ject no 41012.
PCv10
ANALySIS OF CONSUMPTION OF ANTIHyPERTENSIvE DRUgS IN SERBIA FROM 
2007 TO 2011
Milijasevic B., Milijasevic D., Tomic Z., Sabo A., Mikov M., Tomic N.
Faculty of Medicine, University of Novi Sad, Serbia, Novi Sad, Serbia and Montenegro
Objectives: Drugs of first choice in the treatment of hypertension are: β -blockers, 
tiazide diuretics, ACE inhibitors, angiotensin receptor inhibitors and Ca chan-
nel blockers. The aim of this study was to analyze the consumption of antihy-
pertensive drugs in Serbia in the period from 2007 to 2011 year. MethOds: The 
data about the use of drugs were taken from the Agency for Drugs and Medical 
Devices of the Serbia. Results: The use of diuretics during the observed period 
in Serbia is quite small and it ranged from 5 to 6% of the total consumption of all 
drugs from the C group. Consumption of β -blockers was around 12% during all 5 
years. Consumption of calcium channel blockers was less than 12% of the total 
consumption of all drugs from group C in the first 2 years of the observed period. 
However, consumption of such drugs in the last 3 years growing over 18% of the 
tors of a difficult procedure. cOnclusiOns: Factors influencing the difficulty of 
an extraction procedure are the number of leads, the presence of screw leads, the 
presence of dual-coil tachy leads, the years since the oldest lead was implanted and 
the absence of leads with vegetation.
PCv5
LA UTILIDAD PREDICTIvA DEL EUROSCORE PUEDE SER MEjORADA AL 
ADICIONAR vALORES DE PEPTIDO NATRIURéTICO TIPO B O DE HEMOgLOBINA
Hernàndez-Leiva E.1, Dennis R.1, Rondon M.2, Umaña J.P.1, Isaza D.1
1Instituto de Cardiologia-Fundaciòn Cardioinfantil, Bogotà DC, Colombia, 2Pontificia Universidad 
Javeriana, Bogo, Colombia
ObjectivOs: El Euroscore(EU) es el modelo predictivo más usado en cirugía cardi-
aca; sin embargo, sobreestima el riesgo y la información necesaria para calcularlo 
no siempre está disponible. Este estudio fue diseñado para: 1). Definir si adicio-
nar el valor preoperatorio de hemoglobina (HB), péptido natriurético tipo B(BNP) o 
ambos, al EU, mejoran su capacidad predictiva sobre morbimortalidad a 6 meses 
de seguimiento postoperatorio en toda la muestra y en los pacientes diabéticos; y 
2). Evaluar la utilidad de EU en nuestro medio. MetOdOlOgías: Se incluyeron 492 
pacientes quirúrgicos cardiacos. Se comparò directamente la capacidad predictiva 
de BNP y/o HB vs EU. Luego se evaluó en que tanto la incorporación de BNP y/o HB 
al EU, adicionaron en términos de lograr mejor discriminación. Para cada uno de 
los desenlaces se construyeron y compararon curvas ROC. ResultadOs: Sobre 
mortalidad, BNP o HB no adicionan capacidad predictiva al EU ni en la muestra 
global ni en diabéticos. La mortalidad intrahospitalaria fue mejor discriminada 
por EU aislado: área bajo la curva ROC (ABC-ROC): 0.83(IC95%0.75-0.92) y a 6 meses, 
ABC-ROC 0.73 (IC95% 0.64-0.83); en pacientes diabéticos, ABC-ROC 0.95 (IC95%0.91-
1.00) para mortalidad intrahospitalaria y a 6 meses, ABC-ROC 0.84 (IC95% 0.74-0.98). 
La discriminación obtenida con BNP fue buena para bajo gasto cardiaco: ABC-ROC, 
0.72 (IC95% 0.67-0.77); e insuficiencia renal aguda ABC-ROC 0.75 (IC95% 0.76-0.84). 
Los mejores predictores de transfusión fueron EU+HB ó BNP+HB. EU mostró buena 
capacidad predictiva (ABC-ROC≥ 0.70) sobre morbilidad combinada, estancia pro-
longada en cuidado intensivo, bajo gasto cardiaco e insuficiencia renal y a 6 meses 
en la discriminación de evento cerebrovascular, tanto en el grupo total como en 
diabéticos. cOnclusiOnes: La capacidad discriminatoria de EU para mortalidad 
en nuestro medio es muy buena, especialmente en diabéticos. BNP o HB no adi-
cionan capacidad predictiva. En la mayor parte de los desenlaces de morbilidad la 
discriminación obtenida con BNP aislado es comparable a EU.
PCv6
INDIRECT TREATMENT COMPARISON BETwEEN FIxED-DOSE-COMBINATIONS 
OF LOSARTAN/AMLODIPINE AND vALSARTAN/AMLODIPINE IN BLOOD 
PRESSURE CONTROL
Gould A.L.1, Unniachan S.2, Wu D.2
1Merck Research Laboratories, West Point, PA, USA, 2Merck Sharp & Dohme Corp., Whitehouse 
Station, NJ, USA
Objectives: To compare changes in blood pressure after 8 weeks of therapy 
between a fixed-dose combination (FDC) of amlodipine/losartan and amlodipine/
valsartan using a network meta-analysis because there are no trials directly compar-
ing amlodipine/losartan to amlodipine/valsartan. MethOds: A systematic search 
identified six randomized controlled trials of study FDCs and their component 
monotherapies; 3 included amlodipine/losartan and 3 included amlodipine/vals-
artan. Conventional fixed-effects methods were used to conduct the comparisons. 
The change in sitting diastolic and systolic blood pressure (sitDBP, sitSBP) at 8 weeks 
post-randomization was the primary and secondary effect measures. Results: 
Amlodipine/losartan 5/50 mg produced greater reductions in sitDBP (-1.27 mmHg, 
95% confidence interval (CI) -5.7 - 2.2) and sitSBP (-3.7 mmHg, 95% CI -9.0 - 2.9) than 
amlodipine/valsartan 5/80 mg. Amlodipine/losartan 5/100 mg produced a greater 
reduction in sitDBP (-0.45 mmHg, 95% CI -3.7 - 2.7) than amlodipine/valsartan 5/160 
mg while amlodipine/valsartan 5/160 mg had a greater reduction in sitSBP (0.2 
mmHg, 95% CI -6.2 - 6.0) than amlodipine/losartan 5/100 mg. The confidence of supe-
rior antihypertensive efficacy for COZAAR XQ 5/50 mg than amlodipine/valsartan 
5/80 mg is 77% for sitDBP and 89% for sitSBP, while the confidence of greater efficacy 
for amlodipine/losartan 5/100 mg than amlodipine/valsartan 5/160 mg is 61% for 
sitDBP and 48% for sitSBP. With 95% CI, the reduction difference in sitDBP and sitSBP 
between amlodipine/valsartan 5/80 mg and amlodipine/losartan 5/100 mg is not 
expected to exceed 1.6 mmHg and 1.26 mmHg, respectively, and not expected to 
exceed 2.31 mmHg and 5.38 mmHg, respectively with amlodipine/valsartan 5/160 
mg versus amlodipine/losartan 5/100 mg. cOnclusiOns: The blood pressure low-
ering effect with amlodipine/losartan and amlodipine/valsartan was comparable. 
The findings from this network metaanalysis do not indicate a potential superiority 
of the reductions realized with amlodipine/valsarta relative to amlodipine/losartan.
PCv7
COMPARATIvE EFFICACy OF BLOOD PRESSURE LOwERINg DRUgS IN PRIMARy 
PREvENTION FOR ELDERLy PATIENTS
Brouwers F.1, Cohen A.A.1, Courteau J.1, Farand P.1, Cloutier L.2, Asghari S.3, Vanasse A.1
1Université de Sherbrooke, Sherbrooke, QC, Canada, 2Université du Québec à Trois-Rivières 
(UQTR), Trois-Rivières, QC, Canada, 3Memorial University, St. John’s, NF, Canada
Objectives: Differences in efficacy of different classes of blood pressure lowering 
drugs (BPLDs) have been observed in elderly primary prevention populations, with 
beta-blockers (BBs) reported to be less efficacious for primary prevention. In this 
study, we assessed if these differences remained significant in patients that use 
statins concurrently. MethOds: We conducted a series of population-based nested 
case-control studies using administrative data from 104,023 diagnosed hypertensive 
patients without recent antecedents of diabetes or cardiovascular disease (CVD) in 
the province of Quebec (Canada) between 2000 and 2004. Follow-up ended either 
with an outcome event, or at the end of 2009. Individuals with an outcome event (all-
cause death, CVD event) were considered cases. Controls were matched according 
to age, sex, date of cohort entry, and comorbidity index. Conditional logistic regres-
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tal budget impact with this new procedure incorporation under the SUS perspec-
tive. MethOds: The BIA was based on a Markov model with quarterly cycles and 
5-year time horizon in order to predict clinical and economic outcomes in a scenario 
with TAVI incorporation compared to the actual scenario – drug therapy (amiodarone, 
furosemide and digoxin) with or without aortic balloon valvoplasty. Epidemiological 
data were obtained from DATASUS and survival was extrapolated from PARTNER 
cohort B trial by using a Weibull distribution. Resource use, also gathered from this 
trial, included early perioperative complications (30 days) and late events (rehospi-
talization, dialysis, stroke, pacemaker implantation and major vascular complica-
tions). Costs were taken from the official Brazilian public official lists (DATASUS and 
BPS). Market-share data was obtained from Sociedade Brasileira de Hemodinâmica e 
Cardiologia Intervencionista. Results: The estimated number of Brazilian patients 
eligible for SSVS treatment was 795, 922, 1,180, 1,335 and 1,402 respectively for years 1-5 
of analysis. Compared to the current scenario, the inclusion of TAVI procedure with a 
13% market share during the analysis period shows an additional budget through year 
1-5 of 3.5M, 5.0M, 6.7M, 8.1M and 9.4M, consecutively. cOnclusiOns: The incremental 
budget impact to include TAVI as a treatment option in the Brazilian Public Healthcare 
System for SSVS high-risk patients was estimated to be USD 65 million in 5 years.
PCv14
ANáLISE DE IMPACTO ORçAMENTáRIO DO OCLUSOR SEPTAL PERCUTâNEO 
PARA O FECHAMENTO DE COMUNICAçãO INTERATRIAL (CIA) DO TIPO OSTIUM 
SECUNDUM
Senna K.M.S., Costa M.G., Tura B.R., Correia M.G., Santos M.S.
INC, Rio de Janeiro, Brazil
ObjetivOs: Analisar o impacto orçamentário do implante de oclusor septal per-
cutâneo para o fechamento de comunicação interatrial do tipo ostium secundumem 
comparação a cirurgia cardíaca convencional. MétOdOs: Análise sob a perspectiva 
do Sistema Único de Saúde (SUS) em um horizonte temporal de cinco anos, para 
uma população de pacientes portadores de CIA do tipo Ostium Secundum.O modelo 
considerou os custos com as intervenções durante o período de internação e a 
análise da incorporação do oclusor seguiu o pressuposto de uma taxa de utilização 
de 75% dos pacientes portadores de CIA OS. ResultadOs: Apresentou uma redução 
de mais de sete milhões de reais a favor da incorporação do oclusor percutâneo 
em relação a cirurgia como procedimento exclusivo. As análises de sensibilidade 
confirmaram uma economia favorecendo o oclusor percutâneo para o fechamento 
de CIA ostium secundum. E ao cruzar as variações de custos da cirurgia, do oclusor 
e das taxas de utilização para uma melhor aproximação da realidade, o resultado 
permaneceu favorável e demonstrou uma concentração do número de casos na 
faixa entre zero e R$40.000.000,00 em economia. cOnclusões: A análise demon-
strou a possibilidade de redução dos custos para o fechamento de CIA do tipo ostium 
secundumcom a incorporação de uma tecnologia que já vem sendo bem indicada 
e utilizada ao longo dos últimos 36 anos, como uma alternativa segura e eficaz ao 
fechamento cirúrgico tradicional. O implante de oclusor septal percutâneo é uma 
opção repleta de méritos ao evitar que o paciente sofra os traumas físicos e riscos 
associados ao procedimento cirúrgico, bem como os riscos psicológicos causados 
pela estética gerada pela cicatriz cirúrgica e trauma da internação para as crianças.
PCv15
ECONOMIC EvALUATION OF COLLAgENASE vERSUS HyDROgEL DRESSINgS 
FOR CHRONIC-wOUND TREATMENT FROM THE PUBLIC PAyER PERSPECTIvE
Tolentino A.C.1, Murta L.2, Pereira N.2
1Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2ANOVA - Knowledge 
Translation, Rio de Janeiro, Brazil
Objectives: To develop cost-effectiveness analysis of collagenase (CO) versus 
hydrogel (HG) dressings for chronic-wound treatment in adults, under the per-
spective of Brazilian public payers. MethOds: Data from the Brazilian Hospital 
Information System from January 1st to December 31st 2012 was used to deﬁne the 
annual number of hospital admissions due to chronic wounds (only non-surgical 
records with L89 ICD-10 code included). The model assumed that CO is the current 
practice in Brazilian public hospitals and patients are discharged at the time their 
wound heals. The difference in MHT was applied to the average length of stay 
(LOS) reported in the database. Resource use was estimated through expert panel 
and unit costs were obtained from Brazilian ofﬁcial price lists. Results: A total 
of 280,440 hospitalizations were identiﬁed with mean LOS of 4.47 days. The model 
estimated costs for the inpatient period assuming one dressing change for CO and 
HG. The cost per dressing change was estimated as 13.83BRL for CO and 11.95BRL 
for HG and the overall treatment costs were 61.82BRL and 53.42BRL according to the 
LOS. HG-related incremental costs were -8,40BRL indicating a cost-saving proﬁle. 
Addopting HG as wound management protocol would save 527,227.20BRL for the 
2012 cohort. Beneﬁts in terms of reduction in LOS were not accounted in the base 
case scenario. cOnclusiOns: HG dressing has shown higher efﬁcacy when com-
pared to CO dressings, with fewer costs. The clinical and economic incremental 
results between different dressings reinforce the need of evidence-based decision 
making and rational resource allocation.
PCv16
COST ANALySIS OF PULMONARy ARTERIAL HyPERTENSION IN A TERTIARy 
CARE SETTINg IN MExICO CITy
Rely K.1, Ramírez-Neria P.2, Pulido T.3, Escamilla C.4, Alexandre P.K.5, Cañedo A.6,  
Salinas Escudero C.1
1CEAHealthTech, Mexico City, Mexico, 2Instituto Nacional de Cardiología - Ignacio Chávez, México 
D.F., Mexico, 3National Heart Institute, Mexico City, Mexico, 4INSP, Mexico City, Mexico, 5Johns 
Hopkins University, Baltimore, MD, USA, 6Instituto Nacional de Neurología y Neurocirugía, México 
D.F., Mexico
Objectives: The present study determined the total direct health-care costs for the 
management of PAH patients with differing degrees of disease severity. The study 
also aimed to find the key cost drivers in the management of PAH. MethOds: PAH 
patients were recruited from a tertiary care hospital between January 1, 2009 and 
total consumption of all drugs from the C group. Total consumption of drugs acting 
on the renin-angiotensin system (C09) in Serbia in opserved period was over 41 
% of the total consumption of all drugs from the C group. The highest percentage 
in this group belonged to the ACE inhibitors. Consumption of angiotensin recep-
tor inhibitors is small and it is only a few percent of the total consumption of all 
drugs from C09 group. However, consumption of drugs in this subgroup recorded 
steady growth in recent years. cOnclusiOns: In Serbia in the observed period, 
ACE inhibitors are the most frequently used drugs within the group of drugs which 
is used for treatment of hypertension. This research was supported by Provincial 
Secretariat for Science and Technological Development, Autonomous Province of 
Vojvodina project No 114-451-2458/2011 and by Ministry of Science, Republic of 
Serbia, project no 41012.
PCv11
IMPACTO ECONóMICO y EN DISCAPACIDAD DEL INCREMENTRO DE 
UTILIzACIóN DE TROMBOLISIS EN EL CUIDADO AgUDO DE L ICTUS ISQUéMICO 
EN CHILE
Hoffmeister L.1, Mar J.2, Lavados P.3, Comas M.4, Arrospide A.2, Biagini L.1, Castells X.4
1Universidad Mayor, Santiago, Chile, 2Hospital Alto Deba, Mondragon, Spain, 3Universidad del 
Desarrollo, Santiago, Chile, 4Department of Epidemiology and Evaluation, Institut Municipal 
d’Investigació Mèdica-Parc de Salut Mar, Mar Teaching Hospital, Barcelona, Spain; Red de 
Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Barcelona, Spain
ObjectivOs: Estimar el impacto en discapacidad y económico del incremento de 
utilización de trombolisis para el manejo agudo de ictus isquémico (IS) en Chile, 
aplicando un modelo de simulación de eventos discretos. MetOdOlOgías: Se mod-
eló la historia natural y el manejo agudo de los IS para población adulta chilena, 
incorporando tiempos desde el inicio de síntomas al tratamiento y cuatro escenarios 
de utilización de trombolisis: a) utilización actual (1,7%), b) utilización de 11,6% 
tratando todos los pacientes que son atendidos dentro de la ventana terapéutica, 
c) 25% de utilización, y d) 100% de utilización. Se usaron distribuciones empíricas 
y teóricas para incluir la probabilidad y tiempos de los eventos. Se realizó una 
simulación entre 2002-2017, usando el software ARENA. Los resultados fueron la 
prevalencia de discapacidad por escenario. Se realizó un análisis de impacto pre-
supuestario desde la perspectiva del asegurador público de salud, considerando los 
costos directos del tratamiento y de rehabilitación. ResultadOs: En 2017 man-
teniendo la actual utilización de trombolisis (1,7%), la tasa de prevalencia por IS es 
360,8 por 100.000 habitantes, presentando una disminución entre los escenarios, 
siendo 299,8 cuando todos los pacientes son tratados. Con respecto a la utilización 
actual, aumentar el tratamiento al 11,6% evita 779 discapacitados, al 25% evita 
1.783 y tratar a todos los pacientes evita 8.534. A lo largo de la simulación, los costos 
ahorrados por casos de rehabilitación evitados son más bajos que los costos de la 
trombolisis. cOnclusiOnes: La tasa de prevalencia de discapacidad disminuye 
moderadamente al incrementar la utilización de trombolisis. El impacto poblacional 
en discapacidad manteniendo la utilización actual es marginal, siendo recomenda-
ble incrementar su utilización. Los costos directos aumentarían por sobre el costo de 
rehabilitación evitados, sin embargo, es necesario considerar la limitada cobertura 
de atención de la discapacidad en Chile y los costos sociales.
PCv12
PREvALENCE OF RISk FACTORS OF ST ELEvATED MyOCARDIAL INFARCTION
Rasool F.1, Khan M.S.2, Ali A.2, Masood J.2
1The University of Punjab, Lahore,, Pakistan, 2The Islamia University of Bahawalpur, Punjab-
Pakistan, Bahawalpur, Pakistan
Objectives: There is no enough data available in our country about the preva-
lence of risk factors for ST elevation myocardial infarction (STEMI) and which has 
the highest mortality rate in hospitals of Pakistan. The purpose of study was to 
access the age distribution, location of infarct, risk factors, sign & symptoms and 
in-hospital management of STEMI patients in Bahawalpur region, southern Punjab, 
on of the regions with high risk of coronary heart disease. MethOds: A retrospec-
tive study of 400 patients diagnosed as STEMI admitted to Bahawal Victoria Hospital 
(BVH), Bahawalpur, Southern Punjab, Pakistan was done by following their hospital 
record. Results: The mean age of STEMI patients were 40 ±10. Smoking, Diabetes 
and Hypertension were the risk factors (51.5%), (28%), (20.5%) respectively. Anterior 
wall Myocardial infarctions were seen (51.5%). Sweating, vomiting, shortness of 
breath (SOB) & nausea accounted for more than 60% of the symptoms with chest 
pain mostly in left arm. Among the patients who reached early to hospital & received 
Streptokinase (SK) were 150 (75%), those late for SK were 44(22%), thrombolytic 
therapy was contraindicated only in 6 (3%) patients. Most prescribed medication 
are aspirin (100%), clopidogrel (98%), statin (96%), ACE-I (77.5%), nitrates (69.5%), 
beta blocker (60%), anticoagulant (50%), LMW-heparin (33 %). cOnclusiOns: The 
result of our study, in which the risk factors especially smoking were found to have 
a prevalence in patients with STEM1 living in southern Punjab, suggested that STEM 
1 can be prevented by the modification of these risk factors.
CARDIOvASCULAR DISORDERS – Cost Studies
PCv13
A BUDgET IMPACT ANALySIS (BIA) OF TRANSCATHETER AORTIC vALvE 
IMPLANTATION (TAvI) IN HIgH-RISk PATIENTS wITH SyNTOMATIC SEvERE 
vALvE STENOSIS (SSvS) UNDER THE BRAzILIAN PUBLIC HEALTH CARE SySTEM 
(SUS) PERSPECTIvE
Paladini L.1, Nishikawa A.M.1, Bueno C.C.1, Queiroga M.2, Lemos P.2, Clark O.A.C.1
1Evidencias, Campinas, Brazil, 2Sociedade Brasileira de Hemodinâmica e Cardiologia 
Intervencionista (SBHCI), São Paulo, Brazil
Objectives: Aortic valve stenosis is a progressive valvular heart disease with a stand-
ard care that involves a major open surgery. However, part of the patients is ineligible 
for surgery, therefore drug therapy is the only option available. Once TAVI is a less 
invasive surgical option, clinical trials demonstrated significant benefits, although 
procedure and device are costly. The aim of this study was to estimate the incremen-
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each generic was used to estimate one month’s cost of hypertension treatment; 
considering the maximum and minimum dosage for each generic. The affordability 
of treatments was calculated by comparing the total cost of medicines to the daily 
official minimum wage ($63.12MXN, 2013 prices) Results: The number of days’ 
wages required to pay one month of antihypertensive therapy ranged from: 0.08-
4.18 for diuretics, 0.67-1.90 for beta blockers, 1.7-3.99 for calcium channel blockers, 
0.71-3.31 for ACE inhibitors and 2.38-8.11 for ARBs. cOnclusiOns: Cost could be 
a substantial barrier for permanence in antihypertensive treatment, so that should 
be discussed measures to prevent this from happening.
PCv20
TREATMENT COSTS OF ISCHEMIC STROkE PREvENTION AND MANAgEMENT 
IN PATIENTS wITH ATRIAL FIBRILLATION (AF) IN LATIN AMERICA: ARgENTINA, 
BRAzIL, CHILE, AND vENEzUELA
Soriano M.A.1, Leyva-Bravo V.1, González-Rojas G.L.1, Medina-Farina M.2, Duarte M.A.3
1IMS Health, Mexico City, Mexico, 2Hospital Barros Luco, Santiago, Chile, 3Hospital Militar Carlos 
Arvelo, Caracas, Venezuela
Objectives: AF is the most common chronic cardiac arrhythmia worldwide. Most 
patients with AF need life-long treatment to be protected from ischemic stroke. The 
aim was to conduct a high level cost assessment for stroke prevention and manage-
ment in patients with AF [SPAF & SMAF] in 4 Latin American countries. MethOds: 
Overall the costs of SPAF & SMAF were determined through 59 face-to-face interviews 
with cardiologists in Argentina, Brazil, Chile and Venezuela. Treatment costs were 
estimated using benchmarks from major private and public hospitals in each coun-
try. Results: On average, the largest component of real-life medical expenditures 
for SPAF, under appropriate treatment given CHADS2 scores, was prescription drugs, 
which ranged from 68% in private to 75% in public. Annual SPAF treatment ranged in 
price from US$425 in Argentina to US$1,935 in Chile in private institutions and US$85 
in Brazil to US$1,199 in Venezuela in public institutions. Moreover, overall treatment 
costs in Chile were 5X higher than the least expensive country in each sector. For 
SMAF, using rivaroxaban vs the common Vitamin K antagonists resulted in a 24%-46% 
cost reduction for disease treatment at a national level due to better patient adher-
ence. This would decrease the stroke incidence/year, which would translate to US$143 
M /yr in savings. cOnclusiOns: AF is an important source of health care resource 
utilization because of repeated medical examinations, extensive use of laboratory 
tests and pharmacological treatments. Private and public institution cost differences 
are common in all 4 countries. Improving access to novel drugs, such as rivaroxaban, 
could help improve cost allocation, inducing a savings opportunity in each country.
PCv21
HEALTH-ECONOMIC ASSESSMENT OF THE USE OF CATHETER-BASED RENAL 
DENERvATION IN PATIENTS wITH RESISTANT HyPERTENSION IN MExICO
Ceballos R.M.1, Sanchez-Kiobashi R.2, Gay J.G.3, Pietzsch J.B.4, Geisler B.P.4
1Medtronic, Mexico DF, Mexico, 2TI Salud, Mexico DF, Mexico, 3T.I. Salud, Mexico, México D.F., 
Mexico, 4Wing Tech Inc., Menlo Park, CA, USA
Objectives: Catheter-based renal denervation (RDN) is a new therapy for resistant 
hypertension, a condition that affects approx. 10-15% of hypertensive patients, in 
which blood pressure is uncontrolled despite the simultaneous use of three or more 
antihypertensive drugs. Our objective was to assess clinical and cost-effectiveness 
of RDN compared to standard of care (SoC) from the Mexican public payer per-
spective. MethOds: A previously published lifetime Markov model was adapted 
to the Mexican setting to predict clinical endpoints (death, myocardial infarction, 
stroke, heart failure, coronary heart disease, end-stage renal disease) and costs - 
based on Mexican epidemiological and cost data. We evaluated the impact of a 
32 mmHg reduction in systolic blood pressure, from a baseline of 178 mmHg, in 
a 58-year old 43% female, 34% diabetic, and 16% smoking cohort, as observed in 
the Symplicity HTN-2 randomized controlled trial. Direct public health care costs 
were estimated from the published literature and from governmental databases. 
The incremental cost-effectiveness ratio (ICER) was computed as incremental costs 
per life-year gained, discounted at 3%. Deterministic sensitivity analyses were 
performed. Results: RDN was projected to reduce cardiovascular endpoints by 
22-32% over 10 yrs., and 7-17% over lifetime. The lifetime ICER was estimated at 
MXN$ 194,128 (US$ 14,750) per LY gained, and had an incremental cost of MXN$ 
117,916 (US$ 8,959) compared to SoC. Application of higher discount rates led to 
a measured increase in the ICER. cOnclusiOns: Our model projections suggest 
that RDN reduces and delays cardiovascular events and is a cost-effective therapy 
in Mexico when considering most international willingness-to-pay thresholds, but 
remains above the current national government threshold of one GDP/capita of 
MXN$ 139,900 (US$ 10,630) per additional life year.
PCv22
COST-EFFECTIvENESS OF TRANSCATHETER AORTIC-vALvE IMPLANTATION FOR 
SEvERE SyMPTOMATIC AORTIC STENOSIS IN INOPERABLE PATIENTS IN THE 
BRAzILIAN PUBLIC HEALTH CARE SySTEM
Nishikawa A.M.1, Paladini L.1, Borges L.1, Queiroga M.2, Lemos P.2, Clark O.A.C.1
1Evidencias, Campinas, Brazil, 2Sociedade Brasileira de Hemodinâmica e Cardiologia 
Intervencionista (SBHCI), São Paulo, Brazil
Objectives: Aortic stenosis is the most common valvular heart disease in the elderly 
– its prevalence is estimated to be up to 5% in individuals over 75 years. Surgical 
replacement of the aortic valve is considered the standard care and in the absence 
of serious coexisting conditions, the procedure is associated with low operative mor-
tality. However, a significant proportion of patients can not undergo surgery due to 
a high surgical risk associated with advanced age or with the presence of multi-
ple coexisting conditions. Treatment with transcatheter aortic-valve implantation 
(TAVI) is a therapy with potentially lower peri-procedure risk and has been used as 
a therapeutic option in this group of patients considered inoperable. Therefore, this 
study aims to develop a cost-effectiveness analysis of TAVI in patients with severe 
aortic stenosis who are not suitable for surgical treatment. MethOds: A Markov 
model was developed to compare the TAVI versus standard therapy (drug treatment 
2011. One-year costs were identified by applying cost data to medical informa-
tion obtained by review of medical records. Costs included those for medications, 
laboratory and diagnostic tests, clinic visits, emergency room visits and hospital 
stays. Contemporary data were obtained from epidemiological studies, government 
datasets, and other sources to estimate prevalence. National costs (US dollar 2012) 
of treatment for PAH were estimated by extrapolation of mean cost estimate per 
person to national incidence data for PAH. Because of uncertainties surrounding 
some of our estimates such as prevalence, one way sensitivity analyses were under-
taken. Results: A total of 113 PAH patients were identified and their demographic 
and clinical characteristics, patterns of care were examined. The mean age was 38 
years, and 83% were female. The average per patient annual cost was $ 10,869 with-
out specific treatment (min $ 137; max $155,928). The annual cost for the treatment 
of a single PAH patient per year with specific therapy (Bosentan) was calculated in 
$31.433. Aggregate national health care expenditures for treatment of PAH were 
USD 46.6 million In multivariate analysis, length of hospital stay, stay in ICU, were 
all significant independent predictors of treatment. cOnclusiOns: There is a cor-
relation between the cost of HAP and disease severity with hospitalization owing 
to disease severity being a major contributor to cost. With the expected increase in 
the incidence of PAH in Mexico over the coming decades, these results emphasize 
the need for effective preventive and acute medical care.
PCv17
COST-OF-ILLNESS STUDy OF PATIENTS SUBjECTED TO CARDIAC RHyTHM 
MANAgEMENT DEvICES IMPLANTATION: RESULTS FROM A SINgLE TERTIARy 
CENTRE
Fanourgiakis J.
University of Crete, Heraklion, Greece
Objectives: To estimate the procedure (implantation) cost, the total hospitalization 
cost and annual follow-up cost, in patients subjected to pacemaker (PM) and implant-
able cardioverter-defibrillator (ICD) implantation. MethOds: A single-center, pro-
spective, cost-of-illness study was conducted between August 2008 and July 2009. In 
total, 464 consecutive patients were recruited (370 were subjected to PM implantation 
and 94 to ICD implantation). Resource data were assessed at patients’ enrolment in 
the study and at 6th and 12th months of patients’ follow-up. Then, the procedure cost, 
the total hospitalization cost as well as the annual patients’ follow up costs were cal-
culated using a bottom-up approach. Results: The mean (95% confidence interval) 
procedure cost of PM and ICD implantation (including the costs of devices, electrodes, 
other supplies, and personnel’s time) was calculated to be € 1803 (€ 1758–€ 1858) and 
€ 13 521 (€ 13 153–€ 13 892), respectively. The mean total hospitalization cost (includ-
ing procedure cost, hospitalization cost, cost of laboratory and imaging diagnostic 
examinations and the indirect cost attributed to productivity lost due to patient’s 
hospitalization) was € 3926 (€ 3711–€ 4167) for PM and € 17 764 (€ 16 852–€ 18 692) for ICD. 
The mean annual cost (direct and indirect) was € 1816 (€ 1433–€ 2421) for PM and € 2819 
(€ 2115–€ 3703) for ICD. No difference was detected in the annual cost between patients 
with initial implantation and replacement. cOnclusiOns: These data revealed that 
although these devices are associated with a relatively high upfront cost, the annual 
societal cost following the implantation is low. Therefore, implantation of such devices 
should be encouraged since these devices reduce the morbidity and mortality without 
a high economic burden to society.
PCv18
ECONOMIC BURDEN OF CORONARy HEART DISEASE IN THE PATIENTS 
ATTENDINg NATIONAL HEART CENTER, kATHMANDU, NEPAL
Dangi A.1, Lohani S.P.2
1Nobel College, Pokhara University, Kathmandu, Nepal, 2Center for Health Research and 
International Relations, Nobel College, Pokhara University, Kathmandu, Nepal
Objectives: To calculate cost of illness due to coronary heart disease in the patients 
attending National Heart Center, Kathmandu, Nepal. MethOds: Descriptive cross 
sectional survey was conducted. The total number of sample was 120. The sam-
ple was selected by non-probability purposive sampling method. Data entry and 
analysis was done using SPSS 16.0. Categorical variables were compared using 
Independent Sample t-test and cross tabulation was done and chi- square test was 
applied to show significant difference between variables. Results: Agriculture was 
the main source of income of the coronary heart disease household and the aver-
age annual household income was NRs. 1, 54,000 (US $ 1792). The study estimated 
the average cost of illness to be NRs. 30,888.14 (US $ 360) for an outpatient episode 
of coronary heart disease which was 20.05% of the average annual income of CHD 
household. The average total time loss of the CHD household was 8.75 person days. 
The average total direct cost was NRs. 29,600 (US $ 344) of which medical cost was 
the largest component. The average monetary value of time loss by the household 
was found to be 2,981.18 (US $ 35). cOnclusiOns: The study found high cost of 
illness due to centralised system of health care.The findings of the study showed 
that households struggled to cope and adopted unsustainable strategies that dam-
aged asset and caused or sustained impoverishment. Thus, estimated cost appears 
to be sustained economic burden on the individual household.
PCv19
AFFORDABILITy OF ANTIHyPERTENSIvE TREATMENT IN MExICO
Lemus F., Rivas R.
Minister of Health, Mexico, Mexico
Objectives: Hypertension (HT) is one of the most prevalent chronic diseases in 
Mexico. In the last two decades, a substantial increase in the prevalence of HT was 
observed in Mexico from 25% in 1993 to 43.2% in 2006 in adult population (≥ 20 
years old). Almost 50% of population is not under a social security scheme and 
many patients pay for medicines out-of-pocket. This study’s aim was to calculate 
the affordability of different kinds of antihypertensive drugs in Mexico. MethOds: 
Price data for 5 classes of antihypertensive drugs (diuretics, beta blockers, calcium 
channel blockers, ACE inhibitors and angiotensin II receptor antagonists or ARBs) 
were obtained from public internet sources, and the lowest price identified for 
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desenlaces clínicos a partir del grado de función renal de los pacientes con síndrome 
coronario agudo, desde la perspectiva del sistema de salud privado en México. Los 
parámetros clínicos incluyeron riesgos de hemorragia, EVC, infarto y muerte, los 
cuales fueron extraídos de ensayos clínicos y estudios epidemiológicos. Los datos de 
costos fueron tomados de los tabuladores de reembolso disponibles en los sitios de 
internet de las compañías aseguradoras, y las estimaciones de costos estuvieron apoy-
adas por opiniones de expertos. Se realizaron análisis de sensibilidad univariados. Los 
resultados están expresados en dólares americanos a un tipo de cambio de 12 pesos 
mexicanos por dólar. ResultadOs: En la cohorte de pacientes con función renal 
alterada el costo por año de vida ganado con ticagrelor fue de 4168 dls; sin embargo, en 
los pacientes con función renal normal clopidogrel resultó dominante sobre ticagrelor. 
En cuanto a hemorragias evitadas y EVC evitados, clopidogrel también resultó domi-
nante sobre ticagrelor en ambas cohortes de pacientes. El costo por infarto evitado 
con ticagrelor fue de 20,493 dls en los pacientes con función renal alterada y de 2486 
dls en los pacientes con función renal normal. cOnclusiOnes: Clopidogrel resultó 
una estrategia dominante sobre ticagrelor en la mayoría de los desenlaces evaluados, 
tanto en pacientes con función renal como alterada, por lo que puede generar ahorros 
para los pacientes, mientras ofrece un mejor perfil de seguridad.
PCv28
COST-UTILITy OF DAgIBATRAN FOR CHRONIC ATRIAL FIBRILLATION IN 
ARgENTINA
Ferrante D.1, Rudich V.2, Stuart P.2
1Ministry of Health, Argentina, Buenos AIres, Argentina, 2Boehringer Ingelheim, Munro, Argentina
Objectives: Dabigatran has shown to be effective in preventing embolic events 
in chronic atrial fibrillation patients, but it’s cost-utility has not been assessed in 
Argentina. Therefore, our objetive was to estimate the cost-utility of dabigatran used 
in recomended doses (220mg and 300mg) for the prevention of thromboembolic 
events in chronic atrial fibrillation. MethOds: A Markov model was constructed to 
simulate a national cohort of patients aged 65 or more, with chronic atrial fibrillation. 
The strategies compared were dabigatran (220 or 300 mg according to age and kidney 
function) or coumarins. Markov states were no events, ischemic stroke (with different 
severities), hemorragic strokes (with different severities) and death. Baseline charac-
teristics were introduced in the model from a recent National Registry. Stroke risk was 
estimated from baseline characteristics using CHADSVASC2 score. Mortality was esti-
mated from events and age specific mortality. Relative risks both preventing embolic 
events and bleeding were obtained from RELY study. Resource use was obtained from 
the National Admissions Database for stroke admissions and major bleedings. Costs 
were obtained from national health providers, both for anticoagulation costs and 
admission costs. Discount rate was 3%, costs and effects. The results were expressed 
in incremental cost-utility ratios (Argentinean pesos-ARS-per QUALY, 1 USD= 5 ARS). 
Sensitivity analysis variables: stroke risk, 95% CI of relative risks of RELY study, stroke 
costs. Results: In the base case analysis, dabigatran in 220 or 300mg doses shown to 
be more effective than coumarins (incremental QUALYs 0.49), with and incremental 
cost of ARS 5,923, resulting in an ICER of 12,040 ARS per QUALY gained. Dabigatran was 
associated with higher drug costs, but lower events costs. In all one way sensitivity 
analysis, dabigatran remained as a cost-effective strategy. cOnclusiOns: Dabigatran 
is a cost-effective strategy for anticoagulation in chronic atrial fibrillation patients in 
Argentina, even considering different population characteristics, resource use and 
costs of ower local setting.
PCv29
COST-UTILITy OF APIxABAN COMPARED TO wARFARIN FOR STROkE 
PREvENTION IN PATIENTS wITH ATRIAL FIBRILLATION IN COLOMBIA
Rosselli D.1, Rueda J.D.1, García Á.A.1, Rodriguez-Morales A.J.2, Garrido Lecca S.3,  
Vargas Zea N.4, Juarez Garcia A.5, Mould J.F.6, Donato B.M.K.7
1Pontificia Universidad Javeriana, Bogotá, Colombia, 2Universidad Tecnológica de Pereira, Pereira, 
Colombia, 3Bristol-Myers Squibb Company, Lima, Peru, 4Pfizer S.A.S., Bogota, Colombia, 5Bristol-
Myers Squibb Mexico City, Mexico DF, Mexico, Mexico, 6Pfizer, New York, NY, USA, 7Bristol-Myers 
Squibb Company, Wallingford, CT, USA
Objectives: To evaluate the cost-utility of apixaban vs warfarin for stroke preven-
tion in patients with atrial fibrillation (AF) from the Colombian health care system 
perspective. MethOds: A validated Markov decision model was adapted from the 
Colombian Healthcare system perspective. For efficacy and safety inputs, the model 
is based on data from the ARISTOTLE trial and clinical trials of warfarin therapy 
for AF. Resource utilization and costing of events were estimated using a refer-
ence hospital’s billing records and validated with local experts. Costs of procedures 
were obtained from official tariffs (adjusted ISS 2001). The cost of medications were 
obtained from SISMED. The study set the price of apixaban at parity price per day to 
dabigatran 150mg. A discount rate of 3.5% was used for both costs and outcomes. A 
cohort of 1,000 patients was modeled using a lifetime horizon. Probabilistic sensitiv-
ity analysis (PSA) to account for variability in outcomes due to statistic uncertainty 
in inputs as well as univariate sensitivity analyses to examine the effects of changes 
in key model parameters were performed. Results: Warfarin therapy resulted in a 
quality-adjusted life expectancy of 8.20 years at a cost of $14,906,026 COP. Treatment 
with apixaban led to a quality-adjusted life expectancy of 8.64 years at a cost of 
$23,064,028 COP. The cost-utility ratio was calculated at $ 18,392,415 per QALY. Our 
findings were robust in univariate sensitivity analyses varying model inputs across 
plausible ranges. In Monte Carlo analysis, apixaban was cost-effective in 80% of sim-
ulations using the recommended threshold for Colombia by the Ministry of Health of 
$36,000,000 COP per QALY. cOnclusiOns: Apixaban is a cost-effective alternative 
relative to warfarin for stroke prevention in patients with AF in Colombia, assuming 
that it is introduced at a price similar to that of dabigatran.
PCv30
CORRELACIóN ENTRE LOS NIvELES DE LDL-C FRENTE AL RIESgO DE 
PRESENTACIóN DE EvENTO CARDIOvASCULAR
Simbaqueba E., Romero M.
Fundacion Salutia, Bogotá, Colombia
with or without aortic balloon valvuloplasty). Outcomes in the model were based on 
safety and effectiveness (as measured by clinical outcomes of chance of successful 
implantation procedure and survival from PARTNER cohort B trial). Resource use 
included early perioperative complications (30 days) and late events. Cost data were 
obtained from Brazilian public lists (DATASUS and BPS). Results were expressed as the 
reason of incremental cost-effectiveness ratio (ICER) per years gained. Probabilistic 
sensitivity analysis was performed to confirm robustness of the results. Results: 
Compared with standard therapy with or without aortic balloon valvuloplasty, the 
use of TAVI improves survival in 0.97 life years with an incremental cost of US$35,071, 
resulting an ICER of US$36.260/ life year gained. cOnclusiOns: Use of TAVI results 
in improved survival with a low risk of serious adverse events, and demonstrates a 
cost-effectiveness profile when compared to other technologies already incorporated 
by the Brazilian public health system.
PCv24
ANáLISE DE CUSTO-EFETIvIDADE PARA UTILIzAçãO DE OCLUSORES SEPTAIS 
NO FECHAMENTO DE COMUNICAçãO INTERATRIAL (CIA) DO TIPO OSTIUM 
SECUNDUM COMPARADO COM A CIRURgIA CONvENCIONAL
Costa M.G.S.D.1, Santos M.S.1, Correia M.G.1, Santos B.1, Correia M.I.C.1, Cintra M.A.D.C.T.2, 
Almeida J.M.1, Souza T.F.G.D.3
1INC, Rio de Janeiro, Brazil, 2Brazilian Ministry Of Health, Rio de Janeiro, Brazil, 3Universidade 
Federal Fluminense, Niterói, Brazil
ObjetivOs: Análise de custo-efetividade comparando as técnicas de fechamento de 
comunicação interatrial do tipo ostium secundum: cirurgia convencional e implante 
percutâneo com oclusor septal; na perspectiva do sistema único de saúde (SUS) 
brasileiro. MétOdOs: Realizada revisão sistemática da literatura através de busca 
em bases de dados primárias. Avaliação da qualidade da evidência apresentada 
feita através do GRADE (Grading of Recommendations Assessment, Development and 
Evaluation). A partir da metanálise de 15 artigos foram selecionados os desfechos 
de fechamento do CIA, complicações e reprocedimento. Proposto um modelo 
matemático de árvore de decisão que foi utilizado para estimar a razão custo efe-
tividade entre o procedimento de cirurgia convencional e o implante percutâneo 
com oclusor septal, através do software TreeAge 2012 Pro. O desfecho utilizado 
como dado de eficácia foi o número de cirurgias realizadas. Determinação dos 
custos: calculou-se o consumo de recursos variáveis de acordo com o volume 
de atendimentos entre 2007 e 2010, em um hospital especializado em cardiolo-
gia de alta complexidade do Ministério da Saúde. Custos fixos específicos: pro-
cedimentos e serviços hospitalares e profissionais foram determinados a partir 
de valores tabelados retirados do Sigtap (Sistema de Gerenciamento da Tabela de 
Procedimentos, Medicamentos e OPM do SUS, versão 1.2.0909141204; competência 
novembro de 2012). ResultadOs: Reprocedimento: cirurgia = 0,37%; implante = 
1,44% ; complicações: cirurgia = 12,87%; implante = 3,89%; fechamento: cirurgia = 
99,11%; implante imediato = 93,23% e implante Follow-up = 95,21%; custos cirurgia: 
procedimento = R$ 22.045,70; complicações = R$ 1.038,28; custos implante per-
cutâneo: procedimento = R$ 17.671,87; complicações= R$ 421,02. Ao rodarmos o 
modelo de árvore de decisão; o resultado foi favorável ao implante percutâneo, 
com um custo de R$18.408,86, com a probabilidade de ocorrência de cirurgia em 7% 
dos casos. cOnclusões: O fechamento da comunicação interatrial por implante 
percutâneo de oclusor septal demonstrou ser o procedimento mais custo efetivo, 
quando comparado a cirurgia convencional.
PCv25
ANáLISIS DE COSTO-EFECTIvIDAD DE IOxAgLATO vERSUS IODIxANOL EN 
ANgIOgRAFíA CORONARIA
Simbaqueba E.1, Huerfano L.1, Uriza L.F.2, Romero M.1
1Fundacion Salutia, Bogotá, Colombia, 2Hospital Universitario San Ignacio, Pontificia Universidad 
Javeriana, Bogotá, Colombia
ObjectivOs: Realizar un analisis de costo-efectividad del uso de ioxaglato en angio-
grafía coronaria comparado con iodixanol, en pacientes con evento coronario agudo 
(ECA), desde la perspectiva del tercero pagador en Colombia. MetOdOlOgías: Se 
diseñó un árbol de decisiones que simula los eventos clínicos relacionados con la 
angiografía en pacientes con ECA, en un horizonte temporal de un mes. Para un 
paciente con síndrome coronario agudo con edad promedio de 40 años, esperanza 
de vida de 74 años y peso promedio de 65 kg, sometido a angiografía coronaria con 
el uso de ioxaglato o idioxanol en dosis de 320 mgI/ml, se estimó como desenlace la 
sobrevida medida en años de vida salvados (AVS). El modelo incluye la posibilidad 
de presentar re-infarto y/o muerte durante y después de la realización del proced-
imiento (hasta un mes). Los costos de las tecnologías y los eventos fueron estimados 
de la base de datos estatal de costos y del sistema de precios de medicamentos 
(SISMED) en pesos colombianos del 2012. ResultadOs: El ioxaglato mostró mayor 
efectividad (1,1 AVS) frente a iodixanol (29,3 frente a 28,2 respectivamente) y un 
ahorro de COP$ 833.079, mostrando así dominancia en las condiciones evaluadas. 
El análisis de sensibilidad probabilístico tipo Montecarlo, mostró que se mantenía la 
dominancia en el 65% de los casos en 1.000 iteraciones y con variaciones de +/- 50% 
de los datos. cOnclusiOnes: El uso de ioxaglato frente a iodixanol, en las condi-
ciones del caso base y tomando como referencia el desenlace analizado basado en 
la probabilidad de re-infarto durante el procedimiento de angiografía secundario a 
un ECA, se muestra como la opción de elección por su mayor efectividad y menores 
costos, desde el punto de vista del tercero pagador en Colombia.
PCv27
COSTO-EFECTIvIDAD DE CLOPIDOgREL vERSUS TICAgRELOR, AMBOS EN 
COMBINACIóN CON ASA, PARA EL MANEjO DEL SíNDROME CORONARIO 
AgUDO, DESDE LA PERSPECTIvA DEL SISTEMA DE SALUD PRIvADO EN MéxICO
Reyes A.1, Araceli C.2
1Hospital Infantil de México Federico Gomez, MEXICO, Mexico, 2Sanofi Mexico, MEXICO, Mexico
ObjectivOs: Realizar una evaluación económica de clopidogrel versus ticagrelor, 
ambos en combinación con ASA, para el manejo del síndrome coronario agudo en 
México. MetOdOlOgías: Se utilizó un modelo de markov para evaluar distintos 
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PCv33
EvOLUçãO DO USO DE MEDICAMENTOS gENéRICOS NO TRATAMENTO DE 
DOENçAS CRôNICAS – PBM BRASILEIRA
Salles G.R.D.1, Ferreira C.N.2, Santana C.F.S.D.1, Paloni E.D.M.P.2, Drago S.3, Bonachela F.4,  
Souza C.3, Abreu A.A.3
1Orizon, Sao Paulo, Brazil, 2ORIZON - Companhia Brasileira de Gestão de Serviços, Sao Paulo, 
Brazil, 3ORIZON, Sao Paulo, Brazil, 4Orizon, SAO PAULO, SAO PAULO, Brazil
ObjetivOs: Analisar a evolução na aquisição de medicamentos genéricos ao trata-
mento de doenças nos últimos quatro anos em amostra brasileira. MétOdOs: 
Utilizou-se uma amostra de 14.425 participantes do programa de benefício de medi-
camentos da PBM (Programa de Benefício de Medicamentos) Orizon, que consum-
iram medicamentos de uso crônico para tratamento de Hipertensão Arterial Sistêmica 
Sistêmica (HAS), Dislipidemia (DL) e Diabetes Mellitus (DM), nos últimos 4 anos (2009 à 
2012) e verificou a evolução do uso destes medicamentos. ResultadOs: Houve aprox-
imadamente 56% em unidades vendidas de medicamentos genéricos ao longo dos 
últimos 4 anos, contra 44% dos medicamentos de marca (referência ou similar). A difer-
ença no percentual da quantidade de unidades de medicamentos genéricos vendidos, 
comparados com os de marca foi de 9,44% em 2009, 11,42% em 2010, 13,84% em 2011 
e 16,28% em 2012. Os medicamentos genéricos atingiram cerca de 1% de aumento ao 
ano representou cerca de R$ 430mil nos anos de 2009 a 2011, sendo que em 2012 houve 
um decréscimo na quantidade de medicamentos utilizados no ano. cOnclusões: A 
adesão ao tratamento das doenças crônicas HAS, DL e DM foi em sua maioria com o 
uso de medicamentos genéricos que representaram aproximadamente 56% das uni-
dades vendidas nos últimos 4 anos, crescimento no qual foi progressivo e constante no 
período. Dado a vasta cadeia de descontos fornecida por fabricantes de medicamento 
genérico auxilia na adesão e persistência ao tratamento de crônicos, demonstrado que 
o valor do medicamento na compra influencia o tratamento.
PCv34
PROjEçãO DE gASTOS COM MEDICAMENTOS DE USO CRôNICO 
(AMBULATORIAL)
Paloni E.D.M.P.1, Ferreira C.N.1, Santana C.F.S.D.2, Drago S.3, Salles G.R.D.2, Souza C.3, Abreu A.A.3, 
Bonachela F.4
1ORIZON - Companhia Brasileira de Gestão de Serviços, Sao Paulo, Brazil, 2Orizon, Sao Paulo, 
Brazil, 3ORIZON, Sao Paulo, Brazil, 4Orizon, SAO PAULO, SAO PAULO, Brazil
ObjetivOs: Projetar gastos com medicamentos de uso contínuo para patologias 
crônicas, para usuários com plano de beneficio farmácia estimando o grau de sua 
utilização. MétOdOs: Utilizou-se um estudo descritivo de uma população no total de 
574.640 vidas, com alto subsidio na aquisição de medicamentos, utilizando o banco 
de dados da Orizon com mais de 16 milhões de vidas que captura informações de 
consumo de medicamentos pelo plano de beneficio farmácia (PBM) no ano de 2012. 
Foram estimadas as incidências e os gastos mensais com a compra de medicamen-
tos para uso crônico de Hipertensão (HAS), Insuficiência Cardíaca Congestiva (ICC), 
Insuficiência Cardíaca Obstrutiva (ICO), Doença Pulmonar Obstrutiva Crônica (DPOC), 
Asma e Diabetes Mellitus (DM), transformando este consumo em dose diária definida 
(DDD), seguindo a Anatomical Therapeutic Chemical Code(ATC) e dividimos por faixa 
etária para chegar ao valor médio mensal de DDD por faixa etária. O valor da DDD 
para projeção do custo foi calculado baseado nos preços de janeiro de 2013, informa-
dos pela Câmara de Regulação do Mercado de Medicamentos (CMED) considerando 
medicamentos de A à Z. ResultadOs: As patologias cardiovasculares HAS, ICC e ICO 
a incidência mensal foi de 6,03%, consumo médio de 89,63 DDDs e custo R$ 1,01 / DDD, 
as patologias repiratórias DPOC e Asma a incidência mensal foi de 0,39%, consumo 
médio de 35,45 DDDs e custo de R$ 3,50 / DDD e para a patologia de DM dividida em 
hipoglicemiantes orais e injetaveis (insulinas), o resultado para os orais foi: incidên-
cia mensal de 1,89%, consumo médio 47,14 DDDs e custo de R$ 2,26 / DDD e para os 
injetaveis (insulinas) a incidência foi de 0,32%, consumo médio de 35,21 DDDs e custo 
de R$ 7,47 / DDD. cOnclusões: Modelo utilizado para projetar o grau de utilização e 
gastos com medicamentos de patologias crôncias, para beneficio de farmacia.
PCv35
ESTIMATINg THE IMPACT OF STATIN THERAPy ON DIRECT AND SOCIETAL 
COSTS IN MExICO: A COMPARISON TO SwEDEN
Semilla A.P.1, Kowal S.2, Storm M.1, Blanchard T.1
1IHS Global Inc., Washington, DC, USA, 2IMS Health, Redwood City, CA, USA
Objectives: Recent studies have shown a high burden of cardiovascular disease 
(CVD) risk factors in Mexico, potentially signaling rising levels of CVD-related mor-
bidity and mortality. This study models the cost-effectiveness of statins as a class 
of drugs for the secondary prevention of key coronary heart disease (CHD) and 
CVD events, to measure the impact of pharmaceutical innovation on a country-
level basis. MethOds: The investigation uses a value of innovation model cre-
ated for Sweden, the site of many early statin trials, and adapted to Mexico to 
allow a comparison between emerging and developed settings. An 8-state semi-
Markov model was used to simulate the effect of statin use on key health events 
and disease-related societal impacts. Drug impact was modeled at the class level 
using relative risk reductions based on meta-analyses of international statin tri-
als. The subject of the base-case analysis was a 55 year-old male with lifetime 
statin use. Individual level findings were scaled to the total population to enable 
an investigation of cost and health outcome trends at the country level for all inci-
dent cases in 2011. Results: Over an individual’s lifetime, the risk of subsequent 
myocardial infarctions (MIs) and revascularizations decreased in Mexico (MI, RVC: 
-3.3%,-0.5%) and Sweden (MI, RVC: -5.3%, -1.6%) due to the use of statins. At the 
population level, statin use produced lifetime direct cost savings (lowered outpa-
tient, inpatient, and institutionalized costs) of USD$21M in Mexico, and USD$4M 
in Sweden, as well as indirect costs savings (increased productivity and reduced 
premature disease-related retirement) of approximately USD$50M (Mexico) and 
USD$88M (Sweden). cOnclusiOns: In both countries, direct cost savings were 
smaller in scale than indirect savings, indicating the high value of societal benefits 
ObjectivOs: Encontrar la correlación entre la presentación de eventos cardiovas-
culares, infarto agudo de miocardio (IM) y evento cerebro vascular (ECV), con los 
niveles de colesterol de baja densidad (LDL-c) en prevención primaria, que sirva 
como una herramienta para la toma de decisiones sobre acciones específicas para 
el manejo del tema en Colombia. MetOdOlOgías: Se realizó una revisión de 
literatura científica en diferentes bases de datos, seleccionando estudios clínicos 
que mostraran el uso de las estatinas en prevención primaria, en pacientes con 
alto riesgo cardiovascular, y que reportaran desenlaces discriminados por eventos 
cardiovasculares. Los desenlaces de los estudios de presentación de eventos car-
diovasculares se ajustaron a tasas por cada mil pacientes. Se realizó un análisis 
econométrico por medio de una regresión lineal, con el fin de encontrar el término 
de correlación de una variable frente a otra, como lo han sugerido previamente 
varios autores. ResultadOs: Se seleccionaron ocho estudios que utilizaban difer-
entes estatinas y placebo con resultados en los desenlaces analizados (IM y ECV) 
ajustados en periodos por año de exposición. Los pacientes de los estudios no eran 
diferentes en sus características generales, excepto el nivel de LDL-c. Se encontró 
que la tasa de presentación de IM presenta un coeficiente de correlación de 0,015 
frente al cambio de 1 mg/dL de LDL-c para niveles de LDL-c> 130 mg/dL (p< 0,05). 
Para el riesgo de presentación de ECV, se presentó un coeficiente de 0,003 ante el 
cambio de 1 mg/dL, (p< 0,05). cOnclusiOnes: Se evidenció una relación positiva 
estadísticamente significativa entre los niveles de LDL-c y la tasa de presentación 
de los eventos. Sin embargo la probabilidad de presentación de un IM es mucho 
más sensible comparado con el de ECV ante cambios en los niveles de LDL-c en 
prevención primaria. Aunque esta aproximación sugiere una corelación, es nec-
esario estudios clínicos que lo comprueben.
CARDIOvASCULAR DISORDERS – Patient-Reported Outcomes & Patient  
Preference Studies
PCv31
PROxy UTILITy ASSESSMENT IN ACUTE HEART FAILURE
Swinburn P.1, Shingler S.L.2, Ong S.H.3, Lloyd A.J.4
1Oxford Outcomes, An ICON plc Company, Oxford, UK, 2Oxford Outcomes, An ICON Plc Company, 
Oxford, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Oxford Outcomes Ltd., an ICON PLC 
Company, Oxford, Oxon, UK
Objectives: Acute heart failure (AHF) is amongst the most common causes of 
hospitalisation in the U.S. with direct costs estimated to be $20.9 billion in 2010. 
Reducing the duration of hospitalisation for such conditions can have a signifi-
cant impact on resource use and may also have substantial benefit for individual 
patients.The aim of this study was to estimate quality of life (utilities) for patients 
hospitalised with AHF, expressed as a utility score between 0 [dead] and 1.0 [full 
health] . These data could be used to support an analysis of the cost effectiveness 
of an intervention in AHF. MethOds: Proxy assessments of HRQL were collected 
from 50 experienced cardiac nurses (formal caregivers) and 50 family caregivers of 
individuals who had experienced AHF events leading to hospitalisation (informal 
caregivers). Data were collected retrospectively for four time points (day 1, 3, 5 and 7 
post cardiac event) using the EQ-5D health status instrument. Results: The results 
suggest that HRQoL is poor for hospitalised patients but quickly improves over time 
in response to treatment. Formal caregivers reported HRQoL to be substantially 
poorer for individuals immediately after admission to hospital when compared to 
informal caregivers. By day 7 however, formal caregivers rated patients’ HRQoL as 
being better when compared to informal caregivers’ assessments. cOnclusiOns: 
Collection of utility data in severe acute conditions is challenging. This study repre-
sents an attempt to capture such values through the use of proxy assessment. The 
data suggest that hospitalization due to AHF is associated with very poor HRQoL, 
at least in the short term. Utility values for early assessments approximate those 
for conditions such as advanced cancers or major stroke. By day 7 however these 
values demonstrate significant improvement and a return to near normal general 
population levels.
PCv32
DISPOSICIóN A PAgAR y ANáLISIS DE CONjOINT PARA DETERMINAR LAS 
PREFERENCIAS POR LOS PRODUCTOS MEDLEy EN MéxICO
Camacho A.1, Soto H.2
1Sanofi Mexico, Mexico, Mexico, 2Iteliness, Mexico, Mexico
ObjectivOs: Identificar los atributos que definen a un producto como 
Accesible. Considerando las preferencias de los médicos para prescribir y los 
pacientes. MetOdOlOgías: Estudio analítico semi cuantitativo, cualitativo y pro-
spectivo en pacientes con enfermedades crónicas que usan productos farmacéu-
ticos y médicos prescriptores de productos de estas enfermedades, desde el punto 
de vista del sector privado en México. Se aplicaron dos técnicas complementarias, 
disposición a pagar y análisis de Conjoint. Se elaboraron instrumentos de recolec-
ción de datos tanto para la prescripción como adquisición por parte del paciente. Se 
utilizaron métodos estadísticos tanto descriptivos como inferenciales (regresiones 
simples, modelos ANOVA y modelos LOGIT). ResultadOs: Se entrevistaron entre 
15 y 20 médicos por cada especialidad. Los aspectos más importantes para los médi-
cos al momento de prescribir un medicamento son tanto la eficacia como la segu-
ridad, en tercer y cuarto lugar queda la tolerabilidad y el apego al fármaco. Cuando 
se les cuestionó sobre prescribir un fármaco genérico se encontró que para el 50% 
de los medicamentos el precio representa el principal atributo. Se entrevistaron 
120 pacientes que padecieran alguna enfermedad crónico-degenerativa, los cuales 
dieron mayor pesos para elegir un medicamento de patente fueron la eficacia y la 
seguridad. Para los medicamentos genéricos, la eficacia fue el atributo mayor pero el 
precio desplazó a la seguridad. Se identificó que la cantidad a pagar por un medica-
mento Genérico es del 63.93% del precio del medicamento de patente. Por otra parte 
importa la escolaridad de la gente para elegir el medicamento. cOnclusiOnes: Al 
considerar los atributos de accesibilidad los productos Medley son productos que 
se consideran accesibles, ya que ofrecen eficacia y seguridad y a su vez, tienen un 
precio accesible para la población.
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como ingreso, tipo de ocupación y nivel educacional siguen explicando en algún 
grado la desigualdad observada en salud en esta población.
PCv39
ExPLORINg gENDER DIFFERENCES IN POPULATION-BASED PREvALENCES OF 
CARDIOvASCULAR DISEASES IN CHILE AFTER THE HEALTH CARE REFORM OF 
2005
Dressler C.1, Cabieses B.2
1University of York, York, UK, 2Universidad del Desarrollo, Santiago, Chile
Objectives: Cardiovascular diseases (CVDs) are the biggest killer worldwide. Since 
2002 the Cardiovascular Health Program exists in Chile and more people with CVDs 
are treated over time. Few focused evaluations of the equity-centered health care 
reform of 2005 in Chile have been conducted and none of them with a gender focus. 
We aimed at analysing the existence of gender differences in the prevalence of CVDs 
in Chile after this reform. MethOds: Secondary analysis of the cross-sectional 
Chilean Health Survey 2009-2010 (downloaded after approval from the Ministry of 
Health in Chile; n= 5293 adult participants). We explored the relationship between 
CVDs (hypertension and myocardial infarction) and gender (male/female), crude 
and adjusted by potential confounders (individual health-risk factors, demograph-
ics, socioeconomic status, health care provision). Odds Ratios (OR) were estimated 
by weighted logistic regressions in Stata 12.0. Results: The crude prevalence of 
hypertensions were 28.13% (95%CI [26.11-30.24]) and myocardial infarcts 3.19% (95%CI 
[2.47-4.12]). More than half of the population were overweight/obese (39.20%/22.92%) 
and any alcohol consumption in the past month was high (58.42%). Around 40.19% 
currently smoke. Regression models indicated that gender was a significant risk fac-
tors for hypertensions (OR 1.58, 95% CI: 1.23-2.03) as well as having public health care 
insurance (OR1.45, 95% CI: 1.01-2.10). However, gender was not a significant predictor 
of myocardial infarcts, whereas age (OR 1.05, 95% CI: 1.03-1.06) and body mass index 
(OR 1.05, 95% CI: 1.02-1.09) were significant to this condition. cOnclusiOns: This is 
the first study on gender patterns of CVDs after health care reform of 2005 in Chile. It 
uses a national representative survey and it controls for relevant confounders. Results 
suggest that men were less likely to report hypertension than women. This raises 
the hypothesis of whether men are being underdiagnosed and whether current CVD 
programmes in Chile need to attract men that are not defining themselves as sick.
PCv40
TREATMENT PATTERNS OF ATRIAL FIBRILLATION (AF) IN LATIN AMERICA
Leyva-Bravo V.1, Soriano M.A.1, González-Rojas G.L.1, Nieto W.J.2, Novo F.A.3, Guerrero M.L.4
1IMS Health, Mexico City, Mexico, 2Sanatorio de la Trinidad San Isidro, Buenos Aires, Argentina, 
3Hospital Alemán, Buenos Aires, Argentina, 4Servicio Medico de la Direccion Ejecutiva de La 
Magistratura (D.E.M.) Tribunal Supremo de Justicia, Caracas, Venezuela
Objectives: Atrial Fibrillation (AF) is the most common chronic arrhythmia occur-
ring worldwide in the presence of other cardiovascular disease. The objective of the 
current study is to determine real-life treatment patterns for patients with AF in 
Latin America. MethOds: We conducted 59 face-to-face interviews with cardiolo-
gists in four Latin American countries--Argentina, Brazil, Chile and Venezuela-- to 
assess medical treatment. Information from 240 patients from private and public 
institutions was evaluated using CHADS2 scores to identify patients’ risk and to 
determine treatment. Results: Patients with AF undergo a 3-step process to define 
their treatment course: 1) AF evaluation and diagnosis; 2) AF classification: paroxys-
mal, persistent, and permanent; 3) Clinical treatment focused on stroke prevention 
based on symptom relief, optimal treatment of concomitant cardiovascular disease, 
rate control and correction of rhythm disturbance. Overall in all four countries, 
analysis shows that the majority of patients with AF were diagnosed right before 
or at the time of first stroke. The most common type of AF was permanent, except 
in Chile which was paroxysmal. The preferred antiarrythmic was amiodarone; 
the primary vitamin K antagonist used was warfarin in Brazil and Venezuela and 
acenocumarol in Argentina and Chile. cOnclusiOns: Results from the study sug-
gest that there are no significant differences among countries and that the majority 
treat patients following international clinical guidelines. Although the individual 
health care systems need to be considered in terms of relationship of treatment 
patterns with resource use, it is reassuring to note that international standards of 
care are being embraced in major emerging markets.
INDIvIDUAL’S HEALTH – Clinical Outcomes Studies
PIH1
ANáLISE COMPARATIvA DOS ANTICONCEPCIONAIS ORAIS COM DIFERENTES 
CONCENTRAçOES DE ETINILESTRADIOL EM RELAçãO AOS PERFIS DE EFICáCIA 
E DE ADESãO
Freitas M.G., Silva A.S., Elias F.T.S.
Brazilian Ministry of Health, Brasilia, Brazil
ObjetivOs: Analisar as evidências científicas disponíveis sobre anticon-
cepcional oral com apresentação farmacêutica Etinilestradiol (EE) 20mcg + 
Levonorgestrel (LVG) 100mcg, em comparação com a preparação EE 30mcg + 
LVG 150mcg. MétOdOs: Foi realizada ampla busca nas bases de dados Medline 
(via Pubmed), Cochrane Library, Rebrats e CRD. ResultadOs: Dos 53 estudos 
encontrados na estratégia de busca, apenas uma RS disponível na base de dados 
The Cochrane Library foi selecionada por apresentar resultados comparados dos 
mesmos princípios ativos nas dosagens relacionadas à pergunta do estudo. Na 
RS foram incluídos 21 ECRs, comparando contraceptivos orais combinados com 
doses de estrógenos maiores ou menores/iguais a 20 µg. Não houve diferenças 
significativas em termos de eficácia contraceptiva entre os 13 diferentes anticon-
cepcionais. Encontrou-se risco elevado de distúrbios de sangramento para os ACO 
de baixa dose de estrógeno (amenorréia ou sangramento irregular, infrequente 
ou prolongado; sangramento frequente e spotting). Mulheres em uso de EE 20 µg 
e desogestrel 150 µg foram mais suscetíveis a sofrer sangramento irregular (OR 
1.56; 95% IC 1.10 a 2.20) e a ter maior duração do sangramento irregular durante 
o terceiro ciclo (diferença média de 0.7 dias; 95% IC 0.30 a 1.10) que mulheres em 
in both developed and emerging settings. As Mexico’s economy continues to grow, 
the value of investments in health innovation from both a public health and eco-
nomic perspective will rise.
PCv36
EvALUATION OF HOME MEDICATION REvIEw IN COMMUNITy OUT REACH 
PROgRAM
Naik V.1, Nagappa A.N.2, Prabhu N.1, Reddy K.1
1Manipal Univiersity, Manipal, India, 2Manipal University, MCOPS, Manipal, India
Objectives: To Establish the value of WHO-FIP Pharmacuetical Care in chronic 
conditions like diabetes, Hypertnsion and Obesity in a community out reach pro-
gram. The Pharmaceutical Care program is new concept proposed in 2005, to aid 
the patient in improving his knowledge in the area of Drug, Disease and Life style 
by pharmacist. MethOds: The patients are approched at thier homes by a panel of 
health care professionals led by pharmacists. the pharmacist after interacting with 
the patients make the documentation regarding patient current status of knowl-
egde, regarding disease, drugs and life style along with his/her condition of health 
and the life style. The care plan is made by taking into above facts and patients are 
explained the correct way of using the medicine, the correct life style habits and 
idea about diet and physical activity. The patients were again approched after a 
fortnight at thier homes and measurements of Blood pressure, Body Mass Index 
along with Random blood sugar were carried out . All these values are recorded in 
a Pharmacuetical care card, which was issued to individual patients. The patients 
were usually followed upto 3 months in which minimum 6 visits have beed carried 
out. Results: The patients are able to asses the progress of thier condition by fol-
lowing the advice of a health care professional. cOnclusiOns: It is expected that 
patient will under go a cycle of knowlegde attitude and practice model. For assesing 
the value of the program, the pre and post evaluation by EQ 5D questionnaire and 
clinical parameters will be applied.
PCv37
EvOLUCIóN EN EL URUgUAy DE TAzAS DE UTILIzACIóN DE CATETERISMO 
CARDíACO DIAgNOSTICO PAR A CARDIOPATíA CONgéNITA EN MENORES DE 18 
AñOS (1995-2012)
Lombide I., Morales M., Fernandez G., Saona G., Perna A., Gambogi R., Gamboa R.
Fondo Nacional de Recursos, Montevideo, Uruguay
ObjectivOs: Como resultado del advenimiento del ecocardiograma doppler 
color ( EDC) a fines de los 90, muchas cardiopatías congénitas ( CC) son tratadas 
sin Cateterismo cardíaco Diagnóstico (CCD). En el Uruguay el Fondo Nacional de 
Recursos financia CCD desde 1981, estando normatizada su autorización desde el 
2008. Se cuenta con un registro único nacional de CCD. Objetivos: Conocer la evolución 
de la tasa de utilización de CCD en población pediátrica, períodos: 1°:1995 – 1999, 
2º:2003 - 2007, 3º: 2008 - 2012. MetOdOlOgías: Estudio descriptivo de solicitudes de 
CCD para CC en menores de 18 años.Las variables analizadas son : año de solicitud, 
edad, sexo, procedencia, cobertura asistencial, estado de autorización, y población 
nacional discriminada por edad en forma anual. Para analizar la evolución temporal 
de las tasas de solicitudes ajustada por edad y sexo se utilizó una regresión Binomial 
Negativa. ResultadOs: Se observó un descenso significativo de la tasa de solicitudes 
en el devenir de los períodos analizados (RR= 0,93 IC95%= 0,91 - 0,95). Analizada la 
tendencia temporal y tomando como referencia el primer período se observa un 
descenso significativo en las tasas de solicitudes del segundo y tercer período ( RR= 
0,55 IC95%= 0,43 - 0,70 y RR = 0,37 IC95%= 0,29 - 0,47). Al tomar como referencia 
el segundo período, se observa un descenso significativo en el tercer período ( RR 
= 0,67 IC95%= 0.52- 0,85). cOnclusiOnes: El mayor descenso del número de CCD 
observado en el tercer período podría atribuirse a la introducción de normativas para 
autorizar la cobertura financiera de CCD por parte del FNR sumado al protagonismo 
del EDC. La utilización de la normativa resultó una herramienta útil para disminuir el 
uso de procedimientos innecesarios, optimizando la utilización de recursos.
PCv38
DESIgUALDAD EN SALUD RELATIvA AL INgRESO EN CHILE: ANáLISIS DE 
DESCOMPOSICIóN DEL íNDICE DE CONCENTRACIóN EN HIPERTENSIóN, 
DIABETES y DEPRESIóN
Cabieses B.1, Espinoza M.A.2
1Universidad del Desarrollo, Santiago, Chile, 2Pontificia Universidad Católica de Chile, Santiago, 
Chile
ObjectivOs: Existe una clara asociación positiva entre ingreso per cápita y salud. 
Sin embargo, esta asociación no es tan clara cuando el Producto Interno Bruto per-
cápita (PIBpc) supera de los US$18,000. Esta pérdida de asociación es en buena 
parte explicada por las grandes diferencias de resultados en salud entre subgrupos 
de la población, donde uno de sus determinantes más claramente establecidos 
es el ingreso económico. Chile es un país en vías de desarrollo que pretende lle-
gar el año 2018 a un PIBpc > US$18,000. Toda evaluación de políticas en salud no 
debe estar circunscrita a promedios poblacionales sino a la distribución de dichos 
resultados en la población. El objetivo de este estudio fue estudiar la desigualdad 
en salud relativa al ingreso en Chile para tres enfermedades de alta prevalencia: 
hipertensión, diabetes y depresión. MetOdOlOgías: A partir de la encuesta CASEN 
del 2009 (n= 246 924), se estimó el índice de concentración de Erreygers (ICErreygers) 
para cada una de estas enfermedades y se realizó su descomposición basado en 
una regresión probit para estudiar factores asociados legítimos (edad, sexo, estado 
marital, número de miembros del hogar, etnia, rural/urbano) e ilegítimos (ingreso, 
ocupación, educación, calidad de vivienda, previsión de salud). ResultadOs: El 
ICErreygers estimado para hipertensión, diabetes y depresión fue de 0,0030; 0,0037 y 
-0,0012, respectivamente. La descomposición de ICErreygers indica que la mayor parte 
de la desigualdad está explicada por la edad en todos los casos (legítimo). Ingreso 
y ocupación le siguieron de manera consistente en los tres problemas de salud 
estudiados (ilegítimos). cOnclusiOnes: La desigualdad en salud relativa al ingreso 
en hipertensión, diabetes y depresión en Chile muestra estar fundamentalmente 
explicada por factores legítimos como la edad. Sin embargo, factores ilegítimos 
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guías de práctica clínica y la farmacopea Pediadosis. La información se sistema-
tizó y analizó utilizando Epi Info versión 3.5.1 para Windows, se obtuvo estadística 
descriptiva. ResultadOs: El 80.3% de los pacientes recibió antibióticos (n= 122). 
La media de antibióticos prescritos fue 1.8, en un intervalo de 1-4, la moda fue 2. 
Diagnósticos más frecuentes: gastroenteritis 16.4% y bronconeumonía 9.8%. Uso 
de los antibióticos: profiláctico 2% y terapéutico 98%. Antibióticos más frecuentes: 
amikacina 37.4%, ampicilina 25.6% y dicloxacilina 13.7%. Vía de administración más 
frecuente: intravenosa 87%. La calidad de la prescripción fue inadecuada en 93%. 
Errores de prescripción más frecuentes (individuales): duración inadecuada 79.9%, 
dosis inadecuada 63% y medicamento inadecuado 57.5%. cOnclusiOnes: La cali-
dad de prescripción de antibióticos en la unidad médica es preponderantemente 
inadecuada, se requieren estretegias de intervención educativas y gerenciales para 
dar solución al problema. Se sugiere evaluar la calidad de prescripción de otros 
grupos de medicamentos en todos los servicios médicos del hospital.
INDIvIDUAL’S HEALTH – Cost Studies
PIH5
ANáLISIS DE IMPACTO PRESUPUESTAL DEL USO DE LNg SIU COMO MéTODO DE 
CONTRACEPCIóN EN COLOMBIA
Acero G., Romero M.
Fundacion Salutia, Bogotá, Colombia
ObjectivOs: Analizar el impacto presupuestal de incorporar el Sistema 
Intrauterino Liberador de Levonorgestrel (SIU-LNG) en el sistema de salud colombi-
ano como método de contracepción reversible de larga duración. MetOdOlOgías: 
Tomando como referencia un modelo de costo-efectividad que muestra el benefi-
cio del uso de SIU-LNG, se realizó un modelo de impacto presupuestal de la adición 
del SIU-LNG al sistema de salud. Tomando como referencia la población estimada 
en Colombia para 2012 y los datos de uso de estos métodos de planificación de 
la Encuesta Nacional de Demografía y Salud 2010, se estimó el impacto para una 
cohorte fija y con incremento poblacional del uso del SIU-LNG con una tasa de 
reemplazo anual del 30%, hasta 5 años, incluyendo costos directos de salud. Se 
realizó un análisis de sensibilidad univariado, realizando variaciones en la tasa de 
remplazo. ResultadOs: El impacto que tendría SIU-LNG para el sistema de salud 
como método de contracepción usando cohorte fija sería de USD$ 30.422.297,03 
(USD$ 0,65 per cápita) en el primer año, disminuyendo anualmente hasta llegar a 
un impacto acumulado de USD$ 0,31 per cápita a 5 años. Con incrementos anuales 
de población similar a la tasa de crecimiento poblacional, el impacto acumulado 
al quinto año sería de USD$ 0,42 per cápita, correspondiente a USD$ 19.969.830,10. 
Tomando como referencia el valor per cápita asignado para 2012, éste implicaría 
un impacto de 0,21% para el primer año, de -0,02% y -0,03% para el segundo año en 
cohorte móvil o fija, respectivamente. cOnclusiOnes: Los resultados muestran 
que la incorporación de SIU-LNG como método de planificación en el sistema de 
salud colombiano genera ahorro en el gasto a partir del segundo año en las con-
diciones del caso analizado y su impacto es bajo frente a los beneficios en calidad 
de vida que podría generar.
PIH6
A TIME-MOTION COMPARISON OF ITEMIzED TREATMENT COSTS IN FIRST 
vERSUS SUBSEQUENT CyCLES OF IN vITRO FERTILIzATION (IvF): TREATMENTS 
CAN OPTIMIzED FOR IMPROvINg OUTCOMES wHILE INCREASINg PATIENT 
vOLUMES IN COST-CONSTRAINED REgIONS
Jones C.1, Carpinello O.1, Erten M.Z.1, Sills E.S.2
1University of Vermont - College of Medicine, Burlington, VT, USA, 2Pacific Reproductive Center, 
Irvine, CA, USA
Objectives: To anlayze the differences in initial versus subsequent fresh in vitro 
fertilization (IVF) cycles with regard to personnel time, consumables and other 
resources. MethOds: A cross-sectional observational study of 120 patients. 
Observations were made during regular clinic hours in the clinical rooms of a UK 
fertility centre and its affiliated embryology department from January 1, 2002 to 
December 31, 2002. The average time per task was determined for each component 
of treatment by averaging the observed duration for five distinct observations. For 
each member of staff and each component of treatment, the total time (in hours) 
was estimated by multiplying the duration of attendance by a) the percentage of 
patients undergoing each treatment component and b) the frequency of attend-
ance by each staff member, which allowed for the weighted average of personnel 
time and costs along with standard deviations to be calculated. Results: When 
consumables were included, each initial cycle cost the clinic approximately £2246.57 
+/- £151.01. The total amount of time patients spent with staff during subsequent 
fresh IVF cycles was much less than initial cycles, at 6.94 +/- 2.44 hours. The time 
spent with staff equated to £257.53 +/- £90.77, while each subsequent fresh cycle 
cost the clinic approximately £1813.12 +/- £90.77. A total of 9.77 +/- 4.94 more staffing 
hours were spent with patients during initial IVF cycles compared to subsequent 
fresh IVF cycles. This decrease in staffing time created a £319.52 +/- £176.19 dif-
ference between initial and subsequent fresh cycles, while the diminished use of 
consumables on subsequent treatment cycles accounted for a cost-reduction of 
£113.93. Thus, subsequent fresh IVF cycles were, on average, £433.45 +/- £176.19 
less than initial cycles. cOnclusiOns: The details of our study give insight, par-
ticularly in cost-constrained regions, how clinic management may be conducted 
in a cost-efficient manner.
PIH7
COSTO-EFECTIvIDAD DE CARBETOCINA EN COMPARACIóN CON OxITOCINA 
PARA PREvENIR HEMORRAgIA POSPARTO POR ATONíA UTERINA EN PACIENTES 
CON FACTORES DE RIESgO EN COLOMBIA
Rueda C., Caceres L.A., Caicedo Navas A.G.
Independiente, Bogotá, Colombia
ObjectivOs: La hemorragia postparto (HPP) es la principal causa de mortali-
dad materna, el 75% de los casos de HPP son causados por atonía uterina, por lo 
uso de EE 30 µg e desogestrel 150 µg (Akerlund, 1993). Muitos ACO contendo baixa 
dose de estrógeno resultaram em altas taxas de descontinuação (global e através 
de eventos adversos como sangramento irregular). Mulheres em uso de EE 20 µg 
e desogestrel 150 µg tiveram um OR de descontinuação através de sangramento 
irregular igual a 2.59 (95% IC 1.35 a 5.00) em relação ao grupo de mulheres em uso 
de EE 30 µg e desogrestrel 150 µg (Akerlund 1993). cOnclusões: Reduzir a con-
centração de estrógenos para melhorar a segurança pode resultar em baixa adesão 
em função de mudanças inaceitáveis nos padrões de sangramento.
PIH2
COST EFFECTIvENESS EvALUATION OF A ROTAvIRUS vACCINATION PROgRAM 
IN ARgENTINA
Garcia Marti S.1, Alcaraz A.2, Valanzasca P.3, Mc mullen M.1, Standaert A.4, Garay U.5,  
Lepetic A.C.6, Gomez J.A.7
1Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 2Institute 
for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 3Institute for 
Clinical Effectiveness and Health Policy (IECS), CABA, Argentina, 4GlaxoSmithKline, Wavre, 
Belgium, 5IECS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 
6GlaxoSmithKline, Buenos Aires, Argentina, 7GlaxoSmithKline, Victoria, Argentina
Objectives: Rotavirus diarrhea is one of the most important vaccine-preventable 
causes of severe diarrhea in children worldwide. There are two vaccines licensed 
Rotarix® (monovalent attenuated human rotavirus strain) by GlaxoSmithKline and 
RotaTeq® (pentavalent live human-bovine reassortant vaccine) by MSD with simi-
lar results. This study aim was to evaluate the cost-effectiveness of incorporating 
monovalent rotavirus vaccine 2-dose scheme (Rotarix®) compared with the penta-
valent vaccine 3-dose scheme (Rota-Teq®) in the national immunization schedule 
of Argentina. MethOds: A deterministic Markov model based on the lifetime fol-
low up of a birth cohort was used. QALYs as an effect measure, health care sys-
tem perspective and a 5% discount rate for health benefits and costs have been 
used. A review of the literature to obtain epidemiologic and resources utilization 
data was performed. The sources used to estimate the epidemiologic parameters 
were the National Health Surveillance System, the national mortality statistics 
and national database of hospital discharges records. Costs are expressed in local 
currency. PAHO 2012 Revolving Fund vaccine prices were used. Results: Rotarix® 
prevented 177,254 rotavirus cases, 19,376 hospitalizations and 31 deaths while 
Rotateq® prevented 165,022, 17,882 and 28 events respectively. Both vaccination 
strategies were less costly and more effective than the strategy without vaccination 
(total costs $69,700,645 and 2,575 total QALYs lost). When comparing vaccination 
schemes Rotarix® was less expensive ($ 60,174,508 vs. $ 67,545,991 total costs) and 
more effective (1,105 vs. 1,213 total QALYs lost) than Rotateq®, being the dominating 
strategy. Probabilistic sensitivity analysis showed results to be robust of being cost-
effective at a WTP threshold of 1 GDP per capita when comparing the 2-dose scheme 
vs. no vaccination or the 3-dose scheme one. cOnclusiOns: In Argentina both 
rotavirus vaccination schemes dominate the no vaccination strategy and Rotateq® 
(3-dose scheme) was dominated by Rotarix® (2-dose scheme), being this results 
robust in the sensitivity analysis.
PIH3
ROLE OF ANTIOxIDANTS IN RECURRENT PREgNANCy LOSSES, LOw BIRTH 
wEIgHT, AND gESTATIONAL DURATION
Bhatti T.A.
Health Services Academy, Islamabad, Pakistan
Objectives: To study the impact of antioxidants on the maternal and child health 
of women with Recurrent Pregnancy Loss (RPL) and healthy pregnancies. The three 
main variables studied for the purpose included (i) low birth weight (LBW), (ii) ges-
tational duration (GD) and (iii) RPL with a history of RPL. MethOds: The study was 
conducted in two parts. Study 1 focused on the impact of antioxidants on mothers 
with RPL with a sample size of 123 mothers out of 200 cases. Study 2 focused on 
the impact of antioxidants on LBW and GD included a sample of 900 women with 
healthy pregnancy of 6 months. Each of the study groups were divided in to experi-
mental (active arm) and control group (placebo arm). It was hypothesized that 1) 
Oral antioxidant supplementation will reduce the rate of recurrent pregnancy loss; 
2) Oral supplementation of antioxidants during pregnancy will increase the birth 
weight of the child; and 3) Oral supplementation of antioxidants will decrease pre-
mature births. Results: it was found in study 1 that antioxidant supplementation 
reduced the chances of RPL as the chances of conception in women in the active 
arm increased by 36%. Study 2 revealed that the chance of LBW was reduced by 
15% in women that received antioxidant supplements and the average weight of 
their infants in the active arm increased by 0.30kg. It was found that the gestational 
period for women in the active arm increased by 12 days and they were 30 times 
more likely to give birth within their expected date of delivery (EDD). Lastly, it was 
also found that maternal and neonatal mortality was also reduced by 4.4% and 2.9% 
respectively. cOnclusiOns: It is conclusion that antioxidants be made mandatory 
for normal pregnant women and especially women of RPL.
PIH4
CALIDAD DE PRESCRIPCIóN DE ANTIBIóTICOS EN EL SERvICIO DE PEDIATRIA 
DE UN HOSPITAL gENERAL DE CARDENAS, TABASCO, MéxICO
Zavala-González M.A.1, Sánchez-Santana R.2
1Consultor Independiente, Cárdenas, Tabasco, Mexico, 2Secretaría de Salud del Estado de Tabasco, 
Cárdenas, Tabasco, Mexico
ObjectivOs: Evaluar la calidad de la prescripción de antibióticos en el ser-
vicio de pediatría del Hospital General de Cárdenas, Tabasco, México, en el año 
2010. MetOdOlOgías: Estudio de utilización de medicamentos, de tipo transversal. 
Se estudió un universo de N= 678 expedientes de pacientes atendidos durante 2010, 
se tomó una muestra probabilística simple (p= 0.15, d= 0.05, Z= 1.6) de n= 152 expedi-
entes seleccionados sistemáticamente a intervalos de k= 5. Se recopiló información 
sobre antibióticos prescritos, diagnóstico, uso del antibiótico y esquema terapéutico; 
se evaluó la calidad de la prescripción comparando el esquema prescrito contra las 
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PIH10
EvALUACIóN COSTO-EFECTIvIDAD y DE vALOR SOCIAL DE UN PROgRAMA DE 
INTERvENCIóN EN POBLACIóN INFANTIL EN SITUACIóN DE vULNERABILIDAD, 
REzAgO O DéFICIT EN EL DESARROLLO INTEgRAL - CHILE 2012
Vallejos C.1, Reveco R.1, Bachelet V.C.2, Goyenechea M.2, Velasquez M.1, de La Puente C.1, 
Bustos L.1, Zaror C.1
1Universidad de La Frontera, Temuco, Chile, 2Medwave Estudios Ltda., Santiago, Chile
ObjectivOs: En 2009 se crea el Sistema Intersectorial de Protección Social, para 
facilitar el pleno desarrollo de las potencialidades de los niños y niñas en Chile. 
Así, los niños tienen una evaluación periódica del desarrollo psicomotor, y ante la 
presencia de déficit o retraso, acceden a alguna de cuatro modalidades de interven-
ción: Sala de Estimulación, Visita Domiciliaria, Ludoteca, y Servicio Itinerante de 
Estimulación. Estas modalidades se ejecutan en todo el país, y su implementación 
ha significado un importante costo. El objetivo del estudio es realizar un análisis 
costo-efectividad y de valor social de las intervenciones en Chile. MetOdOlOgías: 
Se estudiaron los costos con técnica de microcosteo. Se determinaron costos 
sociales. La efectividad se estudió aplicando el Test Batelle antes y después de la 
intervención. Con estos datos se construye un modelo de simulación de la histo-
ria natural (no intervención) y de los efectos de la intervención en estudio. Para 
evaluar el valor social de las intervenciones, se aplica un instrumento de medición 
de deseabilidad y disponibilidad a pagar. ResultadOs: Los costos de las inter-
venciones presentan importante variabilidad interregional. Las intervenciones son 
efectivas,y hay diferencias de efectividad entre ellas. La evaluación costo-efectividad 
muestra que la inversión por un niño recuperado es alta, y resulta costo-efectiva en 
la medición del efecto estimado a largo plazo (edad escolar y productividad). La dis-
ponibilidad a pagar y la deseabilidad social de este Programa es, en general alta, pero 
notoriamente mayor en las regiones más extremas del país. cOnclusiOnes: La 
evaluación costo-efectividad de un programa de intervenciones destinado a igualar 
oportunidades de desarrollo en las edades más precoces (0 a 4 años) es materia de 
desafío metodológico, pero necesario para el decisor político. Es importante destacar 
que además de las medidas de efectividad, se agrega la dimensión del valor social, 
lo cual pondera significativamente la costo-efectividad.
PIH11
ANáLISIS COSTO-UTILIDAD DE DOS ALTERNATIvAS PARA EL TRATAMIENTO DE 
BEBéS PREMATUROS EN BOgOTá
Castillo M.1, Bernal A.J.1, Rios J.J.1, Ruiz J.G.2, Charpak N.3, Córdoba M.A.4, Córdoba M.A.4
1Universidad de los Andes, Bogotá, Colombia, 2Pontificia Universidad Javeriana, Bogotá, Colombia, 
3Kangaroo Foundation, Bogotá, Colombia, 4Hospital Universitario San Ignacio, Bogotá, Colombia
ObjectivOs: El manejo habitual que se les da a los bebés prematuros consiste 
en mantenerlos hospitalizados en una unidad neonatal. Como alternativa al 
tratamiento habitual se considera el Método Madre Canguro (MMC), el cual busca 
obtener una reducción importante en los costos de hospitalización y disminuir 
los riesgos de infecciones nosocomiales, entre otros. Se realizó un análisis de 
costo-utilidad de las alternativas, el cual considera aspectos cualitativos y cuanti-
tativos. MetOdOlOgías: Se diseñó una metodología para realizar un análisis de 
costo-utilidad de alternativas de tratamiento médico, la cual se aplicó a los manejos 
de bebés prematuros en Bogotá, Colombia. Para la medición de utilidad se utilizó el 
enfoque de Teoría de Utilidad Multiatributo que permite, a través de una función de 
utilidad aditiva, evaluar el desempeño de seis variables relevantes en la valoración 
del estado de salud de cada uno de los bebés incluidos en el análisis. El costo se 
estimó con base en un procedimiento de micro-costeo de los recursos consumidos 
por cada bebé, bajo cada tratamiento. Finalmente, se calcularon las razones incre-
mentales de costo-utilidad (RICU) de los tratamientos. Los modelos se realizaron 
con base en los resultados del estudio Charpack, Ruiz, Calume, & Charpack, 1997, el 
cual registra datos de 593 prematuros con mediciones desde su nacimiento hasta 
cumplir el primer año. ResultadOs: Los valores promedio estimados para MMC 
y el manejo habitual, en utilidad fueron 0.876 y 0.809, y en costos Col$2’810.531 y 
Col$2’997.643, respectivamente. La utilidad presentó diferencia estadística signifi-
cativa, a diferencia de los costos. La RICU estimada fue Col$-2’783.236, lo cual indica 
que el MMC no solo es más efectivo sino menos costoso. cOnclusiOnes: Del 
análisis de Costo-Utilidad realizado, se puede afirmar que el MMC como alternativa 
al cuidado en incubadoras de prematuros estables, con peso de nacimiento menor 
de 2000g, domina al manejo habitual.
INDIvIDUAL’S HEALTH – Patient-Reported Outcomes & Patient Preference Studies
PIH12
MEASUREMENTS OF ADHERENCE TO ORAL THERAPIES AMONg BRAzILIAN 
PATIENTS: A SySTEMATIC REvIEw
Takemoto M.L.S., Guerra R., Fernandes R.A., Pereira A.C.P., Santos P.M.L., Amaral L.M., 
Vasconcellos J.F.
ANOVA, Rio de Janeiro, Brazil
Objectives: To systematically review the measures of adherence to oral therapies 
employed in Brazilian observational studies. MethOds: Observational studies that 
evaluated adherence to oral therapies among Brazilian patients of any disease or 
condition were identified by searching Medline and LILACS, without time limits, 
using a combination of controlled vocabulary and text words for ‘adherence’. To be 
included studies had to fully report methods to assess adherece to oral drugs and 
be conducted with Brazilian patients. Studies examing only persistence measures 
or using lost to follow-up as a proxy to adherence were not deemed eligible. Articles 
were independently reviewed by two researchers to identify relevant studies and 
abstract methodological data. Results: Of the 472 records identified, 61 full-text 
articles were included in the final version of this review. The most frequent thera-
peutic areas were Infectious Diseases (37.7%), Cardiology (24.6%), and Endocrinology 
(8.2%) – HIV/AIDS represented 36.1% of all studies, while High Blood Pressure con-
tributed with 13.1% of the included papers. Sixteen studies adopted more than one 
adherence measures (81 differente evaluations in 61 studies). The most frequently 
used adherence measures were: self-reported (n= 30, 37.0%), the Morisky test (n= 19, 
tanto seleccionar una terapia costo efectiva para prevenir la HPP, es vital para los 
países en vías de desarrollo. Los objectivos de este estudio son de evaluar lo costo-
efectividad e impacto presupuestal de carbetocina en comparación con oxitocina 
para prevenir hemorragia posparto por atonía uterina en partos con factores de 
riesgo. MetOdOlOgías: El modelo incluye un árbol de decisión en Excel y las 
medidas de efectividad fueron: el uso de dosis de uterotónicos adicionales, pérdida 
de sangre durante el parto y perfil de seguridad incluyendo los eventos adversos 
que se presentan durante la preparación y administración del medicamento, todos 
los parámetros clinicos fueron extraídos de evidencia científica y meta-análisis. 
El horizonte temporal corresponde a la duración de la estancia hospitalaria. Se 
incluyeron los gastos hospitalarios para atención de parto por cesárea, los costos 
de uterotonicos adicionales y los relacionados a la preparación y administración 
de medicamentos. Los valores se tomaron de manuales tarifarios y listados de 
precios (Farmaprecios, SISMED, ISS). A los costos de eventos adversos se les aplico 
un coeficiente de ajuste obtenido del Health at a Glance 2011: OECD (Organisation 
for Economic Co-operation and Development). ResultadOs: Los pacientes que 
recibieron carbetocina requieren significativamente menos uterotónicos adicion-
ales que los que recibieron oxitocina (RR 0,65, IC del 95%: 0,53 a 0,80). El costo 
promedio de tratamiento por paciente con oxitocina es 115USD, y con carbetocina 
76USD. En una cohorte de 1000 pacientes el ahorro es de 38.530USD. El análisis de 
sensibilidad con +/- 10% no modifico los resultados. cOnclusiOnes: Carbetocina 
es una terapia costo ahorrativa en Colombia para prevenir HPP en pacientes con 
factores de riesgo.
PIH8
ECONOMIC EvALUATION OF NASOgASTRIC HyDRATION vERSUS 
INTRAvENOUS HyDRATION FOR INFANTS wITH BRONCHIOLITIS:  
A RANDOMISED TRIAL
Murphy B.1, Carter R.1, Oakely E.2, Borland M.3, Neutze J.4, Acworth J.5, Dalziel S.6, Krieser D.7, 
Babl F.8
1Deakin University, Victoria, Australia, 2Royal Children’s Hospital, Melbourne, Australia, 3Princess 
Margaret Hospital, Western Australia, Australia, 4Kidz First Hospital, Auckland, New Zealand, 
5Royal Children’s Hospital, Brisbane, Australia, 6Starship Children’s Hospital, Auckland, New 
Zealand, 7Sunshine Hospital, Victoria, Australia, 8Royal Children’s Hospital, Victoria, Australia
Objectives: Bronchiolitis is a disease of the lower respiratory tract with peak 
incidence in the winter. It is the leading cause of hospitalization during the first 
year of life and a major cause of morbidity and mortality. The estimated cost of 
the Victorian bronchiolitis hospital admissions for 2006 was $8.1 million dollars. 
Nasogastric hydration (NGH) and intravenous hydration (IVH) are two techniques 
for fluid replacement therapy, required in approximately 20% of children admitted 
with bronchiolitis, however there is a lack of agreement on which method is most 
beneficial. MethOds: The study was a multi-centre, three-year, open, randomized 
trial comparing NGH and IVH in children between two months and 12 months of 
age who were admitted to hospital with bronchiolitis and required non-oral fluid 
rehydration. The setting was seven hospitals in Australia and New Zealand between 
2009 and 2011. The primary outcome was ‘length of hospital stay’, with secondary 
outcomes covering ‘intensive care admission’ (ICU), ‘adverse events’ (AEs) and ‘num-
ber of attempts at insertion’. An economic evaluation was conducted alongside the 
trial to assess which approach is more cost-effective, as judged by their net ‘cost 
per child ready for discharge’ ratio. Each study site collected cost data covering 
treatment activities and outcome data including medical interventions, mediation 
received, complications, need for ICU admission and level of respiratory support. 
The reference year was 2009. Results: A total of 759 infants were randomised: 
378 to IVH and 381 to NGH. There was no statistically or clinically significant differ-
ence in the mean length of stay, ICU admission or AEs between treatment groups. 
Success at insertion on first attempt was higher in NGH (85.1%) compared to IVH 
(56.1%), p< 0.001. cOnclusiOns: The full results of the economic evaluation will be 
presented. With no significant difference in outcomes the economic analysis was 
reduced to a cost-minimisation study.
PIH9
COSTO-EFECTIvIDAD DE LAS CINTAS DE URETRA MEDIA COMPARADAS CON EL 
TRATAMIENTO CONvENCIONAL DE LA INCONTINENCIA URINARIA FEMENINA 
DE ESFUERzO EN COLOMBIA
Lopez-Ramos H.E.1, Garcia-Perdomo H.2, Prieto-Martinez V.3, Rosselli D.4, Cortes V.5
1Universidad del Rosario, Bogotá, Colombia, 2Universidad del Valle, Cali, Colombia, 3Universidad 
Nacional de Colombia, Bogotá, Colombia, 4Pontificia Universidad Javeriana, Bogotá, Colombia, 
5Clinica Colsubsidio, Bogotá, Colombia
ObjectivOs: Estimar la costo-efectividad de las cintas de uretra media compara-
das con la colposuspensión retropúbica y el cabestrillo pubovaginal en pacientes 
con incontinencia urinaria femenina de esfuerzo en Colombia. MetOdOlOgías: 
Se construyó un árbol de decisión para comparar las cintas de uretra media con 
la colposuspensión retropúbica y el cabestrillo pubovaginal en el tratamiento 
quirúrgico de la incontinencia urinaria femenina de esfuerzo. La perspectiva 
fue la del tercero pagador, incluyendo todos los costos directos para el sistema 
de salud. Todas las cifras monetarias se expresaron en pesos Colombianos de 
2011. La unidad de resultado fue la mejoría clínica definida como paciente con-
tinente o seca. Los datos de efectividad y seguridad se extrajeron de la literatura. 
Se calculó la razón de costo-efectividad incremental. Se realizaron análisis de 
sensibilidad univariados y probabilísticos para los costos, efectos y supuestos 
del modelo. ResultadOs: Los resultados del modelo indican que el costo por un 
caso adicional de mejoría clínica del cabestrillo comparado con la colposuspen-
sión fue de $10.967.742. El costo por un caso adicional de mejoría clínica de las 
cintas comparadas con el cabestrillo fue de $6.551.724. cOnclusiOnes: Desde 
el punto de vista económico, bajo los supuestos del modelo y desde el punto de 
vista del tercero pagador, las cintas de uretra media para el tratamiento de mujeres 
con incontinencia urinaria de esfuerzo son costo-efectivas para Colombia. Los 
resultados fueron sensibles a los costos de los procedimientos quirúrgicos y a la 
efectividad de los mismos.
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translations based on analysis of qualitative data collected during pilot-testing. 
In an effort to create a universal Spanish version, linguists from various Spanish-
speaking countries were recruited to achieve a translation that could be used in 
all regions in which Spanish is spoken. Results: After the translation phase was 
completed, psychometric testing was carried out. 485 adult items and 139 pediatric 
items from 11 subdomains were tested with native Spanish speakers (2,500 adults 
and 1,200 children) from an online general population panel. Different item banks 
exhibited various levels of differential item functioning (DIF) across Spanish and 
English speaking populations. In order to retain all items in each bank, a hybrid 
approach was used in which English calibration metrics were used for non-DIF 
items and Spanish calibrations were used for items exhibiting DIF. cOnclusiOns: 
Spanish Computer Adaptive Tests (CATs) for Anxiety, Depression, Fatigue, Physical 
Function and Sleep Disturbance are currently available in Assessment Center (www.
assessmentcenter.net).
PIH17
PRELIMINARy RESULTS QUALITy OF LIFE, PHySICAL ACTIvITy, AND 
SEDENTARy BEHAvIOR IN COLLEgE STUDENTS
Mendoza F.J., Parra G., Bastardo Y.M.
Universidad Central de Venezuela, Caracas, Venezuela
Objectives: Being physically active is associated with reduced risk of chronic 
diseases. In this study we examined the associations of physical activity and 
sedentary behavior with perceived quality of life (QoL) in college students in 
Venezuela. MethOds: A convenience sample of 64 students at Central University 
of Venezuela, ranging in age from 17 to 43 years was surveyed using a written 
questionnaire. Quality of life was measured using a single-item from the Health 
Survey Short-Form 36 (SF-36), EuroQol health states descriptive system (EQ-5D), 
and a visual analogue scale (EQ-VAS). The relationships between health status, 
physical activity, and sedentary behavior were estimated computing Kendall’s τ 
correlation coefficients. Statistic analysis was performed by SPSS 13.0. Results: 
The sample consisted of 41 females and 22 males. The sample had a mean age of 
20.54 years (s.d. 3.99 years). Two subjects (3.2%) reported some problems with mobil-
ity. Three subjects (4.8%) reported some problems with usual activity. Ten subjects 
(15.9%) reported some problems with pain. One subject (1.6%) reported extreme 
problems and 10 reported some problems with anxiety. Three subjects (4.8%) rated 
health status of fair or poor. Subjects reported doing vigorous physical activities on 
a mean of 2.05 days during the past week. Subjects reported walking for a mean of 
93.49 minutes during the past week. Subjects reported spending a mean of 301.31 
minutes sitting during the past week. Neither physical activity nor sedentary behav-
ior was associated with quality of life in our population. cOnclusiOns: Study 
limitations include the sample size and the use of a convenient sample. Overall, 
this exploratory study demonstrates that the quality of life of college students in 
Venezuela was good.
INDIvIDUAL’S HEALTH – Health Care Use & Policy Studies
PIH18
COMPARED ANALySIS OF INEQUALITIES IN HEALTH AND INFLUENCE OF 
SOCIAL DETERMINANTS OF HEALTH IN CUBA AND USA
Diaz de León-Castañeda C.1, Ramírez-Fernández D.M.2, Pinzon Florez C.E.1
1Instituto Nacional de Salud Pública, Cuernavaca, Mexico, 2National Institute of Public Health, 
Cuernavaca, Mexico
Objectives: Equity is a desirable goal for health systems performance and the 
comparison of them is important to learn lessons from the best. In the present study 
our goal was to analyze comparatively inequalities in health and the influence of 
social determinants of health in two countries with different social, economical 
and political contexts: Cuba and USA. MethOds: A compared inequalities analy-
sis was made in three health indicators related with the performance of health 
systems: maternal mortality rate (MMR), infant mortality rate (IMR) and life expec-
tancy at birth (LEB) using published geopolitical unities information from USA 
and Cuba in 2008 and through the computation of inequality indexes suggested 
in literature and statistical analysis. Also there were comparatively analyzed the 
effects on these health indicators of three proxy indicators of social determinants 
of health (PISDH’s): percent of rural population (PRP), percent of non white popula-
tion (PNW) and physicians rate (PHR), through the computation of effect indexes 
for significantly Pearson correlations. Results: Cuba showed significantly higher 
inequality than USA in MMR; USA showed higher inequality in LEB; the inequality 
in IMR was statistically not different. The PRP was a risk factor for the LEB in USA 
but a protector factor in Cuba; PNW was a risk factor for MMR and IMR in USA only, 
although with low effect index; PHR was a risk factor for MMR in USA only, perhaps 
by his correlation with another PISDH’s. cOnclusiOns: Important inequalities 
were identified in both countries. The PISDH’s analyzed affected health indica-
tors principally in USA. Another economic PISDH’s are required for more detailed 
comparative analysis in the effects of PISDH’s in health inequalities. There are few 
comparative analysis of health systems in the literature that employ quantitative 
methodology as used in this study.
PIH19
ATENCIóN INTERCULTURAL DEL PARTO vAgINAL EN MéxICO: COSTOS 
ECONóMICOS, DETERMINANTES y RETOS DE LA IMPLEMENTACIóN DE 
POLíTICAS EFECTIvAS EN BENEFICIO DE LAS MUjERES INDígENAS
Heredia I.1, Meneses S.1, Montag D.2, Ibañez M.1, Hernández E.1, González Block M.A.1
1Instituto Nacional de Salud Pública, Cuernavaca, Mexico, 2School of Social and Cultural 
Anthropology, Oxford, UK
ObjectivOs: Estimar los costos de atención del parto vaginal en unidades del 
sector público de salud de Oaxaca y Chiapas, para dos modelos asistenciales 
alternativos (convencional e intercultural), durante 2008-2012 e identificar los 
principales determinantes de la implementación efectiva y puesta a escala de 
modelos interculturales de atención materna en beneficio de la población indí-
23.5%), and pharmacy records (n= 7, 8.6%). Different versions of the Morisky test 
were identified (modified, 4-item, and 8-item). Other validated adherence ques-
tionnaires identified within the studies (with more than one occurence) were: 
MAT (n= 3) and MedTake (n= 2). Pill counting, medical chart review, and serum drug 
determination were used in 4 studies each. None study used electronic monitoring 
of adherence. cOnclusiOns: Data from the available Brazilian studies indicate a 
variety of methods adopted by local researchers for measuring adherence to treat-
ment. Indirect measures are more common, particularly those based on patients’ 
or caregivers’ perception of adherence behaviors. Most studies enrolled HIV/AIDS 
or hypertension patients. Other chronic conditions with long term continuous oral 
therapies were underrepresented.
PIH13
PROMETEx - PROMEvOz, TOOL SUPPORT OF PHARMACEUTICAL CARE FOR THE 
SCOPE OF PROPER ADHESION IN COLOMBIA, 2009-2012
Estrada J.I.1, Serna J.A.2, Toro C.M.3, Rios J.4, Sanchez L.3, Suarez J.E.1
1CES University, Medellin, Colombia, 2EAFIT University, Medellin, Colombia, 3Antioquia 
University, Medellin, Colombia, 4Granada University, Medellin, Colombia
Objectives: To determine if the tool Prometex – Promevoz, helps in reducing the 
drug therapy use problems identified in the Pharmacotherapy Monitoring for 
pharmaceutics. MethOds: Prometex – Promevozis a tool for telephony (voice 
and text messages) you want, combined with other strategies, to maintain and 
increase drug compliance, remembering the exact times of taking medication. 
With prior consent, information is sent to all medications they are prescribed, 
coded for strictly personal interpretation and handling of confidential and bidi-
rectional. A descriptive longitudinal, which includes users with at least two visits 
to Pharmacotherapy Monitoring, a pre and post-deployment of telephony tool. 
Demographic variables are analyzed and compared in an exploratory way in the 
same population type and amount of drug therapy use problems at the begin-
ning and end of use of the tool. Results: A total of 25.6% of patients had at least 
1 drug therapy use problems during the first consultation of Pharmacotherapy 
Monitoring, a situation that changed after the use of Prometex – Promevoz, which 
decreased the proportion of patients with drug therapy use problems to 16.7%. 
A decrease between the two observations of 53.3% with a chi squeare (ji2) of 9,56 
and a p value of 0,002. cOnclusiOns: The tool Prometex – Promevoz appears 
to contribute to the decline in drug therapy use problemsidentified in the 
Pharmacotherapy Monitoring.
PIH14
PATIENT-REPORTED OUTCOMES: ARE THEy wORTH IT? AN ExAMINATION IN 
PRO vALUE THROUgH CASE STUDIES
DeMuro C.1, Gnanasakthy A.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharmaceuticals, East Hanover, 
NJ, USA
Objectives: Increasing competition, pressure from payers and greater regulatory 
constraints require pharmaceutical manufacturers to seek methods for product 
differentiation. One way of differentiating pharmaceuticals is the generation of 
patient-centric value messages utilizing patient-reported outcomes (PROs). PROs 
may be primary or nonprimary endpoints in clinical trials, and commercial use is 
typically dependent on PROs that support key endpoints and appear in labeling 
(US) or in the summary of product characteristics (EU) to support reimbursement. 
However, despite this obvious utility, the cost and logistical complexity of including 
PROs may deter clinical teams. The purpose of this research is to better understand 
the value of PROs and the ability of PROs to provide data critical to decision making 
for patients, clinicians, and payers. MethOds: A detailed case study was conducted 
of three marketed products: ivacaftor, mirabegron, and botulinum type A. Selection 
of these products represent a range of therapeutic areas and may provide insight 
into the differing roles of PROs. For each product available US and European sub-
mission and review documents were analyzed. Results: PROs were included in 
all three submissions. A PRO labeling claim was granted for a primary endpoint for 
mirabegron, and while claims for nonprimary PROs were denied, the review docu-
ments indicate that the decision for drug approval was supported by results of the 
nonprimary endpoints. Ivacaftor was granted a claim based on a nonprimary PRO 
endpoint, though the tool did not meet the specifications of the FDA’s PRO guidance. 
Finally, health authorities recognized the impact on health-related quality of life for 
botulinum type A for migraine in support of a positive appraisal. cOnclusiOns: 
The results of this review indicate that PROs included in clinical trials may have a 
strong influence on the drug approval process, regardless of whether a PRO labeling 
claim is ultimately granted. Further research is warranted.
PIH15
THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SySTEM 
IN SPANISH
Arnold B.J.1, Correia H.2, Pérez B.1, Lent L.1, Cella D.2
1FACITtrans, Elmhurst, IL, USA, 2Northwestern University, Chicago, IL, USA
Objectives: The Patient-Reported Outcomes Measurement Information System 
(PROMIS®) provides accurate and efficient measurement of patient-reported out-
comes. Developed in English using qualitative methods, PROMIS tools measure 
symptoms, such as pain and fatigue, and aspects of health-related quality of life 
across a wide variety of chronic diseases and conditions. MethOds: To enable 
participation of Spanish-speaking populations the PROMIS banks were translated 
into Spanish using methods that would ensure linguistic equivalence and cultural 
appropriateness. The Spanish translation of 825 adult and 156 pediatric items was 
obtained through the FACIT Multilingual Translation Methodology which consists 
of the following ten steps: 1) creation of item definitions; 2) two simultaneous for-
ward translations; 3) reconciliation of forward translations; 4) back-translation of 
reconciliation; 5) expert review of back-translation and previous steps; 6) prelimi-
nary finalization for pilot-testing; 7) cross-cultural harmonization; 8) quality assur-
ance; 9) cognitive testing with native speakers of Spanish; and 10) finalization of 
a712  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 6 6 5 – A 7 2 8  
PIN3
BURDEN OF vARICELLA IN LATIN AMERICA: A SySTEMATIC REvIEw AND 
CRITICAL ANALySIS
Yang H.K.1, Liaw K.L.2, Manoff S.2, Kuter B.1
1Merck & Co, Inc., West Point, PA, USA, 2Merck & Co, Inc., Upper Gwynedd, PA, USA
Objectives: Varicella is a common, vaccine-preventable illness with significant 
public health impact in Latin America (LA). This study aimed to review the epi-
demiology and economic burden of varicella, and to perform a critical analysis 
of available data in LA. MethOds: A comprehensive literature review was con-
ducted in major databases and government websites to identify published data on 
epidemiology and economic burden of varicella in LA. Study data were extracted 
systematically including incidence rates, lifetime prevalence, mortality, type and 
rates of complications, as well as use of health care resources (hospitalizations, phy-
sician office visits, others) and both direct and indirect costs associated with vari-
cella. Critical analyses of study quality and data availability are performed for each 
country. Results: Published studies were identified from ten countries including 
Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Uruguay, and 
Venezuela. Annual incidence rates ranged from 20 per 100,000 in Uruguay up to 
381 per 100,000 in Mexico. Incidence was highest among children < 10 years of age, 
bearing increased utilization of healt health care resources. Bimodal seasonal pat-
terns of varicella were reported in Argentina, Mexico and Uruguay. Most frequent 
complications among hospitalized patients were skin and soft tissue infections, 
respiratory infections and neurological complications. Patients hospitalized for 
varicella stayed generally between 1-5 days. Critical analysis suggested that most 
published studies had limitations including data representativeness and study 
design issues. Data gaps in the epidemiology and economic burden of varicella 
were also found on the country level. cOnclusiOns: Currently there is limited 
information available on burden of varicella in Latin America, potentially due to 
the lack of mandatory reporting and active surveillance systems for varicella in the 
region. Country-specific epidemiological information and varicella-related health 
care resource utilization data are needed to elucidate the disease burden for devel-
oping appropriate immunization recommendations and informing decision makers 
about the value of varicella vaccination.
INFECTION – Cost Studies
PIN4
COSTS AND OUTCOMES ASSOCIATED wITH MULTIDRUg RESISTANT 
STAPHyLOCOCCUS AUREUS BACTEREMIA
Singh S.1, Tiwari P.2
1National Institute of Pharm. Edu & Res (NIPER), S.A.S. NAGAR, Punjab, India, 2National Institute 
of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, India
Objectives: There is a dearth of studies in India that quantifies the impact of mul-
tidrug resistance on key economic and clinical outcomes. The aim of this retrospec-
tive cohort study was to determine the costs of treatment and evaluate the clinical 
outcomes in patients suffering from multidrug resistant (MDR) Staphylococcus aureus 
bacteremia and compare these with the costs and clinical outcomes of patients 
suffering from non-MDR S. aureusbacteremia. MethOds: Data was collected from 
2007 through October 2010 from a private tertiary care hospital in India. Multidrug 
resistance was defined as resistance to ≥ 3 classes of antimicrobial drugs. Resistance 
within a class was defined as resistance to ≥ 1 antimicrobial agent. Results: A 
total of 42 cases were included in the study of which 19 belonged to the MDR cohort 
and 23 to the non-MDR cohort The total mean cost for treating patients in the 
MDR cohort was 1.35 times higher compared to the non-MDR cohort (INR 230,000 
[170,000-623,000] versus INR 171,000 [91,000-310,000]; P = 0.049). Death was reported 
in similar number of patients in both the groups (5 patients and 4 patients in the 
MDR cohort and non-MDR cohort, respectively). The number of deaths attribut-
able to sepsis was also similar between the groups (16% vs. 13%). The total mean 
length of stay in hospital was significantly longer for the MDR cohort compared 
with non-MDR cohort (19 days [16-28] vs. 14 days [9.2-18.5]; P = .024). However, 
after the onset of bacteremia, the difference in the length of stay between the 
groups was not statistically significant (16 days [14-21] vs. 11 days [8-15.5]; P = 
0.12). cOnclusiOns: Multidrug resistance in S. aureus bacteremia was associated 
with a significant increase in hospital costs.
PIN5
COSTOS ECONóMICOS ASOCIADOS A SECUELAS DE MENINgITIS EN COLOMBIA
Alvis-Guzmán N.1, Coronell-Rodriguez W.1, Castañeda-Orjuela C.A.2, De la Hoz-Restrepo F.2
1Universidad de Cartagena, Cartagena de Indias, Colombia, 2Universidad Nacional de Colombia, 
Bogotá, Colombia
ObjectivOs: Estimar los costos económicos asociados al tratamiento de secuelas 
de meningitis en una serie de casos en Colombia. MetOdOlOgías: De la base de 
datos de 253 pacientes atendidos entre 2009 y 2012 en una institución de rehabili-
tación ubicada en Cartagena de indias Colombia, se identificaron 37 diagnóstico de 
meningitis bacteriana y entre estos se confirmaron 19 casos de secuelas. De estos, 
se microcostearon 13 pacientes con secuelas asociadas a un episodio de meningitis 
meningocócica verificada por pruebas de laboratorio. Las perspectivas del costeo 
fueron del sistema de salud y la sociedad. En la primerara se consideraron todos 
los costos médicos directos originados durante el primer año de tratamiento de la 
secuela y en los años subsiguientes. En la perspectiva social, adicionalmente se 
consideraron la compra de órtesis y prótesis, adecuaciones del hogar, gastos de 
transporte y perdida de de productividad, cuando el cuidador tuvo que abandonar el 
trabajo para asistir al paciente. Los costos se expresaron en US dólares de 2012 (Tasa 
de cambio 31 dic 2012 1 USD por COP$ 1768.23). ResultadOs: De los 13 pacientes 
considerados, 5 tenían secuelas de retardo psicomotor, cuatro de hipoacusia neuro-
sensorial, tres de epilepsia y un trastorno del comportamiento. Desde la perspectiva 
del sistema de salud, los costos directos de tratamiento para el primer año y cada 
año subsiguiente fueron US$ 3,106.27 (IC95%: 454.5 – 5,758.0) y US$ 496.1 (IC95%: 
449.2 - 509.3); desde la perspectiva social fueron US$ 4,647.1 (IC95%: 4,183.8 – 5,082.3) 
gena. MetOdOlOgías: Análisis transversal con información de expedientes 
clínicos de 488 usuarias de los servicios estatales de salud. Se realizó un micro-
costeo y se estimaron los costos de la utilización de recursos, desde la perspectiva 
del sector salud. Se realizaron pruebas estadísticas tipo X2 de Pearson y prueba t 
para identificar diferencias en las variables de estudio. Los costos se expresan en 
pesos mexicanos del 2012. Se realizaron entrevistas semi-estructuradas a usuarias 
y actores de niveles estratégicos, tácticos y operativos involucrados en el diseño 
e implementación de modelos interculturales en salud materna en ambos esta-
dos. ResultadOs: El 66% de las mujeres eran indígenas. 80% de los costos se con-
centraron en consultas y hospitalización. El costo promedio por este concepto fue 
de $4188 (modelo convencional) y $4002 (modelo intercultural). Se identificaron dos 
principales modelos interculturales: el parto vertical y la vinculación entre parteras 
tradicionales y prestadores de servicios. Existen divergencias entre las expectativas 
de las usuarias y sus familiares y los actores involucrados en el diseño e implemen-
tación de las intervenciones interculturales y escasa conciencia entre prestadores 
de servicios y tomadores de decisiones sobre la complejidad del significado de la 
atención intercultural en salud materna. cOnclusiOnes: Incorporar elementos 
interculturales en la atención al parto vaginal, no añade costos adicionales al sec-
tor salud, mientras sí puede asociarse con mayor aceptación de las usuarias. Se 
requiere una mayor coordinación entre los actores, para la implementación efectiva 
de intervenciones interculturales, en apoyo a las estrategias de reducción de la 
mortalidad materna.
INFECTION – Clinical Outcomes Studies
PIN1
DyNAMIC MODELINg OF vECTOR-BORNE DISEASES (vBD): THE ExAMPLE OF 
MALARIA
Snedecor S.J.
Pharmerit International, Bethesda, MD, USA
backgROund: VBD, such as Chagas disease, dengue, or malaria, are transmitted 
from to humans by insects or other organisms and can be difficult to control. VBD 
transmission involves a combination of interactions among multiple factors includ-
ing animal hosts, vectors, and humans. Dynamic modeling methodologies used 
to describe infectious disease transmission processes are amenable to a situation 
when infection and interaction of ≥ 1 species, as is the case of VBD. This work dem-
onstrates the use of such methodology for the example of malaria. MethOds: A 
dynamic, compartmental model was developed to simulate malarial disease trans-
mission among the human and mosquito populations. The model consists of a mos-
quito population divided into susceptible, exposed but not infectious, and infectious 
and a human population including susceptible, exposed but not infectious, infec-
tious but immune and infectious susceptible individuals. Parameters include human 
and mosquito birth rates and life expectancies, probabilities of disease transmis-
sion between humans and mosquitoes, and number of mosquito blood meals per 
day. The effect of anti-malarial treatment was modeled to assess epidemiologic 
outcomes under various scenarios. The model was solved analytically to determine 
the expected number of cases per person per year under each scenario. Results: 
When transmission intensity is low, treatment of infected individuals with a therapy 
providing a subsequent 15-day period of immunity reduces the incidence of disease 
from 0.481 with no treatment to 0.475 cases per person per year (pppy). In moderate 
and very high transmission settings the incidence of disease is reduced from 2.385 
to 2.171 cases pppy and 9.899 to 7.007 cases pppy, respectively. cOnclusiOns: This 
model demonstrates the utility of dynamic modeling methodology to examine the 
spread of VBD. Several model parameters may be varied to assess the epidemiologic 
impact of a number of treatments and vector control mechanisms. These models 
may be expanded for cost-effectiveness analysis.
PIN2
ALTERNATIvE HIgH LEvEL DISINFECTANTS TO PROCESSINg FLExIBLE 
ENDOSCOPES
Passeri L.A., Psaltikidis E.M., Leichsenring M.L., Nakamura M.H.Y., Burstoff J.M.
Unicamp, Campinas, Brazil
Objectives: Endoscopy is fundamental in different medical specialties, with 
increasing use. Endoscopes are expensive equipment, complex, thermo sensi-
tive, delicate materials and submitted to high-level disinfection (HLD). The most 
commonly used disinfectant is glutaraldehyde (GLU) due to its high compatibility 
with the materials and low cost. However, evidence of toxicity to professionals 
and the identification of mycobacteria tolerant to GLU caused changes in Brazilian 
legislation on the issue, pressing health services to search for alternative desin-
fectants. Search for evidence on the effectiveness, toxicity and potential damage 
to endoscopes by alternative disinfectants to GLU available in the Brazilian mar-
ket. MethOds: The study sample was semi-critical endoscopes flexible (digestive, 
respiratory and cystoscope), the intervention was HLD with peracetic acid (PA), 
Ortho-Phthalaldehyde (OP) and Electrolyzed Acid Water (EAW), compared to GLU, 
with outcomes HLD effectiveness, toxicity and damage to equipment. Results: 
Were identified 822 publications (2008-2013) on 13 databases, 23 studies were 
selected considering the best quality of available evidence. As for effectiveness, 
the findings draw attention to the intrinsic resistance of subclass Coccidia spp to 
all evaluated disinfectants and acquired tolerance by GLU strain of Mycobacterium 
massilienses which caused an outbreak of infection with more than 2000 cases 
in Brazil. About toxicity, the most frequently reported adverse events are coli-
tis (no definitive causal relationship with the germicide used) and anaphylactic 
reactions by OP in cystoscopy. There is lack of published data on damage caused 
in endoscopes by the disinfectants; the few studies on the theme indicate the 
importance of adequate handling of equipment for conservation of its functional-
ity. cOnclusiOns: The publications show superiority of the PA and OP for effi-
cacy in HLD. Only the OP clearly had adverse event related to their use. There is 
insufficient evidence in literature to assert the inferiority of some disinfectant 
for damage to equipment.
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virological response. DRV in first line position save costs and improves VR versus 
ATV in first line position.
PIN9
COSTO EFECTIvIDAD DEL ANTIBIóTICO ORAL vS. LOCAL EN MUjERES NO 
gESTANTES CON FLUjO vAgINAL SUgESTIvO DE vAgINOSIS BACTERIANA EN 
COLOMBIA
Diaz J.A.1, Garcia-Molina M.2, Chicaiza L.2, Moreno Calderon J.A.2, Prieto Martinez V.2,  
Gaitán H.3, Ruiz A.I.3, Rodríguez A.3, Rincón C.J.2, Urrego J.2
1Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia, 2Facultad de Ciencias 
Económicas, Universidad Nacional de Colombia, Bogotá, Colombia, 3Facultad de Medicina, 
Universidad Nacional de Colombia, Bogotá, Colombia
ObjectivOs: Estimar la costo-efectividad del antibiótico oral vs local en mujeres 
no gestantes con flujo vaginal sugestivo de vaginosis bacteriana. MetOdOlOgías: 
Se compararon cuatro combinaciones de antibióticos para primera opción y ante 
falla clínica: clindamicina vaginal y tinidazol oral dosis única; clindamicina vaginal 
y secnidazol oral dosis única; tinidazol oral dosis única y clindamicina vaginal; sec-
nidazol oral dosis única y clindamicina vaginal. Se construyó un modelo de Markov 
para representar de manera general la historia natural de la vaginosis bacteriana. El 
cambio en el tratamiento ante recurrencia sin eventos adversos se modeló como un 
caso particular mediante un árbol de decisión. La perspectiva fue la del sistema de 
salud incluyendo todos los costos directos. Todas las cifras monetarias se expresaron 
en pesos colombianos de 2010. La unidad de resultado fue la mejoría clínica. Los 
datos de efectividad, seguridad, persistencia y recurrencia se extrajeron de la litera-
tura. Se calculó la razón de costo-efectividad incremental y se realizaron análisis de 
sensibilidad univariados y probabilísticos. ResultadOs: Tanto para el caso general 
como el particular, el esquema clindamicina vaginal como primera opción y tini-
dazol oral dosis única, para tratar persistencia con eventos adversos y recurrencia 
es una estrategia dominante ya que es menos costosa y más efectiva comparado 
con los demás esquemas de tratamiento. Para 1.000 pacientes, el costo de la alter-
nativa dominante es de $16.795.411 con mejoría en 985 casos en el modelo general 
y de $23.979.230 con mejoría en 903 casos en el caso particular. cOnclusiOnes: 
Clindamicina vaginal como primera opción para el tratamiento de la vaginosis bac-
teriana y tinidazol vía oral dosis única para tratar persistencia con eventos adversos 
a la clindamicina y recurrencia es costo-efectiva para Colombia. Los resultados 
fueron robustos a variaciones en los parámetros del modelo.
PIN10
ANáLISIS DE COSTO-EFECTIvIDAD DE LAS vACUNAS NEUMOCóCICAS 
CONjUgADAS 10 y 13 vALENTE PARA NIñOS EN ANTIOQUíA, COLOMBIA
Ordoñez Molina J.E., Orozco Giraldo J.J.
CES University, Medellin, Colombia
ObjectivOs: El Streptococcus pneumoniae es responsable de la enfermedad neu-
mocócica invasiva [ENI] (meningitis, bacteremia) y no invasiva (neumonía, otitis 
media aguda [OMA]). El objetivo de este análisis es estimar la costo-efectividad de 
las vacunas neumocócicas conjugadas 13-valente (PCV13) y 10-valente (PCV10), en 
una cohorte de recién nacidos en Antioquia, Colombia. MetOdOlOgías: Se desar-
rolló un árbol de decisiones. Los comparadores fueron: PCV13 y PCV10 (esquema de 
vacunación 2 + 1) contra no vacunación (NV); cobertura de vacunación del 90%. Se 
simuló una cohorte de recién nacidos en Antioquia (85.955 niños), con horizonte de 5 
años y 3% de descuento anual. El análisis se realizó desde la perspectiva del sistema 
de salud. Los valores de eficacia de las vacunas fueron tomados de la literatura. Los 
costos médicos (US$ 2013) fueron proveídos por una aseguradora nacional, para 
las vacunas fueron tomados de la OPS. Los desenlaces medidos fueron: casos de 
enfermedad evitados y muertes prevenidas por ENI, neumonía, OMA y Años de Vida 
Ganados (AVG) ResultadOs: En 5 años, PCV13 prevendría 52 muertes por infec-
ción neumocócica vs NV (PCV10 prevendría 41 muertes vs NV), evitaría 71 casos de 
ENI vs NV (PCV10 evitaría 55 casos vs NV) y generaría 3.096AVG (691AVG más que 
PCV10). Los costos médicos evitados serían de US$2.5M con PCV13 y US$1.8M con 
PCV10. PCV13 y PCV10 son alternativas costo-efectivas vs la no vacunación, con una 
razón de costo efectividad incremental de US$511.84 y US$737.64 por AVG respec-
tivamente, teniendo en cuenta un umbral de disposición a pagar de 1PIB per cápita 
por AVG (US$7,235). PCV13 fue dominante frente a PCV10 debido al menor costo 
total y mejores desenlaces. cOnclusiOnes: PCV13 es una alternativa dominante 
(costo-ahorradora) vs PCV10, como parte de un programa de vacunación masiva 
para niños de Antioquía, menores de 1 año PCV13 generaría una mayor reducción 
en la mortalidad infantil a causa de enfermedades neumocócicas.
PIN11
THE HEALTH AND ECONOMIC IMPACT OF A QUADRIvALENT HUMAN 
PAPILLOMAvIRUS vACCINE (6/11/16/18) IN COLUMBIA: A TRANSMISSION 
DyNAMIC MODEL-BASED EvALUATION
Kothari S.1, Nwankwo C.1, Pillsbury M.1, Shcheprov A.2, Posso H.3
1Merck & Co., Whitehouse Station, NJ, USA, 2Reveille Technologies Inc., Durham, NC, USA, 3Nueva 
Granada University, Bogatá, Colombia
Objectives: To estimate the potential impact of a quadrivalent human papil-
lomavirus (HPV) (6/11/16/18) vaccine for the prevention of cervical cancer, cervi-
cal intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1 and genital warts in 
Colombia. MethOds: We adapted a previously developed transmission dynamic 
model (Elbasha & Dasbach; 2010) to evaluate the health and economic consequences 
of routine vaccination of nine year old girls in a dynamic Columbian population 
over the course of 100 years. We calibrated the model to the observed data of the 
crude incidence and mortality of cervical cancer, and genital warts attributable 
to HPV 16/18 and 6/11 respectively. The model assumed 85% vaccine coverage 
rate. Results: At 50 years the model shows cumulative reduction in HPV 16/18 
related cervical cancer cases and deaths by 18.1% and 13.9% respectively, and cumu-
lative reduction in the CIN2/3 and HPV 6/11 related CIN1 cases by 46.9% and 59.9% 
correspondingly. At year 100, the vaccination reduces the annual incidence of HPV 
6/11/16/18 related cervical cancer, deaths, CIN2/3 and CIN1 cases by about 99%. At 
y US$ 1,085.7 (IC95%: 1,059.9 – 1,109.14). cOnclusiOnes: Los costos incremen-
tales, desde la perspectiva social, revelan una carga económica importante para las 
familias en el tratamiento de las secuelas de meningitis en Colombia.
PIN6
COST OF ADULTS> 50 yEARS COMMUNITy-ACQUIRED PNEUMONIA IN 
ARgENTINA
Giglio N.D.1, Micone P.2, Giorgi M.A.3, Cursio D.4, Ramirez J.5, Peyrani P.5, Cané A.2
1hospital de niños ricardo gutierrez, Buenos Aires, Argentina, 2universidad austral, Buenos Aires, 
Argentina, 3CEMIC, Buenos Aires, Argentina, 4Infectología-Hospital Municipal Chivilcoy, Chivilcoy, 
Argentina, 5Division of Infectious Diseases, University of Louisville,, Kentucky, KY, USA
Objectives: Community-acquired pneumonia (CAP) is an important cause of 
mortality and morbidity worldwide especially in adults > 50 years. The total cost 
of CAP in this population is unknown in Argentina MethOds: We constructed a 
Markov model to estimate argentinean health care services use and costs of CAP 
in 2010 adults > 50 years cohort. Data about incidence and health care utilization 
were obtained from published reports and a local database. Costs were obtained for 
the public, social security and private health care subsectors and are expressed in 
2012 US dollars Results: We estimated that CAP caused 321.321 illness episodes, 
24.710 deaths, 189.579 hospitalizations, and 642.643 outpatient visits. Direct medi-
cal costs totaled $ USD 340.961.862,9. According to epidemiological data, the public 
subsector accounted for 32%, the social security for 36.20% and the private for 
31.8%. cOnclusiOns: Based on our model the economic burden of CAP is huge 
in Argentina and it remains an important cause of morbidity, mortality as well.
PIN7
APPROACHES FOR ESTIMATINg BURDEN OF PNEUMOCOCCAL AND ROTAvIRUS 
DISEASES: CONCEPTUAL FRAMEwORk AND SySTEMATIC REvIEw
Garcia Marti S.1, Alcaraz A.2, Valanzasca P.2, Ciapponi A.3, Bardach A.2, Sinha A.4, Augustovski 
F.2
1Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 2Institute for 
Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 3Institute for Clinical 
Effectiveness and Health Policy (IECS), CABA, Buenos Aires, Argentina, 4New Jersey Medical 
School, Newark, NY, USA
Objectives: Country level estimation of disease burden promotes the understand-
ing of the problem and can help prioritize the planning and implementation of 
programs, and thus foster the better use of scarce resources. Our aim was to review 
burden of disease (BoD) estimation methods and develop a guidance for conducting 
local disease burden exercises for pneumococcal and rotavirus diseases in Latin 
America and the Caribbe (LAC). MethOds: We developed an algorithm to guide in 
a BoD study based on the availability of the different data sources and a systematic 
review of the different approaches used in the estimation of BoD pneumococcal and 
rotavirus disease studies worldwide. We followed the MOOSE guidelines for sys-
tematic reviews of observational studies, and the PRISMA statement for systematic 
reviews and meta-analyses. We searched studies published between January 1995 to 
September 2010 without language restriction on MEDLINE, EMBASE, LILACS, generic 
and academic Internet search and meta-search engines. Results: The algorithm 
developed include five approaches: based on end results; based on the end and 
intermediate results (using health services); based on incidence and end results; 
partial approach; and based on incidence. The systematic review retrieves 1728 
articles. After pair assessment, we include 92 in title/abstract phase and finally 35 
in full text phase for extraction. Single or multiple approaches based on incidence 
were the most used (57%), based on intermediate results are in the second place 
(53%) and based on final results are the least used (43%). 48% of the based on final 
results studies/substudies, 46% of those based on intermediate results, and 36% 
of those based on incidence were considered to be representative for the jurisdic-
tion of interest. cOnclusiOns: The present work describes a taxonomy of BoD 
estimation and provides guidance for LAC and other LMIC countries according to 
local data availability.
PIN8
A COST-CONSEQUENCE ANALySIS OF DIFFERENT PROTEASE INHIBITORS 
SCHEMES FOR HIv TREATMENT FROM THE COLOMBIAN HEALTH CARE SySTEM 
PERSPECTIvE
Rueda J.D.1, Ariza J.G.2
1Pontificia Universidad Javeriana, Bogotá, Colombia, 2Janssen Cilag, Bogotá, Colombia
Objectives: First-line antiretroviral therapy selection provides the greatest 
opportunity to fully suppress HIV replication and prevent the emergence of drug-
resistant strains that lead to treatment failure and compromise future drug treat-
ment strategies. Currently, two alternative protease inhibitors PIs, lopinavir (LPV) 
and atazanavir (ATV), are included in the Colombian national formulary for the 
treatment of HIV patients. Darunavir (DRV) boosted with low-dose ritonavir has 
demonstrated to be an efficacious PI alternative for treatment of experienced and 
naïve patients. The objective of this study is to compare costs and benefits among 
different PI sequential algorithms of DRV, ATV and LPV from the Colombian Health 
Care System. MethOds: A decision tree was designed using the insurer perspec-
tive to estimate costs and benefits throughout a three years time horizon. Clinical 
data were obtained from the pivotal trials in order to model second line and rescue 
progression and benefits were measured as probability of virological response (VR). 
Only direct costs were considered, such as medications (first line, second line and 
rescue medications), laboratory tests and rescue related inpatient care costs using 
national tariffs and prices from Ministry of Health medication database. Four PI 
schemes were assessed: 1) DRV followed by ATV, 2) ATV followed by DRV, 3) LPV 
followed by ATZ and 4) LPV followed by DRV. Discount rate 3% and exchange rate (1 
USD = 1,794 COP). Results: Direct costs (USD): DRV-ATV (29,747), ATV-DRV (30,191), 
LPV-ATV (24,507) and LPV-DRV (24,157). VR: DRV-ATV (51%), ATV-DRV (49%), LPV-ATV 
(43%) and LPV-DRV (43%). Cost per VR (USD / VR): DRV-ATV (58,327), ATV-DRV (61,614), 
LPV-ATV (56,993) and LPV-DRV (56,179). cOnclusiOns: Using DRV after LPV as a 
first line agent is the sequencing strategy which demonstrates the better cost per 
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V. Ante falla de tratamiento con D se rotó a V o linezolid y en el caso de V se rotó a D o 
linezolid. La media estimada de días de tratamiento fue de 24.4, y la de días de inter-
nación de 13, con 11.8% promedio de ingreso a UTI. Se estimó el tratamiento con dos 
ampollas/día de D y 4 de V. Los C por estrato (V vs D) fueron: E1= 31.112$ vs 10.655$; 
E2= 817$ vs 81,4$; y E3= 23.292$ vs 23.292$. La CE global por caso de B/EI tratado fue: 
V= 13.5187 $/caso y D= 70.901$/caso. cOnclusiOnes: Nuestra estimación de CE, 
indica que una estrategia basada en el uso inicial de daptomicina para el tratami-
ento de las infecciones mencionadas es más costo-efectiva que utilizar vancomicina, 
principalmente por los costos relacionados a la falla de tratamiento de vancomicina.
PIN15
COSTO-EFECTIvIDAD DEL DIAgNOSTICO ETIOLógICO CON PRUEBAS RAPIDAS 
vS. SINDROMICO EN MUjERES NO gESTANTES CON SINTOMAS DE INFECCIóN 
CERvICAL EN COLOMBIA
Diaz J.A.1, Garcia-Molina M.2, Chicaiza L.2, Moreno Calderon J.A.2, Prieto Martinez V.2,  
Gaitán H.3, Ruiz A.I.3, Rodríguez A.3, Rincón C.J.2, Urrego J.2
1Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia, 2Facultad de Ciencias 
Económicas, Universidad Nacional de Colombia, Bogotá, Colombia, 3Facultad de Medicina, 
Universidad Nacional de Colombia, Bogotá, Colombia
ObjectivOs: Estimar la costo-efectividad de la aproximación etiológica con pruebas 
rápidas en el sitio de atención vs el diagnóstico sindrómico en mujeres no gestantes con 
síntomas de infección cervical. MetOdOlOgías: Se construyó un árbol de decisión para 
determinar la razón de costo-efectividad incremental de la aproximación etiológica con 
pruebas rápidas: Acon®Plate (Neisseria-Chlamydia), Acon®Duo (Neisseria-Chlamydia) 
y Acon®Plate (Neisseria)+ QuickVue® (Chlamydia) comparadas con el diagnóstico sin-
drómico, incluyendo tratamiento con antibióticos a la paciente índice y su contacto 
sexual, según el resultado. La perspectiva fue la del sistema de salud incluyendo todos 
los costos directos. Todas las cifras monetarias se expresaron en pesos Colombianos 
de 2010. La unidad de efectividad fue la mejoría clínica. Los datos de las características 
operativas de las pruebas se extrajeron de una cohorte de mujeres sexualmente activas 
(n= 1.444). Los resultados de las alternativas diagnósticas se compararon con el patrón de 
oro (PCR). Los datos de efectividad de los tratamientos fueron tomados de la literatura. Se 
realizaron análisis de sensibilidad univariados y probabilísticos. ResultadOs: La alter-
nativa más eficaz y más costosa fue Acon®Plate + QuickVue®, seguida de Acon®Duo 
y del manejo sindrómico. Acon®Plate fue una estrategia dominada. La razón de costo- 
efectividad incremental de Acon®Plate + QuickVue® fue de $2.782.690 y la de Acon®Duo 
fue de $597.886. La sensibilidad probabilística confirmó el ordenamiento de las alternati-
vas. cOnclusiOnes: Si la disponibilidad a pagar (DAP) por un caso adicional de mejoría 
clínica es mayor que $2.782.690, Acon®Plate + QuickVue® sería la mejor alternativa en 
términos de costo-efectividad; de otro lado, si la DAP por un caso de mejoría clínica 
adicional está entre $ 597.886 y $ 2.782.690, Acon®Duo sería la alternativa costo-efectiva; 
finalmente, si la DAP por un caso de mejoría clínica adicional es menor que $ 597.886 el 
manejo sindrómico sería costo-efectivo.
PIN16
COST-EFFECTIvENESS OF TELAPREvIR IN gENOTyPE 1 CHRONIC HEPATITIS-C 
vIRUS INFECTION IN vENEzUELA
Garcia Marti S.1, Alcaraz A.1, Valanzasca P.1, Garay O.U.2, McMullen M.1, Rey Ares L.1,  
Obando C.A.3, Caporale J.1
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2IECS 
Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 3Janssen (Johnson & 
Johnson), Panama City, Panama
Objectives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + RBV (PR) 
are a new therapeutic option with higher rates of sustained virological response 
(SVR) than dual therapy (PR) alone in chronic hepatitis C. Currently, two alternatives 
of DAA, telaprevir (TVR) and boceprevir (BOC), are available in Venezuela. The aim of 
this study was to evaluate the cost-effectiveness of adding TVR to PR in treatment 
naive and previously treated patients with HCV in Venezuela compared to PR alone 
and with the addition of BOC. MethOds: A lifetime Markov model was developed 
including HCV, cirrhosis, liver transplant and death as health states. QALYs as an 
outcome measure, a health care system perspective and a 5% discount rate for 
health benefits and costs have been used. Costs are expressed in local currency. A 
review of the literature to obtain epidemiologic and resources utilization data was 
performed and when data were not available or validation was needed a Delphi 
panel with local experts was carried out. Deterministic and probabilistic sensitivity 
analysis was performed. Results: In comparison with PR, TVR avoided 174 cirrho-
sis cases and 20 deaths per 1,000 patients and shown an ICER of $70,149/QALY and 
$29,689/QALY for the naïve and for the previously treated patients respectively. TVR 
dominated BOC in naïve patients and in most of the previously treated ones (was 
less costly and more efficacious), except in the partial responders subgroup. These 
results were robust in the sensitivity analysis. cOnclusiOns: TVR dominated BOC 
and was cost-effective against WHO 3GDP criteria in comparison to double therapy 
from the national health care system perspective in Venezuela.
PIN17
PHARMACOECONOMICS OF CERvARIx vACCINES AgAINST HUMAN PAPILLOMA 
vIRUS IN THE REPUBLIC OF kAzAkHSTAN
Nurgozhin T., Gulyaev A., Yermekbayeva B., Kushugulova A., Akhmetova A., Supiev A.
Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan
Objectives: Based on the pharmacoeconomic analysis determine the feasibility of 
vaccine against HPV-associated diseases in Kazakhstan. MethOds: The number of pre-
vented cases of HPV-related diseases, disability, death, and the size of damage avoided 
due to vaccination was determined using static pharmacoeconomic MS Excel model 
which focuses on 4 types of HPV-associated diseases that are targeted by the vaccine 
“Cervarix” (ASCUS, cervical intraepithelial neoplasia of grades 1, 2, 3 and cervical cancer), 
2 outcomes of CC - disability and death. Number of CC cases expected in the cohort 
for the period of survival was determined based on the relative incidence rates (16.0 
per 100 000 female population in Kazakhstan), the cohort of 12 year old girls (122799), 
and the life expectancy in Kazakhstan (73 years). To determine the value of the case of 
50 years the model shows 99.5% and 98% reduction in the annual incidence of HPV 
6/11 related genital warts cases in females and males respectively. cOnclusiOns: 
In Colombia, a quadrivalent HPV vaccination program for 9 year old girls can signifi-
cantly reduce the incidence of cervical cancer, CIN and genital warts.
PIN12
PUBLIC HEALTH IMPACT AND COST EFFECTIvENESS OF PNEUMOCOCCAL 
vACCINATION FOR ADULTS IN PUERTO RICO
Yang H.K.1, O’Brien M.1, Chen J.2, Grabenstein J.1, Dasbach E.2
1Merck & Co, Inc., West Point, PA, USA, 2Merck & Co, Inc., North Wales, PA, USA
Objectives: In 2012, the U.S. Advisory Committee on Immunization Practices (ACIP) 
revised their 1997 adult pneumococcal vaccination recommendation for certain 
high-risk adults with immunocompromising conditions to include a sequential 
regimen of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent 
pneumococcal polysaccharide vaccine (PPSV23), while continuing routine PPSV23 
use for healthy and immunocompetent adults with comorbidities. This study aims 
to examine the public health impact of pneumococcal vaccination for adults in 
Puerto Rico (PR), and cost-effectiveness of 2012 ACIP recommendation relative to 
1997 recommendation. MethOds: A static cohort model that incorporated life-
time costs, health outcomes, and quality-adjusted life-year (QALY) losses associ-
ated with invasive pneumococcal disease (IPD) and non-bacteremic pneumococcal 
pneumonia (NBPP) was developed for a cohort of 50,000 adults 50 years of age in PR. 
Cost-effectiveness of three vaccination strategies: 2012 and 1997 ACIP recommen-
dations, and no vaccination, were evaluated using incremental cost-effectiveness 
ratios (ICERs). Public health impact of the pneumococcal vaccination strategies 
were examined by estimating net costs and burden of disease prevented by pneu-
mococcal vaccination in PR. Results: Compared to no vaccination, pneumococ-
cal vaccination with 2012 ACIP recommendation would reduce IPD cases by 4.4%, 
NBPP hospitalizations by 0.6%, NBPP outpatient visits by 0.9%, and deaths by 1.0% 
with a net cost of $1,721,533. Compared to 1997 ACIP recommendation, vaccination 
with 2012 ACIP recommendation would reduce IPD cases by 0.7%, NBPP hospitaliza-
tions by 0.1%, NBPP outpatient visits by 0.1%, and deaths by 0.2% with a net cost of 
$228,346. Cost-effectiveness analysis showed that compared to 1997 ACIP recom-
mendation, 2012 ACIP recommendation is a more economically efficient strategy 
(ICER of $14,780 per QALY gained vs. no vaccination). cOnclusiOns: Pneumococcal 
vaccination in adults would prevent a substantial portion of pneumococcal-related 
morbidity, mortality, and health care resource utilization use in PR. The 2012 ACIP 
recommendation appears to be a cost-effective vaccination policy for PR.
PIN13
EFECTO DE LA DETERMINACIóN DE LA CONCENTRACIóN CAPILAR DE 
PROTEíNA C REACTIvA EN LA TASA DE PRESCRIPCIóN DE ANTIBIóTICOS PARA 
EL TRATAMIENTO DE INFECCIóN DE víAS RESPIRATORIAS ALTAS (ANáLISIS DE 
COSTO-EFECTIvIDAD)
Mendez G.F.1, Contreras I.2, Keymur-Landeros E.3, Mejia-Arangure E.4
1Instituto Mexicano del Seguro Social, Jalapa, Mexico, 2Instituto Mexicano del Seguro Social, 
México City, Mexico, 3Instituto Mexicano del Seguro Social, Mexico, Mexico, 4HOS Health Outcomes 
Solutions S.A de C.V., Mexico, Mexico
ObjectivOs: En Infección de Vías Respiratorias Altas (IVRA) frecuentemente se pre-
scriben innecesariamente antibióticos, lo que favorece la resistencia e incrementa 
los costos. Se ha demostrado que la proteína C reactiva (PCR) -marcador de respu-
esta inflamatoria aguda-, orienta en la prescripción de antimicrobianos. El estudio 
estimó desde la perspectiva del proveedor de servicios de salud el costo-efectividad 
de contar con la determinación de PCR en una unidad de atención primaria del 
Instituto Mexicano del Seguro Social(IMSS). MetOdOlOgías: Entre febrero y junio 
de 2012, se realizó un estudio comparativo en pacientes con diagnóstico de IVRA, 
quienes fueron asignado aleatoriamente a un grupo con la determinación de PCR, 
cuyo punto de corte para apoyar el uso de antibiótico fue > 100 mg/L; o, sin la prueba. 
En ambos grupos la atención siguió el proceso habitual y los médicos tuvieron 
libertad de decisión. El seguimiento fue por 7 días. Se midió la tasa de prescripción 
de antibióticos y la satisfacción del paciente. Los costos se estimaron con los recur-
sos utilizados durante el seguimiento y se expresaron en dólares norteamericanos 
(tasa de cambio 12.65 pesos/dólar). Se realizó análisis de sensibilidad probabilís-
tico. ResultadOs: Se incluyeron 103 pacientes con PCR y 118 sin PCR. La tasa de 
prescripción de antibióticos en el grupo de PCR fue 0.33(IC95% 0.23–0.42) y sin PCR 
0.81(IC95% 0.73–0.88) p < 0.05. El grado de satisfacción con PCR fue 79%(IC95% 71% 
- 86%) y sin PCR 63% (IC95% 54% - 71%), p = 0.04. El costo promedio de atención con 
PCR fue US$52(IC95% US$48 – US$57) y sin PCR US$49(IC95% US$45 – US$54), p< 0.05. 
La utilización de PCR fue dominante en ambos casos y costo-efectivo independiente-
mente de la disposición a pagar. cOnclusiOnes: Incluir al proceso de atención de 
IVRA la determinación capilar de PCR es una alternativa costo-efectiva en el IMSS.
PIN14
ESTIMACIóN DE LA COSTO-EFECTIvADAD DEL USO DE DAPTOMICINA vS 
vANCOMICINA EN PACIENTES CON BACTERIEMIA y/O ENDOCARDITIS POR  
S. AUREUS RESISTENTE A METICILINA
Paula Micone P.M.
Universidad Austral, Buenos Aires, Argentina
ObjectivOs: Evaluar la CE del uso de D vs V para el tratamiento de B/EI por SAMR 
en Argentina. MetOdOlOgías: Se consideraron los datos de eficacia y seguridad 
de D y V en B/EI del estudio de Fowler, VG y col. (NEJM 2006; 355:653). La estrategia 
de análisis de costos (C) se tomó del estudio de CE publicado por Bhavnani SM y col. 
(CID 2009; 49:691) en 3 estratos (E): E1 C de drogas; E2 C de fallas de tratamientos 
y complicaciones; y E3 C de internación. La utilización de recursos médicos y los 
patrones de tratamiento se estimaron para los tres subsectores de salud (público, 
seguridad social, y privado) a través de la metodología de casos promedio con panel 
Delphi de expertos en infectología. Los datos de C se tomaron de una base de datos 
con prestadores de todo el país y de la base K@iros. Se adoptó la perspectiva del finan-
ciador. ResultadOs: La eficacia (curación) reportada fue de 44% para D y 32% para 
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2012 el consumo de ATB aumentó un 32% (de 7.4 a 9.8 DHD). El patrón de consumo 
total estuvo dado principalmente por las penicilinas de amplio espectro (53%, 61.1 
DHD), siendo la amoxicilina el ATB más usado (44%, 50,5 DHD). cOnclusiOnes: Las 
medidas regulatorias permitieron disminuir el consumo y los costos/DDD de ATB en 
Chile. Sin embargo, el aumento progresivo observado indica la necesidad de revisar 
la calidad en la utilización de los ATB y el cumplimiento de la regulación vigente.
MUSCULAR-SkELETAL DISORDERS – Clinical Outcomes Studies
PMS1
TREATINg PSORIATIC ARTHRITIS wITH BIOLOgICAL DISEASE MODIFyINg 
ANTIRHEUMATIC DRUgS: SySTEMATIC REvIEw AND META-ANALySIS TO 
EvALUATE EFFICACy AND SAFETy
Lemos L.L.P., Reis C.A.L., Barbosa M.M., Oliveira H., Almeida A.M., Acurcio F.A.
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Objectives: To evaluate the efficacy and safety of biological disease modifying 
antirheumatic drugs (DMARDs) adalimumab, etanercept, golimumab and infliximab 
in the treatment of psoriatic arthritis (PA) in adults. MethOds: We conducted a 
systematic review of controlled clinical trials to access the efficacy and safety of 
these agents in patients with active PsA which have or have not been treated with 
biological DMARDs before. The databases MEDLINE, EMBASE, LILACS and Central 
Cochrane where searched until February 2013 to identify articles that reported data 
on clinical improvement measurements and adverse events. Metanalysis were per-
formed using Review Manager® 5.1 and the Random Effect Model. Results: Seven 
RCTs comparing biological DMARDs with placebo where included; two comparing 
either adalimumabe, etanercept and infliximab to placebo, and one comparing goli-
mumab to placebo. After 12 weeks of treatment, adalimumabe and etanercepte were 
more effective than placebo with respect to 20% improvement from baseline in the 
American College of Rheumatology response criteria (ACR 20); Risk Ratio 3.42 ([2.08, 
5.63]; I² 38%) and 4.15 ([2.71, 6.36]; I² 0%), respectively. After 16 weeks, infliximab 
patients also achieved ACR20 in a greater rate than placebo; RR 5.71 ([3.53, 9.25]; 
I² 0%). However, results after 54 weeks of treatment showed no significant differ-
ences between infliximab and placebo; RR 0.98 ([0.82, 1.18]; I² 0%). Golimumab was 
more effective than placebo at 24 weeks; ACR20 RR 4.53 ([2.75, 7.48]). After 16 weeks 
infliximab shown a 50% reduction in the psoriasis area and severity index (PASI50) 
in a greater rate than placebo, RR 10.67 ([5.52, 20.64]; I² 1%), however, once again 54 
weeks results have shown no significant differences between infliximab and pla-
cebo, RR 0.94 ([0.80, 1.12] I² 66%). Adverse events where similar between the biological 
and placebo groups, nevertheless the placebo group showed a slightly higher rate 
of adverse events than adalimumabe; RR 0.68 ([0.50, 0.92]; I² 0%). cOnclusiOns: 
Results show clinical improvement with the use of biological DMARs in the treat-
ment of PA. Still, there is a lack of evidence to support the spread the use of these 
medicines especially in synthetic DMARD naïve patients.
MUSCULAR-SkELETAL DISORDERS – Cost Studies
PMS2
ESTIMATINg THE BUDgET IMPACT IN BRAzILIAN PUBLIC HEALTH CARE 
SySTEM OF TOCILIzUMAB REIMBURSEMENT AS A RHEUMATOID ARTHRITIS 
FIRST-LINE BIOLOgICAL THERAPy
Tsuchiya C.T., Tobaruella F.S., Ramos L.A., Buschinelli C.T., Maximo M.F.M., Gonçalves T.M.
Roche Brazil, São Paulo, Brazil
Objectives: Rheumatoid arthritis (RA) is a systemic autoimmune disease which 
affects 0.5% of the population in developing countries. In Brazilian public health care 
system (SUS) infliximab, etanercept, adalimumab, golimumab, certolizumab (anti-
TNF), abatacept (T-lymphocyte activation inhibitor) and tocilizumab (IL-6 inhibitor) 
are available as biological treatment. However, only anti-TNF therapies are indicated 
as standard of care for first-line biologic therapy. As tocilizumab is a known effective 
and cost-saving drug for this indication, the present study aims to evaluate the budget 
impact of its inclusion in public RA biologics first-line setting. MethOds: A model was 
developed in order to assess the budget impact of tocilizumab reimbursement as a 
first-line biological therapy under SUS perspective from 2014-2018. Only expenditures 
with biologics were accounted according to posology presented in Brazilian Ministry of 
Health RA Guideline considering a mean 67kg-weighted patient. Prices were obtained 
from public disclosures. Forecasts were made pursuant to government sources (IBGE, 
DataSUS) and market research-based data. Different mix scenarios based on vary-
ing growth rate of tocilizumab usage were assessed to evaluate total savings. A two-
way sensitivity analysis was conducted changing diagnosis and biologics use rates. 
Costs were reported in Brazilian currency (BRL1.00~USD0.51 Feb2013). Results: 
Annual costs per patient were BRL20,002, BRL25,625, BRL26,899, BRL18,330, BRL22,386, 
BRL15,232 and BRL27,391, for tocilizumab, etanercept, adalimumab, infliximab, abata-
cept, certolizumab and golimumab, respectively. Concerning different tocilizumab 
public usage scenarios, if it reaches 20% in 2018, savings could sum BRL143,058,554 
(-2.8%) in the analyzed period. Nonetheless by achieving a 40% usage savings 
would be even higher resulting in a potential BRL318,643,978 (-6.3%) economy in 
the same period. Sensitivity analysis showed savings ranges of: BRL101,782,493-
BRL262,029,470 (20% usage scenario) and BRL228,085,067-BRL579,597,311 (40% usage 
scenario). cOnclusiOns: The public inclusion of tocilizumab in 2014 as a RA first-line 
biologic therapy and its usage enhance would result in increasingly savings arousing 
significant impacts in public health care budget.
PMS3
AvALIAçãO DO IMPACTO ORçAMENTáRIO COM A INCORPORAçãO DE 
IMUNOBIOLógICOS EM UMA OPERADORA DE PLANOS DE SAúDE – 2012
Reis H.P.L.C., Magalhães D.D.P., Vieira J.B., Sartori D.P., Fonseca D.B., Filho A.E.A.M., Barsi U.D., 
Gontei M., Alcantara A.C.D.C., Maciel J.A.P., Alencar J.L.L.
Unimed Fortaleza, Fortaleza, Brazil
ObjetivOs: Avaliar o impacto orçamentário com a incorporação de imunobiológi-
cos endovenosos (IMB-EV) em uma Operadora de Planos de Saúde de Fortaleza 
HPV-associated diseases, medical technologies used in CC, CIN 1, CIN2, CIN3, ASCUS, 
the frequency of their use and the price for the services were determined. Results: 
Vaccination cost for cohort of girls (122,799) resulted in 23.2 million USD. The cost of pre-
vented damage is estimated 16.5 million. Additional cost - 6.7 million. Years of life saved 
- 11172. The coefficient of “cost-effectiveness” of using Cervarix vaccine was calculated 
for 598 USD for one year of life saved. The cost of prevented damage was identified to 
be 38.5 million based on the number of prevented cases of CC, CIN 1, CIN2, CIN3, ASCUS 
and the cost of each case of illness, disability, and death. cOnclusiOns: The cost of 
potential annual preventative damage/gain as a result of Cervarix vaccine application 
may reach 38.5 million USD. When comparing the annual preventative damage to the 
annual cost of vaccination for 12 year old girls in Kazakhstan, the cost of prevention was 
estimated to be 1.7 times more than the cost of one vaccine cohort.
PIN18
ANáLISE CUSTO-MINIMIzAçãO (ACM) DO CLORIDRATO DE vALgANCICLOvIR 
COMPARADO COM gANCICLOvIR NA PROFILAxIA DA INFECçãO POR CMv EM 
TRANSPLANTADOS RENAIS
Alves Carvalho L.1, Andrade A.M.1, Monteiro W.M.S.2, Maia R.C.F.2, Secoli S.R.3, Diaz M.D.M.3
1Secretaria de Saúde do Estado da Bahia - Brasil, Salvador, Brazil, 2Secretaria de Saúde do Estado 
do Ceará, FORTALEZA, Brazil, 3Universidade de São Paulo, São Paulo, Brazil
ObjetivOs: Realizar Análise Custo-Minimização (ACM) do Cloridrato de 
Valganciclovir comparado com Ganciclovir na profilaxia da infecção por CMV em 
transplantados renais. MétOdOs: Os dados acerca da eficácia semelhante dos anti-
virais foi obtido por meio de Revisão Sistemática. Foram elencadas as seguintes 
categorias de custo direto: medicamento e materiais descartáveis. Foram simulados 
três esquemas de profilaxia: Ganciclovir 1g intravenoso (IV) 3x/dia durante período 
de internação e Ganciclovir 1g VO por 3x/dia até cem dias (Esquema A); Ganciclovir 
1g IV 3x/dia durante internação seguido pelo Valganciclovir 900mg VO uma vez/
dia até cem dias (Esquema B) e Valganciclovir 900mg VO na internação e após a 
alta até completar cem dias de uso (Esquema C). Foram feitos os cálculos relativos 
aos anos de 2010 e 2011 com base no número estimado de pacientes submetidos a 
transplante de um hospital do Sistema Único de Saúde – Brasil. Os valores dos medi-
camentos foram obtidos no Banco de Preços em Saúde (BPS) do DATASUS e a lista 
de conformidade da Câmara de Regulação do Mercado de Medicamentos (CMED) da 
ANVISA. ResultadOs: Em 2010, o custo médio por paciente do esquema A foi de R$ 
18.097,79, do segundo foi de R$ 22.754,63 e do terceiro foi de R$ 21.096,00. Em 2011, 
o custo médio por paciente do primeiro esquema foi de R$ 16.393,27, do segundo 
foi de R$ 22.603,35 e o terceiro foi de R$ 22.346,00. cOnclusões: Os resultados 
demonstraram menor custo de profilaxia para CMV com Ganciclovir 1g IV, e o seg-
undo menor com Valganciclovir 900 mg VO. A administração IV do Ganciclovir versus 
a VO do valganciclovir devem ser analisadas com outros estudos, considerando-se 
também os riscos inerentes à administração e reações adversas.
PIN19
ECONOMIC EvALUATION OF TREATMENTS FOR CHRONIC HEPATITIS B
Wiens A., Venson R., Lenzi L., Correr C.J., Pontarolo R.
Universidade Federal do Paraná, Curitiba, Brazil
Objectives: To conduct a cost-utility study in the context of Brazil’s Public Health 
Care System of the drugs adefovir, entecavir, interferon alpha, pegylated interferon 
alpha, lamivudine and tenofovir for chronic hepatitis B. MethOds: For efficacy and 
safety data, a systematic review was carried out. Utility data and transition probabili-
ties between health states were searched in the literature. The Markov model was 
developed in a time horizon of 40 years with annual cycles for three groups of patients 
with chronic hepatitis B: HBeAg positive, HBeAg negative, and all patients. These strat-
egies were compared to a fourth group that received no treatment. Discount rates of 
5% were applied and sensitivity analyses were performed. Results: Tenofovir offered 
the best cost-utility ratio for the three evaluated models: U$397, U$385 and U$384 (per 
QALY, respectively for HBeAg positive, negative, and all patients). All other strategies 
were completely dominated. The sequence of cost-utility in the three models was: 
tenofovir, entecavir, lamivudine, adefovir, telbivudine, pegylated interferon alpha, and 
interferon alpha. In the sensitivity analysis, adenofovir became less cost-utility than 
telbivudine in some situations. cOnclusiOns: In this study, tenofovir presented the 
best cost-utility ratio. The results obtained in this study will be valuable in decision-
making and in the review of the clinical protocol, mainly involving the allocation of 
available resources for health care.
INFECTION – Health Care Use & Policy Studies
PIN20
EvOLUCIóN DEL CONSUMO y vENTAS DE ANTIBIóTICOS EN CHILE 1998-2012
Villagra G., Jirón M.
Universidad de Chile, Santiago, Chile
intROductiOn: Desde el año 1999 en Chile se exige la receta médica para la venta 
de antibióticos (ATB) en farmacias. Hasta el momento se desconoce el efecto a 
largo plazo de esta medida sobre el consumo y las ventas de ATB. ObjectivOs: 
Determinar los niveles y tendencias de consumo y ventas de ATB en Chile antes 
y después de implementar la venta con prescripción médica. MetOdOlOgías: 
Mediante un estudio retrospectivo de la base de datos del International Marketing 
System (IMS), se analizaron las ventas de ATB en farmacias entre 1998-2012. Las uni-
dades vendidas se transformaron en Dosis Diaria Definidas (DDD), DDD/1000 hab-
itantes/día (DHD) y costo/DDD. Las tendencias se analizaron mediante regresiones 
lineales. ResultadOs: Se observó una disminución del 17% en el consumo de 
ATB con la aplicación de las medidas regulatorias (11.8 a 9.8 DHD, en 1998 y 2012, 
respectivamente). No obstante, las quinolonas, cefalosporinas y macrólidos aumen-
taron un 298%, 31%, 27%, respectivamente, durante el periodo estudiado. La mayor 
disminución respecto al año 1998 ocurrió en el año 2002 (-38%), mientras que entre 
2002 y 2012 hubo un incremento del 34% en el consumo. El costo/DDD disminuyó 
un 15% entre 1998 y 2003 (0.71 a 0.60 USD/DDD), mientras que entre 2003 y 2012 
aumentó en un 47% llegando a 0.88 USD/DDD en 2012. Durante el periodo 2000-
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PMS6
COSTOS ASOCIADOS A EvENTOS CARDIOvASCULARES EN PACIENTES CON 
ARTRITIS REUMATOIDE AFILIADOS AL RégIMEN SUBSIDIADO EN COLOMBIA
Urrego Novoa J.R.1, Prieto Martinez V.2, López L.3
1Universidad Nacional de Colombia, Bogotá D,C., Colombia, 2Pfizer S.A.S., Bogotá DC, Colombia, 
3Pfizer S.A.S, Bogotá, Colombia
ObjectivOs: Los pacientes con Artritis Reumatoide (AR) tienen un número impor-
tante de manifestaciones extrarticulares incluyendo la enfermedad cardiovascular, 
la cual conduce del 30-50% de todas las muertes. El objetivo de este trabajo es 
estimar los costos asociados a eventos agudos (infarto al miocardio y pericardi-
tis) y crónico (falla cardíaca) de la enfermedad cardiovascular en pacientes con 
AR en Colombia. MetOdOlOgías: Este estudio se realizó desde la perspectiva 
del tercer pagador. Se identificaron los eventos generadores de costo de guías de 
atención aprobadas por el ministerio de salud, con ayuda de un experto clínico se 
construyeron los casos tipo de infarto al miocardio, pericarditis y falla cardíaca, se 
utilizó un costeo por actividades siguiendo la metodología del botton-up, para la 
valoración de procedimientos se emplearon los manuales tarifarios ISS y SOAT, los 
costos de los medicamentos se tomaron del SISMED y el costo de los dispositivos 
médicos se obtuvo de licitaciones públicas. Todas las cifras monetarias se expresan 
en pesos colombianos de 2013. La prevalencia de la AR y el riesgo de ocurrencia 
de los eventos cardiovasculares se tomaron de la literatura. Los datos de asegu-
ramiento provienen de estadísticas nacionales. ResultadOs: El costo promedio 
de atención de los eventos cardiovasculares objeto de estudio en pacientes con AR 
fueron: infarto al miocardio $ 8.518.192 (procedimientos: $ 4.364.209; medicamentos: 
$ 4.004.331; insumos: $ 149.652); pericarditis $ 2.638.233 (procedimientos: $ 2.430.875; 
medicamentos: $ 207.357); falla cardíaca $ 26.435.947 (procedimientos: $ 9.348.420; 
medicamentos: $ 17.087.526). Los costos globales de atención en pacientes con AR 
afiliados al régimen subsidiado de los eventos cardiovasculares de interés serían: 
infarto al miocardio $ 38.106.493.677; pericarditis $ 5.447.190.660; y falla cardíaca $ 
54.582.612.447. cOnclusiOnes: La enfermedad cardiovascular en pacientes con 
AR representa una carga económica de gran impacto para el régimen subsidiado 
en el sistema de salud Colombiano.
PMS7
COSTOS ASOCIADOS A NEUMONíA SEvERA y TUBERCULOSIS EN PACIENTES 
CON ARTRITIS REUMATOIDE QUE HAN RECIDO TRATAMIENTO CON TERAPIA 
BIOLOgICA ANTI-TNF
Varon F.A.1, Urrego Novoa J.R.2, Prieto Martinez V.3
1Fundación Neumológica Colombiana, Bogotá DC, Colombia, 2Universidad Nacional de Colombia, 
Bogotá D,C., Colombia, 3Pfizer S.A.S., Bogotá DC, Colombia
ObjectivOs: Los pacientes con artritis reumatoide (AR) tienen un mayor riesgo de 
padecer infecciones severas, debido a factores de mal pronóstico de la enferme-
dad que han sido identificados como predictores de infección y al tratamiento 
farmacológico con inmunosupresores. En la literatura se encuentran reportados 
como eventos adversos frecuentes respecto a infecciones, la neumonía severa y la 
tuberculosis (TBC) en pacientes que han recibido tratamiento con terapia biológica 
anti-TNF, el objetivo de este trabajo es presentar una estimación de costos médicos 
directos de dichos eventos. MetOdOlOgías: Este estudio se realizó desde la per-
spectiva del tercer pagador. Los eventos generadores de costo para neumonía severa 
se identificaron a partir de una guía de práctica clínica Colombiana y para TBC se 
empleó un protocolo de manejo avalado por el ministerio de salud. Se construyeron 
los casos tipo para cada patología con ayuda de un clínico experto y se utilizó un 
costeo por actividades siguiendo la metodología botton-up. La valoración de los 
procedimientos se realizó teniendo en cuenta los manuales tarifarios ISS y SOAT, 
los costos de los medicamentos se tomaron del SISMED y el costo de los disposi-
tivos médicos se obtuvo de licitaciones públicas. Todas las unidades monetarias 
se expresan en dólares americanos (1 US$ = 1.785 COP). ResultadOs: El costo 
promedio de atención de la neumonía en pacientes que van a la unidad de cuidado 
intensivo (50%) fue US$ 2410 (procedimientos US$ 2194; medicamentos US$ 191; 
insumos US$ 25). El costo promedio de atención de la neumonía en pacientes que 
van a hospitalización (50%) fue US$ 1854 (procedimientos US$1425; medicamentos 
US$392; insumos $ US 37). El costo de atención de TBC fue US$16,438 (procedimien-
tos US$ 299; medicamentos US$ 16,139). cOnclusiOnes: Los costos asociados a 
la atención de la neumonía severa y TBC representan un gran impacto económico 
para el sistema de salud.
PMS9
CUSTOS DAS FRATURAS OSTEOPORóTICAS NO SISTEMA PúBLICO DE SAúDE 
BRASILEIRO
Brandão C.M.R.1, Machado G.P.D.M.1, Drumond H.A.2, Alemão M.M.2, Acurcio F.D.A.1
1Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 2Fundação Hospitalar do Estado de 
Minas Gerais, Belo Horizonte, Brazil
ObjetivOs: Descrever o custo do tratamento hospitalar das fraturas de baixa ener-
gia, típicas da osteoporose, no Sistema Único de Saúde do Brasil. MétOdOs: Foi 
realizado um estudo de custos por procedimentos nas unidades do complexo de 
urgência e emergência da Fundação Hospitalar do Estado de Minas Gerais (Fhemig). 
O período de coleta dos dados foi de janeiro a maio de 2012. O estudo foi composto 
de cinco etapas seqüenciais, que englobam: i. Identificação e definição dos macro-
processos, processos e atividades relacionados às fraturas de quadril, ombros, 
punhos e vertebrais, decorrentes da osteoporose; ii. Elaboração de Mapeamento de 
Processos típicos de pacientes acometidos pela doença submetidos a tratamento 
cirúrgico; iii. Identificação dos recursos consumidos em cada atividade, como tempo 
gasto para cada atividade, materiais médico-hospitalares, órteses e próteses; iv. 
Construção da base de informações interligada com o Sistema de Gestão Hospitalar 
(SIGH – Custos ABC); e v. Realização de Painel de Especialistas para validação do 
estudo. Os valores foram descritos em dólar americano (31 de março de 2012 – taxa 
de cambio: 1 dólar = 1,82 real). ResultadOs: Os maiores custos encontrados foram 
para as fraturas vertebrais, seguido das fraturas dos quadris, ombros e punhos. 
Custos de fraturas vertebrais variaram de $10,054.57 a 20,313.73; das fraturas de 
- Brasil, no ano de 2012. MétOdOs: Foi delineado em janeiro/2012 um cenário 
sob a perspectiva da operadora e com os pacientes potenciais de utilização de 
IMB-EV em primeira linha de tratamento para (Artrite Reumatóide, Espondilite 
Anquilosante, Artrite Psoriática e Doença de Crohn) em sua maior posologia/
doses. Somente custos diretos foram considerados em Reais ($) e utilizou-se 
um paciente padrão com peso médio de 70 kg para o IMB-EV peso-depend-
ente na dose. A análise da incidência das doenças na cartela epidemiológica 
de clientes da operadora permitiu uma extrapolação para determinação do 
custo/tratamento em relação ao número de infusões em relação a cada tipo 
de IMB-EV (Infliximab, Tocilizumab, Abatacepte). Utilizou-se Brasindice 741 
para precificação dos medicamentos. ResultadOs: A partir dos dados cole-
tados foram projetados atendimentos de 50 pacientes em uso de infliximabe 
com um custo anual de R$ 5.051.886,00 e per capta de R$ 101.037,72. Em uso de 
Tocilizumab o custo anual seria de R$ 2.338.944,00 (per capta de R$ 46.778,88) e 
com Abatacepte o custo anual seria de R$ 2.997.498,00 (per capta R$59.949,96). 
Assim o total geral da incorporação com IMB-EV teve um custo projetado de R$ 
10.388.328,00. cOnclusões: A avaliação de custos com medicamentos de alto 
impacto nos orçamentos das instituições de saúde, como os imunobiológicos, nas 
operadoras tem se tornado uma importante ferramenta para um planejamento 
estratégico e sustentável financeiramente. A partir das análises e monitori-
zações, teve-se a tomada de decisão para inclusão de outros IMB subcutâneos 
como Etanercept, Golimumab e Certolizumabe, os quais podem apresentar uma 
relação custo-minimização mais favorável.
PMS4
COMPARINg COSTS PER CLINICAL REMISSION OF TOCILIzUMAB 
MONOTHERAPy vERSUS ADALIMUMAB MONOTHERAPy IN PATIENTS wITH 
RHEUMATOID ARTHRITIS: A BRAzILIAN PRIvATE PERSPECTIvE
Buschinelli C.T., Tsuchiya C.T., Maximo M.F.M., Tobaruella F.S., Gonçalves T.M.
Roche Brazil, São Paulo, Brazil
Objectives: Rheumatoid Arthritis (RA) is an autoimmune disease that causes 
chronic inflammation of the joints. Disease progression leads to a significant 
socioeconomic impact for the individual and for society. In Brazil, there are eight 
approved biologic drugs indicate to treat patients with moderate/severe RA that 
presented previous inadequate response to therapy with DMARDs, including toci-
lizumab (TCZ) and adalimumab (ADA). ADACTA trial (Gabay et al, 2012) showed 
positive results related to TCZ monotherapy for the treatment of moderate/severe 
RA in patients who presented inadequate response to methotrexate therapy or 
were MTX intolerant. This study aims to evaluate costs of TCZ monotherapy vs. 
ADA monotherapy to achieve remission after one year of treatment for adult RA, 
according to ACR70 and DAS28 outcomes. MethOds: An economic evaluation 
based on ADACTA study was performed. Drugs ex-factory prices were used to esti-
mate treatment costs. Regimen was 8 mg/kg every 4 weeks TCZ and 40 mg every 2 
weeks ADA. Costs to achieve remission in one year according to ACR70 and DAS28 
outcomes were compared. The study was conducted from a Brazilian private health 
care perspective, considering only drug costs. Costs were reported in Brazilian Reais 
(BRL1.00= USD0.51 Feb/2013). Results: Annual costs were BRL39,100.06 TCZ vs. 
BRL63,134.76 ADA. After one year of treatment, ACR70 response rates were achieved 
in 32.50% in TCZ group and 17.90% in ADA group. DAS28 remission was achieved in 
39.90% and 10.50% in TCZ and ADA group, respectively. TCZ presented better results 
in costs per clinical remission than ADA (ACR70 BRL120,307.88 vs. BRL352,708.16 
and DAS28 BRL97,995.14 vs. BRL601,283.43). cOnclusiOns: TCZ presented better 
response rates in both ACR70 and DAS28 outcomes and lower annual costs per 
clinical remission compared to ADA, suggesting that TCZ is a better single-agent 
alternative to treat moderate/severe rheumatoid arthritis in Brazilian private health 
care system.
PMS5
ANALyzINg COSTS PER CLINICAL REMISSION OF TOCILIzUMAB 
MONOTHERAPy vERSUS ADALIMUMAB MONOTHERAPy IN RHEUMATOID 
ARTHRITIS FROM A PUBLIC PERSPECTIvE IN BRAzIL
Buschinelli C.T., Maximo M.F.M., Tsuchiya C.T., Tobaruella F.S., Gonçalves T.M.
Roche Brazil, São Paulo, Brazil
Objectives: Rheumatoid Arthritis (RA) is a chronic systemic autoimmune dis-
ease which affects around 0.5% of adult population worldwide. ADACTA (Gabay 
et al, 2012) is the first study designed to compare two approved biologic drugs 
in monotherapy for the treatment of RA. The trial compared tocilizumab mono-
therapy (TCZ) vs. adalimumab monotherapy (ADA) and presented results that 
support TCZ alone as a single-agent therapy for RA patients who are either intol-
erant to methotrexate (MTX) or in whom previous MTX therapy was inadequate. 
Based on ADACTA, this study aims to compare annual costs per clinical remission 
of TCZ vs. ADA in moderate/severe adult RA treatment considering ACR70 and 
DAS28 outcomes. MethOds: Remission data of ACR70 and DAS28 outcomes were 
taken from ADACTA study. Annual costs of TCZ and ADA therapies considered 
labeled dosage and public drugs acquisition’s prices. Based on these data, costs 
per clinical remission after one year of treatment were compared. Regimen was 
8 mg/kg every 4 weeks TCZ and 40 mg every 2 weeks ADA. The average weight 
of 67 kg was assumed. A public health care system perspective was considered 
and only drug costs were evaluated. Drug acquisition prices were assessed from 
public disclosures. Costs were reported in Brazilian Reais (BRL1.00= USD0.51 
Feb/2013). Results: After one year of treatment, annual costs were BRL26,898.56 
ADA and BRL19,945.90 TCZ. Therapy with TCZ as a single-agent showed better 
response rates in both outcomes (ACR70 32.50% TCZ vs. 17.90% ADA and DAS28 
39.90% TCZ vs. 10.50% ADA). Costs per clinical remission considering ACR70 
results were BRL61,372.00 TCZ vs. BRL150,271.28 ADA. Costs per clinical remis-
sion of DAS28 were BRL49,989.72 TCZ vs. BRL256,176.76 ADA. cOnclusiOns: The 
analysis suggests that TCZ represents an effective strategy to treat moderate/
severe adult RA patients in Brazil’s public health care system and presents lower 
costs per clinical remission compared to ADA.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 6 6 5 – A 7 2 8  a717
by 2 studies and one study incorporated both. Cohort simulation of patients with 
severe AS was employed to build cost-effectiveness model by most of the stud-
ies and few used patient-level simulation. Non-steroidal anti-inflammatory drugs 
were considered as comparators in all economic models. Studies employed quality 
adjusted life years (QALY) as their unit of outcome. Euro-quality-of-life-5 dimensions 
was used as the instrument for quality weightings by most studies and health utili-
ties index-3 and general health rating scale were used by others. Bath ankylosing 
spondylitis disease activity index and Bath ankylosing spondylitis functional index 
were used as response and efficacy parameters. Costs and QALYs discounting rate 
varied from 3%-6% and 1.5%-5% respectively. Over a longer time horizon (25-40 
years), the incremental cost-effectiveness ratio per QALY varied from € 7,500-€ 56,000 
for infliximab, € 22,000-€ 32,000 for etanercept, € 23,000 for adalimumab, and € 30,000 
for golimumab. cOnclusiOns: Although biologics are considered expensive, they 
are the only approved therapy options for patients with severe AS. Even though 
existing cost-effectiveness studies have differences in their assumptions and meth-
odologies, they do provide valuable inputs towards building set of disease related 
parameters useful for economic evaluation of next generation biologic agents.
PMS13
COST-EFFECTIvENESS ANALySIS OF ETANERCEPT IN THE TREATMENT OF 
RHEUMATOID ARTHRITIS IN INSTITUTIONAL MARkET IN ECUADOR
Albuja M.F.1, Torres F.G.2, Mould J.3, Estévez C.4
1Pfizer, Quito, Ecuador, 2Makroscopio Cia. Ltda, Quito, Ecuador, 3Pfizer, New York, NY, USA, 4Pfizer 
INC, Quito, Ecuador
Objectives: Rheumatoid arthritis is an autoimmune, inflammatory and chronic 
disease associated with significant morbidity. Due its chronic and progressive nature, 
functional limitations and physical disability cause an important social and eco-
nomic impact. In Ecuador, the prevalence of AR is 0.9%; The incidence is higher in 
women (6.4:1) and the average age is 53.6 years, representing a Public Health prob-
lem. Biologic treatments represent a therapeutic alternative for patients who failed 
disease-modifying antirheumatic drugs. However, their high cost and the high risk 
of tuberculosis are the challenges for clinicians and decision makers. The aim of this 
study was to assess the cost-effectiveness of biologic alternatives in Ecuador from an 
institutional perspective. MethOds: A Markov model was developed to simulate the 
clinical course of patients treated with etanercept (25mg twice a week), adalimumab 
(40 mg every 15 days) and infliximab (3mg/kg initial and at 2nd and 6thweek, every 8 
weeks) as first-line therapies combined with Metotrexate 20 mg/kg per week after 
DMARDs failure, as well as associated costs over one-year period. Effectiveness meas-
ures were: proportion of patients achieving 70% improvement in both, tender or swol-
len joint counts following the ACR70 criteria and quality adjusted life years gained. 
Costs considered included: biologics, concomitant drugs, medical follow-up and side 
effects management. Clinical response of alternatives was extracted from published 
literature, while costs were collected from Official Ecuadorian databases. Results: 
The cost-effectiveness analysis showed the utility in QALYs gained of etanercept, 
adalimumab and infliximab is 0.79; 0,77; and 0,73 respectively, the net costs are: 
USD$ 17092.39 for Etanercept; USD$ 17,940.39 for Adalimumab and USD$32979.60 
for Infliximab. Resulting etanercept the dominant option. cOnclusiOns: The cost 
effectiveness analysis results determinate that etanercept is the most cost effective-
ness option. Due the less production of adverse events including tuberculosis, easy 
and ambulatory application and differential price for institutional market.
PMS14
EvALUACIóN DE COSTO-EFECTIvIDAD DE CERTOLIzUMAB PEgOL COMPARADO 
CON ETANERCEPT EN EL TRATAMIENTO DE ARTRITIS REUMATOIDEA EN 
COLOMBIA
Guzman R.1, Jaramillo L.F.2, Otero W.3
1Instituto de Enfermedades Autoinmunes Renato Guzman, Bogotá, Colombia, 2Clínica de Artritis 
Temprana, Cali, Colombia, 3Servimed E.U., Bucaramanga, Colombia
ObjectivOs: Los Anti TNF alfa son terapia de primera línea para el tratamiento de 
pacientes con Artritis Reumatoidea Activa (AR) con inadecuada respuesta a meto-
trexate u otros DMARs no biológicos, el objetivo del presente estudio es evaluar 
la costo efectividad de certolizumab pegol (CZP) en comparación con el anti TNF 
incluido en el listado de medicamentos del plan de salud en Colombia etaner-
cept (ETA), bajo la perspectiva del sistema de salud con un horizonte temporal de 
un año. MetOdOlOgías: Se construyó modelo basado en árbol de decisiones no 
probabilístico en Excel, la medida de efectividad fue la tasa de respuesta ACR20 
a la semana 52 la cual fue extraída de los estudios pivotales de cada una de los 
medicamentos (TEMPO y RAPID 1), se siguió la metodología para comparaciones 
indirectas de Glenny et al. en donde se ajusta por metotrexato como comparador 
común. Se incluyen costos directos, el costo anual de la terapia se estimó usando los 
valores de la Circular 04 de Noviembre de 2012 de la Comisión Nacional de Precios 
y Dispositivos Médicos y las tarifas SOAT 2012 para gastos médicos complementa-
rios. Se calculó la razón de costo efectividad promedio e incremental y se realizó 
análisis de sensibilidad con +/- 10% de los valores del caso base. ResultadOs: 
El costo anual fue estimado en 19.270USD para ETA y 25.692USD para CZP, la tasa 
de respuesta ACR 20 ajustada fue de 45% para ETA Vs 77% para CZP, la razón de 
costo efectividad fue de 42.755USD para ETA y 33.434USD para CZP y el costo por 
respondedor adicional de CZP comparado con ETA es 201 USD, las conclusiones se 
mantienen en el análisis de sensibilidad. cOnclusiOnes: En Colombia certoli-
zumab pegol resulta costo efectivo frente a etanercept en pacientes con Artritis 
Reumatoidea activa que han tenido respuesta inadecuada a DMARs no biológicos.
PMS15
ESTIMATED COST EFFECTIvENESS OF LOwER-DOSE SUBMICRON DICLOFENAC 
COMPARED wITH TRADITIONAL DICLOFENAC IN BRAzIL
Mladsi D.M.1, Ronquest N.1, Tannus G.2, Fonseca M.3, Saag K.4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Axia.Bio Consulting, São Paulo, Brazil, 
3Federal University of São Paulo / Axia.Bio Consulting, São Paulo, Brazil, 4The University of 
Alabama at Birmingham, Birmingham, AL, USA
quadris de $2,126.41 a 11,012.42. Os custos para as fraturas de ombros variaram de 
$1,355.64 a 4,436.57. E, custos das fraturas de punhos variaram de $454.75 a 3,869.94. 
O maior percentual do custo, na maioria das vezes, estava relacionado às próteses 
e ao tempo de permanência pós-cirúrgico no ambiente hospitalar. cOnclusões: 
Apesar de os maiores custos estarem relacionados às fraturas vertebrais, os des-
fechos clínicos mais relevantes da osteoporose são as fraturas de quadris, devido 
à sua elevada incidência. Fraturas osteoporóticas são, em grande parte, evitáveis, a 
partir do controle dos fatores de risco e medicação preventiva adequada.
PMS10
CUSTO-EFETIvIDADE DO TRATAMENTO PARA OSTEOPOROSE NA POS-
MENOPAUSA NO BRASIL
Brandão C.M.R.1, Machado G.P.D.M.1, Saturnino L.T.M.2, Oliveira G.L.A.D.1, Acurcio F.D.A.1
1Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 2Instituto Nacional de Cardiologia, 
Rio de Janeiro, Brazil
ObjetivOs: Realizar uma avaliação de custo-efetividade dos medicamentos dis-
poníveis para o tratamento da osteoporose na pós-menopausa, sob a perspectiva 
do Sistema Único de Saúde, do Brasil. MétOdOs: Utilizou-se um modelo de Markov 
para simular a progressão da osteoporose na pós-menopausa presumindo-se uma 
coorte hipotética de mulheres de diferentes faixas etárias (40-49 anos, 50-59 anos, 
60-69 anos, 70-79 anos e 80 ou mais) com fraturas prévias. O modelo levou em 
consideração a eficácia do tratamento nos diferentes sítios de fraturas (quadris, 
punhos, ombros e vértebras). Foram comparados o alendronato, risedronato, iban-
dronato, calcitonina, raloxifeno, calcitriol, teriparatida e denosumabe com não ofer-
ecer tratamento medicamentoso. O modelo foi utilizado para estimar os benefícios 
clínicos em termos de anos de vida ganhos e os custos associados ao tratamento 
medicamentoso. Os dados de eficácia foram baseados em revisões sistemáticas com 
metanálise; os custos do tratamento e com internações decorrentes das fraturas 
referiram-se aos custos do Sistema Único de Saúde. O tempo de seguimento foi de 
50 anos ou até a morte. Utilizou-se taxa de desconto de 5% nos custos e benefícios. 
Foram feitas análises de sensibilidade probabilística e considerando-se diferentes 
taxas de desconto. ResultadOs: As estratégias terapêuticas não foram custo-efe-
tivas na faixa etária de 40-49 anos. Aos 50-59 anos, foram custo-efetivos o alendro-
nato e denosumabe; nas faixas etárias mais avançadas (60 anos ou mais), somente 
o alendronato foi custo-efetivo. cOnclusões: As estratégias terapêuticas foram 
custo-efetivas para algumas situações. E, apesar de existirem diferentes opções tera-
pêuticas para o tratamento da osteoporose na pós-menopausa, poucas tem efeito 
em todos os sítios de ação. Nenhuma das estratégias apresentou-se cost-saving.
PMS11
ASSESSMENT OF COST-EFFECTIvENESS MODELS FOR BIOLOgICS IN THE 
MANAgEMENT OF PSORIATIC ARTHRITIS
Gokhale S.1, Jalapu A.1, Mallya U.2, Mpofu S.3
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA, 3Novartis Pharmaceuticals AG, Basel, Switzerland
Objectives: Given biological therapies in psoriatic arthritis (PsA) treatment para-
digm are expensive, cost-effectiveness evaluations can be a valuable tool in payer 
health care decision making. We sought to review the economic evidence and cost-
effectiveness of all available biologics developed for treatment of PsA. MethOds: 
We conducted a structured literature search of published and unpublished litera-
ture from year 1996 to 2012. We included modeling and other economic studies 
that assessed cost-effectiveness of biologics and excluded studies that evaluated 
therapies other than biologics. Results: A total of 9 studies involving moderate 
to severe active PsA patients were analyzed. Most of the cost-effectiveness studies 
were conducted in the UK (N= 6) using direct payer perspective. As no head-to-head 
trials between biological therapies were present, either indirect comparison with 
Bayesian technique or network meta-analyses were used to synthesize evidence. 
Treatment clinical effectiveness was measured by psoriatic arthritis response cri-
teria (PsARC) and/or psoriasis area and severity index (PASI). Functional status was 
measured by health assessment questionnaire (HAQ). Decision analytical model 
with underlying Markov modeling was considered by majority of the studies to 
build the cost-effectiveness model using cohort of patients, while few studies used 
patient level simulations. Disease-modifying anti-rheumatic drugs (DMARDs) were 
primarily considered as comparators. Time horizon varied from 10 years to lifetime. 
All studies employed quality adjusted life years (QALYs) as their measure of effec-
tiveness. Costs and QALYs discounting rate varied from 3.5 to 6% and 1.5 to 3.5% 
respectively. Incremental cost-effectiveness ratio per QALY varied from £17,000 to 
£40,000. cOnclusiOns: Although biologics are considered expensive, they improve 
patient’s quality of life in the long-run. Existing cost-effectiveness studies have 
differences in their assumptions and methodologies, and provide valuable inputs 
towards building the set of disease related parameters. Next generation of biologic 
therapies in the near future can benefit from these analyses.
PMS12
ASSESSMENT OF COST-EFFECTIvENESS MODELS FOR BIOLOgICS IN THE 
MANAgEMENT OF SEvERE ANkyLOSINg SPONDyLITIS
Gokhale S.1, Mallya U.2, Mpofu S.3
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA, 3Novartis Pharmaceuticals AG, Basel, Switzerland
Objectives: Current biologics provide effective clinical benefits to patients with 
ankylosing spondylitis (AS). We sought to review economic evidence supportive 
of cost-effective evaluation for currently available biologics developed for treat-
ment of severe AS that aid in disease management decision-making. MethOds: 
A structured literature search of published and unpublished literature from year 
1996-2012 was conducted. We included modeling and other economic studies that 
assessed cost-effectiveness of biologics and excluded studies evaluating other ther-
apies. Results: Ten studies (infliximab= 5, etanercept= 2, infliximab and etaner-
cept= 1, adalimumab= 1, golimumab= 1) were analyzed. Majority of studies (N= 7) 
were conducted from societal perspective. Health payer perspective was employed 
a718  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 6 6 5 – A 7 2 8  
PMS18
IMPACTO EN LA PRODUCTIvIDAD LABORAL DE UNA COHORTE DE PACIENTES 
CON ARTRITIS REUMATOIDE TRATADOS CON ETANERCEPT (ENBREL®) EN 
COLOMBIA
Jauregui E.1, Upegui A.2, Romero M.2, Mantilla R.1, Maldonado M.C.1, Gonzalez A.1, Dominguez 
A.1, Valero Y.1, Morales C.1, Trouchon M.C.1, Cardona C.1, Muñoz Y.1
1Riesgo de fractura S.A-CAYRE IPS, Bogotá, Colombia, 2Fundacion Salutia, Bogotá, Colombia
ObjectivOs: La Artritis Reumatoide (AR) es una enfermedad inflamatoria crónica, 
progresiva, incapacitante, asociada con altos costos. El objetivo de este estudio 
es analizar los cambios de la productividad laboral (en tiempo) y su impacto 
económico, en una cohorte de pacientes con AR tratados con Etanercept (Enbrel®) 
durante un año en el programa de gerenciamiento de la enfermedad “Evaluación 
día” en la Institución Prestadora de Salud Riesgo de Fractura S.A-CAYRE en Bogotá, 
Colombia. MetOdOlOgías: En el análisis se incluyeron pacientes con AR que ini-
ciaron tratamiento con Enbrel® entre Agosto-2009 y Enero-2011. Como criterio de 
inclusión se requirió la aplicación de una herramienta para medir productividad 
laboral: Work Productivity and Activity Impairment Questionnarie (WPAI), al menos 
en dos oportunidades: al inicio y a los 9-12 meses del tratamiento; los supuestos uti-
lizados fueron: pérdida de productividad en la misma proporción que pérdida labo-
ral, cambio del estatus laboral debido sólo a la enfermedad, productividad individual 
equivalente al PIB per cápita. Se calculó la pérdida económica utilizando como 
referencia el valor de las horas pérdidas estimadas a partir del PIB per cápita de 
Colombia. ResultadOs: Al inicio del tratamiento, 32% de los pacientes eran traba-
jadores, el ausentismo fue del 12,38% y el porcentaje de discapacidad total en el tra-
bajo (presentismo y ausentismo) fue 11,89%. A los 9-12 meses, 28% de los pacientes 
eran trabajadores, el ausentismo fue de 3,26% y la discapacidad total en el trabajo 
de 3,17%. Asumiendo que los resultados obtenidos mediante WPAI no cambian de 
manera importante en el tiempo, se estima que al utilizar Enbrel® los pacientes 
recuperan anualmente $1.086.308 (9%) del PIB per cápita/año. cOnclusiOnes: El 
uso de Enbrel® afecta de manera positiva la productividad laboral de los pacientes 
analizados. Los supuestos permiten apreciar el efecto de Enbrel® en la productivi-
dad, sin hacer referencia a las diferencias salariales entre pacientes.
MUSCULAR-SkELETAL DISORDERS – Patient-Reported Outcomes & Patient 
Preference Studies
PMS19
IMPROvEMENTS IN PHySICAL FUNCTION, HEALTH RELATED QUALITy OF 
LIFE AND wORk PRODUCTIvITy IN PATIENTS wITH RHEUMATOID ARTHRITIS 
TREATED wITH gOLIMUMAB: SUB-ANALySIS OF LATIN AMERICAN PATIENTS 
ENROLLED IN MULITCENTRE PHASE III CLINICAL TRIALS
Strusberg I.1, Pons-Estel B.A.2, Miranda P.3, Genovese M.4, Fleischmann R.M.5, Puig A.6,  
Han C.7, Hsia E.8
1Centro Reumatológico Strusberg, Córdoba, Argentina, 2Hospital Provincial de Rosario, Rosario, 
Argentina, 3Universidad de Chile and Centro de Estudios Reumatologicos, Santiago, Chile, 
4Stanford University, Palo Alto, CA, USA, 5University of Texas Southwestern Medical Center, 
Dallas, TX, USA, 6Johnson and Johnson World Headquarters, New Brunswick, NJ, USA, 7Janssen 
Global Services LLC, Malvern, PA, USA, 8Janssen R&D, Inc, Spring House, PA, USA
Objectives: To examine physical function, health-related quality of life(HRQOL) 
and work productivity in patients enrolled from Latin American countries 
(Argentina,Chile and Mexico) in Phase III clinical trials for golimumab(GLM) in rheu-
matoid arthritis(RA). MethOds: Active RA patients not previously treated with 
methotrexate(MTX)(GO-BEFORE,N= 637) or with inadequate response to MTX(GO-
FORWARD,N= 444) were randomized to SC GLM(50 or 100mg)+MTX or PBO+MTX, 
q4wks.At wk24(GO-FORWARD) or wk52(GO-BEFORE), PBO+MTX group switched 
to GLM 50mg+MTX. Physical function was assessed using HAQ(0-3). HRQOL was 
assessed using SF-36 PCS(0-100) and SF-36 MCS(0-100). Impact of disease on work 
productivity was assessed using a productivity VAS (0-10). Clinically meaningful 
improvement was defined as improvement of ≥ 0.25 point in HAQ, or ≥ 5 points in 
SF-36 PCS and MCS. Results: At baseline, both MTX naive (N= 96) and MTX experi-
enced (N= 56) RA patients enrolled in Latin American region experienced moderate 
to severe physical disability (mean HAQ score of 1.60 to 1.75) and impaired HRQOL 
(mean PCS of 30.0 to 30.3 and mean MCS of 9.4 to 42.6). The impact of RA on pro-
ductivity was severe (mean VAS score of 6.3-6.7). Patients treated with GLM (50 or 
100 mg)+MTX had significantly greater mean improvement than PBO+MTX group in 
HAQ (0.87 vs. 0.56, p= 0.01), PCS (12.44 vs. 6.93, p< 0.01) and work productivity (-3.69 
vs. -2.25, p< 0.01) at wk 24, and greater proportions of patients in GLM+MTX group 
than PBO+MTX achieved clinically meaningful improvement in HAQ (84.04% vs. 
65.45%, p= 0.01), PCS (74.47% vs. 49.09%, p< 0.01) and MCS (45.74% vs. 41.82%, p= 0.73). 
Similar results were observed in patients who were MTX naïve and experienced 
although the magnitudes of improvements were greater in MTX naïve patients 
than MTX-experienced patients. The improvements were sustained over wk52 
and 104. cOnclusiOns: MTX naïve and MTX experienced RA patients from Latin 
America treated with GLM demonstrated improved physical function, HRQOL, and 
work productivity.
PMS20
QUALIDADE DE vIDA DOS PACIENTES QUE UTILIzAM MEDICAMENTOS ANTI-
TNF PARA O TRATAMENTO DE DOENçAS REUMáTICAS NO SISTEMA úNICO DE 
SAúDE EM MINAS gERAIS, BRASIL
Oliveira Junior H.A.
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
ObjetivOs: Descrever o perfil epidemiológico e qualidade de vida dos pacientes em 
tratamento com bloqueadores do fator de necrose tumoral (TNF) no Sistema Único 
de Saúde, em Minas Gerais, Brasil. MétOdOs: Os entrevistados foram pacientes 
que receberam a primeira dispensação de anti-TNF para o tratamento de artrite 
reumatoide (AR), artrite psoriática(AP) e espondilite anquilosante(EA) nas Gerências 
Regionais de Saúde (GRS) de Belo Horizonte e Juiz de Fora, no período de agosto 
de 2011 a março de 2013. Foi utilizado formulário padronizado para investigação 
Objectives: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly pre-
scribed to treat pain and inflammation.Despite their effectiveness, concerns exist 
regarding their safety. Worldwide health authorities, including the Brazilian Society 
of Rheumatology, (Henrique da Mota et al., 2012) advise that NSAIDs should be pre-
scribed at lower doses and for shorter durations. Effectively lowering NSAID dose 
without compromising pain relief has been demonstrated in randomized controlled 
trials of an investigational NSAID, lower-dose submicron diclofenac (LDSD). The 
objective of this study was to estimate the potential reduction in risk of NSAID dose-
related adverse events (AEs), corresponding savings in health care costs, and the 
incremental cost-effectiveness of LDSD compared with conventional diclofenac (CD) 
in Brazil. MethOds: A decision-analytic cost-effectiveness model was developed 
that considered a subset of potential AEs that may be avoided by lowering NSAID 
dosage. Prediction equations estimating the relative risk of upper GI bleeding/per-
foration and major CV events, by diclofenac dosage versus non-NSAID use, were 
estimated by meta-regressions using data from systematic literature reviews. Utilities, 
lifetime costs, and health outcomes associated with AEs in Brazil were literature 
based. The model was validated with clinical experts in Brazil. Results were evaluated 
in one-way and probabilistic sensitivity analyses. Results: The model predicted 
that LDSD vs CD could reduce the occurrence of modeled gastrointestinal events (by 
18%), cardiovascular events (by 7%), and acute renal failure (by 19%), leading to a 10% 
reduction in costs of treating AEs. LDSD was predicted to be cost-effective, with a 
robust incremental cost-effectiveness ratio relatively insensitive to parameter uncer-
tainty. cOnclusiOns: LDSD has the potential to provide clinical and economic value 
to patients using NSAIDs in Brazil. Further investigation regarding the potential effect 
of LDSD on the risk of additional NSAID dose-related toxicities should be explored.
PMS16
COSTO-UTILIDAD DE COLágENA-POLIvINILPIRROLIDONA EN EL TRATAMIENTO 
DE OSTEARTROSIS DE RODILLA I-II FRENTE AL CUIDADO ESTANDAR 
ESTABLECIDO EN LOS PROTOCOLOS vIgENTES DE LAS INSTITUCIONES 
PUBLICAS EN MéxICO
Burbano-Levy X.1, Cardona D.P.2, Palacios E.3, Rico-Alba I.3, Zapata L.3
1Zilonis Health, Inc, Boca Raton, FL, USA, 2Universidad de Antioquia- Facultad De Quimica 
Farmaceutica, Medellín, Colombia, 3Guia Mark, S. A. de C. V., Mexico, DF., Mexico
ObjectivOs: Osteoartrosis es la enfermedad reumática más prevalente en México. 
El surgimiento de alternativas terapéuticas buscando un mejor pronóstico frente 
a los protocolos convencionales, requiere generar información científica para 
establecer el costo-efectividad/utilidad de las mismas. Este estudio evalúa el 
costo-utilidad de colágena-polivinilpirrolidona (colágena-PVP), producto desarrol-
lado en México, frente a las alternativas del protocolo institucional del Instituto 
Mexicano de Seguridad Social (IMSS) en el tratamiento de la osteoartrosis de rodilla 
(OAR). MetOdOlOgías: Se diseñó un modelo probabilístico de Markov para evaluar 
los costos y resultados/utilidades (QALYs) del tratamiento con colágena-PVP com-
parado con AINES en pacientes con OAR I-II. La selección del comparador se basó 
en las recomendaciones de las Guías de Práctica Clínica vigentes en México. Las 
utilidades y probabilidades se fundamentan en la evidencia disponible en la litera-
tura nacional e internacional. El horizonte temporal fue el tiempo de sobrevida de 
la cohorte (53 años) y los costos fueron obtenidos de los listados de adquisiciones 
y GRDs del IMSS y de las tarifas del diario oficial. Se aplicó una tasa de descuento 
del 5% para costos y utilidades. Se realizaron análisis de sensibilidad que con el 
modelo probabilístico estableció el efecto de la incertidumbre ResultadOs: Para 
colágena-PVP, el costo por tratamiento de OAR es de MEX$ 734,572.86. En el grupo 
AINES, el costo del tratamiento fue de MEX$ 806,584.02. El grupo con colágena-PVP 
presentó 9.88 QALYs comparado con 7.99 en el grupo AINES, con un radio costo-
utilidad mayor en este último ($100,949.19/QALY versus MEX$74,349.48/QALY en 
colágena-PVP). El costo ahorrado para obtener un QALY adicional con colágena-PVP 
(RCUI) es de MEX$ 38,101. cOnclusiOnes: Al considerar el referente de un PIB/
cápita como guía para determinar el costo-utilidad cuando no hay medidas de 
disponibilidad a pagar establecidas en un sistema de salud, colágena-PVP es una 
alternativa costo-ahorradora en el tratamiento de OAR en México.
PMS17
ESTUDIO DE COSTO/UTILIDAD DEL TRATAMIENTO HABITUAL DE LA ARTRITIS 
REUMATOIDEA MAS ETANERCEPT vERSUS TRATAMIENTO HABITUAL MáS 
OTROS BIOLógICOS DEL MERCADO CHILENO y vERSUS TRATAMIENTO 
HABITUAL SIN BIOLógICOS
Biagini L., Pezzani M., Rojas R., Hoffmeister L., Fuentes R.
Universidad Mayor, Santiago, Chile
ObjectivOs: Determinar el costo/utilidad incremental (ICER) del esquema habitual 
de tratamiento en la Artritis Reumatoide (AR) más etanercept y compararlo con 
otros esquemas de tratamiento que incluyan agentes biológicos, usando como 
base el esquema habitual sin agentes biológicos. MetOdOlOgías: Se realizó un 
estudio de costo/utilidad usando un modelo de Markov con tres estados de salud: 
AR activa, AR inactiva y Retiro. El punto de vista del estudio fue el del sistema 
público más gasto de bolsillo de los pacientes. Las utilidades fueron medidas en 
una muestra de pacientes chilenas con AR utilizando el instrumento EQ-5D y los 
costos fueron determinados de acuerdo a los costos del Sistema Público de Chile. 
El horizonte temporal del análisis fueron 75 años y se usó una tasa de descuento 
de 3%. ResultadOs: Las utilidades obtenidas fueron de 0,52±0,27 para la AR inac-
tiva (n= 46) y de 0,15±0,33 para la AR activa (n= 35). Usando el criterio del American 
College of Rheumatology de mejoría del 20% en relación a la condición basal (ACR 
20), se obtuvo, usando el tratamiento habitual como base, un ICER de $24.572.914 
(US$ 49.146) para etanercept; de $272.758.563 (US$ 551.614) para Adalimumab; 
y de $441.333.820 (US$ 932.067) para certolizumab. Rituximab, infliximab y goli-
mumab resultaron más costosos pero menos efectivos que el tratamiento habitual. 
Estos resultados no fueron sensibles ni a la variación de las utilidades, ni a 
la variación en el número de ciclos, ni a la variación de la tasa de descuento, ni a la 
variación en el criterio de mejoría (ACR20 vs. ACR50). cOnclusiOnes: Etanercept es 
el producto con el menor ICER en relación al tratamiento habitual de la AR en Chile.
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Objectives: In Rio de Janeiro, the prohibition on driving after drinking alcoholic 
beverage began on March 19th 2009. Media has reported since then a decrease 
in the number of vehicle accidents. A study on hospitalization profile and costs 
was developed from the public perspective to compare pre and post beginning 
of prohibition periods. MethOds: A public secondary database was accessed to 
evaluate three periods: pre prohibition (PRE; April 2008 to March 2009); first (FAP; 
April 2009 to March 2010) and second (SAP; April 2011 to March 2012) years after 
prohibition. For each period, number of hospitalizations, related costs and mortal-
ity rate were evaluated. Costs are presented in 2012 Brazilian Real (BRL). Filters 
for city (Rio de Janeiro), and group (external causes – transport accidents) were 
applied. No limits for procedure type, ICD-10 or patient’s age were used. Results: 
In FAP and SAP, total number of hospitalizations related to transport accidents 
showed a discrete decrease (4,485 and 4,729, respectively) when compared to 
PRE number (4,783). However, hospitalization costs showed a small increase 
in FAP (5,812,999BRL; mean cost per patient: 1,296BRL) and SAP (6,596,924BRL; 
mean cost per patient: 1,398BRL), when compared to PRE (5,677,670BRL; mean 
cost per patient: 1,187BRL). Mortality rate, as well as absolute number of deaths 
has decreased in FAP (165; rate: 3.7) and SAP (211; rate: 4.5) if compared to PRE 
(224; rate: 4.7). Surgical treatment of tibia fracture was the most impacting pro-
cedure in number of hospitalizations (294; 246; and 255 for PRE, FAP and SAP, 
respectively), and two most impacting cost disease were surgical treatment of 
politrauma (956,435BRL; 1,190,927BRL; 1,491,951BRL), and surgical treatment of 
tibia fracture (475,117BRL; 396,793BRL; 391,756BRL), for all three studied peri-
ods. cOnclusiOns: No significant impact in costs were observed after prohibi-
tion on driving after drinking alcohol. Absolute number of hospitalizations and 
mortality rate showed a discrete fall.
PMS24
ESTIMACIóN DE LA PREvALENCIA DE ARTRITIS REUMATOIDE EN MéxICO
Galindo-Suárez R.M.1, Peniche-Otero G.2, Herrera-Rojas J.2, Gryzbowski E.2,  
Muciño-Ortega E.1, Aguirre A.3
1Pfizer S.A. de C.V., Ciudad de México, Mexico, 2Customized Premium Products S.A. de C.V., 
México D.F., Mexico, 3UCB de Mexico, S.A. de C.V., Mexico, D.F., Mexico
ObjectivOs: Estimar la prevalencia de artritis reumatoide (AR) en adultos 
en México durante el año 2009. MetOdOlOgías: Se estimó la prevalencia de 
pacientes con AR en México, basada en los registros de casos nuevos (consulta 
de especialidad en segundo nivel de atención de primera vez y subsecuente) de 
la base de datos de la Secretaría de Salud (datos de 2009, clasificación CIE-10). Se 
excluyeron los casos reportados en consulta familiar ya que de acuerdo a guías 
de práctica clínica, el diagnóstico de artritis reumatoide requiere de validación 
por parte de un reumatólogo. La estructura poblacional se extrajo de fuentes 
gubernamentales oficiales. Los datos fueron analizados con el software DISMOD 
II para generar estimados consistentes de los parámetros epidemiológicos de la 
AR. ResultadOs: La prevalencia estimada de AR para el año 2009 fue de 0.8% 
de la población adulta, equivalente a 879,776 personas. La prevalencia estimada 
por género fue de 0.7% en hombres y de 0.9% en mujeres. De acuerdo a la edad, la 
prevalencia se acentúa después de los 45 años. Según el grado de discapacidad 10% 
de los casos se consideraron como enfermedad severa, 60% AR moderada y 30% 
AR leve. El 97% de los pacientes recibió atención médica institucional: 49% dere-
chohabientes de empresas privadas, 36% del Seguro Popular, 9% trabajadores del 
gobierno federal, 2% trabajadores petroleros y fuerzas armadas y 1% trabajadores 
de gobiernos estatales. cOnclusiOnes: La prevalencia estimada para México es 
consistente con lo reportado a nivel internacional. El número estimado de casos 
por sexo, edad y severidad pueden emplearse como base para diseñar políticas 
específicas, así como gestionar estrategias de atención y realizar la planificación 
de los recursos necesarios para atender a esta población.
PMS25
UNMET NEEDS AND BIOLOgIC USE AMONg PATIENTS wITH RHEUMATOID 
ARTHRITIS IN BRAzIL
de Renteria J.1, DiBonaventura M.2, Suponcic S.2, Pomerantz D.2
1Kantar Health, Munich, Germany, 2Kantar Health, New York, NY, USA
Objectives: Despite their availability, it is unclear the extent to which biologic 
treatments are being used in Brazil. The current study assessed the unmet needs 
of patients with rheumatoid arthritis (RA) in Brazil and the degree to which bio-
logic treatments are currently used. MethOds: Data were obtained from the 
Brazil 2011 and 2012 National Health and Wellness Surveys (NHWS; N= 24,000). 
The Brazil NHWS is a self-reported nationally representative patient survey of 
the adult population (aged 18+), weighted to correct for any socioeconomic sam-
pling bias. Respondents in NHWS who reported a diagnosis of RA (n= 137) were 
examined with respect to their sociodemographics, current treatments, health 
outcomes (e.g., Short Form 12v2), and biologic-related attitudes. Differences in 
health outcomes as a function of severity were examined using general linear 
models. Results: Patients with RA were mostly female (59.12%) and had a mean 
age of (43.76 years). 36.50%, 43.07%, and 20.44% of patients were mild, moderate, 
and severe, respectively. Mean levels of physical health status decreased as sever-
ity increased (Mild= 45.12; Moderate= 41.50; Severe= 38.49, p< .05). All severity levels 
were significantly lower than the population norm of 50 (ps< .05). Similar effects 
were observed for other health outcomes. Despite these unmet needs, only 60.92% 
of moderate-to-severe patients were currently being treated with a prescription 
medication and only 6.90% were using biologic therapy. Post-hoc analyses exam-
ined potential reasons for low biologic uptake among moderate-to-severe patients 
including significantly poorer access (20.27% of RA patients vs. 27.74% of non-RA 
patients had monthly household incomes above R$10,000) and attitudinal factors 
(29.33% reported a fear/strong fear of needles). cOnclusiOns: Our analyses sug-
gest significant decrements in health outcomes among patients with RA in Brazil 
and poor uptake in biologic therapies. Although future research would need to 
more directly test our hypotheses, preliminary analyses suggest that poor access 
and attitudinal factors may play a role.
sobre os medicamentos e reações adversas, comorbidades, atividade das condições 
reumatológicas e avaliação da qualidade de vida. Para avaliação da qualidade de 
vida foi utilizado o HAQ (Health Assessment Questionary), e o EuroQol 5-D (EQ-5D) 
um instrumento genérico de medida de qualidade de vida. ResultadOs: Foram 
entrevistados 204 pacientes ao todo. Desses, 70,2% tinham diagnóstico de AR, 11,7% 
AP e 18% EA. Aproximadamente 74,8% eram do sexo feminino. A média de idade foi 
de 50,71 anos (DP 13,52). O tempo médio com diagnóstico da doença foi de 119,56 
meses (DP= 102,54). A maioria, 67,8%, utilizou adalimumabe, 25% etanercept e 7,2% 
Infliximabe. O valor médio do EQ-5D foi de 0,6247 (DP= 0,178) no total dos pacientes. 
Para os pacientes com AR a média do EQ-5D foi 0,6238 (DP= 0,179), para EA 0,6579 
(DP= 0,178) e para AP 0,5790 (DP= 0,169). cOnclusões: população predominante-
mente do sexo feminino e com uma média de idade de cerca de 51 anos. No geral, 
o score do EQ-5D foi considerado moderado e, dentre as doenças, a que apresentou 
score menor foi a AP.
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DESCRIPCIóN DE UNA COHORTE DE PACIENTES CON ARTRITIS REUMATOIDE 
TRATADOS CON ETANERCEPT (ENBREL®) DENTRO DE UN PROgRAMA DE 
ATENCIóN EN UN CENTRO ESPECIALIzADO EN COLOMBIA
Jauregui E.1, Sanchez O.2, Romero M.2, Mantilla R.1, Maldonado M.C.1, Gonzalez A.1, 
Dominguez A.1, Valero Y.1, Morales C.1, Trouchon M.C.1, Cardona C.1, Muñoz Y.1
1Riesgo de fractura S.A-CAYRE IPS, Bogotá, Colombia, 2Fundacion Salutia, Bogotá, Colombia
ObjectivOs: La Artritis Reumatoide (AR) es una enfermedad articular inflamatoria 
que afecta al 0,5-1,0% de la población adulta mundial. El objetivo de este estudio es 
realizar un análisis descriptivo de la actividad de la enfermedad (DAS28), calidad 
de vida (HAQ – Health Assessment Questionnaire) y depresión (escala de Zung), 
tras un año de seguimiento del programa de gerenciamiento de la enfermedad 
“Evaluación día” para pacientes con AR que iniciaron tratamiento con Etanercept 
(EnbrelÒ) en la Institución Prestadora de Salud Riesgo de fractura S.A-CAYRE en 
Bogotá, Colombia. MetOdOlOgías: En el programa se incluyeron 91 pacientes 
colombianos con AR que iniciaron tratamiento con Enbrel®, tuvieron 4 visitas de 
seguimiento durante un año; como parte del manejo integral de la enfermedad 
se incluyeron paraclínicos, evaluación por reumatólogo, psicólogo, terapeutas y 
clinimetría (DAS28, HAQ y Zung entre otras). Un total de 52 pacientes (57,14%) cum-
plieron criterios de inclusión para el análisis, con una edad promedio de 53,5 años 
y evolución promedio de la enfermedad de 12,2 años. ResultadOs: Al año, 25% de 
los pacientes alcanzó el porcentaje de remisión DAS28 con una reducción de 52,9% 
en alta actividad entre la visita de ingreso y la última visita; 19 pacientes (37,5%) 
presentaron una reducción > 1,2 del DAS28 respecto al inicio del tratamiento. El 
HAQ inicial promedio fue 1,07 y mejoró al disminuir a 0,96 en el último control. Al 
inicio 33,3% de los pacientes tenían algún grado de depresión mayor (Zung) y al año 
de la observación disminuyó a 21,9%. cOnclusiOnes: Los resultados obtenidos 
nos permiten inferir que Enbrel® afecta de manera positiva la evolución de AR 
en un programa de gerenciamiento de la enfermedad. Es importante contar con 
la descripción de programas de gerenciamiento de la enfermedad, con el fin de 
tener data propia de AR en Colombia y brindar el manejo integral que requieren 
las enfermedades crónicas.
PMS22
BARRIERS OF ACCESS TO ELECTIvE ORTHOPEDIC PROCEDURES IN RIO DE 
jANEIRO, BRAzIL
Fernandes R.A.1, Takemoto M.L.S.2, Sauberman M.V.3, Amaral L.M.1, Vasconcellos J.F.2,  
Haas L.C.2, Silva M.A.2, Takemoto M.M.S.1
1ANOVA, Rio de Janeiro, Brazil, 2ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 
3Hospital Municipal Lourenço Jorge, Rio de Janeiro, Rio de Janeiro, Brazil
Objectives: Currently, in Rio de Janeiro state, barriers to patient care who require 
elective surgical procedures in orthopedics are found, thus many patients remain 
long periods on hold until the attendance. This study aims to analyze the frequency 
of hospitalization procedures (HP), total inhospital cost (IC), and total number of 
inhospital days (ID) related to orthopedic elective procedures in Rio de Janeiro 
state, Brazil, from the public perspective in order to identify potential barriers 
of access. MethOds: Orthopedic procedures that require hospitalization were 
selected from the public official hospital information system, for the year 2011. 
These procedures were separated into elective or urgent according to treatment 
indication, and validated by an expert panel. Costs are expressed in 2012 Brazilian 
Real (BRL). A public secondary database was accessed to evaluate HP, IC, and ID 
separated by cities. Results: Rio de Janeiro state is composed by 92 municipalities. 
Total population consists of 15,989,929 inhabitants, and 6,320,446 (39.53%) live in the 
capital (Rio de Janeiro city). In 2011, 18,564 elective HP were performed, with a total 
IC of 21,977,085 BRL, and 145,295 ID. Data from the capital show 10,724 elective HP, 
total IC of 14,399,281 BRL, and 98,458 ID, which represent 57.77%, 65.52%, and 67.76% 
of the state, respectively. When only urgency procedures were analyzed, these rates 
fell to 43.73%, 46.46%, and 49.35%, respectively. cOnclusiOns: Hospitalizations for 
elective orthopedic procedures in Rio de Janeiro state do not present homogeneous 
distribution among municipalities. The capital houses less than 40% of total popu-
lation and accounts for more than 65% of costs and inhospital days. Data suggest 
that municipalities are able to absorb urgency occurrences, but not elective ones, 
creating difficulties for the treatment of patients in need of elective procedures. 
Decentralization of care may be able to reduce such barriers.
PMS23
DRIvINg AFTER DRINkINg: HOSPITALIzATION, MORTALITy RATE, AND COSTS 
PRE AND POST PROHIBITION IN RIO DE jANEIRO, BRAzIL
Fernandes R.A.1, Takemoto M.L.S.1, Sauberman M.V.2, Amaral L.M.1, Silva M.A.1,  
Vasconcellos J.F.1, Haas L.C.1, Takemoto M.M.S.1
1ANOVA, Rio de Janeiro, Brazil, 2Hospital Municipal Lourenço Jorge, Rio de Janeiro, Rio de Janeiro, 
Brazil
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Brazilian patients eligible for Relapsing-Remitting Multiple Sclerosis (RRMS) treat-
ment was estimated to be around 7,098, 2,397 and 498 patients (1st, 2nd and 3rd line 
treatment, respectively) in the first year. Compared to the current scenario, the 
inclusion of natalizumab in the reimbursement protocol for 2nd line shows an addi-
tional budget through the 5 years consecutively as: 124.9K, 365.7K, 652.3K, 912.8K 
and 1.0M (USD). It is expected that during the 5-year analysis, the inclusion of natali-
zumab as 2nd line will increase the budget for MS by 4% with average cost per MS 
patient of USD50.60 (USD13.061 vs USD13.112 per patient/year). cOnclusiOns: The 
estimated budget impact to include natalizumab as a 2nd line treatment option was 
USD3.1M in five years (increment of 4.0% of the current budget) for MS treatment.
PND4
ANáLISIS DE COSTO-EFECTIvIDAD DE DOS FORMULACIONES DE TOxINA 
BOTULíNICA TIPO A (TBA) EN COLOMBIA PARA EL TRATAMIENTO DE LA 
PARáLISIS CEREBRAL INFANTIL (PCI)
Serizawa E.1, Galeano C.2
1Instituto Nacional de Rehabilitacion Servicio de Fisiatria “J.J. Arvelo” adscrito al Ministerio para 
el Poder Popular para la Salud (INR-MPPS), Caracas, Venezuela, 2BIOPAS Laboratoires, Bogotá, 
Colombia
ObjectivOs: La incidencia de PCI es de 1.5 a 5/1000 nacidos vivos, esta representa 
la mayor causa de discapacidad infantil con un alto impacto en salud pública y la 
TBA hace parte del tratamiento integral. Los objectivos de este estudio son de com-
parar la costo-efectividad e impacto presupuestal del tratamiento con TBA Dysport 
500U y Botox 100U en pacientes pediátricos con PCI, bajo la perspectiva del sistema 
de salud colombiano en un horizonte temporal de un año. MetOdOlOgías: Para 
valorar la efectividad y seguridad se realizó revisión sistemática de la literatura; 
para la estimación de costos se utilizó la metodología de caso tipo, validado por 
tres fisiatras. Se estimó el costo de tratamiento anual basados en la “Circular 04 de 
Noviembre de 2012 de la Comisión Nacional de Precios”. El análisis de sensibilidad 
incluye una variación entre el 25% y 30% de las dosis y escenarios sin optimización 
de unidades. Se calculó y comparó el costo promedio de tratar un paciente con PCI 
durante 1 año y el impacto presupuestal en una cohorte 1000 pacientes con cada 
medicamento. ResultadOs: Las dos alternativas son equivalentes en términos de 
respuesta clínica y seguridad de acuerdo a lo encontrado en la evidencia científica. 
El costo promedio de tratamiento por paciente con TBA 500U es USD 2592 vs USD 
3888 con TBA 100U, lo que representa un ahorro anual del 33% con el uso de TBA 
500U. Si se considera una cohorte de 1000 pacientes, la elección de tratar PCI con 
TBA 500 proyecta un ahorro de USD 1,296,000 para el sistema de salud colombiano. 
En el 83% los escenarios del análisis de sensibilidad el uso de TBA 500U se man-
tuvo costo-ahorrativa. cOnclusiOnes: Desde la perspectiva del sistema de salud 
Colombiano el tratamiento de la PCI con TBA 500U resulta costo-ahorrativo vs el 
tratamiento con TBA 100U.
PND5
ANáLISIS DE COSTOS MEDIANTE UN MODELO LINEAL gENERALIzADO DE 
PACIENTES MExICANOS CON SINDROME DE wEST
Pizarro M.1, Soto H.2, Bastida-Mercado E.1, Salazar A.3
1Hospital Infantil de Mexico Federico Gomez, México D.F., Mexico, 2Health Solutions Consulting,  
D. F., Mexico, 3Iteliness Consulting, D. F., Mexico
ObjectivOs: Realizar un análisis de costos del Síndrome de West (SW) mediante 
un modelo lineal generalizado desde la perspectiva institucional del Sector Salud 
de México. MetOdOlOgías: Se identificaron los costos médicos directos de la 
atención de pacientes con SW (CIE-10 G40X) en el período comprendido entre 2000 
y 2010, en el Hospital Infantil de México Federico Gómez (HIMFG). Los costos de 
recursos se obtuvieron del tabulador de cuotas de recuperación del HIMFG ajustados 
por el índice de precio del Sector Salud al 2011, los costos se reportan en MxP.Se 
realizó un modelo lineal generalizado para conocer la distribución de los valores de 
cada concepto evaluado y con estos resultados se realizó un análisis de sensibilidad 
Bootstrap para observar el comportamiento en los costos y la variabilidad de los 
mismos, además de una simulación de Monte Carlo con los intervalos de confianza 
generados. ResultadOs: Se revisaron 86 expedientes de pacientes con SW, 60,7% 
de sexo masculino, la edad de inicio de los espasmos fue en promedio 4.9 meses, 
el tiempo promedio de seguimiento de los pacientes fue de 2.67 años. El costo total 
promedio del seguimiento fue de $45.425,73 correspondiendo el 73,79% del gasto a 
uso de fármacos antiepilépticos, 24,39% a estudios de extensión y el 2,2% restante 
a atención ambulatoria, hospitalizaciones y consulta de urgencias. En relación al 
tiempo de seguimiento, el medicamento con mayor costo durante el seguimiento fue 
la vigabatrina (media $21.924,24, rango $1.051,27 - $101.347,70), seguida del valproato 
de magnesio (media $6.914,75, rango $50,41 - $108.176,50). El análisis de sensibilidad 
realizado mostró que el modelo de costos es robusto y eficaz. cOnclusiOnes: La 
mayor proporción del coste de tratamiento en pacientes con SW correspondió al 
tratamiento antiepiléptico, lo que coincide con otros reportes de la literatura en 
relación al costo generado por el tratamiento farmacológico en pacientes epilép-
ticos.
PND6
BURDEN OF MULTIPLE SCLEROSIS AND UNMET NEEDS IN BRAzIL: COST OF 
ILLNESS STUDy
Silva N.L.1, Takemoto M.2, Damasceno B.3, Fragoso Y.D.4, Finkelsztejn A.5, Gomes M.1
1Novartis Biociências S.A., São Paulo, Brazil, 2ANOVA - Knowledge Translation, Rio de 
Janeiro, Brazil, 3UNICAMP - Hospital de Clínicas, Campinas, Brazil, 4UNIMES - Universidade 
Metropolitana de Santos, Santos, Brazil, 5Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Objectives: To assess both direct medical and non-medical costs of Brazilian mul-
tiple sclerosis (MS) patients. MethOds: This was a cross-sectional, multicenter 
study conducted in 8 Brazilian major MS treatment sites. Costs due to MS treat-
ment were calculated based on the resource utilization related to inpatient days, 
outpatient visits, laboratory and imaging tests, disease modifying therapies (DMTs), 
co-medication, OTC medications, aids and/or home modifications, and professional 
caregiver. Unit costs derived from Brazilian official price lists were applied to the 
NEUROLOgICAL DISORDERS – Clinical Outcomes Studies
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MIxED TREATMENT COMPARISON OF ADvERSE EvENTS FOR Bg-12, 
gLATIRAMER, AND TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSINg 
FORMS OF MULTIPLE SCLEROSIS
Zagmutt F.J.1, Carroll C.A.2
1EpiX Analytics, Boulder, CO, USA, 2Teva Pharmaceuticals, Kansas City, MO, USA
Objectives: Clinical trials of two new oral treatments (Teriflunomide and BG-12) 
for relapsing-remitting multiple sclerosis (RRMS) have been recently published. As 
efficacy is similar between these products and glatiramer, a comparison of their 
relative safety is relevant to physicians, patients, and providers. Our objective was to 
conduct a mixed treatment comparison of adverse event (AEs) in placebo-controlled 
randomized clinical trials of BG-12 240mg BID and TID, Glatiramer 20mg SID, and 
Teriflunomide 7mg and 14 mg SID in RRMS. MethOds: Articles were selected and 
reviewed following Cochrane guidelines. Placebo-controlled phase III RRMS clinical 
trials were eligible for inclusion. Data collected were the total number of patients 
experiencing at least one AE. The odds ratio (OR) of AEs, Credible Interval (CrI), and 
confidence in OR > 1 for all drug pairs were estimated using a Bayesian random 
effects network meta-analysis with placebo as baseline comparator, and multi-
arm adjustment. The mean rank (1-5) and probability of ranking lowest (PrL) of 
all treatments were calculated. The Surface Under Cumulative Ranking (SUCRA) 
summarized overall strength of evidence of the ranking of each treatment (best 
100%, worst 0%). Results: A total of 384 studies were identified and reviewed, and 
3 studies (3737 patients) were included for analysis. Preliminary results are reported. 
Glatiramer exhibited the lowest AEs of all treatments (OR > 1 for all comparisons 
with ≥ 90% confidence), except for borderline non-significantly lower AEs vs. placebo 
(OR= .73;95%CrI= .18-1.98;PL= 89.6%). Patients receiving glatiramer had the lowest AEs 
(rank= 1.4,PrL= 80.3%,SUCRA= 91.7%), followed by placebo (rank= 2.9,PrL= 4.2%,SUCR
A= 62.6%), BG-12 240mg TID (rank= 3.2,PrL= 4.8%,SUCRA= 56.8%), Teriflunomide 7mg 
(rank= 4.2,PrL= 5.5%,SUCRA= 35.3%), BG-12 240mg BID (rank= 4.7,PrL= 1.2%,SUCRA= 
26.9%), and Teriflunomide 14mg (rank= 4.7,PrL= 4.0%,SUCRA= 26.7%). cOnclusiO
ns: Preliminary results suggest that RRMS patients treated with Glatiramer have 
the lowest risk of experiencing AEs, while patients taking Teriflunomide 14mg have 
the highest AEs risk. This evidence may be useful to perform net clinical benefit 
analyses on alternative RRMS treatments.
PND2
EPIDEMIOLOgy AND ECONOMIC STUDIES ON PATIENTS DIAgNOSED wITH 
INSOMNIA: A REvIEw OF THE LITERATURE
Greene N.1, Greene M.2
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Georgia State 
University, Bethel, MA, USA
Objectives: To conduct a systematic review of literature in peer-reviewed 
journals on epidemiology and economic studies on patients diagnosed with 
Insomnia. MethOds: The initial search strategy was developed in the PubMed/
MEDLINE database, and was then translated for the Cochrane and Embase data-
base searches. Search strings for epidemiology and economics studies for Insomnia 
were constructed using varied approaches that included the use of MeSH terms, as 
well as keywords that would afford the best retrieval. Additional parameters were 
placed on the final search strategy to limit the retrieval to articles written in English, 
involving human subjects and published between 2000 and 2010. Results: The 
initial search identified 225 articles for epidemiology and 144 articles for economic 
studies on Insomnia from PubMed/Medline/Embase/Cochrane databases. After 
removing duplicates and non-relevant articles, 40 articles for epidemiology and 13 
for economic studies were included in the study. Twenty-three studies were focused 
on the prevalence of insomnia and the estimates among all of the studies ranged 
from 6.6% to 56%. Two studies focused on one year incidence rates of insomnia; one 
in Canada and the other in the UK. There were 4 studies each on burden of illness 
and cost effectiveness and 5 studies on retrospective claims analysis. The average 
annual direct and indirect per-person costs were $5,010 for individuals with insom-
nia syndrome, $1,431 for individuals presenting with symptoms, and $421 for good 
sleepers. cOnclusiOns: There was a significant variation in the prevalence rates 
of Insomnia across different studies and in different countries. Insomnia results 
in significant direct and indirect costs and indirect costs in comparison to patients 
who were not diagnosed with Insomnia.
NEUROLOgICAL DISORDERS – Cost Studies
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NATALIzUMAB FOR 2ND LINE TREATMENT IN RELAPSINg-REMITTINg 
MULTIPLE SCLEROSIS PATIENTS: 5-yEAR BUDgET IMPACT ANALySIS (BIA) 
FROM THE BRAzILIAN PUBLIC PAyER PERSPECTIvE
Nishikawa A.M.1, Paladini L.1, Liamas A.L.2, Bueno C.C.1, Clark O.A.C.1
1Evidencias, Campinas, Brazil, 2Biogen Idec Brasil, São Paulo, Brazil
Objectives: Multiple sclerosis (MS) is a neurodegenerative disease associated with 
long-term disability and economic impact. With the addition of new agents for the 
MS treatment (e.g. natalizumab), there is a need to evaluate the relative value of 
newer therapies in terms of cost, given health care resource constraints in Brazil. 
Natalizumab is an effective therapeutic option for RRMS patients. Compared to other 
drug options, it shows better efficacy in terms of disease progression and relapse 
rates. Although natalizumab is indicated for 2nd line, the Ministry of Health public 
guidelines recommend natalizumab only in 3rd line treatment for MS. Therefore, a 
BIA has been created to analyze the impact of introducing natalizumab in 2nd line 
treatment in the public system. MethOds: BIA was based in a Markov model with 
monthly cycles and 5-year time horizon and MS epidemiological data were obtained 
from DATASUS. The model compared current MS treatment options reimbursed by 
the Brazilian government - interferon, glatiramer acetate and natalizumab (3rd line) 
with an alternative scenario with natalizumab in 2nd line. Results: Number of 
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decisión desde la perspectiva de un tercer pagador y con tasas de eventos anuales. 
La eficacia de la profilaxis se tomó de la literatura. Los costos incluyeron FVIII, 
hospitalización, consultas por urgencias, colocación y complicaciones del catéter 
venoso central y consultas médicas. La tasa de descuento fue 3% y la utilización de 
recursos se identificó del grupo económico de hemofilia Europeo y se valoró a partir 
de tarifarios locales. La prevalencia de hemofilia se determinó con datos locales. 
Dosis de profilaxis con FVIII: 25U/kg tres veces semanales. Dosis del tratamiento a 
demanda: 40U/kg dos veces diarias por 3,5 días. ResultadOs: En adolescentes de 
10 años y 33kg, la profilaxis con FVIII evitará 118 episodios de sangrado y 47 hemor-
ragias articulares durante el resto de sus vidas, versus a demanda; ICER para el san-
grado fue $6.749 y $17.178 para hemorragias articulares. En adolescentes de 19 años 
y 54kg, la profilaxis con FVIII versus a demanda, evitará 87 episodios de sangrado 
y 34 hemorragias articulares durante el resto de sus vidas; ICER para el sangrado 
fue $11.750 y para hemorragias articulares $29.938. cOnclusiOnes: La profilaxis 
con FVIII es una estrategia costo-efectiva en niños con hemofilia A moderada y que 
presenten 6,4 episodios de sangrado y 2,3 hemorragias articulares, en promedio 
cada año. Si la profilaxis se inicia a una edad más temprana, se prevendrán más 
episodios de sangrado y de hemorragia articular.
PND10
ANáLISIS DE COSTO-EFECTIvIDAD DL TRATAMIENTO PROFILáCTICO vERSUS A 
DEMANDA EN ADULTOS jóvENES CON HEMOFILIA A SEvERA EN COLOMBIA
Ordoñez Molina J.E., Orozco Giraldo J.J.
CES University, Medellin, Colombia
ObjectivOs: La profilaxis con Factor VIII (FVIII) en hemofilia A severa se utiliza 
en países desarrollados, en países en desarrollo hay controversia por sus costos. 
El objetivo de este estudio fue estimar la razón de costo-efectividad incremental 
(ICER) de profilaxis con FVIII versus tratamiento a demanda para prevenir episo-
dios de sangrado y hemorragias articulares en adultos con hemofilia A severa en 
Colombia. MetOdOlOgías: Se utilizó un árbol de decisión desde la perspectiva del 
tercer pagador y con tasas de eventos anuales. La eficacia de la profilaxis se tomó 
de la literatura. Los costos incluyeron FVIII, hospitalización, consultas por urgen-
cias, colocación y complicaciones del catéter venoso central, consultas médicas y 
días de trabajo perdidos. La tasa de descuento fue 3% y la utilización de recursos 
se identificó del grupo económico de hemofilia Europeo y se valoró a partir de tari-
farios locales. La prevalencia de hemofilia se determinó con datos locales. Dosis de 
profilaxis con FVIII: 25U/kg tres veces semanales. Dosis del tratamiento a demanda: 
50U/kg tres veces diarias por una semana durante la hospitalización y 25U/kg tres 
veces semanales por tres semanas ambulatoriamente. ResultadOs: En adultos 
de 20 años y 70kg, la profilaxis con FVIII evitará 168 episodios de sangrado y 66 
hemorragias articulares durante el resto de su vida, versus a demanda; ICER para el 
sangrado fue $5.676 y $14.463 para hemorragias articulares. En adultos de 40 años 
y 70kg, la profilaxis con FVIII evitará 79 episodios de sangrado y 31 hemorragias 
articulares durante el resto de su vida, versus a demanda; ICER para el sangrado 
fue $5.244 y para hemorragias articulares $13.417. cOnclusiOnes: La profilaxis 
con FVIII en pacientes adultos mejora los resultados clínicos versus a demanda. Si 
la profilaxis se inicia a una edad más temprana, se prevendrán más episodios de 
sangrado y de hemorragia articular.
PND11
COST-EFFECTIvENESS ANALySES OF NATALIzUMAB FOR 2ND LINE vERSUS 
gLATIRAMER ACETATE IN THE TREATMENT OF RELAPSINg-REMITTINg 
MULTIPLE SCLEROSIS PATIENTS IN BRAzIL
Nishikawa A.M.1, Paladini L.1, Liamas A.L.2, Bueno C.C.1, Clark O.A.C.1
1Evidencias, Campinas, Brazil, 2Biogen Idec Brasil, São Paulo, Brazil
Objectives: Multiple sclerosis (MS) is a neurologic disease that can dramatically 
affect patients. The aim of this study is to conduct a cost-effectiveness analysis of 
natalizumab (Tysabri®) versus glatiramer acetate (Copaxone®) for treatment of 
Relapsing Remitting Multiple Sclerosis (RRMS) patients from the Brazilian Public 
Healthcare System (SUS) perspective. MethOds: A Markov model with a 20-year 
time horizon comparing natalizumab to glatiramer acetate was developed. Health 
states were based on EDSS and relapses (moderate or severe). We obtained relapse 
and disability progression transition probabilities from natural history studies 
on RRMS patients. In each monthly cycle, patients can discontinue treatment, 
remain stable, progress to higher MS EDSS state, experience Progressive Multifocal 
Leukoencephalopathy (PML) or die. Patients with EDSS score ≥ 7.5 receive best sup-
portive care. Resource use and costs were validated by an expert’s panel and valued 
using Brazilian public official lists (DATASUS and BPS). Costs and outcomes (5%) were 
discounted. Probabilistic sensitivity analyses (PSA) covered variability in efficacy 
and costs. Results: Use of natalizumab was associated with slower EDSS pro-
gression and reduced relapse burden. The life years gained (LYG) with natalizumab 
and glatiramer acetate was 10.65 and 10.09, respectively. Costs associated with 
natalizumab were USD 119.330 and USD 102.275 for glatiramer acetate. Incremental 
cost-effectiveness rate for natalizumab versus glatiramer acetate was USD 30.251/
LYG. PSA has confirmed the consistency of base case results. cOnclusiOns: For 
a patient with RRMS, this model shows that natalizumab was cost-effective when 
compared to treatment with glatiramer acetate, assuming the threshold of USD 
50.000/LYG commonly mentioned by the Ministry of Health in Brazil.
PND12
COST-EFFECTIvENESS ANALySES OF NATALIzUMAB FOR 1ST LINE vERSUS 
INTERFERON BETA-1A 44 MCg IN THE TREATMENT OF HIgHLy ACTIvE 
RELAPSINg-REMITTINg MULTIPLE SCLEROSIS PATIENTS IN BRAzIL
Nishikawa A.M.1, Paladini L.1, Liamas A.L.2, Bueno C.C.1, Clark O.A.C.1
1Evidencias, Campinas, Brazil, 2Biogen Idec Brasil, São Paulo, Brazil
Objectives: Multiple sclerosis (MS) is a neurologic disease that can dramatically 
affect the patient. The aim of this study is to conduct a cost-effectiveness analysis of 
natalizumab (Tysabri®) versus interferon beta-1a (IFNB1a) 44mcg (Rebif®) for treat-
ing Highly Active Relapsing Remitting Multiple Sclerosis (HARRMS) patients. IFNB1a 
yearly frequency and average consumption. Results: The study enrolled 210 MS 
patients, mean age was 40.7 [standard deviation= 11.5] years and 70.7% female. 
Patients with mild disability (according to self-reported Expanded Disability Status 
Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate disability and 15.9% 
had severe disability. The overall yearly direct costs (mean [CI95%]) associated to 
patients with mild, moderate and severe disabilities were: USD18,475 [2,293-34,657], 
USD19,371 [4,651-34,090], and USD19,545 [0-57,659] (1BRL = 0.4937USD), respectively. 
Disease modifying therapies (DMTs) were the major component of the total yearly 
cost, ranging from 93.5% among mild patients to 53.9% in the severe group (85.5% 
in the total sample), followed by aids and home modifications (mild: 2.3%; moder-
ate: 2.3%; severe: 15.1%; total sample: 4.3%). Patients with moderate disability had 
higher absolute costs related to inpatient care, emergency visits, laboratory and 
imaging tests, and DMTs than the other disability groups, while those with severe 
disabilities presented higher costs in the remaining categories (consultations, co-
medications and OTC medications, aids and home modifications, and professional 
caregiver). cOnclusiOns: To our knowledge, this is the first Brazilian study investi-
gating the cost of MS patients. Our findings indicate that MS represent a significant 
economic burden for both the health care system and patients and their families, 
with different expenditures profiles depending on the EDSS level.
PND7
ARgENTINIAN SURvEy IN COST OF ILLNESS AND UNMET NEEDS IN MULTIPLE 
SCLEROSIS: TREATMENT ExPERIENCE & THE COSTS OF MS PATIENTS IN 
ARgENTINA
Kuperman G.
Novartis Argentina, Buenos Aires, Argentina
Objectives: The objective of the study was to assess the cost of MS patients in 
Argentina categorized by disease severity using a societal perspective. MethOds: 
This was a cross-sectional study including MS patients from 21 MS centers in 12 
cities of Argentina conducted to collect information on demographics, disease 
characteristics, disease severity, comorbidities, relapses, resource utilization and 
patient reported outcomes, associated with MS. Patients were stratified by dis-
ease severity using the EDSS (group 1 with EDSS score between 0 and 3; group 2 
with EDSS > 3 and < 7; group 3 with EDSS ≥ 7). Direct and indirect costs included 
in the analysis were: inpatient and outpatient care for relapses, inpatient care for 
other reasons than relapses, consultations, investigations, specific MS treatments, 
wheelchair, professional care, informal care, sick leave and retirement due to MS. 
Second quarter 2012 costs were obtained from public sources and converted to US 
Dollars. Results: A total of266 patients were included. 87.6% had relapsing remit-
ting MS. Mean annual cost per MS patient was USD 36,025 (95% CI 31,985-38,068) for 
patients with an EDSS between 0-3; USD 40,705 (95% CI 37,199-46,300) for patients 
with EDSS > 3 and < 7, and USD 50,712 (95% CI 47,825-62,104) for patients with EDSS 
≥ 7. cOnclusiOns: This is the first Argentine study evaluating the costs of MS 
considering disease severity.
PND8
CHARACTERISTICS OF HOSPITALIzATIONS DUE TO AN EPISODE OF 
RELAPSE IN MULTIPLE SCLEROSIS BRAzILIAN PATIENTS: A RETROSPECTIvE 
ADMINISTRATIvE CLAIMS ANALySIS UNDER THE PUBLIC PAyER PERSPECTIvE
Takemoto M.L.S., Guerra R., Fernandes R.A., Takemoto M.M.S., Santos P.M.L., Haas L.C.,  
Silva M.A.
ANOVA, Rio de Janeiro, Brazil
Objectives: To describe hospital admissions for managing multiple sclerosis (MS) 
relapses in the Brazilian Public Healthcare System (BPHS). MethOds: Data from 
the 2009-2012 period were collected from the BPHS Hospital Information System 
(SIH/SUS), which aggregates administrative data from inpatient admissions in public 
hospitals in the entire country. Individual claims coded as “MS Relapse Inpatient 
Treatment” in the SIH/SUS (regardless ICD-10 codes) were identified in the database 
and compiled by state and year. Results: We obtained data on 5,922 individual 
MS relapse-related claims, homegenously distributed among the 4 years. They 
represented an overall cost of BRL3,729,921 for the 2009-2012 period (ranging from 
BRL806,722 in 2010 to BRL1,033,649 in 2012). The 4-year national average cost per 
inpatient admission BRL629, with mean LOS of 7.51 days and ICU days of 0.22. The 
in-hospital mortality rate ranged from 0.65%-1.60%. The 2012 national rate of MS 
relapse-related hospitalization in the general population (per 100,000, absolute num-
ber of admissions / total population) was 0.79, varying from 0.03/100,000 in Alagoas 
(Northeast region) to 1.78/100,000 in Santa Catarina (South region). All parameters 
were consistently different among Brazilian states. In-hospital deaths were very rare 
in this sample not allowing robust conclusions. It was possible to identify significant 
outliers in the mean cost per admission when states were separately considered (2012 
data: from BRL323 [n= 3] in Sergipe to BRL 4,596 in Espírito Santo [n= 4]). São Paulo was 
the state with higher absolute number of hospitalizations in all years. In 2012, the 
state had 526 admissions, mean cost per event of BRL810, 4 in-hospital deaths (0.76%), 
mean LOS= 6.16, and mean ICU days of 0.36. cOnclusiOns: BPHS administrative 
hospital database can provide insightful information about MS relapse-related admis-
sions. Both geographical and time trends can be examined using SIH/SUS secondary 
data, particularly for diseases with highly specific procedure codes.
PND9
ANáLISIS DE COSTO-EFECTIvIDAD DEL TRATAMIENTO PROFILáCTICO vERSUS 
A DEMANDA EN ADOLESCENTES CON HEMOFILIA A SEvERA EN COLOMBIA
Ordoñez Molina J.E., Orozco Giraldo J.J.
CES University, Medellin, Colombia
ObjectivOs: Algunos adolescentes con hemofilia A moderada reciben profilaxis 
con Factor VIII (FVIII), pero los resultados económicos de esta estrategia de tratami-
ento son desconocidos. El objetivo de este estudio fue estimar la razón de costo-
efectividad incremental (ICER) de profilaxis con FVIII versus tratamiento a demanda 
para prevenir episodios de sangrado y hemorragias articulares en adolescentes 
con hemofilia A moderada en Colombia. MetOdOlOgías: Se utilizó un árbol de 
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Treatments administered with more convenient devices such as DPIs and shorter 
administration times are associated with higher utility and higher stated adherence 
in adult and pediatric patients.
PND15
BURDEN OF MULTIPLE SCLEROSIS AND UNMET NEEDS IN BRAzIL: 
MEASUREMENT OF FATIgUE USINg MODIFIED FATIgUE IMPACT SCALE
Silva N.L.1, Takemoto M.2, Damasceno B.3, Fragoso Y.D.4, Finkelsztejn A.5, Gomes M.1
1Novartis Biociências S.A., São Paulo, Brazil, 2ANOVA - Knowledge Translation, Rio de 
Janeiro, Brazil, 3UNICAMP - Hospital de Clínicas, Campinas, Brazil, 4UNIMES - Universidade 
Metropolitana de Santos, Santos, Brazil, 5Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Objectives: Fatigue is one of the most frequent symptoms in patients with 
multiple sclerosis (MS). This study aimed to examine the severity and impact 
of fatigue in MS Brazilian patients. MethOds: This was a cross-sectional, mul-
ticenter study conducted in 8 Brazilian major MS treatment sites. Fatigue was 
assessed using the Brazilian version of the Modified Fatigue Impact Scale (MFIS), 
which evaluates the impact of fatigue on 3 dimensions of patients’ daily life: 
physical, cognitive and psychosocial. The patient scores 0 (lower impact) to 84 
points (higher impact). The final score was classified according to the level of 
impact: absent (0-38), low (39-58), and high (> 58). Results: The study enrolled 
210 MS patients, of which the mean age was 40.7 [standard deviation = 11.5] years 
and 70.7% were female. Patients with mild disability (according to self-reported 
Expanded Disability Status Scale [EDSS]) represented 40.4% of patients, 43.7% 
had moderate disability and 15.9% had severe disability. In the overall sample, 
the impact of fatigue was considered absent, low and high in 49%, 32% and 19% 
of patients, respectively. Any impact (both low and high summed) was reported 
by 33%, 63%, and 66% of patients with mild, moderate and severe disability, 
respectively. The mean MFIS total score for mild, moderate and severe patients 
was 29.3, 45.0, and 45.4 (38.6 in the total sample). The mean impact scores for 
each domain in the total sample were 20.0 (physical, range 0-36), 14.7 (cogni-
tive, range 0-40), and 3.9 (psychosocial, range 0-8), meaning that fatigue has a 
proportionally higher impact in the physical than the cognitive or psychosocial 
domains. cOnclusiOns: Our findings indicate that over 50% of MS Brazilian 
patients notice some adverse impact of fatigue in their daily lives, particularly 
related to the physical domain.
PND16
BURDEN OF MULTIPLE SCLEROSIS AND UNMET NEEDS IN BRAzIL: 
MEASUREMENT OF HEALTH-RELATED QUALITy OF LIFE USINg EQ-5D
Silva N.L.1, Takemoto M.2, Damasceno B.3, Fragoso Y.D.4, Finkelsztejn A.5, Gomes M.1
1Novartis Biociências S.A., São Paulo, Brazil, 2ANOVA - Knowledge Translation, Rio de 
Janeiro, Brazil, 3UNICAMP - Hospital de Clínicas, Campinas, Brazil, 4UNIMES - Universidade 
Metropolitana de Santos, Santos, Brazil, 5Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Objectives: To measure the health-related quality of life (HRQL) of multiple 
sclerosis (MS) patients and examine potential associations between HRQL and 
patients’ characteristics. MethOds: This was a cross-sectional, multicenter study 
conducted in 8 Brazilian major MS treatment sites. HRQL was assessed using the 
Brazilian version of the EQ-5D and patients self-evaluated their HRQL and health 
status using five dimensions (mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression) and a visual analog scale (VAS). The EQ-5D index 
was calculated based on the value set derived from the UK population, since the 
Brazilian value set is not available. Results: The study enrolled 210 MS patients, 
of which the mean age (standard deviation [SD]) was 40.7 [11.5] years and 70.7% 
were female. Patients with mild disability (according to self-reported Expanded 
Disability Status Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate 
disability and 15.9% had severe disability. Among the 5 assessed HRQL dimensions, 
the ones with higher frequency of self-reported severe limitations were usual 
activities and anxiety/depression (11.0% each). The least impaired dimension was 
self-care, with 63.0% of patients reporting absence of limitation. The mean [SD] VAS 
score was 71.6 [18.9]. The mean EQ-5D index for each level of EDSS (mild, moder-
ate or severe disability) was 0.73 [0.21], 0.49 [0.30], and 0.30 [0.34], respectively. 
In the multivariate analysis, variables related to patients’ characteristics were 
explored and the following were associated with the presence of any limitation 
in at least one dimension: older age, unemployment/retirement, relapses in the 
previous year, emergency department visits in the previous 6 months and lower 
educational level. cOnclusiOns: MS adversely impact patients’ HRQL, especially 
with disability progression and clinical features that can be linked to more severe 
disease.
NEUROLOgICAL DISORDERS – Health Care Use & Policy Studies
PND17
EvALUATION OF TREATMENT PATTERNS AND CLINICAL TRIALS PUBLISHED ON 
PATIENTS DIAgNOSED wITH INSOMNIA: A LITERATURE UPDATE
Greene N.1, Greene M.2
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Georgia State 
University, Bethel, MA, USA
Objectives: To conduct a systematic review of literature in peer-reviewed jour-
nals on real world treatment patterns and clinical trials on patients diagnosed 
with Insomnia. MethOds: A comprehensive literature search was performed 
using relevant search terms to identify articles published from 2000 to 2010 on 
the real world treatment patterns and clinical trials conducted on patients with 
Insomnia. Studies were identified through electronic Embase, Cochrane, Medline, 
and PubMed databases. Additional parameters were placed on the final search 
strategy to limit the retrieval to articles written in English, involving human sub-
jects. Results: Our search yielded 1,153 articles for treatment patterns and clini-
cal trials on patients diagnosed with Insomnia from PubMed/Medline/Embase/
Cochrane databases. After removing duplicates and non-relevant articles, 65 
articles were included for final review. A total of 16 studies had some focus on 
44mcg was chosen as comparator since it is the most widely prescribed disease 
modifying therapy for 1st-line treatment in HARRMS patients in Brazil. MethOds: 
We developed a Markov model with 20-year time horizon comparing natalizumab 
to IFNB1a 44mcg. Health states were based on EDSS and relapses (moderate or 
severe). Since there are no published data evaluating long-term course specifically 
in HARRMS, we assumed transition probabilities on EDSS states based on natural 
history studies on unselected RRMS patients, and relapse probabilities based on 
a post-hoc analysis of the pivotal natalizumab AFFIRM trial. This is a rather con-
servative approach, since disability progression may be slower in this proposed 
model then expected for patients with HARRMS and so the benefit from natali-
zumab could be underappreciated. In each monthly cycle, patients can discontinue 
treatment, remain stable, progress to higher EDSS state, experience Progressive 
Multifocal Leukoencephalopathy or die. Patients with EDSS score≥ 7.5 receive best 
supportive care. Resource use and costs were validated by an expert’s panel and 
valued using Brazilian public official lists (DATASUS and BPS). Costs and outcomes 
were discounted (5%). Probabilistic sensitivity analyses (PSA) covered variability in 
efficacy and costs. Results: Use of natalizumab was associated with slower EDSS 
progression and reduced relapse burden. Life years gained with natalizumab and 
IFNB1a 44mcg were 10.90 and 10.54, and costs were USD119,977 and USD132,446, 
respectively. In the base-case, natalizumab was dominant versus IFNB1a 44mcg. 
PSA has confirmed the consistency of results. cOnclusiOns: For a patient with 
HARRMS, the model shows that natalizumab was dominant when compared to 
IFNB1a 44mcg in the Brazilian Public Healthcare System.
PND13
BURDEN OF MULTIPLE SCLEROSIS AND UNMET NEEDS IN BRAzIL: HEALTH 
CARE RESOURCE UTILIzATION
Silva N.L.1, Takemoto M.2, Damasceno B.3, Fragoso Y.D.4, Finkelsztejn A.5, Gomes M.1
1Novartis Biociências S.A., São Paulo, Brazil, 2ANOVA - Knowledge Translation, Rio de 
Janeiro, Brazil, 3UNICAMP - Hospital de Clínicas, Campinas, Brazil, 4UNIMES - Universidade 
Metropolitana de Santos, Santos, Brazil, 5Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Objectives: To assess the health care resource utilization (HRU) of Brazilian mul-
tiple sclerosis (MS) patients. MethOds: This was a cross-sectional, multicenter 
study conducted in 8 Brazilian major MS treatment sites. HRU was evaluated as 
the percentage of patients self-reporting the consumption of resources. The main 
categories were: hospitalization, consultations, laboratory and imaging tests, dis-
ease modifying therapies (DMTs), co-medication, aidsand/or home modifications. 
Frequency and average consumption were annualized. Results: The study enrolled 
210 MS patients, mean age was 40.7 [standard deviation= 11.5] years and 70.7% 
female. Patients with mild disability (according to self-reported Expanded Disability 
Status Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate disability 
and 15.9% had severe disability.Hospitalization was reported by 23%, 33% and 15% 
of mild, moderate and severe MS patients, with average length of stay of: 7.53, 10.41, 
and 7.40 days, respectively. Most patients (> 96%) had at least one neurologist con-
sultation per year (average 4.94 visits/year in the total sample). Physical therapy was 
the most consumed non-medical consultation (mild: 11%; moderate: 38%; severe: 
64%). Magnetic resonance imagingwas reported by 60%, 68%, and 55% of mild, mod-
erate and severe patients. Patients using at least one DMT during the previous year 
were: 89%, 93%, and 61% of mild, moderate and severe MS patients, respectively. 
The most prescribed DMT was glatiramer acetate (38%, total sample). The most fre-
quent co-medications were: anti-depressants, anti-spasticity, and analgesics. Home 
modification was reported by 19% and 45% of patients with moderate and severe 
disability, respectively. For ambulation, walking stick was used by 35% of moderate 
patients, while wheelchair was needed by 58% of severe patients. cOnclusiOns: To 
our knowledge, this is the first Brazilian study investigating the HRU of MS patients. 
The findings can be useful to better understand MS patients’ needs in terms of 
comprehensive care.
NEUROLOgICAL DISORDERS – Patient-Reported Outcomes & Patient Preference 
Studies
PND14
wHICH CySTIC FIBROSIS INHALED ANTIBIOTIC MEDICINE FEATURES MATTER 
MOST TO ADULT PATIENTS AND PARENTS OF PEDIATRIC PATIENTS?
Mohamed A.F.1, Johnson F.R.1, Balp M.M.2, Calado F.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland
Objectives: To quantify patient and parent preferences and adherence for dif-
ferent administration features of inhaled antibiotic medicines for cystic fibrosis 
(CF). MethOds: Adult patients with a self-reported physician diagnosis of CF and 
parents of pediatric CF patients (6 to 17 years) who had Pseudomonas aeruginosa in 
their lung culture at least twice in one year completed a web-enabled, discrete-
choice experiment survey in the United States. Respondents answered 5 treat-
ment-choice questions with known statistical properties. Each question required 
evaluating a pair of hypothetical CF treatment profiles defined by device type (nebu-
lizer, dry powder inhaler (DPI)), total daily administration and cleaning time, dosing 
frequency, dry cough side effect, and personal cost per cycle. Lung function meas-
ured as forced expiratory volume in one second (FEV1) was held constant between 
the hypothetical CF treatment profiles. Stated adherence questions followed two 
randomly selected treatment-choice questions. Random-parameters logit models 
were used to estimate preference weights for all feature levels and the mean rela-
tive importance of each feature for both samples. Results: A total of 209 adult 
patients and 271 parents completed the survey. Mean age of adult patients was 32 
(SD = 10) years and mean age of pediatric patients was 12 (SD = 3) years. Among 
all respondents, the average time spent taking inhaled antibiotic medicines was 
approximately 40 minutes. Relative importance estimates indicated that switching 
from a 30-minute nebulizer twice daily to a 10-minute DPI twice daily was 6.3 times 
more important for adult patients and 2.0 times more important for parents than an 
improvement in dry cough from moderate to mild. Stated adherence for adult and 
pediatric patients was 20-30% higher for DPIs versus nebulizers. cOnclusiOns: 
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hospitalar e custo do procedimento. MétOdOs: A partir do sistema de faturamento 
do HIAE foram selecionados 538 procedimentos de septoplastia com turbinecto-
mia e sinusectomia realizados no ano de 2011 que utilizaram as técnicas com-
paradas neste estudo. Foram incluídos na análise 517 pacientes, 56 procedimentos 
utilizando o microdebridador e 461 utilizando a técnica convencional. Em média, 
os pacientes que utilizaram o microdebridador possuíam uma faixa etária mais 
elevada e um percentual maior dos pacientes apresentaram diagnóstico de sinusite 
crônica. ResultadOs: Em relação à média de tempo de permanência hospitalar 
esta foi maior no grupo do microdebridador (28 horas versus 22 horas no grupo 
da técnica convencional, p= 0,002). A quantidade média de unidades de cola e de 
hemostático foi maior no grupo que utilizou o microdebridador. Não houve difer-
ença estatística entre os grupos nos desfechos de tempo de cirurgia e nas taxas de 
readmissão hospitalar. No desfecho de dor no pós operatório imediato a diferença 
entre os grupos foi estatisticamente significativa (p = 0,006), indicando um per-
centual maior de pacientes com escore de dor acima de 5 sendo tratados com o 
microdebridador, quando comparado com o grupo convencional. Considerando-se 
o custo do procedimento com a técnica convencional como referência, o uso do 
microdebridador resultou em um aumento médio de 17,4% em relação à técnica 
convencional. cOnclusões: O uso do microdebridador não se mostrou favorável 
nos desfechos avaliados, tendo em vista um aumento do tempo de permanência do 
paciente, uso de colas e hemostáticos em maior quantidade que a técnica conven-
cional e o custo do procedimento foi significativamente mais alto.
PRS5
COMPARINg COPD COSTS By ExACERBATION FREQUENCy AND DySPNOEA 
LEvEL IN A PRIMARy CARE SETTINg IN THE UNITED kINgDOM
Punekar Y.S.1, Shukla A.2, Muellerova H.3
1GlaxoSmithKline, Uxbridge, UK, 2GlaxoSmithKline, Upper Providence, PA, USA, 3GlaxoSmithKline 
R&D, Uxbridge, UK
Objectives: Economic burden in Chronic Obstructive Pulmonary Disease (COPD) 
patients with varying levels of dyspnoea is largely unknown. The objective of this 
retrospective analysis was to estimate the resource use and the associated costs 
incurred by COPD patients with increasing levels of dyspnoea with or without fre-
quent exacerbations. MethOds: A retrospective cohort of prevalent COPD patients 
was identified in the Clinical Practice Research Datalink (CPRD). All patients who had 
at least 12 month pre- and post- cohort entry date (1st prevalent COPD diagnosis 
confirmed by spirometry ≥ April 1, 2009) recorded were included in the analysis. 
Patients were categorised as having none, 1 or 2+ exacerbations in the 12 months 
post cohort entry and further classified using Medical Research Council (MRC) dysp-
noea scale. Study outcomes included general practitioner (GP) visits, community 
treated exacerbations (medical dg for exacerbation or ATB+OCS Rx), hospital treated 
exacerbations and all-cause hospitalisations excluding COPD exacerbations. The 
costs associated with the estimated resource use were calculated using National 
Health Service (NHS) reference costs for 2010-11. Results: The cohort consisted 
of 51,641 COPD patients with 27,764 (53.8%), 12,585 (24.4%) and 11,292 (21.9%) hav-
ing experienced none, 1 and 2+ annual exacerbations post cohort entry. Among all 
patients, the estimated annual COPD management costs, excluding the costs of 
medications, were £1,597, £1,849, £2,298, £2,745 and £3,579 with increasing levels 
of dyspnoea (MRC grade 1-5). The equivalent cost ranges by exacerbation frequency 
were £1,267-£2,235, £2,021-£3,447 and £2,627-£4,709 for patients with none, 1 or 2+ 
annual exacerbations, respectively. cOnclusiOns: Increase in COPD management 
costs with increase in level of dyspnoea occurred in all exacerbation frequency 
groups. Better symptom control and disease management strategies in primary 
care setting may help reduce COPD costs significantly.
PRS6
HEALTH AND ECONOMIC BURDEN OF TOBACCO USE IN SEvEN LATIN 
AMERICAN COUNTRIES: RESULTS FROM A MICROSIMULATION HEALTH 
ECONOMIC MODEL (HEM)
Pichon Riviere A.1, Bardach A.2, Caporale J.3, Augustovski F.2, Alcaraz A.2, Navia M.D.P.4,  
Pinto M.5, Vallejos C.6, Peña Torres E.7, Reynales L.M.8, Gallegos V.9, Huayanay L.10
1IECS - Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 2Institute for 
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Bolivia, 5IFF/Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 6Universidad de La Frontera, Temuco, 
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Objectives: Smoking is the single most preventable cause of disease and death all 
around the world. Our objective was to quantify the disease burden associated with 
smoking in Argentina, Bolivia, Brazil, Chile, Colombia, Mexico and Peru. MethOds: 
The project began with a survey to health Decision Makers (DM) to explore country-
specific information needs. The development stage involved the harmonization of 
a methodology to retrieve local relevant parameters and develop the model struc-
ture. A microsimulation HEM was built considering the availability and quality of 
epidemiological data and relevant outcomes were conceived to suit the identified 
information needs of DMs . It considers all tobacco-related diseases: heart, cerebro-
vascular and chronic obstructive pulmonary disease, pneumonia/influenza, lung 
cancer and nine other neoplasms. A systematic search on effectiveness, local epide-
miology and costs studies was undertaken to populate the model. Calibration and 
validation was performed for each country. Predicted event rates were compared 
to the published rates used as model inputs. External validation was undertaken 
against epidemiological studies not used to provide input data. Results: The cali-
brated model showed all simulated event rates falling within ±10% of the sources 
and a high correlation between published data and model results. In these seven LA 
countries, tobacco is responsible of 259,126 deaths each year. The diseases attrib-
utable to smoking cause a total of 1∙90 million years of life lost due to premature 
death, 0∙64 million years of life lost due to disability and at least 27 billion dollars 
(USD dollars 2013) in direct medical costs each year. cOnclusiOns: Tobacco use is 
real world treatment patterns in Insomnia patients and majority of these stud-
ies focused on benzodiazepine users. The rate of medication use in Insomnia 
patients is fairly low and rates were ranging from 17% to 75%. There were a total 
of 11 trials published testing Eszopiclone use, 10 trials each on Ramelteon and 
Zolpidem, 4 trials on Indiplon, 3 trials on Gaboxadol, 3 trials on Doxepin use in 
patients diagnosed with Insomnia. Several patient reported outcomes measures 
were used in the assessment of various clinical trials. cOnclusiOns: There 
were a variety of agents being used to treat insomnia; while benzodiazepines 
and non-benzodiazepines were largely popular. Products in development need to 
be studied further to determine whether their new mechanisms of action were 
truly beneficial for treatment.
RESPIRATORy-RELATED DISORDERS – Clinical Outcomes Studies
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ACUTE ASTHMA CHARACTERISTICS AND ASTHMA CONTROL IN LATIN 
AMERICA
Montealegre-Golcher F.J.1, Gold L.2, Camacho R.3, Muñoz S.4
1MSD, Carolina, PR, USA, 2University of Washington, Seattle, WA, USA, 3MSD, White House 
Station, NJ, USA, 4Universidad de la Frontera, Temuco, Chile
Objectives: To investigate the patient’s acute asthma characteristics, and iden-
tify predictors of asthma control in a population of asthma patients from five 
Latin American countries. MethOds: Adults and parents of adolescents (12-17 
years) with a physician diagnosed asthma and asthma medication use or asthma 
attacks in the past year were surveyed as part of the 2011 Latin America Asthma 
Insights and Management (AIM) survey. Using Global Initiative for Asthma (GINA) 
guidelines as a reference, respondents were categorized into three levels of asthma 
control: well-controlled, partly- controlled, and uncontrolled. Chi-square tests 
and adjusted logistic regression were used to determine odds ratios (ORs) to 
assess the relation of degree of asthma control with frequency of sudden asthma 
episodes, frequency of asthma symptoms, duration of episodes, day-and night 
time symptoms, utilization of rescue medications, and asthma episodes season-
ality. Results: Data from 2168 adults and parents from asthma patients ≥ 12 
years survey was analyzed. Seven percent (7%) of the patients are controlled, 57% 
partially controlled, and 36% uncontrolled. Adjusted logistic regression models 
showed that patients whose asthma was uncontrolled were significantly more 
likely to have acute sudden asthma episodes compared to patients whose asthma 
was controlled either partially or fully. Similarly, patients with uncontrolled 
asthma were significantly more likely to have higher frequency of asthma episodes 
in most days of the week, increased day and night symptoms than those asthmat-
ics who were controlled cOnclusiOns: Patients who did not have well-controlled 
asthma had more acute episodes as compared to patients whose asthma was 
well-controlled. Our results strongly suggest that the acute asthma requires a 
significant effort to decrease its severity.
PRS3
gRAPHIC HEALTH wARNINgS ON CIgARETTE PACkS IN QATAR: PRE-
IMPLEMENTATION AwARENESS AND PERCEPTION AMONg THE gENERAL 
PUBLIC
Awaisu A., Hagi A., Ashour M.A., Kheir A.N.
Qatar University, Doha, Qatar
Objectives: Graphic health warnings (GHWs) on cigarette packages have been 
found to be significantly associated with increased awareness of smoking-related 
health hazards as well as behavior change. Legislations on GHWs have recently 
been endorsed and GHWs have now been introduced in Qatar. This study aims to 
evaluate the general public’s awareness, beliefs and perceptions on anti-tobacco 
GHW labels on cigarette packs prior to the introduction of the new law. MethOds: 
A cross-sectional survey using a pretested 23-item questionnaire was conducted 
among randomly approached adults in Qatar. Data were analyzed using the IBM 
SPSS® version 19. Responses were analyzed by smoking status (ever-smokers 
vs. never-smokers) to ascertain how these two distinct groups differed in their 
awareness and perceptions related to health warning messages. The demographic 
characteristics and other outcomes of interest were compared using χ 2 or Fishers 
Exact tests. Results: A total of 500 participants (59% male) responded to the sur-
vey. Most notably, ever-smokers did not significantly differ from never-smokers 
on awareness of GHW. About one-third of the respondents had no idea about any 
specific text warning messages on tobacco products sold and nearly 45% of them 
did not know what a GHW was. Furthermore, a substantial proportion (more than 
20%) of the respondents in both groups did not believe that introducing GHWs 
will enhance smoking behavior change. Non-smokers generally tended to have 
more positive attitudes than smokers toward the perceived impact of GHWs (p < 
0.05). cOnclusiOns: A substantial proportion of the general public in Qatar had 
poor awareness about GHWs. This study has important implications on the needs 
to increase awareness about the value of GHWs as well as calls for further research 
to determine the effectiveness of GHW labels on cigarette packages in Qatar and 
the greater Middle Eastern region, where legislations on GHWs are still at infancy.
RESPIRATORy-RELATED DISORDERS – Cost Studies
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IMPACTO DO USO DO MICRODEBRIDADOR NOS DESFECHOS E CUSTOS NAS 
CIRURgIAS ENDOSCóPICAS NASAIS
Costa J.D.B.1, Limoeiro A.C.O.2, Silva F.B.2, Teich V.3, Marques S.A.2
1ALBERT EINSTEIN HOSPITAL, SÃO PAULO, Brazil, 2Albert Einstein Hospital, SÃO PAULO, Brazil, 
3Medinsight – Decisions in Health Care, SÃO PAULO, Brazil
ObjetivOs: O objetivo deste estudo foi comparar as técnicas cirúrgicas com uso 
do microdebridador em relação à técnica convencional nos procedimentos de sep-
toplastia com turbinectomia e sinusectomia, quanto ao tempo de cirurgia, tempo 
de hospitalização, uso de colas e hemostáticos, escore de dor, taxa de readmissão 
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Objectives: Little information exists on the acute treatment provided for rhi-
nosinusitis and its associated costs. We hypothesize that introducing the admin-
istration of mometasone furoate (MFNS) as a treatment for rhinosinusitis will 
have a substantial impact on medical resource costs, outcomes and possibly 
cost-effectiveness. The goal of this paper is to estimate the cost-effectiveness of 
treating patients with rhinosinusitis with MFNS versus amoxicillin. MethOds: A 
decision-analytic model was developed to estimate lifetime costs and outcomes 
associated with MFNS 200µg twice daily and amoxicillin 500mg three times daily 
in treating rhinosinusitis from the Mexican health care perspective. This study 
further do not included MFNS 200µg once daily as a treatment arm because it 
was not found to be superior to amoxicillin. Data sources included published 
literature, clinical trials, official price/tariff lists, and Delphi panel data. The time 
horizon was 2 weeks. The effectiveness outcomes of the study were modeled 
as changes in the Major Symptom Score (MSS). MSS consists of five questions 
concerning rhinorrhoea, post-nasal drip, nasal congestion, sinus headache, and 
facial pain. Costs were valued in US dollar, year 2012 values. Multiple 1-way 
sensitivity analyses and a probabilistic sensitivity analysis using Monte Carlo 
simulation were performed to handle uncertainty. Results: The projected costs 
were US$ 258 with MFNS and $US 272 with. The benefits (changes in the MSS) were 
0.52 with MFNS 0.45 with Amoxicilin. MFNS was associated with a cost savings 
per patient of US$ 14 versus amoxicillin over a period of 2 weeks from a health 
care perspective. The incremental cost-effectiveness ratio for MFNS dominated 
Amoxicilin. Sensitivity analysis confirmed the overall cost savings and gains 
in effectiveness. cOnclusiOns: Our analysis suggests MFNS improves health 
outcomes in a cost-effective manner compared with Amoxicilin. The economic 
value of Amoxicillin is influenced by difficulties involved in diagnosing the condi-
tion, effectiveness, resistance, patient compliance with treatment, and treatment 
failure associated with antibiotics.
RESPIRATORy-RELATED DISORDERS – Health Care Use & Policy Studies
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THE IMPACT OF PUBLIC FORMULARIES & gUIDELINES ON COMMUNITy 
ACQUIRED PNEUMONIA (CAP) DRUgS IN MExICO
Stevens C.A.1, Bache G.2
1PAREXEL Consulting, Waltham, MA, USA, 2PAREXEL Consulting, Uxbridge, UK
Objectives: Pharmaceutical spending in Mexico represents approximately 25% of 
total health expenditures, with this number expected to grow by 14% from 2009-
2014. 90% of Mexico’s population receives health care from the public health system 
or Popular Health Insurance (PHI). A private insurance market has begun to take root. 
This study looks at how the increase in price controls and guidelines may impact 
access to newly approved Community Acquired Pneumonia (CAP) drugs. MethOds: 
An array of published data such as pricing process, current policies, sector-specific 
research articles contributed towards a framework to understand the key factors 
affecting access to CAPs drugs, were gathered. The data then informed a telephone 
survey of national and regional health care stakeholders (N= 6). Results: Findings 
show that in Mexico: 1) New pressures through price negotiations are occurring 
due to economic challenges facing PHI; 2) Private purchasing of pharmaceutical 
products represents 56% of sold units worth 79% of total spend versus public pur-
chase representing 44% of sold units and 21% of total spend; 3) Formularies used by 
public coverage schemes require newly approved drugs for CAP to achieve marketing 
authorization, meet safety requirements and be cost effective versus comparator 
agents; and 4) International reference price serves as a benchmark for establish-
ing a price threshold. cOnclusiOns: Drugs used to treat CAP are compared to 
comparator agents based on cost effectiveness. This will determine placement in 
the public formulary. The private pharmaceutical market may use data from the 
public formulary system when making a determination on price. Existing clinical 
guidelines in the public sector are non-binding, leaving the final decision on use 
to physicians. However, patient access to drugs for CAP may be impacted based on 
price negotiations and cost effectiveness analysis.
PRS13
ASSESSMENT OF THE PERCEPTION AND PRACTICES wITH RESPECT TO 
ANTIBIOTIC USAgE IN PUBLIC THROUgH SOCIAL MEDIA
Priyendu A.1, Koundin A.2, Nagappa A.N.1
1Manipal University, MCOPS, Manipal, India, 2Indegene Life Systems Pvt. Ltd., Bangalore, India
Objectives: To assess the knowledge, perception and practices with respect 
to antibiotic usage amongst the Indian population with an aim to sensitize the 
survey participants about the consequences of misuse of antibiotics. MethOds: 
A questionnaire was designed around the use, misuse and consequences of anti-
biotic resistance based on latest National Policy for Antimicrobial Resistance of 
India. The survey was conducted using social media sites like facebook, twitter 
etc. The responses collected were classified as geographical locations, gender, 
age and occupation. Survey is designed in such a way that all the prevailing 
practices and views of the general public with respect to antibiotic usage are 
covered. Results: The prescription for antibiotic was 25% for common cold. 
Empirical antibiotic prescription was reported for 61% of the respondents. 14% 
preferred for a diagnostic test for guiding antibiotic prescription by doctors. 50% 
of the respondents preferred to purchase antibiotics directly from the chemist 
shops without the prescription of a doctor. Almost half of the respondents were 
not aware about the antibiotic resistance development due to environmental con-
tamination. 35% of the respondents affirmed to stopping the antibiotic regimen 
as soon as their symptoms subsided. cOnclusiOns: The antibiotic resistance 
is a global phenomenon requiring the immediate reforms to curb as the danger 
of multi-drug resistant bacteria is a ticking time bomb. Our results have clearly 
indicated the misuse of antibiotics by public and practitioners which needs to 
be monitored and corrected immediately to prevent the catastrophe of epidem-
ics by MDR bacteria as the new antibiotics are not invented and old drugs are 
becoming ineffective.
responsible for an enormous burden of disease in the region. This evidence-based, 
internally and externally valid HEM showed to be an adequate tool for the assess-
ment of the effects of smoking and could be a useful policy-making tool to estimate 
the cost-effectiveness of tobacco control interventions.
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CUSTOS DE PNEUMONIAS HOSPITALIzADAS NO BRASIL: ANáLISE 
COMPARATIvA POR DIFERENTES MéTODOS DE CUSTEIO
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de Tecnologia em Saúde (IATS), Goiânia - Goiás, Brazil, 3Faculdade de Enfermagem, Universidade 
Federal de Goiás, Goiânia - Goiás, Brazil, 4Departamento de Enfermagem, Pontifícia Universidade 
Católica de Goiás, Goiânia, Brazil, 5Instituto de Patologia Tropical e Saúde Pública, Universidade 
Federal de Goiás. Hospital da Criança, Goiânia - Goiás, Brazil
ObjetivOs: Comparar os custos do tratamento de crianças hospitalizadas por pneu-
monia bacteriana adquirida na comunidade, considerando diferentes metodolo-
gias de custeio. MétOdOs: Estudo prospectivo realizado em Goiânia, Goiás/Brasil. 
Crianças com 28 dias a 35 meses internadas em 2 hospitais foram avaliadas. Três 
metodologias de custeio foram consideradas na perspectiva do Sistema Único de 
Saúde: (i) bottom-up/micro-costing através da revisão de prontuários; (ii) top-down/
micro-costing através de diretriz terapêutica; e (iii) top-down/gross-costing através 
de ressarcimento pago pelo SUS. Casos foram pacientes internados com suspeita 
clínica de pneumonia, receberam antibioticoterapia durante a internação e não 
tiveram diagnóstico final de pneumonia viral. Casos graves foram aqueles interna-
dos em enfermaria enquanto os internados em unidade de terapia intensiva foram 
considerados muito graves. Foram considerados custos diretos (medicamentos, 
honorários médicos e de fisioterapia respiratória, exames e diárias hospitalares 
em UTI e enfermaria) e não-médicos (diárias de acompanhantes). Os custos foram 
estimados em dólares americanos (USD) e reais (R$) considerando a taxa de câmbio 
oficial (1 USD = R$ 1,875) em dezembro de 2011. O teste de Friedman foi utilizado 
para comparar os resultados. ResultadOs: Foram analisados 59 casos (52 graves 
e 7 muito graves). Os custos de casos graves foram R$ 781 (USD 416) por bottom-up/
micro-costing, R$ 641 (USD 342) por top-down/micro-costing e R$ 597 (USD 318) por top-
down/gross-costing (p= 0,015). Para os casos muito graves, os custos foram R$ 3.539 
(USD 1.887) por bottom-up/micro-costing, R$ 3.369 (USD 1.796) por top-down/micro-
costing e R$ 3.175 (USD 1.693) por top-down/gross-costing (p= 0,018). Para ambos os 
grupos, houve diferença significativa apenas entre bottom-up/microcosting e top-down/
gross-costing. cOnclusões: Nossos resultados sugerem a estimativa de custos por 
top-down/micro-costing através de diretriz terapêutica pode ser uma alternativa que 
se aproxima à estimativa considerando o bottom-up/microcosting através de revisão 
de prontuários, considerado o padrão ouro para estimativa de custos de doença.
PRS8
EFFECTIvENESS AND COST ANALySIS OF THE SMOkINg CESSATION PROgRAM 
IN THE PUBLIC HEALTH SySTEM IN BRAzIL
Mendes A.C.R.1, Barcellos R.M.S.2, Ritzel J.B.3, Ribeiro A.P.3, Pereira N.M.4, Oliveira V.C.5,  
Toscano C.M.6
1Federal University of Goias, Goiânia - Goiás, Brazil, 2Secretaria Municipal de Saúde de Goiânia, 
Goiânia - Goiás, Brazil, 3Ministério da Saúde, Brasília, Brazil, 4Universidade Federal de Goiás, 
Goiânia - Goiás, Brazil, 5Instituto Nacional de Câncer, Rio de Janeiro, Brazil, 6Departamento de 
Saúde Coletiva do Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás. 
Pesquisador do Instituto de Avaliação de Tecnologia em Saúde (IATS), Goiânia - Goiás, Brazil
Objectives: To assess the effectiveness and costs of the Smoking Cessation Program 
(SCP) in the Public Unified Health System (SUS) and to estimate the cost for its full 
implementation in the city of Goiânia, Brazil. MethOds: The SCP intervention targets 
group of smokers, and includes medical visits, cognitive-behavioral group therapy, 
and medication use, lasting six months. Costs for SCP intervention and manage-
ment were estimated. The SCP full implementation was defined as the program’s 
expansion to meet the demand of all smokers motivated to quit smoking in the city 
of Goiânia. Direct medical and non-medical direct costs were considered, including 
staff, medications, consumables, general expenses, transportation, travel, events and 
capital costs. Microcosting and activity-based costing methods were used. Cost for 
the federal, state and municipal levels were estimated. The SUS perspective was 
considered. Two-way sensitivity analysis was conducted. Data sources included a 
convenience sample of primary health facilities, municipal and state health depart-
ments, and the Ministry of Health. Costs were estimated in Reais (R$) and U.S. Dollars 
(USD), considering the exchange rate of December/2010, which was 1.67. Quitting rates 
were estimated as the percentage of patients who reported not smoking at the end 
of the intervention. Costs of the SCP are presented as total cost of the intervention; 
costs stratified by component and level of funding source; cost per patient; and cost 
per quitter. Results: The average quitting rate was 37.2%. The cost of SCP in Goiânia 
was R$428,580 (US$257,220), of which 23% were program management costs. Cost 
per patient was R$534 (US$320) and cost per quitter was R$1,433 (US$860). The SCP’s 
full implementation reaching the estimated 37,455 smokers in Goiânia motivated to 
quit would cost R$21.5 million (US$13). cOnclusiOns: The SCP is highly effective. 
Additional efficiency could be gained by expanding patient’s access to the program.
PRS11
CLINICAL AND ECONOMIC ANALySIS OF MOMETASONE FUROATE NASAL 
SPRAy IN THE TREATMENT OF RHINOSINUSITIS IN MExICO
Rely K.1, Blandon V.2, Fonseca A.3, Cañedo A.4, Salinas G.E.5, Alexandre P.K.6
1CEAHealthTech, Mexico City, Mexico, 2Merck Sharp & de Mexico, México D.F., Mexico, 3Merck 
Sharp & Dohme, Mexico City, Mexico, 4Instituto Nacional de Neurología y Neurocirugía, México 
D.F., Mexico, 5Hospital Infantil de México Federico Gómez, Secretaría de Salud, Mexico, D.F., 
Mexico, 6Johns Hopkins University, Baltimore, MD, USA
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robust in the one-way sensibility analyses and the probabilistic sensitivity analy-
sis indicating that the absence of monitoring strategy has the highest probability 
of cost-effectiveness cOnclusiOns: Long-run WBC monitoring based on current 
national detection guidelines is not cost-effective, even by unrealistically high 
agranulocytosis prevalence. New guidelines are needed to improve WBC monitor-
ing in schizophrenic patients receiving Clozapine.
PSy2
OSTEOTOMIA DE ACORTAMIENTO RADIAL EN LA ENFERMEDAD DE kIENBOCk 
(SEgUIMIENTO DE 5 AñOS)
Vazquez Alonso F.
imss hospital de traumatologia y ortopedia lomas verdes, naucalpa edo de mexico, Mexico
ObjectivOs: evaluar los resultados clinicos y funcionales ( grado de satisfacción 
) de paciente con enfermedad de kienbock ttratados con osteotomia de acor-
tamiento radial. MetOdOlOgías: estudio realizado en la umae de traumato-
logia y ortopedia lomas verdes del imss, en el servicio de cirugia de mano, en 
un periodo comprendido entre 2000 al 2003, con seguimiento de 5 años.estudio 
retrospectivo, observacional, transversal. se estudiaron ´18 pacientes de ambos 
sexos con diagnostico de enfermedad de kienbock utilizando la clasificacion de 
litchman, evaluados con las escala de wrist mayo score y QDash. pba estadistica 
de wiscolson ResultadOs: se obtuviero 18 paciente 9 mujeres y 9 hombres, el 
84% obreros 16% al hogar, de acuerdo al resultados de la escla funcional wrist 
mayo score fueron 56% buenos, 33% excelentes, 5.5% malo, 5% regulares, con 25 
puntos de grado de satifaccion de acuerdo al QDash. un paciente fue reinterve-
nido 2 años posteriores al cual se le realizo una artrodesis delas cuatro esqui-
nas. cOnclusiOnes: la evaluacion clinica y funcional, sugiere una eficacia 
aceptable de la osteotomia de acortamiento radial y provee datos alentadorespara 
continuar con este tipo de tratamiento.
PSy3
THE RELATIONSHIP BETwEEN SPECIFIC ANNUAL BLEED RATES AND HEALTH 
OUTCOMES AMONg CHILDREN wITH SEvERE HEMOPHILIA A IN LATIN 
AMERICA
Perez Bianco P.R.1, Berges A.2, Linares A.3, Moreno B.4, Arvizu J.5, Brabata C.5, Xiong Y.6, Ito D.6
1Instituto de Investigaciones Hematologicas - Academia Nacional de Medicina, Buenos Aires, 
Argentina, 2Instituto Mexicano del Seguro Social. Centro Medico Nacional La Raza Hospital 
General, Azcapotzalco, Mexico, 3Clinica Infantil Colsubsidio, Bogotá, Colombia, 4Fundacion 
Panamena de Hemofilia/Hospital del Nino, Panama City, Panama, 5Baxter Healthcare Corporation, 
Miami, FL, USA, 6Baxter Healthcare Corporation, Westlake Village, CA, USA
Objectives: Recurrent bleeding among severe hemophilia A children can lead to 
disability and lower health-related quality of life (HRQOL). Little is known about 
how many bleeds can be endured before patients report an impact on health 
outcomes. The objective was to assess health outcomes of pediatric patients 
reporting a zero annual bleed rate (ABR) to identify the impact of higher ABRs on 
outcomes. MethOds: This cross-sectional survey of parents of severe hemophilia 
A patients aged 2-17 was conducted in Argentina, Chile, Colombia, Mexico and 
Panama. Eligible, consenting patients completed a questionnaire: from October-
November 2009 (Argentina), June-August 2011 (Chile, Colombia, Mexico) and 
September-October 2012 (Panama). HRQOL was measured by the Pediatric Quality 
of Life Inventory (PedsQL). ABR, target joints and school days missed were also 
assessed. Results: A total of 211 parents of severe hemophilia A children com-
pleted the survey. Compared to patients with a 0 ABR who reported a mean PedsQL 
Total score of 76.6, patients with ABR categories of: 3-4, 5-10, 11-20, 21-30, 31-50, 51 
or more showed significantly worse mean PedsQL Total scores of: 66.4, 63.5, 67.4, 
62.5, 62.4 and 59.9 respectively (all p< 0.05). Similarly, compared to patients with 0 
ABR who reported a mean number of target joints of 0.69, patients with higher ABR 
categories showed significantly higher mean target joints: 1.49, 2.57, 3.42, 3.47, 3.74, 
4.67 (all p< .05). Differences in missed days from school showed the same significant 
trend when comparing 0 ABR to ABR categories of 3-4 and beyond. There were no 
significant differences between patients with zero compared to 1-2 ABR on these 
health outcomes. cOnclusiOns: This analysis suggests that even 3-4 bleeds/year 
may have a negative impact on a patient’s joint health, missed school days and 
HRQOL. Efforts to maintain a 0 ABR among pediatric patients with severe hemophilia 
A may help ensure optimal outcomes.
PSy4
EFFICACy AND SAFETy OF BELIMUMAB FOR THE TREATMENT OF SySTEMIC 
LUPUS ERyTHEMATOSUS
Borba H.H.L., Wiens A., Correr C.J., Pontarolo R.
Universidade Federal do Paraná, Curitiba, Brazil
Objectives: To evaluate the efficacy, safety and tolerability of 1 and 10 mg/kg beli-
mumab, a biologic drug, for the treatment of Systemic Lupus Erythematosus (SLE) 
through a meta-analysis, comparing these treatments with placebo. MethOds: A 
systematic review and meta-analysis of randomized, placebo-controlled trials of beli-
mumab was conducted. Data were collected from several databases until August 2012. 
Efficacy outcomes included the SELENA-SLEDAI score (Safety of Estrogens in Lupus 
Erythematosus National Assessment version of the SLE Disease Activity Index), SRI 
(Systemic Lupus Erythematosus Responder Index), normalization of low C3 (< 90 mg/
kg), and anti-dsDNA positive to negative. Data on safety included any adverse events, 
serious adverse events, severe adverse events, death, malignancy, infections, and infu-
sion reactions. We also evaluated withdrawals from treatment due to lack of efficacy 
or adverse events. Results: Fours studies were included in this study. Anti-dsDNA 
positive to negative was the most significant efficacy outcome in our meta-analysis for 
both of the evaluated concentrations. No significant differences in the safety data were 
observed between the belimumab (1 and 10 mg/kg) and placebo groups. Tolerability 
results revealed no significant differences in withdrawals due to lack of efficacy 
and adverse events between the belimumab and placebo groups. cOnclusiOns: 
Belimumab exhibited good efficacy results, especially at 10 mg/kg, a good safety profile, 
and adequate tolerability, which indicates that this biologic drug is a promising therapy 
PRS14
LEvEL OF ASTHMA CONTROL AND HEALTH CARE UTILIzATION IN LATIN 
AMERICA
Montealegre-Golcher F.1, Gold L.2, Allen-Ramey F.3, Jardim J.R.4, Sansores Martinez R.H.5, 
Sullivan S.2
1MSD, Carolina, PR, USA, 2University of Washington, Seattle, WA, USA, 3Merck & Co., Inc., West 
Point, PA, USA, 4Federal University of Sao Paulo, Sao Paulo, Brazil, 5Centro Respiratorio de México 
S.C., Delagacion Tlalpan, Mexico
Objectives: Data on the impact of asthma in Latin American countries is limited. 
The purpose of this study was to examine the association between partly- and 
uncontrolled asthma and asthma-related health care outcomes among patients 
residing in Argentina, Brazil, Mexico, Venezuela and the Common wealth of Puerto 
Rico. MethOds: Adults and parents of adolescents (12-17 years) with physician 
diagnosed asthma and asthma medication use or asthma attacks in the past year 
were surveyed as part of the 2011 Latin America Asthma Insights and Management 
(AIM) survey. Using Global Initiative for Asthma (GINA) guidelines as a reference, 
respondents were categorized into three levels of asthma control: well-controlled, 
partly- controlled, and uncontrolled. Chi-square tests and adjusted logistic regres-
sion were used to determine odds ratios (ORs) to assess the relation of degree of 
asthma control with utilization of asthma medications, health care outcomes, and 
productivity. Results: Data was available for 2169 completed surveys. Overall, 
7% of the patients surveyed had asthma that was classified as well-controlled, 
with the highest proportion in Mexico (9.4%) and the lowest in Venezuela (3.0%). 
Patients whose asthma was not well-controlled were significantly more likely to 
report use of asthma medications (ORs ranging from 1.5-42) and to have had emer-
gency health care visits or hospitalizations for their asthma in the previous year 
(ORs ranging from 2.1-5.9). Respondents with uncontrolled asthma also reported 
significant decreases in productivity due to asthma compared to patients with 
well-controlled asthma. cOnclusiOns: Patients who did not have well-controlled 
asthma had greater utilization rates of asthma medications and emergency health 
care services compared to patients whose asthma was well-controlled. These asso-
ciations strongly suggest that emphasis on improving asthma control could have 
substantial effects on patient productivity and utilization of health care resources.
PRS15
CARACTERíSTICAS SOCIOECONóMICAS DE PACIENTES CON ENFERMEDAD 
vASCULAR CEREBRAL y ANTECEDENTES DE TABAQUISMO TRATADOS EN UN 
HOSPITAL DE TERCER NIvEL DE MéxICO
Quintana Carrillo R.H.1, Matamoros Márquez M.2, Quintana Carrillo E.A.3, San-Juan D.4, 
Aguirre-Cruz L.4
1Universidad Nacional Autónoma de México, Instituto Nacional de Enfermedades Respiratorias, 
Mexico, Mexico, 2Universidad Nacional Autónoma de México, Mexico, Mexico, 3Universidad 
Autónoma de Campeche, Campeche, Mexico, 4Instituto Nacional de Neurología y Neurocirugía, 
Mexico, Mexico
ObjectivOs: Determinar las variables socioeconómicas asociadas a pacientes con 
enfermedad vascular cerebral (EVC) y antecedentes de tabaquismo, tratados en 
un centro neurológico de tercer nivel en México. MetOdOlOgías: Es un estudio 
cuantitativo, descriptivo, transversal y retrospectivo. Los pacientes debían tener 
edades ≥ 35 años, antecedentes de tabaquismo y diagnóstico de EVC; clasificados 
por el sistema CIE-10 (I60-I69). Se revisaron 174 expedientes del 2011. Se utilizó el 
análisis de componentes principales para estimar los pesos de las variables socioec-
onómicas. La adecuación del modelo se realizó mediante la medida de Kaiser-Meyer-
Oklin (KMO), la prueba de Bartlett y la consistencia interna mediante el alpha de 
Crombach (α ). ResultadOs: De los 174 pacientes 78(45%) presentaron antecedentes 
de tabaquismo y de estos 49(63%) fueron hombres, con 58±14 (media, DE) años de 
edad y 9.4±5.3 de escolaridad, nivel socioeconómico de 2.3±1.1, 71(91%) habita en 
departamentos populares y 37(47%) se dedicaron al hogar o fueron trabajadores no 
calificados. Se obtuvo un α = 0.80, KMO= 0.78 y Bartlett (p= 0.000). Dos componentes 
explicaron 58.3% de la varianza total. El primero; (42.02%), se integró por las vari-
ables servicio intra-domiciliario (Ponderación;0.763), estatus socioeconómico (0.749), 
escolaridad (0.748), zona de ubicación (0.673), material de construcción (0.707), ubi-
cación de la vivienda (0.673) y ocupación (0.437). el segundo; (16.24%), con el tipo de 
vivienda (0.564) y número de habitaciones (0.460). cOnclusiOnes: Los pacientes 
atendidos por EVC se caracterizaron por niveles bajos de escolaridad y clasificación 
socioeconómica, ocupaciones poco remunerables y edad avanzada; que los hace 
vulnerables a la enfermedad.
SySTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
PSy1
AgRANULOCyTOSIS DETECTION OUTCOME By CLOzAPINE TREATMENT (ADOC 
STUDy) IN PSyCHIATRy: A COST-EFFECTIvENESS STUDy
Girardin F., Poncet A., Blondon M., Vernaz N., Combescure C.
University of Geneva Hospitals, Geneva, Switzerland
Objectives: White Blood Cell (WBC) monitoring in schizophrenic patients treated 
by Clozapine aims to prevent agranulocytosis. We assess the cost-effectiveness of 
WBC monitoring strategies based on three national regulations and an additional 
weekly short-run monitoring compared to the absence of monitoring. MethOds: 
A decision analytic model was built to perform a cost-utility analysis comparing 
distinct monitoring strategies from a health care perspective with a 3-year time 
horizon. Clinical and resources used parameters were based on national Clozapine 
patients’ registries, cohorts, and pharmacovigilance data; health-related quality 
of life and mortality estimates were derived from literature reviews. Robustness 
of results was challenged with one-way and probabilistic sensitivity analy-
ses. Results: Compared to the absence of monitoring, the number needed to treat 
of all strategies to avoid one death was 5,000. The gains in survival time adjusted 
on quality of life were less than 1 day, resulting in prohibitive incremental cost-
effectiveness ratios (ICER) of at least 1 million USD per QALY gained,. The ICER 
increased with higher frequency and longer monitoring duration. The results remain 
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hibidores, el costo promedio por paciente/mes en demanda es de $ 26,427,616 y el 
costo promedio paciente/mes en profilaxis secundaria es de $ 23,032,817 (p= 0,456). 
Sin contabilizar los medicamentos antinhibidores el costo promedio por paciente/
mes en demanda es de $ 4,143,308 y el costo promedio paciente/mes en profilaxis 
secundaria es de $ 19,113,948 (p< 0,0001). cOnclusiOnes: No se observa diferen-
cia significativa en la tasa de sangrados en los grupos de profilaxis secundaria y 
demanda. El grupo de pacientes con inhibidores experimenta el mayor costo dentro 
de la población observada. Al excluir los inhibidores el costo promedio/paciente/mes 
en profilaxis secundaria es 4,6 veces mayor que el costo en tratamiento a demanda.
PSy8
BIOLOgICAL AgENTS IN THE TREATMENT OF MODERATE TO SEvERE PSORIASIS: 
A PHARMACOECONOMIC ANALySIS
Riveros B.S., Souza T.T., Godoy R.R., Garcia M., Gonçalves P., Rotta I., Otuki M.F., Pontarolo R., 
Correr C.J.
Universidade Federal do Paraná, Curitiba, Brazil
Objectives: To evaluate the cost-effectiveness of biologic agents in the treatment 
of moderate to severe psoriasis. MethOds: Four biologics were assessed: adali-
mumab, etanercept, infliximab and ustekinumab. Direct costs were obtained from 
the perspective of Brazilian Public Health Service (SUS). Probabilities and efficacy 
were extrapolated from literature. Unit costs is the Brazilian currency – Real (R$) 
– and the outcomes considered were PASI90 and PASI75 response (rPASI90 and 
rPASI75, respectively). For each outcome one Markov Model was created with 12 
cycles of 3 months (3 years). Annual discounting of 5% was applied for costs and 
outcomes. The model considered patients with moderate to severe psoriasis who 
had Psoriasis Severity Index or Dermatology Quality of Life Index greater than 10 or were 
unable to take standard systemic therapies. Univariate and probabilistic sensitivity 
analysis was applied to evaluate parametric uncertainties. Results: Results were 
expressed as the financial resources demanded for each patient that have achieved 
and kept rPASI90 or rPASI75. Regarding rPASI90, adalimumab showed to be domi-
nant against the other biologics with a total cost of R$ 64,588.79 (U$ 32,714.78) and 
33,7% of patients with rPASI90 after 3 years of treatment (R$ 191,658.13/rPASI90, U$ 
97,076.50/rPASI90). When rPASI75 is considered as the measure of outcome, adali-
mumab and ustekinumab were dominant against infliximab and etanercept, with R$ 
124,200.41/rPASI75 (U$ 62,908.58/rPASI75) and R$ 114,230.59/rPASI75 (U$ 57,858.78/
rPASI75), respectively. Univariate sensitivity analysis pointed acquisition cost of bio-
logics as the main critical variable. Probabilistic sensitivity analysis shows robust-
ness of our findings. cOnclusiOns: From the perspective of SUS, adalimumab is 
the most cost-effective biological agent for rPASI90. Threshold up to R$ 124,000/
rPASI75 (U$ 62,807.07/rPASI75) favors ustekinumab as the most cost-effective drug, 
while threshold greater than that point to adalimumab. Is being conducted a new 
Markov modelling to evaluate which sequence of biologic agents is the most cost-
effective when failure of initial biological treatment occurs.
PSy9
A COST-EFFECTIvENESS MODEL COMPARINg SUB-CUTANEOUS BIOLOgIC 
TREATMENT FOR SEvERE PLAQUE PSORIASIS IN MExICO
Valencia A.1, Hernandez A.1, Puig A.2
1Janssen, Mexico City, Mexico, 2Johnson and Johnson World Headquarters, New Brunswick, NJ, 
USA
Objectives: To evaluate the cost-effectiveness of different sub-cutaneous bio-
logic treatments for severe plaque psoriatic patients in public institutions in 
Mexico. MethOds: A Markov model was developed to simulate patients with 
moderate-to-severe plaque psoriasis. Biologic therapies compared were usteki-
numab 45mg every 12 weeks, adalimumab 40mg every two weeks, and etanercept 
50mg twice a week. Measured by the Psoriasis Area and Severity Index (PASI), clinical 
response was derived from the latest published meta-analysis. PASI response was 
translated into QALYs in two steps: (1) defining the correlation between PASI levels 
and the Dermatology Life Quality Index (DLQI); and (2) using a formula to predict 
utility from DLQI score derived from a mapping exercise of the DLQI with the EQ-5D. 
The model considered expenditure on drugs, monitoring visits, adverse events and 
inpatient stays. Costs were obtained from Mexican public institutions. Health and 
economic outcomes were estimated over a 10-year time horizon with cycle length 
of 12 weeks. Cost and QALYs were discounted at 5% annually. Results: Etanercept 
is the least costly treatment in Mexican public institutions followed closely by adali-
mumab and ustekinumab. Cost-effectiveness analysis shows that adalimumab was 
an extended dominated strategy by ustekinumab. The incremental cost-per-QALY 
of ustekinumab versus etanercept was US$19,542. cOnclusiOns: Considering the 
GDP per-capita of Mexico in 2010 (US$9,123), and according to the WHO Commission 
on Macroeconomics and Health, ustekinumab is a cost-effective strategy (≤ 3xGDP 
per-capita /QALY gained) versus etanercept, and a more cost-effective strategy vs 
adalimumab by extended dominance. Probabilistic sensitivity analysis results did 
not change the conclusions.
PSy10
ANáLISIS COSTO-EFECTIvIDAD DEL TRATAMIENTO FARMACOLógICO PARA 
LAS MANIFESTACIONES CLíNICAS MUCOCUTáNEAS DE LA ENFERMEDAD DE 
BEHCET
Quirland Lazo C.
Universidad de Chile, Santiago, Chile
ObjectivOs: Determinar la efectividad de la intervenciones farmacológicas dis-
ponibles en Chile para tratar las manifestaciones clínicas de tipo mucocutáneas, 
esto es úlceras orales (UO) y genitales (UG), en la Enfermedad de Behcet (EB). 
Conducir un análisis de costo-efectividad para determinar la alternativa superior 
entre los dos tratamientos que resulten más efectivos. MetOdOlOgías: Se efectuó 
una revisión de la literatura de los trabajos publicados entre 1980-2010, disponibles 
en las bases de dados MEDLINE y Cochrane Library. Se incluyeron en los criterios 
de selección todos los estudios clínicos controlados, aleatorizados, además de revi-
siones sistemáticas y meta-análisis disponibles bajo las palabras claves enfermedad 
for the treatment of SLE. Additional randomized placebo-controlled trials should be 
conducted to establish the efficacy and safety of belimumab.
SySTEMIC DISORDERS/CONDITIONS – Cost Studies
PSy5
IMPACTO FINANCIERO DEL TRATAMIENTO FARMACOLógICO EN PACIENTES 
ADULTOS CON ENFERMEDAD DE gAUCHER TIPO 1 EN MéxICO
Soto-Molina H.1, Pizarro M.2, Huicochea-Bartelt J.L.3, Rubio-Borja M.E.3, Muciño-Ortega E.3, 
Galindo-Suárez R.M.3
1Comercializadora Iteliness S.A. de C.V., Ciudad de México, Mexico, 2Hospital Infantil de Mexico 
Federico Gomez, México D.F., Mexico, 3Pfizer S.A. de C.V., Ciudad de México, Mexico
ObjectivOs: La enfermedad de Gaucher (EG) es una enfermedad de baja preva-
lencia caracterizada por deficiencia de la enzima glucocerebrosidasa ácida, que 
promueve la acumulación del sustrato glucocerebrósido en lisosomas de monocitos-
macrófagos, lo que conduce a hipertrofia del sistema lisosomal celular, infiltrando 
tejido esquelético, medula ósea, bazo, hígado, pulmones y cerebro, causando dis-
función orgánica. El uso de la terapia de remplazo enzimático (TRE) revierte la orga-
nomegalia, previene complicaciones e incrementa la calidad de vida. El propósito 
del estudio fue evaluar el impacto económico de la TRE en pacientes con EG tipo 
1 desde la perspectiva institucional Mexicana. MetOdOlOgías: La prevalencia 
en México de pacientes con EG se extrajo de fuentes publicadas. Se estimaron los 
costos promedio del tratamiento de las TRE disponibles en México en pacientes 
de alto riesgo (60UI/Kg cada 2 semanas durante 6 meses, posteriormente 30UI/
Kg durante 6 meses) y de bajo riesgo (30UI/Kg cada 2 semanas durante 6 meses, 
posteriormente 20UI/Kg durante 6 meses). Los costos de adquisición de las TRE se 
extrajeron de fuentes gubernamentales y se expresan en US$ de 2012. Se estimó el 
impacto presupuestal del uso de TRE a nivel institucional en base al Presupuesto de 
Egresos de la Federación (2012). ResultadOs: El número de pacientes con EG tipo 
1 fue de 22 para bajo riesgo y 8 para alto riesgo. El costo promedio anual de la TRE 
por paciente de bajo riesgo fue de US$153,265, para pacientes de alto riesgo fue de 
$260,551, un 70% más. La carga financiera para las instituciones de salud pública 
fue aproximadamente US$338,000 para pacientes de bajo riesgo y US$575,000 para 
pacientes de alto riesgo, lo que agregado representa el 0.016% del gasto público en 
salud de México. cOnclusiOnes: La estimación del impacto presupuestal de la TRE 
en México es relevante para la planeación de los recursos financieros necesarios.
PSy6
ANáLISIS DE LA CARgA FINANCIERA DE LAS PRINCIPALES ENFERMEDADES 
REUMATOLógICAS
Goycochea M.1, García O.1, Peláez I.1, Tobón U.1, Julian F.1, Rodriguez Mendoza M.M.2, Soto H.3
1Hospital Regional de Alta Especialidad Oaxaca, Oaxaca, Mexico, 2Universidad Autónoma 
Metropolitana, Distrito Federal, Mexico, 3Health Solutions Consulting, D. F., Mexico
ObjectivOs: Realizar un análisis de la carga financiera desde la perspectiva del 
paciente de las principales enfermedades reumatológicas y qué impacto tiene en el gasto 
de las familias en el estado de Oaxaca, México. MetOdOlOgías: Se evaluó el gasto 
catastrófico de las enfermedades reumáticas. En 2011 se encuestó a nueve pacientes 
diagnosticados con enfermedades reumatológicas del hospital de especialidades de la 
SSA y hospitales privados (tres de artritis reumatoide (AR), cuatro de Lupus eritomatoso 
sistémico (LES), uno de Dermatomiositis y uno de Espondilitis Anquilosante (EA)). El 
instrumento de recolección de datos se centró en la carga financiera del manejo de la 
enfermedad. Se evaluaron los costos médicos directos (fisioterapia, estudios de labora-
torio y tratamiento farmacológico), intervenciones quirúrgicas y costos de transporte. 
Se estimó el costo anual del tratamiento con rituximab (2 infusiones de 1000mg por año) 
y qué impacto representaría para el ingreso familiar. ResultadOs: El costo médico 
promedio anual ascendió a $43,271.00, el costo promedio anual con gasto en transporte 
ascendió a $55,537.78, montos que representan el 61% y 79% del ingreso promedio de 
las familias. El 83% de los gastos médicos son causados por gasto en medicamentos. Las 
enfermedades que generaron mayores gastos médicos fueron LES ($7,339.44 promedio 
mensual), Dermatomiositis $4,800 y AR con $1,405.56 promedio mensual. Los gastos 
inesperados como intervenciones quirúrgicas causadas por la enfermedad $9,000 pro-
medio y las hospitalizaciones por complicaciones $8,500. El costo anual del tratamiento 
con rituximab asciende a $117,66.60 monto que representa el 167% del ingreso de las 
familias. cOnclusiOnes: El costo de las enfermedades reumatológicas genera una 
carga financiera importante, los pacientes diagnosticados por una causa reumatológica 
ven mermada su situación financiera, es decir, incurren en gastos catastróficos en salud. 
El uso de tratamientos biológicos sobrepasa los ingresos anuales de las familias.
PSy7
ANáLISIS ECONOMICO DE LA PROFILAxIS SECUNDARIA vERSUS EL 
TRATAMIENTO A DEMANDA DE UNA COHORTE DE PACIENTES COLOMBIANOS 
CON HEMOFILIA A y B SEvERA
Ruiz A.F.1, Guarin N.E.2, Diaz J.A.3, Arevalo H.O.2, Portilla A.1, Machado J.E.1
1Audifarma, Bogotá, Colombia, 2Salud Total, Bogotá, Colombia, 3Facultad de Ciencias, Universidad 
Nacional de Colombia, Bogotá, Colombia
ObjectivOs: Evaluar las diferencias en efectividad y costos de la pro-
filaxis secundaria vs el tratamiento a demanda en pacientes con hemofilia 
severa. MetOdOlOgías: Pacientes: Seguimiento retrospectivo durante 30 meses 
a una cohorte de 52 pacientes con diagnóstico confirmado de Hemofilia A y B severa, 
atendidos por una institución prestadora de servicios de alta complejidad a nivel 
nacional. La permanencia minina dentro de la cohorte fue de 12 meses. Perspectiva: 
Asegurador. Desenlaces en salud: promedio de sangrado articular/pacientes/mes. 
Costos: Se evaluaron los costos médicos directos (atención hospitalaria, atención 
ambulatoria, urgencias, medicamentos), tomados del sistema de información del 
asegurador y del prestador a precios de 2012, en COP. ResultadOs: Desenlaces en 
Salud: Los 52 pacientes aportaron 847 meses de tratamiento en demanda con 154 
sangrados y 539 meses en profilaxis con 93 sangrados. La tasa de sangrado paciente/
mes fue de 0,18 para demanda y de 0,17 para profilaxis (p= 0,627), con un RR de 
0,949 (IC95% 0,78 - 1,15). Costos: Si se toma en cuenta la administración de antin-
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have investigated the utility of pharmacotherapy and epidural steroid injections (ESI) 
in large practice setting. We sought to gather comprehensive data about the char-
acteristics, efficacy, tolerability and quality of life (QoL) of patients with LBP with 
these therapies. MethOds: Information was collected on a standardized form. 
Information included patient characteristics, type and duration of therapies, adverse 
events, pain relief using visual analogue scale (VAS) and QoL by measuring disability 
using modified ODQ at each month of follow-up. Results: Consecutive 81 patients 
were recruited and followed for 6 months. Average baseline pain duration was found 
to be 45.5 months. Combination of drugs and ESI was given in 75 (92%) patients. 
Anticonvulsants (75%) and Antidepressants (57%) were most commonly prescribed 
medications. Change in VAS & ODQ score from baseline to each follow-up at 3 months 
(VAS - 15), 6 months (VAS -25) was significantly (P < 0.05) improved. cOnclusiOns: 
Pregabalin and amitriptyline were most commonly used drugs with maximum pain 
relief and improved Qol. Desired pain relief fluctuated with time. ESI can be promising 
choice when desirable pain relief is not achieved with medications.
SySTEMIC DISORDERS/CONDITIONS – Health Care Use & Policy Studies
PSy14
MULTI-CRITERIA BENEFIT-RISk ASSESSMENT OF BIOLOgICAL AgENTS IN THE 
TREATMENT OF MODERATE TO SEvERE PSORIAIS: A STOCHASTICAL APPROACH
Riveros B.S., Rotta I., Garcia M., Souza T.T., Godoy R.R., Gonçalves P., Otuki M.F., Pontarolo R., 
Correr C.J.
Universidade Federal do Paraná, Curitiba, Brazil
Objectives: To evaluate the benefit-risk of biological agents (BA) in the treatment of 
moderate to severe psoriasis. MethOds: It was performed a mixed treatment com-
parison (MTC) based on all available clinical trials of psoriasis treated with BA. The 
common agent comparator was placebo and the time-horizon was up to 24 weeks 
of treatment. This indirect meta-analysis was followed by a stochastic multicriteria 
acceptability analysis (SMAA) to compare adalimumab, etanercept, infliximab and 
ustekinumab on two benefit and two risk criterias. Efficacy was evaluated by means 
of Psoriasis Area Severity Index 90 and 75 response (rPASI90 and rPASI75, respectively) 
and the risks corresponded to any adverse event (AAE) and serious adverse event 
(SAE). MTC/SMAA analysis was performed for two scenarios: one with missing out-
come preference and the other with ordinal preference information established 
by experts in psoriasis (SAE > rPASI90 > rPASI75 > AAE). Results: Results show 
the same tendency for both created scenarios. Infliximab 5 mg/kg had the highest 
probability of being the 1st-place in MTC/SMAA ranking (84% to 67%). It was followed 
by ustekinumab 90 mg for the 2nd-place (54% to 50%), ustekinumab 45 mg for the 
3rd-place (51% - 50%), adalimumab 80 mg followed by 40 mg (51% - 47%), etanercept 
50 mg TW (74% to 62%) and placebo in the 6th-place(97% - 94%). cOnclusiOns: 
From all available evidence on treatment with BA for psoriasis, the designed method 
was enabled to point that infliximab 5 mg/kg is the BA with the highest probability 
of having the best benefit-risk ratio in the short-term follow up. It is followed by 
ustekinumab 90mg, ustekinumab 45 mg, adalimumab 80--> 40 mg, etanercept 50 
mg TW and placebo, respectively. Our findings can be useful to help on deciding 
which sequence of BA must be defined by guidelines and health services when 
therapy failure happens.
PSy15
DIRECT HEALTH CARE COSTS OF PATIENTS SwITCHINg BIOLOgIC THERAPIES 
IN CHRONIC PLAQUE PSORIASIS
Qureshi A.1, Mallya U.2, Zhang X.3, Li L.3, Lahoz R.4
1Harvard Medical School, Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, 
East Hanover, NJ, USA, 3Beijing Novartis Pharma Co., Ltd., Shanghai, China, 4Novartis 
Pharmaceuticals AG, Basel, Switzerland
Objectives: To describe patient characteristics and costs associated with first year 
biologic therapy use in psoriasis patients who switched or remained on biologic 
therapy. MethOds: Adult patients with psoriasis diagnosis (ICD-9 CM 696.1 or 696.8 
codes, excluding psoriatic arthritis (ICD-9-CM 696.0), rheumatoid arthritis(ICD-9-CM 
714.x), ankylosing spondylitis(ICD-9-CM 720.0), Crohn’s disease(ICD-9-CM 555.x) or 
ulcerative colitis(ICD-9-CM 556.x)) with continuous insurance coverage for one year 
pre and post first biological therapy prescription, having at least one prescription of 
adalimumab, etanercept, infliximab or ustekinumab and no previous use of biologic 
were selected from a privately insured MarketScan® commercial and Medicare 
database, 2012 . Two patient cohorts of switchers and non-switchers were defined 
based on gap of 60 days of therapeutic benefit. Analyses included descriptive sta-
tistics and per member per year costs. Results: Of the 2848 patients who met the 
study criteria, 8.32% (n= 237) switched(S) to another biologic therapy, 1305 (45.82%) 
remained on initial biologic therapy (non-switched (NS)) and 1,306 (45.86%) discon-
tinued their treatment within the first year of initiating biologic therapy. The mean 
age(SD) was 46.9(13.3) years with a higher percentage of males in the non-switched 
group than switched and discontinued groups (59.4% vs. 51.1% and 52.5%, respec-
tively). One year post start of biologic therapy, total health care cost per patient 
(S: US$38,529(24,328), NS: US$32,822(15,913)), all cause hospitalization cost per 
patient (S: US$1713(12,528), NS: US$911(4663)) and all cause emergency room cost 
per patient (S: US$447 (1300), NS: US$266 (1000)) were higher among patients who 
switched to another biologic therapy than among patients who remained on their 
initial biologic therapy. cOnclusiOns: Although few patients switched from their 
initial biologic therapy within first year of initiating treatment, higher direct health 
care costs were observed in this patient group compared to those who remained 
on their initial therapy. These results suggest an unmet need among patients that 
switch biologic therapies in psoriasis.
PSy16
ORPHAN DRUg ACCESS: RISk/REwARD ANALySIS OF LOCAL CLINICAL 
DEvELOPMENT IN CHILE
Ismail A., Dummett H.
Double Helix Consulting, London, UK
de Behcet y tratamiento farmacológico. La evaluación farmacoeconómica se llevó a 
cabo, utilizando un modelo de efecto fijo, desde la perspectiva de un paciente adulto, 
con sistema previsional de salud público, EB activa y las manifestaciones clínicas 
seleccionadas, diagnosticado según el criterio del International Study Group, en 
un horizonte temporal de un año. El análisis de decisión para las dos alternativas 
más efectivas se llevó a cabo a través de DATA 3.5. ResultadOs: De los 38 estu-
dios encontrados en cada una de las bases de datos, 15 cumplieron los criterios de 
selección, con los cuales se calculó el efecto de la intervención. Las alternativas más 
efectivas resultaron ser talidomida de 100 y 300 mg y la suspensión de sucralfato. 
Una vez realizado el análisis costo-efectividad, la suspensión de sucralfato fue domi-
nada por talidomida de 100 mg. cOnclusiOnes: A pesar de la falta de evidencia en 
enfermedades raras y eficacia de tratamientos clásicos, fue posible proponer una 
alternativa costo-efectiva para la EB. No obstante, dada la heterogeneidad de las 
manifestaciones clínicas en enfermedades raras y los costos de los tratamientos, 
resulta necesario proponer análisis alternativos a la costo-efectividad, que permitan 
apoyar a toma de decisiones para estos grupos de pacientes.
PSy11
ANáLISIS DE COSTO-EFECTIvIDAD PARA EL MANEjO FARMACOLógICO DE LA 
HEMOFILIA A SEvERA EN 5 ENTIDADES DE ASEgURAMIENTO EN COLOMBIA
Bryon A., Leisewitz T., Salgar L., Rodriguez F.
HEORT, Miami, FL, USA
intROductiOn: La Federación Mundial de la Hemofilia indica que existen regis-
trados 137.352 pacientes hemofílicos en 77 países, sin embargo se estima que deben 
existir cerca de 400.000 personas en todo el mundo. Un reciente estudio de carga 
de enfermedad genética estima que existirían 2931 colombianos con hemofilia, 
considerando el período de 1996 a 2025. ObjectivOs: Evaluar la costo-efectivi-
dad de tres tratamientos: Kogenate, Advate y Recombinate para el tratamiento de 
Hemofilia tipo A Severa en una población de 1 a 78 años. Describir los resultados 
de pacientes con Hemofilia Severa que reciben profilaxis con distintos productos 
del Factor VIII. MetOdOlOgías: Se adaptó un modelo de Markov que describe 
la historia natural y los resultados de la Hemofilia A Severa. El modelo considera 
siete estados de salud caracterizados por el estado del inhibidor (3 niveles: HR, LR, 
Ninguno), daño articular (Si o no) y la muerte (estado absorbente). ResultadOs: 
Um total de 1.186 pacientes con Hemofilia A, lo que representaría una prevalencia 
del 0,009% dentro de la población afiliada. La ganancia en términos de AVACs es 
similar para los tres tratamientos. Los componentes con el mayor impacto en los 
costos son profilaxis y control de sangrado. Del análisis de sensibilidad determin-
istico, el parámetro con el mayor impacto es la dosis de Advate con profilaxis. Del 
análisis de sensibilidad probabilísticos, Kogenate es una alternativa dominante 
respecto a Advate en 45% de las simulaciones, y en 70.4% de las simulaciones 
respecto a Recombinate. cOnclusiOnes: Se encontró que los costos de Kogenate 
y Recombinate son en su mayoría atribuidos a la profilaxis y aquellos a Advate al 
tratamiento de sangrado. Aunque la eficacia clínica de los productos es similar, las 
diferencias en la incidencia del desarrollo del inhibidor significan menores costos 
y mejor calidad de vida para los pacientes que son tratados con Kogenate.
SySTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes & Patient 
Preference Studies
PSy12
BETA-THALASSEMIA PATIENTS SURvEy ON DEFERRIzATION THERAPy
Xia S.1, Huang L.1, Zhang W.2
1Medical School of Jinan University, Guangzhou, China, 2Beijing Novartis Pharma Co. Ltd., Beijing, 
China
Objectives: To investigate family burden, awareness and treatment status of 
ß-thalassemia patients in China. MethOds: The families with major ß-thalas-
semia received investigation. The questionnaire involved medical management of 
ß-thalassemia, economic burden, life quality and recognition, attitude and behav-
ior of the relatives to the disease. Results: Currently, the mainstay treatment 
of major thalassemia remains transfusion and deferrization therapy, so that the 
treatment cost is about 60,000 to 70,000 RMB per year for a 10-year-old-child and 
this number even rises with the increasing of the age. Therefore, the family burden 
and life quality of the patients is significantly involved during the treatment of 
this disease. Among different diferrization treatment, deferasirox was first choice 
of the patients concerning the cost-effect factors and lower incidence of adverse 
events, exemplified as local injection reactions which are commonly occurred in 
the patients receiving desferrioxamine. Most of the patients chose the convenience 
as the most important factor for the compliance to the treatment. And in addition 
to disease related factors and symptoms as discussed below, convenience was also 
considered as important issue for life quality. Although until now, 70.7% of the 
patients received intravenous desferrioxamine treatment, over half of the patients 
would like to change to a more convenient oral deferrization treatment, and def-
erasirox was considered as the first choice due to the low price of this medicine in 
China. cOnclusiOns: ß-thalassemia as a hereditary disease severely influenced 
the life quality of the patients, increased economic and social burden to the family. 
The medical utility and society should pay more care to the patients and their fami-
lies, especially the grass-root ones. The government should take the responsibility 
to improve the medical reimbursement system for this disease.
PSy13
EFFICACy AND TOLERABILITy OF CT-gUIDED EPIDURAL STEROID INjECTIONS 
AND PHARMACOTHERAPy FOR MANAgINg CHRONIC LOw BACk ACHE wITH 
RADICULOPATHy
Bansal D.1, Purohit V.1, Ghai B.2
1National Institute of Pharmaceutical Education and Research, Mohali, India, 2Post Graduate 
Institute of Medical Education and Research, Chandigarh, Chandigarh, India
Objectives: Substantial number of patients with persistent low back pain (LBP) 
are treated with multimodal spectrum of conservative and invasive therapies. Few 
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PSy18
TOxOCARIASIS: A DISEASE OF HIgH PREvALENCE BUT FORgOTTEN
Passeri L.A., Fialho P.M.M., Correa C.R.S.
Unicamp, Campinas, Brazil
Objectives: Toxocariasis is a anthropozoonosis that occurs in various regions of the 
world, often found in developing countries and in regions where sanitation conditions 
are poor. This disease affects dogs and cats, whose etiologic agents are, respectively, 
Toxocara canis and cati. These mammals are the definitive hosts of this geohelminth 
and a person it’s a paratenic host. Infection in humans can cause acute clinical sever-
ity varied and eventually chronicity. The diagnosis is made by means of the ELISA and 
the classical treatment is done with benzimidazole anthelmintics. The toxocariasis, 
despite not being on the list of neglected diseases of WHO, has aroused little interest 
in academia and even less in health services, despite its prevalence in various regions 
of Brazil. Some studies have discussed the possible association between parasitic 
infections and allergic / atopic diseases and asthma, working with the hypothesis 
that exert immunomodulatory role. To review the literature on the current prevalence 
of toxocariasis in Brazil and its association with other diseases. MethOds: A search 
was performed in electronic databases, Medline, Lilacs, PubMed and Embase. The 
words were: “toxocariasis and Brazil”, in the period from 2008 to 2013, and found 
406 articles, with the inclusion criteria of studies done with humans and presenting 
epidemiological aspects. Results: We selected 90 articles that prove the current high 
prevalence of toxocariasis in various regions, ranging from 11.1% to 65.4%. Several 
studies point to an association of toxocariasis with other diseases of high public 
health relevance. Despite this evidence the Brazilian Public Health System does not 
repayment diagnostic tests for the detection of anti-Toxocara, complicating the clini-
cal and leading to no treatment. cOnclusiOns: The review provides grants for the 
revision of public policies for prevention, diagnosis and treatment of toxocariasis.
backgROund: As many orphan drug (OD) manufacturers expand their businesses 
across emerging markets(EM) they are faced with restrictive and often non-exist-
ent funding pathways. As a result pricing and reimbursement (P&R) negotiations 
remain very challenging, pushing manufactures to explore the value of local clini-
cal development in supporting access. Objectives: To a) understand the value of 
local clinical development for payers, to support reimbursement in Chile, and b) 
compare and contrast against four other emerging markets: Russia, Turkey, India 
and China. MethOds: In-depth interviews were conducted with 3 stakeholders 
per market including national payers, reimbursement committee advisors and rare 
diseases clinical specialists, to understand a) Current OD funding pathways; b) P&R 
decision drivers; and c) Impact of local development on reimbursement. Selected 
value drivers were used to develop a scale and qualitatively measure the risk/
reward analysis of local clinical development on OD access. Results: The impact 
of local development on OD reimbursement varies across markets. Respondents 
in Chile (n= 3) highlighted that clinical development will have a strong influence 
on future willingness to pay, but the opportunity will remain small due to lack 
of clarity around long-term funding. In Turkey (n= 3), providing access to patients 
through compassionate use schemes, prior to obtaining registration, positively 
impacts reimbursement.While in Russia, conducting a local clinical trial adds no 
value to the P&R decision process as cited by payers (n= 3). As for India and China 
where price remains the overriding factor, respondents (n= 6) stated that national 
reimbursement remains a distant prospect. cOnclusiOns: High clinical experts’ 
awareness, strong influence of advocacy groups and developing OD funding path-
ways renders Chile and Turkey the most attractive EM for local development. 
While in comparison, the generation of local patient data is also favoured across 
the remaining markets, price remains the overriding factors influencing access 
and reimbursement.
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